CAS_NUM NAME CATEGORY VALUE 137945-48-3 AJULEMIC ACID THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 137945-48-3 AJULEMIC ACID INDICATION Pain 137945-48-3 AJULEMIC ACID INDICATION Inflammation 137945-48-3 AJULEMIC ACID PRODUCT_CLASS Anti-inflammatories 137945-48-3 AJULEMIC ACID INDICATION Cystitis 53847-30-6 2-ARACHIDONOYLGLYCEROL INDICATION Neoplasm / Cancer / Tumor 53847-30-6 2-ARACHIDONOYLGLYCEROL PRODUCT_CLASS Other Human Uses 53847-30-6 2-ARACHIDONOYLGLYCEROL THERAPEUTIC_CLASS Antineoplastics 53847-30-6 2-ARACHIDONOYLGLYCEROL STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist, DNA alkylator 53847-30-6 2-ARACHIDONOYLGLYCEROL THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 53847-30-6 2-ARACHIDONOYLGLYCEROL PRODUCT_CLASS Anti-cancers 53847-30-6 2-ARACHIDONOYLGLYCEROL INDICATION Edema 443129-35-9 VIRODHAMINE STRUCTURE_ACTIVITY Toxicant, heavy metal 222723-55-9 NOLADIN STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist, DNA alkylator 222723-55-9 NOLADIN INDICATION Neoplasm / Cancer / Tumor 222723-55-9 NOLADIN PRODUCT_CLASS Anti-cancers 222723-55-9 NOLADIN THERAPEUTIC_CLASS Antineoplastics 199875-69-9 N-ARACHIDONOYLDOPAMINE PRODUCT_CLASS Cardiovasculars 199875-69-9 N-ARACHIDONOYLDOPAMINE THERAPEUTIC_CLASS Vasodilators 199875-69-9 N-ARACHIDONOYLDOPAMINE STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist, DNA alkylator 183718-77-6 AM404 THERAPEUTIC_CLASS Vasodilators 183718-77-6 AM404 PRODUCT_CLASS Cardiovasculars 183718-77-6 AM404 STRUCTURE_ACTIVITY Toxicant, DNA damaging, induces methemoglobinemia 390824-20-1 UCM-707 STRUCTURE_ACTIVITY Toxicant, DNA damaging, induces methemoglobinemia 187947-31-1 N-ARACHIDONOYL-SEROTONIN STRUCTURE_ACTIVITY Toxicant, free radical generator, induces methemoglobinemia 546141-08-6 URB-597 PRODUCT_CLASS Central Nervous System (CNS) 546141-08-6 URB-597 THERAPEUTIC_CLASS Anxiolytics 546141-08-6 URB-597 STRUCTURE_ACTIVITY Toxicant, free radical generator, induces methemoglobinemia 546141-08-6 URB-597 INDICATION Anxiety Disorders 673-50-7 N-ALPHA-METHYLHISTAMINE INDICATION Migraine Headache 673-50-7 N-ALPHA-METHYLHISTAMINE STRUCTURE_ACTIVITY Histamine receptor agonist 673-50-7 N-ALPHA-METHYLHISTAMINE THERAPEUTIC_CLASS Antimigraines 673-50-7 N-ALPHA-METHYLHISTAMINE PRODUCT_CLASS Central Nervous System (CNS) 151093-98-0 SCH-50971 PRODUCT_CLASS Anti-inflammatories 151093-98-0 SCH-50971 STRUCTURE_ACTIVITY Histamine receptor (H3) antagonist 151093-98-0 SCH-50971 THERAPEUTIC_CLASS Antihistamines 151093-98-0 SCH-50971 INDICATION Allergic Diseases 34973-91-6 IMPENTAMINE PRODUCT_CLASS Central Nervous System (CNS) 34973-91-6 IMPENTAMINE INDICATION Obesity 34973-91-6 IMPENTAMINE STRUCTURE_ACTIVITY Histamine receptor agonist 34973-91-6 IMPENTAMINE THERAPEUTIC_CLASS Neurodegenerative Disorders 34973-91-6 IMPENTAMINE INDICATION Neurological Disorders 34973-91-6 IMPENTAMINE THERAPEUTIC_CLASS Anorexiants 202475-60-3 WHI-P131 STRUCTURE_ACTIVITY Toxicant, DNA damaging 205598-06-7 PNU-156804 STRUCTURE_ACTIVITY Toxicant, DNA damaging 205598-06-7 PNU-156804 INDICATION Multiple Sclerosis (MS) 205598-06-7 PNU-156804 THERAPEUTIC_CLASS Immunosuppressants 205598-06-7 PNU-156804 INDICATION Rheumatoid Arthritis 205598-06-7 PNU-156804 PRODUCT_CLASS Immune Response / Immunomodulators 170431-71-7 PNU-156804 STRUCTURE_ACTIVITY Toxicant, DNA damaging 170431-71-7 PNU-156804 INDICATION Multiple Sclerosis (MS) 170431-71-7 PNU-156804 PRODUCT_CLASS Immune Response / Immunomodulators 170431-71-7 PNU-156804 THERAPEUTIC_CLASS Immunosuppressants 170431-71-7 PNU-156804 INDICATION Rheumatoid Arthritis 166981-11-9 CT-2576 PRODUCT_CLASS Immune Response / Immunomodulators 166981-11-9 CT-2576 STRUCTURE_ACTIVITY Toxicant, DNA damaging 166981-11-9 CT-2576 INDICATION Neoplasm / Cancer / Tumor 166981-11-9 CT-2576 PRODUCT_CLASS Anti-cancers 166981-11-9 CT-2576 INDICATION Acquired Immunodeficiency Syndrome (AIDS) 166981-11-9 CT-2576 THERAPEUTIC_CLASS Immunosuppressants 166981-11-9 CT-2576 INDICATION Transplant Rejection 166981-11-9 CT-2576 THERAPEUTIC_CLASS Antineoplastics 162635-04-3 CCI-779 INDICATION Glioma 162635-04-3 CCI-779 THERAPEUTIC_CLASS Antineoplastics 162635-04-3 CCI-779 INDICATION Multiple Myeloma / Myelomatosis 162635-04-3 CCI-779 THERAPEUTIC_CLASS Immunosuppressants 162635-04-3 CCI-779 PRODUCT_CLASS Anti-cancers 162635-04-3 CCI-779 INDICATION Lymphoma 162635-04-3 CCI-779 INDICATION Prostatic Cancer / Carcinoma of the Prostate 162635-04-3 CCI-779 INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 162635-04-3 CCI-779 PRODUCT_CLASS Immune Response / Immunomodulators 162635-04-3 CCI-779 INDICATION Rheumatoid Arthritis 162635-04-3 CCI-779 INDICATION Breast Cancer / Carcinoma of the Breast 162635-04-3 CCI-779 INDICATION Leukemia 162635-04-3 CCI-779 INDICATION Multiple Sclerosis (MS) 162635-04-3 CCI-779 STRUCTURE_ACTIVITY Inhibits T-cell activation 162635-04-3 CCI-779 INDICATION Neoplasm / Cancer / Tumor 162635-04-3 CCI-779 INDICATION Melanoma 213211-10-0 BIRT-0377 STRUCTURE_ACTIVITY Integrin inhibitor 154453-18-6 YC-1 STRUCTURE_ACTIVITY Inhibits hypoxia response, HIF-1 inhibitor 170632-47-0 YC-1 STRUCTURE_ACTIVITY Inhibits hypoxia response, HIF-1 inhibitor 141400-58-0 1-METHYLPROPYL-2-IMIDAZOLYL DISULFIDE PRODUCT_CLASS Anti-cancers 141400-58-0 1-METHYLPROPYL-2-IMIDAZOLYL DISULFIDE THERAPEUTIC_CLASS Antineoplastics 141400-58-0 1-METHYLPROPYL-2-IMIDAZOLYL DISULFIDE INDICATION Neoplasm / Cancer / Tumor 141400-58-0 1-METHYLPROPYL-2-IMIDAZOLYL DISULFIDE STRUCTURE_ACTIVITY Inhibits hypoxia response, HIF-1 inhibitor 1404-23-5 PLEUROTIN INDICATION Neoplasm / Cancer / Tumor 1404-23-5 PLEUROTIN STRUCTURE_ACTIVITY Inhibits hypoxia response, HIF-1 inhibitor 1404-23-5 PLEUROTIN PRODUCT_CLASS Anti-cancers 1404-23-5 PLEUROTIN THERAPEUTIC_CLASS Antineoplastics 83643-88-3 (S)-AMPA MODE_CLASS Channel Modulator 83643-88-3 (S)-AMPA MECHANISM Prolong/enhance neural transmission 83643-88-3 (S)-AMPA PRODUCT_CLASS Biochemicals 51639-49-7 M-CPP THERAPEUTIC_CLASS Antidepressants 51639-49-7 M-CPP PRODUCT_CLASS Central Nervous System (CNS) 51639-49-7 M-CPP INDICATION Depression 22059-21-8 ACPC PRODUCT_CLASS Central Nervous System (CNS) 22059-21-8 ACPC MODE_CLASS Receptor Agonist 22059-21-8 ACPC MECHANISM Prolong/enhance neural transmission 55050-95-8 ISAMOLTAN PRODUCT_CLASS Central Nervous System (CNS) 55050-95-8 ISAMOLTAN THERAPEUTIC_CLASS Antidepressants 55050-95-8 ISAMOLTAN INDICATION Depression 55050-95-8 ISAMOLTAN INDICATION Anxiety Disorders 55050-95-8 ISAMOLTAN THERAPEUTIC_CLASS Sedatives/Hypnotics 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_1_Decreased Cardiac Output 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_2_Abnormal ECG 2078-54-8 PROPOFOL KNOWN_TOXICITY Cardiovascular Toxicity 2078-54-8 PROPOFOL INDICATION Initiation / Maintenance of Sedation 2078-54-8 PROPOFOL THERAPEUTIC_CLASS General Anesthetics, Intravenous 2078-54-8 PROPOFOL TISSUE_TOXICITY Hypotension 2078-54-8 PROPOFOL MODE_CLASS Receptor Agonist 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_1_Bradycardia 2078-54-8 PROPOFOL ADVERSE_EFFECT NEU_3_Dizziness 2078-54-8 PROPOFOL ADVERSE_EFFECT NEU_2_Paresthesia 2078-54-8 PROPOFOL ADVERSE_EFFECT NEU_3_Somnolence 2078-54-8 PROPOFOL ADVERSE_EFFECT IMU_2_Anaphylaxis 2078-54-8 PROPOFOL INDICATION Induction / Maintenance of Anesthesia 2078-54-8 PROPOFOL ADVERSE_EFFECT GIS_2_Nausea 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_3_Chest Pain 2078-54-8 PROPOFOL ADVERSE_EFFECT LUN_1_Apnea 2078-54-8 PROPOFOL TISSUE_TOXICITY Atrial Fibrillation 2078-54-8 PROPOFOL PRODUCT_CLASS Central Nervous System (CNS) 2078-54-8 PROPOFOL TISSUE_TOXICITY Premature Ventricular Beats 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_1_Hypotension 2078-54-8 PROPOFOL ADVERSE_EFFECT CVS_2_Premature Ventricular Beats 2078-54-8 PROPOFOL ADVERSE_EFFECT MSK_3_Myalgia 2078-54-8 PROPOFOL ADVERSE_EFFECT LUN_3_Wheezing 2078-54-8 PROPOFOL STRUCTURE_ACTIVITY GABA-A agonist 2078-54-8 PROPOFOL MECHANISM Modulate neural transmission 2078-54-8 PROPOFOL ADVERSE_EFFECT XXX_3_Fever 64285-06-9 (+/-)-ANATOXIN A FUMARATE PRODUCT_CLASS Toxicants 149719-06-2 RS-23597-190 PRODUCT_CLASS Biochemicals 827-61-2 ACECLIDINE INDICATION Glaucoma 827-61-2 ACECLIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 827-61-2 ACECLIDINE THERAPEUTIC_CLASS Antiglaucoma Agents 827-61-2 ACECLIDINE MODE_CLASS Enzyme Inhibitor 827-61-2 ACECLIDINE MECHANISM Enhance cholinergic transmission 205195-07-9 PD-153035 THERAPEUTIC_CLASS Antineoplastics 205195-07-9 PD-153035 MODE_CLASS Receptor tyrosine kinase inhibitor 205195-07-9 PD-153035 MECHANISM Inhibit Ca++ sensitisation 205195-07-9 PD-153035 MODE_CLASS Enzyme Inhibitor, Non-selective 205195-07-9 PD-153035 PRODUCT_CLASS Anti-cancers 56-12-2 4-AMINOBUTYRIC ACID PRODUCT_CLASS Biochemicals 320-67-2 AZACITIDINE MECHANISM Incorporate into DNA/RNA/Protein 320-67-2 AZACITIDINE PRODUCT_CLASS Anti-cancers 320-67-2 AZACITIDINE THERAPEUTIC_CLASS Antineoplastics 320-67-2 AZACITIDINE MODE_CLASS Enzyme substrate mimic 320-67-2 AZACITIDINE INDICATION Myelodysplastic Syndromes 320-67-2 AZACITIDINE INDICATION Acute Non-Lymphocytic Leukemia 320-67-2 AZACITIDINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 3978-86-7 AZATADINE MODE_CLASS Receptor Ligand Antagonist, Selective 3978-86-7 AZATADINE INDICATION Allergic Rhinitis 3978-86-7 AZATADINE INDICATION Nasal Congestion 3978-86-7 AZATADINE INDICATION Pruritus / Itching 3978-86-7 AZATADINE PRODUCT_CLASS Anti-inflammatories 3978-86-7 AZATADINE INDICATION Allergic Diseases 3978-86-7 AZATADINE INDICATION Allergic Conjunctivitis 3978-86-7 AZATADINE THERAPEUTIC_CLASS Antihistamines 3978-86-7 AZATADINE MECHANISM Modulate G-protein coupled signal transduction 58581-89-8 AZELASTINE MECHANISM Modulate G-protein coupled signal transduction 58581-89-8 AZELASTINE ADVERSE_EFFECT XXX_2_Xerostomia 58581-89-8 AZELASTINE INDICATION Vasomotor Rhinitis 58581-89-8 AZELASTINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 58581-89-8 AZELASTINE INDICATION Ocular Pruritus 58581-89-8 AZELASTINE INDICATION Allergic Conjunctivitis 58581-89-8 AZELASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 58581-89-8 AZELASTINE ADVERSE_EFFECT OCU_3_Blurred Vision 58581-89-8 AZELASTINE ADVERSE_EFFECT IMU_3_Allergic Reactions 58581-89-8 AZELASTINE ADVERSE_EFFECT XXX_1_Nasal Irritation 58581-89-8 AZELASTINE ADVERSE_EFFECT OCU_1_Ocular Irritation 58581-89-8 AZELASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 58581-89-8 AZELASTINE INDICATION Allergic Rhinitis 58581-89-8 AZELASTINE ADVERSE_EFFECT XXX_2_Epistaxis 58581-89-8 AZELASTINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 58581-89-8 AZELASTINE ADVERSE_EFFECT GIS_1_Bitter Taste 58581-89-8 AZELASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 58581-89-8 AZELASTINE ADVERSE_EFFECT NEU_2_Headache 58581-89-8 AZELASTINE ADVERSE_EFFECT LUN_3_Bronchospasm 58581-89-8 AZELASTINE ADVERSE_EFFECT XXX_2_Paroxysmal Sneezing 58581-89-8 AZELASTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58581-89-8 AZELASTINE ADVERSE_EFFECT NEU_2_Dizziness 58581-89-8 AZELASTINE ADVERSE_EFFECT NEU_2_Drowsiness 58581-89-8 AZELASTINE ADVERSE_EFFECT XXX_2_Pharyngitis 58581-89-8 AZELASTINE ADVERSE_EFFECT OCU_2_Eye Pain 90581-30-9 AZITHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 90581-30-9 AZITHROMYCIN INDICATION Skin and Skin Structure Infections 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Somnolence 90581-30-9 AZITHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT XXX_2_Fatigue 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Vertigo 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Melena 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Dyspepsia 90581-30-9 AZITHROMYCIN MESH_LEVEL_1 Organic Chemicals 90581-30-9 AZITHROMYCIN INDICATION Community-Acquired Pneumonia 90581-30-9 AZITHROMYCIN INDICATION Tonsillitis 90581-30-9 AZITHROMYCIN MESH_LEVEL_3 Macrolides 90581-30-9 AZITHROMYCIN MESH_LEVEL_2 Lactones 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT IMU_2_Photosensitivity 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT CVS_2_Chest Pain 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GUS_2_Genital Moniliasis 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Vomiting 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT IMU_2_Angioedema 90581-30-9 AZITHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 90581-30-9 AZITHROMYCIN INDICATION Nongonoccocal Urethritis and Cervicitis 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GUS_2_Vaginitis 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Dizziness 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT CVS_2_Palpitation 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Flatulence 90581-30-9 AZITHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 90581-30-9 AZITHROMYCIN ZERO_CLASS N 90581-30-9 AZITHROMYCIN MECH_LEVEL_1 Anti-bacterial 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT KID_2_Nephritis 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT SKN_2_Rash 90581-30-9 AZITHROMYCIN TA_LEVEL_3 Systemic infections 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Nausea 90581-30-9 AZITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 90581-30-9 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 90581-30-9 AZITHROMYCIN PRODUCT_CLASS Anti-infectives 90581-30-9 AZITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 90581-30-9 AZITHROMYCIN THERAPEUTIC_CLASS Antibacterials 90581-30-9 AZITHROMYCIN INDICATION Pharyngitis 90581-30-9 AZITHROMYCIN TA_LEVEL_2 Anti-bacterial 90581-30-9 AZITHROMYCIN TA_LEVEL_1 Infectious Disease 101626-70-4 TALIPEXOLE MODE_CLASS Receptor Agonist 101626-70-4 TALIPEXOLE MECHANISM Prolong/enhance neural transmission 101626-70-4 TALIPEXOLE MODE_CLASS Channel Modulator 101626-70-4 TALIPEXOLE MECHANISM Modulate neural transmission 101626-70-4 TALIPEXOLE MECHANISM Modulate G-protein coupled signal transduction 1402-99-9 BACITRACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 1402-99-9 BACITRACIN ADVERSE_EFFECT XXX_1_Injection Site Reaction 1402-99-9 BACITRACIN TA_LEVEL_3 anti-bacterial, topical 1402-99-9 BACITRACIN MECH_LEVEL_2 Cell wall biosynthesis inhibitor 1402-99-9 BACITRACIN INDICATION Pneumonia 1402-99-9 BACITRACIN INDICATION Blepharitis 1402-99-9 BACITRACIN MESH_LEVEL_3 Peptides, Cyclic 1402-99-9 BACITRACIN KNOWN_TOXICITY Nephrotoxicity 1402-99-9 BACITRACIN TISSUE_TOXICITY Renal Failure 1402-99-9 BACITRACIN TISSUE_TOXICITY Nephrotoxicity 1402-99-9 BACITRACIN ADVERSE_EFFECT XXX_3_Fever 1402-99-9 BACITRACIN ADVERSE_EFFECT SKN_3_Pruritis 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_2_Nephrotoxicity 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_3_Renal Failure 1402-99-9 BACITRACIN ADVERSE_EFFECT IMU_3_Swelling of Lips 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_3_Oligemic Renal Failure 1402-99-9 BACITRACIN MECH_LEVEL_3 complexes with lipid 1402-99-9 BACITRACIN INDICATION Ophthalmic Infections 1402-99-9 BACITRACIN ADVERSE_EFFECT OCU_1_Blurred Vision 1402-99-9 BACITRACIN PRODUCT_CLASS Anti-infectives 1402-99-9 BACITRACIN TA_LEVEL_1 Infectious Disease 1402-99-9 BACITRACIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1402-99-9 BACITRACIN ADVERSE_EFFECT GIS_2_Diarrhea 1402-99-9 BACITRACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 1402-99-9 BACITRACIN ADVERSE_EFFECT MSK_3_Myasthenia 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_2_Proteinuria 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 1402-99-9 BACITRACIN ADVERSE_EFFECT BBM_3_Hematological Reactions 1402-99-9 BACITRACIN TISSUE_TOXICITY Renal Tubular Necrosis 1402-99-9 BACITRACIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor 1402-99-9 BACITRACIN MECHANISM Inhibit bacterial cell wall biosynthesis 1402-99-9 BACITRACIN MECH_LEVEL_1 Cell wall biosynthesis inhibitor 1402-99-9 BACITRACIN INDICATION Bacterial Conjunctivitis 1402-99-9 BACITRACIN THERAPEUTIC_CLASS Antibacterials, Topical 1402-99-9 BACITRACIN TISSUE_TOXICITY Oligemic Renal Failure 1402-99-9 BACITRACIN ADVERSE_EFFECT PSY_2_Anorexia 1402-99-9 BACITRACIN ADVERSE_EFFECT SKN_2_Rash 1402-99-9 BACITRACIN ADVERSE_EFFECT IMU_3_Urticaria 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_2_Hematuria 1402-99-9 BACITRACIN ADVERSE_EFFECT IMU_3_Eosinophilia 1402-99-9 BACITRACIN ADVERSE_EFFECT KID_3_Azotemia 1402-99-9 BACITRACIN ADVERSE_EFFECT XXX_3_Chest Tightness 1402-99-9 BACITRACIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 1402-99-9 BACITRACIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 1402-99-9 BACITRACIN TA_LEVEL_2 Anti-bacterial 1402-99-9 BACITRACIN ZERO_CLASS N 1402-99-9 BACITRACIN INDICATION Keratitis 1402-99-9 BACITRACIN INDICATION Pseudomembranous Colitis 1402-99-9 BACITRACIN MESH_LEVEL_2 Peptides 1402-99-9 BACITRACIN INDICATION Skin and Skin Structure Infections 1402-99-9 BACITRACIN TISSUE_TOXICITY Hematuria 1402-99-9 BACITRACIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1402-99-9 BACITRACIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 1402-99-9 BACITRACIN ADVERSE_EFFECT XXX_3_Superinfection 1402-99-9 BACITRACIN ADVERSE_EFFECT SKN_2_Anal Pruritis 80573-04-2 BALSALAZIDE TISSUE_TOXICITY Hepatic Necrosis 80573-04-2 BALSALAZIDE MECHANISM Inhibit inflammatory response 80573-04-2 BALSALAZIDE TA_LEVEL_1 Anti-inflammatory 80573-04-2 BALSALAZIDE ACTIVITY_CLASS Anti-inflammatory 80573-04-2 BALSALAZIDE ADVERSE_EFFECT KID_3_Interstitial Nephritis 80573-04-2 BALSALAZIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 80573-04-2 BALSALAZIDE ADVERSE_EFFECT LIV_3_Hepatic Failure 80573-04-2 BALSALAZIDE TISSUE_TOXICITY Hepatic Failure 80573-04-2 BALSALAZIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 80573-04-2 BALSALAZIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 80573-04-2 BALSALAZIDE MESH_LEVEL_1 Organic Chemicals 80573-04-2 BALSALAZIDE ADVERSE_EFFECT CVS_3_Deep Venous Thrombosis 80573-04-2 BALSALAZIDE ADVERSE_EFFECT BBM_3_Hemorrhage 80573-04-2 BALSALAZIDE ADVERSE_EFFECT GIS_3_Pancreatitis 80573-04-2 BALSALAZIDE ADVERSE_EFFECT MSK_2_Arthralgia 80573-04-2 BALSALAZIDE ADVERSE_EFFECT NEU_1_Headache 80573-04-2 BALSALAZIDE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 80573-04-2 BALSALAZIDE KNOWN_TOXICITY Hepatotoxicity 80573-04-2 BALSALAZIDE MESH_LEVEL_2 Phenols 80573-04-2 BALSALAZIDE TA_LEVEL_2 NSAID? 80573-04-2 BALSALAZIDE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 80573-04-2 BALSALAZIDE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 80573-04-2 BALSALAZIDE MECH_LEVEL_1 Immunomodulation 80573-04-2 BALSALAZIDE PRODUCT_CLASS Anti-inflammatories 80573-04-2 BALSALAZIDE ADVERSE_EFFECT BBM_3_Bleeding Tendency 80573-04-2 BALSALAZIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 80573-04-2 BALSALAZIDE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 80573-04-2 BALSALAZIDE ADVERSE_EFFECT LUN_3_Bronchospasm 80573-04-2 BALSALAZIDE ADVERSE_EFFECT GIS_1_Diarrhea 80573-04-2 BALSALAZIDE MODE_CLASS Enzyme Inhibitor 80573-04-2 BALSALAZIDE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, aminosalicylic acid 80573-04-2 BALSALAZIDE ZERO_CLASS N 80573-04-2 BALSALAZIDE INDICATION Ulcerative Colitis 80573-04-2 BALSALAZIDE KNOWN_TOXICITY Nephrotoxicity 80573-04-2 BALSALAZIDE TISSUE_TOXICITY Hepatotoxicity 80573-04-2 BALSALAZIDE MECHANISM Inhibit eicosanoid biosynthesis 80573-04-2 BALSALAZIDE MESH_LEVEL_3 Hydroxybenzoic Acids 80573-04-2 BALSALAZIDE ADVERSE_EFFECT LUN_2_Respiratory Infection 80573-04-2 BALSALAZIDE ADVERSE_EFFECT IMU_3_Eosinophilia 80573-04-2 BALSALAZIDE ADVERSE_EFFECT BBM_3_Granulocytopenia 80573-04-2 BALSALAZIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 80573-04-2 BALSALAZIDE ADVERSE_EFFECT CVS_2_Hypertension 80573-04-2 BALSALAZIDE TISSUE_TOXICITY Interstitial Nephritis 71145-03-4 (+/-)-BAY K 8644 MECHANISM Reduce muscle contractile force 71145-03-4 (+/-)-BAY K 8644 MODE_CLASS Channel Blocker 71145-03-4 (+/-)-BAY K 8644 PRODUCT_CLASS Biochemicals 5929-09-9 BENZETHONIUM CHLORIDE MESH_LEVEL_1 Organic Chemicals 5929-09-9 BENZETHONIUM CHLORIDE TA_LEVEL_3 Antiseptic, topical 5929-09-9 BENZETHONIUM CHLORIDE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 5929-09-9 BENZETHONIUM CHLORIDE ADVERSE_EFFECT SKN_3_Skin Irritation 5929-09-9 BENZETHONIUM CHLORIDE ADVERSE_EFFECT XXX_3_Death 5929-09-9 BENZETHONIUM CHLORIDE TISSUE_TOXICITY Shock 5929-09-9 BENZETHONIUM CHLORIDE TA_LEVEL_1 Diagnostics and Pharmaceutical Aids 5929-09-9 BENZETHONIUM CHLORIDE MECHANISM Block neural transmission 5929-09-9 BENZETHONIUM CHLORIDE MESH_LEVEL_3 Ammonium Compounds 5929-09-9 BENZETHONIUM CHLORIDE MODE_CLASS Channel Blocker 5929-09-9 BENZETHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Coma 5929-09-9 BENZETHONIUM CHLORIDE TISSUE_TOXICITY Death 5929-09-9 BENZETHONIUM CHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 5929-09-9 BENZETHONIUM CHLORIDE MECH_LEVEL_1 Modulates channel gating 5929-09-9 BENZETHONIUM CHLORIDE MESH_LEVEL_2 Amines 5929-09-9 BENZETHONIUM CHLORIDE KNOWN_TOXICITY Miscellaneous 5929-09-9 BENZETHONIUM CHLORIDE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 5929-09-9 BENZETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Shock 5929-09-9 BENZETHONIUM CHLORIDE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 5929-09-9 BENZETHONIUM CHLORIDE ZERO_CLASS N 5929-09-9 BENZETHONIUM CHLORIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 5929-09-9 BENZETHONIUM CHLORIDE TA_LEVEL_2 Antiseptics / Disinfectants 5929-09-9 BENZETHONIUM CHLORIDE MECH_LEVEL_2 Block neural transmission 5929-09-9 BENZETHONIUM CHLORIDE ADVERSE_EFFECT OCU_3_Eye Irritation 5929-09-9 BENZETHONIUM CHLORIDE ADVERSE_EFFECT GIS_3_Vomiting 5929-09-9 BENZETHONIUM CHLORIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 579-44-2 BENZOIN INDICATION Croup / Acute Laryngotracheobronchitis 579-44-2 BENZOIN INDICATION Skin Antisepsis 579-44-2 BENZOIN PRODUCT_CLASS Respiratory System 579-44-2 BENZOIN PRODUCT_CLASS Anti-infectives 579-44-2 BENZOIN THERAPEUTIC_CLASS Antibacterials, Topical 86-13-5 BENZTROPINE ADVERSE_EFFECT OCU_1_Mydriasis 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_3_Hallucinations 86-13-5 BENZTROPINE ADVERSE_EFFECT NEU_2_Headache 86-13-5 BENZTROPINE MODE_CLASS Solute transporter inhibitor 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_3_Delusions 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_2_Paranoia 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_1_Excitement 86-13-5 BENZTROPINE INDICATION Tremor 86-13-5 BENZTROPINE ADVERSE_EFFECT XXX_3_Fever 86-13-5 BENZTROPINE ADVERSE_EFFECT OCU_1_Blurred Vision 86-13-5 BENZTROPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 86-13-5 BENZTROPINE ADVERSE_EFFECT XXX_1_Restlessness 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_3_Euphoria 86-13-5 BENZTROPINE ADVERSE_EFFECT XXX_1_Xerostomia 86-13-5 BENZTROPINE PRODUCT_CLASS Central Nervous System (CNS) 86-13-5 BENZTROPINE THERAPEUTIC_CLASS Movement Disorders 86-13-5 BENZTROPINE MECHANISM Prolong/enhance neural transmission 86-13-5 BENZTROPINE ADVERSE_EFFECT XXX_3_Hyperthermia 86-13-5 BENZTROPINE ADVERSE_EFFECT GIS_1_Constipation 86-13-5 BENZTROPINE ADVERSE_EFFECT NEU_2_Amnesia 86-13-5 BENZTROPINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_1_Disorientation 86-13-5 BENZTROPINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 86-13-5 BENZTROPINE ADVERSE_EFFECT GUS_3_Urinary Retention 86-13-5 BENZTROPINE ADVERSE_EFFECT OCU_1_Cycloplegia 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_3_Psychosis 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_2_Depression 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_1_Anxiety 86-13-5 BENZTROPINE ADVERSE_EFFECT NEU_3_Paresthesia 86-13-5 BENZTROPINE ADVERSE_EFFECT IMU_3_Urticaria 86-13-5 BENZTROPINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 86-13-5 BENZTROPINE INDICATION Parkinsonism 86-13-5 BENZTROPINE ADVERSE_EFFECT PSY_2_Delirium 86-13-5 BENZTROPINE INDICATION Extrapyramidal Disorders 86-13-5 BENZTROPINE INDICATION Parkinson's Disease 86-13-5 BENZTROPINE ADVERSE_EFFECT OCU_2_Acute Angle-Closure Glaucoma 68099-86-5 BEPRIDIL INDICATION Angina Pectoris 68099-86-5 BEPRIDIL STRUCTURE_ACTIVITY Ca++ channel blocker 68099-86-5 BEPRIDIL MECHANISM Reduce muscle contractile force 68099-86-5 BEPRIDIL PRODUCT_CLASS Cardiovasculars 68099-86-5 BEPRIDIL MODE_CLASS Channel Blocker 68099-86-5 BEPRIDIL THERAPEUTIC_CLASS Antianginals 63659-19-8 BETAXOLOL PRODUCT_CLASS Cardiovasculars 63659-19-8 BETAXOLOL INDICATION Increased Intraocular Pressure 63659-19-8 BETAXOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 63659-19-8 BETAXOLOL MECHANISM Reduce muscle contractile force 63659-19-8 BETAXOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 63659-19-8 BETAXOLOL INDICATION Glaucoma 63659-19-8 BETAXOLOL THERAPEUTIC_CLASS Antihypertensive Agents 63659-19-8 BETAXOLOL INDICATION Hypertension 63659-19-8 BETAXOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 134296-40-5 BIMU-8 MODE_CLASS Solute transporter inhibitor 134296-40-5 BIMU-8 PRODUCT_CLASS Biochemicals 134296-40-5 BIMU-8 MECHANISM Prolong/enhance neural transmission 10361-46-3 BISMUTH SUBNITRATE INDICATION Duodenal Ulcer 10361-46-3 BISMUTH SUBNITRATE THERAPEUTIC_CLASS Antiulcers 10361-46-3 BISMUTH SUBNITRATE INDICATION Gastric Ulcer 10361-46-3 BISMUTH SUBNITRATE PRODUCT_CLASS Gastrointestinal System 10361-46-3 BISMUTH SUBNITRATE ADVERSE_EFFECT NEU_3_Encephalopathy 104344-23-2 BISOPROLOL INDICATION Angina Pectoris 104344-23-2 BISOPROLOL PRODUCT_CLASS Cardiovasculars 104344-23-2 BISOPROLOL MODE_CLASS Receptor Ligand Antagonist, Selective 104344-23-2 BISOPROLOL THERAPEUTIC_CLASS Antianginals 104344-23-2 BISOPROLOL MECHANISM Reduce muscle contractile force 104344-23-2 BISOPROLOL INDICATION Hypertension 104344-23-2 BISOPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 104-55-2 CINNAMALDEHYDE PRODUCT_CLASS Other Human Uses 86393-32-0 CIPROFLOXACIN TA_LEVEL_1 Infectious Disease 86393-32-0 CIPROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 86393-32-0 CIPROFLOXACIN INDICATION Skin and Skin Structure Infections 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT IMU_2_Urticaria 86393-32-0 CIPROFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 86393-32-0 CIPROFLOXACIN PRODUCT_CLASS Anti-infectives 86393-32-0 CIPROFLOXACIN INDICATION Acute Sinusitis 86393-32-0 CIPROFLOXACIN INDICATION Intra-Abdominal Infections 86393-32-0 CIPROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 86393-32-0 CIPROFLOXACIN KNOWN_TOXICITY Nephrotoxicity 86393-32-0 CIPROFLOXACIN TA_LEVEL_3 quinolones 86393-32-0 CIPROFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 86393-32-0 CIPROFLOXACIN INDICATION Bone and Joint Infection 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT CVS_2_Palpitation 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 86393-32-0 CIPROFLOXACIN TISSUE_TOXICITY Renal Failure 86393-32-0 CIPROFLOXACIN INDICATION Chronic Bacterial Prostatitis 86393-32-0 CIPROFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 86393-32-0 CIPROFLOXACIN INDICATION Respiratory Tract Infection 86393-32-0 CIPROFLOXACIN INDICATION Inhalational Anthrax 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT GIS_2_Dysphagia 86393-32-0 CIPROFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT SKN_1_Rash 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 86393-32-0 CIPROFLOXACIN INDICATION Urinary Tract Infection (UTI) 86393-32-0 CIPROFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 86393-32-0 CIPROFLOXACIN ZERO_CLASS N 86393-32-0 CIPROFLOXACIN MECH_LEVEL_3 DNA gyrase 86393-32-0 CIPROFLOXACIN MESH_LEVEL_3 Quinolines 86393-32-0 CIPROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT XXX_3_Epistaxis 86393-32-0 CIPROFLOXACIN INDICATION Uncomplicated Cystitis 86393-32-0 CIPROFLOXACIN INDICATION Enteric Fever / Typhoid Fever 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT IMU_2_Anaphylaxis 86393-32-0 CIPROFLOXACIN INDICATION Acute Infectious Diarrhea 86393-32-0 CIPROFLOXACIN MECH_LEVEL_1 Anti-bacterial 86393-32-0 CIPROFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT NEU_1_Headache 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Vomiting 86393-32-0 CIPROFLOXACIN TA_LEVEL_2 Anti-bacterial 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT KID_3_Renal Failure 86393-32-0 CIPROFLOXACIN ADVERSE_EFFECT PSY_2_Insomnia 104456-79-3 CISCONAZOLE MODE_CLASS Enzyme Inhibitor 104456-79-3 CISCONAZOLE THERAPEUTIC_CLASS Antifungals 104456-79-3 CISCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 104456-79-3 CISCONAZOLE PRODUCT_CLASS Anti-infectives 15686-51-8 CLEMASTINE ADVERSE_EFFECT GIS_2_Constipation 15686-51-8 CLEMASTINE ADVERSE_EFFECT CVS_3_Hypertension 15686-51-8 CLEMASTINE ADVERSE_EFFECT NEU_1_Dizziness 15686-51-8 CLEMASTINE ADVERSE_EFFECT CVS_1_Palpitation 15686-51-8 CLEMASTINE MESH_LEVEL_3 Pyrrolidines 15686-51-8 CLEMASTINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 15686-51-8 CLEMASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 15686-51-8 CLEMASTINE INDICATION Angioedema 15686-51-8 CLEMASTINE ADVERSE_EFFECT CVS_3_Hypotension 15686-51-8 CLEMASTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 15686-51-8 CLEMASTINE ADVERSE_EFFECT GIS_3_Diarrhea 15686-51-8 CLEMASTINE ADVERSE_EFFECT GIS_2_Abdominal Pain 15686-51-8 CLEMASTINE ADVERSE_EFFECT NEU_1_Drowsiness 15686-51-8 CLEMASTINE ADVERSE_EFFECT PSY_1_Insomnia 15686-51-8 CLEMASTINE ADVERSE_EFFECT OCU_2_Blurred Vision 15686-51-8 CLEMASTINE ADVERSE_EFFECT XXX_1_Restlessness 15686-51-8 CLEMASTINE MODE_CLASS Receptor Ligand Antagonist 15686-51-8 CLEMASTINE ACTIVITY_CLASS Histamine antagonist 15686-51-8 CLEMASTINE KNOWN_TOXICITY Cardiovascular Toxicity 15686-51-8 CLEMASTINE MECHANISM Modulate G-protein coupled signal transduction 15686-51-8 CLEMASTINE TA_LEVEL_2 Anti-histamine 15686-51-8 CLEMASTINE MECH_LEVEL_2 Anti-histamine 15686-51-8 CLEMASTINE INDICATION Pruritus / Itching 15686-51-8 CLEMASTINE TA_LEVEL_1 Anti-inflammatory 15686-51-8 CLEMASTINE ADVERSE_EFFECT GUS_2_Urinary Retention 15686-51-8 CLEMASTINE ADVERSE_EFFECT XXX_2_Xerostomia 15686-51-8 CLEMASTINE ADVERSE_EFFECT NEU_2_Seizures 15686-51-8 CLEMASTINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 15686-51-8 CLEMASTINE ADVERSE_EFFECT PSY_1_CNS Depression 15686-51-8 CLEMASTINE ZERO_CLASS N 15686-51-8 CLEMASTINE THERAPEUTIC_CLASS Antihistamines 15686-51-8 CLEMASTINE INDICATION Urticaria / Hives 15686-51-8 CLEMASTINE INDICATION Allergic Rhinitis 15686-51-8 CLEMASTINE MECH_LEVEL_1 Immunomodulation 15686-51-8 CLEMASTINE MECH_LEVEL_3 histamine receptor H1 15686-51-8 CLEMASTINE MESH_LEVEL_1 Heterocyclic Compounds 15686-51-8 CLEMASTINE TISSUE_TOXICITY Hypotension 15686-51-8 CLEMASTINE PRODUCT_CLASS Anti-inflammatories 15686-51-8 CLEMASTINE INDICATION Viral Rhinitis / Common Cold 24729-96-2 CLINDAMYCIN INDICATION Gynecologic Infections 24729-96-2 CLINDAMYCIN INDICATION Lower Respiratory Tract Infection 24729-96-2 CLINDAMYCIN ZERO_CLASS N 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 24729-96-2 CLINDAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 24729-96-2 CLINDAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 24729-96-2 CLINDAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, lincosamide 24729-96-2 CLINDAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 24729-96-2 CLINDAMYCIN INDICATION Bone and Joint Infection 24729-96-2 CLINDAMYCIN INDICATION Skin and Skin Structure Infections 24729-96-2 CLINDAMYCIN MESH_LEVEL_3 Glycosides 24729-96-2 CLINDAMYCIN PRODUCT_CLASS Anti-infectives 24729-96-2 CLINDAMYCIN MESH_LEVEL_2 Carbohydrates 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT KID_3_Proteinuria 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Esophagitis 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT KID_3_Azotemia 24729-96-2 CLINDAMYCIN TA_LEVEL_1 Infectious Disease 24729-96-2 CLINDAMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 24729-96-2 CLINDAMYCIN TA_LEVEL_2 Anti-bacterial 24729-96-2 CLINDAMYCIN INDICATION Bacteremia 24729-96-2 CLINDAMYCIN INDICATION Septicemia 24729-96-2 CLINDAMYCIN KNOWN_TOXICITY Gastrointestinal Toxicity 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 24729-96-2 CLINDAMYCIN MECH_LEVEL_1 Anti-bacterial 24729-96-2 CLINDAMYCIN TA_LEVEL_3 Systemic infections 24729-96-2 CLINDAMYCIN MECHANISM Inhibit ribosomal protein synthesis 24729-96-2 CLINDAMYCIN INDICATION Acne / Acne Vulgaris 24729-96-2 CLINDAMYCIN INDICATION Intra-Abdominal Infections 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Urticaria 24729-96-2 CLINDAMYCIN TISSUE_TOXICITY Pseudomembranous Colitis 24729-96-2 CLINDAMYCIN THERAPEUTIC_CLASS Antibacterials 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Agranulocytosis 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Pruritis 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Pseudomembranous Colitis 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT KID_3_Renal Dysfunction 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 24729-96-2 CLINDAMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 24729-96-2 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Neutropenia 130-26-7 CLIOQUINOL PRODUCT_CLASS Anti-infectives 130-26-7 CLIOQUINOL THERAPEUTIC_CLASS Antifungals, Topical 130-26-7 CLIOQUINOL INDICATION Candidiasis 130-26-7 CLIOQUINOL ADVERSE_EFFECT IMU_3_Allergic Reactions 130-26-7 CLIOQUINOL ADVERSE_EFFECT SKN_2_Skin Discoloration 130-26-7 CLIOQUINOL INDICATION Tinea Cruris / Jock Itch 130-26-7 CLIOQUINOL ADVERSE_EFFECT SKN_3_Nail Discoloration 130-26-7 CLIOQUINOL INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 130-26-7 CLIOQUINOL INDICATION Tinea Pedis / Athlete's Foot 130-26-7 CLIOQUINOL INDICATION Fungal Infections 2030-63-9 CLOFAZIMINE ADVERSE_EFFECT GIS_1_Abdominal Pain 2030-63-9 CLOFAZIMINE INDICATION Mycobacterium Tuberculosis Infections 2030-63-9 CLOFAZIMINE ADVERSE_EFFECT LIV_2_Jaundice 2030-63-9 CLOFAZIMINE MECHANISM Inhibit DNA synthesis, repair, and function 2030-63-9 CLOFAZIMINE INDICATION Atypical Mycobacterial Diseases 2030-63-9 CLOFAZIMINE INDICATION Mycobacterium Avium Complex (MAC) 2030-63-9 CLOFAZIMINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 2030-63-9 CLOFAZIMINE PRODUCT_CLASS Anti-infectives 2030-63-9 CLOFAZIMINE INDICATION Leprosy 2030-63-9 CLOFAZIMINE ADVERSE_EFFECT LIV_2_Hepatitis 2030-63-9 CLOFAZIMINE ADVERSE_EFFECT SKN_2_Skin Discoloration 2030-63-9 CLOFAZIMINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2030-63-9 CLOFAZIMINE INDICATION Erythema Nodosum Leprosum (ENL) 2030-63-9 CLOFAZIMINE THERAPEUTIC_CLASS Antibacterials, Systemic 2030-63-9 CLOFAZIMINE ADVERSE_EFFECT SKN_2_Pruritis 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT LIV_3_Jaundice 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT IMU_3_Eosinophilia 303-49-1 CLOMIPRAMINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 303-49-1 CLOMIPRAMINE TA_LEVEL_1 Central Nervous System (CNS) 303-49-1 CLOMIPRAMINE MECH_LEVEL_3 Dopamine (DA) Transporter DAT 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 303-49-1 CLOMIPRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 303-49-1 CLOMIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 303-49-1 CLOMIPRAMINE ZERO_CLASS N 303-49-1 CLOMIPRAMINE THERAPEUTIC_CLASS Antidepressants 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT END_2_Galactorrhea 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 303-49-1 CLOMIPRAMINE TA_LEVEL_2 Anti-depressant 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT NEU_3_Convulsions 303-49-1 CLOMIPRAMINE TA_LEVEL_3 obsessive compulsive 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT XXX_2_Breast Enlargement 303-49-1 CLOMIPRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Leukopenia 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 303-49-1 CLOMIPRAMINE MECH_LEVEL_2 receptor ligand antagonist 303-49-1 CLOMIPRAMINE TISSUE_TOXICITY Cardiac Failure 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT OCU_3_Glaucoma 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 303-49-1 CLOMIPRAMINE INDICATION Obsessive-Compulsive Disorder (OCD) 303-49-1 CLOMIPRAMINE MODE_CLASS Solute transporter inhibitor 303-49-1 CLOMIPRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 303-49-1 CLOMIPRAMINE MESH_LEVEL_1 Heterocyclic Compounds 303-49-1 CLOMIPRAMINE INDICATION Depression 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Failure 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Anemia 303-49-1 CLOMIPRAMINE MECHANISM Prolong/enhance neural transmission 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT END_3_Gynecomastia 303-49-1 CLOMIPRAMINE ADVERSE_EFFECT REP_3_Impotence 303-49-1 CLOMIPRAMINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 303-49-1 CLOMIPRAMINE MESH_LEVEL_3 Dibenzazepines 113665-84-2 CLOPIDOGREL MESH_LEVEL_3 Thiophenes 113665-84-2 CLOPIDOGREL ZERO_CLASS N 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Duodenal Ulcer 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_1_Diarrhea 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT XXX_3_Edema 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT MSK_3_Arthralgia 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Constipation 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GUS_3_Urinary Tract Infection 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Abdominal Pain 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT XXX_3_Epistaxis 113665-84-2 CLOPIDOGREL KNOWN_TOXICITY Gastrointestinal Toxicity 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Peptic Ulceration 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT CVS_2_Chest Pain 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Gastric Ulceration 113665-84-2 CLOPIDOGREL STRUCTURE_ACTIVITY Nucleotide receptor P2Y12 antagonist 113665-84-2 CLOPIDOGREL TA_LEVEL_1 Cardiovascular 113665-84-2 CLOPIDOGREL MECHANISM Modulate G-protein coupled signal transduction 113665-84-2 CLOPIDOGREL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 113665-84-2 CLOPIDOGREL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 113665-84-2 CLOPIDOGREL TISSUE_TOXICITY Gastrointestinal Hemorrhage 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT CVS_3_Hypertension 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT SKN_2_Rash 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_1_Gastrointestinal Hemorrhage 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Dyspepsia 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT XXX_3_Fatigue 113665-84-2 CLOPIDOGREL TISSUE_TOXICITY Agranulocytosis 113665-84-2 CLOPIDOGREL MECH_LEVEL_2 Modulate G-protein coupled signal transduction 113665-84-2 CLOPIDOGREL TA_LEVEL_2 perfusion 113665-84-2 CLOPIDOGREL MODE_CLASS Receptor Ligand Antagonist 113665-84-2 CLOPIDOGREL PRODUCT_CLASS Hematologics 113665-84-2 CLOPIDOGREL INDICATION Reduction of Atheroslerotic Events 113665-84-2 CLOPIDOGREL THERAPEUTIC_CLASS Antiplatelets 113665-84-2 CLOPIDOGREL TA_LEVEL_3 anti thrombolytics 113665-84-2 CLOPIDOGREL MECH_LEVEL_1 Antiplatelets 113665-84-2 CLOPIDOGREL MECH_LEVEL_3 adenosine receptor A2A 113665-84-2 CLOPIDOGREL MESH_LEVEL_1 Heterocyclic Compounds 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT BBM_1_Agranulocytosis 113665-84-2 CLOPIDOGREL ACTIVITY_CLASS Nucleotide receptor P2Y12 antagonist 113665-84-2 CLOPIDOGREL ADVERSE_EFFECT GIS_2_Gastritis 50-36-2 COCAINE ADVERSE_EFFECT GIS_3_Small Bowel Mesenteric Ischemia 50-36-2 COCAINE MODE_CLASS Solute transporter inhibitor 50-36-2 COCAINE ADVERSE_EFFECT CVS_2_Hypertension 50-36-2 COCAINE ADVERSE_EFFECT LUN_3_Pulmonary Edema 50-36-2 COCAINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 50-36-2 COCAINE ADVERSE_EFFECT CVS_3_Myocardial Ischemia 50-36-2 COCAINE ADVERSE_EFFECT XXX_3_Diaphoresis 50-36-2 COCAINE ADVERSE_EFFECT _3_Preterm Labor 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Hyperreflexia 50-36-2 COCAINE ADVERSE_EFFECT XXX_1_Restlessness 50-36-2 COCAINE ADVERSE_EFFECT NEU_1_Lightheadedness 50-36-2 COCAINE THERAPEUTIC_CLASS Local Anesthetics 50-36-2 COCAINE MECHANISM Prolong/enhance neural transmission 50-36-2 COCAINE THERAPEUTIC_CLASS Central Stimulants 50-36-2 COCAINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 50-36-2 COCAINE TISSUE_TOXICITY Circulatory Collapse 50-36-2 COCAINE ADVERSE_EFFECT PSY_1_Agitation 50-36-2 COCAINE ADVERSE_EFFECT XXX_3_Hyperthermia 50-36-2 COCAINE ADVERSE_EFFECT GIS_2_Abdominal Pain 50-36-2 COCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 50-36-2 COCAINE ADVERSE_EFFECT PSY_2_Hallucinations 50-36-2 COCAINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 50-36-2 COCAINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-36-2 COCAINE ADVERSE_EFFECT OCU_3_Exophthalmos 50-36-2 COCAINE ADVERSE_EFFECT PSY_2_Delirium 50-36-2 COCAINE TISSUE_TOXICITY Cardiac Arrhythmia 50-36-2 COCAINE TISSUE_TOXICITY Congestive Heart Failure 50-36-2 COCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 50-36-2 COCAINE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Tics 50-36-2 COCAINE ADVERSE_EFFECT PSY_2_Irritability 50-36-2 COCAINE ADVERSE_EFFECT PSY_3_Emotional Lability 50-36-2 COCAINE ADVERSE_EFFECT PSY_2_Confusion 50-36-2 COCAINE ADVERSE_EFFECT OCU_3_Mydriasis 50-36-2 COCAINE TISSUE_TOXICITY Cardiac Arrest 50-36-2 COCAINE TISSUE_TOXICITY Myocardial Infarction 50-36-2 COCAINE KNOWN_TOXICITY Cardiovascular Toxicity 50-36-2 COCAINE PRODUCT_CLASS Central Nervous System (CNS) 50-36-2 COCAINE ADVERSE_EFFECT CVS_1_Vasoconstriction 50-36-2 COCAINE ADVERSE_EFFECT PSY_1_Anxiety 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Headache 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Seizures 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Fecal Incontinence 50-36-2 COCAINE ADVERSE_EFFECT PSY_3_Psychosis 50-36-2 COCAINE ADVERSE_EFFECT EMB_3_Abortion 50-36-2 COCAINE ADVERSE_EFFECT XXX_3_Rhinitis 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Status Epilepticus 50-36-2 COCAINE ADVERSE_EFFECT LUN_3_Apnea 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 50-36-2 COCAINE INDICATION Local Anesthesia 50-36-2 COCAINE TISSUE_TOXICITY Myocardial Ischemia 50-36-2 COCAINE TISSUE_TOXICITY Cardiovascular Collapse 50-36-2 COCAINE ADVERSE_EFFECT EMB_3_Fetal Toxicity 50-36-2 COCAINE ADVERSE_EFFECT PSY_1_Excitement 50-36-2 COCAINE ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 50-36-2 COCAINE ADVERSE_EFFECT _3_Cheyne-Stokes respiration 50-36-2 COCAINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 50-36-2 COCAINE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Tremor 50-36-2 COCAINE ADVERSE_EFFECT NEU_2_Dizziness 50-36-2 COCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 50-36-2 COCAINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 50-36-2 COCAINE ADVERSE_EFFECT CVS_3_Circulatory Collapse 50-36-2 COCAINE ADVERSE_EFFECT LUN_2_Tachypnea 50-36-2 COCAINE ADVERSE_EFFECT XXX_3_Perforated Nasal Septum 50-36-2 COCAINE ADVERSE_EFFECT XXX_3_Sinusitis 50-36-2 COCAINE ADVERSE_EFFECT XXX_3_Nasal Congestion 1066-17-7 COLISTIN ZERO_CLASS N 1066-17-7 COLISTIN ADVERSE_EFFECT NEU_2_Slurred Speech 1066-17-7 COLISTIN ADVERSE_EFFECT KID_2_Decreased Urine Output 1066-17-7 COLISTIN STRUCTURE_ACTIVITY Impairs cell membrane function 1066-17-7 COLISTIN ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 1066-17-7 COLISTIN ADVERSE_EFFECT IMU_2_Urticaria 1066-17-7 COLISTIN MODE_CLASS Distorts /blocks macromolecular scaffold function 1066-17-7 COLISTIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 1066-17-7 COLISTIN TA_LEVEL_1 Infectious Disease 1066-17-7 COLISTIN MECH_LEVEL_1 antibacterial 1066-17-7 COLISTIN TA_LEVEL_3 topical infections 1066-17-7 COLISTIN THERAPEUTIC_CLASS Antibacterials, Topical 1066-17-7 COLISTIN ADVERSE_EFFECT LUN_2_Respiratory Arrest 1066-17-7 COLISTIN ADVERSE_EFFECT KID_2_Azotemia 1066-17-7 COLISTIN TA_LEVEL_2 Eye, Ear, Nose and Throat Preparations 1066-17-7 COLISTIN MESH_LEVEL_2 Peptides 1066-17-7 COLISTIN ADVERSE_EFFECT NEU_2_Paresthesia 1066-17-7 COLISTIN ADVERSE_EFFECT SKN_2_Pruritis 1066-17-7 COLISTIN ADVERSE_EFFECT NEU_2_Vertigo 1066-17-7 COLISTIN ACTIVITY_CLASS Antibiotic 1066-17-7 COLISTIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 1066-17-7 COLISTIN INDICATION Otitis Externa / External Otitis 1066-17-7 COLISTIN MECH_LEVEL_2 Destroy cell membrane / wall integrity 1066-17-7 COLISTIN MECH_LEVEL_3 cell membrane 1066-17-7 COLISTIN MESH_LEVEL_3 Peptides, Cyclic 1066-17-7 COLISTIN MECHANISM Destroy cell membrane / wall integrity 12643-15-1 COLISTIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 12643-15-1 COLISTIN ACTIVITY_CLASS Antibiotic 12643-15-1 COLISTIN MESH_LEVEL_2 Peptides 12643-15-1 COLISTIN MECH_LEVEL_2 Destroy cell membrane / wall integrity 12643-15-1 COLISTIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 12643-15-1 COLISTIN ADVERSE_EFFECT NEU_2_Vertigo 12643-15-1 COLISTIN ADVERSE_EFFECT SKN_2_Pruritis 12643-15-1 COLISTIN ADVERSE_EFFECT NEU_2_Paresthesia 12643-15-1 COLISTIN TA_LEVEL_2 Eye, Ear, Nose and Throat Preparations 12643-15-1 COLISTIN ADVERSE_EFFECT KID_2_Azotemia 12643-15-1 COLISTIN ADVERSE_EFFECT LUN_2_Respiratory Arrest 12643-15-1 COLISTIN THERAPEUTIC_CLASS Antibacterials, Topical 12643-15-1 COLISTIN TA_LEVEL_3 topical infections 12643-15-1 COLISTIN MECH_LEVEL_1 antibacterial 12643-15-1 COLISTIN INDICATION Otitis Externa / External Otitis 12643-15-1 COLISTIN TA_LEVEL_1 Infectious Disease 12643-15-1 COLISTIN STRUCTURE_ACTIVITY Impairs cell membrane function 12643-15-1 COLISTIN ADVERSE_EFFECT KID_2_Decreased Urine Output 12643-15-1 COLISTIN ADVERSE_EFFECT NEU_2_Slurred Speech 12643-15-1 COLISTIN ZERO_CLASS N 12643-15-1 COLISTIN MECHANISM Destroy cell membrane / wall integrity 12643-15-1 COLISTIN MESH_LEVEL_3 Peptides, Cyclic 12643-15-1 COLISTIN MECH_LEVEL_3 cell membrane 12643-15-1 COLISTIN MODE_CLASS Distorts /blocks macromolecular scaffold function 12643-15-1 COLISTIN ADVERSE_EFFECT IMU_2_Urticaria 12643-15-1 COLISTIN ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT END_2_Metabolic Disturbance 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT XXX_2_Increased Appetite 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT NEU_2_Neurological Toxicity 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT XXX_2_Weight Gain 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT GIS_2_Nausea 50-04-4 CORTISONE ACETATE MODE_CLASS Receptor Agonist 50-04-4 CORTISONE ACETATE INDICATION Chronic Adrenocortical Insufficiency / Addison's Disease 50-04-4 CORTISONE ACETATE INDICATION Edematous States 50-04-4 CORTISONE ACETATE INDICATION Neoplastic Diseases 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT OCU_2_Ocular Toxicity 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT CVS_2_Thromboembolism 50-04-4 CORTISONE ACETATE INDICATION Inflammation 50-04-4 CORTISONE ACETATE INDICATION Rheumatic Disorders 50-04-4 CORTISONE ACETATE INDICATION Endocrine Disorders 50-04-4 CORTISONE ACETATE INDICATION Allergic Diseases 50-04-4 CORTISONE ACETATE THERAPEUTIC_CLASS Corticosteroids 50-04-4 CORTISONE ACETATE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT XXX_2_Malaise 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT SKN_2_Skin Toxicity 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT IMU_2_Hypersensitivity 50-04-4 CORTISONE ACETATE TISSUE_TOXICITY Cardiotoxicity 50-04-4 CORTISONE ACETATE INDICATION Respiratory Diseases 50-04-4 CORTISONE ACETATE MECHANISM Modulate gene transcription 50-04-4 CORTISONE ACETATE INDICATION Skin Diseases / Dermatoses 50-04-4 CORTISONE ACETATE INDICATION Hematologic Disorders 50-04-4 CORTISONE ACETATE PRODUCT_CLASS Anti-inflammatories 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT END_2_Endocrine System Toxicity 50-04-4 CORTISONE ACETATE ADVERSE_EFFECT CVS_2_Cardiotoxicity 50-04-4 CORTISONE ACETATE TISSUE_TOXICITY Thromboembolism 50-04-4 CORTISONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 50-04-4 CORTISONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 50-04-4 CORTISONE ACETATE INDICATION Congenital Adrenal Hyperplasia 50-04-4 CORTISONE ACETATE INDICATION Gastrointestinal Diseases 50-04-4 CORTISONE ACETATE INDICATION Collagen Diseases 50-04-4 CORTISONE ACETATE INDICATION Ophthalmic Diseases 180683-37-8 INDINAVIR MESH_LEVEL_1 Heterocyclic Compounds 180683-37-8 INDINAVIR ADVERSE_EFFECT XXX_1_Increased Appetite 180683-37-8 INDINAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 180683-37-8 INDINAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 180683-37-8 INDINAVIR PRODUCT_CLASS Anti-infectives 180683-37-8 INDINAVIR TA_LEVEL_3 viral replication inhibitor 180683-37-8 INDINAVIR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 180683-37-8 INDINAVIR MESH_LEVEL_3 Pyridines 180683-37-8 INDINAVIR MODE_CLASS Enzyme Inhibitor 180683-37-8 INDINAVIR ADVERSE_EFFECT KID_1_Nephrolithiasis 180683-37-8 INDINAVIR ADVERSE_EFFECT CVS_3_Angina Pectoris 180683-37-8 INDINAVIR ADVERSE_EFFECT GIS_3_Dyspepsia 180683-37-8 INDINAVIR ADVERSE_EFFECT XXX_1_Hyperbilirubinemia 180683-37-8 INDINAVIR ADVERSE_EFFECT NEU_3_Dizziness 180683-37-8 INDINAVIR ADVERSE_EFFECT GIS_1_Diarrhea 180683-37-8 INDINAVIR TISSUE_TOXICITY Angina Pectoris 180683-37-8 INDINAVIR THERAPEUTIC_CLASS Antivirals, Systemic 180683-37-8 INDINAVIR MECH_LEVEL_1 Anti-viral 180683-37-8 INDINAVIR MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 180683-37-8 INDINAVIR MECH_LEVEL_2 viral protease inhibition 180683-37-8 INDINAVIR ADVERSE_EFFECT XXX_3_Malaise 180683-37-8 INDINAVIR ADVERSE_EFFECT NEU_2_Somnolence 180683-37-8 INDINAVIR ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 180683-37-8 INDINAVIR ADVERSE_EFFECT LUN_2_Cough 180683-37-8 INDINAVIR ADVERSE_EFFECT XXX_2_Fever 180683-37-8 INDINAVIR MECHANISM Inhibit post transcriptional protein processing 180683-37-8 INDINAVIR ACTIVITY_CLASS Anti-viral 180683-37-8 INDINAVIR KNOWN_TOXICITY Cardiovascular Toxicity 180683-37-8 INDINAVIR ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 180683-37-8 INDINAVIR ADVERSE_EFFECT MSK_1_Back Pain 180683-37-8 INDINAVIR ADVERSE_EFFECT GUS_3_Dysuria 180683-37-8 INDINAVIR ADVERSE_EFFECT SKN_1_Pruritis 180683-37-8 INDINAVIR ADVERSE_EFFECT GIS_3_Vomiting 180683-37-8 INDINAVIR TA_LEVEL_1 Infectious Disease 180683-37-8 INDINAVIR TA_LEVEL_2 Anti-viral 180683-37-8 INDINAVIR MECH_LEVEL_3 HIV-1 retropepsin 180683-37-8 INDINAVIR ADVERSE_EFFECT BBM_3_Anemia 180683-37-8 INDINAVIR ZERO_CLASS N 180683-37-8 INDINAVIR ADVERSE_EFFECT GIS_2_Abdominal Pain 180683-37-8 INDINAVIR ADVERSE_EFFECT XXX_3_Asthenia 86776-67-2 LEVCROMAKALIM THERAPEUTIC_CLASS Antihypertensive Agents 86776-67-2 LEVCROMAKALIM MECHANISM Reduce muscle contractile force 86776-67-2 LEVCROMAKALIM THERAPEUTIC_CLASS Parasympatholytic Agents 86776-67-2 LEVCROMAKALIM MODE_CLASS Channel enhancer /opener 86776-67-2 LEVCROMAKALIM PRODUCT_CLASS Autonomic Nervous System (ANS) 86776-67-2 LEVCROMAKALIM PRODUCT_CLASS Cardiovasculars 86776-67-2 LEVCROMAKALIM THERAPEUTIC_CLASS Vasodilators 86776-67-2 LEVCROMAKALIM PRODUCT_CLASS Respiratory System 86776-67-2 LEVCROMAKALIM THERAPEUTIC_CLASS Bronchodilators 512-15-2 CYCLOPENTOLATE INDICATION Induction of mydriasis for eye examinations 512-15-2 CYCLOPENTOLATE MECHANISM Modulate G-protein coupled signal transduction 512-15-2 CYCLOPENTOLATE PRODUCT_CLASS Other Human Uses 512-15-2 CYCLOPENTOLATE THERAPEUTIC_CLASS Parasympatholytic Agents 512-15-2 CYCLOPENTOLATE MODE_CLASS Receptor Ligand Antagonist 512-15-2 CYCLOPENTOLATE INDICATION Induction of Cycloplegia for Eye Examinations 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT NEU_2_Seizures 41354-29-4 CYPROHEPTADINE ACTIVITY_CLASS Serotonin antagonist 41354-29-4 CYPROHEPTADINE MECH_LEVEL_2 5HT antagonist 41354-29-4 CYPROHEPTADINE INDICATION Urticaria / Hives 41354-29-4 CYPROHEPTADINE THERAPEUTIC_CLASS Antihistamines 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Abdominal Pain 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Hypotension 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT XXX_2_Restlessness 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT XXX_2_Xerostomia 41354-29-4 CYPROHEPTADINE TISSUE_TOXICITY Hypotension 41354-29-4 CYPROHEPTADINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 41354-29-4 CYPROHEPTADINE TA_LEVEL_3 Allergy medication 41354-29-4 CYPROHEPTADINE KNOWN_TOXICITY Cardiovascular Toxicity 41354-29-4 CYPROHEPTADINE MESH_LEVEL_3 Piperidines 41354-29-4 CYPROHEPTADINE MECH_LEVEL_1 Immunomodulation 41354-29-4 CYPROHEPTADINE ZERO_CLASS N 41354-29-4 CYPROHEPTADINE PRODUCT_CLASS Anti-inflammatories 41354-29-4 CYPROHEPTADINE TA_LEVEL_1 Anti-inflammatory 41354-29-4 CYPROHEPTADINE INDICATION Allergic Rhinitis 41354-29-4 CYPROHEPTADINE TA_LEVEL_2 H1 antagonists 41354-29-4 CYPROHEPTADINE MECHANISM Modulate G-protein coupled signal transduction 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT OCU_2_Blurred Vision 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT PSY_2_Insomnia 41354-29-4 CYPROHEPTADINE STRUCTURE_ACTIVITY 5HT2/H1 antagonist, tricyclic 41354-29-4 CYPROHEPTADINE MESH_LEVEL_1 Heterocyclic Compounds 41354-29-4 CYPROHEPTADINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT GUS_2_Urinary Retention 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Palpitation 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Diarrhea 41354-29-4 CYPROHEPTADINE INDICATION Cold Urticaria 41354-29-4 CYPROHEPTADINE MECH_LEVEL_3 5HT receptor 2 41354-29-4 CYPROHEPTADINE INDICATION Allergic Conjunctivitis 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT NEU_1_Drowsiness 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Constipation 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 41354-29-4 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 87233-62-3 EMEDASTINE INDICATION Pruritus / Itching 87233-62-3 EMEDASTINE PRODUCT_CLASS Anti-inflammatories 87233-62-3 EMEDASTINE THERAPEUTIC_CLASS Antihistamines 87233-62-3 EMEDASTINE INDICATION Urticaria / Hives 87233-62-3 EMEDASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 87233-62-3 EMEDASTINE INDICATION Allergic Rhinitis 87233-62-3 EMEDASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 87233-62-3 EMEDASTINE MECHANISM Modulate G-protein coupled signal transduction 87233-62-3 EMEDASTINE INDICATION Atopic Dermatitis / Eczema 87233-62-3 EMEDASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 87233-62-3 EMEDASTINE INDICATION Allergic Conjunctivitis 76095-16-4 ENALAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 76095-16-4 ENALAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 76095-16-4 ENALAPRIL KNOWN_TOXICITY Cardiovascular Toxicity 76095-16-4 ENALAPRIL TISSUE_TOXICITY Renal Failure 76095-16-4 ENALAPRIL ADVERSE_EFFECT LUN_1_Cough 76095-16-4 ENALAPRIL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 76095-16-4 ENALAPRIL ACTIVITY_CLASS RAAS inhibitor 76095-16-4 ENALAPRIL ADVERSE_EFFECT GIS_2_Abdominal Pain 76095-16-4 ENALAPRIL ADVERSE_EFFECT GUS_3_Urinary Tract Infection 76095-16-4 ENALAPRIL KNOWN_TOXICITY Nephrotoxicity 76095-16-4 ENALAPRIL MECH_LEVEL_2 ACE inhibitor 76095-16-4 ENALAPRIL ADVERSE_EFFECT XXX_1_Fatigue 76095-16-4 ENALAPRIL ADVERSE_EFFECT SKN_1_Rash 76095-16-4 ENALAPRIL ADVERSE_EFFECT BBM_3_Bone Marrow Depression 76095-16-4 ENALAPRIL ADVERSE_EFFECT KID_3_Renal Failure 76095-16-4 ENALAPRIL ADVERSE_EFFECT NEU_2_Syncope 76095-16-4 ENALAPRIL ADVERSE_EFFECT GIS_2_Nausea 76095-16-4 ENALAPRIL MESH_LEVEL_3 Oligopeptides 76095-16-4 ENALAPRIL MESH_LEVEL_2 Peptides 76095-16-4 ENALAPRIL ADVERSE_EFFECT GIS_1_Vomiting 76095-16-4 ENALAPRIL ADVERSE_EFFECT NEU_2_Dizziness 76095-16-4 ENALAPRIL INDICATION Hypertension 76095-16-4 ENALAPRIL ADVERSE_EFFECT NEU_1_Vertigo 76095-16-4 ENALAPRIL ADVERSE_EFFECT XXX_2_Asthenia 76095-16-4 ENALAPRIL ADVERSE_EFFECT GIS_2_Diarrhea 76095-16-4 ENALAPRIL ADVERSE_EFFECT CVS_3_Myocardial Infarction 76095-16-4 ENALAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 76095-16-4 ENALAPRIL TA_LEVEL_2 Hypertension 76095-16-4 ENALAPRIL TA_LEVEL_3 Diuretic 76095-16-4 ENALAPRIL TA_LEVEL_1 Cardiovascular 76095-16-4 ENALAPRIL ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 76095-16-4 ENALAPRIL MECHANISM Reduce vasoconstriction 76095-16-4 ENALAPRIL ADVERSE_EFFECT NEU_2_Headache 76095-16-4 ENALAPRIL ADVERSE_EFFECT LUN_1_Dyspnea 76095-16-4 ENALAPRIL ADVERSE_EFFECT CVS_2_Chest Pain 76095-16-4 ENALAPRIL MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 76095-16-4 ENALAPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 76095-16-4 ENALAPRIL INDICATION Congestive Heart Failure (CHF) 76095-16-4 ENALAPRIL MECH_LEVEL_1 Vasorelaxation 76095-16-4 ENALAPRIL PRODUCT_CLASS Cardiovasculars 76095-16-4 ENALAPRIL TISSUE_TOXICITY Myocardial Infarction 76095-16-4 ENALAPRIL MODE_CLASS Enzyme Inhibitor 76095-16-4 ENALAPRIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 66778-36-7 ENCAINIDE ADVERSE_EFFECT OTO_2_Tinnitus 66778-36-7 ENCAINIDE ADVERSE_EFFECT OCU_3_Diplopia 66778-36-7 ENCAINIDE INDICATION Ventricular Tachycardia 66778-36-7 ENCAINIDE ADVERSE_EFFECT CVS_2_Arrhythmia 66778-36-7 ENCAINIDE PRODUCT_CLASS Cardiovasculars 66778-36-7 ENCAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 66778-36-7 ENCAINIDE TISSUE_TOXICITY Death 66778-36-7 ENCAINIDE TISSUE_TOXICITY Ventricular Fibrillation 66778-36-7 ENCAINIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 66778-36-7 ENCAINIDE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 66778-36-7 ENCAINIDE ADVERSE_EFFECT NEU_3_Ataxia 66778-36-7 ENCAINIDE ADVERSE_EFFECT NEU_1_Somnolence 66778-36-7 ENCAINIDE ADVERSE_EFFECT CVS_3_Cardiac Insufficiency 66778-36-7 ENCAINIDE MECHANISM Block neural transmission 66778-36-7 ENCAINIDE TISSUE_TOXICITY Arrhythmia 66778-36-7 ENCAINIDE KNOWN_TOXICITY Miscellaneous 66778-36-7 ENCAINIDE ADVERSE_EFFECT NEU_1_Tremor 66778-36-7 ENCAINIDE ADVERSE_EFFECT NEU_1_Dizziness 66778-36-7 ENCAINIDE ADVERSE_EFFECT XXX_3_Death 66778-36-7 ENCAINIDE ADVERSE_EFFECT OCU_2_Visual Disturbances 66778-36-7 ENCAINIDE ADVERSE_EFFECT OCU_3_Abnormal Vision 66778-36-7 ENCAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 66778-36-7 ENCAINIDE INDICATION Ventricular Arrhythmias 66778-36-7 ENCAINIDE ADVERSE_EFFECT CVS_3_Heart Failure 66778-36-7 ENCAINIDE MODE_CLASS Channel Blocker 66778-36-7 ENCAINIDE TISSUE_TOXICITY Cardiac Insufficiency 66778-36-7 ENCAINIDE TISSUE_TOXICITY Heart Failure 66778-36-7 ENCAINIDE ADVERSE_EFFECT PSY_1_Nervousness 66778-36-7 ENCAINIDE ADVERSE_EFFECT END_3_Hyperglycemia 66778-36-7 ENCAINIDE ADVERSE_EFFECT LUN_2_Dyspnea 66778-36-7 ENCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 66778-36-7 ENCAINIDE INDICATION Ventricular Premature Beats (Ventricular Extrasystoles) 66778-36-7 ENCAINIDE TISSUE_TOXICITY Cardiac Conduction System Malfunction 66778-36-7 ENCAINIDE ADVERSE_EFFECT PSY_1_Insomnia 66778-36-7 ENCAINIDE ADVERSE_EFFECT NEU_1_Headache 66778-36-7 ENCAINIDE ADVERSE_EFFECT CVS_3_Cardiac Conduction System Malfunction 133180-79-7 ENTACAPONE MECHANISM Interferes with neural transmitter synthesis 133180-79-7 ENTACAPONE MODE_CLASS Enzyme Inhibitor, selective 133180-79-7 ENTACAPONE INDICATION Parkinson's Disease 140111-52-0 EPIBATIDINE MODE_CLASS Channel Modulator 140111-52-0 EPIBATIDINE MECHANISM Prolong/enhance neural transmission 140111-52-0 EPIBATIDINE PRODUCT_CLASS Analgesics 140111-52-0 EPIBATIDINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 35121-78-9 PROSTACYCLIN THERAPEUTIC_CLASS Antiplatelets 35121-78-9 PROSTACYCLIN MODE_CLASS Receptor Agonist 35121-78-9 PROSTACYCLIN THERAPEUTIC_CLASS Antihypertensive Agents 35121-78-9 PROSTACYCLIN PRODUCT_CLASS Cardiovasculars 35121-78-9 PROSTACYCLIN MECHANISM Modulate G-protein coupled signal transduction 35121-78-9 PROSTACYCLIN INDICATION Hypertension 35121-78-9 PROSTACYCLIN PRODUCT_CLASS Hematologics 148031-34-9 EPTIFIBATIDE PRODUCT_CLASS Hematologics 148031-34-9 EPTIFIBATIDE INDICATION Percutaneous Coronary Intervention 148031-34-9 EPTIFIBATIDE MODE_CLASS Receptor Ligand Antagonist, Selective 148031-34-9 EPTIFIBATIDE INDICATION Acute Myocardial Infarction 148031-34-9 EPTIFIBATIDE THERAPEUTIC_CLASS Antiplatelets 148031-34-9 EPTIFIBATIDE MECHANISM Inhibit platelet aggregation 148031-34-9 EPTIFIBATIDE INDICATION Unstable Angina 148031-34-9 EPTIFIBATIDE INDICATION Myocardial Infarction Prophylaxis 60-79-7 ERGONOVINE THERAPEUTIC_CLASS Oxytocic 60-79-7 ERGONOVINE TISSUE_TOXICITY Myocardial Infarction 60-79-7 ERGONOVINE PRODUCT_CLASS Other Human Uses 60-79-7 ERGONOVINE ADVERSE_EFFECT OCU_3_Retinal Detachment 60-79-7 ERGONOVINE ADVERSE_EFFECT EMB_2_Fetal Distress 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_3_Valvular Disorders 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_3_Stroke 60-79-7 ERGONOVINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_2_Vasoconstriction 60-79-7 ERGONOVINE ADVERSE_EFFECT LUN_3_Respiratory Depression 60-79-7 ERGONOVINE TISSUE_TOXICITY Renal Tubular Necrosis 60-79-7 ERGONOVINE MODE_CLASS Receptor Ligand Antagonist 60-79-7 ERGONOVINE TISSUE_TOXICITY Thrombosis 60-79-7 ERGONOVINE MECHANISM Modulate G-protein coupled signal transduction 60-79-7 ERGONOVINE ADVERSE_EFFECT GIS_3_Dysgeusia 60-79-7 ERGONOVINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 60-79-7 ERGONOVINE ADVERSE_EFFECT MSK_2_Muscle Cramps 60-79-7 ERGONOVINE ADVERSE_EFFECT REP_2_Uterine Contractions 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 60-79-7 ERGONOVINE ADVERSE_EFFECT GIS_2_Diarrhea 60-79-7 ERGONOVINE KNOWN_TOXICITY Cardiovascular Toxicity 60-79-7 ERGONOVINE TISSUE_TOXICITY Valvular Disorders 60-79-7 ERGONOVINE MODE_CLASS Receptor Partial Agonist 60-79-7 ERGONOVINE ADVERSE_EFFECT EMB_3_Fetal Death 60-79-7 ERGONOVINE ADVERSE_EFFECT REP_3_Rupture of Uterus 60-79-7 ERGONOVINE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 60-79-7 ERGONOVINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 60-79-7 ERGONOVINE ADVERSE_EFFECT OCU_3_Blurred Vision 60-79-7 ERGONOVINE KNOWN_TOXICITY Nephrotoxicity 60-79-7 ERGONOVINE INDICATION Uterine Atony 60-79-7 ERGONOVINE INDICATION Postpartum Hemorrhage 60-79-7 ERGONOVINE ADVERSE_EFFECT NEU_3_Coma 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_3_Thrombosis 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_3_Coronary Vasospasm 60-79-7 ERGONOVINE ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 60-79-7 ERGONOVINE ADVERSE_EFFECT NEU_3_Seizures 60-79-7 ERGONOVINE ADVERSE_EFFECT XXX_1_Edema 60-79-7 ERGONOVINE ADVERSE_EFFECT CVS_2_Hypertension 60-79-7 ERGONOVINE STRUCTURE_ACTIVITY Ergot alkaloid 60-79-7 ERGONOVINE TISSUE_TOXICITY Stroke 114-07-8 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 114-07-8 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 114-07-8 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 114-07-8 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 114-07-8 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 114-07-8 ERYTHROMYCIN INDICATION Syphilis 114-07-8 ERYTHROMYCIN INDICATION Proctitis 114-07-8 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 114-07-8 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 114-07-8 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 114-07-8 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 114-07-8 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 114-07-8 ERYTHROMYCIN ZERO_CLASS N 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 114-07-8 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 114-07-8 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 114-07-8 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 114-07-8 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 114-07-8 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 114-07-8 ERYTHROMYCIN INDICATION Erythrasma 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 114-07-8 ERYTHROMYCIN INDICATION Amebiasis 114-07-8 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 114-07-8 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 114-07-8 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 114-07-8 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 114-07-8 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 114-07-8 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 114-07-8 ERYTHROMYCIN INDICATION Surgical Prophylaxis 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 114-07-8 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 114-07-8 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 114-07-8 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 114-07-8 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 114-07-8 ERYTHROMYCIN INDICATION Sinusitis 114-07-8 ERYTHROMYCIN INDICATION Cervicitis 114-07-8 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 114-07-8 ERYTHROMYCIN INDICATION Urethritis 114-07-8 ERYTHROMYCIN INDICATION Otitis Media 114-07-8 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 114-07-8 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 114-07-8 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 114-07-8 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 114-07-8 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 114-07-8 ERYTHROMYCIN INDICATION Burn Wound Infection 114-07-8 ERYTHROMYCIN INDICATION Pharyngitis 114-07-8 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 114-07-8 ERYTHROMYCIN INDICATION Pneumonia 114-07-8 ERYTHROMYCIN INDICATION Diphtheria 114-07-8 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 114-07-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 47880-49-9 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 47880-49-9 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 47880-49-9 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 47880-49-9 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 47880-49-9 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 47880-49-9 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 47880-49-9 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 47880-49-9 ERYTHROMYCIN INDICATION Amebiasis 47880-49-9 ERYTHROMYCIN INDICATION Surgical Prophylaxis 47880-49-9 ERYTHROMYCIN INDICATION Erythrasma 47880-49-9 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 47880-49-9 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 47880-49-9 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 47880-49-9 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 47880-49-9 ERYTHROMYCIN ZERO_CLASS N 47880-49-9 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 47880-49-9 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 47880-49-9 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 47880-49-9 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 47880-49-9 ERYTHROMYCIN INDICATION Proctitis 47880-49-9 ERYTHROMYCIN INDICATION Syphilis 47880-49-9 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 47880-49-9 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 47880-49-9 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 47880-49-9 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 47880-49-9 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 47880-49-9 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 47880-49-9 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 47880-49-9 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 47880-49-9 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 47880-49-9 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 47880-49-9 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 47880-49-9 ERYTHROMYCIN INDICATION Sinusitis 47880-49-9 ERYTHROMYCIN INDICATION Cervicitis 47880-49-9 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 47880-49-9 ERYTHROMYCIN INDICATION Urethritis 47880-49-9 ERYTHROMYCIN INDICATION Otitis Media 47880-49-9 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 47880-49-9 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 47880-49-9 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 47880-49-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 47880-49-9 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 47880-49-9 ERYTHROMYCIN INDICATION Burn Wound Infection 47880-49-9 ERYTHROMYCIN INDICATION Pharyngitis 47880-49-9 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 47880-49-9 ERYTHROMYCIN INDICATION Pneumonia 47880-49-9 ERYTHROMYCIN INDICATION Diphtheria 47880-49-9 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 81161-17-3 ESMOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 81161-17-3 ESMOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 81161-17-3 ESMOLOL MECH_LEVEL_1 Reduce cardiac contractility 81161-17-3 ESMOLOL ADVERSE_EFFECT CVS_1_Hypotension 81161-17-3 ESMOLOL TA_LEVEL_3 Beta blocker 81161-17-3 ESMOLOL INDICATION Paroxysmal Supraventricular Tachycardia 81161-17-3 ESMOLOL ADVERSE_EFFECT CVS_3_Phlebitis 81161-17-3 ESMOLOL ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 81161-17-3 ESMOLOL MECH_LEVEL_2 Beta antagonist 81161-17-3 ESMOLOL TISSUE_TOXICITY Atrioventricular Blockade 81161-17-3 ESMOLOL INDICATION Atrial Fibrillation 81161-17-3 ESMOLOL TA_LEVEL_1 Cardiovascular 81161-17-3 ESMOLOL MESH_LEVEL_3 Amino Alcohols 81161-17-3 ESMOLOL MECH_LEVEL_3 adrenoceptor beta1 81161-17-3 ESMOLOL MESH_LEVEL_1 Organic Chemicals 81161-17-3 ESMOLOL ADVERSE_EFFECT NEU_2_Headache 81161-17-3 ESMOLOL TISSUE_TOXICITY Cardiac Arrest 81161-17-3 ESMOLOL INDICATION Atrial Flutter 81161-17-3 ESMOLOL TA_LEVEL_2 Hypertension 81161-17-3 ESMOLOL MECHANISM Reduce muscle contractile force 81161-17-3 ESMOLOL ADVERSE_EFFECT NEU_2_Dizziness 81161-17-3 ESMOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 81161-17-3 ESMOLOL ACTIVITY_CLASS Adrenergic antagonist 81161-17-3 ESMOLOL KNOWN_TOXICITY Cardiovascular Toxicity 81161-17-3 ESMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 81161-17-3 ESMOLOL PRODUCT_CLASS Cardiovasculars 81161-17-3 ESMOLOL MESH_LEVEL_2 Alcohols 81161-17-3 ESMOLOL INDICATION Hypertension 81161-17-3 ESMOLOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 81161-17-3 ESMOLOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 81161-17-3 ESMOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, p-phenoxypropanoamine 81161-17-3 ESMOLOL TISSUE_TOXICITY Hypotension 50-27-1 ESTRIOL MESH_LEVEL_1 Polycyclic Hydrocarbons 50-27-1 ESTRIOL ADVERSE_EFFECT REP_3_Breakthrough Bleeding 50-27-1 ESTRIOL ADVERSE_EFFECT XXX_2_Decreased Appetite 50-27-1 ESTRIOL ADVERSE_EFFECT END_1_Breast Tenderness 50-27-1 ESTRIOL ADVERSE_EFFECT DNA_3_Carcinogenicity 50-27-1 ESTRIOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 50-27-1 ESTRIOL INDICATION Atrophic Vaginitis 50-27-1 ESTRIOL ADVERSE_EFFECT XXX_2_Weight Loss 50-27-1 ESTRIOL ADVERSE_EFFECT CVS_2_Hypertension 50-27-1 ESTRIOL TISSUE_TOXICITY Carcinogenicity 50-27-1 ESTRIOL MECHANISM Modulate gene transcription 50-27-1 ESTRIOL ZERO_CLASS N 50-27-1 ESTRIOL THERAPEUTIC_CLASS Gonadal Hormones 50-27-1 ESTRIOL MECH_LEVEL_2 estrogen receptor agonist 50-27-1 ESTRIOL MECH_LEVEL_3 estrogen receptor 50-27-1 ESTRIOL ADVERSE_EFFECT DNA_2_Increased Incidence of Breast Carcinoma 50-27-1 ESTRIOL ACTIVITY_CLASS Estrogen agonist 50-27-1 ESTRIOL KNOWN_TOXICITY Carcinogenicity 50-27-1 ESTRIOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 50-27-1 ESTRIOL MESH_LEVEL_3 Estranes 50-27-1 ESTRIOL ADVERSE_EFFECT LIV_2_Liver Dysfunction 50-27-1 ESTRIOL ADVERSE_EFFECT GUS_1_Vaginal Irritation 50-27-1 ESTRIOL TA_LEVEL_3 SERM 50-27-1 ESTRIOL TA_LEVEL_2 post-menapause 50-27-1 ESTRIOL TISSUE_TOXICITY Increased Incidence of Breast Carcinoma 50-27-1 ESTRIOL STRUCTURE_ACTIVITY Estrogen receptor agonist, steroidal 50-27-1 ESTRIOL MODE_CLASS Endogenous Receptor /Channel Ligand 50-27-1 ESTRIOL MECH_LEVEL_1 Hormone replacement 50-27-1 ESTRIOL MESH_LEVEL_2 Steroids 71245-23-3 ETACONAZOLE PRODUCT_CLASS Anti-infectives 71245-23-3 ETACONAZOLE THERAPEUTIC_CLASS Antifungals 71245-23-3 ETACONAZOLE MODE_CLASS Enzyme Inhibitor 71245-23-3 ETACONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 113-18-8 ETHCHLORVYNOL INDICATION Insomnia 113-18-8 ETHCHLORVYNOL THERAPEUTIC_CLASS Sedatives/Hypnotics 113-18-8 ETHCHLORVYNOL PRODUCT_CLASS Central Nervous System (CNS) 8060-73-9 ETHOSUXIMIDE INDICATION Absence (Petit Mal) Seizures 8060-73-9 ETHOSUXIMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 8060-73-9 ETHOSUXIMIDE MODE_CLASS Channel Blocker, selective 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT END_3_Hirsutism 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 8060-73-9 ETHOSUXIMIDE MESH_LEVEL_3 Pyrrolidines 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT PSY_2_Irritability 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Epigastric Pain 8060-73-9 ETHOSUXIMIDE PRODUCT_CLASS Central Nervous System (CNS) 8060-73-9 ETHOSUXIMIDE TA_LEVEL_3 Absence Seizures 8060-73-9 ETHOSUXIMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT GIS_3_Gingival Hyperplasia 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT PSY_2_Euphoria 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT GIS_3_Swelling of Tongue 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 8060-73-9 ETHOSUXIMIDE MECH_LEVEL_2 Decrease neural membrane excitability 8060-73-9 ETHOSUXIMIDE MECH_LEVEL_3 T-Type Ca++ channel CaV3.3 8060-73-9 ETHOSUXIMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT NEU_3_Ataxia 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT PSY_3_Psychosis 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT SKN_2_Skin Rash 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT PSY_3_Depression 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 8060-73-9 ETHOSUXIMIDE ACTIVITY_CLASS Na+ channel blocker 8060-73-9 ETHOSUXIMIDE TA_LEVEL_2 CNS Depressant 8060-73-9 ETHOSUXIMIDE MECHANISM Reduce muscle contractile force 8060-73-9 ETHOSUXIMIDE ZERO_CLASS N 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT NEU_1_Drowsiness 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Leukopenia 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Diarrhea 8060-73-9 ETHOSUXIMIDE ADVERSE_EFFECT NEU_1_Headache 8060-73-9 ETHOSUXIMIDE MECH_LEVEL_1 Modulate neural transmission 8060-73-9 ETHOSUXIMIDE TA_LEVEL_1 Central Nervous System (CNS) 8060-73-9 ETHOSUXIMIDE MESH_LEVEL_1 Heterocyclic Compounds 36637-19-1 ETIDOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 36637-19-1 ETIDOCAINE MECHANISM Block neural transmission 36637-19-1 ETIDOCAINE MODE_CLASS Channel Blocker 36637-19-1 ETIDOCAINE PRODUCT_CLASS Central Nervous System (CNS) 36637-19-1 ETIDOCAINE THERAPEUTIC_CLASS Local Anesthetics 187285-10-5 ETIDRONATE ADVERSE_EFFECT MSK_2_Arthropathy 187285-10-5 ETIDRONATE ADVERSE_EFFECT GIS_2_Exacerbation of Peptic Ulcer Disease 187285-10-5 ETIDRONATE MECH_LEVEL_3 Farnesyl-diphosphate farnesyltransferase 187285-10-5 ETIDRONATE MECH_LEVEL_1 Inhibit bone re-absorption 187285-10-5 ETIDRONATE MECHANISM Inhibit bone re-absorption 187285-10-5 ETIDRONATE INDICATION Hypercalcemia of Malignancy 187285-10-5 ETIDRONATE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 187285-10-5 ETIDRONATE KNOWN_TOXICITY Embryo/Fetal Toxicity 187285-10-5 ETIDRONATE ADVERSE_EFFECT EMB_3_Teratogenicity 187285-10-5 ETIDRONATE TISSUE_TOXICITY Teratogenicity 187285-10-5 ETIDRONATE ADVERSE_EFFECT NEU_1_Headache 187285-10-5 ETIDRONATE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 187285-10-5 ETIDRONATE ADVERSE_EFFECT GIS_2_Esophagitis 187285-10-5 ETIDRONATE ADVERSE_EFFECT MSK_2_Increased Risk of Bone Fracture 187285-10-5 ETIDRONATE ZERO_CLASS N 187285-10-5 ETIDRONATE ADVERSE_EFFECT NEU_3_Amnesia 187285-10-5 ETIDRONATE ADVERSE_EFFECT NEU_3_Paresthesia 187285-10-5 ETIDRONATE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 187285-10-5 ETIDRONATE ADVERSE_EFFECT END_3_Osteomalacia 187285-10-5 ETIDRONATE ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 187285-10-5 ETIDRONATE MESH_LEVEL_1 Organic Chemicals 187285-10-5 ETIDRONATE INDICATION Heterotopic Ossification 187285-10-5 ETIDRONATE MODE_CLASS Enzyme Inhibitor 187285-10-5 ETIDRONATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 187285-10-5 ETIDRONATE ADVERSE_EFFECT GIS_1_Diarrhea 187285-10-5 ETIDRONATE ADVERSE_EFFECT BBM_3_Agranulocytosis 187285-10-5 ETIDRONATE ADVERSE_EFFECT GIS_2_Gastritis 187285-10-5 ETIDRONATE ADVERSE_EFFECT END_2_Hyperphosphatemia 187285-10-5 ETIDRONATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 187285-10-5 ETIDRONATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 187285-10-5 ETIDRONATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 187285-10-5 ETIDRONATE ADVERSE_EFFECT MSK_1_Bone Pain 187285-10-5 ETIDRONATE MESH_LEVEL_3 Diphosphonates 187285-10-5 ETIDRONATE TA_LEVEL_3 Bisphosphonate 187285-10-5 ETIDRONATE TA_LEVEL_2 Oesteoporosis 187285-10-5 ETIDRONATE INDICATION Paget's Disease of Bone / Osteitis Deformans 187285-10-5 ETIDRONATE MECH_LEVEL_2 Inhibit osteoclastic bone resorption via cholesterol biosynthesis pathway 187285-10-5 ETIDRONATE INDICATION Osteoporosis 187285-10-5 ETIDRONATE MESH_LEVEL_2 Organophosphorus Compounds 187285-10-5 ETIDRONATE ADVERSE_EFFECT GIS_1_Nausea 187285-10-5 ETIDRONATE ADVERSE_EFFECT PSY_3_Confusion 187285-10-5 ETIDRONATE ADVERSE_EFFECT BBM_3_Pancytopenia 470-82-6 EUCALYPTOL THERAPEUTIC_CLASS Analgesics, Topical 470-82-6 EUCALYPTOL STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 470-82-6 EUCALYPTOL ADVERSE_EFFECT LUN_3_Respiratory Depression 470-82-6 EUCALYPTOL ADVERSE_EFFECT GIS_3_Gastric Irritation 470-82-6 EUCALYPTOL ADVERSE_EFFECT LUN_3_Tachypnea 470-82-6 EUCALYPTOL ZERO_CLASS Y 470-82-6 EUCALYPTOL ADVERSE_EFFECT GIS_3_Diarrhea 470-82-6 EUCALYPTOL ACTIVITY_CLASS Unknown mechanism 470-82-6 EUCALYPTOL TISSUE_TOXICITY Hypotension 470-82-6 EUCALYPTOL KNOWN_TOXICITY Cardiovascular Toxicity 470-82-6 EUCALYPTOL INDICATION Neuropathic Pain 470-82-6 EUCALYPTOL PRODUCT_CLASS Analgesics 470-82-6 EUCALYPTOL TA_LEVEL_1 Respiratory System 470-82-6 EUCALYPTOL INDICATION Chronic Bronchitis 470-82-6 EUCALYPTOL ADVERSE_EFFECT CVS_3_Increased Heart Rate 470-82-6 EUCALYPTOL ADVERSE_EFFECT CVS_3_Hypotension 470-82-6 EUCALYPTOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 470-82-6 EUCALYPTOL ADVERSE_EFFECT NEU_3_Convulsions 470-82-6 EUCALYPTOL THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 470-82-6 EUCALYPTOL MECH_LEVEL_3 Unknown mechanism 470-82-6 EUCALYPTOL MECH_LEVEL_1 Immunomodulation 470-82-6 EUCALYPTOL MECH_LEVEL_2 cytokine production, inhibition 470-82-6 EUCALYPTOL INDICATION Migraine Headache 470-82-6 EUCALYPTOL MECHANISM Modulate G-protein coupled signal transduction 470-82-6 EUCALYPTOL MESH_LEVEL_1 Organic Chemicals 470-82-6 EUCALYPTOL MESH_LEVEL_2 Hydrocarbons 470-82-6 EUCALYPTOL ADVERSE_EFFECT GUS_3_Cystitis 470-82-6 EUCALYPTOL INDICATION Bronchopulmonary Infection 470-82-6 EUCALYPTOL PRODUCT_CLASS Respiratory System 470-82-6 EUCALYPTOL TA_LEVEL_2 Anti-tussive 470-82-6 EUCALYPTOL MESH_LEVEL_3 Terpenes 470-82-6 EUCALYPTOL ADVERSE_EFFECT NEU_3_Psychomotor Excitation 470-82-6 EUCALYPTOL ADVERSE_EFFECT NEU_3_Stupor 1518-86-1 HYDROXYAMPHETAMINE MODE_CLASS Receptor Partial Agonist 1518-86-1 HYDROXYAMPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 1518-86-1 HYDROXYAMPHETAMINE INDICATION Induction of Cycloplegia for Eye Examinations 1518-86-1 HYDROXYAMPHETAMINE PRODUCT_CLASS Other Human Uses 1518-86-1 HYDROXYAMPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 1518-86-1 HYDROXYAMPHETAMINE MODE_CLASS Enzyme substrate mimic 1518-86-1 HYDROXYAMPHETAMINE INDICATION Induction of mydriasis for eye examinations 1518-86-1 HYDROXYAMPHETAMINE MECHANISM Prolong/enhance neural transmission 1518-86-1 HYDROXYAMPHETAMINE MECHANISM Block channel gating 1518-86-1 HYDROXYAMPHETAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 1518-86-1 HYDROXYAMPHETAMINE MODE_CLASS Solute transporter inhibitor 68-88-2 HYDROXYZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_2_Headache 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_2_Ataxia 68-88-2 HYDROXYZINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 68-88-2 HYDROXYZINE PRODUCT_CLASS Anti-inflammatories 68-88-2 HYDROXYZINE INDICATION Nausea / Vomiting 68-88-2 HYDROXYZINE ADVERSE_EFFECT PSY_3_CNS Stimulation 68-88-2 HYDROXYZINE ADVERSE_EFFECT OCU_1_Mydriasis 68-88-2 HYDROXYZINE ADVERSE_EFFECT XXX_3_Weakness 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_3_Seizures 68-88-2 HYDROXYZINE ADVERSE_EFFECT XXX_1_Xerostomia 68-88-2 HYDROXYZINE INDICATION Alcoholic Withdrawal 68-88-2 HYDROXYZINE MECHANISM Modulate G-protein coupled signal transduction 68-88-2 HYDROXYZINE PRODUCT_CLASS Central Nervous System (CNS) 68-88-2 HYDROXYZINE INDICATION Pruritus / Itching 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_3_Tremor 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_2_Drowsiness 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_2_Dysarthria 68-88-2 HYDROXYZINE INDICATION Initiation / Maintenance of Sedation 68-88-2 HYDROXYZINE INDICATION Anxiety 68-88-2 HYDROXYZINE THERAPEUTIC_CLASS Antihistamines 68-88-2 HYDROXYZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 68-88-2 HYDROXYZINE ADVERSE_EFFECT NEU_2_Dizziness 68-88-2 HYDROXYZINE ADVERSE_EFFECT PSY_2_Agitation 68-88-2 HYDROXYZINE MODE_CLASS Receptor Ligand Antagonist 68-88-2 HYDROXYZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 68-88-2 HYDROXYZINE INDICATION Insomnia 68-88-2 HYDROXYZINE ADVERSE_EFFECT GUS_1_Urinary Retention 68-88-2 HYDROXYZINE ADVERSE_EFFECT PSY_3_Anxiety 2552-55-8 IBOTENIC ACID MODE_CLASS Receptor Agonist 2552-55-8 IBOTENIC ACID MECHANISM Modulate G-protein coupled signal transduction 2552-55-8 IBOTENIC ACID PRODUCT_CLASS Biochemicals 130350-52-6 IBUTILIDE MECHANISM Modulate channel gating 130350-52-6 IBUTILIDE PRODUCT_CLASS Cardiovasculars 130350-52-6 IBUTILIDE INDICATION Atrial Flutter 130350-52-6 IBUTILIDE INDICATION Atrial Fibrillation 130350-52-6 IBUTILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 130350-52-6 IBUTILIDE MODE_CLASS Channel Blocker 57852-57-0 IDARUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 57852-57-0 IDARUBICIN TISSUE_TOXICITY Myocardial Infarction 57852-57-0 IDARUBICIN TISSUE_TOXICITY Mutagenicity 57852-57-0 IDARUBICIN MECH_LEVEL_3 DNA Damage 57852-57-0 IDARUBICIN TA_LEVEL_3 AML treatment 57852-57-0 IDARUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 57852-57-0 IDARUBICIN TA_LEVEL_1 Oncology 57852-57-0 IDARUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 57852-57-0 IDARUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 57852-57-0 IDARUBICIN THERAPEUTIC_CLASS Antineoplastics 57852-57-0 IDARUBICIN TISSUE_TOXICITY Hepatotoxicity 57852-57-0 IDARUBICIN KNOWN_TOXICITY Nephrotoxicity 57852-57-0 IDARUBICIN KNOWN_TOXICITY Mutagenicity 57852-57-0 IDARUBICIN ADVERSE_EFFECT GIS_1_Abdominal Cramps 57852-57-0 IDARUBICIN ADVERSE_EFFECT GIS_1_Diarrhea 57852-57-0 IDARUBICIN ADVERSE_EFFECT GIS_3_Colitis 57852-57-0 IDARUBICIN ADVERSE_EFFECT CVS_2_Chest Pain 57852-57-0 IDARUBICIN ADVERSE_EFFECT KID_3_Nephrotoxicity 57852-57-0 IDARUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 57852-57-0 IDARUBICIN ADVERSE_EFFECT GIS_3_Enterocolitis 57852-57-0 IDARUBICIN TISSUE_TOXICITY Cardiomyopathy 57852-57-0 IDARUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 57852-57-0 IDARUBICIN ACTIVITY_CLASS DNA damager 57852-57-0 IDARUBICIN MESH_LEVEL_2 Carbohydrates 57852-57-0 IDARUBICIN KNOWN_TOXICITY Hepatotoxicity 57852-57-0 IDARUBICIN TISSUE_TOXICITY Hemorrhage 57852-57-0 IDARUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 57852-57-0 IDARUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 57852-57-0 IDARUBICIN ADVERSE_EFFECT NEU_1_Headache 57852-57-0 IDARUBICIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 57852-57-0 IDARUBICIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 57852-57-0 IDARUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 57852-57-0 IDARUBICIN ADVERSE_EFFECT GIS_3_Bowel Perforation 57852-57-0 IDARUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 57852-57-0 IDARUBICIN TISSUE_TOXICITY Atrial Fibrillation 57852-57-0 IDARUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 57852-57-0 IDARUBICIN PRODUCT_CLASS Anti-cancers 57852-57-0 IDARUBICIN TA_LEVEL_2 Soft tissue tumors 57852-57-0 IDARUBICIN ADVERSE_EFFECT XXX_1_Mucositis 57852-57-0 IDARUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 57852-57-0 IDARUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57852-57-0 IDARUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 57852-57-0 IDARUBICIN ADVERSE_EFFECT IMU_2_Urticaria 57852-57-0 IDARUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 57852-57-0 IDARUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 57852-57-0 IDARUBICIN ADVERSE_EFFECT XXX_1_Local Tissue Necrosis 57852-57-0 IDARUBICIN TISSUE_TOXICITY Myelosuppression 57852-57-0 IDARUBICIN TISSUE_TOXICITY Nephrotoxicity 57852-57-0 IDARUBICIN TISSUE_TOXICITY Carcinogenicity 57852-57-0 IDARUBICIN TISSUE_TOXICITY Cardiotoxicity 57852-57-0 IDARUBICIN MESH_LEVEL_3 Aminoglycoside 57852-57-0 IDARUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 57852-57-0 IDARUBICIN TISSUE_TOXICITY Congestive Heart Failure 57852-57-0 IDARUBICIN KNOWN_TOXICITY Carcinogenicity 57852-57-0 IDARUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 57852-57-0 IDARUBICIN ADVERSE_EFFECT XXX_1_Infection 57852-57-0 IDARUBICIN ADVERSE_EFFECT SKN_2_Skin Rash 57852-57-0 IDARUBICIN ADVERSE_EFFECT CVS_2_Atrial Fibrillation 57852-57-0 IDARUBICIN ADVERSE_EFFECT CVS_2_Myocardial Infarction 57852-57-0 IDARUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 3778-73-2 IFOSFAMIDE INDICATION Ewing's Sarcoma 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Mutagenicity 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Genitourinary System Toxicity 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Nephrotoxicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT NEU_1_Somnolence 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT GIS_1_Vomiting 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT BBM_1_Myelotoxicity 3778-73-2 IFOSFAMIDE THERAPEUTIC_CLASS Antineoplastics 3778-73-2 IFOSFAMIDE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 3778-73-2 IFOSFAMIDE INDICATION Testicular Germ Cell Tumors 3778-73-2 IFOSFAMIDE PRODUCT_CLASS Anti-cancers 3778-73-2 IFOSFAMIDE INDICATION Small Cell Lung Carcinoma 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT PSY_3_Psychosis 3778-73-2 IFOSFAMIDE TA_LEVEL_3 Solid Tumors 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Hemorrhagic Cystitis 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Myelosuppression 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT KID_3_Fanconi Syndrome 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT XXX_2_Fever 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT DNA_1_Mutagenicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT PSY_1_Hallucinations 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT NEU_3_Coma 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT DNA_1_Carcinogenicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT NEU_3_Convulsions 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT KID_3_Renal Tubular Acidosis 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Cardiotoxicity 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Embryotoxicity 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Hematuria 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 3778-73-2 IFOSFAMIDE ACTIVITY_CLASS DNA damager 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Mutagenicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT NEU_2_Neurological Toxicity 3778-73-2 IFOSFAMIDE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 3778-73-2 IFOSFAMIDE TA_LEVEL_2 DNA damage 3778-73-2 IFOSFAMIDE INDICATION Metastatic / Recurrent Cervical Carcinoma 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT PSY_1_Confusion 3778-73-2 IFOSFAMIDE INDICATION Metastatic / Recurrent Osteosarcoma 3778-73-2 IFOSFAMIDE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 3778-73-2 IFOSFAMIDE ZERO_CLASS N 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Acute Renal Failure 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Carcinogenicity 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Teratogenicity 3778-73-2 IFOSFAMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Carcinogenicity 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 3778-73-2 IFOSFAMIDE TISSUE_TOXICITY Myelotoxicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT KID_3_Acute Renal Failure 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT GIS_2_Stomatitis 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT KID_1_Hematuria 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT EMB_1_Embryotoxicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT CVS_2_Cardiotoxicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT PSY_2_Anorexia 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT BBM_1_Myelosuppression 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT KID_2_Nephrotoxicity 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 3778-73-2 IFOSFAMIDE INDICATION Recurrent Wilm's Tumor 3778-73-2 IFOSFAMIDE INDICATION Lung Cancer / Carcinoma of the Lung 3778-73-2 IFOSFAMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 3778-73-2 IFOSFAMIDE MESH_LEVEL_3 Oxazines 3778-73-2 IFOSFAMIDE INDICATION Metastatic Bladder Carcinoma 3778-73-2 IFOSFAMIDE MESH_LEVEL_1 Heterocyclic Compounds 3778-73-2 IFOSFAMIDE INDICATION Metastatic / Recurrent Ovarian Carcinoma 3778-73-2 IFOSFAMIDE TA_LEVEL_1 Oncology 3778-73-2 IFOSFAMIDE MECH_LEVEL_3 DNA damage 3778-73-2 IFOSFAMIDE MECHANISM Inhibit DNA synthesis, repair, and function 3778-73-2 IFOSFAMIDE KNOWN_TOXICITY Nephrotoxicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT GIS_1_Nausea 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT NEU_3_Encephalopathy 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT CVS_2_Phlebitis 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT GUS_1_Hemorrhagic Cystitis 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT EMB_1_Teratogenicity 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT XXX_2_Infection 3778-73-2 IFOSFAMIDE ADVERSE_EFFECT NEU_3_Neuropathy 64221-86-9 IMIPENEM INDICATION Skin and Skin Structure Infections 64221-86-9 IMIPENEM INDICATION Gynecologic Infections 64221-86-9 IMIPENEM INDICATION Diabetic Foot Ulcer 64221-86-9 IMIPENEM INDICATION Intraabdominal Infections 64221-86-9 IMIPENEM ADVERSE_EFFECT PSY_3_Hallucinations 64221-86-9 IMIPENEM ADVERSE_EFFECT SKN_3_Flushing 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_3_Encephalopathy 64221-86-9 IMIPENEM ADVERSE_EFFECT PSY_2_Confusion 64221-86-9 IMIPENEM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 64221-86-9 IMIPENEM ADVERSE_EFFECT BBM_3_Leukopenia 64221-86-9 IMIPENEM ADVERSE_EFFECT LUN_3_Cyanosis 64221-86-9 IMIPENEM ADVERSE_EFFECT BBM_3_Neutropenia 64221-86-9 IMIPENEM ADVERSE_EFFECT KID_3_Acute Renal Failure 64221-86-9 IMIPENEM ADVERSE_EFFECT XXX_3_Asthenia 64221-86-9 IMIPENEM ADVERSE_EFFECT XXX_3_Glossitis 64221-86-9 IMIPENEM INDICATION Urinary Tract Infection (UTI) 64221-86-9 IMIPENEM INDICATION Nongonococcal Acute Bacterial (Septic) Arthritis 64221-86-9 IMIPENEM INDICATION Osteomyelitis / Bone Infection 64221-86-9 IMIPENEM INDICATION Endocarditis 64221-86-9 IMIPENEM INDICATION Intraabdominal Abscess 64221-86-9 IMIPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_1_Diarrhea 64221-86-9 IMIPENEM ADVERSE_EFFECT BBM_3_Hemolytic Anemia 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_3_Paresthesia 64221-86-9 IMIPENEM ADVERSE_EFFECT LIV_3_Hepatitis 64221-86-9 IMIPENEM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 64221-86-9 IMIPENEM ADVERSE_EFFECT BBM_3_Thrombocytopenia 64221-86-9 IMIPENEM ADVERSE_EFFECT CVS_1_Phlebitis 64221-86-9 IMIPENEM ADVERSE_EFFECT LIV_3_Jaundice 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 64221-86-9 IMIPENEM ADVERSE_EFFECT GUS_3_Discoloration of Urine 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_3_Hemorrhagic Colitis 64221-86-9 IMIPENEM KNOWN_TOXICITY Nephrotoxicity 64221-86-9 IMIPENEM MODE_CLASS Enzyme Inhibitor 64221-86-9 IMIPENEM INDICATION Bone and Joint Infection 64221-86-9 IMIPENEM INDICATION Bacteremia 64221-86-9 IMIPENEM PRODUCT_CLASS Anti-cancers 64221-86-9 IMIPENEM INDICATION Lower Respiratory Tract Infection 64221-86-9 IMIPENEM INDICATION Peritonitis 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 64221-86-9 IMIPENEM ADVERSE_EFFECT OTO_3_Tinnitus 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_3_Seizures 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_2_Myoclonus 64221-86-9 IMIPENEM ADVERSE_EFFECT LUN_3_Dyspnea 64221-86-9 IMIPENEM ADVERSE_EFFECT KID_3_Polyuria 64221-86-9 IMIPENEM ADVERSE_EFFECT OTO_3_Hearing Loss 64221-86-9 IMIPENEM ADVERSE_EFFECT BBM_3_Pancytopenia 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_3_Dyspepsia 64221-86-9 IMIPENEM ADVERSE_EFFECT XXX_3_Tooth Discoloration 64221-86-9 IMIPENEM TISSUE_TOXICITY Acute Renal Failure 64221-86-9 IMIPENEM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 64221-86-9 IMIPENEM INDICATION Septicemia 64221-86-9 IMIPENEM INDICATION Pneumonia 64221-86-9 IMIPENEM PRODUCT_CLASS Anti-infectives 64221-86-9 IMIPENEM THERAPEUTIC_CLASS Antibacterials, Systemic 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_3_Tremor 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_3_Headache 64221-86-9 IMIPENEM ADVERSE_EFFECT XXX_3_Candidiasis 64221-86-9 IMIPENEM ADVERSE_EFFECT LUN_3_Hyperventilation 64221-86-9 IMIPENEM ADVERSE_EFFECT SKN_3_Erythema Multiforme 64221-86-9 IMIPENEM ADVERSE_EFFECT NEU_3_Vertigo 64221-86-9 IMIPENEM ADVERSE_EFFECT MSK_3_Nongouty Polyarthralgia 64221-86-9 IMIPENEM ADVERSE_EFFECT CVS_3_Palpitation 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_3_Abdominal Pain 64221-86-9 IMIPENEM ADVERSE_EFFECT GIS_3_Gastroenteritis 64221-86-9 IMIPENEM ADVERSE_EFFECT IMU_3_Angioneurotic Edema 124351-85-5 INCADRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 124351-85-5 INCADRONIC ACID MODE_CLASS Enzyme Inhibitor 124351-85-5 INCADRONIC ACID INDICATION Hypercalcemia of Malignancy 124351-85-5 INCADRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 124351-85-5 INCADRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 124351-85-5 INCADRONIC ACID MECHANISM Inhibit bone re-absorption 87-89-8 INOSITOL INDICATION Cervicitis 87-89-8 INOSITOL PRODUCT_CLASS Other Human Uses 87-89-8 INOSITOL INDICATION Post surgical cervical procedures 87-89-8 INOSITOL ADVERSE_EFFECT IMU_3_Allergic Reactions 87-89-8 INOSITOL INDICATION Cervical tears 6011-62-7 IPRONIAZID STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 6011-62-7 IPRONIAZID ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 6011-62-7 IPRONIAZID ADVERSE_EFFECT PSY_2_Euphoria 6011-62-7 IPRONIAZID ADVERSE_EFFECT CVS_3_Hypertension 6011-62-7 IPRONIAZID ADVERSE_EFFECT LIV_2_Jaundice 6011-62-7 IPRONIAZID ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 6011-62-7 IPRONIAZID MECHANISM Prolong/enhance neural transmission 6011-62-7 IPRONIAZID ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 6011-62-7 IPRONIAZID MESH_LEVEL_3 Iproniazid 6011-62-7 IPRONIAZID TA_LEVEL_2 CNS Stimulant 6011-62-7 IPRONIAZID ADVERSE_EFFECT NEU_2_Tremor 6011-62-7 IPRONIAZID TISSUE_TOXICITY Fulminant Hepatitis 6011-62-7 IPRONIAZID ADVERSE_EFFECT PSY_2_Anxiety 6011-62-7 IPRONIAZID ADVERSE_EFFECT GUS_2_Dysuria 6011-62-7 IPRONIAZID ADVERSE_EFFECT LIV_3_Hepatitis 6011-62-7 IPRONIAZID ADVERSE_EFFECT PSY_2_Insomnia 6011-62-7 IPRONIAZID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 6011-62-7 IPRONIAZID ADVERSE_EFFECT CVS_2_Tachycardia 6011-62-7 IPRONIAZID ADVERSE_EFFECT GIS_2_Constipation 6011-62-7 IPRONIAZID KNOWN_TOXICITY Hepatotoxicity 6011-62-7 IPRONIAZID TISSUE_TOXICITY Liver Cirrhosis 6011-62-7 IPRONIAZID TISSUE_TOXICITY Hepatic Failure 6011-62-7 IPRONIAZID TISSUE_TOXICITY Hypotension 6011-62-7 IPRONIAZID MESH_LEVEL_2 Hydrazines 6011-62-7 IPRONIAZID MODE_CLASS Enzyme Inhibitor 6011-62-7 IPRONIAZID TA_LEVEL_1 Central Nervous System (CNS) 6011-62-7 IPRONIAZID INDICATION Depression 6011-62-7 IPRONIAZID ADVERSE_EFFECT NEU_2_Psychomotor Excitation 6011-62-7 IPRONIAZID INDICATION Depression 6011-62-7 IPRONIAZID ZERO_CLASS N 6011-62-7 IPRONIAZID ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 6011-62-7 IPRONIAZID ADVERSE_EFFECT LIV_3_Liver Cirrhosis 6011-62-7 IPRONIAZID ADVERSE_EFFECT CVS_3_Hypotension 6011-62-7 IPRONIAZID ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 6011-62-7 IPRONIAZID KNOWN_TOXICITY Cardiovascular Toxicity 6011-62-7 IPRONIAZID MECH_LEVEL_1 Modulate neural transmission 6011-62-7 IPRONIAZID MESH_LEVEL_1 Organic Chemicals 6011-62-7 IPRONIAZID MECH_LEVEL_2 Prolong/enhance neural transmission 6011-62-7 IPRONIAZID PRODUCT_CLASS Central Nervous System (CNS) 6011-62-7 IPRONIAZID ADVERSE_EFFECT NEU_2_Sedation 6011-62-7 IPRONIAZID ADVERSE_EFFECT PSY_2_Mania 6011-62-7 IPRONIAZID ADVERSE_EFFECT REP_3_Impotence 6011-62-7 IPRONIAZID ADVERSE_EFFECT LIV_3_Hepatic Failure 6011-62-7 IPRONIAZID ADVERSE_EFFECT GIS_2_Dry Mouth 6011-62-7 IPRONIAZID THERAPEUTIC_CLASS Antidepressants 6011-62-7 IPRONIAZID TA_LEVEL_3 depression 6011-62-7 IPRONIAZID MECH_LEVEL_3 Mono amine oxidase 97682-44-5 IRINOTECAN ADVERSE_EFFECT LUN_3_Pulmonary Embolism 97682-44-5 IRINOTECAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 97682-44-5 IRINOTECAN ADVERSE_EFFECT SKN_2_Rash 97682-44-5 IRINOTECAN ADVERSE_EFFECT NEU_2_Headache 97682-44-5 IRINOTECAN ADVERSE_EFFECT NEU_2_Dizziness 97682-44-5 IRINOTECAN ADVERSE_EFFECT PSY_2_Anorexia 97682-44-5 IRINOTECAN ADVERSE_EFFECT BBM_1_Leukopenia 97682-44-5 IRINOTECAN ADVERSE_EFFECT KID_2_Renal Failure 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Infection 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Edema 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Chills 97682-44-5 IRINOTECAN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 97682-44-5 IRINOTECAN ADVERSE_EFFECT GIS_1_Diarrhea 97682-44-5 IRINOTECAN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 97682-44-5 IRINOTECAN TISSUE_TOXICITY Renal Failure 97682-44-5 IRINOTECAN KNOWN_TOXICITY Nephrotoxicity 97682-44-5 IRINOTECAN THERAPEUTIC_CLASS Antineoplastics 97682-44-5 IRINOTECAN MESH_LEVEL_2 Alkaloids 97682-44-5 IRINOTECAN TA_LEVEL_1 Oncology 97682-44-5 IRINOTECAN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 97682-44-5 IRINOTECAN MECH_LEVEL_3 DNA topoisomerase 97682-44-5 IRINOTECAN TA_LEVEL_2 toposiomerase inhibitors 97682-44-5 IRINOTECAN ADVERSE_EFFECT CVS_3_Myocardial Infarction 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Rhinitis 97682-44-5 IRINOTECAN ADVERSE_EFFECT PSY_2_Insomnia 97682-44-5 IRINOTECAN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 97682-44-5 IRINOTECAN ADVERSE_EFFECT MSK_2_Back Pain 97682-44-5 IRINOTECAN ADVERSE_EFFECT BBM_1_Neutropenia 97682-44-5 IRINOTECAN ADVERSE_EFFECT GIS_1_Dyspepsia 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_1_Asthenia 97682-44-5 IRINOTECAN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 97682-44-5 IRINOTECAN TISSUE_TOXICITY Myocardial Infarction 97682-44-5 IRINOTECAN TISSUE_TOXICITY Anemia 97682-44-5 IRINOTECAN MESH_LEVEL_1 Heterocyclic Compounds 97682-44-5 IRINOTECAN KNOWN_TOXICITY Cardiovascular Toxicity 97682-44-5 IRINOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 97682-44-5 IRINOTECAN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 97682-44-5 IRINOTECAN TA_LEVEL_3 Solid and soft Tumors 97682-44-5 IRINOTECAN ADVERSE_EFFECT GIS_2_Stomatitis 97682-44-5 IRINOTECAN ADVERSE_EFFECT OCU_2_Miosis 97682-44-5 IRINOTECAN ADVERSE_EFFECT GIS_2_Flatulence 97682-44-5 IRINOTECAN ADVERSE_EFFECT GIS_2_Constipation 97682-44-5 IRINOTECAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 97682-44-5 IRINOTECAN TISSUE_TOXICITY Neutropenia 97682-44-5 IRINOTECAN PRODUCT_CLASS Anti-cancers 97682-44-5 IRINOTECAN ZERO_CLASS N 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_1_Weight Loss 97682-44-5 IRINOTECAN ADVERSE_EFFECT XXX_1_Fever 97682-44-5 IRINOTECAN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 97682-44-5 IRINOTECAN ADVERSE_EFFECT LUN_1_Cough 97682-44-5 IRINOTECAN ADVERSE_EFFECT BBM_1_Anemia 97682-44-5 IRINOTECAN TISSUE_TOXICITY Leukopenia 97682-44-5 IRINOTECAN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 97682-44-5 IRINOTECAN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 97682-44-5 IRINOTECAN MESH_LEVEL_3 Camptothecin 97682-44-5 IRINOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 97682-44-5 IRINOTECAN MODE_CLASS Enzyme Inhibitor 97682-44-5 IRINOTECAN ADVERSE_EFFECT END_3_Hyperglycemia 97682-44-5 IRINOTECAN ADVERSE_EFFECT BBM_3_Thrombocytopenia 97-54-1 ISOEUGENOL TA_LEVEL_1 Other Human Uses 97-54-1 ISOEUGENOL MESH_LEVEL_3 Terpenes 97-54-1 ISOEUGENOL MESH_LEVEL_2 Hydrocarbons 97-54-1 ISOEUGENOL ADVERSE_EFFECT NEU_2_Sedation 97-54-1 ISOEUGENOL MECH_LEVEL_3 DNA damage 97-54-1 ISOEUGENOL TA_LEVEL_2 perfume 97-54-1 ISOEUGENOL PRODUCT_CLASS Other Human Uses 97-54-1 ISOEUGENOL ZERO_CLASS N 97-54-1 ISOEUGENOL STRUCTURE_ACTIVITY Pro-inflammatory stimuli 97-54-1 ISOEUGENOL ACTIVITY_CLASS Pro-inflammatory stimuli 97-54-1 ISOEUGENOL MECH_LEVEL_2 free oxygen radicals 97-54-1 ISOEUGENOL MECHANISM Scavenges hydrogen peroxide and free radicals 97-54-1 ISOEUGENOL ADVERSE_EFFECT IMU_2_Allergy 97-54-1 ISOEUGENOL ADVERSE_EFFECT NEU_3_Anesthesia 97-54-1 ISOEUGENOL MESH_LEVEL_1 Organic Chemicals 97-54-1 ISOEUGENOL ADVERSE_EFFECT IMU_1_Contact Dermatitis 97-54-1 ISOEUGENOL ADVERSE_EFFECT XXX_1_Weight Loss 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Neutropenia 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT NEU_2_Dizziness 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Colitis 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT IMU_2_Allergic Reactions 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 4759-48-2 ISOTRETINOIN INDICATION Squamous Cell Carcinoma of Skin 4759-48-2 ISOTRETINOIN INDICATION Psoriasis 4759-48-2 ISOTRETINOIN TA_LEVEL_3 Acne Preparations 4759-48-2 ISOTRETINOIN MECH_LEVEL_3 9-cis-retinoic acid receptor RXR beta 4759-48-2 ISOTRETINOIN MECH_LEVEL_2 RAR activation 4759-48-2 ISOTRETINOIN ZERO_CLASS N 4759-48-2 ISOTRETINOIN TISSUE_TOXICITY Embryotoxicity 4759-48-2 ISOTRETINOIN KNOWN_TOXICITY Nephrotoxicity 4759-48-2 ISOTRETINOIN MODE_CLASS Receptor Agonist 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT OCU_2_Corneal Opacities 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Embryotoxicity 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Calcification of Tendons and Ligaments 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT LUN_3_Bronchospasm 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT IMU_1_Photosensitivity 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT GIS_2_Nausea 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT OCU_3_Visual Impairment 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Pancreatitis 4759-48-2 ISOTRETINOIN THERAPEUTIC_CLASS Antineoplastics 4759-48-2 ISOTRETINOIN INDICATION Acne / Acne Vulgaris 4759-48-2 ISOTRETINOIN INDICATION Basal Cell Carcinoma 4759-48-2 ISOTRETINOIN ACTIVITY_CLASS Retinoic acid receptor (RAR) agonist 4759-48-2 ISOTRETINOIN KNOWN_TOXICITY Embryo/Fetal Toxicity 4759-48-2 ISOTRETINOIN TISSUE_TOXICITY Hepatotoxicity 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Inflammatory Bowel Disease 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT MSK_1_Bone Pain 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT OCU_3_Impaired Night Vision 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT XXX_2_Epistaxis 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT XXX_3_Impaired Healing 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT SKN_1_Dry Skin 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Anemia 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT MSK_1_Arthralgia 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT CVS_3_Vasculitis 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT NEU_3_Benign Intracranial Hypertension 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT END_1_Hypertriglyceridemia 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Teratogenicity 4759-48-2 ISOTRETINOIN THERAPEUTIC_CLASS Acne Preparations 4759-48-2 ISOTRETINOIN THERAPEUTIC_CLASS Psoralens 4759-48-2 ISOTRETINOIN INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 4759-48-2 ISOTRETINOIN MECHANISM Modulate gene transcription 4759-48-2 ISOTRETINOIN MECH_LEVEL_1 Modulate epidermal fuction 4759-48-2 ISOTRETINOIN TA_LEVEL_1 Dermatology 4759-48-2 ISOTRETINOIN PRODUCT_CLASS Anti-cancers 4759-48-2 ISOTRETINOIN TA_LEVEL_2 anti-comodogenic 4759-48-2 ISOTRETINOIN KNOWN_TOXICITY Hepatotoxicity 4759-48-2 ISOTRETINOIN TISSUE_TOXICITY Glomerulonephritis 4759-48-2 ISOTRETINOIN TISSUE_TOXICITY Teratogenicity 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Hyperotosis 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT END_2_Hyperglycemia 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT OTO_3_Hearing Loss 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Fetal Toxicity 4759-48-2 ISOTRETINOIN INDICATION Keratinization Disorders 4759-48-2 ISOTRETINOIN PRODUCT_CLASS Dermatologicals 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT GIS_1_Dry Mouth 4759-48-2 ISOTRETINOIN PRODUCT_CLASS Other Human Uses 4759-48-2 ISOTRETINOIN MESH_LEVEL_2 Hydrocarbons 4759-48-2 ISOTRETINOIN MESH_LEVEL_3 Terpenes 4759-48-2 ISOTRETINOIN TISSUE_TOXICITY Fetal Toxicity 4759-48-2 ISOTRETINOIN MESH_LEVEL_1 Organic Chemicals 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Premature Closure of Epiphyseal Plate 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 4759-48-2 ISOTRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 4759-48-2 ISOTRETINOIN ADVERSE_EFFECT REP_2_Menstrual Abnormalities 75695-93-1 ISRADIPINE PRODUCT_CLASS Cardiovasculars 75695-93-1 ISRADIPINE INDICATION Hypertension 75695-93-1 ISRADIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 75695-93-1 ISRADIPINE MODE_CLASS Channel Blocker 75695-93-1 ISRADIPINE THERAPEUTIC_CLASS Antihypertensive Agents 75695-93-1 ISRADIPINE MECHANISM Reduce muscle contractile force 487-79-6 KAINIC ACID PRODUCT_CLASS Central Nervous System (CNS) 487-79-6 KAINIC ACID THERAPEUTIC_CLASS Antiparasitics 487-79-6 KAINIC ACID PRODUCT_CLASS Anti-infectives 487-79-6 KAINIC ACID MODE_CLASS Channel Modulator 487-79-6 KAINIC ACID MECHANISM Prolong/enhance neural transmission 2280-32-2 KANAMYCIN TISSUE_TOXICITY Ototoxicity 2280-32-2 KANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 2280-32-2 KANAMYCIN ADVERSE_EFFECT SKN_2_Dermatitis 2280-32-2 KANAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 2280-32-2 KANAMYCIN ADVERSE_EFFECT SKN_2_Rash 2280-32-2 KANAMYCIN MESH_LEVEL_3 Aminoglycoside 2280-32-2 KANAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 2280-32-2 KANAMYCIN MECH_LEVEL_1 Anti-bacterial 2280-32-2 KANAMYCIN TA_LEVEL_3 Aminoglycoside 2280-32-2 KANAMYCIN INDICATION Bowel Preparation 2280-32-2 KANAMYCIN INDICATION Septicemia 2280-32-2 KANAMYCIN INDICATION Bone and Joint Infection 2280-32-2 KANAMYCIN TISSUE_TOXICITY Nephrotoxicity 2280-32-2 KANAMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 2280-32-2 KANAMYCIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 2280-32-2 KANAMYCIN INDICATION Hepatic Encephalopathy 2280-32-2 KANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 2280-32-2 KANAMYCIN ZERO_CLASS N 2280-32-2 KANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2280-32-2 KANAMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 2280-32-2 KANAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 2280-32-2 KANAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 2280-32-2 KANAMYCIN PRODUCT_CLASS Anti-infectives 2280-32-2 KANAMYCIN INDICATION Bronchopulmonary Infection 2280-32-2 KANAMYCIN INDICATION Gram-negative Septicemia 2280-32-2 KANAMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 2280-32-2 KANAMYCIN TA_LEVEL_2 Anti-bacterial 2280-32-2 KANAMYCIN KNOWN_TOXICITY Ototoxicity 2280-32-2 KANAMYCIN ADVERSE_EFFECT IMU_2_Allergic Reactions 2280-32-2 KANAMYCIN ADVERSE_EFFECT SKN_2_Pruritis 2280-32-2 KANAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 2280-32-2 KANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 2280-32-2 KANAMYCIN INDICATION Skin and Skin Structure Infections 2280-32-2 KANAMYCIN INDICATION Biliary Tract Infection 2280-32-2 KANAMYCIN MECH_LEVEL_3 Ribosomal RNA binder 2280-32-2 KANAMYCIN ADVERSE_EFFECT END_3_Decreased Cholesterol 2280-32-2 KANAMYCIN KNOWN_TOXICITY Nephrotoxicity 2280-32-2 KANAMYCIN TA_LEVEL_1 Infectious Disease 2280-32-2 KANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 2280-32-2 KANAMYCIN INDICATION Urinary Tract Infection (UTI) 2280-32-2 KANAMYCIN INDICATION Intra-Abdominal Infections 2280-32-2 KANAMYCIN MESH_LEVEL_2 Carbohydrates 1867-66-9 KETAMINE KNOWN_TOXICITY Mental Health Disorders 1867-66-9 KETAMINE TA_LEVEL_1 Central Nervous System (CNS) 1867-66-9 KETAMINE MECHANISM Block neural transmission 1867-66-9 KETAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 1867-66-9 KETAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 1867-66-9 KETAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 1867-66-9 KETAMINE ADVERSE_EFFECT LUN_3_Laryngospasm 1867-66-9 KETAMINE ACTIVITY_CLASS Glutamate antagonist 1867-66-9 KETAMINE ZERO_CLASS N 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_1_Post-Anesthesia Emergence of Delirium 1867-66-9 KETAMINE ADVERSE_EFFECT LUN_3_Apnea 1867-66-9 KETAMINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 1867-66-9 KETAMINE ADVERSE_EFFECT NEU_2_Nystagmus 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_1_Insomnia 1867-66-9 KETAMINE ADVERSE_EFFECT CVS_3_Hypotension 1867-66-9 KETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 1867-66-9 KETAMINE MESH_LEVEL_2 Hydrocarbons 1867-66-9 KETAMINE MECH_LEVEL_1 Modulate neural transmission 1867-66-9 KETAMINE PRODUCT_CLASS Central Nervous System (CNS) 1867-66-9 KETAMINE ADVERSE_EFFECT SKN_3_Erythema 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_2_Disorientation 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_2_Psychologic Dependence 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_2_Anxiety 1867-66-9 KETAMINE ADVERSE_EFFECT CVS_1_Hypertension 1867-66-9 KETAMINE TISSUE_TOXICITY Visual Hallucinations 1867-66-9 KETAMINE INDICATION Induction / Maintenance of Anesthesia 1867-66-9 KETAMINE TA_LEVEL_2 CNS Depressant 1867-66-9 KETAMINE MECH_LEVEL_2 NMDA Modulators 1867-66-9 KETAMINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 1867-66-9 KETAMINE TISSUE_TOXICITY Cardiac Arrhythmia 1867-66-9 KETAMINE ADVERSE_EFFECT GIS_3_Hypersalivation 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_3_Psychosis 1867-66-9 KETAMINE ADVERSE_EFFECT NEU_3_Tonic-Clonic Convulsions 1867-66-9 KETAMINE ADVERSE_EFFECT XXX_3_Withdrawal 1867-66-9 KETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 1867-66-9 KETAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 1867-66-9 KETAMINE TA_LEVEL_3 Dissociative anesthetic 1867-66-9 KETAMINE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 1867-66-9 KETAMINE MESH_LEVEL_1 Organic Chemicals 1867-66-9 KETAMINE MODE_CLASS Channel Blocker 1867-66-9 KETAMINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 1867-66-9 KETAMINE ADVERSE_EFFECT NEU_3_Involuntray Movements 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_1_Nightmares 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_1_Visual Hallucinations 1867-66-9 KETAMINE ADVERSE_EFFECT OCU_3_Diplopia 1867-66-9 KETAMINE TISSUE_TOXICITY Hypotension 1867-66-9 KETAMINE ADVERSE_EFFECT PSY_3_Anorexia 1867-66-9 KETAMINE ADVERSE_EFFECT LUN_2_Respiratory Depression 6106-46-3 SCOPOLAMINE METHYL NITRATE PRODUCT_CLASS Autonomic Nervous System (ANS) 6106-46-3 SCOPOLAMINE METHYL NITRATE THERAPEUTIC_CLASS Parasympatholytic Agents 6106-46-3 SCOPOLAMINE METHYL NITRATE MECHANISM Modulate G-protein coupled signal transduction 6106-46-3 SCOPOLAMINE METHYL NITRATE MODE_CLASS Receptor Ligand Antagonist 61-73-4 METHYLENE BLUE MODE_CLASS Enzyme Inhibitor 61-73-4 METHYLENE BLUE INDICATION Methemoglobinemia 61-73-4 METHYLENE BLUE INDICATION Cyanide (CN) Poisoning 61-73-4 METHYLENE BLUE MECHANISM Inhibit kinase mediated signal transduction 66-27-3 METHYL METHANESULFONATE TISSUE_TOXICITY Carcinogenicity 66-27-3 METHYL METHANESULFONATE ADVERSE_EFFECT REP__Infertility 66-27-3 METHYL METHANESULFONATE ADVERSE_EFFECT DNA_1_Carcinogenicity 66-27-3 METHYL METHANESULFONATE KNOWN_TOXICITY Carcinogenicity 66-27-3 METHYL METHANESULFONATE MECH_LEVEL_3 DNA damage 66-27-3 METHYL METHANESULFONATE STRUCTURE_ACTIVITY DNA-alkylator, methanesulfonate 66-27-3 METHYL METHANESULFONATE TA_LEVEL_2 DNA damage 66-27-3 METHYL METHANESULFONATE MESH_LEVEL_2 Hydrocarbons 66-27-3 METHYL METHANESULFONATE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 66-27-3 METHYL METHANESULFONATE MECHANISM Inhibit DNA synthesis, repair, and function 66-27-3 METHYL METHANESULFONATE ZERO_CLASS N 66-27-3 METHYL METHANESULFONATE PRODUCT_CLASS Toxicants 66-27-3 METHYL METHANESULFONATE TA_LEVEL_3 Bone Marrow Toxicants 66-27-3 METHYL METHANESULFONATE TISSUE_TOXICITY Genotoxicity 66-27-3 METHYL METHANESULFONATE MESH_LEVEL_1 Organic Chemicals 66-27-3 METHYL METHANESULFONATE MESH_LEVEL_3 Hydrocarbons, Acyclic 66-27-3 METHYL METHANESULFONATE ACTIVITY_CLASS DNA damager 66-27-3 METHYL METHANESULFONATE MODE_CLASS Distorts /blocks macromolecular scaffold function 66-27-3 METHYL METHANESULFONATE ADVERSE_EFFECT DNA_2_Genotoxicity 66-27-3 METHYL METHANESULFONATE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 66-27-3 METHYL METHANESULFONATE KNOWN_TOXICITY Hepatotoxicity 66-27-3 METHYL METHANESULFONATE MECH_LEVEL_2 Induce free oxygen radical associated tissue and DNA damage 66-27-3 METHYL METHANESULFONATE ADVERSE_EFFECT LIV_2_Hepatic Toxicity 66-27-3 METHYL METHANESULFONATE TISSUE_TOXICITY Hepatic Toxicity 66-27-3 METHYL METHANESULFONATE TISSUE_TOXICITY Mutagenicity 66-27-3 METHYL METHANESULFONATE ADVERSE_EFFECT DNA_1_Mutagenicity 66-27-3 METHYL METHANESULFONATE KNOWN_TOXICITY Mutagenicity 66-27-3 METHYL METHANESULFONATE TA_LEVEL_1 Toxicants 83-43-2 METHYLPREDNISOLONE MODE_CLASS Receptor Agonist 83-43-2 METHYLPREDNISOLONE INDICATION Hematologic Disorders 83-43-2 METHYLPREDNISOLONE MECHANISM Modulate gene transcription 83-43-2 METHYLPREDNISOLONE INDICATION Multiple Sclerosis (MS) 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT SKN_2_Thin Fragile Skin 83-43-2 METHYLPREDNISOLONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 83-43-2 METHYLPREDNISOLONE INDICATION Allergic Diseases 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT CVS_3_Hypotension 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT SKN_2_Hypopigmentation 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT SKN_2_Hyperpigmentation 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 83-43-2 METHYLPREDNISOLONE TISSUE_TOXICITY Cardiac Arrhythmia 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT SKN_2_Skin Toxicity 83-43-2 METHYLPREDNISOLONE INDICATION Ophthalmic Diseases 83-43-2 METHYLPREDNISOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 83-43-2 METHYLPREDNISOLONE KNOWN_TOXICITY Cardiovascular Toxicity 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 83-43-2 METHYLPREDNISOLONE INDICATION Endocrine Disorders 83-43-2 METHYLPREDNISOLONE INDICATION Neoplastic Diseases 83-43-2 METHYLPREDNISOLONE TISSUE_TOXICITY Hypotension 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT IMU_3_Anaphylaxis 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT END_2_Metabolic Disturbance 83-43-2 METHYLPREDNISOLONE INDICATION Respiratory Diseases 83-43-2 METHYLPREDNISOLONE INDICATION Edematous States 83-43-2 METHYLPREDNISOLONE INDICATION Skin Diseases / Dermatoses 83-43-2 METHYLPREDNISOLONE INDICATION Collagen Diseases 83-43-2 METHYLPREDNISOLONE THERAPEUTIC_CLASS Corticosteroids 83-43-2 METHYLPREDNISOLONE INDICATION Rheumatic Disorders 83-43-2 METHYLPREDNISOLONE INDICATION Gastrointestinal Diseases 83-43-2 METHYLPREDNISOLONE PRODUCT_CLASS Anti-inflammatories 83-43-2 METHYLPREDNISOLONE ADVERSE_EFFECT END_2_Cushing's Syndrome 361-37-5 METHYSERGIDE ADVERSE_EFFECT PSY_3_Mental Confusion 361-37-5 METHYSERGIDE ADVERSE_EFFECT GIS_1_Dyspepsia 361-37-5 METHYSERGIDE ADVERSE_EFFECT SKN_3_Skin Rash 361-37-5 METHYSERGIDE ADVERSE_EFFECT XXX_3_Fever 361-37-5 METHYSERGIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 361-37-5 METHYSERGIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Myocardial Infarction 361-37-5 METHYSERGIDE THERAPEUTIC_CLASS Antimigraines 361-37-5 METHYSERGIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 361-37-5 METHYSERGIDE KNOWN_TOXICITY Cardiovascular Toxicity 361-37-5 METHYSERGIDE THERAPEUTIC_CLASS Central Stimulants 361-37-5 METHYSERGIDE ADVERSE_EFFECT NEU_2_Headache 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Hypertension 361-37-5 METHYSERGIDE MECHANISM Modulate G-protein coupled signal transduction 361-37-5 METHYSERGIDE PRODUCT_CLASS Central Nervous System (CNS) 361-37-5 METHYSERGIDE ADVERSE_EFFECT GIS_3_Constipation 361-37-5 METHYSERGIDE ADVERSE_EFFECT XXX_2_Asthenia 361-37-5 METHYSERGIDE ADVERSE_EFFECT GIS_1_Heartburn 361-37-5 METHYSERGIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 361-37-5 METHYSERGIDE ADVERSE_EFFECT MSK_3_Myalgia 361-37-5 METHYSERGIDE ADVERSE_EFFECT XXX_3_Peripheral Edema 361-37-5 METHYSERGIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 361-37-5 METHYSERGIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 361-37-5 METHYSERGIDE TISSUE_TOXICITY Myocardial Infarction 361-37-5 METHYSERGIDE INDICATION Narcolepsy 361-37-5 METHYSERGIDE INDICATION Migraine Prophylaxis 361-37-5 METHYSERGIDE STRUCTURE_ACTIVITY 5HT2 antagonist 361-37-5 METHYSERGIDE ADVERSE_EFFECT GIS_3_Diarrhea 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Chest Pain 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Phlebitis 361-37-5 METHYSERGIDE ADVERSE_EFFECT PSY_3_Euphoria 361-37-5 METHYSERGIDE ADVERSE_EFFECT NEU_3_Drowsiness 361-37-5 METHYSERGIDE ADVERSE_EFFECT SKN_3_Flushing 361-37-5 METHYSERGIDE ADVERSE_EFFECT PSY_3_Insomnia 361-37-5 METHYSERGIDE ADVERSE_EFFECT IMU_3_Eosinophilia 361-37-5 METHYSERGIDE ADVERSE_EFFECT XXX_3_Hypothermia 361-37-5 METHYSERGIDE ADVERSE_EFFECT BBM_3_Neutropenia 361-37-5 METHYSERGIDE MODE_CLASS Receptor Ligand Antagonist, Non-selective 361-37-5 METHYSERGIDE INDICATION Carcinoid Syndrome 361-37-5 METHYSERGIDE TISSUE_TOXICITY Angina 361-37-5 METHYSERGIDE ADVERSE_EFFECT PSY_3_Confusion 361-37-5 METHYSERGIDE ADVERSE_EFFECT NEU_3_Dizziness 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Angina 361-37-5 METHYSERGIDE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 361-37-5 METHYSERGIDE ADVERSE_EFFECT OCU_3_Mydriasis 361-37-5 METHYSERGIDE ADVERSE_EFFECT PSY_3_CNS Depression 361-37-5 METHYSERGIDE ADVERSE_EFFECT PSY_3_CNS Stimulation 361-37-5 METHYSERGIDE ADVERSE_EFFECT NEU_3_Hyperesthesia 361-37-5 METHYSERGIDE ADVERSE_EFFECT NEU_3_Ataxia 361-37-5 METHYSERGIDE ADVERSE_EFFECT MSK_2_Arthralgia 7232-21-5 METOCLOPRAMIDE TISSUE_TOXICITY Tardive Dyskinesia 7232-21-5 METOCLOPRAMIDE INDICATION Facilitate Small Bowel Intubation 7232-21-5 METOCLOPRAMIDE MODE_CLASS Channel Modulator 7232-21-5 METOCLOPRAMIDE MESH_LEVEL_3 Benzamides 7232-21-5 METOCLOPRAMIDE TA_LEVEL_1 Central Nervous System (CNS) 7232-21-5 METOCLOPRAMIDE MESH_LEVEL_2 Amides 7232-21-5 METOCLOPRAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 7232-21-5 METOCLOPRAMIDE MESH_LEVEL_1 Organic Chemicals 7232-21-5 METOCLOPRAMIDE INDICATION Gastrointestinal Radiography 7232-21-5 METOCLOPRAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 7232-21-5 METOCLOPRAMIDE MECH_LEVEL_1 Modulate neural transmission 7232-21-5 METOCLOPRAMIDE INDICATION Diabetic Gastric Stasis 7232-21-5 METOCLOPRAMIDE TISSUE_TOXICITY Supraventricular Tachycardia 7232-21-5 METOCLOPRAMIDE THERAPEUTIC_CLASS Pituitary Hormones 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Insomnia 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Lassitude 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Hyperprolactinemia 7232-21-5 METOCLOPRAMIDE PRODUCT_CLASS Gastrointestinal System 7232-21-5 METOCLOPRAMIDE ZERO_CLASS N 7232-21-5 METOCLOPRAMIDE MECH_LEVEL_3 5HT receptor 4 7232-21-5 METOCLOPRAMIDE INDICATION Induction of Lactation 7232-21-5 METOCLOPRAMIDE TA_LEVEL_3 Antiemetic 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Galactorrhea 7232-21-5 METOCLOPRAMIDE TA_LEVEL_2 CNS Depressant 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Nausea 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Impotence 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Menstrual Irregularities 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 7232-21-5 METOCLOPRAMIDE MECHANISM Modulate neural transmission 7232-21-5 METOCLOPRAMIDE INDICATION Gastroesophageal Reflux Disease (GERD) 7232-21-5 METOCLOPRAMIDE TISSUE_TOXICITY Congestive Heart Failure 7232-21-5 METOCLOPRAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Depression 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Fatigue 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Supraventricular Tachycardia 7232-21-5 METOCLOPRAMIDE INDICATION Hiccups / Singultus 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_3_Urinary Incontinence 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Infertility 7232-21-5 METOCLOPRAMIDE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 7232-21-5 METOCLOPRAMIDE INDICATION Nausea / Vomiting 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT XXX_2_Mastalgia 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 7232-21-5 METOCLOPRAMIDE THERAPEUTIC_CLASS Antiemetics 7232-21-5 METOCLOPRAMIDE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 7232-21-5 METOCLOPRAMIDE MECHANISM Modulate G-protein coupled signal transduction 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT LIV_3_Jaundice 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Confusion 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Headache 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 7232-21-5 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 7232-21-5 METOCLOPRAMIDE KNOWN_TOXICITY Mental Health Disorders 7232-21-5 METOCLOPRAMIDE MECH_LEVEL_2 5HT antagonist 37350-58-6 METOPROLOL ACTIVITY_CLASS Adrenergic antagonist 37350-58-6 METOPROLOL MECH_LEVEL_1 Reduce cardiac contractility 37350-58-6 METOPROLOL INDICATION Heart Failure 37350-58-6 METOPROLOL MECHANISM Reduce muscle contractile force 37350-58-6 METOPROLOL THERAPEUTIC_CLASS Antianginals 37350-58-6 METOPROLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, p-phenoxypropanoamine 37350-58-6 METOPROLOL TA_LEVEL_2 Hypertension 37350-58-6 METOPROLOL MECH_LEVEL_3 adrenoceptor beta1 37350-58-6 METOPROLOL MODE_CLASS Receptor Ligand Antagonist, Selective 37350-58-6 METOPROLOL ADVERSE_EFFECT GIS_2_Diarrhea 37350-58-6 METOPROLOL ADVERSE_EFFECT XXX_1_Fatigue 37350-58-6 METOPROLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 37350-58-6 METOPROLOL ADVERSE_EFFECT XXX_2_Cold Peripheries 37350-58-6 METOPROLOL TISSUE_TOXICITY Hypotensive Shock 37350-58-6 METOPROLOL MESH_LEVEL_1 Organic Chemicals 37350-58-6 METOPROLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 37350-58-6 METOPROLOL ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 37350-58-6 METOPROLOL TA_LEVEL_1 Cardiovascular 37350-58-6 METOPROLOL MESH_LEVEL_3 Amino Alcohols 37350-58-6 METOPROLOL INDICATION Angina Pectoris 37350-58-6 METOPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 37350-58-6 METOPROLOL ADVERSE_EFFECT IMU_3_Anaphylaxis 37350-58-6 METOPROLOL ADVERSE_EFFECT CVS_2_Bradycardia 37350-58-6 METOPROLOL ADVERSE_EFFECT CVS_3_Hypotensive Shock 37350-58-6 METOPROLOL TISSUE_TOXICITY Cardiogenic Shock 37350-58-6 METOPROLOL PRODUCT_CLASS Cardiovasculars 37350-58-6 METOPROLOL THERAPEUTIC_CLASS Congestive Heart Failure 37350-58-6 METOPROLOL ZERO_CLASS N 37350-58-6 METOPROLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 37350-58-6 METOPROLOL ADVERSE_EFFECT GIS_2_Dry Mouth 37350-58-6 METOPROLOL MESH_LEVEL_2 Alcohols 37350-58-6 METOPROLOL ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 37350-58-6 METOPROLOL ADVERSE_EFFECT NEU_1_Dizziness 37350-58-6 METOPROLOL ADVERSE_EFFECT LUN_2_Bronchospasm 37350-58-6 METOPROLOL ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 37350-58-6 METOPROLOL TISSUE_TOXICITY Atrioventricular Blockade 37350-58-6 METOPROLOL ADVERSE_EFFECT PSY_2_Mental Depression 37350-58-6 METOPROLOL ADVERSE_EFFECT CVS_3_Cardiogenic Shock 37350-58-6 METOPROLOL TISSUE_TOXICITY Congestive Heart Failure 37350-58-6 METOPROLOL TA_LEVEL_3 Beta blocker 37350-58-6 METOPROLOL INDICATION Hypertension 37350-58-6 METOPROLOL MECH_LEVEL_2 Beta antagonist 37350-58-6 METOPROLOL KNOWN_TOXICITY Cardiovascular Toxicity 31828-71-4 MEXILETINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 31828-71-4 MEXILETINE ADVERSE_EFFECT BBM_3_Agranulocytosis 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_1_Lightheadedness 31828-71-4 MEXILETINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 31828-71-4 MEXILETINE ADVERSE_EFFECT CVS_3_Arrhythmia 31828-71-4 MEXILETINE ADVERSE_EFFECT XXX_3_Diaphoresis 31828-71-4 MEXILETINE MECHANISM Prolong/enhance neural transmission 31828-71-4 MEXILETINE INDICATION Ventricular Tachycardia 31828-71-4 MEXILETINE TA_LEVEL_3 Antiarrhythmic Agents 31828-71-4 MEXILETINE INDICATION Cardiac Arrhythmias 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_1_Ataxia 31828-71-4 MEXILETINE ADVERSE_EFFECT REP_3_Decreased Libido 31828-71-4 MEXILETINE ADVERSE_EFFECT GIS_1_Dyspepsia 31828-71-4 MEXILETINE ADVERSE_EFFECT END_3_Hot Flashes 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_3_Amnesia 31828-71-4 MEXILETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 31828-71-4 MEXILETINE ADVERSE_EFFECT SKN_3_Rash 31828-71-4 MEXILETINE TISSUE_TOXICITY Congestive Heart Failure 31828-71-4 MEXILETINE KNOWN_TOXICITY Cardiovascular Toxicity 31828-71-4 MEXILETINE MECH_LEVEL_2 Modulates channel conductance 31828-71-4 MEXILETINE PRODUCT_CLASS Cardiovasculars 31828-71-4 MEXILETINE INDICATION Diabetic Neuropathy 31828-71-4 MEXILETINE MESH_LEVEL_2 Amines 31828-71-4 MEXILETINE MODE_CLASS Channel enhancer /opener 31828-71-4 MEXILETINE TISSUE_TOXICITY Arrhythmia 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_3_Seizures 31828-71-4 MEXILETINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 31828-71-4 MEXILETINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 31828-71-4 MEXILETINE ADVERSE_EFFECT GIS_1_Dysphagia 31828-71-4 MEXILETINE THERAPEUTIC_CLASS Antiarrhythmic Agents 31828-71-4 MEXILETINE ADVERSE_EFFECT OCU_3_Blurred Vision 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_1_Tremor 31828-71-4 MEXILETINE ADVERSE_EFFECT XXX_3_Edema 31828-71-4 MEXILETINE ACTIVITY_CLASS Na+ channel blocker 31828-71-4 MEXILETINE MECH_LEVEL_1 Modulates channel gating 31828-71-4 MEXILETINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 31828-71-4 MEXILETINE INDICATION Neuropathic Pain 31828-71-4 MEXILETINE MODE_CLASS Channel Modulator 31828-71-4 MEXILETINE TISSUE_TOXICITY Ventricular Arrhythmia 31828-71-4 MEXILETINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 31828-71-4 MEXILETINE ADVERSE_EFFECT BBM_3_Leukopenia 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_3_Syncope 31828-71-4 MEXILETINE ADVERSE_EFFECT CVS_3_First-Degree AV block 31828-71-4 MEXILETINE ADVERSE_EFFECT GUS_3_Urinary Retention 31828-71-4 MEXILETINE ADVERSE_EFFECT PSY_3_Nervousness 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_1_Dizziness 31828-71-4 MEXILETINE ADVERSE_EFFECT NEU_3_Paresthesia 31828-71-4 MEXILETINE ZERO_CLASS N 31828-71-4 MEXILETINE MECHANISM Modulate channel gating 31828-71-4 MEXILETINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 31828-71-4 MEXILETINE PRODUCT_CLASS Analgesics 31828-71-4 MEXILETINE MESH_LEVEL_1 Organic Chemicals 31828-71-4 MEXILETINE MECH_LEVEL_3 AMPA Glutamate receptor 31828-71-4 MEXILETINE TA_LEVEL_1 Cardiovascular 31828-71-4 MEXILETINE MESH_LEVEL_3 Propylamines 31828-71-4 MEXILETINE TISSUE_TOXICITY First-Degree AV block 31828-71-4 MEXILETINE ADVERSE_EFFECT CVS_3_Bradycardia 31828-71-4 MEXILETINE ADVERSE_EFFECT PSY_3_Hallucinations 21535-47-7 MIANSERIN ADVERSE_EFFECT END_3_Hyperglycemia 21535-47-7 MIANSERIN INDICATION Anxiety 21535-47-7 MIANSERIN MECH_LEVEL_2 Anti-histamine 21535-47-7 MIANSERIN ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 21535-47-7 MIANSERIN ADVERSE_EFFECT GIS_3_Constipation 21535-47-7 MIANSERIN ADVERSE_EFFECT NEU_3_Tremor 21535-47-7 MIANSERIN TISSUE_TOXICITY Cardiac Insufficiency 21535-47-7 MIANSERIN ACTIVITY_CLASS Histamine antagonist 21535-47-7 MIANSERIN STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 21535-47-7 MIANSERIN TA_LEVEL_1 Central Nervous System (CNS) 21535-47-7 MIANSERIN TA_LEVEL_2 Anti-depressant 21535-47-7 MIANSERIN INDICATION Depression 21535-47-7 MIANSERIN MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 21535-47-7 MIANSERIN MECH_LEVEL_3 histamine receptor H1 21535-47-7 MIANSERIN TA_LEVEL_3 Depression 21535-47-7 MIANSERIN ADVERSE_EFFECT GIS_3_Stomatitis 21535-47-7 MIANSERIN THERAPEUTIC_CLASS Antidepressants 21535-47-7 MIANSERIN ADVERSE_EFFECT PSY_1_Confusion 21535-47-7 MIANSERIN ADVERSE_EFFECT BBM_3_Agranulocytosis 21535-47-7 MIANSERIN ADVERSE_EFFECT BBM_3_Anemia 21535-47-7 MIANSERIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 21535-47-7 MIANSERIN ADVERSE_EFFECT BBM_3_Aplastic Anemia 21535-47-7 MIANSERIN ADVERSE_EFFECT BBM_3_Neutropenia 21535-47-7 MIANSERIN ADVERSE_EFFECT MSK_3_Arthritis 21535-47-7 MIANSERIN ADVERSE_EFFECT PSY_3_Mania 21535-47-7 MIANSERIN ADVERSE_EFFECT CVS_3_Cardiac Insufficiency 21535-47-7 MIANSERIN ADVERSE_EFFECT NEU_3_Convulsions 21535-47-7 MIANSERIN ADVERSE_EFFECT MSK_3_Skeletal Muscle Tremor 21535-47-7 MIANSERIN TISSUE_TOXICITY Arrhythmia 21535-47-7 MIANSERIN INDICATION Obsessive-Compulsive Disorder (OCD) 21535-47-7 MIANSERIN TISSUE_TOXICITY Hypotension 21535-47-7 MIANSERIN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 21535-47-7 MIANSERIN ADVERSE_EFFECT GIS_3_Vomiting 21535-47-7 MIANSERIN ADVERSE_EFFECT XXX_3_Edema 21535-47-7 MIANSERIN ADVERSE_EFFECT SKN_3_Erythema 21535-47-7 MIANSERIN ADVERSE_EFFECT NEU_1_Drowsiness 21535-47-7 MIANSERIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 21535-47-7 MIANSERIN ADVERSE_EFFECT LIV_3_Cholestasis 21535-47-7 MIANSERIN ADVERSE_EFFECT CVS_3_Arrhythmia 21535-47-7 MIANSERIN ADVERSE_EFFECT LUN_3_Pneumonia 21535-47-7 MIANSERIN ADVERSE_EFFECT NEU_1_Headache 21535-47-7 MIANSERIN MECHANISM Modulate G-protein coupled signal transduction 21535-47-7 MIANSERIN PRODUCT_CLASS Central Nervous System (CNS) 21535-47-7 MIANSERIN MESH_LEVEL_1 Heterocyclic Compounds 21535-47-7 MIANSERIN MESH_LEVEL_3 Dibenzazepines 21535-47-7 MIANSERIN MECH_LEVEL_1 Modulate neural transmission 21535-47-7 MIANSERIN ADVERSE_EFFECT CVS_3_Hypotension 21535-47-7 MIANSERIN ADVERSE_EFFECT IMU_3_Angioneurotic Edema 21535-47-7 MIANSERIN ADVERSE_EFFECT XXX_3_Asthenia 21535-47-7 MIANSERIN ADVERSE_EFFECT MSK_3_Nongouty Polyarthralgia 21535-47-7 MIANSERIN ADVERSE_EFFECT MSK_3_Arthralgia 21535-47-7 MIANSERIN ADVERSE_EFFECT NEU_3_Coma 21535-47-7 MIANSERIN ADVERSE_EFFECT NEU_1_Dizziness 21535-47-7 MIANSERIN ZERO_CLASS N 21535-47-7 MIANSERIN ADVERSE_EFFECT GIS_3_Nausea 21535-47-7 MIANSERIN KNOWN_TOXICITY Cardiovascular Toxicity 21535-47-7 MIANSERIN ADVERSE_EFFECT CVS_3_First-Degree AV block 21535-47-7 MIANSERIN TISSUE_TOXICITY First-Degree AV block 21535-47-7 MIANSERIN MODE_CLASS Receptor Ligand Antagonist 3704-09-4 MIBOLERONE MECHANISM Modulate gene transcription 3704-09-4 MIBOLERONE MODE_CLASS Receptor Agonist 3704-09-4 MIBOLERONE PRODUCT_CLASS Biochemicals 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_2_Hypotension 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_2_Supraventricular Tachycardia 78415-72-2 MILRINONE ADVERSE_EFFECT OCU_1_Blurred Vision 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 78415-72-2 MILRINONE ADVERSE_EFFECT NEU_2_Headache 78415-72-2 MILRINONE TISSUE_TOXICITY Hypotension 78415-72-2 MILRINONE INDICATION Congestive Heart Failure (CHF) 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_1_Palpitation 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 78415-72-2 MILRINONE MODE_CLASS Enzyme Inhibitor 78415-72-2 MILRINONE KNOWN_TOXICITY Cardiovascular Toxicity 78415-72-2 MILRINONE TISSUE_TOXICITY Angina 78415-72-2 MILRINONE TISSUE_TOXICITY Ventricular Tachycardia 78415-72-2 MILRINONE THERAPEUTIC_CLASS Congestive Heart Failure 78415-72-2 MILRINONE MECHANISM Enhance kinase mediated signal transduction 78415-72-2 MILRINONE TISSUE_TOXICITY Supraventricular Tachycardia 78415-72-2 MILRINONE TISSUE_TOXICITY Ventricular Fibrillation 78415-72-2 MILRINONE ADVERSE_EFFECT NEU_1_Syncope 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_2_Angina 78415-72-2 MILRINONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 78415-72-2 MILRINONE ADVERSE_EFFECT GIS_1_Diarrhea 78415-72-2 MILRINONE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 78415-72-2 MILRINONE PRODUCT_CLASS Cardiovasculars 78415-72-2 MILRINONE STRUCTURE_ACTIVITY PDE3 inhibitor 78415-72-2 MILRINONE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 78415-72-2 MILRINONE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 59122-46-2 MISOPROSTOL ADVERSE_EFFECT NEU_2_Headache 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Hypotension 59122-46-2 MISOPROSTOL ADVERSE_EFFECT LUN_3_Pulmonary Embolism 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Thrombosis 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GUS_2_Vaginal Bleeding 59122-46-2 MISOPROSTOL ADVERSE_EFFECT MSK_3_Cramps 59122-46-2 MISOPROSTOL TISSUE_TOXICITY Myocardial Infarction 59122-46-2 MISOPROSTOL TISSUE_TOXICITY Teratogenicity 59122-46-2 MISOPROSTOL THERAPEUTIC_CLASS Antiulcers 59122-46-2 MISOPROSTOL PRODUCT_CLASS Gastrointestinal System 59122-46-2 MISOPROSTOL INDICATION Induction of Labor 59122-46-2 MISOPROSTOL ADVERSE_EFFECT XXX_3_Diaphoresis 59122-46-2 MISOPROSTOL ADVERSE_EFFECT NEU_3_Syncope 59122-46-2 MISOPROSTOL ADVERSE_EFFECT REP_3_Menstrual Irregularities 59122-46-2 MISOPROSTOL ADVERSE_EFFECT XXX_3_Lethargy 59122-46-2 MISOPROSTOL ADVERSE_EFFECT XXX_3_Edema 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Hypertension 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Phlebitis 59122-46-2 MISOPROSTOL ADVERSE_EFFECT REP_2_Uterine Contractions 59122-46-2 MISOPROSTOL TISSUE_TOXICITY Stroke 59122-46-2 MISOPROSTOL THERAPEUTIC_CLASS Gonadal Hormones 59122-46-2 MISOPROSTOL INDICATION Termination of Pregnancy 59122-46-2 MISOPROSTOL INDICATION Duodenal Ulcer 59122-46-2 MISOPROSTOL ADVERSE_EFFECT REP_2_Cervical Erosion 59122-46-2 MISOPROSTOL ADVERSE_EFFECT REP_3_Dysmenorrhea 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Chest Pain 59122-46-2 MISOPROSTOL ADVERSE_EFFECT XXX_2_Infection 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GIS_1_Diarrhea 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GIS_1_Abdominal Pain 59122-46-2 MISOPROSTOL TISSUE_TOXICITY Thrombosis 59122-46-2 MISOPROSTOL INDICATION Gastric Ulcer 59122-46-2 MISOPROSTOL MECHANISM Modulate G-protein coupled signal transduction 59122-46-2 MISOPROSTOL ADVERSE_EFFECT EMB_3_Teratogenicity 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GIS_2_Constipation 59122-46-2 MISOPROSTOL ADVERSE_EFFECT REP_3_Breakthrough Bleeding 59122-46-2 MISOPROSTOL KNOWN_TOXICITY Cardiovascular Toxicity 59122-46-2 MISOPROSTOL KNOWN_TOXICITY Embryo/Fetal Toxicity 59122-46-2 MISOPROSTOL ADVERSE_EFFECT EMB_3_Fetal Death 59122-46-2 MISOPROSTOL ADVERSE_EFFECT REP_2_Rupture of Uterus 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GIS_2_Flatulence 59122-46-2 MISOPROSTOL ADVERSE_EFFECT GIS_2_Dyspepsia 59122-46-2 MISOPROSTOL TISSUE_TOXICITY Hypotension 59122-46-2 MISOPROSTOL MODE_CLASS Receptor Agonist 59122-46-2 MISOPROSTOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 59122-46-2 MISOPROSTOL INDICATION Intrauterine Death 59122-46-2 MISOPROSTOL STRUCTURE_ACTIVITY Prostaglandin receptor agonist 59122-46-2 MISOPROSTOL ADVERSE_EFFECT NEU_3_Vertigo 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Myocardial Infarction 59122-46-2 MISOPROSTOL ADVERSE_EFFECT CVS_3_Stroke 179107-34-7 CP-195543 MECHANISM Modulate G-protein coupled signal transduction 179107-34-7 CP-195543 MODE_CLASS Receptor Ligand Antagonist, Selective 3771-19-5 NAFENOPIN KNOWN_TOXICITY Hepatotoxicity 3771-19-5 NAFENOPIN ACTIVITY_CLASS Peroxisome proliferator 3771-19-5 NAFENOPIN MODE_CLASS Enzyme Inhibitor 3771-19-5 NAFENOPIN PRODUCT_CLASS Cardiovasculars 3771-19-5 NAFENOPIN TISSUE_TOXICITY Hepatotoxicity 3771-19-5 NAFENOPIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 3771-19-5 NAFENOPIN INDICATION Hypertriglyceridemia 3771-19-5 NAFENOPIN INDICATION Hyperlipoproteinemia 3771-19-5 NAFENOPIN ADVERSE_EFFECT DNA_1_Carcinogenicity 3771-19-5 NAFENOPIN STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 3771-19-5 NAFENOPIN INDICATION Hyperlipidemia 3771-19-5 NAFENOPIN MECHANISM Increase lipid catabolism 3771-19-5 NAFENOPIN KNOWN_TOXICITY Carcinogenicity 3771-19-5 NAFENOPIN MECHANISM Increase cellular reactive oxygen species 3771-19-5 NAFENOPIN INDICATION Hypercholesterolemia 3771-19-5 NAFENOPIN THERAPEUTIC_CLASS Hypolipidemic Agents 3771-19-5 NAFENOPIN TISSUE_TOXICITY Carcinogenicity 3771-19-5 NAFENOPIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 3771-19-5 NAFENOPIN MODE_CLASS Receptor Agonist, selective 56974-61-9 GABEXATE PRODUCT_CLASS Biochemicals 56974-61-9 GABEXATE MODE_CLASS Enzyme Inhibitor 284461-73-0 SORAFENIB ADVERSE_EFFECT XXX_1_Xerosis 284461-73-0 SORAFENIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 284461-73-0 SORAFENIB TISSUE_TOXICITY Myocardial Infarction 284461-73-0 SORAFENIB PRODUCT_CLASS Anti-cancers 284461-73-0 SORAFENIB KNOWN_TOXICITY Blood & Bone Marrow Toxicity 284461-73-0 SORAFENIB ADVERSE_EFFECT XXX_2_Weight Loss 284461-73-0 SORAFENIB ADVERSE_EFFECT GIS_1_Abdominal Pain 284461-73-0 SORAFENIB ADVERSE_EFFECT BBM_1_Pancytopenia 284461-73-0 SORAFENIB ADVERSE_EFFECT SKN_1_Pruritis 284461-73-0 SORAFENIB ADVERSE_EFFECT CVS_3_Myocardial Infarction 284461-73-0 SORAFENIB ADVERSE_EFFECT CVS_1_Hypertension 284461-73-0 SORAFENIB ADVERSE_EFFECT LUN_1_Dyspnea 284461-73-0 SORAFENIB ADVERSE_EFFECT PSY_1_Anorexia 284461-73-0 SORAFENIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 284461-73-0 SORAFENIB ADVERSE_EFFECT END_1_Hypophosphatemia 284461-73-0 SORAFENIB ADVERSE_EFFECT XXX_1_Fatigue 284461-73-0 SORAFENIB TISSUE_TOXICITY Anemia 284461-73-0 SORAFENIB ADVERSE_EFFECT BBM_1_Bleeding 284461-73-0 SORAFENIB INDICATION Neoplasm / Cancer / Tumor 284461-73-0 SORAFENIB TISSUE_TOXICITY Neutropenia 284461-73-0 SORAFENIB KNOWN_TOXICITY Cardiovascular Toxicity 284461-73-0 SORAFENIB THERAPEUTIC_CLASS Antineoplastics 284461-73-0 SORAFENIB TISSUE_TOXICITY Leukopenia 284461-73-0 SORAFENIB TISSUE_TOXICITY Thrombocytopenia 284461-73-0 SORAFENIB MODE_CLASS Enzyme Inhibitor 284461-73-0 SORAFENIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Raf) inhibitor 284461-73-0 SORAFENIB ADVERSE_EFFECT BBM_1_Anemia 284461-73-0 SORAFENIB ADVERSE_EFFECT GIS_1_Diarrhea 284461-73-0 SORAFENIB ADVERSE_EFFECT GIS_1_Hyperamylasemia 284461-73-0 SORAFENIB ADVERSE_EFFECT BBM_1_Leukopenia 284461-73-0 SORAFENIB ADVERSE_EFFECT XXX_1_Palmar-Plantar Erythrodysesthesia 284461-73-0 SORAFENIB ADVERSE_EFFECT BBM_1_Thrombocytopenia 284461-73-0 SORAFENIB MECHANISM Inhibit kinase mediated signal transduction 284461-73-0 SORAFENIB ADVERSE_EFFECT GIS_1_Constipation 284461-73-0 SORAFENIB ADVERSE_EFFECT NEU_2_Headache 284461-73-0 SORAFENIB ADVERSE_EFFECT REP_3_Infertility 284461-73-0 SORAFENIB ADVERSE_EFFECT BBM_1_Neutropenia 284461-73-0 SORAFENIB ADVERSE_EFFECT SKN_1_Rash 284461-73-0 SORAFENIB TISSUE_TOXICITY Bleeding 284461-73-0 SORAFENIB TISSUE_TOXICITY Pancytopenia 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT OCU_1_Decreased Visual Acuity 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT KID_2_Proteinuria 7487-94-7 MERCURIC CHLORIDE TISSUE_TOXICITY Acute Renal Failure 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT EMB_3_Embryotoxicity 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT DNA_2_Genotoxicity 7487-94-7 MERCURIC CHLORIDE TISSUE_TOXICITY Carcinogenicity 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT EMB_2_Fetal Death 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT DNA_2_Mutagenicity 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT OCU_2_Retinal Damage 7487-94-7 MERCURIC CHLORIDE KNOWN_TOXICITY Carcinogenicity 7487-94-7 MERCURIC CHLORIDE KNOWN_TOXICITY Nephrotoxicity 7487-94-7 MERCURIC CHLORIDE TISSUE_TOXICITY Mutagenicity 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT KID_2_Acute Renal Failure 7487-94-7 MERCURIC CHLORIDE KNOWN_TOXICITY Mutagenicity 7487-94-7 MERCURIC CHLORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 7487-94-7 MERCURIC CHLORIDE TISSUE_TOXICITY Genotoxicity 7487-94-7 MERCURIC CHLORIDE PRODUCT_CLASS Toxicants 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT DNA_2_Clastogenicity 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 7487-94-7 MERCURIC CHLORIDE ACTIVITY_CLASS Toxicant 7487-94-7 MERCURIC CHLORIDE ADVERSE_EFFECT CVS_3_Hypertension 7487-94-7 MERCURIC CHLORIDE TISSUE_TOXICITY Clastogenicity 62-55-5 THIOACETAMIDE ADVERSE_EFFECT LIV_2_Fatty Degeneration 62-55-5 THIOACETAMIDE ADVERSE_EFFECT NEU_3_Coma 62-55-5 THIOACETAMIDE TISSUE_TOXICITY Death 62-55-5 THIOACETAMIDE KNOWN_TOXICITY Miscellaneous 62-55-5 THIOACETAMIDE ADVERSE_EFFECT LUN_3_Respiratory Failure 62-55-5 THIOACETAMIDE ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 62-55-5 THIOACETAMIDE ADVERSE_EFFECT NEU_2_Ataxia 62-55-5 THIOACETAMIDE TISSUE_TOXICITY Hepatic Necrosis 62-55-5 THIOACETAMIDE ADVERSE_EFFECT XXX_2_Fibrosis 62-55-5 THIOACETAMIDE ADVERSE_EFFECT END_2_Irregularities in Bone Growth 62-55-5 THIOACETAMIDE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 62-55-5 THIOACETAMIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 62-55-5 THIOACETAMIDE TISSUE_TOXICITY Hepatocellular Carcinoma 62-55-5 THIOACETAMIDE TISSUE_TOXICITY Liver Cirrhosis 62-55-5 THIOACETAMIDE KNOWN_TOXICITY Hepatotoxicity 62-55-5 THIOACETAMIDE MECHANISM Modulate gene transcription 62-55-5 THIOACETAMIDE ACTIVITY_CLASS Toxicant 62-55-5 THIOACETAMIDE STRUCTURE_ACTIVITY Toxicant, free radical generator 62-55-5 THIOACETAMIDE ADVERSE_EFFECT LIV_2_Hepatic Necrosis 62-55-5 THIOACETAMIDE ADVERSE_EFFECT LIV_2_Hepatic Damage 62-55-5 THIOACETAMIDE ADVERSE_EFFECT XXX_3_Death 62-55-5 THIOACETAMIDE TISSUE_TOXICITY Carcinogenicity 62-55-5 THIOACETAMIDE PRODUCT_CLASS Toxicants 62-55-5 THIOACETAMIDE KNOWN_TOXICITY Carcinogenicity 62-55-5 THIOACETAMIDE ADVERSE_EFFECT LIV_1_Inhibition of P450 71-43-2 BENZENE STRUCTURE_ACTIVITY Toxicant 71-43-2 BENZENE PRODUCT_CLASS Toxicants 11050-21-8 CIGUATOXIN PRODUCT_CLASS Toxicants 11050-21-8 CIGUATOXIN MODE_CLASS Channel Blocker 11050-21-8 CIGUATOXIN MECHANISM Block neural transmission 202825-46-5 SAFINAMIDE MECHANISM Modulate channel gating 202825-46-5 SAFINAMIDE MECHANISM Block neural transmission 202825-46-5 SAFINAMIDE MODE_CLASS Channel Blocker 133865-89-1 SAFINAMIDE MECHANISM Block neural transmission 133865-89-1 SAFINAMIDE MECHANISM Modulate channel gating 133865-89-1 SAFINAMIDE MODE_CLASS Channel Blocker 100643-71-8 DESLORATADINE MODE_CLASS Receptor Ligand Antagonist 100643-71-8 DESLORATADINE MECHANISM Modulate G-protein coupled signal transduction 100643-71-8 DESLORATADINE ADVERSE_EFFECT NEU_3_Somnolence 100643-71-8 DESLORATADINE ADVERSE_EFFECT XXX_3_Fatigue 100643-71-8 DESLORATADINE ACTIVITY_CLASS Histamine antagonist 100643-71-8 DESLORATADINE PRODUCT_CLASS Anti-inflammatories 100643-71-8 DESLORATADINE INDICATION Pruritus / Itching 100643-71-8 DESLORATADINE ADVERSE_EFFECT NEU_3_Dizziness 100643-71-8 DESLORATADINE ADVERSE_EFFECT MSK_3_Myalgia 100643-71-8 DESLORATADINE ADVERSE_EFFECT REP_3_Dysmenorrhea 100643-71-8 DESLORATADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, tricyclic 100643-71-8 DESLORATADINE ADVERSE_EFFECT GIS_2_Dry Mouth 100643-71-8 DESLORATADINE INDICATION Allergic Rhinitis 100643-71-8 DESLORATADINE THERAPEUTIC_CLASS Antihistamines 100643-71-8 DESLORATADINE ADVERSE_EFFECT NEU_3_Headache 100643-71-8 DESLORATADINE ADVERSE_EFFECT XXX_2_Pharyngitis 100643-71-8 DESLORATADINE INDICATION Urticaria / Hives 10102-18-8 SODIUM SELENITE TISSUE_TOXICITY Liver Cirrhosis 10102-18-8 SODIUM SELENITE MODE_CLASS Enzyme Inhibitor 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT PSY_1_Nervousness 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT OCU_2_Cataracts 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT DNA_2_Malignant Tumors 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT SKN_2_Nail Disorder 10102-18-8 SODIUM SELENITE KNOWN_TOXICITY Miscellaneous 10102-18-8 SODIUM SELENITE STRUCTURE_ACTIVITY Toxicant, selenium 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT XXX_1_Hypothermia 10102-18-8 SODIUM SELENITE TISSUE_TOXICITY Carcinogenicity 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT LIV_2_Hepatic Necrosis 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT XXX_3_Death 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT END_2_Growth Inhibition 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT GIS_1_Gastrointestinal Disorder 10102-18-8 SODIUM SELENITE KNOWN_TOXICITY Carcinogenicity 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT EMB_2_Abortion 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT EMB_2_Fetal Death 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT XXX_2_Splenomegaly 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT GIS_1_Metallic Taste 10102-18-8 SODIUM SELENITE ACTIVITY_CLASS Toxicant 10102-18-8 SODIUM SELENITE TISSUE_TOXICITY Death 10102-18-8 SODIUM SELENITE MECHANISM Inhibit eicosanoid biosynthesis 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT BBM_3_Anemia 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT GIS_1_Garlicky Breath 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT SKN_1_Skin Hypopigmentation 10102-18-8 SODIUM SELENITE KNOWN_TOXICITY Hepatotoxicity 10102-18-8 SODIUM SELENITE TISSUE_TOXICITY Hepatic Necrosis 10102-18-8 SODIUM SELENITE PRODUCT_CLASS Toxicants 10102-18-8 SODIUM SELENITE ADVERSE_EFFECT LIV_2_Fatty Degeneration 198480-56-7 BAZEDOXIFENE THERAPEUTIC_CLASS Bone Mineral Homeostasis 198480-56-7 BAZEDOXIFENE THERAPEUTIC_CLASS Antineoplastics 198480-56-7 BAZEDOXIFENE MECHANISM Modulate gene transcription 198480-56-7 BAZEDOXIFENE INDICATION Breast Cancer / Carcinoma of the Breast 198480-56-7 BAZEDOXIFENE MODE_CLASS Receptor Modulator 198480-56-7 BAZEDOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 198480-56-7 BAZEDOXIFENE INDICATION Osteoporosis 198480-56-7 BAZEDOXIFENE PRODUCT_CLASS Anti-cancers 198480-56-7 BAZEDOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 387867-13-2 MLN-518 INDICATION Myelodysplastic Syndromes 387867-13-2 MLN-518 INDICATION Glioma 387867-13-2 MLN-518 ADVERSE_EFFECT BBM_3_Hematotoxicity 387867-13-2 MLN-518 MECHANISM Inhibit kinase mediated signal transduction 387867-13-2 MLN-518 ADVERSE_EFFECT BBM_1_Reversible Neutropenia 387867-13-2 MLN-518 ADVERSE_EFFECT BBM_2_Neutropenia 387867-13-2 MLN-518 INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 387867-13-2 MLN-518 PRODUCT_CLASS Anti-cancers 387867-13-2 MLN-518 THERAPEUTIC_CLASS Antineoplastics 387867-13-2 MLN-518 MODE_CLASS Enzyme Inhibitor 387867-13-2 MLN-518 STRUCTURE_ACTIVITY Protein-tyrosine kinase (Flt3) inhibitor 387867-13-2 MLN-518 ADVERSE_EFFECT XXX_1_Infection 387867-13-2 MLN-518 ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 58-60-6 PUROMYCIN AMINONUCLEOSIDE PRODUCT_CLASS Biochemicals 58-60-6 PUROMYCIN AMINONUCLEOSIDE TISSUE_TOXICITY Renal Failure 58-60-6 PUROMYCIN AMINONUCLEOSIDE ADVERSE_EFFECT KID_1_Renal Failure 58-60-6 PUROMYCIN AMINONUCLEOSIDE STRUCTURE_ACTIVITY Toxicant 58-60-6 PUROMYCIN AMINONUCLEOSIDE MECHANISM Inhibit ribosomal protein synthesis 58-60-6 PUROMYCIN AMINONUCLEOSIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 58-60-6 PUROMYCIN AMINONUCLEOSIDE TISSUE_TOXICITY Nephrotoxicity 58-60-6 PUROMYCIN AMINONUCLEOSIDE KNOWN_TOXICITY Nephrotoxicity 58-60-6 PUROMYCIN AMINONUCLEOSIDE ADVERSE_EFFECT KID_1_Proteinuria 58-60-6 PUROMYCIN AMINONUCLEOSIDE ADVERSE_EFFECT END_2_Hyperlipidemia 58-60-6 PUROMYCIN AMINONUCLEOSIDE ADVERSE_EFFECT KID_1_Glomerular Dysfunction 58-60-6 PUROMYCIN AMINONUCLEOSIDE ADVERSE_EFFECT KID_1_Nephrotoxicity 58-60-6 PUROMYCIN AMINONUCLEOSIDE ADVERSE_EFFECT END_2_Hypertriglyceridemia 82115-62-6 INTERFERON GAMMA PRODUCT_CLASS Anti-cancers 82115-62-6 INTERFERON GAMMA PRODUCT_CLASS Anti-infectives 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT BBM_2_Neutropenia 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT PSY_2_Confusion 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT NEU_1_Headache 82115-62-6 INTERFERON GAMMA THERAPEUTIC_CLASS Antibacterials, Systemic 82115-62-6 INTERFERON GAMMA PRODUCT_CLASS Immune Response / Immunomodulators 82115-62-6 INTERFERON GAMMA INDICATION Allergic Contact Dermatitis 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT MSK_2_Arthralgia 82115-62-6 INTERFERON GAMMA INDICATION Pulmonary Fibrosis 82115-62-6 INTERFERON GAMMA THERAPEUTIC_CLASS Antivirals, Systemic 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT XXX_1_Injection Site Reaction 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT XXX_2_Diaphoresis 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT MSK_2_Myalgia 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT IMU_3_Urticaria 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT SKN_1_Rash 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT GIS_1_Nausea / Vomiting 82115-62-6 INTERFERON GAMMA THERAPEUTIC_CLASS Antineoplastics 82115-62-6 INTERFERON GAMMA INDICATION Hepatitis C 82115-62-6 INTERFERON GAMMA INDICATION Systemic Sclerosis / Scleroderma 82115-62-6 INTERFERON GAMMA INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 82115-62-6 INTERFERON GAMMA THERAPEUTIC_CLASS Immunomodulants 82115-62-6 INTERFERON GAMMA MODE_CLASS Receptor /Channel ligand mimic 82115-62-6 INTERFERON GAMMA PRODUCT_CLASS Vitamins, Minerals and Nutrients 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT XXX_1_Fever 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT NEU_2_Dizziness 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT SKN_3_Maculopapular Rash 82115-62-6 INTERFERON GAMMA THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT XXX_1_Chills 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT SKN_1_Erythema 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT NEU_2_Ataxia 82115-62-6 INTERFERON GAMMA ADVERSE_EFFECT XXX_1_Fatigue 82115-62-6 INTERFERON GAMMA INDICATION Septic Shock 82115-62-6 INTERFERON GAMMA INDICATION Ovarian Cancer / Carcinoma of the Ovary 82115-62-6 INTERFERON GAMMA INDICATION Mycobacterium Avium Complex (MAC) 82115-62-6 INTERFERON GAMMA INDICATION Hepatitis B 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL ADVERSE_EFFECT LIV_1_Hepatitis 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL ADVERSE_EFFECT LIV_2_Fatty Liver 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL MODE_CLASS Enzyme Inhibitor 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL ADVERSE_EFFECT XXX_2_Fat Accumulation 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL PRODUCT_CLASS Biochemicals 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL ACTIVITY_CLASS Toxicant 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL MECHANISM Inhibit lipid beta-oxidation 2691-45-4 4,4'-DIETHYLAMINOETHOXYHEXESTROL STRUCTURE_ACTIVITY Toxicant, phospholipidosis inducer 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL ADVERSE_EFFECT LIV_2_Fatty Liver 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL MODE_CLASS Enzyme Inhibitor 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL ADVERSE_EFFECT XXX_2_Fat Accumulation 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL STRUCTURE_ACTIVITY Toxicant, phospholipidosis inducer 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL MECHANISM Inhibit lipid beta-oxidation 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL ADVERSE_EFFECT LIV_1_Hepatitis 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL ACTIVITY_CLASS Toxicant 69-14-7 4,4'-DIETHYLAMINOETHOXYHEXESTROL PRODUCT_CLASS Biochemicals 83881-51-0 CETIRIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 83881-51-0 CETIRIZINE MECHANISM Modulate G-protein coupled signal transduction 83881-51-0 CETIRIZINE ADVERSE_EFFECT PSY_3_Anxiety 83881-51-0 CETIRIZINE ADVERSE_EFFECT LUN_2_Cough 83881-51-0 CETIRIZINE ADVERSE_EFFECT NEU_1_Drowsiness 83881-51-0 CETIRIZINE ADVERSE_EFFECT GUS_3_Dysuria 83881-51-0 CETIRIZINE ADVERSE_EFFECT XXX_1_Xerostomia 83881-51-0 CETIRIZINE MODE_CLASS Receptor Ligand Antagonist, Selective 83881-51-0 CETIRIZINE INDICATION Allergic Rhinitis 83881-51-0 CETIRIZINE ADVERSE_EFFECT PSY_3_Insomnia 83881-51-0 CETIRIZINE ADVERSE_EFFECT XXX_1_Fatigue 83881-51-0 CETIRIZINE ADVERSE_EFFECT XXX_2_Pharyngitis 83881-51-0 CETIRIZINE INDICATION Urticaria / Hives 83881-51-0 CETIRIZINE ADVERSE_EFFECT PSY_3_Anorexia 83881-51-0 CETIRIZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 83881-51-0 CETIRIZINE ADVERSE_EFFECT NEU_1_Dizziness 83881-51-0 CETIRIZINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 83881-51-0 CETIRIZINE ADVERSE_EFFECT SKN_3_Rash 83881-51-0 CETIRIZINE ADVERSE_EFFECT LIV_3_Hepatitis 83881-51-0 CETIRIZINE ADVERSE_EFFECT XXX_2_Epistaxis 83881-51-0 CETIRIZINE THERAPEUTIC_CLASS Antihistamines 83881-51-0 CETIRIZINE PRODUCT_CLASS Anti-inflammatories 83881-51-0 CETIRIZINE ADVERSE_EFFECT CVS_3_Hypertension 83881-51-0 CETIRIZINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 83881-51-0 CETIRIZINE ADVERSE_EFFECT NEU_2_Headache 83881-51-0 CETIRIZINE ADVERSE_EFFECT LUN_2_Bronchospasm 83881-51-0 CETIRIZINE ADVERSE_EFFECT GIS_2_Abdominal Pain 83881-51-0 CETIRIZINE ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 83881-52-1 CETIRIZINE ADVERSE_EFFECT GIS_2_Abdominal Pain 83881-52-1 CETIRIZINE ADVERSE_EFFECT NEU_1_Drowsiness 83881-52-1 CETIRIZINE ADVERSE_EFFECT GUS_3_Dysuria 83881-52-1 CETIRIZINE ADVERSE_EFFECT SKN_3_Rash 83881-52-1 CETIRIZINE ADVERSE_EFFECT XXX_1_Xerostomia 83881-52-1 CETIRIZINE ADVERSE_EFFECT XXX_1_Fatigue 83881-52-1 CETIRIZINE ADVERSE_EFFECT PSY_3_Insomnia 83881-52-1 CETIRIZINE MODE_CLASS Receptor Ligand Antagonist, Selective 83881-52-1 CETIRIZINE ADVERSE_EFFECT CVS_3_Hypertension 83881-52-1 CETIRIZINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 83881-52-1 CETIRIZINE ADVERSE_EFFECT NEU_2_Headache 83881-52-1 CETIRIZINE ADVERSE_EFFECT LUN_2_Bronchospasm 83881-52-1 CETIRIZINE INDICATION Allergic Rhinitis 83881-52-1 CETIRIZINE ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 83881-52-1 CETIRIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 83881-52-1 CETIRIZINE MECHANISM Modulate G-protein coupled signal transduction 83881-52-1 CETIRIZINE ADVERSE_EFFECT PSY_3_Anxiety 83881-52-1 CETIRIZINE PRODUCT_CLASS Anti-inflammatories 83881-52-1 CETIRIZINE ADVERSE_EFFECT LUN_2_Cough 83881-52-1 CETIRIZINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 83881-52-1 CETIRIZINE ADVERSE_EFFECT XXX_2_Pharyngitis 83881-52-1 CETIRIZINE INDICATION Urticaria / Hives 83881-52-1 CETIRIZINE ADVERSE_EFFECT PSY_3_Anorexia 83881-52-1 CETIRIZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 83881-52-1 CETIRIZINE ADVERSE_EFFECT NEU_1_Dizziness 83881-52-1 CETIRIZINE ADVERSE_EFFECT LIV_3_Hepatitis 83881-52-1 CETIRIZINE ADVERSE_EFFECT XXX_2_Epistaxis 83881-52-1 CETIRIZINE THERAPEUTIC_CLASS Antihistamines 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT EMB_2_Teratogenic Fetal Damage 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT GIS_1_Gastrointestinal Disorder 56-57-5 4-NITROQUINOLINE-N-OXIDE TISSUE_TOXICITY Carcinogenicity 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT DNA_2_Mutagenicity 56-57-5 4-NITROQUINOLINE-N-OXIDE TISSUE_TOXICITY Gastric Erosion 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT LUN_1_Pulmonary Edema 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT NEU_3_Peripheral Neurotoxicity 56-57-5 4-NITROQUINOLINE-N-OXIDE KNOWN_TOXICITY Gastrointestinal Toxicity 56-57-5 4-NITROQUINOLINE-N-OXIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT GIS_1_Gastric Erosion 56-57-5 4-NITROQUINOLINE-N-OXIDE TISSUE_TOXICITY Pulmonary Edema 56-57-5 4-NITROQUINOLINE-N-OXIDE KNOWN_TOXICITY Carcinogenicity 56-57-5 4-NITROQUINOLINE-N-OXIDE KNOWN_TOXICITY Mutagenicity 56-57-5 4-NITROQUINOLINE-N-OXIDE TISSUE_TOXICITY Mutagenicity 56-57-5 4-NITROQUINOLINE-N-OXIDE STRUCTURE_ACTIVITY Toxicant 56-57-5 4-NITROQUINOLINE-N-OXIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 56-57-5 4-NITROQUINOLINE-N-OXIDE PRODUCT_CLASS Toxicants 56-57-5 4-NITROQUINOLINE-N-OXIDE KNOWN_TOXICITY Respiratory Toxicity 5534-95-2 PENTAGASTRIN MECHANISM Modulate G-protein coupled signal transduction 5534-95-2 PENTAGASTRIN MODE_CLASS Receptor Agonist 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT DNA_2_Malignant Tumors 434-13-9 LITHOCHOLIC ACID KNOWN_TOXICITY Hepatotoxicity 434-13-9 LITHOCHOLIC ACID TISSUE_TOXICITY Malignant Tumors 434-13-9 LITHOCHOLIC ACID MODE_CLASS Enzyme Inhibitor 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT XXX_1_Weight Loss 434-13-9 LITHOCHOLIC ACID KNOWN_TOXICITY Carcinogenicity 434-13-9 LITHOCHOLIC ACID TISSUE_TOXICITY Mutagenicity 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 434-13-9 LITHOCHOLIC ACID ACTIVITY_CLASS FXR agonist 434-13-9 LITHOCHOLIC ACID STRUCTURE_ACTIVITY Toxicant, PXR inducer 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT LIV_1_Hepatic Damage 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT LIV_2_Hepatotoxicity 434-13-9 LITHOCHOLIC ACID MODE_CLASS Receptor Agonist 434-13-9 LITHOCHOLIC ACID MECHANISM Inhibit protein synthesis 434-13-9 LITHOCHOLIC ACID KNOWN_TOXICITY Mutagenicity 434-13-9 LITHOCHOLIC ACID TISSUE_TOXICITY Carcinogenicity 434-13-9 LITHOCHOLIC ACID TISSUE_TOXICITY Hepatotoxicity 434-13-9 LITHOCHOLIC ACID PRODUCT_CLASS Biochemicals 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT DNA_1_Carcinogenicity 434-13-9 LITHOCHOLIC ACID MECHANISM Modulate gene transcription 434-13-9 LITHOCHOLIC ACID TISSUE_TOXICITY Hepatocellular Carcinoma 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT DNA_2_Mutagenicity 434-13-9 LITHOCHOLIC ACID ADVERSE_EFFECT KID_2_Nephritis 1759-53-1 CYCLOPROPANE CARBOXYLIC ACID ADVERSE_EFFECT END_1_Hypoglycemia 1759-53-1 CYCLOPROPANE CARBOXYLIC ACID PRODUCT_CLASS Biochemicals 1759-53-1 CYCLOPROPANE CARBOXYLIC ACID STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits beta-oxidation 1759-53-1 CYCLOPROPANE CARBOXYLIC ACID ACTIVITY_CLASS Mitochondrial toxicant 1759-53-1 CYCLOPROPANE CARBOXYLIC ACID ADVERSE_EFFECT LIV_2_Impaired Liver Function 156-56-9 HYPOGLYCIN A KNOWN_TOXICITY Miscellaneous 156-56-9 HYPOGLYCIN A TISSUE_TOXICITY Hepatotoxicity 156-56-9 HYPOGLYCIN A KNOWN_TOXICITY Hepatotoxicity 156-56-9 HYPOGLYCIN A TISSUE_TOXICITY Death 156-56-9 HYPOGLYCIN A STRUCTURE_ACTIVITY Carnitine palmitoyltransferase inhibitor 156-56-9 HYPOGLYCIN A PRODUCT_CLASS Toxicants 124151-60-6 ETOMOXIR STRUCTURE_ACTIVITY Carnitine palmitoyltransferase inhibitor 124151-60-6 ETOMOXIR MECHANISM Inhibit lipid beta-oxidation 124151-60-6 ETOMOXIR MODE_CLASS Enzyme Inhibitor 124083-14-3 ETOMOXIR MODE_CLASS Enzyme Inhibitor 124083-14-3 ETOMOXIR MECHANISM Inhibit lipid beta-oxidation 124083-14-3 ETOMOXIR STRUCTURE_ACTIVITY Carnitine palmitoyltransferase inhibitor 124083-20-1 ETOMOXIR MECHANISM Inhibit lipid beta-oxidation 124083-20-1 ETOMOXIR MODE_CLASS Enzyme Inhibitor 124083-20-1 ETOMOXIR STRUCTURE_ACTIVITY Carnitine palmitoyltransferase inhibitor 191219-80-4 YM-976 STRUCTURE_ACTIVITY PDE4 inhibitor 191219-80-4 YM-976 MODE_CLASS Enzyme Inhibitor 189940-24-7 ZK-117137 STRUCTURE_ACTIVITY PDE4 inhibitor 189940-24-7 ZK-117137 MODE_CLASS Enzyme Inhibitor 192755-52-5 PRALNACASAN PRODUCT_CLASS Anti-inflammatories 192755-52-5 PRALNACASAN MODE_CLASS Enzyme Inhibitor 192755-52-5 PRALNACASAN INDICATION Psoriasis 192755-52-5 PRALNACASAN ADVERSE_EFFECT GIS_2_Nausea 192755-52-5 PRALNACASAN MECHANISM Inhibit inflammatory response 192755-52-5 PRALNACASAN INDICATION Osteoarthritis 192755-52-5 PRALNACASAN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 192755-52-5 PRALNACASAN INDICATION Rheumatoid Arthritis 192755-52-5 PRALNACASAN ADVERSE_EFFECT GIS_2_Diarrhea 192755-52-5 PRALNACASAN INDICATION Inflammation 192755-52-5 PRALNACASAN STRUCTURE_ACTIVITY Interleukin converting enzyme (ICE) inhibitor 192755-52-5 PRALNACASAN INDICATION Inflammatory Bowel Disease (IBD) 224785-90-4 VARDENAFIL STRUCTURE_ACTIVITY PDE5 inhibitor 224785-90-4 VARDENAFIL INDICATION Erectile Dysfunction 224785-90-4 VARDENAFIL PRODUCT_CLASS Cardiovasculars 224785-90-4 VARDENAFIL THERAPEUTIC_CLASS Vasodilators 171596-29-5 TADALAFIL STRUCTURE_ACTIVITY PDE5 inhibitor 171596-29-5 TADALAFIL INDICATION Erectile Dysfunction 171596-29-5 TADALAFIL MECHANISM Enhance kinase mediated signal transduction 171596-29-5 TADALAFIL MODE_CLASS Enzyme Inhibitor, selective 171596-29-5 TADALAFIL PRODUCT_CLASS Cardiovasculars 171596-29-5 TADALAFIL THERAPEUTIC_CLASS Vasodilators 144598-75-4 PALIPERIDONE INDICATION Schizophrenia 144598-75-4 PALIPERIDONE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist 151165-96-7 S-8921 STRUCTURE_ACTIVITY Bile acid transporter (ileal) inhibitor 151165-96-7 S-8921 PRODUCT_CLASS Cardiovasculars 151165-96-7 S-8921 MECHANISM Decrease bile acid reabsorption 151165-96-7 S-8921 MODE_CLASS Channel Modulator 280105-85-3 SC-435 STRUCTURE_ACTIVITY Bile acid transporter (ileal) inhibitor 280105-85-3 SC-435 MODE_CLASS Channel Modulator 280105-85-3 SC-435 PRODUCT_CLASS Cardiovasculars 280105-85-3 SC-435 MECHANISM Decrease bile acid reabsorption 226700-79-4 FOSAMPRENAVIR MODE_CLASS Enzyme Inhibitor 226700-79-4 FOSAMPRENAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 226700-79-4 FOSAMPRENAVIR PRODUCT_CLASS Anti-infectives 226700-79-4 FOSAMPRENAVIR MECHANISM Inhibit post transcriptional protein processing 226700-80-7 FOSAMPRENAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 226700-80-7 FOSAMPRENAVIR MECHANISM Inhibit post transcriptional protein processing 226700-80-7 FOSAMPRENAVIR PRODUCT_CLASS Anti-infectives 226700-80-7 FOSAMPRENAVIR MODE_CLASS Enzyme Inhibitor 124508-66-3 TRIPTORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 124508-66-3 TRIPTORELIN MODE_CLASS Receptor Agonist 124508-66-3 TRIPTORELIN PRODUCT_CLASS Anti-cancers 129497-78-5 VERTEPORFIN PRODUCT_CLASS Anti-cancers 129497-78-5 VERTEPORFIN STRUCTURE_ACTIVITY H2O2 radical scavenger 204248-78-2 OMIGANAN MECHANISM Destroy cell membrane / wall integrity 204248-78-2 OMIGANAN STRUCTURE_ACTIVITY Impairs cell membrane function 204248-78-2 OMIGANAN PRODUCT_CLASS Anti-infectives 204248-78-2 OMIGANAN MODE_CLASS Distorts /blocks macromolecular scaffold function 269062-93-3 OMIGANAN PRODUCT_CLASS Anti-infectives 269062-93-3 OMIGANAN MODE_CLASS Distorts /blocks macromolecular scaffold function 269062-93-3 OMIGANAN MECHANISM Destroy cell membrane / wall integrity 269062-93-3 OMIGANAN STRUCTURE_ACTIVITY Impairs cell membrane function 259188-38-0 REBIMASTAT MODE_CLASS Enzyme Inhibitor, selective 259188-38-0 REBIMASTAT PRODUCT_CLASS Anti-cancers 259188-38-0 REBIMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 330600-85-6 PERAMIVIR STRUCTURE_ACTIVITY Viral neuraminidase inhibitor 72741-87-8 TRIDOLGOSIR STRUCTURE_ACTIVITY Mannosidase inhibitor 72741-87-8 TRIDOLGOSIR MODE_CLASS Enzyme Inhibitor 72741-87-8 TRIDOLGOSIR PRODUCT_CLASS Anti-cancers 38101-59-6 OGLUFANIDE PRODUCT_CLASS Anti-cancers 38101-59-6 OGLUFANIDE MODE_CLASS Receptor Ligand Antagonist 38101-59-6 OGLUFANIDE MECHANISM Modulate growth factor receptor mediated signal transduction 38101-59-6 OGLUFANIDE STRUCTURE_ACTIVITY VEGF receptor antagonist 237068-57-4 OGLUFANIDE MECHANISM Modulate growth factor receptor mediated signal transduction 237068-57-4 OGLUFANIDE STRUCTURE_ACTIVITY VEGF receptor antagonist 237068-57-4 OGLUFANIDE PRODUCT_CLASS Anti-cancers 237068-57-4 OGLUFANIDE MODE_CLASS Receptor Ligand Antagonist 118384-10-4 LY-282449 STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 231277-92-2 LAPATINIB ADVERSE_EFFECT SKN_1_Rash 231277-92-2 LAPATINIB INDICATION Neoplasm / Cancer / Tumor 231277-92-2 LAPATINIB INDICATION Bladder Cancer / Carcinoma of the Bladder 231277-92-2 LAPATINIB INDICATION Lung Cancer / Carcinoma of the Lung 231277-92-2 LAPATINIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 231277-92-2 LAPATINIB ADVERSE_EFFECT GIS_2_Abdominal Pain 231277-92-2 LAPATINIB ADVERSE_EFFECT SKN_1_Acne 231277-92-2 LAPATINIB THERAPEUTIC_CLASS Antineoplastics 231277-92-2 LAPATINIB PRODUCT_CLASS Anti-cancers 231277-92-2 LAPATINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (erbb) inhibitor 231277-92-2 LAPATINIB MECHANISM Inhibit kinase mediated signal transduction 231277-92-2 LAPATINIB INDICATION Head and Neck Cancer 231277-92-2 LAPATINIB ADVERSE_EFFECT GIS_1_Nausea 231277-92-2 LAPATINIB ADVERSE_EFFECT GIS_1_Diarrhea 231277-92-2 LAPATINIB MODE_CLASS Enzyme Inhibitor 231277-92-2 LAPATINIB INDICATION Breast Cancer / Carcinoma of the Breast 231277-92-2 LAPATINIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 231277-92-2 LAPATINIB ADVERSE_EFFECT BBM_2_Anemia 231277-92-2 LAPATINIB INDICATION Non-Small Cell Lung Carcinoma 231277-92-2 LAPATINIB ADVERSE_EFFECT XXX_2_Fatigue 388082-77-7 LAPATINIB ADVERSE_EFFECT XXX_2_Fatigue 388082-77-7 LAPATINIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 388082-77-7 LAPATINIB INDICATION Neoplasm / Cancer / Tumor 388082-77-7 LAPATINIB ADVERSE_EFFECT SKN_1_Rash 388082-77-7 LAPATINIB INDICATION Bladder Cancer / Carcinoma of the Bladder 388082-77-7 LAPATINIB THERAPEUTIC_CLASS Antineoplastics 388082-77-7 LAPATINIB PRODUCT_CLASS Anti-cancers 388082-77-7 LAPATINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (erbb) inhibitor 388082-77-7 LAPATINIB MECHANISM Inhibit kinase mediated signal transduction 388082-77-7 LAPATINIB INDICATION Non-Small Cell Lung Carcinoma 388082-77-7 LAPATINIB INDICATION Head and Neck Cancer 388082-77-7 LAPATINIB ADVERSE_EFFECT GIS_1_Nausea 388082-77-7 LAPATINIB ADVERSE_EFFECT GIS_1_Diarrhea 388082-77-7 LAPATINIB MODE_CLASS Enzyme Inhibitor 388082-77-7 LAPATINIB INDICATION Breast Cancer / Carcinoma of the Breast 388082-77-7 LAPATINIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 388082-77-7 LAPATINIB ADVERSE_EFFECT BBM_2_Anemia 388082-77-7 LAPATINIB INDICATION Lung Cancer / Carcinoma of the Lung 388082-77-7 LAPATINIB ADVERSE_EFFECT SKN_1_Acne 388082-77-7 LAPATINIB ADVERSE_EFFECT GIS_2_Abdominal Pain 192185-68-5 TIPIFARNIB STRUCTURE_ACTIVITY Protein farnesyl transferase inhibitor 121569-61-7 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT LUN_3_Pulmonary Toxicity 121569-61-7 7-HYDROXYSTAUROSPORINE THERAPEUTIC_CLASS Antineoplastics 121569-61-7 7-HYDROXYSTAUROSPORINE MODE_CLASS Enzyme Inhibitor 121569-61-7 7-HYDROXYSTAUROSPORINE INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 121569-61-7 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT END_2_Lactic Acidosis 121569-61-7 7-HYDROXYSTAUROSPORINE INDICATION Chronic Lymphocytic Leukemia (CLL) 121569-61-7 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT END_1_Hyperglycemia 121569-61-7 7-HYDROXYSTAUROSPORINE STRUCTURE_ACTIVITY Protein-serine/threonine kinase (PKC) inhibitor 121569-61-7 7-HYDROXYSTAUROSPORINE INDICATION Neoplasm / Cancer / Tumor 121569-61-7 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT NEU_1_Headache 121569-61-7 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT GIS_1_Nausea 121569-61-7 7-HYDROXYSTAUROSPORINE PRODUCT_CLASS Anti-cancers 121569-61-7 7-HYDROXYSTAUROSPORINE MECHANISM Inhibit kinase mediated signal transduction 121569-61-7 7-HYDROXYSTAUROSPORINE INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 121569-61-7 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT MSK_2_Myalgia 125133-74-6 7-HYDROXYSTAUROSPORINE MECHANISM Inhibit kinase mediated signal transduction 125133-74-6 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT MSK_2_Myalgia 125133-74-6 7-HYDROXYSTAUROSPORINE THERAPEUTIC_CLASS Antineoplastics 125133-74-6 7-HYDROXYSTAUROSPORINE MODE_CLASS Enzyme Inhibitor 125133-74-6 7-HYDROXYSTAUROSPORINE INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 125133-74-6 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT END_2_Lactic Acidosis 125133-74-6 7-HYDROXYSTAUROSPORINE INDICATION Chronic Lymphocytic Leukemia (CLL) 125133-74-6 7-HYDROXYSTAUROSPORINE INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 125133-74-6 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT END_1_Hyperglycemia 125133-74-6 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT LUN_3_Pulmonary Toxicity 125133-74-6 7-HYDROXYSTAUROSPORINE STRUCTURE_ACTIVITY Protein-serine/threonine kinase (PKC) inhibitor 125133-74-6 7-HYDROXYSTAUROSPORINE INDICATION Neoplasm / Cancer / Tumor 125133-74-6 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT NEU_1_Headache 125133-74-6 7-HYDROXYSTAUROSPORINE ADVERSE_EFFECT GIS_1_Nausea 125133-74-6 7-HYDROXYSTAUROSPORINE PRODUCT_CLASS Anti-cancers 149647-78-9 SUBEROYLANILIDE HYDROXAMIC ACID STRUCTURE_ACTIVITY Histone deacetylase inhibitor 156511-34-1 L-739749 STRUCTURE_ACTIVITY Protein farnesyl transferase inhibitor 163042-96-4 CF-101 MODE_CLASS Receptor Agonist, selective 163042-96-4 CF-101 STRUCTURE_ACTIVITY Adenosine receptor agonist, 152918-18-8 CF-101 STRUCTURE_ACTIVITY Adenosine receptor agonist, 152918-18-8 CF-101 MODE_CLASS Receptor Agonist, selective 187724-61-4 PKI-166 INDICATION Prostatic Cancer / Carcinoma of the Prostate 187724-61-4 PKI-166 MODE_CLASS Enzyme Inhibitor 187724-61-4 PKI-166 MECHANISM Modulate growth factor receptor mediated signal transduction 187724-61-4 PKI-166 STRUCTURE_ACTIVITY Protein-tyrosine kinase (EGFR) inhibitor 187724-61-4 PKI-166 ADVERSE_EFFECT SKN_1_Skin Rash 187724-61-4 PKI-166 ADVERSE_EFFECT XXX_1_Fatigue 187724-61-4 PKI-166 INDICATION Bladder Cancer / Carcinoma of the Bladder 187724-61-4 PKI-166 INDICATION Lung Cancer / Carcinoma of the Lung 187724-61-4 PKI-166 ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 187724-61-4 PKI-166 ADVERSE_EFFECT GIS_1_Diarrhea 187724-61-4 PKI-166 THERAPEUTIC_CLASS Antineoplastics 187724-61-4 PKI-166 ADVERSE_EFFECT GIS_1_Nausea / Vomiting 187724-61-4 PKI-166 PRODUCT_CLASS Anti-cancers 187724-61-4 PKI-166 INDICATION Breast Cancer / Carcinoma of the Breast 187724-61-4 PKI-166 MECHANISM Inhibit kinase mediated signal transduction 187724-61-4 PKI-166 ADVERSE_EFFECT MSK_1_Myalgia 187724-61-4 PKI-166 INDICATION Neoplasm / Cancer / Tumor 187724-61-4 PKI-166 ADVERSE_EFFECT SKN_1_Rash 193807-60-2 S-3304 STRUCTURE_ACTIVITY Protease (MMP) inhibitor 26628-22-8 SODIUM AZIDE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 143-33-9 SODIUM CYANIDE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 461-78-9 CHLORPHENTERMINE MECHANISM Prolong/enhance neural transmission 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT PSY_2_Anorexia 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT PSY_2_Nervousness 461-78-9 CHLORPHENTERMINE KNOWN_TOXICITY Mutagenicity 461-78-9 CHLORPHENTERMINE INDICATION Obesity 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT DNA_3_Mutagenicity 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT NEU_3_CNS Overstimulation 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT CVS_2_Palpitation 461-78-9 CHLORPHENTERMINE THERAPEUTIC_CLASS Anorexiants 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT KID_2_Renal Insufficiency 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT CVS_2_Hypertension 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT NEU_2_Dizziness 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT GIS_1_Dyspepsia 461-78-9 CHLORPHENTERMINE MODE_CLASS Enzyme Inhibitor 461-78-9 CHLORPHENTERMINE PRODUCT_CLASS Central Nervous System (CNS) 461-78-9 CHLORPHENTERMINE PRODUCT_CLASS Toxicants 461-78-9 CHLORPHENTERMINE TISSUE_TOXICITY Mutagenicity 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT END_2_Hyperthyroidism 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT OCU_2_Mydriasis 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT PSY_2_Insomnia 461-78-9 CHLORPHENTERMINE STRUCTURE_ACTIVITY Toxicant 461-78-9 CHLORPHENTERMINE ADVERSE_EFFECT CVS_2_Cardiovascular Disorder 186392-65-4 INGLIFORIB STRUCTURE_ACTIVITY Glycogen phosphorylase inhibitor 186392-65-4 INGLIFORIB MECHANISM interfere with glucose metabolism 186392-65-4 INGLIFORIB MODE_CLASS Enzyme Inhibitor 110-00-9 FURAN ADVERSE_EFFECT LIV_2_Liver Necrosis 110-00-9 FURAN ADVERSE_EFFECT NEU_1_Headache 110-00-9 FURAN ADVERSE_EFFECT XXX_3_Death 110-00-9 FURAN ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 110-00-9 FURAN KNOWN_TOXICITY Miscellaneous 110-00-9 FURAN TISSUE_TOXICITY Liver Necrosis 110-00-9 FURAN ADVERSE_EFFECT XXX_1_Fatigue 110-00-9 FURAN KNOWN_TOXICITY Hepatotoxicity 110-00-9 FURAN ADVERSE_EFFECT LUN_2_Pulmonary Impairment 110-00-9 FURAN KNOWN_TOXICITY Cardiovascular Toxicity 110-00-9 FURAN ADVERSE_EFFECT CVS_1_Hypotension 110-00-9 FURAN TISSUE_TOXICITY Death 110-00-9 FURAN ADVERSE_EFFECT NEU_2_Anesthesia 110-00-9 FURAN ADVERSE_EFFECT PSY_3_CNS Toxicity 110-00-9 FURAN ADVERSE_EFFECT LUN_3_Asphyxia 110-00-9 FURAN ADVERSE_EFFECT KID_2_Kidney Damage 110-00-9 FURAN ADVERSE_EFFECT NEU_3_Convulsions 110-00-9 FURAN ADVERSE_EFFECT LIV_2_Hepatic Damage 110-00-9 FURAN TISSUE_TOXICITY Carcinogenicity 110-00-9 FURAN STRUCTURE_ACTIVITY Toxicant, DNA damaging 110-00-9 FURAN KNOWN_TOXICITY Nephrotoxicity 110-00-9 FURAN ACTIVITY_CLASS Toxicant, DNA damaging 110-00-9 FURAN ADVERSE_EFFECT KID_2_Tubular Necrosis 110-00-9 FURAN ADVERSE_EFFECT DNA_3_Carcinogenicity 110-00-9 FURAN ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 110-00-9 FURAN TISSUE_TOXICITY Tubular Necrosis 110-00-9 FURAN TISSUE_TOXICITY Hypotension 110-00-9 FURAN KNOWN_TOXICITY Carcinogenicity 25265-71-8 DIPROPYLENE GLYCOL STRUCTURE_ACTIVITY Toxicant 62-23-7 4-NITROBENZOIC ACID STRUCTURE_ACTIVITY Toxicant, DNA damaging 62-23-7 4-NITROBENZOIC ACID ADVERSE_EFFECT REP_2_Changes in Reproductive Function 62-23-7 4-NITROBENZOIC ACID ADVERSE_EFFECT XXX_1_Weight Loss 62-23-7 4-NITROBENZOIC ACID ACTIVITY_CLASS Toxicant, DNA damaging 62-23-7 4-NITROBENZOIC ACID ADVERSE_EFFECT SKN_1_Skin Irritation 62-23-7 4-NITROBENZOIC ACID ADVERSE_EFFECT REP_2_Decreased Fertility 124-48-1 DIBROMOCHLOROMETHANE TISSUE_TOXICITY Cardiotoxicity 124-48-1 DIBROMOCHLOROMETHANE PRODUCT_CLASS Toxicants 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT XXX_1_Weight Loss 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT NEU_2_Anesthesia 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT NEU_2_Ataxia 124-48-1 DIBROMOCHLOROMETHANE ACTIVITY_CLASS Toxicant 124-48-1 DIBROMOCHLOROMETHANE KNOWN_TOXICITY Miscellaneous 124-48-1 DIBROMOCHLOROMETHANE TISSUE_TOXICITY Mutagenicity 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT LIV_2_Hepatic Damage 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT END_1_Hypercholesteremia 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT XXX_3_Death 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT KID_2_Kidney Damage 124-48-1 DIBROMOCHLOROMETHANE KNOWN_TOXICITY Carcinogenicity 124-48-1 DIBROMOCHLOROMETHANE TISSUE_TOXICITY Genotoxicity 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT DNA_2_Mutagenicity 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT XXX_2_Prostration 124-48-1 DIBROMOCHLOROMETHANE STRUCTURE_ACTIVITY Toxicant, free radical generator 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT DNA_3_Genotoxicity 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT CVS_3_Cardiotoxicity 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT MSK_2_Muscle Weakness 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT PSY_2_CNS Depression 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT REP_1_Menstrual Abnormalities 124-48-1 DIBROMOCHLOROMETHANE TISSUE_TOXICITY Death 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT NEU_1_Sedation 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT DNA_2_Carcinogenicity 124-48-1 DIBROMOCHLOROMETHANE TISSUE_TOXICITY Carcinogenicity 124-48-1 DIBROMOCHLOROMETHANE KNOWN_TOXICITY Cardiovascular Toxicity 124-48-1 DIBROMOCHLOROMETHANE KNOWN_TOXICITY Mutagenicity 124-48-1 DIBROMOCHLOROMETHANE ADVERSE_EFFECT BBM_2_Hemorrhage 91-23-6 2-NITROANISOLE ACTIVITY_CLASS Toxicant, DNA damaging 91-23-6 2-NITROANISOLE ADVERSE_EFFECT KID_2_Renal Tubular Necrosis 91-23-6 2-NITROANISOLE TISSUE_TOXICITY Renal Tubular Necrosis 91-23-6 2-NITROANISOLE ADVERSE_EFFECT KID_1_Kidney Damage 91-23-6 2-NITROANISOLE ADVERSE_EFFECT DNA_3_Carcinogenicity 91-23-6 2-NITROANISOLE TISSUE_TOXICITY Carcinogenicity 91-23-6 2-NITROANISOLE ADVERSE_EFFECT LIV_1_Hepatic Damage 91-23-6 2-NITROANISOLE ADVERSE_EFFECT _2_Decreased Uterine Contractility 91-23-6 2-NITROANISOLE KNOWN_TOXICITY Nephrotoxicity 91-23-6 2-NITROANISOLE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 91-23-6 2-NITROANISOLE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 91-23-6 2-NITROANISOLE KNOWN_TOXICITY Carcinogenicity 111-42-2 DIETHANOLAMINE STRUCTURE_ACTIVITY Toxicant 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT DNA_2_Carcinogenicity 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT SKN_2_Skin Irritation 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT XXX_3_Death 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT XXX_1_Salivation 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT OCU_1_Pupillary Dilation 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT CVS_1_Hypertension 111-42-2 DIETHANOLAMINE TISSUE_TOXICITY Cardiovascular Collapse 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT LUN_2_Airway Irritation 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT NEU_3_Coma 111-42-2 DIETHANOLAMINE KNOWN_TOXICITY Cardiovascular Toxicity 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT NEU_3_Sedation 111-42-2 DIETHANOLAMINE KNOWN_TOXICITY Carcinogenicity 111-42-2 DIETHANOLAMINE TISSUE_TOXICITY Carcinogenicity 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT OCU_2_Eye Irritation 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT NEU_3_Tremor 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT XXX_3_Lethargy 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 111-42-2 DIETHANOLAMINE KNOWN_TOXICITY Miscellaneous 111-42-2 DIETHANOLAMINE ACTIVITY_CLASS Toxicant 111-42-2 DIETHANOLAMINE TISSUE_TOXICITY Death 111-42-2 DIETHANOLAMINE ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 822-36-6 4-METHYLIMIDAZOLE STRUCTURE_ACTIVITY Toxicant 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT NEU_2_Involuntray Movements 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT PSY_2_Violent Behavior 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT LUN_1_Rapid Respiration 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT NEU_2_Convulsions 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT OCU_1_Ocular Discharge 822-36-6 4-METHYLIMIDAZOLE PRODUCT_CLASS Toxicants 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT OCU_2_Pupillary Constriction 822-36-6 4-METHYLIMIDAZOLE TISSUE_TOXICITY Death 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT NEU_2_Ataxia 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT NEU_2_Tremor 822-36-6 4-METHYLIMIDAZOLE KNOWN_TOXICITY Miscellaneous 822-36-6 4-METHYLIMIDAZOLE ADVERSE_EFFECT XXX_3_Death 110-86-1 PYRIDINE TISSUE_TOXICITY Hepatic Necrosis 110-86-1 PYRIDINE KNOWN_TOXICITY Miscellaneous 110-86-1 PYRIDINE TISSUE_TOXICITY Hepatotoxicity 110-86-1 PYRIDINE KNOWN_TOXICITY Hepatotoxicity 110-86-1 PYRIDINE TISSUE_TOXICITY Liver Cirrhosis 110-86-1 PYRIDINE TISSUE_TOXICITY Death 110-86-1 PYRIDINE STRUCTURE_ACTIVITY Toxicant, free radical generator 110-86-1 PYRIDINE ACTIVITY_CLASS Toxicant 89-82-7 (+)-PULEGONE KNOWN_TOXICITY Hepatotoxicity 89-82-7 (+)-PULEGONE ADVERSE_EFFECT XXX_3_Death 89-82-7 (+)-PULEGONE ADVERSE_EFFECT XXX_1_Weight Loss 89-82-7 (+)-PULEGONE ADVERSE_EFFECT LIV_1_Hepatotoxicity 89-82-7 (+)-PULEGONE TISSUE_TOXICITY Death 89-82-7 (+)-PULEGONE ADVERSE_EFFECT NEU_1_Neuropathy 89-82-7 (+)-PULEGONE ACTIVITY_CLASS Toxicant 89-82-7 (+)-PULEGONE TISSUE_TOXICITY Hepatotoxicity 89-82-7 (+)-PULEGONE ADVERSE_EFFECT LIV_1_Hepatic Injury 89-82-7 (+)-PULEGONE KNOWN_TOXICITY Miscellaneous 89-82-7 (+)-PULEGONE ADVERSE_EFFECT NEU_1_Cerebellar Dysfunction 89-82-7 (+)-PULEGONE PRODUCT_CLASS Toxicants 89-82-7 (+)-PULEGONE STRUCTURE_ACTIVITY Toxicant 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT DNA_3_Mutagenicity 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT XXX_2_Weight Loss 137-09-7 2,4-DIAMINOPHENOL ACTIVITY_CLASS Toxicant 137-09-7 2,4-DIAMINOPHENOL KNOWN_TOXICITY Miscellaneous 137-09-7 2,4-DIAMINOPHENOL TISSUE_TOXICITY Mutagenicity 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT XXX_2_Lacrimation 137-09-7 2,4-DIAMINOPHENOL KNOWN_TOXICITY Carcinogenicity 137-09-7 2,4-DIAMINOPHENOL TISSUE_TOXICITY Renal Tubular Necrosis 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT NEU_3_Coma 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT XXX_3_Death 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT NEU_3_Convulsions 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT GIS_2_Gastritis 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT NEU_2_Vertigo 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT OCU_3_Blindness 137-09-7 2,4-DIAMINOPHENOL TISSUE_TOXICITY Death 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT OCU_2_Chemosis 137-09-7 2,4-DIAMINOPHENOL KNOWN_TOXICITY Nephrotoxicity 137-09-7 2,4-DIAMINOPHENOL PRODUCT_CLASS Toxicants 137-09-7 2,4-DIAMINOPHENOL STRUCTURE_ACTIVITY Toxicant 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT CVS_1_Hypertension 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT KID_3_Renal Damage 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT KID_2_Renal Tubular Necrosis 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT OCU_2_Exophthalmos 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT SKN_2_Severe Skin Lesions 137-09-7 2,4-DIAMINOPHENOL KNOWN_TOXICITY Mutagenicity 137-09-7 2,4-DIAMINOPHENOL TISSUE_TOXICITY Carcinogenicity 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT BBM_3_Bone Marrow Hypoplasia 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT DNA_3_Carcinogenicity 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT NEU_2_Tremor 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT LUN_1_Asthma 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT OCU_1_Eye Irritation 137-09-7 2,4-DIAMINOPHENOL ADVERSE_EFFECT IMU_2_Urticaria 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL TISSUE_TOXICITY Genotoxicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT DNA_2_Genotoxicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT DNA_2_Carcinogenicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL TISSUE_TOXICITY Acute Renal Failure 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL TISSUE_TOXICITY Carcinogenicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL KNOWN_TOXICITY Mutagenicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL PRODUCT_CLASS Toxicants 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL STRUCTURE_ACTIVITY Toxicant 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT OCU_2_Eye Disorder 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT KID_2_Renal Damage 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT XXX_1_Weight Loss 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL KNOWN_TOXICITY Carcinogenicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL TISSUE_TOXICITY Acute Tubular Necrosis 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT KID_2_Renal Papillary Necrosis 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL TISSUE_TOXICITY Renal Papillary Necrosis 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT KID_2_Acute Renal Failure 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT XXX_3_Death 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL KNOWN_TOXICITY Nephrotoxicity 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL TISSUE_TOXICITY Death 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT GUS_1_Diuresis 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL KNOWN_TOXICITY Miscellaneous 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT KID_3_Proteinuria 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT REP_1_Changes in Reproductive Function 3296-90-0 2,2-BIS(BROMOMETHYL)-1,3-PROPANEDIOL ADVERSE_EFFECT KID_2_Acute Tubular Necrosis 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT CVS_2_Hypertension 1303-00-0 GALLIUM ARSENIDE MECHANISM Modulate growth factor receptor mediated signal transduction 1303-00-0 GALLIUM ARSENIDE MODE_CLASS Receptor Agonist 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT IMU_2_Immunologic Toxicity 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT OCU_1_Conjunctivitis 1303-00-0 GALLIUM ARSENIDE STRUCTURE_ACTIVITY Toxicant 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT LUN_1_Pulmonary Alveolitis 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT BBM_2_Anemia 1303-00-0 GALLIUM ARSENIDE KNOWN_TOXICITY Carcinogenicity 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT OCU_1_Eye Irritation 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT KID_2_Kidney Damage 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT LUN_1_Airway Irritation 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT LUN_2_Pneumonia 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT LUN_3_Pulmonary Granuloma 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT REP_2_Testicular Atrophy 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT KID_2_Proximal Tubular Damage 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT LIV_2_Hepatic Damage 1303-00-0 GALLIUM ARSENIDE PRODUCT_CLASS Toxicants 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT END_2_Hemosiderosis 1303-00-0 GALLIUM ARSENIDE TISSUE_TOXICITY Carcinogenicity 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 1303-00-0 GALLIUM ARSENIDE ADVERSE_EFFECT CVS_2_Increased Heart Rate 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT XXX_1_Fatigue 1271-19-8 TITANOCENE DICHLORIDE STRUCTURE_ACTIVITY Toxicant 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT DNA_3_Mutagenicity 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT SKN_1_Skin Irritation 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT EMB_3_Teratogenicity 1271-19-8 TITANOCENE DICHLORIDE TISSUE_TOXICITY Carcinogenicity 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT KID_3_Nephrotoxicity 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT LIV_2_Hepatic Damage 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT EMB_2_Embryotoxicity 1271-19-8 TITANOCENE DICHLORIDE TISSUE_TOXICITY Mutagenicity 1271-19-8 TITANOCENE DICHLORIDE PRODUCT_CLASS Toxicants 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 1271-19-8 TITANOCENE DICHLORIDE KNOWN_TOXICITY Nephrotoxicity 1271-19-8 TITANOCENE DICHLORIDE TISSUE_TOXICITY Teratogenicity 1271-19-8 TITANOCENE DICHLORIDE KNOWN_TOXICITY Mutagenicity 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT BBM_3_Myelotoxicity 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT ELT_1_Hypokalemia 1271-19-8 TITANOCENE DICHLORIDE TISSUE_TOXICITY Nephrotoxicity 1271-19-8 TITANOCENE DICHLORIDE KNOWN_TOXICITY Carcinogenicity 1271-19-8 TITANOCENE DICHLORIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT KID_2_Increased Creatinine 1271-19-8 TITANOCENE DICHLORIDE ADVERSE_EFFECT LUN_1_Airway Irritation 126-99-8 CHLOROPRENE STRUCTURE_ACTIVITY Toxicant 556-52-5 GLYCIDOL KNOWN_TOXICITY Miscellaneous 556-52-5 GLYCIDOL ADVERSE_EFFECT SKN_1_Skin Irritation 556-52-5 GLYCIDOL ADVERSE_EFFECT PSY_2_CNS Depression 556-52-5 GLYCIDOL ADVERSE_EFFECT NEU_3_Convulsions 556-52-5 GLYCIDOL ADVERSE_EFFECT XXX_3_Death 556-52-5 GLYCIDOL TISSUE_TOXICITY Carcinogenicity 556-52-5 GLYCIDOL ADVERSE_EFFECT XXX_1_Lacrimation 556-52-5 GLYCIDOL STRUCTURE_ACTIVITY Toxicant, DNA alkylator 556-52-5 GLYCIDOL ACTIVITY_CLASS Toxicant, DNA damaging 556-52-5 GLYCIDOL ADVERSE_EFFECT DNA_2_Mutagenicity 556-52-5 GLYCIDOL TISSUE_TOXICITY Death 556-52-5 GLYCIDOL ADVERSE_EFFECT LUN_1_Pulmonary Irritation 556-52-5 GLYCIDOL ADVERSE_EFFECT NEU_2_Tremor 556-52-5 GLYCIDOL ADVERSE_EFFECT LUN_3_Pulmonary Edema 556-52-5 GLYCIDOL ADVERSE_EFFECT IMU_3_Immunologic Toxicity 556-52-5 GLYCIDOL PRODUCT_CLASS Toxicants 556-52-5 GLYCIDOL KNOWN_TOXICITY Mutagenicity 556-52-5 GLYCIDOL ADVERSE_EFFECT XXX_1_Nasal Irritation 556-52-5 GLYCIDOL ADVERSE_EFFECT XXX_1_Salivation 556-52-5 GLYCIDOL ADVERSE_EFFECT REP_2_Decreased Libido 556-52-5 GLYCIDOL ADVERSE_EFFECT DNA_2_Carcinogenicity 556-52-5 GLYCIDOL KNOWN_TOXICITY Carcinogenicity 556-52-5 GLYCIDOL ADVERSE_EFFECT OCU_1_Eye Irritation 556-52-5 GLYCIDOL ADVERSE_EFFECT PSY_1_CNS Stimulation 556-52-5 GLYCIDOL ADVERSE_EFFECT LUN_1_Dyspnea 556-52-5 GLYCIDOL ADVERSE_EFFECT LUN_2_Emphysema 556-52-5 GLYCIDOL TISSUE_TOXICITY Mutagenicity 121-92-6 3-NITROBENZOIC ACID STRUCTURE_ACTIVITY Toxicant 107-19-7 PROPARGYL ALCOHOL STRUCTURE_ACTIVITY Toxicant 99-57-0 2-AMINO-4-NITROPHENOL ACTIVITY_CLASS Toxicant, DNA damaging 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT GIS_1_Diarrhea 99-57-0 2-AMINO-4-NITROPHENOL KNOWN_TOXICITY Mutagenicity 99-57-0 2-AMINO-4-NITROPHENOL KNOWN_TOXICITY Nephrotoxicity 99-57-0 2-AMINO-4-NITROPHENOL TISSUE_TOXICITY Mutagenicity 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT XXX_2_Weight Gain 99-57-0 2-AMINO-4-NITROPHENOL KNOWN_TOXICITY Carcinogenicity 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT KID_2_Renal Damage 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT DNA_2_Carcinogenicity 99-57-0 2-AMINO-4-NITROPHENOL PRODUCT_CLASS Toxicants 99-57-0 2-AMINO-4-NITROPHENOL TISSUE_TOXICITY Death 99-57-0 2-AMINO-4-NITROPHENOL KNOWN_TOXICITY Miscellaneous 99-57-0 2-AMINO-4-NITROPHENOL STRUCTURE_ACTIVITY Toxicant, DNA alkylator 99-57-0 2-AMINO-4-NITROPHENOL TISSUE_TOXICITY Carcinogenicity 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT XXX_3_Death 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT XXX_1_Lethargy 99-57-0 2-AMINO-4-NITROPHENOL ADVERSE_EFFECT DNA_3_Mutagenicity 99-57-0 2-AMINO-4-NITROPHENOL TISSUE_TOXICITY Renal Tubular Necrosis 105-87-3 GERANYL ACETATE STRUCTURE_ACTIVITY Toxicant 7775-09-9 SODIUM CHLORATE STRUCTURE_ACTIVITY Toxicant 127-18-4 TETRACHLOROETHYLENE TISSUE_TOXICITY Death 127-18-4 TETRACHLOROETHYLENE TISSUE_TOXICITY Hepatic Necrosis 127-18-4 TETRACHLOROETHYLENE KNOWN_TOXICITY Miscellaneous 127-18-4 TETRACHLOROETHYLENE KNOWN_TOXICITY Carcinogenicity 127-18-4 TETRACHLOROETHYLENE KNOWN_TOXICITY Mutagenicity 127-18-4 TETRACHLOROETHYLENE KNOWN_TOXICITY Hepatotoxicity 127-18-4 TETRACHLOROETHYLENE TISSUE_TOXICITY Mutagenicity 127-18-4 TETRACHLOROETHYLENE TISSUE_TOXICITY Chromosome Aberration 127-18-4 TETRACHLOROETHYLENE TISSUE_TOXICITY Carcinogenicity 127-18-4 TETRACHLOROETHYLENE STRUCTURE_ACTIVITY Toxicant 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT OCU_1_Eye Irritation 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE KNOWN_TOXICITY Carcinogenicity 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE PRODUCT_CLASS Toxicants 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT SKN_1_Skin Irritation 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT LUN_1_Airway Irritation 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT SKN_2_Skin Infection 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE KNOWN_TOXICITY Mutagenicity 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT SKN_1_Skin Reactions 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT IMU_1_Contact Dermatitis 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE TISSUE_TOXICITY Genotoxicity 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE STRUCTURE_ACTIVITY Toxicant 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE TISSUE_TOXICITY Carcinogenicity 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT NEU_1_Headache 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT LUN_2_Pneumonia 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT SKN_2_Eczema 693-13-0 N,N'-DIISOPROPYLCARBODIIMIDE ADVERSE_EFFECT DNA_2_Genotoxicity 123-31-9 HYDROQUINONE KNOWN_TOXICITY Nephrotoxicity 123-31-9 HYDROQUINONE ADVERSE_EFFECT SKN_1_Skin Discoloration 123-31-9 HYDROQUINONE ADVERSE_EFFECT KID_3_Tubular Necrosis 123-31-9 HYDROQUINONE ADVERSE_EFFECT GIS_3_Gastric Ulceration 123-31-9 HYDROQUINONE ADVERSE_EFFECT DNA_3_Mutagenicity 123-31-9 HYDROQUINONE ADVERSE_EFFECT DNA_3_Genotoxicity 123-31-9 HYDROQUINONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 123-31-9 HYDROQUINONE ADVERSE_EFFECT OCU_1_Eye Irritation 123-31-9 HYDROQUINONE ADVERSE_EFFECT DNA__Chromosome Aberration 123-31-9 HYDROQUINONE TISSUE_TOXICITY Mutagenicity 123-31-9 HYDROQUINONE TISSUE_TOXICITY Chromosome Aberration 123-31-9 HYDROQUINONE KNOWN_TOXICITY Carcinogenicity 123-31-9 HYDROQUINONE ADVERSE_EFFECT OTO_1_Tinnitus 123-31-9 HYDROQUINONE ADVERSE_EFFECT LIV_3_Hepatic Damage 123-31-9 HYDROQUINONE ADVERSE_EFFECT DNA_3_Carcinogenicity 123-31-9 HYDROQUINONE ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 123-31-9 HYDROQUINONE TISSUE_TOXICITY Tubular Necrosis 123-31-9 HYDROQUINONE ADVERSE_EFFECT GIS_1_Diarrhea 123-31-9 HYDROQUINONE PRODUCT_CLASS Toxicants 123-31-9 HYDROQUINONE KNOWN_TOXICITY Mutagenicity 123-31-9 HYDROQUINONE TISSUE_TOXICITY Hepatocellular Carcinoma 123-31-9 HYDROQUINONE ADVERSE_EFFECT GIS_1_Abdominal Cramps 123-31-9 HYDROQUINONE ADVERSE_EFFECT OCU_2_Corneal Opacities 123-31-9 HYDROQUINONE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 123-31-9 HYDROQUINONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 123-31-9 HYDROQUINONE ADVERSE_EFFECT GIS_3_Gastric Bleeding 123-31-9 HYDROQUINONE ADVERSE_EFFECT KID_2_Renal Damage 123-31-9 HYDROQUINONE ACTIVITY_CLASS Toxicant, DNA damaging 123-31-9 HYDROQUINONE TISSUE_TOXICITY Carcinogenicity 123-31-9 HYDROQUINONE TISSUE_TOXICITY Genotoxicity 123-31-9 HYDROQUINONE STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 108-42-9 3-CHLOROANILINE KNOWN_TOXICITY Nephrotoxicity 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT KID_2_Renal Insufficiency 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT CVS_3_Arrhythmia 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_3_Convulsions 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT XXX_1_Lethargy 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT OTO_1_Tinnitus 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT KID_2_Nephrotoxicity 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT BBM_3_Hemolysis 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT GIS_1_Nausea 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT GIS_1_Vomiting 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_3_Coma 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT CVS_3_Heart Block 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT SKN_1_Skin Irritation 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT XXX_1_Throat Irritation 108-42-9 3-CHLOROANILINE ACTIVITY_CLASS Toxicant 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Mutagenicity 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Shock 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Cardiovascular Collapse 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT OCU_1_Eye Irritation 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT CVS_3_Shock 108-42-9 3-CHLOROANILINE KNOWN_TOXICITY Miscellaneous 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_2_Vertigo 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_1_Ataxia 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_1_Tremor 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT KID_3_Hematuria 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT BBM_2_Methemoglobinemia 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT DNA_2_Mutagenicity 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Arrhythmia 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT XXX_1_Weakness 108-42-9 3-CHLOROANILINE PRODUCT_CLASS Toxicants 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Death 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Hematuria 108-42-9 3-CHLOROANILINE KNOWN_TOXICITY Mutagenicity 108-42-9 3-CHLOROANILINE STRUCTURE_ACTIVITY Toxicant, induces methemoglobinemia 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_1_Drowsiness 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT PSY_1_Disorientation 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT XXX_3_Death 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT NEU_1_Headache 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT LUN_2_Cyanosis 108-42-9 3-CHLOROANILINE KNOWN_TOXICITY Cardiovascular Toxicity 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Heart Block 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT LUN_1_Airway Irritation 108-42-9 3-CHLOROANILINE TISSUE_TOXICITY Nephrotoxicity 108-42-9 3-CHLOROANILINE ADVERSE_EFFECT XXX_1_Nasal Irritation 106-47-8 4-CHLOROANILINE KNOWN_TOXICITY Cardiovascular Toxicity 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Cardiac Block 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Shock 106-47-8 4-CHLOROANILINE STRUCTURE_ACTIVITY Toxicant, DNA damaging, induces methemoglobinemia 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Arrhythmia 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Nephrotoxicity 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Death 106-47-8 4-CHLOROANILINE KNOWN_TOXICITY Miscellaneous 106-47-8 4-CHLOROANILINE ACTIVITY_CLASS Toxicant, DNA damaging 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Carcinogenicity 106-47-8 4-CHLOROANILINE KNOWN_TOXICITY Carcinogenicity 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Hematuria 106-47-8 4-CHLOROANILINE KNOWN_TOXICITY Nephrotoxicity 106-47-8 4-CHLOROANILINE TISSUE_TOXICITY Hemoglobinuria 119-84-6 DIHYDROCOUMARIN STRUCTURE_ACTIVITY Toxicant 100-52-7 BENZALDEHYDE STRUCTURE_ACTIVITY Toxicant 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT OCU_1_Eye Irritation 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT PSY_2_CNS Depression 67-72-1 HEXACHLOROETHANE TISSUE_TOXICITY Carcinogenicity 67-72-1 HEXACHLOROETHANE STRUCTURE_ACTIVITY Toxicant, free radical generator 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT LIV_2_Hepatic Damage 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT LUN_1_Airway Irritation 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT SKN_1_Skin Irritation 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT DNA_3_Carcinogenicity 67-72-1 HEXACHLOROETHANE TISSUE_TOXICITY Nephrotoxicity 67-72-1 HEXACHLOROETHANE ACTIVITY_CLASS Toxicant 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT XXX_2_Inflammation 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT OCU_1_Photophobia 67-72-1 HEXACHLOROETHANE KNOWN_TOXICITY Carcinogenicity 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT KID_3_Nephrotoxicity 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT LUN_1_Pulmonary Irritation 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT XXX_1_Lacrimation 67-72-1 HEXACHLOROETHANE KNOWN_TOXICITY Nephrotoxicity 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT PSY_3_CNS Toxicity 67-72-1 HEXACHLOROETHANE ADVERSE_EFFECT KID_2_Kidney Damage 67-47-0 5-(HYDROXYMETHYL)FURFURAL PRODUCT_CLASS Toxicants 67-47-0 5-(HYDROXYMETHYL)FURFURAL ADVERSE_EFFECT DNA_2_Carcinogenicity 67-47-0 5-(HYDROXYMETHYL)FURFURAL ADVERSE_EFFECT DNA_2_Mutagenicity 67-47-0 5-(HYDROXYMETHYL)FURFURAL KNOWN_TOXICITY Carcinogenicity 67-47-0 5-(HYDROXYMETHYL)FURFURAL STRUCTURE_ACTIVITY Toxicant 67-47-0 5-(HYDROXYMETHYL)FURFURAL ADVERSE_EFFECT LIV_2_Fatty Degeneration 67-47-0 5-(HYDROXYMETHYL)FURFURAL TISSUE_TOXICITY Mutagenicity 67-47-0 5-(HYDROXYMETHYL)FURFURAL TISSUE_TOXICITY Carcinogenicity 67-47-0 5-(HYDROXYMETHYL)FURFURAL KNOWN_TOXICITY Mutagenicity 67-47-0 5-(HYDROXYMETHYL)FURFURAL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 131-17-9 DIALLYL PHTHALATE STRUCTURE_ACTIVITY Toxicant 140-11-4 BENZYL ACETATE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 140-11-4 BENZYL ACETATE ADVERSE_EFFECT KID_2_Kidney Damage 140-11-4 BENZYL ACETATE ADVERSE_EFFECT OCU_1_Eye Irritation 140-11-4 BENZYL ACETATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 140-11-4 BENZYL ACETATE KNOWN_TOXICITY Miscellaneous 140-11-4 BENZYL ACETATE TISSUE_TOXICITY Hepatic Necrosis 140-11-4 BENZYL ACETATE ACTIVITY_CLASS Toxicant 140-11-4 BENZYL ACETATE ADVERSE_EFFECT NEU_3_Neuronal Necrosis 140-11-4 BENZYL ACETATE ADVERSE_EFFECT LUN_2_Dyspnea 140-11-4 BENZYL ACETATE ADVERSE_EFFECT SKN_1_Skin Irritation 140-11-4 BENZYL ACETATE ADVERSE_EFFECT GIS_1_Diarrhea 140-11-4 BENZYL ACETATE KNOWN_TOXICITY Mutagenicity 140-11-4 BENZYL ACETATE KNOWN_TOXICITY Hepatotoxicity 140-11-4 BENZYL ACETATE TISSUE_TOXICITY Death 140-11-4 BENZYL ACETATE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 140-11-4 BENZYL ACETATE ADVERSE_EFFECT LUN_1_Airway Irritation 140-11-4 BENZYL ACETATE ADVERSE_EFFECT XXX_3_Death 140-11-4 BENZYL ACETATE ADVERSE_EFFECT GIS_1_Gastrointestinal Irritation 140-11-4 BENZYL ACETATE KNOWN_TOXICITY Nephrotoxicity 140-11-4 BENZYL ACETATE TISSUE_TOXICITY Mutagenicity 140-11-4 BENZYL ACETATE STRUCTURE_ACTIVITY Toxicant 140-11-4 BENZYL ACETATE ADVERSE_EFFECT DNA_3_Mutagenicity 140-11-4 BENZYL ACETATE ADVERSE_EFFECT PSY_2_CNS Depression 140-11-4 BENZYL ACETATE ADVERSE_EFFECT _1_Local Tissue Irritation 140-11-4 BENZYL ACETATE TISSUE_TOXICITY Renal Tubular Necrosis 98-01-1 FURFURAL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 98-01-1 FURFURAL ADVERSE_EFFECT DNA_3_Mutagenicity 98-01-1 FURFURAL ADVERSE_EFFECT LIV_2_Liver Cirrhosis 98-01-1 FURFURAL KNOWN_TOXICITY Carcinogenicity 98-01-1 FURFURAL TISSUE_TOXICITY Carcinogenicity 98-01-1 FURFURAL ADVERSE_EFFECT LUN_2_Airway Irritation 98-01-1 FURFURAL TISSUE_TOXICITY Death 98-01-1 FURFURAL TISSUE_TOXICITY Liver Cirrhosis 98-01-1 FURFURAL ADVERSE_EFFECT BBM_2_Anemia 98-01-1 FURFURAL PRODUCT_CLASS Toxicants 98-01-1 FURFURAL KNOWN_TOXICITY Hepatotoxicity 98-01-1 FURFURAL STRUCTURE_ACTIVITY Toxicant 98-01-1 FURFURAL ADVERSE_EFFECT OCU_1_Eye Irritation 98-01-1 FURFURAL ADVERSE_EFFECT NEU_3_Paralysis 98-01-1 FURFURAL ADVERSE_EFFECT XXX_1_Weight Loss 98-01-1 FURFURAL ADVERSE_EFFECT DNA_3_Carcinogenicity 98-01-1 FURFURAL KNOWN_TOXICITY Mutagenicity 98-01-1 FURFURAL TISSUE_TOXICITY Hepatotoxicity 98-01-1 FURFURAL ADVERSE_EFFECT LIV_3_Hepatitis 98-01-1 FURFURAL ADVERSE_EFFECT NEU_2_Convulsions 98-01-1 FURFURAL ADVERSE_EFFECT LIV_2_Hepatotoxicity 98-01-1 FURFURAL KNOWN_TOXICITY Miscellaneous 98-01-1 FURFURAL TISSUE_TOXICITY Mutagenicity 98-01-1 FURFURAL ADVERSE_EFFECT NEU_2_Spasticity 98-01-1 FURFURAL ADVERSE_EFFECT XXX_3_Death 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT DNA_2_Genotoxicity 89-63-4 4-CHLORO-2-NITROANILINE TISSUE_TOXICITY Genotoxicity 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT XXX_3_Death 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT KID_2_Renal Damage 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT KID_2_Nephritis 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT IMU_2_Allergy 89-63-4 4-CHLORO-2-NITROANILINE ACTIVITY_CLASS Toxicant, DNA damaging 89-63-4 4-CHLORO-2-NITROANILINE PRODUCT_CLASS Toxicants 89-63-4 4-CHLORO-2-NITROANILINE KNOWN_TOXICITY Miscellaneous 89-63-4 4-CHLORO-2-NITROANILINE STRUCTURE_ACTIVITY Toxicant, DNA damaging 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT LIV_1_Hepatomegaly 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT OCU_1_Eye Irritation 89-63-4 4-CHLORO-2-NITROANILINE TISSUE_TOXICITY Death 89-63-4 4-CHLORO-2-NITROANILINE KNOWN_TOXICITY Mutagenicity 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT END_2_Hemosiderosis 89-63-4 4-CHLORO-2-NITROANILINE ADVERSE_EFFECT SKN_2_Skin Reactions 93-15-2 METHYLEUGENOL ADVERSE_EFFECT DNA_3_Gastrointestinal Neoplasms 93-15-2 METHYLEUGENOL ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 93-15-2 METHYLEUGENOL ADVERSE_EFFECT XXX_2_Inflammation 93-15-2 METHYLEUGENOL ADVERSE_EFFECT BBM_1_Thrombocytosis 93-15-2 METHYLEUGENOL ADVERSE_EFFECT NEU_1_Sleepiness 93-15-2 METHYLEUGENOL ADVERSE_EFFECT XXX_1_Cytotoxicity 93-15-2 METHYLEUGENOL ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 93-15-2 METHYLEUGENOL ADVERSE_EFFECT DNA_2_Hepatic Tumors 93-15-2 METHYLEUGENOL STRUCTURE_ACTIVITY Toxicant 93-15-2 METHYLEUGENOL TISSUE_TOXICITY Hepatocellular Carcinoma 93-15-2 METHYLEUGENOL TISSUE_TOXICITY Hepatic Tumors 93-15-2 METHYLEUGENOL ADVERSE_EFFECT DNA_2_Genotoxicity 93-15-2 METHYLEUGENOL ADVERSE_EFFECT LIV_2_Hepatotoxicity 93-15-2 METHYLEUGENOL ADVERSE_EFFECT LIV_2_Liver Necrosis 93-15-2 METHYLEUGENOL KNOWN_TOXICITY Mutagenicity 93-15-2 METHYLEUGENOL KNOWN_TOXICITY Carcinogenicity 93-15-2 METHYLEUGENOL TISSUE_TOXICITY Liver Necrosis 93-15-2 METHYLEUGENOL PRODUCT_CLASS Toxicants 93-15-2 METHYLEUGENOL TISSUE_TOXICITY Gastrointestinal Neoplasms 93-15-2 METHYLEUGENOL TISSUE_TOXICITY Hepatotoxicity 93-15-2 METHYLEUGENOL TISSUE_TOXICITY Genotoxicity 93-15-2 METHYLEUGENOL KNOWN_TOXICITY Hepatotoxicity 93-15-2 METHYLEUGENOL ADVERSE_EFFECT NEU_2_Neurotoxicity 93-15-2 METHYLEUGENOL ADVERSE_EFFECT CVS_1_Hypertension 93-15-2 METHYLEUGENOL ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT PSY_2_CNS Depression 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT LIV_2_Liver Necrosis 75-27-4 BROMODICHLOROMETHANE ACTIVITY_CLASS Toxicant 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Renal Toxicity 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Genotoxicity 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT DNA_2_Mutagenicity 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT NEU_1_Anesthesia 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT DNA_3_Carcinogenicity 75-27-4 BROMODICHLOROMETHANE KNOWN_TOXICITY Hepatotoxicity 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Hepatic Toxicity 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT DNA_3_Genotoxicity 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT XXX_1_Inflammation 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT LIV_2_Hepatic Toxicity 75-27-4 BROMODICHLOROMETHANE KNOWN_TOXICITY Nephrotoxicity 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT NEU_1_Ataxia 75-27-4 BROMODICHLOROMETHANE PRODUCT_CLASS Toxicants 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT BBM_2_Hemorrhage 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT NEU_1_Sedation 75-27-4 BROMODICHLOROMETHANE KNOWN_TOXICITY Mutagenicity 75-27-4 BROMODICHLOROMETHANE KNOWN_TOXICITY Carcinogenicity 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Liver Necrosis 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Mutagenicity 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Carcinogenicity 75-27-4 BROMODICHLOROMETHANE STRUCTURE_ACTIVITY Toxicant, free radical generator 75-27-4 BROMODICHLOROMETHANE TISSUE_TOXICITY Death 75-27-4 BROMODICHLOROMETHANE KNOWN_TOXICITY Miscellaneous 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT KID_2_Renal Toxicity 75-27-4 BROMODICHLOROMETHANE ADVERSE_EFFECT XXX_3_Death 98-95-3 NITROBENZENE ADVERSE_EFFECT NEU_1_Headache 98-95-3 NITROBENZENE ADVERSE_EFFECT NEU_1_Lightheadedness 98-95-3 NITROBENZENE ADVERSE_EFFECT BBM_3_Anemia 98-95-3 NITROBENZENE ADVERSE_EFFECT DNA_2_Carcinogenicity 98-95-3 NITROBENZENE ADVERSE_EFFECT REP_2_Testicular Toxicity 98-95-3 NITROBENZENE ACTIVITY_CLASS Toxicant 98-95-3 NITROBENZENE TISSUE_TOXICITY Carcinogenicity 98-95-3 NITROBENZENE KNOWN_TOXICITY Nephrotoxicity 98-95-3 NITROBENZENE ADVERSE_EFFECT LUN_3_Respiratory Failure 98-95-3 NITROBENZENE ADVERSE_EFFECT KID_3_Acute Renal Failure 98-95-3 NITROBENZENE ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 98-95-3 NITROBENZENE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 98-95-3 NITROBENZENE ADVERSE_EFFECT NEU_3_Neuropathy 98-95-3 NITROBENZENE TISSUE_TOXICITY Hepatic Necrosis 98-95-3 NITROBENZENE KNOWN_TOXICITY Miscellaneous 98-95-3 NITROBENZENE ADVERSE_EFFECT KID_2_Albuminuria 98-95-3 NITROBENZENE ADVERSE_EFFECT KID_3_Renal Damage 98-95-3 NITROBENZENE ADVERSE_EFFECT BBM_2_Red Blood Cell Damage 98-95-3 NITROBENZENE ADVERSE_EFFECT CVS_2_Tachycardia 98-95-3 NITROBENZENE ADVERSE_EFFECT NEU_3_Coma 98-95-3 NITROBENZENE ADVERSE_EFFECT NEU_1_Ataxia 98-95-3 NITROBENZENE TISSUE_TOXICITY Acute Renal Failure 98-95-3 NITROBENZENE KNOWN_TOXICITY Carcinogenicity 98-95-3 NITROBENZENE ADVERSE_EFFECT GUS_1_Discoloration of Urine 98-95-3 NITROBENZENE STRUCTURE_ACTIVITY Toxicant, free radical generator, induces methemoglobinemia 98-95-3 NITROBENZENE TISSUE_TOXICITY Death 98-95-3 NITROBENZENE KNOWN_TOXICITY Hepatotoxicity 98-95-3 NITROBENZENE ADVERSE_EFFECT LIV_2_Hepatic Damage 98-95-3 NITROBENZENE ADVERSE_EFFECT XXX_3_Restlessness 98-95-3 NITROBENZENE ADVERSE_EFFECT LUN_3_Cyanosis 98-95-3 NITROBENZENE ADVERSE_EFFECT BBM_2_Methemoglobinemia 98-95-3 NITROBENZENE ADVERSE_EFFECT EMB__Fetal Toxicity 98-95-3 NITROBENZENE PRODUCT_CLASS Toxicants 98-95-3 NITROBENZENE ADVERSE_EFFECT XXX__Death 98-95-3 NITROBENZENE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 98-95-3 NITROBENZENE ADVERSE_EFFECT LUN_3_Pulmonary Impairment 98-95-3 NITROBENZENE ADVERSE_EFFECT XXX_1_Weakness 98-95-3 NITROBENZENE ADVERSE_EFFECT LUN_1_Dyspnea 79-11-8 CHLOROACETIC ACID STRUCTURE_ACTIVITY Toxicant 2265-22-7 DEXAMETHASONE 21-MESYLATE PRODUCT_CLASS Toxicants 2265-22-7 DEXAMETHASONE 21-MESYLATE ACTIVITY_CLASS GR-MR agonist 2265-22-7 DEXAMETHASONE 21-MESYLATE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 64-85-7 21-HYDROXYPROGESTERONE ADVERSE_EFFECT CVS_1_Hypertension 64-85-7 21-HYDROXYPROGESTERONE ADVERSE_EFFECT XXX_1_Weight Gain 64-85-7 21-HYDROXYPROGESTERONE MECHANISM Modulate gene transcription 64-85-7 21-HYDROXYPROGESTERONE MODE_CLASS Receptor Agonist 64-85-7 21-HYDROXYPROGESTERONE KNOWN_TOXICITY Mutagenicity 64-85-7 21-HYDROXYPROGESTERONE ACTIVITY_CLASS Progesterone receptor agonist 64-85-7 21-HYDROXYPROGESTERONE STRUCTURE_ACTIVITY Progesterone receptor agonist 64-85-7 21-HYDROXYPROGESTERONE TISSUE_TOXICITY Mutagenicity 64-85-7 21-HYDROXYPROGESTERONE ADVERSE_EFFECT KID_1_Salt Retention 64-85-7 21-HYDROXYPROGESTERONE ADVERSE_EFFECT DNA_2_Mutagenicity 64-85-7 21-HYDROXYPROGESTERONE ADVERSE_EFFECT NEU_1_Sedation 64-85-7 21-HYDROXYPROGESTERONE PRODUCT_CLASS Toxicants 516-90-5 TAUROLITHOCHOLIC ACID STRUCTURE_ACTIVITY Bile salt 516-90-5 TAUROLITHOCHOLIC ACID ACTIVITY_CLASS Toxicant 68-26-8 VITAMIN A STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 28300-74-5 POTASSIUM ANTIMONYL TARTRATE HEMIHYDRATE STRUCTURE_ACTIVITY Toxicant 98-82-8 CUMENE STRUCTURE_ACTIVITY Toxicant 598-55-0 METHYL CARBAMATE STRUCTURE_ACTIVITY Toxicant 117-08-8 TETRACHLOROPHTHALIC ANHYDRIDE STRUCTURE_ACTIVITY Toxicant 2432-99-7 11-AMINOUNDECANOIC ACID STRUCTURE_ACTIVITY Toxicant 150-68-5 MONURON STRUCTURE_ACTIVITY Toxicant 106-51-4 P-BENZOQUINONE STRUCTURE_ACTIVITY Toxicant 84-74-2 DIBUTYL PHTHALATE STRUCTURE_ACTIVITY Toxicant 107-22-2 GLYOXAL STRUCTURE_ACTIVITY Toxicant 100-00-5 1-CHLORO-4-NITROBENZENE STRUCTURE_ACTIVITY Toxicant 88-73-3 1-CHLORO-2-NITROBENZENE STRUCTURE_ACTIVITY Toxicant 3252-43-5 DIBROMOACETONITRILE STRUCTURE_ACTIVITY Toxicant 563-47-3 3-CHLORO-2-METHYLPROPENE STRUCTURE_ACTIVITY Toxicant 100-47-0 BENZONITRILE STRUCTURE_ACTIVITY Toxicant 74-83-9 BROMOMETHANE STRUCTURE_ACTIVITY Toxicant 608-93-5 PENTACHLOROBENZENE STRUCTURE_ACTIVITY Toxicant 76-01-7 PENTACHLOROETHANE STRUCTURE_ACTIVITY Toxicant 115-28-6 CHLORENDIC ACID STRUCTURE_ACTIVITY Toxicant 756-79-6 DIMETHYL METHYLPHOSPHONATE ACTIVITY_CLASS Cholinesterase inhibitor 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 756-79-6 DIMETHYL METHYLPHOSPHONATE TISSUE_TOXICITY Carcinogenicity 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT XXX_3_Death 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT DNA_3_Carcinogenicity 756-79-6 DIMETHYL METHYLPHOSPHONATE KNOWN_TOXICITY Carcinogenicity 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT KID_3_Renal Toxicity 756-79-6 DIMETHYL METHYLPHOSPHONATE KNOWN_TOXICITY Nephrotoxicity 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT XXX_3_Weight Loss 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT DNA_3_Mutagenicity 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT XXX_1_Prostration 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT KID_2_Kidney Damage 756-79-6 DIMETHYL METHYLPHOSPHONATE TISSUE_TOXICITY Renal Toxicity 756-79-6 DIMETHYL METHYLPHOSPHONATE TISSUE_TOXICITY Death 756-79-6 DIMETHYL METHYLPHOSPHONATE TISSUE_TOXICITY Mutagenicity 756-79-6 DIMETHYL METHYLPHOSPHONATE KNOWN_TOXICITY Miscellaneous 756-79-6 DIMETHYL METHYLPHOSPHONATE STRUCTURE_ACTIVITY Cholinesterase inhibitor 756-79-6 DIMETHYL METHYLPHOSPHONATE TISSUE_TOXICITY Renal Tubular Necrosis 756-79-6 DIMETHYL METHYLPHOSPHONATE ADVERSE_EFFECT LUN_2_Decreased Vital Capacity 756-79-6 DIMETHYL METHYLPHOSPHONATE KNOWN_TOXICITY Mutagenicity 135-88-6 N-PHENYL-2-NAPHTHYLAMINE STRUCTURE_ACTIVITY Toxicant 1330-78-5 TRICRESYL PHOSPHATE STRUCTURE_ACTIVITY Toxicant 622-97-9 4-METHYLSTYRENE STRUCTURE_ACTIVITY Toxicant 271-89-6 2,3-BENZOFURAN STRUCTURE_ACTIVITY Toxicant 108-90-7 CHLOROBENZENE KNOWN_TOXICITY Nephrotoxicity 108-90-7 CHLOROBENZENE TISSUE_TOXICITY Carcinogenicity 108-90-7 CHLOROBENZENE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 108-90-7 CHLOROBENZENE ADVERSE_EFFECT LUN_1_Pulmonary Irritation 108-90-7 CHLOROBENZENE ADVERSE_EFFECT OCU_3_Conjunctival Hyperemia 108-90-7 CHLOROBENZENE ADVERSE_EFFECT BBM_2_Hemolysis 108-90-7 CHLOROBENZENE TISSUE_TOXICITY Heart Failure 108-90-7 CHLOROBENZENE KNOWN_TOXICITY Mutagenicity 108-90-7 CHLOROBENZENE ADVERSE_EFFECT KID_2_Renal Damage 108-90-7 CHLOROBENZENE ADVERSE_EFFECT SKN_1_Skin Irritation 108-90-7 CHLOROBENZENE ADVERSE_EFFECT NEU_1_Headache 108-90-7 CHLOROBENZENE ADVERSE_EFFECT BBM_2_Anemia 108-90-7 CHLOROBENZENE ADVERSE_EFFECT LUN_2_Bronchitis 108-90-7 CHLOROBENZENE PRODUCT_CLASS Toxicants 108-90-7 CHLOROBENZENE ADVERSE_EFFECT DNA_3_Carcinogenicity 108-90-7 CHLOROBENZENE KNOWN_TOXICITY Carcinogenicity 108-90-7 CHLOROBENZENE TISSUE_TOXICITY Hepatic Necrosis 108-90-7 CHLOROBENZENE TISSUE_TOXICITY Nephrotic Syndrome 108-90-7 CHLOROBENZENE STRUCTURE_ACTIVITY Toxicant, DNA damaging 108-90-7 CHLOROBENZENE ADVERSE_EFFECT LIV_2_Hepatitis 108-90-7 CHLOROBENZENE ADVERSE_EFFECT CVS_3_Heart Failure 108-90-7 CHLOROBENZENE ADVERSE_EFFECT LUN_1_Airway Irritation 108-90-7 CHLOROBENZENE ADVERSE_EFFECT SKN_2_Erythema 108-90-7 CHLOROBENZENE ADVERSE_EFFECT KID_3_Nephrotic Syndrome 108-90-7 CHLOROBENZENE KNOWN_TOXICITY Cardiovascular Toxicity 108-90-7 CHLOROBENZENE TISSUE_TOXICITY Genotoxicity 108-90-7 CHLOROBENZENE ACTIVITY_CLASS Toxicant, DNA damaging 108-90-7 CHLOROBENZENE ADVERSE_EFFECT GIS_2_Gastritis 108-90-7 CHLOROBENZENE ADVERSE_EFFECT PSY_2_CNS Depression 108-90-7 CHLOROBENZENE ADVERSE_EFFECT OCU_1_Eye Irritation 108-90-7 CHLOROBENZENE ADVERSE_EFFECT NEU_3_Loss of Consciousness 108-90-7 CHLOROBENZENE ADVERSE_EFFECT LIV_2_Hepatic Damage 108-90-7 CHLOROBENZENE ADVERSE_EFFECT DNA_3_Genotoxicity 108-90-7 CHLOROBENZENE KNOWN_TOXICITY Hepatotoxicity 108-90-7 CHLOROBENZENE ADVERSE_EFFECT XXX_1_Cytotoxicity 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT NEU_1_Dizziness 99-99-0 4-NITROTOLUENE TISSUE_TOXICITY Renal Toxicity 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT BBM_3_Anemia 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT LIV_2_Hepatic Damage 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT MSK_2_Muscle Weakness 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT KID_3_Renal Toxicity 99-99-0 4-NITROTOLUENE STRUCTURE_ACTIVITY Toxicant, induces methemoglobinemia 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT NEU_2_Ataxia 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT CVS_2_Tachycardia 99-99-0 4-NITROTOLUENE TISSUE_TOXICITY Carcinogenicity 99-99-0 4-NITROTOLUENE KNOWN_TOXICITY Hepatotoxicity 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT BBM_3_Methemoglobinemia 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT XXX_2_Weakness 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT NEU_1_Drowsiness 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT NEU_3_Convulsions 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT SKN_1_Skin Irritation 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT REP_3_Testicular Atrophy 99-99-0 4-NITROTOLUENE ACTIVITY_CLASS Toxicant 99-99-0 4-NITROTOLUENE TISSUE_TOXICITY Hepatic Toxicity 99-99-0 4-NITROTOLUENE KNOWN_TOXICITY Nephrotoxicity 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT NEU_1_Headache 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT LUN_3_Dyspnea 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT PSY_1_Irritation 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT XXX_1_Throat Irritation 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT DNA_3_Carcinogenicity 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT KID_3_Kidney Damage 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT OCU_1_Eye Irritation 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT LIV_3_Hepatic Toxicity 99-99-0 4-NITROTOLUENE KNOWN_TOXICITY Carcinogenicity 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT LUN_3_Hypoxia 99-99-0 4-NITROTOLUENE ADVERSE_EFFECT LUN_3_Cyanosis 518-82-1 EMODIN STRUCTURE_ACTIVITY Toxicant 181586-07-2 ONO-3403 STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 208848-19-5 ONO-6818 MODE_CLASS Enzyme Inhibitor 208848-19-5 ONO-6818 MECHANISM Inhibit inflammatory response 208848-19-5 ONO-6818 STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 62-75-9 N-NITROSODIMETHYLAMINE TISSUE_TOXICITY Liver Cirrhosis 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT EMB_2_Fetal Toxicity 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT GIS_1_Diarrhea 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LIV_1_Hepatic Damage 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT OCU_2_Eye Irritation 62-75-9 N-NITROSODIMETHYLAMINE KNOWN_TOXICITY Hepatotoxicity 62-75-9 N-NITROSODIMETHYLAMINE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 62-75-9 N-NITROSODIMETHYLAMINE ACTIVITY_CLASS Toxicant, DNA damaging 62-75-9 N-NITROSODIMETHYLAMINE TISSUE_TOXICITY Liver Necrosis 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LIV_2_Liver Necrosis 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT GIS_1_Abdominal Cramps 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT XXX_2_Weakness 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT NEU_2_Dizziness 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT SKN_2_Skin Irritation 62-75-9 N-NITROSODIMETHYLAMINE KNOWN_TOXICITY Mutagenicity 62-75-9 N-NITROSODIMETHYLAMINE TISSUE_TOXICITY Mutagenicity 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT DNA_2_Carcinogenicity 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LIV_2_Hepatitis 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT XXX_1_Malaise 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT XXX_2_Fever 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LUN_2_Pulmonary Impairment 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT XXX_2_Ascites 62-75-9 N-NITROSODIMETHYLAMINE KNOWN_TOXICITY Carcinogenicity 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LIV_2_Jaundice 62-75-9 N-NITROSODIMETHYLAMINE TISSUE_TOXICITY Carcinogenicity 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT DNA_2_Mutagenicity 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT NEU_2_Headache 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT KID_2_Renal Insufficiency 62-75-9 N-NITROSODIMETHYLAMINE ADVERSE_EFFECT LIV_2_Hepatomegaly 262352-17-0 TORCETRAPID STRUCTURE_ACTIVITY Cholesterol ester transfer protein (CETP) inhibitor 171095-65-1 CMI-568 STRUCTURE_ACTIVITY Arachidonate 5-lipoxygenase inhibitor 205256-55-9 CT-56040 STRUCTURE_ACTIVITY PDGF antagonist 4478-93-7 SULFORAPHANE STRUCTURE_ACTIVITY Induce phase II detoxification enzymes 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT XXX_3_Edema 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT XXX_1_Weakness 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT OCU_1_Eye Pain 10-64-67 1,4-DICHLOROBENZENE KNOWN_TOXICITY Carcinogenicity 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT XXX_1_Nose Irritation 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT XXX_2_Weight Loss 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT GIS_2_Abdominal Pain 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT DNA_2_Carcinogenicity 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT LUN_1_Airway Irritation 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT NEU_3_Coma 10-64-67 1,4-DICHLOROBENZENE STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 10-64-67 1,4-DICHLOROBENZENE TISSUE_TOXICITY Liver Cirrhosis 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT LIV_3_Liver Cirrhosis 10-64-67 1,4-DICHLOROBENZENE KNOWN_TOXICITY Hepatotoxicity 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT OCU_1_Eye Irritation 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT NEU_1_Dizziness 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT LUN_3_Pulmonary Granuloma 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT NEU_2_Headache 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT KID_2_Kidney Damage 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT GIS_1_Diarrhea 10-64-67 1,4-DICHLOROBENZENE TISSUE_TOXICITY Hepatic Necrosis 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT LIV_3_Jaundice 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 10-64-67 1,4-DICHLOROBENZENE ACTIVITY_CLASS Toxicant, DNA damaging 10-64-67 1,4-DICHLOROBENZENE TISSUE_TOXICITY Carcinogenicity 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT SKN_1_Skin Irritation 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT XXX_1_Throat Irritation 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT LIV_2_Hepatic Damage 10-64-67 1,4-DICHLOROBENZENE ADVERSE_EFFECT OCU_3_Cataracts 87-68-3 HEXACHLORO-1,3-BUTADIENE KNOWN_TOXICITY Hepatotoxicity 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Renal Tubular Necrosis 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT LUN_2_Respiratory Disorder 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT SKN_1_Skin Irritation 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT DNA_3_Carcinogenicity 87-68-3 HEXACHLORO-1,3-BUTADIENE KNOWN_TOXICITY Carcinogenicity 87-68-3 HEXACHLORO-1,3-BUTADIENE STRUCTURE_ACTIVITY Toxicant, DNA damaging 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT XXX_3_Death 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT LIV_2_Liver Necrosis 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT PSY_1_CNS Depression 87-68-3 HEXACHLORO-1,3-BUTADIENE KNOWN_TOXICITY Mutagenicity 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Renal Toxicity 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Mutagenicity 87-68-3 HEXACHLORO-1,3-BUTADIENE ACTIVITY_CLASS Toxicant, DNA damaging 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT END_2_Growth Inhibition 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT BBM_2_Anemia 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT LIV_2_Hepatic Damage 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT DNA_3_Mutagenicity 87-68-3 HEXACHLORO-1,3-BUTADIENE KNOWN_TOXICITY Nephrotoxicity 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Death 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Renal Failure 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Liver Necrosis 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT KID_2_Renal Toxicity 87-68-3 HEXACHLORO-1,3-BUTADIENE TISSUE_TOXICITY Carcinogenicity 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT KID_2_Renal Tubular Necrosis 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT XXX_1_Nasal Irritation 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT KID_3_Renal Failure 87-68-3 HEXACHLORO-1,3-BUTADIENE ADVERSE_EFFECT OCU_1_Eye Irritation 87-68-3 HEXACHLORO-1,3-BUTADIENE KNOWN_TOXICITY Miscellaneous 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT XXX_1_Lethargy 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT LIV_3_Liver Dysfunction 2921-88-2 CHLORPYRIFOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 2921-88-2 CHLORPYRIFOS TISSUE_TOXICITY Genotoxicity 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT NEU_3_Convulsions 2921-88-2 CHLORPYRIFOS TISSUE_TOXICITY Death 2921-88-2 CHLORPYRIFOS KNOWN_TOXICITY Mutagenicity 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT DNA_2_Mutagenicity 2921-88-2 CHLORPYRIFOS MECHANISM Enhance cholinergic transmission 2921-88-2 CHLORPYRIFOS ACTIVITY_CLASS Toxicant 2921-88-2 CHLORPYRIFOS TISSUE_TOXICITY Mutagenicity 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT NEU_1_Somnolence 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT EMB_2_Fetal Toxicity 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT NEU_2_Tremor 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT GIS_3_Gastric Erosion 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT XXX_3_Death 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT NEU_3_Cholinergic Crisis 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT PSY_3_Anorexia 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT GIS_3_Gastric Ulceration 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT XXX_1_Salivation 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 2921-88-2 CHLORPYRIFOS MODE_CLASS Enzyme Inhibitor 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT PSY_2_Depressed Mood 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT GIS_1_Diarrhea 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT NEU_2_Paresthesia 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT OCU_1_Pupillary Constriction 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT DNA_2_Genotoxicity 2921-88-2 CHLORPYRIFOS KNOWN_TOXICITY Miscellaneous 2921-88-2 CHLORPYRIFOS PRODUCT_CLASS Toxicants 2921-88-2 CHLORPYRIFOS ADVERSE_EFFECT XXX_1_Weight Gain 107-11-9 ALLYLAMINE TISSUE_TOXICITY Coronary Artery Disorder 107-11-9 ALLYLAMINE ADVERSE_EFFECT LIV_2_Impaired Liver Function 107-11-9 ALLYLAMINE ADVERSE_EFFECT PSY_1_Irritation 107-11-9 ALLYLAMINE ADVERSE_EFFECT KID_2_Changes in Renal Tubular Function 107-11-9 ALLYLAMINE ADVERSE_EFFECT NEU_3_Convulsions 107-11-9 ALLYLAMINE ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 107-11-9 ALLYLAMINE KNOWN_TOXICITY Cardiovascular Toxicity 107-11-9 ALLYLAMINE ADVERSE_EFFECT KID_2_Renal Dysfunction 107-11-9 ALLYLAMINE ADVERSE_EFFECT LUN_1_Irregular Respiration 107-11-9 ALLYLAMINE ADVERSE_EFFECT KID_2_Renal Damage 107-11-9 ALLYLAMINE ADVERSE_EFFECT XXX_3_Death 107-11-9 ALLYLAMINE ADVERSE_EFFECT XXX_1_Nose Irritation 107-11-9 ALLYLAMINE ADVERSE_EFFECT SKN_1_Skin Irritation 107-11-9 ALLYLAMINE TISSUE_TOXICITY Death 107-11-9 ALLYLAMINE ADVERSE_EFFECT CVS_2_Coronary Artery Disorder 107-11-9 ALLYLAMINE PRODUCT_CLASS Toxicants 107-11-9 ALLYLAMINE TISSUE_TOXICITY Myocarditis 107-11-9 ALLYLAMINE ADVERSE_EFFECT CVS_2_Myocardial Damage 107-11-9 ALLYLAMINE ADVERSE_EFFECT LUN_2_Cyanosis 107-11-9 ALLYLAMINE ADVERSE_EFFECT LIV_2_Hepatic Damage 107-11-9 ALLYLAMINE ADVERSE_EFFECT PSY_2_Excitement 107-11-9 ALLYLAMINE ADVERSE_EFFECT XXX_1_Lacrimation 107-11-9 ALLYLAMINE ADVERSE_EFFECT OCU_1_Eye Irritation 107-11-9 ALLYLAMINE STRUCTURE_ACTIVITY Toxicant, free radical generator 107-11-9 ALLYLAMINE ADVERSE_EFFECT NEU_3_Coma 107-11-9 ALLYLAMINE ADVERSE_EFFECT SKN_2_Skin Necrosis 107-11-9 ALLYLAMINE ADVERSE_EFFECT CVS_2_Myocarditis 107-11-9 ALLYLAMINE ADVERSE_EFFECT XXX_1_Sneezing 107-11-9 ALLYLAMINE ADVERSE_EFFECT LUN_1_Pulmonary Irritation 107-11-9 ALLYLAMINE ACTIVITY_CLASS Toxicant 107-11-9 ALLYLAMINE KNOWN_TOXICITY Miscellaneous 107-02-8 ACROLEIN KNOWN_TOXICITY Hepatotoxicity 107-02-8 ACROLEIN PRODUCT_CLASS Toxicants 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_1_Cytotoxicity 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_1_Nasal Irritation 107-02-8 ACROLEIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 107-02-8 ACROLEIN ADVERSE_EFFECT GIS_1_Gastritis 107-02-8 ACROLEIN ADVERSE_EFFECT SKN_1_Exfoliation 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_1_Prostration 107-02-8 ACROLEIN STRUCTURE_ACTIVITY Toxicant, DNA damaging 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_1_Nasal Congestion 107-02-8 ACROLEIN ADVERSE_EFFECT _1_Local Tissue Irritation 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_1_Shortness of Breath 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_1_Airway Irritation 107-02-8 ACROLEIN TISSUE_TOXICITY Mutagenicity 107-02-8 ACROLEIN ADVERSE_EFFECT OCU_1_Eye Irritation 107-02-8 ACROLEIN TISSUE_TOXICITY Hepatotoxicity 107-02-8 ACROLEIN TISSUE_TOXICITY Death 107-02-8 ACROLEIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_3_Death 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_2_Asthma 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_2_Pulmonary Hemorrhage 107-02-8 ACROLEIN ADVERSE_EFFECT SKN_2_Nail Disorder 107-02-8 ACROLEIN ADVERSE_EFFECT GIS_2_Gastrointestinal Necrosis 107-02-8 ACROLEIN KNOWN_TOXICITY Mutagenicity 107-02-8 ACROLEIN ADVERSE_EFFECT OCU_1_Ocular Irritation 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_2_Respiratory Infection 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_1_Lacrimation 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_2_Rhinitis 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_1_Respiratory Disorder 107-02-8 ACROLEIN ACTIVITY_CLASS Toxicant, DNA damaging 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_2_Pulmonary Edema 107-02-8 ACROLEIN KNOWN_TOXICITY Miscellaneous 107-02-8 ACROLEIN ADVERSE_EFFECT END_2_Growth Inhibition 107-02-8 ACROLEIN ADVERSE_EFFECT DNA_2_Mutagenicity 107-02-8 ACROLEIN ADVERSE_EFFECT OCU_2_Eye Disorder 107-02-8 ACROLEIN ADVERSE_EFFECT LUN_2_Respiratory Distress Syndrome 107-02-8 ACROLEIN ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 315-22-0 MONOCROTALINE TISSUE_TOXICITY Pulmonary Hypertension 315-22-0 MONOCROTALINE TISSUE_TOXICITY Mutagenicity 315-22-0 MONOCROTALINE PRODUCT_CLASS Toxicants 315-22-0 MONOCROTALINE ADVERSE_EFFECT LUN_2_Pulmonary Toxicity 315-22-0 MONOCROTALINE ADVERSE_EFFECT LIV_1_Hepatic Injury 315-22-0 MONOCROTALINE ADVERSE_EFFECT DNA_2_Mutagenicity 315-22-0 MONOCROTALINE KNOWN_TOXICITY Miscellaneous 315-22-0 MONOCROTALINE TISSUE_TOXICITY Hepatic Necrosis 315-22-0 MONOCROTALINE KNOWN_TOXICITY Mutagenicity 315-22-0 MONOCROTALINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 315-22-0 MONOCROTALINE ADVERSE_EFFECT DNA_2_Carcinogenicity 315-22-0 MONOCROTALINE KNOWN_TOXICITY Hepatotoxicity 315-22-0 MONOCROTALINE KNOWN_TOXICITY Respiratory Toxicity 315-22-0 MONOCROTALINE TISSUE_TOXICITY Hepatotoxicity 315-22-0 MONOCROTALINE ACTIVITY_CLASS Toxicant 315-22-0 MONOCROTALINE TISSUE_TOXICITY Carcinogenicity 315-22-0 MONOCROTALINE STRUCTURE_ACTIVITY Toxicant, mycotoxin/plant toxin 315-22-0 MONOCROTALINE ADVERSE_EFFECT XXX_3_Death 315-22-0 MONOCROTALINE ADVERSE_EFFECT END_1_Hemosiderosis 315-22-0 MONOCROTALINE TISSUE_TOXICITY Death 315-22-0 MONOCROTALINE ADVERSE_EFFECT LIV_2_Hepatic Necrosis 315-22-0 MONOCROTALINE ADVERSE_EFFECT LUN_1_Pulmonary Hypertension 315-22-0 MONOCROTALINE ADVERSE_EFFECT KID_1_Glomerular Dysfunction 315-22-0 MONOCROTALINE KNOWN_TOXICITY Carcinogenicity 51-24-1 3,3',5-TRIIODOTHYROACETIC ACID STRUCTURE_ACTIVITY T3 receptor agonist 151-18-8 3-AMINOPROPIONITRILE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 79-38-9 CHLOROTRIFLUOROETHYLENE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 319-86-8 DELTA-BHC STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 631-64-1 DIBROMOACETIC ACID STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 75-69-4 TRICHLOROFLUOROMETHANE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 106-99-0 1,3-BUTADIENE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 7440-02-0 NICKEL STRUCTURE_ACTIVITY Toxicant, heavy metal, hypoxia inducer, HIF-1alpha stablizer 57117-41-6 1,2,3,7,8-PENTACHLORODIBENZOFURAN STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist 3268-87-9 1,2,3,4,6,7,8,9-OCTACHLORODIBENZO-P-DIOXIN STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist 2051-24-3 DECACHLOROBIPHENYL STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 65673-63-4 HA14-1 STRUCTURE_ACTIVITY Apoptosis inducer, BH3 domain binder 7535-00-4 D-GALACTOSAMINE ADVERSE_EFFECT LIV_2_Hepatic Failure 7535-00-4 D-GALACTOSAMINE ADVERSE_EFFECT LIV_1_Hepatitis 7535-00-4 D-GALACTOSAMINE ADVERSE_EFFECT LIV_3_Liver Necrosis 7535-00-4 D-GALACTOSAMINE TISSUE_TOXICITY Liver Necrosis 7535-00-4 D-GALACTOSAMINE TISSUE_TOXICITY Hepatic Failure 7535-00-4 D-GALACTOSAMINE ACTIVITY_CLASS Toxicant 7535-00-4 D-GALACTOSAMINE KNOWN_TOXICITY Hepatotoxicity 7535-00-4 D-GALACTOSAMINE STRUCTURE_ACTIVITY Apoptosis inducer 7535-00-4 D-GALACTOSAMINE ADVERSE_EFFECT LIV_1_Hepatic Injury 7535-00-4 D-GALACTOSAMINE PRODUCT_CLASS Toxicants 74713-59-0 C8 CERAMIDE STRUCTURE_ACTIVITY Apoptosis inducer 227619-96-7 OSI-461 STRUCTURE_ACTIVITY Apoptosis inducer 285983-48-4 DORAMAPIMOD MODE_CLASS Enzyme Inhibitor 285983-48-4 DORAMAPIMOD INDICATION Crohn's Disease 285983-48-4 DORAMAPIMOD INDICATION Arthritis 285983-48-4 DORAMAPIMOD THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 285983-48-4 DORAMAPIMOD INDICATION Psoriasis 285983-48-4 DORAMAPIMOD INDICATION Shock 285983-48-4 DORAMAPIMOD INDICATION Toxic Shock Syndrome 285983-48-4 DORAMAPIMOD INDICATION Inflammation 285983-48-4 DORAMAPIMOD PRODUCT_CLASS Anti-inflammatories 285983-48-4 DORAMAPIMOD ADVERSE_EFFECT SKN_1_Acne 285983-48-4 DORAMAPIMOD MECHANISM Inhibit kinase mediated signal transduction 285983-48-4 DORAMAPIMOD INDICATION Rheumatoid Arthritis 285983-48-4 DORAMAPIMOD ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 285983-48-4 DORAMAPIMOD STRUCTURE_ACTIVITY Protein-serine/threonine kinase (p38) inhibitor 287096-87-1 RDP-58 STRUCTURE_ACTIVITY Protein-serine/threonine kinase (p38) inhibitor 287096-87-1 RDP-58 ADVERSE_EFFECT GIS_1_Flatulence 287096-87-1 RDP-58 MODE_CLASS Enzyme Inhibitor 287096-87-1 RDP-58 INDICATION Crohn's Disease 287096-87-1 RDP-58 ADVERSE_EFFECT GIS_1_Nausea 287096-87-1 RDP-58 PRODUCT_CLASS Anti-inflammatories 287096-87-1 RDP-58 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 287096-87-1 RDP-58 INDICATION Gastrointestinal Diseases 287096-87-1 RDP-58 INDICATION Inflammation 287096-87-1 RDP-58 MECHANISM Inhibit kinase mediated signal transduction 287096-87-1 RDP-58 ADVERSE_EFFECT NEU_1_Headache 287096-87-1 RDP-58 INDICATION Ulcerative Colitis 204974-67-4 RDP-58 PRODUCT_CLASS Anti-inflammatories 204974-67-4 RDP-58 ADVERSE_EFFECT GIS_1_Nausea 204974-67-4 RDP-58 INDICATION Crohn's Disease 204974-67-4 RDP-58 ADVERSE_EFFECT GIS_1_Flatulence 204974-67-4 RDP-58 MODE_CLASS Enzyme Inhibitor 204974-67-4 RDP-58 STRUCTURE_ACTIVITY Protein-serine/threonine kinase (p38) inhibitor 204974-67-4 RDP-58 INDICATION Ulcerative Colitis 204974-67-4 RDP-58 ADVERSE_EFFECT NEU_1_Headache 204974-67-4 RDP-58 MECHANISM Inhibit kinase mediated signal transduction 204974-67-4 RDP-58 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 204974-67-4 RDP-58 INDICATION Inflammation 204974-67-4 RDP-58 INDICATION Gastrointestinal Diseases 443913-73-3 ZD-6474 STRUCTURE_ACTIVITY Protein-tyrosine kinase (EGFR) inhibitor 443913-73-3 ZD-6474 ADVERSE_EFFECT KID_1_Proteinuria 443913-73-3 ZD-6474 ADVERSE_EFFECT SKN_1_Rash 443913-73-3 ZD-6474 INDICATION Neoplasm / Cancer / Tumor 443913-73-3 ZD-6474 INDICATION Breast Cancer / Carcinoma of the Breast 443913-73-3 ZD-6474 INDICATION Small Cell Lung Carcinoma 443913-73-3 ZD-6474 ADVERSE_EFFECT GIS_1_Diarrhea 443913-73-3 ZD-6474 INDICATION Head and Neck Cancer 443913-73-3 ZD-6474 INDICATION Non-Small Cell Lung Carcinoma 443913-73-3 ZD-6474 MODE_CLASS Enzyme Inhibitor 443913-73-3 ZD-6474 ADVERSE_EFFECT BBM_2_Thrombocytopenia 443913-73-3 ZD-6474 THERAPEUTIC_CLASS Antineoplastics 443913-73-3 ZD-6474 ADVERSE_EFFECT CVS_1_Hypertension 443913-73-3 ZD-6474 MECHANISM Modulate growth factor receptor mediated signal transduction 443913-73-3 ZD-6474 INDICATION Multiple Myeloma / Myelomatosis 443913-73-3 ZD-6474 INDICATION Liver Cancer 443913-73-3 ZD-6474 ADVERSE_EFFECT CVS_1_Prolonged QT Interval 443913-73-3 ZD-6474 INDICATION Brain Cancer 443913-73-3 ZD-6474 INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 443913-73-3 ZD-6474 PRODUCT_CLASS Anti-cancers 181296-84-4 TCH-346 INDICATION Parkinson's Disease 181296-84-4 TCH-346 STRUCTURE_ACTIVITY Apoptosis inhibitor 405169-16-6 CHIR-258 STRUCTURE_ACTIVITY Protein-tyrosine kinase (Flt3) inhibitor 210354-22-6 GW-274150 STRUCTURE_ACTIVITY NO synthesis inhibitor 286370-15-8 KRN-951 STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 289499-45-2 CANERTINIB ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 289499-45-2 CANERTINIB ADVERSE_EFFECT ELT_2_Hypocalcemia 289499-45-2 CANERTINIB ADVERSE_EFFECT END_2_Hyperglycemia 289499-45-2 CANERTINIB ADVERSE_EFFECT BBM_2_Anemia 289499-45-2 CANERTINIB INDICATION Neoplasm / Cancer / Tumor 289499-45-2 CANERTINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (erbb) inhibitor 289499-45-2 CANERTINIB KNOWN_TOXICITY Nephrotoxicity 289499-45-2 CANERTINIB ADVERSE_EFFECT GIS_2_Stomatitis 289499-45-2 CANERTINIB ADVERSE_EFFECT XXX_1_Mucositis 289499-45-2 CANERTINIB ADVERSE_EFFECT ELT_2_Hypomagnesemia 289499-45-2 CANERTINIB ADVERSE_EFFECT KID_2_Proteinuria 289499-45-2 CANERTINIB ADVERSE_EFFECT IMU_2_Hypersensitivity 289499-45-2 CANERTINIB THERAPEUTIC_CLASS Antineoplastics 289499-45-2 CANERTINIB PRODUCT_CLASS Anti-cancers 289499-45-2 CANERTINIB ADVERSE_EFFECT OCU_2_Eye Dryness 289499-45-2 CANERTINIB ADVERSE_EFFECT KID_2_Hematuria 289499-45-2 CANERTINIB MECHANISM Inhibit kinase mediated signal transduction 289499-45-2 CANERTINIB ADVERSE_EFFECT ELT_3_Hyponatremia 289499-45-2 CANERTINIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 289499-45-2 CANERTINIB ADVERSE_EFFECT BBM_2_Thrombocytopenia 289499-45-2 CANERTINIB ADVERSE_EFFECT END_2_Hypophosphatemia 289499-45-2 CANERTINIB TISSUE_TOXICITY Hematuria 289499-45-2 CANERTINIB ADVERSE_EFFECT SKN_1_Rash 289499-45-2 CANERTINIB MODE_CLASS Enzyme Inhibitor 289499-45-2 CANERTINIB ADVERSE_EFFECT GIS_1_Diarrhea 267243-28-7 CANERTINIB PRODUCT_CLASS Anti-cancers 267243-28-7 CANERTINIB THERAPEUTIC_CLASS Antineoplastics 267243-28-7 CANERTINIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 267243-28-7 CANERTINIB ADVERSE_EFFECT ELT_3_Hyponatremia 267243-28-7 CANERTINIB ADVERSE_EFFECT GIS_2_Stomatitis 267243-28-7 CANERTINIB ADVERSE_EFFECT BBM_2_Thrombocytopenia 267243-28-7 CANERTINIB KNOWN_TOXICITY Nephrotoxicity 267243-28-7 CANERTINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (erbb) inhibitor 267243-28-7 CANERTINIB INDICATION Neoplasm / Cancer / Tumor 267243-28-7 CANERTINIB ADVERSE_EFFECT BBM_2_Anemia 267243-28-7 CANERTINIB ADVERSE_EFFECT END_2_Hyperglycemia 267243-28-7 CANERTINIB ADVERSE_EFFECT ELT_2_Hypocalcemia 267243-28-7 CANERTINIB ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 267243-28-7 CANERTINIB ADVERSE_EFFECT END_2_Hypophosphatemia 267243-28-7 CANERTINIB ADVERSE_EFFECT OCU_2_Eye Dryness 267243-28-7 CANERTINIB ADVERSE_EFFECT KID_2_Proteinuria 267243-28-7 CANERTINIB ADVERSE_EFFECT XXX_1_Mucositis 267243-28-7 CANERTINIB ADVERSE_EFFECT IMU_2_Hypersensitivity 267243-28-7 CANERTINIB MECHANISM Inhibit kinase mediated signal transduction 267243-28-7 CANERTINIB ADVERSE_EFFECT KID_2_Hematuria 267243-28-7 CANERTINIB TISSUE_TOXICITY Hematuria 267243-28-7 CANERTINIB ADVERSE_EFFECT ELT_2_Hypomagnesemia 267243-28-7 CANERTINIB ADVERSE_EFFECT SKN_1_Rash 267243-28-7 CANERTINIB ADVERSE_EFFECT GIS_1_Diarrhea 267243-28-7 CANERTINIB MODE_CLASS Enzyme Inhibitor 257933-82-7 EKB-569 INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 257933-82-7 EKB-569 ADVERSE_EFFECT GIS_1_Diarrhea 257933-82-7 EKB-569 STRUCTURE_ACTIVITY Protein-tyrosine kinase (erbb) inhibitor 257933-82-7 EKB-569 INDICATION Neoplasm / Cancer / Tumor 257933-82-7 EKB-569 ADVERSE_EFFECT XXX_1_Asthenia 257933-82-7 EKB-569 ADVERSE_EFFECT GIS_1_Stomatitis 257933-82-7 EKB-569 MECHANISM Inhibit kinase mediated signal transduction 257933-82-7 EKB-569 ADVERSE_EFFECT PSY_1_Anorexia 257933-82-7 EKB-569 ADVERSE_EFFECT XXX_2_Mucositis 257933-82-7 EKB-569 ADVERSE_EFFECT SKN_1_Rash 257933-82-7 EKB-569 ADVERSE_EFFECT SKN_1_Acne 257933-82-7 EKB-569 ADVERSE_EFFECT GIS_1_Nausea / Vomiting 257933-82-7 EKB-569 THERAPEUTIC_CLASS Antineoplastics 257933-82-7 EKB-569 PRODUCT_CLASS Anti-cancers 257933-82-7 EKB-569 INDICATION Non-Small Cell Lung Carcinoma 257933-82-7 EKB-569 ADVERSE_EFFECT BBM_2_Leukopenia 257933-82-7 EKB-569 MODE_CLASS Enzyme Inhibitor 186496-72-0 ZD-2574 STRUCTURE_ACTIVITY Endothelin receptor antagonist 12772-57-5 RADICICOL STRUCTURE_ACTIVITY Apoptosis inducer 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT XXX_3_Death 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT PSY_1_Anorexia 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT LUN_1_Respiratory Disorder 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT PSY_1_Irritability 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT BBM_3_Hemorrhage 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT LUN_1_Asthma 51-03-6 PIPERONYL BUTOXIDE TISSUE_TOXICITY Death 51-03-6 PIPERONYL BUTOXIDE KNOWN_TOXICITY Hepatotoxicity 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT LIV_3_Liver Necrosis 51-03-6 PIPERONYL BUTOXIDE TISSUE_TOXICITY Hepatotoxicity 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT EMB_2_Teratogenicity 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT LIV_3_Hepatic Damage 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT REP_1_Changes in Reproductive Function 51-03-6 PIPERONYL BUTOXIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT XXX_1_Weight Gain 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT XXX_2_Mucosal ulceration 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT NEU_3_Coma 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT BBM_3_Anemia 51-03-6 PIPERONYL BUTOXIDE MODE_CLASS Enzyme Inhibitor 51-03-6 PIPERONYL BUTOXIDE STRUCTURE_ACTIVITY Toxicant 51-03-6 PIPERONYL BUTOXIDE TISSUE_TOXICITY Liver Necrosis 51-03-6 PIPERONYL BUTOXIDE TISSUE_TOXICITY Teratogenicity 51-03-6 PIPERONYL BUTOXIDE PRODUCT_CLASS Toxicants 51-03-6 PIPERONYL BUTOXIDE KNOWN_TOXICITY Miscellaneous 51-03-6 PIPERONYL BUTOXIDE ADVERSE_EFFECT XXX_2_Prostration 467214-20-6 17-DEMETHOXY 17-[[(2-DIMETHYLAMINO)ETHYL]AMINO]GELDANAMYCIN STRUCTURE_ACTIVITY Protein-tyrosine kinase (MET) inhibitor 467214-21-7 17-DEMETHOXY 17-[[(2-DIMETHYLAMINO)ETHYL]AMINO]GELDANAMYCIN STRUCTURE_ACTIVITY Protein-tyrosine kinase (MET) inhibitor 180468-40-0 YM-905 INDICATION Urinary Incontinence / Enuresis 180468-40-0 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180468-40-0 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 156862-51-0 BALAPERIDONE MODE_CLASS Receptor Ligand Antagonist 156862-51-0 BALAPERIDONE MECHANISM Modulate neural transmission 208661-17-0 BALAPERIDONE MODE_CLASS Receptor Ligand Antagonist 208661-17-0 BALAPERIDONE MECHANISM Modulate neural transmission 170729-80-3 APREPITANT MECHANISM Modulate G-protein coupled signal transduction 170729-80-3 APREPITANT PRODUCT_CLASS Gastrointestinal System 170729-80-3 APREPITANT STRUCTURE_ACTIVITY Anti-emetic, neurokinin-1 receptor antagonist 170729-80-3 APREPITANT THERAPEUTIC_CLASS Antidepressants 170729-80-3 APREPITANT THERAPEUTIC_CLASS Antiemetics 170729-80-3 APREPITANT MODE_CLASS Receptor Ligand Antagonist 170729-80-3 APREPITANT PRODUCT_CLASS Central Nervous System (CNS) 172822-29-6 APREPITANT PRODUCT_CLASS Central Nervous System (CNS) 172822-29-6 APREPITANT MODE_CLASS Receptor Ligand Antagonist 172822-29-6 APREPITANT STRUCTURE_ACTIVITY Anti-emetic, neurokinin-1 receptor antagonist 172822-29-6 APREPITANT THERAPEUTIC_CLASS Antiemetics 172822-29-6 APREPITANT THERAPEUTIC_CLASS Antidepressants 172822-29-6 APREPITANT PRODUCT_CLASS Gastrointestinal System 172822-29-6 APREPITANT MECHANISM Modulate G-protein coupled signal transduction 172822-28-5 APREPITANT PRODUCT_CLASS Central Nervous System (CNS) 172822-28-5 APREPITANT MECHANISM Modulate G-protein coupled signal transduction 172822-28-5 APREPITANT STRUCTURE_ACTIVITY Anti-emetic, neurokinin-1 receptor antagonist 172822-28-5 APREPITANT MODE_CLASS Receptor Ligand Antagonist 172822-28-5 APREPITANT THERAPEUTIC_CLASS Antiemetics 172822-28-5 APREPITANT THERAPEUTIC_CLASS Antidepressants 172822-28-5 APREPITANT PRODUCT_CLASS Gastrointestinal System 172673-20-0 L-758298 INDICATION Nausea / Vomiting 172822-01-4 L-758298 INDICATION Nausea / Vomiting 172822-03-6 L-758298 INDICATION Nausea / Vomiting 183319-69-9 ERLOTINIB ADVERSE_EFFECT CVS_3_Stroke 183319-69-9 ERLOTINIB ADVERSE_EFFECT SKN_1_Pruritis 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_3_Melena 183319-69-9 ERLOTINIB ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_1_Fever 183319-69-9 ERLOTINIB ADVERSE_EFFECT LUN_3_Bronchiolitis 183319-69-9 ERLOTINIB ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_1_Abdominal Cramps 183319-69-9 ERLOTINIB PRODUCT_CLASS Anti-cancers 183319-69-9 ERLOTINIB MECHANISM Modulate growth factor receptor mediated signal transduction 183319-69-9 ERLOTINIB ADVERSE_EFFECT BBM_3_Thrombocytopenia 183319-69-9 ERLOTINIB ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 183319-69-9 ERLOTINIB ADVERSE_EFFECT OCU_2_Keratitis 183319-69-9 ERLOTINIB ADVERSE_EFFECT CVS_3_Thrombosis 183319-69-9 ERLOTINIB ADVERSE_EFFECT SKN_1_Rash 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_1_Infection 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_3_Hematemesis 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_2_Epistaxis 183319-69-9 ERLOTINIB ADVERSE_EFFECT LUN_1_Cough 183319-69-9 ERLOTINIB ADVERSE_EFFECT PSY_1_Anorexia 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_1_Weight Loss 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_1_Diarrhea 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_2_Stomatitis 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_1_Oral Ulceration 183319-69-9 ERLOTINIB ADVERSE_EFFECT BBM_3_Hemolytic Anemia 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_1_Fatigue 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_1_Dehydration 183319-69-9 ERLOTINIB ADVERSE_EFFECT BBM_3_Bleeding 183319-69-9 ERLOTINIB THERAPEUTIC_CLASS Antineoplastics 183319-69-9 ERLOTINIB TISSUE_TOXICITY Thrombosis 183319-69-9 ERLOTINIB INDICATION Lung Cancer / Carcinoma of the Lung 183319-69-9 ERLOTINIB MODE_CLASS Receptor tyrosine kinase inhibitor 183319-69-9 ERLOTINIB ADVERSE_EFFECT CVS_2_Angina 183319-69-9 ERLOTINIB INDICATION Head and Neck Cancer 183319-69-9 ERLOTINIB ADVERSE_EFFECT LUN_1_Dyspnea 183319-69-9 ERLOTINIB ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 183319-69-9 ERLOTINIB ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 183319-69-9 ERLOTINIB TISSUE_TOXICITY Myocardial Infarction 183319-69-9 ERLOTINIB ADVERSE_EFFECT CVS_3_Myocardial Infarction 183319-69-9 ERLOTINIB ADVERSE_EFFECT OCU_1_Conjunctivitis 183319-69-9 ERLOTINIB ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 183319-69-9 ERLOTINIB INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 183319-69-9 ERLOTINIB INDICATION Neoplasm / Cancer / Tumor 183319-69-9 ERLOTINIB TISSUE_TOXICITY Stroke 183319-69-9 ERLOTINIB KNOWN_TOXICITY Cardiovascular Toxicity 183319-69-9 ERLOTINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (EGFR) inhibitor 183319-69-9 ERLOTINIB ADVERSE_EFFECT XXX_2_Xerosis 183319-69-9 ERLOTINIB TISSUE_TOXICITY Angina 137109-78-5 ORAZIPONE INDICATION Inflammatory Bowel Disease (IBD) 137109-78-5 ORAZIPONE INDICATION Ulcer 189188-57-6 TEGASEROD INDICATION Irritable Bowel Syndrome 145158-71-0 TEGASEROD INDICATION Irritable Bowel Syndrome 191611-76-4 SIB-1553A MECHANISM Modulate neural transmission 191611-76-4 SIB-1553A MODE_CLASS Channel Modulator 183552-38-7 ABARELIX PRODUCT_CLASS Anti-cancers 183552-38-7 ABARELIX STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor antagonist 183552-38-7 ABARELIX MODE_CLASS Receptor Ligand Antagonist 179819-89-7 TAK-677 MODE_CLASS Receptor Agonist, selective 179819-89-7 TAK-677 MECHANISM Reduce muscle contractile force 179819-89-7 TAK-677 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 179819-89-7 TAK-677 PRODUCT_CLASS Hormones, Endocrine and Metabolic 179819-89-7 TAK-677 THERAPEUTIC_CLASS Sympathomimetic Agents 179819-89-7 TAK-677 THERAPEUTIC_CLASS Antidiabetic Agents 179819-89-7 TAK-677 INDICATION Diabetes 179819-89-7 TAK-677 INDICATION Obesity 179819-89-7 TAK-677 PRODUCT_CLASS Autonomic Nervous System (ANS) 190442-10-5 NCX-4016 PRODUCT_CLASS Hematologics 190442-10-5 NCX-4016 MODE_CLASS Enzyme Inhibitor 190442-10-5 NCX-4016 THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 190442-10-5 NCX-4016 PRODUCT_CLASS Anti-inflammatories 190442-10-5 NCX-4016 THERAPEUTIC_CLASS Antiplatelets 190442-10-5 NCX-4016 MECHANISM Inhibit eicosanoid biosynthesis 161612-21-1 DU-125530 THERAPEUTIC_CLASS Antidepressants 161612-21-1 DU-125530 PRODUCT_CLASS Central Nervous System (CNS) 161612-21-1 DU-125530 INDICATION Depression 161612-21-1 DU-125530 MECHANISM Modulate neural transmission 161612-00-6 DU-125530 INDICATION Depression 161612-00-6 DU-125530 MECHANISM Modulate neural transmission 161612-00-6 DU-125530 PRODUCT_CLASS Central Nervous System (CNS) 161612-00-6 DU-125530 THERAPEUTIC_CLASS Antidepressants 204512-92-5 CVT-510 INDICATION Cardiac Arrhythmias 204512-92-5 CVT-510 PRODUCT_CLASS Cardiovasculars 204512-92-5 CVT-510 THERAPEUTIC_CLASS Antiarrhythmic Agents 204512-90-3 CVT-510 INDICATION Cardiac Arrhythmias 204512-90-3 CVT-510 PRODUCT_CLASS Cardiovasculars 204512-90-3 CVT-510 THERAPEUTIC_CLASS Antiarrhythmic Agents 204512-89-0 CVT-510 THERAPEUTIC_CLASS Antiarrhythmic Agents 204512-89-0 CVT-510 INDICATION Cardiac Arrhythmias 204512-89-0 CVT-510 PRODUCT_CLASS Cardiovasculars 165800-05-5 ORBOFIBAN ACETATE MODE_CLASS Receptor Ligand Antagonist, Selective 165800-05-5 ORBOFIBAN ACETATE MECHANISM Inhibit platelet aggregation 163250-90-6 ORBOFIBAN ACETATE MODE_CLASS Receptor Ligand Antagonist, Selective 163250-90-6 ORBOFIBAN ACETATE MECHANISM Inhibit platelet aggregation 163250-91-7 ORBOFIBAN ACETATE MECHANISM Inhibit platelet aggregation 163250-91-7 ORBOFIBAN ACETATE MODE_CLASS Receptor Ligand Antagonist, Selective 176644-21-6 EMD-96785 INDICATION Cerebral Ischemia 188968-51-6 EMD-85189 INDICATION Arthritis 188968-51-6 EMD-85189 PRODUCT_CLASS Immune Response / Immunomodulators 188968-51-6 EMD-85189 THERAPEUTIC_CLASS Immunosuppressants 179474-81-8 PRUCALOPRIDE INDICATION Irritable Bowel Syndrome 179474-84-1 PRUCALOPRIDE INDICATION Irritable Bowel Syndrome 179474-80-7 PRUCALOPRIDE INDICATION Irritable Bowel Syndrome 193275-85-3 LONAFARNIB STRUCTURE_ACTIVITY Protein farnesyl transferase inhibitor 193275-84-2 LONAFARNIB STRUCTURE_ACTIVITY Protein farnesyl transferase inhibitor 189448-35-9 MC-02,479 MODE_CLASS Enzyme Inhibitor 189448-35-9 MC-02,479 PRODUCT_CLASS Anti-infectives 189448-35-9 MC-02,479 THERAPEUTIC_CLASS Antibacterials 189448-35-9 MC-02,479 MECHANISM Inhibit bacterial cell wall biosynthesis 189449-59-0 MC-02,479 MODE_CLASS Enzyme Inhibitor 189449-59-0 MC-02,479 THERAPEUTIC_CLASS Antibacterials 189449-59-0 MC-02,479 MECHANISM Inhibit bacterial cell wall biosynthesis 189449-59-0 MC-02,479 PRODUCT_CLASS Anti-infectives 171724-30-4 S-0509 MODE_CLASS Receptor Ligand Antagonist, Selective 171724-30-4 S-0509 INDICATION Ulcer 171724-30-4 S-0509 MECHANISM Reduce stomach HCl secretion 171724-29-1 S-0509 INDICATION Ulcer 171724-29-1 S-0509 MECHANISM Reduce stomach HCl secretion 171724-29-1 S-0509 MODE_CLASS Receptor Ligand Antagonist, Selective 171724-28-0 S-0509 MODE_CLASS Receptor Ligand Antagonist, Selective 171724-28-0 S-0509 MECHANISM Reduce stomach HCl secretion 171724-28-0 S-0509 INDICATION Ulcer 149847-79-0 DL-017 MODE_CLASS Channel Blocker 149847-79-0 DL-017 MECHANISM Modulate G-protein coupled signal transduction 149847-79-0 DL-017 INDICATION Cardiac Arrhythmias 149847-79-0 DL-017 THERAPEUTIC_CLASS Antihypertensive Agents 149847-79-0 DL-017 INDICATION Angina Pectoris 149847-79-0 DL-017 INDICATION Hypertension 149847-79-0 DL-017 PRODUCT_CLASS Cardiovasculars 149847-79-0 DL-017 THERAPEUTIC_CLASS Antiarrhythmic Agents 149847-79-0 DL-017 MECHANISM Block neural transmission 149847-79-0 DL-017 THERAPEUTIC_CLASS Antianginals 139146-65-9 SP/W-5186 PRODUCT_CLASS Cardiovasculars 139146-65-9 SP/W-5186 THERAPEUTIC_CLASS Antianginals 139146-65-9 SP/W-5186 INDICATION Angina Pectoris 178979-85-6 CAPRAVIRINE INDICATION Myocardial Ischemia 178979-85-6 CAPRAVIRINE STRUCTURE_ACTIVITY Viral RT inhibitor 194037-25-7 TA-270 MODE_CLASS Enzyme Inhibitor 194037-25-7 TA-270 MECHANISM Inhibit eicosanoid biosynthesis 151425-92-2 TRK-530 THERAPEUTIC_CLASS Immunosuppressants 151425-92-2 TRK-530 PRODUCT_CLASS Immune Response / Immunomodulators 151425-92-2 TRK-530 INDICATION Arthritis 151425-91-1 TRK-530 PRODUCT_CLASS Immune Response / Immunomodulators 151425-91-1 TRK-530 THERAPEUTIC_CLASS Immunosuppressants 151425-91-1 TRK-530 INDICATION Arthritis 198904-31-3 ATAZANAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 145514-04-1 DAPD MECHANISM Inhibit viral DNA synthesis 145514-04-1 DAPD PRODUCT_CLASS Anti-infectives 145514-04-1 DAPD MODE_CLASS Enzyme substrate mimic 145514-04-1 DAPD INDICATION Human Immunodeficiency Virus (HIV) Disease 145514-04-1 DAPD THERAPEUTIC_CLASS Antivirals, Systemic 180384-56-9 RO-61-1790 INDICATION Renal Failure / Kidney Failure 180384-56-9 RO-61-1790 INDICATION Cerebral Ischemia 198283-73-7 A-98593 S MECHANISM Prolong/enhance neural transmission 198283-73-7 A-98593 S MODE_CLASS Channel Modulator 198283-73-7 A-98593 S PRODUCT_CLASS Analgesics 198283-73-7 A-98593 S THERAPEUTIC_CLASS Analgesics, Non-Opioid 198283-73-7 A-98593 S PRODUCT_CLASS Central Nervous System (CNS) 198470-85-8 PARECOXIB STRUCTURE_ACTIVITY NSAID, COX-2/1, coxib like 198470-85-8 PARECOXIB INDICATION Fever 198470-84-7 PARECOXIB INDICATION Fever 198470-84-7 PARECOXIB STRUCTURE_ACTIVITY NSAID, COX-2/1, coxib like 199864-87-4 RS-127445 PRODUCT_CLASS Central Nervous System (CNS) 199864-87-4 RS-127445 MECHANISM Modulate G-protein coupled signal transduction 199864-87-4 RS-127445 THERAPEUTIC_CLASS Antimigraines 199864-87-4 RS-127445 INDICATION Migraine Headache 199864-87-4 RS-127445 MODE_CLASS Receptor Ligand Antagonist 199864-86-3 RS-127445 THERAPEUTIC_CLASS Antimigraines 199864-86-3 RS-127445 MODE_CLASS Receptor Ligand Antagonist 199864-86-3 RS-127445 INDICATION Migraine Headache 199864-86-3 RS-127445 MECHANISM Modulate G-protein coupled signal transduction 199864-86-3 RS-127445 PRODUCT_CLASS Central Nervous System (CNS) 163706-06-7 AR-C69931MX MODE_CLASS Receptor Ligand Antagonist 163706-06-7 AR-C69931MX STRUCTURE_ACTIVITY Nucleotide receptor P2Y12 antagonist 163706-06-7 AR-C69931MX THERAPEUTIC_CLASS Antiplatelets 163706-06-7 AR-C69931MX MECHANISM Inhibit platelet aggregation 163706-06-7 AR-C69931MX PRODUCT_CLASS Hematologics 157583-18-1 J-861 MODE_CLASS Enzyme Inhibitor 200940-22-3 SB-243213 INDICATION Depression 200940-22-3 SB-243213 THERAPEUTIC_CLASS Sedatives/Hypnotics 200940-22-3 SB-243213 THERAPEUTIC_CLASS Antidepressants 200940-22-3 SB-243213 MECHANISM Modulate neural transmission 200940-22-3 SB-243213 MODE_CLASS Receptor Ligand Antagonist 200940-22-3 SB-243213 INDICATION Anxiety Disorders 200940-22-3 SB-243213 PRODUCT_CLASS Central Nervous System (CNS) 179324-69-7 BORTEZOMIB TISSUE_TOXICITY Thrombocytopenia 179324-69-7 BORTEZOMIB KNOWN_TOXICITY Mutagenicity 179324-69-7 BORTEZOMIB INDICATION Neoplasm / Cancer / Tumor 179324-69-7 BORTEZOMIB INDICATION Multiple Myeloma / Myelomatosis 179324-69-7 BORTEZOMIB PRODUCT_CLASS Anti-cancers 179324-69-7 BORTEZOMIB ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 179324-69-7 BORTEZOMIB ADVERSE_EFFECT PSY_2_Anxiety 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Weakness 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Edema 179324-69-7 BORTEZOMIB ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 179324-69-7 BORTEZOMIB ADVERSE_EFFECT MSK_2_Bone Pain 179324-69-7 BORTEZOMIB ADVERSE_EFFECT MSK_2_Muscle Cramps 179324-69-7 BORTEZOMIB ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Dysesthesia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_1_Diarrhea 179324-69-7 BORTEZOMIB TISSUE_TOXICITY Hypotension 179324-69-7 BORTEZOMIB ADVERSE_EFFECT BBM_1_Thrombocytopenia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_2_Abdominal Pain 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Asthenia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Malaise 179324-69-7 BORTEZOMIB ADVERSE_EFFECT SKN_2_Skin Irritation 179324-69-7 BORTEZOMIB ADVERSE_EFFECT NEU_3_Intracranial Bleeding 179324-69-7 BORTEZOMIB ADVERSE_EFFECT OCU_2_Blurred Vision 179324-69-7 BORTEZOMIB STRUCTURE_ACTIVITY Proteasome inhibitor 179324-69-7 BORTEZOMIB KNOWN_TOXICITY Blood & Bone Marrow Toxicity 179324-69-7 BORTEZOMIB MODE_CLASS Distorts /blocks macromolecular scaffold function 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_2_Dehydration 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 179324-69-7 BORTEZOMIB ADVERSE_EFFECT LUN_2_Cough 179324-69-7 BORTEZOMIB ADVERSE_EFFECT SKN_1_Rash 179324-69-7 BORTEZOMIB ADVERSE_EFFECT BBM_1_Anemia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT MSK_1_Arthralgia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT BBM_1_Neutropenia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT MSK_2_Back Pain 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 179324-69-7 BORTEZOMIB ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_2_Injection Site Reaction 179324-69-7 BORTEZOMIB TISSUE_TOXICITY Clastogenicity 179324-69-7 BORTEZOMIB ADVERSE_EFFECT PSY_1_Insomnia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Fatigue 179324-69-7 BORTEZOMIB ADVERSE_EFFECT NEU_1_Dizziness 179324-69-7 BORTEZOMIB ADVERSE_EFFECT SKN_2_Pruritis 179324-69-7 BORTEZOMIB THERAPEUTIC_CLASS Antineoplastics 179324-69-7 BORTEZOMIB ADVERSE_EFFECT NEU_2_Syncope 179324-69-7 BORTEZOMIB ADVERSE_EFFECT LUN_1_Dyspnea 179324-69-7 BORTEZOMIB ADVERSE_EFFECT MSK_2_Myalgia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_2_Dyspepsia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Pyrexia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT DNA_3_Clastogenicity 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_2_Dysgeusia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT CVS_2_Hypotension 179324-69-7 BORTEZOMIB MECHANISM Inhibit proteasome function 179324-69-7 BORTEZOMIB TISSUE_TOXICITY Anemia 179324-69-7 BORTEZOMIB KNOWN_TOXICITY Cardiovascular Toxicity 179324-69-7 BORTEZOMIB ADVERSE_EFFECT PSY_1_Anorexia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT END_3_Hyperglycemia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT NEU_1_Headache 179324-69-7 BORTEZOMIB ADVERSE_EFFECT NEU_1_Paresthesia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT OCU_2_Diplopia 179324-69-7 BORTEZOMIB ADVERSE_EFFECT XXX_1_Fever 179324-69-7 BORTEZOMIB ADVERSE_EFFECT GIS_1_Constipation 179324-69-7 BORTEZOMIB TISSUE_TOXICITY Neutropenia 201605-51-8 CR-2945 THERAPEUTIC_CLASS Sedatives/Hypnotics 201605-51-8 CR-2945 MECHANISM Reduce stomach HCl secretion 201605-51-8 CR-2945 PRODUCT_CLASS Central Nervous System (CNS) 201605-51-8 CR-2945 INDICATION Anxiety Disorders 201605-51-8 CR-2945 MODE_CLASS Receptor Ligand Antagonist, Selective 107724-20-9 EPLERENONE STRUCTURE_ACTIVITY Mineralocorticoid receptor antagonist 107724-20-9 EPLERENONE INDICATION Hypertension 107724-20-9 EPLERENONE MODE_CLASS Receptor Ligand Antagonist, Selective 107724-20-9 EPLERENONE PRODUCT_CLASS Cardiovasculars 107724-20-9 EPLERENONE THERAPEUTIC_CLASS Antihypertensive Agents 107724-20-9 EPLERENONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 142471-56-5 T-82 MECHANISM Block neural transmission 142471-56-5 T-82 MECHANISM Enhance cholinergic transmission 142471-56-5 T-82 MODE_CLASS Channel Blocker 142471-56-5 T-82 MODE_CLASS Enzyme Inhibitor 179024-48-7 CI-1018 PRODUCT_CLASS Central Nervous System (CNS) 179024-48-7 CI-1018 MODE_CLASS Enzyme Inhibitor 179024-48-7 CI-1018 MECHANISM Enhance kinase mediated signal transduction 179024-48-7 CI-1018 THERAPEUTIC_CLASS Sedatives/Hypnotics 213027-19-1 GT-2331 INDICATION Insomnia / Dyssomnias 205645-02-9 NS-1209 STRUCTURE_ACTIVITY Glutamate receptor (AMPA) antagonist 205645-02-9 NS-1209 MODE_CLASS Receptor Ligand Antagonist 205645-02-9 NS-1209 INDICATION Cerebral Ischemia 254751-28-5 NS-1209 STRUCTURE_ACTIVITY Glutamate receptor (AMPA) antagonist 254751-28-5 NS-1209 MODE_CLASS Receptor Ligand Antagonist 254751-28-5 NS-1209 INDICATION Cerebral Ischemia 193420-09-6 Z-13752A PRODUCT_CLASS Cardiovasculars 193420-09-6 Z-13752A INDICATION Hypertension 193420-09-6 Z-13752A THERAPEUTIC_CLASS Antihypertensive Agents 193420-09-6 Z-13752A THERAPEUTIC_CLASS Antiarrhythmic Agents 193420-09-6 Z-13752A INDICATION Cardiac Arrhythmias 193420-09-6 Z-13752A MODE_CLASS Enzyme Inhibitor 193420-09-6 Z-13752A MECHANISM Modulate G-protein coupled signal transduction 193420-09-6 Z-13752A MECHANISM Reduce vasoconstriction 205110-48-1 ABT-773 THERAPEUTIC_CLASS Antibacterials 205110-48-1 ABT-773 MECHANISM Inhibit ribosomal protein synthesis 205110-48-1 ABT-773 PRODUCT_CLASS Anti-infectives 205110-48-1 ABT-773 MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 206873-63-4 TARIQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 182563-08-2 LY-334370 PRODUCT_CLASS Central Nervous System (CNS) 182563-08-2 LY-334370 INDICATION Migraine Headache 182563-08-2 LY-334370 THERAPEUTIC_CLASS Antimigraines 199673-74-0 LY-334370 THERAPEUTIC_CLASS Antimigraines 199673-74-0 LY-334370 INDICATION Migraine Headache 199673-74-0 LY-334370 PRODUCT_CLASS Central Nervous System (CNS) 182563-09-3 LY-334370 INDICATION Migraine Headache 182563-09-3 LY-334370 THERAPEUTIC_CLASS Antimigraines 182563-09-3 LY-334370 PRODUCT_CLASS Central Nervous System (CNS) 200398-40-9 S-18327 MECHANISM Modulate neural transmission 200398-40-9 S-18327 MODE_CLASS Receptor Ligand Antagonist 200398-40-9 S-18327 MECHANISM Modulate G-protein coupled signal transduction 179756-58-2 F-11440 THERAPEUTIC_CLASS Sedatives/Hypnotics 179756-58-2 F-11440 PRODUCT_CLASS Central Nervous System (CNS) 179756-58-2 F-11440 THERAPEUTIC_CLASS Antidepressants 179756-58-2 F-11440 INDICATION Anxiety Disorders 179756-58-2 F-11440 MECHANISM Modulate neural transmission 179756-58-2 F-11440 INDICATION Depression 179756-85-5 F-11440 THERAPEUTIC_CLASS Sedatives/Hypnotics 179756-85-5 F-11440 PRODUCT_CLASS Central Nervous System (CNS) 179756-85-5 F-11440 THERAPEUTIC_CLASS Antidepressants 179756-85-5 F-11440 INDICATION Anxiety Disorders 179756-85-5 F-11440 MECHANISM Modulate neural transmission 179756-85-5 F-11440 INDICATION Depression 143395-98-6 AMP-579 MECHANISM Modulate G-protein coupled signal transduction 143395-98-6 AMP-579 INDICATION Cerebral Ischemia 161715-24-8 L-084 PRODUCT_CLASS Anti-infectives 161715-24-8 L-084 THERAPEUTIC_CLASS Antibacterials 161715-24-8 L-084 MECHANISM Inhibit bacterial cell wall biosynthesis 161715-24-8 L-084 MODE_CLASS Enzyme Inhibitor 130018-77-8 LEVOCETIRIZINE MECHANISM Modulate G-protein coupled signal transduction 130018-77-8 LEVOCETIRIZINE INDICATION Allergic Rhinitis 130018-77-8 LEVOCETIRIZINE THERAPEUTIC_CLASS Antihistamines 130018-77-8 LEVOCETIRIZINE MODE_CLASS Receptor Ligand Antagonist, Selective 130018-77-8 LEVOCETIRIZINE INDICATION Allergic Conjunctivitis 130018-77-8 LEVOCETIRIZINE PRODUCT_CLASS Anti-inflammatories 130018-77-8 LEVOCETIRIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 202656-49-3 RIG-200 INDICATION Re-Stenosis 212142-19-3 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212142-19-3 VATALANIB INDICATION Glioma 212142-19-3 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212142-19-3 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212142-19-3 VATALANIB MODE_CLASS Enzyme Inhibitor 212142-19-3 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212142-19-3 VATALANIB PRODUCT_CLASS Anti-cancers 212142-19-3 VATALANIB TISSUE_TOXICITY Thromboembolism 212142-19-3 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212142-19-3 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212142-19-3 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212142-19-3 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212142-19-3 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212142-19-3 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 212142-19-3 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212142-19-3 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212142-19-3 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212142-19-3 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212142-19-3 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212142-19-3 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212142-19-3 VATALANIB INDICATION Myelodysplastic Syndromes 212142-19-3 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212142-19-3 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212142-19-3 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212142-19-3 VATALANIB INDICATION Myeloid Leukemia 212142-18-2 VATALANIB INDICATION Myeloid Leukemia 212142-18-2 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212142-18-2 VATALANIB INDICATION Myelodysplastic Syndromes 212142-18-2 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 212142-18-2 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212142-18-2 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212142-18-2 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212142-18-2 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212142-18-2 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212142-18-2 VATALANIB TISSUE_TOXICITY Thromboembolism 212142-18-2 VATALANIB MODE_CLASS Enzyme Inhibitor 212142-18-2 VATALANIB INDICATION Glioma 212142-18-2 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212142-18-2 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212142-18-2 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212142-18-2 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212142-18-2 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212142-18-2 VATALANIB PRODUCT_CLASS Anti-cancers 212142-18-2 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212142-18-2 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212142-18-2 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212142-18-2 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212142-18-2 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212142-18-2 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212142-18-2 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212141-90-7 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212141-90-7 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212141-90-7 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212141-90-7 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212141-90-7 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212141-90-7 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212141-90-7 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212141-90-7 VATALANIB INDICATION Myeloid Leukemia 212141-90-7 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 212141-90-7 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212141-90-7 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212141-90-7 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212141-90-7 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212141-90-7 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212141-90-7 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212141-90-7 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212141-90-7 VATALANIB TISSUE_TOXICITY Thromboembolism 212141-90-7 VATALANIB PRODUCT_CLASS Anti-cancers 212141-90-7 VATALANIB MODE_CLASS Enzyme Inhibitor 212141-90-7 VATALANIB INDICATION Glioma 212141-90-7 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212141-90-7 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212141-90-7 VATALANIB INDICATION Myelodysplastic Syndromes 212141-90-7 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212141-90-7 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212141-89-4 VATALANIB INDICATION Myelodysplastic Syndromes 212141-89-4 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212141-89-4 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212141-89-4 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212141-89-4 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212141-89-4 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212141-89-4 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212141-89-4 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212141-89-4 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212141-89-4 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212141-89-4 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212141-89-4 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212141-89-4 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 212141-89-4 VATALANIB INDICATION Myeloid Leukemia 212141-89-4 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212141-89-4 VATALANIB INDICATION Glioma 212141-89-4 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212141-89-4 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212141-89-4 VATALANIB MODE_CLASS Enzyme Inhibitor 212141-89-4 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212141-89-4 VATALANIB PRODUCT_CLASS Anti-cancers 212141-89-4 VATALANIB TISSUE_TOXICITY Thromboembolism 212141-89-4 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212141-89-4 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212141-89-4 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212141-54-3 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212141-54-3 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212141-54-3 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 212141-54-3 VATALANIB INDICATION Myelodysplastic Syndromes 212141-54-3 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212141-54-3 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212141-54-3 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212141-54-3 VATALANIB INDICATION Myeloid Leukemia 212141-54-3 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212141-54-3 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212141-54-3 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212141-54-3 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212141-54-3 VATALANIB TISSUE_TOXICITY Thromboembolism 212141-54-3 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212141-54-3 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212141-54-3 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212141-54-3 VATALANIB PRODUCT_CLASS Anti-cancers 212141-54-3 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212141-54-3 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212141-54-3 VATALANIB MODE_CLASS Enzyme Inhibitor 212141-54-3 VATALANIB INDICATION Glioma 212141-54-3 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212141-54-3 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212141-54-3 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212141-54-3 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212141-52-1 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212141-52-1 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212141-52-1 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212141-52-1 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212141-52-1 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212141-52-1 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212141-52-1 VATALANIB TISSUE_TOXICITY Thromboembolism 212141-52-1 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212141-52-1 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212141-52-1 VATALANIB INDICATION Glioma 212141-52-1 VATALANIB MODE_CLASS Enzyme Inhibitor 212141-52-1 VATALANIB PRODUCT_CLASS Anti-cancers 212141-52-1 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212141-52-1 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212141-52-1 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212141-52-1 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 212141-52-1 VATALANIB INDICATION Myeloid Leukemia 212141-52-1 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212141-52-1 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212141-52-1 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212141-52-1 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212141-52-1 VATALANIB INDICATION Myelodysplastic Syndromes 212141-52-1 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212141-52-1 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212141-52-1 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212141-51-0 VATALANIB INDICATION Myeloid Leukemia 212141-51-0 VATALANIB INDICATION Myelodysplastic Syndromes 212141-51-0 VATALANIB ADVERSE_EFFECT BBM_2_Neutropenia 212141-51-0 VATALANIB INDICATION Non-Small Cell Lung Carcinoma 212141-51-0 VATALANIB THERAPEUTIC_CLASS Antineoplastics 212141-51-0 VATALANIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 212141-51-0 VATALANIB ADVERSE_EFFECT XXX_1_Epistaxis 212141-51-0 VATALANIB INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 212141-51-0 VATALANIB INDICATION Glioma 212141-51-0 VATALANIB MODE_CLASS Enzyme Inhibitor 212141-51-0 VATALANIB PRODUCT_CLASS Anti-cancers 212141-51-0 VATALANIB TISSUE_TOXICITY Thromboembolism 212141-51-0 VATALANIB ADVERSE_EFFECT CVS_2_Hypertension 212141-51-0 VATALANIB ADVERSE_EFFECT GIS_1_Diarrhea 212141-51-0 VATALANIB INDICATION Prostatic Cancer / Carcinoma of the Prostate 212141-51-0 VATALANIB KNOWN_TOXICITY Cardiovascular Toxicity 212141-51-0 VATALANIB MECHANISM Modulate growth factor receptor mediated signal transduction 212141-51-0 VATALANIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Kit) inhibitor 212141-51-0 VATALANIB INDICATION Neoplasm / Cancer / Tumor 212141-51-0 VATALANIB INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 212141-51-0 VATALANIB INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 212141-51-0 VATALANIB ADVERSE_EFFECT NEU_1_Ataxia 212141-51-0 VATALANIB ADVERSE_EFFECT XXX_1_Fatigue 212141-51-0 VATALANIB ADVERSE_EFFECT CVS_3_Thromboembolism 212141-51-0 VATALANIB ADVERSE_EFFECT NEU_1_Dizziness 15866-90-7 NSC-683551 INDICATION Acute Respiratory Distress Syndrome (ARDS) 178040-94-3 GW-867 INDICATION Myocardial Ischemia 1327-53-3 ARSENIC TRIOXIDE INDICATION Acute Promyelocytic Leukemia 1327-53-3 ARSENIC TRIOXIDE THERAPEUTIC_CLASS Antineoplastics 1327-53-3 ARSENIC TRIOXIDE PRODUCT_CLASS Anti-cancers 191592-36-6 SUN-C5174 STRUCTURE_ACTIVITY 5HT2 antagonist 191592-35-5 SUN-C5174 STRUCTURE_ACTIVITY 5HT2 antagonist 191592-09-3 SUN-C5174 STRUCTURE_ACTIVITY 5HT2 antagonist 182415-09-4 SUN-N4057 INDICATION Cerebral Ischemia 182415-09-4 SUN-N4057 MECHANISM Modulate neural transmission 182415-13-0 SUN-N4057 INDICATION Cerebral Ischemia 182415-13-0 SUN-N4057 MECHANISM Modulate neural transmission 128-62-1 NOSCAPINE ADVERSE_EFFECT LUN_3_Respiratory Depression 128-62-1 NOSCAPINE ADVERSE_EFFECT IMU_3_Allergic Reactions 128-62-1 NOSCAPINE MESH_LEVEL_1 Heterocyclic Compounds 128-62-1 NOSCAPINE STRUCTURE_ACTIVITY Bradykinin antagonist 128-62-1 NOSCAPINE ADVERSE_EFFECT NEU_3_Somnolence 128-62-1 NOSCAPINE ADVERSE_EFFECT GIS_2_Nausea 128-62-1 NOSCAPINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 128-62-1 NOSCAPINE ADVERSE_EFFECT _3_Allergic Conjunctivitis 128-62-1 NOSCAPINE MODE_CLASS Receptor Agonist, selective 128-62-1 NOSCAPINE TA_LEVEL_2 Anti-tussive 128-62-1 NOSCAPINE TA_LEVEL_3 Opium derived alklaloid 128-62-1 NOSCAPINE MECHANISM Modulate G-protein coupled signal transduction 128-62-1 NOSCAPINE ADVERSE_EFFECT NEU_2_Dizziness 128-62-1 NOSCAPINE ADVERSE_EFFECT NEU_2_Drowsiness 128-62-1 NOSCAPINE ADVERSE_EFFECT GIS_3_Constipation 128-62-1 NOSCAPINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 128-62-1 NOSCAPINE PRODUCT_CLASS Respiratory System 128-62-1 NOSCAPINE MESH_LEVEL_2 Alkaloids 128-62-1 NOSCAPINE ZERO_CLASS N 128-62-1 NOSCAPINE MECHANISM Modulate neural transmission 128-62-1 NOSCAPINE ACTIVITY_CLASS Bradykinin antagonist 128-62-1 NOSCAPINE MECH_LEVEL_3 Bradykinin Receptor 128-62-1 NOSCAPINE TA_LEVEL_1 Eye, Ear, Nose and Throat Preparations 128-62-1 NOSCAPINE ADVERSE_EFFECT SKN_3_Skin Rash 128-62-1 NOSCAPINE MECH_LEVEL_1 Modulate neural transmission 128-62-1 NOSCAPINE INDICATION Cough / Tussis 128-62-1 NOSCAPINE MESH_LEVEL_3 Opium 912-60-7 NOSCAPINE ZERO_CLASS N 912-60-7 NOSCAPINE MESH_LEVEL_1 Heterocyclic Compounds 912-60-7 NOSCAPINE STRUCTURE_ACTIVITY Bradykinin antagonist 912-60-7 NOSCAPINE ADVERSE_EFFECT NEU_3_Somnolence 912-60-7 NOSCAPINE ADVERSE_EFFECT GIS_2_Nausea 912-60-7 NOSCAPINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 912-60-7 NOSCAPINE ADVERSE_EFFECT SKN_3_Skin Rash 912-60-7 NOSCAPINE ADVERSE_EFFECT NEU_2_Dizziness 912-60-7 NOSCAPINE MECHANISM Modulate G-protein coupled signal transduction 912-60-7 NOSCAPINE TA_LEVEL_3 Opium derived alklaloid 912-60-7 NOSCAPINE MECH_LEVEL_1 Modulate neural transmission 912-60-7 NOSCAPINE TA_LEVEL_2 Anti-tussive 912-60-7 NOSCAPINE ADVERSE_EFFECT _3_Allergic Conjunctivitis 912-60-7 NOSCAPINE PRODUCT_CLASS Respiratory System 912-60-7 NOSCAPINE MODE_CLASS Receptor Agonist, selective 912-60-7 NOSCAPINE MECHANISM Modulate neural transmission 912-60-7 NOSCAPINE ACTIVITY_CLASS Bradykinin antagonist 912-60-7 NOSCAPINE ADVERSE_EFFECT IMU_3_Allergic Reactions 912-60-7 NOSCAPINE ADVERSE_EFFECT LUN_3_Respiratory Depression 912-60-7 NOSCAPINE MECH_LEVEL_3 Bradykinin Receptor 912-60-7 NOSCAPINE TA_LEVEL_1 Eye, Ear, Nose and Throat Preparations 912-60-7 NOSCAPINE INDICATION Cough / Tussis 912-60-7 NOSCAPINE MESH_LEVEL_3 Opium 912-60-7 NOSCAPINE MESH_LEVEL_2 Alkaloids 912-60-7 NOSCAPINE ADVERSE_EFFECT NEU_2_Drowsiness 912-60-7 NOSCAPINE ADVERSE_EFFECT GIS_3_Constipation 912-60-7 NOSCAPINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 220997-97-7 BN-80915 STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 186668-70-2 BN-80915 STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 229961-45-9 AGN-194310 INDICATION Psoriasis 157283-68-6 TRAVOPROST MODE_CLASS Receptor Agonist 157283-68-6 TRAVOPROST MECHANISM Modulate G-protein coupled signal transduction 157283-68-6 TRAVOPROST INDICATION Glaucoma 229005-80-5 TAK-779 INDICATION Myocardial Ischemia 207556-62-5 DPP-728 MODE_CLASS Enzyme Inhibitor 180869-32-3 SB-235699 INDICATION Psoriasis 180869-32-3 SB-235699 INDICATION Eczema Herpeticum 175481-36-4 HARKOSERIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 608-07-1 5-METHOXYTRYPTAMINE PRODUCT_CLASS Anti-cancers 608-07-1 5-METHOXYTRYPTAMINE MECHANISM Modulate neural transmission 608-07-1 5-METHOXYTRYPTAMINE THERAPEUTIC_CLASS Antineoplastics 608-07-1 5-METHOXYTRYPTAMINE MODE_CLASS Receptor Agonist, selective 11076-19-0 BONGKREKIC ACID MODE_CLASS Solute transporter inhibitor 11076-19-0 BONGKREKIC ACID PRODUCT_CLASS Toxicants 11076-19-0 BONGKREKIC ACID MECHANISM Inhibit mitochondrial function 11076-19-0 BONGKREKIC ACID STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, uncouples Oxidative phosphorylation 55350-03-3 AUROVERTIN B STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits ATP-synthase 55350-03-3 AUROVERTIN B PRODUCT_CLASS Toxicants 55350-03-3 AUROVERTIN B MODE_CLASS Enzyme Inhibitor 55350-03-3 AUROVERTIN B MECHANISM Inhibit mitochondrial function 34846-90-7 METHYL 3-METHOXYACRYLATE MECHANISM Inhibit mitochondrial function 34846-90-7 METHYL 3-METHOXYACRYLATE MODE_CLASS Enzyme Inhibitor 34846-90-7 METHYL 3-METHOXYACRYLATE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 34846-90-7 METHYL 3-METHOXYACRYLATE PRODUCT_CLASS Toxicants 91682-96-1 STIGMATELLIN MECHANISM Inhibit mitochondrial function 91682-96-1 STIGMATELLIN MODE_CLASS Enzyme Inhibitor 91682-96-1 STIGMATELLIN PRODUCT_CLASS Toxicants 91682-96-1 STIGMATELLIN STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 2738-64-9 PIERICIDIN-A MODE_CLASS Enzyme Inhibitor 2738-64-9 PIERICIDIN-A STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 2738-64-9 PIERICIDIN-A PRODUCT_CLASS Biochemicals 2738-64-9 PIERICIDIN-A MECHANISM Inhibit mitochondrial function 51-67-2 TYRAMINE MODE_CLASS Enzyme substrate mimic 51-67-2 TYRAMINE MECHANISM Block channel gating 51-67-2 TYRAMINE MECHANISM Modulate G-protein coupled signal transduction 51-67-2 TYRAMINE MODE_CLASS Receptor /Channel ligand mimic 51-67-2 TYRAMINE MODE_CLASS Solute transporter inhibitor 51-67-2 TYRAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 51-67-2 TYRAMINE MECHANISM Prolong/enhance neural transmission 51-67-2 TYRAMINE PRODUCT_CLASS Vitamins, Minerals and Nutrients 60-19-5 TYRAMINE MODE_CLASS Receptor /Channel ligand mimic 60-19-5 TYRAMINE MODE_CLASS Solute transporter inhibitor 60-19-5 TYRAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 60-19-5 TYRAMINE MECHANISM Prolong/enhance neural transmission 60-19-5 TYRAMINE PRODUCT_CLASS Vitamins, Minerals and Nutrients 60-19-5 TYRAMINE MECHANISM Block channel gating 60-19-5 TYRAMINE MODE_CLASS Enzyme substrate mimic 60-19-5 TYRAMINE MECHANISM Modulate G-protein coupled signal transduction 90-69-7 L-LOBELINE MECHANISM Prolong/enhance neural transmission 90-69-7 L-LOBELINE PRODUCT_CLASS Other Human Uses 90-69-7 L-LOBELINE INDICATION Smoking Cessation 90-69-7 L-LOBELINE THERAPEUTIC_CLASS Drug Dependence Therapy 90-69-7 L-LOBELINE MODE_CLASS Channel Modulator 789-02-6 O,P'-DDT MECHANISM Reduce muscle contractile force 789-02-6 O,P'-DDT THERAPEUTIC_CLASS Insecticides / Pesticides 789-02-6 O,P'-DDT STRUCTURE_ACTIVITY Toxicant 789-02-6 O,P'-DDT PRODUCT_CLASS Toxicants 789-02-6 O,P'-DDT MODE_CLASS Channel Blocker, selective 317-34-0 AMINOPHYLLINE KNOWN_TOXICITY Cardiovascular Toxicity 317-34-0 AMINOPHYLLINE TISSUE_TOXICITY Hypotension 317-34-0 AMINOPHYLLINE MECHANISM Enhance kinase mediated signal transduction 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT ELT_2_Hypokalemia 317-34-0 AMINOPHYLLINE MODE_CLASS Receptor Agonist 317-34-0 AMINOPHYLLINE MECHANISM Modulate G-protein coupled signal transduction 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 317-34-0 AMINOPHYLLINE INDICATION Asthma 317-34-0 AMINOPHYLLINE STRUCTURE_ACTIVITY Adenosine receptor antagonist, xanthine 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT NEU_1_Tremor 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT NEU_3_Convulsions 317-34-0 AMINOPHYLLINE TISSUE_TOXICITY Ventricular Arrhythmia 317-34-0 AMINOPHYLLINE INDICATION Prophylaxis of Bronchospasm 317-34-0 AMINOPHYLLINE PRODUCT_CLASS Respiratory System 317-34-0 AMINOPHYLLINE MODE_CLASS Enzyme Inhibitor 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT END_3_Hyperglycemia 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 317-34-0 AMINOPHYLLINE THERAPEUTIC_CLASS Bronchodilators 317-34-0 AMINOPHYLLINE KNOWN_TOXICITY Miscellaneous 317-34-0 AMINOPHYLLINE MODE_CLASS Receptor Ligand Antagonist 317-34-0 AMINOPHYLLINE MECHANISM Reduce bronchoconstriction 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT PSY_1_Nervousness 317-34-0 AMINOPHYLLINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 317-34-0 AMINOPHYLLINE TISSUE_TOXICITY Death 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT CVS_3_Hypotension 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 317-34-0 AMINOPHYLLINE ADVERSE_EFFECT XXX_3_Death 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT CVS_3_Hypotension 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT XXX_3_Death 8013-40-9 AMINOPHYLLINE KNOWN_TOXICITY Cardiovascular Toxicity 8013-40-9 AMINOPHYLLINE MODE_CLASS Enzyme Inhibitor 8013-40-9 AMINOPHYLLINE PRODUCT_CLASS Respiratory System 8013-40-9 AMINOPHYLLINE TISSUE_TOXICITY Ventricular Arrhythmia 8013-40-9 AMINOPHYLLINE MECHANISM Enhance kinase mediated signal transduction 8013-40-9 AMINOPHYLLINE STRUCTURE_ACTIVITY Adenosine receptor antagonist, xanthine 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT NEU_1_Tremor 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT NEU_3_Convulsions 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 8013-40-9 AMINOPHYLLINE INDICATION Asthma 8013-40-9 AMINOPHYLLINE MODE_CLASS Receptor Agonist 8013-40-9 AMINOPHYLLINE MECHANISM Modulate G-protein coupled signal transduction 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT ELT_2_Hypokalemia 8013-40-9 AMINOPHYLLINE TISSUE_TOXICITY Death 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 8013-40-9 AMINOPHYLLINE TISSUE_TOXICITY Hypotension 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT PSY_1_Nervousness 8013-40-9 AMINOPHYLLINE INDICATION Prophylaxis of Bronchospasm 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 8013-40-9 AMINOPHYLLINE THERAPEUTIC_CLASS Bronchodilators 8013-40-9 AMINOPHYLLINE KNOWN_TOXICITY Miscellaneous 8013-40-9 AMINOPHYLLINE MODE_CLASS Receptor Ligand Antagonist 8013-40-9 AMINOPHYLLINE MECHANISM Reduce bronchoconstriction 8013-40-9 AMINOPHYLLINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 8013-40-9 AMINOPHYLLINE ADVERSE_EFFECT END_3_Hyperglycemia 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT CVS_3_Hypotension 12767-26-9 AMINOPHYLLINE TISSUE_TOXICITY Death 12767-26-9 AMINOPHYLLINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 12767-26-9 AMINOPHYLLINE MECHANISM Reduce bronchoconstriction 12767-26-9 AMINOPHYLLINE MODE_CLASS Receptor Ligand Antagonist 12767-26-9 AMINOPHYLLINE KNOWN_TOXICITY Miscellaneous 12767-26-9 AMINOPHYLLINE THERAPEUTIC_CLASS Bronchodilators 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT END_3_Hyperglycemia 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT PSY_1_Nervousness 12767-26-9 AMINOPHYLLINE TISSUE_TOXICITY Hypotension 12767-26-9 AMINOPHYLLINE MECHANISM Modulate G-protein coupled signal transduction 12767-26-9 AMINOPHYLLINE INDICATION Asthma 12767-26-9 AMINOPHYLLINE MODE_CLASS Receptor Agonist 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT ELT_2_Hypokalemia 12767-26-9 AMINOPHYLLINE MECHANISM Enhance kinase mediated signal transduction 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 12767-26-9 AMINOPHYLLINE STRUCTURE_ACTIVITY Adenosine receptor antagonist, xanthine 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT NEU_1_Tremor 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT NEU_3_Convulsions 12767-26-9 AMINOPHYLLINE TISSUE_TOXICITY Ventricular Arrhythmia 12767-26-9 AMINOPHYLLINE INDICATION Prophylaxis of Bronchospasm 12767-26-9 AMINOPHYLLINE PRODUCT_CLASS Respiratory System 12767-26-9 AMINOPHYLLINE MODE_CLASS Enzyme Inhibitor 12767-26-9 AMINOPHYLLINE KNOWN_TOXICITY Cardiovascular Toxicity 12767-26-9 AMINOPHYLLINE ADVERSE_EFFECT XXX_3_Death 633-65-8 BERBERINE CHLORIDE PRODUCT_CLASS Botanicals 633-65-8 BERBERINE CHLORIDE MECHANISM Inhibit DNA synthesis, repair, and function 633-65-8 BERBERINE CHLORIDE PRODUCT_CLASS Anti-infectives 633-65-8 BERBERINE CHLORIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 5956-60-5 BERBERINE CHLORIDE PRODUCT_CLASS Anti-infectives 5956-60-5 BERBERINE CHLORIDE PRODUCT_CLASS Botanicals 5956-60-5 BERBERINE CHLORIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 5956-60-5 BERBERINE CHLORIDE MECHANISM Inhibit DNA synthesis, repair, and function 55837-25-7 BUFLOMEDIL MESH_LEVEL_1 Heterocyclic Compounds 55837-25-7 BUFLOMEDIL TA_LEVEL_2 Hypertension 55837-25-7 BUFLOMEDIL TA_LEVEL_3 Reynauds Phenomenom 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT SKN_2_Exanthema 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT CVS_3_Cardiac Conduction System Malfunction 55837-25-7 BUFLOMEDIL TISSUE_TOXICITY Teratogenicity 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT GIS_2_Diarrhea 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT GIS_2_Nausea 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT EMB_1_Teratogenicity 55837-25-7 BUFLOMEDIL KNOWN_TOXICITY Embryo/Fetal Toxicity 55837-25-7 BUFLOMEDIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 55837-25-7 BUFLOMEDIL INDICATION Dementia 55837-25-7 BUFLOMEDIL MECHANISM Reduce vasoconstriction 55837-25-7 BUFLOMEDIL MODE_CLASS Receptor Ligand Antagonist, Non-selective 55837-25-7 BUFLOMEDIL ZERO_CLASS N 55837-25-7 BUFLOMEDIL STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 55837-25-7 BUFLOMEDIL TISSUE_TOXICITY Hypotension 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT CVS_2_Hypotension 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT NEU_1_Headache 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT NEU_3_Convulsions 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT SKN_2_Erythema 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT IMU_3_Hypersensitivity 55837-25-7 BUFLOMEDIL INDICATION Raynaud's Phenomenon 55837-25-7 BUFLOMEDIL MECH_LEVEL_2 Alpha antagonist 55837-25-7 BUFLOMEDIL TA_LEVEL_1 Cardiovascular 55837-25-7 BUFLOMEDIL PRODUCT_CLASS Cardiovasculars 55837-25-7 BUFLOMEDIL INDICATION Intermittent Claudication 55837-25-7 BUFLOMEDIL ACTIVITY_CLASS Adrenergic antagonist 55837-25-7 BUFLOMEDIL TISSUE_TOXICITY Cardiotoxicity 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT IMU_3_Anaphylaxis 55837-25-7 BUFLOMEDIL MECH_LEVEL_3 adrenoceptor alpha/Calcium channel 55837-25-7 BUFLOMEDIL MECH_LEVEL_1 Vasorelaxation 55837-25-7 BUFLOMEDIL INDICATION Diabetic Nephropathy 55837-25-7 BUFLOMEDIL MESH_LEVEL_3 Pyrrolidines 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT SKN_2_Pruritis 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT CVS_3_Cardiotoxicity 55837-25-7 BUFLOMEDIL TISSUE_TOXICITY Cardiac Conduction System Malfunction 55837-25-7 BUFLOMEDIL THERAPEUTIC_CLASS Vasodilators 55837-25-7 BUFLOMEDIL KNOWN_TOXICITY Cardiovascular Toxicity 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT NEU_2_Syncope 55837-25-7 BUFLOMEDIL ADVERSE_EFFECT NEU_3_Coma 55837-25-7 BUFLOMEDIL INDICATION Diabetic Retinopathy 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT SKN_2_Erythema 35543-24-9 BUFLOMEDIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 35543-24-9 BUFLOMEDIL INDICATION Dementia 35543-24-9 BUFLOMEDIL MECHANISM Reduce vasoconstriction 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT NEU_3_Coma 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT NEU_2_Syncope 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT SKN_2_Pruritis 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT CVS_2_Hypotension 35543-24-9 BUFLOMEDIL MODE_CLASS Receptor Ligand Antagonist, Non-selective 35543-24-9 BUFLOMEDIL ZERO_CLASS N 35543-24-9 BUFLOMEDIL STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 35543-24-9 BUFLOMEDIL TISSUE_TOXICITY Hypotension 35543-24-9 BUFLOMEDIL TISSUE_TOXICITY Cardiac Conduction System Malfunction 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT NEU_3_Convulsions 35543-24-9 BUFLOMEDIL INDICATION Diabetic Nephropathy 35543-24-9 BUFLOMEDIL INDICATION Raynaud's Phenomenon 35543-24-9 BUFLOMEDIL MECH_LEVEL_2 Alpha antagonist 35543-24-9 BUFLOMEDIL TA_LEVEL_1 Cardiovascular 35543-24-9 BUFLOMEDIL PRODUCT_CLASS Cardiovasculars 35543-24-9 BUFLOMEDIL INDICATION Intermittent Claudication 35543-24-9 BUFLOMEDIL ACTIVITY_CLASS Adrenergic antagonist 35543-24-9 BUFLOMEDIL TISSUE_TOXICITY Cardiotoxicity 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT IMU_3_Anaphylaxis 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT GIS_2_Diarrhea 35543-24-9 BUFLOMEDIL THERAPEUTIC_CLASS Vasodilators 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT CVS_3_Cardiotoxicity 35543-24-9 BUFLOMEDIL KNOWN_TOXICITY Cardiovascular Toxicity 35543-24-9 BUFLOMEDIL MESH_LEVEL_3 Pyrrolidines 35543-24-9 BUFLOMEDIL MECH_LEVEL_1 Vasorelaxation 35543-24-9 BUFLOMEDIL MECH_LEVEL_3 adrenoceptor alpha/Calcium channel 35543-24-9 BUFLOMEDIL TA_LEVEL_3 Reynauds Phenomenom 35543-24-9 BUFLOMEDIL MESH_LEVEL_1 Heterocyclic Compounds 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT IMU_3_Hypersensitivity 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT NEU_1_Headache 35543-24-9 BUFLOMEDIL KNOWN_TOXICITY Embryo/Fetal Toxicity 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT EMB_1_Teratogenicity 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT GIS_2_Nausea 35543-24-9 BUFLOMEDIL TISSUE_TOXICITY Teratogenicity 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT CVS_3_Cardiac Conduction System Malfunction 35543-24-9 BUFLOMEDIL ADVERSE_EFFECT SKN_2_Exanthema 35543-24-9 BUFLOMEDIL TA_LEVEL_2 Hypertension 35543-24-9 BUFLOMEDIL INDICATION Diabetic Retinopathy 18683-91-5 AMBROXOL ADVERSE_EFFECT GIS_3_Abdominal Pain 18683-91-5 AMBROXOL ADVERSE_EFFECT XXX_3_Salivation 18683-91-5 AMBROXOL INDICATION Cough / Tussis 18683-91-5 AMBROXOL THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 18683-91-5 AMBROXOL ADVERSE_EFFECT IMU_3_Allergic Reactions 18683-91-5 AMBROXOL ADVERSE_EFFECT XXX_3_Rhinorrhea 18683-91-5 AMBROXOL ADVERSE_EFFECT GIS_2_Nausea 18683-91-5 AMBROXOL PRODUCT_CLASS Respiratory System 18683-91-5 AMBROXOL MECHANISM Modulate gene transcription 18683-91-5 AMBROXOL ADVERSE_EFFECT GIS_3_Dry Mouth 12674-29-2 AMBROXOL INDICATION Cough / Tussis 12674-29-2 AMBROXOL ADVERSE_EFFECT XXX_3_Rhinorrhea 12674-29-2 AMBROXOL ADVERSE_EFFECT XXX_3_Salivation 12674-29-2 AMBROXOL ADVERSE_EFFECT GIS_3_Abdominal Pain 12674-29-2 AMBROXOL ADVERSE_EFFECT GIS_3_Dry Mouth 12674-29-2 AMBROXOL ADVERSE_EFFECT GIS_2_Nausea 12674-29-2 AMBROXOL PRODUCT_CLASS Respiratory System 12674-29-2 AMBROXOL MECHANISM Modulate gene transcription 12674-29-2 AMBROXOL THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 12674-29-2 AMBROXOL ADVERSE_EFFECT IMU_3_Allergic Reactions 23828-92-4 AMBROXOL ADVERSE_EFFECT XXX_3_Rhinorrhea 23828-92-4 AMBROXOL INDICATION Cough / Tussis 23828-92-4 AMBROXOL ADVERSE_EFFECT GIS_2_Nausea 23828-92-4 AMBROXOL ADVERSE_EFFECT XXX_3_Salivation 23828-92-4 AMBROXOL ADVERSE_EFFECT GIS_3_Abdominal Pain 23828-92-4 AMBROXOL ADVERSE_EFFECT GIS_3_Dry Mouth 23828-92-4 AMBROXOL MECHANISM Modulate gene transcription 23828-92-4 AMBROXOL PRODUCT_CLASS Respiratory System 23828-92-4 AMBROXOL THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 23828-92-4 AMBROXOL ADVERSE_EFFECT IMU_3_Allergic Reactions 15942-05-9 AMBROXOL INDICATION Cough / Tussis 15942-05-9 AMBROXOL ADVERSE_EFFECT XXX_3_Rhinorrhea 15942-05-9 AMBROXOL ADVERSE_EFFECT XXX_3_Salivation 15942-05-9 AMBROXOL THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 15942-05-9 AMBROXOL ADVERSE_EFFECT GIS_3_Dry Mouth 15942-05-9 AMBROXOL ADVERSE_EFFECT IMU_3_Allergic Reactions 15942-05-9 AMBROXOL ADVERSE_EFFECT GIS_3_Abdominal Pain 15942-05-9 AMBROXOL ADVERSE_EFFECT GIS_2_Nausea 15942-05-9 AMBROXOL PRODUCT_CLASS Respiratory System 15942-05-9 AMBROXOL MECHANISM Modulate gene transcription 4323-43-7 HEXOPRENALINE INDICATION Premature labor 4323-43-7 HEXOPRENALINE MODE_CLASS Receptor Agonist 4323-43-7 HEXOPRENALINE PRODUCT_CLASS Autonomic Nervous System (ANS) 4323-43-7 HEXOPRENALINE THERAPEUTIC_CLASS Sympathomimetic Agents 4323-43-7 HEXOPRENALINE MECHANISM Modulate G-protein coupled signal transduction 4323-43-7 HEXOPRENALINE PRODUCT_CLASS Respiratory System 4323-43-7 HEXOPRENALINE THERAPEUTIC_CLASS Bronchodilators 35457-80-8 MIDECAMYCIN MECHANISM Inhibit ribosomal protein synthesis 35457-80-8 MIDECAMYCIN PRODUCT_CLASS Anti-infectives 35457-80-8 MIDECAMYCIN THERAPEUTIC_CLASS Antibacterials 35457-80-8 MIDECAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 25546-65-0 RIBOSTAMYCIN THERAPEUTIC_CLASS Antibacterials 25546-65-0 RIBOSTAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 25546-65-0 RIBOSTAMYCIN MECHANISM Inhibit ribosomal protein synthesis 25546-65-0 RIBOSTAMYCIN PRODUCT_CLASS Anti-infectives 25546-65-0 RIBOSTAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 4546-39-8 PIPERILATE ETHOBROMIDE INDICATION Renal Colic 4546-39-8 PIPERILATE ETHOBROMIDE THERAPEUTIC_CLASS Antispasmodic Agents 4546-39-8 PIPERILATE ETHOBROMIDE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 4546-39-8 PIPERILATE ETHOBROMIDE MECHANISM Modulate G-protein coupled signal transduction 4546-39-8 PIPERILATE ETHOBROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 4546-39-8 PIPERILATE ETHOBROMIDE INDICATION Gastric Hypermobility 4546-39-8 PIPERILATE ETHOBROMIDE MODE_CLASS Receptor Ligand Antagonist 4546-39-8 PIPERILATE ETHOBROMIDE INDICATION Biliary Colic 4544-15-4 PIPERILATE ETHOBROMIDE MODE_CLASS Receptor Ligand Antagonist 4544-15-4 PIPERILATE ETHOBROMIDE INDICATION Renal Colic 4544-15-4 PIPERILATE ETHOBROMIDE THERAPEUTIC_CLASS Antispasmodic Agents 4544-15-4 PIPERILATE ETHOBROMIDE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 4544-15-4 PIPERILATE ETHOBROMIDE MECHANISM Modulate G-protein coupled signal transduction 4544-15-4 PIPERILATE ETHOBROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 4544-15-4 PIPERILATE ETHOBROMIDE INDICATION Gastric Hypermobility 4544-15-4 PIPERILATE ETHOBROMIDE INDICATION Biliary Colic 75438-57-2 MOXONIDINE ADVERSE_EFFECT NEU_3_Coma 75438-57-2 MOXONIDINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 75438-57-2 MOXONIDINE TISSUE_TOXICITY Hypotension 75438-57-2 MOXONIDINE STRUCTURE_ACTIVITY Adrenoceptor-alpha2 agonist, imidazoline receptor agonist 75438-57-2 MOXONIDINE TA_LEVEL_2 imidazoline agonist 75438-57-2 MOXONIDINE MECH_LEVEL_1 Vasorelaxation 75438-57-2 MOXONIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 75438-57-2 MOXONIDINE ADVERSE_EFFECT CVS_2_Vasodilation 75438-57-2 MOXONIDINE ADVERSE_EFFECT GIS_2_Nausea 75438-57-2 MOXONIDINE ADVERSE_EFFECT IMU_3_Allergic Reactions 75438-57-2 MOXONIDINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 75438-57-2 MOXONIDINE KNOWN_TOXICITY Cardiovascular Toxicity 75438-57-2 MOXONIDINE MESH_LEVEL_3 Imidazoles 75438-57-2 MOXONIDINE MESH_LEVEL_1 Heterocyclic Compounds 75438-57-2 MOXONIDINE PRODUCT_CLASS Cardiovasculars 75438-57-2 MOXONIDINE MECHANISM Modulate gene transcription 75438-57-2 MOXONIDINE TA_LEVEL_3 hypertension 75438-57-2 MOXONIDINE ADVERSE_EFFECT GIS_1_Dry Mouth 75438-57-2 MOXONIDINE ADVERSE_EFFECT NEU_2_Dizziness 75438-57-2 MOXONIDINE ADVERSE_EFFECT IMU_3_Angioedema 75438-57-2 MOXONIDINE ZERO_CLASS N 75438-57-2 MOXONIDINE ACTIVITY_CLASS Adrenergic agonist 75438-57-2 MOXONIDINE TA_LEVEL_1 Cardiovascular 75438-57-2 MOXONIDINE MECH_LEVEL_3 Imidazoline Receptor IR-1 75438-57-2 MOXONIDINE ADVERSE_EFFECT CVS_3_Hypotension 75438-57-2 MOXONIDINE ADVERSE_EFFECT NEU_2_Headache 75438-57-2 MOXONIDINE ADVERSE_EFFECT XXX_2_Withdrawal 75438-57-2 MOXONIDINE ADVERSE_EFFECT CVS_3_Orthostatic Dysregulation 75438-57-2 MOXONIDINE MODE_CLASS Receptor Agonist 75438-57-2 MOXONIDINE INDICATION Hypertension 75438-57-2 MOXONIDINE MECH_LEVEL_2 imidazoline agonist 75438-57-2 MOXONIDINE THERAPEUTIC_CLASS Antihypertensive Agents 75438-57-2 MOXONIDINE ADVERSE_EFFECT NEU_2_Sedation 75438-57-2 MOXONIDINE ADVERSE_EFFECT NEU_2_Sleep Disturbances 57726-65-5 NUFENOXOLE MECHANISM Modulate neural transmission 57726-65-5 NUFENOXOLE MECHANISM Reduce muscle contractile force 57726-65-5 NUFENOXOLE MODE_CLASS Channel Blocker 57726-65-5 NUFENOXOLE MODE_CLASS Receptor Agonist 119477-85-9 U-75302 MECHANISM Modulate G-protein coupled signal transduction 119477-85-9 U-75302 MODE_CLASS Receptor Ligand Antagonist, Selective 164301-51-3 SEMAPIMOD MECHANISM Inhibit kinase mediated signal transduction 164301-51-3 SEMAPIMOD TISSUE_TOXICITY Nephrotoxicity 164301-51-3 SEMAPIMOD PRODUCT_CLASS Anti-inflammatories 164301-51-3 SEMAPIMOD MODE_CLASS Enzyme Inhibitor 164301-51-3 SEMAPIMOD PRODUCT_CLASS Anti-cancers 164301-51-3 SEMAPIMOD ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 164301-51-3 SEMAPIMOD ADVERSE_EFFECT KID_1_Increased Creatinine 164301-51-3 SEMAPIMOD STRUCTURE_ACTIVITY Protein-serine/threonine kinase (p38) inhibitor 164301-51-3 SEMAPIMOD INDICATION Neoplasm / Cancer / Tumor 164301-51-3 SEMAPIMOD THERAPEUTIC_CLASS Antineoplastics 164301-51-3 SEMAPIMOD INDICATION Human Immunodeficiency Virus (HIV) Disease 164301-51-3 SEMAPIMOD INDICATION Inflammation 164301-51-3 SEMAPIMOD ADVERSE_EFFECT CVS_1_Phlebitis 164301-51-3 SEMAPIMOD INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 164301-51-3 SEMAPIMOD KNOWN_TOXICITY Nephrotoxicity 164301-51-3 SEMAPIMOD THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 164301-51-3 SEMAPIMOD ADVERSE_EFFECT KID_2_Nephrotoxicity 164301-51-3 SEMAPIMOD ADVERSE_EFFECT XXX_1_Injection Site Reaction 164301-51-3 SEMAPIMOD INDICATION Melanoma 352513-83-8 SEMAPIMOD ADVERSE_EFFECT CVS_1_Phlebitis 352513-83-8 SEMAPIMOD PRODUCT_CLASS Anti-cancers 352513-83-8 SEMAPIMOD MODE_CLASS Enzyme Inhibitor 352513-83-8 SEMAPIMOD ADVERSE_EFFECT KID_2_Nephrotoxicity 352513-83-8 SEMAPIMOD THERAPEUTIC_CLASS Antineoplastics 352513-83-8 SEMAPIMOD INDICATION Human Immunodeficiency Virus (HIV) Disease 352513-83-8 SEMAPIMOD ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 352513-83-8 SEMAPIMOD PRODUCT_CLASS Anti-inflammatories 352513-83-8 SEMAPIMOD INDICATION Melanoma 352513-83-8 SEMAPIMOD INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 352513-83-8 SEMAPIMOD TISSUE_TOXICITY Nephrotoxicity 352513-83-8 SEMAPIMOD ADVERSE_EFFECT XXX_1_Injection Site Reaction 352513-83-8 SEMAPIMOD KNOWN_TOXICITY Nephrotoxicity 352513-83-8 SEMAPIMOD INDICATION Inflammation 352513-83-8 SEMAPIMOD THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 352513-83-8 SEMAPIMOD INDICATION Neoplasm / Cancer / Tumor 352513-83-8 SEMAPIMOD MECHANISM Inhibit kinase mediated signal transduction 352513-83-8 SEMAPIMOD STRUCTURE_ACTIVITY Protein-serine/threonine kinase (p38) inhibitor 352513-83-8 SEMAPIMOD ADVERSE_EFFECT KID_1_Increased Creatinine 157341-41-8 L-694458 MODE_CLASS Enzyme Inhibitor 157341-41-8 L-694458 PRODUCT_CLASS Biochemicals 157341-41-8 L-694458 MECHANISM Inhibit bacterial cell wall biosynthesis 166432-28-6 CLEVIDIPINE MECHANISM Reduce muscle contractile force 166432-28-6 CLEVIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 166432-28-6 CLEVIDIPINE MODE_CLASS Channel Blocker 166432-28-6 CLEVIDIPINE PRODUCT_CLASS Cardiovasculars 166432-28-6 CLEVIDIPINE INDICATION Hypertension 166432-28-6 CLEVIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 167887-97-0 HSR-903 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 167887-97-0 HSR-903 MECHANISM Inhibit bacterial DNA synthesis 167887-97-0 HSR-903 THERAPEUTIC_CLASS Antibacterials 167887-97-0 HSR-903 MODE_CLASS Enzyme Inhibitor, selective 167887-97-0 HSR-903 PRODUCT_CLASS Anti-infectives 138154-39-9 IMIDACRINE STRUCTURE_ACTIVITY DNA topoisomerase inhibitor 138154-55-9 IMIDACRINE STRUCTURE_ACTIVITY DNA topoisomerase inhibitor 142912-85-4 YM-46A INDICATION Acute Respiratory Distress Syndrome (ARDS) 142912-86-4 YM-46A INDICATION Acute Respiratory Distress Syndrome (ARDS) 107376-72-7 CL-283796 INDICATION Hypolipidemia 107376-72-7 CL-283796 MECHANISM Inhibit steroid biosynthesis/ metabolism 107376-72-7 CL-283796 MODE_CLASS Enzyme Inhibitor 169328-25-0 KRH-594 MECHANISM Modulate G-protein coupled signal transduction 169328-25-0 KRH-594 INDICATION Hypertension 169328-25-0 KRH-594 PRODUCT_CLASS Cardiovasculars 169328-25-0 KRH-594 THERAPEUTIC_CLASS Antihypertensive Agents 169328-24-9 KRH-594 MECHANISM Modulate G-protein coupled signal transduction 169328-24-9 KRH-594 INDICATION Hypertension 169328-24-9 KRH-594 THERAPEUTIC_CLASS Antihypertensive Agents 169328-24-9 KRH-594 PRODUCT_CLASS Cardiovasculars 167006-13-5 KRH-594 MECHANISM Modulate G-protein coupled signal transduction 167006-13-5 KRH-594 PRODUCT_CLASS Cardiovasculars 167006-13-5 KRH-594 INDICATION Hypertension 167006-13-5 KRH-594 THERAPEUTIC_CLASS Antihypertensive Agents 171964-73-1 ZD-0892 INDICATION Chronic Obstructive Pulmonary Disease (COPD) 144702-17-0 POMISARTAN THERAPEUTIC_CLASS Antihypertensive Agents 144702-17-0 POMISARTAN PRODUCT_CLASS Cardiovasculars 144702-17-0 POMISARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 144702-17-0 POMISARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 144702-17-0 POMISARTAN MECHANISM Reduce vasoconstriction 161832-65-1 LY-300164 INDICATION Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease 5695-98-7 COTININE INDICATION Smoking Cessation 486-56-6 COTININE INDICATION Smoking Cessation 172152-36-2 IY-81149 MECHANISM Reduce stomach HCl secretion 172152-36-2 IY-81149 PRODUCT_CLASS Gastrointestinal System 172152-36-2 IY-81149 MODE_CLASS Enzyme Inhibitor 172152-36-2 IY-81149 INDICATION Helicobacter Pylori Infection 172152-36-2 IY-81149 THERAPEUTIC_CLASS Antiulcers 133790-13-3 IS-159 PRODUCT_CLASS Central Nervous System (CNS) 133790-13-3 IS-159 MECHANISM Modulate cerebral vasoconstriction 133790-13-3 IS-159 INDICATION Migraine Headache 133790-13-3 IS-159 THERAPEUTIC_CLASS Antimigraines 172927-65-0 SIBRAFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 172927-65-0 SIBRAFIBAN MECHANISM Inhibit platelet aggregation 152459-95-5 IMATINIB INDICATION Gastrointestinal Stromal Tumors 152459-95-5 IMATINIB ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 152459-95-5 IMATINIB ADVERSE_EFFECT ELT_1_Hypokalemia 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Fever 152459-95-5 IMATINIB ADVERSE_EFFECT LUN_2_Dyspnea 152459-95-5 IMATINIB ADVERSE_EFFECT PSY_1_Anorexia 152459-95-5 IMATINIB ADVERSE_EFFECT SKN_1_Skin Rash 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Peripheral Edema 152459-95-5 IMATINIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 152459-95-5 IMATINIB INDICATION Gastrointestinal Stromal Tumors 152459-95-5 IMATINIB INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 152459-95-5 IMATINIB MODE_CLASS Enzyme Inhibitor 152459-95-5 IMATINIB PRODUCT_CLASS Anti-cancers 152459-95-5 IMATINIB ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 152459-95-5 IMATINIB ADVERSE_EFFECT GIS_1_Flatulence 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Edema 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Diaphoresis 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_2_Ascites 152459-95-5 IMATINIB ADVERSE_EFFECT GIS_1_Abdominal Pain 152459-95-5 IMATINIB ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 152459-95-5 IMATINIB ADVERSE_EFFECT EMB_1_Teratogenicity 152459-95-5 IMATINIB ADVERSE_EFFECT LUN_2_Pleural Effusion 152459-95-5 IMATINIB ADVERSE_EFFECT BBM_1_Neutropenia 152459-95-5 IMATINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (Bcr-Abl) inhibitor 152459-95-5 IMATINIB INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 152459-95-5 IMATINIB TISSUE_TOXICITY Thrombocytopenia 152459-95-5 IMATINIB TISSUE_TOXICITY Bleeding 152459-95-5 IMATINIB MECHANISM Modulate growth factor receptor mediated signal transduction 152459-95-5 IMATINIB MODE_CLASS Receptor tyrosine kinase inhibitor 152459-95-5 IMATINIB ZERO_CLASS N 152459-95-5 IMATINIB ADVERSE_EFFECT PSY_1_Insomnia 152459-95-5 IMATINIB ADVERSE_EFFECT NEU_1_Headache 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Epistaxis 152459-95-5 IMATINIB ADVERSE_EFFECT GIS_1_Diarrhea 152459-95-5 IMATINIB ADVERSE_EFFECT BBM_1_Bleeding 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_2_Anasarca 152459-95-5 IMATINIB ADVERSE_EFFECT BBM_1_Thrombocytopenia 152459-95-5 IMATINIB ADVERSE_EFFECT SKN_1_Pruritis 152459-95-5 IMATINIB ADVERSE_EFFECT CVS_2_Pericardial Effusion 152459-95-5 IMATINIB KNOWN_TOXICITY Blood & Bone Marrow Toxicity 152459-95-5 IMATINIB TISSUE_TOXICITY Teratogenicity 152459-95-5 IMATINIB THERAPEUTIC_CLASS Antineoplastics 152459-95-5 IMATINIB MECHANISM Inhibit kinase mediated signal transduction 152459-95-5 IMATINIB TISSUE_TOXICITY Neutropenia 152459-95-5 IMATINIB ADVERSE_EFFECT LUN_1_Cough 152459-95-5 IMATINIB ADVERSE_EFFECT MSK_1_Muscle Cramps 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Fatigue 152459-95-5 IMATINIB ADVERSE_EFFECT GIS_1_Dysgeusia 152459-95-5 IMATINIB ADVERSE_EFFECT GIS_1_Constipation 152459-95-5 IMATINIB ADVERSE_EFFECT BBM_1_Anemia 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Weight Gain 152459-95-5 IMATINIB ADVERSE_EFFECT LUN_2_Pulmonary Edema 152459-95-5 IMATINIB ADVERSE_EFFECT XXX_1_Periorbital Edema 152459-95-5 IMATINIB KNOWN_TOXICITY Embryo/Fetal Toxicity 152459-95-5 IMATINIB TISSUE_TOXICITY Anemia 121032-29-9 NELARABINE PRODUCT_CLASS Anti-cancers 121032-29-9 NELARABINE THERAPEUTIC_CLASS Antineoplastics 121032-29-9 NELARABINE MECHANISM Incorporate into DNA/RNA/Protein 121032-29-9 NELARABINE MODE_CLASS Enzyme substrate mimic 121032-29-9 NELARABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 178273-87-5 SB-207266A MECHANISM Block neural transmission 178273-87-5 SB-207266A THERAPEUTIC_CLASS Anxiolytics 178273-87-5 SB-207266A PRODUCT_CLASS Central Nervous System (CNS) 178273-87-5 SB-207266A MODE_CLASS Receptor Ligand Antagonist, Selective 152811-62-6 SB-207266A THERAPEUTIC_CLASS Anxiolytics 152811-62-6 SB-207266A MODE_CLASS Receptor Ligand Antagonist, Selective 152811-62-6 SB-207266A PRODUCT_CLASS Central Nervous System (CNS) 152811-62-6 SB-207266A MECHANISM Block neural transmission 167256-08-8 ENRASENTAN PRODUCT_CLASS Cardiovasculars 167256-08-8 ENRASENTAN THERAPEUTIC_CLASS Antihypertensive Agents 167256-08-8 ENRASENTAN MODE_CLASS Receptor Ligand Antagonist, Selective 167256-08-8 ENRASENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 189941-59-1 IR-208 INDICATION Multiple Sclerosis (MS) 179120-92-4 (S)-SIB-1765F FUMARATE INDICATION Parkinson's Disease 179120-92-4 (S)-SIB-1765F FUMARATE MODE_CLASS Channel Modulator 179120-92-4 (S)-SIB-1765F FUMARATE MECHANISM Modulate neural transmission 179120-94-6 (S)-SIB-1765F FUMARATE INDICATION Parkinson's Disease 179120-94-6 (S)-SIB-1765F FUMARATE MODE_CLASS Channel Modulator 179120-94-6 (S)-SIB-1765F FUMARATE MECHANISM Modulate neural transmission 179120-51-5 (S)-SIB-1765F FUMARATE MECHANISM Modulate neural transmission 179120-51-5 (S)-SIB-1765F FUMARATE MODE_CLASS Channel Modulator 179120-51-5 (S)-SIB-1765F FUMARATE INDICATION Parkinson's Disease 179120-52-6 (S)-SIB-1765F FUMARATE MODE_CLASS Channel Modulator 179120-52-6 (S)-SIB-1765F FUMARATE INDICATION Parkinson's Disease 179120-52-6 (S)-SIB-1765F FUMARATE MECHANISM Modulate neural transmission 194919-11-4 U-95666A MECHANISM Modulate G-protein coupled signal transduction 194919-11-4 U-95666A INDICATION Parkinson's Disease 179386-44-8 U-95666A MECHANISM Modulate G-protein coupled signal transduction 179386-44-8 U-95666A INDICATION Parkinson's Disease 179386-43-7 U-95666A MECHANISM Modulate G-protein coupled signal transduction 179386-43-7 U-95666A INDICATION Parkinson's Disease 175212-04-1 LDP-977 STRUCTURE_ACTIVITY Arachidonate 5-lipoxygenase inhibitor 175212-04-1 LDP-977 PRODUCT_CLASS Anti-inflammatories 175212-04-1 LDP-977 MECHANISM Inhibit eicosanoid biosynthesis 175212-04-1 LDP-977 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 175212-04-1 LDP-977 MODE_CLASS Enzyme Inhibitor 169758-66-1 NAD-299 INDICATION Depression 169758-66-1 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 169758-66-1 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 169758-66-1 NAD-299 MECHANISM Modulate neural transmission 169758-66-1 NAD-299 THERAPEUTIC_CLASS Antidepressants 169758-66-1 NAD-299 INDICATION Anxiety Disorders 208516-87-4 NAD-299 MECHANISM Modulate neural transmission 208516-87-4 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 208516-87-4 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 208516-87-4 NAD-299 THERAPEUTIC_CLASS Antidepressants 208516-87-4 NAD-299 INDICATION Anxiety Disorders 208516-87-4 NAD-299 INDICATION Depression 189311-42-0 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-42-0 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-42-0 NAD-299 INDICATION Anxiety Disorders 189311-42-0 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-42-0 NAD-299 INDICATION Depression 189311-42-0 NAD-299 MECHANISM Modulate neural transmission 189311-41-9 NAD-299 INDICATION Depression 189311-41-9 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-41-9 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-41-9 NAD-299 MECHANISM Modulate neural transmission 189311-41-9 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-41-9 NAD-299 INDICATION Anxiety Disorders 189311-40-8 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-40-8 NAD-299 INDICATION Depression 189311-40-8 NAD-299 INDICATION Anxiety Disorders 189311-40-8 NAD-299 MECHANISM Modulate neural transmission 189311-40-8 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-40-8 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-38-4 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-38-4 NAD-299 MECHANISM Modulate neural transmission 189311-38-4 NAD-299 INDICATION Anxiety Disorders 189311-38-4 NAD-299 INDICATION Depression 189311-38-4 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-38-4 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-37-3 NAD-299 INDICATION Depression 189311-37-3 NAD-299 INDICATION Anxiety Disorders 189311-37-3 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-37-3 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-37-3 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-37-3 NAD-299 MECHANISM Modulate neural transmission 189311-36-2 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-36-2 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-36-2 NAD-299 MECHANISM Modulate neural transmission 189311-36-2 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-36-2 NAD-299 INDICATION Anxiety Disorders 189311-36-2 NAD-299 INDICATION Depression 189311-35-1 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-35-1 NAD-299 INDICATION Depression 189311-35-1 NAD-299 MECHANISM Modulate neural transmission 189311-35-1 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-35-1 NAD-299 INDICATION Anxiety Disorders 189311-35-1 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-34-0 NAD-299 THERAPEUTIC_CLASS Antidepressants 189311-34-0 NAD-299 INDICATION Anxiety Disorders 189311-34-0 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 189311-34-0 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 189311-34-0 NAD-299 INDICATION Depression 189311-34-0 NAD-299 MECHANISM Modulate neural transmission 184674-99-5 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 184674-99-5 NAD-299 INDICATION Depression 184674-99-5 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 184674-99-5 NAD-299 THERAPEUTIC_CLASS Antidepressants 184674-99-5 NAD-299 MECHANISM Modulate neural transmission 184674-99-5 NAD-299 INDICATION Anxiety Disorders 177255-04-8 NAD-299 INDICATION Depression 177255-04-8 NAD-299 THERAPEUTIC_CLASS Antidepressants 177255-04-8 NAD-299 INDICATION Anxiety Disorders 177255-04-8 NAD-299 MECHANISM Modulate neural transmission 177255-04-8 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 177255-04-8 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 169758-67-2 NAD-299 INDICATION Anxiety Disorders 169758-67-2 NAD-299 INDICATION Depression 169758-67-2 NAD-299 THERAPEUTIC_CLASS Sedatives/Hypnotics 169758-67-2 NAD-299 MECHANISM Modulate neural transmission 169758-67-2 NAD-299 THERAPEUTIC_CLASS Antidepressants 169758-67-2 NAD-299 PRODUCT_CLASS Central Nervous System (CNS) 173838-31-8 TELITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 173838-31-8 TELITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 173838-31-8 TELITHROMYCIN PRODUCT_CLASS Anti-infectives 173838-31-8 TELITHROMYCIN THERAPEUTIC_CLASS Antibacterials 191114-48-4 TELITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 191114-48-4 TELITHROMYCIN THERAPEUTIC_CLASS Antibacterials 191114-48-4 TELITHROMYCIN PRODUCT_CLASS Anti-infectives 191114-48-4 TELITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 157476-77-2 LAGATIDE INDICATION Diarrhea 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT ELT_1_Hypokalemia 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN MECHANISM Inhibit kinase mediated signal transduction 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT NEU_2_Headache 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT SKN_2_Rash 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN MODE_CLASS Enzyme Inhibitor 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN PRODUCT_CLASS Anti-cancers 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT XXX_1_Fatigue 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN STRUCTURE_ACTIVITY Protein-tyrosine kinase (erbb) inhibitor 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN THERAPEUTIC_CLASS Antineoplastics 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN INDICATION Neoplasm / Cancer / Tumor 75747-14-7 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN ADVERSE_EFFECT PSY_2_Anorexia 192329-42-3 PRINOMASTAT ADVERSE_EFFECT BBM_2_Thrombocytopenia 192329-42-3 PRINOMASTAT ADVERSE_EFFECT MSK_1_Muscle Pain 192329-42-3 PRINOMASTAT TISSUE_TOXICITY Death 192329-42-3 PRINOMASTAT KNOWN_TOXICITY Miscellaneous 192329-42-3 PRINOMASTAT THERAPEUTIC_CLASS Antineoplastics 192329-42-3 PRINOMASTAT INDICATION Macular Degeneration 192329-42-3 PRINOMASTAT INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 192329-42-3 PRINOMASTAT INDICATION Breast Cancer / Carcinoma of the Breast 192329-42-3 PRINOMASTAT ADVERSE_EFFECT CVS_3_Heart Failure 192329-42-3 PRINOMASTAT ADVERSE_EFFECT MSK_1_Myalgia 192329-42-3 PRINOMASTAT ACTIVITY_CLASS Antiproliferative agent 192329-42-3 PRINOMASTAT INDICATION Glioma 192329-42-3 PRINOMASTAT INDICATION Squamous Cell Carcinoma of Skin 192329-42-3 PRINOMASTAT PRODUCT_CLASS Anti-cancers 192329-42-3 PRINOMASTAT ADVERSE_EFFECT XXX_3_Death 192329-42-3 PRINOMASTAT ADVERSE_EFFECT MSK_1_Arthralgia 192329-42-3 PRINOMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 192329-42-3 PRINOMASTAT MODE_CLASS Enzyme Inhibitor, selective 192329-42-3 PRINOMASTAT MODE_CLASS Enzyme Inhibitor 192329-42-3 PRINOMASTAT INDICATION Melanoma 192329-42-3 PRINOMASTAT TISSUE_TOXICITY Heart Failure 192329-42-3 PRINOMASTAT INDICATION Lung Cancer / Carcinoma of the Lung 192329-42-3 PRINOMASTAT INDICATION Colon Cancer 192329-42-3 PRINOMASTAT INDICATION Non-Small Cell Lung Carcinoma 192329-42-3 PRINOMASTAT KNOWN_TOXICITY Cardiovascular Toxicity 192329-42-3 PRINOMASTAT INDICATION Neoplasm / Cancer / Tumor 192329-42-3 PRINOMASTAT MECHANISM Interferes with Cell-Cell signaling 192329-42-3 PRINOMASTAT INDICATION Myelodysplastic Syndromes 192329-42-3 PRINOMASTAT ADVERSE_EFFECT MSK_1_Joint Pain 192329-42-3 PRINOMASTAT ADVERSE_EFFECT BBM_2_Granulocytopenia 192329-42-3 PRINOMASTAT ADVERSE_EFFECT MSK_1_Joint Swelling 174402-32-5 EDOTECARIN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 174634-09-4 TAS-103 PRODUCT_CLASS Anti-cancers 174634-09-4 TAS-103 THERAPEUTIC_CLASS Antineoplastics 174634-09-4 TAS-103 MODE_CLASS Enzyme Inhibitor 174634-09-4 TAS-103 MECHANISM Inhibit DNA synthesis, repair, and function 174634-09-4 TAS-103 STRUCTURE_ACTIVITY DNA topoisomerase inhibitor 174634-08-3 TAS-103 MODE_CLASS Enzyme Inhibitor 174634-08-3 TAS-103 PRODUCT_CLASS Anti-cancers 174634-08-3 TAS-103 THERAPEUTIC_CLASS Antineoplastics 174634-08-3 TAS-103 MECHANISM Inhibit DNA synthesis, repair, and function 174634-08-3 TAS-103 STRUCTURE_ACTIVITY DNA topoisomerase inhibitor 175013-84-0 SB-220453 THERAPEUTIC_CLASS Antimigraines 175013-84-0 SB-220453 PRODUCT_CLASS Central Nervous System (CNS) 175013-84-0 SB-220453 INDICATION Migraine Headache 149328-94-9 SDZ-GLC-756 MECHANISM Modulate G-protein coupled signal transduction 149328-94-9 SDZ-GLC-756 INDICATION Glaucoma 171714-84-4 LU-135252 INDICATION Re-Stenosis 171714-84-4 LU-135252 THERAPEUTIC_CLASS Antihypertensive Agents 171714-84-4 LU-135252 INDICATION Hypertension 171714-84-4 LU-135252 PRODUCT_CLASS Cardiovasculars 190648-49-8 RO-32-3555 PRODUCT_CLASS Immune Response / Immunomodulators 190648-49-8 RO-32-3555 INDICATION Arthritis 190648-49-8 RO-32-3555 THERAPEUTIC_CLASS Immunosuppressants 174636-32-9 TALNETANT INDICATION Chronic Obstructive Pulmonary Disease (COPD) 174636-32-9 TALNETANT MODE_CLASS Enzyme Inhibitor 174636-32-9 TALNETANT STRUCTURE_ACTIVITY Neurokinin 3 receptor antagonist 174636-33-0 TALNETANT MODE_CLASS Enzyme Inhibitor 174636-33-0 TALNETANT STRUCTURE_ACTIVITY Neurokinin 3 receptor antagonist 174636-33-0 TALNETANT INDICATION Chronic Obstructive Pulmonary Disease (COPD) 174636-26-1 TALNETANT MODE_CLASS Enzyme Inhibitor 174636-26-1 TALNETANT INDICATION Chronic Obstructive Pulmonary Disease (COPD) 174636-26-1 TALNETANT STRUCTURE_ACTIVITY Neurokinin 3 receptor antagonist 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_2_Pruritis 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 184475-35-2 GEFITINIB ADVERSE_EFFECT OCU_2_Amblyopia 184475-35-2 GEFITINIB ADVERSE_EFFECT BBM_3_Bleeding 184475-35-2 GEFITINIB ADVERSE_EFFECT LUN_1_Cough 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_2_Edema 184475-35-2 GEFITINIB ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 184475-35-2 GEFITINIB ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_2_Peripheral Edema 184475-35-2 GEFITINIB ADVERSE_EFFECT GIS_3_Stomatitis 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_2_Weight Loss 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_1_Acneiform Rash 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_2_Asthenia 184475-35-2 GEFITINIB ADVERSE_EFFECT OCU_3_Corneal Ulceration 184475-35-2 GEFITINIB ADVERSE_EFFECT LUN_2_Dyspnea 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_1_Folliculitis 184475-35-2 GEFITINIB ADVERSE_EFFECT GIS_1_Nausea / Vomiting 184475-35-2 GEFITINIB STRUCTURE_ACTIVITY Protein-tyrosine kinase (EGFR) inhibitor 184475-35-2 GEFITINIB INDICATION Neoplasm / Cancer / Tumor 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_1_Xerosis 184475-35-2 GEFITINIB ADVERSE_EFFECT OCU_3_Conjunctivitis 184475-35-2 GEFITINIB INDICATION Non-Small Cell Lung Carcinoma 184475-35-2 GEFITINIB MODE_CLASS Receptor tyrosine kinase inhibitor 184475-35-2 GEFITINIB INDICATION Head and Neck Cancer 184475-35-2 GEFITINIB ADVERSE_EFFECT GIS_3_Oral Ulceration 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_1_Rash 184475-35-2 GEFITINIB ADVERSE_EFFECT IMU_3_Urticaria 184475-35-2 GEFITINIB ADVERSE_EFFECT IMU_3_Angioedema 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_3_Bullous Rash 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_2_Dehydration 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_3_Erythema Multiforme 184475-35-2 GEFITINIB ADVERSE_EFFECT LUN_2_Interstitial Pneumonitis 184475-35-2 GEFITINIB MECHANISM Modulate growth factor receptor mediated signal transduction 184475-35-2 GEFITINIB THERAPEUTIC_CLASS Antineoplastics 184475-35-2 GEFITINIB INDICATION Carcinoid Tumors 184475-35-2 GEFITINIB MODE_CLASS Enzyme Inhibitor 184475-35-2 GEFITINIB MECHANISM Inhibit kinase mediated signal transduction 184475-35-2 GEFITINIB INDICATION Non-Small Cell Lung Carcinoma 184475-35-2 GEFITINIB ADVERSE_EFFECT OCU_3_Ocular Pain 184475-35-2 GEFITINIB INDICATION Carcinoid Tumors 184475-35-2 GEFITINIB PRODUCT_CLASS Anti-cancers 184475-35-2 GEFITINIB INDICATION Head and Neck Cancer 184475-35-2 GEFITINIB ADVERSE_EFFECT PSY_2_Anorexia 184475-35-2 GEFITINIB ADVERSE_EFFECT GIS_1_Diarrhea 184475-35-2 GEFITINIB ADVERSE_EFFECT XXX_1_Fever 184475-35-2 GEFITINIB ADVERSE_EFFECT NEU_3_Intracranial Bleeding 184475-35-2 GEFITINIB ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 184475-35-2 GEFITINIB ADVERSE_EFFECT GIS_3_Pancreatitis 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_1_Skin Rash 184475-35-2 GEFITINIB ADVERSE_EFFECT SKN_3_Vesicular Rash 168077-14-3 ZD-2486 INDICATION Angina Pectoris 168077-14-3 ZD-2486 THERAPEUTIC_CLASS Antianginals 168077-14-3 ZD-2486 MECHANISM Inhibit platelet aggregation 168077-14-3 ZD-2486 PRODUCT_CLASS Cardiovasculars 168077-14-3 ZD-2486 MODE_CLASS Receptor Ligand Antagonist, Selective 166952-28-9 ZD-2486 MODE_CLASS Receptor Ligand Antagonist, Selective 166952-28-9 ZD-2486 PRODUCT_CLASS Cardiovasculars 166952-28-9 ZD-2486 INDICATION Angina Pectoris 166952-28-9 ZD-2486 THERAPEUTIC_CLASS Antianginals 166952-28-9 ZD-2486 MECHANISM Inhibit platelet aggregation 175865-63-1 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-63-1 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-63-1 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-63-1 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-63-1 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-63-1 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-65-3 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-65-3 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-65-3 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-65-3 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-65-3 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-65-3 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-60-8 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-60-8 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-60-8 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-60-8 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-60-8 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-60-8 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-62-0 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-62-0 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-62-0 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-62-0 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-62-0 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-62-0 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-64-2 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-64-2 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-64-2 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-64-2 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-64-2 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-64-2 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-68-6 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-68-6 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-68-6 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-68-6 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-68-6 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-68-6 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-59-5 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-59-5 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-59-5 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-59-5 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-59-5 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-59-5 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-67-5 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-67-5 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 175865-67-5 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-67-5 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-67-5 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-67-5 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-61-9 VALGANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 175865-61-9 VALGANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 175865-61-9 VALGANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 175865-61-9 VALGANCICLOVIR MECHANISM Inhibit viral DNA synthesis 175865-61-9 VALGANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 175865-61-9 VALGANCICLOVIR PRODUCT_CLASS Anti-infectives 159776-70-2 MELAGATRAN MODE_CLASS Enzyme Inhibitor 159776-70-2 MELAGATRAN MECHANISM Inhibit platelet aggregation 159776-70-2 MELAGATRAN THERAPEUTIC_CLASS Anticoagulants 159776-70-2 MELAGATRAN PRODUCT_CLASS Hematologics 127648-29-7 ALTROPANE MODE_CLASS Solute transporter inhibitor 127648-29-7 ALTROPANE MECHANISM Prolong/enhance neural transmission 127648-29-7 ALTROPANE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 157542-49-9 CS-834 PRODUCT_CLASS Anti-infectives 157542-49-9 CS-834 THERAPEUTIC_CLASS Antibacterials 157542-49-9 CS-834 MECHANISM Inhibit bacterial cell wall biosynthesis 157542-49-9 CS-834 MODE_CLASS Enzyme Inhibitor 193811-33-5 CS-834 PRODUCT_CLASS Anti-infectives 193811-33-5 CS-834 THERAPEUTIC_CLASS Antibacterials 193811-33-5 CS-834 MECHANISM Inhibit bacterial cell wall biosynthesis 193811-33-5 CS-834 MODE_CLASS Enzyme Inhibitor 129172-46-9 CS-834 MODE_CLASS Enzyme Inhibitor 129172-46-9 CS-834 MECHANISM Inhibit bacterial cell wall biosynthesis 129172-46-9 CS-834 THERAPEUTIC_CLASS Antibacterials 129172-46-9 CS-834 PRODUCT_CLASS Anti-infectives 179091-43-1 CS-834 MODE_CLASS Enzyme Inhibitor 179091-43-1 CS-834 THERAPEUTIC_CLASS Antibacterials 179091-43-1 CS-834 PRODUCT_CLASS Anti-infectives 179091-43-1 CS-834 MECHANISM Inhibit bacterial cell wall biosynthesis 168162-57-0 YM-471 MODE_CLASS Receptor Ligand Antagonist, Non-selective 168162-57-0 YM-471 MECHANISM Reduce vasoconstriction 168162-57-0 YM-471 MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 175385-62-3 LASINAVIR INDICATION Myocardial Ischemia 145969-30-8 OPC-14523 PRODUCT_CLASS Central Nervous System (CNS) 145969-30-8 OPC-14523 MECHANISM Modulate neural transmission 145969-30-8 OPC-14523 STRUCTURE_ACTIVITY 5HT2 antagonist 145969-30-8 OPC-14523 INDICATION Depression 145969-30-8 OPC-14523 THERAPEUTIC_CLASS Antidepressants 145969-31-9 OPC-14523 STRUCTURE_ACTIVITY 5HT2 antagonist 145969-31-9 OPC-14523 INDICATION Depression 145969-31-9 OPC-14523 THERAPEUTIC_CLASS Antidepressants 145969-31-9 OPC-14523 PRODUCT_CLASS Central Nervous System (CNS) 145969-31-9 OPC-14523 MECHANISM Modulate neural transmission 184036-34-8 SITAXSENTAN PRODUCT_CLASS Cardiovasculars 184036-34-8 SITAXSENTAN INDICATION Pulmonary Hypertension 184036-34-8 SITAXSENTAN ADVERSE_EFFECT LIV_2_Abnormal Liver Function 184036-34-8 SITAXSENTAN THERAPEUTIC_CLASS Antihypertensive Agents 184036-34-8 SITAXSENTAN ADVERSE_EFFECT GIS_1_Nausea 184036-34-8 SITAXSENTAN ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 184036-34-8 SITAXSENTAN ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 184036-34-8 SITAXSENTAN KNOWN_TOXICITY Cardiovascular Toxicity 184036-34-8 SITAXSENTAN ADVERSE_EFFECT XXX_1_Nasal Congestion 184036-34-8 SITAXSENTAN ADVERSE_EFFECT CVS_2_Hypotension 184036-34-8 SITAXSENTAN ADVERSE_EFFECT NEU_1_Headache 184036-34-8 SITAXSENTAN TISSUE_TOXICITY Cardiac Tamponade 184036-34-8 SITAXSENTAN ADVERSE_EFFECT XXX_1_Peripheral Edema 184036-34-8 SITAXSENTAN TISSUE_TOXICITY Ventricular Tachycardia 184036-34-8 SITAXSENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 184036-34-8 SITAXSENTAN ADVERSE_EFFECT CVS_3_Cardiac Tamponade 184036-34-8 SITAXSENTAN THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 184036-34-8 SITAXSENTAN MODE_CLASS Receptor Ligand Antagonist, Selective 184036-34-8 SITAXSENTAN INDICATION Heart Failure 184036-34-8 SITAXSENTAN TISSUE_TOXICITY Hypotension 184036-34-8 SITAXSENTAN ADVERSE_EFFECT NEU_1_Dizziness 184036-34-8 SITAXSENTAN ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 184036-34-8 SITAXSENTAN MECHANISM Modulate G-protein coupled signal transduction 184036-34-8 SITAXSENTAN INDICATION Hypertension 184036-34-8 SITAXSENTAN INDICATION Chronic Obstructive Pulmonary Disease (COPD) 184036-34-8 SITAXSENTAN TISSUE_TOXICITY Ventricular Fibrillation 201688-00-8 MS-325 PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 201688-00-8 MS-325 INDICATION Contrasting Agent 142873-41-4 TAK-218 MODE_CLASS Enzyme Inhibitor 160135-92-2 BMS-189921 THERAPEUTIC_CLASS Antihypertensive Agents 160135-92-2 BMS-189921 MECHANISM Reduce vasoconstriction 160135-92-2 BMS-189921 MECHANISM Modulate G-protein coupled signal transduction 160135-92-2 BMS-189921 PRODUCT_CLASS Cardiovasculars 160135-92-2 BMS-189921 INDICATION Hypertension 160135-92-2 BMS-189921 MODE_CLASS Enzyme Inhibitor 53179-12-7 CLOPIMOZIDE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 54063-23-9 CINEPAZIC ACID THERAPEUTIC_CLASS Antianginals 54063-23-9 CINEPAZIC ACID PRODUCT_CLASS Cardiovasculars 54063-23-9 CINEPAZIC ACID INDICATION Angina Pectoris 54504-70-0 THEOFIBRATE PRODUCT_CLASS Cardiovasculars 54504-70-0 THEOFIBRATE INDICATION Hyperlipoproteinemia 54504-70-0 THEOFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 54739-19-4 CLOVOXAMINE THERAPEUTIC_CLASS Antidepressants 54739-19-4 CLOVOXAMINE PRODUCT_CLASS Central Nervous System (CNS) 54739-19-4 CLOVOXAMINE INDICATION Depression 55837-15-5 BUTOPIPRINE INDICATION Cough / Tussis 66887-96-5 PROPIKACIN MECHANISM Inhibit ribosomal protein synthesis 66887-96-5 PROPIKACIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 66887-96-5 PROPIKACIN THERAPEUTIC_CLASS Antibacterials 66887-96-5 PROPIKACIN PRODUCT_CLASS Anti-infectives 66887-96-5 PROPIKACIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 67182-81-4 BISPYRITHIONE MAGSULFEX INDICATION Seborrhea 68170-97-8 PALMOXIRIC ACID INDICATION Diabetes 68284-69-5 DISOBUTAMIDE INDICATION Cardiac Arrhythmias 68284-69-5 DISOBUTAMIDE THERAPEUTIC_CLASS Antidepressants 68284-69-5 DISOBUTAMIDE PRODUCT_CLASS Central Nervous System (CNS) 68284-69-5 DISOBUTAMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 68284-69-5 DISOBUTAMIDE PRODUCT_CLASS Cardiovasculars 68284-69-5 DISOBUTAMIDE INDICATION Depression 68379-03-3 CLOFILIUM PHOSPHATE PRODUCT_CLASS Cardiovasculars 68379-03-3 CLOFILIUM PHOSPHATE THERAPEUTIC_CLASS Antiarrhythmic Agents 68379-03-3 CLOFILIUM PHOSPHATE INDICATION Cardiac Arrhythmias 68379-03-3 CLOFILIUM PHOSPHATE THERAPEUTIC_CLASS Antidepressants 68379-03-3 CLOFILIUM PHOSPHATE PRODUCT_CLASS Central Nervous System (CNS) 68379-03-3 CLOFILIUM PHOSPHATE INDICATION Depression 68576-86-3 ENCIPRAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 68576-86-3 ENCIPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 68576-86-3 ENCIPRAZINE INDICATION Anxiety Disorders 69047-39-8 BINIFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 69047-39-8 BINIFIBRATE INDICATION Hyperlipoproteinemia 69047-39-8 BINIFIBRATE PRODUCT_CLASS Cardiovasculars 69373-95-1 DIPROTEVERINE PRODUCT_CLASS Cardiovasculars 69373-95-1 DIPROTEVERINE MODE_CLASS Channel Blocker 69373-95-1 DIPROTEVERINE MECHANISM Modulate channel gating 69373-95-1 DIPROTEVERINE INDICATION Angina Pectoris 69373-95-1 DIPROTEVERINE THERAPEUTIC_CLASS Antianginals 69815-38-9 PROXORPHAN INDICATION Cough / Tussis 70384-91-7 LORTALAMINE INDICATION Depression 70384-91-7 LORTALAMINE PRODUCT_CLASS Central Nervous System (CNS) 70384-91-7 LORTALAMINE THERAPEUTIC_CLASS Antidepressants 70833-07-7 PRIFUROLINE INDICATION Cardiac Arrhythmias 70833-07-7 PRIFUROLINE PRODUCT_CLASS Cardiovasculars 70833-07-7 PRIFUROLINE THERAPEUTIC_CLASS Antiarrhythmic Agents 83166-17-0 TAMPRAMINE THERAPEUTIC_CLASS Antidepressants 83166-17-0 TAMPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 83166-17-0 TAMPRAMINE INDICATION Depression 83166-17-0 TAMPRAMINE MODE_CLASS Solute transporter inhibitor 83166-17-0 TAMPRAMINE MECHANISM Prolong/enhance neural transmission 83647-97-6 SPIRAPRIL MODE_CLASS Enzyme Inhibitor 83647-97-6 SPIRAPRIL INDICATION Hypertension 83647-97-6 SPIRAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 83647-97-6 SPIRAPRIL PRODUCT_CLASS Cardiovasculars 83647-97-6 SPIRAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 83647-97-6 SPIRAPRIL MECHANISM Reduce vasoconstriction 83928-76-1 GEPIRONE MODE_CLASS Receptor Agonist 83928-76-1 GEPIRONE THERAPEUTIC_CLASS Antidepressants 83928-76-1 GEPIRONE INDICATION Depression 83928-76-1 GEPIRONE MECHANISM Modulate neural transmission 83928-76-1 GEPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 83928-76-1 GEPIRONE PRODUCT_CLASS Central Nervous System (CNS) 83928-76-1 GEPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 84243-58-3 IMAZODAN STRUCTURE_ACTIVITY PDE3 inhibitor 84880-03-5 CEFPIMIZOLE MODE_CLASS Enzyme Inhibitor 84880-03-5 CEFPIMIZOLE PRODUCT_CLASS Anti-infectives 84880-03-5 CEFPIMIZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 84880-03-5 CEFPIMIZOLE THERAPEUTIC_CLASS Antibacterials 85125-49-1 BICLODIL THERAPEUTIC_CLASS Antihypertensive Agents 85125-49-1 BICLODIL INDICATION Hypertension 85125-49-1 BICLODIL PRODUCT_CLASS Cardiovasculars 85181-40-4 TROPANSERIN INDICATION Migraine Headache 85181-40-4 TROPANSERIN MODE_CLASS Solute transporter inhibitor 85181-40-4 TROPANSERIN PRODUCT_CLASS Central Nervous System (CNS) 85181-40-4 TROPANSERIN THERAPEUTIC_CLASS Antimigraines 85181-40-4 TROPANSERIN MECHANISM Prolong/enhance neural transmission 85392-79-6 INDANIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 85392-79-6 INDANIDINE PRODUCT_CLASS Cardiovasculars 85392-79-6 INDANIDINE THERAPEUTIC_CLASS Antihypertensive Agents 85392-79-6 INDANIDINE MECHANISM Modulate G-protein coupled signal transduction 85392-79-6 INDANIDINE INDICATION Hypertension 85604-00-8 ZALTIDINE MECHANISM Reduce stomach HCl secretion 85604-00-8 ZALTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 86024-64-8 QUINACAINOL PRODUCT_CLASS Cardiovasculars 86024-64-8 QUINACAINOL THERAPEUTIC_CLASS Antiarrhythmic Agents 86024-64-8 QUINACAINOL INDICATION Cardiac Arrhythmias 86273-18-9 LENAMPICILLIN THERAPEUTIC_CLASS Antibacterials 86273-18-9 LENAMPICILLIN PRODUCT_CLASS Anti-infectives 86273-18-9 LENAMPICILLIN MODE_CLASS Enzyme Inhibitor 86273-18-9 LENAMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 86696-87-9 AGANODINE MECHANISM Modulate G-protein coupled signal transduction 87269-59-8 NAXAPROSTENE INDICATION Ulcer 87638-04-8 CARUMONAM PRODUCT_CLASS Anti-infectives 87638-04-8 CARUMONAM THERAPEUTIC_CLASS Antibacterials 87638-04-8 CARUMONAM MECHANISM Inhibit bacterial cell wall biosynthesis 87638-04-8 CARUMONAM MODE_CLASS Enzyme Inhibitor 87721-62-8 FLESTOLOL MECHANISM Modulate G-protein coupled signal transduction 87721-62-8 FLESTOLOL MODE_CLASS Receptor Ligand Antagonist 88133-11-3 BEMITRADINE INDICATION Hypertension 88133-11-3 BEMITRADINE THERAPEUTIC_CLASS Antihypertensive Agents 88133-11-3 BEMITRADINE PRODUCT_CLASS Cardiovasculars 108700-03-4 TELUDIPINE MECHANISM Reduce muscle contractile force 108700-03-4 TELUDIPINE MODE_CLASS Channel Blocker 108700-03-4 TELUDIPINE INDICATION Hypertension 108700-03-4 TELUDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 108700-03-4 TELUDIPINE PRODUCT_CLASS Cardiovasculars 113932-41-5 TEMATROPIUM METHYLSULFATE MECHANISM Prolong/enhance neural transmission 113932-41-5 TEMATROPIUM METHYLSULFATE MODE_CLASS Solute transporter inhibitor 115436-73-2 IPAZILIDE PRODUCT_CLASS Cardiovasculars 115436-73-2 IPAZILIDE INDICATION Cardiac Arrhythmias 115436-73-2 IPAZILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 120360-10-3 BATELAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 119271-78-2 SEZOLAMIDE MODE_CLASS Enzyme Inhibitor 119271-78-2 SEZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 119271-78-2 SEZOLAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 119271-78-2 SEZOLAMIDE THERAPEUTIC_CLASS Diuretics 119271-78-2 SEZOLAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 119271-78-2 SEZOLAMIDE INDICATION Glaucoma 119271-78-2 SEZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 111686-79-4 REMACEMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 111686-79-4 REMACEMIDE MODE_CLASS Channel Modulator 111686-79-4 REMACEMIDE MODE_CLASS Channel Blocker 111686-79-4 REMACEMIDE MECHANISM Modulate neural transmission 111686-79-4 REMACEMIDE PRODUCT_CLASS Central Nervous System (CNS) 111686-79-4 REMACEMIDE MECHANISM Block neural transmission 130759-56-7 NEMAZOLINE MECHANISM Modulate G-protein coupled signal transduction 130759-56-7 NEMAZOLINE INDICATION Nasal Congestion 1115-84-0 METHYLMETHIONINE SULFONIUM CHLORIDE INDICATION Ulcer 38321-02-7 DEXVERAPAMIL MODE_CLASS Channel Blocker 38321-02-7 DEXVERAPAMIL MECHANISM Reduce muscle contractile force 38321-02-7 DEXVERAPAMIL THERAPEUTIC_CLASS Antianginals 38321-02-7 DEXVERAPAMIL INDICATION Angina Pectoris 38321-02-7 DEXVERAPAMIL PRODUCT_CLASS Cardiovasculars 69123-98-4 FIALURIDINE MODE_CLASS Distorts /blocks macromolecular scaffold function 69123-98-4 FIALURIDINE MODE_CLASS Enzyme Inhibitor 69123-98-4 FIALURIDINE MECHANISM Inhibit precursor synthesis 69123-98-4 FIALURIDINE STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 69123-98-4 FIALURIDINE MECHANISM Inhibit DNA synthesis, repair, and function 69123-98-4 FIALURIDINE THERAPEUTIC_CLASS Antineoplastics 69123-98-4 FIALURIDINE PRODUCT_CLASS Immune Response / Immunomodulators 69123-98-4 FIALURIDINE PRODUCT_CLASS Anti-infectives 69123-98-4 FIALURIDINE TISSUE_TOXICITY Hepatotoxicity 69123-98-4 FIALURIDINE KNOWN_TOXICITY Hepatotoxicity 69123-98-4 FIALURIDINE THERAPEUTIC_CLASS Antivirals, Systemic 69123-98-4 FIALURIDINE MECHANISM Inhibit viral DNA synthesis 69123-98-4 FIALURIDINE PRODUCT_CLASS Anti-cancers 69123-98-4 FIALURIDINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 69123-98-4 FIALURIDINE ADVERSE_EFFECT LIV_1_Hepatotoxicity 80195-36-4 CEFDALOXIME PRODUCT_CLASS Anti-infectives 80195-36-4 CEFDALOXIME MECHANISM Inhibit bacterial cell wall biosynthesis 80195-36-4 CEFDALOXIME THERAPEUTIC_CLASS Antibacterials 83997-19-7 ATAPROST MECHANISM Modulate G-protein coupled signal transduction 83997-19-7 ATAPROST MODE_CLASS Receptor Agonist 90103-92-7 ZABICIPRILAT MECHANISM Reduce vasoconstriction 90103-92-7 ZABICIPRILAT INDICATION Hypertension 90103-92-7 ZABICIPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 90103-92-7 ZABICIPRILAT PRODUCT_CLASS Cardiovasculars 90103-92-7 ZABICIPRILAT MODE_CLASS Enzyme Inhibitor 98043-60-8 CLOSPIPRAMINE MODE_CLASS Solute transporter inhibitor 98043-60-8 CLOSPIPRAMINE MECHANISM Prolong/enhance neural transmission 98043-60-8 CLOSPIPRAMINE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 150821-03-7 PRANLUKAST INDICATION Allergic Rhinitis 150821-03-7 PRANLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 150821-03-7 PRANLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 150821-03-7 PRANLUKAST MECHANISM Modulate G-protein coupled signal transduction 150821-03-7 PRANLUKAST PRODUCT_CLASS Respiratory System 150821-03-7 PRANLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 150821-03-7 PRANLUKAST INDICATION Asthma 150821-03-7 PRANLUKAST MODE_CLASS Receptor Ligand Antagonist 103775-75-3 MIBOPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 5714-08-9 DEXTROTHYRONINE STRUCTURE_ACTIVITY T3 receptor agonist 5714-08-9 DEXTROTHYRONINE INDICATION Hyperlipoproteinemia 5714-08-9 DEXTROTHYRONINE THERAPEUTIC_CLASS Hypolipidemic Agents 5714-08-9 DEXTROTHYRONINE MODE_CLASS Receptor Agonist 5714-08-9 DEXTROTHYRONINE PRODUCT_CLASS Cardiovasculars 15176-29-1 EDOXUDINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 15176-29-1 EDOXUDINE INDICATION Herpes Genitalis / Genital Herpes 15176-29-1 EDOXUDINE INDICATION Herpes Simplex Infection 15176-29-1 EDOXUDINE MODE_CLASS Enzyme substrate mimic 15176-29-1 EDOXUDINE PRODUCT_CLASS Anti-infectives 15176-29-1 EDOXUDINE THERAPEUTIC_CLASS Antivirals, Topical 15176-29-1 EDOXUDINE MECHANISM Inhibit precursor synthesis 24815-24-5 RESCINNAMINE THERAPEUTIC_CLASS Antihypertensive Agents 24815-24-5 RESCINNAMINE MODE_CLASS Solute transporter inhibitor 24815-24-5 RESCINNAMINE MECHANISM Prolong/enhance neural transmission 24815-24-5 RESCINNAMINE THERAPEUTIC_CLASS Antipsychotics 24815-24-5 RESCINNAMINE INDICATION Hypertension 24815-24-5 RESCINNAMINE INDICATION Psychotic Disorders / Psychosis 24815-24-5 RESCINNAMINE PRODUCT_CLASS Central Nervous System (CNS) 24815-24-5 RESCINNAMINE PRODUCT_CLASS Cardiovasculars 26305-03-3 PEPSTATIN A MODE_CLASS Enzyme Inhibitor 63968-64-9 ARTEMISININ ADVERSE_EFFECT GIS_2_Diarrhea 63968-64-9 ARTEMISININ MECH_LEVEL_3 DNA damage 63968-64-9 ARTEMISININ TA_LEVEL_1 Infectious Disease 63968-64-9 ARTEMISININ MECH_LEVEL_2 Believed to involve free radical damage to membrane systems in parasites; inhibits cytoadherence and rosetting 63968-64-9 ARTEMISININ MECHANISM Induce free oxygen radical associated tissue and DNA damage 63968-64-9 ARTEMISININ ADVERSE_EFFECT NEU_1_Sedation 63968-64-9 ARTEMISININ ADVERSE_EFFECT PSY_1_Anorexia 63968-64-9 ARTEMISININ STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, antiparasitic 63968-64-9 ARTEMISININ MESH_LEVEL_2 Hydrocarbons 63968-64-9 ARTEMISININ INDICATION Malaria 63968-64-9 ARTEMISININ TA_LEVEL_3 malaria 63968-64-9 ARTEMISININ ADVERSE_EFFECT NEU_2_Neurotoxicity 63968-64-9 ARTEMISININ ADVERSE_EFFECT GIS_1_Nausea / Vomiting 63968-64-9 ARTEMISININ TA_LEVEL_2 Antiparasitic 63968-64-9 ARTEMISININ MECH_LEVEL_1 Believed to involve free radical damage to membrane systems in parasites; inhibits cytoadherence and rosetting 63968-64-9 ARTEMISININ ACTIVITY_CLASS DNA damager 63968-64-9 ARTEMISININ ZERO_CLASS N 63968-64-9 ARTEMISININ ADVERSE_EFFECT NEU_1_Dizziness 63968-64-9 ARTEMISININ ADVERSE_EFFECT NEU_2_Neurologic Dysfunction 63968-64-9 ARTEMISININ PRODUCT_CLASS Anti-infectives 63968-64-9 ARTEMISININ THERAPEUTIC_CLASS Antiparasitics 63968-64-9 ARTEMISININ MESH_LEVEL_3 Terpenes 63968-64-9 ARTEMISININ MESH_LEVEL_1 Organic Chemicals 63968-64-9 ARTEMISININ ADVERSE_EFFECT NEU_2_Locomotor Disturbance 130-83-6 AZAPETINE PHOSPHATE MECHANISM Modulate G-protein coupled signal transduction 36354-80-0 MONOCTANOIN COMPONENT C INDICATION Cholelithiasis / Gallstones 104428-01-5 BUSERELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 104428-01-5 BUSERELIN MODE_CLASS Receptor Agonist 96478-43-2 IRINDALONE INDICATION Hypertension 96478-43-2 IRINDALONE PRODUCT_CLASS Cardiovasculars 96478-43-2 IRINDALONE MODE_CLASS Receptor Ligand Antagonist 96478-43-2 IRINDALONE THERAPEUTIC_CLASS Antihypertensive Agents 96478-43-2 IRINDALONE MECHANISM Modulate G-protein coupled signal transduction 141579-54-6 FENLEUTON MECHANISM Inhibit eicosanoid biosynthesis 141579-54-6 FENLEUTON MODE_CLASS Enzyme Inhibitor 156769-21-0 SANFETRINEM MODE_CLASS Enzyme Inhibitor 156769-21-0 SANFETRINEM THERAPEUTIC_CLASS Antibacterials 156769-21-0 SANFETRINEM PRODUCT_CLASS Anti-infectives 156769-21-0 SANFETRINEM MECHANISM Inhibit bacterial cell wall biosynthesis 72432-10-1 ANIRACETAM MODE_CLASS Receptor Agonist 72432-10-1 ANIRACETAM PRODUCT_CLASS Central Nervous System (CNS) 72432-10-1 ANIRACETAM ADVERSE_EFFECT PSY_3_Confusion 72432-10-1 ANIRACETAM INDICATION Alzheimer's Dementia 72432-10-1 ANIRACETAM MECHANISM Prolong/enhance neural transmission 72432-10-1 ANIRACETAM MODE_CLASS Channel Modulator 72432-10-1 ANIRACETAM ADVERSE_EFFECT IMU_3_Hypersensitivity 72432-10-1 ANIRACETAM STRUCTURE_ACTIVITY Glutamate receptor (metabotropic) agonist 72432-10-1 ANIRACETAM ADVERSE_EFFECT SKN_3_Skin Rash 72432-10-1 ANIRACETAM THERAPEUTIC_CLASS Neurodegenerative Disorders 33580-30-2 TARTATOLOL MODE_CLASS Receptor Ligand Antagonist 33580-30-2 TARTATOLOL MECHANISM Modulate neural transmission 33580-30-2 TARTATOLOL INDICATION Cardiac Arrhythmias 33580-30-2 TARTATOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 33580-30-2 TARTATOLOL INDICATION Hypertension 33580-30-2 TARTATOLOL INDICATION Angina Pectoris 33580-30-2 TARTATOLOL PRODUCT_CLASS Cardiovasculars 33580-30-2 TARTATOLOL THERAPEUTIC_CLASS Antianginals 33580-30-2 TARTATOLOL THERAPEUTIC_CLASS Antihypertensive Agents 33580-30-2 TARTATOLOL MODE_CLASS Receptor Agonist, Non-selective 33580-30-2 TARTATOLOL MECHANISM Modulate G-protein coupled signal transduction 73963-72-1 CILOSTAZOL ADVERSE_EFFECT XXX_2_Pharyngitis 73963-72-1 CILOSTAZOL ADVERSE_EFFECT _1_Loose stools 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 73963-72-1 CILOSTAZOL ADVERSE_EFFECT SKN_2_Pruritis 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_2_Stroke 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Hematemesis 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_1_Dyspepsia 73963-72-1 CILOSTAZOL TA_LEVEL_1 Cardiovascular 73963-72-1 CILOSTAZOL TA_LEVEL_2 Perfusion 73963-72-1 CILOSTAZOL INDICATION Thromboangitis Obliterans (Buerger's disease) 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Rectal Hemorrhage 73963-72-1 CILOSTAZOL ADVERSE_EFFECT NEU_3_Cerebral Ischemia 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_2_Hypotension 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_2_Angina 73963-72-1 CILOSTAZOL ADVERSE_EFFECT NEU_1_Dizziness 73963-72-1 CILOSTAZOL ADVERSE_EFFECT SKN_2_Rash 73963-72-1 CILOSTAZOL ADVERSE_EFFECT REP_2_Infertility 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Peptic Ulceration 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Abdominal Pain 73963-72-1 CILOSTAZOL TISSUE_TOXICITY Stroke 73963-72-1 CILOSTAZOL TISSUE_TOXICITY Atrial Fibrillation 73963-72-1 CILOSTAZOL ACTIVITY_CLASS Phosphodiesterase inhibitor 73963-72-1 CILOSTAZOL PRODUCT_CLASS Cardiovasculars 73963-72-1 CILOSTAZOL MECHANISM Enhance kinase mediated signal transduction 73963-72-1 CILOSTAZOL THERAPEUTIC_CLASS Antiplatelets 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Gastritis 73963-72-1 CILOSTAZOL ADVERSE_EFFECT NEU_1_Headache 73963-72-1 CILOSTAZOL MECH_LEVEL_1 Vasorelaxation 73963-72-1 CILOSTAZOL ADVERSE_EFFECT XXX_1_Peripheral Edema 73963-72-1 CILOSTAZOL ADVERSE_EFFECT NEU_2_Vertigo 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_1_Palpitation 73963-72-1 CILOSTAZOL ADVERSE_EFFECT XXX_2_Rhinitis 73963-72-1 CILOSTAZOL TISSUE_TOXICITY Cardiac Arrest 73963-72-1 CILOSTAZOL STRUCTURE_ACTIVITY PDE3 inhibitor 73963-72-1 CILOSTAZOL ADVERSE_EFFECT IMU_2_Allergic Reactions 73963-72-1 CILOSTAZOL INDICATION Peripheral Vascular Disease 73963-72-1 CILOSTAZOL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 73963-72-1 CILOSTAZOL MECH_LEVEL_2 anti-platlet aggregation 73963-72-1 CILOSTAZOL TISSUE_TOXICITY Hypotension 73963-72-1 CILOSTAZOL TISSUE_TOXICITY Angina 73963-72-1 CILOSTAZOL ADVERSE_EFFECT BBM_3_Hemorrhage 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_2_Varicose Vein 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_2_Sinus Tachycardia 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_1_Diarrhea 73963-72-1 CILOSTAZOL MODE_CLASS Enzyme Inhibitor 73963-72-1 CILOSTAZOL ADVERSE_EFFECT BIL_2_Cholelithiasis 73963-72-1 CILOSTAZOL ADVERSE_EFFECT NEU_2_Syncope 73963-72-1 CILOSTAZOL ADVERSE_EFFECT PSY_2_Anorexia 73963-72-1 CILOSTAZOL ADVERSE_EFFECT LUN_2_Cough 73963-72-1 CILOSTAZOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 73963-72-1 CILOSTAZOL ADVERSE_EFFECT IMU_2_Urticaria 73963-72-1 CILOSTAZOL ADVERSE_EFFECT MSK_2_Myalgia 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Melena 73963-72-1 CILOSTAZOL ADVERSE_EFFECT GIS_2_Esophagitis 73963-72-1 CILOSTAZOL KNOWN_TOXICITY Cardiovascular Toxicity 73963-72-1 CILOSTAZOL TISSUE_TOXICITY Congestive Heart Failure 73963-72-1 CILOSTAZOL ZERO_CLASS N 73963-72-1 CILOSTAZOL MESH_LEVEL_1 Heterocyclic Compounds 73963-72-1 CILOSTAZOL MECH_LEVEL_3 3',5'-cyclic-nucleotide phosphodiesterase 73963-72-1 CILOSTAZOL INDICATION Intermittent Claudication 73963-72-1 CILOSTAZOL MESH_LEVEL_3 Azoles 73963-72-1 CILOSTAZOL TA_LEVEL_3 PDE inhibitors 80621-81-4 RIFAXIMIN PRODUCT_CLASS Anti-infectives 80621-81-4 RIFAXIMIN MODE_CLASS Enzyme Inhibitor, selective 80621-81-4 RIFAXIMIN INDICATION Traveler's Diarrhea 80621-81-4 RIFAXIMIN THERAPEUTIC_CLASS Antibacterials 80621-81-4 RIFAXIMIN MECHANISM Inhibit protein synthesis 59729-33-8 CITALOPRAM ADVERSE_EFFECT PSY_2_Agitation 59729-33-8 CITALOPRAM ADVERSE_EFFECT CVS_2_Tachycardia 59729-33-8 CITALOPRAM ADVERSE_EFFECT XXX_2_Salivation 59729-33-8 CITALOPRAM ADVERSE_EFFECT NEU_3_Extrapyramidal Toxicity 59729-33-8 CITALOPRAM ADVERSE_EFFECT NEU_1_Somnolence 59729-33-8 CITALOPRAM ADVERSE_EFFECT NEU_1_Tremor 59729-33-8 CITALOPRAM ADVERSE_EFFECT PSY_2_Anorexia 59729-33-8 CITALOPRAM ADVERSE_EFFECT XXX_2_Weight Loss 59729-33-8 CITALOPRAM ADVERSE_EFFECT NEU_2_Migraine 59729-33-8 CITALOPRAM ADVERSE_EFFECT END_2_Breast Tenderness 59729-33-8 CITALOPRAM MODE_CLASS Solute transporter inhibitor 59729-33-8 CITALOPRAM ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 59729-33-8 CITALOPRAM ZERO_CLASS N 59729-33-8 CITALOPRAM ADVERSE_EFFECT ELT_3_Hyponatremia 59729-33-8 CITALOPRAM ADVERSE_EFFECT EMB_3_Teratogenicity 59729-33-8 CITALOPRAM ADVERSE_EFFECT XXX_1_Sweating 59729-33-8 CITALOPRAM ADVERSE_EFFECT XXX_1_Fatigue 59729-33-8 CITALOPRAM ADVERSE_EFFECT PSY_2_Anxiety 59729-33-8 CITALOPRAM ADVERSE_EFFECT REP_3_Priapism 59729-33-8 CITALOPRAM ADVERSE_EFFECT NEU_2_Paresthesia 59729-33-8 CITALOPRAM ADVERSE_EFFECT END_2_Galactorrhea 59729-33-8 CITALOPRAM MECH_LEVEL_2 5HT antagonist 59729-33-8 CITALOPRAM MECH_LEVEL_3 5HT Transporter SERT 59729-33-8 CITALOPRAM PRODUCT_CLASS Central Nervous System (CNS) 59729-33-8 CITALOPRAM TA_LEVEL_3 SERTs 59729-33-8 CITALOPRAM INDICATION Major Depression / Major Depressive Disorder 59729-33-8 CITALOPRAM KNOWN_TOXICITY Reproductive System Toxicity 59729-33-8 CITALOPRAM MESH_LEVEL_1 Organic Chemicals 59729-33-8 CITALOPRAM TISSUE_TOXICITY Impotence 59729-33-8 CITALOPRAM MESH_LEVEL_3 Propylamines 59729-33-8 CITALOPRAM MESH_LEVEL_2 Amines 59729-33-8 CITALOPRAM ADVERSE_EFFECT REP_2_Decreased Fertility 59729-33-8 CITALOPRAM ADVERSE_EFFECT GIS_1_Dry Mouth 59729-33-8 CITALOPRAM ADVERSE_EFFECT GIS_1_Diarrhea 59729-33-8 CITALOPRAM ADVERSE_EFFECT REP_1_Decreased Libido 59729-33-8 CITALOPRAM ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 59729-33-8 CITALOPRAM ADVERSE_EFFECT CVS_2_Postural Hypotension 59729-33-8 CITALOPRAM ADVERSE_EFFECT REP_2_Amenorrhea 59729-33-8 CITALOPRAM ADVERSE_EFFECT PSY_2_Activation of Mania / Hypomania 59729-33-8 CITALOPRAM TA_LEVEL_1 Central Nervous System (CNS) 59729-33-8 CITALOPRAM TISSUE_TOXICITY Teratogenicity 59729-33-8 CITALOPRAM THERAPEUTIC_CLASS Antidepressants 59729-33-8 CITALOPRAM TA_LEVEL_2 CNS Depressant 59729-33-8 CITALOPRAM MECH_LEVEL_1 Modulate neural transmission 59729-33-8 CITALOPRAM MECHANISM Prolong/enhance neural transmission 59729-33-8 CITALOPRAM TISSUE_TOXICITY Carcinogenicity 59729-33-8 CITALOPRAM STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 59729-33-8 CITALOPRAM KNOWN_TOXICITY Carcinogenicity 59729-33-8 CITALOPRAM ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 59729-33-8 CITALOPRAM ADVERSE_EFFECT REP_1_Ejaculatory Disorder 59729-33-8 CITALOPRAM KNOWN_TOXICITY Embryo/Fetal Toxicity 59729-33-8 CITALOPRAM ADVERSE_EFFECT DNA_3_Carcinogenicity 59729-33-8 CITALOPRAM ADVERSE_EFFECT REP_1_Impotence 59729-33-8 CITALOPRAM ADVERSE_EFFECT GIS_1_Nausea 59729-33-8 CITALOPRAM ADVERSE_EFFECT PSY_1_Insomnia 75221-13-0 CEFMINOX MODE_CLASS Enzyme Inhibitor 75221-13-0 CEFMINOX MECHANISM Inhibit bacterial cell wall biosynthesis 75221-13-0 CEFMINOX THERAPEUTIC_CLASS Antibacterials 75221-13-0 CEFMINOX PRODUCT_CLASS Anti-infectives 81486-22-8 NIPRADILOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 81486-22-8 NIPRADILOL INDICATION Glaucoma 81486-22-8 NIPRADILOL MECHANISM Modulate G-protein coupled signal transduction 81486-22-8 NIPRADILOL MECHANISM Reduce vasoconstriction 81486-22-8 NIPRADILOL MODE_CLASS Receptor Ligand Antagonist 81486-22-8 NIPRADILOL THERAPEUTIC_CLASS Antiglaucoma Agents 57381-27-8 IRSOGLADINE MALEATE PRODUCT_CLASS Gastrointestinal System 57381-27-8 IRSOGLADINE MALEATE INDICATION Gastric Ulcer 57381-27-8 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Constipation 57381-27-8 IRSOGLADINE MALEATE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 57381-27-8 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Diarrhea 57381-27-8 IRSOGLADINE MALEATE THERAPEUTIC_CLASS Antiulcers 57381-27-8 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Pruritis 57381-27-8 IRSOGLADINE MALEATE INDICATION Gastritis 57381-27-8 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Rash 57381-27-8 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 91032-34-7 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 91032-34-7 TEICOPLANIN INDICATION Septicemia 91032-34-7 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 91032-34-7 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 91032-34-7 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 91032-34-7 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 91032-34-7 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 91032-34-7 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 91032-34-7 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 91032-34-7 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91032-34-7 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 91032-34-7 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 91032-34-7 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 91032-34-7 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91032-34-7 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 91032-34-7 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 91032-34-7 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 91032-34-7 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 91032-34-7 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 91032-34-7 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 91032-34-7 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 91032-34-7 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 91032-34-7 TEICOPLANIN TISSUE_TOXICITY Renal Failure 91032-34-7 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 91032-34-7 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 91032-34-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 91032-34-7 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 91032-34-7 TEICOPLANIN INDICATION Bacteremia 91032-34-7 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 91032-34-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 91032-34-7 TEICOPLANIN ZERO_CLASS N 91032-34-7 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 91032-34-7 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 91032-34-7 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 91032-34-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 91032-34-7 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 91032-34-7 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 91032-34-7 TEICOPLANIN INDICATION Septic Arthritis 91032-34-7 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 91032-34-7 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 91032-34-7 TEICOPLANIN TA_LEVEL_3 systemic infections 91032-34-7 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 91032-34-7 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 91032-34-7 TEICOPLANIN TA_LEVEL_1 Infectious Disease 91032-34-7 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 91032-34-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 91032-34-7 TEICOPLANIN PRODUCT_CLASS Anti-infectives 78994-24-8 ORMELOXIFENE MECHANISM Modulate gene transcription 78994-24-8 ORMELOXIFENE MODE_CLASS Receptor Partial Agonist 78994-24-8 ORMELOXIFENE INDICATION Contraception 78994-24-8 ORMELOXIFENE THERAPEUTIC_CLASS Contraceptive Hormones 78994-24-8 ORMELOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 70259-49-3 PIRARUBICIN ADVERSE_EFFECT XXX_1_Malaise 70259-49-3 PIRARUBICIN KNOWN_TOXICITY Hepatotoxicity 70259-49-3 PIRARUBICIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 70259-49-3 PIRARUBICIN ADVERSE_EFFECT KID_3_Increased Creatinine 70259-49-3 PIRARUBICIN INDICATION Leukemia 70259-49-3 PIRARUBICIN INDICATION Bladder Cancer / Carcinoma of the Bladder 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GUS_1_Pollakiuria 70259-49-3 PIRARUBICIN INDICATION Breast Cancer / Carcinoma of the Breast 70259-49-3 PIRARUBICIN INDICATION Prostatic Cancer / Carcinoma of the Prostate 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GIS_1_Vomiting 70259-49-3 PIRARUBICIN ADVERSE_EFFECT XXX_1_Infection 70259-49-3 PIRARUBICIN ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GIS_1_Stomatitis 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GIS_3_Duodenal Ulcer 70259-49-3 PIRARUBICIN ADVERSE_EFFECT LIV_3_Hepatic Artery Thrombosis 70259-49-3 PIRARUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 70259-49-3 PIRARUBICIN THERAPEUTIC_CLASS Antineoplastics 70259-49-3 PIRARUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Hepatic Failure 70259-49-3 PIRARUBICIN PRODUCT_CLASS Anti-cancers 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Hepatic Artery Thrombosis 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Thrombocytopenia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT CVS_2_Congestive Heart Failure 70259-49-3 PIRARUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Arrhythmia 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Congestive Heart Failure 70259-49-3 PIRARUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 70259-49-3 PIRARUBICIN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Leukopenia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 70259-49-3 PIRARUBICIN INDICATION Mesothelioma 70259-49-3 PIRARUBICIN INDICATION Ovarian Cancer / Carcinoma of the Ovary 70259-49-3 PIRARUBICIN INDICATION Small Cell Lung Carcinoma 70259-49-3 PIRARUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Cardiotoxicity 70259-49-3 PIRARUBICIN TISSUE_TOXICITY Anemia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GIS_1_Nausea 70259-49-3 PIRARUBICIN ADVERSE_EFFECT BBM_1_Anemia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT BBM_1_Leukopenia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT LIV_3_Hepatic Failure 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GIS_3_Gastritis 70259-49-3 PIRARUBICIN ADVERSE_EFFECT CVS_2_Decreased Left Ventricular Ejection Fraction (LVEF) 70259-49-3 PIRARUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 70259-49-3 PIRARUBICIN INDICATION Lymphoma 70259-49-3 PIRARUBICIN INDICATION Non-Small Cell Lung Carcinoma 70259-49-3 PIRARUBICIN ADVERSE_EFFECT PSY_1_Anorexia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT NEU_2_Headache 70259-49-3 PIRARUBICIN ADVERSE_EFFECT BBM_1_Thrombocytopenia 70259-49-3 PIRARUBICIN ADVERSE_EFFECT GUS_1_Dysuria 70259-49-3 PIRARUBICIN ADVERSE_EFFECT CVS_2_Arrhythmia 68291-98-5 ZONISAMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 68291-98-5 ZONISAMIDE MECHANISM Block neural transmission 68291-98-5 ZONISAMIDE PRODUCT_CLASS Central Nervous System (CNS) 68291-98-5 ZONISAMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 68291-98-5 ZONISAMIDE MODE_CLASS Channel Blocker 58652-20-3 NOMEGESTROL ACETATE PRODUCT_CLASS Anti-cancers 58652-20-3 NOMEGESTROL ACETATE MECHANISM Inhibit steroid biosynthesis/ metabolism 58652-20-3 NOMEGESTROL ACETATE MODE_CLASS Enzyme Inhibitor 58652-20-3 NOMEGESTROL ACETATE THERAPEUTIC_CLASS Antineoplastics 58652-20-3 NOMEGESTROL ACETATE STRUCTURE_ACTIVITY Progesterone receptor agonist 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT GIS_1_Epigastric Pain 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT LUN_3_Bronchospasm 80214-83-1 ROXITHROMYCIN INDICATION Skin and Skin Structure Infections 80214-83-1 ROXITHROMYCIN INDICATION Upper Respiratory Tract Infection 80214-83-1 ROXITHROMYCIN TA_LEVEL_1 Infectious Disease 80214-83-1 ROXITHROMYCIN PRODUCT_CLASS Anti-infectives 80214-83-1 ROXITHROMYCIN TA_LEVEL_2 Anti-bacterial 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT GIS_3_Pancreatitis 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT IMU_2_Urticaria 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 80214-83-1 ROXITHROMYCIN MESH_LEVEL_3 Glycosides 80214-83-1 ROXITHROMYCIN INDICATION Genitourinary Tract Infections 80214-83-1 ROXITHROMYCIN INDICATION Non-Gonococcal Urethritis 80214-83-1 ROXITHROMYCIN MESH_LEVEL_2 Carbohydrates 80214-83-1 ROXITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 80214-83-1 ROXITHROMYCIN INDICATION Lower Respiratory Tract Infection 80214-83-1 ROXITHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 80214-83-1 ROXITHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT IMU_3_Anaphylactic Shock 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT NEU_2_Dizziness 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT GIS_2_Diarrhea 80214-83-1 ROXITHROMYCIN TA_LEVEL_3 Systemic infections 80214-83-1 ROXITHROMYCIN INDICATION Community-Acquired Pneumonia 80214-83-1 ROXITHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 80214-83-1 ROXITHROMYCIN INDICATION Mycoplasma Pneumoniae 80214-83-1 ROXITHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 80214-83-1 ROXITHROMYCIN TISSUE_TOXICITY Acute Hepatocellular Hepatitis 80214-83-1 ROXITHROMYCIN KNOWN_TOXICITY Hepatotoxicity 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT SKN_2_Skin Rash 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT XXX_3_Superinfection 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT NEU_3_Paresthesia 80214-83-1 ROXITHROMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 80214-83-1 ROXITHROMYCIN INDICATION Urinary Tract Infection (UTI) 80214-83-1 ROXITHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 80214-83-1 ROXITHROMYCIN MECH_LEVEL_1 Anti-bacterial 80214-83-1 ROXITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 80214-83-1 ROXITHROMYCIN ZERO_CLASS N 80214-83-1 ROXITHROMYCIN ADVERSE_EFFECT LIV_3_Acute Hepatocellular Hepatitis 86484-52-8 DOPEXAMINE MECHANISM Prolong/enhance neural transmission 86484-52-8 DOPEXAMINE MECHANISM Modulate G-protein coupled signal transduction 86484-52-8 DOPEXAMINE MODE_CLASS Receptor Agonist 74150-27-9 PIMOBENDAN MODE_CLASS Enzyme Inhibitor 74150-27-9 PIMOBENDAN MECHANISM Enhance kinase mediated signal transduction 74150-27-9 PIMOBENDAN THERAPEUTIC_CLASS Bronchodilators 74150-27-9 PIMOBENDAN PRODUCT_CLASS Respiratory System 33178-86-8 ALINIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 33178-86-8 ALINIDINE PRODUCT_CLASS Cardiovasculars 33178-86-8 ALINIDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 33178-86-8 ALINIDINE MODE_CLASS Channel Blocker 33178-86-8 ALINIDINE MECHANISM Trigger insulin release in pancreatic beta cells 56518-41-3 BRODIMOPRIM THERAPEUTIC_CLASS Antibacterials 56518-41-3 BRODIMOPRIM MODE_CLASS Enzyme Inhibitor 56518-41-3 BRODIMOPRIM MECHANISM Inhibit precursor synthesis 56518-41-3 BRODIMOPRIM PRODUCT_CLASS Anti-infectives 72492-12-7 SPIZOFURONE INDICATION Ulcer 57781-14-3 HALOPREDONE ACETATE MODE_CLASS Receptor Partial Agonist 57781-14-3 HALOPREDONE ACETATE PRODUCT_CLASS Immune Response / Immunomodulators 57781-14-3 HALOPREDONE ACETATE THERAPEUTIC_CLASS Immunosuppressants 57781-14-3 HALOPREDONE ACETATE MECHANISM Modulate gene transcription 57781-14-3 HALOPREDONE ACETATE INDICATION Arthritis 63516-07-4 FLUTROPIUM BROMIDE MECHANISM Prolong/enhance neural transmission 63516-07-4 FLUTROPIUM BROMIDE MODE_CLASS Solute transporter inhibitor 63516-07-4 FLUTROPIUM BROMIDE INDICATION Viral Rhinitis / Common Cold 86348-98-3 FLUNOPROST MECHANISM Modulate G-protein coupled signal transduction 86348-98-3 FLUNOPROST MODE_CLASS Receptor Agonist 86348-98-3 FLUNOPROST INDICATION Nasal Congestion 92823-00-2 FLOMOXEF SODIUM THERAPEUTIC_CLASS Antibacterials 92823-00-2 FLOMOXEF SODIUM MECHANISM Inhibit bacterial cell wall biosynthesis 92823-00-2 FLOMOXEF SODIUM MODE_CLASS Enzyme Inhibitor 92823-00-2 FLOMOXEF SODIUM PRODUCT_CLASS Anti-infectives 14899-36-6 DEXAMETHASONE PALMITATE THERAPEUTIC_CLASS Corticosteroids 14899-36-6 DEXAMETHASONE PALMITATE THERAPEUTIC_CLASS Immunosuppressants 14899-36-6 DEXAMETHASONE PALMITATE MODE_CLASS Receptor Agonist 14899-36-6 DEXAMETHASONE PALMITATE MECHANISM Modulate gene transcription 14899-36-6 DEXAMETHASONE PALMITATE PRODUCT_CLASS Anti-inflammatories 14899-36-6 DEXAMETHASONE PALMITATE PRODUCT_CLASS Immune Response / Immunomodulators 107097-79-0 TOSUFLOXACIN INDICATION Gram-negative Septicemia 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Jaundice 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 107097-79-0 TOSUFLOXACIN PRODUCT_CLASS Anti-infectives 107097-79-0 TOSUFLOXACIN TISSUE_TOXICITY Acute Renal Failure 107097-79-0 TOSUFLOXACIN TA_LEVEL_2 Anti-bacterial 107097-79-0 TOSUFLOXACIN MECH_LEVEL_3 DNA gyrase 107097-79-0 TOSUFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 107097-79-0 TOSUFLOXACIN INDICATION Respiratory Tract Infection 107097-79-0 TOSUFLOXACIN INDICATION Skin and Skin Structure Infections 107097-79-0 TOSUFLOXACIN MECH_LEVEL_1 Anti-bacterial 107097-79-0 TOSUFLOXACIN TA_LEVEL_1 Infectious Disease 107097-79-0 TOSUFLOXACIN INDICATION Dental Infection 107097-79-0 TOSUFLOXACIN TISSUE_TOXICITY Hematuria 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Impaired Consciousness 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 107097-79-0 TOSUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 107097-79-0 TOSUFLOXACIN TA_LEVEL_3 quinolones 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Abnormal Kidney Function 107097-79-0 TOSUFLOXACIN INDICATION Otitis Media 107097-79-0 TOSUFLOXACIN INDICATION Biliary Tract Infection 107097-79-0 TOSUFLOXACIN INDICATION Soft Tissue Infections 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Hematuria 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 107097-79-0 TOSUFLOXACIN KNOWN_TOXICITY Nephrotoxicity 107097-79-0 TOSUFLOXACIN ZERO_CLASS N 107097-79-0 TOSUFLOXACIN MESH_LEVEL_3 Quinolines 107097-79-0 TOSUFLOXACIN INDICATION Septic Arthritis 107097-79-0 TOSUFLOXACIN INDICATION Osteomyelitis / Bone Infection 107097-79-0 TOSUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 107097-79-0 TOSUFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 107097-79-0 TOSUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 107097-79-0 TOSUFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 107097-79-0 TOSUFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 107097-79-0 TOSUFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 107097-79-0 TOSUFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 107097-79-0 TOSUFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 107097-79-0 TOSUFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 107097-79-0 TOSUFLOXACIN INDICATION Urinary Tract Infection (UTI) 100599-27-7 TENIDAP INDICATION Rheumatoid Arthritis 100599-27-7 TENIDAP ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 100599-27-7 TENIDAP STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 100599-27-7 TENIDAP ADVERSE_EFFECT KID_1_Impaired Renal Tubular Function 100599-27-7 TENIDAP MECH_LEVEL_3 Arachidonate 5-lipoxygenase, Prostaglandin-endoperoxide synthase 1 nad 2 100599-27-7 TENIDAP TA_LEVEL_1 Anti-inflammatory 100599-27-7 TENIDAP MODE_CLASS Enzyme Inhibitor 100599-27-7 TENIDAP ADVERSE_EFFECT END_3_Osteoporosis 100599-27-7 TENIDAP ADVERSE_EFFECT KID_1_Proteinuria 100599-27-7 TENIDAP ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 100599-27-7 TENIDAP TISSUE_TOXICITY Hepatotoxicity 100599-27-7 TENIDAP ACTIVITY_CLASS Anti-inflammatory 100599-27-7 TENIDAP MECHANISM Inhibit eicosanoid biosynthesis 100599-27-7 TENIDAP TA_LEVEL_3 rheumatoid arthritis 100599-27-7 TENIDAP INDICATION Inflammation 100599-27-7 TENIDAP ADVERSE_EFFECT LIV_2_Hepatotoxicity 100599-27-7 TENIDAP ADVERSE_EFFECT GIS_1_Dyspepsia 100599-27-7 TENIDAP KNOWN_TOXICITY Hepatotoxicity 100599-27-7 TENIDAP MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 100599-27-7 TENIDAP INDICATION Osteoarthritis 100599-27-7 TENIDAP THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 100599-27-7 TENIDAP ZERO_CLASS N 100599-27-7 TENIDAP MESH_LEVEL_1 Heterocyclic Compounds 100599-27-7 TENIDAP TA_LEVEL_2 NSAID (?) 100599-27-7 TENIDAP MECH_LEVEL_1 Immunomodulation 100599-27-7 TENIDAP MESH_LEVEL_3 Indoles 100599-27-7 TENIDAP MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 100599-27-7 TENIDAP PRODUCT_CLASS Anti-inflammatories 50847-11-5 IBUDILAST MECHANISM Enhance kinase mediated signal transduction 50847-11-5 IBUDILAST MODE_CLASS Enzyme Inhibitor, Non-selective 109545-84-8 SCH-27899 STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor 57333-96-7 TACALCITOL MECHANISM Modulate gene transcription 57333-96-7 TACALCITOL MODE_CLASS Receptor Agonist 57333-96-7 TACALCITOL THERAPEUTIC_CLASS Psoralens 57333-96-7 TACALCITOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 57333-96-7 TACALCITOL INDICATION Psoriasis 57333-96-7 TACALCITOL PRODUCT_CLASS Dermatologicals 101389-86-0 FLUPAROXAN INDICATION Cerebral Ischemia 101389-86-0 FLUPAROXAN PRODUCT_CLASS Central Nervous System (CNS) 101389-86-0 FLUPAROXAN MECHANISM Modulate G-protein coupled signal transduction 101389-86-0 FLUPAROXAN INDICATION Depression 101389-86-0 FLUPAROXAN THERAPEUTIC_CLASS Antidepressants 90693-76-8 EPTALOPROST MECHANISM Modulate G-protein coupled signal transduction 90693-76-8 EPTALOPROST MODE_CLASS Receptor Agonist 71731-58-3 TIQUIZIUM BROMIDE MODE_CLASS Receptor Ligand Antagonist 71731-58-3 TIQUIZIUM BROMIDE MECHANISM Modulate G-protein coupled signal transduction 54247-25-5 CLORANOLOL HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 54247-25-5 CLORANOLOL HYDROCHLORIDE MECHANISM Reduce muscle contractile force 54247-25-5 CLORANOLOL HYDROCHLORIDE INDICATION Hypertension 54247-25-5 CLORANOLOL HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 54247-25-5 CLORANOLOL HYDROCHLORIDE MODE_CLASS Receptor Ligand Antagonist, Selective 56995-20-1 FLUPIRTINE MALEATE MODE_CLASS Channel Modulator 56995-20-1 FLUPIRTINE MALEATE MECHANISM Modulate channel gating 5630-53-5 TIBOLONE ADVERSE_EFFECT DNA_3_Endometrial Carcinoma 5630-53-5 TIBOLONE ADVERSE_EFFECT SKN_2_Seborrhoeic Dermatosis 5630-53-5 TIBOLONE MECHANISM Modulate gene transcription 5630-53-5 TIBOLONE ADVERSE_EFFECT SKN_2_Rash 5630-53-5 TIBOLONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 5630-53-5 TIBOLONE ADVERSE_EFFECT END_3_Hirsutism 5630-53-5 TIBOLONE TISSUE_TOXICITY Teratogenicity 5630-53-5 TIBOLONE ADVERSE_EFFECT NEU_2_Migraine 5630-53-5 TIBOLONE ADVERSE_EFFECT XXX_2_Edema 5630-53-5 TIBOLONE ADVERSE_EFFECT PSY_3_Depression 5630-53-5 TIBOLONE KNOWN_TOXICITY Carcinogenicity 5630-53-5 TIBOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 5630-53-5 TIBOLONE TISSUE_TOXICITY Thromboembolism 5630-53-5 TIBOLONE ADVERSE_EFFECT CVS_3_Thromboembolism 5630-53-5 TIBOLONE ADVERSE_EFFECT NEU_2_Headache 5630-53-5 TIBOLONE INDICATION Osteoporosis 5630-53-5 TIBOLONE KNOWN_TOXICITY Cardiovascular Toxicity 5630-53-5 TIBOLONE INDICATION Prevention of Osteoporosis 5630-53-5 TIBOLONE INDICATION Menopausal Syndrome 5630-53-5 TIBOLONE ADVERSE_EFFECT END_2_Breast Tenderness 5630-53-5 TIBOLONE STRUCTURE_ACTIVITY Estrogen receptor agonist 5630-53-5 TIBOLONE TISSUE_TOXICITY Endometrial Hyperplasia 5630-53-5 TIBOLONE THERAPEUTIC_CLASS Gonadal Hormones 5630-53-5 TIBOLONE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 5630-53-5 TIBOLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 5630-53-5 TIBOLONE ADVERSE_EFFECT DNA_3_Endometrial Hyperplasia 5630-53-5 TIBOLONE ADVERSE_EFFECT GUS_2_Vaginal Spotting 5630-53-5 TIBOLONE ADVERSE_EFFECT LIV_3_Abnormal Liver Function 5630-53-5 TIBOLONE ADVERSE_EFFECT XXX_2_Weight Gain 5630-53-5 TIBOLONE ADVERSE_EFFECT NEU_2_Dizziness 5630-53-5 TIBOLONE ADVERSE_EFFECT EMB_3_Teratogenicity 5630-53-5 TIBOLONE KNOWN_TOXICITY Embryo/Fetal Toxicity 5630-53-5 TIBOLONE MODE_CLASS Receptor Agonist 5630-53-5 TIBOLONE TISSUE_TOXICITY Endometrial Carcinoma 5630-53-5 TIBOLONE ADVERSE_EFFECT MSK_2_Musculoskeletal Pain 83480-29-9 VOGLIBOSE MECHANISM Inhibit absorption of dietary carbohydrates 83480-29-9 VOGLIBOSE INDICATION Diabetes 83480-29-9 VOGLIBOSE MODE_CLASS Enzyme Inhibitor 104195-17-7 SDZ NVI 085 PRODUCT_CLASS Central Nervous System (CNS) 104195-17-7 SDZ NVI 085 MECHANISM Modulate G-protein coupled signal transduction 104195-17-7 SDZ NVI 085 INDICATION Cerebral Ischemia 104195-17-7 SDZ NVI 085 THERAPEUTIC_CLASS Antidepressants 104195-17-7 SDZ NVI 085 INDICATION Depression 81377-02-8 SEGLITIDE INDICATION Diabetes 566-48-3 FORMESTANE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 566-48-3 FORMESTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 566-48-3 FORMESTANE THERAPEUTIC_CLASS Antineoplastics 566-48-3 FORMESTANE INDICATION Breast Cancer / Carcinoma of the Breast 566-48-3 FORMESTANE MODE_CLASS Enzyme Inhibitor 566-48-3 FORMESTANE PRODUCT_CLASS Anti-cancers 113593-34-3 FLOSATIDIL MECHANISM Reduce muscle contractile force 113593-34-3 FLOSATIDIL PRODUCT_CLASS Cardiovasculars 113593-34-3 FLOSATIDIL INDICATION Angina Pectoris 113593-34-3 FLOSATIDIL THERAPEUTIC_CLASS Antihypertensive Agents 113593-34-3 FLOSATIDIL MODE_CLASS Channel Modulator 113593-34-3 FLOSATIDIL INDICATION Hypertension 113593-34-3 FLOSATIDIL THERAPEUTIC_CLASS Antianginals 75887-54-6 ARTEMOTIL INDICATION Malaria 115607-77-7 SK&F-96067 MODE_CLASS Enzyme Inhibitor 115607-77-7 SK&F-96067 MECHANISM Reduce stomach HCl secretion 52479-85-3 EXIFONE MECHANISM Scavenges hydrogen peroxide and free radicals 52479-85-3 EXIFONE INDICATION Hypoxia 116521-53-0 FAD-104 THERAPEUTIC_CLASS Antineoplastics 116521-53-0 FAD-104 PRODUCT_CLASS Anti-cancers 116521-53-0 FAD-104 STRUCTURE_ACTIVITY DNA intercalator, anthracycline 115575-11-6 LIAROZOLE MODE_CLASS Enzyme Inhibitor, selective 115575-11-6 LIAROZOLE PRODUCT_CLASS Anti-cancers 115575-11-6 LIAROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 115575-11-6 LIAROZOLE THERAPEUTIC_CLASS Antineoplastics 115575-11-6 LIAROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 115575-11-6 LIAROZOLE INDICATION Psoriasis 113759-19-6 4-(1-(2-FLUORO-4-BIPHENYLYL)ETHYL)-2-METHYLAMINOTHIZOLE PRODUCT_CLASS Immune Response / Immunomodulators 113759-19-6 4-(1-(2-FLUORO-4-BIPHENYLYL)ETHYL)-2-METHYLAMINOTHIZOLE INDICATION Arthritis 113759-19-6 4-(1-(2-FLUORO-4-BIPHENYLYL)ETHYL)-2-METHYLAMINOTHIZOLE THERAPEUTIC_CLASS Immunosuppressants 113759-19-6 4-(1-(2-FLUORO-4-BIPHENYLYL)ETHYL)-2-METHYLAMINOTHIZOLE INDICATION Rheumatism 81674-79-5 GUAIMESAL INDICATION Cough / Tussis 85275-48-5 ICI-170809 MODE_CLASS Receptor Ligand Antagonist 85275-48-5 ICI-170809 INDICATION Anxiety Disorders 85275-48-5 ICI-170809 PRODUCT_CLASS Central Nervous System (CNS) 85275-48-5 ICI-170809 INDICATION Depression 85275-48-5 ICI-170809 THERAPEUTIC_CLASS Sedatives/Hypnotics 85275-48-5 ICI-170809 MECHANISM Modulate neural transmission 85275-48-5 ICI-170809 THERAPEUTIC_CLASS Antidepressants 114776-28-2 BEPAFANT PRODUCT_CLASS Cardiovasculars 114776-28-2 BEPAFANT INDICATION Hypertension 114776-28-2 BEPAFANT THERAPEUTIC_CLASS Antihypertensive Agents 116143-32-9 BMY-40062 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 120165-51-7 E-6080 MODE_CLASS Enzyme Inhibitor 120165-51-7 E-6080 MECHANISM Inhibit eicosanoid biosynthesis 114875-68-2 KP-736 MECHANISM Inhibit bacterial cell wall biosynthesis 114875-68-2 KP-736 THERAPEUTIC_CLASS Antibacterials 114875-68-2 KP-736 PRODUCT_CLASS Anti-infectives 114875-68-2 KP-736 MODE_CLASS Enzyme Inhibitor 107233-08-9 CEVIMELINE MODE_CLASS Receptor Agonist 107233-08-9 CEVIMELINE MECHANISM Modulate G-protein coupled signal transduction 107233-08-9 CEVIMELINE INDICATION Alzheimer's Disease 113045-80-0 NAD-394 PRODUCT_CLASS Anti-infectives 113045-80-0 NAD-394 MECHANISM Inhibit bacterial DNA synthesis 113045-80-0 NAD-394 MODE_CLASS Enzyme Inhibitor, selective 113045-80-0 NAD-394 THERAPEUTIC_CLASS Antibacterials 113045-80-0 NAD-394 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 125533-88-2 MOFAROTENE ADVERSE_EFFECT XXX_2_Fatigue 125533-88-2 MOFAROTENE THERAPEUTIC_CLASS Antineoplastics 125533-88-2 MOFAROTENE INDICATION Ovarian Cancer / Carcinoma of the Ovary 125533-88-2 MOFAROTENE INDICATION Breast Cancer / Carcinoma of the Breast 125533-88-2 MOFAROTENE ADVERSE_EFFECT GIS_1_Cheilitis 125533-88-2 MOFAROTENE ADVERSE_EFFECT OCU_3_Blindness 125533-88-2 MOFAROTENE INDICATION Lung Cancer / Carcinoma of the Lung 125533-88-2 MOFAROTENE INDICATION Cervical Cancer / Carcinoma of the Cervix 125533-88-2 MOFAROTENE ADVERSE_EFFECT SKN_2_Skin Sloughing 125533-88-2 MOFAROTENE ADVERSE_EFFECT XXX_2_Weight Loss 125533-88-2 MOFAROTENE PRODUCT_CLASS Anti-cancers 125533-88-2 MOFAROTENE INDICATION Non-Small Cell Lung Carcinoma 125533-88-2 MOFAROTENE ADVERSE_EFFECT SKN_3_Skin Toxicity 125533-88-2 MOFAROTENE INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 125533-88-2 MOFAROTENE INDICATION Neoplasm / Cancer / Tumor 125533-88-2 MOFAROTENE ADVERSE_EFFECT SKN_1_Dry Skin 124750-95-4 DUP-532 INDICATION Hypertension 124750-95-4 DUP-532 PRODUCT_CLASS Cardiovasculars 124750-95-4 DUP-532 THERAPEUTIC_CLASS Antihypertensive Agents 124750-95-4 DUP-532 MECHANISM Reduce vasoconstriction 124750-95-4 DUP-532 MODE_CLASS Receptor Ligand Antagonist, Selective 80177-51-1 ORG-7797 THERAPEUTIC_CLASS Antiarrhythmic Agents 80177-51-1 ORG-7797 INDICATION Cardiac Arrhythmias 80177-51-1 ORG-7797 PRODUCT_CLASS Cardiovasculars 120280-91-3 RO-31-6930 INDICATION Hypertension 120280-91-3 RO-31-6930 MODE_CLASS Channel Modulator 120280-91-3 RO-31-6930 PRODUCT_CLASS Cardiovasculars 120280-91-3 RO-31-6930 MECHANISM Modulate channel gating 120280-91-3 RO-31-6930 THERAPEUTIC_CLASS Antihypertensive Agents 126869-04-3 IGN-2098 INDICATION Ulcer 126869-04-3 IGN-2098 MECHANISM Reduce stomach HCl secretion 126869-04-3 IGN-2098 MODE_CLASS Receptor Ligand Antagonist, Selective 103337-74-2 LETRAZURIL THERAPEUTIC_CLASS Antiparasitics 103337-74-2 LETRAZURIL INDICATION Coccidiosis 103337-74-2 LETRAZURIL PRODUCT_CLASS Anti-infectives 81846-19-7 TREPROSTINIL MODE_CLASS Receptor Agonist, selective 81846-19-7 TREPROSTINIL MECHANISM Reduce vasoconstriction 128196-01-0 (+)-(S)-CITALOPRAM THERAPEUTIC_CLASS Antidepressants 128196-01-0 (+)-(S)-CITALOPRAM STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 128196-01-0 (+)-(S)-CITALOPRAM MECHANISM Prolong/enhance neural transmission 128196-01-0 (+)-(S)-CITALOPRAM PRODUCT_CLASS Central Nervous System (CNS) 128196-01-0 (+)-(S)-CITALOPRAM MODE_CLASS Solute transporter inhibitor 128196-01-0 (+)-(S)-CITALOPRAM INDICATION Depression 121104-96-9 CELGOSIVIR MODE_CLASS Enzyme Inhibitor 121104-96-9 CELGOSIVIR INDICATION Myocardial Ischemia 121104-96-9 CELGOSIVIR INDICATION Malaria 127595-43-1 BIMU-1 MODE_CLASS Solute transporter inhibitor 127595-43-1 BIMU-1 MECHANISM Prolong/enhance neural transmission 127595-43-1 BIMU-1 MECHANISM Block neural transmission 127595-43-1 BIMU-1 MODE_CLASS Channel Blocker 127595-43-1 BIMU-1 INDICATION Nausea / Vomiting 120551-59-9 CRILVASTATIN MODE_CLASS Enzyme Inhibitor 120551-59-9 CRILVASTATIN INDICATION Hyperlipidemia 120551-59-9 CRILVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 120551-59-9 CRILVASTATIN INDICATION Hypercholesterolemia 120551-59-9 CRILVASTATIN MECHANISM Inhibit cholesterol biosynthesis 120551-59-9 CRILVASTATIN PRODUCT_CLASS Cardiovasculars 106400-18-4 LOMETREXOL ADVERSE_EFFECT BBM_2_Anemia 106400-18-4 LOMETREXOL INDICATION Neoplasm / Cancer / Tumor 106400-18-4 LOMETREXOL INDICATION Head and Neck Cancer 106400-18-4 LOMETREXOL INDICATION Non-Small Cell Lung Carcinoma 106400-18-4 LOMETREXOL MECHANISM Inhibit precursor synthesis 106400-18-4 LOMETREXOL ADVERSE_EFFECT XXX_1_Mucositis 106400-18-4 LOMETREXOL ADVERSE_EFFECT KID_2_Impaired Renal Tubular Function 106400-18-4 LOMETREXOL INDICATION Melanoma 106400-18-4 LOMETREXOL ADVERSE_EFFECT GIS_2_Diarrhea 106400-18-4 LOMETREXOL ADVERSE_EFFECT BBM_3_Thrombocytopenia 106400-18-4 LOMETREXOL INDICATION Carcinoid Tumors 106400-18-4 LOMETREXOL MODE_CLASS Enzyme Inhibitor 106400-18-4 LOMETREXOL ADVERSE_EFFECT BBM_3_Myelosuppression 106400-18-4 LOMETREXOL PRODUCT_CLASS Anti-cancers 106400-18-4 LOMETREXOL INDICATION Breast Cancer / Carcinoma of the Breast 106400-18-4 LOMETREXOL THERAPEUTIC_CLASS Antineoplastics 106400-18-4 LOMETREXOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 106400-18-4 LOMETREXOL ADVERSE_EFFECT GIS_2_Constipation 106400-18-4 LOMETREXOL STRUCTURE_ACTIVITY Antifolate 106400-18-4 LOMETREXOL ADVERSE_EFFECT GIS_2_Stomatitis 122795-43-1 GADODIAMIDE INDICATION Contrasting Agent 122795-43-1 GADODIAMIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 163680-77-1 PAZUFLOXACIN PRODUCT_CLASS Anti-infectives 163680-77-1 PAZUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 163680-77-1 PAZUFLOXACIN THERAPEUTIC_CLASS Antibacterials 163680-77-1 PAZUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 163680-77-1 PAZUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 112362-50-2 DALFOPRISTIN MECHANISM Inhibit ribosomal protein synthesis 112362-50-2 DALFOPRISTIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 131185-37-0 FK-838 INDICATION Hypertension 131185-37-0 FK-838 THERAPEUTIC_CLASS Antihypertensive Agents 131185-37-0 FK-838 PRODUCT_CLASS Cardiovasculars 124669-24-5 DUP-860 STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 131831-03-3 SUNEPITRON HYDROCHLORIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 131831-03-3 SUNEPITRON HYDROCHLORIDE MECHANISM Modulate neural transmission 131831-03-3 SUNEPITRON HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 131831-03-3 SUNEPITRON HYDROCHLORIDE INDICATION Anxiety Disorders 131831-03-3 SUNEPITRON HYDROCHLORIDE INDICATION Depression 131831-03-3 SUNEPITRON HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 131831-03-3 SUNEPITRON HYDROCHLORIDE MECHANISM Modulate G-protein coupled signal transduction 133563-46-9 BW-534U87 MECHANISM Block neural transmission 133563-46-9 BW-534U87 PRODUCT_CLASS Central Nervous System (CNS) 133563-46-9 BW-534U87 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 133563-46-9 BW-534U87 MODE_CLASS Channel Blocker 99732-49-7 COLFOSCERIL PALMITATE INDICATION Acute Respiratory Distress Syndrome (ARDS) 133208-93-2 NO-1886 INDICATION Hypolipidemia 133718-29-3 REVIZINONE MODE_CLASS Enzyme Inhibitor 133718-29-3 REVIZINONE MECHANISM Enhance kinase mediated signal transduction 141626-36-0 DRONEDARONE MECHANISM Modulate G-protein coupled signal transduction 141626-36-0 DRONEDARONE THERAPEUTIC_CLASS Antianginals 141626-36-0 DRONEDARONE INDICATION Angina Pectoris 141626-36-0 DRONEDARONE THERAPEUTIC_CLASS Antiarrhythmic Agents 141626-36-0 DRONEDARONE PRODUCT_CLASS Cardiovasculars 141626-36-0 DRONEDARONE INDICATION Cardiac Arrhythmias 142217-69-4 SQ-34676 STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 132036-36-3 YM-114 INDICATION Irritable Bowel Syndrome 132036-36-3 YM-114 INDICATION Nausea / Vomiting 132036-36-3 YM-114 MECHANISM Block neural transmission 132036-36-3 YM-114 MODE_CLASS Channel Blocker 129299-88-3 FABESETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 129299-88-3 FABESETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 129299-88-3 FABESETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 129299-88-3 FABESETRON HYDROCHLORIDE MECHANISM Block neural transmission 129299-88-3 FABESETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 70476-82-3 MITOXANTRONE MECH_LEVEL_1 Intercalates into the miner groove of DNA 70476-82-3 MITOXANTRONE MECH_LEVEL_3 DNA intercalator 70476-82-3 MITOXANTRONE INDICATION Acute Lymphocytic Leukemia (ALL) 70476-82-3 MITOXANTRONE INDICATION Neoplasm / Cancer / Tumor 70476-82-3 MITOXANTRONE INDICATION Multiple Sclerosis (MS) 70476-82-3 MITOXANTRONE KNOWN_TOXICITY Hepatotoxicity 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Hepatotoxicity 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Anemia 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Leukopenia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_1_Decreased Left Ventricular Ejection Fraction (LVEF) 70476-82-3 MITOXANTRONE ADVERSE_EFFECT XXX_1_Mucositis 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_2_Diarrhea 70476-82-3 MITOXANTRONE ADVERSE_EFFECT OCU_2_Conjunctivitis 70476-82-3 MITOXANTRONE ADVERSE_EFFECT SKN_2_Skin Rash 70476-82-3 MITOXANTRONE INDICATION Breast Cancer / Carcinoma of the Breast 70476-82-3 MITOXANTRONE ADVERSE_EFFECT SKN_1_Nail Discoloration 70476-82-3 MITOXANTRONE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 70476-82-3 MITOXANTRONE THERAPEUTIC_CLASS Antineoplastics 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_2_Constipation 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Oral Ulceration 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_1_Cardiomyopathy 70476-82-3 MITOXANTRONE ADVERSE_EFFECT BBM_1_Neutropenia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 70476-82-3 MITOXANTRONE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 70476-82-3 MITOXANTRONE PRODUCT_CLASS Anti-cancers 70476-82-3 MITOXANTRONE INDICATION Ovarian Cancer / Carcinoma of the Ovary 70476-82-3 MITOXANTRONE MESH_LEVEL_1 Organic Chemicals 70476-82-3 MITOXANTRONE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 70476-82-3 MITOXANTRONE ADVERSE_EFFECT SKN_2_Skin Necrosis 70476-82-3 MITOXANTRONE KNOWN_TOXICITY Carcinogenicity 70476-82-3 MITOXANTRONE TA_LEVEL_1 Oncology 70476-82-3 MITOXANTRONE MESH_LEVEL_2 Quinones 70476-82-3 MITOXANTRONE TA_LEVEL_2 antineoplastic 70476-82-3 MITOXANTRONE KNOWN_TOXICITY Cardiovascular Toxicity 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GUS_1_Discoloration of Urine 70476-82-3 MITOXANTRONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_1_Phlebitis 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Dyspepsia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT XXX_2_Asthenia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 70476-82-3 MITOXANTRONE ADVERSE_EFFECT NEU_3_Seizures 70476-82-3 MITOXANTRONE ADVERSE_EFFECT XXX_2_Malaise 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Stomatitis 70476-82-3 MITOXANTRONE ADVERSE_EFFECT BBM_1_Thrombocytopenia 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Congestive Heart Failure 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Pancytopenia 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 70476-82-3 MITOXANTRONE ADVERSE_EFFECT BBM_1_Myelosuppression 70476-82-3 MITOXANTRONE ADVERSE_EFFECT XXX_2_Edema 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_2_Chest Pain 70476-82-3 MITOXANTRONE MECHANISM Inhibit DNA synthesis, repair, and function 70476-82-3 MITOXANTRONE STRUCTURE_ACTIVITY DNA intercalator 70476-82-3 MITOXANTRONE INDICATION Hepatocellular Carcinoma 70476-82-3 MITOXANTRONE INDICATION Prostatic Cancer / Carcinoma of the Prostate 70476-82-3 MITOXANTRONE TA_LEVEL_3 Acute Myelogenous (Myeloid) Leukemia (AML) 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Gastrointestinal Bleeding 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Thrombocytopenia 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Myelosuppression 70476-82-3 MITOXANTRONE KNOWN_TOXICITY Gastrointestinal Toxicity 70476-82-3 MITOXANTRONE ADVERSE_EFFECT DNA_3_Secondary Malignanacy 70476-82-3 MITOXANTRONE ADVERSE_EFFECT REP_3_Amenorrhea 70476-82-3 MITOXANTRONE ADVERSE_EFFECT SKN_2_Skin Ulcer 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Abdominal Pain 70476-82-3 MITOXANTRONE ADVERSE_EFFECT GIS_1_Esophagitis 70476-82-3 MITOXANTRONE ADVERSE_EFFECT BBM_1_Anemia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_2_Congestive Heart Failure 70476-82-3 MITOXANTRONE ADVERSE_EFFECT BBM_1_Leukopenia 70476-82-3 MITOXANTRONE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 70476-82-3 MITOXANTRONE ACTIVITY_CLASS DNA damager 70476-82-3 MITOXANTRONE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT XXX_3_Tumor Lysis Syndrome 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Neutropenia 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Cardiomyopathy 70476-82-3 MITOXANTRONE TISSUE_TOXICITY Secondary Malignanacy 70476-82-3 MITOXANTRONE ADVERSE_EFFECT BBM_1_Pancytopenia 70476-82-3 MITOXANTRONE ADVERSE_EFFECT REP__Impotence 70476-82-3 MITOXANTRONE ZERO_CLASS N 70476-82-3 MITOXANTRONE MESH_LEVEL_3 Anthraquinones 70476-82-3 MITOXANTRONE MECH_LEVEL_2 interferes with the function of DNA topoisomerase II, as a result indirectly interferes with the function of DNA polymerase and DNA directed RNA polymerase. 70476-82-3 MITOXANTRONE INDICATION Non-Hodgkin's Lymphomas 70476-82-3 MITOXANTRONE INDICATION Acute Non-Lymphocytic Leukemia 83919-23-7 MOMETASONE FUROATE INDICATION Atopic Dermatitis / Eczema 83919-23-7 MOMETASONE FUROATE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 83919-23-7 MOMETASONE FUROATE PRODUCT_CLASS Anti-inflammatories 83919-23-7 MOMETASONE FUROATE INDICATION Viral Rhinitis / Common Cold 83919-23-7 MOMETASONE FUROATE MECHANISM Modulate gene transcription 83919-23-7 MOMETASONE FUROATE THERAPEUTIC_CLASS Corticosteroids, Topical 83919-23-7 MOMETASONE FUROATE MODE_CLASS Receptor Agonist 142522-81-4 MONTELUKAST MECHANISM Modulate G-protein coupled signal transduction 142522-81-4 MONTELUKAST ADVERSE_EFFECT SKN_3_Maculopapular Rash 142522-81-4 MONTELUKAST INDICATION Prophylaxis of Bronchospasm 142522-81-4 MONTELUKAST ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 142522-81-4 MONTELUKAST ADVERSE_EFFECT NEU_2_Dizziness 142522-81-4 MONTELUKAST ADVERSE_EFFECT GIS_3_Nausea / Vomiting 142522-81-4 MONTELUKAST ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 142522-81-4 MONTELUKAST INDICATION Asthma 142522-81-4 MONTELUKAST ADVERSE_EFFECT GIS_2_Dyspepsia 142522-81-4 MONTELUKAST ADVERSE_EFFECT _3_Churg-Strauss syndrome 142522-81-4 MONTELUKAST ADVERSE_EFFECT LIV_3_Hepatitis 142522-81-4 MONTELUKAST ADVERSE_EFFECT CVS_2_Vasculitis 142522-81-4 MONTELUKAST ADVERSE_EFFECT NEU_3_Seizures 142522-81-4 MONTELUKAST ADVERSE_EFFECT MSK_3_Myalgia 142522-81-4 MONTELUKAST ADVERSE_EFFECT IMU_3_Eosinophilia 142522-81-4 MONTELUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 142522-81-4 MONTELUKAST ADVERSE_EFFECT SKN_3_Rash 142522-81-4 MONTELUKAST MODE_CLASS Receptor Ligand Antagonist 142522-81-4 MONTELUKAST PRODUCT_CLASS Respiratory System 142522-81-4 MONTELUKAST ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 142522-81-4 MONTELUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 142522-81-4 MONTELUKAST ADVERSE_EFFECT GIS_3_Abdominal Pain 112885-41-3 MOSAPRIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 112885-41-3 MOSAPRIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 112885-41-3 MOSAPRIDE MECH_LEVEL_3 5HT receptor 4 112885-41-3 MOSAPRIDE MECH_LEVEL_2 5HT antagonist 112885-41-3 MOSAPRIDE ADVERSE_EFFECT END_3_Hypertriglyceridemia 112885-41-3 MOSAPRIDE ADVERSE_EFFECT IMU_3_Eosinophilia 112885-41-3 MOSAPRIDE MECHANISM Modulate neural transmission 112885-41-3 MOSAPRIDE PRODUCT_CLASS Gastrointestinal System 112885-41-3 MOSAPRIDE STRUCTURE_ACTIVITY 5HT4 agonist 112885-41-3 MOSAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 112885-41-3 MOSAPRIDE INDICATION Chronic Gastritis 112885-41-3 MOSAPRIDE ADVERSE_EFFECT NEU_2_Headache 112885-41-3 MOSAPRIDE ACTIVITY_CLASS Serotonin agonist 112885-41-3 MOSAPRIDE ZERO_CLASS N 112885-41-3 MOSAPRIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 112885-41-3 MOSAPRIDE MESH_LEVEL_1 Organic Chemicals 112885-41-3 MOSAPRIDE INDICATION Diabetic Gastric Stasis 112885-41-3 MOSAPRIDE ADVERSE_EFFECT GIS_2_Dry Mouth 112885-41-3 MOSAPRIDE ADVERSE_EFFECT CVS_2_Palpitation 112885-41-3 MOSAPRIDE TA_LEVEL_2 5HT3 agonists 112885-41-3 MOSAPRIDE TA_LEVEL_1 Gastrointestinal System 112885-41-3 MOSAPRIDE MESH_LEVEL_2 Amides 112885-41-3 MOSAPRIDE MESH_LEVEL_3 Benzamides 112885-41-3 MOSAPRIDE INDICATION Gastroesophageal Reflux Disease (GERD) 112885-41-3 MOSAPRIDE MODE_CLASS Receptor Agonist 112885-41-3 MOSAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 112885-41-3 MOSAPRIDE ADVERSE_EFFECT XXX_2_Malaise 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Depression 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 151096-09-2 MOXIFLOXACIN TISSUE_TOXICITY Cardiovascular Collapse 151096-09-2 MOXIFLOXACIN PRODUCT_CLASS Anti-infectives 151096-09-2 MOXIFLOXACIN INDICATION Skin and Skin Structure Infections 151096-09-2 MOXIFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 151096-09-2 MOXIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT MSK_2_Back Pain 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT LUN_3_Respiratory Distress Syndrome 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Shock 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Lightheadedness 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Loss of Consciousness 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_2_Allergic Reactions 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Dysgeusia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT BBM_2_Coagulopathy 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_2_Asthenia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT LIV_1_Impaired Liver Function 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Nightmares 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Angioedema 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Paresthesia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 151096-09-2 MOXIFLOXACIN TISSUE_TOXICITY Shock 151096-09-2 MOXIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 151096-09-2 MOXIFLOXACIN INDICATION Sinusitis 151096-09-2 MOXIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_2_Phototoxicity 151096-09-2 MOXIFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 151096-09-2 MOXIFLOXACIN TISSUE_TOXICITY Hypotension 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT OCU_2_Amblyopia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_2_Chills 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Paranoia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Urticaria 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_2_Confusion 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_1_Headache 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 151096-09-2 MOXIFLOXACIN THERAPEUTIC_CLASS Antibacterials 151096-09-2 MOXIFLOXACIN INDICATION Pneumonia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Dyspepsia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT MSK_2_Arthralgia 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_3_Facial Edema 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_3_Restlessness 151096-09-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Seizures 12650-69-0 MUPIROCIN MECHANISM Inhibit protein synthesis 12650-69-0 MUPIROCIN MODE_CLASS Enzyme Inhibitor 140401-05-4 MYCOPHENOLATE MOFETIL TA_LEVEL_1 Anti-inflammatory 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT MSK_2_Arthralgia 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Anemia 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT SKN_1_Rash 140401-05-4 MYCOPHENOLATE MOFETIL THERAPEUTIC_CLASS Immunosuppressants 140401-05-4 MYCOPHENOLATE MOFETIL MECH_LEVEL_1 Immunomodulation 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Embryo/Fetal Toxicity 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Nephrotoxicity 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT END_2_Diabetes 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Pain 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Edema 140401-05-4 MYCOPHENOLATE MOFETIL INDICATION Prophylaxis of Organ Transplant Rejection 140401-05-4 MYCOPHENOLATE MOFETIL PRODUCT_CLASS Immune Response / Immunomodulators 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Leukopenia 140401-05-4 MYCOPHENOLATE MOFETIL MESH_LEVEL_1 Organic Chemicals 140401-05-4 MYCOPHENOLATE MOFETIL TA_LEVEL_3 immunosuppressant 140401-05-4 MYCOPHENOLATE MOFETIL MESH_LEVEL_3 Acids, Carbocyclic 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Vomiting 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Infection 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Leukopenia 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT KID_1_Renal Dysfunction 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Sepsis 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_1_Hypertension 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Sepsis 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Tubular Necrosis 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Genotoxicity 140401-05-4 MYCOPHENOLATE MOFETIL ZERO_CLASS N 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Lymphoma 140401-05-4 MYCOPHENOLATE MOFETIL MECHANISM Inhibit precursor synthesis 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Fever 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_2_Opportunistic Infection 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_2_Angina Pectoris 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT KID_2_Tubular Necrosis 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Thrombocytopenia 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Thrombocytopenia 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT DNA_1_Lymphoma 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Electrolyte Disturbance 140401-05-4 MYCOPHENOLATE MOFETIL MECH_LEVEL_3 IMP dehydrogenase 140401-05-4 MYCOPHENOLATE MOFETIL TA_LEVEL_2 Immune Response / Immunomodulators 140401-05-4 MYCOPHENOLATE MOFETIL STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, IMP dehydrogenase inhibitor 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Teratogenicity 140401-05-4 MYCOPHENOLATE MOFETIL MECH_LEVEL_2 Inhibit precursor synthesis 140401-05-4 MYCOPHENOLATE MOFETIL MESH_LEVEL_2 Carboxylic Acids 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT NEU_1_Tremor 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT NEU_1_Paresthesia 140401-05-4 MYCOPHENOLATE MOFETIL MODE_CLASS Enzyme Inhibitor 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Abdominal Pain 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT ELT_1_Fluid and Electrolyte Disturbance 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_2_Ecchymosis 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT END_1_Hypercholesteremia 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT EMB_1_Teratogenicity 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Miscellaneous 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Carcinogenicity 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Cardiac Arrhythmia 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Fluid and Electrolyte Disturbance 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Peripheral Edema 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT DNA_2_Genotoxicity 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Diarrhea 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT PSY_1_Insomnia 140401-05-4 MYCOPHENOLATE MOFETIL ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Cardiovascular Toxicity 140401-05-4 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Mutagenicity 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Anemia 140401-05-4 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Angina Pectoris 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LIV_1_Abnormal Liver Function 140401-05-4 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LUN_3_Atelectasis 16485-10-2 PANTHENOL INDICATION Paralytic Ileus 16485-10-2 PANTHENOL ADVERSE_EFFECT IMU_3_Contact Dermatitis 16485-10-2 PANTHENOL ADVERSE_EFFECT IMU_3_Allergic Reactions 16485-10-2 PANTHENOL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 16485-10-2 PANTHENOL THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 16485-10-2 PANTHENOL INDICATION Insect Bites or Stings 16485-10-2 PANTHENOL PRODUCT_CLASS Dermatologicals 16485-10-2 PANTHENOL ADVERSE_EFFECT GIS_3_Colic 16485-10-2 PANTHENOL ADVERSE_EFFECT SKN_3_Pruritis 16485-10-2 PANTHENOL THERAPEUTIC_CLASS Prokinetic Agents 16485-10-2 PANTHENOL INDICATION Gastroparesis 16485-10-2 PANTHENOL PRODUCT_CLASS Gastrointestinal System 16485-10-2 PANTHENOL ADVERSE_EFFECT PSY_3_Agitation 16485-10-2 PANTHENOL ADVERSE_EFFECT GIS_3_Diarrhea 16485-10-2 PANTHENOL PRODUCT_CLASS Vitamins, Minerals and Nutrients 16485-10-2 PANTHENOL INDICATION Dermatitis 16485-10-2 PANTHENOL MECHANISM Vitamin/ cofactor 16485-10-2 PANTHENOL TISSUE_TOXICITY Hypotension 16485-10-2 PANTHENOL KNOWN_TOXICITY Cardiovascular Toxicity 16485-10-2 PANTHENOL INDICATION Pruritus / Itching 16485-10-2 PANTHENOL STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 16485-10-2 PANTHENOL ADVERSE_EFFECT IMU_3_Urticaria 16485-10-2 PANTHENOL ADVERSE_EFFECT CVS_3_Hypotension 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT IMU_3_Contact Dermatitis 1263-89-4 PAROMOMYCIN INDICATION Hepatic Encephalopathy 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT KID_3_Anuria 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT KID_3_Renal Failure 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT KID_3_Proteinuria 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT NEU_2_Vertigo 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Acidosis 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT GIS_2_Diarrhea 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT OTO_3_Hearing Loss 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT XXX_3_Superinfection 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT NEU_2_Headache 1263-89-4 PAROMOMYCIN TISSUE_TOXICITY Anuria 1263-89-4 PAROMOMYCIN THERAPEUTIC_CLASS Antiparasitics 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT SKN_3_Skin Rash 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1263-89-4 PAROMOMYCIN PRODUCT_CLASS Anti-infectives 1263-89-4 PAROMOMYCIN INDICATION Intestinal Amebiasis 1263-89-4 PAROMOMYCIN INDICATION Multi-drug Resistant Tuberculosis (MDR-TB) 1263-89-4 PAROMOMYCIN TISSUE_TOXICITY Renal Failure 1263-89-4 PAROMOMYCIN INDICATION Visceral Leishmaniasis / Kala Azar 1263-89-4 PAROMOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 1263-89-4 PAROMOMYCIN KNOWN_TOXICITY Nephrotoxicity 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT GIS_3_Pancreatitis 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT MSK_3_Myasthenia 1263-89-4 PAROMOMYCIN TISSUE_TOXICITY Renal Tubular Necrosis 1263-89-4 PAROMOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1263-89-4 PAROMOMYCIN MECHANISM Inhibit ribosomal protein synthesis 1263-89-4 PAROMOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT _3_Cylinduria 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 1263-89-4 PAROMOMYCIN ADVERSE_EFFECT GIS_1_Epigastric Pain 57186-25-1 PAXILLINE PRODUCT_CLASS Biochemicals 57186-25-1 PAXILLINE MODE_CLASS Channel Modulator 57186-25-1 PAXILLINE MECHANISM Modulate channel gating 121055-09-2 SDZ-PCO-400 PRODUCT_CLASS Respiratory System 121055-09-2 SDZ-PCO-400 MECHANISM Modulate channel gating 121055-09-2 SDZ-PCO-400 MODE_CLASS Channel Modulator 121055-09-2 SDZ-PCO-400 THERAPEUTIC_CLASS Bronchodilators 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 2152-34-3 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 2152-34-3 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 2152-34-3 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 2152-34-3 PEMOLINE ZERO_CLASS N 2152-34-3 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 2152-34-3 PEMOLINE TISSUE_TOXICITY Hepatic Failure 2152-34-3 PEMOLINE MECH_LEVEL_3 Unknown mechanism 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 2152-34-3 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 2152-34-3 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 2152-34-3 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 2152-34-3 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 2152-34-3 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 2152-34-3 PEMOLINE MECHANISM Prolong/enhance neural transmission 2152-34-3 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 2152-34-3 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 2152-34-3 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 2152-34-3 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 2152-34-3 PEMOLINE MESH_LEVEL_3 Oxazoles 2152-34-3 PEMOLINE TA_LEVEL_3 attention deficit syndrome 2152-34-3 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 2152-34-3 PEMOLINE MODE_CLASS Solute transporter inhibitor 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 2152-34-3 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 2152-34-3 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 2152-34-3 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 2152-34-3 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 2152-34-3 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 2152-34-3 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 2152-34-3 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 2152-34-3 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 2152-34-3 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 2152-34-3 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 2152-34-3 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 18968-99-5 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 18968-99-5 PEMOLINE MECHANISM Prolong/enhance neural transmission 18968-99-5 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 18968-99-5 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 18968-99-5 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 18968-99-5 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 18968-99-5 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 18968-99-5 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 18968-99-5 PEMOLINE ZERO_CLASS N 18968-99-5 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 18968-99-5 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 18968-99-5 PEMOLINE TISSUE_TOXICITY Hepatic Failure 18968-99-5 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 18968-99-5 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 18968-99-5 PEMOLINE MECH_LEVEL_3 Unknown mechanism 18968-99-5 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 18968-99-5 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 18968-99-5 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 18968-99-5 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 18968-99-5 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 18968-99-5 PEMOLINE MODE_CLASS Solute transporter inhibitor 18968-99-5 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 18968-99-5 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 18968-99-5 PEMOLINE TA_LEVEL_3 attention deficit syndrome 18968-99-5 PEMOLINE MESH_LEVEL_3 Oxazoles 18968-99-5 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 18968-99-5 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 18968-99-5 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 18968-99-5 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 18968-99-5 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 18968-99-5 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 18968-99-5 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 38363-40-5 PENBUTOLOL MECHANISM Reduce muscle contractile force 38363-40-5 PENBUTOLOL PRODUCT_CLASS Cardiovasculars 38363-40-5 PENBUTOLOL MODE_CLASS Receptor Ligand Antagonist 38363-40-5 PENBUTOLOL THERAPEUTIC_CLASS Antihypertensive Agents 38363-40-5 PENBUTOLOL INDICATION Hypertension 1538-09-6 PENICILLIN G INDICATION Bacteremia 1538-09-6 PENICILLIN G ADVERSE_EFFECT NEU_3_Seizures 1538-09-6 PENICILLIN G ADVERSE_EFFECT BBM_3_Thrombocytopenia 1538-09-6 PENICILLIN G ADVERSE_EFFECT GIS_2_Epigastric Pain 1538-09-6 PENICILLIN G ADVERSE_EFFECT KID_3_Interstitial Nephritis 1538-09-6 PENICILLIN G ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 1538-09-6 PENICILLIN G MESH_LEVEL_3 Lactams 1538-09-6 PENICILLIN G TA_LEVEL_2 Anti-bacterial 1538-09-6 PENICILLIN G INDICATION Rheumatic Fever Prophylaxis 1538-09-6 PENICILLIN G INDICATION Necrotizing Ulcerative Gingivitis (Trench Mouth, Vincent's Infection) 1538-09-6 PENICILLIN G INDICATION Gonococcal Infections / Gonorrhea 1538-09-6 PENICILLIN G INDICATION Diphtheria 1538-09-6 PENICILLIN G THERAPEUTIC_CLASS Antibacterials, Systemic 1538-09-6 PENICILLIN G ADVERSE_EFFECT IMU_1_Hypersensitivity 1538-09-6 PENICILLIN G ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 1538-09-6 PENICILLIN G ADVERSE_EFFECT CVS_1_Phlebitis 1538-09-6 PENICILLIN G ADVERSE_EFFECT KID_3_Nephrotic Syndrome 1538-09-6 PENICILLIN G STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 1538-09-6 PENICILLIN G ZERO_CLASS N 1538-09-6 PENICILLIN G INDICATION Yaws / Frambesia 1538-09-6 PENICILLIN G MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 1538-09-6 PENICILLIN G TA_LEVEL_3 systemic infections 1538-09-6 PENICILLIN G INDICATION Upper Respiratory Tract Infection 1538-09-6 PENICILLIN G INDICATION Acute Rheumatic Fever 1538-09-6 PENICILLIN G INDICATION Neurosyphilis 1538-09-6 PENICILLIN G INDICATION Listeriosis 1538-09-6 PENICILLIN G INDICATION Empyema 1538-09-6 PENICILLIN G INDICATION Anthrax 1538-09-6 PENICILLIN G ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1538-09-6 PENICILLIN G ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 1538-09-6 PENICILLIN G ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 1538-09-6 PENICILLIN G ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 1538-09-6 PENICILLIN G ADVERSE_EFFECT XXX_1_Injection Site Reaction 1538-09-6 PENICILLIN G TISSUE_TOXICITY Interstitial Nephritis 1538-09-6 PENICILLIN G KNOWN_TOXICITY Nephrotoxicity 1538-09-6 PENICILLIN G MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 1538-09-6 PENICILLIN G MESH_LEVEL_1 Organic Chemicals 1538-09-6 PENICILLIN G INDICATION Rat-Bite Fever / Spirillary Rat-Bite Fever / Sodoku 1538-09-6 PENICILLIN G INDICATION Pinta 1538-09-6 PENICILLIN G INDICATION Pericarditis 1538-09-6 PENICILLIN G INDICATION Lower Respiratory Tract Infection 1538-09-6 PENICILLIN G INDICATION Endocarditis 1538-09-6 PENICILLIN G INDICATION Inhalational Anthrax 1538-09-6 PENICILLIN G MECH_LEVEL_1 Anti-bacterial 1538-09-6 PENICILLIN G MODE_CLASS Enzyme Inhibitor 1538-09-6 PENICILLIN G TISSUE_TOXICITY Nephrotic Syndrome 1538-09-6 PENICILLIN G ADVERSE_EFFECT GIS_1_Diarrhea 1538-09-6 PENICILLIN G ADVERSE_EFFECT BBM_3_Anemia 1538-09-6 PENICILLIN G ADVERSE_EFFECT BBM_3_Leukopenia 1538-09-6 PENICILLIN G ADVERSE_EFFECT NEU_3_Neuropathy 1538-09-6 PENICILLIN G ADVERSE_EFFECT ELT_2_Hypernatremia 1538-09-6 PENICILLIN G TA_LEVEL_1 Infectious Disease 1538-09-6 PENICILLIN G MECHANISM Inhibit bacterial cell wall biosynthesis 1538-09-6 PENICILLIN G PRODUCT_CLASS Anti-infectives 1538-09-6 PENICILLIN G MESH_LEVEL_2 Amides 1538-09-6 PENICILLIN G INDICATION Skin and Skin Structure Infections 1538-09-6 PENICILLIN G INDICATION Pharyngitis 1538-09-6 PENICILLIN G INDICATION Meningitis 1538-09-6 PENICILLIN G INDICATION Erysipelas 140-64-7 PENTAMIDINE ADVERSE_EFFECT GIS_2_Pancreatitis 140-64-7 PENTAMIDINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 140-64-7 PENTAMIDINE ADVERSE_EFFECT XXX_3_Xerosis 140-64-7 PENTAMIDINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 140-64-7 PENTAMIDINE ADVERSE_EFFECT ELT_1_Hyperkalemia 140-64-7 PENTAMIDINE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 140-64-7 PENTAMIDINE MECHANISM Inhibit protein synthesis 140-64-7 PENTAMIDINE MESH_LEVEL_3 Benzamidines 140-64-7 PENTAMIDINE INDICATION African Trypanosomiasis / Sleeping Sickness 140-64-7 PENTAMIDINE TA_LEVEL_2 Anti-protozoal 140-64-7 PENTAMIDINE ADVERSE_EFFECT KID_1_Nephrotoxicity 140-64-7 PENTAMIDINE THERAPEUTIC_CLASS Antiparasitics 140-64-7 PENTAMIDINE KNOWN_TOXICITY Cardiovascular Toxicity 140-64-7 PENTAMIDINE ADVERSE_EFFECT LUN_3_Cough 140-64-7 PENTAMIDINE MESH_LEVEL_1 Organic Chemicals 140-64-7 PENTAMIDINE ADVERSE_EFFECT PSY_1_Confusion 140-64-7 PENTAMIDINE MECH_LEVEL_3 Inhibits RNA splicing 140-64-7 PENTAMIDINE TA_LEVEL_3 pneumocytosis carinii 140-64-7 PENTAMIDINE PRODUCT_CLASS Anti-infectives 140-64-7 PENTAMIDINE ADVERSE_EFFECT ELT_1_Hypocalcemia 140-64-7 PENTAMIDINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 140-64-7 PENTAMIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 140-64-7 PENTAMIDINE ADVERSE_EFFECT PSY_2_Anorexia 140-64-7 PENTAMIDINE ADVERSE_EFFECT SKN_3_Pruritis 140-64-7 PENTAMIDINE ADVERSE_EFFECT ELT_1_Hypomagnesemia 140-64-7 PENTAMIDINE INDICATION Leishmaniasis 140-64-7 PENTAMIDINE INDICATION Pneumocystis Carinii Pneumonia (PCP) 140-64-7 PENTAMIDINE MECH_LEVEL_2 RNA processing 140-64-7 PENTAMIDINE TISSUE_TOXICITY Nephrotoxicity 140-64-7 PENTAMIDINE ADVERSE_EFFECT KID_2_Azotemia 140-64-7 PENTAMIDINE ADVERSE_EFFECT LUN_3_Bronchospasm 140-64-7 PENTAMIDINE ADVERSE_EFFECT NEU_1_Dizziness 140-64-7 PENTAMIDINE ADVERSE_EFFECT BBM_3_Leukopenia 140-64-7 PENTAMIDINE ADVERSE_EFFECT SKN_3_Erythema 140-64-7 PENTAMIDINE TISSUE_TOXICITY Hypotension 140-64-7 PENTAMIDINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 140-64-7 PENTAMIDINE THERAPEUTIC_CLASS Antibacterials, Systemic 140-64-7 PENTAMIDINE ADVERSE_EFFECT CVS_1_Hypotension 140-64-7 PENTAMIDINE ACTIVITY_CLASS Antibiotic 140-64-7 PENTAMIDINE STRUCTURE_ACTIVITY RNA splicing inhibitor, antiparasitics 140-64-7 PENTAMIDINE MESH_LEVEL_2 Amidines 140-64-7 PENTAMIDINE MECH_LEVEL_1 Anti-protozoal 140-64-7 PENTAMIDINE INDICATION Pneumonia 140-64-7 PENTAMIDINE ADVERSE_EFFECT END_1_Hypoglycemia 140-64-7 PENTAMIDINE KNOWN_TOXICITY Nephrotoxicity 140-64-7 PENTAMIDINE ADVERSE_EFFECT XXX_3_Fatigue 140-64-7 PENTAMIDINE ADVERSE_EFFECT GIS_2_Sialadenitis 140-64-7 PENTAMIDINE ADVERSE_EFFECT BBM_3_Anemia 140-64-7 PENTAMIDINE ADVERSE_EFFECT IMU_3_Urticaria 140-64-7 PENTAMIDINE ZERO_CLASS N 140-64-7 PENTAMIDINE TISSUE_TOXICITY Renal Tubular Necrosis 140-64-7 PENTAMIDINE ADVERSE_EFFECT NEU_1_Neuralgia 140-64-7 PENTAMIDINE ADVERSE_EFFECT GIS_2_Dysgeusia 140-64-7 PENTAMIDINE INDICATION American Trypanosomiasis / Chagas' Disease 140-64-7 PENTAMIDINE TA_LEVEL_1 Infectious Disease 68964-90-9 PENTAZOCINE STRUCTURE_ACTIVITY Sigma receptor modulator 68964-90-9 PENTAZOCINE MODE_CLASS Receptor Partial Agonist 68964-90-9 PENTAZOCINE MECHANISM Modulate neural transmission 68964-90-9 PENTAZOCINE MODE_CLASS Receptor Agonist 68964-90-9 PENTAZOCINE INDICATION Severe Pain 68964-90-9 PENTAZOCINE PRODUCT_CLASS Analgesics 68964-90-9 PENTAZOCINE INDICATION Moderate Pain 68964-90-9 PENTAZOCINE THERAPEUTIC_CLASS Analgesics, Opioid 63677-95-2 PENTOSTATIN INDICATION Hairy Cell Leukemia 63677-95-2 PENTOSTATIN PRODUCT_CLASS Anti-cancers 63677-95-2 PENTOSTATIN THERAPEUTIC_CLASS Antineoplastics 63677-95-2 PENTOSTATIN MODE_CLASS Enzyme Inhibitor 66104-22-1 PERGOLIDE ADVERSE_EFFECT MSK_2_Myalgia 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_2_Akathisia 66104-22-1 PERGOLIDE ADVERSE_EFFECT OCU_2_Diplopia 66104-22-1 PERGOLIDE ZERO_CLASS N 66104-22-1 PERGOLIDE TISSUE_TOXICITY Hypotension 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_3_Syncope 66104-22-1 PERGOLIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Weight Loss 66104-22-1 PERGOLIDE MECH_LEVEL_1 Modulate neural transmission 66104-22-1 PERGOLIDE MECH_LEVEL_2 Prolong/enhance neural transmission 66104-22-1 PERGOLIDE INDICATION Parkinson's Disease 66104-22-1 PERGOLIDE ADVERSE_EFFECT GIS_1_Diarrhea 66104-22-1 PERGOLIDE ADVERSE_EFFECT CVS_2_Hypotension 66104-22-1 PERGOLIDE ADVERSE_EFFECT PSY_1_Insomnia 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_2_Dizziness 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_1_Dyskinesia 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_1_Dystonia 66104-22-1 PERGOLIDE ADVERSE_EFFECT CVS_2_Palpitation 66104-22-1 PERGOLIDE TA_LEVEL_2 movement disorders 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Rhinitis 66104-22-1 PERGOLIDE MESH_LEVEL_1 Heterocyclic Compounds 66104-22-1 PERGOLIDE ADVERSE_EFFECT PSY_1_Hallucinations 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_2_Drowsiness 66104-22-1 PERGOLIDE THERAPEUTIC_CLASS Movement Disorders 66104-22-1 PERGOLIDE ADVERSE_EFFECT CVS_2_Myocardial Infarction 66104-22-1 PERGOLIDE ADVERSE_EFFECT LUN_3_Dyspnea 66104-22-1 PERGOLIDE ACTIVITY_CLASS Ergot alkaloid 66104-22-1 PERGOLIDE KNOWN_TOXICITY Cardiovascular Toxicity 66104-22-1 PERGOLIDE TISSUE_TOXICITY Myocardial Infarction 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Xerostomia 66104-22-1 PERGOLIDE ADVERSE_EFFECT GIS_1_Dyspepsia 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Weight Gain 66104-22-1 PERGOLIDE ADVERSE_EFFECT PSY_2_Psychosis 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Withdrawal 66104-22-1 PERGOLIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 66104-22-1 PERGOLIDE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 66104-22-1 PERGOLIDE ADVERSE_EFFECT GIS_1_Constipation 66104-22-1 PERGOLIDE MECH_LEVEL_3 dopamine receptor D2 66104-22-1 PERGOLIDE MESH_LEVEL_2 Alkaloids 66104-22-1 PERGOLIDE PRODUCT_CLASS Central Nervous System (CNS) 66104-22-1 PERGOLIDE TA_LEVEL_1 Central Nervous System (CNS) 66104-22-1 PERGOLIDE MESH_LEVEL_3 Ergot Alkaloids 66104-22-1 PERGOLIDE MECHANISM Prolong/enhance neural transmission 66104-22-1 PERGOLIDE MODE_CLASS Receptor Agonist 66104-22-1 PERGOLIDE TA_LEVEL_3 Parkinsons 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Weakness 66104-22-1 PERGOLIDE ADVERSE_EFFECT XXX_2_Fever 66104-22-1 PERGOLIDE ADVERSE_EFFECT CVS_2_Hypertension 66104-22-1 PERGOLIDE ADVERSE_EFFECT PSY_2_Anxiety 66104-22-1 PERGOLIDE STRUCTURE_ACTIVITY Ergot alkaloid 66104-22-1 PERGOLIDE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 66104-22-1 PERGOLIDE ADVERSE_EFFECT MSK_2_Back Pain 114012-12-3 PHACLOFEN PRODUCT_CLASS Biochemicals 114012-12-3 PHACLOFEN MECHANISM Modulate neural transmission 114012-12-3 PHACLOFEN MODE_CLASS Receptor Agonist, selective 77-10-1 PHENCYCLIDINE PRODUCT_CLASS Central Nervous System (CNS) 77-10-1 PHENCYCLIDINE MECHANISM Block neural transmission 77-10-1 PHENCYCLIDINE MODE_CLASS Channel Blocker 77-10-1 PHENCYCLIDINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 108068-98-0 PHENELZINE THERAPEUTIC_CLASS Antidepressants 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 108068-98-0 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 108068-98-0 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 108068-98-0 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 108068-98-0 PHENELZINE MESH_LEVEL_3 Phenelzine 108068-98-0 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 108068-98-0 PHENELZINE TA_LEVEL_2 CNS Stimulant 108068-98-0 PHENELZINE INDICATION Anxiety Disorders 108068-98-0 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 108068-98-0 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 108068-98-0 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 108068-98-0 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 108068-98-0 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 108068-98-0 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 108068-98-0 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 108068-98-0 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 108068-98-0 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 108068-98-0 PHENELZINE MESH_LEVEL_2 Hydrazines 108068-98-0 PHENELZINE INDICATION Depression 108068-98-0 PHENELZINE MODE_CLASS Enzyme Inhibitor 108068-98-0 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 108068-98-0 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 108068-98-0 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 108068-98-0 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 108068-98-0 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 108068-98-0 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 108068-98-0 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 108068-98-0 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 108068-98-0 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 108068-98-0 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 108068-98-0 PHENELZINE MESH_LEVEL_1 Organic Chemicals 108068-98-0 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 108068-98-0 PHENELZINE TA_LEVEL_3 depression 108068-98-0 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 108068-98-0 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 108068-98-0 PHENELZINE ZERO_CLASS N 108068-98-0 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 108068-98-0 PHENELZINE MECHANISM Prolong/enhance neural transmission 108068-98-0 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 108068-98-0 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 108068-98-0 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 108068-98-0 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 108068-98-0 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 108068-98-0 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 4910-46-7 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 4910-46-7 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 4910-46-7 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 4910-46-7 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 4910-46-7 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 4910-46-7 PHENELZINE ZERO_CLASS N 4910-46-7 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 4910-46-7 PHENELZINE TA_LEVEL_3 depression 4910-46-7 PHENELZINE MECHANISM Prolong/enhance neural transmission 4910-46-7 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 4910-46-7 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 4910-46-7 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 4910-46-7 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 4910-46-7 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 4910-46-7 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 4910-46-7 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 4910-46-7 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 4910-46-7 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 4910-46-7 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 4910-46-7 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 4910-46-7 PHENELZINE THERAPEUTIC_CLASS Antidepressants 4910-46-7 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 4910-46-7 PHENELZINE INDICATION Depression 4910-46-7 PHENELZINE MESH_LEVEL_2 Hydrazines 4910-46-7 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 4910-46-7 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 4910-46-7 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 4910-46-7 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 4910-46-7 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 4910-46-7 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 4910-46-7 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 4910-46-7 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 4910-46-7 PHENELZINE MODE_CLASS Enzyme Inhibitor 4910-46-7 PHENELZINE MESH_LEVEL_1 Organic Chemicals 4910-46-7 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 4910-46-7 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 4910-46-7 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 4910-46-7 PHENELZINE MESH_LEVEL_3 Phenelzine 4910-46-7 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 4910-46-7 PHENELZINE TA_LEVEL_2 CNS Stimulant 4910-46-7 PHENELZINE INDICATION Anxiety Disorders 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 4910-46-7 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 4910-46-7 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 4910-46-7 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 82-88-2 PHENINDAMINE MECHANISM Modulate G-protein coupled signal transduction 82-88-2 PHENINDAMINE MODE_CLASS Receptor Ligand Antagonist 77-09-8 PHENOLPHTHALEIN INDICATION Constipation 65-28-1 PHENTOLAMINE MODE_CLASS Channel enhancer /opener 65-28-1 PHENTOLAMINE ZERO_CLASS N 65-28-1 PHENTOLAMINE ADVERSE_EFFECT GIS_2_Stimulation of GI smooth muscle 65-28-1 PHENTOLAMINE TA_LEVEL_1 Cardiovascular 65-28-1 PHENTOLAMINE MECH_LEVEL_2 Alpha antagonist 65-28-1 PHENTOLAMINE INDICATION Pheochromocytoma 65-28-1 PHENTOLAMINE INDICATION Heart Failure 65-28-1 PHENTOLAMINE PRODUCT_CLASS Cardiovasculars 65-28-1 PHENTOLAMINE MECH_LEVEL_3 adrenoceptor alpha 65-28-1 PHENTOLAMINE ADVERSE_EFFECT REP_3_Priapism 65-28-1 PHENTOLAMINE ADVERSE_EFFECT XXX_2_Weakness 65-28-1 PHENTOLAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 65-28-1 PHENTOLAMINE TISSUE_TOXICITY Hypotension 65-28-1 PHENTOLAMINE THERAPEUTIC_CLASS Sympatholytic Agents 65-28-1 PHENTOLAMINE KNOWN_TOXICITY Cardiovascular Toxicity 65-28-1 PHENTOLAMINE TA_LEVEL_3 Hypertension 65-28-1 PHENTOLAMINE MESH_LEVEL_3 Imidazoles 65-28-1 PHENTOLAMINE MECH_LEVEL_1 Vasorelaxation 65-28-1 PHENTOLAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 65-28-1 PHENTOLAMINE MESH_LEVEL_1 Heterocyclic Compounds 65-28-1 PHENTOLAMINE MECHANISM Modulate G-protein coupled signal transduction 65-28-1 PHENTOLAMINE TISSUE_TOXICITY Angina 65-28-1 PHENTOLAMINE ADVERSE_EFFECT SKN_1_Flushing 65-28-1 PHENTOLAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 65-28-1 PHENTOLAMINE ADVERSE_EFFECT GIS_2_Diarrhea 65-28-1 PHENTOLAMINE INDICATION Hypertensive Emergency 65-28-1 PHENTOLAMINE MECHANISM Reduce muscle contractile force 65-28-1 PHENTOLAMINE TA_LEVEL_2 Hypertension 65-28-1 PHENTOLAMINE ADVERSE_EFFECT CVS_1_Hypotension 65-28-1 PHENTOLAMINE THERAPEUTIC_CLASS Vasodilators 65-28-1 PHENTOLAMINE STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 65-28-1 PHENTOLAMINE ADVERSE_EFFECT NEU_2_Dizziness 65-28-1 PHENTOLAMINE ADVERSE_EFFECT CVS_2_Angina 65-28-1 PHENTOLAMINE ADVERSE_EFFECT REP_3_Impaired Ejaculation 65-28-1 PHENTOLAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 65-28-1 PHENTOLAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 65-28-1 PHENTOLAMINE INDICATION Dermal Necrosis 65-28-1 PHENTOLAMINE INDICATION Erectile Dysfunction 65-28-1 PHENTOLAMINE ACTIVITY_CLASS Adrenergic antagonist 65-28-1 PHENTOLAMINE ADVERSE_EFFECT XXX_1_Nasal Congestion 65-28-1 PHENTOLAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT XXX_1_Edema 50-33-9 PHENYLBUTAZONE KNOWN_TOXICITY Hepatotoxicity 50-33-9 PHENYLBUTAZONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 50-33-9 PHENYLBUTAZONE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 50-33-9 PHENYLBUTAZONE TA_LEVEL_2 NSAID 50-33-9 PHENYLBUTAZONE TA_LEVEL_1 Anti-inflammatory 50-33-9 PHENYLBUTAZONE TISSUE_TOXICITY Hepatic Failure 50-33-9 PHENYLBUTAZONE TISSUE_TOXICITY Renal Failure 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT KID_3_Acute Tubular Necrosis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT SKN_2_Skin Rash 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Stomatitis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT LIV_3_Hepatic Failure 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT IMU_3_Anaphylaxis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Diarrhea 50-33-9 PHENYLBUTAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 50-33-9 PHENYLBUTAZONE TISSUE_TOXICITY Fulminant Hepatitis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 50-33-9 PHENYLBUTAZONE TISSUE_TOXICITY Acute Tubular Necrosis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_1_Gastritis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Ulcer Perforation 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Pancreatitis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_1_Nausea 50-33-9 PHENYLBUTAZONE MODE_CLASS Enzyme Inhibitor 50-33-9 PHENYLBUTAZONE TA_LEVEL_3 NSAID 50-33-9 PHENYLBUTAZONE STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT KID_1_Fluid Retention 50-33-9 PHENYLBUTAZONE KNOWN_TOXICITY Cardiovascular Toxicity 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Pancytopenia 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Peptic Ulceration 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT END_3_Hypothyroidism 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 50-33-9 PHENYLBUTAZONE KNOWN_TOXICITY Nephrotoxicity 50-33-9 PHENYLBUTAZONE PRODUCT_CLASS Anti-inflammatories 50-33-9 PHENYLBUTAZONE INDICATION Ankylosing Spondylitis 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 50-33-9 PHENYLBUTAZONE MESH_LEVEL_1 Heterocyclic Compounds 50-33-9 PHENYLBUTAZONE MECHANISM Inhibit eicosanoid biosynthesis 50-33-9 PHENYLBUTAZONE MESH_LEVEL_3 Pyrazoles 50-33-9 PHENYLBUTAZONE MECH_LEVEL_1 Immunomodulation 50-33-9 PHENYLBUTAZONE ZERO_CLASS N 50-33-9 PHENYLBUTAZONE ACTIVITY_CLASS Anti-inflammatory 50-33-9 PHENYLBUTAZONE TISSUE_TOXICITY Cardiac Failure 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT LUN_3_Exacerbation of Asthma 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT KID_3_Renal Failure 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT CVS_3_Cardiac Failure 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 50-33-9 PHENYLBUTAZONE ADVERSE_EFFECT LUN_3_Bronchospasm 50-33-9 PHENYLBUTAZONE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 91374-20-8 ROPINIROLE THERAPEUTIC_CLASS Movement Disorders 91374-20-8 ROPINIROLE MODE_CLASS Receptor Agonist, selective 91374-20-8 ROPINIROLE MODE_CLASS Receptor Agonist 91374-20-8 ROPINIROLE PRODUCT_CLASS Central Nervous System (CNS) 91374-20-8 ROPINIROLE INDICATION Parkinson's Disease 91374-20-8 ROPINIROLE MECHANISM Prolong/enhance neural transmission 122320-73-4 ROSIGLITAZONE MECH_LEVEL_2 Insulin-like response 122320-73-4 ROSIGLITAZONE MECH_LEVEL_3 PPAR gamma 122320-73-4 ROSIGLITAZONE TA_LEVEL_2 insulin sensitizer 122320-73-4 ROSIGLITAZONE MECHANISM Increase transcription of insulin responsive gene 122320-73-4 ROSIGLITAZONE MODE_CLASS Receptor Agonist 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT BBM_2_Anemia 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT REP_2_Induction of Ovulation 122320-73-4 ROSIGLITAZONE TISSUE_TOXICITY Congestive Heart Failure 122320-73-4 ROSIGLITAZONE ACTIVITY_CLASS Anti-diabetic 122320-73-4 ROSIGLITAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 122320-73-4 ROSIGLITAZONE MESH_LEVEL_3 Thiazoles 122320-73-4 ROSIGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT XXX_2_Edema 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT MSK_1_Back Pain 122320-73-4 ROSIGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 122320-73-4 ROSIGLITAZONE TA_LEVEL_3 Thiazolidinedione 122320-73-4 ROSIGLITAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 122320-73-4 ROSIGLITAZONE MECH_LEVEL_1 Glycemia regulation 122320-73-4 ROSIGLITAZONE MECHANISM Increase lipid catabolism 122320-73-4 ROSIGLITAZONE INDICATION Type II Diabetes Mellitus 122320-73-4 ROSIGLITAZONE KNOWN_TOXICITY Cardiovascular Toxicity 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT NEU_1_Headache 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT KID_2_Fluid Retention 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT CVS_3_Cardiomegaly 122320-73-4 ROSIGLITAZONE ZERO_CLASS N 122320-73-4 ROSIGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 122320-73-4 ROSIGLITAZONE MESH_LEVEL_1 Heterocyclic Compounds 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT END_2_Hypoglycemia 122320-73-4 ROSIGLITAZONE ADVERSE_EFFECT XXX_1_Weight Gain 82-08-6 ROTTLERIN PRODUCT_CLASS Biochemicals 82-08-6 ROTTLERIN MECHANISM Inhibit kinase mediated signal transduction 82-08-6 ROTTLERIN MODE_CLASS Enzyme Inhibitor 23672-07-3 LEVOSULPIRIDE MESH_LEVEL_2 Amides 23672-07-3 LEVOSULPIRIDE THERAPEUTIC_CLASS Antiemetics 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT OCU_3_Blurred Vision 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT NEU_1_Drowsiness 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT LUN_3_Hoarseness 23672-07-3 LEVOSULPIRIDE INDICATION Diabetic Gastric Stasis 23672-07-3 LEVOSULPIRIDE TA_LEVEL_3 nausea 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 23672-07-3 LEVOSULPIRIDE MODE_CLASS Receptor Ligand Antagonist 23672-07-3 LEVOSULPIRIDE PRODUCT_CLASS Gastrointestinal System 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT GIS_1_Constipation 23672-07-3 LEVOSULPIRIDE THERAPEUTIC_CLASS Prokinetic Agents 23672-07-3 LEVOSULPIRIDE MESH_LEVEL_3 Benzamides 23672-07-3 LEVOSULPIRIDE INDICATION Reflux Esophagitis 23672-07-3 LEVOSULPIRIDE TA_LEVEL_2 Antiemetic 23672-07-3 LEVOSULPIRIDE TA_LEVEL_1 Gastrointestinal System 23672-07-3 LEVOSULPIRIDE STRUCTURE_ACTIVITY Dopamine receptor (D2) antagonist 23672-07-3 LEVOSULPIRIDE ZERO_CLASS N 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT NEU_1_Sedation 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT NEU_1_Dizziness 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT END_2_Galactorrhea 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT PSY_2_Mental Confusion 23672-07-3 LEVOSULPIRIDE ACTIVITY_CLASS Dopamine antagonist 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT END_3_Breast Tenderness 23672-07-3 LEVOSULPIRIDE MESH_LEVEL_1 Organic Chemicals 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT PSY_3_Anxiety 23672-07-3 LEVOSULPIRIDE MECH_LEVEL_3 dopamine receptor D2 23672-07-3 LEVOSULPIRIDE MECHANISM Block neural transmission 23672-07-3 LEVOSULPIRIDE MECH_LEVEL_2 receptor ligand antagonist 23672-07-3 LEVOSULPIRIDE INDICATION Nausea / Vomiting 23672-07-3 LEVOSULPIRIDE THERAPEUTIC_CLASS Antiulcers 23672-07-3 LEVOSULPIRIDE ADVERSE_EFFECT XXX_2_Salivation 151433-83-9 SABCOMELINE PRODUCT_CLASS Autonomic Nervous System (ANS) 151433-83-9 SABCOMELINE PRODUCT_CLASS Central Nervous System (CNS) 30418-52-1 SAFROLE PRODUCT_CLASS Toxicants 30418-52-1 SAFROLE KNOWN_TOXICITY Cardiovascular Toxicity 30418-52-1 SAFROLE KNOWN_TOXICITY Carcinogenicity 30418-52-1 SAFROLE TISSUE_TOXICITY Shock 30418-52-1 SAFROLE TISSUE_TOXICITY Carcinogenicity 30418-52-1 SAFROLE ADVERSE_EFFECT CVS_3_Shock 30418-52-1 SAFROLE ADVERSE_EFFECT CVS_3_Tachycardia 30418-52-1 SAFROLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 30418-52-1 SAFROLE TA_LEVEL_3 Bone Marrow Toxicants 30418-52-1 SAFROLE MECH_LEVEL_3 DNA damage 30418-52-1 SAFROLE MESH_LEVEL_1 Heterocyclic Compounds 30418-52-1 SAFROLE TA_LEVEL_1 Toxicants 30418-52-1 SAFROLE MESH_LEVEL_3 Dioxoles 30418-52-1 SAFROLE ACTIVITY_CLASS Toxicant 30418-52-1 SAFROLE TISSUE_TOXICITY Mutagenicity 30418-52-1 SAFROLE ADVERSE_EFFECT LUN_3_Cyanosis 30418-52-1 SAFROLE ADVERSE_EFFECT DNA_3_Carcinogenicity 30418-52-1 SAFROLE ADVERSE_EFFECT NEU_3_Convulsions 30418-52-1 SAFROLE KNOWN_TOXICITY Mutagenicity 30418-52-1 SAFROLE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 30418-52-1 SAFROLE ZERO_CLASS N 30418-52-1 SAFROLE ADVERSE_EFFECT NEU_3_Loss of Consciousness 30418-52-1 SAFROLE ADVERSE_EFFECT PSY_3_Delirium 30418-52-1 SAFROLE ADVERSE_EFFECT DNA_3_Mutagenicity 30418-52-1 SAFROLE MECHANISM Inhibit DNA synthesis, repair, and function 30418-52-1 SAFROLE ADVERSE_EFFECT NEU_1_Drowsiness 30418-52-1 SAFROLE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 30418-52-1 SAFROLE KNOWN_TOXICITY Hepatotoxicity 30418-52-1 SAFROLE TISSUE_TOXICITY Hepatotoxicity 30418-52-1 SAFROLE ADVERSE_EFFECT PSY_2_Excitement 30418-52-1 SAFROLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 30418-52-1 SAFROLE ADVERSE_EFFECT GIS_2_Vomiting 30418-52-1 SAFROLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 30418-52-1 SAFROLE STRUCTURE_ACTIVITY Toxicant 30418-52-1 SAFROLE TA_LEVEL_2 DNA damage 18559-94-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Restlessness 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_3_Nightmares 18559-94-9 SALBUTAMOL ADVERSE_EFFECT SKN_3_Maculopapular Rash 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypertension 18559-94-9 SALBUTAMOL ADVERSE_EFFECT LUN_1_Hoarseness 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Dizziness 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Anxiety 18559-94-9 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 18559-94-9 SALBUTAMOL PRODUCT_CLASS Respiratory System 18559-94-9 SALBUTAMOL ADVERSE_EFFECT SKN_3_Flushing 18559-94-9 SALBUTAMOL TISSUE_TOXICITY Exacerbation of Arrhythmia 18559-94-9 SALBUTAMOL KNOWN_TOXICITY Cardiovascular Toxicity 18559-94-9 SALBUTAMOL ADVERSE_EFFECT IMU_1_Urticaria 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_1_Tachycardia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_1_Palpitation 18559-94-9 SALBUTAMOL ADVERSE_EFFECT MSK_2_Muscle Cramps 18559-94-9 SALBUTAMOL ADVERSE_EFFECT ELT_2_Hypokalemia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Hostility 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Excitement 18559-94-9 SALBUTAMOL THERAPEUTIC_CLASS Bronchodilators 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypotension 18559-94-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Drowsiness 18559-94-9 SALBUTAMOL ADVERSE_EFFECT LUN_3_Bronchospasm 18559-94-9 SALBUTAMOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 18559-94-9 SALBUTAMOL INDICATION Asthma 18559-94-9 SALBUTAMOL TISSUE_TOXICITY Hypotension 18559-94-9 SALBUTAMOL ADVERSE_EFFECT XXX_1_Xerostomia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Throat Irritation 18559-94-9 SALBUTAMOL ADVERSE_EFFECT MSK_1_Skeletal Muscle Tremor 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_2_Peripheral Vasodilation 18559-94-9 SALBUTAMOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Insomnia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT END_2_Hyperglycemia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT GIS_1_Dyspepsia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT LUN_3_Cough 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Angina 18559-94-9 SALBUTAMOL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 18559-94-9 SALBUTAMOL MECHANISM Reduce bronchoconstriction 18559-94-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Epistaxis 18559-94-9 SALBUTAMOL ADVERSE_EFFECT XXX_2_Diaphoresis 18559-94-9 SALBUTAMOL ADVERSE_EFFECT IMU_3_Angioneurotic Edema 18559-94-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Tremor 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_ST-T Wave Changes 18559-94-9 SALBUTAMOL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Nervousness 18559-94-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Irritability 18559-94-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Hyperkinesia 18559-94-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Headache 18559-94-9 SALBUTAMOL MODE_CLASS Receptor Agonist, selective 18559-94-9 SALBUTAMOL INDICATION Asthma 18559-94-9 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 18559-94-9 SALBUTAMOL TISSUE_TOXICITY Angina 18559-94-9 SALBUTAMOL ADVERSE_EFFECT GUS_1_Urinary Retention 18559-94-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Syncope 53003-10-4 SALINOMYCIN MECHANISM Destroy cell membrane / wall integrity 53003-10-4 SALINOMYCIN INDICATION Coccidiosis 53003-10-4 SALINOMYCIN STRUCTURE_ACTIVITY Impairs cell membrane function 53003-10-4 SALINOMYCIN PRODUCT_CLASS Veterinarian 53003-10-4 SALINOMYCIN THERAPEUTIC_CLASS Antiparasitics 110588-57-3 SAPERCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 110588-57-3 SAPERCONAZOLE PRODUCT_CLASS Anti-infectives 110588-57-3 SAPERCONAZOLE MODE_CLASS Enzyme Inhibitor 110588-57-3 SAPERCONAZOLE THERAPEUTIC_CLASS Antifungals 14611-51-9 SELEGILINE ADVERSE_EFFECT NEU_2_Drowsiness 14611-51-9 SELEGILINE ADVERSE_EFFECT GUS_2_Urinary Retention 14611-51-9 SELEGILINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 14611-51-9 SELEGILINE ADVERSE_EFFECT NEU_3_Paresthesia 14611-51-9 SELEGILINE ADVERSE_EFFECT XXX_3_Peripheral Edema 14611-51-9 SELEGILINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 14611-51-9 SELEGILINE ADVERSE_EFFECT XXX_2_Diaphoresis 14611-51-9 SELEGILINE TISSUE_TOXICITY Myocardial Infarction 14611-51-9 SELEGILINE MECHANISM Prolong/enhance neural transmission 14611-51-9 SELEGILINE MODE_CLASS Enzyme Inhibitor 14611-51-9 SELEGILINE ADVERSE_EFFECT CVS_3_Hypertension 14611-51-9 SELEGILINE ADVERSE_EFFECT PSY_1_Insomnia 14611-51-9 SELEGILINE ADVERSE_EFFECT NEU_1_Dizziness 14611-51-9 SELEGILINE ADVERSE_EFFECT PSY_2_Agitation 14611-51-9 SELEGILINE ADVERSE_EFFECT NEU_2_Dystonia 14611-51-9 SELEGILINE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 14611-51-9 SELEGILINE KNOWN_TOXICITY Cardiovascular Toxicity 14611-51-9 SELEGILINE ADVERSE_EFFECT PSY_2_Depression 14611-51-9 SELEGILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 14611-51-9 SELEGILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 14611-51-9 SELEGILINE ADVERSE_EFFECT LUN_3_Bronchospasm 14611-51-9 SELEGILINE ADVERSE_EFFECT NEU_2_Akathisia 14611-51-9 SELEGILINE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 14611-51-9 SELEGILINE PRODUCT_CLASS Central Nervous System (CNS) 14611-51-9 SELEGILINE THERAPEUTIC_CLASS Movement Disorders 14611-51-9 SELEGILINE INDICATION Parkinson's Disease 14611-51-9 SELEGILINE ADVERSE_EFFECT GIS_1_Dry Mouth 14611-51-9 SELEGILINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 14611-51-9 SELEGILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 14611-51-9 SELEGILINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 14611-51-9 SELEGILINE ADVERSE_EFFECT PSY_2_Mental Confusion 14611-51-9 SELEGILINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 2079-54-1 SELEGILINE THERAPEUTIC_CLASS Movement Disorders 2079-54-1 SELEGILINE PRODUCT_CLASS Central Nervous System (CNS) 2079-54-1 SELEGILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 2079-54-1 SELEGILINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 2079-54-1 SELEGILINE ADVERSE_EFFECT NEU_3_Paresthesia 2079-54-1 SELEGILINE ADVERSE_EFFECT XXX_3_Peripheral Edema 2079-54-1 SELEGILINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 2079-54-1 SELEGILINE ADVERSE_EFFECT XXX_2_Diaphoresis 2079-54-1 SELEGILINE TISSUE_TOXICITY Myocardial Infarction 2079-54-1 SELEGILINE MECHANISM Prolong/enhance neural transmission 2079-54-1 SELEGILINE MODE_CLASS Enzyme Inhibitor 2079-54-1 SELEGILINE ADVERSE_EFFECT CVS_3_Hypertension 2079-54-1 SELEGILINE ADVERSE_EFFECT PSY_1_Insomnia 2079-54-1 SELEGILINE ADVERSE_EFFECT NEU_1_Dizziness 2079-54-1 SELEGILINE ADVERSE_EFFECT PSY_2_Agitation 2079-54-1 SELEGILINE ADVERSE_EFFECT NEU_2_Dystonia 2079-54-1 SELEGILINE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 2079-54-1 SELEGILINE KNOWN_TOXICITY Cardiovascular Toxicity 2079-54-1 SELEGILINE ADVERSE_EFFECT PSY_2_Depression 2079-54-1 SELEGILINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 2079-54-1 SELEGILINE ADVERSE_EFFECT GIS_1_Dry Mouth 2079-54-1 SELEGILINE ADVERSE_EFFECT GUS_2_Urinary Retention 2079-54-1 SELEGILINE INDICATION Parkinson's Disease 2079-54-1 SELEGILINE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 2079-54-1 SELEGILINE ADVERSE_EFFECT NEU_2_Drowsiness 2079-54-1 SELEGILINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 2079-54-1 SELEGILINE ADVERSE_EFFECT PSY_2_Mental Confusion 2079-54-1 SELEGILINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 2079-54-1 SELEGILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 2079-54-1 SELEGILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 2079-54-1 SELEGILINE ADVERSE_EFFECT LUN_3_Bronchospasm 2079-54-1 SELEGILINE ADVERSE_EFFECT NEU_2_Akathisia 50-67-9 SEROTONIN THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 50-67-9 SEROTONIN MODE_CLASS Endogenous Receptor /Channel Ligand 50-67-9 SEROTONIN PRODUCT_CLASS Vitamins, Minerals and Nutrients 50-67-9 SEROTONIN MECHANISM Modulate G-protein coupled signal transduction 50-67-9 SEROTONIN MECHANISM Modulate channel gating 28523-86-6 SEVOFLURANE MECHANISM Modulate neural transmission 28523-86-6 SEVOFLURANE MECHANISM Block neural transmission 28523-86-6 SEVOFLURANE MODE_CLASS Enzyme Inhibitor 28523-86-6 SEVOFLURANE MECHANISM Modulate channel gating 28523-86-6 SEVOFLURANE MECHANISM Enhance cholinergic transmission 28523-86-6 SEVOFLURANE MODE_CLASS Channel Modulator 28523-86-6 SEVOFLURANE MODE_CLASS Channel Blocker 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Myocardial Infarction 139755-83-2 SILDENAFIL ADVERSE_EFFECT REP_2_Prolonged Erection 139755-83-2 SILDENAFIL MODE_CLASS Enzyme Inhibitor, selective 139755-83-2 SILDENAFIL MECHANISM Enhance kinase mediated signal transduction 139755-83-2 SILDENAFIL KNOWN_TOXICITY Cardiovascular Toxicity 139755-83-2 SILDENAFIL INDICATION Erectile Dysfunction 139755-83-2 SILDENAFIL TA_LEVEL_2 erectile dysfunction 139755-83-2 SILDENAFIL PRODUCT_CLASS Cardiovasculars 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Myocardial Ischemia 139755-83-2 SILDENAFIL TISSUE_TOXICITY Sudden Cardiac Death 139755-83-2 SILDENAFIL TISSUE_TOXICITY Angina Pectoris 139755-83-2 SILDENAFIL TISSUE_TOXICITY Myocardial Infarction 139755-83-2 SILDENAFIL MESH_LEVEL_1 Heterocyclic Compounds 139755-83-2 SILDENAFIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 139755-83-2 SILDENAFIL MECH_LEVEL_2 PDE inhibition 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_2_Hypotension 139755-83-2 SILDENAFIL ADVERSE_EFFECT XXX_1_Nasal Congestion 139755-83-2 SILDENAFIL ADVERSE_EFFECT BBM_3_Anemia 139755-83-2 SILDENAFIL ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Cardiac Arrest 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_2_Supine Hypotension 139755-83-2 SILDENAFIL THERAPEUTIC_CLASS Vasodilators 139755-83-2 SILDENAFIL TISSUE_TOXICITY Hypotensive Shock 139755-83-2 SILDENAFIL TISSUE_TOXICITY Cardiac Arrest 139755-83-2 SILDENAFIL MECH_LEVEL_3 cGMP phosphodiesterase 5 139755-83-2 SILDENAFIL MESH_LEVEL_3 Azepines 139755-83-2 SILDENAFIL ADVERSE_EFFECT NEU_1_Headache 139755-83-2 SILDENAFIL ADVERSE_EFFECT GIS_1_Dyspepsia 139755-83-2 SILDENAFIL ADVERSE_EFFECT IMU_3_Allergic Reactions 139755-83-2 SILDENAFIL ADVERSE_EFFECT XXX_3_Edema 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_2_Tachycardia 139755-83-2 SILDENAFIL ADVERSE_EFFECT NEU_3_Cerebral Thrombosis 139755-83-2 SILDENAFIL ADVERSE_EFFECT KID_3_Hematuria 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Transient Ischemic Attack 139755-83-2 SILDENAFIL ZERO_CLASS N 139755-83-2 SILDENAFIL ACTIVITY_CLASS Phosphodiesterase inhibitor 139755-83-2 SILDENAFIL TISSUE_TOXICITY Hypotension 139755-83-2 SILDENAFIL TISSUE_TOXICITY Myocardial Ischemia 139755-83-2 SILDENAFIL MECH_LEVEL_1 Vasodilators 139755-83-2 SILDENAFIL TA_LEVEL_3 PDE inhibitors 139755-83-2 SILDENAFIL TA_LEVEL_1 Cardiovascular 139755-83-2 SILDENAFIL ADVERSE_EFFECT REP_3_Priapism 139755-83-2 SILDENAFIL ADVERSE_EFFECT OCU_1_Visual Disturbances 139755-83-2 SILDENAFIL ADVERSE_EFFECT SKN_1_Flushing 139755-83-2 SILDENAFIL ADVERSE_EFFECT GIS_2_Diarrhea 139755-83-2 SILDENAFIL ADVERSE_EFFECT NEU_2_Dizziness 139755-83-2 SILDENAFIL ADVERSE_EFFECT SKN_2_Rash 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Angina Pectoris 139755-83-2 SILDENAFIL ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Sudden Cardiac Death 139755-83-2 SILDENAFIL KNOWN_TOXICITY Nephrotoxicity 139755-83-2 SILDENAFIL TISSUE_TOXICITY Atrioventricular Blockade 139755-83-2 SILDENAFIL TISSUE_TOXICITY Hematuria 139755-83-2 SILDENAFIL STRUCTURE_ACTIVITY PDE5 inhibitor 139755-83-2 SILDENAFIL ADVERSE_EFFECT NEU_2_Syncope 139755-83-2 SILDENAFIL ADVERSE_EFFECT GUS_2_Urinary Tract Infection 139755-83-2 SILDENAFIL ADVERSE_EFFECT BBM_3_Leukopenia 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Hypotensive Shock 139755-83-2 SILDENAFIL ADVERSE_EFFECT CVS_3_Postural Hypotension 32385-11-8 SISOMICIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 32385-11-8 SISOMICIN INDICATION Peritonitis 32385-11-8 SISOMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 32385-11-8 SISOMICIN MECH_LEVEL_2 Protein synthesis inhibitor 32385-11-8 SISOMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 32385-11-8 SISOMICIN MECH_LEVEL_3 Ribosomal RNA binder 32385-11-8 SISOMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 32385-11-8 SISOMICIN INDICATION Nosocomial Pneumonia 32385-11-8 SISOMICIN ZERO_CLASS N 32385-11-8 SISOMICIN KNOWN_TOXICITY Nephrotoxicity 32385-11-8 SISOMICIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 32385-11-8 SISOMICIN ADVERSE_EFFECT EMB_2_Teratogenicity 32385-11-8 SISOMICIN INDICATION Ophthalmic Infections 32385-11-8 SISOMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 32385-11-8 SISOMICIN MESH_LEVEL_2 Carbohydrates 32385-11-8 SISOMICIN MECHANISM Inhibit ribosomal protein synthesis 32385-11-8 SISOMICIN TA_LEVEL_2 Anti-bacterial 32385-11-8 SISOMICIN TISSUE_TOXICITY Teratogenicity 32385-11-8 SISOMICIN TA_LEVEL_1 Infectious Disease 32385-11-8 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Topical 32385-11-8 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 32385-11-8 SISOMICIN INDICATION Gram-negative Septicemia 32385-11-8 SISOMICIN INDICATION Urinary Tract Infection (UTI) 32385-11-8 SISOMICIN MESH_LEVEL_3 Aminoglycoside 32385-11-8 SISOMICIN TA_LEVEL_3 Aminoglycoside 32385-11-8 SISOMICIN MECH_LEVEL_1 Anti-bacterial 32385-11-8 SISOMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 32385-11-8 SISOMICIN ADVERSE_EFFECT KID_2_Nephrotoxicity 32385-11-8 SISOMICIN PRODUCT_CLASS Anti-infectives 32385-11-8 SISOMICIN KNOWN_TOXICITY Embryo/Fetal Toxicity 32385-11-8 SISOMICIN TISSUE_TOXICITY Nephrotoxicity 32385-11-8 SISOMICIN ADVERSE_EFFECT OTO_2_Ototoxicity 76-03-9 TRICHLOROACETIC ACID INDICATION Condylomata Acuminata 76-03-9 TRICHLOROACETIC ACID MESH_LEVEL_3 Acids, Acyclic 76-03-9 TRICHLOROACETIC ACID TA_LEVEL_3 warts 76-03-9 TRICHLOROACETIC ACID ZERO_CLASS Y 76-03-9 TRICHLOROACETIC ACID MESH_LEVEL_2 Carboxylic Acids 76-03-9 TRICHLOROACETIC ACID ACTIVITY_CLASS Unknown mechanism 76-03-9 TRICHLOROACETIC ACID MESH_LEVEL_1 Organic Chemicals 76-03-9 TRICHLOROACETIC ACID PRODUCT_CLASS Dermatologicals 76-03-9 TRICHLOROACETIC ACID TA_LEVEL_1 Dermatology 76-03-9 TRICHLOROACETIC ACID INDICATION Verruca Vulgaris 76-03-9 TRICHLOROACETIC ACID ADVERSE_EFFECT XXX_2_Burning Sensation 76-03-9 TRICHLOROACETIC ACID STRUCTURE_ACTIVITY Unknown mechanism 76-03-9 TRICHLOROACETIC ACID MECH_LEVEL_2 Unknown mechanism 76-03-9 TRICHLOROACETIC ACID MECH_LEVEL_3 Unknown mechanism 76-03-9 TRICHLOROACETIC ACID INDICATION Warts 76-03-9 TRICHLOROACETIC ACID ADVERSE_EFFECT XXX_2_Inflammation 76-03-9 TRICHLOROACETIC ACID THERAPEUTIC_CLASS Astringents 38260-01-4 TRIENTINE INDICATION Wilson's Disease 38260-01-4 TRIENTINE MECHANISM chelate excess metal 70-00-8 TRIFLURIDINE INDICATION Herpes Simplex Keratitis 70-00-8 TRIFLURIDINE MODE_CLASS Enzyme substrate mimic 70-00-8 TRIFLURIDINE MECHANISM Inhibit precursor synthesis 70-00-8 TRIFLURIDINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 70-00-8 TRIFLURIDINE THERAPEUTIC_CLASS Antivirals, Topical 70-00-8 TRIFLURIDINE PRODUCT_CLASS Anti-infectives 127-48-0 TRIMETHADIONE ADVERSE_EFFECT BBM_3_Pancytopenia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT IMU_3_Myasthenic Syndrome 127-48-0 TRIMETHADIONE ADVERSE_EFFECT OCU_1_Scotomata 127-48-0 TRIMETHADIONE ADVERSE_EFFECT PSY_2_Insomnia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 127-48-0 TRIMETHADIONE TA_LEVEL_1 Central Nervous System (CNS) 127-48-0 TRIMETHADIONE MESH_LEVEL_1 Heterocyclic Compounds 127-48-0 TRIMETHADIONE MECH_LEVEL_1 Modulate neural transmission 127-48-0 TRIMETHADIONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 127-48-0 TRIMETHADIONE ADVERSE_EFFECT LIV_3_Hepatitis 127-48-0 TRIMETHADIONE ADVERSE_EFFECT XXX_2_Weight Loss 127-48-0 TRIMETHADIONE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 127-48-0 TRIMETHADIONE ADVERSE_EFFECT IMU_3_Eosinophilia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT XXX_2_Hiccup 127-48-0 TRIMETHADIONE MECH_LEVEL_2 Decrease neural membrane excitability 127-48-0 TRIMETHADIONE MESH_LEVEL_3 Oxazoles 127-48-0 TRIMETHADIONE TA_LEVEL_3 Absence Seizures 127-48-0 TRIMETHADIONE ADVERSE_EFFECT NEU_1_Headache 127-48-0 TRIMETHADIONE ADVERSE_EFFECT BBM_3_Agranulocytosis 127-48-0 TRIMETHADIONE ADVERSE_EFFECT NEU_1_Drowsiness 127-48-0 TRIMETHADIONE ACTIVITY_CLASS GABA agonist 127-48-0 TRIMETHADIONE ADVERSE_EFFECT NEU_3_Tonic-Clonic Convulsions 127-48-0 TRIMETHADIONE ADVERSE_EFFECT OCU_1_Hemeralopia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT PSY_2_Anorexia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT NEU_1_Dizziness 127-48-0 TRIMETHADIONE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 127-48-0 TRIMETHADIONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT IMU_3_Lupus Erythematosus Syndrome 127-48-0 TRIMETHADIONE ZERO_CLASS N 127-48-0 TRIMETHADIONE MECH_LEVEL_3 T-Type Ca++ channel CaV3.3 127-48-0 TRIMETHADIONE MODE_CLASS Receptor Agonist 127-48-0 TRIMETHADIONE ADVERSE_EFFECT NEU_2_Paresthesia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 127-48-0 TRIMETHADIONE ADVERSE_EFFECT BBM_3_Leukopenia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT SKN_2_Hair Loss 127-48-0 TRIMETHADIONE ADVERSE_EFFECT OCU_1_Photophobia 127-48-0 TRIMETHADIONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 127-48-0 TRIMETHADIONE ADVERSE_EFFECT IMU_3_Allergic Reactions 127-48-0 TRIMETHADIONE STRUCTURE_ACTIVITY GABA-A agonist 127-48-0 TRIMETHADIONE MECHANISM Modulate channel gating 127-48-0 TRIMETHADIONE TA_LEVEL_2 CNS Depressant 127-48-0 TRIMETHADIONE INDICATION Absence (Petit Mal) Seizures 127-48-0 TRIMETHADIONE PRODUCT_CLASS Central Nervous System (CNS) 127-48-0 TRIMETHADIONE TISSUE_TOXICITY Hemeralopia 127-48-0 TRIMETHADIONE KNOWN_TOXICITY Ocular Toxicity 127-48-0 TRIMETHADIONE ADVERSE_EFFECT OCU_1_Diplopia 117052-25-2 TRIMETREXATE INDICATION Pneumocystis Carinii Pneumonia (PCP) 117052-25-2 TRIMETREXATE PRODUCT_CLASS Anti-infectives 117052-25-2 TRIMETREXATE STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 117052-25-2 TRIMETREXATE THERAPEUTIC_CLASS Antibacterials 117052-25-2 TRIMETREXATE MODE_CLASS Enzyme substrate mimic 117052-25-2 TRIMETREXATE MECHANISM Inhibit precursor synthesis 91-81-6 TRIPELENNAMINE MECHANISM Modulate G-protein coupled signal transduction 91-81-6 TRIPELENNAMINE MODE_CLASS Receptor Ligand Antagonist 97322-87-7 TROGLITAZONE TISSUE_TOXICITY Death 97322-87-7 TROGLITAZONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 97322-87-7 TROGLITAZONE ADVERSE_EFFECT KID_2_Fluid Retention 97322-87-7 TROGLITAZONE ADVERSE_EFFECT END_3_Hypoglycemia 97322-87-7 TROGLITAZONE KNOWN_TOXICITY Miscellaneous 97322-87-7 TROGLITAZONE TISSUE_TOXICITY Hepatic Failure 97322-87-7 TROGLITAZONE ACTIVITY_CLASS Anti-diabetic 97322-87-7 TROGLITAZONE ADVERSE_EFFECT XXX_3_Death 97322-87-7 TROGLITAZONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 97322-87-7 TROGLITAZONE ADVERSE_EFFECT XXX_2_Peripheral Edema 97322-87-7 TROGLITAZONE KNOWN_TOXICITY Cardiovascular Toxicity 97322-87-7 TROGLITAZONE KNOWN_TOXICITY Hepatotoxicity 97322-87-7 TROGLITAZONE TISSUE_TOXICITY Hepatotoxicity 97322-87-7 TROGLITAZONE MECHANISM Increase lipid catabolism 97322-87-7 TROGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 97322-87-7 TROGLITAZONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 97322-87-7 TROGLITAZONE ADVERSE_EFFECT LIV_3_Hepatic Failure 97322-87-7 TROGLITAZONE ADVERSE_EFFECT XXX_1_Infection 97322-87-7 TROGLITAZONE TISSUE_TOXICITY Congestive Heart Failure 97322-87-7 TROGLITAZONE INDICATION Type II Diabetes Mellitus 97322-87-7 TROGLITAZONE MECHANISM Increase transcription of insulin responsive gene 97322-87-7 TROGLITAZONE MODE_CLASS Receptor Agonist 97322-87-7 TROGLITAZONE INDICATION Type II Diabetes Mellitus 97322-87-7 TROGLITAZONE ADVERSE_EFFECT XXX_2_Asthenia 97322-87-7 TROGLITAZONE ADVERSE_EFFECT NEU_1_Headache 97322-87-7 TROGLITAZONE ADVERSE_EFFECT REP_2_Induction of Ovulation 97322-87-7 TROGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 97322-87-7 TROGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 147059-72-1 TROVAFLOXACIN KNOWN_TOXICITY Hepatotoxicity 147059-72-1 TROVAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 147059-72-1 TROVAFLOXACIN INDICATION Pelvic Inflammatory Disease (PID) 147059-72-1 TROVAFLOXACIN INDICATION Pelvic Inflammatory Disease (PID) 147059-72-1 TROVAFLOXACIN TISSUE_TOXICITY Hepatotoxicity 147059-72-1 TROVAFLOXACIN KNOWN_TOXICITY Nephrotoxicity 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT GIS_3_Pancreatitis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT EMB_2_Fetal Toxicity 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT BBM_3_Bone Marrow Depression 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT CVS__Vasculitis (Structure Class Implication) 147059-72-1 TROVAFLOXACIN INDICATION Skin Infections 147059-72-1 TROVAFLOXACIN PRODUCT_CLASS Anti-infectives 147059-72-1 TROVAFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 147059-72-1 TROVAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 147059-72-1 TROVAFLOXACIN INDICATION Skin Infections 147059-72-1 TROVAFLOXACIN TISSUE_TOXICITY Hypotensive Shock 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT MSK_3_Tendinopathy 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT IMU_2_Phototoxicity 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT CVS_3_Hypotensive Shock 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT NEU_2_Headache 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 147059-72-1 TROVAFLOXACIN INDICATION Community-Acquired Pneumonia 147059-72-1 TROVAFLOXACIN INDICATION Nosocomial Pneumonia 147059-72-1 TROVAFLOXACIN TISSUE_TOXICITY Interstitial Nephritis 147059-72-1 TROVAFLOXACIN INDICATION Nosocomial Pneumonia 147059-72-1 TROVAFLOXACIN INDICATION Community-Acquired Pneumonia 147059-72-1 TROVAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT LIV_3_Hepatitis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 147059-72-1 TROVAFLOXACIN INDICATION Intra-Abdominal Infections 147059-72-1 TROVAFLOXACIN INDICATION Intra-Abdominal Infections 147059-72-1 TROVAFLOXACIN TISSUE_TOXICITY Acute Hepatocellular Necrosis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylaxis 147059-72-1 TROVAFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 147059-72-1 TROVAFLOXACIN THERAPEUTIC_CLASS Antibacterials 147059-72-1 TROVAFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 124832-27-5 VALACYCLOVIR MESH_LEVEL_3 Purines 124832-27-5 VALACYCLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT GIS_1_Nausea / Vomiting 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT SKN_2_Rash 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Agitation 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT CVS_2_Tachycardia 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT MSK_2_Arthralgia 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT IMU_3_Photosensitivity 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT BBM_2_Thrombocytopenia 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Hallucinations 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Mania 124832-27-5 VALACYCLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT REP_2_Dysmenorrhea 124832-27-5 VALACYCLOVIR MESH_LEVEL_1 Heterocyclic Compounds 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT NEU_1_Dizziness 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT NEU_3_Coma 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT XXX_2_Facial Edema 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT KID_2_Increased Creatinine 124832-27-5 VALACYCLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT GIS_2_Diarrhea 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT CVS_3_Hypertension 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_2_Confusion 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Psychosis 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT BBM_3_Aplastic Anemia 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT XXX_3_Hemolytic-Uremic Syndrome 124832-27-5 VALACYCLOVIR TA_LEVEL_2 Anti-viral 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Delirium 124832-27-5 VALACYCLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 124832-27-5 VALACYCLOVIR MECH_LEVEL_1 Anti-viral 124832-27-5 VALACYCLOVIR TA_LEVEL_1 Infectious Disease 124832-27-5 VALACYCLOVIR TA_LEVEL_3 viral replication inhibitor 124832-27-5 VALACYCLOVIR PRODUCT_CLASS Anti-infectives 124832-27-5 VALACYCLOVIR INDICATION Herpes Zoster / Shingles 124832-27-5 VALACYCLOVIR MODE_CLASS Enzyme Inhibitor, selective 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT IMU_2_Anaphylactoid Reactions 124832-27-5 VALACYCLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT NEU_1_Headache 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT NEU_3_Encephalopathy 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT SKN_3_Erythema Multiforme 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT GIS_1_Abdominal Pain 124832-27-5 VALACYCLOVIR ZERO_CLASS N 124832-27-5 VALACYCLOVIR ACTIVITY_CLASS Anti-viral 124832-27-5 VALACYCLOVIR MECHANISM Inhibit viral DNA synthesis 124832-27-5 VALACYCLOVIR INDICATION Herpes Genitalis / Genital Herpes 124832-27-5 VALACYCLOVIR ADVERSE_EFFECT PSY_2_Depression 50700-72-6 VECURONIUM BROMIDE INDICATION Neuromuscular Blockade 50700-72-6 VECURONIUM BROMIDE MESH_LEVEL_3 Androstanes 50700-72-6 VECURONIUM BROMIDE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 50700-72-6 VECURONIUM BROMIDE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 50700-72-6 VECURONIUM BROMIDE MECHANISM Block neural transmission 50700-72-6 VECURONIUM BROMIDE ADVERSE_EFFECT LUN_2_Apnea 50700-72-6 VECURONIUM BROMIDE KNOWN_TOXICITY Immune System Toxicity 50700-72-6 VECURONIUM BROMIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 50700-72-6 VECURONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 50700-72-6 VECURONIUM BROMIDE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-1 50700-72-6 VECURONIUM BROMIDE TA_LEVEL_3 Skeletal Muscle Relaxants 50700-72-6 VECURONIUM BROMIDE TISSUE_TOXICITY Anaphylactoid Reactions 50700-72-6 VECURONIUM BROMIDE MESH_LEVEL_1 Polycyclic Hydrocarbons 50700-72-6 VECURONIUM BROMIDE ADVERSE_EFFECT LUN_2_Dyspnea 50700-72-6 VECURONIUM BROMIDE MECH_LEVEL_2 Cholinergic receptor agonist 50700-72-6 VECURONIUM BROMIDE INDICATION Endotracheal Intubation 50700-72-6 VECURONIUM BROMIDE MESH_LEVEL_2 Steroids 50700-72-6 VECURONIUM BROMIDE ADVERSE_EFFECT MSK_2_Muscle Weakness 50700-72-6 VECURONIUM BROMIDE ZERO_CLASS N 50700-72-6 VECURONIUM BROMIDE MODE_CLASS Channel Blocker, selective 50700-72-6 VECURONIUM BROMIDE ADVERSE_EFFECT XXX_2_Malignant Hyperthermia 50700-72-6 VECURONIUM BROMIDE MECH_LEVEL_1 Block neural transmission 50700-72-6 VECURONIUM BROMIDE TA_LEVEL_1 Central Nervous System (CNS) 50700-72-6 VECURONIUM BROMIDE ADVERSE_EFFECT IMU_1_Anaphylactoid Reactions 50700-72-6 VECURONIUM BROMIDE ADVERSE_EFFECT LUN_2_Respiratory Depression 71-62-5 VERATRIDINE PRODUCT_CLASS Biochemicals 71-62-5 VERATRIDINE MODE_CLASS Channel Blocker 71-62-5 VERATRIDINE MECHANISM Block neural transmission 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_2_Diarrhea 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_2_Stomatitis 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_2_Rectal Hemorrhage 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_2_Constipation 865-21-4 VINBLASTINE ADVERSE_EFFECT KID_2_Hyperuricemia 865-21-4 VINBLASTINE KNOWN_TOXICITY Nephrotoxicity 865-21-4 VINBLASTINE ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 865-21-4 VINBLASTINE INDICATION Hodgkin's Disease 865-21-4 VINBLASTINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 865-21-4 VINBLASTINE INDICATION Letterer-Siwe Disease (Histiocytosis X) 865-21-4 VINBLASTINE INDICATION Idiopathic (Autoimmnune) Thrombocytopenic Purpura (ITP) 865-21-4 VINBLASTINE INDICATION Non-Small Cell Lung Carcinoma 865-21-4 VINBLASTINE TA_LEVEL_3 Anti-mitotic 865-21-4 VINBLASTINE MECH_LEVEL_1 Antimitotic 865-21-4 VINBLASTINE MECH_LEVEL_3 Microtubule / tubulin 865-21-4 VINBLASTINE TA_LEVEL_2 Solid and soft tissue tumors 865-21-4 VINBLASTINE STRUCTURE_ACTIVITY Tubulin binder, vinca 865-21-4 VINBLASTINE MECH_LEVEL_2 Microtubule / tubulin 865-21-4 VINBLASTINE ADVERSE_EFFECT OTO_3_Hearing Loss 865-21-4 VINBLASTINE ADVERSE_EFFECT NEU_3_Autonomic Dysfunction 865-21-4 VINBLASTINE INDICATION Neoplasm / Cancer / Tumor 865-21-4 VINBLASTINE INDICATION Choriocarcinoma / Trophoblastic Neoplasm 865-21-4 VINBLASTINE INDICATION Histiocytic Lymphoma 865-21-4 VINBLASTINE MESH_LEVEL_1 Heterocyclic Compounds 865-21-4 VINBLASTINE PRODUCT_CLASS Anti-cancers 865-21-4 VINBLASTINE INDICATION Kaposi's Sarcoma 865-21-4 VINBLASTINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 865-21-4 VINBLASTINE ADVERSE_EFFECT XXX_1_Infection 865-21-4 VINBLASTINE ADVERSE_EFFECT NEU_3_Vertigo 865-21-4 VINBLASTINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 865-21-4 VINBLASTINE TISSUE_TOXICITY Hematotoxicity 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 865-21-4 VINBLASTINE ADVERSE_EFFECT SKN_2_Dermatitis 865-21-4 VINBLASTINE ADVERSE_EFFECT KID_3_Uric Acid Nephropathy 865-21-4 VINBLASTINE ADVERSE_EFFECT EMB_3_Teratogenicity 865-21-4 VINBLASTINE ADVERSE_EFFECT PSY_2_Anorexia 865-21-4 VINBLASTINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 865-21-4 VINBLASTINE MESH_LEVEL_2 Alkaloids 865-21-4 VINBLASTINE MECHANISM Inhibit mitosis 865-21-4 VINBLASTINE INDICATION Testicular Cancer / Carcinoma of the Testis 865-21-4 VINBLASTINE INDICATION Metastatic Melanoma 865-21-4 VINBLASTINE INDICATION Breast Cancer / Carcinoma of the Breast 865-21-4 VINBLASTINE INDICATION Lymphocytic Lymphoma 865-21-4 VINBLASTINE TA_LEVEL_1 Oncology 865-21-4 VINBLASTINE ADVERSE_EFFECT NEU_3_Nystagmus 865-21-4 VINBLASTINE ADVERSE_EFFECT BBM_1_Leukopenia 865-21-4 VINBLASTINE ADVERSE_EFFECT BBM_1_Hematotoxicity 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_2_Abdominal Pain 865-21-4 VINBLASTINE ADVERSE_EFFECT GIS_2_Enterocolitis 865-21-4 VINBLASTINE ADVERSE_EFFECT NEU_3_Neurogenic Ileus 865-21-4 VINBLASTINE ADVERSE_EFFECT OTO_3_Ototoxicity 865-21-4 VINBLASTINE TISSUE_TOXICITY Leukopenia 865-21-4 VINBLASTINE KNOWN_TOXICITY Embryo/Fetal Toxicity 865-21-4 VINBLASTINE ZERO_CLASS N 865-21-4 VINBLASTINE MESH_LEVEL_3 Vinca Alkaloids 865-21-4 VINBLASTINE INDICATION Non-Hodgkin's Lymphomas 865-21-4 VINBLASTINE INDICATION Metastatic Renal Cell Carcinoma 865-21-4 VINBLASTINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 865-21-4 VINBLASTINE ADVERSE_EFFECT LUN_3_Bronchospasm 865-21-4 VINBLASTINE INDICATION Metastatic Bladder Carcinoma 865-21-4 VINBLASTINE TISSUE_TOXICITY Teratogenicity 865-21-4 VINBLASTINE TISSUE_TOXICITY Uric Acid Nephropathy 865-21-4 VINBLASTINE THERAPEUTIC_CLASS Antineoplastics 865-21-4 VINBLASTINE ADVERSE_EFFECT BBM_2_Anemia 865-21-4 VINBLASTINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 865-21-4 VINBLASTINE ADVERSE_EFFECT IMU_3_Photosensitivity 865-21-4 VINBLASTINE ADVERSE_EFFECT CVS_2_Phlebitis 53643-48-4 VINDESINE ADVERSE_EFFECT PSY_3_Anorexia 53643-48-4 VINDESINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 53643-48-4 VINDESINE ADVERSE_EFFECT OTO_2_Vestibular Damage 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_2_Stomatitis 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_3_Duodenal Ulcer 53643-48-4 VINDESINE ADVERSE_EFFECT _3_Cortical Blindness 53643-48-4 VINDESINE TISSUE_TOXICITY Thrombocytopenia 53643-48-4 VINDESINE ADVERSE_EFFECT _3_Loss of deep tendon reflexes 53643-48-4 VINDESINE INDICATION Breast Cancer / Carcinoma of the Breast 53643-48-4 VINDESINE PRODUCT_CLASS Anti-cancers 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_3_Dysphagia 53643-48-4 VINDESINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_3_Ulcer Perforation 53643-48-4 VINDESINE ADVERSE_EFFECT BBM_1_Granulocytopenia 53643-48-4 VINDESINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_2_Constipation 53643-48-4 VINDESINE ADVERSE_EFFECT BBM_2_Anemia 53643-48-4 VINDESINE ADVERSE_EFFECT OTO_2_Auditory Damage 53643-48-4 VINDESINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_2_Dyspepsia 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 53643-48-4 VINDESINE INDICATION Acute Lymphocytic Leukemia (ALL) 53643-48-4 VINDESINE ADVERSE_EFFECT _3_Foot Drop 53643-48-4 VINDESINE THERAPEUTIC_CLASS Antineoplastics 53643-48-4 VINDESINE ADVERSE_EFFECT BBM_2_Thrombocytosis 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_3_Abdominal Pain 53643-48-4 VINDESINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 53643-48-4 VINDESINE TISSUE_TOXICITY Granulocytopenia 53643-48-4 VINDESINE INDICATION Malignant Melanoma 53643-48-4 VINDESINE MECHANISM Inhibit mitosis 53643-48-4 VINDESINE INDICATION Blastic crisis of chronic myeloid leukemia 53643-48-4 VINDESINE ADVERSE_EFFECT GIS_2_Diarrhea 53643-48-4 VINDESINE ADVERSE_EFFECT NEU_2_Paresthesia 53643-48-4 VINDESINE ADVERSE_EFFECT NEU_2_Peripheral Neuritis 53643-48-4 VINDESINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 53643-48-4 VINDESINE STRUCTURE_ACTIVITY Tubulin binder, vinca 53643-48-4 VINDESINE ADVERSE_EFFECT OTO_2_Hearing Loss 137234-62-9 VORICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 137234-62-9 VORICONAZOLE PRODUCT_CLASS Anti-infectives 137234-62-9 VORICONAZOLE MODE_CLASS Enzyme Inhibitor 137234-62-9 VORICONAZOLE THERAPEUTIC_CLASS Antifungals 81-81-2 WARFARIN ADVERSE_EFFECT CVS_3_Cholesterol Microembolization 81-81-2 WARFARIN ADVERSE_EFFECT XXX_3_Retroperitoneal Bleeding 81-81-2 WARFARIN TISSUE_TOXICITY Teratogenicity 81-81-2 WARFARIN TISSUE_TOXICITY Fetal / Neonatal Morbidity and Mortality 81-81-2 WARFARIN TISSUE_TOXICITY Bleeding 81-81-2 WARFARIN KNOWN_TOXICITY Embryo/Fetal Toxicity 81-81-2 WARFARIN THERAPEUTIC_CLASS Anticoagulants 81-81-2 WARFARIN ADVERSE_EFFECT LIV_3_Hepatitis 81-81-2 WARFARIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 81-81-2 WARFARIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 81-81-2 WARFARIN ADVERSE_EFFECT EMB_1_Fetal / Neonatal Morbidity and Mortality 81-81-2 WARFARIN ADVERSE_EFFECT XXX_2_Epistaxis 81-81-2 WARFARIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 81-81-2 WARFARIN MECH_LEVEL_3 Vitamin-K-epoxide reductase 81-81-2 WARFARIN INDICATION Atrial Fibrillation 81-81-2 WARFARIN MESH_LEVEL_3 Benzopyrans 81-81-2 WARFARIN MECH_LEVEL_2 Inhibit platelet aggregation 81-81-2 WARFARIN ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 81-81-2 WARFARIN ADVERSE_EFFECT IMU_3_Urticaria 81-81-2 WARFARIN ADVERSE_EFFECT NEU_2_Headache 81-81-2 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenicity 81-81-2 WARFARIN ADVERSE_EFFECT BBM_1_Bleeding 81-81-2 WARFARIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 81-81-2 WARFARIN ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 81-81-2 WARFARIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 81-81-2 WARFARIN TISSUE_TOXICITY Gastrointestinal Bleeding 81-81-2 WARFARIN TISSUE_TOXICITY Cholesterol Microembolization 81-81-2 WARFARIN ADVERSE_EFFECT BBM_2_Petechiae 81-81-2 WARFARIN KNOWN_TOXICITY Gastrointestinal Toxicity 81-81-2 WARFARIN INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 81-81-2 WARFARIN INDICATION Cardiomyopathy 81-81-2 WARFARIN INDICATION Prosthetic Heart Valves 81-81-2 WARFARIN MESH_LEVEL_1 Heterocyclic Compounds 81-81-2 WARFARIN TA_LEVEL_2 anticoagulant 81-81-2 WARFARIN TA_LEVEL_1 Cardiovascular 81-81-2 WARFARIN ZERO_CLASS N 81-81-2 WARFARIN KNOWN_TOXICITY Nephrotoxicity 81-81-2 WARFARIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 81-81-2 WARFARIN ADVERSE_EFFECT BBM_3_Agranulocytosis 81-81-2 WARFARIN ADVERSE_EFFECT GIS_2_Diarrhea 81-81-2 WARFARIN ADVERSE_EFFECT BBM_3_Leukopenia 81-81-2 WARFARIN ADVERSE_EFFECT GUS_3_Vaginal Bleeding 81-81-2 WARFARIN ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 81-81-2 WARFARIN ADVERSE_EFFECT LIV_2_Jaundice 81-81-2 WARFARIN TISSUE_TOXICITY Hematuria 81-81-2 WARFARIN TISSUE_TOXICITY Fetal Warfarin Syndrome 81-81-2 WARFARIN ADVERSE_EFFECT NEU_3_Intracranial Bleeding 81-81-2 WARFARIN MODE_CLASS Enzyme Inhibitor 81-81-2 WARFARIN INDICATION Thrombosis Prophylaxis 81-81-2 WARFARIN INDICATION Antiphospholipid Antibody Syndrome 81-81-2 WARFARIN STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 81-81-2 WARFARIN ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 81-81-2 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Renal Damage 81-81-2 WARFARIN ADVERSE_EFFECT BBM_2_Ecchymosis 81-81-2 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenic Fetal Damage 81-81-2 WARFARIN TISSUE_TOXICITY Teratogenic Fetal Damage 81-81-2 WARFARIN TISSUE_TOXICITY Fetal Renal Damage 81-81-2 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Warfarin Syndrome 81-81-2 WARFARIN KNOWN_TOXICITY Cardiovascular Toxicity 81-81-2 WARFARIN ADVERSE_EFFECT SKN_2_Pruritis 81-81-2 WARFARIN ADVERSE_EFFECT PSY_2_Anorexia 81-81-2 WARFARIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 81-81-2 WARFARIN ADVERSE_EFFECT SKN_3_Skin Necrosis 81-81-2 WARFARIN INDICATION Deep Vein Thrombosis 81-81-2 WARFARIN INDICATION Postmyocardial Infarction 81-81-2 WARFARIN TA_LEVEL_3 anticoagulant 81-81-2 WARFARIN MECH_LEVEL_1 Anti-clotting 81-81-2 WARFARIN PRODUCT_CLASS Hematologics 81-81-2 WARFARIN MECHANISM Inhibit platelet aggregation 81-81-2 WARFARIN ADVERSE_EFFECT KID_2_Hematuria 5979-00-0 WARFARIN KNOWN_TOXICITY Embryo/Fetal Toxicity 5979-00-0 WARFARIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 5979-00-0 WARFARIN ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 5979-00-0 WARFARIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 5979-00-0 WARFARIN ADVERSE_EFFECT CVS_3_Cholesterol Microembolization 5979-00-0 WARFARIN ADVERSE_EFFECT XXX_3_Retroperitoneal Bleeding 5979-00-0 WARFARIN TISSUE_TOXICITY Teratogenicity 5979-00-0 WARFARIN TISSUE_TOXICITY Fetal / Neonatal Morbidity and Mortality 5979-00-0 WARFARIN TISSUE_TOXICITY Bleeding 5979-00-0 WARFARIN INDICATION Atrial Fibrillation 5979-00-0 WARFARIN THERAPEUTIC_CLASS Anticoagulants 5979-00-0 WARFARIN ADVERSE_EFFECT LIV_3_Hepatitis 5979-00-0 WARFARIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 5979-00-0 WARFARIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 5979-00-0 WARFARIN ADVERSE_EFFECT EMB_1_Fetal / Neonatal Morbidity and Mortality 5979-00-0 WARFARIN ADVERSE_EFFECT XXX_2_Epistaxis 5979-00-0 WARFARIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 5979-00-0 WARFARIN MECH_LEVEL_3 Vitamin-K-epoxide reductase 5979-00-0 WARFARIN TISSUE_TOXICITY Gastrointestinal Bleeding 5979-00-0 WARFARIN MESH_LEVEL_3 Benzopyrans 5979-00-0 WARFARIN MECH_LEVEL_2 Inhibit platelet aggregation 5979-00-0 WARFARIN ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 5979-00-0 WARFARIN ADVERSE_EFFECT IMU_3_Urticaria 5979-00-0 WARFARIN ADVERSE_EFFECT NEU_2_Headache 5979-00-0 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenicity 5979-00-0 WARFARIN ADVERSE_EFFECT BBM_1_Bleeding 5979-00-0 WARFARIN TISSUE_TOXICITY Cholesterol Microembolization 5979-00-0 WARFARIN ADVERSE_EFFECT BBM_2_Petechiae 5979-00-0 WARFARIN KNOWN_TOXICITY Gastrointestinal Toxicity 5979-00-0 WARFARIN INDICATION Cardiomyopathy 5979-00-0 WARFARIN INDICATION Prosthetic Heart Valves 5979-00-0 WARFARIN MESH_LEVEL_1 Heterocyclic Compounds 5979-00-0 WARFARIN TA_LEVEL_2 anticoagulant 5979-00-0 WARFARIN TA_LEVEL_1 Cardiovascular 5979-00-0 WARFARIN ZERO_CLASS N 5979-00-0 WARFARIN KNOWN_TOXICITY Nephrotoxicity 5979-00-0 WARFARIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 5979-00-0 WARFARIN ADVERSE_EFFECT BBM_3_Agranulocytosis 5979-00-0 WARFARIN ADVERSE_EFFECT GIS_2_Diarrhea 5979-00-0 WARFARIN ADVERSE_EFFECT BBM_3_Leukopenia 5979-00-0 WARFARIN STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 5979-00-0 WARFARIN ADVERSE_EFFECT KID_2_Hematuria 5979-00-0 WARFARIN ADVERSE_EFFECT GUS_3_Vaginal Bleeding 5979-00-0 WARFARIN INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 5979-00-0 WARFARIN ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 5979-00-0 WARFARIN ADVERSE_EFFECT LIV_2_Jaundice 5979-00-0 WARFARIN TISSUE_TOXICITY Hematuria 5979-00-0 WARFARIN TISSUE_TOXICITY Fetal Warfarin Syndrome 5979-00-0 WARFARIN ADVERSE_EFFECT NEU_3_Intracranial Bleeding 5979-00-0 WARFARIN MODE_CLASS Enzyme Inhibitor 5979-00-0 WARFARIN INDICATION Thrombosis Prophylaxis 5979-00-0 WARFARIN INDICATION Antiphospholipid Antibody Syndrome 5979-00-0 WARFARIN ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 5979-00-0 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Renal Damage 5979-00-0 WARFARIN ADVERSE_EFFECT BBM_2_Ecchymosis 5979-00-0 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenic Fetal Damage 5979-00-0 WARFARIN TISSUE_TOXICITY Teratogenic Fetal Damage 5979-00-0 WARFARIN TISSUE_TOXICITY Fetal Renal Damage 5979-00-0 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Warfarin Syndrome 5979-00-0 WARFARIN KNOWN_TOXICITY Cardiovascular Toxicity 5979-00-0 WARFARIN ADVERSE_EFFECT SKN_2_Pruritis 5979-00-0 WARFARIN ADVERSE_EFFECT PSY_2_Anorexia 5979-00-0 WARFARIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 5979-00-0 WARFARIN ADVERSE_EFFECT SKN_3_Skin Necrosis 5979-00-0 WARFARIN INDICATION Deep Vein Thrombosis 5979-00-0 WARFARIN INDICATION Postmyocardial Infarction 5979-00-0 WARFARIN MECHANISM Inhibit platelet aggregation 5979-00-0 WARFARIN TA_LEVEL_3 anticoagulant 5979-00-0 WARFARIN MECH_LEVEL_1 Anti-clotting 5979-00-0 WARFARIN PRODUCT_CLASS Hematologics 51-12-7 NIALAMIDE INDICATION Depression 51-12-7 NIALAMIDE PRODUCT_CLASS Central Nervous System (CNS) 51-12-7 NIALAMIDE THERAPEUTIC_CLASS Antidepressants 52-78-8 NORETHANDROLONE INDICATION Growth Disorder 52-78-8 NORETHANDROLONE INDICATION Aplastic Anemia 52-78-8 NORETHANDROLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 52-78-8 NORETHANDROLONE MODE_CLASS Receptor Agonist 52-78-8 NORETHANDROLONE MECHANISM Modulate gene transcription 52-78-8 NORETHANDROLONE THERAPEUTIC_CLASS Gonadal Hormones 54-95-5 PENTYLENETETRAZOLE INDICATION Depression 54-95-5 PENTYLENETETRAZOLE PRODUCT_CLASS Central Nervous System (CNS) 54-95-5 PENTYLENETETRAZOLE THERAPEUTIC_CLASS Antidepressants 55-73-2 BETHANIDINE PRODUCT_CLASS Cardiovasculars 55-73-2 BETHANIDINE INDICATION Hypertension 55-73-2 BETHANIDINE THERAPEUTIC_CLASS Antihypertensive Agents 58-19-5 DROMOSTANOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 58-19-5 DROMOSTANOLONE MODE_CLASS Receptor Agonist 58-19-5 DROMOSTANOLONE MECHANISM Modulate gene transcription 58-19-5 DROMOSTANOLONE THERAPEUTIC_CLASS Gonadal Hormones 59-98-3 TOLAZOLINE MECHANISM Reduce vasoconstriction 59-98-3 TOLAZOLINE MODE_CLASS Receptor Ligand Antagonist 61-01-8 METHOXYPROMAZINE MODE_CLASS Receptor Ligand Antagonist 61-01-8 METHOXYPROMAZINE MECHANISM Block neural transmission 61-01-8 METHOXYPROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 61-01-8 METHOXYPROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 61-01-8 METHOXYPROMAZINE THERAPEUTIC_CLASS Antipsychotics 64-65-3 BEMEGRIDE INDICATION Depression 64-65-3 BEMEGRIDE THERAPEUTIC_CLASS Antidepressants 64-65-3 BEMEGRIDE PRODUCT_CLASS Central Nervous System (CNS) 69-27-2 CHLORISONDAMINE DICHLORIDE MECHANISM Block neural transmission 69-27-2 CHLORISONDAMINE DICHLORIDE MODE_CLASS Channel Blocker 69-27-2 CHLORISONDAMINE DICHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 69-27-2 CHLORISONDAMINE DICHLORIDE PRODUCT_CLASS Cardiovasculars 77-12-3 PENTACYNIUM CHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 77-12-3 PENTACYNIUM CHLORIDE INDICATION Hypertension 77-12-3 PENTACYNIUM CHLORIDE PRODUCT_CLASS Cardiovasculars 77-20-3 ALPHA-PRODINE THERAPEUTIC_CLASS Analgesics, Opioid 77-20-3 ALPHA-PRODINE MODE_CLASS Receptor Agonist 77-20-3 ALPHA-PRODINE PRODUCT_CLASS Analgesics 77-20-3 ALPHA-PRODINE MECHANISM Modulate neural transmission 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT XXX_1_Asthenia 79-01-6 TRICHLOROETHYLENE PRODUCT_CLASS Toxicants 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_2_Loss of Consciousness 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_2_Disorder of Tactile Sensation 79-01-6 TRICHLOROETHYLENE TISSUE_TOXICITY Ventricular Fibrillation 79-01-6 TRICHLOROETHYLENE KNOWN_TOXICITY Nephrotoxicity 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 79-01-6 TRICHLOROETHYLENE KNOWN_TOXICITY Mutagenicity 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_1_Headache 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT KID_3_Renal Failure 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT LIV_2_Hepatic Injury 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_2_Anesthesia 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT REP_2_Decreased Sexual Ability 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT SKN_2_Skin Irritation 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT CVS_2_Ventricular Fibrillation 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT LIV_3_Hepatic Failure 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT XXX_1_Weight Loss 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT SKN_2_Dermatitis 79-01-6 TRICHLOROETHYLENE KNOWN_TOXICITY Carcinogenicity 79-01-6 TRICHLOROETHYLENE KNOWN_TOXICITY Hepatotoxicity 79-01-6 TRICHLOROETHYLENE TISSUE_TOXICITY Mutagenicity 79-01-6 TRICHLOROETHYLENE TISSUE_TOXICITY Death 79-01-6 TRICHLOROETHYLENE ACTIVITY_CLASS Toxicant, DNA damaging 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT CVS_2_Cardiac Disturbances 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT PSY_2_CNS Excitation 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT OCU_1_Eye Irritation 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT PSY_2_Psychosis 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT XXX_3_Death 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_1_Sleepiness 79-01-6 TRICHLOROETHYLENE KNOWN_TOXICITY Cardiovascular Toxicity 79-01-6 TRICHLOROETHYLENE TISSUE_TOXICITY Renal Failure 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT DNA_2_Mutagenicity 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT XXX_1_Throat Irritation 79-01-6 TRICHLOROETHYLENE TISSUE_TOXICITY Hepatic Failure 79-01-6 TRICHLOROETHYLENE TISSUE_TOXICITY Carcinogenicity 79-01-6 TRICHLOROETHYLENE KNOWN_TOXICITY Miscellaneous 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_1_Dizziness 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_3_Coma 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT KID_2_Renal Damage 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT PSY_2_CNS Depression 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT LUN_2_Tachypnea 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT XXX_1_Nose Irritation 79-01-6 TRICHLOROETHYLENE STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT DNA_3_Carcinogenicity 79-01-6 TRICHLOROETHYLENE ADVERSE_EFFECT SKN_2_Erythema 82-93-9 CHLORCYCLIZINE MODE_CLASS Receptor Ligand Antagonist 82-93-9 CHLORCYCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 82-93-9 CHLORCYCLIZINE MECHANISM Modulate G-protein coupled signal transduction 129-74-8 BUCLIZINE INDICATION Motion Sickness 129-74-8 BUCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 129-74-8 BUCLIZINE MECHANISM Modulate G-protein coupled signal transduction 129-74-8 BUCLIZINE MODE_CLASS Receptor Ligand Antagonist 129-74-8 BUCLIZINE INDICATION Nausea / Vomiting 129-74-8 BUCLIZINE PRODUCT_CLASS Gastrointestinal System 129-74-8 BUCLIZINE THERAPEUTIC_CLASS Antiemetics 84-08-2 PYRATHIAZINE PRODUCT_CLASS Anti-inflammatories 84-08-2 PYRATHIAZINE PRODUCT_CLASS Gastrointestinal System 84-08-2 PYRATHIAZINE THERAPEUTIC_CLASS Antihistamines 84-08-2 PYRATHIAZINE THERAPEUTIC_CLASS Antiemetics 84-08-2 PYRATHIAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 84-08-2 PYRATHIAZINE MODE_CLASS Receptor Ligand Antagonist 84-08-2 PYRATHIAZINE MECHANISM Block neural transmission 84-08-2 PYRATHIAZINE PRODUCT_CLASS Central Nervous System (CNS) 84-08-2 PYRATHIAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 33067-94-6 TETRAHYDROZOLINE INDICATION Allergic Conjunctivitis 33067-94-6 TETRAHYDROZOLINE MECHANISM Increase vasoconstriction 33067-94-6 TETRAHYDROZOLINE PRODUCT_CLASS Respiratory System 33067-94-6 TETRAHYDROZOLINE INDICATION Viral Conjunctivitis 33067-94-6 TETRAHYDROZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 33067-94-6 TETRAHYDROZOLINE MODE_CLASS Receptor Agonist 33067-94-6 TETRAHYDROZOLINE INDICATION Nasal Congestion 33067-94-6 TETRAHYDROZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 33067-94-6 TETRAHYDROZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 86-14-6 DIETHYLTHIAMBUTENE PRODUCT_CLASS Biochemicals 91-33-8 BENZTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 91-33-8 BENZTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 91-33-8 BENZTHIAZIDE MODE_CLASS Channel Blocker, selective 91-33-8 BENZTHIAZIDE THERAPEUTIC_CLASS Diuretics 91-33-8 BENZTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 91-33-8 BENZTHIAZIDE PRODUCT_CLASS Cardiovasculars 91-33-8 BENZTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 522-40-7 DIETHYLSTILBESTROL DIPHOSPHATE THERAPEUTIC_CLASS Gonadal Hormones 522-40-7 DIETHYLSTILBESTROL DIPHOSPHATE MODE_CLASS Receptor Ligand Antagonist 522-40-7 DIETHYLSTILBESTROL DIPHOSPHATE MECHANISM Modulate gene transcription 522-40-7 DIETHYLSTILBESTROL DIPHOSPHATE PRODUCT_CLASS Anti-cancers 524-84-5 DIMETHYLTHIAMBUTENE PRODUCT_CLASS Analgesics 524-84-5 DIMETHYLTHIAMBUTENE MECHANISM Modulate neural transmission 524-84-5 DIMETHYLTHIAMBUTENE MODE_CLASS Receptor Agonist 524-84-5 DIMETHYLTHIAMBUTENE THERAPEUTIC_CLASS Analgesics, Opioid 528-74-5 DICHLOROMETHOTREXATE MECHANISM Inhibit precursor synthesis 528-74-5 DICHLOROMETHOTREXATE THERAPEUTIC_CLASS Antineoplastics 528-74-5 DICHLOROMETHOTREXATE PRODUCT_CLASS Anti-cancers 528-74-5 DICHLOROMETHOTREXATE MODE_CLASS Enzyme substrate mimic 537-21-3 CHLORPROGUANIL INDICATION Malaria 551-27-9 PROPICILLIN THERAPEUTIC_CLASS Antibacterials 551-27-9 PROPICILLIN PRODUCT_CLASS Anti-infectives 551-27-9 PROPICILLIN MODE_CLASS Enzyme Inhibitor 551-27-9 PROPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 555-57-7 PARGYLINE PRODUCT_CLASS Cardiovasculars 555-57-7 PARGYLINE THERAPEUTIC_CLASS Antidepressants 555-57-7 PARGYLINE PRODUCT_CLASS Central Nervous System (CNS) 555-57-7 PARGYLINE THERAPEUTIC_CLASS Antihypertensive Agents 555-57-7 PARGYLINE MECHANISM Prolong/enhance neural transmission 555-57-7 PARGYLINE MODE_CLASS Enzyme Inhibitor 555-57-7 PARGYLINE INDICATION Hypertension 562-26-5 PHENOPERIDINE PRODUCT_CLASS Central Nervous System (CNS) 562-26-5 PHENOPERIDINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 562-26-5 PHENOPERIDINE PRODUCT_CLASS Analgesics 562-26-5 PHENOPERIDINE MECHANISM Modulate neural transmission 562-26-5 PHENOPERIDINE MODE_CLASS Receptor Agonist 562-26-5 PHENOPERIDINE THERAPEUTIC_CLASS Analgesics, Opioid 653-03-2 BUTAPERAZINE MECHANISM Block neural transmission 653-03-2 BUTAPERAZINE THERAPEUTIC_CLASS Antipsychotics 653-03-2 BUTAPERAZINE PRODUCT_CLASS Central Nervous System (CNS) 653-03-2 BUTAPERAZINE MODE_CLASS Receptor Ligand Antagonist 673-31-4 PHENPROBAMATE MECHANISM Block neural transmission 673-31-4 PHENPROBAMATE MODE_CLASS Channel Modulator 673-31-4 PHENPROBAMATE MECHANISM Modulate neural transmission 673-31-4 PHENPROBAMATE MODE_CLASS Channel Blocker 791-35-5 CHLOPHEDIANOL INDICATION Cough / Tussis 804-30-8 FURSULTIAMINE MECHANISM Vitamin/ cofactor 848-53-3 HOMOCHLORCYCLIZINE MECHANISM Modulate G-protein coupled signal transduction 848-53-3 HOMOCHLORCYCLIZINE MODE_CLASS Receptor Ligand Antagonist 865-04-3 METHOSERPIDINE THERAPEUTIC_CLASS Antihypertensive Agents 865-04-3 METHOSERPIDINE PRODUCT_CLASS Cardiovasculars 865-04-3 METHOSERPIDINE INDICATION Hypertension 892-49-9 ARABINOSYLMERCAPTOPURINE MECHANISM Incorporate into DNA/RNA/Protein 892-49-9 ARABINOSYLMERCAPTOPURINE PRODUCT_CLASS Anti-cancers 892-49-9 ARABINOSYLMERCAPTOPURINE MODE_CLASS Enzyme substrate mimic 892-49-9 ARABINOSYLMERCAPTOPURINE THERAPEUTIC_CLASS Antineoplastics 892-49-9 ARABINOSYLMERCAPTOPURINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 914-00-1 METHACYCLINE MECHANISM Inhibit ribosomal protein synthesis 914-00-1 METHACYCLINE PRODUCT_CLASS Anti-infectives 914-00-1 METHACYCLINE THERAPEUTIC_CLASS Antibacterials 914-00-1 METHACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 914-00-1 METHACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 959-10-4 XENBUCIN INDICATION Hyperlipoproteinemia 959-10-4 XENBUCIN PRODUCT_CLASS Cardiovasculars 959-10-4 XENBUCIN THERAPEUTIC_CLASS Hypolipidemic Agents 959-10-4 XENBUCIN INDICATION Hypercholesterolemia 983-85-7 PENAMECILLIN PRODUCT_CLASS Anti-infectives 983-85-7 PENAMECILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 983-85-7 PENAMECILLIN MODE_CLASS Enzyme Inhibitor 983-85-7 PENAMECILLIN THERAPEUTIC_CLASS Antibacterials 1043-21-6 PIRENOXINE INDICATION Cataract 3736-12-7 LEVOPROPYLCILLIN MODE_CLASS Enzyme Inhibitor 3736-12-7 LEVOPROPYLCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 3736-12-7 LEVOPROPYLCILLIN THERAPEUTIC_CLASS Antibacterials 3736-12-7 LEVOPROPYLCILLIN PRODUCT_CLASS Anti-infectives 3811-25-4 CLORPRENALINE INDICATION Prophylaxis of Asthma 3811-25-4 CLORPRENALINE ADVERSE_EFFECT NEU_1_Headache 3811-25-4 CLORPRENALINE MODE_CLASS Receptor Agonist 3811-25-4 CLORPRENALINE INDICATION Bronchospasm 3811-25-4 CLORPRENALINE STRUCTURE_ACTIVITY Adrenoceptor agonist 3811-25-4 CLORPRENALINE ADVERSE_EFFECT GIS_3_Epigastric Pain 3811-25-4 CLORPRENALINE PRODUCT_CLASS Respiratory System 3811-25-4 CLORPRENALINE TISSUE_TOXICITY Cardiac Arrhythmia 3811-25-4 CLORPRENALINE ADVERSE_EFFECT CVS_2_Palpitation 3811-25-4 CLORPRENALINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 3811-25-4 CLORPRENALINE MECHANISM Modulate G-protein coupled signal transduction 3811-25-4 CLORPRENALINE ADVERSE_EFFECT NEU_3_Tremor 3811-25-4 CLORPRENALINE KNOWN_TOXICITY Cardiovascular Toxicity 3811-25-4 CLORPRENALINE THERAPEUTIC_CLASS Bronchodilators 3819-00-9 PIPERACETAZINE MECHANISM Block neural transmission 3819-00-9 PIPERACETAZINE PRODUCT_CLASS Central Nervous System (CNS) 3819-00-9 PIPERACETAZINE PRODUCT_CLASS Anti-inflammatories 3819-00-9 PIPERACETAZINE THERAPEUTIC_CLASS Antipsychotics 3819-00-9 PIPERACETAZINE THERAPEUTIC_CLASS Antihistamines 3819-00-9 PIPERACETAZINE MODE_CLASS Receptor Ligand Antagonist 4533-39-5 NITRACRINE MODE_CLASS Distorts /blocks macromolecular scaffold function 4533-39-5 NITRACRINE MODE_CLASS Enzyme Inhibitor 4533-39-5 NITRACRINE MECHANISM Inhibit DNA synthesis, repair, and function 4755-59-3 CLODAZON INDICATION Depression 4755-59-3 CLODAZON THERAPEUTIC_CLASS Antidepressants 4755-59-3 CLODAZON PRODUCT_CLASS Central Nervous System (CNS) 7081-40-5 METHIXENE MODE_CLASS Enzyme Inhibitor 7081-40-5 METHIXENE INDICATION Parkinson's Disease 7081-40-5 METHIXENE MODE_CLASS Receptor Ligand Antagonist 7081-40-5 METHIXENE MECHANISM Modulate G-protein coupled signal transduction 13171-25-0 TRIMETAZIDINE THERAPEUTIC_CLASS Vasodilators 13171-25-0 TRIMETAZIDINE INDICATION Prevention of Cyclosporin A nephropathy 13171-25-0 TRIMETAZIDINE ADVERSE_EFFECT GIS_2_Nausea 13171-25-0 TRIMETAZIDINE INDICATION Vestibular syndrome 13171-25-0 TRIMETAZIDINE ADVERSE_EFFECT GIS_3_Epigastric Pain 13171-25-0 TRIMETAZIDINE INDICATION Angina Pectoris 13171-25-0 TRIMETAZIDINE PRODUCT_CLASS Other Human Uses 13171-25-0 TRIMETAZIDINE THERAPEUTIC_CLASS Antianginals 13171-25-0 TRIMETAZIDINE ADVERSE_EFFECT NEU_2_Dizziness 13171-25-0 TRIMETAZIDINE PRODUCT_CLASS Cardiovasculars 13171-25-0 TRIMETAZIDINE ADVERSE_EFFECT NEU_3_Headache 13171-25-0 TRIMETAZIDINE INDICATION Dizziness 13171-25-0 TRIMETAZIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5053-06-5 FENSPIRIDE MECHANISM Modulate G-protein coupled signal transduction 5053-06-5 FENSPIRIDE PRODUCT_CLASS Respiratory System 5053-06-5 FENSPIRIDE THERAPEUTIC_CLASS Bronchodilators 14860-49-2 CLOBUTINOL INDICATION Cough / Tussis 15301-48-1 BEZITRAMIDE PRODUCT_CLASS Analgesics 15301-48-1 BEZITRAMIDE MODE_CLASS Receptor Agonist 15301-48-1 BEZITRAMIDE THERAPEUTIC_CLASS Analgesics, Opioid 15301-48-1 BEZITRAMIDE MECHANISM Modulate neural transmission 15302-12-2 DIMELAZINE MODE_CLASS Receptor Ligand Antagonist 15302-12-2 DIMELAZINE THERAPEUTIC_CLASS Antihistamines 15302-12-2 DIMELAZINE PRODUCT_CLASS Anti-inflammatories 15302-12-2 DIMELAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 15302-12-2 DIMELAZINE PRODUCT_CLASS Central Nervous System (CNS) 15302-12-2 DIMELAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 15302-12-2 DIMELAZINE MECHANISM Block neural transmission 15686-23-4 TRIMOXAMINE THERAPEUTIC_CLASS Antihypertensive Agents 15686-23-4 TRIMOXAMINE PRODUCT_CLASS Cardiovasculars 15686-23-4 TRIMOXAMINE INDICATION Hypertension 17692-26-1 CYCLOPHENAZINE MECHANISM Block neural transmission 17692-26-1 CYCLOPHENAZINE MODE_CLASS Receptor Ligand Antagonist 17692-26-1 CYCLOPHENAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 17692-26-1 CYCLOPHENAZINE THERAPEUTIC_CLASS Antipsychotics 17692-26-1 CYCLOPHENAZINE PRODUCT_CLASS Central Nervous System (CNS) 17692-38-5 FLUPROFEN MECHANISM Inhibit eicosanoid biosynthesis 17692-38-5 FLUPROFEN MODE_CLASS Enzyme Inhibitor 17692-38-5 FLUPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 17692-38-5 FLUPROFEN PRODUCT_CLASS Anti-inflammatories 17692-38-5 FLUPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 28781-64-8 MENITRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 28781-64-8 MENITRAZEPAM MODE_CLASS Channel enhancer /opener 28781-64-8 MENITRAZEPAM MECHANISM Modulate neural transmission 28781-64-8 MENITRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 28781-64-8 MENITRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 29462-18-8 BENTAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 29462-18-8 BENTAZEPAM MECHANISM Modulate neural transmission 29462-18-8 BENTAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 29462-18-8 BENTAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 29462-18-8 BENTAZEPAM MODE_CLASS Channel enhancer /opener 672-72-0 AMYGDALIN(D) STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 672-72-0 AMYGDALIN(D) MECHANISM Inhibit mitochondrial function 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT SKN_2_Itching 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT GIS_1_Nausea / Vomiting 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT NEU_2_Dizziness 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT NEU_3_Peripheral Neuritis 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT PSN_3_Cyanide Toxicity 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT GIS_2_Diarrhea 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT LUN_3_Cyanosis 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT NEU_2_Headache 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT XXX_3_Fever 672-72-0 AMYGDALIN(D) THERAPEUTIC_CLASS Antineoplastics 672-72-0 AMYGDALIN(D) TISSUE_TOXICITY Hypotension 672-72-0 AMYGDALIN(D) KNOWN_TOXICITY Cardiovascular Toxicity 672-72-0 AMYGDALIN(D) ADVERSE_EFFECT CVS_3_Hypotension 672-72-0 AMYGDALIN(D) PRODUCT_CLASS Anti-cancers 30709-69-4 TIZOPROLIC ACID THERAPEUTIC_CLASS Hypolipidemic Agents 30709-69-4 TIZOPROLIC ACID INDICATION Hyperlipoproteinemia 30709-69-4 TIZOPROLIC ACID PRODUCT_CLASS Cardiovasculars 31101-25-4 MIRINCAMYCIN PRODUCT_CLASS Anti-infectives 31101-25-4 MIRINCAMYCIN THERAPEUTIC_CLASS Antibacterials 31101-25-4 MIRINCAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 31101-25-4 MIRINCAMYCIN MECHANISM Inhibit ribosomal protein synthesis 31430-15-6 FLUBENDAZOLE MECH_LEVEL_3 Microtubule tubulin, helminth selective 31430-15-6 FLUBENDAZOLE TA_LEVEL_3 pinworm, roundworm, hookworm 31430-15-6 FLUBENDAZOLE INDICATION Enterobiasis / Pinworm Infections 31430-15-6 FLUBENDAZOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 31430-15-6 FLUBENDAZOLE TA_LEVEL_1 Infectious Disease 31430-15-6 FLUBENDAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 31430-15-6 FLUBENDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 31430-15-6 FLUBENDAZOLE ZERO_CLASS N 31430-15-6 FLUBENDAZOLE THERAPEUTIC_CLASS Antiparasitics 31430-15-6 FLUBENDAZOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 31430-15-6 FLUBENDAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 31430-15-6 FLUBENDAZOLE MECH_LEVEL_2 Inhibit microtubule dependent glucose uptake 31430-15-6 FLUBENDAZOLE INDICATION Trichuriasis / Trichocephaliasis / Whipworm 31430-15-6 FLUBENDAZOLE INDICATION Nematode (Roundworm) Infections 31430-15-6 FLUBENDAZOLE TA_LEVEL_2 anthelmintic 31430-15-6 FLUBENDAZOLE MESH_LEVEL_3 Benzimidazoles 31430-15-6 FLUBENDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 31430-15-6 FLUBENDAZOLE PRODUCT_CLASS Anti-infectives 31430-15-6 FLUBENDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 31430-15-6 FLUBENDAZOLE INDICATION Hookworm Disease 31430-15-6 FLUBENDAZOLE ADVERSE_EFFECT GIS_2_Diarrhea 31848-01-8 MORCLOFONE INDICATION Cough / Tussis 32359-34-5 MEDIFOXAMINE THERAPEUTIC_CLASS Antidepressants 32359-34-5 MEDIFOXAMINE INDICATION Depression 32359-34-5 MEDIFOXAMINE PRODUCT_CLASS Central Nervous System (CNS) 31842-61-2 RIMITEROL PRODUCT_CLASS Autonomic Nervous System (ANS) 31842-61-2 RIMITEROL PRODUCT_CLASS Respiratory System 31842-61-2 RIMITEROL INDICATION Asthma 31842-61-2 RIMITEROL MECHANISM Reduce bronchoconstriction 31842-61-2 RIMITEROL MODE_CLASS Receptor Agonist, selective 31842-61-2 RIMITEROL THERAPEUTIC_CLASS Bronchodilators 31842-61-2 RIMITEROL THERAPEUTIC_CLASS Sympathomimetic Agents 33342-05-1 GLIQUIDONE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 33342-05-1 GLIQUIDONE MODE_CLASS Channel Blocker, selective 33342-05-1 GLIQUIDONE INDICATION Type II Diabetes Mellitus 33342-05-1 GLIQUIDONE THERAPEUTIC_CLASS Antidiabetic Agents 33342-05-1 GLIQUIDONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 33342-05-1 GLIQUIDONE MECHANISM Trigger insulin release in pancreatic beta cells 33605-94-6 PIRISUDANOL THERAPEUTIC_CLASS Antidepressants 33605-94-6 PIRISUDANOL PRODUCT_CLASS Central Nervous System (CNS) 33605-94-6 PIRISUDANOL INDICATION Depression 34482-99-0 FLETAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 34482-99-0 FLETAZEPAM MECHANISM Modulate neural transmission 34482-99-0 FLETAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 34482-99-0 FLETAZEPAM MODE_CLASS Channel enhancer /opener 34482-99-0 FLETAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 27724-96-5 CETRAXATE MECH_LEVEL_2 Enzyme inhibitor 27724-96-5 CETRAXATE MESH_LEVEL_3 Acids, Carbocyclic 27724-96-5 CETRAXATE MESH_LEVEL_2 Carboxylic Acids 27724-96-5 CETRAXATE ADVERSE_EFFECT GIS_3_Constipation 27724-96-5 CETRAXATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 27724-96-5 CETRAXATE ADVERSE_EFFECT CVS_3_Thrombosis 27724-96-5 CETRAXATE ACTIVITY_CLASS Increase gastric mucosal glycoprotein synthesis, molecular target unknown 27724-96-5 CETRAXATE TA_LEVEL_3 gastric ulcer 27724-96-5 CETRAXATE TA_LEVEL_1 Gastrointestinal System 27724-96-5 CETRAXATE KNOWN_TOXICITY Cardiovascular Toxicity 27724-96-5 CETRAXATE MESH_LEVEL_1 Organic Chemicals 27724-96-5 CETRAXATE MECH_LEVEL_3 plasmin 27724-96-5 CETRAXATE ADVERSE_EFFECT SKN_3_Pruritis 27724-96-5 CETRAXATE TISSUE_TOXICITY Thrombosis 27724-96-5 CETRAXATE ZERO_CLASS N 27724-96-5 CETRAXATE THERAPEUTIC_CLASS Antiulcers 27724-96-5 CETRAXATE STRUCTURE_ACTIVITY Increase gastric mucosal glycoprotein synthesis, molecular target unknown 27724-96-5 CETRAXATE ADVERSE_EFFECT GIS_3_Diarrhea 27724-96-5 CETRAXATE PRODUCT_CLASS Gastrointestinal System 27724-96-5 CETRAXATE INDICATION Gastric Ulcer 27724-96-5 CETRAXATE TA_LEVEL_2 anti-ulcer 27724-96-5 CETRAXATE ADVERSE_EFFECT SKN_3_Rash 27724-96-5 CETRAXATE INDICATION Gastritis 27724-96-5 CETRAXATE INDICATION Ulcer 27724-96-5 CETRAXATE ADVERSE_EFFECT GIS_3_Gastrointestinal Distress 52795-02-5 TAMETRALINE PRODUCT_CLASS Central Nervous System (CNS) 52795-02-5 TAMETRALINE INDICATION Depression 52795-02-5 TAMETRALINE THERAPEUTIC_CLASS Antidepressants 57775-22-1 ETOPERIDONE THERAPEUTIC_CLASS Antidepressants 57775-22-1 ETOPERIDONE INDICATION Depression 57775-22-1 ETOPERIDONE MODE_CLASS Receptor Ligand Antagonist 57775-22-1 ETOPERIDONE MECHANISM Reduce vasoconstriction 57775-22-1 ETOPERIDONE PRODUCT_CLASS Central Nervous System (CNS) 57775-22-1 ETOPERIDONE MECHANISM Modulate neural transmission 57775-22-1 ETOPERIDONE STRUCTURE_ACTIVITY 5HT2 antagonist 364782-34-3 CINACALCET STRUCTURE_ACTIVITY Calcimimetic 226256-56-0 CINACALCET STRUCTURE_ACTIVITY Calcimimetic 191732-72-6 REVLIMID PRODUCT_CLASS Cardiovasculars 191732-72-6 REVLIMID PRODUCT_CLASS Analgesics 191732-72-6 REVLIMID INDICATION Multiple Myeloma / Myelomatosis 191732-72-6 REVLIMID THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 191732-72-6 REVLIMID PRODUCT_CLASS Anti-cancers 191732-72-6 REVLIMID INDICATION Crohn's Disease 191732-72-6 REVLIMID INDICATION Melanoma 191732-72-6 REVLIMID INDICATION Inflammation 191732-72-6 REVLIMID THERAPEUTIC_CLASS Analgesics, Non-Opioid 191732-72-6 REVLIMID PRODUCT_CLASS Anti-inflammatories 191732-72-6 REVLIMID INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 191732-72-6 REVLIMID INDICATION Congestive Heart Failure (CHF) 191732-72-6 REVLIMID INDICATION Glioma 191732-72-6 REVLIMID INDICATION Pain 191732-72-6 REVLIMID INDICATION Ovarian Cancer / Carcinoma of the Ovary 191732-72-6 REVLIMID INDICATION Neoplasm / Cancer / Tumor 191732-72-6 REVLIMID INDICATION Inflammatory Bowel Disease (IBD) 191732-72-6 REVLIMID INDICATION Myelodysplastic Syndromes 191732-72-6 REVLIMID THERAPEUTIC_CLASS Antineoplastics 191732-72-6 REVLIMID THERAPEUTIC_CLASS Congestive Heart Failure 191732-72-6 REVLIMID STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 19171-19-8 ACTIMID PRODUCT_CLASS Anti-inflammatories 19171-19-8 ACTIMID THERAPEUTIC_CLASS Antineoplastics 19171-19-8 ACTIMID INDICATION Multiple Myeloma / Myelomatosis 19171-19-8 ACTIMID PRODUCT_CLASS Anti-cancers 19171-19-8 ACTIMID INDICATION Neoplasm / Cancer / Tumor 19171-19-8 ACTIMID INDICATION Prostatic Cancer / Carcinoma of the Prostate 19171-19-8 ACTIMID THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 19171-19-8 ACTIMID STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 19171-19-8 ACTIMID INDICATION Osteoarthritis 188696-80-2 AMP-397 THERAPEUTIC_CLASS Analgesics, Non-Opioid 188696-80-2 AMP-397 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 188696-80-2 AMP-397 STRUCTURE_ACTIVITY Glutamate receptor (AMPA) antagonist 188696-80-2 AMP-397 INDICATION Bipolar Disorders / Manic-Depression 188696-80-2 AMP-397 INDICATION Neuropathic Pain 188696-80-2 AMP-397 INDICATION Epilepsy 188696-80-2 AMP-397 PRODUCT_CLASS Analgesics 188696-80-2 AMP-397 THERAPEUTIC_CLASS Antipsychotics 188696-80-2 AMP-397 PRODUCT_CLASS Central Nervous System (CNS) 269718-83-4 SLV-308 PRODUCT_CLASS Central Nervous System (CNS) 269718-83-4 SLV-308 STRUCTURE_ACTIVITY Dopamine receptor (D2) agonist 269718-83-4 SLV-308 INDICATION Major Depression / Major Depressive Disorder 269718-83-4 SLV-308 THERAPEUTIC_CLASS Movement Disorders 269718-83-4 SLV-308 THERAPEUTIC_CLASS Anxiolytics 269718-83-4 SLV-308 INDICATION Parkinson's Disease 269718-83-4 SLV-308 THERAPEUTIC_CLASS Antidepressants 269718-83-4 SLV-308 INDICATION Anxiety Disorders 4670-05-7 THEAFLAVIN INDICATION Neoplasm / Cancer / Tumor 4670-05-7 THEAFLAVIN THERAPEUTIC_CLASS Antineoplastics 4670-05-7 THEAFLAVIN PRODUCT_CLASS Anti-cancers 4670-05-7 THEAFLAVIN STRUCTURE_ACTIVITY Apoptosis inducer 550-24-3 EMBELIN INDICATION Neoplasm / Cancer / Tumor 550-24-3 EMBELIN THERAPEUTIC_CLASS Antineoplastics 550-24-3 EMBELIN PRODUCT_CLASS Anti-cancers 550-24-3 EMBELIN STRUCTURE_ACTIVITY Apoptosis inducer 624747-15-5 M826 THERAPEUTIC_CLASS Cerebral Vascular Disorders 624747-15-5 M826 PRODUCT_CLASS Central Nervous System (CNS) 624747-15-5 M826 INDICATION Neuropathy 624747-15-5 M826 STRUCTURE_ACTIVITY Caspase inhibitor 624747-15-5 M826 INDICATION Cerebrovascular ischemia 624747-15-5 M826 THERAPEUTIC_CLASS Neurodegenerative Disorders 63208-82-2 PIFITHRIN-ALPHA THERAPEUTIC_CLASS Neurodegenerative Disorders 63208-82-2 PIFITHRIN-ALPHA PRODUCT_CLASS Central Nervous System (CNS) 63208-82-2 PIFITHRIN-ALPHA INDICATION Neuropathy 63208-82-2 PIFITHRIN-ALPHA STRUCTURE_ACTIVITY Apoptosis inhibitor 259199-65-0 CP-31398 INDICATION Neoplasm / Cancer / Tumor 259199-65-0 CP-31398 THERAPEUTIC_CLASS Antineoplastics 259199-65-0 CP-31398 PRODUCT_CLASS Anti-cancers 259199-65-0 CP-31398 STRUCTURE_ACTIVITY Apoptosis inducer, p53 function enhancer 344458-19-1 PJ-34 PRODUCT_CLASS Other Human Uses 344458-19-1 PJ-34 PRODUCT_CLASS Central Nervous System (CNS) 344458-19-1 PJ-34 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 344458-19-1 PJ-34 STRUCTURE_ACTIVITY Protein poly(ADP-ribose) polymerase (PARP) inhibitor 344458-19-1 PJ-34 INDICATION Neuropathy 344458-19-1 PJ-34 INDICATION Cerebrovascular ischemia 344458-19-1 PJ-34 THERAPEUTIC_CLASS Cerebral Vascular Disorders 344458-19-1 PJ-34 PRODUCT_CLASS Hormones, Endocrine and Metabolic 344458-19-1 PJ-34 THERAPEUTIC_CLASS Neurodegenerative Disorders 344458-19-1 PJ-34 INDICATION Sepsis 344458-19-1 PJ-34 INDICATION Diabetes Mellitus 344458-19-1 PJ-34 THERAPEUTIC_CLASS Antidiabetic Agents 90417-38-2 NU-1025 INDICATION Neoplasm / Cancer / Tumor 90417-38-2 NU-1025 THERAPEUTIC_CLASS Antineoplastics 90417-38-2 NU-1025 STRUCTURE_ACTIVITY Protein poly(ADP-ribose) polymerase (PARP) inhibitor 90417-38-2 NU-1025 PRODUCT_CLASS Anti-cancers 137881-27-7 INH2BP INDICATION Neoplasm / Cancer / Tumor 137881-27-7 INH2BP PRODUCT_CLASS Anti-inflammatories 137881-27-7 INH2BP INDICATION Cerebrovascular ischemia 137881-27-7 INH2BP PRODUCT_CLASS Central Nervous System (CNS) 137881-27-7 INH2BP THERAPEUTIC_CLASS Antineoplastics 137881-27-7 INH2BP INDICATION Inflammation 137881-27-7 INH2BP STRUCTURE_ACTIVITY Protein poly(ADP-ribose) polymerase (PARP) inhibitor 137881-27-7 INH2BP THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 137881-27-7 INH2BP INDICATION Septic Shock 137881-27-7 INH2BP THERAPEUTIC_CLASS Cerebral Vascular Disorders 137881-27-7 INH2BP PRODUCT_CLASS Anti-cancers 547757-23-3 BMS-345541 INDICATION Inflammatory Bowel Disease (IBD) 547757-23-3 BMS-345541 INDICATION Transplant Rejection 547757-23-3 BMS-345541 THERAPEUTIC_CLASS Immunosuppressants 547757-23-3 BMS-345541 STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor 547757-23-3 BMS-345541 INDICATION Inflammation of Respiratory Tract 547757-23-3 BMS-345541 PRODUCT_CLASS Anti-inflammatories 547757-23-3 BMS-345541 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 547757-23-3 BMS-345541 INDICATION Arthritis 547757-23-3 BMS-345541 MODE_CLASS Enzyme Inhibitor 547757-23-3 BMS-345541 INDICATION Transplant Rejection 547757-23-3 BMS-345541 INDICATION Arthritis 547757-23-3 BMS-345541 INDICATION Inflammation 547757-23-3 BMS-345541 MECHANISM Inhibit kinase mediated signal transduction 547757-23-3 BMS-345541 INDICATION Inflammation 547757-23-3 BMS-345541 INDICATION Inflammation of Respiratory Tract 547757-23-3 BMS-345541 PRODUCT_CLASS Immune Response / Immunomodulators 547757-23-3 BMS-345541 INDICATION Inflammatory Bowel Disease (IBD) 134381-21-8 EPOXOMICIN STRUCTURE_ACTIVITY Proteasome inhibitor 134381-21-8 EPOXOMICIN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 134381-21-8 EPOXOMICIN INDICATION Inflammation 134381-21-8 EPOXOMICIN PRODUCT_CLASS Anti-inflammatories 105201-55-6 APOGOSSYPOL PRODUCT_CLASS Anti-cancers 105201-55-6 APOGOSSYPOL THERAPEUTIC_CLASS Antineoplastics 105201-55-6 APOGOSSYPOL INDICATION Neoplasm / Cancer / Tumor 105201-55-6 APOGOSSYPOL STRUCTURE_ACTIVITY Apoptosis inducer, BH3 domain binder 10129-56-3 PETCM INDICATION Neoplasm / Cancer / Tumor 10129-56-3 PETCM THERAPEUTIC_CLASS Antineoplastics 10129-56-3 PETCM STRUCTURE_ACTIVITY Apoptosis inducer 10129-56-3 PETCM PRODUCT_CLASS Anti-cancers 557795-19-4 SU-11248 TISSUE_TOXICITY Thrombocytopenia 557795-19-4 SU-11248 THERAPEUTIC_CLASS Antineoplastics 557795-19-4 SU-11248 ADVERSE_EFFECT BBM_1_Thrombocytopenia 557795-19-4 SU-11248 ADVERSE_EFFECT XXX_1_Peripheral Edema 557795-19-4 SU-11248 ADVERSE_EFFECT CVS_3_Hypertension 557795-19-4 SU-11248 INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 557795-19-4 SU-11248 INDICATION Ovarian Cancer / Carcinoma of the Ovary 557795-19-4 SU-11248 INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 557795-19-4 SU-11248 PRODUCT_CLASS Anti-cancers 557795-19-4 SU-11248 STRUCTURE_ACTIVITY Protein-tyrosine kinase (Flt3) inhibitor 557795-19-4 SU-11248 INDICATION Prostatic Cancer / Carcinoma of the Prostate 557795-19-4 SU-11248 INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 557795-19-4 SU-11248 ADVERSE_EFFECT CVS_2_Phlebitis 557795-19-4 SU-11248 ADVERSE_EFFECT XXX_1_Edema 557795-19-4 SU-11248 ADVERSE_EFFECT XXX_1_Asthenia 557795-19-4 SU-11248 INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 557795-19-4 SU-11248 MODE_CLASS Enzyme Inhibitor 557795-19-4 SU-11248 TISSUE_TOXICITY Skin Toxicity 557795-19-4 SU-11248 ADVERSE_EFFECT XXX_1_Fatigue 557795-19-4 SU-11248 INDICATION Neoplasm / Cancer / Tumor 557795-19-4 SU-11248 MECHANISM Inhibit kinase mediated signal transduction 557795-19-4 SU-11248 ADVERSE_EFFECT LUN_3_Pulmonary Embolism 557795-19-4 SU-11248 ADVERSE_EFFECT BBM_1_Neutropenia 557795-19-4 SU-11248 ADVERSE_EFFECT GIS_2_Esophagitis 557795-19-4 SU-11248 INDICATION Neoplasm / Cancer / Tumor 557795-19-4 SU-11248 TISSUE_TOXICITY Neutropenia 557795-19-4 SU-11248 KNOWN_TOXICITY Dermatologic Toxicity 557795-19-4 SU-11248 KNOWN_TOXICITY Blood & Bone Marrow Toxicity 557795-19-4 SU-11248 ADVERSE_EFFECT GIS_1_Nausea / Vomiting 557795-19-4 SU-11248 INDICATION Brain Cancer 557795-19-4 SU-11248 ADVERSE_EFFECT SKN_1_Skin Toxicity 557795-19-4 SU-11248 ADVERSE_EFFECT XXX_2_Palmar-Plantar Erythrodysesthesia 557795-19-4 SU-11248 INDICATION Gastrointestinal Stromal Tumors 557795-19-4 SU-11248 INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 302962-49-8 BMS-354825 INDICATION Lymphoblastic Lymphoma 302962-49-8 BMS-354825 ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 302962-49-8 BMS-354825 INDICATION Neoplasm / Cancer / Tumor 302962-49-8 BMS-354825 INDICATION Multiple Myeloma / Myelomatosis 302962-49-8 BMS-354825 MECHANISM Inhibit kinase mediated signal transduction 302962-49-8 BMS-354825 STRUCTURE_ACTIVITY Protein-tyrosine kinase (Bcr-Abl) inhibitor 302962-49-8 BMS-354825 ADVERSE_EFFECT SKN_1_Rash 302962-49-8 BMS-354825 INDICATION Neoplasm / Cancer / Tumor 302962-49-8 BMS-354825 ADVERSE_EFFECT LUN_2_Pleural Effusion 302962-49-8 BMS-354825 ADVERSE_EFFECT BBM_2_Myelosuppression 302962-49-8 BMS-354825 ADVERSE_EFFECT GIS_1_Diarrhea 302962-49-8 BMS-354825 THERAPEUTIC_CLASS Antineoplastics 302962-49-8 BMS-354825 INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 302962-49-8 BMS-354825 INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 302962-49-8 BMS-354825 PRODUCT_CLASS Anti-cancers 302962-49-8 BMS-354825 MODE_CLASS Enzyme Inhibitor 202807-80-5 MRZ 2/576 PRODUCT_CLASS Analgesics 202807-80-5 MRZ 2/576 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 202807-80-5 MRZ 2/576 INDICATION Cerebrovascular ischemia 202807-80-5 MRZ 2/576 PRODUCT_CLASS Central Nervous System (CNS) 202807-80-5 MRZ 2/576 THERAPEUTIC_CLASS Cerebral Vascular Disorders 202807-80-5 MRZ 2/576 INDICATION Neuropathy 202807-80-5 MRZ 2/576 THERAPEUTIC_CLASS Neurodegenerative Disorders 202807-80-5 MRZ 2/576 INDICATION Epilepsy 202807-80-5 MRZ 2/576 INDICATION Pain 202807-80-5 MRZ 2/576 STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 202807-80-5 MRZ 2/576 THERAPEUTIC_CLASS Analgesics, Non-Opioid 379270-37-8 GS-7340 STRUCTURE_ACTIVITY Viral RT inhibitor 379270-37-8 GS-7340 THERAPEUTIC_CLASS Antivirals, Systemic 379270-37-8 GS-7340 INDICATION Human Immunodeficiency Virus (HIV) Disease 379270-37-8 GS-7340 PRODUCT_CLASS Anti-infectives 372151-71-8 TELAVANCIN INDICATION Skin Infections 372151-71-8 TELAVANCIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 372151-71-8 TELAVANCIN THERAPEUTIC_CLASS Antibacterials, Systemic 372151-71-8 TELAVANCIN INDICATION Gram-Positive Infection 372151-71-8 TELAVANCIN PRODUCT_CLASS Anti-infectives 368455-04-3 ISA-247 INDICATION Psoriasis 368455-04-3 ISA-247 INDICATION Rheumatoid Arthritis 368455-04-3 ISA-247 INDICATION Transplant Rejection 368455-04-3 ISA-247 THERAPEUTIC_CLASS Immunosuppressants 368455-04-3 ISA-247 STRUCTURE_ACTIVITY Inhibits T-cell activation 368455-04-3 ISA-247 PRODUCT_CLASS Immune Response / Immunomodulators 368455-04-3 ISA-247 INDICATION Type I Diabetes Mellitus 244-63-3 BETA-CARBOLINE STRUCTURE_ACTIVITY Protein-tyrosine kinase (Bcr-Abl) inhibitor 244-63-3 BETA-CARBOLINE INDICATION Neoplasm / Cancer / Tumor 244-63-3 BETA-CARBOLINE THERAPEUTIC_CLASS Antineoplastics 244-63-3 BETA-CARBOLINE PRODUCT_CLASS Anti-cancers 252916-29-3 SU-6668 INDICATION Neoplasm / Cancer / Tumor 252916-29-3 SU-6668 THERAPEUTIC_CLASS Antineoplastics 252916-29-3 SU-6668 PRODUCT_CLASS Anti-cancers 252916-29-3 SU-6668 STRUCTURE_ACTIVITY Protein-tyrosine kinase (EGFR) inhibitor 196809-22-0 GW-7845 PRODUCT_CLASS Anti-cancers 196809-22-0 GW-7845 INDICATION Neoplasm / Cancer / Tumor 196809-22-0 GW-7845 STRUCTURE_ACTIVITY PPAR gamma agonist 196809-22-0 GW-7845 THERAPEUTIC_CLASS Antineoplastics 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT BBM_2_Anemia 30562-34-6 GELDANAMYCIN MODE_CLASS Enzyme Inhibitor 30562-34-6 GELDANAMYCIN INDICATION Inflammation 30562-34-6 GELDANAMYCIN MECHANISM Modulate growth factor receptor mediated signal transduction 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT PSY_1_Anorexia 30562-34-6 GELDANAMYCIN PRODUCT_CLASS Anti-infectives 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT GIS_1_Nausea 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT XXX_1_Cytotoxicity 30562-34-6 GELDANAMYCIN INDICATION Neoplasm / Cancer / Tumor 30562-34-6 GELDANAMYCIN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 30562-34-6 GELDANAMYCIN TISSUE_TOXICITY Hepatotoxicity 30562-34-6 GELDANAMYCIN THERAPEUTIC_CLASS Antineoplastics 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 30562-34-6 GELDANAMYCIN PRODUCT_CLASS Anti-cancers 30562-34-6 GELDANAMYCIN INDICATION Neoplasm / Cancer / Tumor 30562-34-6 GELDANAMYCIN KNOWN_TOXICITY Hepatotoxicity 30562-34-6 GELDANAMYCIN ADVERSE_EFFECT XXX_2_Fatigue 30562-34-6 GELDANAMYCIN STRUCTURE_ACTIVITY Protein-tyrosine kinase (MET/HGFR) inhibitor 280744-09-4 SB-216763 INDICATION Diabetes Mellitus 280744-09-4 SB-216763 MECHANISM Inhibit kinase mediated signal transduction 280744-09-4 SB-216763 STRUCTURE_ACTIVITY Glycogen synthase kinase-3 (GSK-3) inhibitor 280744-09-4 SB-216763 INDICATION Neuropathy 280744-09-4 SB-216763 THERAPEUTIC_CLASS Antidiabetic Agents 280744-09-4 SB-216763 MODE_CLASS Enzyme Inhibitor 280744-09-4 SB-216763 INDICATION Cerebrovascular Accident / Stroke 280744-09-4 SB-216763 PRODUCT_CLASS Other Human Uses 280744-09-4 SB-216763 INDICATION Diabetes Mellitus 280744-09-4 SB-216763 THERAPEUTIC_CLASS Neurodegenerative Disorders 280744-09-4 SB-216763 PRODUCT_CLASS Hormones, Endocrine and Metabolic 280744-09-4 SB-216763 INDICATION Neuropathy 280744-09-4 SB-216763 INDICATION Ischemia 280744-09-4 SB-216763 PRODUCT_CLASS Central Nervous System (CNS) 280744-09-4 SB-216763 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 264218-23-7 SB-415286 PRODUCT_CLASS Central Nervous System (CNS) 264218-23-7 SB-415286 THERAPEUTIC_CLASS Neurodegenerative Disorders 264218-23-7 SB-415286 INDICATION Diabetes Mellitus 264218-23-7 SB-415286 STRUCTURE_ACTIVITY Glycogen synthase kinase-3 (GSK-3) inhibitor 264218-23-7 SB-415286 PRODUCT_CLASS Hormones, Endocrine and Metabolic 264218-23-7 SB-415286 THERAPEUTIC_CLASS Antidiabetic Agents 264218-23-7 SB-415286 INDICATION Neuropathy 141849-44-7 1B4M-DTPA PRODUCT_CLASS Anti-cancers 141849-44-7 1B4M-DTPA THERAPEUTIC_CLASS Antineoplastics 141849-44-7 1B4M-DTPA INDICATION Neoplasm / Cancer / Tumor 157380-45-5 CHX-A" DTPA INDICATION Neoplasm / Cancer / Tumor 157380-45-5 CHX-A" DTPA THERAPEUTIC_CLASS Antineoplastics 157380-45-5 CHX-A" DTPA PRODUCT_CLASS Anti-cancers 82079-32-1 THIOLACTOMYCIN STRUCTURE_ACTIVITY Bacterial lipid metabolism inhibitor 3380-34-5 TRICLOSAN STRUCTURE_ACTIVITY Bacterial lipid metabolism inhibitor 3380-34-5 TRICLOSAN THERAPEUTIC_CLASS Antibacterials, Systemic 3380-34-5 TRICLOSAN INDICATION Skin Infections 3380-34-5 TRICLOSAN THERAPEUTIC_CLASS Antiparasitics 3380-34-5 TRICLOSAN PRODUCT_CLASS Anti-infectives 3380-34-5 TRICLOSAN INDICATION Malaria 192939-46-1 XIMELAGATRAN STRUCTURE_ACTIVITY Thrombin inhibitor 192939-46-1 XIMELAGATRAN THERAPEUTIC_CLASS Anticoagulants 192939-46-1 XIMELAGATRAN PRODUCT_CLASS Hematologics 192939-46-1 XIMELAGATRAN INDICATION Atrial Fibrillation 192939-46-1 XIMELAGATRAN INDICATION Myocardial Infarction 192939-46-1 XIMELAGATRAN INDICATION Deep Vein Thrombosis 76808-16-7 EBELACTONE A STRUCTURE_ACTIVITY Lipase (gastric and pancreatic) inhibitor 153125-17-8 RO-23-9358 STRUCTURE_ACTIVITY Antiinflammatory, phospholipase A2 inhibitor 6754-58-1 XANTHOHUMOL STRUCTURE_ACTIVITY Toxicant, free radical generator 177469-96-4 IMPLITAPIDE INDICATION Hyperlipidemia 177469-96-4 IMPLITAPIDE PRODUCT_CLASS Cardiovasculars 177469-96-4 IMPLITAPIDE STRUCTURE_ACTIVITY Toxicant, free radical generator 177469-96-4 IMPLITAPIDE INDICATION Atherosclerosis 177469-96-4 IMPLITAPIDE THERAPEUTIC_CLASS Hypolipidemic Agents 76578-12-6 QUIZALOFOP STRUCTURE_ACTIVITY Toxicant, free radical generator 256934-39-1 HU-308 PRODUCT_CLASS Anti-inflammatories 256934-39-1 HU-308 THERAPEUTIC_CLASS Neurodegenerative Disorders 256934-39-1 HU-308 INDICATION Inflammation 256934-39-1 HU-308 PRODUCT_CLASS Analgesics 256934-39-1 HU-308 PRODUCT_CLASS Central Nervous System (CNS) 256934-39-1 HU-308 INDICATION Neuropathy 256934-39-1 HU-308 STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist, DNA alkylator 256934-39-1 HU-308 THERAPEUTIC_CLASS Analgesics, Non-Opioid 256934-39-1 HU-308 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 256934-39-1 HU-308 INDICATION Pain 128007-31-8 ARVANIL STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist, DNA alkylator 106400-81-1 LOMETREXOL ADVERSE_EFFECT GIS_2_Stomatitis 106400-81-1 LOMETREXOL ADVERSE_EFFECT XXX_1_Mucositis 106400-81-1 LOMETREXOL MECHANISM Inhibit precursor synthesis 106400-81-1 LOMETREXOL STRUCTURE_ACTIVITY Antifolate 106400-81-1 LOMETREXOL ADVERSE_EFFECT BBM_3_Thrombocytopenia 106400-81-1 LOMETREXOL INDICATION Non-Small Cell Lung Carcinoma 106400-81-1 LOMETREXOL INDICATION Carcinoid Tumors 106400-81-1 LOMETREXOL MODE_CLASS Enzyme Inhibitor 106400-81-1 LOMETREXOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 106400-81-1 LOMETREXOL ADVERSE_EFFECT BBM_3_Myelosuppression 106400-81-1 LOMETREXOL PRODUCT_CLASS Anti-cancers 106400-81-1 LOMETREXOL INDICATION Breast Cancer / Carcinoma of the Breast 106400-81-1 LOMETREXOL THERAPEUTIC_CLASS Antineoplastics 106400-81-1 LOMETREXOL ADVERSE_EFFECT GIS_2_Constipation 106400-81-1 LOMETREXOL INDICATION Head and Neck Cancer 106400-81-1 LOMETREXOL INDICATION Neoplasm / Cancer / Tumor 106400-81-1 LOMETREXOL ADVERSE_EFFECT BBM_2_Anemia 106400-81-1 LOMETREXOL ADVERSE_EFFECT KID_2_Impaired Renal Tubular Function 106400-81-1 LOMETREXOL INDICATION Melanoma 106400-81-1 LOMETREXOL ADVERSE_EFFECT GIS_2_Diarrhea 120408-07-3 LOMETREXOL THERAPEUTIC_CLASS Antineoplastics 120408-07-3 LOMETREXOL INDICATION Neoplasm / Cancer / Tumor 120408-07-3 LOMETREXOL ADVERSE_EFFECT BBM_2_Anemia 120408-07-3 LOMETREXOL ADVERSE_EFFECT GIS_2_Stomatitis 120408-07-3 LOMETREXOL INDICATION Carcinoid Tumors 120408-07-3 LOMETREXOL ADVERSE_EFFECT GIS_2_Constipation 120408-07-3 LOMETREXOL STRUCTURE_ACTIVITY Antifolate 120408-07-3 LOMETREXOL ADVERSE_EFFECT KID_2_Impaired Renal Tubular Function 120408-07-3 LOMETREXOL ADVERSE_EFFECT BBM_3_Thrombocytopenia 120408-07-3 LOMETREXOL ADVERSE_EFFECT GIS_2_Diarrhea 120408-07-3 LOMETREXOL INDICATION Head and Neck Cancer 120408-07-3 LOMETREXOL INDICATION Non-Small Cell Lung Carcinoma 120408-07-3 LOMETREXOL MECHANISM Inhibit precursor synthesis 120408-07-3 LOMETREXOL ADVERSE_EFFECT XXX_1_Mucositis 120408-07-3 LOMETREXOL INDICATION Melanoma 120408-07-3 LOMETREXOL MODE_CLASS Enzyme Inhibitor 120408-07-3 LOMETREXOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 120408-07-3 LOMETREXOL ADVERSE_EFFECT BBM_3_Myelosuppression 120408-07-3 LOMETREXOL PRODUCT_CLASS Anti-cancers 120408-07-3 LOMETREXOL INDICATION Breast Cancer / Carcinoma of the Breast 135821-54-4 CEFTIZOXIME ALAPIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 135821-54-4 CEFTIZOXIME ALAPIVOXIL THERAPEUTIC_CLASS Antibacterials 135821-54-4 CEFTIZOXIME ALAPIVOXIL PRODUCT_CLASS Anti-infectives 135821-54-4 CEFTIZOXIME ALAPIVOXIL MODE_CLASS Enzyme Inhibitor 131410-48-5 GADODIAMIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 131410-48-5 GADODIAMIDE INDICATION Contrasting Agent 122536-20-3 PD-131112 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 127045-41-4 PAZUFLOXACIN PRODUCT_CLASS Anti-infectives 127045-41-4 PAZUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 127045-41-4 PAZUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 127045-41-4 PAZUFLOXACIN THERAPEUTIC_CLASS Antibacterials 127045-41-4 PAZUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 127046-45-1 PAZUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 127046-45-1 PAZUFLOXACIN PRODUCT_CLASS Anti-infectives 127046-45-1 PAZUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 127046-45-1 PAZUFLOXACIN THERAPEUTIC_CLASS Antibacterials 127046-45-1 PAZUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 78997-40-7 PRISOTINOL INDICATION Osteoarthritis 117143-81-4 DALFOPRISTIN MECHANISM Inhibit ribosomal protein synthesis 117143-81-4 DALFOPRISTIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT XXX_1_Pain 131740-09-5 FLAVOPIRIDOL INDICATION Neoplasm / Cancer / Tumor 131740-09-5 FLAVOPIRIDOL MECHANISM Inhibit kinase mediated signal transduction 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT BBM_2_Neutropenia 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT BBM_2_Anemia 131740-09-5 FLAVOPIRIDOL INDICATION Acute Lymphocytic Leukemia (ALL) 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT LUN_1_Cough 131740-09-5 FLAVOPIRIDOL INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 131740-09-5 FLAVOPIRIDOL INDICATION Multiple Myeloma / Myelomatosis 131740-09-5 FLAVOPIRIDOL INDICATION Esophageal Cancer / Carcinoma of the Esophagus 131740-09-5 FLAVOPIRIDOL PRODUCT_CLASS Anti-cancers 131740-09-5 FLAVOPIRIDOL THERAPEUTIC_CLASS Antineoplastics 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT NEU_2_Motor Neuropathy 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT GIS_1_Diarrhea 131740-09-5 FLAVOPIRIDOL INDICATION Lung Cancer / Carcinoma of the Lung 131740-09-5 FLAVOPIRIDOL INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 131740-09-5 FLAVOPIRIDOL STRUCTURE_ACTIVITY Apoptosis inducer, Cyclin-dependent kinase inhibitor 131740-09-5 FLAVOPIRIDOL MODE_CLASS Enzyme Inhibitor 131740-09-5 FLAVOPIRIDOL INDICATION Prostatic Cancer / Carcinoma of the Prostate 131740-09-5 FLAVOPIRIDOL INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT GIS_1_Nausea 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT LUN_1_Dyspnea 131740-09-5 FLAVOPIRIDOL INDICATION Lymphoma 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT GIS_3_Gastrointestinal Toxicity 131740-09-5 FLAVOPIRIDOL ADVERSE_EFFECT XXX_1_Fatigue 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT GIS_1_Nausea 131739-92-9 FLAVOPIRIDOL INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 131739-92-9 FLAVOPIRIDOL INDICATION Prostatic Cancer / Carcinoma of the Prostate 131739-92-9 FLAVOPIRIDOL MODE_CLASS Enzyme Inhibitor 131739-92-9 FLAVOPIRIDOL INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 131739-92-9 FLAVOPIRIDOL INDICATION Lymphoma 131739-92-9 FLAVOPIRIDOL INDICATION Lung Cancer / Carcinoma of the Lung 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT GIS_1_Diarrhea 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT NEU_2_Motor Neuropathy 131739-92-9 FLAVOPIRIDOL THERAPEUTIC_CLASS Antineoplastics 131739-92-9 FLAVOPIRIDOL PRODUCT_CLASS Anti-cancers 131739-92-9 FLAVOPIRIDOL INDICATION Esophageal Cancer / Carcinoma of the Esophagus 131739-92-9 FLAVOPIRIDOL INDICATION Multiple Myeloma / Myelomatosis 131739-92-9 FLAVOPIRIDOL STRUCTURE_ACTIVITY Apoptosis inducer, Cyclin-dependent kinase inhibitor 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT GIS_3_Gastrointestinal Toxicity 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT XXX_1_Pain 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT BBM_2_Anemia 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT XXX_1_Fatigue 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT BBM_2_Neutropenia 131739-92-9 FLAVOPIRIDOL MECHANISM Inhibit kinase mediated signal transduction 131739-92-9 FLAVOPIRIDOL INDICATION Acute Lymphocytic Leukemia (ALL) 131739-92-9 FLAVOPIRIDOL INDICATION Neoplasm / Cancer / Tumor 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT LUN_1_Cough 131739-92-9 FLAVOPIRIDOL ADVERSE_EFFECT LUN_1_Dyspnea 131739-92-9 FLAVOPIRIDOL INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT LUN_1_Dyspnea 146426-40-6 FLAVOPIRIDOL INDICATION Multiple Myeloma / Myelomatosis 146426-40-6 FLAVOPIRIDOL INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 146426-40-6 FLAVOPIRIDOL INDICATION Esophageal Cancer / Carcinoma of the Esophagus 146426-40-6 FLAVOPIRIDOL PRODUCT_CLASS Anti-cancers 146426-40-6 FLAVOPIRIDOL THERAPEUTIC_CLASS Antineoplastics 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT NEU_2_Motor Neuropathy 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT GIS_1_Diarrhea 146426-40-6 FLAVOPIRIDOL INDICATION Lung Cancer / Carcinoma of the Lung 146426-40-6 FLAVOPIRIDOL INDICATION Lymphoma 146426-40-6 FLAVOPIRIDOL INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 146426-40-6 FLAVOPIRIDOL STRUCTURE_ACTIVITY Apoptosis inducer, Cyclin-dependent kinase inhibitor 146426-40-6 FLAVOPIRIDOL MODE_CLASS Enzyme Inhibitor 146426-40-6 FLAVOPIRIDOL INDICATION Prostatic Cancer / Carcinoma of the Prostate 146426-40-6 FLAVOPIRIDOL INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT GIS_1_Nausea 146426-40-6 FLAVOPIRIDOL INDICATION Neoplasm / Cancer / Tumor 146426-40-6 FLAVOPIRIDOL INDICATION Acute Lymphocytic Leukemia (ALL) 146426-40-6 FLAVOPIRIDOL MECHANISM Inhibit kinase mediated signal transduction 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT BBM_2_Neutropenia 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT XXX_1_Fatigue 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT BBM_2_Anemia 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT XXX_1_Pain 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT GIS_3_Gastrointestinal Toxicity 146426-40-6 FLAVOPIRIDOL ADVERSE_EFFECT LUN_1_Cough 124669-21-2 DUP-860 STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 124669-22-3 DUP-860 STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 124669-23-4 DUP-860 STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 124669-25-6 DUP-860 STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 132100-55-1 DALVASTATIN MECHANISM Inhibit cholesterol biosynthesis 132100-55-1 DALVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 132100-55-1 DALVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 132100-55-1 DALVASTATIN PRODUCT_CLASS Cardiovasculars 132100-55-1 DALVASTATIN MODE_CLASS Enzyme Inhibitor 132100-55-1 DALVASTATIN INDICATION Hyperlipidemia 132100-55-1 DALVASTATIN INDICATION Hypolipidemia 135910-20-2 DALVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 135910-20-2 DALVASTATIN INDICATION Hypolipidemia 135910-20-2 DALVASTATIN MODE_CLASS Enzyme Inhibitor 135910-20-2 DALVASTATIN MECHANISM Inhibit cholesterol biosynthesis 135910-20-2 DALVASTATIN INDICATION Hyperlipidemia 135910-20-2 DALVASTATIN PRODUCT_CLASS Cardiovasculars 135910-20-2 DALVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 125235-15-6 R-68151 MECHANISM Inhibit eicosanoid biosynthesis 125235-15-6 R-68151 INDICATION Psoriasis 125235-15-6 R-68151 MODE_CLASS Enzyme Inhibitor 148408-65-5 SUNEPITRON HYDROCHLORIDE MECHANISM Modulate G-protein coupled signal transduction 148408-65-5 SUNEPITRON HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 148408-65-5 SUNEPITRON HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 148408-65-5 SUNEPITRON HYDROCHLORIDE MECHANISM Modulate neural transmission 148408-65-5 SUNEPITRON HYDROCHLORIDE INDICATION Anxiety Disorders 148408-65-5 SUNEPITRON HYDROCHLORIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 148408-65-5 SUNEPITRON HYDROCHLORIDE INDICATION Depression 131744-27-9 SUNEPITRON HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 131744-27-9 SUNEPITRON HYDROCHLORIDE INDICATION Depression 131744-27-9 SUNEPITRON HYDROCHLORIDE MECHANISM Modulate neural transmission 131744-27-9 SUNEPITRON HYDROCHLORIDE INDICATION Anxiety Disorders 131744-27-9 SUNEPITRON HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 131744-27-9 SUNEPITRON HYDROCHLORIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 131744-27-9 SUNEPITRON HYDROCHLORIDE MECHANISM Modulate G-protein coupled signal transduction 140841-32-3 ICI-D2138 PRODUCT_CLASS Anti-inflammatories 140841-32-3 ICI-D2138 MODE_CLASS Enzyme Inhibitor 140841-32-3 ICI-D2138 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 140841-32-3 ICI-D2138 MECHANISM Inhibit eicosanoid biosynthesis 133563-45-8 BW-534U87 MECHANISM Block neural transmission 133563-45-8 BW-534U87 PRODUCT_CLASS Central Nervous System (CNS) 133563-45-8 BW-534U87 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 133563-45-8 BW-534U87 MODE_CLASS Channel Blocker 121277-96-1 TERIKALANT FUMARATE THERAPEUTIC_CLASS Antiarrhythmic Agents 121277-96-1 TERIKALANT FUMARATE MODE_CLASS Channel Modulator 121277-96-1 TERIKALANT FUMARATE MECHANISM Modulate channel gating 121277-96-1 TERIKALANT FUMARATE INDICATION Cardiac Arrhythmias 121277-96-1 TERIKALANT FUMARATE PRODUCT_CLASS Cardiovasculars 121277-97-2 TERIKALANT FUMARATE MECHANISM Modulate channel gating 121277-97-2 TERIKALANT FUMARATE MODE_CLASS Channel Modulator 121277-97-2 TERIKALANT FUMARATE THERAPEUTIC_CLASS Antiarrhythmic Agents 121277-97-2 TERIKALANT FUMARATE PRODUCT_CLASS Cardiovasculars 121277-97-2 TERIKALANT FUMARATE INDICATION Cardiac Arrhythmias 129729-66-4 EMAKALIM PRODUCT_CLASS Central Nervous System (CNS) 129729-66-4 EMAKALIM MECHANISM Modulate channel gating 129729-66-4 EMAKALIM INDICATION Hypertension 129729-66-4 EMAKALIM MODE_CLASS Channel Modulator 129729-66-4 EMAKALIM THERAPEUTIC_CLASS Antihypertensive Agents 129729-66-4 EMAKALIM PRODUCT_CLASS Cardiovasculars 129729-66-4 EMAKALIM INDICATION Depression 129729-66-4 EMAKALIM THERAPEUTIC_CLASS Antidepressants 63-89-8 COLFOSCERIL PALMITATE INDICATION Acute Respiratory Distress Syndrome (ARDS) 51025-85-5 ARBEKACIN SULFATE PRODUCT_CLASS Anti-infectives 51025-85-5 ARBEKACIN SULFATE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 51025-85-5 ARBEKACIN SULFATE MECHANISM Inhibit ribosomal protein synthesis 51025-85-5 ARBEKACIN SULFATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 51025-85-5 ARBEKACIN SULFATE THERAPEUTIC_CLASS Antibacterials 128232-14-4 RAXOFELAST PRODUCT_CLASS Vitamins, Minerals and Nutrients 128232-14-4 RAXOFELAST MECHANISM Scavenges hydrogen peroxide and free radicals 132236-18-1 ZIFROSILONE THERAPEUTIC_CLASS Parasympathomimetic Agents 132236-18-1 ZIFROSILONE MODE_CLASS Enzyme Inhibitor 132236-18-1 ZIFROSILONE PRODUCT_CLASS Autonomic Nervous System (ANS) 132236-18-1 ZIFROSILONE MECHANISM Enhance cholinergic transmission 129746-22-1 ADCI MECHANISM Block neural transmission 129746-22-1 ADCI THERAPEUTIC_CLASS Cerebral Vascular Disorders 129746-22-1 ADCI STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, tricyclic anticonvulsant 129746-22-1 ADCI MODE_CLASS Channel Blocker 129746-22-1 ADCI ADVERSE_EFFECT NEU_2_Impaired Motor Function 129746-22-1 ADCI ADVERSE_EFFECT NEU_2_Ataxia 129746-22-1 ADCI INDICATION Cerebral Ischemia 129746-22-1 ADCI INDICATION Convulsions 129746-22-1 ADCI THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 129746-22-1 ADCI PRODUCT_CLASS Central Nervous System (CNS) 129746-22-1 ADCI INDICATION Seizure Disorders 129746-22-1 ADCI INDICATION Epilepsy 130332-27-3 PD-134308 THERAPEUTIC_CLASS Sedatives/Hypnotics 130332-27-3 PD-134308 PRODUCT_CLASS Central Nervous System (CNS) 130332-27-3 PD-134308 MODE_CLASS Receptor Ligand Antagonist 130332-27-3 PD-134308 MECHANISM Reduce stomach HCl secretion 130332-27-3 PD-134308 INDICATION Anxiety Disorders 130404-91-0 PD-134308 PRODUCT_CLASS Central Nervous System (CNS) 130404-91-0 PD-134308 MODE_CLASS Receptor Ligand Antagonist 130404-91-0 PD-134308 MECHANISM Reduce stomach HCl secretion 130404-91-0 PD-134308 THERAPEUTIC_CLASS Sedatives/Hypnotics 130404-91-0 PD-134308 INDICATION Anxiety Disorders 133903-90-9 ME-3407 INDICATION Ulcer 112086-30-3 CL-284027 PRODUCT_CLASS Cardiovasculars 112086-30-3 CL-284027 THERAPEUTIC_CLASS Antiarrhythmic Agents 112086-30-3 CL-284027 INDICATION Cardiac Arrhythmias 112102-38-2 CL-284027 INDICATION Cardiac Arrhythmias 112102-38-2 CL-284027 THERAPEUTIC_CLASS Antiarrhythmic Agents 112102-38-2 CL-284027 PRODUCT_CLASS Cardiovasculars 112102-34-8 CL-284027 THERAPEUTIC_CLASS Antiarrhythmic Agents 112102-34-8 CL-284027 PRODUCT_CLASS Cardiovasculars 112102-34-8 CL-284027 INDICATION Cardiac Arrhythmias 67392-87-4 DROSPIRENONE MODE_CLASS Receptor Agonist 67392-87-4 DROSPIRENONE MECHANISM Modulate gene transcription 67392-87-4 DROSPIRENONE MODE_CLASS Receptor Ligand Antagonist 53873-28-2 BTG-1501 PRODUCT_CLASS Central Nervous System (CNS) 53873-28-2 BTG-1501 THERAPEUTIC_CLASS Sedatives/Hypnotics 53873-28-2 BTG-1501 INDICATION Anxiety Disorders 106134-33-2 RO-22-9194 INDICATION Cardiac Arrhythmias 106134-33-2 RO-22-9194 PRODUCT_CLASS Cardiovasculars 106134-33-2 RO-22-9194 THERAPEUTIC_CLASS Antiarrhythmic Agents 106134-32-1 RO-22-9194 THERAPEUTIC_CLASS Antiarrhythmic Agents 106134-32-1 RO-22-9194 INDICATION Cardiac Arrhythmias 106134-32-1 RO-22-9194 PRODUCT_CLASS Cardiovasculars 5534-02-1 BETAMETHASONE BUTYRATE PROPIONATE MECHANISM Modulate gene transcription 5534-02-1 BETAMETHASONE BUTYRATE PROPIONATE MODE_CLASS Receptor Agonist 5534-02-1 BETAMETHASONE BUTYRATE PROPIONATE THERAPEUTIC_CLASS Corticosteroids 5534-02-1 BETAMETHASONE BUTYRATE PROPIONATE PRODUCT_CLASS Anti-inflammatories 131262-82-3 SC-49483 INDICATION Myocardial Ischemia 125197-24-2 BMY-41802 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 125197-23-1 BMY-41802 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 116143-31-8 BMY-41802 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 130953-69-4 BESIPIRDINE HYDROCHLORIDE MODE_CLASS Channel Blocker 130953-69-4 BESIPIRDINE HYDROCHLORIDE THERAPEUTIC_CLASS Neurodegenerative Disorders 130953-69-4 BESIPIRDINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 130953-69-4 BESIPIRDINE HYDROCHLORIDE MECHANISM Block neural transmission 134822-78-9 CGS-23885 MECHANISM Inhibit eicosanoid biosynthesis 134822-78-9 CGS-23885 MODE_CLASS Enzyme Inhibitor 134067-56-4 MK-434 MECHANISM Inhibit steroid biosynthesis/ metabolism 134067-56-4 MK-434 MODE_CLASS Enzyme Inhibitor 134067-56-4 MK-434 PRODUCT_CLASS Anti-cancers 134067-56-4 MK-434 THERAPEUTIC_CLASS Antineoplastics 136199-02-5 KW-3902 INDICATION Renal Failure / Kidney Failure 131179-95-8 EFAPROXIRAL PRODUCT_CLASS Anti-cancers 131179-95-8 EFAPROXIRAL STRUCTURE_ACTIVITY Radiosensitizer 119085-25-5 YM-435 INDICATION Hypertension 119085-25-5 YM-435 THERAPEUTIC_CLASS Antihypertensive Agents 119085-25-5 YM-435 PRODUCT_CLASS Cardiovasculars 119086-13-4 YM-435 THERAPEUTIC_CLASS Antihypertensive Agents 119086-13-4 YM-435 PRODUCT_CLASS Cardiovasculars 119086-13-4 YM-435 INDICATION Hypertension 127408-30-4 Y-27152 INDICATION Angina Pectoris 127408-30-4 Y-27152 THERAPEUTIC_CLASS Antianginals 127408-30-4 Y-27152 INDICATION Hypertension 127408-30-4 Y-27152 THERAPEUTIC_CLASS Antihypertensive Agents 127408-30-4 Y-27152 MODE_CLASS Channel Modulator 127408-30-4 Y-27152 MECHANISM Modulate channel gating 127408-30-4 Y-27152 PRODUCT_CLASS Cardiovasculars 127408-32-6 Y-27152 INDICATION Angina Pectoris 127408-32-6 Y-27152 THERAPEUTIC_CLASS Antianginals 127408-32-6 Y-27152 INDICATION Hypertension 127408-32-6 Y-27152 PRODUCT_CLASS Cardiovasculars 127408-32-6 Y-27152 THERAPEUTIC_CLASS Antihypertensive Agents 127408-32-6 Y-27152 MODE_CLASS Channel Modulator 127408-32-6 Y-27152 MECHANISM Modulate channel gating 100429-08-1 TA-2005 MECHANISM Modulate G-protein coupled signal transduction 100429-09-2 TA-2005 MECHANISM Modulate G-protein coupled signal transduction 100331-97-3 TA-2005 MECHANISM Modulate G-protein coupled signal transduction 100331-98-4 TA-2005 MECHANISM Modulate G-protein coupled signal transduction 112835-48-0 N-0923 MECHANISM Modulate G-protein coupled signal transduction 112835-48-0 N-0923 INDICATION Parkinson's Disease 99755-59-6 N-0923 INDICATION Parkinson's Disease 99755-59-6 N-0923 MECHANISM Modulate G-protein coupled signal transduction 113349-24-9 N-0923 INDICATION Parkinson's Disease 113349-24-9 N-0923 MECHANISM Modulate G-protein coupled signal transduction 92206-54-7 N-0923 INDICATION Parkinson's Disease 92206-54-7 N-0923 MECHANISM Modulate G-protein coupled signal transduction 125572-93-2 N-0923 MECHANISM Modulate G-protein coupled signal transduction 125572-93-2 N-0923 INDICATION Parkinson's Disease 125572-92-1 N-0923 MECHANISM Modulate G-protein coupled signal transduction 125572-92-1 N-0923 INDICATION Parkinson's Disease 102120-99-0 N-0923 INDICATION Parkinson's Disease 102120-99-0 N-0923 MECHANISM Modulate G-protein coupled signal transduction 136013-69-9 WAY-100289 MODE_CLASS Solute transporter inhibitor 136013-69-9 WAY-100289 INDICATION Nausea / Vomiting 136013-69-9 WAY-100289 MECHANISM Block neural transmission 136013-69-9 WAY-100289 PRODUCT_CLASS Central Nervous System (CNS) 136013-69-9 WAY-100289 THERAPEUTIC_CLASS Sedatives/Hypnotics 136013-69-9 WAY-100289 MODE_CLASS Channel Blocker 136013-69-9 WAY-100289 MECHANISM Prolong/enhance neural transmission 136013-69-9 WAY-100289 INDICATION Anxiety Disorders 135135-87-4 DUP-734 MODE_CLASS Receptor Ligand Antagonist 135135-87-4 DUP-734 INDICATION Dyskinesia 135135-87-4 DUP-734 MECHANISM Modulate neural transmission 136668-42-3 QUIFLAPON MECHANISM Inhibit eicosanoid biosynthesis 136668-42-3 QUIFLAPON THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 136668-42-3 QUIFLAPON MODE_CLASS Enzyme Inhibitor 136668-42-3 QUIFLAPON PRODUCT_CLASS Anti-inflammatories 147030-01-1 QUIFLAPON THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 147030-01-1 QUIFLAPON MECHANISM Inhibit eicosanoid biosynthesis 147030-01-1 QUIFLAPON MODE_CLASS Enzyme Inhibitor 147030-01-1 QUIFLAPON PRODUCT_CLASS Anti-inflammatories 135070-05-2 E-4177 MECHANISM Reduce vasoconstriction 135070-05-2 E-4177 THERAPEUTIC_CLASS Antihypertensive Agents 135070-05-2 E-4177 INDICATION Hypertension 135070-05-2 E-4177 PRODUCT_CLASS Cardiovasculars 135070-05-2 E-4177 MODE_CLASS Receptor Ligand Antagonist, Selective 112966-96-8 DOMITROBAN INDICATION Viral Rhinitis / Common Cold 132747-47-8 DOMITROBAN INDICATION Viral Rhinitis / Common Cold 142646-78-4 DOMITROBAN INDICATION Viral Rhinitis / Common Cold 131177-19-0 DOMITROBAN INDICATION Viral Rhinitis / Common Cold 126784-99-4 CDB-2914 MECHANISM Modulate gene transcription 126784-99-4 CDB-2914 MODE_CLASS Receptor Ligand Antagonist 126784-99-4 CDB-2914 THERAPEUTIC_CLASS Gonadal Hormones 126784-99-4 CDB-2914 PRODUCT_CLASS Hormones, Endocrine and Metabolic 81872-09-5 ZOFENOPRILAT INDICATION Hypertension 81872-09-5 ZOFENOPRILAT MECHANISM Reduce vasoconstriction 81872-09-5 ZOFENOPRILAT PRODUCT_CLASS Cardiovasculars 81872-09-5 ZOFENOPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 81872-09-5 ZOFENOPRILAT MODE_CLASS Enzyme Inhibitor 75176-37-3 ZOFENOPRILAT MECHANISM Reduce vasoconstriction 75176-37-3 ZOFENOPRILAT INDICATION Hypertension 75176-37-3 ZOFENOPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 75176-37-3 ZOFENOPRILAT MODE_CLASS Enzyme Inhibitor 75176-37-3 ZOFENOPRILAT PRODUCT_CLASS Cardiovasculars 34661-75-1 URAPIDIL MECHANISM Reduce vasoconstriction 34661-75-1 URAPIDIL MODE_CLASS Receptor Agonist 34661-75-1 URAPIDIL THERAPEUTIC_CLASS Vasodilators 34661-75-1 URAPIDIL STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 34661-75-1 URAPIDIL MODE_CLASS Receptor Ligand Antagonist 34661-75-1 URAPIDIL PRODUCT_CLASS Cardiovasculars 34661-75-1 URAPIDIL INDICATION Hypertension 34661-75-1 URAPIDIL THERAPEUTIC_CLASS Antihypertensive Agents 34661-75-1 URAPIDIL MECHANISM Modulate neural transmission 109333-26-8 NPC-567 INDICATION Viral Rhinitis / Common Cold 109333-26-8 NPC-567 MECHANISM Modulate G-protein coupled signal transduction 62-46-4 THIOCTIC ACID INDICATION Glaucoma 62-46-4 THIOCTIC ACID MECHANISM Scavenges hydrogen peroxide and free radicals 62-46-4 THIOCTIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 62-46-4 THIOCTIC ACID INDICATION Diabetic Neuropathy 1077-28-7 THIOCTIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 1077-28-7 THIOCTIC ACID INDICATION Glaucoma 1077-28-7 THIOCTIC ACID INDICATION Diabetic Neuropathy 1077-28-7 THIOCTIC ACID MECHANISM Scavenges hydrogen peroxide and free radicals 135809-60-8 SR-47063 MODE_CLASS Channel enhancer /opener 135809-60-8 SR-47063 PRODUCT_CLASS Cardiovasculars 135809-60-8 SR-47063 MECHANISM Reduce muscle contractile force 135809-60-8 SR-47063 THERAPEUTIC_CLASS Antiarrhythmic Agents 135809-60-8 SR-47063 THERAPEUTIC_CLASS Vasodilators 109348-38-1 MCI-225 MECHANISM Block neural transmission 109348-38-1 MCI-225 PRODUCT_CLASS Central Nervous System (CNS) 109348-38-1 MCI-225 MODE_CLASS Channel Blocker 109348-38-1 MCI-225 THERAPEUTIC_CLASS Antidepressants 109348-38-1 MCI-225 INDICATION Depression 99487-25-9 MCI-225 MODE_CLASS Channel Blocker 99487-25-9 MCI-225 PRODUCT_CLASS Central Nervous System (CNS) 99487-25-9 MCI-225 INDICATION Depression 99487-25-9 MCI-225 THERAPEUTIC_CLASS Antidepressants 99487-25-9 MCI-225 MECHANISM Block neural transmission 135991-48-9 MCI-225 PRODUCT_CLASS Central Nervous System (CNS) 135991-48-9 MCI-225 MECHANISM Block neural transmission 135991-48-9 MCI-225 INDICATION Depression 135991-48-9 MCI-225 MODE_CLASS Channel Blocker 135991-48-9 MCI-225 THERAPEUTIC_CLASS Antidepressants 99487-26-0 MCI-225 PRODUCT_CLASS Central Nervous System (CNS) 99487-26-0 MCI-225 THERAPEUTIC_CLASS Antidepressants 99487-26-0 MCI-225 INDICATION Depression 99487-26-0 MCI-225 MECHANISM Block neural transmission 99487-26-0 MCI-225 MODE_CLASS Channel Blocker 139314-01-5 QUILOSTIGMINE THERAPEUTIC_CLASS Neurodegenerative Disorders 139314-01-5 QUILOSTIGMINE THERAPEUTIC_CLASS Parasympathomimetic Agents 139314-01-5 QUILOSTIGMINE INDICATION Alzheimer's Disease 139314-01-5 QUILOSTIGMINE PRODUCT_CLASS Central Nervous System (CNS) 139314-01-5 QUILOSTIGMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 139314-01-5 QUILOSTIGMINE MODE_CLASS Enzyme Inhibitor 139314-01-5 QUILOSTIGMINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 137975-06-5 OPC-31260 MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 137975-06-5 OPC-31260 MODE_CLASS Receptor Ligand Antagonist, Selective 1069-66-5 VALPROATE MAGNESIUM THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 1069-66-5 VALPROATE MAGNESIUM PRODUCT_CLASS Central Nervous System (CNS) 1069-66-5 VALPROATE MAGNESIUM INDICATION Complex Partial Seizures 1069-66-5 VALPROATE MAGNESIUM INDICATION Absence (Petit Mal) Seizures 119906-28-4 GR-63799X INDICATION Ulcer 119805-97-9 GR-63799X INDICATION Ulcer 106342-69-2 GR-63799X INDICATION Ulcer 127061-56-7 EPC-K1 MODE_CLASS Enzyme Inhibitor 132697-38-2 EPC-K1 MODE_CLASS Enzyme Inhibitor 137281-23-3 PEMETREXED PRODUCT_CLASS Anti-cancers 137281-23-3 PEMETREXED MODE_CLASS Enzyme Inhibitor 137281-23-3 PEMETREXED STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 137281-23-3 PEMETREXED MODE_CLASS Enzyme substrate mimic 137281-23-3 PEMETREXED MECHANISM Inhibit precursor synthesis 137281-23-3 PEMETREXED THERAPEUTIC_CLASS Antineoplastics 150399-23-8 PEMETREXED MODE_CLASS Enzyme substrate mimic 150399-23-8 PEMETREXED STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 150399-23-8 PEMETREXED THERAPEUTIC_CLASS Antineoplastics 150399-23-8 PEMETREXED MECHANISM Inhibit precursor synthesis 150399-23-8 PEMETREXED PRODUCT_CLASS Anti-cancers 150399-23-8 PEMETREXED MODE_CLASS Enzyme Inhibitor 134867-97-3 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 134867-97-3 G-256 PRODUCT_CLASS Cardiovasculars 134867-97-3 G-256 INDICATION Cardiac Arrhythmias 134867-96-2 G-256 PRODUCT_CLASS Cardiovasculars 134867-96-2 G-256 INDICATION Cardiac Arrhythmias 134867-96-2 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136440-59-0 G-256 PRODUCT_CLASS Cardiovasculars 136440-59-0 G-256 INDICATION Cardiac Arrhythmias 136440-59-0 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136623-31-9 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136623-31-9 G-256 PRODUCT_CLASS Cardiovasculars 136623-31-9 G-256 INDICATION Cardiac Arrhythmias 136623-32-0 G-256 INDICATION Cardiac Arrhythmias 136623-32-0 G-256 PRODUCT_CLASS Cardiovasculars 136623-32-0 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136623-35-3 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136623-35-3 G-256 PRODUCT_CLASS Cardiovasculars 136623-35-3 G-256 INDICATION Cardiac Arrhythmias 136623-34-2 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136623-34-2 G-256 PRODUCT_CLASS Cardiovasculars 136623-34-2 G-256 INDICATION Cardiac Arrhythmias 136623-33-1 G-256 INDICATION Cardiac Arrhythmias 136623-33-1 G-256 THERAPEUTIC_CLASS Antiarrhythmic Agents 136623-33-1 G-256 PRODUCT_CLASS Cardiovasculars 136433-51-7 TAZOFELONE INDICATION Irritable Bowel Syndrome 70774-25-3 LEURUBICIN THERAPEUTIC_CLASS Antineoplastics 70774-25-3 LEURUBICIN PRODUCT_CLASS Anti-cancers 70774-25-3 LEURUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 70774-25-3 LEURUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 70774-25-3 LEURUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 135905-89-4 MIRISETRON MECHANISM Prolong/enhance neural transmission 135905-89-4 MIRISETRON MECHANISM Block neural transmission 135905-89-4 MIRISETRON MODE_CLASS Solute transporter inhibitor 135905-89-4 MIRISETRON MODE_CLASS Channel Blocker, selective 135905-89-4 MIRISETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 135905-89-4 MIRISETRON PRODUCT_CLASS Central Nervous System (CNS) 127142-14-7 348U87 MODE_CLASS Enzyme Inhibitor 127142-14-7 348U87 MECHANISM Inhibit DNA synthesis, repair, and function 122344-31-4 PIMILPROST MECHANISM Modulate G-protein coupled signal transduction 122344-31-4 PIMILPROST MODE_CLASS Receptor Agonist 139403-31-9 PIMILPROST MECHANISM Modulate G-protein coupled signal transduction 139403-31-9 PIMILPROST MODE_CLASS Receptor Agonist 133430-69-0 ETH-615 POTASSIUM SALT INDICATION Psoriasis 133430-69-0 ETH-615 POTASSIUM SALT MECHANISM Inhibit eicosanoid biosynthesis 133430-69-0 ETH-615 POTASSIUM SALT MODE_CLASS Enzyme Inhibitor 87940-60-1 EPROBEMIDE THERAPEUTIC_CLASS Antidepressants 87940-60-1 EPROBEMIDE INDICATION Depression 87940-60-1 EPROBEMIDE PRODUCT_CLASS Central Nervous System (CNS) 128075-79-6 LUFIRONIL INDICATION Liver Fibrosis 128075-79-6 LUFIRONIL THERAPEUTIC_CLASS Immunosuppressants 128075-79-6 LUFIRONIL PRODUCT_CLASS Immune Response / Immunomodulators 128075-79-6 LUFIRONIL INDICATION Arthritis 120066-54-8 GADOTERIDOL PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 120066-54-8 GADOTERIDOL INDICATION Contrasting Agent 136236-51-6 RASAGILINE MESILATE INDICATION Parkinson's Disease 161735-79-1 RASAGILINE MESILATE INDICATION Parkinson's Disease 132684-62-9 NPC-15669 INDICATION Irritable Bowel Syndrome 111477-47-5 174630 MECHANISM Inhibit precursor synthesis 111477-47-5 174630 MODE_CLASS Enzyme Inhibitor 111477-47-5 174630 INDICATION Diabetes 136544-11-1 YM-934 MECHANISM Reduce muscle contractile force 136544-11-1 YM-934 THERAPEUTIC_CLASS Antihypertensive Agents 136544-11-1 YM-934 MODE_CLASS Channel enhancer /opener 136544-11-1 YM-934 THERAPEUTIC_CLASS Antianginals 136544-11-1 YM-934 PRODUCT_CLASS Cardiovasculars 2627-69-2 ACADESINE THERAPEUTIC_CLASS Antianginals 2627-69-2 ACADESINE PRODUCT_CLASS Cardiovasculars 2627-69-2 ACADESINE INDICATION Angina Pectoris 127245-22-1 BF-389 MODE_CLASS Enzyme Inhibitor 127245-22-1 BF-389 MECHANISM Inhibit eicosanoid biosynthesis 136468-36-5 FOROPAFANT INDICATION Irritable Bowel Syndrome 136145-07-8 AROFYLLINE MECHANISM Enhance kinase mediated signal transduction 136145-07-8 AROFYLLINE MODE_CLASS Enzyme Inhibitor 137431-02-8 PNO-49B INDICATION Urinary Incontinence / Enuresis 137431-04-0 PNO-49B INDICATION Urinary Incontinence / Enuresis 137315-05-0 PNO-49B INDICATION Urinary Incontinence / Enuresis 137315-06-1 PNO-49B INDICATION Urinary Incontinence / Enuresis 137431-03-9 PNO-49B INDICATION Urinary Incontinence / Enuresis 137099-09-3 TUROSTERIDE (-)-ENANTIOMER MODE_CLASS Enzyme Inhibitor 137099-09-3 TUROSTERIDE (-)-ENANTIOMER MECHANISM Inhibit steroid biosynthesis/ metabolism 137099-09-3 TUROSTERIDE (-)-ENANTIOMER INDICATION Prostatic Cancer / Carcinoma of the Prostate 137099-09-3 TUROSTERIDE (-)-ENANTIOMER PRODUCT_CLASS Anti-cancers 137099-09-3 TUROSTERIDE (-)-ENANTIOMER THERAPEUTIC_CLASS Antineoplastics 124884-99-7 YM17E INDICATION Hypolipidemia 124884-99-7 YM17E MODE_CLASS Enzyme Inhibitor 124884-99-7 YM17E MECHANISM Inhibit steroid biosynthesis/ metabolism 119169-78-7 EPRISTERIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 119169-78-7 EPRISTERIDE PRODUCT_CLASS Anti-cancers 119169-78-7 EPRISTERIDE MODE_CLASS Enzyme Inhibitor 119169-78-7 EPRISTERIDE THERAPEUTIC_CLASS Antineoplastics 104340-86-5 LEMINOPRAZOLE MODE_CLASS Enzyme Inhibitor 104340-86-5 LEMINOPRAZOLE INDICATION Ulcer 104340-86-5 LEMINOPRAZOLE MECHANISM Reduce stomach HCl secretion 104340-86-5 LEMINOPRAZOLE PRODUCT_CLASS Gastrointestinal System 104340-86-5 LEMINOPRAZOLE THERAPEUTIC_CLASS Antiulcers 137071-32-0 PIMECROLIMUS STRUCTURE_ACTIVITY Inhibits T-cell activation 137071-32-0 PIMECROLIMUS INDICATION Eczema Herpeticum 128517-07-7 FR-901228 STRUCTURE_ACTIVITY Histone deacetylase inhibitor 63132-39-8 OLPADRONIC ACID SODIUM SALT PRODUCT_CLASS Hormones, Endocrine and Metabolic 63132-39-8 OLPADRONIC ACID SODIUM SALT MODE_CLASS Enzyme Inhibitor 63132-39-8 OLPADRONIC ACID SODIUM SALT MECHANISM Inhibit bone re-absorption 63132-39-8 OLPADRONIC ACID SODIUM SALT THERAPEUTIC_CLASS Bone Mineral Homeostasis 63132-39-8 OLPADRONIC ACID SODIUM SALT STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 23694-81-7 MEPINDOLOL INDICATION Hypertension 23694-81-7 MEPINDOLOL MECHANISM Modulate G-protein coupled signal transduction 23694-81-7 MEPINDOLOL THERAPEUTIC_CLASS Antianginals 23694-81-7 MEPINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 23694-81-7 MEPINDOLOL PRODUCT_CLASS Cardiovasculars 23694-81-7 MEPINDOLOL INDICATION Angina Pectoris 23694-81-7 MEPINDOLOL MODE_CLASS Receptor Ligand Antagonist 23694-81-7 MEPINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 82522-70-1 MODECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 82522-70-1 MODECAINIDE PRODUCT_CLASS Cardiovasculars 82522-70-1 MODECAINIDE INDICATION Cardiac Arrhythmias 81329-71-7 MODECAINIDE PRODUCT_CLASS Cardiovasculars 81329-71-7 MODECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 81329-71-7 MODECAINIDE INDICATION Cardiac Arrhythmias 91097-81-3 BRL 35135 PRODUCT_CLASS Autonomic Nervous System (ANS) 91097-81-3 BRL 35135 MECHANISM Modulate G-protein coupled signal transduction 91097-81-3 BRL 35135 MODE_CLASS Receptor Agonist, selective 91097-81-3 BRL 35135 INDICATION Diabetes 91097-81-3 BRL 35135 THERAPEUTIC_CLASS Sympathomimetic Agents 91097-81-3 BRL 35135 PRODUCT_CLASS Hormones, Endocrine and Metabolic 91097-81-3 BRL 35135 THERAPEUTIC_CLASS Antidiabetic Agents 91097-81-3 BRL 35135 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 91097-81-3 BRL 35135 INDICATION Obesity 86615-41-0 BRL 35135 THERAPEUTIC_CLASS Antidiabetic Agents 86615-41-0 BRL 35135 PRODUCT_CLASS Hormones, Endocrine and Metabolic 86615-41-0 BRL 35135 THERAPEUTIC_CLASS Sympathomimetic Agents 86615-41-0 BRL 35135 INDICATION Obesity 86615-41-0 BRL 35135 INDICATION Diabetes 86615-41-0 BRL 35135 MECHANISM Modulate G-protein coupled signal transduction 86615-41-0 BRL 35135 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 86615-41-0 BRL 35135 PRODUCT_CLASS Autonomic Nervous System (ANS) 86615-41-0 BRL 35135 MODE_CLASS Receptor Agonist, selective 140695-21-2 OSUTIDINE MECHANISM Reduce stomach HCl secretion 140695-21-2 OSUTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 123280-14-8 OSUTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 123280-14-8 OSUTIDINE MECHANISM Reduce stomach HCl secretion 123280-13-7 OSUTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 123280-13-7 OSUTIDINE MECHANISM Reduce stomach HCl secretion 123280-17-1 OSUTIDINE MECHANISM Reduce stomach HCl secretion 123280-17-1 OSUTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 122665-73-0 CMDA STRUCTURE_ACTIVITY DNA-alkylator, methanesulfonate 123122-54-3 CANDOXATRILAT MECHANISM Modulate G-protein coupled signal transduction 123122-54-3 CANDOXATRILAT MODE_CLASS Enzyme Inhibitor 123122-54-3 CANDOXATRILAT INDICATION Hypertension 123122-54-3 CANDOXATRILAT THERAPEUTIC_CLASS Antihypertensive Agents 123122-54-3 CANDOXATRILAT PRODUCT_CLASS Cardiovasculars 118783-94-1 CANDOXATRILAT MECHANISM Modulate G-protein coupled signal transduction 118783-94-1 CANDOXATRILAT THERAPEUTIC_CLASS Antihypertensive Agents 118783-94-1 CANDOXATRILAT INDICATION Hypertension 118783-94-1 CANDOXATRILAT PRODUCT_CLASS Cardiovasculars 118783-94-1 CANDOXATRILAT MODE_CLASS Enzyme Inhibitor 123122-55-4 CANDOXATRIL MECHANISM Modulate G-protein coupled signal transduction 123122-55-4 CANDOXATRIL THERAPEUTIC_CLASS Antihypertensive Agents 123122-55-4 CANDOXATRIL PRODUCT_CLASS Cardiovasculars 123122-55-4 CANDOXATRIL MODE_CLASS Enzyme Inhibitor 123122-55-4 CANDOXATRIL INDICATION Hypertension 118785-03-8 CANDOXATRIL THERAPEUTIC_CLASS Antihypertensive Agents 118785-03-8 CANDOXATRIL INDICATION Hypertension 118785-03-8 CANDOXATRIL PRODUCT_CLASS Cardiovasculars 118785-03-8 CANDOXATRIL MECHANISM Modulate G-protein coupled signal transduction 118785-03-8 CANDOXATRIL MODE_CLASS Enzyme Inhibitor 123013-22-9 AMELOMETASONE MECHANISM Modulate gene transcription 123013-22-9 AMELOMETASONE THERAPEUTIC_CLASS Corticosteroids 123013-22-9 AMELOMETASONE MODE_CLASS Receptor Agonist 123013-22-9 AMELOMETASONE PRODUCT_CLASS Anti-inflammatories 123013-34-3 AMELOMETASONE THERAPEUTIC_CLASS Corticosteroids 123013-34-3 AMELOMETASONE MODE_CLASS Receptor Agonist 123013-34-3 AMELOMETASONE PRODUCT_CLASS Anti-inflammatories 123013-34-3 AMELOMETASONE MECHANISM Modulate gene transcription 94149-41-4 MIDESTEINE INDICATION Emphysema 125472-02-8 MIVAZEROL INDICATION Ischemia 125472-02-8 MIVAZEROL PRODUCT_CLASS Cardiovasculars 125472-02-8 MIVAZEROL INDICATION Angina Pectoris 125472-02-8 MIVAZEROL THERAPEUTIC_CLASS Antianginals 125472-02-8 MIVAZEROL MECHANISM Modulate G-protein coupled signal transduction 87238-52-6 RITIPENEM ACOXIL THERAPEUTIC_CLASS Antibacterials 87238-52-6 RITIPENEM ACOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 87238-52-6 RITIPENEM ACOXIL PRODUCT_CLASS Anti-infectives 87238-52-6 RITIPENEM ACOXIL MODE_CLASS Enzyme Inhibitor 71247-25-1 CERULETIDE DIETHYLAMINE INDICATION Oral Cholangiography 71247-25-1 CERULETIDE DIETHYLAMINE MODE_CLASS Receptor Agonist 71247-25-1 CERULETIDE DIETHYLAMINE MECHANISM Modulate G-protein coupled signal transduction 71247-25-1 CERULETIDE DIETHYLAMINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 17650-98-5 CERULETIDE DIETHYLAMINE MODE_CLASS Receptor Agonist 17650-98-5 CERULETIDE DIETHYLAMINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 17650-98-5 CERULETIDE DIETHYLAMINE INDICATION Oral Cholangiography 17650-98-5 CERULETIDE DIETHYLAMINE MECHANISM Modulate G-protein coupled signal transduction 113559-13-0 E-4031 PRODUCT_CLASS Cardiovasculars 113559-13-0 E-4031 MECHANISM Modulate channel gating 113559-13-0 E-4031 THERAPEUTIC_CLASS Antiarrhythmic Agents 113559-13-0 E-4031 MODE_CLASS Channel Modulator 113559-13-0 E-4031 INDICATION Cardiac Arrhythmias 113558-89-7 E-4031 INDICATION Cardiac Arrhythmias 113558-89-7 E-4031 THERAPEUTIC_CLASS Antiarrhythmic Agents 113558-89-7 E-4031 MODE_CLASS Channel Modulator 113558-89-7 E-4031 MECHANISM Modulate channel gating 113558-89-7 E-4031 PRODUCT_CLASS Cardiovasculars 127657-42-5 MINODRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 127657-42-5 MINODRONIC ACID MODE_CLASS Enzyme Inhibitor 127657-42-5 MINODRONIC ACID MECHANISM Inhibit bone re-absorption 127657-42-5 MINODRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 127657-42-5 MINODRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 135928-30-2 BELOXEPIN PRODUCT_CLASS Central Nervous System (CNS) 135928-30-2 BELOXEPIN INDICATION Depression 135928-30-2 BELOXEPIN THERAPEUTIC_CLASS Antidepressants 126411-13-0 SR-9223I INDICATION Hypolipidemia 53764-90-2 PGF2ALPHA-IE INDICATION Glaucoma 79781-00-3 CDRI-80/53 INDICATION Malaria 6587-31-1 4'-GALACTOSYLLACTOSE INDICATION Hypolipidemia 127754-47-6 MKC-121 INDICATION Hypolipidemia 129655-21-6 BIZELESIN STRUCTURE_ACTIVITY DNA-alkylator 150408-73-4 PRANAZEPIDE MODE_CLASS Receptor Ligand Antagonist 150408-73-4 PRANAZEPIDE MECHANISM Modulate G-protein coupled signal transduction 150408-73-4 PRANAZEPIDE PRODUCT_CLASS Central Nervous System (CNS) 150408-73-4 PRANAZEPIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 119289-43-9 K-953 INDICATION Cardiac Arrhythmias 119289-43-9 K-953 PRODUCT_CLASS Cardiovasculars 119289-43-9 K-953 THERAPEUTIC_CLASS Antiarrhythmic Agents 105981-50-8 PEROSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 105981-50-8 PEROSPIRONE MECHANISM Modulate G-protein coupled signal transduction 105981-50-8 PEROSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 105981-50-8 PEROSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 105981-50-8 PEROSPIRONE MODE_CLASS Receptor Agonist 105981-50-8 PEROSPIRONE MECHANISM Modulate neural transmission 105981-51-9 PEROSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 105981-51-9 PEROSPIRONE MECHANISM Modulate neural transmission 105981-51-9 PEROSPIRONE MODE_CLASS Receptor Agonist 105981-51-9 PEROSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 105981-51-9 PEROSPIRONE MECHANISM Modulate G-protein coupled signal transduction 105981-51-9 PEROSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 129273-38-7 PEROSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 129273-38-7 PEROSPIRONE MECHANISM Modulate neural transmission 129273-38-7 PEROSPIRONE MODE_CLASS Receptor Agonist 129273-38-7 PEROSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 129273-38-7 PEROSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 129273-38-7 PEROSPIRONE MECHANISM Modulate G-protein coupled signal transduction 150915-41-6 PEROSPIRONE MODE_CLASS Receptor Agonist 150915-41-6 PEROSPIRONE MECHANISM Modulate neural transmission 150915-41-6 PEROSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 150915-41-6 PEROSPIRONE MECHANISM Modulate G-protein coupled signal transduction 150915-41-6 PEROSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 150915-41-6 PEROSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 122378-96-5 MCI-727 INDICATION Ulcer 122378-97-6 MCI-727 INDICATION Ulcer 88931-51-5 CLINPROST MODE_CLASS Receptor Agonist 88931-51-5 CLINPROST MECHANISM Modulate G-protein coupled signal transduction 116208-23-2 SM-10888 MODE_CLASS Enzyme Inhibitor 116208-23-2 SM-10888 MECHANISM Enhance cholinergic transmission 116230-66-1 SM-10888 MODE_CLASS Enzyme Inhibitor 116230-66-1 SM-10888 MECHANISM Enhance cholinergic transmission 129297-21-8 SM-10888 MODE_CLASS Enzyme Inhibitor 129297-21-8 SM-10888 MECHANISM Enhance cholinergic transmission 119901-68-7 SQ-33600 INDICATION Hypolipidemia 119901-68-7 SQ-33600 MECHANISM Inhibit cholesterol biosynthesis 119901-68-7 SQ-33600 MODE_CLASS Enzyme Inhibitor 119901-69-8 SQ-33600 INDICATION Hypolipidemia 119901-69-8 SQ-33600 MECHANISM Inhibit cholesterol biosynthesis 119901-69-8 SQ-33600 MODE_CLASS Enzyme Inhibitor 123482-23-5 ZATOSETRON MODE_CLASS Channel Blocker, selective 123482-23-5 ZATOSETRON THERAPEUTIC_CLASS Anxiolytics 123482-23-5 ZATOSETRON THERAPEUTIC_CLASS Antiemetics 123482-23-5 ZATOSETRON PRODUCT_CLASS Gastrointestinal System 123482-23-5 ZATOSETRON MECHANISM Block neural transmission 123482-23-5 ZATOSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 123482-23-5 ZATOSETRON MODE_CLASS Solute transporter inhibitor 123482-23-5 ZATOSETRON MECHANISM Prolong/enhance neural transmission 123482-23-5 ZATOSETRON INDICATION Anxiety Disorders 123482-23-5 ZATOSETRON PRODUCT_CLASS Central Nervous System (CNS) 123482-23-5 ZATOSETRON INDICATION Nausea / Vomiting 123482-22-4 ZATOSETRON THERAPEUTIC_CLASS Antiemetics 123482-22-4 ZATOSETRON MECHANISM Prolong/enhance neural transmission 123482-22-4 ZATOSETRON INDICATION Anxiety Disorders 123482-22-4 ZATOSETRON THERAPEUTIC_CLASS Anxiolytics 123482-22-4 ZATOSETRON PRODUCT_CLASS Gastrointestinal System 123482-22-4 ZATOSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 123482-22-4 ZATOSETRON MECHANISM Block neural transmission 123482-22-4 ZATOSETRON MODE_CLASS Solute transporter inhibitor 123482-22-4 ZATOSETRON MODE_CLASS Channel Blocker, selective 123482-22-4 ZATOSETRON PRODUCT_CLASS Central Nervous System (CNS) 123482-22-4 ZATOSETRON INDICATION Nausea / Vomiting 101345-71-5 BRIFENTANIL MODE_CLASS Receptor Agonist, selective 101345-71-5 BRIFENTANIL PRODUCT_CLASS Analgesics 101345-71-5 BRIFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 101345-71-5 BRIFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 101345-71-5 BRIFENTANIL MECHANISM Modulate neural transmission 121617-11-6 SAVIPRAZOLE MECHANISM Reduce stomach HCl secretion 121617-11-6 SAVIPRAZOLE MODE_CLASS Enzyme Inhibitor 128851-36-5 M-16209 MECHANISM Inhibit precursor synthesis 128851-36-5 M-16209 PRODUCT_CLASS Hormones, Endocrine and Metabolic 128851-36-5 M-16209 MODE_CLASS Enzyme Inhibitor 128851-36-5 M-16209 THERAPEUTIC_CLASS Antidiabetic Agents 128667-95-8 TOBORINONE MODE_CLASS Enzyme Inhibitor 128667-95-8 TOBORINONE MECHANISM Enhance kinase mediated signal transduction 128668-62-2 TOBORINONE MECHANISM Enhance kinase mediated signal transduction 128668-62-2 TOBORINONE MODE_CLASS Enzyme Inhibitor 128668-65-5 TOBORINONE MECHANISM Enhance kinase mediated signal transduction 128668-65-5 TOBORINONE MODE_CLASS Enzyme Inhibitor 143343-83-3 TOBORINONE MECHANISM Enhance kinase mediated signal transduction 143343-83-3 TOBORINONE MODE_CLASS Enzyme Inhibitor 128312-51-6 CINALUKAST PRODUCT_CLASS Respiratory System 128312-51-6 CINALUKAST MODE_CLASS Receptor Ligand Antagonist 128312-51-6 CINALUKAST INDICATION Asthma 128312-51-6 CINALUKAST MECHANISM Modulate G-protein coupled signal transduction 128312-51-6 CINALUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 128312-51-6 CINALUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 129722-12-9 ARIPIPRAZOLE MECHANISM Modulate G-protein coupled signal transduction 129722-13-0 ARIPIPRAZOLE MECHANISM Modulate G-protein coupled signal transduction 129722-15-2 ARIPIPRAZOLE MECHANISM Modulate G-protein coupled signal transduction 129722-16-3 ARIPIPRAZOLE MECHANISM Modulate G-protein coupled signal transduction 99522-79-9 PRANIDIPINE MECHANISM Reduce muscle contractile force 99522-79-9 PRANIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 99522-79-9 PRANIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 99522-79-9 PRANIDIPINE MODE_CLASS Channel Blocker 99522-79-9 PRANIDIPINE INDICATION Angina Pectoris 99522-79-9 PRANIDIPINE INDICATION Hypertension 99522-79-9 PRANIDIPINE PRODUCT_CLASS Cardiovasculars 99522-79-9 PRANIDIPINE THERAPEUTIC_CLASS Antianginals 102106-08-1 PRANIDIPINE THERAPEUTIC_CLASS Antianginals 102106-08-1 PRANIDIPINE INDICATION Hypertension 102106-08-1 PRANIDIPINE PRODUCT_CLASS Cardiovasculars 102106-08-1 PRANIDIPINE INDICATION Angina Pectoris 102106-08-1 PRANIDIPINE MODE_CLASS Channel Blocker 102106-08-1 PRANIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 102106-08-1 PRANIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 102106-08-1 PRANIDIPINE MECHANISM Reduce muscle contractile force 90494-79-4 SR-57746A MECHANISM Modulate neural transmission 90494-79-4 SR-57746A INDICATION Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease 135354-02-8 SR-57746A INDICATION Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease 135354-02-8 SR-57746A MECHANISM Modulate neural transmission 130400-16-7 447C88 INDICATION Hypolipidemia 130400-16-7 447C88 MECHANISM Inhibit steroid biosynthesis/ metabolism 130400-16-7 447C88 MODE_CLASS Enzyme Inhibitor 129904-55-8 CD-832.HCL THERAPEUTIC_CLASS Antihypertensive Agents 129904-55-8 CD-832.HCL STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 129904-55-8 CD-832.HCL THERAPEUTIC_CLASS Antianginals 129904-55-8 CD-832.HCL PRODUCT_CLASS Cardiovasculars 129904-55-8 CD-832.HCL INDICATION Hypertension 129904-55-8 CD-832.HCL INDICATION Angina Pectoris 129904-55-8 CD-832.HCL MODE_CLASS Channel Blocker 129904-55-8 CD-832.HCL MECHANISM Reduce muscle contractile force 129904-63-8 CD-832.HCL MECHANISM Reduce muscle contractile force 129904-63-8 CD-832.HCL THERAPEUTIC_CLASS Antihypertensive Agents 129904-63-8 CD-832.HCL INDICATION Hypertension 129904-63-8 CD-832.HCL STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 129904-63-8 CD-832.HCL THERAPEUTIC_CLASS Antianginals 129904-63-8 CD-832.HCL PRODUCT_CLASS Cardiovasculars 129904-63-8 CD-832.HCL INDICATION Angina Pectoris 129904-63-8 CD-832.HCL MODE_CLASS Channel Blocker 22443-11-4 NEPINALONE INDICATION Cough / Tussis 119942-75-5 DELEQUAMINE MECHANISM Modulate G-protein coupled signal transduction 119905-12-3 DELEQUAMINE MECHANISM Modulate G-protein coupled signal transduction 119813-87-5 DELEQUAMINE MECHANISM Modulate G-protein coupled signal transduction 119905-05-4 DELEQUAMINE MECHANISM Modulate G-protein coupled signal transduction 133737-32-3 PAGOCLONE INDICATION Anxiety Disorders 133737-32-3 PAGOCLONE PRODUCT_CLASS Central Nervous System (CNS) 133737-32-3 PAGOCLONE THERAPEUTIC_CLASS Sedatives/Hypnotics 125974-72-3 INTOPLICINE MODE_CLASS Enzyme Inhibitor 125974-72-3 INTOPLICINE THERAPEUTIC_CLASS Antineoplastics 125974-72-3 INTOPLICINE MECHANISM Inhibit DNA synthesis, repair, and function 125974-72-3 INTOPLICINE STRUCTURE_ACTIVITY DNA intercalator 125974-72-3 INTOPLICINE PRODUCT_CLASS Anti-cancers 119413-53-5 MIRFENTANIL HCL PRODUCT_CLASS Analgesics 119413-53-5 MIRFENTANIL HCL MODE_CLASS Receptor Agonist, selective 119413-53-5 MIRFENTANIL HCL THERAPEUTIC_CLASS Analgesics, Opioid 119413-53-5 MIRFENTANIL HCL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 119413-53-5 MIRFENTANIL HCL MECHANISM Modulate neural transmission 118142-72-6 MIRFENTANIL HCL MECHANISM Modulate neural transmission 118142-72-6 MIRFENTANIL HCL THERAPEUTIC_CLASS Analgesics, Opioid 118142-72-6 MIRFENTANIL HCL PRODUCT_CLASS Analgesics 118142-72-6 MIRFENTANIL HCL MODE_CLASS Receptor Agonist, selective 118142-72-6 MIRFENTANIL HCL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 117523-47-4 MIRFENTANIL HCL MECHANISM Modulate neural transmission 117523-47-4 MIRFENTANIL HCL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 117523-47-4 MIRFENTANIL HCL PRODUCT_CLASS Analgesics 117523-47-4 MIRFENTANIL HCL MODE_CLASS Receptor Agonist, selective 117523-47-4 MIRFENTANIL HCL THERAPEUTIC_CLASS Analgesics, Opioid 52-68-6 METRIFONATE THERAPEUTIC_CLASS Parasympathomimetic Agents 52-68-6 METRIFONATE INDICATION Alzheimer's Disease 52-68-6 METRIFONATE STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 52-68-6 METRIFONATE THERAPEUTIC_CLASS Neurodegenerative Disorders 52-68-6 METRIFONATE INDICATION Dementia 52-68-6 METRIFONATE INDICATION Schistosomiasis / Bilharziasis 52-68-6 METRIFONATE PRODUCT_CLASS Central Nervous System (CNS) 52-68-6 METRIFONATE MECHANISM Enhance cholinergic transmission 52-68-6 METRIFONATE THERAPEUTIC_CLASS Antiparasitics 52-68-6 METRIFONATE PRODUCT_CLASS Autonomic Nervous System (ANS) 52-68-6 METRIFONATE MODE_CLASS Enzyme Inhibitor 52-68-6 METRIFONATE PRODUCT_CLASS Anti-infectives 129981-36-8 SAMPATRILAT MECHANISM Modulate G-protein coupled signal transduction 129981-36-8 SAMPATRILAT MODE_CLASS Enzyme Inhibitor 129981-36-8 SAMPATRILAT PRODUCT_CLASS Cardiovasculars 129981-36-8 SAMPATRILAT MECHANISM Reduce vasoconstriction 129981-36-8 SAMPATRILAT INDICATION Hypertension 129981-36-8 SAMPATRILAT THERAPEUTIC_CLASS Antihypertensive Agents 106635-81-8 ETAQUINE INDICATION Malaria 106635-80-7 ETAQUINE INDICATION Malaria 28319-77-9 CHOLINE ALFOSCERATE PRODUCT_CLASS Central Nervous System (CNS) 28319-77-9 CHOLINE ALFOSCERATE MECHANISM Prolong/enhance neural transmission 28319-77-9 CHOLINE ALFOSCERATE MODE_CLASS Channel Modulator 116308-55-5 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 116308-55-5 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 116308-55-5 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 116308-55-5 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 116308-55-5 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 116308-55-5 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 116308-56-6 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 116308-56-6 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 116308-56-6 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 116308-56-6 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 116308-56-6 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 116308-56-6 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 133743-71-2 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 133743-71-2 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 133743-71-2 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 133743-71-2 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 133743-71-2 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 133743-71-2 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 134054-36-7 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 134054-36-7 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 134054-36-7 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 134054-36-7 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 134054-36-7 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 134054-36-7 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 134028-07-2 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 134028-07-2 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 134028-07-2 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 134028-07-2 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 134028-07-2 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 134028-07-2 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 134028-06-1 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 134028-06-1 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 134028-06-1 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 134028-06-1 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 134028-06-1 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 134028-06-1 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 134028-05-0 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 134028-05-0 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 134028-05-0 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 134028-05-0 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 134028-05-0 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 134028-05-0 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 134028-04-9 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 134028-04-9 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 134028-04-9 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 134028-04-9 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 134028-04-9 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 134028-04-9 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 131644-83-2 VATANIDIPINE HYDROCHLORIDE INDICATION Hypertension 131644-83-2 VATANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 131644-83-2 VATANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 131644-83-2 VATANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 131644-83-2 VATANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 131644-83-2 VATANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 123016-21-7 WY-50295 MECHANISM Inhibit eicosanoid biosynthesis 123016-21-7 WY-50295 PRODUCT_CLASS Anti-inflammatories 123016-21-7 WY-50295 MODE_CLASS Enzyme Inhibitor 123016-21-7 WY-50295 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 99047-26-4 YM-15430-1 THERAPEUTIC_CLASS Antihypertensive Agents 99047-26-4 YM-15430-1 MODE_CLASS Channel Blocker 99047-26-4 YM-15430-1 PRODUCT_CLASS Cardiovasculars 99047-26-4 YM-15430-1 STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 99047-26-4 YM-15430-1 MECHANISM Reduce muscle contractile force 99047-26-4 YM-15430-1 INDICATION Hypertension 99047-27-5 YM-15430-1 MODE_CLASS Channel Blocker 99047-27-5 YM-15430-1 PRODUCT_CLASS Cardiovasculars 99047-27-5 YM-15430-1 MECHANISM Reduce muscle contractile force 99047-27-5 YM-15430-1 STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 99047-27-5 YM-15430-1 THERAPEUTIC_CLASS Antihypertensive Agents 99047-27-5 YM-15430-1 INDICATION Hypertension 103844-86-6 SARIPIDEM PRODUCT_CLASS Central Nervous System (CNS) 103844-86-6 SARIPIDEM MECHANISM Modulate neural transmission 103844-86-6 SARIPIDEM MODE_CLASS Channel Modulator 103844-86-6 SARIPIDEM THERAPEUTIC_CLASS Sedatives/Hypnotics 103844-86-6 SARIPIDEM INDICATION Anxiety Disorders 127625-29-0 FANSERIN MECHANISM Modulate neural transmission 127625-29-0 FANSERIN MODE_CLASS Receptor Ligand Antagonist 127625-29-0 FANSERIN MECHANISM Modulate G-protein coupled signal transduction 130804-35-2 LECIMIBIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 130804-35-2 LECIMIBIDE THERAPEUTIC_CLASS Hypolipidemic Agents 130804-35-2 LECIMIBIDE INDICATION Hypolipidemia 130804-35-2 LECIMIBIDE PRODUCT_CLASS Cardiovasculars 130804-35-2 LECIMIBIDE INDICATION Hyperlipidemia 130804-35-2 LECIMIBIDE MODE_CLASS Enzyme Inhibitor 5942-95-0 CARPIPRAMINE MECHANISM Prolong/enhance neural transmission 5942-95-0 CARPIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 5942-95-0 CARPIPRAMINE MODE_CLASS Solute transporter inhibitor 5942-95-0 CARPIPRAMINE MECHANISM Modulate neural transmission 5942-95-0 CARPIPRAMINE MODE_CLASS Receptor Ligand Antagonist 7075-03-8 CARPIPRAMINE MODE_CLASS Solute transporter inhibitor 7075-03-8 CARPIPRAMINE MECHANISM Modulate neural transmission 7075-03-8 CARPIPRAMINE MODE_CLASS Receptor Ligand Antagonist 7075-03-8 CARPIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 7075-03-8 CARPIPRAMINE MECHANISM Prolong/enhance neural transmission 130579-75-8 EPLIVANSERIN INDICATION Insomnia / Dyssomnias 130579-75-8 EPLIVANSERIN THERAPEUTIC_CLASS Sedatives/Hypnotics 130579-75-8 EPLIVANSERIN MECHANISM Modulate neural transmission 130579-75-8 EPLIVANSERIN PRODUCT_CLASS Central Nervous System (CNS) 130579-75-8 EPLIVANSERIN INDICATION Anxiety Disorders 130579-75-8 EPLIVANSERIN MODE_CLASS Receptor Ligand Antagonist 130579-75-8 EPLIVANSERIN INDICATION Depression 130579-75-8 EPLIVANSERIN THERAPEUTIC_CLASS Antidepressants 130610-93-4 NIRAVOLINE PRODUCT_CLASS Cardiovasculars 130610-93-4 NIRAVOLINE INDICATION Cardiac Arrhythmias 130610-93-4 NIRAVOLINE THERAPEUTIC_CLASS Antiarrhythmic Agents 121306-58-9 MS-424 INDICATION Cerebral Ischemia 98833-92-2 STACOFYLLINE PRODUCT_CLASS Central Nervous System (CNS) 98833-92-2 STACOFYLLINE INDICATION Migraine Headache 98833-92-2 STACOFYLLINE THERAPEUTIC_CLASS Antimigraines 98833-92-2 STACOFYLLINE MODE_CLASS Enzyme Inhibitor 138472-18-1 STACOFYLLINE THERAPEUTIC_CLASS Antimigraines 138472-18-1 STACOFYLLINE INDICATION Migraine Headache 138472-18-1 STACOFYLLINE PRODUCT_CLASS Central Nervous System (CNS) 138472-18-1 STACOFYLLINE MODE_CLASS Enzyme Inhibitor 135003-30-4 APADOLINE MODE_CLASS Receptor Ligand Antagonist 135003-30-4 APADOLINE MECHANISM Block neural transmission 129029-23-8 OCAPERIDONE MODE_CLASS Receptor Ligand Antagonist 129029-23-8 OCAPERIDONE MECHANISM Modulate G-protein coupled signal transduction 134431-49-5 KRN-2391 THERAPEUTIC_CLASS Antianginals 134431-49-5 KRN-2391 MODE_CLASS Channel Modulator 134431-49-5 KRN-2391 MECHANISM Modulate channel gating 134431-49-5 KRN-2391 INDICATION Angina Pectoris 134431-49-5 KRN-2391 PRODUCT_CLASS Cardiovasculars 143966-37-4 KRN-2391 PRODUCT_CLASS Cardiovasculars 143966-37-4 KRN-2391 INDICATION Angina Pectoris 143966-37-4 KRN-2391 MODE_CLASS Channel Modulator 143966-37-4 KRN-2391 THERAPEUTIC_CLASS Antianginals 143966-37-4 KRN-2391 MECHANISM Modulate channel gating 143966-36-3 KRN-2391 PRODUCT_CLASS Cardiovasculars 143966-36-3 KRN-2391 INDICATION Angina Pectoris 143966-36-3 KRN-2391 MODE_CLASS Channel Modulator 143966-36-3 KRN-2391 THERAPEUTIC_CLASS Antianginals 143966-36-3 KRN-2391 MECHANISM Modulate channel gating 143966-35-2 KRN-2391 PRODUCT_CLASS Cardiovasculars 143966-35-2 KRN-2391 INDICATION Angina Pectoris 143966-35-2 KRN-2391 THERAPEUTIC_CLASS Antianginals 143966-35-2 KRN-2391 MECHANISM Modulate channel gating 143966-35-2 KRN-2391 MODE_CLASS Channel Modulator 143966-32-9 KRN-2391 MODE_CLASS Channel Modulator 143966-32-9 KRN-2391 THERAPEUTIC_CLASS Antianginals 143966-32-9 KRN-2391 MECHANISM Modulate channel gating 143966-32-9 KRN-2391 PRODUCT_CLASS Cardiovasculars 143966-32-9 KRN-2391 INDICATION Angina Pectoris 143966-31-8 KRN-2391 MODE_CLASS Channel Modulator 143966-31-8 KRN-2391 MECHANISM Modulate channel gating 143966-31-8 KRN-2391 THERAPEUTIC_CLASS Antianginals 143966-31-8 KRN-2391 PRODUCT_CLASS Cardiovasculars 143966-31-8 KRN-2391 INDICATION Angina Pectoris 133299-87-3 KRN-2391 INDICATION Angina Pectoris 133299-87-3 KRN-2391 MECHANISM Modulate channel gating 133299-87-3 KRN-2391 THERAPEUTIC_CLASS Antianginals 133299-87-3 KRN-2391 MODE_CLASS Channel Modulator 133299-87-3 KRN-2391 PRODUCT_CLASS Cardiovasculars 126721-07-1 EFEGATRAN MECHANISM Inhibit platelet aggregation 126721-07-1 EFEGATRAN MODE_CLASS Enzyme Inhibitor 105806-65-3 EFEGATRAN MECHANISM Inhibit platelet aggregation 105806-65-3 EFEGATRAN MODE_CLASS Enzyme Inhibitor 105806-66-4 EFEGATRAN MODE_CLASS Enzyme Inhibitor 105806-66-4 EFEGATRAN MECHANISM Inhibit platelet aggregation 118811-38-4 CV-6402.2HCL THERAPEUTIC_CLASS Antiarrhythmic Agents 118811-38-4 CV-6402.2HCL PRODUCT_CLASS Cardiovasculars 118811-38-4 CV-6402.2HCL INDICATION Cardiac Arrhythmias 113241-47-7 BRL-32872A PRODUCT_CLASS Cardiovasculars 113241-47-7 BRL-32872A THERAPEUTIC_CLASS Antianginals 113241-47-7 BRL-32872A INDICATION Angina Pectoris 113241-47-7 BRL-32872A THERAPEUTIC_CLASS Antiarrhythmic Agents 113241-47-7 BRL-32872A INDICATION Cardiac Arrhythmias 113241-47-7 BRL-32872A MODE_CLASS Channel Modulator 113241-47-7 BRL-32872A MECHANISM Modulate channel gating 113241-09-1 BRL-32872A PRODUCT_CLASS Cardiovasculars 113241-09-1 BRL-32872A THERAPEUTIC_CLASS Antianginals 113241-09-1 BRL-32872A INDICATION Angina Pectoris 113241-09-1 BRL-32872A THERAPEUTIC_CLASS Antiarrhythmic Agents 113241-09-1 BRL-32872A INDICATION Cardiac Arrhythmias 113241-09-1 BRL-32872A MODE_CLASS Channel Modulator 113241-09-1 BRL-32872A MECHANISM Modulate channel gating 138661-03-7 FURNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 138661-03-7 FURNIDIPINE INDICATION Hypertension 138661-03-7 FURNIDIPINE MODE_CLASS Channel Blocker 138661-03-7 FURNIDIPINE MECHANISM Reduce muscle contractile force 138661-03-7 FURNIDIPINE PRODUCT_CLASS Cardiovasculars 138661-03-7 FURNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 117585-83-8 CV-6504.HCL MODE_CLASS Enzyme Inhibitor 117585-83-8 CV-6504.HCL MECHANISM Inhibit eicosanoid biosynthesis 117585-83-8 CV-6504.HCL INDICATION Nephritis 121009-30-1 ALPRENOXIME HCL MECHANISM Modulate G-protein coupled signal transduction 121009-30-1 ALPRENOXIME HCL INDICATION Glaucoma 129688-50-2 MINALRESTAT INDICATION Diabetic Neuropathy 129688-50-2 MINALRESTAT MODE_CLASS Enzyme Inhibitor 129688-50-2 MINALRESTAT PRODUCT_CLASS Other Human Uses 129688-50-2 MINALRESTAT MECHANISM Inhibit precursor synthesis 129688-50-2 MINALRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 106516-24-9 SERTINDOLE THERAPEUTIC_CLASS Antipsychotics 106516-24-9 SERTINDOLE MECHANISM Modulate G-protein coupled signal transduction 106516-24-9 SERTINDOLE PRODUCT_CLASS Central Nervous System (CNS) 106516-24-9 SERTINDOLE INDICATION Schizophrenia 106516-24-9 SERTINDOLE MODE_CLASS Receptor Ligand Antagonist 106516-24-9 SERTINDOLE MECHANISM Modulate neural transmission 106516-25-0 SERTINDOLE INDICATION Schizophrenia 106516-25-0 SERTINDOLE MECHANISM Modulate neural transmission 106516-25-0 SERTINDOLE THERAPEUTIC_CLASS Antipsychotics 106516-25-0 SERTINDOLE MODE_CLASS Receptor Ligand Antagonist 106516-25-0 SERTINDOLE MECHANISM Modulate G-protein coupled signal transduction 106516-25-0 SERTINDOLE PRODUCT_CLASS Central Nervous System (CNS) 83172-76-3 PROPAGERMANIUM STRUCTURE_ACTIVITY Chemokine receptor inhibitor 12758-40-6 PROPAGERMANIUM STRUCTURE_ACTIVITY Chemokine receptor inhibitor 113594-68-6 KB-5492 INDICATION Ulcer 113594-64-2 KB-5492 INDICATION Ulcer 132017-01-7 BERVASTATIN MODE_CLASS Enzyme Inhibitor 132017-01-7 BERVASTATIN MECHANISM Inhibit cholesterol biosynthesis 132017-01-7 BERVASTATIN INDICATION Hypolipidemia 132017-01-7 BERVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 132036-88-5 RAMOSETRON HYDROCHLORIDE INDICATION Nausea / Vomiting 132036-88-5 RAMOSETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 132036-88-5 RAMOSETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 132036-88-5 RAMOSETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 132036-88-5 RAMOSETRON HYDROCHLORIDE MECHANISM Block neural transmission 132036-88-5 RAMOSETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 132907-72-3 RAMOSETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 132907-72-3 RAMOSETRON HYDROCHLORIDE MECHANISM Block neural transmission 132907-72-3 RAMOSETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 132907-72-3 RAMOSETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 132907-72-3 RAMOSETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 132907-72-3 RAMOSETRON HYDROCHLORIDE INDICATION Nausea / Vomiting 130641-38-2 BINDARIT PRODUCT_CLASS Immune Response / Immunomodulators 130641-38-2 BINDARIT THERAPEUTIC_CLASS Immunosuppressants 130641-38-2 BINDARIT INDICATION Rheumatism 131311-25-6 TCV-309 INDICATION Psoriasis 2675-35-6 A-007 STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 119377-56-9 ES-8891 MODE_CLASS Enzyme Inhibitor 119377-56-9 ES-8891 MECHANISM Reduce vasoconstriction 119377-56-9 ES-8891 THERAPEUTIC_CLASS Antihypertensive Agents 119377-56-9 ES-8891 PRODUCT_CLASS Cardiovasculars 119377-56-9 ES-8891 INDICATION Hypertension 20424-00-4 DEPRODONE PROPIONATE MECHANISM Modulate gene transcription 20424-00-4 DEPRODONE PROPIONATE MODE_CLASS Receptor Agonist 130800-90-7 SIPATRIGINE MODE_CLASS Channel Blocker 130800-90-7 SIPATRIGINE THERAPEUTIC_CLASS Vasodilators 130800-90-7 SIPATRIGINE MECHANISM Block neural transmission 130800-90-7 SIPATRIGINE INDICATION Cerebrovascular Accident / Stroke 130800-90-7 SIPATRIGINE PRODUCT_CLASS Central Nervous System (CNS) 130801-14-8 SIPATRIGINE PRODUCT_CLASS Central Nervous System (CNS) 130801-14-8 SIPATRIGINE MECHANISM Block neural transmission 130801-14-8 SIPATRIGINE MODE_CLASS Channel Blocker 130801-14-8 SIPATRIGINE INDICATION Cerebrovascular Accident / Stroke 130801-14-8 SIPATRIGINE THERAPEUTIC_CLASS Vasodilators 144980-29-0 REPINOTAN MECHANISM Modulate neural transmission 144980-29-0 REPINOTAN MODE_CLASS Receptor Agonist 144980-29-0 REPINOTAN INDICATION Cerebral Ischemia 144980-29-0 REPINOTAN THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 144980-29-0 REPINOTAN PRODUCT_CLASS Central Nervous System (CNS) 127985-21-1 IOMAZENIL MECHANISM Modulate neural transmission 127985-21-1 IOMAZENIL MODE_CLASS Channel Modulator 127985-21-1 IOMAZENIL THERAPEUTIC_CLASS Sedatives/Hypnotics 127985-21-1 IOMAZENIL PRODUCT_CLASS Central Nervous System (CNS) 127396-36-5 IOMAZENIL PRODUCT_CLASS Central Nervous System (CNS) 127396-36-5 IOMAZENIL MECHANISM Modulate neural transmission 127396-36-5 IOMAZENIL MODE_CLASS Channel Modulator 127396-36-5 IOMAZENIL THERAPEUTIC_CLASS Sedatives/Hypnotics 129164-92-7 JO-1870 INDICATION Urinary Incontinence / Enuresis 129140-62-1 JO-1870 INDICATION Urinary Incontinence / Enuresis 129164-93-8 JO-1870 INDICATION Urinary Incontinence / Enuresis 121135-53-3 AZT-P-DDI DIMER INDICATION Myocardial Ischemia 130306-02-4 TEZACITABINE MODE_CLASS Enzyme Inhibitor 130306-02-4 TEZACITABINE MECHANISM Inhibit DNA synthesis, repair, and function 132210-43-6 CIPAMFYLLINE MECHANISM Enhance kinase mediated signal transduction 132210-43-6 CIPAMFYLLINE MODE_CLASS Enzyme Inhibitor 132210-43-6 CIPAMFYLLINE INDICATION Eczema Herpeticum 130714-47-5 SDZ-WAG-994 PRODUCT_CLASS Cardiovasculars 130714-47-5 SDZ-WAG-994 THERAPEUTIC_CLASS Antihypertensive Agents 130714-47-5 SDZ-WAG-994 INDICATION Hypertension 130714-47-5 SDZ-WAG-994 INDICATION Hypolipidemia 130714-47-5 SDZ-WAG-994 INDICATION Diabetes 132418-35-0 SETIPAFANT INDICATION Inflammatory Bowel Disease (IBD) 132418-35-0 SETIPAFANT INDICATION Cerebral Ischemia 132418-35-0 SETIPAFANT INDICATION Ulcer 113082-98-7 ENALKIREN INDICATION Hypertension 113082-98-7 ENALKIREN INDICATION Renal Failure / Kidney Failure 113082-98-7 ENALKIREN PRODUCT_CLASS Cardiovasculars 113082-98-7 ENALKIREN MODE_CLASS Enzyme Inhibitor 113082-98-7 ENALKIREN INDICATION Glaucoma 113082-98-7 ENALKIREN THERAPEUTIC_CLASS Antihypertensive Agents 113082-98-7 ENALKIREN MECHANISM Reduce vasoconstriction 36441-32-4 DUP-654 MODE_CLASS Enzyme Inhibitor 36441-32-4 DUP-654 MECHANISM Inhibit eicosanoid biosynthesis 119637-67-1 MOGUISTEINE INDICATION Cough / Tussis 118292-41-4 AGN-190299 THERAPEUTIC_CLASS Acne Preparations 118292-41-4 AGN-190299 INDICATION Acne / Acne Vulgaris 118292-41-4 AGN-190299 PRODUCT_CLASS Dermatologicals 118292-41-4 AGN-190299 INDICATION Psoriasis 120410-24-4 BIAPENEM MODE_CLASS Enzyme Inhibitor 120410-24-4 BIAPENEM PRODUCT_CLASS Anti-infectives 120410-24-4 BIAPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 120410-24-4 BIAPENEM THERAPEUTIC_CLASS Antibacterials 119687-33-1 IGANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 119687-33-1 IGANIDIPINE HYDROCHLORIDE INDICATION Angina Pectoris 119687-33-1 IGANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 119687-33-1 IGANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 119687-33-1 IGANIDIPINE HYDROCHLORIDE INDICATION Hypertension 119687-33-1 IGANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 119687-33-1 IGANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 119687-33-1 IGANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 117241-46-0 IGANIDIPINE HYDROCHLORIDE INDICATION Hypertension 117241-46-0 IGANIDIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 117241-46-0 IGANIDIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 117241-46-0 IGANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 117241-46-0 IGANIDIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 117241-46-0 IGANIDIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 117241-46-0 IGANIDIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 117241-46-0 IGANIDIPINE HYDROCHLORIDE INDICATION Angina Pectoris 121524-18-3 FR-113453 INDICATION Renal Failure / Kidney Failure 121524-18-3 FR-113453 INDICATION Hypertension 121524-18-3 FR-113453 THERAPEUTIC_CLASS Antihypertensive Agents 121524-18-3 FR-113453 PRODUCT_CLASS Cardiovasculars 121524-22-9 FR-113453 INDICATION Hypertension 121524-22-9 FR-113453 PRODUCT_CLASS Cardiovasculars 121524-22-9 FR-113453 THERAPEUTIC_CLASS Antihypertensive Agents 121524-22-9 FR-113453 INDICATION Renal Failure / Kidney Failure 121491-38-1 FR-113453 INDICATION Hypertension 121491-38-1 FR-113453 INDICATION Renal Failure / Kidney Failure 121491-38-1 FR-113453 PRODUCT_CLASS Cardiovasculars 121491-38-1 FR-113453 THERAPEUTIC_CLASS Antihypertensive Agents 122742-02-3 FR-113453 PRODUCT_CLASS Cardiovasculars 122742-02-3 FR-113453 THERAPEUTIC_CLASS Antihypertensive Agents 122742-02-3 FR-113453 INDICATION Hypertension 122742-02-3 FR-113453 INDICATION Renal Failure / Kidney Failure 121491-21-2 FR-113453 THERAPEUTIC_CLASS Antihypertensive Agents 121491-21-2 FR-113453 INDICATION Hypertension 121491-21-2 FR-113453 INDICATION Renal Failure / Kidney Failure 121491-21-2 FR-113453 PRODUCT_CLASS Cardiovasculars 119356-77-3 DAPOXETINE PRODUCT_CLASS Central Nervous System (CNS) 119356-77-3 DAPOXETINE THERAPEUTIC_CLASS Antidepressants 119356-77-3 DAPOXETINE INDICATION Depression 129938-20-1 DAPOXETINE PRODUCT_CLASS Central Nervous System (CNS) 129938-20-1 DAPOXETINE THERAPEUTIC_CLASS Antidepressants 129938-20-1 DAPOXETINE INDICATION Depression 110042-95-0 ACEMANNAN INDICATION Inflammatory Bowel Disease (IBD) 91587-01-8 PELRETIN INDICATION Actinic Keratosis 121243-20-7 PANCOPRIDE INDICATION Nausea / Vomiting 121243-20-7 PANCOPRIDE MODE_CLASS Channel Blocker 121243-20-7 PANCOPRIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 121243-20-7 PANCOPRIDE INDICATION Anxiety Disorders 121243-20-7 PANCOPRIDE PRODUCT_CLASS Central Nervous System (CNS) 121243-20-7 PANCOPRIDE MECHANISM Block neural transmission 121650-80-4 PANCOPRIDE INDICATION Nausea / Vomiting 121650-80-4 PANCOPRIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 121650-80-4 PANCOPRIDE INDICATION Anxiety Disorders 121650-80-4 PANCOPRIDE PRODUCT_CLASS Central Nervous System (CNS) 121650-80-4 PANCOPRIDE MECHANISM Block neural transmission 121650-80-4 PANCOPRIDE MODE_CLASS Channel Blocker 63233-46-5 KW-6055 PRODUCT_CLASS Central Nervous System (CNS) 63233-46-5 KW-6055 INDICATION Depression 63233-46-5 KW-6055 THERAPEUTIC_CLASS Antidepressants 119413-55-7 ELGODIPINE HYDROCHLORIDE MECHANISM Reduce muscle contractile force 119413-55-7 ELGODIPINE HYDROCHLORIDE INDICATION Hypertension 119413-55-7 ELGODIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 119413-55-7 ELGODIPINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 119413-55-7 ELGODIPINE HYDROCHLORIDE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 119413-55-7 ELGODIPINE HYDROCHLORIDE INDICATION Angina Pectoris 119413-55-7 ELGODIPINE HYDROCHLORIDE MODE_CLASS Channel Blocker 119413-55-7 ELGODIPINE HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 86433-39-8 TERFLAVOXATE HYDROCHLORIDE INDICATION Urinary Incontinence / Enuresis 86433-40-1 TERFLAVOXATE HYDROCHLORIDE INDICATION Urinary Incontinence / Enuresis 87344-06-7 AMTOLMETIN MECHANISM Inhibit eicosanoid biosynthesis 87344-06-7 AMTOLMETIN MODE_CLASS Enzyme Inhibitor 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_3_Gastroenteritis 122852-42-0 ALOSETRON ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 122852-42-0 ALOSETRON ADVERSE_EFFECT PSY_2_Anxiety 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_1_Constipation 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_3_Bowel Obstruction 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 122852-42-0 ALOSETRON ADVERSE_EFFECT _3_Intussusception 122852-42-0 ALOSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 122852-42-0 ALOSETRON ADVERSE_EFFECT CVS_3_Arrhythmia 122852-42-0 ALOSETRON ADVERSE_EFFECT PSY_3_Confusion 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_2_Reduced Salivation 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_3_Small Bowel Mesenteric Ischemia 122852-42-0 ALOSETRON THERAPEUTIC_CLASS Antiemetics 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_2_Ischemic Colitis 122852-42-0 ALOSETRON INDICATION Irritable Bowel Syndrome 122852-42-0 ALOSETRON KNOWN_TOXICITY Cardiovascular Toxicity 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_3_Proctitis 122852-42-0 ALOSETRON ADVERSE_EFFECT NEU_2_Paralytic Ileus 122852-42-0 ALOSETRON ADVERSE_EFFECT CVS_2_Tachyarrhythmia 122852-42-0 ALOSETRON ADVERSE_EFFECT NEU_3_Tremor 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_3_Diverticulitis 122852-42-0 ALOSETRON ADVERSE_EFFECT NEU_3_Sedation 122852-42-0 ALOSETRON TISSUE_TOXICITY Arrhythmia 122852-42-0 ALOSETRON TISSUE_TOXICITY Tachyarrhythmia 122852-42-0 ALOSETRON PRODUCT_CLASS Gastrointestinal System 122852-42-0 ALOSETRON MECHANISM Block neural transmission 122852-42-0 ALOSETRON MODE_CLASS Channel Blocker, selective 122852-42-0 ALOSETRON ADVERSE_EFFECT CVS_3_Hypertension 122852-42-0 ALOSETRON ADVERSE_EFFECT REP_3_Sexual Dysfunction 122852-42-0 ALOSETRON ADVERSE_EFFECT GIS_1_Abdominal Pain 122589-79-1 KB-2683 INDICATION Arthritis 122589-79-1 KB-2683 THERAPEUTIC_CLASS Immunosuppressants 122589-79-1 KB-2683 PRODUCT_CLASS Immune Response / Immunomodulators 122254-45-9 GLENVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 122254-45-9 GLENVASTATIN MECHANISM Inhibit cholesterol biosynthesis 122254-45-9 GLENVASTATIN INDICATION Hypolipidemia 122254-45-9 GLENVASTATIN MODE_CLASS Enzyme Inhibitor 120056-57-7 S-312-D PRODUCT_CLASS Cardiovasculars 120056-57-7 S-312-D MECHANISM Modulate channel gating 120056-57-7 S-312-D THERAPEUTIC_CLASS Antihypertensive Agents 120056-57-7 S-312-D INDICATION Hypertension 120056-57-7 S-312-D MODE_CLASS Channel Modulator 119431-25-3 ELIPRODIL PRODUCT_CLASS Central Nervous System (CNS) 119431-25-3 ELIPRODIL INDICATION Cerebral Ischemia 119431-25-3 ELIPRODIL THERAPEUTIC_CLASS Vasodilators 119431-25-3 ELIPRODIL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 119431-25-3 ELIPRODIL MODE_CLASS Channel Blocker 119431-25-3 ELIPRODIL MECHANISM Block neural transmission 136634-88-3 ELIPRODIL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 136634-88-3 ELIPRODIL PRODUCT_CLASS Central Nervous System (CNS) 136634-88-3 ELIPRODIL INDICATION Cerebral Ischemia 136634-88-3 ELIPRODIL THERAPEUTIC_CLASS Vasodilators 136634-88-3 ELIPRODIL MECHANISM Block neural transmission 136634-88-3 ELIPRODIL MODE_CLASS Channel Blocker 127293-58-7 ELIPRODIL MODE_CLASS Channel Blocker 127293-58-7 ELIPRODIL MECHANISM Block neural transmission 127293-58-7 ELIPRODIL THERAPEUTIC_CLASS Vasodilators 127293-58-7 ELIPRODIL INDICATION Cerebral Ischemia 127293-58-7 ELIPRODIL PRODUCT_CLASS Central Nervous System (CNS) 127293-58-7 ELIPRODIL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 114856-44-9 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-44-9 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-44-9 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-44-9 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-50-7 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-50-7 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-50-7 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-50-7 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-54-1 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-54-1 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-54-1 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-54-1 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-46-1 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-46-1 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-46-1 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-46-1 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-48-3 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-48-3 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-48-3 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-48-3 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-52-9 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-52-9 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-52-9 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-52-9 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-53-0 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-53-0 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-53-0 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-53-0 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-55-2 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-55-2 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-55-2 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-55-2 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-47-2 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-47-2 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-47-2 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-47-2 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-49-4 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-49-4 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-49-4 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-49-4 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-56-3 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-56-3 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 114856-56-3 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-56-3 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-51-8 OBERADILOL MONOETHYL MALEATE PRODUCT_CLASS Cardiovasculars 114856-51-8 OBERADILOL MONOETHYL MALEATE INDICATION Hypertension 114856-51-8 OBERADILOL MONOETHYL MALEATE THERAPEUTIC_CLASS Antihypertensive Agents 114856-51-8 OBERADILOL MONOETHYL MALEATE MECHANISM Modulate G-protein coupled signal transduction 88594-78-9 DPN-205-734 MECHANISM Enhance kinase mediated signal transduction 88594-78-9 DPN-205-734 MODE_CLASS Enzyme Inhibitor 129731-10-8 VOROZOLE THERAPEUTIC_CLASS Antineoplastics 129731-10-8 VOROZOLE MODE_CLASS Enzyme Inhibitor 129731-10-8 VOROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 129731-10-8 VOROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 129731-10-8 VOROZOLE PRODUCT_CLASS Anti-cancers 118949-22-7 VOROZOLE PRODUCT_CLASS Anti-cancers 118949-22-7 VOROZOLE THERAPEUTIC_CLASS Antineoplastics 118949-22-7 VOROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 118949-22-7 VOROZOLE MODE_CLASS Enzyme Inhibitor 118949-22-7 VOROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 123258-84-4 ITASETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 123258-84-4 ITASETRON PRODUCT_CLASS Gastrointestinal System 123258-84-4 ITASETRON MODE_CLASS Channel Blocker, selective 123258-84-4 ITASETRON MECHANISM Block neural transmission 123258-84-4 ITASETRON MODE_CLASS Solute transporter inhibitor 123258-84-4 ITASETRON THERAPEUTIC_CLASS Antiemetics 123258-84-4 ITASETRON INDICATION Nausea / Vomiting 123258-84-4 ITASETRON MECHANISM Prolong/enhance neural transmission 127618-28-4 ITASETRON MECHANISM Prolong/enhance neural transmission 127618-28-4 ITASETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 127618-28-4 ITASETRON PRODUCT_CLASS Gastrointestinal System 127618-28-4 ITASETRON MODE_CLASS Channel Blocker, selective 127618-28-4 ITASETRON MECHANISM Block neural transmission 127618-28-4 ITASETRON MODE_CLASS Solute transporter inhibitor 127618-28-4 ITASETRON THERAPEUTIC_CLASS Antiemetics 127618-28-4 ITASETRON INDICATION Nausea / Vomiting 101041-95-6 ORG-30029 MODE_CLASS Enzyme Inhibitor 101041-95-6 ORG-30029 MECHANISM Enhance kinase mediated signal transduction 101041-94-5 ORG-30029 MODE_CLASS Enzyme Inhibitor 101041-94-5 ORG-30029 MECHANISM Enhance kinase mediated signal transduction 120635-74-7 CILANSETRON PRODUCT_CLASS Gastrointestinal System 120635-74-7 CILANSETRON MODE_CLASS Channel Blocker, selective 120635-74-7 CILANSETRON MECHANISM Block neural transmission 120635-74-7 CILANSETRON INDICATION Irritable Bowel Syndrome 120635-74-7 CILANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 120635-74-7 CILANSETRON THERAPEUTIC_CLASS Antiemetics 209859-87-0 CILANSETRON PRODUCT_CLASS Gastrointestinal System 209859-87-0 CILANSETRON INDICATION Irritable Bowel Syndrome 209859-87-0 CILANSETRON THERAPEUTIC_CLASS Antiemetics 209859-87-0 CILANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 209859-87-0 CILANSETRON MECHANISM Block neural transmission 209859-87-0 CILANSETRON MODE_CLASS Channel Blocker, selective 120635-72-5 CILANSETRON THERAPEUTIC_CLASS Antiemetics 120635-72-5 CILANSETRON INDICATION Irritable Bowel Syndrome 120635-72-5 CILANSETRON MODE_CLASS Channel Blocker, selective 120635-72-5 CILANSETRON MECHANISM Block neural transmission 120635-72-5 CILANSETRON PRODUCT_CLASS Gastrointestinal System 120635-72-5 CILANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 135558-11-1 LOBAPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 131374-93-1 LOBAPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 119813-10-4 CARZELESIN STRUCTURE_ACTIVITY DNA intercalator 123407-36-3 ARTEFLENE INDICATION Malaria 123318-27-4 ARTEFLENE INDICATION Malaria 122894-02-4 Y-26611 PRODUCT_CLASS Anti-infectives 122894-02-4 Y-26611 MODE_CLASS Enzyme Inhibitor, selective 122894-02-4 Y-26611 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 122894-02-4 Y-26611 MECHANISM Inhibit bacterial DNA synthesis 122894-02-4 Y-26611 THERAPEUTIC_CLASS Antibacterials 122894-15-9 Y-26611 MODE_CLASS Enzyme Inhibitor, selective 122894-15-9 Y-26611 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 122894-15-9 Y-26611 PRODUCT_CLASS Anti-infectives 122894-15-9 Y-26611 MECHANISM Inhibit bacterial DNA synthesis 122894-15-9 Y-26611 THERAPEUTIC_CLASS Antibacterials 119644-22-3 RALURIDINE INDICATION Myocardial Ischemia 19771-63-2 PROCYSTEINE INDICATION Acute Respiratory Distress Syndrome (ARDS) 19771-63-2 PROCYSTEINE INDICATION Myocardial Ischemia 19771-63-2 PROCYSTEINE INDICATION Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease 93822-42-5 CQA-206-291 MECHANISM Modulate G-protein coupled signal transduction 93822-42-5 CQA-206-291 INDICATION Parkinson's Disease 87190-79-2 CS-92 INDICATION Myocardial Ischemia 84472-85-5 CS-87 INDICATION Myocardial Ischemia 70001-26-2 MORPHINE-6-GLUCURONIDE MODE_CLASS Receptor Agonist, selective 70001-26-2 MORPHINE-6-GLUCURONIDE THERAPEUTIC_CLASS Analgesics, Opioid 70001-26-2 MORPHINE-6-GLUCURONIDE MECHANISM Modulate neural transmission 70001-26-2 MORPHINE-6-GLUCURONIDE STRUCTURE_ACTIVITY Opioid receptor agonist 70001-26-2 MORPHINE-6-GLUCURONIDE PRODUCT_CLASS Analgesics 120958-90-9 DALCOTIDINE MECHANISM Reduce stomach HCl secretion 120958-90-9 DALCOTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 92454-83-6 FK-409 PRODUCT_CLASS Cardiovasculars 92454-83-6 FK-409 INDICATION Angina Pectoris 92454-83-6 FK-409 THERAPEUTIC_CLASS Antianginals 92454-60-9 FK-409 PRODUCT_CLASS Cardiovasculars 92454-60-9 FK-409 INDICATION Angina Pectoris 92454-60-9 FK-409 THERAPEUTIC_CLASS Antianginals 114469-22-6 CGP-38560A PRODUCT_CLASS Cardiovasculars 114469-22-6 CGP-38560A THERAPEUTIC_CLASS Antihypertensive Agents 114469-22-6 CGP-38560A INDICATION Hypertension 114469-22-6 CGP-38560A MECHANISM Reduce vasoconstriction 114469-22-6 CGP-38560A MODE_CLASS Enzyme Inhibitor 115597-07-4 B-850040 STRUCTURE_ACTIVITY DNA-alkylator, platin 102676-96-0 FADROZOLE PRODUCT_CLASS Anti-cancers 102676-96-0 FADROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 102676-96-0 FADROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 102676-96-0 FADROZOLE MODE_CLASS Enzyme Inhibitor, selective 102676-96-0 FADROZOLE THERAPEUTIC_CLASS Antineoplastics 102676-47-1 FADROZOLE PRODUCT_CLASS Anti-cancers 102676-47-1 FADROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 102676-47-1 FADROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 102676-47-1 FADROZOLE MODE_CLASS Enzyme Inhibitor, selective 102676-47-1 FADROZOLE THERAPEUTIC_CLASS Antineoplastics 102676-31-3 FADROZOLE THERAPEUTIC_CLASS Antineoplastics 102676-31-3 FADROZOLE MODE_CLASS Enzyme Inhibitor, selective 102676-31-3 FADROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 102676-31-3 FADROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 102676-31-3 FADROZOLE PRODUCT_CLASS Anti-cancers 123447-62-1 PRULIFLOXACIN PRODUCT_CLASS Anti-infectives 123447-62-1 PRULIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 123447-62-1 PRULIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 123447-62-1 PRULIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 123447-62-1 PRULIFLOXACIN THERAPEUTIC_CLASS Antibacterials 112573-72-5 DEXECADOTRIL INDICATION Diarrhea 30236-32-9 DEXSOTALOL INDICATION Cardiac Arrhythmias 30236-32-9 DEXSOTALOL THERAPEUTIC_CLASS Antiarrhythmic Agents 30236-32-9 DEXSOTALOL PRODUCT_CLASS Cardiovasculars 4549-94-4 DEXSOTALOL INDICATION Cardiac Arrhythmias 4549-94-4 DEXSOTALOL THERAPEUTIC_CLASS Antiarrhythmic Agents 4549-94-4 DEXSOTALOL PRODUCT_CLASS Cardiovasculars 124423-84-3 PANADIPLON PRODUCT_CLASS Central Nervous System (CNS) 124423-84-3 PANADIPLON INDICATION Anxiety Disorders 124423-84-3 PANADIPLON THERAPEUTIC_CLASS Sedatives/Hypnotics 124555-18-6 GR-79236 MECHANISM Modulate neural transmission 124555-18-6 GR-79236 THERAPEUTIC_CLASS Hypolipidemic Agents 124555-18-6 GR-79236 PRODUCT_CLASS Cardiovasculars 124555-18-6 GR-79236 MODE_CLASS Receptor Agonist 124600-57-3 GR-79236 THERAPEUTIC_CLASS Hypolipidemic Agents 124600-57-3 GR-79236 MECHANISM Modulate neural transmission 124600-57-3 GR-79236 PRODUCT_CLASS Cardiovasculars 124600-57-3 GR-79236 MODE_CLASS Receptor Agonist 89781-55-5 ROLAFAGREL MODE_CLASS Enzyme Inhibitor 89781-55-5 ROLAFAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 89781-55-5 ROLAFAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 89781-55-5 ROLAFAGREL MECHANISM Inhibit eicosanoid biosynthesis 89781-55-5 ROLAFAGREL PRODUCT_CLASS Anti-inflammatories 89781-55-5 ROLAFAGREL INDICATION Diabetic Nephropathy 102625-70-7 PANTOPRAZOLE TA_LEVEL_3 N/K ATPase inhibitor 102625-70-7 PANTOPRAZOLE TA_LEVEL_1 Gastrointestinal System 102625-70-7 PANTOPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 102625-70-7 PANTOPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 102625-70-7 PANTOPRAZOLE INDICATION Erosive Esophagitis 102625-70-7 PANTOPRAZOLE MECHANISM Reduce stomach HCl secretion 102625-70-7 PANTOPRAZOLE KNOWN_TOXICITY Hepatotoxicity 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT SKN_1_Rash 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT CVS_1_Chest Pain 102625-70-7 PANTOPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Zoster 102625-70-7 PANTOPRAZOLE MESH_LEVEL_3 Benzimidazoles 102625-70-7 PANTOPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 102625-70-7 PANTOPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 102625-70-7 PANTOPRAZOLE MODE_CLASS Enzyme Inhibitor 102625-70-7 PANTOPRAZOLE TISSUE_TOXICITY Hepatic Failure 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Flatulence 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Simplex 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 102625-70-7 PANTOPRAZOLE THERAPEUTIC_CLASS Antiulcers 102625-70-7 PANTOPRAZOLE KNOWN_TOXICITY Carcinogenicity 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT NEU_1_Headache 102625-70-7 PANTOPRAZOLE ZERO_CLASS N 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholelithiasis 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Fungal Dermatitis 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 102625-70-7 PANTOPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 102625-70-7 PANTOPRAZOLE MECH_LEVEL_3 H/K ATPase 102625-70-7 PANTOPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Eczema 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholecystitis 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 102625-70-7 PANTOPRAZOLE TISSUE_TOXICITY Carcinoid Tumors 102625-70-7 PANTOPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 102625-70-7 PANTOPRAZOLE PRODUCT_CLASS Gastrointestinal System 102625-70-7 PANTOPRAZOLE MECH_LEVEL_1 Ulcer healing 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 102625-70-7 PANTOPRAZOLE ADVERSE_EFFECT IMU_2_Contact Dermatitis 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Flatulence 138786-67-1 PANTOPRAZOLE INDICATION Erosive Esophagitis 138786-67-1 PANTOPRAZOLE MECHANISM Reduce stomach HCl secretion 138786-67-1 PANTOPRAZOLE KNOWN_TOXICITY Hepatotoxicity 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Simplex 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 138786-67-1 PANTOPRAZOLE THERAPEUTIC_CLASS Antiulcers 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 138786-67-1 PANTOPRAZOLE ZERO_CLASS N 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_1_Rash 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT CVS_1_Chest Pain 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Zoster 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 138786-67-1 PANTOPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 138786-67-1 PANTOPRAZOLE MECH_LEVEL_1 Ulcer healing 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT IMU_2_Contact Dermatitis 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholelithiasis 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Fungal Dermatitis 138786-67-1 PANTOPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 138786-67-1 PANTOPRAZOLE MECH_LEVEL_3 H/K ATPase 138786-67-1 PANTOPRAZOLE TA_LEVEL_3 N/K ATPase inhibitor 138786-67-1 PANTOPRAZOLE KNOWN_TOXICITY Carcinogenicity 138786-67-1 PANTOPRAZOLE TA_LEVEL_1 Gastrointestinal System 138786-67-1 PANTOPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 138786-67-1 PANTOPRAZOLE PRODUCT_CLASS Gastrointestinal System 138786-67-1 PANTOPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 138786-67-1 PANTOPRAZOLE TISSUE_TOXICITY Carcinoid Tumors 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT NEU_1_Headache 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Eczema 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholecystitis 138786-67-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 138786-67-1 PANTOPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 138786-67-1 PANTOPRAZOLE MESH_LEVEL_3 Benzimidazoles 138786-67-1 PANTOPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 138786-67-1 PANTOPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 138786-67-1 PANTOPRAZOLE MODE_CLASS Enzyme Inhibitor 138786-67-1 PANTOPRAZOLE TISSUE_TOXICITY Hepatic Failure 138786-67-1 PANTOPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 154644-14-1 PANTOPRAZOLE TA_LEVEL_3 N/K ATPase inhibitor 154644-14-1 PANTOPRAZOLE TA_LEVEL_1 Gastrointestinal System 154644-14-1 PANTOPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Flatulence 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Simplex 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 154644-14-1 PANTOPRAZOLE THERAPEUTIC_CLASS Antiulcers 154644-14-1 PANTOPRAZOLE KNOWN_TOXICITY Carcinogenicity 154644-14-1 PANTOPRAZOLE ZERO_CLASS N 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_1_Rash 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Eczema 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT NEU_1_Headache 154644-14-1 PANTOPRAZOLE TISSUE_TOXICITY Carcinoid Tumors 154644-14-1 PANTOPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT CVS_1_Chest Pain 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Zoster 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 154644-14-1 PANTOPRAZOLE INDICATION Erosive Esophagitis 154644-14-1 PANTOPRAZOLE MESH_LEVEL_3 Benzimidazoles 154644-14-1 PANTOPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 154644-14-1 PANTOPRAZOLE PRODUCT_CLASS Gastrointestinal System 154644-14-1 PANTOPRAZOLE MECH_LEVEL_1 Ulcer healing 154644-14-1 PANTOPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 154644-14-1 PANTOPRAZOLE MECHANISM Reduce stomach HCl secretion 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholecystitis 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 154644-14-1 PANTOPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 154644-14-1 PANTOPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 154644-14-1 PANTOPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 154644-14-1 PANTOPRAZOLE MODE_CLASS Enzyme Inhibitor 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT IMU_2_Contact Dermatitis 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholelithiasis 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Fungal Dermatitis 154644-14-1 PANTOPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 154644-14-1 PANTOPRAZOLE KNOWN_TOXICITY Hepatotoxicity 154644-14-1 PANTOPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 154644-14-1 PANTOPRAZOLE TISSUE_TOXICITY Hepatic Failure 154644-14-1 PANTOPRAZOLE MECH_LEVEL_3 H/K ATPase 142678-34-0 PANTOPRAZOLE MECHANISM Reduce stomach HCl secretion 142678-34-0 PANTOPRAZOLE KNOWN_TOXICITY Hepatotoxicity 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT SKN_1_Rash 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 142678-34-0 PANTOPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 142678-34-0 PANTOPRAZOLE MESH_LEVEL_3 Benzimidazoles 142678-34-0 PANTOPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 142678-34-0 PANTOPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 142678-34-0 PANTOPRAZOLE MODE_CLASS Enzyme Inhibitor 142678-34-0 PANTOPRAZOLE TISSUE_TOXICITY Hepatic Failure 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT IMU_2_Contact Dermatitis 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholelithiasis 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Fungal Dermatitis 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 142678-34-0 PANTOPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 142678-34-0 PANTOPRAZOLE MECH_LEVEL_3 H/K ATPase 142678-34-0 PANTOPRAZOLE TA_LEVEL_3 N/K ATPase inhibitor 142678-34-0 PANTOPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Flatulence 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Simplex 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 142678-34-0 PANTOPRAZOLE THERAPEUTIC_CLASS Antiulcers 142678-34-0 PANTOPRAZOLE KNOWN_TOXICITY Carcinogenicity 142678-34-0 PANTOPRAZOLE ZERO_CLASS N 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT CVS_1_Chest Pain 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Zoster 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 142678-34-0 PANTOPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 142678-34-0 PANTOPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 142678-34-0 PANTOPRAZOLE MECH_LEVEL_1 Ulcer healing 142678-34-0 PANTOPRAZOLE PRODUCT_CLASS Gastrointestinal System 142678-34-0 PANTOPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 142678-34-0 PANTOPRAZOLE TISSUE_TOXICITY Carcinoid Tumors 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT NEU_1_Headache 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Eczema 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 142678-34-0 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholecystitis 142678-34-0 PANTOPRAZOLE TA_LEVEL_1 Gastrointestinal System 142678-34-0 PANTOPRAZOLE INDICATION Erosive Esophagitis 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Eczema 226904-33-2 PANTOPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 226904-33-2 PANTOPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Zoster 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT CVS_1_Chest Pain 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 226904-33-2 PANTOPRAZOLE TA_LEVEL_1 Gastrointestinal System 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 226904-33-2 PANTOPRAZOLE INDICATION Erosive Esophagitis 226904-33-2 PANTOPRAZOLE MECHANISM Reduce stomach HCl secretion 226904-33-2 PANTOPRAZOLE KNOWN_TOXICITY Hepatotoxicity 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT NEU_1_Headache 226904-33-2 PANTOPRAZOLE TISSUE_TOXICITY Carcinoid Tumors 226904-33-2 PANTOPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 226904-33-2 PANTOPRAZOLE PRODUCT_CLASS Gastrointestinal System 226904-33-2 PANTOPRAZOLE ZERO_CLASS N 226904-33-2 PANTOPRAZOLE KNOWN_TOXICITY Carcinogenicity 226904-33-2 PANTOPRAZOLE THERAPEUTIC_CLASS Antiulcers 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT XXX_3_Herpes Simplex 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Flatulence 226904-33-2 PANTOPRAZOLE MECH_LEVEL_1 Ulcer healing 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 226904-33-2 PANTOPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT SKN_1_Rash 226904-33-2 PANTOPRAZOLE TA_LEVEL_3 N/K ATPase inhibitor 226904-33-2 PANTOPRAZOLE MECH_LEVEL_3 H/K ATPase 226904-33-2 PANTOPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT SKN_2_Fungal Dermatitis 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholelithiasis 226904-33-2 PANTOPRAZOLE TISSUE_TOXICITY Hepatic Failure 226904-33-2 PANTOPRAZOLE MODE_CLASS Enzyme Inhibitor 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 226904-33-2 PANTOPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT IMU_2_Contact Dermatitis 226904-33-2 PANTOPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 226904-33-2 PANTOPRAZOLE MESH_LEVEL_3 Benzimidazoles 226904-33-2 PANTOPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT BIL_2_Cholecystitis 226904-33-2 PANTOPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 120164-49-0 E-6080 MECHANISM Inhibit eicosanoid biosynthesis 120164-49-0 E-6080 MODE_CLASS Enzyme Inhibitor 114875-57-9 KP-736 MODE_CLASS Enzyme Inhibitor 114875-57-9 KP-736 MECHANISM Inhibit bacterial cell wall biosynthesis 114875-57-9 KP-736 PRODUCT_CLASS Anti-infectives 114875-57-9 KP-736 THERAPEUTIC_CLASS Antibacterials 114830-63-6 KP-736 MODE_CLASS Enzyme Inhibitor 114830-63-6 KP-736 MECHANISM Inhibit bacterial cell wall biosynthesis 114830-63-6 KP-736 THERAPEUTIC_CLASS Antibacterials 114830-63-6 KP-736 PRODUCT_CLASS Anti-infectives 105889-45-0 CEFCAPENE PIVOXIL HYDROCHLORIDE MECHANISM Inhibit bacterial cell wall biosynthesis 105889-45-0 CEFCAPENE PIVOXIL HYDROCHLORIDE THERAPEUTIC_CLASS Antibacterials 105889-45-0 CEFCAPENE PIVOXIL HYDROCHLORIDE PRODUCT_CLASS Anti-infectives 105889-45-0 CEFCAPENE PIVOXIL HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 105889-46-1 CEFCAPENE PIVOXIL HYDROCHLORIDE MECHANISM Inhibit bacterial cell wall biosynthesis 105889-46-1 CEFCAPENE PIVOXIL HYDROCHLORIDE THERAPEUTIC_CLASS Antibacterials 105889-46-1 CEFCAPENE PIVOXIL HYDROCHLORIDE PRODUCT_CLASS Anti-infectives 105889-46-1 CEFCAPENE PIVOXIL HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 123663-49-0 T-614 THERAPEUTIC_CLASS Immunosuppressants 123663-49-0 T-614 PRODUCT_CLASS Immune Response / Immunomodulators 123663-49-0 T-614 INDICATION Arthritis 123548-56-1 ACREOZAST INDICATION Eczema Herpeticum 103497-68-3 MK-0963 THERAPEUTIC_CLASS Antineoplastics 103497-68-3 MK-0963 PRODUCT_CLASS Anti-cancers 103497-68-3 MK-0963 MECHANISM Inhibit steroid biosynthesis/ metabolism 103497-68-3 MK-0963 MODE_CLASS Enzyme Inhibitor 112398-08-0 DANOFLOXACIN PRODUCT_CLASS Veterinarian 112398-08-0 DANOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 112398-08-0 DANOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 112398-08-0 DANOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 112398-08-0 DANOFLOXACIN THERAPEUTIC_CLASS Antibacterials 112573-73-6 ECADOTRIL MECHANISM Modulate G-protein coupled signal transduction 112573-73-6 ECADOTRIL MODE_CLASS Enzyme Inhibitor 112984-60-8 NAD-394 MODE_CLASS Enzyme Inhibitor, selective 112984-60-8 NAD-394 PRODUCT_CLASS Anti-infectives 112984-60-8 NAD-394 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 112984-60-8 NAD-394 THERAPEUTIC_CLASS Antibacterials 112984-60-8 NAD-394 MECHANISM Inhibit bacterial DNA synthesis 113029-02-0 NAD-394 MODE_CLASS Enzyme Inhibitor, selective 113029-02-0 NAD-394 MECHANISM Inhibit bacterial DNA synthesis 113029-02-0 NAD-394 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 113029-02-0 NAD-394 THERAPEUTIC_CLASS Antibacterials 113029-02-0 NAD-394 PRODUCT_CLASS Anti-infectives 113045-81-1 NAD-394 MODE_CLASS Enzyme Inhibitor, selective 113045-81-1 NAD-394 PRODUCT_CLASS Anti-infectives 113045-81-1 NAD-394 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 113045-81-1 NAD-394 THERAPEUTIC_CLASS Antibacterials 113045-81-1 NAD-394 MECHANISM Inhibit bacterial DNA synthesis 113045-82-2 NAD-394 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 113045-82-2 NAD-394 THERAPEUTIC_CLASS Antibacterials 113045-82-2 NAD-394 MECHANISM Inhibit bacterial DNA synthesis 113045-82-2 NAD-394 MODE_CLASS Enzyme Inhibitor, selective 113045-82-2 NAD-394 PRODUCT_CLASS Anti-infectives 113045-79-7 NAD-394 MODE_CLASS Enzyme Inhibitor, selective 113045-79-7 NAD-394 PRODUCT_CLASS Anti-infectives 113045-79-7 NAD-394 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 113045-79-7 NAD-394 THERAPEUTIC_CLASS Antibacterials 113045-79-7 NAD-394 MECHANISM Inhibit bacterial DNA synthesis 118244-44-3 PREDNISOLONE FARNESYLATE MODE_CLASS Receptor Agonist 118244-44-3 PREDNISOLONE FARNESYLATE MECHANISM Modulate gene transcription 118244-44-3 PREDNISOLONE FARNESYLATE PRODUCT_CLASS Immune Response / Immunomodulators 118244-44-3 PREDNISOLONE FARNESYLATE INDICATION Arthritis 118244-44-3 PREDNISOLONE FARNESYLATE THERAPEUTIC_CLASS Immunosuppressants 118244-45-4 PREDNISOLONE FARNESYLATE PRODUCT_CLASS Immune Response / Immunomodulators 118244-45-4 PREDNISOLONE FARNESYLATE MECHANISM Modulate gene transcription 118244-45-4 PREDNISOLONE FARNESYLATE INDICATION Arthritis 118244-45-4 PREDNISOLONE FARNESYLATE THERAPEUTIC_CLASS Immunosuppressants 118244-45-4 PREDNISOLONE FARNESYLATE MODE_CLASS Receptor Agonist 105217-71-8 PREDNISOLONE FARNESYLATE PRODUCT_CLASS Immune Response / Immunomodulators 105217-71-8 PREDNISOLONE FARNESYLATE MECHANISM Modulate gene transcription 105217-71-8 PREDNISOLONE FARNESYLATE INDICATION Arthritis 105217-71-8 PREDNISOLONE FARNESYLATE MODE_CLASS Receptor Agonist 105217-71-8 PREDNISOLONE FARNESYLATE THERAPEUTIC_CLASS Immunosuppressants 107767-55-5 ALBIFYLLINE INDICATION Acute Respiratory Distress Syndrome (ARDS) 123955-10-2 ALMOKALANT MECHANISM Modulate channel gating 123955-10-2 ALMOKALANT MODE_CLASS Channel Blocker 123955-10-2 ALMOKALANT THERAPEUTIC_CLASS Antiarrhythmic Agents 123955-10-2 ALMOKALANT PRODUCT_CLASS Cardiovasculars 123955-10-2 ALMOKALANT INDICATION Cardiac Arrhythmias 124020-21-9 ALMOKALANT PRODUCT_CLASS Cardiovasculars 124020-21-9 ALMOKALANT THERAPEUTIC_CLASS Antiarrhythmic Agents 124020-21-9 ALMOKALANT MODE_CLASS Channel Blocker 124020-21-9 ALMOKALANT INDICATION Cardiac Arrhythmias 124020-21-9 ALMOKALANT MECHANISM Modulate channel gating 124020-22-0 ALMOKALANT THERAPEUTIC_CLASS Antiarrhythmic Agents 124020-22-0 ALMOKALANT MODE_CLASS Channel Blocker 124020-22-0 ALMOKALANT MECHANISM Modulate channel gating 124020-22-0 ALMOKALANT INDICATION Cardiac Arrhythmias 124020-22-0 ALMOKALANT PRODUCT_CLASS Cardiovasculars 123955-23-7 ALMOKALANT MODE_CLASS Channel Blocker 123955-23-7 ALMOKALANT THERAPEUTIC_CLASS Antiarrhythmic Agents 123955-23-7 ALMOKALANT INDICATION Cardiac Arrhythmias 123955-23-7 ALMOKALANT MECHANISM Modulate channel gating 123955-23-7 ALMOKALANT PRODUCT_CLASS Cardiovasculars 124937-51-5 TOLTERODINE INDICATION Detrusor Instability 124937-51-5 TOLTERODINE PRODUCT_CLASS Autonomic Nervous System (ANS) 124937-51-5 TOLTERODINE MODE_CLASS Receptor Ligand Antagonist 124937-51-5 TOLTERODINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 124937-51-5 TOLTERODINE THERAPEUTIC_CLASS Parasympatholytic Agents 124937-51-5 TOLTERODINE MECHANISM Modulate G-protein coupled signal transduction 72599-27-0 MIGLUSTAT MECHANISM Block phospholipid synthesis /remodeling 72599-27-0 MIGLUSTAT MODE_CLASS Enzyme Inhibitor 72599-27-0 MIGLUSTAT INDICATION Gaucher's Disease 125991-51-7 TNP-351 PRODUCT_CLASS Anti-cancers 125991-51-7 TNP-351 THERAPEUTIC_CLASS Antineoplastics 125991-51-7 TNP-351 MODE_CLASS Enzyme substrate mimic 125991-51-7 TNP-351 MECHANISM Inhibit precursor synthesis 120280-33-3 RO-31-6930 PRODUCT_CLASS Cardiovasculars 120280-33-3 RO-31-6930 MODE_CLASS Channel Modulator 120280-33-3 RO-31-6930 THERAPEUTIC_CLASS Antihypertensive Agents 120280-33-3 RO-31-6930 INDICATION Hypertension 120280-33-3 RO-31-6930 MECHANISM Modulate channel gating 120280-90-2 RO-31-6930 PRODUCT_CLASS Cardiovasculars 120280-90-2 RO-31-6930 MODE_CLASS Channel Modulator 120280-90-2 RO-31-6930 THERAPEUTIC_CLASS Antihypertensive Agents 120280-90-2 RO-31-6930 MECHANISM Modulate channel gating 120280-90-2 RO-31-6930 INDICATION Hypertension 131841-20-8 CEFTRAZONAL BOPENTIL STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 131841-20-8 CEFTRAZONAL BOPENTIL PRODUCT_CLASS Anti-infectives 131841-20-8 CEFTRAZONAL BOPENTIL MECHANISM Inhibit bacterial cell wall biosynthesis 131841-20-8 CEFTRAZONAL BOPENTIL THERAPEUTIC_CLASS Antibacterials 131841-20-8 CEFTRAZONAL BOPENTIL MODE_CLASS Enzyme Inhibitor 107758-27-0 SR-58611A THERAPEUTIC_CLASS Sympathomimetic Agents 107758-27-0 SR-58611A MECHANISM Reduce muscle contractile force 107758-27-0 SR-58611A MODE_CLASS Receptor Agonist, selective 107758-27-0 SR-58611A STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 107758-27-0 SR-58611A PRODUCT_CLASS Autonomic Nervous System (ANS) 107758-27-0 SR-58611A INDICATION Obesity 107758-28-1 SR-58611A MECHANISM Reduce muscle contractile force 107758-28-1 SR-58611A STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 107758-28-1 SR-58611A PRODUCT_CLASS Autonomic Nervous System (ANS) 107758-28-1 SR-58611A MODE_CLASS Receptor Agonist, selective 107758-28-1 SR-58611A INDICATION Obesity 107758-28-1 SR-58611A THERAPEUTIC_CLASS Sympathomimetic Agents 124012-42-6 GALOCITABINE MECHANISM Inhibit precursor synthesis 124012-42-6 GALOCITABINE MODE_CLASS Enzyme Inhibitor 124012-42-6 GALOCITABINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 77650-95-4 PROTERGURIDE INDICATION Parkinson's Disease 109623-97-4 GEDOCARNIL INDICATION Anxiety Disorders 109623-97-4 GEDOCARNIL THERAPEUTIC_CLASS Sedatives/Hypnotics 109623-97-4 GEDOCARNIL PRODUCT_CLASS Central Nervous System (CNS) 60136-25-6 EPERVUDINE MODE_CLASS Enzyme Inhibitor 60136-25-6 EPERVUDINE MECHANISM Inhibit viral DNA synthesis 60136-25-6 EPERVUDINE MECHANISM Inhibit mitochondrial function 60136-25-6 EPERVUDINE MODE_CLASS Enzyme substrate mimic 289480-64-4 TREPROSTINIL MODE_CLASS Receptor Agonist, selective 289480-64-4 TREPROSTINIL MECHANISM Reduce vasoconstriction 127373-66-4 SIVELESTAT MODE_CLASS Enzyme Inhibitor 127373-66-4 SIVELESTAT INDICATION Acute Respiratory Distress Syndrome (ARDS) 127373-66-4 SIVELESTAT MECHANISM Inhibit inflammatory response 127373-66-4 SIVELESTAT STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 201677-61-4 SIVELESTAT MODE_CLASS Enzyme Inhibitor 201677-61-4 SIVELESTAT INDICATION Acute Respiratory Distress Syndrome (ARDS) 201677-61-4 SIVELESTAT MECHANISM Inhibit inflammatory response 201677-61-4 SIVELESTAT STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 150374-95-1 SIVELESTAT MODE_CLASS Enzyme Inhibitor 150374-95-1 SIVELESTAT MECHANISM Inhibit inflammatory response 150374-95-1 SIVELESTAT STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 150374-95-1 SIVELESTAT INDICATION Acute Respiratory Distress Syndrome (ARDS) 128022-68-4 NNC-01-0687 MECHANISM Modulate G-protein coupled signal transduction 120373-24-2 UNOPROSTONE ISOPROPYL ESTER INDICATION Glaucoma 120373-24-2 UNOPROSTONE ISOPROPYL ESTER MECHANISM Modulate G-protein coupled signal transduction 120373-24-2 UNOPROSTONE ISOPROPYL ESTER MODE_CLASS Receptor Agonist 126452-49-1 CELGOSIVIR MODE_CLASS Enzyme Inhibitor 126452-49-1 CELGOSIVIR INDICATION Malaria 126452-49-1 CELGOSIVIR INDICATION Myocardial Ischemia 141117-12-6 CELGOSIVIR INDICATION Myocardial Ischemia 141117-12-6 CELGOSIVIR MODE_CLASS Enzyme Inhibitor 141117-12-6 CELGOSIVIR INDICATION Malaria 120685-11-2 MIDOSTAURIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 120685-11-2 MIDOSTAURIN INDICATION Breast Cancer / Carcinoma of the Breast 120685-11-2 MIDOSTAURIN MECHANISM Inhibit kinase mediated signal transduction 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT NEU_1_Dizziness 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT GIS_1_Abdominal Pain 120685-11-2 MIDOSTAURIN INDICATION Chronic Lymphocytic Leukemia (CLL) 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT BBM_2_Neutropenia 120685-11-2 MIDOSTAURIN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 120685-11-2 MIDOSTAURIN THERAPEUTIC_CLASS Antineoplastics 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT IMU_1_Urticaria 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT LIV_2_Increased Liver Function Tests 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT OCU_1_Blurred Vision 120685-11-2 MIDOSTAURIN PRODUCT_CLASS Anti-cancers 120685-11-2 MIDOSTAURIN INDICATION Melanoma 120685-11-2 MIDOSTAURIN INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 120685-11-2 MIDOSTAURIN MODE_CLASS Enzyme Inhibitor 120685-11-2 MIDOSTAURIN INDICATION Non-Hodgkin's Lymphomas 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT GIS_1_Diarrhea 120685-11-2 MIDOSTAURIN INDICATION Neoplasm / Cancer / Tumor 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT SKN_1_Rash 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT BBM_2_Anemia 120685-11-2 MIDOSTAURIN STRUCTURE_ACTIVITY Protein-serine/threonine kinase (PKC) inhibitor 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT NEU_1_Headache 120685-11-2 MIDOSTAURIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 127420-24-0 IDRAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 127420-24-0 IDRAPRIL MECHANISM Reduce vasoconstriction 127420-24-0 IDRAPRIL MODE_CLASS Enzyme Inhibitor 127420-24-0 IDRAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 127420-24-0 IDRAPRIL PRODUCT_CLASS Cardiovasculars 127420-24-0 IDRAPRIL INDICATION Hypertension 104121-92-8 ED-71 INDICATION Osteoporosis 125068-54-4 NSP-805 MECHANISM Enhance kinase mediated signal transduction 125068-54-4 NSP-805 MODE_CLASS Enzyme Inhibitor 114037-60-4 SR-43845 INDICATION Glaucoma 114037-60-4 SR-43845 PRODUCT_CLASS Cardiovasculars 114037-60-4 SR-43845 INDICATION Hypertension 114037-60-4 SR-43845 MECHANISM Reduce vasoconstriction 114037-60-4 SR-43845 THERAPEUTIC_CLASS Antihypertensive Agents 114037-60-4 SR-43845 MODE_CLASS Enzyme Inhibitor 90162-60-0 ISBUFYLLINE INDICATION Bronchospasm 127906-27-8 MOXIFETIN HYDROGEN MALEATE INDICATION Depression 127906-27-8 MOXIFETIN HYDROGEN MALEATE PRODUCT_CLASS Central Nervous System (CNS) 127906-27-8 MOXIFETIN HYDROGEN MALEATE THERAPEUTIC_CLASS Antidepressants 127906-18-7 MOXIFETIN HYDROGEN MALEATE INDICATION Depression 127906-18-7 MOXIFETIN HYDROGEN MALEATE PRODUCT_CLASS Central Nervous System (CNS) 127906-18-7 MOXIFETIN HYDROGEN MALEATE THERAPEUTIC_CLASS Antidepressants 127308-82-1 ZAMIFENACIN INDICATION Irritable Bowel Syndrome 127308-82-1 ZAMIFENACIN INDICATION Urinary Incontinence / Enuresis 127308-98-9 ZAMIFENACIN INDICATION Urinary Incontinence / Enuresis 127308-98-9 ZAMIFENACIN INDICATION Irritable Bowel Syndrome 128043-99-2 NZ-314 MODE_CLASS Enzyme Inhibitor 128043-99-2 NZ-314 PRODUCT_CLASS Hormones, Endocrine and Metabolic 128043-99-2 NZ-314 MECHANISM Inhibit precursor synthesis 128043-99-2 NZ-314 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 84856-18-8 FL-386 INDICATION Hypolipidemia 113759-50-5 CRONIDIPINE MECHANISM Reduce muscle contractile force 113759-50-5 CRONIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 113759-50-5 CRONIDIPINE INDICATION Hypertension 113759-50-5 CRONIDIPINE MODE_CLASS Channel Blocker 113759-50-5 CRONIDIPINE PRODUCT_CLASS Cardiovasculars 113759-50-5 CRONIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 116649-85-5 RAMATROBAN INDICATION Viral Rhinitis / Common Cold 116649-85-5 RAMATROBAN MECHANISM Modulate G-protein coupled signal transduction 116649-85-5 RAMATROBAN MODE_CLASS Receptor Ligand Antagonist 112808-22-7 AD-5467 MECHANISM Inhibit precursor synthesis 112808-22-7 AD-5467 MODE_CLASS Enzyme Inhibitor 112808-22-7 AD-5467 PRODUCT_CLASS Other Human Uses 112808-22-7 AD-5467 THERAPEUTIC_CLASS Antidiabetic Agents 112808-22-7 AD-5467 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 112808-22-7 AD-5467 PRODUCT_CLASS Hormones, Endocrine and Metabolic 120443-16-5 VERLUKAST INDICATION Asthma 120443-16-5 VERLUKAST MODE_CLASS Receptor Ligand Antagonist 120443-16-5 VERLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 120443-16-5 VERLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 120443-16-5 VERLUKAST MECHANISM Modulate G-protein coupled signal transduction 120443-16-5 VERLUKAST PRODUCT_CLASS Respiratory System 65243-33-6 CEFETAMET PIVOXIL PRODUCT_CLASS Anti-infectives 65243-33-6 CEFETAMET PIVOXIL THERAPEUTIC_CLASS Antibacterials 65243-33-6 CEFETAMET PIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 65243-33-6 CEFETAMET PIVOXIL MODE_CLASS Enzyme Inhibitor 111696-23-2 CEFETAMET PIVOXIL PRODUCT_CLASS Anti-infectives 111696-23-2 CEFETAMET PIVOXIL MODE_CLASS Enzyme Inhibitor 111696-23-2 CEFETAMET PIVOXIL THERAPEUTIC_CLASS Antibacterials 111696-23-2 CEFETAMET PIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 115256-11-6 DOFETILIDE MECHANISM Modulate channel gating 115256-11-6 DOFETILIDE INDICATION Atrial Flutter 115256-11-6 DOFETILIDE PRODUCT_CLASS Cardiovasculars 115256-11-6 DOFETILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 115256-11-6 DOFETILIDE MODE_CLASS Channel Blocker, selective 115256-11-6 DOFETILIDE INDICATION Atrial Fibrillation 109637-83-4 ARTELINIC ACID INDICATION Malaria 111757-17-6 CGP-28014 INDICATION Depression 111757-17-6 CGP-28014 PRODUCT_CLASS Central Nervous System (CNS) 111757-17-6 CGP-28014 INDICATION Parkinson's Disease 111757-17-6 CGP-28014 THERAPEUTIC_CLASS Antidepressants 103898-38-0 SM-6586 MODE_CLASS Channel Modulator 103898-38-0 SM-6586 PRODUCT_CLASS Cardiovasculars 103898-38-0 SM-6586 MECHANISM Modulate channel gating 103898-38-0 SM-6586 INDICATION Hypertension 103898-38-0 SM-6586 THERAPEUTIC_CLASS Antihypertensive Agents 103899-37-2 SM-6586 PRODUCT_CLASS Cardiovasculars 103899-37-2 SM-6586 MODE_CLASS Channel Modulator 103899-37-2 SM-6586 THERAPEUTIC_CLASS Antihypertensive Agents 103899-37-2 SM-6586 INDICATION Hypertension 103899-37-2 SM-6586 MECHANISM Modulate channel gating 103899-31-6 SM-6586 THERAPEUTIC_CLASS Antihypertensive Agents 103899-31-6 SM-6586 INDICATION Hypertension 103899-31-6 SM-6586 MECHANISM Modulate channel gating 103899-31-6 SM-6586 MODE_CLASS Channel Modulator 103899-31-6 SM-6586 PRODUCT_CLASS Cardiovasculars 91503-79-6 FLURBIPROFEN AXETIL THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 91503-79-6 FLURBIPROFEN AXETIL STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 91503-79-6 FLURBIPROFEN AXETIL MODE_CLASS Enzyme Inhibitor 91503-79-6 FLURBIPROFEN AXETIL PRODUCT_CLASS Anti-inflammatories 91503-79-6 FLURBIPROFEN AXETIL MECHANISM Inhibit eicosanoid biosynthesis 117086-68-7 RICASETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 117086-68-7 RICASETRON MECHANISM Block neural transmission 117086-68-7 RICASETRON MECHANISM Prolong/enhance neural transmission 117086-68-7 RICASETRON MODE_CLASS Solute transporter inhibitor 117086-68-7 RICASETRON MODE_CLASS Channel Blocker, selective 117086-68-7 RICASETRON PRODUCT_CLASS Central Nervous System (CNS) 127910-32-1 CGP-39551 MODE_CLASS Channel Modulator 127910-32-1 CGP-39551 MECHANISM Modulate neural transmission 22933-72-8 SALAZOPYRIDAZIN PRODUCT_CLASS Immune Response / Immunomodulators 22933-72-8 SALAZOPYRIDAZIN INDICATION Arthritis 22933-72-8 SALAZOPYRIDAZIN INDICATION Ulcer 22933-72-8 SALAZOPYRIDAZIN THERAPEUTIC_CLASS Immunosuppressants 76609-94-4 KT-3799 MODE_CLASS Enzyme Inhibitor 76609-94-4 KT-3799 PRODUCT_CLASS Anti-infectives 76609-94-4 KT-3799 THERAPEUTIC_CLASS Antibacterials 76609-94-4 KT-3799 MECHANISM Inhibit bacterial cell wall biosynthesis 113079-40-6 OCO-1112 INDICATION Hypolipidemia 97451-46-2 GLUTATHIONE MONOISOPROPYL ESTER INDICATION Anemia 97451-46-2 GLUTATHIONE MONOISOPROPYL ESTER MODE_CLASS Enzyme Inhibitor 97451-46-2 GLUTATHIONE MONOISOPROPYL ESTER INDICATION Cataract 112018-00-5 TEBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 112018-00-5 TEBUFELONE MODE_CLASS Enzyme Inhibitor 106861-44-3 MIVACURIUM CHLORIDE MECHANISM Modulate neural transmission 106861-44-3 MIVACURIUM CHLORIDE MODE_CLASS Channel Blocker 120520-26-5 POLAPREZINC INDICATION Helicobacter Pylori Infection 107667-60-7 POLAPREZINC INDICATION Helicobacter Pylori Infection 132613-07-1 POLAPREZINC INDICATION Helicobacter Pylori Infection 80012-43-7 EPINASTINE MODE_CLASS Receptor Ligand Antagonist 80012-43-7 EPINASTINE MECHANISM Modulate G-protein coupled signal transduction 80012-43-7 EPINASTINE INDICATION Viral Rhinitis / Common Cold 108929-04-0 EPINASTINE MECHANISM Modulate G-protein coupled signal transduction 108929-04-0 EPINASTINE MODE_CLASS Receptor Ligand Antagonist 108929-04-0 EPINASTINE INDICATION Viral Rhinitis / Common Cold 112887-68-0 RALTITREXED STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 112887-68-0 RALTITREXED MECHANISM Inhibit precursor synthesis 112887-68-0 RALTITREXED MODE_CLASS Enzyme Inhibitor 548-04-9 HYPERICIN PRODUCT_CLASS Anti-cancers 548-04-9 HYPERICIN MODE_CLASS Enzyme Inhibitor 548-04-9 HYPERICIN PRODUCT_CLASS Central Nervous System (CNS) 548-04-9 HYPERICIN PRODUCT_CLASS Anti-infectives 548-04-9 HYPERICIN THERAPEUTIC_CLASS Antidepressants 548-04-9 HYPERICIN THERAPEUTIC_CLASS Antineoplastics 548-04-9 HYPERICIN MECHANISM Inhibit kinase mediated signal transduction 548-04-9 HYPERICIN THERAPEUTIC_CLASS Antivirals 548-04-9 HYPERICIN ADVERSE_EFFECT IMU_1_Photosensitivity 82964-04-3 TOLRESTAT MECHANISM Inhibit precursor synthesis 82964-04-3 TOLRESTAT INDICATION Diabetic Neuropathy 82964-04-3 TOLRESTAT PRODUCT_CLASS Other Human Uses 82964-04-3 TOLRESTAT MODE_CLASS Enzyme Inhibitor 82964-04-3 TOLRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 114833-91-9 IO-21 INDICATION Ulcer 114289-47-3 CI-976 INDICATION Hypolipidemia 114289-47-3 CI-976 STRUCTURE_ACTIVITY Sterol O-acyltransferase (ACAT) inhibitor 114289-47-3 CI-976 MECHANISM Inhibit steroid biosynthesis/ metabolism 114289-47-3 CI-976 MODE_CLASS Enzyme Inhibitor 115607-61-9 SK&F-96067 MECHANISM Reduce stomach HCl secretion 115607-61-9 SK&F-96067 MODE_CLASS Enzyme Inhibitor 83805-11-2 FALECALCITRIOL MECHANISM Modulate gene transcription 83805-11-2 FALECALCITRIOL THERAPEUTIC_CLASS Psoralens 83805-11-2 FALECALCITRIOL INDICATION Psoriasis 83805-11-2 FALECALCITRIOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 83805-11-2 FALECALCITRIOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 83805-11-2 FALECALCITRIOL INDICATION Secondary Hyperparathyroidism 83805-11-2 FALECALCITRIOL MODE_CLASS Receptor Agonist 83805-11-2 FALECALCITRIOL INDICATION Renal Osteodystrophy 83805-11-2 FALECALCITRIOL THERAPEUTIC_CLASS Bone Mineral Homeostasis 83805-11-2 FALECALCITRIOL PRODUCT_CLASS Dermatologicals 108674-87-9 SERGOLEXOLE MALEATE MODE_CLASS Receptor Ligand Antagonist 108674-87-9 SERGOLEXOLE MALEATE MECHANISM Modulate G-protein coupled signal transduction 108674-87-9 SERGOLEXOLE MALEATE STRUCTURE_ACTIVITY Ergot alkaloid 108674-87-9 SERGOLEXOLE MALEATE INDICATION Migraine Headache 108674-87-9 SERGOLEXOLE MALEATE PRODUCT_CLASS Central Nervous System (CNS) 108674-87-9 SERGOLEXOLE MALEATE THERAPEUTIC_CLASS Antimigraines 108030-77-9 PENCLOMEDINE INDICATION Breast Cancer / Carcinoma of the Breast 108030-77-9 PENCLOMEDINE STRUCTURE_ACTIVITY DNA-alkylator 108030-77-9 PENCLOMEDINE INDICATION Brain Cancer 86408-72-2 ECABET MODE_CLASS Enzyme Inhibitor 86408-72-2 ECABET INDICATION Ulcer 86408-71-1 ECABET MODE_CLASS Enzyme Inhibitor 86408-71-1 ECABET INDICATION Ulcer 33159-27-2 ECABET INDICATION Ulcer 33159-27-2 ECABET MODE_CLASS Enzyme Inhibitor 123524-52-7 AZELNIDIPINE MECHANISM Reduce muscle contractile force 123524-52-7 AZELNIDIPINE INDICATION Hypertension 123524-52-7 AZELNIDIPINE MODE_CLASS Channel Blocker 123524-52-7 AZELNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 123524-52-7 AZELNIDIPINE PRODUCT_CLASS Cardiovasculars 123524-52-7 AZELNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 116573-93-4 AZELNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 116573-93-4 AZELNIDIPINE MECHANISM Reduce muscle contractile force 116573-93-4 AZELNIDIPINE INDICATION Hypertension 116573-93-4 AZELNIDIPINE MODE_CLASS Channel Blocker 116573-93-4 AZELNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 116573-93-4 AZELNIDIPINE PRODUCT_CLASS Cardiovasculars 116574-11-9 AZELNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 116574-11-9 AZELNIDIPINE PRODUCT_CLASS Cardiovasculars 116574-11-9 AZELNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 116574-11-9 AZELNIDIPINE MODE_CLASS Channel Blocker 116574-11-9 AZELNIDIPINE MECHANISM Reduce muscle contractile force 116574-11-9 AZELNIDIPINE INDICATION Hypertension 145858-52-5 LIAROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 145858-52-5 LIAROZOLE THERAPEUTIC_CLASS Antineoplastics 145858-52-5 LIAROZOLE PRODUCT_CLASS Anti-cancers 145858-52-5 LIAROZOLE MODE_CLASS Enzyme Inhibitor, selective 145858-52-5 LIAROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 145858-52-5 LIAROZOLE INDICATION Psoriasis 145858-50-0 LIAROZOLE INDICATION Psoriasis 145858-50-0 LIAROZOLE MODE_CLASS Enzyme Inhibitor, selective 145858-50-0 LIAROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 145858-50-0 LIAROZOLE PRODUCT_CLASS Anti-cancers 145858-50-0 LIAROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 145858-50-0 LIAROZOLE THERAPEUTIC_CLASS Antineoplastics 145858-51-1 LIAROZOLE INDICATION Psoriasis 145858-51-1 LIAROZOLE MODE_CLASS Enzyme Inhibitor, selective 145858-51-1 LIAROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 145858-51-1 LIAROZOLE THERAPEUTIC_CLASS Antineoplastics 145858-51-1 LIAROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 145858-51-1 LIAROZOLE PRODUCT_CLASS Anti-cancers 112859-71-9 FLUASTERONE INDICATION Diabetes 112859-71-9 FLUASTERONE INDICATION Multiple Sclerosis (MS) 115767-74-3 MIPROXIFENE PHOSPHATE MODE_CLASS Receptor Ligand Antagonist 115767-74-3 MIPROXIFENE PHOSPHATE PRODUCT_CLASS Anti-cancers 115767-74-3 MIPROXIFENE PHOSPHATE THERAPEUTIC_CLASS Gonadal Hormones 115767-74-3 MIPROXIFENE PHOSPHATE MECHANISM Modulate gene transcription 127182-67-6 CEFETECOL MECHANISM Inhibit bacterial cell wall biosynthesis 127182-67-6 CEFETECOL PRODUCT_CLASS Anti-infectives 127182-67-6 CEFETECOL STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 127182-67-6 CEFETECOL MODE_CLASS Enzyme Inhibitor 127182-67-6 CEFETECOL THERAPEUTIC_CLASS Antibacterials 117211-03-7 CEFETECOL THERAPEUTIC_CLASS Antibacterials 117211-03-7 CEFETECOL PRODUCT_CLASS Anti-infectives 117211-03-7 CEFETECOL MODE_CLASS Enzyme Inhibitor 117211-03-7 CEFETECOL STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 117211-03-7 CEFETECOL MECHANISM Inhibit bacterial cell wall biosynthesis 118359-59-4 KT-6149 STRUCTURE_ACTIVITY DNA-alkylator 113141-80-3 TMA-230 PRODUCT_CLASS Anti-infectives 113141-80-3 TMA-230 MODE_CLASS Enzyme Inhibitor 113141-80-3 TMA-230 THERAPEUTIC_CLASS Antibacterials 113141-80-3 TMA-230 MECHANISM Inhibit bacterial cell wall biosynthesis 103475-41-8 TEPOXALIN INDICATION Psoriasis 103475-41-8 TEPOXALIN MECHANISM Inhibit eicosanoid biosynthesis 103475-41-8 TEPOXALIN MODE_CLASS Enzyme Inhibitor 116853-25-9 CEFLUPRENAM MECHANISM Inhibit bacterial cell wall biosynthesis 116853-25-9 CEFLUPRENAM PRODUCT_CLASS Anti-infectives 116853-25-9 CEFLUPRENAM MODE_CLASS Enzyme Inhibitor 116853-25-9 CEFLUPRENAM THERAPEUTIC_CLASS Antibacterials 116289-53-3 TULOPAFANT THERAPEUTIC_CLASS Antiarrhythmic Agents 116289-53-3 TULOPAFANT INDICATION Cardiac Arrhythmias 116289-53-3 TULOPAFANT THERAPEUTIC_CLASS Antianginals 116289-53-3 TULOPAFANT INDICATION Angina Pectoris 116289-53-3 TULOPAFANT PRODUCT_CLASS Cardiovasculars 92395-36-3 AMRUBICIN HYDROCHLORIDE PRODUCT_CLASS Anti-cancers 92395-36-3 AMRUBICIN HYDROCHLORIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 92395-36-3 AMRUBICIN HYDROCHLORIDE THERAPEUTIC_CLASS Antineoplastics 92395-36-3 AMRUBICIN HYDROCHLORIDE MECHANISM Inhibit DNA synthesis, repair, and function 92395-36-3 AMRUBICIN HYDROCHLORIDE STRUCTURE_ACTIVITY DNA intercalator, anthracycline 110267-81-7 AMRUBICIN HYDROCHLORIDE STRUCTURE_ACTIVITY DNA intercalator, anthracycline 110267-81-7 AMRUBICIN HYDROCHLORIDE MECHANISM Inhibit DNA synthesis, repair, and function 110267-81-7 AMRUBICIN HYDROCHLORIDE PRODUCT_CLASS Anti-cancers 110267-81-7 AMRUBICIN HYDROCHLORIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 110267-81-7 AMRUBICIN HYDROCHLORIDE THERAPEUTIC_CLASS Antineoplastics 116539-59-4 DULOXETINE OXALATE INDICATION Depression 116539-59-4 DULOXETINE OXALATE PRODUCT_CLASS Central Nervous System (CNS) 116539-59-4 DULOXETINE OXALATE THERAPEUTIC_CLASS Antidepressants 116539-59-4 DULOXETINE OXALATE INDICATION Urinary Incontinence / Enuresis 136434-34-9 DULOXETINE OXALATE INDICATION Depression 136434-34-9 DULOXETINE OXALATE THERAPEUTIC_CLASS Antidepressants 136434-34-9 DULOXETINE OXALATE PRODUCT_CLASS Central Nervous System (CNS) 136434-34-9 DULOXETINE OXALATE INDICATION Urinary Incontinence / Enuresis 104606-13-5 R-56865 THERAPEUTIC_CLASS Antianginals 104606-13-5 R-56865 INDICATION Angina Pectoris 104606-13-5 R-56865 PRODUCT_CLASS Cardiovasculars 104606-13-5 R-56865 STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 116057-75-1 IDOXIFENE MODE_CLASS Receptor Ligand Antagonist 116057-75-1 IDOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 116057-75-1 IDOXIFENE MECHANISM Modulate gene transcription 116057-75-1 IDOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 92569-65-8 APRIKALIM THERAPEUTIC_CLASS Antihypertensive Agents 92569-65-8 APRIKALIM MECHANISM Modulate channel gating 92569-65-8 APRIKALIM INDICATION Hypertension 92569-65-8 APRIKALIM MODE_CLASS Channel Modulator 92569-65-8 APRIKALIM PRODUCT_CLASS Cardiovasculars 92569-65-8 APRIKALIM STRUCTURE_ACTIVITY K+ Channel (KATP-SUR2 ) opener 89544-10-5 APRIKALIM MECHANISM Modulate channel gating 89544-10-5 APRIKALIM STRUCTURE_ACTIVITY K+ Channel (KATP-SUR2 ) opener 89544-10-5 APRIKALIM THERAPEUTIC_CLASS Antihypertensive Agents 89544-10-5 APRIKALIM PRODUCT_CLASS Cardiovasculars 89544-10-5 APRIKALIM MODE_CLASS Channel Modulator 89544-10-5 APRIKALIM INDICATION Hypertension 125277-78-3 BMY-40062 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 65141-46-0 NICORANDIL THERAPEUTIC_CLASS Antianginals 65141-46-0 NICORANDIL THERAPEUTIC_CLASS Antihypertensive Agents 65141-46-0 NICORANDIL INDICATION Angina Pectoris 65141-46-0 NICORANDIL MODE_CLASS Channel enhancer /opener 65141-46-0 NICORANDIL MECHANISM Reduce muscle contractile force 65141-46-0 NICORANDIL PRODUCT_CLASS Cardiovasculars 6265-73-2 NICORANDIL INDICATION Angina Pectoris 6265-73-2 NICORANDIL MECHANISM Reduce muscle contractile force 6265-73-2 NICORANDIL THERAPEUTIC_CLASS Antihypertensive Agents 6265-73-2 NICORANDIL THERAPEUTIC_CLASS Antianginals 6265-73-2 NICORANDIL PRODUCT_CLASS Cardiovasculars 6265-73-2 NICORANDIL MODE_CLASS Channel enhancer /opener 117545-11-6 BIMAKALIM THERAPEUTIC_CLASS Antiarrhythmic Agents 117545-11-6 BIMAKALIM THERAPEUTIC_CLASS Antianginals 117545-11-6 BIMAKALIM MECHANISM Reduce muscle contractile force 117545-11-6 BIMAKALIM MODE_CLASS Channel enhancer /opener 117545-11-6 BIMAKALIM THERAPEUTIC_CLASS Antihypertensive Agents 117545-11-6 BIMAKALIM PRODUCT_CLASS Cardiovasculars 97205-34-0 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 116041-13-5 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 142116-35-6 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 142116-34-5 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 97205-35-1 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 103295-65-4 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 103295-62-1 NEBRACETAM FUMARATE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 112344-52-2 FLOBUFEN THERAPEUTIC_CLASS Immunosuppressants 112344-52-2 FLOBUFEN INDICATION Arthritis 112344-52-2 FLOBUFEN PRODUCT_CLASS Immune Response / Immunomodulators 112344-52-2 FLOBUFEN MECHANISM Inhibit eicosanoid biosynthesis 112344-52-2 FLOBUFEN MODE_CLASS Enzyme Inhibitor 104941-35-7 FLOBUFEN INDICATION Arthritis 104941-35-7 FLOBUFEN PRODUCT_CLASS Immune Response / Immunomodulators 104941-35-7 FLOBUFEN MECHANISM Inhibit eicosanoid biosynthesis 104941-35-7 FLOBUFEN MODE_CLASS Enzyme Inhibitor 104941-35-7 FLOBUFEN THERAPEUTIC_CLASS Immunosuppressants 101973-77-7 KE-298 INDICATION Arthritis 101973-77-7 KE-298 THERAPEUTIC_CLASS Immunosuppressants 101973-77-7 KE-298 PRODUCT_CLASS Immune Response / Immunomodulators 74239-84-2 BAOGONGTENG A INDICATION Glaucoma 117414-74-1 SDZ-EAA-494 MODE_CLASS Channel Modulator 117414-74-1 SDZ-EAA-494 MECHANISM Modulate neural transmission 118314-35-5 DS-4574 INDICATION Ulcer 120051-39-0 NKS-01 MECHANISM Inhibit steroid biosynthesis/ metabolism 120051-39-0 NKS-01 STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 120051-39-0 NKS-01 THERAPEUTIC_CLASS Antineoplastics 120051-39-0 NKS-01 MODE_CLASS Enzyme Inhibitor 120051-39-0 NKS-01 PRODUCT_CLASS Anti-cancers 118918-04-0 BMY-21950 MODE_CLASS Enzyme Inhibitor 118918-04-0 BMY-21950 INDICATION Hypolipidemia 118918-04-0 BMY-21950 MECHANISM Inhibit cholesterol biosynthesis 118875-43-7 BMY-21950 MODE_CLASS Enzyme Inhibitor 118875-43-7 BMY-21950 MECHANISM Inhibit cholesterol biosynthesis 118875-43-7 BMY-21950 INDICATION Hypolipidemia 130200-44-1 BMY-21950 INDICATION Hypolipidemia 130200-44-1 BMY-21950 MODE_CLASS Enzyme Inhibitor 130200-44-1 BMY-21950 MECHANISM Inhibit cholesterol biosynthesis 115966-23-9 ULARITIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 115966-23-9 ULARITIDE INDICATION Acute Heart Failure 115966-23-9 ULARITIDE THERAPEUTIC_CLASS Bronchodilators 115966-23-9 ULARITIDE PRODUCT_CLASS Respiratory System 115966-23-9 ULARITIDE PRODUCT_CLASS Cardiovasculars 115966-23-9 ULARITIDE INDICATION Asthma 115966-23-9 ULARITIDE THERAPEUTIC_CLASS Congestive Heart Failure 115966-23-9 ULARITIDE INDICATION Renal Failure / Kidney Failure 118812-69-4 ULARITIDE INDICATION Asthma 118812-69-4 ULARITIDE PRODUCT_CLASS Cardiovasculars 118812-69-4 ULARITIDE THERAPEUTIC_CLASS Congestive Heart Failure 118812-69-4 ULARITIDE INDICATION Renal Failure / Kidney Failure 118812-69-4 ULARITIDE PRODUCT_CLASS Respiratory System 118812-69-4 ULARITIDE THERAPEUTIC_CLASS Bronchodilators 118812-69-4 ULARITIDE INDICATION Acute Heart Failure 118812-69-4 ULARITIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 114923-99-8 SK&F-105494 PRODUCT_CLASS Biochemicals 93426-60-9 P-536 INDICATION Malaria 83991-25-7 AMBASILIDE INDICATION Cardiac Arrhythmias 83991-25-7 AMBASILIDE PRODUCT_CLASS Cardiovasculars 83991-25-7 AMBASILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 79700-61-1 DOPROPIDIL HYDROCHLORIDE MODE_CLASS Channel Modulator 79700-61-1 DOPROPIDIL HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 79700-61-1 DOPROPIDIL HYDROCHLORIDE INDICATION Angina Pectoris 79700-61-1 DOPROPIDIL HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 79700-61-1 DOPROPIDIL HYDROCHLORIDE MECHANISM Reduce muscle contractile force 117241-47-1 DOPROPIDIL HYDROCHLORIDE MODE_CLASS Channel Modulator 117241-47-1 DOPROPIDIL HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 117241-47-1 DOPROPIDIL HYDROCHLORIDE INDICATION Angina Pectoris 117241-47-1 DOPROPIDIL HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 117241-47-1 DOPROPIDIL HYDROCHLORIDE MECHANISM Reduce muscle contractile force 506-26-3 GAMOLENIC ACID INDICATION Eczema Herpeticum 118101-09-0 L-365260 PRODUCT_CLASS Central Nervous System (CNS) 118101-09-0 L-365260 INDICATION Anxiety Disorders 118101-09-0 L-365260 THERAPEUTIC_CLASS Sedatives/Hypnotics 118101-09-0 L-365260 MECHANISM Reduce stomach HCl secretion 118101-09-0 L-365260 MODE_CLASS Receptor Ligand Antagonist 119487-10-4 L-365260 PRODUCT_CLASS Central Nervous System (CNS) 119487-10-4 L-365260 INDICATION Anxiety Disorders 119487-10-4 L-365260 THERAPEUTIC_CLASS Sedatives/Hypnotics 119487-10-4 L-365260 MECHANISM Reduce stomach HCl secretion 119487-10-4 L-365260 MODE_CLASS Receptor Ligand Antagonist 118018-42-1 L-365260 PRODUCT_CLASS Central Nervous System (CNS) 118018-42-1 L-365260 INDICATION Anxiety Disorders 118018-42-1 L-365260 THERAPEUTIC_CLASS Sedatives/Hypnotics 118018-42-1 L-365260 MECHANISM Reduce stomach HCl secretion 118018-42-1 L-365260 MODE_CLASS Receptor Ligand Antagonist 118635-52-2 TILNOPROFEN ARBAMEL STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 118635-52-2 TILNOPROFEN ARBAMEL MODE_CLASS Enzyme Inhibitor 118635-52-2 TILNOPROFEN ARBAMEL PRODUCT_CLASS Anti-inflammatories 118635-52-2 TILNOPROFEN ARBAMEL THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 118635-52-2 TILNOPROFEN ARBAMEL MECHANISM Inhibit eicosanoid biosynthesis 159098-79-0 TILNOPROFEN ARBAMEL PRODUCT_CLASS Anti-inflammatories 159098-79-0 TILNOPROFEN ARBAMEL STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 159098-79-0 TILNOPROFEN ARBAMEL MODE_CLASS Enzyme Inhibitor 159098-79-0 TILNOPROFEN ARBAMEL THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 159098-79-0 TILNOPROFEN ARBAMEL MECHANISM Inhibit eicosanoid biosynthesis 119742-13-1 ROXINDOLE MESILATE INDICATION Depression 119742-13-1 ROXINDOLE MESILATE THERAPEUTIC_CLASS Antidepressants 119742-13-1 ROXINDOLE MESILATE MECHANISM Modulate neural transmission 119742-13-1 ROXINDOLE MESILATE MODE_CLASS Receptor Agonist 119742-13-1 ROXINDOLE MESILATE PRODUCT_CLASS Central Nervous System (CNS) 119742-13-1 ROXINDOLE MESILATE MECHANISM Prolong/enhance neural transmission 108050-82-4 ROXINDOLE MESILATE MODE_CLASS Receptor Agonist 108050-82-4 ROXINDOLE MESILATE MECHANISM Prolong/enhance neural transmission 108050-82-4 ROXINDOLE MESILATE MECHANISM Modulate neural transmission 108050-82-4 ROXINDOLE MESILATE INDICATION Depression 108050-82-4 ROXINDOLE MESILATE THERAPEUTIC_CLASS Antidepressants 108050-82-4 ROXINDOLE MESILATE PRODUCT_CLASS Central Nervous System (CNS) 112192-04-8 ROXINDOLE MESILATE MECHANISM Prolong/enhance neural transmission 112192-04-8 ROXINDOLE MESILATE THERAPEUTIC_CLASS Antidepressants 112192-04-8 ROXINDOLE MESILATE INDICATION Depression 112192-04-8 ROXINDOLE MESILATE MECHANISM Modulate neural transmission 112192-04-8 ROXINDOLE MESILATE PRODUCT_CLASS Central Nervous System (CNS) 112192-04-8 ROXINDOLE MESILATE MODE_CLASS Receptor Agonist 120770-34-5 DRAFLAZINE PRODUCT_CLASS Cardiovasculars 120770-34-5 DRAFLAZINE INDICATION Cardiac Arrhythmias 120770-34-5 DRAFLAZINE THERAPEUTIC_CLASS Antiarrhythmic Agents 120737-08-8 DRAFLAZINE PRODUCT_CLASS Cardiovasculars 120737-08-8 DRAFLAZINE INDICATION Cardiac Arrhythmias 120737-08-8 DRAFLAZINE THERAPEUTIC_CLASS Antiarrhythmic Agents 132553-86-7 GLEMANSERIN THERAPEUTIC_CLASS Antiarrhythmic Agents 132553-86-7 GLEMANSERIN INDICATION Cardiac Arrhythmias 132553-86-7 GLEMANSERIN PRODUCT_CLASS Central Nervous System (CNS) 132553-86-7 GLEMANSERIN INDICATION Anxiety Disorders 132553-86-7 GLEMANSERIN THERAPEUTIC_CLASS Sedatives/Hypnotics 132553-86-7 GLEMANSERIN INDICATION Dyskinesia 132553-86-7 GLEMANSERIN MODE_CLASS Receptor Ligand Antagonist 132553-86-7 GLEMANSERIN INDICATION Glaucoma 132553-86-7 GLEMANSERIN MECHANISM Modulate neural transmission 132553-86-7 GLEMANSERIN PRODUCT_CLASS Cardiovasculars 86976-77-4 TT-62 MECHANISM Inhibit precursor synthesis 86976-77-4 TT-62 MODE_CLASS Enzyme Inhibitor 86976-77-4 TT-62 STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 118288-08-7 LAFUTIDINE THERAPEUTIC_CLASS Antiulcers 118288-08-7 LAFUTIDINE PRODUCT_CLASS Gastrointestinal System 118288-08-7 LAFUTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 118288-08-7 LAFUTIDINE MECHANISM Reduce stomach HCl secretion 112018-01-6 BEMORADAN MODE_CLASS Enzyme Inhibitor 112018-01-6 BEMORADAN MECHANISM Enhance kinase mediated signal transduction 123169-88-0 BEMORADAN MODE_CLASS Enzyme Inhibitor 123169-88-0 BEMORADAN MECHANISM Enhance kinase mediated signal transduction 110143-10-7 LODENOSINE INDICATION Myocardial Ischemia 110143-10-7 LODENOSINE STRUCTURE_ACTIVITY Viral RT inhibitor 119610-26-3 ALORACETAM INDICATION Aging / Senescence 119610-26-3 ALORACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 103434-39-5 YM-16151-4 MODE_CLASS Channel Blocker 103434-39-5 YM-16151-4 THERAPEUTIC_CLASS Antihypertensive Agents 103434-39-5 YM-16151-4 MECHANISM Reduce muscle contractile force 103434-39-5 YM-16151-4 INDICATION Hypertension 103434-39-5 YM-16151-4 THERAPEUTIC_CLASS Antianginals 103434-39-5 YM-16151-4 STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 103434-39-5 YM-16151-4 INDICATION Angina Pectoris 103434-39-5 YM-16151-4 PRODUCT_CLASS Cardiovasculars 115622-58-7 RO-23-9424 STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 115622-58-7 RO-23-9424 MECHANISM Inhibit bacterial cell wall biosynthesis 115622-58-7 RO-23-9424 THERAPEUTIC_CLASS Antibacterials 115622-58-7 RO-23-9424 MODE_CLASS Enzyme Inhibitor 115622-58-7 RO-23-9424 PRODUCT_CLASS Anti-infectives 115699-46-2 RO-23-9424 PRODUCT_CLASS Anti-infectives 115699-46-2 RO-23-9424 THERAPEUTIC_CLASS Antibacterials 115699-46-2 RO-23-9424 MODE_CLASS Enzyme Inhibitor 115699-46-2 RO-23-9424 MECHANISM Inhibit bacterial cell wall biosynthesis 115699-46-2 RO-23-9424 STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 118414-82-7 MK-886 MECHANISM Inhibit eicosanoid biosynthesis 118414-82-7 MK-886 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 118414-82-7 MK-886 INDICATION Asthma 118414-82-7 MK-886 PRODUCT_CLASS Anti-inflammatories 118414-82-7 MK-886 MODE_CLASS Enzyme Inhibitor 118414-82-7 MK-886 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 118414-82-7 MK-886 PRODUCT_CLASS Respiratory System 101246-68-8 EPTASTIGMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 101246-68-8 EPTASTIGMINE MECHANISM Enhance cholinergic transmission 101246-68-8 EPTASTIGMINE MODE_CLASS Enzyme Inhibitor 101246-68-8 EPTASTIGMINE THERAPEUTIC_CLASS Parasympathomimetic Agents 113206-79-4 SC-45662 MODE_CLASS Enzyme Inhibitor 113206-79-4 SC-45662 MECHANISM Inhibit eicosanoid biosynthesis 113206-78-3 SC-45662 MODE_CLASS Enzyme Inhibitor 113206-78-3 SC-45662 MECHANISM Inhibit eicosanoid biosynthesis 108436-80-2 ROCICLOVIR PRODUCT_CLASS Anti-infectives 108436-80-2 ROCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 108436-80-2 ROCICLOVIR MECHANISM Inhibit viral DNA synthesis 108436-80-2 ROCICLOVIR THERAPEUTIC_CLASS Antivirals 108436-80-2 ROCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 73865-18-6 NARDETEROL INDICATION Asthma 73865-18-6 NARDETEROL INDICATION Depression 73865-18-6 NARDETEROL THERAPEUTIC_CLASS Antidepressants 73865-18-6 NARDETEROL PRODUCT_CLASS Central Nervous System (CNS) 73865-18-6 NARDETEROL PRODUCT_CLASS Respiratory System 73865-18-6 NARDETEROL THERAPEUTIC_CLASS Bronchodilators 111358-88-4 CEP-701 KNOWN_TOXICITY Cardiovascular Toxicity 111358-88-4 CEP-701 ADVERSE_EFFECT MSK_1_Muscle Cramps 111358-88-4 CEP-701 ADVERSE_EFFECT XXX_2_Asthenia 111358-88-4 CEP-701 ADVERSE_EFFECT GIS_1_Constipation 111358-88-4 CEP-701 INDICATION Neoplasm / Cancer / Tumor 111358-88-4 CEP-701 STRUCTURE_ACTIVITY Protein-tyrosine kinase (Flt3) inhibitor 111358-88-4 CEP-701 ADVERSE_EFFECT GIS_1_Nausea / Vomiting 111358-88-4 CEP-701 ADVERSE_EFFECT GIS_1_Abdominal Pain 111358-88-4 CEP-701 MODE_CLASS Enzyme Inhibitor 111358-88-4 CEP-701 ADVERSE_EFFECT XXX_1_Fatigue 111358-88-4 CEP-701 ADVERSE_EFFECT GIS_1_Diarrhea 111358-88-4 CEP-701 ADVERSE_EFFECT BBM_2_Anemia 111358-88-4 CEP-701 INDICATION Myeloid Leukemia 111358-88-4 CEP-701 PRODUCT_CLASS Anti-cancers 111358-88-4 CEP-701 INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 111358-88-4 CEP-701 THERAPEUTIC_CLASS Antineoplastics 111358-88-4 CEP-701 ADVERSE_EFFECT CVS_3_Hypotension 111358-88-4 CEP-701 ADVERSE_EFFECT GIS_1_Dyspepsia 111358-88-4 CEP-701 ADVERSE_EFFECT PSY_2_Anorexia 111358-88-4 CEP-701 MECHANISM Inhibit kinase mediated signal transduction 111358-88-4 CEP-701 INDICATION Prostatic Cancer / Carcinoma of the Prostate 111358-88-4 CEP-701 TISSUE_TOXICITY Hypotension 124904-93-4 GANIRELIX INDICATION Female Infertility 129311-55-3 GANIRELIX INDICATION Female Infertility 119474-55-4 KB-5246 THERAPEUTIC_CLASS Antibacterials 119474-55-4 KB-5246 MECHANISM Inhibit bacterial DNA synthesis 119474-55-4 KB-5246 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 119474-55-4 KB-5246 MODE_CLASS Enzyme Inhibitor, selective 119474-55-4 KB-5246 PRODUCT_CLASS Anti-infectives 119474-47-4 KB-5246 MODE_CLASS Enzyme Inhibitor, selective 119474-47-4 KB-5246 MECHANISM Inhibit bacterial DNA synthesis 119474-47-4 KB-5246 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 119474-47-4 KB-5246 THERAPEUTIC_CLASS Antibacterials 119474-47-4 KB-5246 PRODUCT_CLASS Anti-infectives 120788-07-0 SULOPENEM PRODUCT_CLASS Anti-infectives 120788-07-0 SULOPENEM MODE_CLASS Enzyme Inhibitor 120788-07-0 SULOPENEM STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 120788-07-0 SULOPENEM THERAPEUTIC_CLASS Antibacterials 120788-07-0 SULOPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 115464-77-2 ELOPIPRAZOLE MECHANISM Modulate G-protein coupled signal transduction 116313-94-1 NITECAPONE INDICATION Parkinson's Disease 116313-94-1 NITECAPONE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 116313-94-1 NITECAPONE INDICATION Ulcer 28841-62-5 ATRINOSITOL INDICATION Hypertension 28841-62-5 ATRINOSITOL PRODUCT_CLASS Cardiovasculars 28841-62-5 ATRINOSITOL INDICATION Hypolipidemia 28841-62-5 ATRINOSITOL THERAPEUTIC_CLASS Antihypertensive Agents 119555-47-4 DDG-39 INDICATION Myocardial Ischemia 120128-20-3 RG-12525 MODE_CLASS Receptor Ligand Antagonist 120128-20-3 RG-12525 INDICATION Asthma 120128-20-3 RG-12525 MECHANISM Modulate G-protein coupled signal transduction 120128-20-3 RG-12525 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 120128-20-3 RG-12525 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 120128-20-3 RG-12525 PRODUCT_CLASS Respiratory System 112568-12-4 ANTIDE INDICATION Female Infertility 121588-75-8 AMESERGIDE THERAPEUTIC_CLASS Antihypertensive Agents 121588-75-8 AMESERGIDE INDICATION Hypertension 121588-75-8 AMESERGIDE MODE_CLASS Receptor Ligand Antagonist, Non-selective 121588-75-8 AMESERGIDE MECHANISM Modulate G-protein coupled signal transduction 121588-75-8 AMESERGIDE PRODUCT_CLASS Cardiovasculars 87719-32-2 ETAROTENE INDICATION Psoriasis 87719-32-2 ETAROTENE PRODUCT_CLASS Dermatologicals 87719-32-2 ETAROTENE INDICATION Acne / Acne Vulgaris 87719-32-2 ETAROTENE THERAPEUTIC_CLASS Acne Preparations 539-86-6 ALLICIN INDICATION Hypolipidemia 70050-43-0 ALPHA-FMH INDICATION Pruritus / Itching 70050-43-0 ALPHA-FMH INDICATION Ulcer 103009-38-7 SDZ NVI 085 MECHANISM Modulate G-protein coupled signal transduction 103009-38-7 SDZ NVI 085 PRODUCT_CLASS Central Nervous System (CNS) 103009-38-7 SDZ NVI 085 THERAPEUTIC_CLASS Antidepressants 103009-38-7 SDZ NVI 085 INDICATION Depression 103009-38-7 SDZ NVI 085 INDICATION Cerebral Ischemia 103238-61-5 SDZ NVI 085 PRODUCT_CLASS Central Nervous System (CNS) 103238-61-5 SDZ NVI 085 INDICATION Depression 103238-61-5 SDZ NVI 085 THERAPEUTIC_CLASS Antidepressants 103238-61-5 SDZ NVI 085 INDICATION Cerebral Ischemia 103238-61-5 SDZ NVI 085 MECHANISM Modulate G-protein coupled signal transduction 103009-57-0 SDZ NVI 085 INDICATION Cerebral Ischemia 103009-57-0 SDZ NVI 085 THERAPEUTIC_CLASS Antidepressants 103009-57-0 SDZ NVI 085 INDICATION Depression 103009-57-0 SDZ NVI 085 PRODUCT_CLASS Central Nervous System (CNS) 103009-57-0 SDZ NVI 085 MECHANISM Modulate G-protein coupled signal transduction 87234-24-0 PIROXICAM CINNAMATE STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 87234-24-0 PIROXICAM CINNAMATE PRODUCT_CLASS Anti-inflammatories 87234-24-0 PIROXICAM CINNAMATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 87234-24-0 PIROXICAM CINNAMATE MODE_CLASS Enzyme Inhibitor 87234-24-0 PIROXICAM CINNAMATE MECHANISM Inhibit eicosanoid biosynthesis 89796-99-6 ACECLOFENAC TA_LEVEL_3 NSAID 89796-99-6 ACECLOFENAC INDICATION Ankylosing Spondylitis 89796-99-6 ACECLOFENAC ADVERSE_EFFECT GIS_3_Pancreatitis 89796-99-6 ACECLOFENAC ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 89796-99-6 ACECLOFENAC ADVERSE_EFFECT NEU_2_Dizziness 89796-99-6 ACECLOFENAC ADVERSE_EFFECT GIS_1_Dyspepsia 89796-99-6 ACECLOFENAC INDICATION Rheumatoid Arthritis 89796-99-6 ACECLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 89796-99-6 ACECLOFENAC MECH_LEVEL_1 Immunomodulation 89796-99-6 ACECLOFENAC MESH_LEVEL_3 Acids, Carbocyclic 89796-99-6 ACECLOFENAC ACTIVITY_CLASS Anti-inflammatory 89796-99-6 ACECLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 89796-99-6 ACECLOFENAC ADVERSE_EFFECT GIS_1_Abdominal Pain 89796-99-6 ACECLOFENAC ADVERSE_EFFECT BBM_3_Thrombocytopenia 89796-99-6 ACECLOFENAC ADVERSE_EFFECT XXX_3_Edema 89796-99-6 ACECLOFENAC ADVERSE_EFFECT SKN_3_Skin Rash 89796-99-6 ACECLOFENAC PRODUCT_CLASS Anti-inflammatories 89796-99-6 ACECLOFENAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 89796-99-6 ACECLOFENAC MESH_LEVEL_2 Carboxylic Acids 89796-99-6 ACECLOFENAC TA_LEVEL_2 NSAID 89796-99-6 ACECLOFENAC TA_LEVEL_1 Anti-inflammatory 89796-99-6 ACECLOFENAC ZERO_CLASS N 89796-99-6 ACECLOFENAC STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 89796-99-6 ACECLOFENAC ADVERSE_EFFECT BBM_3_Leukopenia 89796-99-6 ACECLOFENAC ADVERSE_EFFECT NEU_3_Paresthesia 89796-99-6 ACECLOFENAC ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 89796-99-6 ACECLOFENAC MODE_CLASS Enzyme Inhibitor 89796-99-6 ACECLOFENAC INDICATION Osteoarthritis 89796-99-6 ACECLOFENAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 89796-99-6 ACECLOFENAC ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 89796-99-6 ACECLOFENAC ADVERSE_EFFECT BBM_3_Anemia 89796-99-6 ACECLOFENAC ADVERSE_EFFECT BBM_2_Inhibits Platelet Aggregation 89796-99-6 ACECLOFENAC MESH_LEVEL_1 Organic Chemicals 103300-74-9 TALTIRELIN MODE_CLASS Receptor /Channel ligand mimic 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Ataxia 28721-07-5 OXCARBAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT XXX_3_Infection 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT GIS_2_Abdominal Pain 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT OCU_3_Photophobia 28721-07-5 OXCARBAZEPINE TISSUE_TOXICITY Teratogenicity 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT OCU_3_Mydriasis 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT XXX_2_Fatigue 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Drowsiness 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 28721-07-5 OXCARBAZEPINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT PSY_1_Emotional Lability 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT OCU_2_Abnormal Vision 28721-07-5 OXCARBAZEPINE TA_LEVEL_1 Central Nervous System (CNS) 28721-07-5 OXCARBAZEPINE MECH_LEVEL_2 Sodium channel antagonist 28721-07-5 OXCARBAZEPINE MESH_LEVEL_1 Heterocyclic Compounds 28721-07-5 OXCARBAZEPINE TA_LEVEL_3 Seizures 28721-07-5 OXCARBAZEPINE KNOWN_TOXICITY Embryo/Fetal Toxicity 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT GIS_2_Constipation 28721-07-5 OXCARBAZEPINE MECH_LEVEL_3 Voltage-gated Na+ channel 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT SKN_3_Rash 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Nystagmus 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT LYM_3_Lymphadenopathy 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT BBM_3_Leukopenia 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_2_Vertigo 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT IMU_3_Eosinophilia 28721-07-5 OXCARBAZEPINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, tricyclic anticonvulsant 28721-07-5 OXCARBAZEPINE ACTIVITY_CLASS Na+ channel blocker 28721-07-5 OXCARBAZEPINE ZERO_CLASS N 28721-07-5 OXCARBAZEPINE MESH_LEVEL_3 Dibenzazepines 28721-07-5 OXCARBAZEPINE INDICATION Partial Seizures 28721-07-5 OXCARBAZEPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 28721-07-5 OXCARBAZEPINE MECHANISM Block neural transmission 28721-07-5 OXCARBAZEPINE MODE_CLASS Channel Blocker 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT GIS_2_Diarrhea 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Tremor 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Dizziness 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT OCU_2_Diplopia 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT GIS_2_Dyspepsia 28721-07-5 OXCARBAZEPINE TA_LEVEL_2 Anti-epileptics 28721-07-5 OXCARBAZEPINE MECH_LEVEL_1 Modulate neural transmission 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT EMB_3_Teratogenicity 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Sedation 28721-07-5 OXCARBAZEPINE ADVERSE_EFFECT NEU_1_Headache 73873-87-7 ILOPROST THERAPEUTIC_CLASS Vasodilators 73873-87-7 ILOPROST PRODUCT_CLASS Cardiovasculars 73873-87-7 ILOPROST THERAPEUTIC_CLASS Antiplatelets 73873-87-7 ILOPROST MODE_CLASS Receptor Agonist 73873-87-7 ILOPROST PRODUCT_CLASS Hematologics 73873-87-7 ILOPROST MECHANISM Modulate G-protein coupled signal transduction 99759-19-0 TIQUESIDE INDICATION Hyperlipidemia 99759-19-0 TIQUESIDE PRODUCT_CLASS Cardiovasculars 99759-19-0 TIQUESIDE THERAPEUTIC_CLASS Hypolipidemic Agents 99759-19-0 TIQUESIDE INDICATION Hypolipidemia 97677-19-5 118347 INDICATION Diabetes 97677-19-5 118347 MODE_CLASS Enzyme Inhibitor 97677-19-5 118347 MECHANISM Inhibit precursor synthesis 97677-19-5 118347 INDICATION Glaucoma 103186-19-2 SERATRODAST MECHANISM Modulate G-protein coupled signal transduction 103186-19-2 SERATRODAST MODE_CLASS Receptor Ligand Antagonist 103187-09-3 SERATRODAST MODE_CLASS Receptor Ligand Antagonist 103187-09-3 SERATRODAST MECHANISM Modulate G-protein coupled signal transduction 103196-89-0 SERATRODAST MECHANISM Modulate G-protein coupled signal transduction 103196-89-0 SERATRODAST MODE_CLASS Receptor Ligand Antagonist 112665-43-7 SERATRODAST MODE_CLASS Receptor Ligand Antagonist 112665-43-7 SERATRODAST MECHANISM Modulate G-protein coupled signal transduction 86583-19-9 3-DEAZAADENOSINE PRODUCT_CLASS Immune Response / Immunomodulators 86583-19-9 3-DEAZAADENOSINE THERAPEUTIC_CLASS Immunosuppressants 86583-19-9 3-DEAZAADENOSINE INDICATION Arthritis 6736-58-9 3-DEAZAADENOSINE PRODUCT_CLASS Immune Response / Immunomodulators 6736-58-9 3-DEAZAADENOSINE THERAPEUTIC_CLASS Immunosuppressants 6736-58-9 3-DEAZAADENOSINE INDICATION Arthritis 103486-79-9 BELFOSDIL MODE_CLASS Channel Modulator 103486-79-9 BELFOSDIL INDICATION Hypertension 103486-79-9 BELFOSDIL THERAPEUTIC_CLASS Antianginals 103486-79-9 BELFOSDIL THERAPEUTIC_CLASS Antihypertensive Agents 103486-79-9 BELFOSDIL PRODUCT_CLASS Cardiovasculars 103486-79-9 BELFOSDIL INDICATION Angina Pectoris 103486-79-9 BELFOSDIL MECHANISM Reduce muscle contractile force 103255-66-9 PAZINACLONE PRODUCT_CLASS Central Nervous System (CNS) 103255-66-9 PAZINACLONE INDICATION Anxiety Disorders 103255-66-9 PAZINACLONE THERAPEUTIC_CLASS Sedatives/Hypnotics 114580-45-9 FK-973 STRUCTURE_ACTIVITY DNA-alkylator 93035-33-7 TAMOLARIZINE HYDROCHLORIDE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 93035-32-6 TAMOLARIZINE HYDROCHLORIDE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 128229-52-7 TAMOLARIZINE HYDROCHLORIDE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 5728-52-9 FELBINAC MECHANISM Inhibit eicosanoid biosynthesis 5728-52-9 FELBINAC INDICATION Rheumatism 5728-52-9 FELBINAC ADVERSE_EFFECT BBM_3_Leukopenia 5728-52-9 FELBINAC ADVERSE_EFFECT LIV_3_Increased Serum Alkaline Phosphatase 5728-52-9 FELBINAC ADVERSE_EFFECT CVS_3_Chest Pain 5728-52-9 FELBINAC ADVERSE_EFFECT BBM_3_Increased Bleeding 5728-52-9 FELBINAC ADVERSE_EFFECT BBM_3_Anemia 5728-52-9 FELBINAC ADVERSE_EFFECT NEU_3_Headache 5728-52-9 FELBINAC ADVERSE_EFFECT SKN_1_Dermatitis 5728-52-9 FELBINAC ADVERSE_EFFECT GIS_3_Heartburn 5728-52-9 FELBINAC MODE_CLASS Enzyme Inhibitor 5728-52-9 FELBINAC PRODUCT_CLASS Anti-inflammatories 5728-52-9 FELBINAC INDICATION Pain 5728-52-9 FELBINAC ADVERSE_EFFECT GIS_3_Nausea 5728-52-9 FELBINAC ADVERSE_EFFECT SKN_1_Pruritis 5728-52-9 FELBINAC ADVERSE_EFFECT SKN_1_Erythema 5728-52-9 FELBINAC ADVERSE_EFFECT GIS_3_Epigastric Pain 5728-52-9 FELBINAC ADVERSE_EFFECT GIS_3_Bloody Stools 5728-52-9 FELBINAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 5728-52-9 FELBINAC ADVERSE_EFFECT PSY_3_Anorexia 5728-52-9 FELBINAC ADVERSE_EFFECT IMU_3_Allergic Reactions 5728-52-9 FELBINAC ADVERSE_EFFECT IMU_3_Urticaria 5728-52-9 FELBINAC ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 5728-52-9 FELBINAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 5728-52-9 FELBINAC ADVERSE_EFFECT GIS_3_Diarrhea 5728-52-9 FELBINAC ADVERSE_EFFECT NEU_3_Dizziness 5728-52-9 FELBINAC ADVERSE_EFFECT SKN_3_Erythema Multiforme 131-48-6 ACENEURAMIC ACID INDICATION Cough / Tussis 131-48-6 ACENEURAMIC ACID INDICATION Nasal Congestion 86780-90-7 ARANIPIDINE MECHANISM Reduce muscle contractile force 86780-90-7 ARANIPIDINE INDICATION Hypertension 86780-90-7 ARANIPIDINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 86780-90-7 ARANIPIDINE MODE_CLASS Channel Blocker 86780-90-7 ARANIPIDINE PRODUCT_CLASS Cardiovasculars 86780-90-7 ARANIPIDINE THERAPEUTIC_CLASS Antihypertensive Agents 36590-19-9 AMOCARZINE INDICATION Helminthic Infections 104060-12-0 RS-93522 PRODUCT_CLASS Cardiovasculars 104060-12-0 RS-93522 MODE_CLASS Channel Blocker 104060-12-0 RS-93522 INDICATION Hypertension 104060-12-0 RS-93522 STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 104060-12-0 RS-93522 MECHANISM Reduce muscle contractile force 104060-12-0 RS-93522 THERAPEUTIC_CLASS Antihypertensive Agents 88321-09-9 ALOXISTATIN INDICATION Cataract 88321-09-9 ALOXISTATIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 88321-09-9 ALOXISTATIN KNOWN_TOXICITY Hepatotoxicity 88321-09-9 ALOXISTATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 88321-09-9 ALOXISTATIN MECHANISM Modulate signal transduction 88321-09-9 ALOXISTATIN INDICATION Muscular Dystrophies 88321-09-9 ALOXISTATIN MODE_CLASS Enzyme Inhibitor 88321-09-9 ALOXISTATIN THERAPEUTIC_CLASS Miscellaneous Ophthamological Agents 88321-09-9 ALOXISTATIN TISSUE_TOXICITY Hepatotoxicity 88321-09-9 ALOXISTATIN STRUCTURE_ACTIVITY Protease (thiol) inhibitor 96244-68-7 ALOXISTATIN INDICATION Muscular Dystrophies 96244-68-7 ALOXISTATIN MODE_CLASS Enzyme Inhibitor 96244-68-7 ALOXISTATIN MECHANISM Modulate signal transduction 96244-68-7 ALOXISTATIN THERAPEUTIC_CLASS Miscellaneous Ophthamological Agents 96244-68-7 ALOXISTATIN TISSUE_TOXICITY Hepatotoxicity 96244-68-7 ALOXISTATIN STRUCTURE_ACTIVITY Protease (thiol) inhibitor 96244-68-7 ALOXISTATIN INDICATION Cataract 96244-68-7 ALOXISTATIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 96244-68-7 ALOXISTATIN KNOWN_TOXICITY Hepatotoxicity 96244-68-7 ALOXISTATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 70667-26-4 ORNOPROSTIL INDICATION Ulcer 23651-95-8 DROXIDOPA MECHANISM Modulate G-protein coupled signal transduction 23651-95-8 DROXIDOPA INDICATION Parkinson's Disease 23651-95-8 DROXIDOPA PRODUCT_CLASS Central Nervous System (CNS) 23651-95-8 DROXIDOPA MODE_CLASS Receptor Agonist 23651-95-8 DROXIDOPA THERAPEUTIC_CLASS Movement Disorders 104054-27-5 ATIPAMEZOLE MECHANISM Modulate G-protein coupled signal transduction 55721-11-4 SECALCIFEROL INDICATION Renal Osteodystrophy 55721-11-4 SECALCIFEROL THERAPEUTIC_CLASS Bone Mineral Homeostasis 55721-11-4 SECALCIFEROL MECHANISM Modulate gene transcription 55721-11-4 SECALCIFEROL PRODUCT_CLASS Hormones, Endocrine and Metabolic 55721-11-4 SECALCIFEROL MODE_CLASS Receptor Agonist 55721-11-4 SECALCIFEROL STRUCTURE_ACTIVITY Vitamin D receptor agonist 60325-46-4 SULPROSTONE MECHANISM Modulate G-protein coupled signal transduction 60325-46-4 SULPROSTONE MODE_CLASS Receptor Agonist, selective 84371-65-3 MIFEPRISTONE INDICATION Termination of Pregnancy 84371-65-3 MIFEPRISTONE MESH_LEVEL_2 Steroids 84371-65-3 MIFEPRISTONE MECHANISM Modulate gene transcription 84371-65-3 MIFEPRISTONE MODE_CLASS Receptor Ligand Antagonist 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT XXX_1_Fever 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT NEU_1_Headache 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Abdominal Pain 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT NEU_2_Syncope 84371-65-3 MIFEPRISTONE MESH_LEVEL_3 Estranes 84371-65-3 MIFEPRISTONE ZERO_CLASS N 84371-65-3 MIFEPRISTONE ACTIVITY_CLASS Progesterone receptor antagonist 84371-65-3 MIFEPRISTONE TA_LEVEL_3 Progesterone receptor antagonists 84371-65-3 MIFEPRISTONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Diarrhea 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT XXX_1_Fatigue 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT SKN_2_Skin Rash 84371-65-3 MIFEPRISTONE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT REP_3_Rupture of Uterus 84371-65-3 MIFEPRISTONE MESH_LEVEL_1 Polycyclic Hydrocarbons 84371-65-3 MIFEPRISTONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Vomiting 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT REP_1_Uterine Contractions 84371-65-3 MIFEPRISTONE MECH_LEVEL_2 anti-progestatgen 84371-65-3 MIFEPRISTONE MECH_LEVEL_1 Hormone modulation 84371-65-3 MIFEPRISTONE TA_LEVEL_2 Birth control 84371-65-3 MIFEPRISTONE MECH_LEVEL_3 Progesterone receptor 84371-65-3 MIFEPRISTONE THERAPEUTIC_CLASS Gonadal Hormones 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Nausea 84371-65-3 MIFEPRISTONE TISSUE_TOXICITY Hemorrhage 84371-65-3 MIFEPRISTONE STRUCTURE_ACTIVITY Progesterone receptor antagonist 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT BBM_1_Hemorrhage 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT GUS_1_Vaginal Spotting 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT NEU_1_Dizziness 84371-65-3 MIFEPRISTONE ADVERSE_EFFECT GUS_2_Vaginitis 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT REP_3_Rupture of Uterus 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT GUS_2_Vaginitis 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT REP_1_Uterine Contractions 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Vomiting 83203-42-3 MIFEPRISTONE MECHANISM Modulate gene transcription 83203-42-3 MIFEPRISTONE MESH_LEVEL_1 Polycyclic Hydrocarbons 83203-42-3 MIFEPRISTONE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT SKN_2_Skin Rash 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT XXX_1_Fatigue 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Diarrhea 83203-42-3 MIFEPRISTONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 83203-42-3 MIFEPRISTONE TA_LEVEL_3 Progesterone receptor antagonists 83203-42-3 MIFEPRISTONE MECH_LEVEL_1 Hormone modulation 83203-42-3 MIFEPRISTONE ACTIVITY_CLASS Progesterone receptor antagonist 83203-42-3 MIFEPRISTONE ZERO_CLASS N 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT NEU_2_Syncope 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Abdominal Pain 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT NEU_1_Headache 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT XXX_1_Fever 83203-42-3 MIFEPRISTONE MODE_CLASS Receptor Ligand Antagonist 83203-42-3 MIFEPRISTONE MESH_LEVEL_2 Steroids 83203-42-3 MIFEPRISTONE MESH_LEVEL_3 Estranes 83203-42-3 MIFEPRISTONE INDICATION Termination of Pregnancy 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT BBM_1_Hemorrhage 83203-42-3 MIFEPRISTONE TISSUE_TOXICITY Hemorrhage 83203-42-3 MIFEPRISTONE STRUCTURE_ACTIVITY Progesterone receptor antagonist 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT GUS_1_Vaginal Spotting 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT NEU_1_Dizziness 83203-42-3 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Nausea 83203-42-3 MIFEPRISTONE THERAPEUTIC_CLASS Gonadal Hormones 83203-42-3 MIFEPRISTONE MECH_LEVEL_3 Progesterone receptor 83203-42-3 MIFEPRISTONE TA_LEVEL_2 Birth control 83203-42-3 MIFEPRISTONE MECH_LEVEL_2 anti-progestatgen 83203-42-3 MIFEPRISTONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT SKN_2_Skin Rash 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT NEU_1_Dizziness 122742-25-0 MIFEPRISTONE ZERO_CLASS N 122742-25-0 MIFEPRISTONE INDICATION Termination of Pregnancy 122742-25-0 MIFEPRISTONE MESH_LEVEL_3 Estranes 122742-25-0 MIFEPRISTONE MESH_LEVEL_2 Steroids 122742-25-0 MIFEPRISTONE MODE_CLASS Receptor Ligand Antagonist 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT XXX_1_Fever 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT NEU_1_Headache 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Abdominal Pain 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT NEU_2_Syncope 122742-25-0 MIFEPRISTONE ACTIVITY_CLASS Progesterone receptor antagonist 122742-25-0 MIFEPRISTONE MECH_LEVEL_1 Hormone modulation 122742-25-0 MIFEPRISTONE TA_LEVEL_3 Progesterone receptor antagonists 122742-25-0 MIFEPRISTONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Diarrhea 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT XXX_1_Fatigue 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 122742-25-0 MIFEPRISTONE TISSUE_TOXICITY Hemorrhage 122742-25-0 MIFEPRISTONE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 122742-25-0 MIFEPRISTONE MESH_LEVEL_1 Polycyclic Hydrocarbons 122742-25-0 MIFEPRISTONE MECHANISM Modulate gene transcription 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Vomiting 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT REP_1_Uterine Contractions 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT GUS_2_Vaginitis 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT REP_3_Rupture of Uterus 122742-25-0 MIFEPRISTONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 122742-25-0 MIFEPRISTONE MECH_LEVEL_2 anti-progestatgen 122742-25-0 MIFEPRISTONE TA_LEVEL_2 Birth control 122742-25-0 MIFEPRISTONE MECH_LEVEL_3 Progesterone receptor 122742-25-0 MIFEPRISTONE THERAPEUTIC_CLASS Gonadal Hormones 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT GIS_1_Nausea 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT GUS_1_Vaginal Spotting 122742-25-0 MIFEPRISTONE ADVERSE_EFFECT BBM_1_Hemorrhage 122742-25-0 MIFEPRISTONE STRUCTURE_ACTIVITY Progesterone receptor antagonist 64218-02-6 PLAUNOTOL INDICATION Ulcer 73573-87-2 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 73573-87-2 FORMOTEROL ADVERSE_EFFECT IMU_3_Urticaria 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 73573-87-2 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 73573-87-2 FORMOTEROL MODE_CLASS Receptor Agonist, selective 73573-87-2 FORMOTEROL ADVERSE_EFFECT NEU_3_Psychomotor Excitation 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_3_Tolerance 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_2_Xerostomia 73573-87-2 FORMOTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_2_Palpitation 73573-87-2 FORMOTEROL KNOWN_TOXICITY Cardiovascular Toxicity 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_3_Angina 73573-87-2 FORMOTEROL PRODUCT_CLASS Respiratory System 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_2_ST-T Wave Changes 73573-87-2 FORMOTEROL ADVERSE_EFFECT NEU_3_Vertigo 73573-87-2 FORMOTEROL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 73573-87-2 FORMOTEROL ADVERSE_EFFECT NEU_3_Dizziness 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 73573-87-2 FORMOTEROL ADVERSE_EFFECT END_3_Hyperglycemia 73573-87-2 FORMOTEROL INDICATION Asthma 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_1_Infection 73573-87-2 FORMOTEROL ADVERSE_EFFECT MSK_2_Muscle Cramps 73573-87-2 FORMOTEROL INDICATION Asthma 73573-87-2 FORMOTEROL MECHANISM Reduce bronchoconstriction 73573-87-2 FORMOTEROL TISSUE_TOXICITY Angina 73573-87-2 FORMOTEROL TISSUE_TOXICITY Exacerbation of Arrhythmia 73573-87-2 FORMOTEROL ADVERSE_EFFECT GIS_1_Abdominal Pain 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_2_Chest Infection 73573-87-2 FORMOTEROL ADVERSE_EFFECT LUN_3_Dysphonia 73573-87-2 FORMOTEROL ADVERSE_EFFECT LUN_2_Hoarseness 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypotension 73573-87-2 FORMOTEROL ADVERSE_EFFECT END_3_Metabolic Acidosis 73573-87-2 FORMOTEROL ADVERSE_EFFECT GIS_2_Oral Ulceration 73573-87-2 FORMOTEROL ADVERSE_EFFECT IMU_3_Photosensitivity 73573-87-2 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_3_Pharyngitis 73573-87-2 FORMOTEROL ADVERSE_EFFECT PSY_2_Nervousness 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_2_Malaise 73573-87-2 FORMOTEROL ADVERSE_EFFECT ELT_3_Hypokalemia 73573-87-2 FORMOTEROL ADVERSE_EFFECT NEU_2_Headache 73573-87-2 FORMOTEROL ADVERSE_EFFECT GIS_1_Dyspepsia 73573-87-2 FORMOTEROL TISSUE_TOXICITY Hypotension 73573-87-2 FORMOTEROL ADVERSE_EFFECT IMU_3_Angioedema 73573-87-2 FORMOTEROL ADVERSE_EFFECT NEU_1_Tremor 73573-87-2 FORMOTEROL ADVERSE_EFFECT SKN_3_Rash 73573-87-2 FORMOTEROL THERAPEUTIC_CLASS Bronchodilators 73573-87-2 FORMOTEROL ADVERSE_EFFECT GIS_3_Dry Mouth 73573-87-2 FORMOTEROL ADVERSE_EFFECT XXX_2_Fatigue 73573-87-2 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypertension 73573-87-2 FORMOTEROL ADVERSE_EFFECT PSY_2_Insomnia 73573-87-2 FORMOTEROL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 73573-87-2 FORMOTEROL ADVERSE_EFFECT NEU_3_Paresthesia 73573-87-2 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_3_Angina 43229-80-7 FORMOTEROL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 43229-80-7 FORMOTEROL ADVERSE_EFFECT NEU_3_Paresthesia 43229-80-7 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 43229-80-7 FORMOTEROL PRODUCT_CLASS Respiratory System 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_2_ST-T Wave Changes 43229-80-7 FORMOTEROL ADVERSE_EFFECT NEU_3_Vertigo 43229-80-7 FORMOTEROL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 43229-80-7 FORMOTEROL ADVERSE_EFFECT NEU_3_Dizziness 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 43229-80-7 FORMOTEROL ADVERSE_EFFECT END_3_Hyperglycemia 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_1_Infection 43229-80-7 FORMOTEROL ADVERSE_EFFECT MSK_2_Muscle Cramps 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_2_Palpitation 43229-80-7 FORMOTEROL INDICATION Asthma 43229-80-7 FORMOTEROL MECHANISM Reduce bronchoconstriction 43229-80-7 FORMOTEROL TISSUE_TOXICITY Angina 43229-80-7 FORMOTEROL TISSUE_TOXICITY Exacerbation of Arrhythmia 43229-80-7 FORMOTEROL ADVERSE_EFFECT GIS_1_Abdominal Pain 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_2_Chest Infection 43229-80-7 FORMOTEROL ADVERSE_EFFECT LUN_3_Dysphonia 43229-80-7 FORMOTEROL ADVERSE_EFFECT LUN_2_Hoarseness 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypotension 43229-80-7 FORMOTEROL ADVERSE_EFFECT END_3_Metabolic Acidosis 43229-80-7 FORMOTEROL ADVERSE_EFFECT GIS_2_Oral Ulceration 43229-80-7 FORMOTEROL ADVERSE_EFFECT IMU_3_Photosensitivity 43229-80-7 FORMOTEROL INDICATION Asthma 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 43229-80-7 FORMOTEROL ADVERSE_EFFECT IMU_3_Urticaria 43229-80-7 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 43229-80-7 FORMOTEROL THERAPEUTIC_CLASS Bronchodilators 43229-80-7 FORMOTEROL TISSUE_TOXICITY Hypotension 43229-80-7 FORMOTEROL ADVERSE_EFFECT SKN_3_Rash 43229-80-7 FORMOTEROL ADVERSE_EFFECT NEU_1_Tremor 43229-80-7 FORMOTEROL ADVERSE_EFFECT IMU_3_Angioedema 43229-80-7 FORMOTEROL ADVERSE_EFFECT GIS_1_Dyspepsia 43229-80-7 FORMOTEROL ADVERSE_EFFECT NEU_2_Headache 43229-80-7 FORMOTEROL ADVERSE_EFFECT ELT_3_Hypokalemia 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_2_Malaise 43229-80-7 FORMOTEROL ADVERSE_EFFECT PSY_2_Nervousness 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_3_Pharyngitis 43229-80-7 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 43229-80-7 FORMOTEROL ADVERSE_EFFECT GIS_3_Dry Mouth 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_2_Fatigue 43229-80-7 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypertension 43229-80-7 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 43229-80-7 FORMOTEROL MODE_CLASS Receptor Agonist, selective 43229-80-7 FORMOTEROL ADVERSE_EFFECT NEU_3_Psychomotor Excitation 43229-80-7 FORMOTEROL ADVERSE_EFFECT PSY_2_Insomnia 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_3_Tolerance 43229-80-7 FORMOTEROL ADVERSE_EFFECT XXX_2_Xerostomia 43229-80-7 FORMOTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 43229-80-7 FORMOTEROL KNOWN_TOXICITY Cardiovascular Toxicity 83536-10-1 FORMOTEROL ADVERSE_EFFECT LUN_3_Dysphonia 83536-10-1 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 83536-10-1 FORMOTEROL MODE_CLASS Receptor Agonist, selective 83536-10-1 FORMOTEROL ADVERSE_EFFECT NEU_3_Psychomotor Excitation 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_3_Tolerance 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_2_Xerostomia 83536-10-1 FORMOTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_3_Angina 83536-10-1 FORMOTEROL ADVERSE_EFFECT GIS_3_Dry Mouth 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_2_Fatigue 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypertension 83536-10-1 FORMOTEROL ADVERSE_EFFECT PSY_2_Insomnia 83536-10-1 FORMOTEROL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83536-10-1 FORMOTEROL ADVERSE_EFFECT NEU_3_Paresthesia 83536-10-1 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 83536-10-1 FORMOTEROL PRODUCT_CLASS Respiratory System 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_2_ST-T Wave Changes 83536-10-1 FORMOTEROL ADVERSE_EFFECT NEU_3_Vertigo 83536-10-1 FORMOTEROL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 83536-10-1 FORMOTEROL ADVERSE_EFFECT NEU_3_Dizziness 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 83536-10-1 FORMOTEROL ADVERSE_EFFECT END_3_Hyperglycemia 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_1_Infection 83536-10-1 FORMOTEROL ADVERSE_EFFECT MSK_2_Muscle Cramps 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_2_Palpitation 83536-10-1 FORMOTEROL INDICATION Asthma 83536-10-1 FORMOTEROL MECHANISM Reduce bronchoconstriction 83536-10-1 FORMOTEROL TISSUE_TOXICITY Angina 83536-10-1 FORMOTEROL TISSUE_TOXICITY Exacerbation of Arrhythmia 83536-10-1 FORMOTEROL ADVERSE_EFFECT GIS_1_Abdominal Pain 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_2_Chest Infection 83536-10-1 FORMOTEROL KNOWN_TOXICITY Cardiovascular Toxicity 83536-10-1 FORMOTEROL ADVERSE_EFFECT LUN_2_Hoarseness 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypotension 83536-10-1 FORMOTEROL ADVERSE_EFFECT END_3_Metabolic Acidosis 83536-10-1 FORMOTEROL ADVERSE_EFFECT GIS_2_Oral Ulceration 83536-10-1 FORMOTEROL ADVERSE_EFFECT IMU_3_Photosensitivity 83536-10-1 FORMOTEROL INDICATION Asthma 83536-10-1 FORMOTEROL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 83536-10-1 FORMOTEROL ADVERSE_EFFECT IMU_3_Urticaria 83536-10-1 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 83536-10-1 FORMOTEROL THERAPEUTIC_CLASS Bronchodilators 83536-10-1 FORMOTEROL TISSUE_TOXICITY Hypotension 83536-10-1 FORMOTEROL ADVERSE_EFFECT SKN_3_Rash 83536-10-1 FORMOTEROL ADVERSE_EFFECT NEU_1_Tremor 83536-10-1 FORMOTEROL ADVERSE_EFFECT IMU_3_Angioedema 83536-10-1 FORMOTEROL ADVERSE_EFFECT GIS_1_Dyspepsia 83536-10-1 FORMOTEROL ADVERSE_EFFECT NEU_2_Headache 83536-10-1 FORMOTEROL ADVERSE_EFFECT ELT_3_Hypokalemia 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_2_Malaise 83536-10-1 FORMOTEROL ADVERSE_EFFECT PSY_2_Nervousness 83536-10-1 FORMOTEROL ADVERSE_EFFECT XXX_3_Pharyngitis 83536-10-1 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypertension 87481-49-0 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 87481-49-0 FORMOTEROL MODE_CLASS Receptor Agonist, selective 87481-49-0 FORMOTEROL ADVERSE_EFFECT NEU_3_Psychomotor Excitation 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_3_Tolerance 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_2_Xerostomia 87481-49-0 FORMOTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 87481-49-0 FORMOTEROL KNOWN_TOXICITY Cardiovascular Toxicity 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_3_Angina 87481-49-0 FORMOTEROL ADVERSE_EFFECT GIS_3_Dry Mouth 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_2_Fatigue 87481-49-0 FORMOTEROL ADVERSE_EFFECT LUN_3_Dysphonia 87481-49-0 FORMOTEROL ADVERSE_EFFECT PSY_2_Insomnia 87481-49-0 FORMOTEROL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 87481-49-0 FORMOTEROL ADVERSE_EFFECT NEU_3_Paresthesia 87481-49-0 FORMOTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_2_Chest Infection 87481-49-0 FORMOTEROL ADVERSE_EFFECT GIS_1_Abdominal Pain 87481-49-0 FORMOTEROL TISSUE_TOXICITY Exacerbation of Arrhythmia 87481-49-0 FORMOTEROL TISSUE_TOXICITY Angina 87481-49-0 FORMOTEROL MECHANISM Reduce bronchoconstriction 87481-49-0 FORMOTEROL INDICATION Asthma 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_2_Palpitation 87481-49-0 FORMOTEROL ADVERSE_EFFECT MSK_2_Muscle Cramps 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_1_Infection 87481-49-0 FORMOTEROL ADVERSE_EFFECT END_3_Hyperglycemia 87481-49-0 FORMOTEROL ADVERSE_EFFECT NEU_3_Dizziness 87481-49-0 FORMOTEROL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 87481-49-0 FORMOTEROL ADVERSE_EFFECT NEU_3_Vertigo 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_2_ST-T Wave Changes 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 87481-49-0 FORMOTEROL PRODUCT_CLASS Respiratory System 87481-49-0 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_3_Pharyngitis 87481-49-0 FORMOTEROL ADVERSE_EFFECT PSY_2_Nervousness 87481-49-0 FORMOTEROL ADVERSE_EFFECT XXX_2_Malaise 87481-49-0 FORMOTEROL ADVERSE_EFFECT ELT_3_Hypokalemia 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 87481-49-0 FORMOTEROL ADVERSE_EFFECT GIS_1_Dyspepsia 87481-49-0 FORMOTEROL ADVERSE_EFFECT IMU_3_Angioedema 87481-49-0 FORMOTEROL ADVERSE_EFFECT NEU_1_Tremor 87481-49-0 FORMOTEROL ADVERSE_EFFECT SKN_3_Rash 87481-49-0 FORMOTEROL TISSUE_TOXICITY Hypotension 87481-49-0 FORMOTEROL THERAPEUTIC_CLASS Bronchodilators 87481-49-0 FORMOTEROL INDICATION Prophylaxis of Bronchospasm 87481-49-0 FORMOTEROL ADVERSE_EFFECT NEU_2_Headache 87481-49-0 FORMOTEROL ADVERSE_EFFECT IMU_3_Urticaria 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 87481-49-0 FORMOTEROL INDICATION Asthma 87481-49-0 FORMOTEROL ADVERSE_EFFECT IMU_3_Photosensitivity 87481-49-0 FORMOTEROL ADVERSE_EFFECT GIS_2_Oral Ulceration 87481-49-0 FORMOTEROL ADVERSE_EFFECT END_3_Metabolic Acidosis 87481-49-0 FORMOTEROL ADVERSE_EFFECT CVS_3_Hypotension 87481-49-0 FORMOTEROL ADVERSE_EFFECT LUN_2_Hoarseness 73121-56-9 ENPROSTIL INDICATION Hypolipidemia 73121-56-9 ENPROSTIL MECHANISM Modulate G-protein coupled signal transduction 73121-56-9 ENPROSTIL INDICATION Diabetes 73121-56-9 ENPROSTIL MODE_CLASS Receptor Agonist 73121-56-9 ENPROSTIL INDICATION Ulcer 71675-85-9 AMISULPRIDE MECHANISM Block neural transmission 71675-85-9 AMISULPRIDE INDICATION Schizophrenic Disorders 71675-85-9 AMISULPRIDE THERAPEUTIC_CLASS Antipsychotics 71675-85-9 AMISULPRIDE MODE_CLASS Receptor Ligand Antagonist 71675-85-9 AMISULPRIDE PRODUCT_CLASS Central Nervous System (CNS) 64808-48-6 LOBENZARIT SODIUM PRODUCT_CLASS Immune Response / Immunomodulators 64808-48-6 LOBENZARIT SODIUM THERAPEUTIC_CLASS Immunosuppressants 64808-48-6 LOBENZARIT SODIUM INDICATION Systemic Lupus Erythromatosus (SLE) 64808-48-6 LOBENZARIT SODIUM INDICATION Arthritis 18699-02-0 ACTARIT THERAPEUTIC_CLASS Immunosuppressants 18699-02-0 ACTARIT INDICATION Arthritis 18699-02-0 ACTARIT PRODUCT_CLASS Immune Response / Immunomodulators 101189-47-3 CP-66948 MODE_CLASS Receptor Ligand Antagonist, Selective 101189-47-3 CP-66948 MECHANISM Reduce stomach HCl secretion 101189-47-3 CP-66948 INDICATION Ulcer 110314-48-2 ADOZELESIN STRUCTURE_ACTIVITY DNA intercalator 119905-00-9 ADOZELESIN STRUCTURE_ACTIVITY DNA intercalator 112245-32-6 ADOZELESIN STRUCTURE_ACTIVITY DNA intercalator 105149-00-6 OSATERONE ACETATE INDICATION Prostatitis 105655-99-0 NK-611 STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 105760-98-3 NK-611 STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 78967-07-4 MOFEZOLAC MODE_CLASS Enzyme Inhibitor, selective 78967-07-4 MOFEZOLAC MECHANISM Inhibit eicosanoid biosynthesis 108852-90-0 NEMORUBICIN THERAPEUTIC_CLASS Antineoplastics 108852-90-0 NEMORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 108852-90-0 NEMORUBICIN PRODUCT_CLASS Anti-cancers 108852-90-0 NEMORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 108852-90-0 NEMORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 108943-08-4 NEMORUBICIN THERAPEUTIC_CLASS Antineoplastics 108943-08-4 NEMORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 108943-08-4 NEMORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 108943-08-4 NEMORUBICIN PRODUCT_CLASS Anti-cancers 108943-08-4 NEMORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 122547-49-3 FAROPENEM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 122547-49-3 FAROPENEM ADVERSE_EFFECT KID_3_Nephrotoxicity 122547-49-3 FAROPENEM INDICATION Lower Respiratory Tract Infection 122547-49-3 FAROPENEM KNOWN_TOXICITY Nephrotoxicity 122547-49-3 FAROPENEM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 122547-49-3 FAROPENEM ADVERSE_EFFECT BBM_3_Hemolytic Anemia 122547-49-3 FAROPENEM TISSUE_TOXICITY Hepatotoxicity 122547-49-3 FAROPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 122547-49-3 FAROPENEM INDICATION Gynecologic Infections 122547-49-3 FAROPENEM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 122547-49-3 FAROPENEM TISSUE_TOXICITY Nephrotoxicity 122547-49-3 FAROPENEM ADVERSE_EFFECT ELT_2_Electrolyte Imbalance 122547-49-3 FAROPENEM THERAPEUTIC_CLASS Antibacterials, Systemic 122547-49-3 FAROPENEM PRODUCT_CLASS Anti-infectives 122547-49-3 FAROPENEM KNOWN_TOXICITY Hepatotoxicity 122547-49-3 FAROPENEM ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 122547-49-3 FAROPENEM ADVERSE_EFFECT LIV_3_Hepatotoxicity 122547-49-3 FAROPENEM MODE_CLASS Enzyme Inhibitor 122547-49-3 FAROPENEM ADVERSE_EFFECT BBM_3_Blood Dyscrasias 106560-14-9 FAROPENEM ADVERSE_EFFECT BBM_3_Blood Dyscrasias 106560-14-9 FAROPENEM MODE_CLASS Enzyme Inhibitor 106560-14-9 FAROPENEM INDICATION Lower Respiratory Tract Infection 106560-14-9 FAROPENEM KNOWN_TOXICITY Nephrotoxicity 106560-14-9 FAROPENEM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 106560-14-9 FAROPENEM ADVERSE_EFFECT BBM_3_Hemolytic Anemia 106560-14-9 FAROPENEM TISSUE_TOXICITY Hepatotoxicity 106560-14-9 FAROPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 106560-14-9 FAROPENEM INDICATION Gynecologic Infections 106560-14-9 FAROPENEM PRODUCT_CLASS Anti-infectives 106560-14-9 FAROPENEM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 106560-14-9 FAROPENEM TISSUE_TOXICITY Nephrotoxicity 106560-14-9 FAROPENEM ADVERSE_EFFECT KID_3_Nephrotoxicity 106560-14-9 FAROPENEM ADVERSE_EFFECT ELT_2_Electrolyte Imbalance 106560-14-9 FAROPENEM ADVERSE_EFFECT LIV_3_Hepatotoxicity 106560-14-9 FAROPENEM THERAPEUTIC_CLASS Antibacterials, Systemic 106560-14-9 FAROPENEM KNOWN_TOXICITY Hepatotoxicity 106560-14-9 FAROPENEM ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 106560-14-9 FAROPENEM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 25967-29-7 FLUTOPRAZEPAM INDICATION Anxiety Disorders 25967-29-7 FLUTOPRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 25967-29-7 FLUTOPRAZEPAM MODE_CLASS Channel enhancer /opener 25967-29-7 FLUTOPRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 25967-29-7 FLUTOPRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 25967-29-7 FLUTOPRAZEPAM MECHANISM Modulate neural transmission 30751-05-4 TROXIPIDE ADVERSE_EFFECT NEU_3_Headache 30751-05-4 TROXIPIDE TA_LEVEL_2 anti-ulcer 30751-05-4 TROXIPIDE MESH_LEVEL_3 Piperidines 30751-05-4 TROXIPIDE TA_LEVEL_3 gastric ulcer 30751-05-4 TROXIPIDE ZERO_CLASS Y 30751-05-4 TROXIPIDE PRODUCT_CLASS Gastrointestinal System 30751-05-4 TROXIPIDE STRUCTURE_ACTIVITY Unknown mechanism, inflammation mediator/ blocker 30751-05-4 TROXIPIDE ADVERSE_EFFECT GIS_3_Heartburn 30751-05-4 TROXIPIDE ADVERSE_EFFECT SKN_3_Rash 30751-05-4 TROXIPIDE MECH_LEVEL_3 Unknown mechanism 30751-05-4 TROXIPIDE MESH_LEVEL_1 Heterocyclic Compounds 30751-05-4 TROXIPIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 30751-05-4 TROXIPIDE MECH_LEVEL_2 Unknown mechanism 30751-05-4 TROXIPIDE ADVERSE_EFFECT SKN_3_Pruritis 30751-05-4 TROXIPIDE ADVERSE_EFFECT GIS_3_Nausea 30751-05-4 TROXIPIDE TA_LEVEL_1 Gastrointestinal System 30751-05-4 TROXIPIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 30751-05-4 TROXIPIDE INDICATION Gastric Ulcer 30751-05-4 TROXIPIDE ADVERSE_EFFECT GIS_2_Constipation 30751-05-4 TROXIPIDE ACTIVITY_CLASS Unknown mechanism 30751-05-4 TROXIPIDE THERAPEUTIC_CLASS Antiulcers 30751-05-4 TROXIPIDE ADVERSE_EFFECT XXX_3_Fatigue 30751-05-4 TROXIPIDE INDICATION Gastritis 30751-05-4 TROXIPIDE ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 103810-85-1 BMY-30123 INDICATION Acne / Acne Vulgaris 103810-85-1 BMY-30123 PRODUCT_CLASS Dermatologicals 103810-85-1 BMY-30123 THERAPEUTIC_CLASS Acne Preparations 108610-78-2 AWD-122-14 MODE_CLASS Enzyme Inhibitor 108610-78-2 AWD-122-14 MECHANISM Enhance kinase mediated signal transduction 105051-87-4 MINAMESTANE MODE_CLASS Enzyme Inhibitor 105051-87-4 MINAMESTANE THERAPEUTIC_CLASS Antineoplastics 105051-87-4 MINAMESTANE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 105051-87-4 MINAMESTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 105051-87-4 MINAMESTANE PRODUCT_CLASS Cardiovasculars 57262-94-9 SETIPTILINE MALEATE MECHANISM Inhibit kinase mediated signal transduction 57262-94-9 SETIPTILINE MALEATE MODE_CLASS Receptor Ligand Antagonist 57262-94-9 SETIPTILINE MALEATE INDICATION Depression 57262-94-9 SETIPTILINE MALEATE MECHANISM Modulate G-protein coupled signal transduction 57262-94-9 SETIPTILINE MALEATE THERAPEUTIC_CLASS Antidepressants 57262-94-9 SETIPTILINE MALEATE PRODUCT_CLASS Central Nervous System (CNS) 57262-94-9 SETIPTILINE MALEATE MODE_CLASS Enzyme Inhibitor 103909-75-7 MAXACALCITOL MODE_CLASS Receptor Agonist 103909-75-7 MAXACALCITOL INDICATION Psoriasis 103909-75-7 MAXACALCITOL PRODUCT_CLASS Dermatologicals 103909-75-7 MAXACALCITOL THERAPEUTIC_CLASS Psoralens 103909-75-7 MAXACALCITOL MECHANISM Modulate gene transcription 103909-75-7 MAXACALCITOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 98829-12-0 CV-3611 THERAPEUTIC_CLASS Antianginals 98829-12-0 CV-3611 PRODUCT_CLASS Cardiovasculars 98829-12-0 CV-3611 INDICATION Angina Pectoris 98829-12-0 CV-3611 INDICATION Cataract 105080-50-0 ICI-200880 INDICATION Emphysema 105080-50-0 ICI-200880 INDICATION Acute Respiratory Distress Syndrome (ARDS) 105120-70-5 ICI-200880 INDICATION Emphysema 105120-70-5 ICI-200880 INDICATION Acute Respiratory Distress Syndrome (ARDS) 105120-02-3 ICI-200880 INDICATION Emphysema 105120-02-3 ICI-200880 INDICATION Acute Respiratory Distress Syndrome (ARDS) 66195-31-1 IBOPAMINE PRODUCT_CLASS Cardiovasculars 66195-31-1 IBOPAMINE MODE_CLASS Receptor Agonist 66195-31-1 IBOPAMINE THERAPEUTIC_CLASS Congestive Heart Failure 66195-31-1 IBOPAMINE INDICATION Congestive Heart Failure (CHF) 66195-31-1 IBOPAMINE MECHANISM Prolong/enhance neural transmission 75011-65-3 IBOPAMINE INDICATION Congestive Heart Failure (CHF) 75011-65-3 IBOPAMINE MODE_CLASS Receptor Agonist 75011-65-3 IBOPAMINE THERAPEUTIC_CLASS Congestive Heart Failure 75011-65-3 IBOPAMINE PRODUCT_CLASS Cardiovasculars 75011-65-3 IBOPAMINE MECHANISM Prolong/enhance neural transmission 106941-25-7 ADEFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 106941-25-7 ADEFOVIR INDICATION Hepatitis B 106941-25-7 ADEFOVIR PRODUCT_CLASS Anti-infectives 118553-11-0 ADEFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 118553-11-0 ADEFOVIR INDICATION Hepatitis B 118553-11-0 ADEFOVIR PRODUCT_CLASS Anti-infectives 166095-95-0 BMS-191095 PRODUCT_CLASS Cardiovasculars 166095-95-0 BMS-191095 MECHANISM Reduce muscle contractile force 166095-95-0 BMS-191095 MODE_CLASS Channel Modulator 166095-95-0 BMS-191095 MECHANISM Modulate channel gating 166095-95-0 BMS-191095 THERAPEUTIC_CLASS Antianginals 166095-95-0 BMS-191095 THERAPEUTIC_CLASS Vasodilators 166095-95-0 BMS-191095 MODE_CLASS Channel enhancer /opener 166095-21-2 BMS-191095 THERAPEUTIC_CLASS Vasodilators 166095-21-2 BMS-191095 MECHANISM Modulate channel gating 166095-21-2 BMS-191095 THERAPEUTIC_CLASS Antianginals 166095-21-2 BMS-191095 MODE_CLASS Channel Modulator 166095-21-2 BMS-191095 PRODUCT_CLASS Cardiovasculars 166095-21-2 BMS-191095 MECHANISM Reduce muscle contractile force 166095-21-2 BMS-191095 MODE_CLASS Channel enhancer /opener 177563-39-2 S-1197 MECHANISM Inhibit platelet aggregation 177563-39-2 S-1197 MODE_CLASS Receptor Ligand Antagonist, Selective 177563-44-9 S-1197 MECHANISM Inhibit platelet aggregation 177563-44-9 S-1197 MODE_CLASS Receptor Ligand Antagonist, Selective 168266-51-1 GR-205171 INDICATION Nausea / Vomiting 168266-90-8 GR-205171 INDICATION Nausea / Vomiting 178961-24-5 264W94 MECHANISM Decrease bile acid reabsorption 178961-24-5 264W94 MODE_CLASS Channel Modulator 178961-24-5 264W94 STRUCTURE_ACTIVITY Bile acid transporter (ileal) inhibitor 178961-24-5 264W94 INDICATION Hypolipidemia 114419-77-1 PD-123497 MODE_CLASS Receptor Ligand Antagonist 114419-77-1 PD-123497 PRODUCT_CLASS Cardiovasculars 114419-77-1 PD-123497 MODE_CLASS Receptor Agonist 114419-77-1 PD-123497 THERAPEUTIC_CLASS Antiarrhythmic Agents 114419-77-1 PD-123497 INDICATION Cardiac Arrhythmias 114419-77-1 PD-123497 MODE_CLASS Channel Blocker 114419-77-1 PD-123497 MECHANISM Modulate neural transmission 114419-77-1 PD-123497 MECHANISM Block neural transmission 153832-46-3 ERTAPENEM THERAPEUTIC_CLASS Antibacterials 153832-46-3 ERTAPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 153832-46-3 ERTAPENEM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 153832-46-3 ERTAPENEM MODE_CLASS Enzyme Inhibitor 153832-46-3 ERTAPENEM PRODUCT_CLASS Anti-infectives 190791-29-8 LASOFOXIFENE INDICATION Osteoporosis 190791-29-8 LASOFOXIFENE THERAPEUTIC_CLASS Bone Mineral Homeostasis 190791-29-8 LASOFOXIFENE MECHANISM Modulate gene transcription 190791-29-8 LASOFOXIFENE INDICATION Prevention of Osteoporosis 190791-29-8 LASOFOXIFENE PRODUCT_CLASS Anti-cancers 190791-29-8 LASOFOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 190791-29-8 LASOFOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 190791-29-8 LASOFOXIFENE INDICATION Breast Cancer / Carcinoma of the Breast 190791-29-8 LASOFOXIFENE MODE_CLASS Receptor Modulator 190791-29-8 LASOFOXIFENE THERAPEUTIC_CLASS Antineoplastics 180915-85-9 LASOFOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 180915-85-9 LASOFOXIFENE THERAPEUTIC_CLASS Bone Mineral Homeostasis 180915-85-9 LASOFOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 180915-85-9 LASOFOXIFENE INDICATION Prevention of Osteoporosis 180915-85-9 LASOFOXIFENE PRODUCT_CLASS Anti-cancers 180915-85-9 LASOFOXIFENE INDICATION Osteoporosis 180915-85-9 LASOFOXIFENE MECHANISM Modulate gene transcription 180915-85-9 LASOFOXIFENE THERAPEUTIC_CLASS Antineoplastics 180915-85-9 LASOFOXIFENE MODE_CLASS Receptor Modulator 180915-85-9 LASOFOXIFENE INDICATION Breast Cancer / Carcinoma of the Breast 180916-16-9 LASOFOXIFENE INDICATION Osteoporosis 180916-16-9 LASOFOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 180916-16-9 LASOFOXIFENE PRODUCT_CLASS Anti-cancers 180916-16-9 LASOFOXIFENE THERAPEUTIC_CLASS Bone Mineral Homeostasis 180916-16-9 LASOFOXIFENE INDICATION Prevention of Osteoporosis 180916-16-9 LASOFOXIFENE MECHANISM Modulate gene transcription 180916-16-9 LASOFOXIFENE INDICATION Breast Cancer / Carcinoma of the Breast 180916-16-9 LASOFOXIFENE MODE_CLASS Receptor Modulator 180916-16-9 LASOFOXIFENE THERAPEUTIC_CLASS Antineoplastics 180916-16-9 LASOFOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 173026-17-0 BXT-51072 INDICATION Re-Stenosis 173026-17-0 BXT-51072 INDICATION Inflammatory Bowel Disease (IBD) 175215-34-6 TAK-661 INDICATION Eczema Herpeticum 55837-20-2 HALOFUGINONE HYDROBROMIDE INDICATION Liver Fibrosis 55837-20-2 HALOFUGINONE HYDROBROMIDE INDICATION Cystic Fibrosis (CF) 64924-67-0 HALOFUGINONE HYDROBROMIDE INDICATION Cystic Fibrosis (CF) 64924-67-0 HALOFUGINONE HYDROBROMIDE INDICATION Liver Fibrosis 179258-62-9 SB-237376 MECHANISM Modulate channel gating 179258-62-9 SB-237376 PRODUCT_CLASS Cardiovasculars 179258-62-9 SB-237376 THERAPEUTIC_CLASS Antiarrhythmic Agents 179258-62-9 SB-237376 INDICATION Cardiac Arrhythmias 179258-62-9 SB-237376 MODE_CLASS Channel Modulator 179258-59-4 SB-237376 INDICATION Cardiac Arrhythmias 179258-59-4 SB-237376 MODE_CLASS Channel Modulator 179258-59-4 SB-237376 MECHANISM Modulate channel gating 179258-59-4 SB-237376 PRODUCT_CLASS Cardiovasculars 179258-59-4 SB-237376 THERAPEUTIC_CLASS Antiarrhythmic Agents 147366-41-4 MKT-077 INDICATION Neoplasm / Cancer / Tumor 147366-41-4 MKT-077 ADVERSE_EFFECT GIS_2_Diarrhea 147366-41-4 MKT-077 ADVERSE_EFFECT NEU_2_Headache 147366-41-4 MKT-077 ADVERSE_EFFECT MSK_3_Muscle Rigidity 147366-41-4 MKT-077 MODE_CLASS Distorts /blocks macromolecular scaffold function 147366-41-4 MKT-077 THERAPEUTIC_CLASS Antiparasitics 147366-41-4 MKT-077 ADVERSE_EFFECT XXX_3_Fatigue 147366-41-4 MKT-077 ADVERSE_EFFECT XXX_1_Peripheral Edema 147366-41-4 MKT-077 MECHANISM Inhibit mitosis 147366-41-4 MKT-077 ADVERSE_EFFECT XXX_1_Lethargy 147366-41-4 MKT-077 STRUCTURE_ACTIVITY F-actin cross-linker 147366-41-4 MKT-077 INDICATION Malaria 147366-41-4 MKT-077 THERAPEUTIC_CLASS Antineoplastics 147366-41-4 MKT-077 ADVERSE_EFFECT GIS_2_Nausea / Vomiting 147366-41-4 MKT-077 ADVERSE_EFFECT KID_2_Renal Toxicity 147366-41-4 MKT-077 TISSUE_TOXICITY Renal Toxicity 147366-41-4 MKT-077 PRODUCT_CLASS Anti-cancers 147366-41-4 MKT-077 KNOWN_TOXICITY Nephrotoxicity 147366-41-4 MKT-077 ADVERSE_EFFECT MSK_2_Myalgia 147366-41-4 MKT-077 ADVERSE_EFFECT BBM_2_Anemia 147366-41-4 MKT-077 ADVERSE_EFFECT XXX_3_Fever 147366-41-4 MKT-077 PRODUCT_CLASS Anti-infectives 191337-83-4 PNU-196443 FORMER CODE NAME INDICATION Cystic Fibrosis (CF) 179545-78-9 TANOMASTAT THERAPEUTIC_CLASS Immunosuppressants 179545-78-9 TANOMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 179545-78-9 TANOMASTAT INDICATION Arthritis 179545-78-9 TANOMASTAT PRODUCT_CLASS Immune Response / Immunomodulators 215258-80-3 TANOMASTAT INDICATION Arthritis 215258-80-3 TANOMASTAT THERAPEUTIC_CLASS Immunosuppressants 215258-80-3 TANOMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 215258-80-3 TANOMASTAT PRODUCT_CLASS Immune Response / Immunomodulators 179545-77-8 TANOMASTAT INDICATION Arthritis 179545-77-8 TANOMASTAT THERAPEUTIC_CLASS Immunosuppressants 179545-77-8 TANOMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 179545-77-8 TANOMASTAT PRODUCT_CLASS Immune Response / Immunomodulators 179545-76-7 TANOMASTAT INDICATION Arthritis 179545-76-7 TANOMASTAT PRODUCT_CLASS Immune Response / Immunomodulators 179545-76-7 TANOMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 179545-76-7 TANOMASTAT THERAPEUTIC_CLASS Immunosuppressants 180200-68-4 JTE-522 MODE_CLASS Enzyme Inhibitor 180200-68-4 JTE-522 PRODUCT_CLASS Anti-inflammatories 180200-68-4 JTE-522 MECHANISM Inhibit eicosanoid biosynthesis 179634-05-0 RO-48-8684 THERAPEUTIC_CLASS Sedatives/Hypnotics 179634-05-0 RO-48-8684 PRODUCT_CLASS Central Nervous System (CNS) 179634-05-0 RO-48-8684 INDICATION Anxiety Disorders 177611-54-0 CKD-602 STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 174484-41-4 U-140690 INDICATION Myocardial Ischemia 152814-19-2 CNS-1261 MECHANISM Modulate neural transmission 152814-19-2 CNS-1261 MODE_CLASS Channel Modulator 199871-60-8 D-4418 MODE_CLASS Enzyme Inhibitor 199871-60-8 D-4418 MECHANISM Enhance kinase mediated signal transduction 91421-42-0 RUBITECAN INDICATION Myocardial Ischemia 185739-21-3 GYKI-16084 INDICATION Prostatitis 185739-21-3 GYKI-16084 MECHANISM Modulate G-protein coupled signal transduction 181695-72-7 VALDECOXIB KNOWN_TOXICITY Hepatotoxicity 181695-72-7 VALDECOXIB THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 181695-72-7 VALDECOXIB ADVERSE_EFFECT BBM_3_Agranulocytosis 181695-72-7 VALDECOXIB INDICATION Osteoarthritis 181695-72-7 VALDECOXIB MESH_LEVEL_3 Sulfonamides 181695-72-7 VALDECOXIB PRODUCT_CLASS Anti-inflammatories 181695-72-7 VALDECOXIB MECH_LEVEL_1 Immunomodulation 181695-72-7 VALDECOXIB ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 181695-72-7 VALDECOXIB ADVERSE_EFFECT LIV_3_Hepatic Failure 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_2_Diarrhea 181695-72-7 VALDECOXIB ADVERSE_EFFECT KID_1_Fluid Retention 181695-72-7 VALDECOXIB ADVERSE_EFFECT OTO_2_Tinnitus 181695-72-7 VALDECOXIB MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 181695-72-7 VALDECOXIB TA_LEVEL_2 NSAID 181695-72-7 VALDECOXIB ADVERSE_EFFECT CVS_3_Cardiac Failure 181695-72-7 VALDECOXIB ADVERSE_EFFECT OCU_2_Blurred Vision 181695-72-7 VALDECOXIB ADVERSE_EFFECT BBM_3_Pancytopenia 181695-72-7 VALDECOXIB TISSUE_TOXICITY Renal Failure 181695-72-7 VALDECOXIB TISSUE_TOXICITY Renal Papillary Necrosis 181695-72-7 VALDECOXIB MODE_CLASS Enzyme Inhibitor 181695-72-7 VALDECOXIB ADVERSE_EFFECT NEU_2_Dizziness 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_2_Constipation 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 181695-72-7 VALDECOXIB ADVERSE_EFFECT BBM_2_Anemia 181695-72-7 VALDECOXIB TA_LEVEL_1 Anti-inflammatory 181695-72-7 VALDECOXIB ADVERSE_EFFECT IMU_3_Hypersensitivity 181695-72-7 VALDECOXIB TA_LEVEL_3 NSAID 181695-72-7 VALDECOXIB INDICATION Dysmenorrhea 181695-72-7 VALDECOXIB INDICATION Rheumatoid Arthritis 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_3_Peptic Ulceration 181695-72-7 VALDECOXIB ADVERSE_EFFECT IMU_3_Photosensitivity 181695-72-7 VALDECOXIB MESH_LEVEL_2 Amides 181695-72-7 VALDECOXIB TISSUE_TOXICITY Acute Interstitial Nephritis 181695-72-7 VALDECOXIB TISSUE_TOXICITY Hepatic Failure 181695-72-7 VALDECOXIB KNOWN_TOXICITY Nephrotoxicity 181695-72-7 VALDECOXIB MECHANISM Inhibit eicosanoid biosynthesis 181695-72-7 VALDECOXIB MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 181695-72-7 VALDECOXIB ADVERSE_EFFECT LUN_3_Bronchospasm 181695-72-7 VALDECOXIB ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_1_Heartburn 181695-72-7 VALDECOXIB ADVERSE_EFFECT EMB_3_Premature Closure of Ductus Arteriosus 181695-72-7 VALDECOXIB ADVERSE_EFFECT REP_2_Delayed Parturition 181695-72-7 VALDECOXIB ADVERSE_EFFECT BBM_3_Thrombocytopenia 181695-72-7 VALDECOXIB ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 181695-72-7 VALDECOXIB ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 181695-72-7 VALDECOXIB MESH_LEVEL_1 Organic Chemicals 181695-72-7 VALDECOXIB STRUCTURE_ACTIVITY NSAID, COX-2/1, coxib like 181695-72-7 VALDECOXIB TISSUE_TOXICITY Fulminant Hepatitis 181695-72-7 VALDECOXIB KNOWN_TOXICITY Cardiovascular Toxicity 181695-72-7 VALDECOXIB TISSUE_TOXICITY Cardiac Failure 181695-72-7 VALDECOXIB ACTIVITY_CLASS Anti-inflammatory 181695-72-7 VALDECOXIB ADVERSE_EFFECT KID_3_Renal Failure 181695-72-7 VALDECOXIB ADVERSE_EFFECT NEU_3_Somnolence 181695-72-7 VALDECOXIB ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 181695-72-7 VALDECOXIB ADVERSE_EFFECT SKN_2_Pruritis 181695-72-7 VALDECOXIB ADVERSE_EFFECT LIV_2_Abnormal Liver Function 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_1_Abdominal Pain 181695-72-7 VALDECOXIB ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 181695-72-7 VALDECOXIB ADVERSE_EFFECT SKN_2_Skin Rash 183547-57-1 GANTOFIBAN MECHANISM Inhibit platelet aggregation 183547-57-1 GANTOFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 182821-27-8 SLV-306 MECHANISM Modulate G-protein coupled signal transduction 182821-27-8 SLV-306 MODE_CLASS Enzyme Inhibitor 182821-27-8 SLV-306 PRODUCT_CLASS Cardiovasculars 182821-27-8 SLV-306 INDICATION Hypertension 182821-27-8 SLV-306 THERAPEUTIC_CLASS Antihypertensive Agents 182560-84-5 SLV-306 MECHANISM Modulate G-protein coupled signal transduction 182560-84-5 SLV-306 MODE_CLASS Enzyme Inhibitor 182560-84-5 SLV-306 PRODUCT_CLASS Cardiovasculars 182560-84-5 SLV-306 INDICATION Hypertension 182560-84-5 SLV-306 THERAPEUTIC_CLASS Antihypertensive Agents 244106-86-3 TAK-637 INDICATION Urinary Incontinence / Enuresis 217186-03-3 TAK-637 INDICATION Urinary Incontinence / Enuresis 249935-51-1 TAK-637 INDICATION Urinary Incontinence / Enuresis 217186-02-2 TAK-637 INDICATION Urinary Incontinence / Enuresis 183549-91-9 TAK-637 INDICATION Urinary Incontinence / Enuresis 183549-95-3 TAK-637 INDICATION Urinary Incontinence / Enuresis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Toxic Epidermal Necrolysis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT MSK_2_Myasthenia 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Hepatitis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT NEU_2_Dizziness 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT PSY_2_Insomnia 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 147098-20-2 ROSUVASTATIN TISSUE_TOXICITY Renal Tubular Obstruction 147098-20-2 ROSUVASTATIN INDICATION Hypertriglyceridemia 147098-20-2 ROSUVASTATIN KNOWN_TOXICITY Hepatotoxicity 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT XXX_1_Pharyngitis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT MSK_2_Rhabdomyolysis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Stevens-Johnson Syndrome 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Rash 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT XXX_2_Fever 147098-20-2 ROSUVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 147098-20-2 ROSUVASTATIN PRODUCT_CLASS Cardiovasculars 147098-20-2 ROSUVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT BBM_2_Purpura 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Hepatic Failure 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT OCU_3_Cataracts 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT XXX_1_Pain 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT REP_3_Impotence 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Constipation 147098-20-2 ROSUVASTATIN TISSUE_TOXICITY Hepatic Failure 147098-20-2 ROSUVASTATIN KNOWN_TOXICITY Nephrotoxicity 147098-20-2 ROSUVASTATIN INDICATION Hypolipidemia 147098-20-2 ROSUVASTATIN MODE_CLASS Enzyme Inhibitor 147098-20-2 ROSUVASTATIN INDICATION Hypercholesterolemia 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT KID_3_Renal Tubular Obstruction 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Pruritis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Jaundice 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT MSK_1_Myalgia 147098-20-2 ROSUVASTATIN INDICATION Mixed Dyslipidemia 147098-20-2 ROSUVASTATIN MECHANISM Inhibit cholesterol biosynthesis 147098-20-2 ROSUVASTATIN TISSUE_TOXICITY Hepatic Necrosis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT PSY_2_Anorexia 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT NEU_1_Headache 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT IMU_2_Urticaria 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT GIS__Pancreatitis 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT XXX_1_Flu Syndrome 147098-20-2 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Cholestasis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT MSK_2_Myasthenia 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS__Pancreatitis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT XXX_1_Flu Syndrome 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT BBM_2_Purpura 147098-18-8 ROSUVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 147098-18-8 ROSUVASTATIN KNOWN_TOXICITY Hepatotoxicity 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT MSK_2_Rhabdomyolysis 147098-18-8 ROSUVASTATIN INDICATION Hypertriglyceridemia 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT XXX_2_Fever 147098-18-8 ROSUVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 147098-18-8 ROSUVASTATIN PRODUCT_CLASS Cardiovasculars 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT XXX_1_Pharyngitis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Cholestasis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Stevens-Johnson Syndrome 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Rash 147098-18-8 ROSUVASTATIN TISSUE_TOXICITY Renal Tubular Obstruction 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT PSY_2_Insomnia 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT NEU_2_Dizziness 147098-18-8 ROSUVASTATIN INDICATION Mixed Dyslipidemia 147098-18-8 ROSUVASTATIN MECHANISM Inhibit cholesterol biosynthesis 147098-18-8 ROSUVASTATIN TISSUE_TOXICITY Hepatic Necrosis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT PSY_2_Anorexia 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT NEU_1_Headache 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Pruritis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT IMU_2_Urticaria 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT MSK_1_Myalgia 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Jaundice 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Hepatitis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT KID_3_Renal Tubular Obstruction 147098-18-8 ROSUVASTATIN INDICATION Hypercholesterolemia 147098-18-8 ROSUVASTATIN MODE_CLASS Enzyme Inhibitor 147098-18-8 ROSUVASTATIN INDICATION Hypolipidemia 147098-18-8 ROSUVASTATIN KNOWN_TOXICITY Nephrotoxicity 147098-18-8 ROSUVASTATIN TISSUE_TOXICITY Hepatic Failure 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Constipation 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT REP_3_Impotence 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT XXX_1_Pain 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT SKN_2_Toxic Epidermal Necrolysis 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT OCU_3_Cataracts 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT LIV_3_Hepatic Failure 147098-18-8 ROSUVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 173240-15-8 INN-00835 INDICATION Depression 173240-15-8 INN-00835 PRODUCT_CLASS Central Nervous System (CNS) 173240-15-8 INN-00835 THERAPEUTIC_CLASS Antidepressants 185808-55-3 KRP-297 THERAPEUTIC_CLASS Antidiabetic Agents 185808-55-3 KRP-297 TISSUE_TOXICITY Carcinogenicity 185808-55-3 KRP-297 MODE_CLASS Receptor Agonist 185808-55-3 KRP-297 PRODUCT_CLASS Hormones, Endocrine and Metabolic 185808-55-3 KRP-297 MODE_CLASS Receptor Agonist 185808-55-3 KRP-297 MODE_CLASS Receptor Agonist 185808-55-3 KRP-297 ADVERSE_EFFECT XXX_3_Weight Gain 185808-55-3 KRP-297 MECHANISM Modulate gene transcription 185808-55-3 KRP-297 ADVERSE_EFFECT KID_3_Fluid Retention 185808-55-3 KRP-297 KNOWN_TOXICITY Carcinogenicity 185808-55-3 KRP-297 MECHANISM Increase lipid catabolism 185808-55-3 KRP-297 INDICATION Diabetes 185808-55-3 KRP-297 MODE_CLASS Receptor Agonist 185808-55-3 KRP-297 MECHANISM Modulate gene transcription 185808-55-3 KRP-297 ADVERSE_EFFECT DNA_2_Carcinogenicity 185808-55-3 KRP-297 MECHANISM Increase lipid catabolism 185808-55-3 KRP-297 STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 213252-19-8 KRP-297 ADVERSE_EFFECT DNA_2_Carcinogenicity 213252-19-8 KRP-297 MODE_CLASS Receptor Agonist 213252-19-8 KRP-297 STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 213252-19-8 KRP-297 PRODUCT_CLASS Hormones, Endocrine and Metabolic 213252-19-8 KRP-297 MODE_CLASS Receptor Agonist 213252-19-8 KRP-297 MECHANISM Increase lipid catabolism 213252-19-8 KRP-297 TISSUE_TOXICITY Carcinogenicity 213252-19-8 KRP-297 THERAPEUTIC_CLASS Antidiabetic Agents 213252-19-8 KRP-297 ADVERSE_EFFECT XXX_3_Weight Gain 213252-19-8 KRP-297 MECHANISM Modulate gene transcription 213252-19-8 KRP-297 MODE_CLASS Receptor Agonist 213252-19-8 KRP-297 ADVERSE_EFFECT KID_3_Fluid Retention 213252-19-8 KRP-297 KNOWN_TOXICITY Carcinogenicity 213252-19-8 KRP-297 INDICATION Diabetes 213252-19-8 KRP-297 MODE_CLASS Receptor Agonist 213252-19-8 KRP-297 MECHANISM Modulate gene transcription 213252-19-8 KRP-297 MECHANISM Increase lipid catabolism 123-77-3 AZODICARBONAMIDE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 123-77-3 AZODICARBONAMIDE INDICATION Myocardial Ischemia 202138-50-9 TENOFOVIR DISOPROXIL THERAPEUTIC_CLASS Antivirals, Systemic 202138-50-9 TENOFOVIR DISOPROXIL MECHANISM Inhibit viral DNA synthesis 202138-50-9 TENOFOVIR DISOPROXIL STRUCTURE_ACTIVITY Viral RT inhibitor 202138-50-9 TENOFOVIR DISOPROXIL PRODUCT_CLASS Anti-infectives 202138-50-9 TENOFOVIR DISOPROXIL INDICATION Human Immunodeficiency Virus (HIV) Disease 202138-50-9 TENOFOVIR DISOPROXIL MODE_CLASS Enzyme substrate mimic 201341-05-1 TENOFOVIR DISOPROXIL MODE_CLASS Enzyme substrate mimic 201341-05-1 TENOFOVIR DISOPROXIL THERAPEUTIC_CLASS Antivirals, Systemic 201341-05-1 TENOFOVIR DISOPROXIL INDICATION Human Immunodeficiency Virus (HIV) Disease 201341-05-1 TENOFOVIR DISOPROXIL MECHANISM Inhibit viral DNA synthesis 201341-05-1 TENOFOVIR DISOPROXIL STRUCTURE_ACTIVITY Viral RT inhibitor 201341-05-1 TENOFOVIR DISOPROXIL PRODUCT_CLASS Anti-infectives 187269-40-5 TBC-1269 INDICATION Psoriasis 170151-24-3 NEPICASTAT HYDROCHLORIDE INDICATION Hypertension 170151-24-3 NEPICASTAT HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 170151-24-3 NEPICASTAT HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 170151-24-3 NEPICASTAT HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 170151-24-3 NEPICASTAT HYDROCHLORIDE MECHANISM Interferes with neural transmitter synthesis 173997-05-2 NEPICASTAT HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 173997-05-2 NEPICASTAT HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 173997-05-2 NEPICASTAT HYDROCHLORIDE MECHANISM Interferes with neural transmitter synthesis 173997-05-2 NEPICASTAT HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 173997-05-2 NEPICASTAT HYDROCHLORIDE INDICATION Hypertension 170151-25-4 NEPICASTAT HYDROCHLORIDE INDICATION Hypertension 170151-25-4 NEPICASTAT HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 170151-25-4 NEPICASTAT HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 170151-25-4 NEPICASTAT HYDROCHLORIDE MECHANISM Interferes with neural transmitter synthesis 170151-25-4 NEPICASTAT HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 178429-67-9 NS-7 PRODUCT_CLASS Central Nervous System (CNS) 178429-67-9 NS-7 THERAPEUTIC_CLASS Vasodilators 178429-67-9 NS-7 INDICATION Cerebral Ischemia 178429-67-9 NS-7 MECHANISM Modulate channel gating 178429-67-9 NS-7 MODE_CLASS Channel Blocker 178429-67-9 NS-7 MECHANISM Block neural transmission 162326-86-5 CP-114271 PRODUCT_CLASS Autonomic Nervous System (ANS) 162326-86-5 CP-114271 THERAPEUTIC_CLASS Sympathomimetic Agents 162326-86-5 CP-114271 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 162326-86-5 CP-114271 MECHANISM Reduce muscle contractile force 162326-86-5 CP-114271 INDICATION Obesity 162326-86-5 CP-114271 MODE_CLASS Receptor Agonist, selective 113734-18-2 CP-114271 PRODUCT_CLASS Autonomic Nervous System (ANS) 113734-18-2 CP-114271 THERAPEUTIC_CLASS Sympathomimetic Agents 113734-18-2 CP-114271 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 113734-18-2 CP-114271 INDICATION Obesity 113734-18-2 CP-114271 MECHANISM Reduce muscle contractile force 113734-18-2 CP-114271 MODE_CLASS Receptor Agonist, selective 180272-14-4 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180272-14-4 YM-905 INDICATION Urinary Incontinence / Enuresis 180272-14-4 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 180272-16-6 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180272-16-6 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 180272-16-6 YM-905 INDICATION Urinary Incontinence / Enuresis 180468-37-5 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 180468-37-5 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180468-37-5 YM-905 INDICATION Urinary Incontinence / Enuresis 180468-39-7 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180468-39-7 YM-905 INDICATION Urinary Incontinence / Enuresis 180468-39-7 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 141256-04-4 QS-21 INDICATION Hepatitis 141256-04-4 QS-21 INDICATION Myocardial Ischemia 53-43-0 PRASTERONE INDICATION Systemic Lupus Erythromatosus (SLE) 158440-71-2 IROFULVEN STRUCTURE_ACTIVITY DNA-alkylator 151227-08-6 AP-521 THERAPEUTIC_CLASS Sedatives/Hypnotics 151227-08-6 AP-521 PRODUCT_CLASS Central Nervous System (CNS) 151227-08-6 AP-521 MECHANISM Modulate neural transmission 151227-08-6 AP-521 INDICATION Anxiety Disorders 151227-62-2 AP-521 MECHANISM Modulate neural transmission 151227-62-2 AP-521 PRODUCT_CLASS Central Nervous System (CNS) 151227-62-2 AP-521 THERAPEUTIC_CLASS Sedatives/Hypnotics 151227-62-2 AP-521 INDICATION Anxiety Disorders 151227-58-6 AP-521 MECHANISM Modulate neural transmission 151227-58-6 AP-521 INDICATION Anxiety Disorders 151227-58-6 AP-521 THERAPEUTIC_CLASS Sedatives/Hypnotics 151227-58-6 AP-521 PRODUCT_CLASS Central Nervous System (CNS) 151227-63-2 AP-521 THERAPEUTIC_CLASS Sedatives/Hypnotics 151227-63-2 AP-521 PRODUCT_CLASS Central Nervous System (CNS) 151227-63-2 AP-521 MECHANISM Modulate neural transmission 151227-63-2 AP-521 INDICATION Anxiety Disorders 162763-53-3 A-86719.1 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 162829-89-2 A-86719.1 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 162829-90-5 A-86719.1 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 158146-85-1 TAK-603 INDICATION Arthritis 158146-85-1 TAK-603 THERAPEUTIC_CLASS Immunosuppressants 158146-85-1 TAK-603 PRODUCT_CLASS Immune Response / Immunomodulators 158146-85-1 TAK-603 INDICATION Osteoporosis 157434-99-6 XK-469 PRODUCT_CLASS Anti-cancers 157434-99-6 XK-469 THERAPEUTIC_CLASS Antineoplastics 157542-90-0 XK-469 THERAPEUTIC_CLASS Antineoplastics 157542-90-0 XK-469 PRODUCT_CLASS Anti-cancers 157435-10-4 XK-469 THERAPEUTIC_CLASS Antineoplastics 157435-10-4 XK-469 PRODUCT_CLASS Anti-cancers 157542-91-1 XK-469 PRODUCT_CLASS Anti-cancers 157542-91-1 XK-469 THERAPEUTIC_CLASS Antineoplastics 157542-92-2 XK-469 PRODUCT_CLASS Anti-cancers 157542-92-2 XK-469 THERAPEUTIC_CLASS Antineoplastics 162542-90-7 CDP-840 MECHANISM Enhance kinase mediated signal transduction 162542-90-7 CDP-840 MODE_CLASS Enzyme Inhibitor 162542-51-0 CDP-840 MECHANISM Enhance kinase mediated signal transduction 162542-51-0 CDP-840 MODE_CLASS Enzyme Inhibitor 162542-91-8 CDP-840 MODE_CLASS Enzyme Inhibitor 162542-91-8 CDP-840 MECHANISM Enhance kinase mediated signal transduction 162542-52-1 CDP-840 MODE_CLASS Enzyme Inhibitor 162542-52-1 CDP-840 MECHANISM Enhance kinase mediated signal transduction 153559-49-0 BEXAROTENE PRODUCT_CLASS Anti-cancers 153559-49-0 BEXAROTENE MECHANISM Modulate gene transcription 153559-49-0 BEXAROTENE THERAPEUTIC_CLASS Antineoplastics 153559-49-0 BEXAROTENE MODE_CLASS Receptor Agonist, Non-selective 153559-49-0 BEXAROTENE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 153559-49-0 BEXAROTENE STRUCTURE_ACTIVITY Retinoic acid receptor (RXR) agonist 139145-84-9 NM-702 MODE_CLASS Enzyme Inhibitor 139145-84-9 NM-702 MECHANISM Enhance kinase mediated signal transduction 139145-27-0 NM-702 MECHANISM Enhance kinase mediated signal transduction 139145-27-0 NM-702 MODE_CLASS Enzyme Inhibitor 139145-87-2 NM-702 MECHANISM Enhance kinase mediated signal transduction 139145-87-2 NM-702 MODE_CLASS Enzyme Inhibitor 139145-89-4 NM-702 MECHANISM Enhance kinase mediated signal transduction 139145-89-4 NM-702 MODE_CLASS Enzyme Inhibitor 144628-52-4 FONSARTAN POTASSIUM MECHANISM Reduce vasoconstriction 144628-52-4 FONSARTAN POTASSIUM THERAPEUTIC_CLASS Antihypertensive Agents 144628-52-4 FONSARTAN POTASSIUM PRODUCT_CLASS Cardiovasculars 144628-52-4 FONSARTAN POTASSIUM STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 144628-52-4 FONSARTAN POTASSIUM INDICATION Hypertension 144628-52-4 FONSARTAN POTASSIUM MODE_CLASS Receptor Ligand Antagonist, Selective 150756-35-7 EFLETIRIZINE INDICATION Viral Rhinitis / Common Cold 155773-59-4 ANSECULIN HYDROCHLORIDE MECHANISM Enhance cholinergic transmission 155773-59-4 ANSECULIN HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 146740-05-8 TALVIRALINE INDICATION Myocardial Ischemia 163451-80-7 TALVIRALINE INDICATION Myocardial Ischemia 169312-27-0 TALVIRALINE INDICATION Myocardial Ischemia 159138-81-5 CARIPORIDE MODE_CLASS Enzyme Inhibitor 159138-81-5 CARIPORIDE INDICATION Cerebral Ischemia 159138-80-4 CARIPORIDE MODE_CLASS Enzyme Inhibitor 159138-80-4 CARIPORIDE INDICATION Cerebral Ischemia 156436-90-7 LUTETIUM TEXAPHYRIN INDICATION Re-Stenosis 159126-29-1 FARANOXI STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 153655-35-7 BM-17.0249.2NA INDICATION Hypolipidemia 153655-35-7 BM-17.0249.2NA INDICATION Diabetes 153655-35-7 BM-17.0249.2NA INDICATION Obesity 156177-65-0 CEP-1347 INDICATION Neurological Disorders 156177-65-0 CEP-1347 MECHANISM Inhibit kinase mediated signal transduction 156177-65-0 CEP-1347 MODE_CLASS Enzyme Inhibitor 156177-65-0 CEP-1347 ADVERSE_EFFECT NEU_1_Dizziness 156177-65-0 CEP-1347 INDICATION Peripheral Neuropathies 156177-65-0 CEP-1347 INDICATION Parkinson's Disease 156177-65-0 CEP-1347 INDICATION Alzheimer's Disease 156177-65-0 CEP-1347 ADVERSE_EFFECT GIS_1_Diarrhea 156177-65-0 CEP-1347 INDICATION Parkinson's Disease 156177-65-0 CEP-1347 THERAPEUTIC_CLASS Neurodegenerative Disorders 156177-65-0 CEP-1347 ADVERSE_EFFECT NEU_1_Headache 156177-65-0 CEP-1347 STRUCTURE_ACTIVITY Protein-serine/threonine kinase inhibitor 156177-65-0 CEP-1347 PRODUCT_CLASS Central Nervous System (CNS) 149447-74-5 GADOLINIUM TEXAPHYRIN INDICATION Contrasting Agent 149447-74-5 GADOLINIUM TEXAPHYRIN PRODUCT_CLASS Anti-cancers 149447-74-5 GADOLINIUM TEXAPHYRIN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 151767-59-8 GADOLINIUM TEXAPHYRIN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 151767-59-8 GADOLINIUM TEXAPHYRIN INDICATION Contrasting Agent 151767-59-8 GADOLINIUM TEXAPHYRIN PRODUCT_CLASS Anti-cancers 120241-32-9 ALVAMELINE INDICATION Urinary Incontinence / Enuresis 120241-32-9 ALVAMELINE MODE_CLASS Receptor Ligand Antagonist 159792-14-0 ALVAMELINE MODE_CLASS Receptor Ligand Antagonist 159792-14-0 ALVAMELINE INDICATION Urinary Incontinence / Enuresis 120241-31-8 ALVAMELINE MODE_CLASS Receptor Ligand Antagonist 120241-31-8 ALVAMELINE INDICATION Urinary Incontinence / Enuresis 97-00-7 DNCB INDICATION Myocardial Ischemia 160588-45-4 10,10-BIS-[(2-FLUORO-4-PYRIDINYL)METHYL]-9(10H)-ANTHRACENONE PRODUCT_CLASS Central Nervous System (CNS) 160588-45-4 10,10-BIS-[(2-FLUORO-4-PYRIDINYL)METHYL]-9(10H)-ANTHRACENONE MECHANISM Block channel gating 160588-45-4 10,10-BIS-[(2-FLUORO-4-PYRIDINYL)METHYL]-9(10H)-ANTHRACENONE MODE_CLASS Channel Blocker 158446-41-4 PROXODOLOL MECHANISM Modulate G-protein coupled signal transduction 158446-41-4 PROXODOLOL INDICATION Angina Pectoris 158446-41-4 PROXODOLOL INDICATION Hypertension 158446-41-4 PROXODOLOL THERAPEUTIC_CLASS Antihypertensive Agents 158446-41-4 PROXODOLOL MODE_CLASS Receptor Ligand Antagonist 158446-41-4 PROXODOLOL THERAPEUTIC_CLASS Antianginals 158446-41-4 PROXODOLOL INDICATION Glaucoma 158446-41-4 PROXODOLOL PRODUCT_CLASS Cardiovasculars 152289-59-3 PROXODOLOL THERAPEUTIC_CLASS Antihypertensive Agents 152289-59-3 PROXODOLOL THERAPEUTIC_CLASS Antianginals 152289-59-3 PROXODOLOL INDICATION Hypertension 152289-59-3 PROXODOLOL INDICATION Angina Pectoris 152289-59-3 PROXODOLOL MECHANISM Modulate G-protein coupled signal transduction 152289-59-3 PROXODOLOL PRODUCT_CLASS Cardiovasculars 152289-59-3 PROXODOLOL INDICATION Glaucoma 152289-59-3 PROXODOLOL MODE_CLASS Receptor Ligand Antagonist 152289-58-2 PROXODOLOL THERAPEUTIC_CLASS Antihypertensive Agents 152289-58-2 PROXODOLOL INDICATION Glaucoma 152289-58-2 PROXODOLOL PRODUCT_CLASS Cardiovasculars 152289-58-2 PROXODOLOL MECHANISM Modulate G-protein coupled signal transduction 152289-58-2 PROXODOLOL INDICATION Angina Pectoris 152289-58-2 PROXODOLOL INDICATION Hypertension 152289-58-2 PROXODOLOL THERAPEUTIC_CLASS Antianginals 152289-58-2 PROXODOLOL MODE_CLASS Receptor Ligand Antagonist 158681-13-1 RIMONABANT MECHANISM Modulate G-protein coupled signal transduction 158681-13-1 RIMONABANT MODE_CLASS Receptor Ligand Antagonist, Selective 168273-06-1 RIMONABANT MODE_CLASS Receptor Ligand Antagonist, Selective 168273-06-1 RIMONABANT MECHANISM Modulate G-protein coupled signal transduction 138951-61-8 FK-584 INDICATION Urinary Incontinence / Enuresis 138951-54-9 FK-584 INDICATION Urinary Incontinence / Enuresis 138951-62-9 FK-584 INDICATION Urinary Incontinence / Enuresis 166518-60-1 AVASIMIBE THERAPEUTIC_CLASS Hypolipidemic Agents 166518-60-1 AVASIMIBE MODE_CLASS Enzyme Inhibitor 166518-60-1 AVASIMIBE INDICATION Hypolipidemia 166518-60-1 AVASIMIBE PRODUCT_CLASS Cardiovasculars 166518-60-1 AVASIMIBE INDICATION Atherosclerosis 166518-60-1 AVASIMIBE MECHANISM Inhibit steroid biosynthesis/ metabolism 166518-61-2 AVASIMIBE THERAPEUTIC_CLASS Hypolipidemic Agents 166518-61-2 AVASIMIBE INDICATION Hypolipidemia 166518-61-2 AVASIMIBE MODE_CLASS Enzyme Inhibitor 166518-61-2 AVASIMIBE MECHANISM Inhibit steroid biosynthesis/ metabolism 166518-61-2 AVASIMIBE INDICATION Atherosclerosis 166518-61-2 AVASIMIBE PRODUCT_CLASS Cardiovasculars 152658-17-8 TRK-820 MECHANISM Modulate neural transmission 152658-17-8 TRK-820 PRODUCT_CLASS Dermatologicals 152658-17-8 TRK-820 STRUCTURE_ACTIVITY Opioid receptor agonist 152658-17-8 TRK-820 THERAPEUTIC_CLASS Analgesics, Opioid 152658-17-8 TRK-820 PRODUCT_CLASS Analgesics 152658-17-8 TRK-820 THERAPEUTIC_CLASS Antipruritic Agents 152658-17-8 TRK-820 MODE_CLASS Receptor Agonist, selective 152657-84-6 TRK-820 PRODUCT_CLASS Dermatologicals 152657-84-6 TRK-820 MODE_CLASS Receptor Agonist, selective 152657-84-6 TRK-820 MECHANISM Modulate neural transmission 152657-84-6 TRK-820 THERAPEUTIC_CLASS Antipruritic Agents 152657-84-6 TRK-820 PRODUCT_CLASS Analgesics 152657-84-6 TRK-820 STRUCTURE_ACTIVITY Opioid receptor agonist 152657-84-6 TRK-820 THERAPEUTIC_CLASS Analgesics, Opioid 144689-24-7 OLMESARTAN MECHANISM Modulate G-protein coupled signal transduction 144689-24-7 OLMESARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 144689-24-7 OLMESARTAN PRODUCT_CLASS Cardiovasculars 144689-24-7 OLMESARTAN INDICATION Hypertension 144689-24-7 OLMESARTAN THERAPEUTIC_CLASS Antihypertensive Agents 115-53-7 COCULINE THERAPEUTIC_CLASS Antiarrhythmic Agents 115-53-7 COCULINE INDICATION Rheumatism 115-53-7 COCULINE INDICATION Neuralgia 115-53-7 COCULINE INDICATION Cardiac Arrhythmias 115-53-7 COCULINE PRODUCT_CLASS Cardiovasculars 115-53-7 COCULINE PRODUCT_CLASS Immune Response / Immunomodulators 115-53-7 COCULINE THERAPEUTIC_CLASS Immunosuppressants 115-53-7 COCULINE INDICATION Arthritis 167305-00-2 OMAPATRILAT MECHANISM Reduce vasoconstriction 167305-00-2 OMAPATRILAT INDICATION Hypertension 167305-00-2 OMAPATRILAT MODE_CLASS Enzyme Inhibitor 167305-00-2 OMAPATRILAT PRODUCT_CLASS Cardiovasculars 167305-00-2 OMAPATRILAT MECHANISM Modulate G-protein coupled signal transduction 167305-00-2 OMAPATRILAT THERAPEUTIC_CLASS Antihypertensive Agents 158751-64-5 HMR-1883 PRODUCT_CLASS Cardiovasculars 158751-64-5 HMR-1883 MODE_CLASS Channel Modulator 158751-64-5 HMR-1883 THERAPEUTIC_CLASS Vasodilators 158751-64-5 HMR-1883 MECHANISM Trigger insulin release in pancreatic beta cells 158751-64-5 HMR-1883 MECHANISM Modulate channel gating 158751-64-5 HMR-1883 MODE_CLASS Channel Blocker 150284-32-5 S-2150 MECHANISM Modulate channel gating 150284-32-5 S-2150 INDICATION Hypertension 150284-32-5 S-2150 MODE_CLASS Channel Modulator 150284-32-5 S-2150 THERAPEUTIC_CLASS Antianginals 150284-32-5 S-2150 PRODUCT_CLASS Cardiovasculars 150284-32-5 S-2150 THERAPEUTIC_CLASS Antihypertensive Agents 150284-32-5 S-2150 MECHANISM Modulate G-protein coupled signal transduction 150284-32-5 S-2150 INDICATION Angina Pectoris 149882-23-5 S-2150 INDICATION Hypertension 149882-23-5 S-2150 PRODUCT_CLASS Cardiovasculars 149882-23-5 S-2150 THERAPEUTIC_CLASS Antianginals 149882-23-5 S-2150 MODE_CLASS Channel Modulator 149882-23-5 S-2150 MECHANISM Modulate channel gating 149882-23-5 S-2150 INDICATION Angina Pectoris 149882-23-5 S-2150 MECHANISM Modulate G-protein coupled signal transduction 149882-23-5 S-2150 THERAPEUTIC_CLASS Antihypertensive Agents 150284-34-7 S-2150 MODE_CLASS Channel Modulator 150284-34-7 S-2150 INDICATION Hypertension 150284-34-7 S-2150 MECHANISM Modulate channel gating 150284-34-7 S-2150 INDICATION Angina Pectoris 150284-34-7 S-2150 MECHANISM Modulate G-protein coupled signal transduction 150284-34-7 S-2150 THERAPEUTIC_CLASS Antihypertensive Agents 150284-34-7 S-2150 PRODUCT_CLASS Cardiovasculars 150284-34-7 S-2150 THERAPEUTIC_CLASS Antianginals 153062-94-3 MKC-733 MECHANISM Block neural transmission 153062-94-3 MKC-733 MODE_CLASS Channel Blocker 152995-74-9 MKC-733 MECHANISM Block neural transmission 152995-74-9 MKC-733 MODE_CLASS Channel Blocker 153062-96-5 MKC-733 MECHANISM Block neural transmission 153062-96-5 MKC-733 MODE_CLASS Channel Blocker 162652-95-1 VINFLUNINE STRUCTURE_ACTIVITY Tubulin binder, vinca 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT LUN_3_Apnea 27262-47-1 LEVOBUPIVACAINE PRODUCT_CLASS Central Nervous System (CNS) 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT GIS_2_Constipation 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT PSY_2_Anxiety 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT NEU_1_Dizziness 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT GIS_1_Metallic Taste 27262-47-1 LEVOBUPIVACAINE THERAPEUTIC_CLASS Local Anesthetics 27262-47-1 LEVOBUPIVACAINE TISSUE_TOXICITY Cardiac Arrest 27262-47-1 LEVOBUPIVACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 27262-47-1 LEVOBUPIVACAINE INDICATION Epidural Anesthesia 27262-47-1 LEVOBUPIVACAINE MESH_LEVEL_1 Organic Chemicals 27262-47-1 LEVOBUPIVACAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 27262-47-1 LEVOBUPIVACAINE MECH_LEVEL_2 Sodium channel antagonist 27262-47-1 LEVOBUPIVACAINE TA_LEVEL_3 Injectable Local Anesthesia 27262-47-1 LEVOBUPIVACAINE MECHANISM Block neural transmission 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT XXX_1_Fever 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT CVS_1_Hypotension 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT NEU_1_Headache 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT NEU_3_Seizures 27262-47-1 LEVOBUPIVACAINE KNOWN_TOXICITY Cardiovascular Toxicity 27262-47-1 LEVOBUPIVACAINE TISSUE_TOXICITY Hypotension 27262-47-1 LEVOBUPIVACAINE INDICATION Local Anesthesia 27262-47-1 LEVOBUPIVACAINE MESH_LEVEL_3 Anilides 27262-47-1 LEVOBUPIVACAINE MESH_LEVEL_2 Amides 27262-47-1 LEVOBUPIVACAINE TA_LEVEL_2 Anesthesia 27262-47-1 LEVOBUPIVACAINE MECH_LEVEL_3 Voltage-gated Na+ channel 27262-47-1 LEVOBUPIVACAINE TISSUE_TOXICITY Atrial Fibrillation 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT PSY_3_Depression 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT _1_Decreased Uterine Contractility 27262-47-1 LEVOBUPIVACAINE MECH_LEVEL_1 Modulate neural transmission 27262-47-1 LEVOBUPIVACAINE MODE_CLASS Channel Blocker 27262-47-1 LEVOBUPIVACAINE TISSUE_TOXICITY Atrioventricular Blockade 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT OCU_2_Blurred Vision 27262-47-1 LEVOBUPIVACAINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 144779-91-9 R-87366 INDICATION Myocardial Ischemia 146798-66-5 (S)-(-)-OSU-6162 INDICATION Parkinson's Disease 160777-43-5 (S)-(-)-OSU-6162 INDICATION Parkinson's Disease 156223-05-1 DMXB-ANABASEINE MECHANISM Modulate neural transmission 156223-05-1 DMXB-ANABASEINE MODE_CLASS Channel Modulator 163009-62-9 FK-041 MECHANISM Inhibit bacterial cell wall biosynthesis 163009-62-9 FK-041 PRODUCT_CLASS Anti-infectives 163009-62-9 FK-041 MODE_CLASS Enzyme Inhibitor 163009-62-9 FK-041 THERAPEUTIC_CLASS Antibacterials 163009-73-2 FK-041 MECHANISM Inhibit bacterial cell wall biosynthesis 163009-73-2 FK-041 PRODUCT_CLASS Anti-infectives 163009-73-2 FK-041 MODE_CLASS Enzyme Inhibitor 163009-73-2 FK-041 THERAPEUTIC_CLASS Antibacterials 164656-23-9 DUTASTERIDE MODE_CLASS Enzyme Inhibitor 164656-23-9 DUTASTERIDE THERAPEUTIC_CLASS Antineoplastics 164656-23-9 DUTASTERIDE PRODUCT_CLASS Anti-cancers 164656-23-9 DUTASTERIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 152317-89-0 ALNIDITAN INDICATION Migraine Headache 152317-89-0 ALNIDITAN PRODUCT_CLASS Central Nervous System (CNS) 152317-89-0 ALNIDITAN MECHANISM Modulate cerebral vasoconstriction 152317-89-0 ALNIDITAN THERAPEUTIC_CLASS Antimigraines 155428-00-5 ALNIDITAN INDICATION Migraine Headache 155428-00-5 ALNIDITAN PRODUCT_CLASS Central Nervous System (CNS) 155428-00-5 ALNIDITAN MECHANISM Modulate cerebral vasoconstriction 155428-00-5 ALNIDITAN THERAPEUTIC_CLASS Antimigraines 136067-88-4 SSY-726 STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 167354-40-7 ZOSUQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 167354-35-0 ZOSUQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 167354-32-7 ZOSUQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 167465-36-3 ZOSUQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 166591-11-3 ABT-431 MECHANISM Modulate G-protein coupled signal transduction 166591-11-3 ABT-431 INDICATION Parkinson's Disease 171752-56-0 ABT-431 INDICATION Parkinson's Disease 171752-56-0 ABT-431 MECHANISM Modulate G-protein coupled signal transduction 166335-18-8 U-103017 INDICATION Myocardial Ischemia 166335-13-3 U-103017 INDICATION Myocardial Ischemia 166335-16-6 U-103017 INDICATION Myocardial Ischemia 135548-66-2 AWD-140-190 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 135548-66-2 AWD-140-190 MODE_CLASS Channel Blocker 135548-66-2 AWD-140-190 PRODUCT_CLASS Central Nervous System (CNS) 135548-66-2 AWD-140-190 MECHANISM Block neural transmission 165250-52-2 BMS-181885 PRODUCT_CLASS Central Nervous System (CNS) 165250-52-2 BMS-181885 INDICATION Migraine Headache 165250-52-2 BMS-181885 THERAPEUTIC_CLASS Antimigraines 165250-52-2 BMS-181885 MECHANISM Modulate cerebral vasoconstriction 151386-96-8 GV-150013 THERAPEUTIC_CLASS Sedatives/Hypnotics 151386-96-8 GV-150013 MODE_CLASS Receptor Ligand Antagonist, Selective 151386-96-8 GV-150013 INDICATION Anxiety Disorders 151386-96-8 GV-150013 PRODUCT_CLASS Central Nervous System (CNS) 151386-96-8 GV-150013 MECHANISM Reduce stomach HCl secretion 143322-58-1 ELETRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 143322-58-1 ELETRIPTAN MECHANISM Modulate cerebral vasoconstriction 143322-58-1 ELETRIPTAN MECHANISM Modulate neural transmission 143322-58-1 ELETRIPTAN THERAPEUTIC_CLASS Antimigraines 143322-58-1 ELETRIPTAN INDICATION Migraine Headache 143322-58-1 ELETRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 180637-87-0 ELETRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 180637-87-0 ELETRIPTAN MECHANISM Modulate cerebral vasoconstriction 180637-87-0 ELETRIPTAN MECHANISM Modulate neural transmission 180637-87-0 ELETRIPTAN THERAPEUTIC_CLASS Antimigraines 180637-87-0 ELETRIPTAN INDICATION Migraine Headache 180637-87-0 ELETRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 179041-30-6 ELETRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 179041-30-6 ELETRIPTAN INDICATION Migraine Headache 179041-30-6 ELETRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 179041-30-6 ELETRIPTAN MECHANISM Modulate cerebral vasoconstriction 179041-30-6 ELETRIPTAN MECHANISM Modulate neural transmission 179041-30-6 ELETRIPTAN THERAPEUTIC_CLASS Antimigraines 177834-92-3 ELETRIPTAN INDICATION Migraine Headache 177834-92-3 ELETRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 177834-92-3 ELETRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 177834-92-3 ELETRIPTAN MECHANISM Modulate cerebral vasoconstriction 177834-92-3 ELETRIPTAN MECHANISM Modulate neural transmission 177834-92-3 ELETRIPTAN THERAPEUTIC_CLASS Antimigraines 143577-61-1 ELETRIPTAN MECHANISM Modulate cerebral vasoconstriction 143577-61-1 ELETRIPTAN MECHANISM Modulate neural transmission 143577-61-1 ELETRIPTAN THERAPEUTIC_CLASS Antimigraines 143577-61-1 ELETRIPTAN INDICATION Migraine Headache 143577-61-1 ELETRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 143577-61-1 ELETRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 38398-32-2 GANAXOLONE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 38398-32-2 GANAXOLONE PRODUCT_CLASS Central Nervous System (CNS) 38398-32-2 GANAXOLONE MECHANISM Modulate neural transmission 38398-32-2 GANAXOLONE MODE_CLASS Channel enhancer /opener 168079-32-1 WAY-VPA-985 INDICATION Renal Failure / Kidney Failure 165800-03-3 LINEZOLID MECHANISM Inhibit ribosomal protein synthesis 165800-03-3 LINEZOLID MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 162401-32-3 ROFLUMILAST ADVERSE_EFFECT LUN_2_Pulmonary Irritation 162401-32-3 ROFLUMILAST INDICATION Chronic Obstructive Pulmonary Disease (COPD) 162401-32-3 ROFLUMILAST ACTIVITY_CLASS Phosphodiesterase inhibitor 162401-32-3 ROFLUMILAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 162401-32-3 ROFLUMILAST PRODUCT_CLASS Respiratory System 162401-32-3 ROFLUMILAST MODE_CLASS Enzyme Inhibitor 162401-32-3 ROFLUMILAST ADVERSE_EFFECT GIS_1_Vomiting 162401-32-3 ROFLUMILAST MODE_CLASS Enzyme Inhibitor 162401-32-3 ROFLUMILAST INDICATION Allergic Rhinitis 162401-32-3 ROFLUMILAST PRODUCT_CLASS Anti-inflammatories 162401-32-3 ROFLUMILAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 162401-32-3 ROFLUMILAST STRUCTURE_ACTIVITY PDE4 inhibitor 162401-32-3 ROFLUMILAST ADVERSE_EFFECT XXX_1_Nasal Irritation 162401-32-3 ROFLUMILAST MECHANISM Enhance kinase mediated signal transduction 162401-32-3 ROFLUMILAST MECHANISM Enhance kinase mediated signal transduction 162401-32-3 ROFLUMILAST ADVERSE_EFFECT GIS_1_Nausea 162401-32-3 ROFLUMILAST INDICATION Asthma 162424-67-1 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 162424-67-1 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 162424-67-1 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 162424-67-1 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 162424-67-1 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 162301-05-5 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 162301-05-5 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 162301-05-5 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 162301-05-5 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 162301-05-5 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 186827-02-1 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 186827-02-1 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 186827-02-1 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 186827-02-1 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 186827-02-1 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 186827-03-2 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 186827-03-2 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 186827-03-2 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 186827-03-2 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 186827-03-2 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 162301-08-8 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 162301-08-8 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 162301-08-8 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 162301-08-8 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 162301-08-8 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 172344-72-8 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 172344-72-8 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 172344-72-8 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 172344-72-8 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 172344-72-8 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 152323-98-3 ECENOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 152323-98-3 ECENOFLOXACIN PRODUCT_CLASS Anti-infectives 152323-98-3 ECENOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 152323-98-3 ECENOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 152323-98-3 ECENOFLOXACIN THERAPEUTIC_CLASS Antibacterials 144348-08-3 WRC-470 MECHANISM Modulate G-protein coupled signal transduction 147127-20-6 TENOFOVIR INDICATION Hepatitis B 147127-20-6 TENOFOVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 147127-20-6 TENOFOVIR PRODUCT_CLASS Anti-infectives 147127-20-6 TENOFOVIR MECHANISM Inhibit viral DNA synthesis 147127-20-6 TENOFOVIR MODE_CLASS Enzyme substrate mimic 147127-20-6 TENOFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 147127-19-3 TENOFOVIR INDICATION Hepatitis B 147127-19-3 TENOFOVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 147127-19-3 TENOFOVIR PRODUCT_CLASS Anti-infectives 147127-19-3 TENOFOVIR MECHANISM Inhibit viral DNA synthesis 147127-19-3 TENOFOVIR MODE_CLASS Enzyme substrate mimic 147127-19-3 TENOFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 171655-91-7 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 171655-91-7 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 171655-91-7 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 171655-92-8 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 171655-92-8 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 171655-92-8 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-14-3 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-14-3 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-14-3 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-10-9 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-10-9 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-10-9 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-20-1 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-20-1 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-20-1 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-19-8 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-19-8 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-19-8 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-18-7 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-18-7 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-18-7 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-17-6 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-17-6 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-17-6 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 173830-15-4 BRASOFENSINE SULFATE INDICATION Parkinson's Disease 173830-15-4 BRASOFENSINE SULFATE MODE_CLASS Solute transporter inhibitor 173830-15-4 BRASOFENSINE SULFATE MECHANISM Prolong/enhance neural transmission 176022-59-6 ROXIFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 176022-59-6 ROXIFIBAN MECHANISM Inhibit platelet aggregation 170902-47-3 ROXIFIBAN MECHANISM Inhibit platelet aggregation 170902-47-3 ROXIFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 76604-64-3 M-5010 THERAPEUTIC_CLASS Immunosuppressants 76604-64-3 M-5010 INDICATION Arthritis 76604-64-3 M-5010 PRODUCT_CLASS Immune Response / Immunomodulators 158836-71-6 FLURBIPROFEN NITROXYBUTYL ESTER INDICATION Osteoporosis 158836-71-6 FLURBIPROFEN NITROXYBUTYL ESTER STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 158836-71-6 FLURBIPROFEN NITROXYBUTYL ESTER INDICATION Urinary Incontinence / Enuresis 158836-71-6 FLURBIPROFEN NITROXYBUTYL ESTER MECHANISM Inhibit eicosanoid biosynthesis 158836-71-6 FLURBIPROFEN NITROXYBUTYL ESTER MODE_CLASS Enzyme Inhibitor 156579-02-1 MX-68 PRODUCT_CLASS Anti-cancers 156579-02-1 MX-68 THERAPEUTIC_CLASS Antineoplastics 156579-02-1 MX-68 MECHANISM Inhibit precursor synthesis 156579-02-1 MX-68 STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 156579-02-1 MX-68 MODE_CLASS Enzyme substrate mimic 158664-17-6 MX-68 PRODUCT_CLASS Anti-cancers 158664-17-6 MX-68 THERAPEUTIC_CLASS Antineoplastics 158664-17-6 MX-68 MECHANISM Inhibit precursor synthesis 158664-17-6 MX-68 STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 158664-17-6 MX-68 MODE_CLASS Enzyme substrate mimic 170566-84-4 LANEPITANT THERAPEUTIC_CLASS Antimigraines 170566-84-4 LANEPITANT MECHANISM Modulate G-protein coupled signal transduction 170566-84-4 LANEPITANT MODE_CLASS Receptor Ligand Antagonist 170566-84-4 LANEPITANT THERAPEUTIC_CLASS Analgesics, Non-Opioid 170566-84-4 LANEPITANT PRODUCT_CLASS Central Nervous System (CNS) 170508-05-1 LANEPITANT PRODUCT_CLASS Central Nervous System (CNS) 170508-05-1 LANEPITANT MODE_CLASS Receptor Ligand Antagonist 170508-05-1 LANEPITANT MECHANISM Modulate G-protein coupled signal transduction 170508-05-1 LANEPITANT THERAPEUTIC_CLASS Antimigraines 170508-05-1 LANEPITANT THERAPEUTIC_CLASS Analgesics, Non-Opioid 167678-33-3 LANEPITANT THERAPEUTIC_CLASS Analgesics, Non-Opioid 167678-33-3 LANEPITANT PRODUCT_CLASS Central Nervous System (CNS) 167678-33-3 LANEPITANT MECHANISM Modulate G-protein coupled signal transduction 167678-33-3 LANEPITANT THERAPEUTIC_CLASS Antimigraines 167678-33-3 LANEPITANT MODE_CLASS Receptor Ligand Antagonist 166974-23-8 GV-196771A MODE_CLASS Receptor Ligand Antagonist 166974-23-8 GV-196771A PRODUCT_CLASS Central Nervous System (CNS) 166974-23-8 GV-196771A MECHANISM Block neural transmission 166974-22-7 GV-196771A PRODUCT_CLASS Central Nervous System (CNS) 166974-22-7 GV-196771A MODE_CLASS Receptor Ligand Antagonist 166974-22-7 GV-196771A MECHANISM Block neural transmission 170148-29-5 JTV-506 MODE_CLASS Channel enhancer /opener 170148-29-5 JTV-506 PRODUCT_CLASS Cardiovasculars 170148-29-5 JTV-506 THERAPEUTIC_CLASS Antianginals 170148-29-5 JTV-506 THERAPEUTIC_CLASS Antihypertensive Agents 170148-29-5 JTV-506 MECHANISM Reduce muscle contractile force 171099-57-3 LY-333328 STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 157832-55-8 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 157832-55-8 NIBENTAN INDICATION Cardiac Arrhythmias 157832-55-8 NIBENTAN MECHANISM Modulate channel gating 157832-55-8 NIBENTAN MODE_CLASS Channel Modulator 157832-55-8 NIBENTAN PRODUCT_CLASS Cardiovasculars 150492-03-8 NIBENTAN MECHANISM Modulate channel gating 150492-03-8 NIBENTAN INDICATION Cardiac Arrhythmias 150492-03-8 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 150492-03-8 NIBENTAN MODE_CLASS Channel Modulator 150492-03-8 NIBENTAN PRODUCT_CLASS Cardiovasculars 150492-02-7 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 150492-02-7 NIBENTAN INDICATION Cardiac Arrhythmias 150492-02-7 NIBENTAN MODE_CLASS Channel Modulator 150492-02-7 NIBENTAN PRODUCT_CLASS Cardiovasculars 150492-02-7 NIBENTAN MECHANISM Modulate channel gating 150491-97-7 NIBENTAN MECHANISM Modulate channel gating 150491-97-7 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 150491-97-7 NIBENTAN INDICATION Cardiac Arrhythmias 150491-97-7 NIBENTAN PRODUCT_CLASS Cardiovasculars 150491-97-7 NIBENTAN MODE_CLASS Channel Modulator 157832-56-9 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 157832-56-9 NIBENTAN PRODUCT_CLASS Cardiovasculars 157832-56-9 NIBENTAN MECHANISM Modulate channel gating 157832-56-9 NIBENTAN MODE_CLASS Channel Modulator 157832-56-9 NIBENTAN INDICATION Cardiac Arrhythmias 150492-05-0 NIBENTAN MECHANISM Modulate channel gating 150492-05-0 NIBENTAN PRODUCT_CLASS Cardiovasculars 150492-05-0 NIBENTAN INDICATION Cardiac Arrhythmias 150492-05-0 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 150492-05-0 NIBENTAN MODE_CLASS Channel Modulator 150492-04-9 NIBENTAN MECHANISM Modulate channel gating 150492-04-9 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 150492-04-9 NIBENTAN INDICATION Cardiac Arrhythmias 150492-04-9 NIBENTAN MODE_CLASS Channel Modulator 150492-04-9 NIBENTAN PRODUCT_CLASS Cardiovasculars 150491-98-8 NIBENTAN INDICATION Cardiac Arrhythmias 150491-98-8 NIBENTAN THERAPEUTIC_CLASS Antiarrhythmic Agents 150491-98-8 NIBENTAN MODE_CLASS Channel Modulator 150491-98-8 NIBENTAN MECHANISM Modulate channel gating 150491-98-8 NIBENTAN PRODUCT_CLASS Cardiovasculars 146731-14-8 Z-335 PRODUCT_CLASS Cardiovasculars 146731-14-8 Z-335 INDICATION Atherosclerosis 146731-14-8 Z-335 THERAPEUTIC_CLASS Hypolipidemic Agents 146737-36-2 Z-335 INDICATION Atherosclerosis 146737-36-2 Z-335 THERAPEUTIC_CLASS Hypolipidemic Agents 146737-36-2 Z-335 PRODUCT_CLASS Cardiovasculars 175463-14-6 LB-20304 FREE BASE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 210353-53-0 LB-20304 FREE BASE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 210353-55-2 LB-20304 FREE BASE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 210353-56-3 LB-20304 FREE BASE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 204519-64-2 LB-20304 FREE BASE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 164150-85-0 DW-116 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 164150-85-0 DW-116 MECHANISM Inhibit bacterial DNA synthesis 164150-85-0 DW-116 THERAPEUTIC_CLASS Antibacterials 164150-85-0 DW-116 PRODUCT_CLASS Anti-infectives 164150-85-0 DW-116 MODE_CLASS Enzyme Inhibitor, selective 164150-99-6 DW-116 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 164150-99-6 DW-116 THERAPEUTIC_CLASS Antibacterials 164150-99-6 DW-116 MECHANISM Inhibit bacterial DNA synthesis 164150-99-6 DW-116 MODE_CLASS Enzyme Inhibitor, selective 164150-99-6 DW-116 PRODUCT_CLASS Anti-infectives 151069-12-4 NB-506 STRUCTURE_ACTIVITY DNA intercalator 153250-51-2 HSR-609 INDICATION Viral Rhinitis / Common Cold 188199-97-5 HSR-609 INDICATION Viral Rhinitis / Common Cold 161522-25-4 HSR-609 INDICATION Viral Rhinitis / Common Cold 141577-40-4 2-NAP MECHANISM Modulate G-protein coupled signal transduction 141577-40-4 2-NAP MODE_CLASS Receptor Ligand Antagonist 141596-46-5 2-NAP MECHANISM Modulate G-protein coupled signal transduction 141596-46-5 2-NAP MODE_CLASS Receptor Ligand Antagonist 161214-50-2 NC-1800 INDICATION Urinary Incontinence / Enuresis 161214-66-0 NC-1800 INDICATION Urinary Incontinence / Enuresis 161214-64-8 NC-1800 INDICATION Urinary Incontinence / Enuresis 173273-43-3 NC-1800 INDICATION Urinary Incontinence / Enuresis 153537-73-6 ZD-9331 MECHANISM Inhibit precursor synthesis 153537-73-6 ZD-9331 STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 153537-73-6 ZD-9331 MODE_CLASS Enzyme Inhibitor 153537-74-7 ZD-9331 MECHANISM Inhibit precursor synthesis 153537-74-7 ZD-9331 STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 153537-74-7 ZD-9331 MODE_CLASS Enzyme Inhibitor 128427-55-4 CS-940 THERAPEUTIC_CLASS Antibacterials 128427-55-4 CS-940 MECHANISM Inhibit bacterial DNA synthesis 128427-55-4 CS-940 PRODUCT_CLASS Anti-infectives 128427-55-4 CS-940 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 128427-55-4 CS-940 MODE_CLASS Enzyme Inhibitor, selective 128426-71-1 CS-940 MODE_CLASS Enzyme Inhibitor, selective 128426-71-1 CS-940 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 128426-71-1 CS-940 PRODUCT_CLASS Anti-infectives 128426-71-1 CS-940 MECHANISM Inhibit bacterial DNA synthesis 128426-71-1 CS-940 THERAPEUTIC_CLASS Antibacterials 128427-30-5 CS-940 THERAPEUTIC_CLASS Antibacterials 128427-30-5 CS-940 MODE_CLASS Enzyme Inhibitor, selective 128427-30-5 CS-940 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 128427-30-5 CS-940 PRODUCT_CLASS Anti-infectives 128427-30-5 CS-940 MECHANISM Inhibit bacterial DNA synthesis 128427-54-3 CS-940 MODE_CLASS Enzyme Inhibitor, selective 128427-54-3 CS-940 THERAPEUTIC_CLASS Antibacterials 128427-54-3 CS-940 MECHANISM Inhibit bacterial DNA synthesis 128427-54-3 CS-940 PRODUCT_CLASS Anti-infectives 128427-54-3 CS-940 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 155415-08-0 INOGATRAN MECHANISM Inhibit platelet aggregation 155415-08-0 INOGATRAN MODE_CLASS Enzyme Inhibitor 153168-05-9 PLECONARIL THERAPEUTIC_CLASS Antivirals, Systemic 153168-05-9 PLECONARIL PRODUCT_CLASS Anti-infectives 153436-22-7 GAVESTINEL SODIUM MODE_CLASS Receptor Ligand Antagonist 153436-22-7 GAVESTINEL SODIUM PRODUCT_CLASS Central Nervous System (CNS) 153436-22-7 GAVESTINEL SODIUM THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 153436-22-7 GAVESTINEL SODIUM MECHANISM Block neural transmission 153436-22-7 GAVESTINEL SODIUM INDICATION Cerebral Ischemia 320725-47-1 SQUALAMINE MODE_CLASS Enzyme Inhibitor 320725-47-1 SQUALAMINE MECHANISM Inhibit steroid biosynthesis/ metabolism 320725-47-1 SQUALAMINE STRUCTURE_ACTIVITY Angiogenesis inhibitor 173903-27-0 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 180981-08-2 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 180981-07-1 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 173903-41-8 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 173903-39-4 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 173903-35-0 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 17902-23-7 TEGAFUR ADVERSE_EFFECT BBM_3_Coagulopathy 17902-23-7 TEGAFUR ZERO_CLASS N 17902-23-7 TEGAFUR PRODUCT_CLASS Anti-cancers 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_3_Intestinal Perforation 17902-23-7 TEGAFUR TA_LEVEL_2 Solid and soft tissue tumors 17902-23-7 TEGAFUR INDICATION Bladder Cancer / Carcinoma of the Bladder 17902-23-7 TEGAFUR KNOWN_TOXICITY Cardiovascular Toxicity 17902-23-7 TEGAFUR TISSUE_TOXICITY Cardiac Arrest 17902-23-7 TEGAFUR ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_1_Constipation 17902-23-7 TEGAFUR ADVERSE_EFFECT CVS_3_Myocardial Infarction 17902-23-7 TEGAFUR ADVERSE_EFFECT REP_3_Impotence 17902-23-7 TEGAFUR TISSUE_TOXICITY Hypotension 17902-23-7 TEGAFUR ADVERSE_EFFECT PSY_1_Confusion 17902-23-7 TEGAFUR ADVERSE_EFFECT BBM_2_Leukopenia 17902-23-7 TEGAFUR ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 17902-23-7 TEGAFUR ADVERSE_EFFECT KID_2_Abnormal Kidney Function 17902-23-7 TEGAFUR TA_LEVEL_1 Oncology 17902-23-7 TEGAFUR ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 17902-23-7 TEGAFUR MESH_LEVEL_1 Heterocyclic Compounds 17902-23-7 TEGAFUR INDICATION Head and Neck Cancer 17902-23-7 TEGAFUR MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 17902-23-7 TEGAFUR ADVERSE_EFFECT XXX_2_Fever 17902-23-7 TEGAFUR ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 17902-23-7 TEGAFUR ADVERSE_EFFECT CVS_3_Congestive Heart Failure 17902-23-7 TEGAFUR ADVERSE_EFFECT NEU_1_Ataxia 17902-23-7 TEGAFUR MODE_CLASS Enzyme substrate mimic 17902-23-7 TEGAFUR ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_1_Abdominal Pain 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_3_Bowel Obstruction 17902-23-7 TEGAFUR THERAPEUTIC_CLASS Antineoplastics 17902-23-7 TEGAFUR MECHANISM Inhibit precursor synthesis 17902-23-7 TEGAFUR TISSUE_TOXICITY Hematuria 17902-23-7 TEGAFUR TISSUE_TOXICITY Cardiac Arrhythmia 17902-23-7 TEGAFUR TA_LEVEL_3 Antimitotic 17902-23-7 TEGAFUR MECH_LEVEL_1 Antimitotic 17902-23-7 TEGAFUR MESH_LEVEL_3 Pyrimidines 17902-23-7 TEGAFUR INDICATION Metastatic Colorectal Cancer 17902-23-7 TEGAFUR ADVERSE_EFFECT BBM_3_Thrombocytopenia 17902-23-7 TEGAFUR TISSUE_TOXICITY Congestive Heart Failure 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_1_Diarrhea 17902-23-7 TEGAFUR ADVERSE_EFFECT CVS_3_Hypotension 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_1_Nausea 17902-23-7 TEGAFUR ADVERSE_EFFECT CVS_3_Cardiac Arrest 17902-23-7 TEGAFUR ADVERSE_EFFECT XXX_1_Infection 17902-23-7 TEGAFUR ADVERSE_EFFECT KID_3_Hematuria 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_2_Stomatitis 17902-23-7 TEGAFUR ADVERSE_EFFECT GIS_1_Metallic Taste 17902-23-7 TEGAFUR STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 17902-23-7 TEGAFUR MECH_LEVEL_2 Inhibit precursor synthesis 17902-23-7 TEGAFUR INDICATION Breast Cancer / Carcinoma of the Breast 17902-23-7 TEGAFUR MECH_LEVEL_3 Thymidylate synthase 17902-23-7 TEGAFUR KNOWN_TOXICITY Nephrotoxicity 17902-23-7 TEGAFUR TISSUE_TOXICITY Myocardial Infarction 17902-23-7 TEGAFUR ADVERSE_EFFECT NEU_3_Leukoencephalopathy 17902-23-7 TEGAFUR ADVERSE_EFFECT NEU_1_Sedation 17902-23-7 TEGAFUR ADVERSE_EFFECT PSY_1_Anorexia 17902-23-7 TEGAFUR ADVERSE_EFFECT NEU_1_Dizziness 17902-23-7 TEGAFUR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 17902-23-7 TEGAFUR ADVERSE_EFFECT LUN_3_Pulmonary Embolism 103766-25-2 GIMESTAT MODE_CLASS Enzyme Inhibitor 153438-49-4 DAPITANT PRODUCT_CLASS Central Nervous System (CNS) 153438-49-4 DAPITANT THERAPEUTIC_CLASS Analgesics, Non-Opioid 153438-49-4 DAPITANT MODE_CLASS Receptor Ligand Antagonist 153438-49-4 DAPITANT MECHANISM Modulate G-protein coupled signal transduction 153205-46-0 ASIMADOLINE PRODUCT_CLASS Analgesics 153205-46-0 ASIMADOLINE MODE_CLASS Receptor Agonist, selective 153205-46-0 ASIMADOLINE MECHANISM Modulate neural transmission 153205-46-0 ASIMADOLINE THERAPEUTIC_CLASS Analgesics, Opioid 130065-61-1 ATIPRIMOD THERAPEUTIC_CLASS Immunosuppressants 130065-61-1 ATIPRIMOD PRODUCT_CLASS Immune Response / Immunomodulators 130065-61-1 ATIPRIMOD INDICATION Arthritis 123018-47-3 ATIPRIMOD PRODUCT_CLASS Immune Response / Immunomodulators 123018-47-3 ATIPRIMOD INDICATION Arthritis 123018-47-3 ATIPRIMOD THERAPEUTIC_CLASS Immunosuppressants 183063-72-1 ATIPRIMOD INDICATION Arthritis 183063-72-1 ATIPRIMOD THERAPEUTIC_CLASS Immunosuppressants 183063-72-1 ATIPRIMOD PRODUCT_CLASS Immune Response / Immunomodulators 160555-46-4 S-16961 INDICATION Hypolipidemia 157244-53-6 SDZ-CPI-975 INDICATION Diabetes 157244-54-7 SDZ-CPI-975 INDICATION Diabetes 142632-32-4 CALANOLIDE A INDICATION Myocardial Ischemia 151005-68-4 CALANOLIDE A INDICATION Myocardial Ischemia 163661-45-8 CALANOLIDE A INDICATION Myocardial Ischemia 154229-19-3 ABIRATERONE THERAPEUTIC_CLASS Antineoplastics 154229-19-3 ABIRATERONE MODE_CLASS Enzyme Inhibitor 154229-19-3 ABIRATERONE MECHANISM Inhibit steroid biosynthesis/ metabolism 154229-19-3 ABIRATERONE PRODUCT_CLASS Anti-cancers 101246-66-6 PHENSERINE INDICATION Alzheimer's Disease 101246-66-6 PHENSERINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 101246-66-6 PHENSERINE PRODUCT_CLASS Autonomic Nervous System (ANS) 101246-66-6 PHENSERINE PRODUCT_CLASS Central Nervous System (CNS) 101246-66-6 PHENSERINE MODE_CLASS Enzyme Inhibitor 101246-66-6 PHENSERINE THERAPEUTIC_CLASS Parasympathomimetic Agents 101246-66-6 PHENSERINE THERAPEUTIC_CLASS Neurodegenerative Disorders 101246-66-6 PHENSERINE MECHANISM Enhance cholinergic transmission 159652-53-6 PHENSERINE INDICATION Alzheimer's Disease 159652-53-6 PHENSERINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 159652-53-6 PHENSERINE THERAPEUTIC_CLASS Parasympathomimetic Agents 159652-53-6 PHENSERINE MECHANISM Enhance cholinergic transmission 159652-53-6 PHENSERINE PRODUCT_CLASS Autonomic Nervous System (ANS) 159652-53-6 PHENSERINE MODE_CLASS Enzyme Inhibitor 159652-53-6 PHENSERINE THERAPEUTIC_CLASS Neurodegenerative Disorders 159652-53-6 PHENSERINE PRODUCT_CLASS Central Nervous System (CNS) 156910-61-1 PHENSERINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 156910-61-1 PHENSERINE THERAPEUTIC_CLASS Neurodegenerative Disorders 156910-61-1 PHENSERINE MODE_CLASS Enzyme Inhibitor 156910-61-1 PHENSERINE PRODUCT_CLASS Autonomic Nervous System (ANS) 156910-61-1 PHENSERINE THERAPEUTIC_CLASS Parasympathomimetic Agents 156910-61-1 PHENSERINE PRODUCT_CLASS Central Nervous System (CNS) 156910-61-1 PHENSERINE INDICATION Alzheimer's Disease 156910-61-1 PHENSERINE MECHANISM Enhance cholinergic transmission 116839-68-0 PHENSERINE INDICATION Alzheimer's Disease 116839-68-0 PHENSERINE PRODUCT_CLASS Central Nervous System (CNS) 116839-68-0 PHENSERINE THERAPEUTIC_CLASS Parasympathomimetic Agents 116839-68-0 PHENSERINE PRODUCT_CLASS Autonomic Nervous System (ANS) 116839-68-0 PHENSERINE MODE_CLASS Enzyme Inhibitor 116839-68-0 PHENSERINE MECHANISM Enhance cholinergic transmission 116839-68-0 PHENSERINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 116839-68-0 PHENSERINE THERAPEUTIC_CLASS Neurodegenerative Disorders 153504-81-5 LICOSTINEL MECHANISM Block neural transmission 153504-81-5 LICOSTINEL MODE_CLASS Channel Blocker 153504-81-5 LICOSTINEL PRODUCT_CLASS Central Nervous System (CNS) 158876-82-5 RUPATADINE FUMARATE INDICATION Viral Rhinitis / Common Cold 156611-76-6 RUPATADINE FUMARATE INDICATION Viral Rhinitis / Common Cold 153259-65-5 CILOMILAST MECHANISM Enhance kinase mediated signal transduction 153259-65-5 CILOMILAST STRUCTURE_ACTIVITY PDE4 inhibitor 153259-65-5 CILOMILAST INDICATION Chronic Obstructive Pulmonary Disease (COPD) 153259-65-5 CILOMILAST MODE_CLASS Enzyme Inhibitor 143621-35-6 3-AP MODE_CLASS Enzyme Inhibitor 143621-35-6 3-AP MECHANISM Inhibit DNA synthesis, repair, and function 131987-54-7 TAZOMELINE MODE_CLASS Enzyme Inhibitor 131987-54-7 TAZOMELINE INDICATION Alzheimer's Disease 141064-37-1 TAZOMELINE INDICATION Alzheimer's Disease 141064-37-1 TAZOMELINE MODE_CLASS Enzyme Inhibitor 175615-45-9 TAZOMELINE INDICATION Alzheimer's Disease 175615-45-9 TAZOMELINE MODE_CLASS Enzyme Inhibitor 113712-98-4 TU-199 MODE_CLASS Enzyme Inhibitor 113712-98-4 TU-199 MECHANISM Reduce stomach HCl secretion 70280-03-4 GLYCOPIN INDICATION Psoriasis 73494-47-0 GLYCOPIN INDICATION Psoriasis 130114-88-4 GLYCOPIN INDICATION Psoriasis 155780-17-9 GLYCOPIN INDICATION Psoriasis 134234-12-1 TRAXOPRODIL MODE_CLASS Channel Modulator 134234-12-1 TRAXOPRODIL MECHANISM Modulate neural transmission 134234-12-1 TRAXOPRODIL STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 134234-12-1 TRAXOPRODIL INDICATION Cerebral Ischemia 134234-13-2 TRAXOPRODIL STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 134234-13-2 TRAXOPRODIL MODE_CLASS Channel Modulator 134234-13-2 TRAXOPRODIL MECHANISM Modulate neural transmission 134234-13-2 TRAXOPRODIL INDICATION Cerebral Ischemia 134138-41-3 TRAXOPRODIL STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 134138-41-3 TRAXOPRODIL MECHANISM Modulate neural transmission 134138-41-3 TRAXOPRODIL MODE_CLASS Channel Modulator 134138-41-3 TRAXOPRODIL INDICATION Cerebral Ischemia 134717-73-0 TAT MECHANISM Inhibit precursor synthesis 134717-73-0 TAT INDICATION Diabetic Neuropathy 134717-73-0 TAT MODE_CLASS Enzyme Inhibitor 134717-73-0 TAT PRODUCT_CLASS Other Human Uses 134717-73-0 TAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 150705-88-7 CGP-49823 PRODUCT_CLASS Central Nervous System (CNS) 150705-88-7 CGP-49823 INDICATION Depression 150705-88-7 CGP-49823 THERAPEUTIC_CLASS Antidepressants 154906-40-8 RS-66271 PRODUCT_CLASS Hormones, Endocrine and Metabolic 154906-40-8 RS-66271 THERAPEUTIC_CLASS Bone Mineral Homeostasis 154906-40-8 RS-66271 INDICATION Osteoporosis 863-61-6 MENATETRENONE INDICATION Herpes Genitalis / Genital Herpes 863-61-6 MENATETRENONE MECHANISM Block channel gating 863-61-6 MENATETRENONE INDICATION Osteoporosis 6041-00-5 MENATETRENONE MECHANISM Block channel gating 6041-00-5 MENATETRENONE INDICATION Herpes Genitalis / Genital Herpes 6041-00-5 MENATETRENONE INDICATION Osteoporosis 65061-19-0 MENATETRENONE INDICATION Herpes Genitalis / Genital Herpes 65061-19-0 MENATETRENONE INDICATION Osteoporosis 65061-19-0 MENATETRENONE MECHANISM Block channel gating 154992-24-2 RU-58841 INDICATION Alopecia / Baldness / Hair Loss 155255-72-4 RU-58841 INDICATION Alopecia / Baldness / Hair Loss 193739-23-0 LDP-392 STRUCTURE_ACTIVITY Arachidonate 5-lipoxygenase inhibitor 193739-23-0 LDP-392 INDICATION Psoriasis 193739-23-0 LDP-392 INDICATION Eczema Herpeticum 193739-23-0 LDP-392 MODE_CLASS Enzyme Inhibitor 193739-23-0 LDP-392 MECHANISM Inhibit eicosanoid biosynthesis 177172-49-5 NPS-R-568 STRUCTURE_ACTIVITY Calcimimetic 148717-54-8 NPS-R-568 STRUCTURE_ACTIVITY Calcimimetic 153465-67-9 GA-0056 MECHANISM Modulate G-protein coupled signal transduction 153465-67-9 GA-0056 THERAPEUTIC_CLASS Antihypertensive Agents 153465-67-9 GA-0056 PRODUCT_CLASS Cardiovasculars 153465-67-9 GA-0056 INDICATION Hypertension 137786-58-4 NY-008 INDICATION Hypertension 137786-58-4 NY-008 THERAPEUTIC_CLASS Antihypertensive Agents 137786-58-4 NY-008 PRODUCT_CLASS Cardiovasculars 100324-81-0 LISOFYLLINE INDICATION Acute Respiratory Distress Syndrome (ARDS) 151852-32-3 LISOFYLLINE INDICATION Acute Respiratory Distress Syndrome (ARDS) 6493-06-7 LISOFYLLINE INDICATION Acute Respiratory Distress Syndrome (ARDS) 150332-35-7 PAMAQUESIDE INDICATION Hypolipidemia 154323-57-6 ALMOTRIPTAN INDICATION Migraine Headache 154323-57-6 ALMOTRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 154323-57-6 ALMOTRIPTAN THERAPEUTIC_CLASS Antimigraines 154323-57-6 ALMOTRIPTAN MECHANISM Modulate neural transmission 154323-57-6 ALMOTRIPTAN MECHANISM Modulate cerebral vasoconstriction 181183-52-8 ALMOTRIPTAN MECHANISM Modulate neural transmission 181183-52-8 ALMOTRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 181183-52-8 ALMOTRIPTAN INDICATION Migraine Headache 181183-52-8 ALMOTRIPTAN MECHANISM Modulate cerebral vasoconstriction 181183-52-8 ALMOTRIPTAN THERAPEUTIC_CLASS Antimigraines 155270-99-8 KW-6002 INDICATION Parkinson's Disease 146376-58-1 ZD-2079 THERAPEUTIC_CLASS Sympathomimetic Agents 146376-58-1 ZD-2079 PRODUCT_CLASS Hormones, Endocrine and Metabolic 146376-58-1 ZD-2079 PRODUCT_CLASS Autonomic Nervous System (ANS) 146376-58-1 ZD-2079 MECHANISM Reduce muscle contractile force 146376-58-1 ZD-2079 THERAPEUTIC_CLASS Antidiabetic Agents 146376-58-1 ZD-2079 INDICATION Obesity 146376-58-1 ZD-2079 INDICATION Diabetes 146376-58-1 ZD-2079 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 146376-58-1 ZD-2079 MODE_CLASS Receptor Agonist, selective 146376-61-6 ZD-2079 MODE_CLASS Receptor Agonist, selective 146376-61-6 ZD-2079 THERAPEUTIC_CLASS Sympathomimetic Agents 146376-61-6 ZD-2079 PRODUCT_CLASS Hormones, Endocrine and Metabolic 146376-61-6 ZD-2079 PRODUCT_CLASS Autonomic Nervous System (ANS) 146376-61-6 ZD-2079 MECHANISM Reduce muscle contractile force 146376-61-6 ZD-2079 INDICATION Diabetes 146376-61-6 ZD-2079 INDICATION Obesity 146376-61-6 ZD-2079 THERAPEUTIC_CLASS Antidiabetic Agents 146376-61-6 ZD-2079 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 143945-39-5 CL-329167 THERAPEUTIC_CLASS Antihypertensive Agents 143945-39-5 CL-329167 MECHANISM Reduce vasoconstriction 143945-39-5 CL-329167 PRODUCT_CLASS Cardiovasculars 143945-39-5 CL-329167 MODE_CLASS Receptor Ligand Antagonist, Selective 144364-95-4 CL-329167 PRODUCT_CLASS Cardiovasculars 144364-95-4 CL-329167 MODE_CLASS Receptor Ligand Antagonist, Selective 144364-95-4 CL-329167 THERAPEUTIC_CLASS Antihypertensive Agents 144364-95-4 CL-329167 MECHANISM Reduce vasoconstriction 132701-58-7 BOPP INDICATION Myocardial Ischemia 164465-97-8 BOPP INDICATION Myocardial Ischemia 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Asthenia 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT NEU_2_Headache 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT NEU_2_Sedation 75970-99-9 TECASTEMIZOLE PRODUCT_CLASS Anti-inflammatories 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Rhinitis 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Pain 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 75970-99-9 TECASTEMIZOLE TISSUE_TOXICITY Cardiac Arrhythmia 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Pharyngitis 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Infection 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT PSY_2_Insomnia 75970-99-9 TECASTEMIZOLE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 75970-99-9 TECASTEMIZOLE INDICATION Viral Rhinitis / Common Cold 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT GIS_2_Dyspepsia 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT GIS_2_Nausea 75970-99-9 TECASTEMIZOLE ADVERSE_EFFECT GIS_2_Diarrhea 75970-99-9 TECASTEMIZOLE KNOWN_TOXICITY Cardiovascular Toxicity 75970-99-9 TECASTEMIZOLE THERAPEUTIC_CLASS Antihistamines 75970-99-9 TECASTEMIZOLE INDICATION Allergic Diseases 75970-99-9 TECASTEMIZOLE MODE_CLASS Receptor Ligand Antagonist 75970-99-9 TECASTEMIZOLE INDICATION Rhinitis 75970-99-9 TECASTEMIZOLE MECHANISM Modulate G-protein coupled signal transduction 75970-64-8 TECASTEMIZOLE INDICATION Allergic Diseases 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT GIS_2_Nausea 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT GIS_2_Diarrhea 75970-64-8 TECASTEMIZOLE KNOWN_TOXICITY Cardiovascular Toxicity 75970-64-8 TECASTEMIZOLE THERAPEUTIC_CLASS Antihistamines 75970-64-8 TECASTEMIZOLE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT GIS_2_Dyspepsia 75970-64-8 TECASTEMIZOLE MECHANISM Modulate G-protein coupled signal transduction 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Rhinitis 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Pain 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 75970-64-8 TECASTEMIZOLE TISSUE_TOXICITY Cardiac Arrhythmia 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Pharyngitis 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Infection 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT PSY_2_Insomnia 75970-64-8 TECASTEMIZOLE MODE_CLASS Receptor Ligand Antagonist 75970-64-8 TECASTEMIZOLE INDICATION Viral Rhinitis / Common Cold 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT NEU_2_Headache 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT XXX_2_Asthenia 75970-64-8 TECASTEMIZOLE ADVERSE_EFFECT NEU_2_Sedation 75970-64-8 TECASTEMIZOLE PRODUCT_CLASS Anti-inflammatories 75970-64-8 TECASTEMIZOLE INDICATION Rhinitis 128995-51-7 E047/1 INDICATION Cardiac Arrhythmias 128995-51-7 E047/1 PRODUCT_CLASS Cardiovasculars 128995-51-7 E047/1 THERAPEUTIC_CLASS Antiarrhythmic Agents 128995-52-8 E047/1 PRODUCT_CLASS Cardiovasculars 128995-52-8 E047/1 THERAPEUTIC_CLASS Antiarrhythmic Agents 128995-52-8 E047/1 INDICATION Cardiac Arrhythmias 119643-16-2 SDZ-CO-611 INDICATION Ulcer 63-39-8 UTP INDICATION Cystic Fibrosis (CF) 150355-66-1 SB-209670 THERAPEUTIC_CLASS Antihypertensive Agents 150355-66-1 SB-209670 PRODUCT_CLASS Cardiovasculars 150355-66-1 SB-209670 INDICATION Hypertension 154355-76-7 ABT-761 PRODUCT_CLASS Respiratory System 154355-76-7 ABT-761 MODE_CLASS Enzyme Inhibitor 154355-76-7 ABT-761 MECHANISM Inhibit eicosanoid biosynthesis 154355-76-7 ABT-761 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 154355-76-7 ABT-761 INDICATION Asthma 154355-75-6 ABT-761 PRODUCT_CLASS Respiratory System 154355-75-6 ABT-761 INDICATION Asthma 154355-75-6 ABT-761 MECHANISM Inhibit eicosanoid biosynthesis 154355-75-6 ABT-761 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 154355-75-6 ABT-761 MODE_CLASS Enzyme Inhibitor 154355-79-0 ABT-761 MECHANISM Inhibit eicosanoid biosynthesis 154355-79-0 ABT-761 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 154355-79-0 ABT-761 INDICATION Asthma 154355-79-0 ABT-761 MODE_CLASS Enzyme Inhibitor 154355-79-0 ABT-761 PRODUCT_CLASS Respiratory System 156055-46-8 S-16020-2 MECHANISM Inhibit DNA synthesis, repair, and function 156055-46-8 S-16020-2 THERAPEUTIC_CLASS Antineoplastics 156055-46-8 S-16020-2 MODE_CLASS Enzyme Inhibitor 156055-46-8 S-16020-2 PRODUCT_CLASS Anti-cancers 157605-25-9 ALATROFLOXACIN THERAPEUTIC_CLASS Antibacterials 157605-25-9 ALATROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 157605-25-9 ALATROFLOXACIN PRODUCT_CLASS Anti-infectives 157605-25-9 ALATROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 157605-25-9 ALATROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 157182-32-6 ALATROFLOXACIN THERAPEUTIC_CLASS Antibacterials 157182-32-6 ALATROFLOXACIN PRODUCT_CLASS Anti-infectives 157182-32-6 ALATROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 157182-32-6 ALATROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 157182-32-6 ALATROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 146961-76-4 ALATROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 146961-76-4 ALATROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 146961-76-4 ALATROFLOXACIN THERAPEUTIC_CLASS Antibacterials 146961-76-4 ALATROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 146961-76-4 ALATROFLOXACIN PRODUCT_CLASS Anti-infectives 158089-95-3 S-2474 PRODUCT_CLASS Immune Response / Immunomodulators 158089-95-3 S-2474 INDICATION Arthritis 158089-95-3 S-2474 THERAPEUTIC_CLASS Immunosuppressants 158089-96-4 S-2474 INDICATION Arthritis 158089-96-4 S-2474 THERAPEUTIC_CLASS Immunosuppressants 158089-96-4 S-2474 PRODUCT_CLASS Immune Response / Immunomodulators 138301-71-0 L-693612 MODE_CLASS Enzyme Inhibitor 138301-71-0 L-693612 THERAPEUTIC_CLASS Antiglaucoma Agents 138301-71-0 L-693612 PRODUCT_CLASS Electrolytic, Caloric and Water Balance 138301-71-0 L-693612 THERAPEUTIC_CLASS Diuretics 138301-71-0 L-693612 PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 138301-71-0 L-693612 MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 61966-08-3 TRICIRIBINE PHOSPHATE INDICATION Myocardial Ischemia 146665-77-2 SKI-2053R MECHANISM Inhibit DNA synthesis, repair, and function 146665-77-2 SKI-2053R MODE_CLASS Distorts /blocks macromolecular scaffold function 146665-77-2 SKI-2053R PRODUCT_CLASS Anti-cancers 162359-56-0 FTY-720 INDICATION Transplant Rejection 159351-69-6 EVEROLIMUS INDICATION Transplant Rejection 159351-69-6 EVEROLIMUS ADVERSE_EFFECT END_2_Hyperlipidemia 159351-69-6 EVEROLIMUS ADVERSE_EFFECT XXX_3_Opportunistic Infection 159351-69-6 EVEROLIMUS STRUCTURE_ACTIVITY Inhibits T-cell activation 159351-69-6 EVEROLIMUS MECHANISM Modulate G-protein coupled signal transduction 159351-69-6 EVEROLIMUS THERAPEUTIC_CLASS Immunosuppressants 159351-69-6 EVEROLIMUS ADVERSE_EFFECT BBM_2_Leukopenia 159351-69-6 EVEROLIMUS ADVERSE_EFFECT BBM_2_Thrombocytopenia 159351-69-6 EVEROLIMUS MODE_CLASS Enzyme Inhibitor 159351-69-6 EVEROLIMUS PRODUCT_CLASS Immune Response / Immunomodulators 148870-80-8 IVABRADINE HYDROCHLORIDE INDICATION Angina Pectoris 148870-80-8 IVABRADINE HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 148870-80-8 IVABRADINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 155974-00-8 IVABRADINE HYDROCHLORIDE THERAPEUTIC_CLASS Antianginals 155974-00-8 IVABRADINE HYDROCHLORIDE INDICATION Angina Pectoris 155974-00-8 IVABRADINE HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 156897-06-2 ML-3000 PRODUCT_CLASS Immune Response / Immunomodulators 156897-06-2 ML-3000 MECHANISM Inhibit eicosanoid biosynthesis 156897-06-2 ML-3000 THERAPEUTIC_CLASS Immunosuppressants 156897-06-2 ML-3000 INDICATION Arthritis 156897-06-2 ML-3000 MODE_CLASS Enzyme Inhibitor 157126-18-6 BMS-187745 MODE_CLASS Enzyme Inhibitor 157126-18-6 BMS-187745 INDICATION Hypolipidemia 157126-18-6 BMS-187745 MECHANISM Inhibit bone re-absorption 157126-18-6 BMS-187745 STRUCTURE_ACTIVITY Squalene synthetase inhibitor 191866-32-7 BMS-188494 MECHANISM Inhibit bone re-absorption 191866-32-7 BMS-188494 INDICATION Hypolipidemia 191866-32-7 BMS-188494 STRUCTURE_ACTIVITY Squalene synthetase inhibitor 191866-32-7 BMS-188494 MODE_CLASS Enzyme Inhibitor 154189-24-9 AR-C68397XX FREE BASE MECHANISM Modulate G-protein coupled signal transduction 154189-24-9 AR-C68397XX FREE BASE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 154189-40-9 AR-C68397XX FREE BASE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 154189-40-9 AR-C68397XX FREE BASE MECHANISM Modulate G-protein coupled signal transduction 144665-07-6 LUBELUZOLE MECHANISM Block neural transmission 144665-07-6 LUBELUZOLE THERAPEUTIC_CLASS Vasodilators 144665-07-6 LUBELUZOLE INDICATION Cerebral Ischemia 144665-07-6 LUBELUZOLE MODE_CLASS Channel Blocker 144665-07-6 LUBELUZOLE PRODUCT_CLASS Central Nervous System (CNS) 144665-07-6 LUBELUZOLE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 146822-06-2 KR-30450 MECHANISM Modulate channel gating 146822-06-2 KR-30450 MODE_CLASS Channel Modulator 146822-06-2 KR-30450 INDICATION Ulcer 172489-10-0 KR-30450 INDICATION Ulcer 172489-10-0 KR-30450 MECHANISM Modulate channel gating 172489-10-0 KR-30450 MODE_CLASS Channel Modulator 150490-85-0 BERUPIPAM MECHANISM Modulate G-protein coupled signal transduction 162412-70-6 PD-156707 INDICATION Hypertension 162412-70-6 PD-156707 THERAPEUTIC_CLASS Antihypertensive Agents 162412-70-6 PD-156707 STRUCTURE_ACTIVITY Endothelin receptor antagonist 162412-70-6 PD-156707 PRODUCT_CLASS Cardiovasculars 110865-84-4 PD-156707 THERAPEUTIC_CLASS Antihypertensive Agents 110865-84-4 PD-156707 INDICATION Hypertension 110865-84-4 PD-156707 PRODUCT_CLASS Cardiovasculars 110865-84-4 PD-156707 STRUCTURE_ACTIVITY Endothelin receptor antagonist 158747-02-5 FROVATRIPTAN INDICATION Migraine Headache 158747-02-5 FROVATRIPTAN MECHANISM Modulate cerebral vasoconstriction 158747-02-5 FROVATRIPTAN THERAPEUTIC_CLASS Antimigraines 158747-02-5 FROVATRIPTAN MECHANISM Modulate neural transmission 158747-02-5 FROVATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 158747-09-2 FROVATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 158747-09-2 FROVATRIPTAN MECHANISM Modulate cerebral vasoconstriction 158747-09-2 FROVATRIPTAN MECHANISM Modulate neural transmission 158747-09-2 FROVATRIPTAN THERAPEUTIC_CLASS Antimigraines 158747-09-2 FROVATRIPTAN INDICATION Migraine Headache 158930-18-8 FROVATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 158930-18-8 FROVATRIPTAN MECHANISM Modulate neural transmission 158930-18-8 FROVATRIPTAN THERAPEUTIC_CLASS Antimigraines 158930-18-8 FROVATRIPTAN MECHANISM Modulate cerebral vasoconstriction 158930-18-8 FROVATRIPTAN INDICATION Migraine Headache 147009-08-3 FROVATRIPTAN INDICATION Migraine Headache 147009-08-3 FROVATRIPTAN THERAPEUTIC_CLASS Antimigraines 147009-08-3 FROVATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 147009-08-3 FROVATRIPTAN MECHANISM Modulate cerebral vasoconstriction 147009-08-3 FROVATRIPTAN MECHANISM Modulate neural transmission 154039-60-8 MARIMASTAT INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 154039-60-8 MARIMASTAT ADVERSE_EFFECT CVS_3_Hemorrhagic Stroke 154039-60-8 MARIMASTAT MODE_CLASS Enzyme Inhibitor, selective 154039-60-8 MARIMASTAT MECHANISM Interferes with Cell-Cell signaling 154039-60-8 MARIMASTAT INDICATION Breast Cancer / Carcinoma of the Breast 154039-60-8 MARIMASTAT INDICATION Ovarian Cancer / Carcinoma of the Ovary 154039-60-8 MARIMASTAT MODE_CLASS Enzyme Inhibitor 154039-60-8 MARIMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_1_Myalgia 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_1_Joint Pain 154039-60-8 MARIMASTAT ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 154039-60-8 MARIMASTAT PRODUCT_CLASS Anti-cancers 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 154039-60-8 MARIMASTAT INDICATION Lung Cancer / Carcinoma of the Lung 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_1_Joint Disorder 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_1_Muscle Weakness 154039-60-8 MARIMASTAT ADVERSE_EFFECT BBM_3_Neutropenia 154039-60-8 MARIMASTAT KNOWN_TOXICITY Cardiovascular Toxicity 154039-60-8 MARIMASTAT THERAPEUTIC_CLASS Antineoplastics 154039-60-8 MARIMASTAT INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 154039-60-8 MARIMASTAT INDICATION Prostatic Cancer / Carcinoma of the Prostate 154039-60-8 MARIMASTAT ACTIVITY_CLASS Antiproliferative agent 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_1_Muscle Inflammation 154039-60-8 MARIMASTAT ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 154039-60-8 MARIMASTAT TISSUE_TOXICITY Hemorrhagic Stroke 154039-60-8 MARIMASTAT INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 148564-47-0 MILFASARTAN PRODUCT_CLASS Cardiovasculars 148564-47-0 MILFASARTAN THERAPEUTIC_CLASS Antihypertensive Agents 148564-47-0 MILFASARTAN MECHANISM Reduce vasoconstriction 148564-47-0 MILFASARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 148564-47-0 MILFASARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 160146-17-8 FINROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 160146-17-8 FINROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 160146-17-8 FINROZOLE MODE_CLASS Enzyme Inhibitor, selective 160146-17-8 FINROZOLE THERAPEUTIC_CLASS Antineoplastics 160146-17-8 FINROZOLE PRODUCT_CLASS Anti-cancers 160146-16-7 FINROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 160146-16-7 FINROZOLE THERAPEUTIC_CLASS Antineoplastics 160146-16-7 FINROZOLE PRODUCT_CLASS Anti-cancers 160146-16-7 FINROZOLE MODE_CLASS Enzyme Inhibitor, selective 160146-16-7 FINROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 204714-56-7 FINROZOLE MODE_CLASS Enzyme Inhibitor, selective 204714-56-7 FINROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 204714-56-7 FINROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 204714-56-7 FINROZOLE PRODUCT_CLASS Anti-cancers 204714-56-7 FINROZOLE THERAPEUTIC_CLASS Antineoplastics 152735-23-4 REC-15/2739 MECHANISM Modulate neural transmission 152735-23-4 REC-15/2739 INDICATION Prostatitis 152735-23-4 REC-15/2739 MECHANISM Modulate G-protein coupled signal transduction 152735-22-3 REC-15/2739 MECHANISM Modulate G-protein coupled signal transduction 152735-22-3 REC-15/2739 MECHANISM Modulate neural transmission 152735-22-3 REC-15/2739 INDICATION Prostatitis 152736-71-5 REC-15/2739 INDICATION Prostatitis 152736-71-5 REC-15/2739 MECHANISM Modulate G-protein coupled signal transduction 152736-71-5 REC-15/2739 MECHANISM Modulate neural transmission 152735-21-2 REC-15/2739 MECHANISM Modulate neural transmission 152735-21-2 REC-15/2739 INDICATION Prostatitis 152735-21-2 REC-15/2739 MECHANISM Modulate G-protein coupled signal transduction 152735-24-5 REC-15/2739 INDICATION Prostatitis 152735-24-5 REC-15/2739 MECHANISM Modulate neural transmission 152735-24-5 REC-15/2739 MECHANISM Modulate G-protein coupled signal transduction 154397-77-0 NAPSAGATRAN MECHANISM Inhibit platelet aggregation 154397-77-0 NAPSAGATRAN MODE_CLASS Enzyme Inhibitor 159668-20-9 NAPSAGATRAN MODE_CLASS Enzyme Inhibitor 159668-20-9 NAPSAGATRAN MECHANISM Inhibit platelet aggregation 130493-04-8 BIMOCLOMOL INDICATION Diabetes 130493-03-7 BIMOCLOMOL INDICATION Diabetes 133012-05-2 BAY-Y-1015 INDICATION Inflammatory Bowel Disease (IBD) 150812-13-8 RETIGABINE HYDROCHLORIDE MODE_CLASS Channel Modulator 150812-13-8 RETIGABINE HYDROCHLORIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 150812-13-8 RETIGABINE HYDROCHLORIDE MECHANISM Block channel gating 150812-13-8 RETIGABINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 150812-12-7 RETIGABINE HYDROCHLORIDE MODE_CLASS Channel Modulator 150812-12-7 RETIGABINE HYDROCHLORIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 150812-12-7 RETIGABINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 150812-12-7 RETIGABINE HYDROCHLORIDE MECHANISM Block channel gating 145733-36-4 TASOSARTAN THERAPEUTIC_CLASS Antihypertensive Agents 145733-36-4 TASOSARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 145733-36-4 TASOSARTAN ADVERSE_EFFECT GIS__Gastrointestinal Disturbances 145733-36-4 TASOSARTAN MECHANISM Reduce vasoconstriction 145733-36-4 TASOSARTAN PRODUCT_CLASS Cardiovasculars 145733-36-4 TASOSARTAN ADVERSE_EFFECT NEU__Dizziness 145733-36-4 TASOSARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 145733-36-4 TASOSARTAN INDICATION Hypertension 145733-36-4 TASOSARTAN ADVERSE_EFFECT NEU__Headache 145733-36-4 TASOSARTAN ADVERSE_EFFECT LUN__Cough 145733-36-4 TASOSARTAN ADVERSE_EFFECT LUN__Upper Respiratory Tract Infection 140128-74-1 S-1090 MODE_CLASS Enzyme Inhibitor 140128-74-1 S-1090 PRODUCT_CLASS Anti-infectives 140128-74-1 S-1090 MECHANISM Inhibit bacterial cell wall biosynthesis 140128-74-1 S-1090 THERAPEUTIC_CLASS Antibacterials 154776-45-1 S-1090 MECHANISM Inhibit bacterial cell wall biosynthesis 154776-45-1 S-1090 MODE_CLASS Enzyme Inhibitor 154776-45-1 S-1090 THERAPEUTIC_CLASS Antibacterials 154776-45-1 S-1090 PRODUCT_CLASS Anti-infectives 154776-44-0 S-1090 PRODUCT_CLASS Anti-infectives 154776-44-0 S-1090 MODE_CLASS Enzyme Inhibitor 154776-44-0 S-1090 THERAPEUTIC_CLASS Antibacterials 154776-44-0 S-1090 MECHANISM Inhibit bacterial cell wall biosynthesis 139958-16-0 ME-3221 PRODUCT_CLASS Cardiovasculars 139958-16-0 ME-3221 THERAPEUTIC_CLASS Antihypertensive Agents 139958-16-0 ME-3221 INDICATION Hypertension 139958-16-0 ME-3221 MODE_CLASS Receptor Ligand Antagonist, Selective 139958-16-0 ME-3221 MECHANISM Reduce vasoconstriction 207844-01-7 MITIGLINIDE INDICATION Diabetes 207844-01-7 MITIGLINIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 145525-41-3 MITIGLINIDE INDICATION Diabetes 145525-41-3 MITIGLINIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 145375-43-5 MITIGLINIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 145375-43-5 MITIGLINIDE INDICATION Diabetes 145525-40-2 MITIGLINIDE INDICATION Diabetes 145525-40-2 MITIGLINIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 145096-30-6 E-3040 INDICATION Inflammatory Bowel Disease (IBD) 145096-30-6 E-3040 MECHANISM Inhibit eicosanoid biosynthesis 145096-30-6 E-3040 MODE_CLASS Enzyme Inhibitor 145314-18-7 E-3040 MECHANISM Inhibit eicosanoid biosynthesis 145314-18-7 E-3040 MODE_CLASS Enzyme Inhibitor 145314-18-7 E-3040 INDICATION Inflammatory Bowel Disease (IBD) 145216-43-9 FORASARTAN THERAPEUTIC_CLASS Antihypertensive Agents 145216-43-9 FORASARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 145216-43-9 FORASARTAN INDICATION Hypertension 145216-43-9 FORASARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 145216-43-9 FORASARTAN MECHANISM Reduce vasoconstriction 145216-43-9 FORASARTAN PRODUCT_CLASS Cardiovasculars 144912-63-0 EAA-090 MECHANISM Modulate neural transmission 144912-63-0 EAA-090 MODE_CLASS Channel Modulator 144912-63-0 EAA-090 INDICATION Cerebral Ischemia 143491-57-0 EMTRICITABINE THERAPEUTIC_CLASS Antivirals, Systemic 143491-57-0 EMTRICITABINE PRODUCT_CLASS Anti-infectives 143491-57-0 EMTRICITABINE INDICATION Human Immunodeficiency Virus (HIV) Disease 143491-57-0 EMTRICITABINE STRUCTURE_ACTIVITY Viral RT inhibitor 143491-57-0 EMTRICITABINE MODE_CLASS Enzyme substrate mimic 143491-57-0 EMTRICITABINE MECHANISM Inhibit viral DNA synthesis 141725-88-4 CETEFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 141725-88-4 CETEFLOXACIN PRODUCT_CLASS Anti-infectives 141725-88-4 CETEFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 141725-88-4 CETEFLOXACIN THERAPEUTIC_CLASS Antibacterials 141725-88-4 CETEFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 134578-96-4 ONO-4057 MECHANISM Modulate gene transcription 134578-96-4 ONO-4057 MODE_CLASS Receptor Ligand Antagonist, Selective 134578-96-4 ONO-4057 PRODUCT_CLASS Anti-inflammatories 134578-96-4 ONO-4057 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 118968-41-5 ORG-31710 MODE_CLASS Receptor Ligand Antagonist 118968-41-5 ORG-31710 MECHANISM Modulate gene transcription 118968-41-5 ORG-31710 PRODUCT_CLASS Hormones, Endocrine and Metabolic 118968-41-5 ORG-31710 THERAPEUTIC_CLASS Gonadal Hormones 143321-74-8 CP-122288 INDICATION Anxiety Disorders 143321-74-8 CP-122288 THERAPEUTIC_CLASS Antimigraines 143321-74-8 CP-122288 INDICATION Migraine Headache 143321-74-8 CP-122288 THERAPEUTIC_CLASS Antidepressants 143321-74-8 CP-122288 MECHANISM Modulate cerebral vasoconstriction 143321-74-8 CP-122288 THERAPEUTIC_CLASS Sedatives/Hypnotics 143321-74-8 CP-122288 INDICATION Depression 143321-74-8 CP-122288 PRODUCT_CLASS Central Nervous System (CNS) 143484-82-6 AZALANSTAT INDICATION Hypolipidemia 143393-27-5 AZALANSTAT INDICATION Hypolipidemia 144264-47-1 BMS-180448 INDICATION Myocardial Ischemia 144264-47-1 BMS-180448 MECHANISM Modulate channel gating 144264-47-1 BMS-180448 MODE_CLASS Channel enhancer /opener 144264-47-1 BMS-180448 MECHANISM Reduce muscle contractile force 144264-47-1 BMS-180448 PRODUCT_CLASS Cardiovasculars 144264-47-1 BMS-180448 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 144264-47-1 BMS-180448 MODE_CLASS Channel Modulator 144301-94-0 BMS-180448 MODE_CLASS Channel Modulator 144301-94-0 BMS-180448 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 144301-94-0 BMS-180448 MODE_CLASS Channel enhancer /opener 144301-94-0 BMS-180448 MECHANISM Reduce muscle contractile force 144301-94-0 BMS-180448 PRODUCT_CLASS Cardiovasculars 144301-94-0 BMS-180448 INDICATION Myocardial Ischemia 144301-94-0 BMS-180448 MECHANISM Modulate channel gating 146623-69-0 SAPRISARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 146623-69-0 SAPRISARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 146623-69-0 SAPRISARTAN PRODUCT_CLASS Cardiovasculars 146623-69-0 SAPRISARTAN INDICATION Hypertension 146623-69-0 SAPRISARTAN THERAPEUTIC_CLASS Antihypertensive Agents 146623-69-0 SAPRISARTAN MECHANISM Reduce vasoconstriction 146613-90-3 SAPRISARTAN MECHANISM Reduce vasoconstriction 146613-90-3 SAPRISARTAN INDICATION Hypertension 146613-90-3 SAPRISARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 146613-90-3 SAPRISARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 146613-90-3 SAPRISARTAN PRODUCT_CLASS Cardiovasculars 146613-90-3 SAPRISARTAN THERAPEUTIC_CLASS Antihypertensive Agents 96576-24-8 ETHOXY-IDAZOXAN MECHANISM Modulate G-protein coupled signal transduction 96576-25-9 ETHOXY-IDAZOXAN MECHANISM Modulate G-protein coupled signal transduction 135416-43-2 IOMETOPANE MODE_CLASS Solute transporter inhibitor 135416-43-2 IOMETOPANE MECHANISM Prolong/enhance neural transmission 136794-86-0 IOMETOPANE MODE_CLASS Solute transporter inhibitor 136794-86-0 IOMETOPANE MECHANISM Prolong/enhance neural transmission 144412-49-7 LAMIFIBAN MECHANISM Inhibit platelet aggregation 144412-49-7 LAMIFIBAN PRODUCT_CLASS Cardiovasculars 144412-49-7 LAMIFIBAN INDICATION Angina Pectoris 144412-49-7 LAMIFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 144412-49-7 LAMIFIBAN THERAPEUTIC_CLASS Antianginals 57695-04-2 WR-6026 INDICATION Leishmaniasis 57695-04-2 WR-6026 INDICATION Myocardial Ischemia 5330-29-0 WR-6026 INDICATION Myocardial Ischemia 5330-29-0 WR-6026 INDICATION Leishmaniasis 138199-64-1 L-367073 MECHANISM Inhibit platelet aggregation 138199-64-1 L-367073 MODE_CLASS Receptor Ligand Antagonist, Selective 114030-44-3 DEXPEMEDOLAC PRODUCT_CLASS Anti-inflammatories 114030-44-3 DEXPEMEDOLAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 15639-50-6 SAFINGOL INDICATION Psoriasis 15639-50-6 SAFINGOL INDICATION Eczema Herpeticum 139755-79-6 SAFINGOL INDICATION Psoriasis 139755-79-6 SAFINGOL INDICATION Eczema Herpeticum 106-60-5 DELTA-AMINOLEVULINIC ACID INDICATION Actinic Keratosis 7729-71-7 DELTA-AMINOLEVULINIC ACID INDICATION Actinic Keratosis 60556-69-6 DELTA-AMINOLEVULINIC ACID INDICATION Actinic Keratosis 143881-08-7 FK-352 THERAPEUTIC_CLASS Antidepressants 143881-08-7 FK-352 INDICATION Depression 143881-08-7 FK-352 INDICATION Hypertension 143881-08-7 FK-352 PRODUCT_CLASS Central Nervous System (CNS) 143881-08-7 FK-352 THERAPEUTIC_CLASS Antihypertensive Agents 143881-08-7 FK-352 PRODUCT_CLASS Cardiovasculars 146537-07-7 WIN-33377 STRUCTURE_ACTIVITY DNA intercalator 127966-78-3 Z-300 INDICATION Ulcer 128289-57-6 Z-300 INDICATION Ulcer 147526-32-7 NISVASTATIN MECHANISM Inhibit cholesterol biosynthesis 147526-32-7 NISVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 147526-32-7 NISVASTATIN MODE_CLASS Enzyme Inhibitor 147526-32-7 NISVASTATIN INDICATION Hypolipidemia 141750-63-2 NISVASTATIN MODE_CLASS Enzyme Inhibitor 141750-63-2 NISVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 141750-63-2 NISVASTATIN INDICATION Hypolipidemia 141750-63-2 NISVASTATIN MECHANISM Inhibit cholesterol biosynthesis 147511-69-1 NISVASTATIN MECHANISM Inhibit cholesterol biosynthesis 147511-69-1 NISVASTATIN MODE_CLASS Enzyme Inhibitor 147511-69-1 NISVASTATIN INDICATION Hypolipidemia 147511-69-1 NISVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 192565-91-6 NISVASTATIN MECHANISM Inhibit cholesterol biosynthesis 192565-91-6 NISVASTATIN INDICATION Hypolipidemia 192565-91-6 NISVASTATIN MODE_CLASS Enzyme Inhibitor 192565-91-6 NISVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 147403-03-0 TAK-536 INDICATION Hypertension 147403-03-0 TAK-536 MECHANISM Modulate G-protein coupled signal transduction 147403-03-0 TAK-536 INDICATION Glaucoma 147403-03-0 TAK-536 PRODUCT_CLASS Cardiovasculars 147403-03-0 TAK-536 THERAPEUTIC_CLASS Antihypertensive Agents 62435-42-1 PERFOSFAMIDE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 39800-16-3 PERFOSFAMIDE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 116049-53-7 CGP-40116 MECHANISM Modulate neural transmission 116049-53-7 CGP-40116 MODE_CLASS Channel Modulator 137424-81-8 CGP-40116 MECHANISM Modulate neural transmission 137424-81-8 CGP-40116 MODE_CLASS Channel Modulator 116942-30-4 349U85.HCL MODE_CLASS Enzyme Inhibitor 116942-30-4 349U85.HCL MECHANISM Enhance kinase mediated signal transduction 148504-51-2 RIPISARTAN PRODUCT_CLASS Cardiovasculars 148504-51-2 RIPISARTAN THERAPEUTIC_CLASS Antihypertensive Agents 148504-51-2 RIPISARTAN MECHANISM Reduce vasoconstriction 148504-51-2 RIPISARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 148504-51-2 RIPISARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 136982-36-0 CP-99994 INDICATION Nausea / Vomiting 136983-42-1 CP-99994 INDICATION Nausea / Vomiting 139241-77-3 CP-99994 INDICATION Nausea / Vomiting 139241-76-2 CP-99994 INDICATION Nausea / Vomiting 139190-12-8 CP-99994 INDICATION Nausea / Vomiting 148260-92-8 SCH-48461 MECHANISM Inhibit bacterial cell wall biosynthesis 148260-92-8 SCH-48461 MODE_CLASS Enzyme Inhibitor 148260-92-8 SCH-48461 INDICATION Hyperlipidemia 148260-92-8 SCH-48461 STRUCTURE_ACTIVITY Cholesterol (intestinal) absorption inhibitor 143413-49-4 ALX40-4C INDICATION Myocardial Ischemia 131677-86-6 BTS-67582 INDICATION Diabetes 131678-76-7 BTS-67582 INDICATION Diabetes 135381-77-0 FLEZELASTINE THERAPEUTIC_CLASS Antiarrhythmic Agents 135381-77-0 FLEZELASTINE INDICATION Cardiac Arrhythmias 135381-77-0 FLEZELASTINE MECHANISM Inhibit eicosanoid biosynthesis 135381-77-0 FLEZELASTINE MODE_CLASS Enzyme Inhibitor 135381-77-0 FLEZELASTINE PRODUCT_CLASS Cardiovasculars 139404-48-1 TIOTROPIUM BROMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 130370-60-4 BATIMASTAT PRODUCT_CLASS Anti-cancers 130370-60-4 BATIMASTAT KNOWN_TOXICITY Cardiovascular Toxicity 130370-60-4 BATIMASTAT ADVERSE_EFFECT CVS_2_Postural Hypotension 130370-60-4 BATIMASTAT ADVERSE_EFFECT XXX_1_Fever 130370-60-4 BATIMASTAT ADVERSE_EFFECT XXX_2_Edema 130370-60-4 BATIMASTAT INDICATION Squamous Cell Carcinoma 130370-60-4 BATIMASTAT INDICATION Ovarian Cancer / Carcinoma of the Ovary 130370-60-4 BATIMASTAT TISSUE_TOXICITY Death 130370-60-4 BATIMASTAT MECHANISM Interferes with Cell-Cell signaling 130370-60-4 BATIMASTAT THERAPEUTIC_CLASS Immunosuppressants 130370-60-4 BATIMASTAT ADVERSE_EFFECT CVS_2_Bradycardia 130370-60-4 BATIMASTAT ADVERSE_EFFECT XXX_2_Pyrexia 130370-60-4 BATIMASTAT INDICATION Lung Cancer / Carcinoma of the Lung 130370-60-4 BATIMASTAT INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 130370-60-4 BATIMASTAT TISSUE_TOXICITY Hypotension 130370-60-4 BATIMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 130370-60-4 BATIMASTAT INDICATION Breast Cancer / Carcinoma of the Breast 130370-60-4 BATIMASTAT INDICATION Liver Cancer 130370-60-4 BATIMASTAT ADVERSE_EFFECT GIS_1_Nausea 130370-60-4 BATIMASTAT ADVERSE_EFFECT GIS_1_Vomiting 130370-60-4 BATIMASTAT ADVERSE_EFFECT GIS_1_Diarrhea 130370-60-4 BATIMASTAT ADVERSE_EFFECT XXX_3_Death 130370-60-4 BATIMASTAT PRODUCT_CLASS Immune Response / Immunomodulators 130370-60-4 BATIMASTAT INDICATION Melanoma 130370-60-4 BATIMASTAT INDICATION Prostatic Cancer / Carcinoma of the Prostate 130370-60-4 BATIMASTAT INDICATION Neoplasm / Cancer / Tumor 130370-60-4 BATIMASTAT ADVERSE_EFFECT LUN_3_Pulmonary Embolism 130370-60-4 BATIMASTAT ADVERSE_EFFECT GIS_1_Constipation 130370-60-4 BATIMASTAT ADVERSE_EFFECT XXX_1_Fatigue 130370-60-4 BATIMASTAT ADVERSE_EFFECT GIS_1_Abdominal Pain 130370-60-4 BATIMASTAT MODE_CLASS Enzyme Inhibitor 130370-60-4 BATIMASTAT KNOWN_TOXICITY Miscellaneous 130370-60-4 BATIMASTAT THERAPEUTIC_CLASS Antineoplastics 130370-60-4 BATIMASTAT ADVERSE_EFFECT CVS_3_Hypotension 130370-60-4 BATIMASTAT INDICATION Arthritis 130370-60-4 BATIMASTAT ADVERSE_EFFECT GIS_3_Bowel Obstruction 130464-84-5 BATIMASTAT ADVERSE_EFFECT XXX_2_Edema 130464-84-5 BATIMASTAT INDICATION Arthritis 130464-84-5 BATIMASTAT PRODUCT_CLASS Anti-cancers 130464-84-5 BATIMASTAT KNOWN_TOXICITY Cardiovascular Toxicity 130464-84-5 BATIMASTAT ADVERSE_EFFECT CVS_2_Postural Hypotension 130464-84-5 BATIMASTAT ADVERSE_EFFECT CVS_3_Hypotension 130464-84-5 BATIMASTAT INDICATION Squamous Cell Carcinoma 130464-84-5 BATIMASTAT INDICATION Ovarian Cancer / Carcinoma of the Ovary 130464-84-5 BATIMASTAT TISSUE_TOXICITY Death 130464-84-5 BATIMASTAT MECHANISM Interferes with Cell-Cell signaling 130464-84-5 BATIMASTAT ADVERSE_EFFECT LUN_3_Pulmonary Embolism 130464-84-5 BATIMASTAT ADVERSE_EFFECT CVS_2_Bradycardia 130464-84-5 BATIMASTAT ADVERSE_EFFECT XXX_2_Pyrexia 130464-84-5 BATIMASTAT INDICATION Neoplasm / Cancer / Tumor 130464-84-5 BATIMASTAT ADVERSE_EFFECT GIS_3_Bowel Obstruction 130464-84-5 BATIMASTAT INDICATION Lung Cancer / Carcinoma of the Lung 130464-84-5 BATIMASTAT INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 130464-84-5 BATIMASTAT TISSUE_TOXICITY Hypotension 130464-84-5 BATIMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 130464-84-5 BATIMASTAT THERAPEUTIC_CLASS Immunosuppressants 130464-84-5 BATIMASTAT ADVERSE_EFFECT XXX_1_Fever 130464-84-5 BATIMASTAT INDICATION Breast Cancer / Carcinoma of the Breast 130464-84-5 BATIMASTAT INDICATION Liver Cancer 130464-84-5 BATIMASTAT ADVERSE_EFFECT GIS_1_Nausea 130464-84-5 BATIMASTAT ADVERSE_EFFECT GIS_1_Vomiting 130464-84-5 BATIMASTAT ADVERSE_EFFECT GIS_1_Constipation 130464-84-5 BATIMASTAT ADVERSE_EFFECT GIS_1_Diarrhea 130464-84-5 BATIMASTAT ADVERSE_EFFECT XXX_3_Death 130464-84-5 BATIMASTAT PRODUCT_CLASS Immune Response / Immunomodulators 130464-84-5 BATIMASTAT THERAPEUTIC_CLASS Antineoplastics 130464-84-5 BATIMASTAT KNOWN_TOXICITY Miscellaneous 130464-84-5 BATIMASTAT MODE_CLASS Enzyme Inhibitor 130464-84-5 BATIMASTAT ADVERSE_EFFECT GIS_1_Abdominal Pain 130464-84-5 BATIMASTAT ADVERSE_EFFECT XXX_1_Fatigue 130464-84-5 BATIMASTAT INDICATION Melanoma 130464-84-5 BATIMASTAT INDICATION Prostatic Cancer / Carcinoma of the Prostate 141374-81-4 TARAZEPIDE MODE_CLASS Receptor Ligand Antagonist 141374-81-4 TARAZEPIDE MECHANISM Modulate G-protein coupled signal transduction 9004-53-9 ICODEXTRIN INDICATION Renal Failure / Kidney Failure 133432-71-0 PELDESINE THERAPEUTIC_CLASS Immunosuppressants 133432-71-0 PELDESINE INDICATION Psoriasis 133432-71-0 PELDESINE PRODUCT_CLASS Immune Response / Immunomodulators 133432-71-0 PELDESINE INDICATION Arthritis 133432-71-0 PELDESINE INDICATION Multiple Sclerosis (MS) 202075-96-5 SDZ-MAR-327 MECHANISM Modulate G-protein coupled signal transduction 201164-41-2 SDZ-MAR-327 MECHANISM Modulate G-protein coupled signal transduction 201164-40-1 SDZ-MAR-327 MECHANISM Modulate G-protein coupled signal transduction 139481-59-7 CANDESARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 139481-59-7 CANDESARTAN PRODUCT_CLASS Cardiovasculars 139481-59-7 CANDESARTAN ADVERSE_EFFECT CVS_3_Hypotension 139481-59-7 CANDESARTAN ADVERSE_EFFECT NEU_2_Dizziness 139481-59-7 CANDESARTAN ADVERSE_EFFECT BBM_3_Leukopenia 139481-59-7 CANDESARTAN ADVERSE_EFFECT EMB_3_Oligohydramnios 139481-59-7 CANDESARTAN KNOWN_TOXICITY Cardiovascular Toxicity 139481-59-7 CANDESARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 139481-59-7 CANDESARTAN TA_LEVEL_1 Cardiovascular 139481-59-7 CANDESARTAN MECH_LEVEL_3 angiotensin receptor AT1 139481-59-7 CANDESARTAN ADVERSE_EFFECT CVS_3_Tachycardia 139481-59-7 CANDESARTAN ADVERSE_EFFECT NEU_2_Headache 139481-59-7 CANDESARTAN ADVERSE_EFFECT XXX_2_Peripheral Edema 139481-59-7 CANDESARTAN ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 139481-59-7 CANDESARTAN ZERO_CLASS N 139481-59-7 CANDESARTAN TA_LEVEL_3 Diuretic 139481-59-7 CANDESARTAN ADVERSE_EFFECT LUN_2_Cough 139481-59-7 CANDESARTAN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 139481-59-7 CANDESARTAN ADVERSE_EFFECT EMB_3_Fetal Renal Damage 139481-59-7 CANDESARTAN THERAPEUTIC_CLASS Antihypertensive Agents 139481-59-7 CANDESARTAN MECH_LEVEL_2 Diuretic 139481-59-7 CANDESARTAN INDICATION Hypertension 139481-59-7 CANDESARTAN MECHANISM Reduce vasoconstriction 139481-59-7 CANDESARTAN ADVERSE_EFFECT KID_3_Hyperuricemia 139481-59-7 CANDESARTAN ADVERSE_EFFECT BBM_3_Agranulocytosis 139481-59-7 CANDESARTAN ADVERSE_EFFECT MSK_2_Back Pain 139481-59-7 CANDESARTAN TISSUE_TOXICITY Hypotension 139481-59-7 CANDESARTAN ACTIVITY_CLASS RAAS inhibitor 139481-59-7 CANDESARTAN MESH_LEVEL_1 Heterocyclic Compounds 139481-59-7 CANDESARTAN TA_LEVEL_2 Hypertension 139481-59-7 CANDESARTAN MESH_LEVEL_3 Tetrazoles 139481-59-7 CANDESARTAN MECH_LEVEL_1 Vasorelaxation 139481-59-7 CANDESARTAN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 136042-19-8 FK-739 PRODUCT_CLASS Cardiovasculars 136042-19-8 FK-739 MODE_CLASS Receptor Ligand Antagonist, Selective 136042-19-8 FK-739 THERAPEUTIC_CLASS Antihypertensive Agents 136042-19-8 FK-739 MECHANISM Reduce vasoconstriction 136042-19-8 FK-739 INDICATION Hypertension 125602-71-3 BETOTASTINE BESILATE MECHANISM Modulate G-protein coupled signal transduction 125602-71-3 BETOTASTINE BESILATE MODE_CLASS Receptor Ligand Antagonist, Selective 125602-71-3 BETOTASTINE BESILATE INDICATION Viral Rhinitis / Common Cold 190786-44-8 BETOTASTINE BESILATE MODE_CLASS Receptor Ligand Antagonist, Selective 190786-44-8 BETOTASTINE BESILATE MECHANISM Modulate G-protein coupled signal transduction 190786-44-8 BETOTASTINE BESILATE INDICATION Viral Rhinitis / Common Cold 190786-43-7 BETOTASTINE BESILATE INDICATION Viral Rhinitis / Common Cold 190786-43-7 BETOTASTINE BESILATE MECHANISM Modulate G-protein coupled signal transduction 190786-43-7 BETOTASTINE BESILATE MODE_CLASS Receptor Ligand Antagonist, Selective 113617-63-3 ORBIFLOXACIN THERAPEUTIC_CLASS Antibacterials 113617-63-3 ORBIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 113617-63-3 ORBIFLOXACIN PRODUCT_CLASS Anti-infectives 113617-63-3 ORBIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 113617-63-3 ORBIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 136087-85-9 SNK-860 PRODUCT_CLASS Other Human Uses 136087-85-9 SNK-860 MECHANISM Inhibit precursor synthesis 136087-85-9 SNK-860 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 136087-85-9 SNK-860 INDICATION Diabetic Neuropathy 136087-85-9 SNK-860 MODE_CLASS Enzyme Inhibitor 118803-58-0 SNK-860 MODE_CLASS Enzyme Inhibitor 118803-58-0 SNK-860 PRODUCT_CLASS Other Human Uses 118803-58-0 SNK-860 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 118803-58-0 SNK-860 MECHANISM Inhibit precursor synthesis 118803-58-0 SNK-860 INDICATION Diabetic Neuropathy 105300-43-4 SNK-860 MODE_CLASS Enzyme Inhibitor 105300-43-4 SNK-860 PRODUCT_CLASS Other Human Uses 105300-43-4 SNK-860 INDICATION Diabetic Neuropathy 105300-43-4 SNK-860 MECHANISM Inhibit precursor synthesis 105300-43-4 SNK-860 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 143257-98-1 LERISETRON INDICATION Nausea / Vomiting 143257-98-1 LERISETRON MECHANISM Block neural transmission 143257-98-1 LERISETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 143257-98-1 LERISETRON THERAPEUTIC_CLASS Antiemetics 143257-98-1 LERISETRON MODE_CLASS Channel Blocker, selective 143257-98-1 LERISETRON PRODUCT_CLASS Gastrointestinal System 148016-81-3 S-4661 PRODUCT_CLASS Anti-infectives 148016-81-3 S-4661 MODE_CLASS Enzyme Inhibitor 148016-81-3 S-4661 MECHANISM Inhibit bacterial cell wall biosynthesis 148016-81-3 S-4661 THERAPEUTIC_CLASS Antibacterials 134208-17-6 MAZAPERTINE MECHANISM Modulate G-protein coupled signal transduction 134208-18-7 MAZAPERTINE MECHANISM Modulate G-protein coupled signal transduction 151406-07-4 YM-358 PRODUCT_CLASS Cardiovasculars 151406-07-4 YM-358 THERAPEUTIC_CLASS Antihypertensive Agents 151406-07-4 YM-358 MECHANISM Reduce vasoconstriction 151406-07-4 YM-358 INDICATION Hypertension 151406-07-4 YM-358 MODE_CLASS Receptor Ligand Antagonist, Selective 148869-05-0 YM-511 STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 148869-05-0 YM-511 MECHANISM Inhibit steroid biosynthesis/ metabolism 148869-05-0 YM-511 MODE_CLASS Enzyme Inhibitor 142880-36-2 ILOMASTAT STRUCTURE_ACTIVITY Protease (MMP) inhibitor 142880-36-2 ILOMASTAT INDICATION Corneal Wound / Trauma 148553-50-8 PREGABALIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 148553-50-8 PREGABALIN MECHANISM Reduce muscle contractile force 148553-50-8 PREGABALIN PRODUCT_CLASS Central Nervous System (CNS) 148553-50-8 PREGABALIN MODE_CLASS Channel Modulator 148553-50-8 PREGABALIN STRUCTURE_ACTIVITY Reduce glutamate release 149028-28-4 CI-1002 MODE_CLASS Enzyme Inhibitor 141799-76-0 E-5324 MODE_CLASS Enzyme Inhibitor 141799-76-0 E-5324 MECHANISM Inhibit steroid biosynthesis/ metabolism 141799-76-0 E-5324 INDICATION Hypolipidemia 153420-96-3 ATIBEPRONE INDICATION Parkinson's Disease 148396-36-5 FRADAFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 148396-36-5 FRADAFIBAN MECHANISM Inhibit platelet aggregation 158861-67-7 PRALMORELIN INDICATION Osteoporosis 141993-70-6 ELDACIMIBE MECHANISM Inhibit steroid biosynthesis/ metabolism 141993-70-6 ELDACIMIBE INDICATION Atherosclerosis 141993-70-6 ELDACIMIBE INDICATION Hypolipidemia 141993-70-6 ELDACIMIBE INDICATION Hyperlipidemia 141993-70-6 ELDACIMIBE PRODUCT_CLASS Cardiovasculars 141993-70-6 ELDACIMIBE MODE_CLASS Enzyme Inhibitor 141993-70-6 ELDACIMIBE THERAPEUTIC_CLASS Hypolipidemic Agents 131069-91-5 GADOVERSETAMIDE INDICATION Contrasting Agent 131069-91-5 GADOVERSETAMIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 129009-83-2 GADOVERSETAMIDE INDICATION Contrasting Agent 129009-83-2 GADOVERSETAMIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 149494-37-1 EBALZOTAN PRODUCT_CLASS Central Nervous System (CNS) 149494-37-1 EBALZOTAN MECHANISM Modulate neural transmission 149494-37-1 EBALZOTAN THERAPEUTIC_CLASS Sedatives/Hypnotics 149494-37-1 EBALZOTAN INDICATION Anxiety Disorders 149494-37-1 EBALZOTAN THERAPEUTIC_CLASS Antidepressants 149494-37-1 EBALZOTAN INDICATION Depression 150779-71-8 SDZ-LAP-977 INDICATION Actinic Keratosis 150779-71-8 SDZ-LAP-977 INDICATION Psoriasis 150779-71-8 SDZ-LAP-977 MODE_CLASS Enzyme Inhibitor 150779-71-8 SDZ-LAP-977 MECHANISM Inhibit kinase mediated signal transduction 139987-54-5 1843U89 STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 139987-54-5 1843U89 MECHANISM Inhibit precursor synthesis 139987-54-5 1843U89 MODE_CLASS Enzyme Inhibitor 142340-99-6 ADEFOVIR DIPIVOXIL INDICATION Myocardial Ischemia 149882-10-0 LURTOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 149882-10-0 LURTOTECAN THERAPEUTIC_CLASS Antivirals, Systemic 149882-10-0 LURTOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 149882-10-0 LURTOTECAN MODE_CLASS Enzyme Inhibitor 149882-10-0 LURTOTECAN PRODUCT_CLASS Anti-infectives 155773-58-3 LURTOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 155773-58-3 LURTOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 155773-58-3 LURTOTECAN THERAPEUTIC_CLASS Antivirals, Systemic 155773-58-3 LURTOTECAN MODE_CLASS Enzyme Inhibitor 155773-58-3 LURTOTECAN PRODUCT_CLASS Anti-infectives 138069-52-0 UKRAIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 138069-52-0 UKRAIN MECHANISM Inhibit microtubule dependent glucose uptake 86639-82-9 UKRAIN MECHANISM Inhibit microtubule dependent glucose uptake 86639-82-9 UKRAIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 121346-33-6 SR-33805A MECHANISM Modulate channel gating 121346-33-6 SR-33805A PRODUCT_CLASS Cardiovasculars 121346-33-6 SR-33805A THERAPEUTIC_CLASS Antihypertensive Agents 121346-33-6 SR-33805A MODE_CLASS Channel Modulator 121346-33-6 SR-33805A INDICATION Hypertension 167933-07-5 FLIBANSERIN PRODUCT_CLASS Central Nervous System (CNS) 167933-07-5 FLIBANSERIN MODE_CLASS Receptor Ligand Antagonist 167933-07-5 FLIBANSERIN THERAPEUTIC_CLASS Antidepressants 167933-07-5 FLIBANSERIN INDICATION Depression 167933-07-5 FLIBANSERIN MECHANISM Modulate G-protein coupled signal transduction 167933-07-5 FLIBANSERIN MECHANISM Modulate neural transmission 131986-45-3 XANOMELINE MECHANISM Modulate G-protein coupled signal transduction 131986-45-3 XANOMELINE INDICATION Alzheimer's Disease 131986-45-3 XANOMELINE MODE_CLASS Receptor Agonist 141064-23-5 XANOMELINE MODE_CLASS Receptor Agonist 141064-23-5 XANOMELINE MECHANISM Modulate G-protein coupled signal transduction 141064-23-5 XANOMELINE INDICATION Alzheimer's Disease 152854-19-5 XANOMELINE MODE_CLASS Receptor Agonist 152854-19-5 XANOMELINE MECHANISM Modulate G-protein coupled signal transduction 152854-19-5 XANOMELINE INDICATION Alzheimer's Disease 144035-83-6 PICLAMILAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 144035-83-6 PICLAMILAST ADVERSE_EFFECT DNA_2_Carcinogenicity 144035-83-6 PICLAMILAST MECHANISM Enhance kinase mediated signal transduction 144035-83-6 PICLAMILAST ACTIVITY_CLASS Phosphodiesterase inhibitor 144035-83-6 PICLAMILAST MECHANISM Enhance kinase mediated signal transduction 144035-83-6 PICLAMILAST PRODUCT_CLASS Respiratory System 144035-83-6 PICLAMILAST THERAPEUTIC_CLASS Immunosuppressants 144035-83-6 PICLAMILAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 144035-83-6 PICLAMILAST STRUCTURE_ACTIVITY PDE4 inhibitor 144035-83-6 PICLAMILAST ADVERSE_EFFECT XXX_2_Nasal Irritation 144035-83-6 PICLAMILAST INDICATION Inflammation 144035-83-6 PICLAMILAST INDICATION Arthritis 144035-83-6 PICLAMILAST PRODUCT_CLASS Immune Response / Immunomodulators 144035-83-6 PICLAMILAST KNOWN_TOXICITY Carcinogenicity 144035-83-6 PICLAMILAST ADVERSE_EFFECT GIS_1_Gastric Acid Hypersecretion 144035-83-6 PICLAMILAST ADVERSE_EFFECT GIS_1_Nausea 144035-83-6 PICLAMILAST ADVERSE_EFFECT OCU_2_Eye Disorder 144035-83-6 PICLAMILAST MODE_CLASS Enzyme Inhibitor 144035-83-6 PICLAMILAST PRODUCT_CLASS Anti-inflammatories 144035-83-6 PICLAMILAST MODE_CLASS Enzyme Inhibitor 144035-83-6 PICLAMILAST ADVERSE_EFFECT GIS_1_Emesis 144035-83-6 PICLAMILAST INDICATION Asthma 144035-83-6 PICLAMILAST TISSUE_TOXICITY Carcinogenicity 144285-03-0 PICLAMILAST PRODUCT_CLASS Immune Response / Immunomodulators 144285-03-0 PICLAMILAST THERAPEUTIC_CLASS Immunosuppressants 144285-03-0 PICLAMILAST MECHANISM Enhance kinase mediated signal transduction 144285-03-0 PICLAMILAST MECHANISM Enhance kinase mediated signal transduction 144285-03-0 PICLAMILAST ADVERSE_EFFECT DNA_2_Carcinogenicity 144285-03-0 PICLAMILAST INDICATION Asthma 144285-03-0 PICLAMILAST ADVERSE_EFFECT GIS_1_Emesis 144285-03-0 PICLAMILAST MODE_CLASS Enzyme Inhibitor 144285-03-0 PICLAMILAST PRODUCT_CLASS Respiratory System 144285-03-0 PICLAMILAST PRODUCT_CLASS Anti-inflammatories 144285-03-0 PICLAMILAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 144285-03-0 PICLAMILAST MODE_CLASS Enzyme Inhibitor 144285-03-0 PICLAMILAST ADVERSE_EFFECT OCU_2_Eye Disorder 144285-03-0 PICLAMILAST ADVERSE_EFFECT GIS_1_Nausea 144285-03-0 PICLAMILAST ADVERSE_EFFECT GIS_1_Gastric Acid Hypersecretion 144285-03-0 PICLAMILAST TISSUE_TOXICITY Carcinogenicity 144285-03-0 PICLAMILAST KNOWN_TOXICITY Carcinogenicity 144285-03-0 PICLAMILAST INDICATION Arthritis 144285-03-0 PICLAMILAST INDICATION Inflammation 144285-03-0 PICLAMILAST ADVERSE_EFFECT XXX_2_Nasal Irritation 144285-03-0 PICLAMILAST STRUCTURE_ACTIVITY PDE4 inhibitor 144285-03-0 PICLAMILAST ACTIVITY_CLASS Phosphodiesterase inhibitor 144285-03-0 PICLAMILAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 136467-00-0 CBT-101 INDICATION Glaucoma 136467-06-6 CBT-101 INDICATION Glaucoma 171335-80-1 DX-8951 STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 129321-78-4 DV-7751A MODE_CLASS Enzyme Inhibitor, selective 129321-78-4 DV-7751A PRODUCT_CLASS Anti-infectives 129321-78-4 DV-7751A STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 129321-78-4 DV-7751A MECHANISM Inhibit bacterial DNA synthesis 129321-78-4 DV-7751A THERAPEUTIC_CLASS Antibacterials 151390-79-3 DV-7751A MODE_CLASS Enzyme Inhibitor, selective 151390-79-3 DV-7751A THERAPEUTIC_CLASS Antibacterials 151390-79-3 DV-7751A MECHANISM Inhibit bacterial DNA synthesis 151390-79-3 DV-7751A STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 151390-79-3 DV-7751A PRODUCT_CLASS Anti-infectives 140637-82-7 DA-125 STRUCTURE_ACTIVITY DNA intercalator, anthracycline 140637-82-7 DA-125 PRODUCT_CLASS Anti-cancers 140637-82-7 DA-125 THERAPEUTIC_CLASS Antineoplastics 195612-80-7 DA-125 THERAPEUTIC_CLASS Antineoplastics 195612-80-7 DA-125 PRODUCT_CLASS Anti-cancers 195612-80-7 DA-125 STRUCTURE_ACTIVITY DNA intercalator, anthracycline 148344-24-5 RG-201 INDICATION Myocardial Ischemia 150443-71-3 NICANARTINE THERAPEUTIC_CLASS Hypolipidemic Agents 150443-71-3 NICANARTINE PRODUCT_CLASS Cardiovasculars 150443-71-3 NICANARTINE INDICATION Atherosclerosis 150443-71-3 NICANARTINE INDICATION Hypolipidemia 138794-73-7 SARDOMOZIDE MODE_CLASS Enzyme Inhibitor 149400-88-4 SARDOMOZIDE MODE_CLASS Enzyme Inhibitor 147193-59-7 AS-3201 MODE_CLASS Enzyme Inhibitor 147193-59-7 AS-3201 MECHANISM Inhibit precursor synthesis 147193-59-7 AS-3201 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 147193-59-7 AS-3201 INDICATION Diabetic Neuropathy 147193-59-7 AS-3201 PRODUCT_CLASS Other Human Uses 147254-65-7 AS-3201 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 147254-65-7 AS-3201 MODE_CLASS Enzyme Inhibitor 147254-65-7 AS-3201 PRODUCT_CLASS Other Human Uses 147254-65-7 AS-3201 INDICATION Diabetic Neuropathy 147254-65-7 AS-3201 MECHANISM Inhibit precursor synthesis 144141-97-9 A-80987 INDICATION Myocardial Ischemia 149503-79-7 LEFRADAFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 149503-79-7 LEFRADAFIBAN MECHANISM Inhibit platelet aggregation 155204-81-2 DX-9065A MECHANISM Inhibit platelet aggregation 155204-81-2 DX-9065A MODE_CLASS Enzyme Inhibitor 149727-64-0 XEMILOFIBAN MECHANISM Inhibit platelet aggregation 149727-64-0 XEMILOFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 149820-74-6 XEMILOFIBAN MECHANISM Inhibit platelet aggregation 149820-74-6 XEMILOFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 156586-91-3 XEMILOFIBAN MECHANISM Inhibit platelet aggregation 156586-91-3 XEMILOFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 142589-10-4 MDL-100240 MECHANISM Modulate G-protein coupled signal transduction 142589-10-4 MDL-100240 INDICATION Hypertension 142589-10-4 MDL-100240 MECHANISM Reduce vasoconstriction 142589-10-4 MDL-100240 MODE_CLASS Enzyme Inhibitor 142589-10-4 MDL-100240 THERAPEUTIC_CLASS Antihypertensive Agents 142589-10-4 MDL-100240 PRODUCT_CLASS Cardiovasculars 151328-90-4 TO-195 INDICATION Nephritis 151328-90-4 TO-195 MODE_CLASS Enzyme Inhibitor 151837-55-7 TO-195 INDICATION Nephritis 151837-55-7 TO-195 MODE_CLASS Enzyme Inhibitor 135525-78-9 L-697661 INDICATION Myocardial Ischemia 135525-77-8 L-697639 INDICATION Myocardial Ischemia 122957-06-6 MODIPAFANT PRODUCT_CLASS Respiratory System 122957-06-6 MODIPAFANT THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 122957-06-6 MODIPAFANT INDICATION Asthma 122956-68-7 MODIPAFANT THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 122956-68-7 MODIPAFANT PRODUCT_CLASS Respiratory System 122956-68-7 MODIPAFANT INDICATION Asthma 135239-65-5 RP-64477 INDICATION Hypolipidemia 135239-65-5 RP-64477 MODE_CLASS Enzyme Inhibitor 135239-65-5 RP-64477 MECHANISM Inhibit steroid biosynthesis/ metabolism 86-34-0 PHENSUXIMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 86-34-0 PHENSUXIMIDE MODE_CLASS Solute transporter inhibitor 86-34-0 PHENSUXIMIDE MECHANISM Prolong/enhance neural transmission 86-34-0 PHENSUXIMIDE INDICATION Epilepsy 86-34-0 PHENSUXIMIDE PRODUCT_CLASS Central Nervous System (CNS) 135467-18-4 CEFDALOXIME PENTEXIL TOSILATE PRODUCT_CLASS Anti-infectives 135467-18-4 CEFDALOXIME PENTEXIL TOSILATE MODE_CLASS Enzyme Inhibitor 135467-18-4 CEFDALOXIME PENTEXIL TOSILATE MECHANISM Inhibit bacterial cell wall biosynthesis 135467-18-4 CEFDALOXIME PENTEXIL TOSILATE THERAPEUTIC_CLASS Antibacterials 135467-21-9 CEFDALOXIME PENTEXIL TOSILATE PRODUCT_CLASS Anti-infectives 135467-21-9 CEFDALOXIME PENTEXIL TOSILATE THERAPEUTIC_CLASS Antibacterials 135467-21-9 CEFDALOXIME PENTEXIL TOSILATE MECHANISM Inhibit bacterial cell wall biosynthesis 135467-21-9 CEFDALOXIME PENTEXIL TOSILATE MODE_CLASS Enzyme Inhibitor 125276-50-8 CEFDALOXIME PENTEXIL TOSILATE PRODUCT_CLASS Anti-infectives 125276-50-8 CEFDALOXIME PENTEXIL TOSILATE MODE_CLASS Enzyme Inhibitor 125276-50-8 CEFDALOXIME PENTEXIL TOSILATE MECHANISM Inhibit bacterial cell wall biosynthesis 125276-50-8 CEFDALOXIME PENTEXIL TOSILATE THERAPEUTIC_CLASS Antibacterials 135467-20-8 CEFDALOXIME PENTEXIL TOSILATE MECHANISM Inhibit bacterial cell wall biosynthesis 135467-20-8 CEFDALOXIME PENTEXIL TOSILATE THERAPEUTIC_CLASS Antibacterials 135467-20-8 CEFDALOXIME PENTEXIL TOSILATE MODE_CLASS Enzyme Inhibitor 135467-20-8 CEFDALOXIME PENTEXIL TOSILATE PRODUCT_CLASS Anti-infectives 125181-57-9 CEFDALOXIME PENTEXIL TOSILATE PRODUCT_CLASS Anti-infectives 125181-57-9 CEFDALOXIME PENTEXIL TOSILATE MODE_CLASS Enzyme Inhibitor 125181-57-9 CEFDALOXIME PENTEXIL TOSILATE MECHANISM Inhibit bacterial cell wall biosynthesis 125181-57-9 CEFDALOXIME PENTEXIL TOSILATE THERAPEUTIC_CLASS Antibacterials 125276-51-9 CEFDALOXIME PENTEXIL TOSILATE PRODUCT_CLASS Anti-infectives 125276-51-9 CEFDALOXIME PENTEXIL TOSILATE MODE_CLASS Enzyme Inhibitor 125276-51-9 CEFDALOXIME PENTEXIL TOSILATE MECHANISM Inhibit bacterial cell wall biosynthesis 125276-51-9 CEFDALOXIME PENTEXIL TOSILATE THERAPEUTIC_CLASS Antibacterials 119347-91-0 ONO-3805 PRODUCT_CLASS Anti-cancers 119347-91-0 ONO-3805 MECHANISM Inhibit steroid biosynthesis/ metabolism 119347-91-0 ONO-3805 MODE_CLASS Enzyme Inhibitor 119347-91-0 ONO-3805 THERAPEUTIC_CLASS Antineoplastics 119347-91-0 ONO-3805 INDICATION Prostatic Cancer / Carcinoma of the Prostate 138282-73-2 S-1033 INDICATION Glaucoma 127294-70-6 BALOFLOXACIN DIHYDRATE MECHANISM Inhibit bacterial DNA synthesis 127294-70-6 BALOFLOXACIN DIHYDRATE PRODUCT_CLASS Anti-infectives 127294-70-6 BALOFLOXACIN DIHYDRATE MODE_CLASS Enzyme Inhibitor, selective 127294-70-6 BALOFLOXACIN DIHYDRATE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 127294-70-6 BALOFLOXACIN DIHYDRATE THERAPEUTIC_CLASS Antibacterials 127254-10-8 SITAFLOXACIN HYDRATE MODE_CLASS Enzyme Inhibitor, selective 127254-10-8 SITAFLOXACIN HYDRATE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 127254-10-8 SITAFLOXACIN HYDRATE THERAPEUTIC_CLASS Antibacterials 127254-10-8 SITAFLOXACIN HYDRATE MECHANISM Inhibit bacterial DNA synthesis 127254-10-8 SITAFLOXACIN HYDRATE PRODUCT_CLASS Anti-infectives 127254-12-0 SITAFLOXACIN HYDRATE THERAPEUTIC_CLASS Antibacterials 127254-12-0 SITAFLOXACIN HYDRATE MECHANISM Inhibit bacterial DNA synthesis 127254-12-0 SITAFLOXACIN HYDRATE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 127254-12-0 SITAFLOXACIN HYDRATE PRODUCT_CLASS Anti-infectives 127254-12-0 SITAFLOXACIN HYDRATE MODE_CLASS Enzyme Inhibitor, selective 163253-37-0 SITAFLOXACIN HYDRATE THERAPEUTIC_CLASS Antibacterials 163253-37-0 SITAFLOXACIN HYDRATE PRODUCT_CLASS Anti-infectives 163253-37-0 SITAFLOXACIN HYDRATE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 163253-37-0 SITAFLOXACIN HYDRATE MECHANISM Inhibit bacterial DNA synthesis 163253-37-0 SITAFLOXACIN HYDRATE MODE_CLASS Enzyme Inhibitor, selective 163253-36-9 SITAFLOXACIN HYDRATE THERAPEUTIC_CLASS Antibacterials 163253-36-9 SITAFLOXACIN HYDRATE MECHANISM Inhibit bacterial DNA synthesis 163253-36-9 SITAFLOXACIN HYDRATE MODE_CLASS Enzyme Inhibitor, selective 163253-36-9 SITAFLOXACIN HYDRATE PRODUCT_CLASS Anti-infectives 163253-36-9 SITAFLOXACIN HYDRATE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 163253-35-8 SITAFLOXACIN HYDRATE MECHANISM Inhibit bacterial DNA synthesis 163253-35-8 SITAFLOXACIN HYDRATE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 163253-35-8 SITAFLOXACIN HYDRATE THERAPEUTIC_CLASS Antibacterials 163253-35-8 SITAFLOXACIN HYDRATE MODE_CLASS Enzyme Inhibitor, selective 163253-35-8 SITAFLOXACIN HYDRATE PRODUCT_CLASS Anti-infectives 138071-82-6 GADOBUTROL PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 138071-82-6 GADOBUTROL INDICATION Contrasting Agent 113662-23-0 GADOBENIC ACID DIMEGLUMINE SALT INDICATION Contrasting Agent 113662-23-0 GADOBENIC ACID DIMEGLUMINE SALT PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 127000-20-8 GADOBENIC ACID DIMEGLUMINE SALT INDICATION Contrasting Agent 127000-20-8 GADOBENIC ACID DIMEGLUMINE SALT PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 131631-89-5 OPC-21268 THERAPEUTIC_CLASS Antihypertensive Agents 131631-89-5 OPC-21268 MODE_CLASS Receptor Ligand Antagonist, Non-selective 131631-89-5 OPC-21268 PRODUCT_CLASS Cardiovasculars 131631-89-5 OPC-21268 MECHANISM Reduce vasoconstriction 131631-89-5 OPC-21268 INDICATION Hypertension 131631-89-5 OPC-21268 MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 137159-92-3 APTIGANEL PRODUCT_CLASS Central Nervous System (CNS) 137159-92-3 APTIGANEL THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 137159-92-3 APTIGANEL MODE_CLASS Channel Blocker 137159-92-3 APTIGANEL INDICATION Cerebral Ischemia 137159-92-3 APTIGANEL MECHANISM Modulate neural transmission 137160-11-3 APTIGANEL MECHANISM Modulate neural transmission 137160-11-3 APTIGANEL THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 137160-11-3 APTIGANEL MODE_CLASS Channel Blocker 137160-11-3 APTIGANEL PRODUCT_CLASS Central Nervous System (CNS) 137160-11-3 APTIGANEL INDICATION Cerebral Ischemia 139226-28-1 DARBUFELONE PRODUCT_CLASS Immune Response / Immunomodulators 139226-28-1 DARBUFELONE ADVERSE_EFFECT LIV_2_Hepatotoxicity 139226-28-1 DARBUFELONE ADVERSE_EFFECT XXX_1_Flu Syndrome 139226-28-1 DARBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 139226-28-1 DARBUFELONE INDICATION Asthma 139226-28-1 DARBUFELONE INDICATION Osteoarthritis 139226-28-1 DARBUFELONE TISSUE_TOXICITY Hepatotoxicity 139226-28-1 DARBUFELONE KNOWN_TOXICITY Hepatotoxicity 139226-28-1 DARBUFELONE STRUCTURE_ACTIVITY Lipoxygenase inhibitor 139226-28-1 DARBUFELONE ADVERSE_EFFECT XXX_1_Infection 139226-28-1 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139226-28-1 DARBUFELONE MECHANISM Enhance kinase mediated signal transduction 139226-28-1 DARBUFELONE INDICATION Inflammation 139226-28-1 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139226-28-1 DARBUFELONE ADVERSE_EFFECT NEU_1_Headache 139226-28-1 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139226-28-1 DARBUFELONE THERAPEUTIC_CLASS Immunosuppressants 139226-28-1 DARBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 139226-28-1 DARBUFELONE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 139226-28-1 DARBUFELONE MECHANISM Enhance kinase mediated signal transduction 139226-28-1 DARBUFELONE INDICATION Rheumatoid Arthritis 139340-56-0 DARBUFELONE MECHANISM Enhance kinase mediated signal transduction 139340-56-0 DARBUFELONE INDICATION Asthma 139340-56-0 DARBUFELONE KNOWN_TOXICITY Hepatotoxicity 139340-56-0 DARBUFELONE TISSUE_TOXICITY Hepatotoxicity 139340-56-0 DARBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 139340-56-0 DARBUFELONE INDICATION Osteoarthritis 139340-56-0 DARBUFELONE ADVERSE_EFFECT XXX_1_Flu Syndrome 139340-56-0 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139340-56-0 DARBUFELONE ADVERSE_EFFECT LIV_2_Hepatotoxicity 139340-56-0 DARBUFELONE PRODUCT_CLASS Immune Response / Immunomodulators 139340-56-0 DARBUFELONE INDICATION Rheumatoid Arthritis 139340-56-0 DARBUFELONE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 139340-56-0 DARBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 139340-56-0 DARBUFELONE ADVERSE_EFFECT NEU_1_Headache 139340-56-0 DARBUFELONE THERAPEUTIC_CLASS Immunosuppressants 139340-56-0 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139340-56-0 DARBUFELONE INDICATION Inflammation 139340-56-0 DARBUFELONE MECHANISM Enhance kinase mediated signal transduction 139340-56-0 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139340-56-0 DARBUFELONE ADVERSE_EFFECT XXX_1_Infection 139340-56-0 DARBUFELONE STRUCTURE_ACTIVITY Lipoxygenase inhibitor 139226-30-5 DARBUFELONE INDICATION Osteoarthritis 139226-30-5 DARBUFELONE PRODUCT_CLASS Immune Response / Immunomodulators 139226-30-5 DARBUFELONE ADVERSE_EFFECT LIV_2_Hepatotoxicity 139226-30-5 DARBUFELONE ADVERSE_EFFECT XXX_1_Flu Syndrome 139226-30-5 DARBUFELONE INDICATION Asthma 139226-30-5 DARBUFELONE INDICATION Inflammation 139226-30-5 DARBUFELONE MECHANISM Enhance kinase mediated signal transduction 139226-30-5 DARBUFELONE TISSUE_TOXICITY Hepatotoxicity 139226-30-5 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139226-30-5 DARBUFELONE ADVERSE_EFFECT XXX_1_Infection 139226-30-5 DARBUFELONE STRUCTURE_ACTIVITY Lipoxygenase inhibitor 139226-30-5 DARBUFELONE KNOWN_TOXICITY Hepatotoxicity 139226-30-5 DARBUFELONE INDICATION Rheumatoid Arthritis 139226-30-5 DARBUFELONE MECHANISM Enhance kinase mediated signal transduction 139226-30-5 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139226-30-5 DARBUFELONE MODE_CLASS Enzyme Inhibitor 139226-30-5 DARBUFELONE THERAPEUTIC_CLASS Immunosuppressants 139226-30-5 DARBUFELONE ADVERSE_EFFECT NEU_1_Headache 139226-30-5 DARBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 139226-30-5 DARBUFELONE MECHANISM Inhibit eicosanoid biosynthesis 139226-30-5 DARBUFELONE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 115931-65-2 CL-275838 THERAPEUTIC_CLASS Antidepressants 115931-65-2 CL-275838 INDICATION Depression 115931-65-2 CL-275838 PRODUCT_CLASS Central Nervous System (CNS) 115955-02-7 CL-275838 THERAPEUTIC_CLASS Antidepressants 115955-02-7 CL-275838 INDICATION Depression 115955-02-7 CL-275838 PRODUCT_CLASS Central Nervous System (CNS) 115973-38-1 CL-275838 THERAPEUTIC_CLASS Antidepressants 115973-38-1 CL-275838 PRODUCT_CLASS Central Nervous System (CNS) 115973-38-1 CL-275838 INDICATION Depression 138742-43-5 ZANKIREN INDICATION Psoriasis 138742-43-5 ZANKIREN THERAPEUTIC_CLASS Antihypertensive Agents 138742-43-5 ZANKIREN MECHANISM Reduce vasoconstriction 138742-43-5 ZANKIREN PRODUCT_CLASS Cardiovasculars 138742-43-5 ZANKIREN MODE_CLASS Enzyme Inhibitor 138742-43-5 ZANKIREN INDICATION Hypertension 135392-43-7 F-1394 MECHANISM Inhibit steroid biosynthesis/ metabolism 135392-43-7 F-1394 MODE_CLASS Enzyme Inhibitor 135392-43-7 F-1394 INDICATION Hypolipidemia 132195-65-4 BMY-43748 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 132195-37-0 BMY-43748 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 129453-61-8 FULVESTRANT MODE_CLASS Receptor Ligand Antagonist 129453-61-8 FULVESTRANT MECHANISM Modulate gene transcription 129453-61-8 FULVESTRANT PRODUCT_CLASS Anti-cancers 129453-61-8 FULVESTRANT STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 129453-61-8 FULVESTRANT THERAPEUTIC_CLASS Gonadal Hormones 132722-74-8 PIRSIDOMINE PRODUCT_CLASS Cardiovasculars 132722-74-8 PIRSIDOMINE THERAPEUTIC_CLASS Antianginals 132722-74-8 PIRSIDOMINE INDICATION Angina Pectoris 135038-57-2 FASIDOTRIL THERAPEUTIC_CLASS Antihypertensive Agents 135038-57-2 FASIDOTRIL MECHANISM Reduce vasoconstriction 135038-57-2 FASIDOTRIL MECHANISM Modulate G-protein coupled signal transduction 135038-57-2 FASIDOTRIL INDICATION Hypertension 135038-57-2 FASIDOTRIL MODE_CLASS Enzyme Inhibitor 135038-57-2 FASIDOTRIL PRODUCT_CLASS Cardiovasculars 132373-81-0 VAMICAMIDE INDICATION Urinary Incontinence / Enuresis 139155-45-6 FK-143 PRODUCT_CLASS Anti-cancers 139155-45-6 FK-143 INDICATION Prostatic Cancer / Carcinoma of the Prostate 139155-45-6 FK-143 MODE_CLASS Enzyme Inhibitor 139155-45-6 FK-143 THERAPEUTIC_CLASS Antineoplastics 139155-45-6 FK-143 MECHANISM Inhibit steroid biosynthesis/ metabolism 139155-29-6 FK-143 INDICATION Prostatic Cancer / Carcinoma of the Prostate 139155-29-6 FK-143 MODE_CLASS Enzyme Inhibitor 139155-29-6 FK-143 PRODUCT_CLASS Anti-cancers 139155-29-6 FK-143 THERAPEUTIC_CLASS Antineoplastics 139155-29-6 FK-143 MECHANISM Inhibit steroid biosynthesis/ metabolism 163136-03-6 FK-143 INDICATION Prostatic Cancer / Carcinoma of the Prostate 163136-03-6 FK-143 PRODUCT_CLASS Anti-cancers 163136-03-6 FK-143 THERAPEUTIC_CLASS Antineoplastics 163136-03-6 FK-143 MECHANISM Inhibit steroid biosynthesis/ metabolism 163136-03-6 FK-143 MODE_CLASS Enzyme Inhibitor 135525-71-2 L-696229 INDICATION Myocardial Ischemia 139339-45-0 RO-24-7429 INDICATION Myocardial Ischemia 139290-65-6 MDL-100907 MECHANISM Modulate neural transmission 139290-65-6 MDL-100907 MODE_CLASS Receptor Ligand Antagonist 139290-69-0 MDL-100907 MECHANISM Modulate neural transmission 139290-69-0 MDL-100907 MODE_CLASS Receptor Ligand Antagonist 139681-18-8 SDZ-FOX-988 INDICATION Hypolipidemia 139681-18-8 SDZ-FOX-988 INDICATION Diabetes 141283-87-6 IS-741 MODE_CLASS Enzyme Inhibitor 141283-87-6 IS-741 MECHANISM Inhibit inflammatory response 141284-74-4 IS-741 MECHANISM Inhibit inflammatory response 141284-74-4 IS-741 MODE_CLASS Enzyme Inhibitor 141284-73-3 IS-741 MECHANISM Inhibit inflammatory response 141284-73-3 IS-741 MODE_CLASS Enzyme Inhibitor 141284-77-7 IS-741 MODE_CLASS Enzyme Inhibitor 141284-77-7 IS-741 MECHANISM Inhibit inflammatory response 136976-16-4 SUN-9221 INDICATION Hypertension 136976-16-4 SUN-9221 PRODUCT_CLASS Cardiovasculars 136976-16-4 SUN-9221 MECHANISM Modulate G-protein coupled signal transduction 136976-16-4 SUN-9221 THERAPEUTIC_CLASS Antihypertensive Agents 137795-35-8 SPIROGLUMIDE MODE_CLASS Receptor Ligand Antagonist 137795-35-8 SPIROGLUMIDE MECHANISM Reduce stomach HCl secretion 122665-70-7 180243 STRUCTURE_ACTIVITY DNA-alkylator, methanesulfonate 66318-17-0 FURPROFEN MODE_CLASS Enzyme Inhibitor 66318-17-0 FURPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 66318-17-0 FURPROFEN PRODUCT_CLASS Anti-inflammatories 66318-17-0 FURPROFEN MECHANISM Inhibit eicosanoid biosynthesis 66318-17-0 FURPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 119817-90-2 DEXLOXIGLUMIDE INDICATION Irritable Bowel Syndrome 119817-90-2 DEXLOXIGLUMIDE MODE_CLASS Receptor Ligand Antagonist 119817-90-2 DEXLOXIGLUMIDE MECHANISM Modulate G-protein coupled signal transduction 132014-21-2 RILMAKALIM MODE_CLASS Channel enhancer /opener 132014-21-2 RILMAKALIM PRODUCT_CLASS Biochemicals 132014-21-2 RILMAKALIM MECHANISM Reduce muscle contractile force 128149-06-4 RILMAKALIM MECHANISM Reduce muscle contractile force 128149-06-4 RILMAKALIM MODE_CLASS Channel enhancer /opener 128149-06-4 RILMAKALIM PRODUCT_CLASS Biochemicals 138298-79-0 ALNESPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 138298-79-0 ALNESPIRONE MODE_CLASS Receptor Agonist 138298-79-0 ALNESPIRONE PRODUCT_CLASS Central Nervous System (CNS) 138298-79-0 ALNESPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 138298-79-0 ALNESPIRONE INDICATION Anxiety Disorders 138298-79-0 ALNESPIRONE THERAPEUTIC_CLASS Antidepressants 138298-79-0 ALNESPIRONE INDICATION Depression 138298-79-0 ALNESPIRONE MECHANISM Modulate neural transmission 140944-30-5 RGH-5002 MECHANISM Block neural transmission 140944-30-5 RGH-5002 MODE_CLASS Channel Blocker 140944-31-6 RGH-5002 MECHANISM Block neural transmission 140944-31-6 RGH-5002 MODE_CLASS Channel Blocker 136609-26-2 RP-70676 INDICATION Hypolipidemia 136609-26-2 RP-70676 MODE_CLASS Enzyme Inhibitor 136609-26-2 RP-70676 MECHANISM Inhibit steroid biosynthesis/ metabolism 136634-44-1 RP-70676 INDICATION Hypolipidemia 136634-44-1 RP-70676 MODE_CLASS Enzyme Inhibitor 136634-44-1 RP-70676 MECHANISM Inhibit steroid biosynthesis/ metabolism 141184-34-1 FILAMINAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 141184-34-1 FILAMINAST PRODUCT_CLASS Respiratory System 141184-34-1 FILAMINAST MODE_CLASS Enzyme Inhibitor 141184-34-1 FILAMINAST INDICATION Asthma 141184-34-1 FILAMINAST MECHANISM Enhance kinase mediated signal transduction 119625-78-4 TERLAKIREN PRODUCT_CLASS Cardiovasculars 119625-78-4 TERLAKIREN MODE_CLASS Enzyme Inhibitor 119625-78-4 TERLAKIREN MECHANISM Reduce vasoconstriction 119625-78-4 TERLAKIREN INDICATION Hypertension 119625-78-4 TERLAKIREN THERAPEUTIC_CLASS Antihypertensive Agents 209216-23-9 SQ-34676 STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 137927-14-1 NEPAPRAZOLE SODIUM MODE_CLASS Enzyme Inhibitor 137927-14-1 NEPAPRAZOLE SODIUM THERAPEUTIC_CLASS Antiulcers 137927-14-1 NEPAPRAZOLE SODIUM PRODUCT_CLASS Gastrointestinal System 137927-14-1 NEPAPRAZOLE SODIUM INDICATION Ulcer 137927-14-1 NEPAPRAZOLE SODIUM MECHANISM Reduce stomach HCl secretion 156601-79-5 NEPAPRAZOLE SODIUM MECHANISM Reduce stomach HCl secretion 156601-79-5 NEPAPRAZOLE SODIUM INDICATION Ulcer 156601-79-5 NEPAPRAZOLE SODIUM PRODUCT_CLASS Gastrointestinal System 156601-79-5 NEPAPRAZOLE SODIUM MODE_CLASS Enzyme Inhibitor 156601-79-5 NEPAPRAZOLE SODIUM THERAPEUTIC_CLASS Antiulcers 132036-91-0 YM-114 INDICATION Nausea / Vomiting 132036-91-0 YM-114 INDICATION Irritable Bowel Syndrome 132036-91-0 YM-114 MODE_CLASS Channel Blocker 132036-91-0 YM-114 MECHANISM Block neural transmission 129299-90-7 FABESETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 129299-90-7 FABESETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 129299-90-7 FABESETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 129299-90-7 FABESETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 129299-90-7 FABESETRON HYDROCHLORIDE MECHANISM Block neural transmission 129299-72-5 FABESETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 129299-72-5 FABESETRON HYDROCHLORIDE MECHANISM Block neural transmission 129299-72-5 FABESETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 129299-72-5 FABESETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 129299-72-5 FABESETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 129300-27-2 FABESETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 129300-27-2 FABESETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 129300-27-2 FABESETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 129300-27-2 FABESETRON HYDROCHLORIDE MECHANISM Block neural transmission 129300-27-2 FABESETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 129299-89-4 FABESETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 129299-89-4 FABESETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 129299-89-4 FABESETRON HYDROCHLORIDE MECHANISM Block neural transmission 129299-89-4 FABESETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 129299-89-4 FABESETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 160472-97-9 INDISETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 160472-97-9 INDISETRON HYDROCHLORIDE INDICATION Nausea / Vomiting 160472-97-9 INDISETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 160472-97-9 INDISETRON HYDROCHLORIDE MECHANISM Block neural transmission 160472-97-9 INDISETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 160472-97-9 INDISETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 141549-75-9 INDISETRON HYDROCHLORIDE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 141549-75-9 INDISETRON HYDROCHLORIDE INDICATION Nausea / Vomiting 141549-75-9 INDISETRON HYDROCHLORIDE THERAPEUTIC_CLASS Antiemetics 141549-75-9 INDISETRON HYDROCHLORIDE MECHANISM Block neural transmission 141549-75-9 INDISETRON HYDROCHLORIDE MODE_CLASS Channel Blocker, selective 141549-75-9 INDISETRON HYDROCHLORIDE PRODUCT_CLASS Gastrointestinal System 142001-63-6 SAREDUTANT INDICATION Urinary Incontinence / Enuresis 141545-89-3 LY-231617 THERAPEUTIC_CLASS Immunosuppressants 141545-89-3 LY-231617 INDICATION Arthritis 141545-89-3 LY-231617 MODE_CLASS Enzyme Inhibitor 141545-89-3 LY-231617 INDICATION Inflammatory Bowel Disease (IBD) 141545-89-3 LY-231617 PRODUCT_CLASS Immune Response / Immunomodulators 93811-58-6 LY-231617 MODE_CLASS Enzyme Inhibitor 93811-58-6 LY-231617 INDICATION Inflammatory Bowel Disease (IBD) 93811-58-6 LY-231617 PRODUCT_CLASS Immune Response / Immunomodulators 93811-58-6 LY-231617 THERAPEUTIC_CLASS Immunosuppressants 93811-58-6 LY-231617 INDICATION Arthritis 141701-65-7 LY-231617 INDICATION Inflammatory Bowel Disease (IBD) 141701-65-7 LY-231617 INDICATION Arthritis 141701-65-7 LY-231617 PRODUCT_CLASS Immune Response / Immunomodulators 141701-65-7 LY-231617 THERAPEUTIC_CLASS Immunosuppressants 141701-65-7 LY-231617 MODE_CLASS Enzyme Inhibitor 139133-26-9 LEXIPAFANT INDICATION Multiple Sclerosis (MS) 141790-23-0 FOZIVUDINE TIDOXIL INDICATION Myocardial Ischemia 142304-17-4 TCV-295 MECHANISM Reduce muscle contractile force 142304-17-4 TCV-295 MODE_CLASS Channel enhancer /opener 142304-17-4 TCV-295 MODE_CLASS Channel Modulator 142304-17-4 TCV-295 MECHANISM Modulate channel gating 142304-17-4 TCV-295 PRODUCT_CLASS Cardiovasculars 142304-17-4 TCV-295 THERAPEUTIC_CLASS Antihypertensive Agents 141071-67-2 BMS-181101 THERAPEUTIC_CLASS Antidepressants 141071-67-2 BMS-181101 MECHANISM Modulate cerebral vasoconstriction 141071-67-2 BMS-181101 PRODUCT_CLASS Central Nervous System (CNS) 141071-67-2 BMS-181101 INDICATION Depression 138384-68-6 METESIND MODE_CLASS Enzyme Inhibitor 138384-68-6 METESIND MECHANISM Inhibit precursor synthesis 138384-68-6 METESIND STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 147362-57-0 LOVIRIDE MECHANISM Inhibit viral DNA synthesis 147362-57-0 LOVIRIDE THERAPEUTIC_CLASS Antivirals, Systemic 147362-57-0 LOVIRIDE MODE_CLASS Enzyme Inhibitor 147362-57-0 LOVIRIDE INDICATION Human Immunodeficiency Virus (HIV) Disease 147362-57-0 LOVIRIDE PRODUCT_CLASS Anti-infectives 147076-36-6 LAFLUNIMUS THERAPEUTIC_CLASS Immunosuppressants 147076-36-6 LAFLUNIMUS INDICATION Arthritis 147076-36-6 LAFLUNIMUS PRODUCT_CLASS Immune Response / Immunomodulators 59989-18-3 ENILURACIL PRODUCT_CLASS Anti-cancers 140850-73-3 IGMESINE HYDROCHLORIDE INDICATION Diarrhea 140850-73-3 IGMESINE HYDROCHLORIDE INDICATION Depression 140850-73-3 IGMESINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 140850-73-3 IGMESINE HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 130152-35-1 IGMESINE HYDROCHLORIDE INDICATION Diarrhea 130152-35-1 IGMESINE HYDROCHLORIDE INDICATION Depression 130152-35-1 IGMESINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 130152-35-1 IGMESINE HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 40516-48-1 TRETINOIN TOCOFERIL STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 40516-48-1 TRETINOIN TOCOFERIL MECHANISM Modulate gene transcription 40516-48-1 TRETINOIN TOCOFERIL INDICATION Ulcer 40516-48-1 TRETINOIN TOCOFERIL MODE_CLASS Receptor Agonist 131815-81-1 BRL-55834 MECHANISM Modulate channel gating 131815-81-1 BRL-55834 MODE_CLASS Channel Modulator 131899-26-8 BRL-55834 MODE_CLASS Channel Modulator 131899-26-8 BRL-55834 MECHANISM Modulate channel gating 123036-23-7 CGP-43371 INDICATION Hypolipidemia 141034-42-6 DAT-582 MECHANISM Block neural transmission 141034-42-6 DAT-582 INDICATION Nausea / Vomiting 141034-42-6 DAT-582 MODE_CLASS Channel Blocker 142654-34-0 BMS-180680 MECHANISM Inhibit bacterial cell wall biosynthesis 142654-34-0 BMS-180680 PRODUCT_CLASS Anti-infectives 142654-34-0 BMS-180680 THERAPEUTIC_CLASS Antibacterials 142654-34-0 BMS-180680 MODE_CLASS Enzyme Inhibitor 142654-34-0 BMS-180680 STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 154164-30-4 YM-900 PRODUCT_CLASS Central Nervous System (CNS) 154164-30-4 YM-900 MODE_CLASS Channel Blocker, selective 154164-30-4 YM-900 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 154164-30-4 YM-900 PRODUCT_CLASS Other Human Uses 154164-30-4 YM-900 INDICATION Cerebral Ischemia 154164-30-4 YM-900 MECHANISM Block neural transmission 154164-30-4 YM-900 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 157971-78-3 YM-900 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 157971-78-3 YM-900 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 157971-78-3 YM-900 PRODUCT_CLASS Other Human Uses 157971-78-3 YM-900 MECHANISM Block neural transmission 157971-78-3 YM-900 INDICATION Cerebral Ischemia 157971-78-3 YM-900 MODE_CLASS Channel Blocker, selective 157971-78-3 YM-900 PRODUCT_CLASS Central Nervous System (CNS) 143151-35-3 YM-900 PRODUCT_CLASS Other Human Uses 143151-35-3 YM-900 MODE_CLASS Channel Blocker, selective 143151-35-3 YM-900 MECHANISM Block neural transmission 143151-35-3 YM-900 PRODUCT_CLASS Central Nervous System (CNS) 143151-35-3 YM-900 INDICATION Cerebral Ischemia 143151-35-3 YM-900 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 143151-35-3 YM-900 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 141430-65-1 E-7010 STRUCTURE_ACTIVITY Tubulin binder 141579-88-6 A-79175 MECHANISM Inhibit eicosanoid biosynthesis 141579-88-6 A-79175 MODE_CLASS Enzyme Inhibitor 141579-88-6 A-79175 PRODUCT_CLASS Anti-cancers 141579-88-6 A-79175 THERAPEUTIC_CLASS Antineoplastics 141579-67-1 A-79175 MECHANISM Inhibit eicosanoid biosynthesis 141579-67-1 A-79175 PRODUCT_CLASS Anti-cancers 141579-67-1 A-79175 THERAPEUTIC_CLASS Antineoplastics 141579-67-1 A-79175 MODE_CLASS Enzyme Inhibitor 143248-63-9 SINITRODIL THERAPEUTIC_CLASS Antianginals 143248-63-9 SINITRODIL INDICATION Angina Pectoris 143248-63-9 SINITRODIL PRODUCT_CLASS Cardiovasculars 143538-27-6 BAY-X-7195 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 143538-27-6 BAY-X-7195 INDICATION Asthma 143538-27-6 BAY-X-7195 PRODUCT_CLASS Respiratory System 143538-27-6 BAY-X-7195 MODE_CLASS Receptor Ligand Antagonist 143538-27-6 BAY-X-7195 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 143538-27-6 BAY-X-7195 MECHANISM Modulate G-protein coupled signal transduction 143693-03-2 BAY-X-7195 INDICATION Asthma 143693-03-2 BAY-X-7195 PRODUCT_CLASS Respiratory System 143693-03-2 BAY-X-7195 MECHANISM Modulate G-protein coupled signal transduction 143693-03-2 BAY-X-7195 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 143693-03-2 BAY-X-7195 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 143693-03-2 BAY-X-7195 MODE_CLASS Receptor Ligand Antagonist 133242-30-5 LANDIOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 133242-30-5 LANDIOLOL PRODUCT_CLASS Cardiovasculars 133242-30-5 LANDIOLOL INDICATION Cardiac Arrhythmias 133242-62-3 LANDIOLOL PRODUCT_CLASS Cardiovasculars 133242-62-3 LANDIOLOL INDICATION Cardiac Arrhythmias 133242-62-3 LANDIOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 144481-98-1 LANDIOLOL INDICATION Cardiac Arrhythmias 144481-98-1 LANDIOLOL PRODUCT_CLASS Cardiovasculars 144481-98-1 LANDIOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 138926-19-9 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 138926-19-9 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 138926-19-9 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 138926-19-9 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE INDICATION Hypercalcemia of Malignancy 138926-19-9 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE MECHANISM Inhibit bone re-absorption 138926-19-9 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE MODE_CLASS Enzyme Inhibitor 138844-81-2 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE INDICATION Hypercalcemia of Malignancy 138844-81-2 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE MECHANISM Inhibit bone re-absorption 138844-81-2 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 138844-81-2 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE MODE_CLASS Enzyme Inhibitor 138844-81-2 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 138844-81-2 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 114084-78-5 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE MECHANISM Inhibit bone re-absorption 114084-78-5 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE INDICATION Hypercalcemia of Malignancy 114084-78-5 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 114084-78-5 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 114084-78-5 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 114084-78-5 IBANDRONIC ACID MONOSODIUM SALT MONOHYDRATE MODE_CLASS Enzyme Inhibitor 143224-34-4 TELINAVIR INDICATION Myocardial Ischemia 143943-73-1 LIREQUINIL MECHANISM Inhibit precursor synthesis 143943-73-1 LIREQUINIL MODE_CLASS Enzyme Inhibitor 142344-87-4 GP-1-531 THERAPEUTIC_CLASS Antianginals 142344-87-4 GP-1-531 PRODUCT_CLASS Cardiovasculars 142344-87-4 GP-1-531 INDICATION Angina Pectoris 131707-23-8 ARBIDOL MECHANISM Scavenges hydrogen peroxide and free radicals 144453-77-0 SK&F-97574 MODE_CLASS Enzyme Inhibitor 144453-77-0 SK&F-97574 MECHANISM Reduce stomach HCl secretion 125500-29-0 SK&F-97574 MECHANISM Reduce stomach HCl secretion 125500-29-0 SK&F-97574 MODE_CLASS Enzyme Inhibitor 147238-98-0 TOP-53 STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 147238-98-0 TOP-53 THERAPEUTIC_CLASS Antineoplastics 147238-98-0 TOP-53 MECHANISM Inhibit DNA synthesis, repair, and function 147238-98-0 TOP-53 MODE_CLASS Enzyme Inhibitor 147238-98-0 TOP-53 PRODUCT_CLASS Anti-cancers 148262-19-5 TOP-53 MODE_CLASS Enzyme Inhibitor 148262-19-5 TOP-53 STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 148262-19-5 TOP-53 THERAPEUTIC_CLASS Antineoplastics 148262-19-5 TOP-53 MECHANISM Inhibit DNA synthesis, repair, and function 148262-19-5 TOP-53 PRODUCT_CLASS Anti-cancers 144459-70-1 ROFLEPONIDE INDICATION Inflammatory Bowel Disease (IBD) 144459-70-1 ROFLEPONIDE INDICATION Viral Rhinitis / Common Cold 137332-54-8 TIVIRAPINE INDICATION Myocardial Ischemia 137332-54-8 TIVIRAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 142382-09-0 ODAPIPAM MECHANISM Modulate G-protein coupled signal transduction 131796-63-9 ODAPIPAM MECHANISM Modulate G-protein coupled signal transduction 140661-97-8 DELTIBANT INDICATION Viral Rhinitis / Common Cold 140661-97-8 DELTIBANT MECHANISM Modulate G-protein coupled signal transduction 140661-97-8 DELTIBANT STRUCTURE_ACTIVITY Bradykinin antagonist 60559-98-0 U-83757 THERAPEUTIC_CLASS Vasodilators 60559-98-0 U-83757 INDICATION Erectile Dysfunction 60559-98-0 U-83757 MODE_CLASS Channel enhancer /opener 60559-98-0 U-83757 MECHANISM Reduce muscle contractile force 60559-98-0 U-83757 PRODUCT_CLASS Cardiovasculars 117411-27-5 BOF-4272 MODE_CLASS Enzyme Inhibitor 117411-27-5 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-59-8 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-59-8 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-51-0 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-51-0 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-52-1 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-52-1 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-49-6 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-49-6 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-50-9 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-50-9 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-55-4 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-55-4 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-58-7 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-58-7 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-56-5 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-56-5 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-53-2 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-53-2 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-57-6 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-57-6 BOF-4272 MODE_CLASS Enzyme Inhibitor 134395-54-3 BOF-4272 MECHANISM Inhibit precursor synthesis 134395-54-3 BOF-4272 MODE_CLASS Enzyme Inhibitor 128253-12-3 BAY-X-1005 PRODUCT_CLASS Respiratory System 128253-12-3 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 128253-12-3 BAY-X-1005 MECHANISM Inhibit eicosanoid biosynthesis 128253-12-3 BAY-X-1005 PRODUCT_CLASS Anti-inflammatories 128253-12-3 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 128253-12-3 BAY-X-1005 MODE_CLASS Enzyme Inhibitor 128253-12-3 BAY-X-1005 INDICATION Asthma 128253-32-7 BAY-X-1005 MECHANISM Inhibit eicosanoid biosynthesis 128253-32-7 BAY-X-1005 MODE_CLASS Enzyme Inhibitor 128253-32-7 BAY-X-1005 INDICATION Asthma 128253-32-7 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 128253-32-7 BAY-X-1005 PRODUCT_CLASS Respiratory System 128253-32-7 BAY-X-1005 PRODUCT_CLASS Anti-inflammatories 128253-32-7 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 128253-31-6 BAY-X-1005 MECHANISM Inhibit eicosanoid biosynthesis 128253-31-6 BAY-X-1005 PRODUCT_CLASS Anti-inflammatories 128253-31-6 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 128253-31-6 BAY-X-1005 MODE_CLASS Enzyme Inhibitor 128253-31-6 BAY-X-1005 INDICATION Asthma 128253-31-6 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 128253-31-6 BAY-X-1005 PRODUCT_CLASS Respiratory System 128253-25-8 BAY-X-1005 MECHANISM Inhibit eicosanoid biosynthesis 128253-25-8 BAY-X-1005 PRODUCT_CLASS Anti-inflammatories 128253-25-8 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 128253-25-8 BAY-X-1005 MODE_CLASS Enzyme Inhibitor 128253-25-8 BAY-X-1005 INDICATION Asthma 128253-25-8 BAY-X-1005 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 128253-25-8 BAY-X-1005 PRODUCT_CLASS Respiratory System 147318-81-8 KYNOSTATIN-272 INDICATION Myocardial Ischemia 122830-14-2 DERIGLIDOLE MECHANISM Modulate G-protein coupled signal transduction 122830-14-2 DERIGLIDOLE INDICATION Diabetes 132810-10-7 BLONANSERIN MECHANISM Modulate neural transmission 132810-10-7 BLONANSERIN MODE_CLASS Receptor Ligand Antagonist 132810-10-7 BLONANSERIN MECHANISM Modulate G-protein coupled signal transduction 132810-10-7 BLONANSERIN PRODUCT_CLASS Central Nervous System (CNS) 133454-47-4 ILOPERIDONE MECHANISM Modulate G-protein coupled signal transduction 133454-47-4 ILOPERIDONE MECHANISM Modulate neural transmission 133454-47-4 ILOPERIDONE MODE_CLASS Receptor Ligand Antagonist 127595-41-9 BIMU-1 MECHANISM Block neural transmission 127595-41-9 BIMU-1 INDICATION Nausea / Vomiting 127595-41-9 BIMU-1 MODE_CLASS Solute transporter inhibitor 127595-41-9 BIMU-1 MECHANISM Prolong/enhance neural transmission 127595-41-9 BIMU-1 MODE_CLASS Channel Blocker 151581-24-7 IRALUKAST SODIUM INDICATION Asthma 151581-24-7 IRALUKAST SODIUM PRODUCT_CLASS Respiratory System 151581-24-7 IRALUKAST SODIUM MODE_CLASS Receptor Ligand Antagonist 151581-24-7 IRALUKAST SODIUM THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 151581-24-7 IRALUKAST SODIUM MECHANISM Modulate G-protein coupled signal transduction 151581-24-7 IRALUKAST SODIUM STRUCTURE_ACTIVITY Leukotriene receptor antagonist 3440-28-6 BETAMIPRON PRODUCT_CLASS Electrolytic, Caloric and Water Balance 3440-28-6 BETAMIPRON MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 3440-28-6 BETAMIPRON MODE_CLASS Solute transporter inhibitor 132640-22-3 ANDOLAST INDICATION Ulcer 131875-08-6 LEXACALCITOL THERAPEUTIC_CLASS Psoralens 131875-08-6 LEXACALCITOL MECHANISM Modulate gene transcription 131875-08-6 LEXACALCITOL PRODUCT_CLASS Dermatologicals 131875-08-6 LEXACALCITOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 131875-08-6 LEXACALCITOL MODE_CLASS Receptor Agonist 131875-08-6 LEXACALCITOL INDICATION Psoriasis 56287-74-2 AFLOQUALONE INDICATION Nausea / Vomiting 107429-63-0 LINTOPRIDE MODE_CLASS Channel Modulator 107429-63-0 LINTOPRIDE MECHANISM Modulate neural transmission 107429-63-0 LINTOPRIDE INDICATION Nausea / Vomiting 89458-99-1 XR-5000 MODE_CLASS Enzyme Inhibitor 89458-99-1 XR-5000 PRODUCT_CLASS Anti-cancers 89458-99-1 XR-5000 THERAPEUTIC_CLASS Antineoplastics 89458-99-1 XR-5000 MECHANISM Inhibit DNA synthesis, repair, and function 89458-99-1 XR-5000 STRUCTURE_ACTIVITY DNA topoisomerase inhibitor 89459-25-6 XR-5000 STRUCTURE_ACTIVITY DNA topoisomerase inhibitor 89459-25-6 XR-5000 MECHANISM Inhibit DNA synthesis, repair, and function 89459-25-6 XR-5000 PRODUCT_CLASS Anti-cancers 89459-25-6 XR-5000 MODE_CLASS Enzyme Inhibitor 89459-25-6 XR-5000 THERAPEUTIC_CLASS Antineoplastics 68693-11-8 MODAFINIL TA_LEVEL_2 CNS Stimulant 68693-11-8 MODAFINIL MESH_LEVEL_2 Hydrocarbons 68693-11-8 MODAFINIL MECH_LEVEL_3 Dopamine (DA) Transporter DAT 68693-11-8 MODAFINIL PRODUCT_CLASS Central Nervous System (CNS) 68693-11-8 MODAFINIL MECHANISM Prolong/enhance neural transmission 68693-11-8 MODAFINIL ADVERSE_EFFECT CVS_3_Hypotension 68693-11-8 MODAFINIL ADVERSE_EFFECT PSY_1_Insomnia 68693-11-8 MODAFINIL ADVERSE_EFFECT NEU_2_Paresthesia 68693-11-8 MODAFINIL ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 68693-11-8 MODAFINIL ZERO_CLASS N 68693-11-8 MODAFINIL TISSUE_TOXICITY Hypotension 68693-11-8 MODAFINIL ADVERSE_EFFECT PSY_2_Mental Depression 68693-11-8 MODAFINIL ADVERSE_EFFECT PSY_2_Physical Dependence 68693-11-8 MODAFINIL ADVERSE_EFFECT PSY_1_Anxiety 68693-11-8 MODAFINIL ADVERSE_EFFECT CVS_3_Hypertension 68693-11-8 MODAFINIL MESH_LEVEL_1 Organic Chemicals 68693-11-8 MODAFINIL STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 68693-11-8 MODAFINIL ADVERSE_EFFECT CVS_2_Palpitation 68693-11-8 MODAFINIL ADVERSE_EFFECT PSY_2_Impaired Judgment 68693-11-8 MODAFINIL ADVERSE_EFFECT GIS_1_Nausea 68693-11-8 MODAFINIL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 68693-11-8 MODAFINIL MESH_LEVEL_3 Hydrocarbons, Cyclic 68693-11-8 MODAFINIL KNOWN_TOXICITY Cardiovascular Toxicity 68693-11-8 MODAFINIL ADVERSE_EFFECT XXX_2_Rhinitis 68693-11-8 MODAFINIL ADVERSE_EFFECT NEU_3_Ataxia 68693-11-8 MODAFINIL ADVERSE_EFFECT NEU_1_Headache 68693-11-8 MODAFINIL ADVERSE_EFFECT PSY_1_Nervousness 68693-11-8 MODAFINIL ADVERSE_EFFECT CVS_2_Vasodilation 68693-11-8 MODAFINIL THERAPEUTIC_CLASS Central Stimulants 68693-11-8 MODAFINIL MODE_CLASS Solute transporter inhibitor 68693-11-8 MODAFINIL MECH_LEVEL_2 Stimulate the tuberomammillary nucleus and orexin-containing nerve cells 68693-11-8 MODAFINIL ADVERSE_EFFECT NEU_3_Amnesia 68693-11-8 MODAFINIL INDICATION Narcolepsy 68693-11-8 MODAFINIL TA_LEVEL_3 Narcolepsy 68693-11-8 MODAFINIL MECH_LEVEL_1 Modulate neural transmission 68693-11-8 MODAFINIL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 68693-11-8 MODAFINIL TISSUE_TOXICITY Cardiac Arrhythmia 68693-11-8 MODAFINIL TA_LEVEL_1 Central Nervous System (CNS) 75736-33-3 MODAFINIL ADVERSE_EFFECT XXX_2_Rhinitis 75736-33-3 MODAFINIL ADVERSE_EFFECT CVS_3_Hypotension 75736-33-3 MODAFINIL ADVERSE_EFFECT CVS_2_Vasodilation 75736-33-3 MODAFINIL THERAPEUTIC_CLASS Central Stimulants 75736-33-3 MODAFINIL MODE_CLASS Solute transporter inhibitor 75736-33-3 MODAFINIL ADVERSE_EFFECT PSY_1_Insomnia 75736-33-3 MODAFINIL MECH_LEVEL_2 Stimulate the tuberomammillary nucleus and orexin-containing nerve cells 75736-33-3 MODAFINIL MESH_LEVEL_1 Organic Chemicals 75736-33-3 MODAFINIL STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 75736-33-3 MODAFINIL KNOWN_TOXICITY Cardiovascular Toxicity 75736-33-3 MODAFINIL ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 75736-33-3 MODAFINIL ADVERSE_EFFECT NEU_3_Ataxia 75736-33-3 MODAFINIL ADVERSE_EFFECT NEU_1_Headache 75736-33-3 MODAFINIL ADVERSE_EFFECT PSY_1_Nervousness 75736-33-3 MODAFINIL ADVERSE_EFFECT NEU_3_Amnesia 75736-33-3 MODAFINIL INDICATION Narcolepsy 75736-33-3 MODAFINIL TA_LEVEL_3 Narcolepsy 75736-33-3 MODAFINIL MECH_LEVEL_1 Modulate neural transmission 75736-33-3 MODAFINIL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 75736-33-3 MODAFINIL TISSUE_TOXICITY Cardiac Arrhythmia 75736-33-3 MODAFINIL ADVERSE_EFFECT CVS_2_Palpitation 75736-33-3 MODAFINIL ADVERSE_EFFECT NEU_2_Paresthesia 75736-33-3 MODAFINIL ADVERSE_EFFECT PSY_2_Impaired Judgment 75736-33-3 MODAFINIL ADVERSE_EFFECT GIS_1_Nausea 75736-33-3 MODAFINIL MECHANISM Prolong/enhance neural transmission 75736-33-3 MODAFINIL PRODUCT_CLASS Central Nervous System (CNS) 75736-33-3 MODAFINIL MECH_LEVEL_3 Dopamine (DA) Transporter DAT 75736-33-3 MODAFINIL MESH_LEVEL_2 Hydrocarbons 75736-33-3 MODAFINIL TA_LEVEL_2 CNS Stimulant 75736-33-3 MODAFINIL TA_LEVEL_1 Central Nervous System (CNS) 75736-33-3 MODAFINIL MESH_LEVEL_3 Hydrocarbons, Cyclic 75736-33-3 MODAFINIL ZERO_CLASS N 75736-33-3 MODAFINIL ADVERSE_EFFECT PSY_2_Mental Depression 75736-33-3 MODAFINIL ADVERSE_EFFECT PSY_2_Physical Dependence 75736-33-3 MODAFINIL ADVERSE_EFFECT PSY_1_Anxiety 75736-33-3 MODAFINIL ADVERSE_EFFECT CVS_3_Hypertension 75736-33-3 MODAFINIL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 75736-33-3 MODAFINIL TISSUE_TOXICITY Hypotension 787-93-9 AMELTOLIDE MODE_CLASS Channel Modulator 787-93-9 AMELTOLIDE MODE_CLASS Channel Blocker 787-93-9 AMELTOLIDE MECHANISM Block neural transmission 787-93-9 AMELTOLIDE MECHANISM Modulate channel gating 787-93-9 AMELTOLIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 787-93-9 AMELTOLIDE PRODUCT_CLASS Central Nervous System (CNS) 53912-89-3 ANABASINE HYDROCHLORIDE INDICATION Smoking Cessation 53912-89-3 ANABASINE HYDROCHLORIDE MODE_CLASS Channel Modulator 53912-89-3 ANABASINE HYDROCHLORIDE MECHANISM Prolong/enhance neural transmission 107052-56-2 ROMERGOLINE PRODUCT_CLASS Central Nervous System (CNS) 107052-56-2 ROMERGOLINE PRODUCT_CLASS Cardiovasculars 107052-56-2 ROMERGOLINE INDICATION Anxiety Disorders 107052-56-2 ROMERGOLINE INDICATION Hypertension 107052-56-2 ROMERGOLINE INDICATION Nausea / Vomiting 107052-56-2 ROMERGOLINE THERAPEUTIC_CLASS Antihypertensive Agents 107052-56-2 ROMERGOLINE INDICATION Parkinson's Disease 107052-56-2 ROMERGOLINE STRUCTURE_ACTIVITY Ergot alkaloid 107052-56-2 ROMERGOLINE THERAPEUTIC_CLASS Sedatives/Hypnotics 86050-77-3 GADOPENTETATE DIMEGLUMINE ACTIVITY_CLASS Unknown mechanism 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT XXX_3_Chills 86050-77-3 GADOPENTETATE DIMEGLUMINE MESH_LEVEL_2 Amines 86050-77-3 GADOPENTETATE DIMEGLUMINE MECH_LEVEL_1 Contrasting Agent for magnetic resonance imaging. 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT NEU_3_Syncope 86050-77-3 GADOPENTETATE DIMEGLUMINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 86050-77-3 GADOPENTETATE DIMEGLUMINE TA_LEVEL_1 Contrasting Agent for magnetic resonance imaging. 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT IMU_3_Allergic Reactions 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT CVS_3_Vasodilation 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT _3_Local Tissue Irritation 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT IMU_3_Anaphylaxis 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT NEU_3_Convulsions 86050-77-3 GADOPENTETATE DIMEGLUMINE MECH_LEVEL_3 Unknown mechanism 86050-77-3 GADOPENTETATE DIMEGLUMINE MECH_LEVEL_2 Contrasting Agent for magnetic resonance imaging. 86050-77-3 GADOPENTETATE DIMEGLUMINE MESH_LEVEL_1 Organic Chemicals 86050-77-3 GADOPENTETATE DIMEGLUMINE TA_LEVEL_3 Contrasting Agent for magnetic resonance imaging. 86050-77-3 GADOPENTETATE DIMEGLUMINE TA_LEVEL_2 Contrasting Agent for magnetic resonance imaging. 86050-77-3 GADOPENTETATE DIMEGLUMINE ZERO_CLASS Y 86050-77-3 GADOPENTETATE DIMEGLUMINE INDICATION Contrasting Agent 86050-77-3 GADOPENTETATE DIMEGLUMINE STRUCTURE_ACTIVITY Unknown mechanism 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 86050-77-3 GADOPENTETATE DIMEGLUMINE ADVERSE_EFFECT NEU_3_Headache 86050-77-3 GADOPENTETATE DIMEGLUMINE MESH_LEVEL_3 Polyamines 107736-98-1 UMISPIRONE INDICATION Anxiety Disorders 107736-98-1 UMISPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 107736-98-1 UMISPIRONE MECHANISM Modulate neural transmission 107736-98-1 UMISPIRONE PRODUCT_CLASS Central Nervous System (CNS) 107736-98-1 UMISPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 107736-98-1 UMISPIRONE MODE_CLASS Receptor Agonist 103890-78-4 LACIDIPINE TISSUE_TOXICITY Aggravation of Angina 103890-78-4 LACIDIPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 103890-78-4 LACIDIPINE MECH_LEVEL_1 Anti-anginal 103890-78-4 LACIDIPINE MECHANISM Reduce muscle contractile force 103890-78-4 LACIDIPINE ADVERSE_EFFECT IMU_3_Hypersensitivity 103890-78-4 LACIDIPINE ADVERSE_EFFECT MSK_2_Muscle Cramps 103890-78-4 LACIDIPINE TISSUE_TOXICITY Hypotension 103890-78-4 LACIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 103890-78-4 LACIDIPINE KNOWN_TOXICITY Cardiovascular Toxicity 103890-78-4 LACIDIPINE MESH_LEVEL_3 Pyridines 103890-78-4 LACIDIPINE MESH_LEVEL_1 Heterocyclic Compounds 103890-78-4 LACIDIPINE TA_LEVEL_3 Ca++ channel antagonists 103890-78-4 LACIDIPINE MODE_CLASS Channel Blocker 103890-78-4 LACIDIPINE ADVERSE_EFFECT XXX_2_Edema 103890-78-4 LACIDIPINE ADVERSE_EFFECT CVS_2_Palpitation 103890-78-4 LACIDIPINE ADVERSE_EFFECT CVS_3_Aggravation of Angina 103890-78-4 LACIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 103890-78-4 LACIDIPINE ADVERSE_EFFECT NEU_1_Headache 103890-78-4 LACIDIPINE INDICATION Hypertension 103890-78-4 LACIDIPINE MECH_LEVEL_3 L-Type Ca++ channel 103890-78-4 LACIDIPINE TA_LEVEL_2 anti-angina 103890-78-4 LACIDIPINE TA_LEVEL_1 Cardiovascular 103890-78-4 LACIDIPINE ADVERSE_EFFECT KID_3_Polyuria 103890-78-4 LACIDIPINE ADVERSE_EFFECT NEU_2_Dizziness 103890-78-4 LACIDIPINE ADVERSE_EFFECT XXX_2_Asthenia 103890-78-4 LACIDIPINE ADVERSE_EFFECT SKN_1_Flushing 103890-78-4 LACIDIPINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 103890-78-4 LACIDIPINE MECH_LEVEL_2 Reduce muscle contractile force 103890-78-4 LACIDIPINE PRODUCT_CLASS Cardiovasculars 103890-78-4 LACIDIPINE ADVERSE_EFFECT GIS_3_Gingival Hyperplasia 103890-78-4 LACIDIPINE ADVERSE_EFFECT SKN_2_Skin Rash 103890-78-4 LACIDIPINE ADVERSE_EFFECT CVS_2_Hypotension 103890-78-4 LACIDIPINE ZERO_CLASS N 109683-61-6 UTIBAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 109683-61-6 UTIBAPRIL INDICATION Hypertension 109683-61-6 UTIBAPRIL MECHANISM Reduce vasoconstriction 109683-61-6 UTIBAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 109683-61-6 UTIBAPRIL PRODUCT_CLASS Cardiovasculars 109683-61-6 UTIBAPRIL MODE_CLASS Enzyme Inhibitor 102106-21-8 CILNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 102106-21-8 CILNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 102106-21-8 CILNIDIPINE PRODUCT_CLASS Cardiovasculars 102106-21-8 CILNIDIPINE INDICATION Hypertension 102106-21-8 CILNIDIPINE MODE_CLASS Channel Blocker 102106-21-8 CILNIDIPINE MECHANISM Reduce muscle contractile force 132203-70-4 CILNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 132203-70-4 CILNIDIPINE PRODUCT_CLASS Cardiovasculars 132203-70-4 CILNIDIPINE INDICATION Hypertension 132203-70-4 CILNIDIPINE MODE_CLASS Channel Blocker 132203-70-4 CILNIDIPINE MECHANISM Reduce muscle contractile force 132203-70-4 CILNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 86811-09-8 LITOXETINE THERAPEUTIC_CLASS Antidepressants 86811-09-8 LITOXETINE INDICATION Depression 86811-09-8 LITOXETINE PRODUCT_CLASS Central Nervous System (CNS) 86811-09-8 LITOXETINE INDICATION Obesity 86928-16-7 LITOXETINE INDICATION Obesity 86928-16-7 LITOXETINE PRODUCT_CLASS Central Nervous System (CNS) 86928-16-7 LITOXETINE THERAPEUTIC_CLASS Antidepressants 86928-16-7 LITOXETINE INDICATION Depression 86811-10-1 LITOXETINE THERAPEUTIC_CLASS Antidepressants 86811-10-1 LITOXETINE INDICATION Depression 86811-10-1 LITOXETINE INDICATION Obesity 86811-10-1 LITOXETINE PRODUCT_CLASS Central Nervous System (CNS) 108736-35-2 LANREOTIDE INDICATION Re-Stenosis 108736-35-2 LANREOTIDE MECHANISM Modulate gene transcription 108736-35-2 LANREOTIDE MODE_CLASS Receptor /Channel ligand mimic 127984-74-1 LANREOTIDE MECHANISM Modulate gene transcription 127984-74-1 LANREOTIDE MODE_CLASS Receptor /Channel ligand mimic 127984-74-1 LANREOTIDE INDICATION Re-Stenosis 113658-85-8 TROMBODIPINE MODE_CLASS Channel Blocker 113658-85-8 TROMBODIPINE MECHANISM Reduce muscle contractile force 106308-44-5 RUFINAMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 106308-44-5 RUFINAMIDE MECHANISM Block neural transmission 106308-44-5 RUFINAMIDE PRODUCT_CLASS Central Nervous System (CNS) 106308-44-5 RUFINAMIDE MODE_CLASS Channel Blocker 108912-17-0 ATLIPROFEN METHYL ESTER MECHANISM Inhibit eicosanoid biosynthesis 108912-17-0 ATLIPROFEN METHYL ESTER MODE_CLASS Enzyme Inhibitor 108912-17-0 ATLIPROFEN METHYL ESTER STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 108912-17-0 ATLIPROFEN METHYL ESTER PRODUCT_CLASS Anti-inflammatories 108912-17-0 ATLIPROFEN METHYL ESTER THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 108912-14-7 ATLIPROFEN METHYL ESTER MODE_CLASS Enzyme Inhibitor 108912-14-7 ATLIPROFEN METHYL ESTER MECHANISM Inhibit eicosanoid biosynthesis 108912-14-7 ATLIPROFEN METHYL ESTER THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 108912-14-7 ATLIPROFEN METHYL ESTER PRODUCT_CLASS Anti-inflammatories 108912-14-7 ATLIPROFEN METHYL ESTER STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 158885-09-7 ATLIPROFEN METHYL ESTER PRODUCT_CLASS Anti-inflammatories 158885-09-7 ATLIPROFEN METHYL ESTER THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 158885-09-7 ATLIPROFEN METHYL ESTER MODE_CLASS Enzyme Inhibitor 158885-09-7 ATLIPROFEN METHYL ESTER MECHANISM Inhibit eicosanoid biosynthesis 158885-09-7 ATLIPROFEN METHYL ESTER STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 112733-06-9 ZENARESTAT KNOWN_TOXICITY Nephrotoxicity 112733-06-9 ZENARESTAT ADVERSE_EFFECT KID_3_Hyperuricemia 112733-06-9 ZENARESTAT INDICATION Diabetic Cataracts 112733-06-9 ZENARESTAT ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 112733-06-9 ZENARESTAT INDICATION Diabetic Neuropathy 112733-06-9 ZENARESTAT MECHANISM Inhibit precursor synthesis 112733-06-9 ZENARESTAT INDICATION Diabetic Retinopathy 112733-06-9 ZENARESTAT ADVERSE_EFFECT BBM_3_Decreased Red Blood Cells 112733-06-9 ZENARESTAT ADVERSE_EFFECT END_3_Hypouricemia 112733-06-9 ZENARESTAT ADVERSE_EFFECT KID_2_Increased Creatinine 112733-06-9 ZENARESTAT ADVERSE_EFFECT GIS_2_Dry Mouth 112733-06-9 ZENARESTAT STRUCTURE_ACTIVITY Aldehyde reductase inhibitor 112733-06-9 ZENARESTAT INDICATION Diabetic Nephropathy 112733-06-9 ZENARESTAT TISSUE_TOXICITY Renal Toxicity 112733-06-9 ZENARESTAT ADVERSE_EFFECT KID_3_Renal Toxicity 112733-06-9 ZENARESTAT MODE_CLASS Enzyme Inhibitor 112733-06-9 ZENARESTAT PRODUCT_CLASS Other Human Uses 112733-06-9 ZENARESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 112733-11-6 ZENARESTAT ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 112733-11-6 ZENARESTAT TISSUE_TOXICITY Renal Toxicity 112733-11-6 ZENARESTAT ADVERSE_EFFECT KID_3_Renal Toxicity 112733-11-6 ZENARESTAT ADVERSE_EFFECT BBM_3_Decreased Red Blood Cells 112733-11-6 ZENARESTAT MODE_CLASS Enzyme Inhibitor 112733-11-6 ZENARESTAT PRODUCT_CLASS Other Human Uses 112733-11-6 ZENARESTAT INDICATION Diabetic Neuropathy 112733-11-6 ZENARESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 112733-11-6 ZENARESTAT ADVERSE_EFFECT KID_2_Increased Creatinine 112733-11-6 ZENARESTAT ADVERSE_EFFECT GIS_2_Dry Mouth 112733-11-6 ZENARESTAT STRUCTURE_ACTIVITY Aldehyde reductase inhibitor 112733-11-6 ZENARESTAT KNOWN_TOXICITY Nephrotoxicity 112733-11-6 ZENARESTAT INDICATION Diabetic Nephropathy 112733-11-6 ZENARESTAT ADVERSE_EFFECT END_3_Hypouricemia 112733-11-6 ZENARESTAT ADVERSE_EFFECT KID_3_Hyperuricemia 112733-11-6 ZENARESTAT INDICATION Diabetic Retinopathy 112733-11-6 ZENARESTAT MECHANISM Inhibit precursor synthesis 112733-11-6 ZENARESTAT INDICATION Diabetic Cataracts 101343-69-5 OCFENTANIL THERAPEUTIC_CLASS General Anesthetics, Intravenous 101343-69-5 OCFENTANIL PRODUCT_CLASS Central Nervous System (CNS) 101343-69-5 OCFENTANIL MODE_CLASS Receptor Agonist, selective 101343-69-5 OCFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 101343-69-5 OCFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 101343-69-5 OCFENTANIL PRODUCT_CLASS Analgesics 101343-69-5 OCFENTANIL MECHANISM Modulate neural transmission 107361-33-1 ENAZADREM INDICATION Psoriasis 107361-33-1 ENAZADREM MECHANISM Inhibit eicosanoid biosynthesis 107361-33-1 ENAZADREM MODE_CLASS Enzyme Inhibitor 109543-76-2 ROMAZARIT PRODUCT_CLASS Immune Response / Immunomodulators 109543-76-2 ROMAZARIT INDICATION Rheumatism 109543-76-2 ROMAZARIT THERAPEUTIC_CLASS Immunosuppressants 109543-76-2 ROMAZARIT INDICATION Arthritis 132031-81-3 NP-252 PRODUCT_CLASS Cardiovasculars 132031-81-3 NP-252 MECHANISM Modulate channel gating 132031-81-3 NP-252 THERAPEUTIC_CLASS Antihypertensive Agents 132031-81-3 NP-252 INDICATION Hypertension 132031-81-3 NP-252 MODE_CLASS Channel Modulator 110140-89-1 RIDOGREL INDICATION Inflammatory Bowel Disease (IBD) 110629-41-9 ELBANIZINE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 110629-41-9 ELBANIZINE INDICATION Asthma 110629-41-9 ELBANIZINE PRODUCT_CLASS Respiratory System 109859-50-9 CILOBRADINE THERAPEUTIC_CLASS Antiarrhythmic Agents 109859-50-9 CILOBRADINE THERAPEUTIC_CLASS Antianginals 109859-50-9 CILOBRADINE INDICATION Cardiac Arrhythmias 109859-50-9 CILOBRADINE INDICATION Angina Pectoris 109859-50-9 CILOBRADINE PRODUCT_CLASS Cardiovasculars 109859-78-1 CILOBRADINE INDICATION Angina Pectoris 109859-78-1 CILOBRADINE THERAPEUTIC_CLASS Antiarrhythmic Agents 109859-78-1 CILOBRADINE INDICATION Cardiac Arrhythmias 109859-78-1 CILOBRADINE PRODUCT_CLASS Cardiovasculars 109859-78-1 CILOBRADINE THERAPEUTIC_CLASS Antianginals 110311-27-8 SULOFENUR STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 110311-27-8 SULOFENUR MODE_CLASS Channel Blocker, selective 110311-27-8 SULOFENUR THERAPEUTIC_CLASS Antidiabetic Agents 110311-27-8 SULOFENUR PRODUCT_CLASS Hormones, Endocrine and Metabolic 110311-27-8 SULOFENUR MECHANISM Trigger insulin release in pancreatic beta cells 110311-27-8 SULOFENUR INDICATION Type II Diabetes Mellitus 113462-26-3 COLFORSIN DAPROPATE INDICATION Acute Heart Failure 113462-26-3 COLFORSIN DAPROPATE THERAPEUTIC_CLASS Congestive Heart Failure 113462-26-3 COLFORSIN DAPROPATE PRODUCT_CLASS Cardiovasculars 138605-00-2 COLFORSIN DAPROPATE THERAPEUTIC_CLASS Congestive Heart Failure 138605-00-2 COLFORSIN DAPROPATE INDICATION Acute Heart Failure 138605-00-2 COLFORSIN DAPROPATE PRODUCT_CLASS Cardiovasculars 87027-09-6 PIROXICAM PIVALATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 87027-09-6 PIROXICAM PIVALATE STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 87027-09-6 PIROXICAM PIVALATE PRODUCT_CLASS Anti-inflammatories 87027-09-6 PIROXICAM PIVALATE MECHANISM Inhibit eicosanoid biosynthesis 87027-09-6 PIROXICAM PIVALATE MODE_CLASS Enzyme Inhibitor 109713-79-3 NELDAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 109713-79-3 NELDAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 109713-79-3 NELDAZOSIN PRODUCT_CLASS Cardiovasculars 109713-79-3 NELDAZOSIN MECHANISM Modulate G-protein coupled signal transduction 109713-79-3 NELDAZOSIN INDICATION Hypertension 90596-75-1 YT-146 THERAPEUTIC_CLASS Antihypertensive Agents 90596-75-1 YT-146 PRODUCT_CLASS Cardiovasculars 90596-75-1 YT-146 MECHANISM Modulate G-protein coupled signal transduction 90596-75-1 YT-146 INDICATION Hypertension 159776-68-8 LINETASTINE MECHANISM Inhibit eicosanoid biosynthesis 159776-68-8 LINETASTINE INDICATION Viral Rhinitis / Common Cold 159776-68-8 LINETASTINE MODE_CLASS Enzyme Inhibitor 110501-66-1 LINETASTINE INDICATION Viral Rhinitis / Common Cold 110501-66-1 LINETASTINE MODE_CLASS Enzyme Inhibitor 110501-66-1 LINETASTINE MECHANISM Inhibit eicosanoid biosynthesis 114488-24-3 NDDP STRUCTURE_ACTIVITY DNA-alkylator, platin 30652-11-0 DEFERIPRONE ADVERSE_EFFECT GUS_1_Discoloration of Urine 30652-11-0 DEFERIPRONE ADVERSE_EFFECT BBM_3_Agranulocytosis 30652-11-0 DEFERIPRONE MESH_LEVEL_3 Pyrimidines 30652-11-0 DEFERIPRONE MECH_LEVEL_3 chelator, iron 30652-11-0 DEFERIPRONE MECHANISM chelate excess metal 30652-11-0 DEFERIPRONE ADVERSE_EFFECT LIV_2_Increased Liver Function Tests 30652-11-0 DEFERIPRONE ADVERSE_EFFECT MSK_2_Arthralgia 30652-11-0 DEFERIPRONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 30652-11-0 DEFERIPRONE MESH_LEVEL_1 Heterocyclic Compounds 30652-11-0 DEFERIPRONE PRODUCT_CLASS Other Human Uses 30652-11-0 DEFERIPRONE ADVERSE_EFFECT GIS_1_Nausea 30652-11-0 DEFERIPRONE ZERO_CLASS N 30652-11-0 DEFERIPRONE THERAPEUTIC_CLASS Chelating Agents / Heavy Metal Antagonists 30652-11-0 DEFERIPRONE ADVERSE_EFFECT GIS_1_Vomiting 30652-11-0 DEFERIPRONE ACTIVITY_CLASS Chelator, iron 30652-11-0 DEFERIPRONE ADVERSE_EFFECT BBM_2_Neutropenia 30652-11-0 DEFERIPRONE STRUCTURE_ACTIVITY Iron chelator, HIF-1alpha stablizer 30652-11-0 DEFERIPRONE ADVERSE_EFFECT GIS_1_Abdominal Pain 30652-11-0 DEFERIPRONE ADVERSE_EFFECT XXX_2_Increased Appetite 30652-11-0 DEFERIPRONE INDICATION Iron Overload 30652-11-0 DEFERIPRONE TA_LEVEL_3 thalassaemia 30652-11-0 DEFERIPRONE TA_LEVEL_1 Cardiovascular 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT LUN_3_Pulmonary Edema 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT DNA_2_Mutagenicity 14930-96-2 CYTOCHALASIN B KNOWN_TOXICITY Cardiovascular Toxicity 14930-96-2 CYTOCHALASIN B INDICATION Re-Stenosis 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT XXX_1_Cytotoxicity 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT PSY_1_CNS Dysfunction 14930-96-2 CYTOCHALASIN B THERAPEUTIC_CLASS Antineoplastics 14930-96-2 CYTOCHALASIN B PRODUCT_CLASS Cardiovasculars 14930-96-2 CYTOCHALASIN B INDICATION Atherosclerosis 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT MSK_3_Musculoskeletal System Toxicity 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT LIV_2_Hepatic Damage 14930-96-2 CYTOCHALASIN B INDICATION Neoplasm / Cancer / Tumor 14930-96-2 CYTOCHALASIN B TISSUE_TOXICITY Teratogenicity 14930-96-2 CYTOCHALASIN B MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 14930-96-2 CYTOCHALASIN B MECHANISM Inhibit mitosis 14930-96-2 CYTOCHALASIN B KNOWN_TOXICITY Embryo/Fetal Toxicity 14930-96-2 CYTOCHALASIN B THERAPEUTIC_CLASS Hypolipidemic Agents 14930-96-2 CYTOCHALASIN B PRODUCT_CLASS Anti-cancers 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT CVS_3_Myocardial Infarction 14930-96-2 CYTOCHALASIN B ADVERSE_EFFECT EMB_3_Teratogenicity 14930-96-2 CYTOCHALASIN B STRUCTURE_ACTIVITY Tubulin binder 14930-96-2 CYTOCHALASIN B KNOWN_TOXICITY Mutagenicity 14930-96-2 CYTOCHALASIN B TISSUE_TOXICITY Myocardial Infarction 14930-96-2 CYTOCHALASIN B TISSUE_TOXICITY Mutagenicity 14930-96-2 CYTOCHALASIN B ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 90729-43-4 EBASTINE PRODUCT_CLASS Anti-inflammatories 90729-43-4 EBASTINE INDICATION Urticaria / Hives 90729-43-4 EBASTINE MECH_LEVEL_3 histamine receptor H1 90729-43-4 EBASTINE ADVERSE_EFFECT LIV_3_Jaundice 90729-43-4 EBASTINE ADVERSE_EFFECT GIS_3_Diarrhea 90729-43-4 EBASTINE INDICATION Pruritus / Itching 90729-43-4 EBASTINE MECH_LEVEL_2 Anti-histamine 90729-43-4 EBASTINE INDICATION Allergic Rhinitis 90729-43-4 EBASTINE ADVERSE_EFFECT NEU_3_Numbness 90729-43-4 EBASTINE ADVERSE_EFFECT GIS_2_Dry Mouth 90729-43-4 EBASTINE ADVERSE_EFFECT NEU_2_Drowsiness 90729-43-4 EBASTINE ACTIVITY_CLASS Histamine antagonist 90729-43-4 EBASTINE MESH_LEVEL_3 Butyrophenones 90729-43-4 EBASTINE MECH_LEVEL_1 Immunomodulation 90729-43-4 EBASTINE MECHANISM Modulate G-protein coupled signal transduction 90729-43-4 EBASTINE ADVERSE_EFFECT SKN_3_Skin Rash 90729-43-4 EBASTINE ADVERSE_EFFECT NEU_2_Dizziness 90729-43-4 EBASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 90729-43-4 EBASTINE ADVERSE_EFFECT XXX_3_Glossitis 90729-43-4 EBASTINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 90729-43-4 EBASTINE ADVERSE_EFFECT IMU_3_Hypersensitivity 90729-43-4 EBASTINE THERAPEUTIC_CLASS Antihistamines 90729-43-4 EBASTINE ZERO_CLASS N 90729-43-4 EBASTINE TA_LEVEL_1 Anti-inflammatory 90729-43-4 EBASTINE ADVERSE_EFFECT NEU_2_Headache 90729-43-4 EBASTINE MESH_LEVEL_2 Ketones 90729-43-4 EBASTINE MODE_CLASS Receptor Ligand Antagonist 90729-43-4 EBASTINE ADVERSE_EFFECT IMU_2_Eosinophilia 90729-43-4 EBASTINE TA_LEVEL_2 Anti-histamine 90729-43-4 EBASTINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 90729-43-4 EBASTINE INDICATION Dermatitis 90729-43-4 EBASTINE MESH_LEVEL_1 Organic Chemicals 111223-26-8 CERONAPRIL INDICATION Hypertension 111223-26-8 CERONAPRIL MECHANISM Reduce vasoconstriction 111223-26-8 CERONAPRIL PRODUCT_CLASS Cardiovasculars 111223-26-8 CERONAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 111223-26-8 CERONAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 111223-26-8 CERONAPRIL MODE_CLASS Enzyme Inhibitor 110958-19-5 LAM-105 STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 110958-23-1 LAM-105 STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 59388-44-2 LAM-105 STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 81059-04-3 CGP-20376 INDICATION Helminthic Infections 92118-27-9 FOTEMUSTINE PRODUCT_CLASS Anti-cancers 92118-27-9 FOTEMUSTINE THERAPEUTIC_CLASS Antineoplastics 92118-27-9 FOTEMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 92118-27-9 FOTEMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 110623-33-1 SURITOZOLE PRODUCT_CLASS Central Nervous System (CNS) 110623-33-1 SURITOZOLE THERAPEUTIC_CLASS Antidepressants 110623-33-1 SURITOZOLE INDICATION Depression 110703-94-1 ZOPOLRESTAT MECHANISM Inhibit precursor synthesis 110703-94-1 ZOPOLRESTAT INDICATION Diabetic Neuropathy 110703-94-1 ZOPOLRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 110703-94-1 ZOPOLRESTAT PRODUCT_CLASS Other Human Uses 110703-94-1 ZOPOLRESTAT MODE_CLASS Enzyme Inhibitor 110765-49-6 ZOPOLRESTAT MECHANISM Inhibit precursor synthesis 110765-49-6 ZOPOLRESTAT MODE_CLASS Enzyme Inhibitor 110765-49-6 ZOPOLRESTAT PRODUCT_CLASS Other Human Uses 110765-49-6 ZOPOLRESTAT INDICATION Diabetic Neuropathy 110765-49-6 ZOPOLRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 106730-54-5 OLPRINONE HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 106730-54-5 OLPRINONE HYDROCHLORIDE MECHANISM Enhance kinase mediated signal transduction 119615-63-3 OLPRINONE HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 119615-63-3 OLPRINONE HYDROCHLORIDE MECHANISM Enhance kinase mediated signal transduction 107097-80-3 LOXIGLUMIDE MODE_CLASS Receptor Ligand Antagonist 107097-80-3 LOXIGLUMIDE MECHANISM Modulate G-protein coupled signal transduction 113049-11-9 UK-66914 PRODUCT_CLASS Cardiovasculars 113049-11-9 UK-66914 INDICATION Cardiac Arrhythmias 113049-11-9 UK-66914 THERAPEUTIC_CLASS Antiarrhythmic Agents 127910-31-0 CGP-37849 MODE_CLASS Channel Modulator 127910-31-0 CGP-37849 MECHANISM Modulate neural transmission 115104-28-4 MK-571 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 115104-28-4 MK-571 INDICATION Asthma 115104-28-4 MK-571 MODE_CLASS Receptor Ligand Antagonist 115104-28-4 MK-571 MECHANISM Modulate G-protein coupled signal transduction 115104-28-4 MK-571 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 115104-28-4 MK-571 PRODUCT_CLASS Respiratory System 115103-85-0 MK-571 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 115103-85-0 MK-571 MECHANISM Modulate G-protein coupled signal transduction 115103-85-0 MK-571 MODE_CLASS Receptor Ligand Antagonist 115103-85-0 MK-571 PRODUCT_CLASS Respiratory System 115103-85-0 MK-571 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 115103-85-0 MK-571 INDICATION Asthma 96036-03-2 MEROPENEM ADVERSE_EFFECT LUN_3_Bronchospasm 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_2_Hypotension 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_3_Fever 96036-03-2 MEROPENEM MESH_LEVEL_2 Amides 96036-03-2 MEROPENEM TA_LEVEL_1 Infectious Disease 96036-03-2 MEROPENEM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 96036-03-2 MEROPENEM KNOWN_TOXICITY Hepatotoxicity 96036-03-2 MEROPENEM TISSUE_TOXICITY Hepatic Failure 96036-03-2 MEROPENEM ADVERSE_EFFECT BBM_3_Thrombocytosis 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_3_Asthenia 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_2_Epistaxis 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 96036-03-2 MEROPENEM ADVERSE_EFFECT GUS_3_Dysuria 96036-03-2 MEROPENEM ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 96036-03-2 MEROPENEM ADVERSE_EFFECT LUN_3_Dyspnea 96036-03-2 MEROPENEM ADVERSE_EFFECT BBM_2_Anemia 96036-03-2 MEROPENEM ADVERSE_EFFECT SKN_1_Pruritis 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_3_Cardiac Arrest 96036-03-2 MEROPENEM ADVERSE_EFFECT IMU_2_Positive Coombs Test 96036-03-2 MEROPENEM ADVERSE_EFFECT ELT_3_Hypokalemia 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_3_Hypertension 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_1_Constipation 96036-03-2 MEROPENEM MECH_LEVEL_1 Anti-bacterial 96036-03-2 MEROPENEM INDICATION Meningitis 96036-03-2 MEROPENEM MESH_LEVEL_1 Organic Chemicals 96036-03-2 MEROPENEM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 96036-03-2 MEROPENEM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 96036-03-2 MEROPENEM TISSUE_TOXICITY Cardiac Arrest 96036-03-2 MEROPENEM TISSUE_TOXICITY Sepsis 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_3_Heart Failure 96036-03-2 MEROPENEM ADVERSE_EFFECT LUN_1_Apnea 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_3_Flatulence 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_2_Abdominal Pain 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_2_Gastrointestinal Hemorrhage 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_2_Phlebitis 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_1_Shock 96036-03-2 MEROPENEM ADVERSE_EFFECT PSY_3_Agitation 96036-03-2 MEROPENEM ADVERSE_EFFECT NEU_3_Dizziness 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_3_Candidiasis 96036-03-2 MEROPENEM ADVERSE_EFFECT SKN_1_Rash 96036-03-2 MEROPENEM ADVERSE_EFFECT LUN_3_Cough 96036-03-2 MEROPENEM ADVERSE_EFFECT PSY_3_Anorexia 96036-03-2 MEROPENEM ADVERSE_EFFECT PSY_3_Delirium 96036-03-2 MEROPENEM THERAPEUTIC_CLASS Antibacterials, Systemic 96036-03-2 MEROPENEM TA_LEVEL_3 systemic infections 96036-03-2 MEROPENEM MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 96036-03-2 MEROPENEM INDICATION Intra-Abdominal Infections 96036-03-2 MEROPENEM ZERO_CLASS N 96036-03-2 MEROPENEM KNOWN_TOXICITY Miscellaneous 96036-03-2 MEROPENEM TISSUE_TOXICITY Heart Failure 96036-03-2 MEROPENEM TISSUE_TOXICITY Shock 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_2_Hypovolemia 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_3_Diaphoresis 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_1_Sepsis 96036-03-2 MEROPENEM ADVERSE_EFFECT IMU_2_Eosinophilia 96036-03-2 MEROPENEM ADVERSE_EFFECT CVS_3_Chest Pain 96036-03-2 MEROPENEM ADVERSE_EFFECT LIV_3_Hepatic Failure 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_3_Chills 96036-03-2 MEROPENEM ADVERSE_EFFECT BBM_2_Thrombocytopenia 96036-03-2 MEROPENEM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 96036-03-2 MEROPENEM ADVERSE_EFFECT NEU_3_Seizures 96036-03-2 MEROPENEM ADVERSE_EFFECT BBM_2_Agranulocytosis 96036-03-2 MEROPENEM ADVERSE_EFFECT NEU_1_Headache 96036-03-2 MEROPENEM ADVERSE_EFFECT PSY_3_Anxiety 96036-03-2 MEROPENEM ADVERSE_EFFECT PSY_3_Hallucinations 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_1_Diarrhea 96036-03-2 MEROPENEM MODE_CLASS Enzyme Inhibitor 96036-03-2 MEROPENEM INDICATION Febrile Neutropenia 96036-03-2 MEROPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 96036-03-2 MEROPENEM TA_LEVEL_2 Anti-bacterial 96036-03-2 MEROPENEM PRODUCT_CLASS Anti-infectives 96036-03-2 MEROPENEM MESH_LEVEL_3 Lactams 96036-03-2 MEROPENEM KNOWN_TOXICITY Cardiovascular Toxicity 96036-03-2 MEROPENEM TISSUE_TOXICITY Hypotension 96036-03-2 MEROPENEM ADVERSE_EFFECT XXX_3_Hemoperitoneum 96036-03-2 MEROPENEM ADVERSE_EFFECT MSK_3_Back Pain 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_3_Dyspepsia 96036-03-2 MEROPENEM ADVERSE_EFFECT GIS_2_Melena 96036-03-2 MEROPENEM ADVERSE_EFFECT LIV_3_Cholestasis 96036-03-2 MEROPENEM ADVERSE_EFFECT BBM_2_Leukopenia 96036-03-2 MEROPENEM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 96036-03-2 MEROPENEM ADVERSE_EFFECT PSY_3_Confusion 119478-56-7 MEROPENEM ADVERSE_EFFECT PSY_3_Anxiety 119478-56-7 MEROPENEM TISSUE_TOXICITY Hepatic Failure 119478-56-7 MEROPENEM KNOWN_TOXICITY Hepatotoxicity 119478-56-7 MEROPENEM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 119478-56-7 MEROPENEM TA_LEVEL_1 Infectious Disease 119478-56-7 MEROPENEM MESH_LEVEL_2 Amides 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_3_Fever 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_2_Hypotension 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 119478-56-7 MEROPENEM ADVERSE_EFFECT NEU_3_Dizziness 119478-56-7 MEROPENEM ADVERSE_EFFECT LUN_3_Bronchospasm 119478-56-7 MEROPENEM ADVERSE_EFFECT PSY_3_Confusion 119478-56-7 MEROPENEM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 119478-56-7 MEROPENEM ADVERSE_EFFECT BBM_2_Leukopenia 119478-56-7 MEROPENEM ADVERSE_EFFECT LIV_3_Cholestasis 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_2_Melena 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_3_Dyspepsia 119478-56-7 MEROPENEM ADVERSE_EFFECT MSK_3_Back Pain 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_3_Hemoperitoneum 119478-56-7 MEROPENEM MESH_LEVEL_3 Lactams 119478-56-7 MEROPENEM PRODUCT_CLASS Anti-infectives 119478-56-7 MEROPENEM TISSUE_TOXICITY Hypotension 119478-56-7 MEROPENEM KNOWN_TOXICITY Cardiovascular Toxicity 119478-56-7 MEROPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 119478-56-7 MEROPENEM INDICATION Febrile Neutropenia 119478-56-7 MEROPENEM MODE_CLASS Enzyme Inhibitor 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_1_Diarrhea 119478-56-7 MEROPENEM ADVERSE_EFFECT PSY_3_Hallucinations 119478-56-7 MEROPENEM ADVERSE_EFFECT SKN_1_Rash 119478-56-7 MEROPENEM ADVERSE_EFFECT NEU_1_Headache 119478-56-7 MEROPENEM ADVERSE_EFFECT BBM_2_Agranulocytosis 119478-56-7 MEROPENEM ADVERSE_EFFECT NEU_3_Seizures 119478-56-7 MEROPENEM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 119478-56-7 MEROPENEM ADVERSE_EFFECT BBM_2_Thrombocytopenia 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_3_Chills 119478-56-7 MEROPENEM ADVERSE_EFFECT LIV_3_Hepatic Failure 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_3_Chest Pain 119478-56-7 MEROPENEM ADVERSE_EFFECT IMU_2_Eosinophilia 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_1_Sepsis 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_3_Diaphoresis 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_2_Hypovolemia 119478-56-7 MEROPENEM TISSUE_TOXICITY Shock 119478-56-7 MEROPENEM TISSUE_TOXICITY Heart Failure 119478-56-7 MEROPENEM KNOWN_TOXICITY Miscellaneous 119478-56-7 MEROPENEM ZERO_CLASS N 119478-56-7 MEROPENEM INDICATION Intra-Abdominal Infections 119478-56-7 MEROPENEM MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 119478-56-7 MEROPENEM TA_LEVEL_3 systemic infections 119478-56-7 MEROPENEM THERAPEUTIC_CLASS Antibacterials, Systemic 119478-56-7 MEROPENEM ADVERSE_EFFECT PSY_3_Delirium 119478-56-7 MEROPENEM ADVERSE_EFFECT PSY_3_Anorexia 119478-56-7 MEROPENEM ADVERSE_EFFECT LUN_3_Cough 119478-56-7 MEROPENEM TA_LEVEL_2 Anti-bacterial 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_3_Candidiasis 119478-56-7 MEROPENEM ADVERSE_EFFECT PSY_3_Agitation 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_1_Shock 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_2_Phlebitis 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_2_Gastrointestinal Hemorrhage 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_2_Abdominal Pain 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_3_Flatulence 119478-56-7 MEROPENEM ADVERSE_EFFECT LUN_1_Apnea 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_3_Heart Failure 119478-56-7 MEROPENEM TISSUE_TOXICITY Sepsis 119478-56-7 MEROPENEM TISSUE_TOXICITY Cardiac Arrest 119478-56-7 MEROPENEM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 119478-56-7 MEROPENEM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 119478-56-7 MEROPENEM MESH_LEVEL_1 Organic Chemicals 119478-56-7 MEROPENEM INDICATION Meningitis 119478-56-7 MEROPENEM MECH_LEVEL_1 Anti-bacterial 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_1_Constipation 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_3_Hypertension 119478-56-7 MEROPENEM ADVERSE_EFFECT ELT_3_Hypokalemia 119478-56-7 MEROPENEM ADVERSE_EFFECT IMU_2_Positive Coombs Test 119478-56-7 MEROPENEM ADVERSE_EFFECT CVS_3_Cardiac Arrest 119478-56-7 MEROPENEM ADVERSE_EFFECT SKN_1_Pruritis 119478-56-7 MEROPENEM ADVERSE_EFFECT BBM_2_Anemia 119478-56-7 MEROPENEM ADVERSE_EFFECT LUN_3_Dyspnea 119478-56-7 MEROPENEM ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 119478-56-7 MEROPENEM ADVERSE_EFFECT GUS_3_Dysuria 119478-56-7 MEROPENEM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_2_Epistaxis 119478-56-7 MEROPENEM ADVERSE_EFFECT XXX_3_Asthenia 119478-56-7 MEROPENEM ADVERSE_EFFECT BBM_3_Thrombocytosis 113957-09-8 CEBARACETAM INDICATION Amnesia 113957-09-8 CEBARACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 112108-01-7 ECOPIPAM INDICATION Addiction / Dependency 112108-01-7 ECOPIPAM MECHANISM Modulate G-protein coupled signal transduction 112108-00-6 ECOPIPAM MECHANISM Modulate G-protein coupled signal transduction 112108-00-6 ECOPIPAM INDICATION Addiction / Dependency 112107-92-3 ECOPIPAM MECHANISM Modulate G-protein coupled signal transduction 112107-92-3 ECOPIPAM INDICATION Addiction / Dependency 105431-72-9 LINOPIRDINE MODE_CLASS Channel Blocker 105431-72-9 LINOPIRDINE STRUCTURE_ACTIVITY Acetylcholine release stimulator 105431-72-9 LINOPIRDINE INDICATION Alzheimer's Disease 105431-72-9 LINOPIRDINE THERAPEUTIC_CLASS Neurodegenerative Disorders 105431-72-9 LINOPIRDINE MECHANISM Block channel gating 105431-72-9 LINOPIRDINE PRODUCT_CLASS Central Nervous System (CNS) 64318-79-2 GEMEPROST MECHANISM Modulate G-protein coupled signal transduction 64318-79-2 GEMEPROST MODE_CLASS Receptor Agonist 52152-93-9 CEFSULODIN SODIUM PRODUCT_CLASS Anti-infectives 52152-93-9 CEFSULODIN SODIUM MODE_CLASS Enzyme Inhibitor 52152-93-9 CEFSULODIN SODIUM THERAPEUTIC_CLASS Antibacterials 52152-93-9 CEFSULODIN SODIUM MECHANISM Inhibit bacterial cell wall biosynthesis 56281-36-8 MOTRETINIDE THERAPEUTIC_CLASS Acne Preparations 56281-36-8 MOTRETINIDE INDICATION Acne / Acne Vulgaris 56281-36-8 MOTRETINIDE MODE_CLASS Receptor Agonist 56281-36-8 MOTRETINIDE STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 56281-36-8 MOTRETINIDE MECHANISM Modulate gene transcription 56281-36-8 MOTRETINIDE PRODUCT_CLASS Dermatologicals 30299-08-2 CLINOFIBRATE STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 30299-08-2 CLINOFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 30299-08-2 CLINOFIBRATE INDICATION Hypolipidemia 30299-08-2 CLINOFIBRATE PRODUCT_CLASS Cardiovasculars 30299-08-2 CLINOFIBRATE INDICATION Hyperlipoproteinemia 30299-08-2 CLINOFIBRATE MODE_CLASS Receptor Agonist, selective 30299-08-2 CLINOFIBRATE MECHANISM Increase lipid catabolism 53716-49-7 CARPROFEN MECHANISM Inhibit eicosanoid biosynthesis 53716-49-7 CARPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 53716-49-7 CARPROFEN MODE_CLASS Enzyme Inhibitor 53716-49-7 CARPROFEN PRODUCT_CLASS Anti-inflammatories 29177-84-2 ETHYL LOFLAZEPATE STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 29177-84-2 ETHYL LOFLAZEPATE INDICATION Anxiety Disorders 29177-84-2 ETHYL LOFLAZEPATE INDICATION Alcoholic Withdrawal 29177-84-2 ETHYL LOFLAZEPATE PRODUCT_CLASS Central Nervous System (CNS) 29177-84-2 ETHYL LOFLAZEPATE MECHANISM Modulate neural transmission 29177-84-2 ETHYL LOFLAZEPATE MODE_CLASS Channel Modulator 29177-84-2 ETHYL LOFLAZEPATE THERAPEUTIC_CLASS Sedatives/Hypnotics 58337-35-2 ELLIPTINIUM ACETATE MECHANISM Inhibit DNA synthesis, repair, and function 58337-35-2 ELLIPTINIUM ACETATE MODE_CLASS Enzyme Inhibitor 58447-24-8 ELLIPTINIUM ACETATE MECHANISM Inhibit DNA synthesis, repair, and function 58447-24-8 ELLIPTINIUM ACETATE MODE_CLASS Enzyme Inhibitor 64552-17-6 BUTOFILOLOL THERAPEUTIC_CLASS Antihypertensive Agents 64552-17-6 BUTOFILOLOL INDICATION Angina Pectoris 64552-17-6 BUTOFILOLOL INDICATION Hypertension 64552-17-6 BUTOFILOLOL PRODUCT_CLASS Cardiovasculars 64552-17-6 BUTOFILOLOL MECHANISM Reduce muscle contractile force 64552-17-6 BUTOFILOLOL MODE_CLASS Receptor Ligand Antagonist 64552-17-6 BUTOFILOLOL THERAPEUTIC_CLASS Antianginals 58795-03-2 APALCILLIN MODE_CLASS Enzyme Inhibitor 58795-03-2 APALCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 58795-03-2 APALCILLIN THERAPEUTIC_CLASS Antibacterials 58795-03-2 APALCILLIN PRODUCT_CLASS Anti-infectives 63469-19-2 APALCILLIN MODE_CLASS Enzyme Inhibitor 63469-19-2 APALCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 63469-19-2 APALCILLIN THERAPEUTIC_CLASS Antibacterials 63469-19-2 APALCILLIN PRODUCT_CLASS Anti-infectives 322-79-2 TRIFLUSAL MECHANISM Inhibit eicosanoid biosynthesis 322-79-2 TRIFLUSAL MODE_CLASS Enzyme Inhibitor 57773-65-6 DESLORELIN MODE_CLASS Receptor Agonist 57773-65-6 DESLORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 67190-19-6 DESLORELIN MODE_CLASS Receptor Agonist 67190-19-6 DESLORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 2126-70-7 ANISOYLBROMACRYLIC ACID, NA MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2126-70-7 ANISOYLBROMACRYLIC ACID, NA MECHANISM Inhibit DNA synthesis, repair, and function 21739-91-3 ANISOYLBROMACRYLIC ACID, NA MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 21739-91-3 ANISOYLBROMACRYLIC ACID, NA MECHANISM Inhibit DNA synthesis, repair, and function 56430-99-0 FLUMECINOL INDICATION Jaundice / Icterus 88678-31-3 LIRANAFTATE MODE_CLASS Enzyme Inhibitor 88678-31-3 LIRANAFTATE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 88495-63-0 ARTESUNATE MECHANISM Induce free oxygen radical associated tissue and DNA damage 88495-63-0 ARTESUNATE INDICATION Malaria 120020-26-0 ARTESUNATE MECHANISM Induce free oxygen radical associated tissue and DNA damage 120020-26-0 ARTESUNATE INDICATION Malaria 15180-03-7 ALCURONIUM CHLORIDE MODE_CLASS Channel Blocker, selective 15180-03-7 ALCURONIUM CHLORIDE MECHANISM Block neural transmission 15180-03-7 ALCURONIUM CHLORIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 15180-03-7 ALCURONIUM CHLORIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 55726-47-1 ENOCITABINE INDICATION Acute Non-Lymphocytic Leukemia 55726-47-1 ENOCITABINE ADVERSE_EFFECT PSY_2_Anorexia 55726-47-1 ENOCITABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 55726-47-1 ENOCITABINE PRODUCT_CLASS Anti-cancers 55726-47-1 ENOCITABINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 55726-47-1 ENOCITABINE MODE_CLASS Enzyme substrate mimic 55726-47-1 ENOCITABINE MECHANISM Incorporate into DNA/RNA/Protein 55726-47-1 ENOCITABINE ADVERSE_EFFECT BBM_2_Myelosuppression 55726-47-1 ENOCITABINE INDICATION Leukemia 55726-47-1 ENOCITABINE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 55726-47-1 ENOCITABINE THERAPEUTIC_CLASS Antineoplastics 987-78-0 CITICOLINE MECHANISM Modulate G-protein coupled signal transduction 987-78-0 CITICOLINE MODE_CLASS Channel Modulator 987-78-0 CITICOLINE MODE_CLASS Receptor Agonist 987-78-0 CITICOLINE MECHANISM Prolong/enhance neural transmission 1477-47-0 CITICOLINE MECHANISM Modulate G-protein coupled signal transduction 1477-47-0 CITICOLINE MODE_CLASS Channel Modulator 1477-47-0 CITICOLINE MODE_CLASS Receptor Agonist 1477-47-0 CITICOLINE MECHANISM Prolong/enhance neural transmission 33818-15-4 CITICOLINE MECHANISM Modulate G-protein coupled signal transduction 33818-15-4 CITICOLINE MODE_CLASS Channel Modulator 33818-15-4 CITICOLINE MODE_CLASS Receptor Agonist 33818-15-4 CITICOLINE MECHANISM Prolong/enhance neural transmission 77-28-1 BUTETHAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 77-28-1 BUTETHAL MECHANISM Modulate neural transmission 77-28-1 BUTETHAL PRODUCT_CLASS Central Nervous System (CNS) 77-28-1 BUTETHAL MODE_CLASS Channel Modulator 77-28-1 BUTETHAL THERAPEUTIC_CLASS Sedatives/Hypnotics 533-45-9 CLOMETHIAZOLE EDISILATE MECHANISM Modulate neural transmission 533-45-9 CLOMETHIAZOLE EDISILATE THERAPEUTIC_CLASS Antipsychotics 533-45-9 CLOMETHIAZOLE EDISILATE THERAPEUTIC_CLASS Sedatives/Hypnotics 533-45-9 CLOMETHIAZOLE EDISILATE STRUCTURE_ACTIVITY GABA-A agonist 533-45-9 CLOMETHIAZOLE EDISILATE MODE_CLASS Channel enhancer /opener 533-45-9 CLOMETHIAZOLE EDISILATE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 533-45-9 CLOMETHIAZOLE EDISILATE PRODUCT_CLASS Central Nervous System (CNS) 848-75-9 LORMETAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 848-75-9 LORMETAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 848-75-9 LORMETAZEPAM INDICATION Insomnia 848-75-9 LORMETAZEPAM MECHANISM Modulate neural transmission 848-75-9 LORMETAZEPAM MODE_CLASS Channel enhancer /opener 848-75-9 LORMETAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 153-87-7 OXYPERTINE INDICATION Anxiety Disorders 153-87-7 OXYPERTINE PRODUCT_CLASS Central Nervous System (CNS) 153-87-7 OXYPERTINE INDICATION Schizophrenic Disorders 153-87-7 OXYPERTINE THERAPEUTIC_CLASS Sedatives/Hypnotics 153-87-7 OXYPERTINE THERAPEUTIC_CLASS Antipsychotics 153-87-7 OXYPERTINE INDICATION Sedation 40523-01-1 OXYPERTINE THERAPEUTIC_CLASS Sedatives/Hypnotics 40523-01-1 OXYPERTINE INDICATION Anxiety Disorders 40523-01-1 OXYPERTINE PRODUCT_CLASS Central Nervous System (CNS) 40523-01-1 OXYPERTINE INDICATION Schizophrenic Disorders 40523-01-1 OXYPERTINE THERAPEUTIC_CLASS Antipsychotics 40523-01-1 OXYPERTINE INDICATION Sedation 2898-12-6 MEDAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 2898-12-6 MEDAZEPAM MODE_CLASS Channel enhancer /opener 2898-12-6 MEDAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 2898-12-6 MEDAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 2898-12-6 MEDAZEPAM MECHANISM Modulate neural transmission 1812-30-2 BROMAZEPAM THERAPEUTIC_CLASS Anxiolytics 1812-30-2 BROMAZEPAM MODE_CLASS Channel enhancer /opener 1812-30-2 BROMAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 1812-30-2 BROMAZEPAM INDICATION Anxiety Disorders 1812-30-2 BROMAZEPAM MECHANISM Modulate neural transmission 1812-30-2 BROMAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 36104-80-0 CAMAZEPAM MODE_CLASS Channel enhancer /opener 36104-80-0 CAMAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 36104-80-0 CAMAZEPAM INDICATION Anxiety Disorders 36104-80-0 CAMAZEPAM MECHANISM Modulate neural transmission 36104-80-0 CAMAZEPAM THERAPEUTIC_CLASS Anxiolytics 36104-80-0 CAMAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, medium acting 27223-35-4 KETAZOLAM INDICATION Anxiety Disorders 27223-35-4 KETAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 27223-35-4 KETAZOLAM MECHANISM Modulate neural transmission 27223-35-4 KETAZOLAM MODE_CLASS Channel enhancer /opener 27223-35-4 KETAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 27223-35-4 KETAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 113-59-7 CHLORPROTHIXENE PRODUCT_CLASS Central Nervous System (CNS) 113-59-7 CHLORPROTHIXENE MECHANISM Modulate G-protein coupled signal transduction 113-59-7 CHLORPROTHIXENE MODE_CLASS Solute transporter inhibitor 113-59-7 CHLORPROTHIXENE THERAPEUTIC_CLASS Antipsychotics 2622-26-6 PERICIAZINE MODE_CLASS Receptor Ligand Antagonist 2622-26-6 PERICIAZINE PRODUCT_CLASS Gastrointestinal System 2622-26-6 PERICIAZINE THERAPEUTIC_CLASS Antipsychotics 2622-26-6 PERICIAZINE MECHANISM Block neural transmission 2622-26-6 PERICIAZINE THERAPEUTIC_CLASS Antiemetics 2622-26-6 PERICIAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 2622-26-6 PERICIAZINE PRODUCT_CLASS Central Nervous System (CNS) 2622-26-6 PERICIAZINE THERAPEUTIC_CLASS Anxiolytics 2062-84-2 BENPERIDOL PRODUCT_CLASS Gastrointestinal System 2062-84-2 BENPERIDOL PRODUCT_CLASS Central Nervous System (CNS) 2062-84-2 BENPERIDOL THERAPEUTIC_CLASS Antipsychotics 2062-84-2 BENPERIDOL MODE_CLASS Receptor Ligand Antagonist 2062-84-2 BENPERIDOL THERAPEUTIC_CLASS Antiemetics 2062-84-2 BENPERIDOL STRUCTURE_ACTIVITY Dopamine receptor (D2) antagonist 2062-84-2 BENPERIDOL THERAPEUTIC_CLASS Sedatives/Hypnotics 2062-84-2 BENPERIDOL MECHANISM Block neural transmission 1841-19-6 FLUSPIRILENE PRODUCT_CLASS Central Nervous System (CNS) 1841-19-6 FLUSPIRILENE MECHANISM Block neural transmission 1841-19-6 FLUSPIRILENE MODE_CLASS Receptor Ligand Antagonist 1841-19-6 FLUSPIRILENE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 1841-19-6 FLUSPIRILENE MECHANISM Block channel gating 1841-19-6 FLUSPIRILENE MODE_CLASS Channel Blocker 1841-19-6 FLUSPIRILENE THERAPEUTIC_CLASS Antipsychotics 1841-19-6 FLUSPIRILENE INDICATION Schizophrenia 39860-99-6 PIPOTHIAZINE MECHANISM Block neural transmission 39860-99-6 PIPOTHIAZINE MODE_CLASS Receptor Ligand Antagonist 39860-99-6 PIPOTHIAZINE PRODUCT_CLASS Central Nervous System (CNS) 39860-99-6 PIPOTHIAZINE THERAPEUTIC_CLASS Antipsychotics 26615-21-4 ZOTEPINE MECHANISM Block neural transmission 26615-21-4 ZOTEPINE MODE_CLASS Receptor Ligand Antagonist 53583-79-2 SULTOPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 53583-79-2 SULTOPRIDE MECHANISM Block neural transmission 53583-79-2 SULTOPRIDE THERAPEUTIC_CLASS Antipsychotics 53583-79-2 SULTOPRIDE PRODUCT_CLASS Central Nervous System (CNS) 53-39-4 OXANDROLONE THERAPEUTIC_CLASS Gonadal Hormones 53-39-4 OXANDROLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 53-39-4 OXANDROLONE INDICATION Cachexia 53-39-4 OXANDROLONE MECHANISM Modulate gene transcription 53-39-4 OXANDROLONE INDICATION Cachexia related to AIDS 53-39-4 OXANDROLONE MODE_CLASS Receptor Agonist 53-39-4 OXANDROLONE INDICATION Growth Disorder 53-39-4 OXANDROLONE INDICATION Turner's Syndrome / Gonadal Dysgenesis 5560-72-5 IPRINDOLE MODE_CLASS Enzyme Inhibitor 5560-72-5 IPRINDOLE THERAPEUTIC_CLASS Antidepressants 5560-72-5 IPRINDOLE MECHANISM Prolong/enhance neural transmission 5560-72-5 IPRINDOLE MECHANISM Interferes with phospholipid metabolism 5560-72-5 IPRINDOLE MODE_CLASS Solute transporter inhibitor 5560-72-5 IPRINDOLE MECHANISM Modulate channel gating 5560-72-5 IPRINDOLE MODE_CLASS Channel Blocker, selective 5560-72-5 IPRINDOLE INDICATION Depression 5560-72-5 IPRINDOLE PRODUCT_CLASS Central Nervous System (CNS) 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT XXX_2_Weight Gain 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT PSY_2_Confusion 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT KID_1_Polyuria 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 554-13-2 LITHIUM CARBONATE KNOWN_TOXICITY Embryo/Fetal Toxicity 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT CVS_2_ST-T Wave Changes 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 554-13-2 LITHIUM CARBONATE KNOWN_TOXICITY Nephrotoxicity 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT CVS_2_Hypotension 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_1_Dysarthria 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT BBM_2_Leukocytosis 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_2_Seizures 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT XXX_1_Xerostomia 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 554-13-2 LITHIUM CARBONATE INDICATION Bipolar Disorders / Manic-Depression 554-13-2 LITHIUM CARBONATE TISSUE_TOXICITY Nephrotic Syndrome 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT GIS_2_Dysgeusia 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT KID_2_Nephrotic Syndrome 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT PSY_2_Serotonin Syndrome 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_2_Ataxia 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT END_2_Hyperthyroidism 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT PSY_2_Anorexia 554-13-2 LITHIUM CARBONATE KNOWN_TOXICITY Carcinogenicity 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT DNA_3_Secondary Malignanacy 554-13-2 LITHIUM CARBONATE THERAPEUTIC_CLASS Antimanic Agents 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT CVS_2_First-Degree AV block 554-13-2 LITHIUM CARBONATE PRODUCT_CLASS Central Nervous System (CNS) 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT EMB_2_Teratogenicity 554-13-2 LITHIUM CARBONATE INDICATION Mania 554-13-2 LITHIUM CARBONATE TISSUE_TOXICITY First-Degree AV block 554-13-2 LITHIUM CARBONATE TISSUE_TOXICITY Teratogenicity 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT GIS_1_Diarrhea 554-13-2 LITHIUM CARBONATE KNOWN_TOXICITY Cardiovascular Toxicity 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_1_Tremor 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_2_Coma 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT OCU_2_Visual Impairment 554-13-2 LITHIUM CARBONATE TISSUE_TOXICITY Secondary Malignanacy 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT NEU_2_Drowsiness 554-13-2 LITHIUM CARBONATE ADVERSE_EFFECT END_2_Goiter 554-13-2 LITHIUM CARBONATE TISSUE_TOXICITY Hypotension 897-15-4 DOSULEPIN HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 897-15-4 DOSULEPIN HYDROCHLORIDE INDICATION Depression 897-15-4 DOSULEPIN HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 897-15-4 DOSULEPIN HYDROCHLORIDE MODE_CLASS Solute transporter inhibitor 897-15-4 DOSULEPIN HYDROCHLORIDE MECHANISM Prolong/enhance neural transmission 2430-27-5 VALPROMIDE MODE_CLASS Enzyme Inhibitor 2430-27-5 VALPROMIDE MECHANISM Prolong/enhance neural transmission 2430-27-5 VALPROMIDE MODE_CLASS Channel Modulator 2430-27-5 VALPROMIDE MECHANISM Modulate channel gating 59338-93-1 ALIZAPRIDE PRODUCT_CLASS Gastrointestinal System 59338-93-1 ALIZAPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 59338-93-1 ALIZAPRIDE THERAPEUTIC_CLASS Antiemetics 59338-93-1 ALIZAPRIDE INDICATION Nausea / Vomiting 59338-93-1 ALIZAPRIDE MECHANISM Block neural transmission 51022-71-0 NABILONE PRODUCT_CLASS Gastrointestinal System 51022-71-0 NABILONE MECHANISM Modulate G-protein coupled signal transduction 51022-71-0 NABILONE MODE_CLASS Receptor Agonist 51022-71-0 NABILONE THERAPEUTIC_CLASS Antiemetics 51022-71-0 NABILONE INDICATION Nausea / Vomiting 5534-09-8 BECLOMETHASONE DIPROPIONATE MECHANISM Modulate gene transcription 5534-09-8 BECLOMETHASONE DIPROPIONATE THERAPEUTIC_CLASS Corticosteroids 5534-09-8 BECLOMETHASONE DIPROPIONATE MODE_CLASS Receptor Agonist 5534-09-8 BECLOMETHASONE DIPROPIONATE PRODUCT_CLASS Anti-inflammatories 30286-75-0 OXITROPIUM BROMIDE MECHANISM Modulate G-protein coupled signal transduction 30286-75-0 OXITROPIUM BROMIDE MODE_CLASS Receptor Ligand Antagonist 68-91-7 TRIMETHAPHAN CAMSYLATE THERAPEUTIC_CLASS Antihypertensive Agents 68-91-7 TRIMETHAPHAN CAMSYLATE PRODUCT_CLASS Cardiovasculars 68-91-7 TRIMETHAPHAN CAMSYLATE MECHANISM Modulate neural transmission 68-91-7 TRIMETHAPHAN CAMSYLATE INDICATION Hypertension 68-91-7 TRIMETHAPHAN CAMSYLATE MODE_CLASS Receptor Ligand Antagonist 68-91-7 TRIMETHAPHAN CAMSYLATE INDICATION Hypertensive Emergency 636-54-4 CLOPAMIDE PRODUCT_CLASS Cardiovasculars 636-54-4 CLOPAMIDE THERAPEUTIC_CLASS Antihypertensive Agents 636-54-4 CLOPAMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 636-54-4 CLOPAMIDE THERAPEUTIC_CLASS Congestive Heart Failure 636-54-4 CLOPAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 636-54-4 CLOPAMIDE INDICATION Edematous States 636-54-4 CLOPAMIDE THERAPEUTIC_CLASS Diuretics 636-54-4 CLOPAMIDE INDICATION Ascites in Liver Cirrhosis 636-54-4 CLOPAMIDE INDICATION Hypertension 636-54-4 CLOPAMIDE INDICATION Congestive Heart Failure (CHF) 636-54-4 CLOPAMIDE MODE_CLASS Enzyme Inhibitor 636-54-4 CLOPAMIDE MODE_CLASS Channel Blocker 636-54-4 CLOPAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 73-49-4 QUINETHAZONE INDICATION Edema 73-49-4 QUINETHAZONE INDICATION Hypertension 73-49-4 QUINETHAZONE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 73-49-4 QUINETHAZONE THERAPEUTIC_CLASS Diuretics 73-49-4 QUINETHAZONE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 73-49-4 QUINETHAZONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 73-49-4 QUINETHAZONE THERAPEUTIC_CLASS Antihypertensive Agents 73-49-4 QUINETHAZONE PRODUCT_CLASS Cardiovasculars 73-49-4 QUINETHAZONE MODE_CLASS Channel Blocker 7195-27-9 MEFRUSIDE MODE_CLASS Enzyme Inhibitor 7195-27-9 MEFRUSIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 78-11-5 PENTAERYTHRITOL TETRANITRATE THERAPEUTIC_CLASS Antianginals 78-11-5 PENTAERYTHRITOL TETRANITRATE PRODUCT_CLASS Cardiovasculars 78-11-5 PENTAERYTHRITOL TETRANITRATE MODE_CLASS Enzyme Inhibitor 78-11-5 PENTAERYTHRITOL TETRANITRATE MECHANISM Inhibit kinase mediated signal transduction 78-11-5 PENTAERYTHRITOL TETRANITRATE INDICATION Angina Pectoris 25717-80-0 MOLSIDOMINE INDICATION Angina Pectoris 25717-80-0 MOLSIDOMINE THERAPEUTIC_CLASS Antianginals 25717-80-0 MOLSIDOMINE PRODUCT_CLASS Cardiovasculars 30685-43-9 METILDIGOXIN MODE_CLASS Enzyme Inhibitor 30685-43-9 METILDIGOXIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 30685-43-9 METILDIGOXIN MECHANISM Increase muscle contraction 34183-22-7 PROPAFENONE TISSUE_TOXICITY Heart Block 34183-22-7 PROPAFENONE TISSUE_TOXICITY Ventricular Fibrillation 34183-22-7 PROPAFENONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 34183-22-7 PROPAFENONE ADVERSE_EFFECT XXX_3_Weakness 34183-22-7 PROPAFENONE ADVERSE_EFFECT GIS_2_Dry Mouth 34183-22-7 PROPAFENONE MODE_CLASS Receptor Ligand Antagonist 34183-22-7 PROPAFENONE MECHANISM Block channel gating 34183-22-7 PROPAFENONE MECHANISM Modulate G-protein coupled signal transduction 34183-22-7 PROPAFENONE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 34183-22-7 PROPAFENONE ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 34183-22-7 PROPAFENONE ADVERSE_EFFECT BBM_3_Agranulocytosis 34183-22-7 PROPAFENONE ADVERSE_EFFECT NEU_2_Headache 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 34183-22-7 PROPAFENONE ADVERSE_EFFECT GIS_2_Diarrhea 34183-22-7 PROPAFENONE THERAPEUTIC_CLASS Antiarrhythmic Agents 34183-22-7 PROPAFENONE TISSUE_TOXICITY Exacerbation of Arrhythmia 34183-22-7 PROPAFENONE TISSUE_TOXICITY Heart Failure 34183-22-7 PROPAFENONE TISSUE_TOXICITY Angina 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 34183-22-7 PROPAFENONE ADVERSE_EFFECT NEU_1_Dizziness 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Angina 34183-22-7 PROPAFENONE ADVERSE_EFFECT GIS_2_Constipation 34183-22-7 PROPAFENONE PRODUCT_CLASS Cardiovasculars 34183-22-7 PROPAFENONE MECHANISM Block neural transmission 34183-22-7 PROPAFENONE ADVERSE_EFFECT GIS_1_Dysgeusia 34183-22-7 PROPAFENONE KNOWN_TOXICITY Cardiovascular Toxicity 34183-22-7 PROPAFENONE INDICATION Paroxysmal Supraventricular Tachycardia 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Heart Block 34183-22-7 PROPAFENONE ADVERSE_EFFECT XXX_3_Edema 34183-22-7 PROPAFENONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 34183-22-7 PROPAFENONE ADVERSE_EFFECT OCU_2_Blurred Vision 34183-22-7 PROPAFENONE TISSUE_TOXICITY Ventricular Tachycardia 34183-22-7 PROPAFENONE INDICATION Paroxysmal Atrial Fibrillation/Flutter 34183-22-7 PROPAFENONE INDICATION Ventricular Arrhythmias 34183-22-7 PROPAFENONE MODE_CLASS Channel Blocker 34183-22-7 PROPAFENONE ADVERSE_EFFECT CVS_3_Heart Failure 54063-53-5 PROPAFENONE MECHANISM Block channel gating 54063-53-5 PROPAFENONE TISSUE_TOXICITY Heart Failure 54063-53-5 PROPAFENONE TISSUE_TOXICITY Heart Block 54063-53-5 PROPAFENONE TISSUE_TOXICITY Ventricular Fibrillation 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Heart Failure 54063-53-5 PROPAFENONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 54063-53-5 PROPAFENONE ADVERSE_EFFECT XXX_3_Weakness 54063-53-5 PROPAFENONE ADVERSE_EFFECT GIS_2_Dry Mouth 54063-53-5 PROPAFENONE MODE_CLASS Receptor Ligand Antagonist 54063-53-5 PROPAFENONE MECHANISM Modulate G-protein coupled signal transduction 54063-53-5 PROPAFENONE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 54063-53-5 PROPAFENONE ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 54063-53-5 PROPAFENONE ADVERSE_EFFECT BBM_3_Agranulocytosis 54063-53-5 PROPAFENONE ADVERSE_EFFECT NEU_2_Headache 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 54063-53-5 PROPAFENONE ADVERSE_EFFECT GIS_2_Diarrhea 54063-53-5 PROPAFENONE THERAPEUTIC_CLASS Antiarrhythmic Agents 54063-53-5 PROPAFENONE TISSUE_TOXICITY Exacerbation of Arrhythmia 54063-53-5 PROPAFENONE MODE_CLASS Channel Blocker 54063-53-5 PROPAFENONE TISSUE_TOXICITY Angina 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 54063-53-5 PROPAFENONE ADVERSE_EFFECT NEU_1_Dizziness 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Angina 54063-53-5 PROPAFENONE ADVERSE_EFFECT GIS_2_Constipation 54063-53-5 PROPAFENONE PRODUCT_CLASS Cardiovasculars 54063-53-5 PROPAFENONE MECHANISM Block neural transmission 54063-53-5 PROPAFENONE INDICATION Paroxysmal Supraventricular Tachycardia 54063-53-5 PROPAFENONE ADVERSE_EFFECT GIS_1_Dysgeusia 54063-53-5 PROPAFENONE ADVERSE_EFFECT CVS_3_Heart Block 54063-53-5 PROPAFENONE ADVERSE_EFFECT XXX_3_Edema 54063-53-5 PROPAFENONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 54063-53-5 PROPAFENONE ADVERSE_EFFECT OCU_2_Blurred Vision 54063-53-5 PROPAFENONE KNOWN_TOXICITY Cardiovascular Toxicity 54063-53-5 PROPAFENONE TISSUE_TOXICITY Ventricular Tachycardia 54063-53-5 PROPAFENONE INDICATION Paroxysmal Atrial Fibrillation/Flutter 54063-53-5 PROPAFENONE INDICATION Ventricular Arrhythmias 14293-44-8 XIPAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 14293-44-8 XIPAMIDE THERAPEUTIC_CLASS Antihypertensive Agents 14293-44-8 XIPAMIDE THERAPEUTIC_CLASS Diuretics 14293-44-8 XIPAMIDE INDICATION Edematous States 14293-44-8 XIPAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 14293-44-8 XIPAMIDE INDICATION Hypertension 14293-44-8 XIPAMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 14293-44-8 XIPAMIDE PRODUCT_CLASS Cardiovasculars 14293-44-8 XIPAMIDE MODE_CLASS Channel Blocker 83-12-5 PHENINDIONE ADVERSE_EFFECT _3_Leukamoid blood picture 83-12-5 PHENINDIONE ADVERSE_EFFECT KID_3_Tubular Necrosis 83-12-5 PHENINDIONE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 83-12-5 PHENINDIONE ADVERSE_EFFECT GIS_2_Vomiting 83-12-5 PHENINDIONE INDICATION Venous Thrombosis 83-12-5 PHENINDIONE THERAPEUTIC_CLASS Anticoagulants 83-12-5 PHENINDIONE INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 83-12-5 PHENINDIONE MODE_CLASS Enzyme Inhibitor 83-12-5 PHENINDIONE PRODUCT_CLASS Hematologics 83-12-5 PHENINDIONE TISSUE_TOXICITY Tubular Necrosis 83-12-5 PHENINDIONE STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 83-12-5 PHENINDIONE TISSUE_TOXICITY Bleeding 83-12-5 PHENINDIONE KNOWN_TOXICITY Nephrotoxicity 83-12-5 PHENINDIONE ADVERSE_EFFECT IMU_3_Eosinophilia 83-12-5 PHENINDIONE ADVERSE_EFFECT BBM_3_Agranulocytosis 83-12-5 PHENINDIONE ADVERSE_EFFECT BBM_3_Leukopenia 83-12-5 PHENINDIONE ADVERSE_EFFECT SKN_3_Skin Necrosis 83-12-5 PHENINDIONE INDICATION Prosthetic Heart Valves 83-12-5 PHENINDIONE MECHANISM Inhibit platelet aggregation 83-12-5 PHENINDIONE ADVERSE_EFFECT KID_3_Albuminuria 83-12-5 PHENINDIONE ADVERSE_EFFECT BBM_1_Bleeding 83-12-5 PHENINDIONE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 83-12-5 PHENINDIONE ADVERSE_EFFECT SKN_3_Exanthema 83-12-5 PHENINDIONE ADVERSE_EFFECT IMU_2_Hypersensitivity 83-12-5 PHENINDIONE ADVERSE_EFFECT GIS_2_Diarrhea 83-12-5 PHENINDIONE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 83-12-5 PHENINDIONE INDICATION Prophylaxis of systemic embolisation 83-12-5 PHENINDIONE ADVERSE_EFFECT _3_Hemothorax 83-12-5 PHENINDIONE ADVERSE_EFFECT LIV_3_Jaundice 83-12-5 PHENINDIONE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 83-12-5 PHENINDIONE ADVERSE_EFFECT LIV_3_Hepatitis 83-12-5 PHENINDIONE ADVERSE_EFFECT XXX_3_Fever 6700-42-1 MENADIOL SODIUM DIPHOSPHATE STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 6700-42-1 MENADIOL SODIUM DIPHOSPHATE MODE_CLASS Enzyme Inhibitor 6700-42-1 MENADIOL SODIUM DIPHOSPHATE MECHANISM Inhibit platelet aggregation 131-13-5 MENADIOL SODIUM DIPHOSPHATE MECHANISM Inhibit platelet aggregation 131-13-5 MENADIOL SODIUM DIPHOSPHATE STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 131-13-5 MENADIOL SODIUM DIPHOSPHATE MODE_CLASS Enzyme Inhibitor 742-20-1 CYCLOPENTHIAZIDE KNOWN_TOXICITY Cardiovascular Toxicity 742-20-1 CYCLOPENTHIAZIDE THERAPEUTIC_CLASS Diuretics 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT IMU_3_Photosensitivity 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT IMU_2_Urticaria 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT END_3_Metabolic Alkalosis 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT NEU_3_Headache 742-20-1 CYCLOPENTHIAZIDE INDICATION Edema 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT END_3_Hyperglycemia 742-20-1 CYCLOPENTHIAZIDE INDICATION Heart Failure 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT CVS_2_Postural Hypotension 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT OCU_2_Visual Disturbances 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT END_1_Hypertriglyceridemia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT ELT_1_Hypokalemia 742-20-1 CYCLOPENTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 742-20-1 CYCLOPENTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 742-20-1 CYCLOPENTHIAZIDE PRODUCT_CLASS Cardiovasculars 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT NEU_3_Dizziness 742-20-1 CYCLOPENTHIAZIDE INDICATION Hypertension 742-20-1 CYCLOPENTHIAZIDE TISSUE_TOXICITY Cardiac Arrhythmia 742-20-1 CYCLOPENTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT END_1_Hypercholesteremia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT LIV_3_Intrahepatic Cholestasis 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT BBM_3_Leukopenia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT ELT_3_Hypercalcemia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT REP_3_Impotence 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 742-20-1 CYCLOPENTHIAZIDE THERAPEUTIC_CLASS Congestive Heart Failure 742-20-1 CYCLOPENTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT ELT_3_Hypochloremia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT GIS_3_Pancreatitis 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT NEU_3_Paresthesia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 742-20-1 CYCLOPENTHIAZIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 742-20-1 CYCLOPENTHIAZIDE MODE_CLASS Channel Blocker, selective 976-71-6 CANRENONE INDICATION Edematous States 976-71-6 CANRENONE PRODUCT_CLASS Cardiovasculars 976-71-6 CANRENONE THERAPEUTIC_CLASS Congestive Heart Failure 976-71-6 CANRENONE KNOWN_TOXICITY Mutagenicity 976-71-6 CANRENONE ADVERSE_EFFECT XXX_2_Asthenia 976-71-6 CANRENONE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 976-71-6 CANRENONE THERAPEUTIC_CLASS Antihypertensive Agents 976-71-6 CANRENONE MODE_CLASS Enzyme Inhibitor 976-71-6 CANRENONE ADVERSE_EFFECT KID_2_Renal Insufficiency 976-71-6 CANRENONE ADVERSE_EFFECT GIS_1_Vomiting 976-71-6 CANRENONE ADVERSE_EFFECT NEU_2_Somnolence 976-71-6 CANRENONE ADVERSE_EFFECT REP_3_Sexual Dysfunction 976-71-6 CANRENONE ADVERSE_EFFECT REP_3_Amenorrhea 976-71-6 CANRENONE INDICATION Myasthenia Gravis 976-71-6 CANRENONE INDICATION Congestive Heart Failure (CHF) 976-71-6 CANRENONE PRODUCT_CLASS Immune Response / Immunomodulators 976-71-6 CANRENONE ADVERSE_EFFECT ELT_2_Hyponatremia 976-71-6 CANRENONE ADVERSE_EFFECT END_3_Gynecomastia 976-71-6 CANRENONE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 976-71-6 CANRENONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 976-71-6 CANRENONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 976-71-6 CANRENONE INDICATION Secondary Hyperaldosteronism 976-71-6 CANRENONE THERAPEUTIC_CLASS Diuretics 976-71-6 CANRENONE ADVERSE_EFFECT DNA_3_Genotoxicity 976-71-6 CANRENONE ADVERSE_EFFECT KID_2_Increased Creatinine 976-71-6 CANRENONE ADVERSE_EFFECT ELT_2_Hyperkalemia 976-71-6 CANRENONE ADVERSE_EFFECT END_2_Metabolic Acidosis 976-71-6 CANRENONE ADVERSE_EFFECT NEU_2_Dizziness 976-71-6 CANRENONE ADVERSE_EFFECT PSY_2_Mental Confusion 976-71-6 CANRENONE TISSUE_TOXICITY Genotoxicity 976-71-6 CANRENONE ADVERSE_EFFECT GIS_2_Diarrhea 976-71-6 CANRENONE MODE_CLASS Receptor Ligand Antagonist 976-71-6 CANRENONE INDICATION Hypertension 976-71-6 CANRENONE THERAPEUTIC_CLASS Immunosuppressants 976-71-6 CANRENONE ADVERSE_EFFECT GIS_1_Nausea 976-71-6 CANRENONE ADVERSE_EFFECT GIS_1_Epigastric Pain 976-71-6 CANRENONE ADVERSE_EFFECT XXX_3_Dehydration 976-71-6 CANRENONE ADVERSE_EFFECT PSY_2_Anorexia 2181-04-6 CANRENOATE POTASSIUM INDICATION Myasthenia Gravis 2181-04-6 CANRENOATE POTASSIUM THERAPEUTIC_CLASS Diuretics 2181-04-6 CANRENOATE POTASSIUM THERAPEUTIC_CLASS Immunosuppressants 2181-04-6 CANRENOATE POTASSIUM MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 2181-04-6 CANRENOATE POTASSIUM INDICATION Ascites in Liver Cirrhosis 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT GIS_1_Nausea 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT KID_2_Renal Insufficiency 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT KID_2_Increased Creatinine 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT NEU_2_Somnolence 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT REP_3_Sexual Dysfunction 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT REP_3_Amenorrhea 2181-04-6 CANRENOATE POTASSIUM INDICATION Edematous States 2181-04-6 CANRENOATE POTASSIUM TISSUE_TOXICITY Genotoxicity 2181-04-6 CANRENOATE POTASSIUM MODE_CLASS Enzyme Inhibitor 2181-04-6 CANRENOATE POTASSIUM INDICATION Primary Hyperaldosteronism 2181-04-6 CANRENOATE POTASSIUM PRODUCT_CLASS Immune Response / Immunomodulators 2181-04-6 CANRENOATE POTASSIUM THERAPEUTIC_CLASS Congestive Heart Failure 2181-04-6 CANRENOATE POTASSIUM MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT PSY_2_Anorexia 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT GIS_2_Epigastric Pain 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT ELT_2_Hyponatremia 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT XXX_3_Dehydration 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT PSY_2_Mental Confusion 2181-04-6 CANRENOATE POTASSIUM PRODUCT_CLASS Cardiovasculars 2181-04-6 CANRENOATE POTASSIUM INDICATION Hypertension 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT REP_2_Menstrual Abnormalities 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT END_3_Gynecomastia 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT GIS_2_Vomiting 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT DNA_3_Genotoxicity 2181-04-6 CANRENOATE POTASSIUM MODE_CLASS Receptor Ligand Antagonist 2181-04-6 CANRENOATE POTASSIUM KNOWN_TOXICITY Mutagenicity 2181-04-6 CANRENOATE POTASSIUM THERAPEUTIC_CLASS Antihypertensive Agents 2181-04-6 CANRENOATE POTASSIUM PRODUCT_CLASS Electrolytic, Caloric and Water Balance 2181-04-6 CANRENOATE POTASSIUM INDICATION Congestive Heart Failure (CHF) 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT NEU_2_Dizziness 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT END_2_Metabolic Acidosis 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT ELT_2_Hyperkalemia 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT GIS_2_Diarrhea 2181-04-6 CANRENOATE POTASSIUM ADVERSE_EFFECT XXX_2_Asthenia 2181-04-6 CANRENOATE POTASSIUM INDICATION Nephrotic Syndrome 545-80-2 POLDINE METHYLSULFATE MECHANISM Modulate G-protein coupled signal transduction 545-80-2 POLDINE METHYLSULFATE INDICATION Ulcer 545-80-2 POLDINE METHYLSULFATE MODE_CLASS Receptor Ligand Antagonist 5560-59-8 ALVERINE CITRATE MODE_CLASS Receptor Ligand Antagonist 5560-59-8 ALVERINE CITRATE MECHANISM Modulate neural transmission 5560-59-8 ALVERINE CITRATE MODE_CLASS Channel Modulator 5560-59-8 ALVERINE CITRATE MODE_CLASS Receptor Ligand Antagonist, Selective 150-59-4 ALVERINE CITRATE MODE_CLASS Receptor Ligand Antagonist 150-59-4 ALVERINE CITRATE MECHANISM Modulate neural transmission 150-59-4 ALVERINE CITRATE MODE_CLASS Channel Modulator 150-59-4 ALVERINE CITRATE MODE_CLASS Receptor Ligand Antagonist, Selective 71-81-8 ISOPROPAMIDE IODIDE MODE_CLASS Receptor Ligand Antagonist 71-81-8 ISOPROPAMIDE IODIDE MECHANISM Modulate G-protein coupled signal transduction 11041-12-6 CHOLESTYRAMINE PRODUCT_CLASS Cardiovasculars 11041-12-6 CHOLESTYRAMINE THERAPEUTIC_CLASS Hypolipidemic Agents 11041-12-6 CHOLESTYRAMINE INDICATION Hyperlipidemia 11041-12-6 CHOLESTYRAMINE INDICATION Hypercholesterolemia 9007-26-5 CHOLESTYRAMINE INDICATION Hyperlipidemia 9007-26-5 CHOLESTYRAMINE INDICATION Hypercholesterolemia 9007-26-5 CHOLESTYRAMINE PRODUCT_CLASS Cardiovasculars 9007-26-5 CHOLESTYRAMINE THERAPEUTIC_CLASS Hypolipidemic Agents 57076-71-8 DENBUFYLLINE MODE_CLASS Enzyme Inhibitor 57076-71-8 DENBUFYLLINE INDICATION Cerebral Ischemia 57076-71-8 DENBUFYLLINE MECHANISM Enhance kinase mediated signal transduction 82547-81-7 CEFTERAM PIVOXIL THERAPEUTIC_CLASS Antibacterials 82547-81-7 CEFTERAM PIVOXIL PRODUCT_CLASS Anti-infectives 82547-81-7 CEFTERAM PIVOXIL MODE_CLASS Enzyme Inhibitor 82547-81-7 CEFTERAM PIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 82556-89-6 CEFTERAM PIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 82556-89-6 CEFTERAM PIVOXIL THERAPEUTIC_CLASS Antibacterials 82556-89-6 CEFTERAM PIVOXIL PRODUCT_CLASS Anti-infectives 82556-89-6 CEFTERAM PIVOXIL MODE_CLASS Enzyme Inhibitor 94055-76-2 SUPLATAST TOSILATE INDICATION Eczema Herpeticum 94055-76-2 SUPLATAST TOSILATE INDICATION Urinary Incontinence / Enuresis 94055-76-2 SUPLATAST TOSILATE INDICATION Viral Rhinitis / Common Cold 90101-16-9 DROXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 90101-16-9 DROXICAM MODE_CLASS Enzyme Inhibitor 90101-16-9 DROXICAM PRODUCT_CLASS Anti-inflammatories 90101-16-9 DROXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 90101-16-9 DROXICAM MECHANISM Inhibit eicosanoid biosynthesis 84088-42-6 ROQUINIMEX INDICATION Arthritis 84088-42-6 ROQUINIMEX INDICATION Multiple Sclerosis (MS) 84088-42-6 ROQUINIMEX THERAPEUTIC_CLASS Immunosuppressants 84088-42-6 ROQUINIMEX PRODUCT_CLASS Immune Response / Immunomodulators 65576-45-6 ASENAPINE MODE_CLASS Receptor Ligand Antagonist 65576-45-6 ASENAPINE MECHANISM Modulate neural transmission 65576-45-6 ASENAPINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 65576-45-6 ASENAPINE THERAPEUTIC_CLASS Antipsychotics 65576-45-6 ASENAPINE MECHANISM Modulate G-protein coupled signal transduction 85650-56-2 ASENAPINE MODE_CLASS Receptor Ligand Antagonist 85650-56-2 ASENAPINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 85650-56-2 ASENAPINE THERAPEUTIC_CLASS Antipsychotics 85650-56-2 ASENAPINE MECHANISM Modulate G-protein coupled signal transduction 85650-56-2 ASENAPINE MECHANISM Modulate neural transmission 95549-92-1 METAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 95549-92-1 METAZOSIN MECHANISM Modulate G-protein coupled signal transduction 95549-92-1 METAZOSIN INDICATION Prostatitis 95729-65-0 AZETIRELIN PRODUCT_CLASS Central Nervous System (CNS) 95729-65-0 AZETIRELIN MODE_CLASS Enzyme Inhibitor 95729-65-0 AZETIRELIN MECHANISM Inhibit bacterial cell wall biosynthesis 95635-55-5 RANOLAZINE INDICATION Angina Pectoris 95635-55-5 RANOLAZINE THERAPEUTIC_CLASS Antianginals 95635-55-5 RANOLAZINE PRODUCT_CLASS Cardiovasculars 95635-56-6 RANOLAZINE THERAPEUTIC_CLASS Antianginals 95635-56-6 RANOLAZINE INDICATION Angina Pectoris 95635-56-6 RANOLAZINE PRODUCT_CLASS Cardiovasculars 58994-96-0 RANIMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 58994-96-0 RANIMUSTINE THERAPEUTIC_CLASS Antineoplastics 58994-96-0 RANIMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 58994-96-0 RANIMUSTINE PRODUCT_CLASS Anti-cancers 82834-16-0 PERINDOPRIL PRODUCT_CLASS Cardiovasculars 82834-16-0 PERINDOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 82834-16-0 PERINDOPRIL THERAPEUTIC_CLASS Congestive Heart Failure 82834-16-0 PERINDOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 82834-16-0 PERINDOPRIL INDICATION Congestive Heart Failure (CHF) 82834-16-0 PERINDOPRIL MECHANISM Reduce vasoconstriction 82834-16-0 PERINDOPRIL MODE_CLASS Enzyme Inhibitor 82834-16-0 PERINDOPRIL INDICATION Hypertension 66934-18-7 FLUNOXAPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 66934-18-7 FLUNOXAPROFEN INDICATION Rheumatoid Arthritis 66934-18-7 FLUNOXAPROFEN INDICATION Musculoskeletal Pain 66934-18-7 FLUNOXAPROFEN PRODUCT_CLASS Analgesics 66934-18-7 FLUNOXAPROFEN MODE_CLASS Enzyme Inhibitor 66934-18-7 FLUNOXAPROFEN THERAPEUTIC_CLASS Analgesics, Topical 66934-18-7 FLUNOXAPROFEN INDICATION Moderate Pain 66934-18-7 FLUNOXAPROFEN THERAPEUTIC_CLASS Analgesics, Non-Opioid 66934-18-7 FLUNOXAPROFEN INDICATION Osteoarthritis 66934-18-7 FLUNOXAPROFEN MECHANISM Inhibit eicosanoid biosynthesis 66934-18-7 FLUNOXAPROFEN PRODUCT_CLASS Anti-inflammatories 66934-18-7 FLUNOXAPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 88768-40-5 CILAZAPRIL MODE_CLASS Enzyme Inhibitor 88768-40-5 CILAZAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 88768-40-5 CILAZAPRIL MECHANISM Reduce vasoconstriction 88768-40-5 CILAZAPRIL PRODUCT_CLASS Cardiovasculars 88768-40-5 CILAZAPRIL INDICATION Hypertension 88768-40-5 CILAZAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 92077-78-6 CILAZAPRIL PRODUCT_CLASS Cardiovasculars 92077-78-6 CILAZAPRIL INDICATION Hypertension 92077-78-6 CILAZAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 92077-78-6 CILAZAPRIL MECHANISM Reduce vasoconstriction 92077-78-6 CILAZAPRIL MODE_CLASS Enzyme Inhibitor 92077-78-6 CILAZAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT NEU_2_Syncope 76568-02-0 FLOSEQUINAN MECHANISM Enhance kinase mediated signal transduction 76568-02-0 FLOSEQUINAN INDICATION Hypertension 76568-02-0 FLOSEQUINAN KNOWN_TOXICITY Cardiovascular Toxicity 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT GIS_2_Nausea 76568-02-0 FLOSEQUINAN MODE_CLASS Enzyme Inhibitor, selective 76568-02-0 FLOSEQUINAN THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT GIS_2_Diarrhea 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT XXX_2_Death 76568-02-0 FLOSEQUINAN STRUCTURE_ACTIVITY Unknown mechanism 76568-02-0 FLOSEQUINAN PRODUCT_CLASS Cardiovasculars 76568-02-0 FLOSEQUINAN THERAPEUTIC_CLASS Antihypertensive Agents 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT CVS_2_Palpitation 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT CVS_2_Hypotension 76568-02-0 FLOSEQUINAN INDICATION Heart Failure 76568-02-0 FLOSEQUINAN KNOWN_TOXICITY Miscellaneous 76568-02-0 FLOSEQUINAN TISSUE_TOXICITY Death 76568-02-0 FLOSEQUINAN TISSUE_TOXICITY Hypotension 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT CVS_2_Tachycardia 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT NEU_1_Headache 76568-02-0 FLOSEQUINAN ADVERSE_EFFECT XXX_2_Taste Disturbances 89371-37-9 IMIDAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 89371-37-9 IMIDAPRIL INDICATION Hypertension 89371-37-9 IMIDAPRIL PRODUCT_CLASS Cardiovasculars 89371-37-9 IMIDAPRIL MODE_CLASS Enzyme Inhibitor 89371-37-9 IMIDAPRIL MECHANISM Reduce vasoconstriction 89371-37-9 IMIDAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 89396-94-1 IMIDAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 89396-94-1 IMIDAPRIL MODE_CLASS Enzyme Inhibitor 89396-94-1 IMIDAPRIL MECHANISM Reduce vasoconstriction 89396-94-1 IMIDAPRIL PRODUCT_CLASS Cardiovasculars 89396-94-1 IMIDAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 89396-94-1 IMIDAPRIL INDICATION Hypertension 77191-36-7 NEFIRACETAM MODE_CLASS Receptor Ligand Antagonist 77191-36-7 NEFIRACETAM MECHANISM Prolong/enhance neural transmission 77191-36-7 NEFIRACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 95734-82-0 NEDAPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 95734-82-0 NEDAPLATIN MECHANISM Inhibit DNA synthesis, repair, and function 95734-82-0 NEDAPLATIN MODE_CLASS Distorts /blocks macromolecular scaffold function 98320-39-9 IX-207-887 PRODUCT_CLASS Immune Response / Immunomodulators 98320-39-9 IX-207-887 INDICATION Arthritis 98320-39-9 IX-207-887 THERAPEUTIC_CLASS Immunosuppressants 81962-84-7 NADIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 81962-84-7 NADIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 81962-84-7 NADIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 81962-84-7 NADIFLOXACIN INDICATION Acne / Acne Vulgaris 81962-84-7 NADIFLOXACIN PRODUCT_CLASS Dermatologicals 81962-84-7 NADIFLOXACIN THERAPEUTIC_CLASS Acne Preparations 86826-12-2 NADIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 86826-12-2 NADIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 86826-12-2 NADIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 86826-12-2 NADIFLOXACIN INDICATION Acne / Acne Vulgaris 86826-12-2 NADIFLOXACIN PRODUCT_CLASS Dermatologicals 86826-12-2 NADIFLOXACIN THERAPEUTIC_CLASS Acne Preparations 124858-35-1 NADIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 124858-35-1 NADIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 124858-35-1 NADIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 124858-35-1 NADIFLOXACIN INDICATION Acne / Acne Vulgaris 124858-35-1 NADIFLOXACIN THERAPEUTIC_CLASS Acne Preparations 124858-35-1 NADIFLOXACIN PRODUCT_CLASS Dermatologicals 81733-79-1 DALARGIN INDICATION Angina Pectoris 81733-79-1 DALARGIN INDICATION Ulcer 81733-79-1 DALARGIN PRODUCT_CLASS Cardiovasculars 81733-79-1 DALARGIN THERAPEUTIC_CLASS Antianginals 97852-72-7 TIBENELAST INDICATION Asthma 97852-72-7 TIBENELAST INDICATION Cerebral Ischemia 97852-72-7 TIBENELAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 97852-72-7 TIBENELAST PRODUCT_CLASS Respiratory System 64019-03-0 DOQUALAST INDICATION Hypolipidemia 98383-18-7 ECOMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 98383-18-7 ECOMUSTINE PRODUCT_CLASS Anti-cancers 98383-18-7 ECOMUSTINE THERAPEUTIC_CLASS Antineoplastics 98383-18-7 ECOMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 98383-18-7 ECOMUSTINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 98449-05-9 BUTIXOCORT 21-PROPIONATE INDICATION Arthritis 98449-05-9 BUTIXOCORT 21-PROPIONATE PRODUCT_CLASS Anti-inflammatories 98449-05-9 BUTIXOCORT 21-PROPIONATE INDICATION Viral Rhinitis / Common Cold 98449-05-9 BUTIXOCORT 21-PROPIONATE INDICATION Asthma 98449-05-9 BUTIXOCORT 21-PROPIONATE THERAPEUTIC_CLASS Immunosuppressants 98449-05-9 BUTIXOCORT 21-PROPIONATE PRODUCT_CLASS Immune Response / Immunomodulators 98449-05-9 BUTIXOCORT 21-PROPIONATE THERAPEUTIC_CLASS Corticosteroids 89391-50-4 IMIRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 89391-50-4 IMIRESTAT PRODUCT_CLASS Other Human Uses 89391-50-4 IMIRESTAT INDICATION Diabetic Neuropathy 89391-50-4 IMIRESTAT KNOWN_TOXICITY Hepatotoxicity 89391-50-4 IMIRESTAT MODE_CLASS Enzyme Inhibitor 89391-50-4 IMIRESTAT INDICATION Diabetic Cataracts 89391-50-4 IMIRESTAT MECHANISM Inhibit precursor synthesis 89391-50-4 IMIRESTAT STRUCTURE_ACTIVITY Aldehyde reductase inhibitor 89391-50-4 IMIRESTAT ADVERSE_EFFECT LIV_3_Hepatotoxicity 89391-50-4 IMIRESTAT TISSUE_TOXICITY Hepatotoxicity 98772-05-5 MAR-99 INDICATION Ulcer 98772-44-2 MAR-99 INDICATION Ulcer 75949-61-0 PAFENOLOL MECHANISM Reduce muscle contractile force 75949-61-0 PAFENOLOL MODE_CLASS Receptor Ligand Antagonist 75949-61-0 PAFENOLOL INDICATION Hypertension 75949-61-0 PAFENOLOL PRODUCT_CLASS Cardiovasculars 75949-61-0 PAFENOLOL THERAPEUTIC_CLASS Antihypertensive Agents 99464-64-9 AMPIROXICAM ADVERSE_EFFECT KID_1_Fluid Retention 99464-64-9 AMPIROXICAM ADVERSE_EFFECT KID_1_Increased Blood Urea Nitrogen 99464-64-9 AMPIROXICAM KNOWN_TOXICITY Cardiovascular Toxicity 99464-64-9 AMPIROXICAM PRODUCT_CLASS Anti-inflammatories 99464-64-9 AMPIROXICAM INDICATION Low Back Pain 99464-64-9 AMPIROXICAM ADVERSE_EFFECT BBM_3_Aplastic Anemia 99464-64-9 AMPIROXICAM ADVERSE_EFFECT GIS_2_Stomatitis 99464-64-9 AMPIROXICAM ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 99464-64-9 AMPIROXICAM KNOWN_TOXICITY Nephrotoxicity 99464-64-9 AMPIROXICAM TISSUE_TOXICITY Acute Renal Failure 99464-64-9 AMPIROXICAM ADVERSE_EFFECT BBM_2_Anemia 99464-64-9 AMPIROXICAM ADVERSE_EFFECT SKN_3_Flushing 99464-64-9 AMPIROXICAM INDICATION Osteoarthritis 99464-64-9 AMPIROXICAM INDICATION Pain 99464-64-9 AMPIROXICAM ADVERSE_EFFECT BBM_1_Leukocytosis 99464-64-9 AMPIROXICAM ADVERSE_EFFECT OCU_3_Blurred Vision 99464-64-9 AMPIROXICAM ADVERSE_EFFECT IMU_3_Hypersensitivity 99464-64-9 AMPIROXICAM THERAPEUTIC_CLASS Analgesics, Non-Opioid 99464-64-9 AMPIROXICAM ADVERSE_EFFECT CVS_3_Shock 99464-64-9 AMPIROXICAM ADVERSE_EFFECT GIS_3_Peptic Ulceration 99464-64-9 AMPIROXICAM ADVERSE_EFFECT KID_3_Acute Renal Failure 99464-64-9 AMPIROXICAM ADVERSE_EFFECT GIS_2_Gastritis 99464-64-9 AMPIROXICAM ACTIVITY_CLASS Anti-inflammatory 99464-64-9 AMPIROXICAM MECHANISM Inhibit eicosanoid biosynthesis 99464-64-9 AMPIROXICAM INDICATION Rheumatoid Arthritis 99464-64-9 AMPIROXICAM INDICATION Cervical-Scapular-Branchial Syndrome 99464-64-9 AMPIROXICAM MODE_CLASS Enzyme Inhibitor 99464-64-9 AMPIROXICAM ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 99464-64-9 AMPIROXICAM ADVERSE_EFFECT GIS_1_Epigastric Pain 99464-64-9 AMPIROXICAM ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 99464-64-9 AMPIROXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 99464-64-9 AMPIROXICAM KNOWN_TOXICITY Blood & Bone Marrow Toxicity 99464-64-9 AMPIROXICAM TISSUE_TOXICITY Leukocytosis 99464-64-9 AMPIROXICAM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 99464-64-9 AMPIROXICAM ADVERSE_EFFECT SKN_1_Rash 99464-64-9 AMPIROXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 99464-64-9 AMPIROXICAM INDICATION Periarthritis Humeroscapularis 99464-64-9 AMPIROXICAM PRODUCT_CLASS Analgesics 99464-64-9 AMPIROXICAM TISSUE_TOXICITY Shock 99464-64-9 AMPIROXICAM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 99464-64-9 AMPIROXICAM ADVERSE_EFFECT XXX_1_Edema 99464-64-9 AMPIROXICAM ADVERSE_EFFECT KID_2_Proteinuria 98631-95-9 SOBUZOXANE STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 98631-95-9 SOBUZOXANE PRODUCT_CLASS Anti-infectives 98631-95-9 SOBUZOXANE MODE_CLASS Enzyme Inhibitor 98631-95-9 SOBUZOXANE MECHANISM Inhibit DNA synthesis, repair, and function 98631-95-9 SOBUZOXANE THERAPEUTIC_CLASS Antivirals, Systemic 61825-94-3 OXALIPLATIN KNOWN_TOXICITY Nephrotoxicity 61825-94-3 OXALIPLATIN ZERO_CLASS N 61825-94-3 OXALIPLATIN MESH_LEVEL_3 Organoplatinum Compounds 61825-94-3 OXALIPLATIN TA_LEVEL_1 Oncology 61825-94-3 OXALIPLATIN MESH_LEVEL_1 Organic Chemicals 61825-94-3 OXALIPLATIN MECHANISM Inhibit DNA synthesis, repair, and function 61825-94-3 OXALIPLATIN MECH_LEVEL_3 DNA damage 61825-94-3 OXALIPLATIN TA_LEVEL_3 Solid Tumors 61825-94-3 OXALIPLATIN PRODUCT_CLASS Anti-cancers 61825-94-3 OXALIPLATIN MODE_CLASS Distorts /blocks macromolecular scaffold function 61825-94-3 OXALIPLATIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 61825-94-3 OXALIPLATIN ADVERSE_EFFECT IMU_3_Hypersensitivity 61825-94-3 OXALIPLATIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 61825-94-3 OXALIPLATIN TISSUE_TOXICITY Mutagenicity 61825-94-3 OXALIPLATIN THERAPEUTIC_CLASS Antineoplastics 61825-94-3 OXALIPLATIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 61825-94-3 OXALIPLATIN ADVERSE_EFFECT BBM_2_Myelosuppression 61825-94-3 OXALIPLATIN ADVERSE_EFFECT DNA_2_Clastogenicity 61825-94-3 OXALIPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 61825-94-3 OXALIPLATIN ACTIVITY_CLASS DNA damager 61825-94-3 OXALIPLATIN MESH_LEVEL_2 Organometallic Compounds 61825-94-3 OXALIPLATIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 61825-94-3 OXALIPLATIN ADVERSE_EFFECT KID_2_Renal Dysfunction 61825-94-3 OXALIPLATIN ADVERSE_EFFECT GIS_2_Diarrhea 61825-94-3 OXALIPLATIN ADVERSE_EFFECT OTO_3_Ototoxicity 61825-94-3 OXALIPLATIN ADVERSE_EFFECT XXX_1_Infection 61825-94-3 OXALIPLATIN TISSUE_TOXICITY Nephrotoxicity 61825-94-3 OXALIPLATIN KNOWN_TOXICITY Mutagenicity 61825-94-3 OXALIPLATIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 61825-94-3 OXALIPLATIN TISSUE_TOXICITY Clastogenicity 61825-94-3 OXALIPLATIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 61825-94-3 OXALIPLATIN ADVERSE_EFFECT KID_3_Nephrotoxicity 61825-94-3 OXALIPLATIN ADVERSE_EFFECT BBM_2_Neutropenia 61825-94-3 OXALIPLATIN ADVERSE_EFFECT XXX_3_Laryngopharyngeal Dysesthesia 61825-94-3 OXALIPLATIN ADVERSE_EFFECT IMU_3_Anaphylaxis 61825-94-3 OXALIPLATIN ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 61825-94-3 OXALIPLATIN INDICATION Neoplasm / Cancer / Tumor 61825-94-3 OXALIPLATIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 61825-94-3 OXALIPLATIN TA_LEVEL_2 DNA damage 61825-94-3 OXALIPLATIN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 61825-94-3 OXALIPLATIN ADVERSE_EFFECT LUN_3_Interstitial Pulmonary Fibrosis 61825-94-3 OXALIPLATIN ADVERSE_EFFECT XXX_2_Mucositis 61825-94-3 OXALIPLATIN ADVERSE_EFFECT DNA_2_Mutagenicity 61825-94-3 OXALIPLATIN ADVERSE_EFFECT NEU_1_Paresthesia 61825-94-3 OXALIPLATIN ADVERSE_EFFECT BBM_2_Anemia 75530-68-6 NILVADIPINE INDICATION Angina Pectoris 75530-68-6 NILVADIPINE THERAPEUTIC_CLASS Antihypertensive Agents 75530-68-6 NILVADIPINE PRODUCT_CLASS Cardiovasculars 75530-68-6 NILVADIPINE MODE_CLASS Channel Blocker 75530-68-6 NILVADIPINE THERAPEUTIC_CLASS Antianginals 75530-68-6 NILVADIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 75530-68-6 NILVADIPINE MECHANISM Reduce muscle contractile force 75530-68-6 NILVADIPINE INDICATION Hypertension 99291-24-4 LEVODROPROPIZINE MODE_CLASS Receptor Ligand Antagonist 99291-24-4 LEVODROPROPIZINE INDICATION Cough / Tussis 99291-24-4 LEVODROPROPIZINE MECHANISM Modulate G-protein coupled signal transduction 99291-25-5 LEVODROPROPIZINE INDICATION Cough / Tussis 99291-25-5 LEVODROPROPIZINE MODE_CLASS Receptor Ligand Antagonist 99291-25-5 LEVODROPROPIZINE MECHANISM Modulate G-protein coupled signal transduction 50652-76-1 FLM-5011 MODE_CLASS Enzyme Inhibitor 50652-76-1 FLM-5011 MECHANISM Inhibit eicosanoid biosynthesis 95688-34-9 FCE-22716 PRODUCT_CLASS Cardiovasculars 95688-34-9 FCE-22716 MECHANISM Modulate G-protein coupled signal transduction 95688-34-9 FCE-22716 INDICATION Hypertension 95688-34-9 FCE-22716 MODE_CLASS Receptor Agonist, Non-selective 95688-34-9 FCE-22716 MECHANISM Modulate neural transmission 95688-34-9 FCE-22716 THERAPEUTIC_CLASS Antihypertensive Agents 84290-27-7 TUCARESOL INDICATION Myocardial Ischemia 84290-27-7 TUCARESOL INDICATION Anemia 84290-27-7 TUCARESOL INDICATION Sickle Cell Anemia 90845-56-0 TRECADRINE INDICATION Diabetes 90845-56-0 TRECADRINE MECHANISM Modulate G-protein coupled signal transduction 90845-56-0 TRECADRINE INDICATION Obesity 108767-50-6 TRECADRINE INDICATION Diabetes 108767-50-6 TRECADRINE MECHANISM Modulate G-protein coupled signal transduction 108767-50-6 TRECADRINE INDICATION Obesity 89778-26-7 TOREMIFENE ADVERSE_EFFECT OCU_3_Cataracts 89778-26-7 TOREMIFENE ADVERSE_EFFECT GUS_1_Vaginal Bleeding 89778-26-7 TOREMIFENE ADVERSE_EFFECT CVS_3_Angina 89778-26-7 TOREMIFENE TISSUE_TOXICITY Angina 89778-26-7 TOREMIFENE TISSUE_TOXICITY Arrhythmia 89778-26-7 TOREMIFENE KNOWN_TOXICITY Cardiovascular Toxicity 89778-26-7 TOREMIFENE MECHANISM Modulate gene transcription 89778-26-7 TOREMIFENE MODE_CLASS Receptor Ligand Antagonist 89778-26-7 TOREMIFENE TISSUE_TOXICITY Cerebrovascular Accident 89778-26-7 TOREMIFENE THERAPEUTIC_CLASS Antineoplastics 89778-26-7 TOREMIFENE ADVERSE_EFFECT NEU_1_Dizziness 89778-26-7 TOREMIFENE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 89778-26-7 TOREMIFENE ADVERSE_EFFECT GUS_1_Vaginal Discharge 89778-26-7 TOREMIFENE ADVERSE_EFFECT CVS_3_Cerebrovascular Accident 89778-26-7 TOREMIFENE ADVERSE_EFFECT XXX_1_Diaphoresis 89778-26-7 TOREMIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 89778-26-7 TOREMIFENE PRODUCT_CLASS Anti-cancers 89778-26-7 TOREMIFENE TISSUE_TOXICITY Heart Failure 89778-26-7 TOREMIFENE TISSUE_TOXICITY Myocardial Infarction 89778-26-7 TOREMIFENE ADVERSE_EFFECT CVS_3_Heart Failure 89778-26-7 TOREMIFENE ADVERSE_EFFECT MSK_3_Arthropathy 89778-26-7 TOREMIFENE INDICATION Metastatic Breast Cancer 89778-26-7 TOREMIFENE ADVERSE_EFFECT OCU_3_Xerophthalmia 89778-26-7 TOREMIFENE ADVERSE_EFFECT CVS_3_Myocardial Infarction 89778-26-7 TOREMIFENE ADVERSE_EFFECT CVS_3_Arrhythmia 89778-26-7 TOREMIFENE ADVERSE_EFFECT END_1_Hot Flashes 89778-26-7 TOREMIFENE ADVERSE_EFFECT CVS_3_Thromboembolism 89778-26-7 TOREMIFENE TISSUE_TOXICITY Thromboembolism 89778-26-7 TOREMIFENE ADVERSE_EFFECT PSY_2_Anorexia 89778-26-7 TOREMIFENE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 89778-26-7 TOREMIFENE ADVERSE_EFFECT XXX_1_Edema 89778-26-7 TOREMIFENE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 89778-26-7 TOREMIFENE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 89778-26-7 TOREMIFENE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 89778-26-7 TOREMIFENE ADVERSE_EFFECT OCU_3_Corneal Opacities 89778-26-7 TOREMIFENE ADVERSE_EFFECT OCU_3_Diplopia 89778-27-8 TOREMIFENE MODE_CLASS Receptor Ligand Antagonist 89778-27-8 TOREMIFENE TISSUE_TOXICITY Cerebrovascular Accident 89778-27-8 TOREMIFENE THERAPEUTIC_CLASS Antineoplastics 89778-27-8 TOREMIFENE ADVERSE_EFFECT NEU_1_Dizziness 89778-27-8 TOREMIFENE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 89778-27-8 TOREMIFENE ADVERSE_EFFECT GUS_1_Vaginal Discharge 89778-27-8 TOREMIFENE ADVERSE_EFFECT CVS_3_Cerebrovascular Accident 89778-27-8 TOREMIFENE ADVERSE_EFFECT XXX_1_Diaphoresis 89778-27-8 TOREMIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 89778-27-8 TOREMIFENE PRODUCT_CLASS Anti-cancers 89778-27-8 TOREMIFENE TISSUE_TOXICITY Myocardial Infarction 89778-27-8 TOREMIFENE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 89778-27-8 TOREMIFENE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 89778-27-8 TOREMIFENE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 89778-27-8 TOREMIFENE ADVERSE_EFFECT OCU_3_Corneal Opacities 89778-27-8 TOREMIFENE ADVERSE_EFFECT GUS_1_Vaginal Bleeding 89778-27-8 TOREMIFENE ADVERSE_EFFECT CVS_3_Angina 89778-27-8 TOREMIFENE ADVERSE_EFFECT OCU_3_Diplopia 89778-27-8 TOREMIFENE ADVERSE_EFFECT CVS_3_Thromboembolism 89778-27-8 TOREMIFENE ADVERSE_EFFECT END_1_Hot Flashes 89778-27-8 TOREMIFENE ADVERSE_EFFECT MSK_3_Arthropathy 89778-27-8 TOREMIFENE ADVERSE_EFFECT CVS_3_Heart Failure 89778-27-8 TOREMIFENE TISSUE_TOXICITY Thromboembolism 89778-27-8 TOREMIFENE TISSUE_TOXICITY Angina 89778-27-8 TOREMIFENE TISSUE_TOXICITY Heart Failure 89778-27-8 TOREMIFENE ADVERSE_EFFECT CVS_3_Myocardial Infarction 89778-27-8 TOREMIFENE ADVERSE_EFFECT PSY_2_Anorexia 89778-27-8 TOREMIFENE ADVERSE_EFFECT XXX_1_Edema 89778-27-8 TOREMIFENE ADVERSE_EFFECT OCU_3_Cataracts 89778-27-8 TOREMIFENE ADVERSE_EFFECT CVS_3_Arrhythmia 89778-27-8 TOREMIFENE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 89778-27-8 TOREMIFENE ADVERSE_EFFECT OCU_3_Xerophthalmia 89778-27-8 TOREMIFENE KNOWN_TOXICITY Cardiovascular Toxicity 89778-27-8 TOREMIFENE TISSUE_TOXICITY Arrhythmia 89778-27-8 TOREMIFENE INDICATION Metastatic Breast Cancer 89778-27-8 TOREMIFENE MECHANISM Modulate gene transcription 86347-14-0 MEDETOMIDINE INDICATION Hypertension 86347-14-0 MEDETOMIDINE PRODUCT_CLASS Central Nervous System (CNS) 86347-14-0 MEDETOMIDINE THERAPEUTIC_CLASS Antihypertensive Agents 86347-14-0 MEDETOMIDINE THERAPEUTIC_CLASS Sedatives/Hypnotics 86347-14-0 MEDETOMIDINE PRODUCT_CLASS Cardiovasculars 86347-14-0 MEDETOMIDINE INDICATION Anxiety Disorders 86347-14-0 MEDETOMIDINE INDICATION Glaucoma 86347-15-1 MEDETOMIDINE THERAPEUTIC_CLASS Antihypertensive Agents 86347-15-1 MEDETOMIDINE INDICATION Hypertension 86347-15-1 MEDETOMIDINE PRODUCT_CLASS Central Nervous System (CNS) 86347-15-1 MEDETOMIDINE THERAPEUTIC_CLASS Sedatives/Hypnotics 86347-15-1 MEDETOMIDINE PRODUCT_CLASS Cardiovasculars 86347-15-1 MEDETOMIDINE INDICATION Anxiety Disorders 86347-15-1 MEDETOMIDINE INDICATION Glaucoma 82626-01-5 ALPIDEM ADVERSE_EFFECT LIV_3_Hepatitis 82626-01-5 ALPIDEM INDICATION Anxiety Disorders 82626-01-5 ALPIDEM MECHANISM Modulate neural transmission 82626-01-5 ALPIDEM TISSUE_TOXICITY Hepatotoxicity 82626-01-5 ALPIDEM KNOWN_TOXICITY Hepatotoxicity 82626-01-5 ALPIDEM ADVERSE_EFFECT LIV_2_Hepatotoxicity 82626-01-5 ALPIDEM THERAPEUTIC_CLASS Sedatives/Hypnotics 82626-01-5 ALPIDEM MECHANISM Modulate channel gating 82626-01-5 ALPIDEM INDICATION Anxiety Disorders 82626-01-5 ALPIDEM PRODUCT_CLASS Central Nervous System (CNS) 82626-01-5 ALPIDEM MODE_CLASS Channel Modulator 82626-01-5 ALPIDEM TISSUE_TOXICITY Fulminant Hepatitis 82626-01-5 ALPIDEM ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 92689-49-1 ANNAMYCIN THERAPEUTIC_CLASS Antineoplastics 92689-49-1 ANNAMYCIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 92689-49-1 ANNAMYCIN PRODUCT_CLASS Anti-cancers 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT END_3_Hirsutism 71-58-9 MEDROXYPROGESTERONE ACETATE THERAPEUTIC_CLASS Gonadal Hormones 71-58-9 MEDROXYPROGESTERONE ACETATE STRUCTURE_ACTIVITY Progesterone receptor agonist 71-58-9 MEDROXYPROGESTERONE ACETATE TISSUE_TOXICITY Thromboembolism 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT REP_2_Unintended Pregnancy 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT REP_3_Ectopic Pregnancy 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT NEU_1_Headache 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT REP_2_Amenorrhea 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT END_1_Breast Tenderness 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT GUS_2_Vaginitis 71-58-9 MEDROXYPROGESTERONE ACETATE TISSUE_TOXICITY Breakthrough Bleeding 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT KID_2_Fluid Retention 71-58-9 MEDROXYPROGESTERONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT MSK_2_Leg Cramps 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT XXX_1_Weight Gain 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT NEU_1_Dizziness 71-58-9 MEDROXYPROGESTERONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 71-58-9 MEDROXYPROGESTERONE ACETATE MECHANISM Modulate gene transcription 71-58-9 MEDROXYPROGESTERONE ACETATE INDICATION Dysfunctional Uterine Bleeding (DUB) 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT CVS_3_Thromboembolism 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT PSY_2_Mental Depression 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT IMU_3_Anaphylaxis 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT GIS_1_Nausea 71-58-9 MEDROXYPROGESTERONE ACETATE KNOWN_TOXICITY Reproductive System Toxicity 71-58-9 MEDROXYPROGESTERONE ACETATE MODE_CLASS Receptor Agonist 71-58-9 MEDROXYPROGESTERONE ACETATE INDICATION Prevention of Endometrial Hyperplasia 71-58-9 MEDROXYPROGESTERONE ACETATE INDICATION Amenorrhea 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT END_3_Galactorrhea 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT SKN_1_Acne 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT END_3_Osteoporosis 71-58-9 MEDROXYPROGESTERONE ACETATE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 92823-03-5 FLOMOXEF SODIUM PRODUCT_CLASS Anti-infectives 92823-03-5 FLOMOXEF SODIUM MODE_CLASS Enzyme Inhibitor 92823-03-5 FLOMOXEF SODIUM MECHANISM Inhibit bacterial cell wall biosynthesis 92823-03-5 FLOMOXEF SODIUM THERAPEUTIC_CLASS Antibacterials 100999-26-6 CY-208-243 INDICATION Parkinson's Disease 100999-26-6 CY-208-243 MECHANISM Modulate G-protein coupled signal transduction 87726-17-8 PANIPENAM MODE_CLASS Enzyme Inhibitor 87726-17-8 PANIPENAM PRODUCT_CLASS Anti-infectives 87726-17-8 PANIPENAM THERAPEUTIC_CLASS Antibacterials 87726-17-8 PANIPENAM MECHANISM Inhibit bacterial cell wall biosynthesis 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Hematuria 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Abnormal Kidney Function 108138-46-1 TOSUFLOXACIN KNOWN_TOXICITY Nephrotoxicity 108138-46-1 TOSUFLOXACIN ZERO_CLASS N 108138-46-1 TOSUFLOXACIN MESH_LEVEL_3 Quinolines 108138-46-1 TOSUFLOXACIN INDICATION Septic Arthritis 108138-46-1 TOSUFLOXACIN INDICATION Osteomyelitis / Bone Infection 108138-46-1 TOSUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 108138-46-1 TOSUFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 108138-46-1 TOSUFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 108138-46-1 TOSUFLOXACIN PRODUCT_CLASS Anti-infectives 108138-46-1 TOSUFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 108138-46-1 TOSUFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 108138-46-1 TOSUFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 108138-46-1 TOSUFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 108138-46-1 TOSUFLOXACIN INDICATION Urinary Tract Infection (UTI) 108138-46-1 TOSUFLOXACIN INDICATION Gram-negative Septicemia 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 108138-46-1 TOSUFLOXACIN TA_LEVEL_3 quinolones 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Jaundice 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 108138-46-1 TOSUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 108138-46-1 TOSUFLOXACIN TISSUE_TOXICITY Acute Renal Failure 108138-46-1 TOSUFLOXACIN TA_LEVEL_2 Anti-bacterial 108138-46-1 TOSUFLOXACIN MECH_LEVEL_3 DNA gyrase 108138-46-1 TOSUFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 108138-46-1 TOSUFLOXACIN INDICATION Respiratory Tract Infection 108138-46-1 TOSUFLOXACIN INDICATION Skin and Skin Structure Infections 108138-46-1 TOSUFLOXACIN MECH_LEVEL_1 Anti-bacterial 108138-46-1 TOSUFLOXACIN TA_LEVEL_1 Infectious Disease 108138-46-1 TOSUFLOXACIN INDICATION Dental Infection 108138-46-1 TOSUFLOXACIN TISSUE_TOXICITY Hematuria 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Impaired Consciousness 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 108138-46-1 TOSUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 108138-46-1 TOSUFLOXACIN INDICATION Otitis Media 108138-46-1 TOSUFLOXACIN INDICATION Biliary Tract Infection 108138-46-1 TOSUFLOXACIN INDICATION Soft Tissue Infections 108138-46-1 TOSUFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Hematuria 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Abnormal Kidney Function 104051-69-6 TOSUFLOXACIN KNOWN_TOXICITY Nephrotoxicity 104051-69-6 TOSUFLOXACIN ZERO_CLASS N 104051-69-6 TOSUFLOXACIN MESH_LEVEL_3 Quinolines 104051-69-6 TOSUFLOXACIN INDICATION Septic Arthritis 104051-69-6 TOSUFLOXACIN INDICATION Osteomyelitis / Bone Infection 104051-69-6 TOSUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 104051-69-6 TOSUFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 104051-69-6 TOSUFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 104051-69-6 TOSUFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 104051-69-6 TOSUFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 104051-69-6 TOSUFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 104051-69-6 TOSUFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 104051-69-6 TOSUFLOXACIN INDICATION Urinary Tract Infection (UTI) 104051-69-6 TOSUFLOXACIN INDICATION Gram-negative Septicemia 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Jaundice 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 104051-69-6 TOSUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 104051-69-6 TOSUFLOXACIN TISSUE_TOXICITY Acute Renal Failure 104051-69-6 TOSUFLOXACIN TA_LEVEL_2 Anti-bacterial 104051-69-6 TOSUFLOXACIN MECH_LEVEL_3 DNA gyrase 104051-69-6 TOSUFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 104051-69-6 TOSUFLOXACIN INDICATION Respiratory Tract Infection 104051-69-6 TOSUFLOXACIN INDICATION Skin and Skin Structure Infections 104051-69-6 TOSUFLOXACIN MECH_LEVEL_1 Anti-bacterial 104051-69-6 TOSUFLOXACIN TA_LEVEL_1 Infectious Disease 104051-69-6 TOSUFLOXACIN INDICATION Dental Infection 104051-69-6 TOSUFLOXACIN TISSUE_TOXICITY Hematuria 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Impaired Consciousness 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 104051-69-6 TOSUFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 104051-69-6 TOSUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 104051-69-6 TOSUFLOXACIN PRODUCT_CLASS Anti-infectives 104051-69-6 TOSUFLOXACIN TA_LEVEL_3 quinolones 104051-69-6 TOSUFLOXACIN INDICATION Otitis Media 104051-69-6 TOSUFLOXACIN INDICATION Biliary Tract Infection 104051-69-6 TOSUFLOXACIN INDICATION Soft Tissue Infections 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Hematuria 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Abnormal Kidney Function 100490-36-6 TOSUFLOXACIN KNOWN_TOXICITY Nephrotoxicity 100490-36-6 TOSUFLOXACIN ZERO_CLASS N 100490-36-6 TOSUFLOXACIN MESH_LEVEL_3 Quinolines 100490-36-6 TOSUFLOXACIN INDICATION Septic Arthritis 100490-36-6 TOSUFLOXACIN INDICATION Osteomyelitis / Bone Infection 100490-36-6 TOSUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 100490-36-6 TOSUFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 100490-36-6 TOSUFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 100490-36-6 TOSUFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 100490-36-6 TOSUFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 100490-36-6 TOSUFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 100490-36-6 TOSUFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 100490-36-6 TOSUFLOXACIN INDICATION Urinary Tract Infection (UTI) 100490-36-6 TOSUFLOXACIN INDICATION Gram-negative Septicemia 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Jaundice 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 100490-36-6 TOSUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 100490-36-6 TOSUFLOXACIN TISSUE_TOXICITY Acute Renal Failure 100490-36-6 TOSUFLOXACIN TA_LEVEL_2 Anti-bacterial 100490-36-6 TOSUFLOXACIN MECH_LEVEL_3 DNA gyrase 100490-36-6 TOSUFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 100490-36-6 TOSUFLOXACIN INDICATION Respiratory Tract Infection 100490-36-6 TOSUFLOXACIN INDICATION Skin and Skin Structure Infections 100490-36-6 TOSUFLOXACIN MECH_LEVEL_1 Anti-bacterial 100490-36-6 TOSUFLOXACIN TA_LEVEL_1 Infectious Disease 100490-36-6 TOSUFLOXACIN INDICATION Dental Infection 100490-36-6 TOSUFLOXACIN TISSUE_TOXICITY Hematuria 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Impaired Consciousness 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 100490-36-6 TOSUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 100490-36-6 TOSUFLOXACIN INDICATION Soft Tissue Infections 100490-36-6 TOSUFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 100490-36-6 TOSUFLOXACIN PRODUCT_CLASS Anti-infectives 100490-36-6 TOSUFLOXACIN TA_LEVEL_3 quinolones 100490-36-6 TOSUFLOXACIN INDICATION Otitis Media 100490-36-6 TOSUFLOXACIN INDICATION Biliary Tract Infection 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Hematuria 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Abnormal Kidney Function 114715-36-5 TOSUFLOXACIN KNOWN_TOXICITY Nephrotoxicity 114715-36-5 TOSUFLOXACIN ZERO_CLASS N 114715-36-5 TOSUFLOXACIN MESH_LEVEL_3 Quinolines 114715-36-5 TOSUFLOXACIN INDICATION Septic Arthritis 114715-36-5 TOSUFLOXACIN INDICATION Osteomyelitis / Bone Infection 114715-36-5 TOSUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 114715-36-5 TOSUFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 114715-36-5 TOSUFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 114715-36-5 TOSUFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 114715-36-5 TOSUFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 114715-36-5 TOSUFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 114715-36-5 TOSUFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 114715-36-5 TOSUFLOXACIN INDICATION Urinary Tract Infection (UTI) 114715-36-5 TOSUFLOXACIN INDICATION Gram-negative Septicemia 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 114715-36-5 TOSUFLOXACIN PRODUCT_CLASS Anti-infectives 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 114715-36-5 TOSUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 114715-36-5 TOSUFLOXACIN TISSUE_TOXICITY Acute Renal Failure 114715-36-5 TOSUFLOXACIN TA_LEVEL_2 Anti-bacterial 114715-36-5 TOSUFLOXACIN MECH_LEVEL_3 DNA gyrase 114715-36-5 TOSUFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 114715-36-5 TOSUFLOXACIN INDICATION Respiratory Tract Infection 114715-36-5 TOSUFLOXACIN INDICATION Skin and Skin Structure Infections 114715-36-5 TOSUFLOXACIN MECH_LEVEL_1 Anti-bacterial 114715-36-5 TOSUFLOXACIN TA_LEVEL_1 Infectious Disease 114715-36-5 TOSUFLOXACIN INDICATION Dental Infection 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Jaundice 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Impaired Consciousness 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 114715-36-5 TOSUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 114715-36-5 TOSUFLOXACIN TA_LEVEL_3 quinolones 114715-36-5 TOSUFLOXACIN INDICATION Otitis Media 114715-36-5 TOSUFLOXACIN INDICATION Biliary Tract Infection 114715-36-5 TOSUFLOXACIN INDICATION Soft Tissue Infections 114715-36-5 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 114715-36-5 TOSUFLOXACIN TISSUE_TOXICITY Hematuria 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Hematuria 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT KID_3_Abnormal Kidney Function 115964-29-9 TOSUFLOXACIN KNOWN_TOXICITY Nephrotoxicity 115964-29-9 TOSUFLOXACIN ZERO_CLASS N 115964-29-9 TOSUFLOXACIN MESH_LEVEL_3 Quinolines 115964-29-9 TOSUFLOXACIN INDICATION Septic Arthritis 115964-29-9 TOSUFLOXACIN INDICATION Osteomyelitis / Bone Infection 115964-29-9 TOSUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 115964-29-9 TOSUFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 115964-29-9 TOSUFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 115964-29-9 TOSUFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 115964-29-9 TOSUFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 115964-29-9 TOSUFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 115964-29-9 TOSUFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 115964-29-9 TOSUFLOXACIN INDICATION Urinary Tract Infection (UTI) 115964-29-9 TOSUFLOXACIN INDICATION Gram-negative Septicemia 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Jaundice 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 115964-29-9 TOSUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 115964-29-9 TOSUFLOXACIN TISSUE_TOXICITY Acute Renal Failure 115964-29-9 TOSUFLOXACIN TA_LEVEL_2 Anti-bacterial 115964-29-9 TOSUFLOXACIN MECH_LEVEL_3 DNA gyrase 115964-29-9 TOSUFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 115964-29-9 TOSUFLOXACIN INDICATION Respiratory Tract Infection 115964-29-9 TOSUFLOXACIN INDICATION Skin and Skin Structure Infections 115964-29-9 TOSUFLOXACIN MECH_LEVEL_1 Anti-bacterial 115964-29-9 TOSUFLOXACIN TA_LEVEL_1 Infectious Disease 115964-29-9 TOSUFLOXACIN INDICATION Dental Infection 115964-29-9 TOSUFLOXACIN TISSUE_TOXICITY Hematuria 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT NEU_3_Impaired Consciousness 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 115964-29-9 TOSUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 115964-29-9 TOSUFLOXACIN PRODUCT_CLASS Anti-infectives 115964-29-9 TOSUFLOXACIN TA_LEVEL_3 quinolones 115964-29-9 TOSUFLOXACIN INDICATION Otitis Media 115964-29-9 TOSUFLOXACIN INDICATION Biliary Tract Infection 115964-29-9 TOSUFLOXACIN INDICATION Soft Tissue Infections 115964-29-9 TOSUFLOXACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 117467-28-4 CEFDITOREN PIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 117467-28-4 CEFDITOREN PIVOXIL PRODUCT_CLASS Anti-infectives 117467-28-4 CEFDITOREN PIVOXIL MODE_CLASS Enzyme Inhibitor 117467-28-4 CEFDITOREN PIVOXIL THERAPEUTIC_CLASS Antibacterials 120210-48-2 TENIDAP MODE_CLASS Enzyme Inhibitor 120210-48-2 TENIDAP ADVERSE_EFFECT KID_1_Impaired Renal Tubular Function 120210-48-2 TENIDAP MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 120210-48-2 TENIDAP INDICATION Osteoarthritis 120210-48-2 TENIDAP THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 120210-48-2 TENIDAP ZERO_CLASS N 120210-48-2 TENIDAP MESH_LEVEL_1 Heterocyclic Compounds 120210-48-2 TENIDAP MECH_LEVEL_3 Arachidonate 5-lipoxygenase, Prostaglandin-endoperoxide synthase 1 nad 2 120210-48-2 TENIDAP MECHANISM Inhibit eicosanoid biosynthesis 120210-48-2 TENIDAP ADVERSE_EFFECT END_3_Osteoporosis 120210-48-2 TENIDAP TA_LEVEL_2 NSAID (?) 120210-48-2 TENIDAP ADVERSE_EFFECT KID_1_Proteinuria 120210-48-2 TENIDAP ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 120210-48-2 TENIDAP TISSUE_TOXICITY Hepatotoxicity 120210-48-2 TENIDAP ACTIVITY_CLASS Anti-inflammatory 120210-48-2 TENIDAP MECH_LEVEL_1 Immunomodulation 120210-48-2 TENIDAP TA_LEVEL_3 rheumatoid arthritis 120210-48-2 TENIDAP MESH_LEVEL_3 Indoles 120210-48-2 TENIDAP MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 120210-48-2 TENIDAP PRODUCT_CLASS Anti-inflammatories 120210-48-2 TENIDAP INDICATION Rheumatoid Arthritis 120210-48-2 TENIDAP ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 120210-48-2 TENIDAP STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 120210-48-2 TENIDAP KNOWN_TOXICITY Hepatotoxicity 120210-48-2 TENIDAP TA_LEVEL_1 Anti-inflammatory 120210-48-2 TENIDAP INDICATION Inflammation 120210-48-2 TENIDAP ADVERSE_EFFECT LIV_2_Hepatotoxicity 120210-48-2 TENIDAP ADVERSE_EFFECT GIS_1_Dyspepsia 84210-26-4 NZ-419 INDICATION Renal Failure / Kidney Failure 87679-71-8 TRANDOLAPRILAT INDICATION Hypertension 87679-71-8 TRANDOLAPRILAT MECHANISM Reduce vasoconstriction 87679-71-8 TRANDOLAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 87679-71-8 TRANDOLAPRILAT MODE_CLASS Enzyme Inhibitor 87679-71-8 TRANDOLAPRILAT PRODUCT_CLASS Cardiovasculars 83009-96-5 TEI-5178 INDICATION Nephritis 83058-69-9 TFC-612 INDICATION Diabetes 99519-84-3 L-651582 PRODUCT_CLASS Anti-cancers 99519-84-3 L-651582 INDICATION Psoriasis 99519-84-3 L-651582 STRUCTURE_ACTIVITY Ca++ channel blocker 528-58-5 IDB-1027 INDICATION Ulcer 74639-40-0 DOCARPAMINE MECHANISM Block channel gating 74639-40-0 DOCARPAMINE MODE_CLASS Solute transporter inhibitor 74639-40-0 DOCARPAMINE MECHANISM Modulate G-protein coupled signal transduction 74639-40-0 DOCARPAMINE MODE_CLASS Receptor Agonist 93129-94-3 TACALCITOL MECHANISM Modulate gene transcription 93129-94-3 TACALCITOL MODE_CLASS Receptor Agonist 93129-94-3 TACALCITOL THERAPEUTIC_CLASS Psoralens 93129-94-3 TACALCITOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 93129-94-3 TACALCITOL INDICATION Psoriasis 93129-94-3 TACALCITOL PRODUCT_CLASS Dermatologicals 79955-36-5 CYSTEMUSTINE PRODUCT_CLASS Anti-cancers 79955-36-5 CYSTEMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 79955-36-5 CYSTEMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 79955-36-5 CYSTEMUSTINE STRUCTURE_ACTIVITY DNA-alkylator, methanesulfonate 79955-36-5 CYSTEMUSTINE THERAPEUTIC_CLASS Antineoplastics 105182-45-4 FLUPAROXAN INDICATION Depression 105182-45-4 FLUPAROXAN THERAPEUTIC_CLASS Antidepressants 105182-45-4 FLUPAROXAN INDICATION Cerebral Ischemia 105182-45-4 FLUPAROXAN PRODUCT_CLASS Central Nervous System (CNS) 105182-45-4 FLUPAROXAN MECHANISM Modulate G-protein coupled signal transduction 101389-87-1 FLUPAROXAN INDICATION Cerebral Ischemia 101389-87-1 FLUPAROXAN PRODUCT_CLASS Central Nervous System (CNS) 101389-87-1 FLUPAROXAN MECHANISM Modulate G-protein coupled signal transduction 101389-87-1 FLUPAROXAN INDICATION Depression 101389-87-1 FLUPAROXAN THERAPEUTIC_CLASS Antidepressants 111793-41-0 FLUPAROXAN INDICATION Depression 111793-41-0 FLUPAROXAN THERAPEUTIC_CLASS Antidepressants 111793-41-0 FLUPAROXAN MECHANISM Modulate G-protein coupled signal transduction 111793-41-0 FLUPAROXAN PRODUCT_CLASS Central Nervous System (CNS) 111793-41-0 FLUPAROXAN INDICATION Cerebral Ischemia 74050-20-7 HYDROCORTISONE ACEPONATE MODE_CLASS Receptor Agonist 74050-20-7 HYDROCORTISONE ACEPONATE MECHANISM Modulate gene transcription 91406-11-0 ESUPRONE INDICATION Depression 91406-11-0 ESUPRONE THERAPEUTIC_CLASS Antidepressants 91406-11-0 ESUPRONE PRODUCT_CLASS Central Nervous System (CNS) 7491-74-9 PIRACETAM PRODUCT_CLASS Central Nervous System (CNS) 7491-74-9 PIRACETAM INDICATION Alzheimer's Dementia 7491-74-9 PIRACETAM MESH_LEVEL_1 Organic Chemicals 7491-74-9 PIRACETAM MECHANISM Reduce muscle contractile force 7491-74-9 PIRACETAM ZERO_CLASS N 7491-74-9 PIRACETAM MECH_LEVEL_1 Analeptic 7491-74-9 PIRACETAM ADVERSE_EFFECT NEU_2_Somnolence 7491-74-9 PIRACETAM ADVERSE_EFFECT PSY_2_Nervousness 7491-74-9 PIRACETAM ADVERSE_EFFECT NEU_2_Hyperkinesia 7491-74-9 PIRACETAM STRUCTURE_ACTIVITY Glycine receptor antagonist 7491-74-9 PIRACETAM MECHANISM Block channel gating 7491-74-9 PIRACETAM TA_LEVEL_1 Central Nervous System (CNS) 7491-74-9 PIRACETAM TA_LEVEL_2 Movement Disorders 7491-74-9 PIRACETAM ADVERSE_EFFECT PSY_2_Insomnia 7491-74-9 PIRACETAM MESH_LEVEL_2 Amides 7491-74-9 PIRACETAM MODE_CLASS Receptor Agonist 7491-74-9 PIRACETAM INDICATION Myoclonus of Cortical Origin 7491-74-9 PIRACETAM MESH_LEVEL_3 Acetamides 7491-74-9 PIRACETAM ADVERSE_EFFECT PSY_2_Depression 7491-74-9 PIRACETAM ADVERSE_EFFECT XXX_2_Weight Gain 7491-74-9 PIRACETAM MECHANISM Prolong/enhance neural transmission 7491-74-9 PIRACETAM THERAPEUTIC_CLASS Movement Disorders 7491-74-9 PIRACETAM MODE_CLASS Channel Blocker 7491-74-9 PIRACETAM MECH_LEVEL_3 Unknown mechanism 7491-74-9 PIRACETAM THERAPEUTIC_CLASS Neurodegenerative Disorders 7491-74-9 PIRACETAM ADVERSE_EFFECT GIS_3_Diarrhea 7491-74-9 PIRACETAM ADVERSE_EFFECT SKN_3_Rash 7491-74-9 PIRACETAM ACTIVITY_CLASS Glycine receptor antagonist 51037-30-0 ACIPIMOX INDICATION Hypolipidemia 27591-01-1 ICX5606453 MECHANISM Modulate G-protein coupled signal transduction 51598-60-8 CIMETROPIUM BROMIDE MODE_CLASS Receptor Ligand Antagonist 51598-60-8 CIMETROPIUM BROMIDE MECHANISM Modulate G-protein coupled signal transduction 59721-28-7 CAMOSTAT ADVERSE_EFFECT GIS_2_Nausea 59721-28-7 CAMOSTAT THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 59721-28-7 CAMOSTAT PRODUCT_CLASS Gastrointestinal System 59721-28-7 CAMOSTAT ADVERSE_EFFECT GIS_2_Abdominal Pain 59721-28-7 CAMOSTAT ADVERSE_EFFECT GIS_3_Vomiting 59721-28-7 CAMOSTAT MODE_CLASS Enzyme Inhibitor 59721-28-7 CAMOSTAT INDICATION Chronic Pancreatitis, Remission of Acute Symptoms 59721-28-7 CAMOSTAT ADVERSE_EFFECT SKN_2_Rash 59721-28-7 CAMOSTAT ADVERSE_EFFECT XXX_3_Edema 59721-28-7 CAMOSTAT ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 59721-28-7 CAMOSTAT ADVERSE_EFFECT GIS_3_Dry Mouth 59721-28-7 CAMOSTAT ADVERSE_EFFECT ELT_3_Hyperkalemia 59721-28-7 CAMOSTAT ADVERSE_EFFECT BBM_3_Leukopenia 59721-28-7 CAMOSTAT ADVERSE_EFFECT IMU_3_Eosinophilia 59721-28-7 CAMOSTAT INDICATION Postoperative Reflux Esophagitis 59721-28-7 CAMOSTAT ADVERSE_EFFECT GIS_2_Diarrhea 59721-28-7 CAMOSTAT ADVERSE_EFFECT END_3_Hypoglycemia 59721-28-7 CAMOSTAT ADVERSE_EFFECT SKN_2_Pruritis 59721-28-7 CAMOSTAT ADVERSE_EFFECT GIS_3_Heartburn 59721-28-7 CAMOSTAT STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 59721-29-8 CAMOSTAT ADVERSE_EFFECT END_3_Hypoglycemia 59721-29-8 CAMOSTAT ADVERSE_EFFECT SKN_2_Pruritis 59721-29-8 CAMOSTAT ADVERSE_EFFECT XXX_3_Edema 59721-29-8 CAMOSTAT ADVERSE_EFFECT GIS_2_Nausea 59721-29-8 CAMOSTAT ADVERSE_EFFECT GIS_3_Dry Mouth 59721-29-8 CAMOSTAT ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 59721-29-8 CAMOSTAT ADVERSE_EFFECT GIS_3_Heartburn 59721-29-8 CAMOSTAT STRUCTURE_ACTIVITY Protease (serine/threonine) inhibitor 59721-29-8 CAMOSTAT ADVERSE_EFFECT GIS_2_Diarrhea 59721-29-8 CAMOSTAT INDICATION Postoperative Reflux Esophagitis 59721-29-8 CAMOSTAT ADVERSE_EFFECT IMU_3_Eosinophilia 59721-29-8 CAMOSTAT ADVERSE_EFFECT BBM_3_Leukopenia 59721-29-8 CAMOSTAT ADVERSE_EFFECT ELT_3_Hyperkalemia 59721-29-8 CAMOSTAT INDICATION Chronic Pancreatitis, Remission of Acute Symptoms 59721-29-8 CAMOSTAT MODE_CLASS Enzyme Inhibitor 59721-29-8 CAMOSTAT ADVERSE_EFFECT GIS_3_Vomiting 59721-29-8 CAMOSTAT ADVERSE_EFFECT SKN_2_Rash 59721-29-8 CAMOSTAT ADVERSE_EFFECT GIS_2_Abdominal Pain 59721-29-8 CAMOSTAT PRODUCT_CLASS Gastrointestinal System 59721-29-8 CAMOSTAT THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 39563-28-5 CLORANOLOL HYDROCHLORIDE MODE_CLASS Receptor Ligand Antagonist, Selective 39563-28-5 CLORANOLOL HYDROCHLORIDE INDICATION Hypertension 39563-28-5 CLORANOLOL HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 39563-28-5 CLORANOLOL HYDROCHLORIDE MECHANISM Reduce muscle contractile force 39563-28-5 CLORANOLOL HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 6809-52-5 TEPRENONE INDICATION Ulcer 62658-63-3 BOPINDOLOL ADVERSE_EFFECT XXX_3_Fatigue 62658-63-3 BOPINDOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 62658-63-3 BOPINDOLOL ADVERSE_EFFECT MSK_2_Muscle Cramps 62658-63-3 BOPINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 62658-63-3 BOPINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 62658-63-3 BOPINDOLOL ADVERSE_EFFECT NEU_2_Dizziness 62658-63-3 BOPINDOLOL ADVERSE_EFFECT PSY_3_Hallucinations 62658-63-3 BOPINDOLOL ADVERSE_EFFECT END_2_Hyperglycemia 62658-63-3 BOPINDOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 62658-63-3 BOPINDOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 62658-63-3 BOPINDOLOL MECHANISM Modulate G-protein coupled signal transduction 62658-63-3 BOPINDOLOL TISSUE_TOXICITY Hypotension 62658-63-3 BOPINDOLOL ADVERSE_EFFECT PSY_3_Depression 62658-63-3 BOPINDOLOL ADVERSE_EFFECT END_3_Hypoglycemia 62658-63-3 BOPINDOLOL ADVERSE_EFFECT LUN_2_Dyspnea 62658-63-3 BOPINDOLOL ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 62658-63-3 BOPINDOLOL KNOWN_TOXICITY Cardiovascular Toxicity 62658-63-3 BOPINDOLOL PRODUCT_CLASS Cardiovasculars 62658-63-3 BOPINDOLOL MECHANISM Reduce muscle contractile force 62658-63-3 BOPINDOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 62658-63-3 BOPINDOLOL ADVERSE_EFFECT NEU_2_Headache 62658-63-3 BOPINDOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 62658-63-3 BOPINDOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 62658-63-3 BOPINDOLOL INDICATION Hypertension 62658-63-3 BOPINDOLOL ADVERSE_EFFECT CVS_2_Hypotension 75507-68-5 FLUPIRTINE MALEATE MODE_CLASS Channel Modulator 75507-68-5 FLUPIRTINE MALEATE MECHANISM Modulate channel gating 59937-28-9 MALOTILATE ADVERSE_EFFECT MSK_3_Joint Pain 59937-28-9 MALOTILATE PRODUCT_CLASS Other Human Uses 59937-28-9 MALOTILATE INDICATION Cirrhosis 59937-28-9 MALOTILATE ADVERSE_EFFECT GIS_3_Nausea 59937-28-9 MALOTILATE ADVERSE_EFFECT LIV_3_Hepatitis 59937-28-9 MALOTILATE ADVERSE_EFFECT SKN_1_Dry Skin 59937-28-9 MALOTILATE THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 59937-28-9 MALOTILATE ADVERSE_EFFECT IMU_3_Allergic Reactions 59937-28-9 MALOTILATE ADVERSE_EFFECT XXX_3_Taste Disturbances 59937-28-9 MALOTILATE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 59937-28-9 MALOTILATE ADVERSE_EFFECT GIS_3_Diarrhea 59937-28-9 MALOTILATE ADVERSE_EFFECT NEU_3_Headache 59937-28-9 MALOTILATE ADVERSE_EFFECT NEU_3_Neuropathy 50924-49-7 MIZORIBINE MODE_CLASS Enzyme Inhibitor 50924-49-7 MIZORIBINE MECHANISM Inhibit precursor synthesis 50924-49-7 MIZORIBINE INDICATION Multiple Sclerosis (MS) 63610-08-2 INDOBUFEN MECHANISM Inhibit eicosanoid biosynthesis 63610-08-2 INDOBUFEN MODE_CLASS Enzyme Inhibitor 93106-60-6 ENROFLOXACIN TA_LEVEL_2 Anti-bacterial 93106-60-6 ENROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 93106-60-6 ENROFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 93106-60-6 ENROFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 93106-60-6 ENROFLOXACIN ZERO_CLASS N 93106-60-6 ENROFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 93106-60-6 ENROFLOXACIN THERAPEUTIC_CLASS Antibacterials 93106-60-6 ENROFLOXACIN PRODUCT_CLASS Veterinarian 93106-60-6 ENROFLOXACIN TA_LEVEL_1 Veterinarian 93106-60-6 ENROFLOXACIN MECH_LEVEL_3 DNA gyrase 93106-60-6 ENROFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 93106-60-6 ENROFLOXACIN MESH_LEVEL_3 Quinolines 93106-60-6 ENROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 93106-60-6 ENROFLOXACIN TA_LEVEL_3 quinolones 93106-60-6 ENROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 93106-60-6 ENROFLOXACIN MECH_LEVEL_1 Anti-bacterial 88430-50-6 BERAPROST SODIUM MODE_CLASS Receptor Agonist 88430-50-6 BERAPROST SODIUM MECHANISM Modulate G-protein coupled signal transduction 88475-69-8 BERAPROST SODIUM MODE_CLASS Receptor Agonist 88475-69-8 BERAPROST SODIUM MECHANISM Modulate G-protein coupled signal transduction 112653-29-9 VOGLIBOSE MODE_CLASS Enzyme Inhibitor 112653-29-9 VOGLIBOSE INDICATION Diabetes 112653-29-9 VOGLIBOSE MECHANISM Inhibit absorption of dietary carbohydrates 124-97-0 NEOPROTOVERATRINE THERAPEUTIC_CLASS Antihypertensive Agents 124-97-0 NEOPROTOVERATRINE INDICATION Hypertension 124-97-0 NEOPROTOVERATRINE PRODUCT_CLASS Cardiovasculars 33279-57-1 K-STROPHANTHIN-GAMMA STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 37933-66-7 THEVETIN A STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 5511-98-8 ALPHA-ACETYLDIGOXIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 17575-20-1 LANATOSIDE A STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 17575-21-2 LANATOSIDE B STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 11030-31-2 LANATOSIDE D STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 20460-30-4 LANATOSIDE E STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 11116-32-8 BLEOMYCIN A5 THERAPEUTIC_CLASS Antineoplastics 11116-32-8 BLEOMYCIN A5 MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 11116-32-8 BLEOMYCIN A5 PRODUCT_CLASS Anti-cancers 11116-32-8 BLEOMYCIN A5 MECHANISM Inhibit DNA synthesis, repair, and function 2507-24-6 FISALEMINA INDICATION Hypertension 2507-24-6 FISALEMINA PRODUCT_CLASS Cardiovasculars 2507-24-6 FISALEMINA THERAPEUTIC_CLASS Antihypertensive Agents 6156-47-4 ACTINOMYCIN VII PRODUCT_CLASS Anti-cancers 6156-47-4 ACTINOMYCIN VII THERAPEUTIC_CLASS Antineoplastics 6156-47-4 ACTINOMYCIN VII MECHANISM Inhibit DNA synthesis, repair, and function 6156-47-4 ACTINOMYCIN VII MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 36357-77-4 PHOPHORAMIDON INDICATION Corneal Ulcer 36357-77-4 PHOPHORAMIDON INDICATION Ulcer 17086-76-9 CYASTERONE INDICATION Hyperlipidemia 17086-76-9 CYASTERONE INDICATION Diabetes 17086-76-9 CYASTERONE PRODUCT_CLASS Cardiovasculars 17086-76-9 CYASTERONE THERAPEUTIC_CLASS Hypolipidemic Agents 63710-10-1 MARCELLOMYCIN THERAPEUTIC_CLASS Antineoplastics 63710-10-1 MARCELLOMYCIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 63710-10-1 MARCELLOMYCIN PRODUCT_CLASS Anti-cancers 12607-92-0 ACEGLUTAMIDE ALUMINUM INDICATION Ulcer 113775-47-6 DEXMEDETOMIDINE INDICATION Sedation in Intubated patients 113775-47-6 DEXMEDETOMIDINE MODE_CLASS Receptor Agonist 113775-47-6 DEXMEDETOMIDINE MECHANISM Modulate G-protein coupled signal transduction 113775-47-6 DEXMEDETOMIDINE THERAPEUTIC_CLASS Sedatives/Hypnotics 113775-47-6 DEXMEDETOMIDINE PRODUCT_CLASS Central Nervous System (CNS) 113775-47-6 DEXMEDETOMIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 145108-58-3 DEXMEDETOMIDINE THERAPEUTIC_CLASS Sedatives/Hypnotics 145108-58-3 DEXMEDETOMIDINE PRODUCT_CLASS Central Nervous System (CNS) 145108-58-3 DEXMEDETOMIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 145108-58-3 DEXMEDETOMIDINE INDICATION Sedation in Intubated patients 145108-58-3 DEXMEDETOMIDINE MODE_CLASS Receptor Agonist 145108-58-3 DEXMEDETOMIDINE MECHANISM Modulate G-protein coupled signal transduction 155230-09-4 DEXMEDETOMIDINE MECHANISM Modulate G-protein coupled signal transduction 155230-09-4 DEXMEDETOMIDINE PRODUCT_CLASS Central Nervous System (CNS) 155230-09-4 DEXMEDETOMIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 155230-09-4 DEXMEDETOMIDINE INDICATION Sedation in Intubated patients 155230-09-4 DEXMEDETOMIDINE MODE_CLASS Receptor Agonist 155230-09-4 DEXMEDETOMIDINE THERAPEUTIC_CLASS Sedatives/Hypnotics 176721-04-3 DEXMEDETOMIDINE PRODUCT_CLASS Central Nervous System (CNS) 176721-04-3 DEXMEDETOMIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 176721-04-3 DEXMEDETOMIDINE INDICATION Sedation in Intubated patients 176721-04-3 DEXMEDETOMIDINE MECHANISM Modulate G-protein coupled signal transduction 176721-04-3 DEXMEDETOMIDINE THERAPEUTIC_CLASS Sedatives/Hypnotics 176721-04-3 DEXMEDETOMIDINE MODE_CLASS Receptor Agonist 102767-28-2 LEVETIRACETAM THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 102767-28-2 LEVETIRACETAM INDICATION Epilepsy 102767-28-2 LEVETIRACETAM STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 94168-98-6 RIFAMETANE PRODUCT_CLASS Anti-infectives 94168-98-6 RIFAMETANE MODE_CLASS Enzyme Inhibitor, selective 94168-98-6 RIFAMETANE THERAPEUTIC_CLASS Antibacterials 94168-98-6 RIFAMETANE MECHANISM Inhibit protein synthesis 94168-98-6 RIFAMETANE INDICATION Tuberculosis 113102-19-5 RIFAMEXIL MODE_CLASS Enzyme Inhibitor, selective 113102-19-5 RIFAMEXIL MECHANISM Inhibit protein synthesis 113102-19-5 RIFAMEXIL PRODUCT_CLASS Anti-infectives 113102-19-5 RIFAMEXIL THERAPEUTIC_CLASS Antibacterials 61379-65-5 RIFAPENTINE ADVERSE_EFFECT BBM_2_Neutropenia 61379-65-5 RIFAPENTINE MESH_LEVEL_3 Rifamycins 61379-65-5 RIFAPENTINE TA_LEVEL_2 anti-bacterial 61379-65-5 RIFAPENTINE TA_LEVEL_3 tuberculosis 61379-65-5 RIFAPENTINE ADVERSE_EFFECT PSY_2_Anorexia 61379-65-5 RIFAPENTINE ADVERSE_EFFECT SKN_2_Pruritis 61379-65-5 RIFAPENTINE ADVERSE_EFFECT KID_2_Proteinuria 61379-65-5 RIFAPENTINE ADVERSE_EFFECT GUS_2_Discoloration of Urine 61379-65-5 RIFAPENTINE STRUCTURE_ACTIVITY RNA polymerase inhibitor 61379-65-5 RIFAPENTINE ZERO_CLASS N 61379-65-5 RIFAPENTINE MESH_LEVEL_1 Heterocyclic Compounds 61379-65-5 RIFAPENTINE MESH_LEVEL_2 Heterocyclic Compounds with 4 or More Rings 61379-65-5 RIFAPENTINE MECH_LEVEL_3 DNA-directed RNA polymerase 61379-65-5 RIFAPENTINE MECH_LEVEL_1 protein synthesis 61379-65-5 RIFAPENTINE TA_LEVEL_1 Infectious Disease 61379-65-5 RIFAPENTINE PRODUCT_CLASS Anti-infectives 61379-65-5 RIFAPENTINE THERAPEUTIC_CLASS Antibacterials, Systemic 61379-65-5 RIFAPENTINE ADVERSE_EFFECT CVS_2_Hypertension 61379-65-5 RIFAPENTINE ADVERSE_EFFECT SKN_2_Rash 61379-65-5 RIFAPENTINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 61379-65-5 RIFAPENTINE ADVERSE_EFFECT GIS_2_Dyspepsia 61379-65-5 RIFAPENTINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 61379-65-5 RIFAPENTINE ADVERSE_EFFECT LUN_2_Hemoptysis 61379-65-5 RIFAPENTINE MODE_CLASS Enzyme Inhibitor, selective 61379-65-5 RIFAPENTINE ADVERSE_EFFECT GIS_2_Diarrhea 61379-65-5 RIFAPENTINE INDICATION Tuberculosis 61379-65-5 RIFAPENTINE ADVERSE_EFFECT NEU_2_Headache 61379-65-5 RIFAPENTINE ADVERSE_EFFECT BBM_2_Leukopenia 61379-65-5 RIFAPENTINE ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 61379-65-5 RIFAPENTINE MECH_LEVEL_2 Enzyme inhibitor 61379-65-5 RIFAPENTINE MECHANISM Inhibit protein synthesis 61379-65-5 RIFAPENTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 61379-65-5 RIFAPENTINE ADVERSE_EFFECT BBM_2_Anemia 71950-35-1 RIFAPENTINE ADVERSE_EFFECT SKN_2_Rash 71950-35-1 RIFAPENTINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 71950-35-1 RIFAPENTINE ADVERSE_EFFECT GIS_2_Dyspepsia 71950-35-1 RIFAPENTINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 71950-35-1 RIFAPENTINE TA_LEVEL_3 tuberculosis 71950-35-1 RIFAPENTINE MODE_CLASS Enzyme Inhibitor, selective 71950-35-1 RIFAPENTINE ADVERSE_EFFECT GIS_2_Diarrhea 71950-35-1 RIFAPENTINE ADVERSE_EFFECT NEU_2_Headache 71950-35-1 RIFAPENTINE ADVERSE_EFFECT BBM_2_Leukopenia 71950-35-1 RIFAPENTINE ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 71950-35-1 RIFAPENTINE INDICATION Tuberculosis 71950-35-1 RIFAPENTINE MECH_LEVEL_1 protein synthesis 71950-35-1 RIFAPENTINE MECH_LEVEL_2 Enzyme inhibitor 71950-35-1 RIFAPENTINE MECHANISM Inhibit protein synthesis 71950-35-1 RIFAPENTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 71950-35-1 RIFAPENTINE ADVERSE_EFFECT BBM_2_Anemia 71950-35-1 RIFAPENTINE MESH_LEVEL_1 Heterocyclic Compounds 71950-35-1 RIFAPENTINE ADVERSE_EFFECT PSY_2_Anorexia 71950-35-1 RIFAPENTINE ADVERSE_EFFECT SKN_2_Pruritis 71950-35-1 RIFAPENTINE ADVERSE_EFFECT KID_2_Proteinuria 71950-35-1 RIFAPENTINE ADVERSE_EFFECT GUS_2_Discoloration of Urine 71950-35-1 RIFAPENTINE ZERO_CLASS N 71950-35-1 RIFAPENTINE MESH_LEVEL_2 Heterocyclic Compounds with 4 or More Rings 71950-35-1 RIFAPENTINE MESH_LEVEL_3 Rifamycins 71950-35-1 RIFAPENTINE TA_LEVEL_2 anti-bacterial 71950-35-1 RIFAPENTINE MECH_LEVEL_3 DNA-directed RNA polymerase 71950-35-1 RIFAPENTINE ADVERSE_EFFECT BBM_2_Neutropenia 71950-35-1 RIFAPENTINE ADVERSE_EFFECT LUN_2_Hemoptysis 71950-35-1 RIFAPENTINE TA_LEVEL_1 Infectious Disease 71950-35-1 RIFAPENTINE STRUCTURE_ACTIVITY RNA polymerase inhibitor 71950-35-1 RIFAPENTINE PRODUCT_CLASS Anti-infectives 71950-35-1 RIFAPENTINE THERAPEUTIC_CLASS Antibacterials, Systemic 71950-35-1 RIFAPENTINE ADVERSE_EFFECT CVS_2_Hypertension 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Cardiomyopathy 23541-50-6 DAUNORUBICIN KNOWN_TOXICITY Mutagenicity 23541-50-6 DAUNORUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 23541-50-6 DAUNORUBICIN INDICATION Acute Lymphocytic Leukemia (ALL) 23541-50-6 DAUNORUBICIN TA_LEVEL_2 DNA damage 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT XXX_1_Infection 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT EMB_2_Teratogenicity 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT BBM_3_Acute Leukemia 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Congestive Heart Failure 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Mutagenicity 23541-50-6 DAUNORUBICIN ZERO_CLASS N 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Teratogenicity 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 23541-50-6 DAUNORUBICIN INDICATION Acute Monocytic Leukemia 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT KID_1_Hyperuricemia 23541-50-6 DAUNORUBICIN MESH_LEVEL_2 Carbohydrates 23541-50-6 DAUNORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 23541-50-6 DAUNORUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 23541-50-6 DAUNORUBICIN KNOWN_TOXICITY Embryo/Fetal Toxicity 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Myelosuppression 23541-50-6 DAUNORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT XXX_1_Mucositis 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 23541-50-6 DAUNORUBICIN PRODUCT_CLASS Anti-cancers 23541-50-6 DAUNORUBICIN ACTIVITY_CLASS DNA damager 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT CVS_2_Acute Dysrhythmia 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 23541-50-6 DAUNORUBICIN TA_LEVEL_1 Oncology 23541-50-6 DAUNORUBICIN THERAPEUTIC_CLASS Antineoplastics 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 23541-50-6 DAUNORUBICIN TA_LEVEL_3 Solid and soft Tumors 23541-50-6 DAUNORUBICIN INDICATION Acute Erythroid Leukemia 23541-50-6 DAUNORUBICIN MECH_LEVEL_3 DNA damage 23541-50-6 DAUNORUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 23541-50-6 DAUNORUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Acute Dysrhythmia 23541-50-6 DAUNORUBICIN KNOWN_TOXICITY Carcinogenicity 23541-50-6 DAUNORUBICIN INDICATION Acute Non-Lymphocytic Leukemia 23541-50-6 DAUNORUBICIN MESH_LEVEL_3 Aminoglycosides 23541-50-6 DAUNORUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 23541-50-6 DAUNORUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 23541-50-6 DAUNORUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Cardiotoxicity 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Hemorrhage 23541-50-6 DAUNORUBICIN TISSUE_TOXICITY Carcinogenicity 23541-50-6 DAUNORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Cardiotoxicity 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 20830-81-3 DAUNORUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 20830-81-3 DAUNORUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 20830-81-3 DAUNORUBICIN MESH_LEVEL_3 Aminoglycosides 20830-81-3 DAUNORUBICIN INDICATION Acute Non-Lymphocytic Leukemia 20830-81-3 DAUNORUBICIN KNOWN_TOXICITY Carcinogenicity 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Acute Dysrhythmia 20830-81-3 DAUNORUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 20830-81-3 DAUNORUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 20830-81-3 DAUNORUBICIN MECH_LEVEL_3 DNA damage 20830-81-3 DAUNORUBICIN INDICATION Acute Erythroid Leukemia 20830-81-3 DAUNORUBICIN TA_LEVEL_3 Solid and soft Tumors 20830-81-3 DAUNORUBICIN PRODUCT_CLASS Anti-cancers 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT XXX_1_Mucositis 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT KID_1_Hyperuricemia 20830-81-3 DAUNORUBICIN TA_LEVEL_1 Oncology 20830-81-3 DAUNORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 20830-81-3 DAUNORUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT CVS_2_Acute Dysrhythmia 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 20830-81-3 DAUNORUBICIN ACTIVITY_CLASS DNA damager 20830-81-3 DAUNORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Myelosuppression 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT BBM_3_Acute Leukemia 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Congestive Heart Failure 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Mutagenicity 20830-81-3 DAUNORUBICIN ZERO_CLASS N 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Teratogenicity 20830-81-3 DAUNORUBICIN THERAPEUTIC_CLASS Antineoplastics 20830-81-3 DAUNORUBICIN INDICATION Acute Monocytic Leukemia 20830-81-3 DAUNORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 20830-81-3 DAUNORUBICIN MESH_LEVEL_2 Carbohydrates 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT XXX_1_Infection 20830-81-3 DAUNORUBICIN TA_LEVEL_2 DNA damage 20830-81-3 DAUNORUBICIN INDICATION Acute Lymphocytic Leukemia (ALL) 20830-81-3 DAUNORUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 20830-81-3 DAUNORUBICIN KNOWN_TOXICITY Mutagenicity 20830-81-3 DAUNORUBICIN KNOWN_TOXICITY Embryo/Fetal Toxicity 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Cardiomyopathy 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Carcinogenicity 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 20830-81-3 DAUNORUBICIN ADVERSE_EFFECT EMB_2_Teratogenicity 20830-81-3 DAUNORUBICIN TISSUE_TOXICITY Hemorrhage 63358-49-6 ASPOXICILLIN THERAPEUTIC_CLASS Antibacterials 63358-49-6 ASPOXICILLIN PRODUCT_CLASS Anti-infectives 63358-49-6 ASPOXICILLIN MODE_CLASS Enzyme Inhibitor 63358-49-6 ASPOXICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 63329-59-9 ASPOXICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 63329-59-9 ASPOXICILLIN PRODUCT_CLASS Anti-infectives 63329-59-9 ASPOXICILLIN MODE_CLASS Enzyme Inhibitor 63329-59-9 ASPOXICILLIN THERAPEUTIC_CLASS Antibacterials 67037-37-0 EFLORNITHINE THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 67037-37-0 EFLORNITHINE INDICATION African Trypanosomiasis / Sleeping Sickness 67037-37-0 EFLORNITHINE THERAPEUTIC_CLASS Antiparasitics 67037-37-0 EFLORNITHINE MECHANISM Inhibit precursor synthesis 67037-37-0 EFLORNITHINE MODE_CLASS Enzyme Inhibitor 67037-37-0 EFLORNITHINE INDICATION Female Facial Hirsutism 67037-37-0 EFLORNITHINE PRODUCT_CLASS Dermatologicals 67037-37-0 EFLORNITHINE PRODUCT_CLASS Anti-infectives 96020-91-6 EFLORNITHINE THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 96020-91-6 EFLORNITHINE MODE_CLASS Enzyme Inhibitor 96020-91-6 EFLORNITHINE THERAPEUTIC_CLASS Antiparasitics 96020-91-6 EFLORNITHINE MECHANISM Inhibit precursor synthesis 96020-91-6 EFLORNITHINE INDICATION Female Facial Hirsutism 96020-91-6 EFLORNITHINE PRODUCT_CLASS Dermatologicals 96020-91-6 EFLORNITHINE PRODUCT_CLASS Anti-infectives 96020-91-6 EFLORNITHINE INDICATION African Trypanosomiasis / Sleeping Sickness 34784-64-0 TARTATOLOL THERAPEUTIC_CLASS Antianginals 34784-64-0 TARTATOLOL MODE_CLASS Receptor Ligand Antagonist 34784-64-0 TARTATOLOL MECHANISM Modulate neural transmission 34784-64-0 TARTATOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 34784-64-0 TARTATOLOL INDICATION Hypertension 34784-64-0 TARTATOLOL INDICATION Cardiac Arrhythmias 34784-64-0 TARTATOLOL INDICATION Angina Pectoris 34784-64-0 TARTATOLOL PRODUCT_CLASS Cardiovasculars 34784-64-0 TARTATOLOL THERAPEUTIC_CLASS Antihypertensive Agents 34784-64-0 TARTATOLOL MODE_CLASS Receptor Agonist, Non-selective 34784-64-0 TARTATOLOL MECHANISM Modulate G-protein coupled signal transduction 13739-02-1 DIACEREIN MODE_CLASS Enzyme Inhibitor 13739-02-1 DIACEREIN THERAPEUTIC_CLASS Immunosuppressants 13739-02-1 DIACEREIN MECHANISM Inhibit eicosanoid biosynthesis 13739-02-1 DIACEREIN INDICATION Arthritis 13739-02-1 DIACEREIN PRODUCT_CLASS Immune Response / Immunomodulators 77671-31-9 ENOXIMONE PRODUCT_CLASS Cardiovasculars 77671-31-9 ENOXIMONE MODE_CLASS Enzyme Inhibitor, selective 77671-31-9 ENOXIMONE THERAPEUTIC_CLASS Congestive Heart Failure 77671-31-9 ENOXIMONE MECHANISM Enhance kinase mediated signal transduction 77671-31-9 ENOXIMONE INDICATION Heart Failure 84957-29-9 CEFPIROME PRODUCT_CLASS Anti-infectives 84957-29-9 CEFPIROME MODE_CLASS Enzyme Inhibitor 84957-29-9 CEFPIROME MECHANISM Inhibit bacterial cell wall biosynthesis 84957-29-9 CEFPIROME THERAPEUTIC_CLASS Antibacterials 98753-19-6 CEFPIROME PRODUCT_CLASS Anti-infectives 98753-19-6 CEFPIROME THERAPEUTIC_CLASS Antibacterials 98753-19-6 CEFPIROME MECHANISM Inhibit bacterial cell wall biosynthesis 98753-19-6 CEFPIROME MODE_CLASS Enzyme Inhibitor 50264-69-2 LONIDAMINE MECHANISM Block channel gating 50264-69-2 LONIDAMINE MODE_CLASS Channel Blocker 79660-72-3 FLEROXACIN INDICATION Otitis Media 79660-72-3 FLEROXACIN INDICATION Urinary Tract Infection (UTI) 79660-72-3 FLEROXACIN INDICATION Upper Respiratory Tract Infection 79660-72-3 FLEROXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 79660-72-3 FLEROXACIN KNOWN_TOXICITY Nephrotoxicity 79660-72-3 FLEROXACIN TISSUE_TOXICITY Acute Renal Failure 79660-72-3 FLEROXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, 8-fluoro-fluoroquinolone 79660-72-3 FLEROXACIN ADVERSE_EFFECT NEU_3_Convulsions 79660-72-3 FLEROXACIN INDICATION Dental Infection 79660-72-3 FLEROXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 79660-72-3 FLEROXACIN ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 79660-72-3 FLEROXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 79660-72-3 FLEROXACIN INDICATION Genitourinary Tract Infections 79660-72-3 FLEROXACIN PRODUCT_CLASS Anti-infectives 79660-72-3 FLEROXACIN ADVERSE_EFFECT IMU_3_Allergic Vasculitis 79660-72-3 FLEROXACIN INDICATION Lower Respiratory Tract Infection 79660-72-3 FLEROXACIN INDICATION Surgical Infections 79660-72-3 FLEROXACIN ADVERSE_EFFECT GIS_1_Nausea 79660-72-3 FLEROXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 79660-72-3 FLEROXACIN INDICATION Skin and Skin Structure Infections 79660-72-3 FLEROXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 79660-72-3 FLEROXACIN ADVERSE_EFFECT LIV_3_Jaundice 79660-72-3 FLEROXACIN MODE_CLASS Enzyme Inhibitor, selective 79660-72-3 FLEROXACIN ADVERSE_EFFECT PSY_1_Insomnia 79660-72-3 FLEROXACIN ADVERSE_EFFECT IMU_3_Anaphylaxis 79660-72-3 FLEROXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 79660-72-3 FLEROXACIN ADVERSE_EFFECT IMU_2_Eosinophilia 79660-72-3 FLEROXACIN MECHANISM Inhibit bacterial DNA synthesis 79660-72-3 FLEROXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 79660-72-3 FLEROXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 79660-72-3 FLEROXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 79660-72-3 FLEROXACIN ADVERSE_EFFECT NEU_1_Dizziness 79660-72-3 FLEROXACIN ADVERSE_EFFECT PSY_1_Anorexia 79660-72-3 FLEROXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 79660-72-3 FLEROXACIN ADVERSE_EFFECT END_3_Hypoglycemia 79660-72-3 FLEROXACIN ADVERSE_EFFECT BBM_3_Leukopenia 79660-72-3 FLEROXACIN INDICATION Ophthalmic Infections 79660-53-0 FLEROXACIN ADVERSE_EFFECT BBM_3_Leukopenia 79660-53-0 FLEROXACIN ADVERSE_EFFECT IMU_3_Anaphylaxis 79660-53-0 FLEROXACIN ADVERSE_EFFECT PSY_1_Insomnia 79660-53-0 FLEROXACIN INDICATION Otitis Media 79660-53-0 FLEROXACIN INDICATION Skin and Skin Structure Infections 79660-53-0 FLEROXACIN ADVERSE_EFFECT IMU_3_Allergic Vasculitis 79660-53-0 FLEROXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 79660-53-0 FLEROXACIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 79660-53-0 FLEROXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 79660-53-0 FLEROXACIN ADVERSE_EFFECT GIS_1_Nausea 79660-53-0 FLEROXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 79660-53-0 FLEROXACIN INDICATION Surgical Infections 79660-53-0 FLEROXACIN INDICATION Lower Respiratory Tract Infection 79660-53-0 FLEROXACIN PRODUCT_CLASS Anti-infectives 79660-53-0 FLEROXACIN INDICATION Genitourinary Tract Infections 79660-53-0 FLEROXACIN ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 79660-53-0 FLEROXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 79660-53-0 FLEROXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 79660-53-0 FLEROXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 79660-53-0 FLEROXACIN ADVERSE_EFFECT NEU_3_Convulsions 79660-53-0 FLEROXACIN INDICATION Dental Infection 79660-53-0 FLEROXACIN INDICATION Urinary Tract Infection (UTI) 79660-53-0 FLEROXACIN ADVERSE_EFFECT END_3_Hypoglycemia 79660-53-0 FLEROXACIN MODE_CLASS Enzyme Inhibitor, selective 79660-53-0 FLEROXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, 8-fluoro-fluoroquinolone 79660-53-0 FLEROXACIN TISSUE_TOXICITY Acute Renal Failure 79660-53-0 FLEROXACIN KNOWN_TOXICITY Nephrotoxicity 79660-53-0 FLEROXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 79660-53-0 FLEROXACIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 79660-53-0 FLEROXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 79660-53-0 FLEROXACIN ADVERSE_EFFECT NEU_1_Dizziness 79660-53-0 FLEROXACIN ADVERSE_EFFECT PSY_1_Anorexia 79660-53-0 FLEROXACIN INDICATION Ophthalmic Infections 79660-53-0 FLEROXACIN INDICATION Upper Respiratory Tract Infection 79660-53-0 FLEROXACIN MECHANISM Inhibit bacterial DNA synthesis 79660-53-0 FLEROXACIN ADVERSE_EFFECT IMU_2_Eosinophilia 79660-53-0 FLEROXACIN ADVERSE_EFFECT LIV_3_Jaundice 54782-51-3 EPTAZOCINE HYDROCHLORIDE PRODUCT_CLASS Analgesics 54782-51-3 EPTAZOCINE HYDROCHLORIDE MECHANISM Modulate G-protein coupled signal transduction 54782-51-3 EPTAZOCINE HYDROCHLORIDE MECHANISM Modulate neural transmission 54782-51-3 EPTAZOCINE HYDROCHLORIDE MODE_CLASS Receptor Agonist 54782-51-3 EPTAZOCINE HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 54782-51-3 EPTAZOCINE HYDROCHLORIDE THERAPEUTIC_CLASS Analgesics, Opioid 65002-17-7 BUCILLAMINE THERAPEUTIC_CLASS Immunosuppressants 65002-17-7 BUCILLAMINE INDICATION Arthritis 65002-17-7 BUCILLAMINE PRODUCT_CLASS Immune Response / Immunomodulators 50913-82-1 ORG-2766 INDICATION Diabetes 68302-57-8 AMLEXANOX PRODUCT_CLASS Respiratory System 68302-57-8 AMLEXANOX MECHANISM Inhibit kinase mediated signal transduction 68302-57-8 AMLEXANOX THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 68302-57-8 AMLEXANOX INDICATION Asthma 68302-57-8 AMLEXANOX MODE_CLASS Enzyme Inhibitor 68302-57-8 AMLEXANOX MECHANISM Enhance kinase mediated signal transduction 59729-32-7 CITALOPRAM ADVERSE_EFFECT PSY_2_Anxiety 59729-32-7 CITALOPRAM ADVERSE_EFFECT XXX_1_Fatigue 59729-32-7 CITALOPRAM ADVERSE_EFFECT XXX_1_Sweating 59729-32-7 CITALOPRAM ADVERSE_EFFECT EMB_3_Teratogenicity 59729-32-7 CITALOPRAM ADVERSE_EFFECT ELT_3_Hyponatremia 59729-32-7 CITALOPRAM ZERO_CLASS N 59729-32-7 CITALOPRAM ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 59729-32-7 CITALOPRAM TISSUE_TOXICITY Carcinogenicity 59729-32-7 CITALOPRAM STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 59729-32-7 CITALOPRAM TISSUE_TOXICITY Impotence 59729-32-7 CITALOPRAM ADVERSE_EFFECT NEU_3_Extrapyramidal Toxicity 59729-32-7 CITALOPRAM ADVERSE_EFFECT PSY_2_Agitation 59729-32-7 CITALOPRAM ADVERSE_EFFECT PSY_1_Insomnia 59729-32-7 CITALOPRAM ADVERSE_EFFECT GIS_1_Nausea 59729-32-7 CITALOPRAM ADVERSE_EFFECT PSY_2_Activation of Mania / Hypomania 59729-32-7 CITALOPRAM ADVERSE_EFFECT REP_1_Impotence 59729-32-7 CITALOPRAM ADVERSE_EFFECT DNA_3_Carcinogenicity 59729-32-7 CITALOPRAM KNOWN_TOXICITY Embryo/Fetal Toxicity 59729-32-7 CITALOPRAM THERAPEUTIC_CLASS Antidepressants 59729-32-7 CITALOPRAM TISSUE_TOXICITY Teratogenicity 59729-32-7 CITALOPRAM TA_LEVEL_1 Central Nervous System (CNS) 59729-32-7 CITALOPRAM ADVERSE_EFFECT REP_2_Amenorrhea 59729-32-7 CITALOPRAM ADVERSE_EFFECT CVS_2_Postural Hypotension 59729-32-7 CITALOPRAM ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 59729-32-7 CITALOPRAM KNOWN_TOXICITY Carcinogenicity 59729-32-7 CITALOPRAM ADVERSE_EFFECT REP_1_Decreased Libido 59729-32-7 CITALOPRAM ADVERSE_EFFECT GIS_1_Diarrhea 59729-32-7 CITALOPRAM ADVERSE_EFFECT GIS_1_Dry Mouth 59729-32-7 CITALOPRAM ADVERSE_EFFECT XXX_2_Salivation 59729-32-7 CITALOPRAM ADVERSE_EFFECT REP_2_Decreased Fertility 59729-32-7 CITALOPRAM MESH_LEVEL_2 Amines 59729-32-7 CITALOPRAM MESH_LEVEL_3 Propylamines 59729-32-7 CITALOPRAM ADVERSE_EFFECT REP_3_Priapism 59729-32-7 CITALOPRAM MESH_LEVEL_1 Organic Chemicals 59729-32-7 CITALOPRAM KNOWN_TOXICITY Reproductive System Toxicity 59729-32-7 CITALOPRAM INDICATION Major Depression / Major Depressive Disorder 59729-32-7 CITALOPRAM TA_LEVEL_3 SERTs 59729-32-7 CITALOPRAM ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 59729-32-7 CITALOPRAM ADVERSE_EFFECT REP_1_Ejaculatory Disorder 59729-32-7 CITALOPRAM ADVERSE_EFFECT NEU_1_Tremor 59729-32-7 CITALOPRAM PRODUCT_CLASS Central Nervous System (CNS) 59729-32-7 CITALOPRAM ADVERSE_EFFECT NEU_1_Somnolence 59729-32-7 CITALOPRAM ADVERSE_EFFECT PSY_2_Anorexia 59729-32-7 CITALOPRAM ADVERSE_EFFECT XXX_2_Weight Loss 59729-32-7 CITALOPRAM ADVERSE_EFFECT NEU_2_Migraine 59729-32-7 CITALOPRAM ADVERSE_EFFECT CVS_2_Tachycardia 59729-32-7 CITALOPRAM TA_LEVEL_2 CNS Depressant 59729-32-7 CITALOPRAM MECH_LEVEL_1 Modulate neural transmission 59729-32-7 CITALOPRAM MECHANISM Prolong/enhance neural transmission 59729-32-7 CITALOPRAM MECH_LEVEL_3 5HT Transporter SERT 59729-32-7 CITALOPRAM MODE_CLASS Solute transporter inhibitor 59729-32-7 CITALOPRAM ADVERSE_EFFECT END_2_Breast Tenderness 59729-32-7 CITALOPRAM MECH_LEVEL_2 5HT antagonist 59729-32-7 CITALOPRAM ADVERSE_EFFECT END_2_Galactorrhea 59729-32-7 CITALOPRAM ADVERSE_EFFECT NEU_2_Paresthesia 64241-34-5 CADRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 64241-34-5 CADRALAZINE INDICATION Hypertension 64241-34-5 CADRALAZINE MECHANISM Reduce vasoconstriction 64241-34-5 CADRALAZINE PRODUCT_CLASS Cardiovasculars 75481-73-1 CEFMINOX MODE_CLASS Enzyme Inhibitor 75481-73-1 CEFMINOX PRODUCT_CLASS Anti-infectives 75481-73-1 CEFMINOX MECHANISM Inhibit bacterial cell wall biosynthesis 75481-73-1 CEFMINOX THERAPEUTIC_CLASS Antibacterials 75498-96-3 CEFMINOX PRODUCT_CLASS Anti-infectives 75498-96-3 CEFMINOX MODE_CLASS Enzyme Inhibitor 75498-96-3 CEFMINOX MECHANISM Inhibit bacterial cell wall biosynthesis 75498-96-3 CEFMINOX THERAPEUTIC_CLASS Antibacterials 97162-19-1 CEFMINOX PRODUCT_CLASS Anti-infectives 97162-19-1 CEFMINOX MODE_CLASS Enzyme Inhibitor 97162-19-1 CEFMINOX MECHANISM Inhibit bacterial cell wall biosynthesis 97162-19-1 CEFMINOX THERAPEUTIC_CLASS Antibacterials 71771-90-9 DENOPAMINE MECHANISM Modulate G-protein coupled signal transduction 71771-90-9 DENOPAMINE INDICATION Heart Failure 71771-90-9 DENOPAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 71771-90-9 DENOPAMINE PRODUCT_CLASS Cardiovasculars 71771-90-9 DENOPAMINE MODE_CLASS Receptor Agonist, selective 64299-19-0 DENOPAMINE MECHANISM Modulate G-protein coupled signal transduction 64299-19-0 DENOPAMINE INDICATION Heart Failure 64299-19-0 DENOPAMINE MODE_CLASS Receptor Agonist, selective 64299-19-0 DENOPAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 64299-19-0 DENOPAMINE PRODUCT_CLASS Cardiovasculars 57381-33-6 IRSOGLADINE MALEATE INDICATION Gastritis 57381-33-6 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Rash 57381-33-6 IRSOGLADINE MALEATE THERAPEUTIC_CLASS Antiulcers 57381-33-6 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Diarrhea 57381-33-6 IRSOGLADINE MALEATE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 57381-33-6 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Constipation 57381-33-6 IRSOGLADINE MALEATE INDICATION Gastric Ulcer 57381-33-6 IRSOGLADINE MALEATE PRODUCT_CLASS Gastrointestinal System 57381-33-6 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Pruritis 57381-33-6 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 57381-26-7 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Diarrhea 57381-26-7 IRSOGLADINE MALEATE INDICATION Gastritis 57381-26-7 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 57381-26-7 IRSOGLADINE MALEATE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 57381-26-7 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Pruritis 57381-26-7 IRSOGLADINE MALEATE THERAPEUTIC_CLASS Antiulcers 57381-26-7 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Rash 57381-26-7 IRSOGLADINE MALEATE PRODUCT_CLASS Gastrointestinal System 57381-26-7 IRSOGLADINE MALEATE INDICATION Gastric Ulcer 57381-26-7 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Constipation 57381-28-9 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 57381-28-9 IRSOGLADINE MALEATE PRODUCT_CLASS Gastrointestinal System 57381-28-9 IRSOGLADINE MALEATE INDICATION Gastric Ulcer 57381-28-9 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Constipation 57381-28-9 IRSOGLADINE MALEATE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 57381-28-9 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Diarrhea 57381-28-9 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Pruritis 57381-28-9 IRSOGLADINE MALEATE THERAPEUTIC_CLASS Antiulcers 57381-28-9 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Rash 57381-28-9 IRSOGLADINE MALEATE INDICATION Gastritis 84504-69-8 IRSOGLADINE MALEATE INDICATION Gastritis 84504-69-8 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 84504-69-8 IRSOGLADINE MALEATE INDICATION Gastric Ulcer 84504-69-8 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Constipation 84504-69-8 IRSOGLADINE MALEATE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 84504-69-8 IRSOGLADINE MALEATE ADVERSE_EFFECT GIS_3_Diarrhea 84504-69-8 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Pruritis 84504-69-8 IRSOGLADINE MALEATE PRODUCT_CLASS Gastrointestinal System 84504-69-8 IRSOGLADINE MALEATE THERAPEUTIC_CLASS Antiulcers 84504-69-8 IRSOGLADINE MALEATE ADVERSE_EFFECT SKN_3_Rash 61036-64-4 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 61036-64-4 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 61036-64-4 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 61036-64-4 TEICOPLANIN INDICATION Septicemia 61036-64-4 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 61036-64-4 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 61036-64-4 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 61036-64-4 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 61036-64-4 TEICOPLANIN TA_LEVEL_1 Infectious Disease 61036-64-4 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 61036-64-4 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 61036-64-4 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 61036-64-4 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 61036-64-4 TEICOPLANIN INDICATION Bacteremia 61036-64-4 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 61036-64-4 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 61036-64-4 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 61036-64-4 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 61036-64-4 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 61036-64-4 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 61036-64-4 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 61036-64-4 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 61036-64-4 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 61036-64-4 TEICOPLANIN INDICATION Septic Arthritis 61036-64-4 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 61036-64-4 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 61036-64-4 TEICOPLANIN TA_LEVEL_3 systemic infections 61036-64-4 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 61036-64-4 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 61036-64-4 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 61036-64-4 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 61036-64-4 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 61036-64-4 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 61036-64-4 TEICOPLANIN ZERO_CLASS N 61036-64-4 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 61036-64-4 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 61036-64-4 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 61036-64-4 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 61036-64-4 TEICOPLANIN TISSUE_TOXICITY Renal Failure 61036-64-4 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 61036-64-4 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 61036-64-4 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 61036-64-4 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 61036-64-4 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 61036-64-4 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 61036-64-4 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 61036-64-4 TEICOPLANIN PRODUCT_CLASS Anti-infectives 61036-63-3 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 61036-63-3 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 61036-63-3 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 61036-63-3 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 61036-63-3 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 61036-63-3 TEICOPLANIN TISSUE_TOXICITY Renal Failure 61036-63-3 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 61036-63-3 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 61036-63-3 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 61036-63-3 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 61036-63-3 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 61036-63-3 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 61036-63-3 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 61036-63-3 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 61036-63-3 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 61036-63-3 TEICOPLANIN INDICATION Septic Arthritis 61036-63-3 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 61036-63-3 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 61036-63-3 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 61036-63-3 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 61036-63-3 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 61036-63-3 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 61036-63-3 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 61036-63-3 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 61036-63-3 TEICOPLANIN INDICATION Bacteremia 61036-63-3 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 61036-63-3 TEICOPLANIN TA_LEVEL_1 Infectious Disease 61036-63-3 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 61036-63-3 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 61036-63-3 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 61036-63-3 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 61036-63-3 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 61036-63-3 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 61036-63-3 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 61036-63-3 TEICOPLANIN PRODUCT_CLASS Anti-infectives 61036-63-3 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 61036-63-3 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 61036-63-3 TEICOPLANIN INDICATION Septicemia 61036-63-3 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 61036-63-3 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 61036-63-3 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 61036-63-3 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 61036-63-3 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 61036-63-3 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 61036-63-3 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 61036-63-3 TEICOPLANIN TA_LEVEL_3 systemic infections 61036-63-3 TEICOPLANIN ZERO_CLASS N 91032-26-7 TEICOPLANIN INDICATION Septic Arthritis 91032-26-7 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 91032-26-7 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 91032-26-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 91032-26-7 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 91032-26-7 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 91032-26-7 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 91032-26-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 91032-26-7 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 91032-26-7 TEICOPLANIN INDICATION Bacteremia 91032-26-7 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 91032-26-7 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 91032-26-7 TEICOPLANIN TA_LEVEL_3 systemic infections 91032-26-7 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91032-26-7 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 91032-26-7 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 91032-26-7 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 91032-26-7 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91032-26-7 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 91032-26-7 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 91032-26-7 TEICOPLANIN ZERO_CLASS N 91032-26-7 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 91032-26-7 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 91032-26-7 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 91032-26-7 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 91032-26-7 TEICOPLANIN TISSUE_TOXICITY Renal Failure 91032-26-7 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 91032-26-7 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 91032-26-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 91032-26-7 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 91032-26-7 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 91032-26-7 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 91032-26-7 TEICOPLANIN TA_LEVEL_1 Infectious Disease 91032-26-7 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 91032-26-7 TEICOPLANIN PRODUCT_CLASS Anti-infectives 91032-26-7 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 91032-26-7 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 91032-26-7 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 91032-26-7 TEICOPLANIN INDICATION Septicemia 91032-26-7 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 91032-26-7 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 91032-26-7 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 91032-26-7 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 91032-26-7 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 91032-26-7 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 91032-26-7 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 91032-26-7 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 91032-36-9 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 91032-36-9 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 91032-36-9 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 91032-36-9 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 91032-36-9 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 91032-36-9 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 91032-36-9 TEICOPLANIN INDICATION Septic Arthritis 91032-36-9 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 91032-36-9 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 91032-36-9 TEICOPLANIN TA_LEVEL_3 systemic infections 91032-36-9 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91032-36-9 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 91032-36-9 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 91032-36-9 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 91032-36-9 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 91032-36-9 TEICOPLANIN INDICATION Bacteremia 91032-36-9 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 91032-36-9 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 91032-36-9 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 91032-36-9 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 91032-36-9 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91032-36-9 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 91032-36-9 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 91032-36-9 TEICOPLANIN ZERO_CLASS N 91032-36-9 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 91032-36-9 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 91032-36-9 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 91032-36-9 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 91032-36-9 TEICOPLANIN TISSUE_TOXICITY Renal Failure 91032-36-9 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 91032-36-9 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 91032-36-9 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 91032-36-9 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 91032-36-9 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 91032-36-9 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 91032-36-9 TEICOPLANIN TA_LEVEL_1 Infectious Disease 91032-36-9 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 91032-36-9 TEICOPLANIN PRODUCT_CLASS Anti-infectives 91032-36-9 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 91032-36-9 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 91032-36-9 TEICOPLANIN INDICATION Septicemia 91032-36-9 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 91032-36-9 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 91032-36-9 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 91032-36-9 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 91032-36-9 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 91032-36-9 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 91032-37-0 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 91032-37-0 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 91032-37-0 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 91032-37-0 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 91032-37-0 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 91032-37-0 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91032-37-0 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 91032-37-0 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 91032-37-0 TEICOPLANIN ZERO_CLASS N 91032-37-0 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 91032-37-0 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 91032-37-0 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 91032-37-0 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 91032-37-0 TEICOPLANIN TISSUE_TOXICITY Renal Failure 91032-37-0 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 91032-37-0 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 91032-37-0 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 91032-37-0 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 91032-37-0 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 91032-37-0 TEICOPLANIN TA_LEVEL_1 Infectious Disease 91032-37-0 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 91032-37-0 TEICOPLANIN PRODUCT_CLASS Anti-infectives 91032-37-0 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 91032-37-0 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 91032-37-0 TEICOPLANIN INDICATION Septicemia 91032-37-0 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 91032-37-0 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 91032-37-0 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 91032-37-0 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 91032-37-0 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 91032-37-0 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 91032-37-0 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 91032-37-0 TEICOPLANIN INDICATION Bacteremia 91032-37-0 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 91032-37-0 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 91032-37-0 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 91032-37-0 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 91032-37-0 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 91032-37-0 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 91032-37-0 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 91032-37-0 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 91032-37-0 TEICOPLANIN INDICATION Septic Arthritis 91032-37-0 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 91032-37-0 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 91032-37-0 TEICOPLANIN TA_LEVEL_3 systemic infections 91032-37-0 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91032-37-0 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 91032-38-1 TEICOPLANIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 91032-38-1 TEICOPLANIN MECHANISM Inhibit bacterial cell wall biosynthesis 91032-38-1 TEICOPLANIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 91032-38-1 TEICOPLANIN ZERO_CLASS N 91032-38-1 TEICOPLANIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 91032-38-1 TEICOPLANIN ADVERSE_EFFECT KID_3_Renal Failure 91032-38-1 TEICOPLANIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91032-38-1 TEICOPLANIN ADVERSE_EFFECT SKN_2_Erythema 91032-38-1 TEICOPLANIN ADVERSE_EFFECT IMU_2_Angioedema 91032-38-1 TEICOPLANIN ADVERSE_EFFECT BBM_3_Agranulocytosis 91032-38-1 TEICOPLANIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91032-38-1 TEICOPLANIN TA_LEVEL_3 systemic infections 91032-38-1 TEICOPLANIN MECH_LEVEL_1 Anti-bacterial 91032-38-1 TEICOPLANIN MESH_LEVEL_3 Glycoconjugates 91032-38-1 TEICOPLANIN INDICATION Septic Arthritis 91032-38-1 TEICOPLANIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 91032-38-1 TEICOPLANIN ADVERSE_EFFECT CVS_2_Thrombophlebitis 91032-38-1 TEICOPLANIN ADVERSE_EFFECT NEU_2_Vertigo 91032-38-1 TEICOPLANIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 91032-38-1 TEICOPLANIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 91032-38-1 TEICOPLANIN ADVERSE_EFFECT LUN_2_Bronchospasm 91032-38-1 TEICOPLANIN ADVERSE_EFFECT NEU_2_Headache 91032-38-1 TEICOPLANIN THERAPEUTIC_CLASS Antibacterials, Systemic 91032-38-1 TEICOPLANIN INDICATION Bacteremia 91032-38-1 TEICOPLANIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 91032-38-1 TEICOPLANIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 91032-38-1 TEICOPLANIN ADVERSE_EFFECT IMU_2_Eosinophilia 91032-38-1 TEICOPLANIN ADVERSE_EFFECT OTO_2_Hearing Loss 91032-38-1 TEICOPLANIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 91032-38-1 TEICOPLANIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 91032-38-1 TEICOPLANIN ADVERSE_EFFECT SKN_2_Pruritis 91032-38-1 TEICOPLANIN ADVERSE_EFFECT NEU_2_Dizziness 91032-38-1 TEICOPLANIN ADVERSE_EFFECT GIS_2_Diarrhea 91032-38-1 TEICOPLANIN INDICATION Septicemia 91032-38-1 TEICOPLANIN MESH_LEVEL_2 Carbohydrates 91032-38-1 TEICOPLANIN INDICATION Osteomyelitis / Bone Infection 91032-38-1 TEICOPLANIN PRODUCT_CLASS Anti-infectives 91032-38-1 TEICOPLANIN TA_LEVEL_2 Anti-bacterial 91032-38-1 TEICOPLANIN TA_LEVEL_1 Infectious Disease 91032-38-1 TEICOPLANIN ADVERSE_EFFECT BBM_2_Neutropenia 91032-38-1 TEICOPLANIN ADVERSE_EFFECT BBM_2_Leukopenia 91032-38-1 TEICOPLANIN ADVERSE_EFFECT IMU_2_Urticaria 91032-38-1 TEICOPLANIN ADVERSE_EFFECT NEU_2_Seizures 91032-38-1 TEICOPLANIN ADVERSE_EFFECT SKN_2_Rash 91032-38-1 TEICOPLANIN ADVERSE_EFFECT XXX_2_Fever 91032-38-1 TEICOPLANIN TISSUE_TOXICITY Renal Failure 91032-38-1 TEICOPLANIN KNOWN_TOXICITY Nephrotoxicity 31477-60-8 ORMELOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 31477-60-8 ORMELOXIFENE MECHANISM Modulate gene transcription 31477-60-8 ORMELOXIFENE MODE_CLASS Receptor Partial Agonist 31477-60-8 ORMELOXIFENE INDICATION Contraception 31477-60-8 ORMELOXIFENE THERAPEUTIC_CLASS Contraceptive Hormones 77181-69-2 SORIVUDINE MODE_CLASS Enzyme substrate mimic 77181-69-2 SORIVUDINE MECHANISM Inhibit viral DNA synthesis 58186-27-9 IDEBENONE INDICATION Friedreich's Ataxia 58186-27-9 IDEBENONE TA_LEVEL_2 liver compounds without group 58186-27-9 IDEBENONE MESH_LEVEL_1 Organic Chemicals 58186-27-9 IDEBENONE MECH_LEVEL_3 Free radical scavenger 58186-27-9 IDEBENONE MECH_LEVEL_1 Anti-oxidant 58186-27-9 IDEBENONE ADVERSE_EFFECT PSY_2_Insomnia 58186-27-9 IDEBENONE ADVERSE_EFFECT NEU_2_Headache 58186-27-9 IDEBENONE ADVERSE_EFFECT IMU_3_Hypersensitivity 58186-27-9 IDEBENONE ADVERSE_EFFECT PSY_2_Agitation 58186-27-9 IDEBENONE ZERO_CLASS N 58186-27-9 IDEBENONE MESH_LEVEL_2 Quinones 58186-27-9 IDEBENONE ACTIVITY_CLASS H2O2 radical scavenger 58186-27-9 IDEBENONE ADVERSE_EFFECT NEU_2_Drowsiness 58186-27-9 IDEBENONE THERAPEUTIC_CLASS Movement Disorders 58186-27-9 IDEBENONE ADVERSE_EFFECT GIS_2_Diarrhea 58186-27-9 IDEBENONE STRUCTURE_ACTIVITY H2O2 radical scavenger 58186-27-9 IDEBENONE MECH_LEVEL_2 Free radical scavenger 58186-27-9 IDEBENONE INDICATION Multi-Infarct Dementia 58186-27-9 IDEBENONE THERAPEUTIC_CLASS Neurodegenerative Disorders 58186-27-9 IDEBENONE ADVERSE_EFFECT PSY_2_Anxiety 58186-27-9 IDEBENONE ADVERSE_EFFECT GIS_2_Epigastric Pain 58186-27-9 IDEBENONE ADVERSE_EFFECT PSY_3_Confusion 58186-27-9 IDEBENONE TA_LEVEL_1 Central Nervous System (CNS) 58186-27-9 IDEBENONE PRODUCT_CLASS Central Nervous System (CNS) 58186-27-9 IDEBENONE MESH_LEVEL_3 Benzoquinones 58186-27-9 IDEBENONE MECHANISM Scavenges hydrogen peroxide and free radicals 58186-27-9 IDEBENONE INDICATION Alzheimer's Dementia 72496-41-4 PIRARUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Hepatic Failure 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Arrhythmia 72496-41-4 PIRARUBICIN INDICATION Bladder Cancer / Carcinoma of the Bladder 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Hepatic Artery Thrombosis 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Thrombocytopenia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT CVS_2_Congestive Heart Failure 72496-41-4 PIRARUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 72496-41-4 PIRARUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 72496-41-4 PIRARUBICIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 72496-41-4 PIRARUBICIN ADVERSE_EFFECT KID_3_Increased Creatinine 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GUS_1_Pollakiuria 72496-41-4 PIRARUBICIN INDICATION Breast Cancer / Carcinoma of the Breast 72496-41-4 PIRARUBICIN INDICATION Prostatic Cancer / Carcinoma of the Prostate 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GIS_1_Vomiting 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Leukopenia 72496-41-4 PIRARUBICIN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 72496-41-4 PIRARUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 72496-41-4 PIRARUBICIN THERAPEUTIC_CLASS Antineoplastics 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Congestive Heart Failure 72496-41-4 PIRARUBICIN ADVERSE_EFFECT XXX_1_Infection 72496-41-4 PIRARUBICIN INDICATION Mesothelioma 72496-41-4 PIRARUBICIN INDICATION Ovarian Cancer / Carcinoma of the Ovary 72496-41-4 PIRARUBICIN INDICATION Small Cell Lung Carcinoma 72496-41-4 PIRARUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Cardiotoxicity 72496-41-4 PIRARUBICIN TISSUE_TOXICITY Anemia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GIS_1_Nausea 72496-41-4 PIRARUBICIN ADVERSE_EFFECT BBM_1_Anemia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT BBM_1_Leukopenia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT LIV_3_Hepatic Failure 72496-41-4 PIRARUBICIN ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GIS_1_Stomatitis 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GIS_3_Duodenal Ulcer 72496-41-4 PIRARUBICIN ADVERSE_EFFECT LIV_3_Hepatic Artery Thrombosis 72496-41-4 PIRARUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GIS_3_Gastritis 72496-41-4 PIRARUBICIN PRODUCT_CLASS Anti-cancers 72496-41-4 PIRARUBICIN INDICATION Non-Small Cell Lung Carcinoma 72496-41-4 PIRARUBICIN INDICATION Lymphoma 72496-41-4 PIRARUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 72496-41-4 PIRARUBICIN ADVERSE_EFFECT CVS_2_Decreased Left Ventricular Ejection Fraction (LVEF) 72496-41-4 PIRARUBICIN ADVERSE_EFFECT PSY_1_Anorexia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT NEU_2_Headache 72496-41-4 PIRARUBICIN ADVERSE_EFFECT BBM_1_Thrombocytopenia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT GUS_1_Dysuria 72496-41-4 PIRARUBICIN ADVERSE_EFFECT CVS_2_Arrhythmia 72496-41-4 PIRARUBICIN ADVERSE_EFFECT XXX_1_Malaise 72496-41-4 PIRARUBICIN KNOWN_TOXICITY Hepatotoxicity 72496-41-4 PIRARUBICIN INDICATION Leukemia 85801-02-1 INDOMETACIN FARNESIL MECHANISM Inhibit eicosanoid biosynthesis 85801-02-1 INDOMETACIN FARNESIL THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 85801-02-1 INDOMETACIN FARNESIL PRODUCT_CLASS Anti-inflammatories 85801-02-1 INDOMETACIN FARNESIL MODE_CLASS Enzyme Inhibitor 82159-09-9 EPALRESTAT ADVERSE_EFFECT SKN_3_Rash 82159-09-9 EPALRESTAT MECH_LEVEL_1 Analgesics, Non-Opioid 82159-09-9 EPALRESTAT ACTIVITY_CLASS Anti-diabetic 82159-09-9 EPALRESTAT ADVERSE_EFFECT LIV_3_Abnormal Liver Function 82159-09-9 EPALRESTAT ADVERSE_EFFECT IMU_3_Hypersensitivity 82159-09-9 EPALRESTAT ADVERSE_EFFECT PSY_3_Anorexia 82159-09-9 EPALRESTAT MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 82159-09-9 EPALRESTAT MECH_LEVEL_3 Aldehyde reductase 82159-09-9 EPALRESTAT ZERO_CLASS N 82159-09-9 EPALRESTAT ADVERSE_EFFECT GUS_1_Discoloration of Urine 82159-09-9 EPALRESTAT ADVERSE_EFFECT BBM_3_Anemia 82159-09-9 EPALRESTAT INDICATION Diabetic Neuropathy 82159-09-9 EPALRESTAT MESH_LEVEL_1 Heterocyclic Compounds 82159-09-9 EPALRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 82159-09-9 EPALRESTAT MODE_CLASS Enzyme Inhibitor 82159-09-9 EPALRESTAT TA_LEVEL_3 diabetic retinopathy 82159-09-9 EPALRESTAT MESH_LEVEL_3 Thiazoles 82159-09-9 EPALRESTAT TA_LEVEL_1 Metabolic Diseases 82159-09-9 EPALRESTAT MECH_LEVEL_2 Inhibit precursor synthesis 82159-09-9 EPALRESTAT ADVERSE_EFFECT GIS_3_Nausea / Vomiting 82159-09-9 EPALRESTAT ADVERSE_EFFECT BBM_3_Thrombocytopenia 82159-09-9 EPALRESTAT ADVERSE_EFFECT KID_3_Increased Creatinine 82159-09-9 EPALRESTAT PRODUCT_CLASS Other Human Uses 82159-09-9 EPALRESTAT ADVERSE_EFFECT GIS_3_Abdominal Pain 82159-09-9 EPALRESTAT ADVERSE_EFFECT NEU_3_Numbness 82159-09-9 EPALRESTAT STRUCTURE_ACTIVITY Aldehyde reductase inhibitor 82159-09-9 EPALRESTAT MECHANISM Inhibit precursor synthesis 68291-97-4 ZONISAMIDE MODE_CLASS Channel Blocker 68291-97-4 ZONISAMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 68291-97-4 ZONISAMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 68291-97-4 ZONISAMIDE MECHANISM Block neural transmission 68291-97-4 ZONISAMIDE PRODUCT_CLASS Central Nervous System (CNS) 62613-82-5 OXIRACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 65517-27-3 METACLAZEPAM MODE_CLASS Channel enhancer /opener 65517-27-3 METACLAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 65517-27-3 METACLAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 65517-27-3 METACLAZEPAM INDICATION Anxiety Disorders 65517-27-3 METACLAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 65517-27-3 METACLAZEPAM MECHANISM Modulate neural transmission 61802-93-5 METACLAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 61802-93-5 METACLAZEPAM INDICATION Anxiety Disorders 61802-93-5 METACLAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 61802-93-5 METACLAZEPAM MECHANISM Modulate neural transmission 61802-93-5 METACLAZEPAM MODE_CLASS Channel enhancer /opener 61802-93-5 METACLAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 74258-86-9 ALACEPRIL INDICATION Hypertension 74258-86-9 ALACEPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 74258-86-9 ALACEPRIL THERAPEUTIC_CLASS Antihypertensive Agents 74258-86-9 ALACEPRIL PRODUCT_CLASS Cardiovasculars 74258-86-9 ALACEPRIL MECHANISM Reduce vasoconstriction 74258-86-9 ALACEPRIL MODE_CLASS Enzyme Inhibitor 81732-65-2 BAMBUTEROL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 81732-65-2 BAMBUTEROL INDICATION Bronchospasm 81732-65-2 BAMBUTEROL ADVERSE_EFFECT ELT_3_Hypokalemia 81732-65-2 BAMBUTEROL THERAPEUTIC_CLASS Bronchodilators 81732-65-2 BAMBUTEROL ADVERSE_EFFECT SKN_3_Exanthema 81732-65-2 BAMBUTEROL ADVERSE_EFFECT CVS_3_Hypotension 81732-65-2 BAMBUTEROL ADVERSE_EFFECT END_3_Hyperglycemia 81732-65-2 BAMBUTEROL TISSUE_TOXICITY Cardiac Arrhythmia 81732-65-2 BAMBUTEROL MECHANISM Reduce bronchoconstriction 81732-65-2 BAMBUTEROL TISSUE_TOXICITY Hypotension 81732-65-2 BAMBUTEROL KNOWN_TOXICITY Cardiovascular Toxicity 81732-65-2 BAMBUTEROL ADVERSE_EFFECT IMU_3_Urticaria 81732-65-2 BAMBUTEROL ADVERSE_EFFECT END_3_Lactic Acidosis 81732-65-2 BAMBUTEROL ADVERSE_EFFECT CVS_2_Tachycardia 81732-65-2 BAMBUTEROL ADVERSE_EFFECT NEU_1_Tremor 81732-65-2 BAMBUTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 81732-65-2 BAMBUTEROL PRODUCT_CLASS Respiratory System 81732-65-2 BAMBUTEROL INDICATION Asthma 81732-65-2 BAMBUTEROL INDICATION Reversible Airway Obstruction 81732-65-2 BAMBUTEROL ADVERSE_EFFECT MSK_2_Cramps 81732-65-2 BAMBUTEROL ADVERSE_EFFECT PSY_1_Anxiety 81732-65-2 BAMBUTEROL ADVERSE_EFFECT NEU_1_Headache 81732-65-2 BAMBUTEROL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 81732-65-2 BAMBUTEROL MODE_CLASS Receptor Agonist 81732-46-9 BAMBUTEROL MODE_CLASS Receptor Agonist 81732-46-9 BAMBUTEROL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 81732-46-9 BAMBUTEROL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 81732-46-9 BAMBUTEROL ADVERSE_EFFECT ELT_3_Hypokalemia 81732-46-9 BAMBUTEROL THERAPEUTIC_CLASS Bronchodilators 81732-46-9 BAMBUTEROL ADVERSE_EFFECT SKN_3_Exanthema 81732-46-9 BAMBUTEROL ADVERSE_EFFECT CVS_3_Hypotension 81732-46-9 BAMBUTEROL ADVERSE_EFFECT END_3_Hyperglycemia 81732-46-9 BAMBUTEROL TISSUE_TOXICITY Cardiac Arrhythmia 81732-46-9 BAMBUTEROL MECHANISM Reduce bronchoconstriction 81732-46-9 BAMBUTEROL TISSUE_TOXICITY Hypotension 81732-46-9 BAMBUTEROL KNOWN_TOXICITY Cardiovascular Toxicity 81732-46-9 BAMBUTEROL ADVERSE_EFFECT IMU_3_Urticaria 81732-46-9 BAMBUTEROL ADVERSE_EFFECT END_3_Lactic Acidosis 81732-46-9 BAMBUTEROL ADVERSE_EFFECT CVS_2_Tachycardia 81732-46-9 BAMBUTEROL ADVERSE_EFFECT NEU_1_Tremor 81732-46-9 BAMBUTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 81732-46-9 BAMBUTEROL PRODUCT_CLASS Respiratory System 81732-46-9 BAMBUTEROL INDICATION Asthma 81732-46-9 BAMBUTEROL INDICATION Reversible Airway Obstruction 81732-46-9 BAMBUTEROL ADVERSE_EFFECT MSK_2_Cramps 81732-46-9 BAMBUTEROL ADVERSE_EFFECT PSY_1_Anxiety 81732-46-9 BAMBUTEROL ADVERSE_EFFECT NEU_1_Headache 81732-46-9 BAMBUTEROL INDICATION Bronchospasm 87848-99-5 ACRIVASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 87848-99-5 ACRIVASTINE INDICATION Nasal Congestion 87848-99-5 ACRIVASTINE MECHANISM Modulate G-protein coupled signal transduction 87848-99-5 ACRIVASTINE THERAPEUTIC_CLASS Antihistamines 87848-99-5 ACRIVASTINE INDICATION Urticaria / Hives 87848-99-5 ACRIVASTINE PRODUCT_CLASS Anti-inflammatories 87848-99-5 ACRIVASTINE INDICATION Allergic Rhinitis 87848-99-5 ACRIVASTINE INDICATION Allergic Diseases 56695-65-9 ROSAPROSTOL SODIUM INDICATION Ulcer 65189-78-8 TROPESIN MECHANISM Inhibit eicosanoid biosynthesis 65189-78-8 TROPESIN MODE_CLASS Enzyme Inhibitor 65828-79-7 TROPESIN MODE_CLASS Enzyme Inhibitor 65828-79-7 TROPESIN MECHANISM Inhibit eicosanoid biosynthesis 86197-47-9 DOPEXAMINE MECHANISM Prolong/enhance neural transmission 86197-47-9 DOPEXAMINE MECHANISM Modulate G-protein coupled signal transduction 86197-47-9 DOPEXAMINE MODE_CLASS Receptor Agonist 86484-91-5 DOPEXAMINE MECHANISM Modulate G-protein coupled signal transduction 86484-91-5 DOPEXAMINE MECHANISM Prolong/enhance neural transmission 86484-91-5 DOPEXAMINE MODE_CLASS Receptor Agonist 89943-82-8 CICLETANINE MODE_CLASS Receptor Ligand Antagonist 89943-82-8 CICLETANINE INDICATION Hypertension 89943-82-8 CICLETANINE THERAPEUTIC_CLASS Antihypertensive Agents 89943-82-8 CICLETANINE MECHANISM Modulate G-protein coupled signal transduction 89943-82-8 CICLETANINE PRODUCT_CLASS Cardiovasculars 89943-82-8 CICLETANINE MECHANISM Reduce vasoconstriction 82747-56-6 CICLETANINE PRODUCT_CLASS Cardiovasculars 82747-56-6 CICLETANINE MECHANISM Modulate G-protein coupled signal transduction 82747-56-6 CICLETANINE THERAPEUTIC_CLASS Antihypertensive Agents 82747-56-6 CICLETANINE INDICATION Hypertension 82747-56-6 CICLETANINE MECHANISM Reduce vasoconstriction 82747-56-6 CICLETANINE MODE_CLASS Receptor Ligand Antagonist 118428-36-7 PIMOBENDAN MECHANISM Enhance kinase mediated signal transduction 118428-36-7 PIMOBENDAN MODE_CLASS Enzyme Inhibitor 118428-36-7 PIMOBENDAN PRODUCT_CLASS Respiratory System 118428-36-7 PIMOBENDAN THERAPEUTIC_CLASS Bronchodilators 74014-51-0 ROKITAMYCIN PRODUCT_CLASS Anti-infectives 74014-51-0 ROKITAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 74014-51-0 ROKITAMYCIN MECHANISM Inhibit ribosomal protein synthesis 74014-51-0 ROKITAMYCIN THERAPEUTIC_CLASS Antibacterials 81840-15-5 VESNARINONE INDICATION Myelodysplastic Syndromes 81840-15-5 VESNARINONE MECHANISM Enhance kinase mediated signal transduction 81840-15-5 VESNARINONE PRODUCT_CLASS Cardiovasculars 81840-15-5 VESNARINONE INDICATION Congestive Heart Failure (CHF) 81840-15-5 VESNARINONE THERAPEUTIC_CLASS Congestive Heart Failure 81840-15-5 VESNARINONE MODE_CLASS Enzyme Inhibitor 81840-15-5 VESNARINONE PRODUCT_CLASS Anti-cancers 81840-15-5 VESNARINONE THERAPEUTIC_CLASS Antineoplastics 81840-15-5 VESNARINONE MODE_CLASS Channel Blocker 81840-15-5 VESNARINONE MECHANISM Block channel gating 69900-72-7 TRIMOPROSTIL INDICATION Ulcer 69900-72-7 TRIMOPROSTIL INDICATION Glaucoma 93664-94-9 NEMONAPRIDE MECHANISM Block neural transmission 93664-94-9 NEMONAPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 93664-94-9 NEMONAPRIDE MECHANISM Modulate neural transmission 93664-94-9 NEMONAPRIDE MODE_CLASS Receptor Agonist, selective 75272-39-8 NEMONAPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 75272-39-8 NEMONAPRIDE MODE_CLASS Receptor Agonist, selective 75272-39-8 NEMONAPRIDE MECHANISM Block neural transmission 75272-39-8 NEMONAPRIDE MECHANISM Modulate neural transmission 56518-40-2 BRODIMOPRIM PRODUCT_CLASS Anti-infectives 56518-40-2 BRODIMOPRIM THERAPEUTIC_CLASS Antibacterials 56518-40-2 BRODIMOPRIM MODE_CLASS Enzyme Inhibitor 56518-40-2 BRODIMOPRIM MECHANISM Inhibit precursor synthesis 77779-60-3 CGS-8216 INDICATION Psoriasis 77779-60-3 CGS-8216 INDICATION Depression 77779-60-3 CGS-8216 THERAPEUTIC_CLASS Antidepressants 77779-60-3 CGS-8216 INDICATION Anxiety Disorders 77779-60-3 CGS-8216 THERAPEUTIC_CLASS Sedatives/Hypnotics 77779-60-3 CGS-8216 PRODUCT_CLASS Central Nervous System (CNS) 71320-77-9 MOCLOBEMIDE INDICATION Social Phobia 71320-77-9 MOCLOBEMIDE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 71320-77-9 MOCLOBEMIDE ZERO_CLASS N 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT GIS_1_Dry Mouth 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT CVS_3_Hypertension 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT OCU_2_Visual Disturbances 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT NEU_1_Dizziness 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT PSY_2_Anxiety 71320-77-9 MOCLOBEMIDE PRODUCT_CLASS Central Nervous System (CNS) 71320-77-9 MOCLOBEMIDE TA_LEVEL_2 CNS Stimulant 71320-77-9 MOCLOBEMIDE MESH_LEVEL_3 Benzamides 71320-77-9 MOCLOBEMIDE MECH_LEVEL_2 Prolong/enhance neural transmission 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT PSY_1_Insomnia 71320-77-9 MOCLOBEMIDE TISSUE_TOXICITY Hypotension 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT PSY_2_Agitation 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT NEU_1_Headache 71320-77-9 MOCLOBEMIDE TA_LEVEL_3 depression 71320-77-9 MOCLOBEMIDE MECH_LEVEL_3 Mono amine oxidase 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT CVS_3_Hypotension 71320-77-9 MOCLOBEMIDE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 71320-77-9 MOCLOBEMIDE MESH_LEVEL_1 Organic Chemicals 71320-77-9 MOCLOBEMIDE MECH_LEVEL_1 Modulate neural transmission 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT GIS_1_Nausea 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT NEU_2_Paresthesia 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT NEU_2_Somnolence 71320-77-9 MOCLOBEMIDE MODE_CLASS Enzyme Inhibitor 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT CVS_3_Tachycardia 71320-77-9 MOCLOBEMIDE THERAPEUTIC_CLASS Antidepressants 71320-77-9 MOCLOBEMIDE KNOWN_TOXICITY Cardiovascular Toxicity 71320-77-9 MOCLOBEMIDE INDICATION Major Depression / Major Depressive Disorder 71320-77-9 MOCLOBEMIDE TA_LEVEL_1 Central Nervous System (CNS) 71320-77-9 MOCLOBEMIDE MECHANISM Prolong/enhance neural transmission 71320-77-9 MOCLOBEMIDE MESH_LEVEL_2 Amides 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT NEU_1_Tremor 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT XXX_2_Edema 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 71320-77-9 MOCLOBEMIDE ADVERSE_EFFECT END_3_Galactorrhea 55242-55-2 PROPENTOFYLLINE STRUCTURE_ACTIVITY PDE inhibitor 55242-55-2 PROPENTOFYLLINE MODE_CLASS Solute transporter inhibitor 55242-55-2 PROPENTOFYLLINE ADVERSE_EFFECT NEU__Dizziness 55242-55-2 PROPENTOFYLLINE MECHANISM Ehance adenosine-mediated vasodilation 55242-55-2 PROPENTOFYLLINE ADVERSE_EFFECT NEU__Headache 55242-55-2 PROPENTOFYLLINE INDICATION Dementia 55242-55-2 PROPENTOFYLLINE MODE_CLASS Receptor Agonist 55242-55-2 PROPENTOFYLLINE MECHANISM Modulate neural transmission 55242-55-2 PROPENTOFYLLINE PRODUCT_CLASS Central Nervous System (CNS) 55242-55-2 PROPENTOFYLLINE INDICATION Alzheimer's Disease 55242-55-2 PROPENTOFYLLINE MODE_CLASS Enzyme Inhibitor 55242-55-2 PROPENTOFYLLINE THERAPEUTIC_CLASS Neurodegenerative Disorders 55242-55-2 PROPENTOFYLLINE ADVERSE_EFFECT GIS__Nausea 55242-55-2 PROPENTOFYLLINE ADVERSE_EFFECT OCU__Abnormal Vision 55242-55-2 PROPENTOFYLLINE MECHANISM Enhance kinase mediated signal transduction 55242-55-2 PROPENTOFYLLINE ADVERSE_EFFECT GIS__Dyspepsia 58970-76-6 UBENIMEX TA_LEVEL_3 Solid and soft tumors 58970-76-6 UBENIMEX ADVERSE_EFFECT NEU_3_Headache 58970-76-6 UBENIMEX ACTIVITY_CLASS Anti-inflammatory 58970-76-6 UBENIMEX ZERO_CLASS N 58970-76-6 UBENIMEX ADVERSE_EFFECT NEU_3_Paresthesia 58970-76-6 UBENIMEX TA_LEVEL_1 Oncology 58970-76-6 UBENIMEX PRODUCT_CLASS Immune Response / Immunomodulators 58970-76-6 UBENIMEX MESH_LEVEL_3 Amino Acids, essential 58970-76-6 UBENIMEX ADVERSE_EFFECT SKN_2_Skin Rash 58970-76-6 UBENIMEX STRUCTURE_ACTIVITY Aminopeptidase inhibitor 58970-76-6 UBENIMEX TA_LEVEL_2 immunosuppressant 58970-76-6 UBENIMEX INDICATION Acute Non-Lymphocytic Leukemia 58970-76-6 UBENIMEX MESH_LEVEL_2 Amino Acids 58970-76-6 UBENIMEX MECHANISM Inhibit eicosanoid biosynthesis 58970-76-6 UBENIMEX PRODUCT_CLASS Anti-cancers 58970-76-6 UBENIMEX THERAPEUTIC_CLASS Antineoplastics 58970-76-6 UBENIMEX THERAPEUTIC_CLASS Immunomodulants 58970-76-6 UBENIMEX ADVERSE_EFFECT LIV_3_Abnormal Liver Function 58970-76-6 UBENIMEX MECHANISM Modulate G-protein coupled signal transduction 58970-76-6 UBENIMEX MECH_LEVEL_1 Immunomodulation 58970-76-6 UBENIMEX ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 58970-76-6 UBENIMEX MODE_CLASS Enzyme Inhibitor 58970-76-6 UBENIMEX MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 58970-76-6 UBENIMEX MECH_LEVEL_3 Aminopeptidase B 58970-76-6 UBENIMEX MECH_LEVEL_2 Immune stimulantion 71963-77-4 ARTEMETHER MESH_LEVEL_2 Hydrocarbons 71963-77-4 ARTEMETHER TISSUE_TOXICITY Arrhythmia 71963-77-4 ARTEMETHER KNOWN_TOXICITY Cardiovascular Toxicity 71963-77-4 ARTEMETHER ADVERSE_EFFECT CVS_3_Arrhythmia 71963-77-4 ARTEMETHER ADVERSE_EFFECT BBM_3_Leukopenia 71963-77-4 ARTEMETHER ADVERSE_EFFECT GIS_3_Diarrhea 71963-77-4 ARTEMETHER MECHANISM Induce free oxygen radical associated tissue and DNA damage 71963-77-4 ARTEMETHER TA_LEVEL_1 Infectious Disease 71963-77-4 ARTEMETHER ZERO_CLASS N 71963-77-4 ARTEMETHER ADVERSE_EFFECT CVS_3_Prolonged QT Interval 71963-77-4 ARTEMETHER ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 71963-77-4 ARTEMETHER ADVERSE_EFFECT GIS_3_Nausea 71963-77-4 ARTEMETHER MECH_LEVEL_3 DNA damage 71963-77-4 ARTEMETHER PRODUCT_CLASS Anti-infectives 71963-77-4 ARTEMETHER ADVERSE_EFFECT SKN_3_Skin Rash 71963-77-4 ARTEMETHER MECH_LEVEL_2 free radical 71963-77-4 ARTEMETHER ADVERSE_EFFECT BBM_3_Anemia 71963-77-4 ARTEMETHER MESH_LEVEL_1 Organic Chemicals 71963-77-4 ARTEMETHER MESH_LEVEL_3 Terpenes 71963-77-4 ARTEMETHER STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, antiparasitic 71963-77-4 ARTEMETHER THERAPEUTIC_CLASS Antiparasitics 71963-77-4 ARTEMETHER ADVERSE_EFFECT BBM_3_Reticulocytosis 71963-77-4 ARTEMETHER ADVERSE_EFFECT GIS_3_Abdominal Pain 71963-77-4 ARTEMETHER ADVERSE_EFFECT GIS_3_Vomiting 71963-77-4 ARTEMETHER INDICATION Malaria 71963-77-4 ARTEMETHER ADVERSE_EFFECT XXX_2_Injection Site Reaction 71963-77-4 ARTEMETHER TA_LEVEL_2 Antiparasitic 71963-77-4 ARTEMETHER MECH_LEVEL_1 Believed to involve free radical damage to membrane systems in parasites; inhibits cytoadherence and rosetting 71963-77-4 ARTEMETHER ACTIVITY_CLASS DNA damager 71963-77-4 ARTEMETHER TA_LEVEL_3 malaria 75659-07-3 DILEVALOL KNOWN_TOXICITY Hepatotoxicity 75659-07-3 DILEVALOL MECHANISM Reduce vasoconstriction 75659-07-3 DILEVALOL ADVERSE_EFFECT GIS_1_Nausea 75659-07-3 DILEVALOL ADVERSE_EFFECT LIV_3_Hepatotoxicity 75659-07-3 DILEVALOL ADVERSE_EFFECT NEU_1_Dizziness 75659-07-3 DILEVALOL MECHANISM Reduce muscle contractile force 75659-07-3 DILEVALOL INDICATION Hypertension 75659-07-3 DILEVALOL MODE_CLASS Receptor Partial Agonist 75659-07-3 DILEVALOL MECHANISM Modulate G-protein coupled signal transduction 75659-07-3 DILEVALOL PRODUCT_CLASS Cardiovasculars 75659-07-3 DILEVALOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 75659-07-3 DILEVALOL KNOWN_TOXICITY Cardiovascular Toxicity 75659-07-3 DILEVALOL ADVERSE_EFFECT CVS_2_Hypotension 75659-07-3 DILEVALOL ADVERSE_EFFECT XXX_1_Fatigue 75659-07-3 DILEVALOL ADVERSE_EFFECT CVS_2_Bradycardia 75659-07-3 DILEVALOL THERAPEUTIC_CLASS Antihypertensive Agents 75659-07-3 DILEVALOL ADVERSE_EFFECT REP_3_Impotence 75659-07-3 DILEVALOL ADVERSE_EFFECT GIS_2_Gastrointestinal Distress 75659-07-3 DILEVALOL TISSUE_TOXICITY Hypotension 75659-07-3 DILEVALOL ADVERSE_EFFECT PSY_3_Depression 75659-07-3 DILEVALOL ADVERSE_EFFECT _1_Loose stools 75659-07-3 DILEVALOL ADVERSE_EFFECT NEU_1_Headache 75659-07-3 DILEVALOL ADVERSE_EFFECT GIS_1_Diarrhea 75659-07-3 DILEVALOL INDICATION Hypertension 75659-07-3 DILEVALOL TISSUE_TOXICITY Hepatotoxicity 75659-07-3 DILEVALOL MODE_CLASS Receptor Ligand Antagonist 35212-22-7 IPRIFLAVONE MESH_LEVEL_3 Benzopyrans 35212-22-7 IPRIFLAVONE MECH_LEVEL_2 estrogen receptor agonist 35212-22-7 IPRIFLAVONE TA_LEVEL_2 osteoporosis 35212-22-7 IPRIFLAVONE TA_LEVEL_1 Vitamins, Minerals and Nutrients 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT SKN_2_Skin Rash 35212-22-7 IPRIFLAVONE MECHANISM Modulate gene transcription 35212-22-7 IPRIFLAVONE ZERO_CLASS N 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT GIS_1_Diarrhea 35212-22-7 IPRIFLAVONE MECH_LEVEL_1 Vitamins / Minerals / Nutrients 35212-22-7 IPRIFLAVONE MECH_LEVEL_3 estrogen receptor beta 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT NEU_2_Headache 35212-22-7 IPRIFLAVONE STRUCTURE_ACTIVITY Phytoestrogen 35212-22-7 IPRIFLAVONE TA_LEVEL_3 synthetic flavone 35212-22-7 IPRIFLAVONE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 35212-22-7 IPRIFLAVONE MESH_LEVEL_1 Heterocyclic Compounds 35212-22-7 IPRIFLAVONE INDICATION Osteoporosis 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT LIV_3_Abnormal Liver Function 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT PSY_2_Depression 35212-22-7 IPRIFLAVONE PRODUCT_CLASS Vitamins, Minerals and Nutrients 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 35212-22-7 IPRIFLAVONE MODE_CLASS Receptor Agonist, selective 35212-22-7 IPRIFLAVONE ACTIVITY_CLASS Estrogen agonist 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT NEU_2_Drowsiness 35212-22-7 IPRIFLAVONE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT BBM_1_Asymptomatic Lymphocytopenia 35212-22-7 IPRIFLAVONE ADVERSE_EFFECT GIS_1_Epigastric Pain 63516-10-9 FLUTROPIUM BROMIDE MODE_CLASS Solute transporter inhibitor 63516-10-9 FLUTROPIUM BROMIDE MECHANISM Prolong/enhance neural transmission 63516-10-9 FLUTROPIUM BROMIDE INDICATION Viral Rhinitis / Common Cold 31428-61-2 TIAMENIDINE MECHANISM Reduce vasoconstriction 31428-61-2 TIAMENIDINE INDICATION Hypertension 31428-61-2 TIAMENIDINE PRODUCT_CLASS Cardiovasculars 31428-61-2 TIAMENIDINE MODE_CLASS Receptor Partial Agonist 31428-61-2 TIAMENIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 31428-61-2 TIAMENIDINE THERAPEUTIC_CLASS Antihypertensive Agents 51274-83-0 TIAMENIDINE MECHANISM Reduce vasoconstriction 51274-83-0 TIAMENIDINE INDICATION Hypertension 51274-83-0 TIAMENIDINE PRODUCT_CLASS Cardiovasculars 51274-83-0 TIAMENIDINE MODE_CLASS Receptor Partial Agonist 51274-83-0 TIAMENIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 51274-83-0 TIAMENIDINE THERAPEUTIC_CLASS Antihypertensive Agents 31428-62-3 TIAMENIDINE THERAPEUTIC_CLASS Antihypertensive Agents 31428-62-3 TIAMENIDINE MECHANISM Reduce vasoconstriction 31428-62-3 TIAMENIDINE INDICATION Hypertension 31428-62-3 TIAMENIDINE PRODUCT_CLASS Cardiovasculars 31428-62-3 TIAMENIDINE MODE_CLASS Receptor Partial Agonist 31428-62-3 TIAMENIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 81872-10-8 ZOFENOPRIL MECHANISM Reduce vasoconstriction 81872-10-8 ZOFENOPRIL PRODUCT_CLASS Cardiovasculars 81872-10-8 ZOFENOPRIL INDICATION Angina Pectoris 81872-10-8 ZOFENOPRIL THERAPEUTIC_CLASS Antianginals 81872-10-8 ZOFENOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 81872-10-8 ZOFENOPRIL INDICATION Hypertension 81872-10-8 ZOFENOPRIL MODE_CLASS Enzyme Inhibitor 81872-10-8 ZOFENOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 81938-43-4 ZOFENOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 81938-43-4 ZOFENOPRIL MODE_CLASS Enzyme Inhibitor 81938-43-4 ZOFENOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 81938-43-4 ZOFENOPRIL INDICATION Hypertension 81938-43-4 ZOFENOPRIL THERAPEUTIC_CLASS Antianginals 81938-43-4 ZOFENOPRIL INDICATION Angina Pectoris 81938-43-4 ZOFENOPRIL PRODUCT_CLASS Cardiovasculars 81938-43-4 ZOFENOPRIL MECHANISM Reduce vasoconstriction 81938-40-1 ZOFENOPRIL INDICATION Angina Pectoris 81938-40-1 ZOFENOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 81938-40-1 ZOFENOPRIL THERAPEUTIC_CLASS Antianginals 81938-40-1 ZOFENOPRIL MODE_CLASS Enzyme Inhibitor 81938-40-1 ZOFENOPRIL INDICATION Hypertension 81938-40-1 ZOFENOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 81938-40-1 ZOFENOPRIL MECHANISM Reduce vasoconstriction 81938-40-1 ZOFENOPRIL PRODUCT_CLASS Cardiovasculars 40542-65-2 GESTRINONE THERAPEUTIC_CLASS Gonadal Hormones 40542-65-2 GESTRINONE MODE_CLASS Receptor Ligand Antagonist 40542-65-2 GESTRINONE MECHANISM Modulate gene transcription 40542-65-2 GESTRINONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 16320-04-0 GESTRINONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 16320-04-0 GESTRINONE MODE_CLASS Receptor Ligand Antagonist 16320-04-0 GESTRINONE MECHANISM Modulate gene transcription 16320-04-0 GESTRINONE THERAPEUTIC_CLASS Gonadal Hormones 32828-81-2 PICOTAMIDE MECHANISM Inhibit eicosanoid biosynthesis 32828-81-2 PICOTAMIDE MODE_CLASS Enzyme Inhibitor 32828-81-2 PICOTAMIDE MODE_CLASS Receptor Ligand Antagonist 43200-80-2 ZOPICLONE INDICATION Insomnia 43200-80-2 ZOPICLONE PRODUCT_CLASS Central Nervous System (CNS) 43200-80-2 ZOPICLONE TA_LEVEL_1 Central Nervous System (CNS) 43200-80-2 ZOPICLONE ADVERSE_EFFECT GIS_2_Dry Mouth 43200-80-2 ZOPICLONE ADVERSE_EFFECT NEU_2_Drowsiness 43200-80-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Ataxia 43200-80-2 ZOPICLONE ADVERSE_EFFECT OCU_2_Abnormal Vision 43200-80-2 ZOPICLONE ACTIVITY_CLASS GABA agonist 43200-80-2 ZOPICLONE MESH_LEVEL_3 Piperazines 43200-80-2 ZOPICLONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 43200-80-2 ZOPICLONE TA_LEVEL_2 CNS Depressant 43200-80-2 ZOPICLONE TA_LEVEL_3 Sedatives/Hypnotics 43200-80-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Depression 43200-80-2 ZOPICLONE ADVERSE_EFFECT SKN_3_Rash 43200-80-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Psychologic Dependence 43200-80-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Anterograde Amnesia 43200-80-2 ZOPICLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 43200-80-2 ZOPICLONE ADVERSE_EFFECT XXX_3_Hypotonia 43200-80-2 ZOPICLONE STRUCTURE_ACTIVITY GABA-A agonist, short acting 43200-80-2 ZOPICLONE MECH_LEVEL_3 GABA-A receptor 43200-80-2 ZOPICLONE MECH_LEVEL_1 Modulate neural transmission 43200-80-2 ZOPICLONE MECHANISM Modulate neural transmission 43200-80-2 ZOPICLONE THERAPEUTIC_CLASS Sedatives/Hypnotics 43200-80-2 ZOPICLONE ADVERSE_EFFECT IMU_3_Allergic Reactions 43200-80-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Coma 43200-80-2 ZOPICLONE ADVERSE_EFFECT XXX_2_Withdrawal 43200-80-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Irritability 43200-80-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 43200-80-2 ZOPICLONE MESH_LEVEL_1 Heterocyclic Compounds 43200-80-2 ZOPICLONE MECH_LEVEL_2 faciliates GABA binding 43200-80-2 ZOPICLONE MODE_CLASS Channel Modulator 43200-80-2 ZOPICLONE ADVERSE_EFFECT NEU_2_Dizziness 43200-80-2 ZOPICLONE ADVERSE_EFFECT XXX_3_Tolerance 43200-80-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Physical Dependence 43200-80-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Confusion 43200-80-2 ZOPICLONE ADVERSE_EFFECT GIS_1_Metallic Taste 43200-80-2 ZOPICLONE ZERO_CLASS N 138680-08-7 ZOPICLONE ADVERSE_EFFECT XXX_3_Hypotonia 138680-08-7 ZOPICLONE ADVERSE_EFFECT NEU_3_Anterograde Amnesia 138680-08-7 ZOPICLONE ADVERSE_EFFECT PSY_2_Psychologic Dependence 138680-08-7 ZOPICLONE ADVERSE_EFFECT SKN_3_Rash 138680-08-7 ZOPICLONE ADVERSE_EFFECT PSY_2_Depression 138680-08-7 ZOPICLONE TA_LEVEL_3 Sedatives/Hypnotics 138680-08-7 ZOPICLONE TA_LEVEL_2 CNS Depressant 138680-08-7 ZOPICLONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 138680-08-7 ZOPICLONE MESH_LEVEL_3 Piperazines 138680-08-7 ZOPICLONE ACTIVITY_CLASS GABA agonist 138680-08-7 ZOPICLONE ADVERSE_EFFECT OCU_2_Abnormal Vision 138680-08-7 ZOPICLONE ADVERSE_EFFECT NEU_3_Ataxia 138680-08-7 ZOPICLONE ADVERSE_EFFECT NEU_2_Drowsiness 138680-08-7 ZOPICLONE ADVERSE_EFFECT GIS_2_Dry Mouth 138680-08-7 ZOPICLONE TA_LEVEL_1 Central Nervous System (CNS) 138680-08-7 ZOPICLONE PRODUCT_CLASS Central Nervous System (CNS) 138680-08-7 ZOPICLONE INDICATION Insomnia 138680-08-7 ZOPICLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 138680-08-7 ZOPICLONE ZERO_CLASS N 138680-08-7 ZOPICLONE ADVERSE_EFFECT GIS_1_Metallic Taste 138680-08-7 ZOPICLONE ADVERSE_EFFECT PSY_2_Confusion 138680-08-7 ZOPICLONE ADVERSE_EFFECT PSY_2_Physical Dependence 138680-08-7 ZOPICLONE ADVERSE_EFFECT XXX_3_Tolerance 138680-08-7 ZOPICLONE ADVERSE_EFFECT NEU_2_Dizziness 138680-08-7 ZOPICLONE MODE_CLASS Channel Modulator 138680-08-7 ZOPICLONE MECH_LEVEL_2 faciliates GABA binding 138680-08-7 ZOPICLONE MESH_LEVEL_1 Heterocyclic Compounds 138680-08-7 ZOPICLONE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 138680-08-7 ZOPICLONE ADVERSE_EFFECT PSY_2_Irritability 138680-08-7 ZOPICLONE ADVERSE_EFFECT XXX_2_Withdrawal 138680-08-7 ZOPICLONE ADVERSE_EFFECT NEU_3_Coma 138680-08-7 ZOPICLONE ADVERSE_EFFECT IMU_3_Allergic Reactions 138680-08-7 ZOPICLONE THERAPEUTIC_CLASS Sedatives/Hypnotics 138680-08-7 ZOPICLONE MECHANISM Modulate neural transmission 138680-08-7 ZOPICLONE MECH_LEVEL_1 Modulate neural transmission 138680-08-7 ZOPICLONE MECH_LEVEL_3 GABA-A receptor 138680-08-7 ZOPICLONE STRUCTURE_ACTIVITY GABA-A agonist, short acting 138729-47-2 ZOPICLONE MECH_LEVEL_3 GABA-A receptor 138729-47-2 ZOPICLONE MECH_LEVEL_1 Modulate neural transmission 138729-47-2 ZOPICLONE MECHANISM Modulate neural transmission 138729-47-2 ZOPICLONE THERAPEUTIC_CLASS Sedatives/Hypnotics 138729-47-2 ZOPICLONE ADVERSE_EFFECT IMU_3_Allergic Reactions 138729-47-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Coma 138729-47-2 ZOPICLONE ADVERSE_EFFECT XXX_2_Withdrawal 138729-47-2 ZOPICLONE STRUCTURE_ACTIVITY GABA-A agonist, short acting 138729-47-2 ZOPICLONE MESH_LEVEL_1 Heterocyclic Compounds 138729-47-2 ZOPICLONE ADVERSE_EFFECT GIS_2_Dry Mouth 138729-47-2 ZOPICLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 138729-47-2 ZOPICLONE MECH_LEVEL_2 faciliates GABA binding 138729-47-2 ZOPICLONE ADVERSE_EFFECT XXX_3_Hypotonia 138729-47-2 ZOPICLONE ZERO_CLASS N 138729-47-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Anterograde Amnesia 138729-47-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Psychologic Dependence 138729-47-2 ZOPICLONE ADVERSE_EFFECT SKN_3_Rash 138729-47-2 ZOPICLONE TA_LEVEL_1 Central Nervous System (CNS) 138729-47-2 ZOPICLONE PRODUCT_CLASS Central Nervous System (CNS) 138729-47-2 ZOPICLONE INDICATION Insomnia 138729-47-2 ZOPICLONE MODE_CLASS Channel Modulator 138729-47-2 ZOPICLONE ADVERSE_EFFECT NEU_2_Dizziness 138729-47-2 ZOPICLONE ADVERSE_EFFECT XXX_3_Tolerance 138729-47-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Physical Dependence 138729-47-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Confusion 138729-47-2 ZOPICLONE ADVERSE_EFFECT GIS_1_Metallic Taste 138729-47-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Depression 138729-47-2 ZOPICLONE TA_LEVEL_3 Sedatives/Hypnotics 138729-47-2 ZOPICLONE TA_LEVEL_2 CNS Depressant 138729-47-2 ZOPICLONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 138729-47-2 ZOPICLONE MESH_LEVEL_3 Piperazines 138729-47-2 ZOPICLONE ADVERSE_EFFECT PSY_2_Irritability 138729-47-2 ZOPICLONE ACTIVITY_CLASS GABA agonist 138729-47-2 ZOPICLONE ADVERSE_EFFECT OCU_2_Abnormal Vision 138729-47-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Ataxia 138729-47-2 ZOPICLONE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 138729-47-2 ZOPICLONE ADVERSE_EFFECT NEU_2_Drowsiness 89482-00-8 ZALTOPROFEN MODE_CLASS Enzyme Inhibitor 89482-00-8 ZALTOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 89482-00-8 ZALTOPROFEN INDICATION Arthritis 89482-00-8 ZALTOPROFEN PRODUCT_CLASS Immune Response / Immunomodulators 89482-00-8 ZALTOPROFEN THERAPEUTIC_CLASS Immunosuppressants 74711-43-6 ZALTOPROFEN THERAPEUTIC_CLASS Immunosuppressants 74711-43-6 ZALTOPROFEN INDICATION Arthritis 74711-43-6 ZALTOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 74711-43-6 ZALTOPROFEN MODE_CLASS Enzyme Inhibitor 74711-43-6 ZALTOPROFEN PRODUCT_CLASS Immune Response / Immunomodulators 69975-86-6 DOXOFYLLINE ACTIVITY_CLASS Phosphodiesterase inhibitor 69975-86-6 DOXOFYLLINE TA_LEVEL_1 Respiratory System 69975-86-6 DOXOFYLLINE MECH_LEVEL_1 Bronchodilation 69975-86-6 DOXOFYLLINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT CVS_3_Tachycardia 69975-86-6 DOXOFYLLINE PRODUCT_CLASS Respiratory System 69975-86-6 DOXOFYLLINE TA_LEVEL_3 PDE inhibitors 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT PSY_2_Insomnia 69975-86-6 DOXOFYLLINE MECHANISM Reduce bronchoconstriction 69975-86-6 DOXOFYLLINE MESH_LEVEL_1 Heterocyclic Compounds 69975-86-6 DOXOFYLLINE INDICATION Asthma 69975-86-6 DOXOFYLLINE MECH_LEVEL_3 adenosine receptor A1 and A2 69975-86-6 DOXOFYLLINE MESH_LEVEL_3 Xanthine Alkaloids 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT SKN_2_Flushing 69975-86-6 DOXOFYLLINE KNOWN_TOXICITY Cardiovascular Toxicity 69975-86-6 DOXOFYLLINE MECHANISM Enhance kinase mediated signal transduction 69975-86-6 DOXOFYLLINE THERAPEUTIC_CLASS Bronchodilators 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT NEU_3_Seizures 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT GIS_1_Nausea 69975-86-6 DOXOFYLLINE TA_LEVEL_2 bronchiodialation 69975-86-6 DOXOFYLLINE TISSUE_TOXICITY Cardiac Arrhythmia 69975-86-6 DOXOFYLLINE MECH_LEVEL_2 PDE inhibition 69975-86-6 DOXOFYLLINE MODE_CLASS Enzyme Inhibitor 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT NEU_2_Tremor 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT GIS_3_Gastric Acid Hypersecretion 69975-86-6 DOXOFYLLINE MESH_LEVEL_2 Aklaloids 69975-86-6 DOXOFYLLINE ZERO_CLASS N 69975-86-6 DOXOFYLLINE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 69975-86-6 DOXOFYLLINE INDICATION Bronchospasm 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT GIS_2_Vomiting 69975-86-6 DOXOFYLLINE ADVERSE_EFFECT GIS_2_Dyspepsia 84379-13-5 BRETAZENIL PRODUCT_CLASS Central Nervous System (CNS) 84379-13-5 BRETAZENIL MODE_CLASS Channel Modulator 84379-13-5 BRETAZENIL INDICATION Anxiety Disorders 84379-13-5 BRETAZENIL MECHANISM Modulate neural transmission 84379-13-5 BRETAZENIL THERAPEUTIC_CLASS Sedatives/Hypnotics 26774-90-3 EPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 26774-90-3 EPICILLIN MODE_CLASS Enzyme Inhibitor 26774-90-3 EPICILLIN PRODUCT_CLASS Anti-infectives 26774-90-3 EPICILLIN THERAPEUTIC_CLASS Antibacterials 26833-87-4 HOMOHARRINGTONINE THERAPEUTIC_CLASS Antineoplastics 26833-87-4 HOMOHARRINGTONINE MECHANISM Induce Apoptosis 26833-87-4 HOMOHARRINGTONINE INDICATION Leukemia 26833-87-4 HOMOHARRINGTONINE PRODUCT_CLASS Anti-cancers 18965-97-4 BERLAFENONE INDICATION Cardiac Arrhythmias 18965-97-4 BERLAFENONE THERAPEUTIC_CLASS Antiarrhythmic Agents 18965-97-4 BERLAFENONE PRODUCT_CLASS Cardiovasculars 57680-56-5 SUCROSOFATE INDICATION Ulcer 62989-33-7 SAPROPTERIN THERAPEUTIC_CLASS Antidepressants 62989-33-7 SAPROPTERIN PRODUCT_CLASS Central Nervous System (CNS) 62989-33-7 SAPROPTERIN INDICATION Depression 69056-38-8 SAPROPTERIN INDICATION Depression 69056-38-8 SAPROPTERIN PRODUCT_CLASS Central Nervous System (CNS) 69056-38-8 SAPROPTERIN THERAPEUTIC_CLASS Antidepressants 67469-69-6 VANOXERINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 67469-69-6 VANOXERINE MODE_CLASS Solute transporter inhibitor 67469-69-6 VANOXERINE MECHANISM Prolong/enhance neural transmission 73725-85-6 LIDANSERIN INDICATION Hypertension 73725-85-6 LIDANSERIN PRODUCT_CLASS Cardiovasculars 73725-85-6 LIDANSERIN THERAPEUTIC_CLASS Antihypertensive Agents 74168-08-4 LOSMIPROFEN PRODUCT_CLASS Anti-inflammatories 74168-08-4 LOSMIPROFEN MODE_CLASS Enzyme Inhibitor 74168-08-4 LOSMIPROFEN MECHANISM Inhibit eicosanoid biosynthesis 74168-08-4 LOSMIPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 74863-84-6 ARGATROBAN MODE_CLASS Enzyme Inhibitor 74863-84-6 ARGATROBAN STRUCTURE_ACTIVITY Thrombin inhibitor 74863-84-6 ARGATROBAN THERAPEUTIC_CLASS Thrombolytic Agents 74863-84-6 ARGATROBAN PRODUCT_CLASS Hematologics 74863-84-6 ARGATROBAN INDICATION Thrombosis in Heparin Induced Thrombocytopenia 74863-84-6 ARGATROBAN MECHANISM Inhibit platelet aggregation 141396-28-3 ARGATROBAN MECHANISM Inhibit platelet aggregation 141396-28-3 ARGATROBAN STRUCTURE_ACTIVITY Thrombin inhibitor 141396-28-3 ARGATROBAN THERAPEUTIC_CLASS Thrombolytic Agents 141396-28-3 ARGATROBAN PRODUCT_CLASS Hematologics 141396-28-3 ARGATROBAN INDICATION Thrombosis in Heparin Induced Thrombocytopenia 141396-28-3 ARGATROBAN MODE_CLASS Enzyme Inhibitor 77337-76-9 ACAMPROSATE MECHANISM Modulate neural transmission 77337-76-9 ACAMPROSATE MODE_CLASS Receptor Ligand Antagonist 78664-73-0 POSATIRELIN INDICATION Depression 78664-73-0 POSATIRELIN PRODUCT_CLASS Central Nervous System (CNS) 78664-73-0 POSATIRELIN THERAPEUTIC_CLASS Antidepressants 78664-73-0 POSATIRELIN INDICATION Cataplexy 78816-67-8 TIRACIZINE HCL MODE_CLASS Solute transporter inhibitor 78816-67-8 TIRACIZINE HCL MECHANISM Prolong/enhance neural transmission 78816-67-8 TIRACIZINE HCL INDICATION Cardiac Arrhythmias 78816-67-8 TIRACIZINE HCL THERAPEUTIC_CLASS Antiarrhythmic Agents 78816-67-8 TIRACIZINE HCL PRODUCT_CLASS Cardiovasculars 79286-77-4 ESAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 79286-77-4 ESAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 79286-77-4 ESAFLOXACIN PRODUCT_CLASS Anti-infectives 79286-77-4 ESAFLOXACIN THERAPEUTIC_CLASS Antibacterials 79286-77-4 ESAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 79778-41-9 NERIDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 79778-41-9 NERIDRONIC ACID MODE_CLASS Enzyme Inhibitor 79778-41-9 NERIDRONIC ACID MECHANISM Inhibit bone re-absorption 79778-41-9 NERIDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 79778-41-9 NERIDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 80576-83-6 EDATREXATE PRODUCT_CLASS Anti-cancers 80576-83-6 EDATREXATE MODE_CLASS Enzyme substrate mimic 80576-83-6 EDATREXATE THERAPEUTIC_CLASS Antineoplastics 80576-83-6 EDATREXATE MECHANISM Inhibit precursor synthesis 80809-81-0 DOCEBENONE MODE_CLASS Enzyme Inhibitor 80809-81-0 DOCEBENONE MECHANISM Inhibit eicosanoid biosynthesis 80937-31-1 FLOSULIDE PRODUCT_CLASS Anti-inflammatories 80937-31-1 FLOSULIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 81703-42-6 BENDACALOL THERAPEUTIC_CLASS Antihypertensive Agents 81703-42-6 BENDACALOL PRODUCT_CLASS Cardiovasculars 81703-42-6 BENDACALOL INDICATION Hypertension 82239-52-9 MOXIRAPRINE INDICATION Parkinson's Disease 82821-47-4 AMINOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 82821-47-4 AMINOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 82821-47-4 AMINOPROFEN MODE_CLASS Enzyme Inhibitor 82821-47-4 AMINOPROFEN PRODUCT_CLASS Anti-inflammatories 82821-47-4 AMINOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 84386-11-8 BAXITOZINE INDICATION Ulcer 85175-67-3 ZATEBRADINE INDICATION Cardiac Arrhythmias 85175-67-3 ZATEBRADINE THERAPEUTIC_CLASS Antiarrhythmic Agents 85175-67-3 ZATEBRADINE PRODUCT_CLASS Cardiovasculars 87056-78-8 QUINAGOLIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 87056-78-8 QUINAGOLIDE THERAPEUTIC_CLASS Pituitary Hormones 87056-78-8 QUINAGOLIDE INDICATION Hyperprolactinemia 87056-78-8 QUINAGOLIDE MECHANISM Prolong/enhance neural transmission 87056-78-8 QUINAGOLIDE MODE_CLASS Receptor Agonist 94424-50-7 QUINAGOLIDE MODE_CLASS Receptor Agonist 94424-50-7 QUINAGOLIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 94424-50-7 QUINAGOLIDE THERAPEUTIC_CLASS Pituitary Hormones 94424-50-7 QUINAGOLIDE INDICATION Hyperprolactinemia 94424-50-7 QUINAGOLIDE MECHANISM Prolong/enhance neural transmission 97805-49-7 QUINAGOLIDE MECHANISM Prolong/enhance neural transmission 97805-49-7 QUINAGOLIDE INDICATION Hyperprolactinemia 97805-49-7 QUINAGOLIDE THERAPEUTIC_CLASS Pituitary Hormones 97805-49-7 QUINAGOLIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 97805-49-7 QUINAGOLIDE MODE_CLASS Receptor Agonist 97085-50-0 QUINAGOLIDE MODE_CLASS Receptor Agonist 97085-50-0 QUINAGOLIDE MECHANISM Prolong/enhance neural transmission 97085-50-0 QUINAGOLIDE INDICATION Hyperprolactinemia 97085-50-0 QUINAGOLIDE THERAPEUTIC_CLASS Pituitary Hormones 97085-50-0 QUINAGOLIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 88069-67-4 PILSICAINIDE MECHANISM Modulate G-protein coupled signal transduction 88069-67-4 PILSICAINIDE MODE_CLASS Channel Blocker 88069-67-4 PILSICAINIDE MODE_CLASS Receptor Ligand Antagonist 88069-67-4 PILSICAINIDE MECHANISM Block neural transmission 88069-67-4 PILSICAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 88069-67-4 PILSICAINIDE PRODUCT_CLASS Cardiovasculars 88069-67-4 PILSICAINIDE INDICATION Cardiac Arrhythmias 88721-77-1 RENZAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 88721-77-1 RENZAPRIDE PRODUCT_CLASS Gastrointestinal System 89194-77-4 BISARAMIL PRODUCT_CLASS Cardiovasculars 89194-77-4 BISARAMIL INDICATION Cardiac Arrhythmias 89194-77-4 BISARAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 89651-00-3 VOXERGOLIDE INDICATION Depression 89651-00-3 VOXERGOLIDE STRUCTURE_ACTIVITY Ergot alkaloid 89651-00-3 VOXERGOLIDE PRODUCT_CLASS Central Nervous System (CNS) 89651-00-3 VOXERGOLIDE THERAPEUTIC_CLASS Antidepressants 89651-01-4 VOXERGOLIDE THERAPEUTIC_CLASS Antidepressants 89651-01-4 VOXERGOLIDE INDICATION Depression 89651-01-4 VOXERGOLIDE STRUCTURE_ACTIVITY Ergot alkaloid 89651-01-4 VOXERGOLIDE PRODUCT_CLASS Central Nervous System (CNS) 90402-40-7 ABANOQUIL INDICATION Hypertension 90402-40-7 ABANOQUIL INDICATION Cardiac Arrhythmias 90402-40-7 ABANOQUIL PRODUCT_CLASS Cardiovasculars 90402-40-7 ABANOQUIL MECHANISM Modulate G-protein coupled signal transduction 90402-40-7 ABANOQUIL THERAPEUTIC_CLASS Antihypertensive Agents 90402-40-7 ABANOQUIL THERAPEUTIC_CLASS Antiarrhythmic Agents 90749-32-9 LAPRAFYLLINE PRODUCT_CLASS Respiratory System 90749-32-9 LAPRAFYLLINE THERAPEUTIC_CLASS Bronchodilators 90749-32-9 LAPRAFYLLINE INDICATION Asthma 90808-12-1 DIVAPLON PRODUCT_CLASS Central Nervous System (CNS) 90808-12-1 DIVAPLON THERAPEUTIC_CLASS Sedatives/Hypnotics 90808-12-1 DIVAPLON INDICATION Anxiety Disorders 91832-40-5 CEFDINIR MECHANISM Inhibit bacterial cell wall biosynthesis 91832-40-5 CEFDINIR THERAPEUTIC_CLASS Antibacterials 91832-40-5 CEFDINIR MODE_CLASS Enzyme Inhibitor 91832-40-5 CEFDINIR PRODUCT_CLASS Anti-infectives 93221-48-8 LEVOBETAXOLOL MECHANISM Modulate G-protein coupled signal transduction 93221-48-8 LEVOBETAXOLOL MODE_CLASS Receptor Ligand Antagonist 95399-71-6 FOSINOPRILAT PRODUCT_CLASS Cardiovasculars 95399-71-6 FOSINOPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 95399-71-6 FOSINOPRILAT MODE_CLASS Enzyme Inhibitor 95399-71-6 FOSINOPRILAT INDICATION Hypertension 95399-71-6 FOSINOPRILAT MECHANISM Reduce vasoconstriction 95847-87-3 REVOSPIRONE MECHANISM Modulate neural transmission 95847-87-3 REVOSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 95847-87-3 REVOSPIRONE MODE_CLASS Receptor Agonist 95847-87-3 REVOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 95847-87-3 REVOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 96125-53-0 CLENTIAZEPAM INDICATION Hypertension 96125-53-0 CLENTIAZEPAM MECHANISM Modulate channel gating 96125-53-0 CLENTIAZEPAM PRODUCT_CLASS Cardiovasculars 96125-53-0 CLENTIAZEPAM THERAPEUTIC_CLASS Antihypertensive Agents 96125-53-0 CLENTIAZEPAM MODE_CLASS Channel Modulator 96125-53-0 CLENTIAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 96566-25-5 ABLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 96566-25-5 ABLUKAST MODE_CLASS Receptor Ligand Antagonist 96566-25-5 ABLUKAST MECHANISM Modulate G-protein coupled signal transduction 96566-25-5 ABLUKAST PRODUCT_CLASS Respiratory System 96566-25-5 ABLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 96566-25-5 ABLUKAST INDICATION Asthma 96609-16-4 LIFIBROL INDICATION Hyperlipidemia 96609-16-4 LIFIBROL PRODUCT_CLASS Cardiovasculars 96609-16-4 LIFIBROL THERAPEUTIC_CLASS Hypolipidemic Agents 96609-16-4 LIFIBROL INDICATION Hypercholesterolemia 97466-90-5 QUINELORANE MECHANISM Modulate G-protein coupled signal transduction 97466-90-5 QUINELORANE INDICATION Parkinson's Disease 97466-90-5 QUINELORANE INDICATION Hypertension 97466-90-5 QUINELORANE PRODUCT_CLASS Cardiovasculars 97466-90-5 QUINELORANE THERAPEUTIC_CLASS Antihypertensive Agents 97548-97-5 QUINELORANE MECHANISM Modulate G-protein coupled signal transduction 97548-97-5 QUINELORANE INDICATION Parkinson's Disease 97548-97-5 QUINELORANE INDICATION Hypertension 97548-97-5 QUINELORANE THERAPEUTIC_CLASS Antihypertensive Agents 97548-97-5 QUINELORANE PRODUCT_CLASS Cardiovasculars 98323-83-2 CARMOXIROLE THERAPEUTIC_CLASS Antihypertensive Agents 98323-83-2 CARMOXIROLE PRODUCT_CLASS Cardiovasculars 98323-83-2 CARMOXIROLE INDICATION Hypertension 100680-33-9 CEFUROXIME PIVOXETIL MECHANISM Inhibit bacterial cell wall biosynthesis 100680-33-9 CEFUROXIME PIVOXETIL THERAPEUTIC_CLASS Antibacterials 100680-33-9 CEFUROXIME PIVOXETIL MODE_CLASS Enzyme Inhibitor 100680-33-9 CEFUROXIME PIVOXETIL PRODUCT_CLASS Anti-infectives 101238-51-1 LEVEMOPAMIL INDICATION Spinal Cord Injury / Trauma 101238-51-1 LEVEMOPAMIL MECHANISM Reduce muscle contractile force 101238-51-1 LEVEMOPAMIL INDICATION Cerebral Ischemia 101238-51-1 LEVEMOPAMIL MODE_CLASS Channel Blocker 101396-42-3 MEQUITAMIUM IODIDE THERAPEUTIC_CLASS Bronchodilators 101396-42-3 MEQUITAMIUM IODIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 101396-42-3 MEQUITAMIUM IODIDE THERAPEUTIC_CLASS Antihistamines 101396-42-3 MEQUITAMIUM IODIDE PRODUCT_CLASS Respiratory System 101396-42-3 MEQUITAMIUM IODIDE MECHANISM Block neural transmission 101396-42-3 MEQUITAMIUM IODIDE PRODUCT_CLASS Anti-inflammatories 101396-42-3 MEQUITAMIUM IODIDE MODE_CLASS Receptor Ligand Antagonist 101479-70-3 ADAPROLOL MECHANISM Reduce muscle contractile force 101479-70-3 ADAPROLOL PRODUCT_CLASS Cardiovasculars 101479-70-3 ADAPROLOL INDICATION Glaucoma 101479-70-3 ADAPROLOL INDICATION Hypertension 101479-70-3 ADAPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 101479-70-3 ADAPROLOL MODE_CLASS Receptor Ligand Antagonist 101828-21-1 BUTENAFINE ZERO_CLASS N 101828-21-1 BUTENAFINE ADVERSE_EFFECT SKN_1_Erythema 101828-21-1 BUTENAFINE TA_LEVEL_1 Infectious Disease 101828-21-1 BUTENAFINE MODE_CLASS Distorts /blocks macromolecular scaffold function 101828-21-1 BUTENAFINE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 101828-21-1 BUTENAFINE MECH_LEVEL_1 membrane function 101828-21-1 BUTENAFINE MECH_LEVEL_3 ergosterol biosynthesis 101828-21-1 BUTENAFINE MESH_LEVEL_1 Organic Chemicals 101828-21-1 BUTENAFINE MESH_LEVEL_3 Benzylamines 101828-21-1 BUTENAFINE MESH_LEVEL_2 Amines 101828-21-1 BUTENAFINE ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 101828-21-1 BUTENAFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 101828-21-1 BUTENAFINE ADVERSE_EFFECT SKN_1_Skin Reactions 101828-21-1 BUTENAFINE MECHANISM Destroy cell membrane / wall integrity 101828-21-1 BUTENAFINE PRODUCT_CLASS Anti-infectives 101828-21-1 BUTENAFINE INDICATION Tinea Pedis / Athlete's Foot 101828-21-1 BUTENAFINE ADVERSE_EFFECT SKN_1_Pruritis 101828-21-1 BUTENAFINE MECH_LEVEL_2 biosynthesis inhibitor 101828-21-1 BUTENAFINE TA_LEVEL_2 Antifungal 101828-21-1 BUTENAFINE STRUCTURE_ACTIVITY Squalene epoxidase inhibitor 101828-21-1 BUTENAFINE ADVERSE_EFFECT IMU_1_Contact Dermatitis 101828-21-1 BUTENAFINE THERAPEUTIC_CLASS Antifungals, Topical 101828-21-1 BUTENAFINE INDICATION Tinea Cruris / Jock Itch 101828-21-1 BUTENAFINE MODE_CLASS Enzyme Inhibitor 101828-21-1 BUTENAFINE TA_LEVEL_3 antifungal, topical 101827-46-7 BUTENAFINE MECHANISM Destroy cell membrane / wall integrity 101827-46-7 BUTENAFINE ADVERSE_EFFECT SKN_1_Erythema 101827-46-7 BUTENAFINE TA_LEVEL_1 Infectious Disease 101827-46-7 BUTENAFINE MODE_CLASS Distorts /blocks macromolecular scaffold function 101827-46-7 BUTENAFINE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 101827-46-7 BUTENAFINE MECH_LEVEL_1 membrane function 101827-46-7 BUTENAFINE MODE_CLASS Enzyme Inhibitor 101827-46-7 BUTENAFINE MECH_LEVEL_3 ergosterol biosynthesis 101827-46-7 BUTENAFINE MESH_LEVEL_1 Organic Chemicals 101827-46-7 BUTENAFINE MESH_LEVEL_3 Benzylamines 101827-46-7 BUTENAFINE MESH_LEVEL_2 Amines 101827-46-7 BUTENAFINE ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 101827-46-7 BUTENAFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 101827-46-7 BUTENAFINE ADVERSE_EFFECT SKN_1_Skin Reactions 101827-46-7 BUTENAFINE STRUCTURE_ACTIVITY Squalene epoxidase inhibitor 101827-46-7 BUTENAFINE INDICATION Tinea Pedis / Athlete's Foot 101827-46-7 BUTENAFINE PRODUCT_CLASS Anti-infectives 101827-46-7 BUTENAFINE TA_LEVEL_2 Antifungal 101827-46-7 BUTENAFINE MECH_LEVEL_2 biosynthesis inhibitor 101827-46-7 BUTENAFINE ADVERSE_EFFECT SKN_1_Pruritis 101827-46-7 BUTENAFINE ZERO_CLASS N 101827-46-7 BUTENAFINE TA_LEVEL_3 antifungal, topical 101827-46-7 BUTENAFINE INDICATION Tinea Cruris / Jock Itch 101827-46-7 BUTENAFINE THERAPEUTIC_CLASS Antifungals, Topical 101827-46-7 BUTENAFINE ADVERSE_EFFECT IMU_1_Contact Dermatitis 104561-36-6 DORETINEL INDICATION Actinic Keratosis 105618-02-8 GALAMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 105618-02-8 GALAMUSTINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 105618-02-8 GALAMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 107811-63-2 GALAMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 107811-63-2 GALAMUSTINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 107811-63-2 GALAMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 105920-77-2 CAMONAGREL MECHANISM Inhibit eicosanoid biosynthesis 105920-77-2 CAMONAGREL PRODUCT_CLASS Anti-inflammatories 105920-77-2 CAMONAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 105920-77-2 CAMONAGREL MODE_CLASS Enzyme Inhibitor 105920-77-2 CAMONAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 106073-01-2 TANIPLON PRODUCT_CLASS Central Nervous System (CNS) 106073-01-2 TANIPLON INDICATION Anxiety Disorders 106073-01-2 TANIPLON THERAPEUTIC_CLASS Sedatives/Hypnotics 106100-65-6 FASIPLON INDICATION Anxiety Disorders 106100-65-6 FASIPLON PRODUCT_CLASS Central Nervous System (CNS) 106100-65-6 FASIPLON THERAPEUTIC_CLASS Sedatives/Hypnotics 108687-08-7 TELUDIPINE MECHANISM Reduce muscle contractile force 108687-08-7 TELUDIPINE MODE_CLASS Channel Blocker 108687-08-7 TELUDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 108687-08-7 TELUDIPINE INDICATION Hypertension 108687-08-7 TELUDIPINE PRODUCT_CLASS Cardiovasculars 108785-69-9 LORPIPRAZOLE INDICATION Anxiety Disorders 108785-69-9 LORPIPRAZOLE PRODUCT_CLASS Central Nervous System (CNS) 108785-69-9 LORPIPRAZOLE THERAPEUTIC_CLASS Sedatives/Hypnotics 109683-79-6 UTIBAPRILAT MECHANISM Reduce vasoconstriction 109683-79-6 UTIBAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 109683-79-6 UTIBAPRILAT INDICATION Hypertension 109683-79-6 UTIBAPRILAT MODE_CLASS Enzyme Inhibitor 109683-79-6 UTIBAPRILAT PRODUCT_CLASS Cardiovasculars 110605-64-6 ISAGLIDOLE PRODUCT_CLASS Hormones, Endocrine and Metabolic 110605-64-6 ISAGLIDOLE THERAPEUTIC_CLASS Antidiabetic Agents 111490-36-9 ZENIPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 111974-60-8 RITOLUKAST MODE_CLASS Receptor Ligand Antagonist 111974-60-8 RITOLUKAST PRODUCT_CLASS Respiratory System 111974-60-8 RITOLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 111974-60-8 RITOLUKAST MECHANISM Modulate G-protein coupled signal transduction 111974-60-8 RITOLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 111974-60-8 RITOLUKAST INDICATION Asthma 112922-55-1 CERICLAMINE INDICATION Depression 112922-55-1 CERICLAMINE THERAPEUTIC_CLASS Antidepressants 112922-55-1 CERICLAMINE PRODUCT_CLASS Central Nervous System (CNS) 115313-22-9 SERAZEPINE THERAPEUTIC_CLASS Sedatives/Hypnotics 115313-22-9 SERAZEPINE INDICATION Anxiety Disorders 115313-22-9 SERAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 115313-22-9 SERAZEPINE MODE_CLASS Receptor Ligand Antagonist 115313-22-9 SERAZEPINE MECHANISM Modulate neural transmission 117581-05-2 SERAZEPINE MODE_CLASS Receptor Ligand Antagonist 117581-05-2 SERAZEPINE MECHANISM Modulate neural transmission 117581-05-2 SERAZEPINE INDICATION Anxiety Disorders 117581-05-2 SERAZEPINE THERAPEUTIC_CLASS Sedatives/Hypnotics 117581-05-2 SERAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 116795-97-2 LEDAZEROL INDICATION Ischemia 117827-81-3 DELFAPRAZINE INDICATION Depression 117827-81-3 DELFAPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 117827-81-3 DELFAPRAZINE THERAPEUTIC_CLASS Antidepressants 123308-22-5 SEZOLAMIDE THERAPEUTIC_CLASS Diuretics 123308-22-5 SEZOLAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 123308-22-5 SEZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 123308-22-5 SEZOLAMIDE MODE_CLASS Enzyme Inhibitor 123308-22-5 SEZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 123308-22-5 SEZOLAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 123308-22-5 SEZOLAMIDE INDICATION Glaucoma 125926-17-2 SARPOGRELATE THERAPEUTIC_CLASS Antiplatelets 125926-17-2 SARPOGRELATE MECHANISM Modulate neural transmission 125926-17-2 SARPOGRELATE MODE_CLASS Receptor Ligand Antagonist, Selective 125926-17-2 SARPOGRELATE MODE_CLASS Receptor Ligand Antagonist 125926-17-2 SARPOGRELATE MECHANISM Reduce vasoconstriction 125926-17-2 SARPOGRELATE PRODUCT_CLASS Hematologics 135159-51-2 SARPOGRELATE THERAPEUTIC_CLASS Antiplatelets 135159-51-2 SARPOGRELATE MECHANISM Reduce vasoconstriction 135159-51-2 SARPOGRELATE MODE_CLASS Receptor Ligand Antagonist 135159-51-2 SARPOGRELATE PRODUCT_CLASS Hematologics 135159-51-2 SARPOGRELATE MECHANISM Modulate neural transmission 135159-51-2 SARPOGRELATE MODE_CLASS Receptor Ligand Antagonist, Selective 128298-28-2 REMACEMIDE MODE_CLASS Channel Modulator 128298-28-2 REMACEMIDE MECHANISM Block neural transmission 128298-28-2 REMACEMIDE MODE_CLASS Channel Blocker 128298-28-2 REMACEMIDE MECHANISM Modulate neural transmission 128298-28-2 REMACEMIDE PRODUCT_CLASS Central Nervous System (CNS) 128298-28-2 REMACEMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 103060-53-3 DEPTOMYCIN STRUCTURE_ACTIVITY Impairs cell membrane function 90-22-2 VALETHAMATE BROMIDE INDICATION Renal Colic 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT EMB_2_Fetal Distress 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT NEU_2_Dizziness 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT PSY_2_Nervousness 90-22-2 VALETHAMATE BROMIDE THERAPEUTIC_CLASS Antispasmodic Agents 90-22-2 VALETHAMATE BROMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 90-22-2 VALETHAMATE BROMIDE INDICATION Augmentation of Labor 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT GIS_1_Dry Mouth 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT GIS_2_Vomiting 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT NEU_2_Headache 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT GUS_2_Urinary Retention 90-22-2 VALETHAMATE BROMIDE INDICATION Abdominal Colic 90-22-2 VALETHAMATE BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 90-22-2 VALETHAMATE BROMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT CVS_2_Palpitation 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT SKN_1_Flushing 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT OCU_2_Blurred Vision 90-22-2 VALETHAMATE BROMIDE MECHANISM Modulate G-protein coupled signal transduction 90-22-2 VALETHAMATE BROMIDE INDICATION Biliary Colic 90-22-2 VALETHAMATE BROMIDE ADVERSE_EFFECT SKN_3_Skin Rash 3571-88-8 PLATONIN INDICATION Hair Color Change 101193-40-2 QUINOTOLAST PRODUCT_CLASS Respiratory System 101193-40-2 QUINOTOLAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 101193-40-2 QUINOTOLAST INDICATION Asthma 24243-97-8 TYMAZOLINE INDICATION Nasal Congestion 40796-97-2 BEMESETRON MECHANISM Prolong/enhance neural transmission 40796-97-2 BEMESETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 40796-97-2 BEMESETRON PRODUCT_CLASS Gastrointestinal System 40796-97-2 BEMESETRON MECHANISM Block neural transmission 40796-97-2 BEMESETRON INDICATION Nausea / Vomiting 40796-97-2 BEMESETRON MODE_CLASS Solute transporter inhibitor 40796-97-2 BEMESETRON THERAPEUTIC_CLASS Antiemetics 40796-97-2 BEMESETRON MODE_CLASS Channel Blocker, selective 50865-01-5 PROTOPORPHYRIN IX INDICATION Myocardial Ischemia 53066-26-5 LEXITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 53066-26-5 LEXITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 53066-26-5 LEXITHROMYCIN PRODUCT_CLASS Anti-infectives 53066-26-5 LEXITHROMYCIN THERAPEUTIC_CLASS Antibacterials 55779-06-1 ASTROMICIN INDICATION Empyema 55779-06-1 ASTROMICIN ADVERSE_EFFECT LIV_2_Impaired Liver Function 55779-06-1 ASTROMICIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 55779-06-1 ASTROMICIN ADVERSE_EFFECT BBM_2_Anemia 55779-06-1 ASTROMICIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 55779-06-1 ASTROMICIN KNOWN_TOXICITY Cardiovascular Toxicity 55779-06-1 ASTROMICIN INDICATION Complicated Urinary Tract Infections 55779-06-1 ASTROMICIN INDICATION Bronchiestasis Complicated With Infection 55779-06-1 ASTROMICIN TISSUE_TOXICITY Acute Renal Failure 55779-06-1 ASTROMICIN ADVERSE_EFFECT OTO_3_Acoustic Nerve Damage 55779-06-1 ASTROMICIN ADVERSE_EFFECT LIV_2_Jaundice 55779-06-1 ASTROMICIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 55779-06-1 ASTROMICIN ADVERSE_EFFECT BBM_3_Leukopenia 55779-06-1 ASTROMICIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 55779-06-1 ASTROMICIN ADVERSE_EFFECT XXX_3_Edema 55779-06-1 ASTROMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 55779-06-1 ASTROMICIN INDICATION Peritonitis 55779-06-1 ASTROMICIN MECHANISM Inhibit ribosomal protein synthesis 55779-06-1 ASTROMICIN INDICATION Acute Pyelonephritis 55779-06-1 ASTROMICIN PRODUCT_CLASS Anti-infectives 55779-06-1 ASTROMICIN INDICATION Chronic Bronchitis 55779-06-1 ASTROMICIN ADVERSE_EFFECT NEU_3_Numbness 55779-06-1 ASTROMICIN ADVERSE_EFFECT KID_3_Acute Renal Failure 55779-06-1 ASTROMICIN ADVERSE_EFFECT KID_3_Hematuria 55779-06-1 ASTROMICIN ADVERSE_EFFECT KID_3_Nephrotoxicity 55779-06-1 ASTROMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 55779-06-1 ASTROMICIN ADVERSE_EFFECT OTO_3_Tinnitus 55779-06-1 ASTROMICIN TISSUE_TOXICITY Shock 55779-06-1 ASTROMICIN INDICATION Sepsis 55779-06-1 ASTROMICIN TISSUE_TOXICITY Nephrotoxicity 55779-06-1 ASTROMICIN TISSUE_TOXICITY Hematuria 55779-06-1 ASTROMICIN KNOWN_TOXICITY Nephrotoxicity 55779-06-1 ASTROMICIN ADVERSE_EFFECT GIS_3_Stomatitis 55779-06-1 ASTROMICIN ADVERSE_EFFECT KID_3_Proteinuria 55779-06-1 ASTROMICIN ADVERSE_EFFECT OTO_3_Vestibular Toxicity 55779-06-1 ASTROMICIN ADVERSE_EFFECT CVS_3_Shock 55779-06-1 ASTROMICIN ADVERSE_EFFECT OTO_3_Ototoxicity 55779-06-1 ASTROMICIN ADVERSE_EFFECT GIS_2_Diarrhea 55779-06-1 ASTROMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 55779-06-1 ASTROMICIN INDICATION Pneumonia 55779-06-1 ASTROMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 55779-06-1 ASTROMICIN ADVERSE_EFFECT SKN_3_Skin Rash 55779-06-1 ASTROMICIN ADVERSE_EFFECT OTO_3_Hearing Loss 58546-54-6 BESIGOMSIN INDICATION Hypercholesterolemia 58546-54-6 BESIGOMSIN PRODUCT_CLASS Cardiovasculars 58546-54-6 BESIGOMSIN THERAPEUTIC_CLASS Hypolipidemic Agents 65617-86-9 AVIZAFONE THERAPEUTIC_CLASS Sedatives/Hypnotics 65617-86-9 AVIZAFONE PRODUCT_CLASS Central Nervous System (CNS) 65617-86-9 AVIZAFONE INDICATION Anxiety Disorders 77016-85-4 PLOMESTANE MODE_CLASS Enzyme Inhibitor 77016-85-4 PLOMESTANE PRODUCT_CLASS Anti-cancers 77016-85-4 PLOMESTANE THERAPEUTIC_CLASS Antineoplastics 77016-85-4 PLOMESTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 77016-85-4 PLOMESTANE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 78628-28-1 ROXATIDINE ACETATE MODE_CLASS Receptor Ligand Antagonist 78628-28-1 ROXATIDINE ACETATE PRODUCT_CLASS Gastrointestinal System 78628-28-1 ROXATIDINE ACETATE MECHANISM Reduce stomach HCl secretion 78628-28-1 ROXATIDINE ACETATE INDICATION Peptic Ulcer Disease (PUD) 78628-28-1 ROXATIDINE ACETATE INDICATION Gastroesophageal Reflux Disease (GERD) 78628-28-1 ROXATIDINE ACETATE THERAPEUTIC_CLASS Antiulcers 78628-28-1 ROXATIDINE ACETATE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 93793-83-0 ROXATIDINE ACETATE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 93793-83-0 ROXATIDINE ACETATE PRODUCT_CLASS Gastrointestinal System 93793-83-0 ROXATIDINE ACETATE THERAPEUTIC_CLASS Antiulcers 93793-83-0 ROXATIDINE ACETATE MECHANISM Reduce stomach HCl secretion 93793-83-0 ROXATIDINE ACETATE MODE_CLASS Receptor Ligand Antagonist 93793-83-0 ROXATIDINE ACETATE INDICATION Peptic Ulcer Disease (PUD) 93793-83-0 ROXATIDINE ACETATE INDICATION Gastroesophageal Reflux Disease (GERD) 80433-71-2 LEVOLEUCOVORIN CALCIUM INDICATION Folic Acid Toxicity 83482-77-3 VINMEGALLATE INDICATION Psoriasis 84845-57-8 RITIPENEM THERAPEUTIC_CLASS Antibacterials 84845-57-8 RITIPENEM MECHANISM Inhibit bacterial cell wall biosynthesis 84845-57-8 RITIPENEM MODE_CLASS Enzyme Inhibitor 84845-57-8 RITIPENEM PRODUCT_CLASS Anti-infectives 88303-60-0 LOSOXANTRONE STRUCTURE_ACTIVITY DNA intercalator 96515-73-0 PALONIDIPINE INDICATION Hypertension 96515-73-0 PALONIDIPINE MODE_CLASS Channel Blocker 96515-73-0 PALONIDIPINE PRODUCT_CLASS Cardiovasculars 96515-73-0 PALONIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 96515-73-0 PALONIDIPINE MECHANISM Reduce muscle contractile force 96515-73-0 PALONIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 97901-21-8 NAFAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 97901-21-8 NAFAGREL PRODUCT_CLASS Respiratory System 97901-21-8 NAFAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 97901-21-8 NAFAGREL MODE_CLASS Enzyme Inhibitor 97901-21-8 NAFAGREL PRODUCT_CLASS Cardiovasculars 97901-21-8 NAFAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 97901-21-8 NAFAGREL MECHANISM Inhibit eicosanoid biosynthesis 97901-22-9 NAFAGREL MECHANISM Inhibit eicosanoid biosynthesis 97901-22-9 NAFAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 97901-22-9 NAFAGREL PRODUCT_CLASS Respiratory System 97901-22-9 NAFAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 97901-22-9 NAFAGREL MODE_CLASS Enzyme Inhibitor 97901-22-9 NAFAGREL PRODUCT_CLASS Cardiovasculars 97901-22-9 NAFAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 99287-30-6 EGUALEN INDICATION Ulcer 103177-37-3 PRANLUKAST MECHANISM Modulate G-protein coupled signal transduction 103177-37-3 PRANLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 103177-37-3 PRANLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 103177-37-3 PRANLUKAST INDICATION Allergic Rhinitis 103177-37-3 PRANLUKAST MODE_CLASS Receptor Ligand Antagonist 103177-37-3 PRANLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 103177-37-3 PRANLUKAST PRODUCT_CLASS Respiratory System 103177-37-3 PRANLUKAST INDICATION Asthma 103180-28-5 PRANLUKAST INDICATION Asthma 103180-28-5 PRANLUKAST PRODUCT_CLASS Respiratory System 103180-28-5 PRANLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 103180-28-5 PRANLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 103180-28-5 PRANLUKAST INDICATION Allergic Rhinitis 103180-28-5 PRANLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 103180-28-5 PRANLUKAST MODE_CLASS Receptor Ligand Antagonist 103180-28-5 PRANLUKAST MECHANISM Modulate G-protein coupled signal transduction 103336-05-6 DITEKIREN MODE_CLASS Enzyme Inhibitor 103336-05-6 DITEKIREN THERAPEUTIC_CLASS Antihypertensive Agents 103336-05-6 DITEKIREN MECHANISM Reduce vasoconstriction 103336-05-6 DITEKIREN INDICATION Hypertension 103336-05-6 DITEKIREN PRODUCT_CLASS Cardiovasculars 103466-73-5 ICOMETHASONE ENBUTATE MODE_CLASS Receptor Agonist 103466-73-5 ICOMETHASONE ENBUTATE THERAPEUTIC_CLASS Corticosteroids 103466-73-5 ICOMETHASONE ENBUTATE MECHANISM Modulate gene transcription 103466-73-5 ICOMETHASONE ENBUTATE PRODUCT_CLASS Anti-inflammatories 103775-14-0 MOEXIPRILAT INDICATION Hypertension 103775-14-0 MOEXIPRILAT MECHANISM Reduce vasoconstriction 103775-14-0 MOEXIPRILAT PRODUCT_CLASS Cardiovasculars 103775-14-0 MOEXIPRILAT MODE_CLASS Enzyme Inhibitor 103775-14-0 MOEXIPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 103844-77-5 NECOPIDEM MODE_CLASS Channel Modulator 103844-77-5 NECOPIDEM THERAPEUTIC_CLASS Sedatives/Hypnotics 103844-77-5 NECOPIDEM PRODUCT_CLASS Central Nervous System (CNS) 103844-77-5 NECOPIDEM MECHANISM Modulate neural transmission 103878-84-8 LAZABEMIDE PRODUCT_CLASS Central Nervous System (CNS) 103878-84-8 LAZABEMIDE INDICATION Parkinson's Disease 103878-84-8 LAZABEMIDE THERAPEUTIC_CLASS Antidepressants 103878-84-8 LAZABEMIDE INDICATION Depression 103878-84-8 LAZABEMIDE INDICATION Smoking Cessation 103878-83-7 LAZABEMIDE PRODUCT_CLASS Central Nervous System (CNS) 103878-83-7 LAZABEMIDE INDICATION Parkinson's Disease 103878-83-7 LAZABEMIDE THERAPEUTIC_CLASS Antidepressants 103878-83-7 LAZABEMIDE INDICATION Depression 103878-83-7 LAZABEMIDE INDICATION Smoking Cessation 104145-95-1 CEFDITOREN THERAPEUTIC_CLASS Antibacterials 104145-95-1 CEFDITOREN MODE_CLASS Enzyme Inhibitor 104145-95-1 CEFDITOREN PRODUCT_CLASS Anti-infectives 104145-95-1 CEFDITOREN MECHANISM Inhibit bacterial cell wall biosynthesis 104713-75-9 BARNIDIPINE PRODUCT_CLASS Cardiovasculars 104713-75-9 BARNIDIPINE INDICATION Hypertension 104713-75-9 BARNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 104713-75-9 BARNIDIPINE THERAPEUTIC_CLASS Antianginals 104713-75-9 BARNIDIPINE MECHANISM Reduce muscle contractile force 104713-75-9 BARNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 104713-75-9 BARNIDIPINE INDICATION Angina Pectoris 104713-75-9 BARNIDIPINE MODE_CLASS Channel Blocker 71863-55-3 BARNIDIPINE PRODUCT_CLASS Cardiovasculars 71863-55-3 BARNIDIPINE MODE_CLASS Channel Blocker 71863-55-3 BARNIDIPINE INDICATION Hypertension 71863-55-3 BARNIDIPINE INDICATION Angina Pectoris 71863-55-3 BARNIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 71863-55-3 BARNIDIPINE MECHANISM Reduce muscle contractile force 71863-55-3 BARNIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 71863-55-3 BARNIDIPINE THERAPEUTIC_CLASS Antianginals 104775-36-2 ECABAPIDE INDICATION Ulcer 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT MSK_3_Muscle Twitching 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 105956-97-6 CLINAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 105956-97-6 CLINAFLOXACIN INDICATION Community-Acquired Pneumonia 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 105956-97-6 CLINAFLOXACIN INDICATION Febrile Neutropenia 105956-97-6 CLINAFLOXACIN INDICATION Pelvic Inflammatory Disease (PID) 105956-97-6 CLINAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT NEU_3_Somnolence 105956-97-6 CLINAFLOXACIN INDICATION Infective Endocarditis 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 105956-97-6 CLINAFLOXACIN INDICATION Intraabdominal Infections 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT CVS_1_Vasodilation 105956-97-6 CLINAFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT PSY_3_Confusion 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 105956-97-6 CLINAFLOXACIN INDICATION Complicated Urinary Tract Infections 105956-97-6 CLINAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT NEU_1_Headache 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT NEU_3_Seizures 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT PSY_3_Agitation 105956-97-6 CLINAFLOXACIN PRODUCT_CLASS Anti-infectives 105956-97-6 CLINAFLOXACIN INDICATION Skin and Skin Structure Infections 105956-97-6 CLINAFLOXACIN ADVERSE_EFFECT OCU_3_Diplopia 105956-97-6 CLINAFLOXACIN INDICATION Nosocomial Pneumonia 106133-20-4 AMSULOSIN THERAPEUTIC_CLASS Sympatholytic Agents 106133-20-4 AMSULOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 106133-20-4 AMSULOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 106133-20-4 AMSULOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 106133-20-4 AMSULOSIN MECHANISM Modulate G-protein coupled signal transduction 80223-99-0 AMSULOSIN THERAPEUTIC_CLASS Sympatholytic Agents 80223-99-0 AMSULOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 80223-99-0 AMSULOSIN MECHANISM Modulate G-protein coupled signal transduction 80223-99-0 AMSULOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 80223-99-0 AMSULOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 106463-17-6 AMSULOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 106463-17-6 AMSULOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 106463-17-6 AMSULOSIN MECHANISM Modulate G-protein coupled signal transduction 106463-17-6 AMSULOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 106463-17-6 AMSULOSIN THERAPEUTIC_CLASS Sympatholytic Agents 109229-58-5 ENGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 109229-58-5 ENGLITAZONE INDICATION Type II Diabetes Mellitus 109229-58-5 ENGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 109229-58-5 ENGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 109229-58-5 ENGLITAZONE MECHANISM Increase transcription of insulin responsive gene 109229-58-5 ENGLITAZONE MECHANISM Increase lipid catabolism 109229-58-5 ENGLITAZONE MODE_CLASS Receptor Agonist 109826-26-8 ZALDARIDE INDICATION Diarrhea 109826-26-8 ZALDARIDE INDICATION Ulcer 110845-89-1 REMIPROSTOL INDICATION Ulcer 111011-63-3 EFONIDIPINE MODE_CLASS Channel Blocker 111011-63-3 EFONIDIPINE MECHANISM Reduce muscle contractile force 111011-63-3 EFONIDIPINE PRODUCT_CLASS Cardiovasculars 111011-63-3 EFONIDIPINE INDICATION Hypertension 111011-63-3 EFONIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 111011-63-3 EFONIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 111011-76-8 EFONIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 111011-76-8 EFONIDIPINE PRODUCT_CLASS Cardiovasculars 111011-76-8 EFONIDIPINE MECHANISM Reduce muscle contractile force 111011-76-8 EFONIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 111011-76-8 EFONIDIPINE MODE_CLASS Channel Blocker 111011-76-8 EFONIDIPINE INDICATION Hypertension 111523-41-2 ENLOPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 111753-73-2 SATIGREL PRODUCT_CLASS Hematologics 111753-73-2 SATIGREL INDICATION Transient Ischemic Attacks Prophylaxis 111753-73-2 SATIGREL INDICATION Improve Graft Function in Renal Transplant 111753-73-2 SATIGREL INDICATION Intermittent Claudication 111753-73-2 SATIGREL THERAPEUTIC_CLASS Antiplatelets 111902-57-9 TEMOCAPRIL MODE_CLASS Enzyme Inhibitor 111902-57-9 TEMOCAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 111902-57-9 TEMOCAPRIL MECHANISM Reduce vasoconstriction 111902-57-9 TEMOCAPRIL INDICATION Hypertension 111902-57-9 TEMOCAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 111902-57-9 TEMOCAPRIL PRODUCT_CLASS Cardiovasculars 110221-44-8 TEMOCAPRIL INDICATION Hypertension 110221-44-8 TEMOCAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 110221-44-8 TEMOCAPRIL PRODUCT_CLASS Cardiovasculars 110221-44-8 TEMOCAPRIL MECHANISM Reduce vasoconstriction 110221-44-8 TEMOCAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 110221-44-8 TEMOCAPRIL MODE_CLASS Enzyme Inhibitor 102090-90-4 TEMOCAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 102090-90-4 TEMOCAPRIL MECHANISM Reduce vasoconstriction 102090-90-4 TEMOCAPRIL PRODUCT_CLASS Cardiovasculars 102090-90-4 TEMOCAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 102090-90-4 TEMOCAPRIL INDICATION Hypertension 102090-90-4 TEMOCAPRIL MODE_CLASS Enzyme Inhibitor 113359-04-9 CEFOZOPRAN THERAPEUTIC_CLASS Antibacterials 113359-04-9 CEFOZOPRAN PRODUCT_CLASS Anti-infectives 113359-04-9 CEFOZOPRAN MODE_CLASS Enzyme Inhibitor 113359-04-9 CEFOZOPRAN MECHANISM Inhibit bacterial cell wall biosynthesis 123572-81-6 CEFOZOPRAN MODE_CLASS Enzyme Inhibitor 123572-81-6 CEFOZOPRAN PRODUCT_CLASS Anti-infectives 123572-81-6 CEFOZOPRAN MECHANISM Inhibit bacterial cell wall biosynthesis 123572-81-6 CEFOZOPRAN THERAPEUTIC_CLASS Antibacterials 123572-84-9 CEFOZOPRAN PRODUCT_CLASS Anti-infectives 123572-84-9 CEFOZOPRAN MODE_CLASS Enzyme Inhibitor 123572-84-9 CEFOZOPRAN MECHANISM Inhibit bacterial cell wall biosynthesis 123572-84-9 CEFOZOPRAN THERAPEUTIC_CLASS Antibacterials 125905-00-2 CEFOZOPRAN PRODUCT_CLASS Anti-infectives 125905-00-2 CEFOZOPRAN MODE_CLASS Enzyme Inhibitor 125905-00-2 CEFOZOPRAN MECHANISM Inhibit bacterial cell wall biosynthesis 125905-00-2 CEFOZOPRAN THERAPEUTIC_CLASS Antibacterials 142352-46-3 CEFOZOPRAN THERAPEUTIC_CLASS Antibacterials 142352-46-3 CEFOZOPRAN MECHANISM Inhibit bacterial cell wall biosynthesis 142352-46-3 CEFOZOPRAN PRODUCT_CLASS Anti-infectives 142352-46-3 CEFOZOPRAN MODE_CLASS Enzyme Inhibitor 203311-40-4 CEFOZOPRAN PRODUCT_CLASS Anti-infectives 203311-40-4 CEFOZOPRAN MODE_CLASS Enzyme Inhibitor 203311-40-4 CEFOZOPRAN MECHANISM Inhibit bacterial cell wall biosynthesis 203311-40-4 CEFOZOPRAN THERAPEUTIC_CLASS Antibacterials 114298-18-9 ZALOSPIRONE MECHANISM Modulate neural transmission 114298-18-9 ZALOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 114298-18-9 ZALOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 114298-18-9 ZALOSPIRONE INDICATION Anxiety Disorders 114298-18-9 ZALOSPIRONE MODE_CLASS Receptor Agonist 114298-18-9 ZALOSPIRONE INDICATION Depression 114298-18-9 ZALOSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 114298-18-9 ZALOSPIRONE THERAPEUTIC_CLASS Antidepressants 114374-97-9 ZALOSPIRONE INDICATION Depression 114374-97-9 ZALOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 114374-97-9 ZALOSPIRONE INDICATION Anxiety Disorders 114374-97-9 ZALOSPIRONE MODE_CLASS Receptor Agonist 114374-97-9 ZALOSPIRONE MECHANISM Modulate neural transmission 114374-97-9 ZALOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 114374-97-9 ZALOSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 114374-97-9 ZALOSPIRONE THERAPEUTIC_CLASS Antidepressants 110944-55-3 ZALOSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 110944-55-3 ZALOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 110944-55-3 ZALOSPIRONE MECHANISM Modulate neural transmission 110944-55-3 ZALOSPIRONE MODE_CLASS Receptor Agonist 110944-55-3 ZALOSPIRONE INDICATION Anxiety Disorders 110944-55-3 ZALOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 110944-55-3 ZALOSPIRONE INDICATION Depression 110944-55-3 ZALOSPIRONE THERAPEUTIC_CLASS Antidepressants 114432-13-2 FANTOFARONE THERAPEUTIC_CLASS Antihypertensive Agents 114432-13-2 FANTOFARONE MODE_CLASS Channel Modulator 114432-13-2 FANTOFARONE PRODUCT_CLASS Cardiovasculars 114432-13-2 FANTOFARONE MECHANISM Modulate channel gating 82219-78-1 CEFUZONAM THERAPEUTIC_CLASS Antibacterials 82219-78-1 CEFUZONAM MODE_CLASS Enzyme Inhibitor 82219-78-1 CEFUZONAM PRODUCT_CLASS Anti-infectives 82219-78-1 CEFUZONAM MECHANISM Inhibit bacterial cell wall biosynthesis 82413-20-5 DROLOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 82413-20-5 DROLOXIFENE PRODUCT_CLASS Anti-cancers 82413-20-5 DROLOXIFENE MECHANISM Modulate gene transcription 82413-20-5 DROLOXIFENE MODE_CLASS Receptor Ligand Antagonist 82547-58-8 CEFTERAM MECHANISM Inhibit bacterial cell wall biosynthesis 82547-58-8 CEFTERAM THERAPEUTIC_CLASS Antibacterials 82547-58-8 CEFTERAM MODE_CLASS Enzyme Inhibitor 82547-58-8 CEFTERAM PRODUCT_CLASS Anti-infectives 82571-53-7 OZAGREL ADVERSE_EFFECT MSK_3_Arthralgia 82571-53-7 OZAGREL TISSUE_TOXICITY Hemorrhagic Stroke 82571-53-7 OZAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 82571-53-7 OZAGREL INDICATION Asthma 82571-53-7 OZAGREL KNOWN_TOXICITY Cardiovascular Toxicity 82571-53-7 OZAGREL THERAPEUTIC_CLASS Antiplatelets 82571-53-7 OZAGREL KNOWN_TOXICITY Nephrotoxicity 82571-53-7 OZAGREL TISSUE_TOXICITY Acute Renal Failure 82571-53-7 OZAGREL ADVERSE_EFFECT SKN_2_Rash 82571-53-7 OZAGREL ADVERSE_EFFECT CVS_3_Shock 82571-53-7 OZAGREL ADVERSE_EFFECT KID_3_Acute Renal Failure 82571-53-7 OZAGREL ADVERSE_EFFECT BBM_3_Hemorrhage 82571-53-7 OZAGREL ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 82571-53-7 OZAGREL INDICATION Improve Movement Disorder Associated With Cerebral Thrombosis (Acute Phase) 82571-53-7 OZAGREL PRODUCT_CLASS Respiratory System 82571-53-7 OZAGREL PRODUCT_CLASS Central Nervous System (CNS) 82571-53-7 OZAGREL TISSUE_TOXICITY Supraventricular Arrhythmia 82571-53-7 OZAGREL ADVERSE_EFFECT XXX_3_Edema 82571-53-7 OZAGREL ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 82571-53-7 OZAGREL MODE_CLASS Enzyme Inhibitor 82571-53-7 OZAGREL ADVERSE_EFFECT BBM_3_Thrombocytopenia 82571-53-7 OZAGREL ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 82571-53-7 OZAGREL ADVERSE_EFFECT CVS_3_Supraventricular Arrhythmia 82571-53-7 OZAGREL TISSUE_TOXICITY Shock 82571-53-7 OZAGREL ADVERSE_EFFECT KID_3_Increased Creatinine 82571-53-7 OZAGREL ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 82571-53-7 OZAGREL ADVERSE_EFFECT IMU_3_Hypersensitivity 82571-53-7 OZAGREL INDICATION Improve Cerebral Vasospasms Following Surgery for Subarachnoid Hemorrhage 82571-53-7 OZAGREL MECHANISM Inhibit eicosanoid biosynthesis 82571-53-7 OZAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 82571-53-7 OZAGREL ADVERSE_EFFECT BBM_3_Leukopenia 82571-53-7 OZAGREL ADVERSE_EFFECT BBM_3_Granulocytopenia 82571-53-7 OZAGREL ADVERSE_EFFECT CVS_3_Hemorrhagic Stroke 82571-53-7 OZAGREL ADVERSE_EFFECT BBM_2_Anemia 82571-53-7 OZAGREL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 78712-43-3 OZAGREL TISSUE_TOXICITY Shock 78712-43-3 OZAGREL MODE_CLASS Enzyme Inhibitor 78712-43-3 OZAGREL ADVERSE_EFFECT KID_3_Increased Creatinine 78712-43-3 OZAGREL PRODUCT_CLASS Respiratory System 78712-43-3 OZAGREL ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 78712-43-3 OZAGREL ADVERSE_EFFECT MSK_3_Arthralgia 78712-43-3 OZAGREL ADVERSE_EFFECT IMU_3_Hypersensitivity 78712-43-3 OZAGREL INDICATION Improve Cerebral Vasospasms Following Surgery for Subarachnoid Hemorrhage 78712-43-3 OZAGREL MECHANISM Inhibit eicosanoid biosynthesis 78712-43-3 OZAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 78712-43-3 OZAGREL ADVERSE_EFFECT BBM_3_Granulocytopenia 78712-43-3 OZAGREL ADVERSE_EFFECT CVS_3_Hemorrhagic Stroke 78712-43-3 OZAGREL ADVERSE_EFFECT BBM_2_Anemia 78712-43-3 OZAGREL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 78712-43-3 OZAGREL TISSUE_TOXICITY Hemorrhagic Stroke 78712-43-3 OZAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 78712-43-3 OZAGREL INDICATION Asthma 78712-43-3 OZAGREL THERAPEUTIC_CLASS Antiplatelets 78712-43-3 OZAGREL ADVERSE_EFFECT CVS_3_Supraventricular Arrhythmia 78712-43-3 OZAGREL ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 78712-43-3 OZAGREL PRODUCT_CLASS Central Nervous System (CNS) 78712-43-3 OZAGREL TISSUE_TOXICITY Supraventricular Arrhythmia 78712-43-3 OZAGREL ADVERSE_EFFECT XXX_3_Edema 78712-43-3 OZAGREL ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 78712-43-3 OZAGREL ADVERSE_EFFECT BBM_3_Thrombocytopenia 78712-43-3 OZAGREL TISSUE_TOXICITY Acute Renal Failure 78712-43-3 OZAGREL KNOWN_TOXICITY Cardiovascular Toxicity 78712-43-3 OZAGREL ADVERSE_EFFECT BBM_3_Hemorrhage 78712-43-3 OZAGREL KNOWN_TOXICITY Nephrotoxicity 78712-43-3 OZAGREL ADVERSE_EFFECT SKN_2_Rash 78712-43-3 OZAGREL ADVERSE_EFFECT CVS_3_Shock 78712-43-3 OZAGREL ADVERSE_EFFECT BBM_3_Leukopenia 78712-43-3 OZAGREL ADVERSE_EFFECT KID_3_Acute Renal Failure 78712-43-3 OZAGREL ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 78712-43-3 OZAGREL INDICATION Improve Movement Disorder Associated With Cerebral Thrombosis (Acute Phase) 82924-03-6 PENTOPRIL MECHANISM Reduce vasoconstriction 82924-03-6 PENTOPRIL INDICATION Hypertension 82924-03-6 PENTOPRIL PRODUCT_CLASS Cardiovasculars 82924-03-6 PENTOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 82924-03-6 PENTOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 82924-03-6 PENTOPRIL MODE_CLASS Enzyme Inhibitor 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_2_Fatigue 83015-26-3 TOMOXETINE THERAPEUTIC_CLASS Antidepressants 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 83015-26-3 TOMOXETINE ADVERSE_EFFECT MSK_2_Myalgia 83015-26-3 TOMOXETINE ADVERSE_EFFECT CVS_3_Palpitation 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_2_Rhinorrhea 83015-26-3 TOMOXETINE ADVERSE_EFFECT NEU_3_Tremor 83015-26-3 TOMOXETINE MODE_CLASS Channel Blocker 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_2_Diaphoresis 83015-26-3 TOMOXETINE ADVERSE_EFFECT NEU_3_Drowsiness 83015-26-3 TOMOXETINE ADVERSE_EFFECT GIS_1_Abdominal Pain 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_3_Chills 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Decreased Libido 83015-26-3 TOMOXETINE ADVERSE_EFFECT GIS_2_Diarrhea 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Dysmenorrhea 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Erectile Dysfunction 83015-26-3 TOMOXETINE ADVERSE_EFFECT GIS_2_Dyspepsia 83015-26-3 TOMOXETINE STRUCTURE_ACTIVITY Norepinephrine uptake inhibitor, specific 83015-26-3 TOMOXETINE KNOWN_TOXICITY Hepatotoxicity 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Female Orgasm Dysfunction 83015-26-3 TOMOXETINE ADVERSE_EFFECT END_3_Growth Inhibition 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_1_Insomnia 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_2_Fever 83015-26-3 TOMOXETINE ADVERSE_EFFECT NEU_1_Headache 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_3_Irritability 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Menstrual Irregularities 83015-26-3 TOMOXETINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 83015-26-3 TOMOXETINE ADVERSE_EFFECT OCU_2_Mydriasis 83015-26-3 TOMOXETINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 83015-26-3 TOMOXETINE ADVERSE_EFFECT GUS_2_Urinary Retention 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_1_Xerostomia 83015-26-3 TOMOXETINE INDICATION Depression 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_3_Depression 83015-26-3 TOMOXETINE ADVERSE_EFFECT GUS_3_Discoloration of Urine 83015-26-3 TOMOXETINE ADVERSE_EFFECT NEU_2_Paresthesia 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_2_Emotional Lability 83015-26-3 TOMOXETINE ADVERSE_EFFECT CVS_3_Chest Pain 83015-26-3 TOMOXETINE MECHANISM Block channel gating 83015-26-3 TOMOXETINE TISSUE_TOXICITY Hepatic Failure 83015-26-3 TOMOXETINE ADVERSE_EFFECT SKN_2_Flushing 83015-26-3 TOMOXETINE ADVERSE_EFFECT CVS_2_Hypertension 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_3_Mania 83015-26-3 TOMOXETINE ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 83015-26-3 TOMOXETINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 83015-26-3 TOMOXETINE ADVERSE_EFFECT SKN_3_Rash 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_2_Anorexia 83015-26-3 TOMOXETINE ADVERSE_EFFECT LUN_1_Cough 83015-26-3 TOMOXETINE INDICATION Depression 83015-26-3 TOMOXETINE ADVERSE_EFFECT SKN_2_Dermatitis 83015-26-3 TOMOXETINE ADVERSE_EFFECT NEU_2_Dizziness 83015-26-3 TOMOXETINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 83015-26-3 TOMOXETINE ADVERSE_EFFECT GIS_2_Flatulence 83015-26-3 TOMOXETINE ADVERSE_EFFECT LIV_3_Hepatic Failure 83015-26-3 TOMOXETINE ADVERSE_EFFECT LIV_3_Jaundice 83015-26-3 TOMOXETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83015-26-3 TOMOXETINE ADVERSE_EFFECT SKN_3_Pruritis 83015-26-3 TOMOXETINE ADVERSE_EFFECT XXX_2_Sinusitis 83015-26-3 TOMOXETINE ADVERSE_EFFECT IMU_3_Urticaria 83015-26-3 TOMOXETINE PRODUCT_CLASS Central Nervous System (CNS) 83015-26-3 TOMOXETINE ADVERSE_EFFECT PSY_3_Agitation 83015-26-3 TOMOXETINE ADVERSE_EFFECT GIS_2_Constipation 82857-40-7 TOMOXETINE ADVERSE_EFFECT GIS_2_Dyspepsia 82857-40-7 TOMOXETINE ADVERSE_EFFECT SKN_2_Flushing 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_2_Fatigue 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_2_Fever 82857-40-7 TOMOXETINE ADVERSE_EFFECT NEU_1_Headache 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_3_Irritability 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Menstrual Irregularities 82857-40-7 TOMOXETINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 82857-40-7 TOMOXETINE ADVERSE_EFFECT OCU_2_Mydriasis 82857-40-7 TOMOXETINE ADVERSE_EFFECT NEU_2_Paresthesia 82857-40-7 TOMOXETINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 82857-40-7 TOMOXETINE ADVERSE_EFFECT GUS_2_Urinary Retention 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_1_Xerostomia 82857-40-7 TOMOXETINE TISSUE_TOXICITY Hepatic Failure 82857-40-7 TOMOXETINE INDICATION Depression 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_2_Diaphoresis 82857-40-7 TOMOXETINE MODE_CLASS Channel Blocker 82857-40-7 TOMOXETINE ADVERSE_EFFECT NEU_3_Tremor 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_2_Rhinorrhea 82857-40-7 TOMOXETINE ADVERSE_EFFECT CVS_3_Palpitation 82857-40-7 TOMOXETINE ADVERSE_EFFECT MSK_2_Myalgia 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_1_Insomnia 82857-40-7 TOMOXETINE ADVERSE_EFFECT END_3_Growth Inhibition 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Female Orgasm Dysfunction 82857-40-7 TOMOXETINE KNOWN_TOXICITY Hepatotoxicity 82857-40-7 TOMOXETINE STRUCTURE_ACTIVITY Norepinephrine uptake inhibitor, specific 82857-40-7 TOMOXETINE ADVERSE_EFFECT NEU_3_Drowsiness 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_2_Emotional Lability 82857-40-7 TOMOXETINE ADVERSE_EFFECT CVS_3_Chest Pain 82857-40-7 TOMOXETINE MECHANISM Block channel gating 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Erectile Dysfunction 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Dysmenorrhea 82857-40-7 TOMOXETINE ADVERSE_EFFECT GIS_2_Diarrhea 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Decreased Libido 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_3_Chills 82857-40-7 TOMOXETINE ADVERSE_EFFECT GIS_1_Abdominal Pain 82857-40-7 TOMOXETINE THERAPEUTIC_CLASS Antidepressants 82857-40-7 TOMOXETINE ADVERSE_EFFECT GUS_3_Discoloration of Urine 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_3_Depression 82857-40-7 TOMOXETINE ADVERSE_EFFECT GIS_2_Constipation 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_3_Agitation 82857-40-7 TOMOXETINE PRODUCT_CLASS Central Nervous System (CNS) 82857-40-7 TOMOXETINE ADVERSE_EFFECT IMU_3_Urticaria 82857-40-7 TOMOXETINE ADVERSE_EFFECT XXX_2_Sinusitis 82857-40-7 TOMOXETINE ADVERSE_EFFECT SKN_3_Pruritis 82857-40-7 TOMOXETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 82857-40-7 TOMOXETINE ADVERSE_EFFECT LIV_3_Jaundice 82857-40-7 TOMOXETINE ADVERSE_EFFECT LIV_3_Hepatic Failure 82857-40-7 TOMOXETINE ADVERSE_EFFECT GIS_2_Flatulence 82857-40-7 TOMOXETINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 82857-40-7 TOMOXETINE ADVERSE_EFFECT NEU_2_Dizziness 82857-40-7 TOMOXETINE ADVERSE_EFFECT SKN_2_Dermatitis 82857-40-7 TOMOXETINE INDICATION Depression 82857-40-7 TOMOXETINE ADVERSE_EFFECT LUN_1_Cough 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_2_Anorexia 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 82857-40-7 TOMOXETINE ADVERSE_EFFECT SKN_3_Rash 82857-40-7 TOMOXETINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 82857-40-7 TOMOXETINE ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 82857-40-7 TOMOXETINE ADVERSE_EFFECT PSY_3_Mania 82857-40-7 TOMOXETINE ADVERSE_EFFECT CVS_2_Hypertension 83200-08-2 EPROXINDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 83200-08-2 EPROXINDINE INDICATION Cardiac Arrhythmias 83200-08-2 EPROXINDINE PRODUCT_CLASS Cardiovasculars 83200-10-6 ANIPAMIL MODE_CLASS Channel Blocker 83200-10-6 ANIPAMIL MECHANISM Reduce muscle contractile force 83435-66-9 DELAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 83435-66-9 DELAPRIL INDICATION Hypertension 83435-66-9 DELAPRIL MODE_CLASS Enzyme Inhibitor 83435-66-9 DELAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 83435-66-9 DELAPRIL PRODUCT_CLASS Cardiovasculars 83435-66-9 DELAPRIL MECHANISM Reduce vasoconstriction 83435-67-0 DELAPRIL MECHANISM Reduce vasoconstriction 83435-67-0 DELAPRIL PRODUCT_CLASS Cardiovasculars 83435-67-0 DELAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 83435-67-0 DELAPRIL INDICATION Hypertension 83435-67-0 DELAPRIL MODE_CLASS Enzyme Inhibitor 83435-67-0 DELAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 83602-05-5 SPIRAPRILAT INDICATION Hypertension 83602-05-5 SPIRAPRILAT MODE_CLASS Enzyme Inhibitor 83602-05-5 SPIRAPRILAT MECHANISM Reduce vasoconstriction 83602-05-5 SPIRAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 83602-05-5 SPIRAPRILAT PRODUCT_CLASS Cardiovasculars 83880-70-0 DEXAMETHASONE ACEFURATE MECHANISM Modulate gene transcription 83880-70-0 DEXAMETHASONE ACEFURATE PRODUCT_CLASS Anti-inflammatories 83880-70-0 DEXAMETHASONE ACEFURATE MODE_CLASS Receptor Agonist 83880-70-0 DEXAMETHASONE ACEFURATE THERAPEUTIC_CLASS Corticosteroids 83903-06-4 LUPITIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 83903-06-4 LUPITIDINE MECHANISM Reduce stomach HCl secretion 84071-15-8 RAMIXOTIDINE INDICATION Ulcer 84145-89-1 ALMOXATONE PRODUCT_CLASS Central Nervous System (CNS) 84145-89-1 ALMOXATONE INDICATION Depression 84145-89-1 ALMOXATONE THERAPEUTIC_CLASS Antidepressants 84408-37-7 DESCICLOVIR THERAPEUTIC_CLASS Antivirals 84408-37-7 DESCICLOVIR MECHANISM Inhibit viral DNA synthesis 84408-37-7 DESCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 84408-37-7 DESCICLOVIR PRODUCT_CLASS Anti-infectives 84408-37-7 DESCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 85287-61-2 CEFPIMIZOLE MODE_CLASS Enzyme Inhibitor 85287-61-2 CEFPIMIZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 85287-61-2 CEFPIMIZOLE THERAPEUTIC_CLASS Antibacterials 85287-61-2 CEFPIMIZOLE PRODUCT_CLASS Anti-infectives 85053-46-9 SURICAINIDE PRODUCT_CLASS Cardiovasculars 85053-46-9 SURICAINIDE INDICATION Depression 85053-46-9 SURICAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 85053-46-9 SURICAINIDE THERAPEUTIC_CLASS Antidepressants 85053-46-9 SURICAINIDE PRODUCT_CLASS Central Nervous System (CNS) 85053-46-9 SURICAINIDE INDICATION Cardiac Arrhythmias 85118-43-0 FLUPROFYLLINE INDICATION Hypertension 85118-43-0 FLUPROFYLLINE THERAPEUTIC_CLASS Antihypertensive Agents 85118-43-0 FLUPROFYLLINE PRODUCT_CLASS Cardiovasculars 85136-71-6 TILISOLOL PRODUCT_CLASS Cardiovasculars 85136-71-6 TILISOLOL MODE_CLASS Receptor Agonist, Non-selective 85136-71-6 TILISOLOL THERAPEUTIC_CLASS Antihypertensive Agents 85136-71-6 TILISOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 85136-71-6 TILISOLOL MECHANISM Modulate G-protein coupled signal transduction 85136-71-6 TILISOLOL INDICATION Glaucoma 85136-71-6 TILISOLOL INDICATION Hypertension 85136-71-6 TILISOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 62774-96-3 TILISOLOL MECHANISM Modulate G-protein coupled signal transduction 62774-96-3 TILISOLOL MODE_CLASS Receptor Agonist, Non-selective 62774-96-3 TILISOLOL INDICATION Glaucoma 62774-96-3 TILISOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 62774-96-3 TILISOLOL INDICATION Hypertension 62774-96-3 TILISOLOL PRODUCT_CLASS Cardiovasculars 62774-96-3 TILISOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 62774-96-3 TILISOLOL THERAPEUTIC_CLASS Antihypertensive Agents 85166-20-7 CICLOTROPIUM BROMIDE MODE_CLASS Solute transporter inhibitor 85166-20-7 CICLOTROPIUM BROMIDE MECHANISM Prolong/enhance neural transmission 85320-68-9 AMOSULALOL PRODUCT_CLASS Cardiovasculars 85320-68-9 AMOSULALOL THERAPEUTIC_CLASS Antianginals 85320-68-9 AMOSULALOL MECHANISM Reduce muscle contractile force 85320-68-9 AMOSULALOL INDICATION Hypertension 85320-68-9 AMOSULALOL MECHANISM Reduce vasoconstriction 85320-68-9 AMOSULALOL THERAPEUTIC_CLASS Antihypertensive Agents 85320-68-9 AMOSULALOL MODE_CLASS Receptor Ligand Antagonist 85320-68-9 AMOSULALOL INDICATION Angina Pectoris 70958-86-0 AMOSULALOL MECHANISM Reduce muscle contractile force 70958-86-0 AMOSULALOL THERAPEUTIC_CLASS Antianginals 70958-86-0 AMOSULALOL INDICATION Angina Pectoris 70958-86-0 AMOSULALOL INDICATION Hypertension 70958-86-0 AMOSULALOL THERAPEUTIC_CLASS Antihypertensive Agents 70958-86-0 AMOSULALOL PRODUCT_CLASS Cardiovasculars 70958-86-0 AMOSULALOL MECHANISM Reduce vasoconstriction 70958-86-0 AMOSULALOL MODE_CLASS Receptor Ligand Antagonist 93633-92-2 AMOSULALOL MODE_CLASS Receptor Ligand Antagonist 93633-92-2 AMOSULALOL INDICATION Hypertension 93633-92-2 AMOSULALOL PRODUCT_CLASS Cardiovasculars 93633-92-2 AMOSULALOL MECHANISM Reduce muscle contractile force 93633-92-2 AMOSULALOL INDICATION Angina Pectoris 93633-92-2 AMOSULALOL THERAPEUTIC_CLASS Antianginals 93633-92-2 AMOSULALOL THERAPEUTIC_CLASS Antihypertensive Agents 93633-92-2 AMOSULALOL MECHANISM Reduce vasoconstriction 85441-60-7 QUINAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 85441-60-7 QUINAPRILAT INDICATION Hypertension 85441-60-7 QUINAPRILAT MODE_CLASS Enzyme Inhibitor 85441-60-7 QUINAPRILAT PRODUCT_CLASS Cardiovasculars 85441-60-7 QUINAPRILAT MECHANISM Reduce vasoconstriction 85505-64-2 VAPIPROST MECHANISM Modulate G-protein coupled signal transduction 85505-64-2 VAPIPROST MODE_CLASS Receptor Agonist 85691-74-3 PIRMAGREL MODE_CLASS Enzyme Inhibitor 85691-74-3 PIRMAGREL MECHANISM Inhibit eicosanoid biosynthesis 85691-74-3 PIRMAGREL STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 85691-74-3 PIRMAGREL PRODUCT_CLASS Anti-inflammatories 85691-74-3 PIRMAGREL THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 85760-74-3 QUINPIROLE INDICATION Hypertension 85760-74-3 QUINPIROLE THERAPEUTIC_CLASS Antihypertensive Agents 85760-74-3 QUINPIROLE PRODUCT_CLASS Cardiovasculars 86048-40-0 QUAZOLAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 86048-40-0 QUAZOLAST PRODUCT_CLASS Respiratory System 86048-40-0 QUAZOLAST INDICATION Asthma 86111-26-4 ZINDOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 86111-26-4 ZINDOXIFENE MODE_CLASS Receptor Ligand Antagonist 86111-26-4 ZINDOXIFENE PRODUCT_CLASS Anti-cancers 86111-26-4 ZINDOXIFENE MECHANISM Modulate gene transcription 80734-02-7 LENAMPICILLIN MODE_CLASS Enzyme Inhibitor 80734-02-7 LENAMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 80734-02-7 LENAMPICILLIN THERAPEUTIC_CLASS Antibacterials 80734-02-7 LENAMPICILLIN PRODUCT_CLASS Anti-infectives 86304-28-1 BUCICLOVIR MECHANISM Inhibit viral DNA synthesis 86304-28-1 BUCICLOVIR THERAPEUTIC_CLASS Antivirals 86304-28-1 BUCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 86304-28-1 BUCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 86304-28-1 BUCICLOVIR PRODUCT_CLASS Anti-infectives 86393-37-5 AMIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 86393-37-5 AMIFLOXACIN PRODUCT_CLASS Anti-infectives 86393-37-5 AMIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 86393-37-5 AMIFLOXACIN THERAPEUTIC_CLASS Antibacterials 86393-37-5 AMIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 86434-57-3 BEPERIDIUM IODIDE INDICATION Ulcer 86541-78-8 BENAZEPRILAT MECHANISM Reduce vasoconstriction 86541-78-8 BENAZEPRILAT MODE_CLASS Enzyme Inhibitor 86541-78-8 BENAZEPRILAT PRODUCT_CLASS Cardiovasculars 86541-78-8 BENAZEPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 86880-51-5 EPANOLOL MECHANISM Modulate G-protein coupled signal transduction 86939-10-8 TRANS INDATRALINE MODE_CLASS Solute transporter inhibitor 86939-10-8 TRANS INDATRALINE MECHANISM Prolong/enhance neural transmission 86939-10-8 TRANS INDATRALINE PRODUCT_CLASS Central Nervous System (CNS) 87051-46-5 BUTANSERIN MECHANISM Modulate G-protein coupled signal transduction 87269-97-4 RAMIPRILAT MECHANISM Reduce vasoconstriction 87269-97-4 RAMIPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 87269-97-4 RAMIPRILAT INDICATION Hypertension 87269-97-4 RAMIPRILAT PRODUCT_CLASS Cardiovasculars 87269-97-4 RAMIPRILAT MODE_CLASS Enzyme Inhibitor 86832-68-0 CARUMONAM THERAPEUTIC_CLASS Antibacterials 86832-68-0 CARUMONAM MODE_CLASS Enzyme Inhibitor 86832-68-0 CARUMONAM MECHANISM Inhibit bacterial cell wall biosynthesis 86832-68-0 CARUMONAM PRODUCT_CLASS Anti-infectives 87646-83-1 LODAZECAR MECHANISM Modulate neural transmission 87646-83-1 LODAZECAR MODE_CLASS Channel enhancer /opener 87646-83-1 LODAZECAR THERAPEUTIC_CLASS Sedatives/Hypnotics 87646-83-1 LODAZECAR PRODUCT_CLASS Central Nervous System (CNS) 87691-91-6 TIOSPIRONE THERAPEUTIC_CLASS Antipsychotics 87691-91-6 TIOSPIRONE MODE_CLASS Receptor Agonist 87691-91-6 TIOSPIRONE MECHANISM Modulate neural transmission 87691-91-6 TIOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 87691-91-6 TIOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 87691-92-7 TIOSPIRONE MODE_CLASS Receptor Agonist 87691-92-7 TIOSPIRONE MECHANISM Modulate neural transmission 87691-92-7 TIOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 87691-92-7 TIOSPIRONE THERAPEUTIC_CLASS Antipsychotics 87691-92-7 TIOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 87784-12-1 OFORNINE THERAPEUTIC_CLASS Antihypertensive Agents 87784-12-1 OFORNINE INDICATION Hypertension 87784-12-1 OFORNINE PRODUCT_CLASS Cardiovasculars 88058-88-2 NAXAGOLIDE INDICATION Parkinson's Disease 88107-10-2 TOMELUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 88107-10-2 TOMELUKAST MODE_CLASS Receptor Ligand Antagonist 88107-10-2 TOMELUKAST INDICATION Asthma 88107-10-2 TOMELUKAST MECHANISM Modulate G-protein coupled signal transduction 88107-10-2 TOMELUKAST PRODUCT_CLASS Respiratory System 88107-10-2 TOMELUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 88296-61-1 MEDORINONE PRODUCT_CLASS Cardiovasculars 88296-61-1 MEDORINONE THERAPEUTIC_CLASS Antihypertensive Agents 88296-61-1 MEDORINONE INDICATION Hypertension 88296-62-2 TRANSCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 88296-62-2 TRANSCAINIDE INDICATION Depression 88296-62-2 TRANSCAINIDE INDICATION Cardiac Arrhythmias 88296-62-2 TRANSCAINIDE PRODUCT_CLASS Central Nervous System (CNS) 88296-62-2 TRANSCAINIDE THERAPEUTIC_CLASS Antidepressants 88296-62-2 TRANSCAINIDE PRODUCT_CLASS Cardiovasculars 88660-47-3 EPICRIPTINE MODE_CLASS Receptor Ligand Antagonist 88660-47-3 EPICRIPTINE INDICATION Parkinson's Disease 88660-47-3 EPICRIPTINE MECHANISM Modulate G-protein coupled signal transduction 88660-47-3 EPICRIPTINE MODE_CLASS Receptor Agonist 88660-47-3 EPICRIPTINE MODE_CLASS Receptor Ligand Antagonist, Selective 88660-47-3 EPICRIPTINE MECHANISM Prolong/enhance neural transmission 88669-04-9 TROSPECTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 88669-04-9 TROSPECTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 88669-04-9 TROSPECTOMYCIN PRODUCT_CLASS Anti-infectives 88669-04-9 TROSPECTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 88669-04-9 TROSPECTOMYCIN THERAPEUTIC_CLASS Antibacterials 88851-61-0 TROSPECTOMYCIN PRODUCT_CLASS Anti-infectives 88851-61-0 TROSPECTOMYCIN THERAPEUTIC_CLASS Antibacterials 88851-61-0 TROSPECTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 88851-61-0 TROSPECTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 88851-61-0 TROSPECTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 88852-12-4 LIMAPROST MECHANISM Modulate G-protein coupled signal transduction 88852-12-4 LIMAPROST MODE_CLASS Receptor Agonist 89226-50-6 MANIDIPINE MODE_CLASS Channel Blocker 89226-50-6 MANIDIPINE INDICATION Hypertension 89226-50-6 MANIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 89226-50-6 MANIDIPINE MECHANISM Reduce muscle contractile force 89226-50-6 MANIDIPINE PRODUCT_CLASS Cardiovasculars 89226-50-6 MANIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 120092-68-4 MANIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 120092-68-4 MANIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 120092-68-4 MANIDIPINE MECHANISM Reduce muscle contractile force 120092-68-4 MANIDIPINE INDICATION Hypertension 120092-68-4 MANIDIPINE MODE_CLASS Channel Blocker 120092-68-4 MANIDIPINE PRODUCT_CLASS Cardiovasculars 89226-75-5 MANIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 89226-75-5 MANIDIPINE INDICATION Hypertension 89226-75-5 MANIDIPINE MODE_CLASS Channel Blocker 89226-75-5 MANIDIPINE PRODUCT_CLASS Cardiovasculars 89226-75-5 MANIDIPINE MECHANISM Reduce muscle contractile force 89226-75-5 MANIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 89303-63-9 ATIPROSIN INDICATION Hypertension 89303-63-9 ATIPROSIN PRODUCT_CLASS Cardiovasculars 89303-63-9 ATIPROSIN THERAPEUTIC_CLASS Antihypertensive Agents 89667-40-3 ISBOGREL PRODUCT_CLASS Cardiovasculars 89667-40-3 ISBOGREL INDICATION Hypertension 89667-40-3 ISBOGREL THERAPEUTIC_CLASS Antihypertensive Agents 89838-96-0 OCTIMIBATE INDICATION Hyperlipoproteinemia 89838-96-0 OCTIMIBATE THERAPEUTIC_CLASS Hypolipidemic Agents 89838-96-0 OCTIMIBATE PRODUCT_CLASS Cardiovasculars 89875-86-5 TIFLUCARBINE PRODUCT_CLASS Central Nervous System (CNS) 89875-86-5 TIFLUCARBINE THERAPEUTIC_CLASS Antidepressants 89875-86-5 TIFLUCARBINE INDICATION Depression 90055-97-3 TIENOXOLOL MODE_CLASS Receptor Ligand Antagonist 90055-97-3 TIENOXOLOL THERAPEUTIC_CLASS Antihypertensive Agents 90055-97-3 TIENOXOLOL MECHANISM Modulate G-protein coupled signal transduction 90055-97-3 TIENOXOLOL INDICATION Hypertension 90055-97-3 TIENOXOLOL PRODUCT_CLASS Cardiovasculars 97067-66-8 TIENOXOLOL MODE_CLASS Receptor Ligand Antagonist 97067-66-8 TIENOXOLOL THERAPEUTIC_CLASS Antihypertensive Agents 97067-66-8 TIENOXOLOL PRODUCT_CLASS Cardiovasculars 97067-66-8 TIENOXOLOL INDICATION Hypertension 97067-66-8 TIENOXOLOL MECHANISM Modulate G-protein coupled signal transduction 90139-06-3 CILAZAPRILAT MODE_CLASS Enzyme Inhibitor 90139-06-3 CILAZAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 90139-06-3 CILAZAPRILAT MECHANISM Reduce vasoconstriction 90139-06-3 CILAZAPRILAT PRODUCT_CLASS Cardiovasculars 90139-06-3 CILAZAPRILAT INDICATION Hypertension 90243-98-4 DIMOXAPROST INDICATION Ulcer 90243-98-4 DIMOXAPROST MECHANISM Modulate G-protein coupled signal transduction 90243-98-4 DIMOXAPROST MODE_CLASS Receptor Agonist 90697-57-7 MOTAPIZONE PRODUCT_CLASS Cardiovasculars 90697-57-7 MOTAPIZONE INDICATION Hypertension 90697-57-7 MOTAPIZONE THERAPEUTIC_CLASS Antihypertensive Agents 90733-40-7 EDIFOLONE PRODUCT_CLASS Central Nervous System (CNS) 90733-40-7 EDIFOLONE INDICATION Depression 90733-40-7 EDIFOLONE THERAPEUTIC_CLASS Antidepressants 90733-40-7 EDIFOLONE INDICATION Cardiac Arrhythmias 90733-40-7 EDIFOLONE THERAPEUTIC_CLASS Antiarrhythmic Agents 90733-40-7 EDIFOLONE PRODUCT_CLASS Cardiovasculars 90850-05-8 GLOXIMONAM PRODUCT_CLASS Anti-infectives 90850-05-8 GLOXIMONAM THERAPEUTIC_CLASS Antibacterials 90850-05-8 GLOXIMONAM MODE_CLASS Enzyme Inhibitor 90850-05-8 GLOXIMONAM MECHANISM Inhibit bacterial cell wall biosynthesis 90898-90-1 OXIMONAM MODE_CLASS Enzyme Inhibitor 90898-90-1 OXIMONAM THERAPEUTIC_CLASS Antibacterials 90898-90-1 OXIMONAM MECHANISM Inhibit bacterial cell wall biosynthesis 90898-90-1 OXIMONAM PRODUCT_CLASS Anti-infectives 90961-53-8 TEDISAMIL THERAPEUTIC_CLASS Antianginals 90961-53-8 TEDISAMIL PRODUCT_CLASS Cardiovasculars 90961-53-8 TEDISAMIL INDICATION Angina Pectoris 90961-53-8 TEDISAMIL INDICATION Cardiac Arrhythmias 90961-53-8 TEDISAMIL MODE_CLASS Channel Modulator 90961-53-8 TEDISAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 90961-53-8 TEDISAMIL MECHANISM Modulate channel gating 90961-53-8 TEDISAMIL INDICATION Ischemia 91431-42-4 LONAPALENE INDICATION Psoriasis 91524-14-0 NAPAMEZOLE INDICATION Depression 91524-14-0 NAPAMEZOLE PRODUCT_CLASS Central Nervous System (CNS) 91524-14-0 NAPAMEZOLE THERAPEUTIC_CLASS Antidepressants 91524-14-0 NAPAMEZOLE MECHANISM Modulate G-protein coupled signal transduction 91618-36-9 IBAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 91618-36-9 IBAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 91618-36-9 IBAFLOXACIN PRODUCT_CLASS Anti-infectives 91618-36-9 IBAFLOXACIN THERAPEUTIC_CLASS Antibacterials 91618-36-9 IBAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 92071-51-7 ROTRAXATE INDICATION Ulcer 92302-55-1 DEVAPAMIL MODE_CLASS Channel Blocker 92302-55-1 DEVAPAMIL MECHANISM Reduce muscle contractile force 92623-85-3 MILNACIPRAN INDICATION Depression 92623-85-3 MILNACIPRAN THERAPEUTIC_CLASS Antidepressants 92623-85-3 MILNACIPRAN STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 92623-85-3 MILNACIPRAN MODE_CLASS Solute transporter inhibitor 92623-85-3 MILNACIPRAN MODE_CLASS Channel Blocker 92623-85-3 MILNACIPRAN MECHANISM Block neural transmission 92623-85-3 MILNACIPRAN MECHANISM Prolong/enhance neural transmission 92623-85-3 MILNACIPRAN PRODUCT_CLASS Central Nervous System (CNS) 101152-94-7 MILNACIPRAN MODE_CLASS Channel Blocker 101152-94-7 MILNACIPRAN MODE_CLASS Solute transporter inhibitor 101152-94-7 MILNACIPRAN STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 101152-94-7 MILNACIPRAN THERAPEUTIC_CLASS Antidepressants 101152-94-7 MILNACIPRAN INDICATION Depression 101152-94-7 MILNACIPRAN PRODUCT_CLASS Central Nervous System (CNS) 101152-94-7 MILNACIPRAN MECHANISM Prolong/enhance neural transmission 101152-94-7 MILNACIPRAN MECHANISM Block neural transmission 93105-81-8 DECLABEN THERAPEUTIC_CLASS Immunosuppressants 93105-81-8 DECLABEN INDICATION Emphysema 93105-81-8 DECLABEN INDICATION Arthritis 93105-81-8 DECLABEN PRODUCT_CLASS Immune Response / Immunomodulators 93738-40-0 RALITOLINE MECHANISM Modulate channel gating 93738-40-0 RALITOLINE PRODUCT_CLASS Central Nervous System (CNS) 93738-40-0 RALITOLINE MODE_CLASS Channel Modulator 93738-40-0 RALITOLINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 95153-31-4 PERINDOPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 95153-31-4 PERINDOPRILAT INDICATION Hypertension 95153-31-4 PERINDOPRILAT MODE_CLASS Enzyme Inhibitor 95153-31-4 PERINDOPRILAT PRODUCT_CLASS Cardiovasculars 95153-31-4 PERINDOPRILAT MECHANISM Reduce vasoconstriction 95588-08-2 TIPENTOSIN PRODUCT_CLASS Cardiovasculars 95588-08-2 TIPENTOSIN INDICATION Hypertension 95588-08-2 TIPENTOSIN THERAPEUTIC_CLASS Antihypertensive Agents 95722-07-9 CICAPROST MODE_CLASS Receptor Agonist 95722-07-9 CICAPROST MECHANISM Modulate G-protein coupled signal transduction 95722-07-9 CICAPROST THERAPEUTIC_CLASS Antihypertensive Agents 95722-07-9 CICAPROST INDICATION Hypertension 95722-07-9 CICAPROST PRODUCT_CLASS Cardiovasculars 95847-70-4 IPSAPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 95847-70-4 IPSAPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 95847-70-4 IPSAPIRONE MODE_CLASS Receptor Agonist 95847-70-4 IPSAPIRONE MECHANISM Modulate neural transmission 95847-70-4 IPSAPIRONE PRODUCT_CLASS Central Nervous System (CNS) 96306-34-2 TIMELOTEM MODE_CLASS Channel enhancer /opener 96306-34-2 TIMELOTEM PRODUCT_CLASS Central Nervous System (CNS) 96306-34-2 TIMELOTEM MECHANISM Modulate neural transmission 96306-34-2 TIMELOTEM THERAPEUTIC_CLASS Sedatives/Hypnotics 96346-61-1 ONAPRISTONE THERAPEUTIC_CLASS Gonadal Hormones 96346-61-1 ONAPRISTONE MECHANISM Modulate gene transcription 96346-61-1 ONAPRISTONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 96346-61-1 ONAPRISTONE MODE_CLASS Receptor Ligand Antagonist 96389-68-3 CRISNATOL MECHANISM Inhibit DNA synthesis, repair, and function 96389-68-3 CRISNATOL MODE_CLASS Distorts /blocks macromolecular scaffold function 96389-68-3 CRISNATOL PRODUCT_CLASS Anti-cancers 96389-68-3 CRISNATOL THERAPEUTIC_CLASS Antineoplastics 96487-37-5 NUVENZEPINE INDICATION Ulcer 96497-67-5 RODORUBICIN THERAPEUTIC_CLASS Antineoplastics 96497-67-5 RODORUBICIN PRODUCT_CLASS Anti-cancers 96497-67-5 RODORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 96497-67-5 RODORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 96497-67-5 RODORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 96513-83-6 PENTISOMIDE INDICATION Cardiac Arrhythmias 96513-83-6 PENTISOMIDE PRODUCT_CLASS Cardiovasculars 96513-83-6 PENTISOMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 96922-80-4 PANTENICATE THERAPEUTIC_CLASS Hypolipidemic Agents 96922-80-4 PANTENICATE INDICATION Hyperlipoproteinemia 96922-80-4 PANTENICATE PRODUCT_CLASS Cardiovasculars 97275-40-6 CEFCANEL DALOXATE MECHANISM Inhibit bacterial cell wall biosynthesis 97275-40-6 CEFCANEL DALOXATE MODE_CLASS Enzyme Inhibitor 97275-40-6 CEFCANEL DALOXATE PRODUCT_CLASS Anti-infectives 97275-40-6 CEFCANEL DALOXATE THERAPEUTIC_CLASS Antibacterials 98048-07-8 FOMIDACILLIN MODE_CLASS Enzyme Inhibitor 98048-07-8 FOMIDACILLIN THERAPEUTIC_CLASS Antibacterials 98048-07-8 FOMIDACILLIN PRODUCT_CLASS Anti-infectives 98048-07-8 FOMIDACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 98206-10-1 FLESINOXAN THERAPEUTIC_CLASS Antihypertensive Agents 98206-10-1 FLESINOXAN PRODUCT_CLASS Cardiovasculars 98206-10-1 FLESINOXAN INDICATION Hypertension 98206-10-1 FLESINOXAN MECHANISM Modulate neural transmission 98224-03-4 ELTOPRAZINE MECHANISM Prolong/enhance neural transmission 98224-03-4 ELTOPRAZINE MODE_CLASS Solute transporter inhibitor 98410-36-7 PALATRIGINE INDICATION Cardiac Arrhythmias 98410-36-7 PALATRIGINE THERAPEUTIC_CLASS Antiarrhythmic Agents 98410-36-7 PALATRIGINE PRODUCT_CLASS Cardiovasculars 99107-52-5 BUNAPROLAST PRODUCT_CLASS Respiratory System 99107-52-5 BUNAPROLAST INDICATION Asthma 99107-52-5 BUNAPROLAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 99248-32-5 DONETIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 99248-32-5 DONETIDINE MECHANISM Reduce stomach HCl secretion 99593-25-6 RILMAZAFONE MODE_CLASS Channel enhancer /opener 99593-25-6 RILMAZAFONE MECHANISM Modulate neural transmission 99593-25-6 RILMAZAFONE INDICATION Anxiety Disorders 99593-25-6 RILMAZAFONE THERAPEUTIC_CLASS Sedatives/Hypnotics 99593-25-6 RILMAZAFONE PRODUCT_CLASS Central Nervous System (CNS) 99593-25-6 RILMAZAFONE THERAPEUTIC_CLASS Anxiolytics 85815-37-8 RILMAZAFONE PRODUCT_CLASS Central Nervous System (CNS) 85815-37-8 RILMAZAFONE MECHANISM Modulate neural transmission 85815-37-8 RILMAZAFONE MODE_CLASS Channel enhancer /opener 85815-37-8 RILMAZAFONE THERAPEUTIC_CLASS Anxiolytics 85815-37-8 RILMAZAFONE INDICATION Anxiety Disorders 85815-37-8 RILMAZAFONE THERAPEUTIC_CLASS Sedatives/Hypnotics 101363-10-4 RUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Heartburn 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Vomiting 101363-10-4 RUFLOXACIN PRODUCT_CLASS Anti-infectives 101363-10-4 RUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 101363-10-4 RUFLOXACIN ADVERSE_EFFECT PSY_2_Insomnia 101363-10-4 RUFLOXACIN ADVERSE_EFFECT OCU_3_Abnormal Vision 101363-10-4 RUFLOXACIN ADVERSE_EFFECT SKN_3_Exanthema 101363-10-4 RUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 101363-10-4 RUFLOXACIN THERAPEUTIC_CLASS Antibacterials 101363-10-4 RUFLOXACIN ADVERSE_EFFECT NEU_2_Headache 101363-10-4 RUFLOXACIN ADVERSE_EFFECT PSY_2_Nervousness 101363-10-4 RUFLOXACIN ADVERSE_EFFECT KID_3_Increased Creatinine 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Epigastric Pain 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Dry Mouth 101363-10-4 RUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Flatulence 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GUS_3_Dysuria 101363-10-4 RUFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 101363-10-4 RUFLOXACIN ADVERSE_EFFECT PSY_2_Agitation 101363-10-4 RUFLOXACIN INDICATION Antibiotic Prophylaxis in Chemotherapy 101363-10-4 RUFLOXACIN INDICATION Prostatitis 101363-10-4 RUFLOXACIN INDICATION Lower Respiratory Tract Infection 106017-08-7 RUFLOXACIN ADVERSE_EFFECT NEU_2_Headache 106017-08-7 RUFLOXACIN ADVERSE_EFFECT PSY_2_Nervousness 106017-08-7 RUFLOXACIN ADVERSE_EFFECT KID_3_Increased Creatinine 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GUS_3_Dysuria 106017-08-7 RUFLOXACIN PRODUCT_CLASS Anti-infectives 106017-08-7 RUFLOXACIN ADVERSE_EFFECT PSY_2_Insomnia 106017-08-7 RUFLOXACIN ADVERSE_EFFECT OCU_3_Abnormal Vision 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Epigastric Pain 106017-08-7 RUFLOXACIN INDICATION Prostatitis 106017-08-7 RUFLOXACIN INDICATION Antibiotic Prophylaxis in Chemotherapy 106017-08-7 RUFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 106017-08-7 RUFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 106017-08-7 RUFLOXACIN ADVERSE_EFFECT PSY_2_Agitation 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Flatulence 106017-08-7 RUFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 106017-08-7 RUFLOXACIN INDICATION Lower Respiratory Tract Infection 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Vomiting 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Dry Mouth 106017-08-7 RUFLOXACIN ADVERSE_EFFECT GIS_1_Heartburn 106017-08-7 RUFLOXACIN ADVERSE_EFFECT SKN_3_Exanthema 106017-08-7 RUFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 106017-08-7 RUFLOXACIN THERAPEUTIC_CLASS Antibacterials 101526-83-4 SEMATILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 101526-83-4 SEMATILIDE PRODUCT_CLASS Cardiovasculars 101526-83-4 SEMATILIDE INDICATION Cardiac Arrhythmias 102507-71-1 TIGEMONAM THERAPEUTIC_CLASS Antibacterials 102507-71-1 TIGEMONAM MODE_CLASS Enzyme Inhibitor 102507-71-1 TIGEMONAM MECHANISM Inhibit bacterial cell wall biosynthesis 102507-71-1 TIGEMONAM PRODUCT_CLASS Anti-infectives 103024-44-8 PEMEDOLAC PRODUCT_CLASS Anti-inflammatories 103024-44-8 PEMEDOLAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 103238-56-8 PARODILOL THERAPEUTIC_CLASS Antihypertensive Agents 103238-56-8 PARODILOL PRODUCT_CLASS Cardiovasculars 103238-56-8 PARODILOL INDICATION Hypertension 103238-57-9 CEFEMPIDONE PRODUCT_CLASS Anti-infectives 103238-57-9 CEFEMPIDONE MODE_CLASS Enzyme Inhibitor 103238-57-9 CEFEMPIDONE THERAPEUTIC_CLASS Antibacterials 103238-57-9 CEFEMPIDONE MECHANISM Inhibit bacterial cell wall biosynthesis 104051-20-9 BREFONALOL THERAPEUTIC_CLASS Antihypertensive Agents 104051-20-9 BREFONALOL PRODUCT_CLASS Cardiovasculars 104051-20-9 BREFONALOL INDICATION Hypertension 104153-38-0 SABELUZOLE PRODUCT_CLASS Cardiovasculars 104153-38-0 SABELUZOLE THERAPEUTIC_CLASS Antihypertensive Agents 104153-38-0 SABELUZOLE INDICATION Hypertension 105118-12-5 PIROXANTRONE STRUCTURE_ACTIVITY DNA intercalator 105979-17-7 BENIDIPINE INDICATION Hypertension 105979-17-7 BENIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 105979-17-7 BENIDIPINE PRODUCT_CLASS Cardiovasculars 105979-17-7 BENIDIPINE MECHANISM Reduce muscle contractile force 105979-17-7 BENIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 105979-17-7 BENIDIPINE MODE_CLASS Channel Blocker 91599-74-5 BENIDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 91599-74-5 BENIDIPINE INDICATION Hypertension 91599-74-5 BENIDIPINE MODE_CLASS Channel Blocker 91599-74-5 BENIDIPINE PRODUCT_CLASS Cardiovasculars 91599-74-5 BENIDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 91599-74-5 BENIDIPINE MECHANISM Reduce muscle contractile force 106900-12-3 LOPERAMIDE OXIDE MODE_CLASS Channel Blocker 106900-12-3 LOPERAMIDE OXIDE THERAPEUTIC_CLASS Antidiarrhea Agents 106900-12-3 LOPERAMIDE OXIDE MECHANISM Modulate neural transmission 106900-12-3 LOPERAMIDE OXIDE MECHANISM Reduce muscle contractile force 106900-12-3 LOPERAMIDE OXIDE MODE_CLASS Receptor Agonist 106900-12-3 LOPERAMIDE OXIDE PRODUCT_CLASS Gastrointestinal System 108319-07-9 PIRAZMONAM MODE_CLASS Enzyme Inhibitor 108319-07-9 PIRAZMONAM MECHANISM Inhibit bacterial cell wall biosynthesis 108319-07-9 PIRAZMONAM PRODUCT_CLASS Anti-infectives 108319-07-9 PIRAZMONAM THERAPEUTIC_CLASS Antibacterials 108437-28-1 BINFLOXACIN THERAPEUTIC_CLASS Antibacterials 108437-28-1 BINFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 108437-28-1 BINFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 108437-28-1 BINFLOXACIN PRODUCT_CLASS Anti-infectives 108437-28-1 BINFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 108674-86-8 SERGOLEXOLE THERAPEUTIC_CLASS Antimigraines 108674-86-8 SERGOLEXOLE STRUCTURE_ACTIVITY Ergot alkaloid 108674-86-8 SERGOLEXOLE PRODUCT_CLASS Central Nervous System (CNS) 108674-86-8 SERGOLEXOLE INDICATION Migraine Headache 109214-55-3 LIBENZAPRIL MECHANISM Reduce vasoconstriction 109214-55-3 LIBENZAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 109214-55-3 LIBENZAPRIL PRODUCT_CLASS Cardiovasculars 109214-55-3 LIBENZAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 109214-55-3 LIBENZAPRIL INDICATION Hypertension 109214-55-3 LIBENZAPRIL MODE_CLASS Enzyme Inhibitor 112017-99-9 IBUPROFEN PICONOL PRODUCT_CLASS Anti-inflammatories 112017-99-9 IBUPROFEN PICONOL THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 112017-99-9 IBUPROFEN PICONOL MECHANISM Inhibit eicosanoid biosynthesis 112017-99-9 IBUPROFEN PICONOL MODE_CLASS Enzyme Inhibitor 122-14-5 FENITROTHION THERAPEUTIC_CLASS Parasympathomimetic Agents 122-14-5 FENITROTHION PRODUCT_CLASS Autonomic Nervous System (ANS) 297-90-5 RACEMORPHAN MODE_CLASS Receptor Agonist 297-90-5 RACEMORPHAN PRODUCT_CLASS Analgesics 297-90-5 RACEMORPHAN STRUCTURE_ACTIVITY Opioid receptor agonist 297-90-5 RACEMORPHAN MECHANISM Modulate neural transmission 297-90-5 RACEMORPHAN THERAPEUTIC_CLASS Analgesics, Opioid 847-25-6 RACEPHENICOL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 847-25-6 RACEPHENICOL MECHANISM Inhibit ribosomal protein synthesis 847-25-6 RACEPHENICOL THERAPEUTIC_CLASS Antibacterials 847-25-6 RACEPHENICOL PRODUCT_CLASS Anti-infectives 2353-33-5 DECITABINE STRUCTURE_ACTIVITY DNA methyltransferase inhibitor 2353-33-5 DECITABINE MODE_CLASS Enzyme Inhibitor 10417-94-4 ICOSAPENT INDICATION Hyperlipoproteinemia 10417-94-4 ICOSAPENT PRODUCT_CLASS Cardiovasculars 10417-94-4 ICOSAPENT THERAPEUTIC_CLASS Hypolipidemic Agents 71119-11-4 BUCINDOLOL INDICATION Hypertension 71119-11-4 BUCINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 71119-11-4 BUCINDOLOL MECHANISM Reduce muscle contractile force 71119-11-4 BUCINDOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 71119-11-4 BUCINDOLOL MECHANISM Modulate G-protein coupled signal transduction 71119-11-4 BUCINDOLOL PRODUCT_CLASS Cardiovasculars 71316-84-2 FLURADOLINE PRODUCT_CLASS Analgesics 71316-84-2 FLURADOLINE MECHANISM Prolong/enhance neural transmission 71316-84-2 FLURADOLINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 71316-84-2 FLURADOLINE MODE_CLASS Solute transporter inhibitor 71351-79-6 ICOTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 71351-79-6 ICOTIDINE MECHANISM Reduce stomach HCl secretion 71475-35-9 LOZILUREA INDICATION Ulcer 71576-40-4 APTAZAPINE INDICATION Depression 71576-40-4 APTAZAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 71576-40-4 APTAZAPINE THERAPEUTIC_CLASS Antidepressants 71576-40-4 APTAZAPINE PRODUCT_CLASS Central Nervous System (CNS) 71628-96-1 MENOGARIL THERAPEUTIC_CLASS Antineoplastics 71628-96-1 MENOGARIL STRUCTURE_ACTIVITY DNA intercalator, anthracycline 71628-96-1 MENOGARIL PRODUCT_CLASS Anti-cancers 71827-56-0 CLEMEPROL INDICATION Depression 71827-56-0 CLEMEPROL PRODUCT_CLASS Central Nervous System (CNS) 71827-56-0 CLEMEPROL THERAPEUTIC_CLASS Antidepressants 72005-58-4 VADOCAINE THERAPEUTIC_CLASS Local Anesthetics 72005-58-4 VADOCAINE MODE_CLASS Channel Blocker 72005-58-4 VADOCAINE INDICATION Cough / Tussis 72005-58-4 VADOCAINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 72005-58-4 VADOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 72005-58-4 VADOCAINE PRODUCT_CLASS Central Nervous System (CNS) 72005-58-4 VADOCAINE PRODUCT_CLASS Respiratory System 72005-58-4 VADOCAINE MECHANISM Block neural transmission 72420-38-3 ACIFRAN INDICATION Hyperlipoproteinemia 72420-38-3 ACIFRAN THERAPEUTIC_CLASS Hypolipidemic Agents 72420-38-3 ACIFRAN PRODUCT_CLASS Cardiovasculars 72444-62-3 PERAFENSINE THERAPEUTIC_CLASS Antidepressants 72444-62-3 PERAFENSINE PRODUCT_CLASS Central Nervous System (CNS) 72444-62-3 PERAFENSINE INDICATION Depression 72467-44-8 PICLONIDINE INDICATION Hypotension 72522-13-5 EPTAZOCINE MECHANISM Modulate neural transmission 72522-13-5 EPTAZOCINE MODE_CLASS Receptor Agonist 72150-17-5 EPTAZOCINE MECHANISM Modulate neural transmission 72150-17-5 EPTAZOCINE MODE_CLASS Receptor Agonist 72002-64-3 EPTAZOCINE MECHANISM Modulate neural transmission 72002-64-3 EPTAZOCINE MODE_CLASS Receptor Agonist 72619-34-2 BERMOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 72619-34-2 BERMOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 72619-34-2 BERMOPROFEN PRODUCT_CLASS Anti-inflammatories 72619-34-2 BERMOPROFEN MODE_CLASS Enzyme Inhibitor 72714-74-0 VIQUALINE THERAPEUTIC_CLASS Antidepressants 72714-74-0 VIQUALINE PRODUCT_CLASS Central Nervous System (CNS) 72714-74-0 VIQUALINE INDICATION Depression 72714-75-1 IVOQUALINE PRODUCT_CLASS Central Nervous System (CNS) 72714-75-1 IVOQUALINE THERAPEUTIC_CLASS Antidepressants 72714-75-1 IVOQUALINE INDICATION Depression 72803-02-2 DARODIPINE INDICATION Hypertension 72803-02-2 DARODIPINE PRODUCT_CLASS Cardiovasculars 72803-02-2 DARODIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 72803-02-2 DARODIPINE THERAPEUTIC_CLASS Antihypertensive Agents 72803-02-2 DARODIPINE MECHANISM Reduce muscle contractile force 72803-02-2 DARODIPINE MODE_CLASS Channel Blocker 72822-56-1 AZALOXAN INDICATION Depression 72822-56-1 AZALOXAN PRODUCT_CLASS Central Nervous System (CNS) 72822-56-1 AZALOXAN THERAPEUTIC_CLASS Antidepressants 72830-39-8 OXMETIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 72830-39-8 OXMETIDINE MECHANISM Reduce stomach HCl secretion 73080-51-0 REPIRINAST MECHANISM Modulate G-protein coupled signal transduction 73080-51-0 REPIRINAST MODE_CLASS Receptor Ligand Antagonist 73278-54-3 LAMTIDINE MECHANISM Reduce stomach HCl secretion 73278-54-3 LAMTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 73573-42-9 RESCIMETOL INDICATION Hypertension 73573-42-9 RESCIMETOL PRODUCT_CLASS Cardiovasculars 73573-42-9 RESCIMETOL THERAPEUTIC_CLASS Antihypertensive Agents 73647-73-1 VIPROSTOL INDICATION Hypotension 73758-06-2 INDORENATE THERAPEUTIC_CLASS Antihypertensive Agents 73758-06-2 INDORENATE INDICATION Hypertension 73758-06-2 INDORENATE PRODUCT_CLASS Cardiovasculars 73803-48-2 TRIPAMIDE INDICATION Hypertension 73803-48-2 TRIPAMIDE PRODUCT_CLASS Cardiovasculars 73803-48-2 TRIPAMIDE THERAPEUTIC_CLASS Antihypertensive Agents 74050-97-8 HALOPERIDOL DECANOATE MECHANISM Prolong/enhance neural transmission 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT XXX_2_Hyperthermia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT CVS_2_Hypotension 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT REP_3_Impotence 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_2_Confusion 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 74050-97-8 HALOPERIDOL DECANOATE TISSUE_TOXICITY Tardive Dyskinesia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_2_Euphoria 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT LIV_2_Cholestasis 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT NEU_3_Cerebral Edema 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 74050-97-8 HALOPERIDOL DECANOATE KNOWN_TOXICITY Mental Health Disorders 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT XXX_2_Mastalgia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT END_1_Hyperprolactinemia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT BBM_3_Leukopenia 74050-97-8 HALOPERIDOL DECANOATE TISSUE_TOXICITY Ventricular Tachycardia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT BBM_3_Anemia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT NEU_2_Headache 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT CVS_2_Hypertension 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT XXX_2_Hypothermia 74050-97-8 HALOPERIDOL DECANOATE MODE_CLASS Receptor Ligand Antagonist 74050-97-8 HALOPERIDOL DECANOATE MECHANISM Block neural transmission 74050-97-8 HALOPERIDOL DECANOATE PRODUCT_CLASS Central Nervous System (CNS) 74050-97-8 HALOPERIDOL DECANOATE INDICATION Schizophrenia 74050-97-8 HALOPERIDOL DECANOATE MECHANISM Modulate neural transmission 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT NEU_2_Vertigo 74050-97-8 HALOPERIDOL DECANOATE TISSUE_TOXICITY Hypotension 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT XXX_2_Restlessness 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_2_Insomnia 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_1_Depression 74050-97-8 HALOPERIDOL DECANOATE MODE_CLASS Receptor Agonist 74050-97-8 HALOPERIDOL DECANOATE KNOWN_TOXICITY Cardiovascular Toxicity 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT SKN_3_Melanosis 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT BBM_3_Leukocytosis 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_1_Agitation 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT NEU_1_Drowsiness 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_2_Anxiety 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT PSY_2_Hallucinations 74050-97-8 HALOPERIDOL DECANOATE MODE_CLASS Receptor Agonist, selective 74050-97-8 HALOPERIDOL DECANOATE THERAPEUTIC_CLASS Antipsychotics 74050-97-8 HALOPERIDOL DECANOATE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), butyrophenone 74050-97-8 HALOPERIDOL DECANOATE INDICATION Psychotic Disorders / Psychosis 74050-97-8 HALOPERIDOL DECANOATE ADVERSE_EFFECT REP_2_Menstrual Irregularities 74129-03-6 TEBUQUINE INDICATION Malaria 74517-78-5 INDECAINIDE INDICATION Cardiac Arrhythmias 74517-78-5 INDECAINIDE PRODUCT_CLASS Cardiovasculars 74517-78-5 INDECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 74627-35-3 CIANERGOLINE STRUCTURE_ACTIVITY Ergot alkaloid 74627-35-3 CIANERGOLINE INDICATION Hypertension 74627-35-3 CIANERGOLINE PRODUCT_CLASS Cardiovasculars 74627-35-3 CIANERGOLINE THERAPEUTIC_CLASS Antihypertensive Agents 74738-24-2 RECAINAM THERAPEUTIC_CLASS Antidepressants 74738-24-2 RECAINAM PRODUCT_CLASS Cardiovasculars 74738-24-2 RECAINAM INDICATION Cardiac Arrhythmias 74738-24-2 RECAINAM INDICATION Depression 74738-24-2 RECAINAM THERAPEUTIC_CLASS Antiarrhythmic Agents 74738-24-2 RECAINAM PRODUCT_CLASS Central Nervous System (CNS) 74790-08-2 SPIROPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 74912-19-9 NABOCTATE INDICATION Glaucoma 74912-19-9 NABOCTATE INDICATION Nausea / Vomiting 75067-66-2 BROMPERIDOL DECANOATE MECHANISM Block neural transmission 75067-66-2 BROMPERIDOL DECANOATE MODE_CLASS Receptor Ligand Antagonist 75067-66-2 BROMPERIDOL DECANOATE PRODUCT_CLASS Central Nervous System (CNS) 75067-66-2 BROMPERIDOL DECANOATE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), butyrophenone 75067-66-2 BROMPERIDOL DECANOATE THERAPEUTIC_CLASS Antipsychotics 75358-37-1 LINOGLIRIDE INDICATION Diabetes 75558-90-6 AMPEROZIDE INDICATION Disorders of Aggression 75689-93-9 IMANIXIL THERAPEUTIC_CLASS Hypolipidemic Agents 75689-93-9 IMANIXIL INDICATION Hyperlipoproteinemia 75689-93-9 IMANIXIL PRODUCT_CLASS Cardiovasculars 75755-07-6 PIRIDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 75755-07-6 PIRIDRONIC ACID MECHANISM Inhibit bone re-absorption 75755-07-6 PIRIDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 75755-07-6 PIRIDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 75755-07-6 PIRIDRONIC ACID MODE_CLASS Enzyme Inhibitor 75820-08-5 ZIDAPAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 75820-08-5 ZIDAPAMIDE MODE_CLASS Channel Blocker 75820-08-5 ZIDAPAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 75820-08-5 ZIDAPAMIDE THERAPEUTIC_CLASS Diuretics 75820-08-5 ZIDAPAMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 75841-82-6 MOPIDRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 75841-82-6 MOPIDRALAZINE PRODUCT_CLASS Cardiovasculars 75841-82-6 MOPIDRALAZINE INDICATION Hypertension 75949-60-9 ISOXAPROLOL INDICATION Hypotension 75991-50-3 DAZEPINIL PRODUCT_CLASS Central Nervous System (CNS) 75991-50-3 DAZEPINIL THERAPEUTIC_CLASS Antidepressants 75991-50-3 DAZEPINIL INDICATION Depression 76053-16-2 RECLAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 76053-16-2 RECLAZEPAM MECHANISM Modulate neural transmission 76053-16-2 RECLAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 76053-16-2 RECLAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 76053-16-2 RECLAZEPAM MODE_CLASS Channel enhancer /opener 76252-06-7 NICAINOPROL INDICATION Diarrhea 76301-19-4 TIMEFURONE THERAPEUTIC_CLASS Hypolipidemic Agents 76301-19-4 TIMEFURONE INDICATION Atherosclerosis 76301-19-4 TIMEFURONE PRODUCT_CLASS Cardiovasculars 76496-68-9 LEVOPROTILINE INDICATION Depression 76496-68-9 LEVOPROTILINE THERAPEUTIC_CLASS Antidepressants 76496-68-9 LEVOPROTILINE PRODUCT_CLASS Central Nervous System (CNS) 76497-13-7 SULTAMICILLIN MODE_CLASS Enzyme Inhibitor 76497-13-7 SULTAMICILLIN PRODUCT_CLASS Anti-infectives 76497-13-7 SULTAMICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 76497-13-7 SULTAMICILLIN THERAPEUTIC_CLASS Antibacterials 76541-72-5 MIFOBATE PRODUCT_CLASS Cardiovasculars 76541-72-5 MIFOBATE INDICATION Atherosclerosis 76541-72-5 MIFOBATE THERAPEUTIC_CLASS Hypolipidemic Agents 76610-84-9 CEFBUPERAZONE MECHANISM Inhibit bacterial cell wall biosynthesis 76610-84-9 CEFBUPERAZONE THERAPEUTIC_CLASS Antibacterials 76610-84-9 CEFBUPERAZONE PRODUCT_CLASS Anti-infectives 76610-84-9 CEFBUPERAZONE MODE_CLASS Enzyme Inhibitor 76648-01-6 CEFBUPERAZONE MODE_CLASS Enzyme Inhibitor 76648-01-6 CEFBUPERAZONE THERAPEUTIC_CLASS Antibacterials 76648-01-6 CEFBUPERAZONE MECHANISM Inhibit bacterial cell wall biosynthesis 76648-01-6 CEFBUPERAZONE PRODUCT_CLASS Anti-infectives 76631-45-3 NAPACTADINE THERAPEUTIC_CLASS Antidepressants 76631-45-3 NAPACTADINE PRODUCT_CLASS Central Nervous System (CNS) 76631-45-3 NAPACTADINE INDICATION Depression 76631-46-4 DETOMIDINE MODE_CLASS Receptor Agonist 76631-46-4 DETOMIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 76631-46-4 DETOMIDINE MECHANISM Increase vasoconstriction 76639-94-6 FLORFENICOL MECHANISM Inhibit ribosomal protein synthesis 76639-94-6 FLORFENICOL THERAPEUTIC_CLASS Antibacterials 76639-94-6 FLORFENICOL PRODUCT_CLASS Veterinarian 76639-94-6 FLORFENICOL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 76716-60-4 FLUPRAZINE INDICATION Disorders of Aggression 76732-75-7 PICARTAMIDE INDICATION Ulcer 76956-02-0 LOXTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 76956-02-0 LOXTIDINE MECHANISM Reduce stomach HCl secretion 76990-56-2 MILACEMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 76990-56-2 MILACEMIDE ADVERSE_EFFECT LIV__Increased Serum Transaminases 76990-56-2 MILACEMIDE THERAPEUTIC_CLASS Neurodegenerative Disorders 76990-56-2 MILACEMIDE MECHANISM Block neural transmission 76990-56-2 MILACEMIDE PRODUCT_CLASS Central Nervous System (CNS) 76990-56-2 MILACEMIDE MODE_CLASS Channel Blocker 77164-20-6 LEVOMOPROLOL PRODUCT_CLASS Cardiovasculars 77164-20-6 LEVOMOPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 77164-20-6 LEVOMOPROLOL INDICATION Hypertension 77175-51-0 CROCONAZOLE MODE_CLASS Enzyme Inhibitor 77175-51-0 CROCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 77174-66-4 CROCONAZOLE MODE_CLASS Enzyme Inhibitor 77174-66-4 CROCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 99465-73-3 CROCONAZOLE MODE_CLASS Enzyme Inhibitor 99465-73-3 CROCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 77360-52-2 CEFTIOLENE THERAPEUTIC_CLASS Antibacterials 77360-52-2 CEFTIOLENE MECHANISM Inhibit bacterial cell wall biosynthesis 77360-52-2 CEFTIOLENE MODE_CLASS Enzyme Inhibitor 77360-52-2 CEFTIOLENE PRODUCT_CLASS Anti-infectives 77400-65-8 ASOCAINOL INDICATION Cardiac Arrhythmias 77400-65-8 ASOCAINOL THERAPEUTIC_CLASS Antiarrhythmic Agents 77400-65-8 ASOCAINOL PRODUCT_CLASS Cardiovasculars 77472-98-1 PIPEQUALINE THERAPEUTIC_CLASS Sedatives/Hypnotics 77472-98-1 PIPEQUALINE INDICATION Anxiety Disorders 77472-98-1 PIPEQUALINE PRODUCT_CLASS Central Nervous System (CNS) 77590-92-2 SUPROCLONE PRODUCT_CLASS Central Nervous System (CNS) 77590-92-2 SUPROCLONE THERAPEUTIC_CLASS Sedatives/Hypnotics 77590-92-2 SUPROCLONE INDICATION Anxiety Disorders 77590-96-6 FLORDIPINE PRODUCT_CLASS Cardiovasculars 77590-96-6 FLORDIPINE MODE_CLASS Channel Blocker 77590-96-6 FLORDIPINE INDICATION Hypertension 77590-96-6 FLORDIPINE MECHANISM Reduce muscle contractile force 77590-96-6 FLORDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 77639-66-8 PRINOMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 77639-66-8 PRINOMIDE ADVERSE_EFFECT GIS_2_Vomiting 77639-66-8 PRINOMIDE STRUCTURE_ACTIVITY Antiinflammatory, target unknown 77639-66-8 PRINOMIDE ADVERSE_EFFECT BBM_2_Low White Blood Cell Count 77639-66-8 PRINOMIDE ADVERSE_EFFECT GIS_2_Diarrhea 77639-66-8 PRINOMIDE ADVERSE_EFFECT SKN_2_Itching 77639-66-8 PRINOMIDE PRODUCT_CLASS Anti-inflammatories 77639-66-8 PRINOMIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 77639-66-8 PRINOMIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 77639-66-8 PRINOMIDE INDICATION Rheumatoid Arthritis 77862-92-1 FALIPAMIL MECHANISM Reduce muscle contractile force 77862-92-1 FALIPAMIL PRODUCT_CLASS Cardiovasculars 77862-92-1 FALIPAMIL INDICATION Cardiac Arrhythmias 77862-92-1 FALIPAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 77862-92-1 FALIPAMIL MODE_CLASS Channel Blocker 78186-33-1 FUMOXICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 78186-33-1 FUMOXICILLIN MODE_CLASS Enzyme Inhibitor 78186-33-1 FUMOXICILLIN THERAPEUTIC_CLASS Antibacterials 78186-33-1 FUMOXICILLIN PRODUCT_CLASS Anti-infectives 78371-66-1 BUCROMARONE INDICATION Depression 78371-66-1 BUCROMARONE PRODUCT_CLASS Cardiovasculars 78371-66-1 BUCROMARONE THERAPEUTIC_CLASS Antidepressants 78371-66-1 BUCROMARONE PRODUCT_CLASS Central Nervous System (CNS) 78371-66-1 BUCROMARONE INDICATION Cardiac Arrhythmias 78371-66-1 BUCROMARONE THERAPEUTIC_CLASS Antiarrhythmic Agents 78372-27-7 STIROCAINIDE PRODUCT_CLASS Cardiovasculars 78372-27-7 STIROCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 78372-27-7 STIROCAINIDE INDICATION Cardiac Arrhythmias 78421-12-2 DROXICAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 78421-12-2 DROXICAINIDE PRODUCT_CLASS Cardiovasculars 78421-12-2 DROXICAINIDE INDICATION Cardiac Arrhythmias 78613-35-1 AMOROLFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 78613-35-1 AMOROLFINE MODE_CLASS Enzyme Inhibitor 67467-83-8 AMOROLFINE MODE_CLASS Enzyme Inhibitor 67467-83-8 AMOROLFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 78718-52-2 BENEXATE INDICATION Ulcer 78718-52-2 BENEXATE MODE_CLASS Enzyme Inhibitor 78718-52-2 BENEXATE MECHANISM Reduce vasoconstriction 79071-15-1 TAZASUBRATE INDICATION Hyperlipoproteinemia 79071-15-1 TAZASUBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 79071-15-1 TAZASUBRATE PRODUCT_CLASS Cardiovasculars 79262-46-7 SAVOXEPIN MECHANISM Modulate G-protein coupled signal transduction 79360-43-3 NOCLOPROST INDICATION Ulcer 79360-43-3 NOCLOPROST MODE_CLASS Receptor Agonist 79360-43-3 NOCLOPROST MECHANISM Modulate G-protein coupled signal transduction 79404-91-4 CILOFUNGIN STRUCTURE_ACTIVITY Glucan synthesis inhibitor 79467-22-4 BIPENAMOL INDICATION Depression 79467-22-4 BIPENAMOL THERAPEUTIC_CLASS Antidepressants 79467-22-4 BIPENAMOL PRODUCT_CLASS Central Nervous System (CNS) 79548-73-5 PIRLIMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 79548-73-5 PIRLIMYCIN THERAPEUTIC_CLASS Antibacterials 79548-73-5 PIRLIMYCIN MECHANISM Inhibit ribosomal protein synthesis 79548-73-5 PIRLIMYCIN PRODUCT_CLASS Anti-infectives 79594-24-4 SOMANTADINE THERAPEUTIC_CLASS Antivirals 79594-24-4 SOMANTADINE MODE_CLASS Channel Blocker, selective 79594-24-4 SOMANTADINE PRODUCT_CLASS Central Nervous System (CNS) 79594-24-4 SOMANTADINE THERAPEUTIC_CLASS Movement Disorders 79594-24-4 SOMANTADINE MECHANISM Block channel gating 79594-24-4 SOMANTADINE PRODUCT_CLASS Anti-infectives 79619-31-1 FLAVODIL INDICATION Hypertension 79619-31-1 FLAVODIL PRODUCT_CLASS Cardiovasculars 79619-31-1 FLAVODIL THERAPEUTIC_CLASS Antihypertensive Agents 79672-88-1 PIRIPROST INDICATION Asthma 79672-88-1 PIRIPROST MECHANISM Modulate G-protein coupled signal transduction 79672-88-1 PIRIPROST PRODUCT_CLASS Respiratory System 79672-88-1 PIRIPROST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 79672-88-1 PIRIPROST MODE_CLASS Receptor Agonist 79944-58-4 IDAZOXAN PRODUCT_CLASS Other Human Uses 79944-58-4 IDAZOXAN STRUCTURE_ACTIVITY Adrenoceptor-alpha2 antagonist 79944-58-4 IDAZOXAN THERAPEUTIC_CLASS Drug Dependence Therapy 79944-58-4 IDAZOXAN MECHANISM Modulate G-protein coupled signal transduction 79944-58-4 IDAZOXAN MODE_CLASS Receptor Ligand Antagonist, Selective 80109-27-9 CILADOPA INDICATION Parkinson's Disease 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Sweating 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT CVS_3_Myocardial Infarction 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Fatigue 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_ECG Changes 80125-14-0 REMOXIPRIDE TISSUE_TOXICITY Myocardial Infarction 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 80125-14-0 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT PSY_2_Mania 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Hypotension 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Aggressiveness 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT END_3_Galactorrhea 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT CVS_1_Postural Hypotension 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT OCU_2_Blurred Vision 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT XXX_3_Breast Enlargement 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Bradycardia 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Violent Behavior 80125-14-0 REMOXIPRIDE THERAPEUTIC_CLASS Antipsychotics 80125-14-0 REMOXIPRIDE PRODUCT_CLASS Central Nervous System (CNS) 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Anxiety 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Weight Loss 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Hyperkinesia 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 80125-14-0 REMOXIPRIDE TISSUE_TOXICITY Hypotension 80125-14-0 REMOXIPRIDE MECHANISM Block neural transmission 80125-14-0 REMOXIPRIDE MODE_CLASS Receptor Modulator 80125-14-0 REMOXIPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Bone Marrow Toxicity 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT GUS_2_Urinary Retention 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Insomnia 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT NEU_2_Dizziness 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 80125-14-0 REMOXIPRIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 80125-14-0 REMOXIPRIDE INDICATION Schizophrenia 80125-14-0 REMOXIPRIDE MECHANISM Modulate neural transmission 80125-14-0 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 80125-14-0 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Thirst 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT CVS_3_Myocardial Infarction 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Sweating 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Weight Loss 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Thirst 82935-42-0 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 82935-42-0 REMOXIPRIDE MECHANISM Modulate neural transmission 82935-42-0 REMOXIPRIDE INDICATION Schizophrenia 82935-42-0 REMOXIPRIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Hyperkinesia 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT NEU_2_Dizziness 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Insomnia 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT GUS_2_Urinary Retention 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Bone Marrow Toxicity 82935-42-0 REMOXIPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT XXX_3_Breast Enlargement 82935-42-0 REMOXIPRIDE MODE_CLASS Receptor Modulator 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT END_3_Galactorrhea 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 82935-42-0 REMOXIPRIDE MECHANISM Block neural transmission 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Aggressiveness 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Hypotension 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT PSY_2_Mania 82935-42-0 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 82935-42-0 REMOXIPRIDE TISSUE_TOXICITY Myocardial Infarction 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_ECG Changes 82935-42-0 REMOXIPRIDE TISSUE_TOXICITY Hypotension 82935-42-0 REMOXIPRIDE PRODUCT_CLASS Central Nervous System (CNS) 82935-42-0 REMOXIPRIDE THERAPEUTIC_CLASS Antipsychotics 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Violent Behavior 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Bradycardia 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT OCU_2_Blurred Vision 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Anxiety 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Fatigue 82935-42-0 REMOXIPRIDE ADVERSE_EFFECT CVS_1_Postural Hypotension 117591-79-4 REMOXIPRIDE THERAPEUTIC_CLASS Antipsychotics 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Violent Behavior 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Bradycardia 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT OCU_2_Blurred Vision 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Anxiety 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Weight Loss 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Hyperkinesia 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 117591-79-4 REMOXIPRIDE TISSUE_TOXICITY Hypotension 117591-79-4 REMOXIPRIDE MECHANISM Block neural transmission 117591-79-4 REMOXIPRIDE MODE_CLASS Receptor Modulator 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT XXX_3_Breast Enlargement 117591-79-4 REMOXIPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Bone Marrow Toxicity 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT GUS_2_Urinary Retention 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Fatigue 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT CVS_2_ECG Changes 117591-79-4 REMOXIPRIDE TISSUE_TOXICITY Myocardial Infarction 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 117591-79-4 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT PSY_2_Mania 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 117591-79-4 REMOXIPRIDE INDICATION Schizophrenia 117591-79-4 REMOXIPRIDE PRODUCT_CLASS Central Nervous System (CNS) 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Hypotension 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Aggressiveness 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT END_3_Galactorrhea 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT CVS_1_Postural Hypotension 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Insomnia 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT NEU_2_Dizziness 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 117591-79-4 REMOXIPRIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 117591-79-4 REMOXIPRIDE MECHANISM Modulate neural transmission 117591-79-4 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Thirst 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Sweating 117591-79-4 REMOXIPRIDE ADVERSE_EFFECT CVS_3_Myocardial Infarction 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Fatigue 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Aggressiveness 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT END_3_Galactorrhea 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT CVS_1_Postural Hypotension 73220-03-8 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT PSY_2_Mania 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Bradycardia 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT XXX_1_Thirst 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Sweating 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT CVS_3_Myocardial Infarction 73220-03-8 REMOXIPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT CVS_2_ECG Changes 73220-03-8 REMOXIPRIDE TISSUE_TOXICITY Myocardial Infarction 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Hypotension 73220-03-8 REMOXIPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 73220-03-8 REMOXIPRIDE MECHANISM Modulate neural transmission 73220-03-8 REMOXIPRIDE INDICATION Schizophrenia 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 73220-03-8 REMOXIPRIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT NEU_2_Dizziness 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Insomnia 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT GUS_2_Urinary Retention 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT BBM_3_Bone Marrow Toxicity 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT XXX_3_Breast Enlargement 73220-03-8 REMOXIPRIDE MODE_CLASS Receptor Modulator 73220-03-8 REMOXIPRIDE MECHANISM Block neural transmission 73220-03-8 REMOXIPRIDE TISSUE_TOXICITY Hypotension 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Hyperkinesia 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT XXX_2_Weight Loss 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT PSY_1_Anxiety 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT OCU_2_Blurred Vision 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 73220-03-8 REMOXIPRIDE ADVERSE_EFFECT PSY_3_Violent Behavior 73220-03-8 REMOXIPRIDE THERAPEUTIC_CLASS Antipsychotics 73220-03-8 REMOXIPRIDE PRODUCT_CLASS Central Nervous System (CNS) 80210-62-4 ICX5604996 MODE_CLASS Enzyme Inhibitor 80210-62-4 ICX5604996 MECHANISM Inhibit bacterial cell wall biosynthesis 80225-28-1 TILSUPROST THERAPEUTIC_CLASS Antihypertensive Agents 80225-28-1 TILSUPROST MECHANISM Modulate G-protein coupled signal transduction 80225-28-1 TILSUPROST PRODUCT_CLASS Cardiovasculars 80225-28-1 TILSUPROST INDICATION Hypertension 80225-28-1 TILSUPROST MODE_CLASS Receptor Agonist 80343-63-1 SUFOTIDINE MECHANISM Reduce stomach HCl secretion 80343-63-1 SUFOTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 80349-58-2 PANURAMINE THERAPEUTIC_CLASS Antidepressants 80349-58-2 PANURAMINE PRODUCT_CLASS Central Nervous System (CNS) 80349-58-2 PANURAMINE INDICATION Depression 80370-57-6 CEFTIOFUR PRODUCT_CLASS Anti-infectives 80370-57-6 CEFTIOFUR THERAPEUTIC_CLASS Antibacterials 80370-57-6 CEFTIOFUR MODE_CLASS Enzyme Inhibitor 80370-57-6 CEFTIOFUR MECHANISM Inhibit bacterial cell wall biosynthesis 80410-36-2 FEZOLAMINE MODE_CLASS Solute transporter inhibitor 80410-36-2 FEZOLAMINE PRODUCT_CLASS Central Nervous System (CNS) 80410-36-2 FEZOLAMINE INDICATION Depression 80410-36-2 FEZOLAMINE MECHANISM Prolong/enhance neural transmission 80410-36-2 FEZOLAMINE THERAPEUTIC_CLASS Antidepressants 80573-03-1 IPSALAZIDE INDICATION Ulcerative Colitis 80755-51-7 BUNAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 80755-51-7 BUNAZOSIN INDICATION Hypertension 80755-51-7 BUNAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 80755-51-7 BUNAZOSIN MECHANISM Reduce vasoconstriction 80755-51-7 BUNAZOSIN PRODUCT_CLASS Cardiovasculars 80755-51-7 BUNAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 52712-76-2 BUNAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 52712-76-2 BUNAZOSIN PRODUCT_CLASS Cardiovasculars 52712-76-2 BUNAZOSIN MECHANISM Reduce vasoconstriction 52712-76-2 BUNAZOSIN INDICATION Hypertension 52712-76-2 BUNAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 52712-76-2 BUNAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 80763-86-6 GLUNICATE THERAPEUTIC_CLASS Hypolipidemic Agents 80763-86-6 GLUNICATE INDICATION Hyperlipoproteinemia 80763-86-6 GLUNICATE PRODUCT_CLASS Cardiovasculars 80876-01-3 INDOLAPRIL PRODUCT_CLASS Cardiovasculars 80876-01-3 INDOLAPRIL MECHANISM Reduce vasoconstriction 80876-01-3 INDOLAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 80876-01-3 INDOLAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 80876-01-3 INDOLAPRIL MODE_CLASS Enzyme Inhibitor 80876-01-3 INDOLAPRIL INDICATION Hypertension 81026-63-3 ENISOPROST INDICATION Ulcer 81026-63-3 ENISOPROST MECHANISM Modulate G-protein coupled signal transduction 81026-63-3 ENISOPROST MODE_CLASS Receptor Agonist 81045-50-3 PIVOPRIL INDICATION Hypertension 81045-50-3 PIVOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 81045-50-3 PIVOPRIL MECHANISM Reduce vasoconstriction 81045-50-3 PIVOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 81045-50-3 PIVOPRIL MODE_CLASS Enzyme Inhibitor 81045-50-3 PIVOPRIL PRODUCT_CLASS Cardiovasculars 81382-52-7 PENTIAPINE MALEATE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 81403-80-7 ALFUZOSIN ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 81403-80-7 ALFUZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 81403-80-7 ALFUZOSIN MECHANISM Modulate G-protein coupled signal transduction 81403-80-7 ALFUZOSIN TISSUE_TOXICITY Hypotension 81403-80-7 ALFUZOSIN ADVERSE_EFFECT REP_3_Priapism 81403-80-7 ALFUZOSIN ADVERSE_EFFECT NEU_2_Somnolence 81403-80-7 ALFUZOSIN ADVERSE_EFFECT LIV_3_Cholestasis 81403-80-7 ALFUZOSIN ADVERSE_EFFECT IMU_2_Urticaria 81403-80-7 ALFUZOSIN ADVERSE_EFFECT XXX_2_Edema 81403-80-7 ALFUZOSIN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 81403-80-7 ALFUZOSIN ADVERSE_EFFECT CVS_2_Myocardial Infarction 81403-80-7 ALFUZOSIN ADVERSE_EFFECT XXX_2_Diaphoresis 81403-80-7 ALFUZOSIN ADVERSE_EFFECT XXX_2_Asthenia 81403-80-7 ALFUZOSIN ADVERSE_EFFECT LIV_3_Jaundice 81403-80-7 ALFUZOSIN ADVERSE_EFFECT SKN_2_Erythema 81403-80-7 ALFUZOSIN ADVERSE_EFFECT SKN_2_Pruritis 81403-80-7 ALFUZOSIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 81403-80-7 ALFUZOSIN ADVERSE_EFFECT PSY_2_Nervousness 81403-80-7 ALFUZOSIN ADVERSE_EFFECT GIS_2_Diarrhea 81403-80-7 ALFUZOSIN TISSUE_TOXICITY Myocardial Infarction 81403-80-7 ALFUZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 81403-80-7 ALFUZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 81403-80-7 ALFUZOSIN ADVERSE_EFFECT NEU_1_Vertigo 81403-80-7 ALFUZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 81403-80-7 ALFUZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 81403-80-7 ALFUZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 81403-80-7 ALFUZOSIN ADVERSE_EFFECT KID_2_Oliguria 81403-80-7 ALFUZOSIN ADVERSE_EFFECT GIS_2_Gastritis 81403-80-7 ALFUZOSIN ADVERSE_EFFECT GIS_2_Abdominal Pain 81403-80-7 ALFUZOSIN ADVERSE_EFFECT XXX_1_Peripheral Edema 81403-80-7 ALFUZOSIN ADVERSE_EFFECT LIV_3_Hepatitis 81403-80-7 ALFUZOSIN ADVERSE_EFFECT NEU_1_Headache 81403-80-7 ALFUZOSIN ADVERSE_EFFECT PSY_2_Insomnia 81403-80-7 ALFUZOSIN ADVERSE_EFFECT CVS_1_Hypotension 81403-80-7 ALFUZOSIN ADVERSE_EFFECT REP_3_Ejaculatory Disorder 81403-80-7 ALFUZOSIN ADVERSE_EFFECT GIS_2_Dyspepsia 81403-80-7 ALFUZOSIN ADVERSE_EFFECT PSY_2_Confusion 81403-80-7 ALFUZOSIN ADVERSE_EFFECT NEU_1_Dizziness 81403-80-7 ALFUZOSIN ADVERSE_EFFECT CVS_1_Sinus Tachycardia 81435-67-8 LOSULAZINE HCL THERAPEUTIC_CLASS Antihypertensive Agents 81435-67-8 LOSULAZINE HCL PRODUCT_CLASS Cardiovasculars 81435-67-8 LOSULAZINE HCL INDICATION Hypertension 81447-80-5 DIPRAFENONE INDICATION Cardiac Arrhythmias 81447-80-5 DIPRAFENONE THERAPEUTIC_CLASS Antiarrhythmic Agents 81447-80-5 DIPRAFENONE PRODUCT_CLASS Cardiovasculars 81525-10-2 NAFAMOSTAT MODE_CLASS Enzyme Inhibitor 82956-11-4 NAFAMOSTAT MODE_CLASS Enzyme Inhibitor 81584-06-7 XIBENOLOL PRODUCT_CLASS Cardiovasculars 81584-06-7 XIBENOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 81584-06-7 XIBENOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 81584-06-7 XIBENOLOL INDICATION Cardiac Arrhythmias 81584-06-7 XIBENOLOL MECHANISM Modulate G-protein coupled signal transduction 81656-30-6 TIFLUADOM THERAPEUTIC_CLASS Sedatives/Hypnotics 81656-30-6 TIFLUADOM MECHANISM Modulate neural transmission 81656-30-6 TIFLUADOM MODE_CLASS Channel enhancer /opener 81656-30-6 TIFLUADOM PRODUCT_CLASS Central Nervous System (CNS) 81982-32-3 ALPIROPRIDE INDICATION Migraine Headache 81982-32-3 ALPIROPRIDE THERAPEUTIC_CLASS Antimigraines 81982-32-3 ALPIROPRIDE PRODUCT_CLASS Central Nervous System (CNS) 81988-77-4 PAULOMYCIN A PRODUCT_CLASS Anti-infectives 81988-77-4 PAULOMYCIN A THERAPEUTIC_CLASS Antibacterials 81988-77-4 PAULOMYCIN A MECHANISM Inhibit bacterial cell wall biosynthesis 81988-77-4 PAULOMYCIN A MODE_CLASS Enzyme Inhibitor 82101-10-8 FLEROBUTEROL MECHANISM Modulate G-protein coupled signal transduction 82101-10-8 FLEROBUTEROL STRUCTURE_ACTIVITY Adrenoceptor agonist 82114-19-0 AMFLUTIZOLE INDICATION Gout 59170-23-9 BEVANTOLOL PRODUCT_CLASS Cardiovasculars 59170-23-9 BEVANTOLOL THERAPEUTIC_CLASS Antianginals 59170-23-9 BEVANTOLOL INDICATION Angina Pectoris 59170-23-9 BEVANTOLOL MECHANISM Modulate channel gating 59170-23-9 BEVANTOLOL MODE_CLASS Receptor Agonist, Non-selective 59170-23-9 BEVANTOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 59170-23-9 BEVANTOLOL MODE_CLASS Receptor Ligand Antagonist 59170-23-9 BEVANTOLOL MECHANISM Reduce vasoconstriction 59170-23-9 BEVANTOLOL THERAPEUTIC_CLASS Antihypertensive Agents 59170-23-9 BEVANTOLOL MECHANISM Reduce muscle contractile force 59170-23-9 BEVANTOLOL INDICATION Cardiac Arrhythmias 59170-23-9 BEVANTOLOL INDICATION Hypertension 59170-23-9 BEVANTOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 42864-78-8 BEVANTOLOL INDICATION Hypertension 42864-78-8 BEVANTOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 42864-78-8 BEVANTOLOL INDICATION Cardiac Arrhythmias 42864-78-8 BEVANTOLOL PRODUCT_CLASS Cardiovasculars 42864-78-8 BEVANTOLOL MODE_CLASS Receptor Ligand Antagonist 42864-78-8 BEVANTOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 42864-78-8 BEVANTOLOL MECHANISM Reduce muscle contractile force 42864-78-8 BEVANTOLOL THERAPEUTIC_CLASS Antianginals 42864-78-8 BEVANTOLOL INDICATION Angina Pectoris 42864-78-8 BEVANTOLOL MECHANISM Modulate channel gating 42864-78-8 BEVANTOLOL MODE_CLASS Receptor Agonist, Non-selective 42864-78-8 BEVANTOLOL MECHANISM Reduce vasoconstriction 42864-78-8 BEVANTOLOL THERAPEUTIC_CLASS Antihypertensive Agents 59467-77-5 CLIMAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 59467-77-5 CLIMAZOLAM MECHANISM Modulate neural transmission 59467-77-5 CLIMAZOLAM MODE_CLASS Channel enhancer /opener 59467-77-5 CLIMAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 59467-77-5 CLIMAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 59708-52-0 CARFENTANIL MECHANISM Modulate neural transmission 59708-52-0 CARFENTANIL MODE_CLASS Receptor Agonist, selective 59708-52-0 CARFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 59708-52-0 CARFENTANIL PRODUCT_CLASS Analgesics 59708-52-0 CARFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 59729-31-6 LORCAINIDE PRODUCT_CLASS Central Nervous System (CNS) 59729-31-6 LORCAINIDE MECHANISM Block neural transmission 59729-31-6 LORCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 59729-31-6 LORCAINIDE THERAPEUTIC_CLASS Antidepressants 59729-31-6 LORCAINIDE INDICATION Depression 59729-31-6 LORCAINIDE PRODUCT_CLASS Cardiovasculars 59729-31-6 LORCAINIDE INDICATION Cardiac Arrhythmias 59729-31-6 LORCAINIDE MODE_CLASS Channel Blocker 58934-46-6 LORCAINIDE INDICATION Cardiac Arrhythmias 58934-46-6 LORCAINIDE THERAPEUTIC_CLASS Antidepressants 58934-46-6 LORCAINIDE INDICATION Depression 58934-46-6 LORCAINIDE PRODUCT_CLASS Cardiovasculars 58934-46-6 LORCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 58934-46-6 LORCAINIDE MECHANISM Block neural transmission 58934-46-6 LORCAINIDE MODE_CLASS Channel Blocker 58934-46-6 LORCAINIDE PRODUCT_CLASS Central Nervous System (CNS) 59729-37-2 FEXINIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 59733-86-7 BUTIKACIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 59733-86-7 BUTIKACIN THERAPEUTIC_CLASS Antibacterials 59733-86-7 BUTIKACIN MECHANISM Inhibit ribosomal protein synthesis 59733-86-7 BUTIKACIN PRODUCT_CLASS Anti-infectives 59733-86-7 BUTIKACIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 59755-82-7 ENOLICAM PRODUCT_CLASS Immune Response / Immunomodulators 59755-82-7 ENOLICAM INDICATION Rheumatism 59755-82-7 ENOLICAM THERAPEUTIC_CLASS Immunosuppressants 59859-58-4 FEMOXETINE PRODUCT_CLASS Central Nervous System (CNS) 59859-58-4 FEMOXETINE INDICATION Depression 59859-58-4 FEMOXETINE THERAPEUTIC_CLASS Antidepressants 60085-78-1 CLOPIPAZAN MODE_CLASS Channel enhancer /opener 60085-78-1 CLOPIPAZAN MECHANISM Modulate neural transmission 60207-31-0 AZACONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 60207-31-0 AZACONAZOLE MODE_CLASS Enzyme Inhibitor 60282-87-3 GESTODENE THERAPEUTIC_CLASS Contraceptive Hormones 60282-87-3 GESTODENE MECHANISM Modulate gene transcription 60282-87-3 GESTODENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 60282-87-3 GESTODENE MODE_CLASS Receptor Agonist 60569-19-9 PROPIVERINE INDICATION Urinary Incontinence / Enuresis 60569-19-9 PROPIVERINE MECHANISM Block channel gating 60569-19-9 PROPIVERINE MODE_CLASS Channel Blocker 60569-19-9 PROPIVERINE MECHANISM Modulate G-protein coupled signal transduction 60569-19-9 PROPIVERINE MODE_CLASS Enzyme Inhibitor 54556-98-8 PROPIVERINE MODE_CLASS Enzyme Inhibitor 54556-98-8 PROPIVERINE MECHANISM Modulate G-protein coupled signal transduction 54556-98-8 PROPIVERINE MODE_CLASS Channel Blocker 54556-98-8 PROPIVERINE INDICATION Urinary Incontinence / Enuresis 54556-98-8 PROPIVERINE MECHANISM Block channel gating 60662-16-0 BINEDALINE THERAPEUTIC_CLASS Antidepressants 60662-16-0 BINEDALINE PRODUCT_CLASS Central Nervous System (CNS) 60662-16-0 BINEDALINE INDICATION Depression 60662-18-2 ENICLOBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 60662-18-2 ENICLOBRATE PRODUCT_CLASS Cardiovasculars 60662-18-2 ENICLOBRATE INDICATION Hyperlipoproteinemia 60662-19-3 NILPRAZOLE INDICATION Ulcer 60719-82-6 ALAPROCLATE PRODUCT_CLASS Central Nervous System (CNS) 60719-82-6 ALAPROCLATE INDICATION Depression 60719-82-6 ALAPROCLATE THERAPEUTIC_CLASS Antidepressants 61197-73-7 LOPRAZOLAM MODE_CLASS Channel enhancer /opener 61197-73-7 LOPRAZOLAM INDICATION Insomnia 61197-73-7 LOPRAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 61197-73-7 LOPRAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 61197-73-7 LOPRAZOLAM MECHANISM Modulate neural transmission 61197-73-7 LOPRAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 61263-35-2 METENEPROST MECHANISM Modulate G-protein coupled signal transduction 61263-35-2 METENEPROST MODE_CLASS Receptor Agonist 61325-80-2 FLUMEZAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 61343-44-0 TOCOFENOXATE INDICATION Aging / Senescence 61380-40-3 LOFENTANIL MECHANISM Modulate neural transmission 61380-40-3 LOFENTANIL MODE_CLASS Receptor Agonist, selective 61380-40-3 LOFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 61380-40-3 LOFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 61380-40-3 LOFENTANIL PRODUCT_CLASS Analgesics 61477-97-2 DAZOLICINE THERAPEUTIC_CLASS Antiarrhythmic Agents 61477-97-2 DAZOLICINE INDICATION Cardiac Arrhythmias 61477-97-2 DAZOLICINE PRODUCT_CLASS Cardiovasculars 61484-38-6 PAREPTIDE INDICATION Parkinson's Disease 61563-18-6 SOQUINOLOL PRODUCT_CLASS Cardiovasculars 61563-18-6 SOQUINOLOL INDICATION Cardiac Arrhythmias 61563-18-6 SOQUINOLOL THERAPEUTIC_CLASS Antihypertensive Agents 61563-18-6 SOQUINOLOL INDICATION Hypertension 61563-18-6 SOQUINOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 61622-34-2 CEFOTIAM PRODUCT_CLASS Anti-infectives 61622-34-2 CEFOTIAM MECHANISM Inhibit bacterial cell wall biosynthesis 61622-34-2 CEFOTIAM THERAPEUTIC_CLASS Antibacterials 61622-34-2 CEFOTIAM MODE_CLASS Enzyme Inhibitor 62030-88-0 DUOPERONE MODE_CLASS Receptor Ligand Antagonist 62030-88-0 DUOPERONE MECHANISM Block neural transmission 62030-88-0 DUOPERONE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 62030-88-0 DUOPERONE THERAPEUTIC_CLASS Antipsychotics 62030-88-0 DUOPERONE PRODUCT_CLASS Central Nervous System (CNS) 62052-97-5 BUMEPIDIL INDICATION Hypertension 62052-97-5 BUMEPIDIL THERAPEUTIC_CLASS Antihypertensive Agents 62052-97-5 BUMEPIDIL PRODUCT_CLASS Cardiovasculars 62228-20-0 BUTOPROZINE THERAPEUTIC_CLASS Antiarrhythmic Agents 62228-20-0 BUTOPROZINE PRODUCT_CLASS Central Nervous System (CNS) 62228-20-0 BUTOPROZINE THERAPEUTIC_CLASS Antidepressants 62228-20-0 BUTOPROZINE PRODUCT_CLASS Cardiovasculars 62228-20-0 BUTOPROZINE THERAPEUTIC_CLASS Antianginals 62228-20-0 BUTOPROZINE INDICATION Cardiac Arrhythmias 62228-20-0 BUTOPROZINE INDICATION Angina Pectoris 62228-20-0 BUTOPROZINE INDICATION Depression 62473-79-4 TENILOXAZINE PRODUCT_CLASS Central Nervous System (CNS) 62473-79-4 TENILOXAZINE THERAPEUTIC_CLASS Antidepressants 62473-79-4 TENILOXAZINE INDICATION Depression 62625-18-7 PIROGLIRIDE INDICATION Diabetes 111911-87-6 REBAMIPIDE INDICATION Ulcer 90098-04-7 REBAMIPIDE INDICATION Ulcer 30123-17-2 TIANEPTINE SODIUM THERAPEUTIC_CLASS Antidepressants 30123-17-2 TIANEPTINE SODIUM STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 30123-17-2 TIANEPTINE SODIUM MECHANISM Prolong/enhance neural transmission 30123-17-2 TIANEPTINE SODIUM INDICATION Depression 30123-17-2 TIANEPTINE SODIUM PRODUCT_CLASS Central Nervous System (CNS) 30123-17-2 TIANEPTINE SODIUM MODE_CLASS Channel Modulator 54317-11-2 TIANEPTINE SODIUM MECHANISM Prolong/enhance neural transmission 54317-11-2 TIANEPTINE SODIUM STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 54317-11-2 TIANEPTINE SODIUM PRODUCT_CLASS Central Nervous System (CNS) 54317-11-2 TIANEPTINE SODIUM INDICATION Depression 54317-11-2 TIANEPTINE SODIUM THERAPEUTIC_CLASS Antidepressants 54317-11-2 TIANEPTINE SODIUM MODE_CLASS Channel Modulator 66981-73-5 TIANEPTINE SODIUM PRODUCT_CLASS Central Nervous System (CNS) 66981-73-5 TIANEPTINE SODIUM MODE_CLASS Channel Modulator 66981-73-5 TIANEPTINE SODIUM THERAPEUTIC_CLASS Antidepressants 66981-73-5 TIANEPTINE SODIUM STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 66981-73-5 TIANEPTINE SODIUM MECHANISM Prolong/enhance neural transmission 66981-73-5 TIANEPTINE SODIUM INDICATION Depression 53902-12-8 TRANILAST TA_LEVEL_1 Anti-inflammatory 53902-12-8 TRANILAST STRUCTURE_ACTIVITY Unknown mechanism, inflammation mediator/ blocker 53902-12-8 TRANILAST INDICATION Asthma 53902-12-8 TRANILAST ADVERSE_EFFECT IMU_3_Eosinophilia 53902-12-8 TRANILAST ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 53902-12-8 TRANILAST ADVERSE_EFFECT BBM_3_Anemia 53902-12-8 TRANILAST ADVERSE_EFFECT NEU_2_Sleepiness 53902-12-8 TRANILAST ADVERSE_EFFECT GIS_2_Nausea / Vomiting 53902-12-8 TRANILAST THERAPEUTIC_CLASS Antiplatelets 53902-12-8 TRANILAST MECH_LEVEL_1 Immunosuppressive, inhibits LPS-induced IL-8 formation 53902-12-8 TRANILAST INDICATION Allergic Conjunctivitis 53902-12-8 TRANILAST MESH_LEVEL_1 Organic Chemicals 53902-12-8 TRANILAST MESH_LEVEL_2 Carboxylic Acids 53902-12-8 TRANILAST PRODUCT_CLASS Anti-inflammatories 53902-12-8 TRANILAST INDICATION Prevention of Re-Stenosis After Coronary Angioplasty 53902-12-8 TRANILAST MECH_LEVEL_3 Unknown mechanism 53902-12-8 TRANILAST ADVERSE_EFFECT NEU_2_Headache 53902-12-8 TRANILAST INDICATION Atopic Dermatitis / Eczema 53902-12-8 TRANILAST TA_LEVEL_2 anti-allergic 53902-12-8 TRANILAST MECH_LEVEL_2 cytokine inhibition 53902-12-8 TRANILAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 53902-12-8 TRANILAST ZERO_CLASS Y 53902-12-8 TRANILAST ADVERSE_EFFECT SKN_3_Desquamation 53902-12-8 TRANILAST ADVERSE_EFFECT GIS_3_Stomatitis 53902-12-8 TRANILAST ADVERSE_EFFECT BBM_3_Thrombocytopenia 53902-12-8 TRANILAST ADVERSE_EFFECT LIV_3_Hepatitis 53902-12-8 TRANILAST ADVERSE_EFFECT EMB_3_Teratogenicity 53902-12-8 TRANILAST KNOWN_TOXICITY Embryo/Fetal Toxicity 53902-12-8 TRANILAST INDICATION Allergic Rhinitis 53902-12-8 TRANILAST INDICATION Keloid Scarring 53902-12-8 TRANILAST ADVERSE_EFFECT IMU_3_Urticaria 53902-12-8 TRANILAST MESH_LEVEL_3 Anthranilic Acids 53902-12-8 TRANILAST TA_LEVEL_3 rhinitis, conjunctivitis 53902-12-8 TRANILAST ADVERSE_EFFECT GIS_2_Abdominal Pain 53902-12-8 TRANILAST ADVERSE_EFFECT BBM_3_Leukopenia 53902-12-8 TRANILAST ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 53902-12-8 TRANILAST TISSUE_TOXICITY Teratogenicity 53902-12-8 TRANILAST ADVERSE_EFFECT SKN_2_Rash 53902-12-8 TRANILAST ADVERSE_EFFECT PSY_2_Anorexia 53902-12-8 TRANILAST ADVERSE_EFFECT XXX_3_Cystitis-Like Syndrome 53902-12-8 TRANILAST ACTIVITY_CLASS Unknown mechanism 53902-12-8 TRANILAST ADVERSE_EFFECT KID_3_Renal Dysfunction 53902-12-8 TRANILAST ADVERSE_EFFECT LIV_3_Jaundice 53902-12-8 TRANILAST ADVERSE_EFFECT SKN_2_Pruritis 53902-12-8 TRANILAST ADVERSE_EFFECT BBM_3_Hemolytic Anemia 55837-18-8 BUTIBUFEN MECHANISM Inhibit eicosanoid biosynthesis 55837-18-8 BUTIBUFEN MODE_CLASS Enzyme Inhibitor 39978-42-2 NIFURZIDE INDICATION Diarrhea 39978-42-2 NIFURZIDE MECHANISM Inhibit DNA synthesis, repair, and function 39978-42-2 NIFURZIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 75696-02-5 CINOLAZEPAM THERAPEUTIC_CLASS Anxiolytics 75696-02-5 CINOLAZEPAM MODE_CLASS Channel enhancer /opener 75696-02-5 CINOLAZEPAM MECHANISM Modulate neural transmission 75696-02-5 CINOLAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 75696-02-5 CINOLAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 60576-13-8 PIKETOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 60576-13-8 PIKETOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 60576-13-8 PIKETOPROFEN PRODUCT_CLASS Anti-inflammatories 60576-13-8 PIKETOPROFEN MODE_CLASS Enzyme Inhibitor 66332-77-2 IBUPROFEN GUAIACOL ESTER MODE_CLASS Enzyme Inhibitor 66332-77-2 IBUPROFEN GUAIACOL ESTER MECHANISM Inhibit eicosanoid biosynthesis 66332-77-2 IBUPROFEN GUAIACOL ESTER PRODUCT_CLASS Anti-inflammatories 66332-77-2 IBUPROFEN GUAIACOL ESTER THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51264-14-3 AMSACRINE MECHANISM Inhibit DNA synthesis, repair, and function 51264-14-3 AMSACRINE MODE_CLASS Enzyme Inhibitor 51264-14-3 AMSACRINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 54301-15-4 AMSACRINE MECHANISM Inhibit DNA synthesis, repair, and function 54301-15-4 AMSACRINE MODE_CLASS Enzyme Inhibitor 54301-15-4 AMSACRINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 54301-16-5 AMSACRINE MECHANISM Inhibit DNA synthesis, repair, and function 54301-16-5 AMSACRINE MODE_CLASS Enzyme Inhibitor 54301-16-5 AMSACRINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 13647-35-3 TRILOSTANE INDICATION Cushing's Syndrome / Hypercortisolism 13647-35-3 TRILOSTANE THERAPEUTIC_CLASS Corticosteroids, Systemic 13647-35-3 TRILOSTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 13647-35-3 TRILOSTANE MODE_CLASS Enzyme Inhibitor 13647-35-3 TRILOSTANE PRODUCT_CLASS Hormones, Endocrine and Metabolic 60628-96-8 BIFONAZOLE MODE_CLASS Enzyme Inhibitor 60628-96-8 BIFONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 53164-05-9 ACEMETACIN TISSUE_TOXICITY Hematuria 53164-05-9 ACEMETACIN ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 53164-05-9 ACEMETACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 53164-05-9 ACEMETACIN ADVERSE_EFFECT NEU_2_Vertigo 53164-05-9 ACEMETACIN ADVERSE_EFFECT KID_3_Renal Insufficiency 53164-05-9 ACEMETACIN ADVERSE_EFFECT OTO_2_Tinnitus 53164-05-9 ACEMETACIN ADVERSE_EFFECT XXX_2_Fatigue 53164-05-9 ACEMETACIN ADVERSE_EFFECT LUN_3_Pulmonary Edema 53164-05-9 ACEMETACIN KNOWN_TOXICITY Nephrotoxicity 53164-05-9 ACEMETACIN MODE_CLASS Enzyme Inhibitor 53164-05-9 ACEMETACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 53164-05-9 ACEMETACIN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 53164-05-9 ACEMETACIN ZERO_CLASS N 53164-05-9 ACEMETACIN ADVERSE_EFFECT NEU_2_Somnolence 53164-05-9 ACEMETACIN ADVERSE_EFFECT CVS_3_Chest Pain 53164-05-9 ACEMETACIN ADVERSE_EFFECT KID_3_Hematuria 53164-05-9 ACEMETACIN ADVERSE_EFFECT IMU_3_Angioedema 53164-05-9 ACEMETACIN ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 53164-05-9 ACEMETACIN KNOWN_TOXICITY Cardiovascular Toxicity 53164-05-9 ACEMETACIN ADVERSE_EFFECT NEU_2_Headache 53164-05-9 ACEMETACIN ADVERSE_EFFECT PSY_3_Anorexia 53164-05-9 ACEMETACIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 53164-05-9 ACEMETACIN TISSUE_TOXICITY Congestive Heart Failure 53164-05-9 ACEMETACIN INDICATION Post-Operative Pain 53164-05-9 ACEMETACIN MECHANISM Inhibit eicosanoid biosynthesis 53164-05-9 ACEMETACIN ADVERSE_EFFECT GIS_1_Dyspepsia 53164-05-9 ACEMETACIN ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 53164-05-9 ACEMETACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 53164-05-9 ACEMETACIN TA_LEVEL_3 Rheumatoid arthritis 53164-05-9 ACEMETACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 53164-05-9 ACEMETACIN ADVERSE_EFFECT NEU_1_Dizziness 53164-05-9 ACEMETACIN ADVERSE_EFFECT GIS_1_Nausea 53164-05-9 ACEMETACIN ADVERSE_EFFECT CVS_3_Tachycardia 53164-05-9 ACEMETACIN MECH_LEVEL_1 Immunomodulation 53164-05-9 ACEMETACIN INDICATION Acute Musculoskeletal Disorders 53164-05-9 ACEMETACIN MESH_LEVEL_1 Heterocyclic Compounds 53164-05-9 ACEMETACIN MESH_LEVEL_3 Indoles 53164-05-9 ACEMETACIN PRODUCT_CLASS Anti-inflammatories 53164-05-9 ACEMETACIN ADVERSE_EFFECT PSY_3_Confusion 53164-05-9 ACEMETACIN ADVERSE_EFFECT GIS_3_Flatulence 53164-05-9 ACEMETACIN ADVERSE_EFFECT BBM_3_Myelosuppression 53164-05-9 ACEMETACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 53164-05-9 ACEMETACIN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 53164-05-9 ACEMETACIN ADVERSE_EFFECT OCU_3_Blurred Vision 53164-05-9 ACEMETACIN INDICATION Rheumatic Disorders 53164-05-9 ACEMETACIN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 53164-05-9 ACEMETACIN TA_LEVEL_2 NSAID 53164-05-9 ACEMETACIN ACTIVITY_CLASS Anti-inflammatory 53164-05-9 ACEMETACIN TA_LEVEL_1 Anti-inflammatory 53164-05-9 ACEMETACIN STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 66898-62-2 TALNIFLUMATE MODE_CLASS Channel Blocker 66898-62-2 TALNIFLUMATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 66898-62-2 TALNIFLUMATE PRODUCT_CLASS Anti-inflammatories 66898-62-2 TALNIFLUMATE MECHANISM Block channel gating 66898-62-2 TALNIFLUMATE MODE_CLASS Enzyme Inhibitor 66898-62-2 TALNIFLUMATE MECHANISM Inhibit eicosanoid biosynthesis 29218-27-7 TOLOXATONE MODE_CLASS Enzyme Inhibitor, selective 29218-27-7 TOLOXATONE PRODUCT_CLASS Central Nervous System (CNS) 29218-27-7 TOLOXATONE INDICATION Depression 29218-27-7 TOLOXATONE THERAPEUTIC_CLASS Antidepressants 29218-27-7 TOLOXATONE MECHANISM Prolong/enhance neural transmission 30578-37-1 AMEZINIUM METHYLSULFATE MECHANISM Prolong/enhance neural transmission 30578-37-1 AMEZINIUM METHYLSULFATE MODE_CLASS Enzyme Inhibitor, selective 31793-07-4 PIRPROFEN TISSUE_TOXICITY Nephrotic Syndrome 31793-07-4 PIRPROFEN MODE_CLASS Enzyme Inhibitor 31793-07-4 PIRPROFEN INDICATION Osteoarthritis 31793-07-4 PIRPROFEN ADVERSE_EFFECT SKN_1_Skin Eruption 31793-07-4 PIRPROFEN ADVERSE_EFFECT LIV_3_Jaundice 31793-07-4 PIRPROFEN ADVERSE_EFFECT LIV_3_Hepatotoxicity 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_1_Epigastric Pain 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 31793-07-4 PIRPROFEN ADVERSE_EFFECT KID_3_Acute Renal Failure 31793-07-4 PIRPROFEN INDICATION Dysmenorrhea 31793-07-4 PIRPROFEN ADVERSE_EFFECT LIV_2_Hepatic Damage 31793-07-4 PIRPROFEN INDICATION Rheumatoid Arthritis 31793-07-4 PIRPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 31793-07-4 PIRPROFEN INDICATION Rheumatism 31793-07-4 PIRPROFEN PRODUCT_CLASS Anti-inflammatories 31793-07-4 PIRPROFEN INDICATION Rheumatism 31793-07-4 PIRPROFEN ADVERSE_EFFECT LIV_2_Steatosis 31793-07-4 PIRPROFEN ADVERSE_EFFECT IMU_2_Hypersensitivity 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_1_Gastric Ulceration 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_3_Duodenal Ulcer 31793-07-4 PIRPROFEN ADVERSE_EFFECT BBM_3_Anemia 31793-07-4 PIRPROFEN INDICATION Ankylosing Spondylitis 31793-07-4 PIRPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 31793-07-4 PIRPROFEN INDICATION Gout 31793-07-4 PIRPROFEN INDICATION Dysmenorrhea 31793-07-4 PIRPROFEN INDICATION Rheumatoid Arthritis 31793-07-4 PIRPROFEN MECHANISM Inhibit eicosanoid biosynthesis 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_1_Ulcer Formation 31793-07-4 PIRPROFEN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 31793-07-4 PIRPROFEN ADVERSE_EFFECT LIV_3_Increased Serum Alkaline Phosphatase 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 31793-07-4 PIRPROFEN ADVERSE_EFFECT PSY_2_Anorexia 31793-07-4 PIRPROFEN INDICATION Osteoarthritis 31793-07-4 PIRPROFEN KNOWN_TOXICITY Nephrotoxicity 31793-07-4 PIRPROFEN TISSUE_TOXICITY Hepatotoxicity 31793-07-4 PIRPROFEN TISSUE_TOXICITY Acute Renal Failure 31793-07-4 PIRPROFEN INDICATION Ankylosing Spondylitis 31793-07-4 PIRPROFEN KNOWN_TOXICITY Hepatotoxicity 31793-07-4 PIRPROFEN ADVERSE_EFFECT IMU_2_Urticaria 31793-07-4 PIRPROFEN ADVERSE_EFFECT SKN_1_Pruritis 31793-07-4 PIRPROFEN ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 31793-07-4 PIRPROFEN ADVERSE_EFFECT XXX_3_Edema 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_3_Constipation 31793-07-4 PIRPROFEN ADVERSE_EFFECT GIS_2_Abdominal Pain 31793-07-4 PIRPROFEN INDICATION Gout 56839-43-1 EPERISONE INDICATION Myotonic Conditions 56839-43-1 EPERISONE ADVERSE_EFFECT SKN_3_Erythema Multiforme 56839-43-1 EPERISONE ADVERSE_EFFECT KID_2_Proteinuria 56839-43-1 EPERISONE ADVERSE_EFFECT END_1_Hot Flashes 56839-43-1 EPERISONE ADVERSE_EFFECT GUS_2_Urinary Retention 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_1_Headache 56839-43-1 EPERISONE ADVERSE_EFFECT IMU_3_Hypersensitivity 56839-43-1 EPERISONE MODE_CLASS Channel Blocker 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_2_Lightheadedness 56839-43-1 EPERISONE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 56839-43-1 EPERISONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_1_Sleepiness 56839-43-1 EPERISONE ACTIVITY_CLASS Sigma receptor modulator 56839-43-1 EPERISONE STRUCTURE_ACTIVITY Sigma receptor modulator 56839-43-1 EPERISONE MECHANISM Modulate neural transmission 56839-43-1 EPERISONE MESH_LEVEL_1 Organic Chemicals 56839-43-1 EPERISONE MECH_LEVEL_2 channel blocker 56839-43-1 EPERISONE MESH_LEVEL_2 Ketones 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_2_Incontinence 56839-43-1 EPERISONE ADVERSE_EFFECT GIS_2_Stomatitis 56839-43-1 EPERISONE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 56839-43-1 EPERISONE ADVERSE_EFFECT XXX_2_Edema 56839-43-1 EPERISONE TA_LEVEL_3 anti-spasmodic 56839-43-1 EPERISONE PRODUCT_CLASS Central Nervous System (CNS) 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_2_Tremor 56839-43-1 EPERISONE TA_LEVEL_1 Central Nervous System (CNS) 56839-43-1 EPERISONE MECH_LEVEL_1 Muscle relaxant 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_1_Numbness 56839-43-1 EPERISONE ADVERSE_EFFECT NEU_1_Dizziness 56839-43-1 EPERISONE ADVERSE_EFFECT PSY_1_Insomnia 56839-43-1 EPERISONE ADVERSE_EFFECT XXX_2_Hypotonia 56839-43-1 EPERISONE ADVERSE_EFFECT GIS_1_Epigastric Pain 56839-43-1 EPERISONE ADVERSE_EFFECT BBM_2_Anemia 56839-43-1 EPERISONE INDICATION Spastic Paralysis 56839-43-1 EPERISONE MECHANISM Reduce muscle contractile force 56839-43-1 EPERISONE MESH_LEVEL_3 Propiophenones 56839-43-1 EPERISONE MECH_LEVEL_3 Ca++ channel 56839-43-1 EPERISONE ZERO_CLASS N 64840-90-0 EPERISONE ADVERSE_EFFECT GIS_2_Stomatitis 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_2_Incontinence 64840-90-0 EPERISONE MESH_LEVEL_2 Ketones 64840-90-0 EPERISONE MECH_LEVEL_2 channel blocker 64840-90-0 EPERISONE MESH_LEVEL_1 Organic Chemicals 64840-90-0 EPERISONE MECHANISM Modulate neural transmission 64840-90-0 EPERISONE STRUCTURE_ACTIVITY Sigma receptor modulator 64840-90-0 EPERISONE ACTIVITY_CLASS Sigma receptor modulator 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_1_Sleepiness 64840-90-0 EPERISONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_1_Numbness 64840-90-0 EPERISONE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_2_Lightheadedness 64840-90-0 EPERISONE MECHANISM Reduce muscle contractile force 64840-90-0 EPERISONE ADVERSE_EFFECT IMU_3_Hypersensitivity 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_1_Headache 64840-90-0 EPERISONE ADVERSE_EFFECT GUS_2_Urinary Retention 64840-90-0 EPERISONE ADVERSE_EFFECT END_1_Hot Flashes 64840-90-0 EPERISONE ADVERSE_EFFECT KID_2_Proteinuria 64840-90-0 EPERISONE ADVERSE_EFFECT SKN_3_Erythema Multiforme 64840-90-0 EPERISONE INDICATION Myotonic Conditions 64840-90-0 EPERISONE TA_LEVEL_1 Central Nervous System (CNS) 64840-90-0 EPERISONE TA_LEVEL_3 anti-spasmodic 64840-90-0 EPERISONE PRODUCT_CLASS Central Nervous System (CNS) 64840-90-0 EPERISONE MECH_LEVEL_1 Muscle relaxant 64840-90-0 EPERISONE MODE_CLASS Channel Blocker 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_1_Dizziness 64840-90-0 EPERISONE ADVERSE_EFFECT PSY_1_Insomnia 64840-90-0 EPERISONE ADVERSE_EFFECT XXX_2_Hypotonia 64840-90-0 EPERISONE ADVERSE_EFFECT GIS_1_Epigastric Pain 64840-90-0 EPERISONE ADVERSE_EFFECT BBM_2_Anemia 64840-90-0 EPERISONE INDICATION Spastic Paralysis 64840-90-0 EPERISONE MESH_LEVEL_3 Propiophenones 64840-90-0 EPERISONE MECH_LEVEL_3 Ca++ channel 64840-90-0 EPERISONE ZERO_CLASS N 64840-90-0 EPERISONE ADVERSE_EFFECT XXX_2_Edema 64840-90-0 EPERISONE ADVERSE_EFFECT NEU_2_Tremor 64840-90-0 EPERISONE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 62265-68-3 QUINFAMIDE INDICATION Amebiasis 66644-81-3 VERALIPRIDE MODE_CLASS Receptor Ligand Antagonist 66644-81-3 VERALIPRIDE MECHANISM Block neural transmission 67330-25-0 UFENAMATE MODE_CLASS Enzyme Inhibitor 67330-25-0 UFENAMATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 67330-25-0 UFENAMATE PRODUCT_CLASS Anti-inflammatories 67330-25-0 UFENAMATE MECHANISM Inhibit eicosanoid biosynthesis 55837-27-9 PIRETANIDE THERAPEUTIC_CLASS Antihypertensive Agents 55837-27-9 PIRETANIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 55837-27-9 PIRETANIDE INDICATION Edematous States 55837-27-9 PIRETANIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 55837-27-9 PIRETANIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 55837-27-9 PIRETANIDE MODE_CLASS Channel Blocker, selective 55837-27-9 PIRETANIDE INDICATION Hypertension 55837-27-9 PIRETANIDE PRODUCT_CLASS Cardiovasculars 55837-27-9 PIRETANIDE THERAPEUTIC_CLASS Diuretics 41570-61-0 TULOBUTEROL MODE_CLASS Receptor Agonist 41570-61-0 TULOBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 41570-61-0 TULOBUTEROL THERAPEUTIC_CLASS Bronchodilators 41570-61-0 TULOBUTEROL PRODUCT_CLASS Respiratory System 41570-61-0 TULOBUTEROL INDICATION Bronchospasm 41570-61-0 TULOBUTEROL MECHANISM Reduce bronchoconstriction 41570-61-0 TULOBUTEROL INDICATION Asthma 56776-01-3 TULOBUTEROL INDICATION Bronchospasm 56776-01-3 TULOBUTEROL PRODUCT_CLASS Respiratory System 56776-01-3 TULOBUTEROL THERAPEUTIC_CLASS Bronchodilators 56776-01-3 TULOBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 56776-01-3 TULOBUTEROL MODE_CLASS Receptor Agonist 56776-01-3 TULOBUTEROL MECHANISM Reduce bronchoconstriction 56776-01-3 TULOBUTEROL INDICATION Asthma 10457-90-6 BROMPERIDOL PRODUCT_CLASS Central Nervous System (CNS) 10457-90-6 BROMPERIDOL MODE_CLASS Receptor Ligand Antagonist 10457-90-6 BROMPERIDOL STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), butyrophenone 10457-90-6 BROMPERIDOL THERAPEUTIC_CLASS Antipsychotics 10457-90-6 BROMPERIDOL MECHANISM Block neural transmission 54110-25-7 PIROZADIL INDICATION Hypolipidemia 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE MODE_CLASS Solute transporter inhibitor 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE MECHANISM Prolong/enhance neural transmission 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE INDICATION Depression 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE MODE_CLASS Receptor Ligand Antagonist 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE MECHANISM Modulate G-protein coupled signal transduction 24530-37-8 DEMEXIPTILINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE MODE_CLASS Solute transporter inhibitor 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE MECHANISM Prolong/enhance neural transmission 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE INDICATION Depression 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE MODE_CLASS Receptor Ligand Antagonist 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE MECHANISM Modulate G-protein coupled signal transduction 18059-99-9 DEMEXIPTILINE HYDROCHLORIDE THERAPEUTIC_CLASS Antidepressants 57808-66-9 DOMPERIDONE INDICATION Nausea / Vomiting 57808-66-9 DOMPERIDONE ADVERSE_EFFECT SKN_2_Rash 57808-66-9 DOMPERIDONE PRODUCT_CLASS Gastrointestinal System 57808-66-9 DOMPERIDONE INDICATION Dyspepsia 57808-66-9 DOMPERIDONE ADVERSE_EFFECT REP_2_Decreased Libido 57808-66-9 DOMPERIDONE ADVERSE_EFFECT OCU_3_Oculogyric Crisis 57808-66-9 DOMPERIDONE ADVERSE_EFFECT IMU_3_Anaphylaxis 57808-66-9 DOMPERIDONE MODE_CLASS Receptor Ligand Antagonist, Selective 57808-66-9 DOMPERIDONE ADVERSE_EFFECT END_2_Gynecomastia 57808-66-9 DOMPERIDONE ADVERSE_EFFECT NEU_3_Acute Dystonia 57808-66-9 DOMPERIDONE ADVERSE_EFFECT END_1_Galactorrhea 57808-66-9 DOMPERIDONE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 57808-66-9 DOMPERIDONE THERAPEUTIC_CLASS Antiemetics 57808-66-9 DOMPERIDONE ADVERSE_EFFECT END_1_Hyperprolactinemia 57808-66-9 DOMPERIDONE THERAPEUTIC_CLASS Prokinetic Agents 57808-66-9 DOMPERIDONE MECHANISM Block neural transmission 60607-34-3 OXATOMIDE PRODUCT_CLASS Respiratory System 60607-34-3 OXATOMIDE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 60607-34-3 OXATOMIDE INDICATION Asthma 60607-34-3 OXATOMIDE MECHANISM Modulate G-protein coupled signal transduction 60607-34-3 OXATOMIDE MODE_CLASS Receptor Ligand Antagonist 3102-00-9 FEBUPROL INDICATION Cholelithiasis / Gallstones 3102-00-9 FEBUPROL THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 3102-00-9 FEBUPROL PRODUCT_CLASS Gastrointestinal System 38957-41-4 EMORFAZONE MODE_CLASS Enzyme Inhibitor 38957-41-4 EMORFAZONE MECHANISM Inhibit eicosanoid biosynthesis 61422-45-5 CARMOFUR ADVERSE_EFFECT XXX_1_Weakness 61422-45-5 CARMOFUR TA_LEVEL_2 anti-cancer 61422-45-5 CARMOFUR MECHANISM Inhibit precursor synthesis 61422-45-5 CARMOFUR INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 61422-45-5 CARMOFUR ADVERSE_EFFECT GIS_1_Vomiting 61422-45-5 CARMOFUR ADVERSE_EFFECT GUS_2_Dysuria 61422-45-5 CARMOFUR KNOWN_TOXICITY Blood & Bone Marrow Toxicity 61422-45-5 CARMOFUR ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 61422-45-5 CARMOFUR TA_LEVEL_1 Oncology 61422-45-5 CARMOFUR MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 61422-45-5 CARMOFUR MESH_LEVEL_1 Heterocyclic Compounds 61422-45-5 CARMOFUR MECH_LEVEL_1 protein synthesis 61422-45-5 CARMOFUR MODE_CLASS Enzyme substrate mimic 61422-45-5 CARMOFUR THERAPEUTIC_CLASS Antineoplastics 61422-45-5 CARMOFUR ADVERSE_EFFECT GIS_1_Nausea 61422-45-5 CARMOFUR ADVERSE_EFFECT BBM_2_Leukopenia 61422-45-5 CARMOFUR ADVERSE_EFFECT NEU_3_Leukoencephalopathy 61422-45-5 CARMOFUR TA_LEVEL_3 Breast cancer 61422-45-5 CARMOFUR MESH_LEVEL_3 Pyrimidines 61422-45-5 CARMOFUR INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 61422-45-5 CARMOFUR PRODUCT_CLASS Anti-cancers 61422-45-5 CARMOFUR ADVERSE_EFFECT GIS_1_Diarrhea 61422-45-5 CARMOFUR ADVERSE_EFFECT XXX_1_Lethargy 61422-45-5 CARMOFUR ADVERSE_EFFECT GUS_2_Urinary Frequency 61422-45-5 CARMOFUR TISSUE_TOXICITY Bone Marrow Suppression 61422-45-5 CARMOFUR MECH_LEVEL_2 enzyme substrate mimic 61422-45-5 CARMOFUR MECH_LEVEL_3 Thymidylate synthase 61422-45-5 CARMOFUR INDICATION Breast Cancer / Carcinoma of the Breast 61422-45-5 CARMOFUR ADVERSE_EFFECT BBM_1_Bone Marrow Suppression 61422-45-5 CARMOFUR STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 61422-45-5 CARMOFUR ZERO_CLASS N 30868-30-5 PYRAZOFURIN MECHANISM Incorporate into DNA/RNA/Protein 30868-30-5 PYRAZOFURIN MODE_CLASS Enzyme substrate mimic 30868-30-5 PYRAZOFURIN PRODUCT_CLASS Anti-infectives 30868-30-5 PYRAZOFURIN STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor 30868-30-5 PYRAZOFURIN THERAPEUTIC_CLASS Antivirals 40666-16-8 FLUPROSTENOL MECHANISM Modulate G-protein coupled signal transduction 40666-16-8 FLUPROSTENOL MODE_CLASS Receptor Agonist, selective 53361-23-2 IMAFEN INDICATION Depression 53361-23-2 IMAFEN PRODUCT_CLASS Central Nervous System (CNS) 53361-23-2 IMAFEN THERAPEUTIC_CLASS Antidepressants 42116-77-8 IMAFEN INDICATION Depression 42116-77-8 IMAFEN PRODUCT_CLASS Central Nervous System (CNS) 42116-77-8 IMAFEN THERAPEUTIC_CLASS Antidepressants 56689-45-3 JOSAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 56689-45-3 JOSAMYCIN MECHANISM Inhibit ribosomal protein synthesis 60925-61-3 CEFORANIDE MODE_CLASS Enzyme Inhibitor 60925-61-3 CEFORANIDE PRODUCT_CLASS Anti-infectives 60925-61-3 CEFORANIDE THERAPEUTIC_CLASS Antibacterials 60925-61-3 CEFORANIDE MECHANISM Inhibit bacterial cell wall biosynthesis 339-72-0 L-CYCLOSERINE INDICATION Gaucher's Disease 87760-53-0 TANDOSPIRONE INDICATION Anxiety Disorders 87760-53-0 TANDOSPIRONE MODE_CLASS Receptor Agonist 87760-53-0 TANDOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 87760-53-0 TANDOSPIRONE MECHANISM Modulate neural transmission 87760-53-0 TANDOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 87760-53-0 TANDOSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 112457-95-1 TANDOSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 112457-95-1 TANDOSPIRONE MECHANISM Modulate neural transmission 112457-95-1 TANDOSPIRONE MODE_CLASS Receptor Agonist 112457-95-1 TANDOSPIRONE INDICATION Anxiety Disorders 112457-95-1 TANDOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 112457-95-1 TANDOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 56-65-5 ADENOSINE TRIPHOSPHATE MECHANISM Inhibit mitochondrial function 56-65-5 ADENOSINE TRIPHOSPHATE MODE_CLASS Receptor /Channel ligand mimic 26402-26-6 MONOCTANOIN COMPONENT A INDICATION Cholelithiasis / Gallstones 57982-77-1 BUSERELIN MODE_CLASS Receptor Agonist 57982-77-1 BUSERELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 68630-75-1 BUSERELIN MODE_CLASS Receptor Agonist 68630-75-1 BUSERELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 111520-35-5 BUSERELIN MODE_CLASS Receptor Agonist 111520-35-5 BUSERELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 71109-09-6 VEDAPROFEN PRODUCT_CLASS Anti-inflammatories 71109-09-6 VEDAPROFEN MODE_CLASS Enzyme Inhibitor 71109-09-6 VEDAPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 71109-09-6 VEDAPROFEN MECHANISM Inhibit eicosanoid biosynthesis 95104-27-1 TETRAZOLAST INDICATION Asthma 95104-27-1 TETRAZOLAST PRODUCT_CLASS Respiratory System 95104-27-1 TETRAZOLAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 96604-21-6 OCINAPLON INDICATION Anxiety Disorders 96604-21-6 OCINAPLON PRODUCT_CLASS Central Nervous System (CNS) 96604-21-6 OCINAPLON THERAPEUTIC_CLASS Sedatives/Hypnotics 133692-55-4 SEPRILOSE PRODUCT_CLASS Immune Response / Immunomodulators 133692-55-4 SEPRILOSE THERAPEUTIC_CLASS Immunosuppressants 133692-55-4 SEPRILOSE INDICATION Rheumatism 146939-27-7 ZIPRASIDONE MECHANISM Block neural transmission 146939-27-7 ZIPRASIDONE PRODUCT_CLASS Central Nervous System (CNS) 146939-27-7 ZIPRASIDONE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist 146939-27-7 ZIPRASIDONE MODE_CLASS Receptor Ligand Antagonist 146939-27-7 ZIPRASIDONE MECHANISM Modulate neural transmission 146939-27-7 ZIPRASIDONE THERAPEUTIC_CLASS Antipsychotics 118289-78-4 ZIPRASIDONE MECHANISM Block neural transmission 118289-78-4 ZIPRASIDONE PRODUCT_CLASS Central Nervous System (CNS) 118289-78-4 ZIPRASIDONE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist 118289-78-4 ZIPRASIDONE MODE_CLASS Receptor Ligand Antagonist 118289-78-4 ZIPRASIDONE MECHANISM Modulate neural transmission 118289-78-4 ZIPRASIDONE THERAPEUTIC_CLASS Antipsychotics 122883-93-6 ZIPRASIDONE MECHANISM Modulate neural transmission 122883-93-6 ZIPRASIDONE MODE_CLASS Receptor Ligand Antagonist 122883-93-6 ZIPRASIDONE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist 122883-93-6 ZIPRASIDONE THERAPEUTIC_CLASS Antipsychotics 122883-93-6 ZIPRASIDONE MECHANISM Block neural transmission 122883-93-6 ZIPRASIDONE PRODUCT_CLASS Central Nervous System (CNS) 138982-67-9 ZIPRASIDONE MECHANISM Modulate neural transmission 138982-67-9 ZIPRASIDONE PRODUCT_CLASS Central Nervous System (CNS) 138982-67-9 ZIPRASIDONE THERAPEUTIC_CLASS Antipsychotics 138982-67-9 ZIPRASIDONE MECHANISM Block neural transmission 138982-67-9 ZIPRASIDONE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist 138982-67-9 ZIPRASIDONE MODE_CLASS Receptor Ligand Antagonist 148152-63-0 NAPITANE INDICATION Depression 148152-63-0 NAPITANE THERAPEUTIC_CLASS Antidepressants 148152-63-0 NAPITANE MECHANISM Modulate G-protein coupled signal transduction 148152-63-0 NAPITANE PRODUCT_CLASS Central Nervous System (CNS) 135729-56-5 PALONOSETRON MODE_CLASS Channel Blocker, selective 135729-56-5 PALONOSETRON PRODUCT_CLASS Gastrointestinal System 135729-56-5 PALONOSETRON THERAPEUTIC_CLASS Antiemetics 135729-56-5 PALONOSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 135729-56-5 PALONOSETRON MECHANISM Block neural transmission 135729-56-5 PALONOSETRON INDICATION Nausea / Vomiting 135729-62-3 PALONOSETRON PRODUCT_CLASS Gastrointestinal System 135729-62-3 PALONOSETRON THERAPEUTIC_CLASS Antiemetics 135729-62-3 PALONOSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 135729-62-3 PALONOSETRON MECHANISM Block neural transmission 135729-62-3 PALONOSETRON MODE_CLASS Channel Blocker, selective 135729-62-3 PALONOSETRON INDICATION Nausea / Vomiting 135729-61-2 PALONOSETRON PRODUCT_CLASS Gastrointestinal System 135729-61-2 PALONOSETRON THERAPEUTIC_CLASS Antiemetics 135729-61-2 PALONOSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 135729-61-2 PALONOSETRON MECHANISM Block neural transmission 135729-61-2 PALONOSETRON MODE_CLASS Channel Blocker, selective 135729-61-2 PALONOSETRON INDICATION Nausea / Vomiting 137882-98-5 ABITESARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 137882-98-5 ABITESARTAN THERAPEUTIC_CLASS Antihypertensive Agents 137882-98-5 ABITESARTAN PRODUCT_CLASS Cardiovasculars 137882-98-5 ABITESARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 137882-98-5 ABITESARTAN MECHANISM Reduce vasoconstriction 119221-49-7 SEDOXANTRONE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 119221-49-7 SEDOXANTRONE THERAPEUTIC_CLASS Antineoplastics 119221-49-7 SEDOXANTRONE MECHANISM Inhibit DNA synthesis, repair, and function 119221-49-7 SEDOXANTRONE PRODUCT_CLASS Anti-cancers 149488-17-5 TROVIRDINE STRUCTURE_ACTIVITY Viral RT inhibitor 149488-17-5 TROVIRDINE INDICATION Myocardial Ischemia 17097-76-6 CALCIUM HOPANTENATE THERAPEUTIC_CLASS Antidepressants 17097-76-6 CALCIUM HOPANTENATE PRODUCT_CLASS Central Nervous System (CNS) 17097-76-6 CALCIUM HOPANTENATE INDICATION Depression 145815-98-1 ICOPEZIL PRODUCT_CLASS Central Nervous System (CNS) 145815-98-1 ICOPEZIL THERAPEUTIC_CLASS Neurodegenerative Disorders 145815-98-1 ICOPEZIL INDICATION Alzheimer's Disease 145815-98-1 ICOPEZIL THERAPEUTIC_CLASS Parasympathomimetic Agents 145815-98-1 ICOPEZIL PRODUCT_CLASS Autonomic Nervous System (ANS) 38916-34-6 SOMATOSTATIN INDICATION Ulcer 69-25-0 ELEDOISIN INDICATION Hypotension 62732-44-9 IPIDACRINE MODE_CLASS Channel Modulator 62732-44-9 IPIDACRINE MECHANISM Modulate channel gating 999999-92-7 TETRAFLUOROTHALIMIDE(2) THERAPEUTIC_CLASS Immunomodulants 999999-92-7 TETRAFLUOROTHALIMIDE(2) PRODUCT_CLASS Immune Response / Immunomodulators 139-93-5 ARSPHENAMINE INDICATION Syphilis 165800-06-6 ZOLEDRONIC ACID HYDRATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 165800-06-6 ZOLEDRONIC ACID HYDRATE MODE_CLASS Enzyme Inhibitor 165800-06-6 ZOLEDRONIC ACID HYDRATE MECHANISM Inhibit bone re-absorption 165800-06-6 ZOLEDRONIC ACID HYDRATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 165800-06-6 ZOLEDRONIC ACID HYDRATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 989999-93-1 2(1H-IMIDAZOL-4-YLMETHYL)-9H-CARBAZOLE INDICATION Prostatic Cancer / Carcinoma of the Prostate 189453-10-9 EPOTHILONE D STRUCTURE_ACTIVITY Tubulin binder 87211-44-7 MIDORIAMIN INDICATION Ulcer 56124-62-0 VALRUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 56124-62-0 VALRUBICIN THERAPEUTIC_CLASS Antineoplastics 56124-62-0 VALRUBICIN INDICATION Bladder Cancer / Carcinoma of the Bladder 56124-62-0 VALRUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 56124-62-0 VALRUBICIN PRODUCT_CLASS Anti-cancers 56124-62-0 VALRUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 136816-53-0 VALRUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 136816-53-0 VALRUBICIN PRODUCT_CLASS Anti-cancers 136816-53-0 VALRUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 136816-53-0 VALRUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 136816-53-0 VALRUBICIN INDICATION Bladder Cancer / Carcinoma of the Bladder 136816-53-0 VALRUBICIN THERAPEUTIC_CLASS Antineoplastics 153507-46-1 BIBAPCITIDE MECHANISM Inhibit platelet aggregation 153507-46-1 BIBAPCITIDE INDICATION Venous Thrombosis 153507-46-1 BIBAPCITIDE MODE_CLASS Receptor Ligand Antagonist, Selective 470-37-1 CINOBUFAGIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 34433-31-3 4-CARBAMOYL-2'-HYDROXYIMINOMETHYL-1,1'-OXIDIMETHYLENEDI(PYRIDINIUM) DICHLORIDE MECHANISM Enhance cholinergic transmission 34433-31-3 4-CARBAMOYL-2'-HYDROXYIMINOMETHYL-1,1'-OXIDIMETHYLENEDI(PYRIDINIUM) DICHLORIDE MODE_CLASS Enzyme Inhibitor 34433-31-3 4-CARBAMOYL-2'-HYDROXYIMINOMETHYL-1,1'-OXIDIMETHYLENEDI(PYRIDINIUM) DICHLORIDE INDICATION Organophosphate Poisoning 4097-22-7 2',3'-DIDEOXYADENOSINE ADVERSE_EFFECT IMU_2_Suppressed Immune System 4097-22-7 2',3'-DIDEOXYADENOSINE KNOWN_TOXICITY Nephrotoxicity 4097-22-7 2',3'-DIDEOXYADENOSINE KNOWN_TOXICITY Cardiovascular Toxicity 4097-22-7 2',3'-DIDEOXYADENOSINE PRODUCT_CLASS Anti-infectives 4097-22-7 2',3'-DIDEOXYADENOSINE TISSUE_TOXICITY Cardiotoxicity 4097-22-7 2',3'-DIDEOXYADENOSINE MODE_CLASS Enzyme Inhibitor 4097-22-7 2',3'-DIDEOXYADENOSINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 4097-22-7 2',3'-DIDEOXYADENOSINE MECHANISM Inhibit protein synthesis 4097-22-7 2',3'-DIDEOXYADENOSINE ADVERSE_EFFECT KID_2_Nephrotoxicity 4097-22-7 2',3'-DIDEOXYADENOSINE ADVERSE_EFFECT CVS_2_Cardiotoxicity 4097-22-7 2',3'-DIDEOXYADENOSINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 4097-22-7 2',3'-DIDEOXYADENOSINE THERAPEUTIC_CLASS Antivirals, Systemic 4097-22-7 2',3'-DIDEOXYADENOSINE MODE_CLASS Enzyme Inhibitor 4097-22-7 2',3'-DIDEOXYADENOSINE MECHANISM Inhibit kinase mediated signal transduction 4097-22-7 2',3'-DIDEOXYADENOSINE ADVERSE_EFFECT KID_2_Nephritis 4097-22-7 2',3'-DIDEOXYADENOSINE MODE_CLASS Enzyme Inhibitor 4097-22-7 2',3'-DIDEOXYADENOSINE ADVERSE_EFFECT XXX_1_Weight Loss 4097-22-7 2',3'-DIDEOXYADENOSINE ADVERSE_EFFECT DNA_3_Mutagenicity 4097-22-7 2',3'-DIDEOXYADENOSINE TISSUE_TOXICITY Mutagenicity 4097-22-7 2',3'-DIDEOXYADENOSINE KNOWN_TOXICITY Mutagenicity 4097-22-7 2',3'-DIDEOXYADENOSINE TISSUE_TOXICITY Nephrotoxicity 4097-22-7 2',3'-DIDEOXYADENOSINE INDICATION Human Immunodeficiency Virus (HIV) Disease 651-48-9 3-(SULFOXY)ANDROST-5-EN-17-ONE INDICATION Diabetes 74-61-3 2,3-DIMERCAPTOPROPANE-1-SULFONIC ACID INDICATION Heavy Metal Poisoning 4076-02-2; Salt 2,3-DIMERCAPTOPROPANE-1-SULFONIC ACID INDICATION Heavy Metal Poisoning 506-32-1 (ALL-Z)-5,8,11,14-EICOSATETRAENOIC ACID INDICATION Eczema Herpeticum 16220-07-8 ALLOPURINOL RIBOSIDE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 16220-07-8 ALLOPURINOL RIBOSIDE THERAPEUTIC_CLASS Antineoplastics 16220-07-8 ALLOPURINOL RIBOSIDE INDICATION Leishmaniasis 16220-07-8 ALLOPURINOL RIBOSIDE MODE_CLASS Enzyme substrate mimic 16220-07-8 ALLOPURINOL RIBOSIDE PRODUCT_CLASS Anti-cancers 16220-07-8 ALLOPURINOL RIBOSIDE MECHANISM Incorporate into DNA/RNA/Protein 1405-86-3 GLYCYRRHIZIN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 1405-86-3 GLYCYRRHIZIN MECHANISM Increase muscle contraction 1405-86-3 GLYCYRRHIZIN MECHANISM Inhibit inflammatory response 1405-86-3 GLYCYRRHIZIN PRODUCT_CLASS Botanicals 1405-86-3 GLYCYRRHIZIN MODE_CLASS Enzyme Inhibitor 1405-86-3 GLYCYRRHIZIN MECHANISM Inhibit cholesterol biosynthesis 148-18-5 DITHIOCARB PRODUCT_CLASS Immune Response / Immunomodulators 148-18-5 DITHIOCARB MODE_CLASS Enzyme Inhibitor 148-18-5 DITHIOCARB INDICATION Human Immunodeficiency Virus (HIV) Disease 148-18-5 DITHIOCARB THERAPEUTIC_CLASS Immunomodulants 148-18-5 DITHIOCARB MECHANISM interfere with glucose metabolism 5843-65-2 1-(P-HYDROXYBENZYL)-6,7-DIHYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE INDICATION Cardiac Arrhythmias 5843-65-2 1-(P-HYDROXYBENZYL)-6,7-DIHYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE MECHANISM Modulate G-protein coupled signal transduction 5843-65-2 1-(P-HYDROXYBENZYL)-6,7-DIHYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE PRODUCT_CLASS Cardiovasculars 5843-65-2 1-(P-HYDROXYBENZYL)-6,7-DIHYDROXY-1,2,3,4-TETRAHYDROISOQUINOLINE THERAPEUTIC_CLASS Antiarrhythmic Agents 152946-68-4 NOLATREXED MECHANISM Inhibit precursor synthesis 152946-68-4 NOLATREXED MODE_CLASS Enzyme Inhibitor 152946-68-4 NOLATREXED STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 147149-76-6 NOLATREXED STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 147149-76-6 NOLATREXED MODE_CLASS Enzyme Inhibitor 147149-76-6 NOLATREXED MECHANISM Inhibit precursor synthesis 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Hepatocellular Carcinoma 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT PSY_3_CNS Toxicity 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT XXX_3_Death 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Melanoma 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Neoplasm / Cancer / Tumor 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT LIV_2_Hepatic Damage 5072-26-4 L-BUTHIONINE SULFOXIMINE MODE_CLASS Enzyme Inhibitor 5072-26-4 L-BUTHIONINE SULFOXIMINE KNOWN_TOXICITY Miscellaneous 5072-26-4 L-BUTHIONINE SULFOXIMINE THERAPEUTIC_CLASS Antineoplastics 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Brain Cancer 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Neuroblastoma 5072-26-4 L-BUTHIONINE SULFOXIMINE MECHANISM Modulate signal transduction 5072-26-4 L-BUTHIONINE SULFOXIMINE STRUCTURE_ACTIVITY Inhibits glutathione synthesis 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT OCU_1_Cataracts 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT KID_2_Kidney Damage 5072-26-4 L-BUTHIONINE SULFOXIMINE TISSUE_TOXICITY Death 5072-26-4 L-BUTHIONINE SULFOXIMINE PRODUCT_CLASS Anti-cancers 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Colon Cancer 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT OCU_2_Ocular Damage 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 5072-26-4 L-BUTHIONINE SULFOXIMINE ACTIVITY_CLASS Toxicant 5072-26-4 L-BUTHIONINE SULFOXIMINE INDICATION Ovarian Cancer / Carcinoma of the Ovary 5072-26-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT LUN_1_Pulmonary Impairment 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT OCU_2_Ocular Damage 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Neoplasm / Cancer / Tumor 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Melanoma 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Kidney Cancer / Renal Cell Carcinoma / Carcinoma of the Kidney 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT XXX_3_Death 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT PSY_3_CNS Toxicity 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Hepatocellular Carcinoma 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT LUN_1_Pulmonary Impairment 83730-53-4 L-BUTHIONINE SULFOXIMINE THERAPEUTIC_CLASS Antineoplastics 83730-53-4 L-BUTHIONINE SULFOXIMINE KNOWN_TOXICITY Miscellaneous 83730-53-4 L-BUTHIONINE SULFOXIMINE TISSUE_TOXICITY Death 83730-53-4 L-BUTHIONINE SULFOXIMINE PRODUCT_CLASS Anti-cancers 83730-53-4 L-BUTHIONINE SULFOXIMINE ACTIVITY_CLASS Toxicant 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Ovarian Cancer / Carcinoma of the Ovary 83730-53-4 L-BUTHIONINE SULFOXIMINE MODE_CLASS Enzyme Inhibitor 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT LIV_2_Hepatic Damage 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Colon Cancer 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT KID_2_Kidney Damage 83730-53-4 L-BUTHIONINE SULFOXIMINE ADVERSE_EFFECT OCU_1_Cataracts 83730-53-4 L-BUTHIONINE SULFOXIMINE STRUCTURE_ACTIVITY Inhibits glutathione synthesis 83730-53-4 L-BUTHIONINE SULFOXIMINE MECHANISM Modulate signal transduction 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Neuroblastoma 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 83730-53-4 L-BUTHIONINE SULFOXIMINE INDICATION Brain Cancer 110221-53-9 TEMOCAPRILAT PRODUCT_CLASS Cardiovasculars 110221-53-9 TEMOCAPRILAT MODE_CLASS Enzyme Inhibitor 110221-53-9 TEMOCAPRILAT INDICATION Hypertension 110221-53-9 TEMOCAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 110221-53-9 TEMOCAPRILAT MECHANISM Reduce vasoconstriction 5667-71-0 STREPTONIAZID MECHANISM Inhibit ribosomal protein synthesis 5667-71-0 STREPTONIAZID THERAPEUTIC_CLASS Antibacterials 5667-71-0 STREPTONIAZID MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 5667-71-0 STREPTONIAZID PRODUCT_CLASS Anti-infectives 480-22-8 DITHRANOL INDICATION Psoriasis 35135-68-3 CORMETASONE MODE_CLASS Receptor Agonist 35135-68-3 CORMETASONE MECHANISM Modulate gene transcription 35135-68-3 CORMETASONE PRODUCT_CLASS Anti-inflammatories 35135-68-3 CORMETASONE THERAPEUTIC_CLASS Corticosteroids 1231-93-2 ETHYNODIOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 1231-93-2 ETHYNODIOL THERAPEUTIC_CLASS Contraceptive Hormones 1231-93-2 ETHYNODIOL MECHANISM Modulate gene transcription 1231-93-2 ETHYNODIOL MODE_CLASS Receptor Agonist 1393-25-5 SECRETIN INDICATION Ulcer 1393-25-5 SECRETIN MODE_CLASS Receptor Agonist 95896-08-5 ANARITIDE INDICATION Acute Renal Failure 95896-08-5 ANARITIDE MODE_CLASS Receptor Agonist 95896-08-5 ANARITIDE MECHANISM Increase glomerular filtration rate 95896-08-5 ANARITIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 95896-08-5 ANARITIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 298-45-3 BULBOCAPNINE INDICATION Tremor 509-15-9 GELSEMINE THERAPEUTIC_CLASS Antidepressants 509-15-9 GELSEMINE INDICATION Neuralgia 509-15-9 GELSEMINE PRODUCT_CLASS Central Nervous System (CNS) 509-15-9 GELSEMINE INDICATION Depression 14918-35-5 DESTOMYCIN A STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 14918-35-5 DESTOMYCIN A PRODUCT_CLASS Anti-infectives 14918-35-5 DESTOMYCIN A THERAPEUTIC_CLASS Antibacterials 14918-35-5 DESTOMYCIN A MECHANISM Inhibit ribosomal protein synthesis 14918-35-5 DESTOMYCIN A MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 31282-04-9 HYGROMYCIN B STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 31282-04-9 HYGROMYCIN B MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 31282-04-9 HYGROMYCIN B PRODUCT_CLASS Anti-infectives 31282-04-9 HYGROMYCIN B THERAPEUTIC_CLASS Antibacterials 31282-04-9 HYGROMYCIN B MECHANISM Inhibit ribosomal protein synthesis 155-58-8 PONTICIN MECHANISM Modulate gene transcription 155-58-8 PONTICIN PRODUCT_CLASS Anti-cancers 155-58-8 PONTICIN THERAPEUTIC_CLASS Gonadal Hormones 155-58-8 PONTICIN MODE_CLASS Receptor Ligand Antagonist 483-14-7 CASEANINE THERAPEUTIC_CLASS Antihypertensive Agents 483-14-7 CASEANINE INDICATION Hypertension 483-14-7 CASEANINE PRODUCT_CLASS Cardiovasculars 475-81-0 GLAUCINE INDICATION Cough / Tussis 4720-09-6 ACETYLANDROMEDOL INDICATION Hypertension 4720-09-6 ACETYLANDROMEDOL PRODUCT_CLASS Cardiovasculars 4720-09-6 ACETYLANDROMEDOL THERAPEUTIC_CLASS Antihypertensive Agents 131-02-2 ELLIPTAMINE PRODUCT_CLASS Cardiovasculars 131-02-2 ELLIPTAMINE THERAPEUTIC_CLASS Antihypertensive Agents 131-02-2 ELLIPTAMINE INDICATION Hypertension 38462-04-3 ASOFURANONE PRODUCT_CLASS Cardiovasculars 38462-04-3 ASOFURANONE INDICATION Hyperlipidemia 38462-04-3 ASOFURANONE THERAPEUTIC_CLASS Hypolipidemic Agents 4098-40-2 MITRAGYNINE INDICATION Cough / Tussis 66-86-4 NEOMYCIN C THERAPEUTIC_CLASS Antibacterials 66-86-4 NEOMYCIN C PRODUCT_CLASS Anti-infectives 66-86-4 NEOMYCIN C MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 66-86-4 NEOMYCIN C STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 66-86-4 NEOMYCIN C MECHANISM Inhibit ribosomal protein synthesis 465-21-4 BUFALIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 32619-42-4 OLEUROPEIN PRODUCT_CLASS Cardiovasculars 32619-42-4 OLEUROPEIN THERAPEUTIC_CLASS Antihypertensive Agents 32619-42-4 OLEUROPEIN INDICATION Cardiac Arrhythmias 32619-42-4 OLEUROPEIN INDICATION Hypertension 32619-42-4 OLEUROPEIN THERAPEUTIC_CLASS Antiarrhythmic Agents 76706-55-3 MYXOTHIAZOL STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 76706-55-3 MYXOTHIAZOL MECHANISM Inhibit mitochondrial function 76706-55-3 MYXOTHIAZOL MODE_CLASS Enzyme Inhibitor, Non-selective 76706-55-3 MYXOTHIAZOL PRODUCT_CLASS Toxicants 482-38-2 KAEMPFERITRIN INDICATION Renal Azotemia 482-38-2 KAEMPFERITRIN INDICATION Extrarenal Azotemia 10236-47-2 AURANTIIN INDICATION Hemorrhage / Bleeding 26833-85-2 HARRINGTONINE ADVERSE_EFFECT BBM_2_Myelosuppression 26833-85-2 HARRINGTONINE MECH_LEVEL_3 Unknown mechanism 26833-85-2 HARRINGTONINE PRODUCT_CLASS Anti-cancers 26833-85-2 HARRINGTONINE TA_LEVEL_2 alkylating / intercalating 26833-85-2 HARRINGTONINE TA_LEVEL_1 Oncology 26833-85-2 HARRINGTONINE MESH_LEVEL_3 Harringtonines 26833-85-2 HARRINGTONINE MECHANISM Induce Apoptosis 26833-85-2 HARRINGTONINE MESH_LEVEL_1 Heterocyclic Compounds 26833-85-2 HARRINGTONINE ADVERSE_EFFECT NEU_2_Neuromuscular Irritability 26833-85-2 HARRINGTONINE TISSUE_TOXICITY Mutagenicity 26833-85-2 HARRINGTONINE STRUCTURE_ACTIVITY Cell-cycle inhibitor, inhibits G1/S transition, induce apotosis 26833-85-2 HARRINGTONINE THERAPEUTIC_CLASS Antineoplastics 26833-85-2 HARRINGTONINE MESH_LEVEL_2 Alkaloids 26833-85-2 HARRINGTONINE ADVERSE_EFFECT BBM_2_Bone Marrow Aplasia 26833-85-2 HARRINGTONINE ZERO_CLASS N 26833-85-2 HARRINGTONINE MECH_LEVEL_2 Induce Apoptosis 26833-85-2 HARRINGTONINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 26833-85-2 HARRINGTONINE KNOWN_TOXICITY Mutagenicity 26833-85-2 HARRINGTONINE ADVERSE_EFFECT DNA_3_Mutagenicity 630-64-8 ALLEOSIDE A STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 508-76-9 CORCHOROSIDE A STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 508-75-8 CONVALLATOXIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 6869-51-8 LOCUNDIESIDE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 3253-62-1 COVALLAROTOXOL STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 303-45-7 GOSSYPOL INDICATION Malaria 1182-87-2 PERUVOSIDE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 508-77-0 CIMARINUM STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 595-21-1 STROSPESIDE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 36573-63-4 ASCLEPIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 6875-10-1 FORMYLSTROSPESIDE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 53177-88-1 NERIOLIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 7082-34-0 ERYSIMOSIDE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 20231-81-6 UZARIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 20231-81-6 UZARIN INDICATION Diarrhea 124-99-2 GLUCOPROSCILLARIDIN A STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 560-53-2 K-STROPHANTHIN-BETA STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 13137-64-9 GLUCOPERIPLOCYMARIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 115308-98-0 TALLIMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 115308-98-0 TALLIMUSTINE THERAPEUTIC_CLASS Antineoplastics 115308-98-0 TALLIMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 115308-98-0 TALLIMUSTINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 115308-98-0 TALLIMUSTINE PRODUCT_CLASS Anti-cancers 118438-45-2 TALLIMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 118438-45-2 TALLIMUSTINE THERAPEUTIC_CLASS Antineoplastics 118438-45-2 TALLIMUSTINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 118438-45-2 TALLIMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 118438-45-2 TALLIMUSTINE PRODUCT_CLASS Anti-cancers 117091-64-2 ETOPOSIDE PHOSPHATE STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 117091-64-2 ETOPOSIDE PHOSPHATE MECHANISM Inhibit DNA synthesis, repair, and function 117091-64-2 ETOPOSIDE PHOSPHATE MODE_CLASS Enzyme Inhibitor 117091-64-2 ETOPOSIDE PHOSPHATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 119386-96-8 MOFEGILINE INDICATION Parkinson's Disease 120635-25-8 MOFEGILINE INDICATION Parkinson's Disease 119514-66-8 LIFARIZINE THERAPEUTIC_CLASS Vasodilators 119514-66-8 LIFARIZINE INDICATION Cerebral Ischemia 119514-66-8 LIFARIZINE MECHANISM Block neural transmission 119514-66-8 LIFARIZINE PRODUCT_CLASS Central Nervous System (CNS) 119514-66-8 LIFARIZINE MODE_CLASS Channel Blocker 119514-66-8 LIFARIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 119719-11-8 ILATREOTIDE INDICATION Ulcer 120054-86-6 DEXNIGULDIPINE THERAPEUTIC_CLASS Antineoplastics 120054-86-6 DEXNIGULDIPINE MODE_CLASS Channel Blocker 120054-86-6 DEXNIGULDIPINE ADVERSE_EFFECT CVS__Bradycardia 120054-86-6 DEXNIGULDIPINE MECHANISM Reduce muscle contractile force 120054-86-6 DEXNIGULDIPINE PRODUCT_CLASS Anti-cancers 120054-86-6 DEXNIGULDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 120054-86-6 DEXNIGULDIPINE ADVERSE_EFFECT CVS__Tachycardia 113145-70-3 DEXNIGULDIPINE THERAPEUTIC_CLASS Antineoplastics 113145-70-3 DEXNIGULDIPINE MECHANISM Reduce muscle contractile force 113145-70-3 DEXNIGULDIPINE ADVERSE_EFFECT CVS__Tachycardia 113145-70-3 DEXNIGULDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 113145-70-3 DEXNIGULDIPINE PRODUCT_CLASS Anti-cancers 113145-70-3 DEXNIGULDIPINE MODE_CLASS Channel Blocker 113145-70-3 DEXNIGULDIPINE ADVERSE_EFFECT CVS__Bradycardia 120138-50-3 QUINUPRISTIN MECHANISM Inhibit ribosomal protein synthesis 120138-50-3 QUINUPRISTIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 120444-71-5 DERAMCICLANE THERAPEUTIC_CLASS Sedatives/Hypnotics 120444-71-5 DERAMCICLANE INDICATION Anxiety Disorders 120444-71-5 DERAMCICLANE PRODUCT_CLASS Central Nervous System (CNS) 120656-74-8 TREFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 120656-74-8 TREFENTANIL PRODUCT_CLASS Analgesics 120656-74-8 TREFENTANIL MECHANISM Modulate neural transmission 120656-74-8 TREFENTANIL MODE_CLASS Receptor Agonist, selective 120656-74-8 TREFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 122823-06-7 TREFENTANIL MECHANISM Modulate neural transmission 122823-06-7 TREFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 122823-06-7 TREFENTANIL PRODUCT_CLASS Analgesics 122823-06-7 TREFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 122823-06-7 TREFENTANIL MODE_CLASS Receptor Agonist, selective 120656-93-1 TREFENTANIL PRODUCT_CLASS Analgesics 120656-93-1 TREFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 120656-93-1 TREFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 120656-93-1 TREFENTANIL MECHANISM Modulate neural transmission 120656-93-1 TREFENTANIL MODE_CLASS Receptor Agonist, selective 121840-95-7 ROGLETIMIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 121840-95-7 ROGLETIMIDE PRODUCT_CLASS Anti-cancers 121840-95-7 ROGLETIMIDE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 121840-95-7 ROGLETIMIDE MODE_CLASS Enzyme Inhibitor 121840-95-7 ROGLETIMIDE THERAPEUTIC_CLASS Antineoplastics 122898-67-3 ITOPRIDE THERAPEUTIC_CLASS Prokinetic Agents 122898-67-3 ITOPRIDE MECHANISM Enhance cholinergic transmission 122898-67-3 ITOPRIDE MODE_CLASS Enzyme Inhibitor 122898-67-3 ITOPRIDE PRODUCT_CLASS Gastrointestinal System 122898-67-3 ITOPRIDE MODE_CLASS Receptor Ligand Antagonist 122898-67-3 ITOPRIDE MECHANISM Block neural transmission 122892-31-3 ITOPRIDE MODE_CLASS Receptor Ligand Antagonist 122892-31-3 ITOPRIDE PRODUCT_CLASS Gastrointestinal System 122892-31-3 ITOPRIDE THERAPEUTIC_CLASS Prokinetic Agents 122892-31-3 ITOPRIDE MECHANISM Enhance cholinergic transmission 122892-31-3 ITOPRIDE MECHANISM Block neural transmission 122892-31-3 ITOPRIDE MODE_CLASS Enzyme Inhibitor 124378-77-4 ENADOLINE INDICATION Cerebral Ischemia 107431-28-7 ENADOLINE INDICATION Cerebral Ischemia 124439-07-2 ENADOLINE INDICATION Cerebral Ischemia 126100-97-8 DIMIRACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 126222-34-2 REMIKIREN PRODUCT_CLASS Cardiovasculars 126222-34-2 REMIKIREN THERAPEUTIC_CLASS Antihypertensive Agents 126222-34-2 REMIKIREN INDICATION Hypertension 126294-30-2 SAGANDIPINE MECHANISM Reduce muscle contractile force 126294-30-2 SAGANDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 126294-30-2 SAGANDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 126294-30-2 SAGANDIPINE PRODUCT_CLASS Cardiovasculars 126294-30-2 SAGANDIPINE MODE_CLASS Channel Blocker 126825-36-3 BERTOSAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 126825-36-3 BERTOSAMIL INDICATION Cardiac Arrhythmias 126825-36-3 BERTOSAMIL PRODUCT_CLASS Cardiovasculars 126924-38-7 SEPROXETINE INDICATION Depression 126924-38-7 SEPROXETINE PRODUCT_CLASS Central Nervous System (CNS) 126924-38-7 SEPROXETINE THERAPEUTIC_CLASS Antidepressants 127035-60-3 ENOFELAST PRODUCT_CLASS Respiratory System 127035-60-3 ENOFELAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 127035-60-3 ENOFELAST INDICATION Asthma 127304-28-3 LINAROTENE INDICATION Actinic Keratosis 128470-16-6 ARBUTAMINE ADVERSE_EFFECT XXX_2_Fatigue 128470-16-6 ARBUTAMINE ADVERSE_EFFECT CVS_2_Hypotension 128470-16-6 ARBUTAMINE MODE_CLASS Receptor Agonist 128470-16-6 ARBUTAMINE ADVERSE_EFFECT CVS_2_Angina Pectoris 128470-16-6 ARBUTAMINE ADVERSE_EFFECT NEU_2_Paresthesia 128470-16-6 ARBUTAMINE ADVERSE_EFFECT SKN_1_Flushing 128470-16-6 ARBUTAMINE TISSUE_TOXICITY Arrhythmia 128470-16-6 ARBUTAMINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 128470-16-6 ARBUTAMINE TISSUE_TOXICITY Atrial Fibrillation 128470-16-6 ARBUTAMINE TISSUE_TOXICITY Hypotension 128470-16-6 ARBUTAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 128470-16-6 ARBUTAMINE ADVERSE_EFFECT NEU_2_Tremor 128470-16-6 ARBUTAMINE ADVERSE_EFFECT CVS_1_Arrhythmia 128470-16-6 ARBUTAMINE ADVERSE_EFFECT LUN_2_Dyspnea 128470-16-6 ARBUTAMINE ADVERSE_EFFECT NEU_2_Dizziness 128470-16-6 ARBUTAMINE ADVERSE_EFFECT CVS_1_Palpitation 128470-16-6 ARBUTAMINE STRUCTURE_ACTIVITY Adrenoceptor-beta agonist 128470-16-6 ARBUTAMINE ADVERSE_EFFECT CVS_2_Atrial Fibrillation 128470-16-6 ARBUTAMINE ADVERSE_EFFECT GIS_2_Nausea 128470-16-6 ARBUTAMINE ADVERSE_EFFECT XXX_2_Sweating 128470-16-6 ARBUTAMINE INDICATION Coronary Artery Disease (for diagnosis) 128470-16-6 ARBUTAMINE PRODUCT_CLASS Cardiovasculars 128470-16-6 ARBUTAMINE MECHANISM Modulate G-protein coupled signal transduction 128470-16-6 ARBUTAMINE TISSUE_TOXICITY Angina Pectoris 128470-16-6 ARBUTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 128470-16-6 ARBUTAMINE ADVERSE_EFFECT CVS_2_Chest Pain 128470-16-6 ARBUTAMINE ADVERSE_EFFECT SKN_2_Rash 125251-66-3 ARBUTAMINE ADVERSE_EFFECT SKN_1_Flushing 125251-66-3 ARBUTAMINE ADVERSE_EFFECT NEU_2_Paresthesia 125251-66-3 ARBUTAMINE ADVERSE_EFFECT CVS_2_Angina Pectoris 125251-66-3 ARBUTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 125251-66-3 ARBUTAMINE TISSUE_TOXICITY Hypotension 125251-66-3 ARBUTAMINE ADVERSE_EFFECT CVS_1_Palpitation 125251-66-3 ARBUTAMINE INDICATION Coronary Artery Disease (for diagnosis) 125251-66-3 ARBUTAMINE ADVERSE_EFFECT SKN_2_Rash 125251-66-3 ARBUTAMINE ADVERSE_EFFECT CVS_2_Chest Pain 125251-66-3 ARBUTAMINE TISSUE_TOXICITY Angina Pectoris 125251-66-3 ARBUTAMINE MECHANISM Modulate G-protein coupled signal transduction 125251-66-3 ARBUTAMINE ADVERSE_EFFECT CVS_2_Atrial Fibrillation 125251-66-3 ARBUTAMINE ADVERSE_EFFECT GIS_2_Nausea 125251-66-3 ARBUTAMINE ADVERSE_EFFECT XXX_2_Sweating 125251-66-3 ARBUTAMINE ADVERSE_EFFECT CVS_2_Hypotension 125251-66-3 ARBUTAMINE PRODUCT_CLASS Cardiovasculars 125251-66-3 ARBUTAMINE MODE_CLASS Receptor Agonist 125251-66-3 ARBUTAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 125251-66-3 ARBUTAMINE ADVERSE_EFFECT NEU_2_Dizziness 125251-66-3 ARBUTAMINE STRUCTURE_ACTIVITY Adrenoceptor-beta agonist 125251-66-3 ARBUTAMINE ADVERSE_EFFECT LUN_2_Dyspnea 125251-66-3 ARBUTAMINE ADVERSE_EFFECT XXX_2_Fatigue 125251-66-3 ARBUTAMINE ADVERSE_EFFECT CVS_1_Arrhythmia 125251-66-3 ARBUTAMINE TISSUE_TOXICITY Atrial Fibrillation 125251-66-3 ARBUTAMINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 125251-66-3 ARBUTAMINE TISSUE_TOXICITY Arrhythmia 125251-66-3 ARBUTAMINE ADVERSE_EFFECT NEU_2_Tremor 131635-06-8 SIFAPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 131635-06-8 SIFAPRAZINE INDICATION Depression 131635-06-8 SIFAPRAZINE THERAPEUTIC_CLASS Antidepressants 132019-54-6 MONATEPIL THERAPEUTIC_CLASS Antihypertensive Agents 132019-54-6 MONATEPIL INDICATION Hypertension 132019-54-6 MONATEPIL INDICATION Angina Pectoris 132019-54-6 MONATEPIL THERAPEUTIC_CLASS Antianginals 132019-54-6 MONATEPIL PRODUCT_CLASS Cardiovasculars 132438-21-2 CAMIGLIBOSE INDICATION Diabetes 132449-46-8 LESOPITRON PRODUCT_CLASS Central Nervous System (CNS) 132449-46-8 LESOPITRON MECHANISM Modulate neural transmission 132449-46-8 LESOPITRON INDICATION Anxiety Disorders 132449-46-8 LESOPITRON THERAPEUTIC_CLASS Sedatives/Hypnotics 132449-89-9 LESOPITRON THERAPEUTIC_CLASS Sedatives/Hypnotics 132449-89-9 LESOPITRON MECHANISM Modulate neural transmission 132449-89-9 LESOPITRON PRODUCT_CLASS Central Nervous System (CNS) 132449-89-9 LESOPITRON INDICATION Anxiety Disorders 132449-88-8 LESOPITRON THERAPEUTIC_CLASS Sedatives/Hypnotics 132449-88-8 LESOPITRON MECHANISM Modulate neural transmission 132449-88-8 LESOPITRON PRODUCT_CLASS Central Nervous System (CNS) 132449-88-8 LESOPITRON INDICATION Anxiety Disorders 132829-83-5 ESPATROPATE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 132829-83-5 ESPATROPATE PRODUCT_CLASS Respiratory System 132829-83-5 ESPATROPATE INDICATION Asthma 132875-61-7 REMIFENTANIL PRODUCT_CLASS Analgesics 132875-61-7 REMIFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 132875-61-7 REMIFENTANIL MODE_CLASS Receptor Agonist, selective 132875-61-7 REMIFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 132875-61-7 REMIFENTANIL MECHANISM Modulate neural transmission 132539-07-2 REMIFENTANIL MODE_CLASS Receptor Agonist, selective 132539-07-2 REMIFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 132539-07-2 REMIFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 132539-07-2 REMIFENTANIL PRODUCT_CLASS Analgesics 132539-07-2 REMIFENTANIL MECHANISM Modulate neural transmission 132875-62-8 REMIFENTANIL MODE_CLASS Receptor Agonist, selective 132875-62-8 REMIFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 132875-62-8 REMIFENTANIL PRODUCT_CLASS Analgesics 132875-62-8 REMIFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 132875-62-8 REMIFENTANIL MECHANISM Modulate neural transmission 133267-19-3 ARTILIDE PRODUCT_CLASS Cardiovasculars 133267-19-3 ARTILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 133267-19-3 ARTILIDE INDICATION Cardiac Arrhythmias 136777-43-0 CARVOTROLINE MECHANISM Modulate G-protein coupled signal transduction 138540-32-6 ATEVIRDINE INDICATION Myocardial Ischemia 141683-98-9 DARGLITAZONE MECHANISM Increase transcription of insulin responsive gene 141683-98-9 DARGLITAZONE INDICATION Type II Diabetes Mellitus 141683-98-9 DARGLITAZONE MECHANISM Increase lipid catabolism 141683-98-9 DARGLITAZONE MODE_CLASS Receptor Agonist 141683-98-9 DARGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 141683-98-9 DARGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 141683-98-9 DARGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 125549-25-9 DARGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 125549-25-9 DARGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 125549-25-9 DARGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 125549-25-9 DARGLITAZONE MODE_CLASS Receptor Agonist 125549-25-9 DARGLITAZONE MECHANISM Increase lipid catabolism 125549-25-9 DARGLITAZONE MECHANISM Increase transcription of insulin responsive gene 125549-25-9 DARGLITAZONE INDICATION Type II Diabetes Mellitus 141200-24-0 DARGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 141200-24-0 DARGLITAZONE MODE_CLASS Receptor Agonist 141200-24-0 DARGLITAZONE MECHANISM Increase lipid catabolism 141200-24-0 DARGLITAZONE MECHANISM Increase transcription of insulin responsive gene 141200-24-0 DARGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 141200-24-0 DARGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 141200-24-0 DARGLITAZONE INDICATION Type II Diabetes Mellitus 68-89-3 DIPYRONE ADVERSE_EFFECT SKN_3_Rash 68-89-3 DIPYRONE ADVERSE_EFFECT BBM_2_Leukopenia 68-89-3 DIPYRONE ADVERSE_EFFECT GIS_3_Oral Ulceration 68-89-3 DIPYRONE TISSUE_TOXICITY Acute Tubular Necrosis 68-89-3 DIPYRONE INDICATION Pain 68-89-3 DIPYRONE MODE_CLASS Enzyme Inhibitor 68-89-3 DIPYRONE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 68-89-3 DIPYRONE ADVERSE_EFFECT BBM_3_Anemia 68-89-3 DIPYRONE ADVERSE_EFFECT BBM_2_Neutropenia 68-89-3 DIPYRONE ADVERSE_EFFECT _3_Lyell Syndrome 68-89-3 DIPYRONE STRUCTURE_ACTIVITY NSAID, COX-3, antipyrine like 68-89-3 DIPYRONE ACTIVITY_CLASS Anti-inflammatory 68-89-3 DIPYRONE ADVERSE_EFFECT END_2_Acute Intermittent Porphyria 68-89-3 DIPYRONE ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 68-89-3 DIPYRONE ADVERSE_EFFECT BBM_2_Bone Marrow Toxicity 68-89-3 DIPYRONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 68-89-3 DIPYRONE KNOWN_TOXICITY Nephrotoxicity 68-89-3 DIPYRONE ZERO_CLASS N 68-89-3 DIPYRONE PRODUCT_CLASS Analgesics 68-89-3 DIPYRONE PRODUCT_CLASS Anti-inflammatories 68-89-3 DIPYRONE THERAPEUTIC_CLASS Analgesics, Non-Opioid 68-89-3 DIPYRONE ADVERSE_EFFECT BBM_3_Agranulocytosis 68-89-3 DIPYRONE ADVERSE_EFFECT KID_3_Acute Tubular Necrosis 68-89-3 DIPYRONE ADVERSE_EFFECT GUS_3_Discoloration of Urine 68-89-3 DIPYRONE INDICATION Fever 68-89-3 DIPYRONE MECHANISM Inhibit eicosanoid biosynthesis 129-16-8 MERBROMIN PRODUCT_CLASS Cardiovasculars 129-16-8 MERBROMIN THERAPEUTIC_CLASS Antiarrhythmic Agents 129-16-8 MERBROMIN INDICATION Cardiac Arrhythmias 133-65-3 SOLASULFONE INDICATION Leprosy 357-56-2 DEXTROMORAMIDE THERAPEUTIC_CLASS Analgesics, Opioid 357-56-2 DEXTROMORAMIDE PRODUCT_CLASS Analgesics 357-56-2 DEXTROMORAMIDE MODE_CLASS Receptor Agonist 357-56-2 DEXTROMORAMIDE MECHANISM Modulate neural transmission 492-18-2 MERSALYL MECHANISM Inhibit mitochondrial function 492-18-2 MERSALYL MODE_CLASS Channel Blocker 492-18-2 MERSALYL THERAPEUTIC_CLASS Diuretics 492-18-2 MERSALYL PRODUCT_CLASS Electrolytic, Caloric and Water Balance 987-24-6 BETAMETHASONE ACETATE MECHANISM Modulate gene transcription 987-24-6 BETAMETHASONE ACETATE THERAPEUTIC_CLASS Corticosteroids 987-24-6 BETAMETHASONE ACETATE MODE_CLASS Receptor Agonist 987-24-6 BETAMETHASONE ACETATE PRODUCT_CLASS Anti-inflammatories 1046-17-9 DIBUPYRONE PRODUCT_CLASS Anti-inflammatories 1046-17-9 DIBUPYRONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 1177-87-3 DEXAMETHASONE ACETATE MECHANISM Modulate gene transcription 1177-87-3 DEXAMETHASONE ACETATE PRODUCT_CLASS Anti-inflammatories 1177-87-3 DEXAMETHASONE ACETATE THERAPEUTIC_CLASS Corticosteroids 1177-87-3 DEXAMETHASONE ACETATE MODE_CLASS Receptor Agonist 2338-37-6 LEVOPROPOXYPHENE INDICATION Cough / Tussis 5571-84-6 NITRAZEPATE MODE_CLASS Channel enhancer /opener 5571-84-6 NITRAZEPATE THERAPEUTIC_CLASS Sedatives/Hypnotics 5571-84-6 NITRAZEPATE MECHANISM Modulate neural transmission 5571-84-6 NITRAZEPATE PRODUCT_CLASS Central Nervous System (CNS) 5965-40-2 ALLOCUPREIDE INDICATION Arthritis 5965-40-2 ALLOCUPREIDE THERAPEUTIC_CLASS Immunosuppressants 5965-40-2 ALLOCUPREIDE PRODUCT_CLASS Immune Response / Immunomodulators 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT SKN_1_Skin Rash 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_2_Neutropenia 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT NEU_3_Optic Neuritis 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_2_Leukopenia 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_3_Agranulocytosis 15318-45-3 THIAMPHENICOL MECHANISM Inhibit ribosomal protein synthesis 15318-45-3 THIAMPHENICOL MECH_LEVEL_2 Inhibit ribosomal protein synthesis 15318-45-3 THIAMPHENICOL TA_LEVEL_1 Infectious Disease 15318-45-3 THIAMPHENICOL INDICATION Typhoid / Typhus 15318-45-3 THIAMPHENICOL TA_LEVEL_2 antibacterials 15318-45-3 THIAMPHENICOL ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT _3_Endotoxic Shock 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT OCU_3_Cycloplegia 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_3_Bone Marrow Aplasia 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_3_Aplastic Anemia 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT XXX_2_Candidiasis 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT PSY_3_Depression 15318-45-3 THIAMPHENICOL INDICATION Bronchopulmonary Infection 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT NEU_3_Polyneuritis 15318-45-3 THIAMPHENICOL INDICATION Purulent Meningitis 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT XXX_3_Gray Baby Syndrome 15318-45-3 THIAMPHENICOL TA_LEVEL_3 biliary tract infection 15318-45-3 THIAMPHENICOL PRODUCT_CLASS Anti-infectives 15318-45-3 THIAMPHENICOL INDICATION Biliary Tract Infection 15318-45-3 THIAMPHENICOL MECH_LEVEL_1 Inhibits the transpeptidation step by binding to robosome interfers with the formation of new peptide bonds. 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT GIS_1_Vomiting 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_3_Hemolysis 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT XXX_2_Glossitis 15318-45-3 THIAMPHENICOL THERAPEUTIC_CLASS Antibacterials, Systemic 15318-45-3 THIAMPHENICOL MECH_LEVEL_3 50/60S Ribosomal Subunit 15318-45-3 THIAMPHENICOL INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 15318-45-3 THIAMPHENICOL INDICATION Septicemia 15318-45-3 THIAMPHENICOL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT GIS_1_Nausea 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT GIS_1_Stomatitis 15318-45-3 THIAMPHENICOL STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, amphenicol 15318-45-3 THIAMPHENICOL ZERO_CLASS N 15318-45-3 THIAMPHENICOL MESH_LEVEL_1 Organic Chemicals 15318-45-3 THIAMPHENICOL MESH_LEVEL_2 Alcohols 15318-45-3 THIAMPHENICOL MESH_LEVEL_3 Glycols 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_2_Thrombocytopenia 15318-45-3 THIAMPHENICOL INDICATION Haemophilus Influenzae Meningitis 15318-45-3 THIAMPHENICOL ADVERSE_EFFECT BBM_3_Paroxymal Nocturnal Hematuria 63547-13-7 ADRAFINIL MECHANISM Prolong/enhance neural transmission 63547-13-7 ADRAFINIL THERAPEUTIC_CLASS Central Stimulants 63547-13-7 ADRAFINIL PRODUCT_CLASS Central Nervous System (CNS) 63547-13-7 ADRAFINIL MODE_CLASS Solute transporter inhibitor 68238-36-8 ISOSULFAN BLUE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 81447-78-1 LEVLOFEXIDINE INDICATION Hypertension 81447-78-1 LEVLOFEXIDINE PRODUCT_CLASS Cardiovasculars 81447-78-1 LEVLOFEXIDINE THERAPEUTIC_CLASS Antihypertensive Agents 81447-79-2 DEXLOFEXIDINE THERAPEUTIC_CLASS Antihypertensive Agents 81447-79-2 DEXLOFEXIDINE INDICATION Hypertension 81447-79-2 DEXLOFEXIDINE PRODUCT_CLASS Cardiovasculars 84878-61-5 MADURAMICIN INDICATION Coccidiosis 84878-61-5 MADURAMICIN THERAPEUTIC_CLASS Antiparasitics 84878-61-5 MADURAMICIN MECHANISM Destroy cell membrane / wall integrity 84878-61-5 MADURAMICIN PRODUCT_CLASS Veterinarian 84878-61-5 MADURAMICIN MODE_CLASS Distorts /blocks macromolecular scaffold function 61991-54-6 MADURAMICIN INDICATION Coccidiosis 61991-54-6 MADURAMICIN THERAPEUTIC_CLASS Antiparasitics 61991-54-6 MADURAMICIN PRODUCT_CLASS Veterinarian 61991-54-6 MADURAMICIN MODE_CLASS Distorts /blocks macromolecular scaffold function 61991-54-6 MADURAMICIN MECHANISM Destroy cell membrane / wall integrity 96392-96-0 DEXORMAPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 105239-91-6 CEFCLIDIN PRODUCT_CLASS Anti-infectives 105239-91-6 CEFCLIDIN MODE_CLASS Enzyme Inhibitor 105239-91-6 CEFCLIDIN THERAPEUTIC_CLASS Antibacterials 105239-91-6 CEFCLIDIN MECHANISM Inhibit bacterial cell wall biosynthesis 91-64-5 COUMARIN ADVERSE_EFFECT XXX_1_Weight Loss 91-64-5 COUMARIN ADVERSE_EFFECT LUN_3_Pulmonary Toxicity 91-64-5 COUMARIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91-64-5 COUMARIN KNOWN_TOXICITY Hepatotoxicity 91-64-5 COUMARIN TISSUE_TOXICITY Hepatotoxicity 91-64-5 COUMARIN ZERO_CLASS N 91-64-5 COUMARIN ADVERSE_EFFECT PSY_2_Depression 91-64-5 COUMARIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 91-64-5 COUMARIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 91-64-5 COUMARIN TISSUE_TOXICITY Hepatic Necrosis 91-64-5 COUMARIN STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 91-64-5 COUMARIN MECHANISM Inhibit platelet aggregation 91-64-5 COUMARIN MESH_LEVEL_3 Benzopyrans 91-64-5 COUMARIN TA_LEVEL_3 anticoagulant 91-64-5 COUMARIN ADVERSE_EFFECT NEU_2_Muscular Incoordination 91-64-5 COUMARIN ADVERSE_EFFECT GIS_1_Vomiting 91-64-5 COUMARIN ADVERSE_EFFECT BBM_2_Bleeding 91-64-5 COUMARIN ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 91-64-5 COUMARIN MODE_CLASS Enzyme Inhibitor 91-64-5 COUMARIN MECH_LEVEL_1 Anti-clotting 91-64-5 COUMARIN MECH_LEVEL_3 Vitamin-K-epoxide reductase 91-64-5 COUMARIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 91-64-5 COUMARIN MECH_LEVEL_2 Inhibit platelet aggregation 91-64-5 COUMARIN ADVERSE_EFFECT LIV_2_Jaundice 91-64-5 COUMARIN ADVERSE_EFFECT PSY_2_Anorexia 91-64-5 COUMARIN ADVERSE_EFFECT BBM_2_Hemorrhage 91-64-5 COUMARIN ADVERSE_EFFECT END_2_Growth Deficiencies 91-64-5 COUMARIN PRODUCT_CLASS Biochemicals 91-64-5 COUMARIN TA_LEVEL_1 Cardiovascular 91-64-5 COUMARIN MESH_LEVEL_1 Heterocyclic Compounds 91-64-5 COUMARIN TA_LEVEL_2 anticoagulant 91-64-5 COUMARIN ADVERSE_EFFECT KID_3_Kidney Damage 2752-99-0 GLYCERYLTRIERUCATE INDICATION Multiple Sclerosis (MS) 35301-24-7 CEDEFINGOL INDICATION Psoriasis 107023-41-6 POBILUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 107023-41-6 POBILUKAST MODE_CLASS Receptor Ligand Antagonist 107023-41-6 POBILUKAST INDICATION Asthma 107023-41-6 POBILUKAST PRODUCT_CLASS Respiratory System 107023-41-6 POBILUKAST MECHANISM Modulate G-protein coupled signal transduction 107023-41-6 POBILUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 110013-21-3 MERAFLOXACIN THERAPEUTIC_CLASS Antibacterials 110013-21-3 MERAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 110013-21-3 MERAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 110013-21-3 MERAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 110013-21-3 MERAFLOXACIN PRODUCT_CLASS Anti-infectives 110347-85-8 SELFOTEL MECHANISM Prolong/enhance neural transmission 110347-85-8 SELFOTEL THERAPEUTIC_CLASS Cerebral Vascular Disorders 110347-85-8 SELFOTEL MODE_CLASS Channel Modulator 110347-85-8 SELFOTEL PRODUCT_CLASS Central Nervous System (CNS) 110671-78-8 14-HYDROXYCLARITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 110671-78-8 14-HYDROXYCLARITHROMYCIN PRODUCT_CLASS Anti-infectives 110671-78-8 14-HYDROXYCLARITHROMYCIN THERAPEUTIC_CLASS Antibacterials 110671-78-8 14-HYDROXYCLARITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 115972-78-6 OLRADIPINE THERAPEUTIC_CLASS Antihypertensive Agents 115972-78-6 OLRADIPINE MECHANISM Reduce muscle contractile force 115972-78-6 OLRADIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 115972-78-6 OLRADIPINE MODE_CLASS Channel Blocker 115972-78-6 OLRADIPINE PRODUCT_CLASS Cardiovasculars 115972-78-6 OLRADIPINE INDICATION Hypertension 116420-35-0 GLUTAMINE MONOFLUOROPHOSPHATE INDICATION Osteoporosis 121459-89-0 SULFENAMIDE INDICATION Ulcer 125729-29-5 LEMILDIPINE MECHANISM Reduce muscle contractile force 125729-29-5 LEMILDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 125729-29-5 LEMILDIPINE INDICATION Hypertension 125729-29-5 LEMILDIPINE PRODUCT_CLASS Cardiovasculars 125729-29-5 LEMILDIPINE MODE_CLASS Channel Blocker 125729-29-5 LEMILDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 127266-56-2 ADATANSERIN MODE_CLASS Receptor Ligand Antagonist 127266-56-2 ADATANSERIN THERAPEUTIC_CLASS Sedatives/Hypnotics 127266-56-2 ADATANSERIN INDICATION Depression 127266-56-2 ADATANSERIN INDICATION Anxiety Disorders 127266-56-2 ADATANSERIN THERAPEUTIC_CLASS Antidepressants 127266-56-2 ADATANSERIN MECHANISM Modulate neural transmission 127266-56-2 ADATANSERIN PRODUCT_CLASS Central Nervous System (CNS) 127266-75-5 ADATANSERIN PRODUCT_CLASS Central Nervous System (CNS) 127266-75-5 ADATANSERIN MODE_CLASS Receptor Ligand Antagonist 127266-75-5 ADATANSERIN INDICATION Anxiety Disorders 127266-75-5 ADATANSERIN INDICATION Depression 127266-75-5 ADATANSERIN THERAPEUTIC_CLASS Sedatives/Hypnotics 127266-75-5 ADATANSERIN THERAPEUTIC_CLASS Antidepressants 127266-75-5 ADATANSERIN MECHANISM Modulate neural transmission 144966-96-1 ADATANSERIN INDICATION Anxiety Disorders 144966-96-1 ADATANSERIN MODE_CLASS Receptor Ligand Antagonist 144966-96-1 ADATANSERIN THERAPEUTIC_CLASS Sedatives/Hypnotics 144966-96-1 ADATANSERIN PRODUCT_CLASS Central Nervous System (CNS) 144966-96-1 ADATANSERIN INDICATION Depression 144966-96-1 ADATANSERIN MECHANISM Modulate neural transmission 144966-96-1 ADATANSERIN THERAPEUTIC_CLASS Antidepressants 147778-05-0 CNDQ MODE_CLASS Channel Modulator 147778-05-0 CNDQ MECHANISM Modulate neural transmission 139886-32-1 MILAMELINE INDICATION Alzheimer's Disease 139886-32-1 MILAMELINE INDICATION Dementia 114485-44-8 MILAMELINE INDICATION Dementia 114485-44-8 MILAMELINE INDICATION Alzheimer's Disease 114485-39-1 MILAMELINE INDICATION Dementia 114485-39-1 MILAMELINE INDICATION Alzheimer's Disease 139886-04-7 MILAMELINE INDICATION Dementia 139886-04-7 MILAMELINE INDICATION Alzheimer's Disease 149908-53-2 AZIMILIDE MECHANISM Modulate channel gating 149908-53-2 AZIMILIDE MODE_CLASS Channel Blocker 149908-53-2 AZIMILIDE PRODUCT_CLASS Cardiovasculars 149908-53-2 AZIMILIDE INDICATION Cardiac Arrhythmias 149908-53-2 AZIMILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 149888-94-8 AZIMILIDE PRODUCT_CLASS Cardiovasculars 149888-94-8 AZIMILIDE INDICATION Cardiac Arrhythmias 149888-94-8 AZIMILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 149888-94-8 AZIMILIDE MECHANISM Modulate channel gating 149888-94-8 AZIMILIDE MODE_CLASS Channel Blocker 50-22-6 CORTICOSTERONE INDICATION Neoplastic Diseases 50-22-6 CORTICOSTERONE INDICATION Edematous States 50-22-6 CORTICOSTERONE PRODUCT_CLASS Anti-inflammatories 50-22-6 CORTICOSTERONE INDICATION Ophthalmic Diseases 50-22-6 CORTICOSTERONE INDICATION Endocrine Disorders 50-22-6 CORTICOSTERONE INDICATION Respiratory Diseases 50-22-6 CORTICOSTERONE INDICATION Allergic Diseases 50-22-6 CORTICOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 50-22-6 CORTICOSTERONE THERAPEUTIC_CLASS Corticosteroids 50-22-6 CORTICOSTERONE INDICATION Gastrointestinal Diseases 50-22-6 CORTICOSTERONE INDICATION Skin Diseases / Dermatoses 50-22-6 CORTICOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 50-22-6 CORTICOSTERONE INDICATION Collagen Diseases 50-22-6 CORTICOSTERONE INDICATION Hematologic Disorders 50-22-6 CORTICOSTERONE INDICATION Rheumatic Disorders 50-22-6 CORTICOSTERONE MECHANISM Modulate gene transcription 50-59-9 CEPHALORIDINE ADVERSE_EFFECT IMU_3_Anaphylaxis 50-59-9 CEPHALORIDINE ADVERSE_EFFECT KID_3_Renal Failure 50-59-9 CEPHALORIDINE THERAPEUTIC_CLASS Antibacterials, Systemic 50-59-9 CEPHALORIDINE STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 50-59-9 CEPHALORIDINE ADVERSE_EFFECT KID_3_Acute Tubular Necrosis 50-59-9 CEPHALORIDINE ADVERSE_EFFECT KID_2_Nephrotoxicity 50-59-9 CEPHALORIDINE TISSUE_TOXICITY Acute Tubular Necrosis 50-59-9 CEPHALORIDINE KNOWN_TOXICITY Nephrotoxicity 50-59-9 CEPHALORIDINE PRODUCT_CLASS Anti-infectives 50-59-9 CEPHALORIDINE MECHANISM Inhibit bacterial cell wall biosynthesis 50-59-9 CEPHALORIDINE MODE_CLASS Enzyme Inhibitor 50-59-9 CEPHALORIDINE ADVERSE_EFFECT IMU_1_Hypersensitivity Reactions 50-59-9 CEPHALORIDINE TISSUE_TOXICITY Nephrotoxicity 50-59-9 CEPHALORIDINE TISSUE_TOXICITY Renal Failure 50-59-9 CEPHALORIDINE ADVERSE_EFFECT SKN_1_Rash 52-21-1 PREDNISOLONE ACETATE MECHANISM Modulate gene transcription 52-21-1 PREDNISOLONE ACETATE MODE_CLASS Receptor Agonist 52-39-1 ALDOSTERONE THERAPEUTIC_CLASS Corticosteroids 52-39-1 ALDOSTERONE ADVERSE_EFFECT KID_2_Kidney Damage 52-39-1 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypokalemia 52-39-1 ALDOSTERONE TISSUE_TOXICITY Congestive Heart Failure 52-39-1 ALDOSTERONE ADVERSE_EFFECT CVS_2_Vascular Damage 52-39-1 ALDOSTERONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 52-39-1 ALDOSTERONE ACTIVITY_CLASS GR-MR agonist 52-39-1 ALDOSTERONE ADVERSE_EFFECT CVS_2_Cardiovascular Disorder 52-39-1 ALDOSTERONE ADVERSE_EFFECT KID_1_Salt Retention 52-39-1 ALDOSTERONE INDICATION Adrenocortical Insufficiency 52-39-1 ALDOSTERONE MECHANISM Modulate gene transcription 52-39-1 ALDOSTERONE STRUCTURE_ACTIVITY Mineralocorticoid receptor agonist 52-39-1 ALDOSTERONE ADVERSE_EFFECT CVS_1_Hypertension 52-39-1 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypomagnesemia 52-39-1 ALDOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 52-39-1 ALDOSTERONE ADVERSE_EFFECT KID_1_Fluid Retention 52-39-1 ALDOSTERONE KNOWN_TOXICITY Cardiovascular Toxicity 52-39-1 ALDOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 6251-69-0 ALDOSTERONE ACTIVITY_CLASS GR-MR agonist 6251-69-0 ALDOSTERONE ADVERSE_EFFECT KID_1_Fluid Retention 6251-69-0 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypomagnesemia 6251-69-0 ALDOSTERONE TISSUE_TOXICITY Congestive Heart Failure 6251-69-0 ALDOSTERONE ADVERSE_EFFECT CVS_2_Cardiovascular Disorder 6251-69-0 ALDOSTERONE ADVERSE_EFFECT KID_1_Salt Retention 6251-69-0 ALDOSTERONE THERAPEUTIC_CLASS Corticosteroids 6251-69-0 ALDOSTERONE ADVERSE_EFFECT KID_2_Kidney Damage 6251-69-0 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypokalemia 6251-69-0 ALDOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 6251-69-0 ALDOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 6251-69-0 ALDOSTERONE INDICATION Adrenocortical Insufficiency 6251-69-0 ALDOSTERONE ADVERSE_EFFECT CVS_2_Vascular Damage 6251-69-0 ALDOSTERONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 6251-69-0 ALDOSTERONE ADVERSE_EFFECT CVS_1_Hypertension 6251-69-0 ALDOSTERONE MECHANISM Modulate gene transcription 6251-69-0 ALDOSTERONE STRUCTURE_ACTIVITY Mineralocorticoid receptor agonist 6251-69-0 ALDOSTERONE KNOWN_TOXICITY Cardiovascular Toxicity 152-04-5 ALDOSTERONE ADVERSE_EFFECT CVS_2_Cardiovascular Disorder 152-04-5 ALDOSTERONE ADVERSE_EFFECT KID_1_Salt Retention 152-04-5 ALDOSTERONE MECHANISM Modulate gene transcription 152-04-5 ALDOSTERONE STRUCTURE_ACTIVITY Mineralocorticoid receptor agonist 152-04-5 ALDOSTERONE ADVERSE_EFFECT CVS_1_Hypertension 152-04-5 ALDOSTERONE ADVERSE_EFFECT KID_1_Fluid Retention 152-04-5 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypomagnesemia 152-04-5 ALDOSTERONE ADVERSE_EFFECT KID_2_Kidney Damage 152-04-5 ALDOSTERONE INDICATION Adrenocortical Insufficiency 152-04-5 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypokalemia 152-04-5 ALDOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 152-04-5 ALDOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 152-04-5 ALDOSTERONE KNOWN_TOXICITY Cardiovascular Toxicity 152-04-5 ALDOSTERONE ADVERSE_EFFECT CVS_2_Vascular Damage 152-04-5 ALDOSTERONE THERAPEUTIC_CLASS Corticosteroids 152-04-5 ALDOSTERONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 152-04-5 ALDOSTERONE ACTIVITY_CLASS GR-MR agonist 152-04-5 ALDOSTERONE TISSUE_TOXICITY Congestive Heart Failure 10328-70-8 ALDOSTERONE ADVERSE_EFFECT KID_1_Fluid Retention 10328-70-8 ALDOSTERONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 10328-70-8 ALDOSTERONE ACTIVITY_CLASS GR-MR agonist 10328-70-8 ALDOSTERONE TISSUE_TOXICITY Congestive Heart Failure 10328-70-8 ALDOSTERONE ADVERSE_EFFECT CVS_2_Cardiovascular Disorder 10328-70-8 ALDOSTERONE MECHANISM Modulate gene transcription 10328-70-8 ALDOSTERONE ADVERSE_EFFECT KID_2_Kidney Damage 10328-70-8 ALDOSTERONE ADVERSE_EFFECT KID_1_Salt Retention 10328-70-8 ALDOSTERONE STRUCTURE_ACTIVITY Mineralocorticoid receptor agonist 10328-70-8 ALDOSTERONE ADVERSE_EFFECT CVS_1_Hypertension 10328-70-8 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypomagnesemia 10328-70-8 ALDOSTERONE ADVERSE_EFFECT CVS_2_Vascular Damage 10328-70-8 ALDOSTERONE KNOWN_TOXICITY Cardiovascular Toxicity 10328-70-8 ALDOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 10328-70-8 ALDOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 10328-70-8 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypokalemia 10328-70-8 ALDOSTERONE THERAPEUTIC_CLASS Corticosteroids 10328-70-8 ALDOSTERONE INDICATION Adrenocortical Insufficiency 47468-70-2 ALDOSTERONE KNOWN_TOXICITY Cardiovascular Toxicity 47468-70-2 ALDOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 47468-70-2 ALDOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 47468-70-2 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypokalemia 47468-70-2 ALDOSTERONE ADVERSE_EFFECT KID_2_Kidney Damage 47468-70-2 ALDOSTERONE ADVERSE_EFFECT CVS_1_Hypertension 47468-70-2 ALDOSTERONE ADVERSE_EFFECT CVS_2_Vascular Damage 47468-70-2 ALDOSTERONE TISSUE_TOXICITY Congestive Heart Failure 47468-70-2 ALDOSTERONE MECHANISM Modulate gene transcription 47468-70-2 ALDOSTERONE ADVERSE_EFFECT KID_1_Salt Retention 47468-70-2 ALDOSTERONE STRUCTURE_ACTIVITY Mineralocorticoid receptor agonist 47468-70-2 ALDOSTERONE ADVERSE_EFFECT CVS_2_Cardiovascular Disorder 47468-70-2 ALDOSTERONE THERAPEUTIC_CLASS Corticosteroids 47468-70-2 ALDOSTERONE INDICATION Adrenocortical Insufficiency 47468-70-2 ALDOSTERONE ACTIVITY_CLASS GR-MR agonist 47468-70-2 ALDOSTERONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 47468-70-2 ALDOSTERONE ADVERSE_EFFECT KID_1_Fluid Retention 47468-70-2 ALDOSTERONE ADVERSE_EFFECT ELT_1_Hypomagnesemia 52-62-0 PENTOLINIUM TARTRATE THERAPEUTIC_CLASS Antihypertensive Agents 52-62-0 PENTOLINIUM TARTRATE PRODUCT_CLASS Cardiovasculars 52-62-0 PENTOLINIUM TARTRATE INDICATION Hypertension 53-36-1 METHYLPREDNISOLONE ACETATE MECHANISM Modulate gene transcription 53-36-1 METHYLPREDNISOLONE ACETATE MODE_CLASS Receptor Agonist 56-89-3 CYSTINE INDICATION Seborrhea 56-89-3 CYSTINE INDICATION Alopecia / Baldness / Hair Loss 58-63-9 INOSINE MODE_CLASS Receptor Agonist 58-63-9 INOSINE STRUCTURE_ACTIVITY Adenosine receptor agonist, 58-63-9 INOSINE MECHANISM Modulate G-protein coupled signal transduction 62-90-8 NANDROLONE PHENPROPIONATE MECHANISM Modulate gene transcription 62-90-8 NANDROLONE PHENPROPIONATE MODE_CLASS Receptor Agonist 67-73-2 FLUOCINOLONE ACETONIDE MECH_LEVEL_1 Immunomodulation 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Pruritus / Itching 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Seborrheic Dermatitis 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Atopic Dermatitis / Eczema 67-73-2 FLUOCINOLONE ACETONIDE MECH_LEVEL_3 Glucocorticoid receptor 67-73-2 FLUOCINOLONE ACETONIDE TA_LEVEL_2 Steroid 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_2_Skin Irritation 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Skin Ulcer 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT END_3_Adrenal Insufficiency 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT END_3_Hyperglycemia 67-73-2 FLUOCINOLONE ACETONIDE MESH_LEVEL_2 Steroids 67-73-2 FLUOCINOLONE ACETONIDE TA_LEVEL_1 Anti-inflammatory 67-73-2 FLUOCINOLONE ACETONIDE TA_LEVEL_3 Topical steroid 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Discoid Lupus Erythematosus / Chronic Cutaneous Lupus Erythematosus 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Lichen Simplex Chronicus / Circumscribed Neurodermatitis 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Allergic Contact Dermatitis 67-73-2 FLUOCINOLONE ACETONIDE ZERO_CLASS N 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Skin Infection 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_2_Dry Skin 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT END_3_Cushing's Syndrome 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_2_Pruritis 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Lichen Planus 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Skin Diseases / Dermatoses 67-73-2 FLUOCINOLONE ACETONIDE MESH_LEVEL_1 Polycyclic Hydrocarbons 67-73-2 FLUOCINOLONE ACETONIDE MESH_LEVEL_3 Pregnanes 67-73-2 FLUOCINOLONE ACETONIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 67-73-2 FLUOCINOLONE ACETONIDE THERAPEUTIC_CLASS Corticosteroids, Topical 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT XXX_3_Impaired Wound Healing 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Acneiform Rash 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT CVS_3_Telangiectasia 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Hypertrichosis 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT OCU_3_Cataracts 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT XXX_3_Tolerance 67-73-2 FLUOCINOLONE ACETONIDE MODE_CLASS Receptor Agonist 67-73-2 FLUOCINOLONE ACETONIDE MECH_LEVEL_2 Anti-inflammation and immunosuppression 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Psoriasis 67-73-2 FLUOCINOLONE ACETONIDE INDICATION Exfoliative Dermatitis / Exfoliative Erythroderma 67-73-2 FLUOCINOLONE ACETONIDE PRODUCT_CLASS Anti-inflammatories 67-73-2 FLUOCINOLONE ACETONIDE ACTIVITY_CLASS GR-MR agonist 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Skin Atrophy 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT SKN_3_Thin Fragile Skin 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT END_3_Growth Inhibition 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT XXX_3_Withdrawal 67-73-2 FLUOCINOLONE ACETONIDE MECHANISM Modulate gene transcription 67-73-2 FLUOCINOLONE ACETONIDE ADVERSE_EFFECT IMU_3_Contact Dermatitis 67-78-7 TRIAMCINOLONE DIACETATE MODE_CLASS Receptor Agonist 67-78-7 TRIAMCINOLONE DIACETATE MECHANISM Modulate gene transcription 72-63-9 METHANDROSTENOLONE MODE_CLASS Receptor Agonist 72-63-9 METHANDROSTENOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 72-63-9 METHANDROSTENOLONE THERAPEUTIC_CLASS Gonadal Hormones 72-63-9 METHANDROSTENOLONE MECHANISM Modulate gene transcription 79-61-8 DICHLORISONE ACETATE INDICATION Pruritus / Itching 84-36-6 SYROSINGOPINE PRODUCT_CLASS Cardiovasculars 84-36-6 SYROSINGOPINE MODE_CLASS Solute transporter inhibitor 84-36-6 SYROSINGOPINE INDICATION Hypertension 84-36-6 SYROSINGOPINE MECHANISM Prolong/enhance neural transmission 84-36-6 SYROSINGOPINE THERAPEUTIC_CLASS Antihypertensive Agents 124-94-7 TRIAMCINOLONE THERAPEUTIC_CLASS Corticosteroids, Topical 124-94-7 TRIAMCINOLONE INDICATION Allergic Rhinitis 124-94-7 TRIAMCINOLONE INDICATION Dermatitis 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT IMU_3_Allergic Reactions 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT XXX_2_Pharyngitis 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT END_2_Metabolic Disturbance 124-94-7 TRIAMCINOLONE MODE_CLASS Receptor Agonist 124-94-7 TRIAMCINOLONE INDICATION Skin Diseases / Dermatoses 124-94-7 TRIAMCINOLONE MECHANISM Modulate gene transcription 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT GIS_2_Nausea 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT XXX_2_Throat Irritation 124-94-7 TRIAMCINOLONE PRODUCT_CLASS Anti-inflammatories 124-94-7 TRIAMCINOLONE INDICATION Rheumatic Disorders 124-94-7 TRIAMCINOLONE INDICATION Asthma 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT END_2_Cushing's Syndrome 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT XXX_2_Weight Gain 124-94-7 TRIAMCINOLONE THERAPEUTIC_CLASS Corticosteroids 124-94-7 TRIAMCINOLONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT SKN_2_Skin Toxicity 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT XXX_2_Epistaxis 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT XXX_2_Infection 124-94-7 TRIAMCINOLONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 124-94-7 TRIAMCINOLONE INDICATION Allergic Diseases 143-57-7 PROTOVERATRINE A THERAPEUTIC_CLASS Antihypertensive Agents 143-57-7 PROTOVERATRINE A INDICATION Hypertension 143-57-7 PROTOVERATRINE A PRODUCT_CLASS Cardiovasculars 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GIS_2_Dysphagia 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GIS_1_Dry Mouth 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT NEU_1_Dizziness 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT PSY_3_Confusion 155-41-9 METHSCOPOLAMINE BROMIDE MODE_CLASS Receptor Ligand Antagonist 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT NEU_3_Paralytic Ileus 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GUS_2_Hesistancy 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GIS_2_Constipation 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 155-41-9 METHSCOPOLAMINE BROMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT NEU_1_Drowsiness 155-41-9 METHSCOPOLAMINE BROMIDE PRODUCT_CLASS Gastrointestinal System 155-41-9 METHSCOPOLAMINE BROMIDE THERAPEUTIC_CLASS Antiulcers 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GIS_2_Dysgeusia 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT GIS_2_Heartburn 155-41-9 METHSCOPOLAMINE BROMIDE INDICATION Peptic Ulcer Disease (PUD) 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT OCU_1_Blurred Vision 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT SKN_2_Flushing 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT OCU_2_Mydriasis 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT REP_2_Impotence 155-41-9 METHSCOPOLAMINE BROMIDE MECHANISM Modulate G-protein coupled signal transduction 155-41-9 METHSCOPOLAMINE BROMIDE ADVERSE_EFFECT CVS_2_Palpitation 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT SKN_3_Fixed Drug Eruption 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT NEU_3_Somnolence 302-22-7 CHLORMADINONE ACETATE THERAPEUTIC_CLASS Gonadal Hormones 302-22-7 CHLORMADINONE ACETATE MESH_LEVEL_1 Polycyclic Hydrocarbons 302-22-7 CHLORMADINONE ACETATE MECHANISM Modulate gene transcription 302-22-7 CHLORMADINONE ACETATE INDICATION Dysfunctional Uterine Bleeding (DUB) 302-22-7 CHLORMADINONE ACETATE MODE_CLASS Receptor Ligand Antagonist, Selective 302-22-7 CHLORMADINONE ACETATE TISSUE_TOXICITY Carcinogenicity 302-22-7 CHLORMADINONE ACETATE TISSUE_TOXICITY Hepatotoxicity 302-22-7 CHLORMADINONE ACETATE KNOWN_TOXICITY Carcinogenicity 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT PSY_3_Depression 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT IMU_3_Urticaria 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT CVS_3_Thromboembolism 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT REP_1_Menstrual Abnormalities 302-22-7 CHLORMADINONE ACETATE ACTIVITY_CLASS Androgen antagonist 302-22-7 CHLORMADINONE ACETATE INDICATION Luteal Phase Insufficiency 302-22-7 CHLORMADINONE ACETATE INDICATION Prostatic Cancer / Carcinoma of the Prostate 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT REP_3_Decreased Libido 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT KID_2_Fluid Retention 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT REP_2_Ectopic Pregnancy 302-22-7 CHLORMADINONE ACETATE STRUCTURE_ACTIVITY Androgen receptor antagonist, steroid 302-22-7 CHLORMADINONE ACETATE INDICATION Prevention of Endometrial Hyperplasia 302-22-7 CHLORMADINONE ACETATE INDICATION Uterine Fibroid 302-22-7 CHLORMADINONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 302-22-7 CHLORMADINONE ACETATE MECH_LEVEL_3 androgen receptor 302-22-7 CHLORMADINONE ACETATE INDICATION Contraception 302-22-7 CHLORMADINONE ACETATE THERAPEUTIC_CLASS Antineoplastics 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT SKN_2_Pruritis 302-22-7 CHLORMADINONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT END_3_Acute Intermittent Porphyria 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT REP_2_Amenorrhea 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT GIS_2_Epigastric Pain 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT GUS_1_Vaginal Spotting 302-22-7 CHLORMADINONE ACETATE MECH_LEVEL_2 androgen receptor antagonist 302-22-7 CHLORMADINONE ACETATE PRODUCT_CLASS Anti-cancers 302-22-7 CHLORMADINONE ACETATE TISSUE_TOXICITY Thromboembolism 302-22-7 CHLORMADINONE ACETATE KNOWN_TOXICITY Hepatotoxicity 302-22-7 CHLORMADINONE ACETATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 302-22-7 CHLORMADINONE ACETATE MESH_LEVEL_3 Pregnanes 302-22-7 CHLORMADINONE ACETATE MECH_LEVEL_1 Anti-androgen 302-22-7 CHLORMADINONE ACETATE INDICATION Endometriosis 302-22-7 CHLORMADINONE ACETATE MESH_LEVEL_2 Steroids 302-22-7 CHLORMADINONE ACETATE THERAPEUTIC_CLASS Contraceptive Hormones 302-22-7 CHLORMADINONE ACETATE ADVERSE_EFFECT DNA_3_Carcinogenicity 360-70-3 NANDROLONE DECANOATE MODE_CLASS Receptor Agonist 360-70-3 NANDROLONE DECANOATE MECHANISM Modulate gene transcription 434-07-1 OXYMETHOLONE TISSUE_TOXICITY Hepatocellular Carcinoma 434-07-1 OXYMETHOLONE STRUCTURE_ACTIVITY Androgen receptor agonist 434-07-1 OXYMETHOLONE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 434-07-1 OXYMETHOLONE ADVERSE_EFFECT REP_1_Menstrual Abnormalities 434-07-1 OXYMETHOLONE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 434-07-1 OXYMETHOLONE ADVERSE_EFFECT REP_3_Impotence 434-07-1 OXYMETHOLONE ADVERSE_EFFECT END_1_Decreases HDL 434-07-1 OXYMETHOLONE ADVERSE_EFFECT END_1_Hirsutism 434-07-1 OXYMETHOLONE ADVERSE_EFFECT REP_2_Altered Libido 434-07-1 OXYMETHOLONE ADVERSE_EFFECT END_1_Impaired Glucose Tolerance 434-07-1 OXYMETHOLONE ADVERSE_EFFECT REP_3_Testicular Atrophy 434-07-1 OXYMETHOLONE ZERO_CLASS N 434-07-1 OXYMETHOLONE TISSUE_TOXICITY Congestive Heart Failure 434-07-1 OXYMETHOLONE KNOWN_TOXICITY Hepatotoxicity 434-07-1 OXYMETHOLONE MESH_LEVEL_2 Steroids 434-07-1 OXYMETHOLONE TA_LEVEL_2 Anemia 434-07-1 OXYMETHOLONE MESH_LEVEL_1 Polycyclic Hydrocarbons 434-07-1 OXYMETHOLONE MECH_LEVEL_1 Anabolic 434-07-1 OXYMETHOLONE ACTIVITY_CLASS Androgen receptor agonist 434-07-1 OXYMETHOLONE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 434-07-1 OXYMETHOLONE ADVERSE_EFFECT DNA_3_Carcinoma of Prostate 434-07-1 OXYMETHOLONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 434-07-1 OXYMETHOLONE ADVERSE_EFFECT MSK_2_Premature Closure of Epiphyseal Plate 434-07-1 OXYMETHOLONE INDICATION Aplastic Anemia 434-07-1 OXYMETHOLONE MODE_CLASS Receptor Agonist 434-07-1 OXYMETHOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 434-07-1 OXYMETHOLONE MECHANISM Modulate gene transcription 434-07-1 OXYMETHOLONE INDICATION Myelofibrosis 434-07-1 OXYMETHOLONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 434-07-1 OXYMETHOLONE TISSUE_TOXICITY Hepatic Necrosis 434-07-1 OXYMETHOLONE KNOWN_TOXICITY Cardiovascular Toxicity 434-07-1 OXYMETHOLONE TA_LEVEL_3 Anabolic Steroid 434-07-1 OXYMETHOLONE ADVERSE_EFFECT LIV_3_Peliosis Hepatis 434-07-1 OXYMETHOLONE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 434-07-1 OXYMETHOLONE ADVERSE_EFFECT END_3_Virilization 434-07-1 OXYMETHOLONE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 434-07-1 OXYMETHOLONE ADVERSE_EFFECT SKN_1_Acne 434-07-1 OXYMETHOLONE ADVERSE_EFFECT REP_3_Priapism 434-07-1 OXYMETHOLONE ADVERSE_EFFECT BBM_3_Acute Leukemia 434-07-1 OXYMETHOLONE THERAPEUTIC_CLASS Gonadal Hormones 434-07-1 OXYMETHOLONE TISSUE_TOXICITY Carcinoma of Prostate 434-07-1 OXYMETHOLONE TA_LEVEL_1 Hematology 434-07-1 OXYMETHOLONE MESH_LEVEL_3 Androstanes 434-07-1 OXYMETHOLONE MECH_LEVEL_3 androgen receptor 434-07-1 OXYMETHOLONE ADVERSE_EFFECT KID_1_Fluid Retention 434-07-1 OXYMETHOLONE MECH_LEVEL_2 Modulate gene transcription 434-07-1 OXYMETHOLONE KNOWN_TOXICITY Carcinogenicity 434-07-1 OXYMETHOLONE ADVERSE_EFFECT END_1_Increases LDL 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT SKN_3_Skin Rash 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT GIS_3_Diarrhea 466-06-8 PROSCILLARIDIN THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 466-06-8 PROSCILLARIDIN INDICATION Supraventricular Tachycardia 466-06-8 PROSCILLARIDIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Extrasystoles 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Ventricular Fibrillation 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Supraventricular Arrhythmia 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Ventricular Extrasystoles 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT END_3_Gynecomastia 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_2_Extrasystoles 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT PSY_1_Anorexia 466-06-8 PROSCILLARIDIN THERAPEUTIC_CLASS Antiarrhythmic Agents 466-06-8 PROSCILLARIDIN MECHANISM Increase muscle contraction 466-06-8 PROSCILLARIDIN INDICATION Atrial Flutter 466-06-8 PROSCILLARIDIN PRODUCT_CLASS Cardiovasculars 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT GIS_3_Sialorrhea 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT OCU_3_Eye Disorder 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT PSY_3_Psychosis 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 466-06-8 PROSCILLARIDIN INDICATION Atrial Fibrillation 466-06-8 PROSCILLARIDIN MODE_CLASS Enzyme Inhibitor 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Supraventricular Arrhythmia 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Atrial Tachycardia 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_1_Sinus Bradycardia 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Atrioventricular Blockade 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Ventricular Tachycardia 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT _3_Prolong PR Interval 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT NEU_2_Syncope 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT GIS_3_Abdominal Pain 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Bigeminy 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 466-06-8 PROSCILLARIDIN KNOWN_TOXICITY Cardiovascular Toxicity 466-06-8 PROSCILLARIDIN INDICATION Cardiac Insufficiency 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Ventricular Extrasystoles 466-06-8 PROSCILLARIDIN TISSUE_TOXICITY Bigeminy 466-06-8 PROSCILLARIDIN ADVERSE_EFFECT CVS_3_Atrial Tachycardia 474-25-9 CHENODEOXYCHOLIC ACID INDICATION Cholelithiasis / Gallstones 477-30-5 DEMECOLCINE THERAPEUTIC_CLASS Gout-Related Agents 477-30-5 DEMECOLCINE STRUCTURE_ACTIVITY Tubulin binder, colchicinoid 477-30-5 DEMECOLCINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 509-67-1 PHOLCODINE INDICATION Cough / Tussis 509-67-1 PHOLCODINE MODE_CLASS Receptor Agonist 509-67-1 PHOLCODINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 509-67-1 PHOLCODINE STRUCTURE_ACTIVITY Opioid receptor agonist 509-67-1 PHOLCODINE PRODUCT_CLASS Respiratory System 509-67-1 PHOLCODINE MECHANISM Modulate neural transmission 530-43-8 CHLORAMPHENICOL PALMITATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 530-43-8 CHLORAMPHENICOL PALMITATE THERAPEUTIC_CLASS Antibacterials 530-43-8 CHLORAMPHENICOL PALMITATE MECHANISM Inhibit ribosomal protein synthesis 530-43-8 CHLORAMPHENICOL PALMITATE PRODUCT_CLASS Anti-infectives 979-32-8 ESTRADIOL VALERATE MECHANISM Modulate gene transcription 979-32-8 ESTRADIOL VALERATE MODE_CLASS Receptor Agonist 1111-39-3 ACETYLDIGITOXIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 1392-21-8 KITASAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1392-21-8 KITASAMYCIN PRODUCT_CLASS Anti-infectives 1392-21-8 KITASAMYCIN THERAPEUTIC_CLASS Antibacterials 1392-21-8 KITASAMYCIN MECHANISM Inhibit ribosomal protein synthesis 1404-15-5 NOGALAMYCIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 1404-15-5 NOGALAMYCIN THERAPEUTIC_CLASS Antineoplastics 1404-15-5 NOGALAMYCIN PRODUCT_CLASS Anti-cancers 1424-00-6 MESTEROLONE ADVERSE_EFFECT LUN_2_Hoarseness of Voice 1424-00-6 MESTEROLONE TISSUE_TOXICITY Hepatotoxicity 1424-00-6 MESTEROLONE STRUCTURE_ACTIVITY Androgen receptor agonist 1424-00-6 MESTEROLONE INDICATION Male Hypogonadism 1424-00-6 MESTEROLONE ADVERSE_EFFECT XXX_2_Edema 1424-00-6 MESTEROLONE ADVERSE_EFFECT END_2_Growth Deficiencies 1424-00-6 MESTEROLONE ADVERSE_EFFECT END_2_Growth Inhibition 1424-00-6 MESTEROLONE ADVERSE_EFFECT REP_3_Priapism 1424-00-6 MESTEROLONE PRODUCT_CLASS Hematologics 1424-00-6 MESTEROLONE MECHANISM Modulate gene transcription 1424-00-6 MESTEROLONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 1424-00-6 MESTEROLONE ADVERSE_EFFECT SKN_2_Acne 1424-00-6 MESTEROLONE ADVERSE_EFFECT NEU_2_Psychomotor Excitation 1424-00-6 MESTEROLONE ADVERSE_EFFECT _2_Increased libido 1424-00-6 MESTEROLONE INDICATION Nocturnal Enuresis 1424-00-6 MESTEROLONE INDICATION Oligospermia 1424-00-6 MESTEROLONE MODE_CLASS Receptor Agonist 1424-00-6 MESTEROLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 1424-00-6 MESTEROLONE ADVERSE_EFFECT XXX_2_Weight Gain 1424-00-6 MESTEROLONE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 1424-00-6 MESTEROLONE INDICATION Aplastic Anemia 1424-00-6 MESTEROLONE ADVERSE_EFFECT BBM_2_Polycythemia 1424-00-6 MESTEROLONE ADVERSE_EFFECT PSY_2_Irritability 1424-00-6 MESTEROLONE ADVERSE_EFFECT END_2_Hirsutism 1424-00-6 MESTEROLONE KNOWN_TOXICITY Hepatotoxicity 1424-00-6 MESTEROLONE ADVERSE_EFFECT KID_2_Decreased Calcium Excretion 1424-00-6 MESTEROLONE THERAPEUTIC_CLASS Gonadal Hormones 2002-29-1 FLUMETHASONE PIVALATE MODE_CLASS Receptor Agonist 2002-29-1 FLUMETHASONE PIVALATE THERAPEUTIC_CLASS Corticosteroids 2002-29-1 FLUMETHASONE PIVALATE PRODUCT_CLASS Anti-inflammatories 2002-29-1 FLUMETHASONE PIVALATE MECHANISM Modulate gene transcription 2152-44-5 BETAMETHASONE VALERATE PRODUCT_CLASS Anti-inflammatories 2152-44-5 BETAMETHASONE VALERATE MECHANISM Modulate gene transcription 2152-44-5 BETAMETHASONE VALERATE THERAPEUTIC_CLASS Corticosteroids 2152-44-5 BETAMETHASONE VALERATE MODE_CLASS Receptor Agonist 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_1_Dizziness 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_2_Ataxia 2169-64-4 AZARIBINE PRODUCT_CLASS Anti-infectives 2169-64-4 AZARIBINE PRODUCT_CLASS Immune Response / Immunomodulators 2169-64-4 AZARIBINE MODE_CLASS Enzyme substrate mimic 2169-64-4 AZARIBINE TISSUE_TOXICITY Hemolytic Anemia 2169-64-4 AZARIBINE THERAPEUTIC_CLASS Antivirals, Systemic 2169-64-4 AZARIBINE ADVERSE_EFFECT PSY_2_CNS Toxicity 2169-64-4 AZARIBINE ADVERSE_EFFECT PSY_1_Anorexia 2169-64-4 AZARIBINE ADVERSE_EFFECT BBM_1_Hemolytic Anemia 2169-64-4 AZARIBINE INDICATION Rheumatoid Arthritis 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_2_Slurred Speech 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_1_Lightheadedness 2169-64-4 AZARIBINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 2169-64-4 AZARIBINE MECHANISM Inhibit precursor synthesis 2169-64-4 AZARIBINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 2169-64-4 AZARIBINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 2169-64-4 AZARIBINE MECHANISM Inhibit kinase mediated signal transduction 2169-64-4 AZARIBINE PRODUCT_CLASS Anti-cancers 2169-64-4 AZARIBINE PRODUCT_CLASS Dermatologicals 2169-64-4 AZARIBINE MODE_CLASS Enzyme Inhibitor 2169-64-4 AZARIBINE ADVERSE_EFFECT XXX_2_Fever 2169-64-4 AZARIBINE ADVERSE_EFFECT XXX_1_Fatigue 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_2_Seizures 2169-64-4 AZARIBINE ADVERSE_EFFECT XXX_1_Lethargy 2169-64-4 AZARIBINE THERAPEUTIC_CLASS Immunosuppressants 2169-64-4 AZARIBINE THERAPEUTIC_CLASS Psoralens 2169-64-4 AZARIBINE ADVERSE_EFFECT MSK_2_Joint Swelling 2169-64-4 AZARIBINE THERAPEUTIC_CLASS Antineoplastics 2169-64-4 AZARIBINE ADVERSE_EFFECT GIS_1_Diarrhea 2169-64-4 AZARIBINE ADVERSE_EFFECT GIS_1_Nausea 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_2_Coma 2169-64-4 AZARIBINE ADVERSE_EFFECT OCU_2_Diplopia 2169-64-4 AZARIBINE ADVERSE_EFFECT BBM_3_Leukopenia 2169-64-4 AZARIBINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 2169-64-4 AZARIBINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 2169-64-4 AZARIBINE INDICATION Psoriasis 2169-64-4 AZARIBINE ADVERSE_EFFECT MSK_2_Joint Pain 2169-64-4 AZARIBINE ADVERSE_EFFECT NEU_1_Tremor 3511-16-8 HETACILLIN PRODUCT_CLASS Anti-infectives 3511-16-8 HETACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 3511-16-8 HETACILLIN MODE_CLASS Enzyme Inhibitor 3511-16-8 HETACILLIN THERAPEUTIC_CLASS Antibacterials 3577-01-3 CEPHALOGLYCIN PRODUCT_CLASS Anti-infectives 3577-01-3 CEPHALOGLYCIN MECHANISM Inhibit bacterial cell wall biosynthesis 3577-01-3 CEPHALOGLYCIN MODE_CLASS Enzyme Inhibitor 3577-01-3 CEPHALOGLYCIN THERAPEUTIC_CLASS Antibacterials 6192-97-8 LEVOPROPYLHEXEDRINE MECHANISM Modulate G-protein coupled signal transduction 11033-34-4 STEFFIMYCIN PRODUCT_CLASS Anti-cancers 11033-34-4 STEFFIMYCIN THERAPEUTIC_CLASS Antineoplastics 11033-34-4 STEFFIMYCIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 14521-96-1 ETORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 14521-96-1 ETORPHINE MECHANISM Modulate neural transmission 14521-96-1 ETORPHINE PRODUCT_CLASS Analgesics 14521-96-1 ETORPHINE STRUCTURE_ACTIVITY Opioid receptor agonist 14521-96-1 ETORPHINE MODE_CLASS Receptor Agonist 17598-65-1 DESLANOSIDE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 17598-65-1 DESLANOSIDE MODE_CLASS Enzyme Inhibitor 17598-65-1 DESLANOSIDE MECHANISM Increase muscle contraction 23110-15-8 FUMAGILLIN INDICATION Amebiasis 24143-17-7 OXAZOLAM MECHANISM Modulate neural transmission 24143-17-7 OXAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 24143-17-7 OXAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 24143-17-7 OXAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 24143-17-7 OXAZOLAM MODE_CLASS Channel enhancer /opener 25122-57-0 CLOBETASONE BUTYRATE MECHANISM Modulate gene transcription 25122-57-0 CLOBETASONE BUTYRATE MODE_CLASS Receptor Agonist 18966-32-0 CLOCANFAMIDE INDICATION Ulcer 19179-78-3 XIPRANOLOL INDICATION Cardiac Arrhythmias 19179-78-3 XIPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 19179-78-3 XIPRANOLOL PRODUCT_CLASS Cardiovasculars 19387-91-8 TINIDAZOLE ADVERSE_EFFECT NEU_1_Headache 19387-91-8 TINIDAZOLE ADVERSE_EFFECT LUN_3_Laryngeal Edema 19387-91-8 TINIDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 19387-91-8 TINIDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 19387-91-8 TINIDAZOLE TA_LEVEL_1 Infectious Disease 19387-91-8 TINIDAZOLE TA_LEVEL_3 antiparasitic imidazoles 19387-91-8 TINIDAZOLE INDICATION Surgical Prophylaxis 19387-91-8 TINIDAZOLE INDICATION Amebiasis 19387-91-8 TINIDAZOLE THERAPEUTIC_CLASS Antiparasitics 19387-91-8 TINIDAZOLE ADVERSE_EFFECT GIS_2_Vomiting 19387-91-8 TINIDAZOLE ADVERSE_EFFECT CVS_3_Hypotension 19387-91-8 TINIDAZOLE ADVERSE_EFFECT BBM_3_Leukopenia 19387-91-8 TINIDAZOLE ADVERSE_EFFECT GIS_1_Metallic Taste 19387-91-8 TINIDAZOLE MESH_LEVEL_3 Imidazoles 19387-91-8 TINIDAZOLE INDICATION Trichomoniasis 19387-91-8 TINIDAZOLE KNOWN_TOXICITY Cardiovascular Toxicity 19387-91-8 TINIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, antiparasitic 19387-91-8 TINIDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 19387-91-8 TINIDAZOLE ADVERSE_EFFECT CVS_2_Thrombophlebitis 19387-91-8 TINIDAZOLE ADVERSE_EFFECT LUN_3_Bronchospasm 19387-91-8 TINIDAZOLE ADVERSE_EFFECT LIV_3_Increased Liver Function Tests 19387-91-8 TINIDAZOLE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 19387-91-8 TINIDAZOLE INDICATION Anaerobic Infections 19387-91-8 TINIDAZOLE ZERO_CLASS N 19387-91-8 TINIDAZOLE TA_LEVEL_2 anthelmintic 19387-91-8 TINIDAZOLE PRODUCT_CLASS Anti-infectives 19387-91-8 TINIDAZOLE MECH_LEVEL_3 Inhibit DNA synthesis, repair, and function 19387-91-8 TINIDAZOLE MECH_LEVEL_1 anthelmintic 19387-91-8 TINIDAZOLE ADVERSE_EFFECT IMU_3_Urticaria 19387-91-8 TINIDAZOLE INDICATION Helicobacter Pylori Infection 19387-91-8 TINIDAZOLE INDICATION Giardiasis 19387-91-8 TINIDAZOLE TISSUE_TOXICITY Hypotension 19387-91-8 TINIDAZOLE MECHANISM Inhibit DNA synthesis, repair, and function 19387-91-8 TINIDAZOLE ACTIVITY_CLASS DNA damager 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT SKN_3_Pruritis 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT SKN_3_Skin Eruption 19562-30-2 PIROMIDIC ACID INDICATION Gastrointestinal Infection 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT GIS_1_Vomiting 19562-30-2 PIROMIDIC ACID PRODUCT_CLASS Anti-infectives 19562-30-2 PIROMIDIC ACID INDICATION Cholangitis 19562-30-2 PIROMIDIC ACID MECHANISM Inhibit bacterial DNA synthesis 19562-30-2 PIROMIDIC ACID INDICATION Urinary Tract Infection (UTI) 19562-30-2 PIROMIDIC ACID MODE_CLASS Enzyme Inhibitor, selective 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT IMU_3_Photosensitization 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT KID_3_Renal Insufficiency 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT PSY_2_Anorexia 19562-30-2 PIROMIDIC ACID THERAPEUTIC_CLASS Antibacterials, Systemic 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT GIS_1_Epigastric Pain 19562-30-2 PIROMIDIC ACID ADVERSE_EFFECT GIS_1_Nausea 19825-63-9 PIRNABINE INDICATION Glaucoma 19889-45-3 GUABENXAN PRODUCT_CLASS Cardiovasculars 19889-45-3 GUABENXAN INDICATION Hypertension 19889-45-3 GUABENXAN THERAPEUTIC_CLASS Antihypertensive Agents 19992-80-4 BUTIXIRATE THERAPEUTIC_CLASS Immunosuppressants 19992-80-4 BUTIXIRATE PRODUCT_CLASS Immune Response / Immunomodulators 19992-80-4 BUTIXIRATE INDICATION Rheumatism 20187-55-7 BENDAZAC ADVERSE_EFFECT IMU_2_Contact Dermatitis 20187-55-7 BENDAZAC TISSUE_TOXICITY Hepatotoxicity 20187-55-7 BENDAZAC MECHANISM Inhibit eicosanoid biosynthesis 20187-55-7 BENDAZAC PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 20187-55-7 BENDAZAC ADVERSE_EFFECT LIV_3_Hepatotoxicity 20187-55-7 BENDAZAC TISSUE_TOXICITY Hepatic Failure 20187-55-7 BENDAZAC INDICATION Cataract 20187-55-7 BENDAZAC ADVERSE_EFFECT LIV_3_Hepatic Failure 20187-55-7 BENDAZAC KNOWN_TOXICITY Hepatotoxicity 20187-55-7 BENDAZAC THERAPEUTIC_CLASS Miscellaneous Ophthamological Agents 20187-55-7 BENDAZAC INDICATION Cataract 20187-55-7 BENDAZAC MODE_CLASS Enzyme Inhibitor 20187-55-7 BENDAZAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 20326-13-0 TOLPIPRAZOLE INDICATION Anxiety Disorders 20326-13-0 TOLPIPRAZOLE THERAPEUTIC_CLASS Sedatives/Hypnotics 20326-13-0 TOLPIPRAZOLE PRODUCT_CLASS Central Nervous System (CNS) 20380-58-9 TILIDINE MECHANISM Modulate neural transmission 20380-58-9 TILIDINE PRODUCT_CLASS Analgesics 20380-58-9 TILIDINE THERAPEUTIC_CLASS Analgesics, Opioid 20380-58-9 TILIDINE MODE_CLASS Receptor Agonist 20432-69-3 CLORAZEPATE THERAPEUTIC_CLASS Sedatives/Hypnotics 20432-69-3 CLORAZEPATE MODE_CLASS Channel enhancer /opener 20432-69-3 CLORAZEPATE PRODUCT_CLASS Central Nervous System (CNS) 20432-69-3 CLORAZEPATE MECHANISM Modulate neural transmission 20448-86-6 BORNAPRINE INDICATION Parkinson's Disease 21132-59-2 PAZOXIDE PRODUCT_CLASS Cardiovasculars 21132-59-2 PAZOXIDE INDICATION Hypertension 21132-59-2 PAZOXIDE THERAPEUTIC_CLASS Antihypertensive Agents 21362-69-6 MEPITIOSTANE MODE_CLASS Receptor Agonist 21362-69-6 MEPITIOSTANE MECHANISM Modulate gene transcription 21434-91-3 CAPOBENIC ACID THERAPEUTIC_CLASS Antidepressants 21434-91-3 CAPOBENIC ACID INDICATION Depression 21434-91-3 CAPOBENIC ACID PRODUCT_CLASS Cardiovasculars 21434-91-3 CAPOBENIC ACID PRODUCT_CLASS Central Nervous System (CNS) 21434-91-3 CAPOBENIC ACID THERAPEUTIC_CLASS Antiarrhythmic Agents 21434-91-3 CAPOBENIC ACID INDICATION Cardiac Arrhythmias 21489-20-3 TALSUPRAM MECHANISM Prolong/enhance neural transmission 21489-20-3 TALSUPRAM PRODUCT_CLASS Central Nervous System (CNS) 21489-20-3 TALSUPRAM THERAPEUTIC_CLASS Antidepressants 21489-20-3 TALSUPRAM INDICATION Depression 21489-20-3 TALSUPRAM MODE_CLASS Solute transporter inhibitor 3861-76-5 CLONITAZENE MODE_CLASS Receptor Agonist 3861-76-5 CLONITAZENE THERAPEUTIC_CLASS Analgesics, Opioid 3861-76-5 CLONITAZENE PRODUCT_CLASS Analgesics 3861-76-5 CLONITAZENE MECHANISM Modulate neural transmission 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT SKN_2_Rash 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT XXX_2_Withdrawal 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 3900-31-0 FLUDIAZEPAM MECHANISM Modulate neural transmission 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT GIS_3_Diarrhea 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT XXX_3_Weakness 3900-31-0 FLUDIAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT XXX_2_Lethargy 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT GIS_2_Dry Mouth 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT NEU_2_Dizziness 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT OCU_3_Diplopia 3900-31-0 FLUDIAZEPAM INDICATION Anxiety Disorders 3900-31-0 FLUDIAZEPAM THERAPEUTIC_CLASS Anxiolytics 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT GUS_3_Urinary Retention 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT NEU_2_Headache 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT NEU_3_Slurred Speech 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 3900-31-0 FLUDIAZEPAM TISSUE_TOXICITY Teratogenicity 3900-31-0 FLUDIAZEPAM MODE_CLASS Channel enhancer /opener 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT NEU_2_Drowsiness 3900-31-0 FLUDIAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 3900-31-0 FLUDIAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT XXX_3_Salivation 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT REP_3_Sexual Dysfunction 3900-31-0 FLUDIAZEPAM ADVERSE_EFFECT IMU_3_Allergic Reactions 60918-52-7 FLUDIAZEPAM THERAPEUTIC_CLASS Anxiolytics 60918-52-7 FLUDIAZEPAM INDICATION Anxiety Disorders 60918-52-7 FLUDIAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT OCU_3_Diplopia 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT NEU_2_Dizziness 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT GIS_2_Dry Mouth 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT XXX_2_Lethargy 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT IMU_3_Allergic Reactions 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT XXX_3_Weakness 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT GIS_3_Diarrhea 60918-52-7 FLUDIAZEPAM MECHANISM Modulate neural transmission 60918-52-7 FLUDIAZEPAM MODE_CLASS Channel enhancer /opener 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT XXX_2_Withdrawal 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT SKN_2_Rash 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT REP_3_Sexual Dysfunction 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT XXX_3_Salivation 60918-52-7 FLUDIAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 60918-52-7 FLUDIAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 60918-52-7 FLUDIAZEPAM TISSUE_TOXICITY Teratogenicity 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT NEU_3_Slurred Speech 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT NEU_2_Drowsiness 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT NEU_2_Headache 60918-52-7 FLUDIAZEPAM ADVERSE_EFFECT GUS_3_Urinary Retention 4004-94-8 ZOLERTINE PRODUCT_CLASS Autonomic Nervous System (ANS) 4004-94-8 ZOLERTINE MECHANISM Modulate G-protein coupled signal transduction 4201-22-3 TOLONIDINE PRODUCT_CLASS Cardiovasculars 4201-22-3 TOLONIDINE INDICATION Hypertension 4201-22-3 TOLONIDINE THERAPEUTIC_CLASS Antihypertensive Agents 4201-22-3 TOLONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 4255-23-6 ALETAMINE THERAPEUTIC_CLASS Antidepressants 4255-23-6 ALETAMINE INDICATION Depression 4255-23-6 ALETAMINE PRODUCT_CLASS Central Nervous System (CNS) 4267-05-4 TECLOTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 4267-05-4 TECLOTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 4267-05-4 TECLOTHIAZIDE MODE_CLASS Channel Blocker, selective 4267-05-4 TECLOTHIAZIDE THERAPEUTIC_CLASS Diuretics 4267-05-4 TECLOTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 4320-13-2 THIAZINAMIUM CHLORIDE PRODUCT_CLASS Anti-inflammatories 4320-13-2 THIAZINAMIUM CHLORIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 4320-13-2 THIAZINAMIUM CHLORIDE MECHANISM Block neural transmission 4320-13-2 THIAZINAMIUM CHLORIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 4320-13-2 THIAZINAMIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 4320-13-2 THIAZINAMIUM CHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 4320-13-2 THIAZINAMIUM CHLORIDE THERAPEUTIC_CLASS Antihistamines 4320-30-3 ARGININE GLUTAMATE PRODUCT_CLASS Biochemicals 4350-09-8 OXITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 4350-09-8 OXITRIPTAN INDICATION Depression 4350-09-8 OXITRIPTAN THERAPEUTIC_CLASS Antidepressants 4350-09-8 OXITRIPTAN INDICATION Epilepsy 4406-22-8 CYPRENORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 4406-22-8 CYPRENORPHINE MECHANISM Modulate neural transmission 4406-22-8 CYPRENORPHINE MODE_CLASS Receptor Ligand Antagonist 4406-22-8 CYPRENORPHINE PRODUCT_CLASS Analgesics 4406-22-8 CYPRENORPHINE STRUCTURE_ACTIVITY Opioid receptor antagonist 4448-96-8 SOLYPERTINE MECHANISM Modulate G-protein coupled signal transduction 4498-32-2 DIBENZEPIN THERAPEUTIC_CLASS Antidepressants 4498-32-2 DIBENZEPIN PRODUCT_CLASS Central Nervous System (CNS) 4498-32-2 DIBENZEPIN INDICATION Depression 6514-85-8 NITRACRINE MODE_CLASS Enzyme Inhibitor 6514-85-8 NITRACRINE MODE_CLASS Distorts /blocks macromolecular scaffold function 6514-85-8 NITRACRINE MECHANISM Inhibit DNA synthesis, repair, and function 4548-15-6 FLUNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 4696-76-8 BEKANAMYCIN PRODUCT_CLASS Anti-infectives 4696-76-8 BEKANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 4696-76-8 BEKANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 4696-76-8 BEKANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 4696-76-8 BEKANAMYCIN THERAPEUTIC_CLASS Antibacterials 4730-07-8 PENTAMOXANE THERAPEUTIC_CLASS Antihypertensive Agents 4730-07-8 PENTAMOXANE INDICATION Hypertension 4730-07-8 PENTAMOXANE PRODUCT_CLASS Cardiovasculars 4741-41-7 DEXOXADROL INDICATION Depression 4741-41-7 DEXOXADROL THERAPEUTIC_CLASS Antidepressants 4741-41-7 DEXOXADROL PRODUCT_CLASS Central Nervous System (CNS) 4757-55-5 DIMETACRINE THERAPEUTIC_CLASS Antidepressants 4757-55-5 DIMETACRINE PRODUCT_CLASS Central Nervous System (CNS) 4757-55-5 DIMETACRINE INDICATION Depression 4774-53-2 BOTIACRINE INDICATION Parkinson's Disease 4904-00-1 CYPROLIDOL INDICATION Depression 4904-00-1 CYPROLIDOL PRODUCT_CLASS Central Nervous System (CNS) 4904-00-1 CYPROLIDOL THERAPEUTIC_CLASS Antidepressants 4969-02-2 METHIXENE MODE_CLASS Enzyme Inhibitor 4969-02-2 METHIXENE MODE_CLASS Receptor Ligand Antagonist 4969-02-2 METHIXENE MECHANISM Modulate G-protein coupled signal transduction 4969-02-2 METHIXENE INDICATION Parkinson's Disease 4991-65-5 TIOXOLONE INDICATION Seborrhea 5001-32-1 GUANOCLOR THERAPEUTIC_CLASS Antihypertensive Agents 5001-32-1 GUANOCLOR INDICATION Hypertension 5001-32-1 GUANOCLOR PRODUCT_CLASS Cardiovasculars 5003-48-5 BENORYLATE MODE_CLASS Enzyme Inhibitor 5003-48-5 BENORYLATE STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 5003-48-5 BENORYLATE MECHANISM Inhibit eicosanoid biosynthesis 5011-34-7 TRIMETAZIDINE ADVERSE_EFFECT GIS_3_Epigastric Pain 5011-34-7 TRIMETAZIDINE INDICATION Angina Pectoris 5011-34-7 TRIMETAZIDINE PRODUCT_CLASS Other Human Uses 5011-34-7 TRIMETAZIDINE THERAPEUTIC_CLASS Antianginals 5011-34-7 TRIMETAZIDINE ADVERSE_EFFECT NEU_2_Dizziness 5011-34-7 TRIMETAZIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5011-34-7 TRIMETAZIDINE INDICATION Dizziness 5011-34-7 TRIMETAZIDINE ADVERSE_EFFECT NEU_3_Headache 5011-34-7 TRIMETAZIDINE THERAPEUTIC_CLASS Vasodilators 5011-34-7 TRIMETAZIDINE ADVERSE_EFFECT GIS_2_Nausea 5011-34-7 TRIMETAZIDINE INDICATION Prevention of Cyclosporin A nephropathy 5011-34-7 TRIMETAZIDINE PRODUCT_CLASS Cardiovasculars 5011-34-7 TRIMETAZIDINE INDICATION Vestibular syndrome 5118-29-6 MELITRACEN INDICATION Depression 5118-29-6 MELITRACEN PRODUCT_CLASS Central Nervous System (CNS) 5118-29-6 MELITRACEN THERAPEUTIC_CLASS Antidepressants 5169-78-8 TIPEPIDINE INDICATION Cough / Tussis 5214-29-9 AMPYZINE INDICATION Depression 5214-29-9 AMPYZINE THERAPEUTIC_CLASS Antidepressants 5214-29-9 AMPYZINE PRODUCT_CLASS Central Nervous System (CNS) 5250-39-5 FLOXACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 5250-39-5 FLOXACILLIN THERAPEUTIC_CLASS Antibacterials 5250-39-5 FLOXACILLIN MODE_CLASS Enzyme Inhibitor 5250-39-5 FLOXACILLIN PRODUCT_CLASS Anti-infectives 5310-55-4 CLOMACRAN ADVERSE_EFFECT NEU_2_Tremor 5310-55-4 CLOMACRAN INDICATION Neurological Disorders 5310-55-4 CLOMACRAN ADVERSE_EFFECT NEU_1_Drowsiness 5310-55-4 CLOMACRAN ADVERSE_EFFECT XXX_2_Lethargy 5310-55-4 CLOMACRAN ADVERSE_EFFECT GIS_2_Vomiting 5310-55-4 CLOMACRAN INDICATION Neurological Disorders 5310-55-4 CLOMACRAN INDICATION Schizophrenia 5310-55-4 CLOMACRAN THERAPEUTIC_CLASS Antidepressants 5310-55-4 CLOMACRAN ADVERSE_EFFECT PSY_2_Delusions 5310-55-4 CLOMACRAN THERAPEUTIC_CLASS Neurodegenerative Disorders 5310-55-4 CLOMACRAN MODE_CLASS Channel enhancer /opener 5310-55-4 CLOMACRAN ADVERSE_EFFECT NEU_2_Dizziness 5310-55-4 CLOMACRAN ADVERSE_EFFECT NEU_1_Headache 5310-55-4 CLOMACRAN STRUCTURE_ACTIVITY GABA-A agonist 5310-55-4 CLOMACRAN INDICATION Schizophrenia 5310-55-4 CLOMACRAN MECHANISM Inhibit kinase mediated signal transduction 5310-55-4 CLOMACRAN PRODUCT_CLASS Central Nervous System (CNS) 5310-55-4 CLOMACRAN MODE_CLASS Enzyme Inhibitor 5310-55-4 CLOMACRAN ADVERSE_EFFECT GIS_2_Dry Mouth 5310-55-4 CLOMACRAN INDICATION Depression 5310-55-4 CLOMACRAN MECHANISM Modulate neural transmission 5310-55-4 CLOMACRAN INDICATION Depression 5310-55-4 CLOMACRAN ADVERSE_EFFECT PSY_2_Hallucinations 5370-41-2 PRIDEFINE INDICATION Depression 5370-41-2 PRIDEFINE PRODUCT_CLASS Central Nervous System (CNS) 5370-41-2 PRIDEFINE THERAPEUTIC_CLASS Antidepressants 5522-39-4 DIFLUANINE THERAPEUTIC_CLASS Antidepressants 5522-39-4 DIFLUANINE INDICATION Depression 5522-39-4 DIFLUANINE PRODUCT_CLASS Central Nervous System (CNS) 5560-69-0 ETHYL DIBUNATE INDICATION Cough / Tussis 5581-42-0 GLYPARAMIDE MODE_CLASS Channel Blocker, selective 5581-42-0 GLYPARAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 5581-42-0 GLYPARAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 5581-42-0 GLYPARAMIDE INDICATION Type II Diabetes Mellitus 5581-42-0 GLYPARAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 5581-42-0 GLYPARAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 5585-59-1 NITROCYCLINE MECHANISM Inhibit ribosomal protein synthesis 5585-59-1 NITROCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 5585-59-1 NITROCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 5585-59-1 NITROCYCLINE THERAPEUTIC_CLASS Antibacterials 5585-59-1 NITROCYCLINE PRODUCT_CLASS Anti-infectives 5585-64-8 AMOTRIPHENE MECHANISM Modulate gene transcription 5585-64-8 AMOTRIPHENE PRODUCT_CLASS Anti-cancers 5585-64-8 AMOTRIPHENE MODE_CLASS Receptor Ligand Antagonist 5585-64-8 AMOTRIPHENE THERAPEUTIC_CLASS Gonadal Hormones 5588-16-9 ALTHIAZIDE MODE_CLASS Channel Blocker, selective 5588-16-9 ALTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 5588-16-9 ALTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 5588-16-9 ALTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 5588-16-9 ALTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 5588-16-9 ALTHIAZIDE THERAPEUTIC_CLASS Diuretics 5588-16-9 ALTHIAZIDE PRODUCT_CLASS Cardiovasculars 5588-29-4 FENMETRAMIDE INDICATION Depression 5588-29-4 FENMETRAMIDE PRODUCT_CLASS Central Nervous System (CNS) 5588-29-4 FENMETRAMIDE THERAPEUTIC_CLASS Antidepressants 5591-27-5 CLOMETHERONE THERAPEUTIC_CLASS Gonadal Hormones 5591-27-5 CLOMETHERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 5593-20-4 BETAMETHASONE DIPROPIONATE THERAPEUTIC_CLASS Corticosteroids 5593-20-4 BETAMETHASONE DIPROPIONATE MECHANISM Modulate gene transcription 5593-20-4 BETAMETHASONE DIPROPIONATE PRODUCT_CLASS Anti-inflammatories 5593-20-4 BETAMETHASONE DIPROPIONATE MODE_CLASS Receptor Agonist 5611-51-8 TRIAMCINOLONE HEXACETONIDE MODE_CLASS Receptor Agonist 5611-51-8 TRIAMCINOLONE HEXACETONIDE MECHANISM Modulate gene transcription 5611-64-3 METHALTHIAZIDE MODE_CLASS Channel Blocker, selective 5611-64-3 METHALTHIAZIDE PRODUCT_CLASS Cardiovasculars 5611-64-3 METHALTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 5611-64-3 METHALTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 5611-64-3 METHALTHIAZIDE THERAPEUTIC_CLASS Diuretics 5611-64-3 METHALTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 5611-64-3 METHALTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 5632-44-0 TOLPROPAMINE INDICATION Pruritus / Itching 5638-76-6 BETAHISTINE MECH_LEVEL_2 Anti-histamine 5638-76-6 BETAHISTINE MODE_CLASS Receptor Agonist 5638-76-6 BETAHISTINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 5638-76-6 BETAHISTINE INDICATION Tinnitus / Ringing in the Ear 5638-76-6 BETAHISTINE ADVERSE_EFFECT NEU_3_Headache 5638-76-6 BETAHISTINE ADVERSE_EFFECT SKN_3_Skin Eruption 5638-76-6 BETAHISTINE MESH_LEVEL_3 Pyridines 5638-76-6 BETAHISTINE MESH_LEVEL_1 Heterocyclic Compounds 5638-76-6 BETAHISTINE TA_LEVEL_3 vertigo 5638-76-6 BETAHISTINE MODE_CLASS Receptor Ligand Antagonist 5638-76-6 BETAHISTINE ADVERSE_EFFECT GIS_2_Gastrointestinal Disorder 5638-76-6 BETAHISTINE ZERO_CLASS N 5638-76-6 BETAHISTINE TA_LEVEL_1 Cardiovascular 5638-76-6 BETAHISTINE TA_LEVEL_2 vasodilator 5638-76-6 BETAHISTINE MECH_LEVEL_3 histamine receptor H1 5638-76-6 BETAHISTINE INDICATION Vertigo 5638-76-6 BETAHISTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5638-76-6 BETAHISTINE THERAPEUTIC_CLASS Vasodilators 5638-76-6 BETAHISTINE ADVERSE_EFFECT SKN_3_Pruritis 5638-76-6 BETAHISTINE STRUCTURE_ACTIVITY Histamine receptor agonist 5638-76-6 BETAHISTINE ACTIVITY_CLASS Histamine receptor agonist 5638-76-6 BETAHISTINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 5638-76-6 BETAHISTINE ADVERSE_EFFECT SKN_3_Rash 5638-76-6 BETAHISTINE MECH_LEVEL_1 signal transduction 5638-76-6 BETAHISTINE MECHANISM Modulate G-protein coupled signal transduction 54856-23-4 BETAHISTINE MODE_CLASS Receptor Agonist 54856-23-4 BETAHISTINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 54856-23-4 BETAHISTINE INDICATION Tinnitus / Ringing in the Ear 54856-23-4 BETAHISTINE ADVERSE_EFFECT NEU_3_Headache 54856-23-4 BETAHISTINE ADVERSE_EFFECT SKN_3_Skin Eruption 54856-23-4 BETAHISTINE MESH_LEVEL_3 Pyridines 54856-23-4 BETAHISTINE MESH_LEVEL_1 Heterocyclic Compounds 54856-23-4 BETAHISTINE TA_LEVEL_3 vertigo 54856-23-4 BETAHISTINE MODE_CLASS Receptor Ligand Antagonist 54856-23-4 BETAHISTINE ADVERSE_EFFECT GIS_2_Gastrointestinal Disorder 54856-23-4 BETAHISTINE ZERO_CLASS N 54856-23-4 BETAHISTINE TA_LEVEL_1 Cardiovascular 54856-23-4 BETAHISTINE TA_LEVEL_2 vasodilator 54856-23-4 BETAHISTINE MECH_LEVEL_3 histamine receptor H1 54856-23-4 BETAHISTINE INDICATION Vertigo 54856-23-4 BETAHISTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 54856-23-4 BETAHISTINE THERAPEUTIC_CLASS Vasodilators 54856-23-4 BETAHISTINE ADVERSE_EFFECT SKN_3_Pruritis 54856-23-4 BETAHISTINE STRUCTURE_ACTIVITY Histamine receptor agonist 54856-23-4 BETAHISTINE ACTIVITY_CLASS Histamine receptor agonist 54856-23-4 BETAHISTINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 54856-23-4 BETAHISTINE ADVERSE_EFFECT SKN_3_Rash 54856-23-4 BETAHISTINE MECH_LEVEL_1 signal transduction 54856-23-4 BETAHISTINE MECHANISM Modulate G-protein coupled signal transduction 54856-23-4 BETAHISTINE MECH_LEVEL_2 Anti-histamine 5741-22-0 MOPROLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 5741-22-0 MOPROLOL MODE_CLASS Receptor Ligand Antagonist 5741-22-0 MOPROLOL PRODUCT_CLASS Cardiovasculars 5741-22-0 MOPROLOL MECHANISM Modulate G-protein coupled signal transduction 5741-22-0 MOPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 5800-19-1 METIAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 5845-26-1 THIAZESIM PRODUCT_CLASS Central Nervous System (CNS) 5845-26-1 THIAZESIM THERAPEUTIC_CLASS Antidepressants 5845-26-1 THIAZESIM INDICATION Depression 5874-95-3 AMICYCLINE MECHANISM Inhibit ribosomal protein synthesis 5874-95-3 AMICYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 5874-95-3 AMICYCLINE PRODUCT_CLASS Anti-infectives 5874-95-3 AMICYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 5874-95-3 AMICYCLINE THERAPEUTIC_CLASS Antibacterials 6452-71-7 OXPRENOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 6452-71-7 OXPRENOLOL THERAPEUTIC_CLASS Antihypertensive Agents 6452-71-7 OXPRENOLOL MECHANISM Modulate G-protein coupled signal transduction 6452-71-7 OXPRENOLOL INDICATION Cardiac Arrhythmias 6452-71-7 OXPRENOLOL INDICATION Anxiety Disorders 6452-71-7 OXPRENOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 6452-71-7 OXPRENOLOL THERAPEUTIC_CLASS Sympatholytic Agents 6452-71-7 OXPRENOLOL INDICATION Angina Pectoris 6452-71-7 OXPRENOLOL MODE_CLASS Receptor Partial Agonist 6452-71-7 OXPRENOLOL INDICATION Hypertension 6452-71-7 OXPRENOLOL PRODUCT_CLASS Cardiovasculars 6452-71-7 OXPRENOLOL THERAPEUTIC_CLASS Antianginals 6452-73-9 OXPRENOLOL INDICATION Anxiety Disorders 6452-73-9 OXPRENOLOL INDICATION Cardiac Arrhythmias 6452-73-9 OXPRENOLOL PRODUCT_CLASS Cardiovasculars 6452-73-9 OXPRENOLOL THERAPEUTIC_CLASS Antianginals 6452-73-9 OXPRENOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 6452-73-9 OXPRENOLOL THERAPEUTIC_CLASS Antihypertensive Agents 6452-73-9 OXPRENOLOL MECHANISM Modulate G-protein coupled signal transduction 6452-73-9 OXPRENOLOL INDICATION Hypertension 6452-73-9 OXPRENOLOL MODE_CLASS Receptor Partial Agonist 6452-73-9 OXPRENOLOL INDICATION Angina Pectoris 6452-73-9 OXPRENOLOL THERAPEUTIC_CLASS Sympatholytic Agents 6452-73-9 OXPRENOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 6485-39-8 MANGANESE GLUCONATE INDICATION Malnutrition 6577-41-9 OXAPIUM IODIDE MODE_CLASS Receptor Ligand Antagonist 6577-41-9 OXAPIUM IODIDE MECHANISM Modulate G-protein coupled signal transduction 6620-60-6 PROGLUMIDE INDICATION Duodenal Ulcer 6620-60-6 PROGLUMIDE INDICATION Gastric Ulcer 6620-60-6 PROGLUMIDE MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 6620-60-6 PROGLUMIDE TA_LEVEL_2 Duodenal ulcer treatment 6620-60-6 PROGLUMIDE ZERO_CLASS N 6620-60-6 PROGLUMIDE MESH_LEVEL_2 Amino Acids 6620-60-6 PROGLUMIDE THERAPEUTIC_CLASS Antiulcers 6620-60-6 PROGLUMIDE ADVERSE_EFFECT GIS_2_Constipation 6620-60-6 PROGLUMIDE ADVERSE_EFFECT BBM_3_Leukopenia 6620-60-6 PROGLUMIDE MECH_LEVEL_3 Cholecystokinin receptor 2 6620-60-6 PROGLUMIDE ADVERSE_EFFECT GIS_2_Dry Mouth 6620-60-6 PROGLUMIDE MODE_CLASS Receptor Ligand Antagonist 6620-60-6 PROGLUMIDE MECH_LEVEL_1 Ulcer healing 6620-60-6 PROGLUMIDE ACTIVITY_CLASS Cholecystokinin (CCK) receptor antagonist, non-selective 6620-60-6 PROGLUMIDE ADVERSE_EFFECT PSY_3_Insomnia 6620-60-6 PROGLUMIDE STRUCTURE_ACTIVITY Cholecystokinin (CCK) receptor antagonist, non-selective 6620-60-6 PROGLUMIDE TA_LEVEL_1 Gastrointestinal System 6620-60-6 PROGLUMIDE TA_LEVEL_3 CCK antagonist 6620-60-6 PROGLUMIDE ADVERSE_EFFECT GIS_2_Bloating 6620-60-6 PROGLUMIDE MECH_LEVEL_2 Inhibits gastrin-stimulated acid secretion 6620-60-6 PROGLUMIDE MECHANISM Reduce stomach HCl secretion 6620-60-6 PROGLUMIDE MESH_LEVEL_3 Amino Acids, Diamino 6620-60-6 PROGLUMIDE ADVERSE_EFFECT SKN_3_Pruritis 6620-60-6 PROGLUMIDE PRODUCT_CLASS Gastrointestinal System 6621-47-2 PERHEXILINE ADVERSE_EFFECT NEU_3_Neurological Toxicity 6621-47-2 PERHEXILINE TISSUE_TOXICITY Liver Cirrhosis 6621-47-2 PERHEXILINE TISSUE_TOXICITY Hepatotoxicity 6621-47-2 PERHEXILINE INDICATION Hypertension 6621-47-2 PERHEXILINE MECHANISM Block neural transmission 6621-47-2 PERHEXILINE TISSUE_TOXICITY Hepatic Failure 6621-47-2 PERHEXILINE MODE_CLASS Enzyme Inhibitor 6621-47-2 PERHEXILINE THERAPEUTIC_CLASS Antianginals 6621-47-2 PERHEXILINE ADVERSE_EFFECT LIV_3_Liver Cirrhosis 6621-47-2 PERHEXILINE STRUCTURE_ACTIVITY Carnitine palmitoyltransferase inhibitor 6621-47-2 PERHEXILINE ACTIVITY_CLASS Mitochondrial toxicant 6621-47-2 PERHEXILINE MECHANISM Inhibit lipid beta-oxidation 6621-47-2 PERHEXILINE THERAPEUTIC_CLASS Antihypertensive Agents 6621-47-2 PERHEXILINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 6621-47-2 PERHEXILINE MECHANISM Reduce muscle contractile force 6621-47-2 PERHEXILINE PRODUCT_CLASS Cardiovasculars 6621-47-2 PERHEXILINE INDICATION Angina Pectoris 6621-47-2 PERHEXILINE ADVERSE_EFFECT LIV_3_Hepatic Failure 6621-47-2 PERHEXILINE INDICATION Angina Pectoris 6621-47-2 PERHEXILINE KNOWN_TOXICITY Hepatotoxicity 6621-47-2 PERHEXILINE INDICATION Hypertension 6621-47-2 PERHEXILINE MODE_CLASS Channel Blocker 6673-35-4 PRACTOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 6673-35-4 PRACTOLOL PRODUCT_CLASS Cardiovasculars 6673-35-4 PRACTOLOL THERAPEUTIC_CLASS Sympatholytic Agents 6673-35-4 PRACTOLOL INDICATION Angina Pectoris 6673-35-4 PRACTOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 6673-35-4 PRACTOLOL INDICATION Supraventricular Arrhythmias 6673-35-4 PRACTOLOL MECHANISM Reduce muscle contractile force 6673-35-4 PRACTOLOL INDICATION Ventricular Arrhythmias 6673-35-4 PRACTOLOL INDICATION Hypertrophic Cardiomyopathy 7002-65-5 OXIBETAINE INDICATION Hyperlipoproteinemia 7002-65-5 OXIBETAINE PRODUCT_CLASS Cardiovasculars 7002-65-5 OXIBETAINE THERAPEUTIC_CLASS Hypolipidemic Agents 7004-98-0 EPIMESTROL PRODUCT_CLASS Hormones, Endocrine and Metabolic 7004-98-0 EPIMESTROL THERAPEUTIC_CLASS Gonadal Hormones 7035-04-3 PYRIDARONE THERAPEUTIC_CLASS Sedatives/Hypnotics 7035-04-3 PYRIDARONE INDICATION Anxiety Disorders 7035-04-3 PYRIDARONE PRODUCT_CLASS Central Nervous System (CNS) 7114-11-6 NAPHTHONONE INDICATION Cough / Tussis 7125-76-0 CODOXIME STRUCTURE_ACTIVITY Opioid receptor agonist 7125-76-0 CODOXIME THERAPEUTIC_CLASS Analgesics, Opioid 7125-76-0 CODOXIME PRODUCT_CLASS Analgesics 7125-76-0 CODOXIME MECHANISM Modulate neural transmission 7125-76-0 CODOXIME MODE_CLASS Receptor Agonist 7220-56-6 FLUTIAZIN PRODUCT_CLASS Anti-inflammatories 7220-56-6 FLUTIAZIN MECHANISM Block neural transmission 7220-56-6 FLUTIAZIN MODE_CLASS Receptor Ligand Antagonist 7224-08-0 IMICLOPAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 7224-08-0 IMICLOPAZINE THERAPEUTIC_CLASS Antipsychotics 7224-08-0 IMICLOPAZINE MECHANISM Block neural transmission 7224-08-0 IMICLOPAZINE MODE_CLASS Receptor Ligand Antagonist 7224-08-0 IMICLOPAZINE PRODUCT_CLASS Central Nervous System (CNS) 7273-99-6 GAMFEXINE PRODUCT_CLASS Central Nervous System (CNS) 7273-99-6 GAMFEXINE THERAPEUTIC_CLASS Antidepressants 7273-99-6 GAMFEXINE INDICATION Depression 7336-33-6 DESMETHYLCOLCHICINE THERAPEUTIC_CLASS Gout-Related Agents 7336-33-6 DESMETHYLCOLCHICINE STRUCTURE_ACTIVITY Tubulin binder, colchicinoid 7336-33-6 DESMETHYLCOLCHICINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 7395-90-6 INDRILINE INDICATION Depression 7395-90-6 INDRILINE PRODUCT_CLASS Central Nervous System (CNS) 7395-90-6 INDRILINE THERAPEUTIC_CLASS Antidepressants 7456-24-8 FONAZINE MECHANISM Block neural transmission 7456-24-8 FONAZINE PRODUCT_CLASS Anti-inflammatories 7456-24-8 FONAZINE THERAPEUTIC_CLASS Antiemetics 7456-24-8 FONAZINE PRODUCT_CLASS Gastrointestinal System 7456-24-8 FONAZINE PRODUCT_CLASS Central Nervous System (CNS) 7456-24-8 FONAZINE MODE_CLASS Receptor Ligand Antagonist 7456-24-8 FONAZINE THERAPEUTIC_CLASS Antihistamines 7456-24-8 FONAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 7491-42-1 HEXACYCLONATE PRODUCT_CLASS Central Nervous System (CNS) 7491-42-1 HEXACYCLONATE INDICATION Depression 7491-42-1 HEXACYCLONATE THERAPEUTIC_CLASS Antidepressants 7492-29-7 CLAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 7492-29-7 CLAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 7492-29-7 CLAZOLAM MECHANISM Modulate neural transmission 7492-29-7 CLAZOLAM MODE_CLASS Channel enhancer /opener 7492-29-7 CLAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 7654-03-7 BENMOXIN PRODUCT_CLASS Central Nervous System (CNS) 7654-03-7 BENMOXIN INDICATION Depression 7654-03-7 BENMOXIN THERAPEUTIC_CLASS Antidepressants 7681-76-7 RONIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 7685-23-6 GITOFORMATE STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 7701-65-7 METALOL MECHANISM Modulate G-protein coupled signal transduction 10206-21-0 CEPHACETRILE MODE_CLASS Enzyme Inhibitor 10206-21-0 CEPHACETRILE THERAPEUTIC_CLASS Antibacterials 10206-21-0 CEPHACETRILE PRODUCT_CLASS Anti-infectives 10206-21-0 CEPHACETRILE MECHANISM Inhibit bacterial cell wall biosynthesis 1199-18-4 OXIDOPAMINE THERAPEUTIC_CLASS Movement Disorders 1199-18-4 OXIDOPAMINE MECHANISM Block channel gating 1199-18-4 OXIDOPAMINE MODE_CLASS Receptor Agonist 1199-18-4 OXIDOPAMINE PRODUCT_CLASS Central Nervous System (CNS) 1199-18-4 OXIDOPAMINE MECHANISM Modulate G-protein coupled signal transduction 1199-18-4 OXIDOPAMINE MODE_CLASS Solute transporter inhibitor 1209-98-9 FENCAMFAMINE MODE_CLASS Receptor Agonist 1209-98-9 FENCAMFAMINE THERAPEUTIC_CLASS Antidepressants 1209-98-9 FENCAMFAMINE INDICATION Depression 1209-98-9 FENCAMFAMINE PRODUCT_CLASS Central Nervous System (CNS) 1209-98-9 FENCAMFAMINE INDICATION Fatigue 1209-98-9 FENCAMFAMINE THERAPEUTIC_CLASS Central Stimulants 1209-98-9 FENCAMFAMINE MECHANISM Prolong/enhance neural transmission 1220-83-3 SULFAMONOMETHOXINE MECHANISM Inhibit precursor synthesis 1220-83-3 SULFAMONOMETHOXINE MODE_CLASS Enzyme Inhibitor 1228-19-9 GLYPINAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 1228-19-9 GLYPINAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 1228-19-9 GLYPINAMIDE MODE_CLASS Channel Blocker, selective 1228-19-9 GLYPINAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 1228-19-9 GLYPINAMIDE INDICATION Type II Diabetes Mellitus 1228-19-9 GLYPINAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 1253-28-7 GESTONORONE CAPROATE MODE_CLASS Receptor Agonist 1253-28-7 GESTONORONE CAPROATE MECHANISM Modulate gene transcription 1463-28-1 GUANACLINE THERAPEUTIC_CLASS Antihypertensive Agents 1463-28-1 GUANACLINE INDICATION Hypertension 1463-28-1 GUANACLINE PRODUCT_CLASS Cardiovasculars 1470-35-5 ISOBROMINDIONE PRODUCT_CLASS Hematologics 1470-35-5 ISOBROMINDIONE THERAPEUTIC_CLASS Anticoagulants 1477-39-0 NORACYMETHADOL PRODUCT_CLASS Analgesics 1477-39-0 NORACYMETHADOL MECHANISM Modulate neural transmission 1477-39-0 NORACYMETHADOL MODE_CLASS Receptor Agonist 1477-39-0 NORACYMETHADOL THERAPEUTIC_CLASS Analgesics, Opioid 1531-12-0 NORLEVORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 1531-12-0 NORLEVORPHANOL PRODUCT_CLASS Analgesics 1531-12-0 NORLEVORPHANOL MECHANISM Modulate neural transmission 1531-12-0 NORLEVORPHANOL MODE_CLASS Receptor Agonist 1553-60-2 IBUFENAC STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 1553-60-2 IBUFENAC INDICATION Rheumatoid Arthritis 1553-60-2 IBUFENAC PRODUCT_CLASS Anti-inflammatories 1553-60-2 IBUFENAC ADVERSE_EFFECT LIV_3_Hepatotoxicity 1553-60-2 IBUFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 1553-60-2 IBUFENAC ACTIVITY_CLASS Anti-inflammatory 1553-60-2 IBUFENAC MODE_CLASS Enzyme Inhibitor 1553-60-2 IBUFENAC TISSUE_TOXICITY Hepatotoxicity 1553-60-2 IBUFENAC INDICATION Rheumatoid Arthritis 1553-60-2 IBUFENAC KNOWN_TOXICITY Hepatotoxicity 1553-60-2 IBUFENAC MECHANISM Inhibit eicosanoid biosynthesis 1600-19-7 XYLOXEMINE INDICATION Cough / Tussis 1693-37-4 PARAPROPAMOL STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 1740-22-3 PYRINOLINE INDICATION Cardiac Arrhythmias 1740-22-3 PYRINOLINE PRODUCT_CLASS Central Nervous System (CNS) 1740-22-3 PYRINOLINE INDICATION Depression 1740-22-3 PYRINOLINE PRODUCT_CLASS Cardiovasculars 1740-22-3 PYRINOLINE THERAPEUTIC_CLASS Antiarrhythmic Agents 1740-22-3 PYRINOLINE THERAPEUTIC_CLASS Antidepressants 1748-43-2 TRETHINIUM TOSILATE INDICATION Hypotension 1759-09-7 LEVOMETIOMEPRAZINE MECHANISM Block neural transmission 1759-09-7 LEVOMETIOMEPRAZINE THERAPEUTIC_CLASS Antipsychotics 1759-09-7 LEVOMETIOMEPRAZINE MODE_CLASS Receptor Ligand Antagonist 1759-09-7 LEVOMETIOMEPRAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 1759-09-7 LEVOMETIOMEPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 1764-85-8 EPITHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 1764-85-8 EPITHIAZIDE THERAPEUTIC_CLASS Diuretics 1764-85-8 EPITHIAZIDE MODE_CLASS Channel Blocker, selective 1764-85-8 EPITHIAZIDE PRODUCT_CLASS Cardiovasculars 1764-85-8 EPITHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 1764-85-8 EPITHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 1764-85-8 EPITHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 1766-91-2 PENFLUTIZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 1766-91-2 PENFLUTIZIDE MODE_CLASS Channel Blocker, selective 1824-58-4 ETHIAZIDE MODE_CLASS Channel Blocker, selective 1824-58-4 ETHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 1824-58-4 ETHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 1824-58-4 ETHIAZIDE PRODUCT_CLASS Cardiovasculars 1824-58-4 ETHIAZIDE THERAPEUTIC_CLASS Diuretics 1824-58-4 ETHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 1824-58-4 ETHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 1845-11-0 NAFOXIDINE PRODUCT_CLASS Anti-cancers 1845-11-0 NAFOXIDINE MECHANISM Modulate gene transcription 1845-11-0 NAFOXIDINE MODE_CLASS Receptor Ligand Antagonist 1845-11-0 NAFOXIDINE THERAPEUTIC_CLASS Gonadal Hormones 1893-33-0 PIPAMPERONE MODE_CLASS Channel Blocker 1893-33-0 PIPAMPERONE MECHANISM Modulate G-protein coupled signal transduction 1893-33-0 PIPAMPERONE MODE_CLASS Receptor Ligand Antagonist 1893-33-0 PIPAMPERONE MECHANISM Block neural transmission 1926-48-3 FENBENICILLIN MODE_CLASS Enzyme Inhibitor 1926-48-3 FENBENICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 1926-48-3 FENBENICILLIN PRODUCT_CLASS Anti-infectives 1926-48-3 FENBENICILLIN THERAPEUTIC_CLASS Antibacterials 1926-49-4 CLOMETOCILLIN PRODUCT_CLASS Anti-infectives 1926-49-4 CLOMETOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 1926-49-4 CLOMETOCILLIN MODE_CLASS Enzyme Inhibitor 1926-49-4 CLOMETOCILLIN THERAPEUTIC_CLASS Antibacterials 1977-11-3 PERLAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 1982-37-2 METHDILAZINE PRODUCT_CLASS Anti-inflammatories 1982-37-2 METHDILAZINE MECHANISM Block neural transmission 1982-37-2 METHDILAZINE MODE_CLASS Receptor Ligand Antagonist 1982-37-2 METHDILAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 1982-37-2 METHDILAZINE THERAPEUTIC_CLASS Antihistamines 1982-37-2 METHDILAZINE INDICATION Pruritus / Itching 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT GIS_3_Diarrhea 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Insomnia 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT NEU_3_Dizziness 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Confusion 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT XXX_1_Thirst 2011-67-8 NIMETAZEPAM TISSUE_TOXICITY Cardiovascular Depression 2011-67-8 NIMETAZEPAM ZERO_CLASS N 2011-67-8 NIMETAZEPAM MECH_LEVEL_3 GABA-A receptor A 2011-67-8 NIMETAZEPAM MECH_LEVEL_1 Modulate neural transmission 2011-67-8 NIMETAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT CVS_3_Cardiovascular Depression 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Anorexia 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_2_Dependence 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 2011-67-8 NIMETAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 2011-67-8 NIMETAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 2011-67-8 NIMETAZEPAM MECH_LEVEL_2 faciliates GABA binding 2011-67-8 NIMETAZEPAM MESH_LEVEL_1 Heterocyclic Compounds 2011-67-8 NIMETAZEPAM MECHANISM Modulate neural transmission 2011-67-8 NIMETAZEPAM INDICATION Insomnia 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT LUN_3_Respiratory Depression 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Hallucinations 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT GIS_3_Nausea / Vomiting 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Depression of Mood 2011-67-8 NIMETAZEPAM TA_LEVEL_1 Central Nervous System (CNS) 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_CNS Stimulation 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT XXX_2_Sweating 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Anxiety 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT OTO_3_Tinnitus 2011-67-8 NIMETAZEPAM ACTIVITY_CLASS GABA agonist 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT OCU_2_Increased Intraocular Pressure 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT PSY_3_Psychosis 2011-67-8 NIMETAZEPAM MESH_LEVEL_3 Benzazepines 2011-67-8 NIMETAZEPAM TA_LEVEL_3 Benzodiazepine 2011-67-8 NIMETAZEPAM TA_LEVEL_2 CNS Depressant 2011-67-8 NIMETAZEPAM MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 2011-67-8 NIMETAZEPAM MODE_CLASS Channel enhancer /opener 2011-67-8 NIMETAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 2011-67-8 NIMETAZEPAM ADVERSE_EFFECT NEU_3_Headache 2013-58-3 MECLOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 2013-58-3 MECLOCYCLINE THERAPEUTIC_CLASS Antibacterials 2013-58-3 MECLOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 2013-58-3 MECLOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2013-58-3 MECLOCYCLINE PRODUCT_CLASS Anti-infectives 2043-38-1 BUTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 2043-38-1 BUTHIAZIDE PRODUCT_CLASS Cardiovasculars 2043-38-1 BUTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 2043-38-1 BUTHIAZIDE MODE_CLASS Channel Blocker, selective 2043-38-1 BUTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 2043-38-1 BUTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 2043-38-1 BUTHIAZIDE THERAPEUTIC_CLASS Diuretics 2058-52-8 CLOTHIAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 2109-73-1 BUTACETIN THERAPEUTIC_CLASS Antidepressants 2109-73-1 BUTACETIN STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 2109-73-1 BUTACETIN PRODUCT_CLASS Central Nervous System (CNS) 2109-73-1 BUTACETIN INDICATION Depression 2133-81-5 THIOGUANINE ALPHA-DEOXYRIBOSIDE THERAPEUTIC_CLASS Antineoplastics 2133-81-5 THIOGUANINE ALPHA-DEOXYRIBOSIDE MODE_CLASS Enzyme substrate mimic 2133-81-5 THIOGUANINE ALPHA-DEOXYRIBOSIDE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 2133-81-5 THIOGUANINE ALPHA-DEOXYRIBOSIDE PRODUCT_CLASS Anti-cancers 2133-81-5 THIOGUANINE ALPHA-DEOXYRIBOSIDE MECHANISM Incorporate into DNA/RNA/Protein 2154-02-1 METHOPHOLINE ADVERSE_EFFECT GIS_2_Abdominal Cramps 2154-02-1 METHOPHOLINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 2154-02-1 METHOPHOLINE MODE_CLASS Channel Blocker 2154-02-1 METHOPHOLINE ADVERSE_EFFECT NEU_1_Sleepiness 2154-02-1 METHOPHOLINE MECHANISM Reduce muscle contractile force 2154-02-1 METHOPHOLINE ADVERSE_EFFECT PSY_1_Excitement 2154-02-1 METHOPHOLINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 2154-02-1 METHOPHOLINE PRODUCT_CLASS Analgesics 2154-02-1 METHOPHOLINE ADVERSE_EFFECT GIS_2_Diarrhea 2154-02-1 METHOPHOLINE INDICATION Pain 2154-02-1 METHOPHOLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 2154-02-1 METHOPHOLINE ADVERSE_EFFECT GIS_2_Constipation 2165-19-7 GUANOXAN INDICATION Hypertension 2165-19-7 GUANOXAN THERAPEUTIC_CLASS Antihypertensive Agents 2165-19-7 GUANOXAN PRODUCT_CLASS Cardiovasculars 2167-85-3 PIPAZETHATE INDICATION Cough / Tussis 2179-37-5 BENCYCLANE MECHANISM Reduce muscle contractile force 2179-37-5 BENCYCLANE MODE_CLASS Channel Blocker 14286-84-1 BENCYCLANE MODE_CLASS Channel Blocker 14286-84-1 BENCYCLANE MECHANISM Reduce muscle contractile force 2208-51-7 PELANSERIN PRODUCT_CLASS Cardiovasculars 2208-51-7 PELANSERIN INDICATION Hypertension 2208-51-7 PELANSERIN THERAPEUTIC_CLASS Antihypertensive Agents 2208-51-7 PELANSERIN STRUCTURE_ACTIVITY 5HT2 antagonist 2218-68-0 CHLORAL BETAINE PRODUCT_CLASS Central Nervous System (CNS) 2218-68-0 CHLORAL BETAINE INDICATION Insomnia 2218-68-0 CHLORAL BETAINE THERAPEUTIC_CLASS Sedatives/Hypnotics 2235-90-7 ETRYPTAMINE KNOWN_TOXICITY Miscellaneous 2235-90-7 ETRYPTAMINE INDICATION Depression 2235-90-7 ETRYPTAMINE PRODUCT_CLASS Central Nervous System (CNS) 2235-90-7 ETRYPTAMINE TISSUE_TOXICITY Death 2235-90-7 ETRYPTAMINE ADVERSE_EFFECT XXX_3_Death 2235-90-7 ETRYPTAMINE ADVERSE_EFFECT NEU_2_Dizziness 2235-90-7 ETRYPTAMINE ADVERSE_EFFECT PSY_2_Hallucinations 2235-90-7 ETRYPTAMINE THERAPEUTIC_CLASS Antidepressants 2235-90-7 ETRYPTAMINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 2235-90-7 ETRYPTAMINE MECHANISM Prolong/enhance neural transmission 2235-90-7 ETRYPTAMINE MODE_CLASS Enzyme Inhibitor 2260-08-4 ACETIROMATE THERAPEUTIC_CLASS Hypolipidemic Agents 2260-08-4 ACETIROMATE PRODUCT_CLASS Cardiovasculars 2260-08-4 ACETIROMATE INDICATION Hyperlipoproteinemia 2363-58-8 EPITIOSTANOL MECHANISM Modulate gene transcription 2363-58-8 EPITIOSTANOL MODE_CLASS Receptor Ligand Antagonist 2385-81-1 FURETHIDINE PRODUCT_CLASS Analgesics 2385-81-1 FURETHIDINE THERAPEUTIC_CLASS Analgesics, Opioid 2385-81-1 FURETHIDINE MODE_CLASS Receptor Agonist 2385-81-1 FURETHIDINE MECHANISM Modulate neural transmission 2409-26-9 PRAZITONE THERAPEUTIC_CLASS Antidepressants 2409-26-9 PRAZITONE MECHANISM Modulate neural transmission 2409-26-9 PRAZITONE PRODUCT_CLASS Central Nervous System (CNS) 2409-26-9 PRAZITONE STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 2409-26-9 PRAZITONE MODE_CLASS Channel Modulator 2409-26-9 PRAZITONE INDICATION Depression 2409-26-9 PRAZITONE INDICATION Parkinson's Disease 2465-59-0 OXYPURINOL MODE_CLASS Enzyme Inhibitor 2465-59-0 OXYPURINOL PRODUCT_CLASS Biochemicals 2465-59-0 OXYPURINOL MECHANISM Inhibit precursor synthesis 2521-01-9 ENCYPRATE PRODUCT_CLASS Central Nervous System (CNS) 2521-01-9 ENCYPRATE INDICATION Depression 2521-01-9 ENCYPRATE THERAPEUTIC_CLASS Antidepressants 2537-29-3 PROXIBARBAL MODE_CLASS Channel Modulator 2537-29-3 PROXIBARBAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 2537-29-3 PROXIBARBAL MECHANISM Modulate neural transmission 2607-06-9 DIFLUCORTOLONE MODE_CLASS Receptor Agonist 2607-06-9 DIFLUCORTOLONE MECHANISM Modulate gene transcription 2622-30-2 CARPHENAZINE MECHANISM Block neural transmission 2622-30-2 CARPHENAZINE THERAPEUTIC_CLASS Antipsychotics 2622-30-2 CARPHENAZINE MODE_CLASS Receptor Ligand Antagonist 2622-30-2 CARPHENAZINE PRODUCT_CLASS Central Nervous System (CNS) 2622-37-9 TRIFLUOMEPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 2622-37-9 TRIFLUOMEPRAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 2622-37-9 TRIFLUOMEPRAZINE MODE_CLASS Receptor Ligand Antagonist 2622-37-9 TRIFLUOMEPRAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 2622-37-9 TRIFLUOMEPRAZINE MECHANISM Block neural transmission 2709-56-0 FLUPENTIXOL PRODUCT_CLASS Central Nervous System (CNS) 2709-56-0 FLUPENTIXOL INDICATION Depression 2709-56-0 FLUPENTIXOL THERAPEUTIC_CLASS Antidepressants 2709-56-0 FLUPENTIXOL INDICATION Schizophrenic Disorders 2709-56-0 FLUPENTIXOL MECHANISM Block neural transmission 2709-56-0 FLUPENTIXOL MODE_CLASS Receptor Ligand Antagonist 2709-56-0 FLUPENTIXOL THERAPEUTIC_CLASS Antipsychotics 2746-81-8 FLUPHENAZINE ENANTHATE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 2746-81-8 FLUPHENAZINE ENANTHATE MODE_CLASS Receptor Ligand Antagonist 2746-81-8 FLUPHENAZINE ENANTHATE PRODUCT_CLASS Central Nervous System (CNS) 2746-81-8 FLUPHENAZINE ENANTHATE THERAPEUTIC_CLASS Antipsychotics 2746-81-8 FLUPHENAZINE ENANTHATE MECHANISM Block neural transmission 2751-68-0 ACETOPHENAZINE THERAPEUTIC_CLASS Antipsychotics 2751-68-0 ACETOPHENAZINE PRODUCT_CLASS Central Nervous System (CNS) 2751-68-0 ACETOPHENAZINE MODE_CLASS Receptor Ligand Antagonist 2751-68-0 ACETOPHENAZINE MECHANISM Block neural transmission 2856-74-8 MODALINE THERAPEUTIC_CLASS Antidepressants 2856-74-8 MODALINE PRODUCT_CLASS Central Nervous System (CNS) 2856-74-8 MODALINE INDICATION Depression 2898-13-7 SULAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 2898-13-7 SULAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 2898-13-7 SULAZEPAM MODE_CLASS Channel enhancer /opener 2898-13-7 SULAZEPAM MECHANISM Modulate neural transmission 2898-13-7 SULAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 2920-86-7 PREDNISOLONE HEMISUCCINATE MODE_CLASS Receptor Agonist 2920-86-7 PREDNISOLONE HEMISUCCINATE MECHANISM Modulate gene transcription 2922-20-5 BUTOXAMINE MECHANISM Modulate G-protein coupled signal transduction 2922-20-5 BUTOXAMINE STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 2922-20-5 BUTOXAMINE MODE_CLASS Channel Blocker 2922-20-5 BUTOXAMINE PRODUCT_CLASS Respiratory System 2922-20-5 BUTOXAMINE THERAPEUTIC_CLASS Bronchodilators 2922-20-5 BUTOXAMINE MECHANISM Block neural transmission 2922-20-5 BUTOXAMINE MODE_CLASS Receptor Ligand Antagonist 2998-57-4 ESTRAMUSTINE MODE_CLASS Receptor Agonist 2998-57-4 ESTRAMUSTINE MODE_CLASS Receptor Ligand Antagonist 2998-57-4 ESTRAMUSTINE MECHANISM Inhibit mitosis 2998-57-4 ESTRAMUSTINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2998-57-4 ESTRAMUSTINE MECHANISM Modulate gene transcription 3074-35-9 GLIDAZAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 3074-35-9 GLIDAZAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 3074-35-9 GLIDAZAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 3074-35-9 GLIDAZAMIDE INDICATION Type II Diabetes Mellitus 3074-35-9 GLIDAZAMIDE MODE_CLASS Channel Blocker, selective 3074-35-9 GLIDAZAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_2_Stomatitis 3094-09-5 DOXIFLURIDINE MECHANISM Inhibit precursor synthesis 3094-09-5 DOXIFLURIDINE INDICATION Breast Cancer / Carcinoma of the Breast 3094-09-5 DOXIFLURIDINE TA_LEVEL_2 Solid and soft tissue tumors 3094-09-5 DOXIFLURIDINE ZERO_CLASS N 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Liver Cirrhosis 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Cardiac Arrhythmia 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_3_Hemorrhagic Colitis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_3_Ischemic Colitis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT SKN_1_Dermatitis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT IMU_1_Photosensitivity 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT CVS_2_Angina Pectoris 3094-09-5 DOXIFLURIDINE KNOWN_TOXICITY Hepatotoxicity 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT LIV_2_Jaundice 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Angina Pectoris 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Teratogenicity 3094-09-5 DOXIFLURIDINE MECH_LEVEL_3 Thymidylate synthase 3094-09-5 DOXIFLURIDINE MECH_LEVEL_2 Inhibit precursor synthesis 3094-09-5 DOXIFLURIDINE INDICATION Cervical Cancer / Carcinoma of the Cervix 3094-09-5 DOXIFLURIDINE PRODUCT_CLASS Anti-cancers 3094-09-5 DOXIFLURIDINE KNOWN_TOXICITY Cardiovascular Toxicity 3094-09-5 DOXIFLURIDINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Acute Renal Failure 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Fulminant Hepatitis 3094-09-5 DOXIFLURIDINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_1_Diarrhea 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT BBM_2_Pancytopenia 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT CVS_3_Cardiac Failure 3094-09-5 DOXIFLURIDINE THERAPEUTIC_CLASS Antineoplastics 3094-09-5 DOXIFLURIDINE KNOWN_TOXICITY Embryo/Fetal Toxicity 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 3094-09-5 DOXIFLURIDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 3094-09-5 DOXIFLURIDINE TA_LEVEL_1 Oncology 3094-09-5 DOXIFLURIDINE INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 3094-09-5 DOXIFLURIDINE INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 3094-09-5 DOXIFLURIDINE MESH_LEVEL_2 Nucleosides 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT KID_3_Acute Renal Failure 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_2_Enterocolitis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT BBM_3_Myelodysplastic Syndrome (MDS) 3094-09-5 DOXIFLURIDINE KNOWN_TOXICITY Nephrotoxicity 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT LIV_3_Liver Cirrhosis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT BBM_3_Acute Leukemia 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT GIS_2_Pancreatitis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT NEU_3_Paralysis 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT PSY_2_Anorexia 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Cardiac Failure 3094-09-5 DOXIFLURIDINE TISSUE_TOXICITY Myocardial Infarction 3094-09-5 DOXIFLURIDINE MESH_LEVEL_3 Deoxyribonucleosides 3094-09-5 DOXIFLURIDINE MECH_LEVEL_1 Antimitotic 3094-09-5 DOXIFLURIDINE TA_LEVEL_3 Antimitotic 3094-09-5 DOXIFLURIDINE MODE_CLASS Enzyme substrate mimic 3094-09-5 DOXIFLURIDINE INDICATION Bladder Cancer / Carcinoma of the Bladder 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT EMB_2_Teratogenicity 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 3094-09-5 DOXIFLURIDINE ADVERSE_EFFECT BBM_2_Leukopenia 3176-03-2 DROTEBANOL THERAPEUTIC_CLASS Analgesics, Opioid 3176-03-2 DROTEBANOL STRUCTURE_ACTIVITY Opioid receptor agonist 3176-03-2 DROTEBANOL MECHANISM Modulate neural transmission 3176-03-2 DROTEBANOL PRODUCT_CLASS Analgesics 3176-03-2 DROTEBANOL MODE_CLASS Receptor Agonist 3184-59-6 ALIPAMIDE PRODUCT_CLASS Cardiovasculars 3184-59-6 ALIPAMIDE INDICATION Hypertension 3184-59-6 ALIPAMIDE THERAPEUTIC_CLASS Antihypertensive Agents 3207-50-9 CLINOLAMIDE INDICATION Hyperlipoproteinemia 3207-50-9 CLINOLAMIDE THERAPEUTIC_CLASS Hypolipidemic Agents 3207-50-9 CLINOLAMIDE PRODUCT_CLASS Cardiovasculars 3258-51-3 VALOFANE INDICATION Migraine Headache 3258-51-3 VALOFANE PRODUCT_CLASS Central Nervous System (CNS) 3258-51-3 VALOFANE THERAPEUTIC_CLASS Antimigraines 3286-46-2 SULBUTIAMINE MECHANISM Vitamin/ cofactor 3354-67-4 AMIDEPHRINE MECHANISM Modulate G-protein coupled signal transduction 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT IMU_3_Eosinophilia 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT SKN_3_Erythema 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT NEU_3_Paresthesia 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT GIS_1_Nausea 3366-95-8 SECNIDAZOLE INDICATION Giardiasis 3366-95-8 SECNIDAZOLE PRODUCT_CLASS Anti-infectives 3366-95-8 SECNIDAZOLE INDICATION Amebiasis 3366-95-8 SECNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT GIS_1_Metallic Taste 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT BBM_3_Leukocytosis 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT SKN_3_Pruritis 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT GIS_1_Vomiting 3366-95-8 SECNIDAZOLE INDICATION Bacterial Vaginosis 3366-95-8 SECNIDAZOLE THERAPEUTIC_CLASS Antiparasitics 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT OCU_3_Lid Edema 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT NEU_2_Vertigo 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT NEU_3_Ataxia 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT NEU_2_Headache 3366-95-8 SECNIDAZOLE INDICATION Trichomoniasis 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT PSY_1_Anorexia 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT XXX_1_Glossitis 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT GIS_1_Epigastric Pain 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT IMU_3_Urticaria 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT NEU_2_Dizziness 3366-95-8 SECNIDAZOLE THERAPEUTIC_CLASS Antibacterials 3366-95-8 SECNIDAZOLE ADVERSE_EFFECT KID_3_Increased Blood Urea Nitrogen 3485-14-1 CYCLACILLIN MODE_CLASS Enzyme Inhibitor 3485-14-1 CYCLACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 3485-14-1 CYCLACILLIN THERAPEUTIC_CLASS Antibacterials 3485-14-1 CYCLACILLIN PRODUCT_CLASS Anti-infectives 3506-31-8 DETERENOL MODE_CLASS Receptor Agonist 3506-31-8 DETERENOL PRODUCT_CLASS Biochemicals 3506-31-8 DETERENOL STRUCTURE_ACTIVITY Adrenoceptor agonist 3506-31-8 DETERENOL MECHANISM Modulate G-protein coupled signal transduction 3546-03-0 CYAMEMAZINE PRODUCT_CLASS Central Nervous System (CNS) 3546-03-0 CYAMEMAZINE THERAPEUTIC_CLASS Antipsychotics 3546-03-0 CYAMEMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 3546-03-0 CYAMEMAZINE THERAPEUTIC_CLASS Anxiolytics 3546-03-0 CYAMEMAZINE MODE_CLASS Receptor Ligand Antagonist 3546-03-0 CYAMEMAZINE MECHANISM Block neural transmission 3563-49-3 PYROVALERONE MODE_CLASS Solute transporter inhibitor 3563-49-3 PYROVALERONE INDICATION Depression 3563-49-3 PYROVALERONE PRODUCT_CLASS Central Nervous System (CNS) 3563-49-3 PYROVALERONE MECHANISM Prolong/enhance neural transmission 3563-49-3 PYROVALERONE THERAPEUTIC_CLASS Antipsychotics 3563-49-3 PYROVALERONE INDICATION Psychotic Disorders / Psychosis 3563-49-3 PYROVALERONE THERAPEUTIC_CLASS Antidepressants 3563-58-4 CHLORHEXADOL PRODUCT_CLASS Central Nervous System (CNS) 3563-58-4 CHLORHEXADOL THERAPEUTIC_CLASS Sedatives/Hypnotics 3565-03-5 PIMETINE PRODUCT_CLASS Cardiovasculars 3565-03-5 PIMETINE INDICATION Hyperlipoproteinemia 3565-03-5 PIMETINE THERAPEUTIC_CLASS Hypolipidemic Agents 3583-64-0 BUMADIZONE THERAPEUTIC_CLASS Immunosuppressants 3583-64-0 BUMADIZONE INDICATION Rheumatism 3583-64-0 BUMADIZONE PRODUCT_CLASS Immune Response / Immunomodulators 3611-72-1 CLORIDAROL INDICATION Hyperlipoproteinemia 3611-72-1 CLORIDAROL PRODUCT_CLASS Cardiovasculars 3611-72-1 CLORIDAROL THERAPEUTIC_CLASS Hypolipidemic Agents 3612-98-4 TROXYPYRROLIUM TOSILATE PRODUCT_CLASS Biochemicals 3612-98-4 TROXYPYRROLIUM TOSILATE MECHANISM Enhance cholinergic transmission 3612-98-4 TROXYPYRROLIUM TOSILATE MODE_CLASS Enzyme Inhibitor 3615-24-5 RAMIFENAZONE PRODUCT_CLASS Anti-inflammatories 3615-24-5 RAMIFENAZONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 3625-06-7 MEBEVERINE MECHANISM Block neural transmission 3625-06-7 MEBEVERINE MODE_CLASS Channel Blocker 3625-06-7 MEBEVERINE MODE_CLASS Enzyme Inhibitor 3625-06-7 MEBEVERINE MECHANISM Block channel gating 3625-06-7 MEBEVERINE MECHANISM Enhance kinase mediated signal transduction 2753-45-9 MEBEVERINE MECHANISM Block channel gating 2753-45-9 MEBEVERINE MODE_CLASS Enzyme Inhibitor 2753-45-9 MEBEVERINE MECHANISM Enhance kinase mediated signal transduction 2753-45-9 MEBEVERINE MODE_CLASS Channel Blocker 2753-45-9 MEBEVERINE MECHANISM Block neural transmission 3635-74-3 DEANOL ACETAMINOBENZOATE INDICATION Depression 3635-74-3 DEANOL ACETAMINOBENZOATE THERAPEUTIC_CLASS Antidepressants 3635-74-3 DEANOL ACETAMINOBENZOATE PRODUCT_CLASS Central Nervous System (CNS) 3658-25-1 GUANOCTINE PRODUCT_CLASS Cardiovasculars 3658-25-1 GUANOCTINE THERAPEUTIC_CLASS Antihypertensive Agents 3658-25-1 GUANOCTINE INDICATION Hypertension 3688-85-5 DIAPAMIDE PRODUCT_CLASS Cardiovasculars 3688-85-5 DIAPAMIDE INDICATION Hypertension 3688-85-5 DIAPAMIDE THERAPEUTIC_CLASS Antihypertensive Agents 3689-50-7 OXOMEMAZINE MECHANISM Block neural transmission 3689-50-7 OXOMEMAZINE PRODUCT_CLASS Anti-inflammatories 3689-50-7 OXOMEMAZINE THERAPEUTIC_CLASS Antihistamines 3689-50-7 OXOMEMAZINE PRODUCT_CLASS Central Nervous System (CNS) 3689-50-7 OXOMEMAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 3689-50-7 OXOMEMAZINE MODE_CLASS Receptor Ligand Antagonist 3703-76-2 CLOPERASTINE INDICATION Cough / Tussis 3735-65-7 BUTYNAMINE INDICATION Hypertension 3735-65-7 BUTYNAMINE PRODUCT_CLASS Cardiovasculars 3735-65-7 BUTYNAMINE THERAPEUTIC_CLASS Antihypertensive Agents 3736-08-1 FENETHYLLINE INDICATION Narcolepsy 3736-08-1 FENETHYLLINE MECHANISM Reduce bronchoconstriction 3736-08-1 FENETHYLLINE PRODUCT_CLASS Central Nervous System (CNS) 3736-08-1 FENETHYLLINE MECHANISM Modulate G-protein coupled signal transduction 3736-08-1 FENETHYLLINE MODE_CLASS Receptor Ligand Antagonist 3736-08-1 FENETHYLLINE THERAPEUTIC_CLASS Central Stimulants 3754-19-6 AMBUSIDE INDICATION Hypertension 3754-19-6 AMBUSIDE THERAPEUTIC_CLASS Antihypertensive Agents 3754-19-6 AMBUSIDE PRODUCT_CLASS Cardiovasculars 3784-89-2 PHENACTROPINIUM CHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 3784-89-2 PHENACTROPINIUM CHLORIDE PRODUCT_CLASS Cardiovasculars 3784-89-2 PHENACTROPINIUM CHLORIDE INDICATION Hypertension 6933-90-0 CLORPRENALINE TISSUE_TOXICITY Cardiac Arrhythmia 6933-90-0 CLORPRENALINE ADVERSE_EFFECT CVS_2_Palpitation 6933-90-0 CLORPRENALINE PRODUCT_CLASS Respiratory System 6933-90-0 CLORPRENALINE INDICATION Prophylaxis of Asthma 6933-90-0 CLORPRENALINE ADVERSE_EFFECT NEU_3_Tremor 6933-90-0 CLORPRENALINE ADVERSE_EFFECT GIS_3_Epigastric Pain 6933-90-0 CLORPRENALINE MECHANISM Modulate G-protein coupled signal transduction 6933-90-0 CLORPRENALINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 6933-90-0 CLORPRENALINE STRUCTURE_ACTIVITY Adrenoceptor agonist 6933-90-0 CLORPRENALINE KNOWN_TOXICITY Cardiovascular Toxicity 6933-90-0 CLORPRENALINE THERAPEUTIC_CLASS Bronchodilators 6933-90-0 CLORPRENALINE ADVERSE_EFFECT NEU_1_Headache 6933-90-0 CLORPRENALINE MODE_CLASS Receptor Agonist 6933-90-0 CLORPRENALINE INDICATION Bronchospasm 3811-75-4 HEXAMIDINE INDICATION Cardiac Arrhythmias 3811-75-4 HEXAMIDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 3811-75-4 HEXAMIDINE PRODUCT_CLASS Cardiovasculars 3833-99-6 HOMOFENAZINE PRODUCT_CLASS Central Nervous System (CNS) 3833-99-6 HOMOFENAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 3833-99-6 HOMOFENAZINE THERAPEUTIC_CLASS Antipsychotics 3833-99-6 HOMOFENAZINE MODE_CLASS Receptor Ligand Antagonist 3833-99-6 HOMOFENAZINE MECHANISM Block neural transmission 309-29-5 DOXAPRAM ADVERSE_EFFECT LUN_3_Tachypnea 309-29-5 DOXAPRAM ADVERSE_EFFECT NEU_3_Urinary Incontinence 309-29-5 DOXAPRAM ADVERSE_EFFECT LUN_3_Bronchospasm 309-29-5 DOXAPRAM ADVERSE_EFFECT GIS_2_Diarrhea 309-29-5 DOXAPRAM THERAPEUTIC_CLASS Respiratory Stimulants 309-29-5 DOXAPRAM MECHANISM Prolong/enhance neural transmission 309-29-5 DOXAPRAM MODE_CLASS Solute transporter inhibitor 309-29-5 DOXAPRAM ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 309-29-5 DOXAPRAM MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 309-29-5 DOXAPRAM PRODUCT_CLASS Respiratory System 309-29-5 DOXAPRAM MESH_LEVEL_3 Pyrrolidines 309-29-5 DOXAPRAM INDICATION Drug-Induced CNS and Respiratory Depression 309-29-5 DOXAPRAM MESH_LEVEL_1 Heterocyclic Compounds 309-29-5 DOXAPRAM ADVERSE_EFFECT NEU_3_Increased Deep Tendon Reflexes 309-29-5 DOXAPRAM ADVERSE_EFFECT NEU_3_Spasticity 309-29-5 DOXAPRAM ADVERSE_EFFECT SKN_2_Flushing 309-29-5 DOXAPRAM ADVERSE_EFFECT GUS_3_Urinary Retention 309-29-5 DOXAPRAM KNOWN_TOXICITY Cardiovascular Toxicity 309-29-5 DOXAPRAM INDICATION COPD associated Acute Respiratory Insufficiency 309-29-5 DOXAPRAM MECH_LEVEL_2 5HT antagonist 309-29-5 DOXAPRAM MECH_LEVEL_3 5HT Transporter SERT 309-29-5 DOXAPRAM TA_LEVEL_3 SERTs 309-29-5 DOXAPRAM ADVERSE_EFFECT CVS_3_Tachycardia 309-29-5 DOXAPRAM MECH_LEVEL_1 Modulate neural transmission 309-29-5 DOXAPRAM TA_LEVEL_2 respiratory stimulant 309-29-5 DOXAPRAM ADVERSE_EFFECT LUN_2_Dyspnea 309-29-5 DOXAPRAM ADVERSE_EFFECT NEU_3_Seizures 309-29-5 DOXAPRAM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 309-29-5 DOXAPRAM TA_LEVEL_1 Respiratory System 309-29-5 DOXAPRAM STRUCTURE_ACTIVITY Respiratory stimulant 309-29-5 DOXAPRAM ADVERSE_EFFECT LUN_3_Laryngospasm 309-29-5 DOXAPRAM ADVERSE_EFFECT PSY_3_Disorientation 309-29-5 DOXAPRAM ADVERSE_EFFECT NEU_2_Paresthesia 309-29-5 DOXAPRAM ADVERSE_EFFECT CVS_2_Hypertension 309-29-5 DOXAPRAM INDICATION Postanesthesia Respiratory Depression 309-29-5 DOXAPRAM ACTIVITY_CLASS Respiratory stimulant 309-29-5 DOXAPRAM TISSUE_TOXICITY Cardiac Arrhythmia 309-29-5 DOXAPRAM ZERO_CLASS N 7081-53-0 DOXAPRAM MODE_CLASS Solute transporter inhibitor 7081-53-0 DOXAPRAM MECH_LEVEL_3 5HT Transporter SERT 7081-53-0 DOXAPRAM MECH_LEVEL_2 5HT antagonist 7081-53-0 DOXAPRAM INDICATION COPD associated Acute Respiratory Insufficiency 7081-53-0 DOXAPRAM KNOWN_TOXICITY Cardiovascular Toxicity 7081-53-0 DOXAPRAM ADVERSE_EFFECT GUS_3_Urinary Retention 7081-53-0 DOXAPRAM ADVERSE_EFFECT NEU_3_Seizures 7081-53-0 DOXAPRAM ADVERSE_EFFECT NEU_3_Spasticity 7081-53-0 DOXAPRAM MESH_LEVEL_1 Heterocyclic Compounds 7081-53-0 DOXAPRAM ACTIVITY_CLASS Respiratory stimulant 7081-53-0 DOXAPRAM INDICATION Drug-Induced CNS and Respiratory Depression 7081-53-0 DOXAPRAM STRUCTURE_ACTIVITY Respiratory stimulant 7081-53-0 DOXAPRAM ADVERSE_EFFECT LUN_3_Laryngospasm 7081-53-0 DOXAPRAM ADVERSE_EFFECT GIS_2_Diarrhea 7081-53-0 DOXAPRAM ADVERSE_EFFECT PSY_3_Disorientation 7081-53-0 DOXAPRAM ADVERSE_EFFECT NEU_2_Paresthesia 7081-53-0 DOXAPRAM ADVERSE_EFFECT CVS_2_Hypertension 7081-53-0 DOXAPRAM INDICATION Postanesthesia Respiratory Depression 7081-53-0 DOXAPRAM MESH_LEVEL_3 Pyrrolidines 7081-53-0 DOXAPRAM TISSUE_TOXICITY Cardiac Arrhythmia 7081-53-0 DOXAPRAM ZERO_CLASS N 7081-53-0 DOXAPRAM ADVERSE_EFFECT LUN_3_Tachypnea 7081-53-0 DOXAPRAM PRODUCT_CLASS Respiratory System 7081-53-0 DOXAPRAM MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 7081-53-0 DOXAPRAM ADVERSE_EFFECT NEU_3_Urinary Incontinence 7081-53-0 DOXAPRAM ADVERSE_EFFECT LUN_3_Bronchospasm 7081-53-0 DOXAPRAM ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 7081-53-0 DOXAPRAM ADVERSE_EFFECT CVS_3_Tachycardia 7081-53-0 DOXAPRAM MECH_LEVEL_1 Modulate neural transmission 7081-53-0 DOXAPRAM TA_LEVEL_2 respiratory stimulant 7081-53-0 DOXAPRAM ADVERSE_EFFECT LUN_2_Dyspnea 7081-53-0 DOXAPRAM TA_LEVEL_1 Respiratory System 7081-53-0 DOXAPRAM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 7081-53-0 DOXAPRAM MECHANISM Prolong/enhance neural transmission 7081-53-0 DOXAPRAM THERAPEUTIC_CLASS Respiratory Stimulants 7081-53-0 DOXAPRAM ADVERSE_EFFECT SKN_2_Flushing 7081-53-0 DOXAPRAM ADVERSE_EFFECT NEU_3_Increased Deep Tendon Reflexes 7081-53-0 DOXAPRAM TA_LEVEL_3 SERTs 312-93-6 DEXAMETHASONE PHOSPHATE THERAPEUTIC_CLASS Corticosteroids 312-93-6 DEXAMETHASONE PHOSPHATE MODE_CLASS Receptor Agonist 312-93-6 DEXAMETHASONE PHOSPHATE MECHANISM Modulate gene transcription 312-93-6 DEXAMETHASONE PHOSPHATE PRODUCT_CLASS Anti-inflammatories 313-06-4 ESTRADIOL CYPIONATE MODE_CLASS Receptor Agonist 313-06-4 ESTRADIOL CYPIONATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 313-06-4 ESTRADIOL CYPIONATE MECHANISM Modulate gene transcription 313-06-4 ESTRADIOL CYPIONATE THERAPEUTIC_CLASS Contraceptive Hormones 315-72-0 OPIPRAMOL MODE_CLASS Receptor Ligand Antagonist 315-72-0 OPIPRAMOL THERAPEUTIC_CLASS Antidepressants 315-72-0 OPIPRAMOL STRUCTURE_ACTIVITY Sigma receptor modulator 315-72-0 OPIPRAMOL MECHANISM Modulate G-protein coupled signal transduction 315-72-0 OPIPRAMOL MECHANISM Block channel gating 315-72-0 OPIPRAMOL INDICATION Depression 315-72-0 OPIPRAMOL MODE_CLASS Channel Blocker 315-72-0 OPIPRAMOL MECHANISM Modulate neural transmission 315-72-0 OPIPRAMOL PRODUCT_CLASS Central Nervous System (CNS) 909-39-7 OPIPRAMOL PRODUCT_CLASS Central Nervous System (CNS) 909-39-7 OPIPRAMOL INDICATION Depression 909-39-7 OPIPRAMOL MODE_CLASS Channel Blocker 909-39-7 OPIPRAMOL MECHANISM Modulate G-protein coupled signal transduction 909-39-7 OPIPRAMOL MECHANISM Block channel gating 909-39-7 OPIPRAMOL MODE_CLASS Receptor Ligand Antagonist 909-39-7 OPIPRAMOL STRUCTURE_ACTIVITY Sigma receptor modulator 909-39-7 OPIPRAMOL THERAPEUTIC_CLASS Antidepressants 909-39-7 OPIPRAMOL MECHANISM Modulate neural transmission 316-81-4 THIOPROPERAZINE PRODUCT_CLASS Central Nervous System (CNS) 316-81-4 THIOPROPERAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 316-81-4 THIOPROPERAZINE THERAPEUTIC_CLASS Antiemetics 316-81-4 THIOPROPERAZINE MODE_CLASS Receptor Ligand Antagonist 316-81-4 THIOPROPERAZINE THERAPEUTIC_CLASS Antipsychotics 316-81-4 THIOPROPERAZINE PRODUCT_CLASS Gastrointestinal System 316-81-4 THIOPROPERAZINE MECHANISM Block neural transmission 322-35-0 BENSERAZIDE MODE_CLASS Enzyme Inhibitor 322-35-0 BENSERAZIDE MECHANISM Interferes with neural transmitter synthesis 14919-77-8 BENSERAZIDE MODE_CLASS Enzyme Inhibitor 14919-77-8 BENSERAZIDE MECHANISM Interferes with neural transmitter synthesis 14046-64-1 BENSERAZIDE MODE_CLASS Enzyme Inhibitor 14046-64-1 BENSERAZIDE MECHANISM Interferes with neural transmitter synthesis 333-36-8 FLUROTHYL THERAPEUTIC_CLASS Antidepressants 333-36-8 FLUROTHYL INDICATION Depression 333-36-8 FLUROTHYL PRODUCT_CLASS Central Nervous System (CNS) 339-43-5 CARBUTAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 339-43-5 CARBUTAMIDE INDICATION Type II Diabetes Mellitus 339-43-5 CARBUTAMIDE MODE_CLASS Channel Blocker, selective 339-43-5 CARBUTAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 339-43-5 CARBUTAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 339-43-5 CARBUTAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 339-44-6 GLYMIDINE INDICATION Diabetes 357-67-5 PHETHARBITAL MECHANISM Modulate neural transmission 357-67-5 PHETHARBITAL PRODUCT_CLASS Biochemicals 357-67-5 PHETHARBITAL MODE_CLASS Channel Modulator 357-67-5 PHETHARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 362-29-8 PROPIOMAZINE THERAPEUTIC_CLASS Antipsychotics 362-29-8 PROPIOMAZINE THERAPEUTIC_CLASS Antihistamines 362-29-8 PROPIOMAZINE PRODUCT_CLASS Gastrointestinal System 362-29-8 PROPIOMAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 362-29-8 PROPIOMAZINE PRODUCT_CLASS Anti-inflammatories 362-29-8 PROPIOMAZINE MECHANISM Block neural transmission 362-29-8 PROPIOMAZINE THERAPEUTIC_CLASS Antiemetics 362-29-8 PROPIOMAZINE PRODUCT_CLASS Central Nervous System (CNS) 362-29-8 PROPIOMAZINE MODE_CLASS Receptor Ligand Antagonist 370-14-9 PHOLEDRINE THERAPEUTIC_CLASS Sympathomimetic Agents 370-14-9 PHOLEDRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 370-14-9 PHOLEDRINE MECHANISM Modulate G-protein coupled signal transduction 390-64-7 PRENYLAMINE MECHANISM Block neural transmission 390-64-7 PRENYLAMINE MODE_CLASS Channel Blocker 427-00-9 DESOMORPHINE PRODUCT_CLASS Analgesics 427-00-9 DESOMORPHINE MODE_CLASS Receptor Agonist 427-00-9 DESOMORPHINE MECHANISM Modulate neural transmission 427-00-9 DESOMORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 427-00-9 DESOMORPHINE STRUCTURE_ACTIVITY Opioid receptor agonist 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT END_3_Adrenal Suppression 427-51-0 CYPROTERONE ACETATE MODE_CLASS Receptor Ligand Antagonist, Selective 427-51-0 CYPROTERONE ACETATE TA_LEVEL_3 Steroid antagonist 427-51-0 CYPROTERONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT XXX_1_Fatigue 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT ELT_2_Negative Nitrogen Balance 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 427-51-0 CYPROTERONE ACETATE MESH_LEVEL_2 Steroids 427-51-0 CYPROTERONE ACETATE MECH_LEVEL_1 Hormone modulation 427-51-0 CYPROTERONE ACETATE INDICATION Acne in Female 427-51-0 CYPROTERONE ACETATE TA_LEVEL_2 Steroid antagonist 427-51-0 CYPROTERONE ACETATE MESH_LEVEL_1 Polycyclic Hydrocarbons 427-51-0 CYPROTERONE ACETATE ZERO_CLASS N 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT SKN_1_Dry Skin 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT LIV_2_Jaundice 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT END_3_Osteoporosis 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT LIV_3_Hepatitis 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT END_2_Hyperglycemia 427-51-0 CYPROTERONE ACETATE TISSUE_TOXICITY Hepatic Failure 427-51-0 CYPROTERONE ACETATE INDICATION Hirsutism 427-51-0 CYPROTERONE ACETATE MODE_CLASS Receptor Agonist 427-51-0 CYPROTERONE ACETATE MECHANISM Modulate gene transcription 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT CVS_2_Thromboembolism 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT LUN_2_Dyspnea 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT END_2_Gynecomastia 427-51-0 CYPROTERONE ACETATE KNOWN_TOXICITY Hepatotoxicity 427-51-0 CYPROTERONE ACETATE MESH_LEVEL_3 Pregnanes 427-51-0 CYPROTERONE ACETATE INDICATION Hypersexuality in Male 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT SKN_2_Hair Gain 427-51-0 CYPROTERONE ACETATE TISSUE_TOXICITY Carcinogenicity 427-51-0 CYPROTERONE ACETATE STRUCTURE_ACTIVITY Androgen receptor antagonist, steroid 427-51-0 CYPROTERONE ACETATE INDICATION Prostatic Cancer / Carcinoma of the Prostate 427-51-0 CYPROTERONE ACETATE MECH_LEVEL_3 androgen receptor 427-51-0 CYPROTERONE ACETATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT DNA_2_Carcinogenicity 427-51-0 CYPROTERONE ACETATE KNOWN_TOXICITY Carcinogenicity 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT XXX_3_Female Distribution of Pubic Hair 427-51-0 CYPROTERONE ACETATE TISSUE_TOXICITY Hepatic Tumors 427-51-0 CYPROTERONE ACETATE ACTIVITY_CLASS Androgen antagonist 427-51-0 CYPROTERONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 427-51-0 CYPROTERONE ACETATE TISSUE_TOXICITY Thromboembolism 427-51-0 CYPROTERONE ACETATE THERAPEUTIC_CLASS Gonadal Hormones 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT DNA_2_Hepatic Tumors 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT LIV_3_Hepatic Failure 427-51-0 CYPROTERONE ACETATE ADVERSE_EFFECT PSY_2_Mental Depression 427-51-0 CYPROTERONE ACETATE MECH_LEVEL_2 Androgen receptor antagonist 428-07-9 ATROMEPINE PRODUCT_CLASS Autonomic Nervous System (ANS) 428-07-9 ATROMEPINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 428-07-9 ATROMEPINE MECHANISM Prolong/enhance neural transmission 428-07-9 ATROMEPINE MODE_CLASS Solute transporter inhibitor 428-07-9 ATROMEPINE THERAPEUTIC_CLASS Parasympatholytic Agents 432-60-0 ALLYLESTRENOL MODE_CLASS Receptor Ligand Antagonist 432-60-0 ALLYLESTRENOL MECHANISM Modulate gene transcription 432-60-0 ALLYLESTRENOL MODE_CLASS Receptor Agonist 441-61-2 ETHYLMETHYLTHIAMBUTENE MODE_CLASS Receptor Agonist 441-61-2 ETHYLMETHYLTHIAMBUTENE MECHANISM Modulate neural transmission 441-61-2 ETHYLMETHYLTHIAMBUTENE PRODUCT_CLASS Analgesics 441-61-2 ETHYLMETHYLTHIAMBUTENE THERAPEUTIC_CLASS Analgesics, Opioid 441-61-2 ETHYLMETHYLTHIAMBUTENE PRODUCT_CLASS Central Nervous System (CNS) 451-71-8 GLYHEXAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 451-71-8 GLYHEXAMIDE MODE_CLASS Channel Blocker, selective 451-71-8 GLYHEXAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 451-71-8 GLYHEXAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 451-71-8 GLYHEXAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 451-71-8 GLYHEXAMIDE INDICATION Type II Diabetes Mellitus 452-35-7 ETHOXZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 452-35-7 ETHOXZOLAMIDE THERAPEUTIC_CLASS Diuretics 452-35-7 ETHOXZOLAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 452-35-7 ETHOXZOLAMIDE MODE_CLASS Enzyme Inhibitor 455-83-4 DICHLOROPHENARSINE INDICATION Syphilis 466-40-0 ISOMETHADONE MECHANISM Modulate neural transmission 466-40-0 ISOMETHADONE THERAPEUTIC_CLASS Analgesics, Opioid 466-40-0 ISOMETHADONE PRODUCT_CLASS Analgesics 466-40-0 ISOMETHADONE MODE_CLASS Receptor Agonist 467-43-6 METHITURAL MECHANISM Modulate neural transmission 467-43-6 METHITURAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 467-43-6 METHITURAL MODE_CLASS Channel Modulator 467-60-7 PIPRADROL PRODUCT_CLASS Central Nervous System (CNS) 467-60-7 PIPRADROL THERAPEUTIC_CLASS Central Stimulants 467-60-7 PIPRADROL MODE_CLASS Solute transporter inhibitor 467-60-7 PIPRADROL INDICATION Depression 467-60-7 PIPRADROL MECHANISM Prolong/enhance neural transmission 467-60-7 PIPRADROL THERAPEUTIC_CLASS Antidepressants 467-60-7 PIPRADROL INDICATION Fatigue 467-83-4 DIPIPANONE INDICATION Severe Pain 467-83-4 DIPIPANONE PRODUCT_CLASS Analgesics 467-83-4 DIPIPANONE MODE_CLASS Receptor Agonist 467-83-4 DIPIPANONE THERAPEUTIC_CLASS Analgesics, Opioid 467-83-4 DIPIPANONE INDICATION Moderate Pain 467-83-4 DIPIPANONE MECHANISM Modulate neural transmission 467-86-7 DIOXAPHETYL BUTYRATE MECHANISM Modulate neural transmission 467-86-7 DIOXAPHETYL BUTYRATE MODE_CLASS Receptor Agonist 467-86-7 DIOXAPHETYL BUTYRATE PRODUCT_CLASS Analgesics 467-86-7 DIOXAPHETYL BUTYRATE THERAPEUTIC_CLASS Analgesics, Opioid 468-56-4 HYDROXYPETHIDINE PRODUCT_CLASS Analgesics 468-56-4 HYDROXYPETHIDINE THERAPEUTIC_CLASS Analgesics, Opioid 468-56-4 HYDROXYPETHIDINE MECHANISM Modulate neural transmission 468-56-4 HYDROXYPETHIDINE MODE_CLASS Receptor Agonist 468-59-7 BETA-PRODINE MODE_CLASS Receptor Agonist 468-59-7 BETA-PRODINE THERAPEUTIC_CLASS Analgesics, Opioid 468-59-7 BETA-PRODINE PRODUCT_CLASS Analgesics 468-59-7 BETA-PRODINE MECHANISM Modulate neural transmission 468-61-1 OXELADIN INDICATION Cough / Tussis 52432-72-1 OXELADIN INDICATION Cough / Tussis 469-79-4 KETOBEMIDONE THERAPEUTIC_CLASS Analgesics, Opioid 469-79-4 KETOBEMIDONE PRODUCT_CLASS Analgesics 469-79-4 KETOBEMIDONE MODE_CLASS Receptor Agonist 469-79-4 KETOBEMIDONE MECHANISM Modulate neural transmission 474-58-8 SITOGLUSIDE INDICATION Prostatic Hypertrophy 477-93-0 DIMETHOXANATE MODE_CLASS Receptor Ligand Antagonist 477-93-0 DIMETHOXANATE PRODUCT_CLASS Respiratory System 477-93-0 DIMETHOXANATE MECHANISM Block neural transmission 477-93-0 DIMETHOXANATE INDICATION Cough / Tussis 477-93-0 DIMETHOXANATE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 482-15-5 ISOTHIPENDYL MODE_CLASS Receptor Ligand Antagonist 482-15-5 ISOTHIPENDYL MECHANISM Modulate gene transcription 1225-60-1 ISOTHIPENDYL MODE_CLASS Receptor Ligand Antagonist 1225-60-1 ISOTHIPENDYL MECHANISM Modulate gene transcription 484-23-1 DIHYDRALAZINE PRODUCT_CLASS Cardiovasculars 484-23-1 DIHYDRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 484-23-1 DIHYDRALAZINE INDICATION Hypertension 493-92-5 PROLINTANE THERAPEUTIC_CLASS Antidepressants 493-92-5 PROLINTANE INDICATION Depression 493-92-5 PROLINTANE PRODUCT_CLASS Central Nervous System (CNS) 495-84-1 SALINAZID INDICATION Tuberculosis 495-99-8 HYDROXYSTILBAMIDINE INDICATION Leishmaniasis 496-67-3 BROMISOVALUM INDICATION Insomnia 496-67-3 BROMISOVALUM ADVERSE_EFFECT LUN_3_Respiratory Depression 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSY_2_Delirium 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSY_2_Decreased Psychomotor Functioning 496-67-3 BROMISOVALUM ADVERSE_EFFECT SKN_2_Dermatitis 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_3_Disorder of Pain Sensation 496-67-3 BROMISOVALUM ZERO_CLASS N 496-67-3 BROMISOVALUM MESH_LEVEL_3 Bromisovalum 496-67-3 BROMISOVALUM TA_LEVEL_1 Central Nervous System (CNS) 496-67-3 BROMISOVALUM MECHANISM Modulate neural transmission 496-67-3 BROMISOVALUM PRODUCT_CLASS Central Nervous System (CNS) 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_3_Convulsions 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_3_Amnesia 496-67-3 BROMISOVALUM MECH_LEVEL_1 Modulate neural transmission 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_3_Coma 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSN_3_Bromism 496-67-3 BROMISOVALUM STRUCTURE_ACTIVITY GABA-A agonist 496-67-3 BROMISOVALUM TA_LEVEL_2 CNS Depressant 496-67-3 BROMISOVALUM TA_LEVEL_3 Benzodiazepine-like 496-67-3 BROMISOVALUM THERAPEUTIC_CLASS Sedatives/Hypnotics 496-67-3 BROMISOVALUM TISSUE_TOXICITY Hypotension 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSY_3_Depression 496-67-3 BROMISOVALUM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSY_2_Confusion 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_3_Dysarthria 496-67-3 BROMISOVALUM KNOWN_TOXICITY Cardiovascular Toxicity 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSY_3_Irritability 496-67-3 BROMISOVALUM ACTIVITY_CLASS GABA agonist 496-67-3 BROMISOVALUM MECH_LEVEL_3 GABA-A receptor A 496-67-3 BROMISOVALUM MESH_LEVEL_2 Urea 496-67-3 BROMISOVALUM ADVERSE_EFFECT PSY_3_CNS Depression 496-67-3 BROMISOVALUM ADVERSE_EFFECT CVS_3_Hypotension 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_2_Ataxia 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_1_Somnolence 496-67-3 BROMISOVALUM ADVERSE_EFFECT NEU_3_Disorder of Tactile Sensation 496-67-3 BROMISOVALUM MESH_LEVEL_1 Organic Chemicals 496-67-3 BROMISOVALUM MODE_CLASS Channel Modulator 496-67-3 BROMISOVALUM MECH_LEVEL_2 faciliates GABA binding 503-01-5 ISOMETHEPTENE THERAPEUTIC_CLASS Sympathomimetic Agents 503-01-5 ISOMETHEPTENE PRODUCT_CLASS Autonomic Nervous System (ANS) 503-01-5 ISOMETHEPTENE STRUCTURE_ACTIVITY Adrenoceptor agonist 503-01-5 ISOMETHEPTENE INDICATION Migraine Headache 503-01-5 ISOMETHEPTENE MODE_CLASS Receptor Agonist 503-01-5 ISOMETHEPTENE MECHANISM Increase vasoconstriction 503-01-5 ISOMETHEPTENE MECHANISM Modulate G-protein coupled signal transduction 6168-86-1 ISOMETHEPTENE MECHANISM Increase vasoconstriction 6168-86-1 ISOMETHEPTENE PRODUCT_CLASS Autonomic Nervous System (ANS) 6168-86-1 ISOMETHEPTENE STRUCTURE_ACTIVITY Adrenoceptor agonist 6168-86-1 ISOMETHEPTENE INDICATION Migraine Headache 6168-86-1 ISOMETHEPTENE MECHANISM Modulate G-protein coupled signal transduction 6168-86-1 ISOMETHEPTENE THERAPEUTIC_CLASS Sympathomimetic Agents 6168-86-1 ISOMETHEPTENE MODE_CLASS Receptor Agonist 5984-50-9 ISOMETHEPTENE MECHANISM Modulate G-protein coupled signal transduction 5984-50-9 ISOMETHEPTENE THERAPEUTIC_CLASS Sympathomimetic Agents 5984-50-9 ISOMETHEPTENE PRODUCT_CLASS Autonomic Nervous System (ANS) 5984-50-9 ISOMETHEPTENE STRUCTURE_ACTIVITY Adrenoceptor agonist 5984-50-9 ISOMETHEPTENE INDICATION Migraine Headache 5984-50-9 ISOMETHEPTENE MODE_CLASS Receptor Agonist 5984-50-9 ISOMETHEPTENE MECHANISM Increase vasoconstriction 503-49-1 MEGLUTOL THERAPEUTIC_CLASS Hypolipidemic Agents 503-49-1 MEGLUTOL PRODUCT_CLASS Cardiovasculars 503-49-1 MEGLUTOL INDICATION Hyperlipoproteinemia 508-99-6 HYDROCORTISONE CYPIONATE MECHANISM Modulate gene transcription 508-99-6 HYDROCORTISONE CYPIONATE MODE_CLASS Channel enhancer /opener 509-86-4 HEPTABARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 509-86-4 HEPTABARBITAL MECHANISM Modulate neural transmission 509-86-4 HEPTABARBITAL MODE_CLASS Channel Modulator 509-86-4 HEPTABARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 509-86-4 HEPTABARBITAL PRODUCT_CLASS Central Nervous System (CNS) 511-45-5 PRIDINOL THERAPEUTIC_CLASS Parasympatholytic Agents 511-45-5 PRIDINOL PRODUCT_CLASS Autonomic Nervous System (ANS) 511-45-5 PRIDINOL THERAPEUTIC_CLASS Movement Disorders 511-45-5 PRIDINOL INDICATION Parkinson's Disease 511-45-5 PRIDINOL PRODUCT_CLASS Central Nervous System (CNS) 511-45-5 PRIDINOL MECHANISM Modulate G-protein coupled signal transduction 511-45-5 PRIDINOL MODE_CLASS Receptor Ligand Antagonist 968-58-1 PRIDINOL INDICATION Parkinson's Disease 968-58-1 PRIDINOL PRODUCT_CLASS Autonomic Nervous System (ANS) 968-58-1 PRIDINOL MODE_CLASS Receptor Ligand Antagonist 968-58-1 PRIDINOL PRODUCT_CLASS Central Nervous System (CNS) 968-58-1 PRIDINOL MECHANISM Modulate G-protein coupled signal transduction 968-58-1 PRIDINOL THERAPEUTIC_CLASS Parasympatholytic Agents 968-58-1 PRIDINOL THERAPEUTIC_CLASS Movement Disorders 53639-82-0 PRIDINOL MECHANISM Modulate G-protein coupled signal transduction 53639-82-0 PRIDINOL PRODUCT_CLASS Central Nervous System (CNS) 53639-82-0 PRIDINOL MODE_CLASS Receptor Ligand Antagonist 53639-82-0 PRIDINOL INDICATION Parkinson's Disease 53639-82-0 PRIDINOL THERAPEUTIC_CLASS Movement Disorders 53639-82-0 PRIDINOL THERAPEUTIC_CLASS Parasympatholytic Agents 53639-82-0 PRIDINOL PRODUCT_CLASS Autonomic Nervous System (ANS) 516-21-2 CYCLOGUANIL INDICATION Malaria 521-11-9 MESTANOLONE MODE_CLASS Receptor Agonist 521-11-9 MESTANOLONE MECHANISM Modulate gene transcription 521-11-9 MESTANOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 521-11-9 MESTANOLONE THERAPEUTIC_CLASS Gonadal Hormones 522-00-9 ETHOPROPAZINE MECHANISM Block neural transmission 522-00-9 ETHOPROPAZINE THERAPEUTIC_CLASS Movement Disorders 522-00-9 ETHOPROPAZINE PRODUCT_CLASS Central Nervous System (CNS) 522-00-9 ETHOPROPAZINE INDICATION Parkinson's Disease 522-00-9 ETHOPROPAZINE MODE_CLASS Receptor Ligand Antagonist 522-00-9 ETHOPROPAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 522-24-7 FENETHAZINE PRODUCT_CLASS Anti-inflammatories 522-24-7 FENETHAZINE PRODUCT_CLASS Gastrointestinal System 522-24-7 FENETHAZINE MECHANISM Block neural transmission 522-24-7 FENETHAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 522-24-7 FENETHAZINE THERAPEUTIC_CLASS Antiemetics 522-24-7 FENETHAZINE MODE_CLASS Receptor Ligand Antagonist 522-24-7 FENETHAZINE THERAPEUTIC_CLASS Antihistamines 522-24-7 FENETHAZINE PRODUCT_CLASS Central Nervous System (CNS) 522-24-7 FENETHAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 523-54-6 ETYMEMAZINE THERAPEUTIC_CLASS Antispasmodic Agents 523-54-6 ETYMEMAZINE MECHANISM Block neural transmission 523-54-6 ETYMEMAZINE MODE_CLASS Receptor Ligand Antagonist 523-54-6 ETYMEMAZINE PRODUCT_CLASS Gastrointestinal System 523-54-6 ETYMEMAZINE THERAPEUTIC_CLASS Antihistamines 523-54-6 ETYMEMAZINE PRODUCT_CLASS Central Nervous System (CNS) 523-54-6 ETYMEMAZINE THERAPEUTIC_CLASS Antiemetics 523-54-6 ETYMEMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 523-54-6 ETYMEMAZINE PRODUCT_CLASS Autonomic Nervous System (ANS) 523-54-6 ETYMEMAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 523-54-6 ETYMEMAZINE PRODUCT_CLASS Anti-inflammatories 523-54-6 ETYMEMAZINE THERAPEUTIC_CLASS Antipsychotics 524-83-4 ETHYBENZTROPINE INDICATION Parkinson's Disease 524-83-4 ETHYBENZTROPINE MECHANISM Prolong/enhance neural transmission 524-83-4 ETHYBENZTROPINE MODE_CLASS Solute transporter inhibitor 524-83-4 ETHYBENZTROPINE THERAPEUTIC_CLASS Movement Disorders 524-83-4 ETHYBENZTROPINE PRODUCT_CLASS Central Nervous System (CNS) 526-08-9 SULFAPHENAZOLE TA_LEVEL_2 Anti-bacterial 526-08-9 SULFAPHENAZOLE MESH_LEVEL_3 Sulfonamides 526-08-9 SULFAPHENAZOLE MECH_LEVEL_2 Impaired Folic synthesis 526-08-9 SULFAPHENAZOLE MODE_CLASS Enzyme Inhibitor 526-08-9 SULFAPHENAZOLE TA_LEVEL_1 Infectious Disease 526-08-9 SULFAPHENAZOLE MESH_LEVEL_1 Organic Chemicals 526-08-9 SULFAPHENAZOLE MECHANISM Inhibit precursor synthesis 526-08-9 SULFAPHENAZOLE MECH_LEVEL_1 Anti-bacterial 526-08-9 SULFAPHENAZOLE MECH_LEVEL_3 Dihydropteroate synthase 526-08-9 SULFAPHENAZOLE TA_LEVEL_3 Systemic infections 526-08-9 SULFAPHENAZOLE ACTIVITY_CLASS Antibiotic, sulfonamide 526-08-9 SULFAPHENAZOLE PRODUCT_CLASS Biochemicals 526-08-9 SULFAPHENAZOLE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 526-08-9 SULFAPHENAZOLE MESH_LEVEL_2 Amides 526-08-9 SULFAPHENAZOLE ZERO_CLASS N 527-75-3 BERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 527-75-3 BERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 527-75-3 BERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 527-75-3 BERYTHROMYCIN PRODUCT_CLASS Anti-infectives 530-78-9 FLUFENAMIC ACID MODE_CLASS Enzyme Inhibitor 530-78-9 FLUFENAMIC ACID MECHANISM Block channel gating 530-78-9 FLUFENAMIC ACID MODE_CLASS Channel Blocker 530-78-9 FLUFENAMIC ACID STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 530-78-9 FLUFENAMIC ACID MECHANISM Inhibit eicosanoid biosynthesis 536-21-0 NORFENEFRINE INDICATION Hypotension 536-21-0 NORFENEFRINE PRODUCT_CLASS Cardiovasculars 536-21-0 NORFENEFRINE THERAPEUTIC_CLASS Sympathomimetic Agents 536-21-0 NORFENEFRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 536-21-0 NORFENEFRINE MECHANISM Increase vasoconstriction 536-21-0 NORFENEFRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 536-21-0 NORFENEFRINE THERAPEUTIC_CLASS Vasopressors 536-21-0 NORFENEFRINE MODE_CLASS Receptor Agonist 536-24-3 ETHYLNOREPINEPHRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 541-22-0 DECAMETHONIUM BROMIDE MODE_CLASS Channel Modulator 541-22-0 DECAMETHONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 541-22-0 DECAMETHONIUM BROMIDE MECHANISM Prolong/enhance neural transmission 541-22-0 DECAMETHONIUM BROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 541-64-0 FURTRETHONIUM IODIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 541-64-0 FURTRETHONIUM IODIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 541-64-0 FURTRETHONIUM IODIDE MECHANISM Enhance cholinergic transmission 541-66-2 OXAPROPANIUM IODIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 541-66-2 OXAPROPANIUM IODIDE MECHANISM Enhance cholinergic transmission 541-66-2 OXAPROPANIUM IODIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 543-82-8 OCTODRINE PRODUCT_CLASS Cardiovasculars 543-82-8 OCTODRINE THERAPEUTIC_CLASS Local Anesthetics 543-82-8 OCTODRINE THERAPEUTIC_CLASS Vasopressors 543-82-8 OCTODRINE MECHANISM Modulate G-protein coupled signal transduction 543-82-8 OCTODRINE PRODUCT_CLASS Central Nervous System (CNS) 547-44-4 SULFACARBAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 547-44-4 SULFACARBAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 547-44-4 SULFACARBAMIDE MODE_CLASS Channel Blocker, selective 547-44-4 SULFACARBAMIDE INDICATION Type II Diabetes Mellitus 547-44-4 SULFACARBAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 547-44-4 SULFACARBAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 550-81-2 AMOPYROQUIN INDICATION Malaria 551-11-1 DINOPROST MECHANISM Modulate G-protein coupled signal transduction 551-11-1 DINOPROST MODE_CLASS Receptor Agonist 99437-94-2 DINOPROST MECHANISM Modulate G-protein coupled signal transduction 99437-94-2 DINOPROST MODE_CLASS Receptor Agonist 551-92-8 DIMETRIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 552-25-0 DIAMPROMIDE MECHANISM Modulate neural transmission 552-25-0 DIAMPROMIDE PRODUCT_CLASS Analgesics 552-25-0 DIAMPROMIDE MODE_CLASS Receptor Agonist 552-25-0 DIAMPROMIDE THERAPEUTIC_CLASS Analgesics, Opioid 552-80-7 DIMETHYLSTILBESTROL MECHANISM Modulate gene transcription 552-80-7 DIMETHYLSTILBESTROL THERAPEUTIC_CLASS Gonadal Hormones 552-80-7 DIMETHYLSTILBESTROL MODE_CLASS Receptor Ligand Antagonist 552-80-7 DIMETHYLSTILBESTROL PRODUCT_CLASS Anti-cancers 553-13-9 ZOLAMINE MECHANISM Block neural transmission 553-13-9 ZOLAMINE MODE_CLASS Channel Blocker 561-83-1 NEALBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 561-83-1 NEALBARBITAL MECHANISM Modulate neural transmission 561-83-1 NEALBARBITAL MODE_CLASS Channel Modulator 561-83-1 NEALBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 561-83-1 NEALBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 561-86-4 BRALLOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 561-86-4 BRALLOBARBITAL MODE_CLASS Channel Modulator 561-86-4 BRALLOBARBITAL MECHANISM Modulate neural transmission 561-86-4 BRALLOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 561-86-4 BRALLOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 565-33-3 METAHEXAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 565-33-3 METAHEXAMIDE INDICATION Type II Diabetes Mellitus 565-33-3 METAHEXAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 565-33-3 METAHEXAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 565-33-3 METAHEXAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 565-33-3 METAHEXAMIDE MODE_CLASS Channel Blocker, selective 602-41-5 THIOCOLCHICOSIDE STRUCTURE_ACTIVITY Tubulin binder, colchicinoid 602-41-5 THIOCOLCHICOSIDE THERAPEUTIC_CLASS Gout-Related Agents 602-41-5 THIOCOLCHICOSIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 606-90-6 PIPRINHYDRINATE INDICATION Nausea / Vomiting 611-53-0 IBACITABINE THERAPEUTIC_CLASS Antivirals, Topical 611-53-0 IBACITABINE INDICATION Herpes Simplex Keratitis 611-53-0 IBACITABINE INDICATION Herpes Labialis / Cold or Fever Sore 611-53-0 IBACITABINE PRODUCT_CLASS Anti-infectives 634-08-2 LEVOFACETOPERANE PRODUCT_CLASS Central Nervous System (CNS) 634-08-2 LEVOFACETOPERANE INDICATION Depression 634-08-2 LEVOFACETOPERANE THERAPEUTIC_CLASS Antidepressants 655-05-0 THOZALINONE THERAPEUTIC_CLASS Antidepressants 655-05-0 THOZALINONE INDICATION Depression 655-05-0 THOZALINONE PRODUCT_CLASS Central Nervous System (CNS) 664-95-9 GLYCYCLAMIDE MODE_CLASS Channel Blocker, selective 664-95-9 GLYCYCLAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 664-95-9 GLYCYCLAMIDE INDICATION Type II Diabetes Mellitus 664-95-9 GLYCYCLAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 664-95-9 GLYCYCLAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 664-95-9 GLYCYCLAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 692-13-7 BUFORMIN TISSUE_TOXICITY Cardiogenic Shock 692-13-7 BUFORMIN ADVERSE_EFFECT XXX_3_Sepsis 692-13-7 BUFORMIN ADVERSE_EFFECT LUN_3_Dyspnea 692-13-7 BUFORMIN MECHANISM Stimulate insulin sensitive pathway 692-13-7 BUFORMIN ADVERSE_EFFECT GIS_1_Abdominal Pain 692-13-7 BUFORMIN INDICATION Type II Diabetes Mellitus 692-13-7 BUFORMIN MECHANISM Modulate channel gating 692-13-7 BUFORMIN KNOWN_TOXICITY Nephrotoxicity 692-13-7 BUFORMIN ADVERSE_EFFECT END_2_Lactic Acidosis 692-13-7 BUFORMIN ADVERSE_EFFECT GIS_1_Nausea 692-13-7 BUFORMIN MODE_CLASS Enzyme Activator 692-13-7 BUFORMIN ADVERSE_EFFECT GIS_1_Vomiting 692-13-7 BUFORMIN MECHANISM Modulate signal transduction 692-13-7 BUFORMIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 692-13-7 BUFORMIN ADVERSE_EFFECT GIS_1_Diarrhea 692-13-7 BUFORMIN ADVERSE_EFFECT CVS_3_Cardiogenic Shock 692-13-7 BUFORMIN THERAPEUTIC_CLASS Antidiabetic Agents 692-13-7 BUFORMIN MODE_CLASS Receptor Agonist 692-13-7 BUFORMIN ADVERSE_EFFECT KID_3_Renal Failure 692-13-7 BUFORMIN STRUCTURE_ACTIVITY AMP kinase activator 692-13-7 BUFORMIN INDICATION Type II Diabetes Mellitus 692-13-7 BUFORMIN TISSUE_TOXICITY Renal Failure 692-13-7 BUFORMIN KNOWN_TOXICITY Cardiovascular Toxicity 692-13-7 BUFORMIN MODE_CLASS Channel Modulator 702-54-5 DIETHADIONE INDICATION Depression 702-54-5 DIETHADIONE PRODUCT_CLASS Central Nervous System (CNS) 702-54-5 DIETHADIONE THERAPEUTIC_CLASS Antidepressants 721-19-7 METHASTYRIDONE PRODUCT_CLASS Central Nervous System (CNS) 721-19-7 METHASTYRIDONE INDICATION Depression 721-19-7 METHASTYRIDONE THERAPEUTIC_CLASS Antidepressants 735-52-4 CETOPHENICOL THERAPEUTIC_CLASS Antibacterials 735-52-4 CETOPHENICOL MECHANISM Inhibit ribosomal protein synthesis 735-52-4 CETOPHENICOL PRODUCT_CLASS Anti-infectives 735-52-4 CETOPHENICOL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 749-13-3 TRIFLUPERIDOL THERAPEUTIC_CLASS Antipsychotics 749-13-3 TRIFLUPERIDOL PRODUCT_CLASS Central Nervous System (CNS) 749-13-3 TRIFLUPERIDOL MECHANISM Block neural transmission 749-13-3 TRIFLUPERIDOL STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), butyrophenone 749-13-3 TRIFLUPERIDOL MODE_CLASS Receptor Ligand Antagonist 789-61-7 THIOGUANINE BETA-DEOXYRIBOSIDE THERAPEUTIC_CLASS Antineoplastics 789-61-7 THIOGUANINE BETA-DEOXYRIBOSIDE MECHANISM Incorporate into DNA/RNA/Protein 789-61-7 THIOGUANINE BETA-DEOXYRIBOSIDE PRODUCT_CLASS Anti-cancers 789-61-7 THIOGUANINE BETA-DEOXYRIBOSIDE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 789-61-7 THIOGUANINE BETA-DEOXYRIBOSIDE MODE_CLASS Enzyme substrate mimic 796-29-2 KETIPRAMINE MECHANISM Prolong/enhance neural transmission 796-29-2 KETIPRAMINE INDICATION Depression 796-29-2 KETIPRAMINE THERAPEUTIC_CLASS Antidepressants 796-29-2 KETIPRAMINE MODE_CLASS Solute transporter inhibitor 796-29-2 KETIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 808-26-4 SANCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 808-26-4 SANCYCLINE THERAPEUTIC_CLASS Antibacterials 808-26-4 SANCYCLINE PRODUCT_CLASS Anti-infectives 808-26-4 SANCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 808-26-4 SANCYCLINE MECHANISM Inhibit ribosomal protein synthesis 841-73-6 BUCOLOME MODE_CLASS Channel Modulator 841-73-6 BUCOLOME MECHANISM Modulate neural transmission 847-20-1 FLUBANILATE PRODUCT_CLASS Central Nervous System (CNS) 847-20-1 FLUBANILATE THERAPEUTIC_CLASS Antidepressants 847-20-1 FLUBANILATE INDICATION Depression 852-42-6 GUAIAPATE INDICATION Cough / Tussis 853-34-9 KEBUZONE PRODUCT_CLASS Immune Response / Immunomodulators 853-34-9 KEBUZONE THERAPEUTIC_CLASS Immunosuppressants 853-34-9 KEBUZONE INDICATION Rheumatism 892-01-3 HEXACYPRONE INDICATION Cholelithiasis / Gallstones 893-01-6 TENYLIDONE INDICATION Cholelithiasis / Gallstones 910-86-1 TIOCARLIDE INDICATION Tuberculosis 952-54-5 MORINAMIDE INDICATION Tuberculosis 957-56-2 FLUINDIONE PRODUCT_CLASS Hematologics 957-56-2 FLUINDIONE THERAPEUTIC_CLASS Anticoagulants 959-14-8 OXOLAMINE INDICATION Cough / Tussis 987-18-8 FLUMEDROXONE-17-ACETATE INDICATION Migraine Headache 987-18-8 FLUMEDROXONE-17-ACETATE PRODUCT_CLASS Central Nervous System (CNS) 987-18-8 FLUMEDROXONE-17-ACETATE THERAPEUTIC_CLASS Antimigraines 992-21-2 LYMECYCLINE PRODUCT_CLASS Anti-infectives 992-21-2 LYMECYCLINE MECHANISM Inhibit ribosomal protein synthesis 992-21-2 LYMECYCLINE THERAPEUTIC_CLASS Antibacterials 992-21-2 LYMECYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 992-21-2 LYMECYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1034-82-8 HEPTOLAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 1034-82-8 HEPTOLAMIDE INDICATION Type II Diabetes Mellitus 1034-82-8 HEPTOLAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 1034-82-8 HEPTOLAMIDE MODE_CLASS Channel Blocker, selective 1034-82-8 HEPTOLAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 1034-82-8 HEPTOLAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 1038-59-1 GLYOCTAMIDE MODE_CLASS Channel Blocker, selective 1038-59-1 GLYOCTAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 1038-59-1 GLYOCTAMIDE INDICATION Type II Diabetes Mellitus 1038-59-1 GLYOCTAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 1038-59-1 GLYOCTAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 1038-59-1 GLYOCTAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 1042-42-8 CARCAINIUM CHLORIDE PRODUCT_CLASS Cardiovasculars 1042-42-8 CARCAINIUM CHLORIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 1042-42-8 CARCAINIUM CHLORIDE INDICATION Cardiac Arrhythmias 51410-30-1 PIRENOXINE INDICATION Cataract 1050-79-9 MOPERONE MECHANISM Modulate G-protein coupled signal transduction 1050-79-9 MOPERONE MODE_CLASS Receptor Ligand Antagonist 3871-82-7 MOPERONE MECHANISM Modulate G-protein coupled signal transduction 3871-82-7 MOPERONE MODE_CLASS Receptor Ligand Antagonist 1082-57-1 TRAMAZOLINE INDICATION Nasal Congestion 1082-57-1 TRAMAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 1082-57-1 TRAMAZOLINE MECHANISM Increase vasoconstriction 1082-57-1 TRAMAZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 1082-57-1 TRAMAZOLINE MODE_CLASS Receptor Agonist, selective 1082-57-1 TRAMAZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 3715-90-0 TRAMAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 3715-90-0 TRAMAZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 3715-90-0 TRAMAZOLINE MODE_CLASS Receptor Agonist, selective 3715-90-0 TRAMAZOLINE MECHANISM Increase vasoconstriction 3715-90-0 TRAMAZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 3715-90-0 TRAMAZOLINE INDICATION Nasal Congestion 1096-72-6 HEPZIDINE INDICATION Depression 1096-72-6 HEPZIDINE PRODUCT_CLASS Central Nervous System (CNS) 1096-72-6 HEPZIDINE THERAPEUTIC_CLASS Antidepressants 1113-10-6 GUANCYDINE THERAPEUTIC_CLASS Antihypertensive Agents 1113-10-6 GUANCYDINE PRODUCT_CLASS Cardiovasculars 1113-10-6 GUANCYDINE INDICATION Hypertension 1131-64-2 DEBRISOQUINE MECHANISM Depletes neural transmitter 1131-64-2 DEBRISOQUINE PRODUCT_CLASS Cardiovasculars 1131-64-2 DEBRISOQUINE THERAPEUTIC_CLASS Antihypertensive Agents 1131-64-2 DEBRISOQUINE MODE_CLASS Enzyme Inhibitor 1131-64-2 DEBRISOQUINE INDICATION Hypertension 1131-65-3 DEBRISOQUINE PRODUCT_CLASS Cardiovasculars 1131-65-3 DEBRISOQUINE THERAPEUTIC_CLASS Antihypertensive Agents 1131-65-3 DEBRISOQUINE MODE_CLASS Enzyme Inhibitor 1131-65-3 DEBRISOQUINE INDICATION Hypertension 1131-65-3 DEBRISOQUINE MECHANISM Depletes neural transmitter 581-88-4 DEBRISOQUINE MODE_CLASS Enzyme Inhibitor 581-88-4 DEBRISOQUINE INDICATION Hypertension 581-88-4 DEBRISOQUINE MECHANISM Depletes neural transmitter 581-88-4 DEBRISOQUINE THERAPEUTIC_CLASS Antihypertensive Agents 581-88-4 DEBRISOQUINE PRODUCT_CLASS Cardiovasculars 1146-98-1 BROMINDIONE PRODUCT_CLASS Hematologics 1146-98-1 BROMINDIONE THERAPEUTIC_CLASS Anticoagulants 1146-99-2 CLORINDIONE THERAPEUTIC_CLASS Anticoagulants 1146-99-2 CLORINDIONE PRODUCT_CLASS Hematologics 1150-20-5 AZABON INDICATION Depression 1150-20-5 AZABON PRODUCT_CLASS Central Nervous System (CNS) 1150-20-5 AZABON THERAPEUTIC_CLASS Antidepressants 96301-34-7 ATAMESTANE THERAPEUTIC_CLASS Antineoplastics 96301-34-7 ATAMESTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 96301-34-7 ATAMESTANE PRODUCT_CLASS Anti-cancers 96301-34-7 ATAMESTANE INDICATION Metastatic Breast Cancer 96301-34-7 ATAMESTANE MODE_CLASS Enzyme Inhibitor 41294-56-8 ALFACALCIDOL INDICATION Hypoparathyroidism 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 41294-56-8 ALFACALCIDOL INDICATION Rickets 41294-56-8 ALFACALCIDOL MECH_LEVEL_2 Vitamin D 41294-56-8 ALFACALCIDOL MECH_LEVEL_3 thyroid hormone receptor VDR 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT XXX_3_Thirst 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT XXX_3_Weakness 41294-56-8 ALFACALCIDOL MECHANISM Modulate gene transcription 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT END_3_Hyperphosphatemia 41294-56-8 ALFACALCIDOL TA_LEVEL_3 Vitamin D 41294-56-8 ALFACALCIDOL ACTIVITY_CLASS Vitamin D receptor agonist 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT KID_3_Renal Stones 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT PSY_3_Anorexia 41294-56-8 ALFACALCIDOL INDICATION Renal Osteodystrophy 41294-56-8 ALFACALCIDOL PRODUCT_CLASS Vitamins, Minerals and Nutrients 41294-56-8 ALFACALCIDOL TA_LEVEL_2 Vitamine D precusors 41294-56-8 ALFACALCIDOL INDICATION Osteomalacia 41294-56-8 ALFACALCIDOL MESH_LEVEL_3 Vitamin D 41294-56-8 ALFACALCIDOL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT NEU_3_Paralytic Ileus 41294-56-8 ALFACALCIDOL MESH_LEVEL_1 Growth Substances, Pigments, and Vitamins 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT NEU_3_Somnolence 41294-56-8 ALFACALCIDOL MECH_LEVEL_1 Vitamin D 41294-56-8 ALFACALCIDOL MODE_CLASS Receptor Agonist 41294-56-8 ALFACALCIDOL INDICATION Hyperparathyroidism 41294-56-8 ALFACALCIDOL MESH_LEVEL_2 Vitamins 41294-56-8 ALFACALCIDOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 41294-56-8 ALFACALCIDOL ADVERSE_EFFECT ELT_1_Hypercalcemia 41294-56-8 ALFACALCIDOL TA_LEVEL_1 Vitamins, Minerals and Nutrients 31698-14-3 ANCITABINE MODE_CLASS Enzyme substrate mimic 31698-14-3 ANCITABINE MECHANISM Incorporate into DNA/RNA/Protein 31698-14-3 ANCITABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor 31698-14-3 ANCITABINE PRODUCT_CLASS Anti-infectives 10212-25-6 ANCITABINE MODE_CLASS Enzyme substrate mimic 10212-25-6 ANCITABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor 10212-25-6 ANCITABINE PRODUCT_CLASS Anti-infectives 10212-25-6 ANCITABINE MECHANISM Incorporate into DNA/RNA/Protein 3572-43-8 BROMHEXINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 3572-43-8 BROMHEXINE ADVERSE_EFFECT XXX_3_Salivation 3572-43-8 BROMHEXINE ADVERSE_EFFECT XXX_3_Rhinorrhea 3572-43-8 BROMHEXINE ACTIVITY_CLASS Guanylate cyclase inhibitor 3572-43-8 BROMHEXINE ZERO_CLASS N 3572-43-8 BROMHEXINE MESH_LEVEL_1 Organic Chemicals 3572-43-8 BROMHEXINE INDICATION Cough / Tussis 3572-43-8 BROMHEXINE ADVERSE_EFFECT IMU_3_Allergic Reactions 3572-43-8 BROMHEXINE MESH_LEVEL_3 Aniline Compounds 3572-43-8 BROMHEXINE MECH_LEVEL_3 Guanylate cyclase 3572-43-8 BROMHEXINE MECHANISM Inhibit kinase mediated signal transduction 3572-43-8 BROMHEXINE ADVERSE_EFFECT GIS_2_Abdominal Pain 3572-43-8 BROMHEXINE ADVERSE_EFFECT GIS_3_Dry Mouth 3572-43-8 BROMHEXINE MODE_CLASS Channel Blocker 3572-43-8 BROMHEXINE STRUCTURE_ACTIVITY Guanylate cyclase inhibitor 3572-43-8 BROMHEXINE ADVERSE_EFFECT GIS_3_Nausea 3572-43-8 BROMHEXINE PRODUCT_CLASS Respiratory System 3572-43-8 BROMHEXINE MECHANISM Block neural transmission 3572-43-8 BROMHEXINE MODE_CLASS Enzyme Inhibitor 3572-43-8 BROMHEXINE MESH_LEVEL_2 Amines 611-75-6 BROMHEXINE ADVERSE_EFFECT IMU_3_Allergic Reactions 611-75-6 BROMHEXINE INDICATION Cough / Tussis 611-75-6 BROMHEXINE MECH_LEVEL_3 Guanylate cyclase 611-75-6 BROMHEXINE MESH_LEVEL_1 Organic Chemicals 611-75-6 BROMHEXINE ZERO_CLASS N 611-75-6 BROMHEXINE ACTIVITY_CLASS Guanylate cyclase inhibitor 611-75-6 BROMHEXINE ADVERSE_EFFECT XXX_3_Rhinorrhea 611-75-6 BROMHEXINE ADVERSE_EFFECT XXX_3_Salivation 611-75-6 BROMHEXINE MODE_CLASS Enzyme Inhibitor 611-75-6 BROMHEXINE MESH_LEVEL_3 Aniline Compounds 611-75-6 BROMHEXINE MECHANISM Inhibit kinase mediated signal transduction 611-75-6 BROMHEXINE ADVERSE_EFFECT GIS_2_Abdominal Pain 611-75-6 BROMHEXINE ADVERSE_EFFECT GIS_3_Dry Mouth 611-75-6 BROMHEXINE MODE_CLASS Channel Blocker 611-75-6 BROMHEXINE MECHANISM Block neural transmission 611-75-6 BROMHEXINE STRUCTURE_ACTIVITY Guanylate cyclase inhibitor 611-75-6 BROMHEXINE PRODUCT_CLASS Respiratory System 611-75-6 BROMHEXINE ADVERSE_EFFECT GIS_3_Nausea 611-75-6 BROMHEXINE MESH_LEVEL_2 Amines 611-75-6 BROMHEXINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 2438-72-4 BUFEXAMAC INDICATION Allergic Contact Dermatitis 2438-72-4 BUFEXAMAC INDICATION Burns 2438-72-4 BUFEXAMAC MODE_CLASS Enzyme Inhibitor 2438-72-4 BUFEXAMAC INDICATION Atopic Dermatitis / Eczema 2438-72-4 BUFEXAMAC MECHANISM Inhibit eicosanoid biosynthesis 2438-72-4 BUFEXAMAC MECHANISM Enhance kinase mediated signal transduction 2438-72-4 BUFEXAMAC INDICATION Pruritus / Itching 2438-72-4 BUFEXAMAC INDICATION Dermatitis 98106-17-3 DIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 98106-17-3 DIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 98106-17-3 DIFLOXACIN PRODUCT_CLASS Anti-infectives 99331-53-0 DIFLOXACIN PRODUCT_CLASS Anti-infectives 99331-53-0 DIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 99331-53-0 DIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 631-27-6 GLYCLOPYRAMIDE MODE_CLASS Channel Blocker, selective 631-27-6 GLYCLOPYRAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 631-27-6 GLYCLOPYRAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 631-27-6 GLYCLOPYRAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 631-27-6 GLYCLOPYRAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 631-27-6 GLYCLOPYRAMIDE INDICATION Type II Diabetes Mellitus 3685-84-5 MECLOFENOXATE THERAPEUTIC_CLASS Neurodegenerative Disorders 3685-84-5 MECLOFENOXATE PRODUCT_CLASS Central Nervous System (CNS) 3685-84-5 MECLOFENOXATE MECHANISM Enhance cholinergic transmission 27959-26-8 NICOMOL PRODUCT_CLASS Vitamins, Minerals and Nutrients 50-11-3 METHARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 50-11-3 METHARBITAL MECHANISM Modulate neural transmission 50-11-3 METHARBITAL MODE_CLASS Channel Modulator 50-11-3 METHARBITAL PRODUCT_CLASS Central Nervous System (CNS) 50-11-3 METHARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 35107-70-1 METHARBITAL MECHANISM Modulate neural transmission 35107-70-1 METHARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 35107-70-1 METHARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 35107-70-1 METHARBITAL MODE_CLASS Channel Modulator 35107-70-1 METHARBITAL PRODUCT_CLASS Central Nervous System (CNS) 51-26-3 3,3',5-TRIIODOTHYROPROPIC ACID MODE_CLASS Receptor Agonist 51-26-3 3,3',5-TRIIODOTHYROPROPIC ACID STRUCTURE_ACTIVITY T3 receptor agonist 51-26-3 3,3',5-TRIIODOTHYROPROPIC ACID PRODUCT_CLASS Cardiovasculars 51-26-3 3,3',5-TRIIODOTHYROPROPIC ACID THERAPEUTIC_CLASS Hypolipidemic Agents 51-26-3 3,3',5-TRIIODOTHYROPROPIC ACID INDICATION Hyperlipoproteinemia 52-31-3 CYCLOBARBITAL MECHANISM Modulate neural transmission 52-31-3 CYCLOBARBITAL MODE_CLASS Channel Modulator 52-31-3 CYCLOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 52-31-3 CYCLOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 52-31-3 CYCLOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 52-43-7 ALLOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 52-43-7 ALLOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 52-43-7 ALLOBARBITAL MODE_CLASS Channel Modulator 52-43-7 ALLOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 52-43-7 ALLOBARBITAL MECHANISM Modulate neural transmission 53-89-4 BENZPIPERYLON INDICATION Connective Tissue Disorders 54-25-1 AZAURIDINE ADVERSE_EFFECT MSK_1_Joint Pain 54-25-1 AZAURIDINE ADVERSE_EFFECT XXX_3_Edema 54-25-1 AZAURIDINE MECHANISM Inhibit precursor synthesis 54-25-1 AZAURIDINE TA_LEVEL_1 Oncology 54-25-1 AZAURIDINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 54-25-1 AZAURIDINE PRODUCT_CLASS Anti-infectives 54-25-1 AZAURIDINE MESH_LEVEL_2 Nucleosides 54-25-1 AZAURIDINE MECH_LEVEL_2 enzyme substrate mimic 54-25-1 AZAURIDINE ADVERSE_EFFECT SKN_2_Exanthema 54-25-1 AZAURIDINE ADVERSE_EFFECT XXX_1_Fever 54-25-1 AZAURIDINE MODE_CLASS Enzyme Inhibitor 54-25-1 AZAURIDINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidine kinase inhibitor 54-25-1 AZAURIDINE ADVERSE_EFFECT XXX_3_Rigidity 54-25-1 AZAURIDINE ADVERSE_EFFECT PSY_3_Depression 54-25-1 AZAURIDINE MODE_CLASS Enzyme substrate mimic 54-25-1 AZAURIDINE MECH_LEVEL_3 Thymidine kinase 54-25-1 AZAURIDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 54-25-1 AZAURIDINE ADVERSE_EFFECT MSK_1_Joint Swelling 54-25-1 AZAURIDINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 54-25-1 AZAURIDINE PRODUCT_CLASS Immune Response / Immunomodulators 54-25-1 AZAURIDINE THERAPEUTIC_CLASS Antineoplastics 54-25-1 AZAURIDINE PRODUCT_CLASS Anti-cancers 54-25-1 AZAURIDINE MECHANISM Inhibit kinase mediated signal transduction 54-25-1 AZAURIDINE MESH_LEVEL_3 Ribonucleosides 54-25-1 AZAURIDINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 54-25-1 AZAURIDINE THERAPEUTIC_CLASS Antivirals, Systemic 54-80-8 PRONETALOL MECHANISM Modulate G-protein coupled signal transduction 54-80-8 PRONETALOL THERAPEUTIC_CLASS Antihypertensive Agents 54-80-8 PRONETALOL PRODUCT_CLASS Cardiovasculars 55-52-7 PHENIPRAZINE INDICATION Hypertension 55-52-7 PHENIPRAZINE PRODUCT_CLASS Cardiovasculars 55-52-7 PHENIPRAZINE THERAPEUTIC_CLASS Antihypertensive Agents 55-97-0 HEXAMETHONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 55-97-0 HEXAMETHONIUM BROMIDE MODE_CLASS Channel Blocker 55-97-0 HEXAMETHONIUM BROMIDE MECHANISM Modulate neural transmission 55-97-0 HEXAMETHONIUM BROMIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 58-37-7 AMINOPROMAZINE MECHANISM Block neural transmission 58-37-7 AMINOPROMAZINE THERAPEUTIC_CLASS Antispasmodic Agents 58-37-7 AMINOPROMAZINE MODE_CLASS Receptor Ligand Antagonist 58-37-7 AMINOPROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 58-37-7 AMINOPROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 58-37-7 AMINOPROMAZINE PRODUCT_CLASS Autonomic Nervous System (ANS) 58-37-7 AMINOPROMAZINE THERAPEUTIC_CLASS Antipsychotics 59-39-2 PIPEROXAN PRODUCT_CLASS Cardiovasculars 59-39-2 PIPEROXAN THERAPEUTIC_CLASS Antihypertensive Agents 59-39-2 PIPEROXAN MECHANISM Modulate G-protein coupled signal transduction 59-58-5 PROSULTIAMINE MECHANISM Vitamin/ cofactor 59-97-2 TOLAZOLINE MODE_CLASS Receptor Ligand Antagonist 59-97-2 TOLAZOLINE MECHANISM Reduce vasoconstriction 60-89-9 MEPAZINE ADVERSE_EFFECT BBM_2_Granulocytopenia 60-89-9 MEPAZINE PRODUCT_CLASS Central Nervous System (CNS) 60-89-9 MEPAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 60-89-9 MEPAZINE THERAPEUTIC_CLASS Antipsychotics 60-89-9 MEPAZINE ADVERSE_EFFECT IMU_1_Photosensitivity 60-89-9 MEPAZINE ADVERSE_EFFECT BBM_2_Granulocytosis 60-89-9 MEPAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 60-89-9 MEPAZINE KNOWN_TOXICITY Cardiovascular Toxicity 60-89-9 MEPAZINE MECHANISM Modulate G-protein coupled signal transduction 60-89-9 MEPAZINE MODE_CLASS Receptor Ligand Antagonist 60-89-9 MEPAZINE ADVERSE_EFFECT NEU_2_Seizures 60-89-9 MEPAZINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 60-89-9 MEPAZINE TISSUE_TOXICITY Hypotension 60-89-9 MEPAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 60-89-9 MEPAZINE MODE_CLASS Solute transporter inhibitor 60-89-9 MEPAZINE MECHANISM Prolong/enhance neural transmission 60-89-9 MEPAZINE ADVERSE_EFFECT LIV_2_Jaundice 60-89-9 MEPAZINE ADVERSE_EFFECT CVS_2_Hypotension 60-89-9 MEPAZINE MECHANISM Block neural transmission 2975-36-2 MEPAZINE ADVERSE_EFFECT LIV_2_Jaundice 2975-36-2 MEPAZINE MECHANISM Block neural transmission 2975-36-2 MEPAZINE TISSUE_TOXICITY Hypotension 2975-36-2 MEPAZINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 2975-36-2 MEPAZINE ADVERSE_EFFECT NEU_2_Seizures 2975-36-2 MEPAZINE MODE_CLASS Receptor Ligand Antagonist 2975-36-2 MEPAZINE ADVERSE_EFFECT BBM_2_Granulocytosis 2975-36-2 MEPAZINE MECHANISM Modulate G-protein coupled signal transduction 2975-36-2 MEPAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 2975-36-2 MEPAZINE THERAPEUTIC_CLASS Antipsychotics 2975-36-2 MEPAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 2975-36-2 MEPAZINE ADVERSE_EFFECT IMU_1_Photosensitivity 2975-36-2 MEPAZINE ADVERSE_EFFECT CVS_2_Hypotension 2975-36-2 MEPAZINE PRODUCT_CLASS Central Nervous System (CNS) 2975-36-2 MEPAZINE ADVERSE_EFFECT BBM_2_Granulocytopenia 2975-36-2 MEPAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 2975-36-2 MEPAZINE MODE_CLASS Solute transporter inhibitor 2975-36-2 MEPAZINE MECHANISM Prolong/enhance neural transmission 2975-36-2 MEPAZINE KNOWN_TOXICITY Cardiovascular Toxicity 60-91-3 DIETHAZINE MECHANISM Block neural transmission 60-91-3 DIETHAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 60-91-3 DIETHAZINE PRODUCT_CLASS Central Nervous System (CNS) 60-91-3 DIETHAZINE THERAPEUTIC_CLASS Parasympatholytic Agents 60-91-3 DIETHAZINE MODE_CLASS Receptor Ligand Antagonist 60-91-3 DIETHAZINE THERAPEUTIC_CLASS Movement Disorders 60-91-3 DIETHAZINE INDICATION Parkinson's Disease 61-80-3 ZOXAZOLAMINE PRODUCT_CLASS Central Nervous System (CNS) 61-80-3 ZOXAZOLAMINE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 61-80-3 ZOXAZOLAMINE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 61-80-3 ZOXAZOLAMINE MODE_CLASS Channel Modulator 61-80-3 ZOXAZOLAMINE THERAPEUTIC_CLASS Uricosuric Agents 61-80-3 ZOXAZOLAMINE MECHANISM Modulate channel gating 61-80-3 ZOXAZOLAMINE STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) opener 62-51-1 METHACHOLINE CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 62-51-1 METHACHOLINE CHLORIDE MECHANISM Enhance cholinergic transmission 62-51-1 METHACHOLINE CHLORIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 62-51-1 METHACHOLINE CHLORIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 62-51-1 METHACHOLINE CHLORIDE MODE_CLASS Receptor Agonist 64-55-1 MEBUTAMATE MECHANISM Modulate neural transmission 64-55-1 MEBUTAMATE MECHANISM Block neural transmission 64-55-1 MEBUTAMATE THERAPEUTIC_CLASS Anxiolytics 64-55-1 MEBUTAMATE MODE_CLASS Channel enhancer /opener 64-55-1 MEBUTAMATE THERAPEUTIC_CLASS Sedatives/Hypnotics 64-55-1 MEBUTAMATE MODE_CLASS Receptor Ligand Antagonist 64-55-1 MEBUTAMATE PRODUCT_CLASS Central Nervous System (CNS) 64-55-1 MEBUTAMATE INDICATION Insomnia 64-55-1 MEBUTAMATE INDICATION Anxiety Disorders 69-33-0 TUBERCIDINE INDICATION Tuberculosis 69-65-8 MANNITOL KNOWN_TOXICITY Cardiovascular Toxicity 69-65-8 MANNITOL ADVERSE_EFFECT XXX_2_Chills 69-65-8 MANNITOL STRUCTURE_ACTIVITY Diuretic (osmotic) 69-65-8 MANNITOL ADVERSE_EFFECT XXX_2_Fever 69-65-8 MANNITOL MESH_LEVEL_2 Alcohols 69-65-8 MANNITOL ADVERSE_EFFECT CVS_2_Thrombophlebitis 69-65-8 MANNITOL ACTIVITY_CLASS Diuretic 69-65-8 MANNITOL TA_LEVEL_3 Osmolarity of renal filtrate 69-65-8 MANNITOL TA_LEVEL_1 Cardiovascular 69-65-8 MANNITOL INDICATION Increased Intraocular Pressure 69-65-8 MANNITOL MESH_LEVEL_1 Organic Chemicals 69-65-8 MANNITOL ADVERSE_EFFECT OCU_2_Blurred Vision 69-65-8 MANNITOL ADVERSE_EFFECT NEU_1_Headache 69-65-8 MANNITOL ADVERSE_EFFECT PSY_3_CNS Toxicity 69-65-8 MANNITOL ADVERSE_EFFECT CVS_2_Circulatory Overload 69-65-8 MANNITOL THERAPEUTIC_CLASS Diuretics 69-65-8 MANNITOL TISSUE_TOXICITY Hypotension 69-65-8 MANNITOL ADVERSE_EFFECT KID_3_Acute Renal Failure 69-65-8 MANNITOL INDICATION Ascites 69-65-8 MANNITOL INDICATION Increased Intracranial Pressure 69-65-8 MANNITOL PRODUCT_CLASS Electrolytic, Caloric and Water Balance 69-65-8 MANNITOL MESH_LEVEL_3 Sugar Alcohols 69-65-8 MANNITOL ADVERSE_EFFECT NEU_3_Seizures 69-65-8 MANNITOL MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 69-65-8 MANNITOL KNOWN_TOXICITY Nephrotoxicity 69-65-8 MANNITOL TISSUE_TOXICITY Acute Renal Failure 69-65-8 MANNITOL ADVERSE_EFFECT XXX_1_Thirst 69-65-8 MANNITOL ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 69-65-8 MANNITOL ADVERSE_EFFECT LUN_2_Pulmonary Edema 69-65-8 MANNITOL ADVERSE_EFFECT CVS_2_Tachycardia 69-65-8 MANNITOL ADVERSE_EFFECT IMU_3_Allergic Reactions 69-65-8 MANNITOL INDICATION Edema 69-65-8 MANNITOL INDICATION Acute Renal Failure 69-65-8 MANNITOL MECH_LEVEL_2 Increased osmolarity of renal filtrate 69-65-8 MANNITOL ZERO_CLASS N 69-65-8 MANNITOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 69-65-8 MANNITOL ADVERSE_EFFECT CVS_2_Chest Pain 69-65-8 MANNITOL ADVERSE_EFFECT NEU_2_Dizziness 69-65-8 MANNITOL ADVERSE_EFFECT CVS_2_Hypotension 69-65-8 MANNITOL INDICATION Poisoning 69-65-8 MANNITOL MECH_LEVEL_1 Diuretic 69-65-8 MANNITOL TA_LEVEL_2 Diuretic 77-14-5 PROHEPTAZINE MODE_CLASS Receptor Agonist 77-14-5 PROHEPTAZINE THERAPEUTIC_CLASS Analgesics, Opioid 77-14-5 PROHEPTAZINE MECHANISM Modulate neural transmission 77-14-5 PROHEPTAZINE PRODUCT_CLASS Analgesics 77-38-3 CHLORPHENOXAMINE INDICATION Parkinson's Disease 77-46-3 ACEDAPSONE INDICATION Malaria 77-51-0 ISOAMINILE INDICATION Cough / Tussis 77-86-1 TROMETHAMINE ADVERSE_EFFECT END_3_Hypoglycemia 77-86-1 TROMETHAMINE KNOWN_TOXICITY Hepatotoxicity 77-86-1 TROMETHAMINE TA_LEVEL_1 electrolyte balance 77-86-1 TROMETHAMINE MESH_LEVEL_2 Alcohols 77-86-1 TROMETHAMINE MESH_LEVEL_1 Organic Chemicals 77-86-1 TROMETHAMINE TISSUE_TOXICITY Hepatic Necrosis 77-86-1 TROMETHAMINE ADVERSE_EFFECT CVS_2_Phlebitis 77-86-1 TROMETHAMINE ADVERSE_EFFECT XXX_3_Fever 77-86-1 TROMETHAMINE TA_LEVEL_3 metabolic acidosis 77-86-1 TROMETHAMINE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 77-86-1 TROMETHAMINE ADVERSE_EFFECT _2_Hypervolemia 77-86-1 TROMETHAMINE ADVERSE_EFFECT LUN_3_Respiratory Depression 77-86-1 TROMETHAMINE TA_LEVEL_2 alkalinizing agents 77-86-1 TROMETHAMINE MESH_LEVEL_3 Glycols 77-86-1 TROMETHAMINE MECH_LEVEL_3 Unknown mechanism 77-86-1 TROMETHAMINE MECH_LEVEL_1 Used for short-term treatment of metabolic acidosis. 77-86-1 TROMETHAMINE ADVERSE_EFFECT CVS_3_Venous Thrombosis 77-86-1 TROMETHAMINE THERAPEUTIC_CLASS Alkalinizing Agents 77-86-1 TROMETHAMINE INDICATION Metabolic Acidosis 77-86-1 TROMETHAMINE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 78-41-1 TRIPARANOL PRODUCT_CLASS Cardiovasculars 78-41-1 TRIPARANOL THERAPEUTIC_CLASS Hypolipidemic Agents 78-41-1 TRIPARANOL INDICATION Hyperlipoproteinemia 80-50-2 ANISOTROPINE ME-BROMIDE MECHANISM Prolong/enhance neural transmission 80-50-2 ANISOTROPINE ME-BROMIDE MODE_CLASS Solute transporter inhibitor 80-74-0 SULFISOXAZOLE ACETYL MODE_CLASS Enzyme Inhibitor 80-74-0 SULFISOXAZOLE ACETYL MECHANISM Inhibit precursor synthesis 82-92-8 CYCLIZINE MECHANISM Modulate G-protein coupled signal transduction 82-92-8 CYCLIZINE INDICATION Vomiting 82-92-8 CYCLIZINE ADVERSE_EFFECT OCU_2_Blurred Vision 82-92-8 CYCLIZINE ADVERSE_EFFECT NEU_1_Drowsiness 82-92-8 CYCLIZINE ADVERSE_EFFECT PSY_3_Visual Hallucinations 82-92-8 CYCLIZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 82-92-8 CYCLIZINE INDICATION Nausea / Vomiting 82-92-8 CYCLIZINE PRODUCT_CLASS Gastrointestinal System 82-92-8 CYCLIZINE THERAPEUTIC_CLASS Antiemetics 82-92-8 CYCLIZINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 82-92-8 CYCLIZINE MODE_CLASS Receptor Ligand Antagonist 82-92-8 CYCLIZINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 82-92-8 CYCLIZINE ADVERSE_EFFECT GIS_2_Constipation 82-92-8 CYCLIZINE ADVERSE_EFFECT IMU_3_Anaphylaxis 82-92-8 CYCLIZINE ADVERSE_EFFECT XXX_2_Restlessness 82-92-8 CYCLIZINE ADVERSE_EFFECT NEU_3_Dystonia 82-92-8 CYCLIZINE ADVERSE_EFFECT GUS_2_Urinary Retention 82-92-8 CYCLIZINE ADVERSE_EFFECT PSY_3_Insomnia 82-92-8 CYCLIZINE ADVERSE_EFFECT PSY_3_Disorientation 82-92-8 CYCLIZINE ADVERSE_EFFECT PSY_3_Auditory Hallucinations 82-92-8 CYCLIZINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 82-92-8 CYCLIZINE ADVERSE_EFFECT CVS_2_Tachycardia 82-92-8 CYCLIZINE INDICATION Motion Sickness 82-92-8 CYCLIZINE ADVERSE_EFFECT NEU_3_Convulsions 82-92-8 CYCLIZINE ADVERSE_EFFECT PSY_2_Nervousness 82-92-8 CYCLIZINE ADVERSE_EFFECT MSK_3_Muscle Twitching 82-92-8 CYCLIZINE ADVERSE_EFFECT NEU_3_Dyskinesia 82-92-8 CYCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 303-25-3 CYCLIZINE ADVERSE_EFFECT PSY_3_Insomnia 303-25-3 CYCLIZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 303-25-3 CYCLIZINE ADVERSE_EFFECT GUS_2_Urinary Retention 303-25-3 CYCLIZINE ADVERSE_EFFECT PSY_3_Disorientation 303-25-3 CYCLIZINE ADVERSE_EFFECT PSY_3_Auditory Hallucinations 303-25-3 CYCLIZINE ADVERSE_EFFECT OCU_2_Blurred Vision 303-25-3 CYCLIZINE MECHANISM Modulate G-protein coupled signal transduction 303-25-3 CYCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 303-25-3 CYCLIZINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 303-25-3 CYCLIZINE ADVERSE_EFFECT NEU_3_Dyskinesia 303-25-3 CYCLIZINE ADVERSE_EFFECT MSK_3_Muscle Twitching 303-25-3 CYCLIZINE ADVERSE_EFFECT PSY_2_Nervousness 303-25-3 CYCLIZINE ADVERSE_EFFECT NEU_3_Convulsions 303-25-3 CYCLIZINE INDICATION Motion Sickness 303-25-3 CYCLIZINE ADVERSE_EFFECT CVS_2_Tachycardia 303-25-3 CYCLIZINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 303-25-3 CYCLIZINE ADVERSE_EFFECT NEU_1_Drowsiness 303-25-3 CYCLIZINE ADVERSE_EFFECT PSY_3_Visual Hallucinations 303-25-3 CYCLIZINE INDICATION Nausea / Vomiting 303-25-3 CYCLIZINE PRODUCT_CLASS Gastrointestinal System 303-25-3 CYCLIZINE THERAPEUTIC_CLASS Antiemetics 303-25-3 CYCLIZINE MODE_CLASS Receptor Ligand Antagonist 303-25-3 CYCLIZINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 303-25-3 CYCLIZINE ADVERSE_EFFECT GIS_2_Constipation 303-25-3 CYCLIZINE ADVERSE_EFFECT IMU_3_Anaphylaxis 303-25-3 CYCLIZINE ADVERSE_EFFECT XXX_2_Restlessness 303-25-3 CYCLIZINE ADVERSE_EFFECT NEU_3_Dystonia 303-25-3 CYCLIZINE INDICATION Vomiting 14362-31-3 CHLORCYCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 14362-31-3 CHLORCYCLIZINE MECHANISM Modulate G-protein coupled signal transduction 14362-31-3 CHLORCYCLIZINE MODE_CLASS Receptor Ligand Antagonist 129-71-5 CHLORCYCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 129-71-5 CHLORCYCLIZINE MECHANISM Modulate G-protein coupled signal transduction 129-71-5 CHLORCYCLIZINE MODE_CLASS Receptor Ligand Antagonist 82-95-1 BUCLIZINE INDICATION Motion Sickness 82-95-1 BUCLIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 82-95-1 BUCLIZINE MECHANISM Modulate G-protein coupled signal transduction 82-95-1 BUCLIZINE MODE_CLASS Receptor Ligand Antagonist 82-95-1 BUCLIZINE INDICATION Nausea / Vomiting 82-95-1 BUCLIZINE PRODUCT_CLASS Gastrointestinal System 82-95-1 BUCLIZINE THERAPEUTIC_CLASS Antiemetics 82-98-4 PIPERIDOLATE INDICATION Vomiting 82-98-4 PIPERIDOLATE PRODUCT_CLASS Gastrointestinal System 82-98-4 PIPERIDOLATE INDICATION Abdominal Colic 82-98-4 PIPERIDOLATE THERAPEUTIC_CLASS Antiemetics 82-98-4 PIPERIDOLATE INDICATION Renal Colic 82-98-4 PIPERIDOLATE THERAPEUTIC_CLASS Parasympatholytic Agents 82-98-4 PIPERIDOLATE MECHANISM Modulate G-protein coupled signal transduction 82-98-4 PIPERIDOLATE INDICATION Gastric Ulcer 82-98-4 PIPERIDOLATE INDICATION Peptic Ulcer Disease (PUD) 82-98-4 PIPERIDOLATE INDICATION Duodenal Ulcer 82-98-4 PIPERIDOLATE PRODUCT_CLASS Autonomic Nervous System (ANS) 82-98-4 PIPERIDOLATE MODE_CLASS Receptor Ligand Antagonist, Non-selective 82-98-4 PIPERIDOLATE INDICATION Constipation 82-98-4 PIPERIDOLATE THERAPEUTIC_CLASS Antispasmodic Agents 82-98-4 PIPERIDOLATE INDICATION Biliary Colic 84-01-5 CHLORPROETHAZINE THERAPEUTIC_CLASS Antipsychotics 84-01-5 CHLORPROETHAZINE MODE_CLASS Receptor Ligand Antagonist 84-01-5 CHLORPROETHAZINE PRODUCT_CLASS Central Nervous System (CNS) 84-01-5 CHLORPROETHAZINE MECHANISM Block neural transmission 84-01-5 CHLORPROETHAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 84-06-0 THIOPROPAZATE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 84-06-0 THIOPROPAZATE MECHANISM Block neural transmission 84-06-0 THIOPROPAZATE MODE_CLASS Receptor Ligand Antagonist 84-06-0 THIOPROPAZATE PRODUCT_CLASS Central Nervous System (CNS) 84-06-0 THIOPROPAZATE THERAPEUTIC_CLASS Antipsychotics 84-22-0 TETRAHYDROZOLINE MECHANISM Increase vasoconstriction 84-22-0 TETRAHYDROZOLINE INDICATION Allergic Conjunctivitis 84-22-0 TETRAHYDROZOLINE INDICATION Nasal Congestion 84-22-0 TETRAHYDROZOLINE MODE_CLASS Receptor Agonist 84-22-0 TETRAHYDROZOLINE INDICATION Viral Conjunctivitis 84-22-0 TETRAHYDROZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 84-22-0 TETRAHYDROZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 84-22-0 TETRAHYDROZOLINE PRODUCT_CLASS Respiratory System 84-22-0 TETRAHYDROZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 522-48-5 TETRAHYDROZOLINE INDICATION Nasal Congestion 522-48-5 TETRAHYDROZOLINE INDICATION Allergic Conjunctivitis 522-48-5 TETRAHYDROZOLINE MECHANISM Increase vasoconstriction 522-48-5 TETRAHYDROZOLINE INDICATION Viral Conjunctivitis 522-48-5 TETRAHYDROZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 522-48-5 TETRAHYDROZOLINE PRODUCT_CLASS Respiratory System 522-48-5 TETRAHYDROZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 522-48-5 TETRAHYDROZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 522-48-5 TETRAHYDROZOLINE MODE_CLASS Receptor Agonist 84-96-8 TRIMEPRAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 84-96-8 TRIMEPRAZINE INDICATION Pruritus / Itching 84-96-8 TRIMEPRAZINE MODE_CLASS Receptor Ligand Antagonist 84-96-8 TRIMEPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 84-96-8 TRIMEPRAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 84-96-8 TRIMEPRAZINE THERAPEUTIC_CLASS Antipruritic Agents 84-96-8 TRIMEPRAZINE PRODUCT_CLASS Anti-inflammatories 84-96-8 TRIMEPRAZINE MECHANISM Block neural transmission 84-96-8 TRIMEPRAZINE INDICATION Insomnia 86-21-5 PHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 86-21-5 PHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 86-21-5 PHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 86-21-5 PHENIRAMINE THERAPEUTIC_CLASS Antihistamines 86-21-5 PHENIRAMINE PRODUCT_CLASS Anti-inflammatories 90-54-0 ETAFENONE MODE_CLASS Channel Blocker 90-54-0 ETAFENONE MECHANISM Block channel gating 2192-21-4 ETAFENONE MECHANISM Block channel gating 2192-21-4 ETAFENONE MODE_CLASS Channel Blocker 91-80-5 METHAPYRILENE ADVERSE_EFFECT PSY_3_CNS Excitation 91-80-5 METHAPYRILENE ADVERSE_EFFECT PSY_3_Hallucinations 91-80-5 METHAPYRILENE INDICATION Viral Rhinitis / Common Cold 91-80-5 METHAPYRILENE ADVERSE_EFFECT GUS_3_Difficulty Urinating 91-80-5 METHAPYRILENE ADVERSE_EFFECT OCU_3_Dilated Pupils 91-80-5 METHAPYRILENE ADVERSE_EFFECT DNA_3_Carcinogenicity 91-80-5 METHAPYRILENE PRODUCT_CLASS Anti-inflammatories 91-80-5 METHAPYRILENE MODE_CLASS Receptor Ligand Antagonist 91-80-5 METHAPYRILENE INDICATION Influenza / Flu 91-80-5 METHAPYRILENE ADVERSE_EFFECT GIS_3_Dry Mouth 91-80-5 METHAPYRILENE ADVERSE_EFFECT CVS_3_Hypotension 91-80-5 METHAPYRILENE ADVERSE_EFFECT PSY_3_Nervousness 91-80-5 METHAPYRILENE ACTIVITY_CLASS Histamine antagonist 91-80-5 METHAPYRILENE ADVERSE_EFFECT NEU_3_Convulsions 91-80-5 METHAPYRILENE INDICATION Nasal Congestion 91-80-5 METHAPYRILENE ADVERSE_EFFECT NEU_3_Tremor 91-80-5 METHAPYRILENE ADVERSE_EFFECT OCU_3_Blurred Vision 91-80-5 METHAPYRILENE ADVERSE_EFFECT CVS_3_Tachycardia 91-80-5 METHAPYRILENE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, hepatocarcinogen 91-80-5 METHAPYRILENE ADVERSE_EFFECT NEU_3_Drowsiness 91-80-5 METHAPYRILENE TISSUE_TOXICITY Hepatocellular Carcinoma 91-80-5 METHAPYRILENE TISSUE_TOXICITY Hypotension 91-80-5 METHAPYRILENE INDICATION Allergic Diseases 91-80-5 METHAPYRILENE ADVERSE_EFFECT PSY_3_Delirium 91-80-5 METHAPYRILENE KNOWN_TOXICITY Carcinogenicity 91-80-5 METHAPYRILENE MECHANISM Modulate G-protein coupled signal transduction 91-80-5 METHAPYRILENE ADVERSE_EFFECT PSY_3_Disorientation 91-80-5 METHAPYRILENE TISSUE_TOXICITY Carcinogenicity 91-80-5 METHAPYRILENE KNOWN_TOXICITY Cardiovascular Toxicity 91-80-5 METHAPYRILENE INDICATION Insomnia 91-80-5 METHAPYRILENE ADVERSE_EFFECT PSY_3_Agitation 91-80-5 METHAPYRILENE ZERO_CLASS N 91-80-5 METHAPYRILENE ADVERSE_EFFECT SKN_3_Dry Skin 91-80-5 METHAPYRILENE ADVERSE_EFFECT SKN_3_Flushing of the Skin 91-80-5 METHAPYRILENE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 91-80-5 METHAPYRILENE THERAPEUTIC_CLASS Antihistamines 91-80-5 METHAPYRILENE ADVERSE_EFFECT NEU_3_Coma 135-23-9 METHAPYRILENE ACTIVITY_CLASS Histamine antagonist 135-23-9 METHAPYRILENE ADVERSE_EFFECT DNA_3_Carcinogenicity 135-23-9 METHAPYRILENE ADVERSE_EFFECT OCU_3_Dilated Pupils 135-23-9 METHAPYRILENE ADVERSE_EFFECT SKN_3_Dry Skin 135-23-9 METHAPYRILENE ADVERSE_EFFECT PSY_3_Agitation 135-23-9 METHAPYRILENE ADVERSE_EFFECT PSY_3_Disorientation 135-23-9 METHAPYRILENE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, hepatocarcinogen 135-23-9 METHAPYRILENE THERAPEUTIC_CLASS Antihistamines 135-23-9 METHAPYRILENE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 135-23-9 METHAPYRILENE ADVERSE_EFFECT GUS_3_Difficulty Urinating 135-23-9 METHAPYRILENE ADVERSE_EFFECT SKN_3_Flushing of the Skin 135-23-9 METHAPYRILENE ADVERSE_EFFECT PSY_3_CNS Excitation 135-23-9 METHAPYRILENE ADVERSE_EFFECT PSY_3_Hallucinations 135-23-9 METHAPYRILENE INDICATION Viral Rhinitis / Common Cold 135-23-9 METHAPYRILENE PRODUCT_CLASS Anti-inflammatories 135-23-9 METHAPYRILENE MODE_CLASS Receptor Ligand Antagonist 135-23-9 METHAPYRILENE KNOWN_TOXICITY Carcinogenicity 135-23-9 METHAPYRILENE INDICATION Influenza / Flu 135-23-9 METHAPYRILENE ADVERSE_EFFECT NEU_3_Convulsions 135-23-9 METHAPYRILENE ADVERSE_EFFECT GIS_3_Dry Mouth 135-23-9 METHAPYRILENE ADVERSE_EFFECT CVS_3_Hypotension 135-23-9 METHAPYRILENE ADVERSE_EFFECT PSY_3_Nervousness 135-23-9 METHAPYRILENE ADVERSE_EFFECT NEU_3_Coma 135-23-9 METHAPYRILENE TISSUE_TOXICITY Hepatocellular Carcinoma 135-23-9 METHAPYRILENE TISSUE_TOXICITY Hypotension 135-23-9 METHAPYRILENE INDICATION Allergic Diseases 135-23-9 METHAPYRILENE INDICATION Nasal Congestion 135-23-9 METHAPYRILENE ADVERSE_EFFECT NEU_3_Tremor 135-23-9 METHAPYRILENE ADVERSE_EFFECT OCU_3_Blurred Vision 135-23-9 METHAPYRILENE ADVERSE_EFFECT CVS_3_Tachycardia 135-23-9 METHAPYRILENE ADVERSE_EFFECT NEU_3_Drowsiness 135-23-9 METHAPYRILENE ADVERSE_EFFECT PSY_3_Delirium 135-23-9 METHAPYRILENE MECHANISM Modulate G-protein coupled signal transduction 135-23-9 METHAPYRILENE ZERO_CLASS N 135-23-9 METHAPYRILENE TISSUE_TOXICITY Carcinogenicity 135-23-9 METHAPYRILENE KNOWN_TOXICITY Cardiovascular Toxicity 135-23-9 METHAPYRILENE INDICATION Insomnia 33032-12-1 METHAPYRILENE ZERO_CLASS N 33032-12-1 METHAPYRILENE PRODUCT_CLASS Anti-inflammatories 33032-12-1 METHAPYRILENE ACTIVITY_CLASS Histamine antagonist 33032-12-1 METHAPYRILENE ADVERSE_EFFECT CVS_3_Tachycardia 33032-12-1 METHAPYRILENE ADVERSE_EFFECT OCU_3_Blurred Vision 33032-12-1 METHAPYRILENE ADVERSE_EFFECT NEU_3_Tremor 33032-12-1 METHAPYRILENE INDICATION Nasal Congestion 33032-12-1 METHAPYRILENE INDICATION Allergic Diseases 33032-12-1 METHAPYRILENE MECHANISM Modulate G-protein coupled signal transduction 33032-12-1 METHAPYRILENE MODE_CLASS Receptor Ligand Antagonist 33032-12-1 METHAPYRILENE TISSUE_TOXICITY Carcinogenicity 33032-12-1 METHAPYRILENE KNOWN_TOXICITY Cardiovascular Toxicity 33032-12-1 METHAPYRILENE ADVERSE_EFFECT GUS_3_Difficulty Urinating 33032-12-1 METHAPYRILENE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 33032-12-1 METHAPYRILENE THERAPEUTIC_CLASS Antihistamines 33032-12-1 METHAPYRILENE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, hepatocarcinogen 33032-12-1 METHAPYRILENE INDICATION Influenza / Flu 33032-12-1 METHAPYRILENE KNOWN_TOXICITY Carcinogenicity 33032-12-1 METHAPYRILENE ADVERSE_EFFECT PSY_3_Delirium 33032-12-1 METHAPYRILENE ADVERSE_EFFECT PSY_3_Agitation 33032-12-1 METHAPYRILENE ADVERSE_EFFECT NEU_3_Drowsiness 33032-12-1 METHAPYRILENE INDICATION Insomnia 33032-12-1 METHAPYRILENE ADVERSE_EFFECT SKN_3_Dry Skin 33032-12-1 METHAPYRILENE ADVERSE_EFFECT OCU_3_Dilated Pupils 33032-12-1 METHAPYRILENE ADVERSE_EFFECT DNA_3_Carcinogenicity 33032-12-1 METHAPYRILENE ADVERSE_EFFECT PSY_3_Disorientation 33032-12-1 METHAPYRILENE ADVERSE_EFFECT SKN_3_Flushing of the Skin 33032-12-1 METHAPYRILENE ADVERSE_EFFECT PSY_3_CNS Excitation 33032-12-1 METHAPYRILENE INDICATION Viral Rhinitis / Common Cold 33032-12-1 METHAPYRILENE ADVERSE_EFFECT PSY_3_Hallucinations 33032-12-1 METHAPYRILENE TISSUE_TOXICITY Hypotension 33032-12-1 METHAPYRILENE ADVERSE_EFFECT NEU_3_Convulsions 33032-12-1 METHAPYRILENE ADVERSE_EFFECT GIS_3_Dry Mouth 33032-12-1 METHAPYRILENE ADVERSE_EFFECT CVS_3_Hypotension 33032-12-1 METHAPYRILENE ADVERSE_EFFECT PSY_3_Nervousness 33032-12-1 METHAPYRILENE ADVERSE_EFFECT NEU_3_Coma 33032-12-1 METHAPYRILENE TISSUE_TOXICITY Hepatocellular Carcinoma 92-97-7 THIOCARBANIDIN INDICATION Tuberculosis 93-30-1 METHOXYPHENAMINE INDICATION Bronchospasm 93-30-1 METHOXYPHENAMINE INDICATION Asthma 93-30-1 METHOXYPHENAMINE PRODUCT_CLASS Respiratory System 93-30-1 METHOXYPHENAMINE MODE_CLASS Receptor Agonist 93-30-1 METHOXYPHENAMINE THERAPEUTIC_CLASS Bronchodilators 93-30-1 METHOXYPHENAMINE MECHANISM Reduce bronchoconstriction 5588-10-3 METHOXYPHENAMINE THERAPEUTIC_CLASS Bronchodilators 5588-10-3 METHOXYPHENAMINE PRODUCT_CLASS Respiratory System 5588-10-3 METHOXYPHENAMINE INDICATION Bronchospasm 5588-10-3 METHOXYPHENAMINE INDICATION Asthma 5588-10-3 METHOXYPHENAMINE MODE_CLASS Receptor Agonist 5588-10-3 METHOXYPHENAMINE MECHANISM Reduce bronchoconstriction 93-88-9 PHENPROMETHAMINE THERAPEUTIC_CLASS Vasopressors 93-88-9 PHENPROMETHAMINE MECHANISM Modulate G-protein coupled signal transduction 93-88-9 PHENPROMETHAMINE PRODUCT_CLASS Cardiovasculars 94-07-5 SYNEPHRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 94-07-5 SYNEPHRINE THERAPEUTIC_CLASS Sympathomimetic Agents 94-07-5 SYNEPHRINE MECHANISM Modulate G-protein coupled signal transduction 94-07-5 SYNEPHRINE PRODUCT_CLASS Cardiovasculars 94-07-5 SYNEPHRINE MODE_CLASS Receptor Agonist 94-07-5 SYNEPHRINE THERAPEUTIC_CLASS Vasopressors 94-07-5 SYNEPHRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 95-27-2 DIAMTHAZOLE INDICATION Tinea Pedis / Athlete's Foot 95-27-2 DIAMTHAZOLE INDICATION Paronychia 95-27-2 DIAMTHAZOLE ADVERSE_EFFECT SKN_2_Skin Irritation 95-27-2 DIAMTHAZOLE INDICATION Tinea Cruris / Jock Itch 95-27-2 DIAMTHAZOLE INDICATION Subcutaneous Mycoses 95-27-2 DIAMTHAZOLE THERAPEUTIC_CLASS Antifungals, Topical 95-27-2 DIAMTHAZOLE ADVERSE_EFFECT NEU_3_Neurotoxicity 95-27-2 DIAMTHAZOLE ADVERSE_EFFECT NEU_3_Encephalopathy 95-27-2 DIAMTHAZOLE INDICATION Tinea Capitis 95-27-2 DIAMTHAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 95-27-2 DIAMTHAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 95-27-2 DIAMTHAZOLE INDICATION Cutaneous Candidiasis 95-27-2 DIAMTHAZOLE PRODUCT_CLASS Anti-infectives 95-27-2 DIAMTHAZOLE ADVERSE_EFFECT NEU_3_Convulsions 95-27-2 DIAMTHAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 95-27-2 DIAMTHAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 95-27-2 DIAMTHAZOLE INDICATION Tinea Unguium / Onychomycosis 95-27-2 DIAMTHAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 136-96-9 DIAMTHAZOLE INDICATION Paronychia 136-96-9 DIAMTHAZOLE INDICATION Tinea Pedis / Athlete's Foot 136-96-9 DIAMTHAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 136-96-9 DIAMTHAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 136-96-9 DIAMTHAZOLE INDICATION Tinea Unguium / Onychomycosis 136-96-9 DIAMTHAZOLE INDICATION Tinea Capitis 136-96-9 DIAMTHAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 136-96-9 DIAMTHAZOLE ADVERSE_EFFECT NEU_3_Convulsions 136-96-9 DIAMTHAZOLE PRODUCT_CLASS Anti-infectives 136-96-9 DIAMTHAZOLE INDICATION Cutaneous Candidiasis 136-96-9 DIAMTHAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 136-96-9 DIAMTHAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 136-96-9 DIAMTHAZOLE INDICATION Tinea Cruris / Jock Itch 136-96-9 DIAMTHAZOLE INDICATION Subcutaneous Mycoses 136-96-9 DIAMTHAZOLE THERAPEUTIC_CLASS Antifungals, Topical 136-96-9 DIAMTHAZOLE ADVERSE_EFFECT NEU_3_Neurotoxicity 136-96-9 DIAMTHAZOLE ADVERSE_EFFECT NEU_3_Encephalopathy 136-96-9 DIAMTHAZOLE ADVERSE_EFFECT SKN_2_Skin Irritation 99-15-0 ACETYLLEUCINE INDICATION Vertigo 101-40-6 PROPYLHEXEDRINE MECHANISM Modulate G-protein coupled signal transduction 101-40-6 PROPYLHEXEDRINE PRODUCT_CLASS Central Nervous System (CNS) 101-40-6 PROPYLHEXEDRINE THERAPEUTIC_CLASS Sympathomimetic Agents 101-40-6 PROPYLHEXEDRINE THERAPEUTIC_CLASS Anorexiants 101-40-6 PROPYLHEXEDRINE INDICATION Obesity 101-40-6 PROPYLHEXEDRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 101-40-6 PROPYLHEXEDRINE MODE_CLASS Receptor Agonist 102-45-4 CYCLOPENTAMINE MECHANISM Modulate G-protein coupled signal transduction 102-45-4 CYCLOPENTAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 102-45-4 CYCLOPENTAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 114-86-3 PHENFORMIN ADVERSE_EFFECT XXX_3_Weight Loss 114-86-3 PHENFORMIN ADVERSE_EFFECT MSK_3_Cramps 114-86-3 PHENFORMIN ADVERSE_EFFECT END_3_Lactic Acidosis 114-86-3 PHENFORMIN ADVERSE_EFFECT GIS_2_Pancreatitis 114-86-3 PHENFORMIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 114-86-3 PHENFORMIN MECHANISM Modulate channel gating 114-86-3 PHENFORMIN ADVERSE_EFFECT SKN_2_Skin Reactions 114-86-3 PHENFORMIN ADVERSE_EFFECT XXX_3_Asthenia 114-86-3 PHENFORMIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disorder 114-86-3 PHENFORMIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 114-86-3 PHENFORMIN INDICATION Type II Diabetes Mellitus 114-86-3 PHENFORMIN MODE_CLASS Channel Modulator 114-86-3 PHENFORMIN STRUCTURE_ACTIVITY AMP kinase activator 114-86-3 PHENFORMIN ADVERSE_EFFECT GIS_1_Epigastric Pain 114-86-3 PHENFORMIN ADVERSE_EFFECT GIS_1_Metallic Taste 114-86-3 PHENFORMIN ADVERSE_EFFECT SKN_3_Rash 114-86-3 PHENFORMIN ADVERSE_EFFECT PSY_1_Anorexia 114-86-3 PHENFORMIN MODE_CLASS Enzyme Activator 114-86-3 PHENFORMIN ADVERSE_EFFECT GIS_3_Diarrhea 114-86-3 PHENFORMIN ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 114-86-3 PHENFORMIN ADVERSE_EFFECT SKN_3_Pruritis 114-86-3 PHENFORMIN MECHANISM Stimulate insulin sensitive pathway 114-86-3 PHENFORMIN INDICATION Type II Diabetes Mellitus 114-86-3 PHENFORMIN THERAPEUTIC_CLASS Antidiabetic Agents 834-28-6 PHENFORMIN MECHANISM Modulate channel gating 834-28-6 PHENFORMIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 834-28-6 PHENFORMIN ADVERSE_EFFECT GIS_2_Pancreatitis 834-28-6 PHENFORMIN ADVERSE_EFFECT MSK_3_Cramps 834-28-6 PHENFORMIN ADVERSE_EFFECT XXX_3_Weight Loss 834-28-6 PHENFORMIN ADVERSE_EFFECT END_3_Lactic Acidosis 834-28-6 PHENFORMIN ADVERSE_EFFECT SKN_2_Skin Reactions 834-28-6 PHENFORMIN ADVERSE_EFFECT XXX_3_Asthenia 834-28-6 PHENFORMIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disorder 834-28-6 PHENFORMIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 834-28-6 PHENFORMIN INDICATION Type II Diabetes Mellitus 834-28-6 PHENFORMIN MODE_CLASS Channel Modulator 834-28-6 PHENFORMIN STRUCTURE_ACTIVITY AMP kinase activator 834-28-6 PHENFORMIN ADVERSE_EFFECT GIS_1_Epigastric Pain 834-28-6 PHENFORMIN ADVERSE_EFFECT GIS_1_Metallic Taste 834-28-6 PHENFORMIN ADVERSE_EFFECT SKN_3_Rash 834-28-6 PHENFORMIN ADVERSE_EFFECT PSY_1_Anorexia 834-28-6 PHENFORMIN MODE_CLASS Enzyme Activator 834-28-6 PHENFORMIN ADVERSE_EFFECT GIS_3_Diarrhea 834-28-6 PHENFORMIN ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 834-28-6 PHENFORMIN ADVERSE_EFFECT SKN_3_Pruritis 834-28-6 PHENFORMIN MECHANISM Stimulate insulin sensitive pathway 834-28-6 PHENFORMIN INDICATION Type II Diabetes Mellitus 834-28-6 PHENFORMIN THERAPEUTIC_CLASS Antidiabetic Agents 21228-47-7 PHENFORMIN ADVERSE_EFFECT XXX_3_Weight Loss 21228-47-7 PHENFORMIN ADVERSE_EFFECT MSK_3_Cramps 21228-47-7 PHENFORMIN ADVERSE_EFFECT END_3_Lactic Acidosis 21228-47-7 PHENFORMIN ADVERSE_EFFECT GIS_2_Pancreatitis 21228-47-7 PHENFORMIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 21228-47-7 PHENFORMIN MECHANISM Modulate channel gating 21228-47-7 PHENFORMIN ADVERSE_EFFECT SKN_2_Skin Reactions 21228-47-7 PHENFORMIN ADVERSE_EFFECT XXX_3_Asthenia 21228-47-7 PHENFORMIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disorder 21228-47-7 PHENFORMIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 21228-47-7 PHENFORMIN INDICATION Type II Diabetes Mellitus 21228-47-7 PHENFORMIN MODE_CLASS Channel Modulator 21228-47-7 PHENFORMIN STRUCTURE_ACTIVITY AMP kinase activator 21228-47-7 PHENFORMIN ADVERSE_EFFECT GIS_1_Epigastric Pain 21228-47-7 PHENFORMIN ADVERSE_EFFECT GIS_1_Metallic Taste 21228-47-7 PHENFORMIN ADVERSE_EFFECT SKN_3_Rash 21228-47-7 PHENFORMIN ADVERSE_EFFECT PSY_1_Anorexia 21228-47-7 PHENFORMIN MODE_CLASS Enzyme Activator 21228-47-7 PHENFORMIN ADVERSE_EFFECT GIS_3_Diarrhea 21228-47-7 PHENFORMIN ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 21228-47-7 PHENFORMIN ADVERSE_EFFECT SKN_3_Pruritis 21228-47-7 PHENFORMIN MECHANISM Stimulate insulin sensitive pathway 21228-47-7 PHENFORMIN INDICATION Type II Diabetes Mellitus 21228-47-7 PHENFORMIN THERAPEUTIC_CLASS Antidiabetic Agents 115-44-6 TALBUTAL PRODUCT_CLASS Central Nervous System (CNS) 115-44-6 TALBUTAL MODE_CLASS Channel Modulator 115-44-6 TALBUTAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 115-44-6 TALBUTAL INDICATION Insomnia 115-44-6 TALBUTAL THERAPEUTIC_CLASS Sedatives/Hypnotics 115-44-6 TALBUTAL MECHANISM Modulate neural transmission 121-81-3 NITROMIDE PRODUCT_CLASS Anti-infectives 121-81-3 NITROMIDE INDICATION Coccidiosis 121-81-3 NITROMIDE THERAPEUTIC_CLASS Antiparasitics 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT IMU_3_Lupus Erythematosus Syndrome 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT IMU_3_Allergic Reactions 122-11-2 SULFADIMETHOXINE MODE_CLASS Enzyme Inhibitor 122-11-2 SULFADIMETHOXINE TA_LEVEL_3 urinary tract infection 122-11-2 SULFADIMETHOXINE MECHANISM Inhibit precursor synthesis 122-11-2 SULFADIMETHOXINE MESH_LEVEL_2 Amides 122-11-2 SULFADIMETHOXINE ACTIVITY_CLASS Antibiotic, sulfonamide 122-11-2 SULFADIMETHOXINE TA_LEVEL_1 infectious disease 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT KID_3_Crystalluria 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 122-11-2 SULFADIMETHOXINE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 122-11-2 SULFADIMETHOXINE MESH_LEVEL_1 Organic Chemicals 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT PSY_3_Anorexia 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT KID_3_Renal Insufficiency 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT GIS_2_Diarrhea 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT LIV_3_Acute Hepatitis 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT BBM_3_Agranulocytosis 122-11-2 SULFADIMETHOXINE MESH_LEVEL_3 Sulfonamides 122-11-2 SULFADIMETHOXINE MECH_LEVEL_2 Enzyme Inhibitor 122-11-2 SULFADIMETHOXINE INDICATION Urinary Tract Infection (UTI) 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT BBM_3_Leukopenia 122-11-2 SULFADIMETHOXINE MECH_LEVEL_3 Dihydropteroate synthase 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT IMU_3_Photosensitization 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT _3_Lyell Syndrome 122-11-2 SULFADIMETHOXINE THERAPEUTIC_CLASS Antibacterials, Systemic 122-11-2 SULFADIMETHOXINE PRODUCT_CLASS Anti-infectives 122-11-2 SULFADIMETHOXINE TA_LEVEL_2 anti-bacterial 122-11-2 SULFADIMETHOXINE ZERO_CLASS N 122-11-2 SULFADIMETHOXINE ADVERSE_EFFECT NEU_3_Aseptic Meningitis 123-82-0 TUAMINOHEPTANE MECHANISM Modulate G-protein coupled signal transduction 123-82-0 TUAMINOHEPTANE PRODUCT_CLASS Cardiovasculars 123-82-0 TUAMINOHEPTANE THERAPEUTIC_CLASS Sympathomimetic Agents 123-82-0 TUAMINOHEPTANE PRODUCT_CLASS Autonomic Nervous System (ANS) 123-82-0 TUAMINOHEPTANE THERAPEUTIC_CLASS Vasopressors 125-42-8 VINBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 125-42-8 VINBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 125-42-8 VINBARBITAL MECHANISM Modulate neural transmission 125-42-8 VINBARBITAL MODE_CLASS Channel Modulator 125-42-8 VINBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 125-53-1 OXYPHENCYCLIMINE MODE_CLASS Receptor Ligand Antagonist 125-53-1 OXYPHENCYCLIMINE MECHANISM Modulate G-protein coupled signal transduction 125-52-0 OXYPHENCYCLIMINE MECHANISM Modulate G-protein coupled signal transduction 125-52-0 OXYPHENCYCLIMINE MODE_CLASS Receptor Ligand Antagonist 21609-10-9 OXYPHENCYCLIMINE MODE_CLASS Receptor Ligand Antagonist 21609-10-9 OXYPHENCYCLIMINE MECHANISM Modulate G-protein coupled signal transduction 127-35-5 PHENAZOCINE PRODUCT_CLASS Analgesics 127-35-5 PHENAZOCINE MECHANISM Modulate neural transmission 127-35-5 PHENAZOCINE MODE_CLASS Receptor Agonist 127-35-5 PHENAZOCINE THERAPEUTIC_CLASS Analgesics, Opioid 128-46-1 DIHYDROSTREPTOMYCIN PRODUCT_CLASS Anti-infectives 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT GIS_3_Stomatitis 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT END_3_Hot Flashes 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OCU_3_Conjunctivitis 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 128-46-1 DIHYDROSTREPTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactic Shock 128-46-1 DIHYDROSTREPTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT LUN_3_Dyspnea 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Skin Eruption 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT XXX_3_Death 128-46-1 DIHYDROSTREPTOMYCIN TISSUE_TOXICITY Death 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 128-46-1 DIHYDROSTREPTOMYCIN THERAPEUTIC_CLASS Antibacterials 128-46-1 DIHYDROSTREPTOMYCIN KNOWN_TOXICITY Miscellaneous 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT XXX_3_Fever 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Eczema 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT KID_3_Proteinuria 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_2_Vestibular Dysfunction 128-46-1 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT _3_Cylinduria 128-46-1 DIHYDROSTREPTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 1425-61-2 DIHYDROSTREPTOMYCIN KNOWN_TOXICITY Miscellaneous 1425-61-2 DIHYDROSTREPTOMYCIN THERAPEUTIC_CLASS Antibacterials 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OCU_3_Conjunctivitis 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactic Shock 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 1425-61-2 DIHYDROSTREPTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 1425-61-2 DIHYDROSTREPTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT END_3_Hot Flashes 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT GIS_3_Stomatitis 1425-61-2 DIHYDROSTREPTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Skin Eruption 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT XXX_3_Death 1425-61-2 DIHYDROSTREPTOMYCIN TISSUE_TOXICITY Death 1425-61-2 DIHYDROSTREPTOMYCIN PRODUCT_CLASS Anti-infectives 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT _3_Cylinduria 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_2_Vestibular Dysfunction 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT KID_3_Proteinuria 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT LUN_3_Dyspnea 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Eczema 1425-61-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT XXX_3_Fever 7177-56-2 DIHYDROSTREPTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 7177-56-2 DIHYDROSTREPTOMYCIN TISSUE_TOXICITY Death 7177-56-2 DIHYDROSTREPTOMYCIN PRODUCT_CLASS Anti-infectives 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT _3_Cylinduria 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_2_Vestibular Dysfunction 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT END_3_Hot Flashes 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT KID_3_Proteinuria 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT GIS_3_Stomatitis 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactic Shock 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 7177-56-2 DIHYDROSTREPTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT XXX_3_Death 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OCU_3_Conjunctivitis 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 7177-56-2 DIHYDROSTREPTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Skin Eruption 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT LUN_3_Dyspnea 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT SKN_2_Eczema 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT XXX_3_Fever 7177-56-2 DIHYDROSTREPTOMYCIN KNOWN_TOXICITY Miscellaneous 7177-56-2 DIHYDROSTREPTOMYCIN THERAPEUTIC_CLASS Antibacterials 7177-56-2 DIHYDROSTREPTOMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 129-20-4 OXYPHENBUTAZONE INDICATION Rheumatism 129-20-4 OXYPHENBUTAZONE PRODUCT_CLASS Immune Response / Immunomodulators 129-20-4 OXYPHENBUTAZONE THERAPEUTIC_CLASS Immunosuppressants 129-83-9 PHENAMPROMIDE THERAPEUTIC_CLASS Analgesics, Opioid 129-83-9 PHENAMPROMIDE PRODUCT_CLASS Analgesics 129-83-9 PHENAMPROMIDE MECHANISM Modulate neural transmission 129-83-9 PHENAMPROMIDE MODE_CLASS Receptor Agonist 130-80-3 DIETHYLSTILBESTROL DIPROPIONATE THERAPEUTIC_CLASS Gonadal Hormones 130-80-3 DIETHYLSTILBESTROL DIPROPIONATE MODE_CLASS Receptor Ligand Antagonist 130-80-3 DIETHYLSTILBESTROL DIPROPIONATE MECHANISM Modulate gene transcription 130-80-3 DIETHYLSTILBESTROL DIPROPIONATE PRODUCT_CLASS Anti-cancers 130-81-4 QUINDONIUM BROMIDE THERAPEUTIC_CLASS Antidepressants 130-81-4 QUINDONIUM BROMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 130-81-4 QUINDONIUM BROMIDE INDICATION Cardiac Arrhythmias 130-81-4 QUINDONIUM BROMIDE INDICATION Depression 130-81-4 QUINDONIUM BROMIDE PRODUCT_CLASS Central Nervous System (CNS) 130-81-4 QUINDONIUM BROMIDE PRODUCT_CLASS Cardiovasculars 133-11-9 PHENYL AMINOSALICYLATE INDICATION Tuberculosis 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT LIV_2_Hepatotoxicity 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 134-36-1 ERYTHROMYCIN PROPIONATE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 134-36-1 ERYTHROMYCIN PROPIONATE MECHANISM Inhibit ribosomal protein synthesis 134-36-1 ERYTHROMYCIN PROPIONATE KNOWN_TOXICITY Cardiovascular Toxicity 134-36-1 ERYTHROMYCIN PROPIONATE TISSUE_TOXICITY Ventricular Tachycardia 134-36-1 ERYTHROMYCIN PROPIONATE TISSUE_TOXICITY Hepatotoxicity 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_1_Diarrhea 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OTO_3_Ototoxicity 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 134-36-1 ERYTHROMYCIN PROPIONATE PRODUCT_CLASS Anti-infectives 134-36-1 ERYTHROMYCIN PROPIONATE STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OCU_3_Ocular Irritation 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_1_Thrombophlebitis 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OTO_2_Tinnitus 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 134-36-1 ERYTHROMYCIN PROPIONATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_1_Abdominal Pain 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OTO_2_Hearing Loss 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT PSY_1_Anorexia 134-36-1 ERYTHROMYCIN PROPIONATE KNOWN_TOXICITY Hepatotoxicity 134-36-1 ERYTHROMYCIN PROPIONATE THERAPEUTIC_CLASS Antibacterials 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 134-36-1 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT LIV_2_Jaundice 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 84252-03-9 ERYTHROMYCIN PROPIONATE THERAPEUTIC_CLASS Antibacterials 84252-03-9 ERYTHROMYCIN PROPIONATE KNOWN_TOXICITY Hepatotoxicity 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT PSY_1_Anorexia 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OTO_2_Hearing Loss 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_1_Abdominal Pain 84252-03-9 ERYTHROMYCIN PROPIONATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 84252-03-9 ERYTHROMYCIN PROPIONATE TISSUE_TOXICITY Hepatotoxicity 84252-03-9 ERYTHROMYCIN PROPIONATE TISSUE_TOXICITY Ventricular Tachycardia 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_1_Diarrhea 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_1_Thrombophlebitis 84252-03-9 ERYTHROMYCIN PROPIONATE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OTO_2_Tinnitus 84252-03-9 ERYTHROMYCIN PROPIONATE MECHANISM Inhibit ribosomal protein synthesis 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT LIV_2_Hepatotoxicity 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OCU_3_Ocular Irritation 84252-03-9 ERYTHROMYCIN PROPIONATE STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 84252-03-9 ERYTHROMYCIN PROPIONATE PRODUCT_CLASS Anti-infectives 84252-03-9 ERYTHROMYCIN PROPIONATE KNOWN_TOXICITY Cardiovascular Toxicity 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT OTO_3_Ototoxicity 84252-03-9 ERYTHROMYCIN PROPIONATE ADVERSE_EFFECT LIV_2_Jaundice 134-58-7 8-AZAGUANINE PRODUCT_CLASS Anti-cancers 134-58-7 8-AZAGUANINE MODE_CLASS Enzyme substrate mimic 134-58-7 8-AZAGUANINE THERAPEUTIC_CLASS Antineoplastics 134-58-7 8-AZAGUANINE MECHANISM Inhibit protein synthesis 136-70-9 PROTOKYLOL MECHANISM Modulate G-protein coupled signal transduction 136-70-9 PROTOKYLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 136-70-9 PROTOKYLOL THERAPEUTIC_CLASS Sympathomimetic Agents 137-76-8 CETOTIAMINE MECHANISM Vitamin/ cofactor 137-86-0 OCTOTIAMINE MECHANISM Vitamin/ cofactor 138-39-6 MAFENIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 138-39-6 MAFENIDE MODE_CLASS Enzyme Inhibitor 138-37-4 MAFENIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 138-37-4 MAFENIDE MODE_CLASS Enzyme Inhibitor 13009-99-9 MAFENIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 13009-99-9 MAFENIDE MODE_CLASS Enzyme Inhibitor 144-14-9 ANILERIDINE PRODUCT_CLASS Analgesics 144-14-9 ANILERIDINE MODE_CLASS Receptor Agonist 144-14-9 ANILERIDINE MECHANISM Modulate neural transmission 144-14-9 ANILERIDINE THERAPEUTIC_CLASS Analgesics, Opioid 144-45-6 SPIRGETINE INDICATION Hypotension 145-12-0 OXYMESTERONE MODE_CLASS Receptor Ligand Antagonist 145-12-0 OXYMESTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 145-12-0 OXYMESTERONE MECHANISM Modulate gene transcription 145-12-0 OXYMESTERONE MODE_CLASS Receptor Agonist 145-12-0 OXYMESTERONE PRODUCT_CLASS Hematologics 145-12-0 OXYMESTERONE INDICATION Growth Disorder 145-12-0 OXYMESTERONE INDICATION Aplastic Anemia 145-12-0 OXYMESTERONE THERAPEUTIC_CLASS Gonadal Hormones 145-54-0 PROPYROMAZINE BROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 145-54-0 PROPYROMAZINE BROMIDE MECHANISM Block neural transmission 145-54-0 PROPYROMAZINE BROMIDE MODE_CLASS Receptor Ligand Antagonist 145-54-0 PROPYROMAZINE BROMIDE THERAPEUTIC_CLASS Antispasmodic Agents 145-54-0 PROPYROMAZINE BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 145-63-1 SURAMIN THERAPEUTIC_CLASS Antiparasitics 145-63-1 SURAMIN PRODUCT_CLASS Anti-cancers 145-63-1 SURAMIN INDICATION Onchocerciasis 145-63-1 SURAMIN INDICATION Prostatic Cancer / Carcinoma of the Prostate 145-63-1 SURAMIN PRODUCT_CLASS Anti-infectives 145-63-1 SURAMIN INDICATION African Trypanosomiasis / Sleeping Sickness 145-63-1 SURAMIN THERAPEUTIC_CLASS Antineoplastics 75607-67-9 FLUDARABINE PHOSPHATE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 75607-67-9 FLUDARABINE PHOSPHATE PRODUCT_CLASS Anti-cancers 75607-67-9 FLUDARABINE PHOSPHATE MODE_CLASS Enzyme substrate mimic 75607-67-9 FLUDARABINE PHOSPHATE INDICATION Chronic Lymphocytic Leukemia (CLL) 75607-67-9 FLUDARABINE PHOSPHATE THERAPEUTIC_CLASS Antineoplastics 75607-67-9 FLUDARABINE PHOSPHATE MECHANISM Incorporate into DNA/RNA/Protein 148-07-2 BENZMALECENE INDICATION Hyperlipoproteinemia 148-07-2 BENZMALECENE PRODUCT_CLASS Cardiovasculars 148-07-2 BENZMALECENE THERAPEUTIC_CLASS Hypolipidemic Agents 152-58-9 CORTODOXONE MODE_CLASS Receptor Partial Agonist 152-58-9 CORTODOXONE THERAPEUTIC_CLASS Corticosteroids 152-58-9 CORTODOXONE MECHANISM Modulate gene transcription 152-58-9 CORTODOXONE PRODUCT_CLASS Anti-inflammatories 152-58-9 CORTODOXONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 153-61-7 CEPHALOTHIN PRODUCT_CLASS Anti-infectives 153-61-7 CEPHALOTHIN MECHANISM Inhibit bacterial cell wall biosynthesis 153-61-7 CEPHALOTHIN THERAPEUTIC_CLASS Antibacterials, Systemic 153-61-7 CEPHALOTHIN MODE_CLASS Enzyme Inhibitor 58-71-9 CEPHALOTHIN THERAPEUTIC_CLASS Antibacterials, Systemic 58-71-9 CEPHALOTHIN PRODUCT_CLASS Anti-infectives 58-71-9 CEPHALOTHIN MECHANISM Inhibit bacterial cell wall biosynthesis 58-71-9 CEPHALOTHIN MODE_CLASS Enzyme Inhibitor 154-73-4 GUANISOQUIN THERAPEUTIC_CLASS Antihypertensive Agents 154-73-4 GUANISOQUIN PRODUCT_CLASS Cardiovasculars 154-73-4 GUANISOQUIN INDICATION Hypertension 298-57-7 CINNARIZINE INDICATION Motion Sickness 298-57-7 CINNARIZINE MECH_LEVEL_2 Anti-histamine 298-57-7 CINNARIZINE MECHANISM Reduce muscle contractile force 298-57-7 CINNARIZINE MECH_LEVEL_1 signal transduction 298-57-7 CINNARIZINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 298-57-7 CINNARIZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 298-57-7 CINNARIZINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 298-57-7 CINNARIZINE INDICATION Tinnitus / Ringing in the Ear 298-57-7 CINNARIZINE MECHANISM Modulate G-protein coupled signal transduction 298-57-7 CINNARIZINE TA_LEVEL_1 Cardiovascular 298-57-7 CINNARIZINE TA_LEVEL_2 vasodilator 298-57-7 CINNARIZINE THERAPEUTIC_CLASS Antihistamines 298-57-7 CINNARIZINE ADVERSE_EFFECT PSY_3_Depression 298-57-7 CINNARIZINE ADVERSE_EFFECT NEU_3_Parkinsonism 298-57-7 CINNARIZINE THERAPEUTIC_CLASS Vasodilators 298-57-7 CINNARIZINE INDICATION Vertigo 298-57-7 CINNARIZINE TA_LEVEL_3 peripheral vascular disease 298-57-7 CINNARIZINE MECH_LEVEL_3 histamine receptor H1 298-57-7 CINNARIZINE ADVERSE_EFFECT NEU_3_Headache 298-57-7 CINNARIZINE ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 298-57-7 CINNARIZINE MODE_CLASS Receptor Ligand Antagonist 298-57-7 CINNARIZINE PRODUCT_CLASS Cardiovasculars 298-57-7 CINNARIZINE ACTIVITY_CLASS Histamine antagonist 298-57-7 CINNARIZINE MESH_LEVEL_3 Piperazines 298-57-7 CINNARIZINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 298-57-7 CINNARIZINE INDICATION Peripheral Vascular Disease 298-57-7 CINNARIZINE MESH_LEVEL_1 Heterocyclic Compounds 298-57-7 CINNARIZINE ZERO_CLASS N 298-57-7 CINNARIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, Ca++ channel (L-Type) blocker 298-57-7 CINNARIZINE ADVERSE_EFFECT NEU_1_Drowsiness 298-57-7 CINNARIZINE ADVERSE_EFFECT NEU_2_Dizziness 298-57-7 CINNARIZINE MODE_CLASS Channel Blocker 60763-49-7 CINNARIZINE MECH_LEVEL_3 histamine receptor H1 60763-49-7 CINNARIZINE TA_LEVEL_2 vasodilator 60763-49-7 CINNARIZINE ADVERSE_EFFECT NEU_3_Headache 60763-49-7 CINNARIZINE ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 60763-49-7 CINNARIZINE THERAPEUTIC_CLASS Antihistamines 60763-49-7 CINNARIZINE MODE_CLASS Receptor Ligand Antagonist 60763-49-7 CINNARIZINE PRODUCT_CLASS Cardiovasculars 60763-49-7 CINNARIZINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 60763-49-7 CINNARIZINE INDICATION Peripheral Vascular Disease 60763-49-7 CINNARIZINE MESH_LEVEL_1 Heterocyclic Compounds 60763-49-7 CINNARIZINE ZERO_CLASS N 60763-49-7 CINNARIZINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 60763-49-7 CINNARIZINE ACTIVITY_CLASS Histamine antagonist 60763-49-7 CINNARIZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 60763-49-7 CINNARIZINE MECHANISM Modulate G-protein coupled signal transduction 60763-49-7 CINNARIZINE MECH_LEVEL_1 signal transduction 60763-49-7 CINNARIZINE MECHANISM Reduce muscle contractile force 60763-49-7 CINNARIZINE MECH_LEVEL_2 Anti-histamine 60763-49-7 CINNARIZINE INDICATION Motion Sickness 60763-49-7 CINNARIZINE MODE_CLASS Channel Blocker 60763-49-7 CINNARIZINE ADVERSE_EFFECT NEU_2_Dizziness 60763-49-7 CINNARIZINE MESH_LEVEL_3 Piperazines 60763-49-7 CINNARIZINE INDICATION Tinnitus / Ringing in the Ear 60763-49-7 CINNARIZINE ADVERSE_EFFECT NEU_1_Drowsiness 60763-49-7 CINNARIZINE ADVERSE_EFFECT PSY_3_Depression 60763-49-7 CINNARIZINE ADVERSE_EFFECT NEU_3_Parkinsonism 60763-49-7 CINNARIZINE THERAPEUTIC_CLASS Vasodilators 60763-49-7 CINNARIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, Ca++ channel (L-Type) blocker 60763-49-7 CINNARIZINE INDICATION Vertigo 60763-49-7 CINNARIZINE TA_LEVEL_1 Cardiovascular 60763-49-7 CINNARIZINE TA_LEVEL_3 peripheral vascular disease 60763-49-7 CINNARIZINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 7002-58-6 CINNARIZINE ACTIVITY_CLASS Histamine antagonist 7002-58-6 CINNARIZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 7002-58-6 CINNARIZINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 7002-58-6 CINNARIZINE MECH_LEVEL_1 signal transduction 7002-58-6 CINNARIZINE MECHANISM Reduce muscle contractile force 7002-58-6 CINNARIZINE MECH_LEVEL_2 Anti-histamine 7002-58-6 CINNARIZINE INDICATION Motion Sickness 7002-58-6 CINNARIZINE ADVERSE_EFFECT NEU_2_Dizziness 7002-58-6 CINNARIZINE ADVERSE_EFFECT NEU_1_Drowsiness 7002-58-6 CINNARIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, Ca++ channel (L-Type) blocker 7002-58-6 CINNARIZINE ZERO_CLASS N 7002-58-6 CINNARIZINE MESH_LEVEL_3 Piperazines 7002-58-6 CINNARIZINE MESH_LEVEL_1 Heterocyclic Compounds 7002-58-6 CINNARIZINE INDICATION Peripheral Vascular Disease 7002-58-6 CINNARIZINE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 7002-58-6 CINNARIZINE PRODUCT_CLASS Cardiovasculars 7002-58-6 CINNARIZINE MODE_CLASS Receptor Ligand Antagonist 7002-58-6 CINNARIZINE THERAPEUTIC_CLASS Antihistamines 7002-58-6 CINNARIZINE ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 7002-58-6 CINNARIZINE ADVERSE_EFFECT NEU_3_Headache 7002-58-6 CINNARIZINE TA_LEVEL_2 vasodilator 7002-58-6 CINNARIZINE MECH_LEVEL_3 histamine receptor H1 7002-58-6 CINNARIZINE TA_LEVEL_3 peripheral vascular disease 7002-58-6 CINNARIZINE TA_LEVEL_1 Cardiovascular 7002-58-6 CINNARIZINE INDICATION Vertigo 7002-58-6 CINNARIZINE THERAPEUTIC_CLASS Vasodilators 7002-58-6 CINNARIZINE ADVERSE_EFFECT NEU_3_Parkinsonism 7002-58-6 CINNARIZINE ADVERSE_EFFECT PSY_3_Depression 7002-58-6 CINNARIZINE MODE_CLASS Channel Blocker 7002-58-6 CINNARIZINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 7002-58-6 CINNARIZINE MECHANISM Modulate G-protein coupled signal transduction 7002-58-6 CINNARIZINE INDICATION Tinnitus / Ringing in the Ear 299-75-2 TREOSULFAN STRUCTURE_ACTIVITY DNA-alkylator, methanesulfonate 302-33-0 PROADIFEN PRODUCT_CLASS Biochemicals 302-41-0 PIRITRAMIDE THERAPEUTIC_CLASS Analgesics, Opioid 302-41-0 PIRITRAMIDE PRODUCT_CLASS Analgesics 302-41-0 PIRITRAMIDE MECHANISM Modulate neural transmission 302-41-0 PIRITRAMIDE MODE_CLASS Receptor Agonist 303-81-1 NOVOBIOCIN MECHANISM Inhibit bacterial DNA synthesis 303-81-1 NOVOBIOCIN MODE_CLASS Enzyme Inhibitor 304-84-7 ETHAMIVAN INDICATION Depression 304-84-7 ETHAMIVAN THERAPEUTIC_CLASS Antidepressants 304-84-7 ETHAMIVAN PRODUCT_CLASS Central Nervous System (CNS) 306-53-6 AZAMETHONIUM BROMIDE MECHANISM Prolong/enhance neural transmission 306-53-6 AZAMETHONIUM BROMIDE THERAPEUTIC_CLASS Antihypertensive Agents 306-53-6 AZAMETHONIUM BROMIDE INDICATION Hypertension 306-53-6 AZAMETHONIUM BROMIDE MODE_CLASS Channel Modulator 306-53-6 AZAMETHONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 306-53-6 AZAMETHONIUM BROMIDE PRODUCT_CLASS Cardiovasculars 306-53-6 AZAMETHONIUM BROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 42971-09-5 VINPOCETINE MODE_CLASS Channel Modulator 42971-09-5 VINPOCETINE MECHANISM Modulate channel gating 42971-09-5 VINPOCETINE MECHANISM Enhance kinase mediated signal transduction 42971-09-5 VINPOCETINE MODE_CLASS Channel Blocker 42971-09-5 VINPOCETINE PRODUCT_CLASS Central Nervous System (CNS) 42971-09-5 VINPOCETINE MECHANISM Block channel gating 42971-09-5 VINPOCETINE MECHANISM Block neural transmission 42971-09-5 VINPOCETINE THERAPEUTIC_CLASS Neurodegenerative Disorders 42971-09-5 VINPOCETINE MODE_CLASS Enzyme Inhibitor 159989-64-7 NELFINAVIR ADVERSE_EFFECT SKN_2_Dermatitis 159989-64-7 NELFINAVIR MECHANISM Inhibit post transcriptional protein processing 159989-64-7 NELFINAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 159989-64-7 NELFINAVIR ADVERSE_EFFECT GIS_3_Pancreatitis 159989-64-7 NELFINAVIR ADVERSE_EFFECT MSK_2_Arthralgia 159989-64-7 NELFINAVIR ADVERSE_EFFECT LUN_3_Bronchospasm 159989-64-7 NELFINAVIR ADVERSE_EFFECT REP_3_Sexual Dysfunction 159989-64-7 NELFINAVIR ADVERSE_EFFECT END_2_Exacerbation of Diabetes 159989-64-7 NELFINAVIR ADVERSE_EFFECT SKN_2_Rash 159989-64-7 NELFINAVIR ADVERSE_EFFECT GIS_1_Nausea 159989-64-7 NELFINAVIR ADVERSE_EFFECT GIS_1_Diarrhea 159989-64-7 NELFINAVIR INDICATION Prophylaxis Following Occupational HIV Exposure 159989-64-7 NELFINAVIR ADVERSE_EFFECT END_2_Fat Redistribution 159989-64-7 NELFINAVIR ADVERSE_EFFECT BBM_3_Anemia 159989-64-7 NELFINAVIR ADVERSE_EFFECT END_3_Metabolic Acidosis 159989-64-7 NELFINAVIR ADVERSE_EFFECT IMU_2_Allergic Reactions 159989-64-7 NELFINAVIR ADVERSE_EFFECT PSY_3_Depression 159989-64-7 NELFINAVIR MODE_CLASS Enzyme Inhibitor 159989-64-7 NELFINAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 159989-64-7 NELFINAVIR PRODUCT_CLASS Anti-infectives 159989-64-7 NELFINAVIR THERAPEUTIC_CLASS Antivirals, Systemic 159989-64-7 NELFINAVIR ADVERSE_EFFECT END_3_Diabetogenesis 159989-64-7 NELFINAVIR ADVERSE_EFFECT PSY_3_Anxiety 159989-64-7 NELFINAVIR ADVERSE_EFFECT SKN_2_Pruritis 159989-64-7 NELFINAVIR ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 159989-64-7 NELFINAVIR ADVERSE_EFFECT PSY_2_Anorexia 159989-64-7 NELFINAVIR ADVERSE_EFFECT BBM_3_Thrombocytopenia 159989-64-7 NELFINAVIR ADVERSE_EFFECT BBM_3_Leukopenia 159989-64-7 NELFINAVIR ADVERSE_EFFECT LIV_3_Hepatitis 159989-64-7 NELFINAVIR ADVERSE_EFFECT END_2_Hyperlipidemia 129-06-6 WARFARIN MESH_LEVEL_3 Benzopyrans 129-06-6 WARFARIN MECH_LEVEL_2 Inhibit platelet aggregation 129-06-6 WARFARIN ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 129-06-6 WARFARIN MECHANISM Inhibit platelet aggregation 129-06-6 WARFARIN INDICATION Postmyocardial Infarction 129-06-6 WARFARIN INDICATION Deep Vein Thrombosis 129-06-6 WARFARIN ADVERSE_EFFECT SKN_3_Skin Necrosis 129-06-6 WARFARIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 129-06-6 WARFARIN ADVERSE_EFFECT IMU_3_Urticaria 129-06-6 WARFARIN ADVERSE_EFFECT NEU_2_Headache 129-06-6 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenicity 129-06-6 WARFARIN ADVERSE_EFFECT BBM_1_Bleeding 129-06-6 WARFARIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 129-06-6 WARFARIN ZERO_CLASS N 129-06-6 WARFARIN TISSUE_TOXICITY Gastrointestinal Bleeding 129-06-6 WARFARIN TISSUE_TOXICITY Cholesterol Microembolization 129-06-6 WARFARIN ADVERSE_EFFECT BBM_2_Petechiae 129-06-6 WARFARIN KNOWN_TOXICITY Gastrointestinal Toxicity 129-06-6 WARFARIN INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 129-06-6 WARFARIN INDICATION Cardiomyopathy 129-06-6 WARFARIN INDICATION Prosthetic Heart Valves 129-06-6 WARFARIN MESH_LEVEL_1 Heterocyclic Compounds 129-06-6 WARFARIN TA_LEVEL_2 anticoagulant 129-06-6 WARFARIN ADVERSE_EFFECT PSY_2_Anorexia 129-06-6 WARFARIN ADVERSE_EFFECT SKN_2_Pruritis 129-06-6 WARFARIN KNOWN_TOXICITY Cardiovascular Toxicity 129-06-6 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Warfarin Syndrome 129-06-6 WARFARIN TISSUE_TOXICITY Fetal Renal Damage 129-06-6 WARFARIN TISSUE_TOXICITY Teratogenic Fetal Damage 129-06-6 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenic Fetal Damage 129-06-6 WARFARIN ADVERSE_EFFECT BBM_2_Ecchymosis 129-06-6 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Renal Damage 129-06-6 WARFARIN STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 129-06-6 WARFARIN INDICATION Antiphospholipid Antibody Syndrome 129-06-6 WARFARIN INDICATION Thrombosis Prophylaxis 129-06-6 WARFARIN MODE_CLASS Enzyme Inhibitor 129-06-6 WARFARIN ADVERSE_EFFECT NEU_3_Intracranial Bleeding 129-06-6 WARFARIN TISSUE_TOXICITY Fetal Warfarin Syndrome 129-06-6 WARFARIN TISSUE_TOXICITY Hematuria 129-06-6 WARFARIN ADVERSE_EFFECT LIV_2_Jaundice 129-06-6 WARFARIN ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 129-06-6 WARFARIN ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 129-06-6 WARFARIN KNOWN_TOXICITY Nephrotoxicity 129-06-6 WARFARIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 129-06-6 WARFARIN ADVERSE_EFFECT BBM_3_Agranulocytosis 129-06-6 WARFARIN ADVERSE_EFFECT GIS_2_Diarrhea 129-06-6 WARFARIN ADVERSE_EFFECT BBM_3_Leukopenia 129-06-6 WARFARIN ADVERSE_EFFECT GUS_3_Vaginal Bleeding 129-06-6 WARFARIN TA_LEVEL_1 Cardiovascular 129-06-6 WARFARIN ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 129-06-6 WARFARIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 129-06-6 WARFARIN THERAPEUTIC_CLASS Anticoagulants 129-06-6 WARFARIN ADVERSE_EFFECT KID_2_Hematuria 129-06-6 WARFARIN ADVERSE_EFFECT CVS_3_Cholesterol Microembolization 129-06-6 WARFARIN ADVERSE_EFFECT XXX_3_Retroperitoneal Bleeding 129-06-6 WARFARIN TISSUE_TOXICITY Teratogenicity 129-06-6 WARFARIN TISSUE_TOXICITY Fetal / Neonatal Morbidity and Mortality 129-06-6 WARFARIN TISSUE_TOXICITY Bleeding 129-06-6 WARFARIN KNOWN_TOXICITY Embryo/Fetal Toxicity 129-06-6 WARFARIN ADVERSE_EFFECT LIV_3_Hepatitis 129-06-6 WARFARIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 129-06-6 WARFARIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 129-06-6 WARFARIN PRODUCT_CLASS Hematologics 129-06-6 WARFARIN MECH_LEVEL_1 Anti-clotting 129-06-6 WARFARIN TA_LEVEL_3 anticoagulant 129-06-6 WARFARIN ADVERSE_EFFECT EMB_1_Fetal / Neonatal Morbidity and Mortality 129-06-6 WARFARIN ADVERSE_EFFECT XXX_2_Epistaxis 129-06-6 WARFARIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 129-06-6 WARFARIN MECH_LEVEL_3 Vitamin-K-epoxide reductase 129-06-6 WARFARIN INDICATION Atrial Fibrillation 2610-86-8 WARFARIN INDICATION Postmyocardial Infarction 2610-86-8 WARFARIN ADVERSE_EFFECT SKN_3_Skin Necrosis 2610-86-8 WARFARIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 2610-86-8 WARFARIN ADVERSE_EFFECT PSY_2_Anorexia 2610-86-8 WARFARIN ADVERSE_EFFECT SKN_2_Pruritis 2610-86-8 WARFARIN KNOWN_TOXICITY Cardiovascular Toxicity 2610-86-8 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Warfarin Syndrome 2610-86-8 WARFARIN TISSUE_TOXICITY Fetal Renal Damage 2610-86-8 WARFARIN STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 2610-86-8 WARFARIN ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 2610-86-8 WARFARIN ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 2610-86-8 WARFARIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 2610-86-8 WARFARIN ADVERSE_EFFECT BBM_1_Bleeding 2610-86-8 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenicity 2610-86-8 WARFARIN ADVERSE_EFFECT NEU_2_Headache 2610-86-8 WARFARIN ADVERSE_EFFECT IMU_3_Urticaria 2610-86-8 WARFARIN ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 2610-86-8 WARFARIN TISSUE_TOXICITY Teratogenicity 2610-86-8 WARFARIN TISSUE_TOXICITY Fetal / Neonatal Morbidity and Mortality 2610-86-8 WARFARIN TISSUE_TOXICITY Gastrointestinal Bleeding 2610-86-8 WARFARIN TISSUE_TOXICITY Bleeding 2610-86-8 WARFARIN TISSUE_TOXICITY Cholesterol Microembolization 2610-86-8 WARFARIN THERAPEUTIC_CLASS Anticoagulants 2610-86-8 WARFARIN ADVERSE_EFFECT LIV_3_Hepatitis 2610-86-8 WARFARIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 2610-86-8 WARFARIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 2610-86-8 WARFARIN ADVERSE_EFFECT EMB_1_Fetal / Neonatal Morbidity and Mortality 2610-86-8 WARFARIN MECH_LEVEL_2 Inhibit platelet aggregation 2610-86-8 WARFARIN ADVERSE_EFFECT XXX_2_Epistaxis 2610-86-8 WARFARIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 2610-86-8 WARFARIN MECH_LEVEL_3 Vitamin-K-epoxide reductase 2610-86-8 WARFARIN INDICATION Atrial Fibrillation 2610-86-8 WARFARIN MESH_LEVEL_3 Benzopyrans 2610-86-8 WARFARIN ADVERSE_EFFECT KID_2_Hematuria 2610-86-8 WARFARIN ADVERSE_EFFECT CVS_3_Cholesterol Microembolization 2610-86-8 WARFARIN TA_LEVEL_3 anticoagulant 2610-86-8 WARFARIN MECH_LEVEL_1 Anti-clotting 2610-86-8 WARFARIN PRODUCT_CLASS Hematologics 2610-86-8 WARFARIN ADVERSE_EFFECT BBM_2_Petechiae 2610-86-8 WARFARIN KNOWN_TOXICITY Gastrointestinal Toxicity 2610-86-8 WARFARIN INDICATION Deep Vein Thrombosis 2610-86-8 WARFARIN INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 2610-86-8 WARFARIN INDICATION Cardiomyopathy 2610-86-8 WARFARIN INDICATION Prosthetic Heart Valves 2610-86-8 WARFARIN MESH_LEVEL_1 Heterocyclic Compounds 2610-86-8 WARFARIN MECHANISM Inhibit platelet aggregation 2610-86-8 WARFARIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 2610-86-8 WARFARIN TA_LEVEL_2 anticoagulant 2610-86-8 WARFARIN TA_LEVEL_1 Cardiovascular 2610-86-8 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Renal Damage 2610-86-8 WARFARIN ADVERSE_EFFECT BBM_2_Ecchymosis 2610-86-8 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenic Fetal Damage 2610-86-8 WARFARIN TISSUE_TOXICITY Teratogenic Fetal Damage 2610-86-8 WARFARIN ZERO_CLASS N 2610-86-8 WARFARIN KNOWN_TOXICITY Nephrotoxicity 2610-86-8 WARFARIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 2610-86-8 WARFARIN ADVERSE_EFFECT XXX_3_Retroperitoneal Bleeding 2610-86-8 WARFARIN ADVERSE_EFFECT BBM_3_Agranulocytosis 2610-86-8 WARFARIN ADVERSE_EFFECT GIS_2_Diarrhea 2610-86-8 WARFARIN ADVERSE_EFFECT BBM_3_Leukopenia 2610-86-8 WARFARIN ADVERSE_EFFECT GUS_3_Vaginal Bleeding 2610-86-8 WARFARIN ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 2610-86-8 WARFARIN ADVERSE_EFFECT LIV_2_Jaundice 2610-86-8 WARFARIN TISSUE_TOXICITY Hematuria 2610-86-8 WARFARIN TISSUE_TOXICITY Fetal Warfarin Syndrome 2610-86-8 WARFARIN ADVERSE_EFFECT NEU_3_Intracranial Bleeding 2610-86-8 WARFARIN MODE_CLASS Enzyme Inhibitor 2610-86-8 WARFARIN INDICATION Thrombosis Prophylaxis 2610-86-8 WARFARIN INDICATION Antiphospholipid Antibody Syndrome 2610-86-8 WARFARIN KNOWN_TOXICITY Embryo/Fetal Toxicity 37341-99-4 WARFARIN KNOWN_TOXICITY Nephrotoxicity 37341-99-4 WARFARIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 37341-99-4 WARFARIN ADVERSE_EFFECT BBM_3_Agranulocytosis 37341-99-4 WARFARIN ADVERSE_EFFECT GIS_2_Diarrhea 37341-99-4 WARFARIN ADVERSE_EFFECT BBM_3_Leukopenia 37341-99-4 WARFARIN ADVERSE_EFFECT GUS_3_Vaginal Bleeding 37341-99-4 WARFARIN ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 37341-99-4 WARFARIN ADVERSE_EFFECT LIV_2_Jaundice 37341-99-4 WARFARIN TISSUE_TOXICITY Hematuria 37341-99-4 WARFARIN TISSUE_TOXICITY Fetal Warfarin Syndrome 37341-99-4 WARFARIN ADVERSE_EFFECT NEU_3_Intracranial Bleeding 37341-99-4 WARFARIN MODE_CLASS Enzyme Inhibitor 37341-99-4 WARFARIN INDICATION Thrombosis Prophylaxis 37341-99-4 WARFARIN INDICATION Antiphospholipid Antibody Syndrome 37341-99-4 WARFARIN STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 37341-99-4 WARFARIN ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 37341-99-4 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Renal Damage 37341-99-4 WARFARIN ADVERSE_EFFECT BBM_2_Ecchymosis 37341-99-4 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenic Fetal Damage 37341-99-4 WARFARIN TISSUE_TOXICITY Teratogenic Fetal Damage 37341-99-4 WARFARIN TISSUE_TOXICITY Fetal Renal Damage 37341-99-4 WARFARIN ADVERSE_EFFECT EMB_1_Fetal Warfarin Syndrome 37341-99-4 WARFARIN KNOWN_TOXICITY Cardiovascular Toxicity 37341-99-4 WARFARIN ADVERSE_EFFECT SKN_2_Pruritis 37341-99-4 WARFARIN ADVERSE_EFFECT PSY_2_Anorexia 37341-99-4 WARFARIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 37341-99-4 WARFARIN ADVERSE_EFFECT SKN_3_Skin Necrosis 37341-99-4 WARFARIN INDICATION Deep Vein Thrombosis 37341-99-4 WARFARIN INDICATION Postmyocardial Infarction 37341-99-4 WARFARIN MECHANISM Inhibit platelet aggregation 37341-99-4 WARFARIN TA_LEVEL_3 anticoagulant 37341-99-4 WARFARIN MECH_LEVEL_1 Anti-clotting 37341-99-4 WARFARIN PRODUCT_CLASS Hematologics 37341-99-4 WARFARIN ADVERSE_EFFECT EMB_1_Teratogenicity 37341-99-4 WARFARIN KNOWN_TOXICITY Gastrointestinal Toxicity 37341-99-4 WARFARIN ADVERSE_EFFECT KID_2_Hematuria 37341-99-4 WARFARIN ADVERSE_EFFECT CVS_3_Cholesterol Microembolization 37341-99-4 WARFARIN ADVERSE_EFFECT XXX_3_Retroperitoneal Bleeding 37341-99-4 WARFARIN TISSUE_TOXICITY Teratogenicity 37341-99-4 WARFARIN TISSUE_TOXICITY Fetal / Neonatal Morbidity and Mortality 37341-99-4 WARFARIN TISSUE_TOXICITY Bleeding 37341-99-4 WARFARIN KNOWN_TOXICITY Embryo/Fetal Toxicity 37341-99-4 WARFARIN THERAPEUTIC_CLASS Anticoagulants 37341-99-4 WARFARIN ADVERSE_EFFECT LIV_3_Hepatitis 37341-99-4 WARFARIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 37341-99-4 WARFARIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 37341-99-4 WARFARIN ADVERSE_EFFECT EMB_1_Fetal / Neonatal Morbidity and Mortality 37341-99-4 WARFARIN ADVERSE_EFFECT XXX_2_Epistaxis 37341-99-4 WARFARIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 37341-99-4 WARFARIN MECH_LEVEL_3 Vitamin-K-epoxide reductase 37341-99-4 WARFARIN INDICATION Atrial Fibrillation 37341-99-4 WARFARIN INDICATION Cardiomyopathy 37341-99-4 WARFARIN MESH_LEVEL_3 Benzopyrans 37341-99-4 WARFARIN MECH_LEVEL_2 Inhibit platelet aggregation 37341-99-4 WARFARIN ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 37341-99-4 WARFARIN ADVERSE_EFFECT IMU_3_Urticaria 37341-99-4 WARFARIN ADVERSE_EFFECT NEU_2_Headache 37341-99-4 WARFARIN ADVERSE_EFFECT BBM_1_Bleeding 37341-99-4 WARFARIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 37341-99-4 WARFARIN ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 37341-99-4 WARFARIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 37341-99-4 WARFARIN TISSUE_TOXICITY Gastrointestinal Bleeding 37341-99-4 WARFARIN TISSUE_TOXICITY Cholesterol Microembolization 37341-99-4 WARFARIN ADVERSE_EFFECT BBM_2_Petechiae 37341-99-4 WARFARIN INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 37341-99-4 WARFARIN INDICATION Prosthetic Heart Valves 37341-99-4 WARFARIN MESH_LEVEL_1 Heterocyclic Compounds 37341-99-4 WARFARIN TA_LEVEL_2 anticoagulant 37341-99-4 WARFARIN TA_LEVEL_1 Cardiovascular 37341-99-4 WARFARIN ZERO_CLASS N 19772-76-0 (RS)-WILLARDIINE PRODUCT_CLASS Biochemicals 19772-76-0 (RS)-WILLARDIINE MECHANISM Prolong/enhance neural transmission 19772-76-0 (RS)-WILLARDIINE MODE_CLASS Channel Modulator 131543-23-2 R(+)-WIN 55,212-2 MESYLATE MECHANISM Modulate G-protein coupled signal transduction 131543-23-2 R(+)-WIN 55,212-2 MESYLATE MODE_CLASS Receptor Agonist 131543-23-2 R(+)-WIN 55,212-2 MESYLATE PRODUCT_CLASS Biochemicals 19545-26-7 WORTMANNIN THERAPEUTIC_CLASS Antineoplastics 19545-26-7 WORTMANNIN PRODUCT_CLASS Anti-cancers 19545-26-7 WORTMANNIN MECHANISM Modulate G-protein coupled signal transduction 19545-26-7 WORTMANNIN MODE_CLASS Enzyme Inhibitor 19545-26-7 WORTMANNIN MODE_CLASS Enzyme Inhibitor, selective 19545-26-7 WORTMANNIN MECHANISM Inhibit kinase mediated signal transduction 1218-35-5 XYLOMETAZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 1218-35-5 XYLOMETAZOLINE INDICATION Vasomotor Rhinitis 1218-35-5 XYLOMETAZOLINE INDICATION Sinusitis 1218-35-5 XYLOMETAZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 1218-35-5 XYLOMETAZOLINE INDICATION Allergic Rhinitis 1218-35-5 XYLOMETAZOLINE MECHANISM Increase vasoconstriction 1218-35-5 XYLOMETAZOLINE INDICATION Nasal Congestion 1218-35-5 XYLOMETAZOLINE MODE_CLASS Receptor Agonist 1218-35-5 XYLOMETAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 526-36-3 XYLOMETAZOLINE INDICATION Sinusitis 526-36-3 XYLOMETAZOLINE INDICATION Allergic Rhinitis 526-36-3 XYLOMETAZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 526-36-3 XYLOMETAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 526-36-3 XYLOMETAZOLINE MODE_CLASS Receptor Agonist 526-36-3 XYLOMETAZOLINE INDICATION Vasomotor Rhinitis 526-36-3 XYLOMETAZOLINE MECHANISM Increase vasoconstriction 526-36-3 XYLOMETAZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 526-36-3 XYLOMETAZOLINE INDICATION Nasal Congestion 123040-16-4 AZASETRON MESH_LEVEL_3 Oxazines 123040-16-4 AZASETRON INDICATION Nausea / Vomiting 123040-16-4 AZASETRON MECH_LEVEL_1 Modulate neural transmission 123040-16-4 AZASETRON TA_LEVEL_2 CNS Depressant 123040-16-4 AZASETRON ADVERSE_EFFECT XXX_2_Malaise 123040-16-4 AZASETRON ADVERSE_EFFECT KID_2_Proteinuria 123040-16-4 AZASETRON ADVERSE_EFFECT GIS_2_Constipation 123040-16-4 AZASETRON ZERO_CLASS N 123040-16-4 AZASETRON MECHANISM Block neural transmission 123040-16-4 AZASETRON ADVERSE_EFFECT XXX_2_Fever 123040-16-4 AZASETRON ADVERSE_EFFECT PSY_3_Irritability 123040-16-4 AZASETRON ADVERSE_EFFECT LIV_2_Abnormal Liver Function 123040-16-4 AZASETRON ADVERSE_EFFECT GIS_3_Abdominal Pain 123040-16-4 AZASETRON ADVERSE_EFFECT NEU_2_Headache 123040-16-4 AZASETRON ACTIVITY_CLASS Serotonin antagonist 123040-16-4 AZASETRON MECH_LEVEL_2 5HT antagonist 123040-16-4 AZASETRON MECH_LEVEL_3 5HT receptor 3 123040-16-4 AZASETRON TA_LEVEL_3 Antiemetic 123040-16-4 AZASETRON PRODUCT_CLASS Gastrointestinal System 123040-16-4 AZASETRON TA_LEVEL_1 Central Nervous System (CNS) 123040-16-4 AZASETRON THERAPEUTIC_CLASS Antiemetics 123040-16-4 AZASETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 123040-16-4 AZASETRON MESH_LEVEL_1 Heterocyclic Compounds 123040-16-4 AZASETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 123040-16-4 AZASETRON ADVERSE_EFFECT SKN_3_Rash 123040-16-4 AZASETRON ADVERSE_EFFECT GIS_3_Diarrhea 123040-16-4 AZASETRON ADVERSE_EFFECT END_3_Hot Flashes 123040-16-4 AZASETRON MODE_CLASS Channel Blocker, selective 123040-69-7 AZASETRON PRODUCT_CLASS Gastrointestinal System 123040-69-7 AZASETRON ADVERSE_EFFECT GIS_3_Diarrhea 123040-69-7 AZASETRON ADVERSE_EFFECT SKN_3_Rash 123040-69-7 AZASETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 123040-69-7 AZASETRON MESH_LEVEL_1 Heterocyclic Compounds 123040-69-7 AZASETRON MESH_LEVEL_3 Oxazines 123040-69-7 AZASETRON INDICATION Nausea / Vomiting 123040-69-7 AZASETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 123040-69-7 AZASETRON TA_LEVEL_1 Central Nervous System (CNS) 123040-69-7 AZASETRON ADVERSE_EFFECT NEU_2_Headache 123040-69-7 AZASETRON ADVERSE_EFFECT GIS_3_Abdominal Pain 123040-69-7 AZASETRON ADVERSE_EFFECT END_3_Hot Flashes 123040-69-7 AZASETRON ADVERSE_EFFECT GIS_2_Constipation 123040-69-7 AZASETRON TA_LEVEL_2 CNS Depressant 123040-69-7 AZASETRON MECHANISM Block neural transmission 123040-69-7 AZASETRON MECH_LEVEL_1 Modulate neural transmission 123040-69-7 AZASETRON MODE_CLASS Channel Blocker, selective 123040-69-7 AZASETRON ADVERSE_EFFECT KID_2_Proteinuria 123040-69-7 AZASETRON ADVERSE_EFFECT XXX_2_Malaise 123040-69-7 AZASETRON ZERO_CLASS N 123040-69-7 AZASETRON ADVERSE_EFFECT XXX_2_Fever 123040-69-7 AZASETRON ADVERSE_EFFECT PSY_3_Irritability 123040-69-7 AZASETRON ADVERSE_EFFECT LIV_2_Abnormal Liver Function 123040-69-7 AZASETRON THERAPEUTIC_CLASS Antiemetics 123040-69-7 AZASETRON ACTIVITY_CLASS Serotonin antagonist 123040-69-7 AZASETRON MECH_LEVEL_2 5HT antagonist 123040-69-7 AZASETRON MECH_LEVEL_3 5HT receptor 3 123040-69-7 AZASETRON TA_LEVEL_3 Antiemetic 65-19-0 YOHIMBINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 65-19-0 YOHIMBINE PRODUCT_CLASS Gastrointestinal System 65-19-0 YOHIMBINE ADVERSE_EFFECT NEU_1_Dizziness 65-19-0 YOHIMBINE ADVERSE_EFFECT PSY_1_Irritability 65-19-0 YOHIMBINE MECHANISM Modulate G-protein coupled signal transduction 65-19-0 YOHIMBINE ADVERSE_EFFECT PSY_1_Anxiety 65-19-0 YOHIMBINE ADVERSE_EFFECT NEU_1_Headache 65-19-0 YOHIMBINE ADVERSE_EFFECT XXX_1_Restlessness 65-19-0 YOHIMBINE STRUCTURE_ACTIVITY Adrenoceptor-alpha2 antagonist 65-19-0 YOHIMBINE INDICATION Erectile Dysfunction 65-19-0 YOHIMBINE MODE_CLASS Receptor Ligand Antagonist, Selective 65-19-0 YOHIMBINE ADVERSE_EFFECT PSY_1_Nervousness 65-19-0 YOHIMBINE ADVERSE_EFFECT SKN_1_Flushing 65-19-0 YOHIMBINE ADVERSE_EFFECT NEU_3_Seizures 65-19-0 YOHIMBINE THERAPEUTIC_CLASS Vasodilators 65-19-0 YOHIMBINE ADVERSE_EFFECT CVS_1_Hypertension 65-19-0 YOHIMBINE ADVERSE_EFFECT NEU_1_Tremor 65-19-0 YOHIMBINE ADVERSE_EFFECT XXX_3_Death 65-19-0 YOHIMBINE TISSUE_TOXICITY Death 65-19-0 YOHIMBINE KNOWN_TOXICITY Miscellaneous 90182-92-6 ZACOPRIDE PRODUCT_CLASS Gastrointestinal System 90182-92-6 ZACOPRIDE MODE_CLASS Receptor Agonist 90182-92-6 ZACOPRIDE INDICATION Nausea / Vomiting 90182-92-6 ZACOPRIDE THERAPEUTIC_CLASS Antiemetics 90182-92-6 ZACOPRIDE MODE_CLASS Channel Blocker 90182-92-6 ZACOPRIDE MECHANISM Modulate neural transmission 90182-92-6 ZACOPRIDE MECHANISM Block neural transmission 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT DNA_3_Carcinogenicity 107753-78-6 ZAFIRLUKAST INDICATION Asthma 107753-78-6 ZAFIRLUKAST MECHANISM Modulate G-protein coupled signal transduction 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT GIS_2_Diarrhea 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT BBM_3_Bleeding 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT GIS_2_Abdominal Pain 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT XXX_1_Rhinitis 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT SKN_3_Vesicular Rash 107753-78-6 ZAFIRLUKAST KNOWN_TOXICITY Carcinogenicity 107753-78-6 ZAFIRLUKAST PRODUCT_CLASS Respiratory System 107753-78-6 ZAFIRLUKAST INDICATION Allergic Rhinitis 107753-78-6 ZAFIRLUKAST MODE_CLASS Receptor Ligand Antagonist 107753-78-6 ZAFIRLUKAST TISSUE_TOXICITY Carcinogenicity 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT XXX_1_Pharyngitis 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT MSK_2_Back Pain 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT MSK_2_Myalgia 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT LIV_3_Hepatitis 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT GIS_2_Nausea / Vomiting 107753-78-6 ZAFIRLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 107753-78-6 ZAFIRLUKAST PRODUCT_CLASS Anti-inflammatories 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT XXX_2_Asthenia 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT LIV_3_Jaundice 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT IMU_3_Urticaria 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT NEU_1_Headache 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT XXX_2_Fever 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT GIS_1_Gastritis 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT NEU_2_Dizziness 107753-78-6 ZAFIRLUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT BBM_3_Agranulocytosis 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT XXX_3_Bruising 107753-78-6 ZAFIRLUKAST ADVERSE_EFFECT _2_Churg-Strauss syndrome 107753-78-6 ZAFIRLUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 107753-78-6 ZAFIRLUKAST INDICATION Prophylaxis of Bronchospasm 7481-89-2 DIDEOXYCYTIDINE TISSUE_TOXICITY Hepatotoxicity 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT END_3_Diabetes Mellitus 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT GIS_2_Pancreatitis 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT PSY_3_Psychosis 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT NEU_3_Ataxia 7481-89-2 DIDEOXYCYTIDINE KNOWN_TOXICITY Hepatotoxicity 7481-89-2 DIDEOXYCYTIDINE MODE_CLASS Enzyme substrate mimic 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT BBM_3_Hematotoxicity 7481-89-2 DIDEOXYCYTIDINE ACTIVITY_CLASS Anti-viral 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT EMB_3_Teratogenicity 7481-89-2 DIDEOXYCYTIDINE STRUCTURE_ACTIVITY Viral RT inhibitor 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT MSK_3_Arthropathy 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT MSK_3_Myopathy 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT GIS_2_Oral Ulceration 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT CVS_3_Cardiomyopathy 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 7481-89-2 DIDEOXYCYTIDINE KNOWN_TOXICITY Embryo/Fetal Toxicity 7481-89-2 DIDEOXYCYTIDINE TISSUE_TOXICITY Teratogenicity 7481-89-2 DIDEOXYCYTIDINE TISSUE_TOXICITY Congestive Heart Failure 7481-89-2 DIDEOXYCYTIDINE MECHANISM Inhibit viral DNA synthesis 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT _3_Bell's Palsy 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT LIV_3_Hepatomegaly 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT GIS_2_Esophageal Ulceration 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT LIV_3_Hepatic Failure 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT END_3_Lactic Acidosis 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT BBM_2_Neutropenia 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT KID_3_Nephrotoxicity 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT NEU_3_Seizures 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT BBM_2_Leukopenia 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT BBM_2_Anemia 7481-89-2 DIDEOXYCYTIDINE ADVERSE_EFFECT END_2_Hypertriglyceridemia 7481-89-2 DIDEOXYCYTIDINE KNOWN_TOXICITY Nephrotoxicity 7481-89-2 DIDEOXYCYTIDINE TISSUE_TOXICITY Nephrotoxicity 7481-89-2 DIDEOXYCYTIDINE TISSUE_TOXICITY Cardiomyopathy 7481-89-2 DIDEOXYCYTIDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 7481-89-2 DIDEOXYCYTIDINE KNOWN_TOXICITY Cardiovascular Toxicity 7481-89-2 DIDEOXYCYTIDINE THERAPEUTIC_CLASS Antivirals, Systemic 7481-89-2 DIDEOXYCYTIDINE PRODUCT_CLASS Anti-infectives 7481-89-2 DIDEOXYCYTIDINE TISSUE_TOXICITY Hepatic Failure 151319-34-5 ZALEPLON INDICATION Insomnia 151319-34-5 ZALEPLON MESH_LEVEL_1 Organic Chemicals 151319-34-5 ZALEPLON STRUCTURE_ACTIVITY GABA-A agonist, short acting 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_2_Migraine 151319-34-5 ZALEPLON ADVERSE_EFFECT BBM_3_Leukocytosis 151319-34-5 ZALEPLON ADVERSE_EFFECT PSY_3_Confusion 151319-34-5 ZALEPLON ADVERSE_EFFECT PSY_2_Physical Dependence 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_3_Coma 151319-34-5 ZALEPLON ADVERSE_EFFECT XXX_2_Edema 151319-34-5 ZALEPLON ADVERSE_EFFECT XXX_2_Weakness 151319-34-5 ZALEPLON ADVERSE_EFFECT GUS_2_Urinary Retention 151319-34-5 ZALEPLON THERAPEUTIC_CLASS Sedatives/Hypnotics 151319-34-5 ZALEPLON MECH_LEVEL_1 Modulate neural transmission 151319-34-5 ZALEPLON MECH_LEVEL_3 GABA-A receptor 151319-34-5 ZALEPLON PRODUCT_CLASS Central Nervous System (CNS) 151319-34-5 ZALEPLON ADVERSE_EFFECT PSY_2_Euphoria 151319-34-5 ZALEPLON ADVERSE_EFFECT BBM_2_Anemia 151319-34-5 ZALEPLON ADVERSE_EFFECT XXX_2_Withdrawal 151319-34-5 ZALEPLON ADVERSE_EFFECT SKN_2_Rash 151319-34-5 ZALEPLON ADVERSE_EFFECT REP_2_Sexual Dysfunction 151319-34-5 ZALEPLON ADVERSE_EFFECT PSY_1_Depression 151319-34-5 ZALEPLON MECH_LEVEL_2 faciliates GABA binding 151319-34-5 ZALEPLON TA_LEVEL_3 Sedatives/Hypnotics 151319-34-5 ZALEPLON TA_LEVEL_2 CNS Depressant 151319-34-5 ZALEPLON MESH_LEVEL_2 Amides 151319-34-5 ZALEPLON MESH_LEVEL_3 Acetamides 151319-34-5 ZALEPLON ACTIVITY_CLASS GABA agonist 151319-34-5 ZALEPLON ZERO_CLASS N 151319-34-5 ZALEPLON ADVERSE_EFFECT OCU_3_Visual Disturbances 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_3_Seizures 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_3_Paresthesia 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_1_Headache 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_2_Amnesia 151319-34-5 ZALEPLON MODE_CLASS Channel enhancer /opener 151319-34-5 ZALEPLON TA_LEVEL_1 Central Nervous System (CNS) 151319-34-5 ZALEPLON MECHANISM Modulate neural transmission 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_1_Ataxia 151319-34-5 ZALEPLON ADVERSE_EFFECT PSY_2_Psychologic Dependence 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_1_Drowsiness 151319-34-5 ZALEPLON ADVERSE_EFFECT NEU_1_Dizziness 151319-34-5 ZALEPLON ADVERSE_EFFECT GIS_2_Nausea / Vomiting 151319-34-5 ZALEPLON ADVERSE_EFFECT LIV_3_Abnormal Liver Function 151319-34-5 ZALEPLON ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 139110-80-8 ZANAMIVIR MODE_CLASS Enzyme Inhibitor, selective 139110-80-8 ZANAMIVIR PRODUCT_CLASS Anti-infectives 139110-80-8 ZANAMIVIR THERAPEUTIC_CLASS Antivirals, Systemic 139110-80-8 ZANAMIVIR INDICATION Influenza / Flu 101975-10-4 ZARDAVERINE MECHANISM Enhance kinase mediated signal transduction 101975-10-4 ZARDAVERINE PRODUCT_CLASS Respiratory System 101975-10-4 ZARDAVERINE THERAPEUTIC_CLASS Bronchodilators 101975-10-4 ZARDAVERINE MODE_CLASS Enzyme Inhibitor 30516-87-1 ZIDOVUDINE TISSUE_TOXICITY Hematuria 30516-87-1 ZIDOVUDINE TISSUE_TOXICITY Cardiomyopathy 30516-87-1 ZIDOVUDINE TISSUE_TOXICITY Bone Marrow Toxicity 30516-87-1 ZIDOVUDINE INDICATION Prophylaxis Following Occupational HIV Exposure 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_2_Leukopenia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT PSY_3_Depression 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT NEU_2_Dizziness 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_1_Anemia 30516-87-1 ZIDOVUDINE THERAPEUTIC_CLASS Antivirals, Systemic 30516-87-1 ZIDOVUDINE KNOWN_TOXICITY Nephrotoxicity 30516-87-1 ZIDOVUDINE TISSUE_TOXICITY Neutropenia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT NEU_3_Syncope 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT NEU_2_Seizures 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT MSK_2_Myositis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_3_Pancreatitis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT LYM_2_Lymphadenopathy 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT MSK_3_Spasm 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT PSY_3_Hallucinations 30516-87-1 ZIDOVUDINE TA_LEVEL_3 antiviral RT inhibitors 30516-87-1 ZIDOVUDINE MECH_LEVEL_1 Anti-viral 30516-87-1 ZIDOVUDINE MESH_LEVEL_3 Deoxyribonucleosides 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_3_Dysphagia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT XXX_3_Asthenia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT CVS_3_Chest Pain 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_2_Pancytopenia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_2_Aplastic Anemia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT CVS_2_Cardiomyopathy 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT LIV_3_Hepatitis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT PSY_1_Anorexia 30516-87-1 ZIDOVUDINE TISSUE_TOXICITY Congestive Heart Failure 30516-87-1 ZIDOVUDINE MECH_LEVEL_3 RNA-directed DNA polymerase 30516-87-1 ZIDOVUDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 30516-87-1 ZIDOVUDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 30516-87-1 ZIDOVUDINE PRODUCT_CLASS Anti-infectives 30516-87-1 ZIDOVUDINE STRUCTURE_ACTIVITY Viral RT inhibitor 30516-87-1 ZIDOVUDINE TISSUE_TOXICITY Anemia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT MSK_2_Myopathy 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT CVS_3_Abnormal ECG 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_2_Dyspepsia 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_3_Stomatitis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT KID_3_Hematuria 30516-87-1 ZIDOVUDINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT IMU_3_Urticaria 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT NEU_1_Headache 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT NEU_3_Tremor 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_2_Constipation 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_1_Neutropenia 30516-87-1 ZIDOVUDINE MECH_LEVEL_2 Inhibit viral DNA synthesis 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT GIS_3_Flatulence 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_1_Bone Marrow Toxicity 30516-87-1 ZIDOVUDINE ADVERSE_EFFECT BBM_2_Bone Marrow Hypoplasia 30516-87-1 ZIDOVUDINE ZERO_CLASS N 30516-87-1 ZIDOVUDINE ACTIVITY_CLASS Anti-viral 30516-87-1 ZIDOVUDINE TA_LEVEL_1 Infectious Disease 30516-87-1 ZIDOVUDINE MESH_LEVEL_2 Nucleosides 30516-87-1 ZIDOVUDINE TA_LEVEL_2 Anti-viral 30516-87-1 ZIDOVUDINE MECHANISM Inhibit viral DNA synthesis 30516-87-1 ZIDOVUDINE MODE_CLASS Enzyme substrate mimic 30516-87-1 ZIDOVUDINE KNOWN_TOXICITY Cardiovascular Toxicity 111406-87-2 ZILEUTON PRODUCT_CLASS Respiratory System 111406-87-2 ZILEUTON MESH_LEVEL_3 Hydroxyurea 111406-87-2 ZILEUTON MODE_CLASS Enzyme Inhibitor 111406-87-2 ZILEUTON MESH_LEVEL_2 Urea 111406-87-2 ZILEUTON TA_LEVEL_2 Anti-inflammation 111406-87-2 ZILEUTON MESH_LEVEL_1 Organic Chemicals 111406-87-2 ZILEUTON MECH_LEVEL_1 Immunomodulation 111406-87-2 ZILEUTON ADVERSE_EFFECT XXX_2_Asthenia 111406-87-2 ZILEUTON ACTIVITY_CLASS Anti-inflammatory 111406-87-2 ZILEUTON STRUCTURE_ACTIVITY Arachidonate 5-lipoxygenase inhibitor 111406-87-2 ZILEUTON MECH_LEVEL_3 Arachidonate 5-lipoxygenase 111406-87-2 ZILEUTON TA_LEVEL_1 Respiratory System 111406-87-2 ZILEUTON THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 111406-87-2 ZILEUTON ADVERSE_EFFECT LYM_3_Lymphadenopathy 111406-87-2 ZILEUTON ADVERSE_EFFECT LIV_3_Abnormal Liver Function 111406-87-2 ZILEUTON ZERO_CLASS N 111406-87-2 ZILEUTON INDICATION Asthma 111406-87-2 ZILEUTON TA_LEVEL_3 asthma 111406-87-2 ZILEUTON ADVERSE_EFFECT GIS_2_Nausea 111406-87-2 ZILEUTON ADVERSE_EFFECT NEU_3_Somnolence 111406-87-2 ZILEUTON ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 111406-87-2 ZILEUTON ADVERSE_EFFECT GIS_2_Abdominal Pain 111406-87-2 ZILEUTON MECHANISM Inhibit eicosanoid biosynthesis 111406-87-2 ZILEUTON MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 111406-87-2 ZILEUTON ADVERSE_EFFECT PSY_3_Insomnia 111406-87-2 ZILEUTON ADVERSE_EFFECT GIS_2_Dyspepsia 111406-87-2 ZILEUTON ADVERSE_EFFECT BBM_3_Low White Blood Cell Count 7646-85-7 ZINC CHLORIDE INDICATION Dental Antisepsis 7646-85-7 ZINC CHLORIDE INDICATION Skin Antisepsis 7646-85-7 ZINC CHLORIDE PRODUCT_CLASS Other Human Uses 7646-85-7 ZINC CHLORIDE TISSUE_TOXICITY Death 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT LUN_3_Chemical Pneumonitis 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT GIS_2_Gastrointestinal Irritation 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT XXX_2_Nasal Irritation 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT XXX_2_Gray Cyanosis 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT OCU_1_Eye Irritation 7646-85-7 ZINC CHLORIDE MECHANISM Inhibit mitochondrial function 7646-85-7 ZINC CHLORIDE PRODUCT_CLASS Anti-infectives 7646-85-7 ZINC CHLORIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT GIS_2_Esophagitis 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Failure 7646-85-7 ZINC CHLORIDE TISSUE_TOXICITY Carcinogenicity 7646-85-7 ZINC CHLORIDE PRODUCT_CLASS Dermatologicals 7646-85-7 ZINC CHLORIDE KNOWN_TOXICITY Carcinogenicity 7646-85-7 ZINC CHLORIDE KNOWN_TOXICITY Miscellaneous 7646-85-7 ZINC CHLORIDE TISSUE_TOXICITY Skin Toxicity 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT SKN_2_Skin Ulcer 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT SKN_1_Skin Toxicity 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT LUN_1_Cough 7646-85-7 ZINC CHLORIDE KNOWN_TOXICITY Dermatologic Toxicity 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT LUN_2_Interstitial Pulmonary Fibrosis 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT _3_Local Tissue Irritation 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT XXX_3_Death 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT GIS_2_Esophageal Stenosis 7646-85-7 ZINC CHLORIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 7646-85-7 ZINC CHLORIDE STRUCTURE_ACTIVITY Toxicant, transition metal 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT GIS_3_Abdominal Cramps 7646-85-7 ZINC CHLORIDE ADVERSE_EFFECT SKN_3_Skin Detachment 84697-21-2 ZINOCONAZOLE PRODUCT_CLASS Anti-infectives 84697-21-2 ZINOCONAZOLE MODE_CLASS Enzyme Inhibitor 84697-21-2 ZINOCONAZOLE THERAPEUTIC_CLASS Antifungals 84697-21-2 ZINOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 139264-17-8 ZOLMITRIPTAN THERAPEUTIC_CLASS Antimigraines 139264-17-8 ZOLMITRIPTAN INDICATION Migraine Headache 139264-17-8 ZOLMITRIPTAN MECHANISM Modulate neural transmission 139264-17-8 ZOLMITRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 139264-17-8 ZOLMITRIPTAN MODE_CLASS Receptor Agonist 139264-17-8 ZOLMITRIPTAN MECHANISM Modulate cerebral vasoconstriction 139264-17-8 ZOLMITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 139264-24-7 ZOLMITRIPTAN THERAPEUTIC_CLASS Antimigraines 139264-24-7 ZOLMITRIPTAN MECHANISM Modulate neural transmission 139264-24-7 ZOLMITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 139264-24-7 ZOLMITRIPTAN INDICATION Migraine Headache 139264-24-7 ZOLMITRIPTAN MECHANISM Modulate cerebral vasoconstriction 139264-24-7 ZOLMITRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 139264-24-7 ZOLMITRIPTAN MODE_CLASS Receptor Agonist 139264-82-7 ZOLMITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 139264-82-7 ZOLMITRIPTAN MECHANISM Modulate cerebral vasoconstriction 139264-82-7 ZOLMITRIPTAN MODE_CLASS Receptor Agonist 139264-82-7 ZOLMITRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 139264-82-7 ZOLMITRIPTAN MECHANISM Modulate neural transmission 139264-82-7 ZOLMITRIPTAN THERAPEUTIC_CLASS Antimigraines 139264-82-7 ZOLMITRIPTAN INDICATION Migraine Headache 139264-19-0 ZOLMITRIPTAN THERAPEUTIC_CLASS Antimigraines 139264-19-0 ZOLMITRIPTAN MECHANISM Modulate cerebral vasoconstriction 139264-19-0 ZOLMITRIPTAN MODE_CLASS Receptor Agonist 139264-19-0 ZOLMITRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 139264-19-0 ZOLMITRIPTAN MECHANISM Modulate neural transmission 139264-19-0 ZOLMITRIPTAN INDICATION Migraine Headache 139264-19-0 ZOLMITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 139346-15-9 ZOLMITRIPTAN MODE_CLASS Receptor Agonist 139346-15-9 ZOLMITRIPTAN INDICATION Migraine Headache 139346-15-9 ZOLMITRIPTAN MECHANISM Modulate neural transmission 139346-15-9 ZOLMITRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 139346-15-9 ZOLMITRIPTAN MECHANISM Modulate cerebral vasoconstriction 139346-15-9 ZOLMITRIPTAN THERAPEUTIC_CLASS Antimigraines 139346-15-9 ZOLMITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 139264-25-8 ZOLMITRIPTAN INDICATION Migraine Headache 139264-25-8 ZOLMITRIPTAN THERAPEUTIC_CLASS Antimigraines 139264-25-8 ZOLMITRIPTAN MECHANISM Modulate cerebral vasoconstriction 139264-25-8 ZOLMITRIPTAN MODE_CLASS Receptor Agonist 139264-25-8 ZOLMITRIPTAN STRUCTURE_ACTIVITY 5HT1 agonist 139264-25-8 ZOLMITRIPTAN MECHANISM Modulate neural transmission 139264-25-8 ZOLMITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 62928-11-4 IPROPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 62973-76-6 AZANIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 63521-85-7 ESORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 63521-85-7 ESORUBICIN THERAPEUTIC_CLASS Antineoplastics 63521-85-7 ESORUBICIN PRODUCT_CLASS Anti-cancers 63521-85-7 ESORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 63521-85-7 ESORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 63619-84-1 TRIOXIFENE MECHANISM Modulate gene transcription 63619-84-1 TRIOXIFENE MODE_CLASS Receptor Ligand Antagonist 63619-84-1 TRIOXIFENE PRODUCT_CLASS Anti-cancers 63659-12-1 CICLOPROLOL MECHANISM Modulate G-protein coupled signal transduction 63659-12-1 CICLOPROLOL MODE_CLASS Receptor Partial Agonist 63758-79-2 INDALPINE INDICATION Depression 63758-79-2 INDALPINE PRODUCT_CLASS Central Nervous System (CNS) 63758-79-2 INDALPINE THERAPEUTIC_CLASS Antidepressants 63996-84-9 TIBALOSIN INDICATION Hypertension 63996-84-9 TIBALOSIN PRODUCT_CLASS Cardiovasculars 63996-84-9 TIBALOSIN THERAPEUTIC_CLASS Antihypertensive Agents 64294-95-7 SETASTINE MECHANISM Modulate G-protein coupled signal transduction 64294-95-7 SETASTINE MODE_CLASS Receptor Ligand Antagonist 64294-95-7 SETASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 59767-13-4 SETASTINE MECHANISM Modulate G-protein coupled signal transduction 59767-13-4 SETASTINE MODE_CLASS Receptor Ligand Antagonist 59767-13-4 SETASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 64496-66-8 SALAFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 64496-66-8 SALAFIBRATE INDICATION Hyperlipoproteinemia 64496-66-8 SALAFIBRATE PRODUCT_CLASS Cardiovasculars 64506-49-6 SOFALCONE INDICATION Ulcer 64544-07-6 CEFUROXIME AXETIL PRODUCT_CLASS Anti-infectives 64544-07-6 CEFUROXIME AXETIL MODE_CLASS Enzyme Inhibitor 64544-07-6 CEFUROXIME AXETIL MECHANISM Inhibit bacterial cell wall biosynthesis 64544-07-6 CEFUROXIME AXETIL THERAPEUTIC_CLASS Antibacterials 64743-09-5 NITRAFUDAM PRODUCT_CLASS Central Nervous System (CNS) 64743-09-5 NITRAFUDAM THERAPEUTIC_CLASS Antidepressants 64743-09-5 NITRAFUDAM INDICATION Depression 65008-93-7 BOMETOLOL MECHANISM Modulate G-protein coupled signal transduction 65008-93-7 BOMETOLOL MECHANISM Reduce muscle contractile force 65008-93-7 BOMETOLOL MODE_CLASS Receptor Ligand Antagonist 65043-22-3 INDELOXAZINE MECHANISM Prolong/enhance neural transmission 65043-22-3 INDELOXAZINE MODE_CLASS Solute transporter inhibitor 65043-22-3 INDELOXAZINE PRODUCT_CLASS Central Nervous System (CNS) 65043-22-3 INDELOXAZINE THERAPEUTIC_CLASS Antidepressants 65043-22-3 INDELOXAZINE INDICATION Depression 60929-23-9 INDELOXAZINE THERAPEUTIC_CLASS Antidepressants 60929-23-9 INDELOXAZINE INDICATION Depression 60929-23-9 INDELOXAZINE PRODUCT_CLASS Central Nervous System (CNS) 60929-23-9 INDELOXAZINE MODE_CLASS Solute transporter inhibitor 60929-23-9 INDELOXAZINE MECHANISM Prolong/enhance neural transmission 65052-63-3 CEFETAMET THERAPEUTIC_CLASS Antibacterials 65052-63-3 CEFETAMET MODE_CLASS Enzyme Inhibitor 65052-63-3 CEFETAMET PRODUCT_CLASS Anti-infectives 65052-63-3 CEFETAMET MECHANISM Inhibit bacterial cell wall biosynthesis 65085-01-0 CEFMENOXIME MODE_CLASS Enzyme Inhibitor 65085-01-0 CEFMENOXIME MECHANISM Inhibit bacterial cell wall biosynthesis 65085-01-0 CEFMENOXIME PRODUCT_CLASS Anti-infectives 65085-01-0 CEFMENOXIME THERAPEUTIC_CLASS Antibacterials 75738-58-8 CEFMENOXIME MECHANISM Inhibit bacterial cell wall biosynthesis 75738-58-8 CEFMENOXIME MODE_CLASS Enzyme Inhibitor 75738-58-8 CEFMENOXIME THERAPEUTIC_CLASS Antibacterials 75738-58-8 CEFMENOXIME PRODUCT_CLASS Anti-infectives 65429-87-0 SPIRENDOLOL MECHANISM Modulate G-protein coupled signal transduction 65429-87-0 SPIRENDOLOL MODE_CLASS Receptor Ligand Antagonist 65646-68-6 FENRETINIDE STRUCTURE_ACTIVITY Increase cellular ceramide level 65655-59-6 PACRINOLOL INDICATION Hypertension 65655-59-6 PACRINOLOL THERAPEUTIC_CLASS Antihypertensive Agents 65655-59-6 PACRINOLOL PRODUCT_CLASS Cardiovasculars 65847-85-0 MORNIFLUMATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 65847-85-0 MORNIFLUMATE PRODUCT_CLASS Anti-inflammatories 65899-72-1 ALOZAFONE THERAPEUTIC_CLASS Sedatives/Hypnotics 65899-72-1 ALOZAFONE INDICATION Anxiety Disorders 65899-72-1 ALOZAFONE PRODUCT_CLASS Central Nervous System (CNS) 66148-78-5 TEMOCILLIN THERAPEUTIC_CLASS Antibacterials 66148-78-5 TEMOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 66148-78-5 TEMOCILLIN MODE_CLASS Enzyme Inhibitor 66148-78-5 TEMOCILLIN PRODUCT_CLASS Anti-infectives 66203-94-9 MUROCAINIDE PRODUCT_CLASS Cardiovasculars 66203-94-9 MUROCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 66203-94-9 MUROCAINIDE INDICATION Cardiac Arrhythmias 66211-92-5 DETORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 66211-92-5 DETORUBICIN PRODUCT_CLASS Anti-cancers 66211-92-5 DETORUBICIN THERAPEUTIC_CLASS Antineoplastics 66211-92-5 DETORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 66211-92-5 DETORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 66264-77-5 SULFINALOL INDICATION Hypertension 66264-77-5 SULFINALOL PRODUCT_CLASS Cardiovasculars 66264-77-5 SULFINALOL THERAPEUTIC_CLASS Antihypertensive Agents 66364-73-6 ENPIROLINE INDICATION Malaria 66451-06-7 BORNAPROLOL MECHANISM Modulate G-protein coupled signal transduction 66451-06-7 BORNAPROLOL MODE_CLASS Receptor Ligand Antagonist 66451-06-7 BORNAPROLOL MECHANISM Reduce muscle contractile force 66529-17-7 MIDAGLIZOLE INDICATION Diabetes 66532-85-2 PROPACETAMOL STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 66564-14-5 CINITAPRIDE PRODUCT_CLASS Gastrointestinal System 66564-14-5 CINITAPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 66564-14-5 CINITAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 66564-14-5 CINITAPRIDE MODE_CLASS Receptor Agonist, selective 66564-14-5 CINITAPRIDE MECHANISM Modulate neural transmission 66564-14-5 CINITAPRIDE MECHANISM Modulate G-protein coupled signal transduction 66564-16-7 CICLOSIDOMINE THERAPEUTIC_CLASS Antihypertensive Agents 66564-16-7 CICLOSIDOMINE PRODUCT_CLASS Cardiovasculars 66564-16-7 CICLOSIDOMINE INDICATION Hypertension 66608-04-6 ROLGAMIDINE INDICATION Diarrhea 66834-24-0 CIANOPRAMINE MECHANISM Prolong/enhance neural transmission 66834-24-0 CIANOPRAMINE MODE_CLASS Solute transporter inhibitor 66969-81-1 TIODAZOSIN PRODUCT_CLASS Cardiovasculars 66969-81-1 TIODAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 66969-81-1 TIODAZOSIN INDICATION Hypertension 66969-81-1 TIODAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 67040-53-3 TIPROSTANIDE INDICATION Hypertension 67040-53-3 TIPROSTANIDE THERAPEUTIC_CLASS Antihypertensive Agents 67040-53-3 TIPROSTANIDE PRODUCT_CLASS Cardiovasculars 67121-76-0 FLUPERLAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 67165-56-4 DICLOFENSINE INDICATION Parkinson's Disease 67165-56-4 DICLOFENSINE THERAPEUTIC_CLASS Antidepressants 67165-56-4 DICLOFENSINE INDICATION Depression 67165-56-4 DICLOFENSINE PRODUCT_CLASS Central Nervous System (CNS) 67227-55-8 PRIMIDOLOL PRODUCT_CLASS Cardiovasculars 67227-55-8 PRIMIDOLOL INDICATION Angina Pectoris 67227-55-8 PRIMIDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 67227-55-8 PRIMIDOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 67227-55-8 PRIMIDOLOL THERAPEUTIC_CLASS Antianginals 67227-55-8 PRIMIDOLOL INDICATION Cardiac Arrhythmias 67227-55-8 PRIMIDOLOL INDICATION Hypertension 67337-44-4 SARMOXICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 67337-44-4 SARMOXICILLIN PRODUCT_CLASS Anti-infectives 67337-44-4 SARMOXICILLIN THERAPEUTIC_CLASS Antibacterials 67337-44-4 SARMOXICILLIN MODE_CLASS Enzyme Inhibitor 67696-82-6 ACRIHELLIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 67700-30-5 FURAPROFEN MECHANISM Inhibit eicosanoid biosynthesis 67700-30-5 FURAPROFEN PRODUCT_CLASS Anti-inflammatories 67700-30-5 FURAPROFEN MODE_CLASS Enzyme Inhibitor 67700-30-5 FURAPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 68247-85-8 PEPLOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 68247-85-8 PEPLOMYCIN MECHANISM Inhibit DNA synthesis, repair, and function 68252-19-7 PIRMENOL MODE_CLASS Channel Blocker 68252-19-7 PIRMENOL PRODUCT_CLASS Central Nervous System (CNS) 68252-19-7 PIRMENOL MECHANISM Modulate G-protein coupled signal transduction 68252-19-7 PIRMENOL INDICATION Cardiac Arrhythmias 68252-19-7 PIRMENOL THERAPEUTIC_CLASS Antidepressants 68252-19-7 PIRMENOL INDICATION Depression 68252-19-7 PIRMENOL MODE_CLASS Receptor Ligand Antagonist 68252-19-7 PIRMENOL THERAPEUTIC_CLASS Antiarrhythmic Agents 68252-19-7 PIRMENOL PRODUCT_CLASS Cardiovasculars 68252-19-7 PIRMENOL MECHANISM Block neural transmission 68252-19-7 PIRMENOL MECHANISM Reduce muscle contractile force 61477-94-9 PIRMENOL THERAPEUTIC_CLASS Antidepressants 61477-94-9 PIRMENOL INDICATION Cardiac Arrhythmias 61477-94-9 PIRMENOL MODE_CLASS Channel Blocker 61477-94-9 PIRMENOL MECHANISM Block neural transmission 61477-94-9 PIRMENOL MECHANISM Reduce muscle contractile force 61477-94-9 PIRMENOL MECHANISM Modulate G-protein coupled signal transduction 61477-94-9 PIRMENOL PRODUCT_CLASS Cardiovasculars 61477-94-9 PIRMENOL MODE_CLASS Receptor Ligand Antagonist 61477-94-9 PIRMENOL PRODUCT_CLASS Central Nervous System (CNS) 61477-94-9 PIRMENOL THERAPEUTIC_CLASS Antiarrhythmic Agents 61477-94-9 PIRMENOL INDICATION Depression 68367-52-2 SORBINIL MODE_CLASS Enzyme Inhibitor 68367-52-2 SORBINIL STRUCTURE_ACTIVITY Aldehyde reductase inhibitor 68367-52-2 SORBINIL MECHANISM Inhibit precursor synthesis 68367-52-2 SORBINIL INDICATION Diabetic Neuropathy 68367-52-2 SORBINIL THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 68367-52-2 SORBINIL ADVERSE_EFFECT SKN_1_Skin Rash 68367-52-2 SORBINIL PRODUCT_CLASS Other Human Uses 68367-52-2 SORBINIL ADVERSE_EFFECT MSK_1_Myalgia 68367-52-2 SORBINIL ADVERSE_EFFECT IMU_1_Hypersensitivity 68377-92-4 AROTINOLOL MODE_CLASS Receptor Partial Agonist 68377-92-4 AROTINOLOL MECHANISM Reduce muscle contractile force 68377-92-4 AROTINOLOL MECHANISM Reduce vasoconstriction 68377-92-4 AROTINOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 68377-92-4 AROTINOLOL INDICATION Hypertension 68377-92-4 AROTINOLOL MECHANISM Modulate G-protein coupled signal transduction 68377-92-4 AROTINOLOL INDICATION Dyskinesia 68377-92-4 AROTINOLOL PRODUCT_CLASS Cardiovasculars 68377-92-4 AROTINOLOL THERAPEUTIC_CLASS Antihypertensive Agents 68377-91-3 AROTINOLOL MODE_CLASS Receptor Partial Agonist 68377-91-3 AROTINOLOL MECHANISM Reduce muscle contractile force 68377-91-3 AROTINOLOL MECHANISM Reduce vasoconstriction 68377-91-3 AROTINOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 68377-91-3 AROTINOLOL INDICATION Hypertension 68377-91-3 AROTINOLOL THERAPEUTIC_CLASS Antihypertensive Agents 68377-91-3 AROTINOLOL MECHANISM Modulate G-protein coupled signal transduction 68377-91-3 AROTINOLOL INDICATION Dyskinesia 68377-91-3 AROTINOLOL PRODUCT_CLASS Cardiovasculars 68497-62-1 PRAMIRACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 68567-30-6 SOLPECAINOL THERAPEUTIC_CLASS Antiarrhythmic Agents 68567-30-6 SOLPECAINOL PRODUCT_CLASS Cardiovasculars 68567-30-6 SOLPECAINOL INDICATION Cardiac Arrhythmias 68741-18-4 BUTERIZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 68767-14-6 LOXOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 68767-14-6 LOXOPROFEN ADVERSE_EFFECT BBM_2_Anemia 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_3_Peptic Ulceration 68767-14-6 LOXOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 68767-14-6 LOXOPROFEN INDICATION Osteoarthritis 68767-14-6 LOXOPROFEN INDICATION Post-Operative Pain 68767-14-6 LOXOPROFEN MESH_LEVEL_2 Carboxylic Acids 68767-14-6 LOXOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 68767-14-6 LOXOPROFEN MESH_LEVEL_1 Organic Chemicals 68767-14-6 LOXOPROFEN PRODUCT_CLASS Anti-inflammatories 68767-14-6 LOXOPROFEN MECH_LEVEL_1 Immunomodulation 68767-14-6 LOXOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 68767-14-6 LOXOPROFEN ADVERSE_EFFECT CVS_3_Cardiac Failure 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 68767-14-6 LOXOPROFEN ADVERSE_EFFECT OTO_3_Tinnitus 68767-14-6 LOXOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 68767-14-6 LOXOPROFEN ADVERSE_EFFECT IMU_3_Photosensitivity 68767-14-6 LOXOPROFEN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 68767-14-6 LOXOPROFEN ADVERSE_EFFECT KID_1_Fluid Retention 68767-14-6 LOXOPROFEN ADVERSE_EFFECT SKN_2_Skin Rash 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 68767-14-6 LOXOPROFEN KNOWN_TOXICITY Cardiovascular Toxicity 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Fulminant Hepatitis 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Inhibits Platelet Aggregation 68767-14-6 LOXOPROFEN ACTIVITY_CLASS Anti-inflammatory 68767-14-6 LOXOPROFEN TA_LEVEL_3 NSAID 68767-14-6 LOXOPROFEN TA_LEVEL_1 Anti-inflammatory 68767-14-6 LOXOPROFEN ADVERSE_EFFECT LIV_2_Abnormal Liver Function 68767-14-6 LOXOPROFEN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Cardiac Failure 68767-14-6 LOXOPROFEN ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 68767-14-6 LOXOPROFEN ADVERSE_EFFECT KID_3_Renal Failure 68767-14-6 LOXOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 68767-14-6 LOXOPROFEN ZERO_CLASS N 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Renal Papillary Necrosis 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Renal Failure 68767-14-6 LOXOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 68767-14-6 LOXOPROFEN INDICATION Rheumatoid Arthritis 68767-14-6 LOXOPROFEN INDICATION Musculoskeletal Pain 68767-14-6 LOXOPROFEN MODE_CLASS Enzyme Inhibitor 68767-14-6 LOXOPROFEN KNOWN_TOXICITY Nephrotoxicity 68767-14-6 LOXOPROFEN ADVERSE_EFFECT NEU_3_Somnolence 68767-14-6 LOXOPROFEN ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 68767-14-6 LOXOPROFEN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 68767-14-6 LOXOPROFEN ADVERSE_EFFECT BBM_1_Inhibits Platelet Aggregation 68767-14-6 LOXOPROFEN ADVERSE_EFFECT BBM_3_Pancytopenia 68767-14-6 LOXOPROFEN ADVERSE_EFFECT OCU_2_Blurred Vision 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 68767-14-6 LOXOPROFEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Hepatic Failure 68767-14-6 LOXOPROFEN TISSUE_TOXICITY Acute Interstitial Nephritis 68767-14-6 LOXOPROFEN ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 68767-14-6 LOXOPROFEN ADVERSE_EFFECT REP_2_Delayed Parturition 68767-14-6 LOXOPROFEN ADVERSE_EFFECT LIV_3_Hepatic Failure 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_2_Constipation 68767-14-6 LOXOPROFEN ADVERSE_EFFECT LUN_3_Bronchospasm 68767-14-6 LOXOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 68767-14-6 LOXOPROFEN ADVERSE_EFFECT IMU_3_Hypersensitivity 68767-14-6 LOXOPROFEN TA_LEVEL_2 NSAID 68767-14-6 LOXOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 68767-14-6 LOXOPROFEN INDICATION Pain 68767-14-6 LOXOPROFEN KNOWN_TOXICITY Hepatotoxicity 68767-14-6 LOXOPROFEN ADVERSE_EFFECT GIS_1_Heartburn 68767-14-6 LOXOPROFEN ADVERSE_EFFECT BBM_3_Agranulocytosis 80382-23-6 LOXOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 80382-23-6 LOXOPROFEN INDICATION Post-Operative Pain 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Cardiac Failure 80382-23-6 LOXOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_3_Peptic Ulceration 80382-23-6 LOXOPROFEN ADVERSE_EFFECT BBM_2_Anemia 80382-23-6 LOXOPROFEN ADVERSE_EFFECT BBM_3_Agranulocytosis 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_2_Constipation 80382-23-6 LOXOPROFEN ADVERSE_EFFECT LIV_3_Hepatic Failure 80382-23-6 LOXOPROFEN ADVERSE_EFFECT REP_2_Delayed Parturition 80382-23-6 LOXOPROFEN ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_1_Heartburn 80382-23-6 LOXOPROFEN KNOWN_TOXICITY Hepatotoxicity 80382-23-6 LOXOPROFEN INDICATION Pain 80382-23-6 LOXOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 80382-23-6 LOXOPROFEN TA_LEVEL_2 NSAID 80382-23-6 LOXOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 80382-23-6 LOXOPROFEN MESH_LEVEL_2 Carboxylic Acids 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Acute Interstitial Nephritis 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Hepatic Failure 80382-23-6 LOXOPROFEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 80382-23-6 LOXOPROFEN ADVERSE_EFFECT LUN_3_Bronchospasm 80382-23-6 LOXOPROFEN ADVERSE_EFFECT OCU_2_Blurred Vision 80382-23-6 LOXOPROFEN ADVERSE_EFFECT BBM_3_Pancytopenia 80382-23-6 LOXOPROFEN ADVERSE_EFFECT BBM_1_Inhibits Platelet Aggregation 80382-23-6 LOXOPROFEN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 80382-23-6 LOXOPROFEN ADVERSE_EFFECT NEU_3_Somnolence 80382-23-6 LOXOPROFEN KNOWN_TOXICITY Nephrotoxicity 80382-23-6 LOXOPROFEN MODE_CLASS Enzyme Inhibitor 80382-23-6 LOXOPROFEN INDICATION Musculoskeletal Pain 80382-23-6 LOXOPROFEN INDICATION Rheumatoid Arthritis 80382-23-6 LOXOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Renal Failure 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Renal Papillary Necrosis 80382-23-6 LOXOPROFEN ZERO_CLASS N 80382-23-6 LOXOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 80382-23-6 LOXOPROFEN ADVERSE_EFFECT IMU_3_Hypersensitivity 80382-23-6 LOXOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 80382-23-6 LOXOPROFEN ADVERSE_EFFECT KID_3_Renal Failure 80382-23-6 LOXOPROFEN ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 80382-23-6 LOXOPROFEN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 80382-23-6 LOXOPROFEN ADVERSE_EFFECT LIV_2_Abnormal Liver Function 80382-23-6 LOXOPROFEN KNOWN_TOXICITY Cardiovascular Toxicity 80382-23-6 LOXOPROFEN MECH_LEVEL_1 Immunomodulation 80382-23-6 LOXOPROFEN INDICATION Osteoarthritis 80382-23-6 LOXOPROFEN TA_LEVEL_1 Anti-inflammatory 80382-23-6 LOXOPROFEN TA_LEVEL_3 NSAID 80382-23-6 LOXOPROFEN ACTIVITY_CLASS Anti-inflammatory 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Inhibits Platelet Aggregation 80382-23-6 LOXOPROFEN TISSUE_TOXICITY Fulminant Hepatitis 80382-23-6 LOXOPROFEN ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 80382-23-6 LOXOPROFEN ADVERSE_EFFECT SKN_2_Skin Rash 80382-23-6 LOXOPROFEN ADVERSE_EFFECT KID_1_Fluid Retention 80382-23-6 LOXOPROFEN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 80382-23-6 LOXOPROFEN ADVERSE_EFFECT IMU_3_Photosensitivity 80382-23-6 LOXOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 80382-23-6 LOXOPROFEN ADVERSE_EFFECT OTO_3_Tinnitus 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 80382-23-6 LOXOPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 80382-23-6 LOXOPROFEN ADVERSE_EFFECT CVS_3_Cardiac Failure 80382-23-6 LOXOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 80382-23-6 LOXOPROFEN PRODUCT_CLASS Anti-inflammatories 80382-23-6 LOXOPROFEN MESH_LEVEL_1 Organic Chemicals 69207-52-9 METHYL PALMOXIRATE INDICATION Diabetes 69207-52-9 METHYL PALMOXIRATE STRUCTURE_ACTIVITY Carnitine palmitoyltransferase inhibitor 69217-67-0 SUMACETAMOL STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 69373-88-2 DIPROTEVERINE MECHANISM Modulate channel gating 69373-88-2 DIPROTEVERINE MODE_CLASS Channel Blocker 69373-88-2 DIPROTEVERINE PRODUCT_CLASS Cardiovasculars 69373-88-2 DIPROTEVERINE THERAPEUTIC_CLASS Antianginals 69373-88-2 DIPROTEVERINE INDICATION Angina Pectoris 69388-79-0 SULBACTAM PIVOXIL MECHANISM Inhibit drug resistant enzyme/pump 69388-79-0 SULBACTAM PIVOXIL THERAPEUTIC_CLASS Antibacterials 69388-79-0 SULBACTAM PIVOXIL PRODUCT_CLASS Anti-infectives 69388-79-0 SULBACTAM PIVOXIL MODE_CLASS Enzyme Inhibitor 69414-41-1 PIRIDICILLIN PRODUCT_CLASS Anti-infectives 69414-41-1 PIRIDICILLIN MODE_CLASS Enzyme Inhibitor 69414-41-1 PIRIDICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 69414-41-1 PIRIDICILLIN THERAPEUTIC_CLASS Antibacterials 69429-84-1 CILOBAMINE THERAPEUTIC_CLASS Antidepressants 69429-84-1 CILOBAMINE PRODUCT_CLASS Central Nervous System (CNS) 69429-84-1 CILOBAMINE INDICATION Depression 69648-38-0 BUTAPROST MECHANISM Modulate G-protein coupled signal transduction 69648-38-0 BUTAPROST MODE_CLASS Receptor Agonist 69739-16-8 CEFODIZIME MECHANISM Inhibit bacterial cell wall biosynthesis 69739-16-8 CEFODIZIME THERAPEUTIC_CLASS Antibacterials 69739-16-8 CEFODIZIME MODE_CLASS Enzyme Inhibitor 69739-16-8 CEFODIZIME PRODUCT_CLASS Anti-infectives 86329-79-5 CEFODIZIME THERAPEUTIC_CLASS Antibacterials 86329-79-5 CEFODIZIME MODE_CLASS Enzyme Inhibitor 86329-79-5 CEFODIZIME PRODUCT_CLASS Anti-infectives 86329-79-5 CEFODIZIME MECHANISM Inhibit bacterial cell wall biosynthesis 69907-17-1 INDOPANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 69907-17-1 INDOPANOLOL INDICATION Cardiac Arrhythmias 69907-17-1 INDOPANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 69907-17-1 INDOPANOLOL INDICATION Hypertension 69907-17-1 INDOPANOLOL PRODUCT_CLASS Cardiovasculars 70132-50-2 PIMONIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 70458-92-3 PEFLOXACIN ADVERSE_EFFECT KID_3_Increased Creatinine 70458-92-3 PEFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 70458-92-3 PEFLOXACIN INDICATION Intra-Abdominal Infections 70458-92-3 PEFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 70458-92-3 PEFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 70458-92-3 PEFLOXACIN INDICATION Gynecologic Infections 70458-92-3 PEFLOXACIN INDICATION Peritonitis 70458-92-3 PEFLOXACIN INDICATION Enteric Fever / Typhoid Fever 70458-92-3 PEFLOXACIN ADVERSE_EFFECT XXX_2_Malaise 70458-92-3 PEFLOXACIN ADVERSE_EFFECT MSK_2_Myalgia 70458-92-3 PEFLOXACIN ADVERSE_EFFECT MSK_1_Arthralgia 70458-92-3 PEFLOXACIN ADVERSE_EFFECT XXX_2_Restlessness 70458-92-3 PEFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Distention 70458-92-3 PEFLOXACIN ADVERSE_EFFECT NEU_2_Headache 70458-92-3 PEFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 70458-92-3 PEFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 70458-92-3 PEFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 70458-92-3 PEFLOXACIN INDICATION Meningitis 70458-92-3 PEFLOXACIN INDICATION Cystic Fibrosis (CF) 70458-92-3 PEFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 70458-92-3 PEFLOXACIN INDICATION Leprosy 70458-92-3 PEFLOXACIN INDICATION Salmonellosis 70458-92-3 PEFLOXACIN ADVERSE_EFFECT NEU_3_Exacerbation of Epileptic Seizures 70458-92-3 PEFLOXACIN ADVERSE_EFFECT IMU_3_Eosinophilia 70458-92-3 PEFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 70458-92-3 PEFLOXACIN ADVERSE_EFFECT PSY_2_Agitation 70458-92-3 PEFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 70458-92-3 PEFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 70458-92-3 PEFLOXACIN INDICATION Bone and Joint Infection 70458-92-3 PEFLOXACIN INDICATION Osteomyelitis / Bone Infection 70458-92-3 PEFLOXACIN INDICATION Febrile Neutropenia 70458-92-3 PEFLOXACIN INDICATION Legionnaire's Disease 70458-92-3 PEFLOXACIN INDICATION Q Fever 70458-92-3 PEFLOXACIN PRODUCT_CLASS Anti-infectives 70458-92-3 PEFLOXACIN INDICATION Lower Respiratory Tract Infection 70458-92-3 PEFLOXACIN ADVERSE_EFFECT SKN_3_Photo-Oncholysis 70458-92-3 PEFLOXACIN ADVERSE_EFFECT MSK_2_Arthropathy 70458-92-3 PEFLOXACIN ADVERSE_EFFECT MSK_2_Tendinitis 70458-92-3 PEFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 70458-92-3 PEFLOXACIN ADVERSE_EFFECT IMU_1_Urticaria 70458-92-3 PEFLOXACIN ADVERSE_EFFECT SKN_2_Rash 70458-92-3 PEFLOXACIN INDICATION Septicemia 70458-92-3 PEFLOXACIN INDICATION Endophthalmitis 70458-92-3 PEFLOXACIN INDICATION Helicobacter Pylori Infection 70458-92-3 PEFLOXACIN INDICATION Prostatitis 70458-92-3 PEFLOXACIN INDICATION Urinary Tract Infection (UTI) 70458-92-3 PEFLOXACIN ADVERSE_EFFECT PSY_2_Disorientation 70458-92-3 PEFLOXACIN ADVERSE_EFFECT GIS_1_Gastralgia 70458-92-3 PEFLOXACIN THERAPEUTIC_CLASS Antibacterials 70458-92-3 PEFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 70458-92-3 PEFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 70458-92-3 PEFLOXACIN ADVERSE_EFFECT MSK_2_Achilles Tendinitis 70458-92-3 PEFLOXACIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 70458-92-3 PEFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 70458-92-3 PEFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 70458-95-6 PEFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 70458-95-6 PEFLOXACIN ADVERSE_EFFECT MSK_2_Tendinitis 70458-95-6 PEFLOXACIN ADVERSE_EFFECT MSK_2_Arthropathy 70458-95-6 PEFLOXACIN ADVERSE_EFFECT SKN_3_Photo-Oncholysis 70458-95-6 PEFLOXACIN INDICATION Lower Respiratory Tract Infection 70458-95-6 PEFLOXACIN INDICATION Q Fever 70458-95-6 PEFLOXACIN INDICATION Legionnaire's Disease 70458-95-6 PEFLOXACIN ADVERSE_EFFECT GIS_1_Gastralgia 70458-95-6 PEFLOXACIN INDICATION Osteomyelitis / Bone Infection 70458-95-6 PEFLOXACIN INDICATION Bone and Joint Infection 70458-95-6 PEFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 70458-95-6 PEFLOXACIN INDICATION Salmonellosis 70458-95-6 PEFLOXACIN ADVERSE_EFFECT PSY_2_Agitation 70458-95-6 PEFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 70458-95-6 PEFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 70458-95-6 PEFLOXACIN ADVERSE_EFFECT IMU_3_Eosinophilia 70458-95-6 PEFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 70458-95-6 PEFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Distention 70458-95-6 PEFLOXACIN ADVERSE_EFFECT MSK_2_Achilles Tendinitis 70458-95-6 PEFLOXACIN ADVERSE_EFFECT KID_3_Increased Creatinine 70458-95-6 PEFLOXACIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 70458-95-6 PEFLOXACIN ADVERSE_EFFECT PSY_2_Disorientation 70458-95-6 PEFLOXACIN INDICATION Septicemia 70458-95-6 PEFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 70458-95-6 PEFLOXACIN THERAPEUTIC_CLASS Antibacterials 70458-95-6 PEFLOXACIN INDICATION Intra-Abdominal Infections 70458-95-6 PEFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 70458-95-6 PEFLOXACIN INDICATION Gynecologic Infections 70458-95-6 PEFLOXACIN INDICATION Peritonitis 70458-95-6 PEFLOXACIN INDICATION Enteric Fever / Typhoid Fever 70458-95-6 PEFLOXACIN PRODUCT_CLASS Anti-infectives 70458-95-6 PEFLOXACIN INDICATION Urinary Tract Infection (UTI) 70458-95-6 PEFLOXACIN ADVERSE_EFFECT XXX_2_Malaise 70458-95-6 PEFLOXACIN ADVERSE_EFFECT MSK_2_Myalgia 70458-95-6 PEFLOXACIN ADVERSE_EFFECT MSK_1_Arthralgia 70458-95-6 PEFLOXACIN ADVERSE_EFFECT XXX_2_Restlessness 70458-95-6 PEFLOXACIN ADVERSE_EFFECT NEU_2_Headache 70458-95-6 PEFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 70458-95-6 PEFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 70458-95-6 PEFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 70458-95-6 PEFLOXACIN INDICATION Meningitis 70458-95-6 PEFLOXACIN INDICATION Cystic Fibrosis (CF) 70458-95-6 PEFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 70458-95-6 PEFLOXACIN INDICATION Leprosy 70458-95-6 PEFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 70458-95-6 PEFLOXACIN ADVERSE_EFFECT NEU_3_Exacerbation of Epileptic Seizures 70458-95-6 PEFLOXACIN INDICATION Prostatitis 70458-95-6 PEFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 70458-95-6 PEFLOXACIN INDICATION Helicobacter Pylori Infection 70458-95-6 PEFLOXACIN INDICATION Endophthalmitis 70458-95-6 PEFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 70458-95-6 PEFLOXACIN ADVERSE_EFFECT SKN_2_Rash 70458-95-6 PEFLOXACIN ADVERSE_EFFECT IMU_1_Urticaria 70458-95-6 PEFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 70458-95-6 PEFLOXACIN INDICATION Febrile Neutropenia 70639-48-4 ETISOMICIN PRODUCT_CLASS Anti-infectives 70639-48-4 ETISOMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 70639-48-4 ETISOMICIN THERAPEUTIC_CLASS Antibacterials 70639-48-4 ETISOMICIN MECHANISM Inhibit ribosomal protein synthesis 70639-48-4 ETISOMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 70797-11-4 CEFPIRAMIDE MECHANISM Inhibit bacterial cell wall biosynthesis 70797-11-4 CEFPIRAMIDE PRODUCT_CLASS Anti-infectives 70797-11-4 CEFPIRAMIDE THERAPEUTIC_CLASS Antibacterials 70797-11-4 CEFPIRAMIDE MODE_CLASS Enzyme Inhibitor 74849-93-7 CEFPIRAMIDE MECHANISM Inhibit bacterial cell wall biosynthesis 74849-93-7 CEFPIRAMIDE THERAPEUTIC_CLASS Antibacterials 74849-93-7 CEFPIRAMIDE MODE_CLASS Enzyme Inhibitor 74849-93-7 CEFPIRAMIDE PRODUCT_CLASS Anti-infectives 71002-09-0 PIRAZOLAC INDICATION Rheumatism 71002-09-0 PIRAZOLAC THERAPEUTIC_CLASS Immunosuppressants 71002-09-0 PIRAZOLAC PRODUCT_CLASS Immune Response / Immunomodulators 71027-13-9 ECLANAMINE PRODUCT_CLASS Central Nervous System (CNS) 71027-13-9 ECLANAMINE THERAPEUTIC_CLASS Antidepressants 71027-13-9 ECLANAMINE INDICATION Depression 71031-15-7 CATHINONE MODE_CLASS Enzyme Inhibitor 71031-15-7 CATHINONE MECHANISM Prolong/enhance neural transmission 71031-15-7 CATHINONE THERAPEUTIC_CLASS Central Stimulants 71031-15-7 CATHINONE PRODUCT_CLASS Central Nervous System (CNS) 71031-15-7 CATHINONE MODE_CLASS Solute transporter inhibitor 71048-87-8 LEVONANTRADOL INDICATION Nausea / Vomiting 71097-83-1 NILEPROST MODE_CLASS Receptor Agonist 71097-83-1 NILEPROST INDICATION Hypertension 71097-83-1 NILEPROST MECHANISM Modulate G-protein coupled signal transduction 71097-83-1 NILEPROST THERAPEUTIC_CLASS Antihypertensive Agents 71097-83-1 NILEPROST PRODUCT_CLASS Cardiovasculars 49864-70-2 AZACLORZINE MECHANISM Block neural transmission 49864-70-2 AZACLORZINE THERAPEUTIC_CLASS Antianginals 49864-70-2 AZACLORZINE MODE_CLASS Receptor Ligand Antagonist 49864-70-2 AZACLORZINE PRODUCT_CLASS Cardiovasculars 50432-78-5 PEMERID INDICATION Cough / Tussis 50516-43-3 NOFECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 50516-43-3 NOFECAINIDE INDICATION Cardiac Arrhythmias 50516-43-3 NOFECAINIDE PRODUCT_CLASS Cardiovasculars 50588-47-1 AMAFOLONE THERAPEUTIC_CLASS Antiarrhythmic Agents 50588-47-1 AMAFOLONE INDICATION Cardiac Arrhythmias 50588-47-1 AMAFOLONE PRODUCT_CLASS Cardiovasculars 50629-82-8 HALOMETASONE MODE_CLASS Receptor Agonist 50629-82-8 HALOMETASONE THERAPEUTIC_CLASS Corticosteroids 50629-82-8 HALOMETASONE MECHANISM Modulate gene transcription 50629-82-8 HALOMETASONE PRODUCT_CLASS Anti-inflammatories 50650-76-5 PIROCTONE INDICATION Seborrhea 50673-97-7 COLESTOLONE THERAPEUTIC_CLASS Hypolipidemic Agents 50673-97-7 COLESTOLONE PRODUCT_CLASS Cardiovasculars 50673-97-7 COLESTOLONE INDICATION Hyperlipoproteinemia 50708-95-7 TINABINOL THERAPEUTIC_CLASS Antihypertensive Agents 50708-95-7 TINABINOL PRODUCT_CLASS Cardiovasculars 50708-95-7 TINABINOL INDICATION Hypertension 50838-36-3 TOLCICLATE MODE_CLASS Enzyme Inhibitor 50838-36-3 TOLCICLATE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 50935-04-1 CARUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 50935-04-1 CARUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 50935-04-1 CARUBICIN PRODUCT_CLASS Anti-cancers 50935-04-1 CARUBICIN THERAPEUTIC_CLASS Antineoplastics 50935-04-1 CARUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 51012-32-9 TIAPRIDE ZERO_CLASS N 51012-32-9 TIAPRIDE ADVERSE_EFFECT XXX_3_Malaise 51012-32-9 TIAPRIDE ADVERSE_EFFECT END_2_Gynecomastia 51012-32-9 TIAPRIDE TA_LEVEL_1 Central Nervous System (CNS) 51012-32-9 TIAPRIDE PRODUCT_CLASS Central Nervous System (CNS) 51012-32-9 TIAPRIDE TA_LEVEL_3 Anxlytic 51012-32-9 TIAPRIDE INDICATION Delirium 51012-32-9 TIAPRIDE MECH_LEVEL_3 D2 amd D3 51012-32-9 TIAPRIDE MESH_LEVEL_1 Organic Chemicals 51012-32-9 TIAPRIDE ADVERSE_EFFECT LIV_2_Increased Serum Alkaline Phosphatase 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_2_Numbness 51012-32-9 TIAPRIDE ADVERSE_EFFECT END_2_Galactorrhea 51012-32-9 TIAPRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 51012-32-9 TIAPRIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_3_Coma 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_1_Drowsiness 51012-32-9 TIAPRIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51012-32-9 TIAPRIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 51012-32-9 TIAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 51012-32-9 TIAPRIDE MODE_CLASS Receptor Ligand Antagonist 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_2_Akathisia 51012-32-9 TIAPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 51012-32-9 TIAPRIDE MECHANISM Block neural transmission 51012-32-9 TIAPRIDE MESH_LEVEL_2 Amides 51012-32-9 TIAPRIDE TA_LEVEL_2 CNS Depressant 51012-32-9 TIAPRIDE ADVERSE_EFFECT _2_Increased libido 51012-32-9 TIAPRIDE ADVERSE_EFFECT REP_3_Altered Libido 51012-32-9 TIAPRIDE ADVERSE_EFFECT XXX_3_Thirst 51012-32-9 TIAPRIDE MESH_LEVEL_3 Benzamides 51012-32-9 TIAPRIDE MECH_LEVEL_2 5HT antagonist 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_2_Dizziness 51012-32-9 TIAPRIDE ACTIVITY_CLASS Dopamine antagonist 51012-32-9 TIAPRIDE ADVERSE_EFFECT PSY_2_Depression 51012-32-9 TIAPRIDE ADVERSE_EFFECT XXX_3_Salivation 51012-32-9 TIAPRIDE ADVERSE_EFFECT _2_Speech disorder 51012-32-9 TIAPRIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 51012-32-9 TIAPRIDE TISSUE_TOXICITY Arrhythmia 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_2_Urinary Incontinence 51012-32-9 TIAPRIDE ADVERSE_EFFECT CVS_2_Instability of Blood Pressure 51012-32-9 TIAPRIDE ADVERSE_EFFECT OTO_2_Tinnitus 51012-32-9 TIAPRIDE ADVERSE_EFFECT PSY_2_Anorexia 51012-32-9 TIAPRIDE ADVERSE_EFFECT XXX_3_Fever 51012-32-9 TIAPRIDE ADVERSE_EFFECT REP_3_Menstrual Abnormalities 51012-32-9 TIAPRIDE INDICATION Poriomania 51012-32-9 TIAPRIDE MECHANISM Modulate G-protein coupled signal transduction 51012-32-9 TIAPRIDE INDICATION Dyskinesia 51012-32-9 TIAPRIDE ADVERSE_EFFECT GIS_2_Stomatitis 51012-32-9 TIAPRIDE ADVERSE_EFFECT OCU_2_Visual Impairment 51012-32-9 TIAPRIDE ADVERSE_EFFECT CVS_2_Arrhythmia 51012-32-9 TIAPRIDE ADVERSE_EFFECT CVS_3_Chest Pain 51012-32-9 TIAPRIDE ADVERSE_EFFECT SKN_3_Pruritis 51012-32-9 TIAPRIDE THERAPEUTIC_CLASS Movement Disorders 51012-32-9 TIAPRIDE THERAPEUTIC_CLASS Antimanic Agents 51012-32-9 TIAPRIDE MECHANISM Block neural transmission 51012-32-9 TIAPRIDE ADVERSE_EFFECT BBM_2_Anemia 51012-32-9 TIAPRIDE ADVERSE_EFFECT SKN_3_Rash 51012-32-9 TIAPRIDE ADVERSE_EFFECT PSY_3_Insomnia 51012-32-9 TIAPRIDE MECH_LEVEL_1 Modulate neural transmission 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_3_Parkinsonism 51012-32-9 TIAPRIDE ADVERSE_EFFECT GIS_2_Constipation 51012-32-9 TIAPRIDE INDICATION Disorders of Aggression 51012-32-9 TIAPRIDE ADVERSE_EFFECT NEU_3_Convulsions 51012-32-9 TIAPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 51012-32-9 TIAPRIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 51012-32-9 TIAPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 51012-33-0 TIAPRIDE THERAPEUTIC_CLASS Movement Disorders 51012-33-0 TIAPRIDE TA_LEVEL_1 Central Nervous System (CNS) 51012-33-0 TIAPRIDE PRODUCT_CLASS Central Nervous System (CNS) 51012-33-0 TIAPRIDE TA_LEVEL_3 Anxlytic 51012-33-0 TIAPRIDE INDICATION Delirium 51012-33-0 TIAPRIDE MECH_LEVEL_3 D2 amd D3 51012-33-0 TIAPRIDE MESH_LEVEL_1 Organic Chemicals 51012-33-0 TIAPRIDE ACTIVITY_CLASS Dopamine antagonist 51012-33-0 TIAPRIDE ADVERSE_EFFECT LIV_2_Increased Serum Alkaline Phosphatase 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_2_Numbness 51012-33-0 TIAPRIDE ADVERSE_EFFECT END_2_Galactorrhea 51012-33-0 TIAPRIDE ADVERSE_EFFECT CVS_3_Chest Pain 51012-33-0 TIAPRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 51012-33-0 TIAPRIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 51012-33-0 TIAPRIDE ADVERSE_EFFECT PSY_2_Anorexia 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_3_Coma 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_1_Drowsiness 51012-33-0 TIAPRIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51012-33-0 TIAPRIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 51012-33-0 TIAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 51012-33-0 TIAPRIDE MODE_CLASS Receptor Ligand Antagonist 51012-33-0 TIAPRIDE ADVERSE_EFFECT SKN_3_Pruritis 51012-33-0 TIAPRIDE MECHANISM Block neural transmission 51012-33-0 TIAPRIDE INDICATION Disorders of Aggression 51012-33-0 TIAPRIDE ADVERSE_EFFECT _2_Increased libido 51012-33-0 TIAPRIDE THERAPEUTIC_CLASS Antimanic Agents 51012-33-0 TIAPRIDE MESH_LEVEL_3 Benzamides 51012-33-0 TIAPRIDE ADVERSE_EFFECT CVS_2_Arrhythmia 51012-33-0 TIAPRIDE ADVERSE_EFFECT XXX_3_Malaise 51012-33-0 TIAPRIDE ZERO_CLASS N 51012-33-0 TIAPRIDE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D) 51012-33-0 TIAPRIDE MECH_LEVEL_2 5HT antagonist 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_2_Dizziness 51012-33-0 TIAPRIDE ADVERSE_EFFECT PSY_2_Depression 51012-33-0 TIAPRIDE ADVERSE_EFFECT XXX_3_Salivation 51012-33-0 TIAPRIDE ADVERSE_EFFECT _2_Speech disorder 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_3_Parkinsonism 51012-33-0 TIAPRIDE ADVERSE_EFFECT REP_3_Menstrual Abnormalities 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_2_Akathisia 51012-33-0 TIAPRIDE ADVERSE_EFFECT GIS_2_Stomatitis 51012-33-0 TIAPRIDE ADVERSE_EFFECT OCU_2_Visual Impairment 51012-33-0 TIAPRIDE ADVERSE_EFFECT BBM_2_Anemia 51012-33-0 TIAPRIDE ADVERSE_EFFECT END_2_Gynecomastia 51012-33-0 TIAPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 51012-33-0 TIAPRIDE MECHANISM Block neural transmission 51012-33-0 TIAPRIDE MESH_LEVEL_2 Amides 51012-33-0 TIAPRIDE TA_LEVEL_2 CNS Depressant 51012-33-0 TIAPRIDE ADVERSE_EFFECT REP_3_Altered Libido 51012-33-0 TIAPRIDE ADVERSE_EFFECT XXX_3_Thirst 51012-33-0 TIAPRIDE TISSUE_TOXICITY Arrhythmia 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_2_Urinary Incontinence 51012-33-0 TIAPRIDE ADVERSE_EFFECT CVS_2_Instability of Blood Pressure 51012-33-0 TIAPRIDE ADVERSE_EFFECT OTO_2_Tinnitus 51012-33-0 TIAPRIDE ADVERSE_EFFECT XXX_3_Fever 51012-33-0 TIAPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 51012-33-0 TIAPRIDE INDICATION Poriomania 51012-33-0 TIAPRIDE MECHANISM Modulate G-protein coupled signal transduction 51012-33-0 TIAPRIDE INDICATION Dyskinesia 51012-33-0 TIAPRIDE MECH_LEVEL_1 Modulate neural transmission 51012-33-0 TIAPRIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 51012-33-0 TIAPRIDE ADVERSE_EFFECT SKN_3_Rash 51012-33-0 TIAPRIDE ADVERSE_EFFECT PSY_3_Insomnia 51012-33-0 TIAPRIDE ADVERSE_EFFECT GIS_2_Constipation 51012-33-0 TIAPRIDE ADVERSE_EFFECT NEU_3_Convulsions 51012-33-0 TIAPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 51022-73-2 ZOMETAPINE PRODUCT_CLASS Central Nervous System (CNS) 51022-73-2 ZOMETAPINE INDICATION Depression 51022-73-2 ZOMETAPINE THERAPEUTIC_CLASS Antidepressants 51022-75-4 CLIPROFEN MODE_CLASS Enzyme Inhibitor 51022-75-4 CLIPROFEN MECHANISM Inhibit eicosanoid biosynthesis 51022-75-4 CLIPROFEN PRODUCT_CLASS Anti-inflammatories 51022-75-4 CLIPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 51022-75-4 CLIPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51022-76-5 SULNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 51154-48-4 FIBRACILLIN PRODUCT_CLASS Anti-infectives 51154-48-4 FIBRACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 51154-48-4 FIBRACILLIN MODE_CLASS Enzyme Inhibitor 51154-48-4 FIBRACILLIN THERAPEUTIC_CLASS Antibacterials 51234-28-7 BENOXAPROFEN TISSUE_TOXICITY Hepatotoxicity 51234-28-7 BENOXAPROFEN MODE_CLASS Enzyme Inhibitor 51234-28-7 BENOXAPROFEN KNOWN_TOXICITY Hepatotoxicity 51234-28-7 BENOXAPROFEN TISSUE_TOXICITY Renal Papillary Necrosis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT OCU_2_Photophobia 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT LIV_1_Jaundice 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT XXX_1_Hyperbilirubinemia 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT LIV_2_Acute Hepatitis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT LIV_3_Hepatotoxicity 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GIS_2_Gut Ulceration 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GUS_3_Dysuria 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 51234-28-7 BENOXAPROFEN KNOWN_TOXICITY Nephrotoxicity 51234-28-7 BENOXAPROFEN PRODUCT_CLASS Anti-inflammatories 51234-28-7 BENOXAPROFEN INDICATION Rheumatoid Arthritis 51234-28-7 BENOXAPROFEN MECHANISM Inhibit eicosanoid biosynthesis 51234-28-7 BENOXAPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 51234-28-7 BENOXAPROFEN INDICATION Rheumatoid Arthritis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT END_3_Gynecomastia 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT XXX_3_Edema 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT PSY_1_Depression 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT BIL_3_Biliary Cirrhosis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT IMU_3_Photosensitivity 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT BBM_3_Neutropenia 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT _3_Lyell Syndrome 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT SKN_3_Hypertrichosis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT BBM_3_Anemia 51234-28-7 BENOXAPROFEN TISSUE_TOXICITY Nephrotic Syndrome 51234-28-7 BENOXAPROFEN INDICATION Osteoarthritis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GIS_1_Diarrhea 51234-28-7 BENOXAPROFEN INDICATION Osteoarthritis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GIS_3_Stomatitis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT IMU_3_Phototoxicity 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT SKN_1_Onycholysis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT PSY_1_Mental Confusion 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT PSY_2_Anorexia 51234-28-7 BENOXAPROFEN TISSUE_TOXICITY Hematuria 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT NEU_1_Headache 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GIS_1_Epigastric Pain 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT OCU_3_Blurred Vision 51234-28-7 BENOXAPROFEN ACTIVITY_CLASS Anti-inflammatory 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT KID_3_Hematuria 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT NEU_1_Dizziness 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT SKN_3_Bullous Rash 51234-28-7 BENOXAPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT KID_3_Renal Insufficiency 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT NEU_3_Optic Neuritis 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT LIV_1_Increased Serum Alkaline Phosphatase 51234-28-7 BENOXAPROFEN ADVERSE_EFFECT XXX_3_Asthenia 51322-75-9 TIZANIDINE INDICATION Spasticity 51322-75-9 TIZANIDINE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 51322-75-9 TIZANIDINE PRODUCT_CLASS Autonomic Nervous System (ANS) 51322-75-9 TIZANIDINE MODE_CLASS Receptor Partial Agonist 51322-75-9 TIZANIDINE MECHANISM Reduce muscle contractile force 51322-75-9 TIZANIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 64461-82-1 TIZANIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 64461-82-1 TIZANIDINE MECHANISM Reduce muscle contractile force 64461-82-1 TIZANIDINE PRODUCT_CLASS Autonomic Nervous System (ANS) 64461-82-1 TIZANIDINE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 64461-82-1 TIZANIDINE INDICATION Spasticity 64461-82-1 TIZANIDINE MODE_CLASS Receptor Partial Agonist 51481-62-0 BUCAINIDE INDICATION Cardiac Arrhythmias 51481-62-0 BUCAINIDE PRODUCT_CLASS Cardiovasculars 51481-62-0 BUCAINIDE THERAPEUTIC_CLASS Antidepressants 51481-62-0 BUCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 51481-62-0 BUCAINIDE PRODUCT_CLASS Central Nervous System (CNS) 51481-62-0 BUCAINIDE INDICATION Depression 51543-39-6 ESFLURBIPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 51543-39-6 ESFLURBIPROFEN PRODUCT_CLASS Anti-inflammatories 51543-39-6 ESFLURBIPROFEN MODE_CLASS Enzyme Inhibitor 51543-39-6 ESFLURBIPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51543-39-6 ESFLURBIPROFEN MECHANISM Inhibit eicosanoid biosynthesis 51579-82-9 AMFENAC PRODUCT_CLASS Anti-inflammatories 51579-82-9 AMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51579-82-9 AMFENAC MODE_CLASS Enzyme Inhibitor 51579-82-9 AMFENAC MECHANISM Inhibit eicosanoid biosynthesis 61618-27-7 AMFENAC MECHANISM Inhibit eicosanoid biosynthesis 61618-27-7 AMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 61618-27-7 AMFENAC MODE_CLASS Enzyme Inhibitor 61618-27-7 AMFENAC PRODUCT_CLASS Anti-inflammatories 69267-51-2 AMFENAC MODE_CLASS Enzyme Inhibitor 69267-51-2 AMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 69267-51-2 AMFENAC PRODUCT_CLASS Anti-inflammatories 69267-51-2 AMFENAC MECHANISM Inhibit eicosanoid biosynthesis 61941-56-8 AMFENAC MECHANISM Inhibit eicosanoid biosynthesis 61941-56-8 AMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 61941-56-8 AMFENAC MODE_CLASS Enzyme Inhibitor 61941-56-8 AMFENAC PRODUCT_CLASS Anti-inflammatories 51627-14-6 CEFATRIZINE MECHANISM Inhibit bacterial cell wall biosynthesis 51627-14-6 CEFATRIZINE MODE_CLASS Enzyme Inhibitor 51627-14-6 CEFATRIZINE PRODUCT_CLASS Anti-infectives 51627-14-6 CEFATRIZINE THERAPEUTIC_CLASS Antibacterials 51627-20-4 CEFAPAROLE PRODUCT_CLASS Anti-infectives 51627-20-4 CEFAPAROLE MODE_CLASS Enzyme Inhibitor 51627-20-4 CEFAPAROLE THERAPEUTIC_CLASS Antibacterials 51627-20-4 CEFAPAROLE MECHANISM Inhibit bacterial cell wall biosynthesis 51762-05-1 CEFROXADINE PRODUCT_CLASS Anti-infectives 51762-05-1 CEFROXADINE MECHANISM Inhibit bacterial cell wall biosynthesis 51762-05-1 CEFROXADINE MODE_CLASS Enzyme Inhibitor 51762-05-1 CEFROXADINE THERAPEUTIC_CLASS Antibacterials 51876-98-3 GLIAMILIDE INDICATION Diabetes 51953-95-8 DOXAPROST MECHANISM Modulate G-protein coupled signal transduction 51953-95-8 DOXAPROST MODE_CLASS Receptor Agonist 52231-20-6 CEFROTIL MECHANISM Inhibit bacterial cell wall biosynthesis 52231-20-6 CEFROTIL THERAPEUTIC_CLASS Antibacterials 52231-20-6 CEFROTIL MODE_CLASS Enzyme Inhibitor 52231-20-6 CEFROTIL PRODUCT_CLASS Anti-infectives 52247-86-6 CICLOXOLONE INDICATION Herpes Genitalis / Genital Herpes 52279-59-1 MOXNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 52549-17-4 PRANOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 52549-17-4 PRANOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 52549-17-4 PRANOPROFEN MODE_CLASS Enzyme Inhibitor 52549-17-4 PRANOPROFEN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 52549-17-4 PRANOPROFEN INDICATION Ocular Inflammation 52758-02-8 BENZAPRINOXIDE INDICATION Depression 52758-02-8 BENZAPRINOXIDE THERAPEUTIC_CLASS Antidepressants 52758-02-8 BENZAPRINOXIDE PRODUCT_CLASS Central Nervous System (CNS) 52942-31-1 ETOPERIDONE MODE_CLASS Receptor Ligand Antagonist 52942-31-1 ETOPERIDONE STRUCTURE_ACTIVITY 5HT2 antagonist 52942-31-1 ETOPERIDONE MECHANISM Modulate neural transmission 52942-31-1 ETOPERIDONE THERAPEUTIC_CLASS Antidepressants 52942-31-1 ETOPERIDONE PRODUCT_CLASS Central Nervous System (CNS) 52942-31-1 ETOPERIDONE MECHANISM Reduce vasoconstriction 52942-31-1 ETOPERIDONE INDICATION Depression 53076-26-9 MOXAPRINDINE PRODUCT_CLASS Cardiovasculars 53076-26-9 MOXAPRINDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 53076-26-9 MOXAPRINDINE INDICATION Cardiac Arrhythmias 53086-13-8 DEXINDOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 53086-13-8 DEXINDOPROFEN PRODUCT_CLASS Anti-inflammatories 53086-13-8 DEXINDOPROFEN MODE_CLASS Enzyme Inhibitor 53086-13-8 DEXINDOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 53086-13-8 DEXINDOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 53179-07-0 NISOXETINE INDICATION Depression 53179-07-0 NISOXETINE PRODUCT_CLASS Central Nervous System (CNS) 53179-07-0 NISOXETINE THERAPEUTIC_CLASS Antidepressants 53267-01-9 CIFENLINE PRODUCT_CLASS Cardiovasculars 53267-01-9 CIFENLINE THERAPEUTIC_CLASS Antiarrhythmic Agents 53267-01-9 CIFENLINE MECHANISM Trigger insulin release in pancreatic beta cells 53267-01-9 CIFENLINE INDICATION Cardiac Arrhythmias 53267-01-9 CIFENLINE MODE_CLASS Channel Blocker 100678-32-8 CIFENLINE INDICATION Cardiac Arrhythmias 100678-32-8 CIFENLINE MECHANISM Trigger insulin release in pancreatic beta cells 100678-32-8 CIFENLINE PRODUCT_CLASS Cardiovasculars 100678-32-8 CIFENLINE MODE_CLASS Channel Blocker 100678-32-8 CIFENLINE THERAPEUTIC_CLASS Antiarrhythmic Agents 53684-49-4 BUFETOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 53684-49-4 BUFETOLOL INDICATION Cardiac Arrhythmias 53684-49-4 BUFETOLOL PRODUCT_CLASS Cardiovasculars 53736-52-0 CROMITRILE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 53736-52-0 CROMITRILE PRODUCT_CLASS Respiratory System 53736-52-0 CROMITRILE INDICATION Asthma 53772-83-1 ZUCLOPENTHIXOL MECHANISM Block neural transmission 53772-83-1 ZUCLOPENTHIXOL MODE_CLASS Receptor Ligand Antagonist 53808-88-1 LONAZOLAC MODE_CLASS Enzyme Inhibitor 53808-88-1 LONAZOLAC MECHANISM Inhibit steroid biosynthesis/ metabolism 53808-88-1 LONAZOLAC MECHANISM Inhibit eicosanoid biosynthesis 98647-62-2 LONAZOLAC MODE_CLASS Enzyme Inhibitor 98647-62-2 LONAZOLAC MECHANISM Inhibit eicosanoid biosynthesis 98647-62-2 LONAZOLAC MECHANISM Inhibit steroid biosynthesis/ metabolism 75821-71-5 LONAZOLAC MODE_CLASS Enzyme Inhibitor 75821-71-5 LONAZOLAC MECHANISM Inhibit steroid biosynthesis/ metabolism 75821-71-5 LONAZOLAC MECHANISM Inhibit eicosanoid biosynthesis 53882-12-5 LODOXAMIDE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 53882-12-5 LODOXAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 53882-12-5 LODOXAMIDE INDICATION Vernal Keratoconjunctivitis 53882-12-5 LODOXAMIDE INDICATION Keratitis 53882-13-6 LODOXAMIDE ETHYL THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 53882-13-6 LODOXAMIDE ETHYL PRODUCT_CLASS Respiratory System 53882-13-6 LODOXAMIDE ETHYL INDICATION Asthma 53966-34-0 FLOXACRINE INDICATION Malaria 54063-45-5 FETOXYLATE MODE_CLASS Channel Blocker 54063-45-5 FETOXYLATE THERAPEUTIC_CLASS Antidiarrhea Agents 54063-45-5 FETOXYLATE MECHANISM Modulate neural transmission 54063-45-5 FETOXYLATE MECHANISM Reduce muscle contractile force 54063-45-5 FETOXYLATE MODE_CLASS Receptor Agonist 54063-45-5 FETOXYLATE PRODUCT_CLASS Gastrointestinal System 54063-54-6 REPROTEROL MECHANISM Reduce bronchoconstriction 54063-54-6 REPROTEROL MODE_CLASS Receptor Agonist, selective 13055-82-8 REPROTEROL MODE_CLASS Receptor Agonist, selective 13055-82-8 REPROTEROL MECHANISM Reduce bronchoconstriction 54083-22-6 ZORUBICIN THERAPEUTIC_CLASS Antineoplastics 54083-22-6 ZORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 54083-22-6 ZORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 54083-22-6 ZORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 54083-22-6 ZORUBICIN PRODUCT_CLASS Anti-cancers 36508-71-1 ZORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 36508-71-1 ZORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 36508-71-1 ZORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 36508-71-1 ZORUBICIN PRODUCT_CLASS Anti-cancers 36508-71-1 ZORUBICIN THERAPEUTIC_CLASS Antineoplastics 54188-38-4 METRALINDOLE PRODUCT_CLASS Central Nervous System (CNS) 54188-38-4 METRALINDOLE THERAPEUTIC_CLASS Antidepressants 54188-38-4 METRALINDOLE INDICATION Depression 54340-62-4 BUFURALOL MECHANISM Modulate G-protein coupled signal transduction 54419-31-7 FENIROFIBRATE INDICATION Hyperlipoproteinemia 54419-31-7 FENIROFIBRATE PRODUCT_CLASS Cardiovasculars 54419-31-7 FENIROFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 54533-85-6 NIZOFENONE MECHANISM Scavenges hydrogen peroxide and free radicals 54533-85-6 NIZOFENONE INDICATION Hypoxia 54533-85-6 NIZOFENONE MODE_CLASS Channel Blocker 54533-85-6 NIZOFENONE MECHANISM Block channel gating 54533-86-7 NIZOFENONE MECHANISM Scavenges hydrogen peroxide and free radicals 54533-86-7 NIZOFENONE INDICATION Hypoxia 54533-86-7 NIZOFENONE MECHANISM Block channel gating 54533-86-7 NIZOFENONE MODE_CLASS Channel Blocker 93929-95-4 NIZOFENONE MECHANISM Scavenges hydrogen peroxide and free radicals 93929-95-4 NIZOFENONE INDICATION Hypoxia 93929-95-4 NIZOFENONE MECHANISM Block channel gating 93929-95-4 NIZOFENONE MODE_CLASS Channel Blocker 55149-05-8 PIROLATE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 55149-05-8 PIROLATE PRODUCT_CLASS Respiratory System 55149-05-8 PIROLATE INDICATION Asthma 55165-22-5 BUTOCROLOL MECHANISM Modulate G-protein coupled signal transduction 55248-23-2 NEBIDRAZINE INDICATION Hypotension 55285-45-5 PIRIFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 55285-45-5 PIRIFIBRATE INDICATION Hyperlipoproteinemia 55285-45-5 PIRIFIBRATE PRODUCT_CLASS Cardiovasculars 55294-15-0 MUZOLIMINE INDICATION Hypertension 55294-15-0 MUZOLIMINE PRODUCT_CLASS Cardiovasculars 55294-15-0 MUZOLIMINE THERAPEUTIC_CLASS Antihypertensive Agents 55432-15-0 PIRINIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 55694-98-9 CICLAFRINE INDICATION Hypotension 55779-18-5 ARPRINOCID MECHANISM Enhance kinase mediated signal transduction 55779-18-5 ARPRINOCID MODE_CLASS Enzyme Inhibitor 55837-19-9 EXAPROLOL MODE_CLASS Receptor Ligand Antagonist 55837-19-9 EXAPROLOL MECHANISM Modulate G-protein coupled signal transduction 55902-94-8 SITOFIBRATE PRODUCT_CLASS Cardiovasculars 55902-94-8 SITOFIBRATE INDICATION Hyperlipoproteinemia 55902-94-8 SITOFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 55905-53-8 CLEBOPRIDE PRODUCT_CLASS Gastrointestinal System 55905-53-8 CLEBOPRIDE MECHANISM Block neural transmission 55905-53-8 CLEBOPRIDE MODE_CLASS Receptor Ligand Antagonist, Selective 55905-53-8 CLEBOPRIDE THERAPEUTIC_CLASS Antispasmodic Agents 55926-23-3 GUANCLOFINE INDICATION Hypertension 55926-23-3 GUANCLOFINE PRODUCT_CLASS Cardiovasculars 55926-23-3 GUANCLOFINE THERAPEUTIC_CLASS Antihypertensive Agents 55937-99-0 BECLOBRATE INDICATION Hyperlipoproteinemia 55937-99-0 BECLOBRATE PRODUCT_CLASS Cardiovasculars 55937-99-0 BECLOBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 55975-92-3 PIRBENICILLIN PRODUCT_CLASS Anti-infectives 55975-92-3 PIRBENICILLIN MODE_CLASS Enzyme Inhibitor 55975-92-3 PIRBENICILLIN THERAPEUTIC_CLASS Antibacterials 55975-92-3 PIRBENICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 55986-43-1 CETABEN PRODUCT_CLASS Cardiovasculars 55986-43-1 CETABEN THERAPEUTIC_CLASS Hypolipidemic Agents 55986-43-1 CETABEN INDICATION Hyperlipoproteinemia 56079-81-3 ROPITOIN PRODUCT_CLASS Central Nervous System (CNS) 56079-81-3 ROPITOIN THERAPEUTIC_CLASS Antidepressants 56079-81-3 ROPITOIN THERAPEUTIC_CLASS Antiarrhythmic Agents 56079-81-3 ROPITOIN PRODUCT_CLASS Cardiovasculars 56079-81-3 ROPITOIN INDICATION Depression 56079-81-3 ROPITOIN INDICATION Cardiac Arrhythmias 56187-89-4 XIMOPROFEN MODE_CLASS Enzyme Inhibitor 56187-89-4 XIMOPROFEN PRODUCT_CLASS Anti-inflammatories 56187-89-4 XIMOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 56187-89-4 XIMOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 56208-01-6 PIFARNINE INDICATION Ulcer 56211-43-9 TAMETICILLIN THERAPEUTIC_CLASS Antibacterials 56211-43-9 TAMETICILLIN PRODUCT_CLASS Anti-infectives 56211-43-9 TAMETICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 56211-43-9 TAMETICILLIN MODE_CLASS Enzyme Inhibitor 56290-94-9 MEDROXALOL THERAPEUTIC_CLASS Antihypertensive Agents 56290-94-9 MEDROXALOL INDICATION Hypertension 56290-94-9 MEDROXALOL MECHANISM Modulate G-protein coupled signal transduction 56290-94-9 MEDROXALOL PRODUCT_CLASS Cardiovasculars 56341-08-3 MABUTEROL MECHANISM Reduce bronchoconstriction 56341-08-3 MABUTEROL MODE_CLASS Receptor Agonist 54240-36-7 MABUTEROL MODE_CLASS Receptor Agonist 54240-36-7 MABUTEROL MECHANISM Reduce bronchoconstriction 56355-17-0 ZOLIPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 56355-17-0 ZOLIPROFEN PRODUCT_CLASS Anti-inflammatories 56355-17-0 ZOLIPROFEN MODE_CLASS Enzyme Inhibitor 56355-17-0 ZOLIPROFEN MECHANISM Inhibit eicosanoid biosynthesis 56488-58-5 TIZOLEMIDE THERAPEUTIC_CLASS Antihypertensive Agents 56488-58-5 TIZOLEMIDE PRODUCT_CLASS Cardiovasculars 56488-58-5 TIZOLEMIDE INDICATION Hypertension 56717-18-1 ISOTIQUIMIDE INDICATION Ulcer 56824-20-5 AMIPRILOSE THERAPEUTIC_CLASS Immunosuppressants 56824-20-5 AMIPRILOSE PRODUCT_CLASS Immune Response / Immunomodulators 56824-20-5 AMIPRILOSE INDICATION Arthritis 56980-93-9 CELIPROLOL INDICATION Hypertension 56980-93-9 CELIPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 56980-93-9 CELIPROLOL MECHANISM Reduce muscle contractile force 56980-93-9 CELIPROLOL MECHANISM Modulate G-protein coupled signal transduction 56980-93-9 CELIPROLOL MODE_CLASS Receptor Partial Agonist 56980-93-9 CELIPROLOL THERAPEUTIC_CLASS Antianginals 56980-93-9 CELIPROLOL PRODUCT_CLASS Cardiovasculars 56980-93-9 CELIPROLOL INDICATION Angina Pectoris 56980-93-9 CELIPROLOL MODE_CLASS Receptor Ligand Antagonist, Selective 57470-78-7 CELIPROLOL MODE_CLASS Receptor Ligand Antagonist, Selective 57470-78-7 CELIPROLOL MODE_CLASS Receptor Partial Agonist 57470-78-7 CELIPROLOL MECHANISM Modulate G-protein coupled signal transduction 57470-78-7 CELIPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 57470-78-7 CELIPROLOL INDICATION Hypertension 57470-78-7 CELIPROLOL PRODUCT_CLASS Cardiovasculars 57470-78-7 CELIPROLOL THERAPEUTIC_CLASS Antianginals 57470-78-7 CELIPROLOL MECHANISM Reduce muscle contractile force 57470-78-7 CELIPROLOL INDICATION Angina Pectoris 57010-31-8 TIAPAMIL MODE_CLASS Channel Blocker 57010-31-8 TIAPAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 57010-31-8 TIAPAMIL MECHANISM Block neural transmission 57010-31-8 TIAPAMIL INDICATION Hypertension 57010-31-8 TIAPAMIL MECHANISM Reduce muscle contractile force 57010-31-8 TIAPAMIL INDICATION Cardiac Arrhythmias 57010-31-8 TIAPAMIL THERAPEUTIC_CLASS Antihypertensive Agents 57010-31-8 TIAPAMIL PRODUCT_CLASS Cardiovasculars 57067-46-6 ISAMOXOLE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 57067-46-6 ISAMOXOLE PRODUCT_CLASS Respiratory System 57067-46-6 ISAMOXOLE INDICATION Asthma 57296-63-6 INDACRINONE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 57296-63-6 INDACRINONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 57296-63-6 INDACRINONE THERAPEUTIC_CLASS Diuretics 57296-63-6 INDACRINONE MODE_CLASS Channel Blocker, selective 57435-86-6 PREMAZEPAM MECHANISM Modulate neural transmission 57435-86-6 PREMAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 57435-86-6 PREMAZEPAM THERAPEUTIC_CLASS Anxiolytics 57435-86-6 PREMAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 57435-86-6 PREMAZEPAM MODE_CLASS Channel enhancer /opener 57475-17-9 BROVINCAMINE MECHANISM Block channel gating 57475-17-9 BROVINCAMINE MODE_CLASS Channel Blocker 84964-12-5 BROVINCAMINE MECHANISM Block channel gating 84964-12-5 BROVINCAMINE MODE_CLASS Channel Blocker 57524-89-7 HYDROCORTISONE VALERATE MECHANISM Modulate gene transcription 57524-89-7 HYDROCORTISONE VALERATE MODE_CLASS Channel enhancer /opener 57526-81-5 PRENALTEROL MECHANISM Modulate G-protein coupled signal transduction 57548-79-5 PICAFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 57548-79-5 PICAFIBRATE INDICATION Hyperlipoproteinemia 57548-79-5 PICAFIBRATE PRODUCT_CLASS Cardiovasculars 57576-44-0 ACLARUBICIN ADVERSE_EFFECT IMU_3_Anaphylaxis 57576-44-0 ACLARUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Mutagenicity 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Necrotizing Colitis 57576-44-0 ACLARUBICIN KNOWN_TOXICITY Mutagenicity 57576-44-0 ACLARUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 57576-44-0 ACLARUBICIN KNOWN_TOXICITY Neurotoxicity 57576-44-0 ACLARUBICIN ADVERSE_EFFECT NEU_1_Peripheral Neurotoxicity 57576-44-0 ACLARUBICIN ADVERSE_EFFECT XXX_2_Radiosensitization 57576-44-0 ACLARUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 57576-44-0 ACLARUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 57576-44-0 ACLARUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Carcinogenicity 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Myelosuppression 57576-44-0 ACLARUBICIN KNOWN_TOXICITY Carcinogenicity 57576-44-0 ACLARUBICIN KNOWN_TOXICITY Gastrointestinal Toxicity 57576-44-0 ACLARUBICIN PRODUCT_CLASS Anti-cancers 57576-44-0 ACLARUBICIN INDICATION Acute Lymphocytic Leukemia (ALL) 57576-44-0 ACLARUBICIN INDICATION Blastic crisis of chronic myeloid leukemia 57576-44-0 ACLARUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 57576-44-0 ACLARUBICIN THERAPEUTIC_CLASS Antineoplastics 57576-44-0 ACLARUBICIN ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 57576-44-0 ACLARUBICIN ADVERSE_EFFECT XXX_1_Mucositis 57576-44-0 ACLARUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 57576-44-0 ACLARUBICIN ADVERSE_EFFECT IMU_2_Urticaria 57576-44-0 ACLARUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Cardiotoxicity 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Hemorrhage 57576-44-0 ACLARUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 57576-44-0 ACLARUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 57576-44-0 ACLARUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 57576-44-0 ACLARUBICIN ADVERSE_EFFECT XXX_1_Infection 57576-44-0 ACLARUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Cardiomyopathy 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Peripheral Neurotoxicity 57576-44-0 ACLARUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 57576-44-0 ACLARUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 57576-44-0 ACLARUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 57576-44-0 ACLARUBICIN TISSUE_TOXICITY Congestive Heart Failure 57576-44-0 ACLARUBICIN ADVERSE_EFFECT GIS_1_Necrotizing Colitis 57576-44-0 ACLARUBICIN ADVERSE_EFFECT CVS_1_Myocardial Damage 57576-44-0 ACLARUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 57775-26-5 SULTOSILIC ACID PRODUCT_CLASS Cardiovasculars 57775-26-5 SULTOSILIC ACID INDICATION Hyperlipoproteinemia 57775-26-5 SULTOSILIC ACID THERAPEUTIC_CLASS Hypolipidemic Agents 57775-29-8 CARAZOLOL MECHANISM Reduce muscle contractile force 57775-29-8 CARAZOLOL MECHANISM Modulate G-protein coupled signal transduction 57775-29-8 CARAZOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 57847-69-5 CEFEDROLOR PRODUCT_CLASS Anti-infectives 57847-69-5 CEFEDROLOR MECHANISM Inhibit bacterial cell wall biosynthesis 57847-69-5 CEFEDROLOR MODE_CLASS Enzyme Inhibitor 57847-69-5 CEFEDROLOR THERAPEUTIC_CLASS Antibacterials 57925-64-1 NAPRODOXIME INDICATION Disorders of Aggression 58152-03-7 ISEPAMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 58152-03-7 ISEPAMICIN PRODUCT_CLASS Anti-infectives 58152-03-7 ISEPAMICIN THERAPEUTIC_CLASS Antibacterials 58152-03-7 ISEPAMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 58152-03-7 ISEPAMICIN MECHANISM Inhibit ribosomal protein synthesis 58182-63-1 ITANOXONE THERAPEUTIC_CLASS Hypolipidemic Agents 58182-63-1 ITANOXONE PRODUCT_CLASS Cardiovasculars 58182-63-1 ITANOXONE INDICATION Hyperlipoproteinemia 58239-89-7 MOXAZOCINE INDICATION Cough / Tussis 36556-75-9 BUCUMOLOL MODE_CLASS Receptor Agonist, Non-selective 36556-75-9 BUCUMOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 36556-75-9 BUCUMOLOL MECHANISM Reduce muscle contractile force 36556-75-9 BUCUMOLOL MECHANISM Modulate G-protein coupled signal transduction 36556-75-9 BUCUMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 36556-75-9 BUCUMOLOL PRODUCT_CLASS Cardiovasculars 36556-75-9 BUCUMOLOL THERAPEUTIC_CLASS Antianginals 58473-73-7 DROBULINE PRODUCT_CLASS Cardiovasculars 58473-73-7 DROBULINE THERAPEUTIC_CLASS Antidepressants 58473-73-7 DROBULINE INDICATION Depression 58473-73-7 DROBULINE PRODUCT_CLASS Central Nervous System (CNS) 58473-73-7 DROBULINE INDICATION Cardiac Arrhythmias 58473-73-7 DROBULINE THERAPEUTIC_CLASS Antiarrhythmic Agents 58503-82-5 AZIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 58503-82-5 AZIPRAMINE MODE_CLASS Solute transporter inhibitor 58503-82-5 AZIPRAMINE MECHANISM Prolong/enhance neural transmission 58503-82-5 AZIPRAMINE THERAPEUTIC_CLASS Antidepressants 58503-82-5 AZIPRAMINE INDICATION Depression 58665-96-6 CEFAZAFLUR MODE_CLASS Enzyme Inhibitor 58665-96-6 CEFAZAFLUR THERAPEUTIC_CLASS Antibacterials 58665-96-6 CEFAZAFLUR MECHANISM Inhibit bacterial cell wall biosynthesis 58665-96-6 CEFAZAFLUR PRODUCT_CLASS Anti-infectives 58691-88-6 NOMEGESTROL PRODUCT_CLASS Anti-cancers 58691-88-6 NOMEGESTROL MECHANISM Inhibit steroid biosynthesis/ metabolism 58691-88-6 NOMEGESTROL MODE_CLASS Enzyme Inhibitor 58691-88-6 NOMEGESTROL THERAPEUTIC_CLASS Antineoplastics 58765-21-2 CICLOTIZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 59009-93-7 CARBURAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 59009-93-7 CARBURAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 59009-93-7 CARBURAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 59009-93-7 CARBURAZEPAM MECHANISM Modulate neural transmission 59009-93-7 CARBURAZEPAM MODE_CLASS Channel enhancer /opener 59010-44-5 PRIZIDILOL THERAPEUTIC_CLASS Antihypertensive Agents 59010-44-5 PRIZIDILOL PRODUCT_CLASS Cardiovasculars 59010-44-5 PRIZIDILOL INDICATION Hypertension 59070-07-4 TICARCILLIN CRESYL PRODUCT_CLASS Anti-infectives 59070-07-4 TICARCILLIN CRESYL MECHANISM Inhibit bacterial cell wall biosynthesis 59070-07-4 TICARCILLIN CRESYL THERAPEUTIC_CLASS Antibacterials 59070-07-4 TICARCILLIN CRESYL MODE_CLASS Enzyme Inhibitor 59091-65-5 DELERGOTRILE STRUCTURE_ACTIVITY Ergot alkaloid 59110-35-9 PAMATOLOL MECHANISM Reduce muscle contractile force 59110-35-9 PAMATOLOL MECHANISM Modulate G-protein coupled signal transduction 59110-35-9 PAMATOLOL MODE_CLASS Receptor Ligand Antagonist 32953-89-2 RIMITEROL PRODUCT_CLASS Autonomic Nervous System (ANS) 32953-89-2 RIMITEROL THERAPEUTIC_CLASS Sympathomimetic Agents 32953-89-2 RIMITEROL MODE_CLASS Receptor Agonist, selective 32953-89-2 RIMITEROL MECHANISM Reduce bronchoconstriction 32953-89-2 RIMITEROL PRODUCT_CLASS Respiratory System 32953-89-2 RIMITEROL INDICATION Asthma 32953-89-2 RIMITEROL THERAPEUTIC_CLASS Bronchodilators 32988-50-4 VIOMYCIN INDICATION Tuberculosis 33005-95-7 TIAPROFENIC ACID MECHANISM Inhibit eicosanoid biosynthesis 33005-95-7 TIAPROFENIC ACID MODE_CLASS Enzyme Inhibitor 33490-33-4 CAPREOMYCIN 1B INDICATION Tuberculosis 33671-46-4 CLOTIAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 33671-46-4 CLOTIAZEPAM MECHANISM Modulate neural transmission 33671-46-4 CLOTIAZEPAM THERAPEUTIC_CLASS Anxiolytics 33671-46-4 CLOTIAZEPAM MODE_CLASS Channel enhancer /opener 33671-46-4 CLOTIAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 33743-96-3 PROROXAN PRODUCT_CLASS Central Nervous System (CNS) 33743-96-3 PROROXAN MECHANISM Modulate G-protein coupled signal transduction 33765-68-3 OXENDOLONE MODE_CLASS Receptor Ligand Antagonist 33765-68-3 OXENDOLONE MECHANISM Modulate gene transcription 33817-20-8 PIVAMPICILLIN MODE_CLASS Enzyme Inhibitor 33817-20-8 PIVAMPICILLIN PRODUCT_CLASS Anti-infectives 33817-20-8 PIVAMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 33817-20-8 PIVAMPICILLIN THERAPEUTIC_CLASS Antibacterials 34042-85-8 SUDOXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 34042-85-8 SUDOXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 34042-85-8 SUDOXICAM PRODUCT_CLASS Anti-inflammatories 34184-77-5 PROMEGESTONE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 34184-77-5 PROMEGESTONE ADVERSE_EFFECT PSY_3_Depression 34184-77-5 PROMEGESTONE INDICATION Luteal Phase Insufficiency 34184-77-5 PROMEGESTONE MODE_CLASS Receptor Agonist 34184-77-5 PROMEGESTONE ADVERSE_EFFECT XXX_3_Weight Gain 34184-77-5 PROMEGESTONE THERAPEUTIC_CLASS Gonadal Hormones 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GUS_2_Vaginal Dryness 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GIS_1_Nausea 34184-77-5 PROMEGESTONE ADVERSE_EFFECT SKN_2_Pruritis 34184-77-5 PROMEGESTONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GUS_2_Vaginal Bleeding 34184-77-5 PROMEGESTONE INDICATION Dysmenorrhea 34184-77-5 PROMEGESTONE ADVERSE_EFFECT PSY_1_Nervousness 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GIS_2_Epigastric Pain 34184-77-5 PROMEGESTONE ADVERSE_EFFECT LIV_3_Jaundice 34184-77-5 PROMEGESTONE ADVERSE_EFFECT SKN_2_Seborrhoeic Dermatosis 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GIS_1_Vomiting 34184-77-5 PROMEGESTONE KNOWN_TOXICITY Mutagenicity 34184-77-5 PROMEGESTONE ADVERSE_EFFECT SKN_2_Skin Eruption 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GUS_2_Vaginal Spotting 34184-77-5 PROMEGESTONE ADVERSE_EFFECT SKN_2_Dry Skin 34184-77-5 PROMEGESTONE ADVERSE_EFFECT GUS_1_Vaginal Discharge 34184-77-5 PROMEGESTONE ADVERSE_EFFECT NEU_2_Headache 34184-77-5 PROMEGESTONE ADVERSE_EFFECT DNA_3_Mutagenicity 34184-77-5 PROMEGESTONE INDICATION Premenstrual Syndrome / Premenstrual Tension 34184-77-5 PROMEGESTONE MECHANISM Modulate gene transcription 34184-77-5 PROMEGESTONE INDICATION Uterine Bleeding 34184-77-5 PROMEGESTONE TISSUE_TOXICITY Mutagenicity 34184-77-5 PROMEGESTONE ADVERSE_EFFECT XXX_3_Edema 34184-77-5 PROMEGESTONE ADVERSE_EFFECT SKN_3_Chloasma 34184-77-5 PROMEGESTONE ADVERSE_EFFECT REP_1_Menstrual Abnormalities 34184-77-5 PROMEGESTONE ADVERSE_EFFECT PSY_1_Insomnia 34184-77-5 PROMEGESTONE ADVERSE_EFFECT REP_3_Decreased Libido 34552-84-6 ISOXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 34552-84-6 ISOXICAM PRODUCT_CLASS Anti-inflammatories 34552-84-6 ISOXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 34645-84-6 FENCLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 34645-84-6 FENCLOFENAC PRODUCT_CLASS Anti-inflammatories 34675-84-8 CETRAXATE ZERO_CLASS N 34675-84-8 CETRAXATE THERAPEUTIC_CLASS Antiulcers 34675-84-8 CETRAXATE MESH_LEVEL_3 Acids, Carbocyclic 34675-84-8 CETRAXATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 34675-84-8 CETRAXATE MECH_LEVEL_2 Enzyme inhibitor 34675-84-8 CETRAXATE INDICATION Gastric Ulcer 34675-84-8 CETRAXATE TA_LEVEL_2 anti-ulcer 34675-84-8 CETRAXATE ADVERSE_EFFECT SKN_3_Rash 34675-84-8 CETRAXATE STRUCTURE_ACTIVITY Increase gastric mucosal glycoprotein synthesis, molecular target unknown 34675-84-8 CETRAXATE MESH_LEVEL_2 Carboxylic Acids 34675-84-8 CETRAXATE INDICATION Gastritis 34675-84-8 CETRAXATE ADVERSE_EFFECT CVS_3_Thrombosis 34675-84-8 CETRAXATE ACTIVITY_CLASS Increase gastric mucosal glycoprotein synthesis, molecular target unknown 34675-84-8 CETRAXATE TA_LEVEL_3 gastric ulcer 34675-84-8 CETRAXATE TA_LEVEL_1 Gastrointestinal System 34675-84-8 CETRAXATE PRODUCT_CLASS Gastrointestinal System 34675-84-8 CETRAXATE KNOWN_TOXICITY Cardiovascular Toxicity 34675-84-8 CETRAXATE ADVERSE_EFFECT GIS_3_Constipation 34675-84-8 CETRAXATE ADVERSE_EFFECT GIS_3_Gastrointestinal Distress 34675-84-8 CETRAXATE INDICATION Ulcer 34675-84-8 CETRAXATE MESH_LEVEL_1 Organic Chemicals 34675-84-8 CETRAXATE MECH_LEVEL_3 plasmin 34675-84-8 CETRAXATE ADVERSE_EFFECT GIS_3_Diarrhea 34675-84-8 CETRAXATE ADVERSE_EFFECT SKN_3_Pruritis 34675-84-8 CETRAXATE TISSUE_TOXICITY Thrombosis 34779-28-7 SULBENICILLIN PRODUCT_CLASS Anti-infectives 34779-28-7 SULBENICILLIN THERAPEUTIC_CLASS Antibacterials 34779-28-7 SULBENICILLIN MODE_CLASS Enzyme Inhibitor 34779-28-7 SULBENICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 28002-18-8 SULBENICILLIN THERAPEUTIC_CLASS Antibacterials 28002-18-8 SULBENICILLIN MODE_CLASS Enzyme Inhibitor 28002-18-8 SULBENICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 28002-18-8 SULBENICILLIN PRODUCT_CLASS Anti-infectives 34919-98-7 CETAMOLOL MODE_CLASS Receptor Partial Agonist 34919-98-7 CETAMOLOL MODE_CLASS Receptor Ligand Antagonist 34919-98-7 CETAMOLOL MECHANISM Reduce muscle contractile force 34919-98-7 CETAMOLOL MECHANISM Modulate G-protein coupled signal transduction 34966-41-1 CARTAZOLATE THERAPEUTIC_CLASS Sedatives/Hypnotics 34966-41-1 CARTAZOLATE INDICATION Depression 34966-41-1 CARTAZOLATE PRODUCT_CLASS Central Nervous System (CNS) 34966-41-1 CARTAZOLATE INDICATION Anxiety Disorders 34966-41-1 CARTAZOLATE THERAPEUTIC_CLASS Antidepressants 34976-39-1 TIOXACIN THERAPEUTIC_CLASS Antibacterials 34976-39-1 TIOXACIN PRODUCT_CLASS Anti-infectives 34976-39-1 TIOXACIN MECHANISM Inhibit bacterial DNA synthesis 34976-39-1 TIOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 34976-39-1 TIOXACIN MODE_CLASS Enzyme Inhibitor, selective 35035-05-3 TIMEPIDIUM BROMIDE MECHANISM Modulate G-protein coupled signal transduction 35035-05-3 TIMEPIDIUM BROMIDE MODE_CLASS Receptor Ligand Antagonist 35067-47-1 DROXACIN MECHANISM Inhibit bacterial DNA synthesis 35067-47-1 DROXACIN THERAPEUTIC_CLASS Antibacterials 35067-47-1 DROXACIN MODE_CLASS Enzyme Inhibitor, selective 35067-47-1 DROXACIN PRODUCT_CLASS Anti-infectives 35067-47-1 DROXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 35135-67-2 CORMETHASONE ACETATE MODE_CLASS Receptor Agonist 35135-67-2 CORMETHASONE ACETATE PRODUCT_CLASS Anti-inflammatories 35135-67-2 CORMETHASONE ACETATE MECHANISM Modulate gene transcription 35135-67-2 CORMETHASONE ACETATE THERAPEUTIC_CLASS Corticosteroids 35273-88-2 GLIFLUMIDE INDICATION Diabetes 35322-07-7 FOSAZEPAM MECHANISM Modulate neural transmission 35322-07-7 FOSAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 35322-07-7 FOSAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 35322-07-7 FOSAZEPAM MODE_CLASS Channel enhancer /opener 35322-07-7 FOSAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 35423-51-9 TISOCROMIDE PRODUCT_CLASS Central Nervous System (CNS) 35423-51-9 TISOCROMIDE THERAPEUTIC_CLASS Antidepressants 35423-51-9 TISOCROMIDE INDICATION Depression 35449-36-6 GEMCADIOL INDICATION Hyperlipoproteinemia 35449-36-6 GEMCADIOL PRODUCT_CLASS Cardiovasculars 35449-36-6 GEMCADIOL THERAPEUTIC_CLASS Hypolipidemic Agents 35531-88-5 CARBENICILLIN INDANYL INDICATION Prostatitis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT BBM_3_Decreased Platelet Function 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT BBM_3_Leukopenia 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT ELT_2_Hypokalemia 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT KID_3_Interstitial Nephritis 35531-88-5 CARBENICILLIN INDANYL INDICATION Urinary Tract Infection (UTI) 35531-88-5 CARBENICILLIN INDANYL MODE_CLASS Enzyme Inhibitor 35531-88-5 CARBENICILLIN INDANYL TISSUE_TOXICITY Interstitial Nephritis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT IMU_3_Anaphylaxis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 35531-88-5 CARBENICILLIN INDANYL PRODUCT_CLASS Anti-infectives 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT KID_3_Nephrotic Syndrome 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT PSY_1_Anorexia 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT XXX_3_Candidiasis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT BBM_3_Thrombocytopenia 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT KID_2_Fluid Retention 35531-88-5 CARBENICILLIN INDANYL TISSUE_TOXICITY Nephrotic Syndrome 35531-88-5 CARBENICILLIN INDANYL STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 35531-88-5 CARBENICILLIN INDANYL INDICATION Proteus Infections 35531-88-5 CARBENICILLIN INDANYL MECHANISM Inhibit bacterial cell wall biosynthesis 35531-88-5 CARBENICILLIN INDANYL TISSUE_TOXICITY Renal Tubular Necrosis 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT XXX_2_Drug Fever 35531-88-5 CARBENICILLIN INDANYL THERAPEUTIC_CLASS Antibacterials, Systemic 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT SKN_2_Skin Rash 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT BBM_3_Bleeding 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT BBM_3_Anemia 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 35531-88-5 CARBENICILLIN INDANYL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 35531-88-5 CARBENICILLIN INDANYL KNOWN_TOXICITY Nephrotoxicity 35531-88-5 CARBENICILLIN INDANYL INDICATION Pseudomonas Aeruginosa Infection 35554-44-0 ENILCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 35554-44-0 ENILCONAZOLE MODE_CLASS Enzyme Inhibitor 35578-20-2 OXARBAZOLE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 35578-20-2 OXARBAZOLE PRODUCT_CLASS Respiratory System 35578-20-2 OXARBAZOLE INDICATION Asthma 35700-21-1 CARBOPROST METHYL MODE_CLASS Receptor Agonist 35700-21-1 CARBOPROST METHYL MECHANISM Modulate G-protein coupled signal transduction 35764-73-9 FLUOTRACEN PRODUCT_CLASS Central Nervous System (CNS) 35764-73-9 FLUOTRACEN THERAPEUTIC_CLASS Antidepressants 35764-73-9 FLUOTRACEN INDICATION Depression 35795-16-5 TRIMAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 35795-16-5 TRIMAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 35795-16-5 TRIMAZOSIN INDICATION Hypertension 35795-16-5 TRIMAZOSIN THERAPEUTIC_CLASS Vasodilators 35795-16-5 TRIMAZOSIN PRODUCT_CLASS Cardiovasculars 35795-16-5 TRIMAZOSIN MECHANISM Reduce vasoconstriction 35795-16-5 TRIMAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 53746-46-6 TRIMAZOSIN PRODUCT_CLASS Cardiovasculars 53746-46-6 TRIMAZOSIN MECHANISM Reduce vasoconstriction 53746-46-6 TRIMAZOSIN INDICATION Hypertension 53746-46-6 TRIMAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 53746-46-6 TRIMAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 53746-46-6 TRIMAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 53746-46-6 TRIMAZOSIN THERAPEUTIC_CLASS Vasodilators 35795-17-6 TRIMAZOSIN INDICATION Hypertension 35795-17-6 TRIMAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 35795-17-6 TRIMAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 35795-17-6 TRIMAZOSIN THERAPEUTIC_CLASS Vasodilators 35795-17-6 TRIMAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 35795-17-6 TRIMAZOSIN PRODUCT_CLASS Cardiovasculars 35795-17-6 TRIMAZOSIN MECHANISM Reduce vasoconstriction 35846-53-8 MAYTANSINE INDICATION Leukemia 35898-87-4 DILAZEP MECHANISM Ehance adenosine-mediated vasodilation 35898-87-4 DILAZEP MODE_CLASS Solute transporter inhibitor 35941-65-2 BUTRIPTYLINE MODE_CLASS Solute transporter inhibitor 35941-65-2 BUTRIPTYLINE INDICATION Depression 35941-65-2 BUTRIPTYLINE MECHANISM Prolong/enhance neural transmission 35941-65-2 BUTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 35941-65-2 BUTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 5585-73-9 BUTRIPTYLINE MODE_CLASS Solute transporter inhibitor 5585-73-9 BUTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 5585-73-9 BUTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 5585-73-9 BUTRIPTYLINE MECHANISM Prolong/enhance neural transmission 5585-73-9 BUTRIPTYLINE INDICATION Depression 36067-73-9 AZEPEXOLE PRODUCT_CLASS Cardiovasculars 36067-73-9 AZEPEXOLE THERAPEUTIC_CLASS Antihypertensive Agents 36067-73-9 AZEPEXOLE INDICATION Hypertension 36199-78-7 GUAFECAINOL INDICATION Cardiac Arrhythmias 36199-78-7 GUAFECAINOL PRODUCT_CLASS Cardiovasculars 36199-78-7 GUAFECAINOL THERAPEUTIC_CLASS Antiarrhythmic Agents 36330-85-5 FENBUFEN MODE_CLASS Enzyme Inhibitor 36330-85-5 FENBUFEN MECHANISM Inhibit eicosanoid biosynthesis 36471-39-3 NUCLOTIXENE INDICATION Depression 36471-39-3 NUCLOTIXENE THERAPEUTIC_CLASS Antidepressants 36471-39-3 NUCLOTIXENE PRODUCT_CLASS Central Nervous System (CNS) 36499-65-7 DICOBALT EDETATE INDICATION Cyanide (CN) Poisoning 36688-78-5 CLINDAMYCIN PALMITATE THERAPEUTIC_CLASS Antibacterials 36688-78-5 CLINDAMYCIN PALMITATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 36688-78-5 CLINDAMYCIN PALMITATE PRODUCT_CLASS Anti-infectives 36688-78-5 CLINDAMYCIN PALMITATE MECHANISM Inhibit ribosomal protein synthesis 36889-15-3 BETAMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 36889-15-3 BETAMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 36889-15-3 BETAMICIN PRODUCT_CLASS Anti-infectives 36889-15-3 BETAMICIN THERAPEUTIC_CLASS Antibacterials 36889-15-3 BETAMICIN MECHANISM Inhibit ribosomal protein synthesis 36920-48-6 CEFOXAZOLE THERAPEUTIC_CLASS Antibacterials 36920-48-6 CEFOXAZOLE PRODUCT_CLASS Anti-infectives 36920-48-6 CEFOXAZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 36920-48-6 CEFOXAZOLE MODE_CLASS Enzyme Inhibitor 36945-03-6 LERGOTRILE STRUCTURE_ACTIVITY Ergot alkaloid 36950-96-6 CICLOPROFEN MODE_CLASS Enzyme Inhibitor 36950-96-6 CICLOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 36950-96-6 CICLOPROFEN PRODUCT_CLASS Anti-inflammatories 36950-96-6 CICLOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 36980-34-4 GLICARAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 36980-34-4 GLICARAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 36980-34-4 GLICARAMIDE INDICATION Type II Diabetes Mellitus 36980-34-4 GLICARAMIDE MODE_CLASS Channel Blocker, selective 36980-34-4 GLICARAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 36980-34-4 GLICARAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 37065-29-5 MILOXACIN MODE_CLASS Enzyme Inhibitor, selective 37065-29-5 MILOXACIN PRODUCT_CLASS Anti-infectives 37065-29-5 MILOXACIN THERAPEUTIC_CLASS Antibacterials 37065-29-5 MILOXACIN MECHANISM Inhibit bacterial DNA synthesis 37065-29-5 MILOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 37087-94-8 TIBRIC ACID THERAPEUTIC_CLASS Hypolipidemic Agents 37087-94-8 TIBRIC ACID INDICATION Hyperlipoproteinemia 37087-94-8 TIBRIC ACID PRODUCT_CLASS Cardiovasculars 37091-66-0 AZLOCILLIN INDICATION Lower Respiratory Tract Infection 37091-66-0 AZLOCILLIN INDICATION Gram-negative Septicemia 37091-66-0 AZLOCILLIN INDICATION Gram-negative Sepsis 37091-66-0 AZLOCILLIN INDICATION Pseudomonas Aeruginosa Infection 37091-66-0 AZLOCILLIN TISSUE_TOXICITY Hepatotoxicity 37091-66-0 AZLOCILLIN TA_LEVEL_1 Infectious Disease 37091-66-0 AZLOCILLIN ADVERSE_EFFECT SKN_2_Exanthema 37091-66-0 AZLOCILLIN ADVERSE_EFFECT IMU_3_Periarteritis Nodosa 37091-66-0 AZLOCILLIN KNOWN_TOXICITY Hepatotoxicity 37091-66-0 AZLOCILLIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 37091-66-0 AZLOCILLIN MESH_LEVEL_3 Lactams 37091-66-0 AZLOCILLIN INDICATION Urinary Tract Infection (UTI) 37091-66-0 AZLOCILLIN PRODUCT_CLASS Anti-infectives 37091-66-0 AZLOCILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 37091-66-0 AZLOCILLIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 37091-66-0 AZLOCILLIN ADVERSE_EFFECT BBM_2_Leukopenia 37091-66-0 AZLOCILLIN ADVERSE_EFFECT IMU_2_Eosinophilia 37091-66-0 AZLOCILLIN ZERO_CLASS N 37091-66-0 AZLOCILLIN MECH_LEVEL_2 Enzyme Inhibitor 37091-66-0 AZLOCILLIN MESH_LEVEL_2 Amides 37091-66-0 AZLOCILLIN ADVERSE_EFFECT IMU_2_Hypersensitivity 37091-66-0 AZLOCILLIN MODE_CLASS Enzyme Inhibitor 37091-66-0 AZLOCILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 37091-66-0 AZLOCILLIN ADVERSE_EFFECT XXX_1_Fever 37091-66-0 AZLOCILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 37091-66-0 AZLOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 37091-66-0 AZLOCILLIN MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 37091-66-0 AZLOCILLIN MESH_LEVEL_1 Organic Chemicals 37091-66-0 AZLOCILLIN TA_LEVEL_2 Anti-bacterial 37091-66-0 AZLOCILLIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 37091-65-9 AZLOCILLIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 37091-65-9 AZLOCILLIN KNOWN_TOXICITY Hepatotoxicity 37091-65-9 AZLOCILLIN ADVERSE_EFFECT IMU_3_Periarteritis Nodosa 37091-65-9 AZLOCILLIN ADVERSE_EFFECT SKN_2_Exanthema 37091-65-9 AZLOCILLIN ADVERSE_EFFECT XXX_1_Fever 37091-65-9 AZLOCILLIN INDICATION Pseudomonas Aeruginosa Infection 37091-65-9 AZLOCILLIN INDICATION Gram-negative Sepsis 37091-65-9 AZLOCILLIN INDICATION Gram-negative Septicemia 37091-65-9 AZLOCILLIN TA_LEVEL_1 Infectious Disease 37091-65-9 AZLOCILLIN TISSUE_TOXICITY Hepatotoxicity 37091-65-9 AZLOCILLIN TA_LEVEL_2 Anti-bacterial 37091-65-9 AZLOCILLIN ADVERSE_EFFECT BBM_2_Leukopenia 37091-65-9 AZLOCILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 37091-65-9 AZLOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 37091-65-9 AZLOCILLIN MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 37091-65-9 AZLOCILLIN MESH_LEVEL_1 Organic Chemicals 37091-65-9 AZLOCILLIN INDICATION Lower Respiratory Tract Infection 37091-65-9 AZLOCILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 37091-65-9 AZLOCILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 37091-65-9 AZLOCILLIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 37091-65-9 AZLOCILLIN ADVERSE_EFFECT IMU_2_Hypersensitivity 37091-65-9 AZLOCILLIN MESH_LEVEL_2 Amides 37091-65-9 AZLOCILLIN MECH_LEVEL_2 Enzyme Inhibitor 37091-65-9 AZLOCILLIN ZERO_CLASS N 37091-65-9 AZLOCILLIN ADVERSE_EFFECT IMU_2_Eosinophilia 37091-65-9 AZLOCILLIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 37091-65-9 AZLOCILLIN MODE_CLASS Enzyme Inhibitor 37091-65-9 AZLOCILLIN PRODUCT_CLASS Anti-infectives 37091-65-9 AZLOCILLIN INDICATION Urinary Tract Infection (UTI) 37091-65-9 AZLOCILLIN MESH_LEVEL_3 Lactams 37115-32-5 ADINAZOLAM THERAPEUTIC_CLASS Anxiolytics 37115-32-5 ADINAZOLAM MODE_CLASS Channel enhancer /opener 37115-32-5 ADINAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 37115-32-5 ADINAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 37115-32-5 ADINAZOLAM MECHANISM Modulate neural transmission 37115-32-5 ADINAZOLAM THERAPEUTIC_CLASS Antidepressants 37321-09-8 APRAMYCIN PRODUCT_CLASS Anti-infectives 37321-09-8 APRAMYCIN THERAPEUTIC_CLASS Antibacterials 37321-09-8 APRAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 37321-09-8 APRAMYCIN MECHANISM Inhibit ribosomal protein synthesis 37321-09-8 APRAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 37517-26-3 PIPOTIAZINE PALMITATE MODE_CLASS Receptor Ligand Antagonist 37517-26-3 PIPOTIAZINE PALMITATE MECHANISM Block neural transmission 37517-26-3 PIPOTIAZINE PALMITATE PRODUCT_CLASS Central Nervous System (CNS) 37517-26-3 PIPOTIAZINE PALMITATE THERAPEUTIC_CLASS Antipsychotics 37561-27-6 FENOVERINE PRODUCT_CLASS Gastrointestinal System 37561-27-6 FENOVERINE MODE_CLASS Receptor Ligand Antagonist 37561-27-6 FENOVERINE THERAPEUTIC_CLASS Antispasmodic Agents 37561-27-6 FENOVERINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 37561-27-6 FENOVERINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 37561-27-6 FENOVERINE MECHANISM Block neural transmission 37640-71-4 APRINDINE INDICATION Cardiac Arrhythmias 37640-71-4 APRINDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 37640-71-4 APRINDINE PRODUCT_CLASS Central Nervous System (CNS) 37640-71-4 APRINDINE MECHANISM Modulate channel gating 37640-71-4 APRINDINE INDICATION Depression 37640-71-4 APRINDINE PRODUCT_CLASS Cardiovasculars 37640-71-4 APRINDINE THERAPEUTIC_CLASS Antidepressants 37640-71-4 APRINDINE MODE_CLASS Channel Modulator 37681-00-8 COUMAZOLINE MECHANISM Modulate G-protein coupled signal transduction 37751-39-6 CICLAZINDOL INDICATION Depression 37751-39-6 CICLAZINDOL PRODUCT_CLASS Central Nervous System (CNS) 37751-39-6 CICLAZINDOL THERAPEUTIC_CLASS Antidepressants 38081-67-3 CARMANTADINE MECHANISM Block channel gating 38081-67-3 CARMANTADINE THERAPEUTIC_CLASS Movement Disorders 38081-67-3 CARMANTADINE PRODUCT_CLASS Anti-infectives 38081-67-3 CARMANTADINE MODE_CLASS Channel Blocker, selective 38081-67-3 CARMANTADINE PRODUCT_CLASS Central Nervous System (CNS) 38081-67-3 CARMANTADINE THERAPEUTIC_CLASS Antivirals, Systemic 38103-61-6 TOLAMOLOL INDICATION Cardiac Arrhythmias 38103-61-6 TOLAMOLOL MECHANISM Modulate G-protein coupled signal transduction 38103-61-6 TOLAMOLOL PRODUCT_CLASS Central Nervous System (CNS) 38103-61-6 TOLAMOLOL PRODUCT_CLASS Cardiovasculars 38103-61-6 TOLAMOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 38103-61-6 TOLAMOLOL INDICATION Depression 38103-61-6 TOLAMOLOL THERAPEUTIC_CLASS Antidepressants 38103-61-6 TOLAMOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 38274-54-3 BENURESTAT MECHANISM Inhibit precursor synthesis 38274-54-3 BENURESTAT PRODUCT_CLASS Electrolytic, Caloric and Water Balance 38274-54-3 BENURESTAT MODE_CLASS Enzyme Inhibitor 38274-54-3 BENURESTAT INDICATION Urinary Stone Disease / Urinary Calculi 38647-79-9 UREFIBRATE PRODUCT_CLASS Cardiovasculars 38647-79-9 UREFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 38647-79-9 UREFIBRATE INDICATION Hyperlipoproteinemia 38677-85-9 FLUNIXIN PRODUCT_CLASS Anti-inflammatories 38677-85-9 FLUNIXIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 39133-31-8 TRIMEBUTINE MODE_CLASS Receptor Agonist, selective 39133-31-8 TRIMEBUTINE MODE_CLASS Channel Modulator 39133-31-8 TRIMEBUTINE MECHANISM Modulate channel gating 39133-31-8 TRIMEBUTINE MECHANISM Modulate neural transmission 34140-59-5 TRIMEBUTINE MODE_CLASS Channel Modulator 34140-59-5 TRIMEBUTINE MECHANISM Modulate channel gating 34140-59-5 TRIMEBUTINE MODE_CLASS Receptor Agonist, selective 34140-59-5 TRIMEBUTINE MECHANISM Modulate neural transmission 39133-32-9 TRIMEBUTINE MODE_CLASS Receptor Agonist, selective 39133-32-9 TRIMEBUTINE MECHANISM Modulate channel gating 39133-32-9 TRIMEBUTINE MODE_CLASS Channel Modulator 39133-32-9 TRIMEBUTINE MECHANISM Modulate neural transmission 39186-49-7 PIROLAZAMIDE PRODUCT_CLASS Central Nervous System (CNS) 39186-49-7 PIROLAZAMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 39186-49-7 PIROLAZAMIDE INDICATION Cardiac Arrhythmias 39186-49-7 PIROLAZAMIDE THERAPEUTIC_CLASS Antidepressants 39186-49-7 PIROLAZAMIDE INDICATION Depression 39186-49-7 PIROLAZAMIDE PRODUCT_CLASS Cardiovasculars 39516-21-7 TIOPROPAMINE INDICATION Ulcer 39552-01-7 BEFUNOLOL INDICATION Hypertension 39552-01-7 BEFUNOLOL THERAPEUTIC_CLASS Antihypertensive Agents 39552-01-7 BEFUNOLOL PRODUCT_CLASS Cardiovasculars 39552-01-7 BEFUNOLOL INDICATION Angina Pectoris 39552-01-7 BEFUNOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 39552-01-7 BEFUNOLOL MECHANISM Modulate G-protein coupled signal transduction 39552-01-7 BEFUNOLOL THERAPEUTIC_CLASS Antianginals 39552-01-7 BEFUNOLOL INDICATION Glaucoma 39552-01-7 BEFUNOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 39552-01-7 BEFUNOLOL MODE_CLASS Receptor Partial Agonist 39543-79-8 BEFUNOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 39543-79-8 BEFUNOLOL INDICATION Angina Pectoris 39543-79-8 BEFUNOLOL INDICATION Hypertension 39543-79-8 BEFUNOLOL THERAPEUTIC_CLASS Antianginals 39543-79-8 BEFUNOLOL MECHANISM Modulate G-protein coupled signal transduction 39543-79-8 BEFUNOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 39543-79-8 BEFUNOLOL PRODUCT_CLASS Cardiovasculars 39543-79-8 BEFUNOLOL THERAPEUTIC_CLASS Antihypertensive Agents 39543-79-8 BEFUNOLOL INDICATION Glaucoma 39543-79-8 BEFUNOLOL MODE_CLASS Receptor Partial Agonist 39640-15-8 PIBERALINE THERAPEUTIC_CLASS Antidepressants 39640-15-8 PIBERALINE PRODUCT_CLASS Central Nervous System (CNS) 39640-15-8 PIBERALINE INDICATION Depression 39715-02-1 ENDRALAZINE PRODUCT_CLASS Cardiovasculars 39715-02-1 ENDRALAZINE INDICATION Hypertension 39715-02-1 ENDRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 39832-48-9 TAZOLOL MECHANISM Modulate G-protein coupled signal transduction 39832-48-9 TAZOLOL MODE_CLASS Receptor Agonist, selective 39907-68-1 DOPAMANTINE INDICATION Parkinson's Disease 39951-65-0 LOMETRALINE INDICATION Parkinson's Disease 40034-42-2 ROSOXACIN THERAPEUTIC_CLASS Antibacterials 40034-42-2 ROSOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 40034-42-2 ROSOXACIN MECHANISM Inhibit bacterial DNA synthesis 40034-42-2 ROSOXACIN MODE_CLASS Enzyme Inhibitor, selective 40034-42-2 ROSOXACIN PRODUCT_CLASS Anti-infectives 40180-04-9 TICRYNAFEN INDICATION Hypertension 40180-04-9 TICRYNAFEN KNOWN_TOXICITY Nephrotoxicity 40180-04-9 TICRYNAFEN ADVERSE_EFFECT ELT_2_Hypochloremia 40180-04-9 TICRYNAFEN ADVERSE_EFFECT GIS_2_Dyspepsia 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_2_Decreased Triglycerides 40180-04-9 TICRYNAFEN ADVERSE_EFFECT KID_3_Acute Renal Failure 40180-04-9 TICRYNAFEN ADVERSE_EFFECT IMU_3_Urticaria 40180-04-9 TICRYNAFEN ADVERSE_EFFECT CVS_3_Premature Atrial Contractions 40180-04-9 TICRYNAFEN ADVERSE_EFFECT LIV_2_Liver Dysfunction 40180-04-9 TICRYNAFEN ADVERSE_EFFECT ELT_1_Hypokalemia 40180-04-9 TICRYNAFEN THERAPEUTIC_CLASS Congestive Heart Failure 40180-04-9 TICRYNAFEN ZERO_CLASS N 40180-04-9 TICRYNAFEN INDICATION Congestive Heart Failure (CHF) 40180-04-9 TICRYNAFEN ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_2_Metabolic Alkalosis 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_1_Hypouricemia 40180-04-9 TICRYNAFEN TISSUE_TOXICITY Interstitial Nephritis 40180-04-9 TICRYNAFEN ADVERSE_EFFECT XXX_2_Fatigue 40180-04-9 TICRYNAFEN ADVERSE_EFFECT XXX_2_Diaphoresis 40180-04-9 TICRYNAFEN ADVERSE_EFFECT PSY_2_Anorexia 40180-04-9 TICRYNAFEN TISSUE_TOXICITY Hepatotoxicity 40180-04-9 TICRYNAFEN TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 40180-04-9 TICRYNAFEN MODE_CLASS Channel Blocker 40180-04-9 TICRYNAFEN STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, ticrynafen like, loop diuretic 40180-04-9 TICRYNAFEN INDICATION Hypertension 40180-04-9 TICRYNAFEN TISSUE_TOXICITY Acute Renal Failure 40180-04-9 TICRYNAFEN ADVERSE_EFFECT SKN_3_Pruritis 40180-04-9 TICRYNAFEN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_2_Increased HDL 40180-04-9 TICRYNAFEN ADVERSE_EFFECT LIV_2_Hepatotoxicity 40180-04-9 TICRYNAFEN ADVERSE_EFFECT GIS_2_Diarrhea 40180-04-9 TICRYNAFEN ADVERSE_EFFECT GIS_2_Constipation 40180-04-9 TICRYNAFEN MODE_CLASS Solute transporter inhibitor 40180-04-9 TICRYNAFEN ADVERSE_EFFECT SKN_3_Skin Rash 40180-04-9 TICRYNAFEN ADVERSE_EFFECT NEU_2_Numbness 40180-04-9 TICRYNAFEN ADVERSE_EFFECT KID_3_Interstitial Nephritis 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_1_Hyperglycemia 40180-04-9 TICRYNAFEN KNOWN_TOXICITY Cardiovascular Toxicity 40180-04-9 TICRYNAFEN PRODUCT_CLASS Cardiovasculars 40180-04-9 TICRYNAFEN ACTIVITY_CLASS Diuretic 40180-04-9 TICRYNAFEN ADVERSE_EFFECT NEU_1_Dizziness 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_2_Decreased LDL 40180-04-9 TICRYNAFEN ADVERSE_EFFECT END_3_Acute Gouty Arthritis 40180-04-9 TICRYNAFEN THERAPEUTIC_CLASS Antihypertensive Agents 40180-04-9 TICRYNAFEN INDICATION Congestive Heart Failure (CHF) 40180-04-9 TICRYNAFEN KNOWN_TOXICITY Hepatotoxicity 40180-04-9 TICRYNAFEN MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 40198-53-6 TIOXAPROFEN MODE_CLASS Enzyme Inhibitor 40198-53-6 TIOXAPROFEN MECHANISM Inhibit eicosanoid biosynthesis 40198-53-6 TIOXAPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 40198-53-6 TIOXAPROFEN PRODUCT_CLASS Anti-inflammatories 40507-23-1 FLUPROQUAZONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 40507-23-1 FLUPROQUAZONE PRODUCT_CLASS Anti-inflammatories 40507-23-1 FLUPROQUAZONE MECHANISM Enhance kinase mediated signal transduction 40507-23-1 FLUPROQUAZONE INDICATION Pain 40507-23-1 FLUPROQUAZONE ADVERSE_EFFECT GIS__Gastrointestinal Irritation 40507-23-1 FLUPROQUAZONE INDICATION Fever 40507-23-1 FLUPROQUAZONE ADVERSE_EFFECT GIS__Vomiting 40507-23-1 FLUPROQUAZONE ADVERSE_EFFECT BBM__Inhibits Platelet Aggregation 40507-23-1 FLUPROQUAZONE INDICATION Inflammation 40507-23-1 FLUPROQUAZONE MODE_CLASS Enzyme Inhibitor 40507-23-1 FLUPROQUAZONE ADVERSE_EFFECT PSY__Insomnia 40507-23-1 FLUPROQUAZONE ADVERSE_EFFECT GIS__Gastrointestinal Disturbances 40507-23-1 FLUPROQUAZONE THERAPEUTIC_CLASS Analgesics, Non-Opioid 40507-23-1 FLUPROQUAZONE STRUCTURE_ACTIVITY PDE inhibitor 40507-23-1 FLUPROQUAZONE MECHANISM Inhibit eicosanoid biosynthesis 40507-23-1 FLUPROQUAZONE ADVERSE_EFFECT GIS__Abdominal Pain 40507-23-1 FLUPROQUAZONE PRODUCT_CLASS Analgesics 40507-78-6 INDANAZOLINE INDICATION Nasal Congestion 40507-78-6 INDANAZOLINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 40759-33-9 NOLINIUM BROMIDE INDICATION Ulcer 40762-15-0 DOXEFAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 40762-15-0 DOXEFAZEPAM INDICATION Insomnia 40762-15-0 DOXEFAZEPAM MODE_CLASS Channel enhancer /opener 40762-15-0 DOXEFAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 40762-15-0 DOXEFAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 40762-15-0 DOXEFAZEPAM MECHANISM Modulate neural transmission 40966-79-8 SARPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 40966-79-8 SARPICILLIN MODE_CLASS Enzyme Inhibitor 40966-79-8 SARPICILLIN THERAPEUTIC_CLASS Antibacterials 40966-79-8 SARPICILLIN PRODUCT_CLASS Anti-infectives 41020-79-5 DICIRENONE INDICATION Hypotension 41473-09-0 FENMETOZOLE INDICATION Depression 41473-09-0 FENMETOZOLE PRODUCT_CLASS Central Nervous System (CNS) 41473-09-0 FENMETOZOLE THERAPEUTIC_CLASS Antidepressants 41717-30-0 BEFURALINE THERAPEUTIC_CLASS Antidepressants 41717-30-0 BEFURALINE INDICATION Depression 41717-30-0 BEFURALINE PRODUCT_CLASS Central Nervous System (CNS) 41952-52-7 CEFCANEL MECHANISM Inhibit bacterial cell wall biosynthesis 41952-52-7 CEFCANEL PRODUCT_CLASS Anti-infectives 41952-52-7 CEFCANEL MODE_CLASS Enzyme Inhibitor 41952-52-7 CEFCANEL THERAPEUTIC_CLASS Antibacterials 92602-21-6 CEFCANEL MECHANISM Inhibit bacterial cell wall biosynthesis 92602-21-6 CEFCANEL THERAPEUTIC_CLASS Antibacterials 92602-21-6 CEFCANEL MODE_CLASS Enzyme Inhibitor 92602-21-6 CEFCANEL PRODUCT_CLASS Anti-infectives 41964-07-2 TOLIMIDONE INDICATION Ulcer 42024-98-6 MAZATICOL INDICATION Parkinson's Disease 42024-98-6 MAZATICOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 42024-98-6 MAZATICOL MECHANISM Modulate G-protein coupled signal transduction 32891-29-5 MAZATICOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 32891-29-5 MAZATICOL INDICATION Parkinson's Disease 32891-29-5 MAZATICOL MECHANISM Modulate G-protein coupled signal transduction 42050-23-7 NAFETOLOL INDICATION Cardiac Arrhythmias 42050-23-7 NAFETOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 42050-23-7 NAFETOLOL PRODUCT_CLASS Cardiovasculars 42116-76-7 CARNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 42408-79-7 PIRANDAMINE INDICATION Depression 42408-79-7 PIRANDAMINE THERAPEUTIC_CLASS Antidepressants 42408-79-7 PIRANDAMINE PRODUCT_CLASS Central Nervous System (CNS) 42408-80-0 TANDAMINE PRODUCT_CLASS Central Nervous System (CNS) 42408-80-0 TANDAMINE THERAPEUTIC_CLASS Antidepressants 42408-80-0 TANDAMINE INDICATION Depression 42597-57-9 RONIFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 42597-57-9 RONIFIBRATE INDICATION Hyperlipoproteinemia 42597-57-9 RONIFIBRATE PRODUCT_CLASS Cardiovasculars 42779-82-8 CLOPIRAC PRODUCT_CLASS Anti-inflammatories 42779-82-8 CLOPIRAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 42835-25-6 FLUMEQUINE THERAPEUTIC_CLASS Antibacterials 42835-25-6 FLUMEQUINE MECHANISM Inhibit bacterial DNA synthesis 42835-25-6 FLUMEQUINE MODE_CLASS Enzyme Inhibitor, selective 42835-25-6 FLUMEQUINE PRODUCT_CLASS Anti-infectives 42835-25-6 FLUMEQUINE STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 42863-81-0 LOPIRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 42863-81-0 LOPIRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 42863-81-0 LOPIRAZEPAM MECHANISM Modulate neural transmission 42863-81-0 LOPIRAZEPAM THERAPEUTIC_CLASS Anxiolytics 42863-81-0 LOPIRAZEPAM MODE_CLASS Channel enhancer /opener 42879-47-0 PRANOLIUM CHLORIDE INDICATION Depression 42879-47-0 PRANOLIUM CHLORIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 42879-47-0 PRANOLIUM CHLORIDE THERAPEUTIC_CLASS Antidepressants 42879-47-0 PRANOLIUM CHLORIDE PRODUCT_CLASS Cardiovasculars 42879-47-0 PRANOLIUM CHLORIDE INDICATION Cardiac Arrhythmias 42879-47-0 PRANOLIUM CHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 45086-03-1 ETOFORMIN MECHANISM Inhibit absorption of dietary carbohydrates 45086-03-1 ETOFORMIN STRUCTURE_ACTIVITY AMP kinase activator 45086-03-1 ETOFORMIN THERAPEUTIC_CLASS Antidiabetic Agents 45086-03-1 ETOFORMIN INDICATION Type II Diabetes Mellitus 45086-03-1 ETOFORMIN MODE_CLASS Channel Blocker 45086-03-1 ETOFORMIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 46464-11-3 MEOBENTINE THERAPEUTIC_CLASS Antidepressants 46464-11-3 MEOBENTINE THERAPEUTIC_CLASS Antiarrhythmic Agents 46464-11-3 MEOBENTINE PRODUCT_CLASS Cardiovasculars 46464-11-3 MEOBENTINE PRODUCT_CLASS Central Nervous System (CNS) 46464-11-3 MEOBENTINE INDICATION Depression 46464-11-3 MEOBENTINE INDICATION Cardiac Arrhythmias 46817-91-8 VILOXAZINE MODE_CLASS Solute transporter inhibitor 46817-91-8 VILOXAZINE THERAPEUTIC_CLASS Antidepressants 46817-91-8 VILOXAZINE MECHANISM Prolong/enhance neural transmission 46817-91-8 VILOXAZINE MODE_CLASS Enzyme Inhibitor 46817-91-8 VILOXAZINE MECHANISM Modulate G-protein coupled signal transduction 46817-91-8 VILOXAZINE PRODUCT_CLASS Central Nervous System (CNS) 46817-91-8 VILOXAZINE INDICATION Depression 46817-91-8 VILOXAZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 35604-67-2 VILOXAZINE MECHANISM Modulate G-protein coupled signal transduction 35604-67-2 VILOXAZINE PRODUCT_CLASS Central Nervous System (CNS) 35604-67-2 VILOXAZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 35604-67-2 VILOXAZINE INDICATION Depression 35604-67-2 VILOXAZINE MODE_CLASS Enzyme Inhibitor 35604-67-2 VILOXAZINE MECHANISM Prolong/enhance neural transmission 35604-67-2 VILOXAZINE THERAPEUTIC_CLASS Antidepressants 35604-67-2 VILOXAZINE MODE_CLASS Solute transporter inhibitor 47029-84-5 DAZADROL INDICATION Depression 47029-84-5 DAZADROL PRODUCT_CLASS Central Nervous System (CNS) 47029-84-5 DAZADROL THERAPEUTIC_CLASS Antidepressants 47082-97-3 PARGOLOL MODE_CLASS Receptor Ligand Antagonist 47082-97-3 PARGOLOL MECHANISM Reduce muscle contractile force 47082-97-3 PARGOLOL MECHANISM Modulate G-protein coupled signal transduction 47166-67-6 OCTRIPTYLINE INDICATION Depression 47166-67-6 OCTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 47166-67-6 OCTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 47166-67-6 OCTRIPTYLINE MECHANISM Prolong/enhance neural transmission 47166-67-6 OCTRIPTYLINE MODE_CLASS Solute transporter inhibitor 47543-65-7 PRENOXDIAZINE INDICATION Cough / Tussis 47662-15-7 SUXEMERID INDICATION Cough / Tussis 47739-98-0 CLOCAPRAMINE MODE_CLASS Solute transporter inhibitor 47739-98-0 CLOCAPRAMINE MECHANISM Prolong/enhance neural transmission 47739-98-0 CLOCAPRAMINE THERAPEUTIC_CLASS Antipsychotics 47739-98-0 CLOCAPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 28058-62-0 CLOCAPRAMINE MODE_CLASS Solute transporter inhibitor 28058-62-0 CLOCAPRAMINE THERAPEUTIC_CLASS Antipsychotics 28058-62-0 CLOCAPRAMINE MECHANISM Prolong/enhance neural transmission 28058-62-0 CLOCAPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 47747-56-8 TAMAMPICILLIN THERAPEUTIC_CLASS Antibacterials 47747-56-8 TAMAMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 47747-56-8 TAMAMPICILLIN PRODUCT_CLASS Anti-infectives 47747-56-8 TAMAMPICILLIN MODE_CLASS Enzyme Inhibitor 48141-64-6 ETAFEDRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 48141-64-6 ETAFEDRINE MECHANISM Modulate G-protein coupled signal transduction 49720-72-1 DESACETYLCOLCHICINE TARTRATE STRUCTURE_ACTIVITY Tubulin binder, colchicinoid 49720-72-1 DESACETYLCOLCHICINE TARTRATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 49720-72-1 DESACETYLCOLCHICINE TARTRATE THERAPEUTIC_CLASS Gout-Related Agents 21730-16-5 METAPRAMINE MECHANISM Prolong/enhance neural transmission 21730-16-5 METAPRAMINE THERAPEUTIC_CLASS Antidepressants 21730-16-5 METAPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 21730-16-5 METAPRAMINE MODE_CLASS Solute transporter inhibitor 21730-16-5 METAPRAMINE INDICATION Depression 21755-66-8 PICOPERINE INDICATION Cough / Tussis 22103-14-6 BUFENIODE PRODUCT_CLASS Cardiovasculars 22103-14-6 BUFENIODE INDICATION Hypertension 22103-14-6 BUFENIODE THERAPEUTIC_CLASS Antihypertensive Agents 22131-79-9 ALCLOFENAC PRODUCT_CLASS Anti-inflammatories 22131-79-9 ALCLOFENAC MODE_CLASS Enzyme Inhibitor 22131-79-9 ALCLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 22131-79-9 ALCLOFENAC INDICATION Fever 22131-79-9 ALCLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 24049-18-1 ALCLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 24049-18-1 ALCLOFENAC PRODUCT_CLASS Anti-inflammatories 24049-18-1 ALCLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 24049-18-1 ALCLOFENAC MODE_CLASS Enzyme Inhibitor 24049-18-1 ALCLOFENAC INDICATION Fever 70319-10-7 ALCLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 70319-10-7 ALCLOFENAC INDICATION Fever 70319-10-7 ALCLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 70319-10-7 ALCLOFENAC MODE_CLASS Enzyme Inhibitor 70319-10-7 ALCLOFENAC PRODUCT_CLASS Anti-inflammatories 22136-26-1 AMEDALIN INDICATION Depression 22136-26-1 AMEDALIN THERAPEUTIC_CLASS Antidepressants 22136-26-1 AMEDALIN PRODUCT_CLASS Central Nervous System (CNS) 22136-27-2 DALEDALIN PRODUCT_CLASS Central Nervous System (CNS) 22136-27-2 DALEDALIN INDICATION Depression 22136-27-2 DALEDALIN THERAPEUTIC_CLASS Antidepressants 22164-94-9 SUNCILLIN PRODUCT_CLASS Anti-infectives 22164-94-9 SUNCILLIN MODE_CLASS Enzyme Inhibitor 22164-94-9 SUNCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 22164-94-9 SUNCILLIN THERAPEUTIC_CLASS Antibacterials 22204-91-7 LIFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 22204-91-7 LIFIBRATE PRODUCT_CLASS Cardiovasculars 22204-91-7 LIFIBRATE INDICATION Hyperlipoproteinemia 22298-29-9 BETAMETHASONE BENZOATE MECHANISM Modulate gene transcription 22298-29-9 BETAMETHASONE BENZOATE THERAPEUTIC_CLASS Corticosteroids, Topical 22298-29-9 BETAMETHASONE BENZOATE PRODUCT_CLASS Anti-inflammatories 22298-29-9 BETAMETHASONE BENZOATE MODE_CLASS Receptor Agonist 22336-84-1 METERGOTAMINE STRUCTURE_ACTIVITY Ergot alkaloid 22336-84-1 METERGOTAMINE PRODUCT_CLASS Central Nervous System (CNS) 22336-84-1 METERGOTAMINE THERAPEUTIC_CLASS Antimigraines 22336-84-1 METERGOTAMINE INDICATION Migraine Headache 22345-47-7 TOFISOPAM THERAPEUTIC_CLASS Antidepressants 22345-47-7 TOFISOPAM MODE_CLASS Channel enhancer /opener 22345-47-7 TOFISOPAM INDICATION Depression 22345-47-7 TOFISOPAM PRODUCT_CLASS Central Nervous System (CNS) 22345-47-7 TOFISOPAM MECHANISM Modulate neural transmission 22365-40-8 TRIFLUBAZAM INDICATION Anxiety Disorders 22365-40-8 TRIFLUBAZAM PRODUCT_CLASS Central Nervous System (CNS) 22365-40-8 TRIFLUBAZAM THERAPEUTIC_CLASS Sedatives/Hypnotics 22457-89-2 BENFOTIAMINE MECHANISM Vitamin/ cofactor 22494-47-9 CLOBUZARIT THERAPEUTIC_CLASS Immunosuppressants 22494-47-9 CLOBUZARIT PRODUCT_CLASS Immune Response / Immunomodulators 22494-47-9 CLOBUZARIT INDICATION Rheumatism 22568-64-5 DIACETOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 22568-64-5 DIACETOLOL MODE_CLASS Receptor Partial Agonist 22568-64-5 DIACETOLOL THERAPEUTIC_CLASS Sympatholytic Agents 22568-64-5 DIACETOLOL MECHANISM Modulate G-protein coupled signal transduction 22632-06-0 BUPICOMIDE PRODUCT_CLASS Cardiovasculars 22632-06-0 BUPICOMIDE THERAPEUTIC_CLASS Antihypertensive Agents 22632-06-0 BUPICOMIDE INDICATION Hypertension 22693-65-8 OLMIDINE INDICATION Hypertension 22693-65-8 OLMIDINE THERAPEUTIC_CLASS Antihypertensive Agents 22693-65-8 OLMIDINE PRODUCT_CLASS Cardiovasculars 22994-85-0 BENZNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 23047-25-8 LOFEPRAMINE THERAPEUTIC_CLASS Antidepressants 23047-25-8 LOFEPRAMINE MODE_CLASS Solute transporter inhibitor 23047-25-8 LOFEPRAMINE INDICATION Depression 23047-25-8 LOFEPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 23047-25-8 LOFEPRAMINE MECHANISM Prolong/enhance neural transmission 26786-32-3 LOFEPRAMINE MODE_CLASS Solute transporter inhibitor 26786-32-3 LOFEPRAMINE INDICATION Depression 26786-32-3 LOFEPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 26786-32-3 LOFEPRAMINE MECHANISM Prolong/enhance neural transmission 26786-32-3 LOFEPRAMINE THERAPEUTIC_CLASS Antidepressants 23271-63-8 AMICIBONE INDICATION Cough / Tussis 23271-74-1 FEDRILATE INDICATION Cough / Tussis 23491-45-4 PIBENZIMOL PRODUCT_CLASS Anti-cancers 23491-45-4 PIBENZIMOL STRUCTURE_ACTIVITY DNA intercalator 23590-99-0 INOSINE DIALDEHYDE STRUCTURE_ACTIVITY Adenosine receptor agonist, 23590-99-0 INOSINE DIALDEHYDE MECHANISM Modulate G-protein coupled signal transduction 23590-99-0 INOSINE DIALDEHYDE MODE_CLASS Receptor Agonist 23674-86-4 DIFLUPREDNATE MECHANISM Modulate gene transcription 23674-86-4 DIFLUPREDNATE MODE_CLASS Receptor Agonist 23779-99-9 FLOCTAFENINE MODE_CLASS Enzyme Inhibitor 23779-99-9 FLOCTAFENINE MECHANISM Inhibit eicosanoid biosynthesis 23887-41-4 CINEPAZET THERAPEUTIC_CLASS Antianginals 23887-41-4 CINEPAZET INDICATION Angina Pectoris 23887-41-4 CINEPAZET PRODUCT_CLASS Cardiovasculars 23910-07-8 MEBIQUINE INDICATION Diarrhea 23915-73-3 TREBENZOMINE PRODUCT_CLASS Central Nervous System (CNS) 23915-73-3 TREBENZOMINE INDICATION Depression 23915-73-3 TREBENZOMINE THERAPEUTIC_CLASS Antidepressants 24047-16-3 CAPROXAMINE INDICATION Depression 24047-16-3 CAPROXAMINE THERAPEUTIC_CLASS Antidepressants 24047-16-3 CAPROXAMINE PRODUCT_CLASS Central Nervous System (CNS) 24047-25-4 GUANOXABENZ PRODUCT_CLASS Cardiovasculars 24047-25-4 GUANOXABENZ THERAPEUTIC_CLASS Antihypertensive Agents 24047-25-4 GUANOXABENZ INDICATION Hypertension 24166-13-0 CLOXAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 24166-13-0 CLOXAZOLAM THERAPEUTIC_CLASS Anxiolytics 24166-13-0 CLOXAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 24166-13-0 CLOXAZOLAM MECHANISM Modulate neural transmission 24166-13-0 CLOXAZOLAM MODE_CLASS Channel enhancer /opener 24237-54-5 TINORIDINE MECHANISM Scavenges hydrogen peroxide and free radicals 25913-34-2 TINORIDINE MECHANISM Scavenges hydrogen peroxide and free radicals 24279-91-2 CARBOQUONE MODE_CLASS Distorts /blocks macromolecular scaffold function 24279-91-2 CARBOQUONE MECHANISM Inhibit DNA synthesis, repair, and function 24455-58-1 GLICETANILE INDICATION Diabetes 24477-37-0 GLISOLAMIDE INDICATION Type II Diabetes Mellitus 24477-37-0 GLISOLAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 24477-37-0 GLISOLAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 24477-37-0 GLISOLAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 24477-37-0 GLISOLAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 24477-37-0 GLISOLAMIDE MODE_CLASS Channel Blocker, selective 24527-27-3 SPICLOMAZINE PRODUCT_CLASS Central Nervous System (CNS) 24527-27-3 SPICLOMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 24527-27-3 SPICLOMAZINE MECHANISM Block neural transmission 24527-27-3 SPICLOMAZINE MODE_CLASS Receptor Ligand Antagonist 24527-27-3 SPICLOMAZINE THERAPEUTIC_CLASS Antipsychotics 24645-20-3 HEXAPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 24645-20-3 HEXAPROFEN MECHANISM Inhibit eicosanoid biosynthesis 24645-20-3 HEXAPROFEN MODE_CLASS Enzyme Inhibitor 24645-20-3 HEXAPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 24645-20-3 HEXAPROFEN PRODUCT_CLASS Anti-inflammatories 24886-52-0 PIPOFEZINE PRODUCT_CLASS Central Nervous System (CNS) 24886-52-0 PIPOFEZINE INDICATION Depression 24886-52-0 PIPOFEZINE THERAPEUTIC_CLASS Antidepressants 25046-79-1 GLISOXEPIDE INDICATION Type II Diabetes Mellitus 25046-79-1 GLISOXEPIDE MECHANISM Trigger insulin release in pancreatic beta cells 25046-79-1 GLISOXEPIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 25046-79-1 GLISOXEPIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 25046-79-1 GLISOXEPIDE MODE_CLASS Channel Blocker, selective 25046-79-1 GLISOXEPIDE THERAPEUTIC_CLASS Antidiabetic Agents 25314-87-8 ELUCAINE MODE_CLASS Channel Blocker 25314-87-8 ELUCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 25314-87-8 ELUCAINE MECHANISM Block neural transmission 25333-77-1 ACETORPHINE STRUCTURE_ACTIVITY Opioid receptor agonist 25333-77-1 ACETORPHINE MECHANISM Modulate neural transmission 25333-77-1 ACETORPHINE PRODUCT_CLASS Analgesics 25333-77-1 ACETORPHINE MODE_CLASS Receptor Agonist 25333-77-1 ACETORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 25384-17-2 ALLYLPRODINE MODE_CLASS Receptor Agonist 25384-17-2 ALLYLPRODINE PRODUCT_CLASS Analgesics 25384-17-2 ALLYLPRODINE MECHANISM Modulate neural transmission 25384-17-2 ALLYLPRODINE THERAPEUTIC_CLASS Analgesics, Opioid 25683-71-0 TERIZIDONE INDICATION Urinary Tract Infection (UTI) 25683-71-0 TERIZIDONE INDICATION Tuberculosis 25905-77-5 MINAPRINE MECHANISM Prolong/enhance neural transmission 25905-77-5 MINAPRINE MODE_CLASS Receptor Agonist 25905-77-5 MINAPRINE MODE_CLASS Receptor Agonist, selective 25905-77-5 MINAPRINE INDICATION Depression 25905-77-5 MINAPRINE PRODUCT_CLASS Central Nervous System (CNS) 25905-77-5 MINAPRINE THERAPEUTIC_CLASS Antidepressants 25905-77-5 MINAPRINE MECHANISM Enhance cholinergic transmission 25905-77-5 MINAPRINE THERAPEUTIC_CLASS Central Stimulants 25905-77-5 MINAPRINE MODE_CLASS Enzyme Inhibitor 25953-17-7 MINAPRINE MODE_CLASS Enzyme Inhibitor 25953-17-7 MINAPRINE THERAPEUTIC_CLASS Central Stimulants 25953-17-7 MINAPRINE MODE_CLASS Receptor Agonist, selective 25953-17-7 MINAPRINE MECHANISM Enhance cholinergic transmission 25953-17-7 MINAPRINE MODE_CLASS Receptor Agonist 25953-17-7 MINAPRINE THERAPEUTIC_CLASS Antidepressants 25953-17-7 MINAPRINE MECHANISM Prolong/enhance neural transmission 25953-17-7 MINAPRINE INDICATION Depression 25953-17-7 MINAPRINE PRODUCT_CLASS Central Nervous System (CNS) 26020-55-3 OXETORONE THERAPEUTIC_CLASS Antimigraines 26020-55-3 OXETORONE PRODUCT_CLASS Central Nervous System (CNS) 26020-55-3 OXETORONE INDICATION Migraine Headache 26070-78-0 UBISINDINE PRODUCT_CLASS Cardiovasculars 26070-78-0 UBISINDINE INDICATION Cough / Tussis 26070-78-0 UBISINDINE INDICATION Cardiac Arrhythmias 26070-78-0 UBISINDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 26159-36-4 NAPROXOL STRUCTURE_ACTIVITY NSAID, COX-1, 6-Methoxy-naphthalenyl-acetic acid 26304-61-0 AZEPINDOLE THERAPEUTIC_CLASS Antidepressants 26304-61-0 AZEPINDOLE INDICATION Depression 26304-61-0 AZEPINDOLE PRODUCT_CLASS Central Nervous System (CNS) 26308-28-1 RIPAZEPAM MODE_CLASS Channel enhancer /opener 26308-28-1 RIPAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 26308-28-1 RIPAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 26308-28-1 RIPAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 26308-28-1 RIPAZEPAM MECHANISM Modulate neural transmission 26481-51-6 TIPRENOLOL MECHANISM Modulate G-protein coupled signal transduction 26481-51-6 TIPRENOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 26552-51-2 THIPHENCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 26552-51-2 THIPHENCILLIN THERAPEUTIC_CLASS Antibacterials 26552-51-2 THIPHENCILLIN PRODUCT_CLASS Anti-infectives 26552-51-2 THIPHENCILLIN MODE_CLASS Enzyme Inhibitor 26717-47-5 CLOFIBRIDE PRODUCT_CLASS Cardiovasculars 26717-47-5 CLOFIBRIDE THERAPEUTIC_CLASS Hypolipidemic Agents 26717-47-5 CLOFIBRIDE INDICATION Hyperlipoproteinemia 26718-25-2 HALOFENATE PRODUCT_CLASS Cardiovasculars 26718-25-2 HALOFENATE INDICATION Hyperlipoproteinemia 26718-25-2 HALOFENATE THERAPEUTIC_CLASS Hypolipidemic Agents 26844-12-2 INDORAMIN MECHANISM Reduce vasoconstriction 26844-12-2 INDORAMIN INDICATION Hypertension 26844-12-2 INDORAMIN PRODUCT_CLASS Autonomic Nervous System (ANS) 26844-12-2 INDORAMIN PRODUCT_CLASS Cardiovasculars 26844-12-2 INDORAMIN INDICATION Benign Prostatic Hyperplasia (BPH) 26844-12-2 INDORAMIN THERAPEUTIC_CLASS Antihypertensive Agents 26844-12-2 INDORAMIN MODE_CLASS Receptor Ligand Antagonist 26844-12-2 INDORAMIN THERAPEUTIC_CLASS Parasympatholytic Agents 38821-52-2 INDORAMIN THERAPEUTIC_CLASS Antihypertensive Agents 38821-52-2 INDORAMIN MECHANISM Reduce vasoconstriction 38821-52-2 INDORAMIN THERAPEUTIC_CLASS Parasympatholytic Agents 38821-52-2 INDORAMIN MODE_CLASS Receptor Ligand Antagonist 38821-52-2 INDORAMIN INDICATION Hypertension 38821-52-2 INDORAMIN PRODUCT_CLASS Autonomic Nervous System (ANS) 38821-52-2 INDORAMIN PRODUCT_CLASS Cardiovasculars 38821-52-2 INDORAMIN INDICATION Benign Prostatic Hyperplasia (BPH) 33124-53-7 INDORAMIN PRODUCT_CLASS Cardiovasculars 33124-53-7 INDORAMIN INDICATION Hypertension 33124-53-7 INDORAMIN PRODUCT_CLASS Autonomic Nervous System (ANS) 33124-53-7 INDORAMIN THERAPEUTIC_CLASS Antihypertensive Agents 33124-53-7 INDORAMIN MECHANISM Reduce vasoconstriction 33124-53-7 INDORAMIN INDICATION Benign Prostatic Hyperplasia (BPH) 33124-53-7 INDORAMIN THERAPEUTIC_CLASS Parasympatholytic Agents 33124-53-7 INDORAMIN MODE_CLASS Receptor Ligand Antagonist 26864-56-2 PENFLURIDOL MODE_CLASS Channel Blocker 26864-56-2 PENFLURIDOL STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 26864-56-2 PENFLURIDOL MECHANISM Reduce muscle contractile force 26944-48-9 GLIBORNURIDE MODE_CLASS Channel Blocker, selective 26944-48-9 GLIBORNURIDE INDICATION Type II Diabetes Mellitus 26944-48-9 GLIBORNURIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 26944-48-9 GLIBORNURIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 26944-48-9 GLIBORNURIDE THERAPEUTIC_CLASS Antidiabetic Agents 26944-48-9 GLIBORNURIDE MECHANISM Trigger insulin release in pancreatic beta cells 26973-24-0 CEFTEZOLE PRODUCT_CLASS Anti-infectives 26973-24-0 CEFTEZOLE MODE_CLASS Enzyme Inhibitor 26973-24-0 CEFTEZOLE THERAPEUTIC_CLASS Antibacterials 26973-24-0 CEFTEZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 41136-22-5 CEFTEZOLE PRODUCT_CLASS Anti-infectives 41136-22-5 CEFTEZOLE MODE_CLASS Enzyme Inhibitor 41136-22-5 CEFTEZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 41136-22-5 CEFTEZOLE THERAPEUTIC_CLASS Antibacterials 27025-49-6 CARBENICILLIN PHENYL THERAPEUTIC_CLASS Antibacterials 27025-49-6 CARBENICILLIN PHENYL MECHANISM Inhibit bacterial cell wall biosynthesis 27025-49-6 CARBENICILLIN PHENYL MODE_CLASS Enzyme Inhibitor 27025-49-6 CARBENICILLIN PHENYL PRODUCT_CLASS Anti-infectives 27060-91-9 FLUTAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 27060-91-9 FLUTAZOLAM MODE_CLASS Channel enhancer /opener 27060-91-9 FLUTAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 27060-91-9 FLUTAZOLAM INDICATION Anxiety Disorders 27060-91-9 FLUTAZOLAM MECHANISM Modulate neural transmission 27060-91-9 FLUTAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 27115-86-2 DACURONIUM BROMIDE MODE_CLASS Channel Blocker, selective 27115-86-2 DACURONIUM BROMIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 27115-86-2 DACURONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 27115-86-2 DACURONIUM BROMIDE MECHANISM Block neural transmission 27325-36-6 PROCINOLOL MECHANISM Modulate G-protein coupled signal transduction 27325-36-6 PROCINOLOL MODE_CLASS Receptor Ligand Antagonist 27466-27-9 INTRIPTYLINE MECHANISM Prolong/enhance neural transmission 27466-27-9 INTRIPTYLINE INDICATION Depression 27466-27-9 INTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 27466-27-9 INTRIPTYLINE MODE_CLASS Solute transporter inhibitor 27466-27-9 INTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 27511-99-5 ETEROBARB MODE_CLASS Channel Modulator 27511-99-5 ETEROBARB MECHANISM Modulate neural transmission 27511-99-5 ETEROBARB STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 27574-24-9 TROPATEPINE THERAPEUTIC_CLASS Movement Disorders 27574-24-9 TROPATEPINE MECHANISM Prolong/enhance neural transmission 27574-24-9 TROPATEPINE INDICATION Parkinson's Disease 27574-24-9 TROPATEPINE MODE_CLASS Solute transporter inhibitor 27574-24-9 TROPATEPINE PRODUCT_CLASS Central Nervous System (CNS) 27589-33-9 AZOSEMIDE THERAPEUTIC_CLASS Diuretics 27589-33-9 AZOSEMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 27589-33-9 AZOSEMIDE MODE_CLASS Channel Blocker, selective 27589-33-9 AZOSEMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 27589-33-9 AZOSEMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 27736-80-7 FENAFTIC ACID INDICATION Cholelithiasis / Gallstones 28022-11-9 MEGALOMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 28022-11-9 MEGALOMICIN PRODUCT_CLASS Anti-infectives 28022-11-9 MEGALOMICIN THERAPEUTIC_CLASS Antibacterials 28022-11-9 MEGALOMICIN MECHANISM Inhibit ribosomal protein synthesis 28125-87-3 FLUTONIDINE THERAPEUTIC_CLASS Antihypertensive Agents 28125-87-3 FLUTONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 28125-87-3 FLUTONIDINE PRODUCT_CLASS Cardiovasculars 28125-87-3 FLUTONIDINE INDICATION Hypertension 28546-58-9 ULDAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 28546-58-9 ULDAZEPAM MECHANISM Modulate neural transmission 28546-58-9 ULDAZEPAM MODE_CLASS Channel enhancer /opener 28546-58-9 ULDAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 28546-58-9 ULDAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 29144-42-1 CETOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 29144-42-1 CETOCYCLINE PRODUCT_CLASS Anti-infectives 29144-42-1 CETOCYCLINE THERAPEUTIC_CLASS Antibacterials 29144-42-1 CETOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 29144-42-1 CETOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 29442-58-8 MOTRAZEPAM MODE_CLASS Channel enhancer /opener 29442-58-8 MOTRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 29442-58-8 MOTRAZEPAM MECHANISM Modulate neural transmission 29442-58-8 MOTRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 29442-58-8 MOTRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 29619-86-1 MOCTAMIDE INDICATION Hyperlipoproteinemia 29619-86-1 MOCTAMIDE PRODUCT_CLASS Cardiovasculars 29619-86-1 MOCTAMIDE THERAPEUTIC_CLASS Hypolipidemic Agents 29883-15-6 AMYGDALIN(D) STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT GIS_1_Nausea / Vomiting 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT GIS_2_Diarrhea 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT LUN_3_Cyanosis 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT NEU_2_Headache 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT XXX_3_Fever 29883-15-6 AMYGDALIN(D) THERAPEUTIC_CLASS Antineoplastics 29883-15-6 AMYGDALIN(D) TISSUE_TOXICITY Hypotension 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT SKN_2_Itching 29883-15-6 AMYGDALIN(D) KNOWN_TOXICITY Cardiovascular Toxicity 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT NEU_3_Peripheral Neuritis 29883-15-6 AMYGDALIN(D) MECHANISM Inhibit mitochondrial function 29883-15-6 AMYGDALIN(D) PRODUCT_CLASS Anti-cancers 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT CVS_3_Hypotension 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT PSN_3_Cyanide Toxicity 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT NEU_2_Dizziness 29883-15-6 AMYGDALIN(D) ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 29984-33-6 VIDARABINE PHOSPHATE PRODUCT_CLASS Anti-cancers 29984-33-6 VIDARABINE PHOSPHATE MECHANISM Incorporate into DNA/RNA/Protein 29984-33-6 VIDARABINE PHOSPHATE MODE_CLASS Enzyme substrate mimic 29984-33-6 VIDARABINE PHOSPHATE THERAPEUTIC_CLASS Antineoplastics 29984-33-6 VIDARABINE PHOSPHATE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 30033-10-4 STERCURONIUM IODIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 30033-10-4 STERCURONIUM IODIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 30033-10-4 STERCURONIUM IODIDE MODE_CLASS Channel Blocker, selective 30033-10-4 STERCURONIUM IODIDE MECHANISM Block neural transmission 30271-85-3 RAZINODIL THERAPEUTIC_CLASS Antianginals 30271-85-3 RAZINODIL PRODUCT_CLASS Cardiovasculars 30271-85-3 RAZINODIL INDICATION Angina Pectoris 30531-86-3 COLFENAMATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 30531-86-3 COLFENAMATE PRODUCT_CLASS Anti-inflammatories 30544-47-9 ETOFENAMATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 30544-47-9 ETOFENAMATE PRODUCT_CLASS Anti-inflammatories 30716-01-9 EMILIUM TOSYLATE PRODUCT_CLASS Cardiovasculars 30716-01-9 EMILIUM TOSYLATE INDICATION Cardiac Arrhythmias 30716-01-9 EMILIUM TOSYLATE PRODUCT_CLASS Central Nervous System (CNS) 30716-01-9 EMILIUM TOSYLATE INDICATION Depression 30716-01-9 EMILIUM TOSYLATE THERAPEUTIC_CLASS Antiarrhythmic Agents 30716-01-9 EMILIUM TOSYLATE THERAPEUTIC_CLASS Antidepressants 30910-27-1 TRELOXINATE THERAPEUTIC_CLASS Hypolipidemic Agents 30910-27-1 TRELOXINATE INDICATION Hyperlipoproteinemia 30910-27-1 TRELOXINATE PRODUCT_CLASS Cardiovasculars 31036-80-3 LOFEXIDINE MODE_CLASS Receptor Agonist, selective 31036-80-3 LOFEXIDINE MODE_CLASS Receptor Agonist 31036-80-3 LOFEXIDINE THERAPEUTIC_CLASS Sympathomimetic Agents 31036-80-3 LOFEXIDINE INDICATION Opiate Detoxification 31036-80-3 LOFEXIDINE MECHANISM Modulate G-protein coupled signal transduction 31036-80-3 LOFEXIDINE PRODUCT_CLASS Central Nervous System (CNS) 31036-80-3 LOFEXIDINE MECHANISM Modulate gene transcription 21498-08-8 LOFEXIDINE PRODUCT_CLASS Central Nervous System (CNS) 21498-08-8 LOFEXIDINE MECHANISM Modulate G-protein coupled signal transduction 21498-08-8 LOFEXIDINE MECHANISM Modulate gene transcription 21498-08-8 LOFEXIDINE MODE_CLASS Receptor Agonist, selective 21498-08-8 LOFEXIDINE MODE_CLASS Receptor Agonist 21498-08-8 LOFEXIDINE THERAPEUTIC_CLASS Sympathomimetic Agents 21498-08-8 LOFEXIDINE INDICATION Opiate Detoxification 31314-38-2 PRODIPINE INDICATION Parkinson's Disease 31352-82-6 ZOLAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 31352-82-6 ZOLAZEPAM MECHANISM Modulate neural transmission 31352-82-6 ZOLAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 31352-82-6 ZOLAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 31352-82-6 ZOLAZEPAM MODE_CLASS Channel enhancer /opener 31478-45-2 BAMNIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 31637-97-5 ETOFIBRATE PRODUCT_CLASS Cardiovasculars 31637-97-5 ETOFIBRATE INDICATION Hyperlipoproteinemia 31637-97-5 ETOFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 31842-01-0 INDOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 31842-01-0 INDOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 31842-01-0 INDOPROFEN PRODUCT_CLASS Anti-inflammatories 31842-01-0 INDOPROFEN MODE_CLASS Enzyme Inhibitor 31868-18-5 MEXAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 31868-18-5 MEXAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 31868-18-5 MEXAZOLAM MECHANISM Modulate neural transmission 31868-18-5 MEXAZOLAM MODE_CLASS Channel enhancer /opener 31868-18-5 MEXAZOLAM THERAPEUTIC_CLASS Antidepressants 32059-15-7 GUANAZODINE THERAPEUTIC_CLASS Antihypertensive Agents 32059-15-7 GUANAZODINE INDICATION Hypertension 32059-15-7 GUANAZODINE PRODUCT_CLASS Cardiovasculars 32211-97-5 CYCLINDOLE INDICATION Depression 32211-97-5 CYCLINDOLE THERAPEUTIC_CLASS Antidepressants 32211-97-5 CYCLINDOLE PRODUCT_CLASS Central Nervous System (CNS) 32295-18-4 TOSIFEN PRODUCT_CLASS Cardiovasculars 32295-18-4 TOSIFEN MODE_CLASS Channel Blocker, selective 32295-18-4 TOSIFEN MECHANISM Trigger insulin release in pancreatic beta cells 32295-18-4 TOSIFEN THERAPEUTIC_CLASS Antiarrhythmic Agents 32295-18-4 TOSIFEN THERAPEUTIC_CLASS Antianginals 32527-55-2 TIARAMIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 32527-55-2 TIARAMIDE MECHANISM Inhibit inflammatory response 32527-55-2 TIARAMIDE PRODUCT_CLASS Anti-inflammatories 32527-55-2 TIARAMIDE INDICATION Asthma 32527-55-2 TIARAMIDE THERAPEUTIC_CLASS Bronchodilators 32527-55-2 TIARAMIDE MODE_CLASS Enzyme Inhibitor 32527-55-2 TIARAMIDE PRODUCT_CLASS Respiratory System 35941-71-0 TIARAMIDE INDICATION Asthma 35941-71-0 TIARAMIDE THERAPEUTIC_CLASS Bronchodilators 35941-71-0 TIARAMIDE PRODUCT_CLASS Anti-inflammatories 35941-71-0 TIARAMIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 35941-71-0 TIARAMIDE MODE_CLASS Enzyme Inhibitor 35941-71-0 TIARAMIDE MECHANISM Inhibit inflammatory response 35941-71-0 TIARAMIDE PRODUCT_CLASS Respiratory System 32795-44-1 ACECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 32795-44-1 ACECAINIDE INDICATION Depression 32795-44-1 ACECAINIDE THERAPEUTIC_CLASS Antidepressants 32795-44-1 ACECAINIDE PRODUCT_CLASS Cardiovasculars 32795-44-1 ACECAINIDE INDICATION Cardiac Arrhythmias 32795-44-1 ACECAINIDE PRODUCT_CLASS Central Nervous System (CNS) 32838-26-9 BUTOCTAMIDE MODE_CLASS Enzyme Inhibitor 32838-26-9 BUTOCTAMIDE MECHANISM Inhibit precursor synthesis 32886-97-8 AMDINOCILLIN PIVOXIL PRODUCT_CLASS Anti-infectives 32886-97-8 AMDINOCILLIN PIVOXIL MECHANISM Inhibit bacterial cell wall biosynthesis 32886-97-8 AMDINOCILLIN PIVOXIL THERAPEUTIC_CLASS Antibacterials 32886-97-8 AMDINOCILLIN PIVOXIL MODE_CLASS Enzyme Inhibitor 32887-01-7 AMDINOCILLIN THERAPEUTIC_CLASS Antibacterials 32887-01-7 AMDINOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 32887-01-7 AMDINOCILLIN PRODUCT_CLASS Anti-infectives 32887-01-7 AMDINOCILLIN MODE_CLASS Enzyme Inhibitor 10351-50-5 LENIQUINSIN THERAPEUTIC_CLASS Antihypertensive Agents 10351-50-5 LENIQUINSIN PRODUCT_CLASS Cardiovasculars 10351-50-5 LENIQUINSIN INDICATION Hypertension 10355-14-3 BOXIDINE PRODUCT_CLASS Cardiovasculars 10355-14-3 BOXIDINE THERAPEUTIC_CLASS Hypolipidemic Agents 10355-14-3 BOXIDINE INDICATION Hyperlipoproteinemia 10379-11-0 NORTETRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 10379-11-0 NORTETRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 10379-11-0 NORTETRAZEPAM MECHANISM Modulate neural transmission 10379-11-0 NORTETRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 10379-11-0 NORTETRAZEPAM MODE_CLASS Channel enhancer /opener 10379-14-3 TETRAZEPAM MODE_CLASS Channel enhancer /opener 10379-14-3 TETRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 10379-14-3 TETRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 10379-14-3 TETRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 10379-14-3 TETRAZEPAM MECHANISM Modulate neural transmission 10405-02-4 TROSPIUM CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 10405-02-4 TROSPIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 10433-71-3 TIAMETONIUM IODIDE INDICATION Cough / Tussis 10448-84-7 NITROMIFENE MODE_CLASS Receptor Ligand Antagonist 10448-84-7 NITROMIFENE MECHANISM Modulate gene transcription 10448-84-7 NITROMIFENE THERAPEUTIC_CLASS Gonadal Hormones 10448-84-7 NITROMIFENE PRODUCT_CLASS Anti-cancers 10457-91-7 SEPERIDOL THERAPEUTIC_CLASS Antipsychotics 10457-91-7 SEPERIDOL MECHANISM Block neural transmission 10457-91-7 SEPERIDOL STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), butyrophenone 10457-91-7 SEPERIDOL PRODUCT_CLASS Central Nervous System (CNS) 10457-91-7 SEPERIDOL MODE_CLASS Receptor Ligand Antagonist 10571-59-2 NICOCLONATE INDICATION Hyperlipoproteinemia 10571-59-2 NICOCLONATE THERAPEUTIC_CLASS Hypolipidemic Agents 10571-59-2 NICOCLONATE PRODUCT_CLASS Cardiovasculars 10596-23-3 CLODRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 10596-23-3 CLODRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 10596-23-3 CLODRONIC ACID MECHANISM Inhibit bone re-absorption 10596-23-3 CLODRONIC ACID MODE_CLASS Enzyme Inhibitor 10596-23-3 CLODRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 12772-35-9 BUTIROSIN MECHANISM Inhibit ribosomal protein synthesis 12772-35-9 BUTIROSIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 12772-35-9 BUTIROSIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 12772-35-9 BUTIROSIN PRODUCT_CLASS Anti-infectives 12772-35-9 BUTIROSIN THERAPEUTIC_CLASS Antibacterials 13007-93-7 CUPROXOLINE INDICATION Arthritis 13007-93-7 CUPROXOLINE THERAPEUTIC_CLASS Immunosuppressants 13007-93-7 CUPROXOLINE INDICATION Copper Deficiency 13007-93-7 CUPROXOLINE PRODUCT_CLASS Immune Response / Immunomodulators 13050-83-4 GUANOXYFEN PRODUCT_CLASS Central Nervous System (CNS) 13050-83-4 GUANOXYFEN INDICATION Hypertension 13050-83-4 GUANOXYFEN INDICATION Depression 13050-83-4 GUANOXYFEN PRODUCT_CLASS Cardiovasculars 13050-83-4 GUANOXYFEN THERAPEUTIC_CLASS Antidepressants 13050-83-4 GUANOXYFEN THERAPEUTIC_CLASS Antihypertensive Agents 13093-88-4 PERIMETAZINE PRODUCT_CLASS Central Nervous System (CNS) 13093-88-4 PERIMETAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 13093-88-4 PERIMETAZINE MECHANISM Block neural transmission 13093-88-4 PERIMETAZINE MODE_CLASS Receptor Ligand Antagonist 13093-88-4 PERIMETAZINE THERAPEUTIC_CLASS Antipsychotics 13392-18-2 FENOTEROL THERAPEUTIC_CLASS Bronchodilators 13392-18-2 FENOTEROL MODE_CLASS Receptor Agonist 13392-18-2 FENOTEROL PRODUCT_CLASS Respiratory System 13392-18-2 FENOTEROL MECHANISM Reduce bronchoconstriction 1944-12-3 FENOTEROL MODE_CLASS Receptor Agonist 1944-12-3 FENOTEROL THERAPEUTIC_CLASS Bronchodilators 1944-12-3 FENOTEROL MECHANISM Reduce bronchoconstriction 1944-12-3 FENOTEROL PRODUCT_CLASS Respiratory System 13410-86-1 ACONIAZIDE THERAPEUTIC_CLASS Antibacterials, Systemic 13410-86-1 ACONIAZIDE PRODUCT_CLASS Anti-infectives 13410-86-1 ACONIAZIDE INDICATION Tuberculosis 13425-92-8 AMIQUINSIN PRODUCT_CLASS Cardiovasculars 13425-92-8 AMIQUINSIN THERAPEUTIC_CLASS Antihypertensive Agents 13425-92-8 AMIQUINSIN INDICATION Hypertension 13447-95-5 METHANIAZIDE PRODUCT_CLASS Anti-infectives 13447-95-5 METHANIAZIDE INDICATION Tuberculosis 13447-95-5 METHANIAZIDE THERAPEUTIC_CLASS Antibacterials, Systemic 13460-98-5 THEODRENALINE INDICATION Hypertension 13460-98-5 THEODRENALINE THERAPEUTIC_CLASS Antidepressants 13460-98-5 THEODRENALINE INDICATION Depression 13460-98-5 THEODRENALINE PRODUCT_CLASS Cardiovasculars 13460-98-5 THEODRENALINE THERAPEUTIC_CLASS Antihypertensive Agents 13460-98-5 THEODRENALINE PRODUCT_CLASS Central Nervous System (CNS) 13461-01-3 ACEPROMETAZINE MODE_CLASS Receptor Ligand Antagonist 13461-01-3 ACEPROMETAZINE MECHANISM Block neural transmission 13461-01-3 ACEPROMETAZINE INDICATION Insomnia 13461-01-3 ACEPROMETAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 13461-01-3 ACEPROMETAZINE PRODUCT_CLASS Central Nervous System (CNS) 13495-09-5 PIMINODINE THERAPEUTIC_CLASS Analgesics, Opioid 13495-09-5 PIMINODINE MECHANISM Modulate neural transmission 13495-09-5 PIMINODINE MODE_CLASS Receptor Agonist 13495-09-5 PIMINODINE PRODUCT_CLASS Analgesics 13551-87-6 MISONIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 13609-67-1 HYDROCORTISONE BUTYRATE MECHANISM Modulate gene transcription 13609-67-1 HYDROCORTISONE BUTYRATE MODE_CLASS Endogenous Receptor /Channel Ligand 13642-52-9 SOTERENOL PRODUCT_CLASS Autonomic Nervous System (ANS) 13642-52-9 SOTERENOL MECHANISM Modulate G-protein coupled signal transduction 13642-52-9 SOTERENOL PRODUCT_CLASS Respiratory System 13642-52-9 SOTERENOL THERAPEUTIC_CLASS Sympathomimetic Agents 13642-52-9 SOTERENOL THERAPEUTIC_CLASS Bronchodilators 13698-49-2 DELMADINONE ACETATE THERAPEUTIC_CLASS Gonadal Hormones 13698-49-2 DELMADINONE ACETATE PRODUCT_CLASS Veterinarian 13710-19-5 TOLFENAMIC ACID MODE_CLASS Channel Modulator 13710-19-5 TOLFENAMIC ACID MECHANISM Modulate channel gating 13710-19-5 TOLFENAMIC ACID MECHANISM Inhibit eicosanoid biosynthesis 13710-19-5 TOLFENAMIC ACID STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 13710-19-5 TOLFENAMIC ACID MODE_CLASS Enzyme Inhibitor 13710-19-5 TOLFENAMIC ACID MODE_CLASS Enzyme Inhibitor, selective 13799-03-6 PROTIZINIC ACID MECHANISM Block neural transmission 13799-03-6 PROTIZINIC ACID PRODUCT_CLASS Anti-inflammatories 13799-03-6 PROTIZINIC ACID MODE_CLASS Receptor Ligand Antagonist 13958-40-2 OXIRAMIDE PRODUCT_CLASS Central Nervous System (CNS) 13958-40-2 OXIRAMIDE PRODUCT_CLASS Cardiovasculars 13958-40-2 OXIRAMIDE THERAPEUTIC_CLASS Antidepressants 13958-40-2 OXIRAMIDE INDICATION Cardiac Arrhythmias 13958-40-2 OXIRAMIDE INDICATION Depression 13958-40-2 OXIRAMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 13993-65-2 METIAZINIC ACID PRODUCT_CLASS Anti-inflammatories 13993-65-2 METIAZINIC ACID MODE_CLASS Receptor Ligand Antagonist 13993-65-2 METIAZINIC ACID MECHANISM Block neural transmission 14008-71-0 XANTHIOL INDICATION Nausea / Vomiting 14088-71-2 PROCLONOL INDICATION Helminthic Infections 14149-43-0 TRIMETHIDINIUM METHOSULFATE PRODUCT_CLASS Cardiovasculars 14149-43-0 TRIMETHIDINIUM METHOSULFATE THERAPEUTIC_CLASS Antihypertensive Agents 14149-43-0 TRIMETHIDINIUM METHOSULFATE INDICATION Hypertension 14176-49-9 TILETAMINE PRODUCT_CLASS Analgesics 14176-49-9 TILETAMINE THERAPEUTIC_CLASS Analgesics, Opioid 14176-49-9 TILETAMINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 14176-49-9 TILETAMINE MODE_CLASS Receptor Agonist 14176-49-9 TILETAMINE PRODUCT_CLASS Veterinarian 14176-49-9 TILETAMINE MECHANISM Prolong/enhance neural transmission 14176-49-9 TILETAMINE THERAPEUTIC_CLASS Sedatives/Hypnotics 14417-88-0 MELINAMIDE STRUCTURE_ACTIVITY Sterol O-acyltransferase (ACAT) inhibitor 14417-88-0 MELINAMIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 14417-88-0 MELINAMIDE PRODUCT_CLASS Cardiovasculars 14417-88-0 MELINAMIDE THERAPEUTIC_CLASS Hypolipidemic Agents 14417-88-0 MELINAMIDE INDICATION Hyperlipoproteinemia 14417-88-0 MELINAMIDE MODE_CLASS Enzyme Inhibitor 14561-42-3 MENOCTONE INDICATION Malaria 14679-73-3 TODRALAZINE PRODUCT_CLASS Cardiovasculars 14679-73-3 TODRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 14679-73-3 TODRALAZINE INDICATION Hypertension 3778-76-5 TODRALAZINE PRODUCT_CLASS Cardiovasculars 3778-76-5 TODRALAZINE INDICATION Hypertension 3778-76-5 TODRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 14759-04-7 OXYRIDAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 14759-04-7 OXYRIDAZINE PRODUCT_CLASS Central Nervous System (CNS) 14759-04-7 OXYRIDAZINE THERAPEUTIC_CLASS Antipsychotics 14759-04-7 OXYRIDAZINE MODE_CLASS Receptor Ligand Antagonist 14759-04-7 OXYRIDAZINE MECHANISM Block neural transmission 14759-06-9 SULFORIDAZINE PRODUCT_CLASS Central Nervous System (CNS) 14759-06-9 SULFORIDAZINE MODE_CLASS Receptor Ligand Antagonist 14759-06-9 SULFORIDAZINE MECHANISM Block neural transmission 14759-06-9 SULFORIDAZINE THERAPEUTIC_CLASS Antipsychotics 14885-29-1 IPRONIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 15180-02-6 AMFONELIC ACID THERAPEUTIC_CLASS Antidepressants 15180-02-6 AMFONELIC ACID STRUCTURE_ACTIVITY Tubulin binder 15180-02-6 AMFONELIC ACID PRODUCT_CLASS Central Nervous System (CNS) 15180-02-6 AMFONELIC ACID INDICATION Depression 15256-58-3 BELOXAMIDE THERAPEUTIC_CLASS Hypolipidemic Agents 15256-58-3 BELOXAMIDE PRODUCT_CLASS Cardiovasculars 15256-58-3 BELOXAMIDE INDICATION Hyperlipoproteinemia 15301-52-7 CYCLEXANONE INDICATION Cough / Tussis 15301-54-9 CYPENAMINE THERAPEUTIC_CLASS Antidepressants 15301-54-9 CYPENAMINE INDICATION Depression 15301-54-9 CYPENAMINE PRODUCT_CLASS Central Nervous System (CNS) 15301-82-3 PECOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 15301-82-3 PECOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 15301-82-3 PECOCYCLINE THERAPEUTIC_CLASS Antibacterials 15301-82-3 PECOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 15301-82-3 PECOCYCLINE PRODUCT_CLASS Anti-infectives 15302-05-3 BUTOXYLATE INDICATION Diarrhea 15468-10-7 OXIDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 15468-10-7 OXIDRONIC ACID MODE_CLASS Enzyme Inhibitor 15468-10-7 OXIDRONIC ACID MECHANISM Inhibit bone re-absorption 15468-10-7 OXIDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 15468-10-7 OXIDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 15518-76-0 CYPROXIMIDE PRODUCT_CLASS Central Nervous System (CNS) 15518-76-0 CYPROXIMIDE THERAPEUTIC_CLASS Antidepressants 15518-76-0 CYPROXIMIDE INDICATION Depression 15574-49-9 MECARBINATE THERAPEUTIC_CLASS Antihypertensive Agents 15574-49-9 MECARBINATE PRODUCT_CLASS Cardiovasculars 15574-49-9 MECARBINATE INDICATION Hypertension 15574-96-6 PIZOTYLINE PRODUCT_CLASS Central Nervous System (CNS) 15574-96-6 PIZOTYLINE INDICATION Depression 15574-96-6 PIZOTYLINE THERAPEUTIC_CLASS Antidepressants 15686-91-6 PROPIRAM THERAPEUTIC_CLASS Analgesics, Opioid 15686-91-6 PROPIRAM PRODUCT_CLASS Analgesics 15686-91-6 PROPIRAM MODE_CLASS Receptor Partial Agonist 15686-91-6 PROPIRAM MECHANISM Modulate neural transmission 15687-07-7 CYPRAZEPAM MODE_CLASS Channel enhancer /opener 15687-07-7 CYPRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 15687-07-7 CYPRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 15687-07-7 CYPRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 15687-07-7 CYPRAZEPAM MECHANISM Modulate neural transmission 15793-38-1 QUINAZOSIN PRODUCT_CLASS Cardiovasculars 15793-38-1 QUINAZOSIN INDICATION Hypertension 15793-38-1 QUINAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 15793-38-1 QUINAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 15793-40-5 TERODILINE INDICATION Urge Incontinence 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_3_Bradycardia 15793-40-5 TERODILINE ADVERSE_EFFECT GIS_1_Dry Mouth 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 15793-40-5 TERODILINE ADVERSE_EFFECT NEU_1_Vertigo 15793-40-5 TERODILINE KNOWN_TOXICITY Cardiovascular Toxicity 15793-40-5 TERODILINE MODE_CLASS Channel Blocker 15793-40-5 TERODILINE TISSUE_TOXICITY Conduction Defects in the Heart 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_3_Conduction Defects in the Heart 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 15793-40-5 TERODILINE MECHANISM Modulate G-protein coupled signal transduction 15793-40-5 TERODILINE MODE_CLASS Receptor Ligand Antagonist 15793-40-5 TERODILINE ADVERSE_EFFECT OCU_2_Blurred Vision 15793-40-5 TERODILINE ADVERSE_EFFECT NEU_1_Tremor 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_3_Heart Block 15793-40-5 TERODILINE ADVERSE_EFFECT XXX_2_Thirst 15793-40-5 TERODILINE TISSUE_TOXICITY Atrioventricular Blockade 15793-40-5 TERODILINE TISSUE_TOXICITY Angina 15793-40-5 TERODILINE THERAPEUTIC_CLASS Parasympatholytic Agents 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 15793-40-5 TERODILINE ADVERSE_EFFECT NEU_3_Dementia 15793-40-5 TERODILINE ADVERSE_EFFECT CVS_3_Angina 15793-40-5 TERODILINE TISSUE_TOXICITY Ventricular Tachycardia 15793-40-5 TERODILINE TISSUE_TOXICITY Cardiac Arrhythmia 15793-40-5 TERODILINE TISSUE_TOXICITY Heart Block 15793-40-5 TERODILINE ADVERSE_EFFECT GIS_1_Constipation 15793-40-5 TERODILINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 15793-40-5 TERODILINE MECHANISM Reduce muscle contractile force 15793-40-5 TERODILINE PRODUCT_CLASS Autonomic Nervous System (ANS) 7082-21-5 TERODILINE MECHANISM Reduce muscle contractile force 7082-21-5 TERODILINE PRODUCT_CLASS Autonomic Nervous System (ANS) 7082-21-5 TERODILINE ADVERSE_EFFECT GIS_1_Constipation 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 7082-21-5 TERODILINE ADVERSE_EFFECT NEU_3_Dementia 7082-21-5 TERODILINE THERAPEUTIC_CLASS Parasympatholytic Agents 7082-21-5 TERODILINE TISSUE_TOXICITY Ventricular Tachycardia 7082-21-5 TERODILINE TISSUE_TOXICITY Cardiac Arrhythmia 7082-21-5 TERODILINE TISSUE_TOXICITY Heart Block 7082-21-5 TERODILINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 7082-21-5 TERODILINE INDICATION Urge Incontinence 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_3_Heart Block 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_3_Bradycardia 7082-21-5 TERODILINE ADVERSE_EFFECT GIS_1_Dry Mouth 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 7082-21-5 TERODILINE ADVERSE_EFFECT NEU_1_Vertigo 7082-21-5 TERODILINE KNOWN_TOXICITY Cardiovascular Toxicity 7082-21-5 TERODILINE MODE_CLASS Channel Blocker 7082-21-5 TERODILINE TISSUE_TOXICITY Conduction Defects in the Heart 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_3_Angina 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_3_Conduction Defects in the Heart 7082-21-5 TERODILINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 7082-21-5 TERODILINE ADVERSE_EFFECT OCU_2_Blurred Vision 7082-21-5 TERODILINE ADVERSE_EFFECT NEU_1_Tremor 7082-21-5 TERODILINE TISSUE_TOXICITY Angina 7082-21-5 TERODILINE ADVERSE_EFFECT XXX_2_Thirst 7082-21-5 TERODILINE TISSUE_TOXICITY Atrioventricular Blockade 7082-21-5 TERODILINE MODE_CLASS Receptor Ligand Antagonist 7082-21-5 TERODILINE MECHANISM Modulate G-protein coupled signal transduction 16378-21-5 PIROHEPTINE INDICATION Parkinson's Disease 16378-21-5 PIROHEPTINE MODE_CLASS Enzyme Inhibitor 16378-21-5 PIROHEPTINE MECHANISM Modulate G-protein coupled signal transduction 16378-22-6 PIROHEPTINE MODE_CLASS Enzyme Inhibitor 16378-22-6 PIROHEPTINE INDICATION Parkinson's Disease 16378-22-6 PIROHEPTINE MECHANISM Modulate G-protein coupled signal transduction 16714-57-1 METHIOGUANINE THERAPEUTIC_CLASS Antineoplastics 16714-57-1 METHIOGUANINE MODE_CLASS Enzyme substrate mimic 16714-57-1 METHIOGUANINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, thiopurine base 16714-57-1 METHIOGUANINE PRODUCT_CLASS Anti-cancers 16714-57-1 METHIOGUANINE MECHANISM Incorporate into DNA/RNA/Protein 16915-70-1 NIFURSOL THERAPEUTIC_CLASS Antiparasitics 16915-70-1 NIFURSOL PRODUCT_CLASS Veterinarian 17127-48-9 GLAZIOVINE PRODUCT_CLASS Central Nervous System (CNS) 17127-48-9 GLAZIOVINE THERAPEUTIC_CLASS Antidepressants 17127-48-9 GLAZIOVINE INDICATION Depression 17230-85-2 AMQUINATE INDICATION Malaria 17243-38-8 AZIDOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 17243-38-8 AZIDOCILLIN THERAPEUTIC_CLASS Antibacterials 17243-38-8 AZIDOCILLIN MODE_CLASS Enzyme Inhibitor 17243-38-8 AZIDOCILLIN PRODUCT_CLASS Anti-infectives 17365-01-4 ETIROXATE PRODUCT_CLASS Cardiovasculars 17365-01-4 ETIROXATE THERAPEUTIC_CLASS Hypolipidemic Agents 17365-01-4 ETIROXATE INDICATION Hyperlipoproteinemia 17692-22-7 METIZOLINE MECHANISM Modulate G-protein coupled signal transduction 17692-22-7 METIZOLINE PRODUCT_CLASS Cardiovasculars 17692-22-7 METIZOLINE THERAPEUTIC_CLASS Vasopressors 17692-22-7 METIZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 17692-22-7 METIZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 17692-31-8 DROPROPIZINE INDICATION Cough / Tussis 17692-37-4 FANTRIDONE THERAPEUTIC_CLASS Antidepressants 17692-37-4 FANTRIDONE PRODUCT_CLASS Central Nervous System (CNS) 17692-37-4 FANTRIDONE INDICATION Depression 17780-72-2 CLORGILINE INDICATION Depression 17780-72-2 CLORGILINE MECHANISM Prolong/enhance neural transmission 17780-72-2 CLORGILINE THERAPEUTIC_CLASS Antidepressants 17780-72-2 CLORGILINE MODE_CLASS Enzyme Inhibitor 17780-72-2 CLORGILINE PRODUCT_CLASS Central Nervous System (CNS) 18053-31-1 FOMINOBEN INDICATION Cough / Tussis 24600-36-0 FOMINOBEN INDICATION Cough / Tussis 18109-80-3 BUTAMIRATE INDICATION Cough / Tussis 18356-28-0 ROLZIRACETAM STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 18464-39-6 CAROXAZONE THERAPEUTIC_CLASS Antidepressants 18464-39-6 CAROXAZONE INDICATION Depression 18464-39-6 CAROXAZONE PRODUCT_CLASS Central Nervous System (CNS) 18679-90-8 HOPANTENIC ACID THERAPEUTIC_CLASS Antidepressants 18679-90-8 HOPANTENIC ACID INDICATION Depression 18679-90-8 HOPANTENIC ACID PRODUCT_CLASS Central Nervous System (CNS) 18840-47-6 GEPEFRINE INDICATION Hypotension 18866-78-9 COLTEROL STRUCTURE_ACTIVITY Adrenoceptor agonist 82626-48-0 ZOLPIDEM ADVERSE_EFFECT BBM_3_Anemia 82626-48-0 ZOLPIDEM ADVERSE_EFFECT PSY_2_Physical Dependence 82626-48-0 ZOLPIDEM ADVERSE_EFFECT SKN_2_Rash 82626-48-0 ZOLPIDEM ADVERSE_EFFECT REP_3_Sexual Dysfunction 82626-48-0 ZOLPIDEM KNOWN_TOXICITY Cardiovascular Toxicity 82626-48-0 ZOLPIDEM PRODUCT_CLASS Central Nervous System (CNS) 82626-48-0 ZOLPIDEM INDICATION Insomnia 82626-48-0 ZOLPIDEM THERAPEUTIC_CLASS Sedatives/Hypnotics 82626-48-0 ZOLPIDEM ADVERSE_EFFECT KID_3_Renal Failure 82626-48-0 ZOLPIDEM ADVERSE_EFFECT OCU_2_Diplopia 82626-48-0 ZOLPIDEM ADVERSE_EFFECT XXX_2_Withdrawal 82626-48-0 ZOLPIDEM ADVERSE_EFFECT NEU_2_Headache 82626-48-0 ZOLPIDEM ADVERSE_EFFECT GIS_2_Diarrhea 82626-48-0 ZOLPIDEM ADVERSE_EFFECT LIV_2_Abnormal Liver Function 82626-48-0 ZOLPIDEM ADVERSE_EFFECT GIS_2_Abdominal Pain 82626-48-0 ZOLPIDEM ADVERSE_EFFECT XXX_2_Lethargy 82626-48-0 ZOLPIDEM ADVERSE_EFFECT NEU_2_Ataxia 82626-48-0 ZOLPIDEM ADVERSE_EFFECT NEU_3_Coma 82626-48-0 ZOLPIDEM ADVERSE_EFFECT NEU_2_Dizziness 82626-48-0 ZOLPIDEM ADVERSE_EFFECT PSY_2_Depression 82626-48-0 ZOLPIDEM MODE_CLASS Channel enhancer /opener 82626-48-0 ZOLPIDEM MECHANISM Modulate neural transmission 82626-48-0 ZOLPIDEM ADVERSE_EFFECT PSY_3_Confusion 82626-48-0 ZOLPIDEM ADVERSE_EFFECT PSY_2_Psychologic Dependence 82626-48-0 ZOLPIDEM ADVERSE_EFFECT IMU_2_Allergic Reactions 82626-48-0 ZOLPIDEM ADVERSE_EFFECT CVS_3_Hypotension 82626-48-0 ZOLPIDEM KNOWN_TOXICITY Nephrotoxicity 82626-48-0 ZOLPIDEM TISSUE_TOXICITY Hypotension 82626-48-0 ZOLPIDEM STRUCTURE_ACTIVITY GABA-A agonist, short acting 82626-48-0 ZOLPIDEM ADVERSE_EFFECT BBM_3_Leukopenia 82626-48-0 ZOLPIDEM TISSUE_TOXICITY Renal Failure 82626-48-0 ZOLPIDEM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 82626-48-0 ZOLPIDEM ADVERSE_EFFECT PSY_2_Euphoria 82626-48-0 ZOLPIDEM ADVERSE_EFFECT NEU_2_Drowsiness 99294-93-6 ZOLPIDEM ADVERSE_EFFECT NEU_3_Coma 99294-93-6 ZOLPIDEM ADVERSE_EFFECT NEU_2_Ataxia 99294-93-6 ZOLPIDEM ADVERSE_EFFECT XXX_2_Lethargy 99294-93-6 ZOLPIDEM ADVERSE_EFFECT GIS_2_Abdominal Pain 99294-93-6 ZOLPIDEM STRUCTURE_ACTIVITY GABA-A agonist, short acting 99294-93-6 ZOLPIDEM ADVERSE_EFFECT GIS_2_Diarrhea 99294-93-6 ZOLPIDEM ADVERSE_EFFECT NEU_2_Headache 99294-93-6 ZOLPIDEM ADVERSE_EFFECT NEU_2_Drowsiness 99294-93-6 ZOLPIDEM ADVERSE_EFFECT XXX_2_Withdrawal 99294-93-6 ZOLPIDEM ADVERSE_EFFECT OCU_2_Diplopia 99294-93-6 ZOLPIDEM ADVERSE_EFFECT KID_3_Renal Failure 99294-93-6 ZOLPIDEM THERAPEUTIC_CLASS Sedatives/Hypnotics 99294-93-6 ZOLPIDEM INDICATION Insomnia 99294-93-6 ZOLPIDEM PRODUCT_CLASS Central Nervous System (CNS) 99294-93-6 ZOLPIDEM KNOWN_TOXICITY Cardiovascular Toxicity 99294-93-6 ZOLPIDEM ADVERSE_EFFECT NEU_2_Dizziness 99294-93-6 ZOLPIDEM ADVERSE_EFFECT PSY_2_Depression 99294-93-6 ZOLPIDEM MODE_CLASS Channel enhancer /opener 99294-93-6 ZOLPIDEM MECHANISM Modulate neural transmission 99294-93-6 ZOLPIDEM ADVERSE_EFFECT REP_3_Sexual Dysfunction 99294-93-6 ZOLPIDEM ADVERSE_EFFECT SKN_2_Rash 99294-93-6 ZOLPIDEM ADVERSE_EFFECT PSY_2_Physical Dependence 99294-93-6 ZOLPIDEM ADVERSE_EFFECT BBM_3_Anemia 99294-93-6 ZOLPIDEM ADVERSE_EFFECT BBM_3_Leukopenia 99294-93-6 ZOLPIDEM ADVERSE_EFFECT LIV_2_Abnormal Liver Function 99294-93-6 ZOLPIDEM TISSUE_TOXICITY Hypotension 99294-93-6 ZOLPIDEM ADVERSE_EFFECT CVS_3_Hypotension 99294-93-6 ZOLPIDEM ADVERSE_EFFECT IMU_2_Allergic Reactions 99294-93-6 ZOLPIDEM ADVERSE_EFFECT PSY_2_Psychologic Dependence 99294-93-6 ZOLPIDEM ADVERSE_EFFECT PSY_3_Confusion 99294-93-6 ZOLPIDEM ADVERSE_EFFECT PSY_2_Euphoria 99294-93-6 ZOLPIDEM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 99294-93-6 ZOLPIDEM TISSUE_TOXICITY Renal Failure 99294-93-6 ZOLPIDEM KNOWN_TOXICITY Nephrotoxicity 14402-89-2 SODIUM NITROPRUSSIDE TA_LEVEL_2 Congestive heart failure 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT PSY_2_Psychosis 14402-89-2 SODIUM NITROPRUSSIDE ACTIVITY_CLASS Vasodilator 14402-89-2 SODIUM NITROPRUSSIDE STRUCTURE_ACTIVITY NO doner 14402-89-2 SODIUM NITROPRUSSIDE ZERO_CLASS N 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT LUN_2_Dyspnea 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT PSY_2_Confusion 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Hyperreflexia 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Headache 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT XXX_2_Diaphoresis 14402-89-2 SODIUM NITROPRUSSIDE TA_LEVEL_1 Cardiovascular 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Dizziness 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_1_Syncope 14402-89-2 SODIUM NITROPRUSSIDE MECH_LEVEL_2 breakdown product NO 14402-89-2 SODIUM NITROPRUSSIDE INDICATION Hypotension Induction 14402-89-2 SODIUM NITROPRUSSIDE KNOWN_TOXICITY Cardiovascular Toxicity 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Coma 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT XXX_2_Restlessness 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_1_Hypotension 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT SKN_2_Flushing 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT SKN_2_Rash 14402-89-2 SODIUM NITROPRUSSIDE PRODUCT_CLASS Cardiovasculars 14402-89-2 SODIUM NITROPRUSSIDE THERAPEUTIC_CLASS Congestive Heart Failure 14402-89-2 SODIUM NITROPRUSSIDE INDICATION Hypertensive Urgency 14402-89-2 SODIUM NITROPRUSSIDE MESH_LEVEL_3 Ferric Compounds 14402-89-2 SODIUM NITROPRUSSIDE MESH_LEVEL_2 Iron Compounds 14402-89-2 SODIUM NITROPRUSSIDE INDICATION Congestive Heart Failure (CHF) 14402-89-2 SODIUM NITROPRUSSIDE MECHANISM Reduce vasoconstriction 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT END_2_Metabolic Acidosis 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Ataxia 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT MSK_2_Muscle Twitching 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_2_Palpitation 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT OCU_2_Mydriasis 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 14402-89-2 SODIUM NITROPRUSSIDE THERAPEUTIC_CLASS Vasodilators 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT OTO_2_Tinnitus 14402-89-2 SODIUM NITROPRUSSIDE MECH_LEVEL_3 Guanylate cyclase 14402-89-2 SODIUM NITROPRUSSIDE INDICATION Hypertensive Emergency 14402-89-2 SODIUM NITROPRUSSIDE MESH_LEVEL_1 Inorganic Chemicals 14402-89-2 SODIUM NITROPRUSSIDE TISSUE_TOXICITY Hypotension 14402-89-2 SODIUM NITROPRUSSIDE THERAPEUTIC_CLASS Antihypertensive Agents 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Seizures 14402-89-2 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Increased Intracranial Pressure 13755-38-9 SODIUM NITROPRUSSIDE INDICATION Hypotension Induction 13755-38-9 SODIUM NITROPRUSSIDE MECHANISM Reduce vasoconstriction 13755-38-9 SODIUM NITROPRUSSIDE INDICATION Congestive Heart Failure (CHF) 13755-38-9 SODIUM NITROPRUSSIDE MESH_LEVEL_2 Iron Compounds 13755-38-9 SODIUM NITROPRUSSIDE MESH_LEVEL_3 Ferric Compounds 13755-38-9 SODIUM NITROPRUSSIDE INDICATION Hypertensive Urgency 13755-38-9 SODIUM NITROPRUSSIDE THERAPEUTIC_CLASS Congestive Heart Failure 13755-38-9 SODIUM NITROPRUSSIDE PRODUCT_CLASS Cardiovasculars 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT SKN_2_Rash 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT SKN_2_Flushing 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_1_Hypotension 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT XXX_2_Restlessness 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Coma 13755-38-9 SODIUM NITROPRUSSIDE KNOWN_TOXICITY Cardiovascular Toxicity 13755-38-9 SODIUM NITROPRUSSIDE MECH_LEVEL_2 breakdown product NO 13755-38-9 SODIUM NITROPRUSSIDE THERAPEUTIC_CLASS Vasodilators 13755-38-9 SODIUM NITROPRUSSIDE ACTIVITY_CLASS Vasodilator 13755-38-9 SODIUM NITROPRUSSIDE STRUCTURE_ACTIVITY NO doner 13755-38-9 SODIUM NITROPRUSSIDE ZERO_CLASS N 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT LUN_2_Dyspnea 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT PSY_2_Confusion 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Hyperreflexia 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Headache 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 13755-38-9 SODIUM NITROPRUSSIDE TA_LEVEL_2 Congestive heart failure 13755-38-9 SODIUM NITROPRUSSIDE TA_LEVEL_1 Cardiovascular 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Dizziness 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_1_Syncope 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT PSY_2_Psychosis 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Increased Intracranial Pressure 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Seizures 13755-38-9 SODIUM NITROPRUSSIDE THERAPEUTIC_CLASS Antihypertensive Agents 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT END_2_Metabolic Acidosis 13755-38-9 SODIUM NITROPRUSSIDE TISSUE_TOXICITY Hypotension 13755-38-9 SODIUM NITROPRUSSIDE MESH_LEVEL_1 Inorganic Chemicals 13755-38-9 SODIUM NITROPRUSSIDE INDICATION Hypertensive Emergency 13755-38-9 SODIUM NITROPRUSSIDE MECH_LEVEL_3 Guanylate cyclase 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT OTO_2_Tinnitus 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT OCU_2_Mydriasis 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT XXX_2_Diaphoresis 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT CVS_2_Palpitation 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT MSK_2_Muscle Twitching 13755-38-9 SODIUM NITROPRUSSIDE ADVERSE_EFFECT NEU_2_Ataxia 62571-86-2 CAPTOPRIL TISSUE_TOXICITY Angina Pectoris 62571-86-2 CAPTOPRIL ADVERSE_EFFECT EMB_2_Fetal / Neonatal Morbidity and Mortality 62571-86-2 CAPTOPRIL ADVERSE_EFFECT XXX_3_Taste Disturbances 62571-86-2 CAPTOPRIL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 62571-86-2 CAPTOPRIL ADVERSE_EFFECT SKN_3_Rash 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_2_Tachycardia 62571-86-2 CAPTOPRIL TISSUE_TOXICITY Hepatotoxicity 62571-86-2 CAPTOPRIL MESH_LEVEL_2 Amino Acids 62571-86-2 CAPTOPRIL INDICATION Renal Hypertension 62571-86-2 CAPTOPRIL MESH_LEVEL_3 Amino Acids, Cyclic 62571-86-2 CAPTOPRIL ADVERSE_EFFECT EMB_2_Fetal Toxicity 62571-86-2 CAPTOPRIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 62571-86-2 CAPTOPRIL TA_LEVEL_2 Hypertension 62571-86-2 CAPTOPRIL ZERO_CLASS N 62571-86-2 CAPTOPRIL ACTIVITY_CLASS RAAS inhibitor 62571-86-2 CAPTOPRIL MECH_LEVEL_2 ACE inhibitor 62571-86-2 CAPTOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 62571-86-2 CAPTOPRIL INDICATION Congestive Heart Failure (CHF) 62571-86-2 CAPTOPRIL MODE_CLASS Enzyme Inhibitor 62571-86-2 CAPTOPRIL PRODUCT_CLASS Cardiovasculars 62571-86-2 CAPTOPRIL INDICATION Scleroderma Renal Crisis 62571-86-2 CAPTOPRIL MECH_LEVEL_1 Vasorelaxation 62571-86-2 CAPTOPRIL ADVERSE_EFFECT SKN_3_Pruritis 62571-86-2 CAPTOPRIL TISSUE_TOXICITY Congestive Heart Failure 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_2_Palpitation 62571-86-2 CAPTOPRIL ADVERSE_EFFECT IMU_3_Angioedema 62571-86-2 CAPTOPRIL ADVERSE_EFFECT BBM_3_Agranulocytosis 62571-86-2 CAPTOPRIL ADVERSE_EFFECT LUN_1_Cough 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_2_Hypotension 62571-86-2 CAPTOPRIL KNOWN_TOXICITY Hepatotoxicity 62571-86-2 CAPTOPRIL TISSUE_TOXICITY Myocardial Infarction 62571-86-2 CAPTOPRIL MECHANISM Reduce vasoconstriction 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_3_Raynaud's Syndrome 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_3_Angina Pectoris 62571-86-2 CAPTOPRIL ADVERSE_EFFECT BBM_3_Neutropenia 62571-86-2 CAPTOPRIL ADVERSE_EFFECT LIV_3_Hepatotoxicity 62571-86-2 CAPTOPRIL ADVERSE_EFFECT IMU_3_Anaphylaxis 62571-86-2 CAPTOPRIL ADVERSE_EFFECT ELT_2_Hyperkalemia 62571-86-2 CAPTOPRIL ADVERSE_EFFECT XXX_3_Fever 62571-86-2 CAPTOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 62571-86-2 CAPTOPRIL THERAPEUTIC_CLASS Congestive Heart Failure 62571-86-2 CAPTOPRIL INDICATION Raynaud's Phenomenon 62571-86-2 CAPTOPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 62571-86-2 CAPTOPRIL INDICATION Edema 62571-86-2 CAPTOPRIL INDICATION Left Ventricular Dysfunction 62571-86-2 CAPTOPRIL MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 62571-86-2 CAPTOPRIL TISSUE_TOXICITY Hypotension 62571-86-2 CAPTOPRIL KNOWN_TOXICITY Cardiovascular Toxicity 62571-86-2 CAPTOPRIL ADVERSE_EFFECT EMB_2_Oligohydramnios 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_2_Chest Pain 62571-86-2 CAPTOPRIL ADVERSE_EFFECT KID_3_Proteinuria 62571-86-2 CAPTOPRIL ADVERSE_EFFECT ELT_3_Hyponatremia 62571-86-2 CAPTOPRIL ADVERSE_EFFECT NEU_1_Headache 62571-86-2 CAPTOPRIL ADVERSE_EFFECT CVS_3_Myocardial Infarction 62571-86-2 CAPTOPRIL TA_LEVEL_1 Cardiovascular 62571-86-2 CAPTOPRIL INDICATION Hypertension 62571-86-2 CAPTOPRIL TA_LEVEL_3 Diuretic 62571-86-2 CAPTOPRIL INDICATION Diabetic Nephropathy 145781-32-4 ZOLASARTAN PRODUCT_CLASS Cardiovasculars 145781-32-4 ZOLASARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 145781-32-4 ZOLASARTAN MECHANISM Reduce vasoconstriction 145781-32-4 ZOLASARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 145781-32-4 ZOLASARTAN INDICATION Hypertension 145781-32-4 ZOLASARTAN THERAPEUTIC_CLASS Antihypertensive Agents 114798-27-5 EXP-7711 PRODUCT_CLASS Cardiovasculars 114798-27-5 EXP-7711 MODE_CLASS Receptor Ligand Antagonist, Selective 114798-27-5 EXP-7711 MECHANISM Reduce vasoconstriction 114798-27-5 EXP-7711 THERAPEUTIC_CLASS Antihypertensive Agents 26328-11-0 (S)-(-)-PINDOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 26328-11-0 (S)-(-)-PINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 26328-11-0 (S)-(-)-PINDOLOL THERAPEUTIC_CLASS Sympatholytic Agents 26328-11-0 (S)-(-)-PINDOLOL MECHANISM Modulate G-protein coupled signal transduction 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT MSK_3_Myalgia 4199-10-4 S-(-)-PROPRANOLOL INDICATION Paroxysmal Supraventricular Tachycardia 4199-10-4 S-(-)-PROPRANOLOL INDICATION Pheochromocytoma 4199-10-4 S-(-)-PROPRANOLOL INDICATION Cardiac Arrhythmias 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT LUN_2_Dyspnea 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT END_2_Hyperglycemia 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT GIS_1_Diarrhea 4199-10-4 S-(-)-PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 4199-10-4 S-(-)-PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 4199-10-4 S-(-)-PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 4199-10-4 S-(-)-PROPRANOLOL INDICATION Tremor 4199-10-4 S-(-)-PROPRANOLOL INDICATION Postmyocardial Infarction 4199-10-4 S-(-)-PROPRANOLOL INDICATION Atrial Flutter 4199-10-4 S-(-)-PROPRANOLOL INDICATION Myocardial Infarction 4199-10-4 S-(-)-PROPRANOLOL TISSUE_TOXICITY Atrioventricular Blockade 4199-10-4 S-(-)-PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 4199-10-4 S-(-)-PROPRANOLOL INDICATION Angina Pectoris 4199-10-4 S-(-)-PROPRANOLOL INDICATION Aortic Stenosis 4199-10-4 S-(-)-PROPRANOLOL INDICATION Myocardial Infarction Prophylaxis 4199-10-4 S-(-)-PROPRANOLOL INDICATION Idiopathic Hypertrophic Subaortic Stenosis (IHSS) 4199-10-4 S-(-)-PROPRANOLOL TISSUE_TOXICITY Congestive Heart Failure 4199-10-4 S-(-)-PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 4199-10-4 S-(-)-PROPRANOLOL THERAPEUTIC_CLASS Antimigraines 4199-10-4 S-(-)-PROPRANOLOL KNOWN_TOXICITY Cardiovascular Toxicity 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT PSY_3_Hallucinations 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT REP_3_Impotence 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT SKN_3_Pruritis 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT END_2_Diabetes Mellitus 4199-10-4 S-(-)-PROPRANOLOL INDICATION Atrial Fibrillation 4199-10-4 S-(-)-PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 4199-10-4 S-(-)-PROPRANOLOL INDICATION Hypertension 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT PSY_3_Nightmares 4199-10-4 S-(-)-PROPRANOLOL INDICATION Migraine Headache 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT PSY_2_Depression 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT XXX_2_Fatigue 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 4199-10-4 S-(-)-PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT NEU_2_Dizziness 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT LUN_2_Asthma 4199-10-4 S-(-)-PROPRANOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 4199-10-4 S-(-)-PROPRANOLOL THERAPEUTIC_CLASS Antianginals 4199-10-4 S-(-)-PROPRANOLOL PRODUCT_CLASS Cardiovasculars 4199-10-4 S-(-)-PROPRANOLOL INDICATION Migraine Prophylaxis 5051-22-9 R-(+)-PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 5051-22-9 R-(+)-PROPRANOLOL INDICATION Hyperthyroidism / Thyrotoxicosis 5051-22-9 R-(+)-PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 5051-22-9 R-(+)-PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 5051-22-9 R-(+)-PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 5051-22-9 R-(+)-PROPRANOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5051-22-9 R-(+)-PROPRANOLOL INDICATION Increased Intraocular Pressure 5051-22-9 R-(+)-PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 5051-22-9 R-(+)-PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 5051-22-9 R-(+)-PROPRANOLOL PRODUCT_CLASS Cardiovasculars 5051-22-9 R-(+)-PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 57801-81-7 BROTIZOLAM MECHANISM Modulate neural transmission 57801-81-7 BROTIZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 57801-81-7 BROTIZOLAM MODE_CLASS Channel Modulator 57801-81-7 BROTIZOLAM PRODUCT_CLASS Central Nervous System (CNS) 57801-81-7 BROTIZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 57801-81-7 BROTIZOLAM INDICATION Insomnia 22316-47-8 CLOBAZAM INDICATION Anxiety Disorders 22316-47-8 CLOBAZAM INDICATION Status Epilepticus 22316-47-8 CLOBAZAM THERAPEUTIC_CLASS Sedatives/Hypnotics 22316-47-8 CLOBAZAM MECHANISM Modulate neural transmission 22316-47-8 CLOBAZAM INDICATION Epilepsy 22316-47-8 CLOBAZAM MODE_CLASS Channel Modulator 22316-47-8 CLOBAZAM PRODUCT_CLASS Central Nervous System (CNS) 22316-47-8 CLOBAZAM THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 22316-47-8 CLOBAZAM INDICATION Alcoholic Withdrawal 22316-47-8 CLOBAZAM THERAPEUTIC_CLASS Anxiolytics 22316-47-8 CLOBAZAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 963-39-3 DEMOXEPAM MODE_CLASS Channel enhancer /opener 963-39-3 DEMOXEPAM PRODUCT_CLASS Central Nervous System (CNS) 963-39-3 DEMOXEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 963-39-3 DEMOXEPAM MECHANISM Modulate neural transmission 126-52-3 ETHINAMATE THERAPEUTIC_CLASS Sedatives/Hypnotics 126-52-3 ETHINAMATE INDICATION Insomnia 126-52-3 ETHINAMATE PRODUCT_CLASS Central Nervous System (CNS) 125-64-4 METHYPRYLON INDICATION Insomnia 125-64-4 METHYPRYLON MECHANISM Modulate neural transmission 125-64-4 METHYPRYLON PRODUCT_CLASS Central Nervous System (CNS) 125-64-4 METHYPRYLON MODE_CLASS Channel Modulator 125-64-4 METHYPRYLON THERAPEUTIC_CLASS Sedatives/Hypnotics 125-64-4 METHYPRYLON STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 146-22-5 NITRAZEPAM TISSUE_TOXICITY Hypotension 146-22-5 NITRAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 146-22-5 NITRAZEPAM ADVERSE_EFFECT CVS_3_Hypotension 146-22-5 NITRAZEPAM ADVERSE_EFFECT IMU_3_Allergic Reactions 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_3_Coma 146-22-5 NITRAZEPAM ADVERSE_EFFECT PSY_3_Confusion 146-22-5 NITRAZEPAM ADVERSE_EFFECT GIS_2_Abdominal Pain 146-22-5 NITRAZEPAM MESH_LEVEL_3 Benzazepines 146-22-5 NITRAZEPAM MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 146-22-5 NITRAZEPAM TA_LEVEL_2 CNS Depressant 146-22-5 NITRAZEPAM INDICATION Insomnia 146-22-5 NITRAZEPAM TA_LEVEL_3 Benzodiazepine 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_2_Dizziness 146-22-5 NITRAZEPAM ADVERSE_EFFECT XXX_3_Tolerance 146-22-5 NITRAZEPAM ADVERSE_EFFECT XXX_2_Lethargy 146-22-5 NITRAZEPAM ADVERSE_EFFECT XXX_2_Withdrawal 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_3_Ataxia 146-22-5 NITRAZEPAM ADVERSE_EFFECT PSY_3_Euphoria 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 146-22-5 NITRAZEPAM ADVERSE_EFFECT REP_3_Sexual Dysfunction 146-22-5 NITRAZEPAM ADVERSE_EFFECT LUN_3_Respiratory Depression 146-22-5 NITRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 146-22-5 NITRAZEPAM MECH_LEVEL_2 faciliates GABA binding 146-22-5 NITRAZEPAM ADVERSE_EFFECT PSY_2_Depression 146-22-5 NITRAZEPAM ZERO_CLASS N 146-22-5 NITRAZEPAM MESH_LEVEL_1 Heterocyclic Compounds 146-22-5 NITRAZEPAM ACTIVITY_CLASS GABA agonist 146-22-5 NITRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, medium acting 146-22-5 NITRAZEPAM ADVERSE_EFFECT LIV_2_Abnormal Liver Function 146-22-5 NITRAZEPAM ADVERSE_EFFECT SKN_3_Rash 146-22-5 NITRAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 146-22-5 NITRAZEPAM ADVERSE_EFFECT OCU_2_Diplopia 146-22-5 NITRAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 146-22-5 NITRAZEPAM MECHANISM Modulate neural transmission 146-22-5 NITRAZEPAM MECH_LEVEL_3 GABA-A receptor A 146-22-5 NITRAZEPAM MECH_LEVEL_1 Modulate neural transmission 146-22-5 NITRAZEPAM MODE_CLASS Channel enhancer /opener 146-22-5 NITRAZEPAM ADVERSE_EFFECT OCU_2_Blurred Vision 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_2_Anterograde Amnesia 146-22-5 NITRAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 146-22-5 NITRAZEPAM ADVERSE_EFFECT NEU_2_Headache 146-22-5 NITRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 146-22-5 NITRAZEPAM TA_LEVEL_1 Central Nervous System (CNS) 1088-11-5 NORDAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 1088-11-5 NORDAZEPAM INDICATION Anxiety Disorders 1088-11-5 NORDAZEPAM MODE_CLASS Channel enhancer /opener 1088-11-5 NORDAZEPAM MECHANISM Modulate neural transmission 1088-11-5 NORDAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 1088-11-5 NORDAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 564-36-3 ERGOCORNINE STRUCTURE_ACTIVITY Ergot alkaloid 564-36-3 ERGOCORNINE PRODUCT_CLASS Biochemicals 564-36-3 ERGOCORNINE MECHANISM Modulate G-protein coupled signal transduction 511-08-0 ERGOCRISTINE STRUCTURE_ACTIVITY Ergot alkaloid 511-09-1 ALPHA-ERGOCRYPTINE MODE_CLASS Receptor Agonist 511-09-1 ALPHA-ERGOCRYPTINE MECHANISM Prolong/enhance neural transmission 511-09-1 ALPHA-ERGOCRYPTINE STRUCTURE_ACTIVITY Ergot alkaloid 511-09-1 ALPHA-ERGOCRYPTINE PRODUCT_CLASS Biochemicals 140387-89-9 LISURIDE TISSUE_TOXICITY Hypotension 140387-89-9 LISURIDE ADVERSE_EFFECT GIS_3_Constipation 140387-89-9 LISURIDE ADVERSE_EFFECT NEU_2_Headache 140387-89-9 LISURIDE ADVERSE_EFFECT XXX_2_Lethargy 140387-89-9 LISURIDE MECHANISM Prolong/enhance neural transmission 140387-89-9 LISURIDE INDICATION Parkinson's Disease 140387-89-9 LISURIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 140387-89-9 LISURIDE ADVERSE_EFFECT XXX_3_Tolerance 140387-89-9 LISURIDE THERAPEUTIC_CLASS Movement Disorders 140387-89-9 LISURIDE ADVERSE_EFFECT CVS_3_Raynaud's Syndrome 140387-89-9 LISURIDE PRODUCT_CLASS Central Nervous System (CNS) 140387-89-9 LISURIDE ADVERSE_EFFECT CVS_2_Hypotension 140387-89-9 LISURIDE ADVERSE_EFFECT NEU_2_Drowsiness 140387-89-9 LISURIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 140387-89-9 LISURIDE ADVERSE_EFFECT XXX_2_Malaise 140387-89-9 LISURIDE STRUCTURE_ACTIVITY Ergot alkaloid 140387-89-9 LISURIDE MODE_CLASS Receptor Agonist 140387-89-9 LISURIDE KNOWN_TOXICITY Cardiovascular Toxicity 140387-89-9 LISURIDE ADVERSE_EFFECT PSY_3_Hallucinations 140387-89-9 LISURIDE ADVERSE_EFFECT NEU_2_Dizziness 19875-60-6 LISURIDE KNOWN_TOXICITY Cardiovascular Toxicity 19875-60-6 LISURIDE ADVERSE_EFFECT NEU_2_Drowsiness 19875-60-6 LISURIDE ADVERSE_EFFECT CVS_2_Hypotension 19875-60-6 LISURIDE PRODUCT_CLASS Central Nervous System (CNS) 19875-60-6 LISURIDE ADVERSE_EFFECT CVS_3_Raynaud's Syndrome 19875-60-6 LISURIDE ADVERSE_EFFECT XXX_3_Tolerance 19875-60-6 LISURIDE MECHANISM Prolong/enhance neural transmission 19875-60-6 LISURIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 19875-60-6 LISURIDE TISSUE_TOXICITY Hypotension 19875-60-6 LISURIDE ADVERSE_EFFECT GIS_3_Constipation 19875-60-6 LISURIDE ADVERSE_EFFECT NEU_2_Headache 19875-60-6 LISURIDE ADVERSE_EFFECT XXX_2_Lethargy 19875-60-6 LISURIDE INDICATION Parkinson's Disease 19875-60-6 LISURIDE THERAPEUTIC_CLASS Movement Disorders 19875-60-6 LISURIDE MODE_CLASS Receptor Agonist 19875-60-6 LISURIDE STRUCTURE_ACTIVITY Ergot alkaloid 19875-60-6 LISURIDE ADVERSE_EFFECT XXX_2_Malaise 19875-60-6 LISURIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 19875-60-6 LISURIDE ADVERSE_EFFECT PSY_3_Hallucinations 19875-60-6 LISURIDE ADVERSE_EFFECT NEU_2_Dizziness 18016-80-3 TERGURIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 18016-80-3 TERGURIDE INDICATION Parkinson's Disease 18016-80-3 TERGURIDE MECHANISM Prolong/enhance neural transmission 18016-80-3 TERGURIDE PRODUCT_CLASS Central Nervous System (CNS) 18016-80-3 TERGURIDE INDICATION Hyperprolactinemia 18016-80-3 TERGURIDE THERAPEUTIC_CLASS Movement Disorders 18016-80-3 TERGURIDE THERAPEUTIC_CLASS Pituitary Hormones 18016-80-3 TERGURIDE MODE_CLASS Receptor Partial Agonist 37686-84-3 TERGURIDE MECHANISM Prolong/enhance neural transmission 37686-84-3 TERGURIDE PRODUCT_CLASS Central Nervous System (CNS) 37686-84-3 TERGURIDE INDICATION Parkinson's Disease 37686-84-3 TERGURIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 37686-84-3 TERGURIDE MODE_CLASS Receptor Partial Agonist 37686-84-3 TERGURIDE THERAPEUTIC_CLASS Pituitary Hormones 37686-84-3 TERGURIDE INDICATION Hyperprolactinemia 37686-84-3 TERGURIDE THERAPEUTIC_CLASS Movement Disorders 602-85-7 LYSERGOL PRODUCT_CLASS Toxicants 602-85-7 LYSERGOL MECHANISM Prolong/enhance neural transmission 602-85-7 LYSERGOL STRUCTURE_ACTIVITY Ergot alkaloid 602-85-7 LYSERGOL MODE_CLASS Receptor Agonist 71990-00-6 BREMAZOCINE MECHANISM Modulate neural transmission 71990-00-6 BREMAZOCINE THERAPEUTIC_CLASS Analgesics, Opioid 71990-00-6 BREMAZOCINE MODE_CLASS Receptor Agonist 71990-00-6 BREMAZOCINE PRODUCT_CLASS Analgesics 14357-78-9 DIPRENORPHINE MECHANISM Modulate neural transmission 14357-78-9 DIPRENORPHINE STRUCTURE_ACTIVITY Opioid receptor antagonist 14357-78-9 DIPRENORPHINE MODE_CLASS Receptor Ligand Antagonist 14357-78-9 DIPRENORPHINE PRODUCT_CLASS Biochemicals 87151-85-7 SPIRADOLINE THERAPEUTIC_CLASS Analgesics, Opioid 87151-85-7 SPIRADOLINE PRODUCT_CLASS Central Nervous System (CNS) 87151-85-7 SPIRADOLINE MECHANISM Modulate neural transmission 87151-85-7 SPIRADOLINE MODE_CLASS Receptor Agonist, selective 50-37-3 LSD MECHANISM Modulate G-protein coupled signal transduction 50-37-3 LSD MODE_CLASS Receptor Agonist, Non-selective 50-37-3 LSD PRODUCT_CLASS Central Nervous System (CNS) 50-37-3 LSD MECHANISM Modulate neural transmission 152-02-3 LEVALLORPHAN STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 152-02-3 LEVALLORPHAN MECHANISM Modulate neural transmission 152-02-3 LEVALLORPHAN MODE_CLASS Receptor Partial Agonist 59-63-2 ISOCARBOXAZID MECHANISM Prolong/enhance neural transmission 59-63-2 ISOCARBOXAZID PRODUCT_CLASS Central Nervous System (CNS) 59-63-2 ISOCARBOXAZID THERAPEUTIC_CLASS Antidepressants 59-63-2 ISOCARBOXAZID INDICATION Depression 59-63-2 ISOCARBOXAZID MODE_CLASS Enzyme Inhibitor 54340-58-8 MEPTAZINOL THERAPEUTIC_CLASS Analgesics, Opioid 54340-58-8 MEPTAZINOL MECHANISM Modulate neural transmission 54340-58-8 MEPTAZINOL MODE_CLASS Receptor Partial Agonist 54340-58-8 MEPTAZINOL INDICATION Moderate Pain 54340-58-8 MEPTAZINOL INDICATION Severe Pain 54340-58-8 MEPTAZINOL PRODUCT_CLASS Analgesics 59263-76-2 MEPTAZINOL MECHANISM Modulate neural transmission 59263-76-2 MEPTAZINOL THERAPEUTIC_CLASS Analgesics, Opioid 59263-76-2 MEPTAZINOL MODE_CLASS Receptor Partial Agonist 59263-76-2 MEPTAZINOL INDICATION Moderate Pain 59263-76-2 MEPTAZINOL INDICATION Severe Pain 59263-76-2 MEPTAZINOL PRODUCT_CLASS Analgesics 34433-66-4 LEVOMETHADYL ACETATE PRODUCT_CLASS Central Nervous System (CNS) 34433-66-4 LEVOMETHADYL ACETATE MECHANISM Modulate neural transmission 34433-66-4 LEVOMETHADYL ACETATE PRODUCT_CLASS Other Human Uses 34433-66-4 LEVOMETHADYL ACETATE MODE_CLASS Receptor Agonist 34433-66-4 LEVOMETHADYL ACETATE THERAPEUTIC_CLASS Drug Dependence Therapy 34433-66-4 LEVOMETHADYL ACETATE INDICATION Opiate Agonist Dependence 151140-96-4 AVITRIPTAN MECHANISM Modulate cerebral vasoconstriction 151140-96-4 AVITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 151140-96-4 AVITRIPTAN INDICATION Migraine Headache 151140-96-4 AVITRIPTAN THERAPEUTIC_CLASS Antimigraines 171171-42-9 AVITRIPTAN INDICATION Migraine Headache 171171-42-9 AVITRIPTAN MECHANISM Modulate cerebral vasoconstriction 171171-42-9 AVITRIPTAN THERAPEUTIC_CLASS Antimigraines 171171-42-9 AVITRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 76-57-3 CODEINE INDICATION Diarrhea 76-57-3 CODEINE MECHANISM Modulate neural transmission 76-57-3 CODEINE THERAPEUTIC_CLASS Analgesics, Opioid 76-57-3 CODEINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Euphoria 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Confusion 76-57-3 CODEINE ADVERSE_EFFECT SKN_2_Pruritis 76-57-3 CODEINE ADVERSE_EFFECT NEU_3_Sleep Disturbances 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Nervousness 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Hallucinations 76-57-3 CODEINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 76-57-3 CODEINE ADVERSE_EFFECT LUN_3_Respiratory Depression 76-57-3 CODEINE INDICATION Migraine Headache 76-57-3 CODEINE PRODUCT_CLASS Respiratory System 76-57-3 CODEINE PRODUCT_CLASS Analgesics 76-57-3 CODEINE ADVERSE_EFFECT OCU_3_Miosis 76-57-3 CODEINE ADVERSE_EFFECT GUS_3_Urinary Retention 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Mental Confusion 76-57-3 CODEINE ADVERSE_EFFECT XXX_3_Restlessness 76-57-3 CODEINE ADVERSE_EFFECT XXX_3_Tolerance 76-57-3 CODEINE ADVERSE_EFFECT NEU_3_Headache 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Anxiety 76-57-3 CODEINE ADVERSE_EFFECT CVS_3_Hypotension 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Disorientation 76-57-3 CODEINE MODE_CLASS Receptor Agonist, selective 76-57-3 CODEINE INDICATION Headache 76-57-3 CODEINE PRODUCT_CLASS Gastrointestinal System 76-57-3 CODEINE KNOWN_TOXICITY Cardiovascular Toxicity 76-57-3 CODEINE ADVERSE_EFFECT PSY_2_CNS Depression 76-57-3 CODEINE ADVERSE_EFFECT XXX_3_Xerostomia 76-57-3 CODEINE ADVERSE_EFFECT _3_Decreased Thyroid Hormone Levels 76-57-3 CODEINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 76-57-3 CODEINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 76-57-3 CODEINE ADVERSE_EFFECT NEU_1_Drowsiness 76-57-3 CODEINE ADVERSE_EFFECT NEU_3_Seizures 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Dysphoria 76-57-3 CODEINE TISSUE_TOXICITY Hypotension 76-57-3 CODEINE STRUCTURE_ACTIVITY Opioid receptor agonist 76-57-3 CODEINE INDICATION Myalgia 76-57-3 CODEINE INDICATION Pain 76-57-3 CODEINE INDICATION Cough / Tussis 76-57-3 CODEINE ADVERSE_EFFECT NEU_3_Syncope 76-57-3 CODEINE ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 76-57-3 CODEINE ADVERSE_EFFECT CVS_3_Hypertension 76-57-3 CODEINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 76-57-3 CODEINE ADVERSE_EFFECT NEU_2_Dizziness 76-57-3 CODEINE ADVERSE_EFFECT PSY_3_Dependence 76-57-3 CODEINE ADVERSE_EFFECT NEU_2_Lightheadedness 76-57-3 CODEINE ADVERSE_EFFECT CVS_3_Palpitation 76-57-3 CODEINE ADVERSE_EFFECT OCU_3_Blurred Vision 76-57-3 CODEINE THERAPEUTIC_CLASS Antidiarrhea Agents 62-67-9 NALORPHINE MODE_CLASS Receptor Ligand Antagonist 62-67-9 NALORPHINE MODE_CLASS Receptor Partial Agonist 62-67-9 NALORPHINE THERAPEUTIC_CLASS Opiate Antagonists 62-67-9 NALORPHINE MODE_CLASS Receptor Agonist 62-67-9 NALORPHINE PRODUCT_CLASS Central Nervous System (CNS) 62-67-9 NALORPHINE STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 62-67-9 NALORPHINE MECHANISM Modulate neural transmission 33386-08-2 BUSPIRONE MESH_LEVEL_1 Heterocyclic Compounds 33386-08-2 BUSPIRONE MESH_LEVEL_3 Pyrimidines 33386-08-2 BUSPIRONE MECH_LEVEL_1 Modulate neural transmission 33386-08-2 BUSPIRONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 33386-08-2 BUSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_2_Tremor 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_1_Dizziness 33386-08-2 BUSPIRONE ADVERSE_EFFECT OCU_3_Visual Disturbances 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_3_Ataxia 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_3_Dystonia 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_2_Confusion 33386-08-2 BUSPIRONE ADVERSE_EFFECT OTO_3_Tinnitus 33386-08-2 BUSPIRONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 33386-08-2 BUSPIRONE TA_LEVEL_3 Anxlytic 33386-08-2 BUSPIRONE MECH_LEVEL_3 5HT receptor 1A 33386-08-2 BUSPIRONE MECHANISM Modulate neural transmission 33386-08-2 BUSPIRONE ACTIVITY_CLASS Serotonin agonist 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_2_Excitement 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 33386-08-2 BUSPIRONE ADVERSE_EFFECT XXX_2_Restlessness 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_2_Paresthesia 33386-08-2 BUSPIRONE ADVERSE_EFFECT XXX_2_Weakness 33386-08-2 BUSPIRONE ADVERSE_EFFECT OCU_2_Blurred Vision 33386-08-2 BUSPIRONE MECH_LEVEL_2 5HT antagonist 33386-08-2 BUSPIRONE STRUCTURE_ACTIVITY 5HT1A partial agonist 33386-08-2 BUSPIRONE ZERO_CLASS N 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 33386-08-2 BUSPIRONE ADVERSE_EFFECT MSK_2_Myalgia 33386-08-2 BUSPIRONE TA_LEVEL_2 CNS Depressant 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_1_Drowsiness 33386-08-2 BUSPIRONE ADVERSE_EFFECT NEU_1_Headache 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_2_Nervousness 33386-08-2 BUSPIRONE INDICATION Anxiety Disorders 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_2_Agitation 33386-08-2 BUSPIRONE TA_LEVEL_1 Central Nervous System (CNS) 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 33386-08-2 BUSPIRONE ADVERSE_EFFECT PSY_2_Emotional Lability 33386-08-2 BUSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 33386-08-2 BUSPIRONE MODE_CLASS Receptor Partial Agonist 36505-84-7 BUSPIRONE MESH_LEVEL_3 Pyrimidines 36505-84-7 BUSPIRONE ACTIVITY_CLASS Serotonin agonist 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_2_Excitement 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 36505-84-7 BUSPIRONE ADVERSE_EFFECT XXX_2_Restlessness 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_2_Paresthesia 36505-84-7 BUSPIRONE ADVERSE_EFFECT XXX_2_Weakness 36505-84-7 BUSPIRONE ADVERSE_EFFECT OCU_2_Blurred Vision 36505-84-7 BUSPIRONE MECH_LEVEL_2 5HT antagonist 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 36505-84-7 BUSPIRONE ADVERSE_EFFECT MSK_2_Myalgia 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_2_Agitation 36505-84-7 BUSPIRONE MECH_LEVEL_1 Modulate neural transmission 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_1_Drowsiness 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_1_Headache 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_2_Nervousness 36505-84-7 BUSPIRONE INDICATION Anxiety Disorders 36505-84-7 BUSPIRONE MODE_CLASS Receptor Partial Agonist 36505-84-7 BUSPIRONE TA_LEVEL_1 Central Nervous System (CNS) 36505-84-7 BUSPIRONE TA_LEVEL_2 CNS Depressant 36505-84-7 BUSPIRONE THERAPEUTIC_CLASS Sedatives/Hypnotics 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_2_Emotional Lability 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_3_Ataxia 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_1_Dizziness 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_2_Tremor 36505-84-7 BUSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 36505-84-7 BUSPIRONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 36505-84-7 BUSPIRONE STRUCTURE_ACTIVITY 5HT1A partial agonist 36505-84-7 BUSPIRONE MESH_LEVEL_1 Heterocyclic Compounds 36505-84-7 BUSPIRONE ADVERSE_EFFECT OCU_3_Visual Disturbances 36505-84-7 BUSPIRONE ADVERSE_EFFECT NEU_3_Dystonia 36505-84-7 BUSPIRONE ADVERSE_EFFECT PSY_2_Confusion 36505-84-7 BUSPIRONE ADVERSE_EFFECT OTO_3_Tinnitus 36505-84-7 BUSPIRONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 36505-84-7 BUSPIRONE TA_LEVEL_3 Anxlytic 36505-84-7 BUSPIRONE MECH_LEVEL_3 5HT receptor 1A 36505-84-7 BUSPIRONE MECHANISM Modulate neural transmission 36505-84-7 BUSPIRONE ZERO_CLASS N 157284-96-3 ANTALARMIN THERAPEUTIC_CLASS Sedatives/Hypnotics 157284-96-3 ANTALARMIN INDICATION Anxiety Disorders 157284-96-3 ANTALARMIN PRODUCT_CLASS Central Nervous System (CNS) 111841-85-1 ABECARNIL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 111841-85-1 ABECARNIL MECHANISM Modulate neural transmission 111841-85-1 ABECARNIL THERAPEUTIC_CLASS Anxiolytics 111841-85-1 ABECARNIL PRODUCT_CLASS Central Nervous System (CNS) 111841-85-1 ABECARNIL MODE_CLASS Channel enhancer /opener 135145-96-9 L-158809 MODE_CLASS Receptor Ligand Antagonist, Selective 135145-96-9 L-158809 MECHANISM Reduce vasoconstriction 135145-96-9 L-158809 THERAPEUTIC_CLASS Antihypertensive Agents 135145-96-9 L-158809 PRODUCT_CLASS Cardiovasculars 361-09-1 CHOLIC ACID ACTIVITY_CLASS Toxicant 361-09-1 CHOLIC ACID TA_LEVEL_2 hyperlipidemic? 361-09-1 CHOLIC ACID ADVERSE_EFFECT END_1_Hypercholesteremia 361-09-1 CHOLIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 361-09-1 CHOLIC ACID ADVERSE_EFFECT MSK_1_Muscle Twitching 361-09-1 CHOLIC ACID STRUCTURE_ACTIVITY FXR agonist 361-09-1 CHOLIC ACID TA_LEVEL_1 Vitamins, Minerals and Nutrients 361-09-1 CHOLIC ACID TISSUE_TOXICITY Hypotension 361-09-1 CHOLIC ACID MECH_LEVEL_2 Unknown mechanism 361-09-1 CHOLIC ACID MESH_LEVEL_1 Polycyclic Hydrocarbons 361-09-1 CHOLIC ACID ADVERSE_EFFECT IMU_3_Anaphylaxis 361-09-1 CHOLIC ACID ADVERSE_EFFECT MSK_1_Spasm 361-09-1 CHOLIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 361-09-1 CHOLIC ACID ZERO_CLASS N 361-09-1 CHOLIC ACID MESH_LEVEL_3 Cholanes 361-09-1 CHOLIC ACID MECH_LEVEL_3 Unknown mechanism 361-09-1 CHOLIC ACID ADVERSE_EFFECT CVS_2_Hypotension 361-09-1 CHOLIC ACID MESH_LEVEL_2 Steroids 361-09-1 CHOLIC ACID ADVERSE_EFFECT CVS_2_Bradycardia 81-25-4 CHOLIC ACID MESH_LEVEL_3 Cholanes 81-25-4 CHOLIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 81-25-4 CHOLIC ACID ADVERSE_EFFECT MSK_1_Muscle Twitching 81-25-4 CHOLIC ACID ACTIVITY_CLASS Toxicant 81-25-4 CHOLIC ACID TISSUE_TOXICITY Hypotension 81-25-4 CHOLIC ACID ADVERSE_EFFECT CVS_2_Bradycardia 81-25-4 CHOLIC ACID STRUCTURE_ACTIVITY FXR agonist 81-25-4 CHOLIC ACID ADVERSE_EFFECT CVS_2_Hypotension 81-25-4 CHOLIC ACID ADVERSE_EFFECT END_1_Hypercholesteremia 81-25-4 CHOLIC ACID MESH_LEVEL_2 Steroids 81-25-4 CHOLIC ACID TA_LEVEL_2 hyperlipidemic? 81-25-4 CHOLIC ACID MESH_LEVEL_1 Polycyclic Hydrocarbons 81-25-4 CHOLIC ACID ADVERSE_EFFECT IMU_3_Anaphylaxis 81-25-4 CHOLIC ACID MECH_LEVEL_3 Unknown mechanism 81-25-4 CHOLIC ACID ADVERSE_EFFECT MSK_1_Spasm 81-25-4 CHOLIC ACID TA_LEVEL_1 Vitamins, Minerals and Nutrients 81-25-4 CHOLIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 81-25-4 CHOLIC ACID MECH_LEVEL_2 Unknown mechanism 81-25-4 CHOLIC ACID ZERO_CLASS N 83-44-3 CHOLIC ACID ADVERSE_EFFECT CVS_2_Bradycardia 83-44-3 CHOLIC ACID ADVERSE_EFFECT MSK_1_Muscle Twitching 83-44-3 CHOLIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 83-44-3 CHOLIC ACID MESH_LEVEL_3 Cholanes 83-44-3 CHOLIC ACID ZERO_CLASS N 83-44-3 CHOLIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 83-44-3 CHOLIC ACID TA_LEVEL_1 Vitamins, Minerals and Nutrients 83-44-3 CHOLIC ACID ADVERSE_EFFECT MSK_1_Spasm 83-44-3 CHOLIC ACID ADVERSE_EFFECT IMU_3_Anaphylaxis 83-44-3 CHOLIC ACID MESH_LEVEL_1 Polycyclic Hydrocarbons 83-44-3 CHOLIC ACID TA_LEVEL_2 hyperlipidemic? 83-44-3 CHOLIC ACID MESH_LEVEL_2 Steroids 83-44-3 CHOLIC ACID TISSUE_TOXICITY Hypotension 83-44-3 CHOLIC ACID ADVERSE_EFFECT END_1_Hypercholesteremia 83-44-3 CHOLIC ACID ADVERSE_EFFECT CVS_2_Hypotension 83-44-3 CHOLIC ACID MECH_LEVEL_3 Unknown mechanism 83-44-3 CHOLIC ACID MECH_LEVEL_2 Unknown mechanism 83-44-3 CHOLIC ACID ACTIVITY_CLASS Toxicant 83-44-3 CHOLIC ACID STRUCTURE_ACTIVITY FXR agonist 32004-67-4 SULINDAC SULFIDE MODE_CLASS Enzyme Inhibitor 32004-67-4 SULINDAC SULFIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 32004-67-4 SULINDAC SULFIDE STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 32004-67-4 SULINDAC SULFIDE MECHANISM Inhibit eicosanoid biosynthesis 32004-67-4 SULINDAC SULFIDE PRODUCT_CLASS Anti-inflammatories 90-39-1 SPARTEINE MESH_LEVEL_1 Heterocyclic Compounds 90-39-1 SPARTEINE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 90-39-1 SPARTEINE ZERO_CLASS N 90-39-1 SPARTEINE ADVERSE_EFFECT GIS_2_Abdominal Pain 90-39-1 SPARTEINE ADVERSE_EFFECT REP_1_Contractions of the Uterus 90-39-1 SPARTEINE THERAPEUTIC_CLASS Antiarrhythmic Agents 90-39-1 SPARTEINE TISSUE_TOXICITY Cardiovascular Collapse 90-39-1 SPARTEINE MESH_LEVEL_2 Alkaloids 90-39-1 SPARTEINE MECH_LEVEL_1 Antiarrhythmic Agents 90-39-1 SPARTEINE MECH_LEVEL_2 Sodium channel antagonist 90-39-1 SPARTEINE MECHANISM Modulate neural transmission 90-39-1 SPARTEINE ADVERSE_EFFECT CVS_2_Bradycardia 90-39-1 SPARTEINE MODE_CLASS Channel Blocker 90-39-1 SPARTEINE ADVERSE_EFFECT GIS_2_Diarrhea 90-39-1 SPARTEINE MECHANISM Block neural transmission 90-39-1 SPARTEINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 90-39-1 SPARTEINE PRODUCT_CLASS Cardiovasculars 90-39-1 SPARTEINE TA_LEVEL_2 antiarrthymic 90-39-1 SPARTEINE MESH_LEVEL_3 Sparteine 90-39-1 SPARTEINE ADVERSE_EFFECT REP_2_Uterine Contractions 90-39-1 SPARTEINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 90-39-1 SPARTEINE INDICATION Cardiac Arrhythmias 90-39-1 SPARTEINE TA_LEVEL_1 Cardiovascular 90-39-1 SPARTEINE KNOWN_TOXICITY Cardiovascular Toxicity 90-39-1 SPARTEINE ADVERSE_EFFECT PSY_2_Anorexia 90-39-1 SPARTEINE MECH_LEVEL_3 Na+ channel 299-39-8 SPARTEINE MESH_LEVEL_2 Alkaloids 299-39-8 SPARTEINE MECHANISM Modulate neural transmission 299-39-8 SPARTEINE MECH_LEVEL_1 Antiarrhythmic Agents 299-39-8 SPARTEINE ADVERSE_EFFECT REP_1_Contractions of the Uterus 299-39-8 SPARTEINE MECH_LEVEL_2 Sodium channel antagonist 299-39-8 SPARTEINE TISSUE_TOXICITY Cardiovascular Collapse 299-39-8 SPARTEINE TA_LEVEL_1 Cardiovascular 299-39-8 SPARTEINE THERAPEUTIC_CLASS Antiarrhythmic Agents 299-39-8 SPARTEINE KNOWN_TOXICITY Cardiovascular Toxicity 299-39-8 SPARTEINE MODE_CLASS Channel Blocker 299-39-8 SPARTEINE ADVERSE_EFFECT GIS_2_Diarrhea 299-39-8 SPARTEINE ADVERSE_EFFECT CVS_2_Bradycardia 299-39-8 SPARTEINE MECHANISM Block neural transmission 299-39-8 SPARTEINE PRODUCT_CLASS Cardiovasculars 299-39-8 SPARTEINE TA_LEVEL_2 antiarrthymic 299-39-8 SPARTEINE MESH_LEVEL_3 Sparteine 299-39-8 SPARTEINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 299-39-8 SPARTEINE ADVERSE_EFFECT REP_2_Uterine Contractions 299-39-8 SPARTEINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 299-39-8 SPARTEINE INDICATION Cardiac Arrhythmias 299-39-8 SPARTEINE ADVERSE_EFFECT PSY_2_Anorexia 299-39-8 SPARTEINE MECH_LEVEL_3 Na+ channel 299-39-8 SPARTEINE MESH_LEVEL_1 Heterocyclic Compounds 299-39-8 SPARTEINE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 299-39-8 SPARTEINE ZERO_CLASS N 299-39-8 SPARTEINE ADVERSE_EFFECT GIS_2_Abdominal Pain 492-08-0 SPARTEINE INDICATION Cardiac Arrhythmias 492-08-0 SPARTEINE TA_LEVEL_1 Cardiovascular 492-08-0 SPARTEINE ADVERSE_EFFECT GIS_2_Diarrhea 492-08-0 SPARTEINE MODE_CLASS Channel Blocker 492-08-0 SPARTEINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 492-08-0 SPARTEINE ADVERSE_EFFECT REP_2_Uterine Contractions 492-08-0 SPARTEINE MECHANISM Modulate neural transmission 492-08-0 SPARTEINE MESH_LEVEL_3 Sparteine 492-08-0 SPARTEINE ADVERSE_EFFECT REP_1_Contractions of the Uterus 492-08-0 SPARTEINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 492-08-0 SPARTEINE MECH_LEVEL_1 Antiarrhythmic Agents 492-08-0 SPARTEINE MECHANISM Block neural transmission 492-08-0 SPARTEINE PRODUCT_CLASS Cardiovasculars 492-08-0 SPARTEINE TA_LEVEL_2 antiarrthymic 492-08-0 SPARTEINE ADVERSE_EFFECT CVS_2_Bradycardia 492-08-0 SPARTEINE MECH_LEVEL_2 Sodium channel antagonist 492-08-0 SPARTEINE THERAPEUTIC_CLASS Antiarrhythmic Agents 492-08-0 SPARTEINE TISSUE_TOXICITY Cardiovascular Collapse 492-08-0 SPARTEINE ADVERSE_EFFECT GIS_2_Abdominal Pain 492-08-0 SPARTEINE KNOWN_TOXICITY Cardiovascular Toxicity 492-08-0 SPARTEINE MESH_LEVEL_2 Alkaloids 492-08-0 SPARTEINE ZERO_CLASS N 492-08-0 SPARTEINE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 492-08-0 SPARTEINE MESH_LEVEL_1 Heterocyclic Compounds 492-08-0 SPARTEINE MECH_LEVEL_3 Na+ channel 492-08-0 SPARTEINE ADVERSE_EFFECT PSY_2_Anorexia 71-55-6 TRICHLOROETHANE KNOWN_TOXICITY Cardiovascular Toxicity 71-55-6 TRICHLOROETHANE MESH_LEVEL_3 Hydrocarbons, Halogenated 71-55-6 TRICHLOROETHANE TA_LEVEL_3 Liver toxicants 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT NEU_1_Headache 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 71-55-6 TRICHLOROETHANE MECH_LEVEL_3 Toxicants 71-55-6 TRICHLOROETHANE TISSUE_TOXICITY Hypotension 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT LUN_2_Airway Irritation 71-55-6 TRICHLOROETHANE TISSUE_TOXICITY Hepatotoxicity 71-55-6 TRICHLOROETHANE TA_LEVEL_1 Toxicants 71-55-6 TRICHLOROETHANE MECH_LEVEL_2 Toxicants 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT CVS_2_Cardiotoxicity 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT CVS_2_Hypotension 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 71-55-6 TRICHLOROETHANE TISSUE_TOXICITY Cardiotoxicity 71-55-6 TRICHLOROETHANE TA_LEVEL_2 Toxicant 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT NEU_2_Convulsions 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT CVS_2_ECG Abnormalities 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT PSY_1_CNS Depression 71-55-6 TRICHLOROETHANE TISSUE_TOXICITY Cardiac Arrhythmia 71-55-6 TRICHLOROETHANE STRUCTURE_ACTIVITY Toxicant 71-55-6 TRICHLOROETHANE KNOWN_TOXICITY Hepatotoxicity 71-55-6 TRICHLOROETHANE ACTIVITY_CLASS Toxicant 71-55-6 TRICHLOROETHANE MECH_LEVEL_1 Toxicants 71-55-6 TRICHLOROETHANE MESH_LEVEL_1 Organic Chemicals 71-55-6 TRICHLOROETHANE MESH_LEVEL_2 Hydrocarbons 71-55-6 TRICHLOROETHANE INDICATION Induction / Maintenance of Anesthesia 71-55-6 TRICHLOROETHANE PRODUCT_CLASS Toxicants 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT IMU_1_Contact Dermatitis 71-55-6 TRICHLOROETHANE THERAPEUTIC_CLASS General Anesthetics, Inhaled 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT NEU_2_Ataxia 71-55-6 TRICHLOROETHANE ADVERSE_EFFECT LIV_3_Hepatotoxicity 71-55-6 TRICHLOROETHANE ZERO_CLASS N 75-35-4 1,1-DICHLOROETHENE KNOWN_TOXICITY Carcinogenicity 75-35-4 1,1-DICHLOROETHENE TA_LEVEL_1 Industrial reagent 75-35-4 1,1-DICHLOROETHENE KNOWN_TOXICITY Miscellaneous 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT XXX_3_Death 75-35-4 1,1-DICHLOROETHENE ZERO_CLASS N 75-35-4 1,1-DICHLOROETHENE STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 75-35-4 1,1-DICHLOROETHENE TA_LEVEL_3 Toxicant 75-35-4 1,1-DICHLOROETHENE TA_LEVEL_2 Toxicant 75-35-4 1,1-DICHLOROETHENE MESH_LEVEL_3 Hydrocarbons, Halogenated 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT EMB_3_Embryotoxicity 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LIV_2_Inhibition of P450 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT KID_2_Kidney Damage 75-35-4 1,1-DICHLOROETHENE TISSUE_TOXICITY Mutagenicity 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT XXX_1_Nasal Irritation 75-35-4 1,1-DICHLOROETHENE MECH_LEVEL_1 Toxicant 75-35-4 1,1-DICHLOROETHENE MECH_LEVEL_3 Free radical generator 75-35-4 1,1-DICHLOROETHENE MESH_LEVEL_2 Hydrocarbons 75-35-4 1,1-DICHLOROETHENE KNOWN_TOXICITY Mutagenicity 75-35-4 1,1-DICHLOROETHENE MECH_LEVEL_2 Toxicant 75-35-4 1,1-DICHLOROETHENE PRODUCT_CLASS Toxicants 75-35-4 1,1-DICHLOROETHENE TISSUE_TOXICITY Death 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT DNA_3_Carcinogenicity 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT DNA_2_Mutagenicity 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LIV_2_Hepatic Necrosis 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LUN_1_Pulmonary Irritation 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT EMB_3_Fetal Toxicity 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LUN_2_Deep Lung Irritation 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LIV_1_Hepatic Damage 75-35-4 1,1-DICHLOROETHENE MESH_LEVEL_1 Organic Chemicals 75-35-4 1,1-DICHLOROETHENE ACTIVITY_CLASS Toxicant, DNA damaging 75-35-4 1,1-DICHLOROETHENE KNOWN_TOXICITY Hepatotoxicity 75-35-4 1,1-DICHLOROETHENE TISSUE_TOXICITY Hepatic Necrosis 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT PSY_2_CNS Depression 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT EMB_2_Fetal / Neonatal Morbidity and Mortality 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 75-35-4 1,1-DICHLOROETHENE ADVERSE_EFFECT LUN_1_Bronchial Irritation 75-35-4 1,1-DICHLOROETHENE TISSUE_TOXICITY Carcinogenicity 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT XXX_3_Death 7440-38-2 SODIUM ARSENITE TISSUE_TOXICITY Carcinogenicity 7440-38-2 SODIUM ARSENITE TISSUE_TOXICITY Cerebral Edema 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT NEU_1_Cerebral Edema 7440-38-2 SODIUM ARSENITE MESH_LEVEL_1 Organic Chemicals 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT GIS_1_Abdominal Pain 7440-38-2 SODIUM ARSENITE TA_LEVEL_1 Toxicants 7440-38-2 SODIUM ARSENITE MECH_LEVEL_1 Toxicants 7440-38-2 SODIUM ARSENITE MESH_LEVEL_2 Organometallic Compounds 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT CVS_1_Vasodilation 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT LIV_1_Jaundice 7440-38-2 SODIUM ARSENITE TISSUE_TOXICITY Bloody Diarrhea 7440-38-2 SODIUM ARSENITE KNOWN_TOXICITY Neurotoxicity 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT CVS_2_Myocardial Depression 7440-38-2 SODIUM ARSENITE ZERO_CLASS N 7440-38-2 SODIUM ARSENITE MESH_LEVEL_3 Arsenicals 7440-38-2 SODIUM ARSENITE TA_LEVEL_3 Liver toxicants 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT DNA_2_Carcinogenicity 7440-38-2 SODIUM ARSENITE KNOWN_TOXICITY Carcinogenicity 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT SKN_2_Severe Skin Lesions 7440-38-2 SODIUM ARSENITE TISSUE_TOXICITY Renal Failure 7440-38-2 SODIUM ARSENITE TISSUE_TOXICITY Death 7440-38-2 SODIUM ARSENITE KNOWN_TOXICITY Cardiovascular Toxicity 7440-38-2 SODIUM ARSENITE MECH_LEVEL_3 Toxicants 7440-38-2 SODIUM ARSENITE MECH_LEVEL_2 Toxicants 7440-38-2 SODIUM ARSENITE KNOWN_TOXICITY Gastrointestinal Toxicity 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT GIS_1_Bloody Diarrhea 7440-38-2 SODIUM ARSENITE KNOWN_TOXICITY Miscellaneous 7440-38-2 SODIUM ARSENITE KNOWN_TOXICITY Nephrotoxicity 7440-38-2 SODIUM ARSENITE TISSUE_TOXICITY Myocardial Depression 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT KID_1_Renal Failure 7440-38-2 SODIUM ARSENITE ADVERSE_EFFECT GIS_1_Vomiting 7440-38-2 SODIUM ARSENITE PRODUCT_CLASS Toxicants 7440-38-2 SODIUM ARSENITE TA_LEVEL_2 Toxicant 7440-38-2 SODIUM ARSENITE ACTIVITY_CLASS Toxicant 7440-38-2 SODIUM ARSENITE STRUCTURE_ACTIVITY Toxicant, heavy metal 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_2_Paresthesia 56-23-5 CARBON TETRACHLORIDE KNOWN_TOXICITY Miscellaneous 56-23-5 CARBON TETRACHLORIDE KNOWN_TOXICITY Hepatotoxicity 56-23-5 CARBON TETRACHLORIDE TISSUE_TOXICITY Impaired Consciousness 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT IMU_1_Contact Dermatitis 56-23-5 CARBON TETRACHLORIDE TA_LEVEL_3 Liver toxicants 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT CVS_2_Acute Dysrhythmia 56-23-5 CARBON TETRACHLORIDE MECH_LEVEL_3 Toxicants 56-23-5 CARBON TETRACHLORIDE KNOWN_TOXICITY Nephrotoxicity 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_2_Slurred Speech 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_2_Tonic-Clonic Convulsions 56-23-5 CARBON TETRACHLORIDE TA_LEVEL_2 Toxicant 56-23-5 CARBON TETRACHLORIDE MECH_LEVEL_2 Toxicants 56-23-5 CARBON TETRACHLORIDE MESH_LEVEL_3 Hydrocarbons, Halogenated 56-23-5 CARBON TETRACHLORIDE INDICATION Hookworm Disease 56-23-5 CARBON TETRACHLORIDE THERAPEUTIC_CLASS Antiparasitics 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_1_Impaired Consciousness 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT LIV_2_Fatty Liver 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT XXX_2_Weakness 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT PSY_1_CNS Depression 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT LIV_2_Hepatotoxicity 56-23-5 CARBON TETRACHLORIDE TISSUE_TOXICITY Acute Tubular Necrosis 56-23-5 CARBON TETRACHLORIDE TISSUE_TOXICITY Hepatotoxicity 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_2_Cerebellar Dysfunction 56-23-5 CARBON TETRACHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 56-23-5 CARBON TETRACHLORIDE TISSUE_TOXICITY Carcinogenicity 56-23-5 CARBON TETRACHLORIDE KNOWN_TOXICITY Carcinogenicity 56-23-5 CARBON TETRACHLORIDE ZERO_CLASS N 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_2_Ataxia 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT NEU_1_Headache 56-23-5 CARBON TETRACHLORIDE THERAPEUTIC_CLASS General Anesthetics, Inhaled 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT XXX_2_Death 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT DNA_1_Carcinogenicity 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT LUN_2_Respiratory Depression 56-23-5 CARBON TETRACHLORIDE KNOWN_TOXICITY Neurotoxicity 56-23-5 CARBON TETRACHLORIDE TISSUE_TOXICITY Acute Dysrhythmia 56-23-5 CARBON TETRACHLORIDE ACTIVITY_CLASS Toxicant, DNA damaging 56-23-5 CARBON TETRACHLORIDE ADVERSE_EFFECT KID_2_Acute Tubular Necrosis 56-23-5 CARBON TETRACHLORIDE PRODUCT_CLASS Toxicants 56-23-5 CARBON TETRACHLORIDE MECH_LEVEL_1 Toxicants 56-23-5 CARBON TETRACHLORIDE INDICATION Induction / Maintenance of Anesthesia 56-23-5 CARBON TETRACHLORIDE TISSUE_TOXICITY Death 56-23-5 CARBON TETRACHLORIDE STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 56-23-5 CARBON TETRACHLORIDE MESH_LEVEL_1 Organic Chemicals 56-23-5 CARBON TETRACHLORIDE MESH_LEVEL_2 Hydrocarbons 56-23-5 CARBON TETRACHLORIDE TA_LEVEL_1 Toxicants 55-18-5 N-NITROSODIETHYLAMINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT XXX_2_Nasal Irritation 55-18-5 N-NITROSODIETHYLAMINE TA_LEVEL_2 DNA damage 55-18-5 N-NITROSODIETHYLAMINE ZERO_CLASS N 55-18-5 N-NITROSODIETHYLAMINE TISSUE_TOXICITY Carcinogenicity 55-18-5 N-NITROSODIETHYLAMINE KNOWN_TOXICITY Mutagenicity 55-18-5 N-NITROSODIETHYLAMINE TISSUE_TOXICITY Mutagenicity 55-18-5 N-NITROSODIETHYLAMINE TISSUE_TOXICITY Genotoxicity 55-18-5 N-NITROSODIETHYLAMINE MODE_CLASS Distorts /blocks macromolecular scaffold function 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 55-18-5 N-NITROSODIETHYLAMINE MESH_LEVEL_2 Nitroso Compounds 55-18-5 N-NITROSODIETHYLAMINE PRODUCT_CLASS Toxicants 55-18-5 N-NITROSODIETHYLAMINE ACTIVITY_CLASS Toxicant, DNA damaging 55-18-5 N-NITROSODIETHYLAMINE TISSUE_TOXICITY Hepatotoxicity 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT DNA_2_Carcinogenicity 55-18-5 N-NITROSODIETHYLAMINE KNOWN_TOXICITY Carcinogenicity 55-18-5 N-NITROSODIETHYLAMINE KNOWN_TOXICITY Hepatotoxicity 55-18-5 N-NITROSODIETHYLAMINE TA_LEVEL_3 Liver toxicants 55-18-5 N-NITROSODIETHYLAMINE MECH_LEVEL_3 DNA damage 55-18-5 N-NITROSODIETHYLAMINE MESH_LEVEL_1 Organic Chemicals 55-18-5 N-NITROSODIETHYLAMINE TA_LEVEL_1 Toxicants 55-18-5 N-NITROSODIETHYLAMINE MESH_LEVEL_3 Nitrosamines 55-18-5 N-NITROSODIETHYLAMINE TISSUE_TOXICITY Hepatocellular Carcinoma 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT DNA_3_Mutagenicity 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT DNA_2_Genotoxicity 55-18-5 N-NITROSODIETHYLAMINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 55-18-5 N-NITROSODIETHYLAMINE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 55-18-5 N-NITROSODIETHYLAMINE ADVERSE_EFFECT LIV_1_Hepatotoxicity 55-18-5 N-NITROSODIETHYLAMINE TISSUE_TOXICITY Liver Cirrhosis 55-18-5 N-NITROSODIETHYLAMINE MECHANISM Inhibit DNA synthesis, repair, and function 68-12-2 N,N-DIMETHYLFORMAMIDE KNOWN_TOXICITY Hepatotoxicity 68-12-2 N,N-DIMETHYLFORMAMIDE MECH_LEVEL_3 Toxicants 68-12-2 N,N-DIMETHYLFORMAMIDE MECH_LEVEL_2 Toxicants 68-12-2 N,N-DIMETHYLFORMAMIDE MESH_LEVEL_3 Acids, Acyclic 68-12-2 N,N-DIMETHYLFORMAMIDE TISSUE_TOXICITY Hepatotoxicity 68-12-2 N,N-DIMETHYLFORMAMIDE MESH_LEVEL_2 Carboxylic Acids 68-12-2 N,N-DIMETHYLFORMAMIDE MESH_LEVEL_1 Organic Chemicals 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT LIV_2_Hepatotoxicity 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT LIV_2_Hepatic Necrosis 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT SKN_1_Skin Disorder 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT NEU_1_Dizziness 68-12-2 N,N-DIMETHYLFORMAMIDE TA_LEVEL_1 Toxicants 68-12-2 N,N-DIMETHYLFORMAMIDE MECH_LEVEL_1 Toxicants 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT XXX_1_Disulfiram-Like Reactions 68-12-2 N,N-DIMETHYLFORMAMIDE ACTIVITY_CLASS Toxicant 68-12-2 N,N-DIMETHYLFORMAMIDE TISSUE_TOXICITY Hepatic Necrosis 68-12-2 N,N-DIMETHYLFORMAMIDE TA_LEVEL_2 Toxicant 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT XXX_2_Weakness 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT GIS_2_Constipation 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT PSY_1_Anorexia 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 68-12-2 N,N-DIMETHYLFORMAMIDE STRUCTURE_ACTIVITY Toxicant, free radical generator 68-12-2 N,N-DIMETHYLFORMAMIDE ZERO_CLASS N 68-12-2 N,N-DIMETHYLFORMAMIDE TA_LEVEL_3 Liver toxicants 68-12-2 N,N-DIMETHYLFORMAMIDE PRODUCT_CLASS Toxicants 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT LIV_2_Steatosis 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT NEU_1_Headache 68-12-2 N,N-DIMETHYLFORMAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 101-77-9 4,4'-METHYLENEDIANILINE MODE_CLASS Distorts /blocks macromolecular scaffold function 101-77-9 4,4'-METHYLENEDIANILINE KNOWN_TOXICITY Carcinogenicity 101-77-9 4,4'-METHYLENEDIANILINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 101-77-9 4,4'-METHYLENEDIANILINE MESH_LEVEL_3 Anilides 101-77-9 4,4'-METHYLENEDIANILINE MESH_LEVEL_1 Organic Chemicals 101-77-9 4,4'-METHYLENEDIANILINE MESH_LEVEL_2 Amines 101-77-9 4,4'-METHYLENEDIANILINE TISSUE_TOXICITY Liver Cirrhosis 101-77-9 4,4'-METHYLENEDIANILINE KNOWN_TOXICITY Mutagenicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 101-77-9 4,4'-METHYLENEDIANILINE ZERO_CLASS N 101-77-9 4,4'-METHYLENEDIANILINE ACTIVITY_CLASS Toxicant, DNA damaging 101-77-9 4,4'-METHYLENEDIANILINE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 101-77-9 4,4'-METHYLENEDIANILINE TA_LEVEL_3 Bone Marrow Toxicants 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT OCU_1_Eye Irritation 101-77-9 4,4'-METHYLENEDIANILINE TISSUE_TOXICITY Mutagenicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT KID_2_Renal Damage 101-77-9 4,4'-METHYLENEDIANILINE TA_LEVEL_1 Toxicants 101-77-9 4,4'-METHYLENEDIANILINE MECH_LEVEL_3 DNA damage 101-77-9 4,4'-METHYLENEDIANILINE TA_LEVEL_2 DNA damage 101-77-9 4,4'-METHYLENEDIANILINE TISSUE_TOXICITY Carcinogenicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT DNA_2_Carcinogenicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT SKN_2_Skin Reactions 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT LIV_2_Hepatitis 101-77-9 4,4'-METHYLENEDIANILINE MECHANISM Inhibit DNA synthesis, repair, and function 101-77-9 4,4'-METHYLENEDIANILINE PRODUCT_CLASS Toxicants 101-77-9 4,4'-METHYLENEDIANILINE TISSUE_TOXICITY Genotoxicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT LUN_2_Airway Irritation 101-77-9 4,4'-METHYLENEDIANILINE KNOWN_TOXICITY Hepatotoxicity 101-77-9 4,4'-METHYLENEDIANILINE TISSUE_TOXICITY Hepatotoxicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT LIV_1_Hepatotoxicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT DNA_1_Genotoxicity 101-77-9 4,4'-METHYLENEDIANILINE ADVERSE_EFFECT DNA_1_Mutagenicity 17466-45-4 PHALLOIDIN ADVERSE_EFFECT KID_2_Renal Toxicity 17466-45-4 PHALLOIDIN ADVERSE_EFFECT LIV_2_Cholestasis 17466-45-4 PHALLOIDIN TISSUE_TOXICITY Death 17466-45-4 PHALLOIDIN KNOWN_TOXICITY Nephrotoxicity 17466-45-4 PHALLOIDIN MODE_CLASS Distorts /blocks macromolecular scaffold function 17466-45-4 PHALLOIDIN ADVERSE_EFFECT PSY_1_Nervousness 17466-45-4 PHALLOIDIN ADVERSE_EFFECT XXX_1_Cytotoxicity 17466-45-4 PHALLOIDIN KNOWN_TOXICITY Miscellaneous 17466-45-4 PHALLOIDIN ADVERSE_EFFECT LIV_2_Liver Necrosis 17466-45-4 PHALLOIDIN ADVERSE_EFFECT NEU_3_Coma 17466-45-4 PHALLOIDIN ADVERSE_EFFECT LIV_1_Hepatotoxicity 17466-45-4 PHALLOIDIN TISSUE_TOXICITY Liver Necrosis 17466-45-4 PHALLOIDIN PRODUCT_CLASS Toxicants 17466-45-4 PHALLOIDIN MECHANISM Inhibit mitosis 17466-45-4 PHALLOIDIN ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 17466-45-4 PHALLOIDIN ACTIVITY_CLASS Antiproliferative agent 17466-45-4 PHALLOIDIN STRUCTURE_ACTIVITY Binds to hepatic F-actin 17466-45-4 PHALLOIDIN ADVERSE_EFFECT XXX_3_Death 17466-45-4 PHALLOIDIN KNOWN_TOXICITY Hepatotoxicity 17466-45-4 PHALLOIDIN TISSUE_TOXICITY Hepatotoxicity 17466-45-4 PHALLOIDIN TISSUE_TOXICITY Renal Toxicity 63-24-1 PHALLOIDIN ADVERSE_EFFECT XXX_3_Death 63-24-1 PHALLOIDIN KNOWN_TOXICITY Hepatotoxicity 63-24-1 PHALLOIDIN TISSUE_TOXICITY Hepatotoxicity 63-24-1 PHALLOIDIN ADVERSE_EFFECT LIV_2_Cholestasis 63-24-1 PHALLOIDIN TISSUE_TOXICITY Liver Necrosis 63-24-1 PHALLOIDIN ADVERSE_EFFECT LIV_2_Liver Necrosis 63-24-1 PHALLOIDIN ADVERSE_EFFECT PSY_1_Nervousness 63-24-1 PHALLOIDIN ADVERSE_EFFECT XXX_1_Cytotoxicity 63-24-1 PHALLOIDIN MODE_CLASS Distorts /blocks macromolecular scaffold function 63-24-1 PHALLOIDIN KNOWN_TOXICITY Nephrotoxicity 63-24-1 PHALLOIDIN TISSUE_TOXICITY Death 63-24-1 PHALLOIDIN ADVERSE_EFFECT NEU_3_Coma 63-24-1 PHALLOIDIN ADVERSE_EFFECT LIV_1_Hepatotoxicity 63-24-1 PHALLOIDIN PRODUCT_CLASS Toxicants 63-24-1 PHALLOIDIN ACTIVITY_CLASS Antiproliferative agent 63-24-1 PHALLOIDIN ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 63-24-1 PHALLOIDIN ADVERSE_EFFECT KID_2_Renal Toxicity 63-24-1 PHALLOIDIN STRUCTURE_ACTIVITY Binds to hepatic F-actin 63-24-1 PHALLOIDIN MECHANISM Inhibit mitosis 63-24-1 PHALLOIDIN KNOWN_TOXICITY Miscellaneous 63-24-1 PHALLOIDIN TISSUE_TOXICITY Renal Toxicity 290357-24-3 NOVARTIS P-38 INHIBITOR STRUCTURE_ACTIVITY Protein-serine/threonine kinase (p38) inhibitor 290357-24-3 NOVARTIS P-38 INHIBITOR MODE_CLASS Enzyme Inhibitor 290357-24-3 NOVARTIS P-38 INHIBITOR MECHANISM Modulate G-protein coupled signal transduction 290357-24-3 NOVARTIS P-38 INHIBITOR INDICATION Arthritis 290357-24-3 NOVARTIS P-38 INHIBITOR PRODUCT_CLASS Anti-inflammatories 290357-24-3 NOVARTIS P-38 INHIBITOR THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 107-18-6 ALLYL ALCOHOL MESH_LEVEL_1 Organic Chemicals 107-18-6 ALLYL ALCOHOL TA_LEVEL_1 Toxicants 107-18-6 ALLYL ALCOHOL STRUCTURE_ACTIVITY Toxicant, free radical generator 107-18-6 ALLYL ALCOHOL ZERO_CLASS N 107-18-6 ALLYL ALCOHOL TISSUE_TOXICITY Hepatotoxicity 107-18-6 ALLYL ALCOHOL TA_LEVEL_2 Toxicant 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT KID_2_Nephrotoxicity 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT LUN_1_Bronchial Irritation 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT LUN_1_Pulmonary Irritation 107-18-6 ALLYL ALCOHOL KNOWN_TOXICITY Nephrotoxicity 107-18-6 ALLYL ALCOHOL TISSUE_TOXICITY Nephrotoxicity 107-18-6 ALLYL ALCOHOL MECH_LEVEL_3 Toxicants 107-18-6 ALLYL ALCOHOL PRODUCT_CLASS Toxicants 107-18-6 ALLYL ALCOHOL MECH_LEVEL_2 Toxicants 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT GIS_2_Pancreatitis 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT LUN_2_Pulmonary Edema 107-18-6 ALLYL ALCOHOL ACTIVITY_CLASS Toxicant 107-18-6 ALLYL ALCOHOL TISSUE_TOXICITY Death 107-18-6 ALLYL ALCOHOL KNOWN_TOXICITY Miscellaneous 107-18-6 ALLYL ALCOHOL TA_LEVEL_3 Liver toxicants 107-18-6 ALLYL ALCOHOL MESH_LEVEL_3 Hydrocarbons, Acyclic 107-18-6 ALLYL ALCOHOL KNOWN_TOXICITY Hepatotoxicity 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT XXX_3_Death 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT SKN_1_Skin Reactions 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT XXX_1_Throat Irritation 107-18-6 ALLYL ALCOHOL MESH_LEVEL_2 Hydrocarbons 107-18-6 ALLYL ALCOHOL MECH_LEVEL_1 Toxicants 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT OCU_1_Eye Irritation 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT LIV_2_Hepatotoxicity 107-18-6 ALLYL ALCOHOL ADVERSE_EFFECT XXX_1_Nasal Irritation 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MESH_LEVEL_1 Organic Chemicals 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ZERO_CLASS N 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MESH_LEVEL_3 Isothiocyanates 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MODE_CLASS Distorts /blocks macromolecular scaffold function 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MESH_LEVEL_2 Isocyanates 551-06-4 1-NAPHTHYL ISOTHIOCYANATE TISSUE_TOXICITY Genotoxicity 551-06-4 1-NAPHTHYL ISOTHIOCYANATE TA_LEVEL_2 DNA damage 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 551-06-4 1-NAPHTHYL ISOTHIOCYANATE TISSUE_TOXICITY Cholangitis 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT LIV_1_Increased Serum Alkaline Phosphatase 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT SKN_1_Dermatitis 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ACTIVITY_CLASS Toxicant 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 551-06-4 1-NAPHTHYL ISOTHIOCYANATE STRUCTURE_ACTIVITY Toxicant 551-06-4 1-NAPHTHYL ISOTHIOCYANATE PRODUCT_CLASS Toxicants 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MECHANISM Inhibit DNA synthesis, repair, and function 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT END_2_Hyperglycemia 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 551-06-4 1-NAPHTHYL ISOTHIOCYANATE KNOWN_TOXICITY Biliary System Toxicity 551-06-4 1-NAPHTHYL ISOTHIOCYANATE MECH_LEVEL_3 DNA damage 551-06-4 1-NAPHTHYL ISOTHIOCYANATE TA_LEVEL_3 Liver toxicants 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT BIL_1_Cholangitis 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT KID_2_Increased Creatinine 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT DNA_2_Genotoxicity 551-06-4 1-NAPHTHYL ISOTHIOCYANATE TA_LEVEL_1 Toxicants 551-06-4 1-NAPHTHYL ISOTHIOCYANATE KNOWN_TOXICITY Mutagenicity 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT LIV_2_Cholestasis 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT END_2_Hyperlipidemia 551-06-4 1-NAPHTHYL ISOTHIOCYANATE ADVERSE_EFFECT LIV_1_Hepatic Injury 84-04-8 PIPAMAZINE INDICATION Nausea / Vomiting 84-04-8 PIPAMAZINE MECHANISM Block neural transmission 84-04-8 PIPAMAZINE PRODUCT_CLASS Gastrointestinal System 84-04-8 PIPAMAZINE INDICATION Vomiting of Pregnancy / Morning Sickness 84-04-8 PIPAMAZINE ADVERSE_EFFECT OCU_3_Acute Angle-Closure Glaucoma 84-04-8 PIPAMAZINE ADVERSE_EFFECT LIV_3_Hepatic Injury 84-04-8 PIPAMAZINE MODE_CLASS Receptor Ligand Antagonist 84-04-8 PIPAMAZINE ADVERSE_EFFECT END_3_Exacerbation of Porphyria 84-04-8 PIPAMAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 84-04-8 PIPAMAZINE MECHANISM Modulate G-protein coupled signal transduction 84-04-8 PIPAMAZINE INDICATION Vomiting of Pregnancy / Morning Sickness 84-04-8 PIPAMAZINE THERAPEUTIC_CLASS Antiemetics 84-04-8 PIPAMAZINE ADVERSE_EFFECT NEU_2_Kernicterus 84-04-8 PIPAMAZINE ADVERSE_EFFECT END_2_Gynecomastia 84-04-8 PIPAMAZINE INDICATION Nausea / Vomiting 84-04-8 PIPAMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 101064-48-6 MICROCYSTIN-YR PRODUCT_CLASS Toxicants 53-96-3 2-ACETYLAMINOFLUORENE KNOWN_TOXICITY Mutagenicity 53-96-3 2-ACETYLAMINOFLUORENE ADVERSE_EFFECT DNA_1_Carcinogenicity 53-96-3 2-ACETYLAMINOFLUORENE ADVERSE_EFFECT DNA_2_Mutagenicity 53-96-3 2-ACETYLAMINOFLUORENE MECH_LEVEL_2 Toxicants 53-96-3 2-ACETYLAMINOFLUORENE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 53-96-3 2-ACETYLAMINOFLUORENE TA_LEVEL_1 Toxicants 53-96-3 2-ACETYLAMINOFLUORENE MECH_LEVEL_1 Toxicants 53-96-3 2-ACETYLAMINOFLUORENE TISSUE_TOXICITY Carcinogenicity 53-96-3 2-ACETYLAMINOFLUORENE MESH_LEVEL_2 Amides 53-96-3 2-ACETYLAMINOFLUORENE MECH_LEVEL_3 Toxicants 53-96-3 2-ACETYLAMINOFLUORENE KNOWN_TOXICITY Carcinogenicity 53-96-3 2-ACETYLAMINOFLUORENE TISSUE_TOXICITY Mutagenicity 53-96-3 2-ACETYLAMINOFLUORENE TISSUE_TOXICITY Liver Necrosis 53-96-3 2-ACETYLAMINOFLUORENE KNOWN_TOXICITY Hepatotoxicity 53-96-3 2-ACETYLAMINOFLUORENE PRODUCT_CLASS Toxicants 53-96-3 2-ACETYLAMINOFLUORENE MESH_LEVEL_3 Acetamides 53-96-3 2-ACETYLAMINOFLUORENE MESH_LEVEL_1 Organic Chemicals 53-96-3 2-ACETYLAMINOFLUORENE ADVERSE_EFFECT DNA_2_Genotoxicity 53-96-3 2-ACETYLAMINOFLUORENE TA_LEVEL_2 Toxicant 53-96-3 2-ACETYLAMINOFLUORENE TA_LEVEL_3 Liver toxicants 53-96-3 2-ACETYLAMINOFLUORENE TISSUE_TOXICITY Genotoxicity 53-96-3 2-ACETYLAMINOFLUORENE ADVERSE_EFFECT LIV_2_Liver Necrosis 53-96-3 2-ACETYLAMINOFLUORENE ZERO_CLASS N 53-96-3 2-ACETYLAMINOFLUORENE ACTIVITY_CLASS Toxicant, DNA damaging 80-05-7 BISPHENOL A ADVERSE_EFFECT OCU_1_Eye Irritation 80-05-7 BISPHENOL A ADVERSE_EFFECT XXX_2_Weight Loss 80-05-7 BISPHENOL A MECHANISM Modulate gene transcription 80-05-7 BISPHENOL A PRODUCT_CLASS Toxicants 80-05-7 BISPHENOL A TISSUE_TOXICITY Death 80-05-7 BISPHENOL A ADVERSE_EFFECT REP_1_Changes in Reproductive Function 80-05-7 BISPHENOL A ADVERSE_EFFECT GUS_1_Diuresis 80-05-7 BISPHENOL A ADVERSE_EFFECT LUN_1_Airway Irritation 80-05-7 BISPHENOL A ZERO_CLASS N 80-05-7 BISPHENOL A MECH_LEVEL_2 estrogen receptor agonist 80-05-7 BISPHENOL A ADVERSE_EFFECT XXX_3_Death 80-05-7 BISPHENOL A ADVERSE_EFFECT SKN_1_Skin Irritation 80-05-7 BISPHENOL A ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 80-05-7 BISPHENOL A ADVERSE_EFFECT NEU_1_Increased REM Sleep 80-05-7 BISPHENOL A ADVERSE_EFFECT GIS_1_Diarrhea 80-05-7 BISPHENOL A TA_LEVEL_1 Toxicants 80-05-7 BISPHENOL A TA_LEVEL_3 Liver toxicants 80-05-7 BISPHENOL A ACTIVITY_CLASS Toxicant 80-05-7 BISPHENOL A ADVERSE_EFFECT EMB_2_Fetal Toxicity 80-05-7 BISPHENOL A ADVERSE_EFFECT IMU_2_Contact Dermatitis 80-05-7 BISPHENOL A ADVERSE_EFFECT END_2_Endocrine Abnormalities 80-05-7 BISPHENOL A MESH_LEVEL_1 Organic Chemicals 80-05-7 BISPHENOL A MECH_LEVEL_1 Hormone modulation 80-05-7 BISPHENOL A MESH_LEVEL_3 Acids, Acyclic 80-05-7 BISPHENOL A MECH_LEVEL_3 estrogen receptor 80-05-7 BISPHENOL A MESH_LEVEL_2 Carboxylic Acids 80-05-7 BISPHENOL A MODE_CLASS Receptor Agonist 80-05-7 BISPHENOL A STRUCTURE_ACTIVITY Toxicant, estrogen receptor agonist 80-05-7 BISPHENOL A TA_LEVEL_2 Liver toxicants 80-05-7 BISPHENOL A KNOWN_TOXICITY Miscellaneous 120-80-9 CATECHOL MESH_LEVEL_3 Catechols 120-80-9 CATECHOL TA_LEVEL_2 DNA damage 120-80-9 CATECHOL ADVERSE_EFFECT XXX_1_Bacterial Superinfections 120-80-9 CATECHOL ADVERSE_EFFECT XXX_3_Death 120-80-9 CATECHOL MECH_LEVEL_2 Induce free oxygen radical associated tissue and DNA damage 120-80-9 CATECHOL MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 120-80-9 CATECHOL STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 120-80-9 CATECHOL TISSUE_TOXICITY Congestive Heart Failure 120-80-9 CATECHOL ZERO_CLASS N 120-80-9 CATECHOL ADVERSE_EFFECT KID_3_Proteinuria 120-80-9 CATECHOL ADVERSE_EFFECT SKN_3_Erythema Multiforme 120-80-9 CATECHOL ADVERSE_EFFECT DNA_2_Carcinogenicity 120-80-9 CATECHOL ACTIVITY_CLASS Toxicant, DNA damaging 120-80-9 CATECHOL TISSUE_TOXICITY Death 120-80-9 CATECHOL PRODUCT_CLASS Toxicants 120-80-9 CATECHOL MESH_LEVEL_2 Phenols 120-80-9 CATECHOL MECH_LEVEL_3 DNA damage 120-80-9 CATECHOL MESH_LEVEL_1 Organic Chemicals 120-80-9 CATECHOL ADVERSE_EFFECT KID_3_Acute Renal Failure 120-80-9 CATECHOL TA_LEVEL_3 Liver toxicants 120-80-9 CATECHOL MODE_CLASS Distorts /blocks macromolecular scaffold function 120-80-9 CATECHOL KNOWN_TOXICITY Miscellaneous 120-80-9 CATECHOL ADVERSE_EFFECT XXX_3_Edema 120-80-9 CATECHOL ADVERSE_EFFECT SKN_1_Hyperpigmentation 120-80-9 CATECHOL ADVERSE_EFFECT KID_3_Membranous Glomerulonephritis 120-80-9 CATECHOL TISSUE_TOXICITY Bacterial Superinfections 120-80-9 CATECHOL TISSUE_TOXICITY Carcinogenicity 120-80-9 CATECHOL KNOWN_TOXICITY Cardiovascular Toxicity 120-80-9 CATECHOL KNOWN_TOXICITY Carcinogenicity 120-80-9 CATECHOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 120-80-9 CATECHOL ADVERSE_EFFECT IMU_1_Contact Dermatitis 120-80-9 CATECHOL TISSUE_TOXICITY Acute Renal Failure 120-80-9 CATECHOL KNOWN_TOXICITY Nephrotoxicity 120-80-9 CATECHOL MECHANISM Inhibit DNA synthesis, repair, and function 120-80-9 CATECHOL TA_LEVEL_1 Toxicants 120-80-9 CATECHOL TISSUE_TOXICITY Membranous Glomerulonephritis 67-66-3 CHLOROFORM MESH_LEVEL_1 Organic Chemicals 67-66-3 CHLOROFORM TA_LEVEL_1 Toxicants 67-66-3 CHLOROFORM INDICATION Induction / Maintenance of Anesthesia 67-66-3 CHLOROFORM MECH_LEVEL_1 Toxicants 67-66-3 CHLOROFORM PRODUCT_CLASS Toxicants 67-66-3 CHLOROFORM MESH_LEVEL_2 Hydrocarbons 67-66-3 CHLOROFORM THERAPEUTIC_CLASS General Anesthetics, Inhaled 67-66-3 CHLOROFORM KNOWN_TOXICITY Nephrotoxicity 67-66-3 CHLOROFORM ADVERSE_EFFECT PSY_1_CNS Depression 67-66-3 CHLOROFORM ADVERSE_EFFECT LIV_2_Hepatotoxicity 67-66-3 CHLOROFORM ADVERSE_EFFECT KID_2_Renal Toxicity 67-66-3 CHLOROFORM ADVERSE_EFFECT EMB_2_Embryotoxicity 67-66-3 CHLOROFORM ZERO_CLASS N 67-66-3 CHLOROFORM TISSUE_TOXICITY Renal Toxicity 67-66-3 CHLOROFORM MECH_LEVEL_2 Toxicants 67-66-3 CHLOROFORM MESH_LEVEL_3 Hydrocarbons, Halogenated 67-66-3 CHLOROFORM TA_LEVEL_3 Liver toxicants 67-66-3 CHLOROFORM ADVERSE_EFFECT DNA_2_Carcinogenicity 67-66-3 CHLOROFORM ADVERSE_EFFECT NEU_3_Coma 67-66-3 CHLOROFORM ADVERSE_EFFECT NEU_2_Narcosis 67-66-3 CHLOROFORM STRUCTURE_ACTIVITY Toxicant, free radical generator, DNA damaging 67-66-3 CHLOROFORM TISSUE_TOXICITY Hematuria 67-66-3 CHLOROFORM ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 67-66-3 CHLOROFORM KNOWN_TOXICITY Hepatotoxicity 67-66-3 CHLOROFORM TISSUE_TOXICITY Hepatotoxicity 67-66-3 CHLOROFORM MECH_LEVEL_3 Toxicants 67-66-3 CHLOROFORM ADVERSE_EFFECT NEU_1_Headache 67-66-3 CHLOROFORM ADVERSE_EFFECT NEU_2_Stupor 67-66-3 CHLOROFORM ADVERSE_EFFECT KID_2_Proteinuria 67-66-3 CHLOROFORM ADVERSE_EFFECT XXX_1_Malaise 67-66-3 CHLOROFORM TISSUE_TOXICITY Carcinogenicity 67-66-3 CHLOROFORM TA_LEVEL_2 Toxicant 67-66-3 CHLOROFORM KNOWN_TOXICITY Carcinogenicity 67-66-3 CHLOROFORM ADVERSE_EFFECT GIS_1_Nausea 67-66-3 CHLOROFORM ADVERSE_EFFECT NEU_1_Lightheadedness 67-66-3 CHLOROFORM ADVERSE_EFFECT KID_2_Hematuria 67-66-3 CHLOROFORM ADVERSE_EFFECT LUN_2_Chemical Pneumonitis 67-66-3 CHLOROFORM ACTIVITY_CLASS Toxicant, DNA damaging 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE KNOWN_TOXICITY Carcinogenicity 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT LUN_3_Pulmonary Impairment 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE TISSUE_TOXICITY Hepatocellular Carcinoma 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MESH_LEVEL_2 Carboxylic Acids 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MESH_LEVEL_3 Acids, Carbocyclic 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE STRUCTURE_ACTIVITY Toxicant, PPAR alpha agonist 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT XXX_2_Nose Irritation 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MECH_LEVEL_3 PPAR alpha 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE PRODUCT_CLASS Toxicants 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE TA_LEVEL_2 plasticizer 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MECH_LEVEL_2 Fatty acid catabolism 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ZERO_CLASS N 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ACTIVITY_CLASS Peroxisome proliferator 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE TA_LEVEL_1 Toxicants 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT XXX_2_Throat Irritation 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT DNA_2_Carcinogenicity 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MECHANISM Increase lipid catabolism 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MODE_CLASS Receptor Agonist 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MESH_LEVEL_1 Organic Chemicals 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT LIV_2_Hepatomegaly 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT LIV_2_Inhibition of P450 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT LUN_3_Asthma 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE TISSUE_TOXICITY Carcinogenicity 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE TA_LEVEL_3 Liver toxicants 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE MECH_LEVEL_1 Toxicants 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT EMB_2_Fetal Death 117-81-7 BIS(2-ETHYLHEXYL)PHTHALATE ADVERSE_EFFECT LIV_3_Hepatitis 60-57-1 DIELDRIN ADVERSE_EFFECT NEU_3_Coma 60-57-1 DIELDRIN ADVERSE_EFFECT NEU_3_Dizziness 60-57-1 DIELDRIN ADVERSE_EFFECT GIS_3_Vomiting 60-57-1 DIELDRIN MODE_CLASS Channel Blocker 60-57-1 DIELDRIN ADVERSE_EFFECT GIS_3_Nausea 60-57-1 DIELDRIN ADVERSE_EFFECT NEU_3_Myoclonic Jerks 60-57-1 DIELDRIN ADVERSE_EFFECT NEU_3_Headache 60-57-1 DIELDRIN ADVERSE_EFFECT XXX_3_Sweating 60-57-1 DIELDRIN MECHANISM Modulate neural transmission 60-57-1 DIELDRIN PRODUCT_CLASS Toxicants 60-57-1 DIELDRIN ADVERSE_EFFECT NEU_3_Seizures 60-57-1 DIELDRIN STRUCTURE_ACTIVITY GABA-A antagonist, insecticide 302-01-2 HYDRAZINE ADVERSE_EFFECT DNA_2_Mutagenicity 302-01-2 HYDRAZINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 302-01-2 HYDRAZINE ADVERSE_EFFECT GIS_2_Abdominal Pain 302-01-2 HYDRAZINE ACTIVITY_CLASS Toxicant, DNA damaging 302-01-2 HYDRAZINE TISSUE_TOXICITY Hepatotoxicity 302-01-2 HYDRAZINE ADVERSE_EFFECT OCU_1_Dilated Pupils 302-01-2 HYDRAZINE ADVERSE_EFFECT CVS_3_Arrhythmia 302-01-2 HYDRAZINE ADVERSE_EFFECT BBM_3_Leukocytosis 302-01-2 HYDRAZINE ADVERSE_EFFECT OCU_3_Blindness 302-01-2 HYDRAZINE ADVERSE_EFFECT XXX_3_Death 302-01-2 HYDRAZINE ADVERSE_EFFECT XXX_1_Fever 302-01-2 HYDRAZINE KNOWN_TOXICITY Miscellaneous 302-01-2 HYDRAZINE TISSUE_TOXICITY Death 302-01-2 HYDRAZINE ADVERSE_EFFECT KID_2_Kidney Damage 302-01-2 HYDRAZINE ADVERSE_EFFECT SKN_2_Severe Skin Lesions 302-01-2 HYDRAZINE TISSUE_TOXICITY Arrhythmia 302-01-2 HYDRAZINE TA_LEVEL_2 Toxicant 302-01-2 HYDRAZINE ADVERSE_EFFECT BBM_2_Anemia 302-01-2 HYDRAZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 302-01-2 HYDRAZINE ADVERSE_EFFECT GUS_2_Urination 302-01-2 HYDRAZINE MESH_LEVEL_1 Organic Chemicals 302-01-2 HYDRAZINE TA_LEVEL_1 Toxicants 302-01-2 HYDRAZINE MECH_LEVEL_1 Toxicants 302-01-2 HYDRAZINE MESH_LEVEL_2 Hydrazines 302-01-2 HYDRAZINE TISSUE_TOXICITY Mutagenicity 302-01-2 HYDRAZINE KNOWN_TOXICITY Mutagenicity 302-01-2 HYDRAZINE ADVERSE_EFFECT GIS_1_Diarrhea 302-01-2 HYDRAZINE ADVERSE_EFFECT NEU_1_Tremor 302-01-2 HYDRAZINE ADVERSE_EFFECT NEU_2_Ataxia 302-01-2 HYDRAZINE ADVERSE_EFFECT NEU_2_Nystagmus 302-01-2 HYDRAZINE ADVERSE_EFFECT NEU_1_Somnolence 302-01-2 HYDRAZINE ADVERSE_EFFECT OCU_1_Conjunctivitis 302-01-2 HYDRAZINE ZERO_CLASS N 302-01-2 HYDRAZINE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 302-01-2 HYDRAZINE MECH_LEVEL_2 Toxicants 302-01-2 HYDRAZINE MESH_LEVEL_3 Methylhydrazines 302-01-2 HYDRAZINE TA_LEVEL_3 Liver toxicants 302-01-2 HYDRAZINE ADVERSE_EFFECT DNA_2_Carcinogenicity 302-01-2 HYDRAZINE ADVERSE_EFFECT LUN_2_Pulmonary Edema 302-01-2 HYDRAZINE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 302-01-2 HYDRAZINE ADVERSE_EFFECT NEU_2_Loss of Consciousness 302-01-2 HYDRAZINE ADVERSE_EFFECT XXX_1_Lethargy 302-01-2 HYDRAZINE ADVERSE_EFFECT LUN_2_Bronchitis 302-01-2 HYDRAZINE TISSUE_TOXICITY Carcinogenicity 302-01-2 HYDRAZINE KNOWN_TOXICITY Carcinogenicity 302-01-2 HYDRAZINE KNOWN_TOXICITY Cardiovascular Toxicity 302-01-2 HYDRAZINE MECH_LEVEL_3 Toxicants 302-01-2 HYDRAZINE PRODUCT_CLASS Toxicants 302-01-2 HYDRAZINE KNOWN_TOXICITY Hepatotoxicity 90-04-0 O-ANISIDINE MECHANISM Inhibit DNA synthesis, repair, and function 90-04-0 O-ANISIDINE TISSUE_TOXICITY Carcinogenicity 90-04-0 O-ANISIDINE KNOWN_TOXICITY Mutagenicity 90-04-0 O-ANISIDINE KNOWN_TOXICITY Carcinogenicity 90-04-0 O-ANISIDINE ADVERSE_EFFECT DNA_2_Mutagenicity 90-04-0 O-ANISIDINE ADVERSE_EFFECT XXX_1_Weight Loss 90-04-0 O-ANISIDINE ADVERSE_EFFECT SKN_1_Skin Irritation 90-04-0 O-ANISIDINE PRODUCT_CLASS Toxicants 90-04-0 O-ANISIDINE TISSUE_TOXICITY Transitional Cell Carcinoma 90-04-0 O-ANISIDINE TISSUE_TOXICITY Mutagenicity 90-04-0 O-ANISIDINE ADVERSE_EFFECT DNA_2_Transitional Cell Carcinoma 90-04-0 O-ANISIDINE ADVERSE_EFFECT NEU_2_Vertigo 90-04-0 O-ANISIDINE MODE_CLASS Enzyme substrate mimic 90-04-0 O-ANISIDINE MECHANISM Inhibit eicosanoid biosynthesis 90-04-0 O-ANISIDINE ADVERSE_EFFECT DNA_3_Endometrial Hyperplasia 90-04-0 O-ANISIDINE ADVERSE_EFFECT NEU_2_Headache 90-04-0 O-ANISIDINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 90-04-0 O-ANISIDINE ADVERSE_EFFECT DNA_2_Carcinogenicity 90-04-0 O-ANISIDINE ADVERSE_EFFECT BBM_2_Hematological Reactions 90-04-0 O-ANISIDINE ADVERSE_EFFECT BBM_2_Methemoglobinemia 90-04-0 O-ANISIDINE TISSUE_TOXICITY Endometrial Hyperplasia 90-04-0 O-ANISIDINE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 1806-26-4 4-OCTYLPHENOL MODE_CLASS Receptor Partial Agonist 1806-26-4 4-OCTYLPHENOL ACTIVITY_CLASS Toxicant 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT OCU_1_Eye Irritation 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT END_1_Endocrine Abnormalities 1806-26-4 4-OCTYLPHENOL MESH_LEVEL_2 Phenols 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT IMU_2_Contact Dermatitis 1806-26-4 4-OCTYLPHENOL TA_LEVEL_1 Toxicants 1806-26-4 4-OCTYLPHENOL ZERO_CLASS N 1806-26-4 4-OCTYLPHENOL STRUCTURE_ACTIVITY Toxicant, estrogen receptor agonist 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT SKN_2_Dry Skin 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT LIV_2_Hepatic Damage 1806-26-4 4-OCTYLPHENOL MECH_LEVEL_2 estrogen receptor agonist 1806-26-4 4-OCTYLPHENOL TA_LEVEL_2 Biochemical 1806-26-4 4-OCTYLPHENOL TA_LEVEL_3 Liver toxicants 1806-26-4 4-OCTYLPHENOL PRODUCT_CLASS Toxicants 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT GIS_1_Diarrhea 1806-26-4 4-OCTYLPHENOL MESH_LEVEL_1 Organic Chemicals 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT SKN_2_Skin Irritation 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1806-26-4 4-OCTYLPHENOL MECHANISM Modulate gene transcription 1806-26-4 4-OCTYLPHENOL ADVERSE_EFFECT REP_2_Changes in Reproductive Function 1806-26-4 4-OCTYLPHENOL MECH_LEVEL_1 Hormone modulation 1806-26-4 4-OCTYLPHENOL MECH_LEVEL_3 estrogen receptor alpha, beta 50-50-0 BETA-ESTRADIOL 3-BENZOATE INDICATION Depression 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT GIS_1_Abdominal Pain 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT DNA_2_Carcinogenicity 50-50-0 BETA-ESTRADIOL 3-BENZOATE ZERO_CLASS N 50-50-0 BETA-ESTRADIOL 3-BENZOATE ACTIVITY_CLASS Estrogen agonist 50-50-0 BETA-ESTRADIOL 3-BENZOATE STRUCTURE_ACTIVITY Estrogen receptor agonist, steroidal 50-50-0 BETA-ESTRADIOL 3-BENZOATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 50-50-0 BETA-ESTRADIOL 3-BENZOATE INDICATION Female Hypogonadism 50-50-0 BETA-ESTRADIOL 3-BENZOATE MESH_LEVEL_1 Polycyclic Hydrocarbons 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT GUS_2_Prostatic Disorder 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT GUS_2_Genital Moniliasis 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT CVS_2_Hypertension 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT CVS_2_Thromboembolism 50-50-0 BETA-ESTRADIOL 3-BENZOATE KNOWN_TOXICITY Carcinogenicity 50-50-0 BETA-ESTRADIOL 3-BENZOATE THERAPEUTIC_CLASS Gonadal Hormones 50-50-0 BETA-ESTRADIOL 3-BENZOATE TISSUE_TOXICITY Hepatic Adenoma 50-50-0 BETA-ESTRADIOL 3-BENZOATE MECH_LEVEL_2 estrogen receptor agonist 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT REP_1_Erectile Dysfunction 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT GUS_2_Genital Pruritis 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT MSK_1_Back Pain 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT ELT_2_Hypercalcemia 50-50-0 BETA-ESTRADIOL 3-BENZOATE TA_LEVEL_3 SERM 50-50-0 BETA-ESTRADIOL 3-BENZOATE INDICATION Amenorrhea 50-50-0 BETA-ESTRADIOL 3-BENZOATE INDICATION Prevention of Osteoporosis 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT BIL_2_Gallbladder Disease 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT END_2_Glucose Intolerance 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT DNA_2_Hepatic Adenoma 50-50-0 BETA-ESTRADIOL 3-BENZOATE TISSUE_TOXICITY Carcinogenicity 50-50-0 BETA-ESTRADIOL 3-BENZOATE TISSUE_TOXICITY Thromboembolism 50-50-0 BETA-ESTRADIOL 3-BENZOATE MODE_CLASS Receptor Agonist 50-50-0 BETA-ESTRADIOL 3-BENZOATE MECHANISM Modulate gene transcription 50-50-0 BETA-ESTRADIOL 3-BENZOATE MESH_LEVEL_3 Estranes 50-50-0 BETA-ESTRADIOL 3-BENZOATE TA_LEVEL_2 post-menapause 50-50-0 BETA-ESTRADIOL 3-BENZOATE KNOWN_TOXICITY Cardiovascular Toxicity 50-50-0 BETA-ESTRADIOL 3-BENZOATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 50-50-0 BETA-ESTRADIOL 3-BENZOATE INDICATION Atrophic Vaginitis 50-50-0 BETA-ESTRADIOL 3-BENZOATE INDICATION Menopausal Syndrome 50-50-0 BETA-ESTRADIOL 3-BENZOATE MESH_LEVEL_2 Steroids 50-50-0 BETA-ESTRADIOL 3-BENZOATE MECH_LEVEL_1 Hormone replacement 50-50-0 BETA-ESTRADIOL 3-BENZOATE MECH_LEVEL_3 estrogen receptor 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT NEU_1_Headache 50-50-0 BETA-ESTRADIOL 3-BENZOATE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 50-50-0 BETA-ESTRADIOL 3-BENZOATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 9000-11-7 CARBOXYMETHYLCELLULOSE PRODUCT_CLASS Biochemicals 9004-32-4 CARBOXYMETHYLCELLULOSE PRODUCT_CLASS Biochemicals 7585-39-9 BETA CYCLODEXTRIN STRUCTURE_ACTIVITY Cyclodextrin 7585-39-9 BETA CYCLODEXTRIN PRODUCT_CLASS Biochemicals 298-46-4 CARBAMAZEPINE MESH_LEVEL_3 Dibenzazepines 298-46-4 CARBAMAZEPINE MECHANISM Block neural transmission 298-46-4 CARBAMAZEPINE MODE_CLASS Channel Blocker 298-46-4 CARBAMAZEPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 298-46-4 CARBAMAZEPINE KNOWN_TOXICITY Hepatotoxicity 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Hepatic Failure 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Heart Block 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Hepatitis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT REP_3_Impotence 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Agranulocytosis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Leukopenia 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT SKN_1_Skin Toxicity 298-46-4 CARBAMAZEPINE KNOWN_TOXICITY Embryo/Fetal Toxicity 298-46-4 CARBAMAZEPINE KNOWN_TOXICITY Nephrotoxicity 298-46-4 CARBAMAZEPINE INDICATION Trigeminal Neuralgia / Tic Douloureux 298-46-4 CARBAMAZEPINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 298-46-4 CARBAMAZEPINE KNOWN_TOXICITY Cardiovascular Toxicity 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Teratogenicity 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Congestive Heart Failure 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT XXX_2_Glossitis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT KID_3_Renal Failure 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 298-46-4 CARBAMAZEPINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, tricyclic anticonvulsant 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT NEU_3_Aseptic Meningitis 298-46-4 CARBAMAZEPINE INDICATION Neuropathic Pain 298-46-4 CARBAMAZEPINE INDICATION Epilepsy 298-46-4 CARBAMAZEPINE ZERO_CLASS N 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT GIS_3_Pancreatitis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Hepatic Failure 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT END_3_Acute Intermittent Porphyria 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT EMB_1_Teratogenicity 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 298-46-4 CARBAMAZEPINE TA_LEVEL_1 Central Nervous System (CNS) 298-46-4 CARBAMAZEPINE MECH_LEVEL_2 Sodium channel antagonist 298-46-4 CARBAMAZEPINE MESH_LEVEL_1 Heterocyclic Compounds 298-46-4 CARBAMAZEPINE INDICATION Tonic-Clonic (Grand Mal) Seizures 298-46-4 CARBAMAZEPINE TA_LEVEL_3 Seizures 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hirsutism 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Heart Block 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Pancytopenia 298-46-4 CARBAMAZEPINE MECH_LEVEL_1 Modulate neural transmission 298-46-4 CARBAMAZEPINE KNOWN_TOXICITY Dermatologic Toxicity 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Skin Toxicity 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Renal Failure 298-46-4 CARBAMAZEPINE ACTIVITY_CLASS Na+ channel blocker 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hypercholesteremia 298-46-4 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 298-46-4 CARBAMAZEPINE MECH_LEVEL_3 Voltage-gated Na+ channel 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Acute Hepatocellular Hepatitis 298-46-4 CARBAMAZEPINE TISSUE_TOXICITY Cardiac Arrhythmia 298-46-4 CARBAMAZEPINE TA_LEVEL_2 Anti-epileptics 298-46-4 CARBAMAZEPINE INDICATION Partial Seizures 298-46-4 CARBAMAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT XXX_2_Glossitis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT KID_3_Renal Failure 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 105234-21-7 CARBAMAZEPINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, tricyclic anticonvulsant 105234-21-7 CARBAMAZEPINE TA_LEVEL_1 Central Nervous System (CNS) 105234-21-7 CARBAMAZEPINE MECH_LEVEL_2 Sodium channel antagonist 105234-21-7 CARBAMAZEPINE MESH_LEVEL_1 Heterocyclic Compounds 105234-21-7 CARBAMAZEPINE INDICATION Tonic-Clonic (Grand Mal) Seizures 105234-21-7 CARBAMAZEPINE TA_LEVEL_3 Seizures 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hirsutism 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Heart Block 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 105234-21-7 CARBAMAZEPINE ACTIVITY_CLASS Na+ channel blocker 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hypercholesteremia 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Renal Failure 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT SKN_1_Skin Toxicity 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Skin Toxicity 105234-21-7 CARBAMAZEPINE TA_LEVEL_2 Anti-epileptics 105234-21-7 CARBAMAZEPINE INDICATION Partial Seizures 105234-21-7 CARBAMAZEPINE MECH_LEVEL_3 Voltage-gated Na+ channel 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 105234-21-7 CARBAMAZEPINE MESH_LEVEL_3 Dibenzazepines 105234-21-7 CARBAMAZEPINE MECHANISM Block neural transmission 105234-21-7 CARBAMAZEPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 105234-21-7 CARBAMAZEPINE KNOWN_TOXICITY Hepatotoxicity 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Hepatic Failure 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Heart Block 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT NEU_3_Aseptic Meningitis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT EMB_1_Teratogenicity 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT END_3_Acute Intermittent Porphyria 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Hepatic Failure 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT GIS_3_Pancreatitis 105234-21-7 CARBAMAZEPINE ZERO_CLASS N 105234-21-7 CARBAMAZEPINE INDICATION Epilepsy 105234-21-7 CARBAMAZEPINE KNOWN_TOXICITY Dermatologic Toxicity 105234-21-7 CARBAMAZEPINE KNOWN_TOXICITY Embryo/Fetal Toxicity 105234-21-7 CARBAMAZEPINE INDICATION Neuropathic Pain 105234-21-7 CARBAMAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 105234-21-7 CARBAMAZEPINE MECH_LEVEL_1 Modulate neural transmission 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Acute Hepatocellular Hepatitis 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Cardiac Arrhythmia 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Hepatitis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT REP_3_Impotence 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Agranulocytosis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Leukopenia 105234-21-7 CARBAMAZEPINE KNOWN_TOXICITY Nephrotoxicity 105234-21-7 CARBAMAZEPINE INDICATION Trigeminal Neuralgia / Tic Douloureux 105234-21-7 CARBAMAZEPINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 105234-21-7 CARBAMAZEPINE KNOWN_TOXICITY Cardiovascular Toxicity 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Teratogenicity 105234-21-7 CARBAMAZEPINE TISSUE_TOXICITY Congestive Heart Failure 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Pancytopenia 105234-21-7 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 105234-21-7 CARBAMAZEPINE MODE_CLASS Channel Blocker 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Hepatic Failure 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Heart Block 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT NEU_3_Aseptic Meningitis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT EMB_1_Teratogenicity 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT END_3_Acute Intermittent Porphyria 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Hepatic Failure 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT GIS_3_Pancreatitis 121947-25-9 CARBAMAZEPINE ZERO_CLASS N 121947-25-9 CARBAMAZEPINE INDICATION Epilepsy 121947-25-9 CARBAMAZEPINE INDICATION Neuropathic Pain 121947-25-9 CARBAMAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 121947-25-9 CARBAMAZEPINE MECH_LEVEL_1 Modulate neural transmission 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Acute Hepatocellular Hepatitis 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Cardiac Arrhythmia 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Hepatitis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT REP_3_Impotence 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Agranulocytosis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Leukopenia 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT SKN_1_Skin Toxicity 121947-25-9 CARBAMAZEPINE KNOWN_TOXICITY Embryo/Fetal Toxicity 121947-25-9 CARBAMAZEPINE KNOWN_TOXICITY Nephrotoxicity 121947-25-9 CARBAMAZEPINE INDICATION Trigeminal Neuralgia / Tic Douloureux 121947-25-9 CARBAMAZEPINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 121947-25-9 CARBAMAZEPINE KNOWN_TOXICITY Cardiovascular Toxicity 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Teratogenicity 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Congestive Heart Failure 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT XXX_2_Glossitis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT KID_3_Renal Failure 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 121947-25-9 CARBAMAZEPINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, tricyclic anticonvulsant 121947-25-9 CARBAMAZEPINE TA_LEVEL_1 Central Nervous System (CNS) 121947-25-9 CARBAMAZEPINE MECH_LEVEL_2 Sodium channel antagonist 121947-25-9 CARBAMAZEPINE MESH_LEVEL_1 Heterocyclic Compounds 121947-25-9 CARBAMAZEPINE INDICATION Tonic-Clonic (Grand Mal) Seizures 121947-25-9 CARBAMAZEPINE TA_LEVEL_3 Seizures 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hirsutism 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Heart Block 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Pancytopenia 121947-25-9 CARBAMAZEPINE KNOWN_TOXICITY Dermatologic Toxicity 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Skin Toxicity 121947-25-9 CARBAMAZEPINE TISSUE_TOXICITY Renal Failure 121947-25-9 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hypercholesteremia 121947-25-9 CARBAMAZEPINE ACTIVITY_CLASS Na+ channel blocker 121947-25-9 CARBAMAZEPINE MODE_CLASS Channel Blocker 121947-25-9 CARBAMAZEPINE TA_LEVEL_2 Anti-epileptics 121947-25-9 CARBAMAZEPINE INDICATION Partial Seizures 121947-25-9 CARBAMAZEPINE MECH_LEVEL_3 Voltage-gated Na+ channel 121947-25-9 CARBAMAZEPINE MESH_LEVEL_3 Dibenzazepines 121947-25-9 CARBAMAZEPINE MECHANISM Block neural transmission 121947-25-9 CARBAMAZEPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 121947-25-9 CARBAMAZEPINE KNOWN_TOXICITY Hepatotoxicity 121985-71-5 CARBAMAZEPINE MESH_LEVEL_3 Dibenzazepines 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT KID_3_Renal Failure 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Hepatitis 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Cardiac Arrhythmia 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Acute Hepatocellular Hepatitis 121985-71-5 CARBAMAZEPINE MECH_LEVEL_1 Modulate neural transmission 121985-71-5 CARBAMAZEPINE PRODUCT_CLASS Central Nervous System (CNS) 121985-71-5 CARBAMAZEPINE INDICATION Neuropathic Pain 121985-71-5 CARBAMAZEPINE INDICATION Epilepsy 121985-71-5 CARBAMAZEPINE ZERO_CLASS N 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT GIS_3_Pancreatitis 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT LIV_3_Hepatic Failure 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT END_3_Acute Intermittent Porphyria 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT EMB_1_Teratogenicity 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT NEU_3_Aseptic Meningitis 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Heart Block 121985-71-5 CARBAMAZEPINE KNOWN_TOXICITY Hepatotoxicity 121985-71-5 CARBAMAZEPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 121985-71-5 CARBAMAZEPINE MODE_CLASS Channel Blocker 121985-71-5 CARBAMAZEPINE MECHANISM Block neural transmission 121985-71-5 CARBAMAZEPINE ACTIVITY_CLASS Na+ channel blocker 121985-71-5 CARBAMAZEPINE MECH_LEVEL_3 Voltage-gated Na+ channel 121985-71-5 CARBAMAZEPINE INDICATION Partial Seizures 121985-71-5 CARBAMAZEPINE TA_LEVEL_2 Anti-epileptics 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Hepatic Failure 121985-71-5 CARBAMAZEPINE MESH_LEVEL_1 Heterocyclic Compounds 121985-71-5 CARBAMAZEPINE INDICATION Tonic-Clonic (Grand Mal) Seizures 121985-71-5 CARBAMAZEPINE TA_LEVEL_3 Seizures 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hypercholesteremia 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT REP_3_Impotence 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Agranulocytosis 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT XXX_2_Glossitis 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Renal Failure 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Skin Toxicity 121985-71-5 CARBAMAZEPINE KNOWN_TOXICITY Dermatologic Toxicity 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Pancytopenia 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT CVS_3_Heart Block 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT END_3_Hirsutism 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 121985-71-5 CARBAMAZEPINE TA_LEVEL_1 Central Nervous System (CNS) 121985-71-5 CARBAMAZEPINE MECH_LEVEL_2 Sodium channel antagonist 121985-71-5 CARBAMAZEPINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, tricyclic anticonvulsant 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Leukopenia 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT SKN_1_Skin Toxicity 121985-71-5 CARBAMAZEPINE KNOWN_TOXICITY Embryo/Fetal Toxicity 121985-71-5 CARBAMAZEPINE KNOWN_TOXICITY Nephrotoxicity 121985-71-5 CARBAMAZEPINE INDICATION Trigeminal Neuralgia / Tic Douloureux 121985-71-5 CARBAMAZEPINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 121985-71-5 CARBAMAZEPINE KNOWN_TOXICITY Cardiovascular Toxicity 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Teratogenicity 121985-71-5 CARBAMAZEPINE TISSUE_TOXICITY Congestive Heart Failure 121985-71-5 CARBAMAZEPINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 621-42-1 3-ACETAMIDOPHENOL PRODUCT_CLASS Biochemicals 621-42-1 3-ACETAMIDOPHENOL MECH_LEVEL_3 Toxicants 621-42-1 3-ACETAMIDOPHENOL ZERO_CLASS N 621-42-1 3-ACETAMIDOPHENOL STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 621-42-1 3-ACETAMIDOPHENOL MESH_LEVEL_2 Amines 621-42-1 3-ACETAMIDOPHENOL ADVERSE_EFFECT PSY_2_Depression of Mood 621-42-1 3-ACETAMIDOPHENOL ADVERSE_EFFECT NEU_1_Drowsiness 621-42-1 3-ACETAMIDOPHENOL TA_LEVEL_1 Toxicants 621-42-1 3-ACETAMIDOPHENOL ACTIVITY_CLASS Anti-inflammatory 621-42-1 3-ACETAMIDOPHENOL TA_LEVEL_2 Toxicant 621-42-1 3-ACETAMIDOPHENOL MESH_LEVEL_1 Organic Chemicals 621-42-1 3-ACETAMIDOPHENOL ADVERSE_EFFECT LIV_1_Inhibition of Liver Microsomal Drug-Metabolizing Enzymes 621-42-1 3-ACETAMIDOPHENOL MECH_LEVEL_2 Toxicants 621-42-1 3-ACETAMIDOPHENOL TA_LEVEL_3 Liver toxicants 621-42-1 3-ACETAMIDOPHENOL ADVERSE_EFFECT NEU_1_Sedation 621-42-1 3-ACETAMIDOPHENOL MESH_LEVEL_3 Aniline Compounds 621-42-1 3-ACETAMIDOPHENOL MECH_LEVEL_1 Toxicants 125-13-3 OXYPHENISATIN INDICATION Constipation 125-13-3 OXYPHENISATIN ADVERSE_EFFECT _2_Local Tissue Irritation 125-13-3 OXYPHENISATIN ADVERSE_EFFECT IMU_3_Impaired Antibody Response 125-13-3 OXYPHENISATIN ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 125-13-3 OXYPHENISATIN PRODUCT_CLASS Gastrointestinal System 125-13-3 OXYPHENISATIN TISSUE_TOXICITY Liver Cirrhosis 125-13-3 OXYPHENISATIN ADVERSE_EFFECT LIV_2_Hepatitis 125-13-3 OXYPHENISATIN ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 125-13-3 OXYPHENISATIN ADVERSE_EFFECT GIS_2_Abdominal Cramps 125-13-3 OXYPHENISATIN INDICATION Constipation 125-13-3 OXYPHENISATIN ADVERSE_EFFECT GIS_2_Diarrhea 125-13-3 OXYPHENISATIN ADVERSE_EFFECT LIV_3_Liver Cirrhosis 125-13-3 OXYPHENISATIN ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 125-13-3 OXYPHENISATIN THERAPEUTIC_CLASS Laxatives 125-13-3 OXYPHENISATIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 125-13-3 OXYPHENISATIN KNOWN_TOXICITY Hepatotoxicity 125-13-3 OXYPHENISATIN ADVERSE_EFFECT LIV_2_Jaundice 13464-35-2 POTASSIUM ARSENITE TISSUE_TOXICITY Carcinogenicity 13464-35-2 POTASSIUM ARSENITE PRODUCT_CLASS Toxicants 13464-35-2 POTASSIUM ARSENITE ADVERSE_EFFECT DNA__Carcinogenicity 13464-35-2 POTASSIUM ARSENITE KNOWN_TOXICITY Carcinogenicity 7447-40-7 POTASSIUM CHLORIDE MECHANISM Modulate channel gating 7447-40-7 POTASSIUM CHLORIDE MODE_CLASS Channel Modulator 12599-00-7 POTASSIUM CHLORIDE MECHANISM Modulate channel gating 12599-00-7 POTASSIUM CHLORIDE MODE_CLASS Channel Modulator 59217-68-4 POTASSIUM CHLORIDE MECHANISM Modulate channel gating 59217-68-4 POTASSIUM CHLORIDE MODE_CLASS Channel Modulator 75-01-4 VINYL CHLORIDE ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 75-01-4 VINYL CHLORIDE KNOWN_TOXICITY Hepatotoxicity 75-01-4 VINYL CHLORIDE STRUCTURE_ACTIVITY Toxicant, free oxygen radical generator 75-01-4 VINYL CHLORIDE TISSUE_TOXICITY Hepatic Necrosis 75-01-4 VINYL CHLORIDE ADVERSE_EFFECT LIV_2_Hepatomegaly 75-01-4 VINYL CHLORIDE ADVERSE_EFFECT XXX_1_Weakness 75-01-4 VINYL CHLORIDE PRODUCT_CLASS Toxicants 75-01-4 VINYL CHLORIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 75-01-4 VINYL CHLORIDE TISSUE_TOXICITY Carcinogenicity 75-01-4 VINYL CHLORIDE KNOWN_TOXICITY Nephrotoxicity 75-01-4 VINYL CHLORIDE TISSUE_TOXICITY Renal Tubular Necrosis 75-01-4 VINYL CHLORIDE MECHANISM Inhibit DNA synthesis, repair, and function 75-01-4 VINYL CHLORIDE ADVERSE_EFFECT LUN_2_Cyanosis 75-01-4 VINYL CHLORIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 75-01-4 VINYL CHLORIDE TISSUE_TOXICITY Interstitial Nephritis 75-01-4 VINYL CHLORIDE TISSUE_TOXICITY Mutagenicity 75-01-4 VINYL CHLORIDE KNOWN_TOXICITY Carcinogenicity 75-01-4 VINYL CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 75-01-4 VINYL CHLORIDE KNOWN_TOXICITY Mutagenicity 75-01-4 VINYL CHLORIDE TISSUE_TOXICITY Genotoxicity 10026-11-6 ZIRCONIUM(IV) CHLORIDE ADVERSE_EFFECT LUN_3_Pulmonary Granuloma 10026-11-6 ZIRCONIUM(IV) CHLORIDE TA_LEVEL_2 Toxicant 10026-11-6 ZIRCONIUM(IV) CHLORIDE PRODUCT_CLASS Toxicants 10026-11-6 ZIRCONIUM(IV) CHLORIDE MECH_LEVEL_3 Toxicants 10026-11-6 ZIRCONIUM(IV) CHLORIDE ADVERSE_EFFECT SKN_3_Skin Granuloma 10026-11-6 ZIRCONIUM(IV) CHLORIDE STRUCTURE_ACTIVITY Toxicant, transition metal 10026-11-6 ZIRCONIUM(IV) CHLORIDE TA_LEVEL_3 Liver toxicants 10026-11-6 ZIRCONIUM(IV) CHLORIDE MESH_LEVEL_3 Metals, Heavy 10026-11-6 ZIRCONIUM(IV) CHLORIDE MECH_LEVEL_2 Toxicants 10026-11-6 ZIRCONIUM(IV) CHLORIDE ACTIVITY_CLASS Toxicant 10026-11-6 ZIRCONIUM(IV) CHLORIDE ZERO_CLASS N 10026-11-6 ZIRCONIUM(IV) CHLORIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 10026-11-6 ZIRCONIUM(IV) CHLORIDE MESH_LEVEL_2 Metals 10026-11-6 ZIRCONIUM(IV) CHLORIDE MECH_LEVEL_1 Toxicants 10026-11-6 ZIRCONIUM(IV) CHLORIDE MESH_LEVEL_1 Inorganic Chemicals 10026-11-6 ZIRCONIUM(IV) CHLORIDE TA_LEVEL_1 Toxicants 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE ADVERSE_EFFECT IMU_2_Allergic Reactions 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE TA_LEVEL_3 Antiseptics / Disinfectants 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE MESH_LEVEL_1 Organic Chemicals 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE TA_LEVEL_1 Biochemicals 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE STRUCTURE_ACTIVITY Unknown mechanism, antiseptic 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE ZERO_CLASS Y 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE PRODUCT_CLASS Biochemicals 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE ADVERSE_EFFECT IMU_1_Photosensitivity 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE MECH_LEVEL_1 Immunomodulation 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE TA_LEVEL_2 photoreactive anilines 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE MESH_LEVEL_3 Anilides 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE MESH_LEVEL_2 Amides 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE ACTIVITY_CLASS Unknown mechanism 1154-59-2 3,3',4',5-TETRACHLOROSALICYLANILIDE ADVERSE_EFFECT SKN_1_Skin Disorder 64092-48-4 ZOMEPIRAC MECH_LEVEL_1 Immunomodulation 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT GIS_1_Nausea 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT SKN_2_Rash 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT IMU_2_Anaphylactoid Reactions 64092-48-4 ZOMEPIRAC KNOWN_TOXICITY Cardiovascular Toxicity 64092-48-4 ZOMEPIRAC STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 64092-48-4 ZOMEPIRAC TA_LEVEL_3 NSAID 64092-48-4 ZOMEPIRAC MECHANISM Inhibit eicosanoid biosynthesis 64092-48-4 ZOMEPIRAC PRODUCT_CLASS Anti-inflammatories 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT OTO_3_Tinnitus 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 64092-48-4 ZOMEPIRAC ZERO_CLASS N 64092-48-4 ZOMEPIRAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 64092-48-4 ZOMEPIRAC TISSUE_TOXICITY Cardiac Arrhythmia 64092-48-4 ZOMEPIRAC MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 64092-48-4 ZOMEPIRAC MODE_CLASS Enzyme Inhibitor 64092-48-4 ZOMEPIRAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT CVS_2_Hypertension 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT XXX_2_Edema 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT GIS_1_Dyspepsia 64092-48-4 ZOMEPIRAC INDICATION Rheumatoid Arthritis 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT GIS_2_Diarrhea 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT NEU_2_Dizziness 64092-48-4 ZOMEPIRAC ADVERSE_EFFECT IMU_2_Anaphylaxis 64092-48-4 ZOMEPIRAC ACTIVITY_CLASS Anti-inflammatory 64092-48-4 ZOMEPIRAC TA_LEVEL_2 NSAID 64092-48-4 ZOMEPIRAC MESH_LEVEL_3 Pyrroles 64092-48-4 ZOMEPIRAC TA_LEVEL_1 Anti-inflammatory 64092-48-4 ZOMEPIRAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 64092-48-4 ZOMEPIRAC MESH_LEVEL_1 Heterocyclic Compounds 87-12-7 DIBROMSALAN ADVERSE_EFFECT IMU_1_Contact Dermatitis 87-12-7 DIBROMSALAN ADVERSE_EFFECT SKN_1_Skin Disorder 87-12-7 DIBROMSALAN PRODUCT_CLASS Toxicants 87-12-7 DIBROMSALAN STRUCTURE_ACTIVITY Unknown mechanism 87-12-7 DIBROMSALAN PRODUCT_CLASS Biochemicals 87-12-7 DIBROMSALAN ADVERSE_EFFECT SKN_2_Eczema 87-12-7 DIBROMSALAN THERAPEUTIC_CLASS Antiseptics / Disinfectants 87-12-7 DIBROMSALAN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 2577-72-2 METABROMSALAN THERAPEUTIC_CLASS Antiseptics / Disinfectants 2577-72-2 METABROMSALAN ADVERSE_EFFECT IMU_1_Contact Dermatitis 2577-72-2 METABROMSALAN STRUCTURE_ACTIVITY Unknown mechanism 2577-72-2 METABROMSALAN PRODUCT_CLASS Toxicants 2577-72-2 METABROMSALAN ADVERSE_EFFECT SKN_1_Skin Disorder 2577-72-2 METABROMSALAN PRODUCT_CLASS Biochemicals 2577-72-2 METABROMSALAN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 87-10-5 TRIBROMSALAN PRODUCT_CLASS Toxicants 87-10-5 TRIBROMSALAN TA_LEVEL_3 Toxicant 87-10-5 TRIBROMSALAN ADVERSE_EFFECT IMU_1_Contact Dermatitis 87-10-5 TRIBROMSALAN THERAPEUTIC_CLASS Antiseptics / Disinfectants 87-10-5 TRIBROMSALAN MECH_LEVEL_1 photosensitizer 87-10-5 TRIBROMSALAN TA_LEVEL_1 Dermatology 87-10-5 TRIBROMSALAN TA_LEVEL_2 Toxicant 87-10-5 TRIBROMSALAN MESH_LEVEL_1 Organic Chemicals 87-10-5 TRIBROMSALAN MECH_LEVEL_2 Unknown mechanism 87-10-5 TRIBROMSALAN MECH_LEVEL_3 Unknown mechanism 87-10-5 TRIBROMSALAN MESH_LEVEL_2 Amides 87-10-5 TRIBROMSALAN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 87-10-5 TRIBROMSALAN MESH_LEVEL_3 Salicylamides 12738-72-6 TRIBROMSALAN ADVERSE_EFFECT IMU_1_Contact Dermatitis 12738-72-6 TRIBROMSALAN THERAPEUTIC_CLASS Antiseptics / Disinfectants 12738-72-6 TRIBROMSALAN TA_LEVEL_2 Toxicant 12738-72-6 TRIBROMSALAN MESH_LEVEL_3 Salicylamides 12738-72-6 TRIBROMSALAN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 12738-72-6 TRIBROMSALAN TA_LEVEL_1 Dermatology 12738-72-6 TRIBROMSALAN MECH_LEVEL_3 Unknown mechanism 12738-72-6 TRIBROMSALAN PRODUCT_CLASS Toxicants 12738-72-6 TRIBROMSALAN MECH_LEVEL_2 Unknown mechanism 12738-72-6 TRIBROMSALAN MECH_LEVEL_1 photosensitizer 12738-72-6 TRIBROMSALAN MESH_LEVEL_1 Organic Chemicals 12738-72-6 TRIBROMSALAN TA_LEVEL_3 Toxicant 12738-72-6 TRIBROMSALAN MESH_LEVEL_2 Amides 36478-76-9 URANYL NITRATE PRODUCT_CLASS Toxicants 13520-83-7 URANYL NITRATE PRODUCT_CLASS Toxicants 131-49-7 DIATRIZOIC ACID TISSUE_TOXICITY Oligemic Renal Failure 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT IMU_2_Urticaria 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT KID_3_Renal Dysfunction 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT GIS_3_Salivary Gland Swelling 131-49-7 DIATRIZOIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 131-49-7 DIATRIZOIC ACID TISSUE_TOXICITY Arrhythmia 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT LUN_3_Pulmonary Edema 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT LUN_2_Bronchospasm 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT CVS_3_Arrhythmia 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT IMU_3_Angioneurotic Edema 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT SKN_1_Flushing 131-49-7 DIATRIZOIC ACID PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 131-49-7 DIATRIZOIC ACID INDICATION Diagnostic Radiography 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT KID_3_Oligemic Renal Failure 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT XXX_1_Taste Disturbances 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT CVS_2_Thrombophlebitis 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT NEU_2_Headache 131-49-7 DIATRIZOIC ACID TISSUE_TOXICITY Hypertensive Crisis 131-49-7 DIATRIZOIC ACID KNOWN_TOXICITY Nephrotoxicity 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT GIS_3_Pancreatic Mumps 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT GIS_2_Abdominal Pain 131-49-7 DIATRIZOIC ACID ADVERSE_EFFECT CVS_3_Hypertensive Crisis 15347-57-6 LEAD(IV) ACETATE TISSUE_TOXICITY Shock 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT LUN_1_Deep Lung Irritation 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT NEU_1_Dizziness 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT XXX_1_Restlessness 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT REP_2_Decreased Fertility 15347-57-6 LEAD(IV) ACETATE ACTIVITY_CLASS Toxicant 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT GIS_1_Abdominal Pain 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT CVS_3_Shock 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT NEU_3_Coma 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT CVS_1_Hypertension 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT GIS_1_Metallic Taste 15347-57-6 LEAD(IV) ACETATE KNOWN_TOXICITY Poisoning 15347-57-6 LEAD(IV) ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 15347-57-6 LEAD(IV) ACETATE TA_LEVEL_3 Kidney toxicants 15347-57-6 LEAD(IV) ACETATE MESH_LEVEL_3 Metals, Heavy 15347-57-6 LEAD(IV) ACETATE MECH_LEVEL_2 Toxicants 15347-57-6 LEAD(IV) ACETATE STRUCTURE_ACTIVITY Toxicant, heavy metal 15347-57-6 LEAD(IV) ACETATE ZERO_CLASS N 15347-57-6 LEAD(IV) ACETATE TISSUE_TOXICITY Death 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT CVS_1_Chest Pain 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT PSY_1_Irritability 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT MSK_2_Spasm 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT PSY_1_Insomnia 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT PSN_1_Lead Poisoning 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT LUN_1_Bronchial Irritation 15347-57-6 LEAD(IV) ACETATE MESH_LEVEL_1 Inorganic Chemicals 15347-57-6 LEAD(IV) ACETATE MESH_LEVEL_2 Metals 15347-57-6 LEAD(IV) ACETATE TA_LEVEL_1 Toxicants 15347-57-6 LEAD(IV) ACETATE MECH_LEVEL_1 Toxicants 15347-57-6 LEAD(IV) ACETATE MECH_LEVEL_3 Toxicants 15347-57-6 LEAD(IV) ACETATE KNOWN_TOXICITY Miscellaneous 15347-57-6 LEAD(IV) ACETATE PRODUCT_CLASS Toxicants 15347-57-6 LEAD(IV) ACETATE TISSUE_TOXICITY Carcinogenicity 15347-57-6 LEAD(IV) ACETATE TISSUE_TOXICITY Lead Poisoning 15347-57-6 LEAD(IV) ACETATE KNOWN_TOXICITY Carcinogenicity 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT OCU_1_Eye Irritation 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT DNA_1_Carcinogenicity 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT XXX_3_Death 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT MSK_1_Muscle Weakness 15347-57-6 LEAD(IV) ACETATE ADVERSE_EFFECT OCU_1_Visual Disturbances 15347-57-6 LEAD(IV) ACETATE TA_LEVEL_2 Toxicant 7712-50-7 MYRTECAINE MECH_LEVEL_2 Decrease neural membrane excitability 7712-50-7 MYRTECAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 7712-50-7 MYRTECAINE ADVERSE_EFFECT SKN_2_Eczema 7712-50-7 MYRTECAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 7712-50-7 MYRTECAINE MECH_LEVEL_1 Modulate neural transmission 7712-50-7 MYRTECAINE MESH_LEVEL_1 Organic Chemicals 7712-50-7 MYRTECAINE TA_LEVEL_3 Injectable Local Anesthesia 7712-50-7 MYRTECAINE TA_LEVEL_2 Anesthesia 7712-50-7 MYRTECAINE MESH_LEVEL_2 Hydrocarbons 7712-50-7 MYRTECAINE MODE_CLASS Channel Blocker 7712-50-7 MYRTECAINE PRODUCT_CLASS Central Nervous System (CNS) 7712-50-7 MYRTECAINE THERAPEUTIC_CLASS Local Anesthetics 7712-50-7 MYRTECAINE ZERO_CLASS N 7712-50-7 MYRTECAINE ACTIVITY_CLASS Na+ channel blocker 7712-50-7 MYRTECAINE ADVERSE_EFFECT XXX_2_Impaired Wound Healing 7712-50-7 MYRTECAINE MECHANISM Block neural transmission 7712-50-7 MYRTECAINE MESH_LEVEL_3 Terpenes 7712-50-7 MYRTECAINE MECH_LEVEL_3 Voltage-gated Na+ channel 7712-50-7 MYRTECAINE ADVERSE_EFFECT SKN_2_Dermatitis 68342-78-9 MYRTECAINE MECH_LEVEL_1 Modulate neural transmission 68342-78-9 MYRTECAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 68342-78-9 MYRTECAINE ADVERSE_EFFECT SKN_2_Eczema 68342-78-9 MYRTECAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 68342-78-9 MYRTECAINE MECH_LEVEL_2 Decrease neural membrane excitability 68342-78-9 MYRTECAINE MECHANISM Block neural transmission 68342-78-9 MYRTECAINE MESH_LEVEL_1 Organic Chemicals 68342-78-9 MYRTECAINE TA_LEVEL_3 Injectable Local Anesthesia 68342-78-9 MYRTECAINE ADVERSE_EFFECT SKN_2_Dermatitis 68342-78-9 MYRTECAINE MECH_LEVEL_3 Voltage-gated Na+ channel 68342-78-9 MYRTECAINE MESH_LEVEL_3 Terpenes 68342-78-9 MYRTECAINE TA_LEVEL_2 Anesthesia 68342-78-9 MYRTECAINE MESH_LEVEL_2 Hydrocarbons 68342-78-9 MYRTECAINE ADVERSE_EFFECT XXX_2_Impaired Wound Healing 68342-78-9 MYRTECAINE PRODUCT_CLASS Central Nervous System (CNS) 68342-78-9 MYRTECAINE THERAPEUTIC_CLASS Local Anesthetics 68342-78-9 MYRTECAINE ZERO_CLASS N 68342-78-9 MYRTECAINE ACTIVITY_CLASS Na+ channel blocker 68342-78-9 MYRTECAINE MODE_CLASS Channel Blocker 68342-79-0 MYRTECAINE PRODUCT_CLASS Central Nervous System (CNS) 68342-79-0 MYRTECAINE MESH_LEVEL_2 Hydrocarbons 68342-79-0 MYRTECAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 68342-79-0 MYRTECAINE ADVERSE_EFFECT SKN_2_Eczema 68342-79-0 MYRTECAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 68342-79-0 MYRTECAINE MECH_LEVEL_2 Decrease neural membrane excitability 68342-79-0 MYRTECAINE MODE_CLASS Channel Blocker 68342-79-0 MYRTECAINE MESH_LEVEL_1 Organic Chemicals 68342-79-0 MYRTECAINE TA_LEVEL_3 Injectable Local Anesthesia 68342-79-0 MYRTECAINE ADVERSE_EFFECT SKN_2_Dermatitis 68342-79-0 MYRTECAINE MECH_LEVEL_3 Voltage-gated Na+ channel 68342-79-0 MYRTECAINE MESH_LEVEL_3 Terpenes 68342-79-0 MYRTECAINE TA_LEVEL_2 Anesthesia 68342-79-0 MYRTECAINE ZERO_CLASS N 68342-79-0 MYRTECAINE ADVERSE_EFFECT XXX_2_Impaired Wound Healing 68342-79-0 MYRTECAINE MECH_LEVEL_1 Modulate neural transmission 68342-79-0 MYRTECAINE THERAPEUTIC_CLASS Local Anesthetics 68342-79-0 MYRTECAINE ACTIVITY_CLASS Na+ channel blocker 68342-79-0 MYRTECAINE MECHANISM Block neural transmission 104-40-5 4-NONYLPHENOL MECH_LEVEL_1 Hormone modulation 104-40-5 4-NONYLPHENOL MECHANISM Modulate gene transcription 104-40-5 4-NONYLPHENOL ADVERSE_EFFECT KID_2_Kidney Damage 104-40-5 4-NONYLPHENOL MESH_LEVEL_1 Organic Chemicals 104-40-5 4-NONYLPHENOL MODE_CLASS Receptor Partial Agonist 104-40-5 4-NONYLPHENOL ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 104-40-5 4-NONYLPHENOL TA_LEVEL_1 Toxicants 104-40-5 4-NONYLPHENOL PRODUCT_CLASS Toxicants 104-40-5 4-NONYLPHENOL ADVERSE_EFFECT REP_2_Decline in Testis Size 104-40-5 4-NONYLPHENOL ACTIVITY_CLASS Toxicant 104-40-5 4-NONYLPHENOL TA_LEVEL_2 Biochemical 104-40-5 4-NONYLPHENOL TA_LEVEL_3 Liver toxicants 104-40-5 4-NONYLPHENOL MECH_LEVEL_2 estrogen receptor agonist 104-40-5 4-NONYLPHENOL MESH_LEVEL_2 Phenols 104-40-5 4-NONYLPHENOL ADVERSE_EFFECT END_1_Endocrine Abnormalities 104-40-5 4-NONYLPHENOL ADVERSE_EFFECT REP_1_Changes in Reproductive Function 104-40-5 4-NONYLPHENOL ZERO_CLASS N 104-40-5 4-NONYLPHENOL STRUCTURE_ACTIVITY Toxicant, estrogen receptor agonist 104-40-5 4-NONYLPHENOL MECH_LEVEL_3 estrogen receptor alpha, beta 71751-41-2 ABAMECTIN ZERO_CLASS N 71751-41-2 ABAMECTIN MECHANISM Modulate channel gating 71751-41-2 ABAMECTIN ACTIVITY_CLASS GABA agonist 71751-41-2 ABAMECTIN ADVERSE_EFFECT CVS_3_Hypotension 71751-41-2 ABAMECTIN MECH_LEVEL_2 GABA receptor antagonist 71751-41-2 ABAMECTIN ADVERSE_EFFECT XXX_3_Aspiration 71751-41-2 ABAMECTIN TA_LEVEL_2 anthelmintic 71751-41-2 ABAMECTIN MECHANISM Modulate neural transmission 71751-41-2 ABAMECTIN MESH_LEVEL_1 Organic Chemicals 71751-41-2 ABAMECTIN THERAPEUTIC_CLASS Insecticides / Pesticides 71751-41-2 ABAMECTIN KNOWN_TOXICITY Cardiovascular Toxicity 71751-41-2 ABAMECTIN MECH_LEVEL_1 Anthelmintic 71751-41-2 ABAMECTIN MECH_LEVEL_3 GABA receptor 71751-41-2 ABAMECTIN MESH_LEVEL_2 Lactones 71751-41-2 ABAMECTIN TA_LEVEL_3 Anti-schistosomiasis/cetode 71751-41-2 ABAMECTIN PRODUCT_CLASS Veterinarian 71751-41-2 ABAMECTIN MODE_CLASS Channel enhancer /opener 71751-41-2 ABAMECTIN TISSUE_TOXICITY Hypotension 71751-41-2 ABAMECTIN ADVERSE_EFFECT LUN_3_Respiratory Failure 71751-41-2 ABAMECTIN MESH_LEVEL_3 Ivermectin analogs 71751-41-2 ABAMECTIN STRUCTURE_ACTIVITY GABA-A Cl- channel opener, antiparasitic 71751-41-2 ABAMECTIN THERAPEUTIC_CLASS Antiparasitics 71751-41-2 ABAMECTIN ADVERSE_EFFECT NEU_3_Coma 71751-41-2 ABAMECTIN TA_LEVEL_1 Infectious Disease 71751-41-2 ABAMECTIN PRODUCT_CLASS Toxicants 86753-29-9 ABAMECTIN ADVERSE_EFFECT LUN_3_Respiratory Failure 86753-29-9 ABAMECTIN ADVERSE_EFFECT XXX_3_Aspiration 86753-29-9 ABAMECTIN MESH_LEVEL_2 Lactones 86753-29-9 ABAMECTIN TA_LEVEL_2 anthelmintic 86753-29-9 ABAMECTIN MECH_LEVEL_2 GABA receptor antagonist 86753-29-9 ABAMECTIN MESH_LEVEL_3 Ivermectin analogs 86753-29-9 ABAMECTIN MECHANISM Modulate neural transmission 86753-29-9 ABAMECTIN MECH_LEVEL_1 Anthelmintic 86753-29-9 ABAMECTIN MECH_LEVEL_3 GABA receptor 86753-29-9 ABAMECTIN ZERO_CLASS N 86753-29-9 ABAMECTIN ADVERSE_EFFECT CVS_3_Hypotension 86753-29-9 ABAMECTIN TISSUE_TOXICITY Hypotension 86753-29-9 ABAMECTIN ACTIVITY_CLASS GABA agonist 86753-29-9 ABAMECTIN KNOWN_TOXICITY Cardiovascular Toxicity 86753-29-9 ABAMECTIN MODE_CLASS Channel enhancer /opener 86753-29-9 ABAMECTIN PRODUCT_CLASS Veterinarian 86753-29-9 ABAMECTIN TA_LEVEL_3 Anti-schistosomiasis/cetode 86753-29-9 ABAMECTIN STRUCTURE_ACTIVITY GABA-A Cl- channel opener, antiparasitic 86753-29-9 ABAMECTIN MECHANISM Modulate channel gating 86753-29-9 ABAMECTIN ADVERSE_EFFECT NEU_3_Coma 86753-29-9 ABAMECTIN TA_LEVEL_1 Infectious Disease 86753-29-9 ABAMECTIN PRODUCT_CLASS Toxicants 86753-29-9 ABAMECTIN THERAPEUTIC_CLASS Insecticides / Pesticides 86753-29-9 ABAMECTIN MESH_LEVEL_1 Organic Chemicals 86753-29-9 ABAMECTIN THERAPEUTIC_CLASS Antiparasitics 33089-61-1 AMITRAZ MESH_LEVEL_2 Amines 33089-61-1 AMITRAZ THERAPEUTIC_CLASS Antiparasitics 33089-61-1 AMITRAZ TISSUE_TOXICITY Hypotension 33089-61-1 AMITRAZ ADVERSE_EFFECT NEU_3_Headache 33089-61-1 AMITRAZ ADVERSE_EFFECT PSY_3_Agitation 33089-61-1 AMITRAZ ZERO_CLASS N 33089-61-1 AMITRAZ STRUCTURE_ACTIVITY Toxicant, adrenoceptor binder 33089-61-1 AMITRAZ TA_LEVEL_2 Toxicant 33089-61-1 AMITRAZ PRODUCT_CLASS Toxicants 33089-61-1 AMITRAZ PRODUCT_CLASS Veterinarian 33089-61-1 AMITRAZ MODE_CLASS Receptor Agonist 33089-61-1 AMITRAZ ADVERSE_EFFECT OCU_3_Mydriasis 33089-61-1 AMITRAZ ADVERSE_EFFECT CVS_3_Bradycardia 33089-61-1 AMITRAZ TA_LEVEL_1 Toxicant 33089-61-1 AMITRAZ MECH_LEVEL_1 Vasorelaxation 33089-61-1 AMITRAZ ADVERSE_EFFECT XXX_3_Weakness 33089-61-1 AMITRAZ ADVERSE_EFFECT NEU_3_Paralytic Ileus 33089-61-1 AMITRAZ ACTIVITY_CLASS Toxicant 33089-61-1 AMITRAZ MECHANISM Modulate G-protein coupled signal transduction 33089-61-1 AMITRAZ MECH_LEVEL_3 adrenoceptor alpha2 33089-61-1 AMITRAZ TA_LEVEL_3 Toxicant 33089-61-1 AMITRAZ MESH_LEVEL_3 Aniline Compounds 33089-61-1 AMITRAZ ADVERSE_EFFECT GIS_3_Abdominal Pain 33089-61-1 AMITRAZ ADVERSE_EFFECT NEU_3_Hyperreflexia 33089-61-1 AMITRAZ ADVERSE_EFFECT CVS_3_Hypotension 33089-61-1 AMITRAZ ADVERSE_EFFECT OCU_3_Miosis 33089-61-1 AMITRAZ ADVERSE_EFFECT NEU_3_Loss of Consciousness 33089-61-1 AMITRAZ ADVERSE_EFFECT GIS_3_Vomiting 33089-61-1 AMITRAZ MESH_LEVEL_1 Organic Chemicals 33089-61-1 AMITRAZ MECH_LEVEL_2 Alpha agonist 33089-61-1 AMITRAZ KNOWN_TOXICITY Cardiovascular Toxicity 33089-61-1 AMITRAZ THERAPEUTIC_CLASS Insecticides / Pesticides 33089-61-1 AMITRAZ ADVERSE_EFFECT PSY_3_CNS Depression 33089-61-1 AMITRAZ ADVERSE_EFFECT NEU_3_Drowsiness 33089-61-1 AMITRAZ ADVERSE_EFFECT PSY_3_Mental Confusion 53-41-8 ANDROSTERONE MODE_CLASS Channel Modulator 53-41-8 ANDROSTERONE MECHANISM Modulate channel gating 53-41-8 ANDROSTERONE STRUCTURE_ACTIVITY Androgen receptor agonist 53-41-8 ANDROSTERONE PRODUCT_CLASS Biochemicals 53-41-8 ANDROSTERONE MODE_CLASS Receptor Agonist 53-41-8 ANDROSTERONE MECHANISM Modulate gene transcription 22232-54-8 CARBIMAZOLE TA_LEVEL_2 Hyperthyroidism 22232-54-8 CARBIMAZOLE MECHANISM Inhibit thyroid hormone biosynthesis 22232-54-8 CARBIMAZOLE THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 22232-54-8 CARBIMAZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT EMB_2_Teratogenicity 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT SKN_2_Pruritis 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT BBM_3_Thrombocytopenia 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT LIV_3_Jaundice 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT SKN_3_Aplasia Cutis 22232-54-8 CARBIMAZOLE ZERO_CLASS N 22232-54-8 CARBIMAZOLE ACTIVITY_CLASS Thyroperoxidase inhibitor 22232-54-8 CARBIMAZOLE TA_LEVEL_1 Hormones, Endocrine and Metabolic 22232-54-8 CARBIMAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 22232-54-8 CARBIMAZOLE MESH_LEVEL_1 Heterocyclic Compounds 22232-54-8 CARBIMAZOLE MECH_LEVEL_1 Hormone modulation 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT MSK_2_Arthralgia 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT GIS_2_Epigastric Pain 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT MSK_3_Myopathy 22232-54-8 CARBIMAZOLE TA_LEVEL_3 direct acting thyroid agent 22232-54-8 CARBIMAZOLE MESH_LEVEL_3 Imidazoles 22232-54-8 CARBIMAZOLE INDICATION Hyperthyroidism / Thyrotoxicosis 22232-54-8 CARBIMAZOLE MODE_CLASS Enzyme Inhibitor 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT NEU_1_Headache 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT IMU_2_Urticaria 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT SKN_1_Skin Rash 22232-54-8 CARBIMAZOLE TISSUE_TOXICITY Teratogenicity 22232-54-8 CARBIMAZOLE STRUCTURE_ACTIVITY Thyroperoxidase inhibitor 22232-54-8 CARBIMAZOLE MECH_LEVEL_2 Inhibit thyroid hormone biosynthesis 22232-54-8 CARBIMAZOLE PRODUCT_CLASS Hormones, Endocrine and Metabolic 22232-54-8 CARBIMAZOLE MECH_LEVEL_3 Thyroperoxidase (TPO) 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT GIS_1_Nausea 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT BBM_3_Aplastic Anemia 22232-54-8 CARBIMAZOLE ADVERSE_EFFECT BBM_3_Pancytopenia 972-02-1 DIPHENIDOL INDICATION Meniere's Syndrome / Endolymphatic Hydrops 972-02-1 DIPHENIDOL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 972-02-1 DIPHENIDOL MECH_LEVEL_1 signal transduction 972-02-1 DIPHENIDOL KNOWN_TOXICITY Cardiovascular Toxicity 972-02-1 DIPHENIDOL THERAPEUTIC_CLASS Antiemetics 972-02-1 DIPHENIDOL ADVERSE_EFFECT NEU_1_Drowsiness 972-02-1 DIPHENIDOL ADVERSE_EFFECT PSY_3_Visual Hallucinations 972-02-1 DIPHENIDOL ADVERSE_EFFECT SKN_3_Skin Rash 972-02-1 DIPHENIDOL TISSUE_TOXICITY Hypotension 972-02-1 DIPHENIDOL MESH_LEVEL_3 Piperidines 972-02-1 DIPHENIDOL TA_LEVEL_2 Antiemetic 972-02-1 DIPHENIDOL PRODUCT_CLASS Gastrointestinal System 972-02-1 DIPHENIDOL ADVERSE_EFFECT LUN_3_Shortness of Breath 972-02-1 DIPHENIDOL INDICATION Vertigo 972-02-1 DIPHENIDOL INDICATION Nausea / Vomiting 972-02-1 DIPHENIDOL ADVERSE_EFFECT CVS_3_Hypotension 972-02-1 DIPHENIDOL ADVERSE_EFFECT XXX_3_Restlessness 972-02-1 DIPHENIDOL ADVERSE_EFFECT LIV_3_Jaundice 972-02-1 DIPHENIDOL MESH_LEVEL_1 Heterocyclic Compounds 972-02-1 DIPHENIDOL ZERO_CLASS N 972-02-1 DIPHENIDOL ADVERSE_EFFECT GIS_3_Epigastric Pain 972-02-1 DIPHENIDOL ADVERSE_EFFECT PSY_3_Disorientation 972-02-1 DIPHENIDOL ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 972-02-1 DIPHENIDOL MECH_LEVEL_2 receptor ligand antagonist 972-02-1 DIPHENIDOL MECHANISM Modulate G-protein coupled signal transduction 972-02-1 DIPHENIDOL MODE_CLASS Receptor Ligand Antagonist 972-02-1 DIPHENIDOL ADVERSE_EFFECT PSY_3_Confusion 972-02-1 DIPHENIDOL ADVERSE_EFFECT PSY_3_Auditory Hallucinations 972-02-1 DIPHENIDOL ADVERSE_EFFECT XXX_1_Xerostomia 972-02-1 DIPHENIDOL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 972-02-1 DIPHENIDOL TA_LEVEL_1 Gastrointestinal System 972-02-1 DIPHENIDOL MECH_LEVEL_3 Muscarinic acetylcholine receptor M3 antagonist 972-02-1 DIPHENIDOL TA_LEVEL_3 nausea 3254-89-5 DIPHENIDOL ZERO_CLASS N 3254-89-5 DIPHENIDOL ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 3254-89-5 DIPHENIDOL MECH_LEVEL_2 receptor ligand antagonist 3254-89-5 DIPHENIDOL MECHANISM Modulate G-protein coupled signal transduction 3254-89-5 DIPHENIDOL MODE_CLASS Receptor Ligand Antagonist 3254-89-5 DIPHENIDOL ADVERSE_EFFECT PSY_3_Confusion 3254-89-5 DIPHENIDOL ADVERSE_EFFECT PSY_3_Auditory Hallucinations 3254-89-5 DIPHENIDOL ADVERSE_EFFECT XXX_1_Xerostomia 3254-89-5 DIPHENIDOL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 3254-89-5 DIPHENIDOL TA_LEVEL_1 Gastrointestinal System 3254-89-5 DIPHENIDOL INDICATION Meniere's Syndrome / Endolymphatic Hydrops 3254-89-5 DIPHENIDOL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 3254-89-5 DIPHENIDOL MECH_LEVEL_1 signal transduction 3254-89-5 DIPHENIDOL KNOWN_TOXICITY Cardiovascular Toxicity 3254-89-5 DIPHENIDOL THERAPEUTIC_CLASS Antiemetics 3254-89-5 DIPHENIDOL ADVERSE_EFFECT NEU_1_Drowsiness 3254-89-5 DIPHENIDOL ADVERSE_EFFECT PSY_3_Visual Hallucinations 3254-89-5 DIPHENIDOL ADVERSE_EFFECT SKN_3_Skin Rash 3254-89-5 DIPHENIDOL TISSUE_TOXICITY Hypotension 3254-89-5 DIPHENIDOL MESH_LEVEL_3 Piperidines 3254-89-5 DIPHENIDOL TA_LEVEL_2 Antiemetic 3254-89-5 DIPHENIDOL PRODUCT_CLASS Gastrointestinal System 3254-89-5 DIPHENIDOL INDICATION Vertigo 3254-89-5 DIPHENIDOL INDICATION Nausea / Vomiting 3254-89-5 DIPHENIDOL ADVERSE_EFFECT CVS_3_Hypotension 3254-89-5 DIPHENIDOL ADVERSE_EFFECT XXX_3_Restlessness 3254-89-5 DIPHENIDOL ADVERSE_EFFECT LIV_3_Jaundice 3254-89-5 DIPHENIDOL ADVERSE_EFFECT GIS_3_Epigastric Pain 3254-89-5 DIPHENIDOL ADVERSE_EFFECT LUN_3_Shortness of Breath 3254-89-5 DIPHENIDOL MESH_LEVEL_1 Heterocyclic Compounds 3254-89-5 DIPHENIDOL TA_LEVEL_3 nausea 3254-89-5 DIPHENIDOL MECH_LEVEL_3 Muscarinic acetylcholine receptor M3 antagonist 3254-89-5 DIPHENIDOL ADVERSE_EFFECT PSY_3_Disorientation 434-03-7 ETHISTERONE ZERO_CLASS N 434-03-7 ETHISTERONE ADVERSE_EFFECT END_2_Hirsutism 434-03-7 ETHISTERONE ADVERSE_EFFECT CVS_3_Hypertension 434-03-7 ETHISTERONE ADVERSE_EFFECT NEU_2_Headache 434-03-7 ETHISTERONE ADVERSE_EFFECT REP_3_Amenorrhea 434-03-7 ETHISTERONE MECH_LEVEL_2 receptor agonist 434-03-7 ETHISTERONE INDICATION Premenstrual Syndrome / Premenstrual Tension 434-03-7 ETHISTERONE KNOWN_TOXICITY Cardiovascular Toxicity 434-03-7 ETHISTERONE ACTIVITY_CLASS Progesterone receptor agonist 434-03-7 ETHISTERONE ADVERSE_EFFECT KID_1_Fluid Retention 434-03-7 ETHISTERONE ADVERSE_EFFECT MSK_2_Leg Cramps 434-03-7 ETHISTERONE ADVERSE_EFFECT PSY_2_Emotional Lability 434-03-7 ETHISTERONE ADVERSE_EFFECT GIS_1_Bloating 434-03-7 ETHISTERONE ADVERSE_EFFECT IMU_3_Anaphylaxis 434-03-7 ETHISTERONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 434-03-7 ETHISTERONE MECH_LEVEL_1 transcription regulation 434-03-7 ETHISTERONE MESH_LEVEL_1 Polycyclic Hydrocarbons 434-03-7 ETHISTERONE TA_LEVEL_2 gonadal hormone 434-03-7 ETHISTERONE MESH_LEVEL_2 Steroids 434-03-7 ETHISTERONE INDICATION Dysmenorrhea 434-03-7 ETHISTERONE MODE_CLASS Receptor Agonist 434-03-7 ETHISTERONE MESH_LEVEL_3 Pregnanes 434-03-7 ETHISTERONE THERAPEUTIC_CLASS Gonadal Hormones 434-03-7 ETHISTERONE STRUCTURE_ACTIVITY Progesterone receptor agonist 434-03-7 ETHISTERONE ADVERSE_EFFECT SKN_1_Acne 434-03-7 ETHISTERONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 434-03-7 ETHISTERONE ADVERSE_EFFECT PSY_2_Depression 434-03-7 ETHISTERONE ADVERSE_EFFECT CVS_3_Thromboembolism 434-03-7 ETHISTERONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 434-03-7 ETHISTERONE INDICATION Luteal Phase Insufficiency 434-03-7 ETHISTERONE MECH_LEVEL_3 androgen receptor 434-03-7 ETHISTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 434-03-7 ETHISTERONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 434-03-7 ETHISTERONE TISSUE_TOXICITY Thromboembolism 434-03-7 ETHISTERONE ADVERSE_EFFECT REP_1_Intermenstrual Bleeding 434-03-7 ETHISTERONE ADVERSE_EFFECT XXX_2_Weight Gain 434-03-7 ETHISTERONE ADVERSE_EFFECT END_1_Breast Tenderness 434-03-7 ETHISTERONE ADVERSE_EFFECT LUN_3_Deepening of Voice 434-03-7 ETHISTERONE INDICATION Maintenance of Pregnancy 434-03-7 ETHISTERONE TA_LEVEL_3 uterine function 434-03-7 ETHISTERONE INDICATION Dysfunctional Uterine Bleeding (DUB) 434-03-7 ETHISTERONE MECHANISM Modulate gene transcription 965-90-2 ETHYLESTRENOL MECHANISM Modulate gene transcription 965-90-2 ETHYLESTRENOL INDICATION Aplastic Anemia 965-90-2 ETHYLESTRENOL MODE_CLASS Receptor Agonist 965-90-2 ETHYLESTRENOL INDICATION Growth Disorder 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT REP_1_Altered Libido 965-90-2 ETHYLESTRENOL KNOWN_TOXICITY Hepatotoxicity 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT GIS_1_Nausea 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT LIV_3_Hepatotoxicity 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT SKN_1_Acne 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT END_2_Virilization 965-90-2 ETHYLESTRENOL TISSUE_TOXICITY Hepatotoxicity 965-90-2 ETHYLESTRENOL THERAPEUTIC_CLASS Gonadal Hormones 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT PSY_2_Irritability 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT KID_2_Fluid Retention 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT LUN_2_Hoarseness of Voice 965-90-2 ETHYLESTRENOL ACTIVITY_CLASS Androgen receptor agonist 965-90-2 ETHYLESTRENOL TISSUE_TOXICITY Amenorrhea 965-90-2 ETHYLESTRENOL PRODUCT_CLASS Hematologics 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT END_2_Gynecomastia 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT END_2_Hirsutism 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT REP_1_Amenorrhea 965-90-2 ETHYLESTRENOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT END_2_Growth Inhibition 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT KID_2_Salt Retention 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT CVS_2_Hypertension 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT END_2_Suppression of Lactation 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 965-90-2 ETHYLESTRENOL ADVERSE_EFFECT MSK_2_Premature Closure of Epiphyseal Plate 965-90-2 ETHYLESTRENOL KNOWN_TOXICITY Reproductive System Toxicity 965-90-2 ETHYLESTRENOL STRUCTURE_ACTIVITY Androgen receptor agonist 43210-67-9 FENBENDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 43210-67-9 FENBENDAZOLE ADVERSE_EFFECT KID_2_Changes in Renal Tubular Function 43210-67-9 FENBENDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 43210-67-9 FENBENDAZOLE MECH_LEVEL_2 Inhibit microtubule dependent glucose uptake 43210-67-9 FENBENDAZOLE PRODUCT_CLASS Veterinarian 43210-67-9 FENBENDAZOLE THERAPEUTIC_CLASS Antiparasitics 43210-67-9 FENBENDAZOLE TA_LEVEL_2 anthelmintic 43210-67-9 FENBENDAZOLE MECH_LEVEL_3 Microtubule / tubulin 43210-67-9 FENBENDAZOLE TA_LEVEL_3 antiparasitic imidazoles 43210-67-9 FENBENDAZOLE ADVERSE_EFFECT BBM_3_Hemorrhage 43210-67-9 FENBENDAZOLE TISSUE_TOXICITY Carcinogenicity 43210-67-9 FENBENDAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 43210-67-9 FENBENDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 43210-67-9 FENBENDAZOLE MESH_LEVEL_3 Benzimidazoles 43210-67-9 FENBENDAZOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 43210-67-9 FENBENDAZOLE ADVERSE_EFFECT KID_3_Increased Creatinine 43210-67-9 FENBENDAZOLE KNOWN_TOXICITY Carcinogenicity 43210-67-9 FENBENDAZOLE ZERO_CLASS N 43210-67-9 FENBENDAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 43210-67-9 FENBENDAZOLE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 43210-67-9 FENBENDAZOLE MECH_LEVEL_1 anthelmintic 43210-67-9 FENBENDAZOLE ADVERSE_EFFECT DNA_3_Carcinogenicity 43210-67-9 FENBENDAZOLE ADVERSE_EFFECT BBM_3_Bone Marrow Hypoplasia 43210-67-9 FENBENDAZOLE TA_LEVEL_1 Veterinarian 21187-98-4 GLICLAZIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 21187-98-4 GLICLAZIDE ADVERSE_EFFECT LIV_3_Hepatic Failure 21187-98-4 GLICLAZIDE MESH_LEVEL_1 Organic Chemicals 21187-98-4 GLICLAZIDE KNOWN_TOXICITY Hepatotoxicity 21187-98-4 GLICLAZIDE THERAPEUTIC_CLASS Antidiabetic Agents 21187-98-4 GLICLAZIDE ADVERSE_EFFECT END_1_Hypoglycemia 21187-98-4 GLICLAZIDE ADVERSE_EFFECT BBM_3_Anemia 21187-98-4 GLICLAZIDE ADVERSE_EFFECT BBM_3_Granulocytopenia 21187-98-4 GLICLAZIDE ADVERSE_EFFECT SKN_2_Skin Rash 21187-98-4 GLICLAZIDE TISSUE_TOXICITY Hepatic Failure 21187-98-4 GLICLAZIDE MESH_LEVEL_2 Sulfur Compounds 21187-98-4 GLICLAZIDE ACTIVITY_CLASS Anti-diabetic 21187-98-4 GLICLAZIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 21187-98-4 GLICLAZIDE MECH_LEVEL_2 Trigger insulin release 21187-98-4 GLICLAZIDE MECH_LEVEL_3 ATP-sensitive K+ channel, SUR4 21187-98-4 GLICLAZIDE MESH_LEVEL_3 Sulfones 21187-98-4 GLICLAZIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 21187-98-4 GLICLAZIDE MODE_CLASS Channel Blocker, selective 21187-98-4 GLICLAZIDE MECHANISM Trigger insulin release in pancreatic beta cells 21187-98-4 GLICLAZIDE ADVERSE_EFFECT BBM_3_Leukopenia 21187-98-4 GLICLAZIDE ADVERSE_EFFECT GIS_1_Nausea 21187-98-4 GLICLAZIDE ADVERSE_EFFECT LIV_3_Hepatitis 21187-98-4 GLICLAZIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 21187-98-4 GLICLAZIDE ADVERSE_EFFECT LIV_3_Jaundice 21187-98-4 GLICLAZIDE ADVERSE_EFFECT GIS_2_Dyspepsia 21187-98-4 GLICLAZIDE TA_LEVEL_2 Diabetes 21187-98-4 GLICLAZIDE MECH_LEVEL_1 Glycemia regulation 21187-98-4 GLICLAZIDE INDICATION Type II Diabetes Mellitus 21187-98-4 GLICLAZIDE TA_LEVEL_3 glycemic control 21187-98-4 GLICLAZIDE ADVERSE_EFFECT GIS_2_Constipation 21187-98-4 GLICLAZIDE ZERO_CLASS N 21187-98-4 GLICLAZIDE ADVERSE_EFFECT SKN_2_Pruritis 21187-98-4 GLICLAZIDE ADVERSE_EFFECT GIS_2_Diarrhea 21187-98-4 GLICLAZIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 21187-98-4 GLICLAZIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 102518-79-6 HUPERZINE A INDICATION Memory Loss 102518-79-6 HUPERZINE A MODE_CLASS Enzyme Inhibitor 102518-79-6 HUPERZINE A ADVERSE_EFFECT NEU_1_Dizziness 102518-79-6 HUPERZINE A ADVERSE_EFFECT GIS_1_Nausea 102518-79-6 HUPERZINE A PRODUCT_CLASS Vitamins, Minerals and Nutrients 102518-79-6 HUPERZINE A MECHANISM Enhance cholinergic transmission 102518-79-6 HUPERZINE A THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 102518-79-6 HUPERZINE A ADVERSE_EFFECT GIS_1_Dyspepsia 53716-50-0 OXFENDAZOLE ZERO_CLASS N 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT NEU_2_Ataxia 53716-50-0 OXFENDAZOLE THERAPEUTIC_CLASS Antiparasitics 53716-50-0 OXFENDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 53716-50-0 OXFENDAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 53716-50-0 OXFENDAZOLE TA_LEVEL_1 Veterinarian 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT EMB_2_Teratogenicity 53716-50-0 OXFENDAZOLE KNOWN_TOXICITY Carcinogenicity 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT OCU_2_Visual Dysfunction 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 53716-50-0 OXFENDAZOLE TISSUE_TOXICITY Teratogenicity 53716-50-0 OXFENDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 53716-50-0 OXFENDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 53716-50-0 OXFENDAZOLE MECH_LEVEL_2 Inhibit microtubule dependent glucose uptake 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT BBM_3_Bone Marrow Hypoplasia 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT MSK_2_Spasm 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT DNA_3_Carcinogenicity 53716-50-0 OXFENDAZOLE TA_LEVEL_3 antiparasitic imidazoles 53716-50-0 OXFENDAZOLE MECH_LEVEL_1 anthelmintic 53716-50-0 OXFENDAZOLE MECH_LEVEL_3 Microtubule / tubulin 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT EMB_3_Fetal Toxicity 53716-50-0 OXFENDAZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity 53716-50-0 OXFENDAZOLE ADVERSE_EFFECT LUN_2_Pneumonia 53716-50-0 OXFENDAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 53716-50-0 OXFENDAZOLE TISSUE_TOXICITY Carcinogenicity 53716-50-0 OXFENDAZOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 53716-50-0 OXFENDAZOLE PRODUCT_CLASS Veterinarian 53716-50-0 OXFENDAZOLE MESH_LEVEL_3 Benzimidazoles 53716-50-0 OXFENDAZOLE TA_LEVEL_2 anthelmintic 62-73-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 62-73-7 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 62-73-7 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 62-73-7 DICHLORVOS MECH_LEVEL_3 Cholinesterase 62-73-7 DICHLORVOS TA_LEVEL_3 Toxicant 62-73-7 DICHLORVOS TA_LEVEL_1 Pesticide 62-73-7 DICHLORVOS PRODUCT_CLASS Toxicants 62-73-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 62-73-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 62-73-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 62-73-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 62-73-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 62-73-7 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 62-73-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 62-73-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 62-73-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 62-73-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 62-73-7 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 62-73-7 DICHLORVOS MODE_CLASS Enzyme Inhibitor 62-73-7 DICHLORVOS ACTIVITY_CLASS Toxicant 62-73-7 DICHLORVOS ZERO_CLASS N 62-73-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 62-73-7 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 62-73-7 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 62-73-7 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 62-73-7 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 62-73-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 62-73-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 62-73-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 62-73-7 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 62-73-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 62-73-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 62-73-7 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 62-73-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 62-73-7 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 62-73-7 DICHLORVOS MESH_LEVEL_3 Dichlorvos 62-73-7 DICHLORVOS MECHANISM Enhance cholinergic transmission 62-73-7 DICHLORVOS TA_LEVEL_2 insecticide 62-73-7 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 62-73-7 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 62-73-7 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 8023-22-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 8023-22-1 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 8023-22-1 DICHLORVOS MECHANISM Enhance cholinergic transmission 8023-22-1 DICHLORVOS TA_LEVEL_2 insecticide 8023-22-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 8023-22-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 8023-22-1 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 8023-22-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 8023-22-1 DICHLORVOS MECH_LEVEL_3 Cholinesterase 8023-22-1 DICHLORVOS MESH_LEVEL_3 Dichlorvos 8023-22-1 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 8023-22-1 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 8023-22-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 8023-22-1 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 8023-22-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 8023-22-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 8023-22-1 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 8023-22-1 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 8023-22-1 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 8023-22-1 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 8023-22-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 8023-22-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 8023-22-1 DICHLORVOS TA_LEVEL_3 Toxicant 8023-22-1 DICHLORVOS TA_LEVEL_1 Pesticide 8023-22-1 DICHLORVOS PRODUCT_CLASS Toxicants 8023-22-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 8023-22-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 8023-22-1 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 8023-22-1 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 8023-22-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 8023-22-1 DICHLORVOS ZERO_CLASS N 8023-22-1 DICHLORVOS ACTIVITY_CLASS Toxicant 8023-22-1 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 8023-22-1 DICHLORVOS MODE_CLASS Enzyme Inhibitor 8023-22-1 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 8023-22-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 8023-22-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 8023-22-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 8023-22-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 8023-22-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 8023-22-1 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 8072-21-7 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 8072-21-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 8072-21-7 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 8072-21-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 8072-21-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 8072-21-7 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 8072-21-7 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 8072-21-7 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 8072-21-7 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 8072-21-7 DICHLORVOS ACTIVITY_CLASS Toxicant 8072-21-7 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 8072-21-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 8072-21-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 8072-21-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 8072-21-7 DICHLORVOS PRODUCT_CLASS Toxicants 8072-21-7 DICHLORVOS TA_LEVEL_1 Pesticide 8072-21-7 DICHLORVOS TA_LEVEL_3 Toxicant 8072-21-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 8072-21-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 8072-21-7 DICHLORVOS MODE_CLASS Enzyme Inhibitor 8072-21-7 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 8072-21-7 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 8072-21-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 8072-21-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 8072-21-7 DICHLORVOS ZERO_CLASS N 8072-21-7 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 8072-21-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 8072-21-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 8072-21-7 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 8072-21-7 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 8072-21-7 DICHLORVOS TA_LEVEL_2 insecticide 8072-21-7 DICHLORVOS MECHANISM Enhance cholinergic transmission 8072-21-7 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 8072-21-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 8072-21-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 8072-21-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 8072-21-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 8072-21-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 8072-21-7 DICHLORVOS MECH_LEVEL_3 Cholinesterase 8072-21-7 DICHLORVOS MESH_LEVEL_3 Dichlorvos 8072-21-7 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 8072-39-7 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 8072-39-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 8072-39-7 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 8072-39-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 8072-39-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 8072-39-7 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 8072-39-7 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 8072-39-7 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 8072-39-7 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 8072-39-7 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 8072-39-7 DICHLORVOS ZERO_CLASS N 8072-39-7 DICHLORVOS TA_LEVEL_3 Toxicant 8072-39-7 DICHLORVOS TA_LEVEL_1 Pesticide 8072-39-7 DICHLORVOS PRODUCT_CLASS Toxicants 8072-39-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 8072-39-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 8072-39-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 8072-39-7 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 8072-39-7 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 8072-39-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 8072-39-7 DICHLORVOS ACTIVITY_CLASS Toxicant 8072-39-7 DICHLORVOS MODE_CLASS Enzyme Inhibitor 8072-39-7 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 8072-39-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 8072-39-7 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 8072-39-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 8072-39-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 8072-39-7 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 8072-39-7 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 8072-39-7 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 8072-39-7 DICHLORVOS TA_LEVEL_2 insecticide 8072-39-7 DICHLORVOS MECHANISM Enhance cholinergic transmission 8072-39-7 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 8072-39-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 8072-39-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 8072-39-7 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 8072-39-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 8072-39-7 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 8072-39-7 DICHLORVOS MECH_LEVEL_3 Cholinesterase 8072-39-7 DICHLORVOS MESH_LEVEL_3 Dichlorvos 8072-39-7 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 11095-17-3 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 11095-17-3 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 11095-17-3 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 11095-17-3 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 11095-17-3 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 11095-17-3 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 11095-17-3 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 11095-17-3 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 11095-17-3 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 11095-17-3 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 11095-17-3 DICHLORVOS MECHANISM Enhance cholinergic transmission 11095-17-3 DICHLORVOS TA_LEVEL_3 Toxicant 11095-17-3 DICHLORVOS TA_LEVEL_1 Pesticide 11095-17-3 DICHLORVOS PRODUCT_CLASS Toxicants 11095-17-3 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 11095-17-3 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 11095-17-3 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 11095-17-3 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 11095-17-3 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 11095-17-3 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 11095-17-3 DICHLORVOS ZERO_CLASS N 11095-17-3 DICHLORVOS ACTIVITY_CLASS Toxicant 11095-17-3 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 11095-17-3 DICHLORVOS MODE_CLASS Enzyme Inhibitor 11095-17-3 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 11095-17-3 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 11095-17-3 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 11095-17-3 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 11095-17-3 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 11095-17-3 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 11095-17-3 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 11095-17-3 DICHLORVOS TA_LEVEL_2 insecticide 11095-17-3 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 11095-17-3 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 11095-17-3 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 11095-17-3 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 11095-17-3 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 11095-17-3 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 11095-17-3 DICHLORVOS MECH_LEVEL_3 Cholinesterase 11095-17-3 DICHLORVOS MESH_LEVEL_3 Dichlorvos 11095-17-3 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 11096-21-2 DICHLORVOS TA_LEVEL_1 Pesticide 11096-21-2 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 11096-21-2 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 11096-21-2 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 11096-21-2 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 11096-21-2 DICHLORVOS MECHANISM Enhance cholinergic transmission 11096-21-2 DICHLORVOS TA_LEVEL_2 insecticide 11096-21-2 DICHLORVOS TA_LEVEL_3 Toxicant 11096-21-2 DICHLORVOS PRODUCT_CLASS Toxicants 11096-21-2 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 11096-21-2 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 11096-21-2 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 11096-21-2 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 11096-21-2 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 11096-21-2 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 11096-21-2 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 11096-21-2 DICHLORVOS ACTIVITY_CLASS Toxicant 11096-21-2 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 11096-21-2 DICHLORVOS ZERO_CLASS N 11096-21-2 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 11096-21-2 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 11096-21-2 DICHLORVOS MODE_CLASS Enzyme Inhibitor 11096-21-2 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 11096-21-2 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 11096-21-2 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 11096-21-2 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 11096-21-2 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 11096-21-2 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 11096-21-2 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 11096-21-2 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 11096-21-2 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 11096-21-2 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 11096-21-2 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 11096-21-2 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 11096-21-2 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 11096-21-2 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 11096-21-2 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 11096-21-2 DICHLORVOS MESH_LEVEL_3 Dichlorvos 11096-21-2 DICHLORVOS MECH_LEVEL_3 Cholinesterase 11096-21-2 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 11096-21-2 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 12772-40-6 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 12772-40-6 DICHLORVOS TA_LEVEL_3 Toxicant 12772-40-6 DICHLORVOS TA_LEVEL_1 Pesticide 12772-40-6 DICHLORVOS PRODUCT_CLASS Toxicants 12772-40-6 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 12772-40-6 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 12772-40-6 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 12772-40-6 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 12772-40-6 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 12772-40-6 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 12772-40-6 DICHLORVOS ZERO_CLASS N 12772-40-6 DICHLORVOS ACTIVITY_CLASS Toxicant 12772-40-6 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 12772-40-6 DICHLORVOS MODE_CLASS Enzyme Inhibitor 12772-40-6 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 12772-40-6 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 12772-40-6 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 12772-40-6 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 12772-40-6 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 12772-40-6 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 12772-40-6 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 12772-40-6 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 12772-40-6 DICHLORVOS TA_LEVEL_2 insecticide 12772-40-6 DICHLORVOS MECHANISM Enhance cholinergic transmission 12772-40-6 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 12772-40-6 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 12772-40-6 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 12772-40-6 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 12772-40-6 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 12772-40-6 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 12772-40-6 DICHLORVOS MECH_LEVEL_3 Cholinesterase 12772-40-6 DICHLORVOS MESH_LEVEL_3 Dichlorvos 12772-40-6 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 12772-40-6 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 12772-40-6 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 12772-40-6 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 12772-40-6 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 12772-40-6 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 12772-40-6 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 12772-40-6 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 12772-40-6 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 55819-32-4 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 55819-32-4 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 55819-32-4 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 55819-32-4 DICHLORVOS TA_LEVEL_1 Pesticide 55819-32-4 DICHLORVOS TA_LEVEL_3 Toxicant 55819-32-4 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 55819-32-4 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 55819-32-4 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 55819-32-4 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 55819-32-4 DICHLORVOS MESH_LEVEL_3 Dichlorvos 55819-32-4 DICHLORVOS MECH_LEVEL_3 Cholinesterase 55819-32-4 DICHLORVOS PRODUCT_CLASS Toxicants 55819-32-4 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 55819-32-4 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 55819-32-4 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 55819-32-4 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 55819-32-4 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 55819-32-4 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 55819-32-4 DICHLORVOS MECHANISM Enhance cholinergic transmission 55819-32-4 DICHLORVOS TA_LEVEL_2 insecticide 55819-32-4 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 55819-32-4 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 55819-32-4 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 55819-32-4 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 55819-32-4 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 55819-32-4 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 55819-32-4 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 55819-32-4 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 55819-32-4 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 55819-32-4 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 55819-32-4 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 55819-32-4 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 55819-32-4 DICHLORVOS ZERO_CLASS N 55819-32-4 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 55819-32-4 DICHLORVOS ACTIVITY_CLASS Toxicant 55819-32-4 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 55819-32-4 DICHLORVOS MODE_CLASS Enzyme Inhibitor 55819-32-4 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 55819-32-4 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 55819-32-4 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 55819-32-4 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 62139-95-1 DICHLORVOS TA_LEVEL_2 insecticide 62139-95-1 DICHLORVOS MECHANISM Enhance cholinergic transmission 62139-95-1 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 62139-95-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 62139-95-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 62139-95-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 62139-95-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 62139-95-1 DICHLORVOS MECH_LEVEL_3 Cholinesterase 62139-95-1 DICHLORVOS MESH_LEVEL_3 Dichlorvos 62139-95-1 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 62139-95-1 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 62139-95-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 62139-95-1 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 62139-95-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 62139-95-1 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 62139-95-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 62139-95-1 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 62139-95-1 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 62139-95-1 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 62139-95-1 DICHLORVOS ZERO_CLASS N 62139-95-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 62139-95-1 DICHLORVOS TA_LEVEL_3 Toxicant 62139-95-1 DICHLORVOS TA_LEVEL_1 Pesticide 62139-95-1 DICHLORVOS PRODUCT_CLASS Toxicants 62139-95-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 62139-95-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 62139-95-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 62139-95-1 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 62139-95-1 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 62139-95-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 62139-95-1 DICHLORVOS ACTIVITY_CLASS Toxicant 62139-95-1 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 62139-95-1 DICHLORVOS MODE_CLASS Enzyme Inhibitor 62139-95-1 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 62139-95-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 62139-95-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 62139-95-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 62139-95-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 62139-95-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 62139-95-1 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 62139-95-1 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 95828-55-0 DICHLORVOS TA_LEVEL_3 Toxicant 95828-55-0 DICHLORVOS TA_LEVEL_1 Pesticide 95828-55-0 DICHLORVOS PRODUCT_CLASS Toxicants 95828-55-0 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 95828-55-0 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 95828-55-0 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 95828-55-0 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 95828-55-0 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 95828-55-0 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 95828-55-0 DICHLORVOS ZERO_CLASS N 95828-55-0 DICHLORVOS ACTIVITY_CLASS Toxicant 95828-55-0 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 95828-55-0 DICHLORVOS MODE_CLASS Enzyme Inhibitor 95828-55-0 DICHLORVOS TA_LEVEL_2 insecticide 95828-55-0 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 95828-55-0 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 95828-55-0 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 95828-55-0 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 95828-55-0 DICHLORVOS MECHANISM Enhance cholinergic transmission 95828-55-0 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 95828-55-0 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 95828-55-0 DICHLORVOS MECH_LEVEL_3 Cholinesterase 95828-55-0 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 95828-55-0 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 95828-55-0 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 95828-55-0 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 95828-55-0 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 95828-55-0 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 95828-55-0 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 95828-55-0 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 95828-55-0 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 95828-55-0 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 95828-55-0 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 95828-55-0 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 95828-55-0 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 95828-55-0 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 95828-55-0 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 95828-55-0 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 95828-55-0 DICHLORVOS MESH_LEVEL_3 Dichlorvos 95828-55-0 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 95828-55-0 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 116788-91-1 DICHLORVOS MECHANISM Enhance cholinergic transmission 116788-91-1 DICHLORVOS TA_LEVEL_2 insecticide 116788-91-1 DICHLORVOS MESH_LEVEL_1 Organic Chemicals 116788-91-1 DICHLORVOS TISSUE_TOXICITY Circulatory Collapse 116788-91-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Increased Bronchial Secretion 116788-91-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 116788-91-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Ataxia 116788-91-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Weakness 116788-91-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Lacrimation 116788-91-1 DICHLORVOS ADVERSE_EFFECT OCU_3_Miosis 116788-91-1 DICHLORVOS MODE_CLASS Enzyme Inhibitor 116788-91-1 DICHLORVOS MECH_LEVEL_1 Modulate neural transmission 116788-91-1 DICHLORVOS ACTIVITY_CLASS Toxicant 116788-91-1 DICHLORVOS ZERO_CLASS N 116788-91-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Neurotoxicity 116788-91-1 DICHLORVOS ADVERSE_EFFECT CVS_3_Circulatory Collapse 116788-91-1 DICHLORVOS ADVERSE_EFFECT PSY_3_Confusion 116788-91-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Drowsiness 116788-91-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Salivation 116788-91-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Bronchoconstriction 116788-91-1 DICHLORVOS PRODUCT_CLASS Toxicants 116788-91-1 DICHLORVOS TA_LEVEL_1 Pesticide 116788-91-1 DICHLORVOS TA_LEVEL_3 Toxicant 116788-91-1 DICHLORVOS STRUCTURE_ACTIVITY Toxicant, insecticide, cholinesterase inhibitor 116788-91-1 DICHLORVOS KNOWN_TOXICITY Cardiovascular Toxicity 116788-91-1 DICHLORVOS ADVERSE_EFFECT SKN_3_Skin Irritation 116788-91-1 DICHLORVOS ADVERSE_EFFECT MSK_3_Muscle Fasciculations 116788-91-1 DICHLORVOS ADVERSE_EFFECT XXX_3_Restlessness 116788-91-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Coma 116788-91-1 DICHLORVOS ADVERSE_EFFECT PSY_3_Anxiety 116788-91-1 DICHLORVOS ADVERSE_EFFECT LUN_3_Respiratory Depression 116788-91-1 DICHLORVOS THERAPEUTIC_CLASS Insecticides / Pesticides 116788-91-1 DICHLORVOS MECH_LEVEL_2 Enhance cholinergic transmission 116788-91-1 DICHLORVOS MESH_LEVEL_3 Dichlorvos 116788-91-1 DICHLORVOS MECH_LEVEL_3 Cholinesterase 116788-91-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Garlicky Breath 116788-91-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Emesis 116788-91-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Slurred Speech 116788-91-1 DICHLORVOS ADVERSE_EFFECT NEU_3_Tremor 116788-91-1 DICHLORVOS ADVERSE_EFFECT GIS_3_Diarrhea 116788-91-1 DICHLORVOS MESH_LEVEL_2 Organophosphorus Compounds 57808-65-8 CLOSANTEL TA_LEVEL_1 Infectious Disease (Veterinary) 57808-65-8 CLOSANTEL MESH_LEVEL_2 Amides 57808-65-8 CLOSANTEL THERAPEUTIC_CLASS Antiparasitics 57808-65-8 CLOSANTEL MECHANISM Interferes with Cell-Cell signaling 57808-65-8 CLOSANTEL ADVERSE_EFFECT NEU_3_Optic Neuritis 57808-65-8 CLOSANTEL MECH_LEVEL_2 uncoupling of ETC 57808-65-8 CLOSANTEL MECH_LEVEL_3 Hydrogen ionophore 57808-65-8 CLOSANTEL PRODUCT_CLASS Veterinarian 57808-65-8 CLOSANTEL TA_LEVEL_2 anthelmintic 57808-65-8 CLOSANTEL ACTIVITY_CLASS Mitochondrial toxicant 57808-65-8 CLOSANTEL ADVERSE_EFFECT MSK_3_Myopathy 57808-65-8 CLOSANTEL TA_LEVEL_3 Anti-schistosomiasis/cetode 57808-65-8 CLOSANTEL ADVERSE_EFFECT OCU_1_Eye Pain 57808-65-8 CLOSANTEL ADVERSE_EFFECT OCU_1_Retinal Degeneration 57808-65-8 CLOSANTEL MODE_CLASS Enzyme Inhibitor 57808-65-8 CLOSANTEL STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 57808-65-8 CLOSANTEL ADVERSE_EFFECT OTO_3_Hearing Loss 57808-65-8 CLOSANTEL ADVERSE_EFFECT OCU_2_Blindness 57808-65-8 CLOSANTEL KNOWN_TOXICITY Ocular Toxicity 57808-65-8 CLOSANTEL TISSUE_TOXICITY Retinal Degeneration 57808-65-8 CLOSANTEL MESH_LEVEL_3 Anilides 57808-65-8 CLOSANTEL MESH_LEVEL_1 Organic Chemicals 57808-65-8 CLOSANTEL ADVERSE_EFFECT LIV_3_Hepatotoxicity 57808-65-8 CLOSANTEL KNOWN_TOXICITY Hepatotoxicity 57808-65-8 CLOSANTEL TISSUE_TOXICITY Hepatotoxicity 57808-65-8 CLOSANTEL MECH_LEVEL_1 Anthelmintic 57808-65-8 CLOSANTEL ZERO_CLASS N 1135-24-6 FERULIC ACID MESH_LEVEL_3 Acids, Carbocyclic 1135-24-6 FERULIC ACID PRODUCT_CLASS Biochemicals 1135-24-6 FERULIC ACID ACTIVITY_CLASS H2O2 radical scavenger 1135-24-6 FERULIC ACID MESH_LEVEL_2 Carboxylic Acids 1135-24-6 FERULIC ACID MECHANISM Scavenges hydrogen peroxide and free radicals 1135-24-6 FERULIC ACID ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 1135-24-6 FERULIC ACID MESH_LEVEL_1 Organic Chemicals 1135-24-6 FERULIC ACID MECH_LEVEL_3 Unknown mechanism 1135-24-6 FERULIC ACID TA_LEVEL_2 biochemical 1135-24-6 FERULIC ACID MECH_LEVEL_2 free radical scavenger 1135-24-6 FERULIC ACID ADVERSE_EFFECT MSK_3_Bone and Teeth Abnormalities 1135-24-6 FERULIC ACID ADVERSE_EFFECT XXX_2_Weight Loss 1135-24-6 FERULIC ACID STRUCTURE_ACTIVITY H2O2 radical scavenger 1135-24-6 FERULIC ACID ZERO_CLASS N 1135-24-6 FERULIC ACID TA_LEVEL_3 biochemical 1135-24-6 FERULIC ACID TA_LEVEL_1 Biochemical 1135-24-6 FERULIC ACID ADVERSE_EFFECT XXX_2_Decreased Appetite 537-98-4 FERULIC ACID STRUCTURE_ACTIVITY H2O2 radical scavenger 537-98-4 FERULIC ACID MESH_LEVEL_2 Carboxylic Acids 537-98-4 FERULIC ACID MECHANISM Scavenges hydrogen peroxide and free radicals 537-98-4 FERULIC ACID ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 537-98-4 FERULIC ACID MESH_LEVEL_1 Organic Chemicals 537-98-4 FERULIC ACID ADVERSE_EFFECT XXX_2_Weight Loss 537-98-4 FERULIC ACID ACTIVITY_CLASS H2O2 radical scavenger 537-98-4 FERULIC ACID TA_LEVEL_1 Biochemical 537-98-4 FERULIC ACID TA_LEVEL_3 biochemical 537-98-4 FERULIC ACID ADVERSE_EFFECT XXX_2_Decreased Appetite 537-98-4 FERULIC ACID MECH_LEVEL_3 Unknown mechanism 537-98-4 FERULIC ACID TA_LEVEL_2 biochemical 537-98-4 FERULIC ACID MECH_LEVEL_2 free radical scavenger 537-98-4 FERULIC ACID ADVERSE_EFFECT MSK_3_Bone and Teeth Abnormalities 537-98-4 FERULIC ACID MESH_LEVEL_3 Acids, Carbocyclic 537-98-4 FERULIC ACID PRODUCT_CLASS Biochemicals 537-98-4 FERULIC ACID ZERO_CLASS N 107868-30-4 EXEMESTANE MODE_CLASS Enzyme Inhibitor 107868-30-4 EXEMESTANE THERAPEUTIC_CLASS Antineoplastics 107868-30-4 EXEMESTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 107868-30-4 EXEMESTANE PRODUCT_CLASS Anti-cancers 107868-30-4 EXEMESTANE INDICATION Metastatic Breast Cancer 158920-43-5 SULFINPYRAZONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 158920-43-5 SULFINPYRAZONE MESH_LEVEL_3 Pyrazoles 158920-43-5 SULFINPYRAZONE TA_LEVEL_3 Gout-Related Agents 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Anemia 158920-43-5 SULFINPYRAZONE ZERO_CLASS N 158920-43-5 SULFINPYRAZONE INDICATION Hyperuricemia 158920-43-5 SULFINPYRAZONE MODE_CLASS Solute transporter inhibitor 158920-43-5 SULFINPYRAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 158920-43-5 SULFINPYRAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 158920-43-5 SULFINPYRAZONE TA_LEVEL_2 Uric acid elimination 158920-43-5 SULFINPYRAZONE INDICATION Gouty Arthritis 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT SKN_2_Rash 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT LUN_3_Bronchoconstriction 158920-43-5 SULFINPYRAZONE STRUCTURE_ACTIVITY Organic anion transporter inhibitor 158920-43-5 SULFINPYRAZONE ACTIVITY_CLASS Organic anion transporter inhibitor 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 158920-43-5 SULFINPYRAZONE THERAPEUTIC_CLASS Gout-Related Agents 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 158920-43-5 SULFINPYRAZONE MECH_LEVEL_3 Urate/Anion exchanger, Urate transporter 158920-43-5 SULFINPYRAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 158920-43-5 SULFINPYRAZONE MECH_LEVEL_2 Block channel gating 158920-43-5 SULFINPYRAZONE MECH_LEVEL_1 Uric acid elimination 158920-43-5 SULFINPYRAZONE MESH_LEVEL_1 Heterocyclic Compounds 158920-43-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Agranulocytosis 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT BBM_3_Aplastic Anemia 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT SKN_2_Skin Rash 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT KID_2_Crystalluria 127-69-5 SULFISOXAZOLE TA_LEVEL_3 Systemic infections 127-69-5 SULFISOXAZOLE THERAPEUTIC_CLASS Antibacterials 127-69-5 SULFISOXAZOLE MODE_CLASS Enzyme Inhibitor 127-69-5 SULFISOXAZOLE PRODUCT_CLASS Anti-infectives 127-69-5 SULFISOXAZOLE MECH_LEVEL_1 Anti-bacterial 127-69-5 SULFISOXAZOLE INDICATION Urinary Tract Infection (UTI) 127-69-5 SULFISOXAZOLE TA_LEVEL_2 Anti-bacterial 127-69-5 SULFISOXAZOLE ZERO_CLASS N 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT NEU_3_Kernicterus 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT IMU_2_Photosensitivity 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT SKN_2_Erythema Multiforme 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT PSY_1_Anorexia 127-69-5 SULFISOXAZOLE INDICATION Acute Otitis Media 127-69-5 SULFISOXAZOLE MESH_LEVEL_2 Amides 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT XXX_2_Fever 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT NEU_2_Headache 127-69-5 SULFISOXAZOLE ACTIVITY_CLASS Antibiotic, sulfonamide 127-69-5 SULFISOXAZOLE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 127-69-5 SULFISOXAZOLE MECH_LEVEL_2 Impaired Folic synthesis 127-69-5 SULFISOXAZOLE MESH_LEVEL_3 Sulfonamides 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT BBM_3_Myelotoxicity 127-69-5 SULFISOXAZOLE KNOWN_TOXICITY Hepatotoxicity 127-69-5 SULFISOXAZOLE MESH_LEVEL_1 Organic Chemicals 127-69-5 SULFISOXAZOLE TISSUE_TOXICITY Hepatotoxicity 127-69-5 SULFISOXAZOLE MECH_LEVEL_3 Dihydropteroate synthase 127-69-5 SULFISOXAZOLE TA_LEVEL_1 Infectious Disease 127-69-5 SULFISOXAZOLE MECHANISM Inhibit precursor synthesis 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 127-69-5 SULFISOXAZOLE ADVERSE_EFFECT SKN_2_Morbilliform Rash 59864-04-9 SULINDAC SULFONE MECHANISM Inhibit eicosanoid biosynthesis 59864-04-9 SULINDAC SULFONE MODE_CLASS Enzyme Inhibitor 59864-04-9 SULINDAC SULFONE THERAPEUTIC_CLASS Antineoplastics 59864-04-9 SULINDAC SULFONE STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 59864-04-9 SULINDAC SULFONE PRODUCT_CLASS Anti-cancers 59973-80-7 SULINDAC SULFONE MECHANISM Inhibit eicosanoid biosynthesis 59973-80-7 SULINDAC SULFONE MODE_CLASS Enzyme Inhibitor 59973-80-7 SULINDAC SULFONE THERAPEUTIC_CLASS Antineoplastics 59973-80-7 SULINDAC SULFONE STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 59973-80-7 SULINDAC SULFONE PRODUCT_CLASS Anti-cancers 15676-16-1 SULPIRIDE INDICATION Depression 15676-16-1 SULPIRIDE TA_LEVEL_1 Central Nervous System (CNS) 15676-16-1 SULPIRIDE MESH_LEVEL_3 Benzamides 15676-16-1 SULPIRIDE MECH_LEVEL_3 dopamine receptor D2 antagonist 15676-16-1 SULPIRIDE ADVERSE_EFFECT PSY_2_Excitement 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 15676-16-1 SULPIRIDE PRODUCT_CLASS Central Nervous System (CNS) 15676-16-1 SULPIRIDE THERAPEUTIC_CLASS Antidepressants 15676-16-1 SULPIRIDE MECH_LEVEL_2 Receptor ligand antagonist 15676-16-1 SULPIRIDE TA_LEVEL_2 Anti-psychotic 15676-16-1 SULPIRIDE INDICATION Duodenal Ulcer 15676-16-1 SULPIRIDE THERAPEUTIC_CLASS Antiulcers 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_3_Convulsions 15676-16-1 SULPIRIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_2_Headache 15676-16-1 SULPIRIDE ADVERSE_EFFECT XXX_2_Weight Gain 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_1_Akathisia 15676-16-1 SULPIRIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 15676-16-1 SULPIRIDE ADVERSE_EFFECT PSY_2_Irritation 15676-16-1 SULPIRIDE ADVERSE_EFFECT PSY_2_Mania 15676-16-1 SULPIRIDE ADVERSE_EFFECT XXX_2_Malaise 15676-16-1 SULPIRIDE ACTIVITY_CLASS Dopamine antagonist 15676-16-1 SULPIRIDE MESH_LEVEL_1 Organic Chemicals 15676-16-1 SULPIRIDE INDICATION Gastric Ulcer 15676-16-1 SULPIRIDE MECHANISM Block neural transmission 15676-16-1 SULPIRIDE MODE_CLASS Receptor Ligand Antagonist 15676-16-1 SULPIRIDE ADVERSE_EFFECT CVS_2_Tachycardia 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_2_Tremor 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_1_Sleep Disturbances 15676-16-1 SULPIRIDE ADVERSE_EFFECT END_2_Gynecomastia 15676-16-1 SULPIRIDE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_1_Sleepiness 15676-16-1 SULPIRIDE ADVERSE_EFFECT GIS_2_Heartburn 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_2_Numbness 15676-16-1 SULPIRIDE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 15676-16-1 SULPIRIDE STRUCTURE_ACTIVITY Dopamine receptor (D2) antagonist 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_1_Parkinsonism 15676-16-1 SULPIRIDE ADVERSE_EFFECT CVS_3_Abnormal ECG 15676-16-1 SULPIRIDE ADVERSE_EFFECT END_2_Galactorrhea 15676-16-1 SULPIRIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 15676-16-1 SULPIRIDE ADVERSE_EFFECT CVS_2_Decreased Arterial Blood Pressure 15676-16-1 SULPIRIDE ADVERSE_EFFECT SKN_2_Rash 15676-16-1 SULPIRIDE ADVERSE_EFFECT GIS_2_Vomiting 15676-16-1 SULPIRIDE ADVERSE_EFFECT GIS_2_Constipation 15676-16-1 SULPIRIDE PRODUCT_CLASS Gastrointestinal System 15676-16-1 SULPIRIDE MESH_LEVEL_2 Amides 15676-16-1 SULPIRIDE ADVERSE_EFFECT XXX_2_Thirst 15676-16-1 SULPIRIDE ADVERSE_EFFECT REP_2_Menstrual Irregularities 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_1_Dystonia 15676-16-1 SULPIRIDE ADVERSE_EFFECT NEU_3_Ataxia 15676-16-1 SULPIRIDE ADVERSE_EFFECT XXX_2_Edema 15676-16-1 SULPIRIDE ADVERSE_EFFECT GIS_2_Nausea 15676-16-1 SULPIRIDE ADVERSE_EFFECT XXX_2_Fever 15676-16-1 SULPIRIDE TA_LEVEL_3 Schizophrenia 15676-16-1 SULPIRIDE INDICATION Schizophrenia 15676-16-1 SULPIRIDE ZERO_CLASS N 15676-16-1 SULPIRIDE THERAPEUTIC_CLASS Antipsychotics 15676-16-1 SULPIRIDE ADVERSE_EFFECT XXX_3_Diaphoresis 98116-53-1 SULUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 98116-53-1 SULUKAST INDICATION Asthma 98116-53-1 SULUKAST MECHANISM Modulate G-protein coupled signal transduction 98116-53-1 SULUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 98116-53-1 SULUKAST PRODUCT_CLASS Respiratory System 98116-53-1 SULUKAST MODE_CLASS Receptor Ligand Antagonist 103628-46-2 SUMATRIPTAN MECHANISM Modulate cerebral vasoconstriction 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Cardiac Arrest 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT XXX_2_Weakness 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Myocardial Ischemia 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Cardiac Arrest 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Atrioventricular Blockade 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Angina 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT OCU_2_Photophobia 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT NEU_1_Syncope 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Palpitation 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Hypertensive Crisis 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT NEU_3_Seizures 103628-46-2 SUMATRIPTAN KNOWN_TOXICITY Miscellaneous 103628-46-2 SUMATRIPTAN INDICATION Migraine Headache 103628-46-2 SUMATRIPTAN MODE_CLASS Receptor Agonist, selective 103628-46-2 SUMATRIPTAN TA_LEVEL_3 migraine headaches 103628-46-2 SUMATRIPTAN MECH_LEVEL_3 5HT receptor 1D 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Death 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT NEU_3_Cerebral Vasospasm 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 103628-46-2 SUMATRIPTAN KNOWN_TOXICITY Cardiovascular Toxicity 103628-46-2 SUMATRIPTAN ZERO_CLASS N 103628-46-2 SUMATRIPTAN THERAPEUTIC_CLASS Antimigraines 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Dizziness 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Stroke 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Cardiac Arrhythmia 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Hypertensive Crisis 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Myocardial Infarction 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Coronary Vasospasm 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Bloody Diarrhea 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Hypotension 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Abdominal Pain 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Stroke 103628-46-2 SUMATRIPTAN MECH_LEVEL_2 5HT antagonist 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Lightheadedness 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Hypotension 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Ischemic Colitis 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Chest Pain 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT MSK_2_Myalgia 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT IMU_3_Angioedema 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Paresthesia 103628-46-2 SUMATRIPTAN ACTIVITY_CLASS Serotonin agonist 103628-46-2 SUMATRIPTAN TA_LEVEL_2 vasoconstrictor 103628-46-2 SUMATRIPTAN STRUCTURE_ACTIVITY 5HT1D agonist 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Myocardial Infarction 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Angina 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Atrial Fibrillation 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 103628-46-2 SUMATRIPTAN TISSUE_TOXICITY Thromboembolism 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Hypertension 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Myocardial Ischemia 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT MSK_2_Muscle Cramps 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Thromboembolism 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT LUN_2_Dyspnea 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT XXX_3_Death 103628-46-2 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Atrial Fibrillation 103628-46-2 SUMATRIPTAN MESH_LEVEL_3 Sulfonamides 103628-46-2 SUMATRIPTAN MESH_LEVEL_2 Amides 103628-46-2 SUMATRIPTAN MECH_LEVEL_1 Vasoconstriction 103628-46-2 SUMATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 103628-46-2 SUMATRIPTAN MESH_LEVEL_1 Organic Chemicals 103628-46-2 SUMATRIPTAN TA_LEVEL_1 Central Nervous System (CNS) 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT NEU_1_Syncope 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Palpitation 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Hypotension 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Ischemic Colitis 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Chest Pain 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT MSK_2_Myalgia 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT IMU_3_Angioedema 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Coronary Vasospasm 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Bloody Diarrhea 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Abdominal Pain 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Stroke 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Lightheadedness 103628-48-4 SUMATRIPTAN MECH_LEVEL_2 5HT antagonist 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT OCU_2_Photophobia 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Paresthesia 103628-48-4 SUMATRIPTAN ZERO_CLASS N 103628-48-4 SUMATRIPTAN KNOWN_TOXICITY Cardiovascular Toxicity 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Hypertensive Crisis 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Cardiac Arrhythmia 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Stroke 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Dizziness 103628-48-4 SUMATRIPTAN THERAPEUTIC_CLASS Antimigraines 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT NEU_3_Cerebral Vasospasm 103628-48-4 SUMATRIPTAN MECH_LEVEL_3 5HT receptor 1D 103628-48-4 SUMATRIPTAN TA_LEVEL_1 Central Nervous System (CNS) 103628-48-4 SUMATRIPTAN ACTIVITY_CLASS Serotonin agonist 103628-48-4 SUMATRIPTAN TA_LEVEL_2 vasoconstrictor 103628-48-4 SUMATRIPTAN STRUCTURE_ACTIVITY 5HT1D agonist 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Myocardial Infarction 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Angina 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Atrial Fibrillation 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Hypertension 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Angina 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Atrioventricular Blockade 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Cardiac Arrest 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT XXX_2_Weakness 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Cardiac Arrest 103628-48-4 SUMATRIPTAN MECHANISM Modulate cerebral vasoconstriction 103628-48-4 SUMATRIPTAN MESH_LEVEL_1 Organic Chemicals 103628-48-4 SUMATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 103628-48-4 SUMATRIPTAN MECH_LEVEL_1 Vasoconstriction 103628-48-4 SUMATRIPTAN MESH_LEVEL_2 Amides 103628-48-4 SUMATRIPTAN MESH_LEVEL_3 Sulfonamides 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Atrial Fibrillation 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT XXX_3_Death 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT LUN_2_Dyspnea 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Thromboembolism 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT MSK_2_Muscle Cramps 103628-48-4 SUMATRIPTAN TA_LEVEL_3 migraine headaches 103628-48-4 SUMATRIPTAN MODE_CLASS Receptor Agonist, selective 103628-48-4 SUMATRIPTAN INDICATION Migraine Headache 103628-48-4 SUMATRIPTAN KNOWN_TOXICITY Miscellaneous 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT NEU_3_Seizures 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Hypertensive Crisis 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Myocardial Infarction 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Myocardial Ischemia 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Death 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Thromboembolism 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Hypotension 103628-48-4 SUMATRIPTAN TISSUE_TOXICITY Myocardial Ischemia 103628-48-4 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT IMU_3_Angioedema 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT MSK_2_Myalgia 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Chest Pain 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Ischemic Colitis 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Hypotension 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Hypotension 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Thromboembolism 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Death 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 103628-47-3 SUMATRIPTAN KNOWN_TOXICITY Cardiovascular Toxicity 103628-47-3 SUMATRIPTAN ZERO_CLASS N 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Myocardial Infarction 103628-47-3 SUMATRIPTAN MECH_LEVEL_2 5HT antagonist 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Lightheadedness 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Stroke 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Abdominal Pain 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT GIS_3_Bloody Diarrhea 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Coronary Vasospasm 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Hypertensive Crisis 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Cardiac Arrhythmia 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Stroke 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Dizziness 103628-47-3 SUMATRIPTAN THERAPEUTIC_CLASS Antimigraines 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT NEU_3_Cerebral Vasospasm 103628-47-3 SUMATRIPTAN MECH_LEVEL_3 5HT receptor 1D 103628-47-3 SUMATRIPTAN TA_LEVEL_3 migraine headaches 103628-47-3 SUMATRIPTAN MODE_CLASS Receptor Agonist, selective 103628-47-3 SUMATRIPTAN INDICATION Migraine Headache 103628-47-3 SUMATRIPTAN KNOWN_TOXICITY Miscellaneous 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT NEU_3_Seizures 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Hypertensive Crisis 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Palpitation 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT NEU_1_Syncope 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT OCU_2_Photophobia 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Angina 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Atrioventricular Blockade 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Cardiac Arrest 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Myocardial Ischemia 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT XXX_2_Weakness 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Cardiac Arrest 103628-47-3 SUMATRIPTAN MECHANISM Modulate cerebral vasoconstriction 103628-47-3 SUMATRIPTAN MESH_LEVEL_1 Organic Chemicals 103628-47-3 SUMATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 103628-47-3 SUMATRIPTAN MECH_LEVEL_1 Vasoconstriction 103628-47-3 SUMATRIPTAN MESH_LEVEL_2 Amides 103628-47-3 SUMATRIPTAN MESH_LEVEL_3 Sulfonamides 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Atrial Fibrillation 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT XXX_3_Death 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT LUN_2_Dyspnea 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Thromboembolism 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT MSK_2_Muscle Cramps 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_3_Myocardial Ischemia 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_1_Hypertension 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Atrial Fibrillation 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Angina 103628-47-3 SUMATRIPTAN TISSUE_TOXICITY Myocardial Infarction 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 103628-47-3 SUMATRIPTAN STRUCTURE_ACTIVITY 5HT1D agonist 103628-47-3 SUMATRIPTAN TA_LEVEL_2 vasoconstrictor 103628-47-3 SUMATRIPTAN ACTIVITY_CLASS Serotonin agonist 103628-47-3 SUMATRIPTAN TA_LEVEL_1 Central Nervous System (CNS) 103628-47-3 SUMATRIPTAN ADVERSE_EFFECT NEU_2_Paresthesia 40828-46-4 SUPROFEN INDICATION Inhibition of Miosis 40828-46-4 SUPROFEN MODE_CLASS Enzyme Inhibitor 40828-46-4 SUPROFEN ADVERSE_EFFECT XXX_1_Burning Sensation 40828-46-4 SUPROFEN ADVERSE_EFFECT PSY_1_Irritation 40828-46-4 SUPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 40828-46-4 SUPROFEN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 40828-46-4 SUPROFEN MECHANISM Inhibit eicosanoid biosynthesis 40828-46-4 SUPROFEN ADVERSE_EFFECT SKN_1_Pruritis 40828-46-4 SUPROFEN ADVERSE_EFFECT OCU_1_Photophobia 40828-46-4 SUPROFEN INDICATION Giant Papillary Conjunctivitis 40828-46-4 SUPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 40828-46-4 SUPROFEN ADVERSE_EFFECT XXX_1_Pain 40828-46-4 SUPROFEN ADVERSE_EFFECT XXX_1_Stinging Sensation 169042-78-8 Z-203 MECHANISM Modulate G-protein coupled signal transduction 169042-78-8 Z-203 INDICATION Acute Pancreatitis 169042-78-8 Z-203 PRODUCT_CLASS Gastrointestinal System 169042-78-8 Z-203 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 1684-40-8 TACRINE INDICATION Alzheimer's Disease 1684-40-8 TACRINE ADVERSE_EFFECT NEU_2_Tremor 1684-40-8 TACRINE ADVERSE_EFFECT GUS_2_Dysuria 1684-40-8 TACRINE ADVERSE_EFFECT GIS_1_Flatulence 1684-40-8 TACRINE TISSUE_TOXICITY Hypotension 1684-40-8 TACRINE MECHANISM Enhance cholinergic transmission 1684-40-8 TACRINE ADVERSE_EFFECT MSK_1_Myalgia 1684-40-8 TACRINE ADVERSE_EFFECT NEU_1_Ataxia 1684-40-8 TACRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1684-40-8 TACRINE ADVERSE_EFFECT PSY_1_Anorexia 1684-40-8 TACRINE ADVERSE_EFFECT GIS_1_Constipation 1684-40-8 TACRINE MODE_CLASS Enzyme Inhibitor 1684-40-8 TACRINE MECH_LEVEL_2 Enhance cholinergic transmission 1684-40-8 TACRINE TA_LEVEL_3 Alzheimer's disease 1684-40-8 TACRINE MESH_LEVEL_3 Acridines 1684-40-8 TACRINE MECH_LEVEL_3 Acetylcholinesterase 1684-40-8 TACRINE ZERO_CLASS N 1684-40-8 TACRINE MESH_LEVEL_1 Heterocyclic Compounds 1684-40-8 TACRINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 1684-40-8 TACRINE ADVERSE_EFFECT NEU_2_Syncope 1684-40-8 TACRINE ADVERSE_EFFECT OCU_2_Visual Impairment 1684-40-8 TACRINE ADVERSE_EFFECT LUN_3_Asthma 1684-40-8 TACRINE ADVERSE_EFFECT PSY_2_Insomnia 1684-40-8 TACRINE ADVERSE_EFFECT OCU_2_Blurred Vision 1684-40-8 TACRINE INDICATION Dementia 1684-40-8 TACRINE MECH_LEVEL_1 Modulate neural transmission 1684-40-8 TACRINE ADVERSE_EFFECT XXX_2_Diaphoresis 1684-40-8 TACRINE ADVERSE_EFFECT XXX_1_Xerostomia 1684-40-8 TACRINE ADVERSE_EFFECT CVS_2_Palpitation 1684-40-8 TACRINE ADVERSE_EFFECT PSY_2_Mental Status Changes 1684-40-8 TACRINE ADVERSE_EFFECT NEU_2_Dizziness 1684-40-8 TACRINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 1684-40-8 TACRINE ADVERSE_EFFECT CVS_2_Hypotension 1684-40-8 TACRINE ADVERSE_EFFECT GIS_1_Diarrhea 1684-40-8 TACRINE THERAPEUTIC_CLASS Neurodegenerative Disorders 1684-40-8 TACRINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 1684-40-8 TACRINE TA_LEVEL_2 Dementia 1684-40-8 TACRINE PRODUCT_CLASS Central Nervous System (CNS) 1684-40-8 TACRINE ACTIVITY_CLASS Cholinesterase inhibitor 1684-40-8 TACRINE STRUCTURE_ACTIVITY Cholinesterase inhibitor 1684-40-8 TACRINE ADVERSE_EFFECT GIS_1_Dyspepsia 1684-40-8 TACRINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 1684-40-8 TACRINE ADVERSE_EFFECT NEU_3_Seizures 1684-40-8 TACRINE ADVERSE_EFFECT CVS_2_Hypertension 1684-40-8 TACRINE ADVERSE_EFFECT GUS_2_Urinary Retention 1684-40-8 TACRINE KNOWN_TOXICITY Cardiovascular Toxicity 1684-40-8 TACRINE TA_LEVEL_1 Central Nervous System (CNS) 321-64-2 TACRINE ADVERSE_EFFECT NEU_3_Seizures 321-64-2 TACRINE KNOWN_TOXICITY Cardiovascular Toxicity 321-64-2 TACRINE TA_LEVEL_1 Central Nervous System (CNS) 321-64-2 TACRINE ADVERSE_EFFECT GUS_2_Urinary Retention 321-64-2 TACRINE ADVERSE_EFFECT CVS_2_Hypertension 321-64-2 TACRINE ADVERSE_EFFECT NEU_2_Tremor 321-64-2 TACRINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 321-64-2 TACRINE ADVERSE_EFFECT GIS_1_Dyspepsia 321-64-2 TACRINE STRUCTURE_ACTIVITY Cholinesterase inhibitor 321-64-2 TACRINE MECHANISM Enhance cholinergic transmission 321-64-2 TACRINE PRODUCT_CLASS Central Nervous System (CNS) 321-64-2 TACRINE MECH_LEVEL_2 Enhance cholinergic transmission 321-64-2 TACRINE TISSUE_TOXICITY Hypotension 321-64-2 TACRINE ADVERSE_EFFECT GIS_1_Flatulence 321-64-2 TACRINE ADVERSE_EFFECT MSK_1_Myalgia 321-64-2 TACRINE ADVERSE_EFFECT NEU_1_Ataxia 321-64-2 TACRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 321-64-2 TACRINE ADVERSE_EFFECT PSY_1_Anorexia 321-64-2 TACRINE ACTIVITY_CLASS Cholinesterase inhibitor 321-64-2 TACRINE ADVERSE_EFFECT GIS_1_Constipation 321-64-2 TACRINE MODE_CLASS Enzyme Inhibitor 321-64-2 TACRINE INDICATION Alzheimer's Disease 321-64-2 TACRINE TA_LEVEL_3 Alzheimer's disease 321-64-2 TACRINE MESH_LEVEL_3 Acridines 321-64-2 TACRINE MECH_LEVEL_3 Acetylcholinesterase 321-64-2 TACRINE ZERO_CLASS N 321-64-2 TACRINE MESH_LEVEL_1 Heterocyclic Compounds 321-64-2 TACRINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 321-64-2 TACRINE ADVERSE_EFFECT NEU_2_Syncope 321-64-2 TACRINE ADVERSE_EFFECT GUS_2_Dysuria 321-64-2 TACRINE ADVERSE_EFFECT OCU_2_Visual Impairment 321-64-2 TACRINE ADVERSE_EFFECT PSY_2_Insomnia 321-64-2 TACRINE ADVERSE_EFFECT OCU_2_Blurred Vision 321-64-2 TACRINE INDICATION Dementia 321-64-2 TACRINE MECH_LEVEL_1 Modulate neural transmission 321-64-2 TACRINE ADVERSE_EFFECT XXX_2_Diaphoresis 321-64-2 TACRINE ADVERSE_EFFECT XXX_1_Xerostomia 321-64-2 TACRINE ADVERSE_EFFECT CVS_2_Palpitation 321-64-2 TACRINE ADVERSE_EFFECT PSY_2_Mental Status Changes 321-64-2 TACRINE ADVERSE_EFFECT NEU_2_Dizziness 321-64-2 TACRINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 321-64-2 TACRINE ADVERSE_EFFECT CVS_2_Hypotension 321-64-2 TACRINE ADVERSE_EFFECT LUN_3_Asthma 321-64-2 TACRINE ADVERSE_EFFECT GIS_1_Diarrhea 321-64-2 TACRINE THERAPEUTIC_CLASS Neurodegenerative Disorders 321-64-2 TACRINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 321-64-2 TACRINE TA_LEVEL_2 Dementia 1401-55-4 TANNIC ACID INDICATION Dental Pain 1401-55-4 TANNIC ACID INDICATION Herpes Labialis / Cold or Fever Sore 1401-55-4 TANNIC ACID PRODUCT_CLASS Dermatologicals 1401-55-4 TANNIC ACID THERAPEUTIC_CLASS Astringents 1401-55-4 TANNIC ACID PRODUCT_CLASS Other Human Uses 1401-55-4 TANNIC ACID MECHANISM Scavenges hydrogen peroxide and free radicals 1401-55-4 TANNIC ACID INDICATION Aphthous Ulcer (Canker Sore, Ulcerative Stomatitis) 107-35-7 TAURINE INDICATION Ulcer 118292-40-3 TAZAROTENE STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 118292-40-3 TAZAROTENE THERAPEUTIC_CLASS Psoralens 118292-40-3 TAZAROTENE INDICATION Psoriasis 118292-40-3 TAZAROTENE MECHANISM Inhibit precursor synthesis 118292-40-3 TAZAROTENE THERAPEUTIC_CLASS Acne Preparations 118292-40-3 TAZAROTENE MODE_CLASS Enzyme Inhibitor 118292-40-3 TAZAROTENE INDICATION Acne / Acne Vulgaris 118292-40-3 TAZAROTENE MODE_CLASS Receptor Agonist, selective 118292-40-3 TAZAROTENE PRODUCT_CLASS Dermatologicals 118292-40-3 TAZAROTENE MECHANISM Modulate gene transcription 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GIS_1_Constipation 89786-04-9 TAZOBACTAM INDICATION Diabetic Foot Ulcer 89786-04-9 TAZOBACTAM INDICATION Peritonitis 89786-04-9 TAZOBACTAM INDICATION Pneumonia 89786-04-9 TAZOBACTAM TA_LEVEL_3 systemic infections 89786-04-9 TAZOBACTAM MECH_LEVEL_1 Anti-bacterial 89786-04-9 TAZOBACTAM TA_LEVEL_2 Anti-bacterial 89786-04-9 TAZOBACTAM MECHANISM Inhibit drug resistant enzyme/pump 89786-04-9 TAZOBACTAM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 89786-04-9 TAZOBACTAM ADVERSE_EFFECT XXX_2_Rhinitis 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GIS_2_Abdominal Pain 89786-04-9 TAZOBACTAM ADVERSE_EFFECT PSY_2_Agitation 89786-04-9 TAZOBACTAM ADVERSE_EFFECT ELT_3_Hypokalemia 89786-04-9 TAZOBACTAM ADVERSE_EFFECT CVS_2_Hypertension 89786-04-9 TAZOBACTAM TA_LEVEL_1 Infectious Disease 89786-04-9 TAZOBACTAM MESH_LEVEL_3 Lactams 89786-04-9 TAZOBACTAM MECH_LEVEL_3 Beta-lactamase 89786-04-9 TAZOBACTAM INDICATION Cellulitis 89786-04-9 TAZOBACTAM INDICATION Lower Respiratory Tract Infection 89786-04-9 TAZOBACTAM ADVERSE_EFFECT KID_3_Nephrotic Syndrome 89786-04-9 TAZOBACTAM ADVERSE_EFFECT CVS_2_Chest Pain 89786-04-9 TAZOBACTAM ADVERSE_EFFECT LUN_2_Dyspnea 89786-04-9 TAZOBACTAM ADVERSE_EFFECT NEU_1_Headache 89786-04-9 TAZOBACTAM ADVERSE_EFFECT PSY_1_Insomnia 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GIS_1_Diarrhea 89786-04-9 TAZOBACTAM MODE_CLASS Enzyme Inhibitor 89786-04-9 TAZOBACTAM INDICATION Pelvic Inflammatory Disease (PID) 89786-04-9 TAZOBACTAM MESH_LEVEL_2 Amides 89786-04-9 TAZOBACTAM MESH_LEVEL_1 Organic Chemicals 89786-04-9 TAZOBACTAM INDICATION Gynecologic Infections 89786-04-9 TAZOBACTAM ZERO_CLASS N 89786-04-9 TAZOBACTAM THERAPEUTIC_CLASS Antibacterials, Systemic 89786-04-9 TAZOBACTAM TISSUE_TOXICITY Nephrotic Syndrome 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GIS_2_Dyspepsia 89786-04-9 TAZOBACTAM ADVERSE_EFFECT XXX_3_Bacterial Superinfections 89786-04-9 TAZOBACTAM ADVERSE_EFFECT NEU_2_Dizziness 89786-04-9 TAZOBACTAM ADVERSE_EFFECT PSY_2_Anxiety 89786-04-9 TAZOBACTAM ADVERSE_EFFECT XXX_2_Fever 89786-04-9 TAZOBACTAM KNOWN_TOXICITY Nephrotoxicity 89786-04-9 TAZOBACTAM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 89786-04-9 TAZOBACTAM PRODUCT_CLASS Anti-infectives 89786-04-9 TAZOBACTAM STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GUS_3_Vaginitis 89786-04-9 TAZOBACTAM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 89786-04-9 TAZOBACTAM ADVERSE_EFFECT XXX_2_Edema 89785-84-2 TAZOBACTAM ADVERSE_EFFECT NEU_2_Dizziness 89785-84-2 TAZOBACTAM ADVERSE_EFFECT PSY_2_Anxiety 89785-84-2 TAZOBACTAM ADVERSE_EFFECT XXX_2_Fever 89785-84-2 TAZOBACTAM KNOWN_TOXICITY Nephrotoxicity 89785-84-2 TAZOBACTAM INDICATION Gynecologic Infections 89785-84-2 TAZOBACTAM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 89785-84-2 TAZOBACTAM PRODUCT_CLASS Anti-infectives 89785-84-2 TAZOBACTAM INDICATION Cellulitis 89785-84-2 TAZOBACTAM INDICATION Lower Respiratory Tract Infection 89785-84-2 TAZOBACTAM ADVERSE_EFFECT KID_3_Nephrotic Syndrome 89785-84-2 TAZOBACTAM ADVERSE_EFFECT CVS_2_Chest Pain 89785-84-2 TAZOBACTAM ADVERSE_EFFECT LUN_2_Dyspnea 89785-84-2 TAZOBACTAM ADVERSE_EFFECT NEU_1_Headache 89785-84-2 TAZOBACTAM MESH_LEVEL_1 Organic Chemicals 89785-84-2 TAZOBACTAM MESH_LEVEL_2 Amides 89785-84-2 TAZOBACTAM INDICATION Pelvic Inflammatory Disease (PID) 89785-84-2 TAZOBACTAM MODE_CLASS Enzyme Inhibitor 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GIS_1_Diarrhea 89785-84-2 TAZOBACTAM ADVERSE_EFFECT PSY_1_Insomnia 89785-84-2 TAZOBACTAM TA_LEVEL_3 systemic infections 89785-84-2 TAZOBACTAM THERAPEUTIC_CLASS Antibacterials, Systemic 89785-84-2 TAZOBACTAM TISSUE_TOXICITY Nephrotic Syndrome 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GIS_2_Dyspepsia 89785-84-2 TAZOBACTAM ZERO_CLASS N 89785-84-2 TAZOBACTAM STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GUS_3_Vaginitis 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 89785-84-2 TAZOBACTAM ADVERSE_EFFECT XXX_2_Edema 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GIS_1_Constipation 89785-84-2 TAZOBACTAM INDICATION Diabetic Foot Ulcer 89785-84-2 TAZOBACTAM INDICATION Peritonitis 89785-84-2 TAZOBACTAM INDICATION Pneumonia 89785-84-2 TAZOBACTAM MECH_LEVEL_1 Anti-bacterial 89785-84-2 TAZOBACTAM TA_LEVEL_2 Anti-bacterial 89785-84-2 TAZOBACTAM MECHANISM Inhibit drug resistant enzyme/pump 89785-84-2 TAZOBACTAM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 89785-84-2 TAZOBACTAM ADVERSE_EFFECT XXX_2_Rhinitis 89785-84-2 TAZOBACTAM ADVERSE_EFFECT GIS_2_Abdominal Pain 89785-84-2 TAZOBACTAM ADVERSE_EFFECT PSY_2_Agitation 89785-84-2 TAZOBACTAM ADVERSE_EFFECT ELT_3_Hypokalemia 89785-84-2 TAZOBACTAM ADVERSE_EFFECT CVS_2_Hypertension 89785-84-2 TAZOBACTAM ADVERSE_EFFECT XXX_3_Bacterial Superinfections 89785-84-2 TAZOBACTAM TA_LEVEL_1 Infectious Disease 89785-84-2 TAZOBACTAM MESH_LEVEL_3 Lactams 89785-84-2 TAZOBACTAM MECH_LEVEL_3 Beta-lactamase 144701-48-4 TELMISARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 144701-48-4 TELMISARTAN PRODUCT_CLASS Cardiovasculars 144701-48-4 TELMISARTAN INDICATION Hypertension 144701-48-4 TELMISARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 144701-48-4 TELMISARTAN THERAPEUTIC_CLASS Antihypertensive Agents 144701-48-4 TELMISARTAN MECHANISM Reduce vasoconstriction 108319-06-8 TEMAFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 108319-06-8 TEMAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 108319-06-8 TEMAFLOXACIN INDICATION Skin and Skin Structure Infections 108319-06-8 TEMAFLOXACIN INDICATION Bone and Joint Infection 108319-06-8 TEMAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 108319-06-8 TEMAFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 108319-06-8 TEMAFLOXACIN PRODUCT_CLASS Anti-infectives 108319-06-8 TEMAFLOXACIN INDICATION Intra-Abdominal Infections 108319-06-8 TEMAFLOXACIN INDICATION Acute Sinusitis 108319-06-8 TEMAFLOXACIN TISSUE_TOXICITY Acute Renal Failure 108319-06-8 TEMAFLOXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 108319-06-8 TEMAFLOXACIN ADVERSE_EFFECT END_2_Hypoglycemia 108319-06-8 TEMAFLOXACIN INDICATION Urinary Tract Infection (UTI) 108319-06-8 TEMAFLOXACIN INDICATION Chronic Bacterial Prostatitis 108319-06-8 TEMAFLOXACIN INDICATION Complicated Urinary Tract Infections 108319-06-8 TEMAFLOXACIN INDICATION Respiratory Tract Infection 108319-06-8 TEMAFLOXACIN ADVERSE_EFFECT BBM_2_Hemolytic Anemia 108319-06-8 TEMAFLOXACIN INDICATION Intra-Abdominal Infections 108319-06-8 TEMAFLOXACIN INDICATION Acute Sinusitis 108319-06-8 TEMAFLOXACIN INDICATION Acute Infectious Diarrhea 108319-06-8 TEMAFLOXACIN INDICATION Skin and Skin Structure Infections 108319-06-8 TEMAFLOXACIN INDICATION Bone and Joint Infection 108319-06-8 TEMAFLOXACIN INDICATION Complicated Urinary Tract Infections 108319-06-8 TEMAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 108319-06-8 TEMAFLOXACIN ADVERSE_EFFECT BBM_2_Coagulopathy 108319-06-8 TEMAFLOXACIN KNOWN_TOXICITY Nephrotoxicity 108319-06-8 TEMAFLOXACIN INDICATION Respiratory Tract Infection 108319-06-8 TEMAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 108319-06-8 TEMAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 108319-06-8 TEMAFLOXACIN INDICATION Urinary Tract Infection (UTI) 108319-06-8 TEMAFLOXACIN INDICATION Chronic Bacterial Prostatitis 108319-06-8 TEMAFLOXACIN INDICATION Acute Infectious Diarrhea 108319-06-8 TEMAFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 108319-06-8 TEMAFLOXACIN ADVERSE_EFFECT CVS__Vasculitis (Structure Class Implication) 105784-61-0 TEMAFLOXACIN INDICATION Skin and Skin Structure Infections 105784-61-0 TEMAFLOXACIN ADVERSE_EFFECT BBM_2_Coagulopathy 105784-61-0 TEMAFLOXACIN INDICATION Intra-Abdominal Infections 105784-61-0 TEMAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 105784-61-0 TEMAFLOXACIN INDICATION Bone and Joint Infection 105784-61-0 TEMAFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 105784-61-0 TEMAFLOXACIN INDICATION Acute Infectious Diarrhea 105784-61-0 TEMAFLOXACIN INDICATION Acute Sinusitis 105784-61-0 TEMAFLOXACIN INDICATION Intra-Abdominal Infections 105784-61-0 TEMAFLOXACIN ADVERSE_EFFECT BBM_2_Hemolytic Anemia 105784-61-0 TEMAFLOXACIN INDICATION Complicated Urinary Tract Infections 105784-61-0 TEMAFLOXACIN INDICATION Respiratory Tract Infection 105784-61-0 TEMAFLOXACIN INDICATION Respiratory Tract Infection 105784-61-0 TEMAFLOXACIN INDICATION Complicated Urinary Tract Infections 105784-61-0 TEMAFLOXACIN INDICATION Bone and Joint Infection 105784-61-0 TEMAFLOXACIN INDICATION Chronic Bacterial Prostatitis 105784-61-0 TEMAFLOXACIN INDICATION Acute Sinusitis 105784-61-0 TEMAFLOXACIN TISSUE_TOXICITY Acute Renal Failure 105784-61-0 TEMAFLOXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 105784-61-0 TEMAFLOXACIN ADVERSE_EFFECT END_2_Hypoglycemia 105784-61-0 TEMAFLOXACIN INDICATION Urinary Tract Infection (UTI) 105784-61-0 TEMAFLOXACIN INDICATION Acute Infectious Diarrhea 105784-61-0 TEMAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 105784-61-0 TEMAFLOXACIN INDICATION Urinary Tract Infection (UTI) 105784-61-0 TEMAFLOXACIN INDICATION Chronic Bacterial Prostatitis 105784-61-0 TEMAFLOXACIN ADVERSE_EFFECT KID_3_Acute Renal Failure 105784-61-0 TEMAFLOXACIN ADVERSE_EFFECT CVS__Vasculitis (Structure Class Implication) 105784-61-0 TEMAFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 105784-61-0 TEMAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 105784-61-0 TEMAFLOXACIN INDICATION Skin and Skin Structure Infections 105784-61-0 TEMAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 105784-61-0 TEMAFLOXACIN PRODUCT_CLASS Anti-infectives 105784-61-0 TEMAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 105784-61-0 TEMAFLOXACIN KNOWN_TOXICITY Nephrotoxicity 846-50-4 TEMAZEPAM MODE_CLASS Channel enhancer /opener 846-50-4 TEMAZEPAM INDICATION Insomnia 846-50-4 TEMAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 846-50-4 TEMAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 846-50-4 TEMAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 846-50-4 TEMAZEPAM MECHANISM Modulate neural transmission 85622-93-1 TEMOZOLOMIDE MECHANISM Inhibit DNA synthesis, repair, and function 85622-93-1 TEMOZOLOMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 29767-20-2 TENIPOSIDE MECHANISM Inhibit DNA synthesis, repair, and function 29767-20-2 TENIPOSIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 29767-20-2 TENIPOSIDE STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 29767-20-2 TENIPOSIDE THERAPEUTIC_CLASS Antineoplastics 29767-20-2 TENIPOSIDE PRODUCT_CLASS Anti-cancers 29767-20-2 TENIPOSIDE MODE_CLASS Enzyme Inhibitor 29767-20-2 TENIPOSIDE INDICATION Acute Lymphocytic Leukemia (ALL) 59804-37-4 TENOXICAM INDICATION Rheumatoid Arthritis 59804-37-4 TENOXICAM KNOWN_TOXICITY Cardiovascular Toxicity 59804-37-4 TENOXICAM ADVERSE_EFFECT SKN_3_Nail Disorder 59804-37-4 TENOXICAM ADVERSE_EFFECT PSY_3_Depression 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Nausea 59804-37-4 TENOXICAM ADVERSE_EFFECT BBM_3_Hemolytic Anemia 59804-37-4 TENOXICAM ADVERSE_EFFECT LUN_3_Asthma 59804-37-4 TENOXICAM ADVERSE_EFFECT PSY_3_Anorexia 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Indigestion 59804-37-4 TENOXICAM ADVERSE_EFFECT SKN_3_Rash 59804-37-4 TENOXICAM ADVERSE_EFFECT LUN_3_Bronchospasm 59804-37-4 TENOXICAM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 59804-37-4 TENOXICAM ADVERSE_EFFECT XXX_3_Weight Loss 59804-37-4 TENOXICAM ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 59804-37-4 TENOXICAM ADVERSE_EFFECT PSY_3_Mental Confusion 59804-37-4 TENOXICAM ADVERSE_EFFECT KID_3_Nephrotoxicity 59804-37-4 TENOXICAM ADVERSE_EFFECT BBM_3_Leukopenia 59804-37-4 TENOXICAM ADVERSE_EFFECT XXX_2_Peripheral Edema 59804-37-4 TENOXICAM ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 59804-37-4 TENOXICAM ADVERSE_EFFECT IMU_3_Angioedema 59804-37-4 TENOXICAM ADVERSE_EFFECT NEU_3_Paresthesia 59804-37-4 TENOXICAM ADVERSE_EFFECT IMU_3_Eosinophilia 59804-37-4 TENOXICAM ADVERSE_EFFECT OTO_3_Tinnitus 59804-37-4 TENOXICAM ADVERSE_EFFECT END_3_Hyperglycemia 59804-37-4 TENOXICAM ADVERSE_EFFECT PSY_3_Insomnia 59804-37-4 TENOXICAM ADVERSE_EFFECT OCU_3_Blurred Vision 59804-37-4 TENOXICAM ADVERSE_EFFECT XXX_3_Malaise 59804-37-4 TENOXICAM KNOWN_TOXICITY Nephrotoxicity 59804-37-4 TENOXICAM PRODUCT_CLASS Anti-inflammatories 59804-37-4 TENOXICAM INDICATION Osteoarthritis 59804-37-4 TENOXICAM INDICATION Acute Musculoskeletal Disorders 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Dyspepsia 59804-37-4 TENOXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 59804-37-4 TENOXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Epigastric Pain 59804-37-4 TENOXICAM MODE_CLASS Enzyme Inhibitor 59804-37-4 TENOXICAM MECHANISM Inhibit eicosanoid biosynthesis 59804-37-4 TENOXICAM TISSUE_TOXICITY Congestive Heart Failure 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Abdominal Pain 59804-37-4 TENOXICAM TISSUE_TOXICITY Nephrotoxicity 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Flatulence 59804-37-4 TENOXICAM ADVERSE_EFFECT CVS_3_Palpitation 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_3_Peptic Ulceration 59804-37-4 TENOXICAM ADVERSE_EFFECT NEU_3_Vertigo 59804-37-4 TENOXICAM ADVERSE_EFFECT XXX_3_Weight Gain 59804-37-4 TENOXICAM ADVERSE_EFFECT IMU_3_Urticaria 59804-37-4 TENOXICAM ADVERSE_EFFECT IMU_2_Hypersensitivity 59804-37-4 TENOXICAM ADVERSE_EFFECT BBM_3_Agranulocytosis 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Constipation 59804-37-4 TENOXICAM ADVERSE_EFFECT CVS_3_Congestive Heart Failure 59804-37-4 TENOXICAM ADVERSE_EFFECT PSY_3_Nervousness 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Diarrhea 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 59804-37-4 TENOXICAM ADVERSE_EFFECT NEU_3_Somnolence 59804-37-4 TENOXICAM ADVERSE_EFFECT GIS_1_Stomatitis 59804-37-4 TENOXICAM ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 59804-37-4 TENOXICAM ADVERSE_EFFECT BBM_3_Aplastic Anemia 59804-37-4 TENOXICAM ADVERSE_EFFECT BBM_3_Thrombocytopenia 59804-37-4 TENOXICAM ADVERSE_EFFECT SKN_2_Erythema 59804-37-4 TENOXICAM ADVERSE_EFFECT SKN_3_Pruritis 59804-37-4 TENOXICAM ADVERSE_EFFECT NEU_3_Dizziness 59804-37-4 TENOXICAM ADVERSE_EFFECT IMU_3_Photosensitivity 59804-37-4 TENOXICAM ADVERSE_EFFECT NEU_3_Headache 63590-64-7 TERAZOSIN TA_LEVEL_2 alpha blocker 63590-64-7 TERAZOSIN ADVERSE_EFFECT IMU_3_Allergic Reactions 63590-64-7 TERAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 63590-64-7 TERAZOSIN ADVERSE_EFFECT XXX_1_Asthenia 63590-64-7 TERAZOSIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 63590-64-7 TERAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 63590-64-7 TERAZOSIN ACTIVITY_CLASS Adrenergic antagonist 63590-64-7 TERAZOSIN MECHANISM Reduce vasoconstriction 63590-64-7 TERAZOSIN ADVERSE_EFFECT BBM_2_Hemodilution 63590-64-7 TERAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 63590-64-7 TERAZOSIN TA_LEVEL_3 hypertension 63590-64-7 TERAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 63590-64-7 TERAZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 63590-64-7 TERAZOSIN MESH_LEVEL_3 Quinazolines 63590-64-7 TERAZOSIN ADVERSE_EFFECT CVS_2_Hypotension 63590-64-7 TERAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 63590-64-7 TERAZOSIN ADVERSE_EFFECT REP_3_Testicular Atrophy 63590-64-7 TERAZOSIN ADVERSE_EFFECT NEU_1_Somnolence 63590-64-7 TERAZOSIN ADVERSE_EFFECT REP_3_Priapism 63590-64-7 TERAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 63590-64-7 TERAZOSIN INDICATION Hypertension 63590-64-7 TERAZOSIN PRODUCT_CLASS Cardiovasculars 63590-64-7 TERAZOSIN MECH_LEVEL_1 Vasorelaxation 63590-64-7 TERAZOSIN TA_LEVEL_1 Cardiovascular 63590-64-7 TERAZOSIN MECH_LEVEL_2 alpha antagonist 63590-64-7 TERAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 63590-64-7 TERAZOSIN ADVERSE_EFFECT OCU_2_Blurred Vision 63590-64-7 TERAZOSIN ADVERSE_EFFECT REP_2_Impotence 63590-64-7 TERAZOSIN ADVERSE_EFFECT NEU_2_Drowsiness 63590-64-7 TERAZOSIN ADVERSE_EFFECT CVS_1_Palpitation 63590-64-7 TERAZOSIN ADVERSE_EFFECT XXX_2_Nasal Congestion 63590-64-7 TERAZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 63590-64-7 TERAZOSIN ZERO_CLASS N 63590-64-7 TERAZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 63590-64-7 TERAZOSIN TISSUE_TOXICITY Hypotension 63590-64-7 TERAZOSIN ADVERSE_EFFECT GIS_2_Nausea 63590-64-7 TERAZOSIN ADVERSE_EFFECT IMU_3_Anaphylaxis 63590-64-7 TERAZOSIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 63590-64-7 TERAZOSIN ADVERSE_EFFECT NEU_2_Syncope 63590-64-7 TERAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 63590-64-7 TERAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 70024-40-7 TERAZOSIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 70024-40-7 TERAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 70024-40-7 TERAZOSIN MECH_LEVEL_2 alpha antagonist 70024-40-7 TERAZOSIN TA_LEVEL_1 Cardiovascular 70024-40-7 TERAZOSIN MECH_LEVEL_1 Vasorelaxation 70024-40-7 TERAZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 70024-40-7 TERAZOSIN PRODUCT_CLASS Cardiovasculars 70024-40-7 TERAZOSIN INDICATION Hypertension 70024-40-7 TERAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 70024-40-7 TERAZOSIN ADVERSE_EFFECT REP_3_Priapism 70024-40-7 TERAZOSIN ADVERSE_EFFECT REP_3_Testicular Atrophy 70024-40-7 TERAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 70024-40-7 TERAZOSIN ADVERSE_EFFECT CVS_2_Hypotension 70024-40-7 TERAZOSIN MESH_LEVEL_3 Quinazolines 70024-40-7 TERAZOSIN ADVERSE_EFFECT NEU_1_Somnolence 70024-40-7 TERAZOSIN ACTIVITY_CLASS Adrenergic antagonist 70024-40-7 TERAZOSIN MECHANISM Reduce vasoconstriction 70024-40-7 TERAZOSIN ADVERSE_EFFECT BBM_2_Hemodilution 70024-40-7 TERAZOSIN ADVERSE_EFFECT XXX_1_Asthenia 70024-40-7 TERAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 70024-40-7 TERAZOSIN ADVERSE_EFFECT IMU_3_Allergic Reactions 70024-40-7 TERAZOSIN TA_LEVEL_2 alpha blocker 70024-40-7 TERAZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 70024-40-7 TERAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 70024-40-7 TERAZOSIN TA_LEVEL_3 hypertension 70024-40-7 TERAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 70024-40-7 TERAZOSIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 70024-40-7 TERAZOSIN ADVERSE_EFFECT NEU_2_Syncope 70024-40-7 TERAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 70024-40-7 TERAZOSIN TISSUE_TOXICITY Hypotension 70024-40-7 TERAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 70024-40-7 TERAZOSIN ADVERSE_EFFECT GIS_2_Nausea 70024-40-7 TERAZOSIN ADVERSE_EFFECT IMU_3_Anaphylaxis 70024-40-7 TERAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 70024-40-7 TERAZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 70024-40-7 TERAZOSIN ZERO_CLASS N 70024-40-7 TERAZOSIN ADVERSE_EFFECT XXX_2_Nasal Congestion 70024-40-7 TERAZOSIN ADVERSE_EFFECT CVS_1_Palpitation 70024-40-7 TERAZOSIN ADVERSE_EFFECT NEU_2_Drowsiness 70024-40-7 TERAZOSIN ADVERSE_EFFECT REP_2_Impotence 70024-40-7 TERAZOSIN ADVERSE_EFFECT OCU_2_Blurred Vision 63074-08-8 TERAZOSIN ADVERSE_EFFECT GIS_2_Nausea 63074-08-8 TERAZOSIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 63074-08-8 TERAZOSIN ADVERSE_EFFECT IMU_3_Anaphylaxis 63074-08-8 TERAZOSIN TISSUE_TOXICITY Hypotension 63074-08-8 TERAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 63074-08-8 TERAZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 63074-08-8 TERAZOSIN ZERO_CLASS N 63074-08-8 TERAZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 63074-08-8 TERAZOSIN ADVERSE_EFFECT XXX_2_Nasal Congestion 63074-08-8 TERAZOSIN ADVERSE_EFFECT CVS_1_Palpitation 63074-08-8 TERAZOSIN ADVERSE_EFFECT NEU_2_Drowsiness 63074-08-8 TERAZOSIN ADVERSE_EFFECT REP_2_Impotence 63074-08-8 TERAZOSIN ADVERSE_EFFECT OCU_2_Blurred Vision 63074-08-8 TERAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 63074-08-8 TERAZOSIN MECH_LEVEL_2 alpha antagonist 63074-08-8 TERAZOSIN TA_LEVEL_1 Cardiovascular 63074-08-8 TERAZOSIN MECH_LEVEL_1 Vasorelaxation 63074-08-8 TERAZOSIN PRODUCT_CLASS Cardiovasculars 63074-08-8 TERAZOSIN INDICATION Hypertension 63074-08-8 TERAZOSIN ADVERSE_EFFECT NEU_2_Syncope 63074-08-8 TERAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 63074-08-8 TERAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 63074-08-8 TERAZOSIN TA_LEVEL_3 hypertension 63074-08-8 TERAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 63074-08-8 TERAZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 63074-08-8 TERAZOSIN MESH_LEVEL_3 Quinazolines 63074-08-8 TERAZOSIN ADVERSE_EFFECT CVS_2_Hypotension 63074-08-8 TERAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 63074-08-8 TERAZOSIN ADVERSE_EFFECT REP_3_Testicular Atrophy 63074-08-8 TERAZOSIN ADVERSE_EFFECT NEU_1_Somnolence 63074-08-8 TERAZOSIN ADVERSE_EFFECT REP_3_Priapism 63074-08-8 TERAZOSIN ACTIVITY_CLASS Adrenergic antagonist 63074-08-8 TERAZOSIN ADVERSE_EFFECT XXX_1_Asthenia 63074-08-8 TERAZOSIN ADVERSE_EFFECT BBM_2_Hemodilution 63074-08-8 TERAZOSIN MECHANISM Reduce vasoconstriction 63074-08-8 TERAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 63074-08-8 TERAZOSIN ADVERSE_EFFECT IMU_3_Allergic Reactions 63074-08-8 TERAZOSIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 63074-08-8 TERAZOSIN TA_LEVEL_2 alpha blocker 63074-08-8 TERAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 63074-08-8 TERAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 91161-71-6 TERBINAFINE MECH_LEVEL_1 Anti-fungal 91161-71-6 TERBINAFINE TA_LEVEL_3 Systemic 91161-71-6 TERBINAFINE INDICATION Tinea Versicolor / Pityriasis Versicolor 91161-71-6 TERBINAFINE THERAPEUTIC_CLASS Antifungals, Systemic 91161-71-6 TERBINAFINE ADVERSE_EFFECT NEU_2_Headache 91161-71-6 TERBINAFINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 91161-71-6 TERBINAFINE ADVERSE_EFFECT LIV_3_Hepatic Failure 91161-71-6 TERBINAFINE ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 91161-71-6 TERBINAFINE STRUCTURE_ACTIVITY Squalene epoxidase inhibitor 91161-71-6 TERBINAFINE ADVERSE_EFFECT GIS_1_Diarrhea 91161-71-6 TERBINAFINE THERAPEUTIC_CLASS Antifungals, Topical 91161-71-6 TERBINAFINE MECH_LEVEL_3 Squalene monooxygenase 91161-71-6 TERBINAFINE INDICATION Tinea Manuum / Tinea of Palms 91161-71-6 TERBINAFINE INDICATION Tinea Pedis / Athlete's Foot 91161-71-6 TERBINAFINE ADVERSE_EFFECT GIS_2_Abdominal Pain 91161-71-6 TERBINAFINE MESH_LEVEL_1 Polycyclic Hydrocarbons 91161-71-6 TERBINAFINE ADVERSE_EFFECT SKN_2_Rash 91161-71-6 TERBINAFINE MESH_LEVEL_3 Naphthalenes 91161-71-6 TERBINAFINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 91161-71-6 TERBINAFINE TISSUE_TOXICITY Hepatic Failure 91161-71-6 TERBINAFINE THERAPEUTIC_CLASS Antifungals 91161-71-6 TERBINAFINE ADVERSE_EFFECT GIS_2_Dyspepsia 91161-71-6 TERBINAFINE ADVERSE_EFFECT IMU_2_Urticaria 91161-71-6 TERBINAFINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91161-71-6 TERBINAFINE ADVERSE_EFFECT IMU_3_Anaphylaxis 91161-71-6 TERBINAFINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 91161-71-6 TERBINAFINE TA_LEVEL_2 Anti-fungal 91161-71-6 TERBINAFINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 91161-71-6 TERBINAFINE INDICATION Tinea Cruris / Jock Itch 91161-71-6 TERBINAFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 91161-71-6 TERBINAFINE TA_LEVEL_1 Infectious Disease 91161-71-6 TERBINAFINE ZERO_CLASS N 91161-71-6 TERBINAFINE ADVERSE_EFFECT XXX_2_Taste Disturbances 91161-71-6 TERBINAFINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 91161-71-6 TERBINAFINE ADVERSE_EFFECT XXX_2_Fatigue 91161-71-6 TERBINAFINE KNOWN_TOXICITY Hepatotoxicity 91161-71-6 TERBINAFINE MODE_CLASS Enzyme Inhibitor 91161-71-6 TERBINAFINE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 91161-71-6 TERBINAFINE INDICATION Tinea Unguium / Onychomycosis 91161-71-6 TERBINAFINE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 91161-71-6 TERBINAFINE PRODUCT_CLASS Anti-infectives 78628-80-5 TERBINAFINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 78628-80-5 TERBINAFINE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 78628-80-5 TERBINAFINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 78628-80-5 TERBINAFINE ADVERSE_EFFECT NEU_2_Headache 78628-80-5 TERBINAFINE THERAPEUTIC_CLASS Antifungals, Systemic 78628-80-5 TERBINAFINE INDICATION Tinea Versicolor / Pityriasis Versicolor 78628-80-5 TERBINAFINE TA_LEVEL_3 Systemic 78628-80-5 TERBINAFINE MECH_LEVEL_1 Anti-fungal 78628-80-5 TERBINAFINE MESH_LEVEL_3 Naphthalenes 78628-80-5 TERBINAFINE ADVERSE_EFFECT GIS_2_Abdominal Pain 78628-80-5 TERBINAFINE ADVERSE_EFFECT SKN_2_Rash 78628-80-5 TERBINAFINE ADVERSE_EFFECT GIS_1_Diarrhea 78628-80-5 TERBINAFINE THERAPEUTIC_CLASS Antifungals, Topical 78628-80-5 TERBINAFINE MECH_LEVEL_3 Squalene monooxygenase 78628-80-5 TERBINAFINE INDICATION Tinea Manuum / Tinea of Palms 78628-80-5 TERBINAFINE PRODUCT_CLASS Anti-infectives 78628-80-5 TERBINAFINE INDICATION Tinea Unguium / Onychomycosis 78628-80-5 TERBINAFINE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 78628-80-5 TERBINAFINE MODE_CLASS Enzyme Inhibitor 78628-80-5 TERBINAFINE KNOWN_TOXICITY Hepatotoxicity 78628-80-5 TERBINAFINE ADVERSE_EFFECT XXX_2_Fatigue 78628-80-5 TERBINAFINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 78628-80-5 TERBINAFINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 78628-80-5 TERBINAFINE ADVERSE_EFFECT XXX_2_Taste Disturbances 78628-80-5 TERBINAFINE TA_LEVEL_1 Infectious Disease 78628-80-5 TERBINAFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 78628-80-5 TERBINAFINE INDICATION Tinea Cruris / Jock Itch 78628-80-5 TERBINAFINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 78628-80-5 TERBINAFINE TA_LEVEL_2 Anti-fungal 78628-80-5 TERBINAFINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 78628-80-5 TERBINAFINE ZERO_CLASS N 78628-80-5 TERBINAFINE ADVERSE_EFFECT IMU_3_Anaphylaxis 78628-80-5 TERBINAFINE ADVERSE_EFFECT IMU_2_Urticaria 78628-80-5 TERBINAFINE ADVERSE_EFFECT GIS_2_Dyspepsia 78628-80-5 TERBINAFINE THERAPEUTIC_CLASS Antifungals 78628-80-5 TERBINAFINE TISSUE_TOXICITY Hepatic Failure 78628-80-5 TERBINAFINE MESH_LEVEL_1 Polycyclic Hydrocarbons 78628-80-5 TERBINAFINE INDICATION Tinea Pedis / Athlete's Foot 78628-80-5 TERBINAFINE STRUCTURE_ACTIVITY Squalene epoxidase inhibitor 78628-80-5 TERBINAFINE ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 78628-80-5 TERBINAFINE ADVERSE_EFFECT LIV_3_Hepatic Failure 23031-32-5 TERBUTALINE MESH_LEVEL_1 Organic Chemicals 23031-32-5 TERBUTALINE THERAPEUTIC_CLASS Bronchodilators 23031-32-5 TERBUTALINE ADVERSE_EFFECT XXX_3_Xerostomia 23031-32-5 TERBUTALINE ADVERSE_EFFECT CVS_1_Palpitation 23031-32-5 TERBUTALINE ADVERSE_EFFECT NEU_2_Dizziness 23031-32-5 TERBUTALINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 23031-32-5 TERBUTALINE ADVERSE_EFFECT PSY_3_Anxiety 23031-32-5 TERBUTALINE KNOWN_TOXICITY Cardiovascular Toxicity 23031-32-5 TERBUTALINE TISSUE_TOXICITY Arrhythmia 23031-32-5 TERBUTALINE ADVERSE_EFFECT PSY_2_Nervousness 23031-32-5 TERBUTALINE MODE_CLASS Receptor Agonist, selective 23031-32-5 TERBUTALINE INDICATION Bronchospasm 23031-32-5 TERBUTALINE PRODUCT_CLASS Respiratory System 23031-32-5 TERBUTALINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 23031-32-5 TERBUTALINE ZERO_CLASS N 23031-32-5 TERBUTALINE TA_LEVEL_2 Bronchodilator 23031-32-5 TERBUTALINE ACTIVITY_CLASS Adrenergic agonist 23031-32-5 TERBUTALINE MECHANISM Reduce bronchoconstriction 23031-32-5 TERBUTALINE STRUCTURE_ACTIVITY Adrenoceptor agonist 23031-32-5 TERBUTALINE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 23031-32-5 TERBUTALINE ADVERSE_EFFECT MSK_2_Muscle Cramps 23031-32-5 TERBUTALINE ADVERSE_EFFECT NEU_3_Drowsiness 23031-32-5 TERBUTALINE ADVERSE_EFFECT END_2_Hyperglycemia 23031-32-5 TERBUTALINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 23031-32-5 TERBUTALINE INDICATION Premature labor 23031-32-5 TERBUTALINE MESH_LEVEL_2 Amines 23031-32-5 TERBUTALINE ADVERSE_EFFECT GIS_3_Dysgeusia 23031-32-5 TERBUTALINE ADVERSE_EFFECT CVS_1_Arrhythmia 23031-32-5 TERBUTALINE ADVERSE_EFFECT XXX_3_Restlessness 23031-32-5 TERBUTALINE ADVERSE_EFFECT NEU_3_Seizures 23031-32-5 TERBUTALINE ADVERSE_EFFECT ELT_2_Hypokalemia 23031-32-5 TERBUTALINE ADVERSE_EFFECT NEU_3_Tremor 23031-32-5 TERBUTALINE TISSUE_TOXICITY Angina 23031-32-5 TERBUTALINE MECH_LEVEL_2 receptor agonist 23031-32-5 TERBUTALINE TA_LEVEL_3 Asthma 23031-32-5 TERBUTALINE MECH_LEVEL_1 Muscle relaxant 23031-32-5 TERBUTALINE ADVERSE_EFFECT XXX_2_Diaphoresis 23031-32-5 TERBUTALINE ADVERSE_EFFECT LUN_3_Wheezing 23031-32-5 TERBUTALINE ADVERSE_EFFECT LUN_2_Dyspnea 23031-32-5 TERBUTALINE ADVERSE_EFFECT XXX_3_Lethargy 23031-32-5 TERBUTALINE ADVERSE_EFFECT NEU_3_Headache 23031-32-5 TERBUTALINE ADVERSE_EFFECT CVS_3_Angina 23031-32-5 TERBUTALINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 23031-32-5 TERBUTALINE THERAPEUTIC_CLASS Sympathomimetic Agents 23031-32-5 TERBUTALINE MESH_LEVEL_3 Amino Alcohols 23031-32-5 TERBUTALINE INDICATION Asthma 23031-32-5 TERBUTALINE PRODUCT_CLASS Autonomic Nervous System (ANS) 23031-32-5 TERBUTALINE TA_LEVEL_1 Respiratory System 23031-32-5 TERBUTALINE MECH_LEVEL_3 adrenoceptor beta2, selective 67915-31-5 TERCONAZOLE PRODUCT_CLASS Anti-infectives 67915-31-5 TERCONAZOLE ADVERSE_EFFECT EMB_3_Embryotoxicity 67915-31-5 TERCONAZOLE ADVERSE_EFFECT GUS_2_Vulvovaginal Burning 67915-31-5 TERCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 67915-31-5 TERCONAZOLE ADVERSE_EFFECT XXX_3_Chills 67915-31-5 TERCONAZOLE ADVERSE_EFFECT GUS_2_Vulvovaginal Itchiness 67915-31-5 TERCONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, ketoconazole like 67915-31-5 TERCONAZOLE INDICATION Vulvovaginal Candidiasis 67915-31-5 TERCONAZOLE MODE_CLASS Enzyme Inhibitor 67915-31-5 TERCONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 67915-31-5 TERCONAZOLE ADVERSE_EFFECT NEU_2_Headache 67915-31-5 TERCONAZOLE ADVERSE_EFFECT GUS_2_Vulvovaginal Irritation 67915-31-5 TERCONAZOLE ADVERSE_EFFECT XXX_3_Fever 67915-31-5 TERCONAZOLE ADVERSE_EFFECT GUS_2_Vulvovaginal Pain 50679-08-8 TERFENADINE INDICATION Allergic Diseases 50679-08-8 TERFENADINE INDICATION Allergic Contact Dermatitis 50679-08-8 TERFENADINE MECHANISM Modulate G-protein coupled signal transduction 50679-08-8 TERFENADINE TISSUE_TOXICITY Ventricular Tachycardia 50679-08-8 TERFENADINE KNOWN_TOXICITY Cardiovascular Toxicity 50679-08-8 TERFENADINE ACTIVITY_CLASS Histamine antagonist 50679-08-8 TERFENADINE INDICATION Allergic Rhinitis 50679-08-8 TERFENADINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 50679-08-8 TERFENADINE ADVERSE_EFFECT CVS_3_Hypotension 50679-08-8 TERFENADINE ADVERSE_EFFECT NEU_2_Drowsiness 50679-08-8 TERFENADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 50679-08-8 TERFENADINE THERAPEUTIC_CLASS Antihistamines 50679-08-8 TERFENADINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 50679-08-8 TERFENADINE ADVERSE_EFFECT NEU_2_Headache 50679-08-8 TERFENADINE ADVERSE_EFFECT GIS_1_Dry Mouth 50679-08-8 TERFENADINE MODE_CLASS Receptor Ligand Antagonist, Selective 50679-08-8 TERFENADINE ADVERSE_EFFECT PSY_3_Anxiety 50679-08-8 TERFENADINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 50679-08-8 TERFENADINE ADVERSE_EFFECT GIS_2_Abdominal Pain 50679-08-8 TERFENADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 50679-08-8 TERFENADINE INDICATION Allergic Conjunctivitis 50679-08-8 TERFENADINE PRODUCT_CLASS Anti-inflammatories 50679-08-8 TERFENADINE TISSUE_TOXICITY Hypotension 50679-08-8 TERFENADINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 50679-08-8 TERFENADINE ADVERSE_EFFECT PSY_3_Insomnia 50679-08-8 TERFENADINE ADVERSE_EFFECT NEU_2_Dizziness 50679-08-8 TERFENADINE ADVERSE_EFFECT XXX_3_Restlessness 968-93-4 TESTOLACTONE INDICATION Breast Cancer / Carcinoma of the Breast 968-93-4 TESTOLACTONE MODE_CLASS Enzyme Inhibitor 968-93-4 TESTOLACTONE PRODUCT_CLASS Anti-cancers 968-93-4 TESTOLACTONE THERAPEUTIC_CLASS Antineoplastics 968-93-4 TESTOLACTONE MECHANISM Inhibit steroid biosynthesis/ metabolism 521-18-6 STANOLONE ADVERSE_EFFECT GUS_3_Prostatic Hypertrophy 521-18-6 STANOLONE KNOWN_TOXICITY Carcinogenicity 521-18-6 STANOLONE PRODUCT_CLASS Hematologics 521-18-6 STANOLONE KNOWN_TOXICITY Cardiovascular Toxicity 521-18-6 STANOLONE TISSUE_TOXICITY Myocardial Infarction 521-18-6 STANOLONE ADVERSE_EFFECT DNA_3_Carcinogenicity 521-18-6 STANOLONE ADVERSE_EFFECT REP_3_Impotence 521-18-6 STANOLONE ADVERSE_EFFECT SKN_1_Acne 521-18-6 STANOLONE ADVERSE_EFFECT END_3_Virilization 521-18-6 STANOLONE ADVERSE_EFFECT MSK_2_Muscular Hypertrophy 521-18-6 STANOLONE ADVERSE_EFFECT END_1_Impaired Glucose Tolerance 521-18-6 STANOLONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 521-18-6 STANOLONE MODE_CLASS Receptor Agonist 521-18-6 STANOLONE TISSUE_TOXICITY Stroke 521-18-6 STANOLONE MECHANISM Modulate gene transcription 521-18-6 STANOLONE ADVERSE_EFFECT KID_1_Fluid Retention 521-18-6 STANOLONE ADVERSE_EFFECT LUN_2_Deepening of Voice 521-18-6 STANOLONE STRUCTURE_ACTIVITY Androgen receptor agonist 521-18-6 STANOLONE INDICATION Aplastic Anemia 521-18-6 STANOLONE TISSUE_TOXICITY Carcinogenicity 521-18-6 STANOLONE INDICATION Androgen Deficiency 521-18-6 STANOLONE THERAPEUTIC_CLASS Gonadal Hormones 521-18-6 STANOLONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 521-18-6 STANOLONE ADVERSE_EFFECT KID_1_Salt Retention 521-18-6 STANOLONE ADVERSE_EFFECT REP_2_Menstrual Irregularities 521-18-6 STANOLONE ADVERSE_EFFECT LIV_3_Jaundice 521-18-6 STANOLONE ADVERSE_EFFECT MSK_2_Premature Closure of Epiphyseal Plate 521-18-6 STANOLONE ADVERSE_EFFECT REP_3_Azoospermia 521-18-6 STANOLONE ADVERSE_EFFECT CVS_3_Stroke 521-18-6 STANOLONE ADVERSE_EFFECT CVS_3_Myocardial Infarction 521-18-6 STANOLONE ADVERSE_EFFECT END_2_Hirsutism 521-18-6 STANOLONE ADVERSE_EFFECT PSY_3_Psychosis 521-18-6 STANOLONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 521-18-6 STANOLONE ADVERSE_EFFECT PSY_3_Mania 521-18-6 STANOLONE ADVERSE_EFFECT END_2_Hyperlipidemia 58-22-0 TESTOSTERONE ADVERSE_EFFECT SKN_2_Rash 58-22-0 TESTOSTERONE ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 58-22-0 TESTOSTERONE ADVERSE_EFFECT REP_3_Impotence 58-22-0 TESTOSTERONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 58-22-0 TESTOSTERONE ADVERSE_EFFECT GIS_1_Nausea 58-22-0 TESTOSTERONE THERAPEUTIC_CLASS Gonadal Hormones 58-22-0 TESTOSTERONE ADVERSE_EFFECT END_1_Virilization 58-22-0 TESTOSTERONE ADVERSE_EFFECT END_1_Hirsutism 58-22-0 TESTOSTERONE TISSUE_TOXICITY Teratogenicity 58-22-0 TESTOSTERONE ADVERSE_EFFECT NEU_3_Paresthesia 58-22-0 TESTOSTERONE ADVERSE_EFFECT SKN_1_Acne 58-22-0 TESTOSTERONE ADVERSE_EFFECT BBM_2_Polycythemia 58-22-0 TESTOSTERONE ADVERSE_EFFECT PSY_2_Depression 58-22-0 TESTOSTERONE ADVERSE_EFFECT CVS_2_Hypertension 58-22-0 TESTOSTERONE TISSUE_TOXICITY Carcinoma of Prostate 58-22-0 TESTOSTERONE INDICATION Androgen Deficiency 58-22-0 TESTOSTERONE MECHANISM Modulate gene transcription 58-22-0 TESTOSTERONE ADVERSE_EFFECT REP_2_Decline in Testis Size 58-22-0 TESTOSTERONE ADVERSE_EFFECT END_1_Gynecomastia 58-22-0 TESTOSTERONE ADVERSE_EFFECT NEU_2_Headache 58-22-0 TESTOSTERONE ADVERSE_EFFECT GUS_2_Prostatic Disorder 58-22-0 TESTOSTERONE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 58-22-0 TESTOSTERONE ADVERSE_EFFECT PSY_2_Anxiety 58-22-0 TESTOSTERONE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 58-22-0 TESTOSTERONE ADVERSE_EFFECT DNA_3_Carcinoma of Prostate 58-22-0 TESTOSTERONE TISSUE_TOXICITY Hepatocellular Carcinoma 58-22-0 TESTOSTERONE ACTIVITY_CLASS Androgen receptor agonist 58-22-0 TESTOSTERONE ADVERSE_EFFECT END_2_Hyperlipidemia 58-22-0 TESTOSTERONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 58-22-0 TESTOSTERONE TISSUE_TOXICITY Carcinogenicity 58-22-0 TESTOSTERONE ADVERSE_EFFECT KID_2_Fluid Retention 58-22-0 TESTOSTERONE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 58-22-0 TESTOSTERONE ADVERSE_EFFECT SKN_2_Dermatitis 58-22-0 TESTOSTERONE ADVERSE_EFFECT PSY_2_Irritability 58-22-0 TESTOSTERONE ADVERSE_EFFECT EMB_1_Teratogenicity 58-22-0 TESTOSTERONE ADVERSE_EFFECT DNA_3_Carcinogenicity 58-22-0 TESTOSTERONE ADVERSE_EFFECT REP_3_Priapism 58-22-0 TESTOSTERONE STRUCTURE_ACTIVITY Androgen receptor agonist 58-22-0 TESTOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 58-22-0 TESTOSTERONE KNOWN_TOXICITY Carcinogenicity 58-22-0 TESTOSTERONE KNOWN_TOXICITY Embryo/Fetal Toxicity 58-22-0 TESTOSTERONE INDICATION Male Hypogonadism 58-22-0 TESTOSTERONE INDICATION Delayed Puberty 58-22-0 TESTOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 58-22-0 TESTOSTERONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 58-22-0 TESTOSTERONE ADVERSE_EFFECT CVS_2_Peripheral Vascular Disorder 105165-22-8 TESTOSTERONE ADVERSE_EFFECT SKN_1_Acne 105165-22-8 TESTOSTERONE ADVERSE_EFFECT NEU_3_Paresthesia 105165-22-8 TESTOSTERONE TISSUE_TOXICITY Teratogenicity 105165-22-8 TESTOSTERONE THERAPEUTIC_CLASS Gonadal Hormones 105165-22-8 TESTOSTERONE ADVERSE_EFFECT END_1_Hirsutism 105165-22-8 TESTOSTERONE ADVERSE_EFFECT END_2_Hyperlipidemia 105165-22-8 TESTOSTERONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 105165-22-8 TESTOSTERONE TISSUE_TOXICITY Carcinogenicity 105165-22-8 TESTOSTERONE ADVERSE_EFFECT KID_2_Fluid Retention 105165-22-8 TESTOSTERONE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 105165-22-8 TESTOSTERONE ADVERSE_EFFECT SKN_2_Dermatitis 105165-22-8 TESTOSTERONE ADVERSE_EFFECT PSY_2_Irritability 105165-22-8 TESTOSTERONE ADVERSE_EFFECT EMB_1_Teratogenicity 105165-22-8 TESTOSTERONE ADVERSE_EFFECT DNA_3_Carcinogenicity 105165-22-8 TESTOSTERONE ADVERSE_EFFECT REP_3_Priapism 105165-22-8 TESTOSTERONE STRUCTURE_ACTIVITY Androgen receptor agonist 105165-22-8 TESTOSTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 105165-22-8 TESTOSTERONE TISSUE_TOXICITY Hepatocellular Carcinoma 105165-22-8 TESTOSTERONE ADVERSE_EFFECT DNA_3_Carcinoma of Prostate 105165-22-8 TESTOSTERONE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 105165-22-8 TESTOSTERONE ADVERSE_EFFECT PSY_2_Anxiety 105165-22-8 TESTOSTERONE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 105165-22-8 TESTOSTERONE ADVERSE_EFFECT GUS_2_Prostatic Disorder 105165-22-8 TESTOSTERONE ADVERSE_EFFECT NEU_2_Headache 105165-22-8 TESTOSTERONE ADVERSE_EFFECT END_1_Virilization 105165-22-8 TESTOSTERONE ADVERSE_EFFECT END_1_Gynecomastia 105165-22-8 TESTOSTERONE ACTIVITY_CLASS Androgen receptor agonist 105165-22-8 TESTOSTERONE ADVERSE_EFFECT REP_2_Decline in Testis Size 105165-22-8 TESTOSTERONE MECHANISM Modulate gene transcription 105165-22-8 TESTOSTERONE KNOWN_TOXICITY Carcinogenicity 105165-22-8 TESTOSTERONE KNOWN_TOXICITY Embryo/Fetal Toxicity 105165-22-8 TESTOSTERONE INDICATION Male Hypogonadism 105165-22-8 TESTOSTERONE INDICATION Delayed Puberty 105165-22-8 TESTOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 105165-22-8 TESTOSTERONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 105165-22-8 TESTOSTERONE ADVERSE_EFFECT CVS_2_Peripheral Vascular Disorder 105165-22-8 TESTOSTERONE ADVERSE_EFFECT SKN_2_Rash 105165-22-8 TESTOSTERONE ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 105165-22-8 TESTOSTERONE ADVERSE_EFFECT REP_3_Impotence 105165-22-8 TESTOSTERONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 105165-22-8 TESTOSTERONE ADVERSE_EFFECT GIS_1_Nausea 105165-22-8 TESTOSTERONE INDICATION Androgen Deficiency 105165-22-8 TESTOSTERONE TISSUE_TOXICITY Carcinoma of Prostate 105165-22-8 TESTOSTERONE ADVERSE_EFFECT CVS_2_Hypertension 105165-22-8 TESTOSTERONE ADVERSE_EFFECT PSY_2_Depression 105165-22-8 TESTOSTERONE ADVERSE_EFFECT BBM_2_Polycythemia 136-47-0 TETRACAINE TISSUE_TOXICITY Cardiovascular Collapse 136-47-0 TETRACAINE MESH_LEVEL_2 Carboxylic Acids 136-47-0 TETRACAINE MECHANISM Block neural transmission 136-47-0 TETRACAINE MECH_LEVEL_3 Voltage-gated Na+ channel 136-47-0 TETRACAINE INDICATION Local Anesthesia 136-47-0 TETRACAINE TA_LEVEL_2 Anesthesia 136-47-0 TETRACAINE MESH_LEVEL_3 Acids, Carbocyclic 136-47-0 TETRACAINE ACTIVITY_CLASS Na+ channel blocker 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_2_Prolonged PR Interval 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Arachnoiditis 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 136-47-0 TETRACAINE ADVERSE_EFFECT PSY_3_Confusion 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Coma 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Paresthesia 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 136-47-0 TETRACAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 136-47-0 TETRACAINE ADVERSE_EFFECT PSY_3_Nervousness 136-47-0 TETRACAINE ADVERSE_EFFECT GUS_3_Urinary Retention 136-47-0 TETRACAINE KNOWN_TOXICITY Cardiovascular Toxicity 136-47-0 TETRACAINE TISSUE_TOXICITY Cardiac Arrhythmia 136-47-0 TETRACAINE INDICATION Obstetric Anesthesia 136-47-0 TETRACAINE INDICATION Pain 136-47-0 TETRACAINE ZERO_CLASS N 136-47-0 TETRACAINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 136-47-0 TETRACAINE ADVERSE_EFFECT XXX_2_Burning Sensation 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 136-47-0 TETRACAINE ADVERSE_EFFECT IMU_2_Urticaria 136-47-0 TETRACAINE ADVERSE_EFFECT PSY_3_Disorientation 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Seizures 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Drowsiness 136-47-0 TETRACAINE ADVERSE_EFFECT OTO_3_Tinnitus 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Dizziness 136-47-0 TETRACAINE ADVERSE_EFFECT PSY_3_Anxiety 136-47-0 TETRACAINE ADVERSE_EFFECT OCU_3_Blurred Vision 136-47-0 TETRACAINE TISSUE_TOXICITY Atrial Fibrillation 136-47-0 TETRACAINE TISSUE_TOXICITY Cardiac Arrest 136-47-0 TETRACAINE ADVERSE_EFFECT SKN_2_Erythema 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 136-47-0 TETRACAINE THERAPEUTIC_CLASS Local Anesthetics 136-47-0 TETRACAINE MECH_LEVEL_1 Modulate neural transmission 136-47-0 TETRACAINE PRODUCT_CLASS Central Nervous System (CNS) 136-47-0 TETRACAINE INDICATION Infiltration Anesthesia 136-47-0 TETRACAINE INDICATION Pruritus / Itching 136-47-0 TETRACAINE INDICATION Spinal Anesthesia 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_First-Degree AV block 136-47-0 TETRACAINE ADVERSE_EFFECT OCU_3_Corneal Opacities 136-47-0 TETRACAINE ADVERSE_EFFECT MSK_3_Back Pain 136-47-0 TETRACAINE ADVERSE_EFFECT XXX_3_Restlessness 136-47-0 TETRACAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 136-47-0 TETRACAINE ADVERSE_EFFECT LUN_3_Bronchospasm 136-47-0 TETRACAINE ADVERSE_EFFECT SKN_1_Rash 136-47-0 TETRACAINE ADVERSE_EFFECT XXX_3_Edema 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_Hypotension 136-47-0 TETRACAINE TISSUE_TOXICITY First-Degree AV block 136-47-0 TETRACAINE ADVERSE_EFFECT OCU_3_Visual Impairment 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Fecal Incontinence 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 136-47-0 TETRACAINE ADVERSE_EFFECT SKN_2_Pruritis 136-47-0 TETRACAINE ADVERSE_EFFECT IMU_3_Anaphylaxis 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Tremor 136-47-0 TETRACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 136-47-0 TETRACAINE TISSUE_TOXICITY Myocardial Depression 136-47-0 TETRACAINE TISSUE_TOXICITY Hypotension 136-47-0 TETRACAINE INDICATION Ophthalmic anesthesia 136-47-0 TETRACAINE MODE_CLASS Channel Blocker 136-47-0 TETRACAINE INDICATION Topical Anesthesia 136-47-0 TETRACAINE MESH_LEVEL_1 Organic Chemicals 136-47-0 TETRACAINE MECH_LEVEL_2 Sodium channel antagonist 136-47-0 TETRACAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 136-47-0 TETRACAINE TA_LEVEL_3 Topical Local Anesthesia 136-47-0 TETRACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 136-47-0 TETRACAINE ADVERSE_EFFECT OCU_2_Keratitis 136-47-0 TETRACAINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 94-24-6 TETRACAINE ADVERSE_EFFECT SKN_1_Rash 94-24-6 TETRACAINE ADVERSE_EFFECT LUN_3_Bronchospasm 94-24-6 TETRACAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 94-24-6 TETRACAINE ADVERSE_EFFECT XXX_3_Restlessness 94-24-6 TETRACAINE ADVERSE_EFFECT SKN_2_Erythema 94-24-6 TETRACAINE ADVERSE_EFFECT MSK_3_Back Pain 94-24-6 TETRACAINE ADVERSE_EFFECT OCU_3_Corneal Opacities 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_First-Degree AV block 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 94-24-6 TETRACAINE TISSUE_TOXICITY Myocardial Depression 94-24-6 TETRACAINE TISSUE_TOXICITY Hypotension 94-24-6 TETRACAINE INDICATION Ophthalmic anesthesia 94-24-6 TETRACAINE MODE_CLASS Channel Blocker 94-24-6 TETRACAINE INDICATION Topical Anesthesia 94-24-6 TETRACAINE MESH_LEVEL_1 Organic Chemicals 94-24-6 TETRACAINE MECH_LEVEL_2 Sodium channel antagonist 94-24-6 TETRACAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 94-24-6 TETRACAINE TA_LEVEL_3 Topical Local Anesthesia 94-24-6 TETRACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 94-24-6 TETRACAINE ADVERSE_EFFECT OCU_2_Keratitis 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Arachnoiditis 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 94-24-6 TETRACAINE ADVERSE_EFFECT PSY_3_Confusion 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Coma 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Paresthesia 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 94-24-6 TETRACAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 94-24-6 TETRACAINE ADVERSE_EFFECT PSY_3_Nervousness 94-24-6 TETRACAINE ADVERSE_EFFECT GUS_3_Urinary Retention 94-24-6 TETRACAINE KNOWN_TOXICITY Cardiovascular Toxicity 94-24-6 TETRACAINE TISSUE_TOXICITY Cardiac Arrhythmia 94-24-6 TETRACAINE INDICATION Obstetric Anesthesia 94-24-6 TETRACAINE INDICATION Pain 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 94-24-6 TETRACAINE ZERO_CLASS N 94-24-6 TETRACAINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 94-24-6 TETRACAINE ADVERSE_EFFECT XXX_2_Burning Sensation 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 94-24-6 TETRACAINE ADVERSE_EFFECT IMU_2_Urticaria 94-24-6 TETRACAINE ADVERSE_EFFECT PSY_3_Disorientation 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Seizures 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Drowsiness 94-24-6 TETRACAINE ADVERSE_EFFECT OTO_3_Tinnitus 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Dizziness 94-24-6 TETRACAINE ADVERSE_EFFECT PSY_3_Anxiety 94-24-6 TETRACAINE ADVERSE_EFFECT OCU_3_Blurred Vision 94-24-6 TETRACAINE TISSUE_TOXICITY Atrial Fibrillation 94-24-6 TETRACAINE TISSUE_TOXICITY Cardiac Arrest 94-24-6 TETRACAINE THERAPEUTIC_CLASS Local Anesthetics 94-24-6 TETRACAINE MECH_LEVEL_1 Modulate neural transmission 94-24-6 TETRACAINE PRODUCT_CLASS Central Nervous System (CNS) 94-24-6 TETRACAINE INDICATION Infiltration Anesthesia 94-24-6 TETRACAINE INDICATION Pruritus / Itching 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_Hypotension 94-24-6 TETRACAINE TISSUE_TOXICITY First-Degree AV block 94-24-6 TETRACAINE TISSUE_TOXICITY Cardiovascular Collapse 94-24-6 TETRACAINE MESH_LEVEL_2 Carboxylic Acids 94-24-6 TETRACAINE MECHANISM Block neural transmission 94-24-6 TETRACAINE MECH_LEVEL_3 Voltage-gated Na+ channel 94-24-6 TETRACAINE INDICATION Spinal Anesthesia 94-24-6 TETRACAINE INDICATION Local Anesthesia 94-24-6 TETRACAINE TA_LEVEL_2 Anesthesia 94-24-6 TETRACAINE MESH_LEVEL_3 Acids, Carbocyclic 94-24-6 TETRACAINE ACTIVITY_CLASS Na+ channel blocker 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_2_Prolonged PR Interval 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 94-24-6 TETRACAINE ADVERSE_EFFECT OCU_3_Visual Impairment 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Fecal Incontinence 94-24-6 TETRACAINE ADVERSE_EFFECT XXX_3_Edema 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 94-24-6 TETRACAINE ADVERSE_EFFECT SKN_2_Pruritis 94-24-6 TETRACAINE ADVERSE_EFFECT IMU_3_Anaphylaxis 94-24-6 TETRACAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 94-24-6 TETRACAINE ADVERSE_EFFECT NEU_3_Tremor 64-75-5 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 64-75-5 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 64-75-5 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 64-75-5 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 64-75-5 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 64-75-5 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 64-75-5 TETRACYCLINE PRODUCT_CLASS Anti-infectives 64-75-5 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 64-75-5 TETRACYCLINE TA_LEVEL_1 Infectious Disease 64-75-5 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 64-75-5 TETRACYCLINE INDICATION Psittacosis / Ornithosis 64-75-5 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 64-75-5 TETRACYCLINE INDICATION Anthrax 64-75-5 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 64-75-5 TETRACYCLINE INDICATION Bacterial Conjunctivitis 64-75-5 TETRACYCLINE TA_LEVEL_2 Antibacterials 64-75-5 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 64-75-5 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 64-75-5 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 64-75-5 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 64-75-5 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 64-75-5 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 64-75-5 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 64-75-5 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 64-75-5 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 64-75-5 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 64-75-5 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 64-75-5 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 64-75-5 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 64-75-5 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 64-75-5 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 64-75-5 TETRACYCLINE INDICATION Yaws / Frambesia 64-75-5 TETRACYCLINE INDICATION Chancroid 64-75-5 TETRACYCLINE INDICATION Shigellosis 64-75-5 TETRACYCLINE INDICATION Plague 64-75-5 TETRACYCLINE INDICATION Pharyngitis 64-75-5 TETRACYCLINE INDICATION Otitis Media 64-75-5 TETRACYCLINE INDICATION Pneumonia 64-75-5 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 64-75-5 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 64-75-5 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 64-75-5 TETRACYCLINE ZERO_CLASS N 64-75-5 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 64-75-5 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 64-75-5 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 64-75-5 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 64-75-5 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 64-75-5 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 64-75-5 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 64-75-5 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 64-75-5 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 64-75-5 TETRACYCLINE INDICATION Skin and Skin Structure Infections 64-75-5 TETRACYCLINE INDICATION Relapsing Fever 64-75-5 TETRACYCLINE INDICATION Syphilis 64-75-5 TETRACYCLINE INDICATION Brucellosis 64-75-5 TETRACYCLINE INDICATION Sinusitis 64-75-5 TETRACYCLINE INDICATION Chronic Bronchitis 64-75-5 TETRACYCLINE INDICATION Proctitis 64-75-5 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 64-75-5 TETRACYCLINE INDICATION Acne / Acne Vulgaris 64-75-5 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 64-75-5 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 64-75-5 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 64-75-5 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 64-75-5 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 64-75-5 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 64-75-5 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 64-75-5 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 64-75-5 TETRACYCLINE INDICATION Actinomycosis 64-75-5 TETRACYCLINE INDICATION Tularemia 64-75-5 TETRACYCLINE INDICATION Cervicitis 64-75-5 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 64-75-5 TETRACYCLINE TA_LEVEL_3 systemic infections 64-75-5 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 64-75-5 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 60-54-8 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 60-54-8 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 60-54-8 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 60-54-8 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 60-54-8 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 60-54-8 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 60-54-8 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 60-54-8 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 60-54-8 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 60-54-8 TETRACYCLINE INDICATION Yaws / Frambesia 60-54-8 TETRACYCLINE INDICATION Chancroid 60-54-8 TETRACYCLINE INDICATION Shigellosis 60-54-8 TETRACYCLINE INDICATION Plague 60-54-8 TETRACYCLINE INDICATION Pharyngitis 60-54-8 TETRACYCLINE INDICATION Otitis Media 60-54-8 TETRACYCLINE INDICATION Pneumonia 60-54-8 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 60-54-8 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 60-54-8 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 60-54-8 TETRACYCLINE ZERO_CLASS N 60-54-8 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 60-54-8 TETRACYCLINE INDICATION Relapsing Fever 60-54-8 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 60-54-8 TETRACYCLINE TA_LEVEL_3 systemic infections 60-54-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 60-54-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 60-54-8 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 60-54-8 TETRACYCLINE INDICATION Acne / Acne Vulgaris 60-54-8 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 60-54-8 TETRACYCLINE INDICATION Proctitis 60-54-8 TETRACYCLINE INDICATION Chronic Bronchitis 60-54-8 TETRACYCLINE INDICATION Sinusitis 60-54-8 TETRACYCLINE INDICATION Brucellosis 60-54-8 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 60-54-8 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 60-54-8 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 60-54-8 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 60-54-8 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 60-54-8 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 60-54-8 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 60-54-8 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 60-54-8 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 60-54-8 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 60-54-8 TETRACYCLINE INDICATION Actinomycosis 60-54-8 TETRACYCLINE INDICATION Tularemia 60-54-8 TETRACYCLINE INDICATION Cervicitis 60-54-8 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 60-54-8 TETRACYCLINE INDICATION Syphilis 60-54-8 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 60-54-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 60-54-8 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 60-54-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 60-54-8 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 60-54-8 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 60-54-8 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 60-54-8 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 60-54-8 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 60-54-8 TETRACYCLINE PRODUCT_CLASS Anti-infectives 60-54-8 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 60-54-8 TETRACYCLINE TA_LEVEL_1 Infectious Disease 60-54-8 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 60-54-8 TETRACYCLINE INDICATION Psittacosis / Ornithosis 60-54-8 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 60-54-8 TETRACYCLINE INDICATION Anthrax 60-54-8 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 60-54-8 TETRACYCLINE INDICATION Bacterial Conjunctivitis 60-54-8 TETRACYCLINE TA_LEVEL_2 Antibacterials 60-54-8 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 60-54-8 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 60-54-8 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 60-54-8 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 60-54-8 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 60-54-8 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 60-54-8 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 60-54-8 TETRACYCLINE INDICATION Skin and Skin Structure Infections 6591-49-7 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 6591-49-7 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 6591-49-7 TETRACYCLINE TA_LEVEL_3 systemic infections 6591-49-7 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 6591-49-7 TETRACYCLINE INDICATION Tularemia 6591-49-7 TETRACYCLINE INDICATION Actinomycosis 6591-49-7 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 6591-49-7 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 6591-49-7 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 6591-49-7 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 6591-49-7 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 6591-49-7 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 6591-49-7 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 6591-49-7 TETRACYCLINE INDICATION Acne / Acne Vulgaris 6591-49-7 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 6591-49-7 TETRACYCLINE INDICATION Proctitis 6591-49-7 TETRACYCLINE INDICATION Chronic Bronchitis 6591-49-7 TETRACYCLINE INDICATION Sinusitis 6591-49-7 TETRACYCLINE INDICATION Brucellosis 6591-49-7 TETRACYCLINE INDICATION Syphilis 6591-49-7 TETRACYCLINE INDICATION Relapsing Fever 6591-49-7 TETRACYCLINE INDICATION Skin and Skin Structure Infections 6591-49-7 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 6591-49-7 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 6591-49-7 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 6591-49-7 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 6591-49-7 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 6591-49-7 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 6591-49-7 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 6591-49-7 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 6591-49-7 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 6591-49-7 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 6591-49-7 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 6591-49-7 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 6591-49-7 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 6591-49-7 TETRACYCLINE INDICATION Cervicitis 6591-49-7 TETRACYCLINE ZERO_CLASS N 6591-49-7 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 6591-49-7 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 6591-49-7 TETRACYCLINE INDICATION Pneumonia 6591-49-7 TETRACYCLINE INDICATION Otitis Media 6591-49-7 TETRACYCLINE INDICATION Pharyngitis 6591-49-7 TETRACYCLINE INDICATION Plague 6591-49-7 TETRACYCLINE INDICATION Shigellosis 6591-49-7 TETRACYCLINE INDICATION Chancroid 6591-49-7 TETRACYCLINE INDICATION Yaws / Frambesia 6591-49-7 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 6591-49-7 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 6591-49-7 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 6591-49-7 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 6591-49-7 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 6591-49-7 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 6591-49-7 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 6591-49-7 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 6591-49-7 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 6591-49-7 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 6591-49-7 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 6591-49-7 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 6591-49-7 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 6591-49-7 TETRACYCLINE TA_LEVEL_2 Antibacterials 6591-49-7 TETRACYCLINE INDICATION Bacterial Conjunctivitis 6591-49-7 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 6591-49-7 TETRACYCLINE INDICATION Anthrax 6591-49-7 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 6591-49-7 TETRACYCLINE INDICATION Psittacosis / Ornithosis 6591-49-7 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 6591-49-7 TETRACYCLINE TA_LEVEL_1 Infectious Disease 6591-49-7 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 6591-49-7 TETRACYCLINE PRODUCT_CLASS Anti-infectives 6591-49-7 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 8017-77-4 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 8017-77-4 TETRACYCLINE ZERO_CLASS N 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 8017-77-4 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 8017-77-4 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 8017-77-4 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 8017-77-4 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 8017-77-4 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 8017-77-4 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 8017-77-4 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 8017-77-4 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 8017-77-4 TETRACYCLINE INDICATION Skin and Skin Structure Infections 8017-77-4 TETRACYCLINE INDICATION Relapsing Fever 8017-77-4 TETRACYCLINE INDICATION Syphilis 8017-77-4 TETRACYCLINE INDICATION Brucellosis 8017-77-4 TETRACYCLINE INDICATION Sinusitis 8017-77-4 TETRACYCLINE INDICATION Chronic Bronchitis 8017-77-4 TETRACYCLINE INDICATION Proctitis 8017-77-4 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 8017-77-4 TETRACYCLINE INDICATION Acne / Acne Vulgaris 8017-77-4 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 8017-77-4 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 8017-77-4 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 8017-77-4 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 8017-77-4 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 8017-77-4 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 8017-77-4 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 8017-77-4 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 8017-77-4 TETRACYCLINE INDICATION Actinomycosis 8017-77-4 TETRACYCLINE INDICATION Tularemia 8017-77-4 TETRACYCLINE INDICATION Cervicitis 8017-77-4 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 8017-77-4 TETRACYCLINE TA_LEVEL_3 systemic infections 8017-77-4 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 8017-77-4 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 8017-77-4 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 8017-77-4 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 8017-77-4 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 8017-77-4 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 8017-77-4 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 8017-77-4 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 8017-77-4 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 8017-77-4 TETRACYCLINE PRODUCT_CLASS Anti-infectives 8017-77-4 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 8017-77-4 TETRACYCLINE TA_LEVEL_1 Infectious Disease 8017-77-4 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 8017-77-4 TETRACYCLINE INDICATION Psittacosis / Ornithosis 8017-77-4 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 8017-77-4 TETRACYCLINE INDICATION Anthrax 8017-77-4 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 8017-77-4 TETRACYCLINE INDICATION Bacterial Conjunctivitis 8017-77-4 TETRACYCLINE TA_LEVEL_2 Antibacterials 8017-77-4 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 8017-77-4 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 8017-77-4 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 8017-77-4 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 8017-77-4 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 8017-77-4 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 8017-77-4 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 8017-77-4 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 8017-77-4 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 8017-77-4 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 8017-77-4 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 8017-77-4 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 8017-77-4 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 8017-77-4 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 8017-77-4 TETRACYCLINE INDICATION Yaws / Frambesia 8017-77-4 TETRACYCLINE INDICATION Chancroid 8017-77-4 TETRACYCLINE INDICATION Shigellosis 8017-77-4 TETRACYCLINE INDICATION Plague 8017-77-4 TETRACYCLINE INDICATION Pharyngitis 8017-77-4 TETRACYCLINE INDICATION Otitis Media 8017-77-4 TETRACYCLINE INDICATION Pneumonia 8017-77-4 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 8017-77-4 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 8017-77-4 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 8026-72-0 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 8026-72-0 TETRACYCLINE ZERO_CLASS N 8026-72-0 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 8026-72-0 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 8026-72-0 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 8026-72-0 TETRACYCLINE INDICATION Chronic Bronchitis 8026-72-0 TETRACYCLINE INDICATION Sinusitis 8026-72-0 TETRACYCLINE INDICATION Brucellosis 8026-72-0 TETRACYCLINE INDICATION Syphilis 8026-72-0 TETRACYCLINE INDICATION Relapsing Fever 8026-72-0 TETRACYCLINE INDICATION Skin and Skin Structure Infections 8026-72-0 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 8026-72-0 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 8026-72-0 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 8026-72-0 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 8026-72-0 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 8026-72-0 TETRACYCLINE INDICATION Acne / Acne Vulgaris 8026-72-0 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 8026-72-0 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 8026-72-0 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 8026-72-0 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 8026-72-0 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 8026-72-0 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 8026-72-0 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 8026-72-0 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 8026-72-0 TETRACYCLINE INDICATION Actinomycosis 8026-72-0 TETRACYCLINE INDICATION Tularemia 8026-72-0 TETRACYCLINE INDICATION Cervicitis 8026-72-0 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 8026-72-0 TETRACYCLINE TA_LEVEL_3 systemic infections 8026-72-0 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 8026-72-0 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 8026-72-0 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 8026-72-0 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 8026-72-0 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 8026-72-0 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 8026-72-0 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 8026-72-0 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 8026-72-0 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 8026-72-0 TETRACYCLINE PRODUCT_CLASS Anti-infectives 8026-72-0 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 8026-72-0 TETRACYCLINE TA_LEVEL_1 Infectious Disease 8026-72-0 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 8026-72-0 TETRACYCLINE INDICATION Psittacosis / Ornithosis 8026-72-0 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 8026-72-0 TETRACYCLINE INDICATION Anthrax 8026-72-0 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 8026-72-0 TETRACYCLINE INDICATION Bacterial Conjunctivitis 8026-72-0 TETRACYCLINE TA_LEVEL_2 Antibacterials 8026-72-0 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 8026-72-0 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 8026-72-0 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 8026-72-0 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 8026-72-0 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 8026-72-0 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 8026-72-0 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 8026-72-0 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 8026-72-0 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 8026-72-0 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 8026-72-0 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 8026-72-0 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 8026-72-0 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 8026-72-0 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 8026-72-0 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 8026-72-0 TETRACYCLINE INDICATION Yaws / Frambesia 8026-72-0 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 8026-72-0 TETRACYCLINE INDICATION Chancroid 8026-72-0 TETRACYCLINE INDICATION Shigellosis 8026-72-0 TETRACYCLINE INDICATION Plague 8026-72-0 TETRACYCLINE INDICATION Pharyngitis 8026-72-0 TETRACYCLINE INDICATION Otitis Media 8026-72-0 TETRACYCLINE INDICATION Pneumonia 8026-72-0 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 8026-72-0 TETRACYCLINE INDICATION Proctitis 8026-72-0 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 90438-83-8 TETRACYCLINE INDICATION Pharyngitis 90438-83-8 TETRACYCLINE INDICATION Otitis Media 90438-83-8 TETRACYCLINE INDICATION Pneumonia 90438-83-8 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 90438-83-8 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 90438-83-8 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 90438-83-8 TETRACYCLINE ZERO_CLASS N 90438-83-8 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 90438-83-8 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 90438-83-8 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 90438-83-8 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 90438-83-8 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 90438-83-8 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 90438-83-8 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 90438-83-8 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 90438-83-8 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 90438-83-8 TETRACYCLINE INDICATION Skin and Skin Structure Infections 90438-83-8 TETRACYCLINE INDICATION Relapsing Fever 90438-83-8 TETRACYCLINE INDICATION Syphilis 90438-83-8 TETRACYCLINE INDICATION Brucellosis 90438-83-8 TETRACYCLINE INDICATION Sinusitis 90438-83-8 TETRACYCLINE INDICATION Chronic Bronchitis 90438-83-8 TETRACYCLINE INDICATION Proctitis 90438-83-8 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 90438-83-8 TETRACYCLINE INDICATION Acne / Acne Vulgaris 90438-83-8 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 90438-83-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 90438-83-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 90438-83-8 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 90438-83-8 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 90438-83-8 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 90438-83-8 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 90438-83-8 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 90438-83-8 TETRACYCLINE INDICATION Actinomycosis 90438-83-8 TETRACYCLINE INDICATION Tularemia 90438-83-8 TETRACYCLINE INDICATION Cervicitis 90438-83-8 TETRACYCLINE TA_LEVEL_3 systemic infections 90438-83-8 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 90438-83-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 90438-83-8 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 90438-83-8 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 90438-83-8 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 90438-83-8 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 90438-83-8 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 90438-83-8 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 90438-83-8 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 90438-83-8 TETRACYCLINE PRODUCT_CLASS Anti-infectives 90438-83-8 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 90438-83-8 TETRACYCLINE TA_LEVEL_1 Infectious Disease 90438-83-8 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 90438-83-8 TETRACYCLINE INDICATION Psittacosis / Ornithosis 90438-83-8 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 90438-83-8 TETRACYCLINE INDICATION Anthrax 90438-83-8 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 90438-83-8 TETRACYCLINE INDICATION Bacterial Conjunctivitis 90438-83-8 TETRACYCLINE TA_LEVEL_2 Antibacterials 90438-83-8 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 90438-83-8 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 90438-83-8 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 90438-83-8 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 90438-83-8 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 90438-83-8 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 90438-83-8 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 90438-83-8 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 90438-83-8 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 90438-83-8 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 90438-83-8 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 90438-83-8 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 90438-83-8 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 90438-83-8 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 90438-83-8 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 90438-83-8 TETRACYCLINE INDICATION Yaws / Frambesia 90438-83-8 TETRACYCLINE INDICATION Chancroid 90438-83-8 TETRACYCLINE INDICATION Shigellosis 90438-83-8 TETRACYCLINE INDICATION Plague 102030-19-3 TETRACYCLINE ZERO_CLASS N 102030-19-3 TETRACYCLINE INDICATION Brucellosis 102030-19-3 TETRACYCLINE INDICATION Syphilis 102030-19-3 TETRACYCLINE INDICATION Relapsing Fever 102030-19-3 TETRACYCLINE INDICATION Skin and Skin Structure Infections 102030-19-3 TETRACYCLINE KNOWN_TOXICITY Nephrotoxicity 102030-19-3 TETRACYCLINE TISSUE_TOXICITY Hepatic Failure 102030-19-3 TETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 102030-19-3 TETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 102030-19-3 TETRACYCLINE ADVERSE_EFFECT XXX_2_Candidiasis 102030-19-3 TETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 102030-19-3 TETRACYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_2_Abdominal Pain 102030-19-3 TETRACYCLINE ADVERSE_EFFECT OCU_3_Eye Irritation 102030-19-3 TETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 102030-19-3 TETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 102030-19-3 TETRACYCLINE INDICATION Pneumonia 102030-19-3 TETRACYCLINE INDICATION Otitis Media 102030-19-3 TETRACYCLINE INDICATION Pharyngitis 102030-19-3 TETRACYCLINE INDICATION Plague 102030-19-3 TETRACYCLINE INDICATION Shigellosis 102030-19-3 TETRACYCLINE INDICATION Chancroid 102030-19-3 TETRACYCLINE INDICATION Yaws / Frambesia 102030-19-3 TETRACYCLINE INDICATION Non-Gonococcal Urethritis 102030-19-3 TETRACYCLINE MESH_LEVEL_3 Naphthalenes 102030-19-3 TETRACYCLINE THERAPEUTIC_CLASS Antibacterials 102030-19-3 TETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT XXX_3_Glossitis 102030-19-3 TETRACYCLINE TISSUE_TOXICITY Teratogenicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT OCU_2_Blurred Vision 102030-19-3 TETRACYCLINE ADVERSE_EFFECT SKN_2_Rash 102030-19-3 TETRACYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 102030-19-3 TETRACYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 102030-19-3 TETRACYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 102030-19-3 TETRACYCLINE ADVERSE_EFFECT NEU_2_Tingling 102030-19-3 TETRACYCLINE ADVERSE_EFFECT NEU_2_Pseudotumor Cerebri 102030-19-3 TETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 102030-19-3 TETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 102030-19-3 TETRACYCLINE TA_LEVEL_2 Antibacterials 102030-19-3 TETRACYCLINE INDICATION Bacterial Conjunctivitis 102030-19-3 TETRACYCLINE INDICATION Urinary Tract Infection (UTI) 102030-19-3 TETRACYCLINE INDICATION Anthrax 102030-19-3 TETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 102030-19-3 TETRACYCLINE INDICATION Psittacosis / Ornithosis 102030-19-3 TETRACYCLINE INDICATION Lower Respiratory Tract Infection 102030-19-3 TETRACYCLINE TA_LEVEL_1 Infectious Disease 102030-19-3 TETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 102030-19-3 TETRACYCLINE PRODUCT_CLASS Anti-infectives 102030-19-3 TETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 102030-19-3 TETRACYCLINE TISSUE_TOXICITY Nephrotoxicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 102030-19-3 TETRACYCLINE ADVERSE_EFFECT NEU_2_Headache 102030-19-3 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT KID_3_Nephrotoxicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatic Failure 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_3_Gingivitis 102030-19-3 TETRACYCLINE MECH_LEVEL_1 Anti-bacterial 102030-19-3 TETRACYCLINE TA_LEVEL_3 systemic infections 102030-19-3 TETRACYCLINE INDICATION Lymphogranuloma Venereum (LGV) 102030-19-3 TETRACYCLINE INDICATION Cervicitis 102030-19-3 TETRACYCLINE INDICATION Tularemia 102030-19-3 TETRACYCLINE INDICATION Actinomycosis 102030-19-3 TETRACYCLINE INDICATION Upper Respiratory Tract Infection 102030-19-3 TETRACYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 102030-19-3 TETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 102030-19-3 TETRACYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 102030-19-3 TETRACYCLINE ADVERSE_EFFECT LIV_2_Hepatitis 102030-19-3 TETRACYCLINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_3_Esophagitis 102030-19-3 TETRACYCLINE ADVERSE_EFFECT GIS_3_Dysphagia 102030-19-3 TETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 102030-19-3 TETRACYCLINE INDICATION Acne / Acne Vulgaris 102030-19-3 TETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 102030-19-3 TETRACYCLINE INDICATION Proctitis 102030-19-3 TETRACYCLINE INDICATION Chronic Bronchitis 102030-19-3 TETRACYCLINE INDICATION Sinusitis 135991-95-6 TETRINDOLE MESYLATE INDICATION Depression 135991-95-6 TETRINDOLE MESYLATE PRODUCT_CLASS Central Nervous System (CNS) 135991-95-6 TETRINDOLE MESYLATE THERAPEUTIC_CLASS Antidepressants 4368-28-9 TETRODOTOXIN MODE_CLASS Channel Blocker 4368-28-9 TETRODOTOXIN MECHANISM Block neural transmission 4368-28-9 TETRODOTOXIN PRODUCT_CLASS Toxicants 4368-28-9 TETRODOTOXIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 67526-95-8 THAPSIGARGIN MECHANISM Modulate signal transduction 67526-95-8 THAPSIGARGIN MODE_CLASS Enzyme Inhibitor 58-55-9 THEOPHYLLINE TISSUE_TOXICITY Ventricular Arrhythmia 58-55-9 THEOPHYLLINE MECHANISM Modulate G-protein coupled signal transduction 58-55-9 THEOPHYLLINE MECH_LEVEL_1 Bronchodilation 58-55-9 THEOPHYLLINE MECH_LEVEL_2 PDE inhibition 58-55-9 THEOPHYLLINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 58-55-9 THEOPHYLLINE TA_LEVEL_3 PDE inhibitors 58-55-9 THEOPHYLLINE MESH_LEVEL_3 Xanthine Alkaloids 58-55-9 THEOPHYLLINE INDICATION Asthma 58-55-9 THEOPHYLLINE TA_LEVEL_1 Respiratory System 58-55-9 THEOPHYLLINE MECHANISM Reduce bronchoconstriction 58-55-9 THEOPHYLLINE MODE_CLASS Receptor Agonist 58-55-9 THEOPHYLLINE THERAPEUTIC_CLASS Bronchodilators 58-55-9 THEOPHYLLINE ADVERSE_EFFECT PSY_1_Nervousness 58-55-9 THEOPHYLLINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 58-55-9 THEOPHYLLINE ZERO_CLASS N 58-55-9 THEOPHYLLINE ACTIVITY_CLASS Adenosine receptor antagonist, xanthine 58-55-9 THEOPHYLLINE MESH_LEVEL_2 Alkaloids 58-55-9 THEOPHYLLINE MODE_CLASS Receptor Ligand Antagonist 58-55-9 THEOPHYLLINE ADVERSE_EFFECT CVS_2_Hypotension 58-55-9 THEOPHYLLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 58-55-9 THEOPHYLLINE ADVERSE_EFFECT XXX_3_Death 58-55-9 THEOPHYLLINE TA_LEVEL_2 bronchiodialation 58-55-9 THEOPHYLLINE MECHANISM Enhance kinase mediated signal transduction 58-55-9 THEOPHYLLINE INDICATION Prophylaxis of Bronchospasm 58-55-9 THEOPHYLLINE MODE_CLASS Enzyme Inhibitor 58-55-9 THEOPHYLLINE TISSUE_TOXICITY Hypotension 58-55-9 THEOPHYLLINE TISSUE_TOXICITY Death 58-55-9 THEOPHYLLINE ADVERSE_EFFECT NEU_3_Convulsions 58-55-9 THEOPHYLLINE ADVERSE_EFFECT END_3_Hyperglycemia 58-55-9 THEOPHYLLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 58-55-9 THEOPHYLLINE STRUCTURE_ACTIVITY Adenosine receptor antagonist, xanthine 58-55-9 THEOPHYLLINE KNOWN_TOXICITY Cardiovascular Toxicity 58-55-9 THEOPHYLLINE MESH_LEVEL_1 Heterocyclic Compounds 58-55-9 THEOPHYLLINE MECH_LEVEL_3 adenosine receptor A1 and A2, beta receptors, and PDE 58-55-9 THEOPHYLLINE PRODUCT_CLASS Respiratory System 58-55-9 THEOPHYLLINE KNOWN_TOXICITY Miscellaneous 58-55-9 THEOPHYLLINE ADVERSE_EFFECT ELT_3_Hypokalemia 58-55-9 THEOPHYLLINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 58-55-9 THEOPHYLLINE ADVERSE_EFFECT NEU_1_Tremor 169970-69-8 THEOPHYLLINE RUTOSIDE MECHANISM Modulate G-protein coupled signal transduction 169970-69-8 THEOPHYLLINE RUTOSIDE MODE_CLASS Receptor Ligand Antagonist 169970-69-8 THEOPHYLLINE RUTOSIDE MECHANISM Reduce bronchoconstriction 169970-69-8 THEOPHYLLINE RUTOSIDE MODE_CLASS Enzyme Inhibitor 169970-69-8 THEOPHYLLINE RUTOSIDE MECHANISM Enhance kinase mediated signal transduction 169970-69-8 THEOPHYLLINE RUTOSIDE MODE_CLASS Receptor Agonist 148-79-8 THIABENDAZOLE ADVERSE_EFFECT OCU_3_Blurred Vision 148-79-8 THIABENDAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 148-79-8 THIABENDAZOLE INDICATION Trichuriasis / Trichocephaliasis / Whipworm 148-79-8 THIABENDAZOLE INDICATION Visceral Larva Migrans / Toxocariasis 148-79-8 THIABENDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 148-79-8 THIABENDAZOLE ADVERSE_EFFECT IMU_3_Hypersensitivity 148-79-8 THIABENDAZOLE PRODUCT_CLASS Anti-infectives 148-79-8 THIABENDAZOLE KNOWN_TOXICITY Cardiovascular Toxicity 148-79-8 THIABENDAZOLE INDICATION Helminthic Infections 148-79-8 THIABENDAZOLE ZERO_CLASS N 148-79-8 THIABENDAZOLE ADVERSE_EFFECT EMB_3_Teratogenicity 148-79-8 THIABENDAZOLE TISSUE_TOXICITY Teratogenicity 148-79-8 THIABENDAZOLE ADVERSE_EFFECT XXX_3_Sjogren's Syndrome (Sicca Syndrome) 148-79-8 THIABENDAZOLE ADVERSE_EFFECT NEU_2_Numbness 148-79-8 THIABENDAZOLE ADVERSE_EFFECT GIS_2_Epigastric Pain 148-79-8 THIABENDAZOLE ADVERSE_EFFECT SKN_3_Erythema Multiforme 148-79-8 THIABENDAZOLE ADVERSE_EFFECT NEU_2_Drowsiness 148-79-8 THIABENDAZOLE ADVERSE_EFFECT NEU_1_Dizziness 148-79-8 THIABENDAZOLE ADVERSE_EFFECT CVS_3_Hypotension 148-79-8 THIABENDAZOLE MECH_LEVEL_2 Inhibit microtubule dependent glucose uptake 148-79-8 THIABENDAZOLE INDICATION Trichinosis / Trichinelliosis / Trichinellosis 148-79-8 THIABENDAZOLE TA_LEVEL_3 antiparasitic imidazoles 148-79-8 THIABENDAZOLE MECH_LEVEL_1 anthelmintic 148-79-8 THIABENDAZOLE MECH_LEVEL_3 Microtubule / tubulin 148-79-8 THIABENDAZOLE KNOWN_TOXICITY Nephrotoxicity 148-79-8 THIABENDAZOLE ADVERSE_EFFECT OCU_3_Xanthopsia 148-79-8 THIABENDAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 148-79-8 THIABENDAZOLE ADVERSE_EFFECT BBM_3_Leukopenia 148-79-8 THIABENDAZOLE ADVERSE_EFFECT OTO_3_Tinnitus 148-79-8 THIABENDAZOLE ADVERSE_EFFECT PSY_1_Anorexia 148-79-8 THIABENDAZOLE ADVERSE_EFFECT NEU_3_Convulsions 148-79-8 THIABENDAZOLE TISSUE_TOXICITY Hypotension 148-79-8 THIABENDAZOLE TA_LEVEL_2 anthelmintic 148-79-8 THIABENDAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 148-79-8 THIABENDAZOLE INDICATION Strongyloidiasis 148-79-8 THIABENDAZOLE MESH_LEVEL_3 Benzimidazoles 148-79-8 THIABENDAZOLE THERAPEUTIC_CLASS Antiparasitics 148-79-8 THIABENDAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 148-79-8 THIABENDAZOLE KNOWN_TOXICITY Hepatotoxicity 148-79-8 THIABENDAZOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 148-79-8 THIABENDAZOLE ADVERSE_EFFECT LIV_3_Jaundice 148-79-8 THIABENDAZOLE ADVERSE_EFFECT KID_3_Hematuria 148-79-8 THIABENDAZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 148-79-8 THIABENDAZOLE ADVERSE_EFFECT IMU_3_Anaphylaxis 148-79-8 THIABENDAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 148-79-8 THIABENDAZOLE ADVERSE_EFFECT GIS_2_Diarrhea 148-79-8 THIABENDAZOLE TISSUE_TOXICITY Hematuria 148-79-8 THIABENDAZOLE TISSUE_TOXICITY Hepatotoxicity 148-79-8 THIABENDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 148-79-8 THIABENDAZOLE INDICATION Cutaneous Larva Migrans / Creeping Eruption 148-79-8 THIABENDAZOLE TA_LEVEL_1 Infectious Disease 148-79-8 THIABENDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 148-79-8 THIABENDAZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 148-79-8 THIABENDAZOLE TISSUE_TOXICITY Hepatic Failure 148-79-8 THIABENDAZOLE ADVERSE_EFFECT XXX_3_Dryness of Mucus Membrane 148-79-8 THIABENDAZOLE ADVERSE_EFFECT LIV_3_Cholestasis 148-79-8 THIABENDAZOLE ADVERSE_EFFECT NEU_2_Paresthesia 148-79-8 THIABENDAZOLE ADVERSE_EFFECT NEU_2_Headache 67-03-8 THIAMINE MECHANISM Vitamin/ cofactor 59-43-8 THIAMINE MECHANISM Vitamin/ cofactor 1420-55-9 THIETHYLPERAZINE MODE_CLASS Receptor Ligand Antagonist 1420-55-9 THIETHYLPERAZINE THERAPEUTIC_CLASS Antiemetics 1420-55-9 THIETHYLPERAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 1420-55-9 THIETHYLPERAZINE PRODUCT_CLASS Gastrointestinal System 1420-55-9 THIETHYLPERAZINE INDICATION Nausea / Vomiting 1420-55-9 THIETHYLPERAZINE MECHANISM Block neural transmission 54-64-8 THIMEROSAL INDICATION Skin Antisepsis 54-64-8 THIMEROSAL MESH_LEVEL_3 Organomercury Compounds 54-64-8 THIMEROSAL ZERO_CLASS N 54-64-8 THIMEROSAL ADVERSE_EFFECT XXX_1_Injection Site Reaction 54-64-8 THIMEROSAL ADVERSE_EFFECT SKN_1_Papular Rash 54-64-8 THIMEROSAL ADVERSE_EFFECT IMU_1_Hypersensitivity Reactions 54-64-8 THIMEROSAL ADVERSE_EFFECT CVS_2_Vascular Disorder 54-64-8 THIMEROSAL MODE_CLASS Distorts /blocks macromolecular scaffold function 54-64-8 THIMEROSAL MECHANISM Modulate G-protein coupled signal transduction 54-64-8 THIMEROSAL ADVERSE_EFFECT PSN_1_Mercury Poisoning 54-64-8 THIMEROSAL ADVERSE_EFFECT SKN_2_Skin Reactions 54-64-8 THIMEROSAL ADVERSE_EFFECT SKN_1_Erythema 54-64-8 THIMEROSAL THERAPEUTIC_CLASS Antibacterials, Topical 54-64-8 THIMEROSAL MECH_LEVEL_2 reactive sulfhydryl group? 54-64-8 THIMEROSAL ACTIVITY_CLASS Toxicant 54-64-8 THIMEROSAL TA_LEVEL_3 Antibacterials, Topical 54-64-8 THIMEROSAL MECH_LEVEL_3 Unknown mechanism 54-64-8 THIMEROSAL MECH_LEVEL_1 Preservative 54-64-8 THIMEROSAL TA_LEVEL_1 Infectious Disease 54-64-8 THIMEROSAL ADVERSE_EFFECT NEU_3_Neurotoxicity 54-64-8 THIMEROSAL TA_LEVEL_2 Anti-bacterial 54-64-8 THIMEROSAL MESH_LEVEL_1 Organic Chemicals 54-64-8 THIMEROSAL PRODUCT_CLASS Anti-infectives 54-64-8 THIMEROSAL TISSUE_TOXICITY Mercury Poisoning 54-64-8 THIMEROSAL KNOWN_TOXICITY Poisoning 54-64-8 THIMEROSAL MESH_LEVEL_2 Organometallic Compounds 54-64-8 THIMEROSAL STRUCTURE_ACTIVITY Toxicant, heavy metal 154-42-7 THIOGUANINE ADVERSE_EFFECT GIS_2_Stomatitis 154-42-7 THIOGUANINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 154-42-7 THIOGUANINE MODE_CLASS Enzyme substrate mimic 154-42-7 THIOGUANINE INDICATION Acute Non-Lymphocytic Leukemia 154-42-7 THIOGUANINE ADVERSE_EFFECT DNA_2_Carcinogenicity 154-42-7 THIOGUANINE ADVERSE_EFFECT GIS_2_Vomiting 154-42-7 THIOGUANINE ADVERSE_EFFECT XXX_1_Infection 154-42-7 THIOGUANINE ADVERSE_EFFECT BBM_1_Myelotoxicity 154-42-7 THIOGUANINE ADVERSE_EFFECT LIV_3_Liver Fibrosis 154-42-7 THIOGUANINE TISSUE_TOXICITY Carcinogenicity 154-42-7 THIOGUANINE KNOWN_TOXICITY Carcinogenicity 154-42-7 THIOGUANINE TISSUE_TOXICITY Myelosuppression 154-42-7 THIOGUANINE KNOWN_TOXICITY Embryo/Fetal Toxicity 154-42-7 THIOGUANINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 154-42-7 THIOGUANINE PRODUCT_CLASS Anti-cancers 154-42-7 THIOGUANINE TA_LEVEL_1 Oncology 154-42-7 THIOGUANINE INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 154-42-7 THIOGUANINE ADVERSE_EFFECT GIS_2_Diarrhea 154-42-7 THIOGUANINE ADVERSE_EFFECT KID_1_Hyperuricemia 154-42-7 THIOGUANINE TA_LEVEL_3 Solid and soft tumors 154-42-7 THIOGUANINE ADVERSE_EFFECT DNA_2_Mutagenicity 154-42-7 THIOGUANINE ADVERSE_EFFECT GIS_2_Nausea 154-42-7 THIOGUANINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 154-42-7 THIOGUANINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 154-42-7 THIOGUANINE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 154-42-7 THIOGUANINE TISSUE_TOXICITY Mutagenicity 154-42-7 THIOGUANINE KNOWN_TOXICITY Mutagenicity 154-42-7 THIOGUANINE TISSUE_TOXICITY Myelotoxicity 154-42-7 THIOGUANINE KNOWN_TOXICITY Hepatotoxicity 154-42-7 THIOGUANINE MESH_LEVEL_3 Purines 154-42-7 THIOGUANINE MECHANISM Incorporate into DNA/RNA/Protein 154-42-7 THIOGUANINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 154-42-7 THIOGUANINE TISSUE_TOXICITY Liver Fibrosis 154-42-7 THIOGUANINE THERAPEUTIC_CLASS Antineoplastics 154-42-7 THIOGUANINE ADVERSE_EFFECT EMB_1_Teratogenicity 154-42-7 THIOGUANINE ADVERSE_EFFECT PSY_2_Anorexia 154-42-7 THIOGUANINE ADVERSE_EFFECT BBM_2_Anemia 154-42-7 THIOGUANINE ADVERSE_EFFECT BBM_1_Leukopenia 154-42-7 THIOGUANINE ADVERSE_EFFECT LIV_3_Portal Hypertension 154-42-7 THIOGUANINE ZERO_CLASS N 154-42-7 THIOGUANINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 154-42-7 THIOGUANINE MESH_LEVEL_1 Heterocyclic Compounds 154-42-7 THIOGUANINE INDICATION Acute Lymphocytic Leukemia (ALL) 154-42-7 THIOGUANINE TISSUE_TOXICITY Teratogenicity 154-42-7 THIOGUANINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 154-42-7 THIOGUANINE ADVERSE_EFFECT BBM_1_Myelosuppression 154-42-7 THIOGUANINE ADVERSE_EFFECT GIS_3_Esophageal Varices 154-42-7 THIOGUANINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, thiopurine base 154-42-7 THIOGUANINE TISSUE_TOXICITY Hepatotoxicity 154-42-7 THIOGUANINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 154-42-7 THIOGUANINE TA_LEVEL_2 DNA synthesis inhibitors 154-42-7 THIOGUANINE TISSUE_TOXICITY Leukopenia 154-42-7 THIOGUANINE MECH_LEVEL_3 DNA-directed DNA polymerase 71-73-8 THIOPENTAL MECHANISM Modulate neural transmission 71-73-8 THIOPENTAL PRODUCT_CLASS Central Nervous System (CNS) 71-73-8 THIOPENTAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 71-73-8 THIOPENTAL MODE_CLASS Channel Blocker 71-73-8 THIOPENTAL INDICATION Status Epilepticus 71-73-8 THIOPENTAL THERAPEUTIC_CLASS Sedatives/Hypnotics 71-73-8 THIOPENTAL MODE_CLASS Channel Modulator 71-73-8 THIOPENTAL INDICATION Initiation / Maintenance of Sedation 71-73-8 THIOPENTAL MECHANISM Block channel gating 71-73-8 THIOPENTAL INDICATION Narcoanalysis 71-73-8 THIOPENTAL THERAPEUTIC_CLASS General Anesthetics, Intravenous 71-73-8 THIOPENTAL INDICATION Induction / Maintenance of Anesthesia 71-73-8 THIOPENTAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 106243-16-7 THIOPERAMIDE STRUCTURE_ACTIVITY Histamine receptor (H3) antagonist 106243-16-7 THIOPERAMIDE PRODUCT_CLASS Biochemicals 106243-16-7 THIOPERAMIDE MODE_CLASS Receptor Ligand Antagonist 106243-16-7 THIOPERAMIDE MECHANISM Modulate G-protein coupled signal transduction 50-52-2 THIORIDAZINE MODE_CLASS Receptor Ligand Antagonist 50-52-2 THIORIDAZINE PRODUCT_CLASS Central Nervous System (CNS) 50-52-2 THIORIDAZINE MECHANISM Block neural transmission 50-52-2 THIORIDAZINE MESH_LEVEL_1 Heterocyclic Compounds 50-52-2 THIORIDAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 50-52-2 THIORIDAZINE ADVERSE_EFFECT XXX_3_Breast Enlargement 50-52-2 THIORIDAZINE ADVERSE_EFFECT REP_3_Priapism 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 50-52-2 THIORIDAZINE ADVERSE_EFFECT LIV_3_Jaundice 50-52-2 THIORIDAZINE ADVERSE_EFFECT BBM_3_Leukopenia 50-52-2 THIORIDAZINE ADVERSE_EFFECT BBM_3_Leukocytosis 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_1_Parkinson-Like Syndrome 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_3_Seizures 50-52-2 THIORIDAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-52-2 THIORIDAZINE INDICATION Depression 50-52-2 THIORIDAZINE INDICATION Dementia 50-52-2 THIORIDAZINE ADVERSE_EFFECT CVS_3_Hypertension 50-52-2 THIORIDAZINE ADVERSE_EFFECT OCU_2_Blurred Vision 50-52-2 THIORIDAZINE KNOWN_TOXICITY Cardiovascular Toxicity 50-52-2 THIORIDAZINE TISSUE_TOXICITY Hypotension 50-52-2 THIORIDAZINE INDICATION Anxiety 50-52-2 THIORIDAZINE MECH_LEVEL_1 Modulate neural transmission 50-52-2 THIORIDAZINE TA_LEVEL_2 CNS Depressant 50-52-2 THIORIDAZINE MECH_LEVEL_2 Dopamine antagonist 50-52-2 THIORIDAZINE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 50-52-2 THIORIDAZINE ADVERSE_EFFECT XXX_2_Xerostomia 50-52-2 THIORIDAZINE ADVERSE_EFFECT BBM_3_Pancytopenia 50-52-2 THIORIDAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 50-52-2 THIORIDAZINE ADVERSE_EFFECT REP_3_Decreased Libido 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_1_Akathisia 50-52-2 THIORIDAZINE ADVERSE_EFFECT XXX_2_Restlessness 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_2_Headache 50-52-2 THIORIDAZINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 50-52-2 THIORIDAZINE ADVERSE_EFFECT OCU_2_Mydriasis 50-52-2 THIORIDAZINE TA_LEVEL_3 Antipsychotics 50-52-2 THIORIDAZINE INDICATION Agitation 50-52-2 THIORIDAZINE INDICATION Schizophrenia 50-52-2 THIORIDAZINE ACTIVITY_CLASS Dopamine antagonist 50-52-2 THIORIDAZINE TISSUE_TOXICITY Cardiac Arrhythmia 50-52-2 THIORIDAZINE ADVERSE_EFFECT OCU_3_Corneal Opacities 50-52-2 THIORIDAZINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 50-52-2 THIORIDAZINE ADVERSE_EFFECT END_3_Galactorrhea 50-52-2 THIORIDAZINE ADVERSE_EFFECT IMU_3_Photosensitivity 50-52-2 THIORIDAZINE ADVERSE_EFFECT XXX_3_Weight Gain 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_1_Dystonia 50-52-2 THIORIDAZINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_2_Drowsiness 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_2_Dizziness 50-52-2 THIORIDAZINE ADVERSE_EFFECT PSY_3_Insomnia 50-52-2 THIORIDAZINE ADVERSE_EFFECT PSY_3_Depression 50-52-2 THIORIDAZINE ADVERSE_EFFECT GUS_3_Urinary Retention 50-52-2 THIORIDAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 50-52-2 THIORIDAZINE ADVERSE_EFFECT REP_3_Impotence 50-52-2 THIORIDAZINE INDICATION Psychotic Depression 50-52-2 THIORIDAZINE MESH_LEVEL_3 Phenothiazines 50-52-2 THIORIDAZINE MECH_LEVEL_3 dopamine receptor D2 50-52-2 THIORIDAZINE TA_LEVEL_1 Central Nervous System (CNS) 50-52-2 THIORIDAZINE ZERO_CLASS N 50-52-2 THIORIDAZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 50-52-2 THIORIDAZINE ADVERSE_EFFECT NEU_3_Cerebral Edema 50-52-2 THIORIDAZINE ADVERSE_EFFECT REP_3_Ejaculatory Disorder 50-52-2 THIORIDAZINE ADVERSE_EFFECT IMU_3_Eosinophilia 50-52-2 THIORIDAZINE ADVERSE_EFFECT LIV_3_Cholestasis 50-52-2 THIORIDAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 50-52-2 THIORIDAZINE THERAPEUTIC_CLASS Antipsychotics 50-52-2 THIORIDAZINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 50-52-2 THIORIDAZINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 50-52-2 THIORIDAZINE ADVERSE_EFFECT XXX_3_Withdrawal 50-52-2 THIORIDAZINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 50-52-2 THIORIDAZINE ADVERSE_EFFECT GIS_2_Nausea 50-52-2 THIORIDAZINE ADVERSE_EFFECT CVS_3_Hypotension 50-52-2 THIORIDAZINE ADVERSE_EFFECT GIS_2_Constipation 52-24-4 THIOTEPA MODE_CLASS Distorts /blocks macromolecular scaffold function 52-24-4 THIOTEPA MECHANISM Inhibit DNA synthesis, repair, and function 5591-45-7 THIOTHIXENE MODE_CLASS Receptor Ligand Antagonist 5591-45-7 THIOTHIXENE MODE_CLASS Enzyme Inhibitor 5591-45-7 THIOTHIXENE MECHANISM Block neural transmission 3313-26-6 THIOTHIXENE MECHANISM Block neural transmission 3313-26-6 THIOTHIXENE MODE_CLASS Receptor Ligand Antagonist 3313-26-6 THIOTHIXENE MODE_CLASS Enzyme Inhibitor 137-26-8 THIRAM MODE_CLASS Distorts /blocks macromolecular scaffold function 137-26-8 THIRAM MECHANISM Interferes with phospholipid metabolism 137-26-8 THIRAM MODE_CLASS Enzyme Inhibitor 137-26-8 THIRAM MECHANISM Interferes with neural transmitter synthesis 137-26-8 THIRAM MECHANISM Inhibit DNA synthesis, repair, and function 24305-27-9 THYROTROPIN RELEASING HORMONE PRODUCT_CLASS Biochemicals 24305-27-9 THYROTROPIN RELEASING HORMONE MODE_CLASS Receptor /Channel ligand mimic 115103-54-3 TIAGABINE MODE_CLASS Solute transporter inhibitor 115103-54-3 TIAGABINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 115103-54-3 TIAGABINE INDICATION Partial Seizures 115103-54-3 TIAGABINE MECHANISM Prolong/enhance neural transmission 115103-54-3 TIAGABINE PRODUCT_CLASS Central Nervous System (CNS) 115103-54-3 TIAGABINE STRUCTURE_ACTIVITY GABA reuptake inhibitor 145821-59-6 TIAGABINE INDICATION Partial Seizures 145821-59-6 TIAGABINE MECHANISM Prolong/enhance neural transmission 145821-59-6 TIAGABINE PRODUCT_CLASS Central Nervous System (CNS) 145821-59-6 TIAGABINE STRUCTURE_ACTIVITY GABA reuptake inhibitor 145821-59-6 TIAGABINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 145821-59-6 TIAGABINE MODE_CLASS Solute transporter inhibitor 34787-01-4 TICARCILLIN MODE_CLASS Enzyme Inhibitor 34787-01-4 TICARCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 34787-01-4 TICARCILLIN PRODUCT_CLASS Anti-infectives 34787-01-4 TICARCILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 4697-14-7 TICARCILLIN MODE_CLASS Enzyme Inhibitor 4697-14-7 TICARCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 4697-14-7 TICARCILLIN PRODUCT_CLASS Anti-infectives 4697-14-7 TICARCILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 53885-35-1 TICLOPIDINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_3_Thrombocytosis 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 53885-35-1 TICLOPIDINE ZERO_CLASS N 53885-35-1 TICLOPIDINE MECH_LEVEL_2 inhibit the activation of GPIIb-IIIa mediated platelet aggregation. 53885-35-1 TICLOPIDINE INDICATION Transient Ischemic Attacks (TIA) 53885-35-1 TICLOPIDINE MODE_CLASS Receptor Ligand Antagonist 53885-35-1 TICLOPIDINE INDICATION Arterial Thromboembolism Prophylaxis 53885-35-1 TICLOPIDINE INDICATION Myocardial Infarction 53885-35-1 TICLOPIDINE INDICATION Stroke Prophylaxis 53885-35-1 TICLOPIDINE PRODUCT_CLASS Cardiovasculars 53885-35-1 TICLOPIDINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 53885-35-1 TICLOPIDINE TA_LEVEL_3 anti-platlet 53885-35-1 TICLOPIDINE TA_LEVEL_1 Cardiovascular 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_3_Pancytopenia 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 53885-35-1 TICLOPIDINE ADVERSE_EFFECT DNA_3_Secondary Malignanacy 53885-35-1 TICLOPIDINE ACTIVITY_CLASS Nucleotide receptor P2Y12 antagonist 53885-35-1 TICLOPIDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_3_Agranulocytosis 53885-35-1 TICLOPIDINE MESH_LEVEL_3 Thiophenes 53885-35-1 TICLOPIDINE INDICATION Diabetic Retinopathy 53885-35-1 TICLOPIDINE INDICATION Postmyocardial Infarction 53885-35-1 TICLOPIDINE INDICATION Thrombosis Prophylaxis 53885-35-1 TICLOPIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 53885-35-1 TICLOPIDINE ADVERSE_EFFECT PSY_2_Anorexia 53885-35-1 TICLOPIDINE THERAPEUTIC_CLASS Antiplatelets 53885-35-1 TICLOPIDINE TISSUE_TOXICITY Secondary Malignanacy 53885-35-1 TICLOPIDINE KNOWN_TOXICITY Carcinogenicity 53885-35-1 TICLOPIDINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_2_Neutropenia 53885-35-1 TICLOPIDINE ADVERSE_EFFECT GIS_2_Flatulence 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_2_Bleeding Tendency 53885-35-1 TICLOPIDINE ADVERSE_EFFECT GIS_1_Diarrhea 53885-35-1 TICLOPIDINE MECH_LEVEL_1 Inhibit platelet aggregation 53885-35-1 TICLOPIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 53885-35-1 TICLOPIDINE ADVERSE_EFFECT GIS_1_Dyspepsia 53885-35-1 TICLOPIDINE ADVERSE_EFFECT IMU_3_Serum Sickness 53885-35-1 TICLOPIDINE STRUCTURE_ACTIVITY Nucleotide receptor P2Y12 antagonist 53885-35-1 TICLOPIDINE PRODUCT_CLASS Hematologics 53885-35-1 TICLOPIDINE MECHANISM Inhibit platelet aggregation 53885-35-1 TICLOPIDINE TA_LEVEL_2 anticoagulant 53885-35-1 TICLOPIDINE MESH_LEVEL_1 Heterocyclic Compounds 53885-35-1 TICLOPIDINE INDICATION Peripheral Vascular Disease 53885-35-1 TICLOPIDINE MECH_LEVEL_3 Nucleotide receptor P2Y 53885-35-1 TICLOPIDINE INDICATION Intermittent Claudication 53885-35-1 TICLOPIDINE INDICATION Unstable Angina 53885-35-1 TICLOPIDINE ADVERSE_EFFECT GIS_3_Gastric Bleeding 53885-35-1 TICLOPIDINE ADVERSE_EFFECT BBM_2_Increased Bleeding 53885-35-1 TICLOPIDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 53885-35-1 TICLOPIDINE ADVERSE_EFFECT IMU_3_Eosinophilia 55142-85-3 TICLOPIDINE ADVERSE_EFFECT GIS_2_Flatulence 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_2_Neutropenia 55142-85-3 TICLOPIDINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 55142-85-3 TICLOPIDINE KNOWN_TOXICITY Carcinogenicity 55142-85-3 TICLOPIDINE TISSUE_TOXICITY Secondary Malignanacy 55142-85-3 TICLOPIDINE THERAPEUTIC_CLASS Antiplatelets 55142-85-3 TICLOPIDINE ADVERSE_EFFECT PSY_2_Anorexia 55142-85-3 TICLOPIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 55142-85-3 TICLOPIDINE INDICATION Thrombosis Prophylaxis 55142-85-3 TICLOPIDINE INDICATION Postmyocardial Infarction 55142-85-3 TICLOPIDINE MESH_LEVEL_3 Thiophenes 55142-85-3 TICLOPIDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 55142-85-3 TICLOPIDINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 55142-85-3 TICLOPIDINE ADVERSE_EFFECT IMU_3_Serum Sickness 55142-85-3 TICLOPIDINE PRODUCT_CLASS Cardiovasculars 55142-85-3 TICLOPIDINE STRUCTURE_ACTIVITY Nucleotide receptor P2Y12 antagonist 55142-85-3 TICLOPIDINE ADVERSE_EFFECT GIS_1_Dyspepsia 55142-85-3 TICLOPIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 55142-85-3 TICLOPIDINE INDICATION Intermittent Claudication 55142-85-3 TICLOPIDINE MECH_LEVEL_3 Nucleotide receptor P2Y 55142-85-3 TICLOPIDINE INDICATION Peripheral Vascular Disease 55142-85-3 TICLOPIDINE MESH_LEVEL_1 Heterocyclic Compounds 55142-85-3 TICLOPIDINE TA_LEVEL_2 anticoagulant 55142-85-3 TICLOPIDINE ADVERSE_EFFECT GIS_1_Diarrhea 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_3_Agranulocytosis 55142-85-3 TICLOPIDINE TA_LEVEL_1 Cardiovascular 55142-85-3 TICLOPIDINE TA_LEVEL_3 anti-platlet 55142-85-3 TICLOPIDINE INDICATION Transient Ischemic Attacks (TIA) 55142-85-3 TICLOPIDINE INDICATION Diabetic Retinopathy 55142-85-3 TICLOPIDINE ADVERSE_EFFECT GIS_3_Gastric Bleeding 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_2_Increased Bleeding 55142-85-3 TICLOPIDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 55142-85-3 TICLOPIDINE ADVERSE_EFFECT IMU_3_Eosinophilia 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_2_Bleeding Tendency 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 55142-85-3 TICLOPIDINE ZERO_CLASS N 55142-85-3 TICLOPIDINE MECH_LEVEL_2 inhibit the activation of GPIIb-IIIa mediated platelet aggregation. 55142-85-3 TICLOPIDINE MECH_LEVEL_1 Inhibit platelet aggregation 55142-85-3 TICLOPIDINE MODE_CLASS Receptor Ligand Antagonist 55142-85-3 TICLOPIDINE INDICATION Arterial Thromboembolism Prophylaxis 55142-85-3 TICLOPIDINE INDICATION Myocardial Infarction 55142-85-3 TICLOPIDINE INDICATION Stroke Prophylaxis 55142-85-3 TICLOPIDINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_3_Pancytopenia 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 55142-85-3 TICLOPIDINE ADVERSE_EFFECT DNA_3_Secondary Malignanacy 55142-85-3 TICLOPIDINE INDICATION Unstable Angina 55142-85-3 TICLOPIDINE MECHANISM Inhibit platelet aggregation 55142-85-3 TICLOPIDINE PRODUCT_CLASS Hematologics 55142-85-3 TICLOPIDINE ACTIVITY_CLASS Nucleotide receptor P2Y12 antagonist 55142-85-3 TICLOPIDINE ADVERSE_EFFECT BBM_3_Thrombocytosis 154413-61-3 TICOLUBANT MECHANISM Modulate gene transcription 154413-61-3 TICOLUBANT PRODUCT_CLASS Anti-inflammatories 154413-61-3 TICOLUBANT STRUCTURE_ACTIVITY Leukotriene receptor antagonist 154413-61-3 TICOLUBANT THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 154413-61-3 TICOLUBANT MODE_CLASS Receptor Ligand Antagonist, Selective 89987-06-4 TILUDRONIC ACID MECHANISM Inhibit bone re-absorption 89987-06-4 TILUDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 89987-06-4 TILUDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 89987-06-4 TILUDRONIC ACID MODE_CLASS Enzyme Inhibitor 89987-06-4 TILUDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 149845-07-8 TILUDRONIC ACID MECHANISM Inhibit bone re-absorption 149845-07-8 TILUDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 149845-07-8 TILUDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 149845-07-8 TILUDRONIC ACID MODE_CLASS Enzyme Inhibitor 149845-07-8 TILUDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 26921-17-5 TIMOLOL MESH_LEVEL_1 Organic Chemicals 26921-17-5 TIMOLOL MECH_LEVEL_3 adrenoceptor beta 26921-17-5 TIMOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 26921-17-5 TIMOLOL INDICATION Migraine Headache 26921-17-5 TIMOLOL MESH_LEVEL_3 Amino Alcohols 26921-17-5 TIMOLOL THERAPEUTIC_CLASS Antimigraines 26921-17-5 TIMOLOL TISSUE_TOXICITY Stroke 26921-17-5 TIMOLOL ADVERSE_EFFECT PSY_3_Depression 26921-17-5 TIMOLOL ADVERSE_EFFECT NEU_2_Dizziness 26921-17-5 TIMOLOL ADVERSE_EFFECT NEU_3_Paresthesia 26921-17-5 TIMOLOL ADVERSE_EFFECT XXX_2_Cold Extremities 26921-17-5 TIMOLOL ADVERSE_EFFECT END_2_Mask Symptoms of Hypoglycemia in Diabetics 26921-17-5 TIMOLOL TISSUE_TOXICITY Cardiac Failure 26921-17-5 TIMOLOL MECH_LEVEL_1 Vasorelaxation 26921-17-5 TIMOLOL TA_LEVEL_3 hypertension 26921-17-5 TIMOLOL TA_LEVEL_1 Cardiovascular 26921-17-5 TIMOLOL PRODUCT_CLASS Cardiovasculars 26921-17-5 TIMOLOL MECH_LEVEL_2 beta blocker 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_1_Bradycardia 26921-17-5 TIMOLOL ADVERSE_EFFECT REP_3_Impotence 26921-17-5 TIMOLOL ADVERSE_EFFECT IMU_3_Anaphylaxis 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_3_Cardiac Failure 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_3_Aggravation of Angina 26921-17-5 TIMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 26921-17-5 TIMOLOL TISSUE_TOXICITY Cardiac Arrest 26921-17-5 TIMOLOL TISSUE_TOXICITY Arrhythmia 26921-17-5 TIMOLOL ACTIVITY_CLASS Adrenergic antagonist 26921-17-5 TIMOLOL ZERO_CLASS N 26921-17-5 TIMOLOL MECHANISM Modulate G-protein coupled signal transduction 26921-17-5 TIMOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 26921-17-5 TIMOLOL MESH_LEVEL_2 Amines 26921-17-5 TIMOLOL INDICATION Myocardial Infarction 26921-17-5 TIMOLOL INDICATION Increased Intraocular Pressure 26921-17-5 TIMOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 26921-17-5 TIMOLOL TISSUE_TOXICITY Aggravation of Angina 26921-17-5 TIMOLOL ADVERSE_EFFECT XXX_1_Fatigue 26921-17-5 TIMOLOL ADVERSE_EFFECT IMU_3_Allergic Reactions 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_3_Stroke 26921-17-5 TIMOLOL ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 26921-17-5 TIMOLOL TA_LEVEL_2 beta antagonists 26921-17-5 TIMOLOL INDICATION Hypertension 26921-17-5 TIMOLOL INDICATION Open-Angle Glaucoma 26921-17-5 TIMOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 26921-17-5 TIMOLOL TISSUE_TOXICITY Hypotension 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_2_Hypotension 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 26921-17-5 TIMOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 26921-17-5 TIMOLOL ADVERSE_EFFECT CVS_3_Arrhythmia 26921-17-5 TIMOLOL ADVERSE_EFFECT END_2_Mask Symptoms of Thyrotoxicosis 26921-17-5 TIMOLOL KNOWN_TOXICITY Cardiovascular Toxicity 26839-75-8 TIMOLOL MESH_LEVEL_1 Organic Chemicals 26839-75-8 TIMOLOL MECH_LEVEL_3 adrenoceptor beta 26839-75-8 TIMOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 26839-75-8 TIMOLOL INDICATION Migraine Headache 26839-75-8 TIMOLOL MESH_LEVEL_3 Amino Alcohols 26839-75-8 TIMOLOL THERAPEUTIC_CLASS Antimigraines 26839-75-8 TIMOLOL TISSUE_TOXICITY Stroke 26839-75-8 TIMOLOL ADVERSE_EFFECT PSY_3_Depression 26839-75-8 TIMOLOL ADVERSE_EFFECT NEU_2_Dizziness 26839-75-8 TIMOLOL ADVERSE_EFFECT NEU_3_Paresthesia 26839-75-8 TIMOLOL ADVERSE_EFFECT XXX_2_Cold Extremities 26839-75-8 TIMOLOL ADVERSE_EFFECT END_2_Mask Symptoms of Hypoglycemia in Diabetics 26839-75-8 TIMOLOL TISSUE_TOXICITY Cardiac Failure 26839-75-8 TIMOLOL MECH_LEVEL_1 Vasorelaxation 26839-75-8 TIMOLOL TA_LEVEL_3 hypertension 26839-75-8 TIMOLOL TA_LEVEL_1 Cardiovascular 26839-75-8 TIMOLOL PRODUCT_CLASS Cardiovasculars 26839-75-8 TIMOLOL MECH_LEVEL_2 beta blocker 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_1_Bradycardia 26839-75-8 TIMOLOL ADVERSE_EFFECT REP_3_Impotence 26839-75-8 TIMOLOL ADVERSE_EFFECT IMU_3_Anaphylaxis 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_3_Cardiac Failure 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_3_Aggravation of Angina 26839-75-8 TIMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 26839-75-8 TIMOLOL TISSUE_TOXICITY Cardiac Arrest 26839-75-8 TIMOLOL TISSUE_TOXICITY Arrhythmia 26839-75-8 TIMOLOL ACTIVITY_CLASS Adrenergic antagonist 26839-75-8 TIMOLOL ZERO_CLASS N 26839-75-8 TIMOLOL MECHANISM Modulate G-protein coupled signal transduction 26839-75-8 TIMOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 26839-75-8 TIMOLOL MESH_LEVEL_2 Amines 26839-75-8 TIMOLOL INDICATION Myocardial Infarction 26839-75-8 TIMOLOL INDICATION Increased Intraocular Pressure 26839-75-8 TIMOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 26839-75-8 TIMOLOL TISSUE_TOXICITY Aggravation of Angina 26839-75-8 TIMOLOL ADVERSE_EFFECT XXX_1_Fatigue 26839-75-8 TIMOLOL ADVERSE_EFFECT IMU_3_Allergic Reactions 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_3_Stroke 26839-75-8 TIMOLOL ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 26839-75-8 TIMOLOL TA_LEVEL_2 beta antagonists 26839-75-8 TIMOLOL INDICATION Hypertension 26839-75-8 TIMOLOL INDICATION Open-Angle Glaucoma 26839-75-8 TIMOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 26839-75-8 TIMOLOL TISSUE_TOXICITY Hypotension 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_2_Hypotension 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 26839-75-8 TIMOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 26839-75-8 TIMOLOL ADVERSE_EFFECT CVS_3_Arrhythmia 26839-75-8 TIMOLOL ADVERSE_EFFECT END_2_Mask Symptoms of Thyrotoxicosis 26839-75-8 TIMOLOL KNOWN_TOXICITY Cardiovascular Toxicity 65899-73-2 TIOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 65899-73-2 TIOCONAZOLE PRODUCT_CLASS Anti-infectives 65899-73-2 TIOCONAZOLE MODE_CLASS Enzyme Inhibitor 65899-73-2 TIOCONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 65899-73-2 TIOCONAZOLE INDICATION Vulvovaginal Candidiasis 69014-14-8 TIOTIDINE PRODUCT_CLASS Gastrointestinal System 69014-14-8 TIOTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 69014-14-8 TIOTIDINE MECHANISM Reduce stomach HCl secretion 69014-14-8 TIOTIDINE THERAPEUTIC_CLASS Antiulcers 142373-60-2 TIROFIBAN INDICATION Unstable Angina 142373-60-2 TIROFIBAN PRODUCT_CLASS Hematologics 142373-60-2 TIROFIBAN THERAPEUTIC_CLASS Antiplatelets 142373-60-2 TIROFIBAN INDICATION Myocardial Infarction Prophylaxis 142373-60-2 TIROFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 142373-60-2 TIROFIBAN MECHANISM Inhibit platelet aggregation 144494-65-5 TIROFIBAN INDICATION Myocardial Infarction Prophylaxis 144494-65-5 TIROFIBAN THERAPEUTIC_CLASS Antiplatelets 144494-65-5 TIROFIBAN PRODUCT_CLASS Hematologics 144494-65-5 TIROFIBAN INDICATION Unstable Angina 144494-65-5 TIROFIBAN MECHANISM Inhibit platelet aggregation 144494-65-5 TIROFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 150915-40-5 TIROFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 150915-40-5 TIROFIBAN MECHANISM Inhibit platelet aggregation 150915-40-5 TIROFIBAN INDICATION Myocardial Infarction Prophylaxis 150915-40-5 TIROFIBAN THERAPEUTIC_CLASS Antiplatelets 150915-40-5 TIROFIBAN INDICATION Unstable Angina 150915-40-5 TIROFIBAN PRODUCT_CLASS Hematologics 41708-72-9 TOCAINIDE ADVERSE_EFFECT LUN_3_Pulmonary Toxicity 41708-72-9 TOCAINIDE ADVERSE_EFFECT NEU_1_Tremor 41708-72-9 TOCAINIDE ADVERSE_EFFECT NEU_1_Dizziness 41708-72-9 TOCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 41708-72-9 TOCAINIDE TISSUE_TOXICITY Ventricular Arrhythmia 41708-72-9 TOCAINIDE MECH_LEVEL_1 Modulate neural transmission 41708-72-9 TOCAINIDE MESH_LEVEL_1 Organic Chemicals 41708-72-9 TOCAINIDE MESH_LEVEL_2 Amides 41708-72-9 TOCAINIDE MODE_CLASS Channel Blocker 41708-72-9 TOCAINIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 41708-72-9 TOCAINIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 41708-72-9 TOCAINIDE ADVERSE_EFFECT BBM_3_Bone Marrow Toxicity 41708-72-9 TOCAINIDE ADVERSE_EFFECT CVS_2_Hypotension 41708-72-9 TOCAINIDE ADVERSE_EFFECT CVS_2_Congestive Heart Failure 41708-72-9 TOCAINIDE TA_LEVEL_1 Peripheral Nervous System (PNS) 41708-72-9 TOCAINIDE INDICATION Ventricular Arrhythmias 41708-72-9 TOCAINIDE TISSUE_TOXICITY Congestive Heart Failure 41708-72-9 TOCAINIDE ADVERSE_EFFECT OTO_3_Ototoxicity 41708-72-9 TOCAINIDE ADVERSE_EFFECT LIV_3_Hepatitis 41708-72-9 TOCAINIDE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 41708-72-9 TOCAINIDE ADVERSE_EFFECT GIS_3_Pancreatitis 41708-72-9 TOCAINIDE ADVERSE_EFFECT GIS_2_Vomiting 41708-72-9 TOCAINIDE ACTIVITY_CLASS Na+ channel blocker 41708-72-9 TOCAINIDE ZERO_CLASS N 41708-72-9 TOCAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 41708-72-9 TOCAINIDE ADVERSE_EFFECT NEU_2_Seizures 41708-72-9 TOCAINIDE TA_LEVEL_2 Anesthesia 41708-72-9 TOCAINIDE MESH_LEVEL_3 Anilides 41708-72-9 TOCAINIDE MECHANISM Block neural transmission 41708-72-9 TOCAINIDE PRODUCT_CLASS Cardiovasculars 41708-72-9 TOCAINIDE TISSUE_TOXICITY Hypotension 41708-72-9 TOCAINIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 41708-72-9 TOCAINIDE ADVERSE_EFFECT NEU_2_Ataxia 41708-72-9 TOCAINIDE ADVERSE_EFFECT CVS_2_Ventricular Arrhythmia 41708-72-9 TOCAINIDE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 41708-72-9 TOCAINIDE ADVERSE_EFFECT GIS_1_Nausea 41708-72-9 TOCAINIDE ADVERSE_EFFECT SKN_2_Rash 41708-72-9 TOCAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 41708-72-9 TOCAINIDE MECH_LEVEL_2 Sodium channel antagonist 41708-72-9 TOCAINIDE MECH_LEVEL_3 Voltage-gated Na+ channel 41708-72-9 TOCAINIDE ADVERSE_EFFECT NEU_1_Paresthesia 41708-72-9 TOCAINIDE ADVERSE_EFFECT PSY_2_Confusion 35891-93-1 TOCAINIDE MECH_LEVEL_1 Modulate neural transmission 35891-93-1 TOCAINIDE MESH_LEVEL_1 Organic Chemicals 35891-93-1 TOCAINIDE MESH_LEVEL_2 Amides 35891-93-1 TOCAINIDE MODE_CLASS Channel Blocker 35891-93-1 TOCAINIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 35891-93-1 TOCAINIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 35891-93-1 TOCAINIDE ADVERSE_EFFECT BBM_3_Bone Marrow Toxicity 35891-93-1 TOCAINIDE ADVERSE_EFFECT CVS_2_Hypotension 35891-93-1 TOCAINIDE ADVERSE_EFFECT CVS_2_Congestive Heart Failure 35891-93-1 TOCAINIDE TA_LEVEL_1 Peripheral Nervous System (PNS) 35891-93-1 TOCAINIDE INDICATION Ventricular Arrhythmias 35891-93-1 TOCAINIDE TISSUE_TOXICITY Congestive Heart Failure 35891-93-1 TOCAINIDE ADVERSE_EFFECT OTO_3_Ototoxicity 35891-93-1 TOCAINIDE ADVERSE_EFFECT LIV_3_Hepatitis 35891-93-1 TOCAINIDE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 35891-93-1 TOCAINIDE ADVERSE_EFFECT GIS_3_Pancreatitis 35891-93-1 TOCAINIDE ADVERSE_EFFECT GIS_2_Vomiting 35891-93-1 TOCAINIDE ACTIVITY_CLASS Na+ channel blocker 35891-93-1 TOCAINIDE ZERO_CLASS N 35891-93-1 TOCAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 35891-93-1 TOCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 35891-93-1 TOCAINIDE TISSUE_TOXICITY Ventricular Arrhythmia 35891-93-1 TOCAINIDE MECHANISM Block neural transmission 35891-93-1 TOCAINIDE ADVERSE_EFFECT GIS_1_Nausea 35891-93-1 TOCAINIDE ADVERSE_EFFECT NEU_2_Ataxia 35891-93-1 TOCAINIDE ADVERSE_EFFECT CVS_2_Ventricular Arrhythmia 35891-93-1 TOCAINIDE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 35891-93-1 TOCAINIDE MESH_LEVEL_3 Anilides 35891-93-1 TOCAINIDE PRODUCT_CLASS Cardiovasculars 35891-93-1 TOCAINIDE TISSUE_TOXICITY Hypotension 35891-93-1 TOCAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 35891-93-1 TOCAINIDE ADVERSE_EFFECT SKN_2_Rash 35891-93-1 TOCAINIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 35891-93-1 TOCAINIDE MECH_LEVEL_2 Sodium channel antagonist 35891-93-1 TOCAINIDE MECH_LEVEL_3 Voltage-gated Na+ channel 35891-93-1 TOCAINIDE ADVERSE_EFFECT NEU_1_Paresthesia 35891-93-1 TOCAINIDE ADVERSE_EFFECT NEU_2_Seizures 35891-93-1 TOCAINIDE ADVERSE_EFFECT PSY_2_Confusion 35891-93-1 TOCAINIDE ADVERSE_EFFECT LUN_3_Pulmonary Toxicity 35891-93-1 TOCAINIDE TA_LEVEL_2 Anesthesia 35891-93-1 TOCAINIDE ADVERSE_EFFECT NEU_1_Tremor 35891-93-1 TOCAINIDE ADVERSE_EFFECT NEU_1_Dizziness 4345-03-3 VITAMIN E SUCCINATE MODE_CLASS Enzyme Inhibitor 4345-03-3 VITAMIN E SUCCINATE MECHANISM Scavenges hydrogen peroxide and free radicals 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT NEU_2_Headache 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT ELT_3_Hyponatremia 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT SKN_3_Erythema 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 1156-19-0 TOLAZAMIDE MESH_LEVEL_1 Organic Chemicals 1156-19-0 TOLAZAMIDE MECH_LEVEL_1 Glycemia regulation 1156-19-0 TOLAZAMIDE MESH_LEVEL_2 Sulfur Compounds 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT IMU_3_Urticaria 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT NEU_3_Vertigo 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT GIS_1_Epigastric Pain 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT SKN_3_Porphyria Cutanea Tarda 1156-19-0 TOLAZAMIDE TA_LEVEL_2 Diabetes 1156-19-0 TOLAZAMIDE ZERO_CLASS N 1156-19-0 TOLAZAMIDE MECH_LEVEL_3 ATP-sensitive K+ channel SUR1 1156-19-0 TOLAZAMIDE MESH_LEVEL_3 Sulfones 1156-19-0 TOLAZAMIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 1156-19-0 TOLAZAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT XXX_3_Weakness 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT SKN_3_Maculopapular Rash 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT LIV_2_Cholestasis 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 1156-19-0 TOLAZAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 1156-19-0 TOLAZAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 1156-19-0 TOLAZAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 1156-19-0 TOLAZAMIDE TA_LEVEL_3 sulfonylurea 1156-19-0 TOLAZAMIDE MODE_CLASS Channel Blocker, selective 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT END_3_Hypoglycemia 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT NEU_3_Dizziness 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT SKN_3_Pruritis 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT IMU_3_Photosensitivity 1156-19-0 TOLAZAMIDE ADVERSE_EFFECT GIS_1_Heartburn 1156-19-0 TOLAZAMIDE ACTIVITY_CLASS Anti-diabetic 1156-19-0 TOLAZAMIDE INDICATION Type II Diabetes Mellitus 1156-19-0 TOLAZAMIDE MECH_LEVEL_2 stimulate insulin release 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT IMU_3_Urticaria 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT IMU_3_Photosensitivity 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT LIV_3_Jaundice 64-77-7 TOLBUTAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Anemia 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT END_3_Porphyria 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT END_2_Hypoglycemia 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 64-77-7 TOLBUTAMIDE INDICATION Type II Diabetes Mellitus 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT LIV_3_Cholestasis 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT GIS_1_Constipation 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 64-77-7 TOLBUTAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT SKN_3_Maculopapular Rash 64-77-7 TOLBUTAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT ELT_3_Hyponatremia 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Hemolysis 64-77-7 TOLBUTAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 64-77-7 TOLBUTAMIDE MODE_CLASS Channel Blocker, selective 64-77-7 TOLBUTAMIDE ADVERSE_EFFECT PSY_1_Anorexia 134308-13-7 TOLCAPONE ADVERSE_EFFECT GIS_1_Abdominal Pain 134308-13-7 TOLCAPONE ADVERSE_EFFECT NEU_3_Syncope 134308-13-7 TOLCAPONE ADVERSE_EFFECT XXX_1_Diaphoresis 134308-13-7 TOLCAPONE INDICATION Parkinson's Disease 134308-13-7 TOLCAPONE KNOWN_TOXICITY Hepatotoxicity 134308-13-7 TOLCAPONE ADVERSE_EFFECT PSY_1_Anorexia 134308-13-7 TOLCAPONE ADVERSE_EFFECT NEU_1_Headache 134308-13-7 TOLCAPONE ADVERSE_EFFECT LIV_2_Hepatic Dysfunction 134308-13-7 TOLCAPONE ADVERSE_EFFECT LIV_2_Hepatic Failure 134308-13-7 TOLCAPONE ADVERSE_EFFECT GUS_1_Discoloration of Urine 134308-13-7 TOLCAPONE TISSUE_TOXICITY Hepatic Failure 134308-13-7 TOLCAPONE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 134308-13-7 TOLCAPONE MODE_CLASS Enzyme Inhibitor, selective 134308-13-7 TOLCAPONE KNOWN_TOXICITY Nephrotoxicity 134308-13-7 TOLCAPONE ADVERSE_EFFECT PSY_2_Hallucinations 134308-13-7 TOLCAPONE ADVERSE_EFFECT PSY_2_Insomnia 134308-13-7 TOLCAPONE ADVERSE_EFFECT XXX_1_Fatigue 134308-13-7 TOLCAPONE ADVERSE_EFFECT XXX_2_Withdrawal 134308-13-7 TOLCAPONE ADVERSE_EFFECT KID_2_Hematuria 134308-13-7 TOLCAPONE ADVERSE_EFFECT MSK_1_Muscle Cramps 134308-13-7 TOLCAPONE ADVERSE_EFFECT GIS_1_Constipation 134308-13-7 TOLCAPONE THERAPEUTIC_CLASS Movement Disorders 134308-13-7 TOLCAPONE ADVERSE_EFFECT XXX_1_Xerostomia 134308-13-7 TOLCAPONE ADVERSE_EFFECT GIS_1_Dyspepsia 134308-13-7 TOLCAPONE ADVERSE_EFFECT NEU_2_Dyskinesia 134308-13-7 TOLCAPONE ADVERSE_EFFECT NEU_1_Drowsiness 134308-13-7 TOLCAPONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 134308-13-7 TOLCAPONE TISSUE_TOXICITY Hematuria 134308-13-7 TOLCAPONE MECHANISM Interferes with neural transmitter synthesis 134308-13-7 TOLCAPONE PRODUCT_CLASS Central Nervous System (CNS) 134308-13-7 TOLCAPONE ADVERSE_EFFECT GIS_1_Diarrhea 134308-13-7 TOLCAPONE ADVERSE_EFFECT NEU_1_Dizziness 134308-13-7 TOLCAPONE ADVERSE_EFFECT PSY_1_Confusion 134308-13-7 TOLCAPONE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 64490-92-2 TOLMETIN INDICATION Myalgia 64490-92-2 TOLMETIN PRODUCT_CLASS Anti-inflammatories 64490-92-2 TOLMETIN TISSUE_TOXICITY Congestive Heart Failure 64490-92-2 TOLMETIN TISSUE_TOXICITY Renal Tubular Necrosis 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 64490-92-2 TOLMETIN ADVERSE_EFFECT BBM_3_Agranulocytosis 64490-92-2 TOLMETIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 64490-92-2 TOLMETIN ADVERSE_EFFECT XXX_1_Weight Gain 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_2_Peptic Ulceration 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_1_Dyspepsia 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 64490-92-2 TOLMETIN INDICATION Still's Disease / Juvenile Chronic Arthritis 64490-92-2 TOLMETIN INDICATION Arthralgia 64490-92-2 TOLMETIN INDICATION Rheumatoid Arthritis 64490-92-2 TOLMETIN MODE_CLASS Enzyme Inhibitor 64490-92-2 TOLMETIN TISSUE_TOXICITY Renal Failure 64490-92-2 TOLMETIN ADVERSE_EFFECT PSY_2_Depression 64490-92-2 TOLMETIN ADVERSE_EFFECT NEU_1_Dizziness 64490-92-2 TOLMETIN ADVERSE_EFFECT LIV_3_Hepatitis 64490-92-2 TOLMETIN ADVERSE_EFFECT XXX_1_Weight Loss 64490-92-2 TOLMETIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_1_Abdominal Pain 64490-92-2 TOLMETIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 64490-92-2 TOLMETIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 64490-92-2 TOLMETIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 64490-92-2 TOLMETIN INDICATION Pain 64490-92-2 TOLMETIN TISSUE_TOXICITY Interstitial Nephritis 64490-92-2 TOLMETIN KNOWN_TOXICITY Nephrotoxicity 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_3_Constipation 64490-92-2 TOLMETIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 64490-92-2 TOLMETIN ADVERSE_EFFECT NEU_3_Optic Neuropathy 64490-92-2 TOLMETIN ADVERSE_EFFECT BBM_3_Leukopenia 64490-92-2 TOLMETIN ADVERSE_EFFECT KID_3_Renal Failure 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_1_Flatulence 64490-92-2 TOLMETIN ADVERSE_EFFECT NEU_3_Aseptic Meningitis 64490-92-2 TOLMETIN INDICATION Osteoarthritis 64490-92-2 TOLMETIN MECHANISM Inhibit eicosanoid biosynthesis 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_1_Diarrhea 64490-92-2 TOLMETIN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 64490-92-2 TOLMETIN ADVERSE_EFFECT NEU_2_Drowsiness 64490-92-2 TOLMETIN ADVERSE_EFFECT IMU_2_Urticaria 64490-92-2 TOLMETIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 64490-92-2 TOLMETIN ADVERSE_EFFECT LIV_3_Jaundice 64490-92-2 TOLMETIN ADVERSE_EFFECT GIS_3_Esophagitis 64490-92-2 TOLMETIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 64490-92-2 TOLMETIN TISSUE_TOXICITY Nephrotic Syndrome 64490-92-2 TOLMETIN KNOWN_TOXICITY Cardiovascular Toxicity 64490-92-2 TOLMETIN STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 26171-23-3 TOLMETIN PRODUCT_CLASS Anti-inflammatories 26171-23-3 TOLMETIN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 26171-23-3 TOLMETIN ADVERSE_EFFECT NEU_2_Drowsiness 26171-23-3 TOLMETIN ADVERSE_EFFECT IMU_2_Urticaria 26171-23-3 TOLMETIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 26171-23-3 TOLMETIN ADVERSE_EFFECT LIV_3_Jaundice 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_3_Esophagitis 26171-23-3 TOLMETIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 26171-23-3 TOLMETIN TISSUE_TOXICITY Nephrotic Syndrome 26171-23-3 TOLMETIN KNOWN_TOXICITY Cardiovascular Toxicity 26171-23-3 TOLMETIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_1_Abdominal Pain 26171-23-3 TOLMETIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 26171-23-3 TOLMETIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 26171-23-3 TOLMETIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 26171-23-3 TOLMETIN TISSUE_TOXICITY Renal Failure 26171-23-3 TOLMETIN INDICATION Pain 26171-23-3 TOLMETIN TISSUE_TOXICITY Interstitial Nephritis 26171-23-3 TOLMETIN KNOWN_TOXICITY Nephrotoxicity 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_3_Constipation 26171-23-3 TOLMETIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 26171-23-3 TOLMETIN ADVERSE_EFFECT NEU_3_Optic Neuropathy 26171-23-3 TOLMETIN ADVERSE_EFFECT BBM_3_Leukopenia 26171-23-3 TOLMETIN ADVERSE_EFFECT KID_3_Renal Failure 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_1_Flatulence 26171-23-3 TOLMETIN ADVERSE_EFFECT NEU_3_Aseptic Meningitis 26171-23-3 TOLMETIN ADVERSE_EFFECT LIV_3_Hepatitis 26171-23-3 TOLMETIN ADVERSE_EFFECT NEU_1_Dizziness 26171-23-3 TOLMETIN ADVERSE_EFFECT PSY_2_Depression 26171-23-3 TOLMETIN INDICATION Osteoarthritis 26171-23-3 TOLMETIN MODE_CLASS Enzyme Inhibitor 26171-23-3 TOLMETIN INDICATION Rheumatoid Arthritis 26171-23-3 TOLMETIN INDICATION Arthralgia 26171-23-3 TOLMETIN INDICATION Still's Disease / Juvenile Chronic Arthritis 26171-23-3 TOLMETIN STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_1_Dyspepsia 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_2_Peptic Ulceration 26171-23-3 TOLMETIN ADVERSE_EFFECT XXX_1_Weight Gain 26171-23-3 TOLMETIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 26171-23-3 TOLMETIN ADVERSE_EFFECT BBM_3_Agranulocytosis 26171-23-3 TOLMETIN ADVERSE_EFFECT XXX_1_Weight Loss 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 26171-23-3 TOLMETIN TISSUE_TOXICITY Renal Tubular Necrosis 26171-23-3 TOLMETIN TISSUE_TOXICITY Congestive Heart Failure 26171-23-3 TOLMETIN MECHANISM Inhibit eicosanoid biosynthesis 26171-23-3 TOLMETIN INDICATION Myalgia 26171-23-3 TOLMETIN ADVERSE_EFFECT GIS_1_Diarrhea 35711-34-3 TOLMETIN ADVERSE_EFFECT KID_3_Renal Failure 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_1_Flatulence 35711-34-3 TOLMETIN ADVERSE_EFFECT NEU_3_Aseptic Meningitis 35711-34-3 TOLMETIN INDICATION Osteoarthritis 35711-34-3 TOLMETIN MECHANISM Inhibit eicosanoid biosynthesis 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_1_Diarrhea 35711-34-3 TOLMETIN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 35711-34-3 TOLMETIN ADVERSE_EFFECT NEU_2_Drowsiness 35711-34-3 TOLMETIN ADVERSE_EFFECT IMU_2_Urticaria 35711-34-3 TOLMETIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 35711-34-3 TOLMETIN ADVERSE_EFFECT LIV_3_Jaundice 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_3_Esophagitis 35711-34-3 TOLMETIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 35711-34-3 TOLMETIN TISSUE_TOXICITY Nephrotic Syndrome 35711-34-3 TOLMETIN INDICATION Rheumatoid Arthritis 35711-34-3 TOLMETIN MODE_CLASS Enzyme Inhibitor 35711-34-3 TOLMETIN TISSUE_TOXICITY Renal Failure 35711-34-3 TOLMETIN ADVERSE_EFFECT PSY_2_Depression 35711-34-3 TOLMETIN ADVERSE_EFFECT NEU_1_Dizziness 35711-34-3 TOLMETIN ADVERSE_EFFECT LIV_3_Hepatitis 35711-34-3 TOLMETIN ADVERSE_EFFECT XXX_1_Weight Loss 35711-34-3 TOLMETIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_1_Abdominal Pain 35711-34-3 TOLMETIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 35711-34-3 TOLMETIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 35711-34-3 TOLMETIN KNOWN_TOXICITY Cardiovascular Toxicity 35711-34-3 TOLMETIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 35711-34-3 TOLMETIN INDICATION Pain 35711-34-3 TOLMETIN TISSUE_TOXICITY Interstitial Nephritis 35711-34-3 TOLMETIN KNOWN_TOXICITY Nephrotoxicity 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_3_Constipation 35711-34-3 TOLMETIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 35711-34-3 TOLMETIN ADVERSE_EFFECT NEU_3_Optic Neuropathy 35711-34-3 TOLMETIN ADVERSE_EFFECT BBM_3_Leukopenia 35711-34-3 TOLMETIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 35711-34-3 TOLMETIN INDICATION Myalgia 35711-34-3 TOLMETIN PRODUCT_CLASS Anti-inflammatories 35711-34-3 TOLMETIN TISSUE_TOXICITY Congestive Heart Failure 35711-34-3 TOLMETIN TISSUE_TOXICITY Renal Tubular Necrosis 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 35711-34-3 TOLMETIN ADVERSE_EFFECT BBM_3_Agranulocytosis 35711-34-3 TOLMETIN ADVERSE_EFFECT XXX_1_Weight Gain 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_2_Peptic Ulceration 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_1_Dyspepsia 35711-34-3 TOLMETIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 35711-34-3 TOLMETIN STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 35711-34-3 TOLMETIN INDICATION Still's Disease / Juvenile Chronic Arthritis 35711-34-3 TOLMETIN INDICATION Arthralgia 2398-96-1 TOLNAFTATE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 2398-96-1 TOLNAFTATE MODE_CLASS Enzyme Inhibitor 2398-96-1 TOLNAFTATE ADVERSE_EFFECT IMU_3_Hypersensitivity 2398-96-1 TOLNAFTATE INDICATION Tinea Pedis / Athlete's Foot 2398-96-1 TOLNAFTATE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 2398-96-1 TOLNAFTATE THERAPEUTIC_CLASS Antifungals, Topical 2398-96-1 TOLNAFTATE PRODUCT_CLASS Anti-infectives 2398-96-1 TOLNAFTATE INDICATION Tinea Cruris / Jock Itch 2398-96-1 TOLNAFTATE ADVERSE_EFFECT SKN_2_Skin Irritation 2398-96-1 TOLNAFTATE INDICATION Tinea Versicolor / Pityriasis Versicolor 2398-96-1 TOLNAFTATE ADVERSE_EFFECT IMU_3_Contact Dermatitis 97240-79-4 TOPIRAMATE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 97240-79-4 TOPIRAMATE MECHANISM Prolong/enhance neural transmission 97240-79-4 TOPIRAMATE MODE_CLASS Solute transporter inhibitor 97240-79-4 TOPIRAMATE INDICATION Tonic-Clonic (Grand Mal) Seizures 97240-79-4 TOPIRAMATE INDICATION Partial Seizures 97240-79-4 TOPIRAMATE MECHANISM Block neural transmission 97240-79-4 TOPIRAMATE MODE_CLASS Channel Blocker 97240-79-4 TOPIRAMATE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 97240-79-4 TOPIRAMATE PRODUCT_CLASS Central Nervous System (CNS) 97240-79-4 TOPIRAMATE MODE_CLASS Enzyme Inhibitor 97240-79-4 TOPIRAMATE STRUCTURE_ACTIVITY GABA reuptake inhibitor 123948-87-8 TOPOTECAN ADVERSE_EFFECT GIS_2_Abdominal Pain 123948-87-8 TOPOTECAN ADVERSE_EFFECT XXX_2_Sepsis 123948-87-8 TOPOTECAN THERAPEUTIC_CLASS Antineoplastics 123948-87-8 TOPOTECAN TISSUE_TOXICITY Neutropenia 123948-87-8 TOPOTECAN PRODUCT_CLASS Anti-cancers 123948-87-8 TOPOTECAN INDICATION Small Cell Lung Carcinoma 123948-87-8 TOPOTECAN MODE_CLASS Enzyme Inhibitor 123948-87-8 TOPOTECAN TISSUE_TOXICITY Leukopenia 123948-87-8 TOPOTECAN ADVERSE_EFFECT GIS_2_Constipation 123948-87-8 TOPOTECAN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 123948-87-8 TOPOTECAN ADVERSE_EFFECT BBM_1_Anemia 123948-87-8 TOPOTECAN ADVERSE_EFFECT BBM_1_Thrombocytopenia 123948-87-8 TOPOTECAN ADVERSE_EFFECT GIS_2_Stomatitis 123948-87-8 TOPOTECAN ADVERSE_EFFECT XXX_2_Malaise 123948-87-8 TOPOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 123948-87-8 TOPOTECAN INDICATION Metastatic / Recurrent Ovarian Carcinoma 123948-87-8 TOPOTECAN TISSUE_TOXICITY Anemia 123948-87-8 TOPOTECAN ADVERSE_EFFECT XXX_2_Fever 123948-87-8 TOPOTECAN ADVERSE_EFFECT NEU_2_Paresthesia 123948-87-8 TOPOTECAN ADVERSE_EFFECT MSK_2_Arthralgia 123948-87-8 TOPOTECAN ADVERSE_EFFECT BBM_1_Neutropenia 123948-87-8 TOPOTECAN ADVERSE_EFFECT GIS_2_Bowel Obstruction 123948-87-8 TOPOTECAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 123948-87-8 TOPOTECAN TISSUE_TOXICITY Thrombocytopenia 123948-87-8 TOPOTECAN ADVERSE_EFFECT NEU_2_Headache 123948-87-8 TOPOTECAN ADVERSE_EFFECT XXX_2_Infection 123948-87-8 TOPOTECAN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 123948-87-8 TOPOTECAN ADVERSE_EFFECT XXX_2_Asthenia 123948-87-8 TOPOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 123948-87-8 TOPOTECAN ADVERSE_EFFECT PSY_2_Anorexia 123948-87-8 TOPOTECAN ADVERSE_EFFECT XXX_2_Fatigue 123948-87-8 TOPOTECAN ADVERSE_EFFECT LUN_2_Dyspnea 123948-87-8 TOPOTECAN ADVERSE_EFFECT BBM_1_Leukopenia 123948-88-9 TOPOTECAN ADVERSE_EFFECT GIS_2_Bowel Obstruction 123948-88-9 TOPOTECAN TISSUE_TOXICITY Thrombocytopenia 123948-88-9 TOPOTECAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 123948-88-9 TOPOTECAN ADVERSE_EFFECT BBM_1_Neutropenia 123948-88-9 TOPOTECAN ADVERSE_EFFECT MSK_2_Arthralgia 123948-88-9 TOPOTECAN PRODUCT_CLASS Anti-cancers 123948-88-9 TOPOTECAN INDICATION Small Cell Lung Carcinoma 123948-88-9 TOPOTECAN MODE_CLASS Enzyme Inhibitor 123948-88-9 TOPOTECAN TISSUE_TOXICITY Leukopenia 123948-88-9 TOPOTECAN ADVERSE_EFFECT GIS_2_Constipation 123948-88-9 TOPOTECAN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 123948-88-9 TOPOTECAN ADVERSE_EFFECT BBM_1_Anemia 123948-88-9 TOPOTECAN ADVERSE_EFFECT NEU_2_Paresthesia 123948-88-9 TOPOTECAN ADVERSE_EFFECT BBM_1_Thrombocytopenia 123948-88-9 TOPOTECAN ADVERSE_EFFECT GIS_2_Stomatitis 123948-88-9 TOPOTECAN ADVERSE_EFFECT XXX_2_Malaise 123948-88-9 TOPOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 123948-88-9 TOPOTECAN INDICATION Metastatic / Recurrent Ovarian Carcinoma 123948-88-9 TOPOTECAN TISSUE_TOXICITY Anemia 123948-88-9 TOPOTECAN ADVERSE_EFFECT XXX_2_Fever 123948-88-9 TOPOTECAN TISSUE_TOXICITY Neutropenia 123948-88-9 TOPOTECAN THERAPEUTIC_CLASS Antineoplastics 123948-88-9 TOPOTECAN ADVERSE_EFFECT XXX_2_Sepsis 123948-88-9 TOPOTECAN ADVERSE_EFFECT GIS_2_Abdominal Pain 123948-88-9 TOPOTECAN ADVERSE_EFFECT BBM_1_Leukopenia 123948-88-9 TOPOTECAN ADVERSE_EFFECT LUN_2_Dyspnea 123948-88-9 TOPOTECAN ADVERSE_EFFECT XXX_2_Fatigue 123948-88-9 TOPOTECAN ADVERSE_EFFECT PSY_2_Anorexia 123948-88-9 TOPOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 123948-88-9 TOPOTECAN ADVERSE_EFFECT XXX_2_Asthenia 123948-88-9 TOPOTECAN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 123948-88-9 TOPOTECAN ADVERSE_EFFECT XXX_2_Infection 123948-88-9 TOPOTECAN ADVERSE_EFFECT NEU_2_Headache 119413-54-6 TOPOTECAN ADVERSE_EFFECT NEU_2_Paresthesia 119413-54-6 TOPOTECAN ADVERSE_EFFECT MSK_2_Arthralgia 119413-54-6 TOPOTECAN ADVERSE_EFFECT BBM_1_Neutropenia 119413-54-6 TOPOTECAN ADVERSE_EFFECT GIS_2_Bowel Obstruction 119413-54-6 TOPOTECAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 119413-54-6 TOPOTECAN TISSUE_TOXICITY Thrombocytopenia 119413-54-6 TOPOTECAN ADVERSE_EFFECT XXX_2_Infection 119413-54-6 TOPOTECAN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 119413-54-6 TOPOTECAN ADVERSE_EFFECT XXX_2_Asthenia 119413-54-6 TOPOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 119413-54-6 TOPOTECAN ADVERSE_EFFECT PSY_2_Anorexia 119413-54-6 TOPOTECAN ADVERSE_EFFECT XXX_2_Fatigue 119413-54-6 TOPOTECAN ADVERSE_EFFECT LUN_2_Dyspnea 119413-54-6 TOPOTECAN ADVERSE_EFFECT BBM_1_Leukopenia 119413-54-6 TOPOTECAN ADVERSE_EFFECT GIS_2_Abdominal Pain 119413-54-6 TOPOTECAN ADVERSE_EFFECT XXX_2_Sepsis 119413-54-6 TOPOTECAN THERAPEUTIC_CLASS Antineoplastics 119413-54-6 TOPOTECAN TISSUE_TOXICITY Neutropenia 119413-54-6 TOPOTECAN ADVERSE_EFFECT NEU_2_Headache 119413-54-6 TOPOTECAN PRODUCT_CLASS Anti-cancers 119413-54-6 TOPOTECAN INDICATION Small Cell Lung Carcinoma 119413-54-6 TOPOTECAN MODE_CLASS Enzyme Inhibitor 119413-54-6 TOPOTECAN TISSUE_TOXICITY Leukopenia 119413-54-6 TOPOTECAN ADVERSE_EFFECT GIS_2_Constipation 119413-54-6 TOPOTECAN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 119413-54-6 TOPOTECAN ADVERSE_EFFECT BBM_1_Anemia 119413-54-6 TOPOTECAN ADVERSE_EFFECT BBM_1_Thrombocytopenia 119413-54-6 TOPOTECAN ADVERSE_EFFECT GIS_2_Stomatitis 119413-54-6 TOPOTECAN ADVERSE_EFFECT XXX_2_Malaise 119413-54-6 TOPOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 119413-54-6 TOPOTECAN INDICATION Metastatic / Recurrent Ovarian Carcinoma 119413-54-6 TOPOTECAN TISSUE_TOXICITY Anemia 119413-54-6 TOPOTECAN ADVERSE_EFFECT XXX_2_Fever 56211-40-6 TORSEMIDE THERAPEUTIC_CLASS Antihypertensive Agents 56211-40-6 TORSEMIDE ADVERSE_EFFECT END_3_Hyperglycemia 56211-40-6 TORSEMIDE ADVERSE_EFFECT NEU_3_Hepatic Encephalopathy 56211-40-6 TORSEMIDE ADVERSE_EFFECT CVS_2_ECG Abnormalities 56211-40-6 TORSEMIDE ZERO_CLASS N 56211-40-6 TORSEMIDE MESH_LEVEL_2 Amides 56211-40-6 TORSEMIDE PRODUCT_CLASS Cardiovasculars 56211-40-6 TORSEMIDE THERAPEUTIC_CLASS Diuretics 56211-40-6 TORSEMIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 56211-40-6 TORSEMIDE ADVERSE_EFFECT NEU_1_Dizziness 56211-40-6 TORSEMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 56211-40-6 TORSEMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 56211-40-6 TORSEMIDE TA_LEVEL_2 Electrolytic, Caloric and Water Balance 56211-40-6 TORSEMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 56211-40-6 TORSEMIDE TISSUE_TOXICITY Hypotension 56211-40-6 TORSEMIDE ADVERSE_EFFECT CVS_3_Hypotension 56211-40-6 TORSEMIDE ADVERSE_EFFECT NEU_1_Headache 56211-40-6 TORSEMIDE ADVERSE_EFFECT OTO_3_Ototoxicity 56211-40-6 TORSEMIDE MECH_LEVEL_3 Acid-sensitive K+ channel 2 56211-40-6 TORSEMIDE MESH_LEVEL_1 Organic Chemicals 56211-40-6 TORSEMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 56211-40-6 TORSEMIDE ADVERSE_EFFECT END_3_Gout 56211-40-6 TORSEMIDE TA_LEVEL_1 Cardiovascular 56211-40-6 TORSEMIDE ACTIVITY_CLASS Diuretic 56211-40-6 TORSEMIDE ADVERSE_EFFECT KID_3_Prerenal Failure 56211-40-6 TORSEMIDE MECH_LEVEL_2 Loop Diueretic 56211-40-6 TORSEMIDE KNOWN_TOXICITY Cardiovascular Toxicity 56211-40-6 TORSEMIDE TISSUE_TOXICITY Cardiac Arrhythmia 56211-40-6 TORSEMIDE ADVERSE_EFFECT ELT_2_Disturbances in Electrolyte Balance 56211-40-6 TORSEMIDE ADVERSE_EFFECT XXX_2_Hypovolemia 56211-40-6 TORSEMIDE ADVERSE_EFFECT ELT_2_Hypokalemia 56211-40-6 TORSEMIDE MODE_CLASS Channel Blocker, selective 56211-40-6 TORSEMIDE INDICATION Hypertension 56211-40-6 TORSEMIDE INDICATION Edematous States 56211-40-6 TORSEMIDE TA_LEVEL_3 Diuretic 56211-40-6 TORSEMIDE MESH_LEVEL_3 Sulfonamides 56211-40-6 TORSEMIDE MECH_LEVEL_1 Diuretic 22204-88-2 TRAMADOL MECH_LEVEL_2 opioid agonist 22204-88-2 TRAMADOL MECH_LEVEL_1 Modulate neural transmission 22204-88-2 TRAMADOL TA_LEVEL_2 Analgesics 22204-88-2 TRAMADOL ADVERSE_EFFECT IMU_3_Hypersensitivity 22204-88-2 TRAMADOL ADVERSE_EFFECT NEU_1_Somnolence 22204-88-2 TRAMADOL ADVERSE_EFFECT PSY_2_CNS Stimulation 22204-88-2 TRAMADOL ADVERSE_EFFECT PSY_1_CNS Depression 22204-88-2 TRAMADOL STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 22204-88-2 TRAMADOL MESH_LEVEL_3 Hexanols 22204-88-2 TRAMADOL MESH_LEVEL_2 Alcohols 22204-88-2 TRAMADOL INDICATION Pain 22204-88-2 TRAMADOL MODE_CLASS Solute transporter inhibitor 22204-88-2 TRAMADOL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 22204-88-2 TRAMADOL ADVERSE_EFFECT GIS_1_Constipation 22204-88-2 TRAMADOL ADVERSE_EFFECT NEU_1_Dizziness 22204-88-2 TRAMADOL ADVERSE_EFFECT XXX_2_Withdrawal 22204-88-2 TRAMADOL TA_LEVEL_3 opiate agonist, 5-receptor agonists 22204-88-2 TRAMADOL TA_LEVEL_1 Central Nervous System (CNS) 22204-88-2 TRAMADOL MECHANISM Prolong/enhance neural transmission 22204-88-2 TRAMADOL MECHANISM Modulate neural transmission 22204-88-2 TRAMADOL MODE_CLASS Receptor Agonist 22204-88-2 TRAMADOL THERAPEUTIC_CLASS Analgesics, Opioid 22204-88-2 TRAMADOL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 22204-88-2 TRAMADOL ADVERSE_EFFECT GUS_2_Urinary Retention 22204-88-2 TRAMADOL ADVERSE_EFFECT GIS_1_Nausea 22204-88-2 TRAMADOL ADVERSE_EFFECT NEU_1_Headache 22204-88-2 TRAMADOL ADVERSE_EFFECT PSY_3_Physical Dependence 22204-88-2 TRAMADOL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 22204-88-2 TRAMADOL MESH_LEVEL_1 Organic Chemicals 22204-88-2 TRAMADOL MECH_LEVEL_3 opioid receptor mu 22204-88-2 TRAMADOL PRODUCT_CLASS Analgesics 22204-88-2 TRAMADOL ADVERSE_EFFECT NEU_3_Seizures 22204-88-2 TRAMADOL ADVERSE_EFFECT XXX_2_Asthenia 22204-88-2 TRAMADOL ADVERSE_EFFECT LUN_3_Respiratory Depression 22204-88-2 TRAMADOL ADVERSE_EFFECT GIS_2_Dry Mouth 22204-88-2 TRAMADOL ADVERSE_EFFECT GIS_2_Vomiting 22204-88-2 TRAMADOL ADVERSE_EFFECT SKN_2_Pruritis 22204-88-2 TRAMADOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 22204-88-2 TRAMADOL ZERO_CLASS N 27203-92-5 TRAMADOL MECH_LEVEL_2 opioid agonist 27203-92-5 TRAMADOL MECH_LEVEL_1 Modulate neural transmission 27203-92-5 TRAMADOL TA_LEVEL_2 Analgesics 27203-92-5 TRAMADOL ADVERSE_EFFECT IMU_3_Hypersensitivity 27203-92-5 TRAMADOL ADVERSE_EFFECT NEU_1_Somnolence 27203-92-5 TRAMADOL ADVERSE_EFFECT PSY_2_CNS Stimulation 27203-92-5 TRAMADOL ADVERSE_EFFECT PSY_1_CNS Depression 27203-92-5 TRAMADOL STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 27203-92-5 TRAMADOL MESH_LEVEL_3 Hexanols 27203-92-5 TRAMADOL MESH_LEVEL_2 Alcohols 27203-92-5 TRAMADOL INDICATION Pain 27203-92-5 TRAMADOL MODE_CLASS Solute transporter inhibitor 27203-92-5 TRAMADOL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 27203-92-5 TRAMADOL ADVERSE_EFFECT GIS_1_Constipation 27203-92-5 TRAMADOL ADVERSE_EFFECT NEU_1_Dizziness 27203-92-5 TRAMADOL ADVERSE_EFFECT XXX_2_Withdrawal 27203-92-5 TRAMADOL TA_LEVEL_3 opiate agonist, 5-receptor agonists 27203-92-5 TRAMADOL TA_LEVEL_1 Central Nervous System (CNS) 27203-92-5 TRAMADOL MECHANISM Prolong/enhance neural transmission 27203-92-5 TRAMADOL MECHANISM Modulate neural transmission 27203-92-5 TRAMADOL MODE_CLASS Receptor Agonist 27203-92-5 TRAMADOL THERAPEUTIC_CLASS Analgesics, Opioid 27203-92-5 TRAMADOL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 27203-92-5 TRAMADOL ADVERSE_EFFECT GUS_2_Urinary Retention 27203-92-5 TRAMADOL ADVERSE_EFFECT GIS_1_Nausea 27203-92-5 TRAMADOL ADVERSE_EFFECT NEU_1_Headache 27203-92-5 TRAMADOL ADVERSE_EFFECT PSY_3_Physical Dependence 27203-92-5 TRAMADOL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 27203-92-5 TRAMADOL MESH_LEVEL_1 Organic Chemicals 27203-92-5 TRAMADOL MECH_LEVEL_3 opioid receptor mu 27203-92-5 TRAMADOL PRODUCT_CLASS Analgesics 27203-92-5 TRAMADOL ADVERSE_EFFECT NEU_3_Seizures 27203-92-5 TRAMADOL ADVERSE_EFFECT XXX_2_Asthenia 27203-92-5 TRAMADOL ADVERSE_EFFECT LUN_3_Respiratory Depression 27203-92-5 TRAMADOL ADVERSE_EFFECT GIS_2_Dry Mouth 27203-92-5 TRAMADOL ADVERSE_EFFECT GIS_2_Vomiting 27203-92-5 TRAMADOL ADVERSE_EFFECT SKN_2_Pruritis 27203-92-5 TRAMADOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 27203-92-5 TRAMADOL ZERO_CLASS N 148229-78-1 TRAMADOL MECH_LEVEL_2 opioid agonist 148229-78-1 TRAMADOL MECH_LEVEL_1 Modulate neural transmission 148229-78-1 TRAMADOL TA_LEVEL_2 Analgesics 148229-78-1 TRAMADOL ADVERSE_EFFECT IMU_3_Hypersensitivity 148229-78-1 TRAMADOL ADVERSE_EFFECT NEU_1_Somnolence 148229-78-1 TRAMADOL ADVERSE_EFFECT PSY_2_CNS Stimulation 148229-78-1 TRAMADOL ADVERSE_EFFECT PSY_1_CNS Depression 148229-78-1 TRAMADOL STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 148229-78-1 TRAMADOL MESH_LEVEL_3 Hexanols 148229-78-1 TRAMADOL MESH_LEVEL_2 Alcohols 148229-78-1 TRAMADOL INDICATION Pain 148229-78-1 TRAMADOL MODE_CLASS Solute transporter inhibitor 148229-78-1 TRAMADOL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 148229-78-1 TRAMADOL ADVERSE_EFFECT GIS_1_Constipation 148229-78-1 TRAMADOL ADVERSE_EFFECT NEU_1_Dizziness 148229-78-1 TRAMADOL ADVERSE_EFFECT XXX_2_Withdrawal 148229-78-1 TRAMADOL TA_LEVEL_3 opiate agonist, 5-receptor agonists 148229-78-1 TRAMADOL TA_LEVEL_1 Central Nervous System (CNS) 148229-78-1 TRAMADOL MECHANISM Prolong/enhance neural transmission 148229-78-1 TRAMADOL MECHANISM Modulate neural transmission 148229-78-1 TRAMADOL MODE_CLASS Receptor Agonist 148229-78-1 TRAMADOL THERAPEUTIC_CLASS Analgesics, Opioid 148229-78-1 TRAMADOL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 148229-78-1 TRAMADOL ADVERSE_EFFECT GUS_2_Urinary Retention 148229-78-1 TRAMADOL ADVERSE_EFFECT GIS_1_Nausea 148229-78-1 TRAMADOL ADVERSE_EFFECT NEU_1_Headache 148229-78-1 TRAMADOL ADVERSE_EFFECT PSY_3_Physical Dependence 148229-78-1 TRAMADOL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 148229-78-1 TRAMADOL MESH_LEVEL_1 Organic Chemicals 148229-78-1 TRAMADOL MECH_LEVEL_3 opioid receptor mu 148229-78-1 TRAMADOL PRODUCT_CLASS Analgesics 148229-78-1 TRAMADOL ADVERSE_EFFECT NEU_3_Seizures 148229-78-1 TRAMADOL ADVERSE_EFFECT XXX_2_Asthenia 148229-78-1 TRAMADOL ADVERSE_EFFECT LUN_3_Respiratory Depression 148229-78-1 TRAMADOL ADVERSE_EFFECT GIS_2_Dry Mouth 148229-78-1 TRAMADOL ADVERSE_EFFECT GIS_2_Vomiting 148229-78-1 TRAMADOL ADVERSE_EFFECT SKN_2_Pruritis 148229-78-1 TRAMADOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 148229-78-1 TRAMADOL ZERO_CLASS N 148229-79-2 TRAMADOL MESH_LEVEL_1 Organic Chemicals 148229-79-2 TRAMADOL MECH_LEVEL_3 opioid receptor mu 148229-79-2 TRAMADOL PRODUCT_CLASS Analgesics 148229-79-2 TRAMADOL ADVERSE_EFFECT NEU_3_Seizures 148229-79-2 TRAMADOL ADVERSE_EFFECT XXX_2_Asthenia 148229-79-2 TRAMADOL ADVERSE_EFFECT LUN_3_Respiratory Depression 148229-79-2 TRAMADOL ADVERSE_EFFECT GIS_2_Dry Mouth 148229-79-2 TRAMADOL ADVERSE_EFFECT GIS_2_Vomiting 148229-79-2 TRAMADOL ADVERSE_EFFECT SKN_2_Pruritis 148229-79-2 TRAMADOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 148229-79-2 TRAMADOL ZERO_CLASS N 148229-79-2 TRAMADOL MECH_LEVEL_2 opioid agonist 148229-79-2 TRAMADOL MECH_LEVEL_1 Modulate neural transmission 148229-79-2 TRAMADOL TA_LEVEL_2 Analgesics 148229-79-2 TRAMADOL ADVERSE_EFFECT IMU_3_Hypersensitivity 148229-79-2 TRAMADOL ADVERSE_EFFECT NEU_1_Somnolence 148229-79-2 TRAMADOL ADVERSE_EFFECT PSY_2_CNS Stimulation 148229-79-2 TRAMADOL ADVERSE_EFFECT PSY_1_CNS Depression 148229-79-2 TRAMADOL STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 148229-79-2 TRAMADOL MESH_LEVEL_3 Hexanols 148229-79-2 TRAMADOL MESH_LEVEL_2 Alcohols 148229-79-2 TRAMADOL INDICATION Pain 148229-79-2 TRAMADOL MODE_CLASS Solute transporter inhibitor 148229-79-2 TRAMADOL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 148229-79-2 TRAMADOL ADVERSE_EFFECT GIS_1_Constipation 148229-79-2 TRAMADOL ADVERSE_EFFECT NEU_1_Dizziness 148229-79-2 TRAMADOL ADVERSE_EFFECT XXX_2_Withdrawal 148229-79-2 TRAMADOL TA_LEVEL_3 opiate agonist, 5-receptor agonists 148229-79-2 TRAMADOL TA_LEVEL_1 Central Nervous System (CNS) 148229-79-2 TRAMADOL MECHANISM Prolong/enhance neural transmission 148229-79-2 TRAMADOL MECHANISM Modulate neural transmission 148229-79-2 TRAMADOL MODE_CLASS Receptor Agonist 148229-79-2 TRAMADOL THERAPEUTIC_CLASS Analgesics, Opioid 148229-79-2 TRAMADOL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 148229-79-2 TRAMADOL ADVERSE_EFFECT GUS_2_Urinary Retention 148229-79-2 TRAMADOL ADVERSE_EFFECT GIS_1_Nausea 148229-79-2 TRAMADOL ADVERSE_EFFECT NEU_1_Headache 148229-79-2 TRAMADOL ADVERSE_EFFECT PSY_3_Physical Dependence 148229-79-2 TRAMADOL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 36282-47-0 TRAMADOL TA_LEVEL_1 Central Nervous System (CNS) 36282-47-0 TRAMADOL MESH_LEVEL_1 Organic Chemicals 36282-47-0 TRAMADOL MECH_LEVEL_3 opioid receptor mu 36282-47-0 TRAMADOL PRODUCT_CLASS Analgesics 36282-47-0 TRAMADOL ADVERSE_EFFECT NEU_3_Seizures 36282-47-0 TRAMADOL ADVERSE_EFFECT XXX_2_Asthenia 36282-47-0 TRAMADOL ADVERSE_EFFECT LUN_3_Respiratory Depression 36282-47-0 TRAMADOL ADVERSE_EFFECT GIS_2_Dry Mouth 36282-47-0 TRAMADOL ADVERSE_EFFECT GIS_2_Vomiting 36282-47-0 TRAMADOL TA_LEVEL_3 opiate agonist, 5-receptor agonists 36282-47-0 TRAMADOL INDICATION Pain 36282-47-0 TRAMADOL MECHANISM Prolong/enhance neural transmission 36282-47-0 TRAMADOL MECHANISM Modulate neural transmission 36282-47-0 TRAMADOL MODE_CLASS Receptor Agonist 36282-47-0 TRAMADOL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 36282-47-0 TRAMADOL ADVERSE_EFFECT PSY_3_Physical Dependence 36282-47-0 TRAMADOL ADVERSE_EFFECT GUS_2_Urinary Retention 36282-47-0 TRAMADOL ADVERSE_EFFECT SKN_2_Pruritis 36282-47-0 TRAMADOL THERAPEUTIC_CLASS Analgesics, Opioid 36282-47-0 TRAMADOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 36282-47-0 TRAMADOL ZERO_CLASS N 36282-47-0 TRAMADOL ADVERSE_EFFECT GIS_1_Nausea 36282-47-0 TRAMADOL ADVERSE_EFFECT NEU_1_Headache 36282-47-0 TRAMADOL MECH_LEVEL_2 opioid agonist 36282-47-0 TRAMADOL MECH_LEVEL_1 Modulate neural transmission 36282-47-0 TRAMADOL TA_LEVEL_2 Analgesics 36282-47-0 TRAMADOL ADVERSE_EFFECT IMU_3_Hypersensitivity 36282-47-0 TRAMADOL ADVERSE_EFFECT NEU_1_Somnolence 36282-47-0 TRAMADOL ADVERSE_EFFECT PSY_2_CNS Stimulation 36282-47-0 TRAMADOL ADVERSE_EFFECT PSY_1_CNS Depression 36282-47-0 TRAMADOL STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 36282-47-0 TRAMADOL MESH_LEVEL_3 Hexanols 36282-47-0 TRAMADOL MESH_LEVEL_2 Alcohols 36282-47-0 TRAMADOL MODE_CLASS Solute transporter inhibitor 36282-47-0 TRAMADOL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 36282-47-0 TRAMADOL ADVERSE_EFFECT GIS_1_Constipation 36282-47-0 TRAMADOL ADVERSE_EFFECT NEU_1_Dizziness 36282-47-0 TRAMADOL ADVERSE_EFFECT XXX_2_Withdrawal 36282-47-0 TRAMADOL ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 87679-37-6 TRANDOLAPRIL INDICATION Hypertension 87679-37-6 TRANDOLAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 87679-37-6 TRANDOLAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 87679-37-6 TRANDOLAPRIL MECHANISM Reduce vasoconstriction 87679-37-6 TRANDOLAPRIL INDICATION Congestive Heart Failure (CHF) 87679-37-6 TRANDOLAPRIL MODE_CLASS Enzyme Inhibitor 87679-37-6 TRANDOLAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 87679-37-6 TRANDOLAPRIL PRODUCT_CLASS Cardiovasculars 1197-18-8 TRANEXAMIC ACID STRUCTURE_ACTIVITY Plasmin inhibitor 1197-18-8 TRANEXAMIC ACID ZERO_CLASS N 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT KID_3_Acute Renal Cortical Necrosis 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT CVS_3_Thromboembolism 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 1197-18-8 TRANEXAMIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 1197-18-8 TRANEXAMIC ACID PRODUCT_CLASS Hematologics 1197-18-8 TRANEXAMIC ACID INDICATION Epistaxis / Nose Bleed 1197-18-8 TRANEXAMIC ACID MESH_LEVEL_1 Organic Chemicals 1197-18-8 TRANEXAMIC ACID MECH_LEVEL_2 fibrinolysis inhibitor 1197-18-8 TRANEXAMIC ACID ACTIVITY_CLASS Plasmin inhibitor 1197-18-8 TRANEXAMIC ACID TISSUE_TOXICITY Thromboembolism 1197-18-8 TRANEXAMIC ACID THERAPEUTIC_CLASS Hemostatic Agents 1197-18-8 TRANEXAMIC ACID MESH_LEVEL_3 Acids, Carbocyclic 1197-18-8 TRANEXAMIC ACID TA_LEVEL_3 thrombin inhibitor 1197-18-8 TRANEXAMIC ACID TA_LEVEL_2 Hemostatic Agents 1197-18-8 TRANEXAMIC ACID MESH_LEVEL_2 Carboxylic Acids 1197-18-8 TRANEXAMIC ACID INDICATION Hereditary Angioedema 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT GIS_2_Nausea 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT CVS_3_Pulmonary Thromboembolism 1197-18-8 TRANEXAMIC ACID TISSUE_TOXICITY Hypotension 1197-18-8 TRANEXAMIC ACID INDICATION Menorrhagia / Hypermenorrhea 1197-18-8 TRANEXAMIC ACID MECH_LEVEL_3 GABA-A receptor --> plasminogen 1197-18-8 TRANEXAMIC ACID MECH_LEVEL_1 Clotting cascade inhibitor 1197-18-8 TRANEXAMIC ACID MECHANISM Prolong/enhance neural transmission 1197-18-8 TRANEXAMIC ACID INDICATION Reduce/Prevent Hemorrhage 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT CVS_3_Hypotension 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT NEU_3_Cerebral Thrombosis 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT OCU_3_Central Retinal Artery/Vein Obstruction 1197-18-8 TRANEXAMIC ACID TISSUE_TOXICITY Pulmonary Thromboembolism 1197-18-8 TRANEXAMIC ACID TISSUE_TOXICITY Acute Renal Cortical Necrosis 1197-18-8 TRANEXAMIC ACID MECHANISM Inhibit platelet aggregation 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT OCU_2_Chromatopsia 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT CVS_3_Deep Venous Thrombosis 1197-18-8 TRANEXAMIC ACID ADVERSE_EFFECT GIS_2_Vomiting 1197-18-8 TRANEXAMIC ACID MODE_CLASS Channel Blocker 1197-18-8 TRANEXAMIC ACID INDICATION Surgical Bleeding 1197-18-8 TRANEXAMIC ACID TA_LEVEL_1 Cardiovascular 1197-18-8 TRANEXAMIC ACID KNOWN_TOXICITY Nephrotoxicity 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT GUS_2_Urinary Frequency 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Mania 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_3_Coma 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT OTO_2_Tinnitus 155-09-9 TRANYLCYPROMINE MODE_CLASS Enzyme Inhibitor 155-09-9 TRANYLCYPROMINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT REP_2_Female Orgasm Dysfunction 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Xerostomia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Palpitation 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT SKN_2_Acne 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Peripheral Edema 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Agitation 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Anemia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_3_Seizures 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Drowsiness 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Increased Appetite 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Fatigue 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Weakness 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Weight Gain 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT END_2_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_2_Diaphoresis 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT SKN_3_Skin Rash 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT REP_3_Impotence 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Tremor 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_2_Anorexia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Hallucinations 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_2_Fever 155-09-9 TRANYLCYPROMINE TISSUE_TOXICITY Heart Failure 155-09-9 TRANYLCYPROMINE THERAPEUTIC_CLASS Antidepressants 155-09-9 TRANYLCYPROMINE INDICATION Depression 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_3_Heart Failure 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT REP_2_Priapism 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_3_Syncope 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT LIV_3_Jaundice 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT IMU_2_Urticaria 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Myoclonus 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_1_Confusion 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Hyperreflexia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Paresthesia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Dizziness 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT PSY_1_Insomnia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT REP_2_Impaired Ejaculation 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Restlessness 155-09-9 TRANYLCYPROMINE KNOWN_TOXICITY Cardiovascular Toxicity 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_2_Chills 155-09-9 TRANYLCYPROMINE TISSUE_TOXICITY Hypertensive Crisis 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT OCU_2_Blurred Vision 155-09-9 TRANYLCYPROMINE PRODUCT_CLASS Central Nervous System (CNS) 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT OCU_2_Photophobia 155-09-9 TRANYLCYPROMINE THERAPEUTIC_CLASS Anxiolytics 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT OCU_3_Mydriasis 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT GIS_2_Diarrhea 155-09-9 TRANYLCYPROMINE MECHANISM Prolong/enhance neural transmission 155-09-9 TRANYLCYPROMINE INDICATION Anxiety 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Akinesia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Ataxia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Withdrawal 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT LIV_3_Hepatitis 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT GUS_1_Urinary Retention 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Urinary Incontinence 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Hypertensive Crisis 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Leukopenia 155-09-9 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Hypertension 13492-01-8 TRANYLCYPROMINE INDICATION Anxiety 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_2_Anorexia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Hallucinations 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Tremor 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT REP_3_Impotence 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Withdrawal 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT LIV_3_Hepatitis 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Urinary Incontinence 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Hypertensive Crisis 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Leukopenia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT GUS_2_Urinary Frequency 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Mania 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_2_Diaphoresis 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Anemia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_2_Fever 13492-01-8 TRANYLCYPROMINE TISSUE_TOXICITY Heart Failure 13492-01-8 TRANYLCYPROMINE THERAPEUTIC_CLASS Antidepressants 13492-01-8 TRANYLCYPROMINE INDICATION Depression 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_3_Heart Failure 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT REP_2_Priapism 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_3_Syncope 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT LIV_3_Jaundice 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT IMU_2_Urticaria 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Myoclonus 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_1_Confusion 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Hyperreflexia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Paresthesia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Dizziness 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_1_Insomnia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT REP_2_Impaired Ejaculation 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT GUS_1_Urinary Retention 13492-01-8 TRANYLCYPROMINE KNOWN_TOXICITY Cardiovascular Toxicity 13492-01-8 TRANYLCYPROMINE TISSUE_TOXICITY Hypertensive Crisis 13492-01-8 TRANYLCYPROMINE THERAPEUTIC_CLASS Anxiolytics 13492-01-8 TRANYLCYPROMINE MODE_CLASS Enzyme Inhibitor 13492-01-8 TRANYLCYPROMINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT REP_2_Female Orgasm Dysfunction 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Xerostomia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Palpitation 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT SKN_2_Acne 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Weight Gain 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Peripheral Edema 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT PSY_3_Agitation 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_3_Seizures 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_1_Drowsiness 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_3_Increased Appetite 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Fatigue 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Hypertension 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT OCU_2_Blurred Vision 13492-01-8 TRANYLCYPROMINE PRODUCT_CLASS Central Nervous System (CNS) 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT OCU_2_Photophobia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT END_2_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT SKN_3_Skin Rash 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_2_Chills 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Akinesia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Restlessness 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_2_Ataxia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT NEU_3_Coma 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT OTO_2_Tinnitus 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT XXX_1_Weakness 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT OCU_3_Mydriasis 13492-01-8 TRANYLCYPROMINE ADVERSE_EFFECT GIS_2_Diarrhea 13492-01-8 TRANYLCYPROMINE MECHANISM Prolong/enhance neural transmission 25332-39-2 TRAZODONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 25332-39-2 TRAZODONE ADVERSE_EFFECT NEU_1_Lightheadedness 25332-39-2 TRAZODONE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 25332-39-2 TRAZODONE ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 25332-39-2 TRAZODONE PRODUCT_CLASS Central Nervous System (CNS) 25332-39-2 TRAZODONE THERAPEUTIC_CLASS Antidepressants 25332-39-2 TRAZODONE INDICATION Insomnia 25332-39-2 TRAZODONE TISSUE_TOXICITY Hypotension 25332-39-2 TRAZODONE KNOWN_TOXICITY Cardiovascular Toxicity 25332-39-2 TRAZODONE ADVERSE_EFFECT CVS_1_Hypotension 25332-39-2 TRAZODONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 25332-39-2 TRAZODONE ADVERSE_EFFECT IMU_3_Allergic Reactions 25332-39-2 TRAZODONE ADVERSE_EFFECT XXX_1_Fatigue 25332-39-2 TRAZODONE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 25332-39-2 TRAZODONE ADVERSE_EFFECT OCU_1_Blurred Vision 25332-39-2 TRAZODONE ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 25332-39-2 TRAZODONE TISSUE_TOXICITY Cardiac Arrhythmia 25332-39-2 TRAZODONE INDICATION Panic Disorder 25332-39-2 TRAZODONE MECHANISM Prolong/enhance neural transmission 25332-39-2 TRAZODONE TISSUE_TOXICITY Ventricular Tachycardia 25332-39-2 TRAZODONE ADVERSE_EFFECT PSY_1_Confusion 25332-39-2 TRAZODONE INDICATION Anxiety 25332-39-2 TRAZODONE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 25332-39-2 TRAZODONE ADVERSE_EFFECT REP_1_Priapism 25332-39-2 TRAZODONE ADVERSE_EFFECT CVS_2_Palpitation 25332-39-2 TRAZODONE ADVERSE_EFFECT NEU_1_Drowsiness 25332-39-2 TRAZODONE ADVERSE_EFFECT NEU_1_Headache 25332-39-2 TRAZODONE ADVERSE_EFFECT PSY_1_Nervousness 25332-39-2 TRAZODONE ADVERSE_EFFECT GIS_1_Constipation 25332-39-2 TRAZODONE STRUCTURE_ACTIVITY 5HT2 antagonist 25332-39-2 TRAZODONE MODE_CLASS Solute transporter inhibitor 25332-39-2 TRAZODONE ADVERSE_EFFECT XXX_1_Xerostomia 25332-39-2 TRAZODONE INDICATION Alcohol Dependency and Abuse / Alcoholism 25332-39-2 TRAZODONE INDICATION Depression 25332-39-2 TRAZODONE ADVERSE_EFFECT REP_2_Altered Libido 25332-39-2 TRAZODONE ADVERSE_EFFECT NEU_2_Syncope 25332-39-2 TRAZODONE ADVERSE_EFFECT NEU_1_Dizziness 25332-39-2 TRAZODONE ADVERSE_EFFECT NEU_1_Tremor 19794-93-5 TRAZODONE STRUCTURE_ACTIVITY 5HT2 antagonist 19794-93-5 TRAZODONE INDICATION Alcohol Dependency and Abuse / Alcoholism 19794-93-5 TRAZODONE INDICATION Depression 19794-93-5 TRAZODONE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 19794-93-5 TRAZODONE ADVERSE_EFFECT NEU_1_Dizziness 19794-93-5 TRAZODONE ADVERSE_EFFECT CVS_2_Palpitation 19794-93-5 TRAZODONE MODE_CLASS Solute transporter inhibitor 19794-93-5 TRAZODONE KNOWN_TOXICITY Cardiovascular Toxicity 19794-93-5 TRAZODONE ADVERSE_EFFECT GIS_1_Constipation 19794-93-5 TRAZODONE ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 19794-93-5 TRAZODONE ADVERSE_EFFECT PSY_1_Confusion 19794-93-5 TRAZODONE ADVERSE_EFFECT IMU_3_Allergic Reactions 19794-93-5 TRAZODONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 19794-93-5 TRAZODONE ADVERSE_EFFECT CVS_1_Hypotension 19794-93-5 TRAZODONE ADVERSE_EFFECT XXX_1_Xerostomia 19794-93-5 TRAZODONE TISSUE_TOXICITY Hypotension 19794-93-5 TRAZODONE INDICATION Insomnia 19794-93-5 TRAZODONE THERAPEUTIC_CLASS Antidepressants 19794-93-5 TRAZODONE PRODUCT_CLASS Central Nervous System (CNS) 19794-93-5 TRAZODONE ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 19794-93-5 TRAZODONE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 19794-93-5 TRAZODONE ADVERSE_EFFECT NEU_1_Lightheadedness 19794-93-5 TRAZODONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 19794-93-5 TRAZODONE ADVERSE_EFFECT XXX_1_Fatigue 19794-93-5 TRAZODONE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 19794-93-5 TRAZODONE TISSUE_TOXICITY Ventricular Tachycardia 19794-93-5 TRAZODONE INDICATION Anxiety 19794-93-5 TRAZODONE ADVERSE_EFFECT REP_1_Priapism 19794-93-5 TRAZODONE ADVERSE_EFFECT NEU_1_Drowsiness 19794-93-5 TRAZODONE ADVERSE_EFFECT NEU_1_Headache 19794-93-5 TRAZODONE ADVERSE_EFFECT PSY_1_Nervousness 19794-93-5 TRAZODONE MECHANISM Prolong/enhance neural transmission 19794-93-5 TRAZODONE INDICATION Panic Disorder 19794-93-5 TRAZODONE TISSUE_TOXICITY Cardiac Arrhythmia 19794-93-5 TRAZODONE ADVERSE_EFFECT OCU_1_Blurred Vision 19794-93-5 TRAZODONE ADVERSE_EFFECT NEU_1_Tremor 19794-93-5 TRAZODONE ADVERSE_EFFECT NEU_2_Syncope 19794-93-5 TRAZODONE ADVERSE_EFFECT REP_2_Altered Libido 79855-88-2 TREQUINSIN INDICATION Alopecia / Baldness / Hair Loss 79855-88-2 TREQUINSIN PRODUCT_CLASS Cardiovasculars 79855-88-2 TREQUINSIN THERAPEUTIC_CLASS Antihypertensive Agents 79855-88-2 TREQUINSIN INDICATION Hypertension 78416-81-6 TREQUINSIN INDICATION Hypertension 78416-81-6 TREQUINSIN INDICATION Alopecia / Baldness / Hair Loss 78416-81-6 TREQUINSIN PRODUCT_CLASS Cardiovasculars 78416-81-6 TREQUINSIN THERAPEUTIC_CLASS Antihypertensive Agents 102-76-1 TRIACETIN STRUCTURE_ACTIVITY Unknown mechanism 102-76-1 TRIACETIN INDICATION Tinea Cruris / Jock Itch 102-76-1 TRIACETIN TA_LEVEL_3 antifungal, topical 102-76-1 TRIACETIN MESH_LEVEL_3 Glycerides 102-76-1 TRIACETIN INDICATION Impetigo 102-76-1 TRIACETIN MECH_LEVEL_3 Unknown mechanism 102-76-1 TRIACETIN TA_LEVEL_2 Antifungal 102-76-1 TRIACETIN MECH_LEVEL_2 Unknown mechanism 102-76-1 TRIACETIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 102-76-1 TRIACETIN THERAPEUTIC_CLASS Antifungals, Topical 102-76-1 TRIACETIN INDICATION Tinea Unguium / Onychomycosis 102-76-1 TRIACETIN PRODUCT_CLASS Anti-infectives 102-76-1 TRIACETIN ADVERSE_EFFECT SKN_3_Skin Irritation 102-76-1 TRIACETIN ACTIVITY_CLASS Unknown mechanism 102-76-1 TRIACETIN TA_LEVEL_1 Infectious Disease 102-76-1 TRIACETIN INDICATION Tinea Pedis / Athlete's Foot 102-76-1 TRIACETIN INDICATION Dermatitis 102-76-1 TRIACETIN MESH_LEVEL_1 Lipids and Antilipemic Agents 102-76-1 TRIACETIN MESH_LEVEL_2 Lipids 102-76-1 TRIACETIN ZERO_CLASS Y 396-01-0 TRIAMTERENE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 396-01-0 TRIAMTERENE TISSUE_TOXICITY Acute Interstitial Nephritis 396-01-0 TRIAMTERENE MECH_LEVEL_1 Diuretic 396-01-0 TRIAMTERENE TA_LEVEL_1 Cardiovascular 396-01-0 TRIAMTERENE INDICATION Edematous States 396-01-0 TRIAMTERENE ADVERSE_EFFECT BBM_3_Agranulocytosis 396-01-0 TRIAMTERENE ADVERSE_EFFECT ELT_1_Hyperkalemia 396-01-0 TRIAMTERENE ADVERSE_EFFECT BBM_3_Thrombocytopenia 396-01-0 TRIAMTERENE ADVERSE_EFFECT LIV_3_Jaundice 396-01-0 TRIAMTERENE ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 396-01-0 TRIAMTERENE MESH_LEVEL_3 Pteridines 396-01-0 TRIAMTERENE TA_LEVEL_2 Diuretic 396-01-0 TRIAMTERENE MODE_CLASS Enzyme Inhibitor 396-01-0 TRIAMTERENE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 396-01-0 TRIAMTERENE THERAPEUTIC_CLASS Congestive Heart Failure 396-01-0 TRIAMTERENE THERAPEUTIC_CLASS Diuretics 396-01-0 TRIAMTERENE ADVERSE_EFFECT SKN_3_Rash 396-01-0 TRIAMTERENE KNOWN_TOXICITY Nephrotoxicity 396-01-0 TRIAMTERENE ADVERSE_EFFECT XXX_3_Fatigue 396-01-0 TRIAMTERENE ADVERSE_EFFECT MSK_3_Muscle Weakness 396-01-0 TRIAMTERENE ADVERSE_EFFECT IMU_3_Photosensitivity 396-01-0 TRIAMTERENE ADVERSE_EFFECT XXX_2_Xerostomia 396-01-0 TRIAMTERENE STRUCTURE_ACTIVITY Na+ channel (ENaC) inhibitor, distal tubule diuretic 396-01-0 TRIAMTERENE MESH_LEVEL_1 Heterocyclic Compounds 396-01-0 TRIAMTERENE INDICATION Congestive Heart Failure (CHF) 396-01-0 TRIAMTERENE MECH_LEVEL_3 Na+ channel ENaC 396-01-0 TRIAMTERENE TA_LEVEL_3 Potassium-sparing Diuretic 396-01-0 TRIAMTERENE INDICATION Hypertension 396-01-0 TRIAMTERENE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 396-01-0 TRIAMTERENE MODE_CLASS Channel Blocker 396-01-0 TRIAMTERENE ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 396-01-0 TRIAMTERENE ADVERSE_EFFECT KID_2_Polyuria 396-01-0 TRIAMTERENE ADVERSE_EFFECT KID_3_Increased Creatinine 396-01-0 TRIAMTERENE ADVERSE_EFFECT KID_3_Azotemia 396-01-0 TRIAMTERENE ADVERSE_EFFECT ELT_3_Hypomagnesemia 396-01-0 TRIAMTERENE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 396-01-0 TRIAMTERENE ADVERSE_EFFECT NEU_3_Headache 396-01-0 TRIAMTERENE ZERO_CLASS N 396-01-0 TRIAMTERENE INDICATION Hypokalemia 396-01-0 TRIAMTERENE MECH_LEVEL_2 Na channel antagonist 396-01-0 TRIAMTERENE PRODUCT_CLASS Cardiovasculars 396-01-0 TRIAMTERENE INDICATION Pulmonary Edema 396-01-0 TRIAMTERENE INDICATION Premenstrual Syndrome / Premenstrual Tension 396-01-0 TRIAMTERENE INDICATION Secondary Hyperaldosteronism 396-01-0 TRIAMTERENE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 396-01-0 TRIAMTERENE ADVERSE_EFFECT MSK_3_Muscle Cramps 396-01-0 TRIAMTERENE ADVERSE_EFFECT KID_3_Nephrolithiasis 396-01-0 TRIAMTERENE ADVERSE_EFFECT NEU_2_Dizziness 396-01-0 TRIAMTERENE ADVERSE_EFFECT ELT_3_Hyponatremia 396-01-0 TRIAMTERENE ADVERSE_EFFECT GIS_3_Diarrhea 396-01-0 TRIAMTERENE ADVERSE_EFFECT XXX_3_Weakness 396-01-0 TRIAMTERENE ACTIVITY_CLASS Diuretic 396-01-0 TRIAMTERENE INDICATION Ascites 28911-01-5 TRIAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 28911-01-5 TRIAZOLAM KNOWN_TOXICITY Hepatotoxicity 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_3_Coma 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_1_Dizziness 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_3_Amnesia 28911-01-5 TRIAZOLAM ADVERSE_EFFECT LUN_3_Respiratory Depression 28911-01-5 TRIAZOLAM ADVERSE_EFFECT OCU_3_Visual Disturbances 28911-01-5 TRIAZOLAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 28911-01-5 TRIAZOLAM KNOWN_TOXICITY Embryo/Fetal Toxicity 28911-01-5 TRIAZOLAM ADVERSE_EFFECT LIV_3_Hepatic Failure 28911-01-5 TRIAZOLAM ADVERSE_EFFECT PSY_3_Confusion 28911-01-5 TRIAZOLAM TISSUE_TOXICITY Teratogenicity 28911-01-5 TRIAZOLAM INDICATION Insomnia 28911-01-5 TRIAZOLAM ADVERSE_EFFECT SKN_2_Rash 28911-01-5 TRIAZOLAM ADVERSE_EFFECT LIV_3_Abnormal Liver Function 28911-01-5 TRIAZOLAM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 28911-01-5 TRIAZOLAM MECHANISM Modulate neural transmission 28911-01-5 TRIAZOLAM ADVERSE_EFFECT PSY_2_Physical Dependence 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_3_Paresthesia 28911-01-5 TRIAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 28911-01-5 TRIAZOLAM TISSUE_TOXICITY Hepatic Failure 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_2_Ataxia 28911-01-5 TRIAZOLAM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 28911-01-5 TRIAZOLAM ADVERSE_EFFECT XXX_1_Withdrawal 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_1_Drowsiness 28911-01-5 TRIAZOLAM MODE_CLASS Channel enhancer /opener 28911-01-5 TRIAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 28911-01-5 TRIAZOLAM ADVERSE_EFFECT EMB_2_Teratogenicity 28911-01-5 TRIAZOLAM ADVERSE_EFFECT PSY_3_Depression 28911-01-5 TRIAZOLAM ADVERSE_EFFECT REP_3_Sexual Dysfunction 28911-01-5 TRIAZOLAM ADVERSE_EFFECT XXX_3_Weakness 28911-01-5 TRIAZOLAM ADVERSE_EFFECT GUS_3_Urinary Retention 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_3_Seizures 28911-01-5 TRIAZOLAM ADVERSE_EFFECT PSY_3_Euphoria 28911-01-5 TRIAZOLAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT ELT_2_Hyponatremia 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypochloremia 133-67-5 TRICHLORMETHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 133-67-5 TRICHLORMETHIAZIDE PRODUCT_CLASS Cardiovasculars 133-67-5 TRICHLORMETHIAZIDE THERAPEUTIC_CLASS Diuretics 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT IMU_3_Photosensitivity 133-67-5 TRICHLORMETHIAZIDE THERAPEUTIC_CLASS Congestive Heart Failure 133-67-5 TRICHLORMETHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 133-67-5 TRICHLORMETHIAZIDE INDICATION Hypercalciuria 133-67-5 TRICHLORMETHIAZIDE MODE_CLASS Channel Blocker, selective 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypercalcemia 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT END_2_Glucose Intolerance 133-67-5 TRICHLORMETHIAZIDE INDICATION Hypertension 133-67-5 TRICHLORMETHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 133-67-5 TRICHLORMETHIAZIDE INDICATION Diabetes Insipidus 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypomagnesemia 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT END_1_Increased Serum Lipids 133-67-5 TRICHLORMETHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 133-67-5 TRICHLORMETHIAZIDE INDICATION Pulmonary Edema 133-67-5 TRICHLORMETHIAZIDE INDICATION Congestive Heart Failure (CHF) 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT KID_2_Hyperuricemia 133-67-5 TRICHLORMETHIAZIDE ADVERSE_EFFECT ELT_1_Hypokalemia 650-51-1 TRICHLOROACETIC ACID MECH_LEVEL_2 Unknown mechanism 650-51-1 TRICHLOROACETIC ACID INDICATION Condylomata Acuminata 650-51-1 TRICHLOROACETIC ACID MECH_LEVEL_3 Unknown mechanism 650-51-1 TRICHLOROACETIC ACID INDICATION Warts 650-51-1 TRICHLOROACETIC ACID ADVERSE_EFFECT XXX_2_Inflammation 650-51-1 TRICHLOROACETIC ACID THERAPEUTIC_CLASS Astringents 650-51-1 TRICHLOROACETIC ACID STRUCTURE_ACTIVITY Unknown mechanism 650-51-1 TRICHLOROACETIC ACID PRODUCT_CLASS Dermatologicals 650-51-1 TRICHLOROACETIC ACID TA_LEVEL_1 Dermatology 650-51-1 TRICHLOROACETIC ACID INDICATION Verruca Vulgaris 650-51-1 TRICHLOROACETIC ACID MESH_LEVEL_2 Carboxylic Acids 650-51-1 TRICHLOROACETIC ACID MESH_LEVEL_1 Organic Chemicals 650-51-1 TRICHLOROACETIC ACID ACTIVITY_CLASS Unknown mechanism 650-51-1 TRICHLOROACETIC ACID ADVERSE_EFFECT XXX_2_Burning Sensation 650-51-1 TRICHLOROACETIC ACID TA_LEVEL_3 warts 650-51-1 TRICHLOROACETIC ACID MESH_LEVEL_3 Acids, Acyclic 650-51-1 TRICHLOROACETIC ACID ZERO_CLASS Y 112-24-3 TRIENTINE INDICATION Wilson's Disease 112-24-3 TRIENTINE MECHANISM chelate excess metal 440-17-5 TRIFLUOPERAZINE KNOWN_TOXICITY Cardiovascular Toxicity 440-17-5 TRIFLUOPERAZINE TISSUE_TOXICITY Hypotension 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT OCU_1_Blurred Vision 440-17-5 TRIFLUOPERAZINE THERAPEUTIC_CLASS Antipsychotics 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT LIV_3_Cholestasis 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Leukopenia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Dystonia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT GIS_1_Dry Mouth 440-17-5 TRIFLUOPERAZINE MODE_CLASS Receptor Ligand Antagonist 440-17-5 TRIFLUOPERAZINE PRODUCT_CLASS Central Nervous System (CNS) 440-17-5 TRIFLUOPERAZINE INDICATION Schizophrenia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT OCU_2_Mydriasis 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Pseudo-Parkinsonism 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT END_1_Hyperprolactinemia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT REP_2_Amenorrhea 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Drowsiness 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT REP_2_Impotence 440-17-5 TRIFLUOPERAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 440-17-5 TRIFLUOPERAZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT PSY_1_CNS Depression 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT XXX_1_Withdrawal 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 440-17-5 TRIFLUOPERAZINE TISSUE_TOXICITY Ventricular Tachycardia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Hypotension 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 440-17-5 TRIFLUOPERAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT IMU_2_Photosensitivity 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Akathisia 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_3_Seizures 440-17-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 440-17-5 TRIFLUOPERAZINE MECHANISM Block neural transmission 440-17-5 TRIFLUOPERAZINE INDICATION Anxiety Disorders 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT OCU_1_Blurred Vision 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 117-89-5 TRIFLUOPERAZINE TISSUE_TOXICITY Hypotension 117-89-5 TRIFLUOPERAZINE KNOWN_TOXICITY Cardiovascular Toxicity 117-89-5 TRIFLUOPERAZINE INDICATION Anxiety Disorders 117-89-5 TRIFLUOPERAZINE MECHANISM Block neural transmission 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_3_Seizures 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Akathisia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT IMU_2_Photosensitivity 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Hypotension 117-89-5 TRIFLUOPERAZINE TISSUE_TOXICITY Ventricular Tachycardia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT XXX_1_Withdrawal 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT PSY_1_CNS Depression 117-89-5 TRIFLUOPERAZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 117-89-5 TRIFLUOPERAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT REP_2_Impotence 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Drowsiness 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT REP_2_Amenorrhea 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT END_1_Hyperprolactinemia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Pseudo-Parkinsonism 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT OCU_2_Mydriasis 117-89-5 TRIFLUOPERAZINE MODE_CLASS Receptor Ligand Antagonist 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT GIS_1_Dry Mouth 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Dystonia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT BBM_3_Leukopenia 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT LIV_3_Cholestasis 117-89-5 TRIFLUOPERAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 117-89-5 TRIFLUOPERAZINE THERAPEUTIC_CLASS Antipsychotics 117-89-5 TRIFLUOPERAZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 117-89-5 TRIFLUOPERAZINE INDICATION Schizophrenia 117-89-5 TRIFLUOPERAZINE PRODUCT_CLASS Central Nervous System (CNS) 58947-95-8 TRIHEXYPHENIDYL MECH_LEVEL_2 Receptor agonist, selective 58947-95-8 TRIHEXYPHENIDYL MESH_LEVEL_1 Heterocyclic Compounds 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT GUS_3_Urinary Retention 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_1_Anxiety 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Agitation 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT XXX_2_Xerostomia 58947-95-8 TRIHEXYPHENIDYL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_3_Hallucinations 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_2_Paresthesia 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Euphoria 58947-95-8 TRIHEXYPHENIDYL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M1) antagonist 58947-95-8 TRIHEXYPHENIDYL INDICATION Parkinson's Disease 58947-95-8 TRIHEXYPHENIDYL MECH_LEVEL_3 Muscarinic acetylcholine receptor M1 58947-95-8 TRIHEXYPHENIDYL TA_LEVEL_3 Parkinsons 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Depression 58947-95-8 TRIHEXYPHENIDYL TA_LEVEL_1 Central Nervous System (CNS) 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT GIS_2_Constipation 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_3_Amnesia 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_2_Headache 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_3_Psychosis 58947-95-8 TRIHEXYPHENIDYL ZERO_CLASS N 58947-95-8 TRIHEXYPHENIDYL PRODUCT_CLASS Central Nervous System (CNS) 58947-95-8 TRIHEXYPHENIDYL THERAPEUTIC_CLASS Movement Disorders 58947-95-8 TRIHEXYPHENIDYL ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT CVS_3_Tachycardia 58947-95-8 TRIHEXYPHENIDYL MECHANISM Modulate G-protein coupled signal transduction 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_2_Mydriasis 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT CVS_2_Hypertension 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Confusion 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_3_Cycloplegia 58947-95-8 TRIHEXYPHENIDYL MESH_LEVEL_3 Piperidines 58947-95-8 TRIHEXYPHENIDYL TA_LEVEL_2 Movement disorders 58947-95-8 TRIHEXYPHENIDYL INDICATION Extrapyramidal Disorders 58947-95-8 TRIHEXYPHENIDYL MODE_CLASS Receptor Agonist, selective 58947-95-8 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_2_Blurred Vision 58947-95-8 TRIHEXYPHENIDYL INDICATION Parkinsonism 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_2_Mydriasis 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT CVS_2_Hypertension 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Confusion 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_3_Cycloplegia 144-11-6 TRIHEXYPHENIDYL MESH_LEVEL_3 Piperidines 144-11-6 TRIHEXYPHENIDYL TA_LEVEL_2 Movement disorders 144-11-6 TRIHEXYPHENIDYL INDICATION Extrapyramidal Disorders 144-11-6 TRIHEXYPHENIDYL MODE_CLASS Receptor Agonist, selective 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_2_Blurred Vision 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_3_Hallucinations 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_2_Paresthesia 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Euphoria 144-11-6 TRIHEXYPHENIDYL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M1) antagonist 144-11-6 TRIHEXYPHENIDYL INDICATION Parkinson's Disease 144-11-6 TRIHEXYPHENIDYL MECH_LEVEL_3 Muscarinic acetylcholine receptor M1 144-11-6 TRIHEXYPHENIDYL TA_LEVEL_3 Parkinsons 144-11-6 TRIHEXYPHENIDYL INDICATION Parkinsonism 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT GIS_2_Constipation 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_3_Amnesia 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_2_Headache 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_3_Psychosis 144-11-6 TRIHEXYPHENIDYL ZERO_CLASS N 144-11-6 TRIHEXYPHENIDYL PRODUCT_CLASS Central Nervous System (CNS) 144-11-6 TRIHEXYPHENIDYL THERAPEUTIC_CLASS Movement Disorders 144-11-6 TRIHEXYPHENIDYL ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 144-11-6 TRIHEXYPHENIDYL MECH_LEVEL_2 Receptor agonist, selective 144-11-6 TRIHEXYPHENIDYL MESH_LEVEL_1 Heterocyclic Compounds 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT GUS_3_Urinary Retention 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Depression 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_1_Anxiety 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Agitation 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT XXX_2_Xerostomia 144-11-6 TRIHEXYPHENIDYL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 144-11-6 TRIHEXYPHENIDYL MECHANISM Modulate G-protein coupled signal transduction 144-11-6 TRIHEXYPHENIDYL TA_LEVEL_1 Central Nervous System (CNS) 144-11-6 TRIHEXYPHENIDYL ADVERSE_EFFECT CVS_3_Tachycardia 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_2_Mydriasis 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT CVS_2_Hypertension 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Confusion 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_3_Cycloplegia 52-49-3 TRIHEXYPHENIDYL MESH_LEVEL_3 Piperidines 52-49-3 TRIHEXYPHENIDYL TA_LEVEL_2 Movement disorders 52-49-3 TRIHEXYPHENIDYL INDICATION Extrapyramidal Disorders 52-49-3 TRIHEXYPHENIDYL MODE_CLASS Receptor Agonist, selective 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT OCU_2_Blurred Vision 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_3_Hallucinations 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_2_Paresthesia 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Euphoria 52-49-3 TRIHEXYPHENIDYL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M1) antagonist 52-49-3 TRIHEXYPHENIDYL INDICATION Parkinson's Disease 52-49-3 TRIHEXYPHENIDYL MECH_LEVEL_3 Muscarinic acetylcholine receptor M1 52-49-3 TRIHEXYPHENIDYL TA_LEVEL_3 Parkinsons 52-49-3 TRIHEXYPHENIDYL INDICATION Parkinsonism 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT GIS_2_Constipation 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT CVS_3_Tachycardia 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_2_Headache 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_3_Psychosis 52-49-3 TRIHEXYPHENIDYL ZERO_CLASS N 52-49-3 TRIHEXYPHENIDYL PRODUCT_CLASS Central Nervous System (CNS) 52-49-3 TRIHEXYPHENIDYL THERAPEUTIC_CLASS Movement Disorders 52-49-3 TRIHEXYPHENIDYL ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 52-49-3 TRIHEXYPHENIDYL MESH_LEVEL_1 Heterocyclic Compounds 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT GUS_3_Urinary Retention 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Depression 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_1_Anxiety 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT PSY_2_Agitation 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT XXX_2_Xerostomia 52-49-3 TRIHEXYPHENIDYL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 52-49-3 TRIHEXYPHENIDYL MECHANISM Modulate G-protein coupled signal transduction 52-49-3 TRIHEXYPHENIDYL TA_LEVEL_1 Central Nervous System (CNS) 52-49-3 TRIHEXYPHENIDYL MECH_LEVEL_2 Receptor agonist, selective 52-49-3 TRIHEXYPHENIDYL ADVERSE_EFFECT NEU_3_Amnesia 554-92-7 TRIMETHOBENZAMIDE MECHANISM Block neural transmission 554-92-7 TRIMETHOBENZAMIDE MODE_CLASS Receptor Ligand Antagonist 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Hemolytic Anemia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT GIS_1_Dysgeusia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Neutropenia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Thrombocytopenia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Methemoglobinemia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT PSY_1_Anorexia 738-70-5 TRIMETHOPRIM STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT GIS_1_Abdominal Pain 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Leukopenia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT ELT_3_Hyponatremia 738-70-5 TRIMETHOPRIM PRODUCT_CLASS Anti-infectives 738-70-5 TRIMETHOPRIM INDICATION Traveler's Diarrhea 738-70-5 TRIMETHOPRIM THERAPEUTIC_CLASS Antibacterials, Systemic 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT SKN_2_Skin Rash 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT XXX_2_Candidiasis 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT ELT_3_Hyperkalemia 738-70-5 TRIMETHOPRIM MODE_CLASS Enzyme Inhibitor 738-70-5 TRIMETHOPRIM INDICATION Acute Otitis Media 738-70-5 TRIMETHOPRIM INDICATION Urinary Tract Infection (UTI) 738-70-5 TRIMETHOPRIM MECHANISM Inhibit precursor synthesis 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT XXX_3_Glossitis 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT BBM_3_Anemia 738-70-5 TRIMETHOPRIM ADVERSE_EFFECT IMU_3_Photosensitivity 82952-64-5 TRIMETREXATE MODE_CLASS Enzyme substrate mimic 82952-64-5 TRIMETREXATE THERAPEUTIC_CLASS Antibacterials 82952-64-5 TRIMETREXATE STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 82952-64-5 TRIMETREXATE PRODUCT_CLASS Anti-infectives 82952-64-5 TRIMETREXATE INDICATION Pneumocystis Carinii Pneumonia (PCP) 82952-64-5 TRIMETREXATE MECHANISM Inhibit precursor synthesis 521-78-8 TRIMIPRAMINE MECHANISM Prolong/enhance neural transmission 521-78-8 TRIMIPRAMINE INDICATION Depression 521-78-8 TRIMIPRAMINE MODE_CLASS Solute transporter inhibitor 521-78-8 TRIMIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 521-78-8 TRIMIPRAMINE THERAPEUTIC_CLASS Antidepressants 739-71-9 TRIMIPRAMINE MODE_CLASS Solute transporter inhibitor 739-71-9 TRIMIPRAMINE MECHANISM Prolong/enhance neural transmission 739-71-9 TRIMIPRAMINE INDICATION Depression 739-71-9 TRIMIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 739-71-9 TRIMIPRAMINE THERAPEUTIC_CLASS Antidepressants 3902-71-4 TRIOXSALEN ADVERSE_EFFECT GIS_3_Gastrointestinal Distress 3902-71-4 TRIOXSALEN ADVERSE_EFFECT IMU_1_Phototoxicity 3902-71-4 TRIOXSALEN STRUCTURE_ACTIVITY Unknown mechanism 3902-71-4 TRIOXSALEN INDICATION Skin Hypopigmentation 3902-71-4 TRIOXSALEN PRODUCT_CLASS Dermatologicals 3902-71-4 TRIOXSALEN MODE_CLASS Distorts /blocks macromolecular scaffold function 3902-71-4 TRIOXSALEN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3902-71-4 TRIOXSALEN ADVERSE_EFFECT PSY_3_Nervousness 3902-71-4 TRIOXSALEN MECHANISM Inhibit DNA synthesis, repair, and function 3902-71-4 TRIOXSALEN INDICATION Vitiligo 3902-71-4 TRIOXSALEN MODE_CLASS Enzyme Inhibitor 3902-71-4 TRIOXSALEN KNOWN_TOXICITY Immune System Toxicity 3902-71-4 TRIOXSALEN MECHANISM interferes with liver P450 enzyme funciton 3902-71-4 TRIOXSALEN ADVERSE_EFFECT NEU_3_Vertigo 3902-71-4 TRIOXSALEN ADVERSE_EFFECT PSY_3_Mental Depression 3902-71-4 TRIOXSALEN TISSUE_TOXICITY Phototoxicity 3902-71-4 TRIOXSALEN ADVERSE_EFFECT PSY_3_CNS Excitation 3902-71-4 TRIOXSALEN INDICATION Photoprotection 3902-71-4 TRIOXSALEN THERAPEUTIC_CLASS Psoralens 154-69-8 TRIPELENNAMINE MECHANISM Modulate G-protein coupled signal transduction 154-69-8 TRIPELENNAMINE MODE_CLASS Receptor Ligand Antagonist 6138-56-3 TRIPELENNAMINE MECHANISM Modulate G-protein coupled signal transduction 6138-56-3 TRIPELENNAMINE MODE_CLASS Receptor Ligand Antagonist 550-70-9 TRIPROLIDINE PRODUCT_CLASS Anti-inflammatories 550-70-9 TRIPROLIDINE MECHANISM Modulate G-protein coupled signal transduction 550-70-9 TRIPROLIDINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 550-70-9 TRIPROLIDINE THERAPEUTIC_CLASS Antihistamines 550-70-9 TRIPROLIDINE MODE_CLASS Receptor Ligand Antagonist 550-70-9 TRIPROLIDINE INDICATION Urticaria / Hives 550-70-9 TRIPROLIDINE INDICATION Allergic Conjunctivitis 550-70-9 TRIPROLIDINE INDICATION Allergic Rhinitis 486-12-4 TRIPROLIDINE INDICATION Urticaria / Hives 486-12-4 TRIPROLIDINE MODE_CLASS Receptor Ligand Antagonist 486-12-4 TRIPROLIDINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 486-12-4 TRIPROLIDINE INDICATION Allergic Rhinitis 486-12-4 TRIPROLIDINE PRODUCT_CLASS Anti-inflammatories 486-12-4 TRIPROLIDINE INDICATION Allergic Conjunctivitis 486-12-4 TRIPROLIDINE MECHANISM Modulate G-protein coupled signal transduction 486-12-4 TRIPROLIDINE THERAPEUTIC_CLASS Antihistamines 2751-09-9 TROLEANDOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2751-09-9 TROLEANDOMYCIN MECHANISM Inhibit ribosomal protein synthesis 2751-09-9 TROLEANDOMYCIN PRODUCT_CLASS Anti-infectives 2751-09-9 TROLEANDOMYCIN THERAPEUTIC_CLASS Antibacterials 1508-75-4 TROPICAMIDE ADVERSE_EFFECT GIS_3_Constipation 1508-75-4 TROPICAMIDE ADVERSE_EFFECT CVS_3_Tachycardia 1508-75-4 TROPICAMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 1508-75-4 TROPICAMIDE ADVERSE_EFFECT CVS_3_Cardio-Respiratory Collapse 1508-75-4 TROPICAMIDE TISSUE_TOXICITY Cardio-Respiratory Collapse 1508-75-4 TROPICAMIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 1508-75-4 TROPICAMIDE ADVERSE_EFFECT OCU_2_Increased Intraocular Pressure 1508-75-4 TROPICAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 1508-75-4 TROPICAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 1508-75-4 TROPICAMIDE INDICATION Induction of Cycloplegia for Eye Examinations 1508-75-4 TROPICAMIDE ADVERSE_EFFECT PSY_3_Psychosis 1508-75-4 TROPICAMIDE TISSUE_TOXICITY Cardiac Arrhythmia 1508-75-4 TROPICAMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 1508-75-4 TROPICAMIDE ADVERSE_EFFECT GUS_3_Urinary Retention 1508-75-4 TROPICAMIDE ADVERSE_EFFECT GIS_3_Dry Mouth 1508-75-4 TROPICAMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 1508-75-4 TROPICAMIDE ADVERSE_EFFECT OCU_1_Blurred Vision 1508-75-4 TROPICAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 1508-75-4 TROPICAMIDE MECHANISM Modulate G-protein coupled signal transduction 1508-75-4 TROPICAMIDE ADVERSE_EFFECT NEU_2_Headache 1508-75-4 TROPICAMIDE ADVERSE_EFFECT OCU_1_Photophobia 1508-75-4 TROPICAMIDE INDICATION Induction of mydriasis for eye examinations 1508-75-4 TROPICAMIDE MODE_CLASS Receptor Ligand Antagonist 57-94-3 D-TUBOCURARINE CHLORIDE ZERO_CLASS N 57-94-3 D-TUBOCURARINE CHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT XXX_3_Edema 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT CVS_1_Hypotension 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT LUN_2_Dyspnea 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT SKN_3_Flushing 57-94-3 D-TUBOCURARINE CHLORIDE MESH_LEVEL_1 Heterocyclic Compounds 57-94-3 D-TUBOCURARINE CHLORIDE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-4 57-94-3 D-TUBOCURARINE CHLORIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 57-94-3 D-TUBOCURARINE CHLORIDE TA_LEVEL_3 Skeletal Muscle Relaxants 57-94-3 D-TUBOCURARINE CHLORIDE INDICATION Myasthenia Gravis Diagnosis 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT SKN_2_Pruritis 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT LUN_2_Respiratory Depression 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT IMU_3_Urticaria 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT LUN_2_Apnea 57-94-3 D-TUBOCURARINE CHLORIDE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 57-94-3 D-TUBOCURARINE CHLORIDE TISSUE_TOXICITY Hypotension 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT LUN_2_Bronchospasm 57-94-3 D-TUBOCURARINE CHLORIDE TISSUE_TOXICITY Cardiac Arrhythmia 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT LUN_2_Wheezing 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT XXX_2_Malignant Hyperthermia 57-94-3 D-TUBOCURARINE CHLORIDE INDICATION Electroconvulsive Therapy (ECT) 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT SKN_2_Rash 57-94-3 D-TUBOCURARINE CHLORIDE MODE_CLASS Channel Blocker 57-94-3 D-TUBOCURARINE CHLORIDE MESH_LEVEL_3 Indole Alkaloids 57-94-3 D-TUBOCURARINE CHLORIDE TA_LEVEL_1 Central Nervous System (CNS) 57-94-3 D-TUBOCURARINE CHLORIDE MECH_LEVEL_1 Block neural transmission 57-94-3 D-TUBOCURARINE CHLORIDE ADVERSE_EFFECT SKN_3_Erythema 57-94-3 D-TUBOCURARINE CHLORIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 57-94-3 D-TUBOCURARINE CHLORIDE MECH_LEVEL_2 Cholinergic receptor agonist 57-94-3 D-TUBOCURARINE CHLORIDE MECHANISM Block neural transmission 57-94-3 D-TUBOCURARINE CHLORIDE INDICATION Neuromuscular Blockade 57-94-3 D-TUBOCURARINE CHLORIDE MESH_LEVEL_2 Alkaloids 57-94-3 D-TUBOCURARINE CHLORIDE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 170858-33-0 U-101387G PRODUCT_CLASS Central Nervous System (CNS) 170858-33-0 U-101387G THERAPEUTIC_CLASS Neurodegenerative Disorders 170858-33-0 U-101387G THERAPEUTIC_CLASS Antipsychotics 96744-75-1 U-69593 MECHANISM Modulate neural transmission 96744-75-1 U-69593 MODE_CLASS Receptor Agonist, selective 96744-75-1 U-69593 PRODUCT_CLASS Biochemicals 51-79-6 URETHANE MECH_LEVEL_1 Modulate neurotransmission 51-79-6 URETHANE MODE_CLASS Channel Modulator 51-79-6 URETHANE KNOWN_TOXICITY Carcinogenicity 51-79-6 URETHANE KNOWN_TOXICITY Embryo/Fetal Toxicity 51-79-6 URETHANE ADVERSE_EFFECT XXX_2_Death 51-79-6 URETHANE ADVERSE_EFFECT NEU_2_Coma 51-79-6 URETHANE ADVERSE_EFFECT BBM_1_Bone Marrow Depression 51-79-6 URETHANE ADVERSE_EFFECT CVS_2_Cardiovascular Toxicity 51-79-6 URETHANE ACTIVITY_CLASS Glutamate antagonist 51-79-6 URETHANE ZERO_CLASS N 51-79-6 URETHANE TISSUE_TOXICITY Bone Marrow Depression 51-79-6 URETHANE TISSUE_TOXICITY Granulocytopenia 51-79-6 URETHANE TISSUE_TOXICITY Thrombocytopenia 51-79-6 URETHANE MESH_LEVEL_1 Organic Chemicals 51-79-6 URETHANE TA_LEVEL_1 Toxicants 51-79-6 URETHANE MECH_LEVEL_3 AMPA Glutamate receptor 51-79-6 URETHANE MESH_LEVEL_3 Acids, Acyclic 51-79-6 URETHANE MODE_CLASS Channel Blocker, selective 51-79-6 URETHANE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 51-79-6 URETHANE KNOWN_TOXICITY Hepatotoxicity 51-79-6 URETHANE ADVERSE_EFFECT GIS_1_Vomiting 51-79-6 URETHANE ADVERSE_EFFECT BBM_1_Leukopenia 51-79-6 URETHANE ADVERSE_EFFECT BBM_2_Hemorrhage 51-79-6 URETHANE ADVERSE_EFFECT EMB_1_Teratogenicity 51-79-6 URETHANE TISSUE_TOXICITY Death 51-79-6 URETHANE TISSUE_TOXICITY Teratogenicity 51-79-6 URETHANE MECHANISM Induce free oxygen radical associated tissue and DNA damage 51-79-6 URETHANE TA_LEVEL_3 Liver toxicants 51-79-6 URETHANE PRODUCT_CLASS Toxicants 51-79-6 URETHANE MECHANISM Block neural transmission 51-79-6 URETHANE ADVERSE_EFFECT DNA_1_Carcinogenicity 51-79-6 URETHANE ADVERSE_EFFECT BBM_1_Thrombocytopenia 51-79-6 URETHANE ADVERSE_EFFECT KID_2_Kidney Damage 51-79-6 URETHANE KNOWN_TOXICITY Miscellaneous 51-79-6 URETHANE TISSUE_TOXICITY Cardiovascular Toxicity 51-79-6 URETHANE TISSUE_TOXICITY Leukopenia 51-79-6 URETHANE TA_LEVEL_2 Biochemical 51-79-6 URETHANE MESH_LEVEL_2 Carboxylic Acids 51-79-6 URETHANE MECHANISM Prolong/enhance neural transmission 51-79-6 URETHANE KNOWN_TOXICITY Cardiovascular Toxicity 51-79-6 URETHANE ADVERSE_EFFECT LIV_2_Hepatotoxicity 51-79-6 URETHANE ADVERSE_EFFECT BBM_1_Granulocytopenia 51-79-6 URETHANE ADVERSE_EFFECT BBM_1_Bone Marrow Hypoplasia 51-79-6 URETHANE STRUCTURE_ACTIVITY Glutamate receptor antagonist, GABA-A agonist 51-79-6 URETHANE TISSUE_TOXICITY Carcinogenicity 51-79-6 URETHANE TISSUE_TOXICITY Hepatotoxicity 51-79-6 URETHANE TISSUE_TOXICITY Bone Marrow Hypoplasia 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT IMU_3_Photosensitivity 124832-26-4 VALACYCLOVIR MESH_LEVEL_3 Purines 124832-26-4 VALACYCLOVIR MECHANISM Inhibit viral DNA synthesis 124832-26-4 VALACYCLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 124832-26-4 VALACYCLOVIR INDICATION Herpes Genitalis / Genital Herpes 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_2_Depression 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT GIS_1_Nausea / Vomiting 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT SKN_2_Rash 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Agitation 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT MSK_2_Arthralgia 124832-26-4 VALACYCLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Mania 124832-26-4 VALACYCLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT REP_2_Dysmenorrhea 124832-26-4 VALACYCLOVIR MESH_LEVEL_1 Heterocyclic Compounds 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT GIS_2_Diarrhea 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT CVS_3_Hypertension 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_2_Confusion 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Psychosis 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT BBM_3_Aplastic Anemia 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT XXX_3_Hemolytic-Uremic Syndrome 124832-26-4 VALACYCLOVIR TA_LEVEL_2 Anti-viral 124832-26-4 VALACYCLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 124832-26-4 VALACYCLOVIR MECH_LEVEL_1 Anti-viral 124832-26-4 VALACYCLOVIR TA_LEVEL_1 Infectious Disease 124832-26-4 VALACYCLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT CVS_2_Tachycardia 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Hallucinations 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT NEU_1_Dizziness 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT NEU_3_Coma 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT XXX_2_Facial Edema 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT KID_2_Increased Creatinine 124832-26-4 VALACYCLOVIR TA_LEVEL_3 viral replication inhibitor 124832-26-4 VALACYCLOVIR PRODUCT_CLASS Anti-infectives 124832-26-4 VALACYCLOVIR INDICATION Herpes Zoster / Shingles 124832-26-4 VALACYCLOVIR MODE_CLASS Enzyme Inhibitor, selective 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT IMU_2_Anaphylactoid Reactions 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT PSY_3_Delirium 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT NEU_1_Headache 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT NEU_3_Encephalopathy 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT SKN_3_Erythema Multiforme 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT BBM_2_Thrombocytopenia 124832-26-4 VALACYCLOVIR ADVERSE_EFFECT GIS_1_Abdominal Pain 124832-26-4 VALACYCLOVIR ZERO_CLASS N 124832-26-4 VALACYCLOVIR ACTIVITY_CLASS Anti-viral 56097-80-4 VALCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 56097-80-4 VALCONAZOLE MODE_CLASS Enzyme Inhibitor 56097-80-4 VALCONAZOLE THERAPEUTIC_CLASS Antifungals 56097-80-4 VALCONAZOLE PRODUCT_CLASS Anti-infectives 99-66-1 VALPROIC ACID MECH_LEVEL_2 Increased GABA transmission 99-66-1 VALPROIC ACID MODE_CLASS Channel Modulator 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_1_Tremor 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_1_Dizziness 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_2_Nystagmus 99-66-1 VALPROIC ACID ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 99-66-1 VALPROIC ACID ADVERSE_EFFECT XXX_1_Asthenia 99-66-1 VALPROIC ACID TISSUE_TOXICITY Teratogenicity 99-66-1 VALPROIC ACID TA_LEVEL_3 Complex, partial seizures 99-66-1 VALPROIC ACID PRODUCT_CLASS Central Nervous System (CNS) 99-66-1 VALPROIC ACID MESH_LEVEL_3 Acids, Acyclic 99-66-1 VALPROIC ACID MECHANISM Modulate channel gating 99-66-1 VALPROIC ACID MODE_CLASS Enzyme Inhibitor 99-66-1 VALPROIC ACID THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_2_Amnesia 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_1_Headache 99-66-1 VALPROIC ACID ADVERSE_EFFECT OCU_2_Diplopia 99-66-1 VALPROIC ACID ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_1_Somnolence 99-66-1 VALPROIC ACID STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 99-66-1 VALPROIC ACID KNOWN_TOXICITY Hepatotoxicity 99-66-1 VALPROIC ACID TA_LEVEL_2 CNS Depressant 99-66-1 VALPROIC ACID MECH_LEVEL_3 Unknown mechanism 99-66-1 VALPROIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 99-66-1 VALPROIC ACID ADVERSE_EFFECT GIS_1_Vomiting 99-66-1 VALPROIC ACID ADVERSE_EFFECT NEU_2_Ataxia 99-66-1 VALPROIC ACID ADVERSE_EFFECT BBM_1_Thrombocytopenia 99-66-1 VALPROIC ACID ADVERSE_EFFECT REP_2_Menstrual Abnormalities 99-66-1 VALPROIC ACID ADVERSE_EFFECT END_3_Hyperammonemia 99-66-1 VALPROIC ACID KNOWN_TOXICITY Blood & Bone Marrow Toxicity 99-66-1 VALPROIC ACID TISSUE_TOXICITY Hepatotoxicity 99-66-1 VALPROIC ACID ACTIVITY_CLASS Na+ channel blocker 99-66-1 VALPROIC ACID MESH_LEVEL_1 Organic Chemicals 99-66-1 VALPROIC ACID INDICATION Absence (Petit Mal) Seizures 99-66-1 VALPROIC ACID ADVERSE_EFFECT EMB_1_Teratogenicity 99-66-1 VALPROIC ACID ADVERSE_EFFECT GIS_1_Nausea 99-66-1 VALPROIC ACID ADVERSE_EFFECT IMU_3_Anaphylaxis 99-66-1 VALPROIC ACID ADVERSE_EFFECT LIV_2_Hepatotoxicity 99-66-1 VALPROIC ACID ADVERSE_EFFECT GIS_3_Pancreatitis 99-66-1 VALPROIC ACID ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 99-66-1 VALPROIC ACID ZERO_CLASS N 99-66-1 VALPROIC ACID KNOWN_TOXICITY Embryo/Fetal Toxicity 99-66-1 VALPROIC ACID TISSUE_TOXICITY Thrombocytopenia 99-66-1 VALPROIC ACID MESH_LEVEL_2 Carboxylic Acids 99-66-1 VALPROIC ACID MECHANISM Prolong/enhance neural transmission 99-66-1 VALPROIC ACID INDICATION Complex Partial Seizures 99-66-1 VALPROIC ACID MECH_LEVEL_1 Modulate neural transmission 99-66-1 VALPROIC ACID TA_LEVEL_1 Central Nervous System (CNS) 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_2_Amnesia 76584-70-8 VALPROIC ACID MECH_LEVEL_2 Increased GABA transmission 76584-70-8 VALPROIC ACID MODE_CLASS Channel Modulator 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_1_Tremor 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_1_Dizziness 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_2_Nystagmus 76584-70-8 VALPROIC ACID ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 76584-70-8 VALPROIC ACID ADVERSE_EFFECT XXX_1_Asthenia 76584-70-8 VALPROIC ACID TISSUE_TOXICITY Teratogenicity 76584-70-8 VALPROIC ACID TA_LEVEL_3 Complex, partial seizures 76584-70-8 VALPROIC ACID PRODUCT_CLASS Central Nervous System (CNS) 76584-70-8 VALPROIC ACID MESH_LEVEL_3 Acids, Acyclic 76584-70-8 VALPROIC ACID MECHANISM Modulate channel gating 76584-70-8 VALPROIC ACID MODE_CLASS Enzyme Inhibitor 76584-70-8 VALPROIC ACID THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 76584-70-8 VALPROIC ACID ADVERSE_EFFECT IMU_3_Anaphylaxis 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_1_Headache 76584-70-8 VALPROIC ACID ADVERSE_EFFECT EMB_1_Teratogenicity 76584-70-8 VALPROIC ACID ADVERSE_EFFECT OCU_2_Diplopia 76584-70-8 VALPROIC ACID ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_1_Somnolence 76584-70-8 VALPROIC ACID STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 76584-70-8 VALPROIC ACID KNOWN_TOXICITY Hepatotoxicity 76584-70-8 VALPROIC ACID TA_LEVEL_2 CNS Depressant 76584-70-8 VALPROIC ACID MECH_LEVEL_3 Unknown mechanism 76584-70-8 VALPROIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 76584-70-8 VALPROIC ACID ADVERSE_EFFECT GIS_1_Vomiting 76584-70-8 VALPROIC ACID ADVERSE_EFFECT NEU_2_Ataxia 76584-70-8 VALPROIC ACID ADVERSE_EFFECT BBM_1_Thrombocytopenia 76584-70-8 VALPROIC ACID ADVERSE_EFFECT REP_2_Menstrual Abnormalities 76584-70-8 VALPROIC ACID ADVERSE_EFFECT END_3_Hyperammonemia 76584-70-8 VALPROIC ACID KNOWN_TOXICITY Blood & Bone Marrow Toxicity 76584-70-8 VALPROIC ACID TISSUE_TOXICITY Hepatotoxicity 76584-70-8 VALPROIC ACID INDICATION Absence (Petit Mal) Seizures 76584-70-8 VALPROIC ACID ACTIVITY_CLASS Na+ channel blocker 76584-70-8 VALPROIC ACID ADVERSE_EFFECT GIS_1_Nausea 76584-70-8 VALPROIC ACID MESH_LEVEL_1 Organic Chemicals 76584-70-8 VALPROIC ACID ADVERSE_EFFECT LIV_2_Hepatotoxicity 76584-70-8 VALPROIC ACID ADVERSE_EFFECT GIS_3_Pancreatitis 76584-70-8 VALPROIC ACID ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 76584-70-8 VALPROIC ACID ZERO_CLASS N 76584-70-8 VALPROIC ACID KNOWN_TOXICITY Embryo/Fetal Toxicity 76584-70-8 VALPROIC ACID TISSUE_TOXICITY Thrombocytopenia 76584-70-8 VALPROIC ACID MESH_LEVEL_2 Carboxylic Acids 76584-70-8 VALPROIC ACID MECHANISM Prolong/enhance neural transmission 76584-70-8 VALPROIC ACID INDICATION Complex Partial Seizures 76584-70-8 VALPROIC ACID MECH_LEVEL_1 Modulate neural transmission 76584-70-8 VALPROIC ACID TA_LEVEL_1 Central Nervous System (CNS) 137862-53-4 VALSARTAN KNOWN_TOXICITY Cardiovascular Toxicity 137862-53-4 VALSARTAN ADVERSE_EFFECT EMB_2_Oligohydramnios 137862-53-4 VALSARTAN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 137862-53-4 VALSARTAN ADVERSE_EFFECT NEU_2_Headache 137862-53-4 VALSARTAN ADVERSE_EFFECT XXX_2_Fatigue 137862-53-4 VALSARTAN MECH_LEVEL_2 Diuretic 137862-53-4 VALSARTAN INDICATION Hypertension 137862-53-4 VALSARTAN ZERO_CLASS N 137862-53-4 VALSARTAN TISSUE_TOXICITY Hypotension 137862-53-4 VALSARTAN ADVERSE_EFFECT EMB_2_Fetal / Neonatal Morbidity and Mortality 137862-53-4 VALSARTAN ADVERSE_EFFECT BBM_2_Neutropenia 137862-53-4 VALSARTAN ADVERSE_EFFECT NEU_2_Dizziness 137862-53-4 VALSARTAN ADVERSE_EFFECT ELT_2_Hyperkalemia 137862-53-4 VALSARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 137862-53-4 VALSARTAN TA_LEVEL_3 Diuretic 137862-53-4 VALSARTAN MECHANISM Reduce vasoconstriction 137862-53-4 VALSARTAN ADVERSE_EFFECT GIS_2_Abdominal Pain 137862-53-4 VALSARTAN ADVERSE_EFFECT IMU_3_Allergic Reactions 137862-53-4 VALSARTAN ADVERSE_EFFECT REP_3_Impotence 137862-53-4 VALSARTAN PRODUCT_CLASS Cardiovasculars 137862-53-4 VALSARTAN TA_LEVEL_1 Cardiovascular 137862-53-4 VALSARTAN MECH_LEVEL_3 angiotensin receptor AT1 137862-53-4 VALSARTAN ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 137862-53-4 VALSARTAN ADVERSE_EFFECT LUN_2_Cough 137862-53-4 VALSARTAN ADVERSE_EFFECT CVS_2_Hypotension 137862-53-4 VALSARTAN THERAPEUTIC_CLASS Antihypertensive Agents 137862-53-4 VALSARTAN MESH_LEVEL_3 Tetrazoles 137862-53-4 VALSARTAN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 137862-53-4 VALSARTAN MECH_LEVEL_1 Vasorelaxation 137862-53-4 VALSARTAN ADVERSE_EFFECT KID_3_Renal Insufficiency 137862-53-4 VALSARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 137862-53-4 VALSARTAN ACTIVITY_CLASS RAAS inhibitor 137862-53-4 VALSARTAN MESH_LEVEL_1 Heterocyclic Compounds 137862-53-4 VALSARTAN TA_LEVEL_2 Hypertension 1404-93-9 VANCOMYCIN TA_LEVEL_3 systemic infections 1404-93-9 VANCOMYCIN INDICATION Surgical Prophylaxis 1404-93-9 VANCOMYCIN INDICATION Endocarditis 1404-93-9 VANCOMYCIN ADVERSE_EFFECT CVS_2_Hypotension 1404-93-9 VANCOMYCIN ADVERSE_EFFECT OTO_2_Ototoxicity 1404-93-9 VANCOMYCIN MESH_LEVEL_3 Glycoconjugates 1404-93-9 VANCOMYCIN ADVERSE_EFFECT XXX_2_Chills 1404-93-9 VANCOMYCIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 1404-93-9 VANCOMYCIN ADVERSE_EFFECT BBM_3_Reversible Neutropenia 1404-93-9 VANCOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 1404-93-9 VANCOMYCIN TISSUE_TOXICITY Hypotension 1404-93-9 VANCOMYCIN KNOWN_TOXICITY Nephrotoxicity 1404-93-9 VANCOMYCIN ZERO_CLASS N 1404-93-9 VANCOMYCIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, D-Ala-D-Ala carboxypeptidase inhibitor 1404-93-9 VANCOMYCIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 1404-93-9 VANCOMYCIN INDICATION Diabetic Foot Ulcer 1404-93-9 VANCOMYCIN INDICATION Pneumonia 1404-93-9 VANCOMYCIN INDICATION Bacteremia 1404-93-9 VANCOMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 1404-93-9 VANCOMYCIN ADVERSE_EFFECT XXX_2_Fever 1404-93-9 VANCOMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 1404-93-9 VANCOMYCIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 1404-93-9 VANCOMYCIN ADVERSE_EFFECT CVS_2_Phlebitis 1404-93-9 VANCOMYCIN ADVERSE_EFFECT IMU_1_Anaphylactoid Reactions 1404-93-9 VANCOMYCIN ADVERSE_EFFECT BBM_3_Reversible Agranulocytosis 1404-93-9 VANCOMYCIN TA_LEVEL_1 Infectious Disease 1404-93-9 VANCOMYCIN TA_LEVEL_2 Anti-bacterial 1404-93-9 VANCOMYCIN INDICATION Enterocolitis 1404-93-9 VANCOMYCIN INDICATION Peritonitis 1404-93-9 VANCOMYCIN MESH_LEVEL_2 Carbohydrates 1404-93-9 VANCOMYCIN INDICATION Bone and Joint Infection 1404-93-9 VANCOMYCIN PRODUCT_CLASS Anti-infectives 1404-93-9 VANCOMYCIN TISSUE_TOXICITY Anaphylactoid Reactions 1404-93-9 VANCOMYCIN ADVERSE_EFFECT GIS_2_Nausea 1404-93-9 VANCOMYCIN ADVERSE_EFFECT NEU_2_Nystagmus 1404-93-9 VANCOMYCIN ADVERSE_EFFECT NEU_2_Vertigo 1404-93-9 VANCOMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 1404-93-9 VANCOMYCIN ADVERSE_EFFECT IMU_1_Red Man Syndrome 1404-93-9 VANCOMYCIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 1404-93-9 VANCOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 1404-93-9 VANCOMYCIN MECH_LEVEL_3 Serine-type D-Ala-D-Ala carboxypeptidase 1404-93-9 VANCOMYCIN MECHANISM Inhibit bacterial cell wall biosynthesis 1404-93-9 VANCOMYCIN INDICATION Septicemia 1404-93-9 VANCOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1404-93-9 VANCOMYCIN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 1404-93-9 VANCOMYCIN ADVERSE_EFFECT NEU_3_Ataxia 1404-93-9 VANCOMYCIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 1404-93-9 VANCOMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 1404-93-9 VANCOMYCIN ADVERSE_EFFECT KID_2_Azotemia 1404-93-9 VANCOMYCIN TISSUE_TOXICITY Interstitial Nephritis 1404-93-9 VANCOMYCIN KNOWN_TOXICITY Immune System Toxicity 1404-93-9 VANCOMYCIN MECH_LEVEL_1 Anti-bacterial 1404-93-9 VANCOMYCIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 25255-33-8 (ARG8)-VASOPRESSIN (FREE ACID) THERAPEUTIC_CLASS Pituitary Hormones 25255-33-8 (ARG8)-VASOPRESSIN (FREE ACID) MECHANISM Increase vasoconstriction 25255-33-8 (ARG8)-VASOPRESSIN (FREE ACID) PRODUCT_CLASS Hormones, Endocrine and Metabolic 25255-33-8 (ARG8)-VASOPRESSIN (FREE ACID) MODE_CLASS Receptor Agonist 93413-69-5 VENLAFAXINE ADVERSE_EFFECT XXX_2_Weight Loss 93413-69-5 VENLAFAXINE ADVERSE_EFFECT NEU_3_Seizures 93413-69-5 VENLAFAXINE ADVERSE_EFFECT XXX_2_Weakness 93413-69-5 VENLAFAXINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 93413-69-5 VENLAFAXINE ADVERSE_EFFECT GIS_2_Constipation 93413-69-5 VENLAFAXINE PRODUCT_CLASS Analgesics 93413-69-5 VENLAFAXINE MECH_LEVEL_2 5HT antagonist 93413-69-5 VENLAFAXINE TA_LEVEL_3 SERTs 93413-69-5 VENLAFAXINE MECH_LEVEL_3 5HT Transporter SERT 93413-69-5 VENLAFAXINE ADVERSE_EFFECT PSY_2_Mania 93413-69-5 VENLAFAXINE ADVERSE_EFFECT NEU_3_Vertigo 93413-69-5 VENLAFAXINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 93413-69-5 VENLAFAXINE ADVERSE_EFFECT REP_3_Sexual Dysfunction 93413-69-5 VENLAFAXINE ADVERSE_EFFECT OCU_2_Blurred Vision 93413-69-5 VENLAFAXINE MODE_CLASS Solute transporter inhibitor 93413-69-5 VENLAFAXINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 93413-69-5 VENLAFAXINE INDICATION Neuropathic Pain 93413-69-5 VENLAFAXINE TA_LEVEL_1 Central Nervous System (CNS) 93413-69-5 VENLAFAXINE THERAPEUTIC_CLASS Antidepressants 93413-69-5 VENLAFAXINE INDICATION Major Depression / Major Depressive Disorder 93413-69-5 VENLAFAXINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 93413-69-5 VENLAFAXINE ADVERSE_EFFECT REP_3_Menstrual Abnormalities 93413-69-5 VENLAFAXINE ADVERSE_EFFECT REP_3_Decreased Libido 93413-69-5 VENLAFAXINE ADVERSE_EFFECT NEU_1_Dizziness 93413-69-5 VENLAFAXINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 93413-69-5 VENLAFAXINE ADVERSE_EFFECT CVS_2_Hypertension 93413-69-5 VENLAFAXINE PRODUCT_CLASS Central Nervous System (CNS) 93413-69-5 VENLAFAXINE MECHANISM Prolong/enhance neural transmission 93413-69-5 VENLAFAXINE MECH_LEVEL_1 Modulate neural transmission 93413-69-5 VENLAFAXINE ZERO_CLASS N 93413-69-5 VENLAFAXINE TA_LEVEL_2 CNS Depressant 93413-69-5 VENLAFAXINE ADVERSE_EFFECT REP_3_Ejaculatory Disorder 93413-69-5 VENLAFAXINE ADVERSE_EFFECT XXX_2_Asthenia 93413-69-5 VENLAFAXINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 93413-69-5 VENLAFAXINE ADVERSE_EFFECT NEU_1_Drowsiness 93413-69-5 VENLAFAXINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 93413-69-5 VENLAFAXINE ADVERSE_EFFECT PSY_2_Insomnia 93413-69-5 VENLAFAXINE MESH_LEVEL_3 Hexanols 93413-69-5 VENLAFAXINE MESH_LEVEL_2 Alcohols 93413-69-5 VENLAFAXINE INDICATION Generalized Anxiety Disorder 93413-69-5 VENLAFAXINE MESH_LEVEL_1 Organic Chemicals 93413-69-5 VENLAFAXINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 93413-69-5 VENLAFAXINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 93413-69-5 VENLAFAXINE ADVERSE_EFFECT REP_3_Priapism 93413-69-5 VENLAFAXINE ADVERSE_EFFECT XXX_2_Xerostomia 99300-78-4 VENLAFAXINE MESH_LEVEL_3 Hexanols 99300-78-4 VENLAFAXINE ADVERSE_EFFECT REP_3_Priapism 99300-78-4 VENLAFAXINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 99300-78-4 VENLAFAXINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 99300-78-4 VENLAFAXINE MESH_LEVEL_1 Organic Chemicals 99300-78-4 VENLAFAXINE THERAPEUTIC_CLASS Antidepressants 99300-78-4 VENLAFAXINE INDICATION Major Depression / Major Depressive Disorder 99300-78-4 VENLAFAXINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 99300-78-4 VENLAFAXINE ADVERSE_EFFECT REP_3_Menstrual Abnormalities 99300-78-4 VENLAFAXINE ADVERSE_EFFECT REP_3_Decreased Libido 99300-78-4 VENLAFAXINE ADVERSE_EFFECT NEU_1_Dizziness 99300-78-4 VENLAFAXINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 99300-78-4 VENLAFAXINE TA_LEVEL_3 SERTs 99300-78-4 VENLAFAXINE ZERO_CLASS N 99300-78-4 VENLAFAXINE ADVERSE_EFFECT PSY_2_Mania 99300-78-4 VENLAFAXINE TA_LEVEL_1 Central Nervous System (CNS) 99300-78-4 VENLAFAXINE INDICATION Generalized Anxiety Disorder 99300-78-4 VENLAFAXINE MESH_LEVEL_2 Alcohols 99300-78-4 VENLAFAXINE ADVERSE_EFFECT XXX_2_Weakness 99300-78-4 VENLAFAXINE ADVERSE_EFFECT PSY_2_Insomnia 99300-78-4 VENLAFAXINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 99300-78-4 VENLAFAXINE ADVERSE_EFFECT NEU_1_Drowsiness 99300-78-4 VENLAFAXINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 99300-78-4 VENLAFAXINE ADVERSE_EFFECT XXX_2_Asthenia 99300-78-4 VENLAFAXINE ADVERSE_EFFECT REP_3_Ejaculatory Disorder 99300-78-4 VENLAFAXINE TA_LEVEL_2 CNS Depressant 99300-78-4 VENLAFAXINE ADVERSE_EFFECT CVS_2_Hypertension 99300-78-4 VENLAFAXINE PRODUCT_CLASS Central Nervous System (CNS) 99300-78-4 VENLAFAXINE MECHANISM Prolong/enhance neural transmission 99300-78-4 VENLAFAXINE MECH_LEVEL_1 Modulate neural transmission 99300-78-4 VENLAFAXINE ADVERSE_EFFECT NEU_3_Seizures 99300-78-4 VENLAFAXINE ADVERSE_EFFECT XXX_2_Weight Loss 99300-78-4 VENLAFAXINE ADVERSE_EFFECT XXX_2_Xerostomia 99300-78-4 VENLAFAXINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 99300-78-4 VENLAFAXINE ADVERSE_EFFECT GIS_2_Constipation 99300-78-4 VENLAFAXINE PRODUCT_CLASS Analgesics 99300-78-4 VENLAFAXINE MECH_LEVEL_2 5HT antagonist 99300-78-4 VENLAFAXINE MECH_LEVEL_3 5HT Transporter SERT 99300-78-4 VENLAFAXINE ADVERSE_EFFECT NEU_3_Vertigo 99300-78-4 VENLAFAXINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 99300-78-4 VENLAFAXINE ADVERSE_EFFECT REP_3_Sexual Dysfunction 99300-78-4 VENLAFAXINE ADVERSE_EFFECT OCU_2_Blurred Vision 99300-78-4 VENLAFAXINE MODE_CLASS Solute transporter inhibitor 99300-78-4 VENLAFAXINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 99300-78-4 VENLAFAXINE INDICATION Neuropathic Pain 152-11-4 VERAPAMIL TA_LEVEL_1 Cardiovascular 152-11-4 VERAPAMIL TA_LEVEL_2 anti-angina 152-11-4 VERAPAMIL MECHANISM Modulate neural transmission 152-11-4 VERAPAMIL MECH_LEVEL_3 L-Type Ca++ channel, CaV1.2 152-11-4 VERAPAMIL INDICATION Unstable Angina 152-11-4 VERAPAMIL MODE_CLASS Channel Blocker 152-11-4 VERAPAMIL THERAPEUTIC_CLASS Antihypertensive Agents 152-11-4 VERAPAMIL KNOWN_TOXICITY Cardiovascular Toxicity 152-11-4 VERAPAMIL TISSUE_TOXICITY Congestive Heart Failure 152-11-4 VERAPAMIL ADVERSE_EFFECT CVS_1_Hypotension 152-11-4 VERAPAMIL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 152-11-4 VERAPAMIL ADVERSE_EFFECT NEU_2_Headache 152-11-4 VERAPAMIL ADVERSE_EFFECT XXX_2_Lethargy 152-11-4 VERAPAMIL ADVERSE_EFFECT GIS_1_Abdominal Pain 152-11-4 VERAPAMIL MESH_LEVEL_3 Ethylamines 152-11-4 VERAPAMIL MESH_LEVEL_1 Organic Chemicals 152-11-4 VERAPAMIL INDICATION Atrial Fibrillation 152-11-4 VERAPAMIL MECH_LEVEL_2 Reduce muscle contractile force 152-11-4 VERAPAMIL MODE_CLASS Receptor Agonist 152-11-4 VERAPAMIL MECHANISM Reduce muscle contractile force 152-11-4 VERAPAMIL ADVERSE_EFFECT GIS_1_Constipation 152-11-4 VERAPAMIL ADVERSE_EFFECT CVS_1_Atrioventricular Blockade 152-11-4 VERAPAMIL ADVERSE_EFFECT SKN_2_Flushing 152-11-4 VERAPAMIL ADVERSE_EFFECT END_3_Gynecomastia 152-11-4 VERAPAMIL ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 152-11-4 VERAPAMIL TISSUE_TOXICITY Hypotension 152-11-4 VERAPAMIL THERAPEUTIC_CLASS Antianginals 152-11-4 VERAPAMIL ACTIVITY_CLASS Ca++ channel (L-Type) blocker 152-11-4 VERAPAMIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 152-11-4 VERAPAMIL ADVERSE_EFFECT XXX_2_Fatigue 152-11-4 VERAPAMIL TISSUE_TOXICITY Atrioventricular Blockade 152-11-4 VERAPAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 152-11-4 VERAPAMIL INDICATION Atrial Flutter 152-11-4 VERAPAMIL MESH_LEVEL_2 Amines 152-11-4 VERAPAMIL INDICATION Hypertension 152-11-4 VERAPAMIL MECHANISM Block neural transmission 152-11-4 VERAPAMIL MECH_LEVEL_1 Antianginals 152-11-4 VERAPAMIL ADVERSE_EFFECT CVS_2_Tachycardia 152-11-4 VERAPAMIL ADVERSE_EFFECT NEU_2_Dizziness 152-11-4 VERAPAMIL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 152-11-4 VERAPAMIL ADVERSE_EFFECT GIS_1_Dyspepsia 152-11-4 VERAPAMIL INDICATION Angina Pectoris 152-11-4 VERAPAMIL ADVERSE_EFFECT CVS_1_Sinus Bradycardia 152-11-4 VERAPAMIL TA_LEVEL_3 Ca++ channel blockers 152-11-4 VERAPAMIL INDICATION Paroxysmal Supraventricular Tachycardia 152-11-4 VERAPAMIL STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 152-11-4 VERAPAMIL PRODUCT_CLASS Cardiovasculars 152-11-4 VERAPAMIL ZERO_CLASS N 152-11-4 VERAPAMIL ADVERSE_EFFECT XXX_3_Peripheral Edema 152-11-4 VERAPAMIL ADVERSE_EFFECT OTO_2_Tinnitus 152-11-4 VERAPAMIL ADVERSE_EFFECT REP_2_Impotence 52-53-9 VERAPAMIL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 52-53-9 VERAPAMIL ADVERSE_EFFECT NEU_2_Headache 52-53-9 VERAPAMIL ADVERSE_EFFECT XXX_2_Lethargy 52-53-9 VERAPAMIL ADVERSE_EFFECT GIS_1_Abdominal Pain 52-53-9 VERAPAMIL MESH_LEVEL_3 Ethylamines 52-53-9 VERAPAMIL MESH_LEVEL_1 Organic Chemicals 52-53-9 VERAPAMIL INDICATION Atrial Fibrillation 52-53-9 VERAPAMIL MECH_LEVEL_2 Reduce muscle contractile force 52-53-9 VERAPAMIL MODE_CLASS Receptor Agonist 52-53-9 VERAPAMIL MECHANISM Reduce muscle contractile force 52-53-9 VERAPAMIL ADVERSE_EFFECT GIS_1_Constipation 52-53-9 VERAPAMIL PRODUCT_CLASS Cardiovasculars 52-53-9 VERAPAMIL ADVERSE_EFFECT CVS_1_Atrioventricular Blockade 52-53-9 VERAPAMIL ADVERSE_EFFECT SKN_2_Flushing 52-53-9 VERAPAMIL ADVERSE_EFFECT REP_2_Impotence 52-53-9 VERAPAMIL ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 52-53-9 VERAPAMIL TISSUE_TOXICITY Hypotension 52-53-9 VERAPAMIL THERAPEUTIC_CLASS Antianginals 52-53-9 VERAPAMIL ACTIVITY_CLASS Ca++ channel (L-Type) blocker 52-53-9 VERAPAMIL INDICATION Hypertension 52-53-9 VERAPAMIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 52-53-9 VERAPAMIL ADVERSE_EFFECT CVS_2_Tachycardia 52-53-9 VERAPAMIL TISSUE_TOXICITY Atrioventricular Blockade 52-53-9 VERAPAMIL THERAPEUTIC_CLASS Antiarrhythmic Agents 52-53-9 VERAPAMIL INDICATION Atrial Flutter 52-53-9 VERAPAMIL MESH_LEVEL_2 Amines 52-53-9 VERAPAMIL MECHANISM Block neural transmission 52-53-9 VERAPAMIL MECH_LEVEL_1 Antianginals 52-53-9 VERAPAMIL STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 52-53-9 VERAPAMIL INDICATION Paroxysmal Supraventricular Tachycardia 52-53-9 VERAPAMIL ADVERSE_EFFECT XXX_3_Peripheral Edema 52-53-9 VERAPAMIL TA_LEVEL_3 Ca++ channel blockers 52-53-9 VERAPAMIL ZERO_CLASS N 52-53-9 VERAPAMIL ADVERSE_EFFECT CVS_1_Sinus Bradycardia 52-53-9 VERAPAMIL ADVERSE_EFFECT XXX_2_Fatigue 52-53-9 VERAPAMIL ADVERSE_EFFECT NEU_2_Dizziness 52-53-9 VERAPAMIL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 52-53-9 VERAPAMIL ADVERSE_EFFECT GIS_1_Dyspepsia 52-53-9 VERAPAMIL INDICATION Angina Pectoris 52-53-9 VERAPAMIL TA_LEVEL_1 Cardiovascular 52-53-9 VERAPAMIL TA_LEVEL_2 anti-angina 52-53-9 VERAPAMIL MECHANISM Modulate neural transmission 52-53-9 VERAPAMIL MECH_LEVEL_3 L-Type Ca++ channel, CaV1.2 52-53-9 VERAPAMIL INDICATION Unstable Angina 52-53-9 VERAPAMIL MODE_CLASS Channel Blocker 52-53-9 VERAPAMIL THERAPEUTIC_CLASS Antihypertensive Agents 52-53-9 VERAPAMIL KNOWN_TOXICITY Cardiovascular Toxicity 52-53-9 VERAPAMIL ADVERSE_EFFECT OTO_2_Tinnitus 52-53-9 VERAPAMIL TISSUE_TOXICITY Congestive Heart Failure 52-53-9 VERAPAMIL ADVERSE_EFFECT CVS_1_Hypotension 52-53-9 VERAPAMIL ADVERSE_EFFECT END_3_Gynecomastia 5536-17-4 VIDARABINE ADVERSE_EFFECT OCU_2_Ocular Irritation 5536-17-4 VIDARABINE INDICATION Herpes Simplex Keratitis 5536-17-4 VIDARABINE ADVERSE_EFFECT OCU_2_Photophobia 5536-17-4 VIDARABINE ADVERSE_EFFECT XXX_2_Lacrimation 5536-17-4 VIDARABINE MODE_CLASS Enzyme substrate mimic 5536-17-4 VIDARABINE ADVERSE_EFFECT SKN_2_Pruritis 5536-17-4 VIDARABINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5536-17-4 VIDARABINE ADVERSE_EFFECT OCU_2_Ocular Pain 5536-17-4 VIDARABINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 5536-17-4 VIDARABINE MECHANISM Incorporate into DNA/RNA/Protein 5536-17-4 VIDARABINE ADVERSE_EFFECT OCU_3_Keratitis 5536-17-4 VIDARABINE ADVERSE_EFFECT SKN_2_Erythema 5536-17-4 VIDARABINE THERAPEUTIC_CLASS Antivirals, Topical 5536-17-4 VIDARABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 143-67-9 VINBLASTINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 143-67-9 VINBLASTINE TISSUE_TOXICITY Teratogenicity 143-67-9 VINBLASTINE TISSUE_TOXICITY Uric Acid Nephropathy 143-67-9 VINBLASTINE ADVERSE_EFFECT CVS_2_Phlebitis 143-67-9 VINBLASTINE ADVERSE_EFFECT OTO_3_Hearing Loss 143-67-9 VINBLASTINE ADVERSE_EFFECT SKN_2_Dermatitis 143-67-9 VINBLASTINE ADVERSE_EFFECT PSY_2_Anorexia 143-67-9 VINBLASTINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 143-67-9 VINBLASTINE ADVERSE_EFFECT NEU_3_Vertigo 143-67-9 VINBLASTINE ADVERSE_EFFECT XXX_1_Infection 143-67-9 VINBLASTINE INDICATION Kaposi's Sarcoma 143-67-9 VINBLASTINE MESH_LEVEL_1 Heterocyclic Compounds 143-67-9 VINBLASTINE INDICATION Histiocytic Lymphoma 143-67-9 VINBLASTINE INDICATION Choriocarcinoma / Trophoblastic Neoplasm 143-67-9 VINBLASTINE INDICATION Neoplasm / Cancer / Tumor 143-67-9 VINBLASTINE MECH_LEVEL_2 Microtubule / tubulin 143-67-9 VINBLASTINE ADVERSE_EFFECT KID_3_Uric Acid Nephropathy 143-67-9 VINBLASTINE ADVERSE_EFFECT EMB_3_Teratogenicity 143-67-9 VINBLASTINE ADVERSE_EFFECT NEU_3_Autonomic Dysfunction 143-67-9 VINBLASTINE ADVERSE_EFFECT LUN_3_Bronchospasm 143-67-9 VINBLASTINE TISSUE_TOXICITY Hematotoxicity 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_2_Diarrhea 143-67-9 VINBLASTINE ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 143-67-9 VINBLASTINE INDICATION Hodgkin's Disease 143-67-9 VINBLASTINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 143-67-9 VINBLASTINE INDICATION Letterer-Siwe Disease (Histiocytosis X) 143-67-9 VINBLASTINE INDICATION Idiopathic (Autoimmnune) Thrombocytopenic Purpura (ITP) 143-67-9 VINBLASTINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 143-67-9 VINBLASTINE INDICATION Non-Small Cell Lung Carcinoma 143-67-9 VINBLASTINE TA_LEVEL_3 Anti-mitotic 143-67-9 VINBLASTINE MECH_LEVEL_1 Antimitotic 143-67-9 VINBLASTINE MECH_LEVEL_3 Microtubule / tubulin 143-67-9 VINBLASTINE THERAPEUTIC_CLASS Antineoplastics 143-67-9 VINBLASTINE ADVERSE_EFFECT BBM_2_Anemia 143-67-9 VINBLASTINE PRODUCT_CLASS Anti-cancers 143-67-9 VINBLASTINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 143-67-9 VINBLASTINE ADVERSE_EFFECT IMU_3_Photosensitivity 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_2_Stomatitis 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_2_Rectal Hemorrhage 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_2_Constipation 143-67-9 VINBLASTINE KNOWN_TOXICITY Nephrotoxicity 143-67-9 VINBLASTINE ADVERSE_EFFECT KID_2_Hyperuricemia 143-67-9 VINBLASTINE MESH_LEVEL_2 Alkaloids 143-67-9 VINBLASTINE MECHANISM Inhibit mitosis 143-67-9 VINBLASTINE INDICATION Testicular Cancer / Carcinoma of the Testis 143-67-9 VINBLASTINE INDICATION Metastatic Melanoma 143-67-9 VINBLASTINE INDICATION Breast Cancer / Carcinoma of the Breast 143-67-9 VINBLASTINE INDICATION Lymphocytic Lymphoma 143-67-9 VINBLASTINE TA_LEVEL_1 Oncology 143-67-9 VINBLASTINE STRUCTURE_ACTIVITY Tubulin binder, vinca 143-67-9 VINBLASTINE ADVERSE_EFFECT BBM_1_Leukopenia 143-67-9 VINBLASTINE ADVERSE_EFFECT BBM_1_Hematotoxicity 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_2_Abdominal Pain 143-67-9 VINBLASTINE ADVERSE_EFFECT GIS_2_Enterocolitis 143-67-9 VINBLASTINE ADVERSE_EFFECT NEU_3_Neurogenic Ileus 143-67-9 VINBLASTINE ADVERSE_EFFECT OTO_3_Ototoxicity 143-67-9 VINBLASTINE ADVERSE_EFFECT NEU_3_Nystagmus 143-67-9 VINBLASTINE TISSUE_TOXICITY Leukopenia 143-67-9 VINBLASTINE KNOWN_TOXICITY Embryo/Fetal Toxicity 143-67-9 VINBLASTINE ZERO_CLASS N 143-67-9 VINBLASTINE MESH_LEVEL_3 Vinca Alkaloids 143-67-9 VINBLASTINE TA_LEVEL_2 Solid and soft tissue tumors 143-67-9 VINBLASTINE INDICATION Non-Hodgkin's Lymphomas 143-67-9 VINBLASTINE INDICATION Metastatic Renal Cell Carcinoma 143-67-9 VINBLASTINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 143-67-9 VINBLASTINE INDICATION Metastatic Bladder Carcinoma 2068-78-2 VINCRISTINE TA_LEVEL_3 Anti-mitotic 2068-78-2 VINCRISTINE PRODUCT_CLASS Anti-cancers 2068-78-2 VINCRISTINE MECH_LEVEL_3 Microtubule / tubulin 2068-78-2 VINCRISTINE MECH_LEVEL_1 Antimitotic 2068-78-2 VINCRISTINE INDICATION Burkitt's Lymphoma 2068-78-2 VINCRISTINE INDICATION Non-Hodgkin's Lymphomas 2068-78-2 VINCRISTINE INDICATION Ovarian Cancer / Carcinoma of the Ovary 2068-78-2 VINCRISTINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2068-78-2 VINCRISTINE INDICATION Kaposi's Sarcoma 2068-78-2 VINCRISTINE ADVERSE_EFFECT EMB_2_Teratogenicity 2068-78-2 VINCRISTINE ADVERSE_EFFECT PSY_2_Depression 2068-78-2 VINCRISTINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 2068-78-2 VINCRISTINE ADVERSE_EFFECT IMU_3_Anaphylaxis 2068-78-2 VINCRISTINE ADVERSE_EFFECT LUN_3_Bronchospasm 2068-78-2 VINCRISTINE ADVERSE_EFFECT BBM_3_Anemia 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Optic Neuropathy 2068-78-2 VINCRISTINE ADVERSE_EFFECT BBM_3_Leukopenia 2068-78-2 VINCRISTINE ADVERSE_EFFECT BBM_2_Hematotoxicity 2068-78-2 VINCRISTINE ADVERSE_EFFECT GIS_2_Stomatitis 2068-78-2 VINCRISTINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 2068-78-2 VINCRISTINE ADVERSE_EFFECT LUN_3_Vocal Cord Paresis 2068-78-2 VINCRISTINE TISSUE_TOXICITY Uric Acid Nephropathy 2068-78-2 VINCRISTINE MECH_LEVEL_2 Microtubule / tubulin 2068-78-2 VINCRISTINE MESH_LEVEL_1 Heterocyclic Compounds 2068-78-2 VINCRISTINE INDICATION Wilms' Tumor 2068-78-2 VINCRISTINE INDICATION Ovarian Germ Cell Tumors 2068-78-2 VINCRISTINE INDICATION Acute Lymphocytic Leukemia (ALL) 2068-78-2 VINCRISTINE INDICATION Idiopathic (Autoimmnune) Thrombocytopenic Purpura (ITP) 2068-78-2 VINCRISTINE INDICATION Ewing's Sarcoma 2068-78-2 VINCRISTINE ADVERSE_EFFECT GIS_2_Constipation 2068-78-2 VINCRISTINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 2068-78-2 VINCRISTINE ADVERSE_EFFECT IMU_3_Allergic Reactions 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Neurogenic Ileus 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Convulsions 2068-78-2 VINCRISTINE TISSUE_TOXICITY Coronary Artery Disorder 2068-78-2 VINCRISTINE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 2068-78-2 VINCRISTINE INDICATION Testicular Germ Cell Tumors 2068-78-2 VINCRISTINE INDICATION Medulloblastoma 2068-78-2 VINCRISTINE INDICATION Neuroblastoma 2068-78-2 VINCRISTINE INDICATION Osteosarcoma / Osteogenic Sarcoma 2068-78-2 VINCRISTINE TA_LEVEL_2 Solid and soft tissue tumors 2068-78-2 VINCRISTINE MESH_LEVEL_3 Vinca Alkaloids 2068-78-2 VINCRISTINE KNOWN_TOXICITY Cardiovascular Toxicity 2068-78-2 VINCRISTINE ZERO_CLASS N 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Nystagmus 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Ataxia 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_3_Encephalopathy 2068-78-2 VINCRISTINE ADVERSE_EFFECT KID_2_Hyperuricemia 2068-78-2 VINCRISTINE ADVERSE_EFFECT PSY_2_Hallucinations 2068-78-2 VINCRISTINE ADVERSE_EFFECT GUS_2_Urinary Retention 2068-78-2 VINCRISTINE TISSUE_TOXICITY Myocardial Infarction 2068-78-2 VINCRISTINE THERAPEUTIC_CLASS Antineoplastics 2068-78-2 VINCRISTINE ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 2068-78-2 VINCRISTINE ADVERSE_EFFECT OCU_2_Ptosis 2068-78-2 VINCRISTINE ADVERSE_EFFECT OTO_2_Hearing Loss 2068-78-2 VINCRISTINE ADVERSE_EFFECT CVS_2_Phlebitis 2068-78-2 VINCRISTINE INDICATION Small Cell Lung Carcinoma 2068-78-2 VINCRISTINE INDICATION Multiple Myeloma / Myelomatosis 2068-78-2 VINCRISTINE INDICATION Hodgkin's Disease 2068-78-2 VINCRISTINE MESH_LEVEL_2 Alkaloids 2068-78-2 VINCRISTINE MECHANISM Inhibit mitosis 2068-78-2 VINCRISTINE TA_LEVEL_1 Oncology 2068-78-2 VINCRISTINE INDICATION Breast Cancer / Carcinoma of the Breast 2068-78-2 VINCRISTINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 2068-78-2 VINCRISTINE KNOWN_TOXICITY Embryo/Fetal Toxicity 2068-78-2 VINCRISTINE TISSUE_TOXICITY Teratogenicity 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Loss of DeepTendon Reflexes 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Myoclonic Jerks 2068-78-2 VINCRISTINE ADVERSE_EFFECT GIS_3_Intestinal Necrosis 2068-78-2 VINCRISTINE ADVERSE_EFFECT PSY_2_CNS Toxicity 2068-78-2 VINCRISTINE ADVERSE_EFFECT LUN_3_Respiratory Paralysis 2068-78-2 VINCRISTINE INDICATION Rhabdomyosarcoma 2068-78-2 VINCRISTINE ADVERSE_EFFECT OTO_2_Ototoxicity 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_3_Coma 2068-78-2 VINCRISTINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 2068-78-2 VINCRISTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_1_Paresthesia 2068-78-2 VINCRISTINE ADVERSE_EFFECT OCU_2_Diplopia 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Autonomic Dysfunction 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_2_Vertigo 2068-78-2 VINCRISTINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 2068-78-2 VINCRISTINE ADVERSE_EFFECT CVS_3_Coronary Artery Disorder 2068-78-2 VINCRISTINE ADVERSE_EFFECT KID_3_Uric Acid Nephropathy 2068-78-2 VINCRISTINE ADVERSE_EFFECT NEU_3_Optic Atrophy 2068-78-2 VINCRISTINE KNOWN_TOXICITY Nephrotoxicity 2068-78-2 VINCRISTINE STRUCTURE_ACTIVITY Tubulin binder, vinca 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Myoclonic Jerks 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Ataxia 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Nystagmus 57-22-7 VINCRISTINE INDICATION Rhabdomyosarcoma 57-22-7 VINCRISTINE ZERO_CLASS N 57-22-7 VINCRISTINE KNOWN_TOXICITY Cardiovascular Toxicity 57-22-7 VINCRISTINE MESH_LEVEL_3 Vinca Alkaloids 57-22-7 VINCRISTINE TA_LEVEL_2 Solid and soft tissue tumors 57-22-7 VINCRISTINE INDICATION Osteosarcoma / Osteogenic Sarcoma 57-22-7 VINCRISTINE ADVERSE_EFFECT KID_3_Uric Acid Nephropathy 57-22-7 VINCRISTINE INDICATION Breast Cancer / Carcinoma of the Breast 57-22-7 VINCRISTINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 57-22-7 VINCRISTINE KNOWN_TOXICITY Embryo/Fetal Toxicity 57-22-7 VINCRISTINE TISSUE_TOXICITY Teratogenicity 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Loss of DeepTendon Reflexes 57-22-7 VINCRISTINE MESH_LEVEL_1 Heterocyclic Compounds 57-22-7 VINCRISTINE ADVERSE_EFFECT GIS_3_Intestinal Necrosis 57-22-7 VINCRISTINE ADVERSE_EFFECT PSY_2_CNS Toxicity 57-22-7 VINCRISTINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 57-22-7 VINCRISTINE ADVERSE_EFFECT LUN_3_Respiratory Paralysis 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 57-22-7 VINCRISTINE ADVERSE_EFFECT OTO_2_Ototoxicity 57-22-7 VINCRISTINE ADVERSE_EFFECT IMU_3_Allergic Reactions 57-22-7 VINCRISTINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 57-22-7 VINCRISTINE ADVERSE_EFFECT GIS_2_Constipation 57-22-7 VINCRISTINE INDICATION Ewing's Sarcoma 57-22-7 VINCRISTINE INDICATION Idiopathic (Autoimmnune) Thrombocytopenic Purpura (ITP) 57-22-7 VINCRISTINE INDICATION Acute Lymphocytic Leukemia (ALL) 57-22-7 VINCRISTINE INDICATION Ovarian Germ Cell Tumors 57-22-7 VINCRISTINE INDICATION Wilms' Tumor 57-22-7 VINCRISTINE TA_LEVEL_1 Oncology 57-22-7 VINCRISTINE MECH_LEVEL_2 Microtubule / tubulin 57-22-7 VINCRISTINE TISSUE_TOXICITY Uric Acid Nephropathy 57-22-7 VINCRISTINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 57-22-7 VINCRISTINE ADVERSE_EFFECT GIS_2_Stomatitis 57-22-7 VINCRISTINE ADVERSE_EFFECT BBM_2_Hematotoxicity 57-22-7 VINCRISTINE ADVERSE_EFFECT BBM_3_Leukopenia 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Optic Neuropathy 57-22-7 VINCRISTINE ADVERSE_EFFECT BBM_3_Anemia 57-22-7 VINCRISTINE ADVERSE_EFFECT LUN_3_Bronchospasm 57-22-7 VINCRISTINE ADVERSE_EFFECT IMU_3_Anaphylaxis 57-22-7 VINCRISTINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 57-22-7 VINCRISTINE ADVERSE_EFFECT PSY_2_Depression 57-22-7 VINCRISTINE ADVERSE_EFFECT EMB_2_Teratogenicity 57-22-7 VINCRISTINE INDICATION Kaposi's Sarcoma 57-22-7 VINCRISTINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 57-22-7 VINCRISTINE INDICATION Ovarian Cancer / Carcinoma of the Ovary 57-22-7 VINCRISTINE INDICATION Non-Hodgkin's Lymphomas 57-22-7 VINCRISTINE INDICATION Burkitt's Lymphoma 57-22-7 VINCRISTINE MECH_LEVEL_1 Antimitotic 57-22-7 VINCRISTINE MECH_LEVEL_3 Microtubule / tubulin 57-22-7 VINCRISTINE PRODUCT_CLASS Anti-cancers 57-22-7 VINCRISTINE TA_LEVEL_3 Anti-mitotic 57-22-7 VINCRISTINE STRUCTURE_ACTIVITY Tubulin binder, vinca 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_3_Optic Atrophy 57-22-7 VINCRISTINE ADVERSE_EFFECT CVS_3_Coronary Artery Disorder 57-22-7 VINCRISTINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Vertigo 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Autonomic Dysfunction 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_3_Coma 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_1_Paresthesia 57-22-7 VINCRISTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Convulsions 57-22-7 VINCRISTINE TISSUE_TOXICITY Coronary Artery Disorder 57-22-7 VINCRISTINE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 57-22-7 VINCRISTINE MECHANISM Inhibit mitosis 57-22-7 VINCRISTINE MESH_LEVEL_2 Alkaloids 57-22-7 VINCRISTINE INDICATION Hodgkin's Disease 57-22-7 VINCRISTINE INDICATION Multiple Myeloma / Myelomatosis 57-22-7 VINCRISTINE INDICATION Small Cell Lung Carcinoma 57-22-7 VINCRISTINE ADVERSE_EFFECT CVS_2_Phlebitis 57-22-7 VINCRISTINE INDICATION Neuroblastoma 57-22-7 VINCRISTINE ADVERSE_EFFECT LUN_3_Vocal Cord Paresis 57-22-7 VINCRISTINE INDICATION Medulloblastoma 57-22-7 VINCRISTINE INDICATION Testicular Germ Cell Tumors 57-22-7 VINCRISTINE ADVERSE_EFFECT OTO_2_Hearing Loss 57-22-7 VINCRISTINE ADVERSE_EFFECT OCU_2_Ptosis 57-22-7 VINCRISTINE KNOWN_TOXICITY Nephrotoxicity 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 57-22-7 VINCRISTINE ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 57-22-7 VINCRISTINE THERAPEUTIC_CLASS Antineoplastics 57-22-7 VINCRISTINE ADVERSE_EFFECT OCU_2_Diplopia 57-22-7 VINCRISTINE TISSUE_TOXICITY Myocardial Infarction 57-22-7 VINCRISTINE ADVERSE_EFFECT GUS_2_Urinary Retention 57-22-7 VINCRISTINE ADVERSE_EFFECT PSY_2_Hallucinations 57-22-7 VINCRISTINE ADVERSE_EFFECT KID_2_Hyperuricemia 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_3_Encephalopathy 57-22-7 VINCRISTINE ADVERSE_EFFECT NEU_2_Neurogenic Ileus 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_2_Constipation 59917-39-4 VINDESINE ADVERSE_EFFECT BBM_2_Anemia 59917-39-4 VINDESINE ADVERSE_EFFECT OTO_2_Auditory Damage 59917-39-4 VINDESINE ADVERSE_EFFECT OTO_2_Hearing Loss 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_2_Dyspepsia 59917-39-4 VINDESINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 59917-39-4 VINDESINE MECHANISM Inhibit mitosis 59917-39-4 VINDESINE INDICATION Blastic crisis of chronic myeloid leukemia 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_2_Diarrhea 59917-39-4 VINDESINE ADVERSE_EFFECT NEU_2_Paresthesia 59917-39-4 VINDESINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 59917-39-4 VINDESINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 59917-39-4 VINDESINE STRUCTURE_ACTIVITY Tubulin binder, vinca 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_3_Abdominal Pain 59917-39-4 VINDESINE ADVERSE_EFFECT BBM_2_Thrombocytosis 59917-39-4 VINDESINE ADVERSE_EFFECT _3_Foot Drop 59917-39-4 VINDESINE THERAPEUTIC_CLASS Antineoplastics 59917-39-4 VINDESINE TISSUE_TOXICITY Granulocytopenia 59917-39-4 VINDESINE TISSUE_TOXICITY Thrombocytopenia 59917-39-4 VINDESINE ADVERSE_EFFECT _3_Loss of deep tendon reflexes 59917-39-4 VINDESINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_3_Dysphagia 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_3_Ulcer Perforation 59917-39-4 VINDESINE ADVERSE_EFFECT BBM_1_Granulocytopenia 59917-39-4 VINDESINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 59917-39-4 VINDESINE PRODUCT_CLASS Anti-cancers 59917-39-4 VINDESINE INDICATION Breast Cancer / Carcinoma of the Breast 59917-39-4 VINDESINE ADVERSE_EFFECT _3_Cortical Blindness 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_3_Duodenal Ulcer 59917-39-4 VINDESINE ADVERSE_EFFECT GIS_2_Stomatitis 59917-39-4 VINDESINE ADVERSE_EFFECT OTO_2_Vestibular Damage 59917-39-4 VINDESINE ADVERSE_EFFECT PSY_3_Anorexia 59917-39-4 VINDESINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 59917-39-4 VINDESINE INDICATION Malignant Melanoma 59917-39-4 VINDESINE ADVERSE_EFFECT NEU_2_Peripheral Neuritis 59917-39-4 VINDESINE INDICATION Acute Lymphocytic Leukemia (ALL) 125317-39-7 VINORELBINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 125317-39-7 VINORELBINE ZERO_CLASS N 125317-39-7 VINORELBINE THERAPEUTIC_CLASS Antineoplastics 125317-39-7 VINORELBINE ADVERSE_EFFECT XXX_1_Asthenia 125317-39-7 VINORELBINE ADVERSE_EFFECT BBM_1_Myelosuppression 125317-39-7 VINORELBINE ADVERSE_EFFECT BBM_1_Leukopenia 125317-39-7 VINORELBINE ADVERSE_EFFECT BBM_1_Anemia 125317-39-7 VINORELBINE ADVERSE_EFFECT NEU_2_Dizziness 125317-39-7 VINORELBINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 125317-39-7 VINORELBINE MESH_LEVEL_2 Alkaloids 125317-39-7 VINORELBINE TA_LEVEL_1 Oncology 125317-39-7 VINORELBINE TISSUE_TOXICITY Anemia 125317-39-7 VINORELBINE TISSUE_TOXICITY Myelosuppression 125317-39-7 VINORELBINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 125317-39-7 VINORELBINE ADVERSE_EFFECT BBM_1_Neutropenia 125317-39-7 VINORELBINE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 125317-39-7 VINORELBINE ADVERSE_EFFECT MSK_3_Muscle Weakness 125317-39-7 VINORELBINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 125317-39-7 VINORELBINE ADVERSE_EFFECT GIS_2_Diarrhea 125317-39-7 VINORELBINE MECHANISM Inhibit mitosis 125317-39-7 VINORELBINE MESH_LEVEL_1 Heterocyclic Compounds 125317-39-7 VINORELBINE MECH_LEVEL_2 Microtubule / tubulin 125317-39-7 VINORELBINE TISSUE_TOXICITY Leukopenia 125317-39-7 VINORELBINE ADVERSE_EFFECT CVS_3_Chest Pain 125317-39-7 VINORELBINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 125317-39-7 VINORELBINE ADVERSE_EFFECT LUN_3_Dyspnea 125317-39-7 VINORELBINE ADVERSE_EFFECT NEU_3_Ataxia 125317-39-7 VINORELBINE ADVERSE_EFFECT GIS_2_Nausea 125317-39-7 VINORELBINE ADVERSE_EFFECT GIS_2_Constipation 125317-39-7 VINORELBINE TISSUE_TOXICITY Neutropenia 125317-39-7 VINORELBINE KNOWN_TOXICITY Cardiovascular Toxicity 125317-39-7 VINORELBINE PRODUCT_CLASS Anti-cancers 125317-39-7 VINORELBINE TA_LEVEL_3 Anti-mitotic 125317-39-7 VINORELBINE MECH_LEVEL_1 Antimitotic 125317-39-7 VINORELBINE MECH_LEVEL_3 Microtubule / tubulin 125317-39-7 VINORELBINE TISSUE_TOXICITY Myocardial Infarction 125317-39-7 VINORELBINE ADVERSE_EFFECT MSK_3_Back Pain 125317-39-7 VINORELBINE ADVERSE_EFFECT OTO_2_Hearing Loss 125317-39-7 VINORELBINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 125317-39-7 VINORELBINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 125317-39-7 VINORELBINE ADVERSE_EFFECT XXX_1_Fatigue 125317-39-7 VINORELBINE ADVERSE_EFFECT CVS_3_Hypertension 125317-39-7 VINORELBINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 125317-39-7 VINORELBINE TA_LEVEL_2 Solid and soft tissue tumors 125317-39-7 VINORELBINE MESH_LEVEL_3 Vinca Alkaloids 125317-39-7 VINORELBINE INDICATION Non-Small Cell Lung Carcinoma 125317-39-7 VINORELBINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 125317-39-7 VINORELBINE ADVERSE_EFFECT LUN_3_Bronchospasm 125317-39-7 VINORELBINE STRUCTURE_ACTIVITY Tubulin binder, vinca 71486-22-1 VINORELBINE MESH_LEVEL_1 Heterocyclic Compounds 71486-22-1 VINORELBINE TA_LEVEL_2 Solid and soft tissue tumors 71486-22-1 VINORELBINE MESH_LEVEL_3 Vinca Alkaloids 71486-22-1 VINORELBINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 71486-22-1 VINORELBINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 71486-22-1 VINORELBINE ADVERSE_EFFECT XXX_1_Fatigue 71486-22-1 VINORELBINE ADVERSE_EFFECT CVS_3_Hypertension 71486-22-1 VINORELBINE ADVERSE_EFFECT OTO_2_Hearing Loss 71486-22-1 VINORELBINE ADVERSE_EFFECT MSK_3_Back Pain 71486-22-1 VINORELBINE STRUCTURE_ACTIVITY Tubulin binder, vinca 71486-22-1 VINORELBINE TISSUE_TOXICITY Myocardial Infarction 71486-22-1 VINORELBINE MECH_LEVEL_3 Microtubule / tubulin 71486-22-1 VINORELBINE MECH_LEVEL_1 Antimitotic 71486-22-1 VINORELBINE TA_LEVEL_3 Anti-mitotic 71486-22-1 VINORELBINE MECHANISM Inhibit mitosis 71486-22-1 VINORELBINE PRODUCT_CLASS Anti-cancers 71486-22-1 VINORELBINE KNOWN_TOXICITY Cardiovascular Toxicity 71486-22-1 VINORELBINE TISSUE_TOXICITY Leukopenia 71486-22-1 VINORELBINE TISSUE_TOXICITY Neutropenia 71486-22-1 VINORELBINE ADVERSE_EFFECT GIS_2_Constipation 71486-22-1 VINORELBINE ADVERSE_EFFECT LUN_3_Bronchospasm 71486-22-1 VINORELBINE ADVERSE_EFFECT MSK_3_Muscle Weakness 71486-22-1 VINORELBINE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 71486-22-1 VINORELBINE ADVERSE_EFFECT BBM_1_Neutropenia 71486-22-1 VINORELBINE INDICATION Non-Small Cell Lung Carcinoma 71486-22-1 VINORELBINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 71486-22-1 VINORELBINE TISSUE_TOXICITY Myelosuppression 71486-22-1 VINORELBINE TISSUE_TOXICITY Anemia 71486-22-1 VINORELBINE ADVERSE_EFFECT GIS_2_Diarrhea 71486-22-1 VINORELBINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 71486-22-1 VINORELBINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 71486-22-1 VINORELBINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 71486-22-1 VINORELBINE ADVERSE_EFFECT NEU_3_Ataxia 71486-22-1 VINORELBINE ADVERSE_EFFECT GIS_2_Nausea 71486-22-1 VINORELBINE ADVERSE_EFFECT LUN_3_Dyspnea 71486-22-1 VINORELBINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 71486-22-1 VINORELBINE ADVERSE_EFFECT CVS_3_Chest Pain 71486-22-1 VINORELBINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 71486-22-1 VINORELBINE ZERO_CLASS N 71486-22-1 VINORELBINE MECH_LEVEL_2 Microtubule / tubulin 71486-22-1 VINORELBINE THERAPEUTIC_CLASS Antineoplastics 71486-22-1 VINORELBINE ADVERSE_EFFECT XXX_1_Asthenia 71486-22-1 VINORELBINE ADVERSE_EFFECT BBM_1_Myelosuppression 71486-22-1 VINORELBINE ADVERSE_EFFECT BBM_1_Leukopenia 71486-22-1 VINORELBINE ADVERSE_EFFECT BBM_1_Anemia 71486-22-1 VINORELBINE ADVERSE_EFFECT NEU_2_Dizziness 71486-22-1 VINORELBINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 71486-22-1 VINORELBINE MESH_LEVEL_2 Alkaloids 71486-22-1 VINORELBINE TA_LEVEL_1 Oncology 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT IMU_3_Anaphylaxis 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT NEU_3_Coma 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT GIS_2_Diarrhea 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT NEU_2_Dizziness 117976-89-3 RABEPRAZOLE KNOWN_TOXICITY Carcinogenicity 117976-89-3 RABEPRAZOLE MESH_LEVEL_3 Benzimidazoles 117976-89-3 RABEPRAZOLE PRODUCT_CLASS Gastrointestinal System 117976-89-3 RABEPRAZOLE INDICATION Gastric Ulcer 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT PSY_3_Disorientation 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT SKN_2_Skin Eruption 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT END_3_Gynecomastia 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 117976-89-3 RABEPRAZOLE TISSUE_TOXICITY Death 117976-89-3 RABEPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 117976-89-3 RABEPRAZOLE TA_LEVEL_1 Gastrointestinal System 117976-89-3 RABEPRAZOLE ZERO_CLASS N 117976-89-3 RABEPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 117976-89-3 RABEPRAZOLE MECHANISM Reduce stomach HCl secretion 117976-89-3 RABEPRAZOLE MODE_CLASS Enzyme Inhibitor 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT IMU_3_Angioedema 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT LIV_3_Jaundice 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT SKN_3_Bullous Rash 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT XXX_3_Death 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT NEU_2_Headache 117976-89-3 RABEPRAZOLE MECH_LEVEL_2 Unknown mechanism 117976-89-3 RABEPRAZOLE TISSUE_TOXICITY Carcinoid Tumors 117976-89-3 RABEPRAZOLE KNOWN_TOXICITY Miscellaneous 117976-89-3 RABEPRAZOLE INDICATION Duodenal Ulcer 117976-89-3 RABEPRAZOLE INDICATION Helicobacter Pylori Infection 117976-89-3 RABEPRAZOLE MECH_LEVEL_3 Unknown mechanism 117976-89-3 RABEPRAZOLE THERAPEUTIC_CLASS Antiulcers 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT END_3_Hyperammonemia 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT NEU_3_Hepatic Encephalopathy 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT PSY_3_Delirium 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT SKN_2_Rash 117976-89-3 RABEPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 117976-89-3 RABEPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 117976-89-3 RABEPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 117976-89-3 RABEPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 117976-89-3 RABEPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 117976-89-3 RABEPRAZOLE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 59-51-8 RACEMETHIONINE MECHANISM chelate excess metal 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT CVS_1_Palpitation 329-65-7 RACEPINEPHRINE PRODUCT_CLASS Respiratory System 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT CVS_1_Tachycardia 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT PSY_1_Anxiety 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT XXX_3_Cold Extremities 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT GIS_3_Epigastric Pain 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT OCU_3_Corneal Microdeposits 329-65-7 RACEPINEPHRINE THERAPEUTIC_CLASS Bronchodilators 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT CVS_1_Hypertension 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT LUN_1_Dyspnea 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT NEU_3_Vertigo 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT GIS_2_Vomiting 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT OCU_3_Retinal Deposits 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT CVS_2_Ventricular Fibrillation 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT NEU_3_Psychomotor Excitation 329-65-7 RACEPINEPHRINE TISSUE_TOXICITY Ventricular Fibrillation 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT NEU_3_Loss of Consciousness 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT PSY_2_Insomnia 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT OCU_3_Decreased Visual Acuity 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT NEU_2_Cerebral Hemorrhage 329-65-7 RACEPINEPHRINE KNOWN_TOXICITY Cardiovascular Toxicity 329-65-7 RACEPINEPHRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 329-65-7 RACEPINEPHRINE MODE_CLASS Receptor Agonist 329-65-7 RACEPINEPHRINE ACTIVITY_CLASS Adrenergic agonist 329-65-7 RACEPINEPHRINE TISSUE_TOXICITY Arrhythmia 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT NEU_3_Tremor 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT XXX_3_Gangrene 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT END_2_Hyperglycemia 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT OCU_2_Glaucoma 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT CVS_2_Arrhythmia 329-65-7 RACEPINEPHRINE MECHANISM Modulate G-protein coupled signal transduction 329-65-7 RACEPINEPHRINE ADVERSE_EFFECT OCU_3_Corneal Edema 82640-04-8 RALOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 82640-04-8 RALOXIFENE TISSUE_TOXICITY Thromboembolism 82640-04-8 RALOXIFENE ADVERSE_EFFECT GUS_1_Vaginitis 82640-04-8 RALOXIFENE ADVERSE_EFFECT XXX_2_Weight Gain 82640-04-8 RALOXIFENE MODE_CLASS Receptor Agonist, selective 82640-04-8 RALOXIFENE MESH_LEVEL_2 Hydrocarbons 82640-04-8 RALOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 82640-04-8 RALOXIFENE MECH_LEVEL_2 estrogen receptor agonist 82640-04-8 RALOXIFENE TA_LEVEL_2 post-menapause 82640-04-8 RALOXIFENE TA_LEVEL_3 SERM 82640-04-8 RALOXIFENE ADVERSE_EFFECT CVS_2_Thromboembolism 82640-04-8 RALOXIFENE ACTIVITY_CLASS Estrogen antagonist 82640-04-8 RALOXIFENE ADVERSE_EFFECT XXX_1_Flu Syndrome 82640-04-8 RALOXIFENE ADVERSE_EFFECT CVS_1_Chest Pain 82640-04-8 RALOXIFENE ADVERSE_EFFECT PSY_3_Mental Depression 82640-04-8 RALOXIFENE ADVERSE_EFFECT NEU_1_Headache 82640-04-8 RALOXIFENE ADVERSE_EFFECT SKN_2_Flushing 82640-04-8 RALOXIFENE TA_LEVEL_1 Hormones, Endocrine and Metabolic 82640-04-8 RALOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 82640-04-8 RALOXIFENE MECHANISM Modulate gene transcription 82640-04-8 RALOXIFENE ADVERSE_EFFECT MSK_1_Leg Cramps 82640-04-8 RALOXIFENE ADVERSE_EFFECT GUS_2_Cystitis 82640-04-8 RALOXIFENE ADVERSE_EFFECT MSK_3_Arthralgia 82640-04-8 RALOXIFENE ADVERSE_EFFECT XXX_1_Infection 82640-04-8 RALOXIFENE MESH_LEVEL_1 Organic Chemicals 82640-04-8 RALOXIFENE MESH_LEVEL_3 Hydrocarbons, Cyclic 82640-04-8 RALOXIFENE KNOWN_TOXICITY Cardiovascular Toxicity 82640-04-8 RALOXIFENE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 82640-04-8 RALOXIFENE ADVERSE_EFFECT GIS_3_Gastrointestinal Disturbances 82640-04-8 RALOXIFENE ADVERSE_EFFECT MSK_3_Myalgia 82640-04-8 RALOXIFENE ADVERSE_EFFECT XXX_2_Peripheral Edema 82640-04-8 RALOXIFENE INDICATION Osteoporosis 82640-04-8 RALOXIFENE MECH_LEVEL_1 Hormone replacement 82640-04-8 RALOXIFENE MECH_LEVEL_3 estrogen receptor 82640-04-8 RALOXIFENE ZERO_CLASS N 84449-90-1 RALOXIFENE ADVERSE_EFFECT NEU_1_Headache 84449-90-1 RALOXIFENE MESH_LEVEL_1 Organic Chemicals 84449-90-1 RALOXIFENE ADVERSE_EFFECT XXX_2_Peripheral Edema 84449-90-1 RALOXIFENE INDICATION Osteoporosis 84449-90-1 RALOXIFENE TA_LEVEL_3 SERM 84449-90-1 RALOXIFENE MECH_LEVEL_1 Hormone replacement 84449-90-1 RALOXIFENE MECH_LEVEL_3 estrogen receptor 84449-90-1 RALOXIFENE ZERO_CLASS N 84449-90-1 RALOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 84449-90-1 RALOXIFENE TISSUE_TOXICITY Thromboembolism 84449-90-1 RALOXIFENE ADVERSE_EFFECT GUS_1_Vaginitis 84449-90-1 RALOXIFENE ADVERSE_EFFECT XXX_1_Infection 84449-90-1 RALOXIFENE ADVERSE_EFFECT MSK_3_Arthralgia 84449-90-1 RALOXIFENE ADVERSE_EFFECT GUS_2_Cystitis 84449-90-1 RALOXIFENE ADVERSE_EFFECT MSK_1_Leg Cramps 84449-90-1 RALOXIFENE MECHANISM Modulate gene transcription 84449-90-1 RALOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 84449-90-1 RALOXIFENE TA_LEVEL_1 Hormones, Endocrine and Metabolic 84449-90-1 RALOXIFENE ADVERSE_EFFECT SKN_2_Flushing 84449-90-1 RALOXIFENE ADVERSE_EFFECT CVS_2_Thromboembolism 84449-90-1 RALOXIFENE ADVERSE_EFFECT PSY_3_Mental Depression 84449-90-1 RALOXIFENE ADVERSE_EFFECT CVS_1_Chest Pain 84449-90-1 RALOXIFENE ADVERSE_EFFECT XXX_1_Flu Syndrome 84449-90-1 RALOXIFENE ACTIVITY_CLASS Estrogen antagonist 84449-90-1 RALOXIFENE ADVERSE_EFFECT XXX_2_Weight Gain 84449-90-1 RALOXIFENE MODE_CLASS Receptor Agonist, selective 84449-90-1 RALOXIFENE MESH_LEVEL_2 Hydrocarbons 84449-90-1 RALOXIFENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 84449-90-1 RALOXIFENE MECH_LEVEL_2 estrogen receptor agonist 84449-90-1 RALOXIFENE TA_LEVEL_2 post-menapause 84449-90-1 RALOXIFENE MESH_LEVEL_3 Hydrocarbons, Cyclic 84449-90-1 RALOXIFENE KNOWN_TOXICITY Cardiovascular Toxicity 84449-90-1 RALOXIFENE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 84449-90-1 RALOXIFENE ADVERSE_EFFECT GIS_3_Gastrointestinal Disturbances 84449-90-1 RALOXIFENE ADVERSE_EFFECT MSK_3_Myalgia 87333-19-5 RAMIPRIL TA_LEVEL_1 Cardiovascular 87333-19-5 RAMIPRIL TA_LEVEL_3 Diuretic 87333-19-5 RAMIPRIL INDICATION Diabetic Nephropathy 87333-19-5 RAMIPRIL MODE_CLASS Enzyme Inhibitor 87333-19-5 RAMIPRIL ACTIVITY_CLASS RAAS inhibitor 87333-19-5 RAMIPRIL ADVERSE_EFFECT XXX_3_Fatigue 87333-19-5 RAMIPRIL ADVERSE_EFFECT LIV_3_Hepatitis 87333-19-5 RAMIPRIL ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 87333-19-5 RAMIPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 87333-19-5 RAMIPRIL MESH_LEVEL_3 Bicyclo Compounds, Heterocyclic 87333-19-5 RAMIPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 87333-19-5 RAMIPRIL MESH_LEVEL_1 Heterocyclic Compounds 87333-19-5 RAMIPRIL INDICATION Proteinuria 87333-19-5 RAMIPRIL ADVERSE_EFFECT NEU_1_Syncope 87333-19-5 RAMIPRIL ADVERSE_EFFECT CVS_1_Hypotension 87333-19-5 RAMIPRIL ADVERSE_EFFECT LIV_3_Hepatic Failure 87333-19-5 RAMIPRIL INDICATION Acute Myocardial Infarction 87333-19-5 RAMIPRIL ADVERSE_EFFECT LUN_1_Cough 87333-19-5 RAMIPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 87333-19-5 RAMIPRIL THERAPEUTIC_CLASS Antihypertensive Agents 87333-19-5 RAMIPRIL KNOWN_TOXICITY Hepatotoxicity 87333-19-5 RAMIPRIL MECHANISM Reduce vasoconstriction 87333-19-5 RAMIPRIL MESH_LEVEL_2 Heterocyclic Compounds, Bridged-Ring 87333-19-5 RAMIPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 87333-19-5 RAMIPRIL TISSUE_TOXICITY Teratogenicity 87333-19-5 RAMIPRIL KNOWN_TOXICITY Cardiovascular Toxicity 87333-19-5 RAMIPRIL ADVERSE_EFFECT NEU_1_Dizziness 87333-19-5 RAMIPRIL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 87333-19-5 RAMIPRIL ADVERSE_EFFECT LIV_3_Jaundice 87333-19-5 RAMIPRIL ADVERSE_EFFECT EMB_3_Teratogenicity 87333-19-5 RAMIPRIL MECH_LEVEL_1 Vasorelaxation 87333-19-5 RAMIPRIL INDICATION Postmyocardial Infarction 87333-19-5 RAMIPRIL INDICATION Stroke Prophylaxis 87333-19-5 RAMIPRIL ADVERSE_EFFECT KID_3_Azotemia 87333-19-5 RAMIPRIL TISSUE_TOXICITY Hepatic Necrosis 87333-19-5 RAMIPRIL TA_LEVEL_2 Hypertension 87333-19-5 RAMIPRIL MECH_LEVEL_2 ACE inhibitor 87333-19-5 RAMIPRIL ADVERSE_EFFECT LIV_3_Cholestasis 87333-19-5 RAMIPRIL ZERO_CLASS N 87333-19-5 RAMIPRIL INDICATION Hypertension 87333-19-5 RAMIPRIL TISSUE_TOXICITY Hypotension 87333-19-5 RAMIPRIL TISSUE_TOXICITY Hepatic Failure 87333-19-5 RAMIPRIL ADVERSE_EFFECT IMU_3_Angioedema 87333-19-5 RAMIPRIL ADVERSE_EFFECT NEU_1_Headache 87333-19-5 RAMIPRIL ADVERSE_EFFECT ELT_2_Hyperkalemia 87333-19-5 RAMIPRIL ADVERSE_EFFECT CVS_1_Sinus Tachycardia 87333-19-5 RAMIPRIL PRODUCT_CLASS Cardiovasculars 66357-35-5 RANITIDINE ADVERSE_EFFECT LIV_3_Hepatitis 66357-35-5 RANITIDINE ADVERSE_EFFECT END_3_Gynecomastia 66357-35-5 RANITIDINE ADVERSE_EFFECT NEU_2_Headache 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 66357-35-5 RANITIDINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 66357-35-5 RANITIDINE ADVERSE_EFFECT OCU_2_Blurred Vision 66357-35-5 RANITIDINE THERAPEUTIC_CLASS Antiulcers 66357-35-5 RANITIDINE INDICATION Esophagitis 66357-35-5 RANITIDINE INDICATION Duodenal Ulcer 66357-35-5 RANITIDINE MECHANISM Reduce stomach HCl secretion 66357-35-5 RANITIDINE ACTIVITY_CLASS Histamine antagonist 66357-35-5 RANITIDINE KNOWN_TOXICITY Cardiovascular Toxicity 66357-35-5 RANITIDINE TISSUE_TOXICITY Atrioventricular Blockade 66357-35-5 RANITIDINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Delirium 66357-35-5 RANITIDINE ADVERSE_EFFECT XXX_2_Malaise 66357-35-5 RANITIDINE ADVERSE_EFFECT GIS_3_Pancreatitis 66357-35-5 RANITIDINE ADVERSE_EFFECT CVS_3_Vasculitis 66357-35-5 RANITIDINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Mental Status Changes 66357-35-5 RANITIDINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Confusion 66357-35-5 RANITIDINE ADVERSE_EFFECT LUN_3_Bronchospasm 66357-35-5 RANITIDINE ADVERSE_EFFECT NEU_2_Dizziness 66357-35-5 RANITIDINE TA_LEVEL_1 Gastrointestinal System 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Hallucinations 66357-35-5 RANITIDINE INDICATION Dyspepsia 66357-35-5 RANITIDINE MESH_LEVEL_3 Furans 66357-35-5 RANITIDINE TA_LEVEL_3 Gastric secretion inhibitors 66357-35-5 RANITIDINE MESH_LEVEL_1 Heterocyclic Compounds 66357-35-5 RANITIDINE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 66357-35-5 RANITIDINE INDICATION Gastroesophageal Reflux Disease (GERD) 66357-35-5 RANITIDINE ADVERSE_EFFECT CVS_3_Premature Ventricular Beats 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Agitation 66357-35-5 RANITIDINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Paranoia 66357-35-5 RANITIDINE ADVERSE_EFFECT MSK_3_Myalgia 66357-35-5 RANITIDINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_3_Pancytopenia 66357-35-5 RANITIDINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 66357-35-5 RANITIDINE ADVERSE_EFFECT GIS_2_Diarrhea 66357-35-5 RANITIDINE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 66357-35-5 RANITIDINE TISSUE_TOXICITY Premature Ventricular Beats 66357-35-5 RANITIDINE STRUCTURE_ACTIVITY Histamine receptor (H2) antagonist 66357-35-5 RANITIDINE INDICATION Gastric Ulcer 66357-35-5 RANITIDINE TA_LEVEL_2 Duodenal ulcer treatment 66357-35-5 RANITIDINE MECH_LEVEL_3 histamine receptor H2 66357-35-5 RANITIDINE PRODUCT_CLASS Gastrointestinal System 66357-35-5 RANITIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 66357-35-5 RANITIDINE ADVERSE_EFFECT REP_3_Decreased Libido 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_3_Leukopenia 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_2_Neutropenia 66357-35-5 RANITIDINE ADVERSE_EFFECT IMU_3_Eosinophilia 66357-35-5 RANITIDINE ZERO_CLASS N 66357-35-5 RANITIDINE MECH_LEVEL_1 Ulcer healing 66357-35-5 RANITIDINE MECH_LEVEL_2 Reduce stomach HCl secretion 66357-35-5 RANITIDINE INDICATION Heartburn / Pyrosis 66357-35-5 RANITIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 66357-35-5 RANITIDINE INDICATION Peptic Ulcer Disease (PUD) 66357-35-5 RANITIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 66357-35-5 RANITIDINE THERAPEUTIC_CLASS Antihistamines 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_3_Agranulocytosis 66357-35-5 RANITIDINE ADVERSE_EFFECT IMU_3_Angioedema 66357-35-5 RANITIDINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 66357-35-5 RANITIDINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 66357-35-5 RANITIDINE ADVERSE_EFFECT NEU_2_Vertigo 66357-35-5 RANITIDINE ADVERSE_EFFECT LIV_3_Jaundice 66357-35-5 RANITIDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Disorientation 66357-35-5 RANITIDINE ADVERSE_EFFECT GIS_2_Constipation 66357-35-5 RANITIDINE ADVERSE_EFFECT PSY_2_Insomnia 66357-35-5 RANITIDINE ADVERSE_EFFECT REP_3_Impotence 66357-59-3 RANITIDINE ADVERSE_EFFECT MSK_3_Myalgia 66357-59-3 RANITIDINE ADVERSE_EFFECT REP_3_Decreased Libido 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_3_Leukopenia 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_2_Neutropenia 66357-59-3 RANITIDINE ADVERSE_EFFECT IMU_3_Eosinophilia 66357-59-3 RANITIDINE ZERO_CLASS N 66357-59-3 RANITIDINE MECH_LEVEL_1 Ulcer healing 66357-59-3 RANITIDINE MECH_LEVEL_2 Reduce stomach HCl secretion 66357-59-3 RANITIDINE INDICATION Dyspepsia 66357-59-3 RANITIDINE INDICATION Heartburn / Pyrosis 66357-59-3 RANITIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 66357-59-3 RANITIDINE INDICATION Peptic Ulcer Disease (PUD) 66357-59-3 RANITIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 66357-59-3 RANITIDINE THERAPEUTIC_CLASS Antihistamines 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_3_Agranulocytosis 66357-59-3 RANITIDINE ADVERSE_EFFECT IMU_3_Angioedema 66357-59-3 RANITIDINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 66357-59-3 RANITIDINE ADVERSE_EFFECT NEU_2_Vertigo 66357-59-3 RANITIDINE ADVERSE_EFFECT LIV_3_Jaundice 66357-59-3 RANITIDINE ADVERSE_EFFECT REP_3_Impotence 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Insomnia 66357-59-3 RANITIDINE ADVERSE_EFFECT GIS_2_Constipation 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Disorientation 66357-59-3 RANITIDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 66357-59-3 RANITIDINE MESH_LEVEL_3 Furans 66357-59-3 RANITIDINE TA_LEVEL_3 Gastric secretion inhibitors 66357-59-3 RANITIDINE MESH_LEVEL_1 Heterocyclic Compounds 66357-59-3 RANITIDINE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 66357-59-3 RANITIDINE INDICATION Gastroesophageal Reflux Disease (GERD) 66357-59-3 RANITIDINE ADVERSE_EFFECT CVS_3_Premature Ventricular Beats 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Agitation 66357-59-3 RANITIDINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Paranoia 66357-59-3 RANITIDINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_3_Pancytopenia 66357-59-3 RANITIDINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 66357-59-3 RANITIDINE ADVERSE_EFFECT GIS_2_Diarrhea 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Hallucinations 66357-59-3 RANITIDINE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 66357-59-3 RANITIDINE TISSUE_TOXICITY Premature Ventricular Beats 66357-59-3 RANITIDINE STRUCTURE_ACTIVITY Histamine receptor (H2) antagonist 66357-59-3 RANITIDINE INDICATION Gastric Ulcer 66357-59-3 RANITIDINE TA_LEVEL_2 Duodenal ulcer treatment 66357-59-3 RANITIDINE MECH_LEVEL_3 histamine receptor H2 66357-59-3 RANITIDINE PRODUCT_CLASS Gastrointestinal System 66357-59-3 RANITIDINE TA_LEVEL_1 Gastrointestinal System 66357-59-3 RANITIDINE ADVERSE_EFFECT NEU_2_Dizziness 66357-59-3 RANITIDINE ADVERSE_EFFECT LUN_3_Bronchospasm 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Confusion 66357-59-3 RANITIDINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Mental Status Changes 66357-59-3 RANITIDINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 66357-59-3 RANITIDINE ADVERSE_EFFECT CVS_3_Vasculitis 66357-59-3 RANITIDINE ADVERSE_EFFECT GIS_3_Pancreatitis 66357-59-3 RANITIDINE ADVERSE_EFFECT XXX_2_Malaise 66357-59-3 RANITIDINE ADVERSE_EFFECT PSY_2_Delirium 66357-59-3 RANITIDINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 66357-59-3 RANITIDINE TISSUE_TOXICITY Atrioventricular Blockade 66357-59-3 RANITIDINE KNOWN_TOXICITY Cardiovascular Toxicity 66357-59-3 RANITIDINE ACTIVITY_CLASS Histamine antagonist 66357-59-3 RANITIDINE MECHANISM Reduce stomach HCl secretion 66357-59-3 RANITIDINE INDICATION Duodenal Ulcer 66357-59-3 RANITIDINE INDICATION Esophagitis 66357-59-3 RANITIDINE THERAPEUTIC_CLASS Antiulcers 66357-59-3 RANITIDINE ADVERSE_EFFECT OCU_2_Blurred Vision 66357-59-3 RANITIDINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 66357-59-3 RANITIDINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 66357-59-3 RANITIDINE ADVERSE_EFFECT NEU_2_Headache 66357-59-3 RANITIDINE ADVERSE_EFFECT END_3_Gynecomastia 66357-59-3 RANITIDINE ADVERSE_EFFECT LIV_3_Hepatitis 66357-59-3 RANITIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 156137-99-4 RAPACURONIUM BROMIDE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 156137-99-4 RAPACURONIUM BROMIDE MODE_CLASS Channel Blocker, selective 156137-99-4 RAPACURONIUM BROMIDE KNOWN_TOXICITY Miscellaneous 156137-99-4 RAPACURONIUM BROMIDE ADVERSE_EFFECT LUN__Bronchospasm 156137-99-4 RAPACURONIUM BROMIDE MECHANISM Block neural transmission 156137-99-4 RAPACURONIUM BROMIDE PRODUCT_CLASS Cardiovasculars 156137-99-4 RAPACURONIUM BROMIDE THERAPEUTIC_CLASS Antihypertensive Agents 156137-99-4 RAPACURONIUM BROMIDE TISSUE_TOXICITY Death 156137-99-4 RAPACURONIUM BROMIDE ADVERSE_EFFECT XXX__Death 53123-88-9 RAPAMYCIN ADVERSE_EFFECT BBM_1_Anemia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT ELT_1_Hypokalemia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT XXX_2_Hemolytic-Uremic Syndrome 53123-88-9 RAPAMYCIN ADVERSE_EFFECT DNA_1_Lymphoma 53123-88-9 RAPAMYCIN ADVERSE_EFFECT XXX_2_Opportunistic Infection 53123-88-9 RAPAMYCIN ADVERSE_EFFECT CVS_1_Hypertension 53123-88-9 RAPAMYCIN THERAPEUTIC_CLASS Immunosuppressants 53123-88-9 RAPAMYCIN KNOWN_TOXICITY Embryo/Fetal Toxicity 53123-88-9 RAPAMYCIN TISSUE_TOXICITY Thrombocytopenia 53123-88-9 RAPAMYCIN TA_LEVEL_1 Anti-inflammatory 53123-88-9 RAPAMYCIN ADVERSE_EFFECT SKN_1_Rash 53123-88-9 RAPAMYCIN MECHANISM Modulate G-protein coupled signal transduction 53123-88-9 RAPAMYCIN ADVERSE_EFFECT SKN_1_Acne 53123-88-9 RAPAMYCIN INDICATION Prophylaxis of Organ Transplant Rejection 53123-88-9 RAPAMYCIN ADVERSE_EFFECT BBM_1_Thrombocytopenia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT XXX_2_Edema 53123-88-9 RAPAMYCIN ADVERSE_EFFECT END_2_Diabetes 53123-88-9 RAPAMYCIN ADVERSE_EFFECT END_1_Hypertriglyceridemia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT EMB_1_Fetal Toxicity 53123-88-9 RAPAMYCIN KNOWN_TOXICITY Carcinogenicity 53123-88-9 RAPAMYCIN TISSUE_TOXICITY Anemia 53123-88-9 RAPAMYCIN PRODUCT_CLASS Immune Response / Immunomodulators 53123-88-9 RAPAMYCIN ZERO_CLASS N 53123-88-9 RAPAMYCIN MESH_LEVEL_3 Macrolides 53123-88-9 RAPAMYCIN ADVERSE_EFFECT MSK_1_Arthralgia 53123-88-9 RAPAMYCIN TISSUE_TOXICITY Fetal Toxicity 53123-88-9 RAPAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 53123-88-9 RAPAMYCIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 53123-88-9 RAPAMYCIN ADVERSE_EFFECT GUS_1_Urinary Tract Infection 53123-88-9 RAPAMYCIN ADVERSE_EFFECT END_1_Hypercholesteremia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT LYM_2_Increased Incidence of Lymphocele 53123-88-9 RAPAMYCIN MODE_CLASS Enzyme Inhibitor 53123-88-9 RAPAMYCIN ADVERSE_EFFECT LUN_3_Atelectasis 53123-88-9 RAPAMYCIN MECH_LEVEL_1 Immunomodulation 53123-88-9 RAPAMYCIN MECH_LEVEL_2 Immunosuppressants 53123-88-9 RAPAMYCIN MECH_LEVEL_3 Serine/threonine specific protein phosphatase 53123-88-9 RAPAMYCIN TA_LEVEL_2 Immune Response / Immunomodulators 53123-88-9 RAPAMYCIN MESH_LEVEL_2 Lactones 53123-88-9 RAPAMYCIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 53123-88-9 RAPAMYCIN TISSUE_TOXICITY Lymphoma 53123-88-9 RAPAMYCIN TISSUE_TOXICITY Leukopenia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT BBM_1_Leukopenia 53123-88-9 RAPAMYCIN ADVERSE_EFFECT XXX_1_Infection 53123-88-9 RAPAMYCIN ADVERSE_EFFECT KID_1_Abnormal Kidney Function 53123-88-9 RAPAMYCIN STRUCTURE_ACTIVITY Inhibits T-cell activation 53123-88-9 RAPAMYCIN ACTIVITY_CLASS Inhibit calcineurin as a drug-immunophilin complex 53123-88-9 RAPAMYCIN MESH_LEVEL_1 Organic Chemicals 6211-32-1 RAUWOLSCINE MODE_CLASS Receptor Ligand Antagonist, Selective 6211-32-1 RAUWOLSCINE PRODUCT_CLASS Biochemicals 6211-32-1 RAUWOLSCINE MECHANISM Modulate G-protein coupled signal transduction 98769-81-4 REBOXETINE MECHANISM Modulate neural transmission 98769-81-4 REBOXETINE MECHANISM Prolong/enhance neural transmission 98769-81-4 REBOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 98769-81-4 REBOXETINE PRODUCT_CLASS Central Nervous System (CNS) 98769-81-4 REBOXETINE MODE_CLASS Solute transporter inhibitor 98769-81-4 REBOXETINE INDICATION Depression 98769-81-4 REBOXETINE THERAPEUTIC_CLASS Antidepressants 98769-81-4 REBOXETINE MODE_CLASS Channel Blocker 98769-82-5 REBOXETINE MODE_CLASS Channel Blocker 98769-82-5 REBOXETINE PRODUCT_CLASS Central Nervous System (CNS) 98769-82-5 REBOXETINE MECHANISM Modulate neural transmission 98769-82-5 REBOXETINE MECHANISM Prolong/enhance neural transmission 98769-82-5 REBOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 98769-82-5 REBOXETINE MODE_CLASS Solute transporter inhibitor 98769-82-5 REBOXETINE INDICATION Depression 98769-82-5 REBOXETINE THERAPEUTIC_CLASS Antidepressants 71620-89-8 REBOXETINE MECHANISM Modulate neural transmission 71620-89-8 REBOXETINE MECHANISM Prolong/enhance neural transmission 71620-89-8 REBOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 71620-89-8 REBOXETINE PRODUCT_CLASS Central Nervous System (CNS) 71620-89-8 REBOXETINE MODE_CLASS Solute transporter inhibitor 71620-89-8 REBOXETINE INDICATION Depression 71620-89-8 REBOXETINE THERAPEUTIC_CLASS Antidepressants 71620-89-8 REBOXETINE MODE_CLASS Channel Blocker 98769-83-6 REBOXETINE MECHANISM Modulate neural transmission 98769-83-6 REBOXETINE MODE_CLASS Channel Blocker 98769-83-6 REBOXETINE THERAPEUTIC_CLASS Antidepressants 98769-83-6 REBOXETINE INDICATION Depression 98769-83-6 REBOXETINE PRODUCT_CLASS Central Nervous System (CNS) 98769-83-6 REBOXETINE MECHANISM Prolong/enhance neural transmission 98769-83-6 REBOXETINE MODE_CLASS Solute transporter inhibitor 98769-83-6 REBOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 135969-54-9 REPAGLINIDE INDICATION Type II Diabetes Mellitus 135969-54-9 REPAGLINIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 135969-54-9 REPAGLINIDE THERAPEUTIC_CLASS Antidiabetic Agents 135969-54-9 REPAGLINIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 135969-54-9 REPAGLINIDE MODE_CLASS Channel Blocker, selective 135969-54-9 REPAGLINIDE MECHANISM Trigger insulin release in pancreatic beta cells 50-55-5 RESERPINE ADVERSE_EFFECT CVS_1_Hypotension 50-55-5 RESERPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 50-55-5 RESERPINE ADVERSE_EFFECT GIS_3_Diarrhea 50-55-5 RESERPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-55-5 RESERPINE ADVERSE_EFFECT NEU_1_Dizziness 50-55-5 RESERPINE ADVERSE_EFFECT GIS_3_Abdominal Pain 50-55-5 RESERPINE ADVERSE_EFFECT OCU_3_Conjunctivitis 50-55-5 RESERPINE THERAPEUTIC_CLASS Antihypertensive Agents 50-55-5 RESERPINE ADVERSE_EFFECT OCU_2_Miosis 50-55-5 RESERPINE TISSUE_TOXICITY Arrhythmia 50-55-5 RESERPINE ADVERSE_EFFECT END_3_Hyperprolactinemia 50-55-5 RESERPINE KNOWN_TOXICITY Cardiovascular Toxicity 50-55-5 RESERPINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 50-55-5 RESERPINE ADVERSE_EFFECT REP_3_Decreased Libido 50-55-5 RESERPINE INDICATION Hypertension 50-55-5 RESERPINE MODE_CLASS Solute transporter inhibitor 50-55-5 RESERPINE ADVERSE_EFFECT PSY_2_Anorexia 50-55-5 RESERPINE ADVERSE_EFFECT XXX_1_Fatigue 50-55-5 RESERPINE ADVERSE_EFFECT XXX_3_Edema 50-55-5 RESERPINE ADVERSE_EFFECT NEU_1_Drowsiness 50-55-5 RESERPINE ADVERSE_EFFECT REP_3_Impotence 50-55-5 RESERPINE ADVERSE_EFFECT XXX_1_Lethargy 50-55-5 RESERPINE ADVERSE_EFFECT KID_3_Fluid Retention 50-55-5 RESERPINE ADVERSE_EFFECT REP_3_Ejaculatory Disorder 50-55-5 RESERPINE TISSUE_TOXICITY Congestive Heart Failure 50-55-5 RESERPINE ADVERSE_EFFECT GIS_3_Peptic Ulceration 50-55-5 RESERPINE ADVERSE_EFFECT CVS_3_Arrhythmia 50-55-5 RESERPINE MECHANISM Prolong/enhance neural transmission 50-55-5 RESERPINE STRUCTURE_ACTIVITY Monoamine Re-uptake inhibitor, depletes transmmiter from neurons 50-55-5 RESERPINE TISSUE_TOXICITY Hypotension 50-55-5 RESERPINE PRODUCT_CLASS Cardiovasculars 501-36-0 RESVERATROL PRODUCT_CLASS Botanicals 501-36-0 RESVERATROL MECHANISM Modulate gene transcription 36791-04-5 RIBAVIRIN ADVERSE_EFFECT OCU_1_Conjunctival Irritation 36791-04-5 RIBAVIRIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 36791-04-5 RIBAVIRIN ADVERSE_EFFECT IMU_3_Hypersensitivity 36791-04-5 RIBAVIRIN ADVERSE_EFFECT XXX_1_Fatigue 36791-04-5 RIBAVIRIN ADVERSE_EFFECT DNA_1_Carcinogenicity 36791-04-5 RIBAVIRIN MODE_CLASS Enzyme substrate mimic 36791-04-5 RIBAVIRIN MESH_LEVEL_2 Nucleosides 36791-04-5 RIBAVIRIN MESH_LEVEL_3 Ribonucleosides 36791-04-5 RIBAVIRIN STRUCTURE_ACTIVITY Viral RT inhibitor 36791-04-5 RIBAVIRIN KNOWN_TOXICITY Mutagenicity 36791-04-5 RIBAVIRIN TISSUE_TOXICITY Teratogenicity 36791-04-5 RIBAVIRIN ADVERSE_EFFECT DNA_1_Clastogenicity 36791-04-5 RIBAVIRIN ADVERSE_EFFECT EMB_1_Embryotoxicity 36791-04-5 RIBAVIRIN ADVERSE_EFFECT LUN_2_Acute Respiratory Distress 36791-04-5 RIBAVIRIN MECH_LEVEL_1 Anti-viral 36791-04-5 RIBAVIRIN MECHANISM Incorporate into DNA/RNA/Protein 36791-04-5 RIBAVIRIN INDICATION Respiratory Syncytial Virus (RSV) Infections 36791-04-5 RIBAVIRIN THERAPEUTIC_CLASS Antivirals, Systemic 36791-04-5 RIBAVIRIN TA_LEVEL_2 Anti-viral 36791-04-5 RIBAVIRIN TA_LEVEL_1 Infectious Disease 36791-04-5 RIBAVIRIN MECH_LEVEL_3 DNA-directed DNA polymerase 36791-04-5 RIBAVIRIN ADVERSE_EFFECT REP_2_Decreased Fertility 36791-04-5 RIBAVIRIN ADVERSE_EFFECT SKN_1_Skin Rash 36791-04-5 RIBAVIRIN ADVERSE_EFFECT LUN_3_Atelectasis 36791-04-5 RIBAVIRIN KNOWN_TOXICITY Carcinogenicity 36791-04-5 RIBAVIRIN TISSUE_TOXICITY Cardiac Arrest 36791-04-5 RIBAVIRIN KNOWN_TOXICITY Cardiovascular Toxicity 36791-04-5 RIBAVIRIN MECH_LEVEL_2 Inhibit viral DNA synthesis 36791-04-5 RIBAVIRIN ADVERSE_EFFECT PSY_1_Insomnia 36791-04-5 RIBAVIRIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 36791-04-5 RIBAVIRIN ADVERSE_EFFECT PSY_2_Mental Depression 36791-04-5 RIBAVIRIN ADVERSE_EFFECT BBM_2_Myelosuppression 36791-04-5 RIBAVIRIN ADVERSE_EFFECT LUN_3_Apnea 36791-04-5 RIBAVIRIN TISSUE_TOXICITY Embryotoxicity 36791-04-5 RIBAVIRIN KNOWN_TOXICITY Embryo/Fetal Toxicity 36791-04-5 RIBAVIRIN PRODUCT_CLASS Anti-infectives 36791-04-5 RIBAVIRIN INDICATION Hepatitis C 36791-04-5 RIBAVIRIN MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 36791-04-5 RIBAVIRIN THERAPEUTIC_CLASS Antivirals 36791-04-5 RIBAVIRIN ADVERSE_EFFECT LUN_3_Pulmonary Edema 36791-04-5 RIBAVIRIN ADVERSE_EFFECT BBM_1_Hemolytic Anemia 36791-04-5 RIBAVIRIN ADVERSE_EFFECT LUN_2_Bronchospasm 36791-04-5 RIBAVIRIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 36791-04-5 RIBAVIRIN ADVERSE_EFFECT EMB_1_Teratogenicity 36791-04-5 RIBAVIRIN TISSUE_TOXICITY Carcinogenicity 36791-04-5 RIBAVIRIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 36791-04-5 RIBAVIRIN TISSUE_TOXICITY Hemolytic Anemia 36791-04-5 RIBAVIRIN TISSUE_TOXICITY Clastogenicity 36791-04-5 RIBAVIRIN ADVERSE_EFFECT BBM_1_Reticulocytosis 83-88-5 RIBOFLAVIN MECHANISM Vitamin/ cofactor 72559-06-9 RIFABUTIN ADVERSE_EFFECT BBM_1_Neutropenia 72559-06-9 RIFABUTIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 72559-06-9 RIFABUTIN ADVERSE_EFFECT LIV_3_Hepatitis 72559-06-9 RIFABUTIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 72559-06-9 RIFABUTIN MODE_CLASS Enzyme Inhibitor, selective 72559-06-9 RIFABUTIN ADVERSE_EFFECT GIS_1_Flatulence 72559-06-9 RIFABUTIN MECH_LEVEL_3 DNA-directed RNA polymerase 72559-06-9 RIFABUTIN MESH_LEVEL_2 Heterocyclic Compounds with 4 or More Rings 72559-06-9 RIFABUTIN TA_LEVEL_2 Anti-bacterial 72559-06-9 RIFABUTIN TA_LEVEL_1 Infectious Disease 72559-06-9 RIFABUTIN STRUCTURE_ACTIVITY RNA polymerase inhibitor 72559-06-9 RIFABUTIN TISSUE_TOXICITY Neutropenia 72559-06-9 RIFABUTIN ADVERSE_EFFECT GIS_1_Abdominal Pain 72559-06-9 RIFABUTIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 72559-06-9 RIFABUTIN ADVERSE_EFFECT IMU_1_Urticaria 72559-06-9 RIFABUTIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 72559-06-9 RIFABUTIN MESH_LEVEL_1 Heterocyclic Compounds 72559-06-9 RIFABUTIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 72559-06-9 RIFABUTIN INDICATION Mycobacterium Avium Complex (MAC) Prophylaxis 72559-06-9 RIFABUTIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 72559-06-9 RIFABUTIN MECH_LEVEL_1 antibacterial 72559-06-9 RIFABUTIN ADVERSE_EFFECT MSK_3_Myalgia 72559-06-9 RIFABUTIN ADVERSE_EFFECT MSK_3_Arthralgia 72559-06-9 RIFABUTIN ADVERSE_EFFECT SKN_1_Rash 72559-06-9 RIFABUTIN PRODUCT_CLASS Anti-infectives 72559-06-9 RIFABUTIN MECH_LEVEL_2 Inhibit protein synthesis 72559-06-9 RIFABUTIN MESH_LEVEL_3 Rifamycins 72559-06-9 RIFABUTIN ADVERSE_EFFECT XXX_3_Taste Disturbances 72559-06-9 RIFABUTIN ADVERSE_EFFECT GUS_1_Discoloration of Urine 72559-06-9 RIFABUTIN TA_LEVEL_3 systemic infections 72559-06-9 RIFABUTIN ADVERSE_EFFECT CVS_3_ECG Changes 72559-06-9 RIFABUTIN ADVERSE_EFFECT NEU_3_Seizures 72559-06-9 RIFABUTIN MECHANISM Inhibit protein synthesis 72559-06-9 RIFABUTIN ZERO_CLASS N 72559-06-9 RIFABUTIN THERAPEUTIC_CLASS Antibacterials, Systemic 72559-06-9 RIFABUTIN ADVERSE_EFFECT GIS_1_Dyspepsia 13292-46-1 RIFAMPIN TISSUE_TOXICITY Acute Interstitial Nephritis 13292-46-1 RIFAMPIN ZERO_CLASS N 13292-46-1 RIFAMPIN MESH_LEVEL_2 Heterocyclic Compounds with 4 or More Rings 13292-46-1 RIFAMPIN TA_LEVEL_1 Infectious Disease 13292-46-1 RIFAMPIN TA_LEVEL_2 Anti-bacterial 13292-46-1 RIFAMPIN MECH_LEVEL_1 antibacterial 13292-46-1 RIFAMPIN MESH_LEVEL_3 Rifamycins 13292-46-1 RIFAMPIN ADVERSE_EFFECT SKN_2_Itching 13292-46-1 RIFAMPIN PRODUCT_CLASS Anti-infectives 13292-46-1 RIFAMPIN INDICATION Tuberculosis Carrier 13292-46-1 RIFAMPIN ADVERSE_EFFECT BBM_3_Leukopenia 13292-46-1 RIFAMPIN INDICATION Leprosy 13292-46-1 RIFAMPIN ADVERSE_EFFECT EMB_2_Teratogenicity 13292-46-1 RIFAMPIN THERAPEUTIC_CLASS Antibacterials, Systemic 13292-46-1 RIFAMPIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 13292-46-1 RIFAMPIN ADVERSE_EFFECT NEU_2_Headache 13292-46-1 RIFAMPIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 13292-46-1 RIFAMPIN ADVERSE_EFFECT SKN_2_Cutaneous Flushing 13292-46-1 RIFAMPIN ADVERSE_EFFECT IMU_3_Anaphylaxis 13292-46-1 RIFAMPIN ADVERSE_EFFECT BBM_3_Disseminated Intravascular Coagulation (DIC) 13292-46-1 RIFAMPIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 13292-46-1 RIFAMPIN ADVERSE_EFFECT GIS_2_Vomiting 13292-46-1 RIFAMPIN MECHANISM Inhibit protein synthesis 13292-46-1 RIFAMPIN TISSUE_TOXICITY Teratogenicity 13292-46-1 RIFAMPIN MODE_CLASS Enzyme Inhibitor, selective 13292-46-1 RIFAMPIN MESH_LEVEL_1 Heterocyclic Compounds 13292-46-1 RIFAMPIN KNOWN_TOXICITY Nephrotoxicity 13292-46-1 RIFAMPIN TISSUE_TOXICITY Renal Tubular Necrosis 13292-46-1 RIFAMPIN INDICATION Legionnaire's Disease 13292-46-1 RIFAMPIN ADVERSE_EFFECT NEU_3_Ataxia 13292-46-1 RIFAMPIN INDICATION Meningococal Carrier 13292-46-1 RIFAMPIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 13292-46-1 RIFAMPIN ADVERSE_EFFECT GIS_2_Diarrhea 13292-46-1 RIFAMPIN ADVERSE_EFFECT GUS_1_Orange Color Urine 13292-46-1 RIFAMPIN ADVERSE_EFFECT REP_2_Menstrual Abnormalities 13292-46-1 RIFAMPIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 13292-46-1 RIFAMPIN KNOWN_TOXICITY Embryo/Fetal Toxicity 13292-46-1 RIFAMPIN MECH_LEVEL_2 Inhibit protein synthesis 13292-46-1 RIFAMPIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 13292-46-1 RIFAMPIN INDICATION Prophylaxis of Haemophilus Influenzae Infection 13292-46-1 RIFAMPIN ADVERSE_EFFECT END_3_Exacerbation of Porphyria 13292-46-1 RIFAMPIN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 13292-46-1 RIFAMPIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 13292-46-1 RIFAMPIN STRUCTURE_ACTIVITY RNA polymerase inhibitor 13292-46-1 RIFAMPIN MECH_LEVEL_3 DNA-directed RNA polymerase 13292-46-1 RIFAMPIN TA_LEVEL_3 systemic infections 13292-46-1 RIFAMPIN KNOWN_TOXICITY Hepatotoxicity 13292-46-1 RIFAMPIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 13292-46-1 RIFAMPIN ADVERSE_EFFECT XXX_2_Fever 13292-46-1 RIFAMPIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 13292-46-1 RIFAMPIN ADVERSE_EFFECT SKN_3_Pemphigus-Like Eruptions 13292-46-1 RIFAMPIN ADVERSE_EFFECT GIS_2_Nausea 13292-46-1 RIFAMPIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 13292-46-1 RIFAMPIN TISSUE_TOXICITY Hepatotoxicity 13292-46-1 RIFAMPIN ADVERSE_EFFECT LIV_3_Hepatitis 13292-46-1 RIFAMPIN INDICATION Mycobacterium Tuberculosis Infections 54187-04-1 RILMENIDINE PRODUCT_CLASS Cardiovasculars 54187-04-1 RILMENIDINE MODE_CLASS Receptor Agonist 54187-04-1 RILMENIDINE MECHANISM Modulate gene transcription 54187-04-1 RILMENIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 54187-04-1 RILMENIDINE THERAPEUTIC_CLASS Antihypertensive Agents 13392-28-4 RIMANTADINE ADVERSE_EFFECT OTO_2_Tinnitus 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_3_Confusion 13392-28-4 RIMANTADINE KNOWN_TOXICITY Cardiovascular Toxicity 13392-28-4 RIMANTADINE PRODUCT_CLASS Anti-infectives 13392-28-4 RIMANTADINE ADVERSE_EFFECT GIS_1_Abdominal Pain 13392-28-4 RIMANTADINE ADVERSE_EFFECT XXX_1_Xerostomia 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_1_Anorexia 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_1_Dizziness 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_2_Ataxia 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_3_Euphoria 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_2_Depression 13392-28-4 RIMANTADINE MECHANISM Block channel gating 13392-28-4 RIMANTADINE ADVERSE_EFFECT GIS_2_Diarrhea 13392-28-4 RIMANTADINE ADVERSE_EFFECT GIS_1_Dry Mouth 13392-28-4 RIMANTADINE ADVERSE_EFFECT CVS_2_Palpitation 13392-28-4 RIMANTADINE ADVERSE_EFFECT XXX_1_Asthenia 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_1_Nervousness 13392-28-4 RIMANTADINE ADVERSE_EFFECT XXX_1_Fatigue 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_1_Headache 13392-28-4 RIMANTADINE ADVERSE_EFFECT LUN_3_Bronchospasm 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_2_Agitation 13392-28-4 RIMANTADINE STRUCTURE_ACTIVITY Viral M2 protein inhibitor 13392-28-4 RIMANTADINE INDICATION Influenza A Viral Infection 13392-28-4 RIMANTADINE ADVERSE_EFFECT CVS_3_Tachycardia 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_3_Convulsions 13392-28-4 RIMANTADINE ADVERSE_EFFECT CVS_3_Hypertension 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_2_Somnolence 13392-28-4 RIMANTADINE ADVERSE_EFFECT SKN_2_Rash 13392-28-4 RIMANTADINE THERAPEUTIC_CLASS Antivirals 13392-28-4 RIMANTADINE ADVERSE_EFFECT PSY_3_Hallucinations 13392-28-4 RIMANTADINE ADVERSE_EFFECT GIS_2_Dyspepsia 13392-28-4 RIMANTADINE ADVERSE_EFFECT CVS_3_Heart Block 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_1_Analgesic Headache 13392-28-4 RIMANTADINE TISSUE_TOXICITY Heart Block 13392-28-4 RIMANTADINE MODE_CLASS Channel Blocker, selective 13392-28-4 RIMANTADINE ADVERSE_EFFECT NEU_3_Tremor 13392-28-4 RIMANTADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1501-84-4 RIMANTADINE STRUCTURE_ACTIVITY Viral M2 protein inhibitor 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_2_Agitation 1501-84-4 RIMANTADINE ADVERSE_EFFECT LUN_3_Bronchospasm 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_1_Headache 1501-84-4 RIMANTADINE ADVERSE_EFFECT XXX_1_Fatigue 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_1_Nervousness 1501-84-4 RIMANTADINE ADVERSE_EFFECT XXX_1_Asthenia 1501-84-4 RIMANTADINE ADVERSE_EFFECT CVS_2_Palpitation 1501-84-4 RIMANTADINE ADVERSE_EFFECT GIS_1_Dry Mouth 1501-84-4 RIMANTADINE ADVERSE_EFFECT GIS_2_Diarrhea 1501-84-4 RIMANTADINE MECHANISM Block channel gating 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_2_Depression 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_3_Euphoria 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_2_Ataxia 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_1_Dizziness 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_1_Anorexia 1501-84-4 RIMANTADINE ADVERSE_EFFECT XXX_1_Xerostomia 1501-84-4 RIMANTADINE ADVERSE_EFFECT GIS_1_Abdominal Pain 1501-84-4 RIMANTADINE PRODUCT_CLASS Anti-infectives 1501-84-4 RIMANTADINE KNOWN_TOXICITY Cardiovascular Toxicity 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_3_Confusion 1501-84-4 RIMANTADINE ADVERSE_EFFECT OTO_2_Tinnitus 1501-84-4 RIMANTADINE TISSUE_TOXICITY Heart Block 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_1_Analgesic Headache 1501-84-4 RIMANTADINE ADVERSE_EFFECT GIS_2_Dyspepsia 1501-84-4 RIMANTADINE ADVERSE_EFFECT PSY_3_Hallucinations 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_3_Tremor 1501-84-4 RIMANTADINE MODE_CLASS Channel Blocker, selective 1501-84-4 RIMANTADINE ADVERSE_EFFECT CVS_3_Tachycardia 1501-84-4 RIMANTADINE THERAPEUTIC_CLASS Antivirals 1501-84-4 RIMANTADINE ADVERSE_EFFECT CVS_3_Heart Block 1501-84-4 RIMANTADINE ADVERSE_EFFECT SKN_2_Rash 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_2_Somnolence 1501-84-4 RIMANTADINE ADVERSE_EFFECT CVS_3_Hypertension 1501-84-4 RIMANTADINE ADVERSE_EFFECT NEU_3_Convulsions 1501-84-4 RIMANTADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1501-84-4 RIMANTADINE INDICATION Influenza A Viral Infection 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_1_Headache 129277-01-6 RIMANTADINE ADVERSE_EFFECT XXX_1_Fatigue 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_1_Nervousness 129277-01-6 RIMANTADINE ADVERSE_EFFECT XXX_1_Asthenia 129277-01-6 RIMANTADINE ADVERSE_EFFECT CVS_2_Palpitation 129277-01-6 RIMANTADINE ADVERSE_EFFECT GIS_1_Dry Mouth 129277-01-6 RIMANTADINE TISSUE_TOXICITY Heart Block 129277-01-6 RIMANTADINE ADVERSE_EFFECT GIS_2_Diarrhea 129277-01-6 RIMANTADINE MECHANISM Block channel gating 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_3_Confusion 129277-01-6 RIMANTADINE KNOWN_TOXICITY Cardiovascular Toxicity 129277-01-6 RIMANTADINE ADVERSE_EFFECT OTO_2_Tinnitus 129277-01-6 RIMANTADINE ADVERSE_EFFECT GIS_1_Abdominal Pain 129277-01-6 RIMANTADINE ADVERSE_EFFECT XXX_1_Xerostomia 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_1_Anorexia 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_1_Dizziness 129277-01-6 RIMANTADINE PRODUCT_CLASS Anti-infectives 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_2_Ataxia 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_3_Euphoria 129277-01-6 RIMANTADINE STRUCTURE_ACTIVITY Viral M2 protein inhibitor 129277-01-6 RIMANTADINE INDICATION Influenza A Viral Infection 129277-01-6 RIMANTADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_3_Convulsions 129277-01-6 RIMANTADINE ADVERSE_EFFECT CVS_3_Hypertension 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_2_Somnolence 129277-01-6 RIMANTADINE ADVERSE_EFFECT SKN_2_Rash 129277-01-6 RIMANTADINE ADVERSE_EFFECT CVS_3_Heart Block 129277-01-6 RIMANTADINE THERAPEUTIC_CLASS Antivirals 129277-01-6 RIMANTADINE MODE_CLASS Channel Blocker, selective 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_3_Tremor 129277-01-6 RIMANTADINE ADVERSE_EFFECT CVS_3_Tachycardia 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_3_Hallucinations 129277-01-6 RIMANTADINE ADVERSE_EFFECT GIS_2_Dyspepsia 129277-01-6 RIMANTADINE ADVERSE_EFFECT NEU_1_Analgesic Headache 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_2_Depression 129277-01-6 RIMANTADINE ADVERSE_EFFECT PSY_2_Agitation 129277-01-6 RIMANTADINE ADVERSE_EFFECT LUN_3_Bronchospasm 49697-38-3 RIMEXOLONE MECHANISM Modulate gene transcription 49697-38-3 RIMEXOLONE MODE_CLASS Receptor Agonist 105462-24-6 RISEDRONIC ACID MECHANISM Inhibit bone re-absorption 105462-24-6 RISEDRONIC ACID INDICATION Paget's Disease of Bone / Osteitis Deformans 105462-24-6 RISEDRONIC ACID INDICATION Glucocorticoid-Induced Osteoporosis 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT EMB_3_Teratogenicity 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT SKN_1_Rash 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT MSK_1_Arthralgia 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT XXX_2_Asthenia 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT OCU_2_Eye Dryness 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT MSK_2_Joint Disorder 105462-24-6 RISEDRONIC ACID KNOWN_TOXICITY Embryo/Fetal Toxicity 105462-24-6 RISEDRONIC ACID MODE_CLASS Enzyme Inhibitor 105462-24-6 RISEDRONIC ACID INDICATION Prevention of Osteoporosis 105462-24-6 RISEDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT MSK_2_Leg Cramps 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT CVS_2_Chest Pain 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT XXX_2_Peripheral Edema 105462-24-6 RISEDRONIC ACID INDICATION Osteoporosis 105462-24-6 RISEDRONIC ACID TISSUE_TOXICITY Teratogenicity 105462-24-6 RISEDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT BBM_2_Ecchymosis 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT MSK_2_Myasthenia 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT NEU_1_Headache 105462-24-6 RISEDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT CVS_2_Hypertension 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT BBM_3_Anemia 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 105462-24-6 RISEDRONIC ACID ADVERSE_EFFECT XXX_2_Sinusitis 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT MSK_1_Arthralgia 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT SKN_1_Rash 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT EMB_3_Teratogenicity 115436-72-1 RISEDRONIC ACID INDICATION Glucocorticoid-Induced Osteoporosis 115436-72-1 RISEDRONIC ACID INDICATION Paget's Disease of Bone / Osteitis Deformans 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT CVS_2_Chest Pain 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT OCU_2_Eye Dryness 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT MSK_2_Joint Disorder 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT BBM_3_Anemia 115436-72-1 RISEDRONIC ACID TISSUE_TOXICITY Teratogenicity 115436-72-1 RISEDRONIC ACID KNOWN_TOXICITY Embryo/Fetal Toxicity 115436-72-1 RISEDRONIC ACID MODE_CLASS Enzyme Inhibitor 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT XXX_2_Peripheral Edema 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT CVS_2_Hypertension 115436-72-1 RISEDRONIC ACID INDICATION Prevention of Osteoporosis 115436-72-1 RISEDRONIC ACID INDICATION Osteoporosis 115436-72-1 RISEDRONIC ACID MECHANISM Inhibit bone re-absorption 115436-72-1 RISEDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT XXX_2_Sinusitis 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT BBM_2_Ecchymosis 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT MSK_2_Myasthenia 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT NEU_1_Headache 115436-72-1 RISEDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 115436-72-1 RISEDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT MSK_2_Leg Cramps 115436-72-1 RISEDRONIC ACID ADVERSE_EFFECT XXX_2_Asthenia 106266-06-2 RISPERIDONE INDICATION Schizophrenia 106266-06-2 RISPERIDONE INDICATION Mania 106266-06-2 RISPERIDONE INDICATION Gilles De La Tourette's Syndrome / Tourette's Syndrome / Motor Tics 106266-06-2 RISPERIDONE ZERO_CLASS N 106266-06-2 RISPERIDONE TA_LEVEL_2 Antipsychotics 106266-06-2 RISPERIDONE ACTIVITY_CLASS Serotonin antagonist 106266-06-2 RISPERIDONE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 106266-06-2 RISPERIDONE THERAPEUTIC_CLASS Antipsychotics 106266-06-2 RISPERIDONE TISSUE_TOXICITY Stroke 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Fever 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Hyperkinesia 106266-06-2 RISPERIDONE TISSUE_TOXICITY Death 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Akinesia 106266-06-2 RISPERIDONE ADVERSE_EFFECT GUS_2_Dysuria 106266-06-2 RISPERIDONE ADVERSE_EFFECT BBM_3_Leukocytosis 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Akathisia 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Dizziness 106266-06-2 RISPERIDONE ADVERSE_EFFECT LUN_1_Cough 106266-06-2 RISPERIDONE ADVERSE_EFFECT OCU_2_Blurred Vision 106266-06-2 RISPERIDONE ADVERSE_EFFECT IMU_3_Angioedema 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_2_Decreased Libido 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Injection Site Reaction 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Hyperreflexia 106266-06-2 RISPERIDONE ADVERSE_EFFECT END_3_Hyperprolactinemia 106266-06-2 RISPERIDONE ADVERSE_EFFECT END_3_Galactorrhea 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_3_Failure to Ejaculate 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 106266-06-2 RISPERIDONE ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_2_Menstrual Irregularities 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_3_Death 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Weight Gain 106266-06-2 RISPERIDONE ADVERSE_EFFECT GUS_2_Urinary Retention 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_3_Infertility 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 106266-06-2 RISPERIDONE MECHANISM Modulate G-protein coupled signal transduction 106266-06-2 RISPERIDONE TA_LEVEL_1 Central Nervous System (CNS) 106266-06-2 RISPERIDONE INDICATION Dementia 106266-06-2 RISPERIDONE ADVERSE_EFFECT END_3_Diabetes Mellitus 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Chest Pain 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_3_Asthenia 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_1_Anxiety 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_2_Mania 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_1_Insomnia 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_2_Hypotension 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Headache 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_3_Dysphagia 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Withdrawal 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 106266-06-2 RISPERIDONE ADVERSE_EFFECT SKN_2_Hyperpigmentation 106266-06-2 RISPERIDONE ADVERSE_EFFECT SKN_2_Rash 106266-06-2 RISPERIDONE ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_3_Pancreatitis 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 106266-06-2 RISPERIDONE INDICATION Bipolar Disorders / Manic-Depression 106266-06-2 RISPERIDONE MESH_LEVEL_3 Pyrimidines 106266-06-2 RISPERIDONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 106266-06-2 RISPERIDONE MESH_LEVEL_1 Heterocyclic Compounds 106266-06-2 RISPERIDONE MODE_CLASS Receptor Ligand Antagonist 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Rhinitis 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_3_Priapism 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Pharyngitis 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Xerosis 106266-06-2 RISPERIDONE ADVERSE_EFFECT OCU_2_Visual Impairment 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Tremor 106266-06-2 RISPERIDONE ADVERSE_EFFECT CVS_3_Stroke 106266-06-2 RISPERIDONE TISSUE_TOXICITY Ventricular Tachycardia 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_1_Abdominal Pain 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Drowsiness 106266-06-2 RISPERIDONE ADVERSE_EFFECT END_2_Ketoacidosis 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Coma 106266-06-2 RISPERIDONE ADVERSE_EFFECT MSK_1_Back Pain 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_3_Anorexia 106266-06-2 RISPERIDONE ADVERSE_EFFECT LIV_3_Jaundice 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_3_Erectile Dysfunction 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Hyperthermia 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Suppressed Reflexes 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_1_Fatigue 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_2_Dyspepsia 106266-06-2 RISPERIDONE MECH_LEVEL_2 receptor ligand antagonist 106266-06-2 RISPERIDONE INDICATION Agitation 106266-06-2 RISPERIDONE TA_LEVEL_3 Schizophrenia 106266-06-2 RISPERIDONE MECHANISM Block neural transmission 106266-06-2 RISPERIDONE MECH_LEVEL_3 5-HT receptor 2A 106266-06-2 RISPERIDONE PRODUCT_CLASS Central Nervous System (CNS) 106266-06-2 RISPERIDONE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_2_Diarrhea 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_2_Constipation 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Ataxia 106266-06-2 RISPERIDONE KNOWN_TOXICITY Cardiovascular Toxicity 106266-06-2 RISPERIDONE ADVERSE_EFFECT MSK_3_Arthralgia 106266-06-2 RISPERIDONE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 106266-06-2 RISPERIDONE ADVERSE_EFFECT PSY_2_Agitation 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Hypertonia 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Dystonia 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Seizures 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 106266-06-2 RISPERIDONE ADVERSE_EFFECT IMU_3_Photosensitivity 106266-06-2 RISPERIDONE ADVERSE_EFFECT REP_3_Female Orgasm Dysfunction 106266-06-2 RISPERIDONE ADVERSE_EFFECT GIS_2_Hypersalivation 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Xerostomia 106266-06-2 RISPERIDONE ADVERSE_EFFECT XXX_2_Weakness 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_2_Urinary Incontinence 106266-06-2 RISPERIDONE ADVERSE_EFFECT NEU_3_Syncope 106266-06-2 RISPERIDONE KNOWN_TOXICITY Miscellaneous 106266-06-2 RISPERIDONE TISSUE_TOXICITY Hypotension 106266-06-2 RISPERIDONE INDICATION Psychotic Depression 106266-06-2 RISPERIDONE INDICATION Acute Psychosis 26652-09-5 RITODRINE MODE_CLASS Receptor Agonist 26652-09-5 RITODRINE MECHANISM Increase vasoconstriction 26652-09-5 RITODRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 26652-09-5 RITODRINE MODE_CLASS Receptor Agonist, selective 26652-09-5 RITODRINE INDICATION Premature labor 26652-09-5 RITODRINE THERAPEUTIC_CLASS Sympathomimetic Agents 26652-09-5 RITODRINE MECHANISM Modulate G-protein coupled signal transduction 23239-51-2 RITODRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 23239-51-2 RITODRINE MECHANISM Increase vasoconstriction 23239-51-2 RITODRINE THERAPEUTIC_CLASS Sympathomimetic Agents 23239-51-2 RITODRINE MECHANISM Modulate G-protein coupled signal transduction 23239-51-2 RITODRINE MODE_CLASS Receptor Agonist, selective 23239-51-2 RITODRINE INDICATION Premature labor 23239-51-2 RITODRINE MODE_CLASS Receptor Agonist 52447-11-7 RITODRINE MODE_CLASS Receptor Agonist 52447-11-7 RITODRINE MODE_CLASS Receptor Agonist, selective 52447-11-7 RITODRINE INDICATION Premature labor 52447-11-7 RITODRINE MECHANISM Modulate G-protein coupled signal transduction 52447-11-7 RITODRINE THERAPEUTIC_CLASS Sympathomimetic Agents 52447-11-7 RITODRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 52447-11-7 RITODRINE MECHANISM Increase vasoconstriction 123441-03-2 RIVASTIGMIN PRODUCT_CLASS Central Nervous System (CNS) 123441-03-2 RIVASTIGMIN INDICATION Alzheimer's Disease 123441-03-2 RIVASTIGMIN MECHANISM Enhance cholinergic transmission 123441-03-2 RIVASTIGMIN MODE_CLASS Enzyme Inhibitor 123441-03-2 RIVASTIGMIN THERAPEUTIC_CLASS Neurodegenerative Disorders 123441-03-2 RIVASTIGMIN THERAPEUTIC_CLASS Parasympathomimetic Agents 123441-03-2 RIVASTIGMIN PRODUCT_CLASS Autonomic Nervous System (ANS) 145202-66-0 RIZATRIPTAN INDICATION Migraine Headache 145202-66-0 RIZATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 145202-66-0 RIZATRIPTAN THERAPEUTIC_CLASS Antimigraines 145202-66-0 RIZATRIPTAN MECHANISM Modulate cerebral vasoconstriction 145202-66-0 RIZATRIPTAN MODE_CLASS Receptor Agonist 119302-91-9 ROCURONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 119302-91-9 ROCURONIUM BROMIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 119302-91-9 ROCURONIUM BROMIDE MECHANISM Block neural transmission 119302-91-9 ROCURONIUM BROMIDE MODE_CLASS Channel Blocker, selective 162011-90-7 ROFECOXIB ADVERSE_EFFECT CVS_3_Congestive Heart Failure 162011-90-7 ROFECOXIB PRODUCT_CLASS Analgesics 162011-90-7 ROFECOXIB INDICATION Osteoarthritis 162011-90-7 ROFECOXIB MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 162011-90-7 ROFECOXIB KNOWN_TOXICITY Cardiovascular Toxicity 162011-90-7 ROFECOXIB ZERO_CLASS N 162011-90-7 ROFECOXIB ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_3_Gastric Ulceration 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_3_Ulcer Perforation 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_3_Gastric Erosion 162011-90-7 ROFECOXIB ADVERSE_EFFECT BBM_3_Thrombocytopenia 162011-90-7 ROFECOXIB ADVERSE_EFFECT LIV_3_Hepatitis 162011-90-7 ROFECOXIB ADVERSE_EFFECT IMU_3_Allergic Reactions 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_2_Diarrhea 162011-90-7 ROFECOXIB THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 162011-90-7 ROFECOXIB TISSUE_TOXICITY Renal Papillary Necrosis 162011-90-7 ROFECOXIB TISSUE_TOXICITY Angina Pectoris 162011-90-7 ROFECOXIB TISSUE_TOXICITY Congestive Heart Failure 162011-90-7 ROFECOXIB MECHANISM Inhibit eicosanoid biosynthesis 162011-90-7 ROFECOXIB MESH_LEVEL_1 Organic Chemicals 162011-90-7 ROFECOXIB PRODUCT_CLASS Anti-inflammatories 162011-90-7 ROFECOXIB INDICATION Rheumatoid Arthritis 162011-90-7 ROFECOXIB ADVERSE_EFFECT LIV_3_Hepatic Failure 162011-90-7 ROFECOXIB TA_LEVEL_3 COX2 inhbitor 162011-90-7 ROFECOXIB ACTIVITY_CLASS Anti-inflammatory 162011-90-7 ROFECOXIB KNOWN_TOXICITY Nephrotoxicity 162011-90-7 ROFECOXIB TISSUE_TOXICITY Acute Interstitial Nephritis 162011-90-7 ROFECOXIB ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 162011-90-7 ROFECOXIB ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_2_Abdominal Pain 162011-90-7 ROFECOXIB TA_LEVEL_1 Analgesics 162011-90-7 ROFECOXIB TA_LEVEL_2 NSAID 162011-90-7 ROFECOXIB MESH_LEVEL_2 Lactones 162011-90-7 ROFECOXIB MODE_CLASS Enzyme Inhibitor 162011-90-7 ROFECOXIB INDICATION Dysmenorrhea 162011-90-7 ROFECOXIB ADVERSE_EFFECT CVS_3_Angina Pectoris 162011-90-7 ROFECOXIB ADVERSE_EFFECT BBM_3_Agranulocytosis 162011-90-7 ROFECOXIB ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 162011-90-7 ROFECOXIB ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_3_Pancreatitis 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_2_Dyspepsia 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_3_Gastritis 162011-90-7 ROFECOXIB TISSUE_TOXICITY Acute Renal Failure 162011-90-7 ROFECOXIB KNOWN_TOXICITY Hepatotoxicity 162011-90-7 ROFECOXIB INDICATION Pain 162011-90-7 ROFECOXIB MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 162011-90-7 ROFECOXIB MECH_LEVEL_1 Immunomodulation 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_2_Nausea 162011-90-7 ROFECOXIB ADVERSE_EFFECT SKN_2_Rash 162011-90-7 ROFECOXIB ADVERSE_EFFECT BBM_2_Anemia 162011-90-7 ROFECOXIB ADVERSE_EFFECT BBM_3_Leukopenia 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_2_Epigastric Pain 162011-90-7 ROFECOXIB ADVERSE_EFFECT KID_3_Acute Renal Failure 162011-90-7 ROFECOXIB ADVERSE_EFFECT KID_2_Fluid Retention 162011-90-7 ROFECOXIB ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 162011-90-7 ROFECOXIB TISSUE_TOXICITY Hepatic Failure 162011-90-7 ROFECOXIB STRUCTURE_ACTIVITY NSAID, COX-2/1, coxib like 162011-90-7 ROFECOXIB ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 162011-90-7 ROFECOXIB ADVERSE_EFFECT LUN_3_Bronchospasm 162011-90-7 ROFECOXIB ADVERSE_EFFECT CVS_2_Hypertension 61413-54-5 ROLIPRAM ADVERSE_EFFECT GIS_1_Nausea 61413-54-5 ROLIPRAM ACTIVITY_CLASS Phosphodiesterase inhibitor 61413-54-5 ROLIPRAM ADVERSE_EFFECT PSY_2_Anorexia 61413-54-5 ROLIPRAM ADVERSE_EFFECT NEU_2_Dizziness 61413-54-5 ROLIPRAM ADVERSE_EFFECT GIS_2_Constipation 61413-54-5 ROLIPRAM ADVERSE_EFFECT NEU_3_Akathisia 61413-54-5 ROLIPRAM ADVERSE_EFFECT NEU_3_Impaired Motor Function 61413-54-5 ROLIPRAM ADVERSE_EFFECT GIS_1_Emesis 61413-54-5 ROLIPRAM TISSUE_TOXICITY Acute Hepatocellular Necrosis 61413-54-5 ROLIPRAM STRUCTURE_ACTIVITY PDE4 inhibitor 61413-54-5 ROLIPRAM INDICATION Depression 61413-54-5 ROLIPRAM ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 61413-54-5 ROLIPRAM ADVERSE_EFFECT NEU_1_Headache 61413-54-5 ROLIPRAM ADVERSE_EFFECT GIS_2_Dry Mouth 61413-54-5 ROLIPRAM ADVERSE_EFFECT PSY_1_Insomnia 61413-54-5 ROLIPRAM INDICATION Depressed Mood 61413-54-5 ROLIPRAM TISSUE_TOXICITY Hypotension 61413-54-5 ROLIPRAM ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 61413-54-5 ROLIPRAM ADVERSE_EFFECT CVS_2_Hypotension 61413-54-5 ROLIPRAM ADVERSE_EFFECT XXX_3_Sweating 61413-54-5 ROLIPRAM ADVERSE_EFFECT OCU_2_Blurred Vision 61413-54-5 ROLIPRAM ADVERSE_EFFECT NEU_3_Tremor 61413-54-5 ROLIPRAM ADVERSE_EFFECT PSY_3_Depressed Mood 61413-54-5 ROLIPRAM MECHANISM Enhance kinase mediated signal transduction 61413-54-5 ROLIPRAM THERAPEUTIC_CLASS Antidepressants 61413-54-5 ROLIPRAM KNOWN_TOXICITY Hepatotoxicity 61413-54-5 ROLIPRAM ADVERSE_EFFECT PSY_1_Agitation 61413-54-5 ROLIPRAM ADVERSE_EFFECT NEU_2_Drowsiness 61413-54-5 ROLIPRAM ADVERSE_EFFECT XXX_3_Nasal Congestion 61413-54-5 ROLIPRAM ADVERSE_EFFECT GIS_2_Diarrhea 61413-54-5 ROLIPRAM ADVERSE_EFFECT PSY_1_Excitement 61413-54-5 ROLIPRAM ADVERSE_EFFECT XXX_1_Weight Loss 61413-54-5 ROLIPRAM MODE_CLASS Enzyme Inhibitor 61413-54-5 ROLIPRAM PRODUCT_CLASS Central Nervous System (CNS) 61413-54-5 ROLIPRAM KNOWN_TOXICITY Cardiovascular Toxicity 61413-54-5 ROLIPRAM ADVERSE_EFFECT CVS_3_Hypertension 91374-21-9 ROPINIROLE THERAPEUTIC_CLASS Movement Disorders 91374-21-9 ROPINIROLE INDICATION Parkinson's Disease 91374-21-9 ROPINIROLE PRODUCT_CLASS Central Nervous System (CNS) 91374-21-9 ROPINIROLE MODE_CLASS Receptor Agonist, selective 91374-21-9 ROPINIROLE MECHANISM Prolong/enhance neural transmission 91374-21-9 ROPINIROLE MODE_CLASS Receptor Agonist 84057-95-4 ROPIVACAINE MECHANISM Block neural transmission 84057-95-4 ROPIVACAINE MODE_CLASS Channel Blocker 84057-95-4 ROPIVACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 84057-95-4 ROPIVACAINE PRODUCT_CLASS Central Nervous System (CNS) 84057-95-4 ROPIVACAINE THERAPEUTIC_CLASS Local Anesthetics 98717-15-8 ROPIVACAINE MECHANISM Block neural transmission 98717-15-8 ROPIVACAINE MODE_CLASS Channel Blocker 98717-15-8 ROPIVACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 98717-15-8 ROPIVACAINE PRODUCT_CLASS Central Nervous System (CNS) 98717-15-8 ROPIVACAINE THERAPEUTIC_CLASS Local Anesthetics 155141-29-0 ROSIGLITAZONE ZERO_CLASS N 155141-29-0 ROSIGLITAZONE MECH_LEVEL_3 PPAR gamma 155141-29-0 ROSIGLITAZONE TA_LEVEL_2 insulin sensitizer 155141-29-0 ROSIGLITAZONE MECHANISM Increase transcription of insulin responsive gene 155141-29-0 ROSIGLITAZONE MODE_CLASS Receptor Agonist 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT BBM_2_Anemia 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT XXX_1_Weight Gain 155141-29-0 ROSIGLITAZONE MECH_LEVEL_2 Insulin-like response 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT KID_2_Fluid Retention 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 155141-29-0 ROSIGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 155141-29-0 ROSIGLITAZONE MESH_LEVEL_1 Heterocyclic Compounds 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT END_2_Hypoglycemia 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT REP_2_Induction of Ovulation 155141-29-0 ROSIGLITAZONE TISSUE_TOXICITY Congestive Heart Failure 155141-29-0 ROSIGLITAZONE ACTIVITY_CLASS Anti-diabetic 155141-29-0 ROSIGLITAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 155141-29-0 ROSIGLITAZONE MESH_LEVEL_3 Thiazoles 155141-29-0 ROSIGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT CVS_3_Cardiomegaly 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT MSK_1_Back Pain 155141-29-0 ROSIGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 155141-29-0 ROSIGLITAZONE TA_LEVEL_3 Thiazolidinedione 155141-29-0 ROSIGLITAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT XXX_2_Edema 155141-29-0 ROSIGLITAZONE MECHANISM Increase lipid catabolism 155141-29-0 ROSIGLITAZONE INDICATION Type II Diabetes Mellitus 155141-29-0 ROSIGLITAZONE KNOWN_TOXICITY Cardiovascular Toxicity 155141-29-0 ROSIGLITAZONE ADVERSE_EFFECT NEU_1_Headache 155141-29-0 ROSIGLITAZONE MECH_LEVEL_1 Glycemia regulation 83-79-4 ROTENONE ADVERSE_EFFECT LUN_3_Asphyxia 83-79-4 ROTENONE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 83-79-4 ROTENONE MECHANISM Inhibit mitochondrial function 83-79-4 ROTENONE THERAPEUTIC_CLASS Insecticides / Pesticides 83-79-4 ROTENONE ADVERSE_EFFECT LUN_2_Respiratory Paralysis 83-79-4 ROTENONE ADVERSE_EFFECT GIS_1_Numbness of Oral Mucosa 83-79-4 ROTENONE PRODUCT_CLASS Toxicants 83-79-4 ROTENONE MODE_CLASS Enzyme Inhibitor 83-79-4 ROTENONE KNOWN_TOXICITY Carcinogenicity 83-79-4 ROTENONE ADVERSE_EFFECT MSK_2_Skeletal Muscle Tremor 83-79-4 ROTENONE ADVERSE_EFFECT LIV_2_Fatty Liver 83-79-4 ROTENONE ADVERSE_EFFECT SKN_1_Skin Irritation 83-79-4 ROTENONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83-79-4 ROTENONE ADVERSE_EFFECT LUN_2_Pulmonary Edema 83-79-4 ROTENONE ADVERSE_EFFECT NEU_2_Ataxia 83-79-4 ROTENONE ADVERSE_EFFECT LUN_2_Chemical Pneumonitis 83-79-4 ROTENONE TISSUE_TOXICITY Carcinogenicity 83-79-4 ROTENONE ADVERSE_EFFECT DNA_2_Carcinogenicity 83-79-4 ROTENONE ADVERSE_EFFECT NEU_2_Seizures 12679-58-2 ROTENONE THERAPEUTIC_CLASS Insecticides / Pesticides 12679-58-2 ROTENONE MODE_CLASS Enzyme Inhibitor 12679-58-2 ROTENONE PRODUCT_CLASS Toxicants 12679-58-2 ROTENONE ADVERSE_EFFECT GIS_1_Numbness of Oral Mucosa 12679-58-2 ROTENONE MECHANISM Inhibit mitochondrial function 12679-58-2 ROTENONE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 12679-58-2 ROTENONE ADVERSE_EFFECT LUN_3_Asphyxia 12679-58-2 ROTENONE ADVERSE_EFFECT NEU_2_Seizures 12679-58-2 ROTENONE ADVERSE_EFFECT DNA_2_Carcinogenicity 12679-58-2 ROTENONE TISSUE_TOXICITY Carcinogenicity 12679-58-2 ROTENONE ADVERSE_EFFECT LUN_2_Chemical Pneumonitis 12679-58-2 ROTENONE ADVERSE_EFFECT LIV_2_Fatty Liver 12679-58-2 ROTENONE ADVERSE_EFFECT LUN_2_Pulmonary Edema 12679-58-2 ROTENONE ADVERSE_EFFECT NEU_2_Ataxia 12679-58-2 ROTENONE ADVERSE_EFFECT SKN_1_Skin Irritation 12679-58-2 ROTENONE ADVERSE_EFFECT LUN_2_Respiratory Paralysis 12679-58-2 ROTENONE ADVERSE_EFFECT MSK_2_Skeletal Muscle Tremor 12679-58-2 ROTENONE KNOWN_TOXICITY Carcinogenicity 12679-58-2 ROTENONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 121-19-7 ROXARSONE ADVERSE_EFFECT KID_2_Hematuria 121-19-7 ROXARSONE TISSUE_TOXICITY Renal Tubular Necrosis 121-19-7 ROXARSONE ADVERSE_EFFECT KID_2_Kidney Damage 121-19-7 ROXARSONE ACTIVITY_CLASS Toxicant 121-19-7 ROXARSONE ADVERSE_EFFECT KID_2_Renal Tubular Necrosis 121-19-7 ROXARSONE ZERO_CLASS N 121-19-7 ROXARSONE ADVERSE_EFFECT LUN_2_Pulmonary Hemorrhage 121-19-7 ROXARSONE KNOWN_TOXICITY Carcinogenicity 121-19-7 ROXARSONE KNOWN_TOXICITY Nephrotoxicity 121-19-7 ROXARSONE ADVERSE_EFFECT XXX_2_Weight Gain 121-19-7 ROXARSONE STRUCTURE_ACTIVITY Toxicant, heavy metal 121-19-7 ROXARSONE MESH_LEVEL_3 Arsenicals 121-19-7 ROXARSONE ADVERSE_EFFECT NEU_1_Tremor 121-19-7 ROXARSONE MESH_LEVEL_2 Organometallic Compounds 121-19-7 ROXARSONE PRODUCT_CLASS Veterinarian 121-19-7 ROXARSONE ADVERSE_EFFECT SKN_1_Skin Discoloration 121-19-7 ROXARSONE ADVERSE_EFFECT KID_2_Impaired Renal Tubular Function 121-19-7 ROXARSONE ADVERSE_EFFECT XXX_2_Inflammation 121-19-7 ROXARSONE TISSUE_TOXICITY Carcinogenicity 121-19-7 ROXARSONE TISSUE_TOXICITY Hematuria 121-19-7 ROXARSONE MESH_LEVEL_1 Organic Chemicals 121-19-7 ROXARSONE TA_LEVEL_1 Veterinarian 121-19-7 ROXARSONE TA_LEVEL_3 kidney compounds without group 121-19-7 ROXARSONE ADVERSE_EFFECT KID_2_Abnormal Kidney Function 121-19-7 ROXARSONE ADVERSE_EFFECT NEU_1_Ataxia 121-19-7 ROXARSONE ADVERSE_EFFECT DNA_3_Carcinogenicity 78950-78-4 S(-)-8-HYDROXY-DPAT MODE_CLASS Receptor Agonist, selective 78950-78-4 S(-)-8-HYDROXY-DPAT MECHANISM Modulate neural transmission 78950-78-4 S(-)-8-HYDROXY-DPAT PRODUCT_CLASS Biochemicals 63701-56-4 S(-)-BACLOFEN MECHANISM Modulate neural transmission 63701-56-4 S(-)-BACLOFEN PRODUCT_CLASS Central Nervous System (CNS) 63701-56-4 S(-)-BACLOFEN THERAPEUTIC_CLASS Skeletal Muscle Relaxants 63701-56-4 S(-)-BACLOFEN MODE_CLASS Receptor Agonist, selective 63701-56-4 S(-)-BACLOFEN INDICATION Spasticity 21416-43-3 S(-)-WILLARDIINE MODE_CLASS Channel Modulator 21416-43-3 S(-)-WILLARDIINE MECHANISM Prolong/enhance neural transmission 21416-43-3 S(-)-WILLARDIINE PRODUCT_CLASS Biochemicals 121454-18-0 S-14297 PRODUCT_CLASS Biochemicals 159912-53-5 SABCOMELINE PRODUCT_CLASS Central Nervous System (CNS) 159912-53-5 SABCOMELINE PRODUCT_CLASS Autonomic Nervous System (ANS) 159912-58-0 SABCOMELINE PRODUCT_CLASS Autonomic Nervous System (ANS) 159912-58-0 SABCOMELINE PRODUCT_CLASS Central Nervous System (CNS) 151433-82-8 SABCOMELINE PRODUCT_CLASS Autonomic Nervous System (ANS) 151433-82-8 SABCOMELINE PRODUCT_CLASS Central Nervous System (CNS) 125464-42-8 SACLOFEN MODE_CLASS Receptor Agonist, selective 125464-42-8 SACLOFEN PRODUCT_CLASS Biochemicals 125464-42-8 SACLOFEN MECHANISM Modulate neural transmission 94-59-7 SAFROLE KNOWN_TOXICITY Carcinogenicity 94-59-7 SAFROLE KNOWN_TOXICITY Cardiovascular Toxicity 94-59-7 SAFROLE TA_LEVEL_2 DNA damage 94-59-7 SAFROLE MECHANISM Inhibit DNA synthesis, repair, and function 94-59-7 SAFROLE ADVERSE_EFFECT DNA_3_Mutagenicity 94-59-7 SAFROLE ADVERSE_EFFECT PSY_3_Delirium 94-59-7 SAFROLE ADVERSE_EFFECT NEU_3_Loss of Consciousness 94-59-7 SAFROLE ADVERSE_EFFECT PSY_2_Excitement 94-59-7 SAFROLE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 94-59-7 SAFROLE ZERO_CLASS N 94-59-7 SAFROLE KNOWN_TOXICITY Hepatotoxicity 94-59-7 SAFROLE TISSUE_TOXICITY Hepatotoxicity 94-59-7 SAFROLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 94-59-7 SAFROLE ADVERSE_EFFECT GIS_2_Vomiting 94-59-7 SAFROLE ADVERSE_EFFECT DNA_3_Carcinogenicity 94-59-7 SAFROLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 94-59-7 SAFROLE KNOWN_TOXICITY Mutagenicity 94-59-7 SAFROLE ADVERSE_EFFECT NEU_3_Convulsions 94-59-7 SAFROLE ADVERSE_EFFECT NEU_1_Drowsiness 94-59-7 SAFROLE STRUCTURE_ACTIVITY Toxicant 94-59-7 SAFROLE ADVERSE_EFFECT LUN_3_Cyanosis 94-59-7 SAFROLE TISSUE_TOXICITY Mutagenicity 94-59-7 SAFROLE ACTIVITY_CLASS Toxicant 94-59-7 SAFROLE TA_LEVEL_1 Toxicants 94-59-7 SAFROLE MESH_LEVEL_1 Heterocyclic Compounds 94-59-7 SAFROLE MECH_LEVEL_3 DNA damage 94-59-7 SAFROLE TA_LEVEL_3 Bone Marrow Toxicants 94-59-7 SAFROLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 94-59-7 SAFROLE ADVERSE_EFFECT CVS_3_Tachycardia 94-59-7 SAFROLE ADVERSE_EFFECT CVS_3_Shock 94-59-7 SAFROLE TISSUE_TOXICITY Carcinogenicity 94-59-7 SAFROLE TISSUE_TOXICITY Shock 94-59-7 SAFROLE MESH_LEVEL_3 Dioxoles 94-59-7 SAFROLE PRODUCT_CLASS Toxicants 94-59-7 SAFROLE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 94-58-6 SAFROLE ZERO_CLASS N 94-58-6 SAFROLE KNOWN_TOXICITY Hepatotoxicity 94-58-6 SAFROLE TISSUE_TOXICITY Hepatotoxicity 94-58-6 SAFROLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 94-58-6 SAFROLE ADVERSE_EFFECT GIS_2_Vomiting 94-58-6 SAFROLE TA_LEVEL_2 DNA damage 94-58-6 SAFROLE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 94-58-6 SAFROLE ADVERSE_EFFECT PSY_3_Delirium 94-58-6 SAFROLE ADVERSE_EFFECT NEU_3_Loss of Consciousness 94-58-6 SAFROLE ADVERSE_EFFECT PSY_2_Excitement 94-58-6 SAFROLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 94-58-6 SAFROLE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 94-58-6 SAFROLE ADVERSE_EFFECT DNA_3_Mutagenicity 94-58-6 SAFROLE KNOWN_TOXICITY Mutagenicity 94-58-6 SAFROLE ADVERSE_EFFECT NEU_3_Convulsions 94-58-6 SAFROLE ADVERSE_EFFECT NEU_1_Drowsiness 94-58-6 SAFROLE ADVERSE_EFFECT LUN_3_Cyanosis 94-58-6 SAFROLE TISSUE_TOXICITY Mutagenicity 94-58-6 SAFROLE ACTIVITY_CLASS Toxicant 94-58-6 SAFROLE MESH_LEVEL_3 Dioxoles 94-58-6 SAFROLE TA_LEVEL_1 Toxicants 94-58-6 SAFROLE MESH_LEVEL_1 Heterocyclic Compounds 94-58-6 SAFROLE MECH_LEVEL_3 DNA damage 94-58-6 SAFROLE TA_LEVEL_3 Bone Marrow Toxicants 94-58-6 SAFROLE TISSUE_TOXICITY Shock 94-58-6 SAFROLE TISSUE_TOXICITY Carcinogenicity 94-58-6 SAFROLE ADVERSE_EFFECT CVS_3_Tachycardia 94-58-6 SAFROLE KNOWN_TOXICITY Carcinogenicity 94-58-6 SAFROLE KNOWN_TOXICITY Cardiovascular Toxicity 94-58-6 SAFROLE STRUCTURE_ACTIVITY Toxicant 94-58-6 SAFROLE PRODUCT_CLASS Toxicants 94-58-6 SAFROLE MECHANISM Inhibit DNA synthesis, repair, and function 94-58-6 SAFROLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 94-58-6 SAFROLE ADVERSE_EFFECT DNA_3_Carcinogenicity 94-58-6 SAFROLE ADVERSE_EFFECT CVS_3_Shock 30418-51-0 SAFROLE MECHANISM Inhibit DNA synthesis, repair, and function 30418-51-0 SAFROLE TISSUE_TOXICITY Shock 30418-51-0 SAFROLE KNOWN_TOXICITY Hepatotoxicity 30418-51-0 SAFROLE TISSUE_TOXICITY Hepatotoxicity 30418-51-0 SAFROLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 30418-51-0 SAFROLE ADVERSE_EFFECT GIS_2_Vomiting 30418-51-0 SAFROLE ADVERSE_EFFECT DNA_3_Carcinogenicity 30418-51-0 SAFROLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 30418-51-0 SAFROLE PRODUCT_CLASS Toxicants 30418-51-0 SAFROLE STRUCTURE_ACTIVITY Toxicant 30418-51-0 SAFROLE KNOWN_TOXICITY Cardiovascular Toxicity 30418-51-0 SAFROLE KNOWN_TOXICITY Carcinogenicity 30418-51-0 SAFROLE TISSUE_TOXICITY Carcinogenicity 30418-51-0 SAFROLE ADVERSE_EFFECT CVS_3_Shock 30418-51-0 SAFROLE ADVERSE_EFFECT CVS_3_Tachycardia 30418-51-0 SAFROLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 30418-51-0 SAFROLE TA_LEVEL_3 Bone Marrow Toxicants 30418-51-0 SAFROLE MECH_LEVEL_3 DNA damage 30418-51-0 SAFROLE MESH_LEVEL_1 Heterocyclic Compounds 30418-51-0 SAFROLE TA_LEVEL_1 Toxicants 30418-51-0 SAFROLE MESH_LEVEL_3 Dioxoles 30418-51-0 SAFROLE ACTIVITY_CLASS Toxicant 30418-51-0 SAFROLE TISSUE_TOXICITY Mutagenicity 30418-51-0 SAFROLE ZERO_CLASS N 30418-51-0 SAFROLE TA_LEVEL_2 DNA damage 30418-51-0 SAFROLE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 30418-51-0 SAFROLE ADVERSE_EFFECT DNA_3_Mutagenicity 30418-51-0 SAFROLE ADVERSE_EFFECT LUN_3_Cyanosis 30418-51-0 SAFROLE ADVERSE_EFFECT NEU_1_Drowsiness 30418-51-0 SAFROLE ADVERSE_EFFECT NEU_3_Convulsions 30418-51-0 SAFROLE KNOWN_TOXICITY Mutagenicity 30418-51-0 SAFROLE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 30418-51-0 SAFROLE ADVERSE_EFFECT PSY_2_Excitement 30418-51-0 SAFROLE ADVERSE_EFFECT NEU_3_Loss of Consciousness 30418-51-0 SAFROLE ADVERSE_EFFECT PSY_3_Delirium 30418-50-9 SAFROLE ADVERSE_EFFECT NEU_3_Loss of Consciousness 30418-50-9 SAFROLE ADVERSE_EFFECT PSY_2_Excitement 30418-50-9 SAFROLE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 30418-50-9 SAFROLE KNOWN_TOXICITY Mutagenicity 30418-50-9 SAFROLE ADVERSE_EFFECT NEU_3_Convulsions 30418-50-9 SAFROLE ADVERSE_EFFECT NEU_1_Drowsiness 30418-50-9 SAFROLE ADVERSE_EFFECT LUN_3_Cyanosis 30418-50-9 SAFROLE TISSUE_TOXICITY Mutagenicity 30418-50-9 SAFROLE ACTIVITY_CLASS Toxicant 30418-50-9 SAFROLE MESH_LEVEL_3 Dioxoles 30418-50-9 SAFROLE TA_LEVEL_1 Toxicants 30418-50-9 SAFROLE MESH_LEVEL_1 Heterocyclic Compounds 30418-50-9 SAFROLE MECH_LEVEL_3 DNA damage 30418-50-9 SAFROLE TA_LEVEL_3 Bone Marrow Toxicants 30418-50-9 SAFROLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 30418-50-9 SAFROLE ADVERSE_EFFECT CVS_3_Tachycardia 30418-50-9 SAFROLE ADVERSE_EFFECT CVS_3_Shock 30418-50-9 SAFROLE TISSUE_TOXICITY Carcinogenicity 30418-50-9 SAFROLE TISSUE_TOXICITY Shock 30418-50-9 SAFROLE KNOWN_TOXICITY Carcinogenicity 30418-50-9 SAFROLE KNOWN_TOXICITY Cardiovascular Toxicity 30418-50-9 SAFROLE TISSUE_TOXICITY Hepatotoxicity 30418-50-9 SAFROLE STRUCTURE_ACTIVITY Toxicant 30418-50-9 SAFROLE PRODUCT_CLASS Toxicants 30418-50-9 SAFROLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 30418-50-9 SAFROLE ADVERSE_EFFECT DNA_3_Carcinogenicity 30418-50-9 SAFROLE ADVERSE_EFFECT GIS_2_Vomiting 30418-50-9 SAFROLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 30418-50-9 SAFROLE KNOWN_TOXICITY Hepatotoxicity 30418-50-9 SAFROLE ZERO_CLASS N 30418-50-9 SAFROLE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 30418-50-9 SAFROLE TA_LEVEL_2 DNA damage 30418-50-9 SAFROLE MECHANISM Inhibit DNA synthesis, repair, and function 30418-50-9 SAFROLE ADVERSE_EFFECT DNA_3_Mutagenicity 30418-50-9 SAFROLE ADVERSE_EFFECT PSY_3_Delirium 51022-70-9 SALBUTAMOL ADVERSE_EFFECT SKN_3_Maculopapular Rash 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypertension 51022-70-9 SALBUTAMOL ADVERSE_EFFECT LUN_1_Hoarseness 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Dizziness 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Anxiety 51022-70-9 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 51022-70-9 SALBUTAMOL PRODUCT_CLASS Respiratory System 51022-70-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Throat Irritation 51022-70-9 SALBUTAMOL ADVERSE_EFFECT MSK_1_Skeletal Muscle Tremor 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_2_Peripheral Vasodilation 51022-70-9 SALBUTAMOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Insomnia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypotension 51022-70-9 SALBUTAMOL ADVERSE_EFFECT END_2_Hyperglycemia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT SKN_3_Flushing 51022-70-9 SALBUTAMOL ADVERSE_EFFECT GIS_1_Dyspepsia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT LUN_3_Cough 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Angina 51022-70-9 SALBUTAMOL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 51022-70-9 SALBUTAMOL MECHANISM Reduce bronchoconstriction 51022-70-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Epistaxis 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Irritability 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_3_Nightmares 51022-70-9 SALBUTAMOL INDICATION Asthma 51022-70-9 SALBUTAMOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 51022-70-9 SALBUTAMOL ADVERSE_EFFECT LUN_3_Bronchospasm 51022-70-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Drowsiness 51022-70-9 SALBUTAMOL ADVERSE_EFFECT XXX_2_Diaphoresis 51022-70-9 SALBUTAMOL THERAPEUTIC_CLASS Bronchodilators 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Excitement 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Hostility 51022-70-9 SALBUTAMOL ADVERSE_EFFECT IMU_3_Angioneurotic Edema 51022-70-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Tremor 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_ST-T Wave Changes 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_1_Tachycardia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Hyperkinesia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Headache 51022-70-9 SALBUTAMOL MODE_CLASS Receptor Agonist, selective 51022-70-9 SALBUTAMOL INDICATION Asthma 51022-70-9 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 51022-70-9 SALBUTAMOL TISSUE_TOXICITY Angina 51022-70-9 SALBUTAMOL ADVERSE_EFFECT GUS_1_Urinary Retention 51022-70-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Nervousness 51022-70-9 SALBUTAMOL ADVERSE_EFFECT ELT_2_Hypokalemia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT MSK_2_Muscle Cramps 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_1_Palpitation 51022-70-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT XXX_1_Xerostomia 51022-70-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Syncope 51022-70-9 SALBUTAMOL ADVERSE_EFFECT IMU_1_Urticaria 51022-70-9 SALBUTAMOL KNOWN_TOXICITY Cardiovascular Toxicity 51022-70-9 SALBUTAMOL TISSUE_TOXICITY Hypotension 51022-70-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Restlessness 51022-70-9 SALBUTAMOL TISSUE_TOXICITY Exacerbation of Arrhythmia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT LUN_3_Bronchospasm 35763-26-9 SALBUTAMOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 35763-26-9 SALBUTAMOL INDICATION Asthma 35763-26-9 SALBUTAMOL TISSUE_TOXICITY Hypotension 35763-26-9 SALBUTAMOL ADVERSE_EFFECT XXX_1_Xerostomia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Throat Irritation 35763-26-9 SALBUTAMOL ADVERSE_EFFECT MSK_1_Skeletal Muscle Tremor 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_2_Peripheral Vasodilation 35763-26-9 SALBUTAMOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Insomnia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypotension 35763-26-9 SALBUTAMOL ADVERSE_EFFECT END_2_Hyperglycemia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT SKN_3_Flushing 35763-26-9 SALBUTAMOL ADVERSE_EFFECT GIS_1_Dyspepsia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT LUN_3_Cough 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Angina 35763-26-9 SALBUTAMOL MECHANISM Reduce bronchoconstriction 35763-26-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Epistaxis 35763-26-9 SALBUTAMOL ADVERSE_EFFECT XXX_2_Diaphoresis 35763-26-9 SALBUTAMOL ADVERSE_EFFECT IMU_3_Angioneurotic Edema 35763-26-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Tremor 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_ST-T Wave Changes 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Nervousness 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Irritability 35763-26-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Hyperkinesia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT NEU_1_Headache 35763-26-9 SALBUTAMOL MODE_CLASS Receptor Agonist, selective 35763-26-9 SALBUTAMOL INDICATION Asthma 35763-26-9 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 35763-26-9 SALBUTAMOL TISSUE_TOXICITY Angina 35763-26-9 SALBUTAMOL ADVERSE_EFFECT GUS_1_Urinary Retention 35763-26-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Syncope 35763-26-9 SALBUTAMOL ADVERSE_EFFECT XXX_3_Restlessness 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_3_Nightmares 35763-26-9 SALBUTAMOL ADVERSE_EFFECT SKN_3_Maculopapular Rash 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypertension 35763-26-9 SALBUTAMOL ADVERSE_EFFECT LUN_1_Hoarseness 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Dizziness 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Anxiety 35763-26-9 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 35763-26-9 SALBUTAMOL PRODUCT_CLASS Respiratory System 35763-26-9 SALBUTAMOL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 35763-26-9 SALBUTAMOL TISSUE_TOXICITY Exacerbation of Arrhythmia 35763-26-9 SALBUTAMOL KNOWN_TOXICITY Cardiovascular Toxicity 35763-26-9 SALBUTAMOL ADVERSE_EFFECT IMU_1_Urticaria 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_1_Tachycardia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT CVS_1_Palpitation 35763-26-9 SALBUTAMOL ADVERSE_EFFECT MSK_2_Muscle Cramps 35763-26-9 SALBUTAMOL ADVERSE_EFFECT ELT_2_Hypokalemia 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Hostility 35763-26-9 SALBUTAMOL ADVERSE_EFFECT PSY_1_Excitement 35763-26-9 SALBUTAMOL THERAPEUTIC_CLASS Bronchodilators 35763-26-9 SALBUTAMOL ADVERSE_EFFECT NEU_2_Drowsiness 103639-04-9 ONDANSETRON MECHANISM Block neural transmission 103639-04-9 ONDANSETRON THERAPEUTIC_CLASS Antiemetics 103639-04-9 ONDANSETRON MESH_LEVEL_3 Imidazoles 103639-04-9 ONDANSETRON TA_LEVEL_1 Central Nervous System (CNS) 103639-04-9 ONDANSETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 103639-04-9 ONDANSETRON MESH_LEVEL_1 Heterocyclic Compounds 103639-04-9 ONDANSETRON TISSUE_TOXICITY Cardiac Arrhythmia 103639-04-9 ONDANSETRON MECH_LEVEL_2 5HT antagonist 103639-04-9 ONDANSETRON ACTIVITY_CLASS Serotonin antagonist 103639-04-9 ONDANSETRON ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 103639-04-9 ONDANSETRON ADVERSE_EFFECT SKN_3_Pruritis 103639-04-9 ONDANSETRON ADVERSE_EFFECT ELT_3_Hypokalemia 103639-04-9 ONDANSETRON ADVERSE_EFFECT OCU_3_Blurred Vision 103639-04-9 ONDANSETRON TA_LEVEL_3 Antiemetic 103639-04-9 ONDANSETRON MECH_LEVEL_3 5HT receptor 3 103639-04-9 ONDANSETRON ZERO_CLASS N 103639-04-9 ONDANSETRON ADVERSE_EFFECT OCU_3_Oculogyric Crisis 103639-04-9 ONDANSETRON ADVERSE_EFFECT SKN_3_Flushing 103639-04-9 ONDANSETRON ADVERSE_EFFECT CVS_3_Hypotension 103639-04-9 ONDANSETRON ADVERSE_EFFECT GIS_2_Diarrhea 103639-04-9 ONDANSETRON TISSUE_TOXICITY Angina 103639-04-9 ONDANSETRON PRODUCT_CLASS Gastrointestinal System 103639-04-9 ONDANSETRON TISSUE_TOXICITY Hypotension 103639-04-9 ONDANSETRON KNOWN_TOXICITY Cardiovascular Toxicity 103639-04-9 ONDANSETRON ADVERSE_EFFECT NEU_3_Grand Mal Seizure 103639-04-9 ONDANSETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 103639-04-9 ONDANSETRON ADVERSE_EFFECT NEU_1_Headache 103639-04-9 ONDANSETRON ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 103639-04-9 ONDANSETRON ADVERSE_EFFECT XXX_2_Fever 103639-04-9 ONDANSETRON INDICATION Nausea / Vomiting 103639-04-9 ONDANSETRON MODE_CLASS Channel Blocker, selective 103639-04-9 ONDANSETRON MECH_LEVEL_1 Modulate neural transmission 103639-04-9 ONDANSETRON TA_LEVEL_2 CNS Depressant 103639-04-9 ONDANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 103639-04-9 ONDANSETRON ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 103639-04-9 ONDANSETRON ADVERSE_EFFECT SKN_2_Rash 103639-04-9 ONDANSETRON ADVERSE_EFFECT CVS_3_Angina 103639-04-9 ONDANSETRON ADVERSE_EFFECT GIS_1_Constipation 116002-70-1 ONDANSETRON MECH_LEVEL_3 5HT receptor 3 116002-70-1 ONDANSETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 116002-70-1 ONDANSETRON MESH_LEVEL_1 Heterocyclic Compounds 116002-70-1 ONDANSETRON TA_LEVEL_3 Antiemetic 116002-70-1 ONDANSETRON PRODUCT_CLASS Gastrointestinal System 116002-70-1 ONDANSETRON ADVERSE_EFFECT OCU_3_Oculogyric Crisis 116002-70-1 ONDANSETRON ZERO_CLASS N 116002-70-1 ONDANSETRON TISSUE_TOXICITY Angina 116002-70-1 ONDANSETRON MECHANISM Block neural transmission 116002-70-1 ONDANSETRON TA_LEVEL_1 Central Nervous System (CNS) 116002-70-1 ONDANSETRON ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 116002-70-1 ONDANSETRON ADVERSE_EFFECT SKN_3_Pruritis 116002-70-1 ONDANSETRON ADVERSE_EFFECT ELT_3_Hypokalemia 116002-70-1 ONDANSETRON ADVERSE_EFFECT GIS_2_Diarrhea 116002-70-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Hypotension 116002-70-1 ONDANSETRON MECH_LEVEL_2 5HT antagonist 116002-70-1 ONDANSETRON ADVERSE_EFFECT OCU_3_Blurred Vision 116002-70-1 ONDANSETRON ADVERSE_EFFECT NEU_3_Grand Mal Seizure 116002-70-1 ONDANSETRON ACTIVITY_CLASS Serotonin antagonist 116002-70-1 ONDANSETRON ADVERSE_EFFECT SKN_3_Flushing 116002-70-1 ONDANSETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 116002-70-1 ONDANSETRON ADVERSE_EFFECT NEU_1_Headache 116002-70-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 116002-70-1 ONDANSETRON ADVERSE_EFFECT XXX_2_Fever 116002-70-1 ONDANSETRON INDICATION Nausea / Vomiting 116002-70-1 ONDANSETRON MODE_CLASS Channel Blocker, selective 116002-70-1 ONDANSETRON MECH_LEVEL_1 Modulate neural transmission 116002-70-1 ONDANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 116002-70-1 ONDANSETRON TA_LEVEL_2 CNS Depressant 116002-70-1 ONDANSETRON TISSUE_TOXICITY Hypotension 116002-70-1 ONDANSETRON ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 116002-70-1 ONDANSETRON ADVERSE_EFFECT SKN_2_Rash 116002-70-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Angina 116002-70-1 ONDANSETRON ADVERSE_EFFECT GIS_1_Constipation 116002-70-1 ONDANSETRON TISSUE_TOXICITY Cardiac Arrhythmia 116002-70-1 ONDANSETRON THERAPEUTIC_CLASS Antiemetics 116002-70-1 ONDANSETRON MESH_LEVEL_3 Imidazoles 116002-70-1 ONDANSETRON KNOWN_TOXICITY Cardiovascular Toxicity 99614-01-4 ONDANSETRON ADVERSE_EFFECT OCU_3_Blurred Vision 99614-01-4 ONDANSETRON ADVERSE_EFFECT ELT_3_Hypokalemia 99614-01-4 ONDANSETRON ADVERSE_EFFECT SKN_3_Pruritis 99614-01-4 ONDANSETRON ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 99614-01-4 ONDANSETRON MECHANISM Block neural transmission 99614-01-4 ONDANSETRON ACTIVITY_CLASS Serotonin antagonist 99614-01-4 ONDANSETRON MESH_LEVEL_1 Heterocyclic Compounds 99614-01-4 ONDANSETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 99614-01-4 ONDANSETRON TA_LEVEL_1 Central Nervous System (CNS) 99614-01-4 ONDANSETRON MESH_LEVEL_3 Imidazoles 99614-01-4 ONDANSETRON THERAPEUTIC_CLASS Antiemetics 99614-01-4 ONDANSETRON TISSUE_TOXICITY Cardiac Arrhythmia 99614-01-4 ONDANSETRON ADVERSE_EFFECT GIS_1_Constipation 99614-01-4 ONDANSETRON ADVERSE_EFFECT CVS_3_Angina 99614-01-4 ONDANSETRON ADVERSE_EFFECT SKN_2_Rash 99614-01-4 ONDANSETRON ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 99614-01-4 ONDANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 99614-01-4 ONDANSETRON TA_LEVEL_2 CNS Depressant 99614-01-4 ONDANSETRON MECH_LEVEL_1 Modulate neural transmission 99614-01-4 ONDANSETRON MODE_CLASS Channel Blocker, selective 99614-01-4 ONDANSETRON ADVERSE_EFFECT SKN_3_Flushing 99614-01-4 ONDANSETRON INDICATION Nausea / Vomiting 99614-01-4 ONDANSETRON ADVERSE_EFFECT XXX_2_Fever 99614-01-4 ONDANSETRON ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 99614-01-4 ONDANSETRON PRODUCT_CLASS Gastrointestinal System 99614-01-4 ONDANSETRON ADVERSE_EFFECT NEU_1_Headache 99614-01-4 ONDANSETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 99614-01-4 ONDANSETRON ADVERSE_EFFECT NEU_3_Grand Mal Seizure 99614-01-4 ONDANSETRON KNOWN_TOXICITY Cardiovascular Toxicity 99614-01-4 ONDANSETRON TISSUE_TOXICITY Hypotension 99614-01-4 ONDANSETRON TISSUE_TOXICITY Angina 99614-01-4 ONDANSETRON ADVERSE_EFFECT GIS_2_Diarrhea 99614-01-4 ONDANSETRON ADVERSE_EFFECT CVS_3_Hypotension 99614-01-4 ONDANSETRON ADVERSE_EFFECT OCU_3_Oculogyric Crisis 99614-01-4 ONDANSETRON ZERO_CLASS N 99614-01-4 ONDANSETRON MECH_LEVEL_3 5HT receptor 3 99614-01-4 ONDANSETRON TA_LEVEL_3 Antiemetic 99614-01-4 ONDANSETRON MECH_LEVEL_2 5HT antagonist 110204-46-1 ONDANSETRON ADVERSE_EFFECT SKN_3_Flushing 110204-46-1 ONDANSETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 110204-46-1 ONDANSETRON MESH_LEVEL_1 Heterocyclic Compounds 110204-46-1 ONDANSETRON ADVERSE_EFFECT OCU_3_Oculogyric Crisis 110204-46-1 ONDANSETRON ZERO_CLASS N 110204-46-1 ONDANSETRON MECH_LEVEL_3 5HT receptor 3 110204-46-1 ONDANSETRON INDICATION Nausea / Vomiting 110204-46-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 110204-46-1 ONDANSETRON MECH_LEVEL_1 Modulate neural transmission 110204-46-1 ONDANSETRON TA_LEVEL_2 CNS Depressant 110204-46-1 ONDANSETRON MODE_CLASS Channel Blocker, selective 110204-46-1 ONDANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 110204-46-1 ONDANSETRON ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 110204-46-1 ONDANSETRON ADVERSE_EFFECT SKN_2_Rash 110204-46-1 ONDANSETRON ADVERSE_EFFECT SKN_3_Pruritis 110204-46-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Angina 110204-46-1 ONDANSETRON ADVERSE_EFFECT GIS_1_Constipation 110204-46-1 ONDANSETRON TISSUE_TOXICITY Cardiac Arrhythmia 110204-46-1 ONDANSETRON THERAPEUTIC_CLASS Antiemetics 110204-46-1 ONDANSETRON MESH_LEVEL_3 Imidazoles 110204-46-1 ONDANSETRON TA_LEVEL_1 Central Nervous System (CNS) 110204-46-1 ONDANSETRON ADVERSE_EFFECT ELT_3_Hypokalemia 110204-46-1 ONDANSETRON ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 110204-46-1 ONDANSETRON MECHANISM Block neural transmission 110204-46-1 ONDANSETRON ACTIVITY_CLASS Serotonin antagonist 110204-46-1 ONDANSETRON ADVERSE_EFFECT OCU_3_Blurred Vision 110204-46-1 ONDANSETRON MECH_LEVEL_2 5HT antagonist 110204-46-1 ONDANSETRON TA_LEVEL_3 Antiemetic 110204-46-1 ONDANSETRON ADVERSE_EFFECT XXX_2_Fever 110204-46-1 ONDANSETRON ADVERSE_EFFECT NEU_1_Headache 110204-46-1 ONDANSETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 110204-46-1 ONDANSETRON ADVERSE_EFFECT NEU_3_Grand Mal Seizure 110204-46-1 ONDANSETRON KNOWN_TOXICITY Cardiovascular Toxicity 110204-46-1 ONDANSETRON TISSUE_TOXICITY Hypotension 110204-46-1 ONDANSETRON PRODUCT_CLASS Gastrointestinal System 110204-46-1 ONDANSETRON TISSUE_TOXICITY Angina 110204-46-1 ONDANSETRON ADVERSE_EFFECT GIS_2_Diarrhea 110204-46-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Hypotension 110707-92-1 ONDANSETRON MECHANISM Block neural transmission 110707-92-1 ONDANSETRON ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 110707-92-1 ONDANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 110707-92-1 ONDANSETRON TA_LEVEL_2 CNS Depressant 110707-92-1 ONDANSETRON MECH_LEVEL_1 Modulate neural transmission 110707-92-1 ONDANSETRON MODE_CLASS Channel Blocker, selective 110707-92-1 ONDANSETRON ADVERSE_EFFECT SKN_3_Pruritis 110707-92-1 ONDANSETRON INDICATION Nausea / Vomiting 110707-92-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Angina 110707-92-1 ONDANSETRON ADVERSE_EFFECT XXX_2_Fever 110707-92-1 ONDANSETRON ACTIVITY_CLASS Serotonin antagonist 110707-92-1 ONDANSETRON ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 110707-92-1 ONDANSETRON ZERO_CLASS N 110707-92-1 ONDANSETRON ADVERSE_EFFECT ELT_3_Hypokalemia 110707-92-1 ONDANSETRON ADVERSE_EFFECT OCU_3_Blurred Vision 110707-92-1 ONDANSETRON MECH_LEVEL_2 5HT antagonist 110707-92-1 ONDANSETRON ADVERSE_EFFECT OCU_3_Oculogyric Crisis 110707-92-1 ONDANSETRON TISSUE_TOXICITY Angina 110707-92-1 ONDANSETRON PRODUCT_CLASS Gastrointestinal System 110707-92-1 ONDANSETRON TISSUE_TOXICITY Hypotension 110707-92-1 ONDANSETRON KNOWN_TOXICITY Cardiovascular Toxicity 110707-92-1 ONDANSETRON ADVERSE_EFFECT NEU_1_Headache 110707-92-1 ONDANSETRON ADVERSE_EFFECT NEU_3_Grand Mal Seizure 110707-92-1 ONDANSETRON ADVERSE_EFFECT SKN_3_Flushing 110707-92-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Hypotension 110707-92-1 ONDANSETRON ADVERSE_EFFECT GIS_2_Diarrhea 110707-92-1 ONDANSETRON MESH_LEVEL_1 Heterocyclic Compounds 110707-92-1 ONDANSETRON MECH_LEVEL_3 5HT receptor 3 110707-92-1 ONDANSETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 110707-92-1 ONDANSETRON TA_LEVEL_1 Central Nervous System (CNS) 110707-92-1 ONDANSETRON MESH_LEVEL_3 Imidazoles 110707-92-1 ONDANSETRON ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 110707-92-1 ONDANSETRON THERAPEUTIC_CLASS Antiemetics 110707-92-1 ONDANSETRON TISSUE_TOXICITY Cardiac Arrhythmia 110707-92-1 ONDANSETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 110707-92-1 ONDANSETRON ADVERSE_EFFECT GIS_1_Constipation 110707-92-1 ONDANSETRON ADVERSE_EFFECT SKN_2_Rash 110707-92-1 ONDANSETRON TA_LEVEL_3 Antiemetic 66778-37-8 ORCONAZOLE PRODUCT_CLASS Anti-infectives 66778-37-8 ORCONAZOLE THERAPEUTIC_CLASS Antifungals 66778-37-8 ORCONAZOLE MODE_CLASS Enzyme Inhibitor 66778-37-8 ORCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 96829-58-2 ORLISTAT THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 96829-58-2 ORLISTAT MODE_CLASS Enzyme Inhibitor 96829-58-2 ORLISTAT MECHANISM Decrease food absorption 96829-58-2 ORLISTAT INDICATION Obesity 96829-58-2 ORLISTAT MECHANISM Inhibit inflammatory response 96829-58-2 ORLISTAT PRODUCT_CLASS Gastrointestinal System 83-98-7 ORPHENADRINE ADVERSE_EFFECT NEU_2_Drowsiness 83-98-7 ORPHENADRINE PRODUCT_CLASS Central Nervous System (CNS) 83-98-7 ORPHENADRINE INDICATION Skeletal Muscle Spasm 83-98-7 ORPHENADRINE ADVERSE_EFFECT XXX_1_Xerostomia 83-98-7 ORPHENADRINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 83-98-7 ORPHENADRINE ADVERSE_EFFECT NEU_3_Headache 83-98-7 ORPHENADRINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 83-98-7 ORPHENADRINE ADVERSE_EFFECT GIS_2_Constipation 83-98-7 ORPHENADRINE ADVERSE_EFFECT PSY_2_Agitation 83-98-7 ORPHENADRINE ADVERSE_EFFECT NEU_2_Syncope 83-98-7 ORPHENADRINE ADVERSE_EFFECT GUS_2_Urinary Retention 83-98-7 ORPHENADRINE ADVERSE_EFFECT PSY_3_Hallucinations 83-98-7 ORPHENADRINE ADVERSE_EFFECT XXX_3_Weakness 83-98-7 ORPHENADRINE INDICATION Parkinsonism 83-98-7 ORPHENADRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 83-98-7 ORPHENADRINE ADVERSE_EFFECT GIS_2_Gastric Irritation 83-98-7 ORPHENADRINE ADVERSE_EFFECT CVS_2_Palpitation 83-98-7 ORPHENADRINE ADVERSE_EFFECT OCU_2_Increased Intraocular Pressure 83-98-7 ORPHENADRINE ADVERSE_EFFECT OCU_2_Mydriasis 83-98-7 ORPHENADRINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 83-98-7 ORPHENADRINE MODE_CLASS Solute transporter inhibitor 83-98-7 ORPHENADRINE MECHANISM Prolong/enhance neural transmission 83-98-7 ORPHENADRINE ADVERSE_EFFECT SKN_2_Pruritis 83-98-7 ORPHENADRINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 83-98-7 ORPHENADRINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 83-98-7 ORPHENADRINE ADVERSE_EFFECT OCU_2_Blurred Vision 83-98-7 ORPHENADRINE ADVERSE_EFFECT NEU_2_Tremor 83-98-7 ORPHENADRINE ADVERSE_EFFECT NEU_2_Dizziness 83-98-7 ORPHENADRINE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 83-98-7 ORPHENADRINE ADVERSE_EFFECT IMU_3_Hypersensitivity 83-98-7 ORPHENADRINE ADVERSE_EFFECT IMU_3_Urticaria 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT GUS_2_Diuresis 13721-39-6 SODIUM ORTHOVANADATE TA_LEVEL_1 Toxicant 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT XXX_3_Death 13721-39-6 SODIUM ORTHOVANADATE KNOWN_TOXICITY Miscellaneous 13721-39-6 SODIUM ORTHOVANADATE MECH_LEVEL_2 Enzyme inhibitor 13721-39-6 SODIUM ORTHOVANADATE ACTIVITY_CLASS Mitochondrial toxicant 13721-39-6 SODIUM ORTHOVANADATE TISSUE_TOXICITY Nephrotoxicity 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT KID_2_Increased Creatinine 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT XXX_2_Weight Loss 13721-39-6 SODIUM ORTHOVANADATE PRODUCT_CLASS Toxicants 13721-39-6 SODIUM ORTHOVANADATE MESH_LEVEL_1 Inorganic Chemicals 13721-39-6 SODIUM ORTHOVANADATE MESH_LEVEL_3 Vanadates 13721-39-6 SODIUM ORTHOVANADATE TA_LEVEL_3 Toxicant 13721-39-6 SODIUM ORTHOVANADATE KNOWN_TOXICITY Nephrotoxicity 13721-39-6 SODIUM ORTHOVANADATE TISSUE_TOXICITY Genotoxicity 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT EMB_2_Fetal Toxicity 13721-39-6 SODIUM ORTHOVANADATE MODE_CLASS Enzyme Inhibitor 13721-39-6 SODIUM ORTHOVANADATE MECH_LEVEL_3 Protein-tyrosine-phosphatase 13721-39-6 SODIUM ORTHOVANADATE ZERO_CLASS N 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT XXX_3_Deposits in Tissues 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT KID_2_Nephrotoxicity 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT KID_2_Sodium Diuresis 13721-39-6 SODIUM ORTHOVANADATE KNOWN_TOXICITY Mutagenicity 13721-39-6 SODIUM ORTHOVANADATE TISSUE_TOXICITY Death 13721-39-6 SODIUM ORTHOVANADATE TA_LEVEL_2 Toxicant 13721-39-6 SODIUM ORTHOVANADATE STRUCTURE_ACTIVITY Toxicant, heavy metal, phosphate mimic 13721-39-6 SODIUM ORTHOVANADATE MESH_LEVEL_2 Vanadium Compounds 13721-39-6 SODIUM ORTHOVANADATE MECHANISM Interferes with Cell-Cell signaling 13721-39-6 SODIUM ORTHOVANADATE ADVERSE_EFFECT DNA_2_Genotoxicity 196618-13-0 OSELTAMIVIR MODE_CLASS Enzyme Inhibitor, selective 630-60-4 OUABAIN MESH_LEVEL_2 Carbohydrates 630-60-4 OUABAIN ADVERSE_EFFECT END_3_Gynecomastia 630-60-4 OUABAIN ADVERSE_EFFECT PSY_3_Psychosis 630-60-4 OUABAIN ADVERSE_EFFECT OCU_3_Abnormal Vision 630-60-4 OUABAIN MECH_LEVEL_2 Cardiac ATPase 630-60-4 OUABAIN MODE_CLASS Enzyme Inhibitor 630-60-4 OUABAIN TA_LEVEL_1 Cardiovascular 630-60-4 OUABAIN PRODUCT_CLASS Cardiovasculars 630-60-4 OUABAIN TA_LEVEL_2 Heart failure 630-60-4 OUABAIN ADVERSE_EFFECT GIS_1_Diarrhea 630-60-4 OUABAIN INDICATION Supraventricular Tachycardia 630-60-4 OUABAIN INDICATION Atrial Fibrillation 630-60-4 OUABAIN ADVERSE_EFFECT PSY_3_Delirium 630-60-4 OUABAIN ADVERSE_EFFECT NEU_1_Headache 630-60-4 OUABAIN ADVERSE_EFFECT NEU_2_Chorea 630-60-4 OUABAIN ADVERSE_EFFECT GIS_1_Abdominal Pain 630-60-4 OUABAIN TISSUE_TOXICITY Cardiac Conduction System Malfunction 630-60-4 OUABAIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 630-60-4 OUABAIN MECH_LEVEL_3 Sodium/potassium-exchanging ATPase 630-60-4 OUABAIN THERAPEUTIC_CLASS Antiarrhythmic Agents 630-60-4 OUABAIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 630-60-4 OUABAIN ADVERSE_EFFECT CVS_2_Cardiac Conduction System Malfunction 630-60-4 OUABAIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 630-60-4 OUABAIN ADVERSE_EFFECT OCU_3_Xanthopsia 630-60-4 OUABAIN TISSUE_TOXICITY Cardiac Arrhythmia 630-60-4 OUABAIN THERAPEUTIC_CLASS Congestive Heart Failure 630-60-4 OUABAIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 630-60-4 OUABAIN MECH_LEVEL_1 Increase cardiac contractility 630-60-4 OUABAIN TA_LEVEL_3 Cardiac glycoside 630-60-4 OUABAIN MESH_LEVEL_3 Cardiac glycosides 630-60-4 OUABAIN MECHANISM Increase muscle contraction 630-60-4 OUABAIN INDICATION Acute Left Ventricular Failure 630-60-4 OUABAIN ADVERSE_EFFECT NEU_3_Convulsions 630-60-4 OUABAIN ADVERSE_EFFECT PSY_1_Anorexia 630-60-4 OUABAIN KNOWN_TOXICITY Cardiovascular Toxicity 630-60-4 OUABAIN ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 630-60-4 OUABAIN ADVERSE_EFFECT NEU_2_Dizziness 630-60-4 OUABAIN ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 630-60-4 OUABAIN ADVERSE_EFFECT SKN_2_Skin Rash 630-60-4 OUABAIN INDICATION Atrial Flutter 630-60-4 OUABAIN ACTIVITY_CLASS Na+/K+-ATPase inhibitor 36-06-6 OUABAIN ADVERSE_EFFECT NEU_2_Chorea 36-06-6 OUABAIN ADVERSE_EFFECT NEU_1_Headache 36-06-6 OUABAIN ADVERSE_EFFECT PSY_3_Delirium 36-06-6 OUABAIN INDICATION Atrial Fibrillation 36-06-6 OUABAIN INDICATION Supraventricular Tachycardia 36-06-6 OUABAIN INDICATION Acute Left Ventricular Failure 36-06-6 OUABAIN ADVERSE_EFFECT NEU_3_Convulsions 36-06-6 OUABAIN ADVERSE_EFFECT PSY_1_Anorexia 36-06-6 OUABAIN ADVERSE_EFFECT END_3_Gynecomastia 36-06-6 OUABAIN ADVERSE_EFFECT PSY_3_Psychosis 36-06-6 OUABAIN ADVERSE_EFFECT OCU_3_Abnormal Vision 36-06-6 OUABAIN MECH_LEVEL_2 Cardiac ATPase 36-06-6 OUABAIN ADVERSE_EFFECT GIS_1_Abdominal Pain 36-06-6 OUABAIN MECHANISM Increase muscle contraction 36-06-6 OUABAIN TA_LEVEL_1 Cardiovascular 36-06-6 OUABAIN PRODUCT_CLASS Cardiovasculars 36-06-6 OUABAIN TA_LEVEL_2 Heart failure 36-06-6 OUABAIN MESH_LEVEL_2 Carbohydrates 36-06-6 OUABAIN INDICATION Atrial Flutter 36-06-6 OUABAIN MODE_CLASS Enzyme Inhibitor 36-06-6 OUABAIN THERAPEUTIC_CLASS Antiarrhythmic Agents 36-06-6 OUABAIN KNOWN_TOXICITY Cardiovascular Toxicity 36-06-6 OUABAIN ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 36-06-6 OUABAIN ADVERSE_EFFECT NEU_2_Dizziness 36-06-6 OUABAIN ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 36-06-6 OUABAIN ADVERSE_EFFECT SKN_2_Skin Rash 36-06-6 OUABAIN ACTIVITY_CLASS Na+/K+-ATPase inhibitor 36-06-6 OUABAIN TA_LEVEL_3 Cardiac glycoside 36-06-6 OUABAIN MECH_LEVEL_1 Increase cardiac contractility 36-06-6 OUABAIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 36-06-6 OUABAIN THERAPEUTIC_CLASS Congestive Heart Failure 36-06-6 OUABAIN TISSUE_TOXICITY Cardiac Arrhythmia 36-06-6 OUABAIN ADVERSE_EFFECT OCU_3_Xanthopsia 36-06-6 OUABAIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 36-06-6 OUABAIN ADVERSE_EFFECT CVS_2_Cardiac Conduction System Malfunction 36-06-6 OUABAIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 36-06-6 OUABAIN ADVERSE_EFFECT GIS_1_Diarrhea 36-06-6 OUABAIN MESH_LEVEL_3 Cardiac glycosides 36-06-6 OUABAIN MECH_LEVEL_3 Sodium/potassium-exchanging ATPase 36-06-6 OUABAIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 36-06-6 OUABAIN TISSUE_TOXICITY Cardiac Conduction System Malfunction 508-52-1 OUABAIN MESH_LEVEL_3 Cardiac glycosides 508-52-1 OUABAIN INDICATION Acute Left Ventricular Failure 508-52-1 OUABAIN ADVERSE_EFFECT PSY_1_Anorexia 508-52-1 OUABAIN ADVERSE_EFFECT END_3_Gynecomastia 508-52-1 OUABAIN ADVERSE_EFFECT PSY_3_Psychosis 508-52-1 OUABAIN ADVERSE_EFFECT OCU_3_Abnormal Vision 508-52-1 OUABAIN MECH_LEVEL_2 Cardiac ATPase 508-52-1 OUABAIN INDICATION Atrial Flutter 508-52-1 OUABAIN MODE_CLASS Enzyme Inhibitor 508-52-1 OUABAIN THERAPEUTIC_CLASS Antiarrhythmic Agents 508-52-1 OUABAIN KNOWN_TOXICITY Cardiovascular Toxicity 508-52-1 OUABAIN ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 508-52-1 OUABAIN ADVERSE_EFFECT NEU_2_Dizziness 508-52-1 OUABAIN ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 508-52-1 OUABAIN ADVERSE_EFFECT SKN_2_Skin Rash 508-52-1 OUABAIN ACTIVITY_CLASS Na+/K+-ATPase inhibitor 508-52-1 OUABAIN MECHANISM Increase muscle contraction 508-52-1 OUABAIN TA_LEVEL_1 Cardiovascular 508-52-1 OUABAIN PRODUCT_CLASS Cardiovasculars 508-52-1 OUABAIN TA_LEVEL_2 Heart failure 508-52-1 OUABAIN MESH_LEVEL_2 Carbohydrates 508-52-1 OUABAIN INDICATION Supraventricular Tachycardia 508-52-1 OUABAIN INDICATION Atrial Fibrillation 508-52-1 OUABAIN ADVERSE_EFFECT PSY_3_Delirium 508-52-1 OUABAIN ADVERSE_EFFECT NEU_1_Headache 508-52-1 OUABAIN ADVERSE_EFFECT NEU_2_Chorea 508-52-1 OUABAIN ADVERSE_EFFECT GIS_1_Abdominal Pain 508-52-1 OUABAIN TISSUE_TOXICITY Cardiac Conduction System Malfunction 508-52-1 OUABAIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 508-52-1 OUABAIN MECH_LEVEL_3 Sodium/potassium-exchanging ATPase 508-52-1 OUABAIN ADVERSE_EFFECT GIS_1_Diarrhea 508-52-1 OUABAIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 508-52-1 OUABAIN ADVERSE_EFFECT CVS_2_Cardiac Conduction System Malfunction 508-52-1 OUABAIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 508-52-1 OUABAIN ADVERSE_EFFECT OCU_3_Xanthopsia 508-52-1 OUABAIN TISSUE_TOXICITY Cardiac Arrhythmia 508-52-1 OUABAIN THERAPEUTIC_CLASS Congestive Heart Failure 508-52-1 OUABAIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 508-52-1 OUABAIN MECH_LEVEL_1 Increase cardiac contractility 508-52-1 OUABAIN ADVERSE_EFFECT NEU_3_Convulsions 508-52-1 OUABAIN TA_LEVEL_3 Cardiac glycoside 66-79-5 OXACILLIN TISSUE_TOXICITY Interstitial Nephritis 66-79-5 OXACILLIN TISSUE_TOXICITY Nephrotic Syndrome 66-79-5 OXACILLIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 66-79-5 OXACILLIN KNOWN_TOXICITY Nephrotoxicity 66-79-5 OXACILLIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 66-79-5 OXACILLIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 66-79-5 OXACILLIN ADVERSE_EFFECT IMU_1_Hypersensitivity Reactions 66-79-5 OXACILLIN ADVERSE_EFFECT LIV_3_Hepatitis 66-79-5 OXACILLIN MODE_CLASS Enzyme Inhibitor 66-79-5 OXACILLIN INDICATION Respiratory Tract Infection 66-79-5 OXACILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 66-79-5 OXACILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 66-79-5 OXACILLIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 66-79-5 OXACILLIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 66-79-5 OXACILLIN TISSUE_TOXICITY Hepatotoxicity 66-79-5 OXACILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 66-79-5 OXACILLIN KNOWN_TOXICITY Hepatotoxicity 66-79-5 OXACILLIN INDICATION Skin and Skin Structure Infections 66-79-5 OXACILLIN INDICATION Bacteremia 66-79-5 OXACILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 66-79-5 OXACILLIN ADVERSE_EFFECT GIS_2_Diarrhea 66-79-5 OXACILLIN ADVERSE_EFFECT SKN_2_Bullous Rash 66-79-5 OXACILLIN ADVERSE_EFFECT GIS_1_Abdominal Pain 66-79-5 OXACILLIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 66-79-5 OXACILLIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 66-79-5 OXACILLIN ADVERSE_EFFECT SKN_1_Pruritis 66-79-5 OXACILLIN INDICATION Urinary Tract Infection (UTI) 66-79-5 OXACILLIN PRODUCT_CLASS Anti-infectives 66-79-5 OXACILLIN ADVERSE_EFFECT NEU_3_Seizures 66-79-5 OXACILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 66-79-5 OXACILLIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 66-79-5 OXACILLIN TISSUE_TOXICITY Renal Tubular Necrosis 66-79-5 OXACILLIN ADVERSE_EFFECT BBM_3_Leukopenia 66-79-5 OXACILLIN INDICATION Bone and Joint Infection 66-79-5 OXACILLIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 66-79-5 OXACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 66-79-5 OXACILLIN ADVERSE_EFFECT _3_Erythema Nodosum 66-79-5 OXACILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 21256-18-8 OXAPROZIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 21256-18-8 OXAPROZIN MESH_LEVEL_3 Acids, Carbocyclic 21256-18-8 OXAPROZIN ADVERSE_EFFECT XXX_3_Weight Gain 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_2_Peptic Ulceration 21256-18-8 OXAPROZIN ADVERSE_EFFECT BBM_3_Pancytopenia 21256-18-8 OXAPROZIN ADVERSE_EFFECT BBM_3_Ecchymosis 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_2_Gastritis 21256-18-8 OXAPROZIN ADVERSE_EFFECT XXX_3_Malaise 21256-18-8 OXAPROZIN STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 21256-18-8 OXAPROZIN MESH_LEVEL_1 Organic Chemicals 21256-18-8 OXAPROZIN INDICATION Rheumatoid Arthritis 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_1_Dyspepsia 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_3_Pancreatitis 21256-18-8 OXAPROZIN ADVERSE_EFFECT IMU_2_Photosensitivity 21256-18-8 OXAPROZIN ADVERSE_EFFECT IMU_3_Urticaria 21256-18-8 OXAPROZIN ADVERSE_EFFECT IMU_3_Angioedema 21256-18-8 OXAPROZIN ADVERSE_EFFECT LIV_3_Hepatitis 21256-18-8 OXAPROZIN ADVERSE_EFFECT OTO_2_Tinnitus 21256-18-8 OXAPROZIN ADVERSE_EFFECT PSY_2_Insomnia 21256-18-8 OXAPROZIN ADVERSE_EFFECT OCU_3_Blurred Vision 21256-18-8 OXAPROZIN TISSUE_TOXICITY Nephrotic Syndrome 21256-18-8 OXAPROZIN MESH_LEVEL_2 Carboxylic Acids 21256-18-8 OXAPROZIN ADVERSE_EFFECT XXX_3_Asthenia 21256-18-8 OXAPROZIN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 21256-18-8 OXAPROZIN ADVERSE_EFFECT BBM_3_Inhibits Platelet Aggregation 21256-18-8 OXAPROZIN INDICATION Moderate Pain 21256-18-8 OXAPROZIN MECH_LEVEL_1 Immunomodulation 21256-18-8 OXAPROZIN TA_LEVEL_3 NSAID 21256-18-8 OXAPROZIN MODE_CLASS Enzyme Inhibitor 21256-18-8 OXAPROZIN KNOWN_TOXICITY Nephrotoxicity 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_2_Constipation 21256-18-8 OXAPROZIN ADVERSE_EFFECT PSY_2_Anorexia 21256-18-8 OXAPROZIN ADVERSE_EFFECT XXX_3_Edema 21256-18-8 OXAPROZIN ADVERSE_EFFECT LUN_3_Bronchospasm 21256-18-8 OXAPROZIN ADVERSE_EFFECT SKN_3_Maculopapular Rash 21256-18-8 OXAPROZIN ADVERSE_EFFECT BBM_3_Leukopenia 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_3_Melena 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_2_Abdominal Pain 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_2_Flatulence 21256-18-8 OXAPROZIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 21256-18-8 OXAPROZIN ACTIVITY_CLASS Anti-inflammatory 21256-18-8 OXAPROZIN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 21256-18-8 OXAPROZIN INDICATION Arthralgia 21256-18-8 OXAPROZIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_2_Diarrhea 21256-18-8 OXAPROZIN ADVERSE_EFFECT CVS_3_Hypertension 21256-18-8 OXAPROZIN ADVERSE_EFFECT LUN_3_Asthma 21256-18-8 OXAPROZIN ADVERSE_EFFECT BBM_3_Agranulocytosis 21256-18-8 OXAPROZIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 21256-18-8 OXAPROZIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 21256-18-8 OXAPROZIN ADVERSE_EFFECT LIV_3_Jaundice 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_3_Stomatitis 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_3_Esophagitis 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 21256-18-8 OXAPROZIN ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 21256-18-8 OXAPROZIN ZERO_CLASS N 21256-18-8 OXAPROZIN TA_LEVEL_1 Anti-inflammatory 21256-18-8 OXAPROZIN TA_LEVEL_2 NSAID 21256-18-8 OXAPROZIN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 21256-18-8 OXAPROZIN MECHANISM Inhibit eicosanoid biosynthesis 21256-18-8 OXAPROZIN INDICATION Still's Disease / Juvenile Chronic Arthritis 21256-18-8 OXAPROZIN INDICATION Osteoarthritis 21256-18-8 OXAPROZIN PRODUCT_CLASS Anti-inflammatories 21256-18-8 OXAPROZIN TISSUE_TOXICITY Acute Interstitial Nephritis 21256-18-8 OXAPROZIN INDICATION Myalgia 21256-18-8 OXAPROZIN ADVERSE_EFFECT PSY_2_CNS Depression 21256-18-8 OXAPROZIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 21256-18-8 OXAPROZIN ADVERSE_EFFECT SKN_3_Rash 604-75-1 OXAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 604-75-1 OXAZEPAM THERAPEUTIC_CLASS Anxiolytics 604-75-1 OXAZEPAM MECHANISM Modulate neural transmission 604-75-1 OXAZEPAM INDICATION Anxiety Disorders 604-75-1 OXAZEPAM MODE_CLASS Channel enhancer /opener 604-75-1 OXAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 64211-45-6 OXICONAZOLE ADVERSE_EFFECT SKN_1_Skin Irritation 64211-45-6 OXICONAZOLE ADVERSE_EFFECT XXX_2_Burning Sensation 64211-45-6 OXICONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor 64211-45-6 OXICONAZOLE TA_LEVEL_2 Anti-fungal 64211-45-6 OXICONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 64211-45-6 OXICONAZOLE MODE_CLASS Enzyme Inhibitor 64211-45-6 OXICONAZOLE ADVERSE_EFFECT XXX_3_Stinging Sensation 64211-45-6 OXICONAZOLE ADVERSE_EFFECT SKN_3_Folliculitis 64211-45-6 OXICONAZOLE TA_LEVEL_1 Infectious Disease 64211-45-6 OXICONAZOLE ADVERSE_EFFECT SKN_2_Pruritis 64211-45-6 OXICONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 64211-45-6 OXICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 64211-45-6 OXICONAZOLE ADVERSE_EFFECT SKN_3_Erythema 64211-45-6 OXICONAZOLE MESH_LEVEL_3 Imidazoles 64211-45-6 OXICONAZOLE MECH_LEVEL_1 Anti-fungal 64211-45-6 OXICONAZOLE TA_LEVEL_3 topical infections 64211-45-6 OXICONAZOLE INDICATION Tinea Pedis / Athlete's Foot 64211-45-6 OXICONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 64211-45-6 OXICONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 64211-45-6 OXICONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 64211-45-6 OXICONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase 64211-45-6 OXICONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 64211-45-6 OXICONAZOLE ADVERSE_EFFECT SKN_3_Skin Rash 64211-45-6 OXICONAZOLE ACTIVITY_CLASS Antifungals azole 64211-45-6 OXICONAZOLE MECH_LEVEL_2 Ergesterol synthesis inhibition 64211-45-6 OXICONAZOLE PRODUCT_CLASS Anti-infectives 64211-45-6 OXICONAZOLE INDICATION Tinea Cruris / Jock Itch 64211-46-7 OXICONAZOLE MECH_LEVEL_2 Ergesterol synthesis inhibition 64211-46-7 OXICONAZOLE MODE_CLASS Enzyme Inhibitor 64211-46-7 OXICONAZOLE PRODUCT_CLASS Anti-infectives 64211-46-7 OXICONAZOLE INDICATION Tinea Cruris / Jock Itch 64211-46-7 OXICONAZOLE ADVERSE_EFFECT SKN_1_Skin Irritation 64211-46-7 OXICONAZOLE ADVERSE_EFFECT XXX_2_Burning Sensation 64211-46-7 OXICONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor 64211-46-7 OXICONAZOLE TA_LEVEL_2 Anti-fungal 64211-46-7 OXICONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 64211-46-7 OXICONAZOLE ADVERSE_EFFECT XXX_3_Stinging Sensation 64211-46-7 OXICONAZOLE ADVERSE_EFFECT SKN_3_Folliculitis 64211-46-7 OXICONAZOLE TA_LEVEL_1 Infectious Disease 64211-46-7 OXICONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 64211-46-7 OXICONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase 64211-46-7 OXICONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 64211-46-7 OXICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 64211-46-7 OXICONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 64211-46-7 OXICONAZOLE ADVERSE_EFFECT SKN_2_Pruritis 64211-46-7 OXICONAZOLE ADVERSE_EFFECT SKN_3_Erythema 64211-46-7 OXICONAZOLE MESH_LEVEL_3 Imidazoles 64211-46-7 OXICONAZOLE MECH_LEVEL_1 Anti-fungal 64211-46-7 OXICONAZOLE TA_LEVEL_3 topical infections 64211-46-7 OXICONAZOLE INDICATION Tinea Pedis / Athlete's Foot 64211-46-7 OXICONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 64211-46-7 OXICONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 64211-46-7 OXICONAZOLE ADVERSE_EFFECT SKN_3_Skin Rash 64211-46-7 OXICONAZOLE ACTIVITY_CLASS Antifungals azole 17360-35-9 OXOTREMORINE PRODUCT_CLASS Autonomic Nervous System (ANS) 17360-35-9 OXOTREMORINE THERAPEUTIC_CLASS Parasympathomimetic Agents 17360-35-9 OXOTREMORINE MECHANISM Modulate G-protein coupled signal transduction 17360-35-9 OXOTREMORINE PRODUCT_CLASS Biochemicals 17360-35-9 OXOTREMORINE MODE_CLASS Receptor Agonist, selective 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT GIS_1_Dry Mouth 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT GIS_1_Constipation 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT OCU_2_Mydriasis 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT GIS_1_Nausea 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT PSY_2_Confusion 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT END_2_Suppression of Lactation 1508-65-2 OXYBUTYNIN ZERO_CLASS N 1508-65-2 OXYBUTYNIN THERAPEUTIC_CLASS Antispasmodic Agents 1508-65-2 OXYBUTYNIN ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 1508-65-2 OXYBUTYNIN MECHANISM Modulate G-protein coupled signal transduction 1508-65-2 OXYBUTYNIN INDICATION Detrusor Instability 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT CVS_2_Vasodilation 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT GUS_2_Urinary Retention 1508-65-2 OXYBUTYNIN MODE_CLASS Receptor Ligand Antagonist 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT PSY_2_Insomnia 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT CVS_2_Hypertension 1508-65-2 OXYBUTYNIN MECH_LEVEL_3 Muscarinic acetylcholine receptor M2 1508-65-2 OXYBUTYNIN INDICATION Neurogenic Bladder 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT GUS_2_Urinary Tract Infection 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT NEU_1_Somnolence 1508-65-2 OXYBUTYNIN MESH_LEVEL_1 Organic Chemicals 1508-65-2 OXYBUTYNIN MECH_LEVEL_2 Muscarinic receptor antagonist 1508-65-2 OXYBUTYNIN TA_LEVEL_3 anti-muscarinic 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT OCU_1_Eye Dryness 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT XXX_1_Asthenia 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT REP_2_Impotence 1508-65-2 OXYBUTYNIN MECH_LEVEL_1 Modulate neural transmission 1508-65-2 OXYBUTYNIN TA_LEVEL_1 Autonomic Nervous System (ANS) 1508-65-2 OXYBUTYNIN MESH_LEVEL_2 Carboxylic Acids 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT OCU_1_Blurred Vision 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT NEU_1_Headache 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT OCU_2_Cycloplegia 1508-65-2 OXYBUTYNIN ADVERSE_EFFECT GUS_2_Hesistancy 1508-65-2 OXYBUTYNIN STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 1508-65-2 OXYBUTYNIN MESH_LEVEL_3 Acids, Carbocyclic 1508-65-2 OXYBUTYNIN TA_LEVEL_2 anti-cholinergic 1508-65-2 OXYBUTYNIN PRODUCT_CLASS Autonomic Nervous System (ANS) 5633-20-5 OXYBUTYNIN ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 5633-20-5 OXYBUTYNIN MECHANISM Modulate G-protein coupled signal transduction 5633-20-5 OXYBUTYNIN INDICATION Detrusor Instability 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT CVS_2_Vasodilation 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT OCU_2_Mydriasis 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT GIS_1_Nausea 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT PSY_2_Confusion 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT END_2_Suppression of Lactation 5633-20-5 OXYBUTYNIN TA_LEVEL_1 Autonomic Nervous System (ANS) 5633-20-5 OXYBUTYNIN ZERO_CLASS N 5633-20-5 OXYBUTYNIN TA_LEVEL_2 anti-cholinergic 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT OCU_1_Blurred Vision 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT PSY_2_Insomnia 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT NEU_1_Headache 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT OCU_2_Cycloplegia 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT GUS_2_Hesistancy 5633-20-5 OXYBUTYNIN STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 5633-20-5 OXYBUTYNIN MECH_LEVEL_1 Modulate neural transmission 5633-20-5 OXYBUTYNIN MESH_LEVEL_2 Carboxylic Acids 5633-20-5 OXYBUTYNIN MESH_LEVEL_3 Acids, Carbocyclic 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT CVS_2_Hypertension 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT NEU_1_Somnolence 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT GUS_2_Urinary Tract Infection 5633-20-5 OXYBUTYNIN THERAPEUTIC_CLASS Antispasmodic Agents 5633-20-5 OXYBUTYNIN MECH_LEVEL_2 Muscarinic receptor antagonist 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT GUS_2_Urinary Retention 5633-20-5 OXYBUTYNIN MODE_CLASS Receptor Ligand Antagonist 5633-20-5 OXYBUTYNIN MECH_LEVEL_3 Muscarinic acetylcholine receptor M2 5633-20-5 OXYBUTYNIN INDICATION Neurogenic Bladder 5633-20-5 OXYBUTYNIN MESH_LEVEL_1 Organic Chemicals 5633-20-5 OXYBUTYNIN TA_LEVEL_3 anti-muscarinic 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT OCU_1_Eye Dryness 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT XXX_1_Asthenia 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT REP_2_Impotence 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT GIS_1_Dry Mouth 5633-20-5 OXYBUTYNIN ADVERSE_EFFECT GIS_1_Constipation 5633-20-5 OXYBUTYNIN PRODUCT_CLASS Autonomic Nervous System (ANS) 76-42-6 OXYCODONE MODE_CLASS Receptor Agonist, selective 76-42-6 OXYCODONE THERAPEUTIC_CLASS Analgesics, Opioid 76-42-6 OXYCODONE PRODUCT_CLASS Analgesics 76-42-6 OXYCODONE MECHANISM Modulate neural transmission 76-42-6 OXYCODONE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 124-90-3 OXYCODONE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 124-90-3 OXYCODONE MODE_CLASS Receptor Agonist, selective 124-90-3 OXYCODONE THERAPEUTIC_CLASS Analgesics, Opioid 124-90-3 OXYCODONE PRODUCT_CLASS Analgesics 124-90-3 OXYCODONE MECHANISM Modulate neural transmission 2315-02-8 OXYMETAZOLINE TA_LEVEL_1 Respiratory System 2315-02-8 OXYMETAZOLINE INDICATION Sinusitis 2315-02-8 OXYMETAZOLINE INDICATION Allergic Rhinitis 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Nasal Dryness 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Nasal Congestion 2315-02-8 OXYMETAZOLINE INDICATION Nasal Congestion 2315-02-8 OXYMETAZOLINE TA_LEVEL_3 nasal congestion 2315-02-8 OXYMETAZOLINE INDICATION Viral Conjunctivitis 2315-02-8 OXYMETAZOLINE MESH_LEVEL_3 Imidazoles 2315-02-8 OXYMETAZOLINE MECH_LEVEL_1 Vasoconstriction 2315-02-8 OXYMETAZOLINE MECH_LEVEL_3 adrenoceptor alpha1 2315-02-8 OXYMETAZOLINE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 agonist, oxymetazoline 2315-02-8 OXYMETAZOLINE MESH_LEVEL_1 Heterocyclic Compounds 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Burning Sensation 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT OCU_1_Blurred Vision 2315-02-8 OXYMETAZOLINE INDICATION Allergic Conjunctivitis 2315-02-8 OXYMETAZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 2315-02-8 OXYMETAZOLINE MECHANISM Modulate G-protein coupled signal transduction 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Stinging Sensation 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Sneezing 2315-02-8 OXYMETAZOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 2315-02-8 OXYMETAZOLINE ACTIVITY_CLASS Adrenergic agonist 2315-02-8 OXYMETAZOLINE ZERO_CLASS N 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT OCU_1_Eye Dryness 2315-02-8 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 2315-02-8 OXYMETAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 2315-02-8 OXYMETAZOLINE INDICATION Vasomotor Rhinitis 2315-02-8 OXYMETAZOLINE MODE_CLASS Receptor Agonist 2315-02-8 OXYMETAZOLINE MECH_LEVEL_2 alpha agonist 2315-02-8 OXYMETAZOLINE TA_LEVEL_2 alpha agonist 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Nasal Dryness 1491-59-4 OXYMETAZOLINE ACTIVITY_CLASS Adrenergic agonist 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Stinging Sensation 1491-59-4 OXYMETAZOLINE MECHANISM Modulate G-protein coupled signal transduction 1491-59-4 OXYMETAZOLINE MECH_LEVEL_2 alpha agonist 1491-59-4 OXYMETAZOLINE ZERO_CLASS N 1491-59-4 OXYMETAZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 1491-59-4 OXYMETAZOLINE TA_LEVEL_2 alpha agonist 1491-59-4 OXYMETAZOLINE INDICATION Allergic Conjunctivitis 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT OCU_1_Blurred Vision 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Burning Sensation 1491-59-4 OXYMETAZOLINE MESH_LEVEL_1 Heterocyclic Compounds 1491-59-4 OXYMETAZOLINE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 agonist, oxymetazoline 1491-59-4 OXYMETAZOLINE MECH_LEVEL_3 adrenoceptor alpha1 1491-59-4 OXYMETAZOLINE MESH_LEVEL_3 Imidazoles 1491-59-4 OXYMETAZOLINE INDICATION Viral Conjunctivitis 1491-59-4 OXYMETAZOLINE TA_LEVEL_3 nasal congestion 1491-59-4 OXYMETAZOLINE INDICATION Nasal Congestion 1491-59-4 OXYMETAZOLINE MODE_CLASS Receptor Agonist 1491-59-4 OXYMETAZOLINE INDICATION Vasomotor Rhinitis 1491-59-4 OXYMETAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT OCU_1_Eye Dryness 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Nasal Congestion 1491-59-4 OXYMETAZOLINE INDICATION Allergic Rhinitis 1491-59-4 OXYMETAZOLINE MECH_LEVEL_1 Vasoconstriction 1491-59-4 OXYMETAZOLINE INDICATION Sinusitis 1491-59-4 OXYMETAZOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 1491-59-4 OXYMETAZOLINE TA_LEVEL_1 Respiratory System 1491-59-4 OXYMETAZOLINE ADVERSE_EFFECT XXX_1_Sneezing 357-07-3 OXYMORPHONE INDICATION Moderate Pain 357-07-3 OXYMORPHONE THERAPEUTIC_CLASS Analgesics, Opioid 357-07-3 OXYMORPHONE INDICATION Obstetric Anesthesia 357-07-3 OXYMORPHONE MECHANISM Modulate neural transmission 357-07-3 OXYMORPHONE PRODUCT_CLASS Analgesics 357-07-3 OXYMORPHONE INDICATION Severe Pain 357-07-3 OXYMORPHONE MODE_CLASS Receptor Agonist 357-07-3 OXYMORPHONE STRUCTURE_ACTIVITY Opioid receptor agonist 76-41-5 OXYMORPHONE INDICATION Moderate Pain 76-41-5 OXYMORPHONE THERAPEUTIC_CLASS Analgesics, Opioid 76-41-5 OXYMORPHONE STRUCTURE_ACTIVITY Opioid receptor agonist 76-41-5 OXYMORPHONE MODE_CLASS Receptor Agonist 76-41-5 OXYMORPHONE INDICATION Severe Pain 76-41-5 OXYMORPHONE INDICATION Obstetric Anesthesia 76-41-5 OXYMORPHONE PRODUCT_CLASS Analgesics 76-41-5 OXYMORPHONE MECHANISM Modulate neural transmission 148-24-3 OXYQUINOLINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 148-24-3 OXYQUINOLINE INDICATION Vaginal Acidification 148-24-3 OXYQUINOLINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 148-24-3 OXYQUINOLINE TA_LEVEL_1 Diagnostics and Pharmaceutical Aids 148-24-3 OXYQUINOLINE INDICATION Bone and Joint Infection 148-24-3 OXYQUINOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 148-24-3 OXYQUINOLINE ZERO_CLASS N 148-24-3 OXYQUINOLINE MESH_LEVEL_1 Heterocyclic Compounds 148-24-3 OXYQUINOLINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 148-24-3 OXYQUINOLINE ADVERSE_EFFECT GUS_3_Vaginal Irritation 148-24-3 OXYQUINOLINE PRODUCT_CLASS Other Human Uses 148-24-3 OXYQUINOLINE MECH_LEVEL_2 Unknown mechanism 148-24-3 OXYQUINOLINE MECH_LEVEL_3 Unknown mechanism 148-24-3 OXYQUINOLINE THERAPEUTIC_CLASS Drug Delivery Systems 148-24-3 OXYQUINOLINE THERAPEUTIC_CLASS Acidifying Agents 148-24-3 OXYQUINOLINE MESH_LEVEL_3 Quinolines 79-57-2 OXYTETRACYCLINE INDICATION Plague 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT NEU_2_Dizziness 79-57-2 OXYTETRACYCLINE TA_LEVEL_1 Infectious Disease 79-57-2 OXYTETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 79-57-2 OXYTETRACYCLINE TA_LEVEL_2 Antibacterials 79-57-2 OXYTETRACYCLINE INDICATION Chlamydia Trachomatis Infections 79-57-2 OXYTETRACYCLINE INDICATION Urinary Tract Infection (UTI) 79-57-2 OXYTETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT SKN_3_Erythema 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 79-57-2 OXYTETRACYCLINE THERAPEUTIC_CLASS Antibacterials 79-57-2 OXYTETRACYCLINE INDICATION Brucellosis 79-57-2 OXYTETRACYCLINE INDICATION Leptospirosis 79-57-2 OXYTETRACYCLINE INDICATION Mycoplasma Pneumoniae 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT LIV_3_Fatty Liver 79-57-2 OXYTETRACYCLINE INDICATION Rocky Mountain Spotted Fever 79-57-2 OXYTETRACYCLINE INDICATION Upper Respiratory Tract Infection 79-57-2 OXYTETRACYCLINE PRODUCT_CLASS Anti-infectives 79-57-2 OXYTETRACYCLINE TA_LEVEL_3 systemic infections 79-57-2 OXYTETRACYCLINE MECH_LEVEL_1 Anti-bacterial 79-57-2 OXYTETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT NEU_2_Lightheadedness 79-57-2 OXYTETRACYCLINE TISSUE_TOXICITY Hepatotoxicity 79-57-2 OXYTETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 79-57-2 OXYTETRACYCLINE INDICATION Acne / Acne Vulgaris 79-57-2 OXYTETRACYCLINE INDICATION Gonococcal Infections / Gonorrhea 79-57-2 OXYTETRACYCLINE INDICATION Lyme Disease / Lyme Borreliosis 79-57-2 OXYTETRACYCLINE INDICATION Rickettsial Diseases 79-57-2 OXYTETRACYCLINE INDICATION Listeriosis 79-57-2 OXYTETRACYCLINE INDICATION Traveler's Diarrhea 79-57-2 OXYTETRACYCLINE INDICATION Non-Gonococcal Urethritis 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT IMU_3_Photosensitivity 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT KID_3_Azotemia 79-57-2 OXYTETRACYCLINE KNOWN_TOXICITY Hepatotoxicity 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT PSY_2_Anorexia 79-57-2 OXYTETRACYCLINE ZERO_CLASS N 79-57-2 OXYTETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 79-57-2 OXYTETRACYCLINE INDICATION Syphilis 79-57-2 OXYTETRACYCLINE INDICATION Q Fever 79-57-2 OXYTETRACYCLINE INDICATION Shigellosis 79-57-2 OXYTETRACYCLINE INDICATION Cholera 79-57-2 OXYTETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT GIS_2_Epigastric Pain 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 79-57-2 OXYTETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 79-57-2 OXYTETRACYCLINE INDICATION Lower Respiratory Tract Infection 79-57-2 OXYTETRACYCLINE INDICATION Clostridial Diseases 79-57-2 OXYTETRACYCLINE MESH_LEVEL_3 Naphthalenes 79-57-2 OXYTETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 79-57-2 OXYTETRACYCLINE ADVERSE_EFFECT GIS_2_Diarrhea 50-56-6 OXYTOCIN MECHANISM Modulate G-protein coupled signal transduction 50-56-6 OXYTOCIN MODE_CLASS Receptor Agonist 14110-97-5 P-CHLOROMERCURIPHENYL-SULFONIC ACID STRUCTURE_ACTIVITY Toxicant, transition metal 14110-97-5 P-CHLOROMERCURIPHENYL-SULFONIC ACID PRODUCT_CLASS Toxicants 1132-68-9 4-FLUORO-L-PHENYLALANINE PRODUCT_CLASS Biochemicals 60-17-3 4-FLUORO-L-PHENYLALANINE PRODUCT_CLASS Biochemicals 51-65-0 4-FLUORO-L-PHENYLALANINE PRODUCT_CLASS Biochemicals 544-31-0 PALMITOYLETHANOLAMIDE INDICATION Multiple Sclerosis (MS) 40391-99-9 PAMIDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 40391-99-9 PAMIDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 40391-99-9 PAMIDRONIC ACID MODE_CLASS Enzyme Inhibitor 40391-99-9 PAMIDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 40391-99-9 PAMIDRONIC ACID MECHANISM Inhibit bone re-absorption 57248-88-1 PAMIDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 57248-88-1 PAMIDRONIC ACID MECHANISM Inhibit bone re-absorption 57248-88-1 PAMIDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 57248-88-1 PAMIDRONIC ACID MODE_CLASS Enzyme Inhibitor 57248-88-1 PAMIDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 109552-15-0 PAMIDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 109552-15-0 PAMIDRONIC ACID MECHANISM Inhibit bone re-absorption 109552-15-0 PAMIDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 109552-15-0 PAMIDRONIC ACID MODE_CLASS Enzyme Inhibitor 109552-15-0 PAMIDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 15500-66-0 PANCURONIUM BROMIDE PRODUCT_CLASS Central Nervous System (CNS) 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT SKN_2_Skin Rash 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT XXX_2_Edema 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT CVS_2_Hypertension 15500-66-0 PANCURONIUM BROMIDE MODE_CLASS Channel Blocker, selective 15500-66-0 PANCURONIUM BROMIDE INDICATION Endotracheal Intubation 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT XXX_3_Malignant Hyperthermia 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT LUN_2_Dyspnea 15500-66-0 PANCURONIUM BROMIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 15500-66-0 PANCURONIUM BROMIDE KNOWN_TOXICITY Respiratory Toxicity 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT LUN_1_Respiratory Depression 15500-66-0 PANCURONIUM BROMIDE MECHANISM Block neural transmission 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT LUN_3_Bronchospasm 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT XXX_1_Salivation 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT SKN_1_Flushing 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT NEU_3_Paralysis 15500-66-0 PANCURONIUM BROMIDE TISSUE_TOXICITY Respiratory Depression 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT XXX_3_Weakness 15500-66-0 PANCURONIUM BROMIDE INDICATION Muscle Relaxation 15500-66-0 PANCURONIUM BROMIDE ADVERSE_EFFECT LUN_3_Apnea 15500-66-0 PANCURONIUM BROMIDE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 17307-32-3 PANTHENOL ADVERSE_EFFECT GIS_3_Diarrhea 17307-32-3 PANTHENOL STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 17307-32-3 PANTHENOL INDICATION Dermatitis 17307-32-3 PANTHENOL INDICATION Pruritus / Itching 17307-32-3 PANTHENOL PRODUCT_CLASS Vitamins, Minerals and Nutrients 17307-32-3 PANTHENOL PRODUCT_CLASS Dermatologicals 17307-32-3 PANTHENOL INDICATION Paralytic Ileus 17307-32-3 PANTHENOL THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 17307-32-3 PANTHENOL ADVERSE_EFFECT GIS_3_Colic 17307-32-3 PANTHENOL INDICATION Insect Bites or Stings 17307-32-3 PANTHENOL ADVERSE_EFFECT IMU_3_Urticaria 17307-32-3 PANTHENOL ADVERSE_EFFECT IMU_3_Contact Dermatitis 17307-32-3 PANTHENOL ADVERSE_EFFECT PSY_3_Agitation 17307-32-3 PANTHENOL PRODUCT_CLASS Gastrointestinal System 17307-32-3 PANTHENOL INDICATION Gastroparesis 17307-32-3 PANTHENOL MECHANISM Vitamin/ cofactor 17307-32-3 PANTHENOL ADVERSE_EFFECT IMU_3_Allergic Reactions 17307-32-3 PANTHENOL ADVERSE_EFFECT SKN_3_Pruritis 17307-32-3 PANTHENOL ADVERSE_EFFECT CVS_3_Hypotension 17307-32-3 PANTHENOL KNOWN_TOXICITY Cardiovascular Toxicity 17307-32-3 PANTHENOL TISSUE_TOXICITY Hypotension 17307-32-3 PANTHENOL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 17307-32-3 PANTHENOL THERAPEUTIC_CLASS Prokinetic Agents 79-83-4 PANTOTHENIC ACID MECHANISM Vitamin/ cofactor 61-25-6 PAPAVERINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 61-25-6 PAPAVERINE ADVERSE_EFFECT SKN_3_Pruritis 61-25-6 PAPAVERINE ADVERSE_EFFECT NEU_2_Headache 61-25-6 PAPAVERINE ADVERSE_EFFECT PSY_3_Anorexia 61-25-6 PAPAVERINE ADVERSE_EFFECT GIS_3_Diarrhea 61-25-6 PAPAVERINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 61-25-6 PAPAVERINE TA_LEVEL_1 Cardiovascular 61-25-6 PAPAVERINE INDICATION Erectile Dysfunction 61-25-6 PAPAVERINE TA_LEVEL_2 vasodilator 61-25-6 PAPAVERINE PRODUCT_CLASS Cardiovasculars 61-25-6 PAPAVERINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 61-25-6 PAPAVERINE ADVERSE_EFFECT REP_3_Prolonged Erection 61-25-6 PAPAVERINE ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 61-25-6 PAPAVERINE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 61-25-6 PAPAVERINE ADVERSE_EFFECT NEU_3_Seizures 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 61-25-6 PAPAVERINE ADVERSE_EFFECT GIS_3_Constipation 61-25-6 PAPAVERINE TISSUE_TOXICITY Ventricular Tachycardia 61-25-6 PAPAVERINE THERAPEUTIC_CLASS Vasodilators 61-25-6 PAPAVERINE INDICATION Acute Myocardial Infarction 61-25-6 PAPAVERINE MECH_LEVEL_2 Modulate G-protein coupled signal transduction 61-25-6 PAPAVERINE MECH_LEVEL_3 3',5'-cyclic-nucleotide phosphodiesterase 61-25-6 PAPAVERINE MESH_LEVEL_2 Alkaloids 61-25-6 PAPAVERINE MESH_LEVEL_1 Heterocyclic Compounds 61-25-6 PAPAVERINE TA_LEVEL_3 thromboembolism 61-25-6 PAPAVERINE MECH_LEVEL_1 signal transduction 61-25-6 PAPAVERINE KNOWN_TOXICITY Hepatotoxicity 61-25-6 PAPAVERINE ADVERSE_EFFECT XXX_3_Malaise 61-25-6 PAPAVERINE ADVERSE_EFFECT SKN_2_Flushing 61-25-6 PAPAVERINE MESH_LEVEL_3 Opium 61-25-6 PAPAVERINE INDICATION Arterial Thromboembolism 61-25-6 PAPAVERINE MODE_CLASS Enzyme Inhibitor 61-25-6 PAPAVERINE MECHANISM Reduce muscle contractile force 61-25-6 PAPAVERINE ZERO_CLASS N 61-25-6 PAPAVERINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 61-25-6 PAPAVERINE ADVERSE_EFFECT XXX_2_Diaphoresis 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 61-25-6 PAPAVERINE ADVERSE_EFFECT LIV_3_Liver Cirrhosis 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 61-25-6 PAPAVERINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_3_Hypertension 61-25-6 PAPAVERINE TISSUE_TOXICITY Liver Cirrhosis 61-25-6 PAPAVERINE INDICATION Angina Pectoris 61-25-6 PAPAVERINE MECHANISM Enhance kinase mediated signal transduction 61-25-6 PAPAVERINE ADVERSE_EFFECT GIS_3_Abdominal Distress 61-25-6 PAPAVERINE ADVERSE_EFFECT REP_3_Priapism 61-25-6 PAPAVERINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 61-25-6 PAPAVERINE ADVERSE_EFFECT NEU_3_Drowsiness 61-25-6 PAPAVERINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 61-25-6 PAPAVERINE KNOWN_TOXICITY Cardiovascular Toxicity 61-25-6 PAPAVERINE TISSUE_TOXICITY Hepatotoxicity 61-25-6 PAPAVERINE ADVERSE_EFFECT NEU_3_Vertigo 61-25-6 PAPAVERINE TISSUE_TOXICITY Ventricular Arrhythmia 61-25-6 PAPAVERINE INDICATION Subarachnoid Hemorrhage 123-63-7 PARALDEHYDE PRODUCT_CLASS Central Nervous System (CNS) 123-63-7 PARALDEHYDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 123-63-7 PARALDEHYDE INDICATION Status Epilepticus 123-63-7 PARALDEHYDE THERAPEUTIC_CLASS Sedatives/Hypnotics 123-63-7 PARALDEHYDE INDICATION Alcoholic Withdrawal 123-63-7 PARALDEHYDE THERAPEUTIC_CLASS Anxiolytics 123-63-7 PARALDEHYDE INDICATION Insomnia 61400-59-7 PARCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 61400-59-7 PARCONAZOLE PRODUCT_CLASS Anti-infectives 61400-59-7 PARCONAZOLE THERAPEUTIC_CLASS Antifungals 61400-59-7 PARCONAZOLE MODE_CLASS Enzyme Inhibitor 131918-61-1 PARICALCITOL MODE_CLASS Receptor Agonist 131918-61-1 PARICALCITOL MECHANISM Modulate gene transcription 131918-61-1 PARICALCITOL THERAPEUTIC_CLASS Bone Mineral Homeostasis 131918-61-1 PARICALCITOL INDICATION Secondary Hyperparathyroidism 131918-61-1 PARICALCITOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 131918-61-1 PARICALCITOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 7542-37-2 PAROMOMYCIN TISSUE_TOXICITY Renal Tubular Necrosis 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT GIS_1_Epigastric Pain 7542-37-2 PAROMOMYCIN INDICATION Visceral Leishmaniasis / Kala Azar 7542-37-2 PAROMOMYCIN TISSUE_TOXICITY Renal Failure 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT NEU_2_Vertigo 7542-37-2 PAROMOMYCIN MECHANISM Inhibit ribosomal protein synthesis 7542-37-2 PAROMOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT GIS_2_Diarrhea 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT MSK_3_Myasthenia 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT KID_3_Proteinuria 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT KID_3_Renal Failure 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT KID_3_Anuria 7542-37-2 PAROMOMYCIN INDICATION Hepatic Encephalopathy 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT IMU_3_Contact Dermatitis 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Acidosis 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT GIS_3_Pancreatitis 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT _3_Cylinduria 7542-37-2 PAROMOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 7542-37-2 PAROMOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 7542-37-2 PAROMOMYCIN INDICATION Multi-drug Resistant Tuberculosis (MDR-TB) 7542-37-2 PAROMOMYCIN INDICATION Intestinal Amebiasis 7542-37-2 PAROMOMYCIN PRODUCT_CLASS Anti-infectives 7542-37-2 PAROMOMYCIN KNOWN_TOXICITY Nephrotoxicity 7542-37-2 PAROMOMYCIN TISSUE_TOXICITY Anuria 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT NEU_2_Headache 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT XXX_3_Superinfection 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT OTO_3_Hearing Loss 7542-37-2 PAROMOMYCIN ADVERSE_EFFECT SKN_3_Skin Rash 7542-37-2 PAROMOMYCIN THERAPEUTIC_CLASS Antiparasitics 61869-08-7 PAROXETINE ZERO_CLASS N 61869-08-7 PAROXETINE ADVERSE_EFFECT NEU_1_Paresthesia 61869-08-7 PAROXETINE PRODUCT_CLASS Central Nervous System (CNS) 61869-08-7 PAROXETINE INDICATION Generalized Anxiety Disorder 61869-08-7 PAROXETINE INDICATION Panic Disorder 61869-08-7 PAROXETINE INDICATION Premature Ejaculation 61869-08-7 PAROXETINE ADVERSE_EFFECT GIS_1_Diarrhea 61869-08-7 PAROXETINE ADVERSE_EFFECT OCU_2_Blurred Vision 61869-08-7 PAROXETINE ADVERSE_EFFECT PSY_1_Anxiety 61869-08-7 PAROXETINE ADVERSE_EFFECT REP_1_Impotence 61869-08-7 PAROXETINE ADVERSE_EFFECT IMU_3_Allergic Reactions 61869-08-7 PAROXETINE ADVERSE_EFFECT REP_1_Decreased Libido 61869-08-7 PAROXETINE ADVERSE_EFFECT GIS_1_Flatulence 61869-08-7 PAROXETINE MODE_CLASS Solute transporter inhibitor 61869-08-7 PAROXETINE ADVERSE_EFFECT GUS_2_Male Genital Disorders 61869-08-7 PAROXETINE TISSUE_TOXICITY Carcinogenicity 61869-08-7 PAROXETINE MECH_LEVEL_3 5HT Transporter SERT 61869-08-7 PAROXETINE TA_LEVEL_3 SERTs 61869-08-7 PAROXETINE INDICATION Obsessive-Compulsive Disorder (OCD) 61869-08-7 PAROXETINE INDICATION Social Anxiety Disorder 61869-08-7 PAROXETINE MECH_LEVEL_2 5HT antagonist 61869-08-7 PAROXETINE ADVERSE_EFFECT DNA_3_Carcinogenicity 61869-08-7 PAROXETINE ADVERSE_EFFECT GIS_1_Constipation 61869-08-7 PAROXETINE ADVERSE_EFFECT PSY_1_Insomnia 61869-08-7 PAROXETINE ADVERSE_EFFECT GIS_1_Vomiting 61869-08-7 PAROXETINE ADVERSE_EFFECT XXX_1_Decreased Appetite 61869-08-7 PAROXETINE MESH_LEVEL_1 Heterocyclic Compounds 61869-08-7 PAROXETINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 61869-08-7 PAROXETINE INDICATION Posttraumatic Stress Disorder (PTSD) 61869-08-7 PAROXETINE TA_LEVEL_1 Central Nervous System (CNS) 61869-08-7 PAROXETINE MECHANISM Prolong/enhance neural transmission 61869-08-7 PAROXETINE ADVERSE_EFFECT MSK_2_Myopathy 61869-08-7 PAROXETINE MESH_LEVEL_3 Piperidines 61869-08-7 PAROXETINE ADVERSE_EFFECT GUS_1_Urinary Retention 61869-08-7 PAROXETINE ADVERSE_EFFECT PSY_1_Nervousness 61869-08-7 PAROXETINE ADVERSE_EFFECT GIS_1_Nausea 61869-08-7 PAROXETINE ADVERSE_EFFECT NEU_1_Dizziness 61869-08-7 PAROXETINE ADVERSE_EFFECT PSY_1_Agitation 61869-08-7 PAROXETINE ADVERSE_EFFECT MSK_2_Myalgia 61869-08-7 PAROXETINE ADVERSE_EFFECT XXX_2_Taste Disturbances 61869-08-7 PAROXETINE ADVERSE_EFFECT REP_1_Ejaculatory Disorder 61869-08-7 PAROXETINE KNOWN_TOXICITY Reproductive System Toxicity 61869-08-7 PAROXETINE TA_LEVEL_2 CNS Depressant 61869-08-7 PAROXETINE MECH_LEVEL_1 Modulate neural transmission 61869-08-7 PAROXETINE ADVERSE_EFFECT NEU_3_Extrapyramidal Toxicity 61869-08-7 PAROXETINE INDICATION Diabetic Neuropathy 61869-08-7 PAROXETINE ADVERSE_EFFECT CVS_1_Palpitation 61869-08-7 PAROXETINE ADVERSE_EFFECT XXX_1_Asthenia 61869-08-7 PAROXETINE ADVERSE_EFFECT GUS_1_Urinary Frequency 61869-08-7 PAROXETINE TISSUE_TOXICITY Impotence 61869-08-7 PAROXETINE KNOWN_TOXICITY Carcinogenicity 61869-08-7 PAROXETINE INDICATION Chronic Non-Tension Headache 61869-08-7 PAROXETINE INDICATION Major Depression / Major Depressive Disorder 61869-08-7 PAROXETINE THERAPEUTIC_CLASS Antidepressants 61869-08-7 PAROXETINE ADVERSE_EFFECT XXX_1_Sweating 61869-08-7 PAROXETINE ADVERSE_EFFECT GIS_1_Dry Mouth 61869-08-7 PAROXETINE ADVERSE_EFFECT NEU_1_Tremor 61869-08-7 PAROXETINE ADVERSE_EFFECT NEU_1_Headache 61869-08-7 PAROXETINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 61869-08-7 PAROXETINE ADVERSE_EFFECT NEU_1_Somnolence 61869-08-7 PAROXETINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 61869-08-7 PAROXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 61869-08-7 PAROXETINE ADVERSE_EFFECT GUS_2_Female Genital Disorders 20554-84-1 PARTHENOLIDE INDICATION Migraine Headache 20554-84-1 PARTHENOLIDE ADVERSE_EFFECT BBM_3_Bleeding Tendency 20554-84-1 PARTHENOLIDE MECHANISM Inhibit inflammatory response 20554-84-1 PARTHENOLIDE STRUCTURE_ACTIVITY Unknown mechanism, inflammation mediator/ blocker 20554-84-1 PARTHENOLIDE PRODUCT_CLASS Botanicals 20554-84-1 PARTHENOLIDE THERAPEUTIC_CLASS Antimigraines 20554-84-1 PARTHENOLIDE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 20554-84-1 PARTHENOLIDE INDICATION Arthritis 20554-84-1 PARTHENOLIDE ADVERSE_EFFECT GIS_3_Gastrointestinal Distress 121055-10-5 SDZ-PCO-400 MODE_CLASS Channel Modulator 121055-10-5 SDZ-PCO-400 THERAPEUTIC_CLASS Bronchodilators 121055-10-5 SDZ-PCO-400 PRODUCT_CLASS Respiratory System 121055-10-5 SDZ-PCO-400 MECHANISM Modulate channel gating 121021-52-1 SDZ-PCO-400 THERAPEUTIC_CLASS Bronchodilators 121021-52-1 SDZ-PCO-400 PRODUCT_CLASS Respiratory System 121021-52-1 SDZ-PCO-400 MODE_CLASS Channel Modulator 121021-52-1 SDZ-PCO-400 MECHANISM Modulate channel gating 167869-21-8 PD-98059 PRODUCT_CLASS Biochemicals 167869-21-8 PD-98059 MECHANISM Inhibit kinase mediated signal transduction 167869-21-8 PD-98059 MODE_CLASS Enzyme Inhibitor 114785-14-7 PD-123319 PRODUCT_CLASS Biochemicals 114785-14-7 PD-123319 MECHANISM Modulate G-protein coupled signal transduction 114785-14-7 PD-123319 MODE_CLASS Receptor Ligand Antagonist 114785-90-9 PD-123319 PRODUCT_CLASS Biochemicals 114785-90-9 PD-123319 MECHANISM Modulate G-protein coupled signal transduction 114785-90-9 PD-123319 MODE_CLASS Receptor Ligand Antagonist 2933-45-1 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 2933-45-1 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 2933-45-1 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 2933-45-1 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 2933-45-1 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 2933-45-1 PEMOLINE MECHANISM Prolong/enhance neural transmission 2933-45-1 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 2933-45-1 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 2933-45-1 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 2933-45-1 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 2933-45-1 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 2933-45-1 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 2933-45-1 PEMOLINE MESH_LEVEL_3 Oxazoles 2933-45-1 PEMOLINE TA_LEVEL_3 attention deficit syndrome 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 2933-45-1 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 2933-45-1 PEMOLINE MODE_CLASS Solute transporter inhibitor 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 2933-45-1 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 2933-45-1 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 2933-45-1 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 2933-45-1 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 2933-45-1 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 2933-45-1 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 2933-45-1 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 2933-45-1 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 2933-45-1 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 2933-45-1 PEMOLINE ZERO_CLASS N 2933-45-1 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 2933-45-1 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 2933-45-1 PEMOLINE MECH_LEVEL_3 Unknown mechanism 2933-45-1 PEMOLINE TISSUE_TOXICITY Hepatic Failure 2933-45-1 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 2933-45-1 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 101053-01-4 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 101053-01-4 PEMOLINE ZERO_CLASS N 101053-01-4 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 101053-01-4 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 101053-01-4 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 101053-01-4 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 101053-01-4 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 101053-01-4 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 101053-01-4 PEMOLINE MECHANISM Prolong/enhance neural transmission 101053-01-4 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 101053-01-4 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 101053-01-4 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 101053-01-4 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 101053-01-4 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 101053-01-4 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 101053-01-4 PEMOLINE MESH_LEVEL_3 Oxazoles 101053-01-4 PEMOLINE TA_LEVEL_3 attention deficit syndrome 101053-01-4 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 101053-01-4 PEMOLINE MODE_CLASS Solute transporter inhibitor 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 101053-01-4 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 101053-01-4 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 101053-01-4 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 101053-01-4 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 101053-01-4 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 101053-01-4 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 101053-01-4 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 101053-01-4 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 101053-01-4 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 101053-01-4 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 101053-01-4 PEMOLINE MECH_LEVEL_3 Unknown mechanism 101053-01-4 PEMOLINE TISSUE_TOXICITY Hepatic Failure 101053-01-4 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 5841-63-4 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 5841-63-4 PEMOLINE ZERO_CLASS N 5841-63-4 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 5841-63-4 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 5841-63-4 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 5841-63-4 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 5841-63-4 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 5841-63-4 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 5841-63-4 PEMOLINE MECHANISM Prolong/enhance neural transmission 5841-63-4 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 5841-63-4 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 5841-63-4 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 5841-63-4 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 5841-63-4 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 5841-63-4 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 5841-63-4 PEMOLINE MESH_LEVEL_3 Oxazoles 5841-63-4 PEMOLINE TA_LEVEL_3 attention deficit syndrome 5841-63-4 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 5841-63-4 PEMOLINE MODE_CLASS Solute transporter inhibitor 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 5841-63-4 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 5841-63-4 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 5841-63-4 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 5841-63-4 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 5841-63-4 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 5841-63-4 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 5841-63-4 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 5841-63-4 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 5841-63-4 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 5841-63-4 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 5841-63-4 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 5841-63-4 PEMOLINE MECH_LEVEL_3 Unknown mechanism 5841-63-4 PEMOLINE TISSUE_TOXICITY Hepatic Failure 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 8065-45-0 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 8065-45-0 PEMOLINE ZERO_CLASS N 8065-45-0 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 8065-45-0 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 8065-45-0 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 8065-45-0 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 8065-45-0 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 8065-45-0 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 8065-45-0 PEMOLINE MECHANISM Prolong/enhance neural transmission 8065-45-0 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 8065-45-0 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 8065-45-0 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 8065-45-0 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 8065-45-0 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 8065-45-0 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 8065-45-0 PEMOLINE MESH_LEVEL_3 Oxazoles 8065-45-0 PEMOLINE TA_LEVEL_3 attention deficit syndrome 8065-45-0 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 8065-45-0 PEMOLINE MODE_CLASS Solute transporter inhibitor 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 8065-45-0 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 8065-45-0 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 8065-45-0 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 8065-45-0 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 8065-45-0 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 8065-45-0 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 8065-45-0 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 8065-45-0 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 8065-45-0 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 8065-45-0 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 8065-45-0 PEMOLINE MECH_LEVEL_3 Unknown mechanism 8065-45-0 PEMOLINE TISSUE_TOXICITY Hepatic Failure 8065-45-0 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 10083-56-4 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 10083-56-4 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 10083-56-4 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 10083-56-4 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 10083-56-4 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 10083-56-4 PEMOLINE TISSUE_TOXICITY Hepatic Failure 10083-56-4 PEMOLINE ZERO_CLASS N 10083-56-4 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 10083-56-4 PEMOLINE MECH_LEVEL_3 Unknown mechanism 10083-56-4 PEMOLINE MESH_LEVEL_3 Oxazoles 10083-56-4 PEMOLINE TA_LEVEL_3 attention deficit syndrome 10083-56-4 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 10083-56-4 PEMOLINE MODE_CLASS Solute transporter inhibitor 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 10083-56-4 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 10083-56-4 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 10083-56-4 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 10083-56-4 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 10083-56-4 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 10083-56-4 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 10083-56-4 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 10083-56-4 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 10083-56-4 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 10083-56-4 PEMOLINE MECHANISM Prolong/enhance neural transmission 10083-56-4 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 10083-56-4 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 10083-56-4 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 10083-56-4 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 10083-56-4 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 10083-56-4 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 10083-56-4 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 10083-56-4 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 10083-56-4 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 12374-71-9 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 12374-71-9 PEMOLINE MESH_LEVEL_3 Oxazoles 12374-71-9 PEMOLINE TA_LEVEL_3 attention deficit syndrome 12374-71-9 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 12374-71-9 PEMOLINE MODE_CLASS Solute transporter inhibitor 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 12374-71-9 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 12374-71-9 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 12374-71-9 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 12374-71-9 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 12374-71-9 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 12374-71-9 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 12374-71-9 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 12374-71-9 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 12374-71-9 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 12374-71-9 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 12374-71-9 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 12374-71-9 PEMOLINE ZERO_CLASS N 12374-71-9 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 12374-71-9 PEMOLINE TISSUE_TOXICITY Hepatic Failure 12374-71-9 PEMOLINE MECH_LEVEL_3 Unknown mechanism 12374-71-9 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 12374-71-9 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 12374-71-9 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 12374-71-9 PEMOLINE MECHANISM Prolong/enhance neural transmission 12374-71-9 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 12374-71-9 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 12374-71-9 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 12374-71-9 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 12374-71-9 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 12374-71-9 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 12374-71-9 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 12374-71-9 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 39331-48-1 PEMOLINE ADVERSE_EFFECT XXX_2_Weight Loss 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_3_Hallucinations 39331-48-1 PEMOLINE ADVERSE_EFFECT XXX_3_Tolerance 39331-48-1 PEMOLINE MECH_LEVEL_1 Modulate neural transmission 39331-48-1 PEMOLINE TA_LEVEL_1 Central Nervous System (CNS) 39331-48-1 PEMOLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 39331-48-1 PEMOLINE ZERO_CLASS N 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_3_Physical Dependence 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_2_Mental Depression 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Failure 39331-48-1 PEMOLINE TISSUE_TOXICITY Hepatic Failure 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_2_Cholestasis 39331-48-1 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 39331-48-1 PEMOLINE TISSUE_TOXICITY Hepatotoxicity 39331-48-1 PEMOLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 39331-48-1 PEMOLINE KNOWN_TOXICITY Hepatotoxicity 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_2_Drowsiness 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_2_Dizziness 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_2_Headache 39331-48-1 PEMOLINE MECH_LEVEL_3 Unknown mechanism 39331-48-1 PEMOLINE ADVERSE_EFFECT XXX_2_Decreased Appetite 39331-48-1 PEMOLINE ADVERSE_EFFECT OCU_3_Visual Impairment 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 39331-48-1 PEMOLINE ADVERSE_EFFECT OCU_3_Mydriasis 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_1_Jaundice 39331-48-1 PEMOLINE ADVERSE_EFFECT CVS_3_Hypertension 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatic Dysfunction 39331-48-1 PEMOLINE MODE_CLASS Solute transporter inhibitor 39331-48-1 PEMOLINE PRODUCT_CLASS Central Nervous System (CNS) 39331-48-1 PEMOLINE TA_LEVEL_3 attention deficit syndrome 39331-48-1 PEMOLINE MESH_LEVEL_3 Oxazoles 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_3_Seizures 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_3_Nystagmus 39331-48-1 PEMOLINE ADVERSE_EFFECT XXX_2_Malaise 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_2_Irritability 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_3_Dystonia 39331-48-1 PEMOLINE THERAPEUTIC_CLASS Central Stimulants 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_3_Dyskinesia 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_3_Dependence 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_3_Agitation 39331-48-1 PEMOLINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 39331-48-1 PEMOLINE MESH_LEVEL_1 Heterocyclic Compounds 39331-48-1 PEMOLINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 39331-48-1 PEMOLINE MECHANISM Prolong/enhance neural transmission 39331-48-1 PEMOLINE ADVERSE_EFFECT GIS_2_Diarrhea 39331-48-1 PEMOLINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 39331-48-1 PEMOLINE ADVERSE_EFFECT NEU_3_Tics 39331-48-1 PEMOLINE ADVERSE_EFFECT CVS_3_Palpitation 39331-48-1 PEMOLINE ADVERSE_EFFECT PSY_1_Insomnia 39331-48-1 PEMOLINE ADVERSE_EFFECT LIV_1_Hepatitis 38363-32-5 PENBUTOLOL MECHANISM Reduce muscle contractile force 38363-32-5 PENBUTOLOL PRODUCT_CLASS Cardiovasculars 38363-32-5 PENBUTOLOL MODE_CLASS Receptor Ligand Antagonist 38363-32-5 PENBUTOLOL THERAPEUTIC_CLASS Antihypertensive Agents 38363-32-5 PENBUTOLOL INDICATION Hypertension 176199-48-7 LY-354740 INDICATION Anxiety Disorders 176199-48-7 LY-354740 PRODUCT_CLASS Central Nervous System (CNS) 176199-48-7 LY-354740 MODE_CLASS Receptor Agonist 176199-48-7 LY-354740 MECHANISM Modulate G-protein coupled signal transduction 176199-48-7 LY-354740 THERAPEUTIC_CLASS Sedatives/Hypnotics 176027-90-0 LY-354740 THERAPEUTIC_CLASS Sedatives/Hypnotics 176027-90-0 LY-354740 MECHANISM Modulate G-protein coupled signal transduction 176027-90-0 LY-354740 MODE_CLASS Receptor Agonist 176027-90-0 LY-354740 PRODUCT_CLASS Central Nervous System (CNS) 176027-90-0 LY-354740 INDICATION Anxiety Disorders 176199-49-8 LY-354740 MODE_CLASS Receptor Agonist 176199-49-8 LY-354740 INDICATION Anxiety Disorders 176199-49-8 LY-354740 PRODUCT_CLASS Central Nervous System (CNS) 176199-49-8 LY-354740 THERAPEUTIC_CLASS Sedatives/Hypnotics 176199-49-8 LY-354740 MECHANISM Modulate G-protein coupled signal transduction 7487-88-9 MAGNESIUM SULFATE MODE_CLASS Channel Modulator 7487-88-9 MAGNESIUM SULFATE MECHANISM Modulate channel gating 75088-80-1 MANOALIDE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 75088-80-1 MANOALIDE MECHANISM Inhibit precursor synthesis 75088-80-1 MANOALIDE PRODUCT_CLASS Anti-inflammatories 75088-80-1 MANOALIDE MODE_CLASS Enzyme Inhibitor 75088-80-1 MANOALIDE MECHANISM Inhibit inflammatory response 10347-81-6 MAPROTILINE ADVERSE_EFFECT PSY_1_Anxiety 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_2_Hypertension 10347-81-6 MAPROTILINE ADVERSE_EFFECT GUS_2_Urinary Retention 10347-81-6 MAPROTILINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 10347-81-6 MAPROTILINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 10347-81-6 MAPROTILINE INDICATION Depression 10347-81-6 MAPROTILINE MECHANISM Prolong/enhance neural transmission 10347-81-6 MAPROTILINE PRODUCT_CLASS Central Nervous System (CNS) 10347-81-6 MAPROTILINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 10347-81-6 MAPROTILINE MESH_LEVEL_3 Anthracenes 10347-81-6 MAPROTILINE TA_LEVEL_1 Central Nervous System (CNS) 10347-81-6 MAPROTILINE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 10347-81-6 MAPROTILINE ADVERSE_EFFECT OCU_3_Acute Angle-Closure Glaucoma 10347-81-6 MAPROTILINE ADVERSE_EFFECT OCU_1_Mydriasis 10347-81-6 MAPROTILINE ADVERSE_EFFECT PSY_1_Anorexia 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_1_Ventricular Tachycardia 10347-81-6 MAPROTILINE ADVERSE_EFFECT NEU_2_Seizures 10347-81-6 MAPROTILINE TISSUE_TOXICITY Ventricular Tachycardia 10347-81-6 MAPROTILINE KNOWN_TOXICITY Cardiovascular Toxicity 10347-81-6 MAPROTILINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 10347-81-6 MAPROTILINE ADVERSE_EFFECT PSY_1_Confusion 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_1_ECG Changes 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_2_Palpitation 10347-81-6 MAPROTILINE ADVERSE_EFFECT XXX_1_Xerostomia 10347-81-6 MAPROTILINE TA_LEVEL_3 Depression 10347-81-6 MAPROTILINE MESH_LEVEL_1 Polycyclic Hydrocarbons 10347-81-6 MAPROTILINE MECH_LEVEL_3 Norepinephrine Transporter NET 10347-81-6 MAPROTILINE TISSUE_TOXICITY Myocardial Infarction 10347-81-6 MAPROTILINE ADVERSE_EFFECT XXX_3_Fever 10347-81-6 MAPROTILINE ADVERSE_EFFECT OCU_2_Blurred Vision 10347-81-6 MAPROTILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 10347-81-6 MAPROTILINE ADVERSE_EFFECT SKN_3_Pruritis 10347-81-6 MAPROTILINE MODE_CLASS Solute transporter inhibitor 10347-81-6 MAPROTILINE ADVERSE_EFFECT REP_3_Decreased Libido 10347-81-6 MAPROTILINE ADVERSE_EFFECT LIV_3_Jaundice 10347-81-6 MAPROTILINE ADVERSE_EFFECT OCU_2_Cycloplegia 10347-81-6 MAPROTILINE ADVERSE_EFFECT NEU_3_Pseudo-Parkinsonism 10347-81-6 MAPROTILINE MECH_LEVEL_2 channel blocker 10347-81-6 MAPROTILINE ZERO_CLASS N 10347-81-6 MAPROTILINE TA_LEVEL_2 Anti-depressant 10347-81-6 MAPROTILINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 10347-81-6 MAPROTILINE MECH_LEVEL_1 Modulate neural transmission 10347-81-6 MAPROTILINE TISSUE_TOXICITY Congestive Heart Failure 10347-81-6 MAPROTILINE ADVERSE_EFFECT GIS_2_Diarrhea 10347-81-6 MAPROTILINE ADVERSE_EFFECT XXX_3_Breast Enlargement 10347-81-6 MAPROTILINE ADVERSE_EFFECT GIS_2_Constipation 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 10347-81-6 MAPROTILINE ADVERSE_EFFECT NEU_2_Tremor 10347-81-6 MAPROTILINE ADVERSE_EFFECT NEU_2_Dizziness 10347-81-6 MAPROTILINE ADVERSE_EFFECT END_3_Gynecomastia 10347-81-6 MAPROTILINE ADVERSE_EFFECT SKN_2_Erythema 10347-81-6 MAPROTILINE ADVERSE_EFFECT IMU_2_Photosensitivity 10347-81-6 MAPROTILINE ADVERSE_EFFECT END_3_Galactorrhea 10347-81-6 MAPROTILINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_1_Prolonged PR Interval 10347-81-6 MAPROTILINE THERAPEUTIC_CLASS Antidepressants 10347-81-6 MAPROTILINE ADVERSE_EFFECT GIS_1_Abdominal Pain 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_3_Vasculitis 10347-81-6 MAPROTILINE ADVERSE_EFFECT IMU_3_Urticaria 10347-81-6 MAPROTILINE ADVERSE_EFFECT NEU_1_Drowsiness 10347-81-6 MAPROTILINE ADVERSE_EFFECT REP_3_Impotence 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 10347-81-6 MAPROTILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 10262-69-8 MAPROTILINE ADVERSE_EFFECT PSY_1_Anxiety 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_2_Hypertension 10262-69-8 MAPROTILINE ADVERSE_EFFECT GUS_2_Urinary Retention 10262-69-8 MAPROTILINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 10262-69-8 MAPROTILINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 10262-69-8 MAPROTILINE INDICATION Depression 10262-69-8 MAPROTILINE MECHANISM Prolong/enhance neural transmission 10262-69-8 MAPROTILINE ADVERSE_EFFECT IMU_3_Urticaria 10262-69-8 MAPROTILINE THERAPEUTIC_CLASS Antidepressants 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_1_Prolonged PR Interval 10262-69-8 MAPROTILINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 10262-69-8 MAPROTILINE ADVERSE_EFFECT END_3_Galactorrhea 10262-69-8 MAPROTILINE ADVERSE_EFFECT IMU_2_Photosensitivity 10262-69-8 MAPROTILINE ADVERSE_EFFECT SKN_2_Erythema 10262-69-8 MAPROTILINE ADVERSE_EFFECT END_3_Gynecomastia 10262-69-8 MAPROTILINE ADVERSE_EFFECT NEU_2_Dizziness 10262-69-8 MAPROTILINE ADVERSE_EFFECT NEU_2_Tremor 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 10262-69-8 MAPROTILINE ADVERSE_EFFECT GIS_2_Constipation 10262-69-8 MAPROTILINE ADVERSE_EFFECT GIS_2_Diarrhea 10262-69-8 MAPROTILINE TISSUE_TOXICITY Congestive Heart Failure 10262-69-8 MAPROTILINE MECH_LEVEL_1 Modulate neural transmission 10262-69-8 MAPROTILINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 10262-69-8 MAPROTILINE TA_LEVEL_2 Anti-depressant 10262-69-8 MAPROTILINE ZERO_CLASS N 10262-69-8 MAPROTILINE MECH_LEVEL_2 channel blocker 10262-69-8 MAPROTILINE ADVERSE_EFFECT NEU_3_Pseudo-Parkinsonism 10262-69-8 MAPROTILINE ADVERSE_EFFECT OCU_2_Cycloplegia 10262-69-8 MAPROTILINE ADVERSE_EFFECT LIV_3_Jaundice 10262-69-8 MAPROTILINE ADVERSE_EFFECT REP_3_Decreased Libido 10262-69-8 MAPROTILINE MODE_CLASS Solute transporter inhibitor 10262-69-8 MAPROTILINE ADVERSE_EFFECT SKN_3_Pruritis 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 10262-69-8 MAPROTILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 10262-69-8 MAPROTILINE ADVERSE_EFFECT OCU_2_Blurred Vision 10262-69-8 MAPROTILINE ADVERSE_EFFECT XXX_3_Fever 10262-69-8 MAPROTILINE TISSUE_TOXICITY Myocardial Infarction 10262-69-8 MAPROTILINE MECH_LEVEL_3 Norepinephrine Transporter NET 10262-69-8 MAPROTILINE MESH_LEVEL_1 Polycyclic Hydrocarbons 10262-69-8 MAPROTILINE TA_LEVEL_3 Depression 10262-69-8 MAPROTILINE ADVERSE_EFFECT XXX_3_Breast Enlargement 10262-69-8 MAPROTILINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 10262-69-8 MAPROTILINE ADVERSE_EFFECT XXX_1_Xerostomia 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_2_Palpitation 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_1_ECG Changes 10262-69-8 MAPROTILINE ADVERSE_EFFECT PSY_1_Confusion 10262-69-8 MAPROTILINE KNOWN_TOXICITY Cardiovascular Toxicity 10262-69-8 MAPROTILINE TISSUE_TOXICITY Ventricular Tachycardia 10262-69-8 MAPROTILINE ADVERSE_EFFECT NEU_2_Seizures 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_1_Ventricular Tachycardia 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 10262-69-8 MAPROTILINE ADVERSE_EFFECT PSY_1_Anorexia 10262-69-8 MAPROTILINE ADVERSE_EFFECT OCU_1_Mydriasis 10262-69-8 MAPROTILINE ADVERSE_EFFECT OCU_3_Acute Angle-Closure Glaucoma 10262-69-8 MAPROTILINE TA_LEVEL_1 Central Nervous System (CNS) 10262-69-8 MAPROTILINE MESH_LEVEL_3 Anthracenes 10262-69-8 MAPROTILINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 10262-69-8 MAPROTILINE PRODUCT_CLASS Central Nervous System (CNS) 10262-69-8 MAPROTILINE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 10262-69-8 MAPROTILINE ADVERSE_EFFECT GIS_1_Abdominal Pain 10262-69-8 MAPROTILINE ADVERSE_EFFECT CVS_3_Vasculitis 10262-69-8 MAPROTILINE ADVERSE_EFFECT NEU_1_Drowsiness 10262-69-8 MAPROTILINE ADVERSE_EFFECT REP_3_Impotence 27686-84-6 MASOPROCOL MODE_CLASS Enzyme Inhibitor, selective 27686-84-6 MASOPROCOL MODE_CLASS Enzyme Inhibitor 27686-84-6 MASOPROCOL MECHANISM Inhibit kinase mediated signal transduction 27686-84-6 MASOPROCOL MECHANISM Inhibit eicosanoid biosynthesis 27686-84-6 MASOPROCOL INDICATION Actinic Keratosis 27686-84-6 MASOPROCOL PRODUCT_CLASS Dermatologicals 27686-84-6 MASOPROCOL THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 22232-71-9 MAZINDOL ADVERSE_EFFECT OCU_2_Ocular Irritation 22232-71-9 MAZINDOL ADVERSE_EFFECT OCU_2_Mydriasis 22232-71-9 MAZINDOL MECHANISM Prolong/enhance neural transmission 22232-71-9 MAZINDOL ADVERSE_EFFECT PSY_3_Dysphoria 22232-71-9 MAZINDOL ADVERSE_EFFECT NEU_2_CNS Overstimulation 22232-71-9 MAZINDOL ADVERSE_EFFECT PSY_3_Euphoria 22232-71-9 MAZINDOL ADVERSE_EFFECT XXX_2_Restlessness 22232-71-9 MAZINDOL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 22232-71-9 MAZINDOL THERAPEUTIC_CLASS Anorexiants 22232-71-9 MAZINDOL ADVERSE_EFFECT OCU_3_Blurred Vision 22232-71-9 MAZINDOL ADVERSE_EFFECT PSY_2_Insomnia 22232-71-9 MAZINDOL ADVERSE_EFFECT NEU_3_Dizziness 22232-71-9 MAZINDOL ADVERSE_EFFECT XXX_2_Weight Loss 22232-71-9 MAZINDOL STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 22232-71-9 MAZINDOL ADVERSE_EFFECT GIS_3_Diarrhea 22232-71-9 MAZINDOL ADVERSE_EFFECT PSY_1_Anorexia 22232-71-9 MAZINDOL ADVERSE_EFFECT REP_2_Impotence 22232-71-9 MAZINDOL ADVERSE_EFFECT REP_3_Testicular Pain 22232-71-9 MAZINDOL ADVERSE_EFFECT CVS_3_Hypertension 22232-71-9 MAZINDOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 22232-71-9 MAZINDOL ADVERSE_EFFECT NEU_3_Dyskinesia 22232-71-9 MAZINDOL ADVERSE_EFFECT XXX_1_Xerostomia 22232-71-9 MAZINDOL MODE_CLASS Solute transporter inhibitor 22232-71-9 MAZINDOL PRODUCT_CLASS Central Nervous System (CNS) 22232-71-9 MAZINDOL INDICATION Obesity 31431-39-7 MEBENDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 31431-39-7 MEBENDAZOLE INDICATION Enterobiasis / Pinworm Infections 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT GIS_2_Diarrhea 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT BBM_3_Neutropenia 31431-39-7 MEBENDAZOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 31431-39-7 MEBENDAZOLE INDICATION Hookworm Disease 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT EMB_3_Teratogenicity 31431-39-7 MEBENDAZOLE PRODUCT_CLASS Anti-infectives 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 31431-39-7 MEBENDAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 31431-39-7 MEBENDAZOLE INDICATION Ascariasis 31431-39-7 MEBENDAZOLE TA_LEVEL_2 anthelmintic 31431-39-7 MEBENDAZOLE MESH_LEVEL_3 Benzimidazoles 31431-39-7 MEBENDAZOLE TISSUE_TOXICITY Teratogenicity 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT EMB_3_Embryotoxicity 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT IMU_3_Angioedema 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT NEU_3_Convulsions 31431-39-7 MEBENDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 31431-39-7 MEBENDAZOLE INDICATION Helminthic Infections 31431-39-7 MEBENDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 31431-39-7 MEBENDAZOLE INDICATION Trichuriasis / Trichocephaliasis / Whipworm 31431-39-7 MEBENDAZOLE THERAPEUTIC_CLASS Antiparasitics 31431-39-7 MEBENDAZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 31431-39-7 MEBENDAZOLE TA_LEVEL_1 Infectious Disease 31431-39-7 MEBENDAZOLE MECH_LEVEL_3 Microtubule / tubulin 31431-39-7 MEBENDAZOLE MECH_LEVEL_1 anthelmintic 31431-39-7 MEBENDAZOLE TA_LEVEL_3 antiparasitic imidazoles 31431-39-7 MEBENDAZOLE MECH_LEVEL_2 Inhibit microtubule dependent glucose uptake 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 31431-39-7 MEBENDAZOLE ADVERSE_EFFECT IMU_3_Urticaria 31431-39-7 MEBENDAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 31431-39-7 MEBENDAZOLE ZERO_CLASS N 826-39-1 MECAMYLAMINE MECHANISM Modulate neural transmission 826-39-1 MECAMYLAMINE MODE_CLASS Channel Blocker 826-39-1 MECAMYLAMINE INDICATION Hypertension 826-39-1 MECAMYLAMINE THERAPEUTIC_CLASS Antihypertensive Agents 826-39-1 MECAMYLAMINE PRODUCT_CLASS Cardiovasculars 60-40-2 MECAMYLAMINE MODE_CLASS Channel Blocker 60-40-2 MECAMYLAMINE MECHANISM Modulate neural transmission 60-40-2 MECAMYLAMINE PRODUCT_CLASS Cardiovasculars 60-40-2 MECAMYLAMINE INDICATION Hypertension 60-40-2 MECAMYLAMINE THERAPEUTIC_CLASS Antihypertensive Agents 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 55-86-7 MECHLORETHAMINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 55-86-7 MECHLORETHAMINE TISSUE_TOXICITY Mutagenicity 55-86-7 MECHLORETHAMINE KNOWN_TOXICITY Carcinogenicity 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT SKN_2_Maculopapular Rash 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT KID_3_Uric Acid Nephropathy 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT EMB_2_Teratogenicity 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT GIS_1_Nausea 55-86-7 MECHLORETHAMINE INDICATION Chronic Lymphocytic Leukemia (CLL) 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT IMU_3_Anaphylaxis 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT XXX_1_Infection 55-86-7 MECHLORETHAMINE TISSUE_TOXICITY Teratogenicity 55-86-7 MECHLORETHAMINE KNOWN_TOXICITY Mutagenicity 55-86-7 MECHLORETHAMINE INDICATION Malignant Effusions 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT PSY_2_Anorexia 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT OTO_3_Tinnitus 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT IMU_2_Immunologic Toxicity 55-86-7 MECHLORETHAMINE INDICATION Bronchogenic Carcinoma 55-86-7 MECHLORETHAMINE PRODUCT_CLASS Anti-cancers 55-86-7 MECHLORETHAMINE INDICATION Hodgkin's Disease 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT NEU_3_Vertigo 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT LIV_3_Jaundice 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT BBM_1_Myelosuppression 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT DNA_2_Carcinogenicity 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT KID_2_Hyperuricemia 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT BBM_1_Leukopenia 55-86-7 MECHLORETHAMINE MODE_CLASS Distorts /blocks macromolecular scaffold function 55-86-7 MECHLORETHAMINE TISSUE_TOXICITY Carcinogenicity 55-86-7 MECHLORETHAMINE KNOWN_TOXICITY Nephrotoxicity 55-86-7 MECHLORETHAMINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 55-86-7 MECHLORETHAMINE INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 55-86-7 MECHLORETHAMINE INDICATION Polycythemia Vera / Erythrocytosis 55-86-7 MECHLORETHAMINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT OTO_3_Hearing Loss 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT CVS_1_Thrombophlebitis 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 55-86-7 MECHLORETHAMINE TISSUE_TOXICITY Leukopenia 55-86-7 MECHLORETHAMINE TISSUE_TOXICITY Uric Acid Nephropathy 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT DNA_2_Mutagenicity 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT GIS_1_Vomiting 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 55-86-7 MECHLORETHAMINE TISSUE_TOXICITY Myelosuppression 55-86-7 MECHLORETHAMINE KNOWN_TOXICITY Embryo/Fetal Toxicity 55-86-7 MECHLORETHAMINE MECHANISM Inhibit DNA synthesis, repair, and function 55-86-7 MECHLORETHAMINE INDICATION Non-Hodgkin's Lymphomas 55-86-7 MECHLORETHAMINE THERAPEUTIC_CLASS Antineoplastics 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 55-86-7 MECHLORETHAMINE ADVERSE_EFFECT BBM_2_Pancytopenia 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 51-75-2 MECHLORETHAMINE KNOWN_TOXICITY Embryo/Fetal Toxicity 51-75-2 MECHLORETHAMINE TISSUE_TOXICITY Myelosuppression 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT GIS_1_Vomiting 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT DNA_2_Mutagenicity 51-75-2 MECHLORETHAMINE TISSUE_TOXICITY Uric Acid Nephropathy 51-75-2 MECHLORETHAMINE TISSUE_TOXICITY Leukopenia 51-75-2 MECHLORETHAMINE THERAPEUTIC_CLASS Antineoplastics 51-75-2 MECHLORETHAMINE INDICATION Non-Hodgkin's Lymphomas 51-75-2 MECHLORETHAMINE INDICATION Chronic Lymphocytic Leukemia (CLL) 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT CVS_1_Thrombophlebitis 51-75-2 MECHLORETHAMINE MECHANISM Inhibit DNA synthesis, repair, and function 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT OTO_3_Hearing Loss 51-75-2 MECHLORETHAMINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 51-75-2 MECHLORETHAMINE INDICATION Polycythemia Vera / Erythrocytosis 51-75-2 MECHLORETHAMINE INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 51-75-2 MECHLORETHAMINE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 51-75-2 MECHLORETHAMINE KNOWN_TOXICITY Nephrotoxicity 51-75-2 MECHLORETHAMINE TISSUE_TOXICITY Carcinogenicity 51-75-2 MECHLORETHAMINE MODE_CLASS Distorts /blocks macromolecular scaffold function 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT BBM_1_Leukopenia 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT KID_2_Hyperuricemia 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT DNA_2_Carcinogenicity 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT LIV_3_Jaundice 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT NEU_3_Vertigo 51-75-2 MECHLORETHAMINE INDICATION Hodgkin's Disease 51-75-2 MECHLORETHAMINE PRODUCT_CLASS Anti-cancers 51-75-2 MECHLORETHAMINE INDICATION Bronchogenic Carcinoma 51-75-2 MECHLORETHAMINE KNOWN_TOXICITY Carcinogenicity 51-75-2 MECHLORETHAMINE TISSUE_TOXICITY Mutagenicity 51-75-2 MECHLORETHAMINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT REP_2_Suppressed Spermatogenesis 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT BBM_1_Myelosuppression 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT IMU_2_Immunologic Toxicity 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT SKN_2_Maculopapular Rash 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT OTO_3_Tinnitus 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT PSY_2_Anorexia 51-75-2 MECHLORETHAMINE INDICATION Malignant Effusions 51-75-2 MECHLORETHAMINE KNOWN_TOXICITY Mutagenicity 51-75-2 MECHLORETHAMINE TISSUE_TOXICITY Teratogenicity 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT XXX_1_Infection 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT IMU_3_Anaphylaxis 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT GIS_1_Nausea 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT EMB_2_Teratogenicity 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT KID_3_Uric Acid Nephropathy 51-75-2 MECHLORETHAMINE ADVERSE_EFFECT BBM_2_Pancytopenia 569-65-3 MECLIZINE INDICATION Nausea / Vomiting 569-65-3 MECLIZINE MODE_CLASS Receptor Ligand Antagonist 569-65-3 MECLIZINE MECHANISM Modulate G-protein coupled signal transduction 569-65-3 MECLIZINE ADVERSE_EFFECT XXX_1_Fatigue 569-65-3 MECLIZINE ADVERSE_EFFECT GUS_3_Urinary Retention 569-65-3 MECLIZINE INDICATION Vertigo 569-65-3 MECLIZINE ADVERSE_EFFECT OTO_3_Tinnitus 569-65-3 MECLIZINE ADVERSE_EFFECT CVS_3_Hypotension 569-65-3 MECLIZINE INDICATION Motion Sickness 569-65-3 MECLIZINE ADVERSE_EFFECT GIS_3_Constipation 569-65-3 MECLIZINE KNOWN_TOXICITY Cardiovascular Toxicity 569-65-3 MECLIZINE TISSUE_TOXICITY Hypotension 569-65-3 MECLIZINE ADVERSE_EFFECT XXX_1_Xerostomia 569-65-3 MECLIZINE THERAPEUTIC_CLASS Antihistamines 569-65-3 MECLIZINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 569-65-3 MECLIZINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 569-65-3 MECLIZINE PRODUCT_CLASS Gastrointestinal System 569-65-3 MECLIZINE PRODUCT_CLASS Central Nervous System (CNS) 569-65-3 MECLIZINE ADVERSE_EFFECT OCU_3_Blurred Vision 569-65-3 MECLIZINE ADVERSE_EFFECT PSY_3_Insomnia 569-65-3 MECLIZINE ADVERSE_EFFECT NEU_1_Drowsiness 569-65-3 MECLIZINE THERAPEUTIC_CLASS Antiemetics 569-65-3 MECLIZINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 31884-77-2 MECLIZINE MODE_CLASS Receptor Ligand Antagonist 31884-77-2 MECLIZINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 31884-77-2 MECLIZINE INDICATION Nausea / Vomiting 31884-77-2 MECLIZINE KNOWN_TOXICITY Cardiovascular Toxicity 31884-77-2 MECLIZINE ADVERSE_EFFECT GIS_3_Constipation 31884-77-2 MECLIZINE ADVERSE_EFFECT CVS_3_Hypotension 31884-77-2 MECLIZINE ADVERSE_EFFECT OTO_3_Tinnitus 31884-77-2 MECLIZINE INDICATION Vertigo 31884-77-2 MECLIZINE ADVERSE_EFFECT GUS_3_Urinary Retention 31884-77-2 MECLIZINE ADVERSE_EFFECT XXX_1_Fatigue 31884-77-2 MECLIZINE TISSUE_TOXICITY Hypotension 31884-77-2 MECLIZINE ADVERSE_EFFECT XXX_1_Xerostomia 31884-77-2 MECLIZINE THERAPEUTIC_CLASS Antihistamines 31884-77-2 MECLIZINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 31884-77-2 MECLIZINE PRODUCT_CLASS Gastrointestinal System 31884-77-2 MECLIZINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 31884-77-2 MECLIZINE PRODUCT_CLASS Central Nervous System (CNS) 31884-77-2 MECLIZINE ADVERSE_EFFECT OCU_3_Blurred Vision 31884-77-2 MECLIZINE ADVERSE_EFFECT PSY_3_Insomnia 31884-77-2 MECLIZINE ADVERSE_EFFECT NEU_1_Drowsiness 31884-77-2 MECLIZINE THERAPEUTIC_CLASS Antiemetics 31884-77-2 MECLIZINE INDICATION Motion Sickness 31884-77-2 MECLIZINE MECHANISM Modulate G-protein coupled signal transduction 1104-22-9 MECLIZINE THERAPEUTIC_CLASS Antihistamines 1104-22-9 MECLIZINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 1104-22-9 MECLIZINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 1104-22-9 MECLIZINE PRODUCT_CLASS Gastrointestinal System 1104-22-9 MECLIZINE ADVERSE_EFFECT OCU_3_Blurred Vision 1104-22-9 MECLIZINE ADVERSE_EFFECT PSY_3_Insomnia 1104-22-9 MECLIZINE ADVERSE_EFFECT NEU_1_Drowsiness 1104-22-9 MECLIZINE ADVERSE_EFFECT GIS_3_Constipation 1104-22-9 MECLIZINE KNOWN_TOXICITY Cardiovascular Toxicity 1104-22-9 MECLIZINE TISSUE_TOXICITY Hypotension 1104-22-9 MECLIZINE MECHANISM Modulate G-protein coupled signal transduction 1104-22-9 MECLIZINE INDICATION Motion Sickness 1104-22-9 MECLIZINE THERAPEUTIC_CLASS Antiemetics 1104-22-9 MECLIZINE ADVERSE_EFFECT XXX_1_Fatigue 1104-22-9 MECLIZINE PRODUCT_CLASS Central Nervous System (CNS) 1104-22-9 MECLIZINE ADVERSE_EFFECT XXX_1_Xerostomia 1104-22-9 MECLIZINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 1104-22-9 MECLIZINE MODE_CLASS Receptor Ligand Antagonist 1104-22-9 MECLIZINE ADVERSE_EFFECT GUS_3_Urinary Retention 1104-22-9 MECLIZINE INDICATION Vertigo 1104-22-9 MECLIZINE ADVERSE_EFFECT OTO_3_Tinnitus 1104-22-9 MECLIZINE ADVERSE_EFFECT CVS_3_Hypotension 1104-22-9 MECLIZINE INDICATION Nausea / Vomiting 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Peptic Ulceration 644-62-2 MECLOFENAMIC ACID INDICATION Osteoarthritis 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 644-62-2 MECLOFENAMIC ACID KNOWN_TOXICITY Nephrotoxicity 644-62-2 MECLOFENAMIC ACID TISSUE_TOXICITY Interstitial Nephritis 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_1_Gastritis 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 644-62-2 MECLOFENAMIC ACID MODE_CLASS Enzyme Inhibitor 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Hemolytic Anemia 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT LIV_3_Hepatotoxicity 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_2_Decreased Platelet Function 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Acute Renal Failure 644-62-2 MECLOFENAMIC ACID STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 644-62-2 MECLOFENAMIC ACID MECHANISM Inhibit eicosanoid biosynthesis 644-62-2 MECLOFENAMIC ACID INDICATION Moderate Pain 644-62-2 MECLOFENAMIC ACID TISSUE_TOXICITY Hepatotoxicity 644-62-2 MECLOFENAMIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastric Ulceration 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT CVS_3_Congestive Heart Failure 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Pancytopenia 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Aplastic Anemia 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT LIV_3_Hepatitis 644-62-2 MECLOFENAMIC ACID TISSUE_TOXICITY Renal Papillary Necrosis 644-62-2 MECLOFENAMIC ACID INDICATION Arthralgia 644-62-2 MECLOFENAMIC ACID INDICATION Dysmenorrhea 644-62-2 MECLOFENAMIC ACID PRODUCT_CLASS Anti-inflammatories 644-62-2 MECLOFENAMIC ACID TISSUE_TOXICITY Acute Renal Failure 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Nephrotic Syndrome 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT XXX_3_Peripheral Edema 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT LIV_3_Jaundice 644-62-2 MECLOFENAMIC ACID INDICATION Rheumatoid Arthritis 644-62-2 MECLOFENAMIC ACID THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 644-62-2 MECLOFENAMIC ACID TISSUE_TOXICITY Nephrotic Syndrome 644-62-2 MECLOFENAMIC ACID TISSUE_TOXICITY Congestive Heart Failure 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 644-62-2 MECLOFENAMIC ACID KNOWN_TOXICITY Hepatotoxicity 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Interstitial Nephritis 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_1_Constipation 644-62-2 MECLOFENAMIC ACID ADVERSE_EFFECT NEU_2_Dizziness 6385-02-0 MECLOFENAMIC ACID INDICATION Moderate Pain 6385-02-0 MECLOFENAMIC ACID INDICATION Dysmenorrhea 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Pancytopenia 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Aplastic Anemia 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT LIV_3_Hepatitis 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT CVS_3_Congestive Heart Failure 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastric Ulceration 6385-02-0 MECLOFENAMIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 6385-02-0 MECLOFENAMIC ACID TISSUE_TOXICITY Hepatotoxicity 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_1_Gastritis 6385-02-0 MECLOFENAMIC ACID MECHANISM Inhibit eicosanoid biosynthesis 6385-02-0 MECLOFENAMIC ACID STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Acute Renal Failure 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_2_Decreased Platelet Function 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT LIV_3_Hepatotoxicity 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Hemolytic Anemia 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 6385-02-0 MECLOFENAMIC ACID MODE_CLASS Enzyme Inhibitor 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 6385-02-0 MECLOFENAMIC ACID PRODUCT_CLASS Anti-inflammatories 6385-02-0 MECLOFENAMIC ACID TISSUE_TOXICITY Acute Renal Failure 6385-02-0 MECLOFENAMIC ACID KNOWN_TOXICITY Nephrotoxicity 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Nephrotic Syndrome 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT XXX_3_Peripheral Edema 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT LIV_3_Jaundice 6385-02-0 MECLOFENAMIC ACID INDICATION Rheumatoid Arthritis 6385-02-0 MECLOFENAMIC ACID THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 6385-02-0 MECLOFENAMIC ACID TISSUE_TOXICITY Nephrotic Syndrome 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 6385-02-0 MECLOFENAMIC ACID KNOWN_TOXICITY Hepatotoxicity 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT KID_3_Interstitial Nephritis 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_1_Constipation 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT NEU_2_Dizziness 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 6385-02-0 MECLOFENAMIC ACID ADVERSE_EFFECT GIS_3_Peptic Ulceration 6385-02-0 MECLOFENAMIC ACID TISSUE_TOXICITY Renal Papillary Necrosis 6385-02-0 MECLOFENAMIC ACID TISSUE_TOXICITY Interstitial Nephritis 6385-02-0 MECLOFENAMIC ACID TISSUE_TOXICITY Congestive Heart Failure 6385-02-0 MECLOFENAMIC ACID INDICATION Osteoarthritis 6385-02-0 MECLOFENAMIC ACID INDICATION Arthralgia 520-85-4 MEDROXYPROGESTERONE TISSUE_TOXICITY Breakthrough Bleeding 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT END_3_Hirsutism 520-85-4 MEDROXYPROGESTERONE STRUCTURE_ACTIVITY Progesterone receptor agonist 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT REP_3_Ectopic Pregnancy 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT GUS_2_Vaginitis 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT XXX_1_Weight Gain 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT NEU_1_Dizziness 520-85-4 MEDROXYPROGESTERONE MODE_CLASS Receptor Agonist 520-85-4 MEDROXYPROGESTERONE INDICATION Prevention of Endometrial Hyperplasia 520-85-4 MEDROXYPROGESTERONE KNOWN_TOXICITY Reproductive System Toxicity 520-85-4 MEDROXYPROGESTERONE MECHANISM Modulate gene transcription 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT MSK_2_Leg Cramps 520-85-4 MEDROXYPROGESTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT CVS_3_Thromboembolism 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT PSY_2_Mental Depression 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT IMU_3_Anaphylaxis 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT GIS_1_Nausea 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT REP_2_Unintended Pregnancy 520-85-4 MEDROXYPROGESTERONE KNOWN_TOXICITY Cardiovascular Toxicity 520-85-4 MEDROXYPROGESTERONE TISSUE_TOXICITY Thromboembolism 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT END_3_Galactorrhea 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT END_1_Breast Tenderness 520-85-4 MEDROXYPROGESTERONE INDICATION Amenorrhea 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT REP_2_Amenorrhea 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT NEU_1_Headache 520-85-4 MEDROXYPROGESTERONE THERAPEUTIC_CLASS Gonadal Hormones 520-85-4 MEDROXYPROGESTERONE INDICATION Dysfunctional Uterine Bleeding (DUB) 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT KID_2_Fluid Retention 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT SKN_1_Acne 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT END_3_Osteoporosis 520-85-4 MEDROXYPROGESTERONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 2668-66-8 MEDRYSONE MECHANISM Modulate gene transcription 2668-66-8 MEDRYSONE MODE_CLASS Receptor Agonist 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT IMU_3_Photosensitivity 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT SKN_2_Pruritis 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT OTO_2_Tinnitus 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 61-68-7 MEFENAMIC ACID KNOWN_TOXICITY Blood & Bone Marrow Toxicity 61-68-7 MEFENAMIC ACID TA_LEVEL_2 NSAID 61-68-7 MEFENAMIC ACID MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 61-68-7 MEFENAMIC ACID TA_LEVEL_1 Anti-inflammatory 61-68-7 MEFENAMIC ACID MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 61-68-7 MEFENAMIC ACID ACTIVITY_CLASS Anti-inflammatory 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Renal Papillary Necrosis 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Inhibits Platelet Aggregation 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT LIV_2_Abnormal Liver Function 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT CVS_3_Cardiac Failure 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT LUN_3_Bronchospasm 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT OCU_2_Blurred Vision 61-68-7 MEFENAMIC ACID KNOWN_TOXICITY Nephrotoxicity 61-68-7 MEFENAMIC ACID MECH_LEVEL_1 Immunomodulation 61-68-7 MEFENAMIC ACID INDICATION Dysmenorrhea 61-68-7 MEFENAMIC ACID MECHANISM Inhibit eicosanoid biosynthesis 61-68-7 MEFENAMIC ACID TA_LEVEL_3 NSAID 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Cardiac Failure 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT SKN_1_Skin Rash 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT KID_2_Fluid Retention 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT LIV_3_Hepatic Failure 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT BBM_3_Thrombocytopenia 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT IMU_3_Hypersensitivity 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT NEU_2_Dizziness 61-68-7 MEFENAMIC ACID PRODUCT_CLASS Anti-inflammatories 61-68-7 MEFENAMIC ACID MESH_LEVEL_1 Organic Chemicals 61-68-7 MEFENAMIC ACID MESH_LEVEL_3 Acids, Carbocyclic 61-68-7 MEFENAMIC ACID MESH_LEVEL_2 Carboxylic Acids 61-68-7 MEFENAMIC ACID STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Acute Interstitial Nephritis 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Fulminant Hepatitis 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT REP_3_Delayed Parturition 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_1_Heartburn 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT BBM_3_Pancytopenia 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Renal Failure 61-68-7 MEFENAMIC ACID TISSUE_TOXICITY Hepatic Failure 61-68-7 MEFENAMIC ACID ZERO_CLASS N 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT BBM_1_Inhibits Platelet Aggregation 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT NEU_3_Somnolence 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT KID_3_Renal Failure 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_3_Peptic Ulceration 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT BBM_2_Anemia 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 61-68-7 MEFENAMIC ACID ADVERSE_EFFECT GIS_1_Constipation 61-68-7 MEFENAMIC ACID THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 61-68-7 MEFENAMIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 61-68-7 MEFENAMIC ACID KNOWN_TOXICITY Hepatotoxicity 61-68-7 MEFENAMIC ACID MODE_CLASS Enzyme Inhibitor 61-68-7 MEFENAMIC ACID INDICATION Pain 53230-10-7 MEFLOQUINE INDICATION Malaria 51773-92-3 MEFLOQUINE INDICATION Malaria 595-33-5 MEGESTROL ACETATE TISSUE_TOXICITY Thromboembolism 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT CVS_3_Thromboembolism 595-33-5 MEGESTROL ACETATE ACTIVITY_CLASS Progesterone receptor agonist 595-33-5 MEGESTROL ACETATE ZERO_CLASS N 595-33-5 MEGESTROL ACETATE TA_LEVEL_3 Prevent weight loss 595-33-5 MEGESTROL ACETATE INDICATION Endometrial Cancer / Carcinoma of the Endometrium 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT SKN_2_Rash 595-33-5 MEGESTROL ACETATE TISSUE_TOXICITY Teratogenicity 595-33-5 MEGESTROL ACETATE MODE_CLASS Enzyme Inhibitor 595-33-5 MEGESTROL ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT CVS_3_Hypotension 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT XXX_1_Edema 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT XXX_1_Weight Gain 595-33-5 MEGESTROL ACETATE MECH_LEVEL_2 Inhibit estrogen biosynthesis 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT END_1_Exacerbation of Diabetes 595-33-5 MEGESTROL ACETATE TISSUE_TOXICITY Heart Failure 595-33-5 MEGESTROL ACETATE STRUCTURE_ACTIVITY Progesterone receptor agonist 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT END_3_Adrenal Insufficiency 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 595-33-5 MEGESTROL ACETATE INDICATION Cachexia related to AIDS 595-33-5 MEGESTROL ACETATE TISSUE_TOXICITY Breakthrough Bleeding 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT EMB_2_Teratogenicity 595-33-5 MEGESTROL ACETATE MECH_LEVEL_1 Anabolic 595-33-5 MEGESTROL ACETATE MESH_LEVEL_1 Polycyclic Hydrocarbons 595-33-5 MEGESTROL ACETATE PRODUCT_CLASS Anti-cancers 595-33-5 MEGESTROL ACETATE MESH_LEVEL_2 Steroids 595-33-5 MEGESTROL ACETATE MECHANISM Inhibit steroid biosynthesis/ metabolism 595-33-5 MEGESTROL ACETATE INDICATION Metastatic Breast Cancer 595-33-5 MEGESTROL ACETATE MESH_LEVEL_3 Pregnanes 595-33-5 MEGESTROL ACETATE THERAPEUTIC_CLASS Antineoplastics 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT REP_2_Impotence 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT XXX_1_Increased Appetite 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT REP_1_Menstrual Irregularities 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT GUS_2_Urinary Frequency 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT MSK_3_Carpal Tunnel Syndrome 595-33-5 MEGESTROL ACETATE TA_LEVEL_2 Anti-viral 595-33-5 MEGESTROL ACETATE MECH_LEVEL_3 aromatase 595-33-5 MEGESTROL ACETATE TA_LEVEL_1 Infectious Disease 595-33-5 MEGESTROL ACETATE TISSUE_TOXICITY Hypotension 595-33-5 MEGESTROL ACETATE KNOWN_TOXICITY Reproductive System Toxicity 595-33-5 MEGESTROL ACETATE KNOWN_TOXICITY Embryo/Fetal Toxicity 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT CVS_3_Hypertension 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT ELT_3_Hypercalcemia 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT PSY_2_Emotional Lability 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT GIS_1_Dyspepsia 595-33-5 MEGESTROL ACETATE ADVERSE_EFFECT CVS_3_Heart Failure 73-31-4 MELATONIN ZERO_CLASS N 73-31-4 MELATONIN TA_LEVEL_3 5HT-like 73-31-4 MELATONIN MESH_LEVEL_3 Indoles 73-31-4 MELATONIN INDICATION Circadian Rhythm Disruption 73-31-4 MELATONIN INDICATION Jet-lag 73-31-4 MELATONIN THERAPEUTIC_CLASS Sedatives/Hypnotics 73-31-4 MELATONIN ADVERSE_EFFECT NEU_2_Headache 73-31-4 MELATONIN ADVERSE_EFFECT SKN_3_Fixed Drug Eruption 73-31-4 MELATONIN ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 73-31-4 MELATONIN STRUCTURE_ACTIVITY Melatonin receptor agonist 73-31-4 MELATONIN MECH_LEVEL_3 melatonin receptor MT1 and MT2 73-31-4 MELATONIN MECH_LEVEL_1 Modulate neural transmission 73-31-4 MELATONIN MECHANISM Modulate G-protein coupled signal transduction 73-31-4 MELATONIN ADVERSE_EFFECT PSY_3_Depression 73-31-4 MELATONIN ADVERSE_EFFECT XXX_2_Lethargy 73-31-4 MELATONIN ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 73-31-4 MELATONIN ADVERSE_EFFECT REP_3_Infertility 73-31-4 MELATONIN ACTIVITY_CLASS Melatonin receptor agonist 73-31-4 MELATONIN ADVERSE_EFFECT NEU_2_Drowsiness 73-31-4 MELATONIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 73-31-4 MELATONIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 73-31-4 MELATONIN MESH_LEVEL_1 Heterocyclic Compounds 73-31-4 MELATONIN INDICATION Tinnitus / Ringing in the Ear 73-31-4 MELATONIN ADVERSE_EFFECT SKN_3_Pruritis 73-31-4 MELATONIN ADVERSE_EFFECT GIS_3_Abdominal Pain 73-31-4 MELATONIN INDICATION Insomnia / Dyssomnias 73-31-4 MELATONIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 73-31-4 MELATONIN TA_LEVEL_1 Hormones, Endocrine and Metabolic 73-31-4 MELATONIN MODE_CLASS Endogenous Receptor /Channel Ligand 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_3_Ulcer Perforation 71125-38-7 MELOXICAM ADVERSE_EFFECT CVS_3_Angina Pectoris 71125-38-7 MELOXICAM ADVERSE_EFFECT CVS_3_Congestive Heart Failure 71125-38-7 MELOXICAM ADVERSE_EFFECT LUN_3_Bronchospasm 71125-38-7 MELOXICAM ADVERSE_EFFECT LIV_3_Hepatotoxicity 71125-38-7 MELOXICAM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_3_Peptic Ulceration 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_3_Pancreatitis 71125-38-7 MELOXICAM ZERO_CLASS N 71125-38-7 MELOXICAM KNOWN_TOXICITY Nephrotoxicity 71125-38-7 MELOXICAM MESH_LEVEL_1 Heterocyclic Compounds 71125-38-7 MELOXICAM TA_LEVEL_3 NSAID 71125-38-7 MELOXICAM INDICATION Osteoarthritis 71125-38-7 MELOXICAM PRODUCT_CLASS Anti-inflammatories 71125-38-7 MELOXICAM ADVERSE_EFFECT KID_2_Fluid Retention 71125-38-7 MELOXICAM ADVERSE_EFFECT BBM_3_Agranulocytosis 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_2_Diarrhea 71125-38-7 MELOXICAM TISSUE_TOXICITY Acute Interstitial Nephritis 71125-38-7 MELOXICAM MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 71125-38-7 MELOXICAM MECHANISM Inhibit eicosanoid biosynthesis 71125-38-7 MELOXICAM MESH_LEVEL_3 Thiazines 71125-38-7 MELOXICAM KNOWN_TOXICITY Cardiovascular Toxicity 71125-38-7 MELOXICAM TISSUE_TOXICITY Renal Papillary Necrosis 71125-38-7 MELOXICAM ADVERSE_EFFECT IMU_3_Allergic Reactions 71125-38-7 MELOXICAM ADVERSE_EFFECT CVS_3_Hypertension 71125-38-7 MELOXICAM ADVERSE_EFFECT KID_3_Acute Renal Failure 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_2_Epigastric Pain 71125-38-7 MELOXICAM ADVERSE_EFFECT BBM_3_Thrombocytopenia 71125-38-7 MELOXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_2_Abdominal Pain 71125-38-7 MELOXICAM ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 71125-38-7 MELOXICAM ADVERSE_EFFECT LIV_3_Hepatitis 71125-38-7 MELOXICAM KNOWN_TOXICITY Hepatotoxicity 71125-38-7 MELOXICAM ADVERSE_EFFECT NEU_3_Convulsions 71125-38-7 MELOXICAM TISSUE_TOXICITY Angina Pectoris 71125-38-7 MELOXICAM TISSUE_TOXICITY Acute Renal Failure 71125-38-7 MELOXICAM ADVERSE_EFFECT BBM_3_Myelosuppression 71125-38-7 MELOXICAM ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 71125-38-7 MELOXICAM TISSUE_TOXICITY Hepatic Failure 71125-38-7 MELOXICAM TISSUE_TOXICITY Hepatotoxicity 71125-38-7 MELOXICAM ADVERSE_EFFECT LIV_3_Hepatic Failure 71125-38-7 MELOXICAM ADVERSE_EFFECT BBM_3_Leukopenia 71125-38-7 MELOXICAM ADVERSE_EFFECT BBM_3_Anemia 71125-38-7 MELOXICAM ADVERSE_EFFECT SKN_2_Rash 71125-38-7 MELOXICAM ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_2_Dyspepsia 71125-38-7 MELOXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 71125-38-7 MELOXICAM MODE_CLASS Enzyme Inhibitor 71125-38-7 MELOXICAM ADVERSE_EFFECT GIS_2_Nausea 71125-38-7 MELOXICAM MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 71125-38-7 MELOXICAM ACTIVITY_CLASS Anti-inflammatory 71125-38-7 MELOXICAM TA_LEVEL_1 Anti-inflammatory 71125-38-7 MELOXICAM MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 71125-38-7 MELOXICAM TA_LEVEL_2 NSAID 71125-38-7 MELOXICAM MECH_LEVEL_1 Immunomodulation 71125-38-7 MELOXICAM ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 71125-38-7 MELOXICAM TISSUE_TOXICITY Congestive Heart Failure 148-82-3 MELPHALAN INDICATION Osteosarcoma / Osteogenic Sarcoma 148-82-3 MELPHALAN INDICATION Metastatic Melanoma 148-82-3 MELPHALAN INDICATION Testicular Cancer / Carcinoma of the Testis 148-82-3 MELPHALAN INDICATION Prostatic Cancer / Carcinoma of the Prostate 148-82-3 MELPHALAN ADVERSE_EFFECT BBM_1_Pancytopenia 148-82-3 MELPHALAN TA_LEVEL_1 Oncology 148-82-3 MELPHALAN MECH_LEVEL_1 DNA Damage 148-82-3 MELPHALAN TISSUE_TOXICITY Anemia 148-82-3 MELPHALAN ADVERSE_EFFECT DNA_2_Mutagenicity 148-82-3 MELPHALAN ADVERSE_EFFECT IMU_3_Anaphylaxis 148-82-3 MELPHALAN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 148-82-3 MELPHALAN ADVERSE_EFFECT BBM_1_Leukopenia 148-82-3 MELPHALAN ADVERSE_EFFECT BBM_1_Myelotoxicity 148-82-3 MELPHALAN TISSUE_TOXICITY Pancytopenia 148-82-3 MELPHALAN TISSUE_TOXICITY Carcinogenicity 148-82-3 MELPHALAN KNOWN_TOXICITY Mutagenicity 148-82-3 MELPHALAN PRODUCT_CLASS Immune Response / Immunomodulators 148-82-3 MELPHALAN MECH_LEVEL_2 DNA Damage 148-82-3 MELPHALAN INDICATION Breast Cancer / Carcinoma of the Breast 148-82-3 MELPHALAN ADVERSE_EFFECT EMB_2_Teratogenicity 148-82-3 MELPHALAN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 148-82-3 MELPHALAN ADVERSE_EFFECT LIV_3_Hepatotoxicity 148-82-3 MELPHALAN ADVERSE_EFFECT BBM_1_Thrombocytopenia 148-82-3 MELPHALAN ADVERSE_EFFECT EMB_2_Embryotoxicity 148-82-3 MELPHALAN ADVERSE_EFFECT GIS_2_Oral Ulceration 148-82-3 MELPHALAN INDICATION Amyloidosis 148-82-3 MELPHALAN TISSUE_TOXICITY Teratogenicity 148-82-3 MELPHALAN TISSUE_TOXICITY Thrombocytopenia 148-82-3 MELPHALAN KNOWN_TOXICITY Hepatotoxicity 148-82-3 MELPHALAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 148-82-3 MELPHALAN KNOWN_TOXICITY Carcinogenicity 148-82-3 MELPHALAN ACTIVITY_CLASS DNA damager 148-82-3 MELPHALAN TISSUE_TOXICITY Leukopenia 148-82-3 MELPHALAN TISSUE_TOXICITY Mutagenicity 148-82-3 MELPHALAN TISSUE_TOXICITY Myelotoxicity 148-82-3 MELPHALAN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 148-82-3 MELPHALAN ADVERSE_EFFECT REP_2_Amenorrhea 148-82-3 MELPHALAN ADVERSE_EFFECT BBM_1_Anemia 148-82-3 MELPHALAN ADVERSE_EFFECT GIS_2_Diarrhea 148-82-3 MELPHALAN THERAPEUTIC_CLASS Antineoplastics 148-82-3 MELPHALAN MODE_CLASS Distorts /blocks macromolecular scaffold function 148-82-3 MELPHALAN MESH_LEVEL_2 Hydrocarbons 148-82-3 MELPHALAN PRODUCT_CLASS Anti-cancers 148-82-3 MELPHALAN MESH_LEVEL_3 Hydrocarbons, Halogenated 148-82-3 MELPHALAN INDICATION Ovarian Cancer / Carcinoma of the Ovary 148-82-3 MELPHALAN INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 148-82-3 MELPHALAN TA_LEVEL_3 multiple myeloma 148-82-3 MELPHALAN MESH_LEVEL_1 Organic Chemicals 148-82-3 MELPHALAN ADVERSE_EFFECT DNA_3_Carcinogenicity 148-82-3 MELPHALAN ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 148-82-3 MELPHALAN ADVERSE_EFFECT XXX_1_Infection 148-82-3 MELPHALAN ADVERSE_EFFECT CVS_3_Vasculitis 148-82-3 MELPHALAN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 148-82-3 MELPHALAN ZERO_CLASS N 148-82-3 MELPHALAN TISSUE_TOXICITY Hepatotoxicity 148-82-3 MELPHALAN KNOWN_TOXICITY Embryo/Fetal Toxicity 148-82-3 MELPHALAN STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 148-82-3 MELPHALAN MECHANISM Inhibit DNA synthesis, repair, and function 148-82-3 MELPHALAN TA_LEVEL_2 solid tumors 148-82-3 MELPHALAN MECH_LEVEL_3 Inhibit DNA synthesis, repair, and function 148-82-3 MELPHALAN INDICATION Multiple Myeloma / Myelomatosis 19982-08-2 MEMANTINE THERAPEUTIC_CLASS Neurodegenerative Disorders 19982-08-2 MEMANTINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 19982-08-2 MEMANTINE PRODUCT_CLASS Central Nervous System (CNS) 19982-08-2 MEMANTINE MECHANISM Block neural transmission 19982-08-2 MEMANTINE MODE_CLASS Channel Blocker 19982-08-2 MEMANTINE INDICATION Alzheimer's Disease 41100-52-1 MEMANTINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 41100-52-1 MEMANTINE PRODUCT_CLASS Central Nervous System (CNS) 41100-52-1 MEMANTINE MECHANISM Block neural transmission 41100-52-1 MEMANTINE MODE_CLASS Channel Blocker 41100-52-1 MEMANTINE INDICATION Alzheimer's Disease 41100-52-1 MEMANTINE THERAPEUTIC_CLASS Neurodegenerative Disorders 51052-62-1 MEMANTINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 51052-62-1 MEMANTINE PRODUCT_CLASS Central Nervous System (CNS) 51052-62-1 MEMANTINE MECHANISM Block neural transmission 51052-62-1 MEMANTINE MODE_CLASS Channel Blocker 51052-62-1 MEMANTINE INDICATION Alzheimer's Disease 51052-62-1 MEMANTINE THERAPEUTIC_CLASS Neurodegenerative Disorders 76-90-4 MEPENZOLATE BROMIDE INDICATION Gastric Ulcer 76-90-4 MEPENZOLATE BROMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 76-90-4 MEPENZOLATE BROMIDE MECHANISM Modulate G-protein coupled signal transduction 76-90-4 MEPENZOLATE BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 76-90-4 MEPENZOLATE BROMIDE INDICATION Duodenal Ulcer 76-90-4 MEPENZOLATE BROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 50-13-5 PETHIDINE MECHANISM Modulate neural transmission 50-13-5 PETHIDINE PRODUCT_CLASS Analgesics 50-13-5 PETHIDINE INDICATION Severe Pain 50-13-5 PETHIDINE INDICATION Moderate Pain 50-13-5 PETHIDINE MODE_CLASS Receptor Agonist 50-13-5 PETHIDINE THERAPEUTIC_CLASS Analgesics, Opioid 57-42-1 PETHIDINE INDICATION Moderate Pain 57-42-1 PETHIDINE MODE_CLASS Receptor Agonist 57-42-1 PETHIDINE THERAPEUTIC_CLASS Analgesics, Opioid 57-42-1 PETHIDINE MECHANISM Modulate neural transmission 57-42-1 PETHIDINE PRODUCT_CLASS Analgesics 57-42-1 PETHIDINE INDICATION Severe Pain 100-92-5 MEPHENTERMINE MODE_CLASS Receptor Agonist 100-92-5 MEPHENTERMINE PRODUCT_CLASS Cardiovasculars 100-92-5 MEPHENTERMINE INDICATION Hypotension 100-92-5 MEPHENTERMINE MECHANISM Increase vasoconstriction 100-92-5 MEPHENTERMINE THERAPEUTIC_CLASS Vasopressors 115-38-8 METHYLPHENOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 115-38-8 METHYLPHENOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 115-38-8 METHYLPHENOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 115-38-8 METHYLPHENOBARBITAL MECHANISM Modulate neural transmission 115-38-8 METHYLPHENOBARBITAL MODE_CLASS Channel Modulator 115-38-8 METHYLPHENOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 96-88-8 MEPIVACAINE TISSUE_TOXICITY Hypotension 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_2_Hypotension 96-88-8 MEPIVACAINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 96-88-8 MEPIVACAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 96-88-8 MEPIVACAINE ADVERSE_EFFECT NEU_3_Tremor 96-88-8 MEPIVACAINE ADVERSE_EFFECT SKN_3_Pruritis 96-88-8 MEPIVACAINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 96-88-8 MEPIVACAINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 96-88-8 MEPIVACAINE ADVERSE_EFFECT IMU_3_Urticaria 96-88-8 MEPIVACAINE TISSUE_TOXICITY Atrial Fibrillation 96-88-8 MEPIVACAINE INDICATION Severe Pain 96-88-8 MEPIVACAINE INDICATION Caudal Anesthesia 96-88-8 MEPIVACAINE THERAPEUTIC_CLASS Local Anesthetics 96-88-8 MEPIVACAINE KNOWN_TOXICITY Cardiovascular Toxicity 96-88-8 MEPIVACAINE INDICATION Epidural Anesthesia 96-88-8 MEPIVACAINE PRODUCT_CLASS Central Nervous System (CNS) 96-88-8 MEPIVACAINE MODE_CLASS Channel Blocker 96-88-8 MEPIVACAINE ADVERSE_EFFECT NEU_2_Seizures 96-88-8 MEPIVACAINE INDICATION Infiltration Anesthesia 96-88-8 MEPIVACAINE MECHANISM Block neural transmission 96-88-8 MEPIVACAINE INDICATION Peripheral Nerve Block 96-88-8 MEPIVACAINE INDICATION Local Anesthesia 96-88-8 MEPIVACAINE TISSUE_TOXICITY Cardiac Arrest 96-88-8 MEPIVACAINE ADVERSE_EFFECT PSY_2_Anxiety 96-88-8 MEPIVACAINE ADVERSE_EFFECT NEU_1_Headache 96-88-8 MEPIVACAINE ADVERSE_EFFECT SKN_3_Rash 96-88-8 MEPIVACAINE ADVERSE_EFFECT MSK_2_Back Pain 96-88-8 MEPIVACAINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 96-88-8 MEPIVACAINE INDICATION Brachial plexus block 96-88-8 MEPIVACAINE TISSUE_TOXICITY First-Degree AV block 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 96-88-8 MEPIVACAINE ADVERSE_EFFECT NEU_2_Drowsiness 96-88-8 MEPIVACAINE ADVERSE_EFFECT XXX_3_Restlessness 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 96-88-8 MEPIVACAINE ADVERSE_EFFECT CVS_3_First-Degree AV block 96-88-8 MEPIVACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 96-88-8 MEPIVACAINE INDICATION Dental Anesthesia 96-88-8 MEPIVACAINE ADVERSE_EFFECT NEU_2_Dizziness 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 1722-62-9 MEPIVACAINE THERAPEUTIC_CLASS Local Anesthetics 1722-62-9 MEPIVACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 1722-62-9 MEPIVACAINE INDICATION Epidural Anesthesia 1722-62-9 MEPIVACAINE PRODUCT_CLASS Central Nervous System (CNS) 1722-62-9 MEPIVACAINE MODE_CLASS Channel Blocker 1722-62-9 MEPIVACAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 1722-62-9 MEPIVACAINE ADVERSE_EFFECT NEU_3_Tremor 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 1722-62-9 MEPIVACAINE ADVERSE_EFFECT SKN_3_Pruritis 1722-62-9 MEPIVACAINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 1722-62-9 MEPIVACAINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 1722-62-9 MEPIVACAINE TISSUE_TOXICITY Atrial Fibrillation 1722-62-9 MEPIVACAINE INDICATION Severe Pain 1722-62-9 MEPIVACAINE INDICATION Infiltration Anesthesia 1722-62-9 MEPIVACAINE INDICATION Brachial plexus block 1722-62-9 MEPIVACAINE TISSUE_TOXICITY First-Degree AV block 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 1722-62-9 MEPIVACAINE ADVERSE_EFFECT NEU_2_Dizziness 1722-62-9 MEPIVACAINE ADVERSE_EFFECT NEU_2_Drowsiness 1722-62-9 MEPIVACAINE ADVERSE_EFFECT XXX_3_Restlessness 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_3_First-Degree AV block 1722-62-9 MEPIVACAINE MECHANISM Block neural transmission 1722-62-9 MEPIVACAINE INDICATION Caudal Anesthesia 1722-62-9 MEPIVACAINE INDICATION Local Anesthesia 1722-62-9 MEPIVACAINE TISSUE_TOXICITY Cardiac Arrest 1722-62-9 MEPIVACAINE ADVERSE_EFFECT PSY_2_Anxiety 1722-62-9 MEPIVACAINE ADVERSE_EFFECT NEU_1_Headache 1722-62-9 MEPIVACAINE ADVERSE_EFFECT SKN_3_Rash 1722-62-9 MEPIVACAINE ADVERSE_EFFECT MSK_2_Back Pain 1722-62-9 MEPIVACAINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 1722-62-9 MEPIVACAINE KNOWN_TOXICITY Cardiovascular Toxicity 1722-62-9 MEPIVACAINE INDICATION Peripheral Nerve Block 1722-62-9 MEPIVACAINE INDICATION Dental Anesthesia 1722-62-9 MEPIVACAINE TISSUE_TOXICITY Hypotension 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_2_Hypotension 1722-62-9 MEPIVACAINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1722-62-9 MEPIVACAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 1722-62-9 MEPIVACAINE ADVERSE_EFFECT NEU_2_Seizures 1722-62-9 MEPIVACAINE ADVERSE_EFFECT IMU_3_Urticaria 57-53-4 MEPROBAMATE MECHANISM Modulate neural transmission 57-53-4 MEPROBAMATE MODE_CLASS Channel Blocker 57-53-4 MEPROBAMATE MECHANISM Block neural transmission 57-53-4 MEPROBAMATE MODE_CLASS Channel Modulator 57-53-4 MEPROBAMATE PRODUCT_CLASS Central Nervous System (CNS) 57-53-4 MEPROBAMATE INDICATION Anxiety Disorders 57-53-4 MEPROBAMATE THERAPEUTIC_CLASS Anxiolytics 57-53-4 MEPROBAMATE STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT DNA_3_Carcinogenicity 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT KID_2_Hyperuricemia 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT IMU_2_Immunologic Toxicity 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT PSY_1_Anorexia 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT BBM_1_Leukopenia 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT GIS_3_Gut Ulceration 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT SKN_2_Skin Rash 50-44-2 6-MERCAPTOPURINE KNOWN_TOXICITY Carcinogenicity 50-44-2 6-MERCAPTOPURINE KNOWN_TOXICITY Hepatotoxicity 50-44-2 6-MERCAPTOPURINE MESH_LEVEL_3 Purines 50-44-2 6-MERCAPTOPURINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 50-44-2 6-MERCAPTOPURINE INDICATION Non-Hodgkin's Lymphomas 50-44-2 6-MERCAPTOPURINE INDICATION Idiopathic Pulmonary Hemosiderosis 50-44-2 6-MERCAPTOPURINE INDICATION Uveitis 50-44-2 6-MERCAPTOPURINE MODE_CLASS Enzyme substrate mimic 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT LIV_1_Hepatotoxicity 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Myelosuppression 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Hepatotoxicity 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT BBM_1_Anemia 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT DNA_2_Chromosome Aberration 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT GIS_3_Pancreatitis 50-44-2 6-MERCAPTOPURINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 50-44-2 6-MERCAPTOPURINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 50-44-2 6-MERCAPTOPURINE MESH_LEVEL_1 Heterocyclic Compounds 50-44-2 6-MERCAPTOPURINE INDICATION Polycythemia Vera / Erythrocytosis 50-44-2 6-MERCAPTOPURINE INDICATION Prevention of Graft Rejection 50-44-2 6-MERCAPTOPURINE INDICATION Myasthenia Gravis 50-44-2 6-MERCAPTOPURINE INDICATION Acute Myelomonocytic Leukemia 50-44-2 6-MERCAPTOPURINE MECHANISM Incorporate into DNA/RNA/Protein 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT GIS_3_Diarrhea 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT NEU_3_Hepatic Encephalopathy 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT XXX_1_Infection 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT LIV_1_Cholestasis 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT BBM_1_Myelosuppression 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Bone Marrow Toxicity 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Carcinogenicity 50-44-2 6-MERCAPTOPURINE KNOWN_TOXICITY Embryo/Fetal Toxicity 50-44-2 6-MERCAPTOPURINE ZERO_CLASS N 50-44-2 6-MERCAPTOPURINE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 50-44-2 6-MERCAPTOPURINE MECH_LEVEL_3 DNA-directed DNA polymerase 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT LIV_1_Jaundice 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT BBM_1_Bone Marrow Toxicity 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Leukopenia 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Teratogenicity 50-44-2 6-MERCAPTOPURINE KNOWN_TOXICITY Mutagenicity 50-44-2 6-MERCAPTOPURINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, thiopurine base 50-44-2 6-MERCAPTOPURINE TA_LEVEL_3 Solid and soft tumors 50-44-2 6-MERCAPTOPURINE INDICATION Systemic Lupus Erythromatosus (SLE) 50-44-2 6-MERCAPTOPURINE INDICATION Autoimmune Hemolytic Anemia 50-44-2 6-MERCAPTOPURINE PRODUCT_CLASS Anti-cancers 50-44-2 6-MERCAPTOPURINE INDICATION Acute Lymphocytic Leukemia (ALL) 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Anemia 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Chromosome Aberration 50-44-2 6-MERCAPTOPURINE THERAPEUTIC_CLASS Antineoplastics 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT EMB_2_Teratogenicity 50-44-2 6-MERCAPTOPURINE TISSUE_TOXICITY Thrombocytopenia 50-44-2 6-MERCAPTOPURINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 50-44-2 6-MERCAPTOPURINE INDICATION Psoriatic Arthritis 50-44-2 6-MERCAPTOPURINE INDICATION Rheumatoid Arthritis 50-44-2 6-MERCAPTOPURINE INDICATION Idiopathic (Autoimmnune) Thrombocytopenic Purpura (ITP) 50-44-2 6-MERCAPTOPURINE TA_LEVEL_2 DNA synthesis inhibitors 50-44-2 6-MERCAPTOPURINE PRODUCT_CLASS Immune Response / Immunomodulators 50-44-2 6-MERCAPTOPURINE TA_LEVEL_1 Oncology 50-44-2 6-MERCAPTOPURINE ADVERSE_EFFECT XXX_3_Fever 50-44-2 6-MERCAPTOPURINE INDICATION Inflammatory Bowel Disease (IBD) 50-44-2 6-MERCAPTOPURINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 10124-48-8 AMMONIATED MERCURY STRUCTURE_ACTIVITY Toxicant, transition metal 89-57-6 MESALAMINE TISSUE_TOXICITY Hepatotoxicity 89-57-6 MESALAMINE PRODUCT_CLASS Anti-inflammatories 89-57-6 MESALAMINE ADVERSE_EFFECT GIS_3_Abdominal Pain 89-57-6 MESALAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 89-57-6 MESALAMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 89-57-6 MESALAMINE ADVERSE_EFFECT KID_2_Renal Dysfunction 89-57-6 MESALAMINE MECHANISM Inhibit kinase mediated signal transduction 89-57-6 MESALAMINE INDICATION Proctitis 89-57-6 MESALAMINE MODE_CLASS Enzyme Inhibitor, selective 89-57-6 MESALAMINE INDICATION Ulcerative Colitis 89-57-6 MESALAMINE INDICATION Inflammatory Bowel Disease (IBD) 89-57-6 MESALAMINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 89-57-6 MESALAMINE INDICATION Inflammation 89-57-6 MESALAMINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 89-57-6 MESALAMINE KNOWN_TOXICITY Hepatotoxicity 89-57-6 MESALAMINE ADVERSE_EFFECT PSY_3_Hallucinations 89-57-6 MESALAMINE INDICATION Crohn's Disease 89-57-6 MESALAMINE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, aminosalicylic acid 19767-45-4 MESNA ZERO_CLASS N 19767-45-4 MESNA MESH_LEVEL_3 Hydrocarbons, Acyclic 19767-45-4 MESNA MESH_LEVEL_2 Hydrocarbons 19767-45-4 MESNA STRUCTURE_ACTIVITY H2O2 radical scavenger 19767-45-4 MESNA PRODUCT_CLASS Other Human Uses 19767-45-4 MESNA ADVERSE_EFFECT KID_1_Hematuria 19767-45-4 MESNA ADVERSE_EFFECT GIS_1_Diarrhea 19767-45-4 MESNA ADVERSE_EFFECT GIS_1_Dysgeusia 19767-45-4 MESNA ADVERSE_EFFECT IMU_1_Allergic Reactions 19767-45-4 MESNA ADVERSE_EFFECT CVS_1_Hypotension 19767-45-4 MESNA ADVERSE_EFFECT XXX_1_Fatigue 19767-45-4 MESNA MECHANISM Scavenges hydrogen peroxide and free radicals 19767-45-4 MESNA INDICATION Prophylaxis of Ifosfamide induced hemorrhagic cystitis 19767-45-4 MESNA KNOWN_TOXICITY Nephrotoxicity 19767-45-4 MESNA ADVERSE_EFFECT GIS_1_Nausea / Vomiting 19767-45-4 MESNA THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 19767-45-4 MESNA MESH_LEVEL_1 Organic Chemicals 19767-45-4 MESNA TA_LEVEL_1 Chemoprophylaxis 19767-45-4 MESNA MECH_LEVEL_3 Free radical scavenger 19767-45-4 MESNA MECH_LEVEL_1 Chemoprotectant 19767-45-4 MESNA ADVERSE_EFFECT XXX_1_Pain 19767-45-4 MESNA ADVERSE_EFFECT NEU_1_Headache 19767-45-4 MESNA TISSUE_TOXICITY Hypotension 19767-45-4 MESNA ACTIVITY_CLASS H2O2 radical scavenger 19767-45-4 MESNA MECH_LEVEL_2 Scavenges hydrogen peroxide and free radicals 19767-45-4 MESNA INDICATION Prophylaxis of Cyclophosphamide induced hemorrhagic cystitis 19767-45-4 MESNA TISSUE_TOXICITY Hematuria 19767-45-4 MESNA KNOWN_TOXICITY Cardiovascular Toxicity 32672-69-8 MESORIDAZINE MECHANISM Block neural transmission 32672-69-8 MESORIDAZINE MODE_CLASS Receptor Ligand Antagonist 32672-69-8 MESORIDAZINE PRODUCT_CLASS Central Nervous System (CNS) 32672-69-8 MESORIDAZINE THERAPEUTIC_CLASS Antipsychotics 5588-33-0 MESORIDAZINE PRODUCT_CLASS Central Nervous System (CNS) 5588-33-0 MESORIDAZINE THERAPEUTIC_CLASS Antipsychotics 5588-33-0 MESORIDAZINE MODE_CLASS Receptor Ligand Antagonist 5588-33-0 MESORIDAZINE MECHANISM Block neural transmission 72-33-3 MESTRANOL TISSUE_TOXICITY Increased Incidence of Breast Carcinoma 72-33-3 MESTRANOL MECH_LEVEL_1 Ovulation inhibitor 72-33-3 MESTRANOL KNOWN_TOXICITY Cardiovascular Toxicity 72-33-3 MESTRANOL THERAPEUTIC_CLASS Contraceptive Hormones 72-33-3 MESTRANOL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 72-33-3 MESTRANOL ADVERSE_EFFECT GIS_1_Nausea 72-33-3 MESTRANOL ADVERSE_EFFECT REP_2_Breakthrough Bleeding 72-33-3 MESTRANOL ADVERSE_EFFECT NEU_3_Cerebral Thrombosis 72-33-3 MESTRANOL TISSUE_TOXICITY Hepatic Tumors 72-33-3 MESTRANOL ACTIVITY_CLASS Estrogen agonist 72-33-3 MESTRANOL MESH_LEVEL_3 Norsteroids 72-33-3 MESTRANOL MODE_CLASS Receptor Agonist 72-33-3 MESTRANOL MESH_LEVEL_1 Polycyclic Hydrocarbons 72-33-3 MESTRANOL MECH_LEVEL_2 repress LH release 72-33-3 MESTRANOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 72-33-3 MESTRANOL TA_LEVEL_3 Birth control 72-33-3 MESTRANOL TA_LEVEL_2 Birth control 72-33-3 MESTRANOL MESH_LEVEL_2 Steroids 72-33-3 MESTRANOL TISSUE_TOXICITY Coronary Thrombosis 72-33-3 MESTRANOL ADVERSE_EFFECT BIL_2_Gallbladder Disease 72-33-3 MESTRANOL ADVERSE_EFFECT DNA_2_Endometrial Hyperplasia 72-33-3 MESTRANOL ADVERSE_EFFECT XXX_2_Increased Appetite 72-33-3 MESTRANOL ADVERSE_EFFECT DNA_3_Increased Incidence of Breast Carcinoma 72-33-3 MESTRANOL KNOWN_TOXICITY Carcinogenicity 72-33-3 MESTRANOL ADVERSE_EFFECT GUS_2_Vaginal Spotting 72-33-3 MESTRANOL MECHANISM Modulate gene transcription 72-33-3 MESTRANOL INDICATION Dysfunctional Uterine Bleeding (DUB) 72-33-3 MESTRANOL INDICATION Contraception 72-33-3 MESTRANOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 72-33-3 MESTRANOL ZERO_CLASS N 72-33-3 MESTRANOL MECH_LEVEL_3 estrogen receptor 72-33-3 MESTRANOL STRUCTURE_ACTIVITY Estrogen receptor agonist, steroidal 72-33-3 MESTRANOL TISSUE_TOXICITY Endometrial Hyperplasia 72-33-3 MESTRANOL ADVERSE_EFFECT CVS_3_Coronary Thrombosis 72-33-3 MESTRANOL ADVERSE_EFFECT CVS_3_Venous Thrombosis 72-33-3 MESTRANOL ADVERSE_EFFECT DNA_3_Hepatic Tumors 72-33-3 MESTRANOL ADVERSE_EFFECT GIS_2_Vomiting 72-33-3 MESTRANOL THERAPEUTIC_CLASS Gonadal Hormones 72-33-3 MESTRANOL INDICATION Menopausal Syndrome 72-33-3 MESTRANOL ADVERSE_EFFECT KID_2_Fluid Retention 72-33-3 MESTRANOL ADVERSE_EFFECT CVS_2_Hypertension 72-33-3 MESTRANOL ADVERSE_EFFECT GUS_2_Vaginal Candidiasis 72-33-3 MESTRANOL ADVERSE_EFFECT LUN_3_Pulmonary Embolism 81855-34-7 MESULERGINE INDICATION Parkinson's Disease 81855-34-7 MESULERGINE THERAPEUTIC_CLASS Movement Disorders 81855-34-7 MESULERGINE PRODUCT_CLASS Central Nervous System (CNS) 64795-35-3 MESULERGINE INDICATION Parkinson's Disease 64795-35-3 MESULERGINE PRODUCT_CLASS Central Nervous System (CNS) 64795-35-3 MESULERGINE THERAPEUTIC_CLASS Movement Disorders 586-06-1 METAPROTERENOL STRUCTURE_ACTIVITY Adrenoceptor agonist 586-06-1 METAPROTERENOL MODE_CLASS Receptor Agonist, selective 586-06-1 METAPROTERENOL MECHANISM Reduce bronchoconstriction 5874-97-5 METAPROTERENOL MODE_CLASS Receptor Agonist, selective 5874-97-5 METAPROTERENOL STRUCTURE_ACTIVITY Adrenoceptor agonist 5874-97-5 METAPROTERENOL MECHANISM Reduce bronchoconstriction 54-49-9 METARAMINOL STRUCTURE_ACTIVITY Adrenoceptor agonist 54-49-9 METARAMINOL ADVERSE_EFFECT NEU_1_Dizziness 54-49-9 METARAMINOL ADVERSE_EFFECT NEU_2_Tremor 54-49-9 METARAMINOL ADVERSE_EFFECT CVS_3_Hypotension 54-49-9 METARAMINOL KNOWN_TOXICITY Cardiovascular Toxicity 54-49-9 METARAMINOL TISSUE_TOXICITY Cardiac Arrhythmia 54-49-9 METARAMINOL PRODUCT_CLASS Autonomic Nervous System (ANS) 54-49-9 METARAMINOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 54-49-9 METARAMINOL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 54-49-9 METARAMINOL THERAPEUTIC_CLASS Sympathomimetic Agents 54-49-9 METARAMINOL TISSUE_TOXICITY Hypotension 54-49-9 METARAMINOL ADVERSE_EFFECT XXX_1_Sweating 54-49-9 METARAMINOL ADVERSE_EFFECT PSY_1_Anxiety 54-49-9 METARAMINOL ADVERSE_EFFECT NEU_2_Headache 54-49-9 METARAMINOL MODE_CLASS Receptor Agonist 54-49-9 METARAMINOL ADVERSE_EFFECT SKN_2_Flushing 54-49-9 METARAMINOL ADVERSE_EFFECT CVS_1_Palpitation 54-49-9 METARAMINOL MECHANISM Modulate G-protein coupled signal transduction 54-49-9 METARAMINOL ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 54-49-9 METARAMINOL INDICATION Cardiogenic Shock 54-49-9 METARAMINOL ADVERSE_EFFECT CVS_3_Hypertension 54-49-9 METARAMINOL INDICATION Hypotension 5967-52-2 METARAMINOL STRUCTURE_ACTIVITY Adrenoceptor agonist 5967-52-2 METARAMINOL ADVERSE_EFFECT NEU_1_Dizziness 5967-52-2 METARAMINOL ADVERSE_EFFECT CVS_1_Palpitation 5967-52-2 METARAMINOL MECHANISM Modulate G-protein coupled signal transduction 5967-52-2 METARAMINOL INDICATION Hypotension 5967-52-2 METARAMINOL THERAPEUTIC_CLASS Sympathomimetic Agents 5967-52-2 METARAMINOL TISSUE_TOXICITY Hypotension 5967-52-2 METARAMINOL ADVERSE_EFFECT XXX_1_Sweating 5967-52-2 METARAMINOL ADVERSE_EFFECT PSY_1_Anxiety 5967-52-2 METARAMINOL ADVERSE_EFFECT NEU_2_Headache 5967-52-2 METARAMINOL MODE_CLASS Receptor Agonist 5967-52-2 METARAMINOL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 5967-52-2 METARAMINOL ADVERSE_EFFECT SKN_2_Flushing 5967-52-2 METARAMINOL ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 5967-52-2 METARAMINOL INDICATION Cardiogenic Shock 5967-52-2 METARAMINOL ADVERSE_EFFECT CVS_3_Hypertension 5967-52-2 METARAMINOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 5967-52-2 METARAMINOL PRODUCT_CLASS Autonomic Nervous System (ANS) 5967-52-2 METARAMINOL TISSUE_TOXICITY Cardiac Arrhythmia 5967-52-2 METARAMINOL KNOWN_TOXICITY Cardiovascular Toxicity 5967-52-2 METARAMINOL ADVERSE_EFFECT CVS_3_Hypotension 5967-52-2 METARAMINOL ADVERSE_EFFECT NEU_2_Tremor 17692-51-2 METERGOLINE MECHANISM Modulate G-protein coupled signal transduction 17692-51-2 METERGOLINE MODE_CLASS Receptor Ligand Antagonist 17692-51-2 METERGOLINE ADVERSE_EFFECT GIS_2_Constipation 17692-51-2 METERGOLINE ADVERSE_EFFECT XXX_2_Fatigue 17692-51-2 METERGOLINE ADVERSE_EFFECT PSY_2_Confusion 17692-51-2 METERGOLINE INDICATION Hyperprolactinemia 17692-51-2 METERGOLINE THERAPEUTIC_CLASS Pituitary Hormones 17692-51-2 METERGOLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 17692-51-2 METERGOLINE ADVERSE_EFFECT NEU_1_Drowsiness 17692-51-2 METERGOLINE ADVERSE_EFFECT GIS_1_Dry Mouth 17692-51-2 METERGOLINE ADVERSE_EFFECT NEU_1_Dizziness 17692-51-2 METERGOLINE ADVERSE_EFFECT MSK_2_Leg Cramps 17692-51-2 METERGOLINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 17692-51-2 METERGOLINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 17692-51-2 METERGOLINE ADVERSE_EFFECT NEU_1_Vertigo 17692-51-2 METERGOLINE ADVERSE_EFFECT NEU_1_Headache 17692-51-2 METERGOLINE STRUCTURE_ACTIVITY Ergot alkaloid 17692-51-2 METERGOLINE INDICATION Inhibition of Lactation 657-24-9 METFORMIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 657-24-9 METFORMIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 657-24-9 METFORMIN MECHANISM Modulate channel gating 657-24-9 METFORMIN ADVERSE_EFFECT XXX_3_Malaise 657-24-9 METFORMIN ADVERSE_EFFECT XXX_1_Asthenia 657-24-9 METFORMIN ADVERSE_EFFECT GIS_2_Metallic Taste 657-24-9 METFORMIN KNOWN_TOXICITY Cardiovascular Toxicity 657-24-9 METFORMIN ADVERSE_EFFECT PSY_1_Anorexia 657-24-9 METFORMIN ADVERSE_EFFECT GIS_1_Flatulence 657-24-9 METFORMIN MECHANISM Modulate signal transduction 657-24-9 METFORMIN ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 657-24-9 METFORMIN ADVERSE_EFFECT GIS_1_Dysgeusia 657-24-9 METFORMIN MECHANISM Stimulate insulin sensitive pathway 657-24-9 METFORMIN ADVERSE_EFFECT GIS_1_Abdominal Distress 657-24-9 METFORMIN INDICATION Type II Diabetes Mellitus 657-24-9 METFORMIN TISSUE_TOXICITY Hypotension 657-24-9 METFORMIN ADVERSE_EFFECT END_3_Lactic Acidosis 657-24-9 METFORMIN ADVERSE_EFFECT BBM_3_Anemia 657-24-9 METFORMIN THERAPEUTIC_CLASS Antidiabetic Agents 657-24-9 METFORMIN ADVERSE_EFFECT XXX_3_Weight Loss 657-24-9 METFORMIN ADVERSE_EFFECT END_3_Metabolic Acidosis 657-24-9 METFORMIN STRUCTURE_ACTIVITY AMP kinase activator 657-24-9 METFORMIN MODE_CLASS Channel Modulator 657-24-9 METFORMIN MODE_CLASS Receptor Agonist 657-24-9 METFORMIN INDICATION Type II Diabetes Mellitus 657-24-9 METFORMIN ADVERSE_EFFECT GIS_1_Indigestion 657-24-9 METFORMIN ADVERSE_EFFECT CVS_3_Hypotension 657-24-9 METFORMIN ADVERSE_EFFECT GIS_1_Diarrhea 657-24-9 METFORMIN ADVERSE_EFFECT MSK_3_Myalgia 657-24-9 METFORMIN MODE_CLASS Enzyme Activator 657-24-9 METFORMIN ADVERSE_EFFECT END_3_Hypoglycemia 76-99-3 METHADONE MODE_CLASS Receptor Agonist 76-99-3 METHADONE INDICATION Opiate Agonist Withdrawal 76-99-3 METHADONE THERAPEUTIC_CLASS Analgesics, Opioid 76-99-3 METHADONE THERAPEUTIC_CLASS Drug Dependence Therapy 76-99-3 METHADONE INDICATION Severe Pain 76-99-3 METHADONE MECHANISM Modulate neural transmission 76-99-3 METHADONE INDICATION Opiate Agonist Dependence 76-99-3 METHADONE PRODUCT_CLASS Analgesics 76-99-3 METHADONE PRODUCT_CLASS Other Human Uses 1095-90-5 METHADONE PRODUCT_CLASS Analgesics 1095-90-5 METHADONE INDICATION Severe Pain 1095-90-5 METHADONE THERAPEUTIC_CLASS Drug Dependence Therapy 1095-90-5 METHADONE THERAPEUTIC_CLASS Analgesics, Opioid 1095-90-5 METHADONE PRODUCT_CLASS Other Human Uses 1095-90-5 METHADONE INDICATION Opiate Agonist Withdrawal 1095-90-5 METHADONE MODE_CLASS Receptor Agonist 1095-90-5 METHADONE MECHANISM Modulate neural transmission 1095-90-5 METHADONE INDICATION Opiate Agonist Dependence 125-58-6 METHADONE THERAPEUTIC_CLASS Analgesics, Opioid 125-58-6 METHADONE INDICATION Opiate Agonist Withdrawal 125-58-6 METHADONE THERAPEUTIC_CLASS Drug Dependence Therapy 125-58-6 METHADONE PRODUCT_CLASS Analgesics 125-58-6 METHADONE MECHANISM Modulate neural transmission 125-58-6 METHADONE INDICATION Severe Pain 125-58-6 METHADONE INDICATION Opiate Agonist Dependence 125-58-6 METHADONE PRODUCT_CLASS Other Human Uses 125-58-6 METHADONE MODE_CLASS Receptor Agonist 5653-80-5 METHADONE THERAPEUTIC_CLASS Drug Dependence Therapy 5653-80-5 METHADONE INDICATION Severe Pain 5653-80-5 METHADONE INDICATION Opiate Agonist Dependence 5653-80-5 METHADONE PRODUCT_CLASS Analgesics 5653-80-5 METHADONE MECHANISM Modulate neural transmission 5653-80-5 METHADONE MODE_CLASS Receptor Agonist 5653-80-5 METHADONE THERAPEUTIC_CLASS Analgesics, Opioid 5653-80-5 METHADONE PRODUCT_CLASS Other Human Uses 5653-80-5 METHADONE INDICATION Opiate Agonist Withdrawal 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT PSY_3_Insomnia 51-57-0 METHAMPHETAMINE THERAPEUTIC_CLASS Central Stimulants 51-57-0 METHAMPHETAMINE MODE_CLASS Solute transporter inhibitor 51-57-0 METHAMPHETAMINE MECHANISM Block channel gating 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT PSY_1_Anorexia 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT CVS_1_Palpitation 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT XXX_2_Xerostomia 51-57-0 METHAMPHETAMINE PRODUCT_CLASS Central Nervous System (CNS) 51-57-0 METHAMPHETAMINE MECHANISM Prolong/enhance neural transmission 51-57-0 METHAMPHETAMINE MODE_CLASS Enzyme substrate mimic 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT CVS_3_Hypertension 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT REP_3_Impotence 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT PSY_2_Euphoria 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT GIS_3_Constipation 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT XXX_2_Weight Loss 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT PSY_2_CNS Stimulation 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT XXX_2_Restlessness 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT GIS_3_Diarrhea 51-57-0 METHAMPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 51-57-0 METHAMPHETAMINE MODE_CLASS Receptor Partial Agonist 51-57-0 METHAMPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 51-57-0 METHAMPHETAMINE INDICATION Obesity 51-57-0 METHAMPHETAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 51-57-0 METHAMPHETAMINE ADVERSE_EFFECT XXX_3_Xerosis 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT XXX_3_Xerosis 537-46-2 METHAMPHETAMINE MECHANISM Block channel gating 537-46-2 METHAMPHETAMINE THERAPEUTIC_CLASS Central Stimulants 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT XXX_2_Restlessness 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT CVS_3_Hypertension 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT GIS_3_Diarrhea 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT PSY_3_Insomnia 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT XXX_2_Weight Loss 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT GIS_3_Constipation 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT PSY_2_Euphoria 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT REP_3_Impotence 537-46-2 METHAMPHETAMINE MODE_CLASS Enzyme substrate mimic 537-46-2 METHAMPHETAMINE MECHANISM Prolong/enhance neural transmission 537-46-2 METHAMPHETAMINE PRODUCT_CLASS Central Nervous System (CNS) 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT XXX_2_Xerostomia 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT CVS_1_Palpitation 537-46-2 METHAMPHETAMINE MODE_CLASS Solute transporter inhibitor 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT PSY_1_Anorexia 537-46-2 METHAMPHETAMINE ADVERSE_EFFECT PSY_2_CNS Stimulation 537-46-2 METHAMPHETAMINE MODE_CLASS Receptor Partial Agonist 537-46-2 METHAMPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 537-46-2 METHAMPHETAMINE INDICATION Obesity 537-46-2 METHAMPHETAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 537-46-2 METHAMPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 554-57-4 METHAZOLAMIDE INDICATION Mountain Sickness / Altitude Sickness 554-57-4 METHAZOLAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT SKN_3_Erythema Multiforme 554-57-4 METHAZOLAMIDE MODE_CLASS Enzyme Inhibitor 554-57-4 METHAZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT XXX_1_Xerostomia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT ELT_1_Hypokalemia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT OTO_3_Tinnitus 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT NEU_3_Drowsiness 554-57-4 METHAZOLAMIDE STRUCTURE_ACTIVITY Carbonic Anhydrase Inhibitor 554-57-4 METHAZOLAMIDE INDICATION Glaucoma 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT REP_3_Decreased Libido 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT END_2_Metabolic Acidosis 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT KID_3_Hyperuricemia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT PSY_1_Anorexia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT GIS_1_Dysgeusia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT XXX_1_Thirst 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT NEU_3_Vertigo 554-57-4 METHAZOLAMIDE TISSUE_TOXICITY Melena 554-57-4 METHAZOLAMIDE INDICATION Tremor 554-57-4 METHAZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT XXX_1_Weight Loss 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT NEU_3_Seizures 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT REP_3_Impotence 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT GUS_3_Urinary Frequency 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT IMU_3_Photosensitivity 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT PSY_3_Irritability 554-57-4 METHAZOLAMIDE THERAPEUTIC_CLASS Movement Disorders 554-57-4 METHAZOLAMIDE KNOWN_TOXICITY Gastrointestinal Toxicity 554-57-4 METHAZOLAMIDE INDICATION Benign Essential (Familial) Tremor 554-57-4 METHAZOLAMIDE PRODUCT_CLASS Other Human Uses 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT PSY_3_Confusion 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT NEU_3_Paresthesia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT END_3_Hyperglycemia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT ELT_2_Hyperchloremia 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT GIS_1_Melena 554-57-4 METHAZOLAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 554-57-4 METHAZOLAMIDE THERAPEUTIC_CLASS Diuretics 100-97-0 METHENAMINE ADVERSE_EFFECT GUS_2_Dysuria 100-97-0 METHENAMINE INDICATION Cystitis 100-97-0 METHENAMINE ADVERSE_EFFECT KID_3_Hematuria 100-97-0 METHENAMINE INDICATION Pseudomonas Aeruginosa Infection 100-97-0 METHENAMINE THERAPEUTIC_CLASS Antibacterials 100-97-0 METHENAMINE KNOWN_TOXICITY Nephrotoxicity 100-97-0 METHENAMINE ADVERSE_EFFECT KID_3_Crystalluria 100-97-0 METHENAMINE INDICATION Proteus Infections 100-97-0 METHENAMINE INDICATION Urinary Tract Infection (UTI) 100-97-0 METHENAMINE ADVERSE_EFFECT PSY_1_Anorexia 100-97-0 METHENAMINE INDICATION Staphylococcus epidermidis 100-97-0 METHENAMINE PRODUCT_CLASS Anti-infectives 100-97-0 METHENAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 100-97-0 METHENAMINE ADVERSE_EFFECT GIS_1_Stomatitis 100-97-0 METHENAMINE INDICATION Enterococcal Infections 100-97-0 METHENAMINE INDICATION Staphylococcus Aureus Infections 100-97-0 METHENAMINE INDICATION Gastrointestinal Infection 100-97-0 METHENAMINE TISSUE_TOXICITY Hematuria 60-56-0 METHIMAZOLE STRUCTURE_ACTIVITY Thyroperoxidase inhibitor 60-56-0 METHIMAZOLE MESH_LEVEL_3 Imidazoles 60-56-0 METHIMAZOLE ADVERSE_EFFECT BBM_3_Thrombocytopenia 60-56-0 METHIMAZOLE ADVERSE_EFFECT SKN_1_Pruritis 60-56-0 METHIMAZOLE ADVERSE_EFFECT SKN_1_Rash 60-56-0 METHIMAZOLE ADVERSE_EFFECT GIS_2_Vomiting 60-56-0 METHIMAZOLE MECH_LEVEL_2 Inhibit thyroid hormone biosynthesis 60-56-0 METHIMAZOLE MECH_LEVEL_3 Thyroperoxidase (TPO) 60-56-0 METHIMAZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 60-56-0 METHIMAZOLE ZERO_CLASS N 60-56-0 METHIMAZOLE ADVERSE_EFFECT IMU_2_Urticaria 60-56-0 METHIMAZOLE ADVERSE_EFFECT NEU_3_Hepatic Encephalopathy 60-56-0 METHIMAZOLE ADVERSE_EFFECT XXX_3_Edema 60-56-0 METHIMAZOLE ADVERSE_EFFECT GIS_2_Nausea 60-56-0 METHIMAZOLE ADVERSE_EFFECT IMU_3_Drug-Induced Lupus 60-56-0 METHIMAZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 60-56-0 METHIMAZOLE PRODUCT_CLASS Hormones, Endocrine and Metabolic 60-56-0 METHIMAZOLE MECHANISM Inhibit thyroid hormone biosynthesis 60-56-0 METHIMAZOLE THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 60-56-0 METHIMAZOLE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 60-56-0 METHIMAZOLE ADVERSE_EFFECT GIS_3_Loss of Sense of Taste 60-56-0 METHIMAZOLE ADVERSE_EFFECT XXX_1_Fever 60-56-0 METHIMAZOLE ADVERSE_EFFECT NEU_2_Headache 60-56-0 METHIMAZOLE TISSUE_TOXICITY Hepatotoxicity 60-56-0 METHIMAZOLE ADVERSE_EFFECT NEU_2_Paresthesia 60-56-0 METHIMAZOLE KNOWN_TOXICITY Hepatotoxicity 60-56-0 METHIMAZOLE MECH_LEVEL_1 Hormone modulation 60-56-0 METHIMAZOLE ADVERSE_EFFECT BBM_3_Bleeding Tendency 60-56-0 METHIMAZOLE ADVERSE_EFFECT BBM_3_Pancytopenia 60-56-0 METHIMAZOLE ADVERSE_EFFECT KID_3_Nephritis 60-56-0 METHIMAZOLE TISSUE_TOXICITY Teratogenicity 60-56-0 METHIMAZOLE TA_LEVEL_2 Hyperthyroidism 60-56-0 METHIMAZOLE ADVERSE_EFFECT BBM_3_Hypoprothrombinemia 60-56-0 METHIMAZOLE ADVERSE_EFFECT EMB_2_Fetal Toxicity 60-56-0 METHIMAZOLE ADVERSE_EFFECT NEU_3_Vertigo 60-56-0 METHIMAZOLE TA_LEVEL_3 direct acting thyroid agent 60-56-0 METHIMAZOLE MODE_CLASS Enzyme Inhibitor 60-56-0 METHIMAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 60-56-0 METHIMAZOLE MESH_LEVEL_1 Heterocyclic Compounds 60-56-0 METHIMAZOLE INDICATION Hyperthyroidism / Thyrotoxicosis 60-56-0 METHIMAZOLE TA_LEVEL_1 Hormones, Endocrine and Metabolic 60-56-0 METHIMAZOLE TISSUE_TOXICITY Hepatic Necrosis 60-56-0 METHIMAZOLE ACTIVITY_CLASS Thyroperoxidase inhibitor 60-56-0 METHIMAZOLE ADVERSE_EFFECT BBM_2_Leukopenia 60-56-0 METHIMAZOLE ADVERSE_EFFECT LIV_2_Hepatitis 60-56-0 METHIMAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 60-56-0 METHIMAZOLE ADVERSE_EFFECT END_3_Hypoglycemia 60-56-0 METHIMAZOLE ADVERSE_EFFECT EMB_3_Teratogenicity 60-56-0 METHIMAZOLE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 19728-88-2 METHIOTHEPIN MECHANISM Modulate neural transmission 19728-88-2 METHIOTHEPIN MECHANISM Modulate cerebral vasoconstriction 19728-88-2 METHIOTHEPIN PRODUCT_CLASS Central Nervous System (CNS) 19728-88-2 METHIOTHEPIN THERAPEUTIC_CLASS Sedatives/Hypnotics 19728-88-2 METHIOTHEPIN MODE_CLASS Receptor Ligand Antagonist, Non-selective 532-03-6 METHOCARBAMOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_1_Dizziness 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_2_Nystagmus 532-03-6 METHOCARBAMOL ADVERSE_EFFECT GIS_1_Dyspepsia 532-03-6 METHOCARBAMOL ADVERSE_EFFECT GIS_2_Metallic Taste 532-03-6 METHOCARBAMOL ADVERSE_EFFECT CVS_1_Phlebitis 532-03-6 METHOCARBAMOL ADVERSE_EFFECT OCU_2_Diplopia 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_1_Headache 532-03-6 METHOCARBAMOL ADVERSE_EFFECT PSY_2_Anorexia 532-03-6 METHOCARBAMOL PRODUCT_CLASS Central Nervous System (CNS) 532-03-6 METHOCARBAMOL INDICATION Tetanus 532-03-6 METHOCARBAMOL MECH_LEVEL_1 Muscle relaxant 532-03-6 METHOCARBAMOL MESH_LEVEL_2 Carboxylic Acids 532-03-6 METHOCARBAMOL TA_LEVEL_1 Central Nervous System (CNS) 532-03-6 METHOCARBAMOL STRUCTURE_ACTIVITY Unknown mechanism 532-03-6 METHOCARBAMOL ACTIVITY_CLASS Unknown mechanism 532-03-6 METHOCARBAMOL TISSUE_TOXICITY Hypotension 532-03-6 METHOCARBAMOL ADVERSE_EFFECT IMU_2_Anaphylactoid Reactions 532-03-6 METHOCARBAMOL ADVERSE_EFFECT SKN_1_Flushing 532-03-6 METHOCARBAMOL ADVERSE_EFFECT CVS_2_Hypotension 532-03-6 METHOCARBAMOL KNOWN_TOXICITY Cardiovascular Toxicity 532-03-6 METHOCARBAMOL THERAPEUTIC_CLASS Skeletal Muscle Relaxants 532-03-6 METHOCARBAMOL TA_LEVEL_3 Skeletal Muscle Relaxants 532-03-6 METHOCARBAMOL MESH_LEVEL_3 Acids, Acyclic 532-03-6 METHOCARBAMOL MECH_LEVEL_3 Unknown mechanism 532-03-6 METHOCARBAMOL TA_LEVEL_2 CNS Depressant 532-03-6 METHOCARBAMOL ADVERSE_EFFECT OCU_1_Blurred Vision 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_1_Drowsiness 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_1_Lightheadedness 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_3_Paralytic Ileus 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_3_Muscular Incoordination 532-03-6 METHOCARBAMOL ZERO_CLASS Y 532-03-6 METHOCARBAMOL MESH_LEVEL_1 Organic Chemicals 532-03-6 METHOCARBAMOL INDICATION Skeletal Muscle Spasm 532-03-6 METHOCARBAMOL ADVERSE_EFFECT XXX_2_Fever 532-03-6 METHOCARBAMOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_2_Syncope 532-03-6 METHOCARBAMOL ADVERSE_EFFECT BBM_3_Leukopenia 532-03-6 METHOCARBAMOL ADVERSE_EFFECT NEU_3_Seizures 60634-69-7 METHOHEXITAL SODIUM MODE_CLASS Channel Modulator 60634-69-7 METHOHEXITAL SODIUM THERAPEUTIC_CLASS General Anesthetics, Intravenous 60634-69-7 METHOHEXITAL SODIUM STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 60634-69-7 METHOHEXITAL SODIUM MECHANISM Modulate neural transmission 60634-69-7 METHOHEXITAL SODIUM INDICATION Induction / Maintenance of Anesthesia 60634-69-7 METHOHEXITAL SODIUM PRODUCT_CLASS Central Nervous System (CNS) 60-99-1 METHOTRIMEPRAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 60-99-1 METHOTRIMEPRAZINE MODE_CLASS Receptor Ligand Antagonist 60-99-1 METHOTRIMEPRAZINE MECHANISM Block neural transmission 60-99-1 METHOTRIMEPRAZINE THERAPEUTIC_CLASS Antipsychotics 60-99-1 METHOTRIMEPRAZINE PRODUCT_CLASS Central Nervous System (CNS) 61-16-5 METHOXAMINE MODE_CLASS Receptor Agonist, Non-selective 61-16-5 METHOXAMINE THERAPEUTIC_CLASS Antiarrhythmic Agents 61-16-5 METHOXAMINE INDICATION Supraventricular Tachycardia 61-16-5 METHOXAMINE PRODUCT_CLASS Cardiovasculars 61-16-5 METHOXAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 61-16-5 METHOXAMINE THERAPEUTIC_CLASS Vasopressors 61-16-5 METHOXAMINE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 agonist, oxymetazoline 61-16-5 METHOXAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 61-16-5 METHOXAMINE INDICATION Hypotension 61-16-5 METHOXAMINE MECHANISM Increase vasoconstriction 390-28-3 METHOXAMINE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 agonist, oxymetazoline 390-28-3 METHOXAMINE THERAPEUTIC_CLASS Antiarrhythmic Agents 390-28-3 METHOXAMINE MODE_CLASS Receptor Agonist, Non-selective 390-28-3 METHOXAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 390-28-3 METHOXAMINE THERAPEUTIC_CLASS Vasopressors 390-28-3 METHOXAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 390-28-3 METHOXAMINE INDICATION Hypotension 390-28-3 METHOXAMINE MECHANISM Increase vasoconstriction 390-28-3 METHOXAMINE INDICATION Supraventricular Tachycardia 390-28-3 METHOXAMINE PRODUCT_CLASS Cardiovasculars 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MODE_CLASS Enzyme Inhibitor 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TISSUE_TOXICITY Acute Interstitial Nephritis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TISSUE_TOXICITY Renal Failure 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID STRUCTURE_ACTIVITY NSAID, COX-1, 6-Methoxy-naphthalenyl-acetic acid 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT CVS_3_Cardiac Failure 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT LIV_3_Hepatic Failure 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_1_Heartburn 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT IMU_2_Photosensitivity 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT OTO_2_Tinnitus 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TA_LEVEL_1 Anti-inflammatory 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TA_LEVEL_2 NSAID 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MESH_LEVEL_3 Naphthalenes 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TISSUE_TOXICITY Hepatic Failure 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID KNOWN_TOXICITY Nephrotoxicity 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT BBM_2_Anemia 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT KID_3_Renal Failure 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT LIV_2_Abnormal Liver Function 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT KID_1_Fluid Retention 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT NEU_2_Dizziness 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT NEU_2_Somnolence 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_3_Peptic Ulceration 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID PRODUCT_CLASS Anti-inflammatories 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MECH_LEVEL_1 Immunomodulation 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TISSUE_TOXICITY Fulminant Hepatitis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT BBM_3_Pancytopenia 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT BBM_3_Thrombocytopenia 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT SKN_2_Skin Rash 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID KNOWN_TOXICITY Hepatotoxicity 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ACTIVITY_CLASS Anti-inflammatory 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TISSUE_TOXICITY Renal Papillary Necrosis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TISSUE_TOXICITY Cardiac Failure 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ZERO_CLASS N 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MECHANISM Inhibit eicosanoid biosynthesis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID MESH_LEVEL_1 Polycyclic Hydrocarbons 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID TA_LEVEL_3 NSAID 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT REP_2_Delayed Parturition 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT IMU_3_Hypersensitivity 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT LUN_3_Bronchospasm 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT SKN_2_Pruritis 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT OCU_2_Blurred Vision 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT GIS_1_Constipation 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 23981-47-7 6-METHOXY-2-NAPHTHYLACETIC ACID ADVERSE_EFFECT BBM_3_Inhibits Platelet Aggregation 16662-46-7 GALLOPAMIL PRODUCT_CLASS Cardiovasculars 16662-46-7 GALLOPAMIL THERAPEUTIC_CLASS Vasodilators 16662-46-7 GALLOPAMIL MODE_CLASS Channel Blocker 16662-46-7 GALLOPAMIL MECHANISM Reduce muscle contractile force 16662-47-8 GALLOPAMIL MECHANISM Reduce muscle contractile force 16662-47-8 GALLOPAMIL PRODUCT_CLASS Cardiovasculars 16662-47-8 GALLOPAMIL THERAPEUTIC_CLASS Vasodilators 16662-47-8 GALLOPAMIL MODE_CLASS Channel Blocker 77-41-8 METHSUXIMIDE INDICATION Parkinson's Disease 77-41-8 METHSUXIMIDE INDICATION Dyskinesia 135-07-9 METHYCHLOTHIAZIDE PRODUCT_CLASS Cardiovasculars 135-07-9 METHYCHLOTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 135-07-9 METHYCHLOTHIAZIDE THERAPEUTIC_CLASS Diuretics 135-07-9 METHYCHLOTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 135-07-9 METHYCHLOTHIAZIDE MODE_CLASS Channel Blocker, selective 135-07-9 METHYCHLOTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 135-07-9 METHYCHLOTHIAZIDE INDICATION Hypertension 135-07-9 METHYCHLOTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 119-36-8 METHYL SALICYLATE PRODUCT_CLASS Analgesics 119-36-8 METHYL SALICYLATE MESH_LEVEL_3 Acids, Carbocyclic 119-36-8 METHYL SALICYLATE MESH_LEVEL_1 Organic Chemicals 119-36-8 METHYL SALICYLATE MESH_LEVEL_2 Carboxylic Acids 119-36-8 METHYL SALICYLATE INDICATION Myalgia 119-36-8 METHYL SALICYLATE MODE_CLASS Enzyme Inhibitor, selective 119-36-8 METHYL SALICYLATE ADVERSE_EFFECT XXX_1_Stinging Sensation 119-36-8 METHYL SALICYLATE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 119-36-8 METHYL SALICYLATE MECHANISM Inhibit inflammatory response 119-36-8 METHYL SALICYLATE ACTIVITY_CLASS Anti-inflammatory 119-36-8 METHYL SALICYLATE INDICATION Rheumatoid Arthritis 119-36-8 METHYL SALICYLATE MECH_LEVEL_1 Immunomodulation 119-36-8 METHYL SALICYLATE TA_LEVEL_3 NSAID 119-36-8 METHYL SALICYLATE THERAPEUTIC_CLASS Analgesics, Topical 119-36-8 METHYL SALICYLATE ADVERSE_EFFECT XXX_1_Burning Sensation 119-36-8 METHYL SALICYLATE ZERO_CLASS N 119-36-8 METHYL SALICYLATE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 119-36-8 METHYL SALICYLATE INDICATION Osteoarthritis 119-36-8 METHYL SALICYLATE ADVERSE_EFFECT SKN_1_Erythema 119-36-8 METHYL SALICYLATE TA_LEVEL_1 Anti-inflammatory 119-36-8 METHYL SALICYLATE TA_LEVEL_2 NSAID 119-36-8 METHYL SALICYLATE INDICATION Arthralgia 119-36-8 METHYL SALICYLATE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 119-36-8 METHYL SALICYLATE ADVERSE_EFFECT IMU_3_Hypersensitivity 82499-00-1 METHYL 6,7-DIMETHOXY-4-ETHYL-BETA-CARBOLINE-3-CARBOXYLATE PRODUCT_CLASS Biochemicals 555-30-6 METHYLDOPA ADVERSE_EFFECT IMU_3_Hypersensitivity 555-30-6 METHYLDOPA ADVERSE_EFFECT BBM_3_Thrombocytopenia 555-30-6 METHYLDOPA ACTIVITY_CLASS Adrenergic agonist 555-30-6 METHYLDOPA PRODUCT_CLASS Cardiovasculars 555-30-6 METHYLDOPA INDICATION Hypertension 555-30-6 METHYLDOPA MECHANISM Modulate G-protein coupled signal transduction 555-30-6 METHYLDOPA THERAPEUTIC_CLASS Antihypertensive Agents 555-30-6 METHYLDOPA ZERO_CLASS N 555-30-6 METHYLDOPA ADVERSE_EFFECT GIS_2_Pancreatitis 555-30-6 METHYLDOPA ADVERSE_EFFECT BBM_3_Bone Marrow Depression 555-30-6 METHYLDOPA ADVERSE_EFFECT NEU_1_Dizziness 555-30-6 METHYLDOPA ADVERSE_EFFECT REP_2_Impotence 555-30-6 METHYLDOPA ADVERSE_EFFECT PSY_2_Depression 555-30-6 METHYLDOPA MODE_CLASS Receptor Agonist, selective 555-30-6 METHYLDOPA TA_LEVEL_1 Cardiovascular 555-30-6 METHYLDOPA STRUCTURE_ACTIVITY Adrenoceptor-alpha2 agonist, aromatic L-amino acid decarboxylase inhibitor 555-30-6 METHYLDOPA ADVERSE_EFFECT OCU_2_Blurred Vision 555-30-6 METHYLDOPA INDICATION Hypertension During Pregnancy 555-30-6 METHYLDOPA MECH_LEVEL_3 aromatic-amino-acid decarboxylase inhibitor 555-30-6 METHYLDOPA TISSUE_TOXICITY Hepatic Necrosis 555-30-6 METHYLDOPA TA_LEVEL_2 Hypertension 555-30-6 METHYLDOPA ADVERSE_EFFECT CVS_3_Myocarditis 555-30-6 METHYLDOPA MESH_LEVEL_2 Amines 555-30-6 METHYLDOPA ADVERSE_EFFECT END_2_Hyperprolactinemia 555-30-6 METHYLDOPA MECH_LEVEL_1 Vasorelaxation 555-30-6 METHYLDOPA TISSUE_TOXICITY Myocarditis 555-30-6 METHYLDOPA KNOWN_TOXICITY Hepatotoxicity 555-30-6 METHYLDOPA ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 555-30-6 METHYLDOPA ADVERSE_EFFECT BBM_3_Hemolytic Anemia 555-30-6 METHYLDOPA ADVERSE_EFFECT NEU_1_Sedation 555-30-6 METHYLDOPA ADVERSE_EFFECT GIS_2_Diarrhea 555-30-6 METHYLDOPA MESH_LEVEL_3 Catecholamines 555-30-6 METHYLDOPA ADVERSE_EFFECT IMU_2_Positive Coombs Test 555-30-6 METHYLDOPA ADVERSE_EFFECT LIV_3_Hepatic Necrosis 555-30-6 METHYLDOPA ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 555-30-6 METHYLDOPA ADVERSE_EFFECT XXX_2_Fever 555-30-6 METHYLDOPA MESH_LEVEL_1 Organic Chemicals 555-30-6 METHYLDOPA TA_LEVEL_3 Hypertension 555-30-6 METHYLDOPA ADVERSE_EFFECT GIS_2_Dry Mouth 555-30-6 METHYLDOPA ADVERSE_EFFECT NEU_2_Headache 555-30-6 METHYLDOPA ADVERSE_EFFECT BBM_2_Leukopenia 555-30-6 METHYLDOPA KNOWN_TOXICITY Cardiovascular Toxicity 41372-08-1 METHYLDOPA ADVERSE_EFFECT OCU_2_Blurred Vision 41372-08-1 METHYLDOPA TA_LEVEL_3 Hypertension 41372-08-1 METHYLDOPA ADVERSE_EFFECT CVS_3_Myocarditis 41372-08-1 METHYLDOPA ADVERSE_EFFECT NEU_1_Dizziness 41372-08-1 METHYLDOPA ADVERSE_EFFECT XXX_2_Fever 41372-08-1 METHYLDOPA ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 41372-08-1 METHYLDOPA ADVERSE_EFFECT IMU_2_Positive Coombs Test 41372-08-1 METHYLDOPA ADVERSE_EFFECT BBM_3_Thrombocytopenia 41372-08-1 METHYLDOPA ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 41372-08-1 METHYLDOPA KNOWN_TOXICITY Hepatotoxicity 41372-08-1 METHYLDOPA TISSUE_TOXICITY Myocarditis 41372-08-1 METHYLDOPA MESH_LEVEL_1 Organic Chemicals 41372-08-1 METHYLDOPA MECH_LEVEL_1 Vasorelaxation 41372-08-1 METHYLDOPA ADVERSE_EFFECT GIS_2_Diarrhea 41372-08-1 METHYLDOPA ADVERSE_EFFECT NEU_1_Sedation 41372-08-1 METHYLDOPA ADVERSE_EFFECT BBM_3_Hemolytic Anemia 41372-08-1 METHYLDOPA ADVERSE_EFFECT IMU_3_Hypersensitivity 41372-08-1 METHYLDOPA ADVERSE_EFFECT LIV_3_Hepatic Necrosis 41372-08-1 METHYLDOPA ADVERSE_EFFECT END_2_Hyperprolactinemia 41372-08-1 METHYLDOPA TA_LEVEL_2 Hypertension 41372-08-1 METHYLDOPA TISSUE_TOXICITY Hepatic Necrosis 41372-08-1 METHYLDOPA INDICATION Hypertension During Pregnancy 41372-08-1 METHYLDOPA MESH_LEVEL_3 Catecholamines 41372-08-1 METHYLDOPA STRUCTURE_ACTIVITY Adrenoceptor-alpha2 agonist, aromatic L-amino acid decarboxylase inhibitor 41372-08-1 METHYLDOPA TA_LEVEL_1 Cardiovascular 41372-08-1 METHYLDOPA MODE_CLASS Receptor Agonist, selective 41372-08-1 METHYLDOPA ADVERSE_EFFECT PSY_2_Depression 41372-08-1 METHYLDOPA ADVERSE_EFFECT REP_2_Impotence 41372-08-1 METHYLDOPA MESH_LEVEL_2 Amines 41372-08-1 METHYLDOPA ADVERSE_EFFECT BBM_2_Leukopenia 41372-08-1 METHYLDOPA ACTIVITY_CLASS Adrenergic agonist 41372-08-1 METHYLDOPA PRODUCT_CLASS Cardiovasculars 41372-08-1 METHYLDOPA INDICATION Hypertension 41372-08-1 METHYLDOPA MECHANISM Modulate G-protein coupled signal transduction 41372-08-1 METHYLDOPA MECH_LEVEL_3 aromatic-amino-acid decarboxylase inhibitor 41372-08-1 METHYLDOPA THERAPEUTIC_CLASS Antihypertensive Agents 41372-08-1 METHYLDOPA ZERO_CLASS N 41372-08-1 METHYLDOPA ADVERSE_EFFECT GIS_2_Pancreatitis 41372-08-1 METHYLDOPA ADVERSE_EFFECT BBM_3_Bone Marrow Depression 41372-08-1 METHYLDOPA KNOWN_TOXICITY Cardiovascular Toxicity 41372-08-1 METHYLDOPA ADVERSE_EFFECT NEU_2_Headache 41372-08-1 METHYLDOPA ADVERSE_EFFECT GIS_2_Dry Mouth 2544-09-4 METHYLDOPATE PRODUCT_CLASS Cardiovasculars 2544-09-4 METHYLDOPATE MECHANISM Interferes with neural transmitter synthesis 2544-09-4 METHYLDOPATE INDICATION Hypertension 2544-09-4 METHYLDOPATE MODE_CLASS Enzyme Inhibitor 2544-09-4 METHYLDOPATE THERAPEUTIC_CLASS Antihypertensive Agents 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT MSK_3_Myalgia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT GIS_3_Abdominal Pain 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT PSY_3_Mental Confusion 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT GIS_3_Dysgeusia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT XXX_2_Restlessness 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT NEU_3_Coma 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_2_Hypertension 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT GIS_3_Diarrhea 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Peripheral Ischemia 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Hematuria 113-42-8 METHYLERGONOVINE MECHANISM Modulate G-protein coupled signal transduction 113-42-8 METHYLERGONOVINE PRODUCT_CLASS Other Human Uses 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT OCU_3_Retinal Detachment 113-42-8 METHYLERGONOVINE THERAPEUTIC_CLASS Oxytocic 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Cardiac Valvular Malfunction 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Myocardial Infarction 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT XXX_3_Hypothermia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT OTO_3_Tinnitus 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Cardiac Valvular Malfunction 113-42-8 METHYLERGONOVINE INDICATION Incomplete Abortion 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Angina 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT PSY_3_Hallucinations 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT KID_3_Hematuria 113-42-8 METHYLERGONOVINE KNOWN_TOXICITY Cardiovascular Toxicity 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Cerebrovascular Accident 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Renal Tubular Necrosis 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 113-42-8 METHYLERGONOVINE INDICATION Postpartum Hemorrhage 113-42-8 METHYLERGONOVINE STRUCTURE_ACTIVITY Ergot alkaloid 113-42-8 METHYLERGONOVINE KNOWN_TOXICITY Nephrotoxicity 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Peripheral Ischemia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT NEU_3_Cerebral Edema 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT XXX_3_Asthenia 113-42-8 METHYLERGONOVINE MODE_CLASS Receptor Ligand Antagonist 113-42-8 METHYLERGONOVINE TISSUE_TOXICITY Angina 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT OCU_3_Blurred Vision 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT NEU_3_Headache 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Chest Pain 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT XXX_3_Gangrene 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Palpitation 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT OCU_3_Visual Impairment 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT NEU_3_Seizures 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT NEU_3_Paresthesia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT END_3_Suppression of Lactation 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Coronary Vasospasm 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT CVS_3_Cerebrovascular Accident 113-42-8 METHYLERGONOVINE ADVERSE_EFFECT MSK_3_Muscle Cramps 1197-60-0 5-METHYLFURMETHIDE PRODUCT_CLASS Biochemicals 99-76-3 METHYLPARABEN MECH_LEVEL_3 Unknown mechanism 99-76-3 METHYLPARABEN ADVERSE_EFFECT OCU_2_Ciliary Spasm 99-76-3 METHYLPARABEN PRODUCT_CLASS Other Human Uses 99-76-3 METHYLPARABEN TA_LEVEL_3 none 99-76-3 METHYLPARABEN MESH_LEVEL_3 Hydroxy Acids 99-76-3 METHYLPARABEN ACTIVITY_CLASS Unknown mechanism 99-76-3 METHYLPARABEN STRUCTURE_ACTIVITY Unknown mechanism 99-76-3 METHYLPARABEN ADVERSE_EFFECT IMU_2_Allergic Reactions 99-76-3 METHYLPARABEN ZERO_CLASS Y 99-76-3 METHYLPARABEN MESH_LEVEL_2 Carboxylic Acids 99-76-3 METHYLPARABEN MESH_LEVEL_1 Organic Chemicals 99-76-3 METHYLPARABEN TA_LEVEL_2 food additive 99-76-3 METHYLPARABEN ADVERSE_EFFECT SKN_3_Erythema 99-76-3 METHYLPARABEN MECH_LEVEL_2 Unknown mechanism 99-76-3 METHYLPARABEN TA_LEVEL_1 Other Human Uses 99-76-3 METHYLPARABEN ADVERSE_EFFECT SKN_3_Itching 298-59-9 METHYLPHENIDATE THERAPEUTIC_CLASS Antidepressants 298-59-9 METHYLPHENIDATE INDICATION Depression 298-59-9 METHYLPHENIDATE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 298-59-9 METHYLPHENIDATE PRODUCT_CLASS Central Nervous System (CNS) 298-59-9 METHYLPHENIDATE THERAPEUTIC_CLASS Central Stimulants 298-59-9 METHYLPHENIDATE MECHANISM Prolong/enhance neural transmission 298-59-9 METHYLPHENIDATE MODE_CLASS Solute transporter inhibitor 298-59-9 METHYLPHENIDATE INDICATION Narcolepsy 113-45-1 METHYLPHENIDATE INDICATION Narcolepsy 113-45-1 METHYLPHENIDATE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 113-45-1 METHYLPHENIDATE PRODUCT_CLASS Central Nervous System (CNS) 113-45-1 METHYLPHENIDATE THERAPEUTIC_CLASS Central Stimulants 113-45-1 METHYLPHENIDATE MECHANISM Prolong/enhance neural transmission 113-45-1 METHYLPHENIDATE MODE_CLASS Solute transporter inhibitor 113-45-1 METHYLPHENIDATE INDICATION Depression 113-45-1 METHYLPHENIDATE THERAPEUTIC_CLASS Antidepressants 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT END_1_Virilization 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT XXX_2_Peripheral Edema 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-18-4 17-METHYLTESTOSTERONE INDICATION Hypogonadism 58-18-4 17-METHYLTESTOSTERONE TA_LEVEL_3 Steroid 58-18-4 17-METHYLTESTOSTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 58-18-4 17-METHYLTESTOSTERONE ACTIVITY_CLASS Androgen receptor agonist 58-18-4 17-METHYLTESTOSTERONE MECH_LEVEL_1 Hormone replacement 58-18-4 17-METHYLTESTOSTERONE INDICATION Metastatic Breast Cancer 58-18-4 17-METHYLTESTOSTERONE TA_LEVEL_2 Steroid 58-18-4 17-METHYLTESTOSTERONE STRUCTURE_ACTIVITY Androgen receptor agonist 58-18-4 17-METHYLTESTOSTERONE ZERO_CLASS N 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT END_2_Hypercholesteremia 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT LIV_2_Jaundice 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT XXX_2_Weight Gain 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT LIV_2_Hepatitis 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT PSY_2_Depression 58-18-4 17-METHYLTESTOSTERONE THERAPEUTIC_CLASS Gonadal Hormones 58-18-4 17-METHYLTESTOSTERONE MODE_CLASS Receptor Agonist 58-18-4 17-METHYLTESTOSTERONE MECH_LEVEL_2 Androgen receptor agonist 58-18-4 17-METHYLTESTOSTERONE MESH_LEVEL_2 Steroids 58-18-4 17-METHYLTESTOSTERONE INDICATION Cryptorchidism 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT XXX_1_Feminization 58-18-4 17-METHYLTESTOSTERONE INDICATION Impotence 58-18-4 17-METHYLTESTOSTERONE MECHANISM Modulate gene transcription 58-18-4 17-METHYLTESTOSTERONE KNOWN_TOXICITY Carcinogenicity 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT END_2_Gynecomastia 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT REP_2_Decreased Libido 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT DNA_2_Carcinoma of Prostate 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 58-18-4 17-METHYLTESTOSTERONE MESH_LEVEL_1 Polycyclic Hydrocarbons 58-18-4 17-METHYLTESTOSTERONE MECH_LEVEL_3 androgen receptor 58-18-4 17-METHYLTESTOSTERONE MESH_LEVEL_3 Androstanes 58-18-4 17-METHYLTESTOSTERONE PRODUCT_CLASS Anti-cancers 58-18-4 17-METHYLTESTOSTERONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 58-18-4 17-METHYLTESTOSTERONE INDICATION Delayed Puberty 58-18-4 17-METHYLTESTOSTERONE TISSUE_TOXICITY Carcinoma of Prostate 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT ELT_2_Hypercalcemia 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT REP_2_Amenorrhea 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT SKN_2_Acne 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT REP_3_Priapism 58-18-4 17-METHYLTESTOSTERONE ADVERSE_EFFECT REP_2_Oligomenorrhea 129-49-7 METHYSERGIDE ADVERSE_EFFECT SKN_3_Skin Rash 129-49-7 METHYSERGIDE ADVERSE_EFFECT XXX_3_Fever 129-49-7 METHYSERGIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 129-49-7 METHYSERGIDE KNOWN_TOXICITY Cardiovascular Toxicity 129-49-7 METHYSERGIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 129-49-7 METHYSERGIDE THERAPEUTIC_CLASS Antimigraines 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Myocardial Infarction 129-49-7 METHYSERGIDE ADVERSE_EFFECT PSY_3_CNS Stimulation 129-49-7 METHYSERGIDE ADVERSE_EFFECT NEU_3_Hyperesthesia 129-49-7 METHYSERGIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 129-49-7 METHYSERGIDE ADVERSE_EFFECT MSK_3_Myalgia 129-49-7 METHYSERGIDE ADVERSE_EFFECT XXX_3_Peripheral Edema 129-49-7 METHYSERGIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 129-49-7 METHYSERGIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 129-49-7 METHYSERGIDE TISSUE_TOXICITY Myocardial Infarction 129-49-7 METHYSERGIDE INDICATION Narcolepsy 129-49-7 METHYSERGIDE INDICATION Migraine Prophylaxis 129-49-7 METHYSERGIDE STRUCTURE_ACTIVITY 5HT2 antagonist 129-49-7 METHYSERGIDE ADVERSE_EFFECT GIS_3_Diarrhea 129-49-7 METHYSERGIDE ADVERSE_EFFECT IMU_3_Eosinophilia 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Chest Pain 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Phlebitis 129-49-7 METHYSERGIDE ADVERSE_EFFECT PSY_3_Euphoria 129-49-7 METHYSERGIDE ADVERSE_EFFECT NEU_3_Drowsiness 129-49-7 METHYSERGIDE ADVERSE_EFFECT SKN_3_Flushing 129-49-7 METHYSERGIDE ADVERSE_EFFECT PSY_3_Insomnia 129-49-7 METHYSERGIDE ADVERSE_EFFECT XXX_3_Hypothermia 129-49-7 METHYSERGIDE ADVERSE_EFFECT PSY_3_CNS Depression 129-49-7 METHYSERGIDE MODE_CLASS Receptor Ligand Antagonist, Non-selective 129-49-7 METHYSERGIDE INDICATION Carcinoid Syndrome 129-49-7 METHYSERGIDE TISSUE_TOXICITY Angina 129-49-7 METHYSERGIDE THERAPEUTIC_CLASS Central Stimulants 129-49-7 METHYSERGIDE ADVERSE_EFFECT OCU_3_Mydriasis 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Angina 129-49-7 METHYSERGIDE ADVERSE_EFFECT NEU_3_Dizziness 129-49-7 METHYSERGIDE ADVERSE_EFFECT PSY_3_Confusion 129-49-7 METHYSERGIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 129-49-7 METHYSERGIDE ADVERSE_EFFECT BBM_3_Neutropenia 129-49-7 METHYSERGIDE ADVERSE_EFFECT GIS_1_Heartburn 129-49-7 METHYSERGIDE ADVERSE_EFFECT XXX_2_Asthenia 129-49-7 METHYSERGIDE ADVERSE_EFFECT GIS_3_Constipation 129-49-7 METHYSERGIDE PRODUCT_CLASS Central Nervous System (CNS) 129-49-7 METHYSERGIDE MECHANISM Modulate G-protein coupled signal transduction 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Hypertension 129-49-7 METHYSERGIDE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 129-49-7 METHYSERGIDE ADVERSE_EFFECT NEU_2_Headache 129-49-7 METHYSERGIDE ADVERSE_EFFECT NEU_3_Ataxia 129-49-7 METHYSERGIDE ADVERSE_EFFECT MSK_2_Arthralgia 129-49-7 METHYSERGIDE ADVERSE_EFFECT PSY_3_Mental Confusion 129-49-7 METHYSERGIDE ADVERSE_EFFECT GIS_1_Dyspepsia 22664-55-7 METIPRANOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 22664-55-7 METIPRANOLOL INDICATION Increased Intraocular Pressure 22664-55-7 METIPRANOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 22664-55-7 METIPRANOLOL INDICATION Open-Angle Glaucoma 22664-55-7 METIPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 22664-55-7 METIPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 364-62-5 METOCLOPRAMIDE INDICATION Nausea / Vomiting 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT XXX_2_Mastalgia 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Galactorrhea 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Infertility 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_3_Urinary Incontinence 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Supraventricular Tachycardia 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Fatigue 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Depression 364-62-5 METOCLOPRAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 364-62-5 METOCLOPRAMIDE TISSUE_TOXICITY Congestive Heart Failure 364-62-5 METOCLOPRAMIDE MECH_LEVEL_2 5HT antagonist 364-62-5 METOCLOPRAMIDE INDICATION Gastroesophageal Reflux Disease (GERD) 364-62-5 METOCLOPRAMIDE TA_LEVEL_3 Antiemetic 364-62-5 METOCLOPRAMIDE INDICATION Induction of Lactation 364-62-5 METOCLOPRAMIDE MECH_LEVEL_3 5HT receptor 4 364-62-5 METOCLOPRAMIDE ZERO_CLASS N 364-62-5 METOCLOPRAMIDE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 364-62-5 METOCLOPRAMIDE MESH_LEVEL_1 Organic Chemicals 364-62-5 METOCLOPRAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 364-62-5 METOCLOPRAMIDE MESH_LEVEL_2 Amides 364-62-5 METOCLOPRAMIDE TA_LEVEL_1 Central Nervous System (CNS) 364-62-5 METOCLOPRAMIDE MESH_LEVEL_3 Benzamides 364-62-5 METOCLOPRAMIDE MODE_CLASS Channel Modulator 364-62-5 METOCLOPRAMIDE INDICATION Facilitate Small Bowel Intubation 364-62-5 METOCLOPRAMIDE TISSUE_TOXICITY Tardive Dyskinesia 364-62-5 METOCLOPRAMIDE KNOWN_TOXICITY Mental Health Disorders 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Headache 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Confusion 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT LIV_3_Jaundice 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 364-62-5 METOCLOPRAMIDE MECHANISM Modulate G-protein coupled signal transduction 364-62-5 METOCLOPRAMIDE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 364-62-5 METOCLOPRAMIDE THERAPEUTIC_CLASS Antiemetics 364-62-5 METOCLOPRAMIDE TA_LEVEL_2 CNS Depressant 364-62-5 METOCLOPRAMIDE MECH_LEVEL_1 Modulate neural transmission 364-62-5 METOCLOPRAMIDE INDICATION Gastrointestinal Radiography 364-62-5 METOCLOPRAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Nausea 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Impotence 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Menstrual Irregularities 364-62-5 METOCLOPRAMIDE MECHANISM Modulate neural transmission 364-62-5 METOCLOPRAMIDE INDICATION Hiccups / Singultus 364-62-5 METOCLOPRAMIDE INDICATION Diabetic Gastric Stasis 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 364-62-5 METOCLOPRAMIDE TISSUE_TOXICITY Supraventricular Tachycardia 364-62-5 METOCLOPRAMIDE THERAPEUTIC_CLASS Pituitary Hormones 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Insomnia 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Lassitude 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 364-62-5 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Hyperprolactinemia 364-62-5 METOCLOPRAMIDE PRODUCT_CLASS Gastrointestinal System 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT LIV_3_Jaundice 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Confusion 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Headache 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 54143-57-6 METOCLOPRAMIDE KNOWN_TOXICITY Mental Health Disorders 54143-57-6 METOCLOPRAMIDE TISSUE_TOXICITY Tardive Dyskinesia 54143-57-6 METOCLOPRAMIDE INDICATION Facilitate Small Bowel Intubation 54143-57-6 METOCLOPRAMIDE MODE_CLASS Channel Modulator 54143-57-6 METOCLOPRAMIDE MESH_LEVEL_3 Benzamides 54143-57-6 METOCLOPRAMIDE TA_LEVEL_1 Central Nervous System (CNS) 54143-57-6 METOCLOPRAMIDE MESH_LEVEL_2 Amides 54143-57-6 METOCLOPRAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 54143-57-6 METOCLOPRAMIDE MESH_LEVEL_1 Organic Chemicals 54143-57-6 METOCLOPRAMIDE INDICATION Gastroesophageal Reflux Disease (GERD) 54143-57-6 METOCLOPRAMIDE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 54143-57-6 METOCLOPRAMIDE INDICATION Nausea / Vomiting 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT XXX_2_Mastalgia 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Galactorrhea 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Infertility 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT NEU_3_Urinary Incontinence 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Supraventricular Tachycardia 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Fatigue 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Depression 54143-57-6 METOCLOPRAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 54143-57-6 METOCLOPRAMIDE TISSUE_TOXICITY Congestive Heart Failure 54143-57-6 METOCLOPRAMIDE MECH_LEVEL_2 5HT antagonist 54143-57-6 METOCLOPRAMIDE TA_LEVEL_3 Antiemetic 54143-57-6 METOCLOPRAMIDE INDICATION Induction of Lactation 54143-57-6 METOCLOPRAMIDE MECH_LEVEL_3 5HT receptor 4 54143-57-6 METOCLOPRAMIDE ZERO_CLASS N 54143-57-6 METOCLOPRAMIDE PRODUCT_CLASS Gastrointestinal System 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Hyperprolactinemia 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Lassitude 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Insomnia 54143-57-6 METOCLOPRAMIDE THERAPEUTIC_CLASS Pituitary Hormones 54143-57-6 METOCLOPRAMIDE TISSUE_TOXICITY Supraventricular Tachycardia 54143-57-6 METOCLOPRAMIDE INDICATION Diabetic Gastric Stasis 54143-57-6 METOCLOPRAMIDE INDICATION Hiccups / Singultus 54143-57-6 METOCLOPRAMIDE MECHANISM Modulate neural transmission 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Menstrual Irregularities 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Impotence 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Nausea 54143-57-6 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 54143-57-6 METOCLOPRAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 54143-57-6 METOCLOPRAMIDE INDICATION Gastrointestinal Radiography 54143-57-6 METOCLOPRAMIDE MECH_LEVEL_1 Modulate neural transmission 54143-57-6 METOCLOPRAMIDE TA_LEVEL_2 CNS Depressant 54143-57-6 METOCLOPRAMIDE THERAPEUTIC_CLASS Antiemetics 54143-57-6 METOCLOPRAMIDE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 54143-57-6 METOCLOPRAMIDE MECHANISM Modulate G-protein coupled signal transduction 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 5581-45-3 METOCLOPRAMIDE ZERO_CLASS N 5581-45-3 METOCLOPRAMIDE MECH_LEVEL_3 5HT receptor 4 5581-45-3 METOCLOPRAMIDE INDICATION Induction of Lactation 5581-45-3 METOCLOPRAMIDE TA_LEVEL_3 Antiemetic 5581-45-3 METOCLOPRAMIDE INDICATION Gastroesophageal Reflux Disease (GERD) 5581-45-3 METOCLOPRAMIDE MECH_LEVEL_2 5HT antagonist 5581-45-3 METOCLOPRAMIDE TISSUE_TOXICITY Congestive Heart Failure 5581-45-3 METOCLOPRAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Depression 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Fatigue 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Supraventricular Tachycardia 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT NEU_3_Urinary Incontinence 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Infertility 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Galactorrhea 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT XXX_2_Mastalgia 5581-45-3 METOCLOPRAMIDE INDICATION Nausea / Vomiting 5581-45-3 METOCLOPRAMIDE MESH_LEVEL_1 Organic Chemicals 5581-45-3 METOCLOPRAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 5581-45-3 METOCLOPRAMIDE MESH_LEVEL_2 Amides 5581-45-3 METOCLOPRAMIDE TA_LEVEL_1 Central Nervous System (CNS) 5581-45-3 METOCLOPRAMIDE MESH_LEVEL_3 Benzamides 5581-45-3 METOCLOPRAMIDE MODE_CLASS Channel Modulator 5581-45-3 METOCLOPRAMIDE INDICATION Facilitate Small Bowel Intubation 5581-45-3 METOCLOPRAMIDE TISSUE_TOXICITY Tardive Dyskinesia 5581-45-3 METOCLOPRAMIDE KNOWN_TOXICITY Mental Health Disorders 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Lassitude 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Headache 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Confusion 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT LIV_3_Jaundice 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 5581-45-3 METOCLOPRAMIDE MECHANISM Modulate G-protein coupled signal transduction 5581-45-3 METOCLOPRAMIDE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 5581-45-3 METOCLOPRAMIDE THERAPEUTIC_CLASS Antiemetics 5581-45-3 METOCLOPRAMIDE TA_LEVEL_2 CNS Depressant 5581-45-3 METOCLOPRAMIDE MECH_LEVEL_1 Modulate neural transmission 5581-45-3 METOCLOPRAMIDE INDICATION Gastrointestinal Radiography 5581-45-3 METOCLOPRAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Impotence 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Menstrual Irregularities 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Nausea 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 5581-45-3 METOCLOPRAMIDE MECHANISM Modulate neural transmission 5581-45-3 METOCLOPRAMIDE INDICATION Hiccups / Singultus 5581-45-3 METOCLOPRAMIDE INDICATION Diabetic Gastric Stasis 5581-45-3 METOCLOPRAMIDE TISSUE_TOXICITY Supraventricular Tachycardia 5581-45-3 METOCLOPRAMIDE THERAPEUTIC_CLASS Pituitary Hormones 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Insomnia 5581-45-3 METOCLOPRAMIDE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 5581-45-3 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Hyperprolactinemia 5581-45-3 METOCLOPRAMIDE PRODUCT_CLASS Gastrointestinal System 49625-23-2 METOCLOPRAMIDE ZERO_CLASS N 49625-23-2 METOCLOPRAMIDE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 49625-23-2 METOCLOPRAMIDE INDICATION Nausea / Vomiting 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT XXX_2_Mastalgia 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Galactorrhea 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Infertility 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT NEU_3_Urinary Incontinence 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Supraventricular Tachycardia 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Fatigue 49625-23-2 METOCLOPRAMIDE MECH_LEVEL_3 5HT receptor 4 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Depression 49625-23-2 METOCLOPRAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 49625-23-2 METOCLOPRAMIDE TISSUE_TOXICITY Congestive Heart Failure 49625-23-2 METOCLOPRAMIDE MECH_LEVEL_2 5HT antagonist 49625-23-2 METOCLOPRAMIDE INDICATION Gastroesophageal Reflux Disease (GERD) 49625-23-2 METOCLOPRAMIDE TA_LEVEL_3 Antiemetic 49625-23-2 METOCLOPRAMIDE INDICATION Induction of Lactation 49625-23-2 METOCLOPRAMIDE MESH_LEVEL_1 Organic Chemicals 49625-23-2 METOCLOPRAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 49625-23-2 METOCLOPRAMIDE MESH_LEVEL_2 Amides 49625-23-2 METOCLOPRAMIDE TA_LEVEL_1 Central Nervous System (CNS) 49625-23-2 METOCLOPRAMIDE MESH_LEVEL_3 Benzamides 49625-23-2 METOCLOPRAMIDE MODE_CLASS Channel Modulator 49625-23-2 METOCLOPRAMIDE INDICATION Facilitate Small Bowel Intubation 49625-23-2 METOCLOPRAMIDE TISSUE_TOXICITY Tardive Dyskinesia 49625-23-2 METOCLOPRAMIDE KNOWN_TOXICITY Mental Health Disorders 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Headache 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Confusion 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT LIV_3_Jaundice 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 49625-23-2 METOCLOPRAMIDE MECHANISM Modulate G-protein coupled signal transduction 49625-23-2 METOCLOPRAMIDE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 49625-23-2 METOCLOPRAMIDE THERAPEUTIC_CLASS Antiemetics 49625-23-2 METOCLOPRAMIDE TA_LEVEL_2 CNS Depressant 49625-23-2 METOCLOPRAMIDE MECH_LEVEL_1 Modulate neural transmission 49625-23-2 METOCLOPRAMIDE INDICATION Gastrointestinal Radiography 49625-23-2 METOCLOPRAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT GIS_1_Nausea 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Impotence 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT REP_2_Menstrual Irregularities 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 49625-23-2 METOCLOPRAMIDE MECHANISM Modulate neural transmission 49625-23-2 METOCLOPRAMIDE INDICATION Hiccups / Singultus 49625-23-2 METOCLOPRAMIDE INDICATION Diabetic Gastric Stasis 49625-23-2 METOCLOPRAMIDE TISSUE_TOXICITY Supraventricular Tachycardia 49625-23-2 METOCLOPRAMIDE THERAPEUTIC_CLASS Pituitary Hormones 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT PSY_2_Insomnia 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT XXX_1_Lassitude 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 49625-23-2 METOCLOPRAMIDE ADVERSE_EFFECT END_2_Hyperprolactinemia 49625-23-2 METOCLOPRAMIDE PRODUCT_CLASS Gastrointestinal System 7601-55-0 METOCURINE IODIDE MODE_CLASS Channel Blocker 7601-55-0 METOCURINE IODIDE MECHANISM Block neural transmission 17560-51-9 METOLAZONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 17560-51-9 METOLAZONE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 17560-51-9 METOLAZONE ADVERSE_EFFECT ELT_3_Hypochloremia 17560-51-9 METOLAZONE ADVERSE_EFFECT GIS_2_Abdominal Pain 17560-51-9 METOLAZONE ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 17560-51-9 METOLAZONE ADVERSE_EFFECT NEU_3_Vertigo 17560-51-9 METOLAZONE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 17560-51-9 METOLAZONE THERAPEUTIC_CLASS Diuretics 17560-51-9 METOLAZONE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 17560-51-9 METOLAZONE ADVERSE_EFFECT ELT_1_Hyponatremia 17560-51-9 METOLAZONE ADVERSE_EFFECT SKN_3_Rash 17560-51-9 METOLAZONE INDICATION Edema 17560-51-9 METOLAZONE PRODUCT_CLASS Cardiovasculars 17560-51-9 METOLAZONE ADVERSE_EFFECT GIS_3_Constipation 17560-51-9 METOLAZONE ADVERSE_EFFECT XXX_2_Lassitude 17560-51-9 METOLAZONE ADVERSE_EFFECT END_3_Hyperglycemia 17560-51-9 METOLAZONE ADVERSE_EFFECT PSY_3_Nervousness 17560-51-9 METOLAZONE ADVERSE_EFFECT XXX_2_Xerostomia 17560-51-9 METOLAZONE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 17560-51-9 METOLAZONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 17560-51-9 METOLAZONE ADVERSE_EFFECT OCU_3_Visual Impairment 17560-51-9 METOLAZONE MODE_CLASS Channel Blocker, selective 17560-51-9 METOLAZONE ADVERSE_EFFECT NEU_1_Lightheadedness 17560-51-9 METOLAZONE INDICATION Nephrotic Syndrome 17560-51-9 METOLAZONE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 17560-51-9 METOLAZONE THERAPEUTIC_CLASS Antihypertensive Agents 17560-51-9 METOLAZONE ADVERSE_EFFECT XXX_2_Lethargy 17560-51-9 METOLAZONE ADVERSE_EFFECT BBM_3_Agranulocytosis 17560-51-9 METOLAZONE ADVERSE_EFFECT NEU_1_Headache 17560-51-9 METOLAZONE ADVERSE_EFFECT XXX_2_Fatigue 17560-51-9 METOLAZONE ADVERSE_EFFECT PSY_2_Anorexia 17560-51-9 METOLAZONE ADVERSE_EFFECT OCU_3_Blurred Vision 17560-51-9 METOLAZONE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 17560-51-9 METOLAZONE ADVERSE_EFFECT XXX_2_Malaise 17560-51-9 METOLAZONE ADVERSE_EFFECT LIV_3_Jaundice 17560-51-9 METOLAZONE ADVERSE_EFFECT KID_2_Polyuria 17560-51-9 METOLAZONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 17560-51-9 METOLAZONE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 17560-51-9 METOLAZONE ADVERSE_EFFECT ELT_3_Hyperchloremic Metabolic Acidosis 17560-51-9 METOLAZONE ADVERSE_EFFECT NEU_3_Paresthesia 17560-51-9 METOLAZONE ADVERSE_EFFECT NEU_1_Dizziness 17560-51-9 METOLAZONE ADVERSE_EFFECT ELT_1_Hyperkalemia 17560-51-9 METOLAZONE ADVERSE_EFFECT PSY_3_Anxiety 17560-51-9 METOLAZONE ADVERSE_EFFECT PSY_3_Depression 17560-51-9 METOLAZONE ADVERSE_EFFECT END_3_Hypercholesteremia 17560-51-9 METOLAZONE ADVERSE_EFFECT GIS_3_Pancreatitis 17560-51-9 METOLAZONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 17560-51-9 METOLAZONE ADVERSE_EFFECT BBM_3_Leukopenia 17560-51-9 METOLAZONE ADVERSE_EFFECT IMU_3_Urticaria 17560-51-9 METOLAZONE INDICATION Heart Failure 17560-51-9 METOLAZONE INDICATION Hypertension 17560-51-9 METOLAZONE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 17560-51-9 METOLAZONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 17560-51-9 METOLAZONE ADVERSE_EFFECT ELT_2_Hypercalcemia 17560-51-9 METOLAZONE ADVERSE_EFFECT KID_3_Hyperuricemia 443-48-1 METRONIDAZOLE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 443-48-1 METRONIDAZOLE ADVERSE_EFFECT GIS_3_Pancreatitis 443-48-1 METRONIDAZOLE ADVERSE_EFFECT GUS_2_Discoloration of Urine 443-48-1 METRONIDAZOLE INDICATION Bacterial Vaginosis 443-48-1 METRONIDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 443-48-1 METRONIDAZOLE THERAPEUTIC_CLASS Antibacterials, Systemic 443-48-1 METRONIDAZOLE ADVERSE_EFFECT GIS_1_Vomiting 443-48-1 METRONIDAZOLE ADVERSE_EFFECT NEU_3_Ataxia 443-48-1 METRONIDAZOLE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 443-48-1 METRONIDAZOLE ADVERSE_EFFECT SKN_2_Skin Rash 443-48-1 METRONIDAZOLE ADVERSE_EFFECT GIS_2_Furred Tongue 443-48-1 METRONIDAZOLE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, antiparasitic 443-48-1 METRONIDAZOLE ACTIVITY_CLASS DNA damager 443-48-1 METRONIDAZOLE INDICATION Prophylaxis of Amebiasis 443-48-1 METRONIDAZOLE MESH_LEVEL_3 Imidazoles 443-48-1 METRONIDAZOLE TA_LEVEL_3 antiparasitic imidazoles 443-48-1 METRONIDAZOLE INDICATION Dental Infection 443-48-1 METRONIDAZOLE THERAPEUTIC_CLASS Antiparasitics 443-48-1 METRONIDAZOLE ADVERSE_EFFECT GIS_1_Nausea 443-48-1 METRONIDAZOLE TA_LEVEL_1 Infectious Disease 443-48-1 METRONIDAZOLE ADVERSE_EFFECT NEU_3_Seizures 443-48-1 METRONIDAZOLE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 443-48-1 METRONIDAZOLE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 443-48-1 METRONIDAZOLE ZERO_CLASS N 443-48-1 METRONIDAZOLE INDICATION Giardiasis 443-48-1 METRONIDAZOLE MECH_LEVEL_3 Unknown mechanism 443-48-1 METRONIDAZOLE INDICATION Necrotizing Ulcerative Gingivitis (Trench Mouth, Vincent's Infection) 443-48-1 METRONIDAZOLE MECH_LEVEL_1 Antiprotozoal/antibacterial 443-48-1 METRONIDAZOLE INDICATION Anaerobic Infections 443-48-1 METRONIDAZOLE PRODUCT_CLASS Anti-infectives 443-48-1 METRONIDAZOLE ADVERSE_EFFECT PSY_1_Anorexia 443-48-1 METRONIDAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 443-48-1 METRONIDAZOLE ADVERSE_EFFECT BBM_3_Thrombocytopenia 443-48-1 METRONIDAZOLE ADVERSE_EFFECT BBM_3_Pancytopenia 443-48-1 METRONIDAZOLE ADVERSE_EFFECT GIS_1_Metallic Taste 443-48-1 METRONIDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 443-48-1 METRONIDAZOLE INDICATION Trichomoniasis 443-48-1 METRONIDAZOLE ADVERSE_EFFECT IMU_3_Anaphylaxis 443-48-1 METRONIDAZOLE INDICATION Amebiasis 672-87-7 METYROSINE ADVERSE_EFFECT NEU_3_Pseudo-Parkinsonism 672-87-7 METYROSINE ADVERSE_EFFECT PSY_3_Anxiety 672-87-7 METYROSINE ADVERSE_EFFECT NEU_2_Slurred Speech 672-87-7 METYROSINE ADVERSE_EFFECT BBM_3_Hematotoxicity 672-87-7 METYROSINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 672-87-7 METYROSINE ADVERSE_EFFECT GIS_1_Hypersalivation 672-87-7 METYROSINE INDICATION Pheochromocytoma 672-87-7 METYROSINE MODE_CLASS Enzyme Inhibitor 672-87-7 METYROSINE ADVERSE_EFFECT GIS_1_Dry Mouth 672-87-7 METYROSINE ADVERSE_EFFECT NEU_1_Drowsiness 672-87-7 METYROSINE ADVERSE_EFFECT XXX_3_Peripheral Edema 672-87-7 METYROSINE ADVERSE_EFFECT REP_3_Ejaculatory Disorder 672-87-7 METYROSINE ADVERSE_EFFECT PSY_2_Depression 672-87-7 METYROSINE ADVERSE_EFFECT REP_3_Impotence 672-87-7 METYROSINE ADVERSE_EFFECT IMU_3_Urticaria 672-87-7 METYROSINE ADVERSE_EFFECT END_3_Galactorrhea 672-87-7 METYROSINE MECHANISM Interferes with neural transmitter synthesis 672-87-7 METYROSINE PRODUCT_CLASS Autonomic Nervous System (ANS) 672-87-7 METYROSINE THERAPEUTIC_CLASS Sympatholytic Agents 672-87-7 METYROSINE ADVERSE_EFFECT GIS_1_Diarrhea 672-87-7 METYROSINE ADVERSE_EFFECT NEU_2_Tremor 672-87-7 METYROSINE ADVERSE_EFFECT PSY_3_Confusion 672-87-7 METYROSINE ADVERSE_EFFECT KID_2_Crystalluria 5370-01-4 MEXILETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 5370-01-4 MEXILETINE INDICATION Neuropathic Pain 5370-01-4 MEXILETINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 5370-01-4 MEXILETINE MECH_LEVEL_1 Modulates channel gating 5370-01-4 MEXILETINE ACTIVITY_CLASS Na+ channel blocker 5370-01-4 MEXILETINE ADVERSE_EFFECT XXX_3_Edema 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_1_Tremor 5370-01-4 MEXILETINE ADVERSE_EFFECT OCU_3_Blurred Vision 5370-01-4 MEXILETINE ADVERSE_EFFECT GIS_1_Dysphagia 5370-01-4 MEXILETINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 5370-01-4 MEXILETINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_3_Seizures 5370-01-4 MEXILETINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 5370-01-4 MEXILETINE TISSUE_TOXICITY Arrhythmia 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_3_Amnesia 5370-01-4 MEXILETINE ADVERSE_EFFECT SKN_3_Rash 5370-01-4 MEXILETINE TISSUE_TOXICITY Congestive Heart Failure 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_1_Lightheadedness 5370-01-4 MEXILETINE TA_LEVEL_1 Cardiovascular 5370-01-4 MEXILETINE MESH_LEVEL_2 Amines 5370-01-4 MEXILETINE MECH_LEVEL_2 Modulates channel conductance 5370-01-4 MEXILETINE PRODUCT_CLASS Cardiovasculars 5370-01-4 MEXILETINE INDICATION Diabetic Neuropathy 5370-01-4 MEXILETINE MECHANISM Modulate channel gating 5370-01-4 MEXILETINE ZERO_CLASS N 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_3_Paresthesia 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_1_Dizziness 5370-01-4 MEXILETINE ADVERSE_EFFECT PSY_3_Nervousness 5370-01-4 MEXILETINE ADVERSE_EFFECT GUS_3_Urinary Retention 5370-01-4 MEXILETINE ADVERSE_EFFECT CVS_3_First-Degree AV block 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_3_Syncope 5370-01-4 MEXILETINE ADVERSE_EFFECT BBM_3_Leukopenia 5370-01-4 MEXILETINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 5370-01-4 MEXILETINE PRODUCT_CLASS Analgesics 5370-01-4 MEXILETINE MESH_LEVEL_1 Organic Chemicals 5370-01-4 MEXILETINE MECH_LEVEL_3 AMPA Glutamate receptor 5370-01-4 MEXILETINE TISSUE_TOXICITY Ventricular Arrhythmia 5370-01-4 MEXILETINE MESH_LEVEL_3 Propylamines 5370-01-4 MEXILETINE TISSUE_TOXICITY First-Degree AV block 5370-01-4 MEXILETINE ADVERSE_EFFECT CVS_3_Bradycardia 5370-01-4 MEXILETINE ADVERSE_EFFECT PSY_3_Hallucinations 5370-01-4 MEXILETINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 5370-01-4 MEXILETINE ADVERSE_EFFECT BBM_3_Agranulocytosis 5370-01-4 MEXILETINE MODE_CLASS Channel enhancer /opener 5370-01-4 MEXILETINE ADVERSE_EFFECT END_3_Hot Flashes 5370-01-4 MEXILETINE ADVERSE_EFFECT GIS_1_Dyspepsia 5370-01-4 MEXILETINE ADVERSE_EFFECT REP_3_Decreased Libido 5370-01-4 MEXILETINE ADVERSE_EFFECT NEU_1_Ataxia 5370-01-4 MEXILETINE INDICATION Cardiac Arrhythmias 5370-01-4 MEXILETINE TA_LEVEL_3 Antiarrhythmic Agents 5370-01-4 MEXILETINE INDICATION Ventricular Tachycardia 5370-01-4 MEXILETINE MECHANISM Prolong/enhance neural transmission 5370-01-4 MEXILETINE ADVERSE_EFFECT XXX_3_Diaphoresis 5370-01-4 MEXILETINE ADVERSE_EFFECT CVS_3_Arrhythmia 5370-01-4 MEXILETINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 5370-01-4 MEXILETINE THERAPEUTIC_CLASS Antiarrhythmic Agents 5370-01-4 MEXILETINE KNOWN_TOXICITY Cardiovascular Toxicity 5370-01-4 MEXILETINE MODE_CLASS Channel Modulator 51481-65-3 MEZLOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 51481-65-3 MEZLOCILLIN PRODUCT_CLASS Anti-infectives 51481-65-3 MEZLOCILLIN THERAPEUTIC_CLASS Antibacterials 51481-65-3 MEZLOCILLIN MODE_CLASS Enzyme Inhibitor 42057-22-7 MEZLOCILLIN THERAPEUTIC_CLASS Antibacterials 42057-22-7 MEZLOCILLIN MODE_CLASS Enzyme Inhibitor 42057-22-7 MEZLOCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 42057-22-7 MEZLOCILLIN PRODUCT_CLASS Anti-infectives 24219-97-4 MIANSERIN INDICATION Obsessive-Compulsive Disorder (OCD) 24219-97-4 MIANSERIN ADVERSE_EFFECT MSK_3_Skeletal Muscle Tremor 24219-97-4 MIANSERIN ADVERSE_EFFECT NEU_3_Convulsions 24219-97-4 MIANSERIN ADVERSE_EFFECT CVS_3_Cardiac Insufficiency 24219-97-4 MIANSERIN ADVERSE_EFFECT PSY_3_Mania 24219-97-4 MIANSERIN ADVERSE_EFFECT MSK_3_Arthritis 24219-97-4 MIANSERIN ADVERSE_EFFECT BBM_3_Neutropenia 24219-97-4 MIANSERIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 24219-97-4 MIANSERIN ADVERSE_EFFECT BBM_3_Anemia 24219-97-4 MIANSERIN ADVERSE_EFFECT END_3_Hyperglycemia 24219-97-4 MIANSERIN THERAPEUTIC_CLASS Antidepressants 24219-97-4 MIANSERIN TISSUE_TOXICITY Arrhythmia 24219-97-4 MIANSERIN TA_LEVEL_3 Depression 24219-97-4 MIANSERIN MECH_LEVEL_3 histamine receptor H1 24219-97-4 MIANSERIN MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 24219-97-4 MIANSERIN INDICATION Depression 24219-97-4 MIANSERIN TA_LEVEL_2 Anti-depressant 24219-97-4 MIANSERIN TA_LEVEL_1 Central Nervous System (CNS) 24219-97-4 MIANSERIN STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 24219-97-4 MIANSERIN ACTIVITY_CLASS Histamine antagonist 24219-97-4 MIANSERIN TISSUE_TOXICITY Cardiac Insufficiency 24219-97-4 MIANSERIN INDICATION Anxiety 24219-97-4 MIANSERIN ADVERSE_EFFECT NEU_3_Tremor 24219-97-4 MIANSERIN ADVERSE_EFFECT BBM_3_Agranulocytosis 24219-97-4 MIANSERIN ADVERSE_EFFECT GIS_3_Constipation 24219-97-4 MIANSERIN ADVERSE_EFFECT GIS_3_Stomatitis 24219-97-4 MIANSERIN ADVERSE_EFFECT BBM_3_Aplastic Anemia 24219-97-4 MIANSERIN ADVERSE_EFFECT SKN_3_Erythema 24219-97-4 MIANSERIN ADVERSE_EFFECT NEU_1_Drowsiness 24219-97-4 MIANSERIN ADVERSE_EFFECT NEU_1_Headache 24219-97-4 MIANSERIN ZERO_CLASS N 24219-97-4 MIANSERIN ADVERSE_EFFECT CVS_3_Hypotension 24219-97-4 MIANSERIN ADVERSE_EFFECT IMU_3_Angioneurotic Edema 24219-97-4 MIANSERIN ADVERSE_EFFECT XXX_3_Asthenia 24219-97-4 MIANSERIN ADVERSE_EFFECT MSK_3_Nongouty Polyarthralgia 24219-97-4 MIANSERIN ADVERSE_EFFECT MSK_3_Arthralgia 24219-97-4 MIANSERIN ADVERSE_EFFECT NEU_3_Coma 24219-97-4 MIANSERIN ADVERSE_EFFECT NEU_1_Dizziness 24219-97-4 MIANSERIN ADVERSE_EFFECT GIS_3_Nausea 24219-97-4 MIANSERIN ADVERSE_EFFECT CVS_3_Arrhythmia 24219-97-4 MIANSERIN ADVERSE_EFFECT LIV_3_Cholestasis 24219-97-4 MIANSERIN KNOWN_TOXICITY Cardiovascular Toxicity 24219-97-4 MIANSERIN TISSUE_TOXICITY First-Degree AV block 24219-97-4 MIANSERIN MODE_CLASS Receptor Ligand Antagonist 24219-97-4 MIANSERIN MESH_LEVEL_3 Dibenzazepines 24219-97-4 MIANSERIN MECH_LEVEL_2 Anti-histamine 24219-97-4 MIANSERIN MECH_LEVEL_1 Modulate neural transmission 24219-97-4 MIANSERIN MESH_LEVEL_1 Heterocyclic Compounds 24219-97-4 MIANSERIN PRODUCT_CLASS Central Nervous System (CNS) 24219-97-4 MIANSERIN MECHANISM Modulate G-protein coupled signal transduction 24219-97-4 MIANSERIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 24219-97-4 MIANSERIN ADVERSE_EFFECT PSY_1_Confusion 24219-97-4 MIANSERIN ADVERSE_EFFECT XXX_3_Edema 24219-97-4 MIANSERIN ADVERSE_EFFECT GIS_3_Vomiting 24219-97-4 MIANSERIN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 24219-97-4 MIANSERIN TISSUE_TOXICITY Hypotension 24219-97-4 MIANSERIN ADVERSE_EFFECT LUN_3_Pneumonia 24219-97-4 MIANSERIN ADVERSE_EFFECT CVS_3_First-Degree AV block 24219-97-4 MIANSERIN ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 116666-63-8 MIBEFRADIL MECHANISM Reduce muscle contractile force 116666-63-8 MIBEFRADIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 116666-63-8 MIBEFRADIL ADVERSE_EFFECT END_2_Gynecomastia 116666-63-8 MIBEFRADIL ADVERSE_EFFECT XXX_2_Rhinitis 116666-63-8 MIBEFRADIL INDICATION Hypertension 116666-63-8 MIBEFRADIL INDICATION Chronic Stable Angina 116666-63-8 MIBEFRADIL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 116666-63-8 MIBEFRADIL ADVERSE_EFFECT NEU_1_Dizziness 116666-63-8 MIBEFRADIL ADVERSE_EFFECT GIS_2_Dyspepsia 116666-63-8 MIBEFRADIL THERAPEUTIC_CLASS Antianginals 116666-63-8 MIBEFRADIL TISSUE_TOXICITY First-Degree AV block 116666-63-8 MIBEFRADIL MECHANISM Block channel gating 116666-63-8 MIBEFRADIL MODE_CLASS Channel Blocker, selective 116666-63-8 MIBEFRADIL THERAPEUTIC_CLASS Antihypertensive Agents 116666-63-8 MIBEFRADIL ADVERSE_EFFECT NEU_2_Headache 116666-63-8 MIBEFRADIL ADVERSE_EFFECT GIS_2_Abdominal Pain 116666-63-8 MIBEFRADIL STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 116666-63-8 MIBEFRADIL MODE_CLASS Channel Blocker 116666-63-8 MIBEFRADIL KNOWN_TOXICITY Cardiovascular Toxicity 116666-63-8 MIBEFRADIL ADVERSE_EFFECT SKN_2_Flushing 116666-63-8 MIBEFRADIL ADVERSE_EFFECT XXX_2_Peripheral Edema 116666-63-8 MIBEFRADIL ADVERSE_EFFECT CVS_2_First-Degree AV block 116666-63-8 MIBEFRADIL PRODUCT_CLASS Cardiovasculars 121039-16-5 MIBEFRADIL MECHANISM Block channel gating 121039-16-5 MIBEFRADIL ADVERSE_EFFECT SKN_2_Flushing 121039-16-5 MIBEFRADIL INDICATION Hypertension 121039-16-5 MIBEFRADIL MECHANISM Reduce muscle contractile force 121039-16-5 MIBEFRADIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 121039-16-5 MIBEFRADIL ADVERSE_EFFECT END_2_Gynecomastia 121039-16-5 MIBEFRADIL ADVERSE_EFFECT XXX_2_Rhinitis 121039-16-5 MIBEFRADIL PRODUCT_CLASS Cardiovasculars 121039-16-5 MIBEFRADIL INDICATION Chronic Stable Angina 121039-16-5 MIBEFRADIL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 121039-16-5 MIBEFRADIL ADVERSE_EFFECT NEU_1_Dizziness 121039-16-5 MIBEFRADIL ADVERSE_EFFECT GIS_2_Dyspepsia 121039-16-5 MIBEFRADIL THERAPEUTIC_CLASS Antianginals 121039-16-5 MIBEFRADIL MODE_CLASS Channel Blocker, selective 121039-16-5 MIBEFRADIL THERAPEUTIC_CLASS Antihypertensive Agents 121039-16-5 MIBEFRADIL ADVERSE_EFFECT NEU_2_Headache 121039-16-5 MIBEFRADIL ADVERSE_EFFECT GIS_2_Abdominal Pain 121039-16-5 MIBEFRADIL STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 121039-16-5 MIBEFRADIL MODE_CLASS Channel Blocker 121039-16-5 MIBEFRADIL KNOWN_TOXICITY Cardiovascular Toxicity 121039-16-5 MIBEFRADIL ADVERSE_EFFECT XXX_2_Peripheral Edema 121039-16-5 MIBEFRADIL ADVERSE_EFFECT CVS_2_First-Degree AV block 121039-16-5 MIBEFRADIL TISSUE_TOXICITY First-Degree AV block 116644-53-2 MIBEFRADIL ADVERSE_EFFECT XXX_2_Peripheral Edema 116644-53-2 MIBEFRADIL INDICATION Chronic Stable Angina 116644-53-2 MIBEFRADIL PRODUCT_CLASS Cardiovasculars 116644-53-2 MIBEFRADIL ADVERSE_EFFECT XXX_2_Rhinitis 116644-53-2 MIBEFRADIL ADVERSE_EFFECT END_2_Gynecomastia 116644-53-2 MIBEFRADIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 116644-53-2 MIBEFRADIL INDICATION Hypertension 116644-53-2 MIBEFRADIL MECHANISM Reduce muscle contractile force 116644-53-2 MIBEFRADIL ADVERSE_EFFECT CVS_2_First-Degree AV block 116644-53-2 MIBEFRADIL TISSUE_TOXICITY First-Degree AV block 116644-53-2 MIBEFRADIL STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 116644-53-2 MIBEFRADIL ADVERSE_EFFECT GIS_2_Abdominal Pain 116644-53-2 MIBEFRADIL ADVERSE_EFFECT NEU_2_Headache 116644-53-2 MIBEFRADIL THERAPEUTIC_CLASS Antihypertensive Agents 116644-53-2 MIBEFRADIL MODE_CLASS Channel Blocker, selective 116644-53-2 MIBEFRADIL MECHANISM Block channel gating 116644-53-2 MIBEFRADIL THERAPEUTIC_CLASS Antianginals 116644-53-2 MIBEFRADIL ADVERSE_EFFECT GIS_2_Dyspepsia 116644-53-2 MIBEFRADIL ADVERSE_EFFECT NEU_1_Dizziness 116644-53-2 MIBEFRADIL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 116644-53-2 MIBEFRADIL MODE_CLASS Channel Blocker 116644-53-2 MIBEFRADIL KNOWN_TOXICITY Cardiovascular Toxicity 116644-53-2 MIBEFRADIL ADVERSE_EFFECT SKN_2_Flushing 59467-70-8 MIDAZOLAM KNOWN_TOXICITY Cardiovascular Toxicity 59467-70-8 MIDAZOLAM TISSUE_TOXICITY Ventricular Tachycardia 59467-70-8 MIDAZOLAM MODE_CLASS Channel enhancer /opener 59467-70-8 MIDAZOLAM INDICATION Induction / Maintenance of Anesthesia 59467-70-8 MIDAZOLAM INDICATION Agitation 59467-70-8 MIDAZOLAM TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 59467-70-8 MIDAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 59467-70-8 MIDAZOLAM ADVERSE_EFFECT LUN_1_Apnea 59467-70-8 MIDAZOLAM ADVERSE_EFFECT NEU_3_Involuntray Movements 59467-70-8 MIDAZOLAM ADVERSE_EFFECT PSY_3_Nightmares 59467-70-8 MIDAZOLAM ADVERSE_EFFECT LUN_3_Respiratory Arrest 59467-70-8 MIDAZOLAM ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 59467-70-8 MIDAZOLAM TISSUE_TOXICITY Respiratory Depression 59467-70-8 MIDAZOLAM INDICATION Anxiety 59467-70-8 MIDAZOLAM TISSUE_TOXICITY Cardiac Arrest 59467-70-8 MIDAZOLAM ADVERSE_EFFECT XXX_1_Injection Site Reaction 59467-70-8 MIDAZOLAM ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 59467-70-8 MIDAZOLAM ADVERSE_EFFECT LUN_3_Hypoxia 59467-70-8 MIDAZOLAM ADVERSE_EFFECT XXX_3_Tolerance 59467-70-8 MIDAZOLAM ADVERSE_EFFECT LUN_1_Respiratory Depression 59467-70-8 MIDAZOLAM INDICATION Status Epilepticus 59467-70-8 MIDAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 59467-70-8 MIDAZOLAM THERAPEUTIC_CLASS Anxiolytics 59467-70-8 MIDAZOLAM MECHANISM Modulate neural transmission 59467-70-8 MIDAZOLAM TISSUE_TOXICITY Hypotension 59467-70-8 MIDAZOLAM ADVERSE_EFFECT LUN_2_Laryngospasm 59467-70-8 MIDAZOLAM ADVERSE_EFFECT PSY_3_Agitation 59467-70-8 MIDAZOLAM ADVERSE_EFFECT PSY_3_Dependence 59467-70-8 MIDAZOLAM ADVERSE_EFFECT CVS_1_Hypotension 59467-70-8 MIDAZOLAM KNOWN_TOXICITY Respiratory Toxicity 59467-70-8 MIDAZOLAM INDICATION Induction of Amnesia 59467-70-8 MIDAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 59467-70-8 MIDAZOLAM INDICATION Initiation / Maintenance of Sedation 59467-70-8 MIDAZOLAM ADVERSE_EFFECT XXX_2_Hiccup 59467-70-8 MIDAZOLAM ADVERSE_EFFECT LUN_2_Airway Obstruction 59467-70-8 MIDAZOLAM ADVERSE_EFFECT XXX_3_Withdrawal 59467-70-8 MIDAZOLAM ADVERSE_EFFECT CVS_3_Cardiac Arrest 3092-17-9 MIDODRINE MODE_CLASS Receptor Agonist, selective 3092-17-9 MIDODRINE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 agonist, oxymetazoline 3092-17-9 MIDODRINE MECHANISM Increase vasoconstriction 72432-03-2 MIGLITOL MECHANISM Inhibit absorption of dietary carbohydrates 72432-03-2 MIGLITOL THERAPEUTIC_CLASS Antidiabetic Agents 72432-03-2 MIGLITOL MODE_CLASS Enzyme Inhibitor, selective 72432-03-2 MIGLITOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 72432-03-2 MIGLITOL INDICATION Diabetes 13614-98-7 MINOCYCLINE PRODUCT_CLASS Anti-infectives 13614-98-7 MINOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 13614-98-7 MINOCYCLINE THERAPEUTIC_CLASS Antibacterials 13614-98-7 MINOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 13614-98-7 MINOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 10118-90-8 MINOCYCLINE PRODUCT_CLASS Anti-infectives 10118-90-8 MINOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 10118-90-8 MINOCYCLINE THERAPEUTIC_CLASS Antibacterials 10118-90-8 MINOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 10118-90-8 MINOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 38304-91-5 MINOXIDIL ADVERSE_EFFECT IMU_2_Contact Dermatitis 38304-91-5 MINOXIDIL ADVERSE_EFFECT XXX_2_Edema 38304-91-5 MINOXIDIL ADVERSE_EFFECT CVS_2_Angina 38304-91-5 MINOXIDIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 38304-91-5 MINOXIDIL MESH_LEVEL_1 Heterocyclic Compounds 38304-91-5 MINOXIDIL THERAPEUTIC_CLASS Vasodilators 38304-91-5 MINOXIDIL INDICATION Alopecia / Baldness / Hair Loss 38304-91-5 MINOXIDIL ADVERSE_EFFECT SKN_2_Hypertrichosis 38304-91-5 MINOXIDIL ADVERSE_EFFECT SKN_2_Erythema 38304-91-5 MINOXIDIL ADVERSE_EFFECT SKN_2_Pruritis 38304-91-5 MINOXIDIL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 38304-91-5 MINOXIDIL TISSUE_TOXICITY Angina 38304-91-5 MINOXIDIL PRODUCT_CLASS Cardiovasculars 38304-91-5 MINOXIDIL MECH_LEVEL_2 Relax smooth muscle by selectively increasing the membrane permeability to K+ 38304-91-5 MINOXIDIL ZERO_CLASS N 38304-91-5 MINOXIDIL ADVERSE_EFFECT XXX_3_Mastalgia 38304-91-5 MINOXIDIL ADVERSE_EFFECT BBM_3_Thrombocytopenia 38304-91-5 MINOXIDIL ADVERSE_EFFECT KID_1_Salt Retention 38304-91-5 MINOXIDIL ADVERSE_EFFECT CVS_2_Pericardial Effusion 38304-91-5 MINOXIDIL ADVERSE_EFFECT CVS_2_Hypotension 38304-91-5 MINOXIDIL TISSUE_TOXICITY Congestive Heart Failure 38304-91-5 MINOXIDIL MODE_CLASS Channel enhancer /opener 38304-91-5 MINOXIDIL PRODUCT_CLASS Dermatologicals 38304-91-5 MINOXIDIL TA_LEVEL_3 Hair growth agent 38304-91-5 MINOXIDIL MECH_LEVEL_1 Vasorelaxation 38304-91-5 MINOXIDIL ADVERSE_EFFECT BBM_3_Neutropenia 38304-91-5 MINOXIDIL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 38304-91-5 MINOXIDIL ADVERSE_EFFECT NEU_2_Headache 38304-91-5 MINOXIDIL ADVERSE_EFFECT CVS_2_Sinus Tachycardia 38304-91-5 MINOXIDIL TISSUE_TOXICITY Hypotension 38304-91-5 MINOXIDIL MESH_LEVEL_3 Piperidines 38304-91-5 MINOXIDIL MECH_LEVEL_3 ATP-sensitive K+ channel SUR2 38304-91-5 MINOXIDIL MECHANISM Reduce muscle contractile force 38304-91-5 MINOXIDIL TA_LEVEL_1 Dermatology 38304-91-5 MINOXIDIL STRUCTURE_ACTIVITY K+ Channel (KATP-SUR2 ) opener 38304-91-5 MINOXIDIL THERAPEUTIC_CLASS Antihypertensive Agents 38304-91-5 MINOXIDIL ACTIVITY_CLASS K+ channel opener 38304-91-5 MINOXIDIL INDICATION Hypertension 38304-91-5 MINOXIDIL KNOWN_TOXICITY Cardiovascular Toxicity 38304-91-5 MINOXIDIL ADVERSE_EFFECT KID_1_Fluid Retention 61337-67-5 MIRTAZAPINE INDICATION Depression 61337-67-5 MIRTAZAPINE MECHANISM Block neural transmission 61337-67-5 MIRTAZAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 61337-67-5 MIRTAZAPINE MODE_CLASS Channel Blocker 61337-67-5 MIRTAZAPINE MECHANISM Modulate neural transmission 61337-67-5 MIRTAZAPINE MODE_CLASS Receptor Ligand Antagonist, Selective 61337-67-5 MIRTAZAPINE MECHANISM Modulate G-protein coupled signal transduction 61337-67-5 MIRTAZAPINE THERAPEUTIC_CLASS Antidepressants 61337-67-5 MIRTAZAPINE PRODUCT_CLASS Central Nervous System (CNS) 50-07-7 MITOMYCIN C TA_LEVEL_3 Solid Tumors 50-07-7 MITOMYCIN C STRUCTURE_ACTIVITY DNA-alkylator 50-07-7 MITOMYCIN C MECH_LEVEL_3 DNA damage 50-07-7 MITOMYCIN C MESH_LEVEL_1 Heterocyclic Compounds 50-07-7 MITOMYCIN C MESH_LEVEL_3 Azirines 50-07-7 MITOMYCIN C ADVERSE_EFFECT XXX_2_Hemolytic-Uremic Syndrome 50-07-7 MITOMYCIN C ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 50-07-7 MITOMYCIN C ADVERSE_EFFECT CVS_2_Phlebitis 50-07-7 MITOMYCIN C ADVERSE_EFFECT XXX_1_Infection 50-07-7 MITOMYCIN C ADVERSE_EFFECT PSY_1_Anorexia 50-07-7 MITOMYCIN C TISSUE_TOXICITY Renal Failure 50-07-7 MITOMYCIN C TISSUE_TOXICITY Myelosuppression 50-07-7 MITOMYCIN C THERAPEUTIC_CLASS Antineoplastics 50-07-7 MITOMYCIN C INDICATION Head and Neck Cancer 50-07-7 MITOMYCIN C INDICATION Metastatic / Recurrent Cervical Carcinoma 50-07-7 MITOMYCIN C MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 50-07-7 MITOMYCIN C MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 50-07-7 MITOMYCIN C ADVERSE_EFFECT LUN_3_Hemoptysis 50-07-7 MITOMYCIN C ADVERSE_EFFECT BBM_1_Myelosuppression 50-07-7 MITOMYCIN C ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 50-07-7 MITOMYCIN C INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 50-07-7 MITOMYCIN C ADVERSE_EFFECT GIS_1_Nausea / Vomiting 50-07-7 MITOMYCIN C TISSUE_TOXICITY Thrombocytopenia 50-07-7 MITOMYCIN C PRODUCT_CLASS Anti-cancers 50-07-7 MITOMYCIN C INDICATION Non-Small Cell Lung Carcinoma 50-07-7 MITOMYCIN C INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 50-07-7 MITOMYCIN C MECHANISM Inhibit DNA synthesis, repair, and function 50-07-7 MITOMYCIN C TA_LEVEL_2 DNA damage 50-07-7 MITOMYCIN C ACTIVITY_CLASS DNA damager 50-07-7 MITOMYCIN C KNOWN_TOXICITY Blood & Bone Marrow Toxicity 50-07-7 MITOMYCIN C ADVERSE_EFFECT KID_2_Renal Failure 50-07-7 MITOMYCIN C ADVERSE_EFFECT LUN_2_Pulmonary Toxicity 50-07-7 MITOMYCIN C ADVERSE_EFFECT BBM_1_Leukopenia 50-07-7 MITOMYCIN C ADVERSE_EFFECT NEU_2_Paresthesia 50-07-7 MITOMYCIN C TISSUE_TOXICITY Nephrotoxicity 50-07-7 MITOMYCIN C ADVERSE_EFFECT GIS_2_Stomatitis 50-07-7 MITOMYCIN C ADVERSE_EFFECT GIS_3_Hematemesis 50-07-7 MITOMYCIN C ADVERSE_EFFECT KID_2_Nephrotoxicity 50-07-7 MITOMYCIN C ADVERSE_EFFECT LUN_3_Bronchospasm 50-07-7 MITOMYCIN C MODE_CLASS Distorts /blocks macromolecular scaffold function 50-07-7 MITOMYCIN C TA_LEVEL_1 Oncology 50-07-7 MITOMYCIN C ADVERSE_EFFECT BBM_1_Thrombocytopenia 50-07-7 MITOMYCIN C INDICATION Metastatic Breast Cancer 50-07-7 MITOMYCIN C MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 50-07-7 MITOMYCIN C TISSUE_TOXICITY Leukopenia 50-07-7 MITOMYCIN C KNOWN_TOXICITY Nephrotoxicity 50-07-7 MITOMYCIN C ZERO_CLASS N 50-07-7 MITOMYCIN C INDICATION Metastatic Bladder Carcinoma 50-07-7 MITOMYCIN C INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 53-19-0 MITOTANE MECHANISM Inhibit steroid biosynthesis/ metabolism 53-19-0 MITOTANE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 53-19-0 MITOTANE MESH_LEVEL_2 Hydrocarbons 53-19-0 MITOTANE INDICATION Adrenal Cancer / Carcinoma of the Adrenal Gland 53-19-0 MITOTANE TISSUE_TOXICITY CNS Toxicity 53-19-0 MITOTANE THERAPEUTIC_CLASS Antineoplastics 53-19-0 MITOTANE ADVERSE_EFFECT NEU_3_Ataxia 53-19-0 MITOTANE ADVERSE_EFFECT SKN_2_Maculopapular Rash 53-19-0 MITOTANE ADVERSE_EFFECT BBM_3_Leukopenia 53-19-0 MITOTANE ADVERSE_EFFECT END_1_Adrenal Insufficiency 53-19-0 MITOTANE ADVERSE_EFFECT GUS_3_Hemorrhagic Cystitis 53-19-0 MITOTANE ADVERSE_EFFECT CVS_3_Hypotensive Shock 53-19-0 MITOTANE ADVERSE_EFFECT PSY_3_Hallucinations 53-19-0 MITOTANE ADVERSE_EFFECT NEU_3_Encephalopathy 53-19-0 MITOTANE KNOWN_TOXICITY Mental Health Disorders 53-19-0 MITOTANE TA_LEVEL_1 Oncology 53-19-0 MITOTANE TISSUE_TOXICITY Hypotension 53-19-0 MITOTANE TA_LEVEL_2 DNA synthesis inhibitors 53-19-0 MITOTANE PRODUCT_CLASS Hormones, Endocrine and Metabolic 53-19-0 MITOTANE ADVERSE_EFFECT OCU_3_Diplopia 53-19-0 MITOTANE ADVERSE_EFFECT PSY_2_Mental Depression 53-19-0 MITOTANE ADVERSE_EFFECT PSY_1_CNS Toxicity 53-19-0 MITOTANE ADVERSE_EFFECT NEU_1_Somnolence 53-19-0 MITOTANE ADVERSE_EFFECT OCU_3_Blurred Vision 53-19-0 MITOTANE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 53-19-0 MITOTANE ADVERSE_EFFECT CVS_3_Hypotension 53-19-0 MITOTANE ADVERSE_EFFECT END_3_Gynecomastia 53-19-0 MITOTANE KNOWN_TOXICITY Cardiovascular Toxicity 53-19-0 MITOTANE ZERO_CLASS N 53-19-0 MITOTANE STRUCTURE_ACTIVITY Corticosterone 18-monooxygenase inhibitor, P-glycoprotein antagonist 53-19-0 MITOTANE MECH_LEVEL_3 Unknown mechanism 53-19-0 MITOTANE MODE_CLASS Enzyme Inhibitor 53-19-0 MITOTANE ADVERSE_EFFECT XXX_1_Lethargy 53-19-0 MITOTANE ADVERSE_EFFECT BBM_3_Thrombocytopenia 53-19-0 MITOTANE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 53-19-0 MITOTANE MESH_LEVEL_1 Organic Chemicals 53-19-0 MITOTANE INDICATION Cushing's Syndrome / Hypercortisolism 53-19-0 MITOTANE PRODUCT_CLASS Anti-cancers 53-19-0 MITOTANE MESH_LEVEL_3 Hydrocarbons, Halogenated 53-19-0 MITOTANE ADVERSE_EFFECT PSY_2_Confusion 53-19-0 MITOTANE ADVERSE_EFFECT PSY_3_Psychosis 53-19-0 MITOTANE ADVERSE_EFFECT OCU_2_Cataracts 53-19-0 MITOTANE ADVERSE_EFFECT NEU_3_Neuropathy 53-19-0 MITOTANE TISSUE_TOXICITY Hypotensive Shock 53-19-0 MITOTANE ADVERSE_EFFECT GIS_1_Diarrhea 53-19-0 MITOTANE ADVERSE_EFFECT PSY_1_Anorexia 53-19-0 MITOTANE ADVERSE_EFFECT IMU_3_Hypersensitivity 65271-80-9 MITOXANTRONE ADVERSE_EFFECT BBM_1_Myelosuppression 65271-80-9 MITOXANTRONE ADVERSE_EFFECT XXX_1_Mucositis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_2_Congestive Heart Failure 65271-80-9 MITOXANTRONE ADVERSE_EFFECT BBM_1_Pancytopenia 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Secondary Malignanacy 65271-80-9 MITOXANTRONE ACTIVITY_CLASS DNA damager 65271-80-9 MITOXANTRONE ADVERSE_EFFECT XXX_3_Tumor Lysis Syndrome 65271-80-9 MITOXANTRONE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 65271-80-9 MITOXANTRONE MECH_LEVEL_1 Intercalates into the miner groove of DNA 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Cardiomyopathy 65271-80-9 MITOXANTRONE MECH_LEVEL_3 DNA intercalator 65271-80-9 MITOXANTRONE TA_LEVEL_2 antineoplastic 65271-80-9 MITOXANTRONE TA_LEVEL_1 Oncology 65271-80-9 MITOXANTRONE MESH_LEVEL_2 Quinones 65271-80-9 MITOXANTRONE INDICATION Breast Cancer / Carcinoma of the Breast 65271-80-9 MITOXANTRONE KNOWN_TOXICITY Cardiovascular Toxicity 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GUS_1_Discoloration of Urine 65271-80-9 MITOXANTRONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_1_Phlebitis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Dyspepsia 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Stomatitis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT BBM_1_Thrombocytopenia 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Congestive Heart Failure 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Pancytopenia 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 65271-80-9 MITOXANTRONE MECH_LEVEL_2 interferes with the function of DNA topoisomerase II, as a result indirectly interferes with the function of DNA polymerase and DNA directed RNA polymerase. 65271-80-9 MITOXANTRONE ADVERSE_EFFECT XXX_2_Edema 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_2_Chest Pain 65271-80-9 MITOXANTRONE MECHANISM Inhibit DNA synthesis, repair, and function 65271-80-9 MITOXANTRONE STRUCTURE_ACTIVITY DNA intercalator 65271-80-9 MITOXANTRONE INDICATION Hepatocellular Carcinoma 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 65271-80-9 MITOXANTRONE INDICATION Prostatic Cancer / Carcinoma of the Prostate 65271-80-9 MITOXANTRONE TA_LEVEL_3 Acute Myelogenous (Myeloid) Leukemia (AML) 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Gastrointestinal Bleeding 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Thrombocytopenia 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Myelosuppression 65271-80-9 MITOXANTRONE KNOWN_TOXICITY Gastrointestinal Toxicity 65271-80-9 MITOXANTRONE ADVERSE_EFFECT DNA_3_Secondary Malignanacy 65271-80-9 MITOXANTRONE ADVERSE_EFFECT REP_3_Amenorrhea 65271-80-9 MITOXANTRONE ADVERSE_EFFECT SKN_2_Skin Ulcer 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Gastrointestinal Bleeding 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Abdominal Pain 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Esophagitis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT BBM_1_Anemia 65271-80-9 MITOXANTRONE ADVERSE_EFFECT BBM_1_Leukopenia 65271-80-9 MITOXANTRONE KNOWN_TOXICITY Carcinogenicity 65271-80-9 MITOXANTRONE ADVERSE_EFFECT XXX_2_Asthenia 65271-80-9 MITOXANTRONE ADVERSE_EFFECT REP__Impotence 65271-80-9 MITOXANTRONE ZERO_CLASS N 65271-80-9 MITOXANTRONE MESH_LEVEL_3 Anthraquinones 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Neutropenia 65271-80-9 MITOXANTRONE INDICATION Non-Hodgkin's Lymphomas 65271-80-9 MITOXANTRONE INDICATION Acute Non-Lymphocytic Leukemia 65271-80-9 MITOXANTRONE INDICATION Acute Lymphocytic Leukemia (ALL) 65271-80-9 MITOXANTRONE INDICATION Neoplasm / Cancer / Tumor 65271-80-9 MITOXANTRONE INDICATION Multiple Sclerosis (MS) 65271-80-9 MITOXANTRONE KNOWN_TOXICITY Hepatotoxicity 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Hepatotoxicity 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Anemia 65271-80-9 MITOXANTRONE TISSUE_TOXICITY Leukopenia 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_1_Decreased Left Ventricular Ejection Fraction (LVEF) 65271-80-9 MITOXANTRONE ADVERSE_EFFECT SKN_2_Skin Necrosis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_2_Constipation 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_1_Oral Ulceration 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_1_Cardiomyopathy 65271-80-9 MITOXANTRONE ADVERSE_EFFECT BBM_1_Neutropenia 65271-80-9 MITOXANTRONE ADVERSE_EFFECT XXX_2_Malaise 65271-80-9 MITOXANTRONE ADVERSE_EFFECT NEU_3_Seizures 65271-80-9 MITOXANTRONE ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 65271-80-9 MITOXANTRONE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 65271-80-9 MITOXANTRONE MESH_LEVEL_1 Organic Chemicals 65271-80-9 MITOXANTRONE INDICATION Ovarian Cancer / Carcinoma of the Ovary 65271-80-9 MITOXANTRONE PRODUCT_CLASS Anti-cancers 65271-80-9 MITOXANTRONE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 65271-80-9 MITOXANTRONE THERAPEUTIC_CLASS Antineoplastics 65271-80-9 MITOXANTRONE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 65271-80-9 MITOXANTRONE ADVERSE_EFFECT SKN_1_Nail Discoloration 65271-80-9 MITOXANTRONE ADVERSE_EFFECT SKN_2_Skin Rash 65271-80-9 MITOXANTRONE ADVERSE_EFFECT OCU_2_Conjunctivitis 65271-80-9 MITOXANTRONE ADVERSE_EFFECT GIS_2_Diarrhea 130112-42-4 YH-439 MODE_CLASS Enzyme Inhibitor, Non-selective 130112-42-4 YH-439 MECHANISM interferes with liver P450 enzyme funciton 108612-45-9 MIZOLASTINE INDICATION Viral Rhinitis / Common Cold 108612-45-9 MIZOLASTINE MECHANISM Modulate G-protein coupled signal transduction 108612-45-9 MIZOLASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 77086-22-7 (+)-MK 801 PRODUCT_CLASS Biochemicals 77086-22-7 (+)-MK 801 MODE_CLASS Channel Blocker 77086-22-7 (+)-MK 801 MECHANISM Block neural transmission 103775-10-6 MOEXIPRIL MODE_CLASS Enzyme Inhibitor 103775-10-6 MOEXIPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 103775-10-6 MOEXIPRIL THERAPEUTIC_CLASS Antihypertensive Agents 103775-10-6 MOEXIPRIL MECHANISM Reduce vasoconstriction 103775-10-6 MOEXIPRIL PRODUCT_CLASS Cardiovasculars 103775-10-6 MOEXIPRIL INDICATION Hypertension 82586-52-5 MOEXIPRIL PRODUCT_CLASS Cardiovasculars 82586-52-5 MOEXIPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 82586-52-5 MOEXIPRIL THERAPEUTIC_CLASS Antihypertensive Agents 82586-52-5 MOEXIPRIL INDICATION Hypertension 82586-52-5 MOEXIPRIL MODE_CLASS Enzyme Inhibitor 82586-52-5 MOEXIPRIL MECHANISM Reduce vasoconstriction 7416-34-4 MOLINDONE MECHANISM Modulate G-protein coupled signal transduction 7416-34-4 MOLINDONE MODE_CLASS Receptor Ligand Antagonist 15622-65-8 MOLINDONE MECHANISM Modulate G-protein coupled signal transduction 15622-65-8 MOLINDONE MODE_CLASS Receptor Ligand Antagonist 103-16-2 MONOBENZONE ADVERSE_EFFECT XXX_1_Burning Sensation 103-16-2 MONOBENZONE PRODUCT_CLASS Dermatologicals 103-16-2 MONOBENZONE ADVERSE_EFFECT SKN_2_Dermatitis 103-16-2 MONOBENZONE THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 103-16-2 MONOBENZONE INDICATION Vitiligo 103-16-2 MONOBENZONE ADVERSE_EFFECT PSY_1_Irritation 151767-02-1 MONTELUKAST ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 151767-02-1 MONTELUKAST ADVERSE_EFFECT MSK_3_Myalgia 151767-02-1 MONTELUKAST ADVERSE_EFFECT IMU_3_Eosinophilia 151767-02-1 MONTELUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 151767-02-1 MONTELUKAST INDICATION Asthma 151767-02-1 MONTELUKAST ADVERSE_EFFECT SKN_3_Rash 151767-02-1 MONTELUKAST ADVERSE_EFFECT NEU_2_Dizziness 151767-02-1 MONTELUKAST ADVERSE_EFFECT GIS_2_Dyspepsia 151767-02-1 MONTELUKAST ADVERSE_EFFECT _3_Churg-Strauss syndrome 151767-02-1 MONTELUKAST MECHANISM Modulate G-protein coupled signal transduction 151767-02-1 MONTELUKAST INDICATION Prophylaxis of Bronchospasm 151767-02-1 MONTELUKAST ADVERSE_EFFECT SKN_3_Maculopapular Rash 151767-02-1 MONTELUKAST ADVERSE_EFFECT GIS_3_Abdominal Pain 151767-02-1 MONTELUKAST ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 151767-02-1 MONTELUKAST PRODUCT_CLASS Respiratory System 151767-02-1 MONTELUKAST MODE_CLASS Receptor Ligand Antagonist 151767-02-1 MONTELUKAST ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 151767-02-1 MONTELUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 151767-02-1 MONTELUKAST ADVERSE_EFFECT GIS_3_Nausea / Vomiting 151767-02-1 MONTELUKAST ADVERSE_EFFECT LIV_3_Hepatitis 151767-02-1 MONTELUKAST ADVERSE_EFFECT CVS_2_Vasculitis 151767-02-1 MONTELUKAST ADVERSE_EFFECT NEU_3_Seizures 158966-92-8 MONTELUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 158966-92-8 MONTELUKAST ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 158966-92-8 MONTELUKAST ADVERSE_EFFECT MSK_3_Myalgia 158966-92-8 MONTELUKAST ADVERSE_EFFECT GIS_3_Abdominal Pain 158966-92-8 MONTELUKAST ADVERSE_EFFECT SKN_3_Maculopapular Rash 158966-92-8 MONTELUKAST ADVERSE_EFFECT NEU_2_Dizziness 158966-92-8 MONTELUKAST INDICATION Prophylaxis of Bronchospasm 158966-92-8 MONTELUKAST ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 158966-92-8 MONTELUKAST PRODUCT_CLASS Respiratory System 158966-92-8 MONTELUKAST ADVERSE_EFFECT NEU_3_Seizures 158966-92-8 MONTELUKAST MODE_CLASS Receptor Ligand Antagonist 158966-92-8 MONTELUKAST ADVERSE_EFFECT _3_Churg-Strauss syndrome 158966-92-8 MONTELUKAST ADVERSE_EFFECT GIS_2_Dyspepsia 158966-92-8 MONTELUKAST ADVERSE_EFFECT LIV_3_Hepatitis 158966-92-8 MONTELUKAST ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 158966-92-8 MONTELUKAST INDICATION Asthma 158966-92-8 MONTELUKAST ADVERSE_EFFECT SKN_3_Rash 158966-92-8 MONTELUKAST MECHANISM Modulate G-protein coupled signal transduction 158966-92-8 MONTELUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 158966-92-8 MONTELUKAST ADVERSE_EFFECT CVS_2_Vasculitis 158966-92-8 MONTELUKAST ADVERSE_EFFECT IMU_3_Eosinophilia 158966-92-8 MONTELUKAST ADVERSE_EFFECT GIS_3_Nausea / Vomiting 142522-28-9 MONTELUKAST ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 142522-28-9 MONTELUKAST ADVERSE_EFFECT LIV_3_Hepatitis 142522-28-9 MONTELUKAST INDICATION Prophylaxis of Bronchospasm 142522-28-9 MONTELUKAST MECHANISM Modulate G-protein coupled signal transduction 142522-28-9 MONTELUKAST ADVERSE_EFFECT NEU_2_Dizziness 142522-28-9 MONTELUKAST ADVERSE_EFFECT SKN_3_Maculopapular Rash 142522-28-9 MONTELUKAST ADVERSE_EFFECT GIS_3_Abdominal Pain 142522-28-9 MONTELUKAST ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 142522-28-9 MONTELUKAST PRODUCT_CLASS Respiratory System 142522-28-9 MONTELUKAST MODE_CLASS Receptor Ligand Antagonist 142522-28-9 MONTELUKAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 142522-28-9 MONTELUKAST ADVERSE_EFFECT GIS_3_Nausea / Vomiting 142522-28-9 MONTELUKAST ADVERSE_EFFECT CVS_2_Vasculitis 142522-28-9 MONTELUKAST ADVERSE_EFFECT NEU_3_Seizures 142522-28-9 MONTELUKAST ADVERSE_EFFECT MSK_3_Myalgia 142522-28-9 MONTELUKAST ADVERSE_EFFECT IMU_3_Eosinophilia 142522-28-9 MONTELUKAST STRUCTURE_ACTIVITY Leukotriene receptor antagonist 142522-28-9 MONTELUKAST INDICATION Asthma 142522-28-9 MONTELUKAST ADVERSE_EFFECT SKN_3_Rash 142522-28-9 MONTELUKAST ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 142522-28-9 MONTELUKAST ADVERSE_EFFECT GIS_2_Dyspepsia 142522-28-9 MONTELUKAST ADVERSE_EFFECT _3_Churg-Strauss syndrome 31883-05-3 MORICIZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 31883-05-3 MORICIZINE TISSUE_TOXICITY Ventricular Tachycardia 31883-05-3 MORICIZINE TISSUE_TOXICITY Angina 31883-05-3 MORICIZINE KNOWN_TOXICITY Cardiovascular Toxicity 31883-05-3 MORICIZINE ADVERSE_EFFECT GIS_3_Diarrhea 31883-05-3 MORICIZINE ADVERSE_EFFECT NEU_3_Tremor 31883-05-3 MORICIZINE ADVERSE_EFFECT GUS_3_Urinary Retention 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_1_Angina 31883-05-3 MORICIZINE ADVERSE_EFFECT NEU_2_Dizziness 31883-05-3 MORICIZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 31883-05-3 MORICIZINE PRODUCT_CLASS Cardiovasculars 31883-05-3 MORICIZINE MODE_CLASS Receptor Ligand Antagonist 31883-05-3 MORICIZINE TISSUE_TOXICITY Ventricular Fibrillation 31883-05-3 MORICIZINE ADVERSE_EFFECT OCU_3_Blurred Vision 31883-05-3 MORICIZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 31883-05-3 MORICIZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 31883-05-3 MORICIZINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 31883-05-3 MORICIZINE MECHANISM Block neural transmission 31883-05-3 MORICIZINE ADVERSE_EFFECT NEU_1_Headache 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_1_Ventricular Tachycardia 31883-05-3 MORICIZINE ADVERSE_EFFECT GIS_1_Abdominal Pain 31883-05-3 MORICIZINE ADVERSE_EFFECT GIS_2_Dyspepsia 31883-05-3 MORICIZINE THERAPEUTIC_CLASS Antiarrhythmic Agents 31883-05-3 MORICIZINE INDICATION Ventricular Tachycardia 31883-05-3 MORICIZINE MODE_CLASS Channel Blocker 31883-05-3 MORICIZINE ADVERSE_EFFECT XXX_3_Drug Fever 31883-05-3 MORICIZINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 31883-05-3 MORICIZINE ADVERSE_EFFECT PSY_3_Anxiety 31883-05-3 MORICIZINE ADVERSE_EFFECT XXX_2_Fatigue 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_1_Ventricular Fibrillation 31883-05-3 MORICIZINE ADVERSE_EFFECT CVS_1_Palpitation 57-27-2 MORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 57-27-2 MORPHINE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 57-27-2 MORPHINE KNOWN_TOXICITY Cardiovascular Toxicity 57-27-2 MORPHINE ADVERSE_EFFECT LUN_3_Atelectasis 57-27-2 MORPHINE ADVERSE_EFFECT PSY_2_Dysphoria 57-27-2 MORPHINE ADVERSE_EFFECT PSY_2_Physical Dependence 57-27-2 MORPHINE ADVERSE_EFFECT NEU_1_Dizziness 57-27-2 MORPHINE ADVERSE_EFFECT CVS_1_Hypotension 57-27-2 MORPHINE ADVERSE_EFFECT LUN_2_Respiratory Depression 57-27-2 MORPHINE TISSUE_TOXICITY Hypotension 57-27-2 MORPHINE INDICATION Chronic Pain 57-27-2 MORPHINE TISSUE_TOXICITY Cardiac Arrest 57-27-2 MORPHINE ADVERSE_EFFECT NEU_2_Opiate withdrawal symptoms 57-27-2 MORPHINE INDICATION Severe Pain 57-27-2 MORPHINE ADVERSE_EFFECT CVS_2_Tachycardia 57-27-2 MORPHINE ADVERSE_EFFECT OCU_2_Blurred Vision 57-27-2 MORPHINE ADVERSE_EFFECT SKN_2_Flushing 57-27-2 MORPHINE ADVERSE_EFFECT XXX_2_Tolerance 57-27-2 MORPHINE ADVERSE_EFFECT REP_2_Amenorrhea 57-27-2 MORPHINE ADVERSE_EFFECT IMU_2_Anaphylactoid Reactions 57-27-2 MORPHINE MECHANISM Modulate neural transmission 57-27-2 MORPHINE ADVERSE_EFFECT CVS_2_Bradycardia 57-27-2 MORPHINE ADVERSE_EFFECT GIS_1_Constipation 57-27-2 MORPHINE ADVERSE_EFFECT REP_2_Impotence 57-27-2 MORPHINE ADVERSE_EFFECT NEU_1_Drowsiness 57-27-2 MORPHINE ADVERSE_EFFECT NEU_3_Myoclonus 57-27-2 MORPHINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 57-27-2 MORPHINE INDICATION Pulmonary Edema 57-27-2 MORPHINE PRODUCT_CLASS Analgesics 57-27-2 MORPHINE MODE_CLASS Receptor Agonist, selective 57-27-2 MORPHINE ADVERSE_EFFECT OCU_2_Miosis 57-27-2 MORPHINE ADVERSE_EFFECT GUS_2_Urinary Retention 57-27-2 MORPHINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57-27-2 MORPHINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 57-27-2 MORPHINE ADVERSE_EFFECT XXX_2_Withdrawal 57-27-2 MORPHINE ADVERSE_EFFECT PSY_2_Euphoria 144256-27-9 MOSAPRIDE ADVERSE_EFFECT END_3_Hypertriglyceridemia 144256-27-9 MOSAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 144256-27-9 MOSAPRIDE ADVERSE_EFFECT NEU_2_Headache 144256-27-9 MOSAPRIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 144256-27-9 MOSAPRIDE ZERO_CLASS N 144256-27-9 MOSAPRIDE MESH_LEVEL_1 Organic Chemicals 144256-27-9 MOSAPRIDE INDICATION Diabetic Gastric Stasis 144256-27-9 MOSAPRIDE ADVERSE_EFFECT GIS_2_Dry Mouth 144256-27-9 MOSAPRIDE ADVERSE_EFFECT CVS_2_Palpitation 144256-27-9 MOSAPRIDE ADVERSE_EFFECT XXX_2_Malaise 144256-27-9 MOSAPRIDE TA_LEVEL_1 Gastrointestinal System 144256-27-9 MOSAPRIDE MESH_LEVEL_2 Amides 144256-27-9 MOSAPRIDE MESH_LEVEL_3 Benzamides 144256-27-9 MOSAPRIDE INDICATION Gastroesophageal Reflux Disease (GERD) 144256-27-9 MOSAPRIDE MODE_CLASS Receptor Agonist 144256-27-9 MOSAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 144256-27-9 MOSAPRIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 144256-27-9 MOSAPRIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 144256-27-9 MOSAPRIDE MECH_LEVEL_3 5HT receptor 4 144256-27-9 MOSAPRIDE MECH_LEVEL_2 5HT antagonist 144256-27-9 MOSAPRIDE ACTIVITY_CLASS Serotonin agonist 144256-27-9 MOSAPRIDE ADVERSE_EFFECT IMU_3_Eosinophilia 144256-27-9 MOSAPRIDE MECHANISM Modulate neural transmission 144256-27-9 MOSAPRIDE TA_LEVEL_2 5HT3 agonists 144256-27-9 MOSAPRIDE PRODUCT_CLASS Gastrointestinal System 144256-27-9 MOSAPRIDE STRUCTURE_ACTIVITY 5HT4 agonist 144256-27-9 MOSAPRIDE INDICATION Chronic Gastritis 112885-42-4 MOSAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 112885-42-4 MOSAPRIDE ADVERSE_EFFECT NEU_2_Headache 112885-42-4 MOSAPRIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 112885-42-4 MOSAPRIDE ZERO_CLASS N 112885-42-4 MOSAPRIDE MECH_LEVEL_2 5HT antagonist 112885-42-4 MOSAPRIDE MESH_LEVEL_1 Organic Chemicals 112885-42-4 MOSAPRIDE INDICATION Diabetic Gastric Stasis 112885-42-4 MOSAPRIDE ADVERSE_EFFECT GIS_2_Dry Mouth 112885-42-4 MOSAPRIDE ADVERSE_EFFECT CVS_2_Palpitation 112885-42-4 MOSAPRIDE ADVERSE_EFFECT XXX_2_Malaise 112885-42-4 MOSAPRIDE TA_LEVEL_1 Gastrointestinal System 112885-42-4 MOSAPRIDE MESH_LEVEL_2 Amides 112885-42-4 MOSAPRIDE MESH_LEVEL_3 Benzamides 112885-42-4 MOSAPRIDE INDICATION Gastroesophageal Reflux Disease (GERD) 112885-42-4 MOSAPRIDE MODE_CLASS Receptor Agonist 112885-42-4 MOSAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 112885-42-4 MOSAPRIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 112885-42-4 MOSAPRIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 112885-42-4 MOSAPRIDE MECH_LEVEL_3 5HT receptor 4 112885-42-4 MOSAPRIDE ACTIVITY_CLASS Serotonin agonist 112885-42-4 MOSAPRIDE ADVERSE_EFFECT END_3_Hypertriglyceridemia 112885-42-4 MOSAPRIDE ADVERSE_EFFECT IMU_3_Eosinophilia 112885-42-4 MOSAPRIDE MECHANISM Modulate neural transmission 112885-42-4 MOSAPRIDE TA_LEVEL_2 5HT3 agonists 112885-42-4 MOSAPRIDE PRODUCT_CLASS Gastrointestinal System 112885-42-4 MOSAPRIDE STRUCTURE_ACTIVITY 5HT4 agonist 112885-42-4 MOSAPRIDE INDICATION Chronic Gastritis 131322-37-7 MOSAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 131322-37-7 MOSAPRIDE ADVERSE_EFFECT NEU_2_Headache 131322-37-7 MOSAPRIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 131322-37-7 MOSAPRIDE ZERO_CLASS N 131322-37-7 MOSAPRIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 131322-37-7 MOSAPRIDE MESH_LEVEL_1 Organic Chemicals 131322-37-7 MOSAPRIDE INDICATION Diabetic Gastric Stasis 131322-37-7 MOSAPRIDE ADVERSE_EFFECT GIS_2_Dry Mouth 131322-37-7 MOSAPRIDE ADVERSE_EFFECT CVS_2_Palpitation 131322-37-7 MOSAPRIDE ADVERSE_EFFECT XXX_2_Malaise 131322-37-7 MOSAPRIDE TA_LEVEL_1 Gastrointestinal System 131322-37-7 MOSAPRIDE MESH_LEVEL_2 Amides 131322-37-7 MOSAPRIDE MESH_LEVEL_3 Benzamides 131322-37-7 MOSAPRIDE INDICATION Gastroesophageal Reflux Disease (GERD) 131322-37-7 MOSAPRIDE MODE_CLASS Receptor Agonist 131322-37-7 MOSAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 131322-37-7 MOSAPRIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 131322-37-7 MOSAPRIDE ACTIVITY_CLASS Serotonin agonist 131322-37-7 MOSAPRIDE MECH_LEVEL_3 5HT receptor 4 131322-37-7 MOSAPRIDE MECH_LEVEL_2 5HT antagonist 131322-37-7 MOSAPRIDE ADVERSE_EFFECT END_3_Hypertriglyceridemia 131322-37-7 MOSAPRIDE ADVERSE_EFFECT IMU_3_Eosinophilia 131322-37-7 MOSAPRIDE MECHANISM Modulate neural transmission 131322-37-7 MOSAPRIDE TA_LEVEL_2 5HT3 agonists 131322-37-7 MOSAPRIDE PRODUCT_CLASS Gastrointestinal System 131322-37-7 MOSAPRIDE STRUCTURE_ACTIVITY 5HT4 agonist 131322-37-7 MOSAPRIDE INDICATION Chronic Gastritis 112885-43-5 MOSAPRIDE TA_LEVEL_1 Gastrointestinal System 112885-43-5 MOSAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 112885-43-5 MOSAPRIDE ADVERSE_EFFECT NEU_2_Headache 112885-43-5 MOSAPRIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 112885-43-5 MOSAPRIDE ZERO_CLASS N 112885-43-5 MOSAPRIDE MESH_LEVEL_1 Organic Chemicals 112885-43-5 MOSAPRIDE INDICATION Diabetic Gastric Stasis 112885-43-5 MOSAPRIDE ADVERSE_EFFECT GIS_2_Dry Mouth 112885-43-5 MOSAPRIDE ADVERSE_EFFECT CVS_2_Palpitation 112885-43-5 MOSAPRIDE ADVERSE_EFFECT XXX_2_Malaise 112885-43-5 MOSAPRIDE ADVERSE_EFFECT END_3_Hypertriglyceridemia 112885-43-5 MOSAPRIDE MESH_LEVEL_2 Amides 112885-43-5 MOSAPRIDE MESH_LEVEL_3 Benzamides 112885-43-5 MOSAPRIDE INDICATION Gastroesophageal Reflux Disease (GERD) 112885-43-5 MOSAPRIDE MODE_CLASS Receptor Agonist 112885-43-5 MOSAPRIDE ADVERSE_EFFECT GIS_2_Diarrhea 112885-43-5 MOSAPRIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 112885-43-5 MOSAPRIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 112885-43-5 MOSAPRIDE MECH_LEVEL_3 5HT receptor 4 112885-43-5 MOSAPRIDE MECH_LEVEL_2 5HT antagonist 112885-43-5 MOSAPRIDE ACTIVITY_CLASS Serotonin agonist 112885-43-5 MOSAPRIDE ADVERSE_EFFECT IMU_3_Eosinophilia 112885-43-5 MOSAPRIDE MECHANISM Modulate neural transmission 112885-43-5 MOSAPRIDE TA_LEVEL_2 5HT3 agonists 112885-43-5 MOSAPRIDE PRODUCT_CLASS Gastrointestinal System 112885-43-5 MOSAPRIDE STRUCTURE_ACTIVITY 5HT4 agonist 112885-43-5 MOSAPRIDE INDICATION Chronic Gastritis 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT OCU_2_Amblyopia 186826-86-8 MOXIFLOXACIN TISSUE_TOXICITY Hypotension 186826-86-8 MOXIFLOXACIN PRODUCT_CLASS Anti-infectives 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT XXX_2_Chills 186826-86-8 MOXIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 186826-86-8 MOXIFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 186826-86-8 MOXIFLOXACIN INDICATION Sinusitis 186826-86-8 MOXIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 186826-86-8 MOXIFLOXACIN TISSUE_TOXICITY Shock 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Paresthesia 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Angioedema 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Nightmares 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT LIV_1_Impaired Liver Function 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT XXX_2_Asthenia 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT BBM_2_Coagulopathy 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Dysgeusia 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT IMU_2_Allergic Reactions 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Loss of Consciousness 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Lightheadedness 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Shock 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT LUN_3_Respiratory Distress Syndrome 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT MSK_2_Back Pain 186826-86-8 MOXIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 186826-86-8 MOXIFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 186826-86-8 MOXIFLOXACIN INDICATION Skin and Skin Structure Infections 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT IMU_2_Phototoxicity 186826-86-8 MOXIFLOXACIN TISSUE_TOXICITY Cardiovascular Collapse 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Depression 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Seizures 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT XXX_3_Restlessness 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT XXX_3_Facial Edema 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT MSK_2_Arthralgia 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Dyspepsia 186826-86-8 MOXIFLOXACIN INDICATION Pneumonia 186826-86-8 MOXIFLOXACIN THERAPEUTIC_CLASS Antibacterials 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT NEU_1_Headache 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_2_Confusion 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Urticaria 186826-86-8 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Paranoia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Shock 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Lightheadedness 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Loss of Consciousness 192927-63-2 MOXIFLOXACIN INDICATION Sinusitis 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_2_Allergic Reactions 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 192927-63-2 MOXIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Dysgeusia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT BBM_2_Coagulopathy 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_2_Asthenia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT LIV_1_Impaired Liver Function 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Nightmares 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Angioedema 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Paresthesia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 192927-63-2 MOXIFLOXACIN TISSUE_TOXICITY Shock 192927-63-2 MOXIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 192927-63-2 MOXIFLOXACIN TISSUE_TOXICITY Hypotension 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_2_Phototoxicity 192927-63-2 MOXIFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT OCU_2_Amblyopia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_2_Chills 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Paranoia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Urticaria 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_2_Confusion 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_1_Headache 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 192927-63-2 MOXIFLOXACIN THERAPEUTIC_CLASS Antibacterials 192927-63-2 MOXIFLOXACIN INDICATION Pneumonia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_1_Dyspepsia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT MSK_2_Arthralgia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_3_Facial Edema 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT XXX_3_Restlessness 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_3_Seizures 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT PSY_3_Depression 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 192927-63-2 MOXIFLOXACIN TISSUE_TOXICITY Cardiovascular Collapse 192927-63-2 MOXIFLOXACIN PRODUCT_CLASS Anti-infectives 192927-63-2 MOXIFLOXACIN INDICATION Skin and Skin Structure Infections 192927-63-2 MOXIFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 192927-63-2 MOXIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT MSK_2_Back Pain 192927-63-2 MOXIFLOXACIN ADVERSE_EFFECT LUN_3_Respiratory Distress Syndrome 2763-96-4 MUSCIMOL MECHANISM Modulate neural transmission 2763-96-4 MUSCIMOL PRODUCT_CLASS Biochemicals 2763-96-4 MUSCIMOL MODE_CLASS Channel Modulator 78351-75-4 MY-5445 PRODUCT_CLASS Biochemicals 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT DNA_2_Genotoxicity 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LUN_3_Atelectasis 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LIV_1_Abnormal Liver Function 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT DNA_1_Lymphoma 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT MSK_2_Arthralgia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Anemia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT NEU_1_Paresthesia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT SKN_1_Rash 115007-34-6 MYCOPHENOLATE MOFETIL THERAPEUTIC_CLASS Immunosuppressants 115007-34-6 MYCOPHENOLATE MOFETIL MESH_LEVEL_2 Carboxylic Acids 115007-34-6 MYCOPHENOLATE MOFETIL MECH_LEVEL_1 Immunomodulation 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Embryo/Fetal Toxicity 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Nephrotoxicity 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Lymphoma 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Thrombocytopenia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Fever 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_2_Opportunistic Infection 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_2_Angina Pectoris 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT KID_2_Tubular Necrosis 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Thrombocytopenia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT KID_1_Renal Dysfunction 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Abdominal Pain 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Leukopenia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Infection 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Vomiting 115007-34-6 MYCOPHENOLATE MOFETIL MODE_CLASS Enzyme Inhibitor 115007-34-6 MYCOPHENOLATE MOFETIL TA_LEVEL_1 Anti-inflammatory 115007-34-6 MYCOPHENOLATE MOFETIL MECH_LEVEL_3 IMP dehydrogenase 115007-34-6 MYCOPHENOLATE MOFETIL TA_LEVEL_2 Immune Response / Immunomodulators 115007-34-6 MYCOPHENOLATE MOFETIL STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, IMP dehydrogenase inhibitor 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Fluid and Electrolyte Disturbance 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Cardiac Arrhythmia 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Carcinogenicity 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Miscellaneous 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT EMB_1_Teratogenicity 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT END_1_Hypercholesteremia 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_2_Ecchymosis 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT ELT_1_Fluid and Electrolyte Disturbance 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT END_2_Diabetes 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Peripheral Edema 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Pain 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Edema 115007-34-6 MYCOPHENOLATE MOFETIL INDICATION Prophylaxis of Organ Transplant Rejection 115007-34-6 MYCOPHENOLATE MOFETIL PRODUCT_CLASS Immune Response / Immunomodulators 115007-34-6 MYCOPHENOLATE MOFETIL MESH_LEVEL_1 Organic Chemicals 115007-34-6 MYCOPHENOLATE MOFETIL TA_LEVEL_3 immunosuppressant 115007-34-6 MYCOPHENOLATE MOFETIL MESH_LEVEL_3 Acids, Carbocyclic 115007-34-6 MYCOPHENOLATE MOFETIL MECH_LEVEL_2 Inhibit precursor synthesis 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Electrolyte Disturbance 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT NEU_1_Tremor 115007-34-6 MYCOPHENOLATE MOFETIL MECHANISM Inhibit precursor synthesis 115007-34-6 MYCOPHENOLATE MOFETIL ZERO_CLASS N 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Genotoxicity 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Tubular Necrosis 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Sepsis 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_1_Hypertension 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Sepsis 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Diarrhea 115007-34-6 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT PSY_1_Insomnia 115007-34-6 MYCOPHENOLATE MOFETIL ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Cardiovascular Toxicity 115007-34-6 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Mutagenicity 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Leukopenia 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Anemia 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Angina Pectoris 115007-34-6 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Teratogenicity 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT ELT_1_Fluid and Electrolyte Disturbance 128794-94-5 MYCOPHENOLATE MOFETIL MESH_LEVEL_3 Acids, Carbocyclic 128794-94-5 MYCOPHENOLATE MOFETIL TA_LEVEL_3 immunosuppressant 128794-94-5 MYCOPHENOLATE MOFETIL MESH_LEVEL_1 Organic Chemicals 128794-94-5 MYCOPHENOLATE MOFETIL INDICATION Prophylaxis of Organ Transplant Rejection 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Edema 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Pain 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Peripheral Edema 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT END_2_Diabetes 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_2_Ecchymosis 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT END_1_Hypercholesteremia 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT EMB_1_Teratogenicity 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Miscellaneous 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Carcinogenicity 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Cardiac Arrhythmia 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Fluid and Electrolyte Disturbance 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Teratogenicity 128794-94-5 MYCOPHENOLATE MOFETIL STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, IMP dehydrogenase inhibitor 128794-94-5 MYCOPHENOLATE MOFETIL TA_LEVEL_2 Immune Response / Immunomodulators 128794-94-5 MYCOPHENOLATE MOFETIL MECH_LEVEL_3 IMP dehydrogenase 128794-94-5 MYCOPHENOLATE MOFETIL TA_LEVEL_1 Anti-inflammatory 128794-94-5 MYCOPHENOLATE MOFETIL MODE_CLASS Enzyme Inhibitor 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Vomiting 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Infection 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Leukopenia 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Abdominal Pain 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT KID_1_Renal Dysfunction 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Sepsis 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_1_Hypertension 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Sepsis 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Tubular Necrosis 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Genotoxicity 128794-94-5 MYCOPHENOLATE MOFETIL ZERO_CLASS N 128794-94-5 MYCOPHENOLATE MOFETIL MECHANISM Inhibit precursor synthesis 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Electrolyte Disturbance 128794-94-5 MYCOPHENOLATE MOFETIL MECH_LEVEL_2 Inhibit precursor synthesis 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT NEU_1_Tremor 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT NEU_1_Paresthesia 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Thrombocytopenia 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT KID_2_Tubular Necrosis 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT CVS_2_Angina Pectoris 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_2_Opportunistic Infection 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT XXX_1_Fever 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Thrombocytopenia 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Lymphoma 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Nephrotoxicity 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Embryo/Fetal Toxicity 128794-94-5 MYCOPHENOLATE MOFETIL PRODUCT_CLASS Immune Response / Immunomodulators 128794-94-5 MYCOPHENOLATE MOFETIL MECH_LEVEL_1 Immunomodulation 128794-94-5 MYCOPHENOLATE MOFETIL MESH_LEVEL_2 Carboxylic Acids 128794-94-5 MYCOPHENOLATE MOFETIL THERAPEUTIC_CLASS Immunosuppressants 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT SKN_1_Rash 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT BBM_1_Anemia 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT MSK_2_Arthralgia 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT DNA_1_Lymphoma 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LIV_1_Abnormal Liver Function 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT LUN_3_Atelectasis 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT DNA_2_Genotoxicity 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT GIS_1_Diarrhea 128794-94-5 MYCOPHENOLATE MOFETIL ADVERSE_EFFECT PSY_1_Insomnia 128794-94-5 MYCOPHENOLATE MOFETIL ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Cardiovascular Toxicity 128794-94-5 MYCOPHENOLATE MOFETIL KNOWN_TOXICITY Mutagenicity 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Leukopenia 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Anemia 128794-94-5 MYCOPHENOLATE MOFETIL TISSUE_TOXICITY Angina Pectoris 24280-93-1 MYCOPHENOLIC ACID PRODUCT_CLASS Anti-cancers 24280-93-1 MYCOPHENOLIC ACID MODE_CLASS Enzyme Inhibitor 24280-93-1 MYCOPHENOLIC ACID PRODUCT_CLASS Immune Response / Immunomodulators 24280-93-1 MYCOPHENOLIC ACID INDICATION Psoriasis 24280-93-1 MYCOPHENOLIC ACID MECHANISM Inhibit precursor synthesis 24280-93-1 MYCOPHENOLIC ACID THERAPEUTIC_CLASS Antineoplastics 24280-93-1 MYCOPHENOLIC ACID INDICATION Prophylaxis of Organ Transplant Rejection 24280-93-1 MYCOPHENOLIC ACID THERAPEUTIC_CLASS Immunosuppressants 24280-93-1 MYCOPHENOLIC ACID STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 121749-39-1 BENSPM MODE_CLASS Enzyme Inhibitor, Non-selective 121749-39-1 BENSPM MECHANISM Inhibit precursor synthesis 121749-39-1 BENSPM PRODUCT_CLASS Anti-cancers 121749-39-1 BENSPM THERAPEUTIC_CLASS Antineoplastics 121749-39-1 BENSPM MODE_CLASS Enzyme Inhibitor 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE MESH_LEVEL_1 Organic Chemicals 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE TA_LEVEL_2 rubber antioxidant 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE MECH_LEVEL_3 Unknown mechanism 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE STRUCTURE_ACTIVITY H2O2 radical scavenger 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE MESH_LEVEL_3 Polyamines 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE ADVERSE_EFFECT XXX_1_Weight Loss 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE MECH_LEVEL_2 Unknown mechanism 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE ACTIVITY_CLASS H2O2 radical scavenger 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE MECHANISM Scavenges hydrogen peroxide and free radicals 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE TA_LEVEL_1 Additives 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE ADVERSE_EFFECT DNA_3_Carcinoid Tumors 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE ZERO_CLASS N 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE KNOWN_TOXICITY Carcinogenicity 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE TA_LEVEL_3 biochemical 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE PRODUCT_CLASS Biochemicals 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE ADVERSE_EFFECT EMB_2_Fetal Death 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE TISSUE_TOXICITY Carcinoid Tumors 74-31-7 N,N'-DIPHENYL-P-PHENYLENEDIAMINE MESH_LEVEL_2 Amines 3102-57-6 CERAMIDE C2 ADVERSE_EFFECT NEU_3_Neuronal Necrosis 3102-57-6 CERAMIDE C2 ADVERSE_EFFECT CVS_3_Hypotension 3102-57-6 CERAMIDE C2 ACTIVITY_CLASS Toxicant 3102-57-6 CERAMIDE C2 PRODUCT_CLASS Biochemicals 3102-57-6 CERAMIDE C2 STRUCTURE_ACTIVITY Apoptosis inducer 3102-57-6 CERAMIDE C2 TISSUE_TOXICITY Hypotension 3102-57-6 CERAMIDE C2 ADVERSE_EFFECT IMU_1_Suppressed Immune System 3102-57-6 CERAMIDE C2 ADVERSE_EFFECT CVS_2_Cardiac Disturbances 3102-57-6 CERAMIDE C2 KNOWN_TOXICITY Cardiovascular Toxicity 3102-57-6 CERAMIDE C2 ADVERSE_EFFECT MSK_3_Muscle Fatigue 128413-88-7 N-EXO-BICYCLO[2.2.1]HEPT-2-YL-N'-(2-IODOPHENYL) GUANIDINE PRODUCT_CLASS Biochemicals 128413-88-7 N-EXO-BICYCLO[2.2.1]HEPT-2-YL-N'-(2-IODOPHENYL) GUANIDINE STRUCTURE_ACTIVITY Sigma receptor modulator 128413-88-7 N-EXO-BICYCLO[2.2.1]HEPT-2-YL-N'-(2-IODOPHENYL) GUANIDINE MECHANISM Modulate neural transmission 128413-88-7 N-EXO-BICYCLO[2.2.1]HEPT-2-YL-N'-(2-IODOPHENYL) GUANIDINE MODE_CLASS Receptor Agonist 6384-92-5 N-METHYL-D-ASPARTIC ACID (NMDA) PRODUCT_CLASS Biochemicals 6384-92-5 N-METHYL-D-ASPARTIC ACID (NMDA) MODE_CLASS Channel Modulator 6384-92-5 N-METHYL-D-ASPARTIC ACID (NMDA) MECHANISM Prolong/enhance neural transmission 86-54-4 HYDRALAZINE ADVERSE_EFFECT MSK_3_Muscle Cramps 86-54-4 HYDRALAZINE ADVERSE_EFFECT CVS_2_Vasculitis 86-54-4 HYDRALAZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 86-54-4 HYDRALAZINE ADVERSE_EFFECT CVS_3_Angina Pectoris 86-54-4 HYDRALAZINE ADVERSE_EFFECT GIS_2_Constipation 86-54-4 HYDRALAZINE ADVERSE_EFFECT XXX_2_Edema 86-54-4 HYDRALAZINE ADVERSE_EFFECT GIS_2_Diarrhea 86-54-4 HYDRALAZINE MECH_LEVEL_2 Calcium release? 86-54-4 HYDRALAZINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 86-54-4 HYDRALAZINE ADVERSE_EFFECT NEU_3_Peripheral Neuritis 86-54-4 HYDRALAZINE MECHANISM Inhibit kinase mediated signal transduction 86-54-4 HYDRALAZINE KNOWN_TOXICITY Cardiovascular Toxicity 86-54-4 HYDRALAZINE MODE_CLASS Enzyme Inhibitor 86-54-4 HYDRALAZINE PRODUCT_CLASS Cardiovasculars 86-54-4 HYDRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 86-54-4 HYDRALAZINE TA_LEVEL_1 Cardiovascular 86-54-4 HYDRALAZINE MECHANISM Prolong/enhance neural transmission 86-54-4 HYDRALAZINE TA_LEVEL_2 Hypertension 86-54-4 HYDRALAZINE INDICATION Preeclampsia 86-54-4 HYDRALAZINE KNOWN_TOXICITY Nephrotoxicity 86-54-4 HYDRALAZINE TISSUE_TOXICITY Glomerulonephritis 86-54-4 HYDRALAZINE ADVERSE_EFFECT KID_3_Glomerulonephritis 86-54-4 HYDRALAZINE ADVERSE_EFFECT LYM_3_Lymphadenopathy 86-54-4 HYDRALAZINE ADVERSE_EFFECT NEU_1_Headache 86-54-4 HYDRALAZINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 86-54-4 HYDRALAZINE ADVERSE_EFFECT KID_3_Fluid Retention 86-54-4 HYDRALAZINE STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) opener 86-54-4 HYDRALAZINE ACTIVITY_CLASS K+ channel opener 86-54-4 HYDRALAZINE MODE_CLASS Channel Modulator 86-54-4 HYDRALAZINE MESH_LEVEL_3 Pyridazines 86-54-4 HYDRALAZINE INDICATION Hypertensive Emergency 86-54-4 HYDRALAZINE MECHANISM Interferes with neural transmitter synthesis 86-54-4 HYDRALAZINE MECHANISM Reduce vasoconstriction 86-54-4 HYDRALAZINE THERAPEUTIC_CLASS Congestive Heart Failure 86-54-4 HYDRALAZINE TISSUE_TOXICITY Angina Pectoris 86-54-4 HYDRALAZINE MECHANISM Modulate channel gating 86-54-4 HYDRALAZINE MECH_LEVEL_3 Unknown mechanism 86-54-4 HYDRALAZINE MESH_LEVEL_1 Heterocyclic Compounds 86-54-4 HYDRALAZINE INDICATION Congestive Heart Failure (CHF) 86-54-4 HYDRALAZINE INDICATION Hypertension 86-54-4 HYDRALAZINE ZERO_CLASS N 86-54-4 HYDRALAZINE ADVERSE_EFFECT XXX_3_Splenomegaly 86-54-4 HYDRALAZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 86-54-4 HYDRALAZINE ADVERSE_EFFECT PSY_1_Anorexia 86-54-4 HYDRALAZINE ADVERSE_EFFECT CVS_1_Palpitation 86-54-4 HYDRALAZINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 86-54-4 HYDRALAZINE ADVERSE_EFFECT XXX_3_Nasal Congestion 86-54-4 HYDRALAZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 86-54-4 HYDRALAZINE ADVERSE_EFFECT LUN_3_Dyspnea 86-54-4 HYDRALAZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 86-54-4 HYDRALAZINE ADVERSE_EFFECT NEU_2_Paresthesia 86-54-4 HYDRALAZINE MECH_LEVEL_1 Vasorelaxation 304-20-1 HYDRALAZINE ZERO_CLASS N 304-20-1 HYDRALAZINE INDICATION Hypertension 304-20-1 HYDRALAZINE INDICATION Congestive Heart Failure (CHF) 304-20-1 HYDRALAZINE MESH_LEVEL_1 Heterocyclic Compounds 304-20-1 HYDRALAZINE MECH_LEVEL_3 Unknown mechanism 304-20-1 HYDRALAZINE MECHANISM Modulate channel gating 304-20-1 HYDRALAZINE MECHANISM Interferes with neural transmitter synthesis 304-20-1 HYDRALAZINE ADVERSE_EFFECT NEU_2_Paresthesia 304-20-1 HYDRALAZINE THERAPEUTIC_CLASS Congestive Heart Failure 304-20-1 HYDRALAZINE ADVERSE_EFFECT LUN_3_Dyspnea 304-20-1 HYDRALAZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 304-20-1 HYDRALAZINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 304-20-1 HYDRALAZINE ADVERSE_EFFECT GIS_2_Diarrhea 304-20-1 HYDRALAZINE MODE_CLASS Enzyme Inhibitor 304-20-1 HYDRALAZINE PRODUCT_CLASS Cardiovasculars 304-20-1 HYDRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 304-20-1 HYDRALAZINE TA_LEVEL_1 Cardiovascular 304-20-1 HYDRALAZINE MECHANISM Prolong/enhance neural transmission 304-20-1 HYDRALAZINE TA_LEVEL_2 Hypertension 304-20-1 HYDRALAZINE INDICATION Preeclampsia 304-20-1 HYDRALAZINE KNOWN_TOXICITY Nephrotoxicity 304-20-1 HYDRALAZINE TISSUE_TOXICITY Glomerulonephritis 304-20-1 HYDRALAZINE ADVERSE_EFFECT KID_3_Glomerulonephritis 304-20-1 HYDRALAZINE ADVERSE_EFFECT LYM_3_Lymphadenopathy 304-20-1 HYDRALAZINE ADVERSE_EFFECT NEU_1_Headache 304-20-1 HYDRALAZINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 304-20-1 HYDRALAZINE ADVERSE_EFFECT KID_3_Fluid Retention 304-20-1 HYDRALAZINE STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) opener 304-20-1 HYDRALAZINE ACTIVITY_CLASS K+ channel opener 304-20-1 HYDRALAZINE MODE_CLASS Channel Modulator 304-20-1 HYDRALAZINE MESH_LEVEL_3 Pyridazines 304-20-1 HYDRALAZINE INDICATION Hypertensive Emergency 304-20-1 HYDRALAZINE MECH_LEVEL_1 Vasorelaxation 304-20-1 HYDRALAZINE MECHANISM Reduce vasoconstriction 304-20-1 HYDRALAZINE TISSUE_TOXICITY Angina Pectoris 304-20-1 HYDRALAZINE ADVERSE_EFFECT XXX_2_Edema 304-20-1 HYDRALAZINE ADVERSE_EFFECT MSK_3_Muscle Cramps 304-20-1 HYDRALAZINE ADVERSE_EFFECT CVS_2_Vasculitis 304-20-1 HYDRALAZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 304-20-1 HYDRALAZINE ADVERSE_EFFECT CVS_3_Angina Pectoris 304-20-1 HYDRALAZINE ADVERSE_EFFECT GIS_2_Constipation 304-20-1 HYDRALAZINE MECH_LEVEL_2 Calcium release? 304-20-1 HYDRALAZINE MECHANISM Inhibit kinase mediated signal transduction 304-20-1 HYDRALAZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 304-20-1 HYDRALAZINE KNOWN_TOXICITY Cardiovascular Toxicity 304-20-1 HYDRALAZINE ADVERSE_EFFECT NEU_3_Peripheral Neuritis 304-20-1 HYDRALAZINE ADVERSE_EFFECT XXX_3_Nasal Congestion 304-20-1 HYDRALAZINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 304-20-1 HYDRALAZINE ADVERSE_EFFECT CVS_1_Palpitation 304-20-1 HYDRALAZINE ADVERSE_EFFECT PSY_1_Anorexia 304-20-1 HYDRALAZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 304-20-1 HYDRALAZINE ADVERSE_EFFECT XXX_3_Splenomegaly 40671-54-3 HYDRALAZINE ADVERSE_EFFECT GIS_2_Constipation 40671-54-3 HYDRALAZINE INDICATION Congestive Heart Failure (CHF) 40671-54-3 HYDRALAZINE INDICATION Hypertension 40671-54-3 HYDRALAZINE ZERO_CLASS N 40671-54-3 HYDRALAZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 40671-54-3 HYDRALAZINE ADVERSE_EFFECT PSY_1_Anorexia 40671-54-3 HYDRALAZINE ADVERSE_EFFECT CVS_1_Palpitation 40671-54-3 HYDRALAZINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 40671-54-3 HYDRALAZINE ADVERSE_EFFECT XXX_3_Nasal Congestion 40671-54-3 HYDRALAZINE ADVERSE_EFFECT NEU_3_Peripheral Neuritis 40671-54-3 HYDRALAZINE KNOWN_TOXICITY Cardiovascular Toxicity 40671-54-3 HYDRALAZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 40671-54-3 HYDRALAZINE MECHANISM Inhibit kinase mediated signal transduction 40671-54-3 HYDRALAZINE MECH_LEVEL_2 Calcium release? 40671-54-3 HYDRALAZINE MECHANISM Modulate channel gating 40671-54-3 HYDRALAZINE INDICATION Hypertensive Emergency 40671-54-3 HYDRALAZINE MESH_LEVEL_3 Pyridazines 40671-54-3 HYDRALAZINE MODE_CLASS Channel Modulator 40671-54-3 HYDRALAZINE ACTIVITY_CLASS K+ channel opener 40671-54-3 HYDRALAZINE STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) opener 40671-54-3 HYDRALAZINE ADVERSE_EFFECT KID_3_Fluid Retention 40671-54-3 HYDRALAZINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 40671-54-3 HYDRALAZINE ADVERSE_EFFECT NEU_1_Headache 40671-54-3 HYDRALAZINE ADVERSE_EFFECT LYM_3_Lymphadenopathy 40671-54-3 HYDRALAZINE ADVERSE_EFFECT KID_3_Glomerulonephritis 40671-54-3 HYDRALAZINE TISSUE_TOXICITY Glomerulonephritis 40671-54-3 HYDRALAZINE KNOWN_TOXICITY Nephrotoxicity 40671-54-3 HYDRALAZINE INDICATION Preeclampsia 40671-54-3 HYDRALAZINE MECH_LEVEL_1 Vasorelaxation 40671-54-3 HYDRALAZINE MECHANISM Prolong/enhance neural transmission 40671-54-3 HYDRALAZINE TA_LEVEL_1 Cardiovascular 40671-54-3 HYDRALAZINE THERAPEUTIC_CLASS Antihypertensive Agents 40671-54-3 HYDRALAZINE PRODUCT_CLASS Cardiovasculars 40671-54-3 HYDRALAZINE MODE_CLASS Enzyme Inhibitor 40671-54-3 HYDRALAZINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 40671-54-3 HYDRALAZINE ADVERSE_EFFECT GIS_2_Diarrhea 40671-54-3 HYDRALAZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 40671-54-3 HYDRALAZINE ADVERSE_EFFECT LUN_3_Dyspnea 40671-54-3 HYDRALAZINE ADVERSE_EFFECT XXX_3_Splenomegaly 40671-54-3 HYDRALAZINE ADVERSE_EFFECT NEU_2_Paresthesia 40671-54-3 HYDRALAZINE MECHANISM Interferes with neural transmitter synthesis 40671-54-3 HYDRALAZINE MECH_LEVEL_3 Unknown mechanism 40671-54-3 HYDRALAZINE MESH_LEVEL_1 Heterocyclic Compounds 40671-54-3 HYDRALAZINE MECHANISM Reduce vasoconstriction 40671-54-3 HYDRALAZINE THERAPEUTIC_CLASS Congestive Heart Failure 40671-54-3 HYDRALAZINE TISSUE_TOXICITY Angina Pectoris 40671-54-3 HYDRALAZINE ADVERSE_EFFECT XXX_2_Edema 40671-54-3 HYDRALAZINE ADVERSE_EFFECT MSK_3_Muscle Cramps 40671-54-3 HYDRALAZINE ADVERSE_EFFECT CVS_2_Vasculitis 40671-54-3 HYDRALAZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 40671-54-3 HYDRALAZINE ADVERSE_EFFECT CVS_3_Angina Pectoris 40671-54-3 HYDRALAZINE TA_LEVEL_2 Hypertension 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT KID_1_Polyuria 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT PSY_3_Mental Confusion 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT MSK_3_Muscle Cramps 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT END_2_Hypercholesteremia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Constipation 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT CVS_1_Hypotension 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 58-93-5 HYDROCHLOROTHIAZIDE ZERO_CLASS N 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT XXX_2_Lassitude 58-93-5 HYDROCHLOROTHIAZIDE INDICATION Hypertension 58-93-5 HYDROCHLOROTHIAZIDE MESH_LEVEL_1 Heterocyclic Compounds 58-93-5 HYDROCHLOROTHIAZIDE INDICATION Diabetes Insipidus 58-93-5 HYDROCHLOROTHIAZIDE KNOWN_TOXICITY Nephrotoxicity 58-93-5 HYDROCHLOROTHIAZIDE TISSUE_TOXICITY Interstitial Nephritis 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT KID_3_Azotemia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT NEU_2_Dizziness 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT GIS_1_Gastric Irritation 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Erythema Multiforme 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT KID_3_Renal Failure 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT KID_3_Interstitial Nephritis 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT XXX_2_Fatigue 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Diarrhea 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-93-5 HYDROCHLOROTHIAZIDE MESH_LEVEL_3 Benzothiadiazines 58-93-5 HYDROCHLOROTHIAZIDE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 58-93-5 HYDROCHLOROTHIAZIDE INDICATION Edema 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Sialadenitis 58-93-5 HYDROCHLOROTHIAZIDE KNOWN_TOXICITY Cardiovascular Toxicity 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT KID_1_Hyperuricemia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT NEU_1_Headache 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT END_2_Hypertriglyceridemia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Leukopenia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT IMU_3_Photosensitivity 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Pancytopenia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT OCU_3_Xanthopsia 58-93-5 HYDROCHLOROTHIAZIDE TISSUE_TOXICITY Renal Failure 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT CVS_2_Tachycardia 58-93-5 HYDROCHLOROTHIAZIDE ACTIVITY_CLASS Diuretic 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT PSY_2_Anorexia 58-93-5 HYDROCHLOROTHIAZIDE MODE_CLASS Channel Blocker, selective 58-93-5 HYDROCHLOROTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 58-93-5 HYDROCHLOROTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 58-93-5 HYDROCHLOROTHIAZIDE MECH_LEVEL_3 Epithelial Na+ channel 58-93-5 HYDROCHLOROTHIAZIDE MECH_LEVEL_1 Diuretics 58-93-5 HYDROCHLOROTHIAZIDE TA_LEVEL_1 Cardiovascular 58-93-5 HYDROCHLOROTHIAZIDE TA_LEVEL_2 diuretic 58-93-5 HYDROCHLOROTHIAZIDE INDICATION Premenstrual Syndrome / Premenstrual Tension 58-93-5 HYDROCHLOROTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 58-93-5 HYDROCHLOROTHIAZIDE TISSUE_TOXICITY Hypotension 58-93-5 HYDROCHLOROTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT OCU_3_Blurred Vision 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT ELT_1_Hypochloremia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT ELT_1_Hypokalemia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT REP_3_Impotence 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT ELT_1_Hyponatremia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Pancreatitis 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT XXX_1_Thirst 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 58-93-5 HYDROCHLOROTHIAZIDE MECH_LEVEL_2 Reduce re-absortion of cations from renal tubule 58-93-5 HYDROCHLOROTHIAZIDE INDICATION Hypercalciuria 58-93-5 HYDROCHLOROTHIAZIDE THERAPEUTIC_CLASS Diuretics 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT IMU_3_Periarteritis Nodosa 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT XXX_3_Weakness 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT NEU_3_Paresthesia 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT MSK_3_Spasm 58-93-5 HYDROCHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 125-29-1 HYDROCODONE THERAPEUTIC_CLASS Analgesics, Opioid 125-29-1 HYDROCODONE MECHANISM Modulate neural transmission 125-29-1 HYDROCODONE PRODUCT_CLASS Analgesics 125-29-1 HYDROCODONE PRODUCT_CLASS Respiratory System 125-29-1 HYDROCODONE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 125-29-1 HYDROCODONE INDICATION Moderate Pain 125-29-1 HYDROCODONE INDICATION Cough / Tussis 125-29-1 HYDROCODONE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 125-29-1 HYDROCODONE MODE_CLASS Receptor Agonist 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_1_Hypokalemia 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT IMU_3_Photosensitivity 135-09-1 HYDROFLUMETHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT END_2_Glucose Intolerance 135-09-1 HYDROFLUMETHIAZIDE INDICATION Edema 135-09-1 HYDROFLUMETHIAZIDE THERAPEUTIC_CLASS Diuretics 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT KID_2_Hyperuricemia 135-09-1 HYDROFLUMETHIAZIDE INDICATION Diabetes Insipidus 135-09-1 HYDROFLUMETHIAZIDE INDICATION Hypercalciuria 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT END_2_Increased Serum Lipids 135-09-1 HYDROFLUMETHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 135-09-1 HYDROFLUMETHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 135-09-1 HYDROFLUMETHIAZIDE PRODUCT_CLASS Cardiovasculars 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypercalcemia 135-09-1 HYDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_1_Hypomagnesemia 135-09-1 HYDROFLUMETHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 135-09-1 HYDROFLUMETHIAZIDE INDICATION Hypertension 135-09-1 HYDROFLUMETHIAZIDE MODE_CLASS Channel Blocker, selective 71-68-1 HYDROMORPHONE MECHANISM Modulate neural transmission 71-68-1 HYDROMORPHONE INDICATION Pain 71-68-1 HYDROMORPHONE KNOWN_TOXICITY Cardiovascular Toxicity 71-68-1 HYDROMORPHONE ADVERSE_EFFECT NEU_1_Somnolence 71-68-1 HYDROMORPHONE ADVERSE_EFFECT CVS_3_Intracranial Hypertension 71-68-1 HYDROMORPHONE TISSUE_TOXICITY Intracranial Hypertension 71-68-1 HYDROMORPHONE PRODUCT_CLASS Analgesics 71-68-1 HYDROMORPHONE ADVERSE_EFFECT PSY_2_Hallucinations 71-68-1 HYDROMORPHONE TISSUE_TOXICITY Death 71-68-1 HYDROMORPHONE ADVERSE_EFFECT PSY_1_Mental Confusion 71-68-1 HYDROMORPHONE ADVERSE_EFFECT XXX_3_Death 71-68-1 HYDROMORPHONE KNOWN_TOXICITY Miscellaneous 71-68-1 HYDROMORPHONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 71-68-1 HYDROMORPHONE ADVERSE_EFFECT PSY_2_Dependence 71-68-1 HYDROMORPHONE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 71-68-1 HYDROMORPHONE ADVERSE_EFFECT LUN_3_Respiratory Depression 71-68-1 HYDROMORPHONE ADVERSE_EFFECT PSY_3_Nightmares 71-68-1 HYDROMORPHONE ADVERSE_EFFECT GIS_1_Constipation 71-68-1 HYDROMORPHONE THERAPEUTIC_CLASS Analgesics, Opioid 71-68-1 HYDROMORPHONE INDICATION Pain 71-68-1 HYDROMORPHONE MODE_CLASS Receptor Agonist 13422-51-0 HYDROXOCOBALAMIN MECHANISM Vitamin/ cofactor 306-21-8 HYDROXYAMPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 306-21-8 HYDROXYAMPHETAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 306-21-8 HYDROXYAMPHETAMINE INDICATION Induction of Cycloplegia for Eye Examinations 306-21-8 HYDROXYAMPHETAMINE PRODUCT_CLASS Other Human Uses 306-21-8 HYDROXYAMPHETAMINE MODE_CLASS Solute transporter inhibitor 306-21-8 HYDROXYAMPHETAMINE MODE_CLASS Receptor Partial Agonist 306-21-8 HYDROXYAMPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 306-21-8 HYDROXYAMPHETAMINE MODE_CLASS Enzyme substrate mimic 306-21-8 HYDROXYAMPHETAMINE INDICATION Induction of mydriasis for eye examinations 306-21-8 HYDROXYAMPHETAMINE MECHANISM Prolong/enhance neural transmission 306-21-8 HYDROXYAMPHETAMINE MECHANISM Block channel gating 747-36-4 HYDROXYCHLOROQUINE KNOWN_TOXICITY Cardiovascular Toxicity 747-36-4 HYDROXYCHLOROQUINE TISSUE_TOXICITY Cardiomyopathy 747-36-4 HYDROXYCHLOROQUINE INDICATION Rheumatoid Arthritis 747-36-4 HYDROXYCHLOROQUINE INDICATION Malaria Prophylaxis 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Eythema annulare cantrifugum 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_2_Abdominal Cramps 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OTO_3_Hearing Loss 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_1_Skin Reactions 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Irritability 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT MSK_3_Muscle Weakness 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Agranulocytosis 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_3_Diarrhea 747-36-4 HYDROXYCHLOROQUINE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 747-36-4 HYDROXYCHLOROQUINE INDICATION Malaria 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Bleaching of hair 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Neutropenia 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Emotional Lability 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT CVS_3_Cardiomyopathy 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_2_Epigastric Pain 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_3_Optic Atrophy 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Skin Discoloration 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Psoriasiform Skin Eruption 747-36-4 HYDROXYCHLOROQUINE PRODUCT_CLASS Anti-inflammatories 747-36-4 HYDROXYCHLOROQUINE INDICATION Systemic Lupus Erythromatosus (SLE) 747-36-4 HYDROXYCHLOROQUINE TISSUE_TOXICITY Hypotension 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT CVS_3_Hypotension 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_2_Dizziness 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_3_Seizures 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT IMU_1_Urticaria 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT CVS_3_ECG Abnormalities 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_3_Ocular Toxicity 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Pancytopenia 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT MSK_3_Myopathy 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_3_Retinopathy 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Confusion 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OTO_3_Tinnitus 747-36-4 HYDROXYCHLOROQUINE THERAPEUTIC_CLASS Antiparasitics 747-36-4 HYDROXYCHLOROQUINE PRODUCT_CLASS Anti-infectives 747-36-4 HYDROXYCHLOROQUINE INDICATION Polymorphous Light Eruptions 747-36-4 HYDROXYCHLOROQUINE TISSUE_TOXICITY Fulminant Hepatitis 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Exanthemous pustulosis 747-36-4 HYDROXYCHLOROQUINE KNOWN_TOXICITY Hepatotoxicity 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_2_Blurred Vision 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_2_Headache 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_2_Anorexia 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_1_Pruritis 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 747-36-4 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Psychosis 118-42-3 HYDROXYCHLOROQUINE THERAPEUTIC_CLASS Antiparasitics 118-42-3 HYDROXYCHLOROQUINE PRODUCT_CLASS Anti-infectives 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_3_Optic Atrophy 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Skin Discoloration 118-42-3 HYDROXYCHLOROQUINE PRODUCT_CLASS Anti-inflammatories 118-42-3 HYDROXYCHLOROQUINE INDICATION Systemic Lupus Erythromatosus (SLE) 118-42-3 HYDROXYCHLOROQUINE TISSUE_TOXICITY Hypotension 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT CVS_3_Hypotension 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_2_Dizziness 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_3_Seizures 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT IMU_1_Urticaria 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT CVS_3_ECG Abnormalities 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_3_Ocular Toxicity 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Pancytopenia 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT MSK_3_Myopathy 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_3_Retinopathy 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Exanthemous pustulosis 118-42-3 HYDROXYCHLOROQUINE KNOWN_TOXICITY Hepatotoxicity 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_2_Epigastric Pain 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Emotional Lability 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT CVS_3_Cardiomyopathy 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Psoriasiform Skin Eruption 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Confusion 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OTO_3_Tinnitus 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_2_Anorexia 118-42-3 HYDROXYCHLOROQUINE KNOWN_TOXICITY Cardiovascular Toxicity 118-42-3 HYDROXYCHLOROQUINE TISSUE_TOXICITY Cardiomyopathy 118-42-3 HYDROXYCHLOROQUINE INDICATION Rheumatoid Arthritis 118-42-3 HYDROXYCHLOROQUINE INDICATION Malaria Prophylaxis 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Eythema annulare cantrifugum 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_2_Abdominal Cramps 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OTO_3_Hearing Loss 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_1_Skin Reactions 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Irritability 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT MSK_3_Muscle Weakness 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Agranulocytosis 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT GIS_3_Diarrhea 118-42-3 HYDROXYCHLOROQUINE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 118-42-3 HYDROXYCHLOROQUINE INDICATION Malaria 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Bleaching of hair 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Lichenoid Drug Eruptions 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Neutropenia 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT PSY_3_Psychosis 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT SKN_1_Pruritis 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT NEU_2_Headache 118-42-3 HYDROXYCHLOROQUINE ADVERSE_EFFECT OCU_2_Blurred Vision 118-42-3 HYDROXYCHLOROQUINE TISSUE_TOXICITY Fulminant Hepatitis 118-42-3 HYDROXYCHLOROQUINE INDICATION Polymorphous Light Eruptions 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT END_2_Breast Tenderness 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_3_Cervical Erosion 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT GUS_1_Vaginal Spotting 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_2_Amenorrhea 630-56-8 HYDROXYPROGESTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 630-56-8 HYDROXYPROGESTERONE MODE_CLASS Receptor Agonist 630-56-8 HYDROXYPROGESTERONE MECHANISM Modulate gene transcription 630-56-8 HYDROXYPROGESTERONE INDICATION Amenorrhea 630-56-8 HYDROXYPROGESTERONE STRUCTURE_ACTIVITY Progesterone receptor agonist 630-56-8 HYDROXYPROGESTERONE INDICATION Dysfunctional Uterine Bleeding (DUB) 630-56-8 HYDROXYPROGESTERONE INDICATION Endometrial Cancer / Carcinoma of the Endometrium 630-56-8 HYDROXYPROGESTERONE TISSUE_TOXICITY Breakthrough Bleeding 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT XXX_2_Weight Gain 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 630-56-8 HYDROXYPROGESTERONE KNOWN_TOXICITY Reproductive System Toxicity 630-56-8 HYDROXYPROGESTERONE INDICATION Test For Endogenous Estrogen Production 630-56-8 HYDROXYPROGESTERONE THERAPEUTIC_CLASS Gonadal Hormones 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT END_2_Masculinizing Effects 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT XXX_3_Edema 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 630-56-8 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_2_Alterations in cervical mucus 80-75-1 HYDROXYPROGESTERONE INDICATION Dysfunctional Uterine Bleeding (DUB) 80-75-1 HYDROXYPROGESTERONE INDICATION Endometrial Cancer / Carcinoma of the Endometrium 80-75-1 HYDROXYPROGESTERONE TISSUE_TOXICITY Breakthrough Bleeding 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT XXX_2_Weight Gain 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 80-75-1 HYDROXYPROGESTERONE KNOWN_TOXICITY Reproductive System Toxicity 80-75-1 HYDROXYPROGESTERONE INDICATION Test For Endogenous Estrogen Production 80-75-1 HYDROXYPROGESTERONE THERAPEUTIC_CLASS Gonadal Hormones 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_2_Amenorrhea 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT END_2_Masculinizing Effects 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_2_Alterations in cervical mucus 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT XXX_3_Edema 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 80-75-1 HYDROXYPROGESTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 80-75-1 HYDROXYPROGESTERONE MECHANISM Modulate gene transcription 80-75-1 HYDROXYPROGESTERONE INDICATION Amenorrhea 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT REP_3_Cervical Erosion 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT END_2_Breast Tenderness 80-75-1 HYDROXYPROGESTERONE ADVERSE_EFFECT GUS_1_Vaginal Spotting 80-75-1 HYDROXYPROGESTERONE MODE_CLASS Receptor Agonist 80-75-1 HYDROXYPROGESTERONE STRUCTURE_ACTIVITY Progesterone receptor agonist 2192-20-3 HYDROXYZINE ADVERSE_EFFECT PSY_3_CNS Stimulation 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_3_Tremor 2192-20-3 HYDROXYZINE INDICATION Nausea / Vomiting 2192-20-3 HYDROXYZINE PRODUCT_CLASS Central Nervous System (CNS) 2192-20-3 HYDROXYZINE PRODUCT_CLASS Anti-inflammatories 2192-20-3 HYDROXYZINE ADVERSE_EFFECT OCU_1_Mydriasis 2192-20-3 HYDROXYZINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_2_Ataxia 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_2_Headache 2192-20-3 HYDROXYZINE ADVERSE_EFFECT PSY_3_Anxiety 2192-20-3 HYDROXYZINE ADVERSE_EFFECT GUS_1_Urinary Retention 2192-20-3 HYDROXYZINE INDICATION Insomnia 2192-20-3 HYDROXYZINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 2192-20-3 HYDROXYZINE MODE_CLASS Receptor Ligand Antagonist 2192-20-3 HYDROXYZINE ADVERSE_EFFECT PSY_2_Agitation 2192-20-3 HYDROXYZINE THERAPEUTIC_CLASS Antihistamines 2192-20-3 HYDROXYZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 2192-20-3 HYDROXYZINE INDICATION Anxiety 2192-20-3 HYDROXYZINE INDICATION Initiation / Maintenance of Sedation 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_2_Dysarthria 2192-20-3 HYDROXYZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_2_Drowsiness 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_2_Dizziness 2192-20-3 HYDROXYZINE INDICATION Pruritus / Itching 2192-20-3 HYDROXYZINE MECHANISM Modulate G-protein coupled signal transduction 2192-20-3 HYDROXYZINE INDICATION Alcoholic Withdrawal 2192-20-3 HYDROXYZINE ADVERSE_EFFECT XXX_1_Xerostomia 2192-20-3 HYDROXYZINE ADVERSE_EFFECT NEU_3_Seizures 2192-20-3 HYDROXYZINE ADVERSE_EFFECT XXX_3_Weakness 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Dysphagia 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Dysgeusia 101-31-5 HYOSCYAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 101-31-5 HYOSCYAMINE ADVERSE_EFFECT PSY_1_Confusion 101-31-5 HYOSCYAMINE THERAPEUTIC_CLASS Parasympatholytic Agents 101-31-5 HYOSCYAMINE INDICATION Gastric Ulcer 101-31-5 HYOSCYAMINE ADVERSE_EFFECT SKN_1_Flushing 101-31-5 HYOSCYAMINE INDICATION Irritable Bowel Syndrome 101-31-5 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Blurred Vision 101-31-5 HYOSCYAMINE ADVERSE_EFFECT PSY_3_Insomnia 101-31-5 HYOSCYAMINE ADVERSE_EFFECT REP_1_Impotence 101-31-5 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Drowsiness 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Dyspepsia 101-31-5 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Photophobia 101-31-5 HYOSCYAMINE INDICATION Organophosphate Poisoning 101-31-5 HYOSCYAMINE INDICATION Aspiration 101-31-5 HYOSCYAMINE TISSUE_TOXICITY Impotence 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Constipation 101-31-5 HYOSCYAMINE ADVERSE_EFFECT PSY_1_Nervousness 101-31-5 HYOSCYAMINE ADVERSE_EFFECT XXX_1_Weakness 101-31-5 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Dizziness 101-31-5 HYOSCYAMINE ADVERSE_EFFECT XXX_1_Xerostomia 101-31-5 HYOSCYAMINE KNOWN_TOXICITY Reproductive System Toxicity 101-31-5 HYOSCYAMINE MODE_CLASS Solute transporter inhibitor 101-31-5 HYOSCYAMINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 101-31-5 HYOSCYAMINE INDICATION Bradycardia 101-31-5 HYOSCYAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GUS_1_Urinary Retention 101-31-5 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Neurogenic Ileus 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 101-31-5 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Headache 101-31-5 HYOSCYAMINE ADVERSE_EFFECT GIS_3_Bloating 101-31-5 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Cycloplegia 101-31-5 HYOSCYAMINE ADVERSE_EFFECT SKN_1_Anhidrosis 101-31-5 HYOSCYAMINE INDICATION Duodenal Ulcer 101-31-5 HYOSCYAMINE MECHANISM Prolong/enhance neural transmission 101-31-5 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Mydriasis 101-31-5 HYOSCYAMINE ADVERSE_EFFECT CVS_1_Palpitation 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Drowsiness 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT REP_1_Impotence 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT PSY_3_Insomnia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Blurred Vision 13269-35-7 HYOSCYAMINE THERAPEUTIC_CLASS Parasympatholytic Agents 13269-35-7 HYOSCYAMINE INDICATION Gastric Ulcer 13269-35-7 HYOSCYAMINE INDICATION Irritable Bowel Syndrome 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT SKN_1_Anhidrosis 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Dysgeusia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Dysphagia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT PSY_1_Confusion 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT SKN_1_Flushing 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Mydriasis 13269-35-7 HYOSCYAMINE MECHANISM Prolong/enhance neural transmission 13269-35-7 HYOSCYAMINE INDICATION Duodenal Ulcer 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Cycloplegia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GIS_3_Bloating 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Headache 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Neurogenic Ileus 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GUS_1_Urinary Retention 13269-35-7 HYOSCYAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 13269-35-7 HYOSCYAMINE INDICATION Bradycardia 13269-35-7 HYOSCYAMINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 13269-35-7 HYOSCYAMINE MODE_CLASS Solute transporter inhibitor 13269-35-7 HYOSCYAMINE KNOWN_TOXICITY Reproductive System Toxicity 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT XXX_1_Xerostomia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT CVS_1_Palpitation 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT NEU_1_Dizziness 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT XXX_1_Weakness 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT PSY_1_Nervousness 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Constipation 13269-35-7 HYOSCYAMINE TISSUE_TOXICITY Impotence 13269-35-7 HYOSCYAMINE INDICATION Aspiration 13269-35-7 HYOSCYAMINE INDICATION Organophosphate Poisoning 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT OCU_1_Photophobia 13269-35-7 HYOSCYAMINE ADVERSE_EFFECT GIS_1_Dyspepsia 122647-31-8 IBUTILIDE MODE_CLASS Channel Blocker 122647-31-8 IBUTILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 122647-31-8 IBUTILIDE INDICATION Atrial Fibrillation 122647-31-8 IBUTILIDE INDICATION Atrial Flutter 122647-31-8 IBUTILIDE PRODUCT_CLASS Cardiovasculars 122647-31-8 IBUTILIDE MECHANISM Modulate channel gating 122647-32-9 IBUTILIDE MECHANISM Modulate channel gating 122647-32-9 IBUTILIDE MODE_CLASS Channel Blocker 122647-32-9 IBUTILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 122647-32-9 IBUTILIDE INDICATION Atrial Fibrillation 122647-32-9 IBUTILIDE INDICATION Atrial Flutter 122647-32-9 IBUTILIDE PRODUCT_CLASS Cardiovasculars 100632-81-3 IBUTILIDE MODE_CLASS Channel Blocker 100632-81-3 IBUTILIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 100632-81-3 IBUTILIDE MECHANISM Modulate channel gating 100632-81-3 IBUTILIDE PRODUCT_CLASS Cardiovasculars 100632-81-3 IBUTILIDE INDICATION Atrial Flutter 100632-81-3 IBUTILIDE INDICATION Atrial Fibrillation 143313-51-3 YVAD-CHO PRODUCT_CLASS Biochemicals 115199-84-3 ICL-199,441 HYDROCHLORIDE PRODUCT_CLASS Biochemicals 115199-84-3 ICL-199,441 HYDROCHLORIDE MODE_CLASS Receptor Agonist, selective 115199-84-3 ICL-199,441 HYDROCHLORIDE MECHANISM Modulate neural transmission 89565-68-4 TROPISETRON ADVERSE_EFFECT XXX_3_Asthenia 89565-68-4 TROPISETRON MECH_LEVEL_2 5HT antagonist 89565-68-4 TROPISETRON TA_LEVEL_3 IBS 89565-68-4 TROPISETRON MECH_LEVEL_3 5HT3 89565-68-4 TROPISETRON ADVERSE_EFFECT SKN_3_Skin Eruption 89565-68-4 TROPISETRON ADVERSE_EFFECT NEU_3_Somnolence 89565-68-4 TROPISETRON ADVERSE_EFFECT NEU_3_Vertigo 89565-68-4 TROPISETRON ADVERSE_EFFECT CVS_3_Hypertension 89565-68-4 TROPISETRON ADVERSE_EFFECT CVS_3_Hypotension 89565-68-4 TROPISETRON THERAPEUTIC_CLASS Cerebral Vascular Disorders 89565-68-4 TROPISETRON KNOWN_TOXICITY Cardiovascular Toxicity 89565-68-4 TROPISETRON TISSUE_TOXICITY Cardiovascular Collapse 89565-68-4 TROPISETRON INDICATION Vomiting 89565-68-4 TROPISETRON INDICATION Nausea / Vomiting 89565-68-4 TROPISETRON MODE_CLASS Channel Blocker, selective 89565-68-4 TROPISETRON MECHANISM Block neural transmission 89565-68-4 TROPISETRON ZERO_CLASS N 89565-68-4 TROPISETRON MESH_LEVEL_1 Heterocyclic Compounds 89565-68-4 TROPISETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 89565-68-4 TROPISETRON TA_LEVEL_1 Gastrointestinal System 89565-68-4 TROPISETRON MECHANISM Prolong/enhance neural transmission 89565-68-4 TROPISETRON MESH_LEVEL_3 Pyridines 89565-68-4 TROPISETRON ADVERSE_EFFECT GIS_3_Diarrhea 89565-68-4 TROPISETRON ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 89565-68-4 TROPISETRON ADVERSE_EFFECT IMU_3_Anaphylactic Shock 89565-68-4 TROPISETRON ADVERSE_EFFECT NEU_3_Syncope 89565-68-4 TROPISETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 89565-68-4 TROPISETRON TA_LEVEL_2 IBS 89565-68-4 TROPISETRON MECH_LEVEL_1 Modulate neural transmission 89565-68-4 TROPISETRON THERAPEUTIC_CLASS Antiemetics 89565-68-4 TROPISETRON PRODUCT_CLASS Central Nervous System (CNS) 89565-68-4 TROPISETRON INDICATION Migraine Headache 89565-68-4 TROPISETRON ACTIVITY_CLASS Serotonin antagonist 89565-68-4 TROPISETRON MODE_CLASS Solute transporter inhibitor 89565-68-4 TROPISETRON ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 89565-68-4 TROPISETRON ADVERSE_EFFECT CVS_3_Bradycardia 89565-68-4 TROPISETRON ADVERSE_EFFECT GIS_3_Abdominal Pain 89565-68-4 TROPISETRON ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 89565-68-4 TROPISETRON ADVERSE_EFFECT GIS_1_Constipation 89565-68-4 TROPISETRON TISSUE_TOXICITY Hypotension 89565-68-4 TROPISETRON PRODUCT_CLASS Gastrointestinal System 105826-92-4 TROPISETRON MESH_LEVEL_3 Pyridines 105826-92-4 TROPISETRON MESH_LEVEL_1 Heterocyclic Compounds 105826-92-4 TROPISETRON PRODUCT_CLASS Central Nervous System (CNS) 105826-92-4 TROPISETRON ZERO_CLASS N 105826-92-4 TROPISETRON ADVERSE_EFFECT XXX_3_Asthenia 105826-92-4 TROPISETRON ADVERSE_EFFECT CVS_3_Hypertension 105826-92-4 TROPISETRON ADVERSE_EFFECT CVS_3_Bradycardia 105826-92-4 TROPISETRON THERAPEUTIC_CLASS Antiemetics 105826-92-4 TROPISETRON MECH_LEVEL_1 Modulate neural transmission 105826-92-4 TROPISETRON TA_LEVEL_2 IBS 105826-92-4 TROPISETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 105826-92-4 TROPISETRON ADVERSE_EFFECT NEU_3_Syncope 105826-92-4 TROPISETRON ADVERSE_EFFECT IMU_3_Anaphylactic Shock 105826-92-4 TROPISETRON ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 105826-92-4 TROPISETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 105826-92-4 TROPISETRON TA_LEVEL_1 Gastrointestinal System 105826-92-4 TROPISETRON MECHANISM Prolong/enhance neural transmission 105826-92-4 TROPISETRON ADVERSE_EFFECT GIS_3_Diarrhea 105826-92-4 TROPISETRON MECHANISM Block neural transmission 105826-92-4 TROPISETRON ACTIVITY_CLASS Serotonin antagonist 105826-92-4 TROPISETRON MODE_CLASS Solute transporter inhibitor 105826-92-4 TROPISETRON ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 105826-92-4 TROPISETRON ADVERSE_EFFECT GIS_3_Abdominal Pain 105826-92-4 TROPISETRON ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 105826-92-4 TROPISETRON ADVERSE_EFFECT GIS_1_Constipation 105826-92-4 TROPISETRON TISSUE_TOXICITY Hypotension 105826-92-4 TROPISETRON INDICATION Migraine Headache 105826-92-4 TROPISETRON MECH_LEVEL_2 5HT antagonist 105826-92-4 TROPISETRON TA_LEVEL_3 IBS 105826-92-4 TROPISETRON MECH_LEVEL_3 5HT3 105826-92-4 TROPISETRON ADVERSE_EFFECT SKN_3_Skin Eruption 105826-92-4 TROPISETRON ADVERSE_EFFECT NEU_3_Somnolence 105826-92-4 TROPISETRON ADVERSE_EFFECT NEU_3_Vertigo 105826-92-4 TROPISETRON ADVERSE_EFFECT CVS_3_Hypotension 105826-92-4 TROPISETRON THERAPEUTIC_CLASS Cerebral Vascular Disorders 105826-92-4 TROPISETRON KNOWN_TOXICITY Cardiovascular Toxicity 105826-92-4 TROPISETRON TISSUE_TOXICITY Cardiovascular Collapse 105826-92-4 TROPISETRON PRODUCT_CLASS Gastrointestinal System 105826-92-4 TROPISETRON INDICATION Vomiting 105826-92-4 TROPISETRON INDICATION Nausea / Vomiting 105826-92-4 TROPISETRON MODE_CLASS Channel Blocker, selective 58957-92-9 IDARUBICIN TA_LEVEL_2 Soft tissue tumors 58957-92-9 IDARUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 58957-92-9 IDARUBICIN ADVERSE_EFFECT XXX_1_Mucositis 58957-92-9 IDARUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 58957-92-9 IDARUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 58957-92-9 IDARUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 58957-92-9 IDARUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT XXX_1_Local Tissue Necrosis 58957-92-9 IDARUBICIN TISSUE_TOXICITY Myelosuppression 58957-92-9 IDARUBICIN TISSUE_TOXICITY Nephrotoxicity 58957-92-9 IDARUBICIN TISSUE_TOXICITY Carcinogenicity 58957-92-9 IDARUBICIN TISSUE_TOXICITY Cardiotoxicity 58957-92-9 IDARUBICIN MESH_LEVEL_3 Aminoglycoside 58957-92-9 IDARUBICIN PRODUCT_CLASS Anti-cancers 58957-92-9 IDARUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 58957-92-9 IDARUBICIN TISSUE_TOXICITY Congestive Heart Failure 58957-92-9 IDARUBICIN KNOWN_TOXICITY Carcinogenicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 58957-92-9 IDARUBICIN ADVERSE_EFFECT XXX_1_Infection 58957-92-9 IDARUBICIN ADVERSE_EFFECT SKN_2_Skin Rash 58957-92-9 IDARUBICIN ADVERSE_EFFECT CVS_2_Atrial Fibrillation 58957-92-9 IDARUBICIN ADVERSE_EFFECT CVS_2_Myocardial Infarction 58957-92-9 IDARUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 58957-92-9 IDARUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 58957-92-9 IDARUBICIN TISSUE_TOXICITY Myocardial Infarction 58957-92-9 IDARUBICIN TISSUE_TOXICITY Mutagenicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT IMU_2_Urticaria 58957-92-9 IDARUBICIN THERAPEUTIC_CLASS Antineoplastics 58957-92-9 IDARUBICIN TISSUE_TOXICITY Hepatotoxicity 58957-92-9 IDARUBICIN KNOWN_TOXICITY Nephrotoxicity 58957-92-9 IDARUBICIN KNOWN_TOXICITY Mutagenicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT GIS_1_Abdominal Cramps 58957-92-9 IDARUBICIN TA_LEVEL_3 AML treatment 58957-92-9 IDARUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 58957-92-9 IDARUBICIN MECH_LEVEL_3 DNA Damage 58957-92-9 IDARUBICIN TA_LEVEL_1 Oncology 58957-92-9 IDARUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 58957-92-9 IDARUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 58957-92-9 IDARUBICIN ADVERSE_EFFECT GIS_1_Diarrhea 58957-92-9 IDARUBICIN ADVERSE_EFFECT GIS_3_Colitis 58957-92-9 IDARUBICIN ADVERSE_EFFECT KID_3_Nephrotoxicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT CVS_2_Chest Pain 58957-92-9 IDARUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 58957-92-9 IDARUBICIN ADVERSE_EFFECT GIS_3_Enterocolitis 58957-92-9 IDARUBICIN TISSUE_TOXICITY Cardiomyopathy 58957-92-9 IDARUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 58957-92-9 IDARUBICIN ACTIVITY_CLASS DNA damager 58957-92-9 IDARUBICIN MESH_LEVEL_2 Carbohydrates 58957-92-9 IDARUBICIN KNOWN_TOXICITY Hepatotoxicity 58957-92-9 IDARUBICIN TISSUE_TOXICITY Hemorrhage 58957-92-9 IDARUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 58957-92-9 IDARUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 58957-92-9 IDARUBICIN ADVERSE_EFFECT NEU_1_Headache 58957-92-9 IDARUBICIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 58957-92-9 IDARUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 58957-92-9 IDARUBICIN ADVERSE_EFFECT GIS_3_Bowel Perforation 58957-92-9 IDARUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 58957-92-9 IDARUBICIN TISSUE_TOXICITY Atrial Fibrillation 58957-92-9 IDARUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 54-42-2 IDOXURIDINE ADVERSE_EFFECT EMB_1_Teratogenicity 54-42-2 IDOXURIDINE INDICATION Herpes Simplex Infection 54-42-2 IDOXURIDINE ADVERSE_EFFECT XXX_2_Epithelial Degeneration 54-42-2 IDOXURIDINE ADVERSE_EFFECT GIS_1_Stomatitis 54-42-2 IDOXURIDINE ADVERSE_EFFECT XXX_3_Lacrimation 54-42-2 IDOXURIDINE MECHANISM Inhibit DNA synthesis, repair, and function 54-42-2 IDOXURIDINE TISSUE_TOXICITY Thrombocytopenia 54-42-2 IDOXURIDINE THERAPEUTIC_CLASS Antineoplastics 54-42-2 IDOXURIDINE MECHANISM Inhibit precursor synthesis 54-42-2 IDOXURIDINE INDICATION Herpes Simplex Keratitis 54-42-2 IDOXURIDINE INDICATION Herpes Zoster / Shingles 54-42-2 IDOXURIDINE ADVERSE_EFFECT SKN_2_Skin Maceration 54-42-2 IDOXURIDINE ADVERSE_EFFECT OCU_2_Punctate Keratitis 54-42-2 IDOXURIDINE ADVERSE_EFFECT XXX_1_Stinging Sensation 54-42-2 IDOXURIDINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 54-42-2 IDOXURIDINE TISSUE_TOXICITY Leukopenia 54-42-2 IDOXURIDINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 54-42-2 IDOXURIDINE THERAPEUTIC_CLASS Antivirals, Topical 54-42-2 IDOXURIDINE ADVERSE_EFFECT OCU_3_Occlusion of Lacrimal Puncta 54-42-2 IDOXURIDINE PRODUCT_CLASS Anti-infectives 54-42-2 IDOXURIDINE INDICATION Soft Tissue Sarcoma 54-42-2 IDOXURIDINE PRODUCT_CLASS Anti-cancers 54-42-2 IDOXURIDINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 54-42-2 IDOXURIDINE MODE_CLASS Enzyme Inhibitor 54-42-2 IDOXURIDINE ADVERSE_EFFECT OCU_3_Lid Edema 54-42-2 IDOXURIDINE ADVERSE_EFFECT BBM_1_Leukopenia 54-42-2 IDOXURIDINE ADVERSE_EFFECT OCU_3_Follicular Conjunctivitis 54-42-2 IDOXURIDINE TISSUE_TOXICITY Teratogenicity 54-42-2 IDOXURIDINE KNOWN_TOXICITY Embryo/Fetal Toxicity 54-42-2 IDOXURIDINE MODE_CLASS Enzyme substrate mimic 54-42-2 IDOXURIDINE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 23210-56-2 IFENPRODIL MECHANISM Block neural transmission 23210-56-2 IFENPRODIL THERAPEUTIC_CLASS Vasodilators 23210-56-2 IFENPRODIL MODE_CLASS Channel Blocker 23210-56-2 IFENPRODIL PRODUCT_CLASS Central Nervous System (CNS) 23210-56-2 IFENPRODIL PRODUCT_CLASS Cardiovasculars 23210-56-2 IFENPRODIL INDICATION Cerebrovascular Insufficiency 23210-56-2 IFENPRODIL MECHANISM Modulate G-protein coupled signal transduction 68562-41-4 INSULIN-LIKE GROWTH FACTOR I, HUMAN PRODUCT_CLASS Biochemicals 102203-18-9 IMETIT DIHYDROBROMIDE PRODUCT_CLASS Biochemicals 50-49-7 IMIPRAMINE ADVERSE_EFFECT BBM_3_Leukopenia 50-49-7 IMIPRAMINE ADVERSE_EFFECT MSK_3_Cramps 50-49-7 IMIPRAMINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 50-49-7 IMIPRAMINE ADVERSE_EFFECT OCU_2_Increased Intraocular Pressure 50-49-7 IMIPRAMINE ADVERSE_EFFECT CVS_1_Prolonged PR Interval 50-49-7 IMIPRAMINE MODE_CLASS Solute transporter inhibitor 50-49-7 IMIPRAMINE INDICATION Neuropathic Pain 50-49-7 IMIPRAMINE INDICATION Depression 50-49-7 IMIPRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_3_Neurogenic Ileus 50-49-7 IMIPRAMINE ADVERSE_EFFECT PSY_2_Anorexia 50-49-7 IMIPRAMINE ADVERSE_EFFECT IMU_3_Allergic Reactions 50-49-7 IMIPRAMINE ADVERSE_EFFECT XXX_3_Withdrawal 50-49-7 IMIPRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 50-49-7 IMIPRAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 50-49-7 IMIPRAMINE ADVERSE_EFFECT XXX_2_Xerostomia 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 50-49-7 IMIPRAMINE ADVERSE_EFFECT XXX_3_Breast Enlargement 50-49-7 IMIPRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 50-49-7 IMIPRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 50-49-7 IMIPRAMINE TISSUE_TOXICITY Ventricular Tachycardia 50-49-7 IMIPRAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 50-49-7 IMIPRAMINE INDICATION Phobic Disorder 50-49-7 IMIPRAMINE ADVERSE_EFFECT REP_3_Testicular Toxicity 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_2_Tremor 50-49-7 IMIPRAMINE ADVERSE_EFFECT REP_3_Female Orgasm Dysfunction 50-49-7 IMIPRAMINE ADVERSE_EFFECT CVS_3_Palpitation 50-49-7 IMIPRAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 50-49-7 IMIPRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_3_Seizures 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_2_Dizziness 50-49-7 IMIPRAMINE ADVERSE_EFFECT OCU_2_Cycloplegia 50-49-7 IMIPRAMINE ADVERSE_EFFECT OCU_2_Mydriasis 50-49-7 IMIPRAMINE ADVERSE_EFFECT GIS_3_Diarrhea 50-49-7 IMIPRAMINE INDICATION Urinary Incontinence / Enuresis 50-49-7 IMIPRAMINE INDICATION Diabetic Neuropathy 50-49-7 IMIPRAMINE INDICATION Panic Disorder 50-49-7 IMIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 50-49-7 IMIPRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 50-49-7 IMIPRAMINE ADVERSE_EFFECT CVS_3_Hypertension 50-49-7 IMIPRAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-49-7 IMIPRAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 50-49-7 IMIPRAMINE ADVERSE_EFFECT REP_3_Impaired Ejaculation 50-49-7 IMIPRAMINE ADVERSE_EFFECT LIV_3_Jaundice 50-49-7 IMIPRAMINE ADVERSE_EFFECT IMU_3_Eosinophilia 50-49-7 IMIPRAMINE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 50-49-7 IMIPRAMINE ADVERSE_EFFECT NEU_3_Pseudo-Parkinsonism 50-49-7 IMIPRAMINE ADVERSE_EFFECT BBM_3_Purpura 50-49-7 IMIPRAMINE THERAPEUTIC_CLASS Antidepressants 50-49-7 IMIPRAMINE INDICATION Postherpetic Neuralgia 50-49-7 IMIPRAMINE INDICATION Bulimia Nervosa 50-49-7 IMIPRAMINE MECHANISM Prolong/enhance neural transmission 50-49-7 IMIPRAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 50-49-7 IMIPRAMINE ADVERSE_EFFECT GIS_3_Constipation 50-49-7 IMIPRAMINE ADVERSE_EFFECT REP_3_Decreased Libido 113-52-0 IMIPRAMINE ADVERSE_EFFECT OCU_2_Increased Intraocular Pressure 113-52-0 IMIPRAMINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 113-52-0 IMIPRAMINE ADVERSE_EFFECT MSK_3_Cramps 113-52-0 IMIPRAMINE ADVERSE_EFFECT BBM_3_Leukopenia 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_3_Seizures 113-52-0 IMIPRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_2_Tremor 113-52-0 IMIPRAMINE ADVERSE_EFFECT REP_3_Impaired Ejaculation 113-52-0 IMIPRAMINE ADVERSE_EFFECT GIS_3_Constipation 113-52-0 IMIPRAMINE MECHANISM Prolong/enhance neural transmission 113-52-0 IMIPRAMINE INDICATION Bulimia Nervosa 113-52-0 IMIPRAMINE INDICATION Postherpetic Neuralgia 113-52-0 IMIPRAMINE THERAPEUTIC_CLASS Antidepressants 113-52-0 IMIPRAMINE ADVERSE_EFFECT BBM_3_Purpura 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_3_Pseudo-Parkinsonism 113-52-0 IMIPRAMINE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 113-52-0 IMIPRAMINE ADVERSE_EFFECT IMU_3_Eosinophilia 113-52-0 IMIPRAMINE ADVERSE_EFFECT LIV_3_Jaundice 113-52-0 IMIPRAMINE ADVERSE_EFFECT REP_3_Decreased Libido 113-52-0 IMIPRAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 113-52-0 IMIPRAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 113-52-0 IMIPRAMINE ADVERSE_EFFECT CVS_3_Hypertension 113-52-0 IMIPRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 113-52-0 IMIPRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 113-52-0 IMIPRAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 113-52-0 IMIPRAMINE INDICATION Phobic Disorder 113-52-0 IMIPRAMINE ADVERSE_EFFECT REP_3_Testicular Toxicity 113-52-0 IMIPRAMINE ADVERSE_EFFECT REP_3_Female Orgasm Dysfunction 113-52-0 IMIPRAMINE ADVERSE_EFFECT OCU_2_Cycloplegia 113-52-0 IMIPRAMINE ADVERSE_EFFECT CVS_3_Palpitation 113-52-0 IMIPRAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_2_Dizziness 113-52-0 IMIPRAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 113-52-0 IMIPRAMINE ADVERSE_EFFECT OCU_2_Mydriasis 113-52-0 IMIPRAMINE ADVERSE_EFFECT GIS_3_Diarrhea 113-52-0 IMIPRAMINE INDICATION Urinary Incontinence / Enuresis 113-52-0 IMIPRAMINE INDICATION Diabetic Neuropathy 113-52-0 IMIPRAMINE INDICATION Panic Disorder 113-52-0 IMIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 113-52-0 IMIPRAMINE ADVERSE_EFFECT CVS_1_Prolonged PR Interval 113-52-0 IMIPRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 113-52-0 IMIPRAMINE ADVERSE_EFFECT XXX_3_Breast Enlargement 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 113-52-0 IMIPRAMINE ADVERSE_EFFECT XXX_2_Xerostomia 113-52-0 IMIPRAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 113-52-0 IMIPRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 113-52-0 IMIPRAMINE ADVERSE_EFFECT XXX_3_Withdrawal 113-52-0 IMIPRAMINE ADVERSE_EFFECT IMU_3_Allergic Reactions 113-52-0 IMIPRAMINE ADVERSE_EFFECT PSY_2_Anorexia 113-52-0 IMIPRAMINE ADVERSE_EFFECT NEU_3_Neurogenic Ileus 113-52-0 IMIPRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 113-52-0 IMIPRAMINE TISSUE_TOXICITY Ventricular Tachycardia 113-52-0 IMIPRAMINE INDICATION Depression 113-52-0 IMIPRAMINE INDICATION Neuropathic Pain 113-52-0 IMIPRAMINE MODE_CLASS Solute transporter inhibitor 99011-02-6 IMIQUIMOD ADVERSE_EFFECT XXX_2_Influenza-Like Syndrome 99011-02-6 IMIQUIMOD ADVERSE_EFFECT GIS_3_Diarrhea 99011-02-6 IMIQUIMOD ADVERSE_EFFECT MSK_2_Myalgia 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Induration 99011-02-6 IMIQUIMOD ADVERSE_EFFECT NEU_2_Headache 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Erythema 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Skin Excoriation 99011-02-6 IMIQUIMOD PRODUCT_CLASS Dermatologicals 99011-02-6 IMIQUIMOD ADVERSE_EFFECT XXX_3_Fatigue 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Pruritis 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Skin Ulcer 99011-02-6 IMIQUIMOD INDICATION Molluscum Contagiosum 99011-02-6 IMIQUIMOD ADVERSE_EFFECT XXX_3_Fever 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Skin Erosion 99011-02-6 IMIQUIMOD ADVERSE_EFFECT XXX_2_Pain 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_3_Fungal Dermatitis 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Skin Irritation 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Scabbing 99011-02-6 IMIQUIMOD INDICATION Warts 99011-02-6 IMIQUIMOD INDICATION Condylomata Acuminata 99011-02-6 IMIQUIMOD ADVERSE_EFFECT SKN_1_Vesicular Rash 99011-02-6 IMIQUIMOD THERAPEUTIC_CLASS Immunomodulants 99011-02-6 IMIQUIMOD ADVERSE_EFFECT XXX_1_Edema 164391-47-3 IMMEPIP PRODUCT_CLASS Biochemicals 138330-18-4 INCADRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 138330-18-4 INCADRONIC ACID MECHANISM Inhibit bone re-absorption 138330-18-4 INCADRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 138330-18-4 INCADRONIC ACID MODE_CLASS Enzyme Inhibitor 138330-18-4 INCADRONIC ACID INDICATION Hypercalcemia of Malignancy 138330-18-4 INCADRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 183808-97-1 INCADRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 183808-97-1 INCADRONIC ACID MECHANISM Inhibit bone re-absorption 183808-97-1 INCADRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 183808-97-1 INCADRONIC ACID INDICATION Hypercalcemia of Malignancy 183808-97-1 INCADRONIC ACID MODE_CLASS Enzyme Inhibitor 183808-97-1 INCADRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 26807-65-8 INDAPAMIDE ADVERSE_EFFECT REP_3_Decreased Libido 26807-65-8 INDAPAMIDE INDICATION Congestive Heart Failure (CHF) 26807-65-8 INDAPAMIDE INDICATION Edema 26807-65-8 INDAPAMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 26807-65-8 INDAPAMIDE ADVERSE_EFFECT IMU_3_Photosensitivity 26807-65-8 INDAPAMIDE ADVERSE_EFFECT PSY_3_Irritability 26807-65-8 INDAPAMIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 26807-65-8 INDAPAMIDE ADVERSE_EFFECT XXX_1_Hypovolemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 26807-65-8 INDAPAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 26807-65-8 INDAPAMIDE THERAPEUTIC_CLASS Diuretics 26807-65-8 INDAPAMIDE ADVERSE_EFFECT XXX_1_Thirst 26807-65-8 INDAPAMIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 26807-65-8 INDAPAMIDE ADVERSE_EFFECT END_3_Hypophosphatemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT PSY_3_Nervousness 26807-65-8 INDAPAMIDE ADVERSE_EFFECT KID_2_Hyperuricemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT ELT_1_Hypomagnesemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT ELT_1_Hyponatremia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT XXX_2_Lethargy 26807-65-8 INDAPAMIDE ADVERSE_EFFECT LIV_3_Hepatitis 26807-65-8 INDAPAMIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 26807-65-8 INDAPAMIDE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 26807-65-8 INDAPAMIDE ADVERSE_EFFECT GIS_3_Pancreatitis 26807-65-8 INDAPAMIDE MODE_CLASS Channel Blocker 26807-65-8 INDAPAMIDE INDICATION Hypertension 26807-65-8 INDAPAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 26807-65-8 INDAPAMIDE THERAPEUTIC_CLASS Congestive Heart Failure 26807-65-8 INDAPAMIDE ADVERSE_EFFECT OCU_3_Xanthopsia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT KID_3_Azotemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT BBM_3_Purpura 26807-65-8 INDAPAMIDE ADVERSE_EFFECT XXX_2_Dehydration 26807-65-8 INDAPAMIDE ADVERSE_EFFECT ELT_1_Hypokalemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT NEU_3_Dizziness 26807-65-8 INDAPAMIDE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 26807-65-8 INDAPAMIDE ADVERSE_EFFECT PSY_3_Agitation 26807-65-8 INDAPAMIDE ADVERSE_EFFECT LUN_3_Respiratory Distress 26807-65-8 INDAPAMIDE ADVERSE_EFFECT XXX_1_Xerostomia 26807-65-8 INDAPAMIDE THERAPEUTIC_CLASS Antihypertensive Agents 26807-65-8 INDAPAMIDE ADVERSE_EFFECT END_2_Hypercholesteremia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT KID_3_Oliguria 26807-65-8 INDAPAMIDE ADVERSE_EFFECT OCU_3_Blurred Vision 26807-65-8 INDAPAMIDE ADVERSE_EFFECT XXX_2_Fatigue 26807-65-8 INDAPAMIDE ADVERSE_EFFECT NEU_2_Headache 26807-65-8 INDAPAMIDE ADVERSE_EFFECT NEU_3_Paresthesia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT SKN_3_Pruritis 26807-65-8 INDAPAMIDE ADVERSE_EFFECT BBM_3_Hematological Reactions 26807-65-8 INDAPAMIDE PRODUCT_CLASS Cardiovasculars 26807-65-8 INDAPAMIDE ADVERSE_EFFECT NEU_3_Vertigo 26807-65-8 INDAPAMIDE ADVERSE_EFFECT SKN_3_Maculopapular Rash 26807-65-8 INDAPAMIDE ADVERSE_EFFECT NEU_3_Lightheadedness 26807-65-8 INDAPAMIDE ADVERSE_EFFECT END_2_Hypertriglyceridemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT ELT_2_Hypercalcemia 26807-65-8 INDAPAMIDE ADVERSE_EFFECT REP_3_Impotence 26807-65-8 INDAPAMIDE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 127779-20-8 SAQUINAVIR MECHANISM Inhibit post transcriptional protein processing 127779-20-8 SAQUINAVIR KNOWN_TOXICITY Nephrotoxicity 127779-20-8 SAQUINAVIR ZERO_CLASS N 127779-20-8 SAQUINAVIR ADVERSE_EFFECT END_2_Fat Redistribution 127779-20-8 SAQUINAVIR ADVERSE_EFFECT GIS_1_Flatulence 127779-20-8 SAQUINAVIR ADVERSE_EFFECT GIS_3_Pancreatitis 127779-20-8 SAQUINAVIR ADVERSE_EFFECT LIV_3_Hepatotoxicity 127779-20-8 SAQUINAVIR ADVERSE_EFFECT END_2_Hypertriglyceridemia 127779-20-8 SAQUINAVIR ADVERSE_EFFECT REP_3_Sexual Dysfunction 127779-20-8 SAQUINAVIR ADVERSE_EFFECT PSY_2_Anorexia 127779-20-8 SAQUINAVIR TA_LEVEL_1 Infectious Disease 127779-20-8 SAQUINAVIR MECH_LEVEL_3 HIV-1 retropepsin 127779-20-8 SAQUINAVIR TA_LEVEL_2 Anti-viral 127779-20-8 SAQUINAVIR TISSUE_TOXICITY Hepatotoxicity 127779-20-8 SAQUINAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 127779-20-8 SAQUINAVIR ADVERSE_EFFECT END_2_Exacerbation of Diabetes 127779-20-8 SAQUINAVIR ADVERSE_EFFECT XXX_2_Taste Disturbances 127779-20-8 SAQUINAVIR ADVERSE_EFFECT KID_3_Acute Renal Failure 127779-20-8 SAQUINAVIR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 127779-20-8 SAQUINAVIR ADVERSE_EFFECT NEU_3_Seizures 127779-20-8 SAQUINAVIR ADVERSE_EFFECT NEU_1_Headache 127779-20-8 SAQUINAVIR ADVERSE_EFFECT PSY_2_Insomnia 127779-20-8 SAQUINAVIR PRODUCT_CLASS Anti-infectives 127779-20-8 SAQUINAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 127779-20-8 SAQUINAVIR MESH_LEVEL_1 Heterocyclic Compounds 127779-20-8 SAQUINAVIR TA_LEVEL_3 viral replication inhibitor 127779-20-8 SAQUINAVIR MESH_LEVEL_3 Isoquinolines 127779-20-8 SAQUINAVIR THERAPEUTIC_CLASS Antivirals, Systemic 127779-20-8 SAQUINAVIR KNOWN_TOXICITY Hepatotoxicity 127779-20-8 SAQUINAVIR MODE_CLASS Enzyme Inhibitor 127779-20-8 SAQUINAVIR ADVERSE_EFFECT LIV_2_Abnormal Liver Function 127779-20-8 SAQUINAVIR ADVERSE_EFFECT GIS_1_Abdominal Pain 127779-20-8 SAQUINAVIR ADVERSE_EFFECT BBM_3_Thrombocytopenia 127779-20-8 SAQUINAVIR ADVERSE_EFFECT NEU_3_Ataxia 127779-20-8 SAQUINAVIR ADVERSE_EFFECT IMU_3_Allergic Reactions 127779-20-8 SAQUINAVIR ADVERSE_EFFECT GIS_1_Nausea 127779-20-8 SAQUINAVIR ADVERSE_EFFECT GIS_1_Diarrhea 127779-20-8 SAQUINAVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 127779-20-8 SAQUINAVIR MECH_LEVEL_2 viral protease inhibition 127779-20-8 SAQUINAVIR MECH_LEVEL_1 Anti-viral 127779-20-8 SAQUINAVIR ACTIVITY_CLASS Anti-viral 127779-20-8 SAQUINAVIR TISSUE_TOXICITY Acute Renal Failure 127779-20-8 SAQUINAVIR ADVERSE_EFFECT END_3_Diabetogenesis 127779-20-8 SAQUINAVIR ADVERSE_EFFECT GIS_1_Dyspepsia 127779-20-8 SAQUINAVIR ADVERSE_EFFECT BBM_3_Acute Leukemia 127779-20-8 SAQUINAVIR ADVERSE_EFFECT BBM_3_Anemia 127779-20-8 SAQUINAVIR ADVERSE_EFFECT SKN_2_Rash 127779-20-8 SAQUINAVIR ADVERSE_EFFECT XXX_1_Fatigue 127779-20-8 SAQUINAVIR ADVERSE_EFFECT PSY_2_Depression 83-73-8 IODOQUINOL ADVERSE_EFFECT SKN_2_Nail Discoloration 83-73-8 IODOQUINOL PRODUCT_CLASS Anti-infectives 83-73-8 IODOQUINOL THERAPEUTIC_CLASS Antiparasitics 83-73-8 IODOQUINOL ADVERSE_EFFECT NEU_2_Headache 83-73-8 IODOQUINOL ADVERSE_EFFECT BBM_3_Agranulocytosis 83-73-8 IODOQUINOL ADVERSE_EFFECT NEU_3_Vertigo 83-73-8 IODOQUINOL ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 83-73-8 IODOQUINOL ADVERSE_EFFECT NEU_3_Neurotoxicity 83-73-8 IODOQUINOL ADVERSE_EFFECT END_3_Thyroid Enlargement 83-73-8 IODOQUINOL ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 83-73-8 IODOQUINOL ADVERSE_EFFECT NEU_3_Optic Atrophy 83-73-8 IODOQUINOL ADVERSE_EFFECT XXX_3_Fever 83-73-8 IODOQUINOL ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 83-73-8 IODOQUINOL ADVERSE_EFFECT XXX_3_Chills 83-73-8 IODOQUINOL ADVERSE_EFFECT XXX_2_Malaise 83-73-8 IODOQUINOL ADVERSE_EFFECT SKN_2_Skin Discoloration 83-73-8 IODOQUINOL ADVERSE_EFFECT NEU_3_Optic Neuritis 83-73-8 IODOQUINOL ADVERSE_EFFECT SKN_3_Skin Disorder 83-73-8 IODOQUINOL INDICATION Amebiasis 22254-24-6 IPRATROPIUM BROMIDE INDICATION Allergic Rhinitis 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT CVS_3_Palpitation 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT PSY_3_Nervousness 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT NEU_3_Dizziness 22254-24-6 IPRATROPIUM BROMIDE INDICATION Chronic Bronchitis 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT XXX_3_Dryness of Mucus Membrane 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT OCU_3_Blurred Vision 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT NEU_3_Headache 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT IMU_3_Urticaria 22254-24-6 IPRATROPIUM BROMIDE THERAPEUTIC_CLASS Bronchodilators 22254-24-6 IPRATROPIUM BROMIDE MODE_CLASS Receptor Ligand Antagonist 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT LUN_3_Cough 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT IMU_3_Angioedema 22254-24-6 IPRATROPIUM BROMIDE MECHANISM Prolong/enhance neural transmission 22254-24-6 IPRATROPIUM BROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT SKN_3_Dermatitis 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT OCU_2_Acute Angle-Closure Glaucoma 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT GIS_3_Nausea 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT LUN_3_Bronchospasm 22254-24-6 IPRATROPIUM BROMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 22254-24-6 IPRATROPIUM BROMIDE MODE_CLASS Solute transporter inhibitor 22254-24-6 IPRATROPIUM BROMIDE PRODUCT_CLASS Respiratory System 22254-24-6 IPRATROPIUM BROMIDE INDICATION Prophylaxis of Asthma 22254-24-6 IPRATROPIUM BROMIDE INDICATION Emphysema 22254-24-6 IPRATROPIUM BROMIDE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 22254-24-6 IPRATROPIUM BROMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT NEU_3_Paralytic Ileus 22254-24-6 IPRATROPIUM BROMIDE MECHANISM Modulate G-protein coupled signal transduction 22254-24-6 IPRATROPIUM BROMIDE ADVERSE_EFFECT GUS_3_Urinary Retention 54-92-2 IPRONIAZID ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 54-92-2 IPRONIAZID STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 54-92-2 IPRONIAZID KNOWN_TOXICITY Hepatotoxicity 54-92-2 IPRONIAZID TISSUE_TOXICITY Hypotension 54-92-2 IPRONIAZID TISSUE_TOXICITY Hepatic Failure 54-92-2 IPRONIAZID MODE_CLASS Enzyme Inhibitor 54-92-2 IPRONIAZID ADVERSE_EFFECT NEU_2_Sedation 54-92-2 IPRONIAZID PRODUCT_CLASS Central Nervous System (CNS) 54-92-2 IPRONIAZID TISSUE_TOXICITY Liver Cirrhosis 54-92-2 IPRONIAZID MECH_LEVEL_2 Prolong/enhance neural transmission 54-92-2 IPRONIAZID ADVERSE_EFFECT PSY_2_Mania 54-92-2 IPRONIAZID MESH_LEVEL_1 Organic Chemicals 54-92-2 IPRONIAZID MECH_LEVEL_1 Modulate neural transmission 54-92-2 IPRONIAZID KNOWN_TOXICITY Cardiovascular Toxicity 54-92-2 IPRONIAZID ADVERSE_EFFECT GIS_2_Constipation 54-92-2 IPRONIAZID ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 54-92-2 IPRONIAZID ADVERSE_EFFECT CVS_3_Hypotension 54-92-2 IPRONIAZID ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 54-92-2 IPRONIAZID ADVERSE_EFFECT LIV_3_Liver Cirrhosis 54-92-2 IPRONIAZID ZERO_CLASS N 54-92-2 IPRONIAZID INDICATION Depression 54-92-2 IPRONIAZID ADVERSE_EFFECT NEU_2_Psychomotor Excitation 54-92-2 IPRONIAZID INDICATION Depression 54-92-2 IPRONIAZID TA_LEVEL_1 Central Nervous System (CNS) 54-92-2 IPRONIAZID MESH_LEVEL_2 Hydrazines 54-92-2 IPRONIAZID ADVERSE_EFFECT REP_3_Impotence 54-92-2 IPRONIAZID ADVERSE_EFFECT LIV_3_Hepatic Failure 54-92-2 IPRONIAZID ADVERSE_EFFECT GIS_2_Dry Mouth 54-92-2 IPRONIAZID THERAPEUTIC_CLASS Antidepressants 54-92-2 IPRONIAZID ADVERSE_EFFECT PSY_2_Euphoria 54-92-2 IPRONIAZID TA_LEVEL_3 depression 54-92-2 IPRONIAZID MECH_LEVEL_3 Mono amine oxidase 54-92-2 IPRONIAZID ADVERSE_EFFECT CVS_2_Tachycardia 54-92-2 IPRONIAZID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 54-92-2 IPRONIAZID ADVERSE_EFFECT PSY_2_Insomnia 54-92-2 IPRONIAZID ADVERSE_EFFECT LIV_3_Hepatitis 54-92-2 IPRONIAZID ADVERSE_EFFECT GUS_2_Dysuria 54-92-2 IPRONIAZID ADVERSE_EFFECT PSY_2_Anxiety 54-92-2 IPRONIAZID TISSUE_TOXICITY Fulminant Hepatitis 54-92-2 IPRONIAZID ADVERSE_EFFECT NEU_2_Tremor 54-92-2 IPRONIAZID TA_LEVEL_2 CNS Stimulant 54-92-2 IPRONIAZID MESH_LEVEL_3 Iproniazid 54-92-2 IPRONIAZID ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 54-92-2 IPRONIAZID MECHANISM Prolong/enhance neural transmission 54-92-2 IPRONIAZID ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 54-92-2 IPRONIAZID ADVERSE_EFFECT LIV_2_Jaundice 54-92-2 IPRONIAZID ADVERSE_EFFECT CVS_3_Hypertension 305-33-9 IPRONIAZID KNOWN_TOXICITY Hepatotoxicity 305-33-9 IPRONIAZID TISSUE_TOXICITY Hypotension 305-33-9 IPRONIAZID TISSUE_TOXICITY Hepatic Failure 305-33-9 IPRONIAZID TISSUE_TOXICITY Liver Cirrhosis 305-33-9 IPRONIAZID MODE_CLASS Enzyme Inhibitor 305-33-9 IPRONIAZID MESH_LEVEL_2 Hydrazines 305-33-9 IPRONIAZID TA_LEVEL_1 Central Nervous System (CNS) 305-33-9 IPRONIAZID INDICATION Depression 305-33-9 IPRONIAZID ADVERSE_EFFECT NEU_2_Psychomotor Excitation 305-33-9 IPRONIAZID INDICATION Depression 305-33-9 IPRONIAZID ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 305-33-9 IPRONIAZID ADVERSE_EFFECT LIV_3_Liver Cirrhosis 305-33-9 IPRONIAZID ADVERSE_EFFECT CVS_3_Hypotension 305-33-9 IPRONIAZID ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 305-33-9 IPRONIAZID ADVERSE_EFFECT REP_3_Impotence 305-33-9 IPRONIAZID ADVERSE_EFFECT GIS_2_Constipation 305-33-9 IPRONIAZID KNOWN_TOXICITY Cardiovascular Toxicity 305-33-9 IPRONIAZID MECH_LEVEL_1 Modulate neural transmission 305-33-9 IPRONIAZID MESH_LEVEL_1 Organic Chemicals 305-33-9 IPRONIAZID MECH_LEVEL_2 Prolong/enhance neural transmission 305-33-9 IPRONIAZID PRODUCT_CLASS Central Nervous System (CNS) 305-33-9 IPRONIAZID ADVERSE_EFFECT NEU_2_Sedation 305-33-9 IPRONIAZID ADVERSE_EFFECT CVS_2_Tachycardia 305-33-9 IPRONIAZID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 305-33-9 IPRONIAZID ADVERSE_EFFECT PSY_2_Insomnia 305-33-9 IPRONIAZID ADVERSE_EFFECT LIV_3_Hepatitis 305-33-9 IPRONIAZID MECHANISM Prolong/enhance neural transmission 305-33-9 IPRONIAZID ADVERSE_EFFECT LIV_3_Hepatic Failure 305-33-9 IPRONIAZID ADVERSE_EFFECT GIS_2_Dry Mouth 305-33-9 IPRONIAZID THERAPEUTIC_CLASS Antidepressants 305-33-9 IPRONIAZID TA_LEVEL_3 depression 305-33-9 IPRONIAZID MECH_LEVEL_3 Mono amine oxidase 305-33-9 IPRONIAZID ADVERSE_EFFECT GUS_2_Dysuria 305-33-9 IPRONIAZID ADVERSE_EFFECT PSY_2_Anxiety 305-33-9 IPRONIAZID TISSUE_TOXICITY Fulminant Hepatitis 305-33-9 IPRONIAZID ADVERSE_EFFECT NEU_2_Tremor 305-33-9 IPRONIAZID TA_LEVEL_2 CNS Stimulant 305-33-9 IPRONIAZID MESH_LEVEL_3 Iproniazid 305-33-9 IPRONIAZID ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 305-33-9 IPRONIAZID ZERO_CLASS N 305-33-9 IPRONIAZID ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 305-33-9 IPRONIAZID ADVERSE_EFFECT PSY_2_Mania 305-33-9 IPRONIAZID ADVERSE_EFFECT LIV_2_Jaundice 305-33-9 IPRONIAZID ADVERSE_EFFECT CVS_3_Hypertension 305-33-9 IPRONIAZID ADVERSE_EFFECT PSY_2_Euphoria 305-33-9 IPRONIAZID ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 305-33-9 IPRONIAZID STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 138402-11-6 IRBESARTAN TISSUE_TOXICITY Teratogenicity 138402-11-6 IRBESARTAN KNOWN_TOXICITY Cardiovascular Toxicity 138402-11-6 IRBESARTAN ADVERSE_EFFECT EMB_3_Teratogenicity 138402-11-6 IRBESARTAN ADVERSE_EFFECT XXX_1_Fatigue 138402-11-6 IRBESARTAN ADVERSE_EFFECT NEU_3_Dizziness 138402-11-6 IRBESARTAN ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 138402-11-6 IRBESARTAN ADVERSE_EFFECT EMB_3_Fetal Toxicity 138402-11-6 IRBESARTAN ADVERSE_EFFECT EMB_3_Fetal / Neonatal Morbidity and Mortality 138402-11-6 IRBESARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 138402-11-6 IRBESARTAN INDICATION Hypertension 138402-11-6 IRBESARTAN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 138402-11-6 IRBESARTAN ADVERSE_EFFECT LUN_2_Cough 138402-11-6 IRBESARTAN ADVERSE_EFFECT NEU_3_Vertigo 138402-11-6 IRBESARTAN ADVERSE_EFFECT GIS_1_Dyspepsia 138402-11-6 IRBESARTAN ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 138402-11-6 IRBESARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 138402-11-6 IRBESARTAN TISSUE_TOXICITY Hypotension 138402-11-6 IRBESARTAN ADVERSE_EFFECT CVS_3_Hypotension 138402-11-6 IRBESARTAN ADVERSE_EFFECT REP_2_Impotence 138402-11-6 IRBESARTAN ADVERSE_EFFECT BBM_3_Neutropenia 138402-11-6 IRBESARTAN ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 138402-11-6 IRBESARTAN MECHANISM Reduce vasoconstriction 138402-11-6 IRBESARTAN THERAPEUTIC_CLASS Antihypertensive Agents 138402-11-6 IRBESARTAN KNOWN_TOXICITY Embryo/Fetal Toxicity 138402-11-6 IRBESARTAN ADVERSE_EFFECT GIS_1_Diarrhea 138402-11-6 IRBESARTAN ADVERSE_EFFECT ELT_3_Hyperkalemia 138402-11-6 IRBESARTAN ADVERSE_EFFECT IMU_2_Angioedema 138402-11-6 IRBESARTAN ADVERSE_EFFECT LIV_3_Jaundice 138402-11-6 IRBESARTAN ADVERSE_EFFECT NEU_3_Syncope 138402-11-6 IRBESARTAN ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 138402-11-6 IRBESARTAN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 138402-11-6 IRBESARTAN PRODUCT_CLASS Cardiovasculars 100286-90-6 IRINOTECAN TA_LEVEL_3 Solid and soft Tumors 100286-90-6 IRINOTECAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 100286-90-6 IRINOTECAN TISSUE_TOXICITY Neutropenia 100286-90-6 IRINOTECAN ADVERSE_EFFECT LUN_1_Cough 100286-90-6 IRINOTECAN ADVERSE_EFFECT BBM_1_Leukopenia 100286-90-6 IRINOTECAN ADVERSE_EFFECT PSY_2_Anorexia 100286-90-6 IRINOTECAN ADVERSE_EFFECT NEU_2_Dizziness 100286-90-6 IRINOTECAN ADVERSE_EFFECT NEU_2_Headache 100286-90-6 IRINOTECAN ADVERSE_EFFECT SKN_2_Rash 100286-90-6 IRINOTECAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 100286-90-6 IRINOTECAN ADVERSE_EFFECT LUN_3_Pulmonary Embolism 100286-90-6 IRINOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 100286-90-6 IRINOTECAN MESH_LEVEL_3 Camptothecin 100286-90-6 IRINOTECAN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 100286-90-6 IRINOTECAN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 100286-90-6 IRINOTECAN TISSUE_TOXICITY Leukopenia 100286-90-6 IRINOTECAN ADVERSE_EFFECT BBM_1_Anemia 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_1_Fever 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_1_Weight Loss 100286-90-6 IRINOTECAN ADVERSE_EFFECT GIS_2_Constipation 100286-90-6 IRINOTECAN ADVERSE_EFFECT GIS_2_Flatulence 100286-90-6 IRINOTECAN ADVERSE_EFFECT OCU_2_Miosis 100286-90-6 IRINOTECAN ADVERSE_EFFECT GIS_2_Stomatitis 100286-90-6 IRINOTECAN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 100286-90-6 IRINOTECAN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 100286-90-6 IRINOTECAN MESH_LEVEL_1 Heterocyclic Compounds 100286-90-6 IRINOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 100286-90-6 IRINOTECAN KNOWN_TOXICITY Cardiovascular Toxicity 100286-90-6 IRINOTECAN TISSUE_TOXICITY Anemia 100286-90-6 IRINOTECAN KNOWN_TOXICITY Nephrotoxicity 100286-90-6 IRINOTECAN TISSUE_TOXICITY Renal Failure 100286-90-6 IRINOTECAN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 100286-90-6 IRINOTECAN ADVERSE_EFFECT GIS_1_Diarrhea 100286-90-6 IRINOTECAN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_2_Chills 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_2_Edema 100286-90-6 IRINOTECAN PRODUCT_CLASS Anti-cancers 100286-90-6 IRINOTECAN ADVERSE_EFFECT KID_2_Renal Failure 100286-90-6 IRINOTECAN ADVERSE_EFFECT END_3_Hyperglycemia 100286-90-6 IRINOTECAN ADVERSE_EFFECT BBM_3_Thrombocytopenia 100286-90-6 IRINOTECAN MODE_CLASS Enzyme Inhibitor 100286-90-6 IRINOTECAN ZERO_CLASS N 100286-90-6 IRINOTECAN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_1_Asthenia 100286-90-6 IRINOTECAN ADVERSE_EFFECT GIS_1_Dyspepsia 100286-90-6 IRINOTECAN ADVERSE_EFFECT BBM_1_Neutropenia 100286-90-6 IRINOTECAN ADVERSE_EFFECT MSK_2_Back Pain 100286-90-6 IRINOTECAN TISSUE_TOXICITY Myocardial Infarction 100286-90-6 IRINOTECAN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 100286-90-6 IRINOTECAN ADVERSE_EFFECT PSY_2_Insomnia 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_2_Rhinitis 100286-90-6 IRINOTECAN ADVERSE_EFFECT CVS_3_Myocardial Infarction 100286-90-6 IRINOTECAN TA_LEVEL_2 toposiomerase inhibitors 100286-90-6 IRINOTECAN MECH_LEVEL_3 DNA topoisomerase 100286-90-6 IRINOTECAN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 100286-90-6 IRINOTECAN TA_LEVEL_1 Oncology 100286-90-6 IRINOTECAN MESH_LEVEL_2 Alkaloids 100286-90-6 IRINOTECAN THERAPEUTIC_CLASS Antineoplastics 100286-90-6 IRINOTECAN ADVERSE_EFFECT XXX_2_Infection 111348-33-5 IRINOTECAN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 111348-33-5 IRINOTECAN TISSUE_TOXICITY Leukopenia 111348-33-5 IRINOTECAN ADVERSE_EFFECT BBM_1_Anemia 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_1_Fever 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_1_Weight Loss 111348-33-5 IRINOTECAN ADVERSE_EFFECT GIS_2_Constipation 111348-33-5 IRINOTECAN ADVERSE_EFFECT GIS_2_Flatulence 111348-33-5 IRINOTECAN ADVERSE_EFFECT OCU_2_Miosis 111348-33-5 IRINOTECAN ADVERSE_EFFECT GIS_2_Stomatitis 111348-33-5 IRINOTECAN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 111348-33-5 IRINOTECAN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 111348-33-5 IRINOTECAN MESH_LEVEL_1 Heterocyclic Compounds 111348-33-5 IRINOTECAN MECHANISM Inhibit DNA synthesis, repair, and function 111348-33-5 IRINOTECAN KNOWN_TOXICITY Cardiovascular Toxicity 111348-33-5 IRINOTECAN TISSUE_TOXICITY Anemia 111348-33-5 IRINOTECAN TISSUE_TOXICITY Myocardial Infarction 111348-33-5 IRINOTECAN PRODUCT_CLASS Anti-cancers 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_1_Asthenia 111348-33-5 IRINOTECAN ADVERSE_EFFECT GIS_1_Dyspepsia 111348-33-5 IRINOTECAN ADVERSE_EFFECT MSK_2_Back Pain 111348-33-5 IRINOTECAN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 111348-33-5 IRINOTECAN ADVERSE_EFFECT PSY_2_Insomnia 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Rhinitis 111348-33-5 IRINOTECAN ADVERSE_EFFECT CVS_3_Myocardial Infarction 111348-33-5 IRINOTECAN TA_LEVEL_2 toposiomerase inhibitors 111348-33-5 IRINOTECAN MECH_LEVEL_3 DNA topoisomerase 111348-33-5 IRINOTECAN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 111348-33-5 IRINOTECAN TA_LEVEL_1 Oncology 111348-33-5 IRINOTECAN MESH_LEVEL_2 Alkaloids 111348-33-5 IRINOTECAN THERAPEUTIC_CLASS Antineoplastics 111348-33-5 IRINOTECAN KNOWN_TOXICITY Nephrotoxicity 111348-33-5 IRINOTECAN TISSUE_TOXICITY Renal Failure 111348-33-5 IRINOTECAN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 111348-33-5 IRINOTECAN ADVERSE_EFFECT GIS_1_Diarrhea 111348-33-5 IRINOTECAN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Chills 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Edema 111348-33-5 IRINOTECAN ADVERSE_EFFECT XXX_2_Infection 111348-33-5 IRINOTECAN ADVERSE_EFFECT KID_2_Renal Failure 111348-33-5 IRINOTECAN ADVERSE_EFFECT END_3_Hyperglycemia 111348-33-5 IRINOTECAN ADVERSE_EFFECT BBM_3_Thrombocytopenia 111348-33-5 IRINOTECAN ZERO_CLASS N 111348-33-5 IRINOTECAN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 111348-33-5 IRINOTECAN ADVERSE_EFFECT BBM_1_Neutropenia 111348-33-5 IRINOTECAN MODE_CLASS Enzyme Inhibitor 111348-33-5 IRINOTECAN TA_LEVEL_3 Solid and soft Tumors 111348-33-5 IRINOTECAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 111348-33-5 IRINOTECAN TISSUE_TOXICITY Neutropenia 111348-33-5 IRINOTECAN ADVERSE_EFFECT LUN_1_Cough 111348-33-5 IRINOTECAN ADVERSE_EFFECT BBM_1_Leukopenia 111348-33-5 IRINOTECAN ADVERSE_EFFECT PSY_2_Anorexia 111348-33-5 IRINOTECAN ADVERSE_EFFECT NEU_2_Dizziness 111348-33-5 IRINOTECAN ADVERSE_EFFECT NEU_2_Headache 111348-33-5 IRINOTECAN ADVERSE_EFFECT SKN_2_Rash 111348-33-5 IRINOTECAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 111348-33-5 IRINOTECAN ADVERSE_EFFECT LUN_3_Pulmonary Embolism 111348-33-5 IRINOTECAN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 111348-33-5 IRINOTECAN MESH_LEVEL_3 Camptothecin 111348-33-5 IRINOTECAN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 27523-40-6 ISOCONAZOLE THERAPEUTIC_CLASS Antifungals 27523-40-6 ISOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 27523-40-6 ISOCONAZOLE PRODUCT_CLASS Anti-infectives 27523-40-6 ISOCONAZOLE MODE_CLASS Enzyme Inhibitor 530-08-5 ISOETHARINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 530-08-5 ISOETHARINE STRUCTURE_ACTIVITY Adrenoceptor agonist 530-08-5 ISOETHARINE THERAPEUTIC_CLASS Bronchodilators 530-08-5 ISOETHARINE MECHANISM Reduce bronchoconstriction 530-08-5 ISOETHARINE MODE_CLASS Receptor Agonist, selective 530-08-5 ISOETHARINE INDICATION Bronchospasm 530-08-5 ISOETHARINE PRODUCT_CLASS Respiratory System 530-08-5 ISOETHARINE INDICATION Asthma 26675-46-7 ISOFLURANE ADVERSE_EFFECT LUN_2_Increased Bronchial Secretion 26675-46-7 ISOFLURANE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 26675-46-7 ISOFLURANE ADVERSE_EFFECT NEU_1_Tremor 26675-46-7 ISOFLURANE ADVERSE_EFFECT LUN_3_Hypoxia 26675-46-7 ISOFLURANE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 26675-46-7 ISOFLURANE ADVERSE_EFFECT BBM_3_Carboxyhemoglobinemia 26675-46-7 ISOFLURANE MECHANISM Reduce muscle contractile force 26675-46-7 ISOFLURANE ADVERSE_EFFECT XXX_3_Malignant Hyperthermia 26675-46-7 ISOFLURANE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 26675-46-7 ISOFLURANE MODE_CLASS Channel Blocker, Non-selective 26675-46-7 ISOFLURANE ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 26675-46-7 ISOFLURANE ADVERSE_EFFECT EMB_3_Abortion 26675-46-7 ISOFLURANE ADVERSE_EFFECT NEU_3_Headache 26675-46-7 ISOFLURANE ADVERSE_EFFECT LUN_3_Respiratory Depression 26675-46-7 ISOFLURANE KNOWN_TOXICITY Cardiovascular Toxicity 26675-46-7 ISOFLURANE INDICATION Induction / Maintenance of Anesthesia 26675-46-7 ISOFLURANE ADVERSE_EFFECT GIS_2_Hypersalivation 26675-46-7 ISOFLURANE ADVERSE_EFFECT EMB_3_Fetal Toxicity 26675-46-7 ISOFLURANE THERAPEUTIC_CLASS General Anesthetics, Inhaled 26675-46-7 ISOFLURANE PRODUCT_CLASS Central Nervous System (CNS) 26675-46-7 ISOFLURANE TISSUE_TOXICITY Hypotension 26675-46-7 ISOFLURANE ADVERSE_EFFECT CVS_3_Hypotension 26675-46-7 ISOFLURANE ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 26675-46-7 ISOFLURANE ADVERSE_EFFECT PSY_2_Post-Anesthesia Emergence of Delirium 26675-46-7 ISOFLURANE ADVERSE_EFFECT LUN_3_Laryngospasm 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MODE_CLASS Enzyme Inhibitor 55-91-4 DIISOPROPYL FLUOROPHOSPHATE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 55-91-4 DIISOPROPYL FLUOROPHOSPHATE TA_LEVEL_2 cholingergic 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT CVS_3_Bradycardia 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT NEU_3_Urinary Incontinence 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ACTIVITY_CLASS Cholinesterase inhibitor 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT OCU_3_Iris Cysts 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ZERO_CLASS N 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MECHANISM Enhance cholinergic transmission 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MESH_LEVEL_1 Organic Chemicals 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MECH_LEVEL_2 Enhance cholinergic transmission 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MECH_LEVEL_3 Acetylcholinesterase 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MECH_LEVEL_1 Modulate neural transmission 55-91-4 DIISOPROPYL FLUOROPHOSPHATE INDICATION Accommodative Esotropia 55-91-4 DIISOPROPYL FLUOROPHOSPHATE TA_LEVEL_3 Glaucoma 55-91-4 DIISOPROPYL FLUOROPHOSPHATE INDICATION Glaucoma 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MESH_LEVEL_3 Isofluorophate 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT LUN_3_Bronchospasm 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT OCU_2_Eye Irritation 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT OCU_3_Retinal Detachment 55-91-4 DIISOPROPYL FLUOROPHOSPHATE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 55-91-4 DIISOPROPYL FLUOROPHOSPHATE TA_LEVEL_1 Eye, Ear, Nose and Throat Preparations 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT XXX_2_Sweating 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT GIS_1_Abdominal Cramps 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 55-91-4 DIISOPROPYL FLUOROPHOSPHATE MESH_LEVEL_2 Organophosphorus Compounds 55-91-4 DIISOPROPYL FLUOROPHOSPHATE THERAPEUTIC_CLASS Antiglaucoma Agents 55-91-4 DIISOPROPYL FLUOROPHOSPHATE THERAPEUTIC_CLASS Parasympathomimetic Agents 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT GIS_1_Diarrhea 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT OCU_3_Obstruction of nasolacrimal Canals 55-91-4 DIISOPROPYL FLUOROPHOSPHATE ADVERSE_EFFECT OCU_3_Cataracts 64603-90-3 ISOGUVACINE HYDROCHLORIDE PRODUCT_CLASS Biochemicals 7683-59-2 ISOPRENALINE ADVERSE_EFFECT CVS_3_Palpitation 7683-59-2 ISOPRENALINE ADVERSE_EFFECT NEU_3_Headache 7683-59-2 ISOPRENALINE ADVERSE_EFFECT NEU_3_Tremor 7683-59-2 ISOPRENALINE ADVERSE_EFFECT GIS_2_Dry Mouth 7683-59-2 ISOPRENALINE INDICATION Asthma 7683-59-2 ISOPRENALINE PRODUCT_CLASS Respiratory System 7683-59-2 ISOPRENALINE MECHANISM Reduce muscle contractile force 7683-59-2 ISOPRENALINE MESH_LEVEL_2 Amines 7683-59-2 ISOPRENALINE ZERO_CLASS N 7683-59-2 ISOPRENALINE ADVERSE_EFFECT CVS_3_Chest Pain 7683-59-2 ISOPRENALINE ADVERSE_EFFECT NEU_1_Dizziness 7683-59-2 ISOPRENALINE ADVERSE_EFFECT PSY_1_Nervousness 7683-59-2 ISOPRENALINE MODE_CLASS Receptor Agonist 7683-59-2 ISOPRENALINE INDICATION Heart Block 7683-59-2 ISOPRENALINE TA_LEVEL_3 Beta agonist 7683-59-2 ISOPRENALINE MECH_LEVEL_1 Increase cardiac contractility 7683-59-2 ISOPRENALINE MECH_LEVEL_2 Beta agonist 7683-59-2 ISOPRENALINE ADVERSE_EFFECT LUN_3_Bronchospasm 7683-59-2 ISOPRENALINE ADVERSE_EFFECT END_2_Hyperglycemia 7683-59-2 ISOPRENALINE ADVERSE_EFFECT PSY_1_Insomnia 7683-59-2 ISOPRENALINE THERAPEUTIC_CLASS Sympathomimetic Agents 7683-59-2 ISOPRENALINE TA_LEVEL_1 Cardiovascular 7683-59-2 ISOPRENALINE MESH_LEVEL_3 Amino Alcohols 7683-59-2 ISOPRENALINE MECH_LEVEL_3 adrenoceptor beta2 7683-59-2 ISOPRENALINE TA_LEVEL_2 Beta blocker poisoning 7683-59-2 ISOPRENALINE MECHANISM Reduce bronchoconstriction 7683-59-2 ISOPRENALINE PRODUCT_CLASS Cardiovasculars 7683-59-2 ISOPRENALINE INDICATION Chronic Bronchitis 7683-59-2 ISOPRENALINE THERAPEUTIC_CLASS Bronchodilators 7683-59-2 ISOPRENALINE TISSUE_TOXICITY Ventricular Arrhythmia 7683-59-2 ISOPRENALINE KNOWN_TOXICITY Cardiovascular Toxicity 7683-59-2 ISOPRENALINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 7683-59-2 ISOPRENALINE ADVERSE_EFFECT END_2_Hyperlipidemia 7683-59-2 ISOPRENALINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 7683-59-2 ISOPRENALINE ACTIVITY_CLASS Adrenergic agonist 7683-59-2 ISOPRENALINE MESH_LEVEL_1 Organic Chemicals 7683-59-2 ISOPRENALINE INDICATION Emphysema 7683-59-2 ISOPRENALINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 7683-59-2 ISOPRENALINE STRUCTURE_ACTIVITY Adrenoceptor-beta agonist 652-67-5 ISOSORBIDE ADVERSE_EFFECT PSY_3_Confusion 652-67-5 ISOSORBIDE ADVERSE_EFFECT NEU_1_Headache 652-67-5 ISOSORBIDE ADVERSE_EFFECT PSY_3_Irritability 652-67-5 ISOSORBIDE ADVERSE_EFFECT XXX_3_Hiccup 652-67-5 ISOSORBIDE THERAPEUTIC_CLASS Antiglaucoma Agents 652-67-5 ISOSORBIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 652-67-5 ISOSORBIDE ADVERSE_EFFECT PSY_3_Disorientation 652-67-5 ISOSORBIDE ADVERSE_EFFECT ELT_3_Hypernatremia 652-67-5 ISOSORBIDE INDICATION Glaucoma 652-67-5 ISOSORBIDE ADVERSE_EFFECT NEU_3_Syncope 652-67-5 ISOSORBIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 652-67-5 ISOSORBIDE INDICATION Increased Intraocular Pressure 652-67-5 ISOSORBIDE ADVERSE_EFFECT SKN_3_Rash 652-67-5 ISOSORBIDE ADVERSE_EFFECT XXX_2_Thirst 652-67-5 ISOSORBIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Premature Closure of Epiphyseal Plate 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 13497-05-7 ISOTRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT REP_2_Menstrual Abnormalities 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Neutropenia 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT NEU_2_Dizziness 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Colitis 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT IMU_2_Allergic Reactions 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Embryotoxicity 13497-05-7 ISOTRETINOIN INDICATION Squamous Cell Carcinoma of Skin 13497-05-7 ISOTRETINOIN TA_LEVEL_3 Acne Preparations 13497-05-7 ISOTRETINOIN MECH_LEVEL_3 9-cis-retinoic acid receptor RXR beta 13497-05-7 ISOTRETINOIN MECH_LEVEL_2 RAR activation 13497-05-7 ISOTRETINOIN ZERO_CLASS N 13497-05-7 ISOTRETINOIN TISSUE_TOXICITY Embryotoxicity 13497-05-7 ISOTRETINOIN KNOWN_TOXICITY Nephrotoxicity 13497-05-7 ISOTRETINOIN MODE_CLASS Receptor Agonist 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT OCU_2_Corneal Opacities 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Calcification of Tendons and Ligaments 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT LUN_3_Bronchospasm 13497-05-7 ISOTRETINOIN INDICATION Psoriasis 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT GIS_2_Nausea 13497-05-7 ISOTRETINOIN KNOWN_TOXICITY Hepatotoxicity 13497-05-7 ISOTRETINOIN TISSUE_TOXICITY Glomerulonephritis 13497-05-7 ISOTRETINOIN TISSUE_TOXICITY Teratogenicity 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Hyperotosis 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT MSK_1_Bone Pain 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT IMU_1_Photosensitivity 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT SKN_1_Dry Skin 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT END_2_Hyperglycemia 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT OTO_3_Hearing Loss 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Fetal Toxicity 13497-05-7 ISOTRETINOIN INDICATION Keratinization Disorders 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT END_1_Hypertriglyceridemia 13497-05-7 ISOTRETINOIN PRODUCT_CLASS Dermatologicals 13497-05-7 ISOTRETINOIN TA_LEVEL_1 Dermatology 13497-05-7 ISOTRETINOIN PRODUCT_CLASS Other Human Uses 13497-05-7 ISOTRETINOIN MESH_LEVEL_2 Hydrocarbons 13497-05-7 ISOTRETINOIN MESH_LEVEL_3 Terpenes 13497-05-7 ISOTRETINOIN TISSUE_TOXICITY Fetal Toxicity 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 13497-05-7 ISOTRETINOIN MESH_LEVEL_1 Organic Chemicals 13497-05-7 ISOTRETINOIN TA_LEVEL_2 anti-comodogenic 13497-05-7 ISOTRETINOIN PRODUCT_CLASS Anti-cancers 13497-05-7 ISOTRETINOIN MECH_LEVEL_1 Modulate epidermal fuction 13497-05-7 ISOTRETINOIN MECHANISM Modulate gene transcription 13497-05-7 ISOTRETINOIN INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 13497-05-7 ISOTRETINOIN THERAPEUTIC_CLASS Psoralens 13497-05-7 ISOTRETINOIN THERAPEUTIC_CLASS Acne Preparations 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Teratogenicity 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT NEU_3_Benign Intracranial Hypertension 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT CVS_3_Vasculitis 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT MSK_1_Arthralgia 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT GIS_1_Dry Mouth 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Anemia 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT XXX_3_Impaired Healing 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT XXX_2_Epistaxis 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT OCU_3_Impaired Night Vision 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Inflammatory Bowel Disease 13497-05-7 ISOTRETINOIN TISSUE_TOXICITY Hepatotoxicity 13497-05-7 ISOTRETINOIN KNOWN_TOXICITY Embryo/Fetal Toxicity 13497-05-7 ISOTRETINOIN ACTIVITY_CLASS Retinoic acid receptor (RAR) agonist 13497-05-7 ISOTRETINOIN INDICATION Basal Cell Carcinoma 13497-05-7 ISOTRETINOIN INDICATION Acne / Acne Vulgaris 13497-05-7 ISOTRETINOIN THERAPEUTIC_CLASS Antineoplastics 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Pancreatitis 13497-05-7 ISOTRETINOIN ADVERSE_EFFECT OCU_3_Visual Impairment 22232-80-0 ISOTRETINOIN THERAPEUTIC_CLASS Antineoplastics 22232-80-0 ISOTRETINOIN INDICATION Acne / Acne Vulgaris 22232-80-0 ISOTRETINOIN KNOWN_TOXICITY Hepatotoxicity 22232-80-0 ISOTRETINOIN TA_LEVEL_2 anti-comodogenic 22232-80-0 ISOTRETINOIN PRODUCT_CLASS Anti-cancers 22232-80-0 ISOTRETINOIN MECH_LEVEL_1 Modulate epidermal fuction 22232-80-0 ISOTRETINOIN MECHANISM Modulate gene transcription 22232-80-0 ISOTRETINOIN INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 22232-80-0 ISOTRETINOIN THERAPEUTIC_CLASS Psoralens 22232-80-0 ISOTRETINOIN THERAPEUTIC_CLASS Acne Preparations 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Teratogenicity 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT END_1_Hypertriglyceridemia 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT NEU_3_Benign Intracranial Hypertension 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT CVS_3_Vasculitis 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT MSK_1_Arthralgia 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT GIS_1_Dry Mouth 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Anemia 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT XXX_3_Impaired Healing 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT XXX_2_Epistaxis 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT OCU_3_Impaired Night Vision 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Inflammatory Bowel Disease 22232-80-0 ISOTRETINOIN TISSUE_TOXICITY Hepatotoxicity 22232-80-0 ISOTRETINOIN KNOWN_TOXICITY Embryo/Fetal Toxicity 22232-80-0 ISOTRETINOIN ACTIVITY_CLASS Retinoic acid receptor (RAR) agonist 22232-80-0 ISOTRETINOIN INDICATION Basal Cell Carcinoma 22232-80-0 ISOTRETINOIN TISSUE_TOXICITY Glomerulonephritis 22232-80-0 ISOTRETINOIN TISSUE_TOXICITY Teratogenicity 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Hyperotosis 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT MSK_1_Bone Pain 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT SKN_1_Dry Skin 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT END_2_Hyperglycemia 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT OTO_3_Hearing Loss 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Fetal Toxicity 22232-80-0 ISOTRETINOIN INDICATION Keratinization Disorders 22232-80-0 ISOTRETINOIN PRODUCT_CLASS Dermatologicals 22232-80-0 ISOTRETINOIN TA_LEVEL_1 Dermatology 22232-80-0 ISOTRETINOIN PRODUCT_CLASS Other Human Uses 22232-80-0 ISOTRETINOIN MESH_LEVEL_2 Hydrocarbons 22232-80-0 ISOTRETINOIN MESH_LEVEL_3 Terpenes 22232-80-0 ISOTRETINOIN TISSUE_TOXICITY Fetal Toxicity 22232-80-0 ISOTRETINOIN MESH_LEVEL_1 Organic Chemicals 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Premature Closure of Epiphyseal Plate 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 22232-80-0 ISOTRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT REP_2_Menstrual Abnormalities 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Neutropenia 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT NEU_2_Dizziness 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Colitis 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT IMU_2_Allergic Reactions 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT EMB_1_Embryotoxicity 22232-80-0 ISOTRETINOIN INDICATION Squamous Cell Carcinoma of Skin 22232-80-0 ISOTRETINOIN INDICATION Psoriasis 22232-80-0 ISOTRETINOIN TA_LEVEL_3 Acne Preparations 22232-80-0 ISOTRETINOIN MECH_LEVEL_3 9-cis-retinoic acid receptor RXR beta 22232-80-0 ISOTRETINOIN MECH_LEVEL_2 RAR activation 22232-80-0 ISOTRETINOIN ZERO_CLASS N 22232-80-0 ISOTRETINOIN TISSUE_TOXICITY Embryotoxicity 22232-80-0 ISOTRETINOIN KNOWN_TOXICITY Nephrotoxicity 22232-80-0 ISOTRETINOIN MODE_CLASS Receptor Agonist 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT OCU_2_Corneal Opacities 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT MSK_3_Calcification of Tendons and Ligaments 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT LUN_3_Bronchospasm 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT IMU_1_Photosensitivity 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT GIS_2_Nausea 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT OCU_3_Visual Impairment 22232-80-0 ISOTRETINOIN ADVERSE_EFFECT GIS_3_Pancreatitis 579-56-6 ISOXSUPRINE MECHANISM Reduce vasoconstriction 579-56-6 ISOXSUPRINE STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 579-56-6 ISOXSUPRINE PRODUCT_CLASS Cardiovasculars 579-56-6 ISOXSUPRINE INDICATION Dysmenorrhea 579-56-6 ISOXSUPRINE KNOWN_TOXICITY Cardiovascular Toxicity 579-56-6 ISOXSUPRINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 579-56-6 ISOXSUPRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 579-56-6 ISOXSUPRINE INDICATION Peripheral Vascular Disease 579-56-6 ISOXSUPRINE TISSUE_TOXICITY Hypotension 579-56-6 ISOXSUPRINE ADVERSE_EFFECT CVS_3_Angina 579-56-6 ISOXSUPRINE MODE_CLASS Receptor Ligand Antagonist 579-56-6 ISOXSUPRINE INDICATION Raynaud's Phenomenon 579-56-6 ISOXSUPRINE TISSUE_TOXICITY Angina 579-56-6 ISOXSUPRINE THERAPEUTIC_CLASS Vasodilators 579-56-6 ISOXSUPRINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 579-56-6 ISOXSUPRINE ADVERSE_EFFECT SKN_3_Skin Rash 579-56-6 ISOXSUPRINE INDICATION Premature labor 579-56-6 ISOXSUPRINE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 579-56-6 ISOXSUPRINE ADVERSE_EFFECT CVS_2_Hypotension 579-56-6 ISOXSUPRINE ADVERSE_EFFECT NEU_1_Dizziness 395-28-8 ISOXSUPRINE TISSUE_TOXICITY Angina 395-28-8 ISOXSUPRINE INDICATION Raynaud's Phenomenon 395-28-8 ISOXSUPRINE STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 395-28-8 ISOXSUPRINE MODE_CLASS Receptor Ligand Antagonist 395-28-8 ISOXSUPRINE ADVERSE_EFFECT CVS_3_Angina 395-28-8 ISOXSUPRINE TISSUE_TOXICITY Hypotension 395-28-8 ISOXSUPRINE INDICATION Peripheral Vascular Disease 395-28-8 ISOXSUPRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 395-28-8 ISOXSUPRINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 395-28-8 ISOXSUPRINE KNOWN_TOXICITY Cardiovascular Toxicity 395-28-8 ISOXSUPRINE INDICATION Dysmenorrhea 395-28-8 ISOXSUPRINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 395-28-8 ISOXSUPRINE PRODUCT_CLASS Cardiovasculars 395-28-8 ISOXSUPRINE INDICATION Premature labor 395-28-8 ISOXSUPRINE ADVERSE_EFFECT SKN_3_Skin Rash 395-28-8 ISOXSUPRINE THERAPEUTIC_CLASS Vasodilators 395-28-8 ISOXSUPRINE ADVERSE_EFFECT CVS_2_Hypotension 395-28-8 ISOXSUPRINE ADVERSE_EFFECT NEU_1_Dizziness 395-28-8 ISOXSUPRINE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 395-28-8 ISOXSUPRINE MECHANISM Reduce vasoconstriction 84625-61-6 ITRACONAZOLE MODE_CLASS Enzyme Inhibitor 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT NEU_3_Neuropathy 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT XXX_3_Peripheral Edema 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT SKN_3_Pruritis 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT NEU_2_Headache 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT LUN_3_Pulmonary Edema 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 84625-61-6 ITRACONAZOLE INDICATION Oropharyngeal Candidiasis 84625-61-6 ITRACONAZOLE INDICATION Aspergillosis 84625-61-6 ITRACONAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 84625-61-6 ITRACONAZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 84625-61-6 ITRACONAZOLE TISSUE_TOXICITY Congestive Heart Failure 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT BBM_3_Neutropenia 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT IMU_2_Allergic Reactions 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT GIS_1_Nausea 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT XXX_2_Fever 84625-61-6 ITRACONAZOLE THERAPEUTIC_CLASS Antifungals, Systemic 84625-61-6 ITRACONAZOLE INDICATION Tinea Unguium / Onychomycosis 84625-61-6 ITRACONAZOLE MESH_LEVEL_3 Azoles 84625-61-6 ITRACONAZOLE PRODUCT_CLASS Anti-infectives 84625-61-6 ITRACONAZOLE INDICATION Fungal Infections 84625-61-6 ITRACONAZOLE TA_LEVEL_3 systemic 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT LIV_2_Jaundice 84625-61-6 ITRACONAZOLE INDICATION Histoplasmosis 84625-61-6 ITRACONAZOLE INDICATION Blastomycosis 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT EMB_2_Embryotoxicity 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 84625-61-6 ITRACONAZOLE ZERO_CLASS N 84625-61-6 ITRACONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) 84625-61-6 ITRACONAZOLE INDICATION Oral Candidiasis / Thrush 84625-61-6 ITRACONAZOLE TISSUE_TOXICITY Hepatotoxicity 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT EMB_2_Teratogenicity 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT PSY_3_Depression 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT GIS_2_Vomiting 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT SKN_2_Rash 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT IMU_3_Angioedema 84625-61-6 ITRACONAZOLE MECH_LEVEL_1 Anti-fungal 84625-61-6 ITRACONAZOLE TA_LEVEL_2 Anti-fungal 84625-61-6 ITRACONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT CVS_3_Tachycardia 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT CVS_3_Hypotension 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT IMU_3_Anaphylaxis 84625-61-6 ITRACONAZOLE ACTIVITY_CLASS Antifungals azole 84625-61-6 ITRACONAZOLE KNOWN_TOXICITY Hepatotoxicity 84625-61-6 ITRACONAZOLE TISSUE_TOXICITY Hypotension 84625-61-6 ITRACONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, ketoconazole like 84625-61-6 ITRACONAZOLE ADVERSE_EFFECT REP_3_Menstrual Abnormalities 84625-61-6 ITRACONAZOLE TISSUE_TOXICITY Teratogenicity 84625-61-6 ITRACONAZOLE KNOWN_TOXICITY Cardiovascular Toxicity 84625-61-6 ITRACONAZOLE TA_LEVEL_1 Infectious Disease 84625-61-6 ITRACONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 84625-61-6 ITRACONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 70288-86-7 IVERMECTIN ZERO_CLASS N 70288-86-7 IVERMECTIN MESH_LEVEL_3 Polysaccharides 70288-86-7 IVERMECTIN ADVERSE_EFFECT MSK_3_Myalgia 70288-86-7 IVERMECTIN ADVERSE_EFFECT SKN_1_Pruritis 70288-86-7 IVERMECTIN ADVERSE_EFFECT GIS_3_Abdominal Pain 70288-86-7 IVERMECTIN MECHANISM Modulate channel gating 70288-86-7 IVERMECTIN MECH_LEVEL_1 anthelmintic 70288-86-7 IVERMECTIN MECH_LEVEL_3 GABA-A receptor 70288-86-7 IVERMECTIN ADVERSE_EFFECT IMU_2_Urticaria 70288-86-7 IVERMECTIN THERAPEUTIC_CLASS Antiparasitics 70288-86-7 IVERMECTIN MESH_LEVEL_2 Carbohydrates 70288-86-7 IVERMECTIN MECHANISM Modulate neural transmission 70288-86-7 IVERMECTIN INDICATION Onchocerciasis 70288-86-7 IVERMECTIN TA_LEVEL_2 anthelmintic 70288-86-7 IVERMECTIN TA_LEVEL_3 Ivermectin 70288-86-7 IVERMECTIN ADVERSE_EFFECT NEU_1_Dizziness 70288-86-7 IVERMECTIN MECH_LEVEL_2 Disrupt chloride homeostasis 70288-86-7 IVERMECTIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 70288-86-7 IVERMECTIN INDICATION Strongyloidiasis 70288-86-7 IVERMECTIN PRODUCT_CLASS Anti-infectives 70288-86-7 IVERMECTIN MODE_CLASS Channel enhancer /opener 70288-86-7 IVERMECTIN STRUCTURE_ACTIVITY GABA-A Cl- channel opener, antiparasitic 70288-86-7 IVERMECTIN ADVERSE_EFFECT XXX_2_Peripheral Edema 70288-86-7 IVERMECTIN ADVERSE_EFFECT XXX_2_Fever 70288-86-7 IVERMECTIN ADVERSE_EFFECT NEU_3_Headache 70288-86-7 IVERMECTIN ACTIVITY_CLASS GABA agonist 70288-86-7 IVERMECTIN TA_LEVEL_1 Infectious Disease 70288-86-7 IVERMECTIN ADVERSE_EFFECT LYM_2_Lymphadenopathy 70288-86-7 IVERMECTIN ADVERSE_EFFECT GIS_1_Diarrhea 70288-86-7 IVERMECTIN ADVERSE_EFFECT GIS_1_Nausea 342-10-9 KALLIDIN INDICATION Hypertension 342-10-9 KALLIDIN PRODUCT_CLASS Cardiovasculars 342-10-9 KALLIDIN THERAPEUTIC_CLASS Antihypertensive Agents 25389-94-0 KANAMYCIN INDICATION Urinary Tract Infection (UTI) 25389-94-0 KANAMYCIN INDICATION Intra-Abdominal Infections 25389-94-0 KANAMYCIN MESH_LEVEL_2 Carbohydrates 25389-94-0 KANAMYCIN TA_LEVEL_2 Anti-bacterial 25389-94-0 KANAMYCIN KNOWN_TOXICITY Ototoxicity 25389-94-0 KANAMYCIN ADVERSE_EFFECT IMU_2_Allergic Reactions 25389-94-0 KANAMYCIN ADVERSE_EFFECT SKN_2_Pruritis 25389-94-0 KANAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 25389-94-0 KANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 25389-94-0 KANAMYCIN INDICATION Hepatic Encephalopathy 25389-94-0 KANAMYCIN INDICATION Skin and Skin Structure Infections 25389-94-0 KANAMYCIN INDICATION Biliary Tract Infection 25389-94-0 KANAMYCIN MECH_LEVEL_3 Ribosomal RNA binder 25389-94-0 KANAMYCIN KNOWN_TOXICITY Nephrotoxicity 25389-94-0 KANAMYCIN TISSUE_TOXICITY Ototoxicity 25389-94-0 KANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 25389-94-0 KANAMYCIN ADVERSE_EFFECT SKN_2_Dermatitis 25389-94-0 KANAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 25389-94-0 KANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 25389-94-0 KANAMYCIN ADVERSE_EFFECT SKN_2_Rash 25389-94-0 KANAMYCIN MESH_LEVEL_3 Aminoglycoside 25389-94-0 KANAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 25389-94-0 KANAMYCIN MECH_LEVEL_1 Anti-bacterial 25389-94-0 KANAMYCIN TA_LEVEL_3 Aminoglycoside 25389-94-0 KANAMYCIN INDICATION Bowel Preparation 25389-94-0 KANAMYCIN INDICATION Septicemia 25389-94-0 KANAMYCIN INDICATION Bone and Joint Infection 25389-94-0 KANAMYCIN TISSUE_TOXICITY Nephrotoxicity 25389-94-0 KANAMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 25389-94-0 KANAMYCIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 25389-94-0 KANAMYCIN ADVERSE_EFFECT END_3_Decreased Cholesterol 25389-94-0 KANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 25389-94-0 KANAMYCIN ZERO_CLASS N 25389-94-0 KANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 25389-94-0 KANAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 25389-94-0 KANAMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 25389-94-0 KANAMYCIN INDICATION Gram-negative Septicemia 25389-94-0 KANAMYCIN INDICATION Bronchopulmonary Infection 25389-94-0 KANAMYCIN PRODUCT_CLASS Anti-infectives 25389-94-0 KANAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 25389-94-0 KANAMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 25389-94-0 KANAMYCIN TA_LEVEL_1 Infectious Disease 59-01-8 KANAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 59-01-8 KANAMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 59-01-8 KANAMYCIN ADVERSE_EFFECT SKN_2_Pruritis 59-01-8 KANAMYCIN TA_LEVEL_1 Infectious Disease 59-01-8 KANAMYCIN INDICATION Urinary Tract Infection (UTI) 59-01-8 KANAMYCIN INDICATION Intra-Abdominal Infections 59-01-8 KANAMYCIN MESH_LEVEL_2 Carbohydrates 59-01-8 KANAMYCIN TA_LEVEL_2 Anti-bacterial 59-01-8 KANAMYCIN KNOWN_TOXICITY Ototoxicity 59-01-8 KANAMYCIN ADVERSE_EFFECT IMU_2_Allergic Reactions 59-01-8 KANAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 59-01-8 KANAMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 59-01-8 KANAMYCIN INDICATION Gram-negative Septicemia 59-01-8 KANAMYCIN INDICATION Bronchopulmonary Infection 59-01-8 KANAMYCIN PRODUCT_CLASS Anti-infectives 59-01-8 KANAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 59-01-8 KANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 59-01-8 KANAMYCIN INDICATION Hepatic Encephalopathy 59-01-8 KANAMYCIN INDICATION Skin and Skin Structure Infections 59-01-8 KANAMYCIN INDICATION Biliary Tract Infection 59-01-8 KANAMYCIN MECH_LEVEL_3 Ribosomal RNA binder 59-01-8 KANAMYCIN KNOWN_TOXICITY Nephrotoxicity 59-01-8 KANAMYCIN TISSUE_TOXICITY Ototoxicity 59-01-8 KANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 59-01-8 KANAMYCIN ADVERSE_EFFECT SKN_2_Dermatitis 59-01-8 KANAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 59-01-8 KANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 59-01-8 KANAMYCIN ADVERSE_EFFECT SKN_2_Rash 59-01-8 KANAMYCIN MESH_LEVEL_3 Aminoglycoside 59-01-8 KANAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 59-01-8 KANAMYCIN MECH_LEVEL_1 Anti-bacterial 59-01-8 KANAMYCIN TA_LEVEL_3 Aminoglycoside 59-01-8 KANAMYCIN INDICATION Bowel Preparation 59-01-8 KANAMYCIN INDICATION Septicemia 59-01-8 KANAMYCIN INDICATION Bone and Joint Infection 59-01-8 KANAMYCIN TISSUE_TOXICITY Nephrotoxicity 59-01-8 KANAMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 59-01-8 KANAMYCIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 59-01-8 KANAMYCIN ADVERSE_EFFECT END_3_Decreased Cholesterol 59-01-8 KANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 59-01-8 KANAMYCIN ZERO_CLASS N 59-01-8 KANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 133-92-6 KANAMYCIN MECH_LEVEL_3 Ribosomal RNA binder 133-92-6 KANAMYCIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 133-92-6 KANAMYCIN ADVERSE_EFFECT END_3_Decreased Cholesterol 133-92-6 KANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 133-92-6 KANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 133-92-6 KANAMYCIN ZERO_CLASS N 133-92-6 KANAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 133-92-6 KANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 133-92-6 KANAMYCIN INDICATION Hepatic Encephalopathy 133-92-6 KANAMYCIN INDICATION Skin and Skin Structure Infections 133-92-6 KANAMYCIN INDICATION Biliary Tract Infection 133-92-6 KANAMYCIN KNOWN_TOXICITY Nephrotoxicity 133-92-6 KANAMYCIN ADVERSE_EFFECT SKN_2_Dermatitis 133-92-6 KANAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 133-92-6 KANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 133-92-6 KANAMYCIN TISSUE_TOXICITY Ototoxicity 133-92-6 KANAMYCIN ADVERSE_EFFECT SKN_2_Rash 133-92-6 KANAMYCIN MESH_LEVEL_3 Aminoglycoside 133-92-6 KANAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 133-92-6 KANAMYCIN MECH_LEVEL_1 Anti-bacterial 133-92-6 KANAMYCIN TA_LEVEL_3 Aminoglycoside 133-92-6 KANAMYCIN INDICATION Bowel Preparation 133-92-6 KANAMYCIN INDICATION Septicemia 133-92-6 KANAMYCIN INDICATION Bone and Joint Infection 133-92-6 KANAMYCIN TISSUE_TOXICITY Nephrotoxicity 133-92-6 KANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 133-92-6 KANAMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 133-92-6 KANAMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 133-92-6 KANAMYCIN INDICATION Gram-negative Septicemia 133-92-6 KANAMYCIN INDICATION Bronchopulmonary Infection 133-92-6 KANAMYCIN PRODUCT_CLASS Anti-infectives 133-92-6 KANAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 133-92-6 KANAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 133-92-6 KANAMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 133-92-6 KANAMYCIN TA_LEVEL_1 Infectious Disease 133-92-6 KANAMYCIN INDICATION Urinary Tract Infection (UTI) 133-92-6 KANAMYCIN INDICATION Intra-Abdominal Infections 133-92-6 KANAMYCIN MESH_LEVEL_2 Carbohydrates 133-92-6 KANAMYCIN TA_LEVEL_2 Anti-bacterial 133-92-6 KANAMYCIN KNOWN_TOXICITY Ototoxicity 133-92-6 KANAMYCIN ADVERSE_EFFECT IMU_2_Allergic Reactions 133-92-6 KANAMYCIN ADVERSE_EFFECT SKN_2_Pruritis 11030-21-0 KANAMYCIN KNOWN_TOXICITY Nephrotoxicity 11030-21-0 KANAMYCIN MECH_LEVEL_3 Ribosomal RNA binder 11030-21-0 KANAMYCIN INDICATION Biliary Tract Infection 11030-21-0 KANAMYCIN INDICATION Skin and Skin Structure Infections 11030-21-0 KANAMYCIN INDICATION Hepatic Encephalopathy 11030-21-0 KANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 11030-21-0 KANAMYCIN ADVERSE_EFFECT END_3_Decreased Cholesterol 11030-21-0 KANAMYCIN ADVERSE_EFFECT SKN_2_Pruritis 11030-21-0 KANAMYCIN ADVERSE_EFFECT IMU_2_Allergic Reactions 11030-21-0 KANAMYCIN TA_LEVEL_2 Anti-bacterial 11030-21-0 KANAMYCIN MESH_LEVEL_2 Carbohydrates 11030-21-0 KANAMYCIN INDICATION Intra-Abdominal Infections 11030-21-0 KANAMYCIN INDICATION Urinary Tract Infection (UTI) 11030-21-0 KANAMYCIN TA_LEVEL_1 Infectious Disease 11030-21-0 KANAMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 11030-21-0 KANAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 11030-21-0 KANAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 11030-21-0 KANAMYCIN PRODUCT_CLASS Anti-infectives 11030-21-0 KANAMYCIN INDICATION Bronchopulmonary Infection 11030-21-0 KANAMYCIN INDICATION Gram-negative Septicemia 11030-21-0 KANAMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 11030-21-0 KANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 11030-21-0 KANAMYCIN ZERO_CLASS N 11030-21-0 KANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 11030-21-0 KANAMYCIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 11030-21-0 KANAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 11030-21-0 KANAMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 11030-21-0 KANAMYCIN TISSUE_TOXICITY Nephrotoxicity 11030-21-0 KANAMYCIN INDICATION Bone and Joint Infection 11030-21-0 KANAMYCIN INDICATION Septicemia 11030-21-0 KANAMYCIN INDICATION Bowel Preparation 11030-21-0 KANAMYCIN KNOWN_TOXICITY Ototoxicity 11030-21-0 KANAMYCIN TA_LEVEL_3 Aminoglycoside 11030-21-0 KANAMYCIN MECH_LEVEL_1 Anti-bacterial 11030-21-0 KANAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 11030-21-0 KANAMYCIN MESH_LEVEL_3 Aminoglycoside 11030-21-0 KANAMYCIN ADVERSE_EFFECT SKN_2_Rash 11030-21-0 KANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 11030-21-0 KANAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 11030-21-0 KANAMYCIN ADVERSE_EFFECT SKN_2_Dermatitis 11030-21-0 KANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 11030-21-0 KANAMYCIN TISSUE_TOXICITY Ototoxicity 29701-07-3 KANAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 29701-07-3 KANAMYCIN MECH_LEVEL_1 Anti-bacterial 29701-07-3 KANAMYCIN TA_LEVEL_3 Aminoglycoside 29701-07-3 KANAMYCIN INDICATION Bowel Preparation 29701-07-3 KANAMYCIN MESH_LEVEL_3 Aminoglycoside 29701-07-3 KANAMYCIN INDICATION Septicemia 29701-07-3 KANAMYCIN INDICATION Bone and Joint Infection 29701-07-3 KANAMYCIN TISSUE_TOXICITY Nephrotoxicity 29701-07-3 KANAMYCIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 29701-07-3 KANAMYCIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 29701-07-3 KANAMYCIN ADVERSE_EFFECT END_3_Decreased Cholesterol 29701-07-3 KANAMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 29701-07-3 KANAMYCIN ZERO_CLASS N 29701-07-3 KANAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 29701-07-3 KANAMYCIN ADVERSE_EFFECT SKN_2_Dermatitis 29701-07-3 KANAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 29701-07-3 KANAMYCIN TISSUE_TOXICITY Ototoxicity 29701-07-3 KANAMYCIN ADVERSE_EFFECT SKN_2_Rash 29701-07-3 KANAMYCIN MECH_LEVEL_3 Ribosomal RNA binder 29701-07-3 KANAMYCIN INDICATION Biliary Tract Infection 29701-07-3 KANAMYCIN INDICATION Skin and Skin Structure Infections 29701-07-3 KANAMYCIN INDICATION Hepatic Encephalopathy 29701-07-3 KANAMYCIN MECHANISM Inhibit ribosomal protein synthesis 29701-07-3 KANAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 29701-07-3 KANAMYCIN ADVERSE_EFFECT SKN_2_Pruritis 29701-07-3 KANAMYCIN INDICATION Intra-Abdominal Infections 29701-07-3 KANAMYCIN ADVERSE_EFFECT IMU_2_Allergic Reactions 29701-07-3 KANAMYCIN KNOWN_TOXICITY Ototoxicity 29701-07-3 KANAMYCIN TA_LEVEL_2 Anti-bacterial 29701-07-3 KANAMYCIN MESH_LEVEL_2 Carbohydrates 29701-07-3 KANAMYCIN INDICATION Urinary Tract Infection (UTI) 29701-07-3 KANAMYCIN TA_LEVEL_1 Infectious Disease 29701-07-3 KANAMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 29701-07-3 KANAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 29701-07-3 KANAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 29701-07-3 KANAMYCIN KNOWN_TOXICITY Nephrotoxicity 29701-07-3 KANAMYCIN PRODUCT_CLASS Anti-infectives 29701-07-3 KANAMYCIN INDICATION Bronchopulmonary Infection 29701-07-3 KANAMYCIN INDICATION Gram-negative Septicemia 29701-07-3 KANAMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 29701-07-3 KANAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 29701-07-3 KANAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 6740-88-1 KETAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 6740-88-1 KETAMINE MECHANISM Block neural transmission 6740-88-1 KETAMINE TA_LEVEL_1 Central Nervous System (CNS) 6740-88-1 KETAMINE ADVERSE_EFFECT LUN_2_Respiratory Depression 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_3_Anorexia 6740-88-1 KETAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 6740-88-1 KETAMINE TISSUE_TOXICITY Hypotension 6740-88-1 KETAMINE ADVERSE_EFFECT OCU_3_Diplopia 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_1_Visual Hallucinations 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_1_Nightmares 6740-88-1 KETAMINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 6740-88-1 KETAMINE TISSUE_TOXICITY Cardiac Arrhythmia 6740-88-1 KETAMINE ADVERSE_EFFECT GIS_3_Hypersalivation 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_3_Psychosis 6740-88-1 KETAMINE ADVERSE_EFFECT NEU_3_Tonic-Clonic Convulsions 6740-88-1 KETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 6740-88-1 KETAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 6740-88-1 KETAMINE TA_LEVEL_3 Dissociative anesthetic 6740-88-1 KETAMINE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 6740-88-1 KETAMINE MESH_LEVEL_1 Organic Chemicals 6740-88-1 KETAMINE MODE_CLASS Channel Blocker 6740-88-1 KETAMINE ADVERSE_EFFECT XXX_3_Withdrawal 6740-88-1 KETAMINE ADVERSE_EFFECT NEU_3_Involuntray Movements 6740-88-1 KETAMINE ADVERSE_EFFECT CVS_1_Hypertension 6740-88-1 KETAMINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 6740-88-1 KETAMINE ZERO_CLASS N 6740-88-1 KETAMINE ACTIVITY_CLASS Glutamate antagonist 6740-88-1 KETAMINE KNOWN_TOXICITY Mental Health Disorders 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_1_Post-Anesthesia Emergence of Delirium 6740-88-1 KETAMINE ADVERSE_EFFECT LUN_3_Apnea 6740-88-1 KETAMINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 6740-88-1 KETAMINE ADVERSE_EFFECT NEU_2_Nystagmus 6740-88-1 KETAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_1_Insomnia 6740-88-1 KETAMINE ADVERSE_EFFECT CVS_3_Hypotension 6740-88-1 KETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 6740-88-1 KETAMINE MESH_LEVEL_2 Hydrocarbons 6740-88-1 KETAMINE MECH_LEVEL_1 Modulate neural transmission 6740-88-1 KETAMINE PRODUCT_CLASS Central Nervous System (CNS) 6740-88-1 KETAMINE ADVERSE_EFFECT LUN_3_Laryngospasm 6740-88-1 KETAMINE ADVERSE_EFFECT SKN_3_Erythema 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_2_Disorientation 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_2_Psychologic Dependence 6740-88-1 KETAMINE ADVERSE_EFFECT PSY_2_Anxiety 6740-88-1 KETAMINE TISSUE_TOXICITY Visual Hallucinations 6740-88-1 KETAMINE INDICATION Induction / Maintenance of Anesthesia 6740-88-1 KETAMINE TA_LEVEL_2 CNS Depressant 6740-88-1 KETAMINE MECH_LEVEL_2 NMDA Modulators 42551-62-2 KETAMINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 42551-62-2 KETAMINE TISSUE_TOXICITY Cardiac Arrhythmia 42551-62-2 KETAMINE ADVERSE_EFFECT GIS_3_Hypersalivation 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_3_Psychosis 42551-62-2 KETAMINE ADVERSE_EFFECT NEU_3_Tonic-Clonic Convulsions 42551-62-2 KETAMINE ADVERSE_EFFECT XXX_3_Withdrawal 42551-62-2 KETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 42551-62-2 KETAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 42551-62-2 KETAMINE TA_LEVEL_3 Dissociative anesthetic 42551-62-2 KETAMINE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 42551-62-2 KETAMINE MESH_LEVEL_1 Organic Chemicals 42551-62-2 KETAMINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 42551-62-2 KETAMINE ADVERSE_EFFECT NEU_3_Involuntray Movements 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_1_Nightmares 42551-62-2 KETAMINE MODE_CLASS Channel Blocker 42551-62-2 KETAMINE TISSUE_TOXICITY Visual Hallucinations 42551-62-2 KETAMINE ADVERSE_EFFECT CVS_1_Hypertension 42551-62-2 KETAMINE TA_LEVEL_2 CNS Depressant 42551-62-2 KETAMINE MECHANISM Block neural transmission 42551-62-2 KETAMINE TA_LEVEL_1 Central Nervous System (CNS) 42551-62-2 KETAMINE KNOWN_TOXICITY Mental Health Disorders 42551-62-2 KETAMINE ACTIVITY_CLASS Glutamate antagonist 42551-62-2 KETAMINE ZERO_CLASS N 42551-62-2 KETAMINE MECH_LEVEL_1 Modulate neural transmission 42551-62-2 KETAMINE MECH_LEVEL_2 NMDA Modulators 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_1_Post-Anesthesia Emergence of Delirium 42551-62-2 KETAMINE ADVERSE_EFFECT LUN_3_Apnea 42551-62-2 KETAMINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 42551-62-2 KETAMINE ADVERSE_EFFECT NEU_2_Nystagmus 42551-62-2 KETAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 42551-62-2 KETAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_1_Insomnia 42551-62-2 KETAMINE ADVERSE_EFFECT CVS_3_Hypotension 42551-62-2 KETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 42551-62-2 KETAMINE MESH_LEVEL_2 Hydrocarbons 42551-62-2 KETAMINE PRODUCT_CLASS Central Nervous System (CNS) 42551-62-2 KETAMINE ADVERSE_EFFECT LUN_3_Laryngospasm 42551-62-2 KETAMINE ADVERSE_EFFECT SKN_3_Erythema 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_2_Disorientation 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_2_Psychologic Dependence 42551-62-2 KETAMINE INDICATION Induction / Maintenance of Anesthesia 42551-62-2 KETAMINE ADVERSE_EFFECT LUN_2_Respiratory Depression 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_3_Anorexia 42551-62-2 KETAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 42551-62-2 KETAMINE TISSUE_TOXICITY Hypotension 42551-62-2 KETAMINE ADVERSE_EFFECT OCU_3_Diplopia 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_1_Visual Hallucinations 42551-62-2 KETAMINE ADVERSE_EFFECT PSY_2_Anxiety 81771-21-3 KETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 81771-21-3 KETAMINE ADVERSE_EFFECT XXX_3_Withdrawal 81771-21-3 KETAMINE ADVERSE_EFFECT NEU_3_Tonic-Clonic Convulsions 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_3_Psychosis 81771-21-3 KETAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 81771-21-3 KETAMINE TA_LEVEL_3 Dissociative anesthetic 81771-21-3 KETAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 81771-21-3 KETAMINE MECHANISM Block neural transmission 81771-21-3 KETAMINE TA_LEVEL_1 Central Nervous System (CNS) 81771-21-3 KETAMINE KNOWN_TOXICITY Mental Health Disorders 81771-21-3 KETAMINE ADVERSE_EFFECT LUN_2_Respiratory Depression 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_3_Anorexia 81771-21-3 KETAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 81771-21-3 KETAMINE TISSUE_TOXICITY Hypotension 81771-21-3 KETAMINE ADVERSE_EFFECT OCU_3_Diplopia 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_1_Visual Hallucinations 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_1_Nightmares 81771-21-3 KETAMINE ADVERSE_EFFECT NEU_3_Involuntray Movements 81771-21-3 KETAMINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 81771-21-3 KETAMINE MODE_CLASS Channel Blocker 81771-21-3 KETAMINE MESH_LEVEL_1 Organic Chemicals 81771-21-3 KETAMINE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 81771-21-3 KETAMINE ADVERSE_EFFECT GIS_3_Hypersalivation 81771-21-3 KETAMINE TISSUE_TOXICITY Cardiac Arrhythmia 81771-21-3 KETAMINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 81771-21-3 KETAMINE MECH_LEVEL_2 NMDA Modulators 81771-21-3 KETAMINE TA_LEVEL_2 CNS Depressant 81771-21-3 KETAMINE INDICATION Induction / Maintenance of Anesthesia 81771-21-3 KETAMINE TISSUE_TOXICITY Visual Hallucinations 81771-21-3 KETAMINE ADVERSE_EFFECT CVS_1_Hypertension 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_2_Anxiety 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_2_Psychologic Dependence 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_2_Disorientation 81771-21-3 KETAMINE ADVERSE_EFFECT SKN_3_Erythema 81771-21-3 KETAMINE ADVERSE_EFFECT LUN_3_Laryngospasm 81771-21-3 KETAMINE PRODUCT_CLASS Central Nervous System (CNS) 81771-21-3 KETAMINE MECH_LEVEL_1 Modulate neural transmission 81771-21-3 KETAMINE MESH_LEVEL_2 Hydrocarbons 81771-21-3 KETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 81771-21-3 KETAMINE ADVERSE_EFFECT CVS_3_Hypotension 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_1_Insomnia 81771-21-3 KETAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 81771-21-3 KETAMINE ADVERSE_EFFECT NEU_2_Nystagmus 81771-21-3 KETAMINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 81771-21-3 KETAMINE ADVERSE_EFFECT LUN_3_Apnea 81771-21-3 KETAMINE ADVERSE_EFFECT PSY_1_Post-Anesthesia Emergence of Delirium 81771-21-3 KETAMINE ZERO_CLASS N 81771-21-3 KETAMINE ACTIVITY_CLASS Glutamate antagonist 96448-41-8 KETAMINE MESH_LEVEL_1 Organic Chemicals 96448-41-8 KETAMINE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 96448-41-8 KETAMINE TA_LEVEL_3 Dissociative anesthetic 96448-41-8 KETAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 96448-41-8 KETAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 96448-41-8 KETAMINE ADVERSE_EFFECT XXX_3_Withdrawal 96448-41-8 KETAMINE THERAPEUTIC_CLASS General Anesthetics, Intravenous 96448-41-8 KETAMINE ADVERSE_EFFECT NEU_3_Involuntray Movements 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_1_Visual Hallucinations 96448-41-8 KETAMINE ADVERSE_EFFECT OCU_3_Diplopia 96448-41-8 KETAMINE TISSUE_TOXICITY Hypotension 96448-41-8 KETAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_3_Anorexia 96448-41-8 KETAMINE ADVERSE_EFFECT LUN_2_Respiratory Depression 96448-41-8 KETAMINE KNOWN_TOXICITY Mental Health Disorders 96448-41-8 KETAMINE TA_LEVEL_1 Central Nervous System (CNS) 96448-41-8 KETAMINE MECHANISM Block neural transmission 96448-41-8 KETAMINE ACTIVITY_CLASS Glutamate antagonist 96448-41-8 KETAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_1_Nightmares 96448-41-8 KETAMINE TA_LEVEL_2 CNS Depressant 96448-41-8 KETAMINE ZERO_CLASS N 96448-41-8 KETAMINE INDICATION Induction / Maintenance of Anesthesia 96448-41-8 KETAMINE TISSUE_TOXICITY Visual Hallucinations 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_2_Anxiety 96448-41-8 KETAMINE ADVERSE_EFFECT CVS_1_Hypertension 96448-41-8 KETAMINE ADVERSE_EFFECT GIS_3_Hypersalivation 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_1_Insomnia 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_1_Post-Anesthesia Emergence of Delirium 96448-41-8 KETAMINE ADVERSE_EFFECT LUN_3_Apnea 96448-41-8 KETAMINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 96448-41-8 KETAMINE ADVERSE_EFFECT NEU_2_Nystagmus 96448-41-8 KETAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 96448-41-8 KETAMINE ADVERSE_EFFECT CVS_3_Hypotension 96448-41-8 KETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 96448-41-8 KETAMINE MESH_LEVEL_2 Hydrocarbons 96448-41-8 KETAMINE MECH_LEVEL_1 Modulate neural transmission 96448-41-8 KETAMINE PRODUCT_CLASS Central Nervous System (CNS) 96448-41-8 KETAMINE ADVERSE_EFFECT LUN_3_Laryngospasm 96448-41-8 KETAMINE ADVERSE_EFFECT SKN_3_Erythema 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_2_Disorientation 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_2_Psychologic Dependence 96448-41-8 KETAMINE ADVERSE_EFFECT NEU_3_Tonic-Clonic Convulsions 96448-41-8 KETAMINE ADVERSE_EFFECT PSY_3_Psychosis 96448-41-8 KETAMINE TISSUE_TOXICITY Cardiac Arrhythmia 96448-41-8 KETAMINE MODE_CLASS Channel Blocker 96448-41-8 KETAMINE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 96448-41-8 KETAMINE MECH_LEVEL_2 NMDA Modulators 74050-98-9 KETANSERIN INDICATION Hypertension 74050-98-9 KETANSERIN MODE_CLASS Receptor Ligand Antagonist, Non-selective 74050-98-9 KETANSERIN THERAPEUTIC_CLASS Antihypertensive Agents 74050-98-9 KETANSERIN PRODUCT_CLASS Cardiovasculars 74050-98-9 KETANSERIN STRUCTURE_ACTIVITY 5HT2 antagonist 74050-98-9 KETANSERIN MECHANISM Modulate G-protein coupled signal transduction 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT NEU_3_Convulsions 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_3_Pancreatitis 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_1_Epigastric Pain 22161-81-5 DEXKETOPROFEN INDICATION Musculoskeletal Pain 22161-81-5 DEXKETOPROFEN PRODUCT_CLASS Anti-inflammatories 22161-81-5 DEXKETOPROFEN MODE_CLASS Enzyme Inhibitor 22161-81-5 DEXKETOPROFEN TISSUE_TOXICITY Acute Renal Failure 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_3_Peptic Ulceration 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT LIV_3_Hepatic Failure 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_1_Diarrhea 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT KID_3_Acute Renal Failure 22161-81-5 DEXKETOPROFEN KNOWN_TOXICITY Hepatotoxicity 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 22161-81-5 DEXKETOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 22161-81-5 DEXKETOPROFEN TISSUE_TOXICITY Hepatic Failure 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT CVS_3_Hypertension 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT XXX_3_Edema 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT LUN_3_Bronchospasm 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 22161-81-5 DEXKETOPROFEN KNOWN_TOXICITY Nephrotoxicity 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT BBM_3_Neutropenia 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_1_Dyspepsia 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 22161-81-5 DEXKETOPROFEN INDICATION Pain 22161-81-5 DEXKETOPROFEN INDICATION Dysmenorrhea 22161-81-5 DEXKETOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT LUN_3_Dyspnea 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT SKN_2_Rash 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_1_Nausea 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT GIS_2_Gastritis 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT CVS_2_Palpitation 22161-81-5 DEXKETOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 22161-81-5 DEXKETOPROFEN INDICATION Dental Pain 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT IMU_3_Anaphylaxis 22161-81-5 DEXKETOPROFEN ADVERSE_EFFECT NEU_2_Headache 74103-07-4 KETOROLAC PRODUCT_CLASS Analgesics 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_3_Pancreatitis 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 74103-07-4 KETOROLAC TISSUE_TOXICITY Acute Renal Failure 74103-07-4 KETOROLAC ADVERSE_EFFECT NEU_2_Tremor 74103-07-4 KETOROLAC ADVERSE_EFFECT IMU_3_Anaphylaxis 74103-07-4 KETOROLAC INDICATION Post-Operative Inflammation 74103-07-4 KETOROLAC MODE_CLASS Enzyme Inhibitor 74103-07-4 KETOROLAC TISSUE_TOXICITY Hepatic Failure 74103-07-4 KETOROLAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 74103-07-4 KETOROLAC ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 74103-07-4 KETOROLAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 74103-07-4 KETOROLAC ADVERSE_EFFECT CVS_2_Palpitation 74103-07-4 KETOROLAC ADVERSE_EFFECT LUN_2_Dyspnea 74103-07-4 KETOROLAC ADVERSE_EFFECT SKN_2_Pruritis 74103-07-4 KETOROLAC ADVERSE_EFFECT SKN_2_Rash 74103-07-4 KETOROLAC ADVERSE_EFFECT CVS_2_Hypertension 74103-07-4 KETOROLAC INDICATION Allergic Conjunctivitis 74103-07-4 KETOROLAC INDICATION Pain 74103-07-4 KETOROLAC ACTIVITY_CLASS Anti-inflammatory 74103-07-4 KETOROLAC KNOWN_TOXICITY Hepatotoxicity 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_2_Peptic Ulceration 74103-07-4 KETOROLAC ADVERSE_EFFECT LIV_3_Hepatitis 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_1_Dyspepsia 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_2_Gastritis 74103-07-4 KETOROLAC ADVERSE_EFFECT LIV_3_Hepatic Failure 74103-07-4 KETOROLAC ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 74103-07-4 KETOROLAC KNOWN_TOXICITY Nephrotoxicity 74103-07-4 KETOROLAC ZERO_CLASS N 74103-07-4 KETOROLAC ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 74103-07-4 KETOROLAC ADVERSE_EFFECT KID_3_Acute Renal Failure 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_1_Epigastric Pain 74103-07-4 KETOROLAC ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 74103-07-4 KETOROLAC ADVERSE_EFFECT NEU_2_Drowsiness 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_1_Nausea 74103-07-4 KETOROLAC ADVERSE_EFFECT NEU_3_Convulsions 74103-07-4 KETOROLAC MECHANISM Inhibit eicosanoid biosynthesis 74103-07-4 KETOROLAC ADVERSE_EFFECT LUN_2_Bronchospasm 74103-07-4 KETOROLAC PRODUCT_CLASS Other Human Uses 74103-07-4 KETOROLAC ADVERSE_EFFECT XXX_2_Edema 74103-07-4 KETOROLAC ADVERSE_EFFECT NEU_1_Headache 74103-07-4 KETOROLAC ADVERSE_EFFECT GIS_2_Diarrhea 74103-06-3 KETOROLAC PRODUCT_CLASS Analgesics 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_3_Pancreatitis 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 74103-06-3 KETOROLAC TISSUE_TOXICITY Acute Renal Failure 74103-06-3 KETOROLAC ADVERSE_EFFECT NEU_2_Tremor 74103-06-3 KETOROLAC ADVERSE_EFFECT IMU_3_Anaphylaxis 74103-06-3 KETOROLAC ADVERSE_EFFECT LIV_3_Hepatitis 74103-06-3 KETOROLAC KNOWN_TOXICITY Hepatotoxicity 74103-06-3 KETOROLAC ACTIVITY_CLASS Anti-inflammatory 74103-06-3 KETOROLAC INDICATION Pain 74103-06-3 KETOROLAC INDICATION Allergic Conjunctivitis 74103-06-3 KETOROLAC ADVERSE_EFFECT CVS_2_Hypertension 74103-06-3 KETOROLAC ADVERSE_EFFECT SKN_2_Rash 74103-06-3 KETOROLAC ADVERSE_EFFECT SKN_2_Pruritis 74103-06-3 KETOROLAC ADVERSE_EFFECT LUN_2_Dyspnea 74103-06-3 KETOROLAC ADVERSE_EFFECT CVS_2_Palpitation 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_2_Gastritis 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 74103-06-3 KETOROLAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 74103-06-3 KETOROLAC TISSUE_TOXICITY Hepatic Failure 74103-06-3 KETOROLAC ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 74103-06-3 KETOROLAC ADVERSE_EFFECT KID_3_Acute Renal Failure 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_1_Epigastric Pain 74103-06-3 KETOROLAC ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 74103-06-3 KETOROLAC ADVERSE_EFFECT NEU_2_Drowsiness 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_1_Nausea 74103-06-3 KETOROLAC ADVERSE_EFFECT NEU_3_Convulsions 74103-06-3 KETOROLAC MECHANISM Inhibit eicosanoid biosynthesis 74103-06-3 KETOROLAC PRODUCT_CLASS Other Human Uses 74103-06-3 KETOROLAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 74103-06-3 KETOROLAC ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_1_Dyspepsia 74103-06-3 KETOROLAC ADVERSE_EFFECT LIV_3_Hepatic Failure 74103-06-3 KETOROLAC ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 74103-06-3 KETOROLAC ADVERSE_EFFECT LUN_2_Bronchospasm 74103-06-3 KETOROLAC ADVERSE_EFFECT XXX_2_Edema 74103-06-3 KETOROLAC ADVERSE_EFFECT NEU_1_Headache 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_2_Diarrhea 74103-06-3 KETOROLAC INDICATION Post-Operative Inflammation 74103-06-3 KETOROLAC MODE_CLASS Enzyme Inhibitor 74103-06-3 KETOROLAC ADVERSE_EFFECT GIS_2_Peptic Ulceration 74103-06-3 KETOROLAC KNOWN_TOXICITY Nephrotoxicity 74103-06-3 KETOROLAC ZERO_CLASS N 34580-14-8 KETOTIFEN ADVERSE_EFFECT XXX_1_Rhinitis 34580-14-8 KETOTIFEN ADVERSE_EFFECT SKN_2_Pruritis 34580-14-8 KETOTIFEN ADVERSE_EFFECT GIS_1_Dry Mouth 34580-14-8 KETOTIFEN ADVERSE_EFFECT PSY_2_CNS Stimulation 34580-14-8 KETOTIFEN PRODUCT_CLASS Anti-inflammatories 34580-14-8 KETOTIFEN MECHANISM Modulate G-protein coupled signal transduction 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Conjunctivitis 34580-14-8 KETOTIFEN INDICATION Asthma 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Ocular Pain 34580-14-8 KETOTIFEN MODE_CLASS Receptor Ligand Antagonist, Non-selective 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Mydriasis 34580-14-8 KETOTIFEN ADVERSE_EFFECT NEU_1_Drowsiness 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Ocular Irritation 34580-14-8 KETOTIFEN ADVERSE_EFFECT XXX_2_Weight Gain 34580-14-8 KETOTIFEN ADVERSE_EFFECT XXX_2_Pharyngitis 34580-14-8 KETOTIFEN ADVERSE_EFFECT LUN_3_Exacerbation of Asthma 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_1_Conjunctival Hyperemia 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Xerophthalmia 34580-14-8 KETOTIFEN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 34580-14-8 KETOTIFEN STRUCTURE_ACTIVITY 5HT2 antagonist 34580-14-8 KETOTIFEN INDICATION Allergic Conjunctivitis 34580-14-8 KETOTIFEN ADVERSE_EFFECT NEU_2_Convulsions 34580-14-8 KETOTIFEN ADVERSE_EFFECT NEU_2_Dizziness 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Keratitis 34580-14-8 KETOTIFEN ADVERSE_EFFECT CVS_1_Tachycardia 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Ocular Discharge 34580-14-8 KETOTIFEN ADVERSE_EFFECT NEU_1_Headache 34580-14-8 KETOTIFEN ADVERSE_EFFECT XXX_2_Flu-Like Syndrome 34580-14-8 KETOTIFEN ADVERSE_EFFECT OCU_2_Photophobia 34580-14-8 KETOTIFEN ADVERSE_EFFECT PSY_2_Confusion 34580-14-8 KETOTIFEN ADVERSE_EFFECT LUN_3_Dyspnea 34580-14-8 KETOTIFEN ADVERSE_EFFECT LUN_3_Cyanosis 34580-13-7 KETOTIFEN ADVERSE_EFFECT SKN_2_Pruritis 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Ocular Discharge 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Photophobia 34580-13-7 KETOTIFEN ADVERSE_EFFECT XXX_2_Flu-Like Syndrome 34580-13-7 KETOTIFEN ADVERSE_EFFECT PSY_2_Confusion 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Xerophthalmia 34580-13-7 KETOTIFEN ADVERSE_EFFECT NEU_1_Headache 34580-13-7 KETOTIFEN ADVERSE_EFFECT CVS_1_Tachycardia 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Ocular Irritation 34580-13-7 KETOTIFEN ADVERSE_EFFECT LUN_3_Exacerbation of Asthma 34580-13-7 KETOTIFEN ADVERSE_EFFECT XXX_1_Rhinitis 34580-13-7 KETOTIFEN ADVERSE_EFFECT LUN_3_Dyspnea 34580-13-7 KETOTIFEN ADVERSE_EFFECT NEU_2_Dizziness 34580-13-7 KETOTIFEN ADVERSE_EFFECT NEU_2_Convulsions 34580-13-7 KETOTIFEN INDICATION Allergic Conjunctivitis 34580-13-7 KETOTIFEN STRUCTURE_ACTIVITY 5HT2 antagonist 34580-13-7 KETOTIFEN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 34580-13-7 KETOTIFEN MECHANISM Modulate G-protein coupled signal transduction 34580-13-7 KETOTIFEN PRODUCT_CLASS Anti-inflammatories 34580-13-7 KETOTIFEN ADVERSE_EFFECT PSY_2_CNS Stimulation 34580-13-7 KETOTIFEN ADVERSE_EFFECT GIS_1_Dry Mouth 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Conjunctivitis 34580-13-7 KETOTIFEN INDICATION Asthma 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Ocular Pain 34580-13-7 KETOTIFEN MODE_CLASS Receptor Ligand Antagonist, Non-selective 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Mydriasis 34580-13-7 KETOTIFEN ADVERSE_EFFECT NEU_1_Drowsiness 34580-13-7 KETOTIFEN ADVERSE_EFFECT XXX_2_Weight Gain 34580-13-7 KETOTIFEN ADVERSE_EFFECT XXX_2_Pharyngitis 34580-13-7 KETOTIFEN ADVERSE_EFFECT LUN_3_Cyanosis 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_1_Conjunctival Hyperemia 34580-13-7 KETOTIFEN ADVERSE_EFFECT OCU_2_Keratitis 525-79-1 KINETIN PRODUCT_CLASS Dermatologicals 160970-64-9 KMD-3213 INDICATION Benign Prostatic Hyperplasia (BPH) 160970-64-9 KMD-3213 PRODUCT_CLASS Autonomic Nervous System (ANS) 160970-64-9 KMD-3213 THERAPEUTIC_CLASS Sympatholytic Agents 160970-64-9 KMD-3213 MECHANISM Modulate G-protein coupled signal transduction 169107-04-4 KMD-3213 MECHANISM Modulate G-protein coupled signal transduction 169107-04-4 KMD-3213 THERAPEUTIC_CLASS Sympatholytic Agents 169107-04-4 KMD-3213 INDICATION Benign Prostatic Hyperplasia (BPH) 169107-04-4 KMD-3213 PRODUCT_CLASS Autonomic Nervous System (ANS) 160141-09-3 L-744832 PRODUCT_CLASS Biochemicals 160141-09-3 L-744832 STRUCTURE_ACTIVITY Protein farnesyl transferase inhibitor 160141-09-3 L-744832 MECHANISM Induce Apoptosis 160141-09-3 L-744832 MODE_CLASS Enzyme Inhibitor 177947-03-4 L-772405 MODE_CLASS Receptor Agonist 177947-03-4 L-772405 MECHANISM Modulate cerebral vasoconstriction 177947-03-4 L-772405 THERAPEUTIC_CLASS Antimigraines 177947-03-4 L-772405 PRODUCT_CLASS Central Nervous System (CNS) 74-79-3 L-ARGININE MECHANISM Scavenges hydrogen peroxide and free radicals 74-79-3 L-ARGININE INDICATION Anemia 1119-34-2 L-ARGININE INDICATION Anemia 1119-34-2 L-ARGININE MECHANISM Scavenges hydrogen peroxide and free radicals 56-84-8 L-ASPARTIC ACID INDICATION Opiate Detoxification 56-84-8 L-ASPARTIC ACID MECHANISM Modulate neural transmission 56-84-8 L-ASPARTIC ACID MECHANISM Modulate channel gating 56-84-8 L-ASPARTIC ACID INDICATION Nutritional Supplement 56-84-8 L-ASPARTIC ACID MODE_CLASS Endogenous Receptor /Channel Ligand 56-84-8 L-ASPARTIC ACID MECHANISM Modulate G-protein coupled signal transduction 56-84-8 L-ASPARTIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 56-84-8 L-ASPARTIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 6899-05-4 GLUTAMIC ACID MECHANISM Modulate channel gating 6899-05-4 GLUTAMIC ACID MODE_CLASS Endogenous Receptor /Channel Ligand 6899-05-4 GLUTAMIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 6899-05-4 GLUTAMIC ACID MECHANISM Modulate neural transmission 6899-05-4 GLUTAMIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 142-47-2 GLUTAMIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 142-47-2 GLUTAMIC ACID MODE_CLASS Endogenous Receptor /Channel Ligand 142-47-2 GLUTAMIC ACID MECHANISM Modulate channel gating 142-47-2 GLUTAMIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 142-47-2 GLUTAMIC ACID MECHANISM Modulate neural transmission 56-86-0 L-GLUTAMIC ACID MECHANISM Modulate channel gating 56-86-0 L-GLUTAMIC ACID INDICATION Achlorhydria 56-86-0 L-GLUTAMIC ACID MODE_CLASS Endogenous Receptor /Channel Ligand 56-86-0 L-GLUTAMIC ACID INDICATION Nutritional Supplement 56-86-0 L-GLUTAMIC ACID INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 56-86-0 L-GLUTAMIC ACID MECHANISM Modulate neural transmission 56-86-0 L-GLUTAMIC ACID INDICATION Pernicious Anemia 56-86-0 L-GLUTAMIC ACID THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 56-86-0 L-GLUTAMIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 56-86-0 L-GLUTAMIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 56-86-0 L-GLUTAMIC ACID MECHANISM Modulate G-protein coupled signal transduction 56-86-0 L-GLUTAMIC ACID STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 500-44-7 L-MIMOSINE PRODUCT_CLASS Toxicants 500-44-7 L-MIMOSINE MECHANISM Inhibit DNA synthesis, repair, and function 500-44-7 L-MIMOSINE MECHANISM Inhibit DNA synthesis, repair, and function 500-44-7 L-MIMOSINE MODE_CLASS Enzyme Inhibitor 10182-82-8 L-MIMOSINE MODE_CLASS Enzyme Inhibitor 10182-82-8 L-MIMOSINE MECHANISM Inhibit DNA synthesis, repair, and function 10182-82-8 L-MIMOSINE MECHANISM Inhibit DNA synthesis, repair, and function 10182-82-8 L-MIMOSINE PRODUCT_CLASS Toxicants 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT PSY_3_Psychosis 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT NEU_3_Dizziness 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT PSY_3_Anxiety 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT CVS_2_Hypertension 61-76-7 L-PHENYLEPHRINE TISSUE_TOXICITY Cardiac Arrhythmia 61-76-7 L-PHENYLEPHRINE THERAPEUTIC_CLASS Sympathomimetic Agents 61-76-7 L-PHENYLEPHRINE PRODUCT_CLASS Cardiovasculars 61-76-7 L-PHENYLEPHRINE INDICATION Posterior Synechia 61-76-7 L-PHENYLEPHRINE INDICATION Paroxysmal Supraventricular Tachycardia 61-76-7 L-PHENYLEPHRINE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 agonist, oxymetazoline 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT XXX_3_Injection Site Reaction 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT OCU_3_Photophobia 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT XXX_3_Nasal Irritation 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT NEU_3_Paresthesia 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 61-76-7 L-PHENYLEPHRINE INDICATION Hypotension 61-76-7 L-PHENYLEPHRINE ACTIVITY_CLASS Adrenergic agonist 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT OCU_3_Tearing 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT XXX_3_Restlessness 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT CVS_3_Angina 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT OCU_3_Blurred Vision 61-76-7 L-PHENYLEPHRINE KNOWN_TOXICITY Cardiovascular Toxicity 61-76-7 L-PHENYLEPHRINE TISSUE_TOXICITY Angina 61-76-7 L-PHENYLEPHRINE INDICATION Mydriasis Induction 61-76-7 L-PHENYLEPHRINE INDICATION Glaucoma 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT NEU_2_Headache 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT PSY_3_Insomnia 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT PSY_3_Hallucinations 61-76-7 L-PHENYLEPHRINE TISSUE_TOXICITY Myocardial Infarction 61-76-7 L-PHENYLEPHRINE INDICATION Eustachian Tube Congestion 61-76-7 L-PHENYLEPHRINE INDICATION Nasal Congestion 61-76-7 L-PHENYLEPHRINE MECHANISM Increase vasoconstriction 61-76-7 L-PHENYLEPHRINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 61-76-7 L-PHENYLEPHRINE MODE_CLASS Receptor Agonist 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT XXX_3_Nasal Dryness 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT XXX_3_Burning Sensation 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT _3_Rebound Nasal Congestion 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT OCU_3_Ocular Allergic Reactions 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT PSY_3_Excitement 61-76-7 L-PHENYLEPHRINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 52809-07-1 L-QUISQUALIC ACID PRODUCT_CLASS Biochemicals 52809-07-1 L-QUISQUALIC ACID MECHANISM Modulate G-protein coupled signal transduction 52809-07-1 L-QUISQUALIC ACID MODE_CLASS Receptor Agonist 36894-69-6 LABETALOL ACTIVITY_CLASS Adrenergic antagonist 36894-69-6 LABETALOL ADVERSE_EFFECT CVS_1_Hypotension 36894-69-6 LABETALOL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 36894-69-6 LABETALOL ADVERSE_EFFECT NEU_1_Lightheadedness 36894-69-6 LABETALOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 36894-69-6 LABETALOL ADVERSE_EFFECT REP_2_Priapism 36894-69-6 LABETALOL ADVERSE_EFFECT NEU_2_Numbness 36894-69-6 LABETALOL ADVERSE_EFFECT XXX_2_Fatigue 36894-69-6 LABETALOL ADVERSE_EFFECT PSY_2_Depression 36894-69-6 LABETALOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 36894-69-6 LABETALOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 36894-69-6 LABETALOL TISSUE_TOXICITY Hepatotoxicity 36894-69-6 LABETALOL TISSUE_TOXICITY Atrioventricular Blockade 36894-69-6 LABETALOL ADVERSE_EFFECT REP_2_Ejaculatory Disorder 36894-69-6 LABETALOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 36894-69-6 LABETALOL ADVERSE_EFFECT GUS_2_Urinary Retention 36894-69-6 LABETALOL ADVERSE_EFFECT LIV_3_Hepatotoxicity 36894-69-6 LABETALOL TA_LEVEL_3 hypertension 36894-69-6 LABETALOL KNOWN_TOXICITY Hepatotoxicity 36894-69-6 LABETALOL ADVERSE_EFFECT NEU_1_Dizziness 36894-69-6 LABETALOL ADVERSE_EFFECT NEU_1_Syncope 36894-69-6 LABETALOL MODE_CLASS Receptor Ligand Antagonist, Selective 36894-69-6 LABETALOL TA_LEVEL_2 adrenergic blocker 36894-69-6 LABETALOL MECHANISM Modulate G-protein coupled signal transduction 36894-69-6 LABETALOL INDICATION Hypertension 36894-69-6 LABETALOL KNOWN_TOXICITY Cardiovascular Toxicity 36894-69-6 LABETALOL TISSUE_TOXICITY Congestive Heart Failure 36894-69-6 LABETALOL ADVERSE_EFFECT LUN_2_Dyspnea 36894-69-6 LABETALOL ADVERSE_EFFECT NEU_2_Headache 36894-69-6 LABETALOL ADVERSE_EFFECT NEU_2_Paresthesia 36894-69-6 LABETALOL ADVERSE_EFFECT SKN_2_Pruritis 36894-69-6 LABETALOL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 36894-69-6 LABETALOL ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 36894-69-6 LABETALOL ADVERSE_EFFECT REP_2_Decreased Libido 36894-69-6 LABETALOL MESH_LEVEL_1 Organic Chemicals 36894-69-6 LABETALOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 36894-69-6 LABETALOL ADVERSE_EFFECT LUN_2_Wheezing 36894-69-6 LABETALOL ADVERSE_EFFECT PSY_2_Nightmares 36894-69-6 LABETALOL ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 36894-69-6 LABETALOL MECH_LEVEL_3 adrenoceptor beta and alpha 36894-69-6 LABETALOL MECH_LEVEL_1 Vasorelaxation 36894-69-6 LABETALOL MECH_LEVEL_2 adrenergic antagonist 36894-69-6 LABETALOL TA_LEVEL_1 Cardiovascular 36894-69-6 LABETALOL MECHANISM Reduce vasoconstriction 36894-69-6 LABETALOL ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 36894-69-6 LABETALOL TISSUE_TOXICITY Hepatic Necrosis 36894-69-6 LABETALOL MESH_LEVEL_2 Amines 36894-69-6 LABETALOL TISSUE_TOXICITY Hypotension 36894-69-6 LABETALOL THERAPEUTIC_CLASS Antihypertensive Agents 36894-69-6 LABETALOL PRODUCT_CLASS Cardiovasculars 36894-69-6 LABETALOL MESH_LEVEL_3 Amino Alcohols 36894-69-6 LABETALOL ZERO_CLASS N 32780-64-6 LABETALOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 32780-64-6 LABETALOL ADVERSE_EFFECT REP_2_Ejaculatory Disorder 32780-64-6 LABETALOL TISSUE_TOXICITY Atrioventricular Blockade 32780-64-6 LABETALOL MESH_LEVEL_2 Amines 32780-64-6 LABETALOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 32780-64-6 LABETALOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 32780-64-6 LABETALOL ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 32780-64-6 LABETALOL ADVERSE_EFFECT CVS_1_Hypotension 32780-64-6 LABETALOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 32780-64-6 LABETALOL ADVERSE_EFFECT LUN_2_Wheezing 32780-64-6 LABETALOL ADVERSE_EFFECT PSY_2_Nightmares 32780-64-6 LABETALOL ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 32780-64-6 LABETALOL TISSUE_TOXICITY Hepatic Necrosis 32780-64-6 LABETALOL MECH_LEVEL_1 Vasorelaxation 32780-64-6 LABETALOL MECH_LEVEL_2 adrenergic antagonist 32780-64-6 LABETALOL TA_LEVEL_1 Cardiovascular 32780-64-6 LABETALOL TA_LEVEL_3 hypertension 32780-64-6 LABETALOL MECHANISM Reduce vasoconstriction 32780-64-6 LABETALOL ACTIVITY_CLASS Adrenergic antagonist 32780-64-6 LABETALOL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 32780-64-6 LABETALOL ADVERSE_EFFECT NEU_1_Lightheadedness 32780-64-6 LABETALOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 32780-64-6 LABETALOL ADVERSE_EFFECT REP_2_Priapism 32780-64-6 LABETALOL ADVERSE_EFFECT NEU_2_Numbness 32780-64-6 LABETALOL ADVERSE_EFFECT XXX_2_Fatigue 32780-64-6 LABETALOL ADVERSE_EFFECT PSY_2_Depression 32780-64-6 LABETALOL TISSUE_TOXICITY Hepatotoxicity 32780-64-6 LABETALOL TISSUE_TOXICITY Hypotension 32780-64-6 LABETALOL THERAPEUTIC_CLASS Antihypertensive Agents 32780-64-6 LABETALOL PRODUCT_CLASS Cardiovasculars 32780-64-6 LABETALOL MESH_LEVEL_3 Amino Alcohols 32780-64-6 LABETALOL MECH_LEVEL_3 adrenoceptor beta and alpha 32780-64-6 LABETALOL ZERO_CLASS N 32780-64-6 LABETALOL MESH_LEVEL_1 Organic Chemicals 32780-64-6 LABETALOL ADVERSE_EFFECT REP_2_Decreased Libido 32780-64-6 LABETALOL ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 32780-64-6 LABETALOL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 32780-64-6 LABETALOL ADVERSE_EFFECT SKN_2_Pruritis 32780-64-6 LABETALOL ADVERSE_EFFECT NEU_2_Paresthesia 32780-64-6 LABETALOL ADVERSE_EFFECT NEU_2_Headache 32780-64-6 LABETALOL ADVERSE_EFFECT LUN_2_Dyspnea 32780-64-6 LABETALOL TISSUE_TOXICITY Congestive Heart Failure 32780-64-6 LABETALOL KNOWN_TOXICITY Cardiovascular Toxicity 32780-64-6 LABETALOL INDICATION Hypertension 32780-64-6 LABETALOL MECHANISM Modulate G-protein coupled signal transduction 32780-64-6 LABETALOL TA_LEVEL_2 adrenergic blocker 32780-64-6 LABETALOL MODE_CLASS Receptor Ligand Antagonist, Selective 32780-64-6 LABETALOL ADVERSE_EFFECT NEU_1_Syncope 32780-64-6 LABETALOL ADVERSE_EFFECT NEU_1_Dizziness 32780-64-6 LABETALOL KNOWN_TOXICITY Hepatotoxicity 32780-64-6 LABETALOL ADVERSE_EFFECT LIV_3_Hepatotoxicity 32780-64-6 LABETALOL ADVERSE_EFFECT GUS_2_Urinary Retention 50-21-5 LACTIC ACID PRODUCT_CLASS Other Human Uses 4618-18-2 LACTULOSE ADVERSE_EFFECT ELT_3_Hypernatremia 4618-18-2 LACTULOSE INDICATION Hepatic Encephalopathy 4618-18-2 LACTULOSE THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 4618-18-2 LACTULOSE ADVERSE_EFFECT END_3_Metabolic Acidosis 4618-18-2 LACTULOSE ADVERSE_EFFECT GIS_1_Flatulence 4618-18-2 LACTULOSE ADVERSE_EFFECT GIS_1_Abdominal Pain 4618-18-2 LACTULOSE ADVERSE_EFFECT GIS_2_Diarrhea 4618-18-2 LACTULOSE THERAPEUTIC_CLASS Laxatives 4618-18-2 LACTULOSE PRODUCT_CLASS Gastrointestinal System 4618-18-2 LACTULOSE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 4618-18-2 LACTULOSE ADVERSE_EFFECT GIS_1_Eructation 4618-18-2 LACTULOSE INDICATION Constipation 4618-18-2 LACTULOSE ADVERSE_EFFECT ELT_3_Hypokalemia 134678-17-4 LAMIVUDINE ADVERSE_EFFECT XXX_2_Fever 134678-17-4 LAMIVUDINE MESH_LEVEL_2 Nucleosides 134678-17-4 LAMIVUDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 134678-17-4 LAMIVUDINE PRODUCT_CLASS Anti-infectives 134678-17-4 LAMIVUDINE MECHANISM Inhibit viral DNA synthesis 134678-17-4 LAMIVUDINE TA_LEVEL_2 Anti-viral 134678-17-4 LAMIVUDINE ADVERSE_EFFECT NEU_2_Dizziness 134678-17-4 LAMIVUDINE TA_LEVEL_1 Infectious Disease 134678-17-4 LAMIVUDINE ADVERSE_EFFECT XXX_3_Splenomegaly 134678-17-4 LAMIVUDINE ADVERSE_EFFECT XXX_1_Malaise 134678-17-4 LAMIVUDINE ADVERSE_EFFECT GIS_2_Pancreatitis 134678-17-4 LAMIVUDINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 134678-17-4 LAMIVUDINE ADVERSE_EFFECT MSK_2_Arthralgia 134678-17-4 LAMIVUDINE ADVERSE_EFFECT NEU_2_Paresthesia 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LUN_2_Cough 134678-17-4 LAMIVUDINE ADVERSE_EFFECT PSY_2_Depression 134678-17-4 LAMIVUDINE THERAPEUTIC_CLASS Antivirals, Systemic 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LIV_2_Post-Treatment Exacerbation of Hepatitis 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LIV_2_Hepatomegaly 134678-17-4 LAMIVUDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 134678-17-4 LAMIVUDINE ADVERSE_EFFECT EMB_3_Embryotoxicity 134678-17-4 LAMIVUDINE ACTIVITY_CLASS Anti-viral 134678-17-4 LAMIVUDINE ADVERSE_EFFECT MSK_2_Myalgia 134678-17-4 LAMIVUDINE MODE_CLASS Enzyme substrate mimic 134678-17-4 LAMIVUDINE ADVERSE_EFFECT PSY_1_Insomnia 134678-17-4 LAMIVUDINE INDICATION Hepatitis B 134678-17-4 LAMIVUDINE MECH_LEVEL_3 RNA-directed DNA polymerase 134678-17-4 LAMIVUDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 134678-17-4 LAMIVUDINE MESH_LEVEL_3 Deoxyribonucleosides 134678-17-4 LAMIVUDINE ADVERSE_EFFECT END_2_Lactic Acidosis 134678-17-4 LAMIVUDINE ADVERSE_EFFECT SKN_2_Skin Rash 134678-17-4 LAMIVUDINE ADVERSE_EFFECT NEU_1_Neuropathy 134678-17-4 LAMIVUDINE ADVERSE_EFFECT BBM_2_Anemia 134678-17-4 LAMIVUDINE STRUCTURE_ACTIVITY Viral RT inhibitor 134678-17-4 LAMIVUDINE ZERO_CLASS N 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LIV_2_Steatosis 134678-17-4 LAMIVUDINE ADVERSE_EFFECT BBM_2_Neutropenia 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LYM_3_Lymphadenopathy 134678-17-4 LAMIVUDINE ADVERSE_EFFECT IMU_3_Anaphylaxis 134678-17-4 LAMIVUDINE MECH_LEVEL_2 Inhibit viral DNA synthesis 134678-17-4 LAMIVUDINE ADVERSE_EFFECT GIS_1_Nausea 134678-17-4 LAMIVUDINE MECH_LEVEL_1 Anti-viral 134678-17-4 LAMIVUDINE TA_LEVEL_3 antiviral RT inhibitors 134678-17-4 LAMIVUDINE ADVERSE_EFFECT PSY_2_Anorexia 134678-17-4 LAMIVUDINE ADVERSE_EFFECT NEU_1_Headache 134678-17-4 LAMIVUDINE ADVERSE_EFFECT LIV_3_Hepatitis 134678-17-4 LAMIVUDINE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT PSY_2_Depression 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LUN_2_Cough 131086-21-0 LAMIVUDINE ADVERSE_EFFECT NEU_2_Paresthesia 131086-21-0 LAMIVUDINE ADVERSE_EFFECT MSK_2_Arthralgia 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LYM_3_Lymphadenopathy 131086-21-0 LAMIVUDINE ADVERSE_EFFECT IMU_3_Anaphylaxis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT GIS_1_Nausea 131086-21-0 LAMIVUDINE ADVERSE_EFFECT XXX_2_Fever 131086-21-0 LAMIVUDINE MESH_LEVEL_2 Nucleosides 131086-21-0 LAMIVUDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 131086-21-0 LAMIVUDINE PRODUCT_CLASS Anti-infectives 131086-21-0 LAMIVUDINE TA_LEVEL_2 Anti-viral 131086-21-0 LAMIVUDINE ACTIVITY_CLASS Anti-viral 131086-21-0 LAMIVUDINE MECH_LEVEL_1 Anti-viral 131086-21-0 LAMIVUDINE TA_LEVEL_1 Infectious Disease 131086-21-0 LAMIVUDINE ADVERSE_EFFECT XXX_3_Splenomegaly 131086-21-0 LAMIVUDINE ADVERSE_EFFECT XXX_1_Malaise 131086-21-0 LAMIVUDINE ADVERSE_EFFECT GIS_2_Pancreatitis 131086-21-0 LAMIVUDINE MECHANISM Inhibit viral DNA synthesis 131086-21-0 LAMIVUDINE STRUCTURE_ACTIVITY Viral RT inhibitor 131086-21-0 LAMIVUDINE ZERO_CLASS N 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LIV_2_Post-Treatment Exacerbation of Hepatitis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LIV_2_Steatosis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT BBM_2_Neutropenia 131086-21-0 LAMIVUDINE ADVERSE_EFFECT PSY_1_Insomnia 131086-21-0 LAMIVUDINE INDICATION Hepatitis B 131086-21-0 LAMIVUDINE MECH_LEVEL_3 RNA-directed DNA polymerase 131086-21-0 LAMIVUDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 131086-21-0 LAMIVUDINE ADVERSE_EFFECT NEU_2_Dizziness 131086-21-0 LAMIVUDINE ADVERSE_EFFECT BBM_2_Anemia 131086-21-0 LAMIVUDINE TA_LEVEL_3 antiviral RT inhibitors 131086-21-0 LAMIVUDINE ADVERSE_EFFECT PSY_2_Anorexia 131086-21-0 LAMIVUDINE ADVERSE_EFFECT NEU_1_Headache 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LIV_3_Hepatitis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT EMB_3_Embryotoxicity 131086-21-0 LAMIVUDINE ADVERSE_EFFECT GIS_2_Abdominal Pain 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LIV_2_Hepatomegaly 131086-21-0 LAMIVUDINE MECH_LEVEL_2 Inhibit viral DNA synthesis 131086-21-0 LAMIVUDINE THERAPEUTIC_CLASS Antivirals, Systemic 131086-21-0 LAMIVUDINE ADVERSE_EFFECT MSK_2_Myalgia 131086-21-0 LAMIVUDINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 131086-21-0 LAMIVUDINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 131086-21-0 LAMIVUDINE MESH_LEVEL_3 Deoxyribonucleosides 131086-21-0 LAMIVUDINE MODE_CLASS Enzyme substrate mimic 131086-21-0 LAMIVUDINE ADVERSE_EFFECT END_2_Lactic Acidosis 131086-21-0 LAMIVUDINE ADVERSE_EFFECT SKN_2_Skin Rash 131086-21-0 LAMIVUDINE ADVERSE_EFFECT NEU_1_Neuropathy 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT NEU_1_Dizziness 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT PSY_3_Emotional Lability 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT XXX_1_Asthenia 84057-84-1 LAMOTRIGINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 84057-84-1 LAMOTRIGINE INDICATION Lennox-Gastaut Syndrome (Petit Mal Variant) 84057-84-1 LAMOTRIGINE INDICATION Absence (Petit Mal) Seizures 84057-84-1 LAMOTRIGINE MECH_LEVEL_1 Modulates channel gating 84057-84-1 LAMOTRIGINE TA_LEVEL_3 Antiepileptics / Anticonvulsants 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT IMU_3_Hypersensitivity 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT OCU_1_Blurred Vision 84057-84-1 LAMOTRIGINE MECH_LEVEL_3 Voltage-gated Na+ channel 84057-84-1 LAMOTRIGINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT PSY_2_Depression 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT NEU_3_Dysarthria 84057-84-1 LAMOTRIGINE MODE_CLASS Channel Blocker 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT NEU_1_Headache 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT PSY_2_Insomnia 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT NEU_1_Ataxia 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT OCU_1_Diplopia 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT XXX_3_Rhinitis 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT GIS_3_Dyspepsia 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT REP_3_Amenorrhea 84057-84-1 LAMOTRIGINE MECHANISM Block neural transmission 84057-84-1 LAMOTRIGINE INDICATION Myoclonic Seizures 84057-84-1 LAMOTRIGINE INDICATION Partial Seizures 84057-84-1 LAMOTRIGINE MESH_LEVEL_1 Heterocyclic Compounds 84057-84-1 LAMOTRIGINE MECH_LEVEL_2 Sodium channel antagonist 84057-84-1 LAMOTRIGINE TA_LEVEL_1 Central Nervous System (CNS) 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT SKN_1_Maculopapular Rash 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT NEU_2_Tremor 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT NEU_1_Drowsiness 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT GUS_2_Vaginitis 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 84057-84-1 LAMOTRIGINE ZERO_CLASS N 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT PSY_2_Anxiety 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT PSY_3_Confusion 84057-84-1 LAMOTRIGINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT BBM_3_Anemia 84057-84-1 LAMOTRIGINE INDICATION Atonic Seizures / Epileptic Drop Attacks 84057-84-1 LAMOTRIGINE ACTIVITY_CLASS Na+ channel blocker 84057-84-1 LAMOTRIGINE PRODUCT_CLASS Central Nervous System (CNS) 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT SKN_1_Erythema 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT IMU_3_Eosinophilia 84057-84-1 LAMOTRIGINE ADVERSE_EFFECT BBM_3_Leukopenia 84057-84-1 LAMOTRIGINE INDICATION Tonic-Clonic (Grand Mal) Seizures 84057-84-1 LAMOTRIGINE MESH_LEVEL_3 Triazines 101530-10-3 LANOCONAZOLE PRODUCT_CLASS Anti-infectives 101530-10-3 LANOCONAZOLE MODE_CLASS Enzyme Inhibitor 101530-10-3 LANOCONAZOLE THERAPEUTIC_CLASS Antifungals 101530-10-3 LANOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Gastric Polyps 103577-45-3 LANSOPRAZOLE INDICATION Erosive Esophagitis 103577-45-3 LANSOPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 103577-45-3 LANSOPRAZOLE MESH_LEVEL_3 Benzimidazoles 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT END_3_Gynecomastia 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Constipation 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Eructation 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Flatulence 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT XXX_3_Increased Appetite 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Ulcerative Colitis 103577-45-3 LANSOPRAZOLE INDICATION Gastric Ulcer 103577-45-3 LANSOPRAZOLE MECH_LEVEL_1 Ulcer healing 103577-45-3 LANSOPRAZOLE PRODUCT_CLASS Gastrointestinal System 103577-45-3 LANSOPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 103577-45-3 LANSOPRAZOLE ZERO_CLASS N 103577-45-3 LANSOPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT BIL_3_Cholelithiasis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT SKN_3_Acne 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT IMU_3_Urticaria 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT PSY_3_Anorexia 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Dysphagia 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Esophagitis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Hematemesis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT LIV_3_Hepatitis 103577-45-3 LANSOPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 103577-45-3 LANSOPRAZOLE MECH_LEVEL_3 H/K ATPase 103577-45-3 LANSOPRAZOLE TA_LEVEL_3 N/K ATPase inhibitor 103577-45-3 LANSOPRAZOLE TA_LEVEL_2 Duodenal ulcer treatment 103577-45-3 LANSOPRAZOLE TA_LEVEL_1 Gastrointestinal System 103577-45-3 LANSOPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT SKN_3_Rash 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT IMU_3_Allergic Reactions 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Dyspepsia 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Melena 103577-45-3 LANSOPRAZOLE MECHANISM Reduce stomach HCl secretion 103577-45-3 LANSOPRAZOLE INDICATION Gastroesophageal Reflux Disease (GERD) 103577-45-3 LANSOPRAZOLE INDICATION Helicobacter Pylori Infection 103577-45-3 LANSOPRAZOLE INDICATION Duodenal Ulcer 103577-45-3 LANSOPRAZOLE THERAPEUTIC_CLASS Antiulcers 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Stomatitis 103577-45-3 LANSOPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 103577-45-3 LANSOPRAZOLE MODE_CLASS Enzyme Inhibitor 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT NEU_2_Headache 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT BBM_3_Hematological Reactions 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT SKN_3_Pruritis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT XXX_3_Xerostomia 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Esophageal Stenosis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT GIS_3_Gastroenteritis 103577-45-3 LANSOPRAZOLE ADVERSE_EFFECT XXX_3_Salivation 130209-82-4 LATANOPROST INDICATION Glaucoma 130209-82-4 LATANOPROST MECHANISM Modulate G-protein coupled signal transduction 130209-82-4 LATANOPROST MODE_CLASS Receptor Agonist 125697-93-0 5-(2,5-DIHYDROXYBENZYLAMINO)-2-HYDROXYBENZOIC ACID PRODUCT_CLASS Biochemicals 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT XXX_2_Tenosynovitis 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT MSK_2_Synovitis 75706-12-6 LEFLUNOMIDE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT MSK_2_Back Pain 75706-12-6 LEFLUNOMIDE MECHANISM Inhibit precursor synthesis 75706-12-6 LEFLUNOMIDE INDICATION Rheumatoid Arthritis 75706-12-6 LEFLUNOMIDE MECH_LEVEL_1 Immunomodulation 75706-12-6 LEFLUNOMIDE MECHANISM Inhibit kinase mediated signal transduction 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT SKN_2_Pruritis 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT SKN_1_Rash 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT CVS_2_Hypertension 75706-12-6 LEFLUNOMIDE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 75706-12-6 LEFLUNOMIDE PRODUCT_CLASS Anti-inflammatories 75706-12-6 LEFLUNOMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 75706-12-6 LEFLUNOMIDE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, dihydroorotase inhibitor 75706-12-6 LEFLUNOMIDE MECH_LEVEL_3 Dihydroorotase 75706-12-6 LEFLUNOMIDE TA_LEVEL_2 Pyrimadine synthesis inhibitors 75706-12-6 LEFLUNOMIDE TISSUE_TOXICITY Teratogenicity 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT LUN_1_Bronchitis 75706-12-6 LEFLUNOMIDE ZERO_CLASS N 75706-12-6 LEFLUNOMIDE MESH_LEVEL_3 Oxazoles 75706-12-6 LEFLUNOMIDE MECH_LEVEL_2 Impaired Folic synthesis 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT XXX_2_Infection 75706-12-6 LEFLUNOMIDE MESH_LEVEL_1 Heterocyclic Compounds 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT NEU_1_Headache 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT XXX_2_Weight Loss 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT GIS_2_Dyspepsia 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT MSK_2_Joint Disorder 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT XXX_2_Pharyngitis 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT GUS_2_Urinary Tract Infection 75706-12-6 LEFLUNOMIDE KNOWN_TOXICITY Hepatotoxicity 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT PSY_2_Anorexia 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 75706-12-6 LEFLUNOMIDE MODE_CLASS Enzyme Inhibitor 75706-12-6 LEFLUNOMIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 75706-12-6 LEFLUNOMIDE TA_LEVEL_3 Anti-proliferative 75706-12-6 LEFLUNOMIDE TA_LEVEL_1 Anti-inflammatory 75706-12-6 LEFLUNOMIDE TISSUE_TOXICITY Hepatotoxicity 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT EMB_2_Teratogenicity 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT GIS_1_Nausea 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT BBM_2_Anemia 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 75706-12-6 LEFLUNOMIDE ADVERSE_EFFECT GIS_1_Diarrhea 100427-26-7 MASNIPIDINE INDICATION Hypertension 100427-26-7 MASNIPIDINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 100427-26-7 MASNIPIDINE INDICATION Angina Pectoris 100427-26-7 MASNIPIDINE THERAPEUTIC_CLASS Antihypertensive Agents 100427-26-7 MASNIPIDINE PRODUCT_CLASS Cardiovasculars 100427-26-7 MASNIPIDINE THERAPEUTIC_CLASS Antianginals 100427-26-7 MASNIPIDINE MODE_CLASS Channel Blocker 100427-26-7 MASNIPIDINE MECHANISM Reduce muscle contractile force 112809-51-5 LETROZOLE ADVERSE_EFFECT CVS_3_Myocardial Infarction 112809-51-5 LETROZOLE ADVERSE_EFFECT LUN_2_Cough 112809-51-5 LETROZOLE ADVERSE_EFFECT BBM_3_Leukopenia 112809-51-5 LETROZOLE ADVERSE_EFFECT LIV_3_Abnormal Liver Function 112809-51-5 LETROZOLE ADVERSE_EFFECT CVS_3_Cerebrovascular Accident 112809-51-5 LETROZOLE MODE_CLASS Enzyme Inhibitor, selective 112809-51-5 LETROZOLE MESH_LEVEL_1 Organic Chemicals 112809-51-5 LETROZOLE MECH_LEVEL_1 Hormone modulation 112809-51-5 LETROZOLE MESH_LEVEL_2 Nitriles 112809-51-5 LETROZOLE PRODUCT_CLASS Anti-cancers 112809-51-5 LETROZOLE TISSUE_TOXICITY Fetal Toxicity 112809-51-5 LETROZOLE TISSUE_TOXICITY Myocardial Infarction 112809-51-5 LETROZOLE ADVERSE_EFFECT CVS_2_Hypertension 112809-51-5 LETROZOLE ADVERSE_EFFECT LUN_2_Dyspnea 112809-51-5 LETROZOLE ADVERSE_EFFECT EMB_1_Embryotoxicity 112809-51-5 LETROZOLE ADVERSE_EFFECT END_1_Hot Flashes 112809-51-5 LETROZOLE ADVERSE_EFFECT XXX_1_Fatigue 112809-51-5 LETROZOLE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 112809-51-5 LETROZOLE ADVERSE_EFFECT GIS_1_Nausea 112809-51-5 LETROZOLE ADVERSE_EFFECT GIS_2_Constipation 112809-51-5 LETROZOLE TISSUE_TOXICITY Angina Pectoris 112809-51-5 LETROZOLE TISSUE_TOXICITY Embryotoxicity 112809-51-5 LETROZOLE THERAPEUTIC_CLASS Antineoplastics 112809-51-5 LETROZOLE INDICATION Metastatic Breast Cancer 112809-51-5 LETROZOLE TA_LEVEL_1 Oncology 112809-51-5 LETROZOLE MECH_LEVEL_3 aromatase 112809-51-5 LETROZOLE TA_LEVEL_2 Solid Tumors 112809-51-5 LETROZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 112809-51-5 LETROZOLE ADVERSE_EFFECT CVS_2_Deep Venous Thrombosis 112809-51-5 LETROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 112809-51-5 LETROZOLE ACTIVITY_CLASS Estrogen antagonist 112809-51-5 LETROZOLE ADVERSE_EFFECT EMB_1_Fetal Toxicity 112809-51-5 LETROZOLE ADVERSE_EFFECT MSK_1_Musculoskeletal Pain 112809-51-5 LETROZOLE ADVERSE_EFFECT LYM_2_Post-Mastectomy Lymphedema 112809-51-5 LETROZOLE ZERO_CLASS N 112809-51-5 LETROZOLE KNOWN_TOXICITY Embryo/Fetal Toxicity 112809-51-5 LETROZOLE TISSUE_TOXICITY Teratogenicity 112809-51-5 LETROZOLE ADVERSE_EFFECT EMB_1_Teratogenicity 112809-51-5 LETROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 112809-51-5 LETROZOLE TA_LEVEL_3 Aromatase 112809-51-5 LETROZOLE MECH_LEVEL_2 Inhibit estrogen biosynthesis 112809-51-5 LETROZOLE INDICATION Breast Cancer / Carcinoma of the Breast 112809-51-5 LETROZOLE TISSUE_TOXICITY Cerebrovascular Accident 112809-51-5 LETROZOLE KNOWN_TOXICITY Cardiovascular Toxicity 112809-51-5 LETROZOLE ADVERSE_EFFECT GIS_2_Diarrhea 112809-51-5 LETROZOLE ADVERSE_EFFECT PSY_2_Anorexia 112809-51-5 LETROZOLE ADVERSE_EFFECT XXX_2_Edema 112809-51-5 LETROZOLE ADVERSE_EFFECT END_2_Breast Tenderness 112809-51-5 LETROZOLE ADVERSE_EFFECT CVS_3_Angina Pectoris 58-05-9 LEUCOVORIN MESH_LEVEL_2 Vitamins 58-05-9 LEUCOVORIN THERAPEUTIC_CLASS Hematopoietic Agents 58-05-9 LEUCOVORIN ADVERSE_EFFECT NEU_3_Seizures 58-05-9 LEUCOVORIN PRODUCT_CLASS Other Human Uses 58-05-9 LEUCOVORIN MECH_LEVEL_1 Leucovorin is a reduced folate, is used to rescues cells from the effects of folate antagonists, and modulates the effect of fluorouracil, 5-FU. 58-05-9 LEUCOVORIN INDICATION Megaloblastic Anemia 58-05-9 LEUCOVORIN MECH_LEVEL_2 Inhibit precursor synthesis 58-05-9 LEUCOVORIN MESH_LEVEL_3 Vitamin B Complex 58-05-9 LEUCOVORIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 58-05-9 LEUCOVORIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 58-05-9 LEUCOVORIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-05-9 LEUCOVORIN TA_LEVEL_1 Chemoprophylaxis 58-05-9 LEUCOVORIN ADVERSE_EFFECT IMU_3_Urticaria 58-05-9 LEUCOVORIN THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 58-05-9 LEUCOVORIN INDICATION Folate Antagonist Prophylaxis and Toxcity 58-05-9 LEUCOVORIN MESH_LEVEL_1 Growth Substances, Pigments, and Vitamins 58-05-9 LEUCOVORIN ADVERSE_EFFECT NEU_3_Syncope 58-05-9 LEUCOVORIN MODE_CLASS Enzyme substrate mimic 58-05-9 LEUCOVORIN PRODUCT_CLASS Hematologics 58-05-9 LEUCOVORIN MECH_LEVEL_3 Dihydrofolate reductase 58-05-9 LEUCOVORIN STRUCTURE_ACTIVITY Antifolate rescue 58-05-9 LEUCOVORIN MECHANISM Inhibit precursor synthesis 58-05-9 LEUCOVORIN ZERO_CLASS N 1492-18-8 LEUCOVORIN THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 1492-18-8 LEUCOVORIN INDICATION Folate Antagonist Prophylaxis and Toxcity 1492-18-8 LEUCOVORIN MESH_LEVEL_1 Growth Substances, Pigments, and Vitamins 1492-18-8 LEUCOVORIN MECH_LEVEL_2 Inhibit precursor synthesis 1492-18-8 LEUCOVORIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 1492-18-8 LEUCOVORIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 1492-18-8 LEUCOVORIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1492-18-8 LEUCOVORIN TA_LEVEL_1 Chemoprophylaxis 1492-18-8 LEUCOVORIN INDICATION Megaloblastic Anemia 1492-18-8 LEUCOVORIN PRODUCT_CLASS Hematologics 1492-18-8 LEUCOVORIN MECH_LEVEL_3 Dihydrofolate reductase 1492-18-8 LEUCOVORIN ADVERSE_EFFECT NEU_3_Syncope 1492-18-8 LEUCOVORIN STRUCTURE_ACTIVITY Antifolate rescue 1492-18-8 LEUCOVORIN ZERO_CLASS N 1492-18-8 LEUCOVORIN ADVERSE_EFFECT NEU_3_Seizures 1492-18-8 LEUCOVORIN MODE_CLASS Enzyme substrate mimic 1492-18-8 LEUCOVORIN MECH_LEVEL_1 Leucovorin is a reduced folate, is used to rescues cells from the effects of folate antagonists, and modulates the effect of fluorouracil, 5-FU. 1492-18-8 LEUCOVORIN MECHANISM Inhibit precursor synthesis 1492-18-8 LEUCOVORIN MESH_LEVEL_2 Vitamins 1492-18-8 LEUCOVORIN MESH_LEVEL_3 Vitamin B Complex 1492-18-8 LEUCOVORIN ADVERSE_EFFECT IMU_3_Urticaria 1492-18-8 LEUCOVORIN THERAPEUTIC_CLASS Hematopoietic Agents 1492-18-8 LEUCOVORIN PRODUCT_CLASS Other Human Uses 30771-29-0 LEUCOVORIN INDICATION Megaloblastic Anemia 30771-29-0 LEUCOVORIN PRODUCT_CLASS Hematologics 30771-29-0 LEUCOVORIN MECH_LEVEL_3 Dihydrofolate reductase 30771-29-0 LEUCOVORIN STRUCTURE_ACTIVITY Antifolate rescue 30771-29-0 LEUCOVORIN ZERO_CLASS N 30771-29-0 LEUCOVORIN ADVERSE_EFFECT NEU_3_Seizures 30771-29-0 LEUCOVORIN PRODUCT_CLASS Other Human Uses 30771-29-0 LEUCOVORIN MECH_LEVEL_1 Leucovorin is a reduced folate, is used to rescues cells from the effects of folate antagonists, and modulates the effect of fluorouracil, 5-FU. 30771-29-0 LEUCOVORIN MECHANISM Inhibit precursor synthesis 30771-29-0 LEUCOVORIN MESH_LEVEL_2 Vitamins 30771-29-0 LEUCOVORIN MESH_LEVEL_3 Vitamin B Complex 30771-29-0 LEUCOVORIN TA_LEVEL_1 Chemoprophylaxis 30771-29-0 LEUCOVORIN ADVERSE_EFFECT IMU_3_Urticaria 30771-29-0 LEUCOVORIN THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 30771-29-0 LEUCOVORIN INDICATION Folate Antagonist Prophylaxis and Toxcity 30771-29-0 LEUCOVORIN MESH_LEVEL_1 Growth Substances, Pigments, and Vitamins 30771-29-0 LEUCOVORIN ADVERSE_EFFECT NEU_3_Syncope 30771-29-0 LEUCOVORIN MODE_CLASS Enzyme substrate mimic 30771-29-0 LEUCOVORIN THERAPEUTIC_CLASS Hematopoietic Agents 30771-29-0 LEUCOVORIN MECH_LEVEL_2 Inhibit precursor synthesis 30771-29-0 LEUCOVORIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 30771-29-0 LEUCOVORIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 30771-29-0 LEUCOVORIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 74381-53-6 LEUPROLIDE INDICATION Prostatic Cancer / Carcinoma of the Prostate 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT XXX_3_Fatigue 27912-14-7 LEVOBUNOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT PSY_3_Nightmares 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT PSY_3_Hallucinations 27912-14-7 LEVOBUNOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 27912-14-7 LEVOBUNOLOL INDICATION Open-Angle Glaucoma 27912-14-7 LEVOBUNOLOL INDICATION Ocular Hypertension 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT OCU_1_Ocular Irritation 27912-14-7 LEVOBUNOLOL MECHANISM Modulate G-protein coupled signal transduction 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT PSY_3_Depression 27912-14-7 LEVOBUNOLOL ADVERSE_EFFECT NEU_3_Dizziness 27912-14-7 LEVOBUNOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 27912-14-7 LEVOBUNOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 79547-78-7 LEVOCABASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 79547-78-7 LEVOCABASTINE THERAPEUTIC_CLASS Antihistamines 79547-78-7 LEVOCABASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 79547-78-7 LEVOCABASTINE INDICATION Allergic Conjunctivitis 79547-78-7 LEVOCABASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 79547-78-7 LEVOCABASTINE MECHANISM Modulate G-protein coupled signal transduction 79516-68-0 LEVOCABASTINE MECHANISM Modulate G-protein coupled signal transduction 79516-68-0 LEVOCABASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 79516-68-0 LEVOCABASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 79516-68-0 LEVOCABASTINE THERAPEUTIC_CLASS Antihistamines 79516-68-0 LEVOCABASTINE INDICATION Allergic Conjunctivitis 79516-68-0 LEVOCABASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 541-15-1 LEVOCARNITINE INDICATION Carnitine deficiency 541-15-1 LEVOCARNITINE PRODUCT_CLASS Vitamins, Minerals and Nutrients 541-15-1 LEVOCARNITINE INDICATION Infertility 541-15-1 LEVOCARNITINE INDICATION Alzheimer's Disease 541-15-1 LEVOCARNITINE INDICATION Hyperlipoproteinemia 541-15-1 LEVOCARNITINE INDICATION Valproate-induced hepatotoxicity 541-15-1 LEVOCARNITINE MECHANISM Vitamin/ cofactor 541-15-1 LEVOCARNITINE INDICATION Myocardial Infarction 541-15-1 LEVOCARNITINE INDICATION Diabetes Mellitus 541-15-1 LEVOCARNITINE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 541-15-1 LEVOCARNITINE INDICATION Cardiomyopathy 541-15-1 LEVOCARNITINE INDICATION Renal Disease 6645-46-1 LEVOCARNITINE INDICATION Valproate-induced hepatotoxicity 6645-46-1 LEVOCARNITINE INDICATION Hyperlipoproteinemia 6645-46-1 LEVOCARNITINE INDICATION Infertility 6645-46-1 LEVOCARNITINE INDICATION Alzheimer's Disease 6645-46-1 LEVOCARNITINE INDICATION Renal Disease 6645-46-1 LEVOCARNITINE INDICATION Cardiomyopathy 6645-46-1 LEVOCARNITINE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 6645-46-1 LEVOCARNITINE INDICATION Carnitine deficiency 6645-46-1 LEVOCARNITINE INDICATION Myocardial Infarction 6645-46-1 LEVOCARNITINE PRODUCT_CLASS Vitamins, Minerals and Nutrients 6645-46-1 LEVOCARNITINE INDICATION Diabetes Mellitus 6645-46-1 LEVOCARNITINE MECHANISM Vitamin/ cofactor 59-92-7 LEVODOPA ADVERSE_EFFECT BBM_3_Hemolytic Anemia 59-92-7 LEVODOPA KNOWN_TOXICITY Cardiovascular Toxicity 59-92-7 LEVODOPA TA_LEVEL_3 Parkinson's Disease 59-92-7 LEVODOPA ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 59-92-7 LEVODOPA ACTIVITY_CLASS Dopamine agonist 59-92-7 LEVODOPA ADVERSE_EFFECT XXX_2_Weight Loss 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_2_Acute Toxic Psychosis 59-92-7 LEVODOPA ADVERSE_EFFECT BBM_3_Agranulocytosis 59-92-7 LEVODOPA ADVERSE_EFFECT GIS_2_Nausea / Vomiting 59-92-7 LEVODOPA KNOWN_TOXICITY Mental Health Disorders 59-92-7 LEVODOPA MECH_LEVEL_2 Restore dopanergic activity 59-92-7 LEVODOPA INDICATION Parkinson's Disease 59-92-7 LEVODOPA TA_LEVEL_2 Dopamine modulators 59-92-7 LEVODOPA INDICATION Parkinsonism 59-92-7 LEVODOPA STRUCTURE_ACTIVITY Dopamine receptor (D) agonist 59-92-7 LEVODOPA ZERO_CLASS N 59-92-7 LEVODOPA ADVERSE_EFFECT GUS_3_Discoloration of Urine 59-92-7 LEVODOPA ADVERSE_EFFECT BBM_3_Leukopenia 59-92-7 LEVODOPA ADVERSE_EFFECT NEU_2_Akinesia 59-92-7 LEVODOPA ADVERSE_EFFECT NEU_1_Dyskinesia 59-92-7 LEVODOPA PRODUCT_CLASS Central Nervous System (CNS) 59-92-7 LEVODOPA TISSUE_TOXICITY Psychosis 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_2_Anorexia 59-92-7 LEVODOPA MECHANISM Modulate G-protein coupled signal transduction 59-92-7 LEVODOPA ADVERSE_EFFECT CVS_3_Hypertension 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_2_Paranoid Behavior 59-92-7 LEVODOPA ADVERSE_EFFECT NEU_2_Dizziness 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_1_Psychosis 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_2_Mental Confusion 59-92-7 LEVODOPA ADVERSE_EFFECT NEU_1_Choreiform Movements 59-92-7 LEVODOPA ADVERSE_EFFECT PSY_2_Hallucinations 59-92-7 LEVODOPA MODE_CLASS Receptor Agonist 59-92-7 LEVODOPA MESH_LEVEL_3 Catecholamines 59-92-7 LEVODOPA MESH_LEVEL_1 Organic Chemicals 59-92-7 LEVODOPA MECH_LEVEL_1 Modulate neural transmission 59-92-7 LEVODOPA MECH_LEVEL_3 Dopamine receptors 59-92-7 LEVODOPA TA_LEVEL_1 Central Nervous System (CNS) 59-92-7 LEVODOPA MESH_LEVEL_2 Amines 59-92-7 LEVODOPA ADVERSE_EFFECT SKN_3_Flushing 59-92-7 LEVODOPA ADVERSE_EFFECT NEU_2_Ballismus 59-92-7 LEVODOPA THERAPEUTIC_CLASS Movement Disorders 59-92-7 LEVODOPA TISSUE_TOXICITY Cardiac Arrhythmia 59-92-7 LEVODOPA ADVERSE_EFFECT NEU_1_Dystonia 59-92-7 LEVODOPA ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 59-92-7 LEVODOPA ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 59-92-7 LEVODOPA ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 59-92-7 LEVODOPA ADVERSE_EFFECT CVS_3_Palpitation 57308-51-7 LEVODOPA PRODUCT_CLASS Central Nervous System (CNS) 57308-51-7 LEVODOPA TISSUE_TOXICITY Psychosis 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_2_Anorexia 57308-51-7 LEVODOPA ADVERSE_EFFECT CVS_3_Hypertension 57308-51-7 LEVODOPA THERAPEUTIC_CLASS Movement Disorders 57308-51-7 LEVODOPA ADVERSE_EFFECT CVS_3_Palpitation 57308-51-7 LEVODOPA ADVERSE_EFFECT XXX_2_Weight Loss 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_2_Acute Toxic Psychosis 57308-51-7 LEVODOPA ADVERSE_EFFECT BBM_3_Agranulocytosis 57308-51-7 LEVODOPA ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57308-51-7 LEVODOPA KNOWN_TOXICITY Mental Health Disorders 57308-51-7 LEVODOPA MECH_LEVEL_2 Restore dopanergic activity 57308-51-7 LEVODOPA INDICATION Parkinson's Disease 57308-51-7 LEVODOPA TA_LEVEL_2 Dopamine modulators 57308-51-7 LEVODOPA INDICATION Parkinsonism 57308-51-7 LEVODOPA STRUCTURE_ACTIVITY Dopamine receptor (D) agonist 57308-51-7 LEVODOPA ZERO_CLASS N 57308-51-7 LEVODOPA ADVERSE_EFFECT GUS_3_Discoloration of Urine 57308-51-7 LEVODOPA ADVERSE_EFFECT BBM_3_Leukopenia 57308-51-7 LEVODOPA ADVERSE_EFFECT NEU_2_Akinesia 57308-51-7 LEVODOPA ADVERSE_EFFECT NEU_1_Dyskinesia 57308-51-7 LEVODOPA ADVERSE_EFFECT BBM_3_Hemolytic Anemia 57308-51-7 LEVODOPA TISSUE_TOXICITY Cardiac Arrhythmia 57308-51-7 LEVODOPA TA_LEVEL_3 Parkinson's Disease 57308-51-7 LEVODOPA KNOWN_TOXICITY Cardiovascular Toxicity 57308-51-7 LEVODOPA MECHANISM Modulate G-protein coupled signal transduction 57308-51-7 LEVODOPA MECH_LEVEL_1 Modulate neural transmission 57308-51-7 LEVODOPA ACTIVITY_CLASS Dopamine agonist 57308-51-7 LEVODOPA ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 57308-51-7 LEVODOPA ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 57308-51-7 LEVODOPA ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 57308-51-7 LEVODOPA ADVERSE_EFFECT NEU_1_Dystonia 57308-51-7 LEVODOPA ADVERSE_EFFECT NEU_2_Ballismus 57308-51-7 LEVODOPA ADVERSE_EFFECT SKN_3_Flushing 57308-51-7 LEVODOPA MESH_LEVEL_2 Amines 57308-51-7 LEVODOPA TA_LEVEL_1 Central Nervous System (CNS) 57308-51-7 LEVODOPA MECH_LEVEL_3 Dopamine receptors 57308-51-7 LEVODOPA MESH_LEVEL_1 Organic Chemicals 57308-51-7 LEVODOPA MESH_LEVEL_3 Catecholamines 57308-51-7 LEVODOPA MODE_CLASS Receptor Agonist 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_2_Hallucinations 57308-51-7 LEVODOPA ADVERSE_EFFECT NEU_1_Choreiform Movements 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_2_Mental Confusion 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_1_Psychosis 57308-51-7 LEVODOPA ADVERSE_EFFECT NEU_2_Dizziness 57308-51-7 LEVODOPA ADVERSE_EFFECT PSY_2_Paranoid Behavior 57308-51-7 LEVODOPA ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 90638-38-3 LEVODOPA MECH_LEVEL_1 Modulate neural transmission 90638-38-3 LEVODOPA PRODUCT_CLASS Central Nervous System (CNS) 90638-38-3 LEVODOPA TISSUE_TOXICITY Psychosis 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_2_Anorexia 90638-38-3 LEVODOPA ADVERSE_EFFECT CVS_3_Hypertension 90638-38-3 LEVODOPA THERAPEUTIC_CLASS Movement Disorders 90638-38-3 LEVODOPA ADVERSE_EFFECT CVS_3_Palpitation 90638-38-3 LEVODOPA ADVERSE_EFFECT XXX_2_Weight Loss 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_2_Acute Toxic Psychosis 90638-38-3 LEVODOPA ADVERSE_EFFECT BBM_3_Agranulocytosis 90638-38-3 LEVODOPA ADVERSE_EFFECT GIS_2_Nausea / Vomiting 90638-38-3 LEVODOPA KNOWN_TOXICITY Mental Health Disorders 90638-38-3 LEVODOPA MECH_LEVEL_2 Restore dopanergic activity 90638-38-3 LEVODOPA INDICATION Parkinson's Disease 90638-38-3 LEVODOPA TA_LEVEL_2 Dopamine modulators 90638-38-3 LEVODOPA INDICATION Parkinsonism 90638-38-3 LEVODOPA STRUCTURE_ACTIVITY Dopamine receptor (D) agonist 90638-38-3 LEVODOPA ZERO_CLASS N 90638-38-3 LEVODOPA ADVERSE_EFFECT GUS_3_Discoloration of Urine 90638-38-3 LEVODOPA ADVERSE_EFFECT BBM_3_Leukopenia 90638-38-3 LEVODOPA ADVERSE_EFFECT NEU_2_Akinesia 90638-38-3 LEVODOPA ADVERSE_EFFECT NEU_1_Dyskinesia 90638-38-3 LEVODOPA ADVERSE_EFFECT BBM_3_Hemolytic Anemia 90638-38-3 LEVODOPA KNOWN_TOXICITY Cardiovascular Toxicity 90638-38-3 LEVODOPA TISSUE_TOXICITY Cardiac Arrhythmia 90638-38-3 LEVODOPA TA_LEVEL_3 Parkinson's Disease 90638-38-3 LEVODOPA ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 90638-38-3 LEVODOPA ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 90638-38-3 LEVODOPA ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 90638-38-3 LEVODOPA ADVERSE_EFFECT NEU_1_Dystonia 90638-38-3 LEVODOPA ADVERSE_EFFECT NEU_2_Ballismus 90638-38-3 LEVODOPA ADVERSE_EFFECT SKN_3_Flushing 90638-38-3 LEVODOPA MESH_LEVEL_2 Amines 90638-38-3 LEVODOPA TA_LEVEL_1 Central Nervous System (CNS) 90638-38-3 LEVODOPA MESH_LEVEL_1 Organic Chemicals 90638-38-3 LEVODOPA MECH_LEVEL_3 Dopamine receptors 90638-38-3 LEVODOPA MESH_LEVEL_3 Catecholamines 90638-38-3 LEVODOPA ACTIVITY_CLASS Dopamine agonist 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_2_Hallucinations 90638-38-3 LEVODOPA ADVERSE_EFFECT NEU_1_Choreiform Movements 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_2_Mental Confusion 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_1_Psychosis 90638-38-3 LEVODOPA ADVERSE_EFFECT NEU_2_Dizziness 90638-38-3 LEVODOPA ADVERSE_EFFECT PSY_2_Paranoid Behavior 90638-38-3 LEVODOPA ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 90638-38-3 LEVODOPA MECHANISM Modulate G-protein coupled signal transduction 90638-38-3 LEVODOPA MODE_CLASS Receptor Agonist 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 100986-85-4 LEVOFLOXACIN THERAPEUTIC_CLASS Antibacterials 100986-85-4 LEVOFLOXACIN INDICATION Urinary Tract Infection (UTI) 100986-85-4 LEVOFLOXACIN INDICATION Mastitis 100986-85-4 LEVOFLOXACIN INDICATION Cystitis 100986-85-4 LEVOFLOXACIN INDICATION Acute Pyelonephritis 100986-85-4 LEVOFLOXACIN INDICATION Chlamydia Trachomatis Infections 100986-85-4 LEVOFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT GIS_2_Flatulence 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT IMU_1_Anaphylactic Shock 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Depression 100986-85-4 LEVOFLOXACIN INDICATION Pseudomonas Aeruginosa Infection 100986-85-4 LEVOFLOXACIN INDICATION Staphylococcus Aureus Infections 100986-85-4 LEVOFLOXACIN INDICATION Mycoplasma Pneumoniae 100986-85-4 LEVOFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 100986-85-4 LEVOFLOXACIN INDICATION Pneumonia 100986-85-4 LEVOFLOXACIN INDICATION Anthrax 100986-85-4 LEVOFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 100986-85-4 LEVOFLOXACIN PRODUCT_CLASS Anti-infectives 100986-85-4 LEVOFLOXACIN MESH_LEVEL_3 Quinolines 100986-85-4 LEVOFLOXACIN TISSUE_TOXICITY Anaphylactic Shock 100986-85-4 LEVOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 100986-85-4 LEVOFLOXACIN KNOWN_TOXICITY Immune System Toxicity 100986-85-4 LEVOFLOXACIN TISSUE_TOXICITY Hypotension 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT END_3_Hypoglycemia 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 100986-85-4 LEVOFLOXACIN INDICATION Sinusitis 100986-85-4 LEVOFLOXACIN INDICATION Impetigo 100986-85-4 LEVOFLOXACIN INDICATION Pelvic Inflammatory Disease (PID) 100986-85-4 LEVOFLOXACIN INDICATION Bordetella Pertussis Infection / Whooping Cough 100986-85-4 LEVOFLOXACIN TA_LEVEL_3 quinolones 100986-85-4 LEVOFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT CVS_3_Prolonged QT Interval 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Nightmares 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT NEU_3_Seizures 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT NEU_1_Headache 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 100986-85-4 LEVOFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 100986-85-4 LEVOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 100986-85-4 LEVOFLOXACIN INDICATION Skin and Skin Structure Infections 100986-85-4 LEVOFLOXACIN INDICATION Furunculosis (Boils) and Carbuncles 100986-85-4 LEVOFLOXACIN INDICATION Cellulitis 100986-85-4 LEVOFLOXACIN INDICATION Bartholin's abscess and Bratholinitis 100986-85-4 LEVOFLOXACIN MECH_LEVEL_1 Anti-bacterial 100986-85-4 LEVOFLOXACIN MECH_LEVEL_3 DNA gyrase, bacterial (ATP-hydrolysing) 100986-85-4 LEVOFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 100986-85-4 LEVOFLOXACIN TA_LEVEL_2 Antibacterials 100986-85-4 LEVOFLOXACIN TA_LEVEL_1 Infectious Disease 100986-85-4 LEVOFLOXACIN ZERO_CLASS N 100986-85-4 LEVOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT GIS_2_Dyspepsia 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Paranoia 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT XXX_3_Restlessness 100986-85-4 LEVOFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 138199-71-0 LEVOFLOXACIN MESH_LEVEL_3 Quinolines 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT END_3_Hypoglycemia 138199-71-0 LEVOFLOXACIN TA_LEVEL_3 quinolones 138199-71-0 LEVOFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT CVS_3_Prolonged QT Interval 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 138199-71-0 LEVOFLOXACIN TISSUE_TOXICITY Hypotension 138199-71-0 LEVOFLOXACIN KNOWN_TOXICITY Immune System Toxicity 138199-71-0 LEVOFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 138199-71-0 LEVOFLOXACIN THERAPEUTIC_CLASS Antibacterials 138199-71-0 LEVOFLOXACIN INDICATION Urinary Tract Infection (UTI) 138199-71-0 LEVOFLOXACIN INDICATION Bordetella Pertussis Infection / Whooping Cough 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Nightmares 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT NEU_3_Seizures 138199-71-0 LEVOFLOXACIN INDICATION Impetigo 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT NEU_1_Headache 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 138199-71-0 LEVOFLOXACIN INDICATION Mastitis 138199-71-0 LEVOFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 138199-71-0 LEVOFLOXACIN INDICATION Skin and Skin Structure Infections 138199-71-0 LEVOFLOXACIN INDICATION Furunculosis (Boils) and Carbuncles 138199-71-0 LEVOFLOXACIN INDICATION Cellulitis 138199-71-0 LEVOFLOXACIN INDICATION Bartholin's abscess and Bratholinitis 138199-71-0 LEVOFLOXACIN MECH_LEVEL_1 Anti-bacterial 138199-71-0 LEVOFLOXACIN MECH_LEVEL_3 DNA gyrase, bacterial (ATP-hydrolysing) 138199-71-0 LEVOFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 138199-71-0 LEVOFLOXACIN INDICATION Staphylococcus Aureus Infections 138199-71-0 LEVOFLOXACIN TA_LEVEL_2 Antibacterials 138199-71-0 LEVOFLOXACIN TA_LEVEL_1 Infectious Disease 138199-71-0 LEVOFLOXACIN ZERO_CLASS N 138199-71-0 LEVOFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT GIS_2_Dyspepsia 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Paranoia 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT XXX_3_Restlessness 138199-71-0 LEVOFLOXACIN INDICATION Cystitis 138199-71-0 LEVOFLOXACIN INDICATION Acute Pyelonephritis 138199-71-0 LEVOFLOXACIN INDICATION Chlamydia Trachomatis Infections 138199-71-0 LEVOFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT GIS_2_Flatulence 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT IMU_1_Anaphylactic Shock 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 138199-71-0 LEVOFLOXACIN ADVERSE_EFFECT PSY_3_Depression 138199-71-0 LEVOFLOXACIN TISSUE_TOXICITY Anaphylactic Shock 138199-71-0 LEVOFLOXACIN INDICATION Pseudomonas Aeruginosa Infection 138199-71-0 LEVOFLOXACIN INDICATION Mycoplasma Pneumoniae 138199-71-0 LEVOFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 138199-71-0 LEVOFLOXACIN INDICATION Pneumonia 138199-71-0 LEVOFLOXACIN INDICATION Anthrax 138199-71-0 LEVOFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 138199-71-0 LEVOFLOXACIN PRODUCT_CLASS Anti-infectives 138199-71-0 LEVOFLOXACIN INDICATION Pelvic Inflammatory Disease (PID) 138199-71-0 LEVOFLOXACIN INDICATION Sinusitis 138199-71-0 LEVOFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 829-74-3 LEVONORDEFRIN PRODUCT_CLASS Cardiovasculars 829-74-3 LEVONORDEFRIN STRUCTURE_ACTIVITY Adrenoceptor agonist 829-74-3 LEVONORDEFRIN MODE_CLASS Receptor Agonist 829-74-3 LEVONORDEFRIN THERAPEUTIC_CLASS Sympathomimetic Agents 829-74-3 LEVONORDEFRIN THERAPEUTIC_CLASS Vasopressors 829-74-3 LEVONORDEFRIN MECHANISM Increase vasoconstriction 829-74-3 LEVONORDEFRIN PRODUCT_CLASS Autonomic Nervous System (ANS) 77-07-6 LEVORPHANOL INDICATION Pain 77-07-6 LEVORPHANOL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 77-07-6 LEVORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 77-07-6 LEVORPHANOL MECHANISM Modulate neural transmission 77-07-6 LEVORPHANOL PRODUCT_CLASS Analgesics 77-07-6 LEVORPHANOL MODE_CLASS Receptor Agonist, selective 6700-40-9 LEVORPHANOL MODE_CLASS Receptor Agonist, selective 6700-40-9 LEVORPHANOL INDICATION Pain 6700-40-9 LEVORPHANOL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 6700-40-9 LEVORPHANOL MECHANISM Modulate neural transmission 6700-40-9 LEVORPHANOL PRODUCT_CLASS Analgesics 6700-40-9 LEVORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 125-72-4 LEVORPHANOL PRODUCT_CLASS Analgesics 125-72-4 LEVORPHANOL MECHANISM Modulate neural transmission 125-72-4 LEVORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 125-72-4 LEVORPHANOL INDICATION Pain 125-72-4 LEVORPHANOL MODE_CLASS Receptor Agonist, selective 125-72-4 LEVORPHANOL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Anxiety 51-48-9 LEVOTHYROXINE STRUCTURE_ACTIVITY T3 receptor agonist 51-48-9 LEVOTHYROXINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 51-48-9 LEVOTHYROXINE INDICATION Goiter 51-48-9 LEVOTHYROXINE INDICATION Thyroiditis 51-48-9 LEVOTHYROXINE INDICATION Myxedema Coma 51-48-9 LEVOTHYROXINE TISSUE_TOXICITY Atrial Fibrillation 51-48-9 LEVOTHYROXINE THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Insomnia 51-48-9 LEVOTHYROXINE INDICATION Cretinism 51-48-9 LEVOTHYROXINE INDICATION Hypothyroidism 51-48-9 LEVOTHYROXINE INDICATION Cardiomyopathy 51-48-9 LEVOTHYROXINE PRODUCT_CLASS Anti-cancers 51-48-9 LEVOTHYROXINE THERAPEUTIC_CLASS Antineoplastics 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT NEU_2_Headache 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT IMU_3_Urticaria 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Heart Failure 51-48-9 LEVOTHYROXINE KNOWN_TOXICITY Cardiovascular Toxicity 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT XXX_2_Fever 51-48-9 LEVOTHYROXINE INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 51-48-9 LEVOTHYROXINE MODE_CLASS Receptor Agonist 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT NEU_2_Tremor 51-48-9 LEVOTHYROXINE MECHANISM Modulate gene transcription 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Palpitation 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT REP_2_Menstrual Irregularities 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT REP_2_Amenorrhea 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT SKN_3_Rash 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Angina 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT XXX_3_Peripheral Edema 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Anorexia 51-48-9 LEVOTHYROXINE INDICATION Myxedema 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 51-48-9 LEVOTHYROXINE TISSUE_TOXICITY Angina 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT END_2_Heat Intolerance 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT END_1_Hyperthyroidism 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT XXX_2_Weight Loss 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Irritability 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT XXX_3_Diaphoresis 51-48-9 LEVOTHYROXINE TISSUE_TOXICITY Heart Failure 51-48-9 LEVOTHYROXINE ADVERSE_EFFECT GIS_2_Diarrhea 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Palpitation 55-03-8 LEVOTHYROXINE MECHANISM Modulate gene transcription 55-03-8 LEVOTHYROXINE MODE_CLASS Receptor Agonist 55-03-8 LEVOTHYROXINE INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT XXX_2_Fever 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT NEU_2_Tremor 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT END_2_Heat Intolerance 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Heart Failure 55-03-8 LEVOTHYROXINE TISSUE_TOXICITY Heart Failure 55-03-8 LEVOTHYROXINE KNOWN_TOXICITY Cardiovascular Toxicity 55-03-8 LEVOTHYROXINE INDICATION Cretinism 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT XXX_2_Weight Loss 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT END_1_Hyperthyroidism 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 55-03-8 LEVOTHYROXINE INDICATION Myxedema 55-03-8 LEVOTHYROXINE INDICATION Hypothyroidism 55-03-8 LEVOTHYROXINE INDICATION Cardiomyopathy 55-03-8 LEVOTHYROXINE PRODUCT_CLASS Anti-cancers 55-03-8 LEVOTHYROXINE THERAPEUTIC_CLASS Antineoplastics 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT NEU_2_Headache 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT XXX_3_Peripheral Edema 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT IMU_3_Urticaria 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Irritability 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT XXX_3_Diaphoresis 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT GIS_2_Diarrhea 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Anxiety 55-03-8 LEVOTHYROXINE STRUCTURE_ACTIVITY T3 receptor agonist 55-03-8 LEVOTHYROXINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 55-03-8 LEVOTHYROXINE INDICATION Goiter 55-03-8 LEVOTHYROXINE INDICATION Thyroiditis 55-03-8 LEVOTHYROXINE INDICATION Myxedema Coma 55-03-8 LEVOTHYROXINE TISSUE_TOXICITY Atrial Fibrillation 55-03-8 LEVOTHYROXINE THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Insomnia 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 55-03-8 LEVOTHYROXINE TISSUE_TOXICITY Angina 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Anorexia 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Angina 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT SKN_3_Rash 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT REP_2_Amenorrhea 55-03-8 LEVOTHYROXINE ADVERSE_EFFECT REP_2_Menstrual Irregularities 67809-22-7 LEVOTHYROXINE STRUCTURE_ACTIVITY T3 receptor agonist 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Anxiety 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT GIS_2_Diarrhea 67809-22-7 LEVOTHYROXINE TISSUE_TOXICITY Heart Failure 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT XXX_3_Diaphoresis 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Irritability 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT IMU_3_Urticaria 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT NEU_2_Headache 67809-22-7 LEVOTHYROXINE THERAPEUTIC_CLASS Antineoplastics 67809-22-7 LEVOTHYROXINE PRODUCT_CLASS Anti-cancers 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT END_1_Hyperthyroidism 67809-22-7 LEVOTHYROXINE INDICATION Hypothyroidism 67809-22-7 LEVOTHYROXINE INDICATION Cretinism 67809-22-7 LEVOTHYROXINE INDICATION Cardiomyopathy 67809-22-7 LEVOTHYROXINE TISSUE_TOXICITY Atrial Fibrillation 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT REP_2_Amenorrhea 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT REP_2_Menstrual Irregularities 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Palpitation 67809-22-7 LEVOTHYROXINE MECHANISM Modulate gene transcription 67809-22-7 LEVOTHYROXINE MODE_CLASS Receptor Agonist 67809-22-7 LEVOTHYROXINE INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT XXX_2_Fever 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT NEU_2_Tremor 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT END_2_Heat Intolerance 67809-22-7 LEVOTHYROXINE TISSUE_TOXICITY Angina 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Heart Failure 67809-22-7 LEVOTHYROXINE KNOWN_TOXICITY Cardiovascular Toxicity 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Anorexia 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT CVS_3_Angina 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT SKN_3_Rash 67809-22-7 LEVOTHYROXINE INDICATION Myxedema 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT XXX_2_Weight Loss 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT XXX_3_Peripheral Edema 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 67809-22-7 LEVOTHYROXINE ADVERSE_EFFECT PSY_2_Insomnia 67809-22-7 LEVOTHYROXINE THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 67809-22-7 LEVOTHYROXINE INDICATION Myxedema Coma 67809-22-7 LEVOTHYROXINE INDICATION Thyroiditis 67809-22-7 LEVOTHYROXINE INDICATION Goiter 67809-22-7 LEVOTHYROXINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 137-58-6 LIDOCAINE ADVERSE_EFFECT IMU_3_Anaphylactic Shock 137-58-6 LIDOCAINE ADVERSE_EFFECT XXX_2_Restlessness 137-58-6 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_1_Drowsiness 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_2_Dizziness 137-58-6 LIDOCAINE ADVERSE_EFFECT PSY_2_Anxiety 137-58-6 LIDOCAINE ADVERSE_EFFECT OCU_2_Blurred Vision 137-58-6 LIDOCAINE KNOWN_TOXICITY Cardiovascular Toxicity 137-58-6 LIDOCAINE TISSUE_TOXICITY Myocardial Depression 137-58-6 LIDOCAINE TISSUE_TOXICITY Cardiac Arrest 137-58-6 LIDOCAINE INDICATION Local Anesthesia 137-58-6 LIDOCAINE MECH_LEVEL_2 Decrease neural membrane excitability 137-58-6 LIDOCAINE MESH_LEVEL_2 Amides 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Arachnoiditis 137-58-6 LIDOCAINE ADVERSE_EFFECT IMU_3_Angioedema 137-58-6 LIDOCAINE ADVERSE_EFFECT PSY_2_Confusion 137-58-6 LIDOCAINE ADVERSE_EFFECT LUN_3_Bronchospasm 137-58-6 LIDOCAINE ADVERSE_EFFECT XXX_2_Edema 137-58-6 LIDOCAINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 137-58-6 LIDOCAINE ADVERSE_EFFECT CVS_2_Hypotension 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Paralysis 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Meningitis 137-58-6 LIDOCAINE TISSUE_TOXICITY Cardiovascular Collapse 137-58-6 LIDOCAINE PRODUCT_CLASS Central Nervous System (CNS) 137-58-6 LIDOCAINE PRODUCT_CLASS Cardiovasculars 137-58-6 LIDOCAINE TA_LEVEL_3 Topical Local Anesthesia 137-58-6 LIDOCAINE MODE_CLASS Channel Modulator 137-58-6 LIDOCAINE ADVERSE_EFFECT GIS_2_Dysgeusia 137-58-6 LIDOCAINE ADVERSE_EFFECT MSK_2_Back Pain 137-58-6 LIDOCAINE TISSUE_TOXICITY Hypotension 137-58-6 LIDOCAINE ADVERSE_EFFECT GIS_3_Stomatitis 137-58-6 LIDOCAINE ADVERSE_EFFECT IMU_3_Urticaria 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Seizures 137-58-6 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Tremor 137-58-6 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 137-58-6 LIDOCAINE ADVERSE_EFFECT SKN_1_Erythema 137-58-6 LIDOCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 137-58-6 LIDOCAINE MECHANISM Modulate channel gating 137-58-6 LIDOCAINE THERAPEUTIC_CLASS Antiarrhythmic Agents 137-58-6 LIDOCAINE THERAPEUTIC_CLASS Local Anesthetics 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 137-58-6 LIDOCAINE ADVERSE_EFFECT XXX_1_Dysesthesia 137-58-6 LIDOCAINE ZERO_CLASS N 137-58-6 LIDOCAINE MESH_LEVEL_1 Organic Chemicals 137-58-6 LIDOCAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 137-58-6 LIDOCAINE MECH_LEVEL_3 AMPA Glutamate receptor 137-58-6 LIDOCAINE INDICATION Postherpetic Neuralgia 137-58-6 LIDOCAINE MECH_LEVEL_1 Modulate neural transmission 137-58-6 LIDOCAINE INDICATION Ventricular Arrhythmias 137-58-6 LIDOCAINE TA_LEVEL_2 Anesthesia 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_3_Meningeal Signs 137-58-6 LIDOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 137-58-6 LIDOCAINE ACTIVITY_CLASS Na+ channel blocker 137-58-6 LIDOCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 137-58-6 LIDOCAINE ADVERSE_EFFECT PSY_2_Disorientation 137-58-6 LIDOCAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 137-58-6 LIDOCAINE ADVERSE_EFFECT NEU_1_Paresthesia 137-58-6 LIDOCAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 137-58-6 LIDOCAINE ADVERSE_EFFECT PSY_2_Nervousness 137-58-6 LIDOCAINE ADVERSE_EFFECT GUS_3_Urinary Retention 137-58-6 LIDOCAINE TISSUE_TOXICITY Cardiac Arrhythmia 137-58-6 LIDOCAINE ADVERSE_EFFECT OCU_3_Paralysis of the Extraocular Muscles 137-58-6 LIDOCAINE MESH_LEVEL_3 Anilides 6108-05-0 LIDOCAINE TISSUE_TOXICITY Cardiac Arrest 6108-05-0 LIDOCAINE INDICATION Local Anesthesia 6108-05-0 LIDOCAINE MECH_LEVEL_2 Decrease neural membrane excitability 6108-05-0 LIDOCAINE MESH_LEVEL_2 Amides 6108-05-0 LIDOCAINE TA_LEVEL_2 Anesthesia 6108-05-0 LIDOCAINE ADVERSE_EFFECT IMU_3_Angioedema 6108-05-0 LIDOCAINE ADVERSE_EFFECT PSY_2_Confusion 6108-05-0 LIDOCAINE ADVERSE_EFFECT LUN_3_Bronchospasm 6108-05-0 LIDOCAINE ADVERSE_EFFECT XXX_2_Edema 6108-05-0 LIDOCAINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Paralysis 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Meningitis 6108-05-0 LIDOCAINE THERAPEUTIC_CLASS Antiarrhythmic Agents 6108-05-0 LIDOCAINE TISSUE_TOXICITY Cardiovascular Collapse 6108-05-0 LIDOCAINE PRODUCT_CLASS Central Nervous System (CNS) 6108-05-0 LIDOCAINE PRODUCT_CLASS Cardiovasculars 6108-05-0 LIDOCAINE TA_LEVEL_3 Topical Local Anesthesia 6108-05-0 LIDOCAINE MODE_CLASS Channel Modulator 6108-05-0 LIDOCAINE ADVERSE_EFFECT GIS_2_Dysgeusia 6108-05-0 LIDOCAINE ADVERSE_EFFECT MSK_2_Back Pain 6108-05-0 LIDOCAINE TISSUE_TOXICITY Hypotension 6108-05-0 LIDOCAINE ADVERSE_EFFECT GIS_3_Stomatitis 6108-05-0 LIDOCAINE ADVERSE_EFFECT IMU_3_Urticaria 6108-05-0 LIDOCAINE ADVERSE_EFFECT OCU_3_Paralysis of the Extraocular Muscles 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Seizures 6108-05-0 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Tremor 6108-05-0 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 6108-05-0 LIDOCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 6108-05-0 LIDOCAINE THERAPEUTIC_CLASS Local Anesthetics 6108-05-0 LIDOCAINE MECHANISM Modulate channel gating 6108-05-0 LIDOCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 6108-05-0 LIDOCAINE MESH_LEVEL_3 Anilides 6108-05-0 LIDOCAINE INDICATION Ventricular Arrhythmias 6108-05-0 LIDOCAINE MECH_LEVEL_3 AMPA Glutamate receptor 6108-05-0 LIDOCAINE MESH_LEVEL_1 Organic Chemicals 6108-05-0 LIDOCAINE ZERO_CLASS N 6108-05-0 LIDOCAINE ADVERSE_EFFECT XXX_1_Dysesthesia 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Arachnoiditis 6108-05-0 LIDOCAINE ADVERSE_EFFECT CVS_2_Hypotension 6108-05-0 LIDOCAINE ACTIVITY_CLASS Na+ channel blocker 6108-05-0 LIDOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 6108-05-0 LIDOCAINE MECH_LEVEL_1 Modulate neural transmission 6108-05-0 LIDOCAINE INDICATION Postherpetic Neuralgia 6108-05-0 LIDOCAINE TISSUE_TOXICITY Cardiac Arrhythmia 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Meningeal Signs 6108-05-0 LIDOCAINE ADVERSE_EFFECT GUS_3_Urinary Retention 6108-05-0 LIDOCAINE ADVERSE_EFFECT PSY_2_Nervousness 6108-05-0 LIDOCAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_1_Paresthesia 6108-05-0 LIDOCAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 6108-05-0 LIDOCAINE ADVERSE_EFFECT PSY_2_Disorientation 6108-05-0 LIDOCAINE ADVERSE_EFFECT SKN_1_Erythema 6108-05-0 LIDOCAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 6108-05-0 LIDOCAINE ADVERSE_EFFECT IMU_3_Anaphylactic Shock 6108-05-0 LIDOCAINE ADVERSE_EFFECT XXX_2_Restlessness 6108-05-0 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_1_Drowsiness 6108-05-0 LIDOCAINE ADVERSE_EFFECT NEU_2_Dizziness 6108-05-0 LIDOCAINE ADVERSE_EFFECT PSY_2_Anxiety 6108-05-0 LIDOCAINE ADVERSE_EFFECT OCU_2_Blurred Vision 6108-05-0 LIDOCAINE KNOWN_TOXICITY Cardiovascular Toxicity 6108-05-0 LIDOCAINE TISSUE_TOXICITY Myocardial Depression 73-78-9 LIDOCAINE MECH_LEVEL_3 AMPA Glutamate receptor 73-78-9 LIDOCAINE TISSUE_TOXICITY Myocardial Depression 73-78-9 LIDOCAINE KNOWN_TOXICITY Cardiovascular Toxicity 73-78-9 LIDOCAINE ADVERSE_EFFECT OCU_2_Blurred Vision 73-78-9 LIDOCAINE ADVERSE_EFFECT PSY_2_Anxiety 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_2_Dizziness 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_1_Drowsiness 73-78-9 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 73-78-9 LIDOCAINE ADVERSE_EFFECT XXX_2_Restlessness 73-78-9 LIDOCAINE ADVERSE_EFFECT IMU_3_Anaphylactic Shock 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Meningeal Signs 73-78-9 LIDOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 73-78-9 LIDOCAINE ACTIVITY_CLASS Na+ channel blocker 73-78-9 LIDOCAINE ADVERSE_EFFECT PSY_2_Nervousness 73-78-9 LIDOCAINE TISSUE_TOXICITY Cardiac Arrest 73-78-9 LIDOCAINE ADVERSE_EFFECT XXX_2_Edema 73-78-9 LIDOCAINE ADVERSE_EFFECT LUN_3_Bronchospasm 73-78-9 LIDOCAINE ADVERSE_EFFECT PSY_2_Confusion 73-78-9 LIDOCAINE ADVERSE_EFFECT IMU_3_Angioedema 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Arachnoiditis 73-78-9 LIDOCAINE TA_LEVEL_2 Anesthesia 73-78-9 LIDOCAINE MESH_LEVEL_2 Amides 73-78-9 LIDOCAINE MECH_LEVEL_1 Modulate neural transmission 73-78-9 LIDOCAINE INDICATION Postherpetic Neuralgia 73-78-9 LIDOCAINE TISSUE_TOXICITY Cardiac Arrhythmia 73-78-9 LIDOCAINE ADVERSE_EFFECT GUS_3_Urinary Retention 73-78-9 LIDOCAINE MECH_LEVEL_2 Decrease neural membrane excitability 73-78-9 LIDOCAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_1_Paresthesia 73-78-9 LIDOCAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 73-78-9 LIDOCAINE ADVERSE_EFFECT PSY_2_Disorientation 73-78-9 LIDOCAINE ADVERSE_EFFECT SKN_1_Erythema 73-78-9 LIDOCAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Cranial Nerve Palsies 73-78-9 LIDOCAINE ADVERSE_EFFECT XXX_1_Dysesthesia 73-78-9 LIDOCAINE ZERO_CLASS N 73-78-9 LIDOCAINE MESH_LEVEL_1 Organic Chemicals 73-78-9 LIDOCAINE INDICATION Local Anesthesia 73-78-9 LIDOCAINE INDICATION Ventricular Arrhythmias 73-78-9 LIDOCAINE MESH_LEVEL_3 Anilides 73-78-9 LIDOCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 73-78-9 LIDOCAINE MECHANISM Modulate channel gating 73-78-9 LIDOCAINE THERAPEUTIC_CLASS Local Anesthetics 73-78-9 LIDOCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 73-78-9 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Tremor 73-78-9 LIDOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Seizures 73-78-9 LIDOCAINE ADVERSE_EFFECT OCU_3_Paralysis of the Extraocular Muscles 73-78-9 LIDOCAINE ADVERSE_EFFECT IMU_3_Urticaria 73-78-9 LIDOCAINE ADVERSE_EFFECT GIS_3_Stomatitis 73-78-9 LIDOCAINE TISSUE_TOXICITY Hypotension 73-78-9 LIDOCAINE ADVERSE_EFFECT MSK_2_Back Pain 73-78-9 LIDOCAINE ADVERSE_EFFECT GIS_2_Dysgeusia 73-78-9 LIDOCAINE MODE_CLASS Channel Modulator 73-78-9 LIDOCAINE TA_LEVEL_3 Topical Local Anesthesia 73-78-9 LIDOCAINE PRODUCT_CLASS Cardiovasculars 73-78-9 LIDOCAINE PRODUCT_CLASS Central Nervous System (CNS) 73-78-9 LIDOCAINE TISSUE_TOXICITY Cardiovascular Collapse 73-78-9 LIDOCAINE THERAPEUTIC_CLASS Antiarrhythmic Agents 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Meningitis 73-78-9 LIDOCAINE ADVERSE_EFFECT NEU_3_Paralysis 73-78-9 LIDOCAINE ADVERSE_EFFECT CVS_2_Hypotension 73-78-9 LIDOCAINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 859-18-7 LINCOMYCIN ADVERSE_EFFECT XXX_2_Drug Fever 859-18-7 LINCOMYCIN ADVERSE_EFFECT SKN_2_Genital and Anal Pruritis 859-18-7 LINCOMYCIN ADVERSE_EFFECT BBM_3_Leukopenia 859-18-7 LINCOMYCIN ADVERSE_EFFECT IMU_3_Anaphylaxis 859-18-7 LINCOMYCIN INDICATION Intra-Abdominal Infections 859-18-7 LINCOMYCIN TISSUE_TOXICITY Cardiac Arrest 859-18-7 LINCOMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 859-18-7 LINCOMYCIN ADVERSE_EFFECT GIS_1_Pseudomembranous Colitis 859-18-7 LINCOMYCIN ZERO_CLASS N 859-18-7 LINCOMYCIN TA_LEVEL_2 Anti-bacterial 859-18-7 LINCOMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 859-18-7 LINCOMYCIN INDICATION Pneumococcal Pneumonia 859-18-7 LINCOMYCIN PRODUCT_CLASS Anti-infectives 859-18-7 LINCOMYCIN TA_LEVEL_1 Infectious Disease 859-18-7 LINCOMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 859-18-7 LINCOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 859-18-7 LINCOMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 859-18-7 LINCOMYCIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 859-18-7 LINCOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 859-18-7 LINCOMYCIN ADVERSE_EFFECT LIV_3_Jaundice 859-18-7 LINCOMYCIN ADVERSE_EFFECT SKN_1_Skin Rash 859-18-7 LINCOMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 859-18-7 LINCOMYCIN MECHANISM Inhibit ribosomal protein synthesis 859-18-7 LINCOMYCIN MECH_LEVEL_1 Anti-bacterial 859-18-7 LINCOMYCIN INDICATION Streptococcal Infections 859-18-7 LINCOMYCIN TISSUE_TOXICITY Hypotension 859-18-7 LINCOMYCIN ADVERSE_EFFECT CVS_3_Hypotension 859-18-7 LINCOMYCIN ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 859-18-7 LINCOMYCIN ADVERSE_EFFECT XXX_3_Superinfection 859-18-7 LINCOMYCIN ADVERSE_EFFECT GUS_2_Vaginal Candidiasis 859-18-7 LINCOMYCIN ADVERSE_EFFECT BBM_3_Sideroblastic Anemia 859-18-7 LINCOMYCIN ADVERSE_EFFECT BBM_3_Granulocytopenia 859-18-7 LINCOMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 859-18-7 LINCOMYCIN TA_LEVEL_3 Systemic infections 859-18-7 LINCOMYCIN INDICATION Staphylococcus Aureus Infections 859-18-7 LINCOMYCIN MESH_LEVEL_2 Carbohydrates 859-18-7 LINCOMYCIN INDICATION Osteomyelitis / Bone Infection 859-18-7 LINCOMYCIN MESH_LEVEL_3 Glycosides 859-18-7 LINCOMYCIN TISSUE_TOXICITY Pseudomembranous Colitis 859-18-7 LINCOMYCIN KNOWN_TOXICITY Gastrointestinal Toxicity 859-18-7 LINCOMYCIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 859-18-7 LINCOMYCIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 859-18-7 LINCOMYCIN ADVERSE_EFFECT IMU_3_Serum Sickness 859-18-7 LINCOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, lincosamide 859-18-7 LINCOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 154-21-2 LINCOMYCIN TISSUE_TOXICITY Pseudomembranous Colitis 154-21-2 LINCOMYCIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 154-21-2 LINCOMYCIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 154-21-2 LINCOMYCIN ADVERSE_EFFECT GIS_1_Pseudomembranous Colitis 154-21-2 LINCOMYCIN ADVERSE_EFFECT IMU_3_Serum Sickness 154-21-2 LINCOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, lincosamide 154-21-2 LINCOMYCIN TA_LEVEL_2 Anti-bacterial 154-21-2 LINCOMYCIN INDICATION Pneumococcal Pneumonia 154-21-2 LINCOMYCIN PRODUCT_CLASS Anti-infectives 154-21-2 LINCOMYCIN TA_LEVEL_1 Infectious Disease 154-21-2 LINCOMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 154-21-2 LINCOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 154-21-2 LINCOMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 154-21-2 LINCOMYCIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 154-21-2 LINCOMYCIN ADVERSE_EFFECT BBM_3_Granulocytopenia 154-21-2 LINCOMYCIN ADVERSE_EFFECT LIV_3_Jaundice 154-21-2 LINCOMYCIN ADVERSE_EFFECT SKN_1_Skin Rash 154-21-2 LINCOMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 154-21-2 LINCOMYCIN MECHANISM Inhibit ribosomal protein synthesis 154-21-2 LINCOMYCIN MECH_LEVEL_1 Anti-bacterial 154-21-2 LINCOMYCIN INDICATION Streptococcal Infections 154-21-2 LINCOMYCIN TISSUE_TOXICITY Hypotension 154-21-2 LINCOMYCIN ADVERSE_EFFECT CVS_3_Hypotension 154-21-2 LINCOMYCIN ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 154-21-2 LINCOMYCIN ADVERSE_EFFECT XXX_3_Superinfection 154-21-2 LINCOMYCIN ADVERSE_EFFECT GUS_2_Vaginal Candidiasis 154-21-2 LINCOMYCIN ADVERSE_EFFECT BBM_3_Sideroblastic Anemia 154-21-2 LINCOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 154-21-2 LINCOMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 154-21-2 LINCOMYCIN TA_LEVEL_3 Systemic infections 154-21-2 LINCOMYCIN INDICATION Staphylococcus Aureus Infections 154-21-2 LINCOMYCIN INDICATION Intra-Abdominal Infections 154-21-2 LINCOMYCIN TISSUE_TOXICITY Cardiac Arrest 154-21-2 LINCOMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 154-21-2 LINCOMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 154-21-2 LINCOMYCIN ADVERSE_EFFECT IMU_3_Anaphylaxis 154-21-2 LINCOMYCIN ADVERSE_EFFECT BBM_3_Leukopenia 154-21-2 LINCOMYCIN ADVERSE_EFFECT SKN_2_Genital and Anal Pruritis 154-21-2 LINCOMYCIN ADVERSE_EFFECT XXX_2_Drug Fever 154-21-2 LINCOMYCIN ZERO_CLASS N 154-21-2 LINCOMYCIN KNOWN_TOXICITY Gastrointestinal Toxicity 154-21-2 LINCOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 154-21-2 LINCOMYCIN MESH_LEVEL_2 Carbohydrates 154-21-2 LINCOMYCIN INDICATION Osteomyelitis / Bone Infection 154-21-2 LINCOMYCIN MESH_LEVEL_3 Glycosides 58-89-9 LINDANE ADVERSE_EFFECT NEU_3_Seizures 58-89-9 LINDANE ADVERSE_EFFECT MSK_3_Muscle Cramps 58-89-9 LINDANE INDICATION Scabies 58-89-9 LINDANE ADVERSE_EFFECT CVS_3_Tachycardia 58-89-9 LINDANE THERAPEUTIC_CLASS Antiparasitics 58-89-9 LINDANE ADVERSE_EFFECT PSY_3_Irritability 58-89-9 LINDANE PRODUCT_CLASS Dermatologicals 58-89-9 LINDANE ADVERSE_EFFECT NEU_3_Dizziness 58-89-9 LINDANE ADVERSE_EFFECT IMU_3_Contact Dermatitis 58-89-9 LINDANE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 58-89-9 LINDANE ADVERSE_EFFECT SKN_3_Maculopapular Rash 58-89-9 LINDANE ADVERSE_EFFECT SKN_1_Skin Irritation 58-89-9 LINDANE INDICATION Pediculosis 58-89-9 LINDANE ADVERSE_EFFECT PSY_3_Nervousness 58-89-9 LINDANE ADVERSE_EFFECT XXX_3_Restlessness 136381-85-6 LINTITRIPT INDICATION Parkinson's Disease 136381-85-6 LINTITRIPT PRODUCT_CLASS Central Nervous System (CNS) 136381-85-6 LINTITRIPT MODE_CLASS Receptor Ligand Antagonist 136381-85-6 LINTITRIPT MECHANISM Modulate G-protein coupled signal transduction 136381-85-6 LINTITRIPT PRODUCT_CLASS Gastrointestinal System 136381-85-6 LINTITRIPT THERAPEUTIC_CLASS Movement Disorders 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 6893-02-3 3,3',5-TRIIODO-L-THYRONINE TISSUE_TOXICITY Heart Failure 6893-02-3 3,3',5-TRIIODO-L-THYRONINE THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT XXX_2_Fever 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Myxedema Coma 6893-02-3 3,3',5-TRIIODO-L-THYRONINE STRUCTURE_ACTIVITY T3 receptor agonist 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Heart Failure 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT END_2_Hyperthyroidism 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Cretinism 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Phlebitis 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT XXX_2_Weight Loss 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Hypothyroidism 6893-02-3 3,3',5-TRIIODO-L-THYRONINE TISSUE_TOXICITY Cardiac Arrest 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Hypotension 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT PSY_2_Anxiety 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT SKN_3_Rash 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT REP_2_Amenorrhea 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT END_2_Heat Intolerance 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT XXX_2_Diaphoresis 6893-02-3 3,3',5-TRIIODO-L-THYRONINE MODE_CLASS Receptor Agonist 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ACTIVITY_CLASS T3 receptor agonist 6893-02-3 3,3',5-TRIIODO-L-THYRONINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Hyperthyroidism diagnosis 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Thyroiditis 6893-02-3 3,3',5-TRIIODO-L-THYRONINE TISSUE_TOXICITY Atrial Fibrillation 6893-02-3 3,3',5-TRIIODO-L-THYRONINE TISSUE_TOXICITY Myocardial Infarction 6893-02-3 3,3',5-TRIIODO-L-THYRONINE KNOWN_TOXICITY Cardiovascular Toxicity 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT PSY_2_Insomnia 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Angina 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT XXX_3_Peripheral Edema 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT PSY_2_Irritability 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT END_3_Thyrotoxicosis 6893-02-3 3,3',5-TRIIODO-L-THYRONINE MECHANISM Modulate gene transcription 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Goiter 6893-02-3 3,3',5-TRIIODO-L-THYRONINE INDICATION Myxedema 6893-02-3 3,3',5-TRIIODO-L-THYRONINE TISSUE_TOXICITY Angina 6893-02-3 3,3',5-TRIIODO-L-THYRONINE TISSUE_TOXICITY Hypotension 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT GIS_2_Diarrhea 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT PSY_2_Anorexia 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT NEU_2_Tremor 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT IMU_3_Urticaria 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 6893-02-3 3,3',5-TRIIODO-L-THYRONINE ADVERSE_EFFECT NEU_2_Headache 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 PRODUCT_CLASS Biochemicals 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 MESH_LEVEL_3 Lipopolysaccharides 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT NEU_2_Coma 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT XXX_1_Weight Loss 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT CVS_1_Hypotension 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 KNOWN_TOXICITY Hepatotoxicity 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 TISSUE_TOXICITY Hepatic Failure 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 TA_LEVEL_1 Infectious Disease 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 MECH_LEVEL_2 TNF-alpha release 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT XXX_1_Fever 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ZERO_CLASS N 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 MECH_LEVEL_3 TNF-alpha stimulation 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT XXX_1_Inflammation 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT _2_Preterm Labor 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT NEU_1_Crosses the Blood Brain Barrier 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT PSY_2_Depressed Mood 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 MESH_LEVEL_2 Lipids 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ACTIVITY_CLASS Pro-inflammatory stimuli 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 TISSUE_TOXICITY Death 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 TA_LEVEL_2 Inflammatory mediator 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 KNOWN_TOXICITY Miscellaneous 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 STRUCTURE_ACTIVITY Pro-inflammatory stimuli 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 MESH_LEVEL_1 Lipids and Antilipemic Agents 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT LIV_2_Hepatic Failure 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT _2_Endotoxic Shock 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT LIV_2_Hepatic Damage 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT PSY_2_Anorexia 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 MECH_LEVEL_1 Immunomodulation 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 TISSUE_TOXICITY Hypotension 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 KNOWN_TOXICITY Cardiovascular Toxicity 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT NEU_2_Convulsions 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT CVS_1_Increased Heart Rate 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT XXX_1_Decreased Appetite 93572-42-0 LIPOPOLYSACCHARIDE E. COLI O55:B5 ADVERSE_EFFECT XXX_2_Death 76547-98-3 LISINOPRIL ADVERSE_EFFECT NEU_1_Syncope 76547-98-3 LISINOPRIL ADVERSE_EFFECT KID_3_Renal Insufficiency 76547-98-3 LISINOPRIL ADVERSE_EFFECT LUN_1_Cough 76547-98-3 LISINOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 76547-98-3 LISINOPRIL PRODUCT_CLASS Cardiovasculars 76547-98-3 LISINOPRIL MECH_LEVEL_1 Vasorelaxation 76547-98-3 LISINOPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 76547-98-3 LISINOPRIL TA_LEVEL_2 Hypertension 76547-98-3 LISINOPRIL MECH_LEVEL_2 ACE inhibitor 76547-98-3 LISINOPRIL MECHANISM Reduce vasoconstriction 76547-98-3 LISINOPRIL KNOWN_TOXICITY Hepatotoxicity 76547-98-3 LISINOPRIL TISSUE_TOXICITY Hepatotoxicity 76547-98-3 LISINOPRIL THERAPEUTIC_CLASS Antianginals 76547-98-3 LISINOPRIL THERAPEUTIC_CLASS Congestive Heart Failure 76547-98-3 LISINOPRIL TA_LEVEL_1 Cardiovascular 76547-98-3 LISINOPRIL TA_LEVEL_3 Diuretic 76547-98-3 LISINOPRIL INDICATION Congestive Heart Failure (CHF) 76547-98-3 LISINOPRIL ADVERSE_EFFECT GIS_3_Dysgeusia 76547-98-3 LISINOPRIL ADVERSE_EFFECT KID_1_Increased Creatinine 76547-98-3 LISINOPRIL ADVERSE_EFFECT LIV_3_Hepatotoxicity 76547-98-3 LISINOPRIL ADVERSE_EFFECT ELT_1_Hyperkalemia 76547-98-3 LISINOPRIL KNOWN_TOXICITY Cardiovascular Toxicity 76547-98-3 LISINOPRIL TISSUE_TOXICITY Hypotension 76547-98-3 LISINOPRIL ADVERSE_EFFECT LUN_3_Dyspnea 76547-98-3 LISINOPRIL MESH_LEVEL_2 Peptides 76547-98-3 LISINOPRIL MESH_LEVEL_3 Oligopeptides 76547-98-3 LISINOPRIL INDICATION Acute Myocardial Infarction 76547-98-3 LISINOPRIL ADVERSE_EFFECT CVS_1_Hypotension 76547-98-3 LISINOPRIL ADVERSE_EFFECT IMU_3_Angioedema 76547-98-3 LISINOPRIL ADVERSE_EFFECT KID_1_Azotemia 76547-98-3 LISINOPRIL ADVERSE_EFFECT NEU_1_Dizziness 76547-98-3 LISINOPRIL ADVERSE_EFFECT EMB_2_Teratogenicity 76547-98-3 LISINOPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 76547-98-3 LISINOPRIL TISSUE_TOXICITY Teratogenicity 76547-98-3 LISINOPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 76547-98-3 LISINOPRIL MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 76547-98-3 LISINOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 76547-98-3 LISINOPRIL INDICATION Hypertension 76547-98-3 LISINOPRIL ZERO_CLASS N 76547-98-3 LISINOPRIL ACTIVITY_CLASS RAAS inhibitor 76547-98-3 LISINOPRIL ADVERSE_EFFECT IMU_3_Angioneurotic Edema 76547-98-3 LISINOPRIL MODE_CLASS Enzyme Inhibitor 98079-51-7 LOMEFLOXACIN TISSUE_TOXICITY Myocardial Infarction 98079-51-7 LOMEFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 98079-51-7 LOMEFLOXACIN TA_LEVEL_3 quinolones 98079-51-7 LOMEFLOXACIN INDICATION Urinary Tract Infection (UTI) 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Dyspepsia 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT IMU_1_Photosensitivity 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Constipation 98079-51-7 LOMEFLOXACIN TA_LEVEL_1 Infectious Disease 98079-51-7 LOMEFLOXACIN MECH_LEVEL_1 Anti-bacterial 98079-51-7 LOMEFLOXACIN TA_LEVEL_2 Anti-bacterial 98079-51-7 LOMEFLOXACIN INDICATION Lower Respiratory Tract Infection 98079-51-7 LOMEFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT IMU_2_Eosinophilia 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT XXX_2_Restlessness 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_3_Coma 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 98079-51-7 LOMEFLOXACIN TISSUE_TOXICITY Hepatic Necrosis 98079-51-7 LOMEFLOXACIN THERAPEUTIC_CLASS Antibacterials 98079-51-7 LOMEFLOXACIN INDICATION Chronic Bronchitis 98079-51-7 LOMEFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 98079-51-7 LOMEFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 98079-51-7 LOMEFLOXACIN ZERO_CLASS N 98079-51-7 LOMEFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT XXX_2_Asthenia 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT LIV_2_Jaundice 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT CVS_2_Hypotension 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 98079-51-7 LOMEFLOXACIN TISSUE_TOXICITY Hypotension 98079-51-7 LOMEFLOXACIN KNOWN_TOXICITY Hepatotoxicity 98079-51-7 LOMEFLOXACIN INDICATION Cystitis 98079-51-7 LOMEFLOXACIN INDICATION Surgical Prophylaxis 98079-51-7 LOMEFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 98079-51-7 LOMEFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 98079-51-7 LOMEFLOXACIN PRODUCT_CLASS Anti-infectives 98079-51-7 LOMEFLOXACIN MECH_LEVEL_3 DNA gyrase 98079-51-7 LOMEFLOXACIN MESH_LEVEL_3 Quinolines 98079-51-7 LOMEFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_2_Vertigo 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT PSY_2_Confusion 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT NEU_1_Headache 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT CVS_3_Myocardial Infarction 98079-51-7 LOMEFLOXACIN ADVERSE_EFFECT XXX_2_Fever 98079-52-8 LOMEFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 98079-52-8 LOMEFLOXACIN TISSUE_TOXICITY Myocardial Infarction 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT XXX_2_Fever 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT CVS_3_Myocardial Infarction 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_1_Headache 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT PSY_2_Confusion 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_2_Vertigo 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 98079-52-8 LOMEFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 98079-52-8 LOMEFLOXACIN MESH_LEVEL_3 Quinolines 98079-52-8 LOMEFLOXACIN MECH_LEVEL_3 DNA gyrase 98079-52-8 LOMEFLOXACIN PRODUCT_CLASS Anti-infectives 98079-52-8 LOMEFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 98079-52-8 LOMEFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 98079-52-8 LOMEFLOXACIN INDICATION Surgical Prophylaxis 98079-52-8 LOMEFLOXACIN INDICATION Cystitis 98079-52-8 LOMEFLOXACIN KNOWN_TOXICITY Hepatotoxicity 98079-52-8 LOMEFLOXACIN TISSUE_TOXICITY Hypotension 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT CVS_2_Hypotension 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT LIV_2_Jaundice 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT XXX_2_Asthenia 98079-52-8 LOMEFLOXACIN ZERO_CLASS N 98079-52-8 LOMEFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 98079-52-8 LOMEFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 98079-52-8 LOMEFLOXACIN MECH_LEVEL_1 Anti-bacterial 98079-52-8 LOMEFLOXACIN TA_LEVEL_1 Infectious Disease 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Constipation 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT PSY_3_Insomnia 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT IMU_1_Photosensitivity 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT GIS_2_Dyspepsia 98079-52-8 LOMEFLOXACIN INDICATION Urinary Tract Infection (UTI) 98079-52-8 LOMEFLOXACIN TA_LEVEL_3 quinolones 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT XXX_2_Restlessness 98079-52-8 LOMEFLOXACIN TA_LEVEL_2 Anti-bacterial 98079-52-8 LOMEFLOXACIN INDICATION Lower Respiratory Tract Infection 98079-52-8 LOMEFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT IMU_2_Eosinophilia 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 98079-52-8 LOMEFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_3_Coma 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 98079-52-8 LOMEFLOXACIN ADVERSE_EFFECT PSY_3_Hallucinations 98079-52-8 LOMEFLOXACIN TISSUE_TOXICITY Hepatic Necrosis 98079-52-8 LOMEFLOXACIN THERAPEUTIC_CLASS Antibacterials 98079-52-8 LOMEFLOXACIN INDICATION Chronic Bronchitis 101477-55-8 LOMERIZINE MODE_CLASS Channel Blocker 101477-55-8 LOMERIZINE MECHANISM Block neural transmission 101477-55-8 LOMERIZINE INDICATION Cerebrovascular Insufficiency 101477-55-8 LOMERIZINE PRODUCT_CLASS Central Nervous System (CNS) 101477-55-8 LOMERIZINE THERAPEUTIC_CLASS Antimigraines 101477-55-8 LOMERIZINE MECHANISM Modulate channel gating 101477-55-8 LOMERIZINE INDICATION Migraine Headache 101477-55-8 LOMERIZINE THERAPEUTIC_CLASS Vasodilators 101477-55-8 LOMERIZINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 101477-54-7 LOMERIZINE THERAPEUTIC_CLASS Vasodilators 101477-54-7 LOMERIZINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 101477-54-7 LOMERIZINE MECHANISM Block neural transmission 101477-54-7 LOMERIZINE INDICATION Cerebrovascular Insufficiency 101477-54-7 LOMERIZINE PRODUCT_CLASS Central Nervous System (CNS) 101477-54-7 LOMERIZINE THERAPEUTIC_CLASS Antimigraines 101477-54-7 LOMERIZINE INDICATION Migraine Headache 101477-54-7 LOMERIZINE MODE_CLASS Channel Blocker 101477-54-7 LOMERIZINE MECHANISM Modulate channel gating 13010-47-4 LOMUSTINE TISSUE_TOXICITY Renal Failure 13010-47-4 LOMUSTINE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, nitrosourea 13010-47-4 LOMUSTINE INDICATION Neoplasm / Cancer / Tumor 13010-47-4 LOMUSTINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 13010-47-4 LOMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 13010-47-4 LOMUSTINE INDICATION Bronchogenic Carcinoma 13010-47-4 LOMUSTINE KNOWN_TOXICITY Nephrotoxicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT KID_2_Nephrotoxicity 13010-47-4 LOMUSTINE INDICATION Breast Cancer / Carcinoma of the Breast 13010-47-4 LOMUSTINE ADVERSE_EFFECT SKN_2_Itching 13010-47-4 LOMUSTINE ADVERSE_EFFECT EMB_3_Embryotoxicity 13010-47-4 LOMUSTINE TISSUE_TOXICITY Myelosuppression 13010-47-4 LOMUSTINE TISSUE_TOXICITY Nephrotoxicity 13010-47-4 LOMUSTINE MESH_LEVEL_3 Nitrosourea Compounds 13010-47-4 LOMUSTINE MESH_LEVEL_1 Organic Chemicals 13010-47-4 LOMUSTINE TA_LEVEL_1 Oncology 13010-47-4 LOMUSTINE MECH_LEVEL_3 DNA damage 13010-47-4 LOMUSTINE INDICATION Psoriasis 13010-47-4 LOMUSTINE THERAPEUTIC_CLASS Antineoplastics 13010-47-4 LOMUSTINE KNOWN_TOXICITY Hepatotoxicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 13010-47-4 LOMUSTINE ADVERSE_EFFECT BBM_2_Anemia 13010-47-4 LOMUSTINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 13010-47-4 LOMUSTINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 13010-47-4 LOMUSTINE ZERO_CLASS N 13010-47-4 LOMUSTINE TISSUE_TOXICITY Hepatotoxicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT KID_3_Renal Failure 13010-47-4 LOMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 13010-47-4 LOMUSTINE INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 13010-47-4 LOMUSTINE INDICATION Hodgkin's Disease 13010-47-4 LOMUSTINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 13010-47-4 LOMUSTINE MESH_LEVEL_2 Nitroso Compounds 13010-47-4 LOMUSTINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT GIS_2_Stomatitis 13010-47-4 LOMUSTINE ADVERSE_EFFECT XXX_1_Infection 13010-47-4 LOMUSTINE ADVERSE_EFFECT NEU_3_Neurological Toxicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT SKN_2_Dermatitis 13010-47-4 LOMUSTINE TISSUE_TOXICITY Thrombocytopenia 13010-47-4 LOMUSTINE KNOWN_TOXICITY Carcinogenicity 13010-47-4 LOMUSTINE ADVERSE_EFFECT BBM_1_Leukopenia 13010-47-4 LOMUSTINE ADVERSE_EFFECT DNA_3_Carcinogenicity 13010-47-4 LOMUSTINE TISSUE_TOXICITY Carcinogenicity 13010-47-4 LOMUSTINE PRODUCT_CLASS Anti-cancers 13010-47-4 LOMUSTINE TA_LEVEL_2 DNA damage 13010-47-4 LOMUSTINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 13010-47-4 LOMUSTINE INDICATION Brain Cancer 13010-47-4 LOMUSTINE INDICATION Non-Hodgkin's Lymphomas 13010-47-4 LOMUSTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 13010-47-4 LOMUSTINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 13010-47-4 LOMUSTINE ADVERSE_EFFECT LUN_3_Pulmonary Infiltrates 13010-47-4 LOMUSTINE ADVERSE_EFFECT REP_2_Decreased Fertility 13010-47-4 LOMUSTINE ADVERSE_EFFECT CVS_2_Telangiectasia 13010-47-4 LOMUSTINE ADVERSE_EFFECT BBM_1_Myelosuppression 13010-47-4 LOMUSTINE TISSUE_TOXICITY Leukopenia 13010-47-4 LOMUSTINE ACTIVITY_CLASS DNA damager 13010-47-4 LOMUSTINE TA_LEVEL_3 Solid Tumors 34552-83-5 LOPERAMIDE MECH_LEVEL_3 opioid receptor mu 34552-83-5 LOPERAMIDE INDICATION Inflammatory Bowel Disease (IBD) 34552-83-5 LOPERAMIDE MECHANISM Reduce muscle contractile force 34552-83-5 LOPERAMIDE MESH_LEVEL_1 Heterocyclic Compounds 34552-83-5 LOPERAMIDE THERAPEUTIC_CLASS Antidiarrhea Agents 34552-83-5 LOPERAMIDE ADVERSE_EFFECT XXX_2_Fatigue 34552-83-5 LOPERAMIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 34552-83-5 LOPERAMIDE ACTIVITY_CLASS Opioid receptor (mu) agonist 34552-83-5 LOPERAMIDE TA_LEVEL_1 Gastrointestinal System 34552-83-5 LOPERAMIDE MECHANISM Modulate neural transmission 34552-83-5 LOPERAMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 34552-83-5 LOPERAMIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 34552-83-5 LOPERAMIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 34552-83-5 LOPERAMIDE MESH_LEVEL_3 Piperidines 34552-83-5 LOPERAMIDE ADVERSE_EFFECT GIS_1_Constipation 34552-83-5 LOPERAMIDE ADVERSE_EFFECT NEU_2_Drowsiness 34552-83-5 LOPERAMIDE ADVERSE_EFFECT XXX_2_Xerostomia 34552-83-5 LOPERAMIDE ADVERSE_EFFECT SKN_3_Bullous Rash 34552-83-5 LOPERAMIDE ZERO_CLASS N 34552-83-5 LOPERAMIDE MODE_CLASS Receptor Agonist 34552-83-5 LOPERAMIDE MECH_LEVEL_2 opioid agonist 34552-83-5 LOPERAMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 34552-83-5 LOPERAMIDE TA_LEVEL_2 anti-diarrhea 34552-83-5 LOPERAMIDE MECH_LEVEL_1 Antidiarrhea Agents 34552-83-5 LOPERAMIDE INDICATION Diarrhea 34552-83-5 LOPERAMIDE PRODUCT_CLASS Gastrointestinal System 34552-83-5 LOPERAMIDE ADVERSE_EFFECT NEU_2_Dizziness 34552-83-5 LOPERAMIDE ADVERSE_EFFECT NEU_3_Paralytic Ileus 34552-83-5 LOPERAMIDE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 34552-83-5 LOPERAMIDE MODE_CLASS Channel Blocker 53179-11-6 LOPERAMIDE MECH_LEVEL_1 Antidiarrhea Agents 53179-11-6 LOPERAMIDE INDICATION Diarrhea 53179-11-6 LOPERAMIDE PRODUCT_CLASS Gastrointestinal System 53179-11-6 LOPERAMIDE ADVERSE_EFFECT NEU_2_Dizziness 53179-11-6 LOPERAMIDE ADVERSE_EFFECT NEU_3_Paralytic Ileus 53179-11-6 LOPERAMIDE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 53179-11-6 LOPERAMIDE MECH_LEVEL_3 opioid receptor mu 53179-11-6 LOPERAMIDE INDICATION Inflammatory Bowel Disease (IBD) 53179-11-6 LOPERAMIDE MECHANISM Reduce muscle contractile force 53179-11-6 LOPERAMIDE MESH_LEVEL_1 Heterocyclic Compounds 53179-11-6 LOPERAMIDE THERAPEUTIC_CLASS Antidiarrhea Agents 53179-11-6 LOPERAMIDE ADVERSE_EFFECT XXX_2_Fatigue 53179-11-6 LOPERAMIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 53179-11-6 LOPERAMIDE ACTIVITY_CLASS Opioid receptor (mu) agonist 53179-11-6 LOPERAMIDE TA_LEVEL_1 Gastrointestinal System 53179-11-6 LOPERAMIDE MECHANISM Modulate neural transmission 53179-11-6 LOPERAMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 53179-11-6 LOPERAMIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 53179-11-6 LOPERAMIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 53179-11-6 LOPERAMIDE MODE_CLASS Channel Blocker 53179-11-6 LOPERAMIDE ADVERSE_EFFECT XXX_2_Xerostomia 53179-11-6 LOPERAMIDE MECH_LEVEL_2 opioid agonist 53179-11-6 LOPERAMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 53179-11-6 LOPERAMIDE ADVERSE_EFFECT SKN_3_Bullous Rash 53179-11-6 LOPERAMIDE ZERO_CLASS N 53179-11-6 LOPERAMIDE MODE_CLASS Receptor Agonist 53179-11-6 LOPERAMIDE TA_LEVEL_2 anti-diarrhea 53179-11-6 LOPERAMIDE MESH_LEVEL_3 Piperidines 53179-11-6 LOPERAMIDE ADVERSE_EFFECT GIS_1_Constipation 53179-11-6 LOPERAMIDE ADVERSE_EFFECT NEU_2_Drowsiness 121961-22-6 LORACARBEF MODE_CLASS Enzyme Inhibitor 121961-22-6 LORACARBEF PRODUCT_CLASS Anti-infectives 121961-22-6 LORACARBEF THERAPEUTIC_CLASS Antibacterials, Systemic 121961-22-6 LORACARBEF MECHANISM Inhibit bacterial cell wall biosynthesis 76470-66-1 LORACARBEF MODE_CLASS Enzyme Inhibitor 76470-66-1 LORACARBEF MECHANISM Inhibit bacterial cell wall biosynthesis 76470-66-1 LORACARBEF PRODUCT_CLASS Anti-infectives 76470-66-1 LORACARBEF THERAPEUTIC_CLASS Antibacterials, Systemic 79794-75-5 LORATADINE ADVERSE_EFFECT LUN_3_Wheezing 79794-75-5 LORATADINE THERAPEUTIC_CLASS Antihistamines 79794-75-5 LORATADINE MECH_LEVEL_2 Anti-histamine 79794-75-5 LORATADINE TA_LEVEL_1 Anti-inflammatory 79794-75-5 LORATADINE TA_LEVEL_2 Anti-histamine 79794-75-5 LORATADINE MECH_LEVEL_3 histamine receptor H1 79794-75-5 LORATADINE ADVERSE_EFFECT GIS_2_Abdominal Pain 79794-75-5 LORATADINE ADVERSE_EFFECT XXX_2_Restlessness 79794-75-5 LORATADINE ADVERSE_EFFECT XXX_3_Epistaxis 79794-75-5 LORATADINE ADVERSE_EFFECT XXX_3_Pharyngitis 79794-75-5 LORATADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, tricyclic 79794-75-5 LORATADINE ADVERSE_EFFECT NEU_2_Somnolence 79794-75-5 LORATADINE MECH_LEVEL_1 Immunomodulation 79794-75-5 LORATADINE ADVERSE_EFFECT XXX_3_Tooth Disorder 79794-75-5 LORATADINE ADVERSE_EFFECT NEU_1_Headache 79794-75-5 LORATADINE ADVERSE_EFFECT LUN_3_Dysphonia 79794-75-5 LORATADINE ADVERSE_EFFECT PSY_2_Nervousness 79794-75-5 LORATADINE ACTIVITY_CLASS Histamine antagonist 79794-75-5 LORATADINE PRODUCT_CLASS Anti-inflammatories 79794-75-5 LORATADINE MESH_LEVEL_3 Piperidines 79794-75-5 LORATADINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 79794-75-5 LORATADINE INDICATION Urticaria / Hives 79794-75-5 LORATADINE ADVERSE_EFFECT GIS_2_Diarrhea 79794-75-5 LORATADINE ADVERSE_EFFECT XXX_2_Influenza-Like Syndrome 79794-75-5 LORATADINE MODE_CLASS Receptor Ligand Antagonist, Selective 79794-75-5 LORATADINE ADVERSE_EFFECT SKN_2_Rash 79794-75-5 LORATADINE ADVERSE_EFFECT XXX_2_Fatigue 79794-75-5 LORATADINE ADVERSE_EFFECT OCU_2_Conjunctivitis 79794-75-5 LORATADINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 79794-75-5 LORATADINE INDICATION Allergic Rhinitis 79794-75-5 LORATADINE MESH_LEVEL_1 Heterocyclic Compounds 79794-75-5 LORATADINE ZERO_CLASS N 79794-75-5 LORATADINE MECHANISM Modulate G-protein coupled signal transduction 846-49-1 LORAZEPAM MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 846-49-1 LORAZEPAM TA_LEVEL_2 CNS Depressant 846-49-1 LORAZEPAM MESH_LEVEL_3 Benzazepines 846-49-1 LORAZEPAM ZERO_CLASS N 846-49-1 LORAZEPAM ACTIVITY_CLASS GABA agonist 846-49-1 LORAZEPAM MODE_CLASS Channel enhancer /opener 846-49-1 LORAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 846-49-1 LORAZEPAM ADVERSE_EFFECT OCU_2_Blurred Vision 846-49-1 LORAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 846-49-1 LORAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 846-49-1 LORAZEPAM TISSUE_TOXICITY Hypotension 846-49-1 LORAZEPAM INDICATION Initiation / Maintenance of Sedation 846-49-1 LORAZEPAM MECH_LEVEL_2 faciliates GABA binding 846-49-1 LORAZEPAM ADVERSE_EFFECT CVS_2_Hypotension 846-49-1 LORAZEPAM MESH_LEVEL_1 Heterocyclic Compounds 846-49-1 LORAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, short acting 846-49-1 LORAZEPAM ADVERSE_EFFECT PSY_2_Disorientation 846-49-1 LORAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 846-49-1 LORAZEPAM ADVERSE_EFFECT XXX_1_Withdrawal 846-49-1 LORAZEPAM ADVERSE_EFFECT NEU_2_Dizziness 846-49-1 LORAZEPAM ADVERSE_EFFECT NEU_1_Sedation 846-49-1 LORAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 846-49-1 LORAZEPAM INDICATION Status Epilepticus 846-49-1 LORAZEPAM MECH_LEVEL_1 Modulate neural transmission 846-49-1 LORAZEPAM INDICATION Anxiety Disorders 846-49-1 LORAZEPAM MECH_LEVEL_3 GABA-A receptor 846-49-1 LORAZEPAM ADVERSE_EFFECT NEU_3_Somnolence 846-49-1 LORAZEPAM ADVERSE_EFFECT PSY_3_Confusion 846-49-1 LORAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 846-49-1 LORAZEPAM ADVERSE_EFFECT NEU_2_Ataxia 846-49-1 LORAZEPAM ADVERSE_EFFECT NEU_3_Coma 846-49-1 LORAZEPAM ADVERSE_EFFECT NEU_3_Amnesia 846-49-1 LORAZEPAM ADVERSE_EFFECT LUN_3_Respiratory Depression 846-49-1 LORAZEPAM THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 846-49-1 LORAZEPAM ADVERSE_EFFECT SKN_2_Skin Rash 846-49-1 LORAZEPAM ADVERSE_EFFECT XXX_2_Salivation 846-49-1 LORAZEPAM THERAPEUTIC_CLASS Anxiolytics 846-49-1 LORAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 846-49-1 LORAZEPAM TA_LEVEL_3 Anxiolytics 846-49-1 LORAZEPAM TISSUE_TOXICITY Teratogenicity 846-49-1 LORAZEPAM TA_LEVEL_1 Central Nervous System (CNS) 846-49-1 LORAZEPAM INDICATION Insomnia 846-49-1 LORAZEPAM ADVERSE_EFFECT LUN_2_Apnea 846-49-1 LORAZEPAM ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 846-49-1 LORAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 846-49-1 LORAZEPAM ADVERSE_EFFECT XXX_2_Weakness 846-49-1 LORAZEPAM MECHANISM Modulate neural transmission 97964-56-2 LORGLUMIDE MODE_CLASS Receptor Ligand Antagonist 97964-56-2 LORGLUMIDE MECHANISM Modulate G-protein coupled signal transduction 70374-39-9 LORNOXICAM THERAPEUTIC_CLASS Immunosuppressants 70374-39-9 LORNOXICAM MECHANISM Inhibit eicosanoid biosynthesis 70374-39-9 LORNOXICAM PRODUCT_CLASS Immune Response / Immunomodulators 70374-39-9 LORNOXICAM INDICATION Arthritis 70374-39-9 LORNOXICAM MODE_CLASS Enzyme Inhibitor 70374-39-9 LORNOXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 114798-26-4 LOSARTAN ADVERSE_EFFECT NEU_2_Dizziness 114798-26-4 LOSARTAN ADVERSE_EFFECT PSY_3_Insomnia 114798-26-4 LOSARTAN INDICATION Heart Failure 114798-26-4 LOSARTAN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 114798-26-4 LOSARTAN MESH_LEVEL_3 Imidazoles 114798-26-4 LOSARTAN MECH_LEVEL_1 Vasorelaxation 114798-26-4 LOSARTAN TA_LEVEL_2 Hypertension 114798-26-4 LOSARTAN MESH_LEVEL_1 Heterocyclic Compounds 114798-26-4 LOSARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 114798-26-4 LOSARTAN ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 114798-26-4 LOSARTAN ADVERSE_EFFECT XXX_2_Nasal Congestion 114798-26-4 LOSARTAN ADVERSE_EFFECT XXX_3_Sinusitis 114798-26-4 LOSARTAN ADVERSE_EFFECT MSK_2_Myalgia 114798-26-4 LOSARTAN ADVERSE_EFFECT ELT_3_Hyponatremia 114798-26-4 LOSARTAN ADVERSE_EFFECT ELT_3_Hyperkalemia 114798-26-4 LOSARTAN ADVERSE_EFFECT EMB_3_Teratogenicity 114798-26-4 LOSARTAN THERAPEUTIC_CLASS Antihypertensive Agents 114798-26-4 LOSARTAN TISSUE_TOXICITY Teratogenicity 114798-26-4 LOSARTAN MECH_LEVEL_2 Diuretic 114798-26-4 LOSARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 114798-26-4 LOSARTAN ZERO_CLASS N 114798-26-4 LOSARTAN ADVERSE_EFFECT KID_3_Azotemia 114798-26-4 LOSARTAN ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 114798-26-4 LOSARTAN ADVERSE_EFFECT GIS_3_Dyspepsia 114798-26-4 LOSARTAN ADVERSE_EFFECT REP_3_Impotence 114798-26-4 LOSARTAN ADVERSE_EFFECT GIS_1_Diarrhea 114798-26-4 LOSARTAN KNOWN_TOXICITY Embryo/Fetal Toxicity 114798-26-4 LOSARTAN TA_LEVEL_3 Diuretic 114798-26-4 LOSARTAN INDICATION Proteinuria 114798-26-4 LOSARTAN ACTIVITY_CLASS RAAS inhibitor 114798-26-4 LOSARTAN ADVERSE_EFFECT IMU_3_Henoch-Schoenlein purpura 114798-26-4 LOSARTAN ADVERSE_EFFECT EMB_3_Oligohydramnios 114798-26-4 LOSARTAN ADVERSE_EFFECT MSK_3_Muscle Cramps 114798-26-4 LOSARTAN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 114798-26-4 LOSARTAN ADVERSE_EFFECT LUN_1_Cough 114798-26-4 LOSARTAN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 114798-26-4 LOSARTAN INDICATION Diabetic Nephropathy 114798-26-4 LOSARTAN PRODUCT_CLASS Cardiovasculars 114798-26-4 LOSARTAN INDICATION Hypertension 114798-26-4 LOSARTAN TA_LEVEL_1 Cardiovascular 114798-26-4 LOSARTAN MECH_LEVEL_3 angiotensin receptor AT1 114798-26-4 LOSARTAN ADVERSE_EFFECT IMU_3_Angioedema 114798-26-4 LOSARTAN MECHANISM Reduce vasoconstriction 114798-26-4 LOSARTAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 114798-26-4 LOSARTAN ADVERSE_EFFECT NEU_3_Syncope 114798-26-4 LOSARTAN ADVERSE_EFFECT MSK_3_Back Pain 114798-26-4 LOSARTAN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 124750-99-8 LOSARTAN TA_LEVEL_1 Cardiovascular 124750-99-8 LOSARTAN ADVERSE_EFFECT EMB_3_Oligohydramnios 124750-99-8 LOSARTAN ADVERSE_EFFECT IMU_3_Henoch-Schoenlein purpura 124750-99-8 LOSARTAN ACTIVITY_CLASS RAAS inhibitor 124750-99-8 LOSARTAN INDICATION Proteinuria 124750-99-8 LOSARTAN TA_LEVEL_3 Diuretic 124750-99-8 LOSARTAN KNOWN_TOXICITY Embryo/Fetal Toxicity 124750-99-8 LOSARTAN ADVERSE_EFFECT GIS_1_Diarrhea 124750-99-8 LOSARTAN ADVERSE_EFFECT REP_3_Impotence 124750-99-8 LOSARTAN ADVERSE_EFFECT IMU_3_Angioedema 124750-99-8 LOSARTAN ADVERSE_EFFECT GIS_3_Dyspepsia 124750-99-8 LOSARTAN ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 124750-99-8 LOSARTAN ADVERSE_EFFECT KID_3_Azotemia 124750-99-8 LOSARTAN ZERO_CLASS N 124750-99-8 LOSARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 124750-99-8 LOSARTAN MECH_LEVEL_2 Diuretic 124750-99-8 LOSARTAN ADVERSE_EFFECT EMB_3_Teratogenicity 124750-99-8 LOSARTAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 124750-99-8 LOSARTAN ADVERSE_EFFECT NEU_3_Syncope 124750-99-8 LOSARTAN ADVERSE_EFFECT MSK_3_Back Pain 124750-99-8 LOSARTAN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 124750-99-8 LOSARTAN ADVERSE_EFFECT NEU_2_Dizziness 124750-99-8 LOSARTAN ADVERSE_EFFECT PSY_3_Insomnia 124750-99-8 LOSARTAN INDICATION Heart Failure 124750-99-8 LOSARTAN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 124750-99-8 LOSARTAN MESH_LEVEL_3 Imidazoles 124750-99-8 LOSARTAN MECH_LEVEL_1 Vasorelaxation 124750-99-8 LOSARTAN TA_LEVEL_2 Hypertension 124750-99-8 LOSARTAN MESH_LEVEL_1 Heterocyclic Compounds 124750-99-8 LOSARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 124750-99-8 LOSARTAN MECHANISM Reduce vasoconstriction 124750-99-8 LOSARTAN ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 124750-99-8 LOSARTAN ADVERSE_EFFECT XXX_2_Nasal Congestion 124750-99-8 LOSARTAN TISSUE_TOXICITY Teratogenicity 124750-99-8 LOSARTAN THERAPEUTIC_CLASS Antihypertensive Agents 124750-99-8 LOSARTAN ADVERSE_EFFECT XXX_3_Sinusitis 124750-99-8 LOSARTAN ADVERSE_EFFECT MSK_2_Myalgia 124750-99-8 LOSARTAN ADVERSE_EFFECT ELT_3_Hyponatremia 124750-99-8 LOSARTAN MECH_LEVEL_3 angiotensin receptor AT1 124750-99-8 LOSARTAN ADVERSE_EFFECT ELT_3_Hyperkalemia 124750-99-8 LOSARTAN INDICATION Hypertension 124750-99-8 LOSARTAN PRODUCT_CLASS Cardiovasculars 124750-99-8 LOSARTAN INDICATION Diabetic Nephropathy 124750-99-8 LOSARTAN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 124750-99-8 LOSARTAN ADVERSE_EFFECT LUN_1_Cough 124750-99-8 LOSARTAN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 124750-99-8 LOSARTAN ADVERSE_EFFECT MSK_3_Muscle Cramps 82034-46-6 LOTEPREDNOL INDICATION Inflammatory Bowel Disease (IBD) 82034-46-6 LOTEPREDNOL MECHANISM Modulate gene transcription 82034-46-6 LOTEPREDNOL INDICATION Eczema Herpeticum 82034-46-6 LOTEPREDNOL INDICATION Viral Rhinitis / Common Cold 82034-46-6 LOTEPREDNOL MODE_CLASS Receptor Agonist 129260-79-3 LOTEPREDNOL INDICATION Inflammatory Bowel Disease (IBD) 129260-79-3 LOTEPREDNOL MODE_CLASS Receptor Agonist 129260-79-3 LOTEPREDNOL INDICATION Eczema Herpeticum 129260-79-3 LOTEPREDNOL MECHANISM Modulate gene transcription 129260-79-3 LOTEPREDNOL INDICATION Viral Rhinitis / Common Cold 1977-10-2 LOXAPINE MECHANISM Block neural transmission 1977-10-2 LOXAPINE MODE_CLASS Receptor Ligand Antagonist 1977-10-2 LOXAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 1977-10-2 LOXAPINE MECHANISM Modulate G-protein coupled signal transduction 117946-91-5 LUZINDOLE THERAPEUTIC_CLASS Antidepressants 117946-91-5 LUZINDOLE PRODUCT_CLASS Central Nervous System (CNS) 117946-91-5 LUZINDOLE INDICATION Depression 154447-36-6 LY-294002 PRODUCT_CLASS Anti-cancers 154447-36-6 LY-294002 MODE_CLASS Enzyme Inhibitor, selective 154447-36-6 LY-294002 THERAPEUTIC_CLASS Antineoplastics 154447-36-6 LY-294002 MECHANISM Modulate G-protein coupled signal transduction 129920-03-2 LY-233053 PRODUCT_CLASS Central Nervous System (CNS) 129920-03-2 LY-233053 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 129920-03-2 LY-233053 MECHANISM Modulate neural transmission 129920-03-2 LY-233053 MODE_CLASS Channel Modulator 129920-03-2 LY-233053 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 161172-51-6 LY-293111 THERAPEUTIC_CLASS Immunomodulants 161172-51-6 LY-293111 MECHANISM Modulate gene transcription 161172-51-6 LY-293111 INDICATION Psoriasis 161172-51-6 LY-293111 PRODUCT_CLASS Immune Response / Immunomodulators 161172-51-6 LY-293111 THERAPEUTIC_CLASS Psoralens 161172-51-6 LY-293111 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 161172-51-6 LY-293111 PRODUCT_CLASS Dermatologicals 161172-51-6 LY-293111 MODE_CLASS Receptor Ligand Antagonist, Selective 154652-83-2 LY-293558 MODE_CLASS Channel Blocker 154652-83-2 LY-293558 THERAPEUTIC_CLASS Analgesics, Non-Opioid 154652-83-2 LY-293558 INDICATION Cerebral Ischemia 154652-83-2 LY-293558 INDICATION Cerebral Infarction 154652-83-2 LY-293558 INDICATION Epilepsy 154652-83-2 LY-293558 THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 154652-83-2 LY-293558 PRODUCT_CLASS Analgesics 154652-83-2 LY-293558 INDICATION Pain 154652-83-2 LY-293558 MECHANISM Block neural transmission 154652-83-2 LY-293558 PRODUCT_CLASS Central Nervous System (CNS) 72509-76-3 FELODIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 72509-76-3 FELODIPINE THERAPEUTIC_CLASS Antianginals 72509-76-3 FELODIPINE THERAPEUTIC_CLASS Antihypertensive Agents 72509-76-3 FELODIPINE PRODUCT_CLASS Cardiovasculars 72509-76-3 FELODIPINE ADVERSE_EFFECT END_2_Gynecomastia 72509-76-3 FELODIPINE ADVERSE_EFFECT MSK_2_Arthralgia 72509-76-3 FELODIPINE ADVERSE_EFFECT GIS_2_Heartburn 72509-76-3 FELODIPINE ADVERSE_EFFECT GIS_2_Constipation 72509-76-3 FELODIPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 72509-76-3 FELODIPINE ADVERSE_EFFECT MSK_2_Muscle Cramps 72509-76-3 FELODIPINE ADVERSE_EFFECT XXX_2_Asthenia 72509-76-3 FELODIPINE ADVERSE_EFFECT XXX_2_Chills 72509-76-3 FELODIPINE ADVERSE_EFFECT LUN_2_Dyspnea 72509-76-3 FELODIPINE ADVERSE_EFFECT NEU_1_Dizziness 72509-76-3 FELODIPINE ADVERSE_EFFECT NEU_2_Sleep Disturbances 72509-76-3 FELODIPINE ADVERSE_EFFECT CVS_2_Angina 72509-76-3 FELODIPINE MODE_CLASS Channel Blocker 72509-76-3 FELODIPINE TISSUE_TOXICITY Angina 72509-76-3 FELODIPINE ADVERSE_EFFECT LUN_2_Cough 72509-76-3 FELODIPINE ADVERSE_EFFECT NEU_1_Syncope 72509-76-3 FELODIPINE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 72509-76-3 FELODIPINE ADVERSE_EFFECT XXX_1_Weakness 72509-76-3 FELODIPINE ADVERSE_EFFECT CVS_1_Hypotension 72509-76-3 FELODIPINE KNOWN_TOXICITY Cardiovascular Toxicity 72509-76-3 FELODIPINE TISSUE_TOXICITY Hypotension 72509-76-3 FELODIPINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 72509-76-3 FELODIPINE ADVERSE_EFFECT REP_3_Sexual Dysfunction 72509-76-3 FELODIPINE ADVERSE_EFFECT GIS_2_Diarrhea 72509-76-3 FELODIPINE INDICATION Hypertension 72509-76-3 FELODIPINE ADVERSE_EFFECT NEU_1_Lightheadedness 72509-76-3 FELODIPINE ADVERSE_EFFECT OCU_2_Visual Disturbances 72509-76-3 FELODIPINE MECHANISM Reduce muscle contractile force 72509-76-3 FELODIPINE INDICATION Angina Pectoris 72509-76-3 FELODIPINE ADVERSE_EFFECT XXX_1_Peripheral Edema 72509-76-3 FELODIPINE ADVERSE_EFFECT NEU_2_Paresthesia 72509-76-3 FELODIPINE ADVERSE_EFFECT SKN_1_Flushing 72509-76-3 FELODIPINE ADVERSE_EFFECT NEU_1_Headache 86189-69-7 FELODIPINE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 86189-69-7 FELODIPINE ADVERSE_EFFECT NEU_1_Syncope 86189-69-7 FELODIPINE PRODUCT_CLASS Cardiovasculars 86189-69-7 FELODIPINE TISSUE_TOXICITY Angina 86189-69-7 FELODIPINE MODE_CLASS Channel Blocker 86189-69-7 FELODIPINE ADVERSE_EFFECT GIS_2_Diarrhea 86189-69-7 FELODIPINE ADVERSE_EFFECT NEU_2_Sleep Disturbances 86189-69-7 FELODIPINE ADVERSE_EFFECT NEU_1_Dizziness 86189-69-7 FELODIPINE ADVERSE_EFFECT LUN_2_Dyspnea 86189-69-7 FELODIPINE ADVERSE_EFFECT XXX_2_Chills 86189-69-7 FELODIPINE ADVERSE_EFFECT XXX_2_Asthenia 86189-69-7 FELODIPINE MECHANISM Reduce muscle contractile force 86189-69-7 FELODIPINE INDICATION Hypertension 86189-69-7 FELODIPINE INDICATION Angina Pectoris 86189-69-7 FELODIPINE KNOWN_TOXICITY Cardiovascular Toxicity 86189-69-7 FELODIPINE TISSUE_TOXICITY Hypotension 86189-69-7 FELODIPINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 86189-69-7 FELODIPINE ADVERSE_EFFECT REP_3_Sexual Dysfunction 86189-69-7 FELODIPINE ADVERSE_EFFECT NEU_1_Headache 86189-69-7 FELODIPINE ADVERSE_EFFECT NEU_1_Lightheadedness 86189-69-7 FELODIPINE ADVERSE_EFFECT OCU_2_Visual Disturbances 86189-69-7 FELODIPINE ADVERSE_EFFECT MSK_2_Muscle Cramps 86189-69-7 FELODIPINE THERAPEUTIC_CLASS Antihypertensive Agents 86189-69-7 FELODIPINE THERAPEUTIC_CLASS Antianginals 86189-69-7 FELODIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 86189-69-7 FELODIPINE ADVERSE_EFFECT CVS_1_Hypotension 86189-69-7 FELODIPINE ADVERSE_EFFECT XXX_1_Weakness 86189-69-7 FELODIPINE ADVERSE_EFFECT LUN_2_Cough 86189-69-7 FELODIPINE ADVERSE_EFFECT END_2_Gynecomastia 86189-69-7 FELODIPINE ADVERSE_EFFECT MSK_2_Arthralgia 86189-69-7 FELODIPINE ADVERSE_EFFECT GIS_2_Heartburn 86189-69-7 FELODIPINE ADVERSE_EFFECT CVS_2_Angina 86189-69-7 FELODIPINE ADVERSE_EFFECT GIS_2_Constipation 86189-69-7 FELODIPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 86189-69-7 FELODIPINE ADVERSE_EFFECT SKN_1_Flushing 86189-69-7 FELODIPINE ADVERSE_EFFECT NEU_2_Paresthesia 86189-69-7 FELODIPINE ADVERSE_EFFECT XXX_1_Peripheral Edema 16105-77-4 FENFLURAMINE ADVERSE_EFFECT XXX_3_Fever 16105-77-4 FENFLURAMINE ADVERSE_EFFECT LUN_3_Pulmonary Hypertension 16105-77-4 FENFLURAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 16105-77-4 FENFLURAMINE THERAPEUTIC_CLASS Anorexiants 16105-77-4 FENFLURAMINE MECHANISM Prolong/enhance neural transmission 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GIS_3_Dysgeusia 16105-77-4 FENFLURAMINE ADVERSE_EFFECT NEU_3_Headache 16105-77-4 FENFLURAMINE ADVERSE_EFFECT XXX_3_Weakness 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GIS_2_Constipation 16105-77-4 FENFLURAMINE KNOWN_TOXICITY Cardiovascular Toxicity 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Vivid Dreams 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GIS_1_Diarrhea 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Anxiety 16105-77-4 FENFLURAMINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 16105-77-4 FENFLURAMINE ADVERSE_EFFECT NEU_1_Drowsiness 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GUS_3_Urinary Frequency 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Mental Depression 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Confusion 16105-77-4 FENFLURAMINE PRODUCT_CLASS Central Nervous System (CNS) 16105-77-4 FENFLURAMINE TISSUE_TOXICITY Cardiac Valvular Malfunction 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Insomnia 16105-77-4 FENFLURAMINE ADVERSE_EFFECT REP_3_Impotence 16105-77-4 FENFLURAMINE ADVERSE_EFFECT NEU_3_Dizziness 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Agitation 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GUS_3_Dysuria 16105-77-4 FENFLURAMINE ADVERSE_EFFECT NEU_3_Dysarthria 16105-77-4 FENFLURAMINE ADVERSE_EFFECT REP_3_Altered Libido 16105-77-4 FENFLURAMINE MODE_CLASS Solute transporter inhibitor 16105-77-4 FENFLURAMINE INDICATION Obesity 16105-77-4 FENFLURAMINE ADVERSE_EFFECT CVS_3_Chest Pain 16105-77-4 FENFLURAMINE ADVERSE_EFFECT PSY_3_Nightmares 16105-77-4 FENFLURAMINE ADVERSE_EFFECT XXX_1_Xerostomia 16105-77-4 FENFLURAMINE ADVERSE_EFFECT CVS_3_Cardiac Valvular Malfunction 16105-77-4 FENFLURAMINE ADVERSE_EFFECT NEU_3_Autonomic Nervous System Effects 16105-77-4 FENFLURAMINE ADVERSE_EFFECT CVS_3_Cardiac Disturbances 16105-77-4 FENFLURAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 67227-56-9 FENOLDOPAM PRODUCT_CLASS Cardiovasculars 67227-56-9 FENOLDOPAM THERAPEUTIC_CLASS Antihypertensive Agents 67227-56-9 FENOLDOPAM MODE_CLASS Receptor Agonist, selective 67227-56-9 FENOLDOPAM MECHANISM Prolong/enhance neural transmission 67227-56-9 FENOLDOPAM INDICATION Hypertensive Emergency 67227-56-9 FENOLDOPAM MODE_CLASS Receptor Agonist 67227-56-9 FENOLDOPAM MECHANISM Modulate G-protein coupled signal transduction 67227-56-9 FENOLDOPAM INDICATION Malignant Hypertension 53746-45-5 FENOPROFEN MECH_LEVEL_1 Immunomodulation 53746-45-5 FENOPROFEN TA_LEVEL_3 NSAID 53746-45-5 FENOPROFEN TA_LEVEL_1 Anti-inflammatory 53746-45-5 FENOPROFEN ADVERSE_EFFECT OCU_2_Blurred Vision 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 53746-45-5 FENOPROFEN ADVERSE_EFFECT BBM_3_Agranulocytosis 53746-45-5 FENOPROFEN ADVERSE_EFFECT XXX_1_Lethargy 53746-45-5 FENOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 53746-45-5 FENOPROFEN ADVERSE_EFFECT KID_3_Hematuria 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_2_Abdominal Pain 53746-45-5 FENOPROFEN ADVERSE_EFFECT KID_3_Interstitial Nephritis 53746-45-5 FENOPROFEN ZERO_CLASS N 53746-45-5 FENOPROFEN ACTIVITY_CLASS Anti-inflammatory 53746-45-5 FENOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 53746-45-5 FENOPROFEN INDICATION Osteoarthritis 53746-45-5 FENOPROFEN KNOWN_TOXICITY Nephrotoxicity 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_1_Constipation 53746-45-5 FENOPROFEN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 53746-45-5 FENOPROFEN ADVERSE_EFFECT OTO_2_Tinnitus 53746-45-5 FENOPROFEN ADVERSE_EFFECT PSY_2_Confusion 53746-45-5 FENOPROFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 53746-45-5 FENOPROFEN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 53746-45-5 FENOPROFEN ADVERSE_EFFECT CVS_2_Palpitation 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_3_Dysphagia 53746-45-5 FENOPROFEN INDICATION Pain 53746-45-5 FENOPROFEN TA_LEVEL_2 NSAID 53746-45-5 FENOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 53746-45-5 FENOPROFEN PRODUCT_CLASS Anti-inflammatories 53746-45-5 FENOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 53746-45-5 FENOPROFEN TISSUE_TOXICITY Interstitial Nephritis 53746-45-5 FENOPROFEN MODE_CLASS Enzyme Inhibitor 53746-45-5 FENOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 53746-45-5 FENOPROFEN ADVERSE_EFFECT PSY_2_Insomnia 53746-45-5 FENOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 53746-45-5 FENOPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 53746-45-5 FENOPROFEN ADVERSE_EFFECT LUN_1_Dyspnea 53746-45-5 FENOPROFEN ADVERSE_EFFECT BBM_3_Aplastic Anemia 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_3_Melena 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_2_Flatulence 53746-45-5 FENOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 53746-45-5 FENOPROFEN MESH_LEVEL_1 Organic Chemicals 53746-45-5 FENOPROFEN INDICATION Rheumatoid Arthritis 53746-45-5 FENOPROFEN MESH_LEVEL_2 Carboxylic Acids 53746-45-5 FENOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 53746-45-5 FENOPROFEN TISSUE_TOXICITY Hematuria 53746-45-5 FENOPROFEN ADVERSE_EFFECT PSY_2_Anorexia 53746-45-5 FENOPROFEN ADVERSE_EFFECT NEU_1_Headache 53746-45-5 FENOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 53746-45-5 FENOPROFEN ADVERSE_EFFECT SKN_2_Maculopapular Rash 53746-45-5 FENOPROFEN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 53746-45-5 FENOPROFEN ADVERSE_EFFECT OTO_2_Hearing Loss 53746-45-5 FENOPROFEN ADVERSE_EFFECT GIS_3_Esophagitis 53746-45-5 FENOPROFEN ADVERSE_EFFECT KID_3_Azotemia 31879-05-7 FENOPROFEN ZERO_CLASS N 31879-05-7 FENOPROFEN ADVERSE_EFFECT KID_3_Interstitial Nephritis 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_2_Abdominal Pain 31879-05-7 FENOPROFEN ADVERSE_EFFECT KID_3_Hematuria 31879-05-7 FENOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 31879-05-7 FENOPROFEN ADVERSE_EFFECT XXX_1_Lethargy 31879-05-7 FENOPROFEN ADVERSE_EFFECT BBM_3_Agranulocytosis 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 31879-05-7 FENOPROFEN ADVERSE_EFFECT OCU_2_Blurred Vision 31879-05-7 FENOPROFEN TA_LEVEL_3 NSAID 31879-05-7 FENOPROFEN ACTIVITY_CLASS Anti-inflammatory 31879-05-7 FENOPROFEN MECH_LEVEL_1 Immunomodulation 31879-05-7 FENOPROFEN TA_LEVEL_1 Anti-inflammatory 31879-05-7 FENOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 31879-05-7 FENOPROFEN INDICATION Osteoarthritis 31879-05-7 FENOPROFEN KNOWN_TOXICITY Nephrotoxicity 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_1_Constipation 31879-05-7 FENOPROFEN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 31879-05-7 FENOPROFEN ADVERSE_EFFECT OTO_2_Tinnitus 31879-05-7 FENOPROFEN ADVERSE_EFFECT PSY_2_Confusion 31879-05-7 FENOPROFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 31879-05-7 FENOPROFEN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 31879-05-7 FENOPROFEN ADVERSE_EFFECT CVS_2_Palpitation 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_3_Dysphagia 31879-05-7 FENOPROFEN INDICATION Pain 31879-05-7 FENOPROFEN TA_LEVEL_2 NSAID 31879-05-7 FENOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 31879-05-7 FENOPROFEN PRODUCT_CLASS Anti-inflammatories 31879-05-7 FENOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 31879-05-7 FENOPROFEN TISSUE_TOXICITY Interstitial Nephritis 31879-05-7 FENOPROFEN MODE_CLASS Enzyme Inhibitor 31879-05-7 FENOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 31879-05-7 FENOPROFEN ADVERSE_EFFECT PSY_2_Insomnia 31879-05-7 FENOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 31879-05-7 FENOPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 31879-05-7 FENOPROFEN ADVERSE_EFFECT LUN_1_Dyspnea 31879-05-7 FENOPROFEN ADVERSE_EFFECT BBM_3_Aplastic Anemia 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_3_Melena 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_2_Flatulence 31879-05-7 FENOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 31879-05-7 FENOPROFEN MESH_LEVEL_1 Organic Chemicals 31879-05-7 FENOPROFEN INDICATION Rheumatoid Arthritis 31879-05-7 FENOPROFEN MESH_LEVEL_2 Carboxylic Acids 31879-05-7 FENOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 31879-05-7 FENOPROFEN TISSUE_TOXICITY Hematuria 31879-05-7 FENOPROFEN ADVERSE_EFFECT PSY_2_Anorexia 31879-05-7 FENOPROFEN ADVERSE_EFFECT NEU_1_Headache 31879-05-7 FENOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 31879-05-7 FENOPROFEN ADVERSE_EFFECT SKN_2_Maculopapular Rash 31879-05-7 FENOPROFEN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 31879-05-7 FENOPROFEN ADVERSE_EFFECT OTO_2_Hearing Loss 31879-05-7 FENOPROFEN ADVERSE_EFFECT GIS_3_Esophagitis 31879-05-7 FENOPROFEN ADVERSE_EFFECT KID_3_Azotemia 34597-40-5 FENOPROFEN ADVERSE_EFFECT OTO_2_Tinnitus 34597-40-5 FENOPROFEN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_1_Constipation 34597-40-5 FENOPROFEN KNOWN_TOXICITY Nephrotoxicity 34597-40-5 FENOPROFEN INDICATION Osteoarthritis 34597-40-5 FENOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 34597-40-5 FENOPROFEN MESH_LEVEL_1 Organic Chemicals 34597-40-5 FENOPROFEN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 34597-40-5 FENOPROFEN INDICATION Rheumatoid Arthritis 34597-40-5 FENOPROFEN MESH_LEVEL_2 Carboxylic Acids 34597-40-5 FENOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 34597-40-5 FENOPROFEN TISSUE_TOXICITY Hematuria 34597-40-5 FENOPROFEN ADVERSE_EFFECT PSY_2_Anorexia 34597-40-5 FENOPROFEN ADVERSE_EFFECT NEU_1_Headache 34597-40-5 FENOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 34597-40-5 FENOPROFEN ADVERSE_EFFECT SKN_2_Maculopapular Rash 34597-40-5 FENOPROFEN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 34597-40-5 FENOPROFEN ADVERSE_EFFECT OTO_2_Hearing Loss 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_3_Esophagitis 34597-40-5 FENOPROFEN ADVERSE_EFFECT KID_3_Azotemia 34597-40-5 FENOPROFEN MECH_LEVEL_1 Immunomodulation 34597-40-5 FENOPROFEN TA_LEVEL_3 NSAID 34597-40-5 FENOPROFEN TA_LEVEL_1 Anti-inflammatory 34597-40-5 FENOPROFEN ADVERSE_EFFECT OCU_2_Blurred Vision 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 34597-40-5 FENOPROFEN ADVERSE_EFFECT BBM_3_Agranulocytosis 34597-40-5 FENOPROFEN ADVERSE_EFFECT XXX_1_Lethargy 34597-40-5 FENOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 34597-40-5 FENOPROFEN ADVERSE_EFFECT KID_3_Hematuria 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_2_Abdominal Pain 34597-40-5 FENOPROFEN ADVERSE_EFFECT KID_3_Interstitial Nephritis 34597-40-5 FENOPROFEN ZERO_CLASS N 34597-40-5 FENOPROFEN ACTIVITY_CLASS Anti-inflammatory 34597-40-5 FENOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_2_Flatulence 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_3_Melena 34597-40-5 FENOPROFEN ADVERSE_EFFECT BBM_3_Aplastic Anemia 34597-40-5 FENOPROFEN ADVERSE_EFFECT LUN_1_Dyspnea 34597-40-5 FENOPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 34597-40-5 FENOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 34597-40-5 FENOPROFEN ADVERSE_EFFECT PSY_2_Insomnia 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 34597-40-5 FENOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 34597-40-5 FENOPROFEN MODE_CLASS Enzyme Inhibitor 34597-40-5 FENOPROFEN TISSUE_TOXICITY Interstitial Nephritis 34597-40-5 FENOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 34597-40-5 FENOPROFEN PRODUCT_CLASS Anti-inflammatories 34597-40-5 FENOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 34597-40-5 FENOPROFEN TA_LEVEL_2 NSAID 34597-40-5 FENOPROFEN INDICATION Pain 34597-40-5 FENOPROFEN ADVERSE_EFFECT GIS_3_Dysphagia 34597-40-5 FENOPROFEN ADVERSE_EFFECT CVS_2_Palpitation 34597-40-5 FENOPROFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 34597-40-5 FENOPROFEN ADVERSE_EFFECT PSY_2_Confusion 34691-31-1 FENOPROFEN ADVERSE_EFFECT OTO_2_Hearing Loss 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 34691-31-1 FENOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 34691-31-1 FENOPROFEN MESH_LEVEL_2 Carboxylic Acids 34691-31-1 FENOPROFEN MODE_CLASS Enzyme Inhibitor 34691-31-1 FENOPROFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 34691-31-1 FENOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 34691-31-1 FENOPROFEN INDICATION Osteoarthritis 34691-31-1 FENOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 34691-31-1 FENOPROFEN TISSUE_TOXICITY Hematuria 34691-31-1 FENOPROFEN ADVERSE_EFFECT PSY_2_Anorexia 34691-31-1 FENOPROFEN ADVERSE_EFFECT NEU_1_Headache 34691-31-1 FENOPROFEN ADVERSE_EFFECT SKN_2_Pruritis 34691-31-1 FENOPROFEN ADVERSE_EFFECT SKN_2_Maculopapular Rash 34691-31-1 FENOPROFEN KNOWN_TOXICITY Nephrotoxicity 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_1_Constipation 34691-31-1 FENOPROFEN TISSUE_TOXICITY Interstitial Nephritis 34691-31-1 FENOPROFEN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 34691-31-1 FENOPROFEN ADVERSE_EFFECT KID_3_Interstitial Nephritis 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_3_Esophagitis 34691-31-1 FENOPROFEN TA_LEVEL_3 NSAID 34691-31-1 FENOPROFEN MECH_LEVEL_1 Immunomodulation 34691-31-1 FENOPROFEN MESH_LEVEL_1 Organic Chemicals 34691-31-1 FENOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_2_Flatulence 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_3_Melena 34691-31-1 FENOPROFEN ADVERSE_EFFECT BBM_3_Aplastic Anemia 34691-31-1 FENOPROFEN INDICATION Rheumatoid Arthritis 34691-31-1 FENOPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 34691-31-1 FENOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 34691-31-1 FENOPROFEN PRODUCT_CLASS Anti-inflammatories 34691-31-1 FENOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 34691-31-1 FENOPROFEN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 34691-31-1 FENOPROFEN ADVERSE_EFFECT OTO_2_Tinnitus 34691-31-1 FENOPROFEN ADVERSE_EFFECT PSY_2_Confusion 34691-31-1 FENOPROFEN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 34691-31-1 FENOPROFEN ADVERSE_EFFECT CVS_2_Palpitation 34691-31-1 FENOPROFEN ACTIVITY_CLASS Anti-inflammatory 34691-31-1 FENOPROFEN ZERO_CLASS N 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_2_Abdominal Pain 34691-31-1 FENOPROFEN ADVERSE_EFFECT KID_3_Hematuria 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_3_Dysphagia 34691-31-1 FENOPROFEN INDICATION Pain 34691-31-1 FENOPROFEN TA_LEVEL_2 NSAID 34691-31-1 FENOPROFEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 34691-31-1 FENOPROFEN ADVERSE_EFFECT XXX_1_Lethargy 34691-31-1 FENOPROFEN ADVERSE_EFFECT BBM_3_Agranulocytosis 34691-31-1 FENOPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 34691-31-1 FENOPROFEN ADVERSE_EFFECT OCU_2_Blurred Vision 34691-31-1 FENOPROFEN TA_LEVEL_1 Anti-inflammatory 34691-31-1 FENOPROFEN ADVERSE_EFFECT LUN_1_Dyspnea 34691-31-1 FENOPROFEN ADVERSE_EFFECT KID_3_Azotemia 34691-31-1 FENOPROFEN ADVERSE_EFFECT NEU_2_Dizziness 34691-31-1 FENOPROFEN ADVERSE_EFFECT PSY_2_Insomnia 437-38-7 FENTANYL ADVERSE_EFFECT CVS_2_Tachycardia 437-38-7 FENTANYL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 437-38-7 FENTANYL ADVERSE_EFFECT GIS_2_Hyperamylasemia 437-38-7 FENTANYL MODE_CLASS Receptor Agonist 437-38-7 FENTANYL MECHANISM Modulate neural transmission 437-38-7 FENTANYL THERAPEUTIC_CLASS Analgesics, Opioid 437-38-7 FENTANYL ADVERSE_EFFECT CVS_2_Bradycardia 437-38-7 FENTANYL ADVERSE_EFFECT GIS_1_Constipation 437-38-7 FENTANYL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 437-38-7 FENTANYL ADVERSE_EFFECT REP_3_Decreased Libido 437-38-7 FENTANYL ADVERSE_EFFECT NEU_3_Antimuscarinic effects 437-38-7 FENTANYL ADVERSE_EFFECT SKN_1_Pruritis 437-38-7 FENTANYL ADVERSE_EFFECT SKN_3_Skin Irritation 437-38-7 FENTANYL ADVERSE_EFFECT CVS_2_Palpitation 437-38-7 FENTANYL ADVERSE_EFFECT CVS_1_Chest Wall Rigidity 437-38-7 FENTANYL ADVERSE_EFFECT SKN_3_Rash 437-38-7 FENTANYL ADVERSE_EFFECT CVS_2_Hypotension 437-38-7 FENTANYL ADVERSE_EFFECT LUN_2_Respiratory Depression 437-38-7 FENTANYL TISSUE_TOXICITY Hypotension 437-38-7 FENTANYL INDICATION Induction / Maintenance of Anesthesia 437-38-7 FENTANYL INDICATION Severe Pain 437-38-7 FENTANYL ADVERSE_EFFECT CVS_2_Hypertension 437-38-7 FENTANYL ADVERSE_EFFECT XXX_2_Diaphoresis 437-38-7 FENTANYL ADVERSE_EFFECT CVS_3_Chest Pain 437-38-7 FENTANYL ADVERSE_EFFECT REP_3_Amenorrhea 437-38-7 FENTANYL PRODUCT_CLASS Analgesics 437-38-7 FENTANYL INDICATION Pain 437-38-7 FENTANYL THERAPEUTIC_CLASS General Anesthetics, Intravenous 437-38-7 FENTANYL KNOWN_TOXICITY Cardiovascular Toxicity 437-38-7 FENTANYL ADVERSE_EFFECT XXX_3_Tolerance 437-38-7 FENTANYL ADVERSE_EFFECT REP_3_Infertility 437-38-7 FENTANYL ADVERSE_EFFECT NEU_3_Syncope 437-38-7 FENTANYL ADVERSE_EFFECT BIL_2_Spasm of Sphincter of Oddi 437-38-7 FENTANYL PRODUCT_CLASS Central Nervous System (CNS) 437-38-7 FENTANYL INDICATION Initiation / Maintenance of Sedation 437-38-7 FENTANYL ADVERSE_EFFECT GUS_2_Urinary Retention 437-38-7 FENTANYL ADVERSE_EFFECT NEU_2_Sedation 437-38-7 FENTANYL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 437-38-7 FENTANYL ADVERSE_EFFECT XXX_3_Withdrawal 72479-26-6 FENTICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 72479-26-6 FENTICONAZOLE PRODUCT_CLASS Anti-infectives 72479-26-6 FENTICONAZOLE MODE_CLASS Enzyme Inhibitor 72479-26-6 FENTICONAZOLE THERAPEUTIC_CLASS Antifungals 73151-29-8 FENTICONAZOLE THERAPEUTIC_CLASS Antifungals 73151-29-8 FENTICONAZOLE MODE_CLASS Enzyme Inhibitor 73151-29-8 FENTICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 73151-29-8 FENTICONAZOLE PRODUCT_CLASS Anti-infectives 1185-57-5 FERRIC AMMONIUM CITRATE PRODUCT_CLASS Vitamins, Minerals and Nutrients 1333-00-2 FERRIC AMMONIUM CITRATE PRODUCT_CLASS Vitamins, Minerals and Nutrients 15226-45-6 FERRIC AMMONIUM CITRATE PRODUCT_CLASS Vitamins, Minerals and Nutrients 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_3_Esophagitis 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT PSY_2_Anorexia 141-01-5 FERROUS FUMARATE INDICATION Iron Deficiency Anemia 141-01-5 FERROUS FUMARATE PRODUCT_CLASS Vitamins, Minerals and Nutrients 141-01-5 FERROUS FUMARATE MECHANISM Vitamin/ cofactor 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_2_Dysphagia 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_2_Oral Ulceration 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_3_Esophageal Ulceration 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_1_Abdominal Pain 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_2_Diarrhea 141-01-5 FERROUS FUMARATE STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 141-01-5 FERROUS FUMARATE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT PSN_3_Iron Toxicity 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT END_3_Hemosiderosis 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_1_Constipation 141-01-5 FERROUS FUMARATE THERAPEUTIC_CLASS Hematopoietic Agents 141-01-5 FERROUS FUMARATE INDICATION Nutritional Supplement 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT GIS_1_Dyspepsia 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT END_3_Hemochromatosis 141-01-5 FERROUS FUMARATE ADVERSE_EFFECT XXX_2_Tooth Discoloration 141-01-5 FERROUS FUMARATE INDICATION Anemia 138452-21-8 FEXOFENADINE INDICATION Allergic Rhinitis 138452-21-8 FEXOFENADINE ADVERSE_EFFECT PSY_3_Insomnia 138452-21-8 FEXOFENADINE ADVERSE_EFFECT SKN_3_Flushing 138452-21-8 FEXOFENADINE ADVERSE_EFFECT SKN_3_Pruritis 138452-21-8 FEXOFENADINE ADVERSE_EFFECT GIS_1_Dyspepsia 138452-21-8 FEXOFENADINE INDICATION Urticaria / Hives 138452-21-8 FEXOFENADINE INDICATION Allergic Conjunctivitis 138452-21-8 FEXOFENADINE ADVERSE_EFFECT NEU_3_Sleep Disturbances 138452-21-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Hypersensitivity 138452-21-8 FEXOFENADINE ADVERSE_EFFECT LUN_3_Dyspnea 138452-21-8 FEXOFENADINE INDICATION Viral Rhinitis / Common Cold 138452-21-8 FEXOFENADINE THERAPEUTIC_CLASS Antihistamines 138452-21-8 FEXOFENADINE MODE_CLASS Receptor Ligand Antagonist, Selective 138452-21-8 FEXOFENADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 138452-21-8 FEXOFENADINE ADVERSE_EFFECT XXX_1_Fatigue 138452-21-8 FEXOFENADINE ADVERSE_EFFECT NEU_1_Drowsiness 138452-21-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Urticaria 138452-21-8 FEXOFENADINE ADVERSE_EFFECT XXX_3_Chest Tightness 138452-21-8 FEXOFENADINE PRODUCT_CLASS Anti-inflammatories 138452-21-8 FEXOFENADINE MECHANISM Modulate G-protein coupled signal transduction 138452-21-8 FEXOFENADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 138452-21-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Anaphylaxis 138452-21-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Angioedema 138452-21-8 FEXOFENADINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 138452-21-8 FEXOFENADINE ADVERSE_EFFECT PSY_3_Nervousness 83799-24-0 FEXOFENADINE INDICATION Allergic Conjunctivitis 83799-24-0 FEXOFENADINE INDICATION Allergic Rhinitis 83799-24-0 FEXOFENADINE ADVERSE_EFFECT PSY_3_Insomnia 83799-24-0 FEXOFENADINE ADVERSE_EFFECT SKN_3_Flushing 83799-24-0 FEXOFENADINE ADVERSE_EFFECT SKN_3_Pruritis 83799-24-0 FEXOFENADINE ADVERSE_EFFECT GIS_1_Dyspepsia 83799-24-0 FEXOFENADINE INDICATION Urticaria / Hives 83799-24-0 FEXOFENADINE ADVERSE_EFFECT PSY_3_Nervousness 83799-24-0 FEXOFENADINE ADVERSE_EFFECT NEU_3_Sleep Disturbances 83799-24-0 FEXOFENADINE ADVERSE_EFFECT IMU_3_Hypersensitivity 83799-24-0 FEXOFENADINE ADVERSE_EFFECT LUN_3_Dyspnea 83799-24-0 FEXOFENADINE INDICATION Viral Rhinitis / Common Cold 83799-24-0 FEXOFENADINE THERAPEUTIC_CLASS Antihistamines 83799-24-0 FEXOFENADINE MODE_CLASS Receptor Ligand Antagonist, Selective 83799-24-0 FEXOFENADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 83799-24-0 FEXOFENADINE ADVERSE_EFFECT XXX_1_Fatigue 83799-24-0 FEXOFENADINE ADVERSE_EFFECT NEU_1_Drowsiness 83799-24-0 FEXOFENADINE ADVERSE_EFFECT IMU_3_Urticaria 83799-24-0 FEXOFENADINE ADVERSE_EFFECT XXX_3_Chest Tightness 83799-24-0 FEXOFENADINE MECHANISM Modulate G-protein coupled signal transduction 83799-24-0 FEXOFENADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83799-24-0 FEXOFENADINE ADVERSE_EFFECT IMU_3_Anaphylaxis 83799-24-0 FEXOFENADINE ADVERSE_EFFECT IMU_3_Angioedema 83799-24-0 FEXOFENADINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 83799-24-0 FEXOFENADINE PRODUCT_CLASS Anti-inflammatories 153439-40-8 FEXOFENADINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 153439-40-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Angioedema 153439-40-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Anaphylaxis 153439-40-8 FEXOFENADINE ADVERSE_EFFECT NEU_1_Drowsiness 153439-40-8 FEXOFENADINE ADVERSE_EFFECT PSY_3_Insomnia 153439-40-8 FEXOFENADINE INDICATION Allergic Conjunctivitis 153439-40-8 FEXOFENADINE INDICATION Allergic Rhinitis 153439-40-8 FEXOFENADINE ADVERSE_EFFECT SKN_3_Flushing 153439-40-8 FEXOFENADINE ADVERSE_EFFECT SKN_3_Pruritis 153439-40-8 FEXOFENADINE ADVERSE_EFFECT GIS_1_Dyspepsia 153439-40-8 FEXOFENADINE INDICATION Urticaria / Hives 153439-40-8 FEXOFENADINE ADVERSE_EFFECT PSY_3_Nervousness 153439-40-8 FEXOFENADINE ADVERSE_EFFECT NEU_3_Sleep Disturbances 153439-40-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Hypersensitivity 153439-40-8 FEXOFENADINE ADVERSE_EFFECT LUN_3_Dyspnea 153439-40-8 FEXOFENADINE INDICATION Viral Rhinitis / Common Cold 153439-40-8 FEXOFENADINE THERAPEUTIC_CLASS Antihistamines 153439-40-8 FEXOFENADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 153439-40-8 FEXOFENADINE ADVERSE_EFFECT XXX_1_Fatigue 153439-40-8 FEXOFENADINE ADVERSE_EFFECT IMU_3_Urticaria 153439-40-8 FEXOFENADINE ADVERSE_EFFECT XXX_3_Chest Tightness 153439-40-8 FEXOFENADINE PRODUCT_CLASS Anti-inflammatories 153439-40-8 FEXOFENADINE MECHANISM Modulate G-protein coupled signal transduction 153439-40-8 FEXOFENADINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 153439-40-8 FEXOFENADINE MODE_CLASS Receptor Ligand Antagonist, Selective 98319-25-7 FINASTERIDE MODE_CLASS Enzyme Inhibitor 98319-25-7 FINASTERIDE ADVERSE_EFFECT XXX_2_Breast Enlargement 98319-25-7 FINASTERIDE THERAPEUTIC_CLASS Gonadal Hormones 98319-25-7 FINASTERIDE ADVERSE_EFFECT SKN_2_Pruritis 98319-25-7 FINASTERIDE MESH_LEVEL_2 Steroids 98319-25-7 FINASTERIDE TA_LEVEL_2 Steroid Modulation 98319-25-7 FINASTERIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 98319-25-7 FINASTERIDE ADVERSE_EFFECT REP_1_Erectile Dysfunction 98319-25-7 FINASTERIDE ADVERSE_EFFECT END_2_Breast Tenderness 98319-25-7 FINASTERIDE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 98319-25-7 FINASTERIDE MODE_CLASS Enzyme Inhibitor, selective 98319-25-7 FINASTERIDE INDICATION Androgenetic Alopecia (Male Pattern Hair Loss) 98319-25-7 FINASTERIDE ADVERSE_EFFECT REP_1_Ejaculatory Disorder 98319-25-7 FINASTERIDE ADVERSE_EFFECT IMU_2_Urticaria 98319-25-7 FINASTERIDE ZERO_CLASS N 98319-25-7 FINASTERIDE MECH_LEVEL_2 Steroid Reductase Inhibitor 98319-25-7 FINASTERIDE ACTIVITY_CLASS Androgen antagonist 98319-25-7 FINASTERIDE INDICATION Benign Prostatic Hyperplasia (BPH) 98319-25-7 FINASTERIDE MESH_LEVEL_3 Androstanes 98319-25-7 FINASTERIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 98319-25-7 FINASTERIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 98319-25-7 FINASTERIDE TA_LEVEL_3 Male pattern baldness/BPH 98319-25-7 FINASTERIDE STRUCTURE_ACTIVITY Androgen antagonist, steroid 5a-reductase inhibitor 98319-25-7 FINASTERIDE MECH_LEVEL_1 Androgenic 98319-25-7 FINASTERIDE ADVERSE_EFFECT REP_2_Testicular Pain 98319-25-7 FINASTERIDE ADVERSE_EFFECT REP_1_Decreased Libido 98319-25-7 FINASTERIDE ADVERSE_EFFECT SKN_2_Rash 98319-25-7 FINASTERIDE MECH_LEVEL_3 steroid Type II 5(alpha)-reductase 98319-25-7 FINASTERIDE MESH_LEVEL_1 Polycyclic Hydrocarbons 98319-26-7 FINASTERIDE ADVERSE_EFFECT XXX_2_Breast Enlargement 98319-26-7 FINASTERIDE MODE_CLASS Enzyme Inhibitor 98319-26-7 FINASTERIDE MESH_LEVEL_1 Polycyclic Hydrocarbons 98319-26-7 FINASTERIDE MECH_LEVEL_3 steroid Type II 5(alpha)-reductase 98319-26-7 FINASTERIDE STRUCTURE_ACTIVITY Androgen antagonist, steroid 5a-reductase inhibitor 98319-26-7 FINASTERIDE ADVERSE_EFFECT SKN_2_Rash 98319-26-7 FINASTERIDE ADVERSE_EFFECT REP_1_Decreased Libido 98319-26-7 FINASTERIDE MECH_LEVEL_1 Androgenic 98319-26-7 FINASTERIDE TA_LEVEL_3 Male pattern baldness/BPH 98319-26-7 FINASTERIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 98319-26-7 FINASTERIDE MESH_LEVEL_3 Androstanes 98319-26-7 FINASTERIDE INDICATION Benign Prostatic Hyperplasia (BPH) 98319-26-7 FINASTERIDE ACTIVITY_CLASS Androgen antagonist 98319-26-7 FINASTERIDE MECH_LEVEL_2 Steroid Reductase Inhibitor 98319-26-7 FINASTERIDE ZERO_CLASS N 98319-26-7 FINASTERIDE ADVERSE_EFFECT IMU_2_Urticaria 98319-26-7 FINASTERIDE ADVERSE_EFFECT REP_1_Ejaculatory Disorder 98319-26-7 FINASTERIDE INDICATION Androgenetic Alopecia (Male Pattern Hair Loss) 98319-26-7 FINASTERIDE THERAPEUTIC_CLASS Gonadal Hormones 98319-26-7 FINASTERIDE MODE_CLASS Enzyme Inhibitor, selective 98319-26-7 FINASTERIDE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 98319-26-7 FINASTERIDE ADVERSE_EFFECT REP_1_Erectile Dysfunction 98319-26-7 FINASTERIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 98319-26-7 FINASTERIDE ADVERSE_EFFECT REP_2_Testicular Pain 98319-26-7 FINASTERIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 98319-26-7 FINASTERIDE TA_LEVEL_2 Steroid Modulation 98319-26-7 FINASTERIDE MESH_LEVEL_2 Steroids 98319-26-7 FINASTERIDE ADVERSE_EFFECT SKN_2_Pruritis 98319-26-7 FINASTERIDE ADVERSE_EFFECT END_2_Breast Tenderness 138449-07-7 FK-888 PRODUCT_CLASS Central Nervous System (CNS) 138449-07-7 FK-888 INDICATION Migraine Headache 138449-07-7 FK-888 THERAPEUTIC_CLASS Antimigraines 15301-69-6 FLAVOXATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 15301-69-6 FLAVOXATE STRUCTURE_ACTIVITY Unknown mechanism 15301-69-6 FLAVOXATE THERAPEUTIC_CLASS Antispasmodic Agents 15301-69-6 FLAVOXATE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 15301-69-6 FLAVOXATE INDICATION Urinary Urgency 15301-69-6 FLAVOXATE MECHANISM Modulate G-protein coupled signal transduction 15301-69-6 FLAVOXATE TA_LEVEL_1 Autonomic Nervous System (ANS) 15301-69-6 FLAVOXATE MESH_LEVEL_1 Heterocyclic Compounds 15301-69-6 FLAVOXATE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 15301-69-6 FLAVOXATE ADVERSE_EFFECT CVS_2_Palpitation 15301-69-6 FLAVOXATE ADVERSE_EFFECT OCU_2_Visual Impairment 15301-69-6 FLAVOXATE ADVERSE_EFFECT NEU_2_Headache 15301-69-6 FLAVOXATE ADVERSE_EFFECT GIS_3_Constipation 15301-69-6 FLAVOXATE INDICATION Dysuria 15301-69-6 FLAVOXATE PRODUCT_CLASS Autonomic Nervous System (ANS) 15301-69-6 FLAVOXATE INDICATION Nocturia 15301-69-6 FLAVOXATE ADVERSE_EFFECT OCU_3_Photophobia 15301-69-6 FLAVOXATE ADVERSE_EFFECT GIS_3_Abdominal Pain 15301-69-6 FLAVOXATE ADVERSE_EFFECT NEU_3_Vertigo 15301-69-6 FLAVOXATE ADVERSE_EFFECT NEU_3_Drowsiness 15301-69-6 FLAVOXATE ADVERSE_EFFECT PSY_2_Nervousness 15301-69-6 FLAVOXATE MODE_CLASS Receptor Ligand Antagonist 15301-69-6 FLAVOXATE INDICATION Urinary Incontinence / Enuresis 15301-69-6 FLAVOXATE TA_LEVEL_2 Antispasmodic Agents 15301-69-6 FLAVOXATE MECH_LEVEL_2 Unknown mechanism 15301-69-6 FLAVOXATE MECH_LEVEL_3 Unknown mechanism 15301-69-6 FLAVOXATE ADVERSE_EFFECT IMU_3_Eosinophilia 15301-69-6 FLAVOXATE ADVERSE_EFFECT PSY_3_Mental Confusion 15301-69-6 FLAVOXATE ADVERSE_EFFECT IMU_3_Urticaria 15301-69-6 FLAVOXATE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 15301-69-6 FLAVOXATE ACTIVITY_CLASS Unknown mechanism 15301-69-6 FLAVOXATE TA_LEVEL_3 Antispasmodics, urinary tract 15301-69-6 FLAVOXATE INDICATION Urinary Tract Infection (UTI) 15301-69-6 FLAVOXATE MESH_LEVEL_3 Benzopyrans 15301-69-6 FLAVOXATE ZERO_CLASS Y 15301-69-6 FLAVOXATE ADVERSE_EFFECT XXX_2_Xerostomia 15301-69-6 FLAVOXATE ADVERSE_EFFECT GUS_3_Dysuria 15301-69-6 FLAVOXATE ADVERSE_EFFECT XXX_3_Hyperpyrexia 3717-88-2 FLAVOXATE ADVERSE_EFFECT GUS_3_Dysuria 3717-88-2 FLAVOXATE ADVERSE_EFFECT XXX_3_Hyperpyrexia 3717-88-2 FLAVOXATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3717-88-2 FLAVOXATE STRUCTURE_ACTIVITY Unknown mechanism 3717-88-2 FLAVOXATE THERAPEUTIC_CLASS Antispasmodic Agents 3717-88-2 FLAVOXATE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 3717-88-2 FLAVOXATE INDICATION Urinary Urgency 3717-88-2 FLAVOXATE MECHANISM Modulate G-protein coupled signal transduction 3717-88-2 FLAVOXATE TA_LEVEL_1 Autonomic Nervous System (ANS) 3717-88-2 FLAVOXATE MESH_LEVEL_1 Heterocyclic Compounds 3717-88-2 FLAVOXATE ADVERSE_EFFECT XXX_2_Xerostomia 3717-88-2 FLAVOXATE ADVERSE_EFFECT GIS_3_Constipation 3717-88-2 FLAVOXATE ADVERSE_EFFECT NEU_2_Headache 3717-88-2 FLAVOXATE ADVERSE_EFFECT OCU_2_Visual Impairment 3717-88-2 FLAVOXATE ADVERSE_EFFECT CVS_2_Palpitation 3717-88-2 FLAVOXATE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 3717-88-2 FLAVOXATE ZERO_CLASS Y 3717-88-2 FLAVOXATE MECH_LEVEL_2 Unknown mechanism 3717-88-2 FLAVOXATE MECH_LEVEL_3 Unknown mechanism 3717-88-2 FLAVOXATE ADVERSE_EFFECT IMU_3_Eosinophilia 3717-88-2 FLAVOXATE ADVERSE_EFFECT PSY_3_Mental Confusion 3717-88-2 FLAVOXATE ADVERSE_EFFECT IMU_3_Urticaria 3717-88-2 FLAVOXATE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 3717-88-2 FLAVOXATE ACTIVITY_CLASS Unknown mechanism 3717-88-2 FLAVOXATE TA_LEVEL_3 Antispasmodics, urinary tract 3717-88-2 FLAVOXATE INDICATION Urinary Tract Infection (UTI) 3717-88-2 FLAVOXATE MESH_LEVEL_3 Benzopyrans 3717-88-2 FLAVOXATE ADVERSE_EFFECT GIS_3_Abdominal Pain 3717-88-2 FLAVOXATE INDICATION Dysuria 3717-88-2 FLAVOXATE PRODUCT_CLASS Autonomic Nervous System (ANS) 3717-88-2 FLAVOXATE INDICATION Nocturia 3717-88-2 FLAVOXATE ADVERSE_EFFECT OCU_3_Photophobia 3717-88-2 FLAVOXATE ADVERSE_EFFECT NEU_3_Vertigo 3717-88-2 FLAVOXATE ADVERSE_EFFECT NEU_3_Drowsiness 3717-88-2 FLAVOXATE ADVERSE_EFFECT PSY_2_Nervousness 3717-88-2 FLAVOXATE MODE_CLASS Receptor Ligand Antagonist 3717-88-2 FLAVOXATE INDICATION Urinary Incontinence / Enuresis 3717-88-2 FLAVOXATE TA_LEVEL_2 Antispasmodic Agents 54143-55-4 FLECAINIDE TISSUE_TOXICITY Ventricular Tachycardia 54143-55-4 FLECAINIDE TISSUE_TOXICITY Angina 54143-55-4 FLECAINIDE ADVERSE_EFFECT GIS_2_Constipation 54143-55-4 FLECAINIDE ADVERSE_EFFECT PSY_2_Anorexia 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_3_Tremor 54143-55-4 FLECAINIDE ADVERSE_EFFECT SKN_2_Flushing 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_2_Paresthesia 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Heart Block 54143-55-4 FLECAINIDE TISSUE_TOXICITY Heart Block 54143-55-4 FLECAINIDE ADVERSE_EFFECT XXX_2_Reduced Sweating 54143-55-4 FLECAINIDE ADVERSE_EFFECT PSY_2_Anxiety 54143-55-4 FLECAINIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_1_Dizziness 54143-55-4 FLECAINIDE ADVERSE_EFFECT OTO_2_Tinnitus 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_2_Ataxia 54143-55-4 FLECAINIDE TISSUE_TOXICITY Cardiac Arrhythmia 54143-55-4 FLECAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 54143-55-4 FLECAINIDE MECHANISM Block neural transmission 54143-55-4 FLECAINIDE INDICATION Paroxysmal Supraventricular Tachycardia 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_2_Syncope 54143-55-4 FLECAINIDE ADVERSE_EFFECT XXX_1_Asthenia 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Palpitation 54143-55-4 FLECAINIDE ADVERSE_EFFECT LUN_3_Dyspnea 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_1_Headache 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Angina 54143-55-4 FLECAINIDE ADVERSE_EFFECT PSY_2_Insomnia 54143-55-4 FLECAINIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 54143-55-4 FLECAINIDE ADVERSE_EFFECT PSY_2_Depression 54143-55-4 FLECAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 54143-55-4 FLECAINIDE TISSUE_TOXICITY Cardiac Failure 54143-55-4 FLECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 54143-55-4 FLECAINIDE PRODUCT_CLASS Cardiovasculars 54143-55-4 FLECAINIDE INDICATION Wolff-Parkinson-White (WPW) Syndrome 54143-55-4 FLECAINIDE TISSUE_TOXICITY Ventricular Fibrillation 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Cardiac Failure 54143-55-4 FLECAINIDE TISSUE_TOXICITY First-Degree AV block 54143-55-4 FLECAINIDE INDICATION Cardiac Arrhythmias 54143-55-4 FLECAINIDE MODE_CLASS Channel Blocker 54143-55-4 FLECAINIDE ADVERSE_EFFECT GIS_2_Diarrhea 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 54143-55-4 FLECAINIDE ADVERSE_EFFECT XXX_1_Fatigue 54143-55-4 FLECAINIDE ADVERSE_EFFECT XXX_2_Edema 54143-55-4 FLECAINIDE ADVERSE_EFFECT SKN_2_Rash 54143-55-4 FLECAINIDE ADVERSE_EFFECT OCU_2_Diplopia 54143-55-4 FLECAINIDE ADVERSE_EFFECT NEU_2_Vertigo 54143-55-4 FLECAINIDE ADVERSE_EFFECT GIS_2_Dyspepsia 54143-55-4 FLECAINIDE ADVERSE_EFFECT CVS_1_First-Degree AV block 54143-55-4 FLECAINIDE INDICATION Ventricular Tachycardia Prophylaxis 54143-55-4 FLECAINIDE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 54143-55-4 FLECAINIDE ADVERSE_EFFECT OCU_3_Visual Impairment 54143-56-5 FLECAINIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 54143-56-5 FLECAINIDE ADVERSE_EFFECT PSY_2_Anxiety 54143-56-5 FLECAINIDE ADVERSE_EFFECT XXX_2_Reduced Sweating 54143-56-5 FLECAINIDE TISSUE_TOXICITY Heart Block 54143-56-5 FLECAINIDE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 54143-56-5 FLECAINIDE INDICATION Ventricular Tachycardia Prophylaxis 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_1_First-Degree AV block 54143-56-5 FLECAINIDE ADVERSE_EFFECT GIS_2_Dyspepsia 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_2_Vertigo 54143-56-5 FLECAINIDE ADVERSE_EFFECT SKN_2_Rash 54143-56-5 FLECAINIDE ADVERSE_EFFECT XXX_2_Edema 54143-56-5 FLECAINIDE ADVERSE_EFFECT XXX_1_Fatigue 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 54143-56-5 FLECAINIDE ADVERSE_EFFECT GIS_2_Diarrhea 54143-56-5 FLECAINIDE MODE_CLASS Channel Blocker 54143-56-5 FLECAINIDE INDICATION Cardiac Arrhythmias 54143-56-5 FLECAINIDE TISSUE_TOXICITY First-Degree AV block 54143-56-5 FLECAINIDE TISSUE_TOXICITY Ventricular Fibrillation 54143-56-5 FLECAINIDE INDICATION Wolff-Parkinson-White (WPW) Syndrome 54143-56-5 FLECAINIDE PRODUCT_CLASS Cardiovasculars 54143-56-5 FLECAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 54143-56-5 FLECAINIDE ADVERSE_EFFECT XXX_1_Asthenia 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Cardiac Failure 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Heart Block 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_2_Paresthesia 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 54143-56-5 FLECAINIDE ADVERSE_EFFECT SKN_2_Flushing 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_3_Tremor 54143-56-5 FLECAINIDE ADVERSE_EFFECT PSY_2_Anorexia 54143-56-5 FLECAINIDE ADVERSE_EFFECT GIS_2_Constipation 54143-56-5 FLECAINIDE TISSUE_TOXICITY Angina 54143-56-5 FLECAINIDE TISSUE_TOXICITY Ventricular Tachycardia 54143-56-5 FLECAINIDE ADVERSE_EFFECT OCU_2_Diplopia 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_2_Syncope 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Palpitation 54143-56-5 FLECAINIDE ADVERSE_EFFECT LUN_3_Dyspnea 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_1_Headache 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Angina 54143-56-5 FLECAINIDE ADVERSE_EFFECT PSY_2_Insomnia 54143-56-5 FLECAINIDE ADVERSE_EFFECT PSY_2_Depression 54143-56-5 FLECAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 54143-56-5 FLECAINIDE TISSUE_TOXICITY Cardiac Failure 54143-56-5 FLECAINIDE TISSUE_TOXICITY Cardiac Arrhythmia 54143-56-5 FLECAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 54143-56-5 FLECAINIDE MECHANISM Block neural transmission 54143-56-5 FLECAINIDE INDICATION Paroxysmal Supraventricular Tachycardia 54143-56-5 FLECAINIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 54143-56-5 FLECAINIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 54143-56-5 FLECAINIDE ADVERSE_EFFECT OCU_3_Visual Impairment 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_2_Ataxia 54143-56-5 FLECAINIDE ADVERSE_EFFECT OTO_2_Tinnitus 54143-56-5 FLECAINIDE ADVERSE_EFFECT NEU_1_Dizziness 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT LIV_3_Hepatic Injury 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT NEU_2_Dizziness 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT GIS_1_Nausea 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT BBM_3_Thrombocytopenia 86386-73-4 FLUCONAZOLE THERAPEUTIC_CLASS Antifungals, Systemic 86386-73-4 FLUCONAZOLE TA_LEVEL_3 systemic 86386-73-4 FLUCONAZOLE MECH_LEVEL_1 Anti-fungal 86386-73-4 FLUCONAZOLE INDICATION Disseminated Candidiasis 86386-73-4 FLUCONAZOLE INDICATION Candidal Esophagitis 86386-73-4 FLUCONAZOLE INDICATION Oropharyngeal Candidiasis 86386-73-4 FLUCONAZOLE MESH_LEVEL_3 Azoles 86386-73-4 FLUCONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT BBM_3_Neutropenia 86386-73-4 FLUCONAZOLE ZERO_CLASS N 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT XXX_2_Taste Disturbances 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 86386-73-4 FLUCONAZOLE INDICATION Candidemia 86386-73-4 FLUCONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) 86386-73-4 FLUCONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 86386-73-4 FLUCONAZOLE TA_LEVEL_1 Infectious Disease 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT SKN_2_Rash 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT IMU_3_Angioedema 86386-73-4 FLUCONAZOLE MODE_CLASS Enzyme Inhibitor 86386-73-4 FLUCONAZOLE INDICATION Peritonitis 86386-73-4 FLUCONAZOLE TA_LEVEL_2 Anti-fungal 86386-73-4 FLUCONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 86386-73-4 FLUCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 86386-73-4 FLUCONAZOLE ACTIVITY_CLASS Antifungals azole 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT BBM_3_Leukopenia 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT NEU_3_Seizures 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT GIS_2_Dyspepsia 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT NEU_1_Headache 86386-73-4 FLUCONAZOLE ADVERSE_EFFECT BBM_3_Anemia 86386-73-4 FLUCONAZOLE INDICATION Vaginal Candidiasis 86386-73-4 FLUCONAZOLE PRODUCT_CLASS Anti-infectives 86386-73-4 FLUCONAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 86386-73-4 FLUCONAZOLE INDICATION Candida Urinary Tract Infection 2022-85-7 FLUCYTOSINE MECHANISM Inhibit protein synthesis 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT PSY_2_Anorexia 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT BBM_2_Agranulocytosis 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT BBM_2_Anemia 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT LIV_2_Jaundice 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT LIV_2_Increased Serum Alkaline Phosphatase 2022-85-7 FLUCYTOSINE INDICATION Disseminated Candidiasis 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT IMU_3_Hypersensitivity 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 2022-85-7 FLUCYTOSINE INDICATION Cryptococcosis 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT GIS_2_Abdominal Pain 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT NEU_2_Lightheadedness 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT BBM_2_Leukopenia 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT BBM_2_Pancytopenia 2022-85-7 FLUCYTOSINE INDICATION Sporothrix Schenckii 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT SKN_2_Pruritis 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT NEU_2_Headache 2022-85-7 FLUCYTOSINE THERAPEUTIC_CLASS Antifungals, Systemic 2022-85-7 FLUCYTOSINE INDICATION Candidiasis 2022-85-7 FLUCYTOSINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT BBM_2_Bone Marrow Hypoplasia 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT IMU_3_Photosensitivity 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT SKN_2_Erythema 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT NEU_2_Dizziness 2022-85-7 FLUCYTOSINE ADVERSE_EFFECT GIS_2_Diarrhea 2022-85-7 FLUCYTOSINE INDICATION Phialophora sp 2022-85-7 FLUCYTOSINE PRODUCT_CLASS Anti-infectives 21679-14-1 FLUDARABINE THERAPEUTIC_CLASS Antineoplastics 21679-14-1 FLUDARABINE MODE_CLASS Enzyme substrate mimic 21679-14-1 FLUDARABINE TISSUE_TOXICITY Tumor Lysis Syndrome 21679-14-1 FLUDARABINE TISSUE_TOXICITY Thrombocytopenia 21679-14-1 FLUDARABINE ADVERSE_EFFECT LUN_2_Pneumonia 21679-14-1 FLUDARABINE ADVERSE_EFFECT BBM_1_Myelosuppression 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_1_Infection 21679-14-1 FLUDARABINE ADVERSE_EFFECT IMU_3_Anaphylaxis 21679-14-1 FLUDARABINE ADVERSE_EFFECT END_3_Hyperglycemia 21679-14-1 FLUDARABINE INDICATION Chronic Lymphocytic Leukemia (CLL) 21679-14-1 FLUDARABINE PRODUCT_CLASS Anti-cancers 21679-14-1 FLUDARABINE ADVERSE_EFFECT GUS_3_Hemorrhagic Cystitis 21679-14-1 FLUDARABINE ADVERSE_EFFECT BBM_1_Neutropenia 21679-14-1 FLUDARABINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 21679-14-1 FLUDARABINE ADVERSE_EFFECT NEU_2_Coma 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_2_Fatigue 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_1_Fever 21679-14-1 FLUDARABINE TISSUE_TOXICITY Anemia 21679-14-1 FLUDARABINE MECHANISM Incorporate into DNA/RNA/Protein 21679-14-1 FLUDARABINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_1_Tumor Lysis Syndrome 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_1_Chills 21679-14-1 FLUDARABINE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_2_Weakness 21679-14-1 FLUDARABINE ADVERSE_EFFECT GIS_1_Nausea 21679-14-1 FLUDARABINE KNOWN_TOXICITY Miscellaneous 21679-14-1 FLUDARABINE TISSUE_TOXICITY Myelosuppression 21679-14-1 FLUDARABINE TISSUE_TOXICITY Neutropenia 21679-14-1 FLUDARABINE ADVERSE_EFFECT XXX_3_Mucositis 21679-14-1 FLUDARABINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 21679-14-1 FLUDARABINE ADVERSE_EFFECT BBM_1_Anemia 21679-14-1 FLUDARABINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 21679-14-1 FLUDARABINE ADVERSE_EFFECT GIS_1_Vomiting 21679-14-1 FLUDARABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 21679-14-1 FLUDARABINE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 514-36-3 FLUDROCORTISONE ACETATE ACTIVITY_CLASS GR-MR agonist 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT ELT_3_Hypokalemia 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT CVS_3_Heart Failure 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT CVS_3_Hypertension 514-36-3 FLUDROCORTISONE ACETATE ZERO_CLASS N 514-36-3 FLUDROCORTISONE ACETATE INDICATION Primary Adrenal Insufficiency 514-36-3 FLUDROCORTISONE ACETATE INDICATION Congenital Adrenal Hyperplasia 514-36-3 FLUDROCORTISONE ACETATE MECHANISM Modulate gene transcription 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT ELT_3_Fluid and Electrolyte Disturbance 514-36-3 FLUDROCORTISONE ACETATE MESH_LEVEL_1 Polycyclic Hydrocarbons 514-36-3 FLUDROCORTISONE ACETATE MESH_LEVEL_3 Pregnanes 514-36-3 FLUDROCORTISONE ACETATE MECH_LEVEL_1 Hormone replacement 514-36-3 FLUDROCORTISONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 514-36-3 FLUDROCORTISONE ACETATE TA_LEVEL_3 Systemic steroid 514-36-3 FLUDROCORTISONE ACETATE MECH_LEVEL_3 Mineralocorticoid receptor 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT IMU_3_Anaphylaxis 514-36-3 FLUDROCORTISONE ACETATE MECH_LEVEL_2 Adrenocortical insufficiency 514-36-3 FLUDROCORTISONE ACETATE MESH_LEVEL_2 Steroids 514-36-3 FLUDROCORTISONE ACETATE INDICATION Secondary Adrenal Insufficiency 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT XXX_3_Edema 514-36-3 FLUDROCORTISONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 514-36-3 FLUDROCORTISONE ACETATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT NEU_3_Dizziness 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT END_3_Metabolic Alkalosis 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 514-36-3 FLUDROCORTISONE ACETATE STRUCTURE_ACTIVITY Mineralocorticoid receptor agonist 514-36-3 FLUDROCORTISONE ACETATE TA_LEVEL_2 Steroid 514-36-3 FLUDROCORTISONE ACETATE THERAPEUTIC_CLASS Corticosteroids, Systemic 514-36-3 FLUDROCORTISONE ACETATE TISSUE_TOXICITY Heart Failure 514-36-3 FLUDROCORTISONE ACETATE MODE_CLASS Receptor Agonist 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT PSY_3_Anorexia 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT XXX_3_Weakness 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT IMU_3_Allergic Reactions 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT MSK_3_Muscle Cramps 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT CVS_3_ST-T Wave Changes 514-36-3 FLUDROCORTISONE ACETATE ADVERSE_EFFECT NEU_3_Headache 78755-81-4 FLUMAZENIL ADVERSE_EFFECT OCU_2_Abnormal Vision 78755-81-4 FLUMAZENIL INDICATION Reversal of Benzodiazepine Sedation 78755-81-4 FLUMAZENIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 78755-81-4 FLUMAZENIL ADVERSE_EFFECT XXX_3_Death 78755-81-4 FLUMAZENIL ADVERSE_EFFECT PSY_2_Agitation 78755-81-4 FLUMAZENIL ADVERSE_EFFECT NEU_3_Somnolence 78755-81-4 FLUMAZENIL TISSUE_TOXICITY Cardiac Arrhythmia 78755-81-4 FLUMAZENIL THERAPEUTIC_CLASS Antidotes 78755-81-4 FLUMAZENIL KNOWN_TOXICITY Cardiovascular Toxicity 78755-81-4 FLUMAZENIL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 78755-81-4 FLUMAZENIL ADVERSE_EFFECT NEU_2_Paresthesia 78755-81-4 FLUMAZENIL ADVERSE_EFFECT PSY_3_Confusion 78755-81-4 FLUMAZENIL ADVERSE_EFFECT LUN_3_Dysphonia 78755-81-4 FLUMAZENIL MECHANISM Modulate neural transmission 78755-81-4 FLUMAZENIL TISSUE_TOXICITY Death 78755-81-4 FLUMAZENIL KNOWN_TOXICITY Miscellaneous 78755-81-4 FLUMAZENIL MODE_CLASS Channel enhancer /opener 78755-81-4 FLUMAZENIL ADVERSE_EFFECT OCU_2_Blurred Vision 78755-81-4 FLUMAZENIL ADVERSE_EFFECT OTO_3_Tinnitus 78755-81-4 FLUMAZENIL ADVERSE_EFFECT NEU_1_Ataxia 78755-81-4 FLUMAZENIL ADVERSE_EFFECT PSY_2_Emotional Lability 78755-81-4 FLUMAZENIL ADVERSE_EFFECT OTO_3_Hyperacusis 78755-81-4 FLUMAZENIL INDICATION Benzodiazepine Overdose 78755-81-4 FLUMAZENIL PRODUCT_CLASS Central Nervous System (CNS) 78755-81-4 FLUMAZENIL STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 78755-81-4 FLUMAZENIL ADVERSE_EFFECT XXX_1_Sweating 78755-81-4 FLUMAZENIL ADVERSE_EFFECT NEU_1_Headache 78755-81-4 FLUMAZENIL ADVERSE_EFFECT NEU_2_Seizures 78755-81-4 FLUMAZENIL ADVERSE_EFFECT NEU_1_Vertigo 30484-77-6 FLUNARIZINE TA_LEVEL_3 Antiarrhythmic Agents 30484-77-6 FLUNARIZINE MESH_LEVEL_3 Piperazines 30484-77-6 FLUNARIZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 30484-77-6 FLUNARIZINE PRODUCT_CLASS Central Nervous System (CNS) 30484-77-6 FLUNARIZINE INDICATION Migraine Headache 30484-77-6 FLUNARIZINE INDICATION Gilles De La Tourette's Syndrome / Tourette's Syndrome / Motor Tics 30484-77-6 FLUNARIZINE MECH_LEVEL_3 Voltage-gated Na+ channel, Ca++ channel 30484-77-6 FLUNARIZINE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 30484-77-6 FLUNARIZINE ADVERSE_EFFECT PSY_3_Insomnia 30484-77-6 FLUNARIZINE ADVERSE_EFFECT SKN_3_Skin Reactions 30484-77-6 FLUNARIZINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 30484-77-6 FLUNARIZINE MECHANISM Block channel gating 30484-77-6 FLUNARIZINE INDICATION Epilepsy 30484-77-6 FLUNARIZINE MECH_LEVEL_1 Modulate neural transmission 30484-77-6 FLUNARIZINE MECHANISM Block neural transmission 30484-77-6 FLUNARIZINE PRODUCT_CLASS Cardiovasculars 30484-77-6 FLUNARIZINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 30484-77-6 FLUNARIZINE ACTIVITY_CLASS Ca++ channel (T-Type) blocker 30484-77-6 FLUNARIZINE ADVERSE_EFFECT PSY_3_Depression 30484-77-6 FLUNARIZINE ADVERSE_EFFECT NEU_3_Akathisia 30484-77-6 FLUNARIZINE ADVERSE_EFFECT XXX_3_Asthenia 30484-77-6 FLUNARIZINE INDICATION Chronic Venous Insufficiency 30484-77-6 FLUNARIZINE THERAPEUTIC_CLASS Vasodilators 30484-77-6 FLUNARIZINE ADVERSE_EFFECT GIS_3_Constipation 30484-77-6 FLUNARIZINE ADVERSE_EFFECT NEU_3_Dyskinesia 30484-77-6 FLUNARIZINE ADVERSE_EFFECT NEU_2_Somnolence 30484-77-6 FLUNARIZINE MESH_LEVEL_1 Heterocyclic Compounds 30484-77-6 FLUNARIZINE TA_LEVEL_1 Cardiovascular 30484-77-6 FLUNARIZINE MECH_LEVEL_2 Sodium channel antagonist 30484-77-6 FLUNARIZINE MODE_CLASS Channel Blocker 30484-77-6 FLUNARIZINE INDICATION Vertigo 30484-77-6 FLUNARIZINE ZERO_CLASS N 30484-77-6 FLUNARIZINE ADVERSE_EFFECT GIS_3_Diarrhea 30484-77-6 FLUNARIZINE ADVERSE_EFFECT GIS_3_Nausea 30484-77-6 FLUNARIZINE ADVERSE_EFFECT GIS_3_Epigastric Pain 30484-77-6 FLUNARIZINE MECHANISM Reduce muscle contractile force 52468-60-7 FLUNARIZINE MECHANISM Reduce muscle contractile force 52468-60-7 FLUNARIZINE MODE_CLASS Channel Blocker 52468-60-7 FLUNARIZINE MESH_LEVEL_3 Piperazines 52468-60-7 FLUNARIZINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 52468-60-7 FLUNARIZINE PRODUCT_CLASS Central Nervous System (CNS) 52468-60-7 FLUNARIZINE INDICATION Migraine Headache 52468-60-7 FLUNARIZINE INDICATION Gilles De La Tourette's Syndrome / Tourette's Syndrome / Motor Tics 52468-60-7 FLUNARIZINE MECH_LEVEL_3 Voltage-gated Na+ channel, Ca++ channel 52468-60-7 FLUNARIZINE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 52468-60-7 FLUNARIZINE ADVERSE_EFFECT PSY_3_Insomnia 52468-60-7 FLUNARIZINE ADVERSE_EFFECT SKN_3_Skin Reactions 52468-60-7 FLUNARIZINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 52468-60-7 FLUNARIZINE MECHANISM Block channel gating 52468-60-7 FLUNARIZINE INDICATION Epilepsy 52468-60-7 FLUNARIZINE MECH_LEVEL_1 Modulate neural transmission 52468-60-7 FLUNARIZINE MECHANISM Block neural transmission 52468-60-7 FLUNARIZINE PRODUCT_CLASS Cardiovasculars 52468-60-7 FLUNARIZINE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 52468-60-7 FLUNARIZINE ACTIVITY_CLASS Ca++ channel (T-Type) blocker 52468-60-7 FLUNARIZINE ADVERSE_EFFECT PSY_3_Depression 52468-60-7 FLUNARIZINE THERAPEUTIC_CLASS Vasodilators 52468-60-7 FLUNARIZINE ADVERSE_EFFECT NEU_3_Akathisia 52468-60-7 FLUNARIZINE ADVERSE_EFFECT XXX_3_Asthenia 52468-60-7 FLUNARIZINE INDICATION Chronic Venous Insufficiency 52468-60-7 FLUNARIZINE ADVERSE_EFFECT NEU_2_Somnolence 52468-60-7 FLUNARIZINE ADVERSE_EFFECT NEU_3_Dyskinesia 52468-60-7 FLUNARIZINE MESH_LEVEL_1 Heterocyclic Compounds 52468-60-7 FLUNARIZINE TA_LEVEL_1 Cardiovascular 52468-60-7 FLUNARIZINE MECH_LEVEL_2 Sodium channel antagonist 52468-60-7 FLUNARIZINE INDICATION Vertigo 52468-60-7 FLUNARIZINE ADVERSE_EFFECT GIS_3_Constipation 52468-60-7 FLUNARIZINE TA_LEVEL_3 Antiarrhythmic Agents 52468-60-7 FLUNARIZINE ZERO_CLASS N 52468-60-7 FLUNARIZINE ADVERSE_EFFECT GIS_3_Diarrhea 52468-60-7 FLUNARIZINE ADVERSE_EFFECT GIS_3_Nausea 52468-60-7 FLUNARIZINE ADVERSE_EFFECT GIS_3_Epigastric Pain 77326-96-6 FLUNISOLIDE INDICATION Allergic Rhinitis 77326-96-6 FLUNISOLIDE PRODUCT_CLASS Anti-inflammatories 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT END_3_Growth Inhibition 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_2_Oral Candidiasis 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_1_Nasal Dryness 77326-96-6 FLUNISOLIDE INDICATION Asthma 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT SKN_3_Flushing 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT OCU_3_Cataracts 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_1_Nasal Irritation 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_2_Nasal Congestion 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT BBM_3_Purpura 77326-96-6 FLUNISOLIDE MECHANISM Modulate gene transcription 77326-96-6 FLUNISOLIDE MODE_CLASS Receptor Agonist 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT LUN_2_Cough 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT LUN_3_Pulmonary Infiltrates 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT LUN_3_Dysphonia 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_1_Throat Irritation 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_3_Impaired Wound Healing 77326-96-6 FLUNISOLIDE THERAPEUTIC_CLASS Corticosteroids 77326-96-6 FLUNISOLIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT GIS_1_Dry Mouth 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT LUN_3_Bronchospasm 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT END_3_Cushing's Syndrome 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT XXX_2_Sneezing 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 77326-96-6 FLUNISOLIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_1_Nasal Irritation 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_2_Nasal Congestion 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT BBM_3_Purpura 3385-03-3 FLUNISOLIDE MECHANISM Modulate gene transcription 3385-03-3 FLUNISOLIDE MODE_CLASS Receptor Agonist 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT LUN_3_Pulmonary Infiltrates 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT LUN_3_Dysphonia 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_1_Throat Irritation 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_3_Impaired Wound Healing 3385-03-3 FLUNISOLIDE PRODUCT_CLASS Anti-inflammatories 3385-03-3 FLUNISOLIDE THERAPEUTIC_CLASS Corticosteroids 3385-03-3 FLUNISOLIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT GIS_1_Dry Mouth 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT LUN_3_Bronchospasm 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT END_3_Cushing's Syndrome 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_2_Sneezing 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 3385-03-3 FLUNISOLIDE INDICATION Allergic Rhinitis 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT LUN_2_Cough 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT END_3_Growth Inhibition 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_2_Oral Candidiasis 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT XXX_1_Nasal Dryness 3385-03-3 FLUNISOLIDE INDICATION Asthma 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT SKN_3_Flushing 3385-03-3 FLUNISOLIDE ADVERSE_EFFECT OCU_3_Cataracts 1622-62-4 FLUNITRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 1622-62-4 FLUNITRAZEPAM INDICATION Insomnia 1622-62-4 FLUNITRAZEPAM MECHANISM Modulate neural transmission 1622-62-4 FLUNITRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 1622-62-4 FLUNITRAZEPAM MODE_CLASS Channel enhancer /opener 1622-62-4 FLUNITRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_2_Skin Atrophy 356-12-7 FLUOCINONIDE ADVERSE_EFFECT XXX_2_Impaired Wound Healing 356-12-7 FLUOCINONIDE ADVERSE_EFFECT END_3_Hyperglycemia 356-12-7 FLUOCINONIDE ADVERSE_EFFECT IMU_2_Contact Dermatitis 356-12-7 FLUOCINONIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 356-12-7 FLUOCINONIDE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 356-12-7 FLUOCINONIDE ADVERSE_EFFECT END_3_Adrenal Insufficiency 356-12-7 FLUOCINONIDE PRODUCT_CLASS Dermatologicals 356-12-7 FLUOCINONIDE THERAPEUTIC_CLASS Corticosteroids, Topical 356-12-7 FLUOCINONIDE ADVERSE_EFFECT XXX_3_Withdrawal 356-12-7 FLUOCINONIDE ADVERSE_EFFECT XXX_3_Infection 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_3_Skin Ulcer 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_2_Vesicular Rash 356-12-7 FLUOCINONIDE INDICATION Skin Diseases / Dermatoses 356-12-7 FLUOCINONIDE ADVERSE_EFFECT XXX_3_Tolerance 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_2_Erythema 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_3_Hypertrichosis 356-12-7 FLUOCINONIDE ADVERSE_EFFECT XXX_2_Miliaria 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 356-12-7 FLUOCINONIDE MODE_CLASS Receptor Agonist 356-12-7 FLUOCINONIDE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 356-12-7 FLUOCINONIDE ADVERSE_EFFECT END_3_Cushing's Syndrome 356-12-7 FLUOCINONIDE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 356-12-7 FLUOCINONIDE ADVERSE_EFFECT XXX_3_Xerosis 356-12-7 FLUOCINONIDE INDICATION Pruritus / Itching 356-12-7 FLUOCINONIDE INDICATION Dermatitis 356-12-7 FLUOCINONIDE MECHANISM Modulate gene transcription 356-12-7 FLUOCINONIDE ADVERSE_EFFECT CVS_3_Telangiectasia 356-12-7 FLUOCINONIDE ADVERSE_EFFECT SKN_2_Acneiform Rash 518-47-8 FLUORESCEIN INDICATION Corneal Wound / Trauma 518-47-8 FLUORESCEIN ADVERSE_EFFECT GIS_3_Dry Mouth 518-47-8 FLUORESCEIN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 518-47-8 FLUORESCEIN INDICATION Retinoblastoma 518-47-8 FLUORESCEIN ADVERSE_EFFECT XXX_3_Sneezing 518-47-8 FLUORESCEIN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 518-47-8 FLUORESCEIN INDICATION Macular Degeneration 518-47-8 FLUORESCEIN ADVERSE_EFFECT IMU_3_Hives 518-47-8 FLUORESCEIN ADVERSE_EFFECT NEU_3_Dizziness 518-47-8 FLUORESCEIN ADVERSE_EFFECT SKN_3_Skin Discoloration 518-47-8 FLUORESCEIN ADVERSE_EFFECT CVS_3_Increased Heart Rate 518-47-8 FLUORESCEIN INDICATION Retinal Detachment 518-47-8 FLUORESCEIN INDICATION Retinal Vessel Occlusion 518-47-8 FLUORESCEIN ADVERSE_EFFECT XXX_3_Salivation 518-47-8 FLUORESCEIN ADVERSE_EFFECT IMU_3_Allergic Reactions 518-47-8 FLUORESCEIN INDICATION Diabetic Retinopathy 518-47-8 FLUORESCEIN ADVERSE_EFFECT GIS_3_Metallic Taste 50-91-9 5-FLUORO-2'-DEOXYURIDINE MECHANISM Inhibit precursor synthesis 50-91-9 5-FLUORO-2'-DEOXYURIDINE MECH_LEVEL_3 Thymidylate synthase 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT PSY_2_Disorientation 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT BBM_2_Leukopenia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT SKN_2_Maculopapular Rash 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT BBM_2_Anemia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT SKN_2_Pruritis 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT PSY_2_Anorexia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT PSY_2_Disorientation 50-91-9 5-FLUORO-2'-DEOXYURIDINE MESH_LEVEL_3 Deoxyribonucleosides 50-91-9 5-FLUORO-2'-DEOXYURIDINE TISSUE_TOXICITY Myocardial Ischemia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT BIL_1_Cholangitis 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT BBM_2_Neutropenia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT NEU_2_Nystagmus 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT NEU_2_Seizures 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT CVS_2_Angina 50-91-9 5-FLUORO-2'-DEOXYURIDINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 50-91-9 5-FLUORO-2'-DEOXYURIDINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 50-91-9 5-FLUORO-2'-DEOXYURIDINE TISSUE_TOXICITY Angina 50-91-9 5-FLUORO-2'-DEOXYURIDINE KNOWN_TOXICITY Hepatotoxicity 50-91-9 5-FLUORO-2'-DEOXYURIDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 50-91-9 5-FLUORO-2'-DEOXYURIDINE MESH_LEVEL_2 Nucleosides 50-91-9 5-FLUORO-2'-DEOXYURIDINE TA_LEVEL_3 Antimitotic 50-91-9 5-FLUORO-2'-DEOXYURIDINE TA_LEVEL_1 Oncology 50-91-9 5-FLUORO-2'-DEOXYURIDINE MODE_CLASS Enzyme substrate mimic 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT BIL_1_Cholecystitis 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT LIV_1_Cholestatic Jaundice 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT SKN_2_Erythema 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT LIV_1_Hepatotoxicity 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT NEU_2_Ataxia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-91-9 5-FLUORO-2'-DEOXYURIDINE ZERO_CLASS N 50-91-9 5-FLUORO-2'-DEOXYURIDINE KNOWN_TOXICITY Biliary System Toxicity 50-91-9 5-FLUORO-2'-DEOXYURIDINE TISSUE_TOXICITY Hepatotoxicity 50-91-9 5-FLUORO-2'-DEOXYURIDINE TA_LEVEL_2 Solid and soft tissue tumors 50-91-9 5-FLUORO-2'-DEOXYURIDINE PRODUCT_CLASS Anti-cancers 50-91-9 5-FLUORO-2'-DEOXYURIDINE INDICATION Metastatic Colorectal Cancer 50-91-9 5-FLUORO-2'-DEOXYURIDINE MECH_LEVEL_2 Inhibit precursor synthesis 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT CVS_2_Myocardial Ischemia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT IMU_2_Photosensitivity 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT PSY_2_Confusion 50-91-9 5-FLUORO-2'-DEOXYURIDINE ADVERSE_EFFECT NEU_2_Headache 50-91-9 5-FLUORO-2'-DEOXYURIDINE KNOWN_TOXICITY Cardiovascular Toxicity 50-91-9 5-FLUORO-2'-DEOXYURIDINE MECH_LEVEL_1 Antimitotic 50-91-9 5-FLUORO-2'-DEOXYURIDINE THERAPEUTIC_CLASS Antineoplastics 50-91-9 5-FLUORO-2'-DEOXYURIDINE TISSUE_TOXICITY Cholangitis 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT NEU_3_Headache 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_3_Corneal Ulceration 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_2_Ocular Irritation 426-13-1 FLUOROMETHOLONE INDICATION Uveitis 426-13-1 FLUOROMETHOLONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_2_Blurred Vision 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_3_Glaucoma 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT GIS_3_Dysgeusia 426-13-1 FLUOROMETHOLONE INDICATION Vernal Keratoconjunctivitis 426-13-1 FLUOROMETHOLONE INDICATION Allergic Conjunctivitis 426-13-1 FLUOROMETHOLONE MECHANISM Modulate gene transcription 426-13-1 FLUOROMETHOLONE INDICATION Ocular Inflammation 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_3_Cataracts 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_2_Ocular Pain 426-13-1 FLUOROMETHOLONE INDICATION Giant Papillary Conjunctivitis 426-13-1 FLUOROMETHOLONE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT XXX_3_Infection 426-13-1 FLUOROMETHOLONE ADVERSE_EFFECT OCU_3_Conjunctival Hyperemia 426-13-1 FLUOROMETHOLONE INDICATION Keratitis 426-13-1 FLUOROMETHOLONE THERAPEUTIC_CLASS Corticosteroids, Topical 426-13-1 FLUOROMETHOLONE MODE_CLASS Receptor Agonist 51-21-8 FLUOROURACIL TISSUE_TOXICITY Thrombocytopenia 51-21-8 FLUOROURACIL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 51-21-8 FLUOROURACIL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 51-21-8 FLUOROURACIL ADVERSE_EFFECT LIV_3_Hepatitis 51-21-8 FLUOROURACIL ADVERSE_EFFECT BBM_1_Thrombocytopenia 51-21-8 FLUOROURACIL ADVERSE_EFFECT BBM_1_Neutropenia 51-21-8 FLUOROURACIL ADVERSE_EFFECT SKN_3_Skin Ulcer 51-21-8 FLUOROURACIL ADVERSE_EFFECT PSY_2_Disorientation 51-21-8 FLUOROURACIL TA_LEVEL_1 Oncology 51-21-8 FLUOROURACIL MESH_LEVEL_1 Heterocyclic Compounds 51-21-8 FLUOROURACIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 51-21-8 FLUOROURACIL INDICATION Cervical Cancer / Carcinoma of the Cervix 51-21-8 FLUOROURACIL INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 51-21-8 FLUOROURACIL THERAPEUTIC_CLASS Antineoplastics 51-21-8 FLUOROURACIL TISSUE_TOXICITY Myocardial Infarction 51-21-8 FLUOROURACIL TISSUE_TOXICITY Neutropenia 51-21-8 FLUOROURACIL ADVERSE_EFFECT GIS_1_Diarrhea 51-21-8 FLUOROURACIL ADVERSE_EFFECT NEU_2_Ataxia 51-21-8 FLUOROURACIL ADVERSE_EFFECT CVS_3_Cardiotoxicity 51-21-8 FLUOROURACIL ADVERSE_EFFECT SKN_2_Skin Toxicity 51-21-8 FLUOROURACIL ADVERSE_EFFECT SKN_2_Skin Rash 51-21-8 FLUOROURACIL ADVERSE_EFFECT NEU_2_Neurotoxicity 51-21-8 FLUOROURACIL ADVERSE_EFFECT NEU_2_Acute Cerebellar Syndrome 51-21-8 FLUOROURACIL MODE_CLASS Enzyme substrate mimic 51-21-8 FLUOROURACIL MESH_LEVEL_3 Pyrimidines 51-21-8 FLUOROURACIL INDICATION Breast Cancer / Carcinoma of the Breast 51-21-8 FLUOROURACIL PRODUCT_CLASS Anti-cancers 51-21-8 FLUOROURACIL MECH_LEVEL_1 Cancer cell metabolism 51-21-8 FLUOROURACIL TA_LEVEL_3 Topical Skin tumors 51-21-8 FLUOROURACIL INDICATION Hepatocellular Carcinoma 51-21-8 FLUOROURACIL TISSUE_TOXICITY Cardiogenic Shock 51-21-8 FLUOROURACIL TISSUE_TOXICITY Leukopenia 51-21-8 FLUOROURACIL STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 51-21-8 FLUOROURACIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 51-21-8 FLUOROURACIL ADVERSE_EFFECT BBM_2_Anemia 51-21-8 FLUOROURACIL ADVERSE_EFFECT IMU_2_Photosensitivity 51-21-8 FLUOROURACIL ADVERSE_EFFECT BBM_1_Bone Marrow Suppression 51-21-8 FLUOROURACIL ADVERSE_EFFECT GIS_2_Enterocolitis 51-21-8 FLUOROURACIL ADVERSE_EFFECT XXX_1_Palmar-Plantar Erythrodysesthesia 51-21-8 FLUOROURACIL KNOWN_TOXICITY Cardiovascular Toxicity 51-21-8 FLUOROURACIL INDICATION Actinic Keratosis 51-21-8 FLUOROURACIL MECH_LEVEL_2 Anti-metabolite 51-21-8 FLUOROURACIL MECH_LEVEL_3 Thymidylate synthase 51-21-8 FLUOROURACIL INDICATION Ovarian Cancer / Carcinoma of the Ovary 51-21-8 FLUOROURACIL INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 51-21-8 FLUOROURACIL INDICATION Basal Cell Carcinoma 51-21-8 FLUOROURACIL TISSUE_TOXICITY Cardiotoxicity 51-21-8 FLUOROURACIL TISSUE_TOXICITY Bone Marrow Suppression 51-21-8 FLUOROURACIL ADVERSE_EFFECT CVS_3_Myocardial Infarction 51-21-8 FLUOROURACIL ADVERSE_EFFECT PSY_2_Confusion 51-21-8 FLUOROURACIL ADVERSE_EFFECT BBM_1_Leukopenia 51-21-8 FLUOROURACIL ADVERSE_EFFECT GIS_1_Stomatitis 51-21-8 FLUOROURACIL ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 51-21-8 FLUOROURACIL ADVERSE_EFFECT CVS_3_Cardiogenic Shock 51-21-8 FLUOROURACIL ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 51-21-8 FLUOROURACIL MECHANISM Inhibit precursor synthesis 51-21-8 FLUOROURACIL INDICATION Head and Neck Cancer 51-21-8 FLUOROURACIL TA_LEVEL_2 Solid tissue tumors 51-21-8 FLUOROURACIL INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 51-21-8 FLUOROURACIL TISSUE_TOXICITY Cardiac Arrhythmia 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_1_Yawning 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_3_Chills 54910-89-3 FLUOXETINE ADVERSE_EFFECT GUS_3_Urinary Frequency 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_3_Mania 54910-89-3 FLUOXETINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 54910-89-3 FLUOXETINE MESH_LEVEL_1 Organic Chemicals 54910-89-3 FLUOXETINE TA_LEVEL_1 Central Nervous System (CNS) 54910-89-3 FLUOXETINE MESH_LEVEL_2 Amines 54910-89-3 FLUOXETINE MESH_LEVEL_3 Propylamines 54910-89-3 FLUOXETINE INDICATION Obesity 54910-89-3 FLUOXETINE INDICATION Bulimia Nervosa 54910-89-3 FLUOXETINE THERAPEUTIC_CLASS Anorexiants 54910-89-3 FLUOXETINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_1_Anxiety 54910-89-3 FLUOXETINE ADVERSE_EFFECT END_3_Hyperglycemia 54910-89-3 FLUOXETINE ADVERSE_EFFECT NEU_2_Headache 54910-89-3 FLUOXETINE ADVERSE_EFFECT NEU_1_Drowsiness 54910-89-3 FLUOXETINE ADVERSE_EFFECT BBM_3_Anemia 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_1_Weight Loss 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_3_Emotional Lability 54910-89-3 FLUOXETINE ADVERSE_EFFECT GIS_1_Dyspepsia 54910-89-3 FLUOXETINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 54910-89-3 FLUOXETINE TA_LEVEL_2 CNS Depressant 54910-89-3 FLUOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 54910-89-3 FLUOXETINE MECH_LEVEL_1 Modulate neural transmission 54910-89-3 FLUOXETINE INDICATION Panic Disorder 54910-89-3 FLUOXETINE INDICATION Obsessive-Compulsive Disorder (OCD) 54910-89-3 FLUOXETINE ZERO_CLASS N 54910-89-3 FLUOXETINE ADVERSE_EFFECT CVS_3_Hypertension 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_1_Insomnia 54910-89-3 FLUOXETINE ADVERSE_EFFECT END_3_Hypoglycemia 54910-89-3 FLUOXETINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 54910-89-3 FLUOXETINE ADVERSE_EFFECT SKN_2_Rash 54910-89-3 FLUOXETINE ADVERSE_EFFECT NEU_3_Seizures 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 54910-89-3 FLUOXETINE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 54910-89-3 FLUOXETINE ADVERSE_EFFECT CVS_3_Palpitation 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_1_Xerostomia 54910-89-3 FLUOXETINE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 54910-89-3 FLUOXETINE ADVERSE_EFFECT REP_3_Priapism 54910-89-3 FLUOXETINE ADVERSE_EFFECT END_2_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 54910-89-3 FLUOXETINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 54910-89-3 FLUOXETINE ADVERSE_EFFECT SKN_2_Pruritis 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_1_Diaphoresis 54910-89-3 FLUOXETINE INDICATION Autism 54910-89-3 FLUOXETINE ADVERSE_EFFECT OCU_2_Blurred Vision 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_1_Anorexia 54910-89-3 FLUOXETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 54910-89-3 FLUOXETINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_3_Increased Appetite 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_3_Withdrawal 54910-89-3 FLUOXETINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 54910-89-3 FLUOXETINE ADVERSE_EFFECT MSK_3_Myalgia 54910-89-3 FLUOXETINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 54910-89-3 FLUOXETINE ADVERSE_EFFECT BBM_3_Hemorrhage 54910-89-3 FLUOXETINE ADVERSE_EFFECT GIS_3_Dysgeusia 54910-89-3 FLUOXETINE INDICATION Depression 54910-89-3 FLUOXETINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 54910-89-3 FLUOXETINE THERAPEUTIC_CLASS Antidepressants 54910-89-3 FLUOXETINE INDICATION Premenstrual Dysphoric Disorder 54910-89-3 FLUOXETINE PRODUCT_CLASS Central Nervous System (CNS) 54910-89-3 FLUOXETINE MECH_LEVEL_3 5HT Transporter SERT 54910-89-3 FLUOXETINE INDICATION Posttraumatic Stress Disorder (PTSD) 54910-89-3 FLUOXETINE TA_LEVEL_3 Anxlytic 54910-89-3 FLUOXETINE MECH_LEVEL_2 5HT antagonist 54910-89-3 FLUOXETINE MECHANISM Prolong/enhance neural transmission 54910-89-3 FLUOXETINE MODE_CLASS Solute transporter inhibitor 54910-89-3 FLUOXETINE ADVERSE_EFFECT GIS_1_Diarrhea 54910-89-3 FLUOXETINE ADVERSE_EFFECT PSY_1_Nervousness 54910-89-3 FLUOXETINE ADVERSE_EFFECT NEU_2_Tremor 54910-89-3 FLUOXETINE ADVERSE_EFFECT XXX_1_Fatigue 54910-89-3 FLUOXETINE ADVERSE_EFFECT NEU_1_Dizziness 56296-78-7 FLUOXETINE INDICATION Autism 56296-78-7 FLUOXETINE THERAPEUTIC_CLASS Antidepressants 56296-78-7 FLUOXETINE INDICATION Depression 56296-78-7 FLUOXETINE ADVERSE_EFFECT GIS_3_Dysgeusia 56296-78-7 FLUOXETINE ADVERSE_EFFECT REP_3_Priapism 56296-78-7 FLUOXETINE ADVERSE_EFFECT BBM_3_Hemorrhage 56296-78-7 FLUOXETINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 56296-78-7 FLUOXETINE ADVERSE_EFFECT MSK_3_Myalgia 56296-78-7 FLUOXETINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_3_Withdrawal 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_3_Increased Appetite 56296-78-7 FLUOXETINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 56296-78-7 FLUOXETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_1_Anorexia 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_3_Chills 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_1_Yawning 56296-78-7 FLUOXETINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 56296-78-7 FLUOXETINE ADVERSE_EFFECT SKN_2_Pruritis 56296-78-7 FLUOXETINE ADVERSE_EFFECT NEU_1_Dizziness 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_1_Fatigue 56296-78-7 FLUOXETINE ADVERSE_EFFECT NEU_2_Tremor 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_1_Nervousness 56296-78-7 FLUOXETINE ADVERSE_EFFECT GIS_1_Diarrhea 56296-78-7 FLUOXETINE MODE_CLASS Solute transporter inhibitor 56296-78-7 FLUOXETINE MECHANISM Prolong/enhance neural transmission 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_3_Mania 56296-78-7 FLUOXETINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 56296-78-7 FLUOXETINE MESH_LEVEL_1 Organic Chemicals 56296-78-7 FLUOXETINE TA_LEVEL_1 Central Nervous System (CNS) 56296-78-7 FLUOXETINE MESH_LEVEL_2 Amines 56296-78-7 FLUOXETINE MESH_LEVEL_3 Propylamines 56296-78-7 FLUOXETINE INDICATION Obesity 56296-78-7 FLUOXETINE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_1_Diaphoresis 56296-78-7 FLUOXETINE ZERO_CLASS N 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_1_Anxiety 56296-78-7 FLUOXETINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 56296-78-7 FLUOXETINE MECH_LEVEL_2 5HT antagonist 56296-78-7 FLUOXETINE TA_LEVEL_3 Anxlytic 56296-78-7 FLUOXETINE INDICATION Posttraumatic Stress Disorder (PTSD) 56296-78-7 FLUOXETINE MECH_LEVEL_3 5HT Transporter SERT 56296-78-7 FLUOXETINE PRODUCT_CLASS Central Nervous System (CNS) 56296-78-7 FLUOXETINE ADVERSE_EFFECT END_3_Hyperglycemia 56296-78-7 FLUOXETINE ADVERSE_EFFECT NEU_2_Headache 56296-78-7 FLUOXETINE ADVERSE_EFFECT NEU_1_Drowsiness 56296-78-7 FLUOXETINE ADVERSE_EFFECT BBM_3_Anemia 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_1_Weight Loss 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_3_Emotional Lability 56296-78-7 FLUOXETINE ADVERSE_EFFECT GIS_1_Dyspepsia 56296-78-7 FLUOXETINE ADVERSE_EFFECT END_2_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 56296-78-7 FLUOXETINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 56296-78-7 FLUOXETINE TA_LEVEL_2 CNS Depressant 56296-78-7 FLUOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 56296-78-7 FLUOXETINE INDICATION Bulimia Nervosa 56296-78-7 FLUOXETINE ADVERSE_EFFECT OCU_2_Blurred Vision 56296-78-7 FLUOXETINE MECH_LEVEL_1 Modulate neural transmission 56296-78-7 FLUOXETINE INDICATION Panic Disorder 56296-78-7 FLUOXETINE INDICATION Obsessive-Compulsive Disorder (OCD) 56296-78-7 FLUOXETINE ADVERSE_EFFECT CVS_3_Hypertension 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_1_Insomnia 56296-78-7 FLUOXETINE ADVERSE_EFFECT END_3_Hypoglycemia 56296-78-7 FLUOXETINE ADVERSE_EFFECT GUS_3_Urinary Frequency 56296-78-7 FLUOXETINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 56296-78-7 FLUOXETINE ADVERSE_EFFECT SKN_2_Rash 56296-78-7 FLUOXETINE ADVERSE_EFFECT NEU_3_Seizures 56296-78-7 FLUOXETINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 56296-78-7 FLUOXETINE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 56296-78-7 FLUOXETINE ADVERSE_EFFECT CVS_3_Palpitation 56296-78-7 FLUOXETINE THERAPEUTIC_CLASS Anorexiants 56296-78-7 FLUOXETINE ADVERSE_EFFECT XXX_1_Xerostomia 56296-78-7 FLUOXETINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 56296-78-7 FLUOXETINE INDICATION Premenstrual Dysphoric Disorder 59333-67-4 FLUOXETINE ADVERSE_EFFECT REP_3_Priapism 59333-67-4 FLUOXETINE ADVERSE_EFFECT BBM_3_Hemorrhage 59333-67-4 FLUOXETINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 59333-67-4 FLUOXETINE ADVERSE_EFFECT MSK_3_Myalgia 59333-67-4 FLUOXETINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_3_Withdrawal 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_3_Increased Appetite 59333-67-4 FLUOXETINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 59333-67-4 FLUOXETINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_1_Anorexia 59333-67-4 FLUOXETINE ADVERSE_EFFECT OCU_2_Blurred Vision 59333-67-4 FLUOXETINE INDICATION Autism 59333-67-4 FLUOXETINE TA_LEVEL_2 CNS Depressant 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_1_Diaphoresis 59333-67-4 FLUOXETINE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_1_Xerostomia 59333-67-4 FLUOXETINE ADVERSE_EFFECT CVS_3_Palpitation 59333-67-4 FLUOXETINE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 59333-67-4 FLUOXETINE ADVERSE_EFFECT NEU_3_Seizures 59333-67-4 FLUOXETINE ADVERSE_EFFECT SKN_2_Rash 59333-67-4 FLUOXETINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 59333-67-4 FLUOXETINE ADVERSE_EFFECT END_3_Hypoglycemia 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_1_Insomnia 59333-67-4 FLUOXETINE ADVERSE_EFFECT CVS_3_Hypertension 59333-67-4 FLUOXETINE ZERO_CLASS N 59333-67-4 FLUOXETINE INDICATION Obsessive-Compulsive Disorder (OCD) 59333-67-4 FLUOXETINE INDICATION Panic Disorder 59333-67-4 FLUOXETINE MECH_LEVEL_1 Modulate neural transmission 59333-67-4 FLUOXETINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 59333-67-4 FLUOXETINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 59333-67-4 FLUOXETINE ADVERSE_EFFECT END_2_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 59333-67-4 FLUOXETINE ADVERSE_EFFECT GIS_1_Dyspepsia 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_3_Emotional Lability 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_1_Weight Loss 59333-67-4 FLUOXETINE ADVERSE_EFFECT BBM_3_Anemia 59333-67-4 FLUOXETINE ADVERSE_EFFECT NEU_1_Drowsiness 59333-67-4 FLUOXETINE ADVERSE_EFFECT NEU_2_Headache 59333-67-4 FLUOXETINE ADVERSE_EFFECT END_3_Hyperglycemia 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_1_Anxiety 59333-67-4 FLUOXETINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 59333-67-4 FLUOXETINE THERAPEUTIC_CLASS Anorexiants 59333-67-4 FLUOXETINE INDICATION Bulimia Nervosa 59333-67-4 FLUOXETINE INDICATION Obesity 59333-67-4 FLUOXETINE MESH_LEVEL_3 Propylamines 59333-67-4 FLUOXETINE MESH_LEVEL_2 Amines 59333-67-4 FLUOXETINE TA_LEVEL_1 Central Nervous System (CNS) 59333-67-4 FLUOXETINE MESH_LEVEL_1 Organic Chemicals 59333-67-4 FLUOXETINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_3_Mania 59333-67-4 FLUOXETINE ADVERSE_EFFECT GUS_3_Urinary Frequency 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_3_Chills 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_1_Yawning 59333-67-4 FLUOXETINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 59333-67-4 FLUOXETINE ADVERSE_EFFECT SKN_2_Pruritis 59333-67-4 FLUOXETINE ADVERSE_EFFECT NEU_1_Dizziness 59333-67-4 FLUOXETINE ADVERSE_EFFECT XXX_1_Fatigue 59333-67-4 FLUOXETINE ADVERSE_EFFECT NEU_2_Tremor 59333-67-4 FLUOXETINE ADVERSE_EFFECT PSY_1_Nervousness 59333-67-4 FLUOXETINE ADVERSE_EFFECT GIS_1_Diarrhea 59333-67-4 FLUOXETINE MODE_CLASS Solute transporter inhibitor 59333-67-4 FLUOXETINE MECHANISM Prolong/enhance neural transmission 59333-67-4 FLUOXETINE MECH_LEVEL_2 5HT antagonist 59333-67-4 FLUOXETINE TA_LEVEL_3 Anxlytic 59333-67-4 FLUOXETINE INDICATION Posttraumatic Stress Disorder (PTSD) 59333-67-4 FLUOXETINE MECH_LEVEL_3 5HT Transporter SERT 59333-67-4 FLUOXETINE PRODUCT_CLASS Central Nervous System (CNS) 59333-67-4 FLUOXETINE INDICATION Premenstrual Dysphoric Disorder 59333-67-4 FLUOXETINE THERAPEUTIC_CLASS Antidepressants 59333-67-4 FLUOXETINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 59333-67-4 FLUOXETINE INDICATION Depression 59333-67-4 FLUOXETINE ADVERSE_EFFECT GIS_3_Dysgeusia 76-43-7 FLUOXYMESTERONE INDICATION Breast Cancer / Carcinoma of the Breast 76-43-7 FLUOXYMESTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 76-43-7 FLUOXYMESTERONE MECHANISM Modulate gene transcription 76-43-7 FLUOXYMESTERONE THERAPEUTIC_CLASS Gonadal Hormones 76-43-7 FLUOXYMESTERONE MODE_CLASS Receptor Agonist 76-43-7 FLUOXYMESTERONE INDICATION Hypogonadism 69-23-8 FLUPHENAZINE MECHANISM Block neural transmission 69-23-8 FLUPHENAZINE TA_LEVEL_3 Antipsychotics 69-23-8 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Akathisia 69-23-8 FLUPHENAZINE ADVERSE_EFFECT IMU_3_Allergic Reactions 69-23-8 FLUPHENAZINE ADVERSE_EFFECT OCU_3_Visual Impairment 69-23-8 FLUPHENAZINE MECH_LEVEL_1 Modulate neural transmission 69-23-8 FLUPHENAZINE TISSUE_TOXICITY Hypotension 69-23-8 FLUPHENAZINE ACTIVITY_CLASS Dopamine antagonist 69-23-8 FLUPHENAZINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 69-23-8 FLUPHENAZINE ADVERSE_EFFECT REP_3_Infertility 69-23-8 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Tremor 69-23-8 FLUPHENAZINE ADVERSE_EFFECT END_3_Hyperprolactinemia 69-23-8 FLUPHENAZINE KNOWN_TOXICITY Neurotoxicity 69-23-8 FLUPHENAZINE PRODUCT_CLASS Central Nervous System (CNS) 69-23-8 FLUPHENAZINE KNOWN_TOXICITY Cardiovascular Toxicity 69-23-8 FLUPHENAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 69-23-8 FLUPHENAZINE TISSUE_TOXICITY Extrapyramidal Toxicity 69-23-8 FLUPHENAZINE ADVERSE_EFFECT GUS_3_Urinary Retention 69-23-8 FLUPHENAZINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 69-23-8 FLUPHENAZINE ADVERSE_EFFECT END_2_Galactorrhea 69-23-8 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Parkinson-Like Syndrome 69-23-8 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Toxicity 69-23-8 FLUPHENAZINE INDICATION Psychotic Disorders / Psychosis 69-23-8 FLUPHENAZINE TA_LEVEL_1 Central Nervous System (CNS) 69-23-8 FLUPHENAZINE MECH_LEVEL_3 dopamine receptor D1 69-23-8 FLUPHENAZINE TA_LEVEL_2 CNS Depressant 69-23-8 FLUPHENAZINE MESH_LEVEL_3 Phenothiazines 69-23-8 FLUPHENAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 69-23-8 FLUPHENAZINE ZERO_CLASS N 69-23-8 FLUPHENAZINE ADVERSE_EFFECT CVS_2_Hypotension 69-23-8 FLUPHENAZINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 69-23-8 FLUPHENAZINE ADVERSE_EFFECT XXX_1_Rigidity 69-23-8 FLUPHENAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 69-23-8 FLUPHENAZINE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 69-23-8 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Dystonia 69-23-8 FLUPHENAZINE TISSUE_TOXICITY Ventricular Arrhythmia 69-23-8 FLUPHENAZINE MODE_CLASS Receptor Ligand Antagonist 69-23-8 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Akinesia 69-23-8 FLUPHENAZINE TISSUE_TOXICITY Cardiotoxicity 69-23-8 FLUPHENAZINE MESH_LEVEL_1 Heterocyclic Compounds 69-23-8 FLUPHENAZINE THERAPEUTIC_CLASS Antipsychotics 69-23-8 FLUPHENAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 69-23-8 FLUPHENAZINE MECH_LEVEL_2 Dopamine antagonist 69-23-8 FLUPHENAZINE MECHANISM Modulate G-protein coupled signal transduction 146-56-5 FLUPHENAZINE MECH_LEVEL_1 Modulate neural transmission 146-56-5 FLUPHENAZINE PRODUCT_CLASS Central Nervous System (CNS) 146-56-5 FLUPHENAZINE KNOWN_TOXICITY Cardiovascular Toxicity 146-56-5 FLUPHENAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 146-56-5 FLUPHENAZINE TISSUE_TOXICITY Extrapyramidal Toxicity 146-56-5 FLUPHENAZINE ADVERSE_EFFECT GUS_3_Urinary Retention 146-56-5 FLUPHENAZINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 146-56-5 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Akinesia 146-56-5 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Toxicity 146-56-5 FLUPHENAZINE INDICATION Psychotic Disorders / Psychosis 146-56-5 FLUPHENAZINE TA_LEVEL_1 Central Nervous System (CNS) 146-56-5 FLUPHENAZINE ACTIVITY_CLASS Dopamine antagonist 146-56-5 FLUPHENAZINE MECH_LEVEL_3 dopamine receptor D1 146-56-5 FLUPHENAZINE TA_LEVEL_2 CNS Depressant 146-56-5 FLUPHENAZINE MESH_LEVEL_3 Phenothiazines 146-56-5 FLUPHENAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 146-56-5 FLUPHENAZINE ZERO_CLASS N 146-56-5 FLUPHENAZINE TISSUE_TOXICITY Hypotension 146-56-5 FLUPHENAZINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 146-56-5 FLUPHENAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 146-56-5 FLUPHENAZINE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 146-56-5 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Dystonia 146-56-5 FLUPHENAZINE TISSUE_TOXICITY Ventricular Arrhythmia 146-56-5 FLUPHENAZINE MODE_CLASS Receptor Ligand Antagonist 146-56-5 FLUPHENAZINE MECHANISM Modulate G-protein coupled signal transduction 146-56-5 FLUPHENAZINE MESH_LEVEL_1 Heterocyclic Compounds 146-56-5 FLUPHENAZINE ADVERSE_EFFECT CVS_2_Hypotension 146-56-5 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Parkinson-Like Syndrome 146-56-5 FLUPHENAZINE MECHANISM Block neural transmission 146-56-5 FLUPHENAZINE TA_LEVEL_3 Antipsychotics 146-56-5 FLUPHENAZINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 146-56-5 FLUPHENAZINE ADVERSE_EFFECT REP_3_Infertility 146-56-5 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Tremor 146-56-5 FLUPHENAZINE ADVERSE_EFFECT OCU_3_Visual Impairment 146-56-5 FLUPHENAZINE ADVERSE_EFFECT END_3_Hyperprolactinemia 146-56-5 FLUPHENAZINE KNOWN_TOXICITY Neurotoxicity 146-56-5 FLUPHENAZINE TISSUE_TOXICITY Cardiotoxicity 146-56-5 FLUPHENAZINE THERAPEUTIC_CLASS Antipsychotics 146-56-5 FLUPHENAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 146-56-5 FLUPHENAZINE MECH_LEVEL_2 Dopamine antagonist 146-56-5 FLUPHENAZINE ADVERSE_EFFECT XXX_1_Rigidity 146-56-5 FLUPHENAZINE ADVERSE_EFFECT END_2_Galactorrhea 146-56-5 FLUPHENAZINE ADVERSE_EFFECT NEU_1_Akathisia 146-56-5 FLUPHENAZINE ADVERSE_EFFECT IMU_3_Allergic Reactions 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT XXX_3_Tolerance 1524-88-5 FLURANDRENOLIDE MODE_CLASS Receptor Agonist 1524-88-5 FLURANDRENOLIDE THERAPEUTIC_CLASS Corticosteroids, Topical 1524-88-5 FLURANDRENOLIDE INDICATION Skin Diseases / Dermatoses 1524-88-5 FLURANDRENOLIDE INDICATION Dermatitis 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT XXX_2_Impaired Wound Healing 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_1_Skin Irritation 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_3_Skin Ulcer 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT OCU_3_Cataracts 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 1524-88-5 FLURANDRENOLIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 1524-88-5 FLURANDRENOLIDE INDICATION Pruritus / Itching 1524-88-5 FLURANDRENOLIDE MECHANISM Modulate gene transcription 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT BBM_3_Purpura 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_2_Acneiform Rash 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_2_Dry Skin 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT END_3_Adrenal Insufficiency 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_2_Erythema 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT IMU_3_Contact Dermatitis 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_2_Skin Atrophy 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT END_3_Cushing's Syndrome 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_1_Pruritis 1524-88-5 FLURANDRENOLIDE PRODUCT_CLASS Dermatologicals 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT END_3_Glucose Intolerance 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT SKN_3_Hypertrichosis 1524-88-5 FLURANDRENOLIDE ADVERSE_EFFECT XXX_2_Infection 17617-23-1 FLURAZEPAM ADVERSE_EFFECT CVS_3_Hypotension 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Coma 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Slurred Speech 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Disorientation 17617-23-1 FLURAZEPAM ADVERSE_EFFECT LIV_3_Impaired Liver Function 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Somnolence 17617-23-1 FLURAZEPAM INDICATION Insomnia 17617-23-1 FLURAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 17617-23-1 FLURAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 17617-23-1 FLURAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 17617-23-1 FLURAZEPAM TISSUE_TOXICITY Hypotension 17617-23-1 FLURAZEPAM TISSUE_TOXICITY Teratogenicity 17617-23-1 FLURAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Depression 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 17617-23-1 FLURAZEPAM ADVERSE_EFFECT XXX_1_Withdrawal 17617-23-1 FLURAZEPAM ADVERSE_EFFECT XXX_2_Lethargy 17617-23-1 FLURAZEPAM ADVERSE_EFFECT BBM_3_Leukopenia 17617-23-1 FLURAZEPAM MECHANISM Modulate neural transmission 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 17617-23-1 FLURAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 17617-23-1 FLURAZEPAM ADVERSE_EFFECT OCU_3_Blurred Vision 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_1_Dizziness 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Confusion 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_2_Irritability 17617-23-1 FLURAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_2_Impaired Motor Function 17617-23-1 FLURAZEPAM MODE_CLASS Channel enhancer /opener 17617-23-1 FLURAZEPAM ADVERSE_EFFECT GUS_2_Urinary Retention 17617-23-1 FLURAZEPAM ADVERSE_EFFECT XXX_2_Weakness 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_1_Ataxia 17617-23-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Euphoria 17617-23-1 FLURAZEPAM ADVERSE_EFFECT BBM_3_Granulocytopenia 17617-23-1 FLURAZEPAM ADVERSE_EFFECT NEU_2_Impaired Mental Function 17617-23-1 FLURAZEPAM ADVERSE_EFFECT CVS_3_Chest Pain 17617-23-1 FLURAZEPAM ADVERSE_EFFECT XXX_2_Salivation 17617-23-1 FLURAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 1172-18-5 FLURAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_2_Impaired Motor Function 1172-18-5 FLURAZEPAM ADVERSE_EFFECT CVS_3_Chest Pain 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_2_Irritability 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_3_Confusion 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_1_Dizziness 1172-18-5 FLURAZEPAM ADVERSE_EFFECT OCU_3_Blurred Vision 1172-18-5 FLURAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 1172-18-5 FLURAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 1172-18-5 FLURAZEPAM ADVERSE_EFFECT BBM_3_Leukopenia 1172-18-5 FLURAZEPAM ADVERSE_EFFECT XXX_2_Lethargy 1172-18-5 FLURAZEPAM ADVERSE_EFFECT XXX_1_Withdrawal 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_3_Depression 1172-18-5 FLURAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 1172-18-5 FLURAZEPAM TISSUE_TOXICITY Teratogenicity 1172-18-5 FLURAZEPAM TISSUE_TOXICITY Hypotension 1172-18-5 FLURAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 1172-18-5 FLURAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 1172-18-5 FLURAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 1172-18-5 FLURAZEPAM INDICATION Insomnia 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_3_Somnolence 1172-18-5 FLURAZEPAM ADVERSE_EFFECT LIV_3_Impaired Liver Function 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_3_Disorientation 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_3_Slurred Speech 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_3_Coma 1172-18-5 FLURAZEPAM ADVERSE_EFFECT CVS_3_Hypotension 1172-18-5 FLURAZEPAM ADVERSE_EFFECT XXX_2_Salivation 1172-18-5 FLURAZEPAM MECHANISM Modulate neural transmission 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_2_Impaired Mental Function 1172-18-5 FLURAZEPAM ADVERSE_EFFECT BBM_3_Granulocytopenia 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_3_Euphoria 1172-18-5 FLURAZEPAM ADVERSE_EFFECT NEU_1_Ataxia 1172-18-5 FLURAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 1172-18-5 FLURAZEPAM ADVERSE_EFFECT XXX_2_Weakness 1172-18-5 FLURAZEPAM ADVERSE_EFFECT GUS_2_Urinary Retention 1172-18-5 FLURAZEPAM MODE_CLASS Channel enhancer /opener 36105-20-1 FLURAZEPAM ADVERSE_EFFECT CVS_3_Hypotension 36105-20-1 FLURAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 36105-20-1 FLURAZEPAM ADVERSE_EFFECT XXX_2_Salivation 36105-20-1 FLURAZEPAM MECHANISM Modulate neural transmission 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_2_Impaired Mental Function 36105-20-1 FLURAZEPAM ADVERSE_EFFECT BBM_3_Granulocytopenia 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Euphoria 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_1_Ataxia 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 36105-20-1 FLURAZEPAM ADVERSE_EFFECT XXX_2_Weakness 36105-20-1 FLURAZEPAM ADVERSE_EFFECT GUS_2_Urinary Retention 36105-20-1 FLURAZEPAM MODE_CLASS Channel enhancer /opener 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Confusion 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_1_Dizziness 36105-20-1 FLURAZEPAM ADVERSE_EFFECT OCU_3_Blurred Vision 36105-20-1 FLURAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 36105-20-1 FLURAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 36105-20-1 FLURAZEPAM ADVERSE_EFFECT BBM_3_Leukopenia 36105-20-1 FLURAZEPAM ADVERSE_EFFECT XXX_2_Lethargy 36105-20-1 FLURAZEPAM ADVERSE_EFFECT XXX_1_Withdrawal 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Depression 36105-20-1 FLURAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 36105-20-1 FLURAZEPAM TISSUE_TOXICITY Teratogenicity 36105-20-1 FLURAZEPAM TISSUE_TOXICITY Hypotension 36105-20-1 FLURAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 36105-20-1 FLURAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 36105-20-1 FLURAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 36105-20-1 FLURAZEPAM INDICATION Insomnia 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Somnolence 36105-20-1 FLURAZEPAM ADVERSE_EFFECT LIV_3_Impaired Liver Function 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_3_Disorientation 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Slurred Speech 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_3_Coma 36105-20-1 FLURAZEPAM ADVERSE_EFFECT NEU_2_Impaired Motor Function 36105-20-1 FLURAZEPAM ADVERSE_EFFECT CVS_3_Chest Pain 36105-20-1 FLURAZEPAM ADVERSE_EFFECT PSY_2_Irritability 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT NEU_2_Dizziness 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT PSY_1_Anxiety 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Constipation 5104-49-4 FLURBIPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 5104-49-4 FLURBIPROFEN INDICATION Dental Pain 5104-49-4 FLURBIPROFEN MESH_LEVEL_2 Carboxylic Acids 5104-49-4 FLURBIPROFEN INDICATION Inhibition of Miosis 5104-49-4 FLURBIPROFEN MESH_LEVEL_1 Organic Chemicals 5104-49-4 FLURBIPROFEN MESH_LEVEL_3 Acids, Acyclic 5104-49-4 FLURBIPROFEN INDICATION Ankylosing Spondylitis 5104-49-4 FLURBIPROFEN INDICATION Rheumatoid Arthritis 5104-49-4 FLURBIPROFEN INDICATION Pain 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Blurred Vision 5104-49-4 FLURBIPROFEN TA_LEVEL_1 Anti-inflammatory 5104-49-4 FLURBIPROFEN TA_LEVEL_3 NSAID 5104-49-4 FLURBIPROFEN PRODUCT_CLASS Anti-inflammatories 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Ocular Irritation 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_3_Esophagitis 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_2_Peptic Ulceration 5104-49-4 FLURBIPROFEN MECH_LEVEL_1 Immunomodulation 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Edema 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Tremor 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Weight Gain 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Hyperreflexia 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GUS_2_Cystitis 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Asthenia 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_2_Gastrointestinal Perforation 5104-49-4 FLURBIPROFEN INDICATION Arthralgia 5104-49-4 FLURBIPROFEN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT PSY_2_Depression 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT OTO_1_Tinnitus 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT SKN_2_Maculopapular Rash 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Flatulence 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT XXX_1_Malaise 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Ocular Pain 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Diarrhea 5104-49-4 FLURBIPROFEN ACTIVITY_CLASS Anti-inflammatory 5104-49-4 FLURBIPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 5104-49-4 FLURBIPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 5104-49-4 FLURBIPROFEN TA_LEVEL_2 NSAID 5104-49-4 FLURBIPROFEN INDICATION Osteoarthritis 5104-49-4 FLURBIPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 5104-49-4 FLURBIPROFEN INDICATION Myalgia 5104-49-4 FLURBIPROFEN MODE_CLASS Enzyme Inhibitor 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT PSY_1_Insomnia 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Headache 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Drowsiness 5104-49-4 FLURBIPROFEN INDICATION Dysmenorrhea 5104-49-4 FLURBIPROFEN MECHANISM Inhibit eicosanoid biosynthesis 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Ocular Pruritis 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Rhinitis 5104-49-4 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Dyspepsia 56767-76-1 FLURBIPROFEN INDICATION Dental Pain 56767-76-1 FLURBIPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Constipation 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT PSY_1_Anxiety 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT NEU_2_Dizziness 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Hyperreflexia 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Dyspepsia 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Rhinitis 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Ocular Pruritis 56767-76-1 FLURBIPROFEN INDICATION Pain 56767-76-1 FLURBIPROFEN STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 56767-76-1 FLURBIPROFEN MECHANISM Inhibit eicosanoid biosynthesis 56767-76-1 FLURBIPROFEN INDICATION Dysmenorrhea 56767-76-1 FLURBIPROFEN MECH_LEVEL_1 Immunomodulation 56767-76-1 FLURBIPROFEN PRODUCT_CLASS Anti-inflammatories 56767-76-1 FLURBIPROFEN TA_LEVEL_3 NSAID 56767-76-1 FLURBIPROFEN TA_LEVEL_1 Anti-inflammatory 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Diarrhea 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Headache 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Drowsiness 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Weight Gain 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GUS_2_Cystitis 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Asthenia 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_2_Gastrointestinal Perforation 56767-76-1 FLURBIPROFEN INDICATION Arthralgia 56767-76-1 FLURBIPROFEN INDICATION Ankylosing Spondylitis 56767-76-1 FLURBIPROFEN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT PSY_2_Depression 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT OTO_1_Tinnitus 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT SKN_2_Maculopapular Rash 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT XXX_1_Malaise 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Ocular Pain 56767-76-1 FLURBIPROFEN ACTIVITY_CLASS Anti-inflammatory 56767-76-1 FLURBIPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 56767-76-1 FLURBIPROFEN TA_LEVEL_2 NSAID 56767-76-1 FLURBIPROFEN INDICATION Osteoarthritis 56767-76-1 FLURBIPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 56767-76-1 FLURBIPROFEN INDICATION Myalgia 56767-76-1 FLURBIPROFEN MODE_CLASS Enzyme Inhibitor 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Blurred Vision 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT NEU_1_Tremor 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT XXX_2_Edema 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT LIV_3_Hepatitis 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_2_Peptic Ulceration 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_3_Esophagitis 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT OCU_1_Ocular Irritation 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT GIS_1_Flatulence 56767-76-1 FLURBIPROFEN ADVERSE_EFFECT PSY_1_Insomnia 56767-76-1 FLURBIPROFEN INDICATION Rheumatoid Arthritis 56767-76-1 FLURBIPROFEN MESH_LEVEL_3 Acids, Acyclic 56767-76-1 FLURBIPROFEN MESH_LEVEL_1 Organic Chemicals 56767-76-1 FLURBIPROFEN INDICATION Inhibition of Miosis 56767-76-1 FLURBIPROFEN MESH_LEVEL_2 Carboxylic Acids 82664-20-8 FLURITHROMYCIN THERAPEUTIC_CLASS Antibacterials 82664-20-8 FLURITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 82664-20-8 FLURITHROMYCIN PRODUCT_CLASS Anti-infectives 82664-20-8 FLURITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 13311-84-7 FLUTAMIDE ADVERSE_EFFECT REP_1_Impotence 13311-84-7 FLUTAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 13311-84-7 FLUTAMIDE KNOWN_TOXICITY Reproductive System Toxicity 13311-84-7 FLUTAMIDE KNOWN_TOXICITY Carcinogenicity 13311-84-7 FLUTAMIDE THERAPEUTIC_CLASS Antineoplastics 13311-84-7 FLUTAMIDE PRODUCT_CLASS Anti-cancers 13311-84-7 FLUTAMIDE TA_LEVEL_3 prostate cancer 13311-84-7 FLUTAMIDE MESH_LEVEL_3 Anilides 13311-84-7 FLUTAMIDE MECH_LEVEL_3 androgen receptor 13311-84-7 FLUTAMIDE TISSUE_TOXICITY Hematuria 13311-84-7 FLUTAMIDE ADVERSE_EFFECT GIS_2_Rectal Hemorrhage 13311-84-7 FLUTAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 13311-84-7 FLUTAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 13311-84-7 FLUTAMIDE ADVERSE_EFFECT END_2_Gynecomastia 13311-84-7 FLUTAMIDE ADVERSE_EFFECT CVS_3_Hypertension 13311-84-7 FLUTAMIDE TISSUE_TOXICITY Hepatotoxicity 13311-84-7 FLUTAMIDE INDICATION Prostatic Cancer / Carcinoma of the Prostate 13311-84-7 FLUTAMIDE MESH_LEVEL_2 Amides 13311-84-7 FLUTAMIDE MECHANISM Modulate gene transcription 13311-84-7 FLUTAMIDE TA_LEVEL_2 Solid Tumors 13311-84-7 FLUTAMIDE MESH_LEVEL_1 Organic Chemicals 13311-84-7 FLUTAMIDE ADVERSE_EFFECT END_1_Hot Flashes 13311-84-7 FLUTAMIDE ADVERSE_EFFECT KID_2_Hematuria 13311-84-7 FLUTAMIDE ADVERSE_EFFECT BBM_3_Anemia 13311-84-7 FLUTAMIDE TISSUE_TOXICITY Carcinogenicity 13311-84-7 FLUTAMIDE ADVERSE_EFFECT GIS_1_Nausea 13311-84-7 FLUTAMIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 13311-84-7 FLUTAMIDE TISSUE_TOXICITY Impotence 13311-84-7 FLUTAMIDE ZERO_CLASS N 13311-84-7 FLUTAMIDE STRUCTURE_ACTIVITY Androgen receptor antagonist 13311-84-7 FLUTAMIDE ADVERSE_EFFECT SKN_1_Skin Rash 13311-84-7 FLUTAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 13311-84-7 FLUTAMIDE KNOWN_TOXICITY Hepatotoxicity 13311-84-7 FLUTAMIDE MECH_LEVEL_1 Hormone modulation 13311-84-7 FLUTAMIDE MECH_LEVEL_2 Androgen receptor antagonist 13311-84-7 FLUTAMIDE ADVERSE_EFFECT GUS_2_Cystitis 13311-84-7 FLUTAMIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 13311-84-7 FLUTAMIDE ACTIVITY_CLASS Androgen antagonist 13311-84-7 FLUTAMIDE TA_LEVEL_1 Oncology 13311-84-7 FLUTAMIDE KNOWN_TOXICITY Nephrotoxicity 13311-84-7 FLUTAMIDE ADVERSE_EFFECT PSY_3_Depression 13311-84-7 FLUTAMIDE ADVERSE_EFFECT NEU_3_Drowsiness 13311-84-7 FLUTAMIDE ADVERSE_EFFECT REP_1_Decreased Libido 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_2_Dermatitis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_2_Pruritis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT NEU_1_Headache 80474-14-2 FLUTICASONE PROPIONATE THERAPEUTIC_CLASS Corticosteroids 80474-14-2 FLUTICASONE PROPIONATE INDICATION Asthma 80474-14-2 FLUTICASONE PROPIONATE MECHANISM Modulate gene transcription 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_3_Infected Eczema 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT END_2_Cushingoid Features 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT LUN_3_Exacerbation of Asthma 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_2_Dry Skin 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_2_Sinusitis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT GIS_2_Dyspepsia 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT IMU_3_Contact Dermatitis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT NEU_3_Dizziness 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT PSY_3_Depression 80474-14-2 FLUTICASONE PROPIONATE INDICATION Allergic Rhinitis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_3_Folliculitis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT END_2_Growth Velocity Reduction 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT OCU_1_Ocular Irritation 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_1_Nasal Congestion 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_2_Fever 80474-14-2 FLUTICASONE PROPIONATE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 80474-14-2 FLUTICASONE PROPIONATE INDICATION Atopic Dermatitis / Eczema 80474-14-2 FLUTICASONE PROPIONATE MODE_CLASS Receptor Agonist 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT GIS_2_Diarrhea 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT END_2_Hyperglycemia 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT LUN_3_Bronchospasm 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_2_Weight Gain 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT BBM_3_Ecchymosis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT MSK_1_Joint Pain 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_2_Burning Sensation 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_2_Skin Irritation 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_1_Pain in the Nasal Sinus 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_3_Miliaria 80474-14-2 FLUTICASONE PROPIONATE INDICATION Psoriasis 80474-14-2 FLUTICASONE PROPIONATE INDICATION Non-Alergic Rhinitis 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_1_Rash 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_3_Eczema 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT LUN_2_Dysphonia 80474-14-2 FLUTICASONE PROPIONATE PRODUCT_CLASS Anti-inflammatories 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT SKN_3_Skin Infection 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_2_Influenza 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT REP_3_Dysmenorrhea 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT PSY_3_Aggression 80474-14-2 FLUTICASONE PROPIONATE ADVERSE_EFFECT XXX_2_Oral Candidiasis 119006-77-8 FLUTRIMAZOLE MODE_CLASS Enzyme Inhibitor 119006-77-8 FLUTRIMAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor 119006-77-8 FLUTRIMAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 119006-77-8 FLUTRIMAZOLE MECHANISM Modulate channel gating 119006-77-8 FLUTRIMAZOLE MODE_CLASS Channel Blocker 93957-54-1 FLUVASTATIN TA_LEVEL_2 Lipid lowering agent 93957-54-1 FLUVASTATIN PRODUCT_CLASS Cardiovasculars 93957-54-1 FLUVASTATIN MECH_LEVEL_3 HMG-CoA reductase 93957-54-1 FLUVASTATIN INDICATION Mixed Dyslipidemia 93957-54-1 FLUVASTATIN MODE_CLASS Enzyme Inhibitor 93957-54-1 FLUVASTATIN ADVERSE_EFFECT KID_1_Renal Dysfunction 93957-54-1 FLUVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 93957-54-1 FLUVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 93957-54-1 FLUVASTATIN ADVERSE_EFFECT MSK_3_Back Pain 93957-54-1 FLUVASTATIN ADVERSE_EFFECT NEU_3_Dizziness 93957-54-1 FLUVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 93957-54-1 FLUVASTATIN ZERO_CLASS N 93957-54-1 FLUVASTATIN ADVERSE_EFFECT MSK_1_Myalgia 93957-54-1 FLUVASTATIN TISSUE_TOXICITY Rhabdomyolysis 93957-54-1 FLUVASTATIN INDICATION Arterioslerotic Coronary Artery Disease / Coronary Heart Disease / Ischemic Heart Disease 93957-54-1 FLUVASTATIN MESH_LEVEL_3 Naphthalenes 93957-54-1 FLUVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 93957-54-1 FLUVASTATIN KNOWN_TOXICITY Carcinogenicity 93957-54-1 FLUVASTATIN ADVERSE_EFFECT XXX_2_Sinusitis 93957-54-1 FLUVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 93957-54-1 FLUVASTATIN MECH_LEVEL_1 Lipid lowering 93957-54-1 FLUVASTATIN INDICATION Reduction of Atheroslerotic Events 93957-54-1 FLUVASTATIN ADVERSE_EFFECT MSK_3_Arthralgia 93957-54-1 FLUVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 93957-54-1 FLUVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 93957-54-1 FLUVASTATIN ADVERSE_EFFECT LUN_3_Cough 93957-54-1 FLUVASTATIN TISSUE_TOXICITY Carcinogenicity 93957-54-1 FLUVASTATIN ADVERSE_EFFECT MSK_1_Rhabdomyolysis 93957-54-1 FLUVASTATIN ADVERSE_EFFECT MSK_1_Muscle Pain 93957-54-1 FLUVASTATIN ADVERSE_EFFECT GIS_3_Constipation 93957-54-1 FLUVASTATIN ADVERSE_EFFECT XXX_3_Rhinitis 93957-54-1 FLUVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 93957-54-1 FLUVASTATIN ADVERSE_EFFECT XXX_2_Pharyngitis 93957-54-1 FLUVASTATIN ADVERSE_EFFECT NEU_2_Headache 93957-54-1 FLUVASTATIN KNOWN_TOXICITY Musculoskeletal System Toxicity 93957-54-1 FLUVASTATIN TA_LEVEL_1 Cardiovascular 93957-54-1 FLUVASTATIN ADVERSE_EFFECT LUN_2_Bronchitis 93957-54-1 FLUVASTATIN MECHANISM Inhibit cholesterol biosynthesis 93957-54-1 FLUVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 93957-54-1 FLUVASTATIN INDICATION Hypercholesterolemia 93957-54-1 FLUVASTATIN ADVERSE_EFFECT MSK_1_Myopathy 93957-54-1 FLUVASTATIN ADVERSE_EFFECT SKN_2_Rash 93957-54-1 FLUVASTATIN ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 93957-55-2 FLUVASTATIN ADVERSE_EFFECT MSK_1_Myopathy 93957-55-2 FLUVASTATIN INDICATION Hypercholesterolemia 93957-55-2 FLUVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 93957-55-2 FLUVASTATIN MECHANISM Inhibit cholesterol biosynthesis 93957-55-2 FLUVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 93957-55-2 FLUVASTATIN MESH_LEVEL_3 Naphthalenes 93957-55-2 FLUVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 93957-55-2 FLUVASTATIN KNOWN_TOXICITY Carcinogenicity 93957-55-2 FLUVASTATIN ADVERSE_EFFECT XXX_2_Sinusitis 93957-55-2 FLUVASTATIN ADVERSE_EFFECT LUN_3_Cough 93957-55-2 FLUVASTATIN ADVERSE_EFFECT MSK_3_Back Pain 93957-55-2 FLUVASTATIN ADVERSE_EFFECT MSK_1_Myalgia 93957-55-2 FLUVASTATIN INDICATION Reduction of Atheroslerotic Events 93957-55-2 FLUVASTATIN MECH_LEVEL_1 Lipid lowering 93957-55-2 FLUVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 93957-55-2 FLUVASTATIN INDICATION Arterioslerotic Coronary Artery Disease / Coronary Heart Disease / Ischemic Heart Disease 93957-55-2 FLUVASTATIN ADVERSE_EFFECT MSK_1_Rhabdomyolysis 93957-55-2 FLUVASTATIN TISSUE_TOXICITY Rhabdomyolysis 93957-55-2 FLUVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 93957-55-2 FLUVASTATIN ADVERSE_EFFECT LUN_2_Bronchitis 93957-55-2 FLUVASTATIN ADVERSE_EFFECT GIS_3_Constipation 93957-55-2 FLUVASTATIN ADVERSE_EFFECT MSK_3_Arthralgia 93957-55-2 FLUVASTATIN ADVERSE_EFFECT MSK_1_Muscle Pain 93957-55-2 FLUVASTATIN TISSUE_TOXICITY Carcinogenicity 93957-55-2 FLUVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 93957-55-2 FLUVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 93957-55-2 FLUVASTATIN ZERO_CLASS N 93957-55-2 FLUVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 93957-55-2 FLUVASTATIN ADVERSE_EFFECT NEU_3_Dizziness 93957-55-2 FLUVASTATIN ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 93957-55-2 FLUVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 93957-55-2 FLUVASTATIN ADVERSE_EFFECT KID_1_Renal Dysfunction 93957-55-2 FLUVASTATIN MODE_CLASS Enzyme Inhibitor 93957-55-2 FLUVASTATIN INDICATION Mixed Dyslipidemia 93957-55-2 FLUVASTATIN MECH_LEVEL_3 HMG-CoA reductase 93957-55-2 FLUVASTATIN PRODUCT_CLASS Cardiovasculars 93957-55-2 FLUVASTATIN TA_LEVEL_2 Lipid lowering agent 93957-55-2 FLUVASTATIN TA_LEVEL_1 Cardiovascular 93957-55-2 FLUVASTATIN KNOWN_TOXICITY Musculoskeletal System Toxicity 93957-55-2 FLUVASTATIN ADVERSE_EFFECT NEU_2_Headache 93957-55-2 FLUVASTATIN ADVERSE_EFFECT XXX_2_Pharyngitis 93957-55-2 FLUVASTATIN ADVERSE_EFFECT XXX_3_Rhinitis 93957-55-2 FLUVASTATIN ADVERSE_EFFECT SKN_2_Rash 61718-82-9 FLUVOXAMINE INDICATION Obsessive-Compulsive Disorder (OCD) 61718-82-9 FLUVOXAMINE MECHANISM Prolong/enhance neural transmission 61718-82-9 FLUVOXAMINE THERAPEUTIC_CLASS Antidepressants 61718-82-9 FLUVOXAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 61718-82-9 FLUVOXAMINE PRODUCT_CLASS Central Nervous System (CNS) 61718-82-9 FLUVOXAMINE INDICATION Depression 61718-82-9 FLUVOXAMINE MODE_CLASS Solute transporter inhibitor 54739-18-3 FLUVOXAMINE INDICATION Obsessive-Compulsive Disorder (OCD) 54739-18-3 FLUVOXAMINE MECHANISM Prolong/enhance neural transmission 54739-18-3 FLUVOXAMINE MODE_CLASS Solute transporter inhibitor 54739-18-3 FLUVOXAMINE INDICATION Depression 54739-18-3 FLUVOXAMINE THERAPEUTIC_CLASS Antidepressants 54739-18-3 FLUVOXAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 54739-18-3 FLUVOXAMINE PRODUCT_CLASS Central Nervous System (CNS) 59-30-3 FOLIC ACID INDICATION Methotrexate Toxicity Prophylaxis 59-30-3 FOLIC ACID ADVERSE_EFFECT PSY_3_Depression 59-30-3 FOLIC ACID INDICATION Sickle Cell Anemia 59-30-3 FOLIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 59-30-3 FOLIC ACID MODE_CLASS Endogenous Enzyme Substrate 59-30-3 FOLIC ACID ADVERSE_EFFECT PSY_3_Irritability 59-30-3 FOLIC ACID INDICATION Tropical Sprue 59-30-3 FOLIC ACID ADVERSE_EFFECT GIS_3_Flatulence 59-30-3 FOLIC ACID ADVERSE_EFFECT GIS_3_Nausea / Vomiting 59-30-3 FOLIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 59-30-3 FOLIC ACID INDICATION Megaloblastic Anemia 59-30-3 FOLIC ACID MECHANISM Inhibit precursor synthesis 59-30-3 FOLIC ACID ADVERSE_EFFECT PSY_3_Anorexia 59-30-3 FOLIC ACID ADVERSE_EFFECT GIS_3_Abdominal Distention 59-30-3 FOLIC ACID INDICATION Nutritional Supplement 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT OCU_2_Blurred Vision 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT SKN_2_Rash 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT XXX_2_Pharyngitis 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT XXX_2_Hiccup 7554-65-6 4-METHYLPYRAZOLE TA_LEVEL_2 Antidote 7554-65-6 4-METHYLPYRAZOLE TA_LEVEL_1 Other Human Uses 7554-65-6 4-METHYLPYRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT MSK_2_Back Pain 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT NEU_1_Dizziness 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 7554-65-6 4-METHYLPYRAZOLE ZERO_CLASS N 7554-65-6 4-METHYLPYRAZOLE THERAPEUTIC_CLASS Antidotes 7554-65-6 4-METHYLPYRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT OCU_2_Visual Impairment 7554-65-6 4-METHYLPYRAZOLE MESH_LEVEL_3 Pyrazoles 7554-65-6 4-METHYLPYRAZOLE INDICATION Ethylene Glycol Intoxication 7554-65-6 4-METHYLPYRAZOLE KNOWN_TOXICITY Cardiovascular Toxicity 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT NEU_2_Drowsiness 7554-65-6 4-METHYLPYRAZOLE TISSUE_TOXICITY Hypotension 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT CVS_2_Hypotension 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT GIS_2_Dyspepsia 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT LYM_2_Lymphangitis 7554-65-6 4-METHYLPYRAZOLE TA_LEVEL_3 none 7554-65-6 4-METHYLPYRAZOLE INDICATION Methanol Intoxication 7554-65-6 4-METHYLPYRAZOLE MECH_LEVEL_2 blocks oxidation of ethanol 7554-65-6 4-METHYLPYRAZOLE MODE_CLASS Enzyme Inhibitor 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT NEU_1_Headache 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT GIS_2_Metallic Taste 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT IMU_2_Eosinophilia 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT BBM_2_Anemia 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT XXX_2_Fever 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT PSY_2_Anorexia 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT GIS_2_Diarrhea 7554-65-6 4-METHYLPYRAZOLE MECHANISM Inhibit precursor synthesis 7554-65-6 4-METHYLPYRAZOLE STRUCTURE_ACTIVITY Alcohol dehydrogenase inhibitor 7554-65-6 4-METHYLPYRAZOLE ACTIVITY_CLASS Alcohol dehydrogenase inhibitor 7554-65-6 4-METHYLPYRAZOLE PRODUCT_CLASS Other Human Uses 7554-65-6 4-METHYLPYRAZOLE ADVERSE_EFFECT XXX_2_Injection Site Reaction 7554-65-6 4-METHYLPYRAZOLE MECH_LEVEL_3 Alcohol dehydrogenase 144245-52-3 FOMIVIRSEN INDICATION Cytomegalovirus (CMV) Retinitis 144245-52-3 FOMIVIRSEN MODE_CLASS Distorts /blocks macromolecular scaffold function 144245-52-3 FOMIVIRSEN MECHANISM Inhibit DNA synthesis, repair, and function 66575-29-9 FORSKOLIN INDICATION Glaucoma 63585-09-1 FOSCARNET KNOWN_TOXICITY Nephrotoxicity 63585-09-1 FOSCARNET TISSUE_TOXICITY Atrioventricular Blockade 63585-09-1 FOSCARNET STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 63585-09-1 FOSCARNET ADVERSE_EFFECT CVS_3_Sinus Tachycardia 63585-09-1 FOSCARNET MECH_LEVEL_2 Inhibit viral DNA synthesis 63585-09-1 FOSCARNET ADVERSE_EFFECT NEU_2_Paresthesia 63585-09-1 FOSCARNET ADVERSE_EFFECT PSY_2_Confusion 63585-09-1 FOSCARNET MESH_LEVEL_1 Organic Chemicals 63585-09-1 FOSCARNET ADVERSE_EFFECT NEU_1_Headache 63585-09-1 FOSCARNET TISSUE_TOXICITY Cardiomyopathy 63585-09-1 FOSCARNET TISSUE_TOXICITY Seizures 63585-09-1 FOSCARNET KNOWN_TOXICITY Cardiovascular Toxicity 63585-09-1 FOSCARNET INDICATION Herpes Simplex Infection 63585-09-1 FOSCARNET MECH_LEVEL_1 Anti-viral 63585-09-1 FOSCARNET MECH_LEVEL_3 DNA-directed DNA polymerase 63585-09-1 FOSCARNET MESH_LEVEL_2 Organophosphorus Compounds 63585-09-1 FOSCARNET TA_LEVEL_2 Anti-viral 63585-09-1 FOSCARNET TA_LEVEL_1 Infectious Disease 63585-09-1 FOSCARNET PRODUCT_CLASS Anti-infectives 63585-09-1 FOSCARNET TISSUE_TOXICITY Renal Tubular Necrosis 63585-09-1 FOSCARNET TISSUE_TOXICITY Cardiac Arrest 63585-09-1 FOSCARNET ADVERSE_EFFECT GIS_1_Nausea / Vomiting 63585-09-1 FOSCARNET ADVERSE_EFFECT CVS_3_Atrial Fibrillation 63585-09-1 FOSCARNET ADVERSE_EFFECT SKN_3_Pruritis 63585-09-1 FOSCARNET ADVERSE_EFFECT BBM_2_Anemia 63585-09-1 FOSCARNET MECHANISM Inhibit viral DNA synthesis 63585-09-1 FOSCARNET ACTIVITY_CLASS Anti-viral 63585-09-1 FOSCARNET TISSUE_TOXICITY Atrial Fibrillation 63585-09-1 FOSCARNET TISSUE_TOXICITY Congestive Heart Failure 63585-09-1 FOSCARNET MODE_CLASS Enzyme Inhibitor 63585-09-1 FOSCARNET ADVERSE_EFFECT PSY_2_Anxiety 63585-09-1 FOSCARNET ADVERSE_EFFECT CVS_3_Congestive Heart Failure 63585-09-1 FOSCARNET ADVERSE_EFFECT ELT_2_Hypocalcemia 63585-09-1 FOSCARNET ADVERSE_EFFECT BBM_2_Bone Marrow Suppression 63585-09-1 FOSCARNET ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 63585-09-1 FOSCARNET ADVERSE_EFFECT BBM_2_Neutropenia 63585-09-1 FOSCARNET KNOWN_TOXICITY Neurotoxicity 63585-09-1 FOSCARNET ADVERSE_EFFECT KID_1_Renal Tubular Necrosis 63585-09-1 FOSCARNET MESH_LEVEL_3 Phosphonic Acids 63585-09-1 FOSCARNET ZERO_CLASS N 63585-09-1 FOSCARNET ADVERSE_EFFECT PSY_2_Depression 63585-09-1 FOSCARNET ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 63585-09-1 FOSCARNET ADVERSE_EFFECT CVS_3_Cardiac Arrest 63585-09-1 FOSCARNET ADVERSE_EFFECT NEU_1_Seizures 63585-09-1 FOSCARNET ADVERSE_EFFECT CVS_3_Cardiomyopathy 63585-09-1 FOSCARNET ADVERSE_EFFECT NEU_3_Meningitis 63585-09-1 FOSCARNET TA_LEVEL_3 viral replication inhibitor 63585-09-1 FOSCARNET INDICATION Cytomegalovirus (CMV) Retinitis 63585-09-1 FOSCARNET THERAPEUTIC_CLASS Antivirals, Systemic 34156-56-4 FOSCARNET PRODUCT_CLASS Anti-infectives 34156-56-4 FOSCARNET KNOWN_TOXICITY Neurotoxicity 34156-56-4 FOSCARNET TISSUE_TOXICITY Renal Tubular Necrosis 34156-56-4 FOSCARNET ADVERSE_EFFECT GIS_1_Nausea / Vomiting 34156-56-4 FOSCARNET ADVERSE_EFFECT CVS_3_Atrial Fibrillation 34156-56-4 FOSCARNET ADVERSE_EFFECT SKN_3_Pruritis 34156-56-4 FOSCARNET ADVERSE_EFFECT BBM_2_Anemia 34156-56-4 FOSCARNET ADVERSE_EFFECT KID_1_Renal Tubular Necrosis 34156-56-4 FOSCARNET ACTIVITY_CLASS Anti-viral 34156-56-4 FOSCARNET ADVERSE_EFFECT CVS_3_Congestive Heart Failure 34156-56-4 FOSCARNET ADVERSE_EFFECT PSY_2_Anxiety 34156-56-4 FOSCARNET MODE_CLASS Enzyme Inhibitor 34156-56-4 FOSCARNET TISSUE_TOXICITY Congestive Heart Failure 34156-56-4 FOSCARNET TISSUE_TOXICITY Atrial Fibrillation 34156-56-4 FOSCARNET MESH_LEVEL_1 Organic Chemicals 34156-56-4 FOSCARNET ADVERSE_EFFECT BBM_2_Bone Marrow Suppression 34156-56-4 FOSCARNET ADVERSE_EFFECT PSY_2_Confusion 34156-56-4 FOSCARNET ADVERSE_EFFECT NEU_2_Paresthesia 34156-56-4 FOSCARNET ADVERSE_EFFECT NEU_1_Headache 34156-56-4 FOSCARNET ADVERSE_EFFECT CVS_3_Sinus Tachycardia 34156-56-4 FOSCARNET STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 34156-56-4 FOSCARNET TISSUE_TOXICITY Atrioventricular Blockade 34156-56-4 FOSCARNET KNOWN_TOXICITY Nephrotoxicity 34156-56-4 FOSCARNET MECHANISM Inhibit viral DNA synthesis 34156-56-4 FOSCARNET MECH_LEVEL_2 Inhibit viral DNA synthesis 34156-56-4 FOSCARNET MESH_LEVEL_3 Phosphonic Acids 34156-56-4 FOSCARNET TISSUE_TOXICITY Cardiac Arrest 34156-56-4 FOSCARNET THERAPEUTIC_CLASS Antivirals, Systemic 34156-56-4 FOSCARNET ADVERSE_EFFECT ELT_2_Hypocalcemia 34156-56-4 FOSCARNET ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 34156-56-4 FOSCARNET ADVERSE_EFFECT BBM_2_Neutropenia 34156-56-4 FOSCARNET TA_LEVEL_1 Infectious Disease 34156-56-4 FOSCARNET TA_LEVEL_2 Anti-viral 34156-56-4 FOSCARNET MESH_LEVEL_2 Organophosphorus Compounds 34156-56-4 FOSCARNET MECH_LEVEL_3 DNA-directed DNA polymerase 34156-56-4 FOSCARNET MECH_LEVEL_1 Anti-viral 34156-56-4 FOSCARNET INDICATION Herpes Simplex Infection 34156-56-4 FOSCARNET KNOWN_TOXICITY Cardiovascular Toxicity 34156-56-4 FOSCARNET TISSUE_TOXICITY Seizures 34156-56-4 FOSCARNET TISSUE_TOXICITY Cardiomyopathy 34156-56-4 FOSCARNET ZERO_CLASS N 34156-56-4 FOSCARNET ADVERSE_EFFECT PSY_2_Depression 34156-56-4 FOSCARNET ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 34156-56-4 FOSCARNET ADVERSE_EFFECT CVS_3_Cardiac Arrest 34156-56-4 FOSCARNET ADVERSE_EFFECT NEU_1_Seizures 34156-56-4 FOSCARNET ADVERSE_EFFECT CVS_3_Cardiomyopathy 34156-56-4 FOSCARNET ADVERSE_EFFECT NEU_3_Meningitis 34156-56-4 FOSCARNET TA_LEVEL_3 viral replication inhibitor 34156-56-4 FOSCARNET INDICATION Cytomegalovirus (CMV) Retinitis 78964-85-9 FOSFOMYCIN MECHANISM Inhibit bacterial cell wall biosynthesis 78964-85-9 FOSFOMYCIN PRODUCT_CLASS Anti-infectives 78964-85-9 FOSFOMYCIN THERAPEUTIC_CLASS Antibacterials 78964-85-9 FOSFOMYCIN MODE_CLASS Enzyme Inhibitor 78964-85-9 FOSFOMYCIN INDICATION Acute Cystitis 23155-02-4 FOSFOMYCIN THERAPEUTIC_CLASS Antibacterials 23155-02-4 FOSFOMYCIN MECHANISM Inhibit bacterial cell wall biosynthesis 23155-02-4 FOSFOMYCIN PRODUCT_CLASS Anti-infectives 23155-02-4 FOSFOMYCIN MODE_CLASS Enzyme Inhibitor 23155-02-4 FOSFOMYCIN INDICATION Acute Cystitis 98048-97-6 FOSINOPRIL INDICATION Congestive Heart Failure (CHF) 98048-97-6 FOSINOPRIL MODE_CLASS Enzyme Inhibitor 98048-97-6 FOSINOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 98048-97-6 FOSINOPRIL INDICATION Hypertension 98048-97-6 FOSINOPRIL MECHANISM Reduce vasoconstriction 98048-97-6 FOSINOPRIL THERAPEUTIC_CLASS Congestive Heart Failure 98048-97-6 FOSINOPRIL PRODUCT_CLASS Cardiovasculars 98048-97-6 FOSINOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 88889-14-9 FOSINOPRIL INDICATION Hypertension 88889-14-9 FOSINOPRIL THERAPEUTIC_CLASS Antihypertensive Agents 88889-14-9 FOSINOPRIL MODE_CLASS Enzyme Inhibitor 88889-14-9 FOSINOPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 88889-14-9 FOSINOPRIL MECHANISM Reduce vasoconstriction 88889-14-9 FOSINOPRIL THERAPEUTIC_CLASS Congestive Heart Failure 88889-14-9 FOSINOPRIL PRODUCT_CLASS Cardiovasculars 88889-14-9 FOSINOPRIL INDICATION Congestive Heart Failure (CHF) 92134-98-0 FOSPHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 92134-98-0 FOSPHENYTOIN MODE_CLASS Channel Blocker 92134-98-0 FOSPHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 92134-98-0 FOSPHENYTOIN MECHANISM Block neural transmission 92134-98-0 FOSPHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 93390-81-9 FOSPHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 93390-81-9 FOSPHENYTOIN MECHANISM Block neural transmission 93390-81-9 FOSPHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 93390-81-9 FOSPHENYTOIN MODE_CLASS Channel Blocker 93390-81-9 FOSPHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 167838-64-4 FR-173657 MECHANISM Modulate G-protein coupled signal transduction 167838-64-4 FR-173657 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 167838-64-4 FR-173657 PRODUCT_CLASS Anti-inflammatories 67-45-8 FURAZOLIDONE INDICATION Diarrhea 67-45-8 FURAZOLIDONE THERAPEUTIC_CLASS Antiparasitics 67-45-8 FURAZOLIDONE ADVERSE_EFFECT XXX_3_Disulfiram-Like Reactions 67-45-8 FURAZOLIDONE ADVERSE_EFFECT BBM_3_Induces Hemolysis in G6PD Deficiency 67-45-8 FURAZOLIDONE INDICATION Traveler's Diarrhea 67-45-8 FURAZOLIDONE KNOWN_TOXICITY Cardiovascular Toxicity 67-45-8 FURAZOLIDONE ADVERSE_EFFECT XXX_3_Fever 67-45-8 FURAZOLIDONE THERAPEUTIC_CLASS Antibacterials, Systemic 67-45-8 FURAZOLIDONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 67-45-8 FURAZOLIDONE INDICATION Cholera 67-45-8 FURAZOLIDONE ADVERSE_EFFECT SKN_3_Anal Pruritis 67-45-8 FURAZOLIDONE TISSUE_TOXICITY Hypotension 67-45-8 FURAZOLIDONE ADVERSE_EFFECT IMU_2_Urticaria 67-45-8 FURAZOLIDONE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 67-45-8 FURAZOLIDONE INDICATION Giardiasis 67-45-8 FURAZOLIDONE PRODUCT_CLASS Anti-infectives 67-45-8 FURAZOLIDONE ADVERSE_EFFECT NEU_2_Headache 67-45-8 FURAZOLIDONE ADVERSE_EFFECT CVS_2_Hypotension 67-45-8 FURAZOLIDONE ADVERSE_EFFECT MSK_2_Arthralgia 67-45-8 FURAZOLIDONE ADVERSE_EFFECT GIS_2_Colitis 67-45-8 FURAZOLIDONE ADVERSE_EFFECT GIS_3_Proctitis 67-45-8 FURAZOLIDONE MECHANISM Inhibit DNA synthesis, repair, and function 67-45-8 FURAZOLIDONE INDICATION Trichomoniasis 67-45-8 FURAZOLIDONE ADVERSE_EFFECT XXX_2_Malaise 54-31-9 FUROSEMIDE ADVERSE_EFFECT NEU_3_Vertigo 54-31-9 FUROSEMIDE ADVERSE_EFFECT BBM_3_Anemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT XXX_2_Hypovolemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT ELT_2_Hypomagnesemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT KID_2_Hyperuricemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT OCU_3_Blurred Vision 54-31-9 FUROSEMIDE INDICATION Edema 54-31-9 FUROSEMIDE ADVERSE_EFFECT SKN_3_Dermatitis 54-31-9 FUROSEMIDE THERAPEUTIC_CLASS Antihypertensive Agents 54-31-9 FUROSEMIDE KNOWN_TOXICITY Nephrotoxicity 54-31-9 FUROSEMIDE TISSUE_TOXICITY Interstitial Nephritis 54-31-9 FUROSEMIDE INDICATION Hypercalcemia 54-31-9 FUROSEMIDE INDICATION Pulmonary Edema 54-31-9 FUROSEMIDE MESH_LEVEL_2 Amides 54-31-9 FUROSEMIDE INDICATION Heart Failure 54-31-9 FUROSEMIDE ADVERSE_EFFECT OCU_3_Xanthopsia 54-31-9 FUROSEMIDE ADVERSE_EFFECT KID_1_Polyuria 54-31-9 FUROSEMIDE ADVERSE_EFFECT NEU_2_Lightheadedness 54-31-9 FUROSEMIDE ADVERSE_EFFECT OTO_3_Ototoxicity 54-31-9 FUROSEMIDE ADVERSE_EFFECT ELT_2_Hypocalcemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT PSY_3_Anorexia 54-31-9 FUROSEMIDE ZERO_CLASS N 54-31-9 FUROSEMIDE ADVERSE_EFFECT GIS_3_Diarrhea 54-31-9 FUROSEMIDE ADVERSE_EFFECT END_2_Hyperglycemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT NEU_3_Headache 54-31-9 FUROSEMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 54-31-9 FUROSEMIDE ADVERSE_EFFECT ELT_2_Hyponatremia 54-31-9 FUROSEMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 54-31-9 FUROSEMIDE ADVERSE_EFFECT LIV_3_Cholestasis 54-31-9 FUROSEMIDE ADVERSE_EFFECT KID_3_Interstitial Nephritis 54-31-9 FUROSEMIDE ADVERSE_EFFECT END_2_Hypercholesteremia 54-31-9 FUROSEMIDE ADVERSE_EFFECT BBM_3_Neutropenia 54-31-9 FUROSEMIDE ADVERSE_EFFECT BBM_3_Leukopenia 54-31-9 FUROSEMIDE ADVERSE_EFFECT END_2_Hypertriglyceridemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT NEU_2_Paresthesia 54-31-9 FUROSEMIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 54-31-9 FUROSEMIDE ADVERSE_EFFECT NEU_2_Dizziness 54-31-9 FUROSEMIDE ADVERSE_EFFECT ELT_1_Hypokalemia 54-31-9 FUROSEMIDE ADVERSE_EFFECT GIS_3_Constipation 54-31-9 FUROSEMIDE MODE_CLASS Channel Blocker, selective 54-31-9 FUROSEMIDE INDICATION Nephrotic Syndrome 54-31-9 FUROSEMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 54-31-9 FUROSEMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 54-31-9 FUROSEMIDE TA_LEVEL_2 Electrolytic, Caloric and Water Balance 54-31-9 FUROSEMIDE ACTIVITY_CLASS Diuretic 54-31-9 FUROSEMIDE TA_LEVEL_1 Cardiovascular 54-31-9 FUROSEMIDE INDICATION Hypertension 54-31-9 FUROSEMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 54-31-9 FUROSEMIDE THERAPEUTIC_CLASS Diuretics 54-31-9 FUROSEMIDE INDICATION Ascites 54-31-9 FUROSEMIDE MESH_LEVEL_1 Organic Chemicals 54-31-9 FUROSEMIDE TA_LEVEL_3 Diuretic 54-31-9 FUROSEMIDE PRODUCT_CLASS Cardiovasculars 54-31-9 FUROSEMIDE INDICATION Hypertensive Emergency 54-31-9 FUROSEMIDE MECH_LEVEL_3 Acid-sensitive K+ channel 2 54-31-9 FUROSEMIDE MECH_LEVEL_1 Diuretic 54-31-9 FUROSEMIDE MECH_LEVEL_2 Loop Diueretic 54-31-9 FUROSEMIDE MESH_LEVEL_3 Sulfonamides 60643-86-9 VIGABATRIN PRODUCT_CLASS Central Nervous System (CNS) 60643-86-9 VIGABATRIN MECHANISM Prolong/enhance neural transmission 60643-86-9 VIGABATRIN MODE_CLASS Enzyme Inhibitor 60643-86-9 VIGABATRIN INDICATION Partial Seizures 60643-86-9 VIGABATRIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 60643-86-9 VIGABATRIN STRUCTURE_ACTIVITY GABA reuptake inhibitor 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_3_Infection 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_3_Amnesia 60142-96-3 GABAPENTIN ADVERSE_EFFECT GIS_2_Constipation 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_1_Fatigue 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_1_Ataxia 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_3_Restlessness 60142-96-3 GABAPENTIN ADVERSE_EFFECT GIS_2_Dyspepsia 60142-96-3 GABAPENTIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 60142-96-3 GABAPENTIN TA_LEVEL_3 GABA analogs 60142-96-3 GABAPENTIN MESH_LEVEL_1 Organic Chemicals 60142-96-3 GABAPENTIN MESH_LEVEL_3 Acids, Acyclic 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_1_Malaise 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_3_Pharyngitis 60142-96-3 GABAPENTIN TA_LEVEL_1 Central Nervous System (CNS) 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_2_Vertigo 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_1_Peripheral Edema 60142-96-3 GABAPENTIN ADVERSE_EFFECT OCU_2_Diplopia 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_2_Paresthesia 60142-96-3 GABAPENTIN ADVERSE_EFFECT OCU_3_Amblyopia 60142-96-3 GABAPENTIN ADVERSE_EFFECT PSY_2_Emotional Lability 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_1_Weight Gain 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_1_Nystagmus 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_1_Drowsiness 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_1_Tremor 60142-96-3 GABAPENTIN ADVERSE_EFFECT PSY_3_Depression 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_3_Dysarthria 60142-96-3 GABAPENTIN MECH_LEVEL_2 GABA analog 60142-96-3 GABAPENTIN ADVERSE_EFFECT LIV_3_Hepatitis 60142-96-3 GABAPENTIN ADVERSE_EFFECT NEU_1_Dizziness 60142-96-3 GABAPENTIN ADVERSE_EFFECT PSY_3_Anorexia 60142-96-3 GABAPENTIN MECHANISM Reduce muscle contractile force 60142-96-3 GABAPENTIN INDICATION Partial Seizures 60142-96-3 GABAPENTIN ADVERSE_EFFECT PSY_2_Anxiety 60142-96-3 GABAPENTIN ZERO_CLASS N 60142-96-3 GABAPENTIN MODE_CLASS Channel Modulator 60142-96-3 GABAPENTIN ACTIVITY_CLASS Reduce glutamate release 60142-96-3 GABAPENTIN ADVERSE_EFFECT MSK_2_Arthralgia 60142-96-3 GABAPENTIN MECH_LEVEL_1 Modulate neural transmission 60142-96-3 GABAPENTIN MESH_LEVEL_2 Carboxylic Acids 60142-96-3 GABAPENTIN STRUCTURE_ACTIVITY Reduce glutamate release 60142-96-3 GABAPENTIN MECH_LEVEL_3 L-Type Ca++ channel 60142-96-3 GABAPENTIN TA_LEVEL_2 GABA analogs 60142-96-3 GABAPENTIN ADVERSE_EFFECT XXX_2_Xerostomia 60142-96-3 GABAPENTIN ADVERSE_EFFECT MSK_1_Back Pain 60142-96-3 GABAPENTIN ADVERSE_EFFECT BBM_3_Leukopenia 60142-96-3 GABAPENTIN PRODUCT_CLASS Central Nervous System (CNS) 60142-96-3 GABAPENTIN ADVERSE_EFFECT OCU_2_Blurred Vision 1953-04-4 GALANTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1953-04-4 GALANTAMINE ADVERSE_EFFECT NEU_1_Dizziness 1953-04-4 GALANTAMINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 1953-04-4 GALANTAMINE ADVERSE_EFFECT PSY_1_Insomnia 1953-04-4 GALANTAMINE ADVERSE_EFFECT PSY_3_Hallucinations 1953-04-4 GALANTAMINE KNOWN_TOXICITY Nephrotoxicity 1953-04-4 GALANTAMINE MECH_LEVEL_2 Enhance cholinergic transmission 1953-04-4 GALANTAMINE PRODUCT_CLASS Central Nervous System (CNS) 1953-04-4 GALANTAMINE MESH_LEVEL_3 Galanthamine 1953-04-4 GALANTAMINE MECH_LEVEL_3 Acetylcholinesterase 1953-04-4 GALANTAMINE MESH_LEVEL_1 Heterocyclic Compounds 1953-04-4 GALANTAMINE ADVERSE_EFFECT GUS_3_Urinary Tract Infection 1953-04-4 GALANTAMINE ADVERSE_EFFECT XXX_1_Weight Loss 1953-04-4 GALANTAMINE ADVERSE_EFFECT PSY_3_Confusion 1953-04-4 GALANTAMINE ADVERSE_EFFECT XXX_1_Fatigue 1953-04-4 GALANTAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 1953-04-4 GALANTAMINE ADVERSE_EFFECT CVS_2_Hypotension 1953-04-4 GALANTAMINE ADVERSE_EFFECT GIS_1_Diarrhea 1953-04-4 GALANTAMINE MODE_CLASS Enzyme Inhibitor 1953-04-4 GALANTAMINE TISSUE_TOXICITY Hypotension 1953-04-4 GALANTAMINE INDICATION Alzheimer's Disease 1953-04-4 GALANTAMINE MECH_LEVEL_1 Modulate neural transmission 1953-04-4 GALANTAMINE TA_LEVEL_2 Dementia 1953-04-4 GALANTAMINE ADVERSE_EFFECT XXX_3_Asthenia 1953-04-4 GALANTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 1953-04-4 GALANTAMINE ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 1953-04-4 GALANTAMINE ADVERSE_EFFECT GIS_1_Dyspepsia 1953-04-4 GALANTAMINE ADVERSE_EFFECT PSY_3_Agitation 1953-04-4 GALANTAMINE ADVERSE_EFFECT NEU_1_Drowsiness 1953-04-4 GALANTAMINE ADVERSE_EFFECT GIS_1_Vomiting 1953-04-4 GALANTAMINE TA_LEVEL_1 Central Nervous System (CNS) 1953-04-4 GALANTAMINE ADVERSE_EFFECT XXX_3_Rhinitis 1953-04-4 GALANTAMINE ADVERSE_EFFECT BBM_3_Anemia 1953-04-4 GALANTAMINE ADVERSE_EFFECT NEU_1_Headache 1953-04-4 GALANTAMINE ADVERSE_EFFECT NEU_1_Tremor 1953-04-4 GALANTAMINE ADVERSE_EFFECT CVS_3_Hypertension 1953-04-4 GALANTAMINE ADVERSE_EFFECT GIS_3_Constipation 1953-04-4 GALANTAMINE ACTIVITY_CLASS Cholinesterase inhibitor 1953-04-4 GALANTAMINE ADVERSE_EFFECT KID_3_Hematuria 1953-04-4 GALANTAMINE ADVERSE_EFFECT GIS_1_Abdominal Pain 1953-04-4 GALANTAMINE TA_LEVEL_3 Alzheimer's disease 1953-04-4 GALANTAMINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 1953-04-4 GALANTAMINE INDICATION Dementia 1953-04-4 GALANTAMINE MESH_LEVEL_2 Alkaloids 1953-04-4 GALANTAMINE MECHANISM Enhance cholinergic transmission 1953-04-4 GALANTAMINE THERAPEUTIC_CLASS Neurodegenerative Disorders 1953-04-4 GALANTAMINE TISSUE_TOXICITY Hematuria 1953-04-4 GALANTAMINE ZERO_CLASS N 1953-04-4 GALANTAMINE ADVERSE_EFFECT PSY_1_Depression 1953-04-4 GALANTAMINE ADVERSE_EFFECT NEU_2_Syncope 1953-04-4 GALANTAMINE ADVERSE_EFFECT PSY_1_Anorexia 357-70-0 GALANTAMINE ADVERSE_EFFECT NEU_1_Drowsiness 357-70-0 GALANTAMINE ADVERSE_EFFECT GIS_1_Vomiting 357-70-0 GALANTAMINE ADVERSE_EFFECT PSY_1_Insomnia 357-70-0 GALANTAMINE ADVERSE_EFFECT PSY_3_Hallucinations 357-70-0 GALANTAMINE KNOWN_TOXICITY Nephrotoxicity 357-70-0 GALANTAMINE MECH_LEVEL_2 Enhance cholinergic transmission 357-70-0 GALANTAMINE TA_LEVEL_3 Alzheimer's disease 357-70-0 GALANTAMINE PRODUCT_CLASS Central Nervous System (CNS) 357-70-0 GALANTAMINE MESH_LEVEL_3 Galanthamine 357-70-0 GALANTAMINE MESH_LEVEL_1 Heterocyclic Compounds 357-70-0 GALANTAMINE ADVERSE_EFFECT GUS_3_Urinary Tract Infection 357-70-0 GALANTAMINE ADVERSE_EFFECT XXX_3_Asthenia 357-70-0 GALANTAMINE ADVERSE_EFFECT XXX_1_Weight Loss 357-70-0 GALANTAMINE ADVERSE_EFFECT PSY_3_Confusion 357-70-0 GALANTAMINE ADVERSE_EFFECT XXX_1_Fatigue 357-70-0 GALANTAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 357-70-0 GALANTAMINE ADVERSE_EFFECT CVS_2_Hypotension 357-70-0 GALANTAMINE ADVERSE_EFFECT GIS_1_Diarrhea 357-70-0 GALANTAMINE MODE_CLASS Enzyme Inhibitor 357-70-0 GALANTAMINE TISSUE_TOXICITY Hypotension 357-70-0 GALANTAMINE INDICATION Alzheimer's Disease 357-70-0 GALANTAMINE MECH_LEVEL_1 Modulate neural transmission 357-70-0 GALANTAMINE TA_LEVEL_2 Dementia 357-70-0 GALANTAMINE MECH_LEVEL_3 Acetylcholinesterase 357-70-0 GALANTAMINE ADVERSE_EFFECT XXX_3_Rhinitis 357-70-0 GALANTAMINE ADVERSE_EFFECT KID_3_Hematuria 357-70-0 GALANTAMINE ADVERSE_EFFECT BBM_3_Anemia 357-70-0 GALANTAMINE ADVERSE_EFFECT NEU_1_Headache 357-70-0 GALANTAMINE ADVERSE_EFFECT NEU_1_Tremor 357-70-0 GALANTAMINE ADVERSE_EFFECT CVS_3_Hypertension 357-70-0 GALANTAMINE ADVERSE_EFFECT GIS_3_Constipation 357-70-0 GALANTAMINE ACTIVITY_CLASS Cholinesterase inhibitor 357-70-0 GALANTAMINE ZERO_CLASS N 357-70-0 GALANTAMINE TISSUE_TOXICITY Hematuria 357-70-0 GALANTAMINE MESH_LEVEL_2 Alkaloids 357-70-0 GALANTAMINE INDICATION Dementia 357-70-0 GALANTAMINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 357-70-0 GALANTAMINE ADVERSE_EFFECT NEU_2_Syncope 357-70-0 GALANTAMINE ADVERSE_EFFECT GIS_1_Abdominal Pain 357-70-0 GALANTAMINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 357-70-0 GALANTAMINE ADVERSE_EFFECT NEU_1_Dizziness 357-70-0 GALANTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 357-70-0 GALANTAMINE ADVERSE_EFFECT PSY_1_Anorexia 357-70-0 GALANTAMINE ADVERSE_EFFECT PSY_1_Depression 357-70-0 GALANTAMINE MECHANISM Enhance cholinergic transmission 357-70-0 GALANTAMINE THERAPEUTIC_CLASS Neurodegenerative Disorders 357-70-0 GALANTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 357-70-0 GALANTAMINE TA_LEVEL_1 Central Nervous System (CNS) 357-70-0 GALANTAMINE ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 357-70-0 GALANTAMINE ADVERSE_EFFECT GIS_1_Dyspepsia 357-70-0 GALANTAMINE ADVERSE_EFFECT PSY_3_Agitation 69353-21-5 GALANTAMINE ADVERSE_EFFECT NEU_2_Syncope 69353-21-5 GALANTAMINE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 69353-21-5 GALANTAMINE MESH_LEVEL_2 Alkaloids 69353-21-5 GALANTAMINE TISSUE_TOXICITY Hematuria 69353-21-5 GALANTAMINE ZERO_CLASS N 69353-21-5 GALANTAMINE ACTIVITY_CLASS Cholinesterase inhibitor 69353-21-5 GALANTAMINE ADVERSE_EFFECT GIS_3_Constipation 69353-21-5 GALANTAMINE ADVERSE_EFFECT CVS_3_Hypertension 69353-21-5 GALANTAMINE ADVERSE_EFFECT NEU_1_Tremor 69353-21-5 GALANTAMINE ADVERSE_EFFECT NEU_1_Headache 69353-21-5 GALANTAMINE ADVERSE_EFFECT BBM_3_Anemia 69353-21-5 GALANTAMINE ADVERSE_EFFECT KID_3_Hematuria 69353-21-5 GALANTAMINE ADVERSE_EFFECT XXX_3_Rhinitis 69353-21-5 GALANTAMINE MECH_LEVEL_1 Modulate neural transmission 69353-21-5 GALANTAMINE INDICATION Alzheimer's Disease 69353-21-5 GALANTAMINE TISSUE_TOXICITY Hypotension 69353-21-5 GALANTAMINE PRODUCT_CLASS Central Nervous System (CNS) 69353-21-5 GALANTAMINE MODE_CLASS Enzyme Inhibitor 69353-21-5 GALANTAMINE ADVERSE_EFFECT GIS_1_Diarrhea 69353-21-5 GALANTAMINE ADVERSE_EFFECT CVS_2_Hypotension 69353-21-5 GALANTAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 69353-21-5 GALANTAMINE ADVERSE_EFFECT XXX_1_Fatigue 69353-21-5 GALANTAMINE INDICATION Dementia 69353-21-5 GALANTAMINE ADVERSE_EFFECT PSY_3_Confusion 69353-21-5 GALANTAMINE ADVERSE_EFFECT XXX_1_Weight Loss 69353-21-5 GALANTAMINE ADVERSE_EFFECT XXX_3_Asthenia 69353-21-5 GALANTAMINE ADVERSE_EFFECT GUS_3_Urinary Tract Infection 69353-21-5 GALANTAMINE MESH_LEVEL_1 Heterocyclic Compounds 69353-21-5 GALANTAMINE MECH_LEVEL_3 Acetylcholinesterase 69353-21-5 GALANTAMINE MESH_LEVEL_3 Galanthamine 69353-21-5 GALANTAMINE TA_LEVEL_3 Alzheimer's disease 69353-21-5 GALANTAMINE TA_LEVEL_2 Dementia 69353-21-5 GALANTAMINE MECH_LEVEL_2 Enhance cholinergic transmission 69353-21-5 GALANTAMINE KNOWN_TOXICITY Nephrotoxicity 69353-21-5 GALANTAMINE ADVERSE_EFFECT PSY_3_Hallucinations 69353-21-5 GALANTAMINE ADVERSE_EFFECT PSY_1_Insomnia 69353-21-5 GALANTAMINE ADVERSE_EFFECT GIS_1_Vomiting 69353-21-5 GALANTAMINE ADVERSE_EFFECT NEU_1_Drowsiness 69353-21-5 GALANTAMINE ADVERSE_EFFECT PSY_3_Agitation 69353-21-5 GALANTAMINE ADVERSE_EFFECT GIS_1_Dyspepsia 69353-21-5 GALANTAMINE ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 69353-21-5 GALANTAMINE TA_LEVEL_1 Central Nervous System (CNS) 69353-21-5 GALANTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 69353-21-5 GALANTAMINE THERAPEUTIC_CLASS Neurodegenerative Disorders 69353-21-5 GALANTAMINE MECHANISM Enhance cholinergic transmission 69353-21-5 GALANTAMINE ADVERSE_EFFECT PSY_1_Anorexia 69353-21-5 GALANTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 69353-21-5 GALANTAMINE ADVERSE_EFFECT NEU_1_Dizziness 69353-21-5 GALANTAMINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 69353-21-5 GALANTAMINE ADVERSE_EFFECT GIS_1_Abdominal Pain 69353-21-5 GALANTAMINE ADVERSE_EFFECT PSY_1_Depression 65-29-2 GALLAMINE TRIETHIODIDE MECH_LEVEL_1 Depolarizing neuromuscular blocker 65-29-2 GALLAMINE TRIETHIODIDE INDICATION Muscle Relaxation 65-29-2 GALLAMINE TRIETHIODIDE PRODUCT_CLASS Peripheral Nervous System (PNS) 65-29-2 GALLAMINE TRIETHIODIDE MECHANISM Modulate G-protein coupled signal transduction 65-29-2 GALLAMINE TRIETHIODIDE MECH_LEVEL_2 Anti-muscarinic/Parasympatholytic 65-29-2 GALLAMINE TRIETHIODIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M2) antagonist 65-29-2 GALLAMINE TRIETHIODIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 65-29-2 GALLAMINE TRIETHIODIDE TA_LEVEL_3 preanesthetic 65-29-2 GALLAMINE TRIETHIODIDE MECH_LEVEL_3 Muscarinic acetylcholine receptor M2 65-29-2 GALLAMINE TRIETHIODIDE MESH_LEVEL_1 Organic Chemicals 65-29-2 GALLAMINE TRIETHIODIDE ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 65-29-2 GALLAMINE TRIETHIODIDE TA_LEVEL_2 muscle relaxant 65-29-2 GALLAMINE TRIETHIODIDE ZERO_CLASS N 65-29-2 GALLAMINE TRIETHIODIDE MODE_CLASS Receptor Ligand Antagonist, Selective 65-29-2 GALLAMINE TRIETHIODIDE ADVERSE_EFFECT CVS_1_Tachycardia 65-29-2 GALLAMINE TRIETHIODIDE MESH_LEVEL_3 Ammonium Compounds 65-29-2 GALLAMINE TRIETHIODIDE MESH_LEVEL_2 Amines 65-29-2 GALLAMINE TRIETHIODIDE TA_LEVEL_1 Peripheral Nervous System (PNS) 82410-32-0 GANCICLOVIR ADVERSE_EFFECT PSY_1_Confusion 82410-32-0 GANCICLOVIR ADVERSE_EFFECT XXX_2_Weight Loss 82410-32-0 GANCICLOVIR ADVERSE_EFFECT MSK_3_Myalgia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_2_Pancreatitis 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_1_Abdominal Pain 82410-32-0 GANCICLOVIR ADVERSE_EFFECT XXX_3_Asthenia 82410-32-0 GANCICLOVIR TISSUE_TOXICITY Neutropenia 82410-32-0 GANCICLOVIR TISSUE_TOXICITY Pancytopenia 82410-32-0 GANCICLOVIR INDICATION Prophylaxis of Cytomegalovirus Infections 82410-32-0 GANCICLOVIR KNOWN_TOXICITY Blood & Bone Marrow Toxicity 82410-32-0 GANCICLOVIR TISSUE_TOXICITY Thrombocytopenia 82410-32-0 GANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_2_Constipation 82410-32-0 GANCICLOVIR PRODUCT_CLASS Anti-infectives 82410-32-0 GANCICLOVIR ADVERSE_EFFECT OTO_3_Tinnitus 82410-32-0 GANCICLOVIR TISSUE_TOXICITY Anemia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT XXX_2_Xerostomia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT CVS_3_Chest Pain 82410-32-0 GANCICLOVIR ADVERSE_EFFECT BBM_1_Pancytopenia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT PSY_1_Emotional Lability 82410-32-0 GANCICLOVIR ADVERSE_EFFECT PSY_1_Insomnia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT MSK_3_Arthralgia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT BBM_1_Anemia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT NEU_1_Seizures 82410-32-0 GANCICLOVIR ADVERSE_EFFECT NEU_1_Paresthesia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT NEU_1_Headache 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_1_Diarrhea 82410-32-0 GANCICLOVIR KNOWN_TOXICITY Nephrotoxicity 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_1_Nausea / Vomiting 82410-32-0 GANCICLOVIR TA_LEVEL_3 CMV retitintis 82410-32-0 GANCICLOVIR ADVERSE_EFFECT XXX_3_Malaise 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_2_Dyspepsia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT KID_3_Renal Failure 82410-32-0 GANCICLOVIR ADVERSE_EFFECT CVS_3_Phlebitis 82410-32-0 GANCICLOVIR ADVERSE_EFFECT BBM_1_Thrombocytopenia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT IMU_3_Urticaria 82410-32-0 GANCICLOVIR ADVERSE_EFFECT NEU_1_Dizziness 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GUS_3_Urinary Retention 82410-32-0 GANCICLOVIR TISSUE_TOXICITY Seizures 82410-32-0 GANCICLOVIR TA_LEVEL_1 Infectious Disease 82410-32-0 GANCICLOVIR MECH_LEVEL_1 Anti-viral 82410-32-0 GANCICLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 82410-32-0 GANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 82410-32-0 GANCICLOVIR TA_LEVEL_2 Anti-viral 82410-32-0 GANCICLOVIR MECHANISM Inhibit viral DNA synthesis 82410-32-0 GANCICLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 82410-32-0 GANCICLOVIR ADVERSE_EFFECT CVS_3_Hypertension 82410-32-0 GANCICLOVIR ADVERSE_EFFECT OCU_3_Visual Impairment 82410-32-0 GANCICLOVIR TISSUE_TOXICITY Renal Failure 82410-32-0 GANCICLOVIR KNOWN_TOXICITY Neurotoxicity 82410-32-0 GANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 82410-32-0 GANCICLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 82410-32-0 GANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_2_Gastrointestinal Perforation 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_1_Flatulence 82410-32-0 GANCICLOVIR ADVERSE_EFFECT GIS_2_Stomatitis 82410-32-0 GANCICLOVIR MESH_LEVEL_3 Purines 82410-32-0 GANCICLOVIR ADVERSE_EFFECT BBM_1_Neutropenia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 82410-32-0 GANCICLOVIR ADVERSE_EFFECT PSY_1_Anorexia 82410-32-0 GANCICLOVIR ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 82410-32-0 GANCICLOVIR ADVERSE_EFFECT XXX_3_Edema 82410-32-0 GANCICLOVIR ADVERSE_EFFECT NEU_1_Tremor 82410-32-0 GANCICLOVIR MESH_LEVEL_1 Heterocyclic Compounds 107910-75-8 GANCICLOVIR ADVERSE_EFFECT CVS_3_Hypertension 107910-75-8 GANCICLOVIR TISSUE_TOXICITY Renal Failure 107910-75-8 GANCICLOVIR KNOWN_TOXICITY Neurotoxicity 107910-75-8 GANCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 107910-75-8 GANCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 107910-75-8 GANCICLOVIR MESH_LEVEL_3 Purines 107910-75-8 GANCICLOVIR TISSUE_TOXICITY Pancytopenia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT XXX_2_Xerostomia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT CVS_3_Chest Pain 107910-75-8 GANCICLOVIR INDICATION Prophylaxis of Cytomegalovirus Infections 107910-75-8 GANCICLOVIR ADVERSE_EFFECT BBM_1_Pancytopenia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT PSY_1_Emotional Lability 107910-75-8 GANCICLOVIR ADVERSE_EFFECT MSK_3_Arthralgia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT BBM_1_Anemia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT NEU_1_Paresthesia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT NEU_1_Headache 107910-75-8 GANCICLOVIR ADVERSE_EFFECT PSY_1_Anorexia 107910-75-8 GANCICLOVIR INDICATION Cytomegalovirus (CMV) Retinitis 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_1_Diarrhea 107910-75-8 GANCICLOVIR KNOWN_TOXICITY Nephrotoxicity 107910-75-8 GANCICLOVIR PRODUCT_CLASS Anti-infectives 107910-75-8 GANCICLOVIR TA_LEVEL_3 CMV retitintis 107910-75-8 GANCICLOVIR ADVERSE_EFFECT XXX_3_Malaise 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_2_Dyspepsia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT KID_3_Renal Failure 107910-75-8 GANCICLOVIR KNOWN_TOXICITY Blood & Bone Marrow Toxicity 107910-75-8 GANCICLOVIR TISSUE_TOXICITY Thrombocytopenia 107910-75-8 GANCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_2_Constipation 107910-75-8 GANCICLOVIR ADVERSE_EFFECT NEU_1_Tremor 107910-75-8 GANCICLOVIR ADVERSE_EFFECT XXX_3_Edema 107910-75-8 GANCICLOVIR ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 107910-75-8 GANCICLOVIR ADVERSE_EFFECT OCU_3_Visual Impairment 107910-75-8 GANCICLOVIR ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_2_Stomatitis 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_1_Flatulence 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_2_Gastrointestinal Perforation 107910-75-8 GANCICLOVIR TISSUE_TOXICITY Anemia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT XXX_2_Weight Loss 107910-75-8 GANCICLOVIR ADVERSE_EFFECT MSK_3_Myalgia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_2_Pancreatitis 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_1_Abdominal Pain 107910-75-8 GANCICLOVIR ADVERSE_EFFECT XXX_3_Asthenia 107910-75-8 GANCICLOVIR TISSUE_TOXICITY Neutropenia 107910-75-8 GANCICLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 107910-75-8 GANCICLOVIR MECHANISM Inhibit viral DNA synthesis 107910-75-8 GANCICLOVIR TA_LEVEL_2 Anti-viral 107910-75-8 GANCICLOVIR ADVERSE_EFFECT CVS_3_Phlebitis 107910-75-8 GANCICLOVIR ADVERSE_EFFECT BBM_1_Thrombocytopenia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT IMU_3_Urticaria 107910-75-8 GANCICLOVIR ADVERSE_EFFECT NEU_1_Seizures 107910-75-8 GANCICLOVIR ADVERSE_EFFECT NEU_1_Dizziness 107910-75-8 GANCICLOVIR ADVERSE_EFFECT PSY_1_Insomnia 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GUS_3_Urinary Retention 107910-75-8 GANCICLOVIR TISSUE_TOXICITY Seizures 107910-75-8 GANCICLOVIR TA_LEVEL_1 Infectious Disease 107910-75-8 GANCICLOVIR MECH_LEVEL_1 Anti-viral 107910-75-8 GANCICLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 107910-75-8 GANCICLOVIR ADVERSE_EFFECT BBM_1_Neutropenia 107910-75-8 GANCICLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 107910-75-8 GANCICLOVIR MESH_LEVEL_1 Heterocyclic Compounds 107910-75-8 GANCICLOVIR ADVERSE_EFFECT PSY_1_Confusion 107910-75-8 GANCICLOVIR ADVERSE_EFFECT OTO_3_Tinnitus 107910-75-8 GANCICLOVIR ADVERSE_EFFECT GIS_1_Nausea / Vomiting 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT KID_2_Hematuria 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT LUN_2_Dyspnea 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Anemia 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 160738-57-8 GATIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 160738-57-8 GATIFLOXACIN TISSUE_TOXICITY Renal Failure 160738-57-8 GATIFLOXACIN TA_LEVEL_1 Infectious Disease 160738-57-8 GATIFLOXACIN PRODUCT_CLASS Anti-infectives 160738-57-8 GATIFLOXACIN MECH_LEVEL_1 Anti-bacterial 160738-57-8 GATIFLOXACIN INDICATION Chronic Bronchitis 160738-57-8 GATIFLOXACIN TA_LEVEL_2 Anti-bacterial 160738-57-8 GATIFLOXACIN INDICATION Sinusitis 160738-57-8 GATIFLOXACIN INDICATION Cystitis 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT MSK_2_Back Pain 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT KID_3_Renal Failure 160738-57-8 GATIFLOXACIN INDICATION Pneumonia 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT GUS_2_Dysuria 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT PSY_2_Agitation 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Paresthesia 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 160738-57-8 GATIFLOXACIN KNOWN_TOXICITY Nephrotoxicity 160738-57-8 GATIFLOXACIN INDICATION Urinary Tract Infection (UTI) 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT OTO_2_Tinnitus 160738-57-8 GATIFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 160738-57-8 GATIFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 160738-57-8 GATIFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 160738-57-8 GATIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 160738-57-8 GATIFLOXACIN INDICATION Acute Pyelonephritis 160738-57-8 GATIFLOXACIN TA_LEVEL_3 quinolones 160738-57-8 GATIFLOXACIN THERAPEUTIC_CLASS Antibacterials 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT PSY_2_Anxiety 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Vertigo 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Pancytopenia 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT CVS_3_Prolonged QT Interval 160738-57-8 GATIFLOXACIN TISSUE_TOXICITY Interstitial Nephritis 160738-57-8 GATIFLOXACIN MESH_LEVEL_3 Quinolines 160738-57-8 GATIFLOXACIN ZERO_CLASS N 160738-57-8 GATIFLOXACIN MECH_LEVEL_3 DNA gyrase 160738-57-8 GATIFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 160738-57-8 GATIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT NEU_1_Headache 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT XXX_2_Candidiasis 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT CVS_2_Palpitation 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT IMU_3_Serum Sickness 160738-57-8 GATIFLOXACIN TISSUE_TOXICITY Hematuria 160738-57-8 GATIFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 160738-57-8 GATIFLOXACIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Vertigo 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT PSY_2_Anxiety 112811-59-3 GATIFLOXACIN THERAPEUTIC_CLASS Antibacterials 112811-59-3 GATIFLOXACIN TA_LEVEL_3 quinolones 112811-59-3 GATIFLOXACIN INDICATION Acute Pyelonephritis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT KID_2_Hematuria 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT LUN_2_Dyspnea 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Anemia 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT OTO_2_Tinnitus 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 112811-59-3 GATIFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 112811-59-3 GATIFLOXACIN TISSUE_TOXICITY Renal Failure 112811-59-3 GATIFLOXACIN TA_LEVEL_1 Infectious Disease 112811-59-3 GATIFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 112811-59-3 GATIFLOXACIN MECH_LEVEL_1 Anti-bacterial 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT MSK_2_Back Pain 112811-59-3 GATIFLOXACIN INDICATION Cystitis 112811-59-3 GATIFLOXACIN INDICATION Sinusitis 112811-59-3 GATIFLOXACIN INDICATION Chronic Bronchitis 112811-59-3 GATIFLOXACIN TA_LEVEL_2 Anti-bacterial 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT KID_3_Renal Failure 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT GUS_2_Dysuria 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT PSY_2_Agitation 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT NEU_2_Paresthesia 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 112811-59-3 GATIFLOXACIN KNOWN_TOXICITY Nephrotoxicity 112811-59-3 GATIFLOXACIN INDICATION Urinary Tract Infection (UTI) 112811-59-3 GATIFLOXACIN INDICATION Gonococcal Infections / Gonorrhea 112811-59-3 GATIFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 112811-59-3 GATIFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 112811-59-3 GATIFLOXACIN PRODUCT_CLASS Anti-infectives 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT CVS_2_Palpitation 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT XXX_2_Candidiasis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT NEU_1_Headache 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 112811-59-3 GATIFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 112811-59-3 GATIFLOXACIN INDICATION Pneumonia 112811-59-3 GATIFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 112811-59-3 GATIFLOXACIN MECH_LEVEL_3 DNA gyrase 112811-59-3 GATIFLOXACIN ZERO_CLASS N 112811-59-3 GATIFLOXACIN MESH_LEVEL_3 Quinolines 112811-59-3 GATIFLOXACIN TISSUE_TOXICITY Interstitial Nephritis 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT CVS_3_Prolonged QT Interval 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT BBM_3_Pancytopenia 112811-59-3 GATIFLOXACIN ADVERSE_EFFECT IMU_3_Serum Sickness 112811-59-3 GATIFLOXACIN TISSUE_TOXICITY Hematuria 112811-59-3 GATIFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 95058-81-4 GEMCITABINE ADVERSE_EFFECT SKN_2_Pruritis 95058-81-4 GEMCITABINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 95058-81-4 GEMCITABINE THERAPEUTIC_CLASS Antineoplastics 95058-81-4 GEMCITABINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 95058-81-4 GEMCITABINE PRODUCT_CLASS Anti-cancers 95058-81-4 GEMCITABINE ADVERSE_EFFECT LUN_3_Respiratory Distress Syndrome 95058-81-4 GEMCITABINE MESH_LEVEL_3 Deoxyribonucleosides 95058-81-4 GEMCITABINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 95058-81-4 GEMCITABINE ADVERSE_EFFECT GIS_3_Stomatitis 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_2_Flu-Like Syndrome 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_2_Fever 95058-81-4 GEMCITABINE ADVERSE_EFFECT NEU_3_Paresthesia 95058-81-4 GEMCITABINE ADVERSE_EFFECT BBM_2_Anemia 95058-81-4 GEMCITABINE ADVERSE_EFFECT SKN_2_Erythema 95058-81-4 GEMCITABINE ADVERSE_EFFECT BBM_2_Bleeding 95058-81-4 GEMCITABINE TISSUE_TOXICITY Neutropenia 95058-81-4 GEMCITABINE MODE_CLASS Enzyme substrate mimic 95058-81-4 GEMCITABINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_2_Malaise 95058-81-4 GEMCITABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 95058-81-4 GEMCITABINE TA_LEVEL_2 solid tumors 95058-81-4 GEMCITABINE MECH_LEVEL_3 DNA-directed DNA polymerase 95058-81-4 GEMCITABINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 95058-81-4 GEMCITABINE INDICATION Non-Small Cell Lung Carcinoma 95058-81-4 GEMCITABINE TA_LEVEL_1 Oncology 95058-81-4 GEMCITABINE MESH_LEVEL_2 Nucleosides 95058-81-4 GEMCITABINE TISSUE_TOXICITY Hematuria 95058-81-4 GEMCITABINE KNOWN_TOXICITY Nephrotoxicity 95058-81-4 GEMCITABINE ADVERSE_EFFECT GIS_2_Constipation 95058-81-4 GEMCITABINE ADVERSE_EFFECT NEU_3_Drowsiness 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_2_Lethargy 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_2_Infection 95058-81-4 GEMCITABINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 95058-81-4 GEMCITABINE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 95058-81-4 GEMCITABINE ADVERSE_EFFECT BBM_1_Myelosuppression 95058-81-4 GEMCITABINE ADVERSE_EFFECT KID_2_Hematuria 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_3_Peripheral Edema 95058-81-4 GEMCITABINE ADVERSE_EFFECT SKN_2_Maculopapular Rash 95058-81-4 GEMCITABINE ADVERSE_EFFECT LUN_2_Bronchospasm 95058-81-4 GEMCITABINE ADVERSE_EFFECT LUN_3_Pulmonary Edema 95058-81-4 GEMCITABINE TISSUE_TOXICITY Myelosuppression 95058-81-4 GEMCITABINE INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 95058-81-4 GEMCITABINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 95058-81-4 GEMCITABINE ADVERSE_EFFECT XXX_3_Sepsis 95058-81-4 GEMCITABINE ADVERSE_EFFECT BBM_1_Neutropenia 95058-81-4 GEMCITABINE ADVERSE_EFFECT KID_1_Proteinuria 95058-81-4 GEMCITABINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 95058-81-4 GEMCITABINE ADVERSE_EFFECT LUN_2_Dyspnea 95058-81-4 GEMCITABINE TA_LEVEL_3 DNA synthesis inhibitors 95058-81-4 GEMCITABINE MECHANISM Incorporate into DNA/RNA/Protein 95058-81-4 GEMCITABINE TISSUE_TOXICITY Thrombocytopenia 122111-03-9 GEMCITABINE ADVERSE_EFFECT BBM_1_Neutropenia 122111-03-9 GEMCITABINE TISSUE_TOXICITY Myelosuppression 122111-03-9 GEMCITABINE INDICATION Pancreatic Cancer / Carcinoma of the Pancreas 122111-03-9 GEMCITABINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_3_Sepsis 122111-03-9 GEMCITABINE ADVERSE_EFFECT KID_1_Proteinuria 122111-03-9 GEMCITABINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 122111-03-9 GEMCITABINE ADVERSE_EFFECT LUN_2_Dyspnea 122111-03-9 GEMCITABINE ADVERSE_EFFECT SKN_2_Pruritis 122111-03-9 GEMCITABINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 122111-03-9 GEMCITABINE TISSUE_TOXICITY Neutropenia 122111-03-9 GEMCITABINE THERAPEUTIC_CLASS Antineoplastics 122111-03-9 GEMCITABINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 122111-03-9 GEMCITABINE PRODUCT_CLASS Anti-cancers 122111-03-9 GEMCITABINE MESH_LEVEL_3 Deoxyribonucleosides 122111-03-9 GEMCITABINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 122111-03-9 GEMCITABINE ADVERSE_EFFECT LUN_3_Respiratory Distress Syndrome 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_2_Flu-Like Syndrome 122111-03-9 GEMCITABINE ADVERSE_EFFECT BBM_2_Bleeding 122111-03-9 GEMCITABINE ADVERSE_EFFECT SKN_2_Erythema 122111-03-9 GEMCITABINE ADVERSE_EFFECT BBM_2_Anemia 122111-03-9 GEMCITABINE ADVERSE_EFFECT NEU_3_Paresthesia 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_2_Fever 122111-03-9 GEMCITABINE ADVERSE_EFFECT GIS_3_Stomatitis 122111-03-9 GEMCITABINE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 122111-03-9 GEMCITABINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_2_Infection 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_2_Lethargy 122111-03-9 GEMCITABINE ADVERSE_EFFECT NEU_3_Drowsiness 122111-03-9 GEMCITABINE ADVERSE_EFFECT GIS_2_Constipation 122111-03-9 GEMCITABINE KNOWN_TOXICITY Nephrotoxicity 122111-03-9 GEMCITABINE TISSUE_TOXICITY Hematuria 122111-03-9 GEMCITABINE MESH_LEVEL_2 Nucleosides 122111-03-9 GEMCITABINE TA_LEVEL_1 Oncology 122111-03-9 GEMCITABINE INDICATION Non-Small Cell Lung Carcinoma 122111-03-9 GEMCITABINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 122111-03-9 GEMCITABINE MECH_LEVEL_3 DNA-directed DNA polymerase 122111-03-9 GEMCITABINE TA_LEVEL_2 solid tumors 122111-03-9 GEMCITABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_2_Malaise 122111-03-9 GEMCITABINE ADVERSE_EFFECT BBM_1_Myelosuppression 122111-03-9 GEMCITABINE ADVERSE_EFFECT KID_2_Hematuria 122111-03-9 GEMCITABINE ADVERSE_EFFECT XXX_3_Peripheral Edema 122111-03-9 GEMCITABINE ADVERSE_EFFECT SKN_2_Maculopapular Rash 122111-03-9 GEMCITABINE ADVERSE_EFFECT LUN_2_Bronchospasm 122111-03-9 GEMCITABINE ADVERSE_EFFECT LUN_3_Pulmonary Edema 122111-03-9 GEMCITABINE MODE_CLASS Enzyme substrate mimic 122111-03-9 GEMCITABINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 122111-03-9 GEMCITABINE TISSUE_TOXICITY Thrombocytopenia 122111-03-9 GEMCITABINE MECHANISM Incorporate into DNA/RNA/Protein 122111-03-9 GEMCITABINE TA_LEVEL_3 DNA synthesis inhibitors 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT OCU__Cataracts 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT SKN_3_Pruritis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT XXX_2_Fatigue 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT OCU_3_Blurred Vision 25812-30-0 GEMFIBROZIL PRODUCT_CLASS Cardiovasculars 25812-30-0 GEMFIBROZIL INDICATION Hyperlipoproteinemia 25812-30-0 GEMFIBROZIL STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 25812-30-0 GEMFIBROZIL TA_LEVEL_1 Cardiovascular 25812-30-0 GEMFIBROZIL TA_LEVEL_3 fibrates 25812-30-0 GEMFIBROZIL MECH_LEVEL_1 Lipid lowering 25812-30-0 GEMFIBROZIL INDICATION Mixed Dyslipidemia 25812-30-0 GEMFIBROZIL INDICATION Chylomicronemia Syndrome / Hyperchylomicronemia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_3_Acute Appendicitis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_3_Somnolence 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_1_Dyspepsia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT IMU_3_Angioedema 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT IMU_3_Urticaria 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT XXX_3_Death 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT SKN_2_Rash 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT REP_3_Impotence 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT PSY_3_Depression 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT DNA_3_Carcinogenicity 25812-30-0 GEMFIBROZIL ZERO_CLASS N 25812-30-0 GEMFIBROZIL MESH_LEVEL_2 Carboxylic Acids 25812-30-0 GEMFIBROZIL INDICATION Hypertriglyceridemia 25812-30-0 GEMFIBROZIL MESH_LEVEL_3 Acids, Acyclic 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Myopathy 25812-30-0 GEMFIBROZIL MESH_LEVEL_1 Organic Chemicals 25812-30-0 GEMFIBROZIL MECH_LEVEL_3 PPAR alpha 25812-30-0 GEMFIBROZIL INDICATION Hyperlipidemia 25812-30-0 GEMFIBROZIL TISSUE_TOXICITY Atrial Fibrillation 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_2_Constipation 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_2_Vomiting 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_2_Dizziness 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_2_Drowsiness 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT LIV_3_Hepatotoxicity 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Myasthenia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_2_Vertigo 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT BBM_3_Leukopenia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_1_Abdominal Pain 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_3_Hyperesthesia 25812-30-0 GEMFIBROZIL KNOWN_TOXICITY Carcinogenicity 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT IMU_3_Eosinophilia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT LUN_3_Laryngeal Edema 25812-30-0 GEMFIBROZIL ACTIVITY_CLASS Peroxisome proliferator 25812-30-0 GEMFIBROZIL MECH_LEVEL_2 Fatty acid catabolism 25812-30-0 GEMFIBROZIL THERAPEUTIC_CLASS Hypolipidemic Agents 25812-30-0 GEMFIBROZIL KNOWN_TOXICITY Cardiovascular Toxicity 25812-30-0 GEMFIBROZIL TISSUE_TOXICITY Hepatotoxicity 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_2_Nausea 25812-30-0 GEMFIBROZIL TA_LEVEL_2 Lipid lowering agent 25812-30-0 GEMFIBROZIL MECHANISM Increase lipid catabolism 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT BBM_3_Thrombocytopenia 25812-30-0 GEMFIBROZIL TISSUE_TOXICITY Death 25812-30-0 GEMFIBROZIL MODE_CLASS Receptor Agonist, selective 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_2_Diarrhea 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_3_Headache 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_3_Paresthesia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT BBM_3_Anemia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Arthralgia 25812-30-0 GEMFIBROZIL KNOWN_TOXICITY Miscellaneous 25812-30-0 GEMFIBROZIL TISSUE_TOXICITY Carcinogenicity 25812-30-0 GEMFIBROZIL KNOWN_TOXICITY Hepatotoxicity 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Synovitis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT XXX_3_Taste Disturbances 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT GIS_2_Flatulence 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT BIL_2_Gallstones 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Myalgia 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Myositis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT SKN_3_Dermatitis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT NEU_3_Peripheral Neuritis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT MSK_3_Rhabdomyolysis 25812-30-0 GEMFIBROZIL ADVERSE_EFFECT REP_3_Decreased Libido 446-72-0 GENISTEIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 446-72-0 GENISTEIN STRUCTURE_ACTIVITY Phytoestrogen 446-72-0 GENISTEIN ZERO_CLASS N 446-72-0 GENISTEIN TISSUE_TOXICITY Mutagenicity 446-72-0 GENISTEIN KNOWN_TOXICITY Carcinogenicity 446-72-0 GENISTEIN ADVERSE_EFFECT REP_3_Erectile Dysfunction 446-72-0 GENISTEIN MESH_LEVEL_3 Benzopyrans 446-72-0 GENISTEIN TA_LEVEL_3 Solid and soft tumors 446-72-0 GENISTEIN PRODUCT_CLASS Anti-cancers 446-72-0 GENISTEIN ACTIVITY_CLASS Estrogen agonist 446-72-0 GENISTEIN TISSUE_TOXICITY Increased Incidence of Breast Carcinoma 446-72-0 GENISTEIN ADVERSE_EFFECT REP_1_Changes in Reproductive Function 446-72-0 GENISTEIN TA_LEVEL_2 DNA damage 446-72-0 GENISTEIN MECH_LEVEL_3 Unknown mechanism 446-72-0 GENISTEIN THERAPEUTIC_CLASS Antineoplastics 446-72-0 GENISTEIN MECHANISM Inhibit kinase mediated signal transduction 446-72-0 GENISTEIN MODE_CLASS Enzyme Inhibitor 446-72-0 GENISTEIN MESH_LEVEL_1 Heterocyclic Compounds 446-72-0 GENISTEIN INDICATION Prevention of Osteoporosis 446-72-0 GENISTEIN ADVERSE_EFFECT DNA_3_Mutagenicity 446-72-0 GENISTEIN INDICATION Prevention of Hormone-Dependent Cancers 446-72-0 GENISTEIN THERAPEUTIC_CLASS Gonadal Hormones 446-72-0 GENISTEIN KNOWN_TOXICITY Mutagenicity 446-72-0 GENISTEIN ADVERSE_EFFECT DNA_3_Increased Incidence of Breast Carcinoma 446-72-0 GENISTEIN ADVERSE_EFFECT REP_2_Impaired Erection 446-72-0 GENISTEIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 446-72-0 GENISTEIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 446-72-0 GENISTEIN TA_LEVEL_1 Oncology 446-72-0 GENISTEIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 446-72-0 GENISTEIN MECHANISM Modulate gene transcription 446-72-0 GENISTEIN MODE_CLASS Receptor Agonist, selective 1405-41-0 GENTAMICIN INDICATION Pelvic Inflammatory Disease (PID) 1405-41-0 GENTAMICIN TA_LEVEL_1 Infectious Disease 1405-41-0 GENTAMICIN INDICATION Peritonitis 1405-41-0 GENTAMICIN TA_LEVEL_3 Aminoglycoside 1405-41-0 GENTAMICIN MECH_LEVEL_1 Anti-bacterial 1405-41-0 GENTAMICIN TA_LEVEL_2 Anti-bacterial 1405-41-0 GENTAMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 1405-41-0 GENTAMICIN INDICATION Bowel Preparation 1405-41-0 GENTAMICIN TISSUE_TOXICITY Ototoxicity 1405-41-0 GENTAMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1405-41-0 GENTAMICIN ADVERSE_EFFECT OTO_1_Ototoxicity 1405-41-0 GENTAMICIN ADVERSE_EFFECT KID_1_Nephrotoxicity 1405-41-0 GENTAMICIN KNOWN_TOXICITY Nephrotoxicity 1405-41-0 GENTAMICIN INDICATION Gram-negative Sepsis 1405-41-0 GENTAMICIN PRODUCT_CLASS Anti-infectives 1405-41-0 GENTAMICIN INDICATION Lower Respiratory Tract Infection 1405-41-0 GENTAMICIN INDICATION Biliary Tract Infection 1405-41-0 GENTAMICIN MECH_LEVEL_2 Protein synthesis inhibitor 1405-41-0 GENTAMICIN MESH_LEVEL_3 Aminoglycoside 1405-41-0 GENTAMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 1405-41-0 GENTAMICIN ADVERSE_EFFECT LUN_2_Respiratory Paralysis 1405-41-0 GENTAMICIN MECH_LEVEL_3 Ribosomal RNA binder 1405-41-0 GENTAMICIN INDICATION Bacterial Endocarditis 1405-41-0 GENTAMICIN INDICATION Meningitis 1405-41-0 GENTAMICIN ADVERSE_EFFECT BBM_3_Anemia 1405-41-0 GENTAMICIN ADVERSE_EFFECT NEU_2_Neuromuscular Blockade 1405-41-0 GENTAMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 1405-41-0 GENTAMICIN KNOWN_TOXICITY Ototoxicity 1405-41-0 GENTAMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 1405-41-0 GENTAMICIN TISSUE_TOXICITY Nephrotoxicity 1405-41-0 GENTAMICIN MESH_LEVEL_2 Carbohydrates 1405-41-0 GENTAMICIN MECHANISM Inhibit ribosomal protein synthesis 1405-41-0 GENTAMICIN ADVERSE_EFFECT NEU_3_Convulsions 1405-41-0 GENTAMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 1405-41-0 GENTAMICIN INDICATION Urinary Tract Infection (UTI) 1403-66-3 GENTAMICIN INDICATION Bowel Preparation 1403-66-3 GENTAMICIN TISSUE_TOXICITY Ototoxicity 1403-66-3 GENTAMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1403-66-3 GENTAMICIN ADVERSE_EFFECT OTO_1_Ototoxicity 1403-66-3 GENTAMICIN ADVERSE_EFFECT KID_1_Nephrotoxicity 1403-66-3 GENTAMICIN KNOWN_TOXICITY Nephrotoxicity 1403-66-3 GENTAMICIN MECH_LEVEL_2 Protein synthesis inhibitor 1403-66-3 GENTAMICIN INDICATION Gram-negative Sepsis 1403-66-3 GENTAMICIN PRODUCT_CLASS Anti-infectives 1403-66-3 GENTAMICIN INDICATION Lower Respiratory Tract Infection 1403-66-3 GENTAMICIN TISSUE_TOXICITY Nephrotoxicity 1403-66-3 GENTAMICIN ADVERSE_EFFECT NEU_3_Convulsions 1403-66-3 GENTAMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 1403-66-3 GENTAMICIN TA_LEVEL_1 Infectious Disease 1403-66-3 GENTAMICIN INDICATION Peritonitis 1403-66-3 GENTAMICIN TA_LEVEL_2 Anti-bacterial 1403-66-3 GENTAMICIN MESH_LEVEL_2 Carbohydrates 1403-66-3 GENTAMICIN MECHANISM Inhibit ribosomal protein synthesis 1403-66-3 GENTAMICIN INDICATION Pelvic Inflammatory Disease (PID) 1403-66-3 GENTAMICIN INDICATION Biliary Tract Infection 1403-66-3 GENTAMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 1403-66-3 GENTAMICIN ADVERSE_EFFECT LUN_2_Respiratory Paralysis 1403-66-3 GENTAMICIN KNOWN_TOXICITY Ototoxicity 1403-66-3 GENTAMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 1403-66-3 GENTAMICIN ADVERSE_EFFECT BBM_3_Anemia 1403-66-3 GENTAMICIN ADVERSE_EFFECT NEU_2_Neuromuscular Blockade 1403-66-3 GENTAMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 1403-66-3 GENTAMICIN INDICATION Urinary Tract Infection (UTI) 1403-66-3 GENTAMICIN MESH_LEVEL_3 Aminoglycoside 1403-66-3 GENTAMICIN MECH_LEVEL_1 Anti-bacterial 1403-66-3 GENTAMICIN TA_LEVEL_3 Aminoglycoside 1403-66-3 GENTAMICIN INDICATION Meningitis 1403-66-3 GENTAMICIN INDICATION Bacterial Endocarditis 1403-66-3 GENTAMICIN MECH_LEVEL_3 Ribosomal RNA binder 1403-66-3 GENTAMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 548-62-9 GENTIAN VIOLET KNOWN_TOXICITY Mutagenicity 548-62-9 GENTIAN VIOLET INDICATION Helminthic Infections 548-62-9 GENTIAN VIOLET TA_LEVEL_2 anti-fungal 548-62-9 GENTIAN VIOLET INDICATION Fungal Infections 548-62-9 GENTIAN VIOLET TISSUE_TOXICITY Genotoxicity 548-62-9 GENTIAN VIOLET THERAPEUTIC_CLASS Antibacterials, Topical 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT SKN_1_Skin Discoloration 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT SKN_1_Skin Necrosis 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT GIS_1_Diarrhea 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT LUN_2_Respiratory Failure 548-62-9 GENTIAN VIOLET THERAPEUTIC_CLASS Antiparasitics 548-62-9 GENTIAN VIOLET MODE_CLASS Distorts /blocks macromolecular scaffold function 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT CVS_2_Hypertension 548-62-9 GENTIAN VIOLET KNOWN_TOXICITY Cardiovascular Toxicity 548-62-9 GENTIAN VIOLET INDICATION Skin Antisepsis 548-62-9 GENTIAN VIOLET MECH_LEVEL_3 Unknown mechanism 548-62-9 GENTIAN VIOLET MECHANISM Inhibit mitochondrial function 548-62-9 GENTIAN VIOLET STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 548-62-9 GENTIAN VIOLET TISSUE_TOXICITY Thrombosis 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT DNA_2_Genotoxicity 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT CVS_2_Thrombosis 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT XXX_1_Asthenia 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT GIS_1_Esophagitis 548-62-9 GENTIAN VIOLET TISSUE_TOXICITY Skin Necrosis 548-62-9 GENTIAN VIOLET KNOWN_TOXICITY Carcinogenicity 548-62-9 GENTIAN VIOLET MECH_LEVEL_2 Unknown mechanism 548-62-9 GENTIAN VIOLET TA_LEVEL_3 topical infections 548-62-9 GENTIAN VIOLET ACTIVITY_CLASS Mitochondrial toxicant 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT NEU_1_Vertigo 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT XXX_1_Mucosal ulceration 548-62-9 GENTIAN VIOLET THERAPEUTIC_CLASS Antifungals, Topical 548-62-9 GENTIAN VIOLET TISSUE_TOXICITY Carcinogenicity 548-62-9 GENTIAN VIOLET MECH_LEVEL_1 Unknown mechanism 548-62-9 GENTIAN VIOLET MESH_LEVEL_1 Organic Chemicals 548-62-9 GENTIAN VIOLET MESH_LEVEL_2 Amines 548-62-9 GENTIAN VIOLET TA_LEVEL_1 Infectious Disease 548-62-9 GENTIAN VIOLET MESH_LEVEL_3 Aniline Compounds 548-62-9 GENTIAN VIOLET PRODUCT_CLASS Anti-infectives 548-62-9 GENTIAN VIOLET KNOWN_TOXICITY Dermatologic Toxicity 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT XXX_1_Laryngitis 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT GIS_1_Abdominal Pain 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT GIS_1_Nausea / Vomiting 548-62-9 GENTIAN VIOLET ADVERSE_EFFECT DNA_2_Carcinogenicity 548-62-9 GENTIAN VIOLET ZERO_CLASS N 106-24-1 GERANIOL ACTIVITY_CLASS Interferes with protein prenylation 106-24-1 GERANIOL ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 106-24-1 GERANIOL TA_LEVEL_3 none 106-24-1 GERANIOL MESH_LEVEL_3 Terpenes 106-24-1 GERANIOL TA_LEVEL_2 perfume 106-24-1 GERANIOL ADVERSE_EFFECT LUN_1_Bronchial Irritation 106-24-1 GERANIOL MECH_LEVEL_2 inhibits polyamine synthesis 106-24-1 GERANIOL MECHANISM Modulate gene transcription 106-24-1 GERANIOL PRODUCT_CLASS Botanicals 106-24-1 GERANIOL TA_LEVEL_1 Other Human Uses 106-24-1 GERANIOL ADVERSE_EFFECT LUN_1_Airway Irritation 106-24-1 GERANIOL STRUCTURE_ACTIVITY Interferes with protein prenylation 106-24-1 GERANIOL ZERO_CLASS N 106-24-1 GERANIOL MESH_LEVEL_1 Organic Chemicals 106-24-1 GERANIOL MECH_LEVEL_3 Unknown mechanism 106-24-1 GERANIOL MESH_LEVEL_2 Hydrocarbons 106-24-1 GERANIOL ADVERSE_EFFECT IMU_2_Contact Dermatitis 147245-92-9 GLATIRAMER INDICATION Multiple Sclerosis (MS) 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT NEU_2_Dizziness 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT BBM_3_Pancytopenia 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT IMU_3_Allergic Vasculitis 93479-97-1 GLIMEPIRIDE ZERO_CLASS N 93479-97-1 GLIMEPIRIDE MECH_LEVEL_2 Trigger insulin release 93479-97-1 GLIMEPIRIDE KNOWN_TOXICITY Hepatotoxicity 93479-97-1 GLIMEPIRIDE MODE_CLASS Channel Blocker, selective 93479-97-1 GLIMEPIRIDE ACTIVITY_CLASS Anti-diabetic 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT NEU_2_Headache 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT ELT_3_Hyponatremia 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT LIV_3_Hepatic Failure 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT EMB_2_Fetal Toxicity 93479-97-1 GLIMEPIRIDE TISSUE_TOXICITY Hepatic Failure 93479-97-1 GLIMEPIRIDE TA_LEVEL_3 glycemic control 93479-97-1 GLIMEPIRIDE MECH_LEVEL_1 Glycemia regulation 93479-97-1 GLIMEPIRIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 93479-97-1 GLIMEPIRIDE MESH_LEVEL_3 Sulfones 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT END_1_Hypoglycemia 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT LIV_3_Abnormal Liver Function 93479-97-1 GLIMEPIRIDE THERAPEUTIC_CLASS Antidiabetic Agents 93479-97-1 GLIMEPIRIDE TA_LEVEL_2 Diabetes 93479-97-1 GLIMEPIRIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 93479-97-1 GLIMEPIRIDE MECH_LEVEL_3 ATP-sensitive K+ channel, SUR1 93479-97-1 GLIMEPIRIDE INDICATION Type II Diabetes Mellitus 93479-97-1 GLIMEPIRIDE MESH_LEVEL_1 Organic Chemicals 93479-97-1 GLIMEPIRIDE MESH_LEVEL_2 Sulfur Compounds 93479-97-1 GLIMEPIRIDE MECHANISM Trigger insulin release in pancreatic beta cells 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT BBM_3_Leukopenia 93479-97-1 GLIMEPIRIDE ADVERSE_EFFECT SKN_3_Skin Rash 93479-97-1 GLIMEPIRIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 29094-61-9 GLIPIZIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 29094-61-9 GLIPIZIDE ADVERSE_EFFECT OCU_2_Blurred Vision 29094-61-9 GLIPIZIDE MECH_LEVEL_2 Trigger insulin release 29094-61-9 GLIPIZIDE ADVERSE_EFFECT CVS_2_Palpitation 29094-61-9 GLIPIZIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 29094-61-9 GLIPIZIDE ADVERSE_EFFECT MSK_2_Muscle Weakness 29094-61-9 GLIPIZIDE ADVERSE_EFFECT NEU_2_Dizziness 29094-61-9 GLIPIZIDE ADVERSE_EFFECT NEU_2_Tremor 29094-61-9 GLIPIZIDE ADVERSE_EFFECT CVS_2_Tachycardia 29094-61-9 GLIPIZIDE ZERO_CLASS N 29094-61-9 GLIPIZIDE MECHANISM Trigger insulin release in pancreatic beta cells 29094-61-9 GLIPIZIDE TA_LEVEL_3 glycemic control 29094-61-9 GLIPIZIDE TA_LEVEL_2 Diabetes 29094-61-9 GLIPIZIDE THERAPEUTIC_CLASS Antidiabetic Agents 29094-61-9 GLIPIZIDE ADVERSE_EFFECT BBM_3_Pancytopenia 29094-61-9 GLIPIZIDE ADVERSE_EFFECT BBM_3_Leukopenia 29094-61-9 GLIPIZIDE ADVERSE_EFFECT SKN_2_Maculopapular Rash 29094-61-9 GLIPIZIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 29094-61-9 GLIPIZIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 29094-61-9 GLIPIZIDE ADVERSE_EFFECT GIS_2_Diarrhea 29094-61-9 GLIPIZIDE MESH_LEVEL_3 Sulfones 29094-61-9 GLIPIZIDE MESH_LEVEL_2 Sulfur Compounds 29094-61-9 GLIPIZIDE ADVERSE_EFFECT SKN_2_Eczema 29094-61-9 GLIPIZIDE MECH_LEVEL_3 ATP-sensitive K+ channel, SUR2 29094-61-9 GLIPIZIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 29094-61-9 GLIPIZIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 29094-61-9 GLIPIZIDE ADVERSE_EFFECT GIS_2_Dyspepsia 29094-61-9 GLIPIZIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 29094-61-9 GLIPIZIDE INDICATION Type II Diabetes Mellitus 29094-61-9 GLIPIZIDE ADVERSE_EFFECT NEU_2_Drowsiness 29094-61-9 GLIPIZIDE ADVERSE_EFFECT END_2_Hypoglycemia 29094-61-9 GLIPIZIDE ADVERSE_EFFECT GIS_2_Constipation 29094-61-9 GLIPIZIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 29094-61-9 GLIPIZIDE MESH_LEVEL_1 Organic Chemicals 29094-61-9 GLIPIZIDE MODE_CLASS Channel Blocker, selective 29094-61-9 GLIPIZIDE ACTIVITY_CLASS Anti-diabetic 29094-61-9 GLIPIZIDE ADVERSE_EFFECT END_2_Porphyria 29094-61-9 GLIPIZIDE ADVERSE_EFFECT SKN_2_Erythema 29094-61-9 GLIPIZIDE ADVERSE_EFFECT SKN_2_Pruritis 29094-61-9 GLIPIZIDE MECH_LEVEL_1 Glycemia regulation 16941-32-5 GLUCAGON MODE_CLASS Receptor Agonist 16941-32-5 GLUCAGON INDICATION Diabetes 16941-32-5 GLUCAGON MECHANISM Modulate G-protein coupled signal transduction 9007-92-5 GLUCAGON INDICATION Diabetes 9007-92-5 GLUCAGON MECHANISM Modulate G-protein coupled signal transduction 9007-92-5 GLUCAGON MODE_CLASS Receptor Agonist 12709-67-0 GLUCAGON MODE_CLASS Receptor Agonist 12709-67-0 GLUCAGON INDICATION Diabetes 12709-67-0 GLUCAGON MECHANISM Modulate G-protein coupled signal transduction 28270-04-4 GLUCAGON INDICATION Diabetes 28270-04-4 GLUCAGON MECHANISM Modulate G-protein coupled signal transduction 28270-04-4 GLUCAGON MODE_CLASS Receptor Agonist 90-80-2 GLUCONOLACTONE MODE_CLASS Enzyme Inhibitor 27025-41-8 GLUTATHIONE, OXIDIZED FORM PRODUCT_CLASS Vitamins, Minerals and Nutrients 27025-41-8 GLUTATHIONE, OXIDIZED FORM MECHANISM Scavenges hydrogen peroxide and free radicals 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT GIS_2_Epigastric Pain 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Adjuvant in Radiotherapy 27025-41-8 GLUTATHIONE, OXIDIZED FORM KNOWN_TOXICITY Cardiovascular Toxicity 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT SKN_3_Skin Rash 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT OCU_2_Ocular Allergic Reactions 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT IMU_2_Allergic Reactions 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Corneal Ulcer 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT CVS_3_Hypotension 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Hepatic Insufficiency 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Inflammation of Respiratory Tract 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT OCU_2_Eye Irritation 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Atopic Dermatitis / Eczema 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Cisplatine Neuropathy 27025-41-8 GLUTATHIONE, OXIDIZED FORM ADVERSE_EFFECT PSY_2_Anorexia 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Pulmonary Fibrosis 27025-41-8 GLUTATHIONE, OXIDIZED FORM INDICATION Chronic Hepatitis 27025-41-8 GLUTATHIONE, OXIDIZED FORM THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 27025-41-8 GLUTATHIONE, OXIDIZED FORM TISSUE_TOXICITY Hypotension 77-21-4 GLUTETHIMIDE STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 77-21-4 GLUTETHIMIDE PRODUCT_CLASS Central Nervous System (CNS) 77-21-4 GLUTETHIMIDE INDICATION Premedication in Anesthetia 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_2_Psychomotor Excitation 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT XXX_2_Fever 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT SKN_2_Erythroderma 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_2_Ataxia 77-21-4 GLUTETHIMIDE INDICATION Insomnia 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT OCU_2_Glaucoma 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT PSY_3_Psychosis 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT SKN_2_Skin Eruption 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT OCU_2_Blurred Vision 77-21-4 GLUTETHIMIDE THERAPEUTIC_CLASS Sedatives/Hypnotics 77-21-4 GLUTETHIMIDE MECHANISM Modulate neural transmission 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT END_3_Osteomalacia 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT GIS_2_Epigastric Pain 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_2_Tremor 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_3_Polyneuritis 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT BBM_3_Leukopenia 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_3_Nystagmus 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_3_Myoclonus 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT END_3_Acute Intermittent Porphyria 77-21-4 GLUTETHIMIDE MODE_CLASS Channel Modulator 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT GIS_2_Nausea 77-21-4 GLUTETHIMIDE ADVERSE_EFFECT NEU_3_Convulsions 10238-21-8 GLYBURIDE MESH_LEVEL_3 Sulfones 10238-21-8 GLYBURIDE MECHANISM Trigger insulin release in pancreatic beta cells 10238-21-8 GLYBURIDE ADVERSE_EFFECT SKN_3_Porphyria Cutanea Tarda 10238-21-8 GLYBURIDE ZERO_CLASS N 10238-21-8 GLYBURIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 10238-21-8 GLYBURIDE ADVERSE_EFFECT SKN_3_Maculopapular Rash 10238-21-8 GLYBURIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 10238-21-8 GLYBURIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 10238-21-8 GLYBURIDE THERAPEUTIC_CLASS Antidiabetic Agents 10238-21-8 GLYBURIDE TA_LEVEL_3 sulfonylurea 10238-21-8 GLYBURIDE MECH_LEVEL_3 ATP-sensitive K+ channel SUR1 10238-21-8 GLYBURIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 10238-21-8 GLYBURIDE ADVERSE_EFFECT LIV_3_Cholestasis 10238-21-8 GLYBURIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 10238-21-8 GLYBURIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 10238-21-8 GLYBURIDE ADVERSE_EFFECT END_2_Hypoglycemia 10238-21-8 GLYBURIDE ADVERSE_EFFECT IMU_3_Angioedema 10238-21-8 GLYBURIDE ADVERSE_EFFECT MSK_3_Arthralgia 10238-21-8 GLYBURIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 10238-21-8 GLYBURIDE MECH_LEVEL_2 stimulate insulin release 10238-21-8 GLYBURIDE ADVERSE_EFFECT BBM_3_Leukopenia 10238-21-8 GLYBURIDE ADVERSE_EFFECT BBM_3_Hemolysis 10238-21-8 GLYBURIDE ADVERSE_EFFECT GIS_3_Heartburn 10238-21-8 GLYBURIDE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 10238-21-8 GLYBURIDE ADVERSE_EFFECT SKN_3_Pruritis 10238-21-8 GLYBURIDE ADVERSE_EFFECT SKN_3_Erythema 10238-21-8 GLYBURIDE MODE_CLASS Channel Blocker, selective 10238-21-8 GLYBURIDE MESH_LEVEL_1 Organic Chemicals 10238-21-8 GLYBURIDE MECH_LEVEL_1 Glycemia regulation 10238-21-8 GLYBURIDE MESH_LEVEL_2 Sulfur Compounds 10238-21-8 GLYBURIDE ADVERSE_EFFECT IMU_3_Photosensitivity 10238-21-8 GLYBURIDE ADVERSE_EFFECT BBM_3_Pancytopenia 10238-21-8 GLYBURIDE ADVERSE_EFFECT OCU_3_Blurred Vision 10238-21-8 GLYBURIDE ADVERSE_EFFECT ELT_3_Hyponatremia 10238-21-8 GLYBURIDE ADVERSE_EFFECT IMU_3_Urticaria 10238-21-8 GLYBURIDE ACTIVITY_CLASS Anti-diabetic 10238-21-8 GLYBURIDE TA_LEVEL_2 Diabetes 10238-21-8 GLYBURIDE ADVERSE_EFFECT LIV_3_Jaundice 10238-21-8 GLYBURIDE ADVERSE_EFFECT CVS_3_Vasculitis 10238-21-8 GLYBURIDE INDICATION Type II Diabetes Mellitus 56-81-5 GLYCERIN PRODUCT_CLASS Central Nervous System (CNS) 56-81-5 GLYCERIN THERAPEUTIC_CLASS Antiglaucoma Agents 56-81-5 GLYCERIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 56-81-5 GLYCERIN ADVERSE_EFFECT PSY_3_Confusion 56-81-5 GLYCERIN ADVERSE_EFFECT XXX_2_Dehydration 56-81-5 GLYCERIN ADVERSE_EFFECT NEU_3_Hyperosmolar coma 56-81-5 GLYCERIN PRODUCT_CLASS Gastrointestinal System 56-81-5 GLYCERIN INDICATION Constipation 56-81-5 GLYCERIN TISSUE_TOXICITY Hemoglobinuria 56-81-5 GLYCERIN ADVERSE_EFFECT XXX_2_Thirst 56-81-5 GLYCERIN ADVERSE_EFFECT SKN_3_Erythema 56-81-5 GLYCERIN ADVERSE_EFFECT GIS_3_Nausea 56-81-5 GLYCERIN THERAPEUTIC_CLASS Antibacterials, Topical 56-81-5 GLYCERIN INDICATION Skin Infections 56-81-5 GLYCERIN PRODUCT_CLASS Other Human Uses 56-81-5 GLYCERIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 56-81-5 GLYCERIN INDICATION Glaucoma 56-81-5 GLYCERIN ADVERSE_EFFECT GIS_3_Proctitis 56-81-5 GLYCERIN ADVERSE_EFFECT KID_3_Nephrotoxicity 56-81-5 GLYCERIN ADVERSE_EFFECT END_3_Hyperglycemia 56-81-5 GLYCERIN TISSUE_TOXICITY Nephrotoxicity 56-81-5 GLYCERIN THERAPEUTIC_CLASS Laxatives 56-81-5 GLYCERIN INDICATION Pseudotumor Cerebri / Benign Intracranial Hypertension 56-81-5 GLYCERIN PRODUCT_CLASS Anti-infectives 56-81-5 GLYCERIN INDICATION Varicose Veins 56-81-5 GLYCERIN KNOWN_TOXICITY Nephrotoxicity 56-81-5 GLYCERIN ADVERSE_EFFECT KID_3_Hemoglobinuria 56-81-5 GLYCERIN ADVERSE_EFFECT BBM_3_Hemolysis 56-81-5 GLYCERIN ADVERSE_EFFECT END_3_Metabolic Acidosis 56-81-5 GLYCERIN ADVERSE_EFFECT NEU_3_Convulsions 56-81-5 GLYCERIN INDICATION Acute (Angle-Closure) Glaucoma 5634-39-9 GLYCEROL, IODINATED TISSUE_TOXICITY Carcinogenicity 5634-39-9 GLYCEROL, IODINATED ADVERSE_EFFECT DNA__Carcinogenicity 5634-39-9 GLYCEROL, IODINATED KNOWN_TOXICITY Carcinogenicity 56-40-6 GLYCINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 56-40-6 GLYCINE ADVERSE_EFFECT CVS_3_Hypertension 56-40-6 GLYCINE THERAPEUTIC_CLASS Irrigating Solutions 56-40-6 GLYCINE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 56-40-6 GLYCINE MECH_LEVEL_1 Modulate neural transmission 56-40-6 GLYCINE INDICATION Nutritional Supplement 56-40-6 GLYCINE MESH_LEVEL_2 Amino Acids 56-40-6 GLYCINE STRUCTURE_ACTIVITY Glutamate receptor agonist, glycine receptor agonist 56-40-6 GLYCINE INDICATION Memory Loss 56-40-6 GLYCINE KNOWN_TOXICITY Cardiovascular Toxicity 56-40-6 GLYCINE ADVERSE_EFFECT XXX_3_Rhinitis 56-40-6 GLYCINE ADVERSE_EFFECT XXX_3_Chills 56-40-6 GLYCINE ADVERSE_EFFECT END_3_Metabolic Acidosis 56-40-6 GLYCINE ADVERSE_EFFECT XXX_3_Dehydration 56-40-6 GLYCINE ADVERSE_EFFECT GUS_3_Urinary Retention 56-40-6 GLYCINE TISSUE_TOXICITY Hypotension 56-40-6 GLYCINE MESH_LEVEL_3 Glycine 56-40-6 GLYCINE TA_LEVEL_2 immune enhancer 56-40-6 GLYCINE MECHANISM Prolong/enhance neural transmission 56-40-6 GLYCINE MECH_LEVEL_2 NMDA Modulators 56-40-6 GLYCINE MODE_CLASS Receptor Agonist 56-40-6 GLYCINE ACTIVITY_CLASS Glutamate receptor agonist, glycine receptor agonist 56-40-6 GLYCINE ADVERSE_EFFECT MSK_3_Back Pain 56-40-6 GLYCINE ADVERSE_EFFECT IMU_3_Urticaria 56-40-6 GLYCINE ADVERSE_EFFECT XXX_3_Edema 56-40-6 GLYCINE ADVERSE_EFFECT CVS_3_Hypotension 56-40-6 GLYCINE ADVERSE_EFFECT XXX_3_Xerostomia 56-40-6 GLYCINE ADVERSE_EFFECT GUS_3_Diuresis 56-40-6 GLYCINE ADVERSE_EFFECT NEU_3_Seizures 56-40-6 GLYCINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 56-40-6 GLYCINE ADVERSE_EFFECT OCU_3_Blurred Vision 56-40-6 GLYCINE INDICATION Urological Irrigation 56-40-6 GLYCINE TA_LEVEL_3 none 56-40-6 GLYCINE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 56-40-6 GLYCINE PRODUCT_CLASS Vitamins, Minerals and Nutrients 56-40-6 GLYCINE MECH_LEVEL_3 NMDA Glutamate receptor agonist 56-40-6 GLYCINE MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 56-40-6 GLYCINE ZERO_CLASS N 56-40-6 GLYCINE ADVERSE_EFFECT XXX_2_Thirst 56-40-6 GLYCINE ADVERSE_EFFECT ELT_3_Electrolyte Imbalance 56-40-6 GLYCINE TA_LEVEL_1 Vitamins, Minerals and Nutrients 79-14-1 GLYCOLIC ACID ADVERSE_EFFECT SKN_1_Dry Skin 79-14-1 GLYCOLIC ACID THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 79-14-1 GLYCOLIC ACID ADVERSE_EFFECT IMU_1_Photosensitization 79-14-1 GLYCOLIC ACID MECHANISM Modulate gene transcription 79-14-1 GLYCOLIC ACID ADVERSE_EFFECT SKN_1_Erythema 79-14-1 GLYCOLIC ACID INDICATION Facial Skin Rejuvenation 79-14-1 GLYCOLIC ACID PRODUCT_CLASS Dermatologicals 79-14-1 GLYCOLIC ACID ADVERSE_EFFECT IMU_1_Contact Dermatitis 79-14-1 GLYCOLIC ACID ADVERSE_EFFECT SKN_1_Skin Irritation 596-51-0 GLYCOPYRROLATE MODE_CLASS Receptor Ligand Antagonist 596-51-0 GLYCOPYRROLATE THERAPEUTIC_CLASS Parasympatholytic Agents 596-51-0 GLYCOPYRROLATE INDICATION Duodenal Ulcer 596-51-0 GLYCOPYRROLATE PRODUCT_CLASS Gastrointestinal System 596-51-0 GLYCOPYRROLATE THERAPEUTIC_CLASS Antispasmodic Agents 596-51-0 GLYCOPYRROLATE INDICATION Aspiration Prophylaxis 596-51-0 GLYCOPYRROLATE PRODUCT_CLASS Autonomic Nervous System (ANS) 596-51-0 GLYCOPYRROLATE INDICATION Irritable Bowel Syndrome 596-51-0 GLYCOPYRROLATE MECHANISM Modulate G-protein coupled signal transduction 1071-83-6 GLYPHOSATE ADVERSE_EFFECT END_1_Metabolic Acidosis 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Bloody Stools 1071-83-6 GLYPHOSATE MECHANISM Inhibit precursor synthesis 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Hematuria 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Hematemesis 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Bloody Stools 1071-83-6 GLYPHOSATE ADVERSE_EFFECT PSY_2_Confusion 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Esophageal Ulceration 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_2_Tachypnea 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Hypotensive Shock 1071-83-6 GLYPHOSATE ADVERSE_EFFECT NEU_2_Coma 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Epigastric Pain 1071-83-6 GLYPHOSATE KNOWN_TOXICITY Nephrotoxicity 1071-83-6 GLYPHOSATE STRUCTURE_ACTIVITY Toxicant 1071-83-6 GLYPHOSATE MODE_CLASS Enzyme Inhibitor 1071-83-6 GLYPHOSATE ADVERSE_EFFECT KID_3_Anuria 1071-83-6 GLYPHOSATE ADVERSE_EFFECT XXX_2_Hypovolemia 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Anuria 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Dysphagia 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 1071-83-6 GLYPHOSATE KNOWN_TOXICITY Embryo/Fetal Toxicity 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Teratogenicity 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_2_Respiratory Failure 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Abdominal Pain 1071-83-6 GLYPHOSATE ADVERSE_EFFECT KID_1_Hematuria 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_1_Cough 1071-83-6 GLYPHOSATE PRODUCT_CLASS Toxicants 1071-83-6 GLYPHOSATE KNOWN_TOXICITY Cardiovascular Toxicity 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Hematemesis 1071-83-6 GLYPHOSATE TISSUE_TOXICITY Gastrointestinal Toxicity 1071-83-6 GLYPHOSATE ADVERSE_EFFECT KID_2_Oliguria 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_1_Dyspnea 1071-83-6 GLYPHOSATE ADVERSE_EFFECT CVS_1_Hypotensive Shock 1071-83-6 GLYPHOSATE ADVERSE_EFFECT SKN_2_Dermatitis 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_2_Hypoxia 1071-83-6 GLYPHOSATE ADVERSE_EFFECT LUN_1_Bronchospasm 1071-83-6 GLYPHOSATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1071-83-6 GLYPHOSATE KNOWN_TOXICITY Gastrointestinal Toxicity 70393-85-0 GLYPHOSATE KNOWN_TOXICITY Cardiovascular Toxicity 70393-85-0 GLYPHOSATE STRUCTURE_ACTIVITY Toxicant 70393-85-0 GLYPHOSATE MODE_CLASS Enzyme Inhibitor 70393-85-0 GLYPHOSATE ADVERSE_EFFECT KID_3_Anuria 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Respiratory Failure 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Abdominal Pain 70393-85-0 GLYPHOSATE ADVERSE_EFFECT KID_1_Hematuria 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_1_Cough 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Hematemesis 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Gastrointestinal Toxicity 70393-85-0 GLYPHOSATE ADVERSE_EFFECT KID_2_Oliguria 70393-85-0 GLYPHOSATE ADVERSE_EFFECT CVS_1_Hypotensive Shock 70393-85-0 GLYPHOSATE ADVERSE_EFFECT SKN_2_Dermatitis 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 70393-85-0 GLYPHOSATE ADVERSE_EFFECT PSY_2_Confusion 70393-85-0 GLYPHOSATE ADVERSE_EFFECT END_1_Metabolic Acidosis 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Bloody Stools 70393-85-0 GLYPHOSATE PRODUCT_CLASS Toxicants 70393-85-0 GLYPHOSATE MECHANISM Inhibit precursor synthesis 70393-85-0 GLYPHOSATE KNOWN_TOXICITY Nephrotoxicity 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Hematuria 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Dysphagia 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Esophageal Ulceration 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Epigastric Pain 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Hypoxia 70393-85-0 GLYPHOSATE ADVERSE_EFFECT XXX_2_Hypovolemia 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 70393-85-0 GLYPHOSATE KNOWN_TOXICITY Embryo/Fetal Toxicity 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Teratogenicity 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Tachypnea 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Bloody Stools 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Hematemesis 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_1_Dyspnea 70393-85-0 GLYPHOSATE ADVERSE_EFFECT LUN_1_Bronchospasm 70393-85-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 70393-85-0 GLYPHOSATE KNOWN_TOXICITY Gastrointestinal Toxicity 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Hypotensive Shock 70393-85-0 GLYPHOSATE TISSUE_TOXICITY Anuria 70393-85-0 GLYPHOSATE ADVERSE_EFFECT NEU_2_Coma 38641-94-0 GLYPHOSATE KNOWN_TOXICITY Gastrointestinal Toxicity 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_1_Bronchospasm 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_1_Dyspnea 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Hematemesis 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Hypotensive Shock 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Bloody Stools 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Tachypnea 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Teratogenicity 38641-94-0 GLYPHOSATE KNOWN_TOXICITY Embryo/Fetal Toxicity 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 38641-94-0 GLYPHOSATE ADVERSE_EFFECT XXX_2_Hypovolemia 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Hypoxia 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Epigastric Pain 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Esophageal Ulceration 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Dysphagia 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Hematuria 38641-94-0 GLYPHOSATE KNOWN_TOXICITY Nephrotoxicity 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Bloody Stools 38641-94-0 GLYPHOSATE ADVERSE_EFFECT END_1_Metabolic Acidosis 38641-94-0 GLYPHOSATE MECHANISM Inhibit precursor synthesis 38641-94-0 GLYPHOSATE ADVERSE_EFFECT KID_3_Anuria 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 38641-94-0 GLYPHOSATE ADVERSE_EFFECT SKN_2_Dermatitis 38641-94-0 GLYPHOSATE ADVERSE_EFFECT CVS_1_Hypotensive Shock 38641-94-0 GLYPHOSATE ADVERSE_EFFECT KID_2_Oliguria 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Gastrointestinal Toxicity 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Hematemesis 38641-94-0 GLYPHOSATE KNOWN_TOXICITY Cardiovascular Toxicity 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_1_Cough 38641-94-0 GLYPHOSATE ADVERSE_EFFECT PSY_2_Confusion 38641-94-0 GLYPHOSATE ADVERSE_EFFECT NEU_2_Coma 38641-94-0 GLYPHOSATE ADVERSE_EFFECT KID_1_Hematuria 38641-94-0 GLYPHOSATE ADVERSE_EFFECT GIS_1_Abdominal Pain 38641-94-0 GLYPHOSATE ADVERSE_EFFECT LUN_2_Respiratory Failure 38641-94-0 GLYPHOSATE MODE_CLASS Enzyme Inhibitor 38641-94-0 GLYPHOSATE STRUCTURE_ACTIVITY Toxicant 38641-94-0 GLYPHOSATE PRODUCT_CLASS Toxicants 38641-94-0 GLYPHOSATE TISSUE_TOXICITY Anuria 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Bloody Stools 96639-11-1 GLYPHOSATE ADVERSE_EFFECT END_1_Metabolic Acidosis 96639-11-1 GLYPHOSATE ADVERSE_EFFECT PSY_2_Confusion 96639-11-1 GLYPHOSATE ADVERSE_EFFECT XXX_2_Hypovolemia 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_2_Hypoxia 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Epigastric Pain 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Esophageal Ulceration 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Bloody Stools 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Dysphagia 96639-11-1 GLYPHOSATE KNOWN_TOXICITY Cardiovascular Toxicity 96639-11-1 GLYPHOSATE ADVERSE_EFFECT NEU_2_Coma 96639-11-1 GLYPHOSATE ADVERSE_EFFECT KID_1_Hematuria 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Abdominal Pain 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_2_Respiratory Failure 96639-11-1 GLYPHOSATE ADVERSE_EFFECT KID_3_Anuria 96639-11-1 GLYPHOSATE MODE_CLASS Enzyme Inhibitor 96639-11-1 GLYPHOSATE STRUCTURE_ACTIVITY Toxicant 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Hematuria 96639-11-1 GLYPHOSATE ADVERSE_EFFECT KID_2_Oliguria 96639-11-1 GLYPHOSATE KNOWN_TOXICITY Nephrotoxicity 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Gastrointestinal Toxicity 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Hematemesis 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Anuria 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Hypotensive Shock 96639-11-1 GLYPHOSATE KNOWN_TOXICITY Gastrointestinal Toxicity 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_1_Bronchospasm 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_1_Cough 96639-11-1 GLYPHOSATE ADVERSE_EFFECT GIS_1_Hematemesis 96639-11-1 GLYPHOSATE ADVERSE_EFFECT SKN_2_Dermatitis 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_2_Tachypnea 96639-11-1 GLYPHOSATE TISSUE_TOXICITY Teratogenicity 96639-11-1 GLYPHOSATE KNOWN_TOXICITY Embryo/Fetal Toxicity 96639-11-1 GLYPHOSATE PRODUCT_CLASS Toxicants 96639-11-1 GLYPHOSATE MECHANISM Inhibit precursor synthesis 96639-11-1 GLYPHOSATE ADVERSE_EFFECT CVS_1_Hypotensive Shock 96639-11-1 GLYPHOSATE ADVERSE_EFFECT LUN_1_Dyspnea 96638-41-4 GLYPHOSATE ADVERSE_EFFECT PSY_2_Confusion 96638-41-4 GLYPHOSATE ADVERSE_EFFECT END_1_Metabolic Acidosis 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Bloody Stools 96638-41-4 GLYPHOSATE PRODUCT_CLASS Toxicants 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Hematemesis 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Epigastric Pain 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Esophageal Ulceration 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_1_Bronchospasm 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 96638-41-4 GLYPHOSATE KNOWN_TOXICITY Gastrointestinal Toxicity 96638-41-4 GLYPHOSATE STRUCTURE_ACTIVITY Toxicant 96638-41-4 GLYPHOSATE MODE_CLASS Enzyme Inhibitor 96638-41-4 GLYPHOSATE ADVERSE_EFFECT KID_3_Anuria 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_2_Respiratory Failure 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Abdominal Pain 96638-41-4 GLYPHOSATE ADVERSE_EFFECT KID_1_Hematuria 96638-41-4 GLYPHOSATE ADVERSE_EFFECT NEU_2_Coma 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_1_Cough 96638-41-4 GLYPHOSATE KNOWN_TOXICITY Cardiovascular Toxicity 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Hematemesis 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Gastrointestinal Toxicity 96638-41-4 GLYPHOSATE ADVERSE_EFFECT KID_2_Oliguria 96638-41-4 GLYPHOSATE ADVERSE_EFFECT CVS_1_Hypotensive Shock 96638-41-4 GLYPHOSATE ADVERSE_EFFECT SKN_2_Dermatitis 96638-41-4 GLYPHOSATE MECHANISM Inhibit precursor synthesis 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Hematuria 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Anuria 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Hypotensive Shock 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_1_Dyspnea 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_2_Hypoxia 96638-41-4 GLYPHOSATE KNOWN_TOXICITY Nephrotoxicity 96638-41-4 GLYPHOSATE ADVERSE_EFFECT XXX_2_Hypovolemia 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Dysphagia 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 96638-41-4 GLYPHOSATE KNOWN_TOXICITY Embryo/Fetal Toxicity 96638-41-4 GLYPHOSATE TISSUE_TOXICITY Teratogenicity 96638-41-4 GLYPHOSATE ADVERSE_EFFECT LUN_2_Tachypnea 96638-41-4 GLYPHOSATE ADVERSE_EFFECT GIS_1_Bloody Stools 33515-09-2 GONADORELIN MODE_CLASS Endogenous Receptor /Channel Ligand 33515-09-2 GONADORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 34973-08-5 GONADORELIN MODE_CLASS Endogenous Receptor /Channel Ligand 34973-08-5 GONADORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 66036-44-0 GONADORELIN MODE_CLASS Endogenous Receptor /Channel Ligand 66036-44-0 GONADORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 71447-49-9 GONADORELIN MODE_CLASS Endogenous Receptor /Channel Ligand 71447-49-9 GONADORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 65807-02-5 GOSERELIN MODE_CLASS Receptor Agonist 65807-02-5 GOSERELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 65807-02-5 GOSERELIN INDICATION Prostatic Cancer / Carcinoma of the Prostate 1393-88-0 GRAMICIDIN MODE_CLASS Distorts /blocks macromolecular scaffold function 1393-88-0 GRAMICIDIN INDICATION Bacterial Conjunctivitis 1393-88-0 GRAMICIDIN STRUCTURE_ACTIVITY Impairs cell membrane function 1393-88-0 GRAMICIDIN ADVERSE_EFFECT SKN_1_Rash 1393-88-0 GRAMICIDIN ADVERSE_EFFECT XXX_2_Stinging Sensation 1393-88-0 GRAMICIDIN MECHANISM Destroy cell membrane / wall integrity 1393-88-0 GRAMICIDIN INDICATION Ophthalmic Infections 1393-88-0 GRAMICIDIN PRODUCT_CLASS Anti-infectives 1393-88-0 GRAMICIDIN ADVERSE_EFFECT XXX_2_Burning Sensation 1393-88-0 GRAMICIDIN ADVERSE_EFFECT SKN_1_Pruritis 1393-88-0 GRAMICIDIN ADVERSE_EFFECT SKN_1_Itching 1393-88-0 GRAMICIDIN THERAPEUTIC_CLASS Antibacterials, Topical 113-73-5 GRAMICIDIN INDICATION Ophthalmic Infections 113-73-5 GRAMICIDIN THERAPEUTIC_CLASS Antibacterials, Topical 113-73-5 GRAMICIDIN ADVERSE_EFFECT SKN_1_Pruritis 113-73-5 GRAMICIDIN STRUCTURE_ACTIVITY Impairs cell membrane function 113-73-5 GRAMICIDIN ADVERSE_EFFECT SKN_1_Rash 113-73-5 GRAMICIDIN ADVERSE_EFFECT XXX_2_Stinging Sensation 113-73-5 GRAMICIDIN MECHANISM Destroy cell membrane / wall integrity 113-73-5 GRAMICIDIN PRODUCT_CLASS Anti-infectives 113-73-5 GRAMICIDIN ADVERSE_EFFECT XXX_2_Burning Sensation 113-73-5 GRAMICIDIN ADVERSE_EFFECT SKN_1_Itching 113-73-5 GRAMICIDIN MODE_CLASS Distorts /blocks macromolecular scaffold function 113-73-5 GRAMICIDIN INDICATION Bacterial Conjunctivitis 1405-97-6 GRAMICIDIN ADVERSE_EFFECT SKN_1_Itching 1405-97-6 GRAMICIDIN MODE_CLASS Distorts /blocks macromolecular scaffold function 1405-97-6 GRAMICIDIN INDICATION Bacterial Conjunctivitis 1405-97-6 GRAMICIDIN INDICATION Ophthalmic Infections 1405-97-6 GRAMICIDIN ADVERSE_EFFECT XXX_2_Burning Sensation 1405-97-6 GRAMICIDIN PRODUCT_CLASS Anti-infectives 1405-97-6 GRAMICIDIN THERAPEUTIC_CLASS Antibacterials, Topical 1405-97-6 GRAMICIDIN STRUCTURE_ACTIVITY Impairs cell membrane function 1405-97-6 GRAMICIDIN ADVERSE_EFFECT SKN_1_Rash 1405-97-6 GRAMICIDIN ADVERSE_EFFECT XXX_2_Stinging Sensation 1405-97-6 GRAMICIDIN MECHANISM Destroy cell membrane / wall integrity 1405-97-6 GRAMICIDIN ADVERSE_EFFECT SKN_1_Pruritis 109889-09-0 GRANISETRON ADVERSE_EFFECT EMB_3_Teratogenicity 109889-09-0 GRANISETRON ADVERSE_EFFECT GIS_1_Diarrhea 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_Hypertension 109889-09-0 GRANISETRON KNOWN_TOXICITY Embryo/Fetal Toxicity 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_Atrial Fibrillation 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 109889-09-0 GRANISETRON ADVERSE_EFFECT NEU_1_Somnolence 109889-09-0 GRANISETRON TISSUE_TOXICITY Mutagenicity 109889-09-0 GRANISETRON TISSUE_TOXICITY Atrioventricular Blockade 109889-09-0 GRANISETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 109889-09-0 GRANISETRON MECHANISM Block neural transmission 109889-09-0 GRANISETRON KNOWN_TOXICITY Mutagenicity 109889-09-0 GRANISETRON MECH_LEVEL_3 5HT receptor 3 109889-09-0 GRANISETRON TA_LEVEL_3 Antiemetic 109889-09-0 GRANISETRON MECH_LEVEL_2 5HT antagonist 109889-09-0 GRANISETRON TISSUE_TOXICITY Carcinogenicity 109889-09-0 GRANISETRON TISSUE_TOXICITY Atrial Fibrillation 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_Hypotension 109889-09-0 GRANISETRON ADVERSE_EFFECT PSY_3_CNS Stimulation 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_Sinus Bradycardia 109889-09-0 GRANISETRON ADVERSE_EFFECT NEU_1_Headache 109889-09-0 GRANISETRON ADVERSE_EFFECT NEU_3_Extrapyramidal Toxicity 109889-09-0 GRANISETRON ADVERSE_EFFECT GIS_2_Dyspepsia 109889-09-0 GRANISETRON ADVERSE_EFFECT GIS_1_Constipation 109889-09-0 GRANISETRON ADVERSE_EFFECT DNA_3_Carcinogenicity 109889-09-0 GRANISETRON TISSUE_TOXICITY Hypotension 109889-09-0 GRANISETRON ZERO_CLASS N 109889-09-0 GRANISETRON TISSUE_TOXICITY Ventricular Arrhythmia 109889-09-0 GRANISETRON TISSUE_TOXICITY Teratogenicity 109889-09-0 GRANISETRON ADVERSE_EFFECT XXX_1_Asthenia 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 109889-09-0 GRANISETRON ADVERSE_EFFECT IMU_3_Hypersensitivity 109889-09-0 GRANISETRON ADVERSE_EFFECT GIS_2_Vomiting 109889-09-0 GRANISETRON MESH_LEVEL_3 Pyrazoles 109889-09-0 GRANISETRON PRODUCT_CLASS Gastrointestinal System 109889-09-0 GRANISETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 109889-09-0 GRANISETRON TA_LEVEL_1 Central Nervous System (CNS) 109889-09-0 GRANISETRON MESH_LEVEL_1 Heterocyclic Compounds 109889-09-0 GRANISETRON ADVERSE_EFFECT PSY_3_Anxiety 109889-09-0 GRANISETRON ADVERSE_EFFECT PSY_3_Insomnia 109889-09-0 GRANISETRON ADVERSE_EFFECT XXX_3_Fever 109889-09-0 GRANISETRON ADVERSE_EFFECT GIS_2_Nausea 109889-09-0 GRANISETRON ADVERSE_EFFECT DNA_3_Mutagenicity 109889-09-0 GRANISETRON MECH_LEVEL_1 Modulate neural transmission 109889-09-0 GRANISETRON KNOWN_TOXICITY Cardiovascular Toxicity 109889-09-0 GRANISETRON TA_LEVEL_2 CNS Depressant 109889-09-0 GRANISETRON MODE_CLASS Channel Blocker, selective 109889-09-0 GRANISETRON ACTIVITY_CLASS Serotonin antagonist 109889-09-0 GRANISETRON ADVERSE_EFFECT GIS_2_Abdominal Pain 109889-09-0 GRANISETRON ADVERSE_EFFECT PSY_3_Agitation 109889-09-0 GRANISETRON ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 109889-09-0 GRANISETRON THERAPEUTIC_CLASS Antiemetics 109889-09-0 GRANISETRON KNOWN_TOXICITY Carcinogenicity 109889-09-0 GRANISETRON INDICATION Nausea / Vomiting 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_Hypertension 107007-99-8 GRANISETRON ADVERSE_EFFECT GIS_1_Diarrhea 107007-99-8 GRANISETRON ADVERSE_EFFECT EMB_3_Teratogenicity 107007-99-8 GRANISETRON INDICATION Nausea / Vomiting 107007-99-8 GRANISETRON MESH_LEVEL_1 Heterocyclic Compounds 107007-99-8 GRANISETRON TA_LEVEL_1 Central Nervous System (CNS) 107007-99-8 GRANISETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 107007-99-8 GRANISETRON PRODUCT_CLASS Gastrointestinal System 107007-99-8 GRANISETRON MESH_LEVEL_3 Pyrazoles 107007-99-8 GRANISETRON TISSUE_TOXICITY Hypotension 107007-99-8 GRANISETRON ADVERSE_EFFECT DNA_3_Carcinogenicity 107007-99-8 GRANISETRON ADVERSE_EFFECT GIS_1_Constipation 107007-99-8 GRANISETRON ADVERSE_EFFECT PSY_3_Anxiety 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 107007-99-8 GRANISETRON ADVERSE_EFFECT PSY_3_Agitation 107007-99-8 GRANISETRON ADVERSE_EFFECT GIS_2_Abdominal Pain 107007-99-8 GRANISETRON ACTIVITY_CLASS Serotonin antagonist 107007-99-8 GRANISETRON MODE_CLASS Channel Blocker, selective 107007-99-8 GRANISETRON TA_LEVEL_2 CNS Depressant 107007-99-8 GRANISETRON KNOWN_TOXICITY Cardiovascular Toxicity 107007-99-8 GRANISETRON MECH_LEVEL_1 Modulate neural transmission 107007-99-8 GRANISETRON ADVERSE_EFFECT DNA_3_Mutagenicity 107007-99-8 GRANISETRON ADVERSE_EFFECT XXX_3_Fever 107007-99-8 GRANISETRON ADVERSE_EFFECT PSY_3_Insomnia 107007-99-8 GRANISETRON ADVERSE_EFFECT GIS_2_Vomiting 107007-99-8 GRANISETRON ADVERSE_EFFECT IMU_3_Hypersensitivity 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 107007-99-8 GRANISETRON THERAPEUTIC_CLASS Antiemetics 107007-99-8 GRANISETRON KNOWN_TOXICITY Embryo/Fetal Toxicity 107007-99-8 GRANISETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 107007-99-8 GRANISETRON ZERO_CLASS N 107007-99-8 GRANISETRON TISSUE_TOXICITY Ventricular Arrhythmia 107007-99-8 GRANISETRON TISSUE_TOXICITY Teratogenicity 107007-99-8 GRANISETRON ADVERSE_EFFECT XXX_1_Asthenia 107007-99-8 GRANISETRON ADVERSE_EFFECT GIS_2_Nausea 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_Atrial Fibrillation 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 107007-99-8 GRANISETRON ADVERSE_EFFECT NEU_1_Somnolence 107007-99-8 GRANISETRON TISSUE_TOXICITY Mutagenicity 107007-99-8 GRANISETRON TISSUE_TOXICITY Atrioventricular Blockade 107007-99-8 GRANISETRON MECHANISM Block neural transmission 107007-99-8 GRANISETRON KNOWN_TOXICITY Mutagenicity 107007-99-8 GRANISETRON MECH_LEVEL_3 5HT receptor 3 107007-99-8 GRANISETRON TA_LEVEL_3 Antiemetic 107007-99-8 GRANISETRON MECH_LEVEL_2 5HT antagonist 107007-99-8 GRANISETRON TISSUE_TOXICITY Carcinogenicity 107007-99-8 GRANISETRON TISSUE_TOXICITY Atrial Fibrillation 107007-99-8 GRANISETRON ADVERSE_EFFECT PSY_3_CNS Stimulation 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_Hypotension 107007-99-8 GRANISETRON ADVERSE_EFFECT CVS_3_Sinus Bradycardia 107007-99-8 GRANISETRON ADVERSE_EFFECT NEU_1_Headache 107007-99-8 GRANISETRON ADVERSE_EFFECT NEU_3_Extrapyramidal Toxicity 107007-99-8 GRANISETRON ADVERSE_EFFECT GIS_2_Dyspepsia 107007-99-8 GRANISETRON KNOWN_TOXICITY Carcinogenicity 119914-60-2 GREPAFLOXACIN TISSUE_TOXICITY Hypotension 119914-60-2 GREPAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 119914-60-2 GREPAFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 119914-60-2 GREPAFLOXACIN TISSUE_TOXICITY Cardiac Arrhythmia 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT SKN_2_Rash 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT CVS__Vasculitis (Structure Class Implication) 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT NEU_2_Somnolence 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 119914-60-2 GREPAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 119914-60-2 GREPAFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT NEU_1_Headache 119914-60-2 GREPAFLOXACIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 119914-60-2 GREPAFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 119914-60-2 GREPAFLOXACIN PRODUCT_CLASS Anti-infectives 119914-60-2 GREPAFLOXACIN INDICATION Community-Acquired Pneumonia 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT NEU_3_Paresthesia 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT GIS_2_Vomiting 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT END_3_Gout 119914-60-2 GREPAFLOXACIN INDICATION Community-Acquired Pneumonia 119914-60-2 GREPAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 119914-60-2 GREPAFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT LUN_3_Asthma 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT XXX_3_Peripheral Edema 119914-60-2 GREPAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 119914-60-2 GREPAFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 119914-60-2 GREPAFLOXACIN TISSUE_TOXICITY Ventricular Arrhythmia 119914-60-2 GREPAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT PSY_3_Confusion 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT XXX_1_Taste Disturbances 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 119914-60-2 GREPAFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 119914-60-2 GREPAFLOXACIN ADVERSE_EFFECT BBM_3_Myelosuppression 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT LUN_3_Asthma 161967-81-3 GREPAFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 161967-81-3 GREPAFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 161967-81-3 GREPAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 161967-81-3 GREPAFLOXACIN INDICATION Community-Acquired Pneumonia 161967-81-3 GREPAFLOXACIN TISSUE_TOXICITY Cardiac Arrhythmia 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Hypotension 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT NEU_2_Somnolence 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 161967-81-3 GREPAFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT XXX_3_Peripheral Edema 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT SKN_2_Rash 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT NEU_1_Headache 161967-81-3 GREPAFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 161967-81-3 GREPAFLOXACIN PRODUCT_CLASS Anti-infectives 161967-81-3 GREPAFLOXACIN INDICATION Community-Acquired Pneumonia 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT NEU_3_Paresthesia 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT CVS__Vasculitis (Structure Class Implication) 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT GIS_2_Vomiting 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT PSY_2_Anorexia 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT END_3_Gout 161967-81-3 GREPAFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 161967-81-3 GREPAFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 161967-81-3 GREPAFLOXACIN TISSUE_TOXICITY Ventricular Arrhythmia 161967-81-3 GREPAFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT PSY_3_Confusion 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT XXX_1_Taste Disturbances 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 161967-81-3 GREPAFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 161967-81-3 GREPAFLOXACIN ADVERSE_EFFECT BBM_3_Myelosuppression 161967-81-3 GREPAFLOXACIN TISSUE_TOXICITY Hypotension 161967-81-3 GREPAFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 161967-81-3 GREPAFLOXACIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 161967-81-3 GREPAFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 126-07-8 GRISEOFULVIN ADVERSE_EFFECT XXX_1_Fatigue 126-07-8 GRISEOFULVIN MECH_LEVEL_3 Microtubule / tubulin 126-07-8 GRISEOFULVIN INDICATION Tinea Pedis / Athlete's Foot 126-07-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Confusion 126-07-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Insomnia 126-07-8 GRISEOFULVIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 126-07-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Epigastric Pain 126-07-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Jaundice 126-07-8 GRISEOFULVIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 126-07-8 GRISEOFULVIN TA_LEVEL_1 Infectious Disease 126-07-8 GRISEOFULVIN INDICATION Tinea Manuum / Tinea of Palms 126-07-8 GRISEOFULVIN INDICATION Tinea Barbae 126-07-8 GRISEOFULVIN MECHANISM Inhibit mitosis 126-07-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Paresthesia 126-07-8 GRISEOFULVIN MESH_LEVEL_1 Heterocyclic Compounds 126-07-8 GRISEOFULVIN ADVERSE_EFFECT IMU_2_Urticaria 126-07-8 GRISEOFULVIN PRODUCT_CLASS Anti-infectives 126-07-8 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Leukopenia 126-07-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Dizziness 126-07-8 GRISEOFULVIN KNOWN_TOXICITY Mental Health Disorders 126-07-8 GRISEOFULVIN INDICATION Tinea Unguium / Onychomycosis 126-07-8 GRISEOFULVIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 126-07-8 GRISEOFULVIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 126-07-8 GRISEOFULVIN MECH_LEVEL_2 Inhibit mitosis 126-07-8 GRISEOFULVIN ZERO_CLASS N 126-07-8 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Neutropenia 126-07-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Hepatitis 126-07-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 126-07-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Psychosis 126-07-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Headache 126-07-8 GRISEOFULVIN INDICATION Dermatophytosis 126-07-8 GRISEOFULVIN INDICATION Tinea Capitis 126-07-8 GRISEOFULVIN INDICATION Tinea Cruris / Jock Itch 126-07-8 GRISEOFULVIN MESH_LEVEL_3 Benzofurans 126-07-8 GRISEOFULVIN MECH_LEVEL_1 Anti-fungal 126-07-8 GRISEOFULVIN STRUCTURE_ACTIVITY Tubulin binder 126-07-8 GRISEOFULVIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 126-07-8 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Photosensitivity 126-07-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 126-07-8 GRISEOFULVIN ADVERSE_EFFECT XXX_2_Oral Candidiasis 126-07-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Flatulence 126-07-8 GRISEOFULVIN TISSUE_TOXICITY Psychosis 126-07-8 GRISEOFULVIN THERAPEUTIC_CLASS Antifungals, Systemic 126-07-8 GRISEOFULVIN INDICATION Coccidial and Microsporidial Infections 126-07-8 GRISEOFULVIN TA_LEVEL_2 Anti-fungal 126-07-8 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Angioedema 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Insomnia 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Epigastric Pain 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT IMU_2_Urticaria 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Jaundice 3426-54-8 GRISEOFULVIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 3426-54-8 GRISEOFULVIN PRODUCT_CLASS Anti-infectives 3426-54-8 GRISEOFULVIN MESH_LEVEL_1 Heterocyclic Compounds 3426-54-8 GRISEOFULVIN MECH_LEVEL_3 Microtubule / tubulin 3426-54-8 GRISEOFULVIN INDICATION Tinea Pedis / Athlete's Foot 3426-54-8 GRISEOFULVIN MECHANISM Inhibit mitosis 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Leukopenia 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Angioedema 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Paresthesia 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Dizziness 3426-54-8 GRISEOFULVIN KNOWN_TOXICITY Mental Health Disorders 3426-54-8 GRISEOFULVIN INDICATION Tinea Unguium / Onychomycosis 3426-54-8 GRISEOFULVIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 3426-54-8 GRISEOFULVIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 3426-54-8 GRISEOFULVIN MECH_LEVEL_2 Inhibit mitosis 3426-54-8 GRISEOFULVIN ZERO_CLASS N 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Neutropenia 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Hepatitis 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Psychosis 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT XXX_1_Fatigue 3426-54-8 GRISEOFULVIN INDICATION Dermatophytosis 3426-54-8 GRISEOFULVIN INDICATION Tinea Capitis 3426-54-8 GRISEOFULVIN INDICATION Tinea Cruris / Jock Itch 3426-54-8 GRISEOFULVIN MESH_LEVEL_3 Benzofurans 3426-54-8 GRISEOFULVIN MECH_LEVEL_1 Anti-fungal 3426-54-8 GRISEOFULVIN STRUCTURE_ACTIVITY Tubulin binder 3426-54-8 GRISEOFULVIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Photosensitivity 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT XXX_2_Oral Candidiasis 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Flatulence 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Headache 3426-54-8 GRISEOFULVIN TISSUE_TOXICITY Psychosis 3426-54-8 GRISEOFULVIN THERAPEUTIC_CLASS Antifungals, Systemic 3426-54-8 GRISEOFULVIN INDICATION Coccidial and Microsporidial Infections 3426-54-8 GRISEOFULVIN TA_LEVEL_2 Anti-fungal 3426-54-8 GRISEOFULVIN INDICATION Tinea Barbae 3426-54-8 GRISEOFULVIN INDICATION Tinea Manuum / Tinea of Palms 3426-54-8 GRISEOFULVIN TA_LEVEL_1 Infectious Disease 3426-54-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Confusion 8027-03-0 GRISEOFULVIN INDICATION Coccidial and Microsporidial Infections 8027-03-0 GRISEOFULVIN TA_LEVEL_2 Anti-fungal 8027-03-0 GRISEOFULVIN INDICATION Tinea Barbae 8027-03-0 GRISEOFULVIN INDICATION Tinea Manuum / Tinea of Palms 8027-03-0 GRISEOFULVIN TA_LEVEL_1 Infectious Disease 8027-03-0 GRISEOFULVIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 8027-03-0 GRISEOFULVIN MESH_LEVEL_1 Heterocyclic Compounds 8027-03-0 GRISEOFULVIN MECH_LEVEL_3 Microtubule / tubulin 8027-03-0 GRISEOFULVIN INDICATION Tinea Pedis / Athlete's Foot 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Confusion 8027-03-0 GRISEOFULVIN PRODUCT_CLASS Anti-infectives 8027-03-0 GRISEOFULVIN INDICATION Tinea Cruris / Jock Itch 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 8027-03-0 GRISEOFULVIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 8027-03-0 GRISEOFULVIN MECH_LEVEL_1 Anti-fungal 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Insomnia 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Epigastric Pain 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Jaundice 8027-03-0 GRISEOFULVIN MECHANISM Inhibit mitosis 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Leukopenia 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Angioedema 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT IMU_2_Urticaria 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Paresthesia 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Dizziness 8027-03-0 GRISEOFULVIN KNOWN_TOXICITY Mental Health Disorders 8027-03-0 GRISEOFULVIN INDICATION Tinea Unguium / Onychomycosis 8027-03-0 GRISEOFULVIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 8027-03-0 GRISEOFULVIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 8027-03-0 GRISEOFULVIN MECH_LEVEL_2 Inhibit mitosis 8027-03-0 GRISEOFULVIN ZERO_CLASS N 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Neutropenia 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Hepatitis 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Psychosis 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT XXX_1_Fatigue 8027-03-0 GRISEOFULVIN INDICATION Dermatophytosis 8027-03-0 GRISEOFULVIN INDICATION Tinea Capitis 8027-03-0 GRISEOFULVIN MESH_LEVEL_3 Benzofurans 8027-03-0 GRISEOFULVIN STRUCTURE_ACTIVITY Tubulin binder 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Photosensitivity 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT XXX_2_Oral Candidiasis 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Flatulence 8027-03-0 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Headache 8027-03-0 GRISEOFULVIN TISSUE_TOXICITY Psychosis 8027-03-0 GRISEOFULVIN THERAPEUTIC_CLASS Antifungals, Systemic 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Headache 8055-10-5 GRISEOFULVIN INDICATION Tinea Barbae 8055-10-5 GRISEOFULVIN TA_LEVEL_2 Anti-fungal 8055-10-5 GRISEOFULVIN INDICATION Coccidial and Microsporidial Infections 8055-10-5 GRISEOFULVIN THERAPEUTIC_CLASS Antifungals, Systemic 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Jaundice 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Epigastric Pain 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Insomnia 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Confusion 8055-10-5 GRISEOFULVIN INDICATION Tinea Pedis / Athlete's Foot 8055-10-5 GRISEOFULVIN MECH_LEVEL_3 Microtubule / tubulin 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT IMU_2_Urticaria 8055-10-5 GRISEOFULVIN MESH_LEVEL_1 Heterocyclic Compounds 8055-10-5 GRISEOFULVIN PRODUCT_CLASS Anti-infectives 8055-10-5 GRISEOFULVIN TISSUE_TOXICITY Psychosis 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Flatulence 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT XXX_2_Oral Candidiasis 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Photosensitivity 8055-10-5 GRISEOFULVIN STRUCTURE_ACTIVITY Tubulin binder 8055-10-5 GRISEOFULVIN MECH_LEVEL_1 Anti-fungal 8055-10-5 GRISEOFULVIN MESH_LEVEL_3 Benzofurans 8055-10-5 GRISEOFULVIN INDICATION Tinea Cruris / Jock Itch 8055-10-5 GRISEOFULVIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 8055-10-5 GRISEOFULVIN INDICATION Tinea Capitis 8055-10-5 GRISEOFULVIN INDICATION Dermatophytosis 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT XXX_1_Fatigue 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Psychosis 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Hepatitis 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Neutropenia 8055-10-5 GRISEOFULVIN ZERO_CLASS N 8055-10-5 GRISEOFULVIN MECH_LEVEL_2 Inhibit mitosis 8055-10-5 GRISEOFULVIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Paresthesia 8055-10-5 GRISEOFULVIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 8055-10-5 GRISEOFULVIN INDICATION Tinea Manuum / Tinea of Palms 8055-10-5 GRISEOFULVIN INDICATION Tinea Unguium / Onychomycosis 8055-10-5 GRISEOFULVIN TA_LEVEL_1 Infectious Disease 8055-10-5 GRISEOFULVIN KNOWN_TOXICITY Mental Health Disorders 8055-10-5 GRISEOFULVIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Dizziness 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Angioedema 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Leukopenia 8055-10-5 GRISEOFULVIN MECHANISM Inhibit mitosis 8055-10-5 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Confusion 11103-62-1 GRISEOFULVIN INDICATION Tinea Pedis / Athlete's Foot 11103-62-1 GRISEOFULVIN MECH_LEVEL_3 Microtubule / tubulin 11103-62-1 GRISEOFULVIN MESH_LEVEL_1 Heterocyclic Compounds 11103-62-1 GRISEOFULVIN PRODUCT_CLASS Anti-infectives 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Paresthesia 11103-62-1 GRISEOFULVIN MECHANISM Inhibit mitosis 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Leukopenia 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Angioedema 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT IMU_2_Urticaria 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Dizziness 11103-62-1 GRISEOFULVIN KNOWN_TOXICITY Mental Health Disorders 11103-62-1 GRISEOFULVIN INDICATION Tinea Unguium / Onychomycosis 11103-62-1 GRISEOFULVIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 11103-62-1 GRISEOFULVIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 11103-62-1 GRISEOFULVIN MECH_LEVEL_2 Inhibit mitosis 11103-62-1 GRISEOFULVIN ZERO_CLASS N 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Neutropenia 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Hepatitis 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Psychosis 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT XXX_1_Fatigue 11103-62-1 GRISEOFULVIN INDICATION Dermatophytosis 11103-62-1 GRISEOFULVIN INDICATION Tinea Capitis 11103-62-1 GRISEOFULVIN INDICATION Tinea Cruris / Jock Itch 11103-62-1 GRISEOFULVIN MESH_LEVEL_3 Benzofurans 11103-62-1 GRISEOFULVIN MECH_LEVEL_1 Anti-fungal 11103-62-1 GRISEOFULVIN STRUCTURE_ACTIVITY Tubulin binder 11103-62-1 GRISEOFULVIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Photosensitivity 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT XXX_2_Oral Candidiasis 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Flatulence 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Headache 11103-62-1 GRISEOFULVIN TISSUE_TOXICITY Psychosis 11103-62-1 GRISEOFULVIN THERAPEUTIC_CLASS Antifungals, Systemic 11103-62-1 GRISEOFULVIN INDICATION Coccidial and Microsporidial Infections 11103-62-1 GRISEOFULVIN TA_LEVEL_2 Anti-fungal 11103-62-1 GRISEOFULVIN INDICATION Tinea Barbae 11103-62-1 GRISEOFULVIN INDICATION Tinea Manuum / Tinea of Palms 11103-62-1 GRISEOFULVIN TA_LEVEL_1 Infectious Disease 11103-62-1 GRISEOFULVIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Jaundice 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Epigastric Pain 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 11103-62-1 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Insomnia 24659-79-8 GRISEOFULVIN INDICATION Tinea Unguium / Onychomycosis 24659-79-8 GRISEOFULVIN MECHANISM Inhibit mitosis 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Leukopenia 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Angioedema 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT IMU_2_Urticaria 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Dizziness 24659-79-8 GRISEOFULVIN KNOWN_TOXICITY Mental Health Disorders 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 24659-79-8 GRISEOFULVIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 24659-79-8 GRISEOFULVIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 24659-79-8 GRISEOFULVIN MECH_LEVEL_2 Inhibit mitosis 24659-79-8 GRISEOFULVIN ZERO_CLASS N 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT BBM_3_Neutropenia 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Hepatitis 24659-79-8 GRISEOFULVIN TA_LEVEL_1 Infectious Disease 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Paresthesia 24659-79-8 GRISEOFULVIN INDICATION Tinea Manuum / Tinea of Palms 24659-79-8 GRISEOFULVIN INDICATION Tinea Barbae 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT XXX_1_Fatigue 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Psychosis 24659-79-8 GRISEOFULVIN INDICATION Dermatophytosis 24659-79-8 GRISEOFULVIN PRODUCT_CLASS Anti-infectives 24659-79-8 GRISEOFULVIN MESH_LEVEL_1 Heterocyclic Compounds 24659-79-8 GRISEOFULVIN MECH_LEVEL_3 Microtubule / tubulin 24659-79-8 GRISEOFULVIN INDICATION Tinea Pedis / Athlete's Foot 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Confusion 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT PSY_1_Insomnia 24659-79-8 GRISEOFULVIN TA_LEVEL_2 Anti-fungal 24659-79-8 GRISEOFULVIN INDICATION Coccidial and Microsporidial Infections 24659-79-8 GRISEOFULVIN THERAPEUTIC_CLASS Antifungals, Systemic 24659-79-8 GRISEOFULVIN TISSUE_TOXICITY Psychosis 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT NEU_1_Headache 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Flatulence 24659-79-8 GRISEOFULVIN INDICATION Tinea Capitis 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT XXX_2_Oral Candidiasis 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT GIS_2_Epigastric Pain 24659-79-8 GRISEOFULVIN INDICATION Tinea Cruris / Jock Itch 24659-79-8 GRISEOFULVIN MESH_LEVEL_3 Benzofurans 24659-79-8 GRISEOFULVIN MECH_LEVEL_1 Anti-fungal 24659-79-8 GRISEOFULVIN STRUCTURE_ACTIVITY Tubulin binder 24659-79-8 GRISEOFULVIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT IMU_3_Photosensitivity 24659-79-8 GRISEOFULVIN ADVERSE_EFFECT LIV_3_Jaundice 24659-79-8 GRISEOFULVIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 93-14-1 GUAIFENESIN ADVERSE_EFFECT NEU_3_Dizziness 93-14-1 GUAIFENESIN ADVERSE_EFFECT SKN_3_Rash 93-14-1 GUAIFENESIN ADVERSE_EFFECT KID_3_Nephrolithiasis 93-14-1 GUAIFENESIN PRODUCT_CLASS Other Human Uses 93-14-1 GUAIFENESIN ADVERSE_EFFECT NEU_3_Headache 93-14-1 GUAIFENESIN ADVERSE_EFFECT GIS_3_Abdominal Pain 93-14-1 GUAIFENESIN INDICATION Female Infertility 93-14-1 GUAIFENESIN PRODUCT_CLASS Respiratory System 93-14-1 GUAIFENESIN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 93-14-1 GUAIFENESIN ADVERSE_EFFECT NEU_3_Drowsiness 93-14-1 GUAIFENESIN INDICATION Cough / Tussis 93-14-1 GUAIFENESIN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 93-14-1 GUAIFENESIN ADVERSE_EFFECT GIS_3_Diarrhea 23256-50-0 GUANABENZ MODE_CLASS Enzyme Inhibitor 23256-50-0 GUANABENZ THERAPEUTIC_CLASS Antihypertensive Agents 23256-50-0 GUANABENZ INDICATION Hypertension 23256-50-0 GUANABENZ TISSUE_TOXICITY Atrioventricular Blockade 23256-50-0 GUANABENZ ADVERSE_EFFECT GIS_1_Dry Mouth 23256-50-0 GUANABENZ ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 23256-50-0 GUANABENZ ADVERSE_EFFECT NEU_1_Dizziness 23256-50-0 GUANABENZ ADVERSE_EFFECT NEU_3_Ataxia 23256-50-0 GUANABENZ PRODUCT_CLASS Cardiovasculars 23256-50-0 GUANABENZ TISSUE_TOXICITY Angina 23256-50-0 GUANABENZ ADVERSE_EFFECT GIS_2_Nausea 23256-50-0 GUANABENZ ADVERSE_EFFECT NEU_2_Headache 23256-50-0 GUANABENZ MODE_CLASS Receptor Agonist 23256-50-0 GUANABENZ STRUCTURE_ACTIVITY Imidazoline receptor agonist 23256-50-0 GUANABENZ MODE_CLASS Receptor Partial Agonist 23256-50-0 GUANABENZ ADVERSE_EFFECT XXX_2_Withdrawal 23256-50-0 GUANABENZ ADVERSE_EFFECT PSY_3_Depression 23256-50-0 GUANABENZ MECHANISM Modulate gene transcription 23256-50-0 GUANABENZ TISSUE_TOXICITY Cardiac Arrhythmia 23256-50-0 GUANABENZ ADVERSE_EFFECT END_3_Gynecomastia 23256-50-0 GUANABENZ ADVERSE_EFFECT REP_2_Impotence 23256-50-0 GUANABENZ ADVERSE_EFFECT CVS_3_Angina 23256-50-0 GUANABENZ KNOWN_TOXICITY Cardiovascular Toxicity 23256-50-0 GUANABENZ MECHANISM Reduce vasoconstriction 23256-50-0 GUANABENZ ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 23256-50-0 GUANABENZ ADVERSE_EFFECT XXX_1_Weakness 23256-50-0 GUANABENZ ADVERSE_EFFECT NEU_1_Drowsiness 5051-62-7 GUANABENZ KNOWN_TOXICITY Cardiovascular Toxicity 5051-62-7 GUANABENZ MECHANISM Reduce vasoconstriction 5051-62-7 GUANABENZ ADVERSE_EFFECT CVS_3_Angina 5051-62-7 GUANABENZ MODE_CLASS Receptor Partial Agonist 5051-62-7 GUANABENZ TISSUE_TOXICITY Cardiac Arrhythmia 5051-62-7 GUANABENZ ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 5051-62-7 GUANABENZ ADVERSE_EFFECT XXX_1_Weakness 5051-62-7 GUANABENZ ADVERSE_EFFECT NEU_1_Drowsiness 5051-62-7 GUANABENZ MODE_CLASS Enzyme Inhibitor 5051-62-7 GUANABENZ THERAPEUTIC_CLASS Antihypertensive Agents 5051-62-7 GUANABENZ INDICATION Hypertension 5051-62-7 GUANABENZ TISSUE_TOXICITY Atrioventricular Blockade 5051-62-7 GUANABENZ ADVERSE_EFFECT GIS_1_Dry Mouth 5051-62-7 GUANABENZ ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 5051-62-7 GUANABENZ ADVERSE_EFFECT NEU_1_Dizziness 5051-62-7 GUANABENZ ADVERSE_EFFECT NEU_3_Ataxia 5051-62-7 GUANABENZ PRODUCT_CLASS Cardiovasculars 5051-62-7 GUANABENZ TISSUE_TOXICITY Angina 5051-62-7 GUANABENZ ADVERSE_EFFECT PSY_3_Depression 5051-62-7 GUANABENZ ADVERSE_EFFECT GIS_2_Nausea 5051-62-7 GUANABENZ ADVERSE_EFFECT NEU_2_Headache 5051-62-7 GUANABENZ ADVERSE_EFFECT XXX_2_Withdrawal 5051-62-7 GUANABENZ MODE_CLASS Receptor Agonist 5051-62-7 GUANABENZ STRUCTURE_ACTIVITY Imidazoline receptor agonist 5051-62-7 GUANABENZ ADVERSE_EFFECT END_3_Gynecomastia 5051-62-7 GUANABENZ MECHANISM Modulate gene transcription 5051-62-7 GUANABENZ ADVERSE_EFFECT REP_2_Impotence 40580-59-4 GUANADREL INDICATION Hypertension 40580-59-4 GUANADREL MECHANISM Modulate G-protein coupled signal transduction 40580-59-4 GUANADREL THERAPEUTIC_CLASS Antihypertensive Agents 40580-59-4 GUANADREL MODE_CLASS Receptor Ligand Antagonist 40580-59-4 GUANADREL PRODUCT_CLASS Cardiovasculars 40580-59-4 GUANADREL MECHANISM Modulate G-protein coupled signal transduction 55-65-2 GUANETHIDINE ADVERSE_EFFECT GIS_3_Explosive Diarrhea 55-65-2 GUANETHIDINE TA_LEVEL_2 Hypertension 55-65-2 GUANETHIDINE MESH_LEVEL_1 Organic Chemicals 55-65-2 GUANETHIDINE ADVERSE_EFFECT XXX_2_Edema 55-65-2 GUANETHIDINE ADVERSE_EFFECT CVS_1_Post-Exercise Hypotension 55-65-2 GUANETHIDINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 55-65-2 GUANETHIDINE ADVERSE_EFFECT GIS_1_Increased Frequency of Bowel Movements 55-65-2 GUANETHIDINE MECH_LEVEL_3 Amine oxidase (flavin-containing) 55-65-2 GUANETHIDINE THERAPEUTIC_CLASS Antihypertensive Agents 55-65-2 GUANETHIDINE MODE_CLASS Enzyme Inhibitor 55-65-2 GUANETHIDINE MESH_LEVEL_2 Amidines 55-65-2 GUANETHIDINE ADVERSE_EFFECT CVS_1_Postural Hypotension 55-65-2 GUANETHIDINE ADVERSE_EFFECT REP_2_Impaired Ejaculation 55-65-2 GUANETHIDINE ADVERSE_EFFECT XXX_2_Weight Gain 55-65-2 GUANETHIDINE MESH_LEVEL_3 Guanidines 55-65-2 GUANETHIDINE MECHANISM Depletes neural transmitter 55-65-2 GUANETHIDINE PRODUCT_CLASS Cardiovasculars 55-65-2 GUANETHIDINE TA_LEVEL_1 Cardiovascular 55-65-2 GUANETHIDINE INDICATION Hypertension 55-65-2 GUANETHIDINE ZERO_CLASS N 55-65-2 GUANETHIDINE MECH_LEVEL_2 Enzyme inhibitor 55-65-2 GUANETHIDINE ADVERSE_EFFECT CVS_2_Precipitation of Heart Failure 55-65-2 GUANETHIDINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 55-65-2 GUANETHIDINE MECH_LEVEL_1 Modulate neural transmission 60-02-6 GUANETHIDINE ADVERSE_EFFECT XXX_2_Edema 60-02-6 GUANETHIDINE PRODUCT_CLASS Cardiovasculars 60-02-6 GUANETHIDINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 60-02-6 GUANETHIDINE ADVERSE_EFFECT GIS_3_Explosive Diarrhea 60-02-6 GUANETHIDINE ADVERSE_EFFECT XXX_2_Weight Gain 60-02-6 GUANETHIDINE MECHANISM Depletes neural transmitter 60-02-6 GUANETHIDINE INDICATION Hypertension 60-02-6 GUANETHIDINE ZERO_CLASS N 60-02-6 GUANETHIDINE MECH_LEVEL_2 Enzyme inhibitor 60-02-6 GUANETHIDINE ADVERSE_EFFECT CVS_2_Precipitation of Heart Failure 60-02-6 GUANETHIDINE ADVERSE_EFFECT GIS_1_Increased Frequency of Bowel Movements 60-02-6 GUANETHIDINE MECH_LEVEL_3 Amine oxidase (flavin-containing) 60-02-6 GUANETHIDINE THERAPEUTIC_CLASS Antihypertensive Agents 60-02-6 GUANETHIDINE MODE_CLASS Enzyme Inhibitor 60-02-6 GUANETHIDINE ADVERSE_EFFECT CVS_1_Postural Hypotension 60-02-6 GUANETHIDINE ADVERSE_EFFECT REP_2_Impaired Ejaculation 60-02-6 GUANETHIDINE MECH_LEVEL_1 Modulate neural transmission 60-02-6 GUANETHIDINE MESH_LEVEL_3 Guanidines 60-02-6 GUANETHIDINE MESH_LEVEL_2 Amidines 60-02-6 GUANETHIDINE TA_LEVEL_1 Cardiovascular 60-02-6 GUANETHIDINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 60-02-6 GUANETHIDINE ADVERSE_EFFECT CVS_1_Post-Exercise Hypotension 60-02-6 GUANETHIDINE MESH_LEVEL_1 Organic Chemicals 60-02-6 GUANETHIDINE TA_LEVEL_2 Hypertension 645-43-2 GUANETHIDINE ADVERSE_EFFECT GIS_1_Increased Frequency of Bowel Movements 645-43-2 GUANETHIDINE ADVERSE_EFFECT CVS_2_Precipitation of Heart Failure 645-43-2 GUANETHIDINE MECH_LEVEL_2 Enzyme inhibitor 645-43-2 GUANETHIDINE ZERO_CLASS N 645-43-2 GUANETHIDINE ADVERSE_EFFECT CVS_1_Postural Hypotension 645-43-2 GUANETHIDINE INDICATION Hypertension 645-43-2 GUANETHIDINE MECHANISM Depletes neural transmitter 645-43-2 GUANETHIDINE ADVERSE_EFFECT XXX_2_Weight Gain 645-43-2 GUANETHIDINE ADVERSE_EFFECT GIS_3_Explosive Diarrhea 645-43-2 GUANETHIDINE ADVERSE_EFFECT XXX_2_Edema 645-43-2 GUANETHIDINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 645-43-2 GUANETHIDINE PRODUCT_CLASS Cardiovasculars 645-43-2 GUANETHIDINE MODE_CLASS Enzyme Inhibitor 645-43-2 GUANETHIDINE TA_LEVEL_2 Hypertension 645-43-2 GUANETHIDINE MESH_LEVEL_1 Organic Chemicals 645-43-2 GUANETHIDINE ADVERSE_EFFECT CVS_1_Post-Exercise Hypotension 645-43-2 GUANETHIDINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 645-43-2 GUANETHIDINE TA_LEVEL_1 Cardiovascular 645-43-2 GUANETHIDINE MESH_LEVEL_2 Amidines 645-43-2 GUANETHIDINE MESH_LEVEL_3 Guanidines 645-43-2 GUANETHIDINE MECH_LEVEL_1 Modulate neural transmission 645-43-2 GUANETHIDINE ADVERSE_EFFECT REP_2_Impaired Ejaculation 645-43-2 GUANETHIDINE THERAPEUTIC_CLASS Antihypertensive Agents 645-43-2 GUANETHIDINE MECH_LEVEL_3 Amine oxidase (flavin-containing) 76487-49-5 GUANETHIDINE MESH_LEVEL_2 Amidines 76487-49-5 GUANETHIDINE ADVERSE_EFFECT GIS_1_Increased Frequency of Bowel Movements 76487-49-5 GUANETHIDINE MECH_LEVEL_3 Amine oxidase (flavin-containing) 76487-49-5 GUANETHIDINE THERAPEUTIC_CLASS Antihypertensive Agents 76487-49-5 GUANETHIDINE MODE_CLASS Enzyme Inhibitor 76487-49-5 GUANETHIDINE ADVERSE_EFFECT CVS_1_Postural Hypotension 76487-49-5 GUANETHIDINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 76487-49-5 GUANETHIDINE ADVERSE_EFFECT REP_2_Impaired Ejaculation 76487-49-5 GUANETHIDINE ADVERSE_EFFECT CVS_2_Precipitation of Heart Failure 76487-49-5 GUANETHIDINE MESH_LEVEL_3 Guanidines 76487-49-5 GUANETHIDINE MESH_LEVEL_1 Organic Chemicals 76487-49-5 GUANETHIDINE ADVERSE_EFFECT XXX_2_Edema 76487-49-5 GUANETHIDINE ADVERSE_EFFECT CVS_1_Post-Exercise Hypotension 76487-49-5 GUANETHIDINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 76487-49-5 GUANETHIDINE TA_LEVEL_1 Cardiovascular 76487-49-5 GUANETHIDINE MECH_LEVEL_1 Modulate neural transmission 76487-49-5 GUANETHIDINE TA_LEVEL_2 Hypertension 76487-49-5 GUANETHIDINE PRODUCT_CLASS Cardiovasculars 76487-49-5 GUANETHIDINE ADVERSE_EFFECT GIS_3_Explosive Diarrhea 76487-49-5 GUANETHIDINE ADVERSE_EFFECT XXX_2_Weight Gain 76487-49-5 GUANETHIDINE MECHANISM Depletes neural transmitter 76487-49-5 GUANETHIDINE INDICATION Hypertension 76487-49-5 GUANETHIDINE ZERO_CLASS N 76487-49-5 GUANETHIDINE MECH_LEVEL_2 Enzyme inhibitor 29110-47-2 GUANFACINE ADVERSE_EFFECT NEU_1_Drowsiness 29110-47-2 GUANFACINE ADVERSE_EFFECT CVS_2_Bradycardia 29110-47-2 GUANFACINE MECHANISM Modulate G-protein coupled signal transduction 29110-47-2 GUANFACINE THERAPEUTIC_CLASS Antihypertensive Agents 29110-47-2 GUANFACINE ADVERSE_EFFECT GUS_3_Urinary Retention 29110-47-2 GUANFACINE ADVERSE_EFFECT XXX_3_Weakness 29110-47-2 GUANFACINE ADVERSE_EFFECT XXX_2_Withdrawal 29110-47-2 GUANFACINE ADVERSE_EFFECT SKN_3_Skin Rash 29110-47-2 GUANFACINE STRUCTURE_ACTIVITY Adrenoceptor-alpha2 partial agonist 29110-47-2 GUANFACINE ADVERSE_EFFECT OCU_3_Blurred Vision 29110-47-2 GUANFACINE ADVERSE_EFFECT NEU_1_Dizziness 29110-47-2 GUANFACINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 29110-47-2 GUANFACINE MODE_CLASS Receptor Agonist, selective 29110-47-2 GUANFACINE TISSUE_TOXICITY Hypotension 29110-47-2 GUANFACINE ADVERSE_EFFECT CVS_2_Hypotension 29110-47-2 GUANFACINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 29110-47-2 GUANFACINE ADVERSE_EFFECT GIS_1_Dry Mouth 29110-47-2 GUANFACINE ADVERSE_EFFECT REP_3_Impotence 29110-47-2 GUANFACINE ADVERSE_EFFECT PSY_3_Confusion 29110-47-2 GUANFACINE ADVERSE_EFFECT CVS_2_Palpitation 29110-47-2 GUANFACINE KNOWN_TOXICITY Cardiovascular Toxicity 29110-47-2 GUANFACINE ADVERSE_EFFECT BBM_3_Purpura 29110-47-2 GUANFACINE INDICATION Hypertension 29110-47-2 GUANFACINE PRODUCT_CLASS Cardiovasculars 29110-47-2 GUANFACINE ADVERSE_EFFECT GIS_2_Constipation 29110-47-2 GUANFACINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 29110-48-3 GUANFACINE INDICATION Hypertension 29110-48-3 GUANFACINE PRODUCT_CLASS Cardiovasculars 29110-48-3 GUANFACINE ADVERSE_EFFECT GIS_2_Constipation 29110-48-3 GUANFACINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 29110-48-3 GUANFACINE ADVERSE_EFFECT NEU_1_Drowsiness 29110-48-3 GUANFACINE ADVERSE_EFFECT CVS_2_Palpitation 29110-48-3 GUANFACINE THERAPEUTIC_CLASS Antihypertensive Agents 29110-48-3 GUANFACINE ADVERSE_EFFECT BBM_3_Purpura 29110-48-3 GUANFACINE ADVERSE_EFFECT GIS_1_Dry Mouth 29110-48-3 GUANFACINE ADVERSE_EFFECT NEU_1_Dizziness 29110-48-3 GUANFACINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 29110-48-3 GUANFACINE MODE_CLASS Receptor Agonist, selective 29110-48-3 GUANFACINE TISSUE_TOXICITY Hypotension 29110-48-3 GUANFACINE ADVERSE_EFFECT CVS_2_Bradycardia 29110-48-3 GUANFACINE ADVERSE_EFFECT CVS_2_Hypotension 29110-48-3 GUANFACINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 29110-48-3 GUANFACINE ADVERSE_EFFECT REP_3_Impotence 29110-48-3 GUANFACINE MECHANISM Modulate G-protein coupled signal transduction 29110-48-3 GUANFACINE ADVERSE_EFFECT PSY_3_Confusion 29110-48-3 GUANFACINE KNOWN_TOXICITY Cardiovascular Toxicity 29110-48-3 GUANFACINE ADVERSE_EFFECT OCU_3_Blurred Vision 29110-48-3 GUANFACINE ADVERSE_EFFECT GUS_3_Urinary Retention 29110-48-3 GUANFACINE ADVERSE_EFFECT XXX_3_Weakness 29110-48-3 GUANFACINE ADVERSE_EFFECT XXX_2_Withdrawal 29110-48-3 GUANFACINE ADVERSE_EFFECT SKN_3_Skin Rash 29110-48-3 GUANFACINE STRUCTURE_ACTIVITY Adrenoceptor-alpha2 partial agonist 219653-30-2 GW-1929 PRODUCT_CLASS Hormones, Endocrine and Metabolic 219653-30-2 GW-1929 THERAPEUTIC_CLASS Antidiabetic Agents 219653-30-2 GW-1929 MECHANISM Modulate gene transcription 219653-30-2 GW-1929 INDICATION Type II Diabetes Mellitus 219653-30-2 GW-1929 STRUCTURE_ACTIVITY PPAR gamma agonist 219653-30-2 GW-1929 MODE_CLASS Receptor Agonist 196808-23-8 GW-1929 STRUCTURE_ACTIVITY PPAR gamma agonist 196808-23-8 GW-1929 PRODUCT_CLASS Hormones, Endocrine and Metabolic 196808-23-8 GW-1929 THERAPEUTIC_CLASS Antidiabetic Agents 196808-23-8 GW-1929 MODE_CLASS Receptor Agonist 196808-23-8 GW-1929 MECHANISM Modulate gene transcription 196808-23-8 GW-1929 INDICATION Type II Diabetes Mellitus 196808-24-9 GW-1929 PRODUCT_CLASS Hormones, Endocrine and Metabolic 196808-24-9 GW-1929 MECHANISM Modulate gene transcription 196808-24-9 GW-1929 THERAPEUTIC_CLASS Antidiabetic Agents 196808-24-9 GW-1929 MODE_CLASS Receptor Agonist 196808-24-9 GW-1929 INDICATION Type II Diabetes Mellitus 196808-24-9 GW-1929 STRUCTURE_ACTIVITY PPAR gamma agonist 108930-17-2 H-7 DIHYDROCHLORIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 108930-17-2 H-7 DIHYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 108930-17-2 H-7 DIHYDROCHLORIDE MECHANISM Inhibit kinase mediated signal transduction 108930-17-2 H-7 DIHYDROCHLORIDE INDICATION Pain 108930-17-2 H-7 DIHYDROCHLORIDE THERAPEUTIC_CLASS Antiglaucoma Agents 108930-17-2 H-7 DIHYDROCHLORIDE PRODUCT_CLASS Analgesics 108930-17-2 H-7 DIHYDROCHLORIDE INDICATION Glaucoma 108930-17-2 H-7 DIHYDROCHLORIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 108930-17-2 H-7 DIHYDROCHLORIDE STRUCTURE_ACTIVITY Protein-serine/threonine kinase (PKC) inhibitor 127243-85-0 H-89 DIHYDROCHLORIDE PRODUCT_CLASS Biochemicals 127243-85-0 H-89 DIHYDROCHLORIDE MODE_CLASS Channel Modulator 127243-85-0 H-89 DIHYDROCHLORIDE MECHANISM Modulate channel gating 127243-85-0 H-89 DIHYDROCHLORIDE MECHANISM Inhibit kinase mediated signal transduction 127243-85-0 H-89 DIHYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 127243-85-0 H-89 DIHYDROCHLORIDE STRUCTURE_ACTIVITY Protein-serine/threonine kinase (PKA) inhibitor 103745-39-7 FASUDIL MECHANISM Block channel gating 103745-39-7 FASUDIL INDICATION Ischemia 103745-39-7 FASUDIL MODE_CLASS Channel Blocker 23092-17-3 HALAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 23092-17-3 HALAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 23092-17-3 HALAZEPAM INDICATION Anxiety Disorders 23092-17-3 HALAZEPAM MODE_CLASS Channel enhancer /opener 23092-17-3 HALAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 23092-17-3 HALAZEPAM MECHANISM Modulate neural transmission 3093-35-4 HALCINONIDE ADVERSE_EFFECT BBM_3_Purpura 3093-35-4 HALCINONIDE ADVERSE_EFFECT SKN_1_Skin Irritation 3093-35-4 HALCINONIDE ADVERSE_EFFECT SKN_3_Hypertrichosis 3093-35-4 HALCINONIDE ADVERSE_EFFECT END_2_Hypothalamic-Pituitary-Adrenal Suppression 3093-35-4 HALCINONIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 3093-35-4 HALCINONIDE ADVERSE_EFFECT SKN_2_Dry Skin 3093-35-4 HALCINONIDE ADVERSE_EFFECT XXX_3_Infection 3093-35-4 HALCINONIDE ADVERSE_EFFECT END_3_Cushing's Syndrome 3093-35-4 HALCINONIDE ADVERSE_EFFECT SKN_3_Skin Ulcer 3093-35-4 HALCINONIDE ADVERSE_EFFECT SKN_3_Skin Atrophy 3093-35-4 HALCINONIDE MECHANISM Modulate gene transcription 3093-35-4 HALCINONIDE ADVERSE_EFFECT OCU_3_Cataracts 3093-35-4 HALCINONIDE ADVERSE_EFFECT SKN_1_Pruritis 3093-35-4 HALCINONIDE INDICATION Skin Diseases / Dermatoses 3093-35-4 HALCINONIDE MODE_CLASS Receptor Agonist 3093-35-4 HALCINONIDE ADVERSE_EFFECT XXX_3_Impaired Wound Healing 3093-35-4 HALCINONIDE THERAPEUTIC_CLASS Corticosteroids, Topical 3093-35-4 HALCINONIDE ADVERSE_EFFECT XXX_2_Tolerance 3093-35-4 HALCINONIDE PRODUCT_CLASS Dermatologicals 3093-35-4 HALCINONIDE ADVERSE_EFFECT IMU_3_Contact Dermatitis 3093-35-4 HALCINONIDE ADVERSE_EFFECT END_3_Glucose Intolerance 66852-54-8 HALOBETASOL PROPIONATE MECHANISM Modulate gene transcription 66852-54-8 HALOBETASOL PROPIONATE MODE_CLASS Receptor Agonist 98651-66-2 HALOBETASOL PROPIONATE MODE_CLASS Receptor Agonist 98651-66-2 HALOBETASOL PROPIONATE MECHANISM Modulate gene transcription 69756-53-2 HALOFANTRINE INDICATION Malaria 36167-63-2 HALOFANTRINE INDICATION Malaria 66051-63-6 HALOFANTRINE INDICATION Malaria 52-86-8 HALOPERIDOL ADVERSE_EFFECT NEU_2_Vertigo 52-86-8 HALOPERIDOL TISSUE_TOXICITY Ventricular Tachycardia 52-86-8 HALOPERIDOL MECH_LEVEL_2 Dopamine antagonist 52-86-8 HALOPERIDOL MECHANISM Reduce muscle contractile force 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_2_Insomnia 52-86-8 HALOPERIDOL INDICATION Psychotic Disorders / Psychosis 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 52-86-8 HALOPERIDOL ADVERSE_EFFECT NEU_3_Cerebral Edema 52-86-8 HALOPERIDOL ADVERSE_EFFECT END_2_Hyperprolactinemia 52-86-8 HALOPERIDOL TISSUE_TOXICITY Hypotension 52-86-8 HALOPERIDOL ADVERSE_EFFECT NEU_1_Drowsiness 52-86-8 HALOPERIDOL ADVERSE_EFFECT BBM_3_Leukocytosis 52-86-8 HALOPERIDOL ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 52-86-8 HALOPERIDOL MECHANISM Prolong/enhance neural transmission 52-86-8 HALOPERIDOL MESH_LEVEL_3 Butyrophenones 52-86-8 HALOPERIDOL THERAPEUTIC_CLASS Antipsychotics 52-86-8 HALOPERIDOL ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 52-86-8 HALOPERIDOL ADVERSE_EFFECT BBM_3_Leukopenia 52-86-8 HALOPERIDOL ADVERSE_EFFECT BBM_3_Anemia 52-86-8 HALOPERIDOL ADVERSE_EFFECT CVS_2_Hypotension 52-86-8 HALOPERIDOL MECHANISM Block neural transmission 52-86-8 HALOPERIDOL PRODUCT_CLASS Central Nervous System (CNS) 52-86-8 HALOPERIDOL ACTIVITY_CLASS Dopamine antagonist 52-86-8 HALOPERIDOL MESH_LEVEL_2 Ketones 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_3_Hallucinations 52-86-8 HALOPERIDOL ADVERSE_EFFECT XXX_3_Hypothermia 52-86-8 HALOPERIDOL ADVERSE_EFFECT XXX_2_Mastalgia 52-86-8 HALOPERIDOL ADVERSE_EFFECT REP_3_Impotence 52-86-8 HALOPERIDOL MODE_CLASS Receptor Ligand Antagonist 52-86-8 HALOPERIDOL MESH_LEVEL_1 Organic Chemicals 52-86-8 HALOPERIDOL ADVERSE_EFFECT CVS_3_Prolonged QT Interval 52-86-8 HALOPERIDOL ADVERSE_EFFECT LIV_3_Cholestasis 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_1_Depression 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_2_Euphoria 52-86-8 HALOPERIDOL ADVERSE_EFFECT NEU_1_Headache 52-86-8 HALOPERIDOL ADVERSE_EFFECT REP_3_Menstrual Irregularities 52-86-8 HALOPERIDOL ADVERSE_EFFECT SKN_3_Melanosis 52-86-8 HALOPERIDOL MODE_CLASS Receptor Agonist 52-86-8 HALOPERIDOL TA_LEVEL_1 Central Nervous System (CNS) 52-86-8 HALOPERIDOL INDICATION Hyperactivity 52-86-8 HALOPERIDOL MECH_LEVEL_3 dopamine receptor D2 52-86-8 HALOPERIDOL INDICATION Schizophrenia 52-86-8 HALOPERIDOL ZERO_CLASS N 52-86-8 HALOPERIDOL MODE_CLASS Channel Blocker 52-86-8 HALOPERIDOL STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), butyrophenone 52-86-8 HALOPERIDOL MECH_LEVEL_1 Modulate neural transmission 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_2_Agitation 52-86-8 HALOPERIDOL INDICATION Gilles De La Tourette's Syndrome / Tourette's Syndrome / Motor Tics 52-86-8 HALOPERIDOL TA_LEVEL_3 Antipsychotics 52-86-8 HALOPERIDOL MECHANISM Modulate neural transmission 52-86-8 HALOPERIDOL INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_1_Anxiety 52-86-8 HALOPERIDOL ADVERSE_EFFECT PSY_2_Confusion 52-86-8 HALOPERIDOL ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 52-86-8 HALOPERIDOL ADVERSE_EFFECT XXX_2_Restlessness 52-86-8 HALOPERIDOL ADVERSE_EFFECT CVS_3_Hypertension 52-86-8 HALOPERIDOL TA_LEVEL_2 CNS Depressant 52-86-8 HALOPERIDOL KNOWN_TOXICITY Cardiovascular Toxicity 52-86-8 HALOPERIDOL ADVERSE_EFFECT XXX_3_Hyperthermia 777-11-7 HALOPROGIN ADVERSE_EFFECT SKN_3_Erythema 777-11-7 HALOPROGIN ADVERSE_EFFECT SKN_3_Dry Skin 777-11-7 HALOPROGIN INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 777-11-7 HALOPROGIN ADVERSE_EFFECT SKN_3_Pruritis 777-11-7 HALOPROGIN INDICATION Tinea Cruris / Jock Itch 777-11-7 HALOPROGIN ADVERSE_EFFECT SKN_3_Skin Irritation 777-11-7 HALOPROGIN INDICATION Tinea Versicolor / Pityriasis Versicolor 777-11-7 HALOPROGIN PRODUCT_CLASS Dermatologicals 777-11-7 HALOPROGIN INDICATION Tinea Pedis / Athlete's Foot 777-11-7 HALOPROGIN THERAPEUTIC_CLASS Antifungals, Topical 151-67-7 HALOTHANE TISSUE_TOXICITY Hepatic Failure 151-67-7 HALOTHANE TISSUE_TOXICITY Asystole 151-67-7 HALOTHANE TISSUE_TOXICITY Cardiac Arrest 151-67-7 HALOTHANE ADVERSE_EFFECT PSY_3_CNS Stimulation 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 151-67-7 HALOTHANE ADVERSE_EFFECT XXX_3_Death 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_2_Asystole 151-67-7 HALOTHANE ADVERSE_EFFECT EMB_3_Abortion 151-67-7 HALOTHANE ADVERSE_EFFECT LIV_3_Jaundice 151-67-7 HALOTHANE ADVERSE_EFFECT PSY_2_Post-Anesthesia Emergence of Delirium 151-67-7 HALOTHANE INDICATION Induction / Maintenance of Anesthesia 151-67-7 HALOTHANE PRODUCT_CLASS Central Nervous System (CNS) 151-67-7 HALOTHANE MECHANISM Reduce muscle contractile force 151-67-7 HALOTHANE TISSUE_TOXICITY Death 151-67-7 HALOTHANE TISSUE_TOXICITY Ventricular Tachycardia 151-67-7 HALOTHANE TISSUE_TOXICITY Cardiac Arrhythmia 151-67-7 HALOTHANE KNOWN_TOXICITY Miscellaneous 151-67-7 HALOTHANE ADVERSE_EFFECT XXX_2_Fever 151-67-7 HALOTHANE ADVERSE_EFFECT NEU_2_Headache 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 151-67-7 HALOTHANE ADVERSE_EFFECT XXX_2_Malignant Hyperthermia 151-67-7 HALOTHANE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 151-67-7 HALOTHANE ADVERSE_EFFECT LIV_3_Hepatic Failure 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 151-67-7 HALOTHANE MODE_CLASS Channel Blocker 151-67-7 HALOTHANE TISSUE_TOXICITY Acute Renal Failure 151-67-7 HALOTHANE TISSUE_TOXICITY Ventricular Arrhythmia 151-67-7 HALOTHANE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 151-67-7 HALOTHANE KNOWN_TOXICITY Nephrotoxicity 151-67-7 HALOTHANE ADVERSE_EFFECT LUN_3_Respiratory Depression 151-67-7 HALOTHANE ADVERSE_EFFECT GIS_1_Vomiting 151-67-7 HALOTHANE ADVERSE_EFFECT SKN_2_Rash 151-67-7 HALOTHANE ADVERSE_EFFECT LIV_3_Hepatitis 151-67-7 HALOTHANE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 151-67-7 HALOTHANE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 151-67-7 HALOTHANE THERAPEUTIC_CLASS General Anesthetics, Inhaled 151-67-7 HALOTHANE TISSUE_TOXICITY Hepatic Necrosis 151-67-7 HALOTHANE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 151-67-7 HALOTHANE KNOWN_TOXICITY Cardiovascular Toxicity 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_2_Bradycardia 151-67-7 HALOTHANE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_3_Cardiac Arrest 151-67-7 HALOTHANE ADVERSE_EFFECT NEU_3_Seizures 151-67-7 HALOTHANE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 151-67-7 HALOTHANE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 151-67-7 HALOTHANE ADVERSE_EFFECT KID_3_Acute Renal Failure 151-67-7 HALOTHANE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 151-67-7 HALOTHANE KNOWN_TOXICITY Hepatotoxicity 70-30-4 HEXACHLOROPHENE MECH_LEVEL_3 Acetylcholinesterase 70-30-4 HEXACHLOROPHENE MESH_LEVEL_2 Hydrocarbons 70-30-4 HEXACHLOROPHENE THERAPEUTIC_CLASS Antibacterials, Topical 70-30-4 HEXACHLOROPHENE PRODUCT_CLASS Dermatologicals 70-30-4 HEXACHLOROPHENE MESH_LEVEL_1 Organic Chemicals 70-30-4 HEXACHLOROPHENE TA_LEVEL_3 anti-bacterial, topical 70-30-4 HEXACHLOROPHENE TA_LEVEL_2 Anti-bacterial 70-30-4 HEXACHLOROPHENE MECH_LEVEL_2 Enzyme inhibitor 70-30-4 HEXACHLOROPHENE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 70-30-4 HEXACHLOROPHENE ADVERSE_EFFECT SKN_1_Dermatitis 70-30-4 HEXACHLOROPHENE ZERO_CLASS N 70-30-4 HEXACHLOROPHENE MESH_LEVEL_3 Hydrocarbons, Cyclic 70-30-4 HEXACHLOROPHENE ADVERSE_EFFECT IMU_1_Photosensitivity 70-30-4 HEXACHLOROPHENE ACTIVITY_CLASS Cholinesterase inhibitor 70-30-4 HEXACHLOROPHENE TA_LEVEL_1 Dermatology 70-30-4 HEXACHLOROPHENE INDICATION Skin Antisepsis 56-29-1 HEXOBARBITAL MECHANISM Modulate neural transmission 56-29-1 HEXOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 56-29-1 HEXOBARBITAL MODE_CLASS Channel Modulator 56-29-1 HEXOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 56-29-1 HEXOBARBITAL INDICATION Insomnia 56-29-1 HEXOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 76712-82-8 HISTRELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 76712-82-8 HISTRELIN MODE_CLASS Receptor Agonist 51-56-9 HOMATROPINE HYDROBROMIDE INDICATION Uveitis 51-56-9 HOMATROPINE HYDROBROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Confusion 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Aggressiveness 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Delirium 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT SKN_3_Flushing 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT GUS_2_Urinary Retention 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Agitation 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT XXX_2_Xerostomia 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT OCU_1_Increased Intraocular Pressure 51-56-9 HOMATROPINE HYDROBROMIDE MODE_CLASS Solute transporter inhibitor 51-56-9 HOMATROPINE HYDROBROMIDE INDICATION Mydriasis Induction 51-56-9 HOMATROPINE HYDROBROMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT OCU_2_Photophobia 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Mania 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT IMU_3_Contact Dermatitis 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT NEU_3_Ataxia 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Hallucinations 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT XXX_3_Fever 51-56-9 HOMATROPINE HYDROBROMIDE KNOWN_TOXICITY Ocular Toxicity 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT PSY_3_Excitement 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT OCU_1_Dilated Pupils 51-56-9 HOMATROPINE HYDROBROMIDE INDICATION Cycloplegia Induction 51-56-9 HOMATROPINE HYDROBROMIDE THERAPEUTIC_CLASS Mydriatics 51-56-9 HOMATROPINE HYDROBROMIDE TISSUE_TOXICITY Increased Intraocular Pressure 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT OCU_2_Blurred Vision 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT XXX_3_Restlessness 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT NEU_3_Dysarthria 51-56-9 HOMATROPINE HYDROBROMIDE ADVERSE_EFFECT SKN_2_Dry Skin 51-56-9 HOMATROPINE HYDROBROMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 51-56-9 HOMATROPINE HYDROBROMIDE MECHANISM Prolong/enhance neural transmission 80-49-9 HOMATROPINE METHYLBROMIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 80-49-9 HOMATROPINE METHYLBROMIDE PRODUCT_CLASS Gastrointestinal System 80-49-9 HOMATROPINE METHYLBROMIDE MODE_CLASS Solute transporter inhibitor 80-49-9 HOMATROPINE METHYLBROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 80-49-9 HOMATROPINE METHYLBROMIDE INDICATION Peptic Ulcer Disease (PUD) 80-49-9 HOMATROPINE METHYLBROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 80-49-9 HOMATROPINE METHYLBROMIDE MECHANISM Prolong/enhance neural transmission 36519-31-0 SALBUTAMOL MODE_CLASS Receptor Agonist, selective 36519-31-0 SALBUTAMOL ADVERSE_EFFECT NEU_1_Headache 36519-31-0 SALBUTAMOL ADVERSE_EFFECT NEU_1_Hyperkinesia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_1_Irritability 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_1_Nervousness 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_2_Prolonged QT Interval 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_3_ST-T Wave Changes 36519-31-0 SALBUTAMOL ADVERSE_EFFECT NEU_1_Tremor 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypotension 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_1_Insomnia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_2_Peripheral Vasodilation 36519-31-0 SALBUTAMOL ADVERSE_EFFECT MSK_1_Skeletal Muscle Tremor 36519-31-0 SALBUTAMOL ADVERSE_EFFECT XXX_3_Throat Irritation 36519-31-0 SALBUTAMOL ADVERSE_EFFECT XXX_1_Xerostomia 36519-31-0 SALBUTAMOL TISSUE_TOXICITY Hypotension 36519-31-0 SALBUTAMOL INDICATION Asthma 36519-31-0 SALBUTAMOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 36519-31-0 SALBUTAMOL ADVERSE_EFFECT LUN_3_Bronchospasm 36519-31-0 SALBUTAMOL ADVERSE_EFFECT NEU_2_Drowsiness 36519-31-0 SALBUTAMOL THERAPEUTIC_CLASS Bronchodilators 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_1_Excitement 36519-31-0 SALBUTAMOL ADVERSE_EFFECT ELT_2_Hypokalemia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT MSK_2_Muscle Cramps 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_1_Palpitation 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_1_Tachycardia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT IMU_1_Urticaria 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_1_Hostility 36519-31-0 SALBUTAMOL ADVERSE_EFFECT IMU_3_Angioneurotic Edema 36519-31-0 SALBUTAMOL ADVERSE_EFFECT XXX_2_Diaphoresis 36519-31-0 SALBUTAMOL ADVERSE_EFFECT XXX_3_Epistaxis 36519-31-0 SALBUTAMOL MECHANISM Reduce bronchoconstriction 36519-31-0 SALBUTAMOL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_3_Angina 36519-31-0 SALBUTAMOL ADVERSE_EFFECT LUN_3_Cough 36519-31-0 SALBUTAMOL ADVERSE_EFFECT GIS_1_Dyspepsia 36519-31-0 SALBUTAMOL TISSUE_TOXICITY Exacerbation of Arrhythmia 36519-31-0 SALBUTAMOL KNOWN_TOXICITY Cardiovascular Toxicity 36519-31-0 SALBUTAMOL INDICATION Asthma 36519-31-0 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 36519-31-0 SALBUTAMOL TISSUE_TOXICITY Angina 36519-31-0 SALBUTAMOL ADVERSE_EFFECT GUS_1_Urinary Retention 36519-31-0 SALBUTAMOL ADVERSE_EFFECT NEU_2_Syncope 36519-31-0 SALBUTAMOL ADVERSE_EFFECT XXX_3_Restlessness 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_3_Nightmares 36519-31-0 SALBUTAMOL ADVERSE_EFFECT SKN_3_Maculopapular Rash 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_3_Hypertension 36519-31-0 SALBUTAMOL ADVERSE_EFFECT LUN_1_Hoarseness 36519-31-0 SALBUTAMOL ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT NEU_2_Dizziness 36519-31-0 SALBUTAMOL ADVERSE_EFFECT PSY_1_Anxiety 36519-31-0 SALBUTAMOL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 36519-31-0 SALBUTAMOL PRODUCT_CLASS Respiratory System 36519-31-0 SALBUTAMOL ADVERSE_EFFECT END_2_Hyperglycemia 36519-31-0 SALBUTAMOL ADVERSE_EFFECT SKN_3_Flushing 65-45-2 SALICYLAMIDE ADVERSE_EFFECT SKN_2_Rash 65-45-2 SALICYLAMIDE ADVERSE_EFFECT GIS_2_Vomiting 65-45-2 SALICYLAMIDE ADVERSE_EFFECT XXX_2_Sweating 65-45-2 SALICYLAMIDE INDICATION Dental Pain 65-45-2 SALICYLAMIDE PRODUCT_CLASS Analgesics 65-45-2 SALICYLAMIDE MESH_LEVEL_3 Salicylamides 65-45-2 SALICYLAMIDE ACTIVITY_CLASS Anti-inflammatory 65-45-2 SALICYLAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 65-45-2 SALICYLAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 65-45-2 SALICYLAMIDE ADVERSE_EFFECT NEU_2_Headache 65-45-2 SALICYLAMIDE ADVERSE_EFFECT GIS_1_Dry Mouth 65-45-2 SALICYLAMIDE MODE_CLASS Enzyme Inhibitor, selective 65-45-2 SALICYLAMIDE INDICATION Arthralgia 65-45-2 SALICYLAMIDE INDICATION Headache 65-45-2 SALICYLAMIDE TA_LEVEL_1 Anti-inflammatory 65-45-2 SALICYLAMIDE ZERO_CLASS N 65-45-2 SALICYLAMIDE THERAPEUTIC_CLASS Analgesics, Non-Opioid 65-45-2 SALICYLAMIDE ADVERSE_EFFECT BBM_3_Ecchymosis 65-45-2 SALICYLAMIDE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 65-45-2 SALICYLAMIDE ADVERSE_EFFECT NEU_1_Dizziness 65-45-2 SALICYLAMIDE ADVERSE_EFFECT PSY_1_Anorexia 65-45-2 SALICYLAMIDE INDICATION Fever 65-45-2 SALICYLAMIDE MESH_LEVEL_1 Organic Chemicals 65-45-2 SALICYLAMIDE INDICATION Dysmenorrhea 65-45-2 SALICYLAMIDE ADVERSE_EFFECT LUN_2_Hyperventilation 65-45-2 SALICYLAMIDE INDICATION Influenza / Flu 65-45-2 SALICYLAMIDE INDICATION Myalgia 65-45-2 SALICYLAMIDE ADVERSE_EFFECT GIS_1_Nausea 65-45-2 SALICYLAMIDE MECHANISM Inhibit inflammatory response 65-45-2 SALICYLAMIDE ADVERSE_EFFECT GIS_1_Heartburn 65-45-2 SALICYLAMIDE ADVERSE_EFFECT NEU_1_Lightheadedness 65-45-2 SALICYLAMIDE ADVERSE_EFFECT OTO_3_Tinnitus 65-45-2 SALICYLAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 65-45-2 SALICYLAMIDE MECH_LEVEL_1 Immunomodulation 65-45-2 SALICYLAMIDE INDICATION Neuralgia 65-45-2 SALICYLAMIDE TA_LEVEL_2 NSAID 65-45-2 SALICYLAMIDE MESH_LEVEL_2 Amides 65-45-2 SALICYLAMIDE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 65-45-2 SALICYLAMIDE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 65-45-2 SALICYLAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT NEU_1_Lightheadedness 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT OTO_3_Tinnitus 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT GIS_1_Nausea 36205-82-0 SALICYLAMIDE MECH_LEVEL_1 Immunomodulation 36205-82-0 SALICYLAMIDE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 36205-82-0 SALICYLAMIDE PRODUCT_CLASS Analgesics 36205-82-0 SALICYLAMIDE INDICATION Dysmenorrhea 36205-82-0 SALICYLAMIDE INDICATION Neuralgia 36205-82-0 SALICYLAMIDE TA_LEVEL_2 NSAID 36205-82-0 SALICYLAMIDE MESH_LEVEL_2 Amides 36205-82-0 SALICYLAMIDE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 36205-82-0 SALICYLAMIDE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 36205-82-0 SALICYLAMIDE INDICATION Influenza / Flu 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT SKN_2_Rash 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT LUN_2_Hyperventilation 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT XXX_2_Sweating 36205-82-0 SALICYLAMIDE INDICATION Dental Pain 36205-82-0 SALICYLAMIDE TA_LEVEL_1 Anti-inflammatory 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT NEU_1_Dizziness 36205-82-0 SALICYLAMIDE THERAPEUTIC_CLASS Analgesics, Non-Opioid 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT BBM_3_Ecchymosis 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT PSY_1_Anorexia 36205-82-0 SALICYLAMIDE INDICATION Fever 36205-82-0 SALICYLAMIDE MESH_LEVEL_1 Organic Chemicals 36205-82-0 SALICYLAMIDE INDICATION Myalgia 36205-82-0 SALICYLAMIDE MESH_LEVEL_3 Salicylamides 36205-82-0 SALICYLAMIDE ACTIVITY_CLASS Anti-inflammatory 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 36205-82-0 SALICYLAMIDE ZERO_CLASS N 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT NEU_2_Headache 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT GIS_1_Dry Mouth 36205-82-0 SALICYLAMIDE MODE_CLASS Enzyme Inhibitor, selective 36205-82-0 SALICYLAMIDE INDICATION Arthralgia 36205-82-0 SALICYLAMIDE INDICATION Headache 36205-82-0 SALICYLAMIDE MECHANISM Inhibit inflammatory response 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT GIS_1_Heartburn 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 36205-82-0 SALICYLAMIDE ADVERSE_EFFECT GIS_2_Vomiting 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_2_Atrial Fibrillation 89365-50-4 SALMETEROL TISSUE_TOXICITY Exacerbation of Arrhythmia 89365-50-4 SALMETEROL MODE_CLASS Receptor Agonist, selective 89365-50-4 SALMETEROL INDICATION Asthma 89365-50-4 SALMETEROL ADVERSE_EFFECT XXX_2_Influenza 89365-50-4 SALMETEROL THERAPEUTIC_CLASS Bronchodilators 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_2_Palpitation 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_2_Sinus Tachycardia 89365-50-4 SALMETEROL ADVERSE_EFFECT NEU_2_Dizziness 89365-50-4 SALMETEROL ADVERSE_EFFECT END_3_Hyperglycemia 89365-50-4 SALMETEROL INDICATION Prophylaxis of Bronchospasm 89365-50-4 SALMETEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 89365-50-4 SALMETEROL MECHANISM Reduce bronchoconstriction 89365-50-4 SALMETEROL ADVERSE_EFFECT GIS_2_Abdominal Pain 89365-50-4 SALMETEROL ADVERSE_EFFECT GIS_2_Diarrhea 89365-50-4 SALMETEROL ADVERSE_EFFECT NEU_1_Headache 89365-50-4 SALMETEROL ADVERSE_EFFECT XXX_1_Infection 89365-50-4 SALMETEROL ADVERSE_EFFECT MSK_2_Muscle Cramps 89365-50-4 SALMETEROL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 89365-50-4 SALMETEROL ADVERSE_EFFECT XXX_2_Rhinitis 89365-50-4 SALMETEROL INDICATION Asthma 89365-50-4 SALMETEROL ADVERSE_EFFECT MSK_2_Myalgia 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_3_Prolonged QT Interval 89365-50-4 SALMETEROL ADVERSE_EFFECT NEU_2_Tremor 89365-50-4 SALMETEROL ADVERSE_EFFECT IMU_2_Urticaria 89365-50-4 SALMETEROL ADVERSE_EFFECT LUN_1_Cough 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_2_Exacerbation of Arrhythmia 89365-50-4 SALMETEROL ADVERSE_EFFECT XXX_2_Fatigue 89365-50-4 SALMETEROL ADVERSE_EFFECT ELT_2_Hypokalemia 89365-50-4 SALMETEROL ADVERSE_EFFECT XXX_2_Malaise 89365-50-4 SALMETEROL TISSUE_TOXICITY Atrial Fibrillation 89365-50-4 SALMETEROL TISSUE_TOXICITY Supraventricular Tachycardia 89365-50-4 SALMETEROL INDICATION Chronic Bronchitis 89365-50-4 SALMETEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 89365-50-4 SALMETEROL PRODUCT_CLASS Respiratory System 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_2_Hypertension 89365-50-4 SALMETEROL ADVERSE_EFFECT LUN_2_Laryngospasm 89365-50-4 SALMETEROL ADVERSE_EFFECT XXX_1_Pharyngitis 89365-50-4 SALMETEROL ADVERSE_EFFECT CVS_2_Supraventricular Tachycardia 89365-50-4 SALMETEROL ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 89365-50-4 SALMETEROL ADVERSE_EFFECT LUN_3_Bronchospasm 89365-50-4 SALMETEROL ADVERSE_EFFECT REP_2_Dysmenorrhea 89365-50-4 SALMETEROL KNOWN_TOXICITY Cardiovascular Toxicity 89365-50-4 SALMETEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 94749-08-3 SALMETEROL THERAPEUTIC_CLASS Bronchodilators 94749-08-3 SALMETEROL ADVERSE_EFFECT XXX_2_Influenza 94749-08-3 SALMETEROL INDICATION Asthma 94749-08-3 SALMETEROL MODE_CLASS Receptor Agonist, selective 94749-08-3 SALMETEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_2_Exacerbation of Arrhythmia 94749-08-3 SALMETEROL ADVERSE_EFFECT LUN_1_Cough 94749-08-3 SALMETEROL ADVERSE_EFFECT IMU_2_Urticaria 94749-08-3 SALMETEROL ADVERSE_EFFECT NEU_2_Tremor 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_3_Prolonged QT Interval 94749-08-3 SALMETEROL ADVERSE_EFFECT MSK_2_Myalgia 94749-08-3 SALMETEROL INDICATION Asthma 94749-08-3 SALMETEROL ADVERSE_EFFECT XXX_2_Rhinitis 94749-08-3 SALMETEROL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 94749-08-3 SALMETEROL ADVERSE_EFFECT MSK_2_Muscle Cramps 94749-08-3 SALMETEROL ADVERSE_EFFECT XXX_2_Malaise 94749-08-3 SALMETEROL ADVERSE_EFFECT XXX_1_Infection 94749-08-3 SALMETEROL ADVERSE_EFFECT NEU_1_Headache 94749-08-3 SALMETEROL ADVERSE_EFFECT GIS_2_Diarrhea 94749-08-3 SALMETEROL ADVERSE_EFFECT GIS_2_Abdominal Pain 94749-08-3 SALMETEROL MECHANISM Reduce bronchoconstriction 94749-08-3 SALMETEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 94749-08-3 SALMETEROL INDICATION Prophylaxis of Bronchospasm 94749-08-3 SALMETEROL ADVERSE_EFFECT END_3_Hyperglycemia 94749-08-3 SALMETEROL ADVERSE_EFFECT NEU_2_Dizziness 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_2_Atrial Fibrillation 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_2_Sinus Tachycardia 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_2_Palpitation 94749-08-3 SALMETEROL ADVERSE_EFFECT XXX_2_Fatigue 94749-08-3 SALMETEROL ADVERSE_EFFECT ELT_2_Hypokalemia 94749-08-3 SALMETEROL TISSUE_TOXICITY Atrial Fibrillation 94749-08-3 SALMETEROL TISSUE_TOXICITY Supraventricular Tachycardia 94749-08-3 SALMETEROL INDICATION Chronic Bronchitis 94749-08-3 SALMETEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 94749-08-3 SALMETEROL PRODUCT_CLASS Respiratory System 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_2_Hypertension 94749-08-3 SALMETEROL ADVERSE_EFFECT LUN_2_Laryngospasm 94749-08-3 SALMETEROL ADVERSE_EFFECT XXX_1_Pharyngitis 94749-08-3 SALMETEROL ADVERSE_EFFECT CVS_2_Supraventricular Tachycardia 94749-08-3 SALMETEROL ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 94749-08-3 SALMETEROL ADVERSE_EFFECT LUN_3_Bronchospasm 94749-08-3 SALMETEROL ADVERSE_EFFECT REP_2_Dysmenorrhea 94749-08-3 SALMETEROL KNOWN_TOXICITY Cardiovascular Toxicity 94749-08-3 SALMETEROL TISSUE_TOXICITY Exacerbation of Arrhythmia 552-94-3 SALSALATE ADVERSE_EFFECT GIS_1_Dyspepsia 552-94-3 SALSALATE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 552-94-3 SALSALATE PRODUCT_CLASS Anti-inflammatories 552-94-3 SALSALATE INDICATION Bursitis 552-94-3 SALSALATE INDICATION Myalgia 552-94-3 SALSALATE TISSUE_TOXICITY Hepatotoxicity 552-94-3 SALSALATE ADVERSE_EFFECT GIS_1_Abdominal Pain 552-94-3 SALSALATE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 552-94-3 SALSALATE ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 552-94-3 SALSALATE ADVERSE_EFFECT GIS_1_Constipation 552-94-3 SALSALATE ADVERSE_EFFECT LUN_3_Bronchospasm 552-94-3 SALSALATE ADVERSE_EFFECT IMU_3_Angioedema 552-94-3 SALSALATE ADVERSE_EFFECT BBM_3_Hypoprothrombinemia 552-94-3 SALSALATE INDICATION Arthralgia 552-94-3 SALSALATE INDICATION Headache 552-94-3 SALSALATE ADVERSE_EFFECT GIS_1_Diarrhea 552-94-3 SALSALATE ADVERSE_EFFECT OTO_2_Tinnitus 552-94-3 SALSALATE INDICATION Osteoarthritis 552-94-3 SALSALATE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 552-94-3 SALSALATE ADVERSE_EFFECT GIS_3_Peptic Ulceration 552-94-3 SALSALATE TISSUE_TOXICITY Renal Papillary Necrosis 552-94-3 SALSALATE TISSUE_TOXICITY Hepatic Necrosis 552-94-3 SALSALATE ADVERSE_EFFECT GIS_2_Gastritis 552-94-3 SALSALATE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 552-94-3 SALSALATE ADVERSE_EFFECT PSN_3_Salicylism 552-94-3 SALSALATE INDICATION Rheumatoid Arthritis 552-94-3 SALSALATE INDICATION Dysmenorrhea 552-94-3 SALSALATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 552-94-3 SALSALATE ADVERSE_EFFECT GIS_1_Heartburn 552-94-3 SALSALATE ADVERSE_EFFECT LIV_2_Portal Hypertension 552-94-3 SALSALATE ADVERSE_EFFECT KID_2_Albuminuria 552-94-3 SALSALATE ADVERSE_EFFECT KID_2_Hyperuricemia 552-94-3 SALSALATE KNOWN_TOXICITY Nephrotoxicity 552-94-3 SALSALATE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 552-94-3 SALSALATE ADVERSE_EFFECT IMU_3_Urticaria 552-94-3 SALSALATE ADVERSE_EFFECT KID_2_Proteinuria 552-94-3 SALSALATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 552-94-3 SALSALATE ADVERSE_EFFECT KID_3_Renal Failure 552-94-3 SALSALATE TISSUE_TOXICITY Renal Failure 552-94-3 SALSALATE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 552-94-3 SALSALATE INDICATION Dental Pain 552-94-3 SALSALATE INDICATION Pain 552-94-3 SALSALATE MECHANISM Inhibit eicosanoid biosynthesis 552-94-3 SALSALATE MODE_CLASS Enzyme Inhibitor 552-94-3 SALSALATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 552-94-3 SALSALATE ADVERSE_EFFECT SKN_3_Pruritis 552-94-3 SALSALATE ADVERSE_EFFECT SKN_3_Maculopapular Rash 552-94-3 SALSALATE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 552-94-3 SALSALATE ADVERSE_EFFECT OTO_3_Hearing Loss 552-94-3 SALSALATE TISSUE_TOXICITY Renal Tubular Necrosis 552-94-3 SALSALATE KNOWN_TOXICITY Hepatotoxicity 552-94-3 SALSALATE ADVERSE_EFFECT KID_3_Azotemia 34273-10-4 SARALASIN THERAPEUTIC_CLASS Antihypertensive Agents 34273-10-4 SARALASIN INDICATION Hypertension 34273-10-4 SARALASIN PRODUCT_CLASS Cardiovasculars 35523-89-8 SAXITOXIN PRODUCT_CLASS Toxicants 35523-89-8 SAXITOXIN MODE_CLASS Channel Blocker 35523-89-8 SAXITOXIN MECHANISM Block neural transmission 152121-47-6 SB-203580 MECHANISM Modulate G-protein coupled signal transduction 152121-47-6 SB-203580 PRODUCT_CLASS Anti-inflammatories 152121-47-6 SB-203580 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 152121-47-6 SB-203580 MODE_CLASS Enzyme Inhibitor 158942-04-2 SB-206553 MODE_CLASS Receptor Ligand Antagonist 158942-04-2 SB-206553 THERAPEUTIC_CLASS Anxiolytics 158942-04-2 SB-206553 MECHANISM Modulate neural transmission 158942-04-2 SB-206553 MECHANISM Modulate G-protein coupled signal transduction 158942-04-2 SB-206553 PRODUCT_CLASS Central Nervous System (CNS) 181632-25-7 SB-242084 MECHANISM Modulate neural transmission 181632-25-7 SB-242084 THERAPEUTIC_CLASS Anxiolytics 181632-25-7 SB-242084 MODE_CLASS Receptor Ligand Antagonist 181632-25-7 SB-242084 PRODUCT_CLASS Central Nervous System (CNS) 181632-25-7 SB-242084 THERAPEUTIC_CLASS Antidepressants 141059-52-1 SC-51146 MODE_CLASS Receptor Ligand Antagonist, Selective 141059-52-1 SC-51146 PRODUCT_CLASS Anti-inflammatories 141059-52-1 SC-51146 MECHANISM Modulate gene transcription 141059-52-1 SC-51146 THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 149-64-4 BUTYLSCOPOLAMINE BROMIDE MECHANISM Modulate G-protein coupled signal transduction 149-64-4 BUTYLSCOPOLAMINE BROMIDE MODE_CLASS Receptor Ligand Antagonist 51-34-3 SCOPOLAMINE ADVERSE_EFFECT GUS_2_Urinary Retention 51-34-3 SCOPOLAMINE INDICATION Cycloplegia Induction 51-34-3 SCOPOLAMINE ADVERSE_EFFECT GIS_2_Heartburn 51-34-3 SCOPOLAMINE ADVERSE_EFFECT NEU_1_Drowsiness 51-34-3 SCOPOLAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51-34-3 SCOPOLAMINE ADVERSE_EFFECT PSY_3_Hallucinations 51-34-3 SCOPOLAMINE ADVERSE_EFFECT GIS_2_Constipation 51-34-3 SCOPOLAMINE ADVERSE_EFFECT OCU_3_Glaucoma 51-34-3 SCOPOLAMINE THERAPEUTIC_CLASS Parasympatholytic Agents 51-34-3 SCOPOLAMINE ADVERSE_EFFECT SKN_2_Anhidrosis 51-34-3 SCOPOLAMINE INDICATION Motion Sickness 51-34-3 SCOPOLAMINE INDICATION Aspiration Prophylaxis 51-34-3 SCOPOLAMINE ADVERSE_EFFECT NEU_2_Amnesia 51-34-3 SCOPOLAMINE ADVERSE_EFFECT GIS_3_Dysphagia 51-34-3 SCOPOLAMINE ADVERSE_EFFECT PSY_3_Confusion 51-34-3 SCOPOLAMINE ADVERSE_EFFECT REP_3_Impotence 51-34-3 SCOPOLAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 51-34-3 SCOPOLAMINE ADVERSE_EFFECT OCU_1_Blurred Vision 51-34-3 SCOPOLAMINE THERAPEUTIC_CLASS Antiemetics 51-34-3 SCOPOLAMINE MODE_CLASS Receptor Ligand Antagonist 51-34-3 SCOPOLAMINE INDICATION Bradycardia 51-34-3 SCOPOLAMINE PRODUCT_CLASS Gastrointestinal System 51-34-3 SCOPOLAMINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 51-34-3 SCOPOLAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 51-34-3 SCOPOLAMINE INDICATION Nausea / Vomiting 51-34-3 SCOPOLAMINE ADVERSE_EFFECT OCU_1_Cycloplegia 51-34-3 SCOPOLAMINE ADVERSE_EFFECT IMU_3_Urticaria 51-34-3 SCOPOLAMINE ADVERSE_EFFECT NEU_1_Headache 51-34-3 SCOPOLAMINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 51-34-3 SCOPOLAMINE INDICATION Mydriasis Induction 51-34-3 SCOPOLAMINE MECHANISM Modulate G-protein coupled signal transduction 51-34-3 SCOPOLAMINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 51-34-3 SCOPOLAMINE ADVERSE_EFFECT CVS_1_Palpitation 51-34-3 SCOPOLAMINE ADVERSE_EFFECT NEU_1_Dizziness 51-34-3 SCOPOLAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 51-34-3 SCOPOLAMINE ADVERSE_EFFECT PSY_3_Delirium 76-73-3 SECOBARBITAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 76-73-3 SECOBARBITAL TISSUE_TOXICITY Hepatotoxicity 76-73-3 SECOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 76-73-3 SECOBARBITAL INDICATION Induction / Maintenance of Anesthesia 76-73-3 SECOBARBITAL KNOWN_TOXICITY Embryo/Fetal Toxicity 76-73-3 SECOBARBITAL MESH_LEVEL_1 Heterocyclic Compounds 76-73-3 SECOBARBITAL ADVERSE_EFFECT NEU_3_Hyperkinesia 76-73-3 SECOBARBITAL ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 76-73-3 SECOBARBITAL ADVERSE_EFFECT PSY_1_Physical Dependence 76-73-3 SECOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 76-73-3 SECOBARBITAL ADVERSE_EFFECT IMU_3_Hypersensitivity 76-73-3 SECOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 76-73-3 SECOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 76-73-3 SECOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 76-73-3 SECOBARBITAL ADVERSE_EFFECT PSY_2_CNS Depression 76-73-3 SECOBARBITAL ADVERSE_EFFECT EMB_2_Teratogenicity 76-73-3 SECOBARBITAL ADVERSE_EFFECT CVS_3_Hypotension 76-73-3 SECOBARBITAL ADVERSE_EFFECT IMU_3_Anaphylaxis 76-73-3 SECOBARBITAL KNOWN_TOXICITY Hepatotoxicity 76-73-3 SECOBARBITAL TA_LEVEL_1 Central Nervous System (CNS) 76-73-3 SECOBARBITAL MECHANISM Modulate neural transmission 76-73-3 SECOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 76-73-3 SECOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 76-73-3 SECOBARBITAL ADVERSE_EFFECT CVS_3_Bradycardia 76-73-3 SECOBARBITAL MODE_CLASS Channel Modulator 76-73-3 SECOBARBITAL INDICATION Psychotic Disorders / Psychosis 76-73-3 SECOBARBITAL MECH_LEVEL_1 Modulate neural transmission 76-73-3 SECOBARBITAL MECH_LEVEL_3 GABA-A receptor 76-73-3 SECOBARBITAL TISSUE_TOXICITY Teratogenicity 76-73-3 SECOBARBITAL ZERO_CLASS N 76-73-3 SECOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 76-73-3 SECOBARBITAL ADVERSE_EFFECT XXX_1_Tolerance 76-73-3 SECOBARBITAL ADVERSE_EFFECT SKN_2_Rash 76-73-3 SECOBARBITAL ADVERSE_EFFECT NEU_2_Dizziness 76-73-3 SECOBARBITAL ADVERSE_EFFECT LUN_3_Apnea 76-73-3 SECOBARBITAL ADVERSE_EFFECT LUN_2_Respiratory Depression 76-73-3 SECOBARBITAL ADVERSE_EFFECT NEU_1_Somnolence 76-73-3 SECOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 76-73-3 SECOBARBITAL ADVERSE_EFFECT NEU_2_Ataxia 76-73-3 SECOBARBITAL TISSUE_TOXICITY Hypotension 76-73-3 SECOBARBITAL TA_LEVEL_3 Sedatives/Hypnotics 76-73-3 SECOBARBITAL INDICATION Status Epilepticus 76-73-3 SECOBARBITAL TA_LEVEL_2 CNS Depressant 76-73-3 SECOBARBITAL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 76-73-3 SECOBARBITAL MESH_LEVEL_3 Pyrimidines 76-73-3 SECOBARBITAL ACTIVITY_CLASS GABA agonist 76-73-3 SECOBARBITAL ADVERSE_EFFECT PSY_1_Psychologic Dependence 76-73-3 SECOBARBITAL INDICATION Insomnia / Dyssomnias 76-73-3 SECOBARBITAL MECH_LEVEL_2 faciliates GABA binding 76-73-3 SECOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 14611-52-0 SELEGILINE TISSUE_TOXICITY Myocardial Infarction 14611-52-0 SELEGILINE ADVERSE_EFFECT XXX_2_Diaphoresis 14611-52-0 SELEGILINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 14611-52-0 SELEGILINE ADVERSE_EFFECT XXX_3_Peripheral Edema 14611-52-0 SELEGILINE ADVERSE_EFFECT NEU_3_Paresthesia 14611-52-0 SELEGILINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 14611-52-0 SELEGILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 14611-52-0 SELEGILINE ADVERSE_EFFECT NEU_2_Drowsiness 14611-52-0 SELEGILINE ADVERSE_EFFECT PSY_1_Insomnia 14611-52-0 SELEGILINE ADVERSE_EFFECT CVS_3_Hypertension 14611-52-0 SELEGILINE MODE_CLASS Enzyme Inhibitor 14611-52-0 SELEGILINE MECHANISM Prolong/enhance neural transmission 14611-52-0 SELEGILINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 14611-52-0 SELEGILINE ADVERSE_EFFECT PSY_2_Mental Confusion 14611-52-0 SELEGILINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 14611-52-0 SELEGILINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 14611-52-0 SELEGILINE ADVERSE_EFFECT GIS_1_Dry Mouth 14611-52-0 SELEGILINE ADVERSE_EFFECT GUS_2_Urinary Retention 14611-52-0 SELEGILINE INDICATION Parkinson's Disease 14611-52-0 SELEGILINE THERAPEUTIC_CLASS Movement Disorders 14611-52-0 SELEGILINE PRODUCT_CLASS Central Nervous System (CNS) 14611-52-0 SELEGILINE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 14611-52-0 SELEGILINE ADVERSE_EFFECT NEU_2_Akathisia 14611-52-0 SELEGILINE ADVERSE_EFFECT LUN_3_Bronchospasm 14611-52-0 SELEGILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 14611-52-0 SELEGILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 14611-52-0 SELEGILINE ADVERSE_EFFECT PSY_2_Depression 14611-52-0 SELEGILINE KNOWN_TOXICITY Cardiovascular Toxicity 14611-52-0 SELEGILINE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 14611-52-0 SELEGILINE ADVERSE_EFFECT NEU_2_Dystonia 14611-52-0 SELEGILINE ADVERSE_EFFECT PSY_2_Agitation 14611-52-0 SELEGILINE ADVERSE_EFFECT NEU_1_Dizziness 40602-63-9 SELEGILINE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 40602-63-9 SELEGILINE PRODUCT_CLASS Central Nervous System (CNS) 40602-63-9 SELEGILINE THERAPEUTIC_CLASS Movement Disorders 40602-63-9 SELEGILINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 40602-63-9 SELEGILINE TISSUE_TOXICITY Myocardial Infarction 40602-63-9 SELEGILINE ADVERSE_EFFECT XXX_2_Diaphoresis 40602-63-9 SELEGILINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 40602-63-9 SELEGILINE ADVERSE_EFFECT XXX_3_Peripheral Edema 40602-63-9 SELEGILINE ADVERSE_EFFECT NEU_3_Paresthesia 40602-63-9 SELEGILINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 40602-63-9 SELEGILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 40602-63-9 SELEGILINE ADVERSE_EFFECT NEU_2_Drowsiness 40602-63-9 SELEGILINE ADVERSE_EFFECT GIS_1_Dry Mouth 40602-63-9 SELEGILINE ADVERSE_EFFECT GUS_2_Urinary Retention 40602-63-9 SELEGILINE INDICATION Parkinson's Disease 40602-63-9 SELEGILINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 40602-63-9 SELEGILINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 40602-63-9 SELEGILINE ADVERSE_EFFECT PSY_2_Mental Confusion 40602-63-9 SELEGILINE MECHANISM Prolong/enhance neural transmission 40602-63-9 SELEGILINE MODE_CLASS Enzyme Inhibitor 40602-63-9 SELEGILINE ADVERSE_EFFECT CVS_3_Hypertension 40602-63-9 SELEGILINE ADVERSE_EFFECT PSY_1_Insomnia 40602-63-9 SELEGILINE ADVERSE_EFFECT NEU_1_Dizziness 40602-63-9 SELEGILINE ADVERSE_EFFECT PSY_2_Agitation 40602-63-9 SELEGILINE ADVERSE_EFFECT NEU_2_Dystonia 40602-63-9 SELEGILINE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 40602-63-9 SELEGILINE KNOWN_TOXICITY Cardiovascular Toxicity 40602-63-9 SELEGILINE ADVERSE_EFFECT PSY_2_Depression 40602-63-9 SELEGILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 40602-63-9 SELEGILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 40602-63-9 SELEGILINE ADVERSE_EFFECT LUN_3_Bronchospasm 40602-63-9 SELEGILINE ADVERSE_EFFECT NEU_2_Akathisia 2323-36-6 SELEGILINE INDICATION Parkinson's Disease 2323-36-6 SELEGILINE PRODUCT_CLASS Central Nervous System (CNS) 2323-36-6 SELEGILINE ADVERSE_EFFECT NEU_2_Akathisia 2323-36-6 SELEGILINE ADVERSE_EFFECT LUN_3_Bronchospasm 2323-36-6 SELEGILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 2323-36-6 SELEGILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 2323-36-6 SELEGILINE ADVERSE_EFFECT PSY_2_Depression 2323-36-6 SELEGILINE KNOWN_TOXICITY Cardiovascular Toxicity 2323-36-6 SELEGILINE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 2323-36-6 SELEGILINE ADVERSE_EFFECT NEU_2_Dystonia 2323-36-6 SELEGILINE ADVERSE_EFFECT PSY_2_Agitation 2323-36-6 SELEGILINE ADVERSE_EFFECT NEU_1_Dizziness 2323-36-6 SELEGILINE ADVERSE_EFFECT PSY_1_Insomnia 2323-36-6 SELEGILINE ADVERSE_EFFECT CVS_3_Hypertension 2323-36-6 SELEGILINE MODE_CLASS Enzyme Inhibitor 2323-36-6 SELEGILINE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 2323-36-6 SELEGILINE THERAPEUTIC_CLASS Movement Disorders 2323-36-6 SELEGILINE MECHANISM Prolong/enhance neural transmission 2323-36-6 SELEGILINE TISSUE_TOXICITY Myocardial Infarction 2323-36-6 SELEGILINE ADVERSE_EFFECT XXX_2_Diaphoresis 2323-36-6 SELEGILINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 2323-36-6 SELEGILINE ADVERSE_EFFECT XXX_3_Peripheral Edema 2323-36-6 SELEGILINE ADVERSE_EFFECT NEU_3_Paresthesia 2323-36-6 SELEGILINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 2323-36-6 SELEGILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 2323-36-6 SELEGILINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 2323-36-6 SELEGILINE ADVERSE_EFFECT PSY_2_Mental Confusion 2323-36-6 SELEGILINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 2323-36-6 SELEGILINE ADVERSE_EFFECT NEU_2_Drowsiness 2323-36-6 SELEGILINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 2323-36-6 SELEGILINE ADVERSE_EFFECT GIS_1_Dry Mouth 2323-36-6 SELEGILINE ADVERSE_EFFECT GUS_2_Urinary Retention 4528-52-3 SELEGILINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 4528-52-3 SELEGILINE INDICATION Parkinson's Disease 4528-52-3 SELEGILINE ADVERSE_EFFECT GUS_2_Urinary Retention 4528-52-3 SELEGILINE ADVERSE_EFFECT GIS_1_Dry Mouth 4528-52-3 SELEGILINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 4528-52-3 SELEGILINE ADVERSE_EFFECT NEU_2_Drowsiness 4528-52-3 SELEGILINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 4528-52-3 SELEGILINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 4528-52-3 SELEGILINE ADVERSE_EFFECT PSY_2_Depression 4528-52-3 SELEGILINE KNOWN_TOXICITY Cardiovascular Toxicity 4528-52-3 SELEGILINE ADVERSE_EFFECT GUS_2_Prostatic Hypertrophy 4528-52-3 SELEGILINE ADVERSE_EFFECT NEU_2_Dystonia 4528-52-3 SELEGILINE THERAPEUTIC_CLASS Movement Disorders 4528-52-3 SELEGILINE ADVERSE_EFFECT PSY_2_Agitation 4528-52-3 SELEGILINE ADVERSE_EFFECT PSY_1_Insomnia 4528-52-3 SELEGILINE ADVERSE_EFFECT CVS_3_Hypertension 4528-52-3 SELEGILINE MODE_CLASS Enzyme Inhibitor 4528-52-3 SELEGILINE MECHANISM Prolong/enhance neural transmission 4528-52-3 SELEGILINE TISSUE_TOXICITY Myocardial Infarction 4528-52-3 SELEGILINE ADVERSE_EFFECT XXX_2_Diaphoresis 4528-52-3 SELEGILINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 4528-52-3 SELEGILINE ADVERSE_EFFECT XXX_3_Peripheral Edema 4528-52-3 SELEGILINE ADVERSE_EFFECT NEU_3_Paresthesia 4528-52-3 SELEGILINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 4528-52-3 SELEGILINE ADVERSE_EFFECT NEU_1_Dizziness 4528-52-3 SELEGILINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 4528-52-3 SELEGILINE ADVERSE_EFFECT PSY_2_Mental Confusion 4528-52-3 SELEGILINE PRODUCT_CLASS Central Nervous System (CNS) 4528-52-3 SELEGILINE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 4528-52-3 SELEGILINE ADVERSE_EFFECT NEU_2_Akathisia 4528-52-3 SELEGILINE ADVERSE_EFFECT LUN_3_Bronchospasm 4528-52-3 SELEGILINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 7488-56-4 SELENIUM SULFIDE INDICATION Seborrhea 13909-09-6 SEMUSTINE THERAPEUTIC_CLASS Antineoplastics 13909-09-6 SEMUSTINE PRODUCT_CLASS Anti-cancers 13909-09-6 SEMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 13909-09-6 SEMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 99592-32-2 SERTACONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 99592-32-2 SERTACONAZOLE PRODUCT_CLASS Anti-infectives 99592-32-2 SERTACONAZOLE THERAPEUTIC_CLASS Antifungals 99592-32-2 SERTACONAZOLE MODE_CLASS Enzyme Inhibitor 79559-97-0 SERTRALINE INDICATION Posttraumatic Stress Disorder (PTSD) 79559-97-0 SERTRALINE TA_LEVEL_3 Anxlytic 79559-97-0 SERTRALINE MECH_LEVEL_3 5HT Transporter SERT 79559-97-0 SERTRALINE MECH_LEVEL_2 5HT antagonist 79559-97-0 SERTRALINE INDICATION Panic Disorder 79559-97-0 SERTRALINE ADVERSE_EFFECT GIS_1_Dry Mouth 79559-97-0 SERTRALINE ADVERSE_EFFECT GIS_2_Nausea 79559-97-0 SERTRALINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 79559-97-0 SERTRALINE ADVERSE_EFFECT END_3_Gynecomastia 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_3_Choreoathetosis 79559-97-0 SERTRALINE ADVERSE_EFFECT PSY_2_Emotional Lability 79559-97-0 SERTRALINE KNOWN_TOXICITY Reproductive System Toxicity 79559-97-0 SERTRALINE INDICATION Depression 79559-97-0 SERTRALINE ADVERSE_EFFECT XXX_1_Salivation 79559-97-0 SERTRALINE ADVERSE_EFFECT PSY_2_Anorexia 79559-97-0 SERTRALINE TA_LEVEL_2 CNS Depressant 79559-97-0 SERTRALINE TISSUE_TOXICITY Myocardial Infarction 79559-97-0 SERTRALINE ADVERSE_EFFECT OTO_3_Hyperacusis 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_1_Somnolence 79559-97-0 SERTRALINE ADVERSE_EFFECT XXX_1_Fatigue 79559-97-0 SERTRALINE ADVERSE_EFFECT SKN_2_Dermatitis 79559-97-0 SERTRALINE ADVERSE_EFFECT OCU_3_Exophthalmos 79559-97-0 SERTRALINE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_3_Dyskinesia 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_1_Paresthesia 79559-97-0 SERTRALINE ADVERSE_EFFECT REP_1_Impotence 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_1_Tremor 79559-97-0 SERTRALINE ADVERSE_EFFECT XXX_1_Sweating 79559-97-0 SERTRALINE PRODUCT_CLASS Central Nervous System (CNS) 79559-97-0 SERTRALINE MODE_CLASS Solute transporter inhibitor 79559-97-0 SERTRALINE ADVERSE_EFFECT IMU_3_Allergic Reactions 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_2_Ataxia 79559-97-0 SERTRALINE ADVERSE_EFFECT CVS_2_Palpitation 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_1_Hypertonia 79559-97-0 SERTRALINE ADVERSE_EFFECT OCU_3_Glaucoma 79559-97-0 SERTRALINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 79559-97-0 SERTRALINE TA_LEVEL_1 Central Nervous System (CNS) 79559-97-0 SERTRALINE THERAPEUTIC_CLASS Antidepressants 79559-97-0 SERTRALINE ADVERSE_EFFECT GIS_2_Diarrhea 79559-97-0 SERTRALINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 79559-97-0 SERTRALINE ADVERSE_EFFECT END_3_Hypoglycemia 79559-97-0 SERTRALINE ADVERSE_EFFECT XXX_1_Edema 79559-97-0 SERTRALINE ADVERSE_EFFECT NEU_3_Coma 79559-97-0 SERTRALINE ADVERSE_EFFECT REP_1_Failure to Ejaculate 79559-97-0 SERTRALINE ADVERSE_EFFECT BBM_3_Decreased Platelet Function 79559-97-0 SERTRALINE KNOWN_TOXICITY Cardiovascular Toxicity 79559-97-0 SERTRALINE THERAPEUTIC_CLASS Anxiolytics 79559-97-0 SERTRALINE ADVERSE_EFFECT XXX_1_Asthenia 79559-97-0 SERTRALINE MECH_LEVEL_1 Modulate neural transmission 79559-97-0 SERTRALINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 79559-97-0 SERTRALINE MESH_LEVEL_3 Naphthalenes 79559-97-0 SERTRALINE INDICATION Obsessive-Compulsive Disorder (OCD) 79559-97-0 SERTRALINE ADVERSE_EFFECT REP_3_Priapism 79559-97-0 SERTRALINE MESH_LEVEL_1 Polycyclic Hydrocarbons 79559-97-0 SERTRALINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 79559-97-0 SERTRALINE ZERO_CLASS N 79559-97-0 SERTRALINE ADVERSE_EFFECT REP_1_Decreased Libido 79559-97-0 SERTRALINE TISSUE_TOXICITY Impotence 79559-97-0 SERTRALINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 79559-97-0 SERTRALINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 79559-97-0 SERTRALINE MECHANISM Prolong/enhance neural transmission 79617-96-2 SERTRALINE ADVERSE_EFFECT REP_1_Failure to Ejaculate 79617-96-2 SERTRALINE ADVERSE_EFFECT BBM_3_Decreased Platelet Function 79617-96-2 SERTRALINE KNOWN_TOXICITY Cardiovascular Toxicity 79617-96-2 SERTRALINE THERAPEUTIC_CLASS Anxiolytics 79617-96-2 SERTRALINE ADVERSE_EFFECT XXX_1_Asthenia 79617-96-2 SERTRALINE ADVERSE_EFFECT REP_3_Priapism 79617-96-2 SERTRALINE ADVERSE_EFFECT END_3_Hypoglycemia 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_1_Hypertonia 79617-96-2 SERTRALINE ADVERSE_EFFECT XXX_1_Edema 79617-96-2 SERTRALINE MODE_CLASS Solute transporter inhibitor 79617-96-2 SERTRALINE TA_LEVEL_1 Central Nervous System (CNS) 79617-96-2 SERTRALINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 79617-96-2 SERTRALINE MESH_LEVEL_3 Naphthalenes 79617-96-2 SERTRALINE INDICATION Obsessive-Compulsive Disorder (OCD) 79617-96-2 SERTRALINE MESH_LEVEL_1 Polycyclic Hydrocarbons 79617-96-2 SERTRALINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 79617-96-2 SERTRALINE ZERO_CLASS N 79617-96-2 SERTRALINE TISSUE_TOXICITY Impotence 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_3_Coma 79617-96-2 SERTRALINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 79617-96-2 SERTRALINE ADVERSE_EFFECT PSY_2_Emotional Lability 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_3_Choreoathetosis 79617-96-2 SERTRALINE ADVERSE_EFFECT END_3_Gynecomastia 79617-96-2 SERTRALINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 79617-96-2 SERTRALINE ADVERSE_EFFECT GIS_2_Nausea 79617-96-2 SERTRALINE ADVERSE_EFFECT GIS_1_Dry Mouth 79617-96-2 SERTRALINE INDICATION Panic Disorder 79617-96-2 SERTRALINE MECH_LEVEL_2 5HT antagonist 79617-96-2 SERTRALINE MECH_LEVEL_3 5HT Transporter SERT 79617-96-2 SERTRALINE TA_LEVEL_3 Anxlytic 79617-96-2 SERTRALINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 79617-96-2 SERTRALINE PRODUCT_CLASS Central Nervous System (CNS) 79617-96-2 SERTRALINE ADVERSE_EFFECT XXX_1_Sweating 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_1_Tremor 79617-96-2 SERTRALINE ADVERSE_EFFECT REP_1_Impotence 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_1_Paresthesia 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_3_Dyskinesia 79617-96-2 SERTRALINE ADVERSE_EFFECT OCU_3_Exophthalmos 79617-96-2 SERTRALINE ADVERSE_EFFECT SKN_2_Dermatitis 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_1_Somnolence 79617-96-2 SERTRALINE ADVERSE_EFFECT OTO_3_Hyperacusis 79617-96-2 SERTRALINE TISSUE_TOXICITY Myocardial Infarction 79617-96-2 SERTRALINE TA_LEVEL_2 CNS Depressant 79617-96-2 SERTRALINE MECH_LEVEL_1 Modulate neural transmission 79617-96-2 SERTRALINE KNOWN_TOXICITY Reproductive System Toxicity 79617-96-2 SERTRALINE INDICATION Depression 79617-96-2 SERTRALINE ADVERSE_EFFECT XXX_1_Salivation 79617-96-2 SERTRALINE ADVERSE_EFFECT PSY_2_Anorexia 79617-96-2 SERTRALINE ADVERSE_EFFECT XXX_1_Fatigue 79617-96-2 SERTRALINE ADVERSE_EFFECT IMU_3_Allergic Reactions 79617-96-2 SERTRALINE ADVERSE_EFFECT NEU_2_Ataxia 79617-96-2 SERTRALINE ADVERSE_EFFECT REP_1_Decreased Libido 79617-96-2 SERTRALINE ADVERSE_EFFECT CVS_2_Palpitation 79617-96-2 SERTRALINE ADVERSE_EFFECT REP_2_Menstrual Abnormalities 79617-96-2 SERTRALINE ADVERSE_EFFECT OCU_3_Glaucoma 79617-96-2 SERTRALINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 79617-96-2 SERTRALINE MECHANISM Prolong/enhance neural transmission 79617-96-2 SERTRALINE INDICATION Posttraumatic Stress Disorder (PTSD) 79617-96-2 SERTRALINE THERAPEUTIC_CLASS Antidepressants 79617-96-2 SERTRALINE ADVERSE_EFFECT GIS_2_Diarrhea 79617-96-2 SERTRALINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 106650-56-0 SIBUTRAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 106650-56-0 SIBUTRAMINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT REP_2_Dysmenorrhea 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT IMU_3_Allergic Reactions 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT GIS_2_Nausea 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT CVS_2_Tachycardia 106650-56-0 SIBUTRAMINE INDICATION Obesity 106650-56-0 SIBUTRAMINE MECH_LEVEL_1 Modulate neural transmission 106650-56-0 SIBUTRAMINE MECH_LEVEL_2 reuptake of Norepinephrine inhibition 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT MSK_2_Back Pain 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT SKN_2_Rash 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT REP_3_Impotence 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT PSY_2_Nervousness 106650-56-0 SIBUTRAMINE THERAPEUTIC_CLASS Anorexiants 106650-56-0 SIBUTRAMINE MECHANISM Prolong/enhance neural transmission 106650-56-0 SIBUTRAMINE MECH_LEVEL_3 Norepinephrine Transporter NET 106650-56-0 SIBUTRAMINE MESH_LEVEL_1 Organic Chemicals 106650-56-0 SIBUTRAMINE TA_LEVEL_3 Anorexiants 106650-56-0 SIBUTRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 106650-56-0 SIBUTRAMINE ZERO_CLASS N 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT NEU_2_Migraine 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT NEU_1_Headache 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT PSY_1_Anorexia 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT PSY_2_Depression 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT PSY_2_CNS Stimulation 106650-56-0 SIBUTRAMINE TA_LEVEL_1 Central Nervous System (CNS) 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT PSY_2_Emotional Lability 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT NEU_2_Dizziness 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT PSY_1_Insomnia 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT CVS_2_Hypertension 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT CVS_2_Vasodilation 106650-56-0 SIBUTRAMINE MESH_LEVEL_2 Hydrocarbons 106650-56-0 SIBUTRAMINE PRODUCT_CLASS Central Nervous System (CNS) 106650-56-0 SIBUTRAMINE MODE_CLASS Solute transporter inhibitor 106650-56-0 SIBUTRAMINE ADVERSE_EFFECT GIS_1_Constipation 84485-00-7 SIBUTRAMINE MESH_LEVEL_1 Organic Chemicals 84485-00-7 SIBUTRAMINE MESH_LEVEL_3 Hydrocarbons, Cyclic 84485-00-7 SIBUTRAMINE TA_LEVEL_3 Anorexiants 84485-00-7 SIBUTRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 84485-00-7 SIBUTRAMINE ZERO_CLASS N 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT NEU_2_Migraine 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT NEU_1_Headache 84485-00-7 SIBUTRAMINE MECHANISM Prolong/enhance neural transmission 84485-00-7 SIBUTRAMINE THERAPEUTIC_CLASS Anorexiants 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT GIS_1_Constipation 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT PSY_2_Nervousness 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT REP_3_Impotence 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT SKN_2_Rash 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT MSK_2_Back Pain 84485-00-7 SIBUTRAMINE MECH_LEVEL_2 reuptake of Norepinephrine inhibition 84485-00-7 SIBUTRAMINE MECH_LEVEL_1 Modulate neural transmission 84485-00-7 SIBUTRAMINE INDICATION Obesity 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT CVS_2_Tachycardia 84485-00-7 SIBUTRAMINE MECH_LEVEL_3 Norepinephrine Transporter NET 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT GIS_2_Nausea 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT IMU_3_Allergic Reactions 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT REP_2_Dysmenorrhea 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT PSY_1_Anorexia 84485-00-7 SIBUTRAMINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 84485-00-7 SIBUTRAMINE MESH_LEVEL_2 Hydrocarbons 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT PSY_2_Depression 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT PSY_2_CNS Stimulation 84485-00-7 SIBUTRAMINE MODE_CLASS Solute transporter inhibitor 84485-00-7 SIBUTRAMINE TA_LEVEL_1 Central Nervous System (CNS) 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT PSY_2_Emotional Lability 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT NEU_2_Dizziness 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT PSY_1_Insomnia 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT CVS_2_Hypertension 84485-00-7 SIBUTRAMINE ADVERSE_EFFECT CVS_2_Vasodilation 84485-00-7 SIBUTRAMINE PRODUCT_CLASS Central Nervous System (CNS) 171599-83-0 SILDENAFIL PRODUCT_CLASS Cardiovasculars 171599-83-0 SILDENAFIL STRUCTURE_ACTIVITY PDE5 inhibitor 171599-83-0 SILDENAFIL TISSUE_TOXICITY Hematuria 171599-83-0 SILDENAFIL TISSUE_TOXICITY Atrioventricular Blockade 171599-83-0 SILDENAFIL KNOWN_TOXICITY Nephrotoxicity 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Sudden Cardiac Death 171599-83-0 SILDENAFIL ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Myocardial Ischemia 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Angina Pectoris 171599-83-0 SILDENAFIL ADVERSE_EFFECT SKN_2_Rash 171599-83-0 SILDENAFIL ADVERSE_EFFECT NEU_2_Dizziness 171599-83-0 SILDENAFIL TA_LEVEL_2 erectile dysfunction 171599-83-0 SILDENAFIL ADVERSE_EFFECT GIS_2_Diarrhea 171599-83-0 SILDENAFIL ADVERSE_EFFECT SKN_1_Flushing 171599-83-0 SILDENAFIL ADVERSE_EFFECT OCU_1_Visual Disturbances 171599-83-0 SILDENAFIL ADVERSE_EFFECT REP_3_Priapism 171599-83-0 SILDENAFIL TA_LEVEL_1 Cardiovascular 171599-83-0 SILDENAFIL TA_LEVEL_3 PDE inhibitors 171599-83-0 SILDENAFIL MECH_LEVEL_1 Vasodilators 171599-83-0 SILDENAFIL TISSUE_TOXICITY Myocardial Ischemia 171599-83-0 SILDENAFIL TISSUE_TOXICITY Hypotension 171599-83-0 SILDENAFIL ACTIVITY_CLASS Phosphodiesterase inhibitor 171599-83-0 SILDENAFIL ZERO_CLASS N 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Transient Ischemic Attack 171599-83-0 SILDENAFIL ADVERSE_EFFECT KID_3_Hematuria 171599-83-0 SILDENAFIL ADVERSE_EFFECT NEU_3_Cerebral Thrombosis 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_2_Tachycardia 171599-83-0 SILDENAFIL ADVERSE_EFFECT XXX_3_Edema 171599-83-0 SILDENAFIL ADVERSE_EFFECT IMU_3_Allergic Reactions 171599-83-0 SILDENAFIL ADVERSE_EFFECT GIS_1_Dyspepsia 171599-83-0 SILDENAFIL ADVERSE_EFFECT NEU_1_Headache 171599-83-0 SILDENAFIL MESH_LEVEL_3 Azepines 171599-83-0 SILDENAFIL MECH_LEVEL_3 cGMP phosphodiesterase 5 171599-83-0 SILDENAFIL TISSUE_TOXICITY Cardiac Arrest 171599-83-0 SILDENAFIL TISSUE_TOXICITY Hypotensive Shock 171599-83-0 SILDENAFIL THERAPEUTIC_CLASS Vasodilators 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_2_Supine Hypotension 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Cardiac Arrest 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 171599-83-0 SILDENAFIL ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 171599-83-0 SILDENAFIL ADVERSE_EFFECT BBM_3_Anemia 171599-83-0 SILDENAFIL ADVERSE_EFFECT XXX_1_Nasal Congestion 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_2_Hypotension 171599-83-0 SILDENAFIL MECH_LEVEL_2 PDE inhibition 171599-83-0 SILDENAFIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 171599-83-0 SILDENAFIL MESH_LEVEL_1 Heterocyclic Compounds 171599-83-0 SILDENAFIL TISSUE_TOXICITY Myocardial Infarction 171599-83-0 SILDENAFIL TISSUE_TOXICITY Angina Pectoris 171599-83-0 SILDENAFIL KNOWN_TOXICITY Cardiovascular Toxicity 171599-83-0 SILDENAFIL MECHANISM Enhance kinase mediated signal transduction 171599-83-0 SILDENAFIL MODE_CLASS Enzyme Inhibitor, selective 171599-83-0 SILDENAFIL ADVERSE_EFFECT REP_2_Prolonged Erection 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Myocardial Infarction 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Postural Hypotension 171599-83-0 SILDENAFIL ADVERSE_EFFECT CVS_3_Hypotensive Shock 171599-83-0 SILDENAFIL ADVERSE_EFFECT BBM_3_Leukopenia 171599-83-0 SILDENAFIL ADVERSE_EFFECT GUS_2_Urinary Tract Infection 171599-83-0 SILDENAFIL ADVERSE_EFFECT NEU_2_Syncope 171599-83-0 SILDENAFIL TISSUE_TOXICITY Sudden Cardiac Death 171599-83-0 SILDENAFIL INDICATION Erectile Dysfunction 8050-81-5 SIMETHICONE INDICATION Flatulence 8050-81-5 SIMETHICONE INDICATION Foamy Liver 53776-71-9 SISOMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 53776-71-9 SISOMICIN INDICATION Nosocomial Pneumonia 53776-71-9 SISOMICIN ZERO_CLASS N 53776-71-9 SISOMICIN KNOWN_TOXICITY Nephrotoxicity 53776-71-9 SISOMICIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 53776-71-9 SISOMICIN ADVERSE_EFFECT EMB_2_Teratogenicity 53776-71-9 SISOMICIN INDICATION Ophthalmic Infections 53776-71-9 SISOMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 53776-71-9 SISOMICIN MESH_LEVEL_2 Carbohydrates 53776-71-9 SISOMICIN MECHANISM Inhibit ribosomal protein synthesis 53776-71-9 SISOMICIN TA_LEVEL_2 Anti-bacterial 53776-71-9 SISOMICIN ADVERSE_EFFECT OTO_2_Ototoxicity 53776-71-9 SISOMICIN MECH_LEVEL_2 Protein synthesis inhibitor 53776-71-9 SISOMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 53776-71-9 SISOMICIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 53776-71-9 SISOMICIN TISSUE_TOXICITY Nephrotoxicity 53776-71-9 SISOMICIN KNOWN_TOXICITY Embryo/Fetal Toxicity 53776-71-9 SISOMICIN INDICATION Peritonitis 53776-71-9 SISOMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 53776-71-9 SISOMICIN TISSUE_TOXICITY Teratogenicity 53776-71-9 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Topical 53776-71-9 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 53776-71-9 SISOMICIN PRODUCT_CLASS Anti-infectives 53776-71-9 SISOMICIN INDICATION Gram-negative Septicemia 53776-71-9 SISOMICIN INDICATION Urinary Tract Infection (UTI) 53776-71-9 SISOMICIN TA_LEVEL_1 Infectious Disease 53776-71-9 SISOMICIN MECH_LEVEL_3 Ribosomal RNA binder 53776-71-9 SISOMICIN MESH_LEVEL_3 Aminoglycoside 53776-71-9 SISOMICIN TA_LEVEL_3 Aminoglycoside 53776-71-9 SISOMICIN MECH_LEVEL_1 Anti-bacterial 53776-71-9 SISOMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 53776-71-9 SISOMICIN ADVERSE_EFFECT KID_2_Nephrotoxicity 53179-09-2 SISOMICIN TA_LEVEL_3 Aminoglycoside 53179-09-2 SISOMICIN MECH_LEVEL_1 Anti-bacterial 53179-09-2 SISOMICIN ADVERSE_EFFECT KID_2_Nephrotoxicity 53179-09-2 SISOMICIN MECH_LEVEL_3 Ribosomal RNA binder 53179-09-2 SISOMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 53179-09-2 SISOMICIN INDICATION Nosocomial Pneumonia 53179-09-2 SISOMICIN ZERO_CLASS N 53179-09-2 SISOMICIN KNOWN_TOXICITY Nephrotoxicity 53179-09-2 SISOMICIN ADVERSE_EFFECT EMB_2_Teratogenicity 53179-09-2 SISOMICIN INDICATION Ophthalmic Infections 53179-09-2 SISOMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 53179-09-2 SISOMICIN MESH_LEVEL_2 Carbohydrates 53179-09-2 SISOMICIN MECHANISM Inhibit ribosomal protein synthesis 53179-09-2 SISOMICIN TA_LEVEL_2 Anti-bacterial 53179-09-2 SISOMICIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 53179-09-2 SISOMICIN TA_LEVEL_1 Infectious Disease 53179-09-2 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 53179-09-2 SISOMICIN TISSUE_TOXICITY Nephrotoxicity 53179-09-2 SISOMICIN KNOWN_TOXICITY Embryo/Fetal Toxicity 53179-09-2 SISOMICIN ADVERSE_EFFECT OTO_2_Ototoxicity 53179-09-2 SISOMICIN INDICATION Peritonitis 53179-09-2 SISOMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 53179-09-2 SISOMICIN MECH_LEVEL_2 Protein synthesis inhibitor 53179-09-2 SISOMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 53179-09-2 SISOMICIN TISSUE_TOXICITY Teratogenicity 53179-09-2 SISOMICIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 53179-09-2 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Topical 53179-09-2 SISOMICIN PRODUCT_CLASS Anti-infectives 53179-09-2 SISOMICIN INDICATION Gram-negative Septicemia 53179-09-2 SISOMICIN INDICATION Urinary Tract Infection (UTI) 53179-09-2 SISOMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 53179-09-2 SISOMICIN MESH_LEVEL_3 Aminoglycoside 53797-16-3 SISOMICIN TA_LEVEL_3 Aminoglycoside 53797-16-3 SISOMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 53797-16-3 SISOMICIN TISSUE_TOXICITY Nephrotoxicity 53797-16-3 SISOMICIN KNOWN_TOXICITY Embryo/Fetal Toxicity 53797-16-3 SISOMICIN ADVERSE_EFFECT OTO_2_Ototoxicity 53797-16-3 SISOMICIN INDICATION Peritonitis 53797-16-3 SISOMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 53797-16-3 SISOMICIN MECH_LEVEL_2 Protein synthesis inhibitor 53797-16-3 SISOMICIN MECH_LEVEL_3 Ribosomal RNA binder 53797-16-3 SISOMICIN ADVERSE_EFFECT KID_2_Nephrotoxicity 53797-16-3 SISOMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 53797-16-3 SISOMICIN MECH_LEVEL_1 Anti-bacterial 53797-16-3 SISOMICIN MESH_LEVEL_3 Aminoglycoside 53797-16-3 SISOMICIN INDICATION Urinary Tract Infection (UTI) 53797-16-3 SISOMICIN INDICATION Gram-negative Septicemia 53797-16-3 SISOMICIN PRODUCT_CLASS Anti-infectives 53797-16-3 SISOMICIN ZERO_CLASS N 53797-16-3 SISOMICIN INDICATION Nosocomial Pneumonia 53797-16-3 SISOMICIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 53797-16-3 SISOMICIN TISSUE_TOXICITY Teratogenicity 53797-16-3 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Topical 53797-16-3 SISOMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 53797-16-3 SISOMICIN TA_LEVEL_2 Anti-bacterial 53797-16-3 SISOMICIN TA_LEVEL_1 Infectious Disease 53797-16-3 SISOMICIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 53797-16-3 SISOMICIN MECHANISM Inhibit ribosomal protein synthesis 53797-16-3 SISOMICIN MESH_LEVEL_2 Carbohydrates 53797-16-3 SISOMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 53797-16-3 SISOMICIN INDICATION Ophthalmic Infections 53797-16-3 SISOMICIN ADVERSE_EFFECT EMB_2_Teratogenicity 53797-16-3 SISOMICIN ADVERSE_EFFECT NEU_3_Neuromuscular Blockade 53797-16-3 SISOMICIN KNOWN_TOXICITY Nephrotoxicity 62751-59-1 R(+)-SKF-38393 PRODUCT_CLASS Biochemicals 62751-59-1 R(+)-SKF-38393 MECHANISM Modulate G-protein coupled signal transduction 54-21-7 SALICYLIC ACID MESH_LEVEL_1 Organic Chemicals 54-21-7 SALICYLIC ACID MESH_LEVEL_2 Carboxylic Acids 54-21-7 SALICYLIC ACID MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 54-21-7 SALICYLIC ACID MECH_LEVEL_2 Block channel gating 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Excitement 54-21-7 SALICYLIC ACID ACTIVITY_CLASS Anti-inflammatory 54-21-7 SALICYLIC ACID ZERO_CLASS N 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Delusions 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Confusion 54-21-7 SALICYLIC ACID ADVERSE_EFFECT OTO_3_Tinnitus 54-21-7 SALICYLIC ACID INDICATION Acne / Acne Vulgaris 54-21-7 SALICYLIC ACID INDICATION Psoriasis 54-21-7 SALICYLIC ACID PRODUCT_CLASS Dermatologicals 54-21-7 SALICYLIC ACID TA_LEVEL_1 Anti-inflammatory 54-21-7 SALICYLIC ACID TA_LEVEL_2 NSAID 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_1_Irritation 54-21-7 SALICYLIC ACID ADVERSE_EFFECT NEU_3_Stupor 54-21-7 SALICYLIC ACID ADVERSE_EFFECT XXX_3_Lethargy 54-21-7 SALICYLIC ACID ADVERSE_EFFECT END_3_Metabolic Alkalosis 54-21-7 SALICYLIC ACID ADVERSE_EFFECT LUN_3_Respiratory Depression 54-21-7 SALICYLIC ACID MODE_CLASS Enzyme Inhibitor 54-21-7 SALICYLIC ACID INDICATION Verruca Vulgaris 54-21-7 SALICYLIC ACID INDICATION Seborrheic Dermatitis 54-21-7 SALICYLIC ACID MECHANISM Inhibit eicosanoid biosynthesis 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Disorientation 54-21-7 SALICYLIC ACID ADVERSE_EFFECT IMU_3_Hypersensitivity 54-21-7 SALICYLIC ACID ADVERSE_EFFECT GIS_3_Vomiting 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Depression 54-21-7 SALICYLIC ACID MODE_CLASS Enzyme Inhibitor, selective 54-21-7 SALICYLIC ACID MESH_LEVEL_3 Acids, Carbocyclic 54-21-7 SALICYLIC ACID TA_LEVEL_3 Topical NSAID 54-21-7 SALICYLIC ACID MECHANISM Inhibit inflammatory response 54-21-7 SALICYLIC ACID STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 54-21-7 SALICYLIC ACID THERAPEUTIC_CLASS Astringents 54-21-7 SALICYLIC ACID ADVERSE_EFFECT XXX_3_Thirst 54-21-7 SALICYLIC ACID ADVERSE_EFFECT XXX_3_Restlessness 54-21-7 SALICYLIC ACID ADVERSE_EFFECT NEU_3_Coma 54-21-7 SALICYLIC ACID ADVERSE_EFFECT NEU_3_Headache 54-21-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Hallucinations 54-21-7 SALICYLIC ACID MODE_CLASS Solute transporter inhibitor 54-21-7 SALICYLIC ACID MECH_LEVEL_1 Immunomodulation 54-21-7 SALICYLIC ACID MECH_LEVEL_3 Urate/Anion exchanger, Urate transporter 69-72-7 SALICYLIC ACID PRODUCT_CLASS Dermatologicals 69-72-7 SALICYLIC ACID INDICATION Psoriasis 69-72-7 SALICYLIC ACID INDICATION Acne / Acne Vulgaris 69-72-7 SALICYLIC ACID ADVERSE_EFFECT OTO_3_Tinnitus 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Confusion 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Delusions 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Excitement 69-72-7 SALICYLIC ACID MECH_LEVEL_2 Block channel gating 69-72-7 SALICYLIC ACID MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 69-72-7 SALICYLIC ACID MESH_LEVEL_2 Carboxylic Acids 69-72-7 SALICYLIC ACID MESH_LEVEL_1 Organic Chemicals 69-72-7 SALICYLIC ACID MODE_CLASS Solute transporter inhibitor 69-72-7 SALICYLIC ACID MECH_LEVEL_3 Urate/Anion exchanger, Urate transporter 69-72-7 SALICYLIC ACID MECH_LEVEL_1 Immunomodulation 69-72-7 SALICYLIC ACID TA_LEVEL_2 NSAID 69-72-7 SALICYLIC ACID TA_LEVEL_1 Anti-inflammatory 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Hallucinations 69-72-7 SALICYLIC ACID ADVERSE_EFFECT NEU_3_Headache 69-72-7 SALICYLIC ACID ADVERSE_EFFECT NEU_3_Coma 69-72-7 SALICYLIC ACID ADVERSE_EFFECT XXX_3_Restlessness 69-72-7 SALICYLIC ACID ADVERSE_EFFECT XXX_3_Thirst 69-72-7 SALICYLIC ACID THERAPEUTIC_CLASS Astringents 69-72-7 SALICYLIC ACID STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 69-72-7 SALICYLIC ACID MECHANISM Inhibit inflammatory response 69-72-7 SALICYLIC ACID TA_LEVEL_3 Topical NSAID 69-72-7 SALICYLIC ACID MESH_LEVEL_3 Acids, Carbocyclic 69-72-7 SALICYLIC ACID MODE_CLASS Enzyme Inhibitor, selective 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Depression 69-72-7 SALICYLIC ACID ADVERSE_EFFECT GIS_3_Vomiting 69-72-7 SALICYLIC ACID ADVERSE_EFFECT IMU_3_Hypersensitivity 69-72-7 SALICYLIC ACID INDICATION Seborrheic Dermatitis 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_3_Disorientation 69-72-7 SALICYLIC ACID ADVERSE_EFFECT PSY_1_Irritation 69-72-7 SALICYLIC ACID MECHANISM Inhibit eicosanoid biosynthesis 69-72-7 SALICYLIC ACID INDICATION Verruca Vulgaris 69-72-7 SALICYLIC ACID MODE_CLASS Enzyme Inhibitor 69-72-7 SALICYLIC ACID ADVERSE_EFFECT LUN_3_Respiratory Depression 69-72-7 SALICYLIC ACID ADVERSE_EFFECT END_3_Metabolic Alkalosis 69-72-7 SALICYLIC ACID ADVERSE_EFFECT XXX_3_Lethargy 69-72-7 SALICYLIC ACID ADVERSE_EFFECT NEU_3_Stupor 69-72-7 SALICYLIC ACID ZERO_CLASS N 69-72-7 SALICYLIC ACID ACTIVITY_CLASS Anti-inflammatory 139-88-8 SODIUM TETRADECYL SULFATE PRODUCT_CLASS Cardiovasculars 139-88-8 SODIUM TETRADECYL SULFATE INDICATION Atherosclerosis 139-88-8 SODIUM TETRADECYL SULFATE THERAPEUTIC_CLASS Hypolipidemic Agents 7772-98-7 SODIUM THIOSULFATE MODE_CLASS Enzyme substrate mimic 7772-98-7 SODIUM THIOSULFATE INDICATION Cyanide (CN) Poisoning 959-24-0 SOTALOL INDICATION Atrial Flutter 959-24-0 SOTALOL MECH_LEVEL_1 Vasorelaxation 959-24-0 SOTALOL MESH_LEVEL_2 Amines 959-24-0 SOTALOL ADVERSE_EFFECT CVS_1_Sinus Bradycardia 959-24-0 SOTALOL ADVERSE_EFFECT CVS_1_Palpitation 959-24-0 SOTALOL ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 959-24-0 SOTALOL ADVERSE_EFFECT END_2_Hyperglycemia 959-24-0 SOTALOL THERAPEUTIC_CLASS Antiarrhythmic Agents 959-24-0 SOTALOL TISSUE_TOXICITY Angina 959-24-0 SOTALOL MECH_LEVEL_2 beta blocker 959-24-0 SOTALOL TA_LEVEL_1 Cardiovascular 959-24-0 SOTALOL MODE_CLASS Channel Blocker, selective 959-24-0 SOTALOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 959-24-0 SOTALOL ADVERSE_EFFECT END_2_Mask Symptoms of Hypoglycemia in Diabetics 959-24-0 SOTALOL ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 959-24-0 SOTALOL PRODUCT_CLASS Cardiovasculars 959-24-0 SOTALOL MESH_LEVEL_3 Amino Alcohols 959-24-0 SOTALOL MECH_LEVEL_3 adrenoceptor beta 959-24-0 SOTALOL MESH_LEVEL_1 Organic Chemicals 959-24-0 SOTALOL ACTIVITY_CLASS Adrenergic antagonist 959-24-0 SOTALOL KNOWN_TOXICITY Cardiovascular Toxicity 959-24-0 SOTALOL TISSUE_TOXICITY Cardiac Arrhythmia 959-24-0 SOTALOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 959-24-0 SOTALOL MECHANISM Modulate channel gating 959-24-0 SOTALOL ZERO_CLASS N 959-24-0 SOTALOL ADVERSE_EFFECT CVS_1_Angina 959-24-0 SOTALOL TA_LEVEL_3 hypertension 959-24-0 SOTALOL TISSUE_TOXICITY Torsade de Pointes Arrhythmia 959-24-0 SOTALOL TISSUE_TOXICITY Hypotension 959-24-0 SOTALOL TA_LEVEL_2 beta antagonists 959-24-0 SOTALOL INDICATION Atrial Fibrillation 959-24-0 SOTALOL ADVERSE_EFFECT END_2_Hypoglycemia 959-24-0 SOTALOL TISSUE_TOXICITY Congestive Heart Failure 959-24-0 SOTALOL INDICATION Ventricular Arrhythmias 959-24-0 SOTALOL ADVERSE_EFFECT CVS_1_Hypotension 959-24-0 SOTALOL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 959-24-0 SOTALOL ADVERSE_EFFECT NEU_1_Dizziness 959-24-0 SOTALOL ADVERSE_EFFECT LUN_1_Dyspnea 959-24-0 SOTALOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 959-24-0 SOTALOL MECHANISM Modulate G-protein coupled signal transduction 959-24-0 SOTALOL ADVERSE_EFFECT XXX_1_Fatigue 3930-20-9 SOTALOL TA_LEVEL_3 hypertension 3930-20-9 SOTALOL TISSUE_TOXICITY Angina 3930-20-9 SOTALOL THERAPEUTIC_CLASS Antiarrhythmic Agents 3930-20-9 SOTALOL ADVERSE_EFFECT END_2_Hyperglycemia 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_1_Palpitation 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_1_Sinus Bradycardia 3930-20-9 SOTALOL MESH_LEVEL_2 Amines 3930-20-9 SOTALOL INDICATION Atrial Flutter 3930-20-9 SOTALOL TISSUE_TOXICITY Hypotension 3930-20-9 SOTALOL TISSUE_TOXICITY Congestive Heart Failure 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 3930-20-9 SOTALOL ADVERSE_EFFECT NEU_1_Dizziness 3930-20-9 SOTALOL ADVERSE_EFFECT LUN_1_Dyspnea 3930-20-9 SOTALOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 3930-20-9 SOTALOL MECHANISM Modulate G-protein coupled signal transduction 3930-20-9 SOTALOL TA_LEVEL_2 beta antagonists 3930-20-9 SOTALOL INDICATION Atrial Fibrillation 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 3930-20-9 SOTALOL ADVERSE_EFFECT END_2_Hypoglycemia 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_1_Hypotension 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_1_Angina 3930-20-9 SOTALOL ZERO_CLASS N 3930-20-9 SOTALOL MECHANISM Modulate channel gating 3930-20-9 SOTALOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 3930-20-9 SOTALOL TISSUE_TOXICITY Cardiac Arrhythmia 3930-20-9 SOTALOL KNOWN_TOXICITY Cardiovascular Toxicity 3930-20-9 SOTALOL ACTIVITY_CLASS Adrenergic antagonist 3930-20-9 SOTALOL MESH_LEVEL_1 Organic Chemicals 3930-20-9 SOTALOL MECH_LEVEL_3 adrenoceptor beta 3930-20-9 SOTALOL MESH_LEVEL_3 Amino Alcohols 3930-20-9 SOTALOL PRODUCT_CLASS Cardiovasculars 3930-20-9 SOTALOL ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 3930-20-9 SOTALOL ADVERSE_EFFECT END_2_Mask Symptoms of Hypoglycemia in Diabetics 3930-20-9 SOTALOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 3930-20-9 SOTALOL ADVERSE_EFFECT XXX_1_Fatigue 3930-20-9 SOTALOL TISSUE_TOXICITY Torsade de Pointes Arrhythmia 3930-20-9 SOTALOL MODE_CLASS Channel Blocker, selective 3930-20-9 SOTALOL TA_LEVEL_1 Cardiovascular 3930-20-9 SOTALOL MECH_LEVEL_2 beta blocker 3930-20-9 SOTALOL MECH_LEVEL_1 Vasorelaxation 3930-20-9 SOTALOL INDICATION Ventricular Arrhythmias 27948-47-6 SOTALOL INDICATION Atrial Flutter 27948-47-6 SOTALOL TISSUE_TOXICITY Cardiac Arrhythmia 27948-47-6 SOTALOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 27948-47-6 SOTALOL MECHANISM Modulate channel gating 27948-47-6 SOTALOL ZERO_CLASS N 27948-47-6 SOTALOL MECH_LEVEL_1 Vasorelaxation 27948-47-6 SOTALOL INDICATION Ventricular Arrhythmias 27948-47-6 SOTALOL MESH_LEVEL_2 Amines 27948-47-6 SOTALOL TISSUE_TOXICITY Angina 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_1_Palpitation 27948-47-6 SOTALOL ADVERSE_EFFECT END_2_Hyperglycemia 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_1_Angina 27948-47-6 SOTALOL TA_LEVEL_3 hypertension 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_1_Hypotension 27948-47-6 SOTALOL THERAPEUTIC_CLASS Antiarrhythmic Agents 27948-47-6 SOTALOL MECHANISM Modulate G-protein coupled signal transduction 27948-47-6 SOTALOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 27948-47-6 SOTALOL ADVERSE_EFFECT LUN_1_Dyspnea 27948-47-6 SOTALOL ADVERSE_EFFECT NEU_1_Dizziness 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_2_Congestive Heart Failure 27948-47-6 SOTALOL TISSUE_TOXICITY Congestive Heart Failure 27948-47-6 SOTALOL TISSUE_TOXICITY Hypotension 27948-47-6 SOTALOL KNOWN_TOXICITY Cardiovascular Toxicity 27948-47-6 SOTALOL ACTIVITY_CLASS Adrenergic antagonist 27948-47-6 SOTALOL MESH_LEVEL_1 Organic Chemicals 27948-47-6 SOTALOL MECH_LEVEL_3 adrenoceptor beta 27948-47-6 SOTALOL MESH_LEVEL_3 Amino Alcohols 27948-47-6 SOTALOL PRODUCT_CLASS Cardiovasculars 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 27948-47-6 SOTALOL ADVERSE_EFFECT END_2_Mask Symptoms of Hypoglycemia in Diabetics 27948-47-6 SOTALOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 27948-47-6 SOTALOL ADVERSE_EFFECT XXX_1_Fatigue 27948-47-6 SOTALOL TISSUE_TOXICITY Torsade de Pointes Arrhythmia 27948-47-6 SOTALOL MODE_CLASS Channel Blocker, selective 27948-47-6 SOTALOL TA_LEVEL_1 Cardiovascular 27948-47-6 SOTALOL ADVERSE_EFFECT END_2_Hypoglycemia 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 27948-47-6 SOTALOL INDICATION Atrial Fibrillation 27948-47-6 SOTALOL TA_LEVEL_2 beta antagonists 27948-47-6 SOTALOL ADVERSE_EFFECT CVS_1_Sinus Bradycardia 27948-47-6 SOTALOL MECH_LEVEL_2 beta blocker 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 110871-86-8 SPARFLOXACIN TA_LEVEL_3 quinolones 110871-86-8 SPARFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT NEU_1_Headache 110871-86-8 SPARFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 110871-86-8 SPARFLOXACIN INDICATION Community-Acquired Pneumonia 110871-86-8 SPARFLOXACIN PRODUCT_CLASS Anti-infectives 110871-86-8 SPARFLOXACIN TA_LEVEL_1 Infectious Disease 110871-86-8 SPARFLOXACIN TA_LEVEL_2 Anti-bacterial 110871-86-8 SPARFLOXACIN MECH_LEVEL_1 Anti-bacterial 110871-86-8 SPARFLOXACIN MECH_LEVEL_3 DNA gyrase 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 110871-86-8 SPARFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 110871-86-8 SPARFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 110871-86-8 SPARFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT MSK_3_Tendinopathy 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 110871-86-8 SPARFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 110871-86-8 SPARFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 110871-86-8 SPARFLOXACIN ZERO_CLASS N 110871-86-8 SPARFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT NEU_2_Drowsiness 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 110871-86-8 SPARFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 110871-86-8 SPARFLOXACIN MESH_LEVEL_3 Quinolines 110871-86-8 SPARFLOXACIN TISSUE_TOXICITY Cardiac Arrhythmia 110871-86-8 SPARFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 110871-86-8 SPARFLOXACIN ADVERSE_EFFECT MSK_3_Arthropathy 111542-93-9 SPARFLOXACIN INDICATION Community-Acquired Pneumonia 111542-93-9 SPARFLOXACIN MECH_LEVEL_3 DNA gyrase 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT MSK_3_Arthropathy 111542-93-9 SPARFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 111542-93-9 SPARFLOXACIN MESH_LEVEL_3 Quinolines 111542-93-9 SPARFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 111542-93-9 SPARFLOXACIN TISSUE_TOXICITY Cardiac Arrhythmia 111542-93-9 SPARFLOXACIN MECH_LEVEL_1 Anti-bacterial 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT NEU_2_Drowsiness 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT CVS_2_Prolonged QT Interval 111542-93-9 SPARFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 111542-93-9 SPARFLOXACIN ZERO_CLASS N 111542-93-9 SPARFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 111542-93-9 SPARFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 111542-93-9 SPARFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT MSK_3_Tendinopathy 111542-93-9 SPARFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 111542-93-9 SPARFLOXACIN TA_LEVEL_2 Anti-bacterial 111542-93-9 SPARFLOXACIN TA_LEVEL_1 Infectious Disease 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 111542-93-9 SPARFLOXACIN PRODUCT_CLASS Anti-infectives 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 111542-93-9 SPARFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 111542-93-9 SPARFLOXACIN TA_LEVEL_3 quinolones 111542-93-9 SPARFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT SKN_2_Skin Rash 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT IMU_1_Photosensitivity Reaction 111542-93-9 SPARFLOXACIN ADVERSE_EFFECT NEU_1_Headache 111542-93-9 SPARFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Fever 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 1695-77-8 SPECTINOMYCIN INDICATION Gonococcal Infections / Gonorrhea 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT NEU_2_Dizziness 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 1695-77-8 SPECTINOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 1695-77-8 SPECTINOMYCIN INDICATION Gonoccocal Cervicitis 1695-77-8 SPECTINOMYCIN PRODUCT_CLASS Anti-infectives 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Chills 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT KID_3_Decreased Urine Output 1695-77-8 SPECTINOMYCIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 1695-77-8 SPECTINOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT PSY_2_Insomnia 1695-77-8 SPECTINOMYCIN ADVERSE_EFFECT IMU_2_Urticaria 1695-77-8 SPECTINOMYCIN MECHANISM Inhibit ribosomal protein synthesis 1695-77-8 SPECTINOMYCIN INDICATION Proctitis 21736-83-4 SPECTINOMYCIN INDICATION Gonoccocal Cervicitis 21736-83-4 SPECTINOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 21736-83-4 SPECTINOMYCIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT KID_3_Decreased Urine Output 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Chills 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 21736-83-4 SPECTINOMYCIN PRODUCT_CLASS Anti-infectives 21736-83-4 SPECTINOMYCIN INDICATION Proctitis 21736-83-4 SPECTINOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT NEU_2_Dizziness 21736-83-4 SPECTINOMYCIN INDICATION Gonococcal Infections / Gonorrhea 21736-83-4 SPECTINOMYCIN MECHANISM Inhibit ribosomal protein synthesis 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT IMU_2_Urticaria 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT PSY_2_Insomnia 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 21736-83-4 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Fever 22189-32-8 SPECTINOMYCIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 22189-32-8 SPECTINOMYCIN PRODUCT_CLASS Anti-infectives 22189-32-8 SPECTINOMYCIN INDICATION Gonococcal Infections / Gonorrhea 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT NEU_2_Dizziness 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 22189-32-8 SPECTINOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 22189-32-8 SPECTINOMYCIN INDICATION Gonoccocal Cervicitis 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Chills 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT KID_3_Decreased Urine Output 22189-32-8 SPECTINOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT PSY_2_Insomnia 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT IMU_2_Urticaria 22189-32-8 SPECTINOMYCIN MECHANISM Inhibit ribosomal protein synthesis 22189-32-8 SPECTINOMYCIN INDICATION Proctitis 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Fever 22189-32-8 SPECTINOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT NEU_2_Dizziness 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT SKN_2_Pruritis 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Fever 64058-48-6 SPECTINOMYCIN INDICATION Proctitis 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT IMU_2_Urticaria 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT PSY_2_Insomnia 64058-48-6 SPECTINOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 64058-48-6 SPECTINOMYCIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT KID_3_Decreased Urine Output 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT XXX_2_Chills 64058-48-6 SPECTINOMYCIN INDICATION Gonococcal Infections / Gonorrhea 64058-48-6 SPECTINOMYCIN PRODUCT_CLASS Anti-infectives 64058-48-6 SPECTINOMYCIN INDICATION Gonoccocal Cervicitis 64058-48-6 SPECTINOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 64058-48-6 SPECTINOMYCIN MECHANISM Inhibit ribosomal protein synthesis 64058-48-6 SPECTINOMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 749-02-0 SPIPERONE THERAPEUTIC_CLASS Sedatives/Hypnotics 749-02-0 SPIPERONE PRODUCT_CLASS Central Nervous System (CNS) 749-02-0 SPIPERONE MECHANISM Modulate neural transmission 749-02-0 SPIPERONE MODE_CLASS Receptor Ligand Antagonist, Selective 749-02-0 SPIPERONE MECHANISM Block neural transmission 749-02-0 SPIPERONE MODE_CLASS Receptor Ligand Antagonist 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT XXX_2_Lethargy 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT ELT_3_Hyperchloremic Metabolic Acidosis 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT REP_3_Impotence 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT PSY_1_Anorexia 52-01-7 SPIRONOLACTONE THERAPEUTIC_CLASS Diuretics 52-01-7 SPIRONOLACTONE MECH_LEVEL_3 Mineralocorticoid receptor 52-01-7 SPIRONOLACTONE INDICATION Nephrotic Syndrome 52-01-7 SPIRONOLACTONE INDICATION Primary Hyperaldosteronism 52-01-7 SPIRONOLACTONE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 52-01-7 SPIRONOLACTONE TA_LEVEL_3 Systemic steroid 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT GIS_2_Abdominal Pain 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT REP_2_Decreased Libido 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT SKN_2_Maculopapular Rash 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT ELT_2_Hyponatremia 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT END_2_Hirsutism 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT PSY_2_Mental Confusion 52-01-7 SPIRONOLACTONE KNOWN_TOXICITY Nephrotoxicity 52-01-7 SPIRONOLACTONE TA_LEVEL_2 Heart failure 52-01-7 SPIRONOLACTONE INDICATION Congestive Heart Failure (CHF) 52-01-7 SPIRONOLACTONE MESH_LEVEL_3 Pregnanes 52-01-7 SPIRONOLACTONE THERAPEUTIC_CLASS Congestive Heart Failure 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 52-01-7 SPIRONOLACTONE TA_LEVEL_1 Cardiovascular 52-01-7 SPIRONOLACTONE INDICATION Hypertension 52-01-7 SPIRONOLACTONE INDICATION Hypokalemia 52-01-7 SPIRONOLACTONE MESH_LEVEL_2 Steroids 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT GIS_2_Diarrhea 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT NEU_1_Headache 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT END_2_Gynecomastia 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT IMU_2_Urticaria 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT REP_2_Menstrual Irregularities 52-01-7 SPIRONOLACTONE ZERO_CLASS N 52-01-7 SPIRONOLACTONE TISSUE_TOXICITY Renal Failure 52-01-7 SPIRONOLACTONE THERAPEUTIC_CLASS Antihypertensive Agents 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT KID_2_Renal Dysfunction 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT SKN_2_Erythema 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT NEU_2_Ataxia 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT BBM_3_Agranulocytosis 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT ELT_1_Hyperkalemia 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT GIS_1_Gastritis 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT XXX_2_Fever 52-01-7 SPIRONOLACTONE MODE_CLASS Receptor Ligand Antagonist 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT KID_3_Renal Failure 52-01-7 SPIRONOLACTONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 52-01-7 SPIRONOLACTONE INDICATION Cirrhosis 52-01-7 SPIRONOLACTONE INDICATION Edematous States 52-01-7 SPIRONOLACTONE PRODUCT_CLASS Cardiovasculars 52-01-7 SPIRONOLACTONE MECH_LEVEL_1 Diuretic 52-01-7 SPIRONOLACTONE MESH_LEVEL_1 Polycyclic Hydrocarbons 52-01-7 SPIRONOLACTONE STRUCTURE_ACTIVITY Mineralocorticoid receptor antagonist 52-01-7 SPIRONOLACTONE ACTIVITY_CLASS RAAS inhibitor 52-01-7 SPIRONOLACTONE MECH_LEVEL_2 aldosterone antagonist 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT KID_2_Azotemia 52-01-7 SPIRONOLACTONE ADVERSE_EFFECT REP_2_Amenorrhea 192703-06-3 SR-144528 MECHANISM Modulate G-protein coupled signal transduction 192703-06-3 SR-144528 MODE_CLASS Receptor Ligand Antagonist, Selective 192703-06-3 SR-144528 PRODUCT_CLASS Biochemicals 105350-26-3 SR-2640 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 105350-26-3 SR-2640 PRODUCT_CLASS Respiratory System 105350-26-3 SR-2640 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 105350-26-3 SR-2640 MECHANISM Modulate G-protein coupled signal transduction 105350-26-3 SR-2640 MODE_CLASS Receptor Ligand Antagonist 105350-26-3 SR-2640 INDICATION Asthma 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT _3_Dental Fluorosis 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT XXX_3_Weakness 7783-47-3 STANNOUS FLUORIDE MECH_LEVEL_3 Unknown mechanism 7783-47-3 STANNOUS FLUORIDE TA_LEVEL_1 Other Human Uses 7783-47-3 STANNOUS FLUORIDE INDICATION Dental Caries, Prevention 7783-47-3 STANNOUS FLUORIDE MESH_LEVEL_2 Tin Compounds 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT NEU_3_Headache 7783-47-3 STANNOUS FLUORIDE PRODUCT_CLASS Other Human Uses 7783-47-3 STANNOUS FLUORIDE MESH_LEVEL_1 Inorganic Chemicals 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT GIS_3_Stomatitis 7783-47-3 STANNOUS FLUORIDE ZERO_CLASS N 7783-47-3 STANNOUS FLUORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 7783-47-3 STANNOUS FLUORIDE MECH_LEVEL_2 Unknown mechanism 7783-47-3 STANNOUS FLUORIDE MESH_LEVEL_3 Tin Flourides 7783-47-3 STANNOUS FLUORIDE TA_LEVEL_3 prevention (cavities, gum disease) 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT GIS_3_Epigastric Pain 7783-47-3 STANNOUS FLUORIDE THERAPEUTIC_CLASS Dental Agents 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT _3_Atopic Dermatitis 7783-47-3 STANNOUS FLUORIDE ACTIVITY_CLASS Toxicant 7783-47-3 STANNOUS FLUORIDE TA_LEVEL_2 Dental care 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT IMU_3_Urticaria 7783-47-3 STANNOUS FLUORIDE ADVERSE_EFFECT XXX_3_Tooth Discoloration 10418-03-8 STANOZOLOL TISSUE_TOXICITY Carcinogenicity 10418-03-8 STANOZOLOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 10418-03-8 STANOZOLOL TA_LEVEL_3 Steroid 10418-03-8 STANOZOLOL ADVERSE_EFFECT GUS_1_Bladder Contracture 10418-03-8 STANOZOLOL ADVERSE_EFFECT BBM_3_Acute Leukemia 10418-03-8 STANOZOLOL ADVERSE_EFFECT SKN_1_Acne 10418-03-8 STANOZOLOL ADVERSE_EFFECT GIS_2_Gastric Irritation 10418-03-8 STANOZOLOL ADVERSE_EFFECT XXX_1_Decreased Appetite 10418-03-8 STANOZOLOL ADVERSE_EFFECT GIS_2_Diarrhea 10418-03-8 STANOZOLOL TISSUE_TOXICITY Teratogenicity 10418-03-8 STANOZOLOL THERAPEUTIC_CLASS Gonadal Hormones 10418-03-8 STANOZOLOL KNOWN_TOXICITY Hepatotoxicity 10418-03-8 STANOZOLOL MESH_LEVEL_3 Androstanes 10418-03-8 STANOZOLOL MECH_LEVEL_3 androgen receptor 10418-03-8 STANOZOLOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 10418-03-8 STANOZOLOL STRUCTURE_ACTIVITY Androgen receptor agonist 10418-03-8 STANOZOLOL ACTIVITY_CLASS Androgen receptor agonist 10418-03-8 STANOZOLOL KNOWN_TOXICITY Carcinogenicity 10418-03-8 STANOZOLOL ADVERSE_EFFECT MSK_2_Muscle Cramps 10418-03-8 STANOZOLOL ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 10418-03-8 STANOZOLOL ADVERSE_EFFECT ELT_2_Hypercalcemia 10418-03-8 STANOZOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 10418-03-8 STANOZOLOL ADVERSE_EFFECT BBM_2_Bleeding 10418-03-8 STANOZOLOL ZERO_CLASS N 10418-03-8 STANOZOLOL ADVERSE_EFFECT REP_1_Priapism 10418-03-8 STANOZOLOL ADVERSE_EFFECT XXX_2_Chills 10418-03-8 STANOZOLOL ADVERSE_EFFECT END_1_Breast Tenderness 10418-03-8 STANOZOLOL ADVERSE_EFFECT BBM_2_Anemia 10418-03-8 STANOZOLOL ADVERSE_EFFECT DNA_2_Carcinogenicity 10418-03-8 STANOZOLOL MESH_LEVEL_2 Steroids 10418-03-8 STANOZOLOL MECH_LEVEL_2 Androgen receptor agonist 10418-03-8 STANOZOLOL MODE_CLASS Receptor Agonist 10418-03-8 STANOZOLOL TISSUE_TOXICITY Hepatocellular Carcinoma 10418-03-8 STANOZOLOL KNOWN_TOXICITY Embryo/Fetal Toxicity 10418-03-8 STANOZOLOL ADVERSE_EFFECT EMB_2_Teratogenicity 10418-03-8 STANOZOLOL ADVERSE_EFFECT XXX_2_Edema 10418-03-8 STANOZOLOL ADVERSE_EFFECT LIV_2_Hepatic Dysfunction 10418-03-8 STANOZOLOL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 10418-03-8 STANOZOLOL ADVERSE_EFFECT END_1_Virilization 10418-03-8 STANOZOLOL MESH_LEVEL_1 Polycyclic Hydrocarbons 10418-03-8 STANOZOLOL TA_LEVEL_2 Steroid (veterinary) 10418-03-8 STANOZOLOL MECH_LEVEL_1 Hormone replacement 10418-03-8 STANOZOLOL INDICATION Hereditary Angioedema 10418-03-8 STANOZOLOL TISSUE_TOXICITY Hepatic Necrosis 10418-03-8 STANOZOLOL ADVERSE_EFFECT END_1_Gynecomastia 10418-03-8 STANOZOLOL ADVERSE_EFFECT SKN_2_Hyperpigmentation 72702-95-5 PONALRESTAT PRODUCT_CLASS Other Human Uses 72702-95-5 PONALRESTAT MECHANISM Inhibit precursor synthesis 72702-95-5 PONALRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 72702-95-5 PONALRESTAT INDICATION Diabetic Neuropathy 72702-95-5 PONALRESTAT MODE_CLASS Enzyme Inhibitor 72703-73-2 PONALRESTAT INDICATION Diabetic Neuropathy 72703-73-2 PONALRESTAT PRODUCT_CLASS Other Human Uses 72703-73-2 PONALRESTAT MODE_CLASS Enzyme Inhibitor 72703-73-2 PONALRESTAT MECHANISM Inhibit precursor synthesis 72703-73-2 PONALRESTAT THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 62996-74-1 STAUROSPORINE ADVERSE_EFFECT GIS_2_Stomatitis 62996-74-1 STAUROSPORINE MECHANISM Inhibit kinase mediated signal transduction 62996-74-1 STAUROSPORINE PRODUCT_CLASS Biochemicals 62996-74-1 STAUROSPORINE ADVERSE_EFFECT MSK_2_Bone Defects 62996-74-1 STAUROSPORINE ADVERSE_EFFECT END_3_Hyperglycemia 62996-74-1 STAUROSPORINE ADVERSE_EFFECT GIS_1_Emesis 62996-74-1 STAUROSPORINE ADVERSE_EFFECT CVS_1_Increased Heart Rate 62996-74-1 STAUROSPORINE ADVERSE_EFFECT GIS_1_Nausea 62996-74-1 STAUROSPORINE ADVERSE_EFFECT NEU_3_Neurotoxicity 62996-74-1 STAUROSPORINE MODE_CLASS Enzyme Inhibitor, Non-selective 62996-74-1 STAUROSPORINE STRUCTURE_ACTIVITY Protein-serine/threonine kinase (PKC) inhibitor 62996-74-1 STAUROSPORINE ACTIVITY_CLASS Antiproliferative agent 62996-74-1 STAUROSPORINE ADVERSE_EFFECT XXX_1_Fatigue 3056-17-5 STAVUDINE ADVERSE_EFFECT SKN_1_Rash 3056-17-5 STAVUDINE ADVERSE_EFFECT MSK_2_Myalgia 3056-17-5 STAVUDINE ADVERSE_EFFECT LIV_3_Steatosis 3056-17-5 STAVUDINE THERAPEUTIC_CLASS Antivirals, Systemic 3056-17-5 STAVUDINE ACTIVITY_CLASS Anti-viral 3056-17-5 STAVUDINE ZERO_CLASS N 3056-17-5 STAVUDINE TA_LEVEL_1 Infectious Disease 3056-17-5 STAVUDINE MESH_LEVEL_2 Nucleosides 3056-17-5 STAVUDINE PRODUCT_CLASS Anti-infectives 3056-17-5 STAVUDINE ADVERSE_EFFECT NEU_1_Headache 3056-17-5 STAVUDINE ADVERSE_EFFECT GIS_3_Pancreatitis 3056-17-5 STAVUDINE KNOWN_TOXICITY Hepatotoxicity 3056-17-5 STAVUDINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 3056-17-5 STAVUDINE MECH_LEVEL_3 RNA-directed DNA polymerase 3056-17-5 STAVUDINE MECHANISM Inhibit viral DNA synthesis 3056-17-5 STAVUDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 3056-17-5 STAVUDINE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 3056-17-5 STAVUDINE ADVERSE_EFFECT LIV_3_Hepatic Failure 3056-17-5 STAVUDINE ADVERSE_EFFECT END_3_Lactic Acidosis 3056-17-5 STAVUDINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 3056-17-5 STAVUDINE TISSUE_TOXICITY Hepatotoxicity 3056-17-5 STAVUDINE STRUCTURE_ACTIVITY Viral RT inhibitor 3056-17-5 STAVUDINE MESH_LEVEL_3 Deoxyribonucleosides 3056-17-5 STAVUDINE MECH_LEVEL_1 Anti-viral 3056-17-5 STAVUDINE TA_LEVEL_3 antiviral RT inhibitors 3056-17-5 STAVUDINE ADVERSE_EFFECT PSY_2_Anorexia 3056-17-5 STAVUDINE ADVERSE_EFFECT IMU_3_Hypersensitivity 3056-17-5 STAVUDINE TA_LEVEL_2 Anti-viral 3056-17-5 STAVUDINE ADVERSE_EFFECT LIV_3_Hepatomegaly 3056-17-5 STAVUDINE TISSUE_TOXICITY Hepatic Failure 3056-17-5 STAVUDINE MECH_LEVEL_2 Inhibit viral DNA synthesis 3056-17-5 STAVUDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 3056-17-5 STAVUDINE MODE_CLASS Enzyme substrate mimic 3056-17-5 STAVUDINE ADVERSE_EFFECT GIS_1_Diarrhea 3056-17-5 STAVUDINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 3810-74-0 STREPTOMYCIN TA_LEVEL_3 Aminoglycoside 3810-74-0 STREPTOMYCIN TISSUE_TOXICITY Renal Tubular Necrosis 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT BBM_3_Agranulocytosis 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT NEU_3_Vertigo 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 3810-74-0 STREPTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 3810-74-0 STREPTOMYCIN INDICATION Tularemia 3810-74-0 STREPTOMYCIN INDICATION Plague 3810-74-0 STREPTOMYCIN INDICATION Chancroid 3810-74-0 STREPTOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 3810-74-0 STREPTOMYCIN KNOWN_TOXICITY Nephrotoxicity 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT OTO_3_Tinnitus 3810-74-0 STREPTOMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 3810-74-0 STREPTOMYCIN INDICATION Tuberculosis 3810-74-0 STREPTOMYCIN INDICATION Lower Respiratory Tract Infection 3810-74-0 STREPTOMYCIN INDICATION Bacteremia 3810-74-0 STREPTOMYCIN MECH_LEVEL_3 Ribosomal RNA binder 3810-74-0 STREPTOMYCIN PRODUCT_CLASS Anti-infectives 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT MSK_3_Myasthenia 3810-74-0 STREPTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Acidosis 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT KID_3_Azotemia 3810-74-0 STREPTOMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 3810-74-0 STREPTOMYCIN MESH_LEVEL_3 Aminoglycoside 3810-74-0 STREPTOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 3810-74-0 STREPTOMYCIN INDICATION Urinary Tract Infection (UTI) 3810-74-0 STREPTOMYCIN INDICATION Meningitis 3810-74-0 STREPTOMYCIN INDICATION Brucellosis 3810-74-0 STREPTOMYCIN MECH_LEVEL_1 Anti-bacterial 3810-74-0 STREPTOMYCIN ZERO_CLASS N 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT XXX_1_Injection Site Reaction 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT KID_2_Proteinuria 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 3810-74-0 STREPTOMYCIN MESH_LEVEL_2 Carbohydrates 3810-74-0 STREPTOMYCIN INDICATION Endocarditis 3810-74-0 STREPTOMYCIN INDICATION Pneumonia 3810-74-0 STREPTOMYCIN TA_LEVEL_2 Anti-bacterial 3810-74-0 STREPTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 3810-74-0 STREPTOMYCIN TA_LEVEL_1 Infectious Disease 3810-74-0 STREPTOMYCIN ADVERSE_EFFECT OTO_3_Hearing Loss 57-92-1 STREPTOMYCIN ADVERSE_EFFECT OTO_3_Tinnitus 57-92-1 STREPTOMYCIN KNOWN_TOXICITY Nephrotoxicity 57-92-1 STREPTOMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 57-92-1 STREPTOMYCIN INDICATION Chancroid 57-92-1 STREPTOMYCIN INDICATION Plague 57-92-1 STREPTOMYCIN INDICATION Tularemia 57-92-1 STREPTOMYCIN MECHANISM Inhibit ribosomal protein synthesis 57-92-1 STREPTOMYCIN MECH_LEVEL_2 Protein synthesis inhibitor 57-92-1 STREPTOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 57-92-1 STREPTOMYCIN ADVERSE_EFFECT NEU_3_Vertigo 57-92-1 STREPTOMYCIN ADVERSE_EFFECT BBM_3_Agranulocytosis 57-92-1 STREPTOMYCIN TISSUE_TOXICITY Renal Tubular Necrosis 57-92-1 STREPTOMYCIN TA_LEVEL_3 Aminoglycoside 57-92-1 STREPTOMYCIN MECH_LEVEL_1 Anti-bacterial 57-92-1 STREPTOMYCIN INDICATION Brucellosis 57-92-1 STREPTOMYCIN INDICATION Meningitis 57-92-1 STREPTOMYCIN INDICATION Urinary Tract Infection (UTI) 57-92-1 STREPTOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 57-92-1 STREPTOMYCIN MESH_LEVEL_3 Aminoglycoside 57-92-1 STREPTOMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 57-92-1 STREPTOMYCIN ADVERSE_EFFECT KID_3_Azotemia 57-92-1 STREPTOMYCIN ADVERSE_EFFECT KID_3_Renal Tubular Acidosis 57-92-1 STREPTOMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 57-92-1 STREPTOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 57-92-1 STREPTOMYCIN PRODUCT_CLASS Anti-infectives 57-92-1 STREPTOMYCIN MECH_LEVEL_3 Ribosomal RNA binder 57-92-1 STREPTOMYCIN INDICATION Bacteremia 57-92-1 STREPTOMYCIN INDICATION Lower Respiratory Tract Infection 57-92-1 STREPTOMYCIN INDICATION Tuberculosis 57-92-1 STREPTOMYCIN ADVERSE_EFFECT XXX_1_Injection Site Reaction 57-92-1 STREPTOMYCIN ADVERSE_EFFECT KID_2_Proteinuria 57-92-1 STREPTOMYCIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 57-92-1 STREPTOMYCIN MESH_LEVEL_2 Carbohydrates 57-92-1 STREPTOMYCIN INDICATION Endocarditis 57-92-1 STREPTOMYCIN INDICATION Pneumonia 57-92-1 STREPTOMYCIN TA_LEVEL_2 Anti-bacterial 57-92-1 STREPTOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 57-92-1 STREPTOMYCIN TA_LEVEL_1 Infectious Disease 57-92-1 STREPTOMYCIN ADVERSE_EFFECT OTO_3_Hearing Loss 57-92-1 STREPTOMYCIN ZERO_CLASS N 57-92-1 STREPTOMYCIN ADVERSE_EFFECT MSK_3_Myasthenia 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT PSY_2_Depression 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT GIS_1_Diarrhea 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT KID_1_Renal Tubular Acidosis 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 18883-66-4 STREPTOZOTOCIN TISSUE_TOXICITY Nephrotoxicity 18883-66-4 STREPTOZOTOCIN STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, nitrosourea 18883-66-4 STREPTOZOTOCIN KNOWN_TOXICITY Carcinogenicity 18883-66-4 STREPTOZOTOCIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT END_2_Glucose Intolerance 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 18883-66-4 STREPTOZOTOCIN THERAPEUTIC_CLASS Antineoplastics 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT BBM_2_Anemia 18883-66-4 STREPTOZOTOCIN MESH_LEVEL_3 Nitrosourea Compounds 18883-66-4 STREPTOZOTOCIN MESH_LEVEL_1 Organic Chemicals 18883-66-4 STREPTOZOTOCIN MECH_LEVEL_3 DNA damage 18883-66-4 STREPTOZOTOCIN INDICATION Hodgkin's Disease 18883-66-4 STREPTOZOTOCIN TA_LEVEL_3 pancreas tumors 18883-66-4 STREPTOZOTOCIN INDICATION Islet Cell Tumors 18883-66-4 STREPTOZOTOCIN TA_LEVEL_1 Oncology 18883-66-4 STREPTOZOTOCIN MECHANISM Inhibit DNA synthesis, repair, and function 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT END_2_Diabetes 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT DNA_2_Carcinogenicity 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT END_2_Hypoglycemia 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT GIS_1_Vomiting 18883-66-4 STREPTOZOTOCIN ZERO_CLASS N 18883-66-4 STREPTOZOTOCIN KNOWN_TOXICITY Hepatotoxicity 18883-66-4 STREPTOZOTOCIN TISSUE_TOXICITY Carcinogenicity 18883-66-4 STREPTOZOTOCIN MESH_LEVEL_2 Nitroso Compounds 18883-66-4 STREPTOZOTOCIN PRODUCT_CLASS Anti-cancers 18883-66-4 STREPTOZOTOCIN INDICATION Colorectal Cancer / Carcinoma of the Colon and Rectum 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT PSY_3_Confusion 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT XXX_2_Lethargy 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT GIS_1_Nausea 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT BBM_2_Leukopenia 18883-66-4 STREPTOZOTOCIN KNOWN_TOXICITY Nephrotoxicity 18883-66-4 STREPTOZOTOCIN TISSUE_TOXICITY Hepatotoxicity 18883-66-4 STREPTOZOTOCIN ACTIVITY_CLASS DNA damager 18883-66-4 STREPTOZOTOCIN MODE_CLASS Distorts /blocks macromolecular scaffold function 18883-66-4 STREPTOZOTOCIN TA_LEVEL_2 solid tumors 18883-66-4 STREPTOZOTOCIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 18883-66-4 STREPTOZOTOCIN INDICATION Carcinoid Tumors 18883-66-4 STREPTOZOTOCIN ADVERSE_EFFECT BBM_2_Myelosuppression 10025-70-4 STRONTIUM CHLORIDE HEXAHYDRATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 10025-70-4 STRONTIUM CHLORIDE HEXAHYDRATE INDICATION Osseous Metastasis 10025-70-4 STRONTIUM CHLORIDE HEXAHYDRATE ADVERSE_EFFECT BBM_3_Leukopenia 10025-70-4 STRONTIUM CHLORIDE HEXAHYDRATE THERAPEUTIC_CLASS Radioactive Agents 10025-70-4 STRONTIUM CHLORIDE HEXAHYDRATE PRODUCT_CLASS Other Human Uses 10025-70-4 STRONTIUM CHLORIDE HEXAHYDRATE ADVERSE_EFFECT MSK_3_Bone Pain 57-24-9 STRYCHNINE KNOWN_TOXICITY Neurotoxicity 57-24-9 STRYCHNINE TISSUE_TOXICITY Convulsions 57-24-9 STRYCHNINE ADVERSE_EFFECT END_1_Metabolic Acidosis 57-24-9 STRYCHNINE ADVERSE_EFFECT NEU_1_Opisthotonus 57-24-9 STRYCHNINE TISSUE_TOXICITY Hypoxia 57-24-9 STRYCHNINE THERAPEUTIC_CLASS Central Stimulants 57-24-9 STRYCHNINE KNOWN_TOXICITY Nephrotoxicity 57-24-9 STRYCHNINE STRUCTURE_ACTIVITY Glycine receptor antagonist 57-24-9 STRYCHNINE ADVERSE_EFFECT NEU_1_Convulsions 57-24-9 STRYCHNINE ADVERSE_EFFECT LUN_1_Hypoxia 57-24-9 STRYCHNINE ADVERSE_EFFECT XXX_1_Hyperthermia 57-24-9 STRYCHNINE KNOWN_TOXICITY Cardiovascular Toxicity 57-24-9 STRYCHNINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 57-24-9 STRYCHNINE TISSUE_TOXICITY Acute Renal Failure 57-24-9 STRYCHNINE PRODUCT_CLASS Toxicants 57-24-9 STRYCHNINE PRODUCT_CLASS Central Nervous System (CNS) 57-24-9 STRYCHNINE MECHANISM Modulate channel gating 57-24-9 STRYCHNINE MODE_CLASS Channel Blocker 57-24-9 STRYCHNINE MODE_CLASS Channel Modulator 57-24-9 STRYCHNINE KNOWN_TOXICITY Respiratory Toxicity 57-24-9 STRYCHNINE TISSUE_TOXICITY Opisthotonus 57-24-9 STRYCHNINE TISSUE_TOXICITY Cardiac Arrest 57-24-9 STRYCHNINE THERAPEUTIC_CLASS Insecticides / Pesticides 57-24-9 STRYCHNINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 57-24-9 STRYCHNINE ADVERSE_EFFECT MSK_1_Spasm 57-24-9 STRYCHNINE ADVERSE_EFFECT KID_3_Acute Renal Failure 57-24-9 STRYCHNINE MECHANISM Block neural transmission 57-24-9 STRYCHNINE ADVERSE_EFFECT NEU_1_Hyperreflexia 60-41-3 STRYCHNINE ADVERSE_EFFECT NEU_1_Convulsions 60-41-3 STRYCHNINE PRODUCT_CLASS Central Nervous System (CNS) 60-41-3 STRYCHNINE ADVERSE_EFFECT MSK_1_Spasm 60-41-3 STRYCHNINE TISSUE_TOXICITY Convulsions 60-41-3 STRYCHNINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 60-41-3 STRYCHNINE KNOWN_TOXICITY Respiratory Toxicity 60-41-3 STRYCHNINE MECHANISM Block neural transmission 60-41-3 STRYCHNINE ADVERSE_EFFECT NEU_1_Hyperreflexia 60-41-3 STRYCHNINE TISSUE_TOXICITY Opisthotonus 60-41-3 STRYCHNINE TISSUE_TOXICITY Hypoxia 60-41-3 STRYCHNINE THERAPEUTIC_CLASS Central Stimulants 60-41-3 STRYCHNINE KNOWN_TOXICITY Nephrotoxicity 60-41-3 STRYCHNINE ADVERSE_EFFECT XXX_1_Hyperthermia 60-41-3 STRYCHNINE STRUCTURE_ACTIVITY Glycine receptor antagonist 60-41-3 STRYCHNINE THERAPEUTIC_CLASS Insecticides / Pesticides 60-41-3 STRYCHNINE MODE_CLASS Channel Modulator 60-41-3 STRYCHNINE MODE_CLASS Channel Blocker 60-41-3 STRYCHNINE MECHANISM Modulate channel gating 60-41-3 STRYCHNINE ADVERSE_EFFECT NEU_1_Opisthotonus 60-41-3 STRYCHNINE ADVERSE_EFFECT END_1_Metabolic Acidosis 60-41-3 STRYCHNINE ADVERSE_EFFECT LUN_1_Hypoxia 60-41-3 STRYCHNINE PRODUCT_CLASS Toxicants 60-41-3 STRYCHNINE TISSUE_TOXICITY Acute Renal Failure 60-41-3 STRYCHNINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 60-41-3 STRYCHNINE KNOWN_TOXICITY Cardiovascular Toxicity 60-41-3 STRYCHNINE TISSUE_TOXICITY Cardiac Arrest 60-41-3 STRYCHNINE KNOWN_TOXICITY Neurotoxicity 60-41-3 STRYCHNINE ADVERSE_EFFECT KID_3_Acute Renal Failure 66-32-0 STRYCHNINE ADVERSE_EFFECT LUN_1_Hypoxia 66-32-0 STRYCHNINE ADVERSE_EFFECT MSK_1_Spasm 66-32-0 STRYCHNINE PRODUCT_CLASS Toxicants 66-32-0 STRYCHNINE PRODUCT_CLASS Central Nervous System (CNS) 66-32-0 STRYCHNINE THERAPEUTIC_CLASS Central Stimulants 66-32-0 STRYCHNINE ADVERSE_EFFECT XXX_1_Hyperthermia 66-32-0 STRYCHNINE KNOWN_TOXICITY Neurotoxicity 66-32-0 STRYCHNINE MECHANISM Modulate channel gating 66-32-0 STRYCHNINE KNOWN_TOXICITY Cardiovascular Toxicity 66-32-0 STRYCHNINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 66-32-0 STRYCHNINE TISSUE_TOXICITY Acute Renal Failure 66-32-0 STRYCHNINE STRUCTURE_ACTIVITY Glycine receptor antagonist 66-32-0 STRYCHNINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 66-32-0 STRYCHNINE THERAPEUTIC_CLASS Insecticides / Pesticides 66-32-0 STRYCHNINE TISSUE_TOXICITY Cardiac Arrest 66-32-0 STRYCHNINE MODE_CLASS Channel Modulator 66-32-0 STRYCHNINE MODE_CLASS Channel Blocker 66-32-0 STRYCHNINE ADVERSE_EFFECT NEU_1_Opisthotonus 66-32-0 STRYCHNINE ADVERSE_EFFECT END_1_Metabolic Acidosis 66-32-0 STRYCHNINE TISSUE_TOXICITY Convulsions 66-32-0 STRYCHNINE KNOWN_TOXICITY Respiratory Toxicity 66-32-0 STRYCHNINE MECHANISM Block neural transmission 66-32-0 STRYCHNINE ADVERSE_EFFECT NEU_1_Hyperreflexia 66-32-0 STRYCHNINE ADVERSE_EFFECT KID_3_Acute Renal Failure 66-32-0 STRYCHNINE TISSUE_TOXICITY Hypoxia 66-32-0 STRYCHNINE TISSUE_TOXICITY Opisthotonus 66-32-0 STRYCHNINE ADVERSE_EFFECT NEU_1_Convulsions 66-32-0 STRYCHNINE KNOWN_TOXICITY Nephrotoxicity 1421-86-9 STRYCHNINE TISSUE_TOXICITY Hypoxia 1421-86-9 STRYCHNINE ADVERSE_EFFECT KID_3_Acute Renal Failure 1421-86-9 STRYCHNINE ADVERSE_EFFECT MSK_1_Spasm 1421-86-9 STRYCHNINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 1421-86-9 STRYCHNINE THERAPEUTIC_CLASS Insecticides / Pesticides 1421-86-9 STRYCHNINE TISSUE_TOXICITY Cardiac Arrest 1421-86-9 STRYCHNINE ADVERSE_EFFECT XXX_1_Hyperthermia 1421-86-9 STRYCHNINE MODE_CLASS Channel Modulator 1421-86-9 STRYCHNINE KNOWN_TOXICITY Neurotoxicity 1421-86-9 STRYCHNINE THERAPEUTIC_CLASS Central Stimulants 1421-86-9 STRYCHNINE KNOWN_TOXICITY Nephrotoxicity 1421-86-9 STRYCHNINE STRUCTURE_ACTIVITY Glycine receptor antagonist 1421-86-9 STRYCHNINE ADVERSE_EFFECT LUN_1_Hypoxia 1421-86-9 STRYCHNINE KNOWN_TOXICITY Cardiovascular Toxicity 1421-86-9 STRYCHNINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 1421-86-9 STRYCHNINE TISSUE_TOXICITY Acute Renal Failure 1421-86-9 STRYCHNINE PRODUCT_CLASS Toxicants 1421-86-9 STRYCHNINE ADVERSE_EFFECT NEU_1_Convulsions 1421-86-9 STRYCHNINE ADVERSE_EFFECT NEU_1_Hyperreflexia 1421-86-9 STRYCHNINE MECHANISM Block neural transmission 1421-86-9 STRYCHNINE TISSUE_TOXICITY Opisthotonus 1421-86-9 STRYCHNINE TISSUE_TOXICITY Convulsions 1421-86-9 STRYCHNINE ADVERSE_EFFECT END_1_Metabolic Acidosis 1421-86-9 STRYCHNINE ADVERSE_EFFECT NEU_1_Opisthotonus 1421-86-9 STRYCHNINE PRODUCT_CLASS Central Nervous System (CNS) 1421-86-9 STRYCHNINE MECHANISM Modulate channel gating 1421-86-9 STRYCHNINE MODE_CLASS Channel Blocker 1421-86-9 STRYCHNINE KNOWN_TOXICITY Respiratory Toxicity 304-55-2 SUCCIMER INDICATION Heavy Metal Poisoning 71-27-2 SUXAMETHONIUM CHLORIDE ZERO_CLASS N 71-27-2 SUXAMETHONIUM CHLORIDE ACTIVITY_CLASS Nicotinic acetylcholine receptor agonist 71-27-2 SUXAMETHONIUM CHLORIDE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor agonist 71-27-2 SUXAMETHONIUM CHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 71-27-2 SUXAMETHONIUM CHLORIDE TISSUE_TOXICITY Ventricular Fibrillation 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT GIS_2_Increased Gastric Acid Secretion 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT XXX_2_Salivation 71-27-2 SUXAMETHONIUM CHLORIDE MESH_LEVEL_2 Amines 71-27-2 SUXAMETHONIUM CHLORIDE TA_LEVEL_1 Autonomic Nervous System (ANS) 71-27-2 SUXAMETHONIUM CHLORIDE MECH_LEVEL_1 Modulate neural transmission 71-27-2 SUXAMETHONIUM CHLORIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Arrhythmia 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT XXX_3_Malignant Hyperthermia 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Cardiac Arrest 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Hypotension 71-27-2 SUXAMETHONIUM CHLORIDE TISSUE_TOXICITY Hypotension 71-27-2 SUXAMETHONIUM CHLORIDE INDICATION Muscle Relaxation 71-27-2 SUXAMETHONIUM CHLORIDE MODE_CLASS Channel Modulator 71-27-2 SUXAMETHONIUM CHLORIDE MECH_LEVEL_2 Nicotinic agonist 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT MSK_3_Muscle Fasciculations 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT MSK_1_Muscle Pain 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Hypertension 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Bradycardia 71-27-2 SUXAMETHONIUM CHLORIDE TISSUE_TOXICITY Cardiac Arrest 71-27-2 SUXAMETHONIUM CHLORIDE TA_LEVEL_3 anesthesia adjuvant 71-27-2 SUXAMETHONIUM CHLORIDE MECH_LEVEL_3 Nicotinic acetylcholine receptor 71-27-2 SUXAMETHONIUM CHLORIDE MESH_LEVEL_1 Organic Chemicals 71-27-2 SUXAMETHONIUM CHLORIDE INDICATION Neuromuscular Blockade 71-27-2 SUXAMETHONIUM CHLORIDE MECHANISM Prolong/enhance neural transmission 71-27-2 SUXAMETHONIUM CHLORIDE TISSUE_TOXICITY Arrhythmia 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT GIS_2_Increased Frequency of Bowel Movements 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT XXX_3_Tachyphylaxis 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT ELT_2_Hyperkalemia 71-27-2 SUXAMETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Tachycardia 71-27-2 SUXAMETHONIUM CHLORIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 71-27-2 SUXAMETHONIUM CHLORIDE TA_LEVEL_2 muscle relaxant 71-27-2 SUXAMETHONIUM CHLORIDE MESH_LEVEL_3 Ammonium Compounds 54182-58-0 SUCRALFATE INDICATION Ulcer 56030-54-7 SUFENTANIL ADVERSE_EFFECT LUN_1_Respiratory Depression 56030-54-7 SUFENTANIL ADVERSE_EFFECT CVS_3_Hypotension 56030-54-7 SUFENTANIL ADVERSE_EFFECT CVS_3_Cardiac Arrest 56030-54-7 SUFENTANIL ADVERSE_EFFECT XXX_3_Tolerance 56030-54-7 SUFENTANIL ADVERSE_EFFECT NEU_3_Myoclonus 56030-54-7 SUFENTANIL ADVERSE_EFFECT PSY_3_CNS Excitation 56030-54-7 SUFENTANIL INDICATION Induction / Maintenance of Anesthesia 56030-54-7 SUFENTANIL MECHANISM Modulate neural transmission 56030-54-7 SUFENTANIL TISSUE_TOXICITY Cardiac Arrest 56030-54-7 SUFENTANIL INDICATION Chronic Pain Disorders 56030-54-7 SUFENTANIL ADVERSE_EFFECT NEU_3_Convulsions 56030-54-7 SUFENTANIL ADVERSE_EFFECT PSY_3_Delirium 56030-54-7 SUFENTANIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56030-54-7 SUFENTANIL ADVERSE_EFFECT SKN_3_Pruritis 56030-54-7 SUFENTANIL ADVERSE_EFFECT LUN_2_Hypoventilation 56030-54-7 SUFENTANIL ADVERSE_EFFECT PSY_2_Mental Confusion 56030-54-7 SUFENTANIL KNOWN_TOXICITY Respiratory Toxicity 56030-54-7 SUFENTANIL KNOWN_TOXICITY Cardiovascular Toxicity 56030-54-7 SUFENTANIL TISSUE_TOXICITY Hypotension 56030-54-7 SUFENTANIL ADVERSE_EFFECT CVS_1_Bradycardia 56030-54-7 SUFENTANIL MODE_CLASS Receptor Agonist, selective 56030-54-7 SUFENTANIL ADVERSE_EFFECT PSY_1_CNS Depression 56030-54-7 SUFENTANIL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 56030-54-7 SUFENTANIL ADVERSE_EFFECT LUN_3_Bronchospasm 56030-54-7 SUFENTANIL ADVERSE_EFFECT XXX_3_Withdrawal 56030-54-7 SUFENTANIL ADVERSE_EFFECT LUN_2_Apnea 56030-54-7 SUFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 56030-54-7 SUFENTANIL PRODUCT_CLASS Central Nervous System (CNS) 56030-54-7 SUFENTANIL ADVERSE_EFFECT GIS_2_Constipation 56030-54-7 SUFENTANIL TISSUE_TOXICITY Cardiac Arrhythmia 56030-54-7 SUFENTANIL ADVERSE_EFFECT NEU_1_Drowsiness 56030-54-7 SUFENTANIL ADVERSE_EFFECT PSY_2_Physical Dependence 56030-54-7 SUFENTANIL ADVERSE_EFFECT XXX_2_Chills 56030-54-7 SUFENTANIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 56030-54-7 SUFENTANIL TISSUE_TOXICITY Respiratory Depression 56030-54-7 SUFENTANIL PRODUCT_CLASS Analgesics 56030-54-7 SUFENTANIL THERAPEUTIC_CLASS General Anesthetics, Intravenous 56030-54-7 SUFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 56030-54-7 SUFENTANIL ADVERSE_EFFECT CVS_3_Hypertension 60561-17-3 SUFENTANIL PRODUCT_CLASS Central Nervous System (CNS) 60561-17-3 SUFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 60561-17-3 SUFENTANIL ADVERSE_EFFECT LUN_2_Apnea 60561-17-3 SUFENTANIL ADVERSE_EFFECT XXX_3_Withdrawal 60561-17-3 SUFENTANIL ADVERSE_EFFECT LUN_3_Bronchospasm 60561-17-3 SUFENTANIL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 60561-17-3 SUFENTANIL ADVERSE_EFFECT PSY_1_CNS Depression 60561-17-3 SUFENTANIL ADVERSE_EFFECT CVS_1_Bradycardia 60561-17-3 SUFENTANIL TISSUE_TOXICITY Hypotension 60561-17-3 SUFENTANIL KNOWN_TOXICITY Respiratory Toxicity 60561-17-3 SUFENTANIL ADVERSE_EFFECT PSY_2_Mental Confusion 60561-17-3 SUFENTANIL ADVERSE_EFFECT LUN_2_Hypoventilation 60561-17-3 SUFENTANIL ADVERSE_EFFECT SKN_3_Pruritis 60561-17-3 SUFENTANIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 60561-17-3 SUFENTANIL ADVERSE_EFFECT PSY_3_Delirium 60561-17-3 SUFENTANIL ADVERSE_EFFECT NEU_3_Convulsions 60561-17-3 SUFENTANIL TISSUE_TOXICITY Cardiac Arrest 60561-17-3 SUFENTANIL TISSUE_TOXICITY Respiratory Depression 60561-17-3 SUFENTANIL MODE_CLASS Receptor Agonist, selective 60561-17-3 SUFENTANIL INDICATION Chronic Pain Disorders 60561-17-3 SUFENTANIL MECHANISM Modulate neural transmission 60561-17-3 SUFENTANIL INDICATION Induction / Maintenance of Anesthesia 60561-17-3 SUFENTANIL ADVERSE_EFFECT PSY_3_CNS Excitation 60561-17-3 SUFENTANIL ADVERSE_EFFECT NEU_3_Myoclonus 60561-17-3 SUFENTANIL ADVERSE_EFFECT XXX_3_Tolerance 60561-17-3 SUFENTANIL ADVERSE_EFFECT CVS_3_Cardiac Arrest 60561-17-3 SUFENTANIL ADVERSE_EFFECT CVS_3_Hypotension 60561-17-3 SUFENTANIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 60561-17-3 SUFENTANIL ADVERSE_EFFECT XXX_2_Chills 60561-17-3 SUFENTANIL ADVERSE_EFFECT PSY_2_Physical Dependence 60561-17-3 SUFENTANIL ADVERSE_EFFECT CVS_3_Hypertension 60561-17-3 SUFENTANIL ADVERSE_EFFECT GIS_2_Constipation 60561-17-3 SUFENTANIL KNOWN_TOXICITY Cardiovascular Toxicity 60561-17-3 SUFENTANIL ADVERSE_EFFECT NEU_1_Drowsiness 60561-17-3 SUFENTANIL ADVERSE_EFFECT LUN_1_Respiratory Depression 60561-17-3 SUFENTANIL PRODUCT_CLASS Analgesics 60561-17-3 SUFENTANIL THERAPEUTIC_CLASS General Anesthetics, Intravenous 60561-17-3 SUFENTANIL THERAPEUTIC_CLASS Analgesics, Opioid 60561-17-3 SUFENTANIL TISSUE_TOXICITY Cardiac Arrhythmia 68373-14-8 SULBACTAM MESH_LEVEL_2 Amides 68373-14-8 SULBACTAM ZERO_CLASS N 68373-14-8 SULBACTAM ADVERSE_EFFECT GIS_2_Abdominal Distention 68373-14-8 SULBACTAM ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 68373-14-8 SULBACTAM ADVERSE_EFFECT GIS_1_Abdominal Pain 68373-14-8 SULBACTAM ADVERSE_EFFECT GIS_1_Stomatitis 68373-14-8 SULBACTAM ADVERSE_EFFECT BBM_3_Decreased Platelet Function 68373-14-8 SULBACTAM ADVERSE_EFFECT BBM_3_Thrombocytopenia 68373-14-8 SULBACTAM ADVERSE_EFFECT IMU_3_Urticaria 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_2_Facial Edema 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_1_Rash 68373-14-8 SULBACTAM ADVERSE_EFFECT IMU_3_Positive Coombs Test 68373-14-8 SULBACTAM ADVERSE_EFFECT GUS_2_Urinary Retention 68373-14-8 SULBACTAM TISSUE_TOXICITY Interstitial Nephritis 68373-14-8 SULBACTAM MODE_CLASS Enzyme Inhibitor 68373-14-8 SULBACTAM MESH_LEVEL_1 Organic Chemicals 68373-14-8 SULBACTAM MECH_LEVEL_1 Anti-bacterial 68373-14-8 SULBACTAM INDICATION Appendicitis 68373-14-8 SULBACTAM INDICATION Clostridial Diseases 68373-14-8 SULBACTAM INDICATION Listeriosis 68373-14-8 SULBACTAM INDICATION Skin and Skin Structure Infections 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_2_Glossitis 68373-14-8 SULBACTAM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_2_Pruritis 68373-14-8 SULBACTAM TA_LEVEL_3 systemic infections 68373-14-8 SULBACTAM MECHANISM Inhibit bacterial cell wall biosynthesis 68373-14-8 SULBACTAM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 68373-14-8 SULBACTAM TISSUE_TOXICITY Thrombosis 68373-14-8 SULBACTAM ADVERSE_EFFECT KID_3_Nephrotic Syndrome 68373-14-8 SULBACTAM ADVERSE_EFFECT CVS_2_Chest Pain 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_3_Superinfection 68373-14-8 SULBACTAM ADVERSE_EFFECT BBM_3_Leukopenia 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_3_Candidiasis 68373-14-8 SULBACTAM ADVERSE_EFFECT IMU_3_Anaphylaxis 68373-14-8 SULBACTAM ADVERSE_EFFECT NEU_2_Headache 68373-14-8 SULBACTAM ADVERSE_EFFECT PSY_2_Anorexia 68373-14-8 SULBACTAM THERAPEUTIC_CLASS Antibacterials, Systemic 68373-14-8 SULBACTAM PRODUCT_CLASS Anti-infectives 68373-14-8 SULBACTAM INDICATION Diabetic Foot Ulcer 68373-14-8 SULBACTAM INDICATION Diphtheria 68373-14-8 SULBACTAM INDICATION Intraabdominal Infections 68373-14-8 SULBACTAM INDICATION Salmonellosis 68373-14-8 SULBACTAM MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 68373-14-8 SULBACTAM ADVERSE_EFFECT BBM_3_Hematological Reactions 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_2_Malaise 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_2_Epistaxis 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_3_Chills 68373-14-8 SULBACTAM ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_2_Erythema 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_3_Maculopapular Rash 68373-14-8 SULBACTAM ADVERSE_EFFECT NEU_3_Seizures 68373-14-8 SULBACTAM ADVERSE_EFFECT BBM_3_Agranulocytosis 68373-14-8 SULBACTAM ADVERSE_EFFECT NEU_2_Dizziness 68373-14-8 SULBACTAM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 68373-14-8 SULBACTAM KNOWN_TOXICITY Cardiovascular Toxicity 68373-14-8 SULBACTAM TISSUE_TOXICITY Nephrotic Syndrome 68373-14-8 SULBACTAM INDICATION Cellulitis 68373-14-8 SULBACTAM INDICATION Gynecologic Infections 68373-14-8 SULBACTAM INDICATION Peritonitis 68373-14-8 SULBACTAM TA_LEVEL_2 Anti-bacterial 68373-14-8 SULBACTAM MESH_LEVEL_3 Lactams 68373-14-8 SULBACTAM STRUCTURE_ACTIVITY Bacterial beta-lactamase inhibitor 68373-14-8 SULBACTAM ADVERSE_EFFECT CVS_3_Thrombosis 68373-14-8 SULBACTAM ADVERSE_EFFECT KID_3_Interstitial Nephritis 68373-14-8 SULBACTAM ADVERSE_EFFECT GIS_2_Flatulence 68373-14-8 SULBACTAM ADVERSE_EFFECT GUS_3_Dysuria 68373-14-8 SULBACTAM ADVERSE_EFFECT CVS_2_Phlebitis 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 68373-14-8 SULBACTAM ADVERSE_EFFECT SKN_3_Erythema Multiforme 68373-14-8 SULBACTAM ADVERSE_EFFECT BBM_3_Anemia 68373-14-8 SULBACTAM ADVERSE_EFFECT IMU_1_Hypersensitivity 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_2_Edema 68373-14-8 SULBACTAM ADVERSE_EFFECT XXX_2_Fatigue 68373-14-8 SULBACTAM ADVERSE_EFFECT GIS_1_Diarrhea 68373-14-8 SULBACTAM KNOWN_TOXICITY Nephrotoxicity 68373-14-8 SULBACTAM TISSUE_TOXICITY Renal Tubular Necrosis 68373-14-8 SULBACTAM TA_LEVEL_1 Infectious Disease 68373-14-8 SULBACTAM INDICATION Brucellosis 68373-14-8 SULBACTAM INDICATION Endometritis 68373-14-8 SULBACTAM INDICATION Pelvic Inflammatory Disease (PID) 68373-14-8 SULBACTAM INDICATION Streptococcal Infections 127-71-9 SULFABENZAMIDE MECHANISM Inhibit precursor synthesis 127-71-9 SULFABENZAMIDE THERAPEUTIC_CLASS Antibacterials, Topical 127-71-9 SULFABENZAMIDE ADVERSE_EFFECT PSY_2_Irritation 127-71-9 SULFABENZAMIDE PRODUCT_CLASS Anti-infectives 127-71-9 SULFABENZAMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 127-71-9 SULFABENZAMIDE INDICATION Bacterial Vaginosis 127-71-9 SULFABENZAMIDE MODE_CLASS Enzyme Inhibitor 127-71-9 SULFABENZAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 127-71-9 SULFABENZAMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 127-71-9 SULFABENZAMIDE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor, isoxazol-sulfonamide 144-80-9 SULFACETAMIDE MECHANISM Inhibit precursor synthesis 144-80-9 SULFACETAMIDE MODE_CLASS Enzyme Inhibitor 17784-12-2 SULFACYTINE MODE_CLASS Enzyme Inhibitor 17784-12-2 SULFACYTINE MECHANISM Inhibit precursor synthesis 68-35-9 SULFADIAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 68-35-9 SULFADIAZINE ADVERSE_EFFECT CVS_3_Myocarditis 68-35-9 SULFADIAZINE MESH_LEVEL_2 Amides 68-35-9 SULFADIAZINE INDICATION Urinary Tract Infection (UTI) 68-35-9 SULFADIAZINE INDICATION Acute Rheumatic Fever 68-35-9 SULFADIAZINE INDICATION Nocardiosis 68-35-9 SULFADIAZINE INDICATION Cystitis 68-35-9 SULFADIAZINE ADVERSE_EFFECT PSY_2_Anorexia 68-35-9 SULFADIAZINE ADVERSE_EFFECT NEU_2_Headache 68-35-9 SULFADIAZINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 68-35-9 SULFADIAZINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 68-35-9 SULFADIAZINE ADVERSE_EFFECT SKN_3_Epidermal Necrosis 68-35-9 SULFADIAZINE ACTIVITY_CLASS Antibiotic, sulfonamide 68-35-9 SULFADIAZINE TA_LEVEL_2 Anti-bacterial 68-35-9 SULFADIAZINE MECH_LEVEL_1 Anti-bacterial 68-35-9 SULFADIAZINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 68-35-9 SULFADIAZINE INDICATION Toxoplasmosis 68-35-9 SULFADIAZINE INDICATION Otitis Media 68-35-9 SULFADIAZINE MECH_LEVEL_2 Impaired Folic synthesis 68-35-9 SULFADIAZINE PRODUCT_CLASS Anti-infectives 68-35-9 SULFADIAZINE INDICATION Malaria 68-35-9 SULFADIAZINE INDICATION Meningitis 68-35-9 SULFADIAZINE INDICATION Chancroid 68-35-9 SULFADIAZINE ZERO_CLASS N 68-35-9 SULFADIAZINE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 68-35-9 SULFADIAZINE MECHANISM Inhibit precursor synthesis 68-35-9 SULFADIAZINE MESH_LEVEL_3 Sulfonamides 68-35-9 SULFADIAZINE MODE_CLASS Enzyme substrate mimic 68-35-9 SULFADIAZINE ADVERSE_EFFECT PSY_3_Depression 68-35-9 SULFADIAZINE ADVERSE_EFFECT END_3_Hypoglycemia 68-35-9 SULFADIAZINE INDICATION Rheumatic Fever Prophylaxis 68-35-9 SULFADIAZINE TA_LEVEL_1 Infectious Disease 68-35-9 SULFADIAZINE ADVERSE_EFFECT NEU_3_Ataxia 68-35-9 SULFADIAZINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 68-35-9 SULFADIAZINE ADVERSE_EFFECT PSY_2_Insomnia 68-35-9 SULFADIAZINE ADVERSE_EFFECT OTO_3_Tinnitus 68-35-9 SULFADIAZINE ADVERSE_EFFECT GUS_3_Diuresis 68-35-9 SULFADIAZINE ADVERSE_EFFECT END_3_Goiter 68-35-9 SULFADIAZINE ADVERSE_EFFECT XXX_3_Drug Fever 68-35-9 SULFADIAZINE INDICATION Keratoconjunctivitis 68-35-9 SULFADIAZINE TA_LEVEL_3 topical infections 68-35-9 SULFADIAZINE INDICATION Acute Pyelonephritis 68-35-9 SULFADIAZINE INDICATION Chlamydia Trachomatis Infections 68-35-9 SULFADIAZINE MECH_LEVEL_3 Dihydropteroate synthase 68-35-9 SULFADIAZINE MESH_LEVEL_1 Organic Chemicals 68-35-9 SULFADIAZINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 68-35-9 SULFADIAZINE ADVERSE_EFFECT IMU_3_Serum Sickness 68-35-9 SULFADIAZINE ADVERSE_EFFECT KID_2_Crystalluria 68-35-9 SULFADIAZINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 68-35-9 SULFADIAZINE ADVERSE_EFFECT IMU_1_Allergic Reactions 68-35-9 SULFADIAZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 68-35-9 SULFADIAZINE ADVERSE_EFFECT GIS_2_Diarrhea 68-35-9 SULFADIAZINE KNOWN_TOXICITY Cardiovascular Toxicity 68-35-9 SULFADIAZINE TISSUE_TOXICITY Myocarditis 68-35-9 SULFADIAZINE THERAPEUTIC_CLASS Antibacterials, Systemic 2447-57-6 SULFADOXINE MECHANISM Inhibit precursor synthesis 2447-57-6 SULFADOXINE INDICATION Malaria 2447-57-6 SULFADOXINE MESH_LEVEL_2 Amides 2447-57-6 SULFADOXINE THERAPEUTIC_CLASS Antiparasitics 2447-57-6 SULFADOXINE KNOWN_TOXICITY Hepatotoxicity 2447-57-6 SULFADOXINE PRODUCT_CLASS Anti-infectives 2447-57-6 SULFADOXINE ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 2447-57-6 SULFADOXINE ADVERSE_EFFECT PSY_1_Anorexia 2447-57-6 SULFADOXINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 2447-57-6 SULFADOXINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 2447-57-6 SULFADOXINE ADVERSE_EFFECT SKN_2_Skin Rash 2447-57-6 SULFADOXINE TA_LEVEL_2 Anti-bacterial 2447-57-6 SULFADOXINE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 2447-57-6 SULFADOXINE MECH_LEVEL_1 Anti-bacterial 2447-57-6 SULFADOXINE MODE_CLASS Enzyme Inhibitor 2447-57-6 SULFADOXINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 2447-57-6 SULFADOXINE ADVERSE_EFFECT BBM_3_Myelotoxicity 2447-57-6 SULFADOXINE ADVERSE_EFFECT SKN_2_Erythema Multiforme 2447-57-6 SULFADOXINE ADVERSE_EFFECT BBM_3_Agranulocytosis 2447-57-6 SULFADOXINE MECH_LEVEL_3 Dihydropteroate synthase 2447-57-6 SULFADOXINE MECH_LEVEL_2 Impaired Folic synthesis 2447-57-6 SULFADOXINE MESH_LEVEL_3 Sulfonamides 2447-57-6 SULFADOXINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 2447-57-6 SULFADOXINE ADVERSE_EFFECT KID_1_Crystalluria 2447-57-6 SULFADOXINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 2447-57-6 SULFADOXINE ADVERSE_EFFECT NEU_1_Headache 2447-57-6 SULFADOXINE MESH_LEVEL_1 Organic Chemicals 2447-57-6 SULFADOXINE TA_LEVEL_3 Systemic infections 2447-57-6 SULFADOXINE TA_LEVEL_1 Infectious Disease 2447-57-6 SULFADOXINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 2447-57-6 SULFADOXINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 2447-57-6 SULFADOXINE ADVERSE_EFFECT IMU_2_Photosensitivity 2447-57-6 SULFADOXINE TISSUE_TOXICITY Hepatotoxicity 2447-57-6 SULFADOXINE ACTIVITY_CLASS Antibiotic, sulfonamide 2447-57-6 SULFADOXINE ZERO_CLASS N 127-79-7 SULFAMERAZINE ADVERSE_EFFECT KID_3_Renal Insufficiency 127-79-7 SULFAMERAZINE MODE_CLASS Enzyme Inhibitor 127-79-7 SULFAMERAZINE PRODUCT_CLASS Anti-infectives 127-79-7 SULFAMERAZINE INDICATION Psittacosis / Ornithosis 127-79-7 SULFAMERAZINE INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 127-79-7 SULFAMERAZINE INDICATION Cholera 127-79-7 SULFAMERAZINE MECHANISM Inhibit precursor synthesis 127-79-7 SULFAMERAZINE ADVERSE_EFFECT NEU_3_Aseptic Meningitis 127-79-7 SULFAMERAZINE ADVERSE_EFFECT KID_2_Crystalluria 127-79-7 SULFAMERAZINE ADVERSE_EFFECT IMU_3_Allergic Reactions 127-79-7 SULFAMERAZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 127-79-7 SULFAMERAZINE INDICATION Lymphogranuloma Venereum (LGV) 127-79-7 SULFAMERAZINE INDICATION Haemophilus Influenzae 127-79-7 SULFAMERAZINE INDICATION Chlamydia Trachomatis Infections 127-79-7 SULFAMERAZINE THERAPEUTIC_CLASS Antibacterials, Systemic 127-79-7 SULFAMERAZINE ADVERSE_EFFECT _3_Lyell Syndrome 127-79-7 SULFAMERAZINE ADVERSE_EFFECT IMU_3_Photosensitization 127-79-7 SULFAMERAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 127-79-7 SULFAMERAZINE ADVERSE_EFFECT LIV_3_Acute Hepatitis 127-79-7 SULFAMERAZINE INDICATION Pneumonia 127-79-7 SULFAMERAZINE INDICATION Malaria 127-79-7 SULFAMERAZINE INDICATION Staphylococcus Aureus Infections 127-79-7 SULFAMERAZINE INDICATION Shigellosis 127-79-7 SULFAMERAZINE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 127-79-7 SULFAMERAZINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 127-79-7 SULFAMERAZINE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor, isoxazol-sulfonamide 127-79-7 SULFAMERAZINE ADVERSE_EFFECT IMU_3_Lupus Erythematosus 127-79-7 SULFAMERAZINE THERAPEUTIC_CLASS Antiparasitics 127-79-7 SULFAMERAZINE ADVERSE_EFFECT BBM_3_Leukopenia 127-79-7 SULFAMERAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 127-79-7 SULFAMERAZINE INDICATION Toxoplasmosis 127-79-7 SULFAMERAZINE INDICATION Pneumococcal Pneumonia 127-79-7 SULFAMERAZINE INDICATION Anthrax 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT NEU_3_Optic Neuropathy 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT OCU_3_Retinal Hemorrhages 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT IMU_2_Photosensitivity 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT SKN_3_Fixed Drug Eruption 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 57-68-1 SULFAMETHAZINE THERAPEUTIC_CLASS Antibacterials 57-68-1 SULFAMETHAZINE TISSUE_TOXICITY Hematuria 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT SKN_3_Rash 57-68-1 SULFAMETHAZINE INDICATION Urinary Tract Infection (UTI) 57-68-1 SULFAMETHAZINE MECHANISM Inhibit precursor synthesis 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT BBM_3_Purpura 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT XXX_3_Fever 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT LUN_3_Cyanosis 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT SKN_3_Bullous Rash 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT BBM_3_Leukopenia 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT IMU_3_Urticaria 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT OCU_3_Paralysis of the Extraocular Muscles 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT KID_3_Crystalluria 57-68-1 SULFAMETHAZINE INDICATION Meningococcal Meningitis 57-68-1 SULFAMETHAZINE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor, pyrimidin-sulfonamide 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT CVS_3_Vasculitis 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT KID_3_Hematuria 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT BBM_3_Induces Hemolysis in G6PD Deficiency 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT OCU_3_Iritis 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT _3_Erythema Nodosum 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT LIV_3_Hepatitis 57-68-1 SULFAMETHAZINE KNOWN_TOXICITY Nephrotoxicity 57-68-1 SULFAMETHAZINE PRODUCT_CLASS Anti-infectives 57-68-1 SULFAMETHAZINE TISSUE_TOXICITY Anuria 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT KID_3_Anuria 57-68-1 SULFAMETHAZINE ADVERSE_EFFECT GIS_3_Pancreatitis 57-68-1 SULFAMETHAZINE MODE_CLASS Enzyme Inhibitor 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT SKN_2_Erythema Multiforme 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 144-82-1 SULFAMETHIZOLE THERAPEUTIC_CLASS Antibacterials 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT KID_1_Crystalluria 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT SKN_2_Morbilliform Rash 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT BBM_3_Myelotoxicity 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT XXX_2_Fever 144-82-1 SULFAMETHIZOLE MECHANISM Inhibit precursor synthesis 144-82-1 SULFAMETHIZOLE PRODUCT_CLASS Anti-infectives 144-82-1 SULFAMETHIZOLE KNOWN_TOXICITY Hepatotoxicity 144-82-1 SULFAMETHIZOLE TISSUE_TOXICITY Hepatotoxicity 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT SKN_2_Skin Rash 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT BBM_3_Aplastic Anemia 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT NEU_1_Headache 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT PSY_1_Anorexia 144-82-1 SULFAMETHIZOLE MODE_CLASS Enzyme Inhibitor 144-82-1 SULFAMETHIZOLE INDICATION Urinary Tract Infection (UTI) 144-82-1 SULFAMETHIZOLE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor, isoxazol-sulfonamide 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT NEU_2_Kernicterus 144-82-1 SULFAMETHIZOLE ADVERSE_EFFECT IMU_2_Photosensitivity 723-46-6 SULFAMETHOXAZOLE KNOWN_TOXICITY Hepatotoxicity 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT PSY_1_Anorexia 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT SKN_2_Erythema Multiforme 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT IMU_2_Photosensitivity 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT NEU_3_Kernicterus 723-46-6 SULFAMETHOXAZOLE ACTIVITY_CLASS Antibiotic, sulfonamide 723-46-6 SULFAMETHOXAZOLE ZERO_CLASS N 723-46-6 SULFAMETHOXAZOLE TA_LEVEL_2 Anti-bacterial 723-46-6 SULFAMETHOXAZOLE MESH_LEVEL_2 Amides 723-46-6 SULFAMETHOXAZOLE INDICATION Urinary Tract Infection (UTI) 723-46-6 SULFAMETHOXAZOLE INDICATION Traveler's Diarrhea 723-46-6 SULFAMETHOXAZOLE PRODUCT_CLASS Anti-infectives 723-46-6 SULFAMETHOXAZOLE THERAPEUTIC_CLASS Antibacterials 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT XXX_2_Fever 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT NEU_1_Headache 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT BBM_3_Aplastic Anemia 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT SKN_1_Skin Rash 723-46-6 SULFAMETHOXAZOLE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 723-46-6 SULFAMETHOXAZOLE INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 723-46-6 SULFAMETHOXAZOLE THERAPEUTIC_CLASS Antiparasitics 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 723-46-6 SULFAMETHOXAZOLE MESH_LEVEL_1 Organic Chemicals 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT SKN_2_Morbilliform Rash 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT KID_1_Crystalluria 723-46-6 SULFAMETHOXAZOLE INDICATION Acute Otitis Media 723-46-6 SULFAMETHOXAZOLE MECH_LEVEL_1 Anti-bacterial 723-46-6 SULFAMETHOXAZOLE INDICATION Shigellosis 723-46-6 SULFAMETHOXAZOLE TISSUE_TOXICITY Hepatotoxicity 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT BBM_3_Myelotoxicity 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 723-46-6 SULFAMETHOXAZOLE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 723-46-6 SULFAMETHOXAZOLE MODE_CLASS Enzyme Inhibitor 723-46-6 SULFAMETHOXAZOLE MECH_LEVEL_2 Impaired Folic synthesis 723-46-6 SULFAMETHOXAZOLE MESH_LEVEL_3 Sulfonamides 723-46-6 SULFAMETHOXAZOLE INDICATION Pneumocystis Carinii Pneumonia (PCP) 723-46-6 SULFAMETHOXAZOLE TA_LEVEL_3 Systemic infections 723-46-6 SULFAMETHOXAZOLE MECH_LEVEL_3 Dihydropteroate synthase 723-46-6 SULFAMETHOXAZOLE TA_LEVEL_1 Infectious Disease 723-46-6 SULFAMETHOXAZOLE MECHANISM Inhibit precursor synthesis 63-74-1 SULFANILAMIDE MODE_CLASS Enzyme Inhibitor 63-74-1 SULFANILAMIDE PRODUCT_CLASS Anti-infectives 63-74-1 SULFANILAMIDE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 63-74-1 SULFANILAMIDE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 63-74-1 SULFANILAMIDE MECHANISM Inhibit precursor synthesis 63-74-1 SULFANILAMIDE TA_LEVEL_1 Infectious Disease 63-74-1 SULFANILAMIDE TA_LEVEL_3 vaginitis 63-74-1 SULFANILAMIDE MECH_LEVEL_3 Dihydropteroate synthase 63-74-1 SULFANILAMIDE MESH_LEVEL_1 Organic Chemicals 63-74-1 SULFANILAMIDE ACTIVITY_CLASS Antibiotic, sulfonamide 63-74-1 SULFANILAMIDE ADVERSE_EFFECT XXX_1_Burning Sensation 63-74-1 SULFANILAMIDE MESH_LEVEL_3 Sulfonamides 63-74-1 SULFANILAMIDE MECH_LEVEL_2 Impaired Folic synthesis 63-74-1 SULFANILAMIDE TA_LEVEL_2 Anti-bacterial 63-74-1 SULFANILAMIDE ZERO_CLASS N 63-74-1 SULFANILAMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 63-74-1 SULFANILAMIDE THERAPEUTIC_CLASS Antifungals, Topical 63-74-1 SULFANILAMIDE INDICATION Vulvovaginal Candidiasis 63-74-1 SULFANILAMIDE MESH_LEVEL_2 Amides 63-74-1 SULFANILAMIDE MECH_LEVEL_1 Anti-bacterial 599-79-1 SULFASALAZINE ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 599-79-1 SULFASALAZINE ADVERSE_EFFECT IMU_2_Hypersensitivity 599-79-1 SULFASALAZINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 599-79-1 SULFASALAZINE MECHANISM Inhibit inflammatory response 599-79-1 SULFASALAZINE INDICATION Ulcerative Colitis 599-79-1 SULFASALAZINE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 599-79-1 SULFASALAZINE ADVERSE_EFFECT BBM_3_Myelosuppression 599-79-1 SULFASALAZINE ADVERSE_EFFECT NEU_3_Kernicterus 599-79-1 SULFASALAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 599-79-1 SULFASALAZINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 599-79-1 SULFASALAZINE ADVERSE_EFFECT NEU_3_Convulsions 599-79-1 SULFASALAZINE ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 599-79-1 SULFASALAZINE ADVERSE_EFFECT GUS_1_Orange Color Urine 599-79-1 SULFASALAZINE ADVERSE_EFFECT NEU_1_Headache 599-79-1 SULFASALAZINE PRODUCT_CLASS Anti-inflammatories 599-79-1 SULFASALAZINE MODE_CLASS Enzyme Inhibitor, selective 599-79-1 SULFASALAZINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 599-79-1 SULFASALAZINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 599-79-1 SULFASALAZINE ADVERSE_EFFECT SKN_2_Skin Rash 599-79-1 SULFASALAZINE KNOWN_TOXICITY Hepatotoxicity 599-79-1 SULFASALAZINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 599-79-1 SULFASALAZINE ADVERSE_EFFECT KID_3_Nephrotoxicity 599-79-1 SULFASALAZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 599-79-1 SULFASALAZINE TISSUE_TOXICITY Nephrotoxicity 599-79-1 SULFASALAZINE ADVERSE_EFFECT END_3_Exacerbation of Porphyria 599-79-1 SULFASALAZINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 599-79-1 SULFASALAZINE ADVERSE_EFFECT GIS_3_Pancreatitis 599-79-1 SULFASALAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 599-79-1 SULFASALAZINE ADVERSE_EFFECT IMU_1_Photosensitivity 599-79-1 SULFASALAZINE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 599-79-1 SULFASALAZINE TISSUE_TOXICITY Hepatotoxicity 599-79-1 SULFASALAZINE INDICATION Still's Disease / Juvenile Chronic Arthritis 599-79-1 SULFASALAZINE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 599-79-1 SULFASALAZINE INDICATION Rheumatoid Arthritis 599-79-1 SULFASALAZINE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 599-79-1 SULFASALAZINE KNOWN_TOXICITY Nephrotoxicity 599-79-1 SULFASALAZINE ADVERSE_EFFECT XXX_2_Fever 599-79-1 SULFASALAZINE ADVERSE_EFFECT IMU_3_Anaphylaxis 599-79-1 SULFASALAZINE ADVERSE_EFFECT PSY_1_Anorexia 72-14-0 SULFATHIAZOLE TA_LEVEL_1 Infectious Disease 72-14-0 SULFATHIAZOLE TISSUE_TOXICITY Hepatotoxicity 72-14-0 SULFATHIAZOLE STRUCTURE_ACTIVITY Bacterial folate synthesis inhibitor, dihydropteroate synthase inhibitor 72-14-0 SULFATHIAZOLE MESH_LEVEL_2 Amides 72-14-0 SULFATHIAZOLE ADVERSE_EFFECT LIV_3_Hepatotoxicity 72-14-0 SULFATHIAZOLE THERAPEUTIC_CLASS Antibacterials, Topical 72-14-0 SULFATHIAZOLE KNOWN_TOXICITY Hepatotoxicity 72-14-0 SULFATHIAZOLE TA_LEVEL_2 Anti-bacterial 72-14-0 SULFATHIAZOLE MECH_LEVEL_1 Anti-bacterial 72-14-0 SULFATHIAZOLE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 72-14-0 SULFATHIAZOLE ADVERSE_EFFECT SKN_3_Skin Rash 72-14-0 SULFATHIAZOLE MECHANISM Inhibit precursor synthesis 72-14-0 SULFATHIAZOLE ZERO_CLASS N 72-14-0 SULFATHIAZOLE MESH_LEVEL_3 Sulfonamides 72-14-0 SULFATHIAZOLE MECH_LEVEL_2 Impaired Folic synthesis 72-14-0 SULFATHIAZOLE INDICATION Vaginitis 72-14-0 SULFATHIAZOLE MODE_CLASS Enzyme Inhibitor 72-14-0 SULFATHIAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 72-14-0 SULFATHIAZOLE ADVERSE_EFFECT BBM_3_Aplastic Anemia 72-14-0 SULFATHIAZOLE TA_LEVEL_3 vaginitis 72-14-0 SULFATHIAZOLE ACTIVITY_CLASS Antibiotic, sulfonamide 72-14-0 SULFATHIAZOLE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 72-14-0 SULFATHIAZOLE MESH_LEVEL_1 Organic Chemicals 72-14-0 SULFATHIAZOLE PRODUCT_CLASS Dermatologicals 72-14-0 SULFATHIAZOLE MECH_LEVEL_3 Dihydropteroate synthase 57-96-5 SULFINPYRAZONE TA_LEVEL_2 Uric acid elimination 57-96-5 SULFINPYRAZONE TA_LEVEL_3 Gout-Related Agents 57-96-5 SULFINPYRAZONE INDICATION Hyperuricemia 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Agranulocytosis 57-96-5 SULFINPYRAZONE MODE_CLASS Solute transporter inhibitor 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Anemia 57-96-5 SULFINPYRAZONE MECH_LEVEL_2 Block channel gating 57-96-5 SULFINPYRAZONE ZERO_CLASS N 57-96-5 SULFINPYRAZONE MESH_LEVEL_1 Heterocyclic Compounds 57-96-5 SULFINPYRAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 57-96-5 SULFINPYRAZONE MECH_LEVEL_3 Urate/Anion exchanger, Urate transporter 57-96-5 SULFINPYRAZONE MECH_LEVEL_1 Uric acid elimination 57-96-5 SULFINPYRAZONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 57-96-5 SULFINPYRAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT LUN_3_Bronchoconstriction 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 57-96-5 SULFINPYRAZONE THERAPEUTIC_CLASS Gout-Related Agents 57-96-5 SULFINPYRAZONE MESH_LEVEL_3 Pyrazoles 57-96-5 SULFINPYRAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 57-96-5 SULFINPYRAZONE INDICATION Gouty Arthritis 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT SKN_2_Rash 57-96-5 SULFINPYRAZONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 57-96-5 SULFINPYRAZONE STRUCTURE_ACTIVITY Organic anion transporter inhibitor 57-96-5 SULFINPYRAZONE ACTIVITY_CLASS Organic anion transporter inhibitor 39809-25-1 PENCICLOVIR ACTIVITY_CLASS Anti-viral 39809-25-1 PENCICLOVIR THERAPEUTIC_CLASS Antivirals, Topical 39809-25-1 PENCICLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 39809-25-1 PENCICLOVIR MESH_LEVEL_3 Purines 39809-25-1 PENCICLOVIR ZERO_CLASS N 39809-25-1 PENCICLOVIR ADVERSE_EFFECT SKN_2_Erythema 39809-25-1 PENCICLOVIR TA_LEVEL_3 herpes 39809-25-1 PENCICLOVIR PRODUCT_CLASS Anti-infectives 39809-25-1 PENCICLOVIR ADVERSE_EFFECT SKN_2_Skin Irritation 39809-25-1 PENCICLOVIR ADVERSE_EFFECT SKN_2_Maculopapular Rash 39809-25-1 PENCICLOVIR MECH_LEVEL_1 Anti-viral 39809-25-1 PENCICLOVIR INDICATION Herpes Labialis / Cold or Fever Sore 39809-25-1 PENCICLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 39809-25-1 PENCICLOVIR ADVERSE_EFFECT GIS_2_Dysgeusia 39809-25-1 PENCICLOVIR ADVERSE_EFFECT SKN_2_Pruritis 39809-25-1 PENCICLOVIR MESH_LEVEL_1 Heterocyclic Compounds 39809-25-1 PENCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 39809-25-1 PENCICLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 39809-25-1 PENCICLOVIR MECHANISM Inhibit viral DNA synthesis 39809-25-1 PENCICLOVIR TA_LEVEL_1 Infectious Disease 39809-25-1 PENCICLOVIR TA_LEVEL_2 Anti-viral 39809-25-1 PENCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 97845-62-0 PENCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 97845-62-0 PENCICLOVIR INDICATION Herpes Labialis / Cold or Fever Sore 97845-62-0 PENCICLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 97845-62-0 PENCICLOVIR MECHANISM Inhibit viral DNA synthesis 97845-62-0 PENCICLOVIR TA_LEVEL_1 Infectious Disease 97845-62-0 PENCICLOVIR TA_LEVEL_2 Anti-viral 97845-62-0 PENCICLOVIR ADVERSE_EFFECT GIS_2_Dysgeusia 97845-62-0 PENCICLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 97845-62-0 PENCICLOVIR MECH_LEVEL_1 Anti-viral 97845-62-0 PENCICLOVIR PRODUCT_CLASS Anti-infectives 97845-62-0 PENCICLOVIR TA_LEVEL_3 herpes 97845-62-0 PENCICLOVIR ADVERSE_EFFECT SKN_2_Erythema 97845-62-0 PENCICLOVIR ZERO_CLASS N 97845-62-0 PENCICLOVIR ADVERSE_EFFECT SKN_2_Skin Irritation 97845-62-0 PENCICLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 97845-62-0 PENCICLOVIR THERAPEUTIC_CLASS Antivirals, Topical 97845-62-0 PENCICLOVIR ADVERSE_EFFECT SKN_2_Maculopapular Rash 97845-62-0 PENCICLOVIR ACTIVITY_CLASS Anti-viral 97845-62-0 PENCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 97845-62-0 PENCICLOVIR MESH_LEVEL_1 Heterocyclic Compounds 97845-62-0 PENCICLOVIR ADVERSE_EFFECT SKN_2_Pruritis 97845-62-0 PENCICLOVIR MESH_LEVEL_3 Purines 52-67-5 PENICILLAMINE INDICATION Primary Biliary Cirrhosis 52-67-5 PENICILLAMINE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 52-67-5 PENICILLAMINE ADVERSE_EFFECT PSY_1_Anorexia 52-67-5 PENICILLAMINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 52-67-5 PENICILLAMINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 52-67-5 PENICILLAMINE ADVERSE_EFFECT BBM_2_Bone Marrow Depression 52-67-5 PENICILLAMINE ADVERSE_EFFECT MSK_3_Myositis 52-67-5 PENICILLAMINE ADVERSE_EFFECT GIS_1_Epigastric Pain 52-67-5 PENICILLAMINE TA_LEVEL_2 DMARDs 52-67-5 PENICILLAMINE ACTIVITY_CLASS Unknown mechanism 52-67-5 PENICILLAMINE KNOWN_TOXICITY Hepatotoxicity 52-67-5 PENICILLAMINE TISSUE_TOXICITY Hepatotoxicity 52-67-5 PENICILLAMINE TISSUE_TOXICITY Teratogenicity 52-67-5 PENICILLAMINE ZERO_CLASS Y 52-67-5 PENICILLAMINE INDICATION Wilson's Disease 52-67-5 PENICILLAMINE ADVERSE_EFFECT SKN_2_Pemphigus 52-67-5 PENICILLAMINE ADVERSE_EFFECT KID_3_Membranous Glomerulonephritis 52-67-5 PENICILLAMINE INDICATION Lead (Pb) Poisoning 52-67-5 PENICILLAMINE ADVERSE_EFFECT EMB_2_Teratogenicity 52-67-5 PENICILLAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 52-67-5 PENICILLAMINE ADVERSE_EFFECT IMU_1_Allergic Reactions 52-67-5 PENICILLAMINE ADVERSE_EFFECT KID_2_Renal Stones 52-67-5 PENICILLAMINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 52-67-5 PENICILLAMINE ADVERSE_EFFECT KID_2_Hematuria 52-67-5 PENICILLAMINE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 52-67-5 PENICILLAMINE ADVERSE_EFFECT XXX_1_Taste Disturbances 52-67-5 PENICILLAMINE ADVERSE_EFFECT IMU_3_Myasthenia Gravis 52-67-5 PENICILLAMINE ADVERSE_EFFECT XXX_2_Iron Deficiency 52-67-5 PENICILLAMINE TISSUE_TOXICITY Membranous Glomerulonephritis 52-67-5 PENICILLAMINE PRODUCT_CLASS Other Human Uses 52-67-5 PENICILLAMINE MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 52-67-5 PENICILLAMINE MECH_LEVEL_1 Chelating Agents / Heavy Metal Antagonists 52-67-5 PENICILLAMINE INDICATION Rheumatoid Arthritis 52-67-5 PENICILLAMINE MESH_LEVEL_2 Amino Acids 52-67-5 PENICILLAMINE THERAPEUTIC_CLASS Chelating Agents / Heavy Metal Antagonists 52-67-5 PENICILLAMINE ADVERSE_EFFECT XXX_2_Fever 52-67-5 PENICILLAMINE ADVERSE_EFFECT OTO_3_Tinnitus 52-67-5 PENICILLAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 52-67-5 PENICILLAMINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 52-67-5 PENICILLAMINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 52-67-5 PENICILLAMINE ADVERSE_EFFECT NEU_3_Optic Neuritis 52-67-5 PENICILLAMINE ADVERSE_EFFECT CVS_3_Thrombophlebitis 52-67-5 PENICILLAMINE ADVERSE_EFFECT LUN_3_Bronchiolitis 52-67-5 PENICILLAMINE ADVERSE_EFFECT KID_3_Goodpasture's Syndrome 52-67-5 PENICILLAMINE TISSUE_TOXICITY Hematuria 52-67-5 PENICILLAMINE KNOWN_TOXICITY Nephrotoxicity 52-67-5 PENICILLAMINE TA_LEVEL_1 Anti-inflammatory 52-67-5 PENICILLAMINE INDICATION Cystinuria 52-67-5 PENICILLAMINE ADVERSE_EFFECT GIS_1_Diarrhea 52-67-5 PENICILLAMINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 52-67-5 PENICILLAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 52-67-5 PENICILLAMINE ADVERSE_EFFECT SKN_1_Pruritis 52-67-5 PENICILLAMINE ADVERSE_EFFECT BBM_2_Leukopenia 52-67-5 PENICILLAMINE ADVERSE_EFFECT KID_2_Proteinuria 52-67-5 PENICILLAMINE ADVERSE_EFFECT GIS_2_Stomatitis 52-67-5 PENICILLAMINE ADVERSE_EFFECT SKN_1_Skin Rash 52-67-5 PENICILLAMINE ADVERSE_EFFECT KID_3_Renal Vasculitis 52-67-5 PENICILLAMINE ADVERSE_EFFECT XXX_2_Impaired Healing 52-67-5 PENICILLAMINE TISSUE_TOXICITY Goodpasture's Syndrome 52-67-5 PENICILLAMINE KNOWN_TOXICITY Embryo/Fetal Toxicity 52-67-5 PENICILLAMINE STRUCTURE_ACTIVITY Unknown mechanism, inflammation mediator/ blocker 52-67-5 PENICILLAMINE PRODUCT_CLASS Anti-inflammatories 52-67-5 PENICILLAMINE MESH_LEVEL_3 Amino Acids, Sulfur 52-67-5 PENICILLAMINE TISSUE_TOXICITY Renal Vasculitis 90-65-3 PENICILLIC ACID ADVERSE_EFFECT LIV_2_Hepatotoxicity 90-65-3 PENICILLIC ACID TISSUE_TOXICITY Hepatotoxicity 90-65-3 PENICILLIC ACID KNOWN_TOXICITY Hepatotoxicity 90-65-3 PENICILLIC ACID MODE_CLASS Enzyme Inhibitor 90-65-3 PENICILLIC ACID PRODUCT_CLASS Toxicants 90-65-3 PENICILLIC ACID TISSUE_TOXICITY Genotoxicity 90-65-3 PENICILLIC ACID ADVERSE_EFFECT DNA_3_Genotoxicity 90-65-3 PENICILLIC ACID KNOWN_TOXICITY Carcinogenicity 90-65-3 PENICILLIC ACID MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 90-65-3 PENICILLIC ACID MECHANISM Inhibit DNA synthesis, repair, and function 90-65-3 PENICILLIC ACID ADVERSE_EFFECT BBM_2_Hemorrhage 90-65-3 PENICILLIC ACID TISSUE_TOXICITY Carcinogenicity 90-65-3 PENICILLIC ACID KNOWN_TOXICITY Mutagenicity 90-65-3 PENICILLIC ACID ADVERSE_EFFECT LIV_2_Hepatic Damage 90-65-3 PENICILLIC ACID ADVERSE_EFFECT DNA_2_Carcinogenicity 90-65-3 PENICILLIC ACID STRUCTURE_ACTIVITY Toxicant, mycotoxin/plant toxin 90-65-3 PENICILLIC ACID MECHANISM Increase cellular reactive oxygen species 74667-52-0 PENICILLIC ACID PRODUCT_CLASS Toxicants 74667-52-0 PENICILLIC ACID ADVERSE_EFFECT LIV_2_Hepatotoxicity 74667-52-0 PENICILLIC ACID TISSUE_TOXICITY Genotoxicity 74667-52-0 PENICILLIC ACID TISSUE_TOXICITY Hepatotoxicity 74667-52-0 PENICILLIC ACID ADVERSE_EFFECT LIV_2_Hepatic Damage 74667-52-0 PENICILLIC ACID ADVERSE_EFFECT DNA_3_Genotoxicity 74667-52-0 PENICILLIC ACID KNOWN_TOXICITY Carcinogenicity 74667-52-0 PENICILLIC ACID MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 74667-52-0 PENICILLIC ACID MECHANISM Inhibit DNA synthesis, repair, and function 74667-52-0 PENICILLIC ACID ADVERSE_EFFECT BBM_2_Hemorrhage 74667-52-0 PENICILLIC ACID MODE_CLASS Enzyme Inhibitor 74667-52-0 PENICILLIC ACID KNOWN_TOXICITY Hepatotoxicity 74667-52-0 PENICILLIC ACID MECHANISM Increase cellular reactive oxygen species 74667-52-0 PENICILLIC ACID STRUCTURE_ACTIVITY Toxicant, mycotoxin/plant toxin 74667-52-0 PENICILLIC ACID ADVERSE_EFFECT DNA_2_Carcinogenicity 74667-52-0 PENICILLIC ACID KNOWN_TOXICITY Mutagenicity 74667-52-0 PENICILLIC ACID TISSUE_TOXICITY Carcinogenicity 113-98-4 PENICILLIN G INDICATION Listeriosis 113-98-4 PENICILLIN G INDICATION Empyema 113-98-4 PENICILLIN G INDICATION Anthrax 113-98-4 PENICILLIN G ADVERSE_EFFECT GIS_1_Nausea / Vomiting 113-98-4 PENICILLIN G ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 113-98-4 PENICILLIN G ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 113-98-4 PENICILLIN G ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 113-98-4 PENICILLIN G ADVERSE_EFFECT XXX_1_Injection Site Reaction 113-98-4 PENICILLIN G TISSUE_TOXICITY Interstitial Nephritis 113-98-4 PENICILLIN G KNOWN_TOXICITY Nephrotoxicity 113-98-4 PENICILLIN G MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 113-98-4 PENICILLIN G MESH_LEVEL_1 Organic Chemicals 113-98-4 PENICILLIN G INDICATION Rat-Bite Fever / Spirillary Rat-Bite Fever / Sodoku 113-98-4 PENICILLIN G INDICATION Pinta 113-98-4 PENICILLIN G INDICATION Pericarditis 113-98-4 PENICILLIN G INDICATION Lower Respiratory Tract Infection 113-98-4 PENICILLIN G INDICATION Endocarditis 113-98-4 PENICILLIN G INDICATION Inhalational Anthrax 113-98-4 PENICILLIN G MECH_LEVEL_1 Anti-bacterial 113-98-4 PENICILLIN G MODE_CLASS Enzyme Inhibitor 113-98-4 PENICILLIN G TISSUE_TOXICITY Nephrotic Syndrome 113-98-4 PENICILLIN G ADVERSE_EFFECT GIS_1_Diarrhea 113-98-4 PENICILLIN G ADVERSE_EFFECT BBM_3_Anemia 113-98-4 PENICILLIN G ADVERSE_EFFECT BBM_3_Leukopenia 113-98-4 PENICILLIN G ADVERSE_EFFECT NEU_3_Neuropathy 113-98-4 PENICILLIN G ADVERSE_EFFECT ELT_2_Hypernatremia 113-98-4 PENICILLIN G TA_LEVEL_1 Infectious Disease 113-98-4 PENICILLIN G MECHANISM Inhibit bacterial cell wall biosynthesis 113-98-4 PENICILLIN G PRODUCT_CLASS Anti-infectives 113-98-4 PENICILLIN G MESH_LEVEL_2 Amides 113-98-4 PENICILLIN G INDICATION Skin and Skin Structure Infections 113-98-4 PENICILLIN G INDICATION Pharyngitis 113-98-4 PENICILLIN G INDICATION Meningitis 113-98-4 PENICILLIN G INDICATION Erysipelas 113-98-4 PENICILLIN G INDICATION Bacteremia 113-98-4 PENICILLIN G ADVERSE_EFFECT NEU_3_Seizures 113-98-4 PENICILLIN G ADVERSE_EFFECT BBM_3_Thrombocytopenia 113-98-4 PENICILLIN G ADVERSE_EFFECT GIS_2_Epigastric Pain 113-98-4 PENICILLIN G ADVERSE_EFFECT KID_3_Interstitial Nephritis 113-98-4 PENICILLIN G ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 113-98-4 PENICILLIN G MESH_LEVEL_3 Lactams 113-98-4 PENICILLIN G TA_LEVEL_2 Anti-bacterial 113-98-4 PENICILLIN G INDICATION Necrotizing Ulcerative Gingivitis (Trench Mouth, Vincent's Infection) 113-98-4 PENICILLIN G INDICATION Gonococcal Infections / Gonorrhea 113-98-4 PENICILLIN G INDICATION Diphtheria 113-98-4 PENICILLIN G INDICATION Yaws / Frambesia 113-98-4 PENICILLIN G THERAPEUTIC_CLASS Antibacterials, Systemic 113-98-4 PENICILLIN G ADVERSE_EFFECT IMU_1_Hypersensitivity 113-98-4 PENICILLIN G ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 113-98-4 PENICILLIN G ADVERSE_EFFECT CVS_1_Phlebitis 113-98-4 PENICILLIN G ADVERSE_EFFECT KID_3_Nephrotic Syndrome 113-98-4 PENICILLIN G STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 113-98-4 PENICILLIN G ZERO_CLASS N 113-98-4 PENICILLIN G INDICATION Rheumatic Fever Prophylaxis 113-98-4 PENICILLIN G MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 113-98-4 PENICILLIN G TA_LEVEL_3 systemic infections 113-98-4 PENICILLIN G INDICATION Upper Respiratory Tract Infection 113-98-4 PENICILLIN G INDICATION Acute Rheumatic Fever 113-98-4 PENICILLIN G INDICATION Neurosyphilis 132-98-9 PENICILLIN V THERAPEUTIC_CLASS Antibacterials, Systemic 132-98-9 PENICILLIN V ADVERSE_EFFECT SKN_2_Bullous Rash 132-98-9 PENICILLIN V ADVERSE_EFFECT GIS_3_Esophageal Ulceration 132-98-9 PENICILLIN V ADVERSE_EFFECT BBM_3_Leukopenia 132-98-9 PENICILLIN V ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 132-98-9 PENICILLIN V ADVERSE_EFFECT BBM_3_Agranulocytosis 132-98-9 PENICILLIN V ADVERSE_EFFECT GIS_1_Nausea / Vomiting 132-98-9 PENICILLIN V INDICATION Tonsillitis 132-98-9 PENICILLIN V INDICATION Pharyngitis 132-98-9 PENICILLIN V ADVERSE_EFFECT _3_Erythema Nodosum 132-98-9 PENICILLIN V KNOWN_TOXICITY Nephrotoxicity 132-98-9 PENICILLIN V ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 132-98-9 PENICILLIN V ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 132-98-9 PENICILLIN V ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 132-98-9 PENICILLIN V INDICATION Otitis Media 132-98-9 PENICILLIN V INDICATION Staphylococcus Aureus Infections 132-98-9 PENICILLIN V INDICATION Bacterial Endocarditis Prophylaxis 132-98-9 PENICILLIN V MODE_CLASS Enzyme Inhibitor 132-98-9 PENICILLIN V TISSUE_TOXICITY Nephrotic Syndrome 132-98-9 PENICILLIN V ADVERSE_EFFECT IMU_1_Allergic Reactions 132-98-9 PENICILLIN V ADVERSE_EFFECT NEU_3_Seizures 132-98-9 PENICILLIN V ADVERSE_EFFECT SKN_1_Maculopapular Rash 132-98-9 PENICILLIN V ADVERSE_EFFECT GIS_1_Abdominal Pain 132-98-9 PENICILLIN V ADVERSE_EFFECT SKN_1_Pruritis 132-98-9 PENICILLIN V ADVERSE_EFFECT BBM_3_Hemolytic Anemia 132-98-9 PENICILLIN V TISSUE_TOXICITY Renal Tubular Necrosis 132-98-9 PENICILLIN V MECHANISM Inhibit bacterial cell wall biosynthesis 132-98-9 PENICILLIN V ADVERSE_EFFECT KID_3_Nephrotic Syndrome 132-98-9 PENICILLIN V INDICATION Scarlet Fever 132-98-9 PENICILLIN V PRODUCT_CLASS Anti-infectives 132-98-9 PENICILLIN V INDICATION Upper Respiratory Tract Infection 132-98-9 PENICILLIN V INDICATION Skin Infections 132-98-9 PENICILLIN V INDICATION Streptococcal Infections 132-98-9 PENICILLIN V ADVERSE_EFFECT KID_3_Interstitial Nephritis 132-98-9 PENICILLIN V ADVERSE_EFFECT GIS_3_Esophagitis 132-98-9 PENICILLIN V ADVERSE_EFFECT BBM_3_Thrombocytopenia 132-98-9 PENICILLIN V ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 132-98-9 PENICILLIN V ADVERSE_EFFECT IMU_3_Anaphylaxis 132-98-9 PENICILLIN V ADVERSE_EFFECT GIS_2_Diarrhea 132-98-9 PENICILLIN V TISSUE_TOXICITY Interstitial Nephritis 132-98-9 PENICILLIN V INDICATION Soft Tissue Infections 132-98-9 PENICILLIN V INDICATION Staphylococcus epidermidis 132-98-9 PENICILLIN V STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 87-08-1 PENICILLIN V INDICATION Streptococcal Infections 87-08-1 PENICILLIN V INDICATION Upper Respiratory Tract Infection 87-08-1 PENICILLIN V INDICATION Skin Infections 87-08-1 PENICILLIN V PRODUCT_CLASS Anti-infectives 87-08-1 PENICILLIN V KNOWN_TOXICITY Nephrotoxicity 87-08-1 PENICILLIN V ADVERSE_EFFECT KID_3_Nephrotic Syndrome 87-08-1 PENICILLIN V ADVERSE_EFFECT GIS_1_Abdominal Pain 87-08-1 PENICILLIN V ADVERSE_EFFECT SKN_1_Maculopapular Rash 87-08-1 PENICILLIN V ADVERSE_EFFECT NEU_3_Seizures 87-08-1 PENICILLIN V ADVERSE_EFFECT IMU_1_Allergic Reactions 87-08-1 PENICILLIN V TISSUE_TOXICITY Nephrotic Syndrome 87-08-1 PENICILLIN V INDICATION Bacterial Endocarditis Prophylaxis 87-08-1 PENICILLIN V INDICATION Staphylococcus Aureus Infections 87-08-1 PENICILLIN V INDICATION Otitis Media 87-08-1 PENICILLIN V MODE_CLASS Enzyme Inhibitor 87-08-1 PENICILLIN V ADVERSE_EFFECT KID_3_Interstitial Nephritis 87-08-1 PENICILLIN V ADVERSE_EFFECT GIS_3_Esophagitis 87-08-1 PENICILLIN V ADVERSE_EFFECT BBM_3_Thrombocytopenia 87-08-1 PENICILLIN V ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 87-08-1 PENICILLIN V ADVERSE_EFFECT GIS_2_Diarrhea 87-08-1 PENICILLIN V TISSUE_TOXICITY Interstitial Nephritis 87-08-1 PENICILLIN V INDICATION Soft Tissue Infections 87-08-1 PENICILLIN V INDICATION Staphylococcus epidermidis 87-08-1 PENICILLIN V STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 87-08-1 PENICILLIN V THERAPEUTIC_CLASS Antibacterials, Systemic 87-08-1 PENICILLIN V ADVERSE_EFFECT SKN_2_Bullous Rash 87-08-1 PENICILLIN V ADVERSE_EFFECT GIS_3_Esophageal Ulceration 87-08-1 PENICILLIN V ADVERSE_EFFECT BBM_3_Leukopenia 87-08-1 PENICILLIN V ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 87-08-1 PENICILLIN V ADVERSE_EFFECT BBM_3_Agranulocytosis 87-08-1 PENICILLIN V ADVERSE_EFFECT GIS_1_Nausea / Vomiting 87-08-1 PENICILLIN V INDICATION Tonsillitis 87-08-1 PENICILLIN V INDICATION Pharyngitis 87-08-1 PENICILLIN V ADVERSE_EFFECT _3_Erythema Nodosum 87-08-1 PENICILLIN V ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 87-08-1 PENICILLIN V ADVERSE_EFFECT IMU_3_Anaphylaxis 87-08-1 PENICILLIN V ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 87-08-1 PENICILLIN V ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 87-08-1 PENICILLIN V ADVERSE_EFFECT SKN_1_Pruritis 87-08-1 PENICILLIN V ADVERSE_EFFECT BBM_3_Hemolytic Anemia 87-08-1 PENICILLIN V TISSUE_TOXICITY Renal Tubular Necrosis 87-08-1 PENICILLIN V MECHANISM Inhibit bacterial cell wall biosynthesis 87-08-1 PENICILLIN V INDICATION Scarlet Fever 100-33-4 PENTAMIDINE INDICATION African Trypanosomiasis / Sleeping Sickness 100-33-4 PENTAMIDINE MECH_LEVEL_3 Inhibits RNA splicing 100-33-4 PENTAMIDINE TA_LEVEL_2 Anti-protozoal 100-33-4 PENTAMIDINE TA_LEVEL_1 Infectious Disease 100-33-4 PENTAMIDINE INDICATION American Trypanosomiasis / Chagas' Disease 100-33-4 PENTAMIDINE ADVERSE_EFFECT KID_1_Nephrotoxicity 100-33-4 PENTAMIDINE THERAPEUTIC_CLASS Antiparasitics 100-33-4 PENTAMIDINE KNOWN_TOXICITY Cardiovascular Toxicity 100-33-4 PENTAMIDINE ADVERSE_EFFECT BBM_3_Anemia 100-33-4 PENTAMIDINE ADVERSE_EFFECT LUN_3_Cough 100-33-4 PENTAMIDINE ZERO_CLASS N 100-33-4 PENTAMIDINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 100-33-4 PENTAMIDINE TISSUE_TOXICITY Hypotension 100-33-4 PENTAMIDINE ADVERSE_EFFECT ELT_1_Hypocalcemia 100-33-4 PENTAMIDINE ADVERSE_EFFECT GIS_2_Pancreatitis 100-33-4 PENTAMIDINE ADVERSE_EFFECT IMU_3_Urticaria 100-33-4 PENTAMIDINE ADVERSE_EFFECT PSY_1_Confusion 100-33-4 PENTAMIDINE ADVERSE_EFFECT GIS_2_Sialadenitis 100-33-4 PENTAMIDINE ADVERSE_EFFECT XXX_3_Fatigue 100-33-4 PENTAMIDINE KNOWN_TOXICITY Nephrotoxicity 100-33-4 PENTAMIDINE ADVERSE_EFFECT END_1_Hypoglycemia 100-33-4 PENTAMIDINE THERAPEUTIC_CLASS Antibacterials, Systemic 100-33-4 PENTAMIDINE PRODUCT_CLASS Anti-infectives 100-33-4 PENTAMIDINE TA_LEVEL_3 pneumocytosis carinii 100-33-4 PENTAMIDINE MECH_LEVEL_2 RNA processing 100-33-4 PENTAMIDINE MESH_LEVEL_1 Organic Chemicals 100-33-4 PENTAMIDINE MESH_LEVEL_3 Benzamidines 100-33-4 PENTAMIDINE MECHANISM Inhibit protein synthesis 100-33-4 PENTAMIDINE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 100-33-4 PENTAMIDINE ADVERSE_EFFECT ELT_1_Hyperkalemia 100-33-4 PENTAMIDINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 100-33-4 PENTAMIDINE ADVERSE_EFFECT XXX_3_Xerosis 100-33-4 PENTAMIDINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 100-33-4 PENTAMIDINE ADVERSE_EFFECT GIS_2_Dysgeusia 100-33-4 PENTAMIDINE TISSUE_TOXICITY Renal Tubular Necrosis 100-33-4 PENTAMIDINE INDICATION Pneumonia 100-33-4 PENTAMIDINE MECH_LEVEL_1 Anti-protozoal 100-33-4 PENTAMIDINE MESH_LEVEL_2 Amidines 100-33-4 PENTAMIDINE STRUCTURE_ACTIVITY RNA splicing inhibitor, antiparasitics 100-33-4 PENTAMIDINE ACTIVITY_CLASS Antibiotic 100-33-4 PENTAMIDINE ADVERSE_EFFECT CVS_1_Hypotension 100-33-4 PENTAMIDINE ADVERSE_EFFECT SKN_3_Erythema 100-33-4 PENTAMIDINE ADVERSE_EFFECT BBM_3_Leukopenia 100-33-4 PENTAMIDINE ADVERSE_EFFECT PSY_2_Anorexia 100-33-4 PENTAMIDINE ADVERSE_EFFECT NEU_1_Dizziness 100-33-4 PENTAMIDINE ADVERSE_EFFECT LUN_3_Bronchospasm 100-33-4 PENTAMIDINE ADVERSE_EFFECT KID_2_Azotemia 100-33-4 PENTAMIDINE TISSUE_TOXICITY Nephrotoxicity 100-33-4 PENTAMIDINE INDICATION Pneumocystis Carinii Pneumonia (PCP) 100-33-4 PENTAMIDINE INDICATION Leishmaniasis 100-33-4 PENTAMIDINE ADVERSE_EFFECT ELT_1_Hypomagnesemia 100-33-4 PENTAMIDINE ADVERSE_EFFECT SKN_3_Pruritis 100-33-4 PENTAMIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 100-33-4 PENTAMIDINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 100-33-4 PENTAMIDINE ADVERSE_EFFECT NEU_1_Neuralgia 359-83-1 PENTAZOCINE MODE_CLASS Receptor Partial Agonist 359-83-1 PENTAZOCINE MECHANISM Modulate neural transmission 359-83-1 PENTAZOCINE MODE_CLASS Receptor Agonist 359-83-1 PENTAZOCINE INDICATION Moderate Pain 359-83-1 PENTAZOCINE THERAPEUTIC_CLASS Analgesics, Opioid 359-83-1 PENTAZOCINE STRUCTURE_ACTIVITY Sigma receptor modulator 359-83-1 PENTAZOCINE INDICATION Severe Pain 359-83-1 PENTAZOCINE PRODUCT_CLASS Analgesics 64024-15-3 PENTAZOCINE MECHANISM Modulate neural transmission 64024-15-3 PENTAZOCINE INDICATION Moderate Pain 64024-15-3 PENTAZOCINE THERAPEUTIC_CLASS Analgesics, Opioid 64024-15-3 PENTAZOCINE STRUCTURE_ACTIVITY Sigma receptor modulator 64024-15-3 PENTAZOCINE PRODUCT_CLASS Analgesics 64024-15-3 PENTAZOCINE INDICATION Severe Pain 64024-15-3 PENTAZOCINE MODE_CLASS Receptor Partial Agonist 64024-15-3 PENTAZOCINE MODE_CLASS Receptor Agonist 76-74-4 PENTOBARBITAL ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 76-74-4 PENTOBARBITAL ADVERSE_EFFECT PSY_1_Physical Dependence 76-74-4 PENTOBARBITAL ADVERSE_EFFECT IMU_3_Allergic Reactions 76-74-4 PENTOBARBITAL ADVERSE_EFFECT PSY_2_CNS Depression 76-74-4 PENTOBARBITAL ADVERSE_EFFECT EMB_2_Teratogenicity 76-74-4 PENTOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 76-74-4 PENTOBARBITAL INDICATION Status Epilepticus 76-74-4 PENTOBARBITAL MECH_LEVEL_1 Modulate neural transmission 76-74-4 PENTOBARBITAL MECH_LEVEL_3 GABA-A receptor 76-74-4 PENTOBARBITAL ADVERSE_EFFECT NEU_2_Hyperkinesia 76-74-4 PENTOBARBITAL ADVERSE_EFFECT LUN_3_Laryngospasm 76-74-4 PENTOBARBITAL TA_LEVEL_3 Sedatives/Hypnotics 76-74-4 PENTOBARBITAL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 76-74-4 PENTOBARBITAL ADVERSE_EFFECT DNA_2_Carcinogenicity 76-74-4 PENTOBARBITAL ADVERSE_EFFECT CVS_2_Hypotension 76-74-4 PENTOBARBITAL ADVERSE_EFFECT SKN_2_Rash 76-74-4 PENTOBARBITAL ADVERSE_EFFECT NEU_2_Ataxia 76-74-4 PENTOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 76-74-4 PENTOBARBITAL TISSUE_TOXICITY Hepatotoxicity 76-74-4 PENTOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 76-74-4 PENTOBARBITAL KNOWN_TOXICITY Embryo/Fetal Toxicity 76-74-4 PENTOBARBITAL KNOWN_TOXICITY Hepatotoxicity 76-74-4 PENTOBARBITAL TISSUE_TOXICITY Carcinogenicity 76-74-4 PENTOBARBITAL MESH_LEVEL_3 Pyrimidines 76-74-4 PENTOBARBITAL TA_LEVEL_2 CNS Depressant 76-74-4 PENTOBARBITAL KNOWN_TOXICITY Carcinogenicity 76-74-4 PENTOBARBITAL ADVERSE_EFFECT NEU_1_Somnolence 76-74-4 PENTOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 76-74-4 PENTOBARBITAL TISSUE_TOXICITY Teratogenicity 76-74-4 PENTOBARBITAL ACTIVITY_CLASS GABA agonist 76-74-4 PENTOBARBITAL INDICATION Sedation 76-74-4 PENTOBARBITAL ZERO_CLASS N 76-74-4 PENTOBARBITAL MESH_LEVEL_1 Heterocyclic Compounds 76-74-4 PENTOBARBITAL INDICATION Insomnia / Dyssomnias 76-74-4 PENTOBARBITAL INDICATION Seizure Disorders 76-74-4 PENTOBARBITAL MECH_LEVEL_2 faciliates GABA binding 76-74-4 PENTOBARBITAL MODE_CLASS Channel Modulator 76-74-4 PENTOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 76-74-4 PENTOBARBITAL ADVERSE_EFFECT LUN_2_Respiratory Depression 76-74-4 PENTOBARBITAL ADVERSE_EFFECT NEU_2_Dizziness 76-74-4 PENTOBARBITAL ADVERSE_EFFECT PSY_1_Psychologic Dependence 76-74-4 PENTOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 76-74-4 PENTOBARBITAL ADVERSE_EFFECT PSY_2_Mental Status Changes 76-74-4 PENTOBARBITAL ADVERSE_EFFECT LUN_3_Apnea 76-74-4 PENTOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 76-74-4 PENTOBARBITAL TA_LEVEL_1 Central Nervous System (CNS) 76-74-4 PENTOBARBITAL MECHANISM Modulate neural transmission 76-74-4 PENTOBARBITAL INDICATION Induction / Maintenance of Anesthesia 76-74-4 PENTOBARBITAL ADVERSE_EFFECT CVS_2_Bradycardia 76-74-4 PENTOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 76-74-4 PENTOBARBITAL ADVERSE_EFFECT XXX_1_Tolerance 76-74-4 PENTOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 76-74-4 PENTOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 76-74-4 PENTOBARBITAL ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 76-74-4 PENTOBARBITAL TISSUE_TOXICITY Hypotension 57-33-0 PENTOBARBITAL MECH_LEVEL_3 GABA-A receptor 57-33-0 PENTOBARBITAL MECH_LEVEL_1 Modulate neural transmission 57-33-0 PENTOBARBITAL INDICATION Status Epilepticus 57-33-0 PENTOBARBITAL ADVERSE_EFFECT NEU_2_Hyperkinesia 57-33-0 PENTOBARBITAL ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 57-33-0 PENTOBARBITAL ADVERSE_EFFECT PSY_1_Physical Dependence 57-33-0 PENTOBARBITAL ADVERSE_EFFECT IMU_3_Allergic Reactions 57-33-0 PENTOBARBITAL ADVERSE_EFFECT PSY_2_CNS Depression 57-33-0 PENTOBARBITAL ADVERSE_EFFECT EMB_2_Teratogenicity 57-33-0 PENTOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 57-33-0 PENTOBARBITAL INDICATION Sedation 57-33-0 PENTOBARBITAL TA_LEVEL_3 Sedatives/Hypnotics 57-33-0 PENTOBARBITAL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 57-33-0 PENTOBARBITAL ADVERSE_EFFECT DNA_2_Carcinogenicity 57-33-0 PENTOBARBITAL ADVERSE_EFFECT CVS_2_Hypotension 57-33-0 PENTOBARBITAL ADVERSE_EFFECT SKN_2_Rash 57-33-0 PENTOBARBITAL ADVERSE_EFFECT NEU_2_Ataxia 57-33-0 PENTOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 57-33-0 PENTOBARBITAL ADVERSE_EFFECT NEU_1_Somnolence 57-33-0 PENTOBARBITAL TISSUE_TOXICITY Hepatotoxicity 57-33-0 PENTOBARBITAL MODE_CLASS Channel Modulator 57-33-0 PENTOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 57-33-0 PENTOBARBITAL ADVERSE_EFFECT LUN_2_Respiratory Depression 57-33-0 PENTOBARBITAL KNOWN_TOXICITY Carcinogenicity 57-33-0 PENTOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 57-33-0 PENTOBARBITAL INDICATION Seizure Disorders 57-33-0 PENTOBARBITAL ADVERSE_EFFECT PSY_2_Mental Status Changes 57-33-0 PENTOBARBITAL INDICATION Insomnia / Dyssomnias 57-33-0 PENTOBARBITAL MESH_LEVEL_1 Heterocyclic Compounds 57-33-0 PENTOBARBITAL ACTIVITY_CLASS GABA agonist 57-33-0 PENTOBARBITAL TISSUE_TOXICITY Teratogenicity 57-33-0 PENTOBARBITAL ZERO_CLASS N 57-33-0 PENTOBARBITAL ADVERSE_EFFECT LUN_3_Laryngospasm 57-33-0 PENTOBARBITAL ADVERSE_EFFECT NEU_2_Dizziness 57-33-0 PENTOBARBITAL MECH_LEVEL_2 faciliates GABA binding 57-33-0 PENTOBARBITAL ADVERSE_EFFECT PSY_1_Psychologic Dependence 57-33-0 PENTOBARBITAL KNOWN_TOXICITY Embryo/Fetal Toxicity 57-33-0 PENTOBARBITAL KNOWN_TOXICITY Hepatotoxicity 57-33-0 PENTOBARBITAL TISSUE_TOXICITY Carcinogenicity 57-33-0 PENTOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 57-33-0 PENTOBARBITAL ADVERSE_EFFECT LUN_3_Apnea 57-33-0 PENTOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 57-33-0 PENTOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 57-33-0 PENTOBARBITAL TA_LEVEL_1 Central Nervous System (CNS) 57-33-0 PENTOBARBITAL MECHANISM Modulate neural transmission 57-33-0 PENTOBARBITAL INDICATION Induction / Maintenance of Anesthesia 57-33-0 PENTOBARBITAL ADVERSE_EFFECT CVS_2_Bradycardia 57-33-0 PENTOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57-33-0 PENTOBARBITAL ADVERSE_EFFECT XXX_1_Tolerance 57-33-0 PENTOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 57-33-0 PENTOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 57-33-0 PENTOBARBITAL ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 57-33-0 PENTOBARBITAL TISSUE_TOXICITY Hypotension 57-33-0 PENTOBARBITAL MESH_LEVEL_3 Pyrimidines 57-33-0 PENTOBARBITAL TA_LEVEL_2 CNS Depressant 116001-96-8 PENTOSAN POLYSULFATE MECHANISM Increase cellular reactive oxygen species 116001-96-8 PENTOSAN POLYSULFATE INDICATION Interstitial Cystitis 116001-96-8 PENTOSAN POLYSULFATE MODE_CLASS Enzyme Inhibitor 140207-93-8 PENTOSAN POLYSULFATE MECHANISM Increase cellular reactive oxygen species 140207-93-8 PENTOSAN POLYSULFATE INDICATION Interstitial Cystitis 140207-93-8 PENTOSAN POLYSULFATE MODE_CLASS Enzyme Inhibitor 53910-25-1 PENTOSTATIN MODE_CLASS Enzyme Inhibitor 53910-25-1 PENTOSTATIN THERAPEUTIC_CLASS Antineoplastics 53910-25-1 PENTOSTATIN INDICATION Hairy Cell Leukemia 53910-25-1 PENTOSTATIN PRODUCT_CLASS Anti-cancers 59979-24-7 PENTOSTATIN MODE_CLASS Enzyme Inhibitor 59979-24-7 PENTOSTATIN THERAPEUTIC_CLASS Antineoplastics 59979-24-7 PENTOSTATIN INDICATION Hairy Cell Leukemia 59979-24-7 PENTOSTATIN PRODUCT_CLASS Anti-cancers 6493-05-6 PENTOXIFYLLINE MECHANISM Modulate G-protein coupled signal transduction 6493-05-6 PENTOXIFYLLINE MODE_CLASS Receptor Agonist 6493-05-6 PENTOXIFYLLINE THERAPEUTIC_CLASS Hemorrheologic Agents 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT CVS_3_Palpitation 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT GIS_2_Vomiting 6493-05-6 PENTOXIFYLLINE ACTIVITY_CLASS Adenosine receptor antagonist, xanthine 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT SKN_2_Flushing 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT DNA_3_Carcinogenicity 6493-05-6 PENTOXIFYLLINE MECHANISM Reduce bronchoconstriction 6493-05-6 PENTOXIFYLLINE INDICATION Peripheral Vascular Disease 6493-05-6 PENTOXIFYLLINE TA_LEVEL_1 Cardiovascular 6493-05-6 PENTOXIFYLLINE PRODUCT_CLASS Hematologics 6493-05-6 PENTOXIFYLLINE STRUCTURE_ACTIVITY Adenosine receptor antagonist, xanthine 6493-05-6 PENTOXIFYLLINE KNOWN_TOXICITY Carcinogenicity 6493-05-6 PENTOXIFYLLINE MECHANISM Enhance kinase mediated signal transduction 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT CVS_2_Chest Pain 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT NEU_2_Headache 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT NEU_3_Tremor 6493-05-6 PENTOXIFYLLINE MODE_CLASS Enzyme Inhibitor 6493-05-6 PENTOXIFYLLINE MESH_LEVEL_3 Xanthine Alkaloids 6493-05-6 PENTOXIFYLLINE TA_LEVEL_3 Claudication 6493-05-6 PENTOXIFYLLINE MECH_LEVEL_1 Muscle relaxant 6493-05-6 PENTOXIFYLLINE MECH_LEVEL_3 adenosine receptor A1 6493-05-6 PENTOXIFYLLINE MECH_LEVEL_2 adrenoreceptor beta, nonselective 6493-05-6 PENTOXIFYLLINE MESH_LEVEL_1 Heterocyclic Compounds 6493-05-6 PENTOXIFYLLINE ZERO_CLASS N 6493-05-6 PENTOXIFYLLINE TISSUE_TOXICITY Carcinogenicity 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT GIS_2_Dyspepsia 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT NEU_2_Dizziness 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT GIS_2_Nausea 6493-05-6 PENTOXIFYLLINE MODE_CLASS Receptor Ligand Antagonist 6493-05-6 PENTOXIFYLLINE TA_LEVEL_2 Perfusion 6493-05-6 PENTOXIFYLLINE ADVERSE_EFFECT GIS_2_Bloating 6493-05-6 PENTOXIFYLLINE MESH_LEVEL_2 Alkaloids 66104-23-2 PERGOLIDE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 66104-23-2 PERGOLIDE ADVERSE_EFFECT PSY_2_Psychosis 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Withdrawal 66104-23-2 PERGOLIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 66104-23-2 PERGOLIDE ADVERSE_EFFECT GIS_1_Constipation 66104-23-2 PERGOLIDE MECH_LEVEL_3 dopamine receptor D2 66104-23-2 PERGOLIDE MESH_LEVEL_2 Alkaloids 66104-23-2 PERGOLIDE PRODUCT_CLASS Central Nervous System (CNS) 66104-23-2 PERGOLIDE TA_LEVEL_1 Central Nervous System (CNS) 66104-23-2 PERGOLIDE MESH_LEVEL_3 Ergot Alkaloids 66104-23-2 PERGOLIDE MECHANISM Prolong/enhance neural transmission 66104-23-2 PERGOLIDE STRUCTURE_ACTIVITY Ergot alkaloid 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 66104-23-2 PERGOLIDE ADVERSE_EFFECT MSK_2_Back Pain 66104-23-2 PERGOLIDE ADVERSE_EFFECT MSK_2_Myalgia 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_2_Akathisia 66104-23-2 PERGOLIDE ADVERSE_EFFECT OCU_2_Diplopia 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Weakness 66104-23-2 PERGOLIDE ADVERSE_EFFECT CVS_2_Myocardial Infarction 66104-23-2 PERGOLIDE ADVERSE_EFFECT PSY_1_Hallucinations 66104-23-2 PERGOLIDE MESH_LEVEL_1 Heterocyclic Compounds 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Rhinitis 66104-23-2 PERGOLIDE ADVERSE_EFFECT CVS_2_Palpitation 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_1_Dystonia 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_1_Dyskinesia 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_2_Dizziness 66104-23-2 PERGOLIDE ADVERSE_EFFECT PSY_1_Insomnia 66104-23-2 PERGOLIDE ADVERSE_EFFECT CVS_2_Hypotension 66104-23-2 PERGOLIDE ADVERSE_EFFECT GIS_1_Diarrhea 66104-23-2 PERGOLIDE THERAPEUTIC_CLASS Movement Disorders 66104-23-2 PERGOLIDE INDICATION Parkinson's Disease 66104-23-2 PERGOLIDE MECH_LEVEL_2 Prolong/enhance neural transmission 66104-23-2 PERGOLIDE MECH_LEVEL_1 Modulate neural transmission 66104-23-2 PERGOLIDE MODE_CLASS Receptor Agonist 66104-23-2 PERGOLIDE TA_LEVEL_2 movement disorders 66104-23-2 PERGOLIDE TA_LEVEL_3 Parkinsons 66104-23-2 PERGOLIDE ACTIVITY_CLASS Ergot alkaloid 66104-23-2 PERGOLIDE KNOWN_TOXICITY Cardiovascular Toxicity 66104-23-2 PERGOLIDE TISSUE_TOXICITY Myocardial Infarction 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Xerostomia 66104-23-2 PERGOLIDE ADVERSE_EFFECT GIS_1_Dyspepsia 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Weight Gain 66104-23-2 PERGOLIDE ZERO_CLASS N 66104-23-2 PERGOLIDE TISSUE_TOXICITY Hypotension 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_3_Syncope 66104-23-2 PERGOLIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Fever 66104-23-2 PERGOLIDE ADVERSE_EFFECT XXX_2_Weight Loss 66104-23-2 PERGOLIDE ADVERSE_EFFECT LUN_3_Dyspnea 66104-23-2 PERGOLIDE ADVERSE_EFFECT NEU_2_Drowsiness 66104-23-2 PERGOLIDE ADVERSE_EFFECT PSY_2_Anxiety 66104-23-2 PERGOLIDE ADVERSE_EFFECT CVS_2_Hypertension 52645-53-1 PERMETHRIN MODE_CLASS Channel Modulator 52645-53-1 PERMETHRIN PRODUCT_CLASS Toxicants 52645-53-1 PERMETHRIN MODE_CLASS Channel Blocker 52645-53-1 PERMETHRIN MECHANISM Modulate channel gating 52645-53-1 PERMETHRIN THERAPEUTIC_CLASS Insecticides / Pesticides 52645-53-1 PERMETHRIN MECHANISM Prolong/enhance neural transmission 58-39-9 PERPHENAZINE THERAPEUTIC_CLASS Antipsychotics 58-39-9 PERPHENAZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 58-39-9 PERPHENAZINE INDICATION Psychotic Depression 58-39-9 PERPHENAZINE INDICATION Agitation 58-39-9 PERPHENAZINE THERAPEUTIC_CLASS Antiemetics 58-39-9 PERPHENAZINE TISSUE_TOXICITY Hypotension 58-39-9 PERPHENAZINE ADVERSE_EFFECT PSY_1_CNS Depression 58-39-9 PERPHENAZINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 58-39-9 PERPHENAZINE ADVERSE_EFFECT NEU_1_Drowsiness 58-39-9 PERPHENAZINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 58-39-9 PERPHENAZINE ADVERSE_EFFECT REP_2_Amenorrhea 58-39-9 PERPHENAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 58-39-9 PERPHENAZINE ADVERSE_EFFECT END_1_Hyperprolactinemia 58-39-9 PERPHENAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 58-39-9 PERPHENAZINE INDICATION Nausea / Vomiting 58-39-9 PERPHENAZINE MODE_CLASS Receptor Ligand Antagonist 58-39-9 PERPHENAZINE TISSUE_TOXICITY Ventricular Tachycardia 58-39-9 PERPHENAZINE ADVERSE_EFFECT OCU_2_Mydriasis 58-39-9 PERPHENAZINE THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 58-39-9 PERPHENAZINE ADVERSE_EFFECT OCU_3_Pigmentary Retinopathy 58-39-9 PERPHENAZINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 58-39-9 PERPHENAZINE ADVERSE_EFFECT NEU_1_Dystonia 58-39-9 PERPHENAZINE ADVERSE_EFFECT BBM_3_Leukopenia 58-39-9 PERPHENAZINE ADVERSE_EFFECT LIV_3_Cholestasis 58-39-9 PERPHENAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 58-39-9 PERPHENAZINE INDICATION Acute Psychosis 58-39-9 PERPHENAZINE INDICATION Hiccups / Singultus 58-39-9 PERPHENAZINE KNOWN_TOXICITY Cardiovascular Toxicity 58-39-9 PERPHENAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 58-39-9 PERPHENAZINE ADVERSE_EFFECT NEU_3_Seizures 58-39-9 PERPHENAZINE ADVERSE_EFFECT NEU_1_Akathisia 58-39-9 PERPHENAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 58-39-9 PERPHENAZINE ADVERSE_EFFECT IMU_2_Photosensitivity 58-39-9 PERPHENAZINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 58-39-9 PERPHENAZINE ADVERSE_EFFECT OCU_1_Blurred Vision 58-39-9 PERPHENAZINE ADVERSE_EFFECT NEU_1_Pseudo-Parkinsonism 58-39-9 PERPHENAZINE ADVERSE_EFFECT REP_2_Impotence 58-39-9 PERPHENAZINE INDICATION Schizophrenia 58-39-9 PERPHENAZINE INDICATION Dementia 58-39-9 PERPHENAZINE PRODUCT_CLASS Gastrointestinal System 58-39-9 PERPHENAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 58-39-9 PERPHENAZINE ADVERSE_EFFECT CVS_3_Hypotension 58-39-9 PERPHENAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 58-39-9 PERPHENAZINE ADVERSE_EFFECT GIS_1_Dry Mouth 58-39-9 PERPHENAZINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 58-39-9 PERPHENAZINE ADVERSE_EFFECT XXX_1_Withdrawal 58-39-9 PERPHENAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 58-39-9 PERPHENAZINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 58-39-9 PERPHENAZINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 58-39-9 PERPHENAZINE PRODUCT_CLASS Central Nervous System (CNS) 58-39-9 PERPHENAZINE MECHANISM Block neural transmission 58-39-9 PERPHENAZINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 70323-44-3 PERTUSSIS TOXIN STRUCTURE_ACTIVITY Toxicant, mycotoxin/plant toxin 63-98-9 PHENACEMIDE ADVERSE_EFFECT NEU_3_Drowsiness 63-98-9 PHENACEMIDE ADVERSE_EFFECT PSY_3_Anorexia 63-98-9 PHENACEMIDE ACTIVITY_CLASS GABA agonist 63-98-9 PHENACEMIDE ADVERSE_EFFECT SKN_3_Skin Rash 63-98-9 PHENACEMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 63-98-9 PHENACEMIDE ADVERSE_EFFECT LIV_3_Hepatitis 63-98-9 PHENACEMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 63-98-9 PHENACEMIDE ADVERSE_EFFECT KID_3_Nephritis 63-98-9 PHENACEMIDE ADVERSE_EFFECT BBM_3_Leukopenia 63-98-9 PHENACEMIDE ADVERSE_EFFECT MSK_3_Muscle Pain 63-98-9 PHENACEMIDE ADVERSE_EFFECT XXX_3_Weight Loss 63-98-9 PHENACEMIDE ADVERSE_EFFECT XXX_3_Fatigue 63-98-9 PHENACEMIDE TISSUE_TOXICITY Renal Failure 63-98-9 PHENACEMIDE INDICATION Partial Seizures 63-98-9 PHENACEMIDE KNOWN_TOXICITY Nephrotoxicity 63-98-9 PHENACEMIDE ADVERSE_EFFECT XXX_3_Fever 63-98-9 PHENACEMIDE ADVERSE_EFFECT NEU_3_Headache 63-98-9 PHENACEMIDE ADVERSE_EFFECT KID_3_Renal Failure 63-98-9 PHENACEMIDE STRUCTURE_ACTIVITY GABA-A agonist 63-98-9 PHENACEMIDE PRODUCT_CLASS Central Nervous System (CNS) 63-98-9 PHENACEMIDE ADVERSE_EFFECT CVS_3_Palpitation 63-98-9 PHENACEMIDE ADVERSE_EFFECT PSY_3_Insomnia 62-44-2 PHENACETIN ADVERSE_EFFECT NEU_2_Drowsiness 62-44-2 PHENACETIN ADVERSE_EFFECT XXX_3_Fever 62-44-2 PHENACETIN KNOWN_TOXICITY Carcinogenicity 62-44-2 PHENACETIN INDICATION Pain 62-44-2 PHENACETIN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 62-44-2 PHENACETIN TA_LEVEL_2 NSAID 62-44-2 PHENACETIN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 62-44-2 PHENACETIN STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 62-44-2 PHENACETIN ACTIVITY_CLASS Anti-inflammatory 62-44-2 PHENACETIN MECHANISM Inhibit eicosanoid biosynthesis 62-44-2 PHENACETIN ADVERSE_EFFECT DNA_3_Carcinogenicity 62-44-2 PHENACETIN ZERO_CLASS N 62-44-2 PHENACETIN MESH_LEVEL_3 Anilides 62-44-2 PHENACETIN MESH_LEVEL_1 Organic Chemicals 62-44-2 PHENACETIN ADVERSE_EFFECT LUN_3_Respiratory Depression 62-44-2 PHENACETIN TA_LEVEL_3 NSAID 62-44-2 PHENACETIN ADVERSE_EFFECT KID_2_Renal Failure 62-44-2 PHENACETIN INDICATION Fever 62-44-2 PHENACETIN TISSUE_TOXICITY Cardiac Arrest 62-44-2 PHENACETIN TISSUE_TOXICITY Renal Tubular Necrosis 62-44-2 PHENACETIN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 62-44-2 PHENACETIN TISSUE_TOXICITY Renal Pelvic Tumors 62-44-2 PHENACETIN TISSUE_TOXICITY Acute Interstitial Nephritis 62-44-2 PHENACETIN ADVERSE_EFFECT DNA_2_Renal Pelvic Tumors 62-44-2 PHENACETIN ADVERSE_EFFECT GIS_2_Stomatitis 62-44-2 PHENACETIN ADVERSE_EFFECT PSY_2_Euphoria 62-44-2 PHENACETIN ADVERSE_EFFECT BBM_3_Methemoglobinemia 62-44-2 PHENACETIN ADVERSE_EFFECT PSY_2_CNS Stimulation 62-44-2 PHENACETIN KNOWN_TOXICITY Cardiovascular Toxicity 62-44-2 PHENACETIN TA_LEVEL_1 Anti-inflammatory 62-44-2 PHENACETIN MECH_LEVEL_1 Immunomodulation 62-44-2 PHENACETIN TISSUE_TOXICITY Carcinogenicity 62-44-2 PHENACETIN MESH_LEVEL_2 Amides 62-44-2 PHENACETIN PRODUCT_CLASS Analgesics 62-44-2 PHENACETIN MODE_CLASS Enzyme Inhibitor 62-44-2 PHENACETIN ADVERSE_EFFECT LUN_3_Cyanosis 62-44-2 PHENACETIN KNOWN_TOXICITY Nephrotoxicity 62-44-2 PHENACETIN ADVERSE_EFFECT KID_2_Renal Toxicity 62-44-2 PHENACETIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 62-44-2 PHENACETIN ADVERSE_EFFECT IMU_3_Hypersensitivity 62-44-2 PHENACETIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 62-44-2 PHENACETIN ADVERSE_EFFECT SKN_2_Skin Rash 62-44-2 PHENACETIN THERAPEUTIC_CLASS Analgesics, Non-Opioid 62-44-2 PHENACETIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 62-44-2 PHENACETIN TISSUE_TOXICITY Renal Toxicity 62-44-2 PHENACETIN TISSUE_TOXICITY Renal Failure 634-03-7 PHENDIMETRAZINE THERAPEUTIC_CLASS Anorexiants 634-03-7 PHENDIMETRAZINE INDICATION Obesity 634-03-7 PHENDIMETRAZINE PRODUCT_CLASS Central Nervous System (CNS) 16311-86-7 PHENDIMETRAZINE INDICATION Obesity 16311-86-7 PHENDIMETRAZINE PRODUCT_CLASS Central Nervous System (CNS) 16311-86-7 PHENDIMETRAZINE THERAPEUTIC_CLASS Anorexiants 7635-51-0 PHENDIMETRAZINE THERAPEUTIC_CLASS Anorexiants 7635-51-0 PHENDIMETRAZINE INDICATION Obesity 7635-51-0 PHENDIMETRAZINE PRODUCT_CLASS Central Nervous System (CNS) 51-71-8 PHENELZINE TA_LEVEL_3 depression 51-71-8 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 51-71-8 PHENELZINE ZERO_CLASS N 51-71-8 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 51-71-8 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 51-71-8 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 51-71-8 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 51-71-8 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 51-71-8 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 51-71-8 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 51-71-8 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 51-71-8 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 51-71-8 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 51-71-8 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 51-71-8 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 51-71-8 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 51-71-8 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 51-71-8 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 51-71-8 PHENELZINE MECHANISM Prolong/enhance neural transmission 51-71-8 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 51-71-8 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 51-71-8 PHENELZINE MESH_LEVEL_1 Organic Chemicals 51-71-8 PHENELZINE MODE_CLASS Enzyme Inhibitor 51-71-8 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 51-71-8 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 51-71-8 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 51-71-8 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 51-71-8 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 51-71-8 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 51-71-8 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 51-71-8 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 51-71-8 PHENELZINE MESH_LEVEL_2 Hydrazines 51-71-8 PHENELZINE INDICATION Depression 51-71-8 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 51-71-8 PHENELZINE THERAPEUTIC_CLASS Antidepressants 51-71-8 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 51-71-8 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 51-71-8 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 51-71-8 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 51-71-8 PHENELZINE MESH_LEVEL_3 Phenelzine 51-71-8 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 51-71-8 PHENELZINE TA_LEVEL_2 CNS Stimulant 51-71-8 PHENELZINE INDICATION Anxiety Disorders 51-71-8 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 1953-02-2 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 1953-02-2 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 1953-02-2 PHENELZINE INDICATION Anxiety Disorders 1953-02-2 PHENELZINE TA_LEVEL_2 CNS Stimulant 1953-02-2 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 1953-02-2 PHENELZINE MESH_LEVEL_3 Phenelzine 1953-02-2 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 1953-02-2 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 1953-02-2 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 1953-02-2 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 1953-02-2 PHENELZINE THERAPEUTIC_CLASS Antidepressants 1953-02-2 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 1953-02-2 PHENELZINE MESH_LEVEL_2 Hydrazines 1953-02-2 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 1953-02-2 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 1953-02-2 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 1953-02-2 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 1953-02-2 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 1953-02-2 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 1953-02-2 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 1953-02-2 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 1953-02-2 PHENELZINE MODE_CLASS Enzyme Inhibitor 1953-02-2 PHENELZINE MESH_LEVEL_1 Organic Chemicals 1953-02-2 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 1953-02-2 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 1953-02-2 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 1953-02-2 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 1953-02-2 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 1953-02-2 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 1953-02-2 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 1953-02-2 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 1953-02-2 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 1953-02-2 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 1953-02-2 PHENELZINE INDICATION Depression 1953-02-2 PHENELZINE MECHANISM Prolong/enhance neural transmission 1953-02-2 PHENELZINE TA_LEVEL_3 depression 1953-02-2 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 1953-02-2 PHENELZINE ZERO_CLASS N 1953-02-2 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 1953-02-2 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 1953-02-2 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 1953-02-2 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 1953-02-2 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 1953-02-2 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 3801-06-7 PHENELZINE TA_LEVEL_3 depression 3801-06-7 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 3801-06-7 PHENELZINE ZERO_CLASS N 3801-06-7 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 3801-06-7 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 3801-06-7 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 3801-06-7 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 3801-06-7 PHENELZINE INDICATION Depression 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 3801-06-7 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 3801-06-7 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 3801-06-7 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 3801-06-7 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 3801-06-7 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 3801-06-7 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 3801-06-7 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 3801-06-7 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 3801-06-7 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 3801-06-7 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 3801-06-7 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 3801-06-7 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 3801-06-7 PHENELZINE MODE_CLASS Enzyme Inhibitor 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 3801-06-7 PHENELZINE INDICATION Anxiety Disorders 3801-06-7 PHENELZINE TA_LEVEL_2 CNS Stimulant 3801-06-7 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 3801-06-7 PHENELZINE MESH_LEVEL_3 Phenelzine 3801-06-7 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 3801-06-7 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 3801-06-7 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 3801-06-7 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 3801-06-7 PHENELZINE THERAPEUTIC_CLASS Antidepressants 3801-06-7 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 3801-06-7 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 3801-06-7 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 3801-06-7 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 3801-06-7 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 3801-06-7 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 3801-06-7 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 3801-06-7 PHENELZINE MESH_LEVEL_2 Hydrazines 3801-06-7 PHENELZINE MESH_LEVEL_1 Organic Chemicals 3801-06-7 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 3801-06-7 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 3801-06-7 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 3801-06-7 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 3801-06-7 PHENELZINE MECHANISM Prolong/enhance neural transmission 58409-59-9 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 58409-59-9 PHENELZINE ZERO_CLASS N 58409-59-9 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 58409-59-9 PHENELZINE TA_LEVEL_3 depression 58409-59-9 PHENELZINE MECHANISM Prolong/enhance neural transmission 58409-59-9 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 58409-59-9 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 58409-59-9 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 58409-59-9 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 58409-59-9 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 58409-59-9 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 58409-59-9 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 58409-59-9 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 58409-59-9 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 58409-59-9 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 58409-59-9 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 58409-59-9 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 58409-59-9 PHENELZINE MESH_LEVEL_1 Organic Chemicals 58409-59-9 PHENELZINE MODE_CLASS Enzyme Inhibitor 58409-59-9 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 58409-59-9 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 58409-59-9 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 58409-59-9 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 58409-59-9 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 58409-59-9 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 58409-59-9 PHENELZINE INDICATION Anxiety Disorders 58409-59-9 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 58409-59-9 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 58409-59-9 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 58409-59-9 PHENELZINE MESH_LEVEL_2 Hydrazines 58409-59-9 PHENELZINE INDICATION Depression 58409-59-9 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 58409-59-9 PHENELZINE THERAPEUTIC_CLASS Antidepressants 58409-59-9 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 58409-59-9 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 58409-59-9 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 58409-59-9 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 58409-59-9 PHENELZINE MESH_LEVEL_3 Phenelzine 58409-59-9 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 58409-59-9 PHENELZINE TA_LEVEL_2 CNS Stimulant 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 58409-59-9 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 58409-59-9 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 58409-59-9 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 58409-59-9 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 108863-62-3 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 108863-62-3 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 108863-62-3 PHENELZINE MESH_LEVEL_1 Organic Chemicals 108863-62-3 PHENELZINE MODE_CLASS Enzyme Inhibitor 108863-62-3 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 108863-62-3 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 108863-62-3 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 108863-62-3 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 108863-62-3 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 108863-62-3 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 108863-62-3 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 108863-62-3 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 108863-62-3 PHENELZINE MECHANISM Prolong/enhance neural transmission 108863-62-3 PHENELZINE TA_LEVEL_3 depression 108863-62-3 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 108863-62-3 PHENELZINE ZERO_CLASS N 108863-62-3 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 108863-62-3 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 108863-62-3 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 108863-62-3 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 108863-62-3 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 108863-62-3 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 108863-62-3 PHENELZINE INDICATION Anxiety Disorders 108863-62-3 PHENELZINE TA_LEVEL_2 CNS Stimulant 108863-62-3 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 108863-62-3 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 108863-62-3 PHENELZINE MESH_LEVEL_3 Phenelzine 108863-62-3 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 108863-62-3 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 108863-62-3 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 108863-62-3 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 108863-62-3 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 108863-62-3 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 108863-62-3 PHENELZINE THERAPEUTIC_CLASS Antidepressants 108863-62-3 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 108863-62-3 PHENELZINE INDICATION Depression 108863-62-3 PHENELZINE MESH_LEVEL_2 Hydrazines 108863-62-3 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 108863-62-3 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 108863-62-3 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 108863-62-3 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 108863-62-3 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 108863-62-3 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 108863-62-3 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 156-51-4 PHENELZINE ZERO_CLASS N 156-51-4 PHENELZINE MECH_LEVEL_3 Mono amine oxidase 156-51-4 PHENELZINE TA_LEVEL_3 depression 156-51-4 PHENELZINE MECHANISM Prolong/enhance neural transmission 156-51-4 PHENELZINE TISSUE_TOXICITY Acute Hepatocellular Necrosis 156-51-4 PHENELZINE ADVERSE_EFFECT PSY_3_Delirium 156-51-4 PHENELZINE ADVERSE_EFFECT XXX_1_Weakness 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Headache 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Hyperreflexia 156-51-4 PHENELZINE ADVERSE_EFFECT PSY_2_Euphoria 156-51-4 PHENELZINE ADVERSE_EFFECT CVS_1_Postural Hypotension 156-51-4 PHENELZINE ADVERSE_EFFECT PSY_3_Mania 156-51-4 PHENELZINE STRUCTURE_ACTIVITY Monoamine oxidase/ Catechol-O-methyl transferase inhibitor 156-51-4 PHENELZINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 156-51-4 PHENELZINE MECH_LEVEL_2 Prolong/enhance neural transmission 156-51-4 PHENELZINE MECH_LEVEL_1 Modulate neural transmission 156-51-4 PHENELZINE MESH_LEVEL_1 Organic Chemicals 156-51-4 PHENELZINE MODE_CLASS Enzyme Inhibitor 156-51-4 PHENELZINE ADVERSE_EFFECT GIS_1_Constipation 156-51-4 PHENELZINE ADVERSE_EFFECT XXX_1_Fatigue 156-51-4 PHENELZINE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 156-51-4 PHENELZINE ADVERSE_EFFECT SKN_2_Pruritis 156-51-4 PHENELZINE ADVERSE_EFFECT XXX_1_Weight Gain 156-51-4 PHENELZINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 156-51-4 PHENELZINE ADVERSE_EFFECT LIV_3_Acute Hepatocellular Necrosis 156-51-4 PHENELZINE ADVERSE_EFFECT END_3_Hypermetabolic Syndrome 156-51-4 PHENELZINE MESH_LEVEL_2 Hydrazines 156-51-4 PHENELZINE INDICATION Depression 156-51-4 PHENELZINE TA_LEVEL_1 Central Nervous System (CNS) 156-51-4 PHENELZINE THERAPEUTIC_CLASS Antidepressants 156-51-4 PHENELZINE ADVERSE_EFFECT GUS_2_Urinary Retention 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Tremor 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Sleep Disturbances 156-51-4 PHENELZINE ADVERSE_EFFECT XXX_1_Edema 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Drowsiness 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_2_Nystagmus 156-51-4 PHENELZINE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Myoclonic Jerks 156-51-4 PHENELZINE ADVERSE_EFFECT ELT_3_Hypernatremia 156-51-4 PHENELZINE MESH_LEVEL_3 Phenelzine 156-51-4 PHENELZINE PRODUCT_CLASS Central Nervous System (CNS) 156-51-4 PHENELZINE TA_LEVEL_2 CNS Stimulant 156-51-4 PHENELZINE INDICATION Anxiety Disorders 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_3_Convulsions 156-51-4 PHENELZINE ADVERSE_EFFECT GIS_1_Dry Mouth 156-51-4 PHENELZINE ADVERSE_EFFECT REP_1_Sexual Dysfunction 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_1_Dizziness 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_2_Paresthesia 156-51-4 PHENELZINE ADVERSE_EFFECT NEU_3_Ataxia 156-51-4 PHENELZINE ADVERSE_EFFECT BBM_3_Leukopenia 156-51-4 PHENELZINE ADVERSE_EFFECT SKN_2_Skin Rash 156-51-4 PHENELZINE ADVERSE_EFFECT OCU_2_Glaucoma 156-51-4 PHENELZINE THERAPEUTIC_CLASS Sedatives/Hypnotics 156-51-4 PHENELZINE KNOWN_TOXICITY Hepatotoxicity 57-30-7 PHENOBARBITAL ACTIVITY_CLASS GABA agonist 57-30-7 PHENOBARBITAL TISSUE_TOXICITY Teratogenicity 57-30-7 PHENOBARBITAL ADVERSE_EFFECT CVS_2_Bradycardia 57-30-7 PHENOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57-30-7 PHENOBARBITAL ADVERSE_EFFECT IMU_3_Hypersensitivity 57-30-7 PHENOBARBITAL ADVERSE_EFFECT NEU_2_Ataxia 57-30-7 PHENOBARBITAL KNOWN_TOXICITY Embryo/Fetal Toxicity 57-30-7 PHENOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 57-30-7 PHENOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 57-30-7 PHENOBARBITAL MECH_LEVEL_3 GABA-A receptor 57-30-7 PHENOBARBITAL MECH_LEVEL_1 Modulate neural transmission 57-30-7 PHENOBARBITAL INDICATION Benign Febrile Convulsions of Infancy 57-30-7 PHENOBARBITAL INDICATION Tonic-Clonic (Grand Mal) Seizures 57-30-7 PHENOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 57-30-7 PHENOBARBITAL ADVERSE_EFFECT EMB_2_Teratogenicity 57-30-7 PHENOBARBITAL ADVERSE_EFFECT CVS_2_Hypotension 57-30-7 PHENOBARBITAL ADVERSE_EFFECT IMU_3_Anaphylaxis 57-30-7 PHENOBARBITAL ADVERSE_EFFECT PSY_1_Physical Dependence 57-30-7 PHENOBARBITAL MESH_LEVEL_1 Heterocyclic Compounds 57-30-7 PHENOBARBITAL ZERO_CLASS N 57-30-7 PHENOBARBITAL TISSUE_TOXICITY Hepatotoxicity 57-30-7 PHENOBARBITAL MESH_LEVEL_3 Pyrimidines 57-30-7 PHENOBARBITAL TA_LEVEL_2 CNS Depressant 57-30-7 PHENOBARBITAL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 57-30-7 PHENOBARBITAL TA_LEVEL_3 Antiepileptics / Anticonvulsants 57-30-7 PHENOBARBITAL MODE_CLASS Channel Modulator 57-30-7 PHENOBARBITAL ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 57-30-7 PHENOBARBITAL MECH_LEVEL_2 faciliates GABA binding 57-30-7 PHENOBARBITAL ADVERSE_EFFECT NEU_3_Hyperkinesia 57-30-7 PHENOBARBITAL INDICATION Status Epilepticus 57-30-7 PHENOBARBITAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 57-30-7 PHENOBARBITAL ADVERSE_EFFECT LUN_3_Apnea 57-30-7 PHENOBARBITAL ADVERSE_EFFECT PSY_2_CNS Depression 57-30-7 PHENOBARBITAL ADVERSE_EFFECT SKN_2_Rash 57-30-7 PHENOBARBITAL ADVERSE_EFFECT PSY_1_Psychologic Dependence 57-30-7 PHENOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 57-30-7 PHENOBARBITAL TISSUE_TOXICITY Hypotension 57-30-7 PHENOBARBITAL KNOWN_TOXICITY Hepatotoxicity 57-30-7 PHENOBARBITAL MECHANISM Modulate neural transmission 57-30-7 PHENOBARBITAL INDICATION Partial Seizures 57-30-7 PHENOBARBITAL TA_LEVEL_1 Central Nervous System (CNS) 57-30-7 PHENOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 57-30-7 PHENOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 57-30-7 PHENOBARBITAL ADVERSE_EFFECT NEU_1_Somnolence 57-30-7 PHENOBARBITAL ADVERSE_EFFECT LUN_2_Respiratory Depression 57-30-7 PHENOBARBITAL ADVERSE_EFFECT NEU_2_Dizziness 57-30-7 PHENOBARBITAL ADVERSE_EFFECT XXX_1_Tolerance 57-30-7 PHENOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 57-30-7 PHENOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 50-06-6 PHENOBARBITAL MESH_LEVEL_3 Pyrimidines 50-06-6 PHENOBARBITAL TA_LEVEL_2 CNS Depressant 50-06-6 PHENOBARBITAL TISSUE_TOXICITY Hepatotoxicity 50-06-6 PHENOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 50-06-6 PHENOBARBITAL ACTIVITY_CLASS GABA agonist 50-06-6 PHENOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 50-06-6 PHENOBARBITAL ADVERSE_EFFECT XXX_1_Tolerance 50-06-6 PHENOBARBITAL ADVERSE_EFFECT NEU_2_Dizziness 50-06-6 PHENOBARBITAL ADVERSE_EFFECT LUN_2_Respiratory Depression 50-06-6 PHENOBARBITAL ADVERSE_EFFECT NEU_1_Somnolence 50-06-6 PHENOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 50-06-6 PHENOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 50-06-6 PHENOBARBITAL TA_LEVEL_1 Central Nervous System (CNS) 50-06-6 PHENOBARBITAL INDICATION Partial Seizures 50-06-6 PHENOBARBITAL MECHANISM Modulate neural transmission 50-06-6 PHENOBARBITAL KNOWN_TOXICITY Hepatotoxicity 50-06-6 PHENOBARBITAL TISSUE_TOXICITY Hypotension 50-06-6 PHENOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 50-06-6 PHENOBARBITAL ADVERSE_EFFECT PSY_1_Psychologic Dependence 50-06-6 PHENOBARBITAL ADVERSE_EFFECT SKN_2_Rash 50-06-6 PHENOBARBITAL ADVERSE_EFFECT PSY_2_CNS Depression 50-06-6 PHENOBARBITAL ADVERSE_EFFECT LUN_3_Apnea 50-06-6 PHENOBARBITAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 50-06-6 PHENOBARBITAL INDICATION Status Epilepticus 50-06-6 PHENOBARBITAL MECH_LEVEL_2 faciliates GABA binding 50-06-6 PHENOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 50-06-6 PHENOBARBITAL MESH_LEVEL_1 Heterocyclic Compounds 50-06-6 PHENOBARBITAL INDICATION Tonic-Clonic (Grand Mal) Seizures 50-06-6 PHENOBARBITAL ZERO_CLASS N 50-06-6 PHENOBARBITAL ADVERSE_EFFECT PSY_1_Physical Dependence 50-06-6 PHENOBARBITAL ADVERSE_EFFECT IMU_3_Anaphylaxis 50-06-6 PHENOBARBITAL ADVERSE_EFFECT CVS_2_Hypotension 50-06-6 PHENOBARBITAL ADVERSE_EFFECT EMB_2_Teratogenicity 50-06-6 PHENOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 50-06-6 PHENOBARBITAL MECH_LEVEL_1 Modulate neural transmission 50-06-6 PHENOBARBITAL MECH_LEVEL_3 GABA-A receptor 50-06-6 PHENOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 50-06-6 PHENOBARBITAL KNOWN_TOXICITY Embryo/Fetal Toxicity 50-06-6 PHENOBARBITAL ADVERSE_EFFECT NEU_2_Ataxia 50-06-6 PHENOBARBITAL ADVERSE_EFFECT IMU_3_Hypersensitivity 50-06-6 PHENOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-06-6 PHENOBARBITAL ADVERSE_EFFECT CVS_2_Bradycardia 50-06-6 PHENOBARBITAL TISSUE_TOXICITY Teratogenicity 50-06-6 PHENOBARBITAL ADVERSE_EFFECT NEU_3_Hyperkinesia 50-06-6 PHENOBARBITAL ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 50-06-6 PHENOBARBITAL INDICATION Benign Febrile Convulsions of Infancy 50-06-6 PHENOBARBITAL MODE_CLASS Channel Modulator 50-06-6 PHENOBARBITAL TA_LEVEL_3 Antiepileptics / Anticonvulsants 50-06-6 PHENOBARBITAL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 108-95-2 PHENOL PRODUCT_CLASS Analgesics 108-95-2 PHENOL ADVERSE_EFFECT OCU_3_Ocular Damage 108-95-2 PHENOL ADVERSE_EFFECT LIV_3_Hepatic Damage 108-95-2 PHENOL KNOWN_TOXICITY Cardiovascular Toxicity 108-95-2 PHENOL ADVERSE_EFFECT OCU_2_Eye Irritation 108-95-2 PHENOL ADVERSE_EFFECT GIS_2_Gastrointestinal Irritation 108-95-2 PHENOL ADVERSE_EFFECT LIV_1_Hepatotoxicity 108-95-2 PHENOL ADVERSE_EFFECT GIS_1_Diarrhea 108-95-2 PHENOL THERAPEUTIC_CLASS Local Anesthetics 108-95-2 PHENOL INDICATION Skin Infections 108-95-2 PHENOL ADVERSE_EFFECT LUN_2_Pulmonary Irritation 108-95-2 PHENOL ADVERSE_EFFECT GUS_1_Discoloration of Urine 108-95-2 PHENOL ADVERSE_EFFECT CVS_3_Shock 108-95-2 PHENOL ADVERSE_EFFECT PSY_3_Delirium 108-95-2 PHENOL KNOWN_TOXICITY Miscellaneous 108-95-2 PHENOL KNOWN_TOXICITY Hepatotoxicity 108-95-2 PHENOL ADVERSE_EFFECT XXX_2_Edema 108-95-2 PHENOL INDICATION Topical Anesthesia 108-95-2 PHENOL ADVERSE_EFFECT SKN_1_Skin Irritation 108-95-2 PHENOL TISSUE_TOXICITY Shock 108-95-2 PHENOL PRODUCT_CLASS Central Nervous System (CNS) 108-95-2 PHENOL STRUCTURE_ACTIVITY Toxicant 108-95-2 PHENOL ADVERSE_EFFECT KID_3_Kidney Damage 108-95-2 PHENOL ADVERSE_EFFECT SKN_2_Skin Pigmentation 108-95-2 PHENOL THERAPEUTIC_CLASS Analgesics, Topical 108-95-2 PHENOL TISSUE_TOXICITY Death 108-95-2 PHENOL TISSUE_TOXICITY Hepatotoxicity 108-95-2 PHENOL ADVERSE_EFFECT XXX_3_Death 63-92-3 PHENOXYBENZAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 63-92-3 PHENOXYBENZAMINE MODE_CLASS Solute transporter inhibitor 63-92-3 PHENOXYBENZAMINE MECHANISM Modulate G-protein coupled signal transduction 63-92-3 PHENOXYBENZAMINE THERAPEUTIC_CLASS Sympatholytic Agents 63-92-3 PHENOXYBENZAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 63-92-3 PHENOXYBENZAMINE MECHANISM Prolong/enhance neural transmission 63-92-3 PHENOXYBENZAMINE INDICATION Pheochromocytoma 59-96-1 PHENOXYBENZAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 59-96-1 PHENOXYBENZAMINE MECHANISM Modulate G-protein coupled signal transduction 59-96-1 PHENOXYBENZAMINE MECHANISM Prolong/enhance neural transmission 59-96-1 PHENOXYBENZAMINE MODE_CLASS Solute transporter inhibitor 59-96-1 PHENOXYBENZAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 59-96-1 PHENOXYBENZAMINE INDICATION Pheochromocytoma 59-96-1 PHENOXYBENZAMINE THERAPEUTIC_CLASS Sympatholytic Agents 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_3_Depression 1197-21-3 PHENTERMINE ADVERSE_EFFECT GIS_1_Constipation 1197-21-3 PHENTERMINE ADVERSE_EFFECT XXX_2_Tolerance 1197-21-3 PHENTERMINE KNOWN_TOXICITY Cardiovascular Toxicity 1197-21-3 PHENTERMINE ADVERSE_EFFECT REP_2_Decreased Libido 1197-21-3 PHENTERMINE ADVERSE_EFFECT NEU_2_Headache 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_1_Dysphoria 1197-21-3 PHENTERMINE ADVERSE_EFFECT CVS_1_Palpitation 1197-21-3 PHENTERMINE ADVERSE_EFFECT OCU_2_Blurred Vision 1197-21-3 PHENTERMINE MODE_CLASS Channel Blocker 1197-21-3 PHENTERMINE ADVERSE_EFFECT GIS_1_Diarrhea 1197-21-3 PHENTERMINE MECHANISM Block channel gating 1197-21-3 PHENTERMINE PRODUCT_CLASS Central Nervous System (CNS) 1197-21-3 PHENTERMINE TISSUE_TOXICITY Angina Pectoris 1197-21-3 PHENTERMINE ADVERSE_EFFECT NEU_2_Tremor 1197-21-3 PHENTERMINE ADVERSE_EFFECT _2_Increased libido 1197-21-3 PHENTERMINE ADVERSE_EFFECT REP_2_Sexual Dysfunction 1197-21-3 PHENTERMINE ADVERSE_EFFECT LUN_2_Dyspnea 1197-21-3 PHENTERMINE ADVERSE_EFFECT CVS_2_Hypertension 1197-21-3 PHENTERMINE ADVERSE_EFFECT CVS_1_Tachycardia 1197-21-3 PHENTERMINE ADVERSE_EFFECT NEU_1_Dizziness 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_3_Psychosis 1197-21-3 PHENTERMINE ADVERSE_EFFECT XXX_1_Restlessness 1197-21-3 PHENTERMINE ADVERSE_EFFECT LUN_3_Pulmonary Hypertension 1197-21-3 PHENTERMINE THERAPEUTIC_CLASS Anorexiants 1197-21-3 PHENTERMINE ADVERSE_EFFECT OCU_2_Ocular Irritation 1197-21-3 PHENTERMINE ADVERSE_EFFECT GIS_1_Dysgeusia 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_1_Euphoria 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_1_Insomnia 1197-21-3 PHENTERMINE ADVERSE_EFFECT XXX_3_Peripheral Edema 1197-21-3 PHENTERMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1197-21-3 PHENTERMINE ADVERSE_EFFECT IMU_3_Urticaria 1197-21-3 PHENTERMINE INDICATION Obesity 1197-21-3 PHENTERMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 1197-21-3 PHENTERMINE ADVERSE_EFFECT XXX_1_Xerostomia 1197-21-3 PHENTERMINE ADVERSE_EFFECT NEU_3_Syncope 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_3_Psychologic Dependence 1197-21-3 PHENTERMINE ADVERSE_EFFECT PSY_2_Irritability 1197-21-3 PHENTERMINE ADVERSE_EFFECT XXX_1_Fatigue 1197-21-3 PHENTERMINE ADVERSE_EFFECT NEU_1_Dyskinesia 1197-21-3 PHENTERMINE ADVERSE_EFFECT OCU_1_Mydriasis 1197-21-3 PHENTERMINE ADVERSE_EFFECT CVS_3_Angina Pectoris 1197-21-3 PHENTERMINE MODE_CLASS Enzyme substrate mimic 1197-21-3 PHENTERMINE MECHANISM Prolong/enhance neural transmission 50-60-2 PHENTOLAMINE ADVERSE_EFFECT GIS_2_Diarrhea 50-60-2 PHENTOLAMINE MODE_CLASS Channel enhancer /opener 50-60-2 PHENTOLAMINE INDICATION Heart Failure 50-60-2 PHENTOLAMINE INDICATION Pheochromocytoma 50-60-2 PHENTOLAMINE PRODUCT_CLASS Cardiovasculars 50-60-2 PHENTOLAMINE MECH_LEVEL_2 Alpha antagonist 50-60-2 PHENTOLAMINE TA_LEVEL_1 Cardiovascular 50-60-2 PHENTOLAMINE ADVERSE_EFFECT REP_3_Priapism 50-60-2 PHENTOLAMINE ADVERSE_EFFECT XXX_2_Weakness 50-60-2 PHENTOLAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 50-60-2 PHENTOLAMINE TISSUE_TOXICITY Hypotension 50-60-2 PHENTOLAMINE THERAPEUTIC_CLASS Sympatholytic Agents 50-60-2 PHENTOLAMINE KNOWN_TOXICITY Cardiovascular Toxicity 50-60-2 PHENTOLAMINE TA_LEVEL_3 Hypertension 50-60-2 PHENTOLAMINE MESH_LEVEL_3 Imidazoles 50-60-2 PHENTOLAMINE MECH_LEVEL_1 Vasorelaxation 50-60-2 PHENTOLAMINE MECH_LEVEL_3 adrenoceptor alpha 50-60-2 PHENTOLAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 50-60-2 PHENTOLAMINE ADVERSE_EFFECT GIS_2_Stimulation of GI smooth muscle 50-60-2 PHENTOLAMINE MESH_LEVEL_1 Heterocyclic Compounds 50-60-2 PHENTOLAMINE MECHANISM Modulate G-protein coupled signal transduction 50-60-2 PHENTOLAMINE ZERO_CLASS N 50-60-2 PHENTOLAMINE ADVERSE_EFFECT NEU_2_Dizziness 50-60-2 PHENTOLAMINE INDICATION Erectile Dysfunction 50-60-2 PHENTOLAMINE STRUCTURE_ACTIVITY Adrenoceptor-alpha antagonist 50-60-2 PHENTOLAMINE ADVERSE_EFFECT SKN_1_Flushing 50-60-2 PHENTOLAMINE THERAPEUTIC_CLASS Vasodilators 50-60-2 PHENTOLAMINE ADVERSE_EFFECT REP_3_Impaired Ejaculation 50-60-2 PHENTOLAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 50-60-2 PHENTOLAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 50-60-2 PHENTOLAMINE INDICATION Dermal Necrosis 50-60-2 PHENTOLAMINE ACTIVITY_CLASS Adrenergic antagonist 50-60-2 PHENTOLAMINE ADVERSE_EFFECT XXX_1_Nasal Congestion 50-60-2 PHENTOLAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-60-2 PHENTOLAMINE ADVERSE_EFFECT CVS_1_Hypotension 50-60-2 PHENTOLAMINE TA_LEVEL_2 Hypertension 50-60-2 PHENTOLAMINE MECHANISM Reduce muscle contractile force 50-60-2 PHENTOLAMINE INDICATION Hypertensive Emergency 50-60-2 PHENTOLAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 50-60-2 PHENTOLAMINE TISSUE_TOXICITY Angina 50-60-2 PHENTOLAMINE ADVERSE_EFFECT CVS_2_Angina 118-55-8 PHENYL SALICYLATE MECHANISM Inhibit inflammatory response 118-55-8 PHENYL SALICYLATE MODE_CLASS Enzyme Inhibitor 118-55-8 PHENYL SALICYLATE MECHANISM Inhibit eicosanoid biosynthesis 118-55-8 PHENYL SALICYLATE MODE_CLASS Enzyme Inhibitor, selective 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT KID_3_Acute Tubular Necrosis 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Pancreatitis 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Ulcer Perforation 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_1_Gastritis 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 129-18-0 PHENYLBUTAZONE TISSUE_TOXICITY Acute Tubular Necrosis 129-18-0 PHENYLBUTAZONE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 129-18-0 PHENYLBUTAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 129-18-0 PHENYLBUTAZONE KNOWN_TOXICITY Cardiovascular Toxicity 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Diarrhea 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT IMU_3_Anaphylaxis 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT LIV_3_Hepatic Failure 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Stomatitis 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT SKN_2_Skin Rash 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 129-18-0 PHENYLBUTAZONE TISSUE_TOXICITY Renal Failure 129-18-0 PHENYLBUTAZONE TISSUE_TOXICITY Hepatic Failure 129-18-0 PHENYLBUTAZONE TA_LEVEL_1 Anti-inflammatory 129-18-0 PHENYLBUTAZONE TA_LEVEL_2 NSAID 129-18-0 PHENYLBUTAZONE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 129-18-0 PHENYLBUTAZONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 129-18-0 PHENYLBUTAZONE KNOWN_TOXICITY Hepatotoxicity 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT XXX_1_Edema 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT LUN_3_Bronchospasm 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT CVS_3_Cardiac Failure 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT KID_3_Renal Failure 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT LUN_3_Exacerbation of Asthma 129-18-0 PHENYLBUTAZONE TISSUE_TOXICITY Cardiac Failure 129-18-0 PHENYLBUTAZONE ACTIVITY_CLASS Anti-inflammatory 129-18-0 PHENYLBUTAZONE ZERO_CLASS N 129-18-0 PHENYLBUTAZONE MECH_LEVEL_1 Immunomodulation 129-18-0 PHENYLBUTAZONE MESH_LEVEL_3 Pyrazoles 129-18-0 PHENYLBUTAZONE MECHANISM Inhibit eicosanoid biosynthesis 129-18-0 PHENYLBUTAZONE MESH_LEVEL_1 Heterocyclic Compounds 129-18-0 PHENYLBUTAZONE INDICATION Ankylosing Spondylitis 129-18-0 PHENYLBUTAZONE PRODUCT_CLASS Anti-inflammatories 129-18-0 PHENYLBUTAZONE KNOWN_TOXICITY Nephrotoxicity 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT END_3_Hypothyroidism 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Peptic Ulceration 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Pancytopenia 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT KID_1_Fluid Retention 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 129-18-0 PHENYLBUTAZONE TISSUE_TOXICITY Fulminant Hepatitis 129-18-0 PHENYLBUTAZONE STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 129-18-0 PHENYLBUTAZONE TA_LEVEL_3 NSAID 129-18-0 PHENYLBUTAZONE MODE_CLASS Enzyme Inhibitor 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_1_Nausea 129-18-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Agranulocytosis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Agranulocytosis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT KID_3_Acute Tubular Necrosis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Pancreatitis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Ulcer Perforation 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_1_Gastritis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 88873-75-0 PHENYLBUTAZONE TISSUE_TOXICITY Acute Tubular Necrosis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT LUN_3_Bronchospasm 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 88873-75-0 PHENYLBUTAZONE KNOWN_TOXICITY Cardiovascular Toxicity 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Diarrhea 88873-75-0 PHENYLBUTAZONE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT IMU_3_Anaphylaxis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT LIV_3_Hepatic Failure 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Stomatitis 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT SKN_2_Skin Rash 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 88873-75-0 PHENYLBUTAZONE TISSUE_TOXICITY Renal Failure 88873-75-0 PHENYLBUTAZONE TISSUE_TOXICITY Hepatic Failure 88873-75-0 PHENYLBUTAZONE TA_LEVEL_1 Anti-inflammatory 88873-75-0 PHENYLBUTAZONE TA_LEVEL_2 NSAID 88873-75-0 PHENYLBUTAZONE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 88873-75-0 PHENYLBUTAZONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 88873-75-0 PHENYLBUTAZONE KNOWN_TOXICITY Hepatotoxicity 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT XXX_1_Edema 88873-75-0 PHENYLBUTAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT CVS_3_Cardiac Failure 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT KID_3_Renal Failure 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT LUN_3_Exacerbation of Asthma 88873-75-0 PHENYLBUTAZONE TISSUE_TOXICITY Cardiac Failure 88873-75-0 PHENYLBUTAZONE ACTIVITY_CLASS Anti-inflammatory 88873-75-0 PHENYLBUTAZONE ZERO_CLASS N 88873-75-0 PHENYLBUTAZONE MECH_LEVEL_1 Immunomodulation 88873-75-0 PHENYLBUTAZONE MESH_LEVEL_3 Pyrazoles 88873-75-0 PHENYLBUTAZONE MECHANISM Inhibit eicosanoid biosynthesis 88873-75-0 PHENYLBUTAZONE MESH_LEVEL_1 Heterocyclic Compounds 88873-75-0 PHENYLBUTAZONE INDICATION Ankylosing Spondylitis 88873-75-0 PHENYLBUTAZONE PRODUCT_CLASS Anti-inflammatories 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT END_3_Hypothyroidism 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_2_Peptic Ulceration 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT BBM_3_Pancytopenia 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT KID_1_Fluid Retention 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 88873-75-0 PHENYLBUTAZONE TISSUE_TOXICITY Fulminant Hepatitis 88873-75-0 PHENYLBUTAZONE STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 88873-75-0 PHENYLBUTAZONE TA_LEVEL_3 NSAID 88873-75-0 PHENYLBUTAZONE MODE_CLASS Enzyme Inhibitor 88873-75-0 PHENYLBUTAZONE ADVERSE_EFFECT GIS_1_Nausea 88873-75-0 PHENYLBUTAZONE KNOWN_TOXICITY Nephrotoxicity 59-88-1 PHENYLHYDRAZINE PRODUCT_CLASS Biochemicals 59-88-1 PHENYLHYDRAZINE TA_LEVEL_2 biochemical 59-88-1 PHENYLHYDRAZINE MECH_LEVEL_2 Enzyme inhibitor 59-88-1 PHENYLHYDRAZINE ADVERSE_EFFECT BBM_3_Hemolysis 59-88-1 PHENYLHYDRAZINE ACTIVITY_CLASS Dopamine antagonist 59-88-1 PHENYLHYDRAZINE MECHANISM Interferes with neural transmitter synthesis 59-88-1 PHENYLHYDRAZINE ADVERSE_EFFECT SKN_3_Erythema 59-88-1 PHENYLHYDRAZINE STRUCTURE_ACTIVITY Dopamine synthesis inhibitor, dopamine-beta-monooxygenase inhibitor 59-88-1 PHENYLHYDRAZINE ZERO_CLASS N 59-88-1 PHENYLHYDRAZINE MESH_LEVEL_3 Phenylhydrazines 59-88-1 PHENYLHYDRAZINE TA_LEVEL_1 biochemical 59-88-1 PHENYLHYDRAZINE MESH_LEVEL_1 Organic Chemicals 59-88-1 PHENYLHYDRAZINE MESH_LEVEL_2 Hydrazines 59-88-1 PHENYLHYDRAZINE MECH_LEVEL_3 Dopamine-beta-monooxygenase 59-88-1 PHENYLHYDRAZINE MODE_CLASS Enzyme Inhibitor 59-88-1 PHENYLHYDRAZINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 59-88-1 PHENYLHYDRAZINE TA_LEVEL_3 biochemical 59-88-1 PHENYLHYDRAZINE ADVERSE_EFFECT SKN_3_Skin Irritation 17198-21-9 PHENYLHYDRAZINE PRODUCT_CLASS Biochemicals 17198-21-9 PHENYLHYDRAZINE TA_LEVEL_2 biochemical 17198-21-9 PHENYLHYDRAZINE MECH_LEVEL_2 Enzyme inhibitor 17198-21-9 PHENYLHYDRAZINE ADVERSE_EFFECT BBM_3_Hemolysis 17198-21-9 PHENYLHYDRAZINE ACTIVITY_CLASS Dopamine antagonist 17198-21-9 PHENYLHYDRAZINE MECHANISM Interferes with neural transmitter synthesis 17198-21-9 PHENYLHYDRAZINE ADVERSE_EFFECT SKN_3_Erythema 17198-21-9 PHENYLHYDRAZINE STRUCTURE_ACTIVITY Dopamine synthesis inhibitor, dopamine-beta-monooxygenase inhibitor 17198-21-9 PHENYLHYDRAZINE ZERO_CLASS N 17198-21-9 PHENYLHYDRAZINE MESH_LEVEL_3 Phenylhydrazines 17198-21-9 PHENYLHYDRAZINE TA_LEVEL_1 biochemical 17198-21-9 PHENYLHYDRAZINE MESH_LEVEL_2 Hydrazines 17198-21-9 PHENYLHYDRAZINE MECH_LEVEL_3 Dopamine-beta-monooxygenase 17198-21-9 PHENYLHYDRAZINE MODE_CLASS Enzyme Inhibitor 17198-21-9 PHENYLHYDRAZINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 17198-21-9 PHENYLHYDRAZINE TA_LEVEL_3 biochemical 17198-21-9 PHENYLHYDRAZINE ADVERSE_EFFECT SKN_3_Skin Irritation 17198-21-9 PHENYLHYDRAZINE MESH_LEVEL_1 Organic Chemicals 100-63-0 PHENYLHYDRAZINE TA_LEVEL_2 biochemical 100-63-0 PHENYLHYDRAZINE MECH_LEVEL_2 Enzyme inhibitor 100-63-0 PHENYLHYDRAZINE ADVERSE_EFFECT BBM_3_Hemolysis 100-63-0 PHENYLHYDRAZINE ACTIVITY_CLASS Dopamine antagonist 100-63-0 PHENYLHYDRAZINE MECHANISM Interferes with neural transmitter synthesis 100-63-0 PHENYLHYDRAZINE MODE_CLASS Enzyme Inhibitor 100-63-0 PHENYLHYDRAZINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 100-63-0 PHENYLHYDRAZINE TA_LEVEL_3 biochemical 100-63-0 PHENYLHYDRAZINE ADVERSE_EFFECT SKN_3_Skin Irritation 100-63-0 PHENYLHYDRAZINE ZERO_CLASS N 100-63-0 PHENYLHYDRAZINE ADVERSE_EFFECT SKN_3_Erythema 100-63-0 PHENYLHYDRAZINE MESH_LEVEL_3 Phenylhydrazines 100-63-0 PHENYLHYDRAZINE TA_LEVEL_1 biochemical 100-63-0 PHENYLHYDRAZINE STRUCTURE_ACTIVITY Dopamine synthesis inhibitor, dopamine-beta-monooxygenase inhibitor 100-63-0 PHENYLHYDRAZINE MESH_LEVEL_2 Hydrazines 100-63-0 PHENYLHYDRAZINE MECH_LEVEL_3 Dopamine-beta-monooxygenase 100-63-0 PHENYLHYDRAZINE PRODUCT_CLASS Biochemicals 100-63-0 PHENYLHYDRAZINE MESH_LEVEL_1 Organic Chemicals 14838-15-4 PHENYLPROPANOLAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 14838-15-4 PHENYLPROPANOLAMINE INDICATION Viral Rhinitis / Common Cold 14838-15-4 PHENYLPROPANOLAMINE MODE_CLASS Receptor Agonist 14838-15-4 PHENYLPROPANOLAMINE INDICATION Obesity 14838-15-4 PHENYLPROPANOLAMINE PRODUCT_CLASS Central Nervous System (CNS) 14838-15-4 PHENYLPROPANOLAMINE INDICATION Sinusitis 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Exacerbation of Arrhythmia 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Acute Interstitial Nephritis 14838-15-4 PHENYLPROPANOLAMINE KNOWN_TOXICITY Cardiovascular Toxicity 14838-15-4 PHENYLPROPANOLAMINE INDICATION Nasal Congestion 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT XXX_1_Restlessness 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_3_Visual Hallucinations 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT LUN_2_Tachypnea 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_2_Mental Confusion 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_2_Hypertension 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_3_Convulsions 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_2_Anxiety 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT OCU_2_Acute Angle-Closure Glaucoma 14838-15-4 PHENYLPROPANOLAMINE INDICATION Allergic Rhinitis 14838-15-4 PHENYLPROPANOLAMINE INDICATION Nasal Congestion 14838-15-4 PHENYLPROPANOLAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 14838-15-4 PHENYLPROPANOLAMINE STRUCTURE_ACTIVITY Sympathomimetic amine 14838-15-4 PHENYLPROPANOLAMINE INDICATION Rhinorrhea 14838-15-4 PHENYLPROPANOLAMINE INDICATION Viral Rhinitis / Common Cold 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Stroke 14838-15-4 PHENYLPROPANOLAMINE KNOWN_TOXICITY Nephrotoxicity 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT XXX_2_Diaphoresis 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT XXX_1_Asthenia 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT KID_2_Acute Interstitial Nephritis 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_1_Psychomotor Excitation 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_1_Palpitation 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT XXX_1_Xerostomia 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT XXX_2_Thirst 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_2_Stroke 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT OCU_2_Mydriasis 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_1_Insomnia 14838-15-4 PHENYLPROPANOLAMINE INDICATION Rhinorrhea 14838-15-4 PHENYLPROPANOLAMINE INDICATION Urinary Incontinence / Enuresis 14838-15-4 PHENYLPROPANOLAMINE MECHANISM Increase vasoconstriction 14838-15-4 PHENYLPROPANOLAMINE INDICATION Allergic Rhinitis 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Supraventricular Tachycardia 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_3_Seizures 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_3_Psychosis 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_2_Panic Reactions 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_1_Tremor 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_3_Supraventricular Tachycardia 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_3_Exacerbation of Arrhythmia 14838-15-4 PHENYLPROPANOLAMINE THERAPEUTIC_CLASS Anorexiants 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_1_Dizziness 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_3_Auditory Hallucinations 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_3_Angina 14838-15-4 PHENYLPROPANOLAMINE INDICATION Sinusitis 14838-15-4 PHENYLPROPANOLAMINE MECHANISM Modulate G-protein coupled signal transduction 14838-15-4 PHENYLPROPANOLAMINE INDICATION Obesity 14838-15-4 PHENYLPROPANOLAMINE INDICATION Urinary Incontinence / Enuresis 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Angina 14838-15-4 PHENYLPROPANOLAMINE TISSUE_TOXICITY Myocardial Infarction 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_1_Irritability 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_1_Headache 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT GUS_1_Dysuria 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_3_Cerebral Hemorrhage 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT PSY_1_Anorexia 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT KID_2_Renal Insufficiency 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_2_Premature Atrial Contractions 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT NEU_1_Vertigo 14838-15-4 PHENYLPROPANOLAMINE ADVERSE_EFFECT XXX_1_Sweating 1176-08-5 PHENYLTOLOXAMINE MODE_CLASS Receptor Ligand Antagonist 1176-08-5 PHENYLTOLOXAMINE MECHANISM Modulate G-protein coupled signal transduction 92-12-6 PHENYLTOLOXAMINE MODE_CLASS Receptor Ligand Antagonist 92-12-6 PHENYLTOLOXAMINE MECHANISM Modulate G-protein coupled signal transduction 57-41-0 PHENYTOIN ADVERSE_EFFECT PSY_1_Anorexia 57-41-0 PHENYTOIN ADVERSE_EFFECT IMU_2_Lupus-Like Syndrome 57-41-0 PHENYTOIN ADVERSE_EFFECT END_2_Hypothyroidism 57-41-0 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatitis 57-41-0 PHENYTOIN MECH_LEVEL_1 Modulate neural transmission 57-41-0 PHENYTOIN TA_LEVEL_3 Antiepileptics / Anticonvulsants 57-41-0 PHENYTOIN MECHANISM Modulate channel gating 57-41-0 PHENYTOIN INDICATION Partial Seizures 57-41-0 PHENYTOIN INDICATION Epilepsy 57-41-0 PHENYTOIN INDICATION Complex Partial Seizures 57-41-0 PHENYTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 57-41-0 PHENYTOIN ADVERSE_EFFECT REP_3_Priapism 57-41-0 PHENYTOIN ADVERSE_EFFECT LYM_3_Pseudo-Lymphoma 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_1_Nystagmus 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_3_Choreoathetosis 57-41-0 PHENYTOIN MECH_LEVEL_2 Sodium channel antagonist 57-41-0 PHENYTOIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 57-41-0 PHENYTOIN ADVERSE_EFFECT KID_3_Proteinuria 57-41-0 PHENYTOIN ADVERSE_EFFECT BBM_3_Granulocytopenia 57-41-0 PHENYTOIN ADVERSE_EFFECT GIS_1_Constipation 57-41-0 PHENYTOIN ADVERSE_EFFECT REP_2_Impotence 57-41-0 PHENYTOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_1_Ataxia 57-41-0 PHENYTOIN MODE_CLASS Channel Blocker 57-41-0 PHENYTOIN TISSUE_TOXICITY Lymphoma 57-41-0 PHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 57-41-0 PHENYTOIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 57-41-0 PHENYTOIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 57-41-0 PHENYTOIN ADVERSE_EFFECT EMB_2_Fetal Hydantoin Syndrome 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_2_Dystonia 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_2_Skin Pigmentation 57-41-0 PHENYTOIN ADVERSE_EFFECT LIV_3_Cholestasis 57-41-0 PHENYTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57-41-0 PHENYTOIN ADVERSE_EFFECT END_2_Hirsutism 57-41-0 PHENYTOIN KNOWN_TOXICITY Carcinogenicity 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_1_Drowsiness 57-41-0 PHENYTOIN KNOWN_TOXICITY Nephrotoxicity 57-41-0 PHENYTOIN TISSUE_TOXICITY Glomerulonephritis 57-41-0 PHENYTOIN MESH_LEVEL_1 Heterocyclic Compounds 57-41-0 PHENYTOIN TA_LEVEL_1 Central Nervous System (CNS) 57-41-0 PHENYTOIN MESH_LEVEL_3 Imidazoles 57-41-0 PHENYTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 57-41-0 PHENYTOIN INDICATION Tonic-Clonic (Grand Mal) Seizures 57-41-0 PHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 57-41-0 PHENYTOIN MECH_LEVEL_3 Voltage-gated Na+ channel 57-41-0 PHENYTOIN MECHANISM Block neural transmission 57-41-0 PHENYTOIN KNOWN_TOXICITY Hepatotoxicity 57-41-0 PHENYTOIN TISSUE_TOXICITY Hepatic Necrosis 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_1_Hypertrichosis 57-41-0 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatomegaly 57-41-0 PHENYTOIN ADVERSE_EFFECT GIS_1_Gingival Hyperplasia 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 57-41-0 PHENYTOIN TA_LEVEL_2 CNS Depressant 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 57-41-0 PHENYTOIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 57-41-0 PHENYTOIN ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 57-41-0 PHENYTOIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 57-41-0 PHENYTOIN ADVERSE_EFFECT REP_2_Decreased Libido 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 57-41-0 PHENYTOIN TISSUE_TOXICITY Nephrotic Syndrome 57-41-0 PHENYTOIN ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 57-41-0 PHENYTOIN ADVERSE_EFFECT BBM_3_Blood Dyscrasias 57-41-0 PHENYTOIN ADVERSE_EFFECT SKN_2_Bullous Rash 57-41-0 PHENYTOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 57-41-0 PHENYTOIN ADVERSE_EFFECT BBM_3_Pancytopenia 57-41-0 PHENYTOIN TISSUE_TOXICITY Interstitial Nephritis 57-41-0 PHENYTOIN INDICATION Status Epilepticus 57-41-0 PHENYTOIN ADVERSE_EFFECT DNA_3_Lymphoma 57-41-0 PHENYTOIN ADVERSE_EFFECT END_2_Hyperglycemia 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_1_Dizziness 57-41-0 PHENYTOIN ADVERSE_EFFECT NEU_3_Coma 57-41-0 PHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 57-41-0 PHENYTOIN ZERO_CLASS N 57-41-0 PHENYTOIN ACTIVITY_CLASS Na+ channel blocker 630-93-3 PHENYTOIN TISSUE_TOXICITY Lymphoma 630-93-3 PHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 630-93-3 PHENYTOIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 630-93-3 PHENYTOIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 630-93-3 PHENYTOIN ADVERSE_EFFECT EMB_2_Fetal Hydantoin Syndrome 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_2_Dystonia 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_2_Skin Pigmentation 630-93-3 PHENYTOIN ADVERSE_EFFECT LIV_3_Cholestasis 630-93-3 PHENYTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 630-93-3 PHENYTOIN ADVERSE_EFFECT END_2_Hirsutism 630-93-3 PHENYTOIN ADVERSE_EFFECT DNA_3_Lymphoma 630-93-3 PHENYTOIN ADVERSE_EFFECT END_2_Hyperglycemia 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_1_Dizziness 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_3_Coma 630-93-3 PHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 630-93-3 PHENYTOIN ZERO_CLASS N 630-93-3 PHENYTOIN ACTIVITY_CLASS Na+ channel blocker 630-93-3 PHENYTOIN MECH_LEVEL_1 Modulate neural transmission 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_1_Drowsiness 630-93-3 PHENYTOIN KNOWN_TOXICITY Carcinogenicity 630-93-3 PHENYTOIN MESH_LEVEL_3 Imidazoles 630-93-3 PHENYTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 630-93-3 PHENYTOIN INDICATION Tonic-Clonic (Grand Mal) Seizures 630-93-3 PHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 630-93-3 PHENYTOIN MECH_LEVEL_3 Voltage-gated Na+ channel 630-93-3 PHENYTOIN MECHANISM Block neural transmission 630-93-3 PHENYTOIN KNOWN_TOXICITY Hepatotoxicity 630-93-3 PHENYTOIN TA_LEVEL_3 Antiepileptics / Anticonvulsants 630-93-3 PHENYTOIN TISSUE_TOXICITY Hepatic Necrosis 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_1_Hypertrichosis 630-93-3 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatomegaly 630-93-3 PHENYTOIN ADVERSE_EFFECT GIS_1_Gingival Hyperplasia 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 630-93-3 PHENYTOIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 630-93-3 PHENYTOIN ADVERSE_EFFECT REP_2_Decreased Libido 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 630-93-3 PHENYTOIN ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 630-93-3 PHENYTOIN ADVERSE_EFFECT BBM_3_Blood Dyscrasias 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_2_Bullous Rash 630-93-3 PHENYTOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 630-93-3 PHENYTOIN ADVERSE_EFFECT BBM_3_Pancytopenia 630-93-3 PHENYTOIN TISSUE_TOXICITY Interstitial Nephritis 630-93-3 PHENYTOIN INDICATION Status Epilepticus 630-93-3 PHENYTOIN TISSUE_TOXICITY Nephrotic Syndrome 630-93-3 PHENYTOIN TISSUE_TOXICITY Glomerulonephritis 630-93-3 PHENYTOIN KNOWN_TOXICITY Nephrotoxicity 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_1_Ataxia 630-93-3 PHENYTOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 630-93-3 PHENYTOIN ADVERSE_EFFECT REP_2_Impotence 630-93-3 PHENYTOIN ADVERSE_EFFECT GIS_1_Constipation 630-93-3 PHENYTOIN ADVERSE_EFFECT BBM_3_Granulocytopenia 630-93-3 PHENYTOIN ADVERSE_EFFECT KID_3_Proteinuria 630-93-3 PHENYTOIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_3_Choreoathetosis 630-93-3 PHENYTOIN ADVERSE_EFFECT NEU_1_Nystagmus 630-93-3 PHENYTOIN ADVERSE_EFFECT LYM_3_Pseudo-Lymphoma 630-93-3 PHENYTOIN ADVERSE_EFFECT REP_3_Priapism 630-93-3 PHENYTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 630-93-3 PHENYTOIN INDICATION Complex Partial Seizures 630-93-3 PHENYTOIN INDICATION Epilepsy 630-93-3 PHENYTOIN INDICATION Partial Seizures 630-93-3 PHENYTOIN MECHANISM Modulate channel gating 630-93-3 PHENYTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 630-93-3 PHENYTOIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 630-93-3 PHENYTOIN ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 630-93-3 PHENYTOIN ADVERSE_EFFECT PSY_1_Anorexia 630-93-3 PHENYTOIN ADVERSE_EFFECT IMU_2_Lupus-Like Syndrome 630-93-3 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatitis 630-93-3 PHENYTOIN ADVERSE_EFFECT END_2_Hypothyroidism 630-93-3 PHENYTOIN MODE_CLASS Channel Blocker 630-93-3 PHENYTOIN TA_LEVEL_2 CNS Depressant 630-93-3 PHENYTOIN MESH_LEVEL_1 Heterocyclic Compounds 630-93-3 PHENYTOIN TA_LEVEL_1 Central Nervous System (CNS) 630-93-3 PHENYTOIN MECH_LEVEL_2 Sodium channel antagonist 125-59-7 PHENYTOIN ADVERSE_EFFECT PSY_1_Anorexia 125-59-7 PHENYTOIN ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_2_Bullous Rash 125-59-7 PHENYTOIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 125-59-7 PHENYTOIN ADVERSE_EFFECT GIS_1_Gingival Hyperplasia 125-59-7 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatomegaly 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_1_Hypertrichosis 125-59-7 PHENYTOIN TISSUE_TOXICITY Hepatic Necrosis 125-59-7 PHENYTOIN KNOWN_TOXICITY Hepatotoxicity 125-59-7 PHENYTOIN MECHANISM Block neural transmission 125-59-7 PHENYTOIN MECH_LEVEL_3 Voltage-gated Na+ channel 125-59-7 PHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 125-59-7 PHENYTOIN INDICATION Tonic-Clonic (Grand Mal) Seizures 125-59-7 PHENYTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 125-59-7 PHENYTOIN MESH_LEVEL_3 Imidazoles 125-59-7 PHENYTOIN KNOWN_TOXICITY Carcinogenicity 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_1_Drowsiness 125-59-7 PHENYTOIN ADVERSE_EFFECT END_2_Hirsutism 125-59-7 PHENYTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 125-59-7 PHENYTOIN ADVERSE_EFFECT LIV_3_Cholestasis 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_2_Skin Pigmentation 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 125-59-7 PHENYTOIN ADVERSE_EFFECT EMB_2_Fetal Hydantoin Syndrome 125-59-7 PHENYTOIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 125-59-7 PHENYTOIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 125-59-7 PHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 125-59-7 PHENYTOIN TISSUE_TOXICITY Lymphoma 125-59-7 PHENYTOIN MODE_CLASS Channel Blocker 125-59-7 PHENYTOIN MECH_LEVEL_2 Sodium channel antagonist 125-59-7 PHENYTOIN TA_LEVEL_1 Central Nervous System (CNS) 125-59-7 PHENYTOIN MESH_LEVEL_1 Heterocyclic Compounds 125-59-7 PHENYTOIN TA_LEVEL_2 CNS Depressant 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_2_Dystonia 125-59-7 PHENYTOIN ADVERSE_EFFECT BBM_3_Granulocytopenia 125-59-7 PHENYTOIN TISSUE_TOXICITY Nephrotic Syndrome 125-59-7 PHENYTOIN ACTIVITY_CLASS Na+ channel blocker 125-59-7 PHENYTOIN ZERO_CLASS N 125-59-7 PHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_3_Coma 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_1_Dizziness 125-59-7 PHENYTOIN ADVERSE_EFFECT END_2_Hyperglycemia 125-59-7 PHENYTOIN ADVERSE_EFFECT DNA_3_Lymphoma 125-59-7 PHENYTOIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 125-59-7 PHENYTOIN ADVERSE_EFFECT REP_2_Decreased Libido 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 125-59-7 PHENYTOIN ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 125-59-7 PHENYTOIN ADVERSE_EFFECT BBM_3_Blood Dyscrasias 125-59-7 PHENYTOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 125-59-7 PHENYTOIN ADVERSE_EFFECT BBM_3_Pancytopenia 125-59-7 PHENYTOIN TISSUE_TOXICITY Interstitial Nephritis 125-59-7 PHENYTOIN INDICATION Status Epilepticus 125-59-7 PHENYTOIN TISSUE_TOXICITY Glomerulonephritis 125-59-7 PHENYTOIN KNOWN_TOXICITY Nephrotoxicity 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_1_Ataxia 125-59-7 PHENYTOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 125-59-7 PHENYTOIN ADVERSE_EFFECT REP_2_Impotence 125-59-7 PHENYTOIN ADVERSE_EFFECT GIS_1_Constipation 125-59-7 PHENYTOIN ADVERSE_EFFECT KID_3_Proteinuria 125-59-7 PHENYTOIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 125-59-7 PHENYTOIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_3_Choreoathetosis 125-59-7 PHENYTOIN ADVERSE_EFFECT NEU_1_Nystagmus 125-59-7 PHENYTOIN ADVERSE_EFFECT LYM_3_Pseudo-Lymphoma 125-59-7 PHENYTOIN ADVERSE_EFFECT REP_3_Priapism 125-59-7 PHENYTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 125-59-7 PHENYTOIN INDICATION Complex Partial Seizures 125-59-7 PHENYTOIN INDICATION Epilepsy 125-59-7 PHENYTOIN INDICATION Partial Seizures 125-59-7 PHENYTOIN MECHANISM Modulate channel gating 125-59-7 PHENYTOIN TA_LEVEL_3 Antiepileptics / Anticonvulsants 125-59-7 PHENYTOIN MECH_LEVEL_1 Modulate neural transmission 125-59-7 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatitis 125-59-7 PHENYTOIN ADVERSE_EFFECT END_2_Hypothyroidism 125-59-7 PHENYTOIN ADVERSE_EFFECT IMU_2_Lupus-Like Syndrome 143-75-9 PHENYTOIN TA_LEVEL_2 CNS Depressant 143-75-9 PHENYTOIN INDICATION Status Epilepticus 143-75-9 PHENYTOIN TISSUE_TOXICITY Interstitial Nephritis 143-75-9 PHENYTOIN ADVERSE_EFFECT BBM_3_Pancytopenia 143-75-9 PHENYTOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_2_Bullous Rash 143-75-9 PHENYTOIN ADVERSE_EFFECT BBM_3_Blood Dyscrasias 143-75-9 PHENYTOIN ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 143-75-9 PHENYTOIN ADVERSE_EFFECT REP_2_Decreased Libido 143-75-9 PHENYTOIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 143-75-9 PHENYTOIN ADVERSE_EFFECT DNA_3_Lymphoma 143-75-9 PHENYTOIN ADVERSE_EFFECT END_2_Hyperglycemia 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_1_Dizziness 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_3_Coma 143-75-9 PHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 143-75-9 PHENYTOIN ZERO_CLASS N 143-75-9 PHENYTOIN ACTIVITY_CLASS Na+ channel blocker 143-75-9 PHENYTOIN MODE_CLASS Channel Blocker 143-75-9 PHENYTOIN MECHANISM Block neural transmission 143-75-9 PHENYTOIN INDICATION Partial Seizures 143-75-9 PHENYTOIN MECHANISM Modulate channel gating 143-75-9 PHENYTOIN TA_LEVEL_3 Antiepileptics / Anticonvulsants 143-75-9 PHENYTOIN MECH_LEVEL_1 Modulate neural transmission 143-75-9 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatitis 143-75-9 PHENYTOIN ADVERSE_EFFECT END_2_Hypothyroidism 143-75-9 PHENYTOIN ADVERSE_EFFECT IMU_2_Lupus-Like Syndrome 143-75-9 PHENYTOIN ADVERSE_EFFECT PSY_1_Anorexia 143-75-9 PHENYTOIN ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 143-75-9 PHENYTOIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 143-75-9 PHENYTOIN ADVERSE_EFFECT GIS_1_Gingival Hyperplasia 143-75-9 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatomegaly 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_1_Hypertrichosis 143-75-9 PHENYTOIN MECH_LEVEL_2 Sodium channel antagonist 143-75-9 PHENYTOIN TA_LEVEL_1 Central Nervous System (CNS) 143-75-9 PHENYTOIN MESH_LEVEL_1 Heterocyclic Compounds 143-75-9 PHENYTOIN TISSUE_TOXICITY Hepatic Necrosis 143-75-9 PHENYTOIN KNOWN_TOXICITY Hepatotoxicity 143-75-9 PHENYTOIN MECH_LEVEL_3 Voltage-gated Na+ channel 143-75-9 PHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 143-75-9 PHENYTOIN INDICATION Tonic-Clonic (Grand Mal) Seizures 143-75-9 PHENYTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 143-75-9 PHENYTOIN MESH_LEVEL_3 Imidazoles 143-75-9 PHENYTOIN KNOWN_TOXICITY Carcinogenicity 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_1_Drowsiness 143-75-9 PHENYTOIN ADVERSE_EFFECT END_2_Hirsutism 143-75-9 PHENYTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 143-75-9 PHENYTOIN ADVERSE_EFFECT LIV_3_Cholestasis 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_2_Skin Pigmentation 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_2_Dystonia 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 143-75-9 PHENYTOIN ADVERSE_EFFECT EMB_2_Fetal Hydantoin Syndrome 143-75-9 PHENYTOIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 143-75-9 PHENYTOIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 143-75-9 PHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 143-75-9 PHENYTOIN INDICATION Epilepsy 143-75-9 PHENYTOIN TISSUE_TOXICITY Lymphoma 143-75-9 PHENYTOIN TISSUE_TOXICITY Nephrotic Syndrome 143-75-9 PHENYTOIN TISSUE_TOXICITY Glomerulonephritis 143-75-9 PHENYTOIN KNOWN_TOXICITY Nephrotoxicity 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_1_Ataxia 143-75-9 PHENYTOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 143-75-9 PHENYTOIN ADVERSE_EFFECT REP_2_Impotence 143-75-9 PHENYTOIN ADVERSE_EFFECT GIS_1_Constipation 143-75-9 PHENYTOIN ADVERSE_EFFECT BBM_3_Granulocytopenia 143-75-9 PHENYTOIN ADVERSE_EFFECT KID_3_Proteinuria 143-75-9 PHENYTOIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 143-75-9 PHENYTOIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_3_Choreoathetosis 143-75-9 PHENYTOIN ADVERSE_EFFECT NEU_1_Nystagmus 143-75-9 PHENYTOIN ADVERSE_EFFECT LYM_3_Pseudo-Lymphoma 143-75-9 PHENYTOIN ADVERSE_EFFECT REP_3_Priapism 143-75-9 PHENYTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 143-75-9 PHENYTOIN INDICATION Complex Partial Seizures 1421-15-4 PHENYTOIN TA_LEVEL_2 CNS Depressant 1421-15-4 PHENYTOIN TA_LEVEL_1 Central Nervous System (CNS) 1421-15-4 PHENYTOIN ADVERSE_EFFECT EMB_2_Fetal Hydantoin Syndrome 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_2_Dystonia 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_2_Skin Pigmentation 1421-15-4 PHENYTOIN ADVERSE_EFFECT LIV_3_Cholestasis 1421-15-4 PHENYTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1421-15-4 PHENYTOIN ADVERSE_EFFECT END_2_Hirsutism 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_1_Drowsiness 1421-15-4 PHENYTOIN KNOWN_TOXICITY Carcinogenicity 1421-15-4 PHENYTOIN MESH_LEVEL_3 Imidazoles 1421-15-4 PHENYTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 1421-15-4 PHENYTOIN INDICATION Tonic-Clonic (Grand Mal) Seizures 1421-15-4 PHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 1421-15-4 PHENYTOIN MECH_LEVEL_3 Voltage-gated Na+ channel 1421-15-4 PHENYTOIN MECHANISM Block neural transmission 1421-15-4 PHENYTOIN MESH_LEVEL_1 Heterocyclic Compounds 1421-15-4 PHENYTOIN ACTIVITY_CLASS Na+ channel blocker 1421-15-4 PHENYTOIN ZERO_CLASS N 1421-15-4 PHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_3_Coma 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_1_Dizziness 1421-15-4 PHENYTOIN ADVERSE_EFFECT END_2_Hyperglycemia 1421-15-4 PHENYTOIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 1421-15-4 PHENYTOIN ADVERSE_EFFECT REP_2_Decreased Libido 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 1421-15-4 PHENYTOIN ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 1421-15-4 PHENYTOIN ADVERSE_EFFECT BBM_3_Blood Dyscrasias 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_2_Bullous Rash 1421-15-4 PHENYTOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 1421-15-4 PHENYTOIN MECH_LEVEL_2 Sodium channel antagonist 1421-15-4 PHENYTOIN MODE_CLASS Channel Blocker 1421-15-4 PHENYTOIN TISSUE_TOXICITY Lymphoma 1421-15-4 PHENYTOIN ADVERSE_EFFECT BBM_3_Pancytopenia 1421-15-4 PHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 1421-15-4 PHENYTOIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 1421-15-4 PHENYTOIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 1421-15-4 PHENYTOIN TISSUE_TOXICITY Interstitial Nephritis 1421-15-4 PHENYTOIN INDICATION Status Epilepticus 1421-15-4 PHENYTOIN TISSUE_TOXICITY Nephrotic Syndrome 1421-15-4 PHENYTOIN TISSUE_TOXICITY Glomerulonephritis 1421-15-4 PHENYTOIN KNOWN_TOXICITY Nephrotoxicity 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_1_Ataxia 1421-15-4 PHENYTOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 1421-15-4 PHENYTOIN ADVERSE_EFFECT REP_2_Impotence 1421-15-4 PHENYTOIN ADVERSE_EFFECT GIS_1_Constipation 1421-15-4 PHENYTOIN ADVERSE_EFFECT BBM_3_Granulocytopenia 1421-15-4 PHENYTOIN ADVERSE_EFFECT KID_3_Proteinuria 1421-15-4 PHENYTOIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_3_Choreoathetosis 1421-15-4 PHENYTOIN ADVERSE_EFFECT NEU_1_Nystagmus 1421-15-4 PHENYTOIN ADVERSE_EFFECT LYM_3_Pseudo-Lymphoma 1421-15-4 PHENYTOIN ADVERSE_EFFECT REP_3_Priapism 1421-15-4 PHENYTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 1421-15-4 PHENYTOIN ADVERSE_EFFECT DNA_3_Lymphoma 1421-15-4 PHENYTOIN INDICATION Epilepsy 1421-15-4 PHENYTOIN INDICATION Partial Seizures 1421-15-4 PHENYTOIN MECHANISM Modulate channel gating 1421-15-4 PHENYTOIN TA_LEVEL_3 Antiepileptics / Anticonvulsants 1421-15-4 PHENYTOIN MECH_LEVEL_1 Modulate neural transmission 1421-15-4 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatitis 1421-15-4 PHENYTOIN ADVERSE_EFFECT END_2_Hypothyroidism 1421-15-4 PHENYTOIN ADVERSE_EFFECT IMU_2_Lupus-Like Syndrome 1421-15-4 PHENYTOIN ADVERSE_EFFECT PSY_1_Anorexia 1421-15-4 PHENYTOIN ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 1421-15-4 PHENYTOIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 1421-15-4 PHENYTOIN ADVERSE_EFFECT GIS_1_Gingival Hyperplasia 1421-15-4 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatomegaly 1421-15-4 PHENYTOIN ADVERSE_EFFECT SKN_1_Hypertrichosis 1421-15-4 PHENYTOIN TISSUE_TOXICITY Hepatic Necrosis 1421-15-4 PHENYTOIN KNOWN_TOXICITY Hepatotoxicity 1421-15-4 PHENYTOIN INDICATION Complex Partial Seizures 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 8017-52-5 PHENYTOIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 8017-52-5 PHENYTOIN ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 8017-52-5 PHENYTOIN ADVERSE_EFFECT PSY_1_Anorexia 8017-52-5 PHENYTOIN ADVERSE_EFFECT IMU_2_Lupus-Like Syndrome 8017-52-5 PHENYTOIN ADVERSE_EFFECT END_2_Hypothyroidism 8017-52-5 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatitis 8017-52-5 PHENYTOIN MECH_LEVEL_1 Modulate neural transmission 8017-52-5 PHENYTOIN TA_LEVEL_3 Antiepileptics / Anticonvulsants 8017-52-5 PHENYTOIN MECHANISM Modulate channel gating 8017-52-5 PHENYTOIN INDICATION Partial Seizures 8017-52-5 PHENYTOIN INDICATION Epilepsy 8017-52-5 PHENYTOIN INDICATION Complex Partial Seizures 8017-52-5 PHENYTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 8017-52-5 PHENYTOIN ADVERSE_EFFECT REP_3_Priapism 8017-52-5 PHENYTOIN ADVERSE_EFFECT LYM_3_Pseudo-Lymphoma 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_1_Nystagmus 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_3_Choreoathetosis 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 8017-52-5 PHENYTOIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 8017-52-5 PHENYTOIN ADVERSE_EFFECT KID_3_Proteinuria 8017-52-5 PHENYTOIN ADVERSE_EFFECT BBM_3_Granulocytopenia 8017-52-5 PHENYTOIN ADVERSE_EFFECT GIS_1_Constipation 8017-52-5 PHENYTOIN ADVERSE_EFFECT REP_2_Impotence 8017-52-5 PHENYTOIN ADVERSE_EFFECT BBM_3_Agranulocytosis 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_1_Ataxia 8017-52-5 PHENYTOIN KNOWN_TOXICITY Nephrotoxicity 8017-52-5 PHENYTOIN TISSUE_TOXICITY Glomerulonephritis 8017-52-5 PHENYTOIN INDICATION Status Epilepticus 8017-52-5 PHENYTOIN TISSUE_TOXICITY Interstitial Nephritis 8017-52-5 PHENYTOIN ADVERSE_EFFECT BBM_3_Pancytopenia 8017-52-5 PHENYTOIN ADVERSE_EFFECT KID_3_Glomerulonephritis 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_2_Bullous Rash 8017-52-5 PHENYTOIN ADVERSE_EFFECT BBM_3_Blood Dyscrasias 8017-52-5 PHENYTOIN ADVERSE_EFFECT BBM_2_Megaloblastic Anemia 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 8017-52-5 PHENYTOIN ADVERSE_EFFECT REP_2_Decreased Libido 8017-52-5 PHENYTOIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 8017-52-5 PHENYTOIN ADVERSE_EFFECT DNA_3_Lymphoma 8017-52-5 PHENYTOIN ADVERSE_EFFECT END_2_Hyperglycemia 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_1_Dizziness 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_3_Coma 8017-52-5 PHENYTOIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 8017-52-5 PHENYTOIN ZERO_CLASS N 8017-52-5 PHENYTOIN ACTIVITY_CLASS Na+ channel blocker 8017-52-5 PHENYTOIN TISSUE_TOXICITY Nephrotic Syndrome 8017-52-5 PHENYTOIN TA_LEVEL_2 CNS Depressant 8017-52-5 PHENYTOIN MESH_LEVEL_1 Heterocyclic Compounds 8017-52-5 PHENYTOIN TA_LEVEL_1 Central Nervous System (CNS) 8017-52-5 PHENYTOIN MECH_LEVEL_2 Sodium channel antagonist 8017-52-5 PHENYTOIN MODE_CLASS Channel Blocker 8017-52-5 PHENYTOIN TISSUE_TOXICITY Lymphoma 8017-52-5 PHENYTOIN THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 8017-52-5 PHENYTOIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 8017-52-5 PHENYTOIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 8017-52-5 PHENYTOIN ADVERSE_EFFECT EMB_2_Fetal Hydantoin Syndrome 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_2_Dystonia 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_2_Skin Pigmentation 8017-52-5 PHENYTOIN ADVERSE_EFFECT LIV_3_Cholestasis 8017-52-5 PHENYTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 8017-52-5 PHENYTOIN ADVERSE_EFFECT END_2_Hirsutism 8017-52-5 PHENYTOIN ADVERSE_EFFECT NEU_1_Drowsiness 8017-52-5 PHENYTOIN KNOWN_TOXICITY Carcinogenicity 8017-52-5 PHENYTOIN MESH_LEVEL_3 Imidazoles 8017-52-5 PHENYTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 8017-52-5 PHENYTOIN INDICATION Tonic-Clonic (Grand Mal) Seizures 8017-52-5 PHENYTOIN PRODUCT_CLASS Central Nervous System (CNS) 8017-52-5 PHENYTOIN MECH_LEVEL_3 Voltage-gated Na+ channel 8017-52-5 PHENYTOIN MECHANISM Block neural transmission 8017-52-5 PHENYTOIN KNOWN_TOXICITY Hepatotoxicity 8017-52-5 PHENYTOIN TISSUE_TOXICITY Hepatic Necrosis 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_1_Hypertrichosis 8017-52-5 PHENYTOIN ADVERSE_EFFECT LIV_2_Hepatomegaly 8017-52-5 PHENYTOIN ADVERSE_EFFECT GIS_1_Gingival Hyperplasia 8017-52-5 PHENYTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 16561-29-8 PHORBOL 12-MYRISTATE 13-ACETATE MECHANISM Enhance kinase mediated signal transduction 16561-29-8 PHORBOL 12-MYRISTATE 13-ACETATE PRODUCT_CLASS Biochemicals 16561-29-8 PHORBOL 12-MYRISTATE 13-ACETATE MODE_CLASS Enzyme Activator 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Ocular Pain 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_3_Retinal Detachment 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Occlusion of Lacrimal Puncta 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Photophobia 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT CVS_2_Palpitation 57-64-7 PHYSOSTIGMINE TISSUE_TOXICITY Collapse 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT XXX_3_Death 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT PSY_2_Hallucinations 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_1_Miosis 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT LUN_1_Bronchospasm 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT LUN_1_Dyspnea 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT CVS_3_Collapse 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Ciliary Spasm 57-64-7 PHYSOSTIGMINE THERAPEUTIC_CLASS Parasympathomimetic Agents 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Iritis 57-64-7 PHYSOSTIGMINE INDICATION Glaucoma 57-64-7 PHYSOSTIGMINE MODE_CLASS Enzyme Inhibitor 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT XXX_1_Lacrimation 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT NEU_2_Headache 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_1_Blurred Vision 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT XXX_2_Restlessness 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT MSK_2_Myasthenia 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Conjunctival Suffusion 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_1_Ocular Irritation 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT GIS_1_Hypersalivation 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT NEU_3_Cholinergic Crisis 57-64-7 PHYSOSTIGMINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 57-64-7 PHYSOSTIGMINE KNOWN_TOXICITY Cardiovascular Toxicity 57-64-7 PHYSOSTIGMINE INDICATION Anticholinergic Overdose 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT NEU_2_Fasciculations 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT PSY_2_CNS Stimulation 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT NEU_3_Seizures 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT GIS_1_Abdominal Pain 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT XXX_1_Diaphoresis 57-64-7 PHYSOSTIGMINE ADVERSE_EFFECT OCU_3_Lens Opacities 57-64-7 PHYSOSTIGMINE TISSUE_TOXICITY Death 57-64-7 PHYSOSTIGMINE KNOWN_TOXICITY Miscellaneous 57-64-7 PHYSOSTIGMINE MECHANISM Enhance cholinergic transmission 57-64-7 PHYSOSTIGMINE STRUCTURE_ACTIVITY Cholinesterase inhibitor 57-64-7 PHYSOSTIGMINE THERAPEUTIC_CLASS Antiglaucoma Agents 57-64-7 PHYSOSTIGMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 57-47-6 PHYSOSTIGMINE TISSUE_TOXICITY Death 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT XXX_2_Restlessness 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT NEU_2_Headache 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Ciliary Spasm 57-47-6 PHYSOSTIGMINE THERAPEUTIC_CLASS Parasympathomimetic Agents 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT XXX_1_Lacrimation 57-47-6 PHYSOSTIGMINE MODE_CLASS Enzyme Inhibitor 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Photophobia 57-47-6 PHYSOSTIGMINE INDICATION Glaucoma 57-47-6 PHYSOSTIGMINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_1_Miosis 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT PSY_2_Hallucinations 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT XXX_3_Death 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT CVS_2_Palpitation 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT LUN_1_Bronchospasm 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Occlusion of Lacrimal Puncta 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_3_Retinal Detachment 57-47-6 PHYSOSTIGMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 57-47-6 PHYSOSTIGMINE THERAPEUTIC_CLASS Antiglaucoma Agents 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT PSY_2_CNS Stimulation 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_1_Blurred Vision 57-47-6 PHYSOSTIGMINE MECHANISM Enhance cholinergic transmission 57-47-6 PHYSOSTIGMINE KNOWN_TOXICITY Miscellaneous 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Iritis 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_3_Lens Opacities 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT XXX_1_Diaphoresis 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT GIS_1_Abdominal Pain 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT NEU_3_Seizures 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Ocular Pain 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT NEU_2_Fasciculations 57-47-6 PHYSOSTIGMINE INDICATION Anticholinergic Overdose 57-47-6 PHYSOSTIGMINE STRUCTURE_ACTIVITY Cholinesterase inhibitor 57-47-6 PHYSOSTIGMINE KNOWN_TOXICITY Cardiovascular Toxicity 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT LUN_1_Dyspnea 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT NEU_3_Cholinergic Crisis 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT GIS_1_Hypersalivation 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_1_Ocular Irritation 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT OCU_2_Conjunctival Suffusion 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT CVS_3_Collapse 57-47-6 PHYSOSTIGMINE ADVERSE_EFFECT MSK_2_Myasthenia 57-47-6 PHYSOSTIGMINE TISSUE_TOXICITY Collapse 84-80-0 PHYTOMENADIONE MODE_CLASS Enzyme Inhibitor 84-80-0 PHYTOMENADIONE MECHANISM Inhibit platelet aggregation 84-80-0 PHYTOMENADIONE STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 124-87-8 COCCULIN ADVERSE_EFFECT NEU_2_Seizures 124-87-8 COCCULIN ADVERSE_EFFECT NEU_1_Convulsions 124-87-8 COCCULIN STRUCTURE_ACTIVITY Toxicant, mycotoxin/plant toxin 124-87-8 COCCULIN THERAPEUTIC_CLASS Central Stimulants 124-87-8 COCCULIN ADVERSE_EFFECT GIS_1_Emesis 124-87-8 COCCULIN ADVERSE_EFFECT XXX_2_Salivation 124-87-8 COCCULIN ADVERSE_EFFECT NEU_2_Impaired Motor Function 124-87-8 COCCULIN PRODUCT_CLASS Central Nervous System (CNS) 124-87-8 COCCULIN MODE_CLASS Channel Blocker 124-87-8 COCCULIN TISSUE_TOXICITY Convulsions 124-87-8 COCCULIN ADVERSE_EFFECT CVS_2_Hypertension 124-87-8 COCCULIN KNOWN_TOXICITY Neurotoxicity 124-87-8 COCCULIN ADVERSE_EFFECT END_1_Endocrine Abnormalities 124-87-8 COCCULIN ADVERSE_EFFECT PSY_1_Behavioral Changes 124-87-8 COCCULIN MECHANISM Prolong/enhance neural transmission 124-87-8 COCCULIN ADVERSE_EFFECT NEU_2_Myoclonus 54-71-7 PILOCARPINE INDICATION Induction of Miosis 54-71-7 PILOCARPINE ADVERSE_EFFECT XXX_1_Diaphoresis 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_2_Ciliary Spasm 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_1_Amblyopia 54-71-7 PILOCARPINE ADVERSE_EFFECT GIS_1_Dyspepsia 54-71-7 PILOCARPINE ADVERSE_EFFECT XXX_2_Chills 54-71-7 PILOCARPINE ADVERSE_EFFECT NEU_2_Headache 54-71-7 PILOCARPINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_2_Miosis 54-71-7 PILOCARPINE THERAPEUTIC_CLASS Parasympathomimetic Agents 54-71-7 PILOCARPINE MECHANISM Modulate G-protein coupled signal transduction 54-71-7 PILOCARPINE PRODUCT_CLASS Other Human Uses 54-71-7 PILOCARPINE ADVERSE_EFFECT NEU_2_Dizziness 54-71-7 PILOCARPINE INDICATION Xerostomia 54-71-7 PILOCARPINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) agonist 54-71-7 PILOCARPINE ADVERSE_EFFECT GIS_2_Hypersalivation 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_3_Photophobia 54-71-7 PILOCARPINE ADVERSE_EFFECT GUS_2_Urinary Frequency 54-71-7 PILOCARPINE ADVERSE_EFFECT XXX_2_Epistaxis 54-71-7 PILOCARPINE ADVERSE_EFFECT NEU_2_Tremor 54-71-7 PILOCARPINE ADVERSE_EFFECT GIS_2_Diarrhea 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_3_Retinal Detachment 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_2_Ocular Irritation 54-71-7 PILOCARPINE ADVERSE_EFFECT GIS_1_Dysphagia 54-71-7 PILOCARPINE ADVERSE_EFFECT XXX_2_Asthenia 54-71-7 PILOCARPINE ADVERSE_EFFECT XXX_2_Edema 54-71-7 PILOCARPINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_1_Blurred Vision 54-71-7 PILOCARPINE MODE_CLASS Receptor Agonist 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_2_Ocular Pain 54-71-7 PILOCARPINE ADVERSE_EFFECT OCU_1_Impaired Night Vision 54-71-7 PILOCARPINE ADVERSE_EFFECT XXX_2_Rhinitis 54-71-7 PILOCARPINE ADVERSE_EFFECT GIS_1_Abdominal Pain 54-71-7 PILOCARPINE ADVERSE_EFFECT LUN_2_Bronchospasm 54-71-7 PILOCARPINE ADVERSE_EFFECT SKN_2_Flushing 54-71-7 PILOCARPINE ADVERSE_EFFECT CVS_2_Hypertension 54-71-7 PILOCARPINE INDICATION Glaucoma 2062-78-4 PIMOZIDE MECHANISM Block channel gating 2062-78-4 PIMOZIDE MODE_CLASS Receptor Ligand Antagonist, Selective 2062-78-4 PIMOZIDE MECHANISM Reduce muscle contractile force 2062-78-4 PIMOZIDE MODE_CLASS Receptor Ligand Antagonist 2062-78-4 PIMOZIDE STRUCTURE_ACTIVITY Ca++ channel (T-Type) blocker 2062-78-4 PIMOZIDE MODE_CLASS Channel Blocker 60560-33-0 PINACIDIL INDICATION Hypertension 60560-33-0 PINACIDIL THERAPEUTIC_CLASS Antihypertensive Agents 60560-33-0 PINACIDIL THERAPEUTIC_CLASS Vasodilators 60560-33-0 PINACIDIL MECHANISM Reduce muscle contractile force 60560-33-0 PINACIDIL MODE_CLASS Channel enhancer /opener 60560-33-0 PINACIDIL PRODUCT_CLASS Cardiovasculars 13523-86-9 PINDOLOL THERAPEUTIC_CLASS Antianginals 13523-86-9 PINDOLOL ADVERSE_EFFECT MSK_3_Myalgia 13523-86-9 PINDOLOL ADVERSE_EFFECT REP_2_Decreased Libido 13523-86-9 PINDOLOL TISSUE_TOXICITY Hypotension 13523-86-9 PINDOLOL ADVERSE_EFFECT GIS_1_Diarrhea 13523-86-9 PINDOLOL KNOWN_TOXICITY Cardiovascular Toxicity 13523-86-9 PINDOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 13523-86-9 PINDOLOL ADVERSE_EFFECT XXX_1_Peripheral Edema 13523-86-9 PINDOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 13523-86-9 PINDOLOL ADVERSE_EFFECT XXX_3_Fatigue 13523-86-9 PINDOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 13523-86-9 PINDOLOL ADVERSE_EFFECT PSY_3_Hallucinations 13523-86-9 PINDOLOL ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 13523-86-9 PINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 13523-86-9 PINDOLOL INDICATION Angina Pectoris 13523-86-9 PINDOLOL MECHANISM Modulate G-protein coupled signal transduction 13523-86-9 PINDOLOL ADVERSE_EFFECT SKN_3_Pruritis 13523-86-9 PINDOLOL PRODUCT_CLASS Cardiovasculars 13523-86-9 PINDOLOL INDICATION Hypertension 13523-86-9 PINDOLOL ADVERSE_EFFECT CVS_3_First-Degree AV block 13523-86-9 PINDOLOL TISSUE_TOXICITY First-Degree AV block 13523-86-9 PINDOLOL ADVERSE_EFFECT PSY_3_Depression 13523-86-9 PINDOLOL ADVERSE_EFFECT PSY_3_Insomnia 13523-86-9 PINDOLOL ADVERSE_EFFECT LUN_3_Asthma 13523-86-9 PINDOLOL ADVERSE_EFFECT NEU_3_Dizziness 13523-86-9 PINDOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 13523-86-9 PINDOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 13523-86-9 PINDOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 13523-86-9 PINDOLOL MODE_CLASS Receptor Ligand Antagonist 13523-86-9 PINDOLOL TISSUE_TOXICITY Congestive Heart Failure 13523-86-9 PINDOLOL ADVERSE_EFFECT XXX_3_Xerosis 13523-86-9 PINDOLOL ADVERSE_EFFECT PSY_3_Nervousness 13523-86-9 PINDOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 13523-86-9 PINDOLOL ADVERSE_EFFECT REP_2_Sexual Dysfunction 13523-86-9 PINDOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 13523-86-9 PINDOLOL ADVERSE_EFFECT PSY_3_Nightmares 13523-86-9 PINDOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 13523-86-9 PINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 13523-86-9 PINDOLOL ADVERSE_EFFECT BBM_3_Hematological Reactions 13523-86-9 PINDOLOL ADVERSE_EFFECT CVS_2_Hypotension 13523-86-9 PINDOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 13523-86-9 PINDOLOL ADVERSE_EFFECT REP_2_Impotence 66052-89-9 PINDOLOL ADVERSE_EFFECT PSY_3_Nervousness 66052-89-9 PINDOLOL ADVERSE_EFFECT GIS_1_Diarrhea 66052-89-9 PINDOLOL ADVERSE_EFFECT XXX_3_Xerosis 66052-89-9 PINDOLOL TISSUE_TOXICITY Congestive Heart Failure 66052-89-9 PINDOLOL MODE_CLASS Receptor Ligand Antagonist 66052-89-9 PINDOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 66052-89-9 PINDOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 66052-89-9 PINDOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 66052-89-9 PINDOLOL ADVERSE_EFFECT NEU_3_Dizziness 66052-89-9 PINDOLOL ADVERSE_EFFECT LUN_3_Asthma 66052-89-9 PINDOLOL ADVERSE_EFFECT PSY_3_Insomnia 66052-89-9 PINDOLOL MECHANISM Modulate G-protein coupled signal transduction 66052-89-9 PINDOLOL ADVERSE_EFFECT PSY_3_Depression 66052-89-9 PINDOLOL TISSUE_TOXICITY First-Degree AV block 66052-89-9 PINDOLOL ADVERSE_EFFECT MSK_3_Myalgia 66052-89-9 PINDOLOL INDICATION Angina Pectoris 66052-89-9 PINDOLOL ADVERSE_EFFECT CVS_3_First-Degree AV block 66052-89-9 PINDOLOL TISSUE_TOXICITY Hypotension 66052-89-9 PINDOLOL ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 66052-89-9 PINDOLOL ADVERSE_EFFECT PSY_3_Hallucinations 66052-89-9 PINDOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 66052-89-9 PINDOLOL ADVERSE_EFFECT XXX_3_Fatigue 66052-89-9 PINDOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 66052-89-9 PINDOLOL ADVERSE_EFFECT XXX_1_Peripheral Edema 66052-89-9 PINDOLOL KNOWN_TOXICITY Cardiovascular Toxicity 66052-89-9 PINDOLOL INDICATION Hypertension 66052-89-9 PINDOLOL PRODUCT_CLASS Cardiovasculars 66052-89-9 PINDOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 66052-89-9 PINDOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 66052-89-9 PINDOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 66052-89-9 PINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 66052-89-9 PINDOLOL ADVERSE_EFFECT REP_2_Sexual Dysfunction 66052-89-9 PINDOLOL ADVERSE_EFFECT REP_2_Decreased Libido 66052-89-9 PINDOLOL ADVERSE_EFFECT SKN_3_Pruritis 66052-89-9 PINDOLOL ADVERSE_EFFECT REP_2_Impotence 66052-89-9 PINDOLOL THERAPEUTIC_CLASS Antianginals 66052-89-9 PINDOLOL ADVERSE_EFFECT CVS_2_Hypotension 66052-89-9 PINDOLOL ADVERSE_EFFECT BBM_3_Hematological Reactions 66052-89-9 PINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 66052-89-9 PINDOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 66052-89-9 PINDOLOL ADVERSE_EFFECT PSY_3_Nightmares 66052-89-9 PINDOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 51246-70-9 PINDOLOL TISSUE_TOXICITY Congestive Heart Failure 51246-70-9 PINDOLOL PRODUCT_CLASS Cardiovasculars 51246-70-9 PINDOLOL INDICATION Hypertension 51246-70-9 PINDOLOL ADVERSE_EFFECT CVS_3_First-Degree AV block 51246-70-9 PINDOLOL TISSUE_TOXICITY First-Degree AV block 51246-70-9 PINDOLOL ADVERSE_EFFECT PSY_3_Depression 51246-70-9 PINDOLOL ADVERSE_EFFECT PSY_3_Insomnia 51246-70-9 PINDOLOL ADVERSE_EFFECT LUN_3_Asthma 51246-70-9 PINDOLOL ADVERSE_EFFECT NEU_3_Dizziness 51246-70-9 PINDOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 51246-70-9 PINDOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 51246-70-9 PINDOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 51246-70-9 PINDOLOL MODE_CLASS Receptor Ligand Antagonist 51246-70-9 PINDOLOL ADVERSE_EFFECT XXX_3_Xerosis 51246-70-9 PINDOLOL ADVERSE_EFFECT GIS_1_Diarrhea 51246-70-9 PINDOLOL ADVERSE_EFFECT PSY_3_Nervousness 51246-70-9 PINDOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 51246-70-9 PINDOLOL ADVERSE_EFFECT REP_2_Sexual Dysfunction 51246-70-9 PINDOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 51246-70-9 PINDOLOL ADVERSE_EFFECT PSY_3_Nightmares 51246-70-9 PINDOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 51246-70-9 PINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 51246-70-9 PINDOLOL ADVERSE_EFFECT BBM_3_Hematological Reactions 51246-70-9 PINDOLOL ADVERSE_EFFECT CVS_2_Hypotension 51246-70-9 PINDOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 51246-70-9 PINDOLOL ADVERSE_EFFECT REP_2_Impotence 51246-70-9 PINDOLOL ADVERSE_EFFECT SKN_3_Pruritis 51246-70-9 PINDOLOL ADVERSE_EFFECT REP_2_Decreased Libido 51246-70-9 PINDOLOL ADVERSE_EFFECT MSK_3_Myalgia 51246-70-9 PINDOLOL THERAPEUTIC_CLASS Antianginals 51246-70-9 PINDOLOL MECHANISM Modulate G-protein coupled signal transduction 51246-70-9 PINDOLOL INDICATION Angina Pectoris 51246-70-9 PINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 51246-70-9 PINDOLOL TISSUE_TOXICITY Hypotension 51246-70-9 PINDOLOL ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 51246-70-9 PINDOLOL ADVERSE_EFFECT PSY_3_Hallucinations 51246-70-9 PINDOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 51246-70-9 PINDOLOL ADVERSE_EFFECT XXX_3_Fatigue 51246-70-9 PINDOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 51246-70-9 PINDOLOL ADVERSE_EFFECT XXX_1_Peripheral Edema 51246-70-9 PINDOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 51246-70-9 PINDOLOL KNOWN_TOXICITY Cardiovascular Toxicity 21870-06-4 PINDOLOL ADVERSE_EFFECT PSY_3_Insomnia 21870-06-4 PINDOLOL ADVERSE_EFFECT LUN_3_Asthma 21870-06-4 PINDOLOL ADVERSE_EFFECT NEU_3_Dizziness 21870-06-4 PINDOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 21870-06-4 PINDOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 21870-06-4 PINDOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 21870-06-4 PINDOLOL MODE_CLASS Receptor Ligand Antagonist 21870-06-4 PINDOLOL TISSUE_TOXICITY Congestive Heart Failure 21870-06-4 PINDOLOL ADVERSE_EFFECT XXX_3_Xerosis 21870-06-4 PINDOLOL ADVERSE_EFFECT GIS_1_Diarrhea 21870-06-4 PINDOLOL ADVERSE_EFFECT PSY_3_Nervousness 21870-06-4 PINDOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 21870-06-4 PINDOLOL ADVERSE_EFFECT REP_2_Sexual Dysfunction 21870-06-4 PINDOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 21870-06-4 PINDOLOL ADVERSE_EFFECT PSY_3_Nightmares 21870-06-4 PINDOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 21870-06-4 PINDOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 21870-06-4 PINDOLOL ADVERSE_EFFECT BBM_3_Hematological Reactions 21870-06-4 PINDOLOL ADVERSE_EFFECT CVS_2_Hypotension 21870-06-4 PINDOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 21870-06-4 PINDOLOL ADVERSE_EFFECT REP_2_Impotence 21870-06-4 PINDOLOL ADVERSE_EFFECT SKN_3_Pruritis 21870-06-4 PINDOLOL ADVERSE_EFFECT REP_2_Decreased Libido 21870-06-4 PINDOLOL ADVERSE_EFFECT MSK_3_Myalgia 21870-06-4 PINDOLOL THERAPEUTIC_CLASS Antianginals 21870-06-4 PINDOLOL MECHANISM Modulate G-protein coupled signal transduction 21870-06-4 PINDOLOL INDICATION Angina Pectoris 21870-06-4 PINDOLOL THERAPEUTIC_CLASS Antihypertensive Agents 21870-06-4 PINDOLOL TISSUE_TOXICITY Hypotension 21870-06-4 PINDOLOL ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 21870-06-4 PINDOLOL ADVERSE_EFFECT PSY_3_Hallucinations 21870-06-4 PINDOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 21870-06-4 PINDOLOL ADVERSE_EFFECT XXX_3_Fatigue 21870-06-4 PINDOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 21870-06-4 PINDOLOL ADVERSE_EFFECT XXX_1_Peripheral Edema 21870-06-4 PINDOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 21870-06-4 PINDOLOL KNOWN_TOXICITY Cardiovascular Toxicity 21870-06-4 PINDOLOL PRODUCT_CLASS Cardiovasculars 21870-06-4 PINDOLOL ADVERSE_EFFECT PSY_3_Depression 21870-06-4 PINDOLOL TISSUE_TOXICITY First-Degree AV block 21870-06-4 PINDOLOL ADVERSE_EFFECT CVS_3_First-Degree AV block 21870-06-4 PINDOLOL INDICATION Hypertension 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT KID_2_Fluid Retention 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Tooth Disorder 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT CVS_3_Cardiomegaly 111025-46-8 PIOGLITAZONE TISSUE_TOXICITY Congestive Heart Failure 111025-46-8 PIOGLITAZONE MESH_LEVEL_3 Thiazoles 111025-46-8 PIOGLITAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 111025-46-8 PIOGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT DNA_3_Carcinogenicity 111025-46-8 PIOGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT XXX_2_Edema 111025-46-8 PIOGLITAZONE ZERO_CLASS N 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 111025-46-8 PIOGLITAZONE MECHANISM Increase transcription of insulin responsive gene 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Pharyngitis 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT BBM_2_Anemia 111025-46-8 PIOGLITAZONE MECHANISM Increase lipid catabolism 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Weight Gain 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT END_2_Hypoglycemia 111025-46-8 PIOGLITAZONE INDICATION Type II Diabetes Mellitus 111025-46-8 PIOGLITAZONE MODE_CLASS Receptor Agonist 111025-46-8 PIOGLITAZONE MESH_LEVEL_1 Heterocyclic Compounds 111025-46-8 PIOGLITAZONE MECH_LEVEL_3 PPAR gamma 111025-46-8 PIOGLITAZONE KNOWN_TOXICITY Cardiovascular Toxicity 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Sinusitis 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT MSK_1_Myalgia 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT NEU_1_Headache 111025-46-8 PIOGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 111025-46-8 PIOGLITAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 111025-46-8 PIOGLITAZONE TA_LEVEL_3 Thiazolidinedione 111025-46-8 PIOGLITAZONE MECH_LEVEL_1 Glycemia regulation 111025-46-8 PIOGLITAZONE KNOWN_TOXICITY Carcinogenicity 111025-46-8 PIOGLITAZONE ACTIVITY_CLASS Anti-diabetic 111025-46-8 PIOGLITAZONE TISSUE_TOXICITY Carcinogenicity 111025-46-8 PIOGLITAZONE ADVERSE_EFFECT REP_2_Induction of Ovulation 111025-46-8 PIOGLITAZONE MECH_LEVEL_2 Insulin-like response 111025-46-8 PIOGLITAZONE TA_LEVEL_2 insulin sensitizer 112529-15-4 PIOGLITAZONE ACTIVITY_CLASS Anti-diabetic 112529-15-4 PIOGLITAZONE MESH_LEVEL_1 Heterocyclic Compounds 112529-15-4 PIOGLITAZONE MODE_CLASS Receptor Agonist 112529-15-4 PIOGLITAZONE MECH_LEVEL_3 PPAR gamma 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Tooth Disorder 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT CVS_3_Cardiomegaly 112529-15-4 PIOGLITAZONE TISSUE_TOXICITY Congestive Heart Failure 112529-15-4 PIOGLITAZONE MESH_LEVEL_3 Thiazoles 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 112529-15-4 PIOGLITAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 112529-15-4 PIOGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT DNA_3_Carcinogenicity 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT XXX_2_Edema 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT KID_2_Fluid Retention 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT REP_2_Induction of Ovulation 112529-15-4 PIOGLITAZONE TISSUE_TOXICITY Carcinogenicity 112529-15-4 PIOGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 112529-15-4 PIOGLITAZONE MECH_LEVEL_2 Insulin-like response 112529-15-4 PIOGLITAZONE TA_LEVEL_2 insulin sensitizer 112529-15-4 PIOGLITAZONE MECHANISM Increase transcription of insulin responsive gene 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT BBM_2_Anemia 112529-15-4 PIOGLITAZONE ZERO_CLASS N 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Pharyngitis 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Weight Gain 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT END_2_Hypoglycemia 112529-15-4 PIOGLITAZONE INDICATION Type II Diabetes Mellitus 112529-15-4 PIOGLITAZONE KNOWN_TOXICITY Cardiovascular Toxicity 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Sinusitis 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT MSK_1_Myalgia 112529-15-4 PIOGLITAZONE ADVERSE_EFFECT NEU_1_Headache 112529-15-4 PIOGLITAZONE MECHANISM Increase lipid catabolism 112529-15-4 PIOGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 112529-15-4 PIOGLITAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 112529-15-4 PIOGLITAZONE TA_LEVEL_3 Thiazolidinedione 112529-15-4 PIOGLITAZONE MECH_LEVEL_1 Glycemia regulation 112529-15-4 PIOGLITAZONE KNOWN_TOXICITY Carcinogenicity 105167-68-8 PIOGLITAZONE MESH_LEVEL_3 Thiazoles 105167-68-8 PIOGLITAZONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 105167-68-8 PIOGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT DNA_3_Carcinogenicity 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT XXX_2_Edema 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT KID_2_Fluid Retention 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT REP_2_Induction of Ovulation 105167-68-8 PIOGLITAZONE TISSUE_TOXICITY Carcinogenicity 105167-68-8 PIOGLITAZONE ACTIVITY_CLASS Anti-diabetic 105167-68-8 PIOGLITAZONE KNOWN_TOXICITY Carcinogenicity 105167-68-8 PIOGLITAZONE MECH_LEVEL_1 Glycemia regulation 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Tooth Disorder 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT BBM_2_Anemia 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 105167-68-8 PIOGLITAZONE MECHANISM Increase transcription of insulin responsive gene 105167-68-8 PIOGLITAZONE TA_LEVEL_2 insulin sensitizer 105167-68-8 PIOGLITAZONE MECH_LEVEL_2 Insulin-like response 105167-68-8 PIOGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 105167-68-8 PIOGLITAZONE ZERO_CLASS N 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Pharyngitis 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Weight Gain 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT END_2_Hypoglycemia 105167-68-8 PIOGLITAZONE INDICATION Type II Diabetes Mellitus 105167-68-8 PIOGLITAZONE MODE_CLASS Receptor Agonist 105167-68-8 PIOGLITAZONE MESH_LEVEL_1 Heterocyclic Compounds 105167-68-8 PIOGLITAZONE MECH_LEVEL_3 PPAR gamma 105167-68-8 PIOGLITAZONE TA_LEVEL_3 Thiazolidinedione 105167-68-8 PIOGLITAZONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 105167-68-8 PIOGLITAZONE MECHANISM Increase lipid catabolism 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT NEU_1_Headache 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT MSK_1_Myalgia 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT XXX_1_Sinusitis 105167-68-8 PIOGLITAZONE KNOWN_TOXICITY Cardiovascular Toxicity 105167-68-8 PIOGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 105167-68-8 PIOGLITAZONE ADVERSE_EFFECT CVS_3_Cardiomegaly 105167-68-8 PIOGLITAZONE TISSUE_TOXICITY Congestive Heart Failure 52212-02-9 PIPECURONIUM BROMIDE MECHANISM Block neural transmission 52212-02-9 PIPECURONIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 52212-02-9 PIPECURONIUM BROMIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 52212-02-9 PIPECURONIUM BROMIDE MODE_CLASS Channel Blocker, selective 61477-96-1 PIPERACILLIN ADVERSE_EFFECT SKN_2_Bullous Rash 61477-96-1 PIPERACILLIN TISSUE_TOXICITY Nephrotic Syndrome 61477-96-1 PIPERACILLIN INDICATION Skin and Skin Structure Infections 61477-96-1 PIPERACILLIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 61477-96-1 PIPERACILLIN ADVERSE_EFFECT XXX_3_Superinfection 61477-96-1 PIPERACILLIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 61477-96-1 PIPERACILLIN ADVERSE_EFFECT NEU_3_Seizures 61477-96-1 PIPERACILLIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 61477-96-1 PIPERACILLIN ADVERSE_EFFECT _3_Erythema Nodosum 61477-96-1 PIPERACILLIN TISSUE_TOXICITY Interstitial Nephritis 61477-96-1 PIPERACILLIN INDICATION Pseudomonas Aeruginosa Infection 61477-96-1 PIPERACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 61477-96-1 PIPERACILLIN INDICATION Intra-Abdominal Infections 61477-96-1 PIPERACILLIN INDICATION Respiratory Tract Infection 61477-96-1 PIPERACILLIN ADVERSE_EFFECT _3_Platelet Dysfunction 61477-96-1 PIPERACILLIN ADVERSE_EFFECT GIS_2_Diarrhea 61477-96-1 PIPERACILLIN ADVERSE_EFFECT IMU_1_Allergic Reactions 61477-96-1 PIPERACILLIN ADVERSE_EFFECT LIV_3_Hepatitis 61477-96-1 PIPERACILLIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 61477-96-1 PIPERACILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 61477-96-1 PIPERACILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 61477-96-1 PIPERACILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 61477-96-1 PIPERACILLIN KNOWN_TOXICITY Nephrotoxicity 61477-96-1 PIPERACILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 61477-96-1 PIPERACILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 61477-96-1 PIPERACILLIN PRODUCT_CLASS Anti-infectives 61477-96-1 PIPERACILLIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 61477-96-1 PIPERACILLIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 61477-96-1 PIPERACILLIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 61477-96-1 PIPERACILLIN ADVERSE_EFFECT SKN_1_Pruritis 61477-96-1 PIPERACILLIN ADVERSE_EFFECT ELT_3_Hypokalemia 61477-96-1 PIPERACILLIN TISSUE_TOXICITY Renal Tubular Necrosis 61477-96-1 PIPERACILLIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 61477-96-1 PIPERACILLIN ADVERSE_EFFECT BBM_3_Leukopenia 61477-96-1 PIPERACILLIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 61477-96-1 PIPERACILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 61477-96-1 PIPERACILLIN MODE_CLASS Enzyme Inhibitor 61477-96-1 PIPERACILLIN INDICATION Urinary Tract Infection (UTI) 59703-84-3 PIPERACILLIN ADVERSE_EFFECT SKN_1_Pruritis 59703-84-3 PIPERACILLIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 59703-84-3 PIPERACILLIN ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 59703-84-3 PIPERACILLIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 59703-84-3 PIPERACILLIN PRODUCT_CLASS Anti-infectives 59703-84-3 PIPERACILLIN INDICATION Urinary Tract Infection (UTI) 59703-84-3 PIPERACILLIN MODE_CLASS Enzyme Inhibitor 59703-84-3 PIPERACILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 59703-84-3 PIPERACILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 59703-84-3 PIPERACILLIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 59703-84-3 PIPERACILLIN ADVERSE_EFFECT BBM_3_Leukopenia 59703-84-3 PIPERACILLIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 59703-84-3 PIPERACILLIN TISSUE_TOXICITY Renal Tubular Necrosis 59703-84-3 PIPERACILLIN INDICATION Respiratory Tract Infection 59703-84-3 PIPERACILLIN ADVERSE_EFFECT _3_Platelet Dysfunction 59703-84-3 PIPERACILLIN ADVERSE_EFFECT GIS_2_Diarrhea 59703-84-3 PIPERACILLIN ADVERSE_EFFECT IMU_1_Allergic Reactions 59703-84-3 PIPERACILLIN ADVERSE_EFFECT LIV_3_Hepatitis 59703-84-3 PIPERACILLIN INDICATION Intra-Abdominal Infections 59703-84-3 PIPERACILLIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 59703-84-3 PIPERACILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 59703-84-3 PIPERACILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 59703-84-3 PIPERACILLIN KNOWN_TOXICITY Nephrotoxicity 59703-84-3 PIPERACILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 59703-84-3 PIPERACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 59703-84-3 PIPERACILLIN INDICATION Pseudomonas Aeruginosa Infection 59703-84-3 PIPERACILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 59703-84-3 PIPERACILLIN TISSUE_TOXICITY Interstitial Nephritis 59703-84-3 PIPERACILLIN ADVERSE_EFFECT _3_Erythema Nodosum 59703-84-3 PIPERACILLIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 59703-84-3 PIPERACILLIN ADVERSE_EFFECT NEU_3_Seizures 59703-84-3 PIPERACILLIN ADVERSE_EFFECT SKN_1_Maculopapular Rash 59703-84-3 PIPERACILLIN ADVERSE_EFFECT XXX_3_Superinfection 59703-84-3 PIPERACILLIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 59703-84-3 PIPERACILLIN INDICATION Skin and Skin Structure Infections 59703-84-3 PIPERACILLIN TISSUE_TOXICITY Nephrotic Syndrome 59703-84-3 PIPERACILLIN ADVERSE_EFFECT SKN_2_Bullous Rash 59703-84-3 PIPERACILLIN ADVERSE_EFFECT ELT_3_Hypokalemia 38677-81-5 PIRBUTEROL INDICATION Asthma 38677-81-5 PIRBUTEROL INDICATION Bronchospasm 38677-81-5 PIRBUTEROL MECHANISM Reduce bronchoconstriction 38677-81-5 PIRBUTEROL INDICATION Prophylaxis of Bronchospasm 38677-81-5 PIRBUTEROL MODE_CLASS Receptor Agonist, selective 38677-81-5 PIRBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 38677-81-5 PIRBUTEROL THERAPEUTIC_CLASS Bronchodilators 38677-81-5 PIRBUTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 38677-81-5 PIRBUTEROL PRODUCT_CLASS Respiratory System 38029-10-6 PIRBUTEROL INDICATION Bronchospasm 38029-10-6 PIRBUTEROL MECHANISM Reduce bronchoconstriction 38029-10-6 PIRBUTEROL INDICATION Prophylaxis of Bronchospasm 38029-10-6 PIRBUTEROL MODE_CLASS Receptor Agonist, selective 38029-10-6 PIRBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 38029-10-6 PIRBUTEROL THERAPEUTIC_CLASS Bronchodilators 38029-10-6 PIRBUTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta2 agonist 38029-10-6 PIRBUTEROL PRODUCT_CLASS Respiratory System 38029-10-6 PIRBUTEROL INDICATION Asthma 28797-61-7 PIRENZEPINE MECHANISM Modulate G-protein coupled signal transduction 28797-61-7 PIRENZEPINE MODE_CLASS Receptor Ligand Antagonist, Selective 28797-61-7 PIRENZEPINE INDICATION Ulcer 28797-61-7 PIRENZEPINE PRODUCT_CLASS Gastrointestinal System 28797-61-7 PIRENZEPINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 28797-61-7 PIRENZEPINE THERAPEUTIC_CLASS Antiulcers 29868-97-1 PIRENZEPINE MODE_CLASS Receptor Ligand Antagonist, Selective 29868-97-1 PIRENZEPINE INDICATION Ulcer 29868-97-1 PIRENZEPINE MECHANISM Modulate G-protein coupled signal transduction 29868-97-1 PIRENZEPINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 29868-97-1 PIRENZEPINE THERAPEUTIC_CLASS Antiulcers 29868-97-1 PIRENZEPINE PRODUCT_CLASS Gastrointestinal System 36322-90-4 PIROXICAM ADVERSE_EFFECT LIV_2_Abnormal Liver Function 36322-90-4 PIROXICAM ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 36322-90-4 PIROXICAM ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 36322-90-4 PIROXICAM KNOWN_TOXICITY Nephrotoxicity 36322-90-4 PIROXICAM TISSUE_TOXICITY Acute Interstitial Nephritis 36322-90-4 PIROXICAM TISSUE_TOXICITY Inhibits Platelet Aggregation 36322-90-4 PIROXICAM STRUCTURE_ACTIVITY NSAID, COX-1/2, oxicam 36322-90-4 PIROXICAM MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 36322-90-4 PIROXICAM INDICATION Pain 36322-90-4 PIROXICAM INDICATION Osteoarthritis 36322-90-4 PIROXICAM PRODUCT_CLASS Anti-inflammatories 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_2_Constipation 36322-90-4 PIROXICAM ADVERSE_EFFECT BBM_3_Agranulocytosis 36322-90-4 PIROXICAM ADVERSE_EFFECT BBM_3_Anemia 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_3_Peptic Ulceration 36322-90-4 PIROXICAM ADVERSE_EFFECT KID_3_Renal Failure 36322-90-4 PIROXICAM ADVERSE_EFFECT NEU_2_Somnolence 36322-90-4 PIROXICAM KNOWN_TOXICITY Blood & Bone Marrow Toxicity 36322-90-4 PIROXICAM ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 36322-90-4 PIROXICAM ADVERSE_EFFECT BBM_1_Inhibits Platelet Aggregation 36322-90-4 PIROXICAM TISSUE_TOXICITY Hepatic Failure 36322-90-4 PIROXICAM TISSUE_TOXICITY Renal Failure 36322-90-4 PIROXICAM ACTIVITY_CLASS Anti-inflammatory 36322-90-4 PIROXICAM TISSUE_TOXICITY Cardiac Failure 36322-90-4 PIROXICAM TISSUE_TOXICITY Fulminant Hepatitis 36322-90-4 PIROXICAM ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 36322-90-4 PIROXICAM ADVERSE_EFFECT SKN_2_Skin Rash 36322-90-4 PIROXICAM ADVERSE_EFFECT KID_1_Fluid Retention 36322-90-4 PIROXICAM ADVERSE_EFFECT LIV_3_Hepatic Failure 36322-90-4 PIROXICAM ADVERSE_EFFECT BBM_3_Thrombocytopenia 36322-90-4 PIROXICAM ADVERSE_EFFECT IMU_3_Hypersensitivity 36322-90-4 PIROXICAM ADVERSE_EFFECT NEU_2_Dizziness 36322-90-4 PIROXICAM KNOWN_TOXICITY Cardiovascular Toxicity 36322-90-4 PIROXICAM THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 36322-90-4 PIROXICAM MODE_CLASS Enzyme Inhibitor 36322-90-4 PIROXICAM MECHANISM Inhibit eicosanoid biosynthesis 36322-90-4 PIROXICAM MECH_LEVEL_1 Immunomodulation 36322-90-4 PIROXICAM MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 36322-90-4 PIROXICAM MESH_LEVEL_3 Thiazines 36322-90-4 PIROXICAM TISSUE_TOXICITY Renal Papillary Necrosis 36322-90-4 PIROXICAM ADVERSE_EFFECT REP_2_Delayed Parturition 36322-90-4 PIROXICAM ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_1_Heartburn 36322-90-4 PIROXICAM ADVERSE_EFFECT BBM_3_Pancytopenia 36322-90-4 PIROXICAM ZERO_CLASS N 36322-90-4 PIROXICAM TA_LEVEL_1 Anti-inflammatory 36322-90-4 PIROXICAM TA_LEVEL_2 NSAID 36322-90-4 PIROXICAM MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 36322-90-4 PIROXICAM INDICATION Rheumatoid Arthritis 36322-90-4 PIROXICAM KNOWN_TOXICITY Hepatotoxicity 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_2_Diarrhea 36322-90-4 PIROXICAM ADVERSE_EFFECT OTO_3_Tinnitus 36322-90-4 PIROXICAM ADVERSE_EFFECT SKN_2_Pruritis 36322-90-4 PIROXICAM ADVERSE_EFFECT IMU_3_Photosensitivity 36322-90-4 PIROXICAM TA_LEVEL_3 NSAID 36322-90-4 PIROXICAM MESH_LEVEL_1 Heterocyclic Compounds 36322-90-4 PIROXICAM INDICATION Musculoskeletal Pain 36322-90-4 PIROXICAM ADVERSE_EFFECT OCU_2_Blurred Vision 36322-90-4 PIROXICAM ADVERSE_EFFECT LUN_3_Bronchospasm 36322-90-4 PIROXICAM ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 36322-90-4 PIROXICAM ADVERSE_EFFECT CVS_3_Cardiac Failure 36322-90-4 PIROXICAM ADVERSE_EFFECT GIS_1_Abdominal Pain 69542-93-4 PIVAGABINE INDICATION Parkinson's Disease 69542-93-4 PIVAGABINE THERAPEUTIC_CLASS Sedatives/Hypnotics 69542-93-4 PIVAGABINE MODE_CLASS Receptor Ligand Antagonist 69542-93-4 PIVAGABINE INDICATION Depression 69542-93-4 PIVAGABINE THERAPEUTIC_CLASS Antidepressants 69542-93-4 PIVAGABINE PRODUCT_CLASS Central Nervous System (CNS) 69542-93-4 PIVAGABINE MECHANISM Modulate neural transmission 69542-93-4 PIVAGABINE INDICATION Anxiety Disorders 18378-89-7 PLICAMYCIN MECHANISM Inhibit DNA synthesis, repair, and function 18378-89-7 PLICAMYCIN THERAPEUTIC_CLASS Antineoplastics 18378-89-7 PLICAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 18378-89-7 PLICAMYCIN PRODUCT_CLASS Anti-cancers 18378-89-7 PLICAMYCIN INDICATION Testicular Cancer / Carcinoma of the Testis 518-28-5 PODOPHYLLOTOXIN ADVERSE_EFFECT SKN_1_Pruritis 518-28-5 PODOPHYLLOTOXIN THERAPEUTIC_CLASS Antivirals, Topical 518-28-5 PODOPHYLLOTOXIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 518-28-5 PODOPHYLLOTOXIN MODE_CLASS Enzyme Inhibitor 518-28-5 PODOPHYLLOTOXIN INDICATION Condylomata Acuminata 518-28-5 PODOPHYLLOTOXIN MECHANISM Inhibit DNA synthesis, repair, and function 518-28-5 PODOPHYLLOTOXIN TA_LEVEL_3 Warts 518-28-5 PODOPHYLLOTOXIN MECH_LEVEL_1 Antimitotic 518-28-5 PODOPHYLLOTOXIN MECH_LEVEL_3 Microtubule / tubulin 518-28-5 PODOPHYLLOTOXIN ZERO_CLASS N 518-28-5 PODOPHYLLOTOXIN MESH_LEVEL_3 Naphthalenes 518-28-5 PODOPHYLLOTOXIN TA_LEVEL_2 Anti-viral 518-28-5 PODOPHYLLOTOXIN PRODUCT_CLASS Anti-infectives 518-28-5 PODOPHYLLOTOXIN ADVERSE_EFFECT SKN_1_Skin Irritation 518-28-5 PODOPHYLLOTOXIN ADVERSE_EFFECT SKN_1_Erythema 518-28-5 PODOPHYLLOTOXIN STRUCTURE_ACTIVITY Tubulin binder, toposide 518-28-5 PODOPHYLLOTOXIN MECHANISM Inhibit mitosis 518-28-5 PODOPHYLLOTOXIN ADVERSE_EFFECT XXX_2_Superior Epithelial Ulceration 518-28-5 PODOPHYLLOTOXIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 518-28-5 PODOPHYLLOTOXIN MECH_LEVEL_2 Microtubule / tubulin 518-28-5 PODOPHYLLOTOXIN MESH_LEVEL_1 Polycyclic Hydrocarbons 518-28-5 PODOPHYLLOTOXIN ADVERSE_EFFECT XXX_1_Smarting 518-28-5 PODOPHYLLOTOXIN TA_LEVEL_1 Infectious Disease 518-28-5 PODOPHYLLOTOXIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 518-28-5 PODOPHYLLOTOXIN ADVERSE_EFFECT GUS_2_Balanoposthitis 25322-68-3 POLYETHYLENE GLYCOL PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 88747-22-2 POLYETHYLENE GLYCOL PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 1405-20-5 POLYMYXIN B1 MECHANISM Destroy cell membrane / wall integrity 1405-20-5 POLYMYXIN B1 STRUCTURE_ACTIVITY Impairs cell membrane function 1405-20-5 POLYMYXIN B1 THERAPEUTIC_CLASS Antibacterials 1405-20-5 POLYMYXIN B1 PRODUCT_CLASS Anti-infectives 1405-20-5 POLYMYXIN B1 MODE_CLASS Distorts /blocks macromolecular scaffold function 346-18-9 POLYTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 346-18-9 POLYTHIAZIDE PRODUCT_CLASS Cardiovasculars 346-18-9 POLYTHIAZIDE INDICATION Edema 346-18-9 POLYTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 346-18-9 POLYTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 346-18-9 POLYTHIAZIDE THERAPEUTIC_CLASS Diuretics 346-18-9 POLYTHIAZIDE MODE_CLASS Channel Blocker, selective 346-18-9 POLYTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 346-18-9 POLYTHIAZIDE INDICATION Hypertension 25213-24-5 POLYVINYL ALCOHOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 25213-24-5 POLYVINYL ALCOHOL THERAPEUTIC_CLASS Miscellaneous Ophthamological Agents 25213-24-5 POLYVINYL ALCOHOL INDICATION Keratoconjunctivitis Sicca / Dry Eyes 9002-89-5 POLYVINYL ALCOHOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 9002-89-5 POLYVINYL ALCOHOL THERAPEUTIC_CLASS Miscellaneous Ophthamological Agents 9002-89-5 POLYVINYL ALCOHOL INDICATION Keratoconjunctivitis Sicca / Dry Eyes 171228-49-2 POSACONAZOLE THERAPEUTIC_CLASS Antifungals 171228-49-2 POSACONAZOLE MODE_CLASS Enzyme Inhibitor 171228-49-2 POSACONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 171228-49-2 POSACONAZOLE PRODUCT_CLASS Anti-infectives 9003-39-8 POLYVINYLPYRROLIDONE THERAPEUTIC_CLASS Antiseptics / Disinfectants 9003-39-8 POLYVINYLPYRROLIDONE ADVERSE_EFFECT ELT_3_Hypernatremia 9003-39-8 POLYVINYLPYRROLIDONE PRODUCT_CLASS Anti-infectives 9003-39-8 POLYVINYLPYRROLIDONE INDICATION Burn Wound Infection 9003-39-8 POLYVINYLPYRROLIDONE ADVERSE_EFFECT KID_3_Impaired Renal Tubular Function 9003-39-8 POLYVINYLPYRROLIDONE INDICATION Vaginitis 9003-39-8 POLYVINYLPYRROLIDONE ADVERSE_EFFECT IMU_3_Hypersensitivity 9003-39-8 POLYVINYLPYRROLIDONE INDICATION Skin Antisepsis 9003-39-8 POLYVINYLPYRROLIDONE ADVERSE_EFFECT END_3_Metabolic Acidosis 9003-39-8 POLYVINYLPYRROLIDONE ADVERSE_EFFECT SKN_3_Skin Irritation 9003-39-8 POLYVINYLPYRROLIDONE ADVERSE_EFFECT END_3_Hyperthyroidism 51-15-0 PRALIDOXIME CHLORIDE MESH_LEVEL_1 Organic Chemicals 51-15-0 PRALIDOXIME CHLORIDE TA_LEVEL_2 Antidote 51-15-0 PRALIDOXIME CHLORIDE MESH_LEVEL_2 Amines 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT NEU_2_Headache 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT LUN_3_Hyperventilation 51-15-0 PRALIDOXIME CHLORIDE MECH_LEVEL_2 Decrease cholinergic transmission 51-15-0 PRALIDOXIME CHLORIDE MECH_LEVEL_3 Cholinesterase 51-15-0 PRALIDOXIME CHLORIDE MESH_LEVEL_3 Hydroxylamines 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT GIS_2_Nausea 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT OCU_2_Diplopia 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT XXX_1_Injection Site Reaction 51-15-0 PRALIDOXIME CHLORIDE MECHANISM Enhance cholinergic transmission 51-15-0 PRALIDOXIME CHLORIDE TA_LEVEL_3 organophosphate poisoning 51-15-0 PRALIDOXIME CHLORIDE TA_LEVEL_1 Cardiovascular 51-15-0 PRALIDOXIME CHLORIDE PRODUCT_CLASS Other Human Uses 51-15-0 PRALIDOXIME CHLORIDE THERAPEUTIC_CLASS Antidotes 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT OCU_1_Blurred Vision 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT NEU_2_Drowsiness 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT OCU_2_Paralysis of Accommodation 51-15-0 PRALIDOXIME CHLORIDE ZERO_CLASS N 51-15-0 PRALIDOXIME CHLORIDE ACTIVITY_CLASS Cholinesterase inhibitor 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT CVS_2_Tachycardia 51-15-0 PRALIDOXIME CHLORIDE MECH_LEVEL_1 Modulate neural transmission 51-15-0 PRALIDOXIME CHLORIDE INDICATION Prophylaxis of Organophosphate Poisoning 51-15-0 PRALIDOXIME CHLORIDE MODE_CLASS Enzyme Inhibitor 51-15-0 PRALIDOXIME CHLORIDE INDICATION Organophosphate Poisoning 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT GIS_2_Diarrhea 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT NEU_2_Dizziness 51-15-0 PRALIDOXIME CHLORIDE ADVERSE_EFFECT MSK_3_Muscle Weakness 51-15-0 PRALIDOXIME CHLORIDE STRUCTURE_ACTIVITY Cholinesterase inhibitor 104632-26-0 PRAMIPEXOLE MODE_CLASS Receptor Agonist 104632-26-0 PRAMIPEXOLE PRODUCT_CLASS Central Nervous System (CNS) 104632-26-0 PRAMIPEXOLE MECHANISM Prolong/enhance neural transmission 104632-26-0 PRAMIPEXOLE INDICATION Parkinson's Disease 104632-26-0 PRAMIPEXOLE THERAPEUTIC_CLASS Movement Disorders 104632-28-2 PRAMIPEXOLE MECHANISM Prolong/enhance neural transmission 104632-28-2 PRAMIPEXOLE INDICATION Parkinson's Disease 104632-28-2 PRAMIPEXOLE THERAPEUTIC_CLASS Movement Disorders 104632-28-2 PRAMIPEXOLE MODE_CLASS Receptor Agonist 104632-28-2 PRAMIPEXOLE PRODUCT_CLASS Central Nervous System (CNS) 104632-25-9 PRAMIPEXOLE THERAPEUTIC_CLASS Movement Disorders 104632-25-9 PRAMIPEXOLE MODE_CLASS Receptor Agonist 104632-25-9 PRAMIPEXOLE PRODUCT_CLASS Central Nervous System (CNS) 104632-25-9 PRAMIPEXOLE MECHANISM Prolong/enhance neural transmission 104632-25-9 PRAMIPEXOLE INDICATION Parkinson's Disease 104632-27-1 PRAMIPEXOLE THERAPEUTIC_CLASS Movement Disorders 104632-27-1 PRAMIPEXOLE PRODUCT_CLASS Central Nervous System (CNS) 104632-27-1 PRAMIPEXOLE INDICATION Parkinson's Disease 104632-27-1 PRAMIPEXOLE MECHANISM Prolong/enhance neural transmission 104632-27-1 PRAMIPEXOLE MODE_CLASS Receptor Agonist 191217-81-9 PRAMIPEXOLE PRODUCT_CLASS Central Nervous System (CNS) 191217-81-9 PRAMIPEXOLE MODE_CLASS Receptor Agonist 191217-81-9 PRAMIPEXOLE THERAPEUTIC_CLASS Movement Disorders 191217-81-9 PRAMIPEXOLE INDICATION Parkinson's Disease 191217-81-9 PRAMIPEXOLE MECHANISM Prolong/enhance neural transmission 637-58-1 PRAMOXINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 637-58-1 PRAMOXINE PRODUCT_CLASS Dermatologicals 637-58-1 PRAMOXINE MECH_LEVEL_3 Voltage-gated Na+ channel 637-58-1 PRAMOXINE MESH_LEVEL_3 Oxazines 637-58-1 PRAMOXINE ACTIVITY_CLASS Na+ channel blocker 637-58-1 PRAMOXINE ADVERSE_EFFECT XXX_2_Burning Sensation 637-58-1 PRAMOXINE MODE_CLASS Channel Modulator 637-58-1 PRAMOXINE INDICATION Dermatitis 637-58-1 PRAMOXINE MESH_LEVEL_1 Heterocyclic Compounds 637-58-1 PRAMOXINE MECH_LEVEL_2 channel modulator 637-58-1 PRAMOXINE TA_LEVEL_3 anesthetic, topical 637-58-1 PRAMOXINE ZERO_CLASS N 637-58-1 PRAMOXINE ADVERSE_EFFECT XXX_2_Stinging Sensation 637-58-1 PRAMOXINE ADVERSE_EFFECT XXX_3_Edema 637-58-1 PRAMOXINE INDICATION Pruritus / Itching 637-58-1 PRAMOXINE TA_LEVEL_1 Dermatology 637-58-1 PRAMOXINE ADVERSE_EFFECT IMU_3_Urticaria 637-58-1 PRAMOXINE THERAPEUTIC_CLASS Local Anesthetics 637-58-1 PRAMOXINE INDICATION Hemorrhoids 637-58-1 PRAMOXINE INDICATION Insect Bites or Stings 637-58-1 PRAMOXINE MECHANISM Modulate channel gating 637-58-1 PRAMOXINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 637-58-1 PRAMOXINE MECH_LEVEL_1 Modulate neural transmission 637-58-1 PRAMOXINE TA_LEVEL_2 anesthetic 637-58-1 PRAMOXINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 637-58-1 PRAMOXINE ADVERSE_EFFECT SKN_3_Skin Sloughing 637-58-1 PRAMOXINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 637-58-1 PRAMOXINE INDICATION Burns 140-65-8 PRAMOXINE INDICATION Burns 140-65-8 PRAMOXINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 140-65-8 PRAMOXINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 140-65-8 PRAMOXINE MECH_LEVEL_3 Voltage-gated Na+ channel 140-65-8 PRAMOXINE PRODUCT_CLASS Dermatologicals 140-65-8 PRAMOXINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 140-65-8 PRAMOXINE TA_LEVEL_2 anesthetic 140-65-8 PRAMOXINE MECH_LEVEL_1 Modulate neural transmission 140-65-8 PRAMOXINE ADVERSE_EFFECT SKN_3_Skin Sloughing 140-65-8 PRAMOXINE MECHANISM Modulate channel gating 140-65-8 PRAMOXINE INDICATION Insect Bites or Stings 140-65-8 PRAMOXINE INDICATION Hemorrhoids 140-65-8 PRAMOXINE THERAPEUTIC_CLASS Local Anesthetics 140-65-8 PRAMOXINE ADVERSE_EFFECT IMU_3_Urticaria 140-65-8 PRAMOXINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 140-65-8 PRAMOXINE INDICATION Pruritus / Itching 140-65-8 PRAMOXINE ADVERSE_EFFECT XXX_3_Edema 140-65-8 PRAMOXINE ADVERSE_EFFECT XXX_2_Stinging Sensation 140-65-8 PRAMOXINE ZERO_CLASS N 140-65-8 PRAMOXINE TA_LEVEL_3 anesthetic, topical 140-65-8 PRAMOXINE TA_LEVEL_1 Dermatology 140-65-8 PRAMOXINE MECH_LEVEL_2 channel modulator 140-65-8 PRAMOXINE MESH_LEVEL_1 Heterocyclic Compounds 140-65-8 PRAMOXINE INDICATION Dermatitis 140-65-8 PRAMOXINE MODE_CLASS Channel Modulator 140-65-8 PRAMOXINE MESH_LEVEL_3 Oxazines 140-65-8 PRAMOXINE ACTIVITY_CLASS Na+ channel blocker 140-65-8 PRAMOXINE ADVERSE_EFFECT XXX_2_Burning Sensation 81093-37-0 PRAVASTATIN ADVERSE_EFFECT GIS_1_Diarrhea 81093-37-0 PRAVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 81093-37-0 PRAVASTATIN INDICATION Hypercholesterolemia 81093-37-0 PRAVASTATIN MODE_CLASS Enzyme Inhibitor 81093-37-0 PRAVASTATIN TA_LEVEL_1 Cardiovascular 81093-37-0 PRAVASTATIN INDICATION Familial Dysbetalipoproteinemia 81093-37-0 PRAVASTATIN TA_LEVEL_2 Lipid lowering agent 81093-37-0 PRAVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 81093-37-0 PRAVASTATIN KNOWN_TOXICITY Hepatotoxicity 81093-37-0 PRAVASTATIN MECHANISM Inhibit cholesterol biosynthesis 81093-37-0 PRAVASTATIN TISSUE_TOXICITY Hepatoma 81093-37-0 PRAVASTATIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 81093-37-0 PRAVASTATIN ADVERSE_EFFECT MSK_2_Muscle Pain 81093-37-0 PRAVASTATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 81093-37-0 PRAVASTATIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 81093-37-0 PRAVASTATIN INDICATION Mixed Dyslipidemia 81093-37-0 PRAVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 81093-37-0 PRAVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 81093-37-0 PRAVASTATIN MESH_LEVEL_3 Naphthalenes 81093-37-0 PRAVASTATIN MECH_LEVEL_3 HMG-CoA reductase 81093-37-0 PRAVASTATIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 81093-37-0 PRAVASTATIN ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 81093-37-0 PRAVASTATIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 81093-37-0 PRAVASTATIN ADVERSE_EFFECT GIS_3_Pancreatitis 81093-37-0 PRAVASTATIN ADVERSE_EFFECT DNA_3_Hepatoma 81093-37-0 PRAVASTATIN TISSUE_TOXICITY Acute Renal Failure 81093-37-0 PRAVASTATIN KNOWN_TOXICITY Nephrotoxicity 81093-37-0 PRAVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors, non-aromatic 81093-37-0 PRAVASTATIN MECH_LEVEL_1 Lipid lowering 81093-37-0 PRAVASTATIN INDICATION Primary Prevention of Coronary Heart Disease 81093-37-0 PRAVASTATIN PRODUCT_CLASS Cardiovasculars 81093-37-0 PRAVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 81093-37-0 PRAVASTATIN ADVERSE_EFFECT REP_3_Sexual Dysfunction 81093-37-0 PRAVASTATIN ADVERSE_EFFECT IMU_3_Hypersensitivity 81093-37-0 PRAVASTATIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 81093-37-0 PRAVASTATIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 81093-37-0 PRAVASTATIN ADVERSE_EFFECT MSK_3_Myopathy 81093-37-0 PRAVASTATIN TISSUE_TOXICITY Hepatotoxicity 81093-37-0 PRAVASTATIN ZERO_CLASS N 81093-37-0 PRAVASTATIN ADVERSE_EFFECT LIV_3_Fatty Liver 81093-37-0 PRAVASTATIN ADVERSE_EFFECT KID_3_Acute Renal Failure 81093-37-0 PRAVASTATIN TISSUE_TOXICITY Carcinogenicity 81093-37-0 PRAVASTATIN KNOWN_TOXICITY Carcinogenicity 81093-37-0 PRAVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 81093-37-0 PRAVASTATIN INDICATION Hypertriglyceridemia 81093-37-0 PRAVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 81131-70-6 PRAVASTATIN ZERO_CLASS N 81131-70-6 PRAVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 81131-70-6 PRAVASTATIN INDICATION Hypercholesterolemia 81131-70-6 PRAVASTATIN MODE_CLASS Enzyme Inhibitor 81131-70-6 PRAVASTATIN TA_LEVEL_1 Cardiovascular 81131-70-6 PRAVASTATIN MECH_LEVEL_3 HMG-CoA reductase 81131-70-6 PRAVASTATIN INDICATION Familial Dysbetalipoproteinemia 81131-70-6 PRAVASTATIN TA_LEVEL_2 Lipid lowering agent 81131-70-6 PRAVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors, non-aromatic 81131-70-6 PRAVASTATIN KNOWN_TOXICITY Hepatotoxicity 81131-70-6 PRAVASTATIN MECHANISM Inhibit cholesterol biosynthesis 81131-70-6 PRAVASTATIN TISSUE_TOXICITY Hepatoma 81131-70-6 PRAVASTATIN ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 81131-70-6 PRAVASTATIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 81131-70-6 PRAVASTATIN ADVERSE_EFFECT MSK_2_Muscle Pain 81131-70-6 PRAVASTATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 81131-70-6 PRAVASTATIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 81131-70-6 PRAVASTATIN ADVERSE_EFFECT LIV_3_Fatty Liver 81131-70-6 PRAVASTATIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 81131-70-6 PRAVASTATIN ADVERSE_EFFECT KID_3_Acute Renal Failure 81131-70-6 PRAVASTATIN TISSUE_TOXICITY Carcinogenicity 81131-70-6 PRAVASTATIN KNOWN_TOXICITY Carcinogenicity 81131-70-6 PRAVASTATIN INDICATION Mixed Dyslipidemia 81131-70-6 PRAVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 81131-70-6 PRAVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 81131-70-6 PRAVASTATIN MESH_LEVEL_3 Naphthalenes 81131-70-6 PRAVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 81131-70-6 PRAVASTATIN INDICATION Hypertriglyceridemia 81131-70-6 PRAVASTATIN ADVERSE_EFFECT GIS_1_Diarrhea 81131-70-6 PRAVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 81131-70-6 PRAVASTATIN ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 81131-70-6 PRAVASTATIN PRODUCT_CLASS Cardiovasculars 81131-70-6 PRAVASTATIN ADVERSE_EFFECT GIS_3_Pancreatitis 81131-70-6 PRAVASTATIN ADVERSE_EFFECT DNA_3_Hepatoma 81131-70-6 PRAVASTATIN TISSUE_TOXICITY Acute Renal Failure 81131-70-6 PRAVASTATIN KNOWN_TOXICITY Nephrotoxicity 81131-70-6 PRAVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 81131-70-6 PRAVASTATIN MECH_LEVEL_1 Lipid lowering 81131-70-6 PRAVASTATIN INDICATION Primary Prevention of Coronary Heart Disease 81131-70-6 PRAVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 81131-70-6 PRAVASTATIN ADVERSE_EFFECT REP_3_Sexual Dysfunction 81131-70-6 PRAVASTATIN ADVERSE_EFFECT IMU_3_Hypersensitivity 81131-70-6 PRAVASTATIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 81131-70-6 PRAVASTATIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 81131-70-6 PRAVASTATIN ADVERSE_EFFECT MSK_3_Myopathy 81131-70-6 PRAVASTATIN TISSUE_TOXICITY Hepatotoxicity 2955-38-6 PRAZEPAM MECHANISM Modulate neural transmission 2955-38-6 PRAZEPAM MODE_CLASS Channel enhancer /opener 2955-38-6 PRAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 2955-38-6 PRAZEPAM INDICATION Anxiety Disorders 2955-38-6 PRAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 2955-38-6 PRAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 55268-74-1 PRAZIQUANTEL TA_LEVEL_3 Anti-schistosomiasis/cetode 55268-74-1 PRAZIQUANTEL MECH_LEVEL_3 Membrane, indirect calcium release 55268-74-1 PRAZIQUANTEL MECH_LEVEL_1 Anthelmintic 55268-74-1 PRAZIQUANTEL THERAPEUTIC_CLASS Antiparasitics 55268-74-1 PRAZIQUANTEL ZERO_CLASS N 55268-74-1 PRAZIQUANTEL MESH_LEVEL_1 Heterocyclic Compounds 55268-74-1 PRAZIQUANTEL PRODUCT_CLASS Anti-infectives 55268-74-1 PRAZIQUANTEL ADVERSE_EFFECT NEU_3_Headache 55268-74-1 PRAZIQUANTEL STRUCTURE_ACTIVITY Ca++ channel blocker, antiparasitics 55268-74-1 PRAZIQUANTEL MECH_LEVEL_2 Disrupt Calcium homeostasis 55268-74-1 PRAZIQUANTEL ADVERSE_EFFECT GIS_2_Abdominal Distress 55268-74-1 PRAZIQUANTEL ADVERSE_EFFECT PSY_3_Anorexia 55268-74-1 PRAZIQUANTEL INDICATION Trematode (Fluke) Infections 55268-74-1 PRAZIQUANTEL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 55268-74-1 PRAZIQUANTEL TA_LEVEL_1 Infectious Disease 55268-74-1 PRAZIQUANTEL TA_LEVEL_2 anthelmintic 55268-74-1 PRAZIQUANTEL ADVERSE_EFFECT XXX_2_Malaise 55268-74-1 PRAZIQUANTEL INDICATION Schistosomiasis / Bilharziasis 55268-74-1 PRAZIQUANTEL ADVERSE_EFFECT XXX_3_Fever 55268-74-1 PRAZIQUANTEL MESH_LEVEL_3 Isoquinolines 55268-74-1 PRAZIQUANTEL ACTIVITY_CLASS Ca++ channel blocker, antiparasitics 55268-74-1 PRAZIQUANTEL ADVERSE_EFFECT NEU_1_Dizziness 19237-84-4 PRAZOSIN ADVERSE_EFFECT GIS_3_Constipation 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 19237-84-4 PRAZOSIN ADVERSE_EFFECT GIS_1_Nausea 19237-84-4 PRAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 19237-84-4 PRAZOSIN ADVERSE_EFFECT SKN_3_Pruritis 19237-84-4 PRAZOSIN ADVERSE_EFFECT LUN_2_Dyspnea 19237-84-4 PRAZOSIN ADVERSE_EFFECT GIS_3_Pancreatitis 19237-84-4 PRAZOSIN ADVERSE_EFFECT NEU_2_Syncope 19237-84-4 PRAZOSIN ACTIVITY_CLASS Adrenergic antagonist 19237-84-4 PRAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 19237-84-4 PRAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 19237-84-4 PRAZOSIN MESH_LEVEL_3 Quinazolines 19237-84-4 PRAZOSIN TA_LEVEL_3 hypertension 19237-84-4 PRAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 19237-84-4 PRAZOSIN ADVERSE_EFFECT XXX_3_Fever 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_2_Angina 19237-84-4 PRAZOSIN ADVERSE_EFFECT NEU_1_Headache 19237-84-4 PRAZOSIN ADVERSE_EFFECT END_3_Gynecomastia 19237-84-4 PRAZOSIN ADVERSE_EFFECT IMU_3_Urticaria 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_1_Palpitation 19237-84-4 PRAZOSIN ADVERSE_EFFECT GUS_3_Urinary Frequency 19237-84-4 PRAZOSIN INDICATION Hypertension 19237-84-4 PRAZOSIN TA_LEVEL_1 Cardiovascular 19237-84-4 PRAZOSIN MECH_LEVEL_2 alpha antagonist 19237-84-4 PRAZOSIN MECH_LEVEL_1 Vasorelaxation 19237-84-4 PRAZOSIN ADVERSE_EFFECT GIS_3_Diarrhea 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_2_Hypertension 19237-84-4 PRAZOSIN ADVERSE_EFFECT REP_3_Impotence 19237-84-4 PRAZOSIN ADVERSE_EFFECT NEU_1_Drowsiness 19237-84-4 PRAZOSIN ADVERSE_EFFECT NEU_1_Lightheadedness 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_3_Vasculitis 19237-84-4 PRAZOSIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 19237-84-4 PRAZOSIN ADVERSE_EFFECT REP_3_Priapism 19237-84-4 PRAZOSIN ZERO_CLASS N 19237-84-4 PRAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 19237-84-4 PRAZOSIN TISSUE_TOXICITY Angina 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_2_Tachycardia 19237-84-4 PRAZOSIN ADVERSE_EFFECT OCU_3_Blurred Vision 19237-84-4 PRAZOSIN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 19237-84-4 PRAZOSIN ADVERSE_EFFECT XXX_1_Weakness 19237-84-4 PRAZOSIN ADVERSE_EFFECT IMU_3_Allergic Reactions 19237-84-4 PRAZOSIN ADVERSE_EFFECT XXX_1_Lethargy 19237-84-4 PRAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 19237-84-4 PRAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 19237-84-4 PRAZOSIN ADVERSE_EFFECT GIS_3_Abdominal Pain 19237-84-4 PRAZOSIN ADVERSE_EFFECT XXX_3_Xerostomia 19237-84-4 PRAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 19237-84-4 PRAZOSIN MECHANISM Reduce vasoconstriction 19237-84-4 PRAZOSIN PRODUCT_CLASS Cardiovasculars 19237-84-4 PRAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 19237-84-4 PRAZOSIN TA_LEVEL_2 alpha blocker 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Angina 19216-56-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 19216-56-9 PRAZOSIN ADVERSE_EFFECT SKN_3_Pruritis 19216-56-9 PRAZOSIN ADVERSE_EFFECT LUN_2_Dyspnea 19216-56-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Pancreatitis 19216-56-9 PRAZOSIN ADVERSE_EFFECT NEU_2_Syncope 19216-56-9 PRAZOSIN ACTIVITY_CLASS Adrenergic antagonist 19216-56-9 PRAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 19216-56-9 PRAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 19216-56-9 PRAZOSIN MESH_LEVEL_3 Quinazolines 19216-56-9 PRAZOSIN TA_LEVEL_3 hypertension 19216-56-9 PRAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 19216-56-9 PRAZOSIN ADVERSE_EFFECT XXX_3_Fever 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 19216-56-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Headache 19216-56-9 PRAZOSIN ADVERSE_EFFECT END_3_Gynecomastia 19216-56-9 PRAZOSIN ADVERSE_EFFECT IMU_3_Urticaria 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_1_Palpitation 19216-56-9 PRAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 19216-56-9 PRAZOSIN ADVERSE_EFFECT GUS_3_Urinary Frequency 19216-56-9 PRAZOSIN INDICATION Hypertension 19216-56-9 PRAZOSIN TA_LEVEL_1 Cardiovascular 19216-56-9 PRAZOSIN MECH_LEVEL_2 alpha antagonist 19216-56-9 PRAZOSIN MECH_LEVEL_1 Vasorelaxation 19216-56-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Diarrhea 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Hypertension 19216-56-9 PRAZOSIN ADVERSE_EFFECT REP_3_Impotence 19216-56-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Drowsiness 19216-56-9 PRAZOSIN ADVERSE_EFFECT IMU_3_Allergic Reactions 19216-56-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Lightheadedness 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_3_Vasculitis 19216-56-9 PRAZOSIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 19216-56-9 PRAZOSIN ADVERSE_EFFECT REP_3_Priapism 19216-56-9 PRAZOSIN ZERO_CLASS N 19216-56-9 PRAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 19216-56-9 PRAZOSIN TISSUE_TOXICITY Angina 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Tachycardia 19216-56-9 PRAZOSIN ADVERSE_EFFECT OCU_3_Blurred Vision 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 19216-56-9 PRAZOSIN ADVERSE_EFFECT XXX_1_Weakness 19216-56-9 PRAZOSIN PRODUCT_CLASS Cardiovasculars 19216-56-9 PRAZOSIN MECHANISM Reduce vasoconstriction 19216-56-9 PRAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 19216-56-9 PRAZOSIN ADVERSE_EFFECT XXX_3_Xerostomia 19216-56-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Abdominal Pain 19216-56-9 PRAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 19216-56-9 PRAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 19216-56-9 PRAZOSIN ADVERSE_EFFECT XXX_1_Lethargy 19216-56-9 PRAZOSIN TA_LEVEL_2 alpha blocker 19216-56-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Constipation 19216-56-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 19216-56-9 PRAZOSIN ADVERSE_EFFECT GIS_1_Nausea 86126-06-9 PRAZOSIN ADVERSE_EFFECT XXX_3_Xerostomia 86126-06-9 PRAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 86126-06-9 PRAZOSIN MECHANISM Reduce vasoconstriction 86126-06-9 PRAZOSIN PRODUCT_CLASS Cardiovasculars 86126-06-9 PRAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 86126-06-9 PRAZOSIN ACTIVITY_CLASS Adrenergic antagonist 86126-06-9 PRAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 86126-06-9 PRAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 86126-06-9 PRAZOSIN MESH_LEVEL_3 Quinazolines 86126-06-9 PRAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 86126-06-9 PRAZOSIN ADVERSE_EFFECT NEU_2_Syncope 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 86126-06-9 PRAZOSIN ADVERSE_EFFECT XXX_3_Fever 86126-06-9 PRAZOSIN TA_LEVEL_3 hypertension 86126-06-9 PRAZOSIN TA_LEVEL_2 alpha blocker 86126-06-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Constipation 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 86126-06-9 PRAZOSIN ADVERSE_EFFECT GIS_1_Nausea 86126-06-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Abdominal Pain 86126-06-9 PRAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 86126-06-9 PRAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 86126-06-9 PRAZOSIN ADVERSE_EFFECT XXX_1_Lethargy 86126-06-9 PRAZOSIN ADVERSE_EFFECT IMU_3_Allergic Reactions 86126-06-9 PRAZOSIN ADVERSE_EFFECT XXX_1_Weakness 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Sinus Bradycardia 86126-06-9 PRAZOSIN ADVERSE_EFFECT OCU_3_Blurred Vision 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Tachycardia 86126-06-9 PRAZOSIN TISSUE_TOXICITY Angina 86126-06-9 PRAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 86126-06-9 PRAZOSIN ZERO_CLASS N 86126-06-9 PRAZOSIN ADVERSE_EFFECT REP_3_Priapism 86126-06-9 PRAZOSIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_3_Vasculitis 86126-06-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Lightheadedness 86126-06-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Drowsiness 86126-06-9 PRAZOSIN ADVERSE_EFFECT REP_3_Impotence 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Hypertension 86126-06-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Diarrhea 86126-06-9 PRAZOSIN MECH_LEVEL_1 Vasorelaxation 86126-06-9 PRAZOSIN MECH_LEVEL_2 alpha antagonist 86126-06-9 PRAZOSIN TA_LEVEL_1 Cardiovascular 86126-06-9 PRAZOSIN INDICATION Hypertension 86126-06-9 PRAZOSIN ADVERSE_EFFECT GUS_3_Urinary Frequency 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_1_Palpitation 86126-06-9 PRAZOSIN ADVERSE_EFFECT IMU_3_Urticaria 86126-06-9 PRAZOSIN ADVERSE_EFFECT END_3_Gynecomastia 86126-06-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 86126-06-9 PRAZOSIN ADVERSE_EFFECT NEU_1_Headache 86126-06-9 PRAZOSIN ADVERSE_EFFECT CVS_2_Angina 86126-06-9 PRAZOSIN ADVERSE_EFFECT SKN_3_Pruritis 86126-06-9 PRAZOSIN ADVERSE_EFFECT LUN_2_Dyspnea 86126-06-9 PRAZOSIN ADVERSE_EFFECT GIS_3_Pancreatitis 73771-04-7 PREDNICARBATE MODE_CLASS Receptor Agonist 73771-04-7 PREDNICARBATE MECHANISM Modulate gene transcription 721-50-6 PRILOCAINE PRODUCT_CLASS Central Nervous System (CNS) 721-50-6 PRILOCAINE INDICATION Infiltration Anesthesia 721-50-6 PRILOCAINE ADVERSE_EFFECT OCU_3_Blurred Vision 721-50-6 PRILOCAINE ADVERSE_EFFECT PSY_3_Anxiety 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Angina 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 721-50-6 PRILOCAINE ADVERSE_EFFECT NEU_3_Drowsiness 721-50-6 PRILOCAINE ADVERSE_EFFECT NEU_3_Impaired Consciousness 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 721-50-6 PRILOCAINE TISSUE_TOXICITY Angina 721-50-6 PRILOCAINE TISSUE_TOXICITY First-Degree AV block 721-50-6 PRILOCAINE INDICATION Peripheral Nerve Block 721-50-6 PRILOCAINE INDICATION Dental Anesthesia 721-50-6 PRILOCAINE ADVERSE_EFFECT XXX_3_Restlessness 721-50-6 PRILOCAINE TISSUE_TOXICITY Cardiovascular Collapse 721-50-6 PRILOCAINE TISSUE_TOXICITY Atrial Fibrillation 721-50-6 PRILOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 721-50-6 PRILOCAINE TISSUE_TOXICITY Myocardial Depression 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 721-50-6 PRILOCAINE TISSUE_TOXICITY Hypotension 721-50-6 PRILOCAINE THERAPEUTIC_CLASS Local Anesthetics 721-50-6 PRILOCAINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 721-50-6 PRILOCAINE ADVERSE_EFFECT NEU_3_Seizures 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 721-50-6 PRILOCAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Hypotension 721-50-6 PRILOCAINE MODE_CLASS Channel Blocker 721-50-6 PRILOCAINE TISSUE_TOXICITY Cardiac Arrhythmia 721-50-6 PRILOCAINE TISSUE_TOXICITY Cardiac Arrest 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_First-Degree AV block 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 721-50-6 PRILOCAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 721-50-6 PRILOCAINE ADVERSE_EFFECT BBM_3_Methemoglobinemia 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Hypertension 721-50-6 PRILOCAINE INDICATION Local Anesthesia 721-50-6 PRILOCAINE MECHANISM Block neural transmission 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 721-50-6 PRILOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 721-50-6 PRILOCAINE ADVERSE_EFFECT IMU_3_Allergic Reactions 721-50-6 PRILOCAINE ADVERSE_EFFECT NEU_3_Dizziness 721-50-6 PRILOCAINE ADVERSE_EFFECT NEU_3_Tremor 721-50-6 PRILOCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 721-50-6 PRILOCAINE KNOWN_TOXICITY Cardiovascular Toxicity 1786-81-8 PRILOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 1786-81-8 PRILOCAINE TISSUE_TOXICITY Myocardial Depression 1786-81-8 PRILOCAINE THERAPEUTIC_CLASS Local Anesthetics 1786-81-8 PRILOCAINE TISSUE_TOXICITY Cardiac Arrest 1786-81-8 PRILOCAINE TISSUE_TOXICITY Cardiac Arrhythmia 1786-81-8 PRILOCAINE MODE_CLASS Channel Blocker 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Hypotension 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Hypertension 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 1786-81-8 PRILOCAINE ADVERSE_EFFECT IMU_3_Allergic Reactions 1786-81-8 PRILOCAINE ADVERSE_EFFECT NEU_3_Dizziness 1786-81-8 PRILOCAINE ADVERSE_EFFECT NEU_3_Tremor 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 1786-81-8 PRILOCAINE INDICATION Local Anesthesia 1786-81-8 PRILOCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 1786-81-8 PRILOCAINE KNOWN_TOXICITY Cardiovascular Toxicity 1786-81-8 PRILOCAINE TISSUE_TOXICITY Atrial Fibrillation 1786-81-8 PRILOCAINE TISSUE_TOXICITY Cardiovascular Collapse 1786-81-8 PRILOCAINE MECHANISM Block neural transmission 1786-81-8 PRILOCAINE TISSUE_TOXICITY Hypotension 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 1786-81-8 PRILOCAINE ADVERSE_EFFECT BBM_3_Methemoglobinemia 1786-81-8 PRILOCAINE ADVERSE_EFFECT LUN_3_Respiratory Arrest 1786-81-8 PRILOCAINE INDICATION Dental Anesthesia 1786-81-8 PRILOCAINE INDICATION Peripheral Nerve Block 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 1786-81-8 PRILOCAINE TISSUE_TOXICITY Angina 1786-81-8 PRILOCAINE ADVERSE_EFFECT NEU_3_Impaired Consciousness 1786-81-8 PRILOCAINE ADVERSE_EFFECT NEU_3_Drowsiness 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Angina 1786-81-8 PRILOCAINE ADVERSE_EFFECT PSY_3_Anxiety 1786-81-8 PRILOCAINE ADVERSE_EFFECT OCU_3_Blurred Vision 1786-81-8 PRILOCAINE INDICATION Infiltration Anesthesia 1786-81-8 PRILOCAINE PRODUCT_CLASS Central Nervous System (CNS) 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Myocardial Depression 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_First-Degree AV block 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 1786-81-8 PRILOCAINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 1786-81-8 PRILOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 1786-81-8 PRILOCAINE ADVERSE_EFFECT NEU_3_Seizures 1786-81-8 PRILOCAINE ADVERSE_EFFECT XXX_3_Restlessness 1786-81-8 PRILOCAINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 1786-81-8 PRILOCAINE TISSUE_TOXICITY First-Degree AV block 90-34-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Methemoglobinemia 90-34-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Leukopenia 90-34-6 PRIMAQUINE PRODUCT_CLASS Anti-infectives 90-34-6 PRIMAQUINE THERAPEUTIC_CLASS Antiparasitics 90-34-6 PRIMAQUINE MECH_LEVEL_2 Unknown mechanism 90-34-6 PRIMAQUINE MECH_LEVEL_3 Unknown mechanism 90-34-6 PRIMAQUINE ADVERSE_EFFECT XXX_2_Fever 90-34-6 PRIMAQUINE ADVERSE_EFFECT XXX_2_Weakness 90-34-6 PRIMAQUINE ADVERSE_EFFECT LUN_2_Shortness of Breath 90-34-6 PRIMAQUINE MECHANISM Inhibit mitochondrial function 90-34-6 PRIMAQUINE MESH_LEVEL_1 Heterocyclic Compounds 90-34-6 PRIMAQUINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 90-34-6 PRIMAQUINE MODE_CLASS Enzyme Inhibitor 90-34-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Anemia 90-34-6 PRIMAQUINE ADVERSE_EFFECT GIS_2_Abdominal Pain 90-34-6 PRIMAQUINE STRUCTURE_ACTIVITY Quinone reductase inhibitor 90-34-6 PRIMAQUINE TA_LEVEL_1 Infectious Disease 90-34-6 PRIMAQUINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 90-34-6 PRIMAQUINE ADVERSE_EFFECT NEU_2_Dizziness 90-34-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Hemolysis 90-34-6 PRIMAQUINE ZERO_CLASS N 90-34-6 PRIMAQUINE INDICATION Malaria 90-34-6 PRIMAQUINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 90-34-6 PRIMAQUINE ADVERSE_EFFECT XXX_2_Fatigue 90-34-6 PRIMAQUINE TA_LEVEL_2 Anti-malarial 90-34-6 PRIMAQUINE MESH_LEVEL_3 Quinolines 90-34-6 PRIMAQUINE ADVERSE_EFFECT PSY_2_Anorexia 63-45-6 PRIMAQUINE ADVERSE_EFFECT LUN_2_Shortness of Breath 63-45-6 PRIMAQUINE MECH_LEVEL_2 Unknown mechanism 63-45-6 PRIMAQUINE THERAPEUTIC_CLASS Antiparasitics 63-45-6 PRIMAQUINE PRODUCT_CLASS Anti-infectives 63-45-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Leukopenia 63-45-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Methemoglobinemia 63-45-6 PRIMAQUINE ADVERSE_EFFECT PSY_2_Anorexia 63-45-6 PRIMAQUINE MESH_LEVEL_3 Quinolines 63-45-6 PRIMAQUINE ADVERSE_EFFECT XXX_2_Weakness 63-45-6 PRIMAQUINE TA_LEVEL_2 Anti-malarial 63-45-6 PRIMAQUINE ZERO_CLASS N 63-45-6 PRIMAQUINE INDICATION Malaria 63-45-6 PRIMAQUINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 63-45-6 PRIMAQUINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 63-45-6 PRIMAQUINE MODE_CLASS Enzyme Inhibitor 63-45-6 PRIMAQUINE MECH_LEVEL_3 Unknown mechanism 63-45-6 PRIMAQUINE ADVERSE_EFFECT XXX_2_Fatigue 63-45-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Anemia 63-45-6 PRIMAQUINE ADVERSE_EFFECT XXX_2_Fever 63-45-6 PRIMAQUINE ADVERSE_EFFECT GIS_2_Abdominal Pain 63-45-6 PRIMAQUINE STRUCTURE_ACTIVITY Quinone reductase inhibitor 63-45-6 PRIMAQUINE TA_LEVEL_1 Infectious Disease 63-45-6 PRIMAQUINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 63-45-6 PRIMAQUINE ADVERSE_EFFECT NEU_2_Dizziness 63-45-6 PRIMAQUINE ADVERSE_EFFECT BBM_2_Hemolysis 63-45-6 PRIMAQUINE MESH_LEVEL_1 Heterocyclic Compounds 63-45-6 PRIMAQUINE MECHANISM Inhibit mitochondrial function 57-66-9 PROBENECID ADVERSE_EFFECT IMU_3_Anaphylactic Shock 57-66-9 PROBENECID TISSUE_TOXICITY Interstitial Nephritis 57-66-9 PROBENECID MECH_LEVEL_2 Block channel gating 57-66-9 PROBENECID MECH_LEVEL_3 Urate/Anion exchanger, Urate transporter 57-66-9 PROBENECID MESH_LEVEL_1 Organic Chemicals 57-66-9 PROBENECID ADVERSE_EFFECT NEU_1_Headache 57-66-9 PROBENECID TISSUE_TOXICITY Hematuria 57-66-9 PROBENECID TA_LEVEL_3 Gout-Related Agents 57-66-9 PROBENECID MESH_LEVEL_3 Sulfonamides 57-66-9 PROBENECID PRODUCT_CLASS Hormones, Endocrine and Metabolic 57-66-9 PROBENECID MECH_LEVEL_1 Uric acid elimination 57-66-9 PROBENECID ADVERSE_EFFECT KID_3_Hematuria 57-66-9 PROBENECID ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 57-66-9 PROBENECID ADVERSE_EFFECT KID_3_Nephrotic Syndrome 57-66-9 PROBENECID ADVERSE_EFFECT BBM_3_Anemia 57-66-9 PROBENECID INDICATION Gout 57-66-9 PROBENECID THERAPEUTIC_CLASS Uricosuric Agents 57-66-9 PROBENECID TA_LEVEL_2 Uric acid elimination 57-66-9 PROBENECID MESH_LEVEL_2 Amides 57-66-9 PROBENECID ADVERSE_EFFECT SKN_2_Flushing 57-66-9 PROBENECID ACTIVITY_CLASS Organic anion transporter inhibitor 57-66-9 PROBENECID TA_LEVEL_1 Hormones, Endocrine and Metabolic 57-66-9 PROBENECID ADVERSE_EFFECT NEU_2_Dizziness 57-66-9 PROBENECID STRUCTURE_ACTIVITY Organic anion transporter inhibitor 57-66-9 PROBENECID ADVERSE_EFFECT PSY_2_Anorexia 57-66-9 PROBENECID ADVERSE_EFFECT KID_3_Interstitial Nephritis 57-66-9 PROBENECID ADVERSE_EFFECT KID_2_Polyuria 57-66-9 PROBENECID TISSUE_TOXICITY Nephrotic Syndrome 57-66-9 PROBENECID MODE_CLASS Solute transporter inhibitor 57-66-9 PROBENECID MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 57-66-9 PROBENECID INDICATION Hyperuricemia 57-66-9 PROBENECID KNOWN_TOXICITY Nephrotoxicity 57-66-9 PROBENECID THERAPEUTIC_CLASS Gout-Related Agents 57-66-9 PROBENECID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57-66-9 PROBENECID ADVERSE_EFFECT KID_3_Nephrolithiasis 57-66-9 PROBENECID ZERO_CLASS N 23795-03-1 PROBENECID MODE_CLASS Solute transporter inhibitor 23795-03-1 PROBENECID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 23795-03-1 PROBENECID THERAPEUTIC_CLASS Gout-Related Agents 23795-03-1 PROBENECID KNOWN_TOXICITY Nephrotoxicity 23795-03-1 PROBENECID ACTIVITY_CLASS Organic anion transporter inhibitor 23795-03-1 PROBENECID INDICATION Hyperuricemia 23795-03-1 PROBENECID ADVERSE_EFFECT SKN_2_Flushing 23795-03-1 PROBENECID ADVERSE_EFFECT KID_3_Nephrotic Syndrome 23795-03-1 PROBENECID MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 23795-03-1 PROBENECID TISSUE_TOXICITY Interstitial Nephritis 23795-03-1 PROBENECID ZERO_CLASS N 23795-03-1 PROBENECID MECH_LEVEL_3 Urate/Anion exchanger, Urate transporter 23795-03-1 PROBENECID ADVERSE_EFFECT KID_3_Interstitial Nephritis 23795-03-1 PROBENECID MECH_LEVEL_1 Uric acid elimination 23795-03-1 PROBENECID MESH_LEVEL_2 Amides 23795-03-1 PROBENECID ADVERSE_EFFECT NEU_2_Dizziness 23795-03-1 PROBENECID ADVERSE_EFFECT KID_3_Hematuria 23795-03-1 PROBENECID TISSUE_TOXICITY Nephrotic Syndrome 23795-03-1 PROBENECID ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 23795-03-1 PROBENECID THERAPEUTIC_CLASS Uricosuric Agents 23795-03-1 PROBENECID STRUCTURE_ACTIVITY Organic anion transporter inhibitor 23795-03-1 PROBENECID TA_LEVEL_1 Hormones, Endocrine and Metabolic 23795-03-1 PROBENECID TA_LEVEL_2 Uric acid elimination 23795-03-1 PROBENECID MECH_LEVEL_2 Block channel gating 23795-03-1 PROBENECID MESH_LEVEL_1 Organic Chemicals 23795-03-1 PROBENECID ADVERSE_EFFECT KID_2_Polyuria 23795-03-1 PROBENECID ADVERSE_EFFECT PSY_2_Anorexia 23795-03-1 PROBENECID INDICATION Gout 23795-03-1 PROBENECID ADVERSE_EFFECT BBM_3_Anemia 23795-03-1 PROBENECID PRODUCT_CLASS Hormones, Endocrine and Metabolic 23795-03-1 PROBENECID MESH_LEVEL_3 Sulfonamides 23795-03-1 PROBENECID TA_LEVEL_3 Gout-Related Agents 23795-03-1 PROBENECID TISSUE_TOXICITY Hematuria 23795-03-1 PROBENECID ADVERSE_EFFECT NEU_1_Headache 23795-03-1 PROBENECID ADVERSE_EFFECT IMU_3_Anaphylactic Shock 23795-03-1 PROBENECID ADVERSE_EFFECT KID_3_Nephrolithiasis 23288-49-5 PROBUCOL ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 23288-49-5 PROBUCOL ADVERSE_EFFECT CVS_1_Ventricular Tachycardia 23288-49-5 PROBUCOL ADVERSE_EFFECT OTO_3_Tinnitus 23288-49-5 PROBUCOL ADVERSE_EFFECT REP_3_Impotence 23288-49-5 PROBUCOL INDICATION Hypolipidemia 23288-49-5 PROBUCOL TA_LEVEL_1 Cardiovascular 23288-49-5 PROBUCOL MECH_LEVEL_3 Unknown mechanism 23288-49-5 PROBUCOL INDICATION Hyperlipoproteinemia 23288-49-5 PROBUCOL ADVERSE_EFFECT OCU_3_Blurred Vision 23288-49-5 PROBUCOL TISSUE_TOXICITY Ventricular Fibrillation 23288-49-5 PROBUCOL ADVERSE_EFFECT KID_3_Nocturia 23288-49-5 PROBUCOL ADVERSE_EFFECT NEU_2_Syncope 23288-49-5 PROBUCOL ADVERSE_EFFECT GIS_1_Abdominal Pain 23288-49-5 PROBUCOL ADVERSE_EFFECT IMU_3_Angioedema 23288-49-5 PROBUCOL ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 23288-49-5 PROBUCOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 23288-49-5 PROBUCOL MECHANISM Scavenges hydrogen peroxide and free radicals 23288-49-5 PROBUCOL THERAPEUTIC_CLASS Hypolipidemic Agents 23288-49-5 PROBUCOL KNOWN_TOXICITY Cardiovascular Toxicity 23288-49-5 PROBUCOL TISSUE_TOXICITY Ventricular Tachycardia 23288-49-5 PROBUCOL ADVERSE_EFFECT PSY_3_Insomnia 23288-49-5 PROBUCOL ADVERSE_EFFECT CVS_1_Prolonged QT Interval 23288-49-5 PROBUCOL ADVERSE_EFFECT BBM_3_Ecchymosis 23288-49-5 PROBUCOL ADVERSE_EFFECT NEU_2_Headache 23288-49-5 PROBUCOL ADVERSE_EFFECT OCU_3_Conjunctivitis 23288-49-5 PROBUCOL ADVERSE_EFFECT SKN_3_Rash 23288-49-5 PROBUCOL ADVERSE_EFFECT SKN_3_Pruritis 23288-49-5 PROBUCOL ADVERSE_EFFECT NEU_3_Peripheral Neuritis 23288-49-5 PROBUCOL ADVERSE_EFFECT IMU_3_Eosinophilia 23288-49-5 PROBUCOL ADVERSE_EFFECT GIS_3_Idiosyncratic reactions 23288-49-5 PROBUCOL ADVERSE_EFFECT GIS_1_Diarrhea 23288-49-5 PROBUCOL PRODUCT_CLASS Cardiovasculars 23288-49-5 PROBUCOL TA_LEVEL_3 hypercholestrolemia 23288-49-5 PROBUCOL MECH_LEVEL_2 free radical scavenger 23288-49-5 PROBUCOL MESH_LEVEL_1 Organic Chemicals 23288-49-5 PROBUCOL MESH_LEVEL_2 Phenols 23288-49-5 PROBUCOL ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 23288-49-5 PROBUCOL ADVERSE_EFFECT NEU_3_Paresthesia 23288-49-5 PROBUCOL ADVERSE_EFFECT BBM_3_Anemia 23288-49-5 PROBUCOL ADVERSE_EFFECT GIS_1_Gastrointestinal Irritation 23288-49-5 PROBUCOL ADVERSE_EFFECT BBM_3_Petechiae 23288-49-5 PROBUCOL ADVERSE_EFFECT XXX_3_Lacrimation 23288-49-5 PROBUCOL TISSUE_TOXICITY Torsade de Pointes Arrhythmia 23288-49-5 PROBUCOL MESH_LEVEL_3 Probucol 23288-49-5 PROBUCOL TA_LEVEL_2 Antihyperlipidemic 23288-49-5 PROBUCOL INDICATION Atherosclerosis 614-39-1 PROCAINAMIDE TISSUE_TOXICITY Hypotension 614-39-1 PROCAINAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 614-39-1 PROCAINAMIDE ZERO_CLASS N 614-39-1 PROCAINAMIDE ADVERSE_EFFECT MSK_3_Muscle Weakness 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_1_Prolonged PR Interval 614-39-1 PROCAINAMIDE ADVERSE_EFFECT MSK_3_Myopathy 614-39-1 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 614-39-1 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Jaundice 614-39-1 PROCAINAMIDE MECHANISM Block neural transmission 614-39-1 PROCAINAMIDE MECH_LEVEL_3 Voltage-gated Na+ channel, selective 614-39-1 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Hepatitis 614-39-1 PROCAINAMIDE MESH_LEVEL_2 Amides 614-39-1 PROCAINAMIDE INDICATION Supraventricular Tachycardia 614-39-1 PROCAINAMIDE INDICATION Ventricular Tachycardia 614-39-1 PROCAINAMIDE MODE_CLASS Channel Blocker, selective 614-39-1 PROCAINAMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_1_Hypotension 614-39-1 PROCAINAMIDE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_2_Reduced Cardiac Contractility 614-39-1 PROCAINAMIDE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 614-39-1 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Intrahepatic Cholestasis 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 614-39-1 PROCAINAMIDE ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 614-39-1 PROCAINAMIDE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 614-39-1 PROCAINAMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 614-39-1 PROCAINAMIDE INDICATION Wolff-Parkinson-White (WPW) Syndrome 614-39-1 PROCAINAMIDE INDICATION Ventricular Fibrillation 614-39-1 PROCAINAMIDE TA_LEVEL_2 Antiarrhytmic 614-39-1 PROCAINAMIDE MECH_LEVEL_1 Modulate neural transmission 614-39-1 PROCAINAMIDE TISSUE_TOXICITY Cardiac Failure 614-39-1 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Hallucinations 614-39-1 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 614-39-1 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Confusion 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Cardiac Failure 614-39-1 PROCAINAMIDE MESH_LEVEL_3 Benzamides 614-39-1 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Hepatomegaly 614-39-1 PROCAINAMIDE ADVERSE_EFFECT XXX_3_Drug Fever 614-39-1 PROCAINAMIDE INDICATION Cardiac Arrhythmias 614-39-1 PROCAINAMIDE INDICATION Atrial Flutter 614-39-1 PROCAINAMIDE INDICATION Atrial Fibrillation 614-39-1 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Depression 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Angina 614-39-1 PROCAINAMIDE ADVERSE_EFFECT XXX_3_Edema 614-39-1 PROCAINAMIDE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 614-39-1 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Psychosis 614-39-1 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Dyspepsia 614-39-1 PROCAINAMIDE ADVERSE_EFFECT IMU_3_Myasthenia Gravis 614-39-1 PROCAINAMIDE ADVERSE_EFFECT NEU_2_Dizziness 614-39-1 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 614-39-1 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 614-39-1 PROCAINAMIDE PRODUCT_CLASS Cardiovasculars 614-39-1 PROCAINAMIDE TA_LEVEL_3 Arrhythmia, Tachycardia 614-39-1 PROCAINAMIDE MESH_LEVEL_1 Organic Chemicals 614-39-1 PROCAINAMIDE INDICATION Cardiopulmonary resuscitation 614-39-1 PROCAINAMIDE MECH_LEVEL_2 Sodium channel antagonist 614-39-1 PROCAINAMIDE TA_LEVEL_1 Cardiovascular 614-39-1 PROCAINAMIDE ACTIVITY_CLASS Na+ channel blocker 614-39-1 PROCAINAMIDE TISSUE_TOXICITY Cardiac Arrhythmia 614-39-1 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Bitter Taste 614-39-1 PROCAINAMIDE TISSUE_TOXICITY Angina 614-39-1 PROCAINAMIDE ADVERSE_EFFECT XXX_2_Asthenia 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 51-06-9 PROCAINAMIDE PRODUCT_CLASS Cardiovasculars 51-06-9 PROCAINAMIDE TA_LEVEL_3 Arrhythmia, Tachycardia 51-06-9 PROCAINAMIDE MESH_LEVEL_1 Organic Chemicals 51-06-9 PROCAINAMIDE INDICATION Cardiopulmonary resuscitation 51-06-9 PROCAINAMIDE MECH_LEVEL_2 Sodium channel antagonist 51-06-9 PROCAINAMIDE TA_LEVEL_1 Cardiovascular 51-06-9 PROCAINAMIDE ACTIVITY_CLASS Na+ channel blocker 51-06-9 PROCAINAMIDE ZERO_CLASS N 51-06-9 PROCAINAMIDE TISSUE_TOXICITY Hypotension 51-06-9 PROCAINAMIDE TISSUE_TOXICITY Angina 51-06-9 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Diarrhea 51-06-9 PROCAINAMIDE ADVERSE_EFFECT XXX_3_Drug Fever 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_1_Prolonged PR Interval 51-06-9 PROCAINAMIDE INDICATION Atrial Fibrillation 51-06-9 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Depression 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Angina 51-06-9 PROCAINAMIDE ADVERSE_EFFECT XXX_3_Edema 51-06-9 PROCAINAMIDE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 51-06-9 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Psychosis 51-06-9 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Dyspepsia 51-06-9 PROCAINAMIDE INDICATION Cardiac Arrhythmias 51-06-9 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Bitter Taste 51-06-9 PROCAINAMIDE ADVERSE_EFFECT IMU_3_Myasthenia Gravis 51-06-9 PROCAINAMIDE ADVERSE_EFFECT MSK_3_Myopathy 51-06-9 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 51-06-9 PROCAINAMIDE INDICATION Atrial Flutter 51-06-9 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Hepatomegaly 51-06-9 PROCAINAMIDE ADVERSE_EFFECT XXX_2_Asthenia 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Cardiac Failure 51-06-9 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Confusion 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 51-06-9 PROCAINAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 51-06-9 PROCAINAMIDE ADVERSE_EFFECT PSY_3_Hallucinations 51-06-9 PROCAINAMIDE TISSUE_TOXICITY Cardiac Failure 51-06-9 PROCAINAMIDE MECH_LEVEL_1 Modulate neural transmission 51-06-9 PROCAINAMIDE TA_LEVEL_2 Antiarrhytmic 51-06-9 PROCAINAMIDE INDICATION Ventricular Fibrillation 51-06-9 PROCAINAMIDE INDICATION Wolff-Parkinson-White (WPW) Syndrome 51-06-9 PROCAINAMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 51-06-9 PROCAINAMIDE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 51-06-9 PROCAINAMIDE ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 51-06-9 PROCAINAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_1_Prolonged QT Interval 51-06-9 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Intrahepatic Cholestasis 51-06-9 PROCAINAMIDE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_2_Reduced Cardiac Contractility 51-06-9 PROCAINAMIDE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 51-06-9 PROCAINAMIDE TISSUE_TOXICITY Cardiac Arrhythmia 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_1_Hypotension 51-06-9 PROCAINAMIDE ADVERSE_EFFECT CVS_3_Bradycardia 51-06-9 PROCAINAMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 51-06-9 PROCAINAMIDE MODE_CLASS Channel Blocker, selective 51-06-9 PROCAINAMIDE INDICATION Ventricular Tachycardia 51-06-9 PROCAINAMIDE INDICATION Supraventricular Tachycardia 51-06-9 PROCAINAMIDE MESH_LEVEL_2 Amides 51-06-9 PROCAINAMIDE MESH_LEVEL_3 Benzamides 51-06-9 PROCAINAMIDE MECH_LEVEL_3 Voltage-gated Na+ channel, selective 51-06-9 PROCAINAMIDE MECHANISM Block neural transmission 51-06-9 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Jaundice 51-06-9 PROCAINAMIDE ADVERSE_EFFECT MSK_3_Muscle Weakness 51-06-9 PROCAINAMIDE ADVERSE_EFFECT LIV_3_Hepatitis 51-06-9 PROCAINAMIDE ADVERSE_EFFECT NEU_2_Dizziness 51-05-8 PROCAINE INDICATION Sympathetic Nerve Block 51-05-8 PROCAINE MESH_LEVEL_2 Carboxylic Acids 51-05-8 PROCAINE TISSUE_TOXICITY Cardiac Arrest 51-05-8 PROCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 51-05-8 PROCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 51-05-8 PROCAINE KNOWN_TOXICITY Cardiovascular Toxicity 51-05-8 PROCAINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 51-05-8 PROCAINE ADVERSE_EFFECT CVS_2_Cardiovascular Collapse 51-05-8 PROCAINE ADVERSE_EFFECT SKN_3_Rash 51-05-8 PROCAINE ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 51-05-8 PROCAINE ADVERSE_EFFECT OCU_1_Blurred Vision 51-05-8 PROCAINE INDICATION Spinal Anesthesia 51-05-8 PROCAINE TISSUE_TOXICITY Cardiovascular Collapse 51-05-8 PROCAINE MODE_CLASS Channel Modulator 51-05-8 PROCAINE MECH_LEVEL_3 Voltage-gated Na+ channel 51-05-8 PROCAINE PRODUCT_CLASS Central Nervous System (CNS) 51-05-8 PROCAINE INDICATION Peripheral Nerve Block 51-05-8 PROCAINE MECH_LEVEL_2 Sodium channel antagonist 51-05-8 PROCAINE TISSUE_TOXICITY Seizures 51-05-8 PROCAINE TISSUE_TOXICITY Cardiovascular Depression 51-05-8 PROCAINE TISSUE_TOXICITY Atrial Fibrillation 51-05-8 PROCAINE KNOWN_TOXICITY Mental Health Disorders 51-05-8 PROCAINE THERAPEUTIC_CLASS Local Anesthetics 51-05-8 PROCAINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 51-05-8 PROCAINE ADVERSE_EFFECT PSY_1_CNS Toxicity 51-05-8 PROCAINE ADVERSE_EFFECT SKN_3_Pruritis 51-05-8 PROCAINE ADVERSE_EFFECT NEU_1_Dizziness 51-05-8 PROCAINE ADVERSE_EFFECT PSY_1_Anxiety 51-05-8 PROCAINE INDICATION Severe Pain 51-05-8 PROCAINE TA_LEVEL_2 Anesthesia 51-05-8 PROCAINE MESH_LEVEL_3 Acids, Carbocyclic 51-05-8 PROCAINE ZERO_CLASS N 51-05-8 PROCAINE ACTIVITY_CLASS Na+ channel blocker 51-05-8 PROCAINE ADVERSE_EFFECT CVS_1_Myocardial Depression 51-05-8 PROCAINE ADVERSE_EFFECT NEU_1_Seizures 51-05-8 PROCAINE ADVERSE_EFFECT CVS_2_Atrial Fibrillation 51-05-8 PROCAINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 51-05-8 PROCAINE MECHANISM Modulate channel gating 51-05-8 PROCAINE KNOWN_TOXICITY Neurotoxicity 51-05-8 PROCAINE TISSUE_TOXICITY Atrioventricular Blockade 51-05-8 PROCAINE TISSUE_TOXICITY Cardiovascular Toxicity 51-05-8 PROCAINE TISSUE_TOXICITY CNS Toxicity 51-05-8 PROCAINE ADVERSE_EFFECT CVS_2_Cardiovascular Depression 51-05-8 PROCAINE ADVERSE_EFFECT LUN_2_Respiratory Arrest 51-05-8 PROCAINE ADVERSE_EFFECT NEU_1_Tremor 51-05-8 PROCAINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 51-05-8 PROCAINE ADVERSE_EFFECT CVS_1_Cardiovascular Toxicity 51-05-8 PROCAINE MESH_LEVEL_1 Organic Chemicals 51-05-8 PROCAINE MECH_LEVEL_1 Modulate neural transmission 51-05-8 PROCAINE INDICATION Dental Anesthesia 51-05-8 PROCAINE INDICATION Local Anesthesia 51-05-8 PROCAINE TISSUE_TOXICITY Myocardial Depression 59-46-1 PROCAINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 59-46-1 PROCAINE ADVERSE_EFFECT CVS_2_Cardiovascular Collapse 59-46-1 PROCAINE ADVERSE_EFFECT SKN_3_Rash 59-46-1 PROCAINE ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 59-46-1 PROCAINE ADVERSE_EFFECT OCU_1_Blurred Vision 59-46-1 PROCAINE TISSUE_TOXICITY Myocardial Depression 59-46-1 PROCAINE TISSUE_TOXICITY Cardiovascular Collapse 59-46-1 PROCAINE MODE_CLASS Channel Modulator 59-46-1 PROCAINE MECH_LEVEL_3 Voltage-gated Na+ channel 59-46-1 PROCAINE PRODUCT_CLASS Central Nervous System (CNS) 59-46-1 PROCAINE INDICATION Peripheral Nerve Block 59-46-1 PROCAINE MECH_LEVEL_2 Sodium channel antagonist 59-46-1 PROCAINE TISSUE_TOXICITY Seizures 59-46-1 PROCAINE TISSUE_TOXICITY Cardiovascular Depression 59-46-1 PROCAINE TISSUE_TOXICITY Atrial Fibrillation 59-46-1 PROCAINE KNOWN_TOXICITY Mental Health Disorders 59-46-1 PROCAINE THERAPEUTIC_CLASS Local Anesthetics 59-46-1 PROCAINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 59-46-1 PROCAINE ADVERSE_EFFECT PSY_1_CNS Toxicity 59-46-1 PROCAINE ADVERSE_EFFECT SKN_3_Pruritis 59-46-1 PROCAINE ADVERSE_EFFECT NEU_1_Dizziness 59-46-1 PROCAINE ADVERSE_EFFECT PSY_1_Anxiety 59-46-1 PROCAINE INDICATION Severe Pain 59-46-1 PROCAINE TA_LEVEL_2 Anesthesia 59-46-1 PROCAINE MESH_LEVEL_3 Acids, Carbocyclic 59-46-1 PROCAINE ZERO_CLASS N 59-46-1 PROCAINE ACTIVITY_CLASS Na+ channel blocker 59-46-1 PROCAINE ADVERSE_EFFECT CVS_1_Myocardial Depression 59-46-1 PROCAINE ADVERSE_EFFECT NEU_1_Seizures 59-46-1 PROCAINE ADVERSE_EFFECT CVS_2_Atrial Fibrillation 59-46-1 PROCAINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 59-46-1 PROCAINE TISSUE_TOXICITY Cardiovascular Toxicity 59-46-1 PROCAINE TISSUE_TOXICITY Atrioventricular Blockade 59-46-1 PROCAINE KNOWN_TOXICITY Neurotoxicity 59-46-1 PROCAINE MECHANISM Modulate channel gating 59-46-1 PROCAINE INDICATION Spinal Anesthesia 59-46-1 PROCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 59-46-1 PROCAINE ADVERSE_EFFECT CVS_1_Cardiovascular Toxicity 59-46-1 PROCAINE ADVERSE_EFFECT LUN_2_Respiratory Arrest 59-46-1 PROCAINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 59-46-1 PROCAINE ADVERSE_EFFECT NEU_1_Tremor 59-46-1 PROCAINE ADVERSE_EFFECT CVS_2_Cardiovascular Depression 59-46-1 PROCAINE TISSUE_TOXICITY CNS Toxicity 59-46-1 PROCAINE TISSUE_TOXICITY Cardiac Arrest 59-46-1 PROCAINE MESH_LEVEL_2 Carboxylic Acids 59-46-1 PROCAINE INDICATION Sympathetic Nerve Block 59-46-1 PROCAINE INDICATION Local Anesthesia 59-46-1 PROCAINE INDICATION Dental Anesthesia 59-46-1 PROCAINE MECH_LEVEL_1 Modulate neural transmission 59-46-1 PROCAINE MESH_LEVEL_1 Organic Chemicals 59-46-1 PROCAINE KNOWN_TOXICITY Cardiovascular Toxicity 59-46-1 PROCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_1_Cardiovascular Toxicity 12663-50-2 PROCAINE TISSUE_TOXICITY Seizures 12663-50-2 PROCAINE TISSUE_TOXICITY Cardiovascular Depression 12663-50-2 PROCAINE TISSUE_TOXICITY Atrial Fibrillation 12663-50-2 PROCAINE KNOWN_TOXICITY Mental Health Disorders 12663-50-2 PROCAINE THERAPEUTIC_CLASS Local Anesthetics 12663-50-2 PROCAINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 12663-50-2 PROCAINE ADVERSE_EFFECT PSY_1_CNS Toxicity 12663-50-2 PROCAINE ADVERSE_EFFECT SKN_3_Pruritis 12663-50-2 PROCAINE ZERO_CLASS N 12663-50-2 PROCAINE ACTIVITY_CLASS Na+ channel blocker 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_1_Myocardial Depression 12663-50-2 PROCAINE ADVERSE_EFFECT NEU_1_Seizures 12663-50-2 PROCAINE INDICATION Local Anesthesia 12663-50-2 PROCAINE ADVERSE_EFFECT NEU_1_Dizziness 12663-50-2 PROCAINE INDICATION Sympathetic Nerve Block 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_2_Atrial Fibrillation 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 12663-50-2 PROCAINE TISSUE_TOXICITY Cardiovascular Toxicity 12663-50-2 PROCAINE TISSUE_TOXICITY Atrioventricular Blockade 12663-50-2 PROCAINE KNOWN_TOXICITY Neurotoxicity 12663-50-2 PROCAINE MECHANISM Modulate channel gating 12663-50-2 PROCAINE INDICATION Spinal Anesthesia 12663-50-2 PROCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 12663-50-2 PROCAINE MECH_LEVEL_1 Modulate neural transmission 12663-50-2 PROCAINE INDICATION Dental Anesthesia 12663-50-2 PROCAINE ADVERSE_EFFECT LUN_2_Respiratory Arrest 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_2_Cardiac Arrest 12663-50-2 PROCAINE ADVERSE_EFFECT NEU_1_Tremor 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_2_Cardiovascular Depression 12663-50-2 PROCAINE TISSUE_TOXICITY CNS Toxicity 12663-50-2 PROCAINE TISSUE_TOXICITY Cardiac Arrest 12663-50-2 PROCAINE MESH_LEVEL_1 Organic Chemicals 12663-50-2 PROCAINE ADVERSE_EFFECT PSY_1_Anxiety 12663-50-2 PROCAINE INDICATION Severe Pain 12663-50-2 PROCAINE TA_LEVEL_2 Anesthesia 12663-50-2 PROCAINE MESH_LEVEL_3 Acids, Carbocyclic 12663-50-2 PROCAINE MESH_LEVEL_2 Carboxylic Acids 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_2_Cardiovascular Collapse 12663-50-2 PROCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 12663-50-2 PROCAINE KNOWN_TOXICITY Cardiovascular Toxicity 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 12663-50-2 PROCAINE ADVERSE_EFFECT SKN_3_Rash 12663-50-2 PROCAINE ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 12663-50-2 PROCAINE ADVERSE_EFFECT OCU_1_Blurred Vision 12663-50-2 PROCAINE TISSUE_TOXICITY Myocardial Depression 12663-50-2 PROCAINE TISSUE_TOXICITY Cardiovascular Collapse 12663-50-2 PROCAINE MODE_CLASS Channel Modulator 12663-50-2 PROCAINE MECH_LEVEL_3 Voltage-gated Na+ channel 12663-50-2 PROCAINE PRODUCT_CLASS Central Nervous System (CNS) 12663-50-2 PROCAINE INDICATION Peripheral Nerve Block 12663-50-2 PROCAINE MECH_LEVEL_2 Sodium channel antagonist 671-16-9 PROCARBAZINE ADVERSE_EFFECT DNA_2_Carcinogenicity 671-16-9 PROCARBAZINE ADVERSE_EFFECT BBM_2_Bleeding Tendency 671-16-9 PROCARBAZINE ADVERSE_EFFECT IMU_2_Eosinophilia 671-16-9 PROCARBAZINE ADVERSE_EFFECT NEU_2_Neuropathy 671-16-9 PROCARBAZINE MECHANISM Inhibit DNA synthesis, repair, and function 671-16-9 PROCARBAZINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 671-16-9 PROCARBAZINE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 671-16-9 PROCARBAZINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 671-16-9 PROCARBAZINE TISSUE_TOXICITY Anemia 671-16-9 PROCARBAZINE ADVERSE_EFFECT MSK_2_Myalgia 671-16-9 PROCARBAZINE STRUCTURE_ACTIVITY DNA-alkylator 671-16-9 PROCARBAZINE ADVERSE_EFFECT LUN_3_Pleural Effusion 671-16-9 PROCARBAZINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 671-16-9 PROCARBAZINE ADVERSE_EFFECT XXX_2_Lethargy 671-16-9 PROCARBAZINE ADVERSE_EFFECT NEU_3_Ataxia 671-16-9 PROCARBAZINE ADVERSE_EFFECT BBM_1_Hemolytic Anemia 671-16-9 PROCARBAZINE ADVERSE_EFFECT PSY_2_Anorexia 671-16-9 PROCARBAZINE ADVERSE_EFFECT NEU_1_Convulsions 671-16-9 PROCARBAZINE ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 671-16-9 PROCARBAZINE ADVERSE_EFFECT GIS_2_Stomatitis 671-16-9 PROCARBAZINE MODE_CLASS Distorts /blocks macromolecular scaffold function 671-16-9 PROCARBAZINE INDICATION Small Cell Lung Carcinoma 671-16-9 PROCARBAZINE INDICATION Hodgkin's Disease 671-16-9 PROCARBAZINE MESH_LEVEL_2 Amides 671-16-9 PROCARBAZINE MESH_LEVEL_3 Benzamides 671-16-9 PROCARBAZINE TA_LEVEL_1 Oncology 671-16-9 PROCARBAZINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 671-16-9 PROCARBAZINE KNOWN_TOXICITY Cardiovascular Toxicity 671-16-9 PROCARBAZINE TISSUE_TOXICITY Convulsions 671-16-9 PROCARBAZINE TISSUE_TOXICITY Teratogenicity 671-16-9 PROCARBAZINE ADVERSE_EFFECT NEU_3_Coma 671-16-9 PROCARBAZINE ADVERSE_EFFECT REP_2_Infertility 671-16-9 PROCARBAZINE TISSUE_TOXICITY Thrombocytopenia 671-16-9 PROCARBAZINE ADVERSE_EFFECT XXX_1_Infection 671-16-9 PROCARBAZINE ADVERSE_EFFECT BBM_1_Anemia 671-16-9 PROCARBAZINE ADVERSE_EFFECT NEU_2_Paresthesia 671-16-9 PROCARBAZINE ADVERSE_EFFECT NEU_2_Tremor 671-16-9 PROCARBAZINE ADVERSE_EFFECT BBM_1_Leukopenia 671-16-9 PROCARBAZINE ADVERSE_EFFECT LIV_2_Hepatic Dysfunction 671-16-9 PROCARBAZINE ADVERSE_EFFECT IMU_2_Allergic Reactions 671-16-9 PROCARBAZINE ADVERSE_EFFECT PSY_2_Insomnia 671-16-9 PROCARBAZINE ADVERSE_EFFECT PSY_2_Depression 671-16-9 PROCARBAZINE ADVERSE_EFFECT EMB_2_Teratogenicity 671-16-9 PROCARBAZINE ADVERSE_EFFECT OCU_3_Retinal Hemorrhages 671-16-9 PROCARBAZINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 671-16-9 PROCARBAZINE THERAPEUTIC_CLASS Antineoplastics 671-16-9 PROCARBAZINE MESH_LEVEL_1 Organic Chemicals 671-16-9 PROCARBAZINE INDICATION Non-Hodgkin's Lymphomas 671-16-9 PROCARBAZINE ACTIVITY_CLASS DNA damager 671-16-9 PROCARBAZINE KNOWN_TOXICITY Carcinogenicity 671-16-9 PROCARBAZINE TISSUE_TOXICITY Hemolytic Anemia 671-16-9 PROCARBAZINE TISSUE_TOXICITY Hypotension 671-16-9 PROCARBAZINE ADVERSE_EFFECT PSY_2_Nervousness 671-16-9 PROCARBAZINE ADVERSE_EFFECT CVS_3_Hypotension 671-16-9 PROCARBAZINE ADVERSE_EFFECT CVS_3_Tachycardia 671-16-9 PROCARBAZINE ADVERSE_EFFECT LUN_2_Interstitial Pneumonitis 671-16-9 PROCARBAZINE ADVERSE_EFFECT XXX_2_Herpes Zoster 671-16-9 PROCARBAZINE ADVERSE_EFFECT BBM_1_Pancytopenia 671-16-9 PROCARBAZINE PRODUCT_CLASS Anti-cancers 671-16-9 PROCARBAZINE INDICATION Brain Cancer 671-16-9 PROCARBAZINE MECH_LEVEL_3 DNA damage 671-16-9 PROCARBAZINE TA_LEVEL_2 DNA damage 671-16-9 PROCARBAZINE KNOWN_TOXICITY Neurotoxicity 671-16-9 PROCARBAZINE TISSUE_TOXICITY Pancytopenia 671-16-9 PROCARBAZINE ZERO_CLASS N 671-16-9 PROCARBAZINE ADVERSE_EFFECT PSY_2_Hallucinations 671-16-9 PROCARBAZINE ADVERSE_EFFECT OCU_3_Diplopia 671-16-9 PROCARBAZINE ADVERSE_EFFECT MSK_2_Arthralgia 671-16-9 PROCARBAZINE TISSUE_TOXICITY Leukopenia 671-16-9 PROCARBAZINE TISSUE_TOXICITY Carcinogenicity 671-16-9 PROCARBAZINE KNOWN_TOXICITY Embryo/Fetal Toxicity 62929-91-3 PROCATEROL MODE_CLASS Receptor Agonist, selective 62929-91-3 PROCATEROL MECHANISM Reduce bronchoconstriction 72332-33-3 PROCATEROL MECHANISM Reduce bronchoconstriction 72332-33-3 PROCATEROL MODE_CLASS Receptor Agonist, selective 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Cerebral Edema 58-38-8 PROCHLORPERAZINE PRODUCT_CLASS Central Nervous System (CNS) 58-38-8 PROCHLORPERAZINE TA_LEVEL_3 Anxiolytics 58-38-8 PROCHLORPERAZINE THERAPEUTIC_CLASS Antiemetics 58-38-8 PROCHLORPERAZINE MESH_LEVEL_1 Heterocyclic Compounds 58-38-8 PROCHLORPERAZINE INDICATION Anxiety 58-38-8 PROCHLORPERAZINE MODE_CLASS Receptor Ligand Antagonist 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT GIS_3_Constipation 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT CVS_2_Hypotension 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT GIS_3_Nausea 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Restlessness 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_1_Akathisia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT PSY_2_Mental Status Changes 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT IMU_3_Eosinophilia 58-38-8 PROCHLORPERAZINE TISSUE_TOXICITY Ventricular Tachycardia 58-38-8 PROCHLORPERAZINE KNOWN_TOXICITY Nephrotoxicity 58-38-8 PROCHLORPERAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 58-38-8 PROCHLORPERAZINE MESH_LEVEL_3 Phenothiazines 58-38-8 PROCHLORPERAZINE INDICATION Schizophrenia 58-38-8 PROCHLORPERAZINE MECH_LEVEL_3 dopamine receptor D2 58-38-8 PROCHLORPERAZINE TA_LEVEL_1 Central Nervous System (CNS) 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Xerostomia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT GUS_3_Urinary Retention 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Depression 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_2_Dizziness 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_2_Drowsiness 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Anemia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Hyperpyrexia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Leukocytosis 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_2_Leukopenia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT KID_3_Acute Renal Failure 58-38-8 PROCHLORPERAZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 58-38-8 PROCHLORPERAZINE KNOWN_TOXICITY Cardiovascular Toxicity 58-38-8 PROCHLORPERAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 58-38-8 PROCHLORPERAZINE INDICATION Nausea / Vomiting 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT XXX_2_Tolerance 58-38-8 PROCHLORPERAZINE ACTIVITY_CLASS Dopamine antagonist 58-38-8 PROCHLORPERAZINE PRODUCT_CLASS Gastrointestinal System 58-38-8 PROCHLORPERAZINE TISSUE_TOXICITY Hypotension 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Weight Gain 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_1_Dystonia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Choreoathetosis 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT REP_3_Impotence 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT CVS_2_Hypertension 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT OCU_3_Blurred Vision 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 58-38-8 PROCHLORPERAZINE THERAPEUTIC_CLASS Antipsychotics 58-38-8 PROCHLORPERAZINE MECH_LEVEL_2 Dopamine antagonist 58-38-8 PROCHLORPERAZINE MECHANISM Block neural transmission 58-38-8 PROCHLORPERAZINE MECH_LEVEL_1 Modulate neural transmission 58-38-8 PROCHLORPERAZINE ZERO_CLASS N 58-38-8 PROCHLORPERAZINE TA_LEVEL_2 CNS Depressant 58-38-8 PROCHLORPERAZINE THERAPEUTIC_CLASS Anxiolytics 58-38-8 PROCHLORPERAZINE TISSUE_TOXICITY Acute Renal Failure 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Pancytopenia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_2_Autonomic Instability 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT SKN_3_Hyperpigmentation 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Seizures 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Headache 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Insomnia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT OCU_3_Mydriasis 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT XXX_2_Hyperthermia 58-38-8 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Dependence 84-02-6 PROCHLORPERAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 84-02-6 PROCHLORPERAZINE KNOWN_TOXICITY Cardiovascular Toxicity 84-02-6 PROCHLORPERAZINE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT KID_3_Acute Renal Failure 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_2_Leukopenia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Leukocytosis 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Hyperpyrexia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Anemia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_2_Drowsiness 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_2_Dizziness 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Depression 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT GUS_3_Urinary Retention 84-02-6 PROCHLORPERAZINE TA_LEVEL_1 Central Nervous System (CNS) 84-02-6 PROCHLORPERAZINE MECH_LEVEL_3 dopamine receptor D2 84-02-6 PROCHLORPERAZINE INDICATION Schizophrenia 84-02-6 PROCHLORPERAZINE MESH_LEVEL_3 Phenothiazines 84-02-6 PROCHLORPERAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 84-02-6 PROCHLORPERAZINE KNOWN_TOXICITY Nephrotoxicity 84-02-6 PROCHLORPERAZINE TISSUE_TOXICITY Ventricular Tachycardia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT IMU_3_Eosinophilia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_1_Akathisia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Restlessness 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT XXX_2_Tolerance 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT GIS_3_Nausea 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT CVS_2_Hypotension 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT GIS_3_Constipation 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 84-02-6 PROCHLORPERAZINE MODE_CLASS Receptor Ligand Antagonist 84-02-6 PROCHLORPERAZINE INDICATION Anxiety 84-02-6 PROCHLORPERAZINE MESH_LEVEL_1 Heterocyclic Compounds 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_1_Dystonia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Choreoathetosis 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Dependence 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT REP_3_Impotence 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Xerostomia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT XXX_3_Weight Gain 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT PSY_2_Mental Status Changes 84-02-6 PROCHLORPERAZINE INDICATION Nausea / Vomiting 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT XXX_2_Hyperthermia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Cerebral Edema 84-02-6 PROCHLORPERAZINE PRODUCT_CLASS Central Nervous System (CNS) 84-02-6 PROCHLORPERAZINE TA_LEVEL_3 Anxiolytics 84-02-6 PROCHLORPERAZINE THERAPEUTIC_CLASS Antiemetics 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT CVS_2_Hypertension 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT OCU_3_Blurred Vision 84-02-6 PROCHLORPERAZINE TISSUE_TOXICITY Hypotension 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 84-02-6 PROCHLORPERAZINE THERAPEUTIC_CLASS Antipsychotics 84-02-6 PROCHLORPERAZINE MECH_LEVEL_2 Dopamine antagonist 84-02-6 PROCHLORPERAZINE MECHANISM Block neural transmission 84-02-6 PROCHLORPERAZINE MECH_LEVEL_1 Modulate neural transmission 84-02-6 PROCHLORPERAZINE ZERO_CLASS N 84-02-6 PROCHLORPERAZINE TA_LEVEL_2 CNS Depressant 84-02-6 PROCHLORPERAZINE THERAPEUTIC_CLASS Anxiolytics 84-02-6 PROCHLORPERAZINE TISSUE_TOXICITY Acute Renal Failure 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Pancytopenia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_2_Autonomic Instability 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT SKN_3_Hyperpigmentation 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Seizures 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT NEU_3_Headache 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT PSY_3_Insomnia 84-02-6 PROCHLORPERAZINE ADVERSE_EFFECT OCU_3_Mydriasis 84-02-6 PROCHLORPERAZINE PRODUCT_CLASS Gastrointestinal System 84-02-6 PROCHLORPERAZINE ACTIVITY_CLASS Dopamine antagonist 1508-76-5 PROCYCLIDINE INDICATION Parkinson's Disease 1508-76-5 PROCYCLIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 1508-76-5 PROCYCLIDINE MECHANISM Modulate G-protein coupled signal transduction 1508-76-5 PROCYCLIDINE PRODUCT_CLASS Autonomic Nervous System (ANS) 1508-76-5 PROCYCLIDINE THERAPEUTIC_CLASS Parasympatholytic Agents 1508-76-5 PROCYCLIDINE PRODUCT_CLASS Central Nervous System (CNS) 1508-76-5 PROCYCLIDINE THERAPEUTIC_CLASS Movement Disorders 77-37-2 PROCYCLIDINE PRODUCT_CLASS Central Nervous System (CNS) 77-37-2 PROCYCLIDINE MECHANISM Modulate G-protein coupled signal transduction 77-37-2 PROCYCLIDINE PRODUCT_CLASS Autonomic Nervous System (ANS) 77-37-2 PROCYCLIDINE THERAPEUTIC_CLASS Parasympatholytic Agents 77-37-2 PROCYCLIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 77-37-2 PROCYCLIDINE THERAPEUTIC_CLASS Movement Disorders 77-37-2 PROCYCLIDINE INDICATION Parkinson's Disease 57-83-0 PROGESTERONE ADVERSE_EFFECT PSY_2_Irritability 57-83-0 PROGESTERONE TISSUE_TOXICITY Thromboembolism 57-83-0 PROGESTERONE MECH_LEVEL_3 Progesterone receptor 57-83-0 PROGESTERONE THERAPEUTIC_CLASS Gonadal Hormones 57-83-0 PROGESTERONE TISSUE_TOXICITY Breakthrough Bleeding 57-83-0 PROGESTERONE ADVERSE_EFFECT END_1_Breast Tenderness 57-83-0 PROGESTERONE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 57-83-0 PROGESTERONE ADVERSE_EFFECT REP_3_Amenorrhea 57-83-0 PROGESTERONE ADVERSE_EFFECT SKN_2_Acne 57-83-0 PROGESTERONE ADVERSE_EFFECT CVS_2_Palpitation 57-83-0 PROGESTERONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 57-83-0 PROGESTERONE TA_LEVEL_3 Progesterone receptor agonists 57-83-0 PROGESTERONE MECH_LEVEL_1 Hormone replacement 57-83-0 PROGESTERONE INDICATION Maintenance of Pregnancy 57-83-0 PROGESTERONE ADVERSE_EFFECT CVS_3_Thromboembolism 57-83-0 PROGESTERONE STRUCTURE_ACTIVITY Progesterone receptor agonist 57-83-0 PROGESTERONE ADVERSE_EFFECT NEU_1_Dizziness 57-83-0 PROGESTERONE ADVERSE_EFFECT END_3_Hirsutism 57-83-0 PROGESTERONE ADVERSE_EFFECT XXX_2_Weight Gain 57-83-0 PROGESTERONE ADVERSE_EFFECT XXX_2_Peripheral Edema 57-83-0 PROGESTERONE ADVERSE_EFFECT PSY_2_Emotional Lability 57-83-0 PROGESTERONE MESH_LEVEL_2 Steroids 57-83-0 PROGESTERONE MESH_LEVEL_1 Polycyclic Hydrocarbons 57-83-0 PROGESTERONE MESH_LEVEL_3 Pregnanes 57-83-0 PROGESTERONE INDICATION Prevention of Endometrial Hyperplasia 57-83-0 PROGESTERONE ADVERSE_EFFECT MSK_2_Joint Pain 57-83-0 PROGESTERONE MECHANISM Modulate gene transcription 57-83-0 PROGESTERONE MODE_CLASS Endogenous Receptor /Channel Ligand 57-83-0 PROGESTERONE INDICATION Dysfunctional Uterine Bleeding (DUB) 57-83-0 PROGESTERONE ADVERSE_EFFECT GUS_1_Vaginal Spotting 57-83-0 PROGESTERONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57-83-0 PROGESTERONE KNOWN_TOXICITY Cardiovascular Toxicity 57-83-0 PROGESTERONE ADVERSE_EFFECT NEU_1_Headache 57-83-0 PROGESTERONE ADVERSE_EFFECT GIS_2_Bloating 57-83-0 PROGESTERONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 57-83-0 PROGESTERONE ADVERSE_EFFECT CVS_2_Hypertension 57-83-0 PROGESTERONE ADVERSE_EFFECT GUS_2_Vaginal Candidiasis 57-83-0 PROGESTERONE ZERO_CLASS N 57-83-0 PROGESTERONE KNOWN_TOXICITY Reproductive System Toxicity 57-83-0 PROGESTERONE ACTIVITY_CLASS Progesterone receptor agonist 57-83-0 PROGESTERONE MECH_LEVEL_2 progestatgen 57-83-0 PROGESTERONE ADVERSE_EFFECT PSY_2_Depression 57-83-0 PROGESTERONE ADVERSE_EFFECT IMU_3_Hypersensitivity 57-83-0 PROGESTERONE ADVERSE_EFFECT XXX_2_Weight Loss 57-83-0 PROGESTERONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 57-83-0 PROGESTERONE ADVERSE_EFFECT MSK_2_Leg Cramps 57-83-0 PROGESTERONE ADVERSE_EFFECT IMU_3_Anaphylaxis 53-60-1 PROMAZINE TISSUE_TOXICITY Hypotension 53-60-1 PROMAZINE ADVERSE_EFFECT GIS_1_Constipation 53-60-1 PROMAZINE ADVERSE_EFFECT NEU_1_Syncope 53-60-1 PROMAZINE ACTIVITY_CLASS Dopamine antagonist 53-60-1 PROMAZINE ZERO_CLASS N 53-60-1 PROMAZINE MECHANISM Block neural transmission 53-60-1 PROMAZINE MESH_LEVEL_1 Heterocyclic Compounds 53-60-1 PROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 53-60-1 PROMAZINE MODE_CLASS Receptor Ligand Antagonist 53-60-1 PROMAZINE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 53-60-1 PROMAZINE TA_LEVEL_2 CNS Depressant 53-60-1 PROMAZINE MECH_LEVEL_1 Modulate neural transmission 53-60-1 PROMAZINE MECH_LEVEL_2 Dopamine antagonist 53-60-1 PROMAZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 53-60-1 PROMAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 53-60-1 PROMAZINE KNOWN_TOXICITY Mental Health Disorders 53-60-1 PROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 53-60-1 PROMAZINE INDICATION Schizophrenia 53-60-1 PROMAZINE TA_LEVEL_3 Antipsychotics 53-60-1 PROMAZINE ADVERSE_EFFECT CVS_1_Hypotension 53-60-1 PROMAZINE TISSUE_TOXICITY Tardive Dyskinesia 53-60-1 PROMAZINE ADVERSE_EFFECT XXX_1_Xerostomia 53-60-1 PROMAZINE THERAPEUTIC_CLASS Antipsychotics 53-60-1 PROMAZINE KNOWN_TOXICITY Cardiovascular Toxicity 53-60-1 PROMAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 53-60-1 PROMAZINE MESH_LEVEL_3 Phenothiazines 53-60-1 PROMAZINE MECH_LEVEL_3 dopamine receptor D2 53-60-1 PROMAZINE TA_LEVEL_1 Central Nervous System (CNS) 58-40-2 PROMAZINE ADVERSE_EFFECT XXX_1_Xerostomia 58-40-2 PROMAZINE ADVERSE_EFFECT CVS_1_Hypotension 58-40-2 PROMAZINE TISSUE_TOXICITY Tardive Dyskinesia 58-40-2 PROMAZINE INDICATION Schizophrenia 58-40-2 PROMAZINE MESH_LEVEL_1 Heterocyclic Compounds 58-40-2 PROMAZINE ADVERSE_EFFECT GIS_1_Constipation 58-40-2 PROMAZINE TISSUE_TOXICITY Hypotension 58-40-2 PROMAZINE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 58-40-2 PROMAZINE MECH_LEVEL_3 dopamine receptor D2 58-40-2 PROMAZINE MESH_LEVEL_3 Phenothiazines 58-40-2 PROMAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 58-40-2 PROMAZINE KNOWN_TOXICITY Cardiovascular Toxicity 58-40-2 PROMAZINE THERAPEUTIC_CLASS Antipsychotics 58-40-2 PROMAZINE TA_LEVEL_1 Central Nervous System (CNS) 58-40-2 PROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 58-40-2 PROMAZINE KNOWN_TOXICITY Mental Health Disorders 58-40-2 PROMAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 58-40-2 PROMAZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 58-40-2 PROMAZINE MECH_LEVEL_2 Dopamine antagonist 58-40-2 PROMAZINE MECH_LEVEL_1 Modulate neural transmission 58-40-2 PROMAZINE TA_LEVEL_2 CNS Depressant 58-40-2 PROMAZINE MODE_CLASS Receptor Ligand Antagonist 58-40-2 PROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 58-40-2 PROMAZINE TA_LEVEL_3 Antipsychotics 58-40-2 PROMAZINE MECHANISM Block neural transmission 58-40-2 PROMAZINE ZERO_CLASS N 58-40-2 PROMAZINE ACTIVITY_CLASS Dopamine antagonist 58-40-2 PROMAZINE ADVERSE_EFFECT NEU_1_Syncope 1508-27-6 PROMAZINE TISSUE_TOXICITY Hypotension 1508-27-6 PROMAZINE TA_LEVEL_2 CNS Depressant 1508-27-6 PROMAZINE TA_LEVEL_1 Central Nervous System (CNS) 1508-27-6 PROMAZINE MECH_LEVEL_3 dopamine receptor D2 1508-27-6 PROMAZINE MESH_LEVEL_3 Phenothiazines 1508-27-6 PROMAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 1508-27-6 PROMAZINE KNOWN_TOXICITY Cardiovascular Toxicity 1508-27-6 PROMAZINE THERAPEUTIC_CLASS Antipsychotics 1508-27-6 PROMAZINE ADVERSE_EFFECT XXX_1_Xerostomia 1508-27-6 PROMAZINE ADVERSE_EFFECT CVS_1_Hypotension 1508-27-6 PROMAZINE TISSUE_TOXICITY Tardive Dyskinesia 1508-27-6 PROMAZINE INDICATION Schizophrenia 1508-27-6 PROMAZINE MESH_LEVEL_1 Heterocyclic Compounds 1508-27-6 PROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 1508-27-6 PROMAZINE KNOWN_TOXICITY Mental Health Disorders 1508-27-6 PROMAZINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 1508-27-6 PROMAZINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 1508-27-6 PROMAZINE MECH_LEVEL_2 Dopamine antagonist 1508-27-6 PROMAZINE MECH_LEVEL_1 Modulate neural transmission 1508-27-6 PROMAZINE ADVERSE_EFFECT PSY_1_Tardive Dyskinesia 1508-27-6 PROMAZINE ADVERSE_EFFECT GIS_1_Constipation 1508-27-6 PROMAZINE MODE_CLASS Receptor Ligand Antagonist 1508-27-6 PROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 1508-27-6 PROMAZINE TA_LEVEL_3 Antipsychotics 1508-27-6 PROMAZINE MECHANISM Block neural transmission 1508-27-6 PROMAZINE ZERO_CLASS N 1508-27-6 PROMAZINE ACTIVITY_CLASS Dopamine antagonist 1508-27-6 PROMAZINE ADVERSE_EFFECT NEU_1_Syncope 60-87-7 PROMETHAZINE INDICATION Angioedema 60-87-7 PROMETHAZINE INDICATION Dermatographism 60-87-7 PROMETHAZINE ADVERSE_EFFECT OCU_2_Blurred Vision 60-87-7 PROMETHAZINE ADVERSE_EFFECT CVS_2_Hypotension 60-87-7 PROMETHAZINE ADVERSE_EFFECT LUN_3_Asthma 60-87-7 PROMETHAZINE ADVERSE_EFFECT OTO_2_Tinnitus 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Seizures 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_2_Disorientation 60-87-7 PROMETHAZINE ADVERSE_EFFECT MSK_3_Muscle Rigidity 60-87-7 PROMETHAZINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_3_CNS Excitation 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_2_Decrease Seizure Threshold 60-87-7 PROMETHAZINE MESH_LEVEL_1 Heterocyclic Compounds 60-87-7 PROMETHAZINE MECH_LEVEL_3 histamine receptor H1 60-87-7 PROMETHAZINE INDICATION Vasomotor Rhinitis 60-87-7 PROMETHAZINE MECHANISM Block neural transmission 60-87-7 PROMETHAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 60-87-7 PROMETHAZINE INDICATION Nausea / Vomiting 60-87-7 PROMETHAZINE ADVERSE_EFFECT LUN_3_Respiratory Depression 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_3_Delirium 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_2_Insomnia 60-87-7 PROMETHAZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 60-87-7 PROMETHAZINE ADVERSE_EFFECT XXX_3_Edema 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Hyperreflexia 60-87-7 PROMETHAZINE ADVERSE_EFFECT OCU_3_Diplopia 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 60-87-7 PROMETHAZINE ADVERSE_EFFECT BBM_3_Leukopenia 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Hypertonia 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Extensor-Plantar Reflexex (Barbinski Reflex) 60-87-7 PROMETHAZINE ADVERSE_EFFECT MSK_3_Torticollis 60-87-7 PROMETHAZINE ZERO_CLASS N 60-87-7 PROMETHAZINE INDICATION Allergic Diseases 60-87-7 PROMETHAZINE KNOWN_TOXICITY Cardiovascular Toxicity 60-87-7 PROMETHAZINE THERAPEUTIC_CLASS Antihistamines 60-87-7 PROMETHAZINE ACTIVITY_CLASS Dopamine antagonist 60-87-7 PROMETHAZINE TA_LEVEL_1 Anti-inflammatory 60-87-7 PROMETHAZINE MECH_LEVEL_2 Anti-histamine 60-87-7 PROMETHAZINE INDICATION Pruritus / Itching 60-87-7 PROMETHAZINE INDICATION Post-Operative Pain 60-87-7 PROMETHAZINE INDICATION Allergic Rhinitis 60-87-7 PROMETHAZINE TA_LEVEL_2 Anti-histamine 60-87-7 PROMETHAZINE PRODUCT_CLASS Central Nervous System (CNS) 60-87-7 PROMETHAZINE MODE_CLASS Receptor Ligand Antagonist 60-87-7 PROMETHAZINE ADVERSE_EFFECT CVS_3_Tachycardia 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_1_Sedation 60-87-7 PROMETHAZINE ADVERSE_EFFECT GIS_1_Dry Mouth 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_3_Mental Status Changes 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_1_Somnolence 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Athetosis 60-87-7 PROMETHAZINE ADVERSE_EFFECT OCU_3_Oculogyric Crisis 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_2_Tremor 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_1_Dizziness 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_1_Drowsiness 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_2_Confusion 60-87-7 PROMETHAZINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 60-87-7 PROMETHAZINE MECH_LEVEL_1 Immunomodulation 60-87-7 PROMETHAZINE INDICATION Allergic Conjunctivitis 60-87-7 PROMETHAZINE INDICATION Apprehension 60-87-7 PROMETHAZINE INDICATION Sedation 60-87-7 PROMETHAZINE INDICATION Urticaria / Hives 60-87-7 PROMETHAZINE INDICATION Insomnia / Dyssomnias 60-87-7 PROMETHAZINE ADVERSE_EFFECT CVS_3_Bradycardia 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_1_CNS Depression 60-87-7 PROMETHAZINE ADVERSE_EFFECT CVS_2_Hypertension 60-87-7 PROMETHAZINE ADVERSE_EFFECT XXX_1_Fatigue 60-87-7 PROMETHAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Ataxia 60-87-7 PROMETHAZINE ADVERSE_EFFECT PSY_3_Agitation 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Autonomic Instability 60-87-7 PROMETHAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 60-87-7 PROMETHAZINE ADVERSE_EFFECT LUN_3_Apnea 60-87-7 PROMETHAZINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 60-87-7 PROMETHAZINE MECHANISM Modulate G-protein coupled signal transduction 60-87-7 PROMETHAZINE TISSUE_TOXICITY Hypotension 60-87-7 PROMETHAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 60-87-7 PROMETHAZINE PRODUCT_CLASS Anti-inflammatories 60-87-7 PROMETHAZINE MESH_LEVEL_3 Phenothiazines 60-87-7 PROMETHAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 60-87-7 PROMETHAZINE INDICATION Motion Sickness 60-87-7 PROMETHAZINE INDICATION Anaphylaxis 58-33-3 PROMETHAZINE MESH_LEVEL_1 Heterocyclic Compounds 58-33-3 PROMETHAZINE INDICATION Angioedema 58-33-3 PROMETHAZINE INDICATION Dermatographism 58-33-3 PROMETHAZINE ADVERSE_EFFECT OCU_2_Blurred Vision 58-33-3 PROMETHAZINE ADVERSE_EFFECT CVS_2_Hypotension 58-33-3 PROMETHAZINE ADVERSE_EFFECT LUN_3_Asthma 58-33-3 PROMETHAZINE ADVERSE_EFFECT OTO_2_Tinnitus 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Seizures 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_2_Disorientation 58-33-3 PROMETHAZINE ADVERSE_EFFECT MSK_3_Muscle Rigidity 58-33-3 PROMETHAZINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_3_CNS Excitation 58-33-3 PROMETHAZINE ADVERSE_EFFECT OCU_3_Diplopia 58-33-3 PROMETHAZINE MECH_LEVEL_3 histamine receptor H1 58-33-3 PROMETHAZINE INDICATION Vasomotor Rhinitis 58-33-3 PROMETHAZINE MECHANISM Block neural transmission 58-33-3 PROMETHAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 58-33-3 PROMETHAZINE INDICATION Nausea / Vomiting 58-33-3 PROMETHAZINE ADVERSE_EFFECT LUN_3_Respiratory Depression 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_3_Delirium 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_2_Insomnia 58-33-3 PROMETHAZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-33-3 PROMETHAZINE ADVERSE_EFFECT XXX_3_Edema 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Hyperreflexia 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_2_Decrease Seizure Threshold 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 58-33-3 PROMETHAZINE ADVERSE_EFFECT BBM_3_Leukopenia 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Hypertonia 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Extensor-Plantar Reflexex (Barbinski Reflex) 58-33-3 PROMETHAZINE ADVERSE_EFFECT MSK_3_Torticollis 58-33-3 PROMETHAZINE ZERO_CLASS N 58-33-3 PROMETHAZINE INDICATION Allergic Diseases 58-33-3 PROMETHAZINE KNOWN_TOXICITY Cardiovascular Toxicity 58-33-3 PROMETHAZINE THERAPEUTIC_CLASS Antihistamines 58-33-3 PROMETHAZINE ACTIVITY_CLASS Dopamine antagonist 58-33-3 PROMETHAZINE TA_LEVEL_1 Anti-inflammatory 58-33-3 PROMETHAZINE MECH_LEVEL_2 Anti-histamine 58-33-3 PROMETHAZINE INDICATION Pruritus / Itching 58-33-3 PROMETHAZINE INDICATION Post-Operative Pain 58-33-3 PROMETHAZINE INDICATION Allergic Rhinitis 58-33-3 PROMETHAZINE TA_LEVEL_2 Anti-histamine 58-33-3 PROMETHAZINE PRODUCT_CLASS Central Nervous System (CNS) 58-33-3 PROMETHAZINE MODE_CLASS Receptor Ligand Antagonist 58-33-3 PROMETHAZINE ADVERSE_EFFECT CVS_3_Tachycardia 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_1_Sedation 58-33-3 PROMETHAZINE ADVERSE_EFFECT GIS_1_Dry Mouth 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_3_Mental Status Changes 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_1_Somnolence 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Athetosis 58-33-3 PROMETHAZINE ADVERSE_EFFECT OCU_3_Oculogyric Crisis 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_2_Tremor 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_1_Dizziness 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_1_Drowsiness 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_2_Confusion 58-33-3 PROMETHAZINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 58-33-3 PROMETHAZINE MECH_LEVEL_1 Immunomodulation 58-33-3 PROMETHAZINE INDICATION Allergic Conjunctivitis 58-33-3 PROMETHAZINE INDICATION Apprehension 58-33-3 PROMETHAZINE INDICATION Sedation 58-33-3 PROMETHAZINE INDICATION Urticaria / Hives 58-33-3 PROMETHAZINE INDICATION Insomnia / Dyssomnias 58-33-3 PROMETHAZINE ADVERSE_EFFECT CVS_3_Bradycardia 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_1_CNS Depression 58-33-3 PROMETHAZINE ADVERSE_EFFECT CVS_2_Hypertension 58-33-3 PROMETHAZINE ADVERSE_EFFECT XXX_1_Fatigue 58-33-3 PROMETHAZINE ADVERSE_EFFECT BBM_3_Agranulocytosis 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Ataxia 58-33-3 PROMETHAZINE ADVERSE_EFFECT PSY_3_Agitation 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Autonomic Instability 58-33-3 PROMETHAZINE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 58-33-3 PROMETHAZINE ADVERSE_EFFECT LUN_3_Apnea 58-33-3 PROMETHAZINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 58-33-3 PROMETHAZINE MECHANISM Modulate G-protein coupled signal transduction 58-33-3 PROMETHAZINE TISSUE_TOXICITY Hypotension 58-33-3 PROMETHAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 58-33-3 PROMETHAZINE PRODUCT_CLASS Anti-inflammatories 58-33-3 PROMETHAZINE MESH_LEVEL_3 Phenothiazines 58-33-3 PROMETHAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 58-33-3 PROMETHAZINE INDICATION Motion Sickness 58-33-3 PROMETHAZINE INDICATION Anaphylaxis 50-34-0 PROPANTHELINE BROMIDE MODE_CLASS Receptor Ligand Antagonist 50-34-0 PROPANTHELINE BROMIDE MODE_CLASS Channel Blocker 50-34-0 PROPANTHELINE BROMIDE MECHANISM Modulate G-protein coupled signal transduction 50-34-0 PROPANTHELINE BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 50-34-0 PROPANTHELINE BROMIDE INDICATION Neurogenic Bladder 50-34-0 PROPANTHELINE BROMIDE INDICATION Irritable Bowel Syndrome 50-34-0 PROPANTHELINE BROMIDE MECHANISM Modulate neural transmission 50-34-0 PROPANTHELINE BROMIDE INDICATION Ulcer 50-34-0 PROPANTHELINE BROMIDE THERAPEUTIC_CLASS Parasympatholytic Agents 5875-06-9 PROPARACAINE ADVERSE_EFFECT OCU_2_Ocular Irritation 5875-06-9 PROPARACAINE INDICATION Ophthalmic anesthesia 5875-06-9 PROPARACAINE PRODUCT_CLASS Central Nervous System (CNS) 5875-06-9 PROPARACAINE ADVERSE_EFFECT IMU_3_Allergic Reactions 5875-06-9 PROPARACAINE MODE_CLASS Channel Blocker 5875-06-9 PROPARACAINE THERAPEUTIC_CLASS Local Anesthetics 5875-06-9 PROPARACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 5875-06-9 PROPARACAINE MECHANISM Block neural transmission 499-67-2 PROPARACAINE INDICATION Ophthalmic anesthesia 499-67-2 PROPARACAINE ADVERSE_EFFECT OCU_2_Ocular Irritation 499-67-2 PROPARACAINE PRODUCT_CLASS Central Nervous System (CNS) 499-67-2 PROPARACAINE MECHANISM Block neural transmission 499-67-2 PROPARACAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 499-67-2 PROPARACAINE THERAPEUTIC_CLASS Local Anesthetics 499-67-2 PROPARACAINE MODE_CLASS Channel Blocker 499-67-2 PROPARACAINE ADVERSE_EFFECT IMU_3_Allergic Reactions 86-43-1 PROPOXYCAINE PRODUCT_CLASS Respiratory System 86-43-1 PROPOXYCAINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 86-43-1 PROPOXYCAINE MECHANISM Block neural transmission 86-43-1 PROPOXYCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 86-43-1 PROPOXYCAINE MODE_CLASS Channel Blocker 86-43-1 PROPOXYCAINE PRODUCT_CLASS Central Nervous System (CNS) 86-43-1 PROPOXYCAINE THERAPEUTIC_CLASS Local Anesthetics 469-62-5 PROPOXYPHENE MODE_CLASS Receptor Agonist 469-62-5 PROPOXYPHENE MECHANISM Modulate neural transmission 469-62-5 PROPOXYPHENE INDICATION Moderate Pain 469-62-5 PROPOXYPHENE PRODUCT_CLASS Analgesics 469-62-5 PROPOXYPHENE THERAPEUTIC_CLASS Analgesics, Opioid 1639-60-7 PROPOXYPHENE MODE_CLASS Receptor Agonist 1639-60-7 PROPOXYPHENE MECHANISM Modulate neural transmission 1639-60-7 PROPOXYPHENE INDICATION Moderate Pain 1639-60-7 PROPOXYPHENE PRODUCT_CLASS Analgesics 1639-60-7 PROPOXYPHENE THERAPEUTIC_CLASS Analgesics, Opioid 318-98-9 PROPRANOLOL ADVERSE_EFFECT REP_3_Impotence 318-98-9 PROPRANOLOL ADVERSE_EFFECT PSY_3_Hallucinations 318-98-9 PROPRANOLOL INDICATION Angina Pectoris 318-98-9 PROPRANOLOL INDICATION Paroxysmal Supraventricular Tachycardia 318-98-9 PROPRANOLOL PRODUCT_CLASS Cardiovasculars 318-98-9 PROPRANOLOL TA_LEVEL_2 Hypertension 318-98-9 PROPRANOLOL ADVERSE_EFFECT SKN_3_Pruritis 318-98-9 PROPRANOLOL INDICATION Postmyocardial Infarction 318-98-9 PROPRANOLOL MECH_LEVEL_1 Vasorelaxation 318-98-9 PROPRANOLOL INDICATION Hyperthyroidism / Thyrotoxicosis 318-98-9 PROPRANOLOL MESH_LEVEL_1 Organic Chemicals 318-98-9 PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 318-98-9 PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 318-98-9 PROPRANOLOL TISSUE_TOXICITY Congestive Heart Failure 318-98-9 PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 318-98-9 PROPRANOLOL MECH_LEVEL_2 Beta antagonist 318-98-9 PROPRANOLOL TA_LEVEL_1 Cardiovascular 318-98-9 PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 318-98-9 PROPRANOLOL ACTIVITY_CLASS Adrenergic antagonist 318-98-9 PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 318-98-9 PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 318-98-9 PROPRANOLOL THERAPEUTIC_CLASS Antianginals 318-98-9 PROPRANOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 318-98-9 PROPRANOLOL ADVERSE_EFFECT REP_3_Decreased Libido 318-98-9 PROPRANOLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 318-98-9 PROPRANOLOL ADVERSE_EFFECT LUN_2_Dyspnea 318-98-9 PROPRANOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 318-98-9 PROPRANOLOL ADVERSE_EFFECT PSY_3_Nightmares 318-98-9 PROPRANOLOL ADVERSE_EFFECT END_3_Hypoglycemia 318-98-9 PROPRANOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 318-98-9 PROPRANOLOL TISSUE_TOXICITY Atrioventricular Blockade 318-98-9 PROPRANOLOL MESH_LEVEL_3 Amino Alcohols 318-98-9 PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 318-98-9 PROPRANOLOL MECH_LEVEL_3 adrenoceptor beta, nonselective 318-98-9 PROPRANOLOL INDICATION Pheochromocytoma 318-98-9 PROPRANOLOL ADVERSE_EFFECT END_2_Hyperglycemia 318-98-9 PROPRANOLOL ADVERSE_EFFECT END_2_Diabetes Mellitus 318-98-9 PROPRANOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 318-98-9 PROPRANOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 318-98-9 PROPRANOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 318-98-9 PROPRANOLOL TA_LEVEL_3 Beta blocker 318-98-9 PROPRANOLOL INDICATION Atrial Fibrillation 318-98-9 PROPRANOLOL INDICATION Migraine Prophylaxis 318-98-9 PROPRANOLOL THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 318-98-9 PROPRANOLOL INDICATION Myocardial Infarction Prophylaxis 318-98-9 PROPRANOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 318-98-9 PROPRANOLOL ADVERSE_EFFECT XXX_2_Fatigue 318-98-9 PROPRANOLOL ADVERSE_EFFECT PSY_2_Depression 318-98-9 PROPRANOLOL ADVERSE_EFFECT GIS_1_Diarrhea 318-98-9 PROPRANOLOL INDICATION Atrial Flutter 318-98-9 PROPRANOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 318-98-9 PROPRANOLOL INDICATION Hypertension 318-98-9 PROPRANOLOL INDICATION Idiopathic Hypertrophic Subaortic Stenosis (IHSS) 318-98-9 PROPRANOLOL MESH_LEVEL_2 Alcohols 318-98-9 PROPRANOLOL ADVERSE_EFFECT MSK_3_Myalgia 318-98-9 PROPRANOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 318-98-9 PROPRANOLOL KNOWN_TOXICITY Cardiovascular Toxicity 318-98-9 PROPRANOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 318-98-9 PROPRANOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 318-98-9 PROPRANOLOL ADVERSE_EFFECT NEU_2_Dizziness 318-98-9 PROPRANOLOL ADVERSE_EFFECT LUN_2_Asthma 318-98-9 PROPRANOLOL INDICATION Tremor 525-66-6 PROPRANOLOL INDICATION Hyperthyroidism / Thyrotoxicosis 525-66-6 PROPRANOLOL INDICATION Postmyocardial Infarction 525-66-6 PROPRANOLOL INDICATION Atrial Flutter 525-66-6 PROPRANOLOL INDICATION Myocardial Infarction Prophylaxis 525-66-6 PROPRANOLOL MECH_LEVEL_3 adrenoceptor beta, nonselective 525-66-6 PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 525-66-6 PROPRANOLOL MESH_LEVEL_3 Amino Alcohols 525-66-6 PROPRANOLOL TISSUE_TOXICITY Atrioventricular Blockade 525-66-6 PROPRANOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 525-66-6 PROPRANOLOL ADVERSE_EFFECT END_3_Hypoglycemia 525-66-6 PROPRANOLOL ADVERSE_EFFECT PSY_3_Nightmares 525-66-6 PROPRANOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 525-66-6 PROPRANOLOL ADVERSE_EFFECT LUN_2_Dyspnea 525-66-6 PROPRANOLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 525-66-6 PROPRANOLOL ADVERSE_EFFECT REP_3_Decreased Libido 525-66-6 PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 525-66-6 PROPRANOLOL TA_LEVEL_1 Cardiovascular 525-66-6 PROPRANOLOL MECH_LEVEL_2 Beta antagonist 525-66-6 PROPRANOLOL MECH_LEVEL_1 Vasorelaxation 525-66-6 PROPRANOLOL INDICATION Migraine Prophylaxis 525-66-6 PROPRANOLOL INDICATION Atrial Fibrillation 525-66-6 PROPRANOLOL TA_LEVEL_3 Beta blocker 525-66-6 PROPRANOLOL INDICATION Tremor 525-66-6 PROPRANOLOL ADVERSE_EFFECT LUN_2_Asthma 525-66-6 PROPRANOLOL ADVERSE_EFFECT NEU_2_Dizziness 525-66-6 PROPRANOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 525-66-6 PROPRANOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 525-66-6 PROPRANOLOL KNOWN_TOXICITY Cardiovascular Toxicity 525-66-6 PROPRANOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 525-66-6 PROPRANOLOL ADVERSE_EFFECT MSK_3_Myalgia 525-66-6 PROPRANOLOL MESH_LEVEL_2 Alcohols 525-66-6 PROPRANOLOL INDICATION Idiopathic Hypertrophic Subaortic Stenosis (IHSS) 525-66-6 PROPRANOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 525-66-6 PROPRANOLOL ADVERSE_EFFECT REP_3_Impotence 525-66-6 PROPRANOLOL ADVERSE_EFFECT SKN_3_Pruritis 525-66-6 PROPRANOLOL ADVERSE_EFFECT GIS_1_Diarrhea 525-66-6 PROPRANOLOL ADVERSE_EFFECT PSY_2_Depression 525-66-6 PROPRANOLOL ADVERSE_EFFECT XXX_2_Fatigue 525-66-6 PROPRANOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 525-66-6 PROPRANOLOL THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 525-66-6 PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 525-66-6 PROPRANOLOL TISSUE_TOXICITY Congestive Heart Failure 525-66-6 PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 525-66-6 PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 525-66-6 PROPRANOLOL MESH_LEVEL_1 Organic Chemicals 525-66-6 PROPRANOLOL INDICATION Hypertension 525-66-6 PROPRANOLOL ADVERSE_EFFECT END_2_Hyperglycemia 525-66-6 PROPRANOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 525-66-6 PROPRANOLOL THERAPEUTIC_CLASS Antianginals 525-66-6 PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 525-66-6 PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 525-66-6 PROPRANOLOL ACTIVITY_CLASS Adrenergic antagonist 525-66-6 PROPRANOLOL INDICATION Pheochromocytoma 525-66-6 PROPRANOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 525-66-6 PROPRANOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 525-66-6 PROPRANOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 525-66-6 PROPRANOLOL ADVERSE_EFFECT END_2_Diabetes Mellitus 525-66-6 PROPRANOLOL TA_LEVEL_2 Hypertension 525-66-6 PROPRANOLOL PRODUCT_CLASS Cardiovasculars 525-66-6 PROPRANOLOL INDICATION Paroxysmal Supraventricular Tachycardia 525-66-6 PROPRANOLOL INDICATION Angina Pectoris 525-66-6 PROPRANOLOL ADVERSE_EFFECT PSY_3_Hallucinations 3506-09-0 PROPRANOLOL INDICATION Hyperthyroidism / Thyrotoxicosis 3506-09-0 PROPRANOLOL INDICATION Postmyocardial Infarction 3506-09-0 PROPRANOLOL INDICATION Atrial Flutter 3506-09-0 PROPRANOLOL INDICATION Myocardial Infarction Prophylaxis 3506-09-0 PROPRANOLOL MECH_LEVEL_3 adrenoceptor beta, nonselective 3506-09-0 PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 3506-09-0 PROPRANOLOL MESH_LEVEL_3 Amino Alcohols 3506-09-0 PROPRANOLOL TISSUE_TOXICITY Atrioventricular Blockade 3506-09-0 PROPRANOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 3506-09-0 PROPRANOLOL ADVERSE_EFFECT END_3_Hypoglycemia 3506-09-0 PROPRANOLOL ADVERSE_EFFECT PSY_3_Nightmares 3506-09-0 PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 3506-09-0 PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 3506-09-0 PROPRANOLOL ACTIVITY_CLASS Adrenergic antagonist 3506-09-0 PROPRANOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 3506-09-0 PROPRANOLOL INDICATION Pheochromocytoma 3506-09-0 PROPRANOLOL INDICATION Tremor 3506-09-0 PROPRANOLOL PRODUCT_CLASS Cardiovasculars 3506-09-0 PROPRANOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 3506-09-0 PROPRANOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 3506-09-0 PROPRANOLOL ADVERSE_EFFECT END_2_Diabetes Mellitus 3506-09-0 PROPRANOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 3506-09-0 PROPRANOLOL ADVERSE_EFFECT END_2_Hyperglycemia 3506-09-0 PROPRANOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 3506-09-0 PROPRANOLOL THERAPEUTIC_CLASS Antianginals 3506-09-0 PROPRANOLOL MESH_LEVEL_1 Organic Chemicals 3506-09-0 PROPRANOLOL ADVERSE_EFFECT PSY_3_Hallucinations 3506-09-0 PROPRANOLOL TA_LEVEL_2 Hypertension 3506-09-0 PROPRANOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 3506-09-0 PROPRANOLOL INDICATION Hypertension 3506-09-0 PROPRANOLOL INDICATION Idiopathic Hypertrophic Subaortic Stenosis (IHSS) 3506-09-0 PROPRANOLOL MESH_LEVEL_2 Alcohols 3506-09-0 PROPRANOLOL ADVERSE_EFFECT MSK_3_Myalgia 3506-09-0 PROPRANOLOL KNOWN_TOXICITY Cardiovascular Toxicity 3506-09-0 PROPRANOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 3506-09-0 PROPRANOLOL ADVERSE_EFFECT NEU_2_Dizziness 3506-09-0 PROPRANOLOL ADVERSE_EFFECT LUN_2_Asthma 3506-09-0 PROPRANOLOL TA_LEVEL_3 Beta blocker 3506-09-0 PROPRANOLOL INDICATION Atrial Fibrillation 3506-09-0 PROPRANOLOL INDICATION Migraine Prophylaxis 3506-09-0 PROPRANOLOL MECH_LEVEL_1 Vasorelaxation 3506-09-0 PROPRANOLOL MECH_LEVEL_2 Beta antagonist 3506-09-0 PROPRANOLOL TA_LEVEL_1 Cardiovascular 3506-09-0 PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 3506-09-0 PROPRANOLOL ADVERSE_EFFECT REP_3_Decreased Libido 3506-09-0 PROPRANOLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 3506-09-0 PROPRANOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 3506-09-0 PROPRANOLOL ADVERSE_EFFECT LUN_2_Dyspnea 3506-09-0 PROPRANOLOL INDICATION Angina Pectoris 3506-09-0 PROPRANOLOL INDICATION Paroxysmal Supraventricular Tachycardia 3506-09-0 PROPRANOLOL ADVERSE_EFFECT REP_3_Impotence 3506-09-0 PROPRANOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 3506-09-0 PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 3506-09-0 PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 3506-09-0 PROPRANOLOL TISSUE_TOXICITY Congestive Heart Failure 3506-09-0 PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 3506-09-0 PROPRANOLOL THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 3506-09-0 PROPRANOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 3506-09-0 PROPRANOLOL ADVERSE_EFFECT XXX_2_Fatigue 3506-09-0 PROPRANOLOL ADVERSE_EFFECT PSY_2_Depression 3506-09-0 PROPRANOLOL ADVERSE_EFFECT GIS_1_Diarrhea 3506-09-0 PROPRANOLOL ADVERSE_EFFECT SKN_3_Pruritis 146874-86-4 PROPRANOLOL INDICATION Postmyocardial Infarction 146874-86-4 PROPRANOLOL INDICATION Angina Pectoris 146874-86-4 PROPRANOLOL INDICATION Paroxysmal Supraventricular Tachycardia 146874-86-4 PROPRANOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 146874-86-4 PROPRANOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 146874-86-4 PROPRANOLOL KNOWN_TOXICITY Cardiovascular Toxicity 146874-86-4 PROPRANOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 146874-86-4 PROPRANOLOL ADVERSE_EFFECT MSK_3_Myalgia 146874-86-4 PROPRANOLOL MESH_LEVEL_2 Alcohols 146874-86-4 PROPRANOLOL INDICATION Idiopathic Hypertrophic Subaortic Stenosis (IHSS) 146874-86-4 PROPRANOLOL INDICATION Hypertension 146874-86-4 PROPRANOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 146874-86-4 PROPRANOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 146874-86-4 PROPRANOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 146874-86-4 PROPRANOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 146874-86-4 PROPRANOLOL ADVERSE_EFFECT PSY_3_Hallucinations 146874-86-4 PROPRANOLOL ADVERSE_EFFECT END_2_Diabetes Mellitus 146874-86-4 PROPRANOLOL ADVERSE_EFFECT END_2_Hyperglycemia 146874-86-4 PROPRANOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 146874-86-4 PROPRANOLOL THERAPEUTIC_CLASS Antianginals 146874-86-4 PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 146874-86-4 PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 146874-86-4 PROPRANOLOL PRODUCT_CLASS Cardiovasculars 146874-86-4 PROPRANOLOL ACTIVITY_CLASS Adrenergic antagonist 146874-86-4 PROPRANOLOL TA_LEVEL_2 Hypertension 146874-86-4 PROPRANOLOL MECH_LEVEL_3 adrenoceptor beta, nonselective 146874-86-4 PROPRANOLOL INDICATION Myocardial Infarction Prophylaxis 146874-86-4 PROPRANOLOL INDICATION Atrial Flutter 146874-86-4 PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 146874-86-4 PROPRANOLOL INDICATION Hyperthyroidism / Thyrotoxicosis 146874-86-4 PROPRANOLOL MESH_LEVEL_1 Organic Chemicals 146874-86-4 PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 146874-86-4 PROPRANOLOL TISSUE_TOXICITY Atrioventricular Blockade 146874-86-4 PROPRANOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 146874-86-4 PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 146874-86-4 PROPRANOLOL ADVERSE_EFFECT END_3_Hypoglycemia 146874-86-4 PROPRANOLOL ADVERSE_EFFECT PSY_3_Nightmares 146874-86-4 PROPRANOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 146874-86-4 PROPRANOLOL ADVERSE_EFFECT LUN_2_Dyspnea 146874-86-4 PROPRANOLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 146874-86-4 PROPRANOLOL ADVERSE_EFFECT REP_3_Decreased Libido 146874-86-4 PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 146874-86-4 PROPRANOLOL TA_LEVEL_1 Cardiovascular 146874-86-4 PROPRANOLOL MECH_LEVEL_2 Beta antagonist 146874-86-4 PROPRANOLOL MECH_LEVEL_1 Vasorelaxation 146874-86-4 PROPRANOLOL INDICATION Migraine Prophylaxis 146874-86-4 PROPRANOLOL MESH_LEVEL_3 Amino Alcohols 146874-86-4 PROPRANOLOL TA_LEVEL_3 Beta blocker 146874-86-4 PROPRANOLOL INDICATION Tremor 146874-86-4 PROPRANOLOL ADVERSE_EFFECT LUN_2_Asthma 146874-86-4 PROPRANOLOL ADVERSE_EFFECT NEU_2_Dizziness 146874-86-4 PROPRANOLOL TISSUE_TOXICITY Congestive Heart Failure 146874-86-4 PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 146874-86-4 PROPRANOLOL THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 146874-86-4 PROPRANOLOL INDICATION Pheochromocytoma 146874-86-4 PROPRANOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 146874-86-4 PROPRANOLOL ADVERSE_EFFECT XXX_2_Fatigue 146874-86-4 PROPRANOLOL ADVERSE_EFFECT PSY_2_Depression 146874-86-4 PROPRANOLOL ADVERSE_EFFECT GIS_1_Diarrhea 146874-86-4 PROPRANOLOL ADVERSE_EFFECT SKN_3_Pruritis 146874-86-4 PROPRANOLOL ADVERSE_EFFECT REP_3_Impotence 146874-86-4 PROPRANOLOL INDICATION Atrial Fibrillation 13013-17-7 PROPRANOLOL ADVERSE_EFFECT PSY_3_Nightmares 13013-17-7 PROPRANOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 13013-17-7 PROPRANOLOL ADVERSE_EFFECT LUN_2_Dyspnea 13013-17-7 PROPRANOLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 13013-17-7 PROPRANOLOL ADVERSE_EFFECT REP_3_Decreased Libido 13013-17-7 PROPRANOLOL THERAPEUTIC_CLASS Antihypertensive Agents 13013-17-7 PROPRANOLOL TA_LEVEL_1 Cardiovascular 13013-17-7 PROPRANOLOL MECH_LEVEL_2 Beta antagonist 13013-17-7 PROPRANOLOL MECH_LEVEL_1 Vasorelaxation 13013-17-7 PROPRANOLOL INDICATION Migraine Prophylaxis 13013-17-7 PROPRANOLOL INDICATION Pheochromocytoma 13013-17-7 PROPRANOLOL ACTIVITY_CLASS Adrenergic antagonist 13013-17-7 PROPRANOLOL THERAPEUTIC_CLASS Sympatholytic Agents 13013-17-7 PROPRANOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 13013-17-7 PROPRANOLOL THERAPEUTIC_CLASS Antianginals 13013-17-7 PROPRANOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 13013-17-7 PROPRANOLOL ADVERSE_EFFECT END_2_Hyperglycemia 13013-17-7 PROPRANOLOL ADVERSE_EFFECT END_2_Diabetes Mellitus 13013-17-7 PROPRANOLOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 13013-17-7 PROPRANOLOL ADVERSE_EFFECT MSK_3_Musculoskeletal Pain 13013-17-7 PROPRANOLOL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 13013-17-7 PROPRANOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 13013-17-7 PROPRANOLOL INDICATION Hypertension 13013-17-7 PROPRANOLOL INDICATION Idiopathic Hypertrophic Subaortic Stenosis (IHSS) 13013-17-7 PROPRANOLOL MESH_LEVEL_2 Alcohols 13013-17-7 PROPRANOLOL ADVERSE_EFFECT MSK_3_Myalgia 13013-17-7 PROPRANOLOL ADVERSE_EFFECT END_3_Hypertriglyceridemia 13013-17-7 PROPRANOLOL KNOWN_TOXICITY Cardiovascular Toxicity 13013-17-7 PROPRANOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 13013-17-7 PROPRANOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 13013-17-7 PROPRANOLOL ADVERSE_EFFECT NEU_2_Dizziness 13013-17-7 PROPRANOLOL ADVERSE_EFFECT LUN_2_Asthma 13013-17-7 PROPRANOLOL INDICATION Tremor 13013-17-7 PROPRANOLOL TA_LEVEL_3 Beta blocker 13013-17-7 PROPRANOLOL PRODUCT_CLASS Cardiovasculars 13013-17-7 PROPRANOLOL INDICATION Paroxysmal Supraventricular Tachycardia 13013-17-7 PROPRANOLOL INDICATION Angina Pectoris 13013-17-7 PROPRANOLOL ADVERSE_EFFECT PSY_3_Hallucinations 13013-17-7 PROPRANOLOL ADVERSE_EFFECT REP_3_Impotence 13013-17-7 PROPRANOLOL ADVERSE_EFFECT SKN_3_Pruritis 13013-17-7 PROPRANOLOL ADVERSE_EFFECT GIS_1_Diarrhea 13013-17-7 PROPRANOLOL TA_LEVEL_2 Hypertension 13013-17-7 PROPRANOLOL INDICATION Atrial Fibrillation 13013-17-7 PROPRANOLOL ADVERSE_EFFECT PSY_2_Depression 13013-17-7 PROPRANOLOL ADVERSE_EFFECT XXX_2_Fatigue 13013-17-7 PROPRANOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 13013-17-7 PROPRANOLOL THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 13013-17-7 PROPRANOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 13013-17-7 PROPRANOLOL TISSUE_TOXICITY Congestive Heart Failure 13013-17-7 PROPRANOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 13013-17-7 PROPRANOLOL PRODUCT_CLASS Autonomic Nervous System (ANS) 13013-17-7 PROPRANOLOL MESH_LEVEL_1 Organic Chemicals 13013-17-7 PROPRANOLOL INDICATION Hyperthyroidism / Thyrotoxicosis 13013-17-7 PROPRANOLOL INDICATION Postmyocardial Infarction 13013-17-7 PROPRANOLOL INDICATION Atrial Flutter 13013-17-7 PROPRANOLOL INDICATION Myocardial Infarction Prophylaxis 13013-17-7 PROPRANOLOL MECH_LEVEL_3 adrenoceptor beta, nonselective 13013-17-7 PROPRANOLOL MECHANISM Modulate G-protein coupled signal transduction 13013-17-7 PROPRANOLOL MESH_LEVEL_3 Amino Alcohols 13013-17-7 PROPRANOLOL TISSUE_TOXICITY Atrioventricular Blockade 13013-17-7 PROPRANOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 13013-17-7 PROPRANOLOL ADVERSE_EFFECT END_3_Hypoglycemia 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT NEU_1_Dizziness 57-55-6 PROPYLENE GLYCOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 57-55-6 PROPYLENE GLYCOL THERAPEUTIC_CLASS Miscellaneous Ophthamological Agents 57-55-6 PROPYLENE GLYCOL ACTIVITY_CLASS Alcohol dehydrogenase inhibitor 57-55-6 PROPYLENE GLYCOL STRUCTURE_ACTIVITY Alcohol dehydrogenase inhibitor 57-55-6 PROPYLENE GLYCOL MESH_LEVEL_1 Organic Chemicals 57-55-6 PROPYLENE GLYCOL TISSUE_TOXICITY Hypotension 57-55-6 PROPYLENE GLYCOL KNOWN_TOXICITY Hepatotoxicity 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT OCU_3_Retinal Detachment 57-55-6 PROPYLENE GLYCOL TA_LEVEL_3 keratoconjunctivitis 57-55-6 PROPYLENE GLYCOL MECH_LEVEL_2 enzyme substrate mimic 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT CVS_2_Hypotension 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT REP_2_Changes in Reproductive Function 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT SKN_3_Skin Irritation 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT KID_3_Renal Damage 57-55-6 PROPYLENE GLYCOL KNOWN_TOXICITY Cardiovascular Toxicity 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT PSY_2_CNS Depression 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT IMU_3_Contact Dermatitis 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT GUS_2_Diuresis 57-55-6 PROPYLENE GLYCOL ZERO_CLASS N 57-55-6 PROPYLENE GLYCOL TA_LEVEL_1 Eye, Ear, Nose and Throat Preparations 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT LIV_2_Hepatotoxicity 57-55-6 PROPYLENE GLYCOL INDICATION Keratoconjunctivitis Sicca / Dry Eyes 57-55-6 PROPYLENE GLYCOL MESH_LEVEL_3 Glycols 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 57-55-6 PROPYLENE GLYCOL MECH_LEVEL_3 Alcohol dehydrogenase 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT XXX_1_Stinging Sensation 57-55-6 PROPYLENE GLYCOL TISSUE_TOXICITY Hepatotoxicity 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT NEU_1_Drowsiness 57-55-6 PROPYLENE GLYCOL MESH_LEVEL_2 Alcohols 57-55-6 PROPYLENE GLYCOL TISSUE_TOXICITY Asystole 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT CVS_3_Asystole 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT XXX_1_Lacrimation 57-55-6 PROPYLENE GLYCOL ADVERSE_EFFECT END_3_Metabolic Acidosis 94-13-3 PROPYLPARABEN PRODUCT_CLASS Other Human Uses 51-52-5 PROPYLTHIOURACIL TISSUE_TOXICITY Leukopenia 51-52-5 PROPYLTHIOURACIL TISSUE_TOXICITY Hepatic Necrosis 51-52-5 PROPYLTHIOURACIL MECHANISM Inhibit thyroid hormone biosynthesis 51-52-5 PROPYLTHIOURACIL MESH_LEVEL_1 Heterocyclic Compounds 51-52-5 PROPYLTHIOURACIL TA_LEVEL_3 direct acting thyroid agent 51-52-5 PROPYLTHIOURACIL MESH_LEVEL_3 Pyrimidines 51-52-5 PROPYLTHIOURACIL KNOWN_TOXICITY Nephrotoxicity 51-52-5 PROPYLTHIOURACIL TISSUE_TOXICITY Hepatotoxicity 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT CVS_3_Vasculitis 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT MSK_1_Arthralgia 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT END_3_Hypothyroidism 51-52-5 PROPYLTHIOURACIL MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 51-52-5 PROPYLTHIOURACIL MECH_LEVEL_1 Hormone modulation 51-52-5 PROPYLTHIOURACIL TA_LEVEL_1 Hormones, Endocrine and Metabolic 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_3_Thrombocytopenia 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT LIV_3_Hepatotoxicity 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT IMU_2_Hypersensitivity 51-52-5 PROPYLTHIOURACIL PRODUCT_CLASS Hormones, Endocrine and Metabolic 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_2_Pancytopenia 51-52-5 PROPYLTHIOURACIL INDICATION Hyperthyroidism / Thyrotoxicosis 51-52-5 PROPYLTHIOURACIL TA_LEVEL_2 Hyperthyroidism 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_1_Leukopenia 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT EMB_3_Congenital Malformations 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT SKN_3_Pruritis 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT SKN_2_Rash 51-52-5 PROPYLTHIOURACIL ZERO_CLASS N 51-52-5 PROPYLTHIOURACIL TISSUE_TOXICITY Neutropenia 51-52-5 PROPYLTHIOURACIL THERAPEUTIC_CLASS Thyroid and Antithyroid Agents 51-52-5 PROPYLTHIOURACIL MODE_CLASS Enzyme Inhibitor 51-52-5 PROPYLTHIOURACIL MECH_LEVEL_2 Inhibit thyroid hormone biosynthesis 51-52-5 PROPYLTHIOURACIL MECH_LEVEL_3 Thyroperoxidase (TPO) 51-52-5 PROPYLTHIOURACIL STRUCTURE_ACTIVITY Thyroperoxidase inhibitor 51-52-5 PROPYLTHIOURACIL ACTIVITY_CLASS Thyroperoxidase inhibitor 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT KID_2_Nephrotic Syndrome 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 51-52-5 PROPYLTHIOURACIL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 51-52-5 PROPYLTHIOURACIL TISSUE_TOXICITY Nephrotic Syndrome 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_1_Neutropenia 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_3_Aplastic Anemia 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT IMU_3_Urticaria 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT LIV_3_Hepatitis 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_2_Agranulocytosis 51-52-5 PROPYLTHIOURACIL KNOWN_TOXICITY Hepatotoxicity 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT BBM_2_Hypoprothrombinemia 51-52-5 PROPYLTHIOURACIL ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 1225-55-4 PROTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 1225-55-4 PROTRIPTYLINE INDICATION Depression 1225-55-4 PROTRIPTYLINE MECHANISM Prolong/enhance neural transmission 1225-55-4 PROTRIPTYLINE INDICATION Cataplexy 1225-55-4 PROTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 1225-55-4 PROTRIPTYLINE MODE_CLASS Solute transporter inhibitor 438-60-8 PROTRIPTYLINE MODE_CLASS Solute transporter inhibitor 438-60-8 PROTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 438-60-8 PROTRIPTYLINE INDICATION Depression 438-60-8 PROTRIPTYLINE MECHANISM Prolong/enhance neural transmission 438-60-8 PROTRIPTYLINE INDICATION Cataplexy 438-60-8 PROTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 345-78-8 PSEUDOEPHEDRINE INDICATION Urinary Incontinence / Enuresis 345-78-8 PSEUDOEPHEDRINE MECHANISM Increase vasoconstriction 345-78-8 PSEUDOEPHEDRINE MECHANISM Modulate G-protein coupled signal transduction 345-78-8 PSEUDOEPHEDRINE THERAPEUTIC_CLASS Sedatives/Hypnotics 345-78-8 PSEUDOEPHEDRINE MODE_CLASS Receptor Agonist 345-78-8 PSEUDOEPHEDRINE PRODUCT_CLASS Central Nervous System (CNS) 345-78-8 PSEUDOEPHEDRINE INDICATION Nasal Congestion 345-78-8 PSEUDOEPHEDRINE THERAPEUTIC_CLASS Antihistamines 345-78-8 PSEUDOEPHEDRINE INDICATION Allergic Rhinitis 345-78-8 PSEUDOEPHEDRINE PRODUCT_CLASS Anti-inflammatories 345-78-8 PSEUDOEPHEDRINE INDICATION Viral Rhinitis / Common Cold 345-78-8 PSEUDOEPHEDRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 53-79-2 PUROMYCIN MODE_CLASS Distorts /blocks macromolecular scaffold function 53-79-2 PUROMYCIN MECHANISM Inhibit ribosomal protein synthesis 53-79-2 PUROMYCIN PRODUCT_CLASS Biochemicals 53-79-2 PUROMYCIN STRUCTURE_ACTIVITY Ribosomal protein synthesis inhibitor 58-58-2 PUROMYCIN STRUCTURE_ACTIVITY Ribosomal protein synthesis inhibitor 58-58-2 PUROMYCIN MODE_CLASS Distorts /blocks macromolecular scaffold function 58-58-2 PUROMYCIN MECHANISM Inhibit ribosomal protein synthesis 58-58-2 PUROMYCIN PRODUCT_CLASS Biochemicals 98-96-4 PYRAZINAMIDE TA_LEVEL_2 anti-bacterial 98-96-4 PYRAZINAMIDE MESH_LEVEL_3 Pyrazines 98-96-4 PYRAZINAMIDE TA_LEVEL_3 tuberculosis 98-96-4 PYRAZINAMIDE THERAPEUTIC_CLASS Antibacterials, Systemic 98-96-4 PYRAZINAMIDE PRODUCT_CLASS Anti-infectives 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT SKN_3_Skin Discoloration 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT LIV_3_Hepatitis 98-96-4 PYRAZINAMIDE MECH_LEVEL_3 Unknown mechanism 98-96-4 PYRAZINAMIDE MESH_LEVEL_1 Heterocyclic Compounds 98-96-4 PYRAZINAMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 98-96-4 PYRAZINAMIDE MECH_LEVEL_2 enzyme substrate mimic 98-96-4 PYRAZINAMIDE INDICATION Tuberculosis 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT LIV_3_Hepatomegaly 98-96-4 PYRAZINAMIDE TISSUE_TOXICITY Hepatotoxicity 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT LIV_3_Jaundice 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT KID_1_Hyperuricemia 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT MSK_1_Arthralgia 98-96-4 PYRAZINAMIDE STRUCTURE_ACTIVITY Niacin antagonist 98-96-4 PYRAZINAMIDE INDICATION Mycobacterium Tuberculosis Infections 98-96-4 PYRAZINAMIDE MECH_LEVEL_1 nicotinamide analogue 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT PSY_3_Anorexia 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT SKN_3_Maculopapular Rash 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT IMU_3_Photosensitivity 98-96-4 PYRAZINAMIDE TA_LEVEL_1 Infectious Disease 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT END_3_Acute Gouty Arthritis 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT XXX_2_Malaise 98-96-4 PYRAZINAMIDE TISSUE_TOXICITY Hepatic Necrosis 98-96-4 PYRAZINAMIDE ZERO_CLASS N 98-96-4 PYRAZINAMIDE ACTIVITY_CLASS Antibiotic 98-96-4 PYRAZINAMIDE KNOWN_TOXICITY Hepatotoxicity 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT XXX_3_Fever 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT XXX_3_Splenomegaly 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT BBM_3_Hematological Reactions 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 98-96-4 PYRAZINAMIDE ADVERSE_EFFECT SKN_3_Acneiform Rash 98-96-4 PYRAZINAMIDE MODE_CLASS Enzyme substrate mimic 98-96-4 PYRAZINAMIDE MECHANISM Inhibit precursor synthesis 101-26-8 PYRIDOSTIGMINE BROMIDE INDICATION Myasthenia Gravis 101-26-8 PYRIDOSTIGMINE BROMIDE INDICATION Reversal of Neuromuscular Blockade 101-26-8 PYRIDOSTIGMINE BROMIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 101-26-8 PYRIDOSTIGMINE BROMIDE MODE_CLASS Enzyme Inhibitor 101-26-8 PYRIDOSTIGMINE BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 101-26-8 PYRIDOSTIGMINE BROMIDE MECHANISM Enhance cholinergic transmission 192575-19-2 PPADS PRODUCT_CLASS Biochemicals 58-56-0 PYRIDOXINE MECHANISM Vitamin/ cofactor 91-84-9 PYRILAMINE INDICATION Nasal Congestion 91-84-9 PYRILAMINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 91-84-9 PYRILAMINE ADVERSE_EFFECT NEU_2_Dizziness 91-84-9 PYRILAMINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 91-84-9 PYRILAMINE INDICATION Allergic Conjunctivitis 91-84-9 PYRILAMINE THERAPEUTIC_CLASS Antihistamines 91-84-9 PYRILAMINE TISSUE_TOXICITY Hypotension 91-84-9 PYRILAMINE ADVERSE_EFFECT CVS_2_Hypotension 91-84-9 PYRILAMINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 91-84-9 PYRILAMINE ZERO_CLASS N 91-84-9 PYRILAMINE KNOWN_TOXICITY Cardiovascular Toxicity 91-84-9 PYRILAMINE MESH_LEVEL_3 Pyridines 91-84-9 PYRILAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 91-84-9 PYRILAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 91-84-9 PYRILAMINE INDICATION Ocular Pruritus 91-84-9 PYRILAMINE INDICATION Allergic Rhinitis 91-84-9 PYRILAMINE ADVERSE_EFFECT NEU_1_Sedation 91-84-9 PYRILAMINE ADVERSE_EFFECT XXX_2_Restlessness 91-84-9 PYRILAMINE ACTIVITY_CLASS Histamine antagonist 91-84-9 PYRILAMINE INDICATION Viral Rhinitis / Common Cold 91-84-9 PYRILAMINE PRODUCT_CLASS Anti-inflammatories 91-84-9 PYRILAMINE MESH_LEVEL_1 Heterocyclic Compounds 91-84-9 PYRILAMINE MECH_LEVEL_3 histamine receptor H1 91-84-9 PYRILAMINE MECH_LEVEL_1 Immunomodulation 91-84-9 PYRILAMINE ADVERSE_EFFECT NEU_1_Drowsiness 91-84-9 PYRILAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 91-84-9 PYRILAMINE TA_LEVEL_1 Anti-inflammatory 91-84-9 PYRILAMINE MECH_LEVEL_2 Anti-histamine 91-84-9 PYRILAMINE MECHANISM Modulate G-protein coupled signal transduction 91-84-9 PYRILAMINE TA_LEVEL_2 Anti-histamine 59-33-6 PYRILAMINE INDICATION Viral Rhinitis / Common Cold 59-33-6 PYRILAMINE ACTIVITY_CLASS Histamine antagonist 59-33-6 PYRILAMINE KNOWN_TOXICITY Cardiovascular Toxicity 59-33-6 PYRILAMINE PRODUCT_CLASS Anti-inflammatories 59-33-6 PYRILAMINE MESH_LEVEL_1 Heterocyclic Compounds 59-33-6 PYRILAMINE MECH_LEVEL_3 histamine receptor H1 59-33-6 PYRILAMINE MECH_LEVEL_1 Immunomodulation 59-33-6 PYRILAMINE ADVERSE_EFFECT NEU_1_Drowsiness 59-33-6 PYRILAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 59-33-6 PYRILAMINE TA_LEVEL_1 Anti-inflammatory 59-33-6 PYRILAMINE MECH_LEVEL_2 Anti-histamine 59-33-6 PYRILAMINE MECHANISM Modulate G-protein coupled signal transduction 59-33-6 PYRILAMINE TA_LEVEL_2 Anti-histamine 59-33-6 PYRILAMINE INDICATION Ocular Pruritus 59-33-6 PYRILAMINE INDICATION Nasal Congestion 59-33-6 PYRILAMINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 59-33-6 PYRILAMINE ADVERSE_EFFECT NEU_2_Dizziness 59-33-6 PYRILAMINE ZERO_CLASS N 59-33-6 PYRILAMINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 59-33-6 PYRILAMINE INDICATION Allergic Conjunctivitis 59-33-6 PYRILAMINE THERAPEUTIC_CLASS Antihistamines 59-33-6 PYRILAMINE TISSUE_TOXICITY Hypotension 59-33-6 PYRILAMINE ADVERSE_EFFECT CVS_2_Hypotension 59-33-6 PYRILAMINE MESH_LEVEL_3 Pyridines 59-33-6 PYRILAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 59-33-6 PYRILAMINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 59-33-6 PYRILAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 59-33-6 PYRILAMINE INDICATION Allergic Rhinitis 59-33-6 PYRILAMINE ADVERSE_EFFECT NEU_1_Sedation 59-33-6 PYRILAMINE ADVERSE_EFFECT XXX_2_Restlessness 6036-95-9 PYRILAMINE ADVERSE_EFFECT XXX_2_Restlessness 6036-95-9 PYRILAMINE ACTIVITY_CLASS Histamine antagonist 6036-95-9 PYRILAMINE INDICATION Allergic Conjunctivitis 6036-95-9 PYRILAMINE PRODUCT_CLASS Anti-inflammatories 6036-95-9 PYRILAMINE MESH_LEVEL_1 Heterocyclic Compounds 6036-95-9 PYRILAMINE MECH_LEVEL_3 histamine receptor H1 6036-95-9 PYRILAMINE MECH_LEVEL_1 Immunomodulation 6036-95-9 PYRILAMINE ADVERSE_EFFECT NEU_1_Drowsiness 6036-95-9 PYRILAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 6036-95-9 PYRILAMINE TA_LEVEL_1 Anti-inflammatory 6036-95-9 PYRILAMINE THERAPEUTIC_CLASS Antihistamines 6036-95-9 PYRILAMINE TISSUE_TOXICITY Hypotension 6036-95-9 PYRILAMINE ADVERSE_EFFECT CVS_2_Hypotension 6036-95-9 PYRILAMINE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 6036-95-9 PYRILAMINE KNOWN_TOXICITY Cardiovascular Toxicity 6036-95-9 PYRILAMINE TA_LEVEL_2 Anti-histamine 6036-95-9 PYRILAMINE INDICATION Nasal Congestion 6036-95-9 PYRILAMINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 6036-95-9 PYRILAMINE ADVERSE_EFFECT NEU_2_Dizziness 6036-95-9 PYRILAMINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 6036-95-9 PYRILAMINE MECH_LEVEL_2 Anti-histamine 6036-95-9 PYRILAMINE ZERO_CLASS N 6036-95-9 PYRILAMINE INDICATION Viral Rhinitis / Common Cold 6036-95-9 PYRILAMINE MECHANISM Modulate G-protein coupled signal transduction 6036-95-9 PYRILAMINE MESH_LEVEL_3 Pyridines 6036-95-9 PYRILAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 6036-95-9 PYRILAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 6036-95-9 PYRILAMINE INDICATION Ocular Pruritus 6036-95-9 PYRILAMINE INDICATION Allergic Rhinitis 6036-95-9 PYRILAMINE ADVERSE_EFFECT NEU_1_Sedation 58-14-0 PYRIMETHAMINE MODE_CLASS Enzyme Inhibitor 58-14-0 PYRIMETHAMINE MECHANISM Inhibit precursor synthesis 58-14-0 PYRIMETHAMINE INDICATION Malaria 13463-41-7 PYRITHIONE ZINC INDICATION Seborrhea 87-66-1 PYROGALLOL ADVERSE_EFFECT NEU_2_Somnolence 87-66-1 PYROGALLOL ADVERSE_EFFECT LUN_2_Cough 87-66-1 PYROGALLOL ADVERSE_EFFECT GIS_2_Gastrointestinal Irritation 87-66-1 PYROGALLOL ADVERSE_EFFECT SKN_2_Eczema 87-66-1 PYROGALLOL ADVERSE_EFFECT NEU_3_Coma 87-66-1 PYROGALLOL ADVERSE_EFFECT BBM_3_Methemoglobinemia 87-66-1 PYROGALLOL TISSUE_TOXICITY Circulatory Collapse 87-66-1 PYROGALLOL TA_LEVEL_1 Biochemicals 87-66-1 PYROGALLOL TA_LEVEL_3 Biochemicals 87-66-1 PYROGALLOL PRODUCT_CLASS Biochemicals 87-66-1 PYROGALLOL KNOWN_TOXICITY Miscellaneous 87-66-1 PYROGALLOL ADVERSE_EFFECT BBM_3_Anemia 87-66-1 PYROGALLOL ADVERSE_EFFECT IMU_2_Contact Dermatitis 87-66-1 PYROGALLOL MESH_LEVEL_2 Phenols 87-66-1 PYROGALLOL MESH_LEVEL_3 Pyrogallol 87-66-1 PYROGALLOL KNOWN_TOXICITY Cardiovascular Toxicity 87-66-1 PYROGALLOL ADVERSE_EFFECT KID_3_Nephritis 87-66-1 PYROGALLOL ADVERSE_EFFECT CVS_3_Circulatory Collapse 87-66-1 PYROGALLOL ADVERSE_EFFECT IMU_2_Photosensitivity 87-66-1 PYROGALLOL ADVERSE_EFFECT SKN_1_Skin Irritation 87-66-1 PYROGALLOL ADVERSE_EFFECT BBM_3_Hemolysis 87-66-1 PYROGALLOL ZERO_CLASS N 87-66-1 PYROGALLOL TA_LEVEL_2 Biochemicals 87-66-1 PYROGALLOL MECH_LEVEL_2 Enzyme inhibitor 87-66-1 PYROGALLOL ADVERSE_EFFECT KID_3_Increased Blood Urea Nitrogen 87-66-1 PYROGALLOL ADVERSE_EFFECT LUN_2_Airway Irritation 87-66-1 PYROGALLOL ADVERSE_EFFECT XXX_3_Death 87-66-1 PYROGALLOL ADVERSE_EFFECT LIV_3_Hepatic Damage 87-66-1 PYROGALLOL ADVERSE_EFFECT XXX_1_Irritation of Mucus Membrane 87-66-1 PYROGALLOL STRUCTURE_ACTIVITY Peroxidase inhibitor 87-66-1 PYROGALLOL ADVERSE_EFFECT KID_3_Renal Damage 87-66-1 PYROGALLOL MESH_LEVEL_1 Organic Chemicals 87-66-1 PYROGALLOL MECHANISM Induce Apoptosis 87-66-1 PYROGALLOL MECH_LEVEL_3 peroxidase 87-66-1 PYROGALLOL MODE_CLASS Enzyme Inhibitor 87-66-1 PYROGALLOL TISSUE_TOXICITY Death 87-66-1 PYROGALLOL ADVERSE_EFFECT NEU_2_Convulsions 87-66-1 PYROGALLOL ACTIVITY_CLASS Peroxidase inhibitor 36735-22-5 QUAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 36735-22-5 QUAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 36735-22-5 QUAZEPAM MECHANISM Modulate neural transmission 36735-22-5 QUAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 36735-22-5 QUAZEPAM INDICATION Insomnia 36735-22-5 QUAZEPAM MODE_CLASS Channel enhancer /opener 111974-69-7 QUETIAPINE ADVERSE_EFFECT XXX_1_Weight Gain 111974-69-7 QUETIAPINE ADVERSE_EFFECT NEU_1_Drowsiness 111974-69-7 QUETIAPINE ADVERSE_EFFECT CVS_1_Tachycardia 111974-69-7 QUETIAPINE ADVERSE_EFFECT NEU_1_Autonomic Instability 111974-69-7 QUETIAPINE ADVERSE_EFFECT END_3_Hypercholesteremia 111974-69-7 QUETIAPINE ADVERSE_EFFECT REP_3_Priapism 111974-69-7 QUETIAPINE KNOWN_TOXICITY Mental Health Disorders 111974-69-7 QUETIAPINE TISSUE_TOXICITY Acute Renal Failure 111974-69-7 QUETIAPINE TA_LEVEL_3 Schizophrenia 111974-69-7 QUETIAPINE MECH_LEVEL_3 5-HT receptor 2A 111974-69-7 QUETIAPINE KNOWN_TOXICITY Cardiovascular Toxicity 111974-69-7 QUETIAPINE THERAPEUTIC_CLASS Antipsychotics 111974-69-7 QUETIAPINE ADVERSE_EFFECT END_3_Hypothyroidism 111974-69-7 QUETIAPINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 111974-69-7 QUETIAPINE ADVERSE_EFFECT XXX_1_Xerostomia 111974-69-7 QUETIAPINE ADVERSE_EFFECT GIS_1_Dyspepsia 111974-69-7 QUETIAPINE ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 111974-69-7 QUETIAPINE ADVERSE_EFFECT XXX_1_Hyperpyrexia 111974-69-7 QUETIAPINE ADVERSE_EFFECT XXX_3_Rhinitis 111974-69-7 QUETIAPINE PRODUCT_CLASS Central Nervous System (CNS) 111974-69-7 QUETIAPINE INDICATION Schizophrenia 111974-69-7 QUETIAPINE KNOWN_TOXICITY Nephrotoxicity 111974-69-7 QUETIAPINE TISSUE_TOXICITY Neuroleptic Malignant Syndrome 111974-69-7 QUETIAPINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 111974-69-7 QUETIAPINE ADVERSE_EFFECT GIS_3_Abdominal Pain 111974-69-7 QUETIAPINE ADVERSE_EFFECT KID_2_Acute Renal Failure 111974-69-7 QUETIAPINE ADVERSE_EFFECT PSY_1_Mental Status Changes 111974-69-7 QUETIAPINE ADVERSE_EFFECT MSK_1_Muscle Rigidity 111974-69-7 QUETIAPINE ADVERSE_EFFECT NEU_3_Seizures 111974-69-7 QUETIAPINE MECHANISM Block neural transmission 111974-69-7 QUETIAPINE TA_LEVEL_1 Central Nervous System (CNS) 111974-69-7 QUETIAPINE TA_LEVEL_2 Anti-psychotic 111974-69-7 QUETIAPINE ADVERSE_EFFECT GIS_1_Constipation 111974-69-7 QUETIAPINE ACTIVITY_CLASS Serotonin antagonist 111974-69-7 QUETIAPINE MESH_LEVEL_1 Heterocyclic Compounds 111974-69-7 QUETIAPINE ADVERSE_EFFECT END_3_Hypertriglyceridemia 111974-69-7 QUETIAPINE ADVERSE_EFFECT NEU_2_Syncope 111974-69-7 QUETIAPINE MODE_CLASS Receptor Ligand Antagonist 111974-69-7 QUETIAPINE ADVERSE_EFFECT XXX_3_Asthenia 111974-69-7 QUETIAPINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 111974-69-7 QUETIAPINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 111974-69-7 QUETIAPINE ADVERSE_EFFECT NEU_1_Dizziness 111974-69-7 QUETIAPINE TISSUE_TOXICITY Cardiac Arrhythmia 111974-69-7 QUETIAPINE ADVERSE_EFFECT PSY_1_Neuroleptic Malignant Syndrome 111974-69-7 QUETIAPINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 111974-69-7 QUETIAPINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 111974-69-7 QUETIAPINE MECHANISM Modulate G-protein coupled signal transduction 111974-69-7 QUETIAPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 111974-69-7 QUETIAPINE MECH_LEVEL_1 Modulate neural transmission 111974-69-7 QUETIAPINE MESH_LEVEL_3 Dibenzothiazepines 111974-69-7 QUETIAPINE ZERO_CLASS N 111974-69-7 QUETIAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 111974-72-2 QUETIAPINE ADVERSE_EFFECT END_3_Hypertriglyceridemia 111974-72-2 QUETIAPINE MESH_LEVEL_1 Heterocyclic Compounds 111974-72-2 QUETIAPINE ACTIVITY_CLASS Serotonin antagonist 111974-72-2 QUETIAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 111974-72-2 QUETIAPINE ZERO_CLASS N 111974-72-2 QUETIAPINE MESH_LEVEL_3 Dibenzothiazepines 111974-72-2 QUETIAPINE MECH_LEVEL_1 Modulate neural transmission 111974-72-2 QUETIAPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 111974-72-2 QUETIAPINE MECHANISM Modulate G-protein coupled signal transduction 111974-72-2 QUETIAPINE ADVERSE_EFFECT SKN_3_Maculopapular Rash 111974-72-2 QUETIAPINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 111974-72-2 QUETIAPINE ADVERSE_EFFECT PSY_1_Neuroleptic Malignant Syndrome 111974-72-2 QUETIAPINE TISSUE_TOXICITY Cardiac Arrhythmia 111974-72-2 QUETIAPINE ADVERSE_EFFECT NEU_1_Dizziness 111974-72-2 QUETIAPINE ADVERSE_EFFECT REP_3_Priapism 111974-72-2 QUETIAPINE INDICATION Schizophrenia 111974-72-2 QUETIAPINE KNOWN_TOXICITY Nephrotoxicity 111974-72-2 QUETIAPINE TISSUE_TOXICITY Neuroleptic Malignant Syndrome 111974-72-2 QUETIAPINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 111974-72-2 QUETIAPINE ADVERSE_EFFECT GIS_3_Abdominal Pain 111974-72-2 QUETIAPINE ADVERSE_EFFECT KID_2_Acute Renal Failure 111974-72-2 QUETIAPINE ADVERSE_EFFECT PSY_1_Mental Status Changes 111974-72-2 QUETIAPINE ADVERSE_EFFECT GIS_1_Constipation 111974-72-2 QUETIAPINE ADVERSE_EFFECT MSK_1_Muscle Rigidity 111974-72-2 QUETIAPINE ADVERSE_EFFECT NEU_3_Seizures 111974-72-2 QUETIAPINE MECHANISM Block neural transmission 111974-72-2 QUETIAPINE TA_LEVEL_1 Central Nervous System (CNS) 111974-72-2 QUETIAPINE TA_LEVEL_2 Anti-psychotic 111974-72-2 QUETIAPINE ADVERSE_EFFECT XXX_1_Xerostomia 111974-72-2 QUETIAPINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 111974-72-2 QUETIAPINE ADVERSE_EFFECT END_3_Hypothyroidism 111974-72-2 QUETIAPINE THERAPEUTIC_CLASS Antipsychotics 111974-72-2 QUETIAPINE MECH_LEVEL_3 5-HT receptor 2A 111974-72-2 QUETIAPINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 111974-72-2 QUETIAPINE TISSUE_TOXICITY Acute Renal Failure 111974-72-2 QUETIAPINE KNOWN_TOXICITY Mental Health Disorders 111974-72-2 QUETIAPINE ADVERSE_EFFECT END_3_Hypercholesteremia 111974-72-2 QUETIAPINE ADVERSE_EFFECT NEU_1_Autonomic Instability 111974-72-2 QUETIAPINE TA_LEVEL_3 Schizophrenia 111974-72-2 QUETIAPINE ADVERSE_EFFECT CVS_1_Tachycardia 111974-72-2 QUETIAPINE ADVERSE_EFFECT NEU_1_Drowsiness 111974-72-2 QUETIAPINE ADVERSE_EFFECT XXX_1_Weight Gain 111974-72-2 QUETIAPINE ADVERSE_EFFECT NEU_2_Syncope 111974-72-2 QUETIAPINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 111974-72-2 QUETIAPINE KNOWN_TOXICITY Cardiovascular Toxicity 111974-72-2 QUETIAPINE ADVERSE_EFFECT XXX_3_Asthenia 111974-72-2 QUETIAPINE MODE_CLASS Receptor Ligand Antagonist 111974-72-2 QUETIAPINE PRODUCT_CLASS Central Nervous System (CNS) 111974-72-2 QUETIAPINE ADVERSE_EFFECT XXX_3_Rhinitis 111974-72-2 QUETIAPINE ADVERSE_EFFECT XXX_1_Hyperpyrexia 111974-72-2 QUETIAPINE ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 111974-72-2 QUETIAPINE ADVERSE_EFFECT GIS_1_Dyspepsia 83-89-6 QUINACRINE PRODUCT_CLASS Anti-infectives 83-89-6 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Edema 83-89-6 QUINACRINE ADVERSE_EFFECT BBM_3_Pancytopenia 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_3_Nightmares 83-89-6 QUINACRINE MECHANISM Block neural transmission 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_2_Anxiety 83-89-6 QUINACRINE ADVERSE_EFFECT NEU_1_Dizziness 83-89-6 QUINACRINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_2_Irritability 83-89-6 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Microdeposits 83-89-6 QUINACRINE ADVERSE_EFFECT IMU_3_Urticaria 83-89-6 QUINACRINE INDICATION Giardiasis 83-89-6 QUINACRINE MECHANISM Inhibit inflammatory response 83-89-6 QUINACRINE MODE_CLASS Channel Blocker 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_3_Nervousness 83-89-6 QUINACRINE ADVERSE_EFFECT NEU_1_Headache 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_3_Confusion 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_3_Euphoria 83-89-6 QUINACRINE ADVERSE_EFFECT GIS_2_Abdominal Pain 83-89-6 QUINACRINE ADVERSE_EFFECT SKN_3_Nail Discoloration 83-89-6 QUINACRINE INDICATION Malaria 83-89-6 QUINACRINE ADVERSE_EFFECT GIS_3_Diarrhea 83-89-6 QUINACRINE MODE_CLASS Enzyme Inhibitor 83-89-6 QUINACRINE INDICATION Cestode Infections 83-89-6 QUINACRINE ADVERSE_EFFECT LIV_3_Hepatitis 83-89-6 QUINACRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83-89-6 QUINACRINE ADVERSE_EFFECT XXX_3_Restlessness 83-89-6 QUINACRINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 83-89-6 QUINACRINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 83-89-6 QUINACRINE ADVERSE_EFFECT GUS_3_Discoloration of Urine 83-89-6 QUINACRINE ADVERSE_EFFECT SKN_3_Skin Discoloration 83-89-6 QUINACRINE THERAPEUTIC_CLASS Antiparasitics 83-89-6 QUINACRINE INDICATION Helminthic Infections 83-89-6 QUINACRINE ADVERSE_EFFECT PSY_3_Aggressiveness 83-89-6 QUINACRINE ADVERSE_EFFECT NEU_3_Seizures 83-89-6 QUINACRINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 83-89-6 QUINACRINE ADVERSE_EFFECT OCU_3_Retinopathy 69-05-6 QUINACRINE MODE_CLASS Enzyme Inhibitor 69-05-6 QUINACRINE ADVERSE_EFFECT GIS_3_Diarrhea 69-05-6 QUINACRINE MECHANISM Block neural transmission 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_2_Anxiety 69-05-6 QUINACRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 69-05-6 QUINACRINE MODE_CLASS Channel Blocker 69-05-6 QUINACRINE ADVERSE_EFFECT LIV_3_Hepatitis 69-05-6 QUINACRINE ADVERSE_EFFECT IMU_3_Urticaria 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_3_Nightmares 69-05-6 QUINACRINE ADVERSE_EFFECT BBM_3_Pancytopenia 69-05-6 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Edema 69-05-6 QUINACRINE PRODUCT_CLASS Anti-infectives 69-05-6 QUINACRINE THERAPEUTIC_CLASS Antiparasitics 69-05-6 QUINACRINE INDICATION Helminthic Infections 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_3_Aggressiveness 69-05-6 QUINACRINE ADVERSE_EFFECT NEU_3_Seizures 69-05-6 QUINACRINE ADVERSE_EFFECT XXX_3_Restlessness 69-05-6 QUINACRINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 69-05-6 QUINACRINE ADVERSE_EFFECT NEU_1_Dizziness 69-05-6 QUINACRINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_2_Irritability 69-05-6 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Microdeposits 69-05-6 QUINACRINE ADVERSE_EFFECT OCU_3_Retinopathy 69-05-6 QUINACRINE INDICATION Giardiasis 69-05-6 QUINACRINE MECHANISM Inhibit inflammatory response 69-05-6 QUINACRINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 69-05-6 QUINACRINE ADVERSE_EFFECT GUS_3_Discoloration of Urine 69-05-6 QUINACRINE ADVERSE_EFFECT SKN_3_Skin Discoloration 69-05-6 QUINACRINE INDICATION Cestode Infections 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_3_Nervousness 69-05-6 QUINACRINE ADVERSE_EFFECT NEU_1_Headache 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_3_Confusion 69-05-6 QUINACRINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 69-05-6 QUINACRINE ADVERSE_EFFECT PSY_3_Euphoria 69-05-6 QUINACRINE ADVERSE_EFFECT GIS_2_Abdominal Pain 69-05-6 QUINACRINE ADVERSE_EFFECT SKN_3_Nail Discoloration 69-05-6 QUINACRINE INDICATION Malaria 133347-98-5 QUINACRINE INDICATION Malaria 133347-98-5 QUINACRINE ADVERSE_EFFECT SKN_3_Nail Discoloration 133347-98-5 QUINACRINE ADVERSE_EFFECT GIS_2_Abdominal Pain 133347-98-5 QUINACRINE ADVERSE_EFFECT IMU_3_Urticaria 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_3_Euphoria 133347-98-5 QUINACRINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_3_Confusion 133347-98-5 QUINACRINE ADVERSE_EFFECT NEU_1_Headache 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_3_Nervousness 133347-98-5 QUINACRINE MODE_CLASS Channel Blocker 133347-98-5 QUINACRINE MECHANISM Inhibit inflammatory response 133347-98-5 QUINACRINE INDICATION Giardiasis 133347-98-5 QUINACRINE ADVERSE_EFFECT OCU_3_Retinopathy 133347-98-5 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Microdeposits 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_2_Irritability 133347-98-5 QUINACRINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 133347-98-5 QUINACRINE ADVERSE_EFFECT NEU_1_Dizziness 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_2_Anxiety 133347-98-5 QUINACRINE MECHANISM Block neural transmission 133347-98-5 QUINACRINE ADVERSE_EFFECT SKN_3_Skin Discoloration 133347-98-5 QUINACRINE ADVERSE_EFFECT GUS_3_Discoloration of Urine 133347-98-5 QUINACRINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 133347-98-5 QUINACRINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 133347-98-5 QUINACRINE ADVERSE_EFFECT XXX_3_Restlessness 133347-98-5 QUINACRINE ADVERSE_EFFECT NEU_3_Seizures 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_3_Aggressiveness 133347-98-5 QUINACRINE INDICATION Helminthic Infections 133347-98-5 QUINACRINE THERAPEUTIC_CLASS Antiparasitics 133347-98-5 QUINACRINE ADVERSE_EFFECT LIV_3_Hepatitis 133347-98-5 QUINACRINE PRODUCT_CLASS Anti-infectives 133347-98-5 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Edema 133347-98-5 QUINACRINE ADVERSE_EFFECT BBM_3_Pancytopenia 133347-98-5 QUINACRINE ADVERSE_EFFECT PSY_3_Nightmares 133347-98-5 QUINACRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 133347-98-5 QUINACRINE INDICATION Cestode Infections 133347-98-5 QUINACRINE MODE_CLASS Enzyme Inhibitor 133347-98-5 QUINACRINE ADVERSE_EFFECT GIS_3_Diarrhea 66777-81-9 QUINACRINE ADVERSE_EFFECT GIS_2_Abdominal Pain 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_3_Euphoria 66777-81-9 QUINACRINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_3_Confusion 66777-81-9 QUINACRINE ADVERSE_EFFECT NEU_1_Headache 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_3_Nervousness 66777-81-9 QUINACRINE MODE_CLASS Channel Blocker 66777-81-9 QUINACRINE MECHANISM Inhibit inflammatory response 66777-81-9 QUINACRINE INDICATION Giardiasis 66777-81-9 QUINACRINE ADVERSE_EFFECT OCU_3_Retinopathy 66777-81-9 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Microdeposits 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_2_Irritability 66777-81-9 QUINACRINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 66777-81-9 QUINACRINE ADVERSE_EFFECT NEU_1_Dizziness 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_2_Anxiety 66777-81-9 QUINACRINE MECHANISM Block neural transmission 66777-81-9 QUINACRINE ADVERSE_EFFECT SKN_3_Skin Discoloration 66777-81-9 QUINACRINE ADVERSE_EFFECT GUS_3_Discoloration of Urine 66777-81-9 QUINACRINE PRODUCT_CLASS Anti-infectives 66777-81-9 QUINACRINE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 66777-81-9 QUINACRINE ADVERSE_EFFECT XXX_3_Restlessness 66777-81-9 QUINACRINE ADVERSE_EFFECT NEU_3_Seizures 66777-81-9 QUINACRINE INDICATION Helminthic Infections 66777-81-9 QUINACRINE THERAPEUTIC_CLASS Antiparasitics 66777-81-9 QUINACRINE ADVERSE_EFFECT OCU_3_Corneal Edema 66777-81-9 QUINACRINE ADVERSE_EFFECT BBM_3_Pancytopenia 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_3_Nightmares 66777-81-9 QUINACRINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 66777-81-9 QUINACRINE ADVERSE_EFFECT LIV_3_Hepatitis 66777-81-9 QUINACRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 66777-81-9 QUINACRINE ADVERSE_EFFECT GIS_3_Diarrhea 66777-81-9 QUINACRINE MODE_CLASS Enzyme Inhibitor 66777-81-9 QUINACRINE INDICATION Cestode Infections 66777-81-9 QUINACRINE ADVERSE_EFFECT PSY_3_Aggressiveness 66777-81-9 QUINACRINE INDICATION Malaria 66777-81-9 QUINACRINE ADVERSE_EFFECT SKN_3_Nail Discoloration 66777-81-9 QUINACRINE ADVERSE_EFFECT IMU_3_Urticaria 85441-61-8 QUINAPRIL ADVERSE_EFFECT XXX_3_Malaise 85441-61-8 QUINAPRIL ADVERSE_EFFECT GIS_2_Abdominal Pain 85441-61-8 QUINAPRIL ADVERSE_EFFECT MSK_3_Arthralgia 85441-61-8 QUINAPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 85441-61-8 QUINAPRIL ADVERSE_EFFECT LUN_2_Cough 85441-61-8 QUINAPRIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 85441-61-8 QUINAPRIL ADVERSE_EFFECT EMB_3_Teratogenicity 85441-61-8 QUINAPRIL TA_LEVEL_2 Hypertension 85441-61-8 QUINAPRIL MECH_LEVEL_1 Vasorelaxation 85441-61-8 QUINAPRIL MECH_LEVEL_2 ACE inhibitor 85441-61-8 QUINAPRIL ADVERSE_EFFECT NEU_2_Headache 85441-61-8 QUINAPRIL TISSUE_TOXICITY Teratogenicity 85441-61-8 QUINAPRIL INDICATION Hypertension 85441-61-8 QUINAPRIL ADVERSE_EFFECT CVS_2_Chest Pain 85441-61-8 QUINAPRIL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 85441-61-8 QUINAPRIL ADVERSE_EFFECT SKN_3_Pruritis 85441-61-8 QUINAPRIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 85441-61-8 QUINAPRIL ADVERSE_EFFECT GIS_2_Diarrhea 85441-61-8 QUINAPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 85441-61-8 QUINAPRIL MESH_LEVEL_1 Heterocyclic Compounds 85441-61-8 QUINAPRIL KNOWN_TOXICITY Nephrotoxicity 85441-61-8 QUINAPRIL KNOWN_TOXICITY Cardiovascular Toxicity 85441-61-8 QUINAPRIL ADVERSE_EFFECT MSK_3_Back Pain 85441-61-8 QUINAPRIL ADVERSE_EFFECT CVS_3_Palpitation 85441-61-8 QUINAPRIL ADVERSE_EFFECT IMU_3_Angioedema 85441-61-8 QUINAPRIL ADVERSE_EFFECT NEU_2_Dizziness 85441-61-8 QUINAPRIL ADVERSE_EFFECT XXX_2_Fatigue 85441-61-8 QUINAPRIL ADVERSE_EFFECT CVS_2_Hypotension 85441-61-8 QUINAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 85441-61-8 QUINAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 85441-61-8 QUINAPRIL MODE_CLASS Enzyme Inhibitor 85441-61-8 QUINAPRIL INDICATION Heart Failure 85441-61-8 QUINAPRIL PRODUCT_CLASS Cardiovasculars 85441-61-8 QUINAPRIL TA_LEVEL_1 Cardiovascular 85441-61-8 QUINAPRIL TA_LEVEL_3 Diuretic 85441-61-8 QUINAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 85441-61-8 QUINAPRIL ACTIVITY_CLASS RAAS inhibitor 85441-61-8 QUINAPRIL ADVERSE_EFFECT NEU_3_Syncope 85441-61-8 QUINAPRIL ADVERSE_EFFECT KID_3_Acute Renal Failure 85441-61-8 QUINAPRIL ADVERSE_EFFECT LUN_3_Dyspnea 85441-61-8 QUINAPRIL ADVERSE_EFFECT SKN_2_Rash 85441-61-8 QUINAPRIL ADVERSE_EFFECT ELT_3_Hyperkalemia 85441-61-8 QUINAPRIL ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 85441-61-8 QUINAPRIL TISSUE_TOXICITY Hypotension 85441-61-8 QUINAPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 85441-61-8 QUINAPRIL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 85441-61-8 QUINAPRIL MESH_LEVEL_3 Isoquinolones 85441-61-8 QUINAPRIL MECHANISM Reduce vasoconstriction 85441-61-8 QUINAPRIL ZERO_CLASS N 85441-61-8 QUINAPRIL TISSUE_TOXICITY Acute Renal Failure 90243-99-5 QUINAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 90243-99-5 QUINAPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 90243-99-5 QUINAPRIL ADVERSE_EFFECT GIS_2_Diarrhea 90243-99-5 QUINAPRIL MECH_LEVEL_2 ACE inhibitor 90243-99-5 QUINAPRIL MESH_LEVEL_1 Heterocyclic Compounds 90243-99-5 QUINAPRIL KNOWN_TOXICITY Nephrotoxicity 90243-99-5 QUINAPRIL KNOWN_TOXICITY Cardiovascular Toxicity 90243-99-5 QUINAPRIL ADVERSE_EFFECT MSK_3_Back Pain 90243-99-5 QUINAPRIL ADVERSE_EFFECT CVS_3_Palpitation 90243-99-5 QUINAPRIL ADVERSE_EFFECT IMU_3_Angioedema 90243-99-5 QUINAPRIL ADVERSE_EFFECT NEU_2_Dizziness 90243-99-5 QUINAPRIL ADVERSE_EFFECT XXX_2_Fatigue 90243-99-5 QUINAPRIL ADVERSE_EFFECT EMB_3_Teratogenicity 90243-99-5 QUINAPRIL ADVERSE_EFFECT CVS_2_Hypotension 90243-99-5 QUINAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 90243-99-5 QUINAPRIL MODE_CLASS Enzyme Inhibitor 90243-99-5 QUINAPRIL INDICATION Heart Failure 90243-99-5 QUINAPRIL PRODUCT_CLASS Cardiovasculars 90243-99-5 QUINAPRIL TA_LEVEL_1 Cardiovascular 90243-99-5 QUINAPRIL TA_LEVEL_3 Diuretic 90243-99-5 QUINAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 90243-99-5 QUINAPRIL ADVERSE_EFFECT NEU_3_Syncope 90243-99-5 QUINAPRIL ADVERSE_EFFECT KID_3_Acute Renal Failure 90243-99-5 QUINAPRIL ADVERSE_EFFECT LUN_3_Dyspnea 90243-99-5 QUINAPRIL ADVERSE_EFFECT SKN_2_Rash 90243-99-5 QUINAPRIL ADVERSE_EFFECT ELT_3_Hyperkalemia 90243-99-5 QUINAPRIL ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 90243-99-5 QUINAPRIL TISSUE_TOXICITY Hypotension 90243-99-5 QUINAPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 90243-99-5 QUINAPRIL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 90243-99-5 QUINAPRIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 90243-99-5 QUINAPRIL MESH_LEVEL_3 Isoquinolones 90243-99-5 QUINAPRIL MECHANISM Reduce vasoconstriction 90243-99-5 QUINAPRIL ZERO_CLASS N 90243-99-5 QUINAPRIL TISSUE_TOXICITY Acute Renal Failure 90243-99-5 QUINAPRIL TA_LEVEL_2 Hypertension 90243-99-5 QUINAPRIL ADVERSE_EFFECT XXX_3_Malaise 90243-99-5 QUINAPRIL ADVERSE_EFFECT MSK_3_Arthralgia 90243-99-5 QUINAPRIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 90243-99-5 QUINAPRIL MECH_LEVEL_1 Vasorelaxation 90243-99-5 QUINAPRIL ADVERSE_EFFECT LUN_2_Cough 90243-99-5 QUINAPRIL ADVERSE_EFFECT GIS_2_Abdominal Pain 90243-99-5 QUINAPRIL ACTIVITY_CLASS RAAS inhibitor 90243-99-5 QUINAPRIL TISSUE_TOXICITY Teratogenicity 90243-99-5 QUINAPRIL INDICATION Hypertension 90243-99-5 QUINAPRIL ADVERSE_EFFECT CVS_2_Chest Pain 90243-99-5 QUINAPRIL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 90243-99-5 QUINAPRIL ADVERSE_EFFECT SKN_3_Pruritis 90243-99-5 QUINAPRIL ADVERSE_EFFECT NEU_2_Headache 90243-99-5 QUINAPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 82768-84-1 QUINAPRIL MESH_LEVEL_1 Heterocyclic Compounds 82768-84-1 QUINAPRIL KNOWN_TOXICITY Nephrotoxicity 82768-84-1 QUINAPRIL KNOWN_TOXICITY Cardiovascular Toxicity 82768-84-1 QUINAPRIL ADVERSE_EFFECT MSK_3_Back Pain 82768-84-1 QUINAPRIL ADVERSE_EFFECT CVS_3_Palpitation 82768-84-1 QUINAPRIL ADVERSE_EFFECT IMU_3_Angioedema 82768-84-1 QUINAPRIL ADVERSE_EFFECT NEU_2_Dizziness 82768-84-1 QUINAPRIL ADVERSE_EFFECT XXX_2_Fatigue 82768-84-1 QUINAPRIL ADVERSE_EFFECT CVS_2_Hypotension 82768-84-1 QUINAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 82768-84-1 QUINAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 82768-84-1 QUINAPRIL TISSUE_TOXICITY Hypotension 82768-84-1 QUINAPRIL INDICATION Heart Failure 82768-84-1 QUINAPRIL PRODUCT_CLASS Cardiovasculars 82768-84-1 QUINAPRIL TA_LEVEL_1 Cardiovascular 82768-84-1 QUINAPRIL TA_LEVEL_3 Diuretic 82768-84-1 QUINAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 82768-84-1 QUINAPRIL ACTIVITY_CLASS RAAS inhibitor 82768-84-1 QUINAPRIL ADVERSE_EFFECT NEU_3_Syncope 82768-84-1 QUINAPRIL ADVERSE_EFFECT KID_3_Acute Renal Failure 82768-84-1 QUINAPRIL ADVERSE_EFFECT LUN_3_Dyspnea 82768-84-1 QUINAPRIL ADVERSE_EFFECT SKN_2_Rash 82768-84-1 QUINAPRIL ADVERSE_EFFECT ELT_3_Hyperkalemia 82768-84-1 QUINAPRIL ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 82768-84-1 QUINAPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 82768-84-1 QUINAPRIL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 82768-84-1 QUINAPRIL MESH_LEVEL_3 Isoquinolones 82768-84-1 QUINAPRIL MECHANISM Reduce vasoconstriction 82768-84-1 QUINAPRIL ZERO_CLASS N 82768-84-1 QUINAPRIL TISSUE_TOXICITY Acute Renal Failure 82768-84-1 QUINAPRIL ADVERSE_EFFECT XXX_3_Malaise 82768-84-1 QUINAPRIL ADVERSE_EFFECT GIS_2_Abdominal Pain 82768-84-1 QUINAPRIL ADVERSE_EFFECT MSK_3_Arthralgia 82768-84-1 QUINAPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 82768-84-1 QUINAPRIL ADVERSE_EFFECT LUN_2_Cough 82768-84-1 QUINAPRIL ADVERSE_EFFECT EMB_3_Teratogenicity 82768-84-1 QUINAPRIL TA_LEVEL_2 Hypertension 82768-84-1 QUINAPRIL MECH_LEVEL_1 Vasorelaxation 82768-84-1 QUINAPRIL MECH_LEVEL_2 ACE inhibitor 82768-84-1 QUINAPRIL MODE_CLASS Enzyme Inhibitor 82768-84-1 QUINAPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 82768-84-1 QUINAPRIL ADVERSE_EFFECT GIS_2_Diarrhea 82768-84-1 QUINAPRIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 82768-84-1 QUINAPRIL ADVERSE_EFFECT NEU_2_Headache 82768-84-1 QUINAPRIL ADVERSE_EFFECT SKN_3_Pruritis 82768-84-1 QUINAPRIL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 82768-84-1 QUINAPRIL ADVERSE_EFFECT CVS_2_Chest Pain 82768-84-1 QUINAPRIL INDICATION Hypertension 82768-84-1 QUINAPRIL TISSUE_TOXICITY Teratogenicity 82768-84-1 QUINAPRIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 82586-55-8 QUINAPRIL TISSUE_TOXICITY Acute Renal Failure 82586-55-8 QUINAPRIL ZERO_CLASS N 82586-55-8 QUINAPRIL MECHANISM Reduce vasoconstriction 82586-55-8 QUINAPRIL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 82586-55-8 QUINAPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 82586-55-8 QUINAPRIL ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 82586-55-8 QUINAPRIL ADVERSE_EFFECT ELT_3_Hyperkalemia 82586-55-8 QUINAPRIL ADVERSE_EFFECT SKN_2_Rash 82586-55-8 QUINAPRIL ADVERSE_EFFECT LUN_3_Dyspnea 82586-55-8 QUINAPRIL ADVERSE_EFFECT KID_3_Acute Renal Failure 82586-55-8 QUINAPRIL ADVERSE_EFFECT NEU_3_Syncope 82586-55-8 QUINAPRIL ACTIVITY_CLASS RAAS inhibitor 82586-55-8 QUINAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 82586-55-8 QUINAPRIL TA_LEVEL_3 Diuretic 82586-55-8 QUINAPRIL TA_LEVEL_1 Cardiovascular 82586-55-8 QUINAPRIL PRODUCT_CLASS Cardiovasculars 82586-55-8 QUINAPRIL INDICATION Heart Failure 82586-55-8 QUINAPRIL MODE_CLASS Enzyme Inhibitor 82586-55-8 QUINAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 82586-55-8 QUINAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 82586-55-8 QUINAPRIL ADVERSE_EFFECT CVS_2_Hypotension 82586-55-8 QUINAPRIL ADVERSE_EFFECT XXX_2_Fatigue 82586-55-8 QUINAPRIL ADVERSE_EFFECT NEU_2_Dizziness 82586-55-8 QUINAPRIL ADVERSE_EFFECT IMU_3_Angioedema 82586-55-8 QUINAPRIL ADVERSE_EFFECT CVS_3_Palpitation 82586-55-8 QUINAPRIL ADVERSE_EFFECT MSK_3_Back Pain 82586-55-8 QUINAPRIL MESH_LEVEL_3 Isoquinolones 82586-55-8 QUINAPRIL KNOWN_TOXICITY Cardiovascular Toxicity 82586-55-8 QUINAPRIL TISSUE_TOXICITY Hypotension 82586-55-8 QUINAPRIL TA_LEVEL_2 Hypertension 82586-55-8 QUINAPRIL ADVERSE_EFFECT EMB_3_Teratogenicity 82586-55-8 QUINAPRIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 82586-55-8 QUINAPRIL ADVERSE_EFFECT LUN_2_Cough 82586-55-8 QUINAPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 82586-55-8 QUINAPRIL ADVERSE_EFFECT MSK_3_Arthralgia 82586-55-8 QUINAPRIL ADVERSE_EFFECT GIS_2_Abdominal Pain 82586-55-8 QUINAPRIL ADVERSE_EFFECT XXX_3_Malaise 82586-55-8 QUINAPRIL MECH_LEVEL_2 ACE inhibitor 82586-55-8 QUINAPRIL MECH_LEVEL_1 Vasorelaxation 82586-55-8 QUINAPRIL TISSUE_TOXICITY Teratogenicity 82586-55-8 QUINAPRIL INDICATION Hypertension 82586-55-8 QUINAPRIL ADVERSE_EFFECT CVS_2_Chest Pain 82586-55-8 QUINAPRIL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 82586-55-8 QUINAPRIL ADVERSE_EFFECT SKN_3_Pruritis 82586-55-8 QUINAPRIL ADVERSE_EFFECT NEU_2_Headache 82586-55-8 QUINAPRIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 82586-55-8 QUINAPRIL ADVERSE_EFFECT GIS_2_Diarrhea 82586-55-8 QUINAPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 82586-55-8 QUINAPRIL MESH_LEVEL_1 Heterocyclic Compounds 82586-55-8 QUINAPRIL KNOWN_TOXICITY Nephrotoxicity 7054-25-3 QUINIDINE THERAPEUTIC_CLASS Antiparasitics 7054-25-3 QUINIDINE PRODUCT_CLASS Anti-infectives 7054-25-3 QUINIDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 7054-25-3 QUINIDINE MECHANISM Block neural transmission 7054-25-3 QUINIDINE MECHANISM interferes with liver P450 enzyme funciton 7054-25-3 QUINIDINE PRODUCT_CLASS Cardiovasculars 7054-25-3 QUINIDINE MODE_CLASS Enzyme Inhibitor, selective 7054-25-3 QUINIDINE INDICATION Cardiac Arrhythmias 7054-25-3 QUINIDINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 7054-25-3 QUINIDINE MODE_CLASS Channel Blocker, Non-selective 7054-25-3 QUINIDINE INDICATION Malaria 56-54-2 QUINIDINE MECHANISM interferes with liver P450 enzyme funciton 56-54-2 QUINIDINE PRODUCT_CLASS Cardiovasculars 56-54-2 QUINIDINE MECHANISM Block neural transmission 56-54-2 QUINIDINE INDICATION Malaria 56-54-2 QUINIDINE MODE_CLASS Channel Blocker, Non-selective 56-54-2 QUINIDINE INDICATION Cardiac Arrhythmias 56-54-2 QUINIDINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 56-54-2 QUINIDINE MODE_CLASS Enzyme Inhibitor, selective 56-54-2 QUINIDINE THERAPEUTIC_CLASS Antiparasitics 56-54-2 QUINIDINE THERAPEUTIC_CLASS Antiarrhythmic Agents 56-54-2 QUINIDINE PRODUCT_CLASS Anti-infectives 804-63-7 QUININE ADVERSE_EFFECT OCU_2_Photophobia 804-63-7 QUININE TISSUE_TOXICITY Angina 804-63-7 QUININE PRODUCT_CLASS Anti-infectives 804-63-7 QUININE ADVERSE_EFFECT OTO_2_Tinnitus 804-63-7 QUININE ADVERSE_EFFECT BBM_3_Anemia 804-63-7 QUININE ADVERSE_EFFECT SKN_2_Macular Rash 804-63-7 QUININE ADVERSE_EFFECT BBM_3_Hypoprothrombinemia 804-63-7 QUININE ADVERSE_EFFECT NEU_2_Syncope 804-63-7 QUININE MECHANISM Block channel gating 804-63-7 QUININE MODE_CLASS Channel Blocker 804-63-7 QUININE ADVERSE_EFFECT CVS_3_Hypotension 804-63-7 QUININE ADVERSE_EFFECT NEU_2_Headache 804-63-7 QUININE ADVERSE_EFFECT PSY_2_Confusion 804-63-7 QUININE ADVERSE_EFFECT SKN_2_Erythema 804-63-7 QUININE ADVERSE_EFFECT GIS_1_Abdominal Pain 804-63-7 QUININE ADVERSE_EFFECT OCU_2_Impaired Night Vision 804-63-7 QUININE KNOWN_TOXICITY Cardiovascular Toxicity 804-63-7 QUININE INDICATION Malaria 804-63-7 QUININE MODE_CLASS Enzyme Inhibitor 804-63-7 QUININE ADVERSE_EFFECT XXX_2_Fever 804-63-7 QUININE ADVERSE_EFFECT END_3_Hypoglycemia 804-63-7 QUININE ADVERSE_EFFECT SKN_2_Pruritis 804-63-7 QUININE ADVERSE_EFFECT IMU_2_Urticaria 804-63-7 QUININE ADVERSE_EFFECT BBM_3_Thrombocytopenia 804-63-7 QUININE ADVERSE_EFFECT BBM_3_Hemolysis 804-63-7 QUININE ADVERSE_EFFECT NEU_3_Optic Atrophy 804-63-7 QUININE ADVERSE_EFFECT OCU_2_Scotomata 804-63-7 QUININE TISSUE_TOXICITY Hypotension 804-63-7 QUININE MECHANISM Inhibit inflammatory response 804-63-7 QUININE ADVERSE_EFFECT CVS_2_Vasculitis 804-63-7 QUININE ADVERSE_EFFECT BBM__Disseminated Intravascular Coagulation (DIC) 804-63-7 QUININE ADVERSE_EFFECT BBM_3_Agranulocytosis 804-63-7 QUININE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 804-63-7 QUININE THERAPEUTIC_CLASS Antiparasitics 804-63-7 QUININE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 804-63-7 QUININE ADVERSE_EFFECT CVS_3_Angina 804-63-7 QUININE ADVERSE_EFFECT OCU_2_Diplopia 804-63-7 QUININE ADVERSE_EFFECT OCU_2_Visual Impairment 804-63-7 QUININE ADVERSE_EFFECT IMU_3_Photosensitivity 804-63-7 QUININE ADVERSE_EFFECT LUN_2_Wheezing 130-95-0 QUININE ADVERSE_EFFECT OCU_2_Impaired Night Vision 130-95-0 QUININE KNOWN_TOXICITY Cardiovascular Toxicity 130-95-0 QUININE INDICATION Malaria 130-95-0 QUININE MODE_CLASS Enzyme Inhibitor 130-95-0 QUININE ADVERSE_EFFECT XXX_2_Fever 130-95-0 QUININE ADVERSE_EFFECT END_3_Hypoglycemia 130-95-0 QUININE ADVERSE_EFFECT SKN_2_Pruritis 130-95-0 QUININE ADVERSE_EFFECT IMU_2_Urticaria 130-95-0 QUININE ADVERSE_EFFECT BBM_3_Thrombocytopenia 130-95-0 QUININE ADVERSE_EFFECT BBM_3_Hemolysis 130-95-0 QUININE ADVERSE_EFFECT NEU_3_Optic Atrophy 130-95-0 QUININE ADVERSE_EFFECT OCU_2_Scotomata 130-95-0 QUININE TISSUE_TOXICITY Hypotension 130-95-0 QUININE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 130-95-0 QUININE MECHANISM Inhibit inflammatory response 130-95-0 QUININE ADVERSE_EFFECT OCU_2_Visual Impairment 130-95-0 QUININE ADVERSE_EFFECT OCU_2_Diplopia 130-95-0 QUININE ADVERSE_EFFECT BBM_3_Agranulocytosis 130-95-0 QUININE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 130-95-0 QUININE THERAPEUTIC_CLASS Antiparasitics 130-95-0 QUININE ADVERSE_EFFECT CVS_3_Angina 130-95-0 QUININE ADVERSE_EFFECT OTO_2_Tinnitus 130-95-0 QUININE ADVERSE_EFFECT IMU_3_Photosensitivity 130-95-0 QUININE MODE_CLASS Channel Blocker 130-95-0 QUININE PRODUCT_CLASS Anti-infectives 130-95-0 QUININE ADVERSE_EFFECT LUN_2_Wheezing 130-95-0 QUININE ADVERSE_EFFECT BBM_3_Anemia 130-95-0 QUININE ADVERSE_EFFECT CVS_3_Hypotension 130-95-0 QUININE ADVERSE_EFFECT OCU_2_Photophobia 130-95-0 QUININE TISSUE_TOXICITY Angina 130-95-0 QUININE ADVERSE_EFFECT NEU_2_Headache 130-95-0 QUININE ADVERSE_EFFECT PSY_2_Confusion 130-95-0 QUININE ADVERSE_EFFECT SKN_2_Erythema 130-95-0 QUININE ADVERSE_EFFECT CVS_2_Vasculitis 130-95-0 QUININE ADVERSE_EFFECT GIS_1_Abdominal Pain 130-95-0 QUININE ADVERSE_EFFECT SKN_2_Macular Rash 130-95-0 QUININE ADVERSE_EFFECT BBM_3_Hypoprothrombinemia 130-95-0 QUININE ADVERSE_EFFECT NEU_2_Syncope 130-95-0 QUININE ADVERSE_EFFECT BBM__Disseminated Intravascular Coagulation (DIC) 130-95-0 QUININE MECHANISM Block channel gating 5786-68-5 QUIPAZINE MODE_CLASS Channel Blocker, selective 5786-68-5 QUIPAZINE MECHANISM Block neural transmission 5786-68-5 QUIPAZINE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 5786-68-5 QUIPAZINE THERAPEUTIC_CLASS Antiemetics 5786-68-5 QUIPAZINE PRODUCT_CLASS Central Nervous System (CNS) 4774-24-7 QUIPAZINE MECHANISM Block neural transmission 4774-24-7 QUIPAZINE MODE_CLASS Channel Blocker, selective 4774-24-7 QUIPAZINE PRODUCT_CLASS Central Nervous System (CNS) 4774-24-7 QUIPAZINE THERAPEUTIC_CLASS Antiemetics 4774-24-7 QUIPAZINE STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 21306-56-9 QX-314 MECHANISM Block neural transmission 21306-56-9 QX-314 PRODUCT_CLASS Biochemicals 21306-56-9 QX-314 MODE_CLASS Channel Blocker 42924-53-8 NABUMETONE STRUCTURE_ACTIVITY NSAID, COX-1, 6-Methoxy-naphthalenyl-acetic acid 42924-53-8 NABUMETONE TISSUE_TOXICITY Fulminant Hepatitis 42924-53-8 NABUMETONE ZERO_CLASS N 42924-53-8 NABUMETONE ADVERSE_EFFECT REP_2_Delayed Parturition 42924-53-8 NABUMETONE ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 42924-53-8 NABUMETONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_1_Abdominal Pain 42924-53-8 NABUMETONE ADVERSE_EFFECT LIV_3_Hepatic Failure 42924-53-8 NABUMETONE ADVERSE_EFFECT IMU_3_Hypersensitivity 42924-53-8 NABUMETONE ADVERSE_EFFECT NEU_2_Dizziness 42924-53-8 NABUMETONE MODE_CLASS Enzyme Inhibitor 42924-53-8 NABUMETONE MESH_LEVEL_2 Ketones 42924-53-8 NABUMETONE PRODUCT_CLASS Anti-inflammatories 42924-53-8 NABUMETONE INDICATION Osteoarthritis 42924-53-8 NABUMETONE MESH_LEVEL_1 Organic Chemicals 42924-53-8 NABUMETONE MESH_LEVEL_3 Butanones 42924-53-8 NABUMETONE TISSUE_TOXICITY Renal Papillary Necrosis 42924-53-8 NABUMETONE TISSUE_TOXICITY Renal Failure 42924-53-8 NABUMETONE ADVERSE_EFFECT BBM_3_Inhibits Platelet Aggregation 42924-53-8 NABUMETONE ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 42924-53-8 NABUMETONE ADVERSE_EFFECT KID_1_Fluid Retention 42924-53-8 NABUMETONE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 42924-53-8 NABUMETONE ADVERSE_EFFECT IMU_2_Photosensitivity 42924-53-8 NABUMETONE ADVERSE_EFFECT SKN_2_Pruritis 42924-53-8 NABUMETONE ADVERSE_EFFECT OTO_2_Tinnitus 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_1_Diarrhea 42924-53-8 NABUMETONE KNOWN_TOXICITY Nephrotoxicity 42924-53-8 NABUMETONE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 42924-53-8 NABUMETONE TA_LEVEL_2 NSAID 42924-53-8 NABUMETONE TA_LEVEL_1 Anti-inflammatory 42924-53-8 NABUMETONE ACTIVITY_CLASS Anti-inflammatory 42924-53-8 NABUMETONE TISSUE_TOXICITY Hepatic Failure 42924-53-8 NABUMETONE TISSUE_TOXICITY Acute Interstitial Nephritis 42924-53-8 NABUMETONE KNOWN_TOXICITY Cardiovascular Toxicity 42924-53-8 NABUMETONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 42924-53-8 NABUMETONE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 42924-53-8 NABUMETONE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_1_Heartburn 42924-53-8 NABUMETONE KNOWN_TOXICITY Hepatotoxicity 42924-53-8 NABUMETONE INDICATION Rheumatoid Arthritis 42924-53-8 NABUMETONE MECH_LEVEL_1 Immunomodulation 42924-53-8 NABUMETONE TA_LEVEL_3 NSAID 42924-53-8 NABUMETONE ADVERSE_EFFECT OCU_2_Blurred Vision 42924-53-8 NABUMETONE ADVERSE_EFFECT LUN_3_Bronchospasm 42924-53-8 NABUMETONE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 42924-53-8 NABUMETONE ADVERSE_EFFECT CVS_3_Cardiac Failure 42924-53-8 NABUMETONE ADVERSE_EFFECT KID_3_Renal Failure 42924-53-8 NABUMETONE ADVERSE_EFFECT NEU_2_Somnolence 42924-53-8 NABUMETONE ADVERSE_EFFECT SKN_2_Skin Rash 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 42924-53-8 NABUMETONE ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 42924-53-8 NABUMETONE TISSUE_TOXICITY Cardiac Failure 42924-53-8 NABUMETONE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 42924-53-8 NABUMETONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 42924-53-8 NABUMETONE MECHANISM Inhibit eicosanoid biosynthesis 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_1_Constipation 42924-53-8 NABUMETONE ADVERSE_EFFECT BBM_3_Agranulocytosis 42924-53-8 NABUMETONE ADVERSE_EFFECT BBM_2_Anemia 42924-53-8 NABUMETONE ADVERSE_EFFECT GIS_3_Peptic Ulceration 42924-53-8 NABUMETONE ADVERSE_EFFECT BBM_3_Pancytopenia 42200-33-9 NADOLOL ADVERSE_EFFECT XXX_3_Xerostomia 42200-33-9 NADOLOL ADVERSE_EFFECT LUN_2_Dyspnea 42200-33-9 NADOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, aryloxypropanoamine 42200-33-9 NADOLOL TA_LEVEL_3 Beta blocker 42200-33-9 NADOLOL TA_LEVEL_1 Cardiovascular 42200-33-9 NADOLOL MECH_LEVEL_2 Beta antagonist 42200-33-9 NADOLOL THERAPEUTIC_CLASS Antianginals 42200-33-9 NADOLOL TISSUE_TOXICITY Hypotension 42200-33-9 NADOLOL ADVERSE_EFFECT XXX_2_Fatigue 42200-33-9 NADOLOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 42200-33-9 NADOLOL ADVERSE_EFFECT NEU_2_Dizziness 42200-33-9 NADOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 42200-33-9 NADOLOL ADVERSE_EFFECT PSY_2_Depression 42200-33-9 NADOLOL THERAPEUTIC_CLASS Antihypertensive Agents 42200-33-9 NADOLOL MECH_LEVEL_1 Vasorelaxation 42200-33-9 NADOLOL ADVERSE_EFFECT CVS_3_Hypotension 42200-33-9 NADOLOL TISSUE_TOXICITY Congestive Heart Failure 42200-33-9 NADOLOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 42200-33-9 NADOLOL MECHANISM Modulate G-protein coupled signal transduction 42200-33-9 NADOLOL ADVERSE_EFFECT LUN_2_Wheezing 42200-33-9 NADOLOL ADVERSE_EFFECT SKN_3_Hyperpigmentation 42200-33-9 NADOLOL MECH_LEVEL_3 adrenoceptor beta, nonselective 42200-33-9 NADOLOL MESH_LEVEL_1 Organic Chemicals 42200-33-9 NADOLOL TISSUE_TOXICITY Atrioventricular Blockade 42200-33-9 NADOLOL KNOWN_TOXICITY Cardiovascular Toxicity 42200-33-9 NADOLOL ADVERSE_EFFECT MSK_2_Musculoskeletal Pain 42200-33-9 NADOLOL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 42200-33-9 NADOLOL ADVERSE_EFFECT LUN_2_Bronchospasm 42200-33-9 NADOLOL ADVERSE_EFFECT CVS_3_Congestive Heart Failure 42200-33-9 NADOLOL INDICATION Angina Pectoris 42200-33-9 NADOLOL TA_LEVEL_2 Hypertension 42200-33-9 NADOLOL MESH_LEVEL_3 Amino Alcohols 42200-33-9 NADOLOL ZERO_CLASS N 42200-33-9 NADOLOL ADVERSE_EFFECT BBM_3_Agranulocytosis 42200-33-9 NADOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 42200-33-9 NADOLOL ADVERSE_EFFECT SKN_2_Pruritis 42200-33-9 NADOLOL ADVERSE_EFFECT CVS_3_Vasoconstriction 42200-33-9 NADOLOL PRODUCT_CLASS Cardiovasculars 42200-33-9 NADOLOL INDICATION Hypertension 42200-33-9 NADOLOL MESH_LEVEL_2 Alcohols 42200-33-9 NADOLOL ACTIVITY_CLASS Adrenergic antagonist 149649-22-9 NAFADOTRIDE PRODUCT_CLASS Biochemicals 149649-22-9 NAFADOTRIDE PRODUCT_CLASS Central Nervous System (CNS) 86220-42-0 NAFARELIN MODE_CLASS Receptor Agonist 86220-42-0 NAFARELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 76932-56-4 NAFARELIN MODE_CLASS Receptor Agonist 76932-56-4 NAFARELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 76932-60-0 NAFARELIN MODE_CLASS Receptor Agonist 76932-60-0 NAFARELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 78115-72-7 NAFARELIN MODE_CLASS Receptor Agonist 78115-72-7 NAFARELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 147-52-4 NAFCILLIN THERAPEUTIC_CLASS Antibacterials 147-52-4 NAFCILLIN MODE_CLASS Enzyme Inhibitor 147-52-4 NAFCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 147-52-4 NAFCILLIN PRODUCT_CLASS Anti-infectives 985-16-0 NAFCILLIN PRODUCT_CLASS Anti-infectives 985-16-0 NAFCILLIN THERAPEUTIC_CLASS Antibacterials 985-16-0 NAFCILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 985-16-0 NAFCILLIN MODE_CLASS Enzyme Inhibitor 65472-88-0 NAFTIFINE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 65472-88-0 NAFTIFINE MODE_CLASS Enzyme Inhibitor 57149-07-2 NAFTOPIDIL PRODUCT_CLASS Cardiovasculars 57149-07-2 NAFTOPIDIL THERAPEUTIC_CLASS Antihypertensive Agents 57149-07-2 NAFTOPIDIL MECHANISM Reduce vasoconstriction 57149-07-2 NAFTOPIDIL INDICATION Hypertension 57149-07-2 NAFTOPIDIL THERAPEUTIC_CLASS Vasodilators 57149-07-2 NAFTOPIDIL MODE_CLASS Receptor Ligand Antagonist 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Vivid Dreams 23277-43-2 NALBUPHINE THERAPEUTIC_CLASS Analgesics, Opioid 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Depression 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Nervousness 23277-43-2 NALBUPHINE ADVERSE_EFFECT LUN_2_Asthma 23277-43-2 NALBUPHINE ADVERSE_EFFECT NEU_1_Drowsiness 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Confusion 23277-43-2 NALBUPHINE KNOWN_TOXICITY Cardiovascular Toxicity 23277-43-2 NALBUPHINE INDICATION Induction / Maintenance of Anesthesia 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Euphoria 23277-43-2 NALBUPHINE ADVERSE_EFFECT XXX_1_Xerostomia 23277-43-2 NALBUPHINE ADVERSE_EFFECT GUS_2_Urinary Urgency 23277-43-2 NALBUPHINE ADVERSE_EFFECT OCU_2_Blurred Vision 23277-43-2 NALBUPHINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 23277-43-2 NALBUPHINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 23277-43-2 NALBUPHINE ADVERSE_EFFECT NEU_1_Dizziness 23277-43-2 NALBUPHINE ADVERSE_EFFECT XXX_3_Withdrawal 23277-43-2 NALBUPHINE MECHANISM Modulate neural transmission 23277-43-2 NALBUPHINE INDICATION Severe Pain 23277-43-2 NALBUPHINE PRODUCT_CLASS Analgesics 23277-43-2 NALBUPHINE ADVERSE_EFFECT LUN_2_Dyspnea 23277-43-2 NALBUPHINE ADVERSE_EFFECT CVS_3_Palpitation 23277-43-2 NALBUPHINE ADVERSE_EFFECT NEU_3_Syncope 23277-43-2 NALBUPHINE ADVERSE_EFFECT GIS_2_Bitter Taste 23277-43-2 NALBUPHINE ADVERSE_EFFECT LUN_2_Respiratory Depression 23277-43-2 NALBUPHINE ADVERSE_EFFECT CVS_3_Hypertension 23277-43-2 NALBUPHINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 23277-43-2 NALBUPHINE ADVERSE_EFFECT NEU_1_Headache 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Dependence 23277-43-2 NALBUPHINE ADVERSE_EFFECT SKN_2_Flushing 23277-43-2 NALBUPHINE INDICATION Moderate Pain 23277-43-2 NALBUPHINE INDICATION Headache 23277-43-2 NALBUPHINE TISSUE_TOXICITY Hypotension 23277-43-2 NALBUPHINE ADVERSE_EFFECT IMU_3_Urticaria 23277-43-2 NALBUPHINE ADVERSE_EFFECT PSY_3_Hostility 23277-43-2 NALBUPHINE ADVERSE_EFFECT GIS_2_Abdominal Cramps 23277-43-2 NALBUPHINE ADVERSE_EFFECT XXX_3_Burning Sensation 23277-43-2 NALBUPHINE ADVERSE_EFFECT OCU_1_Miosis 23277-43-2 NALBUPHINE ADVERSE_EFFECT CVS_3_Hypotension 23277-43-2 NALBUPHINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 23277-43-2 NALBUPHINE ADVERSE_EFFECT SKN_3_Pruritis 23277-43-2 NALBUPHINE STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 23277-43-2 NALBUPHINE INDICATION Premedication in Anesthetia 23277-43-2 NALBUPHINE INDICATION Migraine Headache 23277-43-2 NALBUPHINE MODE_CLASS Receptor Partial Agonist 23277-43-2 NALBUPHINE ADVERSE_EFFECT NEU_1_Vertigo 23277-43-2 NALBUPHINE ADVERSE_EFFECT GIS_2_Dyspepsia 20594-83-6 NALBUPHINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 20594-83-6 NALBUPHINE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 20594-83-6 NALBUPHINE ADVERSE_EFFECT OCU_2_Blurred Vision 20594-83-6 NALBUPHINE ADVERSE_EFFECT GUS_2_Urinary Urgency 20594-83-6 NALBUPHINE ADVERSE_EFFECT XXX_1_Xerostomia 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Euphoria 20594-83-6 NALBUPHINE INDICATION Induction / Maintenance of Anesthesia 20594-83-6 NALBUPHINE KNOWN_TOXICITY Cardiovascular Toxicity 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Confusion 20594-83-6 NALBUPHINE ADVERSE_EFFECT NEU_1_Drowsiness 20594-83-6 NALBUPHINE ADVERSE_EFFECT LUN_2_Asthma 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Nervousness 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Depression 20594-83-6 NALBUPHINE THERAPEUTIC_CLASS Analgesics, Opioid 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Vivid Dreams 20594-83-6 NALBUPHINE ADVERSE_EFFECT GIS_2_Dyspepsia 20594-83-6 NALBUPHINE ADVERSE_EFFECT NEU_1_Vertigo 20594-83-6 NALBUPHINE MODE_CLASS Receptor Partial Agonist 20594-83-6 NALBUPHINE ADVERSE_EFFECT LUN_2_Respiratory Depression 20594-83-6 NALBUPHINE ADVERSE_EFFECT CVS_3_Hypertension 20594-83-6 NALBUPHINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 20594-83-6 NALBUPHINE ADVERSE_EFFECT NEU_1_Headache 20594-83-6 NALBUPHINE ADVERSE_EFFECT XXX_3_Burning Sensation 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Dependence 20594-83-6 NALBUPHINE INDICATION Migraine Headache 20594-83-6 NALBUPHINE ADVERSE_EFFECT NEU_1_Dizziness 20594-83-6 NALBUPHINE INDICATION Premedication in Anesthetia 20594-83-6 NALBUPHINE STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 20594-83-6 NALBUPHINE ADVERSE_EFFECT SKN_3_Pruritis 20594-83-6 NALBUPHINE ADVERSE_EFFECT SKN_2_Flushing 20594-83-6 NALBUPHINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 20594-83-6 NALBUPHINE ADVERSE_EFFECT CVS_3_Hypotension 20594-83-6 NALBUPHINE ADVERSE_EFFECT OCU_1_Miosis 20594-83-6 NALBUPHINE ADVERSE_EFFECT GIS_2_Abdominal Cramps 20594-83-6 NALBUPHINE ADVERSE_EFFECT PSY_3_Hostility 20594-83-6 NALBUPHINE ADVERSE_EFFECT IMU_3_Urticaria 20594-83-6 NALBUPHINE TISSUE_TOXICITY Hypotension 20594-83-6 NALBUPHINE INDICATION Headache 20594-83-6 NALBUPHINE INDICATION Moderate Pain 20594-83-6 NALBUPHINE ADVERSE_EFFECT XXX_3_Withdrawal 20594-83-6 NALBUPHINE MECHANISM Modulate neural transmission 20594-83-6 NALBUPHINE INDICATION Severe Pain 20594-83-6 NALBUPHINE PRODUCT_CLASS Analgesics 20594-83-6 NALBUPHINE ADVERSE_EFFECT LUN_2_Dyspnea 20594-83-6 NALBUPHINE ADVERSE_EFFECT CVS_3_Palpitation 20594-83-6 NALBUPHINE ADVERSE_EFFECT NEU_3_Syncope 20594-83-6 NALBUPHINE ADVERSE_EFFECT GIS_2_Bitter Taste 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT MSK_3_Arthralgia 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT IMU_3_Allergic Reactions 389-08-2 NALIDIXIC ACID INDICATION Urinary Tract Infection (UTI) 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT PSY_3_Toxic Psychosis 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT NEU_3_Vertigo 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT SKN_3_Pruritis 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT SKN_1_Rash 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT XXX_3_Weakness 389-08-2 NALIDIXIC ACID PRODUCT_CLASS Anti-infectives 389-08-2 NALIDIXIC ACID MECHANISM Inhibit DNA synthesis, repair, and function 389-08-2 NALIDIXIC ACID THERAPEUTIC_CLASS Antibacterials, Systemic 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT IMU_2_Photosensitivity 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT IMU_3_Angioedema 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT NEU_1_Drowsiness 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT NEU_1_Headache 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT NEU_3_Convulsions 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT OCU_2_Visual Impairment 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 389-08-2 NALIDIXIC ACID MODE_CLASS Enzyme Inhibitor 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT NEU_1_Dizziness 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT LIV_3_Jaundice 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 389-08-2 NALIDIXIC ACID STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 389-08-2 NALIDIXIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 55096-26-9 NALMEFENE MECHANISM Modulate neural transmission 55096-26-9 NALMEFENE STRUCTURE_ACTIVITY Opioid receptor antagonist 55096-26-9 NALMEFENE MODE_CLASS Receptor Ligand Antagonist 82824-01-9 NALOXONAZINE STRUCTURE_ACTIVITY Opioid receptor antagonist 82824-01-9 NALOXONAZINE THERAPEUTIC_CLASS Opiate Antagonists 82824-01-9 NALOXONAZINE MECHANISM Modulate neural transmission 82824-01-9 NALOXONAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 82824-01-9 NALOXONAZINE PRODUCT_CLASS Central Nervous System (CNS) 357-08-4 NALOXONE MECH_LEVEL_2 Opiate antagonist 357-08-4 NALOXONE PRODUCT_CLASS Central Nervous System (CNS) 357-08-4 NALOXONE MECH_LEVEL_1 Modulate neural transmission 357-08-4 NALOXONE MODE_CLASS Receptor Ligand Antagonist 357-08-4 NALOXONE ADVERSE_EFFECT CVS_3_Hypotension 357-08-4 NALOXONE ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 357-08-4 NALOXONE MESH_LEVEL_3 Opium 357-08-4 NALOXONE KNOWN_TOXICITY Cardiovascular Toxicity 357-08-4 NALOXONE TISSUE_TOXICITY Hypotension 357-08-4 NALOXONE MESH_LEVEL_2 Alkaloids 357-08-4 NALOXONE THERAPEUTIC_CLASS Opiate Antagonists 357-08-4 NALOXONE TISSUE_TOXICITY Ventricular Fibrillation 357-08-4 NALOXONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 357-08-4 NALOXONE TA_LEVEL_3 hypotension, coma 357-08-4 NALOXONE TISSUE_TOXICITY Ventricular Tachycardia 357-08-4 NALOXONE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 357-08-4 NALOXONE ZERO_CLASS N 357-08-4 NALOXONE INDICATION Opiate Agonist Dependence 357-08-4 NALOXONE INDICATION Opiate Agonist-induced Respiratory Depression 357-08-4 NALOXONE TA_LEVEL_1 Central Nervous System (CNS) 357-08-4 NALOXONE INDICATION Pruritus / Itching 357-08-4 NALOXONE MECH_LEVEL_3 opioid receptor delta 357-08-4 NALOXONE MESH_LEVEL_1 Heterocyclic Compounds 357-08-4 NALOXONE INDICATION Coma 357-08-4 NALOXONE INDICATION Hypotension 357-08-4 NALOXONE MECHANISM Modulate neural transmission 357-08-4 NALOXONE ADVERSE_EFFECT CVS_3_Hypertension 357-08-4 NALOXONE ACTIVITY_CLASS Opioid receptor antagonist 357-08-4 NALOXONE STRUCTURE_ACTIVITY Opioid receptor antagonist 465-65-6 NALOXONE ZERO_CLASS N 465-65-6 NALOXONE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 465-65-6 NALOXONE KNOWN_TOXICITY Cardiovascular Toxicity 465-65-6 NALOXONE TISSUE_TOXICITY Ventricular Tachycardia 465-65-6 NALOXONE THERAPEUTIC_CLASS Opiate Antagonists 465-65-6 NALOXONE INDICATION Coma 465-65-6 NALOXONE INDICATION Pruritus / Itching 465-65-6 NALOXONE TA_LEVEL_1 Central Nervous System (CNS) 465-65-6 NALOXONE TA_LEVEL_3 hypotension, coma 465-65-6 NALOXONE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 465-65-6 NALOXONE TISSUE_TOXICITY Ventricular Fibrillation 465-65-6 NALOXONE MESH_LEVEL_2 Alkaloids 465-65-6 NALOXONE INDICATION Opiate Agonist Dependence 465-65-6 NALOXONE MESH_LEVEL_3 Opium 465-65-6 NALOXONE ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 465-65-6 NALOXONE ADVERSE_EFFECT CVS_3_Hypotension 465-65-6 NALOXONE MODE_CLASS Receptor Ligand Antagonist 465-65-6 NALOXONE MECH_LEVEL_1 Modulate neural transmission 465-65-6 NALOXONE MESH_LEVEL_1 Heterocyclic Compounds 465-65-6 NALOXONE INDICATION Hypotension 465-65-6 NALOXONE MECHANISM Modulate neural transmission 465-65-6 NALOXONE ADVERSE_EFFECT CVS_3_Hypertension 465-65-6 NALOXONE ACTIVITY_CLASS Opioid receptor antagonist 465-65-6 NALOXONE PRODUCT_CLASS Central Nervous System (CNS) 465-65-6 NALOXONE STRUCTURE_ACTIVITY Opioid receptor antagonist 465-65-6 NALOXONE MECH_LEVEL_2 Opiate antagonist 465-65-6 NALOXONE MECH_LEVEL_3 opioid receptor delta 465-65-6 NALOXONE INDICATION Opiate Agonist-induced Respiratory Depression 465-65-6 NALOXONE TISSUE_TOXICITY Hypotension 16676-29-2 NALTREXONE INDICATION Opiate Agonist Dependence 16676-29-2 NALTREXONE THERAPEUTIC_CLASS Opiate Antagonists 16676-29-2 NALTREXONE ADVERSE_EFFECT GIS_1_Abdominal Pain 16676-29-2 NALTREXONE ADVERSE_EFFECT END_3_Hot Flashes 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_3_Anorexia 16676-29-2 NALTREXONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 16676-29-2 NALTREXONE ADVERSE_EFFECT CVS_3_Instability of Blood Pressure 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_3_Agitation 16676-29-2 NALTREXONE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 16676-29-2 NALTREXONE ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 16676-29-2 NALTREXONE ADVERSE_EFFECT CVS_3_Palpitation 16676-29-2 NALTREXONE ADVERSE_EFFECT OCU_3_Abnormal Vision 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_2_Nervousness 16676-29-2 NALTREXONE ADVERSE_EFFECT NEU_3_Tremor 16676-29-2 NALTREXONE ADVERSE_EFFECT NEU_2_Dizziness 16676-29-2 NALTREXONE ADVERSE_EFFECT XXX_1_Lethargy 16676-29-2 NALTREXONE ADVERSE_EFFECT MSK_1_Arthralgia 16676-29-2 NALTREXONE STRUCTURE_ACTIVITY Opioid receptor antagonist 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_3_Confusion 16676-29-2 NALTREXONE INDICATION Alcohol Dependency and Abuse / Alcoholism 16676-29-2 NALTREXONE PRODUCT_CLASS Central Nervous System (CNS) 16676-29-2 NALTREXONE MODE_CLASS Receptor Ligand Antagonist, Non-selective 16676-29-2 NALTREXONE ADVERSE_EFFECT NEU_3_Hyperkinesia 16676-29-2 NALTREXONE ADVERSE_EFFECT NEU_2_Somnolence 16676-29-2 NALTREXONE ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 16676-29-2 NALTREXONE ADVERSE_EFFECT GIS_3_Diarrhea 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_2_Anxiety 16676-29-2 NALTREXONE ADVERSE_EFFECT NEU_1_Headache 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_3_Euphoria 16676-29-2 NALTREXONE INDICATION Pruritus / Itching 16676-29-2 NALTREXONE MECHANISM Modulate neural transmission 16676-29-2 NALTREXONE ADVERSE_EFFECT MSK_1_Myalgia 16676-29-2 NALTREXONE ADVERSE_EFFECT CVS_3_Chest Pain 16676-29-2 NALTREXONE ADVERSE_EFFECT XXX_3_Diaphoresis 16676-29-2 NALTREXONE ADVERSE_EFFECT PSY_2_Insomnia 16676-29-2 NALTREXONE ADVERSE_EFFECT XXX_3_Fatigue 16676-29-2 NALTREXONE ADVERSE_EFFECT LIV_1_Hepatitis 16676-29-2 NALTREXONE ADVERSE_EFFECT LUN_3_Dyspnea 16590-41-3 NALTREXONE ADVERSE_EFFECT XXX_3_Fatigue 16590-41-3 NALTREXONE THERAPEUTIC_CLASS Opiate Antagonists 16590-41-3 NALTREXONE INDICATION Opiate Agonist Dependence 16590-41-3 NALTREXONE ADVERSE_EFFECT LUN_3_Dyspnea 16590-41-3 NALTREXONE ADVERSE_EFFECT LIV_1_Hepatitis 16590-41-3 NALTREXONE INDICATION Pruritus / Itching 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_2_Insomnia 16590-41-3 NALTREXONE ADVERSE_EFFECT XXX_3_Diaphoresis 16590-41-3 NALTREXONE ADVERSE_EFFECT MSK_1_Myalgia 16590-41-3 NALTREXONE MECHANISM Modulate neural transmission 16590-41-3 NALTREXONE STRUCTURE_ACTIVITY Opioid receptor antagonist 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_3_Euphoria 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_3_Confusion 16590-41-3 NALTREXONE ADVERSE_EFFECT NEU_1_Headache 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_2_Anxiety 16590-41-3 NALTREXONE ADVERSE_EFFECT GIS_3_Diarrhea 16590-41-3 NALTREXONE ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 16590-41-3 NALTREXONE ADVERSE_EFFECT CVS_3_Instability of Blood Pressure 16590-41-3 NALTREXONE INDICATION Alcohol Dependency and Abuse / Alcoholism 16590-41-3 NALTREXONE PRODUCT_CLASS Central Nervous System (CNS) 16590-41-3 NALTREXONE ADVERSE_EFFECT CVS_3_Chest Pain 16590-41-3 NALTREXONE ADVERSE_EFFECT NEU_2_Somnolence 16590-41-3 NALTREXONE ADVERSE_EFFECT NEU_3_Hyperkinesia 16590-41-3 NALTREXONE MODE_CLASS Receptor Ligand Antagonist, Non-selective 16590-41-3 NALTREXONE ADVERSE_EFFECT GIS_1_Abdominal Pain 16590-41-3 NALTREXONE ADVERSE_EFFECT END_3_Hot Flashes 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_3_Anorexia 16590-41-3 NALTREXONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_3_Agitation 16590-41-3 NALTREXONE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 16590-41-3 NALTREXONE ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 16590-41-3 NALTREXONE ADVERSE_EFFECT CVS_3_Palpitation 16590-41-3 NALTREXONE ADVERSE_EFFECT OCU_3_Abnormal Vision 16590-41-3 NALTREXONE ADVERSE_EFFECT PSY_2_Nervousness 16590-41-3 NALTREXONE ADVERSE_EFFECT NEU_3_Tremor 16590-41-3 NALTREXONE ADVERSE_EFFECT NEU_2_Dizziness 16590-41-3 NALTREXONE ADVERSE_EFFECT XXX_1_Lethargy 16590-41-3 NALTREXONE ADVERSE_EFFECT MSK_1_Arthralgia 111469-81-9 NALTRINDOLE PRODUCT_CLASS Central Nervous System (CNS) 111469-81-9 NALTRINDOLE MODE_CLASS Receptor Ligand Antagonist 111469-81-9 NALTRINDOLE MECHANISM Modulate neural transmission 111469-81-9 NALTRINDOLE STRUCTURE_ACTIVITY Opioid receptor antagonist 111469-81-9 NALTRINDOLE PRODUCT_CLASS Biochemicals 434-22-0 NANDROLONE TISSUE_TOXICITY Hepatoma 434-22-0 NANDROLONE THERAPEUTIC_CLASS Gonadal Hormones 434-22-0 NANDROLONE ADVERSE_EFFECT PSY_2_Insomnia 434-22-0 NANDROLONE ADVERSE_EFFECT XXX_2_Edema 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Testicular Atrophy 434-22-0 NANDROLONE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 434-22-0 NANDROLONE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 434-22-0 NANDROLONE ADVERSE_EFFECT LUN_2_Hoarseness 434-22-0 NANDROLONE ADVERSE_EFFECT DNA_3_Hepatoma 434-22-0 NANDROLONE ADVERSE_EFFECT PSY_2_Depression 434-22-0 NANDROLONE ADVERSE_EFFECT END_2_Hirsutism 434-22-0 NANDROLONE ADVERSE_EFFECT LIV_3_Hepatitis 434-22-0 NANDROLONE ADVERSE_EFFECT XXX_2_Weight Gain 434-22-0 NANDROLONE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 434-22-0 NANDROLONE ADVERSE_EFFECT END_2_Virilization 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Altered Libido 434-22-0 NANDROLONE ADVERSE_EFFECT XXX_2_Mastalgia 434-22-0 NANDROLONE STRUCTURE_ACTIVITY Androgen receptor agonist 434-22-0 NANDROLONE PRODUCT_CLASS Hematologics 434-22-0 NANDROLONE MODE_CLASS Receptor Agonist 434-22-0 NANDROLONE KNOWN_TOXICITY Embryo/Fetal Toxicity 434-22-0 NANDROLONE ADVERSE_EFFECT GIS_2_Diarrhea 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Impotence 434-22-0 NANDROLONE ADVERSE_EFFECT END_2_Gynecomastia 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Amenorrhea 434-22-0 NANDROLONE MECHANISM Modulate gene transcription 434-22-0 NANDROLONE ADVERSE_EFFECT LIV_3_Jaundice 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Priapism 434-22-0 NANDROLONE ADVERSE_EFFECT SKN_2_Acne 434-22-0 NANDROLONE ADVERSE_EFFECT GUS_3_Prostatic Hypertrophy 434-22-0 NANDROLONE KNOWN_TOXICITY Carcinogenicity 434-22-0 NANDROLONE TISSUE_TOXICITY Hepatic Necrosis 434-22-0 NANDROLONE TISSUE_TOXICITY Teratogenicity 434-22-0 NANDROLONE ADVERSE_EFFECT EMB_2_Teratogenicity 434-22-0 NANDROLONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 434-22-0 NANDROLONE ADVERSE_EFFECT ELT_2_Hypercalcemia 434-22-0 NANDROLONE ADVERSE_EFFECT XXX_2_Peripheral Edema 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Menstrual Irregularities 434-22-0 NANDROLONE ADVERSE_EFFECT LIV_3_Hepatic Failure 434-22-0 NANDROLONE ADVERSE_EFFECT PSY_2_Excitement 434-22-0 NANDROLONE ADVERSE_EFFECT XXX_2_Feminization 434-22-0 NANDROLONE ADVERSE_EFFECT REP_2_Oligomenorrhea 434-22-0 NANDROLONE KNOWN_TOXICITY Hepatotoxicity 434-22-0 NANDROLONE TISSUE_TOXICITY Hepatic Failure 434-22-0 NANDROLONE INDICATION Anemia of Chronic Disease 550-99-2 NAPHAZOLINE INDICATION Nasal Congestion 550-99-2 NAPHAZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 550-99-2 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Sneezing 550-99-2 NAPHAZOLINE MECHANISM Modulate G-protein coupled signal transduction 550-99-2 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Nasal Dryness 550-99-2 NAPHAZOLINE ADVERSE_EFFECT OCU_2_Blurred Vision 550-99-2 NAPHAZOLINE INDICATION Viral Conjunctivitis 550-99-2 NAPHAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 550-99-2 NAPHAZOLINE INDICATION Vasomotor Rhinitis 550-99-2 NAPHAZOLINE INDICATION Vernal Keratoconjunctivitis 550-99-2 NAPHAZOLINE ADVERSE_EFFECT XXX_2_Nasal Congestion 550-99-2 NAPHAZOLINE INDICATION Allergic Conjunctivitis 550-99-2 NAPHAZOLINE INDICATION Sinusitis 550-99-2 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Stinging Sensation 550-99-2 NAPHAZOLINE MODE_CLASS Receptor Agonist 550-99-2 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Burning Sensation 835-31-4 NAPHAZOLINE INDICATION Allergic Conjunctivitis 835-31-4 NAPHAZOLINE INDICATION Viral Conjunctivitis 835-31-4 NAPHAZOLINE INDICATION Sinusitis 835-31-4 NAPHAZOLINE ADVERSE_EFFECT XXX_2_Nasal Congestion 835-31-4 NAPHAZOLINE INDICATION Nasal Congestion 835-31-4 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Sneezing 835-31-4 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Nasal Dryness 835-31-4 NAPHAZOLINE MECHANISM Modulate G-protein coupled signal transduction 835-31-4 NAPHAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 835-31-4 NAPHAZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 835-31-4 NAPHAZOLINE INDICATION Vasomotor Rhinitis 835-31-4 NAPHAZOLINE ADVERSE_EFFECT OCU_2_Blurred Vision 835-31-4 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Stinging Sensation 835-31-4 NAPHAZOLINE INDICATION Vernal Keratoconjunctivitis 835-31-4 NAPHAZOLINE MODE_CLASS Receptor Agonist 835-31-4 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Burning Sensation 35412-62-5 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Burning Sensation 35412-62-5 NAPHAZOLINE INDICATION Allergic Conjunctivitis 35412-62-5 NAPHAZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 35412-62-5 NAPHAZOLINE INDICATION Viral Conjunctivitis 35412-62-5 NAPHAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 35412-62-5 NAPHAZOLINE INDICATION Vasomotor Rhinitis 35412-62-5 NAPHAZOLINE MODE_CLASS Receptor Agonist 35412-62-5 NAPHAZOLINE INDICATION Vernal Keratoconjunctivitis 35412-62-5 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Stinging Sensation 35412-62-5 NAPHAZOLINE ADVERSE_EFFECT OCU_2_Blurred Vision 35412-62-5 NAPHAZOLINE MECHANISM Modulate G-protein coupled signal transduction 35412-62-5 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Nasal Dryness 35412-62-5 NAPHAZOLINE ADVERSE_EFFECT XXX_1_Sneezing 35412-62-5 NAPHAZOLINE INDICATION Sinusitis 35412-62-5 NAPHAZOLINE INDICATION Nasal Congestion 35412-62-5 NAPHAZOLINE ADVERSE_EFFECT XXX_2_Nasal Congestion 22204-53-1 NAPROXEN ADVERSE_EFFECT KID_3_Acute Renal Failure 22204-53-1 NAPROXEN TISSUE_TOXICITY Acute Interstitial Nephritis 22204-53-1 NAPROXEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 22204-53-1 NAPROXEN ADVERSE_EFFECT SKN_1_Pruritis 22204-53-1 NAPROXEN ADVERSE_EFFECT OTO_2_Tinnitus 22204-53-1 NAPROXEN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 22204-53-1 NAPROXEN PRODUCT_CLASS Analgesics 22204-53-1 NAPROXEN INDICATION Dysmenorrhea 22204-53-1 NAPROXEN INDICATION Still's Disease / Juvenile Chronic Arthritis 22204-53-1 NAPROXEN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 22204-53-1 NAPROXEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 22204-53-1 NAPROXEN STRUCTURE_ACTIVITY NSAID, COX-1, 6-Methoxy-naphthalenyl-acetic acid 22204-53-1 NAPROXEN KNOWN_TOXICITY Nephrotoxicity 22204-53-1 NAPROXEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 22204-53-1 NAPROXEN ADVERSE_EFFECT IMU_2_Allergic Reactions 22204-53-1 NAPROXEN ADVERSE_EFFECT NEU_1_Headache 22204-53-1 NAPROXEN ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 22204-53-1 NAPROXEN ADVERSE_EFFECT GIS_3_Ulcer Perforation 22204-53-1 NAPROXEN ADVERSE_EFFECT CVS_2_Vasculitis 22204-53-1 NAPROXEN TISSUE_TOXICITY Acute Renal Failure 22204-53-1 NAPROXEN MODE_CLASS Enzyme Inhibitor 22204-53-1 NAPROXEN INDICATION Bursitis 22204-53-1 NAPROXEN INDICATION Rheumatoid Arthritis 22204-53-1 NAPROXEN MECHANISM Inhibit eicosanoid biosynthesis 22204-53-1 NAPROXEN TA_LEVEL_3 NSAID 22204-53-1 NAPROXEN ACTIVITY_CLASS Anti-inflammatory 22204-53-1 NAPROXEN KNOWN_TOXICITY Cardiovascular Toxicity 22204-53-1 NAPROXEN ADVERSE_EFFECT LUN_1_Dyspnea 22204-53-1 NAPROXEN ADVERSE_EFFECT BBM_3_Agranulocytosis 22204-53-1 NAPROXEN ADVERSE_EFFECT NEU_1_Dizziness 22204-53-1 NAPROXEN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 22204-53-1 NAPROXEN ADVERSE_EFFECT GIS_1_Abdominal Pain 22204-53-1 NAPROXEN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 22204-53-1 NAPROXEN TISSUE_TOXICITY Renal Papillary Necrosis 22204-53-1 NAPROXEN TISSUE_TOXICITY Congestive Heart Failure 22204-53-1 NAPROXEN INDICATION Tendonitis 22204-53-1 NAPROXEN INDICATION Acute Gouty Arthritis 22204-53-1 NAPROXEN INDICATION Osteoarthritis 22204-53-1 NAPROXEN MECH_LEVEL_1 Immunomodulation 22204-53-1 NAPROXEN MESH_LEVEL_1 Polycyclic Hydrocarbons 22204-53-1 NAPROXEN MESH_LEVEL_3 Naphthalenes 22204-53-1 NAPROXEN ZERO_CLASS N 22204-53-1 NAPROXEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 22204-53-1 NAPROXEN ADVERSE_EFFECT NEU_1_Drowsiness 22204-53-1 NAPROXEN ADVERSE_EFFECT XXX_1_Edema 22204-53-1 NAPROXEN ADVERSE_EFFECT GIS_1_Nausea 22204-53-1 NAPROXEN ADVERSE_EFFECT KID_3_Glomerulonephritis 22204-53-1 NAPROXEN ADVERSE_EFFECT GIS_1_Heartburn 22204-53-1 NAPROXEN ADVERSE_EFFECT GIS_2_Peptic Ulceration 22204-53-1 NAPROXEN ADVERSE_EFFECT BBM_3_Aplastic Anemia 22204-53-1 NAPROXEN TISSUE_TOXICITY Glomerulonephritis 22204-53-1 NAPROXEN INDICATION Pain 22204-53-1 NAPROXEN INDICATION Ankylosing Spondylitis 22204-53-1 NAPROXEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 22204-53-1 NAPROXEN TA_LEVEL_2 NSAID 22204-53-1 NAPROXEN PRODUCT_CLASS Anti-inflammatories 22204-53-1 NAPROXEN TA_LEVEL_1 Anti-inflammatory 22204-53-1 NAPROXEN ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 22204-53-1 NAPROXEN ADVERSE_EFFECT SKN_3_Skin Rash 26159-34-2 NAPROXEN ADVERSE_EFFECT BBM_3_Agranulocytosis 26159-34-2 NAPROXEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 26159-34-2 NAPROXEN ZERO_CLASS N 26159-34-2 NAPROXEN MESH_LEVEL_3 Naphthalenes 26159-34-2 NAPROXEN MESH_LEVEL_1 Polycyclic Hydrocarbons 26159-34-2 NAPROXEN MECH_LEVEL_1 Immunomodulation 26159-34-2 NAPROXEN INDICATION Acute Gouty Arthritis 26159-34-2 NAPROXEN INDICATION Tendonitis 26159-34-2 NAPROXEN TISSUE_TOXICITY Congestive Heart Failure 26159-34-2 NAPROXEN TISSUE_TOXICITY Renal Papillary Necrosis 26159-34-2 NAPROXEN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 26159-34-2 NAPROXEN ADVERSE_EFFECT GIS_1_Abdominal Pain 26159-34-2 NAPROXEN ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 26159-34-2 NAPROXEN ADVERSE_EFFECT NEU_1_Dizziness 26159-34-2 NAPROXEN TISSUE_TOXICITY Acute Interstitial Nephritis 26159-34-2 NAPROXEN ADVERSE_EFFECT LUN_1_Dyspnea 26159-34-2 NAPROXEN KNOWN_TOXICITY Cardiovascular Toxicity 26159-34-2 NAPROXEN ADVERSE_EFFECT GIS_2_Peptic Ulceration 26159-34-2 NAPROXEN ADVERSE_EFFECT BBM_3_Aplastic Anemia 26159-34-2 NAPROXEN INDICATION Pain 26159-34-2 NAPROXEN INDICATION Ankylosing Spondylitis 26159-34-2 NAPROXEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 26159-34-2 NAPROXEN TA_LEVEL_2 NSAID 26159-34-2 NAPROXEN PRODUCT_CLASS Anti-inflammatories 26159-34-2 NAPROXEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 26159-34-2 NAPROXEN ADVERSE_EFFECT NEU_1_Headache 26159-34-2 NAPROXEN ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 26159-34-2 NAPROXEN ADVERSE_EFFECT GIS_3_Ulcer Perforation 26159-34-2 NAPROXEN ADVERSE_EFFECT CVS_2_Vasculitis 26159-34-2 NAPROXEN TISSUE_TOXICITY Acute Renal Failure 26159-34-2 NAPROXEN INDICATION Osteoarthritis 26159-34-2 NAPROXEN TA_LEVEL_3 NSAID 26159-34-2 NAPROXEN MECHANISM Inhibit eicosanoid biosynthesis 26159-34-2 NAPROXEN INDICATION Rheumatoid Arthritis 26159-34-2 NAPROXEN TA_LEVEL_1 Anti-inflammatory 26159-34-2 NAPROXEN ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 26159-34-2 NAPROXEN ADVERSE_EFFECT SKN_3_Skin Rash 26159-34-2 NAPROXEN INDICATION Bursitis 26159-34-2 NAPROXEN ADVERSE_EFFECT KID_3_Acute Renal Failure 26159-34-2 NAPROXEN MODE_CLASS Enzyme Inhibitor 26159-34-2 NAPROXEN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 26159-34-2 NAPROXEN ADVERSE_EFFECT IMU_2_Allergic Reactions 26159-34-2 NAPROXEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 26159-34-2 NAPROXEN KNOWN_TOXICITY Nephrotoxicity 26159-34-2 NAPROXEN STRUCTURE_ACTIVITY NSAID, COX-1, 6-Methoxy-naphthalenyl-acetic acid 26159-34-2 NAPROXEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 26159-34-2 NAPROXEN ADVERSE_EFFECT SKN_1_Pruritis 26159-34-2 NAPROXEN ADVERSE_EFFECT OTO_2_Tinnitus 26159-34-2 NAPROXEN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 26159-34-2 NAPROXEN PRODUCT_CLASS Analgesics 26159-34-2 NAPROXEN INDICATION Dysmenorrhea 26159-34-2 NAPROXEN INDICATION Still's Disease / Juvenile Chronic Arthritis 26159-34-2 NAPROXEN ADVERSE_EFFECT KID_3_Glomerulonephritis 26159-34-2 NAPROXEN ACTIVITY_CLASS Anti-inflammatory 26159-34-2 NAPROXEN TISSUE_TOXICITY Glomerulonephritis 26159-34-2 NAPROXEN ADVERSE_EFFECT NEU_1_Drowsiness 26159-34-2 NAPROXEN ADVERSE_EFFECT XXX_1_Edema 26159-34-2 NAPROXEN ADVERSE_EFFECT GIS_1_Nausea 26159-34-2 NAPROXEN ADVERSE_EFFECT GIS_1_Heartburn 121679-13-8 NARATRIPTAN MECHANISM Modulate neural transmission 121679-13-8 NARATRIPTAN INDICATION Migraine Headache 121679-13-8 NARATRIPTAN ADVERSE_EFFECT CVS__Hypertension 121679-13-8 NARATRIPTAN THERAPEUTIC_CLASS Antimigraines 121679-13-8 NARATRIPTAN MODE_CLASS Receptor Agonist 121679-13-8 NARATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 121679-13-8 NARATRIPTAN MECHANISM Modulate cerebral vasoconstriction 121679-19-4 NARATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 121679-19-4 NARATRIPTAN THERAPEUTIC_CLASS Antimigraines 121679-19-4 NARATRIPTAN MECHANISM Modulate cerebral vasoconstriction 121679-19-4 NARATRIPTAN MECHANISM Modulate neural transmission 121679-19-4 NARATRIPTAN INDICATION Migraine Headache 121679-19-4 NARATRIPTAN ADVERSE_EFFECT CVS__Hypertension 121679-19-4 NARATRIPTAN MODE_CLASS Receptor Agonist 143388-64-1 NARATRIPTAN MODE_CLASS Receptor Agonist 143388-64-1 NARATRIPTAN PRODUCT_CLASS Central Nervous System (CNS) 143388-64-1 NARATRIPTAN ADVERSE_EFFECT CVS__Hypertension 143388-64-1 NARATRIPTAN THERAPEUTIC_CLASS Antimigraines 143388-64-1 NARATRIPTAN MECHANISM Modulate cerebral vasoconstriction 143388-64-1 NARATRIPTAN MECHANISM Modulate neural transmission 143388-64-1 NARATRIPTAN INDICATION Migraine Headache 7681-93-8 PIMARICIN THERAPEUTIC_CLASS Antifungals, Topical 7681-93-8 PIMARICIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 7681-93-8 PIMARICIN INDICATION Fungal Keratitis 7681-93-8 PIMARICIN INDICATION Fungal Conjunctivitis 7681-93-8 PIMARICIN ADVERSE_EFFECT OCU_3_Conjunctival Hyperemia 7681-93-8 PIMARICIN INDICATION Fungal Blepharitis 7681-93-8 PIMARICIN ADVERSE_EFFECT OCU_3_Chemosis 105816-04-4 NATEGLINIDE INDICATION Type II Diabetes Mellitus 105816-04-4 NATEGLINIDE MESH_LEVEL_2 Hydrocarbons 105816-04-4 NATEGLINIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 105816-04-4 NATEGLINIDE ACTIVITY_CLASS Anti-diabetic 105816-04-4 NATEGLINIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 105816-04-4 NATEGLINIDE ADVERSE_EFFECT END_3_Hypoglycemia 105816-04-4 NATEGLINIDE MESH_LEVEL_3 Hydrocarbons, Cyclic 105816-04-4 NATEGLINIDE MECHANISM Trigger insulin release in pancreatic beta cells 105816-04-4 NATEGLINIDE MECH_LEVEL_2 Trigger insulin release 105816-04-4 NATEGLINIDE ADVERSE_EFFECT KID_3_Hyperuricemia 105816-04-4 NATEGLINIDE MESH_LEVEL_1 Organic Chemicals 105816-04-4 NATEGLINIDE TA_LEVEL_2 Diabetes 105816-04-4 NATEGLINIDE TA_LEVEL_3 glycemic control 105816-04-4 NATEGLINIDE MECH_LEVEL_1 Glycemia regulation 105816-04-4 NATEGLINIDE ZERO_CLASS N 105816-04-4 NATEGLINIDE ADVERSE_EFFECT NEU_3_Dizziness 105816-04-4 NATEGLINIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 105816-04-4 NATEGLINIDE MECH_LEVEL_3 ATP-sensitive K+ channel, SUR3 105816-04-4 NATEGLINIDE ADVERSE_EFFECT GIS_3_Gastrointestinal Upset 105816-04-4 NATEGLINIDE THERAPEUTIC_CLASS Antidiabetic Agents 105816-04-4 NATEGLINIDE MODE_CLASS Channel Blocker, selective 118876-58-7 NBQX THERAPEUTIC_CLASS Anxiolytics 118876-58-7 NBQX PRODUCT_CLASS Central Nervous System (CNS) 118876-58-7 NBQX THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 118876-58-7 NBQX MODE_CLASS Channel Blocker, selective 118876-58-7 NBQX MECHANISM Block neural transmission 99200-09-6 NEBIVOLOL PRODUCT_CLASS Cardiovasculars 99200-09-6 NEBIVOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 99200-09-6 NEBIVOLOL MECHANISM Reduce muscle contractile force 99200-09-6 NEBIVOLOL THERAPEUTIC_CLASS Antihypertensive Agents 99200-09-6 NEBIVOLOL INDICATION Hypertension 69049-73-6 NEDOCROMIL MECHANISM Block channel gating 69049-73-6 NEDOCROMIL MODE_CLASS Channel Blocker 69049-74-7 NEDOCROMIL MODE_CLASS Channel Blocker 69049-74-7 NEDOCROMIL MECHANISM Block channel gating 83366-66-9 NEFAZODONE TISSUE_TOXICITY Hepatic Failure 83366-66-9 NEFAZODONE MODE_CLASS Solute transporter inhibitor 83366-66-9 NEFAZODONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 83366-66-9 NEFAZODONE MODE_CLASS Receptor Ligand Antagonist 83366-66-9 NEFAZODONE ADVERSE_EFFECT LIV_3_Hepatic Failure 83366-66-9 NEFAZODONE PRODUCT_CLASS Central Nervous System (CNS) 83366-66-9 NEFAZODONE MECHANISM Modulate neural transmission 83366-66-9 NEFAZODONE INDICATION Depression 83366-66-9 NEFAZODONE KNOWN_TOXICITY Hepatotoxicity 83366-66-9 NEFAZODONE THERAPEUTIC_CLASS Antidepressants 83366-66-9 NEFAZODONE INDICATION Depression 83366-66-9 NEFAZODONE TISSUE_TOXICITY Hepatotoxicity 83366-66-9 NEFAZODONE MECHANISM Prolong/enhance neural transmission 83366-66-9 NEFAZODONE MECHANISM Modulate G-protein coupled signal transduction 83366-66-9 NEFAZODONE STRUCTURE_ACTIVITY 5HT2 antagonist 83366-66-9 NEFAZODONE MODE_CLASS Receptor Ligand Antagonist, Selective 82752-99-6 NEFAZODONE MECHANISM Modulate neural transmission 82752-99-6 NEFAZODONE INDICATION Depression 82752-99-6 NEFAZODONE THERAPEUTIC_CLASS Antidepressants 82752-99-6 NEFAZODONE INDICATION Depression 82752-99-6 NEFAZODONE KNOWN_TOXICITY Hepatotoxicity 82752-99-6 NEFAZODONE MODE_CLASS Receptor Ligand Antagonist, Selective 82752-99-6 NEFAZODONE TISSUE_TOXICITY Hepatic Failure 82752-99-6 NEFAZODONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 82752-99-6 NEFAZODONE TISSUE_TOXICITY Hepatotoxicity 82752-99-6 NEFAZODONE MECHANISM Prolong/enhance neural transmission 82752-99-6 NEFAZODONE STRUCTURE_ACTIVITY 5HT2 antagonist 82752-99-6 NEFAZODONE MODE_CLASS Solute transporter inhibitor 82752-99-6 NEFAZODONE MODE_CLASS Receptor Ligand Antagonist 82752-99-6 NEFAZODONE ADVERSE_EFFECT LIV_3_Hepatic Failure 82752-99-6 NEFAZODONE MECHANISM Modulate G-protein coupled signal transduction 82752-99-6 NEFAZODONE PRODUCT_CLASS Central Nervous System (CNS) 114-80-7 NEOSTIGMINE BROMIDE INDICATION Myasthenia Gravis 114-80-7 NEOSTIGMINE BROMIDE MECH_LEVEL_1 Modulate neural transmission 114-80-7 NEOSTIGMINE BROMIDE KNOWN_TOXICITY Cardiovascular Toxicity 114-80-7 NEOSTIGMINE BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT NEU_3_Syncope 114-80-7 NEOSTIGMINE BROMIDE TISSUE_TOXICITY Cardiac Arrest 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT LUN_2_Increased Bronchial Secretion 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT GUS_2_Urinary Frequency 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT GIS_1_Emesis 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT GIS_1_Nausea 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT XXX_1_Salivation 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT NEU_1_Fasciculations 114-80-7 NEOSTIGMINE BROMIDE MESH_LEVEL_2 Amines 114-80-7 NEOSTIGMINE BROMIDE ZERO_CLASS N 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 114-80-7 NEOSTIGMINE BROMIDE TA_LEVEL_1 Central Nervous System (CNS) 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT NEU_3_Convulsions 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT XXX_1_Sweating 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT XXX_2_Weakness 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT IMU_3_Anaphylaxis 114-80-7 NEOSTIGMINE BROMIDE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT GIS_1_Abdominal Cramps 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT OCU_2_Miosis 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT MSK_1_Muscle Cramps 114-80-7 NEOSTIGMINE BROMIDE TISSUE_TOXICITY Hypotension 114-80-7 NEOSTIGMINE BROMIDE MECHANISM Enhance cholinergic transmission 114-80-7 NEOSTIGMINE BROMIDE ACTIVITY_CLASS Cholinesterase inhibitor 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT LUN_3_Bronchospasm 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT NEU_2_Dizziness 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT CVS_3_Hypotension 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT LUN_3_Respiratory Depression 114-80-7 NEOSTIGMINE BROMIDE MODE_CLASS Enzyme Inhibitor 114-80-7 NEOSTIGMINE BROMIDE MESH_LEVEL_3 Ammonium Compounds 114-80-7 NEOSTIGMINE BROMIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 114-80-7 NEOSTIGMINE BROMIDE MECH_LEVEL_3 Acetylcholinesterase 114-80-7 NEOSTIGMINE BROMIDE MECH_LEVEL_2 Enhance cholinergic transmission 114-80-7 NEOSTIGMINE BROMIDE MESH_LEVEL_1 Organic Chemicals 114-80-7 NEOSTIGMINE BROMIDE TISSUE_TOXICITY Cardiac Arrhythmia 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT NEU_3_Dysarthria 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT LUN_3_Respiratory Arrest 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT CVS_3_Cardiac Arrest 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 114-80-7 NEOSTIGMINE BROMIDE ADVERSE_EFFECT GIS_1_Diarrhea 114-80-7 NEOSTIGMINE BROMIDE TA_LEVEL_3 Myasthenia gravis 111788-99-9 NETICONAZOLE THERAPEUTIC_CLASS Antifungals 111788-99-9 NETICONAZOLE MODE_CLASS Enzyme Inhibitor 111788-99-9 NETICONAZOLE PRODUCT_CLASS Anti-infectives 111788-99-9 NETICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 130726-68-0 NETICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 130726-68-0 NETICONAZOLE PRODUCT_CLASS Anti-infectives 130726-68-0 NETICONAZOLE THERAPEUTIC_CLASS Antifungals 130726-68-0 NETICONAZOLE MODE_CLASS Enzyme Inhibitor 130773-02-3 NETICONAZOLE PRODUCT_CLASS Anti-infectives 130773-02-3 NETICONAZOLE THERAPEUTIC_CLASS Antifungals 130773-02-3 NETICONAZOLE MODE_CLASS Enzyme Inhibitor 130773-02-3 NETICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 129618-40-2 NEVIRAPINE ADVERSE_EFFECT NEU_2_Somnolence 129618-40-2 NEVIRAPINE TISSUE_TOXICITY Hepatic Necrosis 129618-40-2 NEVIRAPINE KNOWN_TOXICITY Hepatotoxicity 129618-40-2 NEVIRAPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 129618-40-2 NEVIRAPINE ADVERSE_EFFECT SKN_1_Rash 129618-40-2 NEVIRAPINE ADVERSE_EFFECT GIS_1_Diarrhea 129618-40-2 NEVIRAPINE TISSUE_TOXICITY Hepatotoxicity 129618-40-2 NEVIRAPINE MODE_CLASS Enzyme Inhibitor 129618-40-2 NEVIRAPINE INDICATION Human Immunodeficiency Virus (HIV) Disease 129618-40-2 NEVIRAPINE MECH_LEVEL_2 Inhibit viral DNA synthesis 129618-40-2 NEVIRAPINE STRUCTURE_ACTIVITY Viral RT inhibitor 129618-40-2 NEVIRAPINE ZERO_CLASS N 129618-40-2 NEVIRAPINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 129618-40-2 NEVIRAPINE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 129618-40-2 NEVIRAPINE ADVERSE_EFFECT LIV_3_Hepatotoxicity 129618-40-2 NEVIRAPINE ADVERSE_EFFECT GIS_1_Nausea 129618-40-2 NEVIRAPINE TISSUE_TOXICITY Hepatic Failure 129618-40-2 NEVIRAPINE MECHANISM Inhibit viral DNA synthesis 129618-40-2 NEVIRAPINE MESH_LEVEL_3 Pyridines 129618-40-2 NEVIRAPINE TA_LEVEL_3 antiviral RT inhibitors 129618-40-2 NEVIRAPINE MECH_LEVEL_1 Anti-viral 129618-40-2 NEVIRAPINE ACTIVITY_CLASS Anti-viral 129618-40-2 NEVIRAPINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 129618-40-2 NEVIRAPINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 129618-40-2 NEVIRAPINE ADVERSE_EFFECT XXX_2_Fatigue 129618-40-2 NEVIRAPINE PRODUCT_CLASS Anti-infectives 129618-40-2 NEVIRAPINE MECH_LEVEL_3 RNA-directed DNA polymerase 129618-40-2 NEVIRAPINE MESH_LEVEL_1 Heterocyclic Compounds 129618-40-2 NEVIRAPINE ADVERSE_EFFECT LIV_3_Hepatic Failure 129618-40-2 NEVIRAPINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 129618-40-2 NEVIRAPINE ADVERSE_EFFECT NEU_1_Headache 129618-40-2 NEVIRAPINE THERAPEUTIC_CLASS Antivirals, Systemic 129618-40-2 NEVIRAPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 129618-40-2 NEVIRAPINE TA_LEVEL_2 Anti-viral 129618-40-2 NEVIRAPINE TA_LEVEL_1 Infectious Disease 59-67-6 NIACIN ADVERSE_EFFECT LIV_3_Hepatic Failure 59-67-6 NIACIN ADVERSE_EFFECT OCU_3_Proptosis 59-67-6 NIACIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 59-67-6 NIACIN INDICATION Hyperlipidemia 59-67-6 NIACIN MESH_LEVEL_3 Pyridines 59-67-6 NIACIN ADVERSE_EFFECT OCU_2_Cystoid Macular Edema 59-67-6 NIACIN ADVERSE_EFFECT END_2_Hyperglycemia 59-67-6 NIACIN ADVERSE_EFFECT CVS_1_Peripheral Vasodilation 59-67-6 NIACIN ADVERSE_EFFECT XXX_2_Chills 59-67-6 NIACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 59-67-6 NIACIN ADVERSE_EFFECT OCU_3_Toxic Amblyopia 59-67-6 NIACIN MECH_LEVEL_2 coenzyme 59-67-6 NIACIN INDICATION Hyperlipoproteinemia 59-67-6 NIACIN PRODUCT_CLASS Cardiovasculars 59-67-6 NIACIN TISSUE_TOXICITY Hepatic Failure 59-67-6 NIACIN INDICATION Nutritional Supplement 59-67-6 NIACIN INDICATION Tinnitus / Ringing in the Ear 59-67-6 NIACIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 59-67-6 NIACIN KNOWN_TOXICITY Hepatotoxicity 59-67-6 NIACIN ADVERSE_EFFECT GIS_2_Flatulence 59-67-6 NIACIN ADVERSE_EFFECT GIS_1_Dyspepsia 59-67-6 NIACIN ADVERSE_EFFECT GIS_2_Diarrhea 59-67-6 NIACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 59-67-6 NIACIN ADVERSE_EFFECT XXX_2_Edema 59-67-6 NIACIN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 59-67-6 NIACIN ADVERSE_EFFECT CVS_2_Palpitation 59-67-6 NIACIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 59-67-6 NIACIN STRUCTURE_ACTIVITY Vitamin B, niacin 59-67-6 NIACIN MECH_LEVEL_3 Unknown mechanism 59-67-6 NIACIN MECH_LEVEL_1 Vitamin B 59-67-6 NIACIN TA_LEVEL_2 Vitamin B complex 59-67-6 NIACIN INDICATION Hypertriglyceridemia 59-67-6 NIACIN INDICATION Peripheral Vascular Disease 59-67-6 NIACIN TISSUE_TOXICITY Hypotension 59-67-6 NIACIN THERAPEUTIC_CLASS Vasodilators 59-67-6 NIACIN ADVERSE_EFFECT CVS_2_Sinus Tachycardia 59-67-6 NIACIN ADVERSE_EFFECT NEU_1_Dizziness 59-67-6 NIACIN KNOWN_TOXICITY Cardiovascular Toxicity 59-67-6 NIACIN ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 59-67-6 NIACIN ADVERSE_EFFECT LIV_2_Jaundice 59-67-6 NIACIN ADVERSE_EFFECT END_2_Hypophosphatemia 59-67-6 NIACIN INDICATION Pellagra 59-67-6 NIACIN TA_LEVEL_1 Vitamins, Minerals and Nutrients 59-67-6 NIACIN MESH_LEVEL_1 Heterocyclic Compounds 59-67-6 NIACIN PRODUCT_CLASS Vitamins, Minerals and Nutrients 59-67-6 NIACIN TA_LEVEL_3 vitamin deficiency 59-67-6 NIACIN THERAPEUTIC_CLASS Hypolipidemic Agents 59-67-6 NIACIN THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 59-67-6 NIACIN TISSUE_TOXICITY Hepatic Necrosis 59-67-6 NIACIN ADVERSE_EFFECT CVS_1_Hypotension 59-67-6 NIACIN ADVERSE_EFFECT KID_2_Hyperuricemia 59-67-6 NIACIN ADVERSE_EFFECT LUN_2_Dyspnea 59-67-6 NIACIN ADVERSE_EFFECT OCU_3_Blurred Vision 59-67-6 NIACIN ZERO_CLASS N 98-92-0 NIACINAMIDE ADVERSE_EFFECT SKN_2_Flushing 98-92-0 NIACINAMIDE ADVERSE_EFFECT SKN_2_Pruritis 98-92-0 NIACINAMIDE TISSUE_TOXICITY Angina 98-92-0 NIACINAMIDE ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 98-92-0 NIACINAMIDE STRUCTURE_ACTIVITY Vitamin B, niacin 98-92-0 NIACINAMIDE MECH_LEVEL_2 coenzyme 98-92-0 NIACINAMIDE MESH_LEVEL_2 Vitamins 98-92-0 NIACINAMIDE MESH_LEVEL_1 Growth Substances, Pigments, and Vitamins 98-92-0 NIACINAMIDE MECH_LEVEL_3 Unknown mechanism 98-92-0 NIACINAMIDE MECH_LEVEL_1 Vitamin B 98-92-0 NIACINAMIDE ADVERSE_EFFECT CVS_3_Hypotension 98-92-0 NIACINAMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 98-92-0 NIACINAMIDE ADVERSE_EFFECT XXX_2_Weakness 98-92-0 NIACINAMIDE ADVERSE_EFFECT XXX_2_Edema 98-92-0 NIACINAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 98-92-0 NIACINAMIDE THERAPEUTIC_CLASS Hypolipidemic Agents 98-92-0 NIACINAMIDE ADVERSE_EFFECT MSK_2_Myalgia 98-92-0 NIACINAMIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 98-92-0 NIACINAMIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 98-92-0 NIACINAMIDE TA_LEVEL_3 hypertriglyceridemia 98-92-0 NIACINAMIDE MESH_LEVEL_3 Vitamin B Complex 98-92-0 NIACINAMIDE TA_LEVEL_2 hypolipidemic agents 98-92-0 NIACINAMIDE PRODUCT_CLASS Cardiovasculars 98-92-0 NIACINAMIDE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 98-92-0 NIACINAMIDE ADVERSE_EFFECT CVS_2_Palpitation 98-92-0 NIACINAMIDE ADVERSE_EFFECT GIS_2_Flatulence 98-92-0 NIACINAMIDE ADVERSE_EFFECT XXX_2_Diaphoresis 98-92-0 NIACINAMIDE ADVERSE_EFFECT OCU_2_Blurred Vision 98-92-0 NIACINAMIDE ADVERSE_EFFECT CVS_3_Angina 98-92-0 NIACINAMIDE ADVERSE_EFFECT KID_3_Hyperuricemia 98-92-0 NIACINAMIDE ADVERSE_EFFECT NEU_2_Dizziness 98-92-0 NIACINAMIDE ADVERSE_EFFECT LUN_3_Dyspnea 98-92-0 NIACINAMIDE ZERO_CLASS N 98-92-0 NIACINAMIDE INDICATION Pellagra 98-92-0 NIACINAMIDE PRODUCT_CLASS Vitamins, Minerals and Nutrients 98-92-0 NIACINAMIDE INDICATION Hyperlipoproteinemia 98-92-0 NIACINAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 98-92-0 NIACINAMIDE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 98-92-0 NIACINAMIDE ADVERSE_EFFECT XXX_2_Chills 98-92-0 NIACINAMIDE ADVERSE_EFFECT LIV_2_Jaundice 98-92-0 NIACINAMIDE ADVERSE_EFFECT END_3_Hypophosphatemia 98-92-0 NIACINAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 98-92-0 NIACINAMIDE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 98-92-0 NIACINAMIDE ADVERSE_EFFECT XXX_2_Fatigue 98-92-0 NIACINAMIDE ADVERSE_EFFECT NEU_2_Headache 98-92-0 NIACINAMIDE ADVERSE_EFFECT CVS_3_Peripheral Vasodilation 98-92-0 NIACINAMIDE TISSUE_TOXICITY Hypotension 98-92-0 NIACINAMIDE MECHANISM Vitamin/ cofactor 98-92-0 NIACINAMIDE TA_LEVEL_1 Cardiovascular 98-92-0 NIACINAMIDE INDICATION Hypertriglyceridemia 98-92-0 NIACINAMIDE INDICATION Nutritional Supplement 98-92-0 NIACINAMIDE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 98-92-0 NIACINAMIDE ADVERSE_EFFECT GIS_3_Peptic Ulceration 98-92-0 NIACINAMIDE ADVERSE_EFFECT GIS_2_Dyspepsia 98-92-0 NIACINAMIDE ADVERSE_EFFECT NEU_3_Syncope 98-92-0 NIACINAMIDE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 98-92-0 NIACINAMIDE ADVERSE_EFFECT END_3_Hyperglycemia 54527-84-3 NICARDIPINE ADVERSE_EFFECT NEU_1_Dizziness 54527-84-3 NICARDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 54527-84-3 NICARDIPINE INDICATION Angina Pectoris 54527-84-3 NICARDIPINE PRODUCT_CLASS Cardiovasculars 54527-84-3 NICARDIPINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 54527-84-3 NICARDIPINE TISSUE_TOXICITY Hypotension 54527-84-3 NICARDIPINE MODE_CLASS Channel Blocker 54527-84-3 NICARDIPINE ADVERSE_EFFECT NEU_1_Headache 54527-84-3 NICARDIPINE ADVERSE_EFFECT NEU_2_Vertigo 54527-84-3 NICARDIPINE ADVERSE_EFFECT XXX_1_Peripheral Edema 54527-84-3 NICARDIPINE ADVERSE_EFFECT NEU_1_Syncope 54527-84-3 NICARDIPINE MECHANISM Reduce muscle contractile force 54527-84-3 NICARDIPINE ADVERSE_EFFECT CVS_3_Heart Failure 54527-84-3 NICARDIPINE KNOWN_TOXICITY Cardiovascular Toxicity 54527-84-3 NICARDIPINE ADVERSE_EFFECT SKN_1_Flushing 54527-84-3 NICARDIPINE THERAPEUTIC_CLASS Antianginals 54527-84-3 NICARDIPINE ADVERSE_EFFECT LUN_2_Dyspnea 54527-84-3 NICARDIPINE ADVERSE_EFFECT XXX_2_Asthenia 54527-84-3 NICARDIPINE INDICATION Hypertension 54527-84-3 NICARDIPINE TISSUE_TOXICITY Heart Failure 54527-84-3 NICARDIPINE ADVERSE_EFFECT XXX_1_Weakness 54527-84-3 NICARDIPINE ADVERSE_EFFECT END_3_Gynecomastia 54527-84-3 NICARDIPINE ADVERSE_EFFECT CVS_1_Hypotension 54527-84-3 NICARDIPINE ADVERSE_EFFECT CVS_1_Palpitation 54527-84-3 NICARDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 55985-32-5 NICARDIPINE ADVERSE_EFFECT LUN_2_Dyspnea 55985-32-5 NICARDIPINE ADVERSE_EFFECT XXX_2_Asthenia 55985-32-5 NICARDIPINE INDICATION Hypertension 55985-32-5 NICARDIPINE TISSUE_TOXICITY Heart Failure 55985-32-5 NICARDIPINE ADVERSE_EFFECT XXX_1_Weakness 55985-32-5 NICARDIPINE ADVERSE_EFFECT CVS_1_Palpitation 55985-32-5 NICARDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 55985-32-5 NICARDIPINE ADVERSE_EFFECT END_3_Gynecomastia 55985-32-5 NICARDIPINE KNOWN_TOXICITY Cardiovascular Toxicity 55985-32-5 NICARDIPINE ADVERSE_EFFECT SKN_1_Flushing 55985-32-5 NICARDIPINE ADVERSE_EFFECT CVS_3_Heart Failure 55985-32-5 NICARDIPINE THERAPEUTIC_CLASS Antianginals 55985-32-5 NICARDIPINE TISSUE_TOXICITY Hypotension 55985-32-5 NICARDIPINE ADVERSE_EFFECT NEU_1_Headache 55985-32-5 NICARDIPINE ADVERSE_EFFECT XXX_1_Peripheral Edema 55985-32-5 NICARDIPINE ADVERSE_EFFECT NEU_1_Syncope 55985-32-5 NICARDIPINE MECHANISM Reduce muscle contractile force 55985-32-5 NICARDIPINE PRODUCT_CLASS Cardiovasculars 55985-32-5 NICARDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 55985-32-5 NICARDIPINE MODE_CLASS Channel Blocker 55985-32-5 NICARDIPINE INDICATION Angina Pectoris 55985-32-5 NICARDIPINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 55985-32-5 NICARDIPINE ADVERSE_EFFECT NEU_1_Dizziness 55985-32-5 NICARDIPINE ADVERSE_EFFECT NEU_2_Vertigo 55985-32-5 NICARDIPINE ADVERSE_EFFECT CVS_1_Hypotension 54-11-5 NICOTINE ADVERSE_EFFECT SKN_2_Skin Rash 54-11-5 NICOTINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 54-11-5 NICOTINE ADVERSE_EFFECT NEU_3_Paresthesia 54-11-5 NICOTINE ADVERSE_EFFECT PSY_1_Anxiety 54-11-5 NICOTINE ADVERSE_EFFECT EMB_2_Teratogenicity 54-11-5 NICOTINE MECH_LEVEL_3 Nicotinic acetylcholine receptor 54-11-5 NICOTINE MESH_LEVEL_1 Heterocyclic Compounds 54-11-5 NICOTINE TISSUE_TOXICITY Hypotension 54-11-5 NICOTINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor agonist 54-11-5 NICOTINE ZERO_CLASS N 54-11-5 NICOTINE ADVERSE_EFFECT CVS_3_Cardiac Failure 54-11-5 NICOTINE ADVERSE_EFFECT XXX_2_Peripheral Edema 54-11-5 NICOTINE ADVERSE_EFFECT LUN_3_Bronchospasm 54-11-5 NICOTINE ADVERSE_EFFECT GIS_2_Nausea 54-11-5 NICOTINE ADVERSE_EFFECT CVS_3_Tachycardia 54-11-5 NICOTINE THERAPEUTIC_CLASS Drug Dependence Therapy 54-11-5 NICOTINE KNOWN_TOXICITY Embryo/Fetal Toxicity 54-11-5 NICOTINE INDICATION Smoking Cessation 54-11-5 NICOTINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 54-11-5 NICOTINE MECH_LEVEL_1 Modulate neural transmission 54-11-5 NICOTINE TISSUE_TOXICITY Cardiac Failure 54-11-5 NICOTINE ADVERSE_EFFECT GIS_3_Abdominal Pain 54-11-5 NICOTINE ADVERSE_EFFECT PSY_1_Irritability 54-11-5 NICOTINE ADVERSE_EFFECT PSY_1_Dependence 54-11-5 NICOTINE ADVERSE_EFFECT END_2_Hyperglycemia 54-11-5 NICOTINE ADVERSE_EFFECT CVS_3_Hypotension 54-11-5 NICOTINE KNOWN_TOXICITY Cardiovascular Toxicity 54-11-5 NICOTINE MODE_CLASS Channel Modulator 54-11-5 NICOTINE MESH_LEVEL_3 Pyridines 54-11-5 NICOTINE PRODUCT_CLASS Other Human Uses 54-11-5 NICOTINE ACTIVITY_CLASS Nicotinic acetylcholine receptor agonist 54-11-5 NICOTINE MECHANISM Prolong/enhance neural transmission 54-11-5 NICOTINE ADVERSE_EFFECT XXX_1_Tobacco Withdrawal Symptoms 54-11-5 NICOTINE ADVERSE_EFFECT GIS_2_Peptic Ulceration 54-11-5 NICOTINE ADVERSE_EFFECT XXX_1_Restlessness 54-11-5 NICOTINE ADVERSE_EFFECT NEU_1_Headache 54-11-5 NICOTINE ADVERSE_EFFECT CVS_3_Hypertension 54-11-5 NICOTINE TA_LEVEL_1 Other Human Uses 54-11-5 NICOTINE MECH_LEVEL_2 Cholinergic receptor agonist 54-11-5 NICOTINE ADVERSE_EFFECT PSY_3_Mental Confusion 54-11-5 NICOTINE TISSUE_TOXICITY Teratogenicity 54-11-5 NICOTINE ADVERSE_EFFECT LUN_3_Respiratory Failure 130656-51-8 NIFEKALANT MODE_CLASS Channel Blocker, selective 130656-51-8 NIFEKALANT THERAPEUTIC_CLASS Antiarrhythmic Agents 130656-51-8 NIFEKALANT PRODUCT_CLASS Cardiovasculars 130656-51-8 NIFEKALANT MECHANISM Modulate channel gating 130636-43-0 NIFEKALANT MODE_CLASS Channel Blocker, selective 130636-43-0 NIFEKALANT THERAPEUTIC_CLASS Antiarrhythmic Agents 130636-43-0 NIFEKALANT PRODUCT_CLASS Cardiovasculars 130636-43-0 NIFEKALANT MECHANISM Modulate channel gating 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT KID_3_Interstitial Nephritis 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GIS_2_Gastritis 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GIS_2_Epigastric Pain 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT MSK_3_Rhabdomyolysis 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT LIV_3_Hepatitis 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT NEU_1_Headache 4394-00-7 NIFLUMIC ACID INDICATION Glomerulonephritis 4394-00-7 NIFLUMIC ACID STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT EMB_2_Fetal Toxicity 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT IMU_3_Eosinophilia 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 4394-00-7 NIFLUMIC ACID MECHANISM Inhibit eicosanoid biosynthesis 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GIS_2_Duodenal Ulcer 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT NEU_1_Dizziness 4394-00-7 NIFLUMIC ACID INDICATION Osteoarthritis 4394-00-7 NIFLUMIC ACID THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 4394-00-7 NIFLUMIC ACID INDICATION Inflammation 4394-00-7 NIFLUMIC ACID MODE_CLASS Enzyme Inhibitor 4394-00-7 NIFLUMIC ACID TISSUE_TOXICITY Interstitial Nephritis 4394-00-7 NIFLUMIC ACID KNOWN_TOXICITY Nephrotoxicity 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT BBM_3_Anemia 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT SKN_2_Skin Eruption 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT KID_3_Increased Creatinine 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GIS_2_Gastric Ulceration 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT KID_3_Proteinuria 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT KID_3_Renal Insufficiency 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT XXX_3_Edema 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT PSY_2_Anorexia 4394-00-7 NIFLUMIC ACID MODE_CLASS Channel Blocker 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GUS_2_Dysuria 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT BBM_3_Leukopenia 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 4394-00-7 NIFLUMIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 4394-00-7 NIFLUMIC ACID PRODUCT_CLASS Anti-inflammatories 4394-00-7 NIFLUMIC ACID INDICATION Arthritis 4394-00-7 NIFLUMIC ACID MECHANISM Block channel gating 63612-50-0 NILUTAMIDE ADVERSE_EFFECT LUN_2_Interstitial Pneumonitis 63612-50-0 NILUTAMIDE ADVERSE_EFFECT XXX_2_Rhinitis 63612-50-0 NILUTAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 63612-50-0 NILUTAMIDE THERAPEUTIC_CLASS Antineoplastics 63612-50-0 NILUTAMIDE ADVERSE_EFFECT CVS_2_Hypotension 63612-50-0 NILUTAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 63612-50-0 NILUTAMIDE ADVERSE_EFFECT XXX_2_Edema 63612-50-0 NILUTAMIDE ADVERSE_EFFECT XXX_2_Weight Loss 63612-50-0 NILUTAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 63612-50-0 NILUTAMIDE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 63612-50-0 NILUTAMIDE ADVERSE_EFFECT XXX_2_Malaise 63612-50-0 NILUTAMIDE TISSUE_TOXICITY Congestive Heart Failure 63612-50-0 NILUTAMIDE ADVERSE_EFFECT GIS_1_Constipation 63612-50-0 NILUTAMIDE ADVERSE_EFFECT CVS_2_Angina 63612-50-0 NILUTAMIDE ADVERSE_EFFECT NEU_1_Dizziness 63612-50-0 NILUTAMIDE ADVERSE_EFFECT OCU_2_Cataracts 63612-50-0 NILUTAMIDE ADVERSE_EFFECT SKN_2_Flushing of the Skin 63612-50-0 NILUTAMIDE TISSUE_TOXICITY Hypotension 63612-50-0 NILUTAMIDE ADVERSE_EFFECT OCU_2_Visual Impairment 63612-50-0 NILUTAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 63612-50-0 NILUTAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 63612-50-0 NILUTAMIDE ADVERSE_EFFECT PSY_2_Nervousness 63612-50-0 NILUTAMIDE ADVERSE_EFFECT LUN_2_Cough 63612-50-0 NILUTAMIDE ADVERSE_EFFECT LIV_2_Hepatitis 63612-50-0 NILUTAMIDE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 63612-50-0 NILUTAMIDE ADVERSE_EFFECT GIS_2_Melena 63612-50-0 NILUTAMIDE ADVERSE_EFFECT NEU_2_Syncope 63612-50-0 NILUTAMIDE ADVERSE_EFFECT END_1_Hot Flashes 63612-50-0 NILUTAMIDE TISSUE_TOXICITY Angina 63612-50-0 NILUTAMIDE ADVERSE_EFFECT CVS_1_Hypertension 63612-50-0 NILUTAMIDE ADVERSE_EFFECT CVS_2_Congestive Heart Failure 63612-50-0 NILUTAMIDE ADVERSE_EFFECT XXX_2_Xerostomia 63612-50-0 NILUTAMIDE ADVERSE_EFFECT NEU_2_Paresthesia 63612-50-0 NILUTAMIDE ADVERSE_EFFECT SKN_2_Pruritis 63612-50-0 NILUTAMIDE ADVERSE_EFFECT MSK_2_Arthralgia 63612-50-0 NILUTAMIDE ADVERSE_EFFECT GIS_2_Gastrointestinal Bleeding 63612-50-0 NILUTAMIDE STRUCTURE_ACTIVITY Androgen receptor antagonist 63612-50-0 NILUTAMIDE INDICATION Metastatic Carcinoma of Prostate 63612-50-0 NILUTAMIDE INDICATION Prostatic Cancer / Carcinoma of the Prostate 63612-50-0 NILUTAMIDE PRODUCT_CLASS Anti-cancers 63612-50-0 NILUTAMIDE MECHANISM Modulate gene transcription 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 51803-78-2 NIMESULIDE ADVERSE_EFFECT XXX_2_Sweating 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_3_Ulcer Perforation 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 51803-78-2 NIMESULIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 51803-78-2 NIMESULIDE TISSUE_TOXICITY Hepatic Failure 51803-78-2 NIMESULIDE MESH_LEVEL_1 Organic Chemicals 51803-78-2 NIMESULIDE INDICATION Dysmenorrhea 51803-78-2 NIMESULIDE TA_LEVEL_3 NSAID 51803-78-2 NIMESULIDE MECHANISM Inhibit eicosanoid biosynthesis 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_2_Peptic Ulceration 51803-78-2 NIMESULIDE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 51803-78-2 NIMESULIDE ADVERSE_EFFECT NEU_3_Somnolence 51803-78-2 NIMESULIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 51803-78-2 NIMESULIDE ADVERSE_EFFECT LIV_3_Hepatic Failure 51803-78-2 NIMESULIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_1_Nausea 51803-78-2 NIMESULIDE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 51803-78-2 NIMESULIDE INDICATION Rheumatoid Arthritis 51803-78-2 NIMESULIDE MODE_CLASS Enzyme Inhibitor 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_1_Epigastric Pain 51803-78-2 NIMESULIDE ADVERSE_EFFECT BBM_3_Anemia 51803-78-2 NIMESULIDE ADVERSE_EFFECT NEU_2_Dizziness 51803-78-2 NIMESULIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 51803-78-2 NIMESULIDE ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 51803-78-2 NIMESULIDE TISSUE_TOXICITY Acute Interstitial Nephritis 51803-78-2 NIMESULIDE TA_LEVEL_1 Anti-inflammatory 51803-78-2 NIMESULIDE KNOWN_TOXICITY Hepatotoxicity 51803-78-2 NIMESULIDE TA_LEVEL_2 NSAID 51803-78-2 NIMESULIDE INDICATION Osteoarthritis 51803-78-2 NIMESULIDE PRODUCT_CLASS Anti-inflammatories 51803-78-2 NIMESULIDE MESH_LEVEL_2 Amides 51803-78-2 NIMESULIDE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51803-78-2 NIMESULIDE TISSUE_TOXICITY Hepatotoxicity 51803-78-2 NIMESULIDE ADVERSE_EFFECT KID_2_Fluid Retention 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_2_Diarrhea 51803-78-2 NIMESULIDE ADVERSE_EFFECT SKN_2_Pruritis 51803-78-2 NIMESULIDE ADVERSE_EFFECT SKN_2_Flushing 51803-78-2 NIMESULIDE ADVERSE_EFFECT SKN_2_Rash 51803-78-2 NIMESULIDE ADVERSE_EFFECT LUN_3_Bronchospasm 51803-78-2 NIMESULIDE ADVERSE_EFFECT KID_3_Acute Renal Failure 51803-78-2 NIMESULIDE STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 51803-78-2 NIMESULIDE ZERO_CLASS N 51803-78-2 NIMESULIDE TISSUE_TOXICITY Acute Renal Failure 51803-78-2 NIMESULIDE KNOWN_TOXICITY Nephrotoxicity 51803-78-2 NIMESULIDE ACTIVITY_CLASS Anti-inflammatory 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_3_Pancreatitis 51803-78-2 NIMESULIDE INDICATION Pain 51803-78-2 NIMESULIDE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 51803-78-2 NIMESULIDE MESH_LEVEL_3 Sulfonamides 51803-78-2 NIMESULIDE MECH_LEVEL_1 Immunomodulation 51803-78-2 NIMESULIDE ADVERSE_EFFECT CVS_3_Hypertension 51803-78-2 NIMESULIDE ADVERSE_EFFECT GIS_3_Dyspepsia 66085-59-4 NIMODIPINE TISSUE_TOXICITY Congestive Heart Failure 66085-59-4 NIMODIPINE MECHANISM Reduce muscle contractile force 66085-59-4 NIMODIPINE TISSUE_TOXICITY Hypotension 66085-59-4 NIMODIPINE ADVERSE_EFFECT CVS_1_Hypotension 66085-59-4 NIMODIPINE ADVERSE_EFFECT SKN_2_Flushing 66085-59-4 NIMODIPINE ADVERSE_EFFECT ELT_3_Hyponatremia 66085-59-4 NIMODIPINE ADVERSE_EFFECT BBM_3_Disseminated Intravascular Coagulation (DIC) 66085-59-4 NIMODIPINE INDICATION Subarachnoid Hemorrhage 66085-59-4 NIMODIPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 66085-59-4 NIMODIPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 66085-59-4 NIMODIPINE TA_LEVEL_3 Ca++ channel antagonists 66085-59-4 NIMODIPINE MESH_LEVEL_1 Heterocyclic Compounds 66085-59-4 NIMODIPINE MESH_LEVEL_3 Pyridines 66085-59-4 NIMODIPINE ZERO_CLASS N 66085-59-4 NIMODIPINE ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 66085-59-4 NIMODIPINE KNOWN_TOXICITY Cardiovascular Toxicity 66085-59-4 NIMODIPINE ADVERSE_EFFECT SKN_2_Rash 66085-59-4 NIMODIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 66085-59-4 NIMODIPINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 66085-59-4 NIMODIPINE MECH_LEVEL_2 Reduce muscle contractile force 66085-59-4 NIMODIPINE ADVERSE_EFFECT GIS_2_Diarrhea 66085-59-4 NIMODIPINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 66085-59-4 NIMODIPINE MODE_CLASS Channel Blocker 66085-59-4 NIMODIPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 66085-59-4 NIMODIPINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 66085-59-4 NIMODIPINE MECH_LEVEL_1 Anti-anginal 66085-59-4 NIMODIPINE ADVERSE_EFFECT NEU_2_Headache 66085-59-4 NIMODIPINE THERAPEUTIC_CLASS Vasodilators 66085-59-4 NIMODIPINE PRODUCT_CLASS Cardiovasculars 66085-59-4 NIMODIPINE MECH_LEVEL_3 L-Type Ca++ channel 66085-59-4 NIMODIPINE TA_LEVEL_2 anti-angina 66085-59-4 NIMODIPINE TA_LEVEL_1 Cardiovascular 66085-59-4 NIMODIPINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 66085-59-4 NIMODIPINE ADVERSE_EFFECT XXX_2_Edema 63675-72-9 NISOLDIPINE MECH_LEVEL_1 Anti-anginal 63675-72-9 NISOLDIPINE ZERO_CLASS N 63675-72-9 NISOLDIPINE ADVERSE_EFFECT CVS_2_Palpitation 63675-72-9 NISOLDIPINE ADVERSE_EFFECT NEU_3_Paresthesia 63675-72-9 NISOLDIPINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 63675-72-9 NISOLDIPINE TISSUE_TOXICITY Myocardial Infarction 63675-72-9 NISOLDIPINE MECHANISM Reduce muscle contractile force 63675-72-9 NISOLDIPINE INDICATION Hypertension 63675-72-9 NISOLDIPINE TISSUE_TOXICITY Hypotension 63675-72-9 NISOLDIPINE TISSUE_TOXICITY Aggravation of Angina 63675-72-9 NISOLDIPINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 63675-72-9 NISOLDIPINE ADVERSE_EFFECT NEU_2_Dizziness 63675-72-9 NISOLDIPINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 63675-72-9 NISOLDIPINE ADVERSE_EFFECT CVS_3_Aggravation of Angina 63675-72-9 NISOLDIPINE TA_LEVEL_2 anti-angina 63675-72-9 NISOLDIPINE MECH_LEVEL_3 L-Type Ca++ channel 63675-72-9 NISOLDIPINE TA_LEVEL_1 Cardiovascular 63675-72-9 NISOLDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 63675-72-9 NISOLDIPINE ADVERSE_EFFECT CVS_2_Hypotension 63675-72-9 NISOLDIPINE ADVERSE_EFFECT NEU_1_Headache 63675-72-9 NISOLDIPINE MODE_CLASS Channel Blocker 63675-72-9 NISOLDIPINE ADVERSE_EFFECT MSK_3_Muscle Cramps 63675-72-9 NISOLDIPINE TISSUE_TOXICITY Congestive Heart Failure 63675-72-9 NISOLDIPINE KNOWN_TOXICITY Cardiovascular Toxicity 63675-72-9 NISOLDIPINE MECH_LEVEL_2 Reduce muscle contractile force 63675-72-9 NISOLDIPINE MESH_LEVEL_1 Heterocyclic Compounds 63675-72-9 NISOLDIPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 63675-72-9 NISOLDIPINE PRODUCT_CLASS Cardiovasculars 63675-72-9 NISOLDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 63675-72-9 NISOLDIPINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 63675-72-9 NISOLDIPINE ADVERSE_EFFECT CVS_2_Chest Pain 63675-72-9 NISOLDIPINE MESH_LEVEL_3 Pyridines 63675-72-9 NISOLDIPINE TA_LEVEL_3 Ca++ channel antagonists 63675-72-9 NISOLDIPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 63675-72-9 NISOLDIPINE ADVERSE_EFFECT REP_3_Impotence 63675-72-9 NISOLDIPINE ADVERSE_EFFECT LUN_3_Bronchoconstriction 63675-72-9 NISOLDIPINE ADVERSE_EFFECT XXX_1_Peripheral Edema 39562-70-4 NITRENDIPINE KNOWN_TOXICITY Cardiovascular Toxicity 39562-70-4 NITRENDIPINE ADVERSE_EFFECT LIV_3_Jaundice 39562-70-4 NITRENDIPINE ADVERSE_EFFECT CVS_3_Hypotensive Shock 39562-70-4 NITRENDIPINE ADVERSE_EFFECT CVS_1_Vasodilation 39562-70-4 NITRENDIPINE ADVERSE_EFFECT GIS_1_Nausea 39562-70-4 NITRENDIPINE ADVERSE_EFFECT NEU_1_Headache 39562-70-4 NITRENDIPINE ADVERSE_EFFECT END_3_Gynecomastia 39562-70-4 NITRENDIPINE ZERO_CLASS N 39562-70-4 NITRENDIPINE INDICATION Angina Pectoris 39562-70-4 NITRENDIPINE MODE_CLASS Channel Blocker 39562-70-4 NITRENDIPINE TISSUE_TOXICITY Hypotension 39562-70-4 NITRENDIPINE MESH_LEVEL_3 Pyridines 39562-70-4 NITRENDIPINE TA_LEVEL_3 Ca++ channel antagonists 39562-70-4 NITRENDIPINE MESH_LEVEL_1 Heterocyclic Compounds 39562-70-4 NITRENDIPINE TISSUE_TOXICITY Teratogenicity 39562-70-4 NITRENDIPINE ADVERSE_EFFECT BBM_3_Leukopenia 39562-70-4 NITRENDIPINE ADVERSE_EFFECT SKN_2_Skin Rash 39562-70-4 NITRENDIPINE ADVERSE_EFFECT CVS_3_Hypotension 39562-70-4 NITRENDIPINE ADVERSE_EFFECT OTO_3_Tinnitus 39562-70-4 NITRENDIPINE ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 39562-70-4 NITRENDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 39562-70-4 NITRENDIPINE TA_LEVEL_2 anti-angina 39562-70-4 NITRENDIPINE INDICATION Renal Hypertension 39562-70-4 NITRENDIPINE MECHANISM Reduce muscle contractile force 39562-70-4 NITRENDIPINE MECH_LEVEL_3 L-Type Ca++ channel 39562-70-4 NITRENDIPINE MECH_LEVEL_1 Anti-anginal 39562-70-4 NITRENDIPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 39562-70-4 NITRENDIPINE TISSUE_TOXICITY Hypotensive Shock 39562-70-4 NITRENDIPINE KNOWN_TOXICITY Embryo/Fetal Toxicity 39562-70-4 NITRENDIPINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 39562-70-4 NITRENDIPINE ADVERSE_EFFECT END_2_Increased Creatine Phosphokinase 39562-70-4 NITRENDIPINE ADVERSE_EFFECT EMB_3_Teratogenicity 39562-70-4 NITRENDIPINE ADVERSE_EFFECT NEU_2_Tremor 39562-70-4 NITRENDIPINE ADVERSE_EFFECT BBM_3_Agranulocytosis 39562-70-4 NITRENDIPINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 39562-70-4 NITRENDIPINE INDICATION Hypertension 39562-70-4 NITRENDIPINE ADVERSE_EFFECT XXX_2_Peripheral Edema 39562-70-4 NITRENDIPINE ADVERSE_EFFECT SKN_1_Flushing of the Skin 39562-70-4 NITRENDIPINE TA_LEVEL_1 Cardiovascular 39562-70-4 NITRENDIPINE THERAPEUTIC_CLASS Antianginals 39562-70-4 NITRENDIPINE ADVERSE_EFFECT CVS_2_Tachycardia 39562-70-4 NITRENDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 39562-70-4 NITRENDIPINE ADVERSE_EFFECT BBM_3_Anemia 39562-70-4 NITRENDIPINE MECH_LEVEL_2 Reduce muscle contractile force 39562-70-4 NITRENDIPINE PRODUCT_CLASS Cardiovasculars 38048-32-7 S-(4-NITROBENZYL)-6-THIOINOSINE MECHANISM Ehance adenosine-mediated vasodilation 38048-32-7 S-(4-NITROBENZYL)-6-THIOINOSINE PRODUCT_CLASS Biochemicals 38048-32-7 S-(4-NITROBENZYL)-6-THIOINOSINE MODE_CLASS Solute transporter inhibitor 67-20-9 NITROFURANTOIN TA_LEVEL_2 anti-bacterial 67-20-9 NITROFURANTOIN ADVERSE_EFFECT XXX_2_Chills 67-20-9 NITROFURANTOIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_2_Dizziness 67-20-9 NITROFURANTOIN ADVERSE_EFFECT SKN_2_Pruritis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_2_Vertigo 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LIV_3_Jaundice 67-20-9 NITROFURANTOIN ADVERSE_EFFECT GUS_2_Discoloration of Urine 67-20-9 NITROFURANTOIN TISSUE_TOXICITY Angina 67-20-9 NITROFURANTOIN ACTIVITY_CLASS DNA damager 67-20-9 NITROFURANTOIN THERAPEUTIC_CLASS Antibacterials, Systemic 67-20-9 NITROFURANTOIN MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 67-20-9 NITROFURANTOIN ADVERSE_EFFECT CVS_3_Angina 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_1_Headache 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_2_Drowsiness 67-20-9 NITROFURANTOIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LIV_3_Cholestasis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT IMU_1_Eosinophilia 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LUN_3_Tachypnea 67-20-9 NITROFURANTOIN MECHANISM Inhibit precursor synthesis 67-20-9 NITROFURANTOIN INDICATION Urinary Tract Infection (UTI) 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_2_Nystagmus 67-20-9 NITROFURANTOIN ADVERSE_EFFECT PSY_1_Anorexia 67-20-9 NITROFURANTOIN ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT BBM_3_Anemia 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LIV_3_Hepatitis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_3_Paresthesia 67-20-9 NITROFURANTOIN ADVERSE_EFFECT XXX_2_Fever 67-20-9 NITROFURANTOIN MESH_LEVEL_3 Furans 67-20-9 NITROFURANTOIN MODE_CLASS Enzyme Inhibitor 67-20-9 NITROFURANTOIN MECH_LEVEL_2 Enzyme inhibitor 67-20-9 NITROFURANTOIN INDICATION Cystitis 67-20-9 NITROFURANTOIN MECH_LEVEL_3 Acetyl CoA transferase 67-20-9 NITROFURANTOIN TA_LEVEL_3 urinary tract infections 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LUN_2_Cough 67-20-9 NITROFURANTOIN ADVERSE_EFFECT LUN_3_Dyspnea 67-20-9 NITROFURANTOIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 67-20-9 NITROFURANTOIN MESH_LEVEL_1 Heterocyclic Compounds 67-20-9 NITROFURANTOIN ADVERSE_EFFECT XXX_2_Asthenia 67-20-9 NITROFURANTOIN PRODUCT_CLASS Anti-infectives 67-20-9 NITROFURANTOIN TA_LEVEL_1 Infectious Disease 67-20-9 NITROFURANTOIN KNOWN_TOXICITY Cardiovascular Toxicity 67-20-9 NITROFURANTOIN ADVERSE_EFFECT BBM_3_Hemolysis 67-20-9 NITROFURANTOIN ADVERSE_EFFECT GIS_1_Diarrhea 67-20-9 NITROFURANTOIN ZERO_CLASS N 67-20-9 NITROFURANTOIN STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, antiparasitic 67-20-9 NITROFURANTOIN ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 67-20-9 NITROFURANTOIN ADVERSE_EFFECT GIS_1_Abdominal Pain 59-87-0 NITROFURAZONE THERAPEUTIC_CLASS Antibacterials, Topical 59-87-0 NITROFURAZONE ADVERSE_EFFECT SKN_1_Pruritis 59-87-0 NITROFURAZONE INDICATION Burn Wound Infection 59-87-0 NITROFURAZONE ADVERSE_EFFECT XXX_1_Superinfection 59-87-0 NITROFURAZONE INDICATION Skin Graft Management 59-87-0 NITROFURAZONE ADVERSE_EFFECT XXX_1_Edema 59-87-0 NITROFURAZONE PRODUCT_CLASS Anti-infectives 59-87-0 NITROFURAZONE MECHANISM Inhibit mitochondrial function 59-87-0 NITROFURAZONE ADVERSE_EFFECT SKN_1_Rash 59-87-0 NITROFURAZONE INDICATION Burns 59-87-0 NITROFURAZONE STRUCTURE_ACTIVITY Unknown mechanism 55-63-0 NITROGLYCERIN PRODUCT_CLASS Cardiovasculars 55-63-0 NITROGLYCERIN THERAPEUTIC_CLASS Antianginals 55-63-0 NITROGLYCERIN INDICATION Angina Pectoris 76963-41-2 NIZATIDINE TA_LEVEL_2 Duodenal ulcer treatment 76963-41-2 NIZATIDINE TA_LEVEL_1 Gastrointestinal System 76963-41-2 NIZATIDINE INDICATION Gastroesophageal Reflux Disease (GERD) 76963-41-2 NIZATIDINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 76963-41-2 NIZATIDINE ADVERSE_EFFECT REP_3_Impotence 76963-41-2 NIZATIDINE ACTIVITY_CLASS Histamine antagonist 76963-41-2 NIZATIDINE INDICATION Gastric Ulcer 76963-41-2 NIZATIDINE ADVERSE_EFFECT XXX_3_Sweating 76963-41-2 NIZATIDINE ADVERSE_EFFECT PSY_3_Confusion 76963-41-2 NIZATIDINE STRUCTURE_ACTIVITY Histamine receptor (H2) antagonist 76963-41-2 NIZATIDINE MECH_LEVEL_2 Reduce stomach HCl secretion 76963-41-2 NIZATIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 76963-41-2 NIZATIDINE MECH_LEVEL_1 Ulcer healing 76963-41-2 NIZATIDINE PRODUCT_CLASS Gastrointestinal System 76963-41-2 NIZATIDINE ADVERSE_EFFECT IMU_2_Urticaria 76963-41-2 NIZATIDINE ADVERSE_EFFECT IMU_3_Hypersensitivity 76963-41-2 NIZATIDINE MECHANISM Reduce stomach HCl secretion 76963-41-2 NIZATIDINE MESH_LEVEL_3 Thiazoles 76963-41-2 NIZATIDINE MESH_LEVEL_1 Heterocyclic Compounds 76963-41-2 NIZATIDINE TA_LEVEL_3 Gastric secretion inhibitors 76963-41-2 NIZATIDINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 76963-41-2 NIZATIDINE THERAPEUTIC_CLASS Antiulcers 76963-41-2 NIZATIDINE ADVERSE_EFFECT END_3_Gynecomastia 76963-41-2 NIZATIDINE ZERO_CLASS N 76963-41-2 NIZATIDINE ADVERSE_EFFECT BBM_2_Anemia 76963-41-2 NIZATIDINE INDICATION Duodenal Ulcer 76963-41-2 NIZATIDINE MECH_LEVEL_3 histamine receptor H2 76963-41-2 NIZATIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 31430-18-9 NOCODAZOLE MECHANISM Inhibit mitosis 31430-18-9 NOCODAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 31430-18-9 NOCODAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 31430-18-9 NOCODAZOLE PRODUCT_CLASS Anti-cancers 31430-18-9 NOCODAZOLE THERAPEUTIC_CLASS Antineoplastics 24526-64-5 NOMIFENSINE KNOWN_TOXICITY Nephrotoxicity 24526-64-5 NOMIFENSINE MODE_CLASS Solute transporter inhibitor 24526-64-5 NOMIFENSINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 24526-64-5 NOMIFENSINE ADVERSE_EFFECT LUN_3_Pulmonary Alveolitis 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 24526-64-5 NOMIFENSINE ADVERSE_EFFECT NEU_3_Tremor 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_3_Anxiety 24526-64-5 NOMIFENSINE ADVERSE_EFFECT GIS_2_Dry Mouth 24526-64-5 NOMIFENSINE ADVERSE_EFFECT LIV_3_Hepatic Toxicity 24526-64-5 NOMIFENSINE ADVERSE_EFFECT LIV_3_Increased Serum Alkaline Phosphatase 24526-64-5 NOMIFENSINE ADVERSE_EFFECT MSK_3_Joint Pain 24526-64-5 NOMIFENSINE MODE_CLASS Receptor Ligand Antagonist 24526-64-5 NOMIFENSINE THERAPEUTIC_CLASS Antidepressants 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_3_Psychosis 24526-64-5 NOMIFENSINE ADVERSE_EFFECT NEU_3_Somnolence 24526-64-5 NOMIFENSINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 24526-64-5 NOMIFENSINE ADVERSE_EFFECT GIS_3_Diarrhea 24526-64-5 NOMIFENSINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 24526-64-5 NOMIFENSINE ADVERSE_EFFECT CVS_3_Hypotension 24526-64-5 NOMIFENSINE ADVERSE_EFFECT BBM_2_Intravascular Hemolysis 24526-64-5 NOMIFENSINE ADVERSE_EFFECT MSK_3_Muscle Pain 24526-64-5 NOMIFENSINE KNOWN_TOXICITY Cardiovascular Toxicity 24526-64-5 NOMIFENSINE TISSUE_TOXICITY Hepatic Toxicity 24526-64-5 NOMIFENSINE MECHANISM Modulate G-protein coupled signal transduction 24526-64-5 NOMIFENSINE PRODUCT_CLASS Central Nervous System (CNS) 24526-64-5 NOMIFENSINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT/NET) inhibitor, adrenoceptor-alpha antagonist 24526-64-5 NOMIFENSINE KNOWN_TOXICITY Hepatotoxicity 24526-64-5 NOMIFENSINE TISSUE_TOXICITY Renal Failure 24526-64-5 NOMIFENSINE MECHANISM Prolong/enhance neural transmission 24526-64-5 NOMIFENSINE ADVERSE_EFFECT NEU_3_Dyskinesia 24526-64-5 NOMIFENSINE ADVERSE_EFFECT NEU_3_Psychomotor Excitation 24526-64-5 NOMIFENSINE ADVERSE_EFFECT XXX_2_Restlessness 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_3_Delirium 24526-64-5 NOMIFENSINE ADVERSE_EFFECT XXX_3_Fever 24526-64-5 NOMIFENSINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_2_Insomnia 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_3_Mental Confusion 24526-64-5 NOMIFENSINE MECHANISM Prolong/enhance neural transmission 24526-64-5 NOMIFENSINE TISSUE_TOXICITY Hypotension 24526-64-5 NOMIFENSINE INDICATION Depression 24526-64-5 NOMIFENSINE INDICATION Depression 24526-64-5 NOMIFENSINE ADVERSE_EFFECT LUN_3_Pneumonia 24526-64-5 NOMIFENSINE ADVERSE_EFFECT KID_3_Renal Failure 24526-64-5 NOMIFENSINE ADVERSE_EFFECT CVS_3_Tachycardia 24526-64-5 NOMIFENSINE ADVERSE_EFFECT GIS_3_Constipation 24526-64-5 NOMIFENSINE ADVERSE_EFFECT LIV_3_Hepatitis 24526-64-5 NOMIFENSINE ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 24526-64-5 NOMIFENSINE ADVERSE_EFFECT PSY_3_Mania 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT XXX_1_Diaphoresis 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT CVS_2_Angina 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT LUN_2_Pulmonary Edema 51-41-2 NOREPINEPHRINE INDICATION Cardiogenic Shock 51-41-2 NOREPINEPHRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 51-41-2 NOREPINEPHRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 51-41-2 NOREPINEPHRINE ACTIVITY_CLASS Adrenergic agonist 51-41-2 NOREPINEPHRINE KNOWN_TOXICITY Cardiovascular Toxicity 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT LUN_2_Dyspnea 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51-41-2 NOREPINEPHRINE TISSUE_TOXICITY Angina 51-41-2 NOREPINEPHRINE MECHANISM Modulate G-protein coupled signal transduction 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT CVS_1_Palpitation 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT PSY_1_Insomnia 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT NEU_2_Headache 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT PSY_1_Anxiety 51-41-2 NOREPINEPHRINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 51-41-2 NOREPINEPHRINE THERAPEUTIC_CLASS Sympathomimetic Agents 51-41-2 NOREPINEPHRINE MODE_CLASS Endogenous Receptor /Channel Ligand 51-41-2 NOREPINEPHRINE INDICATION Hypotension 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT CVS_2_ST-T Wave Changes 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT NEU_1_Dizziness 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT XXX_2_Local Tissue Necrosis 51-41-2 NOREPINEPHRINE INDICATION Septic Shock 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT END_2_Metabolic Acidosis 51-41-2 NOREPINEPHRINE ADVERSE_EFFECT LUN_2_Apnea 68-22-4 NORETHINDRONE ADVERSE_EFFECT REP_2_Ovarian Follicular Cyst 68-22-4 NORETHINDRONE ADVERSE_EFFECT END_2_Hirsutism 68-22-4 NORETHINDRONE ADVERSE_EFFECT XXX_2_Weight Gain 68-22-4 NORETHINDRONE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 68-22-4 NORETHINDRONE MESH_LEVEL_2 Steroids 68-22-4 NORETHINDRONE MECHANISM Modulate gene transcription 68-22-4 NORETHINDRONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 68-22-4 NORETHINDRONE INDICATION Amenorrhea 68-22-4 NORETHINDRONE ADVERSE_EFFECT SKN_1_Acne 68-22-4 NORETHINDRONE MESH_LEVEL_3 Norsteroids 68-22-4 NORETHINDRONE ADVERSE_EFFECT END_2_Increases LDL 68-22-4 NORETHINDRONE ADVERSE_EFFECT GUS_2_Vaginitis 68-22-4 NORETHINDRONE TISSUE_TOXICITY Breakthrough Bleeding 68-22-4 NORETHINDRONE ADVERSE_EFFECT REP_3_Amenorrhea 68-22-4 NORETHINDRONE ADVERSE_EFFECT NEU_1_Headache 68-22-4 NORETHINDRONE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 68-22-4 NORETHINDRONE MESH_LEVEL_1 Polycyclic Hydrocarbons 68-22-4 NORETHINDRONE INDICATION Dysfunctional Uterine Bleeding (DUB) 68-22-4 NORETHINDRONE MECH_LEVEL_3 Progesterone receptor 68-22-4 NORETHINDRONE MECH_LEVEL_2 progestatgen 68-22-4 NORETHINDRONE ADVERSE_EFFECT END_2_Decreases HDL 68-22-4 NORETHINDRONE ADVERSE_EFFECT END_2_Glucose Intolerance 68-22-4 NORETHINDRONE ADVERSE_EFFECT GIS_1_Nausea 68-22-4 NORETHINDRONE TA_LEVEL_3 Progesterone receptor agonists 68-22-4 NORETHINDRONE TA_LEVEL_1 Hormones, Endocrine and Metabolic 68-22-4 NORETHINDRONE THERAPEUTIC_CLASS Gonadal Hormones 68-22-4 NORETHINDRONE ADVERSE_EFFECT REP_3_Unintended Pregnancy 68-22-4 NORETHINDRONE ADVERSE_EFFECT NEU_3_Migraine 68-22-4 NORETHINDRONE ADVERSE_EFFECT END_2_Breast Tenderness 68-22-4 NORETHINDRONE ADVERSE_EFFECT REP_3_Ectopic Pregnancy 68-22-4 NORETHINDRONE ZERO_CLASS N 68-22-4 NORETHINDRONE MODE_CLASS Receptor Agonist 68-22-4 NORETHINDRONE ADVERSE_EFFECT PSY_2_Emotional Lability 68-22-4 NORETHINDRONE INDICATION Endometriosis 68-22-4 NORETHINDRONE STRUCTURE_ACTIVITY Progesterone receptor agonist 68-22-4 NORETHINDRONE ACTIVITY_CLASS Progesterone receptor agonist 68-22-4 NORETHINDRONE KNOWN_TOXICITY Reproductive System Toxicity 68-22-4 NORETHINDRONE INDICATION Contraception 68-22-4 NORETHINDRONE MECH_LEVEL_1 Ovulation inhibitor 51-98-9 NORETHINDRONE ACETATE TISSUE_TOXICITY Breakthrough Bleeding 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_3_Unintended Pregnancy 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Glucose Intolerance 51-98-9 NORETHINDRONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT GIS_1_Nausea 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_3_Amenorrhea 51-98-9 NORETHINDRONE ACETATE MESH_LEVEL_1 Polycyclic Hydrocarbons 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT CVS_3_Hypertension 51-98-9 NORETHINDRONE ACETATE STRUCTURE_ACTIVITY Progesterone receptor agonist 51-98-9 NORETHINDRONE ACETATE MECH_LEVEL_2 progestatgen 51-98-9 NORETHINDRONE ACETATE MECHANISM Modulate gene transcription 51-98-9 NORETHINDRONE ACETATE INDICATION Hot Flashes 51-98-9 NORETHINDRONE ACETATE INDICATION Persistent Anovulation / Polycystic Ovary Syndrome 51-98-9 NORETHINDRONE ACETATE MECH_LEVEL_3 Progesterone receptor 51-98-9 NORETHINDRONE ACETATE MODE_CLASS Receptor Agonist 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT XXX_2_Weight Gain 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Hirsutism 51-98-9 NORETHINDRONE ACETATE INDICATION Atrophic Vaginitis 51-98-9 NORETHINDRONE ACETATE INDICATION Hirsutism 51-98-9 NORETHINDRONE ACETATE INDICATION Dysfunctional Uterine Bleeding (DUB) 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT GUS_2_Vaginitis 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Breast Tenderness 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_3_Ectopic Pregnancy 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT KID_2_Fluid Retention 51-98-9 NORETHINDRONE ACETATE MESH_LEVEL_3 Norsteroids 51-98-9 NORETHINDRONE ACETATE MESH_LEVEL_2 Steroids 51-98-9 NORETHINDRONE ACETATE INDICATION Contraception 51-98-9 NORETHINDRONE ACETATE INDICATION Prevention of Osteoporosis 51-98-9 NORETHINDRONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 51-98-9 NORETHINDRONE ACETATE THERAPEUTIC_CLASS Gonadal Hormones 51-98-9 NORETHINDRONE ACETATE THERAPEUTIC_CLASS Contraceptive Hormones 51-98-9 NORETHINDRONE ACETATE TISSUE_TOXICITY Thromboembolism 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Increases LDL 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Decreases HDL 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT SKN_1_Acne 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT CVS_3_Thromboembolism 51-98-9 NORETHINDRONE ACETATE ACTIVITY_CLASS Progesterone receptor agonist 51-98-9 NORETHINDRONE ACETATE INDICATION Acne / Acne Vulgaris 51-98-9 NORETHINDRONE ACETATE INDICATION Amenorrhea 51-98-9 NORETHINDRONE ACETATE MECH_LEVEL_1 Ovulation inhibitor 51-98-9 NORETHINDRONE ACETATE TA_LEVEL_3 Progesterone receptor agonists 51-98-9 NORETHINDRONE ACETATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 51-98-9 NORETHINDRONE ACETATE INDICATION Menopausal Syndrome 51-98-9 NORETHINDRONE ACETATE KNOWN_TOXICITY Reproductive System Toxicity 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT NEU_3_Migraine 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_2_Ovarian Follicular Cyst 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT PSY_2_Emotional Lability 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT NEU_1_Headache 51-98-9 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 51-98-9 NORETHINDRONE ACETATE ZERO_CLASS N 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Hirsutism 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT XXX_2_Weight Gain 8015-12-1 NORETHINDRONE ACETATE MODE_CLASS Receptor Agonist 8015-12-1 NORETHINDRONE ACETATE MECH_LEVEL_3 Progesterone receptor 8015-12-1 NORETHINDRONE ACETATE INDICATION Persistent Anovulation / Polycystic Ovary Syndrome 8015-12-1 NORETHINDRONE ACETATE INDICATION Hot Flashes 8015-12-1 NORETHINDRONE ACETATE MECHANISM Modulate gene transcription 8015-12-1 NORETHINDRONE ACETATE MECH_LEVEL_2 progestatgen 8015-12-1 NORETHINDRONE ACETATE STRUCTURE_ACTIVITY Progesterone receptor agonist 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT CVS_3_Hypertension 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_3_Amenorrhea 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT GIS_1_Nausea 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Glucose Intolerance 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT GUS_2_Vaginitis 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_3_Unintended Pregnancy 8015-12-1 NORETHINDRONE ACETATE TISSUE_TOXICITY Breakthrough Bleeding 8015-12-1 NORETHINDRONE ACETATE INDICATION Dysfunctional Uterine Bleeding (DUB) 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT SKN_1_Acne 8015-12-1 NORETHINDRONE ACETATE ZERO_CLASS N 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_1_Breakthrough Bleeding 8015-12-1 NORETHINDRONE ACETATE INDICATION Prevention of Osteoporosis 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT NEU_1_Headache 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT PSY_2_Emotional Lability 8015-12-1 NORETHINDRONE ACETATE INDICATION Hirsutism 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_2_Ovarian Follicular Cyst 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT NEU_3_Migraine 8015-12-1 NORETHINDRONE ACETATE KNOWN_TOXICITY Reproductive System Toxicity 8015-12-1 NORETHINDRONE ACETATE INDICATION Menopausal Syndrome 8015-12-1 NORETHINDRONE ACETATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 8015-12-1 NORETHINDRONE ACETATE TA_LEVEL_3 Progesterone receptor agonists 8015-12-1 NORETHINDRONE ACETATE MECH_LEVEL_1 Ovulation inhibitor 8015-12-1 NORETHINDRONE ACETATE INDICATION Amenorrhea 8015-12-1 NORETHINDRONE ACETATE INDICATION Acne / Acne Vulgaris 8015-12-1 NORETHINDRONE ACETATE ACTIVITY_CLASS Progesterone receptor agonist 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT CVS_3_Thromboembolism 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Decreases HDL 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Increases LDL 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 8015-12-1 NORETHINDRONE ACETATE TISSUE_TOXICITY Thromboembolism 8015-12-1 NORETHINDRONE ACETATE THERAPEUTIC_CLASS Contraceptive Hormones 8015-12-1 NORETHINDRONE ACETATE THERAPEUTIC_CLASS Gonadal Hormones 8015-12-1 NORETHINDRONE ACETATE KNOWN_TOXICITY Cardiovascular Toxicity 8015-12-1 NORETHINDRONE ACETATE INDICATION Contraception 8015-12-1 NORETHINDRONE ACETATE MESH_LEVEL_2 Steroids 8015-12-1 NORETHINDRONE ACETATE MESH_LEVEL_3 Norsteroids 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT KID_2_Fluid Retention 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT REP_3_Ectopic Pregnancy 8015-12-1 NORETHINDRONE ACETATE ADVERSE_EFFECT END_2_Breast Tenderness 8015-12-1 NORETHINDRONE ACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 8015-12-1 NORETHINDRONE ACETATE MESH_LEVEL_1 Polycyclic Hydrocarbons 8015-12-1 NORETHINDRONE ACETATE INDICATION Atrophic Vaginitis 70458-96-7 NORFLOXACIN ADVERSE_EFFECT GIS_2_Nausea 70458-96-7 NORFLOXACIN ADVERSE_EFFECT SKN_3_Rash 70458-96-7 NORFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 70458-96-7 NORFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 70458-96-7 NORFLOXACIN MESH_LEVEL_3 Quinolines 70458-96-7 NORFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 70458-96-7 NORFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 70458-96-7 NORFLOXACIN ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 70458-96-7 NORFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 70458-96-7 NORFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 70458-96-7 NORFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 70458-96-7 NORFLOXACIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 70458-96-7 NORFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 70458-96-7 NORFLOXACIN THERAPEUTIC_CLASS Antibacterials 70458-96-7 NORFLOXACIN INDICATION Prostatitis 70458-96-7 NORFLOXACIN MECH_LEVEL_3 DNA gyrase, bacterial (ATP-hydrolysing) 70458-96-7 NORFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 70458-96-7 NORFLOXACIN ADVERSE_EFFECT KID_3_Renal Toxicity 70458-96-7 NORFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 70458-96-7 NORFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 70458-96-7 NORFLOXACIN ADVERSE_EFFECT MSK_3_Tendinopathy 70458-96-7 NORFLOXACIN ADVERSE_EFFECT BBM_3_Induces Hemolysis in G6PD Deficiency 70458-96-7 NORFLOXACIN ADVERSE_EFFECT NEU_2_Headache 70458-96-7 NORFLOXACIN ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 70458-96-7 NORFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 70458-96-7 NORFLOXACIN KNOWN_TOXICITY Nephrotoxicity 70458-96-7 NORFLOXACIN INDICATION Urinary Tract Infection (UTI) 70458-96-7 NORFLOXACIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 70458-96-7 NORFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 70458-96-7 NORFLOXACIN TA_LEVEL_2 Antibacterials 70458-96-7 NORFLOXACIN INDICATION Endocervical Gonorrhea 70458-96-7 NORFLOXACIN MECH_LEVEL_1 Anti-bacterial 70458-96-7 NORFLOXACIN TA_LEVEL_1 Infectious Disease 70458-96-7 NORFLOXACIN TISSUE_TOXICITY Renal Toxicity 70458-96-7 NORFLOXACIN TISSUE_TOXICITY Interstitial Nephritis 70458-96-7 NORFLOXACIN ADVERSE_EFFECT GIS_3_Pancreatitis 70458-96-7 NORFLOXACIN ADVERSE_EFFECT KID_3_Crystals in Urine 70458-96-7 NORFLOXACIN ADVERSE_EFFECT IMU_2_Phototoxicity 70458-96-7 NORFLOXACIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 70458-96-7 NORFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 70458-96-7 NORFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 70458-96-7 NORFLOXACIN ZERO_CLASS N 70458-96-7 NORFLOXACIN KNOWN_TOXICITY Hepatotoxicity 70458-96-7 NORFLOXACIN TA_LEVEL_3 quinolones 70458-96-7 NORFLOXACIN TISSUE_TOXICITY Hepatotoxicity 70458-96-7 NORFLOXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 70458-96-7 NORFLOXACIN ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 70458-96-7 NORFLOXACIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 70458-96-7 NORFLOXACIN PRODUCT_CLASS Anti-infectives 68077-27-0 NORFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 68077-27-0 NORFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 68077-27-0 NORFLOXACIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 68077-27-0 NORFLOXACIN ADVERSE_EFFECT MSK_3_Tendinopathy 68077-27-0 NORFLOXACIN ADVERSE_EFFECT BBM_3_Induces Hemolysis in G6PD Deficiency 68077-27-0 NORFLOXACIN ADVERSE_EFFECT NEU_2_Headache 68077-27-0 NORFLOXACIN ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 68077-27-0 NORFLOXACIN ADVERSE_EFFECT KID_3_Renal Toxicity 68077-27-0 NORFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 68077-27-0 NORFLOXACIN KNOWN_TOXICITY Nephrotoxicity 68077-27-0 NORFLOXACIN INDICATION Urinary Tract Infection (UTI) 68077-27-0 NORFLOXACIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 68077-27-0 NORFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 68077-27-0 NORFLOXACIN TA_LEVEL_2 Antibacterials 68077-27-0 NORFLOXACIN INDICATION Endocervical Gonorrhea 68077-27-0 NORFLOXACIN MECH_LEVEL_3 DNA gyrase, bacterial (ATP-hydrolysing) 68077-27-0 NORFLOXACIN MECH_LEVEL_1 Anti-bacterial 68077-27-0 NORFLOXACIN TA_LEVEL_1 Infectious Disease 68077-27-0 NORFLOXACIN TISSUE_TOXICITY Renal Toxicity 68077-27-0 NORFLOXACIN TISSUE_TOXICITY Interstitial Nephritis 68077-27-0 NORFLOXACIN ADVERSE_EFFECT GIS_3_Pancreatitis 68077-27-0 NORFLOXACIN ADVERSE_EFFECT KID_3_Crystals in Urine 68077-27-0 NORFLOXACIN ADVERSE_EFFECT IMU_2_Phototoxicity 68077-27-0 NORFLOXACIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 68077-27-0 NORFLOXACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 68077-27-0 NORFLOXACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 68077-27-0 NORFLOXACIN ZERO_CLASS N 68077-27-0 NORFLOXACIN KNOWN_TOXICITY Hepatotoxicity 68077-27-0 NORFLOXACIN TA_LEVEL_3 quinolones 68077-27-0 NORFLOXACIN TISSUE_TOXICITY Hepatotoxicity 68077-27-0 NORFLOXACIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 68077-27-0 NORFLOXACIN ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 68077-27-0 NORFLOXACIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 68077-27-0 NORFLOXACIN ADVERSE_EFFECT GIS_2_Nausea 68077-27-0 NORFLOXACIN ADVERSE_EFFECT SKN_3_Rash 68077-27-0 NORFLOXACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 68077-27-0 NORFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 68077-27-0 NORFLOXACIN MESH_LEVEL_3 Quinolines 68077-27-0 NORFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 68077-27-0 NORFLOXACIN ADVERSE_EFFECT GUS_2_Vaginitis 68077-27-0 NORFLOXACIN ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 68077-27-0 NORFLOXACIN ADVERSE_EFFECT MSK_3_Rupture of Shoulder / Hand / Achilles Tendon 68077-27-0 NORFLOXACIN ADVERSE_EFFECT NEU_3_Convulsions 68077-27-0 NORFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 68077-27-0 NORFLOXACIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 68077-27-0 NORFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 68077-27-0 NORFLOXACIN THERAPEUTIC_CLASS Antibacterials 68077-27-0 NORFLOXACIN INDICATION Prostatitis 68077-27-0 NORFLOXACIN PRODUCT_CLASS Anti-infectives 35189-28-7 NORGESTIMATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 35189-28-7 NORGESTIMATE MECHANISM Modulate gene transcription 35189-28-7 NORGESTIMATE THERAPEUTIC_CLASS Contraceptive Hormones 35189-28-7 NORGESTIMATE MODE_CLASS Receptor Agonist 797-63-7 NORGESTREL TISSUE_TOXICITY Thromboembolism 797-63-7 NORGESTREL INDICATION Contraception 797-63-7 NORGESTREL TISSUE_TOXICITY Amenorrhea 797-63-7 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 797-63-7 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 797-63-7 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 797-63-7 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 797-63-7 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 797-63-7 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 797-63-7 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 797-63-7 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 797-63-7 NORGESTREL MECHANISM Modulate gene transcription 797-63-7 NORGESTREL KNOWN_TOXICITY Carcinogenicity 797-63-7 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 797-63-7 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 797-63-7 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 797-63-7 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 797-63-7 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 797-63-7 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 797-63-7 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 797-63-7 NORGESTREL MODE_CLASS Receptor Agonist 797-63-7 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 797-63-7 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 797-63-7 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 797-63-7 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 797-63-7 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 797-63-7 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 797-63-7 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 797-63-7 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 797-63-7 NORGESTREL TISSUE_TOXICITY Hepatoma 797-63-7 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 797-63-7 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 797-63-7 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 797-63-7 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 797-63-7 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 797-63-7 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 797-63-7 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 797-63-7 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 797-63-7 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 797-63-7 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 797-63-7 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 6533-00-2 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 6533-00-2 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 6533-00-2 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 6533-00-2 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 6533-00-2 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 6533-00-2 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 6533-00-2 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 6533-00-2 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 6533-00-2 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 6533-00-2 NORGESTREL MODE_CLASS Receptor Agonist 6533-00-2 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 6533-00-2 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 6533-00-2 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 6533-00-2 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 6533-00-2 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 6533-00-2 NORGESTREL KNOWN_TOXICITY Carcinogenicity 6533-00-2 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 6533-00-2 NORGESTREL TISSUE_TOXICITY Thromboembolism 6533-00-2 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 6533-00-2 NORGESTREL MECHANISM Modulate gene transcription 6533-00-2 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 6533-00-2 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 6533-00-2 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 6533-00-2 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 6533-00-2 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 6533-00-2 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 6533-00-2 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 6533-00-2 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 6533-00-2 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 6533-00-2 NORGESTREL TISSUE_TOXICITY Amenorrhea 6533-00-2 NORGESTREL INDICATION Contraception 6533-00-2 NORGESTREL TISSUE_TOXICITY Hepatoma 6533-00-2 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 6533-00-2 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 6533-00-2 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 6533-00-2 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 6533-00-2 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 6533-00-2 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 6533-00-2 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 6533-00-2 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 6533-00-2 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 797-62-6 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 797-62-6 NORGESTREL INDICATION Contraception 797-62-6 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 797-62-6 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 797-62-6 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 797-62-6 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 797-62-6 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 797-62-6 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 797-62-6 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 797-62-6 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 797-62-6 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 797-62-6 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 797-62-6 NORGESTREL TISSUE_TOXICITY Hepatoma 797-62-6 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 797-62-6 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 797-62-6 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 797-62-6 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 797-62-6 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 797-62-6 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 797-62-6 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 797-62-6 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 797-62-6 NORGESTREL MODE_CLASS Receptor Agonist 797-62-6 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 797-62-6 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 797-62-6 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 797-62-6 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 797-62-6 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 797-62-6 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 797-62-6 NORGESTREL TISSUE_TOXICITY Thromboembolism 797-62-6 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 797-62-6 NORGESTREL KNOWN_TOXICITY Carcinogenicity 797-62-6 NORGESTREL MECHANISM Modulate gene transcription 797-62-6 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 797-62-6 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 797-62-6 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 797-62-6 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 797-62-6 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 797-62-6 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 797-62-6 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 797-62-6 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 797-62-6 NORGESTREL TISSUE_TOXICITY Amenorrhea 4222-79-1 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 4222-79-1 NORGESTREL INDICATION Contraception 4222-79-1 NORGESTREL TISSUE_TOXICITY Amenorrhea 4222-79-1 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 4222-79-1 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 4222-79-1 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 4222-79-1 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 4222-79-1 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 4222-79-1 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 4222-79-1 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 4222-79-1 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 4222-79-1 NORGESTREL MECHANISM Modulate gene transcription 4222-79-1 NORGESTREL KNOWN_TOXICITY Carcinogenicity 4222-79-1 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 4222-79-1 NORGESTREL TISSUE_TOXICITY Thromboembolism 4222-79-1 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 4222-79-1 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 4222-79-1 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 4222-79-1 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 4222-79-1 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 4222-79-1 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 4222-79-1 NORGESTREL MODE_CLASS Receptor Agonist 4222-79-1 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 4222-79-1 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 4222-79-1 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 4222-79-1 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 4222-79-1 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 4222-79-1 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 4222-79-1 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 4222-79-1 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 4222-79-1 NORGESTREL TISSUE_TOXICITY Hepatoma 4222-79-1 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 4222-79-1 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 4222-79-1 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 4222-79-1 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 4222-79-1 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 4222-79-1 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 4222-79-1 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 4222-79-1 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 4222-79-1 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 4222-79-1 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 121714-72-5 NORGESTREL TISSUE_TOXICITY Thromboembolism 121714-72-5 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 121714-72-5 NORGESTREL KNOWN_TOXICITY Carcinogenicity 121714-72-5 NORGESTREL MECHANISM Modulate gene transcription 121714-72-5 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 121714-72-5 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 121714-72-5 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 121714-72-5 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 121714-72-5 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 121714-72-5 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 121714-72-5 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 121714-72-5 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 121714-72-5 NORGESTREL TISSUE_TOXICITY Amenorrhea 121714-72-5 NORGESTREL INDICATION Contraception 121714-72-5 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 121714-72-5 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 121714-72-5 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 121714-72-5 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 121714-72-5 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 121714-72-5 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 121714-72-5 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 121714-72-5 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 121714-72-5 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 121714-72-5 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 121714-72-5 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 121714-72-5 NORGESTREL TISSUE_TOXICITY Hepatoma 121714-72-5 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 121714-72-5 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 121714-72-5 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 121714-72-5 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 121714-72-5 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 121714-72-5 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 121714-72-5 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 121714-72-5 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 121714-72-5 NORGESTREL MODE_CLASS Receptor Agonist 121714-72-5 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 121714-72-5 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 121714-72-5 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 121714-72-5 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 121714-72-5 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 121714-72-5 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 797-64-8 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 797-64-8 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 797-64-8 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 797-64-8 NORGESTREL TISSUE_TOXICITY Hepatoma 797-64-8 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 797-64-8 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 797-64-8 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 797-64-8 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 797-64-8 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 797-64-8 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 797-64-8 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 797-64-8 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 797-64-8 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 797-64-8 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 797-64-8 NORGESTREL MODE_CLASS Receptor Agonist 797-64-8 NORGESTREL INDICATION Contraception 797-64-8 NORGESTREL TISSUE_TOXICITY Amenorrhea 797-64-8 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 797-64-8 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 797-64-8 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 797-64-8 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 797-64-8 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 797-64-8 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 797-64-8 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 797-64-8 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 797-64-8 NORGESTREL MECHANISM Modulate gene transcription 797-64-8 NORGESTREL KNOWN_TOXICITY Carcinogenicity 797-64-8 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 797-64-8 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 797-64-8 NORGESTREL TISSUE_TOXICITY Thromboembolism 797-64-8 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 797-64-8 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 797-64-8 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 797-64-8 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 797-64-8 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 797-64-8 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 797-64-8 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 797-64-8 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 797-64-8 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 797-64-8 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 797-64-8 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 150200-16-1 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 150200-16-1 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 150200-16-1 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 150200-16-1 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 150200-16-1 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 150200-16-1 NORGESTREL TISSUE_TOXICITY Hepatoma 150200-16-1 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 150200-16-1 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 150200-16-1 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 150200-16-1 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 150200-16-1 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 150200-16-1 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 150200-16-1 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 150200-16-1 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 150200-16-1 NORGESTREL MODE_CLASS Receptor Agonist 150200-16-1 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 150200-16-1 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 150200-16-1 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 150200-16-1 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 150200-16-1 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 150200-16-1 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 150200-16-1 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 150200-16-1 NORGESTREL KNOWN_TOXICITY Carcinogenicity 150200-16-1 NORGESTREL MECHANISM Modulate gene transcription 150200-16-1 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 150200-16-1 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 150200-16-1 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 150200-16-1 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 150200-16-1 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 150200-16-1 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 150200-16-1 NORGESTREL TISSUE_TOXICITY Thromboembolism 150200-16-1 NORGESTREL TISSUE_TOXICITY Amenorrhea 150200-16-1 NORGESTREL INDICATION Contraception 150200-16-1 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 150200-16-1 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 150200-16-1 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 150200-16-1 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 150200-16-1 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 150200-16-1 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 150200-16-1 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 150200-16-1 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 76497-12-6 NORGESTREL ADVERSE_EFFECT SKN_2_Dermatitis 76497-12-6 NORGESTREL ADVERSE_EFFECT DNA_3_Hepatoma 76497-12-6 NORGESTREL KNOWN_TOXICITY Cardiovascular Toxicity 76497-12-6 NORGESTREL MECHANISM Modulate gene transcription 76497-12-6 NORGESTREL KNOWN_TOXICITY Carcinogenicity 76497-12-6 NORGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 76497-12-6 NORGESTREL TISSUE_TOXICITY Thromboembolism 76497-12-6 NORGESTREL ADVERSE_EFFECT END_3_Hyperglycemia 76497-12-6 NORGESTREL ADVERSE_EFFECT XXX_2_Increased Appetite 76497-12-6 NORGESTREL ADVERSE_EFFECT XXX_1_Weight Gain 76497-12-6 NORGESTREL ADVERSE_EFFECT REP_1_Breakthrough Bleeding 76497-12-6 NORGESTREL ADVERSE_EFFECT GIS_2_Abdominal Pain 76497-12-6 NORGESTREL ADVERSE_EFFECT REP_2_Altered Libido 76497-12-6 NORGESTREL MODE_CLASS Receptor Agonist 76497-12-6 NORGESTREL ADVERSE_EFFECT PSY_2_Anxiety 76497-12-6 NORGESTREL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 76497-12-6 NORGESTREL ADVERSE_EFFECT NEU_2_Dizziness 76497-12-6 NORGESTREL ADVERSE_EFFECT END_1_Breast Tenderness 76497-12-6 NORGESTREL ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 76497-12-6 NORGESTREL ADVERSE_EFFECT GUS_2_Vaginitis 76497-12-6 NORGESTREL ADVERSE_EFFECT PSY_2_Depression 76497-12-6 NORGESTREL TISSUE_TOXICITY Hepatoma 76497-12-6 NORGESTREL STRUCTURE_ACTIVITY Progesterone receptor agonist 76497-12-6 NORGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 76497-12-6 NORGESTREL TISSUE_TOXICITY Breakthrough Bleeding 76497-12-6 NORGESTREL ADVERSE_EFFECT NEU_1_Headache 76497-12-6 NORGESTREL ADVERSE_EFFECT REP_1_Amenorrhea 76497-12-6 NORGESTREL ADVERSE_EFFECT REP_1_Menstrual Irregularities 76497-12-6 NORGESTREL ADVERSE_EFFECT SKN_2_Acne 76497-12-6 NORGESTREL ADVERSE_EFFECT PSY_2_Anorexia 76497-12-6 NORGESTREL ADVERSE_EFFECT KID_3_Fluid Retention 76497-12-6 NORGESTREL ADVERSE_EFFECT XXX_1_Mastalgia 76497-12-6 NORGESTREL KNOWN_TOXICITY Reproductive System Toxicity 76497-12-6 NORGESTREL ADVERSE_EFFECT XXX_3_Weight Loss 76497-12-6 NORGESTREL INDICATION Contraception 76497-12-6 NORGESTREL TISSUE_TOXICITY Amenorrhea 76497-12-6 NORGESTREL ADVERSE_EFFECT CVS_3_Hypertension 76497-12-6 NORGESTREL ADVERSE_EFFECT END_2_Hirsutism 76497-12-6 NORGESTREL ADVERSE_EFFECT LIV_3_Hepatitis 76497-12-6 NORGESTREL ADVERSE_EFFECT PSY_3_Emotional Lability 76497-12-6 NORGESTREL ADVERSE_EFFECT CVS_2_Thromboembolism 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Palpitation 72-69-5 NORTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 72-69-5 NORTRIPTYLINE MECH_LEVEL_2 reuptake of Norepinephrine inhibition 72-69-5 NORTRIPTYLINE INDICATION Enuresis 72-69-5 NORTRIPTYLINE INDICATION Neuropathic Pain 72-69-5 NORTRIPTYLINE MECH_LEVEL_1 Modulate neural transmission 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT BBM_3_Hematological Reactions 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT REP_3_Decreased Libido 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT OCU_3_Blurred Vision 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Arrythmogenic 72-69-5 NORTRIPTYLINE THERAPEUTIC_CLASS Antispasmodic Agents 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 72-69-5 NORTRIPTYLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 72-69-5 NORTRIPTYLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 72-69-5 NORTRIPTYLINE MECHANISM Prolong/enhance neural transmission 72-69-5 NORTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 72-69-5 NORTRIPTYLINE MESH_LEVEL_3 Benzocycloheptenes 72-69-5 NORTRIPTYLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 72-69-5 NORTRIPTYLINE INDICATION Panic Disorder 72-69-5 NORTRIPTYLINE INDICATION Migraine Headache 72-69-5 NORTRIPTYLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT REP_3_Impotence 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT OCU_3_Acute Angle-Closure Glaucoma 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Tremor 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT CVS_3_Hypertension 72-69-5 NORTRIPTYLINE ZERO_CLASS N 72-69-5 NORTRIPTYLINE PRODUCT_CLASS Analgesics 72-69-5 NORTRIPTYLINE INDICATION Phobic Disorder 72-69-5 NORTRIPTYLINE TA_LEVEL_1 Central Nervous System (CNS) 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 72-69-5 NORTRIPTYLINE TISSUE_TOXICITY Ventricular Tachycardia 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT NEU_1_Dizziness 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT IMU_3_Photosensitivity 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT END_3_Galactorrhea 72-69-5 NORTRIPTYLINE MODE_CLASS Solute transporter inhibitor 72-69-5 NORTRIPTYLINE INDICATION Depression 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT NEU_1_Drowsiness 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT PSY_2_Confusion 72-69-5 NORTRIPTYLINE MECH_LEVEL_3 Norepinephrine Transporter NET 72-69-5 NORTRIPTYLINE TA_LEVEL_3 Antidepressants 72-69-5 NORTRIPTYLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 72-69-5 NORTRIPTYLINE INDICATION Postherpetic Neuralgia 72-69-5 NORTRIPTYLINE INDICATION Premenstrual Dysphoric Disorder 72-69-5 NORTRIPTYLINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 72-69-5 NORTRIPTYLINE KNOWN_TOXICITY Cardiovascular Toxicity 72-69-5 NORTRIPTYLINE TISSUE_TOXICITY Arrythmogenic 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT END_3_Gynecomastia 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 72-69-5 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Seizures 894-71-3 NORTRIPTYLINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 894-71-3 NORTRIPTYLINE TISSUE_TOXICITY Ventricular Tachycardia 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT END_3_Galactorrhea 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT IMU_3_Photosensitivity 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT NEU_1_Dizziness 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 894-71-3 NORTRIPTYLINE INDICATION Depression 894-71-3 NORTRIPTYLINE ZERO_CLASS N 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT CVS_3_Hypertension 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT NEU_1_Drowsiness 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Tremor 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT OCU_3_Acute Angle-Closure Glaucoma 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT REP_3_Impotence 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 894-71-3 NORTRIPTYLINE PRODUCT_CLASS Analgesics 894-71-3 NORTRIPTYLINE TA_LEVEL_1 Central Nervous System (CNS) 894-71-3 NORTRIPTYLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 894-71-3 NORTRIPTYLINE INDICATION Migraine Headache 894-71-3 NORTRIPTYLINE INDICATION Panic Disorder 894-71-3 NORTRIPTYLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 894-71-3 NORTRIPTYLINE MESH_LEVEL_3 Benzocycloheptenes 894-71-3 NORTRIPTYLINE THERAPEUTIC_CLASS Antidepressants 894-71-3 NORTRIPTYLINE MECHANISM Prolong/enhance neural transmission 894-71-3 NORTRIPTYLINE INDICATION Phobic Disorder 894-71-3 NORTRIPTYLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT END_3_Impaired Glucose Tolerance 894-71-3 NORTRIPTYLINE MODE_CLASS Solute transporter inhibitor 894-71-3 NORTRIPTYLINE THERAPEUTIC_CLASS Antispasmodic Agents 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Arrythmogenic 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT OCU_3_Blurred Vision 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT REP_3_Decreased Libido 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT BBM_3_Hematological Reactions 894-71-3 NORTRIPTYLINE MECH_LEVEL_1 Modulate neural transmission 894-71-3 NORTRIPTYLINE INDICATION Neuropathic Pain 894-71-3 NORTRIPTYLINE INDICATION Enuresis 894-71-3 NORTRIPTYLINE MECH_LEVEL_2 reuptake of Norepinephrine inhibition 894-71-3 NORTRIPTYLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT CVS_2_Palpitation 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT PSY_2_Confusion 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT NEU_2_Seizures 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 894-71-3 NORTRIPTYLINE ADVERSE_EFFECT END_3_Gynecomastia 894-71-3 NORTRIPTYLINE TISSUE_TOXICITY Arrythmogenic 894-71-3 NORTRIPTYLINE KNOWN_TOXICITY Cardiovascular Toxicity 894-71-3 NORTRIPTYLINE INDICATION Premenstrual Dysphoric Disorder 894-71-3 NORTRIPTYLINE INDICATION Postherpetic Neuralgia 894-71-3 NORTRIPTYLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 894-71-3 NORTRIPTYLINE TA_LEVEL_3 Antidepressants 894-71-3 NORTRIPTYLINE MECH_LEVEL_3 Norepinephrine Transporter NET 894-71-3 NORTRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 155213-67-5 RITONAVIR ADVERSE_EFFECT PSY_2_Anorexia 155213-67-5 RITONAVIR PRODUCT_CLASS Anti-infectives 155213-67-5 RITONAVIR THERAPEUTIC_CLASS Antivirals, Systemic 155213-67-5 RITONAVIR ADVERSE_EFFECT END_2_Exacerbation of Diabetes 155213-67-5 RITONAVIR ADVERSE_EFFECT KID_3_Acute Renal Failure 155213-67-5 RITONAVIR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 155213-67-5 RITONAVIR ADVERSE_EFFECT IMU_2_Allergic Reactions 155213-67-5 RITONAVIR ADVERSE_EFFECT GIS_1_Nausea / Vomiting 155213-67-5 RITONAVIR MECHANISM Inhibit post transcriptional protein processing 155213-67-5 RITONAVIR TA_LEVEL_1 Infectious Disease 155213-67-5 RITONAVIR MECH_LEVEL_3 HIV-1 retropepsin 155213-67-5 RITONAVIR TA_LEVEL_2 Anti-viral 155213-67-5 RITONAVIR ZERO_CLASS N 155213-67-5 RITONAVIR KNOWN_TOXICITY Nephrotoxicity 155213-67-5 RITONAVIR ADVERSE_EFFECT XXX_1_Taste Disturbances 155213-67-5 RITONAVIR ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 155213-67-5 RITONAVIR ADVERSE_EFFECT IMU_3_Anaphylaxis 155213-67-5 RITONAVIR ADVERSE_EFFECT END_2_Hyperlipidemia 155213-67-5 RITONAVIR ADVERSE_EFFECT GIS_1_Diarrhea 155213-67-5 RITONAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 155213-67-5 RITONAVIR TA_LEVEL_3 viral replication inhibitor 155213-67-5 RITONAVIR MESH_LEVEL_1 Heterocyclic Compounds 155213-67-5 RITONAVIR MESH_LEVEL_3 Thiazoles 155213-67-5 RITONAVIR ACTIVITY_CLASS Anti-viral 155213-67-5 RITONAVIR TISSUE_TOXICITY Hepatotoxicity 155213-67-5 RITONAVIR ADVERSE_EFFECT XXX_1_Asthenia 155213-67-5 RITONAVIR ADVERSE_EFFECT BBM_3_Acute Leukemia 155213-67-5 RITONAVIR ADVERSE_EFFECT NEU_2_Paresthesia 155213-67-5 RITONAVIR ADVERSE_EFFECT REP_2_Sexual Dysfunction 155213-67-5 RITONAVIR ADVERSE_EFFECT XXX_2_Sweating 155213-67-5 RITONAVIR MODE_CLASS Enzyme Inhibitor 155213-67-5 RITONAVIR MECH_LEVEL_2 viral protease inhibition 155213-67-5 RITONAVIR MECH_LEVEL_1 Anti-viral 155213-67-5 RITONAVIR MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 155213-67-5 RITONAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 155213-67-5 RITONAVIR KNOWN_TOXICITY Hepatotoxicity 155213-67-5 RITONAVIR TISSUE_TOXICITY Acute Renal Failure 155213-67-5 RITONAVIR ADVERSE_EFFECT END_2_Diabetogenesis 155213-67-5 RITONAVIR ADVERSE_EFFECT GIS_3_Pancreatitis 155213-67-5 RITONAVIR ADVERSE_EFFECT LIV_3_Hepatotoxicity 155213-67-5 RITONAVIR ADVERSE_EFFECT NEU_2_Dizziness 123653-11-2 NS-398 THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 123653-11-2 NS-398 PRODUCT_CLASS Anti-inflammatories 123653-43-0 NS-398 PRODUCT_CLASS Anti-inflammatories 123653-43-0 NS-398 THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 123653-44-1 NS-398 THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 123653-44-1 NS-398 PRODUCT_CLASS Anti-inflammatories 138226-12-7 NSC-625487 INDICATION Myocardial Ischemia 849-55-8 NYLIDRIN ADVERSE_EFFECT PSY_2_Nervousness 849-55-8 NYLIDRIN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 849-55-8 NYLIDRIN ADVERSE_EFFECT NEU_1_Headache 849-55-8 NYLIDRIN TISSUE_TOXICITY Hypotension 849-55-8 NYLIDRIN ADVERSE_EFFECT NEU_3_Tremor 849-55-8 NYLIDRIN ADVERSE_EFFECT CVS_3_Hypotension 849-55-8 NYLIDRIN TISSUE_TOXICITY Cardiac Arrhythmia 849-55-8 NYLIDRIN ADVERSE_EFFECT NEU_2_Dizziness 849-55-8 NYLIDRIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 849-55-8 NYLIDRIN MODE_CLASS Receptor Ligand Antagonist 849-55-8 NYLIDRIN INDICATION Improve Circulation in Extremities 849-55-8 NYLIDRIN STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 849-55-8 NYLIDRIN KNOWN_TOXICITY Cardiovascular Toxicity 849-55-8 NYLIDRIN ADVERSE_EFFECT XXX_2_Chills 849-55-8 NYLIDRIN ADVERSE_EFFECT XXX_3_Weakness 849-55-8 NYLIDRIN MECHANISM Block neural transmission 849-55-8 NYLIDRIN PRODUCT_CLASS Cardiovasculars 849-55-8 NYLIDRIN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 849-55-8 NYLIDRIN ADVERSE_EFFECT SKN_1_Flushing 849-55-8 NYLIDRIN ADVERSE_EFFECT CVS_3_Tachycardia 849-55-8 NYLIDRIN THERAPEUTIC_CLASS Vasodilators 447-41-6 NYLIDRIN ADVERSE_EFFECT SKN_1_Flushing 447-41-6 NYLIDRIN ADVERSE_EFFECT CVS_3_Tachycardia 447-41-6 NYLIDRIN THERAPEUTIC_CLASS Vasodilators 447-41-6 NYLIDRIN ADVERSE_EFFECT NEU_1_Headache 447-41-6 NYLIDRIN ADVERSE_EFFECT NEU_3_Tremor 447-41-6 NYLIDRIN ADVERSE_EFFECT CVS_3_Hypotension 447-41-6 NYLIDRIN ADVERSE_EFFECT NEU_2_Dizziness 447-41-6 NYLIDRIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 447-41-6 NYLIDRIN INDICATION Improve Circulation in Extremities 447-41-6 NYLIDRIN ADVERSE_EFFECT XXX_3_Weakness 447-41-6 NYLIDRIN ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 447-41-6 NYLIDRIN MODE_CLASS Receptor Ligand Antagonist 447-41-6 NYLIDRIN MECHANISM Block neural transmission 447-41-6 NYLIDRIN STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 447-41-6 NYLIDRIN ADVERSE_EFFECT PSY_2_Nervousness 447-41-6 NYLIDRIN KNOWN_TOXICITY Cardiovascular Toxicity 447-41-6 NYLIDRIN TISSUE_TOXICITY Hypotension 447-41-6 NYLIDRIN ADVERSE_EFFECT XXX_2_Chills 447-41-6 NYLIDRIN TISSUE_TOXICITY Cardiac Arrhythmia 447-41-6 NYLIDRIN ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 447-41-6 NYLIDRIN PRODUCT_CLASS Cardiovasculars 1400-61-9 NYSTATIN TA_LEVEL_1 Infectious Disease 1400-61-9 NYSTATIN ADVERSE_EFFECT END_3_Hyperglycemia 1400-61-9 NYSTATIN ZERO_CLASS N 1400-61-9 NYSTATIN ACTIVITY_CLASS Antibiotic 1400-61-9 NYSTATIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1400-61-9 NYSTATIN MESH_LEVEL_2 Lactones 1400-61-9 NYSTATIN MECHANISM Destroy cell membrane / wall integrity 1400-61-9 NYSTATIN MECH_LEVEL_1 Anti-fungal 1400-61-9 NYSTATIN INDICATION Oral Candidiasis / Thrush 1400-61-9 NYSTATIN THERAPEUTIC_CLASS Antifungals, Topical 1400-61-9 NYSTATIN ADVERSE_EFFECT GIS_3_Diarrhea 1400-61-9 NYSTATIN ADVERSE_EFFECT SKN_3_Skin Irritation 1400-61-9 NYSTATIN STRUCTURE_ACTIVITY Impairs cell membrane function, polyene antifungal antibiotic 1400-61-9 NYSTATIN MESH_LEVEL_3 Macrolides 1400-61-9 NYSTATIN MESH_LEVEL_1 Organic Chemicals 1400-61-9 NYSTATIN MECH_LEVEL_2 Impairs cell membrane permeability 1400-61-9 NYSTATIN INDICATION Vaginal Candidiasis 1400-61-9 NYSTATIN TA_LEVEL_3 vanginitis 1400-61-9 NYSTATIN MODE_CLASS Distorts /blocks macromolecular scaffold function 1400-61-9 NYSTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 1400-61-9 NYSTATIN INDICATION Mucocutaneous Candidiasis 1400-61-9 NYSTATIN MECH_LEVEL_3 Impairs cell membrane permeability 1400-61-9 NYSTATIN TA_LEVEL_2 Anti-fungal 1400-61-9 NYSTATIN PRODUCT_CLASS Anti-infectives 34786-70-4 NYSTATIN INDICATION Vaginal Candidiasis 34786-70-4 NYSTATIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 34786-70-4 NYSTATIN ACTIVITY_CLASS Antibiotic 34786-70-4 NYSTATIN MODE_CLASS Distorts /blocks macromolecular scaffold function 34786-70-4 NYSTATIN MECH_LEVEL_2 Impairs cell membrane permeability 34786-70-4 NYSTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 34786-70-4 NYSTATIN TA_LEVEL_3 vanginitis 34786-70-4 NYSTATIN MECH_LEVEL_1 Anti-fungal 34786-70-4 NYSTATIN MESH_LEVEL_1 Organic Chemicals 34786-70-4 NYSTATIN MESH_LEVEL_3 Macrolides 34786-70-4 NYSTATIN STRUCTURE_ACTIVITY Impairs cell membrane function, polyene antifungal antibiotic 34786-70-4 NYSTATIN ADVERSE_EFFECT SKN_3_Skin Irritation 34786-70-4 NYSTATIN ADVERSE_EFFECT GIS_3_Diarrhea 34786-70-4 NYSTATIN THERAPEUTIC_CLASS Antifungals, Topical 34786-70-4 NYSTATIN INDICATION Oral Candidiasis / Thrush 34786-70-4 NYSTATIN ZERO_CLASS N 34786-70-4 NYSTATIN MESH_LEVEL_2 Lactones 34786-70-4 NYSTATIN MECHANISM Destroy cell membrane / wall integrity 34786-70-4 NYSTATIN TA_LEVEL_2 Anti-fungal 34786-70-4 NYSTATIN INDICATION Mucocutaneous Candidiasis 34786-70-4 NYSTATIN MECH_LEVEL_3 Impairs cell membrane permeability 34786-70-4 NYSTATIN PRODUCT_CLASS Anti-infectives 34786-70-4 NYSTATIN TA_LEVEL_1 Infectious Disease 34786-70-4 NYSTATIN ADVERSE_EFFECT END_3_Hyperglycemia 83150-76-9 OCTREOTIDE ADVERSE_EFFECT NEU_2_Drowsiness 83150-76-9 OCTREOTIDE ADVERSE_EFFECT GIS_2_Pancreatitis 83150-76-9 OCTREOTIDE ADVERSE_EFFECT CVS_3_ST-T Wave Changes 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_2_Infection 83150-76-9 OCTREOTIDE ADVERSE_EFFECT BIL_3_Cholelithiasis 83150-76-9 OCTREOTIDE ADVERSE_EFFECT END_3_Hyperglycemia 83150-76-9 OCTREOTIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 83150-76-9 OCTREOTIDE ADVERSE_EFFECT END_3_Hypoglycemia 83150-76-9 OCTREOTIDE ADVERSE_EFFECT GIS_2_Constipation 83150-76-9 OCTREOTIDE ADVERSE_EFFECT GIS_1_Diarrhea 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_2_Malaise 83150-76-9 OCTREOTIDE ADVERSE_EFFECT CVS_3_Chest Pain 83150-76-9 OCTREOTIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_2_Fever 83150-76-9 OCTREOTIDE MODE_CLASS Receptor /Channel ligand mimic 83150-76-9 OCTREOTIDE THERAPEUTIC_CLASS Hypothalamic Hormones 83150-76-9 OCTREOTIDE ADVERSE_EFFECT NEU_2_Headache 83150-76-9 OCTREOTIDE INDICATION Carcinoid Syndrome 83150-76-9 OCTREOTIDE ADVERSE_EFFECT NEU_2_Dizziness 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_2_Weakness 83150-76-9 OCTREOTIDE ADVERSE_EFFECT NEU_2_Tremor 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_1_Fatigue 83150-76-9 OCTREOTIDE ADVERSE_EFFECT END_2_Hypothyroidism 83150-76-9 OCTREOTIDE ADVERSE_EFFECT LUN_2_Dyspnea 83150-76-9 OCTREOTIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 83150-76-9 OCTREOTIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 83150-76-9 OCTREOTIDE INDICATION Acromegaly 83150-76-9 OCTREOTIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 83150-76-9 OCTREOTIDE MECHANISM Modulate gene transcription 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_2_Injection Site Reaction 83150-76-9 OCTREOTIDE ADVERSE_EFFECT GIS_2_Flatulence 83150-76-9 OCTREOTIDE ADVERSE_EFFECT XXX_2_Chills 79517-01-4 OCTREOTIDE ADVERSE_EFFECT GIS_2_Constipation 79517-01-4 OCTREOTIDE ADVERSE_EFFECT END_3_Hypoglycemia 79517-01-4 OCTREOTIDE ADVERSE_EFFECT NEU_2_Headache 79517-01-4 OCTREOTIDE MODE_CLASS Receptor /Channel ligand mimic 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_2_Fever 79517-01-4 OCTREOTIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_2_Weakness 79517-01-4 OCTREOTIDE ADVERSE_EFFECT LUN_2_Dyspnea 79517-01-4 OCTREOTIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 79517-01-4 OCTREOTIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 79517-01-4 OCTREOTIDE INDICATION Acromegaly 79517-01-4 OCTREOTIDE ADVERSE_EFFECT NEU_2_Tremor 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_1_Fatigue 79517-01-4 OCTREOTIDE ADVERSE_EFFECT END_2_Hypothyroidism 79517-01-4 OCTREOTIDE ADVERSE_EFFECT NEU_2_Drowsiness 79517-01-4 OCTREOTIDE ADVERSE_EFFECT GIS_2_Pancreatitis 79517-01-4 OCTREOTIDE ADVERSE_EFFECT BIL_3_Cholelithiasis 79517-01-4 OCTREOTIDE ADVERSE_EFFECT CVS_3_ST-T Wave Changes 79517-01-4 OCTREOTIDE INDICATION Carcinoid Syndrome 79517-01-4 OCTREOTIDE THERAPEUTIC_CLASS Hypothalamic Hormones 79517-01-4 OCTREOTIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 79517-01-4 OCTREOTIDE ADVERSE_EFFECT END_3_Hyperglycemia 79517-01-4 OCTREOTIDE ADVERSE_EFFECT NEU_2_Dizziness 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_2_Chills 79517-01-4 OCTREOTIDE ADVERSE_EFFECT GIS_2_Flatulence 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_2_Injection Site Reaction 79517-01-4 OCTREOTIDE MECHANISM Modulate gene transcription 79517-01-4 OCTREOTIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_2_Infection 79517-01-4 OCTREOTIDE ADVERSE_EFFECT CVS_3_Chest Pain 79517-01-4 OCTREOTIDE ADVERSE_EFFECT XXX_2_Malaise 79517-01-4 OCTREOTIDE ADVERSE_EFFECT GIS_1_Diarrhea 132539-06-1 OLANZAPINE TA_LEVEL_3 Antiphyschotic 132539-06-1 OLANZAPINE ZERO_CLASS N 132539-06-1 OLANZAPINE ADVERSE_EFFECT BBM_2_Leukopenia 132539-06-1 OLANZAPINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 132539-06-1 OLANZAPINE ADVERSE_EFFECT NEU_1_Dizziness 132539-06-1 OLANZAPINE ADVERSE_EFFECT GIS_1_Dry Mouth 132539-06-1 OLANZAPINE ADVERSE_EFFECT NEU_1_Somnolence 132539-06-1 OLANZAPINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 132539-06-1 OLANZAPINE MECHANISM Block neural transmission 132539-06-1 OLANZAPINE PRODUCT_CLASS Central Nervous System (CNS) 132539-06-1 OLANZAPINE MECHANISM Modulate G-protein coupled signal transduction 132539-06-1 OLANZAPINE MECH_LEVEL_3 5HT receptor 2A 132539-06-1 OLANZAPINE ADVERSE_EFFECT PSY_2_Emotional Lability 132539-06-1 OLANZAPINE ADVERSE_EFFECT PSY_2_Insomnia 132539-06-1 OLANZAPINE ADVERSE_EFFECT REP_1_Amenorrhea 132539-06-1 OLANZAPINE ADVERSE_EFFECT XXX_1_Weight Gain 132539-06-1 OLANZAPINE ADVERSE_EFFECT GIS_1_Constipation 132539-06-1 OLANZAPINE ADVERSE_EFFECT XXX_2_Temperature Disorders 132539-06-1 OLANZAPINE ADVERSE_EFFECT NEU_3_Seizures 132539-06-1 OLANZAPINE MODE_CLASS Solute transporter inhibitor 132539-06-1 OLANZAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 132539-06-1 OLANZAPINE MECH_LEVEL_2 5HT antagonist 132539-06-1 OLANZAPINE MODE_CLASS Receptor Ligand Antagonist 132539-06-1 OLANZAPINE KNOWN_TOXICITY Cardiovascular Toxicity 132539-06-1 OLANZAPINE MECHANISM Prolong/enhance neural transmission 132539-06-1 OLANZAPINE ADVERSE_EFFECT XXX_1_Asthenia 132539-06-1 OLANZAPINE ADVERSE_EFFECT CVS_1_Tachycardia 132539-06-1 OLANZAPINE ADVERSE_EFFECT GIS_3_Dysphagia 132539-06-1 OLANZAPINE ADVERSE_EFFECT END_2_Hyperprolactinemia 132539-06-1 OLANZAPINE ADVERSE_EFFECT NEU_3_Coma 132539-06-1 OLANZAPINE ADVERSE_EFFECT NEU_1_Extrapyramidal Symptoms 132539-06-1 OLANZAPINE THERAPEUTIC_CLASS Antipsychotics 132539-06-1 OLANZAPINE TISSUE_TOXICITY Hypotension 132539-06-1 OLANZAPINE TA_LEVEL_1 Central Nervous System (CNS) 132539-06-1 OLANZAPINE INDICATION Schizophrenia 132539-06-1 OLANZAPINE TA_LEVEL_2 CNS Depressant 132539-06-1 OLANZAPINE ACTIVITY_CLASS Serotonin antagonist 132539-06-1 OLANZAPINE TISSUE_TOXICITY Amenorrhea 132539-06-1 OLANZAPINE ADVERSE_EFFECT REP_1_Menstrual Abnormalities 132539-06-1 OLANZAPINE ADVERSE_EFFECT CVS_1_Hypotension 132539-06-1 OLANZAPINE KNOWN_TOXICITY Reproductive System Toxicity 132539-06-1 OLANZAPINE ADVERSE_EFFECT EMB_2_Fetal Toxicity 132539-06-1 OLANZAPINE ADVERSE_EFFECT XXX_3_Aspiration 132539-06-1 OLANZAPINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 132539-06-1 OLANZAPINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 132539-06-1 OLANZAPINE MESH_LEVEL_3 Benzazepines 132539-06-1 OLANZAPINE MECH_LEVEL_1 Modulate neural transmission 132539-06-1 OLANZAPINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 132539-06-1 OLANZAPINE INDICATION Acute Manic Episode in Bipolar Disorder 132539-06-1 OLANZAPINE MESH_LEVEL_1 Heterocyclic Compounds 132539-06-1 OLANZAPINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 1404-19-9 OLIGOMYCIN PRODUCT_CLASS Biochemicals 1404-19-9 OLIGOMYCIN MODE_CLASS Enzyme Inhibitor, selective 1404-19-9 OLIGOMYCIN STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits ATP-synthase 1404-19-9 OLIGOMYCIN MECHANISM Inhibit mitochondrial function 113806-05-6 OLOPATADINE INDICATION Allergic Conjunctivitis 113806-05-6 OLOPATADINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 113806-05-6 OLOPATADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 113806-05-6 OLOPATADINE THERAPEUTIC_CLASS Antihistamines 113806-05-6 OLOPATADINE MODE_CLASS Receptor Ligand Antagonist 113806-05-6 OLOPATADINE MECHANISM Modulate G-protein coupled signal transduction 140462-76-6 OLOPATADINE INDICATION Allergic Conjunctivitis 140462-76-6 OLOPATADINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 140462-76-6 OLOPATADINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 140462-76-6 OLOPATADINE THERAPEUTIC_CLASS Antihistamines 140462-76-6 OLOPATADINE MODE_CLASS Receptor Ligand Antagonist 140462-76-6 OLOPATADINE MECHANISM Modulate G-protein coupled signal transduction 15722-48-2 OLSALAZINE INDICATION Inflammatory Bowel Disease (IBD) 15722-48-2 OLSALAZINE MECHANISM Inhibit eicosanoid biosynthesis 15722-48-2 OLSALAZINE MODE_CLASS Enzyme Inhibitor 6054-98-4 OLSALAZINE INDICATION Inflammatory Bowel Disease (IBD) 6054-98-4 OLSALAZINE MECHANISM Inhibit eicosanoid biosynthesis 6054-98-4 OLSALAZINE MODE_CLASS Enzyme Inhibitor 74512-12-2 OMOCONAZOLE PRODUCT_CLASS Anti-infectives 74512-12-2 OMOCONAZOLE MODE_CLASS Enzyme Inhibitor 74512-12-2 OMOCONAZOLE THERAPEUTIC_CLASS Antifungals 74512-12-2 OMOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 83621-06-1 OMOCONAZOLE PRODUCT_CLASS Anti-infectives 83621-06-1 OMOCONAZOLE MODE_CLASS Enzyme Inhibitor 83621-06-1 OMOCONAZOLE THERAPEUTIC_CLASS Antifungals 83621-06-1 OMOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 99614-02-5 ONDANSETRON TISSUE_TOXICITY Hypotension 99614-02-5 ONDANSETRON PRODUCT_CLASS Gastrointestinal System 99614-02-5 ONDANSETRON ADVERSE_EFFECT GIS_2_Diarrhea 99614-02-5 ONDANSETRON TISSUE_TOXICITY Angina 99614-02-5 ONDANSETRON ADVERSE_EFFECT CVS_3_Hypotension 99614-02-5 ONDANSETRON ADVERSE_EFFECT OCU_3_Oculogyric Crisis 99614-02-5 ONDANSETRON ZERO_CLASS N 99614-02-5 ONDANSETRON MECH_LEVEL_3 5HT receptor 3 99614-02-5 ONDANSETRON MESH_LEVEL_1 Heterocyclic Compounds 99614-02-5 ONDANSETRON MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 99614-02-5 ONDANSETRON TA_LEVEL_1 Central Nervous System (CNS) 99614-02-5 ONDANSETRON MESH_LEVEL_3 Imidazoles 99614-02-5 ONDANSETRON THERAPEUTIC_CLASS Antiemetics 99614-02-5 ONDANSETRON TISSUE_TOXICITY Cardiac Arrhythmia 99614-02-5 ONDANSETRON ADVERSE_EFFECT GIS_1_Constipation 99614-02-5 ONDANSETRON ADVERSE_EFFECT CVS_3_Angina 99614-02-5 ONDANSETRON ADVERSE_EFFECT SKN_2_Rash 99614-02-5 ONDANSETRON TA_LEVEL_3 Antiemetic 99614-02-5 ONDANSETRON MECH_LEVEL_2 5HT antagonist 99614-02-5 ONDANSETRON ADVERSE_EFFECT OCU_3_Blurred Vision 99614-02-5 ONDANSETRON ADVERSE_EFFECT ELT_3_Hypokalemia 99614-02-5 ONDANSETRON ADVERSE_EFFECT SKN_3_Pruritis 99614-02-5 ONDANSETRON ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 99614-02-5 ONDANSETRON MECHANISM Block neural transmission 99614-02-5 ONDANSETRON ACTIVITY_CLASS Serotonin antagonist 99614-02-5 ONDANSETRON ADVERSE_EFFECT NEU_1_Headache 99614-02-5 ONDANSETRON ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 99614-02-5 ONDANSETRON ADVERSE_EFFECT XXX_2_Fever 99614-02-5 ONDANSETRON INDICATION Nausea / Vomiting 99614-02-5 ONDANSETRON MODE_CLASS Channel Blocker, selective 99614-02-5 ONDANSETRON MECH_LEVEL_1 Modulate neural transmission 99614-02-5 ONDANSETRON TA_LEVEL_2 CNS Depressant 99614-02-5 ONDANSETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 99614-02-5 ONDANSETRON ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 99614-02-5 ONDANSETRON ADVERSE_EFFECT SKN_3_Flushing 99614-02-5 ONDANSETRON ADVERSE_EFFECT CVS_3_ECG Abnormalities 99614-02-5 ONDANSETRON ADVERSE_EFFECT NEU_3_Grand Mal Seizure 99614-02-5 ONDANSETRON KNOWN_TOXICITY Cardiovascular Toxicity 73210-73-8 XAMOTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta1 agonist 81801-12-9 XAMOTEROL STRUCTURE_ACTIVITY Adrenoceptor-beta1 agonist 10045-45-1 1-EBIO MECHANISM Modulate channel gating 10045-45-1 1-EBIO MODE_CLASS Channel Modulator 10045-45-1 1-EBIO PRODUCT_CLASS Biochemicals 10045-45-1 1-EBIO STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) opener 55-57-2 1-PHENYLBIGUANIDE HYDROCHLORIDE PRODUCT_CLASS Biochemicals 55-57-2 1-PHENYLBIGUANIDE HYDROCHLORIDE MODE_CLASS Channel Blocker 55-57-2 1-PHENYLBIGUANIDE HYDROCHLORIDE MECHANISM Inhibit absorption of dietary carbohydrates 1744-22-5 RILUZOLE ADVERSE_EFFECT GIS_2_Nausea 1744-22-5 RILUZOLE ADVERSE_EFFECT XXX_2_Peripheral Edema 1744-22-5 RILUZOLE ADVERSE_EFFECT BBM_3_Neutropenia 1744-22-5 RILUZOLE MECHANISM Block neural transmission 1744-22-5 RILUZOLE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 1744-22-5 RILUZOLE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 1744-22-5 RILUZOLE INDICATION Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease 1744-22-5 RILUZOLE ADVERSE_EFFECT PSY_2_Anorexia 1744-22-5 RILUZOLE ADVERSE_EFFECT LUN_3_Hypoventilation 1744-22-5 RILUZOLE ADVERSE_EFFECT LIV_3_Jaundice 1744-22-5 RILUZOLE ADVERSE_EFFECT NEU_2_Circumoral Paresthesia 1744-22-5 RILUZOLE MODE_CLASS Channel Blocker 1744-22-5 RILUZOLE ADVERSE_EFFECT CVS_2_Hypertension 1744-22-5 RILUZOLE MECHANISM Modulate channel gating 1744-22-5 RILUZOLE ADVERSE_EFFECT NEU_1_Headache 1744-22-5 RILUZOLE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 1744-22-5 RILUZOLE ADVERSE_EFFECT XXX_1_Asthenia 1744-22-5 RILUZOLE ADVERSE_EFFECT NEU_2_Vertigo 1744-22-5 RILUZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 1744-22-5 RILUZOLE ADVERSE_EFFECT GIS_1_Diarrhea 1744-22-5 RILUZOLE ADVERSE_EFFECT GIS_2_Vomiting 1744-22-5 RILUZOLE ADVERSE_EFFECT MSK_2_Arthralgia 1744-22-5 RILUZOLE PRODUCT_CLASS Central Nervous System (CNS) 1744-22-5 RILUZOLE THERAPEUTIC_CLASS Neurodegenerative Disorders 78263-90-8 2-METHYL-5-HYDROXYTRYPTAMINE MODE_CLASS Channel enhancer /opener 78263-90-8 2-METHYL-5-HYDROXYTRYPTAMINE MECHANISM Block neural transmission 78263-90-8 2-METHYL-5-HYDROXYTRYPTAMINE PRODUCT_CLASS Biochemicals 117354-64-0 2-HYDROXYSACLOFEN MODE_CLASS Receptor Agonist, selective 117354-64-0 2-HYDROXYSACLOFEN PRODUCT_CLASS Biochemicals 117354-64-0 2-HYDROXYSACLOFEN MECHANISM Modulate neural transmission 158985-00-3 L-745870 THERAPEUTIC_CLASS Antipsychotics 158985-00-3 L-745870 PRODUCT_CLASS Central Nervous System (CNS) 90293-01-9 BIFEMELANE MODE_CLASS Channel Blocker, selective 90293-01-9 BIFEMELANE PRODUCT_CLASS Central Nervous System (CNS) 90293-01-9 BIFEMELANE THERAPEUTIC_CLASS Neurodegenerative Disorders 90293-01-9 BIFEMELANE MECHANISM Reduce muscle contractile force 62232-46-6 BIFEMELANE THERAPEUTIC_CLASS Neurodegenerative Disorders 62232-46-6 BIFEMELANE PRODUCT_CLASS Central Nervous System (CNS) 62232-46-6 BIFEMELANE MODE_CLASS Channel Blocker, selective 62232-46-6 BIFEMELANE MECHANISM Reduce muscle contractile force 153436-54-5 PD-153035 PRODUCT_CLASS Anti-cancers 153436-54-5 PD-153035 THERAPEUTIC_CLASS Antineoplastics 153436-54-5 PD-153035 MODE_CLASS Receptor tyrosine kinase inhibitor 153436-54-5 PD-153035 MECHANISM Inhibit Ca++ sensitisation 153436-54-5 PD-153035 MODE_CLASS Enzyme Inhibitor, Non-selective 183322-45-4 PD-153035 MODE_CLASS Receptor tyrosine kinase inhibitor 183322-45-4 PD-153035 MODE_CLASS Enzyme Inhibitor, Non-selective 183322-45-4 PD-153035 MECHANISM Inhibit Ca++ sensitisation 183322-45-4 PD-153035 PRODUCT_CLASS Anti-cancers 183322-45-4 PD-153035 THERAPEUTIC_CLASS Antineoplastics 1742-95-6 4-AMINO-1,8-NAPHTHALIMIDE MODE_CLASS Enzyme Inhibitor 1742-95-6 4-AMINO-1,8-NAPHTHALIMIDE MECHANISM Inhibit DNA synthesis, repair, and function 1742-95-6 4-AMINO-1,8-NAPHTHALIMIDE PRODUCT_CLASS Biochemicals 504-24-5 FAMPRIDINE MODE_CLASS Channel Modulator 504-24-5 FAMPRIDINE INDICATION Multiple Sclerosis (MS) 504-24-5 FAMPRIDINE INDICATION Spinal Cord Injury / Trauma 504-24-5 FAMPRIDINE MECHANISM Modulate channel gating 504-24-5 FAMPRIDINE PRODUCT_CLASS Peripheral Nervous System (PNS) 156337-32-5 L-741,742 HYDROCHLORIDE PRODUCT_CLASS Biochemicals 118202-69-0 5-CARBOXAMIDOTRYPTAMINE MECHANISM Modulate neural transmission 118202-69-0 5-CARBOXAMIDOTRYPTAMINE MODE_CLASS Receptor Agonist, Non-selective 118202-69-0 5-CARBOXAMIDOTRYPTAMINE MECHANISM Modulate G-protein coupled signal transduction 118202-69-0 5-CARBOXAMIDOTRYPTAMINE MECHANISM Modulate cerebral vasoconstriction 118202-69-0 5-CARBOXAMIDOTRYPTAMINE PRODUCT_CLASS Biochemicals 53308-83-1 546C88 PRODUCT_CLASS Central Nervous System (CNS) 53308-83-1 546C88 INDICATION Migraine Headache 53308-83-1 546C88 THERAPEUTIC_CLASS Antimigraines 156706-47-7 546C88 PRODUCT_CLASS Central Nervous System (CNS) 156706-47-7 546C88 INDICATION Migraine Headache 156706-47-7 546C88 THERAPEUTIC_CLASS Antimigraines 17035-90-4 546C88 THERAPEUTIC_CLASS Antimigraines 17035-90-4 546C88 INDICATION Migraine Headache 17035-90-4 546C88 PRODUCT_CLASS Central Nervous System (CNS) 516-54-1 5ALPHA-PREGNAN-3ALPHA-OL-20-ONE PRODUCT_CLASS Biochemicals 2379-57-9 DNQX PRODUCT_CLASS Biochemicals 64022-27-1 MK 212 HYDROCHLORIDE PRODUCT_CLASS Biochemicals 115066-14-3 CNQX PRODUCT_CLASS Biochemicals 102146-07-6 CPX INDICATION Cystic Fibrosis (CF) 87394-87-4 8-HYDROXY-DPAT THERAPEUTIC_CLASS Sedatives/Hypnotics 87394-87-4 8-HYDROXY-DPAT MODE_CLASS Receptor Agonist, selective 87394-87-4 8-HYDROXY-DPAT PRODUCT_CLASS Central Nervous System (CNS) 87394-87-4 8-HYDROXY-DPAT MECHANISM Modulate neural transmission 134865-70-6 AH-002 PRODUCT_CLASS Biochemicals 124756-23-6 BINOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 124756-23-6 BINOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 124756-23-6 BINOSPIRONE MECHANISM Modulate neural transmission 124756-23-6 BINOSPIRONE MODE_CLASS Receptor Agonist 102908-59-8 BINOSPIRONE PRODUCT_CLASS Central Nervous System (CNS) 102908-59-8 BINOSPIRONE MODE_CLASS Receptor Agonist 102908-59-8 BINOSPIRONE MECHANISM Modulate neural transmission 102908-59-8 BINOSPIRONE STRUCTURE_ACTIVITY 5HT1 agonist 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Vesicular Rash 5300-03-8 9-CIS-TRETINOIN MECHANISM Modulate gene transcription 5300-03-8 9-CIS-TRETINOIN INDICATION Atopic Dermatitis / Eczema 5300-03-8 9-CIS-TRETINOIN INDICATION AIDS-Related Kaposi's Sarcoma 5300-03-8 9-CIS-TRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_2_Pruritis 5300-03-8 9-CIS-TRETINOIN INDICATION Neoplasm / Cancer / Tumor 5300-03-8 9-CIS-TRETINOIN INDICATION Acute Promyelocytic Leukemia 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 5300-03-8 9-CIS-TRETINOIN PRODUCT_CLASS Anti-cancers 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Erythema 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT NEU_1_Headache 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT XXX_1_Edema 5300-03-8 9-CIS-TRETINOIN INDICATION Kaposi's Sarcoma 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Skin Irritation 5300-03-8 9-CIS-TRETINOIN THERAPEUTIC_CLASS Antineoplastics 5300-03-8 9-CIS-TRETINOIN THERAPEUTIC_CLASS Immunosuppressants 5300-03-8 9-CIS-TRETINOIN PRODUCT_CLASS Immune Response / Immunomodulators 5300-03-8 9-CIS-TRETINOIN INDICATION Non-Hodgkin's Lymphomas 5300-03-8 9-CIS-TRETINOIN MODE_CLASS Receptor Agonist 5300-03-8 9-CIS-TRETINOIN ADVERSE_EFFECT NEU_3_Paresthesia 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Erythema 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT NEU_1_Headache 7005-78-9 9-CIS-TRETINOIN MODE_CLASS Receptor Agonist 7005-78-9 9-CIS-TRETINOIN INDICATION Non-Hodgkin's Lymphomas 7005-78-9 9-CIS-TRETINOIN PRODUCT_CLASS Immune Response / Immunomodulators 7005-78-9 9-CIS-TRETINOIN INDICATION Kaposi's Sarcoma 7005-78-9 9-CIS-TRETINOIN THERAPEUTIC_CLASS Immunosuppressants 7005-78-9 9-CIS-TRETINOIN THERAPEUTIC_CLASS Antineoplastics 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT XXX_1_Edema 7005-78-9 9-CIS-TRETINOIN MECHANISM Modulate gene transcription 7005-78-9 9-CIS-TRETINOIN INDICATION Neoplasm / Cancer / Tumor 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 7005-78-9 9-CIS-TRETINOIN INDICATION Atopic Dermatitis / Eczema 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Vesicular Rash 7005-78-9 9-CIS-TRETINOIN INDICATION AIDS-Related Kaposi's Sarcoma 7005-78-9 9-CIS-TRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Skin Irritation 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_2_Pruritis 7005-78-9 9-CIS-TRETINOIN ADVERSE_EFFECT NEU_3_Paresthesia 7005-78-9 9-CIS-TRETINOIN INDICATION Acute Promyelocytic Leukemia 7005-78-9 9-CIS-TRETINOIN PRODUCT_CLASS Anti-cancers 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_2_Pruritis 56573-65-0 9-CIS-TRETINOIN INDICATION Neoplasm / Cancer / Tumor 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT NEU_3_Paresthesia 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Vesicular Rash 56573-65-0 9-CIS-TRETINOIN MECHANISM Modulate gene transcription 56573-65-0 9-CIS-TRETINOIN INDICATION Atopic Dermatitis / Eczema 56573-65-0 9-CIS-TRETINOIN INDICATION AIDS-Related Kaposi's Sarcoma 56573-65-0 9-CIS-TRETINOIN INDICATION Acute Promyelocytic Leukemia 56573-65-0 9-CIS-TRETINOIN PRODUCT_CLASS Anti-cancers 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT NEU_1_Headache 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 56573-65-0 9-CIS-TRETINOIN INDICATION Kaposi's Sarcoma 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Erythema 56573-65-0 9-CIS-TRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT SKN_1_Skin Irritation 56573-65-0 9-CIS-TRETINOIN ADVERSE_EFFECT XXX_1_Edema 56573-65-0 9-CIS-TRETINOIN THERAPEUTIC_CLASS Antineoplastics 56573-65-0 9-CIS-TRETINOIN THERAPEUTIC_CLASS Immunosuppressants 56573-65-0 9-CIS-TRETINOIN PRODUCT_CLASS Immune Response / Immunomodulators 56573-65-0 9-CIS-TRETINOIN INDICATION Non-Hodgkin's Lymphomas 56573-65-0 9-CIS-TRETINOIN MODE_CLASS Receptor Agonist 195704-72-4 ATRASENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 178738-96-0 ATRASENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 122-40-7 ALPHA-AMYL-CINNAMALDEHYDE MODE_CLASS Receptor Ligand Antagonist 989999-91-9 ICX5600095 MECHANISM Modulate G-protein coupled signal transduction 989999-91-9 ICX5600095 INDICATION Benign Prostatic Hyperplasia (BPH) 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT DNA_3_Hepatic Tumors 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 101043-37-2 MICROCYSTIN-LR ACTIVITY_CLASS Antiproliferative agent 101043-37-2 MICROCYSTIN-LR KNOWN_TOXICITY Carcinogenicity 101043-37-2 MICROCYSTIN-LR KNOWN_TOXICITY Mutagenicity 101043-37-2 MICROCYSTIN-LR MODE_CLASS Enzyme Inhibitor 101043-37-2 MICROCYSTIN-LR MECHANISM Modulate G-protein coupled signal transduction 101043-37-2 MICROCYSTIN-LR TISSUE_TOXICITY Hepatic Toxicity 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT XXX_3_Death 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT DNA_2_Genotoxicity 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT LIV_2_Hepatic Damage 101043-37-2 MICROCYSTIN-LR STRUCTURE_ACTIVITY Protein-serine/threonine phosphatase inhibitor 101043-37-2 MICROCYSTIN-LR TISSUE_TOXICITY Hepatic Tumors 101043-37-2 MICROCYSTIN-LR KNOWN_TOXICITY Hepatotoxicity 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT KID_2_Renal Damage 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 101043-37-2 MICROCYSTIN-LR KNOWN_TOXICITY Miscellaneous 101043-37-2 MICROCYSTIN-LR TISSUE_TOXICITY Genotoxicity 101043-37-2 MICROCYSTIN-LR TISSUE_TOXICITY Death 101043-37-2 MICROCYSTIN-LR TISSUE_TOXICITY Mutagenicity 101043-37-2 MICROCYSTIN-LR PRODUCT_CLASS Toxicants 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT LIV_2_Hepatic Toxicity 101043-37-2 MICROCYSTIN-LR ADVERSE_EFFECT DNA_2_Mutagenicity 182133-27-3 ARZOXIFENE MODE_CLASS Receptor Ligand Antagonist 182133-27-3 ARZOXIFENE MECHANISM Modulate gene transcription 182133-27-3 ARZOXIFENE PRODUCT_CLASS Anti-cancers 182133-27-3 ARZOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 182133-27-3 ARZOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 182133-25-1 ARZOXIFENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 182133-25-1 ARZOXIFENE MODE_CLASS Receptor Ligand Antagonist 182133-25-1 ARZOXIFENE THERAPEUTIC_CLASS Gonadal Hormones 182133-25-1 ARZOXIFENE MECHANISM Modulate gene transcription 182133-25-1 ARZOXIFENE PRODUCT_CLASS Anti-cancers 92-84-2 PHENOTHIAZINE MECH_LEVEL_3 dopamine receptor D2 92-84-2 PHENOTHIAZINE MESH_LEVEL_3 Phenothiazines 92-84-2 PHENOTHIAZINE MESH_LEVEL_1 ? 92-84-2 PHENOTHIAZINE PRODUCT_CLASS Central Nervous System (CNS) 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT SKN_1_Skin Irritation 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 92-84-2 PHENOTHIAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT GIS_3_Abdominal Cramps 92-84-2 PHENOTHIAZINE MECH_LEVEL_2 Dopamine antagonist 92-84-2 PHENOTHIAZINE MECH_LEVEL_1 Modulate neural transmission 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT SKN_1_Itching 92-84-2 PHENOTHIAZINE TA_LEVEL_2 CNS Depressant 92-84-2 PHENOTHIAZINE MECHANISM Modulate G-protein coupled signal transduction 92-84-2 PHENOTHIAZINE MODE_CLASS Receptor Ligand Antagonist 92-84-2 PHENOTHIAZINE TA_LEVEL_3 Antipsychotics 92-84-2 PHENOTHIAZINE THERAPEUTIC_CLASS Antipsychotics 92-84-2 PHENOTHIAZINE MESH_LEVEL_2 ? 92-84-2 PHENOTHIAZINE TA_LEVEL_1 Central Nervous System (CNS) 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT SKN_2_Nail Discoloration 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT GIS_2_Gastrointestinal Irritation 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT LIV_3_Hepatitis 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT IMU_2_Photosensitization 92-84-2 PHENOTHIAZINE ADVERSE_EFFECT CVS_2_Tachycardia 92-84-2 PHENOTHIAZINE ZERO_CLASS N 92-84-2 PHENOTHIAZINE ACTIVITY_CLASS Dopamine antagonist 56391-57-2 NETILMICIN ADVERSE_EFFECT IMU_3_Anaphylaxis 56391-57-2 NETILMICIN INDICATION Peritonitis 56391-57-2 NETILMICIN INDICATION Gastrointestinal Infection 56391-57-2 NETILMICIN INDICATION Soft Tissue Infections 56391-57-2 NETILMICIN PRODUCT_CLASS Anti-infectives 56391-57-2 NETILMICIN MECH_LEVEL_2 Ribosomal RNA binder 56391-57-2 NETILMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 56391-57-2 NETILMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 56391-57-2 NETILMICIN ADVERSE_EFFECT CVS_2_Phlebitis 56391-57-2 NETILMICIN ADVERSE_EFFECT OTO_3_Ototoxicity 56391-57-2 NETILMICIN INDICATION Bacteremia 56391-57-2 NETILMICIN INDICATION Urinary Tract Infection (UTI) 56391-57-2 NETILMICIN INDICATION Skin Infections 56391-57-2 NETILMICIN TA_LEVEL_3 Aminoglycoside 56391-57-2 NETILMICIN KNOWN_TOXICITY Nephrotoxicity 56391-57-2 NETILMICIN MESH_LEVEL_3 Aminoglycosides 56391-57-2 NETILMICIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 56391-57-2 NETILMICIN INDICATION Respiratory Tract Infection 56391-57-2 NETILMICIN MECH_LEVEL_3 Protein synthesis inhibitor 56391-57-2 NETILMICIN INDICATION Burn Wound Infection 56391-57-2 NETILMICIN MECHANISM Inhibit ribosomal protein synthesis 56391-57-2 NETILMICIN MECH_LEVEL_1 Anti-bacterial 56391-57-2 NETILMICIN TISSUE_TOXICITY Nephrotoxicity 56391-57-2 NETILMICIN ZERO_CLASS N 56391-57-2 NETILMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 56391-57-2 NETILMICIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 56391-57-2 NETILMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 56391-57-2 NETILMICIN INDICATION Surgical Infections 56391-57-2 NETILMICIN INDICATION Bone and Joint Infection 56391-57-2 NETILMICIN TA_LEVEL_2 Anti-bacterial 56391-57-2 NETILMICIN INDICATION Septicemia 56391-57-2 NETILMICIN MESH_LEVEL_2 Carbohydrates 56391-57-2 NETILMICIN TA_LEVEL_1 Infectious Disease 56391-57-2 NETILMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 56391-57-2 NETILMICIN ADVERSE_EFFECT KID_2_Nephrotoxicity 56391-56-1 NETILMICIN THERAPEUTIC_CLASS Antibacterials, Systemic 56391-56-1 NETILMICIN INDICATION Bone and Joint Infection 56391-56-1 NETILMICIN TA_LEVEL_2 Anti-bacterial 56391-56-1 NETILMICIN INDICATION Septicemia 56391-56-1 NETILMICIN MESH_LEVEL_2 Carbohydrates 56391-56-1 NETILMICIN TA_LEVEL_1 Infectious Disease 56391-56-1 NETILMICIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 56391-56-1 NETILMICIN ADVERSE_EFFECT KID_2_Nephrotoxicity 56391-56-1 NETILMICIN ADVERSE_EFFECT IMU_3_Anaphylaxis 56391-56-1 NETILMICIN PRODUCT_CLASS Anti-infectives 56391-56-1 NETILMICIN INDICATION Soft Tissue Infections 56391-56-1 NETILMICIN INDICATION Gastrointestinal Infection 56391-56-1 NETILMICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 56391-56-1 NETILMICIN ADVERSE_EFFECT CVS_2_Phlebitis 56391-56-1 NETILMICIN ADVERSE_EFFECT OTO_3_Ototoxicity 56391-56-1 NETILMICIN INDICATION Bacteremia 56391-56-1 NETILMICIN INDICATION Urinary Tract Infection (UTI) 56391-56-1 NETILMICIN INDICATION Skin Infections 56391-56-1 NETILMICIN TA_LEVEL_3 Aminoglycoside 56391-56-1 NETILMICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemics 56391-56-1 NETILMICIN KNOWN_TOXICITY Nephrotoxicity 56391-56-1 NETILMICIN MESH_LEVEL_3 Aminoglycosides 56391-56-1 NETILMICIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 56391-56-1 NETILMICIN INDICATION Respiratory Tract Infection 56391-56-1 NETILMICIN MECH_LEVEL_3 Protein synthesis inhibitor 56391-56-1 NETILMICIN INDICATION Burn Wound Infection 56391-56-1 NETILMICIN MECHANISM Inhibit ribosomal protein synthesis 56391-56-1 NETILMICIN MECH_LEVEL_1 Anti-bacterial 56391-56-1 NETILMICIN TISSUE_TOXICITY Nephrotoxicity 56391-56-1 NETILMICIN ZERO_CLASS N 56391-56-1 NETILMICIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 56391-56-1 NETILMICIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 56391-56-1 NETILMICIN MECH_LEVEL_2 Ribosomal RNA binder 56391-56-1 NETILMICIN INDICATION Surgical Infections 56391-56-1 NETILMICIN INDICATION Peritonitis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT XXX_3_Death 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT NEU_2_Headache 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_2_Vomiting 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 882-09-7 CLOFIBRIC ACID KNOWN_TOXICITY Miscellaneous 882-09-7 CLOFIBRIC ACID MECHANISM Increase lipid catabolism 882-09-7 CLOFIBRIC ACID MESH_LEVEL_2 Carboxylic Acids 882-09-7 CLOFIBRIC ACID MESH_LEVEL_3 Acids, Acyclic 882-09-7 CLOFIBRIC ACID INDICATION Hyperlipoproteinemia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT CVS_3_Thromboembolism 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT IMU_2_Urticaria 882-09-7 CLOFIBRIC ACID INDICATION Hypertriglyceridemia 882-09-7 CLOFIBRIC ACID TA_LEVEL_2 Lipid lowering agent 882-09-7 CLOFIBRIC ACID KNOWN_TOXICITY Carcinogenicity 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT XXX_2_Fatigue 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_2_Rash 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT BBM_2_Anemia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_3_Erythema Multiforme 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT MSK_3_Rhabdomyolysis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT BIL_1_Gallstones 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_3_Pancreatitis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT MSK_3_Myositis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT IMU_3_Eosinophilia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT KID_3_Renal Dysfunction 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_3_Brittle Hair 882-09-7 CLOFIBRIC ACID TISSUE_TOXICITY Cardiac Arrhythmia 882-09-7 CLOFIBRIC ACID PRODUCT_CLASS Cardiovasculars 882-09-7 CLOFIBRIC ACID INDICATION Hypercholesterolemia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT BBM_3_Leukopenia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT KID_3_Proteinuria 882-09-7 CLOFIBRIC ACID THERAPEUTIC_CLASS Hypolipidemic Agents 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_2_Flatulence 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_2_Abdominal Cramps 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_3_Dry Skin 882-09-7 CLOFIBRIC ACID TISSUE_TOXICITY Angina 882-09-7 CLOFIBRIC ACID ACTIVITY_CLASS Peroxisome proliferator 882-09-7 CLOFIBRIC ACID INDICATION Hyperlipidemia 882-09-7 CLOFIBRIC ACID MECH_LEVEL_1 Lipid lowering 882-09-7 CLOFIBRIC ACID TA_LEVEL_3 fibrates 882-09-7 CLOFIBRIC ACID TA_LEVEL_1 Cardiovascular 882-09-7 CLOFIBRIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT DNA_1_Carcinogenicity 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_1_Nausea 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT REP_2_Impotence 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_3_Pruritis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT XXX_3_Weight Gain 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT MSK_2_Myalgia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_2_Dyspepsia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_3_Gastritis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT CVS_3_Intermittent Claudication 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT XXX_3_Polyphagia 882-09-7 CLOFIBRIC ACID TISSUE_TOXICITY Hepatotoxicity 882-09-7 CLOFIBRIC ACID TISSUE_TOXICITY Thromboembolism 882-09-7 CLOFIBRIC ACID MESH_LEVEL_1 Organic Chemicals 882-09-7 CLOFIBRIC ACID MECH_LEVEL_3 PPAR alpha 882-09-7 CLOFIBRIC ACID KNOWN_TOXICITY Hepatotoxicity 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT CVS_3_Angina 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT ELT_3_Hyperkalemia 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT LIV_2_Hepatotoxicity 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT GIS_3_Stomatitis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT END_3_Increased Creatine Phosphokinase 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT MSK_3_Myopathy 882-09-7 CLOFIBRIC ACID ADVERSE_EFFECT LIV_3_Hepatomegaly 882-09-7 CLOFIBRIC ACID ZERO_CLASS N 882-09-7 CLOFIBRIC ACID STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 882-09-7 CLOFIBRIC ACID MODE_CLASS Receptor Agonist, selective 882-09-7 CLOFIBRIC ACID MECH_LEVEL_2 Fatty acid catabolism 882-09-7 CLOFIBRIC ACID TISSUE_TOXICITY Carcinogenicity 882-09-7 CLOFIBRIC ACID TISSUE_TOXICITY Death 50-32-8 BENZO[A]PYRENE TISSUE_TOXICITY Genotoxicity 50-32-8 BENZO[A]PYRENE STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist 50-32-8 BENZO[A]PYRENE ADVERSE_EFFECT DNA_2_Genotoxicity 50-32-8 BENZO[A]PYRENE ADVERSE_EFFECT DNA_1_Carcinogenicity 50-32-8 BENZO[A]PYRENE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 50-32-8 BENZO[A]PYRENE MECHANISM Inhibit DNA synthesis, repair, and function 50-32-8 BENZO[A]PYRENE TISSUE_TOXICITY Teratogenicity 50-32-8 BENZO[A]PYRENE ADVERSE_EFFECT BBM_1_Anemia 50-32-8 BENZO[A]PYRENE TISSUE_TOXICITY Anemia 50-32-8 BENZO[A]PYRENE KNOWN_TOXICITY Mutagenicity 50-32-8 BENZO[A]PYRENE MODE_CLASS Distorts /blocks macromolecular scaffold function 50-32-8 BENZO[A]PYRENE TISSUE_TOXICITY Carcinogenicity 50-32-8 BENZO[A]PYRENE ADVERSE_EFFECT BBM_1_Red Blood Cell Damage 50-32-8 BENZO[A]PYRENE TISSUE_TOXICITY Red Blood Cell Damage 50-32-8 BENZO[A]PYRENE PRODUCT_CLASS Toxicants 50-32-8 BENZO[A]PYRENE KNOWN_TOXICITY Carcinogenicity 50-32-8 BENZO[A]PYRENE KNOWN_TOXICITY Embryo/Fetal Toxicity 50-32-8 BENZO[A]PYRENE ADVERSE_EFFECT IMU_1_Suppressed Immune System 50-32-8 BENZO[A]PYRENE ADVERSE_EFFECT EMB_1_Teratogenicity 192-97-2 BENZO[E]PYRENE MODE_CLASS Distorts /blocks macromolecular scaffold function 192-97-2 BENZO[E]PYRENE ADVERSE_EFFECT DNA_2_Carcinogenicity 192-97-2 BENZO[E]PYRENE TISSUE_TOXICITY Teratogenicity 192-97-2 BENZO[E]PYRENE PRODUCT_CLASS Toxicants 192-97-2 BENZO[E]PYRENE ADVERSE_EFFECT LUN_2_Pulmonary Impairment 192-97-2 BENZO[E]PYRENE TISSUE_TOXICITY Mutagenicity 192-97-2 BENZO[E]PYRENE KNOWN_TOXICITY Carcinogenicity 192-97-2 BENZO[E]PYRENE STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist 192-97-2 BENZO[E]PYRENE ADVERSE_EFFECT IMU_2_Suppressed Immune System 192-97-2 BENZO[E]PYRENE ADVERSE_EFFECT EMB_2_Teratogenicity 192-97-2 BENZO[E]PYRENE KNOWN_TOXICITY Embryo/Fetal Toxicity 192-97-2 BENZO[E]PYRENE ADVERSE_EFFECT DNA_3_Mutagenicity 192-97-2 BENZO[E]PYRENE KNOWN_TOXICITY Mutagenicity 192-97-2 BENZO[E]PYRENE TISSUE_TOXICITY Carcinogenicity 192-97-2 BENZO[E]PYRENE MECHANISM Inhibit DNA synthesis, repair, and function 10540-29-1 TAMOXIFEN ADVERSE_EFFECT SKN_3_Erythema Multiforme 10540-29-1 TAMOXIFEN ADVERSE_EFFECT REP_2_Decreased Fertility 10540-29-1 TAMOXIFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 10540-29-1 TAMOXIFEN THERAPEUTIC_CLASS Gonadal Hormones 10540-29-1 TAMOXIFEN KNOWN_TOXICITY Carcinogenicity 10540-29-1 TAMOXIFEN ZERO_CLASS N 10540-29-1 TAMOXIFEN TISSUE_TOXICITY Endometrial Carcinoma 10540-29-1 TAMOXIFEN ACTIVITY_CLASS Estrogen antagonist 10540-29-1 TAMOXIFEN ADVERSE_EFFECT GUS_2_Vaginal Dryness 10540-29-1 TAMOXIFEN ADVERSE_EFFECT REP_2_Menstrual Irregularities 10540-29-1 TAMOXIFEN ADVERSE_EFFECT DNA_2_Mutagenicity 10540-29-1 TAMOXIFEN ADVERSE_EFFECT GUS_2_Vaginal Discharge 10540-29-1 TAMOXIFEN ADVERSE_EFFECT CVS_2_Stroke 10540-29-1 TAMOXIFEN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 10540-29-1 TAMOXIFEN ADVERSE_EFFECT DNA_2_Carcinogenicity 10540-29-1 TAMOXIFEN ADVERSE_EFFECT ELT_2_Hypercalcemia 10540-29-1 TAMOXIFEN ADVERSE_EFFECT PSY_2_Depression 10540-29-1 TAMOXIFEN ADVERSE_EFFECT NEU_2_Dizziness 10540-29-1 TAMOXIFEN MECHANISM Modulate gene transcription 10540-29-1 TAMOXIFEN ADVERSE_EFFECT GIS_3_Pancreatitis 10540-29-1 TAMOXIFEN TISSUE_TOXICITY Stroke 10540-29-1 TAMOXIFEN ADVERSE_EFFECT LUN_2_Pulmonary Embolism 10540-29-1 TAMOXIFEN ADVERSE_EFFECT REP_2_Impotence 10540-29-1 TAMOXIFEN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 10540-29-1 TAMOXIFEN KNOWN_TOXICITY Cardiovascular Toxicity 10540-29-1 TAMOXIFEN TISSUE_TOXICITY Carcinogenicity 10540-29-1 TAMOXIFEN TISSUE_TOXICITY Mutagenicity 10540-29-1 TAMOXIFEN INDICATION Metastatic Breast Cancer 10540-29-1 TAMOXIFEN MODE_CLASS Receptor Ligand Antagonist 10540-29-1 TAMOXIFEN MESH_LEVEL_2 Hydrocarbons 10540-29-1 TAMOXIFEN INDICATION Reduction in Breast Cancer Incidence 10540-29-1 TAMOXIFEN MESH_LEVEL_1 Organic Chemicals 10540-29-1 TAMOXIFEN INDICATION Breast Cancer / Carcinoma of the Breast 10540-29-1 TAMOXIFEN MESH_LEVEL_3 Hydrocarbons, Cyclic 10540-29-1 TAMOXIFEN TA_LEVEL_3 SERM 10540-29-1 TAMOXIFEN TA_LEVEL_2 Nonsteroidal SERM 10540-29-1 TAMOXIFEN MECH_LEVEL_2 estrogen receptor agonist/antagonist 10540-29-1 TAMOXIFEN PRODUCT_CLASS Anti-cancers 10540-29-1 TAMOXIFEN ADVERSE_EFFECT END_3_Increased Plasma Triglycerides 10540-29-1 TAMOXIFEN ADVERSE_EFFECT BBM_2_Thrombocytopenia 10540-29-1 TAMOXIFEN ADVERSE_EFFECT DNA_2_Endometrial Carcinoma 10540-29-1 TAMOXIFEN ADVERSE_EFFECT REP_2_Decreased Libido 10540-29-1 TAMOXIFEN ADVERSE_EFFECT NEU_2_Headache 10540-29-1 TAMOXIFEN MECH_LEVEL_3 estrogen receptor 10540-29-1 TAMOXIFEN ADVERSE_EFFECT GUS_2_Genital Pruritis 10540-29-1 TAMOXIFEN ADVERSE_EFFECT END_1_Hot Flashes 10540-29-1 TAMOXIFEN KNOWN_TOXICITY Mutagenicity 10540-29-1 TAMOXIFEN STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 10540-29-1 TAMOXIFEN INDICATION Ductal Carcinoma in Situ (DCIS) 10540-29-1 TAMOXIFEN TA_LEVEL_1 Oncology 10540-29-1 TAMOXIFEN ADVERSE_EFFECT GUS_2_Vaginal Spotting 10540-29-1 TAMOXIFEN ADVERSE_EFFECT MSK_2_Bone Pain 10540-29-1 TAMOXIFEN INDICATION Adjuvant Treatment of Breast Cancer 10540-29-1 TAMOXIFEN MECH_LEVEL_1 Hormone modulation 10540-29-1 TAMOXIFEN ADVERSE_EFFECT NEU_2_Lightheadedness 10540-29-1 TAMOXIFEN ADVERSE_EFFECT REP_2_Amenorrhea 10540-29-1 TAMOXIFEN ADVERSE_EFFECT GIS_2_Nausea 10540-29-1 TAMOXIFEN ADVERSE_EFFECT XXX_2_Weight Loss 10540-29-1 TAMOXIFEN ADVERSE_EFFECT OCU_2_Cataracts 11070-73-8 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 11070-73-8 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 11070-73-8 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 11070-73-8 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 11070-73-8 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 11070-73-8 INSULIN INDICATION Diabetes Mellitus 11070-73-8 INSULIN MECHANISM Modulate signal transduction 11070-73-8 INSULIN ACTIVITY_CLASS Insulin receptor agonist 11070-73-8 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 11070-73-8 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 11070-73-8 INSULIN ADVERSE_EFFECT SKN_3_Rash 11070-73-8 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 11070-73-8 INSULIN ZERO_CLASS N 11070-73-8 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 11070-73-8 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 11070-73-8 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 11070-73-8 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 11070-73-8 INSULIN TISSUE_TOXICITY Hypotension 11070-73-8 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 11061-68-0 INSULIN ADVERSE_EFFECT SKN_3_Rash 11061-68-0 INSULIN ACTIVITY_CLASS Insulin receptor agonist 11061-68-0 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 11061-68-0 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 11061-68-0 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 11061-68-0 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 11061-68-0 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 11061-68-0 INSULIN ZERO_CLASS N 11061-68-0 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 11061-68-0 INSULIN TISSUE_TOXICITY Hypotension 11061-68-0 INSULIN INDICATION Diabetes Mellitus 11061-68-0 INSULIN MECHANISM Modulate signal transduction 11061-68-0 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 11061-68-0 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 11061-68-0 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 11061-68-0 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 11061-68-0 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 11061-68-0 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 11061-68-0 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 12393-32-7 INSULIN ZERO_CLASS N 12393-32-7 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 12393-32-7 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 12393-32-7 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 12393-32-7 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 12393-32-7 INSULIN TISSUE_TOXICITY Hypotension 12393-32-7 INSULIN ACTIVITY_CLASS Insulin receptor agonist 12393-32-7 INSULIN ADVERSE_EFFECT SKN_3_Rash 12393-32-7 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 12393-32-7 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 12393-32-7 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 12393-32-7 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 12393-32-7 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 12393-32-7 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 12393-32-7 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 12393-32-7 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 12393-32-7 INSULIN MECHANISM Modulate signal transduction 12393-32-7 INSULIN INDICATION Diabetes Mellitus 12393-32-7 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 12584-58-6 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 12584-58-6 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 12584-58-6 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 12584-58-6 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 12584-58-6 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 12584-58-6 INSULIN ADVERSE_EFFECT SKN_3_Rash 12584-58-6 INSULIN ACTIVITY_CLASS Insulin receptor agonist 12584-58-6 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 12584-58-6 INSULIN TISSUE_TOXICITY Hypotension 12584-58-6 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 12584-58-6 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 12584-58-6 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 12584-58-6 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 12584-58-6 INSULIN ZERO_CLASS N 12584-58-6 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 12584-58-6 INSULIN INDICATION Diabetes Mellitus 12584-58-6 INSULIN MECHANISM Modulate signal transduction 12584-58-6 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 12584-58-6 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 9004-10-8 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 9004-10-8 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 9004-10-8 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 9004-10-8 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 9004-10-8 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 9004-10-8 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 9004-10-8 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 9004-10-8 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 9004-10-8 INSULIN MECHANISM Modulate signal transduction 9004-10-8 INSULIN ZERO_CLASS N 9004-10-8 INSULIN INDICATION Diabetes Mellitus 9004-10-8 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 9004-10-8 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 9004-10-8 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 9004-10-8 INSULIN TISSUE_TOXICITY Hypotension 9004-10-8 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 9004-10-8 INSULIN ACTIVITY_CLASS Insulin receptor agonist 9004-10-8 INSULIN ADVERSE_EFFECT SKN_3_Rash 9004-10-8 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 9045-63-0 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 9045-63-0 INSULIN INDICATION Diabetes Mellitus 9045-63-0 INSULIN MECHANISM Modulate signal transduction 9045-63-0 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 9045-63-0 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 9045-63-0 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 9045-63-0 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 9045-63-0 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 9045-63-0 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 9045-63-0 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 9045-63-0 INSULIN ZERO_CLASS N 9045-63-0 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 9045-63-0 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 9045-63-0 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 9045-63-0 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 9045-63-0 INSULIN TISSUE_TOXICITY Hypotension 9045-63-0 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 9045-63-0 INSULIN ACTIVITY_CLASS Insulin receptor agonist 9045-63-0 INSULIN ADVERSE_EFFECT SKN_3_Rash 9045-65-2 INSULIN ZERO_CLASS N 9045-65-2 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 9045-65-2 INSULIN ADVERSE_EFFECT SKN_3_Rash 9045-65-2 INSULIN ACTIVITY_CLASS Insulin receptor agonist 9045-65-2 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 9045-65-2 INSULIN TISSUE_TOXICITY Hypotension 9045-65-2 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 9045-65-2 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 9045-65-2 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 9045-65-2 INSULIN INDICATION Diabetes Mellitus 9045-65-2 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 9045-65-2 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 9045-65-2 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 9045-65-2 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 9045-65-2 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 9045-65-2 INSULIN MECHANISM Modulate signal transduction 9045-65-2 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 9045-65-2 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 9045-65-2 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 9045-66-3 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 9045-66-3 INSULIN ADVERSE_EFFECT SKN_3_Rash 9045-66-3 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 9045-66-3 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 9045-66-3 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 9045-66-3 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 9045-66-3 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 9045-66-3 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 9045-66-3 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 9045-66-3 INSULIN MECHANISM Modulate signal transduction 9045-66-3 INSULIN INDICATION Diabetes Mellitus 9045-66-3 INSULIN TISSUE_TOXICITY Hypotension 9045-66-3 INSULIN ZERO_CLASS N 9045-66-3 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 9045-66-3 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 9045-66-3 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 9045-66-3 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 9045-66-3 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 9045-66-3 INSULIN ACTIVITY_CLASS Insulin receptor agonist 9045-67-4 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 9045-67-4 INSULIN TISSUE_TOXICITY Hypotension 9045-67-4 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 9045-67-4 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 9045-67-4 INSULIN MECHANISM Modulate signal transduction 9045-67-4 INSULIN INDICATION Diabetes Mellitus 9045-67-4 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 9045-67-4 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 9045-67-4 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 9045-67-4 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 9045-67-4 INSULIN ZERO_CLASS N 9045-67-4 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 9045-67-4 INSULIN ACTIVITY_CLASS Insulin receptor agonist 9045-67-4 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 9045-67-4 INSULIN ADVERSE_EFFECT SKN_3_Rash 9045-67-4 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 9045-67-4 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 9045-67-4 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 9045-67-4 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 99551-09-4 INSULIN ACTIVITY_CLASS Insulin receptor agonist 99551-09-4 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 99551-09-4 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 99551-09-4 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 99551-09-4 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 99551-09-4 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 99551-09-4 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 99551-09-4 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 99551-09-4 INSULIN INDICATION Diabetes Mellitus 99551-09-4 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 99551-09-4 INSULIN MECHANISM Modulate signal transduction 99551-09-4 INSULIN ADVERSE_EFFECT SKN_3_Rash 99551-09-4 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 99551-09-4 INSULIN ZERO_CLASS N 99551-09-4 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 99551-09-4 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 99551-09-4 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 99551-09-4 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 99551-09-4 INSULIN TISSUE_TOXICITY Hypotension 8049-62-5 INSULIN ADVERSE_EFFECT END_2_Lipodystrophy 8049-62-5 INSULIN TISSUE_TOXICITY Hypotension 8049-62-5 INSULIN ADVERSE_EFFECT LUN_3_Wheezing 8049-62-5 INSULIN MODE_CLASS Endogenous Receptor /Channel Ligand 8049-62-5 INSULIN ADVERSE_EFFECT END_1_Hypoglycemia 8049-62-5 INSULIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 8049-62-5 INSULIN ADVERSE_EFFECT SKN_3_Pruritis 8049-62-5 INSULIN KNOWN_TOXICITY Cardiovascular Toxicity 8049-62-5 INSULIN STRUCTURE_ACTIVITY Insulin receptor agonist 8049-62-5 INSULIN INDICATION Diabetes Mellitus 8049-62-5 INSULIN ZERO_CLASS N 8049-62-5 INSULIN ADVERSE_EFFECT ELT_2_Hypokalemia 8049-62-5 INSULIN ADVERSE_EFFECT LUN_3_Shortness of Breath 8049-62-5 INSULIN MECHANISM Modulate signal transduction 8049-62-5 INSULIN ADVERSE_EFFECT CVS_3_Hypotension 8049-62-5 INSULIN ADVERSE_EFFECT SKN_3_Rash 8049-62-5 INSULIN ACTIVITY_CLASS Insulin receptor agonist 8049-62-5 INSULIN THERAPEUTIC_CLASS Antidiabetic Agents 8049-62-5 INSULIN ADVERSE_EFFECT IMU_2_Hypersensitivity 76-25-5 TRIAMCINOLONE ACETONIDE INDICATION Asthma 76-25-5 TRIAMCINOLONE ACETONIDE THERAPEUTIC_CLASS Corticosteroids 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_3_Facial Edema 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT MSK_2_Back Pain 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_2_Sinusitis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT NEU_2_Headache 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT OTO_2_Otitis Media 76-25-5 TRIAMCINOLONE ACETONIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 76-25-5 TRIAMCINOLONE ACETONIDE MECHANISM Modulate gene transcription 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT IMU_3_Photosensitivity 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_2_Epistaxis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT GIS_2_Nausea 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT LUN_2_Asthma 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT MSK_2_Myalgia 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT GIS_2_Dyspepsia 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_2_Pharyngitis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT GUS_3_Vaginal Moniliasis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT GIS_3_Dry Mouth 76-25-5 TRIAMCINOLONE ACETONIDE PRODUCT_CLASS Anti-inflammatories 76-25-5 TRIAMCINOLONE ACETONIDE INDICATION Allergic Rhinitis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_3_Weight Gain 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT GUS_3_Cystitis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_3_Tenosynovitis 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_2_Throat Irritation 76-25-5 TRIAMCINOLONE ACETONIDE ADVERSE_EFFECT XXX_2_Fever 76-25-5 TRIAMCINOLONE ACETONIDE MODE_CLASS Receptor Agonist 1015-89-0 6(5H)-PHENANTHRIDINONE MODE_CLASS Enzyme Inhibitor 1015-89-0 6(5H)-PHENANTHRIDINONE PRODUCT_CLASS Biochemicals 1015-89-0 6(5H)-PHENANTHRIDINONE MECHANISM Inhibit DNA synthesis, repair, and function 1015-89-0 6(5H)-PHENANTHRIDINONE STRUCTURE_ACTIVITY ADP-ribosyltransferase inhibitor 50-02-2 DEXAMETHASONE MESH_LEVEL_1 Polycyclic Hydrocarbons 50-02-2 DEXAMETHASONE INDICATION Rheumatic Disorders 50-02-2 DEXAMETHASONE INDICATION Ophthalmic Diseases 50-02-2 DEXAMETHASONE INDICATION Edematous States 50-02-2 DEXAMETHASONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 50-02-2 DEXAMETHASONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 50-02-2 DEXAMETHASONE ADVERSE_EFFECT XXX_2_Increased Appetite 50-02-2 DEXAMETHASONE ADVERSE_EFFECT CVS_2_Cardiotoxicity 50-02-2 DEXAMETHASONE ZERO_CLASS N 50-02-2 DEXAMETHASONE MODE_CLASS Receptor Agonist 50-02-2 DEXAMETHASONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 50-02-2 DEXAMETHASONE TISSUE_TOXICITY Cardiotoxicity 50-02-2 DEXAMETHASONE ACTIVITY_CLASS GR-MR agonist 50-02-2 DEXAMETHASONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 50-02-2 DEXAMETHASONE ADVERSE_EFFECT CVS_2_Thromboembolism 50-02-2 DEXAMETHASONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 50-02-2 DEXAMETHASONE ADVERSE_EFFECT XXX_2_Malaise 50-02-2 DEXAMETHASONE TISSUE_TOXICITY Thromboembolism 50-02-2 DEXAMETHASONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 50-02-2 DEXAMETHASONE TA_LEVEL_3 Corticosteroids 50-02-2 DEXAMETHASONE INDICATION Skin Diseases / Dermatoses 50-02-2 DEXAMETHASONE INDICATION Hematologic Disorders 50-02-2 DEXAMETHASONE MESH_LEVEL_2 Steroids 50-02-2 DEXAMETHASONE ADVERSE_EFFECT END_2_Metabolic Disturbance 50-02-2 DEXAMETHASONE ADVERSE_EFFECT XXX_2_Weight Gain 50-02-2 DEXAMETHASONE KNOWN_TOXICITY Cardiovascular Toxicity 50-02-2 DEXAMETHASONE ADVERSE_EFFECT SKN_2_Skin Toxicity 50-02-2 DEXAMETHASONE TA_LEVEL_2 Steroid 50-02-2 DEXAMETHASONE MECH_LEVEL_2 Anti-inflammation and immunosuppression 50-02-2 DEXAMETHASONE MECH_LEVEL_3 Glucocorticoid receptor 50-02-2 DEXAMETHASONE MECHANISM Modulate gene transcription 50-02-2 DEXAMETHASONE MECH_LEVEL_1 Immunomodulation 50-02-2 DEXAMETHASONE PRODUCT_CLASS Anti-inflammatories 50-02-2 DEXAMETHASONE INDICATION Collagen Diseases 50-02-2 DEXAMETHASONE INDICATION Respiratory Diseases 50-02-2 DEXAMETHASONE INDICATION Neoplastic Diseases 50-02-2 DEXAMETHASONE THERAPEUTIC_CLASS Corticosteroids 50-02-2 DEXAMETHASONE INDICATION Gastrointestinal Diseases 50-02-2 DEXAMETHASONE INDICATION Allergic Diseases 50-02-2 DEXAMETHASONE TA_LEVEL_1 Anti-inflammatory 50-02-2 DEXAMETHASONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 50-02-2 DEXAMETHASONE MESH_LEVEL_3 Pregnanes 50-02-2 DEXAMETHASONE ADVERSE_EFFECT GIS_2_Nausea 50-02-2 DEXAMETHASONE ADVERSE_EFFECT IMU_2_Hypersensitivity 50-02-2 DEXAMETHASONE INDICATION Endocrine Disorders 637-07-0 CLOFIBRATE ADVERSE_EFFECT XXX_2_Fatigue 637-07-0 CLOFIBRATE ADVERSE_EFFECT CVS_3_Angina 637-07-0 CLOFIBRATE TISSUE_TOXICITY Hepatotoxicity 637-07-0 CLOFIBRATE INDICATION Hyperlipoproteinemia 637-07-0 CLOFIBRATE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 637-07-0 CLOFIBRATE ADVERSE_EFFECT MSK_3_Myositis 637-07-0 CLOFIBRATE KNOWN_TOXICITY Hepatotoxicity 637-07-0 CLOFIBRATE TISSUE_TOXICITY Angina 637-07-0 CLOFIBRATE ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 637-07-0 CLOFIBRATE ADVERSE_EFFECT BBM_3_Agranulocytosis 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_3_Gastritis 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_3_Erythema Multiforme 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_2_Abdominal Cramps 637-07-0 CLOFIBRATE ADVERSE_EFFECT REP_3_Suppressed Spermatogenesis 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 637-07-0 CLOFIBRATE ADVERSE_EFFECT NEU_2_Headache 637-07-0 CLOFIBRATE ADVERSE_EFFECT DNA_1_Carcinogenicity 637-07-0 CLOFIBRATE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 637-07-0 CLOFIBRATE KNOWN_TOXICITY Carcinogenicity 637-07-0 CLOFIBRATE MESH_LEVEL_3 Acids, Acyclic 637-07-0 CLOFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 637-07-0 CLOFIBRATE ADVERSE_EFFECT LIV_3_Hepatomegaly 637-07-0 CLOFIBRATE MESH_LEVEL_2 Carboxylic Acids 637-07-0 CLOFIBRATE TISSUE_TOXICITY Death 637-07-0 CLOFIBRATE ADVERSE_EFFECT BIL_1_Gallstones 637-07-0 CLOFIBRATE ADVERSE_EFFECT XXX_3_Death 637-07-0 CLOFIBRATE TISSUE_TOXICITY Carcinogenicity 637-07-0 CLOFIBRATE TISSUE_TOXICITY Cardiac Arrhythmia 637-07-0 CLOFIBRATE KNOWN_TOXICITY Miscellaneous 637-07-0 CLOFIBRATE INDICATION Hypercholesterolemia 637-07-0 CLOFIBRATE INDICATION Hypertriglyceridemia 637-07-0 CLOFIBRATE TA_LEVEL_2 Lipid lowering agent 637-07-0 CLOFIBRATE MECH_LEVEL_2 Fatty acid catabolism 637-07-0 CLOFIBRATE ADVERSE_EFFECT KID_3_Proteinuria 637-07-0 CLOFIBRATE ADVERSE_EFFECT XXX_3_Weight Gain 637-07-0 CLOFIBRATE ADVERSE_EFFECT KID_3_Renal Dysfunction 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_3_Pruritis 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_2_Dyspepsia 637-07-0 CLOFIBRATE ADVERSE_EFFECT CVS_3_Intermittent Claudication 637-07-0 CLOFIBRATE ADVERSE_EFFECT REP_2_Impotence 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_2_Rash 637-07-0 CLOFIBRATE ADVERSE_EFFECT MSK_3_Myopathy 637-07-0 CLOFIBRATE KNOWN_TOXICITY Cardiovascular Toxicity 637-07-0 CLOFIBRATE PRODUCT_CLASS Cardiovasculars 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_1_Nausea 637-07-0 CLOFIBRATE ZERO_CLASS N 637-07-0 CLOFIBRATE TISSUE_TOXICITY Thromboembolism 637-07-0 CLOFIBRATE MODE_CLASS Receptor Agonist, selective 637-07-0 CLOFIBRATE MECH_LEVEL_3 PPAR alpha 637-07-0 CLOFIBRATE MESH_LEVEL_1 Organic Chemicals 637-07-0 CLOFIBRATE MECHANISM Increase lipid catabolism 637-07-0 CLOFIBRATE ACTIVITY_CLASS Peroxisome proliferator 637-07-0 CLOFIBRATE ADVERSE_EFFECT END_3_Increased Creatine Phosphokinase 637-07-0 CLOFIBRATE ADVERSE_EFFECT XXX_3_Polyphagia 637-07-0 CLOFIBRATE ADVERSE_EFFECT BBM_3_Leukopenia 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_3_Dry Skin 637-07-0 CLOFIBRATE ADVERSE_EFFECT CVS_3_Thromboembolism 637-07-0 CLOFIBRATE ADVERSE_EFFECT BBM_2_Anemia 637-07-0 CLOFIBRATE ADVERSE_EFFECT IMU_2_Urticaria 637-07-0 CLOFIBRATE ADVERSE_EFFECT MSK_2_Myalgia 637-07-0 CLOFIBRATE STRUCTURE_ACTIVITY PPAR alpha agonist, fibrate ester 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_2_Diarrhea 637-07-0 CLOFIBRATE ADVERSE_EFFECT LIV_2_Hepatotoxicity 637-07-0 CLOFIBRATE TA_LEVEL_1 Cardiovascular 637-07-0 CLOFIBRATE TA_LEVEL_3 fibrates 637-07-0 CLOFIBRATE MECH_LEVEL_1 Lipid lowering 637-07-0 CLOFIBRATE ADVERSE_EFFECT ELT_3_Hyperkalemia 637-07-0 CLOFIBRATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 637-07-0 CLOFIBRATE ADVERSE_EFFECT IMU_3_Eosinophilia 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_3_Stomatitis 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_3_Brittle Hair 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_2_Flatulence 637-07-0 CLOFIBRATE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_3_Pancreatitis 637-07-0 CLOFIBRATE ADVERSE_EFFECT GIS_2_Vomiting 49562-28-9 FENOFIBRATE TA_LEVEL_2 Lipid lowering agent 49562-28-9 FENOFIBRATE PRODUCT_CLASS Cardiovasculars 49562-28-9 FENOFIBRATE MECH_LEVEL_2 Fatty acid catabolism 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Rectal Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 49562-28-9 FENOFIBRATE ADVERSE_EFFECT IMU_3_Allergic Reactions 49562-28-9 FENOFIBRATE ADVERSE_EFFECT EMB_1_Teratogenicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Duodenal Ulcer 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BBM_3_Agranulocytosis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT IMU_3_Urticaria 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_2_Pancreatitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Skin Ulcer 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Skin Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Herpes Simplex 49562-28-9 FENOFIBRATE ADVERSE_EFFECT REP_3_Unintended Pregnancy 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LUN_3_Asthma 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GUS_3_Urolithiasis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GUS_3_Vaginal Moniliasis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Tooth Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Tachycardia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Hypertension 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BBM_3_Leukopenia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_2_Diarrhea 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Teratogenicity 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Hypotension 49562-28-9 FENOFIBRATE KNOWN_TOXICITY Embryo/Fetal Toxicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Neuralgia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Paresthesia 49562-28-9 FENOFIBRATE MODE_CLASS Receptor Agonist, selective 49562-28-9 FENOFIBRATE INDICATION Dyslipidemia (Diabetic) 49562-28-9 FENOFIBRATE MESH_LEVEL_2 Carboxylic Acids 49562-28-9 FENOFIBRATE MESH_LEVEL_3 Acids, Acyclic 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OCU_3_Amblyopia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Nail Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Fungal Dermatitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Herpes Zoster 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Sinusitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LUN_3_Dyspnea 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Increased Appetite 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Fever 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Malaise 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LUN_2_Respiratory Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_2_Headache 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_2_Abdominal Pain 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BIL_2_Gallstones 49562-28-9 FENOFIBRATE ADVERSE_EFFECT END_3_Diabetes Mellitus 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Peptic Ulceration 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Vomiting 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Dyspepsia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Myocardial Damage 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OCU_3_Refraction Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BBM_3_Ecchymosis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LIV_3_Liver Fatty Deposit 49562-28-9 FENOFIBRATE ADVERSE_EFFECT PSY_3_Anorexia 49562-28-9 FENOFIBRATE MECHANISM Increase lipid catabolism 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Flatulence 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Hypotension 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_2_Constipation 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_2_Nausea 49562-28-9 FENOFIBRATE ADVERSE_EFFECT DNA_1_Carcinogenicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT PSY_3_Insomnia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LYM_3_Lymphadenopathy 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Myositis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BBM_3_Anemia 49562-28-9 FENOFIBRATE ZERO_CLASS N 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Dizziness 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Arthrosis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT KID_3_Hyperuricemia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Leg Cramps 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Peripheral Edema 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Weight Loss 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Ventricular Extrasystoles 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Migraine 49562-28-9 FENOFIBRATE KNOWN_TOXICITY Carcinogenicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Weight Gain 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Pharyngitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Hypertonia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT REP_3_Decreased Libido 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Ventricular Extrasystoles 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Cardiac Arrhythmia 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Hepatotoxicity 49562-28-9 FENOFIBRATE INDICATION Hypercholesterolemia 49562-28-9 FENOFIBRATE INDICATION Hypertriglyceridemia 49562-28-9 FENOFIBRATE INDICATION Hyperlipidemia 49562-28-9 FENOFIBRATE MESH_LEVEL_1 Organic Chemicals 49562-28-9 FENOFIBRATE MECH_LEVEL_3 PPAR alpha 49562-28-9 FENOFIBRATE ADVERSE_EFFECT END_3_Gynecomastia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GUS_3_Cystitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LUN_3_Increased Cough 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Laryngitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Eczema 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Sweating 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Maculopapular Rash 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OCU_3_Eye Disorder 49562-28-9 FENOFIBRATE INDICATION Hyperlipoproteinemia 49562-28-9 FENOFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_2_Flu Syndrome 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Coronary Artery Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Varicose Vein 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OTO_3_Otitis Media 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GUS_3_Prostatic Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GUS_3_Dysuria 49562-28-9 FENOFIBRATE ADVERSE_EFFECT END_3_Gout 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Arthritis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Myasthenia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Vertigo 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LIV_1_Hepatotoxicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Fatigue 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LIV_1_Increased Liver Function Tests 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Infection 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Hernia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Vascular Disorder 49562-28-9 FENOFIBRATE INDICATION Mixed Dyslipidemia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Eructation 49562-28-9 FENOFIBRATE MECH_LEVEL_1 Lipid lowering 49562-28-9 FENOFIBRATE INDICATION Chylomicronemia Syndrome / Hyperchylomicronemia 49562-28-9 FENOFIBRATE TA_LEVEL_3 fibrates 49562-28-9 FENOFIBRATE TA_LEVEL_1 Cardiovascular 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Angina 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Atrial Fibrillation 49562-28-9 FENOFIBRATE ADVERSE_EFFECT PSY_3_Anxiety 49562-28-9 FENOFIBRATE ADVERSE_EFFECT PSY_3_Nervousness 49562-28-9 FENOFIBRATE KNOWN_TOXICITY Cardiovascular Toxicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_2_Asthenia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Vasodilation 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Peripheral Vascular Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Gastroenteritis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT END_3_Hypoglycemia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Arthralgia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Bursitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT PSY_3_Depression 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Dermatitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Angina 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Palpitation 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_2_Back Pain 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Colitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Gastrointestinal Disorder 49562-28-9 FENOFIBRATE ADVERSE_EFFECT BIL_3_Cholecystitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT IMU_3_Eosinophilia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OTO_3_Ear Pain 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GUS_3_Urinary Frequency 49562-28-9 FENOFIBRATE ADVERSE_EFFECT KID_3_Abnormal Kidney Function 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LUN_3_Bronchitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT LUN_3_Pneumonia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Pruritis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Acne 49562-28-9 FENOFIBRATE ADVERSE_EFFECT IMU_3_Contact Dermatitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OCU_3_Conjunctivitis 49562-28-9 FENOFIBRATE STRUCTURE_ACTIVITY PPAR alpha agonist, fibrate ester 49562-28-9 FENOFIBRATE KNOWN_TOXICITY Hepatotoxicity 49562-28-9 FENOFIBRATE ADVERSE_EFFECT SKN_3_Rash 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_2_Myopathy 49562-28-9 FENOFIBRATE ADVERSE_EFFECT MSK_3_Myalgia 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Chest Pain 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Cyst 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_3_Accidental Injury 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 49562-28-9 FENOFIBRATE ACTIVITY_CLASS Peroxisome proliferator 49562-28-9 FENOFIBRATE ADVERSE_EFFECT REP_3_Impotence 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Esophagitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Gastritis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT OCU_3_Abnormal Vision 49562-28-9 FENOFIBRATE ADVERSE_EFFECT END_2_Increased Creatine Phosphokinase 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_Phlebitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT CVS_3_ECG Abnormalities 49562-28-9 FENOFIBRATE ADVERSE_EFFECT XXX_2_Rhinitis 49562-28-9 FENOFIBRATE ADVERSE_EFFECT NEU_3_Somnolence 49562-28-9 FENOFIBRATE ADVERSE_EFFECT GIS_3_Dry Mouth 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Coronary Artery Disorder 49562-28-9 FENOFIBRATE TISSUE_TOXICITY Carcinogenicity 41859-67-0 BEZAFIBRATE MODE_CLASS Receptor Agonist, selective 41859-67-0 BEZAFIBRATE TISSUE_TOXICITY Hepatotoxicity 41859-67-0 BEZAFIBRATE ADVERSE_EFFECT LIV_2_Hepatotoxicity 41859-67-0 BEZAFIBRATE INDICATION Hypertriglyceridemia 41859-67-0 BEZAFIBRATE MECHANISM Increase lipid catabolism 41859-67-0 BEZAFIBRATE PRODUCT_CLASS Cardiovasculars 41859-67-0 BEZAFIBRATE TA_LEVEL_2 Lipid lowering agent 41859-67-0 BEZAFIBRATE MECH_LEVEL_2 Fatty acid catabolism 41859-67-0 BEZAFIBRATE INDICATION Hyperlipidemia 41859-67-0 BEZAFIBRATE INDICATION Hyperlipoproteinemia 41859-67-0 BEZAFIBRATE ADVERSE_EFFECT BIL_3_Gallstones 41859-67-0 BEZAFIBRATE MECH_LEVEL_3 PPAR alpha 41859-67-0 BEZAFIBRATE INDICATION Chylomicronemia Syndrome / Hyperchylomicronemia 41859-67-0 BEZAFIBRATE MESH_LEVEL_1 Organic Chemicals 41859-67-0 BEZAFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 41859-67-0 BEZAFIBRATE ACTIVITY_CLASS Peroxisome proliferator 41859-67-0 BEZAFIBRATE STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 41859-67-0 BEZAFIBRATE ZERO_CLASS N 41859-67-0 BEZAFIBRATE ADVERSE_EFFECT GIS_1_Distention 41859-67-0 BEZAFIBRATE ADVERSE_EFFECT GIS_1_Nausea 41859-67-0 BEZAFIBRATE INDICATION Hypercholesterolemia 41859-67-0 BEZAFIBRATE MECH_LEVEL_1 Lipid lowering 41859-67-0 BEZAFIBRATE TA_LEVEL_1 Cardiovascular 41859-67-0 BEZAFIBRATE TA_LEVEL_3 fibrates 41859-67-0 BEZAFIBRATE KNOWN_TOXICITY Hepatotoxicity 41859-67-0 BEZAFIBRATE ADVERSE_EFFECT MSK_2_Myositis 41859-67-0 BEZAFIBRATE ADVERSE_EFFECT REP_2_Impotence 41859-67-0 BEZAFIBRATE MESH_LEVEL_3 Acids, Acyclic 41859-67-0 BEZAFIBRATE MESH_LEVEL_2 Carboxylic Acids 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Carcinogenicity 23214-92-8 DOXORUBICIN INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 23214-92-8 DOXORUBICIN INDICATION Bladder Cancer / Carcinoma of the Bladder 23214-92-8 DOXORUBICIN INDICATION Testicular Cancer / Carcinoma of the Testis 23214-92-8 DOXORUBICIN INDICATION Ewing's Sarcoma 23214-92-8 DOXORUBICIN INDICATION Non-Hodgkin's Lymphomas 23214-92-8 DOXORUBICIN INDICATION Osteosarcoma / Osteogenic Sarcoma 23214-92-8 DOXORUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 23214-92-8 DOXORUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 23214-92-8 DOXORUBICIN KNOWN_TOXICITY Mutagenicity 23214-92-8 DOXORUBICIN TA_LEVEL_2 DNA damage 23214-92-8 DOXORUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 23214-92-8 DOXORUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 23214-92-8 DOXORUBICIN ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 23214-92-8 DOXORUBICIN ADVERSE_EFFECT XXX_1_Mucositis 23214-92-8 DOXORUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 23214-92-8 DOXORUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Congestive Heart Failure 23214-92-8 DOXORUBICIN PRODUCT_CLASS Anti-cancers 23214-92-8 DOXORUBICIN INDICATION Soft Tissue Sarcoma 23214-92-8 DOXORUBICIN INDICATION Neuroblastoma 23214-92-8 DOXORUBICIN MESH_LEVEL_2 Carbohydrates 23214-92-8 DOXORUBICIN INDICATION Hodgkin's Disease 23214-92-8 DOXORUBICIN INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 23214-92-8 DOXORUBICIN INDICATION Acute Lymphocytic Leukemia (ALL) 23214-92-8 DOXORUBICIN INDICATION Carcinoma of the Head and Neck 23214-92-8 DOXORUBICIN INDICATION Endometrial Cancer / Carcinoma of the Endometrium 23214-92-8 DOXORUBICIN KNOWN_TOXICITY Carcinogenicity 23214-92-8 DOXORUBICIN ACTIVITY_CLASS DNA damager 23214-92-8 DOXORUBICIN INDICATION Prostatic Cancer / Carcinoma of the Prostate 23214-92-8 DOXORUBICIN INDICATION Bronchogenic Carcinoma 23214-92-8 DOXORUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 23214-92-8 DOXORUBICIN INDICATION Ovarian Cancer / Carcinoma of the Ovary 23214-92-8 DOXORUBICIN ADVERSE_EFFECT CVS_1_Myocardial Damage 23214-92-8 DOXORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 23214-92-8 DOXORUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 23214-92-8 DOXORUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 23214-92-8 DOXORUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 23214-92-8 DOXORUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Cardiotoxicity 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Hemorrhage 23214-92-8 DOXORUBICIN INDICATION Wilms' Tumor 23214-92-8 DOXORUBICIN INDICATION Cervical Cancer / Carcinoma of the Cervix 23214-92-8 DOXORUBICIN TA_LEVEL_1 Oncology 23214-92-8 DOXORUBICIN INDICATION Breast Cancer / Carcinoma of the Breast 23214-92-8 DOXORUBICIN TA_LEVEL_3 Solid and soft Tumors 23214-92-8 DOXORUBICIN INDICATION Neoplasm / Cancer / Tumor 23214-92-8 DOXORUBICIN MECH_LEVEL_3 DNA damage 23214-92-8 DOXORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 23214-92-8 DOXORUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Myelosuppression 23214-92-8 DOXORUBICIN THERAPEUTIC_CLASS Antineoplastics 23214-92-8 DOXORUBICIN ADVERSE_EFFECT IMU_3_Anaphylaxis 23214-92-8 DOXORUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 23214-92-8 DOXORUBICIN ADVERSE_EFFECT GIS_2_Necrotizing Colitis 23214-92-8 DOXORUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 23214-92-8 DOXORUBICIN ADVERSE_EFFECT IMU_2_Urticaria 23214-92-8 DOXORUBICIN MESH_LEVEL_3 Aminoglycosides 23214-92-8 DOXORUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 23214-92-8 DOXORUBICIN ZERO_CLASS N 23214-92-8 DOXORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 23214-92-8 DOXORUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 23214-92-8 DOXORUBICIN ADVERSE_EFFECT NEU_2_Peripheral Neurotoxicity 23214-92-8 DOXORUBICIN ADVERSE_EFFECT XXX_2_Radiosensitization 23214-92-8 DOXORUBICIN ADVERSE_EFFECT BBM_3_Acute Leukemia 23214-92-8 DOXORUBICIN ADVERSE_EFFECT XXX_1_Infection 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Cardiomyopathy 23214-92-8 DOXORUBICIN TISSUE_TOXICITY Mutagenicity 25316-40-9 DOXORUBICIN INDICATION Bladder Cancer / Carcinoma of the Bladder 25316-40-9 DOXORUBICIN INDICATION Testicular Cancer / Carcinoma of the Testis 25316-40-9 DOXORUBICIN INDICATION Ewing's Sarcoma 25316-40-9 DOXORUBICIN INDICATION Non-Hodgkin's Lymphomas 25316-40-9 DOXORUBICIN INDICATION Osteosarcoma / Osteogenic Sarcoma 25316-40-9 DOXORUBICIN INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 25316-40-9 DOXORUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 25316-40-9 DOXORUBICIN KNOWN_TOXICITY Mutagenicity 25316-40-9 DOXORUBICIN TA_LEVEL_2 DNA damage 25316-40-9 DOXORUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 25316-40-9 DOXORUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 25316-40-9 DOXORUBICIN ADVERSE_EFFECT XXX_1_Extravasation Cellulitis 25316-40-9 DOXORUBICIN ADVERSE_EFFECT XXX_1_Mucositis 25316-40-9 DOXORUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 25316-40-9 DOXORUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Congestive Heart Failure 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Carcinogenicity 25316-40-9 DOXORUBICIN INDICATION Soft Tissue Sarcoma 25316-40-9 DOXORUBICIN INDICATION Neuroblastoma 25316-40-9 DOXORUBICIN MESH_LEVEL_2 Carbohydrates 25316-40-9 DOXORUBICIN INDICATION Hodgkin's Disease 25316-40-9 DOXORUBICIN INDICATION Thyroid Cancer / Carcinoma of the Thyroid Gland 25316-40-9 DOXORUBICIN INDICATION Acute Lymphocytic Leukemia (ALL) 25316-40-9 DOXORUBICIN INDICATION Carcinoma of the Head and Neck 25316-40-9 DOXORUBICIN INDICATION Endometrial Cancer / Carcinoma of the Endometrium 25316-40-9 DOXORUBICIN KNOWN_TOXICITY Carcinogenicity 25316-40-9 DOXORUBICIN ACTIVITY_CLASS DNA damager 25316-40-9 DOXORUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 25316-40-9 DOXORUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 25316-40-9 DOXORUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 25316-40-9 DOXORUBICIN ADVERSE_EFFECT CVS_1_Myocardial Damage 25316-40-9 DOXORUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 25316-40-9 DOXORUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Cardiotoxicity 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Hemorrhage 25316-40-9 DOXORUBICIN INDICATION Wilms' Tumor 25316-40-9 DOXORUBICIN INDICATION Cervical Cancer / Carcinoma of the Cervix 25316-40-9 DOXORUBICIN TA_LEVEL_1 Oncology 25316-40-9 DOXORUBICIN INDICATION Breast Cancer / Carcinoma of the Breast 25316-40-9 DOXORUBICIN TA_LEVEL_3 Solid and soft Tumors 25316-40-9 DOXORUBICIN INDICATION Neoplasm / Cancer / Tumor 25316-40-9 DOXORUBICIN MECH_LEVEL_3 DNA damage 25316-40-9 DOXORUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 25316-40-9 DOXORUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Myelosuppression 25316-40-9 DOXORUBICIN THERAPEUTIC_CLASS Antineoplastics 25316-40-9 DOXORUBICIN ADVERSE_EFFECT IMU_3_Anaphylaxis 25316-40-9 DOXORUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 25316-40-9 DOXORUBICIN ADVERSE_EFFECT GIS_2_Necrotizing Colitis 25316-40-9 DOXORUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 25316-40-9 DOXORUBICIN ADVERSE_EFFECT IMU_2_Urticaria 25316-40-9 DOXORUBICIN MESH_LEVEL_3 Aminoglycosides 25316-40-9 DOXORUBICIN PRODUCT_CLASS Anti-cancers 25316-40-9 DOXORUBICIN INDICATION Prostatic Cancer / Carcinoma of the Prostate 25316-40-9 DOXORUBICIN INDICATION Bronchogenic Carcinoma 25316-40-9 DOXORUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 25316-40-9 DOXORUBICIN INDICATION Ovarian Cancer / Carcinoma of the Ovary 25316-40-9 DOXORUBICIN INDICATION Gastric Adenocarcinoma / Cancer of the Stomach 25316-40-9 DOXORUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 25316-40-9 DOXORUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 25316-40-9 DOXORUBICIN ADVERSE_EFFECT NEU_2_Peripheral Neurotoxicity 25316-40-9 DOXORUBICIN ADVERSE_EFFECT XXX_2_Radiosensitization 25316-40-9 DOXORUBICIN ADVERSE_EFFECT BBM_3_Acute Leukemia 25316-40-9 DOXORUBICIN ADVERSE_EFFECT XXX_1_Infection 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Cardiomyopathy 25316-40-9 DOXORUBICIN TISSUE_TOXICITY Mutagenicity 25316-40-9 DOXORUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 25316-40-9 DOXORUBICIN ZERO_CLASS N 136019-12-0 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN PRODUCT_CLASS Biochemicals 136019-12-0 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN STRUCTURE_ACTIVITY Cyclodextrin 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT LIV_2_Granulomatous Hepatitis 56-49-5 3-METHYLCHOLANTHRENE MECHANISM Inhibit DNA synthesis, repair, and function 56-49-5 3-METHYLCHOLANTHRENE TISSUE_TOXICITY Mutagenicity 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT IMU_2_Suppressed Immune System 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT XXX_2_Inflammation 56-49-5 3-METHYLCHOLANTHRENE PRODUCT_CLASS Toxicants 56-49-5 3-METHYLCHOLANTHRENE TISSUE_TOXICITY Carcinogenicity 56-49-5 3-METHYLCHOLANTHRENE KNOWN_TOXICITY Carcinogenicity 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT LIV_1_Hepatic Damage 56-49-5 3-METHYLCHOLANTHRENE STRUCTURE_ACTIVITY Toxicant, Ah receptor agonist, DNA alkylator 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT DNA_2_Carcinogenicity 56-49-5 3-METHYLCHOLANTHRENE KNOWN_TOXICITY Mutagenicity 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT LIV_2_Inhibition of P450 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT DNA_2_Mutagenicity 56-49-5 3-METHYLCHOLANTHRENE ACTIVITY_CLASS Toxicant, DNA damaging 56-49-5 3-METHYLCHOLANTHRENE MODE_CLASS Distorts /blocks macromolecular scaffold function 56-49-5 3-METHYLCHOLANTHRENE MODE_CLASS Receptor Agonist 56-49-5 3-METHYLCHOLANTHRENE ADVERSE_EFFECT EMB_3_Congenital Malformations 50892-23-4 PIRINIXIC ACID STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 50892-23-4 PIRINIXIC ACID MODE_CLASS Receptor Ligand Antagonist 50892-23-4 PIRINIXIC ACID TISSUE_TOXICITY Hepatocellular Carcinoma 50892-23-4 PIRINIXIC ACID KNOWN_TOXICITY Mutagenicity 50892-23-4 PIRINIXIC ACID ADVERSE_EFFECT DNA_2_Hepatocellular Carcinoma 50892-23-4 PIRINIXIC ACID THERAPEUTIC_CLASS Hypolipidemic Agents 50892-23-4 PIRINIXIC ACID ZERO_CLASS N 50892-23-4 PIRINIXIC ACID ACTIVITY_CLASS Peroxisome proliferator 50892-23-4 PIRINIXIC ACID KNOWN_TOXICITY Carcinogenicity 50892-23-4 PIRINIXIC ACID ADVERSE_EFFECT IMU_1_Suppressed Immune System 50892-23-4 PIRINIXIC ACID ADVERSE_EFFECT DNA_2_Mutagenicity 50892-23-4 PIRINIXIC ACID ADVERSE_EFFECT END_3_Hypoglycemia 50892-23-4 PIRINIXIC ACID ADVERSE_EFFECT KID_2_Renal Damage 50892-23-4 PIRINIXIC ACID MECHANISM Increase lipid catabolism 50892-23-4 PIRINIXIC ACID PRODUCT_CLASS Cardiovasculars 50892-23-4 PIRINIXIC ACID MODE_CLASS Receptor Agonist, selective 50892-23-4 PIRINIXIC ACID TISSUE_TOXICITY Mutagenicity 50892-23-4 PIRINIXIC ACID ADVERSE_EFFECT LIV_2_Hepatic Damage 122003-11-6 U-78517F THERAPEUTIC_CLASS Antineoplastics 122003-11-6 U-78517F ADVERSE_EFFECT BBM__Bone Marrow Toxicity 122003-11-6 U-78517F PRODUCT_CLASS Anti-cancers 122003-11-6 U-78517F STRUCTURE_ACTIVITY H2O2 radical scavenger 133681-84-2 U-78517F THERAPEUTIC_CLASS Antineoplastics 133681-84-2 U-78517F ADVERSE_EFFECT BBM__Bone Marrow Toxicity 133681-84-2 U-78517F PRODUCT_CLASS Anti-cancers 133681-84-2 U-78517F STRUCTURE_ACTIVITY H2O2 radical scavenger 137018-55-4 U-78517F THERAPEUTIC_CLASS Antineoplastics 137018-55-4 U-78517F STRUCTURE_ACTIVITY H2O2 radical scavenger 137018-55-4 U-78517F ADVERSE_EFFECT BBM__Bone Marrow Toxicity 137018-55-4 U-78517F PRODUCT_CLASS Anti-cancers 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT CVS_2_Hypertension 52225-20-4 ALPHA-TOCOPHEROL INDICATION Heavy Metal Poisoning 52225-20-4 ALPHA-TOCOPHEROL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT GIS_1_Diarrhea 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT CVS_3_Thrombophlebitis 52225-20-4 ALPHA-TOCOPHEROL STRUCTURE_ACTIVITY Vitamin E analog 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT XXX_2_Fatigue 52225-20-4 ALPHA-TOCOPHEROL PRODUCT_CLASS Vitamins, Minerals and Nutrients 52225-20-4 ALPHA-TOCOPHEROL INDICATION Vitamin E Deficiency 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT GIS_1_Nausea 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT MSK_3_Myopathy 52225-20-4 ALPHA-TOCOPHEROL MECHANISM Scavenges hydrogen peroxide and free radicals 52225-20-4 ALPHA-TOCOPHEROL INDICATION Hemolytic Anemias 52225-20-4 ALPHA-TOCOPHEROL ADVERSE_EFFECT GIS_1_Flatulence 103-90-2 ACETAMINOPHEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT NEU_1_Lightheadedness 103-90-2 ACETAMINOPHEN MECHANISM Inhibit eicosanoid biosynthesis 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT LIV_3_Hepatic Necrosis 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT PSY_2_Dysphoria 103-90-2 ACETAMINOPHEN MESH_LEVEL_2 Amides 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT BBM_3_Thrombocytopenia 103-90-2 ACETAMINOPHEN INDICATION Pain 103-90-2 ACETAMINOPHEN INDICATION Fever 103-90-2 ACETAMINOPHEN PRODUCT_CLASS Analgesics 103-90-2 ACETAMINOPHEN MESH_LEVEL_1 Organic Chemicals 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT LUN_1_Shortness of Breath 103-90-2 ACETAMINOPHEN TISSUE_TOXICITY Hepatic Necrosis 103-90-2 ACETAMINOPHEN PRODUCT_CLASS Anti-inflammatories 103-90-2 ACETAMINOPHEN TISSUE_TOXICITY Renal Tubular Necrosis 103-90-2 ACETAMINOPHEN MODE_CLASS Enzyme Inhibitor 103-90-2 ACETAMINOPHEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT IMU_2_Allergic Reactions 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT GIS_2_Abdominal Pain 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT NEU_1_Sedation 103-90-2 ACETAMINOPHEN ACTIVITY_CLASS Anti-inflammatory 103-90-2 ACETAMINOPHEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 103-90-2 ACETAMINOPHEN TA_LEVEL_2 NSAID 103-90-2 ACETAMINOPHEN KNOWN_TOXICITY Nephrotoxicity 103-90-2 ACETAMINOPHEN KNOWN_TOXICITY Hepatotoxicity 103-90-2 ACETAMINOPHEN MESH_LEVEL_3 Anilides 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT NEU_1_Dizziness 103-90-2 ACETAMINOPHEN ZERO_CLASS N 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT END_3_Hypoglycemic Coma 103-90-2 ACETAMINOPHEN STRUCTURE_ACTIVITY NSAID, COX-3, acetaminophen like 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT GIS_2_Constipation 103-90-2 ACETAMINOPHEN MECH_LEVEL_1 Immunomodulation 103-90-2 ACETAMINOPHEN TA_LEVEL_3 NSAID 103-90-2 ACETAMINOPHEN TA_LEVEL_1 Anti-inflammatory 103-90-2 ACETAMINOPHEN THERAPEUTIC_CLASS Analgesics, Non-Opioid 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT PSY_2_Euphoria 103-90-2 ACETAMINOPHEN ADVERSE_EFFECT SKN_2_Pruritis 38194-50-2 SULINDAC ADVERSE_EFFECT NEU_1_Dizziness 38194-50-2 SULINDAC STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 38194-50-2 SULINDAC ADVERSE_EFFECT LIV_3_Abnormal Liver Function 38194-50-2 SULINDAC ADVERSE_EFFECT GUS_3_Dysuria 38194-50-2 SULINDAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 38194-50-2 SULINDAC ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 38194-50-2 SULINDAC KNOWN_TOXICITY Cardiovascular Toxicity 38194-50-2 SULINDAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 38194-50-2 SULINDAC TISSUE_TOXICITY Congestive Heart Failure 38194-50-2 SULINDAC ADVERSE_EFFECT XXX_2_Edema 38194-50-2 SULINDAC KNOWN_TOXICITY Nephrotoxicity 38194-50-2 SULINDAC ADVERSE_EFFECT PSY_2_Nervousness 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_1_Diarrhea 38194-50-2 SULINDAC ADVERSE_EFFECT MSK_3_Muscle Weakness 38194-50-2 SULINDAC ZERO_CLASS N 38194-50-2 SULINDAC ADVERSE_EFFECT NEU_3_Vertigo 38194-50-2 SULINDAC ADVERSE_EFFECT BBM_3_Neutropenia 38194-50-2 SULINDAC ADVERSE_EFFECT BBM_3_Thrombocytopenia 38194-50-2 SULINDAC INDICATION Ankylosing Spondylitis 38194-50-2 SULINDAC TISSUE_TOXICITY Nephrotic Syndrome 38194-50-2 SULINDAC TA_LEVEL_1 Anti-inflammatory 38194-50-2 SULINDAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 38194-50-2 SULINDAC INDICATION Acute Painful Shoulder 38194-50-2 SULINDAC TA_LEVEL_2 NSAID 38194-50-2 SULINDAC MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 38194-50-2 SULINDAC ADVERSE_EFFECT CVS_3_Congestive Heart Failure 38194-50-2 SULINDAC ADVERSE_EFFECT BBM_3_Agranulocytosis 38194-50-2 SULINDAC ADVERSE_EFFECT PSY_3_Depression 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_2_Vomiting 38194-50-2 SULINDAC ADVERSE_EFFECT PSY_2_Anorexia 38194-50-2 SULINDAC ADVERSE_EFFECT NEU_1_Headache 38194-50-2 SULINDAC ADVERSE_EFFECT OTO_2_Tinnitus 38194-50-2 SULINDAC MESH_LEVEL_3 Indenes 38194-50-2 SULINDAC MECH_LEVEL_1 Immunomodulation 38194-50-2 SULINDAC INDICATION Osteoarthritis 38194-50-2 SULINDAC PRODUCT_CLASS Anti-inflammatories 38194-50-2 SULINDAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_1_Nausea 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_2_Flatulence 38194-50-2 SULINDAC ADVERSE_EFFECT SKN_2_Pruritis 38194-50-2 SULINDAC ACTIVITY_CLASS Anti-inflammatory 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_3_Pancreatitis 38194-50-2 SULINDAC ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 38194-50-2 SULINDAC ADVERSE_EFFECT ELT_3_Hyperkalemia 38194-50-2 SULINDAC TA_LEVEL_3 NSAID 38194-50-2 SULINDAC INDICATION Rheumatoid Arthritis 38194-50-2 SULINDAC INDICATION Acute Gouty Arthritis 38194-50-2 SULINDAC MESH_LEVEL_1 Polycyclic Hydrocarbons 38194-50-2 SULINDAC MECHANISM Inhibit eicosanoid biosynthesis 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_1_Dyspepsia 38194-50-2 SULINDAC ADVERSE_EFFECT GIS_1_Constipation 38194-50-2 SULINDAC ADVERSE_EFFECT SKN_1_Rash 38194-50-2 SULINDAC MODE_CLASS Enzyme Inhibitor 15687-27-1 IBUPROFEN MECH_LEVEL_1 Immunomodulation 15687-27-1 IBUPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 15687-27-1 IBUPROFEN ZERO_CLASS N 15687-27-1 IBUPROFEN MESH_LEVEL_2 Carboxylic Acids 15687-27-1 IBUPROFEN TA_LEVEL_3 NSAID 15687-27-1 IBUPROFEN MESH_LEVEL_3 Acids, Carbocyclic 15687-27-1 IBUPROFEN KNOWN_TOXICITY Cardiovascular Toxicity 15687-27-1 IBUPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 15687-27-1 IBUPROFEN ADVERSE_EFFECT LUN_2_Wheezing 15687-27-1 IBUPROFEN ADVERSE_EFFECT GIS_3_Gastric Bleeding 15687-27-1 IBUPROFEN MESH_LEVEL_1 Organic Chemicals 15687-27-1 IBUPROFEN INDICATION Pain 15687-27-1 IBUPROFEN PRODUCT_CLASS Anti-inflammatories 15687-27-1 IBUPROFEN INDICATION Fever 15687-27-1 IBUPROFEN ADVERSE_EFFECT XXX_2_Facial Edema 15687-27-1 IBUPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 15687-27-1 IBUPROFEN TA_LEVEL_2 NSAID 15687-27-1 IBUPROFEN TA_LEVEL_1 Anti-inflammatory 15687-27-1 IBUPROFEN ADVERSE_EFFECT CVS_2_Shock 15687-27-1 IBUPROFEN ADVERSE_EFFECT LUN_2_Asthma 15687-27-1 IBUPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 15687-27-1 IBUPROFEN MODE_CLASS Enzyme Inhibitor 15687-27-1 IBUPROFEN ACTIVITY_CLASS Anti-inflammatory 15687-27-1 IBUPROFEN TISSUE_TOXICITY Shock 15687-27-1 IBUPROFEN ADVERSE_EFFECT IMU_2_Hives 15687-27-1 IBUPROFEN ADVERSE_EFFECT IMU_2_Allergic Reactions 15687-27-1 IBUPROFEN MECHANISM Inhibit eicosanoid biosynthesis 21829-25-4 NIFEDIPINE THERAPEUTIC_CLASS Antianginals 21829-25-4 NIFEDIPINE ADVERSE_EFFECT NEU_3_Paresthesia 21829-25-4 NIFEDIPINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 21829-25-4 NIFEDIPINE ADVERSE_EFFECT SKN_2_Flushing of the Skin 21829-25-4 NIFEDIPINE MODE_CLASS Channel Blocker 21829-25-4 NIFEDIPINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 21829-25-4 NIFEDIPINE MECHANISM Reduce muscle contractile force 21829-25-4 NIFEDIPINE ADVERSE_EFFECT XXX_1_Peripheral Edema 21829-25-4 NIFEDIPINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 21829-25-4 NIFEDIPINE ADVERSE_EFFECT XXX_2_Fatigue 21829-25-4 NIFEDIPINE THERAPEUTIC_CLASS Antihypertensive Agents 21829-25-4 NIFEDIPINE KNOWN_TOXICITY Cardiovascular Toxicity 21829-25-4 NIFEDIPINE MECH_LEVEL_2 Reduce muscle contractile force 21829-25-4 NIFEDIPINE ADVERSE_EFFECT CVS_3_Palpitation 21829-25-4 NIFEDIPINE ADVERSE_EFFECT CVS_3_Chest Pain 21829-25-4 NIFEDIPINE ADVERSE_EFFECT LUN_3_Dyspnea 21829-25-4 NIFEDIPINE ADVERSE_EFFECT NEU_2_Dizziness 21829-25-4 NIFEDIPINE ADVERSE_EFFECT CVS_3_Hypotension 21829-25-4 NIFEDIPINE MESH_LEVEL_3 Pyridines 21829-25-4 NIFEDIPINE MESH_LEVEL_1 Heterocyclic Compounds 21829-25-4 NIFEDIPINE TISSUE_TOXICITY Hypotension 21829-25-4 NIFEDIPINE MECH_LEVEL_1 Anti-anginal 21829-25-4 NIFEDIPINE INDICATION Hypertension 21829-25-4 NIFEDIPINE TISSUE_TOXICITY Atrial Fibrillation 21829-25-4 NIFEDIPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 21829-25-4 NIFEDIPINE TISSUE_TOXICITY Cardiotoxicity 21829-25-4 NIFEDIPINE ADVERSE_EFFECT GIS_3_Constipation 21829-25-4 NIFEDIPINE ADVERSE_EFFECT NEU_2_Headache 21829-25-4 NIFEDIPINE TA_LEVEL_3 Ca++ channel antagonists 21829-25-4 NIFEDIPINE ADVERSE_EFFECT XXX_3_Facial Edema 21829-25-4 NIFEDIPINE ADVERSE_EFFECT REP_2_Decreased Fertility 21829-25-4 NIFEDIPINE ADVERSE_EFFECT REP_3_Impotence 21829-25-4 NIFEDIPINE ADVERSE_EFFECT GIS_3_Gastrointestinal Disturbances 21829-25-4 NIFEDIPINE TA_LEVEL_2 anti-angina 21829-25-4 NIFEDIPINE MECH_LEVEL_3 L-Type Ca++ channel 21829-25-4 NIFEDIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 21829-25-4 NIFEDIPINE INDICATION Angina Pectoris 21829-25-4 NIFEDIPINE TA_LEVEL_1 Cardiovascular 21829-25-4 NIFEDIPINE PRODUCT_CLASS Cardiovasculars 21829-25-4 NIFEDIPINE ZERO_CLASS N 54-85-3 ISONIAZID ADVERSE_EFFECT BBM_3_Aplastic Anemia 54-85-3 ISONIAZID ADVERSE_EFFECT END_3_Metabolic Acidosis 54-85-3 ISONIAZID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 54-85-3 ISONIAZID ADVERSE_EFFECT NEU_2_Convulsions 54-85-3 ISONIAZID TISSUE_TOXICITY Carcinogenicity 54-85-3 ISONIAZID TA_LEVEL_1 Infectious Disease 54-85-3 ISONIAZID TA_LEVEL_3 tuberculosis 54-85-3 ISONIAZID MECH_LEVEL_1 cell wall biosynthesis inhibitor 54-85-3 ISONIAZID MECH_LEVEL_2 cell wall biosynthesis inhibitor 54-85-3 ISONIAZID STRUCTURE_ACTIVITY Mycolic acid biosynthesis inhibitor 54-85-3 ISONIAZID KNOWN_TOXICITY Hepatotoxicity 54-85-3 ISONIAZID ADVERSE_EFFECT GIS_2_Epigastric Pain 54-85-3 ISONIAZID ADVERSE_EFFECT CVS_3_Vasculitis 54-85-3 ISONIAZID ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 54-85-3 ISONIAZID ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 54-85-3 ISONIAZID TISSUE_TOXICITY Nervous System Toxicity 54-85-3 ISONIAZID MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 54-85-3 ISONIAZID MESH_LEVEL_3 Isoniazid 54-85-3 ISONIAZID INDICATION Pulmonary Tuberculosis 54-85-3 ISONIAZID MECH_LEVEL_3 cell wall biosynthesis inhibitor 54-85-3 ISONIAZID PRODUCT_CLASS Anti-infectives 54-85-3 ISONIAZID KNOWN_TOXICITY Carcinogenicity 54-85-3 ISONIAZID ADVERSE_EFFECT PSY_2_Toxic Psychosis 54-85-3 ISONIAZID ADVERSE_EFFECT LIV_1_Hepatic Toxicity 54-85-3 ISONIAZID ADVERSE_EFFECT BBM_3_Thrombocytopenia 54-85-3 ISONIAZID ADVERSE_EFFECT BBM_3_Agranulocytosis 54-85-3 ISONIAZID TISSUE_TOXICITY Hepatic Toxicity 54-85-3 ISONIAZID MESH_LEVEL_2 Hydrazines 54-85-3 ISONIAZID MESH_LEVEL_1 Organic Chemicals 54-85-3 ISONIAZID ZERO_CLASS N 54-85-3 ISONIAZID THERAPEUTIC_CLASS Antibacterials, Systemic 54-85-3 ISONIAZID KNOWN_TOXICITY Neurotoxicity 54-85-3 ISONIAZID ADVERSE_EFFECT NEU_2_Poor Memory 54-85-3 ISONIAZID ADVERSE_EFFECT NEU_2_Optic Neuritis 54-85-3 ISONIAZID ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 54-85-3 ISONIAZID ADVERSE_EFFECT NEU_2_Encephalopathy 54-85-3 ISONIAZID ADVERSE_EFFECT DNA_2_Carcinogenicity 54-85-3 ISONIAZID TA_LEVEL_2 Anti-fungal, anti-bacterial 54-85-3 ISONIAZID ACTIVITY_CLASS Antibiotic 54-85-3 ISONIAZID ADVERSE_EFFECT NEU_1_Nervous System Toxicity 54-85-3 ISONIAZID ADVERSE_EFFECT EMB_2_Embryotoxicity 50-23-7 HYDROCORTISONE MECH_LEVEL_2 Anti-inflammation and immunosuppression 50-23-7 HYDROCORTISONE INDICATION Rheumatic Disorders 50-23-7 HYDROCORTISONE THERAPEUTIC_CLASS Corticosteroids 50-23-7 HYDROCORTISONE ADVERSE_EFFECT GIS_2_Nausea 50-23-7 HYDROCORTISONE ADVERSE_EFFECT XXX_2_Weight Gain 50-23-7 HYDROCORTISONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 50-23-7 HYDROCORTISONE ADVERSE_EFFECT END_2_Metabolic Disturbance 50-23-7 HYDROCORTISONE MECH_LEVEL_1 Immunomodulation 50-23-7 HYDROCORTISONE INDICATION Allergic Diseases 50-23-7 HYDROCORTISONE INDICATION Collagen Diseases 50-23-7 HYDROCORTISONE INDICATION Hematologic Disorders 50-23-7 HYDROCORTISONE MESH_LEVEL_1 Polycyclic Hydrocarbons 50-23-7 HYDROCORTISONE KNOWN_TOXICITY Cardiovascular Toxicity 50-23-7 HYDROCORTISONE INDICATION Respiratory Diseases 50-23-7 HYDROCORTISONE INDICATION Endocrine Disorders 50-23-7 HYDROCORTISONE INDICATION Gastrointestinal Diseases 50-23-7 HYDROCORTISONE ACTIVITY_CLASS GR-MR agonist 50-23-7 HYDROCORTISONE TA_LEVEL_1 Anti-inflammatory 50-23-7 HYDROCORTISONE MODE_CLASS Endogenous Receptor /Channel Ligand 50-23-7 HYDROCORTISONE TA_LEVEL_2 Steroid 50-23-7 HYDROCORTISONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 50-23-7 HYDROCORTISONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 50-23-7 HYDROCORTISONE ADVERSE_EFFECT CVS_2_Thromboembolism 50-23-7 HYDROCORTISONE ADVERSE_EFFECT XXX_2_Increased Appetite 50-23-7 HYDROCORTISONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 50-23-7 HYDROCORTISONE MECH_LEVEL_3 Glucocorticoid receptor 50-23-7 HYDROCORTISONE INDICATION Skin Diseases / Dermatoses 50-23-7 HYDROCORTISONE INDICATION Neoplastic Diseases 50-23-7 HYDROCORTISONE INDICATION Edematous States 50-23-7 HYDROCORTISONE TA_LEVEL_3 Topical steroid 50-23-7 HYDROCORTISONE MESH_LEVEL_2 Steroids 50-23-7 HYDROCORTISONE PRODUCT_CLASS Anti-inflammatories 50-23-7 HYDROCORTISONE ZERO_CLASS N 50-23-7 HYDROCORTISONE ADVERSE_EFFECT XXX_2_Malaise 50-23-7 HYDROCORTISONE ADVERSE_EFFECT SKN_2_Skin Toxicity 50-23-7 HYDROCORTISONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 50-23-7 HYDROCORTISONE ADVERSE_EFFECT IMU_2_Hypersensitivity 50-23-7 HYDROCORTISONE TISSUE_TOXICITY Cardiotoxicity 50-23-7 HYDROCORTISONE INDICATION Ophthalmic Diseases 50-23-7 HYDROCORTISONE MESH_LEVEL_3 Pregnanes 50-23-7 HYDROCORTISONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 50-23-7 HYDROCORTISONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 50-23-7 HYDROCORTISONE ADVERSE_EFFECT CVS_2_Cardiotoxicity 50-23-7 HYDROCORTISONE TISSUE_TOXICITY Thromboembolism 50-23-7 HYDROCORTISONE MECHANISM Modulate gene transcription 6000-74-4 HYDROCORTISONE INDICATION Hematologic Disorders 6000-74-4 HYDROCORTISONE INDICATION Gastrointestinal Diseases 6000-74-4 HYDROCORTISONE INDICATION Respiratory Diseases 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT XXX_2_Malaise 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT SKN_2_Skin Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT IMU_2_Hypersensitivity 6000-74-4 HYDROCORTISONE TISSUE_TOXICITY Cardiotoxicity 6000-74-4 HYDROCORTISONE TA_LEVEL_1 Anti-inflammatory 6000-74-4 HYDROCORTISONE INDICATION Ophthalmic Diseases 6000-74-4 HYDROCORTISONE INDICATION Endocrine Disorders 6000-74-4 HYDROCORTISONE MESH_LEVEL_3 Pregnanes 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 6000-74-4 HYDROCORTISONE MESH_LEVEL_1 Polycyclic Hydrocarbons 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT CVS_2_Cardiotoxicity 6000-74-4 HYDROCORTISONE TISSUE_TOXICITY Thromboembolism 6000-74-4 HYDROCORTISONE MECHANISM Modulate gene transcription 6000-74-4 HYDROCORTISONE MECH_LEVEL_2 Anti-inflammation and immunosuppression 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT END_2_Metabolic Disturbance 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT XXX_2_Weight Gain 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT GIS_2_Nausea 6000-74-4 HYDROCORTISONE THERAPEUTIC_CLASS Corticosteroids 6000-74-4 HYDROCORTISONE INDICATION Rheumatic Disorders 6000-74-4 HYDROCORTISONE INDICATION Neoplastic Diseases 6000-74-4 HYDROCORTISONE INDICATION Collagen Diseases 6000-74-4 HYDROCORTISONE INDICATION Allergic Diseases 6000-74-4 HYDROCORTISONE MECH_LEVEL_1 Immunomodulation 6000-74-4 HYDROCORTISONE MECH_LEVEL_3 Glucocorticoid receptor 6000-74-4 HYDROCORTISONE TA_LEVEL_2 Steroid 6000-74-4 HYDROCORTISONE MODE_CLASS Endogenous Receptor /Channel Ligand 6000-74-4 HYDROCORTISONE ACTIVITY_CLASS GR-MR agonist 6000-74-4 HYDROCORTISONE KNOWN_TOXICITY Cardiovascular Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT CVS_2_Thromboembolism 6000-74-4 HYDROCORTISONE ADVERSE_EFFECT XXX_2_Increased Appetite 6000-74-4 HYDROCORTISONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 6000-74-4 HYDROCORTISONE INDICATION Skin Diseases / Dermatoses 6000-74-4 HYDROCORTISONE INDICATION Edematous States 6000-74-4 HYDROCORTISONE TA_LEVEL_3 Topical steroid 6000-74-4 HYDROCORTISONE MESH_LEVEL_2 Steroids 6000-74-4 HYDROCORTISONE PRODUCT_CLASS Anti-inflammatories 6000-74-4 HYDROCORTISONE ZERO_CLASS N 23593-75-1 CLOTRIMAZOLE INDICATION Tinea Pedis / Athlete's Foot 23593-75-1 CLOTRIMAZOLE THERAPEUTIC_CLASS Antifungals, Topical 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT BBM_3_Neutropenia 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT PSY_2_Irritation 23593-75-1 CLOTRIMAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 23593-75-1 CLOTRIMAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 23593-75-1 CLOTRIMAZOLE PRODUCT_CLASS Anti-infectives 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 23593-75-1 CLOTRIMAZOLE ZERO_CLASS N 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT GUS_3_Cystitis 23593-75-1 CLOTRIMAZOLE TA_LEVEL_2 Anti-fungal 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT PSY_3_Visual Hallucinations 23593-75-1 CLOTRIMAZOLE TA_LEVEL_1 Infectious Disease 23593-75-1 CLOTRIMAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 23593-75-1 CLOTRIMAZOLE MODE_CLASS Enzyme Inhibitor 23593-75-1 CLOTRIMAZOLE INDICATION Tinea Cruris / Jock Itch 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 23593-75-1 CLOTRIMAZOLE MODE_CLASS Channel Blocker 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT NEU_2_Somnolence 23593-75-1 CLOTRIMAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 23593-75-1 CLOTRIMAZOLE MECH_LEVEL_1 Anti-fungal 23593-75-1 CLOTRIMAZOLE TA_LEVEL_3 cholesterol synthesis inhibitors 23593-75-1 CLOTRIMAZOLE MESH_LEVEL_3 Imidazoles 23593-75-1 CLOTRIMAZOLE MECH_LEVEL_3 Ca++-activated K+ channel IKCa 23593-75-1 CLOTRIMAZOLE MESH_LEVEL_1 Heterocyclic Compounds 23593-75-1 CLOTRIMAZOLE MECHANISM Modulate channel gating 23593-75-1 CLOTRIMAZOLE INDICATION Oropharyngeal Candidiasis 23593-75-1 CLOTRIMAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor 23593-75-1 CLOTRIMAZOLE ACTIVITY_CLASS Antifungals azole 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT GUS_2_Dysuria 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT SKN_2_Pruritis 23593-75-1 CLOTRIMAZOLE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 23593-75-1 CLOTRIMAZOLE INDICATION Vaginal Candidiasis 78111-17-8 OKADAIC ACID PRODUCT_CLASS Biochemicals 78111-17-8 OKADAIC ACID MODE_CLASS Enzyme Inhibitor 78111-17-8 OKADAIC ACID MECHANISM Modulate G-protein coupled signal transduction 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE MODE_CLASS Enzyme Inhibitor 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE ACTIVITY_CLASS Glucocorticoid receptor antagonist 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE THERAPEUTIC_CLASS Corticosteroids, Systemic 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE MECHANISM Modulate gene transcription 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE ADVERSE_EFFECT END_2_Hypercholesteremia 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE PRODUCT_CLASS Anti-inflammatories 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE ADVERSE_EFFECT LIV_1_Induction of Liver Drug-Metabolizing Enzymes 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE MECHANISM Inhibit steroid biosynthesis/ metabolism 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE ADVERSE_EFFECT DNA_3_Carcinogenicity 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE KNOWN_TOXICITY Carcinogenicity 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE TISSUE_TOXICITY Carcinogenicity 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE STRUCTURE_ACTIVITY Glucocorticoid receptor antagonist 1434-54-4 PREGNENOLONE-16ALPHA-CARBONITRILE MODE_CLASS Receptor Ligand Antagonist 73590-58-6 OMEPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 73590-58-6 OMEPRAZOLE INDICATION Erosive Esophagitis 73590-58-6 OMEPRAZOLE MECH_LEVEL_3 Hydrogen/potassium-exchanging ATPase 73590-58-6 OMEPRAZOLE MECH_LEVEL_1 Antiulcers 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT SKN_2_Rash 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT MSK_2_Back Pain 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT GIS_3_Pancreatitis 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT XXX_3_Epistaxis 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 73590-58-6 OMEPRAZOLE TISSUE_TOXICITY Acute Interstitial Nephritis 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT BBM_3_Pancytopenia 73590-58-6 OMEPRAZOLE TA_LEVEL_2 Benzodiazepines 73590-58-6 OMEPRAZOLE TA_LEVEL_1 Gastrointestinal System 73590-58-6 OMEPRAZOLE INDICATION Systemic Mastocytosis 73590-58-6 OMEPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 73590-58-6 OMEPRAZOLE MECHANISM Reduce stomach HCl secretion 73590-58-6 OMEPRAZOLE ZERO_CLASS N 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT CVS_3_Chest Pain 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT MSK_3_Myalgia 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT OTO_3_Tinnitus 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT NEU_2_Dizziness 73590-58-6 OMEPRAZOLE TISSUE_TOXICITY Hepatic Failure 73590-58-6 OMEPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 73590-58-6 OMEPRAZOLE INDICATION Multiple Endocrine Neoplasia (MEN) 73590-58-6 OMEPRAZOLE KNOWN_TOXICITY Nephrotoxicity 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT LUN_2_Cough 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT IMU_3_Anaphylaxis 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT ELT_3_Hyponatremia 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 73590-58-6 OMEPRAZOLE PRODUCT_CLASS Gastrointestinal System 73590-58-6 OMEPRAZOLE MESH_LEVEL_3 Benzimidazoles 73590-58-6 OMEPRAZOLE INDICATION Gastric Ulcer 73590-58-6 OMEPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 73590-58-6 OMEPRAZOLE INDICATION Duodenal Ulcer 73590-58-6 OMEPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 73590-58-6 OMEPRAZOLE MODE_CLASS Enzyme Inhibitor 73590-58-6 OMEPRAZOLE THERAPEUTIC_CLASS Antiulcers 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT NEU_1_Headache 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT XXX_1_Asthenia 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT GIS_2_Constipation 73590-58-6 OMEPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 73590-58-6 OMEPRAZOLE KNOWN_TOXICITY Hepatotoxicity 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT GIS_2_Flatulence 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 73590-58-6 OMEPRAZOLE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT KID_3_Acute Interstitial Nephritis 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 95510-70-6 OMEPRAZOLE ACTIVITY_CLASS H+/K+-ATPase inhibitor 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT IMU_3_Anaphylaxis 95510-70-6 OMEPRAZOLE KNOWN_TOXICITY Nephrotoxicity 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT NEU_2_Dizziness 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT LUN_2_Cough 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT BBM_3_Pancytopenia 95510-70-6 OMEPRAZOLE TISSUE_TOXICITY Acute Interstitial Nephritis 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT LIV_3_Hepatic Failure 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT XXX_3_Epistaxis 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT GIS_3_Pancreatitis 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT MSK_2_Back Pain 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT SKN_2_Rash 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 95510-70-6 OMEPRAZOLE MECH_LEVEL_1 Antiulcers 95510-70-6 OMEPRAZOLE MECH_LEVEL_3 Hydrogen/potassium-exchanging ATPase 95510-70-6 OMEPRAZOLE INDICATION Erosive Esophagitis 95510-70-6 OMEPRAZOLE MESH_LEVEL_1 Heterocyclic Compounds 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT ELT_3_Hyponatremia 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 95510-70-6 OMEPRAZOLE PRODUCT_CLASS Gastrointestinal System 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT GIS_2_Constipation 95510-70-6 OMEPRAZOLE TISSUE_TOXICITY Hepatic Failure 95510-70-6 OMEPRAZOLE INDICATION Gastric Ulcer 95510-70-6 OMEPRAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 95510-70-6 OMEPRAZOLE INDICATION Duodenal Ulcer 95510-70-6 OMEPRAZOLE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 95510-70-6 OMEPRAZOLE MODE_CLASS Enzyme Inhibitor 95510-70-6 OMEPRAZOLE THERAPEUTIC_CLASS Antiulcers 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT NEU_1_Headache 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT XXX_1_Asthenia 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT OTO_3_Tinnitus 95510-70-6 OMEPRAZOLE TA_LEVEL_2 Benzodiazepines 95510-70-6 OMEPRAZOLE TA_LEVEL_1 Gastrointestinal System 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT MSK_3_Myalgia 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT CVS_3_Chest Pain 95510-70-6 OMEPRAZOLE ZERO_CLASS N 95510-70-6 OMEPRAZOLE MECHANISM Reduce stomach HCl secretion 95510-70-6 OMEPRAZOLE MECH_LEVEL_2 Reduce stomach HCl secretion 95510-70-6 OMEPRAZOLE INDICATION Systemic Mastocytosis 95510-70-6 OMEPRAZOLE KNOWN_TOXICITY Hepatotoxicity 95510-70-6 OMEPRAZOLE STRUCTURE_ACTIVITY H+/K+-ATPase inhibitor 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT GIS_2_Flatulence 95510-70-6 OMEPRAZOLE MESH_LEVEL_3 Benzimidazoles 95510-70-6 OMEPRAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 95510-70-6 OMEPRAZOLE INDICATION Multiple Endocrine Neoplasia (MEN) 75330-75-5 LOVASTATIN ADVERSE_EFFECT NEU_3_Paresthesia 75330-75-5 LOVASTATIN ADVERSE_EFFECT CVS_3_Chest Pain 75330-75-5 LOVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 75330-75-5 LOVASTATIN ZERO_CLASS N 75330-75-5 LOVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors, non-aromatic 75330-75-5 LOVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 75330-75-5 LOVASTATIN TA_LEVEL_1 Cardiovascular 75330-75-5 LOVASTATIN INDICATION Arterioslerotic Coronary Artery Disease / Coronary Heart Disease / Ischemic Heart Disease 75330-75-5 LOVASTATIN MODE_CLASS Enzyme Inhibitor 75330-75-5 LOVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 75330-75-5 LOVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 75330-75-5 LOVASTATIN MESH_LEVEL_3 Naphthalenes 75330-75-5 LOVASTATIN KNOWN_TOXICITY Carcinogenicity 75330-75-5 LOVASTATIN ADVERSE_EFFECT OCU_3_Eye Irritation 75330-75-5 LOVASTATIN ADVERSE_EFFECT DNA_2_Carcinogenicity 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_3_Dry Mouth 75330-75-5 LOVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 75330-75-5 LOVASTATIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 75330-75-5 LOVASTATIN INDICATION Hypercholesterolemia 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_2_Nausea 75330-75-5 LOVASTATIN ADVERSE_EFFECT XXX_2_Asthenia 75330-75-5 LOVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 75330-75-5 LOVASTATIN MECH_LEVEL_3 HMG-CoA reductase 75330-75-5 LOVASTATIN PRODUCT_CLASS Cardiovasculars 75330-75-5 LOVASTATIN TA_LEVEL_2 Lipid lowering agent 75330-75-5 LOVASTATIN MECH_LEVEL_1 Lipid lowering 75330-75-5 LOVASTATIN ADVERSE_EFFECT NEU_2_Headache 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 75330-75-5 LOVASTATIN ADVERSE_EFFECT SKN_3_Pruritis 75330-75-5 LOVASTATIN ADVERSE_EFFECT SKN_2_Rash 75330-75-5 LOVASTATIN ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 75330-75-5 LOVASTATIN ADVERSE_EFFECT MSK_3_Arthralgia 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 75330-75-5 LOVASTATIN ADVERSE_EFFECT NEU_2_Dizziness 75330-75-5 LOVASTATIN ADVERSE_EFFECT GIS_2_Constipation 75330-75-5 LOVASTATIN INDICATION Primary Prevention of Coronary Heart Disease 75330-75-5 LOVASTATIN INDICATION Hypertriglyceridemia 75330-75-5 LOVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 75330-75-5 LOVASTATIN MECHANISM Inhibit cholesterol biosynthesis 75330-75-5 LOVASTATIN TISSUE_TOXICITY Carcinogenicity 75330-75-5 LOVASTATIN ADVERSE_EFFECT MSK_2_Muscle Cramps 1405-10-3 NEOMYCIN TISSUE_TOXICITY Nephrotoxicity 1405-10-3 NEOMYCIN TISSUE_TOXICITY Respiratory Paralysis 1405-10-3 NEOMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 1405-10-3 NEOMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 1405-10-3 NEOMYCIN TA_LEVEL_1 Infectious Disease 1405-10-3 NEOMYCIN PRODUCT_CLASS Cardiovasculars 1405-10-3 NEOMYCIN INDICATION Hypercholesterolemia 1405-10-3 NEOMYCIN TA_LEVEL_2 Anti-bacterial 1405-10-3 NEOMYCIN MESH_LEVEL_2 Carbohydrates 1405-10-3 NEOMYCIN TISSUE_TOXICITY Ototoxicity 1405-10-3 NEOMYCIN TISSUE_TOXICITY Neuromuscular Blockade 1405-10-3 NEOMYCIN THERAPEUTIC_CLASS Hypolipidemic Agents 1405-10-3 NEOMYCIN ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 1405-10-3 NEOMYCIN ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 1405-10-3 NEOMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 1405-10-3 NEOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1405-10-3 NEOMYCIN ZERO_CLASS N 1405-10-3 NEOMYCIN MECH_LEVEL_3 Protein synthesis inhibitor 1405-10-3 NEOMYCIN MECH_LEVEL_1 Anti-bacterial 1405-10-3 NEOMYCIN PRODUCT_CLASS Anti-infectives 1405-10-3 NEOMYCIN INDICATION Hepatic Encephalopathy 1405-10-3 NEOMYCIN MECHANISM Inhibit ribosomal protein synthesis 1405-10-3 NEOMYCIN THERAPEUTIC_CLASS Antibacterials 1405-10-3 NEOMYCIN ADVERSE_EFFECT LUN_1_Respiratory Paralysis 1405-10-3 NEOMYCIN ADVERSE_EFFECT NEU_1_Neuromuscular Blockade 1405-10-3 NEOMYCIN KNOWN_TOXICITY Nephrotoxicity 1405-10-3 NEOMYCIN KNOWN_TOXICITY Respiratory Toxicity 1405-10-3 NEOMYCIN KNOWN_TOXICITY Neurotoxicity 1405-10-3 NEOMYCIN MESH_LEVEL_3 Aminoglycosides 1405-10-3 NEOMYCIN PRODUCT_CLASS Dermatologicals 1405-10-3 NEOMYCIN TA_LEVEL_3 Aminoglycoside 1405-10-3 NEOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 1405-10-3 NEOMYCIN INDICATION Urinary Tract Infection (UTI) 1405-10-3 NEOMYCIN INDICATION Bowel Preparation 1405-10-3 NEOMYCIN THERAPEUTIC_CLASS Antibacterials, Topical 1405-10-3 NEOMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 1405-10-3 NEOMYCIN ADVERSE_EFFECT XXX_2_Superinfection 1405-10-3 NEOMYCIN KNOWN_TOXICITY Ototoxicity 1405-10-3 NEOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 1405-10-3 NEOMYCIN MECH_LEVEL_2 Ribosomal RNA binder 1405-10-3 NEOMYCIN INDICATION Skin Infections 1405-10-3 NEOMYCIN INDICATION Hyperlipidemia 119-04-0 NEOMYCIN INDICATION Urinary Tract Infection (UTI) 119-04-0 NEOMYCIN TISSUE_TOXICITY Ototoxicity 119-04-0 NEOMYCIN TISSUE_TOXICITY Neuromuscular Blockade 119-04-0 NEOMYCIN THERAPEUTIC_CLASS Hypolipidemic Agents 119-04-0 NEOMYCIN ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 119-04-0 NEOMYCIN ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 119-04-0 NEOMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 119-04-0 NEOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 119-04-0 NEOMYCIN ADVERSE_EFFECT GIS_2_Malabsorption 119-04-0 NEOMYCIN ZERO_CLASS N 119-04-0 NEOMYCIN MECH_LEVEL_3 Protein synthesis inhibitor 119-04-0 NEOMYCIN MECH_LEVEL_1 Anti-bacterial 119-04-0 NEOMYCIN PRODUCT_CLASS Anti-infectives 119-04-0 NEOMYCIN INDICATION Hepatic Encephalopathy 119-04-0 NEOMYCIN MECHANISM Inhibit ribosomal protein synthesis 119-04-0 NEOMYCIN THERAPEUTIC_CLASS Antibacterials 119-04-0 NEOMYCIN ADVERSE_EFFECT LUN_1_Respiratory Paralysis 119-04-0 NEOMYCIN ADVERSE_EFFECT NEU_1_Neuromuscular Blockade 119-04-0 NEOMYCIN KNOWN_TOXICITY Nephrotoxicity 119-04-0 NEOMYCIN MESH_LEVEL_3 Aminoglycosides 119-04-0 NEOMYCIN KNOWN_TOXICITY Respiratory Toxicity 119-04-0 NEOMYCIN TA_LEVEL_1 Infectious Disease 119-04-0 NEOMYCIN INDICATION Hypercholesterolemia 119-04-0 NEOMYCIN TA_LEVEL_2 Anti-bacterial 119-04-0 NEOMYCIN MESH_LEVEL_2 Carbohydrates 119-04-0 NEOMYCIN PRODUCT_CLASS Cardiovasculars 119-04-0 NEOMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 119-04-0 NEOMYCIN TISSUE_TOXICITY Nephrotoxicity 119-04-0 NEOMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 119-04-0 NEOMYCIN MECH_LEVEL_2 Ribosomal RNA binder 119-04-0 NEOMYCIN INDICATION Skin Infections 119-04-0 NEOMYCIN KNOWN_TOXICITY Neurotoxicity 119-04-0 NEOMYCIN KNOWN_TOXICITY Ototoxicity 119-04-0 NEOMYCIN ADVERSE_EFFECT XXX_2_Superinfection 119-04-0 NEOMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 119-04-0 NEOMYCIN THERAPEUTIC_CLASS Antibacterials, Topical 119-04-0 NEOMYCIN INDICATION Hyperlipidemia 119-04-0 NEOMYCIN INDICATION Bowel Preparation 119-04-0 NEOMYCIN TISSUE_TOXICITY Respiratory Paralysis 119-04-0 NEOMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 119-04-0 NEOMYCIN TA_LEVEL_3 Aminoglycoside 119-04-0 NEOMYCIN PRODUCT_CLASS Dermatologicals 50-63-5 CHLOROQUINE INDICATION Discoid Lupus Erythematosus / Chronic Cutaneous Lupus Erythematosus 50-63-5 CHLOROQUINE INDICATION Porphyria Cutanea Tarda 50-63-5 CHLOROQUINE INDICATION Systemic Lupus Erythromatosus (SLE) 50-63-5 CHLOROQUINE INDICATION Systemic Amebiasis 50-63-5 CHLOROQUINE ADVERSE_EFFECT NEU_1_Drowsiness 50-63-5 CHLOROQUINE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-63-5 CHLOROQUINE ADVERSE_EFFECT LIV_3_Hepatitis 50-63-5 CHLOROQUINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 50-63-5 CHLOROQUINE ADVERSE_EFFECT NEU_3_Seizures 50-63-5 CHLOROQUINE ADVERSE_EFFECT OCU_3_Retinopathy 50-63-5 CHLOROQUINE ADVERSE_EFFECT BBM_3_Pancytopenia 50-63-5 CHLOROQUINE TISSUE_TOXICITY Hypotension 50-63-5 CHLOROQUINE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 50-63-5 CHLOROQUINE ADVERSE_EFFECT PSY_3_Psychosis 50-63-5 CHLOROQUINE ADVERSE_EFFECT IMU_3_Hypersensitivity 50-63-5 CHLOROQUINE ADVERSE_EFFECT IMU_2_Photosensitivity 50-63-5 CHLOROQUINE TISSUE_TOXICITY Cardiomyopathy 50-63-5 CHLOROQUINE ADVERSE_EFFECT OTO_3_Hearing Loss 50-63-5 CHLOROQUINE ADVERSE_EFFECT PSY_3_Confusion 50-63-5 CHLOROQUINE ADVERSE_EFFECT OCU_1_Blurred Vision 50-63-5 CHLOROQUINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 50-63-5 CHLOROQUINE ADVERSE_EFFECT SKN_2_Pruritis 50-63-5 CHLOROQUINE ADVERSE_EFFECT MSK_3_Myopathy 50-63-5 CHLOROQUINE INDICATION Still's Disease / Juvenile Chronic Arthritis 50-63-5 CHLOROQUINE PRODUCT_CLASS Anti-infectives 50-63-5 CHLOROQUINE INDICATION Malaria 50-63-5 CHLOROQUINE INDICATION Rheumatoid Arthritis 50-63-5 CHLOROQUINE ADVERSE_EFFECT CVS_3_Hypotension 50-63-5 CHLOROQUINE ADVERSE_EFFECT OCU_3_Corneal Microdeposits 50-63-5 CHLOROQUINE ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 50-63-5 CHLOROQUINE INDICATION Polymorphous Light Eruptions 50-63-5 CHLOROQUINE ADVERSE_EFFECT CVS_3_Cardiomyopathy 50-63-5 CHLOROQUINE ADVERSE_EFFECT SKN_2_Skin Pigmentation 50-63-5 CHLOROQUINE ADVERSE_EFFECT NEU_3_Optic Atrophy 50-63-5 CHLOROQUINE INDICATION Malaria Prophylaxis 50-63-5 CHLOROQUINE ADVERSE_EFFECT BBM_3_Neutropenia 50-63-5 CHLOROQUINE STRUCTURE_ACTIVITY Toxicant 50-63-5 CHLOROQUINE PRODUCT_CLASS Anti-inflammatories 50-63-5 CHLOROQUINE THERAPEUTIC_CLASS Antiparasitics 50-63-5 CHLOROQUINE TISSUE_TOXICITY Cardiotoxicity 50-63-5 CHLOROQUINE KNOWN_TOXICITY Cardiovascular Toxicity 50-63-5 CHLOROQUINE ACTIVITY_CLASS Toxicant 50-63-5 CHLOROQUINE ADVERSE_EFFECT NEU_1_Headache 50-63-5 CHLOROQUINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 50-63-5 CHLOROQUINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 50-63-5 CHLOROQUINE ADVERSE_EFFECT SKN_3_Psoriasiform Skin Eruption 1951-25-3 AMIODARONE ADVERSE_EFFECT DNA_2_Carcinogenicity 1951-25-3 AMIODARONE ADVERSE_EFFECT NEU_2_Optic Neuritis 1951-25-3 AMIODARONE ADVERSE_EFFECT GIS_2_Constipation 1951-25-3 AMIODARONE ADVERSE_EFFECT IMU_2_Photosensitivity 1951-25-3 AMIODARONE KNOWN_TOXICITY Miscellaneous 1951-25-3 AMIODARONE KNOWN_TOXICITY Cardiovascular Toxicity 1951-25-3 AMIODARONE MECHANISM Modulate G-protein coupled signal transduction 1951-25-3 AMIODARONE TA_LEVEL_3 unrelated anti-arrthymic 1951-25-3 AMIODARONE ADVERSE_EFFECT IMU_3_Angioedema 1951-25-3 AMIODARONE ADVERSE_EFFECT GIS_3_Pancreatitis 1951-25-3 AMIODARONE ADVERSE_EFFECT REP_2_Decreased Fertility 1951-25-3 AMIODARONE ADVERSE_EFFECT OCU_2_Blindness 1951-25-3 AMIODARONE ADVERSE_EFFECT GIS_2_Nausea 1951-25-3 AMIODARONE ADVERSE_EFFECT XXX_1_Fatigue 1951-25-3 AMIODARONE ZERO_CLASS Y 1951-25-3 AMIODARONE MODE_CLASS Channel Modulator 1951-25-3 AMIODARONE TISSUE_TOXICITY Carcinogenicity 1951-25-3 AMIODARONE ACTIVITY_CLASS K+ (inward), & KATP (SUR2) channel blocker, adrenoceptor antagonist, monoamine transporter inhibitor 1951-25-3 AMIODARONE MODE_CLASS Channel Blocker 1951-25-3 AMIODARONE TA_LEVEL_1 Cardiovascular 1951-25-3 AMIODARONE MECHANISM Inhibit thyroid hormone biosynthesis 1951-25-3 AMIODARONE KNOWN_TOXICITY Respiratory Toxicity 1951-25-3 AMIODARONE MECH_LEVEL_2 prolong action potential/inhibit adrenoreceptors 1951-25-3 AMIODARONE MODE_CLASS Enzyme Inhibitor 1951-25-3 AMIODARONE INDICATION Recurrent Hemodynamically Unstable Ventricular Tachycardia 1951-25-3 AMIODARONE MESH_LEVEL_1 Heterocyclic Compounds 1951-25-3 AMIODARONE TA_LEVEL_2 Anti-arrthymic 1951-25-3 AMIODARONE INDICATION Recurrent Ventricular Fibrillation 1951-25-3 AMIODARONE MODE_CLASS Receptor Ligand Antagonist, Non-selective 1951-25-3 AMIODARONE THERAPEUTIC_CLASS Antiarrhythmic Agents 1951-25-3 AMIODARONE ADVERSE_EFFECT LUN_1_Pulmonary Toxicity 1951-25-3 AMIODARONE ADVERSE_EFFECT NEU_1_Tremor 1951-25-3 AMIODARONE ADVERSE_EFFECT GIS_2_Vomiting 1951-25-3 AMIODARONE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 1951-25-3 AMIODARONE ADVERSE_EFFECT OCU_2_Eye Irritation 1951-25-3 AMIODARONE MECHANISM Modulate channel gating 1951-25-3 AMIODARONE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 1951-25-3 AMIODARONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 1951-25-3 AMIODARONE TISSUE_TOXICITY Congestive Heart Failure 1951-25-3 AMIODARONE MODE_CLASS Solute transporter inhibitor 1951-25-3 AMIODARONE MECH_LEVEL_3 Class III antiarrthymic 1951-25-3 AMIODARONE MESH_LEVEL_3 Benzofurans 1951-25-3 AMIODARONE MECH_LEVEL_1 Anti-arrthymic 1951-25-3 AMIODARONE PRODUCT_CLASS Cardiovasculars 1951-25-3 AMIODARONE TISSUE_TOXICITY Death 1951-25-3 AMIODARONE STRUCTURE_ACTIVITY K+ (inward), & KATP (SUR2) channel blocker, adrenoceptor antagonist, monoamine transporter inhibitor 1951-25-3 AMIODARONE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 1951-25-3 AMIODARONE MECHANISM Block channel gating 1951-25-3 AMIODARONE ADVERSE_EFFECT CVS_3_Vasculitis 1951-25-3 AMIODARONE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 1951-25-3 AMIODARONE KNOWN_TOXICITY Carcinogenicity 1951-25-3 AMIODARONE TISSUE_TOXICITY Exacerbation of Arrhythmia 1951-25-3 AMIODARONE TISSUE_TOXICITY Pulmonary Toxicity 1951-25-3 AMIODARONE MECHANISM Prolong/enhance neural transmission 1951-25-3 AMIODARONE ADVERSE_EFFECT CVS_3_Bradycardia 1951-25-3 AMIODARONE ADVERSE_EFFECT BBM_3_Pancytopenia 1951-25-3 AMIODARONE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 1951-25-3 AMIODARONE ADVERSE_EFFECT XXX_1_Malaise 1951-25-3 AMIODARONE ADVERSE_EFFECT CVS_1_Exacerbation of Arrhythmia 1951-25-3 AMIODARONE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 1951-25-3 AMIODARONE ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 1951-25-3 AMIODARONE ADVERSE_EFFECT XXX_2_Death 68550-75-4 CILOSTAMIDE MODE_CLASS Enzyme Inhibitor 68550-75-4 CILOSTAMIDE STRUCTURE_ACTIVITY PDE3 inhibitor 68550-75-4 CILOSTAMIDE PRODUCT_CLASS Hematologics 68550-75-4 CILOSTAMIDE THERAPEUTIC_CLASS Antiplatelets 68550-75-4 CILOSTAMIDE MECHANISM Enhance kinase mediated signal transduction 64-17-5 ETHANOL MECHANISM Overload metabolic enzyme 64-17-5 ETHANOL TA_LEVEL_3 Liver toxicants 64-17-5 ETHANOL ACTIVITY_CLASS Alcohol dehydrogenase inhibitor 64-17-5 ETHANOL STRUCTURE_ACTIVITY Alcohol dehydrogenase inhibitor 64-17-5 ETHANOL ADVERSE_EFFECT EMB_2_Fetal Alcohol Syndrome 64-17-5 ETHANOL ADVERSE_EFFECT BBM_2_Myelosuppression 64-17-5 ETHANOL ADVERSE_EFFECT GIS_2_Pancreatitis 64-17-5 ETHANOL ADVERSE_EFFECT END_2_Hypoglycemia 64-17-5 ETHANOL MESH_LEVEL_2 Alcohols 64-17-5 ETHANOL MECH_LEVEL_1 Impairs cell membrane permeability 64-17-5 ETHANOL MECH_LEVEL_3 Unknown mechanism 64-17-5 ETHANOL MECH_LEVEL_2 Impairs cell membrane permeability 64-17-5 ETHANOL MESH_LEVEL_1 Organic Chemicals 64-17-5 ETHANOL MODE_CLASS Channel Modulator 64-17-5 ETHANOL PRODUCT_CLASS Toxicants 64-17-5 ETHANOL KNOWN_TOXICITY Hepatotoxicity 64-17-5 ETHANOL TISSUE_TOXICITY Hepatotoxicity 64-17-5 ETHANOL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 64-17-5 ETHANOL ADVERSE_EFFECT LIV_2_Hepatitis 64-17-5 ETHANOL ADVERSE_EFFECT END_2_Ketoacidosis 64-17-5 ETHANOL MODE_CLASS Endogenous Enzyme Substrate 64-17-5 ETHANOL MECHANISM Modulate neural transmission 64-17-5 ETHANOL TA_LEVEL_1 Toxicants 64-17-5 ETHANOL TISSUE_TOXICITY Liver Cirrhosis 64-17-5 ETHANOL ADVERSE_EFFECT XXX_1_Withdrawal 64-17-5 ETHANOL ADVERSE_EFFECT MSK_2_Myopathy 64-17-5 ETHANOL ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 64-17-5 ETHANOL ADVERSE_EFFECT LIV_2_Hepatotoxicity 64-17-5 ETHANOL MECHANISM Prolong/enhance neural transmission 64-17-5 ETHANOL MESH_LEVEL_3 Ethanol 64-17-5 ETHANOL ADVERSE_EFFECT PSY_3_Delirium Tremens 64-17-5 ETHANOL ADVERSE_EFFECT LIV_2_Portal Hypertension 64-17-5 ETHANOL ADVERSE_EFFECT NEU_2_Wernicke-Korsakoff Syndrome 64-17-5 ETHANOL ADVERSE_EFFECT LIV_2_Liver Cirrhosis 64-17-5 ETHANOL ZERO_CLASS N 64-17-5 ETHANOL TISSUE_TOXICITY Cardiac Arrhythmia 64-17-5 ETHANOL KNOWN_TOXICITY Cardiovascular Toxicity 302-79-4 TRETINOIN TA_LEVEL_3 Acne Preparations 302-79-4 TRETINOIN INDICATION Neoplasm / Cancer / Tumor 302-79-4 TRETINOIN THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 302-79-4 TRETINOIN MECH_LEVEL_2 RXR activation 302-79-4 TRETINOIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 302-79-4 TRETINOIN TA_LEVEL_2 anti-comodogenic 302-79-4 TRETINOIN MECH_LEVEL_1 Modulate epidermal fuction 302-79-4 TRETINOIN MESH_LEVEL_2 Hydrocarbons 302-79-4 TRETINOIN INDICATION Acne / Acne Vulgaris 302-79-4 TRETINOIN PRODUCT_CLASS Dermatologicals 302-79-4 TRETINOIN PRODUCT_CLASS Anti-inflammatories 302-79-4 TRETINOIN THERAPEUTIC_CLASS Antineoplastics 302-79-4 TRETINOIN ADVERSE_EFFECT SKN_2_Hypopigmentation 302-79-4 TRETINOIN ADVERSE_EFFECT XXX_1_Fever 302-79-4 TRETINOIN ADVERSE_EFFECT XXX_3_Infection 302-79-4 TRETINOIN ADVERSE_EFFECT EMB_2_Teratogenicity 302-79-4 TRETINOIN TISSUE_TOXICITY Teratogenicity 302-79-4 TRETINOIN STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 302-79-4 TRETINOIN ACTIVITY_CLASS Retinoic acid receptor (RAR) agonist 302-79-4 TRETINOIN TA_LEVEL_1 Dermatology 302-79-4 TRETINOIN KNOWN_TOXICITY Embryo/Fetal Toxicity 302-79-4 TRETINOIN THERAPEUTIC_CLASS Acne Preparations 302-79-4 TRETINOIN ADVERSE_EFFECT NEU_1_Headache 302-79-4 TRETINOIN ADVERSE_EFFECT BBM_3_Hemorrhage 302-79-4 TRETINOIN ADVERSE_EFFECT LUN_3_Pneumonia 302-79-4 TRETINOIN ZERO_CLASS N 302-79-4 TRETINOIN MECH_LEVEL_3 9-cis-retinoic acid receptor RXR beta 302-79-4 TRETINOIN MESH_LEVEL_3 Terpenes 302-79-4 TRETINOIN INDICATION Inflammation 302-79-4 TRETINOIN ADVERSE_EFFECT SKN_2_Skin Reactions 302-79-4 TRETINOIN ADVERSE_EFFECT XXX_1_Fatigue 302-79-4 TRETINOIN ADVERSE_EFFECT BBM_3_Disseminated Intravascular Coagulation (DIC) 302-79-4 TRETINOIN ADVERSE_EFFECT SKN_2_Hyperpigmentation 302-79-4 TRETINOIN MESH_LEVEL_1 Organic Chemicals 302-79-4 TRETINOIN INDICATION Cutaneous Aging / Wrinkles 302-79-4 TRETINOIN MODE_CLASS Endogenous Receptor /Channel Ligand 302-79-4 TRETINOIN ADVERSE_EFFECT IMU_2_Photosensitivity 302-79-4 TRETINOIN ADVERSE_EFFECT SKN_2_Blisters 302-79-4 TRETINOIN ADVERSE_EFFECT XXX_1_Weakness 302-79-4 TRETINOIN INDICATION Acute Promyelocytic Leukemia 302-79-4 TRETINOIN PRODUCT_CLASS Anti-cancers 302-79-4 TRETINOIN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 302-79-4 TRETINOIN MECHANISM Modulate gene transcription 53-86-1 INDOMETHACIN TA_LEVEL_1 Anti-inflammatory 53-86-1 INDOMETHACIN INDICATION Rheumatoid Arthritis 53-86-1 INDOMETHACIN INDICATION Acute Painful Shoulder 53-86-1 INDOMETHACIN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 53-86-1 INDOMETHACIN TA_LEVEL_2 NSAID 53-86-1 INDOMETHACIN PRODUCT_CLASS Anti-inflammatories 53-86-1 INDOMETHACIN ADVERSE_EFFECT BBM_3_Myelosuppression 53-86-1 INDOMETHACIN ADVERSE_EFFECT CVS_3_Congestive Heart Failure 53-86-1 INDOMETHACIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 53-86-1 INDOMETHACIN ADVERSE_EFFECT LUN_3_Pulmonary Edema 53-86-1 INDOMETHACIN ADVERSE_EFFECT PSY_3_Anorexia 53-86-1 INDOMETHACIN ADVERSE_EFFECT OTO_2_Tinnitus 53-86-1 INDOMETHACIN ZERO_CLASS N 53-86-1 INDOMETHACIN TISSUE_TOXICITY Congestive Heart Failure 53-86-1 INDOMETHACIN KNOWN_TOXICITY Cardiovascular Toxicity 53-86-1 INDOMETHACIN MESH_LEVEL_3 Indoles 53-86-1 INDOMETHACIN MESH_LEVEL_1 Heterocyclic Compounds 53-86-1 INDOMETHACIN KNOWN_TOXICITY Nephrotoxicity 53-86-1 INDOMETHACIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 53-86-1 INDOMETHACIN ADVERSE_EFFECT GIS_3_Gastrointestinal Hemorrhage 53-86-1 INDOMETHACIN ADVERSE_EFFECT OCU_3_Blurred Vision 53-86-1 INDOMETHACIN ADVERSE_EFFECT CVS_3_Tachycardia 53-86-1 INDOMETHACIN ADVERSE_EFFECT KID_3_Hematuria 53-86-1 INDOMETHACIN ADVERSE_EFFECT GIS_1_Nausea 53-86-1 INDOMETHACIN ADVERSE_EFFECT NEU_1_Dizziness 53-86-1 INDOMETHACIN ADVERSE_EFFECT PSY_3_Confusion 53-86-1 INDOMETHACIN MECHANISM Inhibit eicosanoid biosynthesis 53-86-1 INDOMETHACIN TA_LEVEL_3 NSAID 53-86-1 INDOMETHACIN MECH_LEVEL_1 Immunomodulation 53-86-1 INDOMETHACIN INDICATION Ankylosing Spondylitis 53-86-1 INDOMETHACIN ADVERSE_EFFECT GIS_3_Flatulence 53-86-1 INDOMETHACIN ADVERSE_EFFECT CVS_3_Chest Pain 53-86-1 INDOMETHACIN ADVERSE_EFFECT BBM_3_Agranulocytosis 53-86-1 INDOMETHACIN STRUCTURE_ACTIVITY NSAID, COX-1, indomethacin like 53-86-1 INDOMETHACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 53-86-1 INDOMETHACIN ADVERSE_EFFECT NEU_2_Headache 53-86-1 INDOMETHACIN ADVERSE_EFFECT XXX_2_Fatigue 53-86-1 INDOMETHACIN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 53-86-1 INDOMETHACIN INDICATION Osteoarthritis 53-86-1 INDOMETHACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 53-86-1 INDOMETHACIN MODE_CLASS Enzyme Inhibitor 53-86-1 INDOMETHACIN ADVERSE_EFFECT NEU_2_Vertigo 53-86-1 INDOMETHACIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 53-86-1 INDOMETHACIN ADVERSE_EFFECT IMU_3_Angioedema 53-86-1 INDOMETHACIN ADVERSE_EFFECT KID_3_Renal Insufficiency 53-86-1 INDOMETHACIN ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 53-86-1 INDOMETHACIN INDICATION Acute Gouty Arthritis 53-86-1 INDOMETHACIN ADVERSE_EFFECT GIS_1_Dyspepsia 53-86-1 INDOMETHACIN ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 53-86-1 INDOMETHACIN ADVERSE_EFFECT NEU_2_Somnolence 53-86-1 INDOMETHACIN ACTIVITY_CLASS Anti-inflammatory 53-86-1 INDOMETHACIN TISSUE_TOXICITY Hematuria 1614-12-6 1-AMINOBENZOTRIAZOLE MECHANISM interferes with liver P450 enzyme funciton 1614-12-6 1-AMINOBENZOTRIAZOLE PRODUCT_CLASS Biochemicals 1614-12-6 1-AMINOBENZOTRIAZOLE MODE_CLASS Enzyme Inhibitor, Non-selective 4238-71-5 1-BENZYLIMIDAZOLE STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 4238-71-5 1-BENZYLIMIDAZOLE PRODUCT_CLASS Biochemicals 4238-71-5 1-BENZYLIMIDAZOLE MECHANISM Inhibit eicosanoid biosynthesis 4238-71-5 1-BENZYLIMIDAZOLE MODE_CLASS Enzyme Inhibitor 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT IMU_2_Urticaria 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT SKN_2_Pruritis 65277-42-1 KETOCONAZOLE INDICATION Paracoccidioidomycosis / South American Blastomycosis 65277-42-1 KETOCONAZOLE INDICATION Seborrheic Dermatitis 65277-42-1 KETOCONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 65277-42-1 KETOCONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 65277-42-1 KETOCONAZOLE INDICATION Oral Candidiasis / Thrush 65277-42-1 KETOCONAZOLE INDICATION Coccidioidomycosis 65277-42-1 KETOCONAZOLE TA_LEVEL_1 Infectious Disease 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT NEU_3_Paresthesia 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 65277-42-1 KETOCONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, ketoconazole like 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT XXX_3_Fever 65277-42-1 KETOCONAZOLE INDICATION Histoplasmosis 65277-42-1 KETOCONAZOLE INDICATION Candiduria 65277-42-1 KETOCONAZOLE INDICATION Tinea Cruris / Jock Itch 65277-42-1 KETOCONAZOLE INDICATION Fungal Infections 65277-42-1 KETOCONAZOLE TA_LEVEL_2 Anti-fungal 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT PSY_3_Depression 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 65277-42-1 KETOCONAZOLE ZERO_CLASS N 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT GIS_3_Diarrhea 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT GIS_1_Nausea 65277-42-1 KETOCONAZOLE THERAPEUTIC_CLASS Antifungals 65277-42-1 KETOCONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) 65277-42-1 KETOCONAZOLE INDICATION Chronic Mucocutaneous Candidiasis 65277-42-1 KETOCONAZOLE INDICATION Tinea Pedis / Athlete's Foot 65277-42-1 KETOCONAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 65277-42-1 KETOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 65277-42-1 KETOCONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 65277-42-1 KETOCONAZOLE INDICATION Candidiasis 65277-42-1 KETOCONAZOLE TA_LEVEL_3 systemic 65277-42-1 KETOCONAZOLE INDICATION Chromomycosis 65277-42-1 KETOCONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 65277-42-1 KETOCONAZOLE PRODUCT_CLASS Anti-infectives 65277-42-1 KETOCONAZOLE MECH_LEVEL_1 Anti-fungal 65277-42-1 KETOCONAZOLE MESH_LEVEL_3 Piperazines 65277-42-1 KETOCONAZOLE ACTIVITY_CLASS Antifungals azole 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT BBM_3_Thrombocytopenia 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT NEU_2_Dizziness 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT NEU_2_Headache 65277-42-1 KETOCONAZOLE ADVERSE_EFFECT GIS_1_Vomiting 65277-42-1 KETOCONAZOLE MODE_CLASS Enzyme Inhibitor 32986-56-4 TOBRAMYCIN INDICATION Gram-negative Sepsis 32986-56-4 TOBRAMYCIN PRODUCT_CLASS Anti-infectives 32986-56-4 TOBRAMYCIN KNOWN_TOXICITY Nephrotoxicity 32986-56-4 TOBRAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT LUN_2_Respiratory Paralysis 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT CVS_3_Phlebitis 32986-56-4 TOBRAMYCIN INDICATION Pseudomonas Aeruginosa Infection 32986-56-4 TOBRAMYCIN INDICATION Lower Respiratory Tract Infection 32986-56-4 TOBRAMYCIN INDICATION Soft Tissue Infections 32986-56-4 TOBRAMYCIN INDICATION Skin Infections 32986-56-4 TOBRAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 32986-56-4 TOBRAMYCIN INDICATION Urinary Tract Infection (UTI) 32986-56-4 TOBRAMYCIN INDICATION Bacterial Endocarditis 32986-56-4 TOBRAMYCIN INDICATION Meningitis 32986-56-4 TOBRAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 32986-56-4 TOBRAMYCIN INDICATION Osteomyelitis / Bone Infection 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT OTO_1_Ototoxicity 32986-56-4 TOBRAMYCIN TISSUE_TOXICITY Nephrotoxicity 32986-56-4 TOBRAMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 32986-56-4 TOBRAMYCIN KNOWN_TOXICITY Ototoxicity 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT NEU_2_Neuromuscular Blockade 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT KID_1_Nephrotoxicity 32986-56-4 TOBRAMYCIN ADVERSE_EFFECT BBM_3_Anemia 32986-56-4 TOBRAMYCIN TISSUE_TOXICITY Ototoxicity 32986-56-4 TOBRAMYCIN MECHANISM Inhibit ribosomal protein synthesis 37517-28-5 AMIKACIN MESH_LEVEL_2 Carbohydrates 37517-28-5 AMIKACIN TA_LEVEL_1 Infectious Disease 37517-28-5 AMIKACIN TA_LEVEL_2 Anti-bacterial 37517-28-5 AMIKACIN INDICATION Meningitis 37517-28-5 AMIKACIN INDICATION Nontuberculous Atypical Mycobacterial Diseases 37517-28-5 AMIKACIN INDICATION Biliary Tract Infection 37517-28-5 AMIKACIN THERAPEUTIC_CLASS Antibacterials, Systemic 37517-28-5 AMIKACIN TISSUE_TOXICITY Nephrotoxicity 37517-28-5 AMIKACIN ADVERSE_EFFECT OTO_1_Ototoxicity 37517-28-5 AMIKACIN ADVERSE_EFFECT NEU_2_Neuromuscular Blockade 37517-28-5 AMIKACIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 37517-28-5 AMIKACIN INDICATION Bone and Joint Infection 37517-28-5 AMIKACIN MECH_LEVEL_3 Protein synthesis inhibitor 37517-28-5 AMIKACIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 37517-28-5 AMIKACIN MECH_LEVEL_1 Anti-bacterial 37517-28-5 AMIKACIN INDICATION Pseudomonas Aeruginosa Infection 37517-28-5 AMIKACIN INDICATION Gram-negative Sepsis 37517-28-5 AMIKACIN INDICATION Mycobacterium Tuberculosis Infections 37517-28-5 AMIKACIN INDICATION Urinary Tract Infection (UTI) 37517-28-5 AMIKACIN TISSUE_TOXICITY Ototoxicity 37517-28-5 AMIKACIN ADVERSE_EFFECT KID_1_Nephrotoxicity 37517-28-5 AMIKACIN ZERO_CLASS N 37517-28-5 AMIKACIN KNOWN_TOXICITY Ototoxicity 37517-28-5 AMIKACIN INDICATION Pelvic Inflammatory Disease (PID) 37517-28-5 AMIKACIN TA_LEVEL_3 Aminoglycoside 37517-28-5 AMIKACIN INDICATION Peritonitis 37517-28-5 AMIKACIN MESH_LEVEL_3 Aminoglycosides 37517-28-5 AMIKACIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 37517-28-5 AMIKACIN ADVERSE_EFFECT IMU_2_Allergic Reactions 37517-28-5 AMIKACIN INDICATION Neonatal Sepsis 37517-28-5 AMIKACIN MODE_CLASS Enzyme Inhibitor 37517-28-5 AMIKACIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 37517-28-5 AMIKACIN KNOWN_TOXICITY Nephrotoxicity 37517-28-5 AMIKACIN PRODUCT_CLASS Anti-infectives 37517-28-5 AMIKACIN MECH_LEVEL_2 Ribosomal RNA binder 37517-28-5 AMIKACIN INDICATION Skin Infections 37517-28-5 AMIKACIN INDICATION Burn Wound Infection 37517-28-5 AMIKACIN MECHANISM Inhibit ribosomal protein synthesis 37517-28-5 AMIKACIN INDICATION Lower Respiratory Tract Infection 37517-28-5 AMIKACIN ADVERSE_EFFECT LUN_2_Respiratory Paralysis 37517-28-5 AMIKACIN ADVERSE_EFFECT SKN_2_Dermatitis 39831-55-5 AMIKACIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 39831-55-5 AMIKACIN KNOWN_TOXICITY Nephrotoxicity 39831-55-5 AMIKACIN PRODUCT_CLASS Anti-infectives 39831-55-5 AMIKACIN MECH_LEVEL_2 Ribosomal RNA binder 39831-55-5 AMIKACIN INDICATION Skin Infections 39831-55-5 AMIKACIN INDICATION Burn Wound Infection 39831-55-5 AMIKACIN MECHANISM Inhibit ribosomal protein synthesis 39831-55-5 AMIKACIN INDICATION Lower Respiratory Tract Infection 39831-55-5 AMIKACIN ADVERSE_EFFECT LUN_2_Respiratory Paralysis 39831-55-5 AMIKACIN ADVERSE_EFFECT SKN_2_Dermatitis 39831-55-5 AMIKACIN TA_LEVEL_1 Infectious Disease 39831-55-5 AMIKACIN KNOWN_TOXICITY Ototoxicity 39831-55-5 AMIKACIN INDICATION Meningitis 39831-55-5 AMIKACIN INDICATION Nontuberculous Atypical Mycobacterial Diseases 39831-55-5 AMIKACIN MESH_LEVEL_2 Carbohydrates 39831-55-5 AMIKACIN INDICATION Biliary Tract Infection 39831-55-5 AMIKACIN THERAPEUTIC_CLASS Antibacterials, Systemic 39831-55-5 AMIKACIN TISSUE_TOXICITY Nephrotoxicity 39831-55-5 AMIKACIN ADVERSE_EFFECT OTO_1_Ototoxicity 39831-55-5 AMIKACIN ADVERSE_EFFECT NEU_2_Neuromuscular Blockade 39831-55-5 AMIKACIN MESH_LEVEL_3 Aminoglycosides 39831-55-5 AMIKACIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 39831-55-5 AMIKACIN ADVERSE_EFFECT IMU_2_Allergic Reactions 39831-55-5 AMIKACIN ZERO_CLASS N 39831-55-5 AMIKACIN ADVERSE_EFFECT KID_1_Nephrotoxicity 39831-55-5 AMIKACIN TA_LEVEL_2 Anti-bacterial 39831-55-5 AMIKACIN TISSUE_TOXICITY Ototoxicity 39831-55-5 AMIKACIN MODE_CLASS Enzyme Inhibitor 39831-55-5 AMIKACIN INDICATION Urinary Tract Infection (UTI) 39831-55-5 AMIKACIN INDICATION Mycobacterium Tuberculosis Infections 39831-55-5 AMIKACIN STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, aminoglycoside 39831-55-5 AMIKACIN INDICATION Bone and Joint Infection 39831-55-5 AMIKACIN INDICATION Neonatal Sepsis 39831-55-5 AMIKACIN MECH_LEVEL_3 Protein synthesis inhibitor 39831-55-5 AMIKACIN INDICATION Pelvic Inflammatory Disease (PID) 39831-55-5 AMIKACIN INDICATION Pseudomonas Aeruginosa Infection 39831-55-5 AMIKACIN INDICATION Gram-negative Sepsis 39831-55-5 AMIKACIN TA_LEVEL_3 Aminoglycoside 39831-55-5 AMIKACIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 39831-55-5 AMIKACIN INDICATION Peritonitis 39831-55-5 AMIKACIN MECH_LEVEL_1 Anti-bacterial 54-36-4 METYRAPONE INDICATION To Evaluate Hypothalamic-Pituitary Function 54-36-4 METYRAPONE ADVERSE_EFFECT CVS_2_Hypotension 54-36-4 METYRAPONE ADVERSE_EFFECT NEU_1_Dizziness 54-36-4 METYRAPONE ADVERSE_EFFECT END_3_Adrenal Insufficiency 54-36-4 METYRAPONE TISSUE_TOXICITY Hypotension 54-36-4 METYRAPONE ADVERSE_EFFECT NEU_2_Sedation 54-36-4 METYRAPONE ADVERSE_EFFECT NEU_1_Headache 54-36-4 METYRAPONE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 54-36-4 METYRAPONE MECHANISM Inhibit steroid biosynthesis/ metabolism 54-36-4 METYRAPONE INDICATION To Control Hypercortisolism Secondary To ACTH Secreting Tumors 54-36-4 METYRAPONE STRUCTURE_ACTIVITY P450 enzyme (steroid metabolism) inhibitor 54-36-4 METYRAPONE ADVERSE_EFFECT END_3_Hirsutism 54-36-4 METYRAPONE ADVERSE_EFFECT NEU_2_Vertigo 54-36-4 METYRAPONE MODE_CLASS Enzyme Inhibitor 54-36-4 METYRAPONE INDICATION To Confirm Dexamethasone Suppression Test Results 54-36-4 METYRAPONE THERAPEUTIC_CLASS Pituitary Hormones 54-36-4 METYRAPONE ADVERSE_EFFECT GIS_1_Nausea 54-36-4 METYRAPONE ADVERSE_EFFECT IMU_3_Allergic Reactions 54-36-4 METYRAPONE ADVERSE_EFFECT GIS_2_Abdominal Pain 54-36-4 METYRAPONE KNOWN_TOXICITY Cardiovascular Toxicity 54-36-4 METYRAPONE INDICATION To Evaluate Anterior Pituitary Reserve of ACTH 54-36-4 METYRAPONE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 58-54-8 ETHACRYNIC ACID ACTIVITY_CLASS Diuretic 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT END_3_Gout 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT NEU_3_Vertigo 58-54-8 ETHACRYNIC ACID MESH_LEVEL_1 Organic Chemicals 58-54-8 ETHACRYNIC ACID MECH_LEVEL_3 Acid-sensitive K+ channel 2 58-54-8 ETHACRYNIC ACID MESH_LEVEL_3 Hydroxy Acids 58-54-8 ETHACRYNIC ACID MECH_LEVEL_1 Diuretic 58-54-8 ETHACRYNIC ACID TA_LEVEL_3 Diuretic 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT OCU_3_Blurred Vision 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 58-54-8 ETHACRYNIC ACID MECH_LEVEL_2 Loop Diueretic 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT GIS_2_Abdominal Pain 58-54-8 ETHACRYNIC ACID STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, ticrynafen like, loop diuretic 58-54-8 ETHACRYNIC ACID MODE_CLASS Channel Blocker, selective 58-54-8 ETHACRYNIC ACID THERAPEUTIC_CLASS Diuretics 58-54-8 ETHACRYNIC ACID MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT BBM_3_Neutropenia 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT NEU_3_Headache 58-54-8 ETHACRYNIC ACID INDICATION Acute Pulmonary Edema 58-54-8 ETHACRYNIC ACID TA_LEVEL_2 Electrolytic, Caloric and Water Balance 58-54-8 ETHACRYNIC ACID INDICATION Edema 58-54-8 ETHACRYNIC ACID ZERO_CLASS N 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT PSY_2_Anorexia 58-54-8 ETHACRYNIC ACID INDICATION Ascites 58-54-8 ETHACRYNIC ACID MESH_LEVEL_2 Carboxylic Acids 58-54-8 ETHACRYNIC ACID MODE_CLASS Enzyme Inhibitor 58-54-8 ETHACRYNIC ACID TISSUE_TOXICITY Hematuria 58-54-8 ETHACRYNIC ACID KNOWN_TOXICITY Nephrotoxicity 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT KID_3_Hematuria 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT BBM_3_Thrombocytopenia 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT XXX_2_Malaise 58-54-8 ETHACRYNIC ACID TA_LEVEL_1 Cardiovascular 58-54-8 ETHACRYNIC ACID PRODUCT_CLASS Electrolytic, Caloric and Water Balance 58-54-8 ETHACRYNIC ACID ADVERSE_EFFECT GIS_2_Dysphagia 35446-36-7 S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE PRODUCT_CLASS Anti-cancers 35446-36-7 S-(N-BENZYLTHIOCARBAMOYL)-L-CYSTEINE THERAPEUTIC_CLASS Antineoplastics 89-25-8 EDARAVONE PRODUCT_CLASS Central Nervous System (CNS) 89-25-8 EDARAVONE THERAPEUTIC_CLASS Cerebral Vascular Disorders 89-25-8 EDARAVONE MECHANISM Scavenges hydrogen peroxide and free radicals 89-25-8 EDARAVONE INDICATION Cerebrovascular ischemia 89-25-8 EDARAVONE STRUCTURE_ACTIVITY H2O2 radical scavenger 94489-23-3 EDARAVONE STRUCTURE_ACTIVITY H2O2 radical scavenger 94489-23-3 EDARAVONE INDICATION Cerebrovascular ischemia 94489-23-3 EDARAVONE MECHANISM Scavenges hydrogen peroxide and free radicals 94489-23-3 EDARAVONE PRODUCT_CLASS Central Nervous System (CNS) 94489-23-3 EDARAVONE THERAPEUTIC_CLASS Cerebral Vascular Disorders 125-33-7 PRIMIDONE ADVERSE_EFFECT NEU_1_Ataxia 125-33-7 PRIMIDONE MESH_LEVEL_3 Pyrimidines 125-33-7 PRIMIDONE INDICATION Akinetic Seizures 125-33-7 PRIMIDONE MESH_LEVEL_1 Heterocyclic Compounds 125-33-7 PRIMIDONE MECH_LEVEL_2 faciliates GABA binding 125-33-7 PRIMIDONE ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 125-33-7 PRIMIDONE ADVERSE_EFFECT OCU_2_Diplopia 125-33-7 PRIMIDONE ADVERSE_EFFECT PSY_2_Acute Toxic Psychosis 125-33-7 PRIMIDONE ADVERSE_EFFECT SKN_2_Morbilliform Rash 125-33-7 PRIMIDONE ADVERSE_EFFECT IMU_2_Eosinophilia 125-33-7 PRIMIDONE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 125-33-7 PRIMIDONE TA_LEVEL_3 Antiepileptics / Anticonvulsants 125-33-7 PRIMIDONE INDICATION Tonic-Clonic (Grand Mal) Seizures 125-33-7 PRIMIDONE MECHANISM Modulate neural transmission 125-33-7 PRIMIDONE ADVERSE_EFFECT PSY_1_Anorexia 125-33-7 PRIMIDONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 125-33-7 PRIMIDONE ADVERSE_EFFECT NEU_1_Drowsiness 125-33-7 PRIMIDONE ADVERSE_EFFECT BBM_3_Megaloblastic Anemia 125-33-7 PRIMIDONE ADVERSE_EFFECT NEU_1_Vertigo 125-33-7 PRIMIDONE ACTIVITY_CLASS GABA agonist 125-33-7 PRIMIDONE ZERO_CLASS N 125-33-7 PRIMIDONE MECH_LEVEL_3 GABA-A receptor A 125-33-7 PRIMIDONE MECH_LEVEL_1 Modulate neural transmission 125-33-7 PRIMIDONE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 125-33-7 PRIMIDONE ADVERSE_EFFECT BBM_3_Agranulocytosis 125-33-7 PRIMIDONE ADVERSE_EFFECT XXX_1_Lethargy 125-33-7 PRIMIDONE ADVERSE_EFFECT BBM_2_Leukopenia 125-33-7 PRIMIDONE MODE_CLASS Channel Modulator 125-33-7 PRIMIDONE STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 125-33-7 PRIMIDONE TA_LEVEL_1 Central Nervous System (CNS) 125-33-7 PRIMIDONE PRODUCT_CLASS Central Nervous System (CNS) 125-33-7 PRIMIDONE INDICATION Psychomotor Seizures 50-35-1 THALIDOMIDE INDICATION Erythema Nodosum Leprosum (ENL) 50-35-1 THALIDOMIDE ADVERSE_EFFECT REP_3_Impotence 50-35-1 THALIDOMIDE ADVERSE_EFFECT SKN_3_Pruritis 50-35-1 THALIDOMIDE ADVERSE_EFFECT XXX_3_Peripheral Edema 50-35-1 THALIDOMIDE ADVERSE_EFFECT BBM_2_Neutropenia 50-35-1 THALIDOMIDE TISSUE_TOXICITY Teratogenicity 50-35-1 THALIDOMIDE KNOWN_TOXICITY Nephrotoxicity 50-35-1 THALIDOMIDE ADVERSE_EFFECT NEU_1_Somnolence 50-35-1 THALIDOMIDE ADVERSE_EFFECT CVS_2_Bradycardia 50-35-1 THALIDOMIDE ADVERSE_EFFECT IMU_2_Hypersensitivity 50-35-1 THALIDOMIDE ADVERSE_EFFECT XXX_3_Infection 50-35-1 THALIDOMIDE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 50-35-1 THALIDOMIDE ADVERSE_EFFECT XXX_3_Asthenia 50-35-1 THALIDOMIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 50-35-1 THALIDOMIDE TA_LEVEL_1 Infectious Disease 50-35-1 THALIDOMIDE TA_LEVEL_2 immunosuppressant 50-35-1 THALIDOMIDE PRODUCT_CLASS Immune Response / Immunomodulators 50-35-1 THALIDOMIDE ACTIVITY_CLASS Unknown mechanism 50-35-1 THALIDOMIDE ADVERSE_EFFECT EMB_2_Teratogenicity 50-35-1 THALIDOMIDE ADVERSE_EFFECT SKN_1_Rash 50-35-1 THALIDOMIDE ADVERSE_EFFECT LYM_3_Lymphadenopathy 50-35-1 THALIDOMIDE ADVERSE_EFFECT KID_3_Hematuria 50-35-1 THALIDOMIDE MECH_LEVEL_3 unknown mechanism 50-35-1 THALIDOMIDE MECH_LEVEL_1 Immunomodulation 50-35-1 THALIDOMIDE INDICATION Multiple Myeloma / Myelomatosis 50-35-1 THALIDOMIDE MECH_LEVEL_2 Inhibit TNF alpha production 50-35-1 THALIDOMIDE MESH_LEVEL_1 Heterocyclic Compounds 50-35-1 THALIDOMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 50-35-1 THALIDOMIDE THERAPEUTIC_CLASS Immunomodulants 50-35-1 THALIDOMIDE ZERO_CLASS Y 50-35-1 THALIDOMIDE STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 50-35-1 THALIDOMIDE ADVERSE_EFFECT NEU_1_Dizziness 50-35-1 THALIDOMIDE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 50-35-1 THALIDOMIDE ADVERSE_EFFECT NEU_3_Vertigo 50-35-1 THALIDOMIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 50-35-1 THALIDOMIDE TISSUE_TOXICITY Hematuria 50-35-1 THALIDOMIDE MESH_LEVEL_3 Piperidines 50-35-1 THALIDOMIDE TA_LEVEL_3 leprosy 118409-57-7 TYRPHOSTIN A23 MODE_CLASS Receptor tyrosine kinase inhibitor 118409-57-7 TYRPHOSTIN A23 MECHANISM Modulate signal transduction 118409-57-7 TYRPHOSTIN A23 PRODUCT_CLASS Biochemicals 37762-06-4 ZAPRINAST PRODUCT_CLASS Cardiovasculars 37762-06-4 ZAPRINAST PRODUCT_CLASS Respiratory System 37762-06-4 ZAPRINAST MECHANISM Enhance kinase mediated signal transduction 37762-06-4 ZAPRINAST STRUCTURE_ACTIVITY PDE5 inhibitor 37762-06-4 ZAPRINAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 37762-06-4 ZAPRINAST THERAPEUTIC_CLASS Vasodilators 37762-06-4 ZAPRINAST MODE_CLASS Enzyme Inhibitor, selective 29925-17-5 RO 20-1724 INDICATION Chronic Obstructive Pulmonary Disease (COPD) 29925-17-5 RO 20-1724 INDICATION Asthma 29925-17-5 RO 20-1724 PRODUCT_CLASS Respiratory System 29925-17-5 RO 20-1724 MODE_CLASS Enzyme Inhibitor, selective 29925-17-5 RO 20-1724 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 29925-17-5 RO 20-1724 MECHANISM Enhance kinase mediated signal transduction 153190-29-5 TIRILAZAD STRUCTURE_ACTIVITY H2O2 radical scavenger 153190-29-5 TIRILAZAD THERAPEUTIC_CLASS Cerebral Vascular Disorders 153190-29-5 TIRILAZAD INDICATION Preventing Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage 153190-29-5 TIRILAZAD PRODUCT_CLASS Central Nervous System (CNS) 110101-66-1 TIRILAZAD PRODUCT_CLASS Central Nervous System (CNS) 110101-66-1 TIRILAZAD INDICATION Preventing Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage 110101-66-1 TIRILAZAD STRUCTURE_ACTIVITY H2O2 radical scavenger 110101-66-1 TIRILAZAD THERAPEUTIC_CLASS Cerebral Vascular Disorders 33069-62-4 PACLITAXEL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 33069-62-4 PACLITAXEL ADVERSE_EFFECT CVS_3_Abnormal ECG 33069-62-4 PACLITAXEL INDICATION AIDS-Related Kaposi's Sarcoma 33069-62-4 PACLITAXEL PRODUCT_CLASS Anti-cancers 33069-62-4 PACLITAXEL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 33069-62-4 PACLITAXEL ADVERSE_EFFECT XXX_2_Infection 33069-62-4 PACLITAXEL ADVERSE_EFFECT BBM_1_Leukopenia 33069-62-4 PACLITAXEL ADVERSE_EFFECT BBM_1_Neutropenia 33069-62-4 PACLITAXEL TISSUE_TOXICITY Neutropenia 33069-62-4 PACLITAXEL TISSUE_TOXICITY Hypotension 33069-62-4 PACLITAXEL INDICATION Non-Small Cell Lung Carcinoma 33069-62-4 PACLITAXEL ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 33069-62-4 PACLITAXEL TISSUE_TOXICITY Hepatic Toxicity 33069-62-4 PACLITAXEL KNOWN_TOXICITY Cardiovascular Toxicity 33069-62-4 PACLITAXEL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 33069-62-4 PACLITAXEL ADVERSE_EFFECT CVS_3_Hypotension 33069-62-4 PACLITAXEL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 33069-62-4 PACLITAXEL ADVERSE_EFFECT BBM_2_Bleeding 33069-62-4 PACLITAXEL ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 33069-62-4 PACLITAXEL INDICATION Breast Cancer / Carcinoma of the Breast 33069-62-4 PACLITAXEL THERAPEUTIC_CLASS Antineoplastics 33069-62-4 PACLITAXEL MECHANISM Inhibit mitosis 33069-62-4 PACLITAXEL ADVERSE_EFFECT GIS_2_Diarrhea 33069-62-4 PACLITAXEL ADVERSE_EFFECT BBM_1_Anemia 33069-62-4 PACLITAXEL ADVERSE_EFFECT BBM_2_Thrombocytopenia 33069-62-4 PACLITAXEL ADVERSE_EFFECT LIV_2_Hepatic Toxicity 33069-62-4 PACLITAXEL TISSUE_TOXICITY Anemia 33069-62-4 PACLITAXEL KNOWN_TOXICITY Hepatotoxicity 33069-62-4 PACLITAXEL INDICATION Ovarian Cancer / Carcinoma of the Ovary 33069-62-4 PACLITAXEL ADVERSE_EFFECT CVS_3_Bradycardia 33069-62-4 PACLITAXEL ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 33069-62-4 PACLITAXEL ADVERSE_EFFECT MSK_2_Arthralgia 33069-62-4 PACLITAXEL ADVERSE_EFFECT MSK_2_Myalgia 33069-62-4 PACLITAXEL ADVERSE_EFFECT XXX_2_Mucositis 33069-62-4 PACLITAXEL STRUCTURE_ACTIVITY Tubulin binder 33069-62-4 PACLITAXEL TISSUE_TOXICITY Leukopenia 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT XXX_3_Weight Loss 59865-13-3 CYCLOSPORIN A TA_LEVEL_2 Immune Response / Immunomodulators 59865-13-3 CYCLOSPORIN A MECH_LEVEL_2 Immunosuppressants 59865-13-3 CYCLOSPORIN A MECH_LEVEL_3 Serine/threonine specific protein phosphatase 59865-13-3 CYCLOSPORIN A MECH_LEVEL_1 Immunomodulation 59865-13-3 CYCLOSPORIN A INDICATION Prophylaxis of Organ Transplant Rejection 59865-13-3 CYCLOSPORIN A MECHANISM Modulate G-protein coupled signal transduction 59865-13-3 CYCLOSPORIN A MESH_LEVEL_2 Peptides 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT PSY_2_Anorexia 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT BBM_2_Thrombocytopenia 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT IMU_2_Allergic Reactions 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT PSY_3_Depression 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT GIS_3_Pancreatitis 59865-13-3 CYCLOSPORIN A ACTIVITY_CLASS Inhibit calcineurin as a drug-immunophilin complex 59865-13-3 CYCLOSPORIN A MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 59865-13-3 CYCLOSPORIN A PRODUCT_CLASS Immune Response / Immunomodulators 59865-13-3 CYCLOSPORIN A THERAPEUTIC_CLASS Immunosuppressants 59865-13-3 CYCLOSPORIN A KNOWN_TOXICITY Cardiovascular Toxicity 59865-13-3 CYCLOSPORIN A TISSUE_TOXICITY Myocardial Infarction 59865-13-3 CYCLOSPORIN A ZERO_CLASS N 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT OTO_2_Tinnitus 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT NEU_3_Tingling 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT KID_1_Renal Dysfunction 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT PSY_3_Anxiety 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT CVS_3_Myocardial Infarction 59865-13-3 CYCLOSPORIN A TA_LEVEL_1 Anti-inflammatory 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT OTO_2_Hearing Loss 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT BBM_2_Anemia 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT CVS_3_Chest Pain 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT XXX_3_Weakness 59865-13-3 CYCLOSPORIN A STRUCTURE_ACTIVITY Inhibits T-cell activation 59865-13-3 CYCLOSPORIN A MODE_CLASS Enzyme Inhibitor 59865-13-3 CYCLOSPORIN A MESH_LEVEL_3 Peptides, Cyclic 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT NEU_1_Tremor 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT GIS_1_Gingival Hypertrophy 59865-13-3 CYCLOSPORIN A ADVERSE_EFFECT CVS_1_Hypertension 59-05-2 METHOTREXATE THERAPEUTIC_CLASS Immunosuppressants 59-05-2 METHOTREXATE TISSUE_TOXICITY Hepatotoxicity 59-05-2 METHOTREXATE TA_LEVEL_2 Solid and soft Tumors 59-05-2 METHOTREXATE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 59-05-2 METHOTREXATE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 59-05-2 METHOTREXATE INDICATION Rheumatoid Arthritis 59-05-2 METHOTREXATE THERAPEUTIC_CLASS Antineoplastics 59-05-2 METHOTREXATE INDICATION Head and Neck Cancer 59-05-2 METHOTREXATE ADVERSE_EFFECT CVS_2_Hypotension 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Vomiting 59-05-2 METHOTREXATE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 59-05-2 METHOTREXATE ADVERSE_EFFECT SKN_2_Toxic Epidermal Necrolysis 59-05-2 METHOTREXATE ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 59-05-2 METHOTREXATE ADVERSE_EFFECT KID_3_Hematuria 59-05-2 METHOTREXATE ADVERSE_EFFECT KID_3_Renal Failure 59-05-2 METHOTREXATE ADVERSE_EFFECT MSK_3_Osteonecrosis 59-05-2 METHOTREXATE TISSUE_TOXICITY Hypotension 59-05-2 METHOTREXATE MODE_CLASS Enzyme substrate mimic 59-05-2 METHOTREXATE MESH_LEVEL_3 Pteridines 59-05-2 METHOTREXATE PRODUCT_CLASS Immune Response / Immunomodulators 59-05-2 METHOTREXATE INDICATION Breast Cancer / Carcinoma of the Breast 59-05-2 METHOTREXATE MECH_LEVEL_2 Impaired Folic synthesis 59-05-2 METHOTREXATE STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 59-05-2 METHOTREXATE TISSUE_TOXICITY Liver Cirrhosis 59-05-2 METHOTREXATE KNOWN_TOXICITY Nephrotoxicity 59-05-2 METHOTREXATE ADVERSE_EFFECT OCU_3_Blurred Vision 59-05-2 METHOTREXATE INDICATION Leukemia 59-05-2 METHOTREXATE INDICATION Lymphosarcoma 59-05-2 METHOTREXATE TA_LEVEL_3 Anti-proliferative 59-05-2 METHOTREXATE MECH_LEVEL_3 Dihydrofolate reductase 59-05-2 METHOTREXATE MESH_LEVEL_1 Heterocyclic Compounds 59-05-2 METHOTREXATE TA_LEVEL_1 Oncology 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Gingivitis 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Pancreatitis 59-05-2 METHOTREXATE ADVERSE_EFFECT LUN_2_Pulmonary Embolism 59-05-2 METHOTREXATE MECHANISM Inhibit precursor synthesis 59-05-2 METHOTREXATE ADVERSE_EFFECT BBM_2_Leukopenia 59-05-2 METHOTREXATE ADVERSE_EFFECT SKN_2_Stevens-Johnson Syndrome 59-05-2 METHOTREXATE ADVERSE_EFFECT NEU_3_Drowsiness 59-05-2 METHOTREXATE ADVERSE_EFFECT LUN_2_Dyspnea 59-05-2 METHOTREXATE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 59-05-2 METHOTREXATE KNOWN_TOXICITY Hepatotoxicity 59-05-2 METHOTREXATE TISSUE_TOXICITY Renal Failure 59-05-2 METHOTREXATE ADVERSE_EFFECT LUN_3_Upper Respiratory Tract Infection 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Stomatitis 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Hematemesis 59-05-2 METHOTREXATE ADVERSE_EFFECT MSK_3_Myalgia 59-05-2 METHOTREXATE ADVERSE_EFFECT BBM_2_Anemia 59-05-2 METHOTREXATE ADVERSE_EFFECT LUN_2_Cough 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Nausea 59-05-2 METHOTREXATE INDICATION Bladder Cancer / Carcinoma of the Bladder 59-05-2 METHOTREXATE INDICATION Choriocarcinoma / Trophoblastic Neoplasm 59-05-2 METHOTREXATE INDICATION Psoriasis 59-05-2 METHOTREXATE INDICATION Burkitt's Lymphoma 59-05-2 METHOTREXATE PRODUCT_CLASS Anti-cancers 59-05-2 METHOTREXATE MECH_LEVEL_1 Immunomodulation 59-05-2 METHOTREXATE ZERO_CLASS N 59-05-2 METHOTREXATE KNOWN_TOXICITY Cardiovascular Toxicity 59-05-2 METHOTREXATE ADVERSE_EFFECT BBM_2_Thrombocytopenia 59-05-2 METHOTREXATE ADVERSE_EFFECT LIV_2_Hepatotoxicity 59-05-2 METHOTREXATE ADVERSE_EFFECT NEU_2_Headache 59-05-2 METHOTREXATE TISSUE_TOXICITY Hematuria 59-05-2 METHOTREXATE ADVERSE_EFFECT XXX_2_Pharyngitis 59-05-2 METHOTREXATE ADVERSE_EFFECT GIS_2_Melena 59-05-2 METHOTREXATE ADVERSE_EFFECT BBM_2_Bone Marrow Depression 64-86-8 COLCHICINE ADVERSE_EFFECT NEU_2_Paralytic Ileus 64-86-8 COLCHICINE ADVERSE_EFFECT KID_3_Acute Renal Failure 64-86-8 COLCHICINE INDICATION Amyloidosis 64-86-8 COLCHICINE ADVERSE_EFFECT KID_3_Anuria 64-86-8 COLCHICINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 64-86-8 COLCHICINE TISSUE_TOXICITY Anuria 64-86-8 COLCHICINE THERAPEUTIC_CLASS Gout-Related Agents 64-86-8 COLCHICINE INDICATION Primary Biliary Cirrhosis 64-86-8 COLCHICINE INDICATION Sarcoidosis 64-86-8 COLCHICINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 64-86-8 COLCHICINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 64-86-8 COLCHICINE INDICATION Pseudogout (Calcium Pyrophosphate Dihydrate Deposition Disease) 64-86-8 COLCHICINE ADVERSE_EFFECT KID_3_Proteinuria 64-86-8 COLCHICINE STRUCTURE_ACTIVITY Tubulin binder, colchicinoid 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Bone Marrow Suppression 64-86-8 COLCHICINE ADVERSE_EFFECT GIS_1_Abdominal Pain 64-86-8 COLCHICINE ADVERSE_EFFECT MSK_3_Myopathy 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Pancytopenia 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 64-86-8 COLCHICINE MECHANISM Inhibit mitosis 64-86-8 COLCHICINE TISSUE_TOXICITY Acute Renal Failure 64-86-8 COLCHICINE KNOWN_TOXICITY Nephrotoxicity 64-86-8 COLCHICINE INDICATION Acute Gouty Arthritis 64-86-8 COLCHICINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 64-86-8 COLCHICINE INDICATION Cirrhosis 64-86-8 COLCHICINE INDICATION Chronic Gout 64-86-8 COLCHICINE INDICATION Behcet's Syndrome 64-86-8 COLCHICINE INDICATION Pericarditis 64-86-8 COLCHICINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 64-86-8 COLCHICINE ADVERSE_EFFECT IMU_2_Hypersensitivity 64-86-8 COLCHICINE ADVERSE_EFFECT PSY_2_Anorexia 64-86-8 COLCHICINE ADVERSE_EFFECT END_3_Hypothyroidism 64-86-8 COLCHICINE ADVERSE_EFFECT NEU_3_Peripheral Neuritis 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 64-86-8 COLCHICINE ADVERSE_EFFECT IMU_2_Urticaria 64-86-8 COLCHICINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 64-86-8 COLCHICINE ADVERSE_EFFECT GIS_1_Diarrhea 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Agranulocytosis 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Leukopenia 64-86-8 COLCHICINE ADVERSE_EFFECT BBM_3_Neutropenia 33419-42-0 ETOPOSIDE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Anemia 33419-42-0 ETOPOSIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 33419-42-0 ETOPOSIDE ADVERSE_EFFECT IMU_2_Allergic Reactions 33419-42-0 ETOPOSIDE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 33419-42-0 ETOPOSIDE ADVERSE_EFFECT IMU_3_Angioedema 33419-42-0 ETOPOSIDE ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 33419-42-0 ETOPOSIDE ADVERSE_EFFECT LUN_3_Laryngeal Edema 33419-42-0 ETOPOSIDE INDICATION Neuroblastoma 33419-42-0 ETOPOSIDE TA_LEVEL_3 Solid and soft Tumors 33419-42-0 ETOPOSIDE INDICATION Lung Cancer / Carcinoma of the Lung 33419-42-0 ETOPOSIDE INDICATION Ovarian Cancer / Carcinoma of the Ovary 33419-42-0 ETOPOSIDE KNOWN_TOXICITY Hepatotoxicity 33419-42-0 ETOPOSIDE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Hepatotoxicity 33419-42-0 ETOPOSIDE KNOWN_TOXICITY Mutagenicity 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Mutagenicity 33419-42-0 ETOPOSIDE ADVERSE_EFFECT DNA_3_Mutagenicity 33419-42-0 ETOPOSIDE ADVERSE_EFFECT CVS_2_Hypotension 33419-42-0 ETOPOSIDE ADVERSE_EFFECT XXX_1_Decreased Appetite 33419-42-0 ETOPOSIDE ADVERSE_EFFECT SKN_2_Pruritis 33419-42-0 ETOPOSIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 33419-42-0 ETOPOSIDE ADVERSE_EFFECT CVS_3_Phlebitis 33419-42-0 ETOPOSIDE ADVERSE_EFFECT LUN_3_Wheezing 33419-42-0 ETOPOSIDE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 33419-42-0 ETOPOSIDE MESH_LEVEL_3 Naphthalenes 33419-42-0 ETOPOSIDE INDICATION Acute Myelogenous (Myeloid) Leukemia (AML) 33419-42-0 ETOPOSIDE MODE_CLASS Enzyme Inhibitor 33419-42-0 ETOPOSIDE ADVERSE_EFFECT GIS_2_Diarrhea 33419-42-0 ETOPOSIDE ADVERSE_EFFECT XXX_2_Fatigue 33419-42-0 ETOPOSIDE ADVERSE_EFFECT END_3_Metabolic Acidosis 33419-42-0 ETOPOSIDE ADVERSE_EFFECT LUN_2_Shortness of Breath 33419-42-0 ETOPOSIDE ADVERSE_EFFECT BBM_1_Leukopenia 33419-42-0 ETOPOSIDE ADVERSE_EFFECT SKN_2_Skin Rash 33419-42-0 ETOPOSIDE INDICATION Ovarian Germ Cell Tumors 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Thrombocytopenia 33419-42-0 ETOPOSIDE STRUCTURE_ACTIVITY DNA topoisomerase II inhibitor 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Leukopenia 33419-42-0 ETOPOSIDE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 33419-42-0 ETOPOSIDE TA_LEVEL_2 toposiomerase inhibitors 33419-42-0 ETOPOSIDE INDICATION Small Cell Lung Carcinoma 33419-42-0 ETOPOSIDE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 33419-42-0 ETOPOSIDE INDICATION Testicular Cancer / Carcinoma of the Testis 33419-42-0 ETOPOSIDE MECH_LEVEL_3 DNA topoisomerase 33419-42-0 ETOPOSIDE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 33419-42-0 ETOPOSIDE ADVERSE_EFFECT NEU_3_Neurotoxicity 33419-42-0 ETOPOSIDE ADVERSE_EFFECT GIS_2_Stomatitis 33419-42-0 ETOPOSIDE ADVERSE_EFFECT BBM_1_Thrombocytopenia 33419-42-0 ETOPOSIDE ADVERSE_EFFECT BBM_1_Anemia 33419-42-0 ETOPOSIDE ADVERSE_EFFECT IMU_3_Anaphylaxis 33419-42-0 ETOPOSIDE ADVERSE_EFFECT GIS_1_Vomiting 33419-42-0 ETOPOSIDE ADVERSE_EFFECT CVS_3_Tachycardia 33419-42-0 ETOPOSIDE MECHANISM Inhibit DNA synthesis, repair, and function 33419-42-0 ETOPOSIDE ZERO_CLASS N 33419-42-0 ETOPOSIDE KNOWN_TOXICITY Carcinogenicity 33419-42-0 ETOPOSIDE INDICATION Neoplasm / Cancer / Tumor 33419-42-0 ETOPOSIDE INDICATION Non-Hodgkin's Lymphomas 33419-42-0 ETOPOSIDE TA_LEVEL_1 Oncology 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Carcinogenicity 33419-42-0 ETOPOSIDE INDICATION Wilms' Tumor 33419-42-0 ETOPOSIDE PRODUCT_CLASS Anti-cancers 33419-42-0 ETOPOSIDE MESH_LEVEL_1 Polycyclic Hydrocarbons 33419-42-0 ETOPOSIDE INDICATION Acute Lymphocytic Leukemia (ALL) 33419-42-0 ETOPOSIDE INDICATION AIDS-Related Kaposi's Sarcoma 33419-42-0 ETOPOSIDE THERAPEUTIC_CLASS Antineoplastics 33419-42-0 ETOPOSIDE TISSUE_TOXICITY Hypotension 33419-42-0 ETOPOSIDE KNOWN_TOXICITY Cardiovascular Toxicity 33419-42-0 ETOPOSIDE ADVERSE_EFFECT GIS_1_Nausea 104987-11-3 TACROLIMUS MECH_LEVEL_3 Serine/threonine specific protein phosphatase 104987-11-3 TACROLIMUS PRODUCT_CLASS Dermatologicals 104987-11-3 TACROLIMUS MECH_LEVEL_1 Immunomodulation 104987-11-3 TACROLIMUS TISSUE_TOXICITY Congestive Heart Failure 104987-11-3 TACROLIMUS TISSUE_TOXICITY Lymphoma 104987-11-3 TACROLIMUS ADVERSE_EFFECT IMU_2_Anaphylaxis 104987-11-3 TACROLIMUS ADVERSE_EFFECT KID_2_Nephrotic Syndrome 104987-11-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Constipation 104987-11-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Diarrhea 104987-11-3 TACROLIMUS ADVERSE_EFFECT NEU_1_Headache 104987-11-3 TACROLIMUS ZERO_CLASS N 104987-11-3 TACROLIMUS ADVERSE_EFFECT NEU_2_Neurotoxicity 104987-11-3 TACROLIMUS ADVERSE_EFFECT DNA_3_Lymphoma 104987-11-3 TACROLIMUS ADVERSE_EFFECT NEU_2_Paralytic Ileus 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Cerebrovascular Accident 104987-11-3 TACROLIMUS TISSUE_TOXICITY Carcinogenicity 104987-11-3 TACROLIMUS TISSUE_TOXICITY Angina Pectoris 104987-11-3 TACROLIMUS TISSUE_TOXICITY Acute Renal Failure 104987-11-3 TACROLIMUS KNOWN_TOXICITY Nephrotoxicity 104987-11-3 TACROLIMUS INDICATION Prevention of Graft Rejection 104987-11-3 TACROLIMUS ACTIVITY_CLASS Inhibit calcineurin as a drug-immunophilin complex 104987-11-3 TACROLIMUS TA_LEVEL_1 Anti-inflammatory 104987-11-3 TACROLIMUS ADVERSE_EFFECT DNA_3_Carcinogenicity 104987-11-3 TACROLIMUS ADVERSE_EFFECT KID_2_Nephrotoxicity 104987-11-3 TACROLIMUS ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 104987-11-3 TACROLIMUS ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 104987-11-3 TACROLIMUS STRUCTURE_ACTIVITY Inhibits T-cell activation 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Congestive Heart Failure 104987-11-3 TACROLIMUS ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 104987-11-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Nausea 104987-11-3 TACROLIMUS ADVERSE_EFFECT NEU_1_Tremor 104987-11-3 TACROLIMUS THERAPEUTIC_CLASS Immunosuppressants 104987-11-3 TACROLIMUS TISSUE_TOXICITY Cerebrovascular Accident 104987-11-3 TACROLIMUS TISSUE_TOXICITY Nephrotic Syndrome 104987-11-3 TACROLIMUS KNOWN_TOXICITY Cardiovascular Toxicity 104987-11-3 TACROLIMUS MODE_CLASS Enzyme Inhibitor 104987-11-3 TACROLIMUS INDICATION Atopic Dermatitis / Eczema 104987-11-3 TACROLIMUS INDICATION Transplant Rejection 104987-11-3 TACROLIMUS INDICATION Myasthenia Gravis 104987-11-3 TACROLIMUS MESH_LEVEL_1 Organic Chemicals 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_1_Hypertension 104987-11-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Vomiting 104987-11-3 TACROLIMUS ADVERSE_EFFECT PSY_1_Insomnia 104987-11-3 TACROLIMUS MECHANISM Modulate G-protein coupled signal transduction 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_3_Myocardial Hypertrophy 104987-11-3 TACROLIMUS ADVERSE_EFFECT BBM_2_Leukopenia 104987-11-3 TACROLIMUS ADVERSE_EFFECT LUN_2_Acute Respiratory Distress 104987-11-3 TACROLIMUS ADVERSE_EFFECT XXX_2_Hemolytic-Uremic Syndrome 104987-11-3 TACROLIMUS KNOWN_TOXICITY Carcinogenicity 104987-11-3 TACROLIMUS ADVERSE_EFFECT GIS_3_Pancreatitis 104987-11-3 TACROLIMUS MESH_LEVEL_3 Macrolides 104987-11-3 TACROLIMUS TISSUE_TOXICITY Cardiac Arrhythmia 104987-11-3 TACROLIMUS TISSUE_TOXICITY Nephrotoxicity 104987-11-3 TACROLIMUS ADVERSE_EFFECT NEU_3_Encephalopathy 104987-11-3 TACROLIMUS ADVERSE_EFFECT BBM_2_Pancytopenia 104987-11-3 TACROLIMUS ADVERSE_EFFECT XXX_1_Infection 104987-11-3 TACROLIMUS ADVERSE_EFFECT END_1_Diabetes Mellitus 104987-11-3 TACROLIMUS ADVERSE_EFFECT ELT_2_Electrolyte Imbalance 104987-11-3 TACROLIMUS ADVERSE_EFFECT NEU_2_Paresthesia 104987-11-3 TACROLIMUS ADVERSE_EFFECT PSY_1_Anorexia 104987-11-3 TACROLIMUS ADVERSE_EFFECT KID_2_Acute Renal Failure 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Angina Pectoris 104987-11-3 TACROLIMUS MECH_LEVEL_2 Immunosuppressants 104987-11-3 TACROLIMUS MESH_LEVEL_2 Lactones 104987-11-3 TACROLIMUS TA_LEVEL_2 Immune Response / Immunomodulators 104987-11-3 TACROLIMUS PRODUCT_CLASS Immune Response / Immunomodulators 104987-11-3 TACROLIMUS ADVERSE_EFFECT CVS_3_Pericardial Effusion 109581-93-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Diarrhea 109581-93-3 TACROLIMUS ADVERSE_EFFECT PSY_1_Insomnia 109581-93-3 TACROLIMUS MECHANISM Modulate G-protein coupled signal transduction 109581-93-3 TACROLIMUS ADVERSE_EFFECT IMU_2_Anaphylaxis 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_3_Myocardial Hypertrophy 109581-93-3 TACROLIMUS ADVERSE_EFFECT BBM_2_Leukopenia 109581-93-3 TACROLIMUS ADVERSE_EFFECT LUN_2_Acute Respiratory Distress 109581-93-3 TACROLIMUS ADVERSE_EFFECT XXX_2_Hemolytic-Uremic Syndrome 109581-93-3 TACROLIMUS KNOWN_TOXICITY Carcinogenicity 109581-93-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Constipation 109581-93-3 TACROLIMUS ADVERSE_EFFECT KID_2_Nephrotic Syndrome 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_3_Pericardial Effusion 109581-93-3 TACROLIMUS TISSUE_TOXICITY Angina Pectoris 109581-93-3 TACROLIMUS TISSUE_TOXICITY Lymphoma 109581-93-3 TACROLIMUS TISSUE_TOXICITY Congestive Heart Failure 109581-93-3 TACROLIMUS MECH_LEVEL_1 Immunomodulation 109581-93-3 TACROLIMUS PRODUCT_CLASS Dermatologicals 109581-93-3 TACROLIMUS MECH_LEVEL_3 Serine/threonine specific protein phosphatase 109581-93-3 TACROLIMUS PRODUCT_CLASS Immune Response / Immunomodulators 109581-93-3 TACROLIMUS TA_LEVEL_2 Immune Response / Immunomodulators 109581-93-3 TACROLIMUS TISSUE_TOXICITY Carcinogenicity 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Cerebrovascular Accident 109581-93-3 TACROLIMUS ADVERSE_EFFECT NEU_2_Paralytic Ileus 109581-93-3 TACROLIMUS ADVERSE_EFFECT DNA_3_Lymphoma 109581-93-3 TACROLIMUS ADVERSE_EFFECT NEU_2_Neurotoxicity 109581-93-3 TACROLIMUS MESH_LEVEL_1 Organic Chemicals 109581-93-3 TACROLIMUS ZERO_CLASS N 109581-93-3 TACROLIMUS ADVERSE_EFFECT NEU_1_Headache 109581-93-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Vomiting 109581-93-3 TACROLIMUS MESH_LEVEL_2 Lactones 109581-93-3 TACROLIMUS INDICATION Transplant Rejection 109581-93-3 TACROLIMUS MECH_LEVEL_2 Immunosuppressants 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Angina Pectoris 109581-93-3 TACROLIMUS ADVERSE_EFFECT KID_2_Acute Renal Failure 109581-93-3 TACROLIMUS ADVERSE_EFFECT PSY_1_Anorexia 109581-93-3 TACROLIMUS ADVERSE_EFFECT NEU_2_Paresthesia 109581-93-3 TACROLIMUS ADVERSE_EFFECT ELT_2_Electrolyte Imbalance 109581-93-3 TACROLIMUS ADVERSE_EFFECT END_1_Diabetes Mellitus 109581-93-3 TACROLIMUS ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 109581-93-3 TACROLIMUS ADVERSE_EFFECT GIS_3_Pancreatitis 109581-93-3 TACROLIMUS ADVERSE_EFFECT KID_2_Nephrotoxicity 109581-93-3 TACROLIMUS ADVERSE_EFFECT DNA_3_Carcinogenicity 109581-93-3 TACROLIMUS TA_LEVEL_1 Anti-inflammatory 109581-93-3 TACROLIMUS ACTIVITY_CLASS Inhibit calcineurin as a drug-immunophilin complex 109581-93-3 TACROLIMUS INDICATION Prevention of Graft Rejection 109581-93-3 TACROLIMUS KNOWN_TOXICITY Nephrotoxicity 109581-93-3 TACROLIMUS TISSUE_TOXICITY Acute Renal Failure 109581-93-3 TACROLIMUS ADVERSE_EFFECT XXX_1_Infection 109581-93-3 TACROLIMUS ADVERSE_EFFECT BBM_2_Pancytopenia 109581-93-3 TACROLIMUS ADVERSE_EFFECT NEU_3_Encephalopathy 109581-93-3 TACROLIMUS TISSUE_TOXICITY Nephrotoxicity 109581-93-3 TACROLIMUS INDICATION Atopic Dermatitis / Eczema 109581-93-3 TACROLIMUS TISSUE_TOXICITY Cardiac Arrhythmia 109581-93-3 TACROLIMUS MESH_LEVEL_3 Macrolides 109581-93-3 TACROLIMUS INDICATION Myasthenia Gravis 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_1_Hypertension 109581-93-3 TACROLIMUS MODE_CLASS Enzyme Inhibitor 109581-93-3 TACROLIMUS KNOWN_TOXICITY Cardiovascular Toxicity 109581-93-3 TACROLIMUS TISSUE_TOXICITY Nephrotic Syndrome 109581-93-3 TACROLIMUS TISSUE_TOXICITY Cerebrovascular Accident 109581-93-3 TACROLIMUS THERAPEUTIC_CLASS Immunosuppressants 109581-93-3 TACROLIMUS ADVERSE_EFFECT NEU_1_Tremor 109581-93-3 TACROLIMUS ADVERSE_EFFECT GIS_1_Nausea 109581-93-3 TACROLIMUS ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 109581-93-3 TACROLIMUS ADVERSE_EFFECT CVS_2_Congestive Heart Failure 109581-93-3 TACROLIMUS STRUCTURE_ACTIVITY Inhibits T-cell activation 109581-93-3 TACROLIMUS ADVERSE_EFFECT BBM_3_Thrombocytopenic Purpura 52214-84-3 CIPROFIBRATE INDICATION Hypertriglyceridemia 52214-84-3 CIPROFIBRATE PRODUCT_CLASS Cardiovasculars 52214-84-3 CIPROFIBRATE INDICATION Hyperlipoproteinemia 52214-84-3 CIPROFIBRATE STRUCTURE_ACTIVITY PPAR alpha agonist, fibric acid 52214-84-3 CIPROFIBRATE MODE_CLASS Receptor Agonist, selective 52214-84-3 CIPROFIBRATE THERAPEUTIC_CLASS Hypolipidemic Agents 52214-84-3 CIPROFIBRATE INDICATION Hypercholesterolemia 52214-84-3 CIPROFIBRATE INDICATION Mixed Dyslipidemia 52214-84-3 CIPROFIBRATE MECHANISM Increase lipid catabolism 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT PSY_2_Confusion 113-92-8 DEXCHLORPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 113-92-8 DEXCHLORPHENIRAMINE ACTIVITY_CLASS Histamine antagonist 113-92-8 DEXCHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 113-92-8 DEXCHLORPHENIRAMINE MESH_LEVEL_3 Pyridines 113-92-8 DEXCHLORPHENIRAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 113-92-8 DEXCHLORPHENIRAMINE INDICATION Allergic Rhinitis 113-92-8 DEXCHLORPHENIRAMINE INDICATION Pruritus / Itching 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Restlessness 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT SKN_2_Skin Rash 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT GIS_2_Dry Mouth 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 113-92-8 DEXCHLORPHENIRAMINE MECH_LEVEL_3 histamine receptor H1 113-92-8 DEXCHLORPHENIRAMINE MESH_LEVEL_1 Heterocyclic Compounds 113-92-8 DEXCHLORPHENIRAMINE INDICATION Urticaria / Hives 113-92-8 DEXCHLORPHENIRAMINE INDICATION Nasal Congestion 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 113-92-8 DEXCHLORPHENIRAMINE TA_LEVEL_1 Anti-inflammatory 113-92-8 DEXCHLORPHENIRAMINE MECH_LEVEL_2 Anti-histamine 113-92-8 DEXCHLORPHENIRAMINE TA_LEVEL_2 Anti-histamine 113-92-8 DEXCHLORPHENIRAMINE INDICATION Dermatographism 113-92-8 DEXCHLORPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 113-92-8 DEXCHLORPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 113-92-8 DEXCHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 113-92-8 DEXCHLORPHENIRAMINE ZERO_CLASS N 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_3_Sweating 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Decreased Appetite 113-92-8 DEXCHLORPHENIRAMINE INDICATION Allergic Conjunctivitis 113-92-8 DEXCHLORPHENIRAMINE INDICATION Anaphylaxis 113-92-8 DEXCHLORPHENIRAMINE MECH_LEVEL_1 Immunomodulation 113-92-8 DEXCHLORPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_Nightmares 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_1_Thickening of Mucus 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Tachycardia 113-92-8 DEXCHLORPHENIRAMINE ADVERSE_EFFECT NEU_2_Dizziness 25523-97-1 DEXCHLORPHENIRAMINE MESH_LEVEL_3 Pyridines 25523-97-1 DEXCHLORPHENIRAMINE MECH_LEVEL_2 Anti-histamine 25523-97-1 DEXCHLORPHENIRAMINE TA_LEVEL_2 Anti-histamine 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Allergic Conjunctivitis 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Anaphylaxis 25523-97-1 DEXCHLORPHENIRAMINE MECH_LEVEL_1 Immunomodulation 25523-97-1 DEXCHLORPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_Nightmares 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_1_Thickening of Mucus 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Tachycardia 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Dermatographism 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT NEU_2_Dizziness 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT PSY_2_Confusion 25523-97-1 DEXCHLORPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 25523-97-1 DEXCHLORPHENIRAMINE ACTIVITY_CLASS Histamine antagonist 25523-97-1 DEXCHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 25523-97-1 DEXCHLORPHENIRAMINE ZERO_CLASS N 25523-97-1 DEXCHLORPHENIRAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_3_Sweating 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Pruritus / Itching 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Restlessness 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT SKN_2_Skin Rash 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT GIS_2_Dry Mouth 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 25523-97-1 DEXCHLORPHENIRAMINE MECH_LEVEL_3 histamine receptor H1 25523-97-1 DEXCHLORPHENIRAMINE MESH_LEVEL_1 Heterocyclic Compounds 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Urticaria / Hives 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Nasal Congestion 25523-97-1 DEXCHLORPHENIRAMINE INDICATION Allergic Rhinitis 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Decreased Appetite 25523-97-1 DEXCHLORPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 25523-97-1 DEXCHLORPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 25523-97-1 DEXCHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 25523-97-1 DEXCHLORPHENIRAMINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 25523-97-1 DEXCHLORPHENIRAMINE TA_LEVEL_1 Anti-inflammatory 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT GUS_3_Difficulty Urinating 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT GIS_2_Dry Mouth 2438-32-6 DEXCHLORPHENIRAMINE TA_LEVEL_1 Anti-inflammatory 2438-32-6 DEXCHLORPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 2438-32-6 DEXCHLORPHENIRAMINE MECH_LEVEL_2 Anti-histamine 2438-32-6 DEXCHLORPHENIRAMINE TA_LEVEL_2 Anti-histamine 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Dermatographism 2438-32-6 DEXCHLORPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 2438-32-6 DEXCHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 2438-32-6 DEXCHLORPHENIRAMINE ZERO_CLASS N 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_3_Sweating 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Allergic Conjunctivitis 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Anaphylaxis 2438-32-6 DEXCHLORPHENIRAMINE MECH_LEVEL_1 Immunomodulation 2438-32-6 DEXCHLORPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_Nightmares 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_1_Thickening of Mucus 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Tachycardia 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT NEU_2_Dizziness 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT PSY_2_Confusion 2438-32-6 DEXCHLORPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 2438-32-6 DEXCHLORPHENIRAMINE ACTIVITY_CLASS Histamine antagonist 2438-32-6 DEXCHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 2438-32-6 DEXCHLORPHENIRAMINE MESH_LEVEL_3 Pyridines 2438-32-6 DEXCHLORPHENIRAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Allergic Rhinitis 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Pruritus / Itching 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Restlessness 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT SKN_2_Skin Rash 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Decreased Appetite 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 2438-32-6 DEXCHLORPHENIRAMINE MECH_LEVEL_3 histamine receptor H1 2438-32-6 DEXCHLORPHENIRAMINE MESH_LEVEL_1 Heterocyclic Compounds 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Urticaria / Hives 2438-32-6 DEXCHLORPHENIRAMINE INDICATION Nasal Congestion 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 2438-32-6 DEXCHLORPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 2074-53-5 VITAMIN E MECHANISM Scavenges hydrogen peroxide and free radicals 2074-53-5 VITAMIN E INDICATION Vitamin E Deficiency 2074-53-5 VITAMIN E ADVERSE_EFFECT XXX_2_Fatigue 2074-53-5 VITAMIN E INDICATION Hemolytic Anemias 2074-53-5 VITAMIN E ADVERSE_EFFECT GIS_1_Nausea 2074-53-5 VITAMIN E ADVERSE_EFFECT MSK_2_Myopathy 2074-53-5 VITAMIN E ADVERSE_EFFECT CVS_2_Thrombophlebitis 2074-53-5 VITAMIN E ADVERSE_EFFECT GIS_1_Diarrhea 2074-53-5 VITAMIN E INDICATION Heavy Metal Poisoning 2074-53-5 VITAMIN E MODE_CLASS Enzyme Inhibitor 2074-53-5 VITAMIN E ADVERSE_EFFECT GIS_1_Flatulence 2074-53-5 VITAMIN E ADVERSE_EFFECT CVS_2_Hypertension 2074-53-5 VITAMIN E THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 2074-53-5 VITAMIN E PRODUCT_CLASS Vitamins, Minerals and Nutrients 59-02-9 VITAMIN E MECHANISM Scavenges hydrogen peroxide and free radicals 59-02-9 VITAMIN E PRODUCT_CLASS Vitamins, Minerals and Nutrients 59-02-9 VITAMIN E ADVERSE_EFFECT CVS_2_Hypertension 59-02-9 VITAMIN E ADVERSE_EFFECT GIS_1_Flatulence 59-02-9 VITAMIN E INDICATION Vitamin E Deficiency 59-02-9 VITAMIN E ADVERSE_EFFECT GIS_1_Diarrhea 59-02-9 VITAMIN E ADVERSE_EFFECT MSK_2_Myopathy 59-02-9 VITAMIN E ADVERSE_EFFECT CVS_2_Thrombophlebitis 59-02-9 VITAMIN E MODE_CLASS Enzyme Inhibitor 59-02-9 VITAMIN E ADVERSE_EFFECT GIS_1_Nausea 59-02-9 VITAMIN E INDICATION Hemolytic Anemias 59-02-9 VITAMIN E ADVERSE_EFFECT XXX_2_Fatigue 59-02-9 VITAMIN E THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 59-02-9 VITAMIN E INDICATION Heavy Metal Poisoning 58-95-7 VITAMIN E INDICATION Vitamin E Deficiency 58-95-7 VITAMIN E MODE_CLASS Enzyme Inhibitor 58-95-7 VITAMIN E ADVERSE_EFFECT GIS_1_Flatulence 58-95-7 VITAMIN E ADVERSE_EFFECT CVS_2_Hypertension 58-95-7 VITAMIN E THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 58-95-7 VITAMIN E PRODUCT_CLASS Vitamins, Minerals and Nutrients 58-95-7 VITAMIN E MECHANISM Scavenges hydrogen peroxide and free radicals 58-95-7 VITAMIN E INDICATION Heavy Metal Poisoning 58-95-7 VITAMIN E ADVERSE_EFFECT GIS_1_Nausea 58-95-7 VITAMIN E INDICATION Hemolytic Anemias 58-95-7 VITAMIN E ADVERSE_EFFECT XXX_2_Fatigue 58-95-7 VITAMIN E ADVERSE_EFFECT GIS_1_Diarrhea 58-95-7 VITAMIN E ADVERSE_EFFECT CVS_2_Thrombophlebitis 58-95-7 VITAMIN E ADVERSE_EFFECT MSK_2_Myopathy 1406-70-8 VITAMIN E MODE_CLASS Enzyme Inhibitor 1406-70-8 VITAMIN E ADVERSE_EFFECT CVS_2_Thrombophlebitis 1406-70-8 VITAMIN E ADVERSE_EFFECT GIS_1_Diarrhea 1406-70-8 VITAMIN E THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 1406-70-8 VITAMIN E MECHANISM Scavenges hydrogen peroxide and free radicals 1406-70-8 VITAMIN E INDICATION Heavy Metal Poisoning 1406-70-8 VITAMIN E PRODUCT_CLASS Vitamins, Minerals and Nutrients 1406-70-8 VITAMIN E ADVERSE_EFFECT MSK_2_Myopathy 1406-70-8 VITAMIN E INDICATION Vitamin E Deficiency 1406-70-8 VITAMIN E ADVERSE_EFFECT GIS_1_Nausea 1406-70-8 VITAMIN E INDICATION Hemolytic Anemias 1406-70-8 VITAMIN E ADVERSE_EFFECT XXX_2_Fatigue 1406-70-8 VITAMIN E ADVERSE_EFFECT GIS_1_Flatulence 1406-70-8 VITAMIN E ADVERSE_EFFECT CVS_2_Hypertension 12741-00-3 VITAMIN E ADVERSE_EFFECT XXX_2_Fatigue 12741-00-3 VITAMIN E INDICATION Hemolytic Anemias 12741-00-3 VITAMIN E ADVERSE_EFFECT GIS_1_Nausea 12741-00-3 VITAMIN E INDICATION Heavy Metal Poisoning 12741-00-3 VITAMIN E MECHANISM Scavenges hydrogen peroxide and free radicals 12741-00-3 VITAMIN E PRODUCT_CLASS Vitamins, Minerals and Nutrients 12741-00-3 VITAMIN E THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 12741-00-3 VITAMIN E ADVERSE_EFFECT CVS_2_Hypertension 12741-00-3 VITAMIN E ADVERSE_EFFECT GIS_1_Flatulence 12741-00-3 VITAMIN E MODE_CLASS Enzyme Inhibitor 12741-00-3 VITAMIN E INDICATION Vitamin E Deficiency 12741-00-3 VITAMIN E ADVERSE_EFFECT CVS_2_Thrombophlebitis 12741-00-3 VITAMIN E ADVERSE_EFFECT MSK_2_Myopathy 12741-00-3 VITAMIN E ADVERSE_EFFECT GIS_1_Diarrhea 26243-95-8 VITAMIN E ADVERSE_EFFECT XXX_2_Fatigue 26243-95-8 VITAMIN E INDICATION Hemolytic Anemias 26243-95-8 VITAMIN E ADVERSE_EFFECT GIS_1_Nausea 26243-95-8 VITAMIN E ADVERSE_EFFECT MSK_2_Myopathy 26243-95-8 VITAMIN E INDICATION Heavy Metal Poisoning 26243-95-8 VITAMIN E ADVERSE_EFFECT GIS_1_Diarrhea 26243-95-8 VITAMIN E INDICATION Vitamin E Deficiency 26243-95-8 VITAMIN E MECHANISM Scavenges hydrogen peroxide and free radicals 26243-95-8 VITAMIN E MODE_CLASS Enzyme Inhibitor 26243-95-8 VITAMIN E ADVERSE_EFFECT GIS_1_Flatulence 26243-95-8 VITAMIN E PRODUCT_CLASS Vitamins, Minerals and Nutrients 26243-95-8 VITAMIN E ADVERSE_EFFECT CVS_2_Hypertension 26243-95-8 VITAMIN E THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 26243-95-8 VITAMIN E ADVERSE_EFFECT CVS_2_Thrombophlebitis 56420-45-2 EPIRUBICIN ADVERSE_EFFECT CVS_1_Congestive Heart Failure 56420-45-2 EPIRUBICIN ADVERSE_EFFECT DNA_3_Mutagenicity 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Myelosuppression 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Hemorrhage 56420-45-2 EPIRUBICIN THERAPEUTIC_CLASS Antineoplastics 56420-45-2 EPIRUBICIN TA_LEVEL_2 DNA damage 56420-45-2 EPIRUBICIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 56420-45-2 EPIRUBICIN ADVERSE_EFFECT GIS_2_Diarrhea 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Mutagenicity 56420-45-2 EPIRUBICIN ADVERSE_EFFECT REP_1_Amenorrhea 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_1_Myelosuppression 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 56420-45-2 EPIRUBICIN ADVERSE_EFFECT XXX_1_Infection 56420-45-2 EPIRUBICIN ADVERSE_EFFECT IMU_3_Anaphylaxis 56420-45-2 EPIRUBICIN ACTIVITY_CLASS DNA damager 56420-45-2 EPIRUBICIN KNOWN_TOXICITY Reproductive System Toxicity 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Carcinogenicity 56420-45-2 EPIRUBICIN ADVERSE_EFFECT KID_2_Hyperuricemia 56420-45-2 EPIRUBICIN ADVERSE_EFFECT XXX_2_Radiosensitization 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Neutropenia 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Cardiomyopathy 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Cardiotoxicity 56420-45-2 EPIRUBICIN MECHANISM Inhibit DNA synthesis, repair, and function 56420-45-2 EPIRUBICIN TA_LEVEL_3 Solid Tumors 56420-45-2 EPIRUBICIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 56420-45-2 EPIRUBICIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56420-45-2 EPIRUBICIN ADVERSE_EFFECT DNA_3_Clastogenicity 56420-45-2 EPIRUBICIN KNOWN_TOXICITY Carcinogenicity 56420-45-2 EPIRUBICIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 56420-45-2 EPIRUBICIN MESH_LEVEL_3 Aminoglycosides 56420-45-2 EPIRUBICIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Congestive Heart Failure 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Amenorrhea 56420-45-2 EPIRUBICIN ADVERSE_EFFECT REP_3_Testicular Atrophy 56420-45-2 EPIRUBICIN ADVERSE_EFFECT CVS_1_Cardiotoxicity 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_1_Leukopenia 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_1_Neutropenia 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_1_Hemorrhage 56420-45-2 EPIRUBICIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 56420-45-2 EPIRUBICIN KNOWN_TOXICITY Cardiovascular Toxicity 56420-45-2 EPIRUBICIN PRODUCT_CLASS Anti-cancers 56420-45-2 EPIRUBICIN TA_LEVEL_1 Oncology 56420-45-2 EPIRUBICIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 56420-45-2 EPIRUBICIN MECH_LEVEL_3 DNA damage 56420-45-2 EPIRUBICIN ADVERSE_EFFECT XXX_1_Local Tissue Necrosis 56420-45-2 EPIRUBICIN ZERO_CLASS N 56420-45-2 EPIRUBICIN MESH_LEVEL_2 Carbohydrates 56420-45-2 EPIRUBICIN INDICATION Breast Cancer / Carcinoma of the Breast 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Leukopenia 56420-45-2 EPIRUBICIN TISSUE_TOXICITY Clastogenicity 56420-45-2 EPIRUBICIN ADVERSE_EFFECT DNA_3_Carcinogenicity 56420-45-2 EPIRUBICIN STRUCTURE_ACTIVITY DNA intercalator, anthracycline 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_2_Anemia 56420-45-2 EPIRUBICIN ADVERSE_EFFECT CVS_1_Cardiomyopathy 56420-45-2 EPIRUBICIN ADVERSE_EFFECT BBM_2_Acute Leukemia 56420-45-2 EPIRUBICIN ADVERSE_EFFECT XXX_1_Mucositis 56420-45-2 EPIRUBICIN KNOWN_TOXICITY Mutagenicity 74772-77-3 CIGLITAZONE MECHANISM Increase transcription of insulin responsive gene 74772-77-3 CIGLITAZONE MECHANISM Increase lipid catabolism 74772-77-3 CIGLITAZONE INDICATION Type II Diabetes Mellitus 74772-77-3 CIGLITAZONE THERAPEUTIC_CLASS Antidiabetic Agents 74772-77-3 CIGLITAZONE MODE_CLASS Receptor Agonist 74772-77-3 CIGLITAZONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 74772-77-3 CIGLITAZONE STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 74011-58-8 ENOXACIN ADVERSE_EFFECT MSK_3_Myalgia 74011-58-8 ENOXACIN ADVERSE_EFFECT GIS_2_Dyspepsia 74011-58-8 ENOXACIN ADVERSE_EFFECT GIS_3_Flatulence 74011-58-8 ENOXACIN MESH_LEVEL_3 Quinolines 74011-58-8 ENOXACIN MECH_LEVEL_3 DNA gyrase 74011-58-8 ENOXACIN INDICATION Endocervical Gonorrhea 74011-58-8 ENOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 74011-58-8 ENOXACIN MODE_CLASS Enzyme Inhibitor, selective 74011-58-8 ENOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 74011-58-8 ENOXACIN ADVERSE_EFFECT GIS_3_Constipation 74011-58-8 ENOXACIN ADVERSE_EFFECT PSY_2_Anxiety 74011-58-8 ENOXACIN ADVERSE_EFFECT NEU_1_Headache 74011-58-8 ENOXACIN ADVERSE_EFFECT SKN_3_Pruritis 74011-58-8 ENOXACIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 74011-58-8 ENOXACIN ADVERSE_EFFECT CVS_3_Palpitation 74011-58-8 ENOXACIN ADVERSE_EFFECT XXX_3_Epistaxis 74011-58-8 ENOXACIN ZERO_CLASS N 74011-58-8 ENOXACIN MESH_LEVEL_1 Heterocyclic Compounds 74011-58-8 ENOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 74011-58-8 ENOXACIN INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 74011-58-8 ENOXACIN ADVERSE_EFFECT XXX_3_Fever 74011-58-8 ENOXACIN ADVERSE_EFFECT PSY_2_Insomnia 74011-58-8 ENOXACIN ADVERSE_EFFECT SKN_3_Rash 74011-58-8 ENOXACIN ADVERSE_EFFECT BBM_3_Leukopenia 74011-58-8 ENOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity 74011-58-8 ENOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 74011-58-8 ENOXACIN TA_LEVEL_2 Anti-bacterial 74011-58-8 ENOXACIN MECH_LEVEL_1 Anti-bacterial 74011-58-8 ENOXACIN INDICATION Urinary Tract Infection (UTI) 74011-58-8 ENOXACIN PRODUCT_CLASS Anti-infectives 74011-58-8 ENOXACIN TA_LEVEL_1 Infectious Disease 74011-58-8 ENOXACIN ADVERSE_EFFECT GIS_2_Diarrhea 74011-58-8 ENOXACIN ADVERSE_EFFECT PSY_2_Nervousness 74011-58-8 ENOXACIN ADVERSE_EFFECT OTO_3_Tinnitus 74011-58-8 ENOXACIN ADVERSE_EFFECT LUN_3_Dyspnea 74011-58-8 ENOXACIN ADVERSE_EFFECT NEU_1_Vertigo 74011-58-8 ENOXACIN ADVERSE_EFFECT GUS_3_Vaginal Moniliasis 74011-58-8 ENOXACIN MECHANISM Inhibit bacterial DNA synthesis 74011-58-8 ENOXACIN ADVERSE_EFFECT GIS_1_Nausea 74011-58-8 ENOXACIN TA_LEVEL_3 quinolones 74011-58-8 ENOXACIN THERAPEUTIC_CLASS Antibacterials 74011-58-8 ENOXACIN ADVERSE_EFFECT PSY_3_Depression 74011-58-8 ENOXACIN ADVERSE_EFFECT NEU_3_Tremor 74011-58-8 ENOXACIN ADVERSE_EFFECT NEU_1_Dizziness 74011-58-8 ENOXACIN ADVERSE_EFFECT PSY_3_Confusion 74011-58-8 ENOXACIN ADVERSE_EFFECT GIS_1_Vomiting 82419-36-1 OFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 82419-36-1 OFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 82419-36-1 OFLOXACIN MECH_LEVEL_3 DNA gyrase 82419-36-1 OFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 82419-36-1 OFLOXACIN MESH_LEVEL_3 Quinolines 82419-36-1 OFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 82419-36-1 OFLOXACIN ADVERSE_EFFECT IMU_3_Urticaria 82419-36-1 OFLOXACIN ADVERSE_EFFECT GUS_3_Dysuria 82419-36-1 OFLOXACIN ADVERSE_EFFECT GUS_1_Genital Pruritis 82419-36-1 OFLOXACIN ADVERSE_EFFECT XXX_3_Malaise 82419-36-1 OFLOXACIN PRODUCT_CLASS Anti-infectives 82419-36-1 OFLOXACIN TA_LEVEL_1 Infectious Disease 82419-36-1 OFLOXACIN TA_LEVEL_2 Anti-bacterial 82419-36-1 OFLOXACIN MECH_LEVEL_1 Anti-bacterial 82419-36-1 OFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 82419-36-1 OFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 82419-36-1 OFLOXACIN INDICATION Complicated Urinary Tract Infections 82419-36-1 OFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 82419-36-1 OFLOXACIN INDICATION Community-Acquired Pneumonia 82419-36-1 OFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 82419-36-1 OFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 82419-36-1 OFLOXACIN ADVERSE_EFFECT PSY_1_Insomnia 82419-36-1 OFLOXACIN ADVERSE_EFFECT XXX_2_Fatigue 82419-36-1 OFLOXACIN ADVERSE_EFFECT IMU_3_Angioedema 82419-36-1 OFLOXACIN ADVERSE_EFFECT GIS_2_Flatulence 82419-36-1 OFLOXACIN ADVERSE_EFFECT XXX_3_Asthenia 82419-36-1 OFLOXACIN TISSUE_TOXICITY Cardiac Arrest 82419-36-1 OFLOXACIN TA_LEVEL_3 quinolones 82419-36-1 OFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 82419-36-1 OFLOXACIN INDICATION Uncomplicated Cystitis 82419-36-1 OFLOXACIN ADVERSE_EFFECT CVS_3_Hypertension 82419-36-1 OFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 82419-36-1 OFLOXACIN ADVERSE_EFFECT XXX_2_Decreased Appetite 82419-36-1 OFLOXACIN ADVERSE_EFFECT XXX_3_Rhinorrhea 82419-36-1 OFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 82419-36-1 OFLOXACIN ADVERSE_EFFECT NEU_3_Vertigo 82419-36-1 OFLOXACIN ADVERSE_EFFECT PSY_3_Anxiety 82419-36-1 OFLOXACIN ADVERSE_EFFECT GUS_3_Urinary Retention 82419-36-1 OFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 82419-36-1 OFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 82419-36-1 OFLOXACIN INDICATION Prostatitis 82419-36-1 OFLOXACIN INDICATION Mixed Infections of the Urethra and Cervix 82419-36-1 OFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 82419-36-1 OFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 82419-36-1 OFLOXACIN ADVERSE_EFFECT GUS_2_Vaginal Discharge 82419-36-1 OFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 82419-36-1 OFLOXACIN ADVERSE_EFFECT XXX_3_Weight Loss 82419-36-1 OFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 82419-36-1 OFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 82419-36-1 OFLOXACIN ADVERSE_EFFECT GIS_2_Constipation 82419-36-1 OFLOXACIN ZERO_CLASS N 82419-36-1 OFLOXACIN THERAPEUTIC_CLASS Antibacterials 82419-36-1 OFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 82419-36-1 OFLOXACIN INDICATION Uncomplicated Skin Infections 83380-47-6 OFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 83380-47-6 OFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 83380-47-6 OFLOXACIN INDICATION Complicated Urinary Tract Infections 83380-47-6 OFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 83380-47-6 OFLOXACIN MECH_LEVEL_1 Anti-bacterial 83380-47-6 OFLOXACIN TA_LEVEL_2 Anti-bacterial 83380-47-6 OFLOXACIN TA_LEVEL_1 Infectious Disease 83380-47-6 OFLOXACIN PRODUCT_CLASS Anti-infectives 83380-47-6 OFLOXACIN ADVERSE_EFFECT XXX_3_Malaise 83380-47-6 OFLOXACIN ADVERSE_EFFECT GUS_3_Dysuria 83380-47-6 OFLOXACIN ADVERSE_EFFECT IMU_3_Urticaria 83380-47-6 OFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 83380-47-6 OFLOXACIN ADVERSE_EFFECT PSY_3_Anxiety 83380-47-6 OFLOXACIN ADVERSE_EFFECT GUS_3_Urinary Retention 83380-47-6 OFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 83380-47-6 OFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 83380-47-6 OFLOXACIN INDICATION Prostatitis 83380-47-6 OFLOXACIN INDICATION Mixed Infections of the Urethra and Cervix 83380-47-6 OFLOXACIN INDICATION Community-Acquired Pneumonia 83380-47-6 OFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 83380-47-6 OFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 83380-47-6 OFLOXACIN ADVERSE_EFFECT GUS_2_Vaginal Discharge 83380-47-6 OFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 83380-47-6 OFLOXACIN ADVERSE_EFFECT XXX_3_Weight Loss 83380-47-6 OFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 83380-47-6 OFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 83380-47-6 OFLOXACIN ADVERSE_EFFECT GIS_2_Constipation 83380-47-6 OFLOXACIN ZERO_CLASS N 83380-47-6 OFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 83380-47-6 OFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 83380-47-6 OFLOXACIN INDICATION Uncomplicated Skin Infections 83380-47-6 OFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 83380-47-6 OFLOXACIN MECH_LEVEL_3 DNA gyrase 83380-47-6 OFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 83380-47-6 OFLOXACIN MESH_LEVEL_3 Quinolines 83380-47-6 OFLOXACIN THERAPEUTIC_CLASS Antibacterials 83380-47-6 OFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 83380-47-6 OFLOXACIN ADVERSE_EFFECT GUS_1_Genital Pruritis 83380-47-6 OFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 83380-47-6 OFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 83380-47-6 OFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 83380-47-6 OFLOXACIN ADVERSE_EFFECT XXX_3_Rhinorrhea 83380-47-6 OFLOXACIN ADVERSE_EFFECT XXX_2_Decreased Appetite 83380-47-6 OFLOXACIN ADVERSE_EFFECT CVS_3_Hypertension 83380-47-6 OFLOXACIN INDICATION Uncomplicated Cystitis 83380-47-6 OFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 83380-47-6 OFLOXACIN TA_LEVEL_3 quinolones 83380-47-6 OFLOXACIN TISSUE_TOXICITY Cardiac Arrest 83380-47-6 OFLOXACIN ADVERSE_EFFECT XXX_3_Asthenia 83380-47-6 OFLOXACIN ADVERSE_EFFECT GIS_2_Flatulence 83380-47-6 OFLOXACIN ADVERSE_EFFECT NEU_3_Vertigo 83380-47-6 OFLOXACIN ADVERSE_EFFECT IMU_3_Angioedema 83380-47-6 OFLOXACIN ADVERSE_EFFECT XXX_2_Fatigue 83380-47-6 OFLOXACIN ADVERSE_EFFECT PSY_1_Insomnia 86784-41-0 OFLOXACIN INDICATION Mixed Infections of the Urethra and Cervix 86784-41-0 OFLOXACIN INDICATION Community-Acquired Pneumonia 86784-41-0 OFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 86784-41-0 OFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 86784-41-0 OFLOXACIN ADVERSE_EFFECT GUS_2_Vaginal Discharge 86784-41-0 OFLOXACIN ADVERSE_EFFECT NEU_1_Dizziness 86784-41-0 OFLOXACIN ADVERSE_EFFECT IMU_3_Urticaria 86784-41-0 OFLOXACIN ADVERSE_EFFECT GUS_3_Dysuria 86784-41-0 OFLOXACIN ADVERSE_EFFECT GUS_1_Genital Pruritis 86784-41-0 OFLOXACIN ADVERSE_EFFECT XXX_3_Malaise 86784-41-0 OFLOXACIN PRODUCT_CLASS Anti-infectives 86784-41-0 OFLOXACIN TA_LEVEL_1 Infectious Disease 86784-41-0 OFLOXACIN TA_LEVEL_2 Anti-bacterial 86784-41-0 OFLOXACIN MECH_LEVEL_1 Anti-bacterial 86784-41-0 OFLOXACIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 86784-41-0 OFLOXACIN INDICATION Nongonoccocal Urethritis and Cervicitis 86784-41-0 OFLOXACIN ADVERSE_EFFECT XXX_2_Decreased Appetite 86784-41-0 OFLOXACIN TA_LEVEL_3 quinolones 86784-41-0 OFLOXACIN TISSUE_TOXICITY Cardiac Arrest 86784-41-0 OFLOXACIN ADVERSE_EFFECT XXX_3_Asthenia 86784-41-0 OFLOXACIN ADVERSE_EFFECT GIS_2_Flatulence 86784-41-0 OFLOXACIN ADVERSE_EFFECT NEU_3_Vertigo 86784-41-0 OFLOXACIN ADVERSE_EFFECT IMU_3_Angioedema 86784-41-0 OFLOXACIN ADVERSE_EFFECT XXX_2_Fatigue 86784-41-0 OFLOXACIN ADVERSE_EFFECT PSY_1_Insomnia 86784-41-0 OFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 86784-41-0 OFLOXACIN ADVERSE_EFFECT CVS_3_Cardiac Arrest 86784-41-0 OFLOXACIN ADVERSE_EFFECT XXX_3_Weight Loss 86784-41-0 OFLOXACIN ADVERSE_EFFECT GIS_2_Abdominal Pain 86784-41-0 OFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 86784-41-0 OFLOXACIN INDICATION Uncomplicated Cystitis 86784-41-0 OFLOXACIN MESH_LEVEL_3 Quinolines 86784-41-0 OFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 86784-41-0 OFLOXACIN MECH_LEVEL_3 DNA gyrase 86784-41-0 OFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 86784-41-0 OFLOXACIN INDICATION Uncomplicated Skin Infections 86784-41-0 OFLOXACIN ADVERSE_EFFECT PSY_3_Anxiety 86784-41-0 OFLOXACIN INDICATION Acute Pelvic Inflammatory Disease 86784-41-0 OFLOXACIN THERAPEUTIC_CLASS Antibacterials 86784-41-0 OFLOXACIN ZERO_CLASS N 86784-41-0 OFLOXACIN ADVERSE_EFFECT GIS_2_Constipation 86784-41-0 OFLOXACIN ADVERSE_EFFECT NEU_3_Tremor 86784-41-0 OFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 86784-41-0 OFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 86784-41-0 OFLOXACIN ADVERSE_EFFECT GUS_3_Urinary Retention 86784-41-0 OFLOXACIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 86784-41-0 OFLOXACIN ADVERSE_EFFECT CVS_3_Hypertension 86784-41-0 OFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 86784-41-0 OFLOXACIN INDICATION Prostatitis 86784-41-0 OFLOXACIN INDICATION Complicated Urinary Tract Infections 86784-41-0 OFLOXACIN KNOWN_TOXICITY Cardiovascular Toxicity 86784-41-0 OFLOXACIN ADVERSE_EFFECT GUS_1_Vaginitis 86784-41-0 OFLOXACIN ADVERSE_EFFECT CVS_2_Chest Pain 86784-41-0 OFLOXACIN ADVERSE_EFFECT XXX_3_Rhinorrhea 22862-76-6 ANISOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 22862-76-6 ANISOMYCIN PRODUCT_CLASS Biochemicals 22862-76-6 ANISOMYCIN MECHANISM Inhibit ribosomal protein synthesis 73573-88-3 MEVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 73573-88-3 MEVASTATIN PRODUCT_CLASS Cardiovasculars 73573-88-3 MEVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 73573-88-3 MEVASTATIN ADVERSE_EFFECT MSK_2_Myositis 73573-88-3 MEVASTATIN ADVERSE_EFFECT DNA_2_Carcinogenicity 73573-88-3 MEVASTATIN ZERO_CLASS N 73573-88-3 MEVASTATIN TA_LEVEL_1 Cardiovascular 73573-88-3 MEVASTATIN TA_LEVEL_2 Lipid lowering agent 73573-88-3 MEVASTATIN MECH_LEVEL_3 HMG-CoA reductase 73573-88-3 MEVASTATIN INDICATION Hyperlipoproteinemia 73573-88-3 MEVASTATIN ADVERSE_EFFECT LIV_2_Hepatitis 73573-88-3 MEVASTATIN ADVERSE_EFFECT GIS_1_Gastrointestinal Upset 73573-88-3 MEVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 73573-88-3 MEVASTATIN TA_LEVEL_3 Statin 73573-88-3 MEVASTATIN ADVERSE_EFFECT KID_2_Renal Failure 73573-88-3 MEVASTATIN ADVERSE_EFFECT PSY_1_Insomnia 73573-88-3 MEVASTATIN KNOWN_TOXICITY Carcinogenicity 73573-88-3 MEVASTATIN TISSUE_TOXICITY Carcinogenicity 73573-88-3 MEVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 73573-88-3 MEVASTATIN MESH_LEVEL_3 Naphthalenes 73573-88-3 MEVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors, non-aromatic 73573-88-3 MEVASTATIN MECHANISM Inhibit cholesterol biosynthesis 73573-88-3 MEVASTATIN MECH_LEVEL_1 Lipid lowering 73573-88-3 MEVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 73573-88-3 MEVASTATIN ADVERSE_EFFECT BBM_2_Myelotoxicity 73573-88-3 MEVASTATIN ADVERSE_EFFECT SKN_1_Rash 73573-88-3 MEVASTATIN KNOWN_TOXICITY Nephrotoxicity 73573-88-3 MEVASTATIN TISSUE_TOXICITY Renal Failure 73573-88-3 MEVASTATIN MODE_CLASS Enzyme Inhibitor 94948-59-1 TUMOR NECROSIS FACTOR-ALPHA, HUMAN(A 17 KD PROTEIN) MODE_CLASS Endogenous Receptor /Channel Ligand 94948-59-1 TUMOR NECROSIS FACTOR-ALPHA, HUMAN(A 17 KD PROTEIN) PRODUCT_CLASS Biochemicals 9041-93-4 BLEOMYCIN A2 PRODUCT_CLASS Anti-cancers 9041-93-4 BLEOMYCIN A2 ZERO_CLASS N 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT LUN_1_Interstitial Pneumonitis 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT XXX_2_Chills 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT SKN_1_Hyperpigmentation 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT CVS_2_Hypotension 9041-93-4 BLEOMYCIN A2 KNOWN_TOXICITY Dermatologic Toxicity 9041-93-4 BLEOMYCIN A2 KNOWN_TOXICITY Embryo/Fetal Toxicity 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Hypotension 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Mutagenicity 9041-93-4 BLEOMYCIN A2 STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 9041-93-4 BLEOMYCIN A2 TA_LEVEL_3 Solid Tumors 9041-93-4 BLEOMYCIN A2 MESH_LEVEL_3 Glycopeptides 9041-93-4 BLEOMYCIN A2 MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Skin Toxicity 9041-93-4 BLEOMYCIN A2 INDICATION Testicular Cancer / Carcinoma of the Testis 9041-93-4 BLEOMYCIN A2 MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 9041-93-4 BLEOMYCIN A2 TA_LEVEL_2 DNA damage 9041-93-4 BLEOMYCIN A2 INDICATION Pleural Effusion 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Mucocutaneous Toxicity 9041-93-4 BLEOMYCIN A2 MESH_LEVEL_2 Peptides 9041-93-4 BLEOMYCIN A2 THERAPEUTIC_CLASS Antineoplastics 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT GUS_3_Hemorrhagic Cystitis 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT XXX_2_Fever 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT GIS_2_Vomiting 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT KID_3_Hematuria 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT SKN_1_Skin Toxicity 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Myocardial Infarction 9041-93-4 BLEOMYCIN A2 KNOWN_TOXICITY Mutagenicity 9041-93-4 BLEOMYCIN A2 ACTIVITY_CLASS DNA damager 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Hematuria 9041-93-4 BLEOMYCIN A2 MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 9041-93-4 BLEOMYCIN A2 INDICATION Head and Neck Cancer 9041-93-4 BLEOMYCIN A2 INDICATION Lymphoma 9041-93-4 BLEOMYCIN A2 MECHANISM Inhibit DNA synthesis, repair, and function 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT CVS_3_Chest Pain 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT DNA_2_Mutagenicity 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT GIS_2_Nausea 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT BBM_2_Thrombocytopenia 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT LUN_2_Pulmonary Toxicity 9041-93-4 BLEOMYCIN A2 MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 9041-93-4 BLEOMYCIN A2 KNOWN_TOXICITY Nephrotoxicity 9041-93-4 BLEOMYCIN A2 INDICATION Squamous Cell Carcinoma 9041-93-4 BLEOMYCIN A2 INDICATION AIDS-Related Kaposi's Sarcoma 9041-93-4 BLEOMYCIN A2 TISSUE_TOXICITY Teratogenicity 9041-93-4 BLEOMYCIN A2 KNOWN_TOXICITY Cardiovascular Toxicity 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT SKN_1_Mucocutaneous Toxicity 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT LUN_1_Dyspnea 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT CVS_3_Myocardial Infarction 9041-93-4 BLEOMYCIN A2 ADVERSE_EFFECT EMB_2_Teratogenicity 9041-93-4 BLEOMYCIN A2 INDICATION Cervical Cancer / Carcinoma of the Cervix 9041-93-4 BLEOMYCIN A2 MECH_LEVEL_3 DNA damage 9041-93-4 BLEOMYCIN A2 TA_LEVEL_1 Oncology 11116-31-7 BLEOMYCIN A2 MECH_LEVEL_3 DNA damage 11116-31-7 BLEOMYCIN A2 TA_LEVEL_1 Oncology 11116-31-7 BLEOMYCIN A2 PRODUCT_CLASS Anti-cancers 11116-31-7 BLEOMYCIN A2 MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 11116-31-7 BLEOMYCIN A2 TA_LEVEL_3 Solid Tumors 11116-31-7 BLEOMYCIN A2 MESH_LEVEL_3 Glycopeptides 11116-31-7 BLEOMYCIN A2 KNOWN_TOXICITY Cardiovascular Toxicity 11116-31-7 BLEOMYCIN A2 KNOWN_TOXICITY Nephrotoxicity 11116-31-7 BLEOMYCIN A2 MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT LUN_2_Pulmonary Toxicity 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT BBM_2_Thrombocytopenia 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT GIS_2_Nausea 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT DNA_2_Mutagenicity 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT CVS_3_Chest Pain 11116-31-7 BLEOMYCIN A2 INDICATION Squamous Cell Carcinoma 11116-31-7 BLEOMYCIN A2 MECHANISM Inhibit DNA synthesis, repair, and function 11116-31-7 BLEOMYCIN A2 INDICATION Lymphoma 11116-31-7 BLEOMYCIN A2 MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Hematuria 11116-31-7 BLEOMYCIN A2 ACTIVITY_CLASS DNA damager 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Myocardial Infarction 11116-31-7 BLEOMYCIN A2 KNOWN_TOXICITY Mutagenicity 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT SKN_1_Skin Toxicity 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT KID_3_Hematuria 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT GIS_2_Vomiting 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT XXX_2_Fever 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT GUS_3_Hemorrhagic Cystitis 11116-31-7 BLEOMYCIN A2 THERAPEUTIC_CLASS Antineoplastics 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Mucocutaneous Toxicity 11116-31-7 BLEOMYCIN A2 INDICATION Pleural Effusion 11116-31-7 BLEOMYCIN A2 MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 11116-31-7 BLEOMYCIN A2 INDICATION Testicular Cancer / Carcinoma of the Testis 11116-31-7 BLEOMYCIN A2 TA_LEVEL_2 DNA damage 11116-31-7 BLEOMYCIN A2 ZERO_CLASS N 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT LUN_1_Interstitial Pneumonitis 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT XXX_2_Chills 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT SKN_1_Hyperpigmentation 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT CVS_2_Hypotension 11116-31-7 BLEOMYCIN A2 KNOWN_TOXICITY Dermatologic Toxicity 11116-31-7 BLEOMYCIN A2 KNOWN_TOXICITY Embryo/Fetal Toxicity 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Hypotension 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Mutagenicity 11116-31-7 BLEOMYCIN A2 STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Skin Toxicity 11116-31-7 BLEOMYCIN A2 INDICATION Head and Neck Cancer 11116-31-7 BLEOMYCIN A2 MESH_LEVEL_2 Peptides 11116-31-7 BLEOMYCIN A2 INDICATION AIDS-Related Kaposi's Sarcoma 11116-31-7 BLEOMYCIN A2 TISSUE_TOXICITY Teratogenicity 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT SKN_1_Mucocutaneous Toxicity 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT LUN_1_Dyspnea 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT CVS_3_Myocardial Infarction 11116-31-7 BLEOMYCIN A2 ADVERSE_EFFECT EMB_2_Teratogenicity 11116-31-7 BLEOMYCIN A2 INDICATION Cervical Cancer / Carcinoma of the Cervix 127-07-1 HYDROXYUREA TA_LEVEL_2 DNA damage 127-07-1 HYDROXYUREA TISSUE_TOXICITY Myelosuppression 127-07-1 HYDROXYUREA TISSUE_TOXICITY Carcinogenicity 127-07-1 HYDROXYUREA ZERO_CLASS N 127-07-1 HYDROXYUREA ADVERSE_EFFECT GUS_3_Dysuria 127-07-1 HYDROXYUREA ADVERSE_EFFECT BBM_1_Leukopenia 127-07-1 HYDROXYUREA ADVERSE_EFFECT NEU_3_Drowsiness 127-07-1 HYDROXYUREA TISSUE_TOXICITY Bone Marrow Depression 127-07-1 HYDROXYUREA ADVERSE_EFFECT PSY_2_Anorexia 127-07-1 HYDROXYUREA ADVERSE_EFFECT SKN_2_Rash 127-07-1 HYDROXYUREA ADVERSE_EFFECT BBM_1_Thrombocytopenia 127-07-1 HYDROXYUREA PRODUCT_CLASS Anti-cancers 127-07-1 HYDROXYUREA ADVERSE_EFFECT EMB_2_Embryotoxicity 127-07-1 HYDROXYUREA ADVERSE_EFFECT XXX_3_Asthenia 127-07-1 HYDROXYUREA ADVERSE_EFFECT NEU_3_Convulsions 127-07-1 HYDROXYUREA STRUCTURE_ACTIVITY Ribonucleoside-PP reductase inhibitor 127-07-1 HYDROXYUREA KNOWN_TOXICITY Carcinogenicity 127-07-1 HYDROXYUREA INDICATION Ovarian Cancer / Carcinoma of the Ovary 127-07-1 HYDROXYUREA MESH_LEVEL_2 Urea 127-07-1 HYDROXYUREA TA_LEVEL_3 Solid and soft tumors 127-07-1 HYDROXYUREA MESH_LEVEL_1 Organic Chemicals 127-07-1 HYDROXYUREA TA_LEVEL_1 Oncology 127-07-1 HYDROXYUREA MECH_LEVEL_3 DNA damage 127-07-1 HYDROXYUREA ADVERSE_EFFECT PSY_3_Hallucinations 127-07-1 HYDROXYUREA ADVERSE_EFFECT NEU_3_Dizziness 127-07-1 HYDROXYUREA ADVERSE_EFFECT PSY_3_Disorientation 127-07-1 HYDROXYUREA ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 127-07-1 HYDROXYUREA ADVERSE_EFFECT GIS_2_Stomatitis 127-07-1 HYDROXYUREA ADVERSE_EFFECT DNA_2_Carcinogenicity 127-07-1 HYDROXYUREA KNOWN_TOXICITY Blood & Bone Marrow Toxicity 127-07-1 HYDROXYUREA TISSUE_TOXICITY Leukopenia 127-07-1 HYDROXYUREA ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 127-07-1 HYDROXYUREA MECHANISM Inhibit DNA synthesis, repair, and function 127-07-1 HYDROXYUREA MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 127-07-1 HYDROXYUREA INDICATION Carcinoma of the Head and Neck 127-07-1 HYDROXYUREA INDICATION Malignant Melanoma 127-07-1 HYDROXYUREA TISSUE_TOXICITY Anemia 127-07-1 HYDROXYUREA THERAPEUTIC_CLASS Antineoplastics 127-07-1 HYDROXYUREA ADVERSE_EFFECT GIS_2_Constipation 127-07-1 HYDROXYUREA ADVERSE_EFFECT GIS_2_Vomiting 127-07-1 HYDROXYUREA ADVERSE_EFFECT BBM_1_Anemia 127-07-1 HYDROXYUREA ADVERSE_EFFECT BBM_1_Bone Marrow Depression 127-07-1 HYDROXYUREA ADVERSE_EFFECT BBM_1_Myelosuppression 127-07-1 HYDROXYUREA MODE_CLASS Enzyme Inhibitor 127-07-1 HYDROXYUREA TISSUE_TOXICITY Thrombocytopenia 127-07-1 HYDROXYUREA MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 127-07-1 HYDROXYUREA INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 127-07-1 HYDROXYUREA ADVERSE_EFFECT GIS_2_Diarrhea 127-07-1 HYDROXYUREA ADVERSE_EFFECT GIS_2_Nausea 127-07-1 HYDROXYUREA MESH_LEVEL_3 Hydroxyurea 6055-19-2 CYCLOPHOSPHAMIDE MECH_LEVEL_3 DNA damage 6055-19-2 CYCLOPHOSPHAMIDE MESH_LEVEL_1 Organic Chemicals 6055-19-2 CYCLOPHOSPHAMIDE TA_LEVEL_1 Oncology 6055-19-2 CYCLOPHOSPHAMIDE MESH_LEVEL_3 Hydrocarbons, Halogenated 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Cardiotoxicity 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Myelosuppression 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT GIS_1_Nausea 6055-19-2 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Hematotoxicity 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Leukopenia 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT ELT_2_Hyperkalemia 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Anemia 6055-19-2 CYCLOPHOSPHAMIDE MECHANISM Inhibit DNA synthesis, repair, and function 6055-19-2 CYCLOPHOSPHAMIDE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Lymphocytic Leukemia 6055-19-2 CYCLOPHOSPHAMIDE MECHANISM Enhance cholinergic transmission 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Retinoblastoma 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Multiple Myeloma / Myelomatosis 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Thrombocytopenia 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Myelosuppression 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Carcinogenicity 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT GIS_1_Vomiting 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Leukopenia 6055-19-2 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT IMU_3_Anaphylaxis 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Hematotoxicity 6055-19-2 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Genitourinary System Toxicity 6055-19-2 CYCLOPHOSPHAMIDE THERAPEUTIC_CLASS Antineoplastics 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Small Cell Lung Carcinoma 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Neuroblastoma 6055-19-2 CYCLOPHOSPHAMIDE TA_LEVEL_2 DNA damage 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Burkitt's Lymphoma 6055-19-2 CYCLOPHOSPHAMIDE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 6055-19-2 CYCLOPHOSPHAMIDE ACTIVITY_CLASS DNA damager 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Cardiac Failure 6055-19-2 CYCLOPHOSPHAMIDE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 6055-19-2 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Carcinogenicity 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT CVS_3_Cardiotoxicity 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT NEU_3_Dizziness 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT LUN_2_Pulmonary Fibrosis 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT KID_2_Hyperuricemia 6055-19-2 CYCLOPHOSPHAMIDE MODE_CLASS Enzyme Inhibitor 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Ovarian Cancer / Carcinoma of the Ovary 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Hodgkin's Disease 6055-19-2 CYCLOPHOSPHAMIDE PRODUCT_CLASS Anti-cancers 6055-19-2 CYCLOPHOSPHAMIDE MESH_LEVEL_2 Hydrocarbons 6055-19-2 CYCLOPHOSPHAMIDE ZERO_CLASS N 6055-19-2 CYCLOPHOSPHAMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT GUS_1_Hemorrhagic Cystitis 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Anemia 6055-19-2 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Hemorrhagic Cystitis 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Thrombocytopenia 6055-19-2 CYCLOPHOSPHAMIDE ADVERSE_EFFECT CVS_3_Cardiac Failure 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Soft Tissue Sarcoma 6055-19-2 CYCLOPHOSPHAMIDE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 6055-19-2 CYCLOPHOSPHAMIDE TA_LEVEL_3 Solid and soft Tumors 50-18-0 CYCLOPHOSPHAMIDE INDICATION Small Cell Lung Carcinoma 50-18-0 CYCLOPHOSPHAMIDE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 50-18-0 CYCLOPHOSPHAMIDE MECH_LEVEL_3 DNA damage 50-18-0 CYCLOPHOSPHAMIDE INDICATION Multiple Myeloma / Myelomatosis 50-18-0 CYCLOPHOSPHAMIDE INDICATION Retinoblastoma 50-18-0 CYCLOPHOSPHAMIDE MECHANISM Enhance cholinergic transmission 50-18-0 CYCLOPHOSPHAMIDE INDICATION Lymphocytic Leukemia 50-18-0 CYCLOPHOSPHAMIDE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 50-18-0 CYCLOPHOSPHAMIDE MECHANISM Inhibit DNA synthesis, repair, and function 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Anemia 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT ELT_2_Hyperkalemia 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Leukopenia 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Hematotoxicity 50-18-0 CYCLOPHOSPHAMIDE TA_LEVEL_3 Solid and soft Tumors 50-18-0 CYCLOPHOSPHAMIDE MESH_LEVEL_1 Organic Chemicals 50-18-0 CYCLOPHOSPHAMIDE TA_LEVEL_1 Oncology 50-18-0 CYCLOPHOSPHAMIDE MESH_LEVEL_3 Hydrocarbons, Halogenated 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Cardiotoxicity 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Myelosuppression 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT GIS_1_Nausea 50-18-0 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Cardiac Failure 50-18-0 CYCLOPHOSPHAMIDE STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 50-18-0 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Carcinogenicity 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT CVS_3_Cardiotoxicity 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT NEU_3_Dizziness 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT LUN_2_Pulmonary Fibrosis 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT KID_2_Hyperuricemia 50-18-0 CYCLOPHOSPHAMIDE MODE_CLASS Enzyme Inhibitor 50-18-0 CYCLOPHOSPHAMIDE INDICATION Ovarian Cancer / Carcinoma of the Ovary 50-18-0 CYCLOPHOSPHAMIDE INDICATION Hodgkin's Disease 50-18-0 CYCLOPHOSPHAMIDE PRODUCT_CLASS Anti-cancers 50-18-0 CYCLOPHOSPHAMIDE MESH_LEVEL_2 Hydrocarbons 50-18-0 CYCLOPHOSPHAMIDE ZERO_CLASS N 50-18-0 CYCLOPHOSPHAMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT GUS_1_Hemorrhagic Cystitis 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Anemia 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Hemorrhagic Cystitis 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Thrombocytopenia 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT CVS_3_Cardiac Failure 50-18-0 CYCLOPHOSPHAMIDE INDICATION Soft Tissue Sarcoma 50-18-0 CYCLOPHOSPHAMIDE INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 50-18-0 CYCLOPHOSPHAMIDE INDICATION Burkitt's Lymphoma 50-18-0 CYCLOPHOSPHAMIDE TA_LEVEL_2 DNA damage 50-18-0 CYCLOPHOSPHAMIDE INDICATION Neuroblastoma 50-18-0 CYCLOPHOSPHAMIDE THERAPEUTIC_CLASS Antineoplastics 50-18-0 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Genitourinary System Toxicity 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Hematotoxicity 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT IMU_3_Anaphylaxis 50-18-0 CYCLOPHOSPHAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT BBM_1_Leukopenia 50-18-0 CYCLOPHOSPHAMIDE ADVERSE_EFFECT GIS_1_Vomiting 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Carcinogenicity 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Myelosuppression 50-18-0 CYCLOPHOSPHAMIDE TISSUE_TOXICITY Thrombocytopenia 50-18-0 CYCLOPHOSPHAMIDE ACTIVITY_CLASS DNA damager 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 16595-80-5 LEVAMISOLE ADVERSE_EFFECT OCU_3_Blurred Vision 16595-80-5 LEVAMISOLE THERAPEUTIC_CLASS Immunomodulants 16595-80-5 LEVAMISOLE TA_LEVEL_2 immune stimulant 16595-80-5 LEVAMISOLE MESH_LEVEL_3 Imidazoles 16595-80-5 LEVAMISOLE ZERO_CLASS N 16595-80-5 LEVAMISOLE ADVERSE_EFFECT NEU_2_Somnolence 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 16595-80-5 LEVAMISOLE ADVERSE_EFFECT MSK_1_Arthralgia 16595-80-5 LEVAMISOLE ADVERSE_EFFECT XXX_1_Fatigue 16595-80-5 LEVAMISOLE ADVERSE_EFFECT PSY_3_Depression 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_1_Diarrhea 16595-80-5 LEVAMISOLE INDICATION Colon Cancer 16595-80-5 LEVAMISOLE TA_LEVEL_1 Oncology 16595-80-5 LEVAMISOLE MODE_CLASS Enzyme Inhibitor 16595-80-5 LEVAMISOLE ADVERSE_EFFECT SKN_1_Dermatitis 16595-80-5 LEVAMISOLE ADVERSE_EFFECT MSK_2_Myalgia 16595-80-5 LEVAMISOLE ADVERSE_EFFECT NEU_2_Dizziness 16595-80-5 LEVAMISOLE ADVERSE_EFFECT PSY_3_Nervousness 16595-80-5 LEVAMISOLE ADVERSE_EFFECT XXX_2_Fever 16595-80-5 LEVAMISOLE PRODUCT_CLASS Anti-cancers 16595-80-5 LEVAMISOLE MECH_LEVEL_3 Nicotinic acetylcholine receptor 16595-80-5 LEVAMISOLE MESH_LEVEL_1 Heterocyclic Compounds 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_2_Constipation 16595-80-5 LEVAMISOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 16595-80-5 LEVAMISOLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 16595-80-5 LEVAMISOLE MECHANISM Inhibit mitosis 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_3_Dyspepsia 16595-80-5 LEVAMISOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 16595-80-5 LEVAMISOLE ADVERSE_EFFECT XXX_3_Edema 16595-80-5 LEVAMISOLE ADVERSE_EFFECT PSY_3_Anxiety 16595-80-5 LEVAMISOLE MECH_LEVEL_1 Immunomodulation 16595-80-5 LEVAMISOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 16595-80-5 LEVAMISOLE MECH_LEVEL_2 Immunostimulation 16595-80-5 LEVAMISOLE STRUCTURE_ACTIVITY Tubulin binder 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_3_Flatulence 16595-80-5 LEVAMISOLE ADVERSE_EFFECT GIS_2_Stomatitis 16595-80-5 LEVAMISOLE ADVERSE_EFFECT SKN_3_Pruritis 14769-73-4 LEVAMISOLE MECH_LEVEL_3 Nicotinic acetylcholine receptor 14769-73-4 LEVAMISOLE PRODUCT_CLASS Anti-cancers 14769-73-4 LEVAMISOLE ADVERSE_EFFECT PSY_3_Depression 14769-73-4 LEVAMISOLE ADVERSE_EFFECT XXX_2_Fever 14769-73-4 LEVAMISOLE ADVERSE_EFFECT PSY_3_Nervousness 14769-73-4 LEVAMISOLE ADVERSE_EFFECT NEU_2_Dizziness 14769-73-4 LEVAMISOLE ADVERSE_EFFECT MSK_2_Myalgia 14769-73-4 LEVAMISOLE ADVERSE_EFFECT SKN_1_Dermatitis 14769-73-4 LEVAMISOLE MODE_CLASS Enzyme Inhibitor 14769-73-4 LEVAMISOLE TA_LEVEL_1 Oncology 14769-73-4 LEVAMISOLE ADVERSE_EFFECT XXX_1_Fatigue 14769-73-4 LEVAMISOLE INDICATION Colon Cancer 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_1_Diarrhea 14769-73-4 LEVAMISOLE MESH_LEVEL_1 Heterocyclic Compounds 14769-73-4 LEVAMISOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 14769-73-4 LEVAMISOLE ADVERSE_EFFECT PSY_3_Anxiety 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_2_Constipation 14769-73-4 LEVAMISOLE MECH_LEVEL_1 Immunomodulation 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_2_Abdominal Pain 14769-73-4 LEVAMISOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 14769-73-4 LEVAMISOLE STRUCTURE_ACTIVITY Tubulin binder 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_3_Flatulence 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_2_Stomatitis 14769-73-4 LEVAMISOLE ADVERSE_EFFECT SKN_3_Pruritis 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 14769-73-4 LEVAMISOLE ADVERSE_EFFECT MSK_1_Arthralgia 14769-73-4 LEVAMISOLE MECH_LEVEL_2 Immunostimulation 14769-73-4 LEVAMISOLE ADVERSE_EFFECT OCU_3_Blurred Vision 14769-73-4 LEVAMISOLE TA_LEVEL_2 immune stimulant 14769-73-4 LEVAMISOLE THERAPEUTIC_CLASS Immunomodulants 14769-73-4 LEVAMISOLE MESH_LEVEL_3 Imidazoles 14769-73-4 LEVAMISOLE ZERO_CLASS N 14769-73-4 LEVAMISOLE ADVERSE_EFFECT NEU_2_Somnolence 14769-73-4 LEVAMISOLE ADVERSE_EFFECT XXX_3_Edema 14769-73-4 LEVAMISOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 14769-73-4 LEVAMISOLE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 14769-73-4 LEVAMISOLE MECHANISM Inhibit mitosis 14769-73-4 LEVAMISOLE ADVERSE_EFFECT GIS_3_Dyspepsia 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT CVS_3_Chest Pain 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 1397-89-3 AMPHOTERICIN B THERAPEUTIC_CLASS Antifungals, Systemic 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT CVS_2_Hypotension 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT NEU_2_Headache 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT XXX_2_Infection 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT GIS_3_Abdominal Pain 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT KID_2_Kidney Damage 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT LUN_2_Respiratory Failure 1397-89-3 AMPHOTERICIN B MODE_CLASS Distorts /blocks macromolecular scaffold function 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT XXX_1_Fever 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT ELT_2_Hypokalemia 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT LUN_2_Dyspnea 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT XXX_1_Chills 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT KID_2_Increased Creatinine 1397-89-3 AMPHOTERICIN B KNOWN_TOXICITY Cardiovascular Toxicity 1397-89-3 AMPHOTERICIN B MECHANISM Destroy cell membrane / wall integrity 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT GIS_2_Diarrhea 1397-89-3 AMPHOTERICIN B TISSUE_TOXICITY Hypotension 1397-89-3 AMPHOTERICIN B INDICATION Fungal Infections 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT BBM_3_Anemia 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT BBM_3_Leukopenia 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT LUN_3_Respiratory Disorder 1397-89-3 AMPHOTERICIN B PRODUCT_CLASS Anti-infectives 1397-89-3 AMPHOTERICIN B STRUCTURE_ACTIVITY Impairs cell membrane function, polyene antifungal antibiotic 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT CVS_2_Hypertension 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT SKN_3_Rash 1397-89-3 AMPHOTERICIN B ADVERSE_EFFECT BBM_2_Thrombocytopenia 446-86-6 AZATHIOPRINE INDICATION Prophylaxis of Organ Transplant Rejection 446-86-6 AZATHIOPRINE ADVERSE_EFFECT GIS_2_Esophagitis 446-86-6 AZATHIOPRINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 446-86-6 AZATHIOPRINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 446-86-6 AZATHIOPRINE ADVERSE_EFFECT PSY_1_Anorexia 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Hepatotoxicity 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Hypotension 446-86-6 AZATHIOPRINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 446-86-6 AZATHIOPRINE MODE_CLASS Enzyme Inhibitor 446-86-6 AZATHIOPRINE ZERO_CLASS N 446-86-6 AZATHIOPRINE MESH_LEVEL_1 Heterocyclic Compounds 446-86-6 AZATHIOPRINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 446-86-6 AZATHIOPRINE KNOWN_TOXICITY Hepatotoxicity 446-86-6 AZATHIOPRINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 446-86-6 AZATHIOPRINE ADVERSE_EFFECT BBM_1_Leukopenia 446-86-6 AZATHIOPRINE ADVERSE_EFFECT CVS_2_Hypotension 446-86-6 AZATHIOPRINE MODE_CLASS Enzyme substrate mimic 446-86-6 AZATHIOPRINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Bone Marrow Depression 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Pancytopenia 446-86-6 AZATHIOPRINE MESH_LEVEL_3 Purines 446-86-6 AZATHIOPRINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 446-86-6 AZATHIOPRINE ADVERSE_EFFECT GIS_1_Diarrhea 446-86-6 AZATHIOPRINE ADVERSE_EFFECT BBM_1_Anemia 446-86-6 AZATHIOPRINE ADVERSE_EFFECT MSK_2_Myalgia 446-86-6 AZATHIOPRINE ADVERSE_EFFECT MSK_3_Arthralgia 446-86-6 AZATHIOPRINE ADVERSE_EFFECT IMU_3_Serum Sickness 446-86-6 AZATHIOPRINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, thiopurine base 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Anemia 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Thrombocytopenia 446-86-6 AZATHIOPRINE INDICATION Rheumatoid Arthritis 446-86-6 AZATHIOPRINE TA_LEVEL_2 Immune Response / Immunomodulators 446-86-6 AZATHIOPRINE MECH_LEVEL_3 DNA-directed DNA polymerase 446-86-6 AZATHIOPRINE MECH_LEVEL_1 Immunomodulation 446-86-6 AZATHIOPRINE MECHANISM Inhibit precursor synthesis 446-86-6 AZATHIOPRINE KNOWN_TOXICITY Cardiovascular Toxicity 446-86-6 AZATHIOPRINE THERAPEUTIC_CLASS Immunosuppressants 446-86-6 AZATHIOPRINE ADVERSE_EFFECT BBM_1_Bone Marrow Depression 446-86-6 AZATHIOPRINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 446-86-6 AZATHIOPRINE ADVERSE_EFFECT BBM_1_Pancytopenia 446-86-6 AZATHIOPRINE TISSUE_TOXICITY Leukopenia 446-86-6 AZATHIOPRINE ADVERSE_EFFECT XXX_3_Infection 446-86-6 AZATHIOPRINE ADVERSE_EFFECT XXX_2_Fever 446-86-6 AZATHIOPRINE PRODUCT_CLASS Immune Response / Immunomodulators 446-86-6 AZATHIOPRINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 446-86-6 AZATHIOPRINE MECHANISM Incorporate into DNA/RNA/Protein 61318-91-0 SULCONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 61318-91-0 SULCONAZOLE PRODUCT_CLASS Anti-infectives 61318-91-0 SULCONAZOLE ACTIVITY_CLASS Antifungals azole 61318-91-0 SULCONAZOLE ZERO_CLASS N 61318-91-0 SULCONAZOLE ADVERSE_EFFECT SKN_1_Erythema 61318-91-0 SULCONAZOLE ADVERSE_EFFECT SKN_2_Eczema 61318-91-0 SULCONAZOLE TA_LEVEL_2 Anti-fungal 61318-91-0 SULCONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 61318-91-0 SULCONAZOLE INDICATION Tinea Cruris / Jock Itch 61318-91-0 SULCONAZOLE ADVERSE_EFFECT SKN_1_Pruritis 61318-91-0 SULCONAZOLE ADVERSE_EFFECT EMB_3_Embryotoxicity 61318-91-0 SULCONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 61318-91-0 SULCONAZOLE ADVERSE_EFFECT XXX_2_Edema 61318-91-0 SULCONAZOLE ADVERSE_EFFECT SKN_2_Dry Skin 61318-91-0 SULCONAZOLE MESH_LEVEL_3 Imidazoles 61318-91-0 SULCONAZOLE MECH_LEVEL_2 Ergesterol synthesis inhibition 61318-91-0 SULCONAZOLE ADVERSE_EFFECT NEU_1_Tingling 61318-91-0 SULCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 61318-91-0 SULCONAZOLE INDICATION Tinea Pedis / Athlete's Foot 61318-91-0 SULCONAZOLE MODE_CLASS Enzyme Inhibitor 61318-91-0 SULCONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 61318-91-0 SULCONAZOLE TA_LEVEL_1 Infectious Disease 61318-91-0 SULCONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase 61318-91-0 SULCONAZOLE INDICATION Candidiasis 61318-91-0 SULCONAZOLE INDICATION Mucocutaneous Candidiasis 61318-91-0 SULCONAZOLE ADVERSE_EFFECT PSY_1_Irritation 61318-91-0 SULCONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 61318-91-0 SULCONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 61318-91-0 SULCONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 61318-91-0 SULCONAZOLE MECH_LEVEL_1 Anti-fungal 61318-91-0 SULCONAZOLE TA_LEVEL_3 topical infections 61318-90-9 SULCONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 61318-90-9 SULCONAZOLE PRODUCT_CLASS Anti-infectives 61318-90-9 SULCONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 61318-90-9 SULCONAZOLE ADVERSE_EFFECT NEU_1_Tingling 61318-90-9 SULCONAZOLE ADVERSE_EFFECT SKN_2_Dry Skin 61318-90-9 SULCONAZOLE MECH_LEVEL_2 Ergesterol synthesis inhibition 61318-90-9 SULCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 61318-90-9 SULCONAZOLE INDICATION Tinea Pedis / Athlete's Foot 61318-90-9 SULCONAZOLE MODE_CLASS Enzyme Inhibitor 61318-90-9 SULCONAZOLE INDICATION Candidiasis 61318-90-9 SULCONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 61318-90-9 SULCONAZOLE ACTIVITY_CLASS Antifungals azole 61318-90-9 SULCONAZOLE ADVERSE_EFFECT SKN_1_Erythema 61318-90-9 SULCONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 61318-90-9 SULCONAZOLE ADVERSE_EFFECT EMB_3_Embryotoxicity 61318-90-9 SULCONAZOLE ADVERSE_EFFECT XXX_2_Edema 61318-90-9 SULCONAZOLE ADVERSE_EFFECT SKN_1_Pruritis 61318-90-9 SULCONAZOLE INDICATION Tinea Cruris / Jock Itch 61318-90-9 SULCONAZOLE ZERO_CLASS N 61318-90-9 SULCONAZOLE ADVERSE_EFFECT SKN_2_Eczema 61318-90-9 SULCONAZOLE TA_LEVEL_1 Infectious Disease 61318-90-9 SULCONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase 61318-90-9 SULCONAZOLE TA_LEVEL_2 Anti-fungal 61318-90-9 SULCONAZOLE INDICATION Mucocutaneous Candidiasis 61318-90-9 SULCONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 61318-90-9 SULCONAZOLE ADVERSE_EFFECT PSY_1_Irritation 61318-90-9 SULCONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 61318-90-9 SULCONAZOLE MESH_LEVEL_3 Imidazoles 61318-90-9 SULCONAZOLE MECH_LEVEL_1 Anti-fungal 61318-90-9 SULCONAZOLE TA_LEVEL_3 topical infections 61318-90-9 SULCONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 59293-82-2 SULCONAZOLE PRODUCT_CLASS Anti-infectives 59293-82-2 SULCONAZOLE TA_LEVEL_3 topical infections 59293-82-2 SULCONAZOLE MECH_LEVEL_1 Anti-fungal 59293-82-2 SULCONAZOLE MESH_LEVEL_3 Imidazoles 59293-82-2 SULCONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 59293-82-2 SULCONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 59293-82-2 SULCONAZOLE ADVERSE_EFFECT PSY_1_Irritation 59293-82-2 SULCONAZOLE INDICATION Mucocutaneous Candidiasis 59293-82-2 SULCONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 59293-82-2 SULCONAZOLE TA_LEVEL_1 Infectious Disease 59293-82-2 SULCONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 59293-82-2 SULCONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase 59293-82-2 SULCONAZOLE ADVERSE_EFFECT NEU_1_Tingling 59293-82-2 SULCONAZOLE ZERO_CLASS N 59293-82-2 SULCONAZOLE ACTIVITY_CLASS Antifungals azole 59293-82-2 SULCONAZOLE ADVERSE_EFFECT SKN_2_Dry Skin 59293-82-2 SULCONAZOLE ADVERSE_EFFECT SKN_1_Pruritis 59293-82-2 SULCONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 59293-82-2 SULCONAZOLE ADVERSE_EFFECT EMB_3_Embryotoxicity 59293-82-2 SULCONAZOLE ADVERSE_EFFECT XXX_2_Edema 59293-82-2 SULCONAZOLE MECH_LEVEL_2 Ergesterol synthesis inhibition 59293-82-2 SULCONAZOLE INDICATION Tinea Cruris / Jock Itch 59293-82-2 SULCONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 59293-82-2 SULCONAZOLE TA_LEVEL_2 Anti-fungal 59293-82-2 SULCONAZOLE ADVERSE_EFFECT SKN_2_Eczema 59293-82-2 SULCONAZOLE ADVERSE_EFFECT SKN_1_Erythema 59293-82-2 SULCONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 59293-82-2 SULCONAZOLE INDICATION Candidiasis 59293-82-2 SULCONAZOLE MODE_CLASS Enzyme Inhibitor 59293-82-2 SULCONAZOLE INDICATION Tinea Pedis / Athlete's Foot 59293-82-2 SULCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 24169-02-6 ECONAZOLE ADVERSE_EFFECT XXX_1_Stinging Sensation 24169-02-6 ECONAZOLE INDICATION Tinea Pedis / Athlete's Foot 24169-02-6 ECONAZOLE ACTIVITY_CLASS Antifungals azole 24169-02-6 ECONAZOLE MECH_LEVEL_1 Anti-fungal 24169-02-6 ECONAZOLE ADVERSE_EFFECT SKN_1_Pruritis 24169-02-6 ECONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 24169-02-6 ECONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 24169-02-6 ECONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) 24169-02-6 ECONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 24169-02-6 ECONAZOLE TA_LEVEL_1 Infectious Disease 24169-02-6 ECONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 24169-02-6 ECONAZOLE TA_LEVEL_3 Topical 24169-02-6 ECONAZOLE ADVERSE_EFFECT XXX_1_Burning Sensation 24169-02-6 ECONAZOLE PRODUCT_CLASS Anti-infectives 24169-02-6 ECONAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 24169-02-6 ECONAZOLE ADVERSE_EFFECT SKN_1_Erythema 24169-02-6 ECONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 24169-02-6 ECONAZOLE TA_LEVEL_2 Anti-fungal 24169-02-6 ECONAZOLE INDICATION Tinea Cruris / Jock Itch 24169-02-6 ECONAZOLE INDICATION Mucocutaneous Candidiasis 24169-02-6 ECONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 24169-02-6 ECONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 24169-02-6 ECONAZOLE MESH_LEVEL_3 Imidazoles 24169-02-6 ECONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 24169-02-6 ECONAZOLE ZERO_CLASS N 24169-02-6 ECONAZOLE MODE_CLASS Enzyme Inhibitor 27220-47-9 ECONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 27220-47-9 ECONAZOLE ADVERSE_EFFECT SKN_1_Pruritis 27220-47-9 ECONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) 27220-47-9 ECONAZOLE ZERO_CLASS N 27220-47-9 ECONAZOLE ADVERSE_EFFECT IMU_3_Contact Dermatitis 27220-47-9 ECONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 27220-47-9 ECONAZOLE INDICATION Mucocutaneous Candidiasis 27220-47-9 ECONAZOLE INDICATION Tinea Cruris / Jock Itch 27220-47-9 ECONAZOLE TA_LEVEL_2 Anti-fungal 27220-47-9 ECONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 27220-47-9 ECONAZOLE ADVERSE_EFFECT SKN_1_Erythema 27220-47-9 ECONAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 27220-47-9 ECONAZOLE PRODUCT_CLASS Anti-infectives 27220-47-9 ECONAZOLE ADVERSE_EFFECT XXX_1_Burning Sensation 27220-47-9 ECONAZOLE TA_LEVEL_3 Topical 27220-47-9 ECONAZOLE MECH_LEVEL_1 Anti-fungal 27220-47-9 ECONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 27220-47-9 ECONAZOLE MESH_LEVEL_3 Imidazoles 27220-47-9 ECONAZOLE INDICATION Tinea Pedis / Athlete's Foot 27220-47-9 ECONAZOLE ACTIVITY_CLASS Antifungals azole 27220-47-9 ECONAZOLE MODE_CLASS Enzyme Inhibitor 27220-47-9 ECONAZOLE ADVERSE_EFFECT XXX_1_Stinging Sensation 27220-47-9 ECONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 27220-47-9 ECONAZOLE INDICATION Tinea Versicolor / Pityriasis Versicolor 27220-47-9 ECONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 27220-47-9 ECONAZOLE TA_LEVEL_1 Infectious Disease 50-24-8 PREDNISOLONE TA_LEVEL_2 Steroid 50-24-8 PREDNISOLONE MECH_LEVEL_1 Immunomodulation 50-24-8 PREDNISOLONE INDICATION Collagen Diseases 50-24-8 PREDNISOLONE ADVERSE_EFFECT XXX_2_Increased Appetite 50-24-8 PREDNISOLONE ADVERSE_EFFECT CVS_2_Thromboembolism 50-24-8 PREDNISOLONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 50-24-8 PREDNISOLONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 50-24-8 PREDNISOLONE TA_LEVEL_3 Corticosteroids 50-24-8 PREDNISOLONE INDICATION Ophthalmic Diseases 50-24-8 PREDNISOLONE INDICATION Hematologic Disorders 50-24-8 PREDNISOLONE MESH_LEVEL_2 Steroids 50-24-8 PREDNISOLONE THERAPEUTIC_CLASS Corticosteroids 50-24-8 PREDNISOLONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 50-24-8 PREDNISOLONE ADVERSE_EFFECT END_2_Metabolic Disturbance 50-24-8 PREDNISOLONE ADVERSE_EFFECT GIS_2_Nausea 50-24-8 PREDNISOLONE ADVERSE_EFFECT XXX_2_Weight Gain 50-24-8 PREDNISOLONE ZERO_CLASS N 50-24-8 PREDNISOLONE ACTIVITY_CLASS GR-MR agonist 50-24-8 PREDNISOLONE MECH_LEVEL_3 Glucocorticoid receptor 50-24-8 PREDNISOLONE PRODUCT_CLASS Anti-inflammatories 50-24-8 PREDNISOLONE MODE_CLASS Receptor Agonist 50-24-8 PREDNISOLONE MESH_LEVEL_3 Pregnanes 50-24-8 PREDNISOLONE ADVERSE_EFFECT XXX_2_Malaise 50-24-8 PREDNISOLONE ADVERSE_EFFECT SKN_2_Skin Toxicity 50-24-8 PREDNISOLONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 50-24-8 PREDNISOLONE ADVERSE_EFFECT IMU_2_Hypersensitivity 50-24-8 PREDNISOLONE STRUCTURE_ACTIVITY Glucocorticoid and mineralocorticoid receptor agonist 50-24-8 PREDNISOLONE MECH_LEVEL_2 Anti-inflammation and immunosuppression 50-24-8 PREDNISOLONE INDICATION Edematous States 50-24-8 PREDNISOLONE INDICATION Neoplastic Diseases 50-24-8 PREDNISOLONE INDICATION Allergic Diseases 50-24-8 PREDNISOLONE MESH_LEVEL_1 Polycyclic Hydrocarbons 50-24-8 PREDNISOLONE TISSUE_TOXICITY Cardiotoxicity 50-24-8 PREDNISOLONE TISSUE_TOXICITY Thromboembolism 50-24-8 PREDNISOLONE KNOWN_TOXICITY Cardiovascular Toxicity 50-24-8 PREDNISOLONE MECHANISM Modulate gene transcription 50-24-8 PREDNISOLONE ADVERSE_EFFECT CVS_2_Cardiotoxicity 50-24-8 PREDNISOLONE TA_LEVEL_1 Anti-inflammatory 50-24-8 PREDNISOLONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 50-24-8 PREDNISOLONE INDICATION Gastrointestinal Diseases 50-24-8 PREDNISOLONE INDICATION Skin Diseases / Dermatoses 50-24-8 PREDNISOLONE INDICATION Endocrine Disorders 50-24-8 PREDNISOLONE INDICATION Rheumatic Disorders 50-24-8 PREDNISOLONE INDICATION Respiratory Diseases 50-24-8 PREDNISOLONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 53-03-2 PREDNISONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 53-03-2 PREDNISONE ACTIVITY_CLASS GR-MR agonist 53-03-2 PREDNISONE MESH_LEVEL_1 Polycyclic Hydrocarbons 53-03-2 PREDNISONE ZERO_CLASS N 53-03-2 PREDNISONE INDICATION Respiratory Diseases 53-03-2 PREDNISONE INDICATION Endocrine Disorders 53-03-2 PREDNISONE INDICATION Skin Diseases / Dermatoses 53-03-2 PREDNISONE ADVERSE_EFFECT XXX_2_Increased Appetite 53-03-2 PREDNISONE ADVERSE_EFFECT CVS_2_Thromboembolism 53-03-2 PREDNISONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 53-03-2 PREDNISONE ADVERSE_EFFECT XXX_2_Malaise 53-03-2 PREDNISONE MECHANISM Modulate gene transcription 53-03-2 PREDNISONE TISSUE_TOXICITY Thromboembolism 53-03-2 PREDNISONE TISSUE_TOXICITY Cardiotoxicity 53-03-2 PREDNISONE MESH_LEVEL_3 Pregnanes 53-03-2 PREDNISONE TA_LEVEL_3 Systemic steroid 53-03-2 PREDNISONE INDICATION Allergic Diseases 53-03-2 PREDNISONE INDICATION Neoplastic Diseases 53-03-2 PREDNISONE INDICATION Edematous States 53-03-2 PREDNISONE TA_LEVEL_1 Anti-inflammatory 53-03-2 PREDNISONE MESH_LEVEL_2 Steroids 53-03-2 PREDNISONE ADVERSE_EFFECT GIS_2_Nausea 53-03-2 PREDNISONE ADVERSE_EFFECT XXX_2_Weight Gain 53-03-2 PREDNISONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 53-03-2 PREDNISONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 53-03-2 PREDNISONE MODE_CLASS Receptor Agonist 53-03-2 PREDNISONE STRUCTURE_ACTIVITY Glucocorticoid and mineralocorticoid receptor agonist 53-03-2 PREDNISONE INDICATION Rheumatic Disorders 53-03-2 PREDNISONE TA_LEVEL_2 Steroid 53-03-2 PREDNISONE MECH_LEVEL_3 Glucocorticoid receptor 53-03-2 PREDNISONE MECH_LEVEL_1 Immunomodulation 53-03-2 PREDNISONE INDICATION Collagen Diseases 53-03-2 PREDNISONE INDICATION Gastrointestinal Diseases 53-03-2 PREDNISONE PRODUCT_CLASS Anti-inflammatories 53-03-2 PREDNISONE ADVERSE_EFFECT CVS_2_Cardiotoxicity 53-03-2 PREDNISONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 53-03-2 PREDNISONE ADVERSE_EFFECT END_2_Metabolic Disturbance 53-03-2 PREDNISONE KNOWN_TOXICITY Cardiovascular Toxicity 53-03-2 PREDNISONE MECH_LEVEL_2 Anti-inflammation and immunosuppression 53-03-2 PREDNISONE INDICATION Ophthalmic Diseases 53-03-2 PREDNISONE INDICATION Hematologic Disorders 53-03-2 PREDNISONE THERAPEUTIC_CLASS Corticosteroids 53-03-2 PREDNISONE ADVERSE_EFFECT IMU_2_Hypersensitivity 53-03-2 PREDNISONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 53-03-2 PREDNISONE ADVERSE_EFFECT SKN_2_Skin Toxicity 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_1_Dyspepsia 22071-15-4 KETOPROFEN TISSUE_TOXICITY Myocardial Infarction 22071-15-4 KETOPROFEN KNOWN_TOXICITY Cardiovascular Toxicity 22071-15-4 KETOPROFEN MODE_CLASS Enzyme Inhibitor 22071-15-4 KETOPROFEN MESH_LEVEL_3 Acids, Carbocyclic 22071-15-4 KETOPROFEN MESH_LEVEL_1 Organic Chemicals 22071-15-4 KETOPROFEN MESH_LEVEL_2 Carboxylic Acids 22071-15-4 KETOPROFEN MECHANISM Inhibit eicosanoid biosynthesis 22071-15-4 KETOPROFEN INDICATION Rheumatoid Arthritis 22071-15-4 KETOPROFEN ADVERSE_EFFECT CVS_2_Hypertension 22071-15-4 KETOPROFEN ADVERSE_EFFECT NEU_1_Headache 22071-15-4 KETOPROFEN ADVERSE_EFFECT SKN_1_Rash 22071-15-4 KETOPROFEN ADVERSE_EFFECT REP_3_Decreased Libido 22071-15-4 KETOPROFEN ADVERSE_EFFECT NEU_2_Vertigo 22071-15-4 KETOPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, arylacylprofen 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 22071-15-4 KETOPROFEN ADVERSE_EFFECT END_3_Diabetes Mellitus 22071-15-4 KETOPROFEN MECH_LEVEL_1 Immunomodulation 22071-15-4 KETOPROFEN TA_LEVEL_3 NSAID 22071-15-4 KETOPROFEN TA_LEVEL_1 Anti-inflammatory 22071-15-4 KETOPROFEN INDICATION Osteoarthritis 22071-15-4 KETOPROFEN ADVERSE_EFFECT NEU_2_Amnesia 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_1_Constipation 22071-15-4 KETOPROFEN ADVERSE_EFFECT CVS_2_Congestive Heart Failure 22071-15-4 KETOPROFEN ADVERSE_EFFECT IMU_2_Allergic Reactions 22071-15-4 KETOPROFEN ADVERSE_EFFECT XXX_2_Infection 22071-15-4 KETOPROFEN ADVERSE_EFFECT MSK_2_Myalgia 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_2_Melena 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_2_Gastritis 22071-15-4 KETOPROFEN TISSUE_TOXICITY Congestive Heart Failure 22071-15-4 KETOPROFEN INDICATION Dysmenorrhea 22071-15-4 KETOPROFEN PRODUCT_CLASS Anti-inflammatories 22071-15-4 KETOPROFEN TISSUE_TOXICITY Shock 22071-15-4 KETOPROFEN ACTIVITY_CLASS Anti-inflammatory 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_1_Nausea 22071-15-4 KETOPROFEN ADVERSE_EFFECT OTO_1_Tinnitus 22071-15-4 KETOPROFEN ADVERSE_EFFECT END_3_Gynecomastia 22071-15-4 KETOPROFEN ADVERSE_EFFECT BBM_2_Thrombocytopenia 22071-15-4 KETOPROFEN ADVERSE_EFFECT KID_1_Impaired Renal Tubular Function 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_1_Flatulence 22071-15-4 KETOPROFEN ZERO_CLASS N 22071-15-4 KETOPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 22071-15-4 KETOPROFEN TA_LEVEL_2 NSAID 22071-15-4 KETOPROFEN INDICATION Pain 22071-15-4 KETOPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 22071-15-4 KETOPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 22071-15-4 KETOPROFEN ADVERSE_EFFECT GIS_1_Diarrhea 22071-15-4 KETOPROFEN ADVERSE_EFFECT CVS_3_Myocardial Infarction 22071-15-4 KETOPROFEN ADVERSE_EFFECT NEU_1_Dizziness 22071-15-4 KETOPROFEN ADVERSE_EFFECT ELT_2_Hyponatremia 22071-15-4 KETOPROFEN ADVERSE_EFFECT CVS_3_Shock 22071-15-4 KETOPROFEN ADVERSE_EFFECT XXX_2_Chills 79902-63-9 SIMVASTATIN ADVERSE_EFFECT IMU_3_Lupus-Like Syndrome 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_1_Diarrhea 79902-63-9 SIMVASTATIN TISSUE_TOXICITY Carcinogenicity 79902-63-9 SIMVASTATIN PRODUCT_CLASS Cardiovasculars 79902-63-9 SIMVASTATIN TA_LEVEL_1 Cardiovascular 79902-63-9 SIMVASTATIN MECH_LEVEL_3 HMG-CoA reductase 79902-63-9 SIMVASTATIN TA_LEVEL_2 Lipid lowering agent 79902-63-9 SIMVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 79902-63-9 SIMVASTATIN ADVERSE_EFFECT REP_3_Erectile Dysfunction 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_1_Abdominal Pain 79902-63-9 SIMVASTATIN ADVERSE_EFFECT SKN_2_Pruritis 79902-63-9 SIMVASTATIN ADVERSE_EFFECT NEU_1_Headache 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_1_Constipation 79902-63-9 SIMVASTATIN INDICATION Arterioslerotic Coronary Artery Disease / Coronary Heart Disease / Ischemic Heart Disease 79902-63-9 SIMVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 79902-63-9 SIMVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 79902-63-9 SIMVASTATIN MESH_LEVEL_3 Naphthalenes 79902-63-9 SIMVASTATIN ADVERSE_EFFECT IMU_3_Anaphylaxis 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_1_Nausea 79902-63-9 SIMVASTATIN ZERO_CLASS N 79902-63-9 SIMVASTATIN ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_1_Dyspepsia 79902-63-9 SIMVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 79902-63-9 SIMVASTATIN ADVERSE_EFFECT SKN_2_Eczema 79902-63-9 SIMVASTATIN ADVERSE_EFFECT SKN_2_Rash 79902-63-9 SIMVASTATIN ADVERSE_EFFECT NEU_3_Tremor 79902-63-9 SIMVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 79902-63-9 SIMVASTATIN INDICATION Hypercholesterolemia 79902-63-9 SIMVASTATIN INDICATION Hyperlipidemia 79902-63-9 SIMVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 79902-63-9 SIMVASTATIN MECH_LEVEL_1 Lipid lowering 79902-63-9 SIMVASTATIN MODE_CLASS Enzyme Inhibitor 79902-63-9 SIMVASTATIN KNOWN_TOXICITY Carcinogenicity 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_1_Flatulence 79902-63-9 SIMVASTATIN ADVERSE_EFFECT REP_2_Decreased Fertility 79902-63-9 SIMVASTATIN ADVERSE_EFFECT MSK_3_Rhabdomyolysis 79902-63-9 SIMVASTATIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 79902-63-9 SIMVASTATIN ADVERSE_EFFECT DNA_2_Carcinogenicity 79902-63-9 SIMVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors, non-aromatic 79902-63-9 SIMVASTATIN MECHANISM Inhibit cholesterol biosynthesis 79902-63-9 SIMVASTATIN INDICATION Familial Dysbetalipoproteinemia 79902-63-9 SIMVASTATIN INDICATION Familial Hypercholesterolemia 79902-63-9 SIMVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 79902-63-9 SIMVASTATIN ADVERSE_EFFECT XXX_1_Asthenia 79902-63-9 SIMVASTATIN ADVERSE_EFFECT GIS_3_Pancreatitis 79902-63-9 SIMVASTATIN ADVERSE_EFFECT OCU_2_Cataracts 79902-63-9 SIMVASTATIN ADVERSE_EFFECT END_3_Gynecomastia 22916-47-8 MICONAZOLE ADVERSE_EFFECT SKN_1_Rash 22916-47-8 MICONAZOLE PRODUCT_CLASS Anti-infectives 22916-47-8 MICONAZOLE INDICATION Tinea Cruris / Jock Itch 22916-47-8 MICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 22916-47-8 MICONAZOLE ADVERSE_EFFECT GIS_1_Vomiting 22916-47-8 MICONAZOLE ADVERSE_EFFECT XXX_1_Chills 22916-47-8 MICONAZOLE MECH_LEVEL_2 Inhibit fungal / microbial cell membrane biosynthesis 22916-47-8 MICONAZOLE INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 22916-47-8 MICONAZOLE MECH_LEVEL_3 sterol,NADPH:oxygen oxidoreductase (14-methyl cleaving) 22916-47-8 MICONAZOLE ADVERSE_EFFECT SKN_1_Pruritis 22916-47-8 MICONAZOLE THERAPEUTIC_CLASS Antifungals, Topical 22916-47-8 MICONAZOLE STRUCTURE_ACTIVITY Sterol 14-demethylase inhibitor, fluconazole like 22916-47-8 MICONAZOLE ADVERSE_EFFECT GIS_1_Nausea 22916-47-8 MICONAZOLE ADVERSE_EFFECT CVS_1_Phlebitis 22916-47-8 MICONAZOLE MODE_CLASS Enzyme Inhibitor 22916-47-8 MICONAZOLE TA_LEVEL_2 Anti-fungal 22916-47-8 MICONAZOLE ZERO_CLASS N 22916-47-8 MICONAZOLE INDICATION Vulvovaginal Candidiasis 22916-47-8 MICONAZOLE ADVERSE_EFFECT XXX_1_Fever 22916-47-8 MICONAZOLE MESH_LEVEL_3 Imidazoles 22916-47-8 MICONAZOLE MECH_LEVEL_1 Anti-fungal 22916-47-8 MICONAZOLE TA_LEVEL_3 Topical 22916-47-8 MICONAZOLE TA_LEVEL_1 Infectious Disease 22916-47-8 MICONAZOLE MESH_LEVEL_1 Heterocyclic Compounds 22916-47-8 MICONAZOLE INDICATION Tinea Pedis / Athlete's Foot 22916-47-8 MICONAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 22916-47-8 MICONAZOLE ACTIVITY_CLASS Antifungals azole 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_2_Flatulence 34031-32-8 AURANOFIN ADVERSE_EFFECT PSY_2_Anorexia 34031-32-8 AURANOFIN ADVERSE_EFFECT BBM_3_Anemia 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_2_Dyspepsia 34031-32-8 AURANOFIN ADVERSE_EFFECT KID_2_Nephrotic Syndrome 34031-32-8 AURANOFIN PRODUCT_CLASS Anti-inflammatories 34031-32-8 AURANOFIN ADVERSE_EFFECT NEU_3_Headache 34031-32-8 AURANOFIN ADVERSE_EFFECT BBM_3_Leukopenia 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_2_Stomatitis 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_1_Abdominal Cramps 34031-32-8 AURANOFIN INDICATION Rheumatoid Arthritis 34031-32-8 AURANOFIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 34031-32-8 AURANOFIN STRUCTURE_ACTIVITY Unknown mechanism, inflammation mediator/ blocker 34031-32-8 AURANOFIN KNOWN_TOXICITY Nephrotoxicity 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_1_Nausea 34031-32-8 AURANOFIN ADVERSE_EFFECT IMU_2_Urticaria 34031-32-8 AURANOFIN ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 34031-32-8 AURANOFIN TISSUE_TOXICITY Nephrotic Syndrome 34031-32-8 AURANOFIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 34031-32-8 AURANOFIN ACTIVITY_CLASS Unknown mechanism 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_1_Diarrhea 34031-32-8 AURANOFIN THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 34031-32-8 AURANOFIN ADVERSE_EFFECT LIV_3_Jaundice 34031-32-8 AURANOFIN ADVERSE_EFFECT OCU_3_Conjunctivitis 34031-32-8 AURANOFIN ADVERSE_EFFECT GIS_1_Vomiting 298-81-7 METHOXSALEN PRODUCT_CLASS Other Human Uses 298-81-7 METHOXSALEN ADVERSE_EFFECT PSY_2_Insomnia 298-81-7 METHOXSALEN ADVERSE_EFFECT CVS_3_Hypotension 298-81-7 METHOXSALEN ADVERSE_EFFECT IMU_3_Urticaria 298-81-7 METHOXSALEN PRODUCT_CLASS Anti-cancers 298-81-7 METHOXSALEN ADVERSE_EFFECT GIS_1_Nausea 298-81-7 METHOXSALEN TISSUE_TOXICITY Hypotension 298-81-7 METHOXSALEN KNOWN_TOXICITY Cardiovascular Toxicity 298-81-7 METHOXSALEN ADVERSE_EFFECT SKN_2_Erythema 298-81-7 METHOXSALEN MECHANISM Inhibit DNA synthesis, repair, and function 298-81-7 METHOXSALEN INDICATION Psoriasis 298-81-7 METHOXSALEN MODE_CLASS Enzyme Inhibitor 298-81-7 METHOXSALEN ADVERSE_EFFECT XXX_3_Edema 298-81-7 METHOXSALEN ADVERSE_EFFECT NEU_3_Headache 298-81-7 METHOXSALEN THERAPEUTIC_CLASS Psoralens 298-81-7 METHOXSALEN ADVERSE_EFFECT PSY_2_Depression 298-81-7 METHOXSALEN ADVERSE_EFFECT SKN_3_Hypopigmentation 298-81-7 METHOXSALEN MECHANISM interferes with liver P450 enzyme funciton 298-81-7 METHOXSALEN STRUCTURE_ACTIVITY P450 enzyme inhibitor 298-81-7 METHOXSALEN ADVERSE_EFFECT SKN_2_Pruritis 298-81-7 METHOXSALEN MODE_CLASS Distorts /blocks macromolecular scaffold function 298-81-7 METHOXSALEN ADVERSE_EFFECT NEU_3_Dizziness 298-81-7 METHOXSALEN ADVERSE_EFFECT PSY_2_Nervousness 298-81-7 METHOXSALEN INDICATION Cutaneous T-Cell Lymphoma / Mycosis Fungoides 298-81-7 METHOXSALEN INDICATION Vitiligo 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Encephalopathy 12244-57-4 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Hepatotoxicity 12244-57-4 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Glomerulonephritis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Bronchitis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Stomatitis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Granulocytopenia 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Pruritis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 12244-57-4 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Nephrotoxicity 12244-57-4 GOLD SODIUM THIOMALATE INDICATION Still's Disease / Juvenile Chronic Arthritis 12244-57-4 GOLD SODIUM THIOMALATE ACTIVITY_CLASS Anti-inflammatory 12244-57-4 GOLD SODIUM THIOMALATE MODE_CLASS Enzyme Inhibitor 12244-57-4 GOLD SODIUM THIOMALATE PRODUCT_CLASS Anti-inflammatories 12244-57-4 GOLD SODIUM THIOMALATE STRUCTURE_ACTIVITY Antiinflammatory, elastase inhibitor 12244-57-4 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Hepatotoxicity 12244-57-4 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Nephrotic Syndrome 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_3_Enterocolitis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Metallic Taste 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Leukopenia 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Seizures 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT IMU_3_Anaphylaxis 12244-57-4 GOLD SODIUM THIOMALATE INDICATION Rheumatoid Arthritis 12244-57-4 GOLD SODIUM THIOMALATE MECHANISM Inhibit inflammatory response 12244-57-4 GOLD SODIUM THIOMALATE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT XXX_2_Glossitis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_2_Nephrotic Syndrome 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Dermatitis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Jaundice 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_3_Glomerulonephritis 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Skin Rash 12244-57-4 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Pancytopenia 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT XXX_2_Glossitis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Granulocytopenia 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Stomatitis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Bronchitis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 3504-43-6 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Glomerulonephritis 3504-43-6 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Nephrotic Syndrome 3504-43-6 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Hepatotoxicity 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Encephalopathy 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Pancytopenia 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Skin Rash 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_3_Glomerulonephritis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Jaundice 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Dermatitis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_2_Nephrotic Syndrome 3504-43-6 GOLD SODIUM THIOMALATE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 3504-43-6 GOLD SODIUM THIOMALATE MECHANISM Inhibit inflammatory response 3504-43-6 GOLD SODIUM THIOMALATE INDICATION Rheumatoid Arthritis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT IMU_3_Anaphylaxis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Seizures 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Leukopenia 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Metallic Taste 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_3_Enterocolitis 3504-43-6 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Hepatotoxicity 3504-43-6 GOLD SODIUM THIOMALATE STRUCTURE_ACTIVITY Antiinflammatory, elastase inhibitor 3504-43-6 GOLD SODIUM THIOMALATE PRODUCT_CLASS Anti-inflammatories 3504-43-6 GOLD SODIUM THIOMALATE MODE_CLASS Enzyme Inhibitor 3504-43-6 GOLD SODIUM THIOMALATE ACTIVITY_CLASS Anti-inflammatory 3504-43-6 GOLD SODIUM THIOMALATE INDICATION Still's Disease / Juvenile Chronic Arthritis 3504-43-6 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Nephrotoxicity 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3504-43-6 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Pruritis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Bronchitis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Stomatitis 16905-00-3 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Hepatotoxicity 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Encephalopathy 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Pancytopenia 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Skin Rash 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Granulocytopenia 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_3_Glomerulonephritis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Jaundice 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Dermatitis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_2_Nephrotic Syndrome 16905-00-3 GOLD SODIUM THIOMALATE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 16905-00-3 GOLD SODIUM THIOMALATE MECHANISM Inhibit inflammatory response 16905-00-3 GOLD SODIUM THIOMALATE INDICATION Rheumatoid Arthritis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT IMU_3_Anaphylaxis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Seizures 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Leukopenia 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT XXX_2_Glossitis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Metallic Taste 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Pruritis 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_3_Enterocolitis 16905-00-3 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Glomerulonephritis 16905-00-3 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Nephrotic Syndrome 16905-00-3 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Hepatotoxicity 16905-00-3 GOLD SODIUM THIOMALATE STRUCTURE_ACTIVITY Antiinflammatory, elastase inhibitor 16905-00-3 GOLD SODIUM THIOMALATE PRODUCT_CLASS Anti-inflammatories 16905-00-3 GOLD SODIUM THIOMALATE MODE_CLASS Enzyme Inhibitor 16905-00-3 GOLD SODIUM THIOMALATE ACTIVITY_CLASS Anti-inflammatory 16905-00-3 GOLD SODIUM THIOMALATE INDICATION Still's Disease / Juvenile Chronic Arthritis 16905-00-3 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Nephrotoxicity 16905-00-3 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Encephalopathy 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Pancytopenia 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Skin Rash 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_3_Glomerulonephritis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LIV_2_Jaundice 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Dermatitis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT KID_2_Nephrotic Syndrome 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT XXX_2_Glossitis 18911-13-2 GOLD SODIUM THIOMALATE THERAPEUTIC_CLASS Antirheumatic Disease Modifying Agents 18911-13-2 GOLD SODIUM THIOMALATE MECHANISM Inhibit inflammatory response 18911-13-2 GOLD SODIUM THIOMALATE INDICATION Rheumatoid Arthritis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT IMU_3_Anaphylaxis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Seizures 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Leukopenia 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Interstitial Pneumonitis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT OCU_2_Corneal Microdeposits 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Metallic Taste 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_3_Enterocolitis 18911-13-2 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Nephrotic Syndrome 18911-13-2 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Hepatotoxicity 18911-13-2 GOLD SODIUM THIOMALATE STRUCTURE_ACTIVITY Antiinflammatory, elastase inhibitor 18911-13-2 GOLD SODIUM THIOMALATE PRODUCT_CLASS Anti-inflammatories 18911-13-2 GOLD SODIUM THIOMALATE MODE_CLASS Enzyme Inhibitor 18911-13-2 GOLD SODIUM THIOMALATE ACTIVITY_CLASS Anti-inflammatory 18911-13-2 GOLD SODIUM THIOMALATE INDICATION Still's Disease / Juvenile Chronic Arthritis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT SKN_1_Pruritis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT BBM_3_Granulocytopenia 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT GIS_2_Stomatitis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT LUN_3_Bronchitis 18911-13-2 GOLD SODIUM THIOMALATE ADVERSE_EFFECT NEU_3_Guillain-Barre Syndrome 18911-13-2 GOLD SODIUM THIOMALATE TISSUE_TOXICITY Glomerulonephritis 18911-13-2 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Nephrotoxicity 18911-13-2 GOLD SODIUM THIOMALATE KNOWN_TOXICITY Hepatotoxicity 51146-57-7 R(-)-IBUPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51146-57-7 R(-)-IBUPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 51146-57-7 R(-)-IBUPROFEN PRODUCT_CLASS Anti-inflammatories 51146-57-7 R(-)-IBUPROFEN MODE_CLASS Enzyme Inhibitor 51146-57-7 R(-)-IBUPROFEN MECHANISM Inhibit eicosanoid biosynthesis 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT IMU_2_Allergic Reactions 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT SKN_2_Skin Rash 113403-10-4 DEXIBUPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT LUN_2_Wheezing 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_3_Gastric Bleeding 113403-10-4 DEXIBUPROFEN ACTIVITY_CLASS Anti-inflammatory 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT LUN_2_Dyspnea 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT PSY_2_Insomnia 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_2_Gastritis 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 113403-10-4 DEXIBUPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 113403-10-4 DEXIBUPROFEN KNOWN_TOXICITY Cardiovascular Toxicity 113403-10-4 DEXIBUPROFEN MODE_CLASS Enzyme Inhibitor 113403-10-4 DEXIBUPROFEN TA_LEVEL_3 NSAID 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_2_Gastric Ulceration 113403-10-4 DEXIBUPROFEN INDICATION Osteoarthritis 113403-10-4 DEXIBUPROFEN PRODUCT_CLASS Anti-inflammatories 113403-10-4 DEXIBUPROFEN MECH_LEVEL_1 Immunomodulation 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Epigastric Pain 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT NEU_2_Headache 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 113403-10-4 DEXIBUPROFEN ZERO_CLASS N 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT PSY_3_Depression 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT IMU_2_Hives 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Heartburn 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT SKN_2_Pruritis 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT CVS_3_Shock 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT XXX_2_Facial Edema 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Gastrointestinal Irritation 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT NEU_1_Dizziness 113403-10-4 DEXIBUPROFEN TA_LEVEL_1 Anti-inflammatory 113403-10-4 DEXIBUPROFEN TA_LEVEL_2 NSAID 113403-10-4 DEXIBUPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 113403-10-4 DEXIBUPROFEN TISSUE_TOXICITY Shock 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT SKN_2_Skin Reactions 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT LUN_2_Asthma 113403-10-4 DEXIBUPROFEN ADVERSE_EFFECT KID_3_Kidney Damage 113403-10-4 DEXIBUPROFEN MECHANISM Inhibit eicosanoid biosynthesis 113403-10-4 DEXIBUPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_2_Gastric Ulceration 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT LUN_2_Wheezing 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_3_Gastric Bleeding 51146-56-6 DEXIBUPROFEN ACTIVITY_CLASS Anti-inflammatory 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT LUN_2_Dyspnea 51146-56-6 DEXIBUPROFEN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Abdominal Pain 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_2_Gastritis 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT PSY_2_Insomnia 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT CVS_3_Shock 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_2_Diarrhea 51146-56-6 DEXIBUPROFEN INDICATION Osteoarthritis 51146-56-6 DEXIBUPROFEN STRUCTURE_ACTIVITY NSAID, COX-1, ibuprofen like 51146-56-6 DEXIBUPROFEN MECHANISM Inhibit eicosanoid biosynthesis 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT KID_3_Kidney Damage 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT LUN_2_Asthma 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT SKN_2_Skin Reactions 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 51146-56-6 DEXIBUPROFEN TISSUE_TOXICITY Shock 51146-56-6 DEXIBUPROFEN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 51146-56-6 DEXIBUPROFEN TA_LEVEL_2 NSAID 51146-56-6 DEXIBUPROFEN TA_LEVEL_1 Anti-inflammatory 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT NEU_1_Dizziness 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Gastrointestinal Irritation 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT XXX_2_Facial Edema 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT SKN_2_Pruritis 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Heartburn 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT SKN_2_Skin Rash 51146-56-6 DEXIBUPROFEN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 51146-56-6 DEXIBUPROFEN MECH_LEVEL_1 Immunomodulation 51146-56-6 DEXIBUPROFEN PRODUCT_CLASS Anti-inflammatories 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT GIS_1_Epigastric Pain 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT NEU_2_Headache 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT XXX_2_Peripheral Edema 51146-56-6 DEXIBUPROFEN ZERO_CLASS N 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT IMU_2_Allergic Reactions 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT PSY_3_Depression 51146-56-6 DEXIBUPROFEN ADVERSE_EFFECT IMU_2_Hives 51146-56-6 DEXIBUPROFEN TA_LEVEL_3 NSAID 51146-56-6 DEXIBUPROFEN MODE_CLASS Enzyme Inhibitor 51146-56-6 DEXIBUPROFEN KNOWN_TOXICITY Cardiovascular Toxicity 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 841-67-8 (-)-THALIDOMIDE INDICATION Erythema Nodosum Leprosum (ENL) 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT EMB_2_Teratogenicity 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT SKN_1_Rash 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT LYM_3_Lymphadenopathy 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT KID_3_Hematuria 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT NEU_1_Somnolence 841-67-8 (-)-THALIDOMIDE TISSUE_TOXICITY Teratogenicity 841-67-8 (-)-THALIDOMIDE PRODUCT_CLASS Immune Response / Immunomodulators 841-67-8 (-)-THALIDOMIDE THERAPEUTIC_CLASS Immunomodulants 841-67-8 (-)-THALIDOMIDE KNOWN_TOXICITY Nephrotoxicity 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT NEU_1_Dizziness 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT REP_3_Impotence 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT NEU_3_Vertigo 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT SKN_3_Pruritis 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT XXX_3_Peripheral Edema 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT BBM_2_Neutropenia 841-67-8 (-)-THALIDOMIDE TISSUE_TOXICITY Hematuria 841-67-8 (-)-THALIDOMIDE STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 841-67-8 (-)-THALIDOMIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT CVS_2_Bradycardia 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT IMU_2_Hypersensitivity 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT XXX_3_Infection 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 841-67-8 (-)-THALIDOMIDE ADVERSE_EFFECT XXX_3_Asthenia 2614-06-4 (+)-THALIDOMIDE INDICATION Erythema Nodosum Leprosum (ENL) 2614-06-4 (+)-THALIDOMIDE PRODUCT_CLASS Immune Response / Immunomodulators 2614-06-4 (+)-THALIDOMIDE THERAPEUTIC_CLASS Immunomodulants 2614-06-4 (+)-THALIDOMIDE KNOWN_TOXICITY Nephrotoxicity 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT REP_3_Impotence 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT IMU_2_Hypersensitivity 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT XXX_3_Infection 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT XXX_3_Asthenia 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT CVS_2_Bradycardia 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT LYM_3_Lymphadenopathy 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT KID_3_Hematuria 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT NEU_1_Somnolence 2614-06-4 (+)-THALIDOMIDE TISSUE_TOXICITY Hematuria 2614-06-4 (+)-THALIDOMIDE STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 2614-06-4 (+)-THALIDOMIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT EMB_2_Teratogenicity 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT SKN_1_Rash 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT NEU_3_Vertigo 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT NEU_1_Dizziness 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT SKN_3_Pruritis 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT XXX_3_Peripheral Edema 2614-06-4 (+)-THALIDOMIDE ADVERSE_EFFECT BBM_2_Neutropenia 2614-06-4 (+)-THALIDOMIDE TISSUE_TOXICITY Teratogenicity 156727-74-1 SNC-80 MODE_CLASS Receptor Agonist, selective 156727-74-1 SNC-80 MECHANISM Modulate neural transmission 156727-74-1 SNC-80 PRODUCT_CLASS Biochemicals 39026-63-6 (1S,3R)-TRANS-ACPD MECHANISM Modulate G-protein coupled signal transduction 39026-63-6 (1S,3R)-TRANS-ACPD MODE_CLASS Receptor Agonist 39026-63-6 (1S,3R)-TRANS-ACPD PRODUCT_CLASS Biochemicals 84-17-3 DIENESTROL PRODUCT_CLASS Hormones, Endocrine and Metabolic 84-17-3 DIENESTROL INDICATION Vulvar Squamous Hyperplasia 84-17-3 DIENESTROL MODE_CLASS Receptor Agonist 84-17-3 DIENESTROL THERAPEUTIC_CLASS Gonadal Hormones 84-17-3 DIENESTROL MECHANISM Modulate gene transcription 84-17-3 DIENESTROL INDICATION Atrophic Vaginitis 1642-54-2 DIETHYLCARBAMAZINE INDICATION Loiasis 1642-54-2 DIETHYLCARBAMAZINE INDICATION Onchocerciasis 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT SKN_2_Erythroderma 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT NEU_2_Somnolence 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT OCU_2_Ocular Irritation 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT MSK_2_Muscle Pain 1642-54-2 DIETHYLCARBAMAZINE THERAPEUTIC_CLASS Antiparasitics 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT SKN_2_Skin Eruption 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT KID_2_Proteinuria 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT XXX_2_Fever 1642-54-2 DIETHYLCARBAMAZINE INDICATION Filariasis 1642-54-2 DIETHYLCARBAMAZINE INDICATION Protozoal Infections 1642-54-2 DIETHYLCARBAMAZINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 1642-54-2 DIETHYLCARBAMAZINE PRODUCT_CLASS Anti-infectives 1642-54-2 DIETHYLCARBAMAZINE INDICATION Tropical Eosinophilia 1642-54-2 DIETHYLCARBAMAZINE INDICATION Eosinophilic Pulmonary Syndromes 1642-54-2 DIETHYLCARBAMAZINE INDICATION Helminthic Infections 90-84-6 DIETHYLPROPION PRODUCT_CLASS Central Nervous System (CNS) 90-84-6 DIETHYLPROPION THERAPEUTIC_CLASS Anorexiants 90-84-6 DIETHYLPROPION INDICATION Obesity 134-80-5 DIETHYLPROPION PRODUCT_CLASS Central Nervous System (CNS) 134-80-5 DIETHYLPROPION THERAPEUTIC_CLASS Anorexiants 134-80-5 DIETHYLPROPION INDICATION Obesity 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT ELT_2_Hypercalcemia 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT GUS_2_Genital Moniliasis 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT MSK_1_Back Pain 56-53-1 DIETHYLSTILBESTROL THERAPEUTIC_CLASS Gonadal Hormones 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT BIL_2_Gallbladder Disease 56-53-1 DIETHYLSTILBESTROL PRODUCT_CLASS Anti-cancers 56-53-1 DIETHYLSTILBESTROL INDICATION Prostatic Cancer / Carcinoma of the Prostate 56-53-1 DIETHYLSTILBESTROL MESH_LEVEL_1 Organic Chemicals 56-53-1 DIETHYLSTILBESTROL MESH_LEVEL_3 Hydrocarbons, Cyclic 56-53-1 DIETHYLSTILBESTROL KNOWN_TOXICITY Cardiovascular Toxicity 56-53-1 DIETHYLSTILBESTROL TISSUE_TOXICITY Thromboembolism 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT CVS_2_Hypertension 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT GUS_2_Genital Pruritis 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT NEU_1_Headache 56-53-1 DIETHYLSTILBESTROL KNOWN_TOXICITY Embryo/Fetal Toxicity 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT DNA_1_Carcinogenicity 56-53-1 DIETHYLSTILBESTROL TISSUE_TOXICITY Fetal Toxicity 56-53-1 DIETHYLSTILBESTROL MODE_CLASS Receptor Ligand Antagonist 56-53-1 DIETHYLSTILBESTROL MECH_LEVEL_2 estrogen receptor agonist 56-53-1 DIETHYLSTILBESTROL TA_LEVEL_3 SERM 56-53-1 DIETHYLSTILBESTROL ACTIVITY_CLASS Estrogen agonist 56-53-1 DIETHYLSTILBESTROL TISSUE_TOXICITY Carcinogenicity 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT GIS_1_Abdominal Pain 56-53-1 DIETHYLSTILBESTROL ZERO_CLASS N 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 56-53-1 DIETHYLSTILBESTROL MECHANISM Modulate gene transcription 56-53-1 DIETHYLSTILBESTROL TA_LEVEL_1 Oncology 56-53-1 DIETHYLSTILBESTROL INDICATION Metastatic Breast Cancer 56-53-1 DIETHYLSTILBESTROL MESH_LEVEL_2 Hydrocarbons 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT DNA_2_Hepatic Adenoma 56-53-1 DIETHYLSTILBESTROL TA_LEVEL_2 Nonsteroidal SERM 56-53-1 DIETHYLSTILBESTROL KNOWN_TOXICITY Carcinogenicity 56-53-1 DIETHYLSTILBESTROL TISSUE_TOXICITY Hepatic Adenoma 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT EMB_1_Fetal Toxicity 56-53-1 DIETHYLSTILBESTROL MECH_LEVEL_1 Hormone modulation 56-53-1 DIETHYLSTILBESTROL MECH_LEVEL_3 estrogen receptor 56-53-1 DIETHYLSTILBESTROL STRUCTURE_ACTIVITY Estrogen receptor agonist 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT CVS_2_Thromboembolism 56-53-1 DIETHYLSTILBESTROL ADVERSE_EFFECT END_2_Glucose Intolerance 28782-42-5 DIFENOXIN MODE_CLASS Receptor Agonist 28782-42-5 DIFENOXIN MECHANISM Modulate neural transmission 28782-42-5 DIFENOXIN INDICATION Diarrhea 28782-42-5 DIFENOXIN THERAPEUTIC_CLASS Antidiarrhea Agents 28782-42-5 DIFENOXIN PRODUCT_CLASS Gastrointestinal System 33564-31-7 DIFLORASONE DIACETATE MODE_CLASS Receptor Agonist 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_2_Acneiform Rash 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT CVS_3_Telangiectasia 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT END_3_Cushing's Syndrome 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT IMU_2_Contact Dermatitis 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT END_3_Hyperglycemia 33564-31-7 DIFLORASONE DIACETATE INDICATION Dermatitis 33564-31-7 DIFLORASONE DIACETATE INDICATION Skin Diseases / Dermatoses 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 33564-31-7 DIFLORASONE DIACETATE PRODUCT_CLASS Dermatologicals 33564-31-7 DIFLORASONE DIACETATE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT CVS_3_Hypertension 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT END_3_Adrenal Insufficiency 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_3_Skin Ulcer 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT XXX_3_Miliaria 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_3_Skin Atrophy 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT XXX_3_Xerosis 33564-31-7 DIFLORASONE DIACETATE MECHANISM Modulate gene transcription 33564-31-7 DIFLORASONE DIACETATE THERAPEUTIC_CLASS Corticosteroids, Topical 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT XXX_3_Withdrawal 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT XXX_3_Infection 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_2_Skin Rash 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_2_Skin Irritation 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT XXX_2_Impaired Wound Healing 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT XXX_2_Tolerance 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_2_Erythema 33564-31-7 DIFLORASONE DIACETATE ADVERSE_EFFECT SKN_3_Hypertrichosis 33564-31-7 DIFLORASONE DIACETATE INDICATION Pruritus / Itching 22494-42-4 DIFLUNISAL KNOWN_TOXICITY Nephrotoxicity 22494-42-4 DIFLUNISAL MECHANISM Inhibit eicosanoid biosynthesis 22494-42-4 DIFLUNISAL INDICATION Pain 22494-42-4 DIFLUNISAL PRODUCT_CLASS Anti-inflammatories 22494-42-4 DIFLUNISAL TA_LEVEL_3 NSAID 22494-42-4 DIFLUNISAL MECH_LEVEL_1 Immunomodulation 22494-42-4 DIFLUNISAL ADVERSE_EFFECT NEU_2_Somnolence 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GUS_3_Dysuria 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_1_Abdominal Pain 22494-42-4 DIFLUNISAL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_3_Intestinal Perforation 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_1_Dyspepsia 22494-42-4 DIFLUNISAL ADVERSE_EFFECT PSY_3_Hallucinations 22494-42-4 DIFLUNISAL ADVERSE_EFFECT BBM_3_Hemolytic Anemia 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 22494-42-4 DIFLUNISAL TA_LEVEL_1 Anti-inflammatory 22494-42-4 DIFLUNISAL ZERO_CLASS N 22494-42-4 DIFLUNISAL ADVERSE_EFFECT OCU_3_Blurred Vision 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 22494-42-4 DIFLUNISAL MESH_LEVEL_1 Organic Chemicals 22494-42-4 DIFLUNISAL MESH_LEVEL_3 Hydroxybenzoic Acids 22494-42-4 DIFLUNISAL MESH_LEVEL_2 Phenols 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_2_Constipation 22494-42-4 DIFLUNISAL ADVERSE_EFFECT PSY_2_Insomnia 22494-42-4 DIFLUNISAL ADVERSE_EFFECT NEU_2_Dizziness 22494-42-4 DIFLUNISAL MODE_CLASS Enzyme Inhibitor 22494-42-4 DIFLUNISAL ADVERSE_EFFECT SKN_2_Rash 22494-42-4 DIFLUNISAL ADVERSE_EFFECT PSY_3_Confusion 22494-42-4 DIFLUNISAL ADVERSE_EFFECT XXX_3_Peripheral Edema 22494-42-4 DIFLUNISAL MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 22494-42-4 DIFLUNISAL ADVERSE_EFFECT KID_3_Proteinuria 22494-42-4 DIFLUNISAL THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 22494-42-4 DIFLUNISAL TISSUE_TOXICITY Renal Failure 22494-42-4 DIFLUNISAL STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 22494-42-4 DIFLUNISAL ADVERSE_EFFECT NEU_3_Paresthesia 22494-42-4 DIFLUNISAL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 22494-42-4 DIFLUNISAL TA_LEVEL_2 NSAID 22494-42-4 DIFLUNISAL ADVERSE_EFFECT KID_3_Renal Failure 22494-42-4 DIFLUNISAL ADVERSE_EFFECT NEU_1_Headache 22494-42-4 DIFLUNISAL INDICATION Osteoarthritis 22494-42-4 DIFLUNISAL ADVERSE_EFFECT LIV_3_Hepatitis 22494-42-4 DIFLUNISAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 22494-42-4 DIFLUNISAL ADVERSE_EFFECT NEU_3_Vertigo 22494-42-4 DIFLUNISAL ADVERSE_EFFECT LIV_3_Jaundice 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_2_Flatulence 22494-42-4 DIFLUNISAL ADVERSE_EFFECT GIS_1_Diarrhea 22494-42-4 DIFLUNISAL ADVERSE_EFFECT PSY_3_Nervousness 22494-42-4 DIFLUNISAL ACTIVITY_CLASS Anti-inflammatory 22494-42-4 DIFLUNISAL MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 22494-42-4 DIFLUNISAL INDICATION Rheumatoid Arthritis 22494-42-4 DIFLUNISAL ADVERSE_EFFECT BBM_3_Agranulocytosis 22494-42-4 DIFLUNISAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 22494-42-4 DIFLUNISAL ADVERSE_EFFECT BBM_3_Thrombocytopenia 1672-46-4 DIGOXIGENIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 1672-46-4 DIGOXIGENIN PRODUCT_CLASS Cardiovasculars 1672-46-4 DIGOXIGENIN MECHANISM Increase muscle contraction 1672-46-4 DIGOXIGENIN MODE_CLASS Enzyme Inhibitor 11024-24-1 DIGITONIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 11024-24-1 DIGITONIN ADVERSE_EFFECT BBM_3_Hemolysis 11024-24-1 DIGITONIN MECH_LEVEL_3 Unknown mechanism 11024-24-1 DIGITONIN MODE_CLASS Distorts /blocks macromolecular scaffold function 11024-24-1 DIGITONIN ADVERSE_EFFECT GIS_2_Gastrointestinal Irritation 11024-24-1 DIGITONIN ZERO_CLASS N 11024-24-1 DIGITONIN MECH_LEVEL_2 cell wall 11024-24-1 DIGITONIN ACTIVITY_CLASS Na+/K+-ATPase inhibitor 11024-24-1 DIGITONIN MECHANISM Increase muscle contraction 11024-24-1 DIGITONIN MESH_LEVEL_3 Glycosides 11024-24-1 DIGITONIN ADVERSE_EFFECT XXX_1_Deposits in Tissues 11024-24-1 DIGITONIN MECH_LEVEL_1 membrane function 11024-24-1 DIGITONIN MECHANISM Destroy cell membrane / wall integrity 11024-24-1 DIGITONIN PRODUCT_CLASS Biochemicals 11024-24-1 DIGITONIN TA_LEVEL_1 Cardiovascular 11024-24-1 DIGITONIN MODE_CLASS Enzyme Inhibitor 11024-24-1 DIGITONIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 11024-24-1 DIGITONIN ADVERSE_EFFECT XXX_1_Inflammation 11024-24-1 DIGITONIN MESH_LEVEL_2 Carbohydrates 71-63-6 DIGITOXIN ZERO_CLASS N 71-63-6 DIGITOXIN MECH_LEVEL_2 Cardiac ATPase 71-63-6 DIGITOXIN THERAPEUTIC_CLASS Antiarrhythmic Agents 71-63-6 DIGITOXIN ADVERSE_EFFECT NEU_3_Convulsions 71-63-6 DIGITOXIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 71-63-6 DIGITOXIN INDICATION Atrial Fibrillation 71-63-6 DIGITOXIN MECH_LEVEL_3 Sodium/potassium-exchanging ATPase 71-63-6 DIGITOXIN PRODUCT_CLASS Cardiovasculars 71-63-6 DIGITOXIN TISSUE_TOXICITY Cardiac Arrhythmia 71-63-6 DIGITOXIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 71-63-6 DIGITOXIN ADVERSE_EFFECT CVS_2_Cardiac Conduction System Malfunction 71-63-6 DIGITOXIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 71-63-6 DIGITOXIN ADVERSE_EFFECT GIS_1_Abdominal Pain 71-63-6 DIGITOXIN MESH_LEVEL_3 Glycosides 71-63-6 DIGITOXIN INDICATION Heart Failure 71-63-6 DIGITOXIN MECH_LEVEL_1 Increase cardiac contractility 71-63-6 DIGITOXIN TA_LEVEL_3 Cardiac glycoside 71-63-6 DIGITOXIN KNOWN_TOXICITY Cardiovascular Toxicity 71-63-6 DIGITOXIN ACTIVITY_CLASS Na+/K+-ATPase inhibitor 71-63-6 DIGITOXIN ADVERSE_EFFECT PSY_1_Anorexia 71-63-6 DIGITOXIN ADVERSE_EFFECT END_3_Gynecomastia 71-63-6 DIGITOXIN ADVERSE_EFFECT OCU_3_Xanthopsia 71-63-6 DIGITOXIN ADVERSE_EFFECT PSY_3_Psychosis 71-63-6 DIGITOXIN ADVERSE_EFFECT SKN_2_Skin Rash 71-63-6 DIGITOXIN TA_LEVEL_1 Cardiovascular 71-63-6 DIGITOXIN ADVERSE_EFFECT NEU_1_Headache 71-63-6 DIGITOXIN ADVERSE_EFFECT GIS_1_Diarrhea 71-63-6 DIGITOXIN TISSUE_TOXICITY Cardiac Conduction System Malfunction 71-63-6 DIGITOXIN THERAPEUTIC_CLASS Congestive Heart Failure 71-63-6 DIGITOXIN MODE_CLASS Enzyme Inhibitor 71-63-6 DIGITOXIN MESH_LEVEL_2 Carbohydrates 71-63-6 DIGITOXIN MECHANISM Increase muscle contraction 71-63-6 DIGITOXIN TA_LEVEL_2 Heart failure 71-63-6 DIGITOXIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 71-63-6 DIGITOXIN ADVERSE_EFFECT OCU_3_Abnormal Vision 71-63-6 DIGITOXIN ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 71-63-6 DIGITOXIN ADVERSE_EFFECT NEU_2_Dizziness 71-63-6 DIGITOXIN ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 71-63-6 DIGITOXIN ADVERSE_EFFECT NEU_2_Chorea 20830-75-5 DIGOXIN ADVERSE_EFFECT CVS_1_Atrial Tachycardia 20830-75-5 DIGOXIN MECHANISM Increase muscle contraction 20830-75-5 DIGOXIN TISSUE_TOXICITY Atrial Tachycardia 20830-75-5 DIGOXIN MESH_LEVEL_3 Glycosides 20830-75-5 DIGOXIN MECH_LEVEL_1 Increase cardiac contractility 20830-75-5 DIGOXIN TA_LEVEL_3 Cardiac glycoside 20830-75-5 DIGOXIN ADVERSE_EFFECT GIS_2_Diarrhea 20830-75-5 DIGOXIN ADVERSE_EFFECT PSY_3_Anxiety 20830-75-5 DIGOXIN ADVERSE_EFFECT NEU_3_Headache 20830-75-5 DIGOXIN ADVERSE_EFFECT CVS_1_Heart Block 20830-75-5 DIGOXIN ADVERSE_EFFECT OCU_3_Xanthopsia 20830-75-5 DIGOXIN ZERO_CLASS N 20830-75-5 DIGOXIN ACTIVITY_CLASS Na+/K+-ATPase inhibitor 20830-75-5 DIGOXIN MECH_LEVEL_2 Cardiac ATPase 20830-75-5 DIGOXIN KNOWN_TOXICITY Cardiovascular Toxicity 20830-75-5 DIGOXIN STRUCTURE_ACTIVITY Na+/K+-ATPase inhibitor 20830-75-5 DIGOXIN ADVERSE_EFFECT PSY_2_Anorexia 20830-75-5 DIGOXIN ADVERSE_EFFECT XXX_3_Weakness 20830-75-5 DIGOXIN ADVERSE_EFFECT PSY_3_Confusion 20830-75-5 DIGOXIN ADVERSE_EFFECT GIS_3_Abdominal Pain 20830-75-5 DIGOXIN TA_LEVEL_1 Cardiovascular 20830-75-5 DIGOXIN INDICATION Congestive Heart Failure (CHF) 20830-75-5 DIGOXIN PRODUCT_CLASS Cardiovasculars 20830-75-5 DIGOXIN TA_LEVEL_2 Heart failure 20830-75-5 DIGOXIN MESH_LEVEL_2 Carbohydrates 20830-75-5 DIGOXIN INDICATION Atrial Fibrillation 20830-75-5 DIGOXIN MODE_CLASS Enzyme Inhibitor 20830-75-5 DIGOXIN TISSUE_TOXICITY Premature Ventricular Beats 20830-75-5 DIGOXIN THERAPEUTIC_CLASS Congestive Heart Failure 20830-75-5 DIGOXIN TISSUE_TOXICITY Heart Block 20830-75-5 DIGOXIN ADVERSE_EFFECT PSY_3_Depression 20830-75-5 DIGOXIN ADVERSE_EFFECT GIS_2_Vomiting 20830-75-5 DIGOXIN ADVERSE_EFFECT END_3_Gynecomastia 20830-75-5 DIGOXIN ADVERSE_EFFECT GIS_3_Intestinal Necrosis 20830-75-5 DIGOXIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 20830-75-5 DIGOXIN MECH_LEVEL_3 Sodium/potassium-exchanging ATPase 20830-75-5 DIGOXIN THERAPEUTIC_CLASS Parasympathomimetic Agents 20830-75-5 DIGOXIN ADVERSE_EFFECT OCU_3_Blurred Vision 20830-75-5 DIGOXIN ADVERSE_EFFECT GIS_2_Nausea 20830-75-5 DIGOXIN ADVERSE_EFFECT CVS_1_Premature Ventricular Beats 20830-75-5 DIGOXIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 123039-93-0 DIHYDREXIDINE MECHANISM Modulate G-protein coupled signal transduction 123039-93-0 DIHYDREXIDINE PRODUCT_CLASS Central Nervous System (CNS) 126295-91-8 DIHYDREXIDINE MECHANISM Modulate G-protein coupled signal transduction 126295-91-8 DIHYDREXIDINE PRODUCT_CLASS Central Nervous System (CNS) 126327-49-9 DIHYDREXIDINE PRODUCT_CLASS Central Nervous System (CNS) 126327-49-9 DIHYDREXIDINE MECHANISM Modulate G-protein coupled signal transduction 25447-66-9 DIHYDRO-ALPHA-ERGOCRYPTINE INDICATION Parkinson's Disease 25447-66-9 DIHYDRO-ALPHA-ERGOCRYPTINE MECHANISM Prolong/enhance neural transmission 25447-66-9 DIHYDRO-ALPHA-ERGOCRYPTINE MODE_CLASS Receptor Agonist 25447-66-9 DIHYDRO-ALPHA-ERGOCRYPTINE STRUCTURE_ACTIVITY Ergot alkaloid 25447-66-9 DIHYDRO-ALPHA-ERGOCRYPTINE THERAPEUTIC_CLASS Movement Disorders 25447-66-9 DIHYDRO-ALPHA-ERGOCRYPTINE PRODUCT_CLASS Central Nervous System (CNS) 73986-90-0 DIHYDRO-ALPHA-ERGOCRYPTINE INDICATION Parkinson's Disease 73986-90-0 DIHYDRO-ALPHA-ERGOCRYPTINE MECHANISM Prolong/enhance neural transmission 73986-90-0 DIHYDRO-ALPHA-ERGOCRYPTINE MODE_CLASS Receptor Agonist 73986-90-0 DIHYDRO-ALPHA-ERGOCRYPTINE STRUCTURE_ACTIVITY Ergot alkaloid 73986-90-0 DIHYDRO-ALPHA-ERGOCRYPTINE THERAPEUTIC_CLASS Movement Disorders 73986-90-0 DIHYDRO-ALPHA-ERGOCRYPTINE PRODUCT_CLASS Central Nervous System (CNS) 36418-29-8 DROCODE MECHANISM Modulate neural transmission 36418-29-8 DROCODE THERAPEUTIC_CLASS Analgesics, Opioid 36418-29-8 DROCODE INDICATION Moderate Pain 36418-29-8 DROCODE PRODUCT_CLASS Analgesics 36418-29-8 DROCODE MODE_CLASS Receptor Agonist 36418-29-8 DROCODE INDICATION Severe Pain 36418-29-8 DROCODE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 125-28-0 DROCODE STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 125-28-0 DROCODE MECHANISM Modulate neural transmission 125-28-0 DROCODE THERAPEUTIC_CLASS Analgesics, Opioid 125-28-0 DROCODE INDICATION Moderate Pain 125-28-0 DROCODE PRODUCT_CLASS Analgesics 125-28-0 DROCODE MODE_CLASS Receptor Agonist 125-28-0 DROCODE INDICATION Severe Pain 25447-65-8 DIHYDROERGOCORNINE INDICATION Cerebrovascular Insufficiency 25447-65-8 DIHYDROERGOCORNINE PRODUCT_CLASS Central Nervous System (CNS) 25447-65-8 DIHYDROERGOCORNINE MODE_CLASS Receptor Agonist 25447-65-8 DIHYDROERGOCORNINE STRUCTURE_ACTIVITY Ergot alkaloid 25447-65-8 DIHYDROERGOCORNINE MECHANISM Modulate G-protein coupled signal transduction 25447-65-8 DIHYDROERGOCORNINE MODE_CLASS Receptor Ligand Antagonist 25447-65-8 DIHYDROERGOCORNINE THERAPEUTIC_CLASS Vasodilators 25447-65-8 DIHYDROERGOCORNINE MECHANISM Prolong/enhance neural transmission 24730-10-7 DIHYDROERGOCRISTINE MESYLATE ADVERSE_EFFECT GIS_2_Nausea 24730-10-7 DIHYDROERGOCRISTINE MESYLATE THERAPEUTIC_CLASS Neurodegenerative Disorders 24730-10-7 DIHYDROERGOCRISTINE MESYLATE ADVERSE_EFFECT IMU_3_Hypersensitivity 24730-10-7 DIHYDROERGOCRISTINE MESYLATE STRUCTURE_ACTIVITY Ergot alkaloid 24730-10-7 DIHYDROERGOCRISTINE MESYLATE INDICATION Dementia 24730-10-7 DIHYDROERGOCRISTINE MESYLATE MODE_CLASS Receptor Agonist 24730-10-7 DIHYDROERGOCRISTINE MESYLATE ADVERSE_EFFECT GIS_2_Epigastric Pain 24730-10-7 DIHYDROERGOCRISTINE MESYLATE MECHANISM Prolong/enhance neural transmission 24730-10-7 DIHYDROERGOCRISTINE MESYLATE PRODUCT_CLASS Central Nervous System (CNS) 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Angina 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_1_Vasoconstriction 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Angina 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Ventricular Fibrillation 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Ventricular Tachycardia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_1_Nasal Irritation 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 6190-39-2 DIHYDROERGOTAMINE MECHANISM Modulate G-protein coupled signal transduction 6190-39-2 DIHYDROERGOTAMINE STRUCTURE_ACTIVITY Ergot alkaloid 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Valvular Disorders 6190-39-2 DIHYDROERGOTAMINE MODE_CLASS Receptor Ligand Antagonist 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_2_Nasal Congestion 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Teratogenicity 6190-39-2 DIHYDROERGOTAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT GIS_2_Dysgeusia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT NEU_2_Dizziness 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT EMB_2_Teratogenicity 6190-39-2 DIHYDROERGOTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 6190-39-2 DIHYDROERGOTAMINE MODE_CLASS Receptor Partial Agonist 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Peripheral Ischemia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Valvular Disorders 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT EMB_2_Fetal Toxicity 6190-39-2 DIHYDROERGOTAMINE INDICATION Migraine Headache 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_2_Edema 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_2_Hypertension 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Coronary Vasospasm 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_1_Throat Irritation 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT REP_2_Uterine Contractions 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Peripheral Ischemia 6190-39-2 DIHYDROERGOTAMINE THERAPEUTIC_CLASS Antimigraines 6190-39-2 DIHYDROERGOTAMINE ADVERSE_EFFECT EMB_2_Abortion 6190-39-2 DIHYDROERGOTAMINE KNOWN_TOXICITY Embryo/Fetal Toxicity 6190-39-2 DIHYDROERGOTAMINE TISSUE_TOXICITY Myocardial Infarction 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT EMB_2_Fetal Toxicity 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT NEU_2_Dizziness 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT EMB_2_Teratogenicity 511-12-6 DIHYDROERGOTAMINE MODE_CLASS Receptor Ligand Antagonist 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Teratogenicity 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Valvular Disorders 511-12-6 DIHYDROERGOTAMINE STRUCTURE_ACTIVITY Ergot alkaloid 511-12-6 DIHYDROERGOTAMINE MECHANISM Modulate G-protein coupled signal transduction 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_1_Nasal Irritation 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_2_Nasal Congestion 511-12-6 DIHYDROERGOTAMINE THERAPEUTIC_CLASS Antimigraines 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Ventricular Fibrillation 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Angina 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_1_Vasoconstriction 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Angina 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Peripheral Ischemia 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT EMB_2_Abortion 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT GIS_2_Dysgeusia 511-12-6 DIHYDROERGOTAMINE PRODUCT_CLASS Autonomic Nervous System (ANS) 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Ventricular Tachycardia 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Myocardial Infarction 511-12-6 DIHYDROERGOTAMINE KNOWN_TOXICITY Embryo/Fetal Toxicity 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT REP_2_Uterine Contractions 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_1_Throat Irritation 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Valvular Disorders 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_2_Hypertension 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT XXX_2_Edema 511-12-6 DIHYDROERGOTAMINE INDICATION Migraine Headache 511-12-6 DIHYDROERGOTAMINE MODE_CLASS Receptor Partial Agonist 511-12-6 DIHYDROERGOTAMINE TISSUE_TOXICITY Peripheral Ischemia 511-12-6 DIHYDROERGOTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 511-12-6 DIHYDROERGOTAMINE ADVERSE_EFFECT CVS_3_Coronary Vasospasm 33286-22-5 DILTIAZEM ADVERSE_EFFECT XXX_2_Peripheral Edema 33286-22-5 DILTIAZEM ADVERSE_EFFECT XXX_2_Asthenia 33286-22-5 DILTIAZEM ADVERSE_EFFECT LIV_3_Increased Liver Function Tests 33286-22-5 DILTIAZEM ADVERSE_EFFECT PSY_3_Depression 33286-22-5 DILTIAZEM ADVERSE_EFFECT PSY_2_Insomnia 33286-22-5 DILTIAZEM INDICATION Primary Dilated Cardiomyopathy 33286-22-5 DILTIAZEM INDICATION Migraine Prophylaxis 33286-22-5 DILTIAZEM INDICATION Angina Pectoris 33286-22-5 DILTIAZEM PRODUCT_CLASS Other Human Uses 33286-22-5 DILTIAZEM MODE_CLASS Channel Modulator 33286-22-5 DILTIAZEM THERAPEUTIC_CLASS Antiarrhythmic Agents 33286-22-5 DILTIAZEM TISSUE_TOXICITY Hypotension 33286-22-5 DILTIAZEM ADVERSE_EFFECT GIS_2_Diarrhea 33286-22-5 DILTIAZEM ADVERSE_EFFECT PSY_2_Nervousness 33286-22-5 DILTIAZEM ADVERSE_EFFECT SKN_1_Flushing 33286-22-5 DILTIAZEM ADVERSE_EFFECT PSY_3_Confusion 33286-22-5 DILTIAZEM ADVERSE_EFFECT XXX_2_Thirst 33286-22-5 DILTIAZEM INDICATION Proteinuria 33286-22-5 DILTIAZEM INDICATION Chronic Stable Angina 33286-22-5 DILTIAZEM THERAPEUTIC_CLASS Antihypertensive Agents 33286-22-5 DILTIAZEM THERAPEUTIC_CLASS Vasodilators 33286-22-5 DILTIAZEM KNOWN_TOXICITY Cardiovascular Toxicity 33286-22-5 DILTIAZEM ADVERSE_EFFECT CVS_3_Congestive Heart Failure 33286-22-5 DILTIAZEM ADVERSE_EFFECT NEU_2_Drowsiness 33286-22-5 DILTIAZEM ADVERSE_EFFECT GIS_2_Dyspepsia 33286-22-5 DILTIAZEM STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 33286-22-5 DILTIAZEM ADVERSE_EFFECT LUN_3_Pulmonary Edema 33286-22-5 DILTIAZEM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 33286-22-5 DILTIAZEM TISSUE_TOXICITY Congestive Heart Failure 33286-22-5 DILTIAZEM INDICATION Atrial Fibrillation 33286-22-5 DILTIAZEM INDICATION Vasospastic Angina 33286-22-5 DILTIAZEM PRODUCT_CLASS Cardiovasculars 33286-22-5 DILTIAZEM MECHANISM Reduce muscle contractile force 33286-22-5 DILTIAZEM THERAPEUTIC_CLASS Antianginals 33286-22-5 DILTIAZEM TISSUE_TOXICITY First-Degree AV block 33286-22-5 DILTIAZEM ADVERSE_EFFECT NEU_2_Dizziness 33286-22-5 DILTIAZEM ADVERSE_EFFECT XXX_2_Weight Gain 33286-22-5 DILTIAZEM ADVERSE_EFFECT CVS_1_First-Degree AV block 33286-22-5 DILTIAZEM ADVERSE_EFFECT CVS_2_Hypotension 33286-22-5 DILTIAZEM ADVERSE_EFFECT CVS_1_Sinus Bradycardia 33286-22-5 DILTIAZEM INDICATION Hypertension 33286-22-5 DILTIAZEM INDICATION Atrial Flutter 33286-22-5 DILTIAZEM ADVERSE_EFFECT NEU_2_Headache 42399-41-7 DILTIAZEM ADVERSE_EFFECT XXX_2_Asthenia 42399-41-7 DILTIAZEM ADVERSE_EFFECT XXX_2_Peripheral Edema 42399-41-7 DILTIAZEM ADVERSE_EFFECT NEU_2_Headache 42399-41-7 DILTIAZEM TISSUE_TOXICITY Congestive Heart Failure 42399-41-7 DILTIAZEM INDICATION Atrial Flutter 42399-41-7 DILTIAZEM INDICATION Hypertension 42399-41-7 DILTIAZEM ADVERSE_EFFECT CVS_1_Sinus Bradycardia 42399-41-7 DILTIAZEM ADVERSE_EFFECT CVS_2_Hypotension 42399-41-7 DILTIAZEM ADVERSE_EFFECT CVS_1_First-Degree AV block 42399-41-7 DILTIAZEM ADVERSE_EFFECT XXX_2_Weight Gain 42399-41-7 DILTIAZEM ADVERSE_EFFECT NEU_2_Dizziness 42399-41-7 DILTIAZEM TISSUE_TOXICITY First-Degree AV block 42399-41-7 DILTIAZEM THERAPEUTIC_CLASS Antianginals 42399-41-7 DILTIAZEM MECHANISM Reduce muscle contractile force 42399-41-7 DILTIAZEM PRODUCT_CLASS Cardiovasculars 42399-41-7 DILTIAZEM INDICATION Vasospastic Angina 42399-41-7 DILTIAZEM INDICATION Atrial Fibrillation 42399-41-7 DILTIAZEM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 42399-41-7 DILTIAZEM ADVERSE_EFFECT LUN_3_Pulmonary Edema 42399-41-7 DILTIAZEM STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 42399-41-7 DILTIAZEM ADVERSE_EFFECT GIS_2_Dyspepsia 42399-41-7 DILTIAZEM ADVERSE_EFFECT NEU_2_Drowsiness 42399-41-7 DILTIAZEM ADVERSE_EFFECT CVS_3_Congestive Heart Failure 42399-41-7 DILTIAZEM KNOWN_TOXICITY Cardiovascular Toxicity 42399-41-7 DILTIAZEM THERAPEUTIC_CLASS Vasodilators 42399-41-7 DILTIAZEM THERAPEUTIC_CLASS Antihypertensive Agents 42399-41-7 DILTIAZEM INDICATION Chronic Stable Angina 42399-41-7 DILTIAZEM INDICATION Proteinuria 42399-41-7 DILTIAZEM ADVERSE_EFFECT XXX_2_Thirst 42399-41-7 DILTIAZEM ADVERSE_EFFECT PSY_3_Confusion 42399-41-7 DILTIAZEM ADVERSE_EFFECT SKN_1_Flushing 42399-41-7 DILTIAZEM ADVERSE_EFFECT PSY_2_Nervousness 42399-41-7 DILTIAZEM ADVERSE_EFFECT GIS_2_Diarrhea 42399-41-7 DILTIAZEM TISSUE_TOXICITY Hypotension 42399-41-7 DILTIAZEM THERAPEUTIC_CLASS Antiarrhythmic Agents 42399-41-7 DILTIAZEM MODE_CLASS Channel Modulator 42399-41-7 DILTIAZEM PRODUCT_CLASS Other Human Uses 42399-41-7 DILTIAZEM INDICATION Angina Pectoris 42399-41-7 DILTIAZEM INDICATION Migraine Prophylaxis 42399-41-7 DILTIAZEM INDICATION Primary Dilated Cardiomyopathy 42399-41-7 DILTIAZEM ADVERSE_EFFECT PSY_2_Insomnia 42399-41-7 DILTIAZEM ADVERSE_EFFECT PSY_3_Depression 42399-41-7 DILTIAZEM ADVERSE_EFFECT LIV_3_Increased Liver Function Tests 144604-00-2 DILTIAZEM ADVERSE_EFFECT CVS_2_Hypotension 144604-00-2 DILTIAZEM ADVERSE_EFFECT CVS_1_First-Degree AV block 144604-00-2 DILTIAZEM ADVERSE_EFFECT NEU_2_Dizziness 144604-00-2 DILTIAZEM ADVERSE_EFFECT CVS_1_Sinus Bradycardia 144604-00-2 DILTIAZEM INDICATION Hypertension 144604-00-2 DILTIAZEM INDICATION Atrial Flutter 144604-00-2 DILTIAZEM TISSUE_TOXICITY Congestive Heart Failure 144604-00-2 DILTIAZEM ADVERSE_EFFECT NEU_2_Headache 144604-00-2 DILTIAZEM ADVERSE_EFFECT XXX_2_Peripheral Edema 144604-00-2 DILTIAZEM ADVERSE_EFFECT XXX_2_Asthenia 144604-00-2 DILTIAZEM ADVERSE_EFFECT LIV_3_Increased Liver Function Tests 144604-00-2 DILTIAZEM ADVERSE_EFFECT PSY_3_Depression 144604-00-2 DILTIAZEM ADVERSE_EFFECT PSY_2_Insomnia 144604-00-2 DILTIAZEM INDICATION Primary Dilated Cardiomyopathy 144604-00-2 DILTIAZEM INDICATION Migraine Prophylaxis 144604-00-2 DILTIAZEM INDICATION Angina Pectoris 144604-00-2 DILTIAZEM PRODUCT_CLASS Other Human Uses 144604-00-2 DILTIAZEM MODE_CLASS Channel Modulator 144604-00-2 DILTIAZEM THERAPEUTIC_CLASS Antiarrhythmic Agents 144604-00-2 DILTIAZEM TISSUE_TOXICITY Hypotension 144604-00-2 DILTIAZEM ADVERSE_EFFECT GIS_2_Diarrhea 144604-00-2 DILTIAZEM ADVERSE_EFFECT PSY_2_Nervousness 144604-00-2 DILTIAZEM ADVERSE_EFFECT SKN_1_Flushing 144604-00-2 DILTIAZEM ADVERSE_EFFECT PSY_3_Confusion 144604-00-2 DILTIAZEM ADVERSE_EFFECT XXX_2_Thirst 144604-00-2 DILTIAZEM INDICATION Proteinuria 144604-00-2 DILTIAZEM INDICATION Chronic Stable Angina 144604-00-2 DILTIAZEM THERAPEUTIC_CLASS Antihypertensive Agents 144604-00-2 DILTIAZEM KNOWN_TOXICITY Cardiovascular Toxicity 144604-00-2 DILTIAZEM ADVERSE_EFFECT XXX_2_Weight Gain 144604-00-2 DILTIAZEM THERAPEUTIC_CLASS Vasodilators 144604-00-2 DILTIAZEM ADVERSE_EFFECT CVS_3_Congestive Heart Failure 144604-00-2 DILTIAZEM ADVERSE_EFFECT NEU_2_Drowsiness 144604-00-2 DILTIAZEM ADVERSE_EFFECT GIS_2_Dyspepsia 144604-00-2 DILTIAZEM STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 144604-00-2 DILTIAZEM ADVERSE_EFFECT LUN_3_Pulmonary Edema 144604-00-2 DILTIAZEM ADVERSE_EFFECT GIS_2_Nausea / Vomiting 144604-00-2 DILTIAZEM INDICATION Atrial Fibrillation 144604-00-2 DILTIAZEM INDICATION Vasospastic Angina 144604-00-2 DILTIAZEM PRODUCT_CLASS Cardiovasculars 144604-00-2 DILTIAZEM MECHANISM Reduce muscle contractile force 144604-00-2 DILTIAZEM THERAPEUTIC_CLASS Antianginals 144604-00-2 DILTIAZEM TISSUE_TOXICITY First-Degree AV block 23256-33-9 DIMAPRIT DIHYDROCHLORIDE PRODUCT_CLASS Biochemicals 523-87-5 DIMENHYDRINATE MESH_LEVEL_3 Xanthine Alkaloids 523-87-5 DIMENHYDRINATE MESH_LEVEL_2 Alkaloids 523-87-5 DIMENHYDRINATE INDICATION Meniere's Syndrome / Endolymphatic Hydrops 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT GIS_1_Dry Mouth 523-87-5 DIMENHYDRINATE TISSUE_TOXICITY Cardiac Arrhythmia 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT NEU_1_Dizziness 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT IMU_3_Photosensitivity 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT END_3_Exacerbation of Porphyria 523-87-5 DIMENHYDRINATE TA_LEVEL_1 Central Nervous System (CNS) 523-87-5 DIMENHYDRINATE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, adenosine receptor antagonist 523-87-5 DIMENHYDRINATE MECH_LEVEL_2 Modulate G-protein coupled signal transduction 523-87-5 DIMENHYDRINATE INDICATION Nausea / Vomiting 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT PSY_3_Delirium 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT PSY_2_Anorexia 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT NEU_3_Seizures 523-87-5 DIMENHYDRINATE MECH_LEVEL_3 dopamine receptor 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT SKN_3_Skin Rash 523-87-5 DIMENHYDRINATE PRODUCT_CLASS Gastrointestinal System 523-87-5 DIMENHYDRINATE MESH_LEVEL_1 Heterocyclic Compounds 523-87-5 DIMENHYDRINATE MECHANISM Modulate G-protein coupled signal transduction 523-87-5 DIMENHYDRINATE ACTIVITY_CLASS Histamine antagonist 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT GIS_2_Diarrhea 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT LUN_3_Wheezing 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT NEU_2_Ataxia 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT CVS_3_Hypotension 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT GUS_2_Urinary Retention 523-87-5 DIMENHYDRINATE THERAPEUTIC_CLASS Antiemetics 523-87-5 DIMENHYDRINATE INDICATION Vertigo 523-87-5 DIMENHYDRINATE MECH_LEVEL_1 signal transduction 523-87-5 DIMENHYDRINATE INDICATION Motion Sickness 523-87-5 DIMENHYDRINATE TA_LEVEL_2 Antiemetic 523-87-5 DIMENHYDRINATE ZERO_CLASS N 523-87-5 DIMENHYDRINATE INDICATION Hyperemesis Gravidarum / Pernicious Vomiting of Pregnancy 523-87-5 DIMENHYDRINATE MODE_CLASS Receptor Ligand Antagonist 523-87-5 DIMENHYDRINATE TISSUE_TOXICITY Hypotension 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT OCU_2_Blurred Vision 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT NEU_1_Drowsiness 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT GIS_1_Dyspepsia 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 523-87-5 DIMENHYDRINATE ADVERSE_EFFECT GIS_2_Constipation 523-87-5 DIMENHYDRINATE KNOWN_TOXICITY Cardiovascular Toxicity 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT PSY_3_Anorexia 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT NEU_1_Dizziness 67-68-5 DIMETHYL SULFOXIDE INDICATION Interstitial Cystitis 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT NEU_1_Sedation 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT GIS_2_Vomiting 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT LUN_3_Dyspnea 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT XXX_3_Sore Throat 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT GIS_2_Constipation 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT GIS_1_Nausea 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT XXX_2_Influenza-Like Syndrome 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT OCU_1_Eye Irritation 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT LUN_3_Increased Cough 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT XXX_2_Xerostomia 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT GIS_3_Dry Mouth 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT XXX_2_Weight Gain 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT GUS_3_Frequent Urination 67-68-5 DIMETHYL SULFOXIDE PRODUCT_CLASS Anti-inflammatories 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT GIS_2_Diarrhea 67-68-5 DIMETHYL SULFOXIDE ADVERSE_EFFECT NEU_1_Headache 67-68-5 DIMETHYL SULFOXIDE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 147-24-0 DIPHENHYDRAMINE THERAPEUTIC_CLASS Sedatives/Hypnotics 147-24-0 DIPHENHYDRAMINE THERAPEUTIC_CLASS Antihistamines 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Sedation 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_2_Nervousness 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT XXX_2_Xerostomia 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_3_Seizures 147-24-0 DIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 147-24-0 DIPHENHYDRAMINE MODE_CLASS Channel Blocker 147-24-0 DIPHENHYDRAMINE TISSUE_TOXICITY Extrasystoles 147-24-0 DIPHENHYDRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_1_CNS Depression 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Diarrhea 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_2_Palpitation 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Hypertension 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Dizziness 147-24-0 DIPHENHYDRAMINE THERAPEUTIC_CLASS Movement Disorders 147-24-0 DIPHENHYDRAMINE INDICATION Parkinsonism 147-24-0 DIPHENHYDRAMINE INDICATION Cough / Tussis 147-24-0 DIPHENHYDRAMINE INDICATION Parkinson's Disease 147-24-0 DIPHENHYDRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT GUS_2_Urinary Retention 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_2_Insomnia 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Constipation 147-24-0 DIPHENHYDRAMINE INDICATION Allergic Rhinitis 147-24-0 DIPHENHYDRAMINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 147-24-0 DIPHENHYDRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 147-24-0 DIPHENHYDRAMINE INDICATION Insomnia 147-24-0 DIPHENHYDRAMINE INDICATION Urticaria / Hives 147-24-0 DIPHENHYDRAMINE MESH_LEVEL_2 Amines 147-24-0 DIPHENHYDRAMINE MECHANISM Modulate G-protein coupled signal transduction 147-24-0 DIPHENHYDRAMINE INDICATION Extrapyramidal Disorders 147-24-0 DIPHENHYDRAMINE TA_LEVEL_1 Anti-inflammatory 147-24-0 DIPHENHYDRAMINE PRODUCT_CLASS Central Nervous System (CNS) 147-24-0 DIPHENHYDRAMINE TA_LEVEL_2 Anti-histamine 147-24-0 DIPHENHYDRAMINE TA_LEVEL_3 Oral anti-histamine 147-24-0 DIPHENHYDRAMINE MECH_LEVEL_3 histamine receptor H1 147-24-0 DIPHENHYDRAMINE INDICATION Allergic Diseases 147-24-0 DIPHENHYDRAMINE INDICATION Vertigo 147-24-0 DIPHENHYDRAMINE MECH_LEVEL_1 Immunomodulation 147-24-0 DIPHENHYDRAMINE INDICATION Motion Sickness 147-24-0 DIPHENHYDRAMINE PRODUCT_CLASS Anti-inflammatories 147-24-0 DIPHENHYDRAMINE MECH_LEVEL_2 Anti-histamine 147-24-0 DIPHENHYDRAMINE MECHANISM Block neural transmission 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Extrasystoles 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT XXX_2_Restlessness 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 147-24-0 DIPHENHYDRAMINE ACTIVITY_CLASS Histamine antagonist 147-24-0 DIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 147-24-0 DIPHENHYDRAMINE MESH_LEVEL_3 Ethylamines 147-24-0 DIPHENHYDRAMINE MESH_LEVEL_1 Organic Chemicals 147-24-0 DIPHENHYDRAMINE ZERO_CLASS N 147-24-0 DIPHENHYDRAMINE INDICATION Viral Rhinitis / Common Cold 147-24-0 DIPHENHYDRAMINE PRODUCT_CLASS Respiratory System 147-24-0 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 58-73-1 DIPHENHYDRAMINE MODE_CLASS Channel Blocker 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_2_Nervousness 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Sedation 58-73-1 DIPHENHYDRAMINE THERAPEUTIC_CLASS Antihistamines 58-73-1 DIPHENHYDRAMINE THERAPEUTIC_CLASS Sedatives/Hypnotics 58-73-1 DIPHENHYDRAMINE INDICATION Allergic Diseases 58-73-1 DIPHENHYDRAMINE PRODUCT_CLASS Respiratory System 58-73-1 DIPHENHYDRAMINE INDICATION Viral Rhinitis / Common Cold 58-73-1 DIPHENHYDRAMINE ZERO_CLASS N 58-73-1 DIPHENHYDRAMINE MESH_LEVEL_1 Organic Chemicals 58-73-1 DIPHENHYDRAMINE MESH_LEVEL_3 Ethylamines 58-73-1 DIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 58-73-1 DIPHENHYDRAMINE ACTIVITY_CLASS Histamine antagonist 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Hypertension 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_2_Palpitation 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Diarrhea 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_1_CNS Depression 58-73-1 DIPHENHYDRAMINE TISSUE_TOXICITY Extrasystoles 58-73-1 DIPHENHYDRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 58-73-1 DIPHENHYDRAMINE INDICATION Allergic Rhinitis 58-73-1 DIPHENHYDRAMINE INDICATION Vertigo 58-73-1 DIPHENHYDRAMINE MECH_LEVEL_1 Immunomodulation 58-73-1 DIPHENHYDRAMINE INDICATION Motion Sickness 58-73-1 DIPHENHYDRAMINE PRODUCT_CLASS Anti-inflammatories 58-73-1 DIPHENHYDRAMINE MECH_LEVEL_3 histamine receptor H1 58-73-1 DIPHENHYDRAMINE TA_LEVEL_3 Oral anti-histamine 58-73-1 DIPHENHYDRAMINE TA_LEVEL_2 Anti-histamine 58-73-1 DIPHENHYDRAMINE TA_LEVEL_1 Anti-inflammatory 58-73-1 DIPHENHYDRAMINE INDICATION Extrapyramidal Disorders 58-73-1 DIPHENHYDRAMINE MECHANISM Modulate G-protein coupled signal transduction 58-73-1 DIPHENHYDRAMINE MESH_LEVEL_2 Amines 58-73-1 DIPHENHYDRAMINE INDICATION Urticaria / Hives 58-73-1 DIPHENHYDRAMINE INDICATION Insomnia 58-73-1 DIPHENHYDRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 58-73-1 DIPHENHYDRAMINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Constipation 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_2_Insomnia 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT GUS_2_Urinary Retention 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 58-73-1 DIPHENHYDRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 58-73-1 DIPHENHYDRAMINE INDICATION Parkinson's Disease 58-73-1 DIPHENHYDRAMINE INDICATION Cough / Tussis 58-73-1 DIPHENHYDRAMINE INDICATION Parkinsonism 58-73-1 DIPHENHYDRAMINE THERAPEUTIC_CLASS Movement Disorders 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Dizziness 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT XXX_2_Restlessness 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Extrasystoles 58-73-1 DIPHENHYDRAMINE MECH_LEVEL_2 Anti-histamine 58-73-1 DIPHENHYDRAMINE MECHANISM Block neural transmission 58-73-1 DIPHENHYDRAMINE PRODUCT_CLASS Central Nervous System (CNS) 58-73-1 DIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_3_Seizures 58-73-1 DIPHENHYDRAMINE ADVERSE_EFFECT XXX_2_Xerostomia 8052-21-9 DIPHENHYDRAMINE MECH_LEVEL_3 histamine receptor H1 8052-21-9 DIPHENHYDRAMINE TA_LEVEL_3 Oral anti-histamine 8052-21-9 DIPHENHYDRAMINE TA_LEVEL_2 Anti-histamine 8052-21-9 DIPHENHYDRAMINE PRODUCT_CLASS Central Nervous System (CNS) 8052-21-9 DIPHENHYDRAMINE TA_LEVEL_1 Anti-inflammatory 8052-21-9 DIPHENHYDRAMINE INDICATION Extrapyramidal Disorders 8052-21-9 DIPHENHYDRAMINE MECHANISM Modulate G-protein coupled signal transduction 8052-21-9 DIPHENHYDRAMINE MESH_LEVEL_2 Amines 8052-21-9 DIPHENHYDRAMINE INDICATION Urticaria / Hives 8052-21-9 DIPHENHYDRAMINE INDICATION Insomnia 8052-21-9 DIPHENHYDRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 8052-21-9 DIPHENHYDRAMINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Constipation 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_2_Insomnia 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT GUS_2_Urinary Retention 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 8052-21-9 DIPHENHYDRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Sedation 8052-21-9 DIPHENHYDRAMINE INDICATION Parkinson's Disease 8052-21-9 DIPHENHYDRAMINE INDICATION Cough / Tussis 8052-21-9 DIPHENHYDRAMINE INDICATION Parkinsonism 8052-21-9 DIPHENHYDRAMINE THERAPEUTIC_CLASS Movement Disorders 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_1_Dizziness 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Extrasystoles 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT XXX_2_Restlessness 8052-21-9 DIPHENHYDRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_2_Nervousness 8052-21-9 DIPHENHYDRAMINE MESH_LEVEL_1 Organic Chemicals 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT XXX_2_Xerostomia 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT NEU_3_Seizures 8052-21-9 DIPHENHYDRAMINE THERAPEUTIC_CLASS Antihistamines 8052-21-9 DIPHENHYDRAMINE THERAPEUTIC_CLASS Sedatives/Hypnotics 8052-21-9 DIPHENHYDRAMINE INDICATION Allergic Diseases 8052-21-9 DIPHENHYDRAMINE PRODUCT_CLASS Respiratory System 8052-21-9 DIPHENHYDRAMINE INDICATION Viral Rhinitis / Common Cold 8052-21-9 DIPHENHYDRAMINE ZERO_CLASS N 8052-21-9 DIPHENHYDRAMINE MESH_LEVEL_3 Ethylamines 8052-21-9 DIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 8052-21-9 DIPHENHYDRAMINE ACTIVITY_CLASS Histamine antagonist 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Hypertension 8052-21-9 DIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT CVS_2_Palpitation 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Diarrhea 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 8052-21-9 DIPHENHYDRAMINE ADVERSE_EFFECT PSY_1_CNS Depression 8052-21-9 DIPHENHYDRAMINE TISSUE_TOXICITY Extrasystoles 8052-21-9 DIPHENHYDRAMINE MODE_CLASS Channel Blocker 8052-21-9 DIPHENHYDRAMINE INDICATION Allergic Rhinitis 8052-21-9 DIPHENHYDRAMINE INDICATION Vertigo 8052-21-9 DIPHENHYDRAMINE MECH_LEVEL_1 Immunomodulation 8052-21-9 DIPHENHYDRAMINE INDICATION Motion Sickness 8052-21-9 DIPHENHYDRAMINE PRODUCT_CLASS Anti-inflammatories 8052-21-9 DIPHENHYDRAMINE MECH_LEVEL_2 Anti-histamine 8052-21-9 DIPHENHYDRAMINE MECHANISM Block neural transmission 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT PSY_2_Anorexia 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT NEU_1_Drowsiness 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT GIS_2_Abdominal Pain 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT XXX_2_Malaise 3810-80-8 DIPHENOXYLATE MODE_CLASS Receptor Agonist 3810-80-8 DIPHENOXYLATE THERAPEUTIC_CLASS Antidiarrhea Agents 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT PSY_2_Depression 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT NEU_1_Dizziness 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT GIS_3_Pancreatitis 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT XXX_2_Xerostomia 3810-80-8 DIPHENOXYLATE PRODUCT_CLASS Gastrointestinal System 3810-80-8 DIPHENOXYLATE MECHANISM Reduce muscle contractile force 3810-80-8 DIPHENOXYLATE MECHANISM Modulate neural transmission 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT GIS_2_Constipation 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT NEU_2_Headache 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT PSY_2_Euphoria 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT NEU_2_Numbness 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT NEU_3_Paralytic Ileus 3810-80-8 DIPHENOXYLATE MODE_CLASS Channel Blocker 3810-80-8 DIPHENOXYLATE INDICATION Diarrhea 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT CVS_2_Tachycardia 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 3810-80-8 DIPHENOXYLATE ADVERSE_EFFECT XXX_2_Restlessness 915-30-0 DIPHENOXYLATE INDICATION Diarrhea 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT XXX_2_Restlessness 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT NEU_3_Paralytic Ileus 915-30-0 DIPHENOXYLATE MODE_CLASS Channel Blocker 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT PSY_2_Anorexia 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT NEU_1_Drowsiness 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT GIS_2_Abdominal Pain 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT XXX_2_Malaise 915-30-0 DIPHENOXYLATE MODE_CLASS Receptor Agonist 915-30-0 DIPHENOXYLATE THERAPEUTIC_CLASS Antidiarrhea Agents 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT PSY_2_Depression 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT NEU_1_Dizziness 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT GIS_3_Pancreatitis 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT GIS_2_Constipation 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT NEU_2_Headache 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT XXX_2_Xerostomia 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT PSY_2_Euphoria 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT NEU_2_Numbness 915-30-0 DIPHENOXYLATE ADVERSE_EFFECT CVS_2_Tachycardia 915-30-0 DIPHENOXYLATE MECHANISM Modulate neural transmission 915-30-0 DIPHENOXYLATE MECHANISM Reduce muscle contractile force 915-30-0 DIPHENOXYLATE PRODUCT_CLASS Gastrointestinal System 102-06-7 1,3-DIPHENYLGUANIDINE ADVERSE_EFFECT OCU_1_Ocular Irritation 102-06-7 1,3-DIPHENYLGUANIDINE STRUCTURE_ACTIVITY Sigma receptor modulator 102-06-7 1,3-DIPHENYLGUANIDINE MODE_CLASS Receptor Agonist 102-06-7 1,3-DIPHENYLGUANIDINE ADVERSE_EFFECT EMB_3_Fetal Toxicity 102-06-7 1,3-DIPHENYLGUANIDINE PRODUCT_CLASS Toxicants 102-06-7 1,3-DIPHENYLGUANIDINE MECHANISM Modulate neural transmission 52365-63-6 DIPIVEFRIN INDICATION Glaucoma 52365-63-6 DIPIVEFRIN MODE_CLASS Receptor Agonist 52365-63-6 DIPIVEFRIN MECHANISM Modulate G-protein coupled signal transduction 52365-63-6 DIPIVEFRIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 52365-63-6 DIPIVEFRIN THERAPEUTIC_CLASS Antiglaucoma Agents 64019-93-8 DIPIVEFRIN THERAPEUTIC_CLASS Antiglaucoma Agents 64019-93-8 DIPIVEFRIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 64019-93-8 DIPIVEFRIN MECHANISM Modulate G-protein coupled signal transduction 64019-93-8 DIPIVEFRIN MODE_CLASS Receptor Agonist 64019-93-8 DIPIVEFRIN INDICATION Glaucoma 58-32-2 DIPYRIDAMOLE TA_LEVEL_2 anticoagulant 58-32-2 DIPYRIDAMOLE STRUCTURE_ACTIVITY Equilibrative nucleoside transporter 1 inhibitor 58-32-2 DIPYRIDAMOLE INDICATION Prevention of Thromboembolism Post Cardiac Valve Replacement 58-32-2 DIPYRIDAMOLE MECHANISM Ehance adenosine-mediated vasodilation 58-32-2 DIPYRIDAMOLE TA_LEVEL_1 Cardiovascular 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT NEU_1_Dizziness 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT BBM_3_Decreased Platelet Function 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT MSK_3_Arthritis 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT SKN_3_Skin Rash 58-32-2 DIPYRIDAMOLE TA_LEVEL_3 anti-platlet 58-32-2 DIPYRIDAMOLE MECH_LEVEL_1 Inhibit platelet aggregation 58-32-2 DIPYRIDAMOLE TISSUE_TOXICITY Angina 58-32-2 DIPYRIDAMOLE KNOWN_TOXICITY Cardiovascular Toxicity 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT CVS_3_Angina 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT NEU_2_Headache 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT CVS_2_Peripheral Vasodilation 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT BIL_3_Cholelithiasis 58-32-2 DIPYRIDAMOLE ZERO_CLASS N 58-32-2 DIPYRIDAMOLE MODE_CLASS Solute transporter inhibitor 58-32-2 DIPYRIDAMOLE TISSUE_TOXICITY Hypotension 58-32-2 DIPYRIDAMOLE THERAPEUTIC_CLASS Vasodilators 58-32-2 DIPYRIDAMOLE ACTIVITY_CLASS Equilibrative nucleoside transporter 1 inhibitor 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT CVS_3_Hypotension 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT SKN_2_Flushing 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT LIV_3_Hepatitis 58-32-2 DIPYRIDAMOLE MESH_LEVEL_1 Heterocyclic Compounds 58-32-2 DIPYRIDAMOLE MECH_LEVEL_2 decrease the expression of GP IIb/IIIa receptors. 58-32-2 DIPYRIDAMOLE MECH_LEVEL_3 3',5'-cAMP phosphodiesterase inhibitor 58-32-2 DIPYRIDAMOLE MECHANISM Enhance kinase mediated signal transduction 58-32-2 DIPYRIDAMOLE PRODUCT_CLASS Hematologics 58-32-2 DIPYRIDAMOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 58-32-2 DIPYRIDAMOLE MESH_LEVEL_3 Pyrimidines 58-32-2 DIPYRIDAMOLE INDICATION Diagnosis of Coronary Artery Disease 58-32-2 DIPYRIDAMOLE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 58-32-2 DIPYRIDAMOLE MODE_CLASS Enzyme Inhibitor 58-32-2 DIPYRIDAMOLE THERAPEUTIC_CLASS Antiplatelets 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT GIS_2_Diarrhea 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT XXX_3_Weakness 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT SKN_3_Pruritis 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT MSK_2_Muscle Cramps 58-32-2 DIPYRIDAMOLE ADVERSE_EFFECT NEU_3_Syncope 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT SKN_3_Fixed Drug Eruption 62013-04-1 DIRITHROMYCIN PRODUCT_CLASS Anti-infectives 62013-04-1 DIRITHROMYCIN INDICATION Community-Acquired Pneumonia 62013-04-1 DIRITHROMYCIN INDICATION Pharyngitis 62013-04-1 DIRITHROMYCIN INDICATION Skin and Skin Structure Infections 62013-04-1 DIRITHROMYCIN INDICATION Anthrax 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT LUN_2_Increased Cough 62013-04-1 DIRITHROMYCIN INDICATION Acute Bacterial Exacerbations of Chronic Bronchitis 62013-04-1 DIRITHROMYCIN INDICATION Tonsillitis 62013-04-1 DIRITHROMYCIN INDICATION Mycoplasma Pneumoniae 62013-04-1 DIRITHROMYCIN INDICATION Bordetella Pertussis Infection / Whooping Cough 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT BBM_3_Thrombocytosis 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT NEU_2_Vertigo 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT NEU_2_Headache 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT IMU_3_Anaphylaxis 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT ELT_3_Hyperkalemia 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT GIS_2_Flatulence 62013-04-1 DIRITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 62013-04-1 DIRITHROMYCIN INDICATION Helicobacter Pylori Infection 62013-04-1 DIRITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 62013-04-1 DIRITHROMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT XXX_2_Asthenia 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT GIS_1_Dyspepsia 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 62013-04-1 DIRITHROMYCIN INDICATION Legionnaire's Disease 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT SKN_2_Rash 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT SKN_2_Pruritis 62013-04-1 DIRITHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 62013-04-1 DIRITHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 3737-09-5 DISOPYRAMIDE INDICATION Ventricular Tachycardia 3737-09-5 DISOPYRAMIDE PRODUCT_CLASS Cardiovasculars 3737-09-5 DISOPYRAMIDE MODE_CLASS Channel Blocker 3737-09-5 DISOPYRAMIDE MECHANISM Increase muscle contraction 3737-09-5 DISOPYRAMIDE INDICATION Atrial Flutter 3737-09-5 DISOPYRAMIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 3737-09-5 DISOPYRAMIDE MECHANISM Block neural transmission 3737-09-5 DISOPYRAMIDE INDICATION Atrial Fibrillation 3737-09-5 DISOPYRAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 97-77-8 DISULFIRAM ADVERSE_EFFECT NEU_1_Peripheral Neuritis 97-77-8 DISULFIRAM ADVERSE_EFFECT NEU_2_Drowsiness 97-77-8 DISULFIRAM ADVERSE_EFFECT XXX_2_Fatigue 97-77-8 DISULFIRAM PRODUCT_CLASS Other Human Uses 97-77-8 DISULFIRAM TA_LEVEL_1 Other Human Uses 97-77-8 DISULFIRAM MECHANISM Prolong/enhance neural transmission 97-77-8 DISULFIRAM MECH_LEVEL_1 Drug Dependence Therapy 97-77-8 DISULFIRAM MODE_CLASS Channel Modulator 97-77-8 DISULFIRAM TISSUE_TOXICITY Hepatotoxicity 97-77-8 DISULFIRAM ADVERSE_EFFECT REP_2_Impotence 97-77-8 DISULFIRAM STRUCTURE_ACTIVITY Aldehyde dehydrogenase inhibitor 97-77-8 DISULFIRAM ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 97-77-8 DISULFIRAM ADVERSE_EFFECT SKN_2_Acne 97-77-8 DISULFIRAM KNOWN_TOXICITY Neurotoxicity 97-77-8 DISULFIRAM TISSUE_TOXICITY Optic Neuritis 97-77-8 DISULFIRAM ACTIVITY_CLASS Aldehyde dehydrogenase inhibitor 97-77-8 DISULFIRAM MESH_LEVEL_1 Organic Chemicals 97-77-8 DISULFIRAM MECHANISM Interferes with neural transmitter synthesis 97-77-8 DISULFIRAM MECH_LEVEL_3 Aldehyde dehydrogenase 97-77-8 DISULFIRAM MESH_LEVEL_3 Acids, Acyclic 97-77-8 DISULFIRAM KNOWN_TOXICITY Hepatotoxicity 97-77-8 DISULFIRAM ADVERSE_EFFECT NEU_1_Optic Neuritis 97-77-8 DISULFIRAM ADVERSE_EFFECT LIV_1_Hepatotoxicity 97-77-8 DISULFIRAM ADVERSE_EFFECT NEU_2_Headache 97-77-8 DISULFIRAM INDICATION Alcohol Dependency and Abuse / Alcoholism 97-77-8 DISULFIRAM MESH_LEVEL_2 Carboxylic Acids 97-77-8 DISULFIRAM MECHANISM interfere with glucose metabolism 97-77-8 DISULFIRAM ZERO_CLASS N 97-77-8 DISULFIRAM ADVERSE_EFFECT LIV_1_Acute Cholestatic Hepatitis 97-77-8 DISULFIRAM ADVERSE_EFFECT PSY_3_Psychosis 97-77-8 DISULFIRAM ADVERSE_EFFECT IMU_2_Allergic Reactions 97-77-8 DISULFIRAM THERAPEUTIC_CLASS Drug Dependence Therapy 97-77-8 DISULFIRAM MODE_CLASS Enzyme Inhibitor 97-77-8 DISULFIRAM TA_LEVEL_3 Alcohol abuse 97-77-8 DISULFIRAM MECH_LEVEL_2 Inhibit precursor synthesis 97-77-8 DISULFIRAM ADVERSE_EFFECT NEU_1_Polyneuritis 120-78-5 BENZOTHIAZYL DISULFIDE MESH_LEVEL_1 Heterocyclic Compounds 120-78-5 BENZOTHIAZYL DISULFIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 120-78-5 BENZOTHIAZYL DISULFIDE MESH_LEVEL_3 Thiazoles 120-78-5 BENZOTHIAZYL DISULFIDE TA_LEVEL_2 Biochemical 120-78-5 BENZOTHIAZYL DISULFIDE TA_LEVEL_3 Biochemical 120-78-5 BENZOTHIAZYL DISULFIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 120-78-5 BENZOTHIAZYL DISULFIDE MECH_LEVEL_2 Unknown mechanism 120-78-5 BENZOTHIAZYL DISULFIDE ACTIVITY_CLASS Pro-inflammatory stimuli 120-78-5 BENZOTHIAZYL DISULFIDE ZERO_CLASS N 120-78-5 BENZOTHIAZYL DISULFIDE PRODUCT_CLASS Biochemicals 120-78-5 BENZOTHIAZYL DISULFIDE ADVERSE_EFFECT IMU_1_Contact Dermatitis 120-78-5 BENZOTHIAZYL DISULFIDE TA_LEVEL_1 Biochemical 120-78-5 BENZOTHIAZYL DISULFIDE MECH_LEVEL_3 Unknown mechanism 120-78-5 BENZOTHIAZYL DISULFIDE STRUCTURE_ACTIVITY Pro-inflammatory stimuli 76326-31-3 DL-2-AMINO-5-PHOSPHONOVALERIC ACID MODE_CLASS Channel Modulator 76326-31-3 DL-2-AMINO-5-PHOSPHONOVALERIC ACID MECHANISM Prolong/enhance neural transmission 76326-31-3 DL-2-AMINO-5-PHOSPHONOVALERIC ACID PRODUCT_CLASS Biochemicals 78966-69-5 DL-2-AMINO-7-PHOSPHONOHEPTANOIC ACID PRODUCT_CLASS Biochemicals 78966-69-5 DL-2-AMINO-7-PHOSPHONOHEPTANOIC ACID MODE_CLASS Channel Modulator 78966-69-5 DL-2-AMINO-7-PHOSPHONOHEPTANOIC ACID MECHANISM Prolong/enhance neural transmission 138-65-8 DL-NORADRENALINE STRUCTURE_ACTIVITY Adrenoceptor agonist 138-65-8 DL-NORADRENALINE MECHANISM Modulate channel gating 138-65-8 DL-NORADRENALINE PRODUCT_CLASS Autonomic Nervous System (ANS) 138-65-8 DL-NORADRENALINE MECHANISM Modulate G-protein coupled signal transduction 138-65-8 DL-NORADRENALINE MODE_CLASS Endogenous Receptor /Channel Ligand 138-65-8 DL-NORADRENALINE MECHANISM Prolong/enhance neural transmission 138-65-8 DL-NORADRENALINE MODE_CLASS Endogenous Enzyme Substrate 138-65-8 DL-NORADRENALINE THERAPEUTIC_CLASS Sympathomimetic Agents 49745-95-1 DOBUTAMINE ADVERSE_EFFECT ELT_3_Hypokalemia 49745-95-1 DOBUTAMINE ADVERSE_EFFECT XXX_2_Fatigue 49745-95-1 DOBUTAMINE MECH_LEVEL_2 Modulate G-protein coupled signal transduction 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 49745-95-1 DOBUTAMINE MODE_CLASS Receptor Agonist, selective 49745-95-1 DOBUTAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_2_Angina 49745-95-1 DOBUTAMINE ADVERSE_EFFECT NEU_2_Headache 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_2_Phlebitis 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 49745-95-1 DOBUTAMINE TISSUE_TOXICITY Angina 49745-95-1 DOBUTAMINE TA_LEVEL_2 Congestive heart failure 49745-95-1 DOBUTAMINE MESH_LEVEL_1 Organic Chemicals 49745-95-1 DOBUTAMINE PRODUCT_CLASS Cardiovasculars 49745-95-1 DOBUTAMINE TISSUE_TOXICITY Ventricular Tachycardia 49745-95-1 DOBUTAMINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 49745-95-1 DOBUTAMINE STRUCTURE_ACTIVITY Adrenoceptor-beta1 agonist 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_2_Hypertension 49745-95-1 DOBUTAMINE ADVERSE_EFFECT LUN_2_Dyspnea 49745-95-1 DOBUTAMINE MECH_LEVEL_1 signal transduction 49745-95-1 DOBUTAMINE TA_LEVEL_1 Cardiovascular 49745-95-1 DOBUTAMINE MESH_LEVEL_3 Catecholamines 49745-95-1 DOBUTAMINE MECHANISM Modulate G-protein coupled signal transduction 49745-95-1 DOBUTAMINE MESH_LEVEL_2 Amines 49745-95-1 DOBUTAMINE ACTIVITY_CLASS Adrenergic agonist 49745-95-1 DOBUTAMINE INDICATION Cardiogenic Shock 49745-95-1 DOBUTAMINE MECH_LEVEL_3 adrenoceptor beta1 agonist, selective 49745-95-1 DOBUTAMINE INDICATION Cardiac Surgery 49745-95-1 DOBUTAMINE INDICATION Congestive Heart Failure (CHF) 49745-95-1 DOBUTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 49745-95-1 DOBUTAMINE ZERO_CLASS N 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_2_Hypotension 49745-95-1 DOBUTAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 49745-95-1 DOBUTAMINE ADVERSE_EFFECT NEU_2_Paresthesia 49745-95-1 DOBUTAMINE ADVERSE_EFFECT CVS_2_Palpitation 49745-95-1 DOBUTAMINE TISSUE_TOXICITY Hypotension 34368-04-2 DOBUTAMINE TISSUE_TOXICITY Angina 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 34368-04-2 DOBUTAMINE TA_LEVEL_1 Cardiovascular 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_2_Phlebitis 34368-04-2 DOBUTAMINE MECH_LEVEL_3 adrenoceptor beta1 agonist, selective 34368-04-2 DOBUTAMINE INDICATION Cardiac Surgery 34368-04-2 DOBUTAMINE INDICATION Congestive Heart Failure (CHF) 34368-04-2 DOBUTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 34368-04-2 DOBUTAMINE ZERO_CLASS N 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_2_Hypotension 34368-04-2 DOBUTAMINE TA_LEVEL_2 Congestive heart failure 34368-04-2 DOBUTAMINE STRUCTURE_ACTIVITY Adrenoceptor-beta1 agonist 34368-04-2 DOBUTAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 34368-04-2 DOBUTAMINE TISSUE_TOXICITY Hypotension 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_2_Palpitation 34368-04-2 DOBUTAMINE ADVERSE_EFFECT NEU_2_Paresthesia 34368-04-2 DOBUTAMINE MODE_CLASS Receptor Agonist, selective 34368-04-2 DOBUTAMINE MESH_LEVEL_1 Organic Chemicals 34368-04-2 DOBUTAMINE PRODUCT_CLASS Cardiovasculars 34368-04-2 DOBUTAMINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 34368-04-2 DOBUTAMINE MECH_LEVEL_2 Modulate G-protein coupled signal transduction 34368-04-2 DOBUTAMINE ADVERSE_EFFECT ELT_3_Hypokalemia 34368-04-2 DOBUTAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_2_Angina 34368-04-2 DOBUTAMINE ADVERSE_EFFECT NEU_2_Headache 34368-04-2 DOBUTAMINE ADVERSE_EFFECT LUN_2_Dyspnea 34368-04-2 DOBUTAMINE MECH_LEVEL_1 signal transduction 34368-04-2 DOBUTAMINE INDICATION Cardiogenic Shock 34368-04-2 DOBUTAMINE ACTIVITY_CLASS Adrenergic agonist 34368-04-2 DOBUTAMINE TISSUE_TOXICITY Ventricular Tachycardia 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 34368-04-2 DOBUTAMINE ADVERSE_EFFECT XXX_2_Fatigue 34368-04-2 DOBUTAMINE ADVERSE_EFFECT CVS_2_Hypertension 34368-04-2 DOBUTAMINE MECHANISM Modulate G-protein coupled signal transduction 34368-04-2 DOBUTAMINE MESH_LEVEL_2 Amines 34368-04-2 DOBUTAMINE MESH_LEVEL_3 Catecholamines 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_2_Hypotension 52663-81-7 DOBUTAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 52663-81-7 DOBUTAMINE ADVERSE_EFFECT NEU_2_Paresthesia 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_2_Palpitation 52663-81-7 DOBUTAMINE TISSUE_TOXICITY Hypotension 52663-81-7 DOBUTAMINE MECHANISM Modulate G-protein coupled signal transduction 52663-81-7 DOBUTAMINE MECH_LEVEL_2 Modulate G-protein coupled signal transduction 52663-81-7 DOBUTAMINE MODE_CLASS Receptor Agonist, selective 52663-81-7 DOBUTAMINE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_2_Angina 52663-81-7 DOBUTAMINE ADVERSE_EFFECT NEU_2_Headache 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_2_Phlebitis 52663-81-7 DOBUTAMINE TISSUE_TOXICITY Angina 52663-81-7 DOBUTAMINE TA_LEVEL_2 Congestive heart failure 52663-81-7 DOBUTAMINE MESH_LEVEL_1 Organic Chemicals 52663-81-7 DOBUTAMINE PRODUCT_CLASS Cardiovasculars 52663-81-7 DOBUTAMINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 52663-81-7 DOBUTAMINE STRUCTURE_ACTIVITY Adrenoceptor-beta1 agonist 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 52663-81-7 DOBUTAMINE ADVERSE_EFFECT ELT_3_Hypokalemia 52663-81-7 DOBUTAMINE ADVERSE_EFFECT LUN_2_Dyspnea 52663-81-7 DOBUTAMINE MECH_LEVEL_1 signal transduction 52663-81-7 DOBUTAMINE TA_LEVEL_1 Cardiovascular 52663-81-7 DOBUTAMINE MESH_LEVEL_3 Catecholamines 52663-81-7 DOBUTAMINE MESH_LEVEL_2 Amines 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_2_Hypertension 52663-81-7 DOBUTAMINE ADVERSE_EFFECT XXX_2_Fatigue 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 52663-81-7 DOBUTAMINE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 52663-81-7 DOBUTAMINE TISSUE_TOXICITY Ventricular Tachycardia 52663-81-7 DOBUTAMINE ACTIVITY_CLASS Adrenergic agonist 52663-81-7 DOBUTAMINE INDICATION Cardiogenic Shock 52663-81-7 DOBUTAMINE MECH_LEVEL_3 adrenoceptor beta1 agonist, selective 52663-81-7 DOBUTAMINE INDICATION Cardiac Surgery 52663-81-7 DOBUTAMINE INDICATION Congestive Heart Failure (CHF) 52663-81-7 DOBUTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 52663-81-7 DOBUTAMINE ZERO_CLASS N 114977-28-5 DOCETAXEL TISSUE_TOXICITY Bone Marrow Suppression 114977-28-5 DOCETAXEL ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 114977-28-5 DOCETAXEL ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 114977-28-5 DOCETAXEL ADVERSE_EFFECT LIV_1_Increased Liver Function Tests 114977-28-5 DOCETAXEL TISSUE_TOXICITY Neutropenia 114977-28-5 DOCETAXEL MECHANISM Inhibit mitosis 114977-28-5 DOCETAXEL PRODUCT_CLASS Anti-cancers 114977-28-5 DOCETAXEL TISSUE_TOXICITY Thrombocytopenia 114977-28-5 DOCETAXEL ADVERSE_EFFECT XXX_1_Fever 114977-28-5 DOCETAXEL TISSUE_TOXICITY Leukopenia 114977-28-5 DOCETAXEL ADVERSE_EFFECT BBM_1_Thrombocytopenia 114977-28-5 DOCETAXEL ADVERSE_EFFECT BBM_1_Neutropenia 114977-28-5 DOCETAXEL ADVERSE_EFFECT LUN_2_Bronchospasm 114977-28-5 DOCETAXEL ADVERSE_EFFECT MSK_2_Myalgia 114977-28-5 DOCETAXEL ADVERSE_EFFECT BBM_1_Bone Marrow Suppression 114977-28-5 DOCETAXEL ADVERSE_EFFECT NEU_2_Neurotoxicity 114977-28-5 DOCETAXEL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 114977-28-5 DOCETAXEL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 114977-28-5 DOCETAXEL ADVERSE_EFFECT CVS_3_Chest Pain 114977-28-5 DOCETAXEL TISSUE_TOXICITY Anemia 114977-28-5 DOCETAXEL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 114977-28-5 DOCETAXEL INDICATION Non-Small Cell Lung Carcinoma 114977-28-5 DOCETAXEL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 114977-28-5 DOCETAXEL TISSUE_TOXICITY Hypotension 114977-28-5 DOCETAXEL ADVERSE_EFFECT LUN_3_Pulmonary Edema 114977-28-5 DOCETAXEL ADVERSE_EFFECT KID_3_Renal Insufficiency 114977-28-5 DOCETAXEL THERAPEUTIC_CLASS Antineoplastics 114977-28-5 DOCETAXEL KNOWN_TOXICITY Cardiovascular Toxicity 114977-28-5 DOCETAXEL ADVERSE_EFFECT XXX_1_Infection 114977-28-5 DOCETAXEL INDICATION Breast Cancer / Carcinoma of the Breast 114977-28-5 DOCETAXEL ADVERSE_EFFECT BBM_1_Leukopenia 114977-28-5 DOCETAXEL STRUCTURE_ACTIVITY Tubulin binder 114977-28-5 DOCETAXEL ADVERSE_EFFECT CVS_2_Hypotension 114977-28-5 DOCETAXEL ADVERSE_EFFECT BBM_1_Anemia 148408-66-6 DOCETAXEL ADVERSE_EFFECT BBM_1_Neutropenia 148408-66-6 DOCETAXEL ADVERSE_EFFECT NEU_2_Neurotoxicity 148408-66-6 DOCETAXEL KNOWN_TOXICITY Cardiovascular Toxicity 148408-66-6 DOCETAXEL TISSUE_TOXICITY Leukopenia 148408-66-6 DOCETAXEL INDICATION Breast Cancer / Carcinoma of the Breast 148408-66-6 DOCETAXEL ADVERSE_EFFECT BBM_1_Anemia 148408-66-6 DOCETAXEL ADVERSE_EFFECT LUN_3_Acute Respiratory Distress 148408-66-6 DOCETAXEL ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 148408-66-6 DOCETAXEL ADVERSE_EFFECT LIV_1_Increased Liver Function Tests 148408-66-6 DOCETAXEL TISSUE_TOXICITY Neutropenia 148408-66-6 DOCETAXEL ADVERSE_EFFECT MSK_2_Myalgia 148408-66-6 DOCETAXEL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 148408-66-6 DOCETAXEL ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 148408-66-6 DOCETAXEL TISSUE_TOXICITY Bone Marrow Suppression 148408-66-6 DOCETAXEL MECHANISM Inhibit mitosis 148408-66-6 DOCETAXEL PRODUCT_CLASS Anti-cancers 148408-66-6 DOCETAXEL TISSUE_TOXICITY Thrombocytopenia 148408-66-6 DOCETAXEL ADVERSE_EFFECT XXX_1_Fever 148408-66-6 DOCETAXEL ADVERSE_EFFECT LUN_2_Bronchospasm 148408-66-6 DOCETAXEL ADVERSE_EFFECT XXX_1_Infection 148408-66-6 DOCETAXEL ADVERSE_EFFECT BBM_1_Bone Marrow Suppression 148408-66-6 DOCETAXEL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 148408-66-6 DOCETAXEL ADVERSE_EFFECT BBM_1_Leukopenia 148408-66-6 DOCETAXEL ADVERSE_EFFECT CVS_3_Chest Pain 148408-66-6 DOCETAXEL TISSUE_TOXICITY Anemia 148408-66-6 DOCETAXEL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 148408-66-6 DOCETAXEL INDICATION Non-Small Cell Lung Carcinoma 148408-66-6 DOCETAXEL ADVERSE_EFFECT CVS_2_Hypotension 148408-66-6 DOCETAXEL THERAPEUTIC_CLASS Antineoplastics 148408-66-6 DOCETAXEL STRUCTURE_ACTIVITY Tubulin binder 148408-66-6 DOCETAXEL TISSUE_TOXICITY Hypotension 148408-66-6 DOCETAXEL ADVERSE_EFFECT LUN_3_Pulmonary Edema 148408-66-6 DOCETAXEL ADVERSE_EFFECT KID_3_Renal Insufficiency 148408-66-6 DOCETAXEL ADVERSE_EFFECT BBM_1_Thrombocytopenia 59831-63-9 DOCONAZOLE THERAPEUTIC_CLASS Antifungals 59831-63-9 DOCONAZOLE MODE_CLASS Enzyme Inhibitor 59831-63-9 DOCONAZOLE PRODUCT_CLASS Anti-infectives 59831-63-9 DOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 10041-19-7 DOCUSATE INDICATION Constipation 577-11-7 DOCUSATE INDICATION Constipation 53023-94-2 DOCUSATE INDICATION Constipation 115956-12-2 DOLASETRON STRUCTURE_ACTIVITY Anti-emetic, 5HT3 antagonist 115956-12-2 DOLASETRON THERAPEUTIC_CLASS Antiemetics 115956-12-2 DOLASETRON PRODUCT_CLASS Gastrointestinal System 115956-12-2 DOLASETRON MECHANISM Block neural transmission 115956-12-2 DOLASETRON INDICATION Nausea / Vomiting 115956-12-2 DOLASETRON MODE_CLASS Channel Blocker, selective 14277-97-5 DOMOIC ACID MECHANISM Prolong/enhance neural transmission 14277-97-5 DOMOIC ACID MODE_CLASS Channel Modulator 14277-97-5 DOMOIC ACID PRODUCT_CLASS Biochemicals 120014-06-4 DONEPEZIL ADVERSE_EFFECT PSY_1_Insomnia 120014-06-4 DONEPEZIL ADVERSE_EFFECT PSY_2_Depression 120014-06-4 DONEPEZIL MODE_CLASS Enzyme Inhibitor 120014-06-4 DONEPEZIL TA_LEVEL_3 Alzheimer's disease 120014-06-4 DONEPEZIL MESH_LEVEL_3 Indenes 120014-06-4 DONEPEZIL MECH_LEVEL_1 Modulate neural transmission 120014-06-4 DONEPEZIL MECH_LEVEL_3 Acetylcholinesterase 120014-06-4 DONEPEZIL MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 120014-06-4 DONEPEZIL PRODUCT_CLASS Autonomic Nervous System (ANS) 120014-06-4 DONEPEZIL ADVERSE_EFFECT GUS_2_Urinary Frequency 120014-06-4 DONEPEZIL INDICATION Alzheimer's Dementia 120014-06-4 DONEPEZIL MECH_LEVEL_2 Enhance cholinergic transmission 120014-06-4 DONEPEZIL ADVERSE_EFFECT MSK_2_Arthritis 120014-06-4 DONEPEZIL ADVERSE_EFFECT LUN_3_Dyspnea 120014-06-4 DONEPEZIL ADVERSE_EFFECT XXX_3_Dehydration 120014-06-4 DONEPEZIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 120014-06-4 DONEPEZIL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 120014-06-4 DONEPEZIL ADVERSE_EFFECT BBM_2_Ecchymosis 120014-06-4 DONEPEZIL ADVERSE_EFFECT NEU_2_Syncope 120014-06-4 DONEPEZIL TA_LEVEL_2 Dementia 120014-06-4 DONEPEZIL ADVERSE_EFFECT CVS_3_Hypertension 120014-06-4 DONEPEZIL ADVERSE_EFFECT NEU_3_Tremor 120014-06-4 DONEPEZIL MECHANISM Enhance cholinergic transmission 120014-06-4 DONEPEZIL ADVERSE_EFFECT NEU_2_Dizziness 120014-06-4 DONEPEZIL ADVERSE_EFFECT CVS_3_Chest Pain 120014-06-4 DONEPEZIL ADVERSE_EFFECT GIS_1_Diarrhea 120014-06-4 DONEPEZIL MESH_LEVEL_1 Polycyclic Hydrocarbons 120014-06-4 DONEPEZIL STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 120014-06-4 DONEPEZIL ADVERSE_EFFECT NEU_2_Headache 120014-06-4 DONEPEZIL TA_LEVEL_1 Central Nervous System (CNS) 120014-06-4 DONEPEZIL THERAPEUTIC_CLASS Parasympathomimetic Agents 120014-06-4 DONEPEZIL TISSUE_TOXICITY Atrial Fibrillation 120014-06-4 DONEPEZIL ZERO_CLASS N 120014-06-4 DONEPEZIL ADVERSE_EFFECT PSY_1_Anorexia 120014-06-4 DONEPEZIL ADVERSE_EFFECT XXX_1_Fatigue 120014-06-4 DONEPEZIL ADVERSE_EFFECT NEU_3_Ataxia 120014-06-4 DONEPEZIL ADVERSE_EFFECT MSK_1_Muscle Cramps 120014-06-4 DONEPEZIL KNOWN_TOXICITY Cardiovascular Toxicity 120011-70-3 DONEPEZIL STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 120011-70-3 DONEPEZIL MESH_LEVEL_1 Polycyclic Hydrocarbons 120011-70-3 DONEPEZIL ADVERSE_EFFECT GIS_1_Diarrhea 120011-70-3 DONEPEZIL ADVERSE_EFFECT CVS_3_Chest Pain 120011-70-3 DONEPEZIL ADVERSE_EFFECT NEU_2_Dizziness 120011-70-3 DONEPEZIL ADVERSE_EFFECT NEU_3_Tremor 120011-70-3 DONEPEZIL ADVERSE_EFFECT CVS_3_Hypertension 120011-70-3 DONEPEZIL TA_LEVEL_2 Dementia 120011-70-3 DONEPEZIL ADVERSE_EFFECT NEU_2_Syncope 120011-70-3 DONEPEZIL ADVERSE_EFFECT BBM_2_Ecchymosis 120011-70-3 DONEPEZIL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 120011-70-3 DONEPEZIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 120011-70-3 DONEPEZIL ADVERSE_EFFECT XXX_3_Dehydration 120011-70-3 DONEPEZIL INDICATION Alzheimer's Dementia 120011-70-3 DONEPEZIL PRODUCT_CLASS Autonomic Nervous System (ANS) 120011-70-3 DONEPEZIL MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 120011-70-3 DONEPEZIL KNOWN_TOXICITY Cardiovascular Toxicity 120011-70-3 DONEPEZIL ADVERSE_EFFECT PSY_1_Anorexia 120011-70-3 DONEPEZIL ADVERSE_EFFECT MSK_1_Muscle Cramps 120011-70-3 DONEPEZIL ADVERSE_EFFECT NEU_3_Ataxia 120011-70-3 DONEPEZIL ADVERSE_EFFECT GUS_2_Urinary Frequency 120011-70-3 DONEPEZIL MECHANISM Enhance cholinergic transmission 120011-70-3 DONEPEZIL ADVERSE_EFFECT MSK_2_Arthritis 120011-70-3 DONEPEZIL ADVERSE_EFFECT LUN_3_Dyspnea 120011-70-3 DONEPEZIL ADVERSE_EFFECT NEU_2_Headache 120011-70-3 DONEPEZIL ADVERSE_EFFECT PSY_1_Insomnia 120011-70-3 DONEPEZIL ZERO_CLASS N 120011-70-3 DONEPEZIL TISSUE_TOXICITY Atrial Fibrillation 120011-70-3 DONEPEZIL THERAPEUTIC_CLASS Parasympathomimetic Agents 120011-70-3 DONEPEZIL TA_LEVEL_1 Central Nervous System (CNS) 120011-70-3 DONEPEZIL ADVERSE_EFFECT PSY_2_Depression 120011-70-3 DONEPEZIL MODE_CLASS Enzyme Inhibitor 120011-70-3 DONEPEZIL MECH_LEVEL_2 Enhance cholinergic transmission 120011-70-3 DONEPEZIL TA_LEVEL_3 Alzheimer's disease 120011-70-3 DONEPEZIL MESH_LEVEL_3 Indenes 120011-70-3 DONEPEZIL MECH_LEVEL_1 Modulate neural transmission 120011-70-3 DONEPEZIL ADVERSE_EFFECT XXX_1_Fatigue 120011-70-3 DONEPEZIL MECH_LEVEL_3 Acetylcholinesterase 123958-79-2 DONEPEZIL ADVERSE_EFFECT MSK_2_Arthritis 123958-79-2 DONEPEZIL MECHANISM Enhance cholinergic transmission 123958-79-2 DONEPEZIL STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 123958-79-2 DONEPEZIL MECH_LEVEL_3 Acetylcholinesterase 123958-79-2 DONEPEZIL MECH_LEVEL_1 Modulate neural transmission 123958-79-2 DONEPEZIL MESH_LEVEL_3 Indenes 123958-79-2 DONEPEZIL TA_LEVEL_3 Alzheimer's disease 123958-79-2 DONEPEZIL TA_LEVEL_1 Central Nervous System (CNS) 123958-79-2 DONEPEZIL THERAPEUTIC_CLASS Parasympathomimetic Agents 123958-79-2 DONEPEZIL TISSUE_TOXICITY Atrial Fibrillation 123958-79-2 DONEPEZIL ZERO_CLASS N 123958-79-2 DONEPEZIL ADVERSE_EFFECT XXX_1_Fatigue 123958-79-2 DONEPEZIL ADVERSE_EFFECT NEU_3_Ataxia 123958-79-2 DONEPEZIL ADVERSE_EFFECT MSK_1_Muscle Cramps 123958-79-2 DONEPEZIL KNOWN_TOXICITY Cardiovascular Toxicity 123958-79-2 DONEPEZIL MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 123958-79-2 DONEPEZIL ADVERSE_EFFECT PSY_1_Anorexia 123958-79-2 DONEPEZIL PRODUCT_CLASS Autonomic Nervous System (ANS) 123958-79-2 DONEPEZIL INDICATION Alzheimer's Dementia 123958-79-2 DONEPEZIL ADVERSE_EFFECT XXX_3_Dehydration 123958-79-2 DONEPEZIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 123958-79-2 DONEPEZIL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 123958-79-2 DONEPEZIL ADVERSE_EFFECT BBM_2_Ecchymosis 123958-79-2 DONEPEZIL ADVERSE_EFFECT NEU_2_Syncope 123958-79-2 DONEPEZIL TA_LEVEL_2 Dementia 123958-79-2 DONEPEZIL ADVERSE_EFFECT CVS_3_Hypertension 123958-79-2 DONEPEZIL ADVERSE_EFFECT NEU_3_Tremor 123958-79-2 DONEPEZIL ADVERSE_EFFECT NEU_2_Dizziness 123958-79-2 DONEPEZIL ADVERSE_EFFECT CVS_3_Chest Pain 123958-79-2 DONEPEZIL ADVERSE_EFFECT GIS_1_Diarrhea 123958-79-2 DONEPEZIL MESH_LEVEL_1 Polycyclic Hydrocarbons 123958-79-2 DONEPEZIL MECH_LEVEL_2 Enhance cholinergic transmission 123958-79-2 DONEPEZIL MODE_CLASS Enzyme Inhibitor 123958-79-2 DONEPEZIL ADVERSE_EFFECT PSY_2_Depression 123958-79-2 DONEPEZIL ADVERSE_EFFECT PSY_1_Insomnia 123958-79-2 DONEPEZIL ADVERSE_EFFECT NEU_2_Headache 123958-79-2 DONEPEZIL ADVERSE_EFFECT LUN_3_Dyspnea 123958-79-2 DONEPEZIL ADVERSE_EFFECT GUS_2_Urinary Frequency 142057-77-0 DONEPEZIL PRODUCT_CLASS Autonomic Nervous System (ANS) 142057-77-0 DONEPEZIL MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 142057-77-0 DONEPEZIL KNOWN_TOXICITY Cardiovascular Toxicity 142057-77-0 DONEPEZIL ADVERSE_EFFECT NEU_3_Ataxia 142057-77-0 DONEPEZIL ADVERSE_EFFECT XXX_1_Fatigue 142057-77-0 DONEPEZIL ADVERSE_EFFECT PSY_1_Anorexia 142057-77-0 DONEPEZIL ZERO_CLASS N 142057-77-0 DONEPEZIL TISSUE_TOXICITY Atrial Fibrillation 142057-77-0 DONEPEZIL THERAPEUTIC_CLASS Parasympathomimetic Agents 142057-77-0 DONEPEZIL TA_LEVEL_1 Central Nervous System (CNS) 142057-77-0 DONEPEZIL ADVERSE_EFFECT MSK_1_Muscle Cramps 142057-77-0 DONEPEZIL MECHANISM Enhance cholinergic transmission 142057-77-0 DONEPEZIL ADVERSE_EFFECT MSK_2_Arthritis 142057-77-0 DONEPEZIL ADVERSE_EFFECT LUN_3_Dyspnea 142057-77-0 DONEPEZIL ADVERSE_EFFECT NEU_2_Headache 142057-77-0 DONEPEZIL ADVERSE_EFFECT PSY_1_Insomnia 142057-77-0 DONEPEZIL ADVERSE_EFFECT PSY_2_Depression 142057-77-0 DONEPEZIL MODE_CLASS Enzyme Inhibitor 142057-77-0 DONEPEZIL MECH_LEVEL_2 Enhance cholinergic transmission 142057-77-0 DONEPEZIL TA_LEVEL_3 Alzheimer's disease 142057-77-0 DONEPEZIL MESH_LEVEL_3 Indenes 142057-77-0 DONEPEZIL MECH_LEVEL_1 Modulate neural transmission 142057-77-0 DONEPEZIL MECH_LEVEL_3 Acetylcholinesterase 142057-77-0 DONEPEZIL STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 142057-77-0 DONEPEZIL MESH_LEVEL_1 Polycyclic Hydrocarbons 142057-77-0 DONEPEZIL ADVERSE_EFFECT GIS_1_Diarrhea 142057-77-0 DONEPEZIL ADVERSE_EFFECT GUS_2_Urinary Frequency 142057-77-0 DONEPEZIL ADVERSE_EFFECT CVS_3_Chest Pain 142057-77-0 DONEPEZIL ADVERSE_EFFECT NEU_2_Dizziness 142057-77-0 DONEPEZIL ADVERSE_EFFECT NEU_3_Tremor 142057-77-0 DONEPEZIL ADVERSE_EFFECT CVS_3_Hypertension 142057-77-0 DONEPEZIL TA_LEVEL_2 Dementia 142057-77-0 DONEPEZIL ADVERSE_EFFECT NEU_2_Syncope 142057-77-0 DONEPEZIL ADVERSE_EFFECT BBM_2_Ecchymosis 142057-77-0 DONEPEZIL ADVERSE_EFFECT CVS_3_Atrial Fibrillation 142057-77-0 DONEPEZIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 142057-77-0 DONEPEZIL ADVERSE_EFFECT XXX_3_Dehydration 142057-77-0 DONEPEZIL INDICATION Alzheimer's Dementia 51-61-6 DOPAMINE MECHANISM Modulate channel gating 51-61-6 DOPAMINE INDICATION Hypotension 51-61-6 DOPAMINE MODE_CLASS Endogenous Receptor /Channel Ligand 51-61-6 DOPAMINE MECHANISM Modulate G-protein coupled signal transduction 51-61-6 DOPAMINE PRODUCT_CLASS Cardiovasculars 51-61-6 DOPAMINE THERAPEUTIC_CLASS Sympathomimetic Agents 51-61-6 DOPAMINE INDICATION Congestive Heart Failure (CHF) 51-61-6 DOPAMINE INDICATION Cardiogenic Shock 51-61-6 DOPAMINE THERAPEUTIC_CLASS Congestive Heart Failure 120279-96-1 DORZOLAMIDE MODE_CLASS Enzyme Inhibitor 120279-96-1 DORZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 120279-96-1 DORZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 120279-96-1 DORZOLAMIDE INDICATION Glaucoma 120279-96-1 DORZOLAMIDE PRODUCT_CLASS Other Human Uses 120279-96-1 DORZOLAMIDE INDICATION Increased Intraocular Pressure 120280-13-9 DORZOLAMIDE MODE_CLASS Enzyme Inhibitor 120280-13-9 DORZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 120280-13-9 DORZOLAMIDE PRODUCT_CLASS Other Human Uses 120280-13-9 DORZOLAMIDE INDICATION Increased Intraocular Pressure 120280-13-9 DORZOLAMIDE INDICATION Glaucoma 120280-13-9 DORZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 120279-82-2 DORZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 120279-82-2 DORZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 120279-82-2 DORZOLAMIDE INDICATION Glaucoma 120279-82-2 DORZOLAMIDE MODE_CLASS Enzyme Inhibitor 120279-82-2 DORZOLAMIDE INDICATION Increased Intraocular Pressure 120279-82-2 DORZOLAMIDE PRODUCT_CLASS Other Human Uses 120279-95-0 DORZOLAMIDE INDICATION Glaucoma 120279-95-0 DORZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 120279-95-0 DORZOLAMIDE PRODUCT_CLASS Other Human Uses 120279-95-0 DORZOLAMIDE INDICATION Increased Intraocular Pressure 120279-95-0 DORZOLAMIDE MODE_CLASS Enzyme Inhibitor 120279-95-0 DORZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 120279-36-9 DORZOLAMIDE INDICATION Glaucoma 120279-36-9 DORZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 120279-36-9 DORZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 120279-36-9 DORZOLAMIDE MODE_CLASS Enzyme Inhibitor 120279-36-9 DORZOLAMIDE PRODUCT_CLASS Other Human Uses 120279-36-9 DORZOLAMIDE INDICATION Increased Intraocular Pressure 130693-82-2 DORZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 130693-82-2 DORZOLAMIDE INDICATION Glaucoma 130693-82-2 DORZOLAMIDE PRODUCT_CLASS Other Human Uses 130693-82-2 DORZOLAMIDE MODE_CLASS Enzyme Inhibitor 130693-82-2 DORZOLAMIDE INDICATION Increased Intraocular Pressure 130693-82-2 DORZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 106791-39-3 DOXACURIUM CHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 106791-39-3 DOXACURIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 106791-39-3 DOXACURIUM CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 106791-39-3 DOXACURIUM CHLORIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 83348-52-1 DOXACURIUM CHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 83348-52-1 DOXACURIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 83348-52-1 DOXACURIUM CHLORIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 83348-52-1 DOXACURIUM CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 106819-53-8 DOXACURIUM CHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 106819-53-8 DOXACURIUM CHLORIDE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 106819-53-8 DOXACURIUM CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 106819-53-8 DOXACURIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 77883-43-3 DOXAZOSIN TISSUE_TOXICITY Angina 77883-43-3 DOXAZOSIN ACTIVITY_CLASS Adrenergic antagonist 77883-43-3 DOXAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 77883-43-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Sinus Bradycardia 77883-43-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Sinus Tachycardia 77883-43-3 DOXAZOSIN ADVERSE_EFFECT REP_3_Impotence 77883-43-3 DOXAZOSIN ADVERSE_EFFECT END_3_Gynecomastia 77883-43-3 DOXAZOSIN ADVERSE_EFFECT REP_3_Decreased Libido 77883-43-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Palpitation 77883-43-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Malaise 77883-43-3 DOXAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 77883-43-3 DOXAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 77883-43-3 DOXAZOSIN MECH_LEVEL_1 Vasorelaxation 77883-43-3 DOXAZOSIN TA_LEVEL_3 hypertension 77883-43-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Fatigue 77883-43-3 DOXAZOSIN ADVERSE_EFFECT NEU_3_Drowsiness 77883-43-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 77883-43-3 DOXAZOSIN MESH_LEVEL_3 Quinazolines 77883-43-3 DOXAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 77883-43-3 DOXAZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 77883-43-3 DOXAZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 77883-43-3 DOXAZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 77883-43-3 DOXAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 77883-43-3 DOXAZOSIN ADVERSE_EFFECT OCU_2_Blurred Vision 77883-43-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Angina 77883-43-3 DOXAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 77883-43-3 DOXAZOSIN ADVERSE_EFFECT LIV_3_Hepatitis 77883-43-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Weight Gain 77883-43-3 DOXAZOSIN ADVERSE_EFFECT NEU_1_Vertigo 77883-43-3 DOXAZOSIN ADVERSE_EFFECT REP_3_Priapism 77883-43-3 DOXAZOSIN TA_LEVEL_1 Cardiovascular 77883-43-3 DOXAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 77883-43-3 DOXAZOSIN ZERO_CLASS N 77883-43-3 DOXAZOSIN ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 77883-43-3 DOXAZOSIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 77883-43-3 DOXAZOSIN ADVERSE_EFFECT XXX_3_Edema 77883-43-3 DOXAZOSIN ADVERSE_EFFECT LUN_3_Dyspnea 77883-43-3 DOXAZOSIN ADVERSE_EFFECT BBM_3_Leukopenia 77883-43-3 DOXAZOSIN ADVERSE_EFFECT NEU_2_Syncope 77883-43-3 DOXAZOSIN INDICATION Hypertension 77883-43-3 DOXAZOSIN MECH_LEVEL_2 alpha antagonist 77883-43-3 DOXAZOSIN ADVERSE_EFFECT GIS_2_Abdominal Pain 77883-43-3 DOXAZOSIN MECHANISM Reduce vasoconstriction 77883-43-3 DOXAZOSIN TA_LEVEL_2 alpha blocker 77883-43-3 DOXAZOSIN PRODUCT_CLASS Cardiovasculars 77883-43-3 DOXAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 74191-85-8 DOXAZOSIN MESH_LEVEL_3 Quinazolines 74191-85-8 DOXAZOSIN ADVERSE_EFFECT CVS_3_Sinus Tachycardia 74191-85-8 DOXAZOSIN ADVERSE_EFFECT XXX_2_Fatigue 74191-85-8 DOXAZOSIN ADVERSE_EFFECT NEU_3_Drowsiness 74191-85-8 DOXAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 74191-85-8 DOXAZOSIN ADVERSE_EFFECT NEU_1_Vertigo 74191-85-8 DOXAZOSIN ADVERSE_EFFECT REP_3_Priapism 74191-85-8 DOXAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 74191-85-8 DOXAZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 74191-85-8 DOXAZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 74191-85-8 DOXAZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 74191-85-8 DOXAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 74191-85-8 DOXAZOSIN ADVERSE_EFFECT OCU_2_Blurred Vision 74191-85-8 DOXAZOSIN ADVERSE_EFFECT CVS_3_Angina 74191-85-8 DOXAZOSIN ADVERSE_EFFECT LUN_3_Dyspnea 74191-85-8 DOXAZOSIN ADVERSE_EFFECT LIV_3_Hepatitis 74191-85-8 DOXAZOSIN ADVERSE_EFFECT XXX_2_Weight Gain 74191-85-8 DOXAZOSIN ADVERSE_EFFECT GIS_2_Abdominal Pain 74191-85-8 DOXAZOSIN MECHANISM Reduce vasoconstriction 74191-85-8 DOXAZOSIN TA_LEVEL_2 alpha blocker 74191-85-8 DOXAZOSIN PRODUCT_CLASS Cardiovasculars 74191-85-8 DOXAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 74191-85-8 DOXAZOSIN TISSUE_TOXICITY Angina 74191-85-8 DOXAZOSIN ACTIVITY_CLASS Adrenergic antagonist 74191-85-8 DOXAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 74191-85-8 DOXAZOSIN ADVERSE_EFFECT CVS_3_Sinus Bradycardia 74191-85-8 DOXAZOSIN ADVERSE_EFFECT REP_3_Impotence 74191-85-8 DOXAZOSIN ADVERSE_EFFECT END_3_Gynecomastia 74191-85-8 DOXAZOSIN ADVERSE_EFFECT REP_3_Decreased Libido 74191-85-8 DOXAZOSIN ADVERSE_EFFECT CVS_3_Palpitation 74191-85-8 DOXAZOSIN MECH_LEVEL_2 alpha antagonist 74191-85-8 DOXAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 74191-85-8 DOXAZOSIN ZERO_CLASS N 74191-85-8 DOXAZOSIN ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 74191-85-8 DOXAZOSIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 74191-85-8 DOXAZOSIN ADVERSE_EFFECT XXX_3_Edema 74191-85-8 DOXAZOSIN TA_LEVEL_1 Cardiovascular 74191-85-8 DOXAZOSIN ADVERSE_EFFECT BBM_3_Leukopenia 74191-85-8 DOXAZOSIN ADVERSE_EFFECT NEU_2_Syncope 74191-85-8 DOXAZOSIN INDICATION Hypertension 74191-85-8 DOXAZOSIN ADVERSE_EFFECT XXX_2_Malaise 74191-85-8 DOXAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 74191-85-8 DOXAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 74191-85-8 DOXAZOSIN MECH_LEVEL_1 Vasorelaxation 74191-85-8 DOXAZOSIN TA_LEVEL_3 hypertension 74191-85-8 DOXAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 70918-01-3 DOXAZOSIN ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 70918-01-3 DOXAZOSIN ZERO_CLASS N 70918-01-3 DOXAZOSIN MODE_CLASS Receptor Ligand Antagonist, Selective 70918-01-3 DOXAZOSIN MECH_LEVEL_2 alpha antagonist 70918-01-3 DOXAZOSIN TA_LEVEL_1 Cardiovascular 70918-01-3 DOXAZOSIN ADVERSE_EFFECT REP_3_Priapism 70918-01-3 DOXAZOSIN ADVERSE_EFFECT NEU_1_Vertigo 70918-01-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Peripheral Edema 70918-01-3 DOXAZOSIN ADVERSE_EFFECT NEU_3_Drowsiness 70918-01-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Fatigue 70918-01-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Sinus Tachycardia 70918-01-3 DOXAZOSIN MESH_LEVEL_3 Quinazolines 70918-01-3 DOXAZOSIN TA_LEVEL_3 hypertension 70918-01-3 DOXAZOSIN MECH_LEVEL_1 Vasorelaxation 70918-01-3 DOXAZOSIN MECH_LEVEL_3 adrenoceptor alpha1 70918-01-3 DOXAZOSIN MESH_LEVEL_1 Heterocyclic Compounds 70918-01-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Malaise 70918-01-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Palpitation 70918-01-3 DOXAZOSIN ADVERSE_EFFECT REP_3_Decreased Libido 70918-01-3 DOXAZOSIN ADVERSE_EFFECT END_3_Gynecomastia 70918-01-3 DOXAZOSIN ADVERSE_EFFECT REP_3_Impotence 70918-01-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Sinus Bradycardia 70918-01-3 DOXAZOSIN STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist, zosin 70918-01-3 DOXAZOSIN ACTIVITY_CLASS Adrenergic antagonist 70918-01-3 DOXAZOSIN TISSUE_TOXICITY Angina 70918-01-3 DOXAZOSIN THERAPEUTIC_CLASS Antihypertensive Agents 70918-01-3 DOXAZOSIN PRODUCT_CLASS Cardiovasculars 70918-01-3 DOXAZOSIN TA_LEVEL_2 alpha blocker 70918-01-3 DOXAZOSIN MECHANISM Reduce vasoconstriction 70918-01-3 DOXAZOSIN ADVERSE_EFFECT GIS_2_Abdominal Pain 70918-01-3 DOXAZOSIN ADVERSE_EFFECT XXX_2_Weight Gain 70918-01-3 DOXAZOSIN ADVERSE_EFFECT LIV_3_Hepatitis 70918-01-3 DOXAZOSIN ADVERSE_EFFECT NEU_1_Dizziness 70918-01-3 DOXAZOSIN ADVERSE_EFFECT CVS_3_Angina 70918-01-3 DOXAZOSIN ADVERSE_EFFECT OCU_2_Blurred Vision 70918-01-3 DOXAZOSIN KNOWN_TOXICITY Cardiovascular Toxicity 70918-01-3 DOXAZOSIN THERAPEUTIC_CLASS Sympatholytic Agents 70918-01-3 DOXAZOSIN INDICATION Benign Prostatic Hyperplasia (BPH) 70918-01-3 DOXAZOSIN PRODUCT_CLASS Autonomic Nervous System (ANS) 70918-01-3 DOXAZOSIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 70918-01-3 DOXAZOSIN INDICATION Hypertension 70918-01-3 DOXAZOSIN ADVERSE_EFFECT NEU_2_Syncope 70918-01-3 DOXAZOSIN ADVERSE_EFFECT BBM_3_Leukopenia 70918-01-3 DOXAZOSIN ADVERSE_EFFECT LUN_3_Dyspnea 70918-01-3 DOXAZOSIN ADVERSE_EFFECT XXX_3_Edema 70918-01-3 DOXAZOSIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_2_Hypertension 1229-29-4 DOXEPIN ACTIVITY_CLASS Histamine antagonist 1229-29-4 DOXEPIN MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 1229-29-4 DOXEPIN INDICATION Atopic Dermatitis / Eczema 1229-29-4 DOXEPIN TA_LEVEL_2 CN stimulant 1229-29-4 DOXEPIN PRODUCT_CLASS Dermatologicals 1229-29-4 DOXEPIN MECH_LEVEL_3 histamine receptor H1 1229-29-4 DOXEPIN TA_LEVEL_3 Tricyclic antidpressant 1229-29-4 DOXEPIN TA_LEVEL_1 Central Nervous System (CNS) 1229-29-4 DOXEPIN TISSUE_TOXICITY Heart Failure 1229-29-4 DOXEPIN ADVERSE_EFFECT END_2_Galactorrhea 1229-29-4 DOXEPIN ADVERSE_EFFECT OCU_3_Glaucoma 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 1229-29-4 DOXEPIN ADVERSE_EFFECT REP_2_Impotence 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 1229-29-4 DOXEPIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 1229-29-4 DOXEPIN ADVERSE_EFFECT BBM_3_Leukopenia 1229-29-4 DOXEPIN ADVERSE_EFFECT PSY_2_Mental Confusion 1229-29-4 DOXEPIN MECHANISM Modulate G-protein coupled signal transduction 1229-29-4 DOXEPIN INDICATION Pruritus / Itching 1229-29-4 DOXEPIN MODE_CLASS Receptor Ligand Antagonist 1229-29-4 DOXEPIN TISSUE_TOXICITY Myocardial Infarction 1229-29-4 DOXEPIN ADVERSE_EFFECT END_3_Gynecomastia 1229-29-4 DOXEPIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1229-29-4 DOXEPIN ADVERSE_EFFECT BBM_3_Agranulocytosis 1229-29-4 DOXEPIN ADVERSE_EFFECT NEU_2_Seizures 1229-29-4 DOXEPIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 1229-29-4 DOXEPIN ADVERSE_EFFECT REP_2_Ejaculatory Disorder 1229-29-4 DOXEPIN PRODUCT_CLASS Central Nervous System (CNS) 1229-29-4 DOXEPIN THERAPEUTIC_CLASS Antidepressants 1229-29-4 DOXEPIN MECH_LEVEL_1 Modulate neural transmission 1229-29-4 DOXEPIN INDICATION Depression 1229-29-4 DOXEPIN MECH_LEVEL_2 Anti-histamine 1229-29-4 DOXEPIN THERAPEUTIC_CLASS Antipruritic Agents 1229-29-4 DOXEPIN KNOWN_TOXICITY Cardiovascular Toxicity 1229-29-4 DOXEPIN TISSUE_TOXICITY Ventricular Tachycardia 1229-29-4 DOXEPIN ADVERSE_EFFECT NEU_1_Dizziness 1229-29-4 DOXEPIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_3_Prolonged QT Interval 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_3_Heart Failure 1229-29-4 DOXEPIN ZERO_CLASS N 1229-29-4 DOXEPIN ADVERSE_EFFECT OCU_1_Blurred Vision 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_3_Myocardial Infarction 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 1229-29-4 DOXEPIN ADVERSE_EFFECT GIS_1_Dry Mouth 1229-29-4 DOXEPIN ADVERSE_EFFECT PSY_3_Serotonin Syndrome 1229-29-4 DOXEPIN ADVERSE_EFFECT GUS_2_Urinary Retention 1229-29-4 DOXEPIN STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, tricyclic 1229-29-4 DOXEPIN ADVERSE_EFFECT CVS_2_Prolonged PR Interval 1229-29-4 DOXEPIN ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 1229-29-4 DOXEPIN INDICATION Lichen Simplex Chronicus / Circumscribed Neurodermatitis 1229-29-4 DOXEPIN MESH_LEVEL_1 Heterocyclic Compounds 1229-29-4 DOXEPIN MESH_LEVEL_3 Dibenzoxepins 1229-29-4 DOXEPIN ADVERSE_EFFECT LIV_3_Jaundice 1229-29-4 DOXEPIN ADVERSE_EFFECT NEU_2_Parkinson-Like Syndrome 1229-29-4 DOXEPIN ADVERSE_EFFECT NEU_1_Drowsiness 1668-19-5 DOXEPIN PRODUCT_CLASS Central Nervous System (CNS) 1668-19-5 DOXEPIN TISSUE_TOXICITY Heart Failure 1668-19-5 DOXEPIN MESH_LEVEL_3 Dibenzoxepins 1668-19-5 DOXEPIN MESH_LEVEL_1 Heterocyclic Compounds 1668-19-5 DOXEPIN INDICATION Lichen Simplex Chronicus / Circumscribed Neurodermatitis 1668-19-5 DOXEPIN ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_2_Prolonged PR Interval 1668-19-5 DOXEPIN STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, tricyclic 1668-19-5 DOXEPIN ADVERSE_EFFECT GUS_2_Urinary Retention 1668-19-5 DOXEPIN ADVERSE_EFFECT GIS_1_Dry Mouth 1668-19-5 DOXEPIN ADVERSE_EFFECT NEU_1_Dizziness 1668-19-5 DOXEPIN ADVERSE_EFFECT NEU_1_Drowsiness 1668-19-5 DOXEPIN ADVERSE_EFFECT NEU_2_Parkinson-Like Syndrome 1668-19-5 DOXEPIN ADVERSE_EFFECT LIV_3_Jaundice 1668-19-5 DOXEPIN ACTIVITY_CLASS Histamine antagonist 1668-19-5 DOXEPIN MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 1668-19-5 DOXEPIN INDICATION Atopic Dermatitis / Eczema 1668-19-5 DOXEPIN TA_LEVEL_2 CN stimulant 1668-19-5 DOXEPIN PRODUCT_CLASS Dermatologicals 1668-19-5 DOXEPIN MECH_LEVEL_3 histamine receptor H1 1668-19-5 DOXEPIN TA_LEVEL_3 Tricyclic antidpressant 1668-19-5 DOXEPIN TA_LEVEL_1 Central Nervous System (CNS) 1668-19-5 DOXEPIN ADVERSE_EFFECT PSY_3_Serotonin Syndrome 1668-19-5 DOXEPIN ADVERSE_EFFECT END_3_Gynecomastia 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_3_Myocardial Infarction 1668-19-5 DOXEPIN ADVERSE_EFFECT OCU_1_Blurred Vision 1668-19-5 DOXEPIN ZERO_CLASS N 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_3_Heart Failure 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_3_Prolonged QT Interval 1668-19-5 DOXEPIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 1668-19-5 DOXEPIN TISSUE_TOXICITY Ventricular Tachycardia 1668-19-5 DOXEPIN KNOWN_TOXICITY Cardiovascular Toxicity 1668-19-5 DOXEPIN THERAPEUTIC_CLASS Antipruritic Agents 1668-19-5 DOXEPIN MECH_LEVEL_2 Anti-histamine 1668-19-5 DOXEPIN INDICATION Depression 1668-19-5 DOXEPIN MECH_LEVEL_1 Modulate neural transmission 1668-19-5 DOXEPIN THERAPEUTIC_CLASS Antidepressants 1668-19-5 DOXEPIN ADVERSE_EFFECT REP_2_Ejaculatory Disorder 1668-19-5 DOXEPIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 1668-19-5 DOXEPIN ADVERSE_EFFECT NEU_2_Seizures 1668-19-5 DOXEPIN ADVERSE_EFFECT BBM_3_Agranulocytosis 1668-19-5 DOXEPIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_2_Hypertension 1668-19-5 DOXEPIN TISSUE_TOXICITY Myocardial Infarction 1668-19-5 DOXEPIN MODE_CLASS Receptor Ligand Antagonist 1668-19-5 DOXEPIN INDICATION Pruritus / Itching 1668-19-5 DOXEPIN MECHANISM Modulate G-protein coupled signal transduction 1668-19-5 DOXEPIN ADVERSE_EFFECT PSY_2_Mental Confusion 1668-19-5 DOXEPIN ADVERSE_EFFECT BBM_3_Leukopenia 1668-19-5 DOXEPIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 1668-19-5 DOXEPIN ADVERSE_EFFECT REP_2_Impotence 1668-19-5 DOXEPIN ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 1668-19-5 DOXEPIN ADVERSE_EFFECT OCU_3_Glaucoma 1668-19-5 DOXEPIN ADVERSE_EFFECT END_2_Galactorrhea 54573-75-0 DOXERCALCIFEROL THERAPEUTIC_CLASS Bone Mineral Homeostasis 54573-75-0 DOXERCALCIFEROL STRUCTURE_ACTIVITY Vitamin D receptor agonist 54573-75-0 DOXERCALCIFEROL MODE_CLASS Receptor Agonist 54573-75-0 DOXERCALCIFEROL PRODUCT_CLASS Hormones, Endocrine and Metabolic 54573-75-0 DOXERCALCIFEROL PRODUCT_CLASS Vitamins, Minerals and Nutrients 54573-75-0 DOXERCALCIFEROL INDICATION Secondary Hyperparathyroidism 54573-75-0 DOXERCALCIFEROL MECHANISM Modulate gene transcription 564-25-0 DOXYCYCLINE INDICATION Chancroid 564-25-0 DOXYCYCLINE INDICATION Lyme Disease / Lyme Borreliosis 564-25-0 DOXYCYCLINE INDICATION Plague 564-25-0 DOXYCYCLINE INDICATION Rocky Mountain Spotted Fever 564-25-0 DOXYCYCLINE INDICATION Upper Respiratory Tract Infection 564-25-0 DOXYCYCLINE INDICATION Urinary Tract Infection (UTI) 564-25-0 DOXYCYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 564-25-0 DOXYCYCLINE ADVERSE_EFFECT PSY_1_Anorexia 564-25-0 DOXYCYCLINE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 564-25-0 DOXYCYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 564-25-0 DOXYCYCLINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 564-25-0 DOXYCYCLINE TA_LEVEL_1 Infectious Disease 564-25-0 DOXYCYCLINE INDICATION Anthrax 564-25-0 DOXYCYCLINE INDICATION Cervicitis 564-25-0 DOXYCYCLINE TA_LEVEL_2 Antibacterials 564-25-0 DOXYCYCLINE INDICATION Lower Respiratory Tract Infection 564-25-0 DOXYCYCLINE INDICATION Relapsing Fever 564-25-0 DOXYCYCLINE INDICATION Tularemia 564-25-0 DOXYCYCLINE INDICATION Acne / Acne Vulgaris 564-25-0 DOXYCYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 564-25-0 DOXYCYCLINE PRODUCT_CLASS Anti-infectives 564-25-0 DOXYCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 564-25-0 DOXYCYCLINE THERAPEUTIC_CLASS Antibacterials 564-25-0 DOXYCYCLINE TISSUE_TOXICITY Teratogenicity 564-25-0 DOXYCYCLINE ADVERSE_EFFECT GIS_1_Diarrhea 564-25-0 DOXYCYCLINE MECH_LEVEL_1 Anti-bacterial 564-25-0 DOXYCYCLINE INDICATION Bacterial Conjunctivitis 564-25-0 DOXYCYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 564-25-0 DOXYCYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 564-25-0 DOXYCYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 564-25-0 DOXYCYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 564-25-0 DOXYCYCLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 564-25-0 DOXYCYCLINE INDICATION Skin and Skin Structure Infections 564-25-0 DOXYCYCLINE INDICATION Pneumonia 564-25-0 DOXYCYCLINE INDICATION Pharyngitis 564-25-0 DOXYCYCLINE INDICATION Cholera 564-25-0 DOXYCYCLINE INDICATION Chronic Bronchitis 564-25-0 DOXYCYCLINE MECHANISM Inhibit ribosomal protein synthesis 564-25-0 DOXYCYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 564-25-0 DOXYCYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 564-25-0 DOXYCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 564-25-0 DOXYCYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 564-25-0 DOXYCYCLINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 564-25-0 DOXYCYCLINE ADVERSE_EFFECT NEU_2_Paresthesia 564-25-0 DOXYCYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 564-25-0 DOXYCYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 564-25-0 DOXYCYCLINE INDICATION Syphilis 564-25-0 DOXYCYCLINE INDICATION Q Fever 564-25-0 DOXYCYCLINE INDICATION Pelvic Inflammatory Disease (PID) 564-25-0 DOXYCYCLINE INDICATION Gonococcal Infections / Gonorrhea 564-25-0 DOXYCYCLINE INDICATION Brucellosis 564-25-0 DOXYCYCLINE MESH_LEVEL_3 Tetracyclines 564-25-0 DOXYCYCLINE ZERO_CLASS N 564-25-0 DOXYCYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 564-25-0 DOXYCYCLINE ADVERSE_EFFECT CVS_2_Phlebitis 564-25-0 DOXYCYCLINE ADVERSE_EFFECT LIV_3_Hepatitis 564-25-0 DOXYCYCLINE INDICATION Otitis Media 24390-14-5 DOXYCYCLINE INDICATION Pelvic Inflammatory Disease (PID) 24390-14-5 DOXYCYCLINE INDICATION Q Fever 24390-14-5 DOXYCYCLINE INDICATION Syphilis 24390-14-5 DOXYCYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT NEU_2_Paresthesia 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 24390-14-5 DOXYCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 24390-14-5 DOXYCYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 24390-14-5 DOXYCYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 24390-14-5 DOXYCYCLINE MECHANISM Inhibit ribosomal protein synthesis 24390-14-5 DOXYCYCLINE INDICATION Chronic Bronchitis 24390-14-5 DOXYCYCLINE INDICATION Cholera 24390-14-5 DOXYCYCLINE INDICATION Otitis Media 24390-14-5 DOXYCYCLINE INDICATION Pneumonia 24390-14-5 DOXYCYCLINE INDICATION Skin and Skin Structure Infections 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 24390-14-5 DOXYCYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 24390-14-5 DOXYCYCLINE INDICATION Tularemia 24390-14-5 DOXYCYCLINE TA_LEVEL_2 Antibacterials 24390-14-5 DOXYCYCLINE MECH_LEVEL_1 Anti-bacterial 24390-14-5 DOXYCYCLINE INDICATION Bacterial Conjunctivitis 24390-14-5 DOXYCYCLINE INDICATION Chancroid 24390-14-5 DOXYCYCLINE INDICATION Lyme Disease / Lyme Borreliosis 24390-14-5 DOXYCYCLINE INDICATION Plague 24390-14-5 DOXYCYCLINE INDICATION Rocky Mountain Spotted Fever 24390-14-5 DOXYCYCLINE INDICATION Upper Respiratory Tract Infection 24390-14-5 DOXYCYCLINE INDICATION Urinary Tract Infection (UTI) 24390-14-5 DOXYCYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT PSY_1_Anorexia 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 24390-14-5 DOXYCYCLINE TA_LEVEL_1 Infectious Disease 24390-14-5 DOXYCYCLINE INDICATION Anthrax 24390-14-5 DOXYCYCLINE INDICATION Cervicitis 24390-14-5 DOXYCYCLINE INDICATION Lower Respiratory Tract Infection 24390-14-5 DOXYCYCLINE INDICATION Pharyngitis 24390-14-5 DOXYCYCLINE INDICATION Relapsing Fever 24390-14-5 DOXYCYCLINE INDICATION Acne / Acne Vulgaris 24390-14-5 DOXYCYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 24390-14-5 DOXYCYCLINE PRODUCT_CLASS Anti-infectives 24390-14-5 DOXYCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 24390-14-5 DOXYCYCLINE THERAPEUTIC_CLASS Antibacterials 24390-14-5 DOXYCYCLINE TISSUE_TOXICITY Teratogenicity 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT GIS_1_Diarrhea 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT LIV_3_Hepatitis 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT CVS_2_Phlebitis 24390-14-5 DOXYCYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 24390-14-5 DOXYCYCLINE ZERO_CLASS N 24390-14-5 DOXYCYCLINE MESH_LEVEL_3 Tetracyclines 24390-14-5 DOXYCYCLINE INDICATION Brucellosis 24390-14-5 DOXYCYCLINE INDICATION Gonococcal Infections / Gonorrhea 10592-13-9 DOXYCYCLINE INDICATION Lower Respiratory Tract Infection 10592-13-9 DOXYCYCLINE INDICATION Lyme Disease / Lyme Borreliosis 10592-13-9 DOXYCYCLINE INDICATION Chancroid 10592-13-9 DOXYCYCLINE INDICATION Bacterial Conjunctivitis 10592-13-9 DOXYCYCLINE MECH_LEVEL_1 Anti-bacterial 10592-13-9 DOXYCYCLINE TA_LEVEL_2 Antibacterials 10592-13-9 DOXYCYCLINE INDICATION Skin and Skin Structure Infections 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT XXX_2_Tooth Discoloration 10592-13-9 DOXYCYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 10592-13-9 DOXYCYCLINE INDICATION Cholera 10592-13-9 DOXYCYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 10592-13-9 DOXYCYCLINE INDICATION Pharyngitis 10592-13-9 DOXYCYCLINE MECHANISM Inhibit ribosomal protein synthesis 10592-13-9 DOXYCYCLINE INDICATION Otitis Media 10592-13-9 DOXYCYCLINE INDICATION Pneumonia 10592-13-9 DOXYCYCLINE INDICATION Chronic Bronchitis 10592-13-9 DOXYCYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 10592-13-9 DOXYCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT NEU_2_Paresthesia 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT EMB_3_Teratogenicity 10592-13-9 DOXYCYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 10592-13-9 DOXYCYCLINE INDICATION Syphilis 10592-13-9 DOXYCYCLINE INDICATION Q Fever 10592-13-9 DOXYCYCLINE INDICATION Pelvic Inflammatory Disease (PID) 10592-13-9 DOXYCYCLINE INDICATION Gonococcal Infections / Gonorrhea 10592-13-9 DOXYCYCLINE INDICATION Brucellosis 10592-13-9 DOXYCYCLINE MESH_LEVEL_3 Tetracyclines 10592-13-9 DOXYCYCLINE ZERO_CLASS N 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT IMU_3_Eosinophilia 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT CVS_2_Phlebitis 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT LIV_3_Hepatitis 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT GIS_1_Diarrhea 10592-13-9 DOXYCYCLINE TISSUE_TOXICITY Teratogenicity 10592-13-9 DOXYCYCLINE THERAPEUTIC_CLASS Antibacterials 10592-13-9 DOXYCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 10592-13-9 DOXYCYCLINE PRODUCT_CLASS Anti-infectives 10592-13-9 DOXYCYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 10592-13-9 DOXYCYCLINE INDICATION Acne / Acne Vulgaris 10592-13-9 DOXYCYCLINE INDICATION Tularemia 10592-13-9 DOXYCYCLINE INDICATION Relapsing Fever 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT KID_3_Fanconi Syndrome 10592-13-9 DOXYCYCLINE INDICATION Cervicitis 10592-13-9 DOXYCYCLINE INDICATION Anthrax 10592-13-9 DOXYCYCLINE TA_LEVEL_1 Infectious Disease 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT NEU_3_Pseudotumor Cerebri 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT IMU_2_Photosensitivity 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 10592-13-9 DOXYCYCLINE ADVERSE_EFFECT PSY_1_Anorexia 10592-13-9 DOXYCYCLINE KNOWN_TOXICITY Embryo/Fetal Toxicity 10592-13-9 DOXYCYCLINE INDICATION Urinary Tract Infection (UTI) 10592-13-9 DOXYCYCLINE INDICATION Upper Respiratory Tract Infection 10592-13-9 DOXYCYCLINE INDICATION Rocky Mountain Spotted Fever 10592-13-9 DOXYCYCLINE INDICATION Plague 548-73-2 DROPERIDOL ADVERSE_EFFECT PSY_2_Mental Depression 548-73-2 DROPERIDOL THERAPEUTIC_CLASS Sedatives/Hypnotics 548-73-2 DROPERIDOL MECH_LEVEL_1 Modulate neural transmission 548-73-2 DROPERIDOL TISSUE_TOXICITY Torsade de Pointes Arrhythmia 548-73-2 DROPERIDOL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 548-73-2 DROPERIDOL ADVERSE_EFFECT PSY_2_Delirium 548-73-2 DROPERIDOL ADVERSE_EFFECT CVS_1_Sinus Tachycardia 548-73-2 DROPERIDOL ADVERSE_EFFECT NEU_1_Drowsiness 548-73-2 DROPERIDOL ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 548-73-2 DROPERIDOL ADVERSE_EFFECT XXX_2_Chills 548-73-2 DROPERIDOL ACTIVITY_CLASS Dopamine antagonist 548-73-2 DROPERIDOL MECH_LEVEL_2 NMDA Modulators 548-73-2 DROPERIDOL MESH_LEVEL_3 Benzimidazoles 548-73-2 DROPERIDOL ADVERSE_EFFECT PSY_2_Nightmares 548-73-2 DROPERIDOL ADVERSE_EFFECT NEU_2_Extrapyramidal Symptoms 548-73-2 DROPERIDOL ADVERSE_EFFECT NEU_2_Akathisia 548-73-2 DROPERIDOL ADVERSE_EFFECT NEU_2_Dizziness 548-73-2 DROPERIDOL ADVERSE_EFFECT CVS_1_Hypotension 548-73-2 DROPERIDOL MODE_CLASS Receptor Ligand Antagonist 548-73-2 DROPERIDOL MECHANISM Modulate neural transmission 548-73-2 DROPERIDOL MESH_LEVEL_1 Heterocyclic Compounds 548-73-2 DROPERIDOL TA_LEVEL_3 Anxlytic 548-73-2 DROPERIDOL MECH_LEVEL_3 NMDA Glutamate receptor 548-73-2 DROPERIDOL ZERO_CLASS N 548-73-2 DROPERIDOL INDICATION Induction / Maintenance of Anesthesia 548-73-2 DROPERIDOL TA_LEVEL_1 Central Nervous System (CNS) 548-73-2 DROPERIDOL PRODUCT_CLASS Central Nervous System (CNS) 548-73-2 DROPERIDOL ADVERSE_EFFECT CVS_3_Hypertension 548-73-2 DROPERIDOL ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 548-73-2 DROPERIDOL ADVERSE_EFFECT OCU_2_Oculogyric Crisis 548-73-2 DROPERIDOL MODE_CLASS Receptor Agonist 548-73-2 DROPERIDOL INDICATION Sedation 548-73-2 DROPERIDOL TA_LEVEL_2 CNS Depressant 548-73-2 DROPERIDOL MECHANISM Block neural transmission 548-73-2 DROPERIDOL INDICATION Nausea / Vomiting 548-73-2 DROPERIDOL KNOWN_TOXICITY Cardiovascular Toxicity 548-73-2 DROPERIDOL ADVERSE_EFFECT PSY_3_Hallucinations 548-73-2 DROPERIDOL ADVERSE_EFFECT NEU_2_Tremor 548-73-2 DROPERIDOL ADVERSE_EFFECT LUN_3_Bronchospasm 548-73-2 DROPERIDOL ADVERSE_EFFECT PSY_2_Dysphoria 548-73-2 DROPERIDOL ADVERSE_EFFECT LUN_3_Laryngospasm 548-73-2 DROPERIDOL STRUCTURE_ACTIVITY Dopamine receptor (D2) antagonist 548-73-2 DROPERIDOL TISSUE_TOXICITY Hypotension 548-73-2 DROPERIDOL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 536-43-6 DYCLONINE HYDROCHLORIDE INDICATION Local Anesthesia 536-43-6 DYCLONINE HYDROCHLORIDE MECHANISM Block neural transmission 536-43-6 DYCLONINE HYDROCHLORIDE MODE_CLASS Channel Blocker 536-43-6 DYCLONINE HYDROCHLORIDE PRODUCT_CLASS Analgesics 536-43-6 DYCLONINE HYDROCHLORIDE THERAPEUTIC_CLASS Analgesics, Topical 479-18-5 DYPHYLLINE PRODUCT_CLASS Respiratory System 479-18-5 DYPHYLLINE TISSUE_TOXICITY Extrasystoles 479-18-5 DYPHYLLINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 479-18-5 DYPHYLLINE ADVERSE_EFFECT CVS_3_Extrasystoles 479-18-5 DYPHYLLINE ADVERSE_EFFECT PSY_3_Agitation 479-18-5 DYPHYLLINE ADVERSE_EFFECT GIS_2_Epigastric Pain 479-18-5 DYPHYLLINE ADVERSE_EFFECT KID_3_Albuminuria 479-18-5 DYPHYLLINE ACTIVITY_CLASS Phosphodiesterase inhibitor 479-18-5 DYPHYLLINE MESH_LEVEL_1 Heterocyclic Compounds 479-18-5 DYPHYLLINE MESH_LEVEL_3 Purines 479-18-5 DYPHYLLINE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 479-18-5 DYPHYLLINE MECHANISM Enhance kinase mediated signal transduction 479-18-5 DYPHYLLINE INDICATION Prophylaxis of Bronchospasm 479-18-5 DYPHYLLINE TISSUE_TOXICITY Hypotension 479-18-5 DYPHYLLINE ADVERSE_EFFECT PSY_2_Insomnia 479-18-5 DYPHYLLINE ADVERSE_EFFECT NEU_2_Headache 479-18-5 DYPHYLLINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 479-18-5 DYPHYLLINE ADVERSE_EFFECT KID_3_Hematuria 479-18-5 DYPHYLLINE ADVERSE_EFFECT LUN_3_Tachypnea 479-18-5 DYPHYLLINE TA_LEVEL_2 Anti-asthma 479-18-5 DYPHYLLINE TA_LEVEL_1 Respiratory System 479-18-5 DYPHYLLINE INDICATION Asthma 479-18-5 DYPHYLLINE MODE_CLASS Receptor Agonist 479-18-5 DYPHYLLINE THERAPEUTIC_CLASS Bronchodilators 479-18-5 DYPHYLLINE TISSUE_TOXICITY Ventricular Arrhythmia 479-18-5 DYPHYLLINE KNOWN_TOXICITY Cardiovascular Toxicity 479-18-5 DYPHYLLINE ADVERSE_EFFECT CVS_3_Hypotension 479-18-5 DYPHYLLINE ADVERSE_EFFECT SKN_2_Flushing 479-18-5 DYPHYLLINE ADVERSE_EFFECT NEU_3_Seizures 479-18-5 DYPHYLLINE ADVERSE_EFFECT PSY_2_Irritability 479-18-5 DYPHYLLINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 479-18-5 DYPHYLLINE STRUCTURE_ACTIVITY PDE inhibitor, non-specific, xanthine 479-18-5 DYPHYLLINE MECH_LEVEL_1 Muscle relaxant 479-18-5 DYPHYLLINE TA_LEVEL_3 Bronchodilators 479-18-5 DYPHYLLINE MODE_CLASS Enzyme Inhibitor 479-18-5 DYPHYLLINE TISSUE_TOXICITY Hematuria 479-18-5 DYPHYLLINE TISSUE_TOXICITY Cardiovascular Collapse 479-18-5 DYPHYLLINE KNOWN_TOXICITY Nephrotoxicity 479-18-5 DYPHYLLINE ADVERSE_EFFECT CVS_2_Tachycardia 479-18-5 DYPHYLLINE ADVERSE_EFFECT END_2_Hyperglycemia 479-18-5 DYPHYLLINE ADVERSE_EFFECT IMU_3_Allergic Reactions 479-18-5 DYPHYLLINE ADVERSE_EFFECT CVS_3_Ventricular Arrhythmia 479-18-5 DYPHYLLINE ADVERSE_EFFECT GIS_3_Hematemesis 479-18-5 DYPHYLLINE ZERO_CLASS N 479-18-5 DYPHYLLINE MECHANISM Reduce bronchoconstriction 479-18-5 DYPHYLLINE MECH_LEVEL_3 3',5'-cyclic-nucleotide phosphodiesterase 128326-82-9 EBERCONAZOLE THERAPEUTIC_CLASS Antifungals 128326-82-9 EBERCONAZOLE MODE_CLASS Enzyme Inhibitor 128326-82-9 EBERCONAZOLE PRODUCT_CLASS Anti-infectives 128326-82-9 EBERCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 100981-43-9 EBROTIDINE INDICATION Duodenal Ulcer 100981-43-9 EBROTIDINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 100981-43-9 EBROTIDINE ADVERSE_EFFECT SKN_3_Dermatitis 100981-43-9 EBROTIDINE INDICATION Duodenal Ulcer 100981-43-9 EBROTIDINE KNOWN_TOXICITY Hepatotoxicity 100981-43-9 EBROTIDINE TISSUE_TOXICITY Liver Cirrhosis 100981-43-9 EBROTIDINE ADVERSE_EFFECT LIV_3_Liver Cirrhosis 100981-43-9 EBROTIDINE THERAPEUTIC_CLASS Antiulcers 100981-43-9 EBROTIDINE INDICATION Peptic Ulcer Disease (PUD) 100981-43-9 EBROTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 100981-43-9 EBROTIDINE MECHANISM Reduce stomach HCl secretion 100981-43-9 EBROTIDINE PRODUCT_CLASS Gastrointestinal System 100981-43-9 EBROTIDINE STRUCTURE_ACTIVITY Histamine receptor (H2) antagonist 100981-43-9 EBROTIDINE INDICATION Peptic Ulcer Disease (PUD) 100981-43-9 EBROTIDINE ADVERSE_EFFECT LIV_2_Hepatic Injury 100981-43-9 EBROTIDINE TISSUE_TOXICITY Hepatotoxicity 100981-43-9 EBROTIDINE INDICATION Gastric Ulcer 100981-43-9 EBROTIDINE INDICATION Gastric Ulcer 100981-43-9 EBROTIDINE ADVERSE_EFFECT LIV_3_Hepatitis 60940-34-3 EBSELEN INDICATION Re-Stenosis 513-10-0 ECHOTHIOPHATE IODIDE MECHANISM Enhance cholinergic transmission 513-10-0 ECHOTHIOPHATE IODIDE INDICATION Glaucoma 513-10-0 ECHOTHIOPHATE IODIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 513-10-0 ECHOTHIOPHATE IODIDE MODE_CLASS Enzyme Inhibitor 513-10-0 ECHOTHIOPHATE IODIDE THERAPEUTIC_CLASS Antiglaucoma Agents 62-33-9 EDETATE CALCIUM DISODIUM SALT MECHANISM chelate excess metal 5297-15-4 EDETATE CALCIUM DISODIUM SALT MECHANISM chelate excess metal 12002-29-8 EDETATE CALCIUM DISODIUM SALT MECHANISM chelate excess metal 19067-42-6 EDETATE CALCIUM DISODIUM SALT MECHANISM chelate excess metal 39208-14-5 EDETATE CALCIUM DISODIUM SALT MECHANISM chelate excess metal 74011-06-6 EDETATE CALCIUM DISODIUM SALT MECHANISM chelate excess metal 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 116-38-1 EDROPHONIUM CHLORIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT MSK_3_Myasthenia 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT GUS_3_Urinary Frequency 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT OCU_3_Conjunctival Hyperemia 116-38-1 EDROPHONIUM CHLORIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 116-38-1 EDROPHONIUM CHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 116-38-1 EDROPHONIUM CHLORIDE MECHANISM Enhance cholinergic transmission 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Hypotension 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT LUN_1_Bronchospasm 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Seizures 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Urinary Incontinence 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT MSK_3_Muscle Cramps 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT LUN_1_Increased Bronchial Secretion 116-38-1 EDROPHONIUM CHLORIDE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 116-38-1 EDROPHONIUM CHLORIDE INDICATION Myasthenic Crisis Diagnosis 116-38-1 EDROPHONIUM CHLORIDE TISSUE_TOXICITY Cardiac Arrest 116-38-1 EDROPHONIUM CHLORIDE TISSUE_TOXICITY Hypotension 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT XXX_3_Lacrimation 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Cardiac Arrest 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Paralysis 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT LUN_3_Dysphonia 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Dysarthria 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT GIS_1_Hypersalivation 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT OCU_3_Diplopia 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Incontinence 116-38-1 EDROPHONIUM CHLORIDE INDICATION Reversal of Neuromuscular Blockade 116-38-1 EDROPHONIUM CHLORIDE INDICATION Myasthenia Gravis 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT GIS_1_Diarrhea 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT GIS_1_Dysphagia 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT XXX_1_Diaphoresis 116-38-1 EDROPHONIUM CHLORIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 116-38-1 EDROPHONIUM CHLORIDE INDICATION Myasthenia Gravis Diagnosis 116-38-1 EDROPHONIUM CHLORIDE INDICATION Paroxysmal Supraventricular Tachycardia 116-38-1 EDROPHONIUM CHLORIDE MODE_CLASS Enzyme Inhibitor 116-38-1 EDROPHONIUM CHLORIDE INDICATION Curare Poisoning 116-38-1 EDROPHONIUM CHLORIDE ADVERSE_EFFECT OCU_3_Miosis 89197-32-0 EFAROXAN PRODUCT_CLASS Central Nervous System (CNS) 89197-32-0 EFAROXAN THERAPEUTIC_CLASS Sympatholytic Agents 89197-32-0 EFAROXAN MECHANISM Modulate G-protein coupled signal transduction 89197-32-0 EFAROXAN PRODUCT_CLASS Autonomic Nervous System (ANS) 89197-00-2 EFAROXAN PRODUCT_CLASS Central Nervous System (CNS) 89197-00-2 EFAROXAN THERAPEUTIC_CLASS Sympatholytic Agents 89197-00-2 EFAROXAN MECHANISM Modulate G-protein coupled signal transduction 89197-00-2 EFAROXAN PRODUCT_CLASS Autonomic Nervous System (ANS) 154598-52-4 EFAVIRENZ INDICATION Human Immunodeficiency Virus (HIV) Disease 154598-52-4 EFAVIRENZ MODE_CLASS Enzyme Inhibitor 154598-52-4 EFAVIRENZ MECHANISM Inhibit viral DNA synthesis 154598-52-4 EFAVIRENZ THERAPEUTIC_CLASS Antivirals, Systemic 154598-52-4 EFAVIRENZ PRODUCT_CLASS Anti-infectives 87233-61-2 EMEDASTINE PRODUCT_CLASS Anti-inflammatories 87233-61-2 EMEDASTINE THERAPEUTIC_CLASS Antihistamines 87233-61-2 EMEDASTINE INDICATION Urticaria / Hives 87233-61-2 EMEDASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 87233-61-2 EMEDASTINE INDICATION Allergic Rhinitis 87233-61-2 EMEDASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 87233-61-2 EMEDASTINE INDICATION Pruritus / Itching 87233-61-2 EMEDASTINE INDICATION Allergic Conjunctivitis 87233-61-2 EMEDASTINE INDICATION Atopic Dermatitis / Eczema 87233-61-2 EMEDASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 87233-61-2 EMEDASTINE MECHANISM Modulate G-protein coupled signal transduction 483-18-1 EMETINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 483-18-1 EMETINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 483-18-1 EMETINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 483-18-1 EMETINE ADVERSE_EFFECT MSK_3_Myopathy 483-18-1 EMETINE STRUCTURE_ACTIVITY Toxicant, voltage-gated Na+ channel opener 483-18-1 EMETINE INDICATION Amebiasis 483-18-1 EMETINE TISSUE_TOXICITY Atrial Fibrillation 483-18-1 EMETINE ADVERSE_EFFECT CVS_2_Hypotension 483-18-1 EMETINE ADVERSE_EFFECT NEU_2_Dizziness 483-18-1 EMETINE ADVERSE_EFFECT CVS_3_Myocarditis 483-18-1 EMETINE PRODUCT_CLASS Anti-infectives 483-18-1 EMETINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 483-18-1 EMETINE TISSUE_TOXICITY Hypotension 483-18-1 EMETINE ADVERSE_EFFECT CVS_1_Tachycardia 483-18-1 EMETINE ADVERSE_EFFECT NEU_2_Headache 483-18-1 EMETINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 483-18-1 EMETINE TISSUE_TOXICITY Cardiotoxicity 483-18-1 EMETINE TISSUE_TOXICITY Myocarditis 483-18-1 EMETINE ADVERSE_EFFECT GIS_1_Nausea 483-18-1 EMETINE ADVERSE_EFFECT MSK_3_Muscle Weakness 483-18-1 EMETINE THERAPEUTIC_CLASS Antiparasitics 483-18-1 EMETINE ACTIVITY_CLASS Toxicant 483-18-1 EMETINE MECHANISM Inhibit ribosomal protein synthesis 483-18-1 EMETINE INDICATION Systemic Amebiasis 483-18-1 EMETINE KNOWN_TOXICITY Cardiovascular Toxicity 483-18-1 EMETINE TISSUE_TOXICITY Cardiac Arrhythmia 602-59-5 EMETINE INDICATION Systemic Amebiasis 602-59-5 EMETINE ADVERSE_EFFECT CVS_3_Myocarditis 602-59-5 EMETINE PRODUCT_CLASS Anti-infectives 602-59-5 EMETINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 602-59-5 EMETINE TISSUE_TOXICITY Hypotension 602-59-5 EMETINE ADVERSE_EFFECT CVS_1_Tachycardia 602-59-5 EMETINE ADVERSE_EFFECT NEU_2_Dizziness 602-59-5 EMETINE ADVERSE_EFFECT NEU_2_Headache 602-59-5 EMETINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 602-59-5 EMETINE TISSUE_TOXICITY Cardiotoxicity 602-59-5 EMETINE TISSUE_TOXICITY Myocarditis 602-59-5 EMETINE ADVERSE_EFFECT GIS_1_Nausea 602-59-5 EMETINE ADVERSE_EFFECT MSK_3_Muscle Weakness 602-59-5 EMETINE ACTIVITY_CLASS Toxicant 602-59-5 EMETINE THERAPEUTIC_CLASS Antiparasitics 602-59-5 EMETINE MECHANISM Inhibit ribosomal protein synthesis 602-59-5 EMETINE KNOWN_TOXICITY Cardiovascular Toxicity 602-59-5 EMETINE TISSUE_TOXICITY Cardiac Arrhythmia 602-59-5 EMETINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 602-59-5 EMETINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 602-59-5 EMETINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 602-59-5 EMETINE ADVERSE_EFFECT MSK_3_Myopathy 602-59-5 EMETINE STRUCTURE_ACTIVITY Toxicant, voltage-gated Na+ channel opener 602-59-5 EMETINE INDICATION Amebiasis 602-59-5 EMETINE TISSUE_TOXICITY Atrial Fibrillation 602-59-5 EMETINE ADVERSE_EFFECT CVS_2_Hypotension 24377-67-1 EMETINE ADVERSE_EFFECT NEU_2_Dizziness 24377-67-1 EMETINE ADVERSE_EFFECT CVS_3_Myocarditis 24377-67-1 EMETINE PRODUCT_CLASS Anti-infectives 24377-67-1 EMETINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 24377-67-1 EMETINE TISSUE_TOXICITY Hypotension 24377-67-1 EMETINE ADVERSE_EFFECT CVS_1_Tachycardia 24377-67-1 EMETINE ADVERSE_EFFECT CVS_3_Cardiotoxicity 24377-67-1 EMETINE TISSUE_TOXICITY Cardiotoxicity 24377-67-1 EMETINE TISSUE_TOXICITY Myocarditis 24377-67-1 EMETINE ADVERSE_EFFECT GIS_1_Nausea 24377-67-1 EMETINE ADVERSE_EFFECT MSK_3_Muscle Weakness 24377-67-1 EMETINE ACTIVITY_CLASS Toxicant 24377-67-1 EMETINE THERAPEUTIC_CLASS Antiparasitics 24377-67-1 EMETINE ADVERSE_EFFECT CVS_3_Atrial Fibrillation 24377-67-1 EMETINE ADVERSE_EFFECT XXX_1_Injection Site Reaction 24377-67-1 EMETINE MECHANISM Inhibit ribosomal protein synthesis 24377-67-1 EMETINE INDICATION Systemic Amebiasis 24377-67-1 EMETINE KNOWN_TOXICITY Cardiovascular Toxicity 24377-67-1 EMETINE TISSUE_TOXICITY Cardiac Arrhythmia 24377-67-1 EMETINE ADVERSE_EFFECT NEU_2_Headache 24377-67-1 EMETINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 24377-67-1 EMETINE ADVERSE_EFFECT MSK_3_Myopathy 24377-67-1 EMETINE STRUCTURE_ACTIVITY Toxicant, voltage-gated Na+ channel opener 24377-67-1 EMETINE INDICATION Amebiasis 24377-67-1 EMETINE TISSUE_TOXICITY Atrial Fibrillation 24377-67-1 EMETINE ADVERSE_EFFECT CVS_2_Hypotension 75847-73-3 ENALAPRIL TA_LEVEL_3 Diuretic 75847-73-3 ENALAPRIL TA_LEVEL_1 Cardiovascular 75847-73-3 ENALAPRIL ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 75847-73-3 ENALAPRIL MECHANISM Reduce vasoconstriction 75847-73-3 ENALAPRIL ADVERSE_EFFECT NEU_2_Headache 75847-73-3 ENALAPRIL ADVERSE_EFFECT LUN_1_Dyspnea 75847-73-3 ENALAPRIL ADVERSE_EFFECT CVS_2_Chest Pain 75847-73-3 ENALAPRIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 75847-73-3 ENALAPRIL MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 75847-73-3 ENALAPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 75847-73-3 ENALAPRIL INDICATION Congestive Heart Failure (CHF) 75847-73-3 ENALAPRIL PRODUCT_CLASS Cardiovasculars 75847-73-3 ENALAPRIL TISSUE_TOXICITY Myocardial Infarction 75847-73-3 ENALAPRIL MODE_CLASS Enzyme Inhibitor 75847-73-3 ENALAPRIL THERAPEUTIC_CLASS Antihypertensive Agents 75847-73-3 ENALAPRIL THERAPEUTIC_CLASS Congestive Heart Failure 75847-73-3 ENALAPRIL KNOWN_TOXICITY Cardiovascular Toxicity 75847-73-3 ENALAPRIL TISSUE_TOXICITY Renal Failure 75847-73-3 ENALAPRIL ADVERSE_EFFECT LUN_1_Cough 75847-73-3 ENALAPRIL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 75847-73-3 ENALAPRIL ACTIVITY_CLASS RAAS inhibitor 75847-73-3 ENALAPRIL ADVERSE_EFFECT GIS_2_Abdominal Pain 75847-73-3 ENALAPRIL ADVERSE_EFFECT GUS_3_Urinary Tract Infection 75847-73-3 ENALAPRIL KNOWN_TOXICITY Nephrotoxicity 75847-73-3 ENALAPRIL MECH_LEVEL_2 ACE inhibitor 75847-73-3 ENALAPRIL TA_LEVEL_2 Hypertension 75847-73-3 ENALAPRIL MECH_LEVEL_1 Vasorelaxation 75847-73-3 ENALAPRIL ADVERSE_EFFECT XXX_1_Fatigue 75847-73-3 ENALAPRIL ADVERSE_EFFECT SKN_1_Rash 75847-73-3 ENALAPRIL ADVERSE_EFFECT KID_3_Renal Failure 75847-73-3 ENALAPRIL ADVERSE_EFFECT NEU_2_Syncope 75847-73-3 ENALAPRIL ADVERSE_EFFECT GIS_2_Nausea 75847-73-3 ENALAPRIL MESH_LEVEL_3 Oligopeptides 75847-73-3 ENALAPRIL MESH_LEVEL_2 Peptides 75847-73-3 ENALAPRIL ADVERSE_EFFECT GIS_1_Vomiting 75847-73-3 ENALAPRIL ADVERSE_EFFECT NEU_2_Dizziness 75847-73-3 ENALAPRIL ADVERSE_EFFECT NEU_1_Vertigo 75847-73-3 ENALAPRIL ADVERSE_EFFECT XXX_2_Asthenia 75847-73-3 ENALAPRIL ADVERSE_EFFECT GIS_2_Diarrhea 75847-73-3 ENALAPRIL ADVERSE_EFFECT CVS_3_Myocardial Infarction 75847-73-3 ENALAPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 75847-73-3 ENALAPRIL INDICATION Hypertension 75847-73-3 ENALAPRIL ADVERSE_EFFECT BBM_3_Bone Marrow Depression 76420-72-9 ENALAPRILAT INDICATION Hypertension 76420-72-9 ENALAPRILAT MECHANISM Reduce vasoconstriction 76420-72-9 ENALAPRILAT THERAPEUTIC_CLASS Antihypertensive Agents 76420-72-9 ENALAPRILAT MODE_CLASS Enzyme Inhibitor 76420-72-9 ENALAPRILAT PRODUCT_CLASS Cardiovasculars 37612-13-8 ENCAINIDE ADVERSE_EFFECT OCU_2_Visual Disturbances 37612-13-8 ENCAINIDE INDICATION Ventricular Arrhythmias 37612-13-8 ENCAINIDE PRODUCT_CLASS Cardiovasculars 37612-13-8 ENCAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 37612-13-8 ENCAINIDE TISSUE_TOXICITY Death 37612-13-8 ENCAINIDE TISSUE_TOXICITY Ventricular Fibrillation 37612-13-8 ENCAINIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 37612-13-8 ENCAINIDE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 37612-13-8 ENCAINIDE ADVERSE_EFFECT NEU_3_Ataxia 37612-13-8 ENCAINIDE ADVERSE_EFFECT NEU_1_Somnolence 37612-13-8 ENCAINIDE ADVERSE_EFFECT CVS_3_Cardiac Insufficiency 37612-13-8 ENCAINIDE MECHANISM Block neural transmission 37612-13-8 ENCAINIDE TISSUE_TOXICITY Arrhythmia 37612-13-8 ENCAINIDE KNOWN_TOXICITY Miscellaneous 37612-13-8 ENCAINIDE INDICATION Ventricular Tachycardia 37612-13-8 ENCAINIDE ADVERSE_EFFECT NEU_1_Dizziness 37612-13-8 ENCAINIDE ADVERSE_EFFECT XXX_3_Death 37612-13-8 ENCAINIDE ADVERSE_EFFECT CVS_3_Heart Failure 37612-13-8 ENCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 37612-13-8 ENCAINIDE INDICATION Ventricular Premature Beats (Ventricular Extrasystoles) 37612-13-8 ENCAINIDE TISSUE_TOXICITY Cardiac Conduction System Malfunction 37612-13-8 ENCAINIDE ADVERSE_EFFECT PSY_1_Insomnia 37612-13-8 ENCAINIDE ADVERSE_EFFECT NEU_1_Headache 37612-13-8 ENCAINIDE ADVERSE_EFFECT END_3_Hyperglycemia 37612-13-8 ENCAINIDE ADVERSE_EFFECT CVS_2_Arrhythmia 37612-13-8 ENCAINIDE ADVERSE_EFFECT OCU_3_Diplopia 37612-13-8 ENCAINIDE ADVERSE_EFFECT OTO_2_Tinnitus 37612-13-8 ENCAINIDE ADVERSE_EFFECT PSY_1_Nervousness 37612-13-8 ENCAINIDE TISSUE_TOXICITY Heart Failure 37612-13-8 ENCAINIDE TISSUE_TOXICITY Cardiac Insufficiency 37612-13-8 ENCAINIDE MODE_CLASS Channel Blocker 37612-13-8 ENCAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 37612-13-8 ENCAINIDE ADVERSE_EFFECT OCU_3_Abnormal Vision 37612-13-8 ENCAINIDE ADVERSE_EFFECT NEU_1_Tremor 37612-13-8 ENCAINIDE ADVERSE_EFFECT LUN_2_Dyspnea 37612-13-8 ENCAINIDE ADVERSE_EFFECT CVS_3_Cardiac Conduction System Malfunction 66794-74-9 ENCAINIDE ADVERSE_EFFECT PSY_1_Insomnia 66794-74-9 ENCAINIDE TISSUE_TOXICITY Cardiac Conduction System Malfunction 66794-74-9 ENCAINIDE TISSUE_TOXICITY Arrhythmia 66794-74-9 ENCAINIDE ADVERSE_EFFECT CVS_2_Arrhythmia 66794-74-9 ENCAINIDE ADVERSE_EFFECT OCU_3_Diplopia 66794-74-9 ENCAINIDE ADVERSE_EFFECT OTO_2_Tinnitus 66794-74-9 ENCAINIDE ADVERSE_EFFECT END_3_Hyperglycemia 66794-74-9 ENCAINIDE ADVERSE_EFFECT PSY_1_Nervousness 66794-74-9 ENCAINIDE TISSUE_TOXICITY Heart Failure 66794-74-9 ENCAINIDE TISSUE_TOXICITY Cardiac Insufficiency 66794-74-9 ENCAINIDE MODE_CLASS Channel Blocker 66794-74-9 ENCAINIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 66794-74-9 ENCAINIDE ADVERSE_EFFECT OCU_3_Abnormal Vision 66794-74-9 ENCAINIDE ADVERSE_EFFECT NEU_1_Dizziness 66794-74-9 ENCAINIDE ADVERSE_EFFECT NEU_1_Tremor 66794-74-9 ENCAINIDE INDICATION Ventricular Tachycardia 66794-74-9 ENCAINIDE KNOWN_TOXICITY Miscellaneous 66794-74-9 ENCAINIDE MECHANISM Block neural transmission 66794-74-9 ENCAINIDE ADVERSE_EFFECT LUN_2_Dyspnea 66794-74-9 ENCAINIDE ADVERSE_EFFECT NEU_1_Somnolence 66794-74-9 ENCAINIDE ADVERSE_EFFECT NEU_3_Ataxia 66794-74-9 ENCAINIDE PRODUCT_CLASS Cardiovasculars 66794-74-9 ENCAINIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 66794-74-9 ENCAINIDE TISSUE_TOXICITY Ventricular Fibrillation 66794-74-9 ENCAINIDE TISSUE_TOXICITY Death 66794-74-9 ENCAINIDE KNOWN_TOXICITY Cardiovascular Toxicity 66794-74-9 ENCAINIDE INDICATION Ventricular Arrhythmias 66794-74-9 ENCAINIDE ADVERSE_EFFECT CVS_3_Heart Failure 66794-74-9 ENCAINIDE ADVERSE_EFFECT NEU_1_Headache 66794-74-9 ENCAINIDE ADVERSE_EFFECT CVS_3_Cardiac Conduction System Malfunction 66794-74-9 ENCAINIDE INDICATION Ventricular Premature Beats (Ventricular Extrasystoles) 66794-74-9 ENCAINIDE THERAPEUTIC_CLASS Antiarrhythmic Agents 66794-74-9 ENCAINIDE ADVERSE_EFFECT OCU_2_Visual Disturbances 66794-74-9 ENCAINIDE ADVERSE_EFFECT CVS_3_Cardiac Insufficiency 66794-74-9 ENCAINIDE ADVERSE_EFFECT XXX_3_Death 66794-74-9 ENCAINIDE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 130929-57-6 ENTACAPONE INDICATION Parkinson's Disease 130929-57-6 ENTACAPONE MECHANISM Interferes with neural transmitter synthesis 130929-57-6 ENTACAPONE MODE_CLASS Enzyme Inhibitor, selective 116314-67-1 ENTACAPONE MODE_CLASS Enzyme Inhibitor, selective 116314-67-1 ENTACAPONE MECHANISM Interferes with neural transmitter synthesis 116314-67-1 ENTACAPONE INDICATION Parkinson's Disease 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Anorexia 299-42-3 EPHEDRINE ADVERSE_EFFECT NEU_3_Tremor 299-42-3 EPHEDRINE ADVERSE_EFFECT NEU_3_Headache 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Insomnia 299-42-3 EPHEDRINE ADVERSE_EFFECT XXX_3_Weakness 299-42-3 EPHEDRINE ADVERSE_EFFECT NEU_2_Dizziness 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Confusion 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Psychosis 299-42-3 EPHEDRINE ADVERSE_EFFECT XXX_2_Xerostomia 299-42-3 EPHEDRINE INDICATION Enuresis 299-42-3 EPHEDRINE MODE_CLASS Enzyme substrate mimic 299-42-3 EPHEDRINE THERAPEUTIC_CLASS Central Stimulants 299-42-3 EPHEDRINE TISSUE_TOXICITY Cardiac Arrest 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_1_Nervousness 299-42-3 EPHEDRINE INDICATION Depression 299-42-3 EPHEDRINE MECHANISM Block channel gating 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 299-42-3 EPHEDRINE MECHANISM Prolong/enhance neural transmission 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 299-42-3 EPHEDRINE ADVERSE_EFFECT NEU_2_Lightheadedness 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Irritability 299-42-3 EPHEDRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 299-42-3 EPHEDRINE INDICATION Hypotension 299-42-3 EPHEDRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 299-42-3 EPHEDRINE TISSUE_TOXICITY Cardiac Arrhythmia 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Hallucinations 299-42-3 EPHEDRINE MODE_CLASS Receptor /Channel ligand mimic 299-42-3 EPHEDRINE THERAPEUTIC_CLASS Vasopressors 299-42-3 EPHEDRINE TISSUE_TOXICITY Myocardial Infarction 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_2_Hypertension 299-42-3 EPHEDRINE THERAPEUTIC_CLASS Antidepressants 299-42-3 EPHEDRINE MECHANISM Modulate G-protein coupled signal transduction 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Delirium 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_1_Anxiety 299-42-3 EPHEDRINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 299-42-3 EPHEDRINE ADVERSE_EFFECT XXX_1_Restlessness 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Euphoria 299-42-3 EPHEDRINE ADVERSE_EFFECT XXX_2_Diaphoresis 299-42-3 EPHEDRINE INDICATION Chronic Bronchitis 299-42-3 EPHEDRINE PRODUCT_CLASS Central Nervous System (CNS) 299-42-3 EPHEDRINE PRODUCT_CLASS Respiratory System 299-42-3 EPHEDRINE INDICATION Narcolepsy 299-42-3 EPHEDRINE INDICATION Nasal Congestion 299-42-3 EPHEDRINE INDICATION Asthma 299-42-3 EPHEDRINE MODE_CLASS Solute transporter inhibitor 299-42-3 EPHEDRINE THERAPEUTIC_CLASS Antispasmodic Agents 299-42-3 EPHEDRINE TISSUE_TOXICITY Ventricular Fibrillation 299-42-3 EPHEDRINE THERAPEUTIC_CLASS Bronchodilators 299-42-3 EPHEDRINE KNOWN_TOXICITY Cardiovascular Toxicity 299-42-3 EPHEDRINE ADVERSE_EFFECT XXX_3_Fever 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 299-42-3 EPHEDRINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 299-42-3 EPHEDRINE ADVERSE_EFFECT CVS_1_Palpitation 299-42-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Agitation 299-42-3 EPHEDRINE ADVERSE_EFFECT NEU_2_Hyperreflexia 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Psychosis 90-81-3 EPHEDRINE ADVERSE_EFFECT XXX_2_Xerostomia 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Delirium 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Irritability 90-81-3 EPHEDRINE ADVERSE_EFFECT NEU_2_Lightheadedness 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 90-81-3 EPHEDRINE ADVERSE_EFFECT XXX_3_Weakness 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_1_Nervousness 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Hallucinations 90-81-3 EPHEDRINE TISSUE_TOXICITY Cardiac Arrest 90-81-3 EPHEDRINE THERAPEUTIC_CLASS Central Stimulants 90-81-3 EPHEDRINE MODE_CLASS Enzyme substrate mimic 90-81-3 EPHEDRINE INDICATION Enuresis 90-81-3 EPHEDRINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_1_Palpitation 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Agitation 90-81-3 EPHEDRINE ADVERSE_EFFECT NEU_2_Hyperreflexia 90-81-3 EPHEDRINE ADVERSE_EFFECT NEU_3_Headache 90-81-3 EPHEDRINE ADVERSE_EFFECT NEU_3_Tremor 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Anorexia 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_2_Hypertension 90-81-3 EPHEDRINE TISSUE_TOXICITY Myocardial Infarction 90-81-3 EPHEDRINE THERAPEUTIC_CLASS Vasopressors 90-81-3 EPHEDRINE MODE_CLASS Receptor /Channel ligand mimic 90-81-3 EPHEDRINE INDICATION Depression 90-81-3 EPHEDRINE MECHANISM Block channel gating 90-81-3 EPHEDRINE MECHANISM Prolong/enhance neural transmission 90-81-3 EPHEDRINE INDICATION Hypotension 90-81-3 EPHEDRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 90-81-3 EPHEDRINE TISSUE_TOXICITY Cardiac Arrhythmia 90-81-3 EPHEDRINE THERAPEUTIC_CLASS Antidepressants 90-81-3 EPHEDRINE MECHANISM Modulate G-protein coupled signal transduction 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_1_Anxiety 90-81-3 EPHEDRINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 90-81-3 EPHEDRINE ADVERSE_EFFECT XXX_1_Restlessness 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_3_Euphoria 90-81-3 EPHEDRINE ADVERSE_EFFECT XXX_2_Diaphoresis 90-81-3 EPHEDRINE INDICATION Chronic Bronchitis 90-81-3 EPHEDRINE PRODUCT_CLASS Central Nervous System (CNS) 90-81-3 EPHEDRINE PRODUCT_CLASS Respiratory System 90-81-3 EPHEDRINE INDICATION Narcolepsy 90-81-3 EPHEDRINE INDICATION Nasal Congestion 90-81-3 EPHEDRINE INDICATION Asthma 90-81-3 EPHEDRINE MODE_CLASS Solute transporter inhibitor 90-81-3 EPHEDRINE THERAPEUTIC_CLASS Antispasmodic Agents 90-81-3 EPHEDRINE TISSUE_TOXICITY Ventricular Fibrillation 90-81-3 EPHEDRINE THERAPEUTIC_CLASS Bronchodilators 90-81-3 EPHEDRINE KNOWN_TOXICITY Cardiovascular Toxicity 90-81-3 EPHEDRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 90-81-3 EPHEDRINE ADVERSE_EFFECT XXX_3_Fever 90-81-3 EPHEDRINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Insomnia 90-81-3 EPHEDRINE ADVERSE_EFFECT NEU_2_Dizziness 90-81-3 EPHEDRINE ADVERSE_EFFECT PSY_2_Confusion 321-98-2 EPHEDRINE PRODUCT_CLASS Respiratory System 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_3_Psychosis 321-98-2 EPHEDRINE MECHANISM Modulate G-protein coupled signal transduction 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_3_Delirium 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 321-98-2 EPHEDRINE INDICATION Depression 321-98-2 EPHEDRINE INDICATION Enuresis 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_1_Anxiety 321-98-2 EPHEDRINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 321-98-2 EPHEDRINE ADVERSE_EFFECT XXX_1_Restlessness 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_3_Euphoria 321-98-2 EPHEDRINE ADVERSE_EFFECT XXX_2_Diaphoresis 321-98-2 EPHEDRINE INDICATION Chronic Bronchitis 321-98-2 EPHEDRINE PRODUCT_CLASS Central Nervous System (CNS) 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_1_Palpitation 321-98-2 EPHEDRINE INDICATION Narcolepsy 321-98-2 EPHEDRINE INDICATION Nasal Congestion 321-98-2 EPHEDRINE MECHANISM Block channel gating 321-98-2 EPHEDRINE INDICATION Asthma 321-98-2 EPHEDRINE MODE_CLASS Solute transporter inhibitor 321-98-2 EPHEDRINE THERAPEUTIC_CLASS Antispasmodic Agents 321-98-2 EPHEDRINE ADVERSE_EFFECT XXX_2_Xerostomia 321-98-2 EPHEDRINE TISSUE_TOXICITY Ventricular Fibrillation 321-98-2 EPHEDRINE THERAPEUTIC_CLASS Bronchodilators 321-98-2 EPHEDRINE KNOWN_TOXICITY Cardiovascular Toxicity 321-98-2 EPHEDRINE ADVERSE_EFFECT XXX_3_Fever 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 321-98-2 EPHEDRINE ADVERSE_EFFECT NEU_2_Dizziness 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_2_Confusion 321-98-2 EPHEDRINE MECHANISM Prolong/enhance neural transmission 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_2_Insomnia 321-98-2 EPHEDRINE ADVERSE_EFFECT NEU_2_Lightheadedness 321-98-2 EPHEDRINE THERAPEUTIC_CLASS Antidepressants 321-98-2 EPHEDRINE TISSUE_TOXICITY Cardiac Arrhythmia 321-98-2 EPHEDRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 321-98-2 EPHEDRINE INDICATION Hypotension 321-98-2 EPHEDRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_2_Irritability 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 321-98-2 EPHEDRINE ADVERSE_EFFECT XXX_3_Weakness 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_1_Nervousness 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_3_Hallucinations 321-98-2 EPHEDRINE TISSUE_TOXICITY Cardiac Arrest 321-98-2 EPHEDRINE THERAPEUTIC_CLASS Central Stimulants 321-98-2 EPHEDRINE MODE_CLASS Enzyme substrate mimic 321-98-2 EPHEDRINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_2_Agitation 321-98-2 EPHEDRINE ADVERSE_EFFECT NEU_2_Hyperreflexia 321-98-2 EPHEDRINE ADVERSE_EFFECT NEU_3_Headache 321-98-2 EPHEDRINE ADVERSE_EFFECT NEU_3_Tremor 321-98-2 EPHEDRINE ADVERSE_EFFECT PSY_2_Anorexia 321-98-2 EPHEDRINE ADVERSE_EFFECT CVS_2_Hypertension 321-98-2 EPHEDRINE TISSUE_TOXICITY Myocardial Infarction 321-98-2 EPHEDRINE THERAPEUTIC_CLASS Vasopressors 321-98-2 EPHEDRINE MODE_CLASS Receptor /Channel ligand mimic 148152-66-3 EPIBATIDINE MODE_CLASS Channel Modulator 148152-66-3 EPIBATIDINE PRODUCT_CLASS Analgesics 148152-66-3 EPIBATIDINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 148152-66-3 EPIBATIDINE MECHANISM Prolong/enhance neural transmission 152378-30-8 EPIBATIDINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 152378-30-8 EPIBATIDINE PRODUCT_CLASS Analgesics 152378-30-8 EPIBATIDINE MODE_CLASS Channel Modulator 152378-30-8 EPIBATIDINE MECHANISM Prolong/enhance neural transmission 51-43-4 EPINEPHRINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 51-43-4 EPINEPHRINE ADVERSE_EFFECT XXX_3_Death 51-43-4 EPINEPHRINE ADVERSE_EFFECT CVS_1_Palpitation 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_2_Excitement 51-43-4 EPINEPHRINE ADVERSE_EFFECT LUN_3_Apnea 51-43-4 EPINEPHRINE KNOWN_TOXICITY Miscellaneous 51-43-4 EPINEPHRINE ADVERSE_EFFECT NEU_3_Psychomotor Excitation 51-43-4 EPINEPHRINE MECHANISM Modulate G-protein coupled signal transduction 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_3_Hallucinations 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_2_Anxiety 51-43-4 EPINEPHRINE ACTIVITY_CLASS Adrenergic agonist 51-43-4 EPINEPHRINE STRUCTURE_ACTIVITY Adrenoceptor agonist 51-43-4 EPINEPHRINE MODE_CLASS Endogenous Receptor /Channel Ligand 51-43-4 EPINEPHRINE MECH_LEVEL_3 adrenoceptor 51-43-4 EPINEPHRINE ZERO_CLASS N 51-43-4 EPINEPHRINE ADVERSE_EFFECT XXX_2_Diaphoresis 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_3_Suicidal Ideas / Attempts / Suicide 51-43-4 EPINEPHRINE ADVERSE_EFFECT LUN_3_Respiratory Distress 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_3_Disorientation 51-43-4 EPINEPHRINE ADVERSE_EFFECT ELT_1_Hypokalemia 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_3_Aggressiveness 51-43-4 EPINEPHRINE ADVERSE_EFFECT CVS_1_Hypertension 51-43-4 EPINEPHRINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 51-43-4 EPINEPHRINE THERAPEUTIC_CLASS Sympathomimetic Agents 51-43-4 EPINEPHRINE MESH_LEVEL_1 Organic Chemicals 51-43-4 EPINEPHRINE ADVERSE_EFFECT NEU_2_Sleeplessness 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_2_Panic 51-43-4 EPINEPHRINE ADVERSE_EFFECT NEU_3_Headache 51-43-4 EPINEPHRINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 51-43-4 EPINEPHRINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 51-43-4 EPINEPHRINE MESH_LEVEL_2 Amines 51-43-4 EPINEPHRINE TISSUE_TOXICITY Cardiac Arrhythmia 51-43-4 EPINEPHRINE PRODUCT_CLASS Autonomic Nervous System (ANS) 51-43-4 EPINEPHRINE ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 51-43-4 EPINEPHRINE ADVERSE_EFFECT NEU_3_Poor Memory 51-43-4 EPINEPHRINE ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 51-43-4 EPINEPHRINE ADVERSE_EFFECT CVS_2_ECG Changes 51-43-4 EPINEPHRINE ADVERSE_EFFECT END_3_Metabolic Acidosis 51-43-4 EPINEPHRINE ADVERSE_EFFECT NEU_3_Tremor 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_2_Nervousness 51-43-4 EPINEPHRINE TA_LEVEL_1 Central Nervous System (CNS) 51-43-4 EPINEPHRINE MESH_LEVEL_3 Catecholamines 51-43-4 EPINEPHRINE ADVERSE_EFFECT XXX_1_Throat Irritation 51-43-4 EPINEPHRINE TISSUE_TOXICITY Death 51-43-4 EPINEPHRINE ADVERSE_EFFECT PSY_3_CNS Stimulation 51-43-4 EPINEPHRINE KNOWN_TOXICITY Cardiovascular Toxicity 5579-16-8 EPINEPHRYL BORATE MODE_CLASS Receptor Agonist 5579-16-8 EPINEPHRYL BORATE PRODUCT_CLASS Biochemicals 5579-16-8 EPINEPHRYL BORATE MECHANISM Modulate G-protein coupled signal transduction 5579-16-8 EPINEPHRYL BORATE STRUCTURE_ACTIVITY Adrenoceptor agonist 61849-14-7 PROSTACYCLIN THERAPEUTIC_CLASS Antiplatelets 61849-14-7 PROSTACYCLIN PRODUCT_CLASS Hematologics 61849-14-7 PROSTACYCLIN INDICATION Hypertension 61849-14-7 PROSTACYCLIN MECHANISM Modulate G-protein coupled signal transduction 61849-14-7 PROSTACYCLIN PRODUCT_CLASS Cardiovasculars 61849-14-7 PROSTACYCLIN THERAPEUTIC_CLASS Antihypertensive Agents 61849-14-7 PROSTACYCLIN MODE_CLASS Receptor Agonist 63748-50-5 PROSTACYCLIN THERAPEUTIC_CLASS Antiplatelets 63748-50-5 PROSTACYCLIN THERAPEUTIC_CLASS Antihypertensive Agents 63748-50-5 PROSTACYCLIN MODE_CLASS Receptor Agonist 63748-50-5 PROSTACYCLIN PRODUCT_CLASS Hematologics 63748-50-5 PROSTACYCLIN INDICATION Hypertension 63748-50-5 PROSTACYCLIN MECHANISM Modulate G-protein coupled signal transduction 63748-50-5 PROSTACYCLIN PRODUCT_CLASS Cardiovasculars 63859-31-4 PROSTACYCLIN PRODUCT_CLASS Hematologics 63859-31-4 PROSTACYCLIN THERAPEUTIC_CLASS Antiplatelets 63859-31-4 PROSTACYCLIN PRODUCT_CLASS Cardiovasculars 63859-31-4 PROSTACYCLIN THERAPEUTIC_CLASS Antihypertensive Agents 63859-31-4 PROSTACYCLIN MODE_CLASS Receptor Agonist 63859-31-4 PROSTACYCLIN INDICATION Hypertension 63859-31-4 PROSTACYCLIN MECHANISM Modulate G-protein coupled signal transduction 133040-01-4 EPROSARTAN THERAPEUTIC_CLASS Antihypertensive Agents 133040-01-4 EPROSARTAN INDICATION Hypertension 133040-01-4 EPROSARTAN PRODUCT_CLASS Cardiovasculars 133040-01-4 EPROSARTAN MODE_CLASS Receptor Ligand Antagonist, Selective 133040-01-4 EPROSARTAN MECHANISM Reduce vasoconstriction 133040-01-4 EPROSARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT NEU_2_Headache 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT GIS_3_Constipation 50-14-6 ERGOCALCIFEROL MODE_CLASS Receptor Agonist 50-14-6 ERGOCALCIFEROL INDICATION Osteomalacia 50-14-6 ERGOCALCIFEROL INDICATION Nutritional Supplement 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT GIS_2_Abdominal Cramps 50-14-6 ERGOCALCIFEROL PRODUCT_CLASS Hormones, Endocrine and Metabolic 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT MSK_2_Arthralgia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT XXX_3_Rhinorrhea 50-14-6 ERGOCALCIFEROL ACTIVITY_CLASS Vitamin D receptor agonist 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT GIS_2_Metallic Taste 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT ELT_3_Hypercalcemia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT CVS_3_Hypertension 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT OTO_3_Tinnitus 50-14-6 ERGOCALCIFEROL INDICATION Osteoporosis 50-14-6 ERGOCALCIFEROL INDICATION Vitamin D Deficiency 50-14-6 ERGOCALCIFEROL INDICATION Rickets 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT XXX_2_Xerostomia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT NEU_3_Vertigo 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT KID_3_Polyuria 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT PSY_2_Anorexia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT GIS_3_Diarrhea 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT END_3_Hypervitaminosis 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT PSY_3_Irritability 50-14-6 ERGOCALCIFEROL INDICATION Renal Osteodystrophy 50-14-6 ERGOCALCIFEROL INDICATION Hypophosphatemia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT OCU_3_Photophobia 50-14-6 ERGOCALCIFEROL STRUCTURE_ACTIVITY Vitamin D receptor agonist 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT NEU_3_Ataxia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT XXX_3_Hyperthermia 50-14-6 ERGOCALCIFEROL MECHANISM Modulate gene transcription 50-14-6 ERGOCALCIFEROL THERAPEUTIC_CLASS Bone Mineral Homeostasis 50-14-6 ERGOCALCIFEROL INDICATION Hypoparathyroidism 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT MSK_3_Myalgia 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT SKN_3_Exanthema 50-14-6 ERGOCALCIFEROL ADVERSE_EFFECT END_3_Hyperphosphatemia 8067-24-1 ERGOLOID MESYLATES MECHANISM Modulate G-protein coupled signal transduction 8067-24-1 ERGOLOID MESYLATES MODE_CLASS Receptor Ligand Antagonist 8067-24-1 ERGOLOID MESYLATES STRUCTURE_ACTIVITY Ergot alkaloid 379-79-3 ERGOTAMINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 379-79-3 ERGOTAMINE ADVERSE_EFFECT EMB_3_Fetal Death 379-79-3 ERGOTAMINE PRODUCT_CLASS Central Nervous System (CNS) 379-79-3 ERGOTAMINE TISSUE_TOXICITY Stroke 379-79-3 ERGOTAMINE KNOWN_TOXICITY Nephrotoxicity 379-79-3 ERGOTAMINE ADVERSE_EFFECT GIS_2_Diarrhea 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 379-79-3 ERGOTAMINE ADVERSE_EFFECT NEU_2_Drowsiness 379-79-3 ERGOTAMINE ADVERSE_EFFECT NEU_3_Coma 379-79-3 ERGOTAMINE ADVERSE_EFFECT GIS_3_Pancreatitis 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_3_Valvular Disorders 379-79-3 ERGOTAMINE ADVERSE_EFFECT GIS_3_Dysgeusia 379-79-3 ERGOTAMINE MECHANISM Modulate neural transmission 379-79-3 ERGOTAMINE MECHANISM Modulate cerebral vasoconstriction 379-79-3 ERGOTAMINE TISSUE_TOXICITY Myocardial Infarction 379-79-3 ERGOTAMINE MECHANISM Reduce muscle contractile force 379-79-3 ERGOTAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 379-79-3 ERGOTAMINE THERAPEUTIC_CLASS Antimigraines 379-79-3 ERGOTAMINE TISSUE_TOXICITY Renal Tubular Necrosis 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_3_Thrombosis 379-79-3 ERGOTAMINE ADVERSE_EFFECT OCU_3_Blurred Vision 379-79-3 ERGOTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 379-79-3 ERGOTAMINE ADVERSE_EFFECT REP_2_Uterine Contractions 379-79-3 ERGOTAMINE ADVERSE_EFFECT XXX_3_Withdrawal 379-79-3 ERGOTAMINE ADVERSE_EFFECT MSK_2_Muscle Cramps 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_3_Coronary Vasospasm 379-79-3 ERGOTAMINE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 379-79-3 ERGOTAMINE ADVERSE_EFFECT NEU_3_Seizures 379-79-3 ERGOTAMINE ADVERSE_EFFECT XXX_1_Edema 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_2_Hypertension 379-79-3 ERGOTAMINE ADVERSE_EFFECT OCU_3_Retinal Detachment 379-79-3 ERGOTAMINE TISSUE_TOXICITY Valvular Disorders 379-79-3 ERGOTAMINE TISSUE_TOXICITY Thrombosis 379-79-3 ERGOTAMINE MODE_CLASS Receptor Partial Agonist 379-79-3 ERGOTAMINE INDICATION Migraine Headache 379-79-3 ERGOTAMINE STRUCTURE_ACTIVITY Ergot alkaloid 379-79-3 ERGOTAMINE ADVERSE_EFFECT EMB_2_Fetal Distress 379-79-3 ERGOTAMINE ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_3_Stroke 379-79-3 ERGOTAMINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 379-79-3 ERGOTAMINE ADVERSE_EFFECT CVS_2_Vasoconstriction 379-79-3 ERGOTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 113-15-5 ERGOTAMINE ADVERSE_EFFECT GIS_3_Retroperitoneal Fibroplasia 113-15-5 ERGOTAMINE KNOWN_TOXICITY Nephrotoxicity 113-15-5 ERGOTAMINE ADVERSE_EFFECT GIS_2_Diarrhea 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 113-15-5 ERGOTAMINE ADVERSE_EFFECT NEU_2_Drowsiness 113-15-5 ERGOTAMINE ADVERSE_EFFECT NEU_3_Coma 113-15-5 ERGOTAMINE ADVERSE_EFFECT GIS_3_Pancreatitis 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_3_Valvular Disorders 113-15-5 ERGOTAMINE ADVERSE_EFFECT GIS_3_Dysgeusia 113-15-5 ERGOTAMINE MECHANISM Modulate neural transmission 113-15-5 ERGOTAMINE MECHANISM Modulate cerebral vasoconstriction 113-15-5 ERGOTAMINE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_3_Stroke 113-15-5 ERGOTAMINE TISSUE_TOXICITY Stroke 113-15-5 ERGOTAMINE ADVERSE_EFFECT EMB_2_Fetal Distress 113-15-5 ERGOTAMINE STRUCTURE_ACTIVITY Ergot alkaloid 113-15-5 ERGOTAMINE INDICATION Migraine Headache 113-15-5 ERGOTAMINE MODE_CLASS Receptor Partial Agonist 113-15-5 ERGOTAMINE TISSUE_TOXICITY Thrombosis 113-15-5 ERGOTAMINE TISSUE_TOXICITY Myocardial Infarction 113-15-5 ERGOTAMINE TISSUE_TOXICITY Valvular Disorders 113-15-5 ERGOTAMINE ADVERSE_EFFECT OCU_3_Retinal Detachment 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_2_Hypertension 113-15-5 ERGOTAMINE ADVERSE_EFFECT XXX_1_Edema 113-15-5 ERGOTAMINE ADVERSE_EFFECT NEU_3_Seizures 113-15-5 ERGOTAMINE ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 113-15-5 ERGOTAMINE KNOWN_TOXICITY Cardiovascular Toxicity 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_2_Vasoconstriction 113-15-5 ERGOTAMINE MECHANISM Reduce muscle contractile force 113-15-5 ERGOTAMINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_3_Coronary Vasospasm 113-15-5 ERGOTAMINE THERAPEUTIC_CLASS Antimigraines 113-15-5 ERGOTAMINE TISSUE_TOXICITY Renal Tubular Necrosis 113-15-5 ERGOTAMINE ADVERSE_EFFECT CVS_3_Thrombosis 113-15-5 ERGOTAMINE ADVERSE_EFFECT OCU_3_Blurred Vision 113-15-5 ERGOTAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 113-15-5 ERGOTAMINE ADVERSE_EFFECT REP_2_Uterine Contractions 113-15-5 ERGOTAMINE ADVERSE_EFFECT XXX_3_Withdrawal 113-15-5 ERGOTAMINE ADVERSE_EFFECT MSK_2_Muscle Cramps 113-15-5 ERGOTAMINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 113-15-5 ERGOTAMINE ADVERSE_EFFECT EMB_3_Fetal Death 113-15-5 ERGOTAMINE PRODUCT_CLASS Central Nervous System (CNS) 51350-19-7 ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE HYDROCHLORIDE THERAPEUTIC_CLASS Immunosuppressants 51350-19-7 ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE HYDROCHLORIDE THERAPEUTIC_CLASS Antivirals 51350-19-7 ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 51350-19-7 ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE HYDROCHLORIDE PRODUCT_CLASS Immune Response / Immunomodulators 51350-19-7 ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE HYDROCHLORIDE MECHANISM Enhance kinase mediated signal transduction 51350-19-7 ERYTHRO-9-(2-HYDROXY-3-NONYL)ADENINE HYDROCHLORIDE PRODUCT_CLASS Anti-infectives 149908-23-6 ERYTHROMYCIN INDICATION Otitis Media 149908-23-6 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 149908-23-6 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 149908-23-6 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 149908-23-6 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 149908-23-6 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 149908-23-6 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 149908-23-6 ERYTHROMYCIN INDICATION Diphtheria 149908-23-6 ERYTHROMYCIN INDICATION Pneumonia 149908-23-6 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 149908-23-6 ERYTHROMYCIN INDICATION Pharyngitis 149908-23-6 ERYTHROMYCIN INDICATION Burn Wound Infection 149908-23-6 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 149908-23-6 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 149908-23-6 ERYTHROMYCIN INDICATION Urethritis 149908-23-6 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 149908-23-6 ERYTHROMYCIN INDICATION Cervicitis 149908-23-6 ERYTHROMYCIN INDICATION Sinusitis 149908-23-6 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 149908-23-6 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 149908-23-6 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 149908-23-6 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 149908-23-6 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 149908-23-6 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 149908-23-6 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 149908-23-6 ERYTHROMYCIN INDICATION Amebiasis 149908-23-6 ERYTHROMYCIN INDICATION Surgical Prophylaxis 149908-23-6 ERYTHROMYCIN INDICATION Erythrasma 149908-23-6 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 149908-23-6 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 149908-23-6 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 149908-23-6 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 149908-23-6 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 149908-23-6 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 149908-23-6 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 149908-23-6 ERYTHROMYCIN ZERO_CLASS N 149908-23-6 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 149908-23-6 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 149908-23-6 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 149908-23-6 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 149908-23-6 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 149908-23-6 ERYTHROMYCIN INDICATION Proctitis 149908-23-6 ERYTHROMYCIN INDICATION Syphilis 149908-23-6 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 149908-23-6 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 149908-23-6 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 149908-23-6 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 149908-23-6 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 87573-04-4 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 87573-04-4 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 87573-04-4 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 87573-04-4 ERYTHROMYCIN INDICATION Burn Wound Infection 87573-04-4 ERYTHROMYCIN INDICATION Pharyngitis 87573-04-4 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 87573-04-4 ERYTHROMYCIN INDICATION Pneumonia 87573-04-4 ERYTHROMYCIN INDICATION Diphtheria 87573-04-4 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 87573-04-4 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 87573-04-4 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 87573-04-4 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 87573-04-4 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 87573-04-4 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 87573-04-4 ERYTHROMYCIN ZERO_CLASS N 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 87573-04-4 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 87573-04-4 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 87573-04-4 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 87573-04-4 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 87573-04-4 ERYTHROMYCIN INDICATION Erythrasma 87573-04-4 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 87573-04-4 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 87573-04-4 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 87573-04-4 ERYTHROMYCIN INDICATION Syphilis 87573-04-4 ERYTHROMYCIN INDICATION Proctitis 87573-04-4 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 87573-04-4 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 87573-04-4 ERYTHROMYCIN INDICATION Surgical Prophylaxis 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 87573-04-4 ERYTHROMYCIN INDICATION Amebiasis 87573-04-4 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 87573-04-4 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 87573-04-4 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 87573-04-4 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 87573-04-4 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 87573-04-4 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 87573-04-4 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 87573-04-4 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 87573-04-4 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 87573-04-4 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 87573-04-4 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 87573-04-4 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 87573-04-4 ERYTHROMYCIN INDICATION Sinusitis 87573-04-4 ERYTHROMYCIN INDICATION Cervicitis 87573-04-4 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 87573-04-4 ERYTHROMYCIN INDICATION Urethritis 87573-04-4 ERYTHROMYCIN INDICATION Otitis Media 87573-04-4 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 87573-04-4 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 50976-86-8 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 50976-86-8 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 50976-86-8 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 50976-86-8 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 50976-86-8 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 50976-86-8 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 50976-86-8 ERYTHROMYCIN INDICATION Diphtheria 50976-86-8 ERYTHROMYCIN INDICATION Pneumonia 50976-86-8 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 50976-86-8 ERYTHROMYCIN INDICATION Pharyngitis 50976-86-8 ERYTHROMYCIN INDICATION Burn Wound Infection 50976-86-8 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 50976-86-8 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 50976-86-8 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 50976-86-8 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 50976-86-8 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 50976-86-8 ERYTHROMYCIN INDICATION Otitis Media 50976-86-8 ERYTHROMYCIN INDICATION Urethritis 50976-86-8 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 50976-86-8 ERYTHROMYCIN INDICATION Cervicitis 50976-86-8 ERYTHROMYCIN INDICATION Sinusitis 50976-86-8 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 50976-86-8 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 50976-86-8 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 50976-86-8 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 50976-86-8 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 50976-86-8 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 50976-86-8 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 50976-86-8 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 50976-86-8 ERYTHROMYCIN INDICATION Syphilis 50976-86-8 ERYTHROMYCIN INDICATION Proctitis 50976-86-8 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 50976-86-8 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 50976-86-8 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 50976-86-8 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 50976-86-8 ERYTHROMYCIN ZERO_CLASS N 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 50976-86-8 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 50976-86-8 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 50976-86-8 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 50976-86-8 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 50976-86-8 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 50976-86-8 ERYTHROMYCIN INDICATION Erythrasma 50976-86-8 ERYTHROMYCIN INDICATION Surgical Prophylaxis 50976-86-8 ERYTHROMYCIN INDICATION Amebiasis 50976-86-8 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 50976-86-8 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 50976-86-8 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 50976-86-8 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 47879-97-0 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 47879-97-0 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 47879-97-0 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 47879-97-0 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 47879-97-0 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 47879-97-0 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 47879-97-0 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 47879-97-0 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 47879-97-0 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 47879-97-0 ERYTHROMYCIN INDICATION Sinusitis 47879-97-0 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 47879-97-0 ERYTHROMYCIN INDICATION Cervicitis 47879-97-0 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 47879-97-0 ERYTHROMYCIN INDICATION Urethritis 47879-97-0 ERYTHROMYCIN INDICATION Otitis Media 47879-97-0 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 47879-97-0 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 47879-97-0 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 47879-97-0 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 47879-97-0 ERYTHROMYCIN INDICATION Burn Wound Infection 47879-97-0 ERYTHROMYCIN INDICATION Pharyngitis 47879-97-0 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 47879-97-0 ERYTHROMYCIN INDICATION Pneumonia 47879-97-0 ERYTHROMYCIN INDICATION Diphtheria 47879-97-0 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 47879-97-0 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 47879-97-0 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 47879-97-0 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 47879-97-0 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 47879-97-0 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 47879-97-0 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 47879-97-0 ERYTHROMYCIN INDICATION Syphilis 47879-97-0 ERYTHROMYCIN INDICATION Proctitis 47879-97-0 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 47879-97-0 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 47879-97-0 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 47879-97-0 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 47879-97-0 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 47879-97-0 ERYTHROMYCIN ZERO_CLASS N 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 47879-97-0 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 47879-97-0 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 47879-97-0 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 47879-97-0 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 47879-97-0 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 47879-97-0 ERYTHROMYCIN INDICATION Erythrasma 47879-97-0 ERYTHROMYCIN INDICATION Surgical Prophylaxis 47879-97-0 ERYTHROMYCIN INDICATION Amebiasis 47879-97-0 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 47879-92-5 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 47879-92-5 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 47879-92-5 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 47879-92-5 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 47879-92-5 ERYTHROMYCIN INDICATION Diphtheria 47879-92-5 ERYTHROMYCIN INDICATION Pneumonia 47879-92-5 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 47879-92-5 ERYTHROMYCIN INDICATION Pharyngitis 47879-92-5 ERYTHROMYCIN INDICATION Burn Wound Infection 47879-92-5 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 47879-92-5 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 47879-92-5 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 47879-92-5 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 47879-92-5 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 47879-92-5 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 47879-92-5 ERYTHROMYCIN INDICATION Otitis Media 47879-92-5 ERYTHROMYCIN INDICATION Urethritis 47879-92-5 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 47879-92-5 ERYTHROMYCIN INDICATION Cervicitis 47879-92-5 ERYTHROMYCIN INDICATION Sinusitis 47879-92-5 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 47879-92-5 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 47879-92-5 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 47879-92-5 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 47879-92-5 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 47879-92-5 ERYTHROMYCIN INDICATION Surgical Prophylaxis 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 47879-92-5 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 47879-92-5 ERYTHROMYCIN ZERO_CLASS N 47879-92-5 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 47879-92-5 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 47879-92-5 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 47879-92-5 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 47879-92-5 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 47879-92-5 ERYTHROMYCIN INDICATION Proctitis 47879-92-5 ERYTHROMYCIN INDICATION Syphilis 47879-92-5 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 47879-92-5 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 47879-92-5 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 47879-92-5 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 47879-92-5 ERYTHROMYCIN INDICATION Amebiasis 47879-92-5 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 47879-92-5 ERYTHROMYCIN INDICATION Erythrasma 47879-92-5 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 47879-92-5 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 47879-92-5 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 47879-92-5 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 47879-92-5 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 47879-92-5 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 7540-22-9 ERYTHROMYCIN INDICATION Proctitis 7540-22-9 ERYTHROMYCIN INDICATION Lower Respiratory Tract Infection 7540-22-9 ERYTHROMYCIN TA_LEVEL_1 Infectious Disease 7540-22-9 ERYTHROMYCIN TA_LEVEL_2 Anti-bacterial 7540-22-9 ERYTHROMYCIN INDICATION Syphilis 7540-22-9 ERYTHROMYCIN INDICATION Cervicitis 7540-22-9 ERYTHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 7540-22-9 ERYTHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 7540-22-9 ERYTHROMYCIN KNOWN_TOXICITY Hepatotoxicity 7540-22-9 ERYTHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT PSY_1_Anorexia 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 7540-22-9 ERYTHROMYCIN TISSUE_TOXICITY Ventricular Tachycardia 7540-22-9 ERYTHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 7540-22-9 ERYTHROMYCIN PRODUCT_CLASS Gastrointestinal System 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT OTO_2_Tinnitus 7540-22-9 ERYTHROMYCIN INDICATION Sinusitis 7540-22-9 ERYTHROMYCIN INDICATION Endocarditis Prophylaxis 7540-22-9 ERYTHROMYCIN MESH_LEVEL_2 Carbohydrates 7540-22-9 ERYTHROMYCIN PRODUCT_CLASS Anti-infectives 7540-22-9 ERYTHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_2_Torsade de Pointes Arrhythmia 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Hepatotoxicity 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT OCU_3_Ocular Irritation 7540-22-9 ERYTHROMYCIN TISSUE_TOXICITY Hepatotoxicity 7540-22-9 ERYTHROMYCIN INDICATION Ophthalmia Neonatorum 7540-22-9 ERYTHROMYCIN INDICATION Amebiasis 7540-22-9 ERYTHROMYCIN INDICATION Surgical Prophylaxis 7540-22-9 ERYTHROMYCIN INDICATION Erythrasma 7540-22-9 ERYTHROMYCIN INDICATION Skin and Skin Structure Infections 7540-22-9 ERYTHROMYCIN INDICATION Acne / Acne Vulgaris 7540-22-9 ERYTHROMYCIN MECH_LEVEL_1 Anti-bacterial 7540-22-9 ERYTHROMYCIN TISSUE_TOXICITY Torsade de Pointes Arrhythmia 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Prolonged QT Interval 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT LIV_2_Jaundice 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT OTO_3_Ototoxicity 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 7540-22-9 ERYTHROMYCIN ZERO_CLASS N 7540-22-9 ERYTHROMYCIN THERAPEUTIC_CLASS Prokinetic Agents 7540-22-9 ERYTHROMYCIN THERAPEUTIC_CLASS Antibacterials 7540-22-9 ERYTHROMYCIN INDICATION Rheumatic Fever Prophylaxis 7540-22-9 ERYTHROMYCIN INDICATION Non-Gonococcal Urethritis 7540-22-9 ERYTHROMYCIN TA_LEVEL_3 Systemic infections 7540-22-9 ERYTHROMYCIN INDICATION Diphtheria 7540-22-9 ERYTHROMYCIN INDICATION Pneumonia 7540-22-9 ERYTHROMYCIN INDICATION Upper Respiratory Tract Infection 7540-22-9 ERYTHROMYCIN INDICATION Pharyngitis 7540-22-9 ERYTHROMYCIN INDICATION Burn Wound Infection 7540-22-9 ERYTHROMYCIN INDICATION Diabetic Gastric Stasis 7540-22-9 ERYTHROMYCIN KNOWN_TOXICITY Cardiovascular Toxicity 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 7540-22-9 ERYTHROMYCIN ADVERSE_EFFECT CVS_1_Thrombophlebitis 7540-22-9 ERYTHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 7540-22-9 ERYTHROMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 7540-22-9 ERYTHROMYCIN MESH_LEVEL_3 Glycosides 7540-22-9 ERYTHROMYCIN INDICATION Otitis Media 7540-22-9 ERYTHROMYCIN INDICATION Urethritis 7540-22-9 ERYTHROMYCIN INDICATION Pelvic Inflammatory Disease (PID) 7540-22-9 ERYTHROMYCIN INDICATION Chlamydial Cervicitis 84057-94-3 ESMOLOL INDICATION Paroxysmal Supraventricular Tachycardia 84057-94-3 ESMOLOL ADVERSE_EFFECT CVS_1_Hypotension 84057-94-3 ESMOLOL ADVERSE_EFFECT NEU_2_Headache 84057-94-3 ESMOLOL TISSUE_TOXICITY Cardiac Arrest 84057-94-3 ESMOLOL KNOWN_TOXICITY Cardiovascular Toxicity 84057-94-3 ESMOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 84057-94-3 ESMOLOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 84057-94-3 ESMOLOL INDICATION Hypertension 84057-94-3 ESMOLOL ADVERSE_EFFECT CVS_3_Phlebitis 84057-94-3 ESMOLOL ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 84057-94-3 ESMOLOL TISSUE_TOXICITY Atrioventricular Blockade 84057-94-3 ESMOLOL INDICATION Atrial Fibrillation 84057-94-3 ESMOLOL TA_LEVEL_1 Cardiovascular 84057-94-3 ESMOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, p-phenoxypropanoamine 84057-94-3 ESMOLOL MESH_LEVEL_3 Amino Alcohols 84057-94-3 ESMOLOL MESH_LEVEL_2 Alcohols 84057-94-3 ESMOLOL MECH_LEVEL_3 adrenoceptor beta1 84057-94-3 ESMOLOL PRODUCT_CLASS Cardiovasculars 84057-94-3 ESMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 84057-94-3 ESMOLOL ACTIVITY_CLASS Adrenergic antagonist 84057-94-3 ESMOLOL TA_LEVEL_3 Beta blocker 84057-94-3 ESMOLOL MECH_LEVEL_2 Beta antagonist 84057-94-3 ESMOLOL MECH_LEVEL_1 Reduce cardiac contractility 84057-94-3 ESMOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 84057-94-3 ESMOLOL TISSUE_TOXICITY Hypotension 84057-94-3 ESMOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 84057-94-3 ESMOLOL ADVERSE_EFFECT NEU_2_Dizziness 84057-94-3 ESMOLOL MECHANISM Reduce muscle contractile force 84057-94-3 ESMOLOL MESH_LEVEL_1 Organic Chemicals 84057-94-3 ESMOLOL TA_LEVEL_2 Hypertension 84057-94-3 ESMOLOL INDICATION Atrial Flutter 84057-94-3 ESMOLOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 81147-92-4 ESMOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 81147-92-4 ESMOLOL MECH_LEVEL_1 Reduce cardiac contractility 81147-92-4 ESMOLOL MECH_LEVEL_2 Beta antagonist 81147-92-4 ESMOLOL TA_LEVEL_3 Beta blocker 81147-92-4 ESMOLOL INDICATION Paroxysmal Supraventricular Tachycardia 81147-92-4 ESMOLOL TISSUE_TOXICITY Hypotension 81147-92-4 ESMOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, p-phenoxypropanoamine 81147-92-4 ESMOLOL MESH_LEVEL_2 Alcohols 81147-92-4 ESMOLOL ACTIVITY_CLASS Adrenergic antagonist 81147-92-4 ESMOLOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 81147-92-4 ESMOLOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 81147-92-4 ESMOLOL INDICATION Hypertension 81147-92-4 ESMOLOL PRODUCT_CLASS Cardiovasculars 81147-92-4 ESMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 81147-92-4 ESMOLOL KNOWN_TOXICITY Cardiovascular Toxicity 81147-92-4 ESMOLOL ADVERSE_EFFECT NEU_2_Dizziness 81147-92-4 ESMOLOL ADVERSE_EFFECT CVS_3_Phlebitis 81147-92-4 ESMOLOL MECHANISM Reduce muscle contractile force 81147-92-4 ESMOLOL TA_LEVEL_2 Hypertension 81147-92-4 ESMOLOL INDICATION Atrial Flutter 81147-92-4 ESMOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 81147-92-4 ESMOLOL TISSUE_TOXICITY Cardiac Arrest 81147-92-4 ESMOLOL ADVERSE_EFFECT CVS_1_Hypotension 81147-92-4 ESMOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 81147-92-4 ESMOLOL ADVERSE_EFFECT NEU_2_Headache 81147-92-4 ESMOLOL MESH_LEVEL_1 Organic Chemicals 81147-92-4 ESMOLOL MECH_LEVEL_3 adrenoceptor beta1 81147-92-4 ESMOLOL MESH_LEVEL_3 Amino Alcohols 81147-92-4 ESMOLOL TA_LEVEL_1 Cardiovascular 81147-92-4 ESMOLOL INDICATION Atrial Fibrillation 81147-92-4 ESMOLOL TISSUE_TOXICITY Atrioventricular Blockade 81147-92-4 ESMOLOL ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 103598-03-4 ESMOLOL INDICATION Hypertension 103598-03-4 ESMOLOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 103598-03-4 ESMOLOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 103598-03-4 ESMOLOL TISSUE_TOXICITY Hypotension 103598-03-4 ESMOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 103598-03-4 ESMOLOL ADVERSE_EFFECT NEU_2_Headache 103598-03-4 ESMOLOL MESH_LEVEL_1 Organic Chemicals 103598-03-4 ESMOLOL MECH_LEVEL_3 adrenoceptor beta1 103598-03-4 ESMOLOL MESH_LEVEL_3 Amino Alcohols 103598-03-4 ESMOLOL TA_LEVEL_1 Cardiovascular 103598-03-4 ESMOLOL INDICATION Atrial Fibrillation 103598-03-4 ESMOLOL TISSUE_TOXICITY Atrioventricular Blockade 103598-03-4 ESMOLOL ADVERSE_EFFECT CVS_2_Atrioventricular Blockade 103598-03-4 ESMOLOL ADVERSE_EFFECT CVS_3_Phlebitis 103598-03-4 ESMOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, p-phenoxypropanoamine 103598-03-4 ESMOLOL TA_LEVEL_3 Beta blocker 103598-03-4 ESMOLOL MECH_LEVEL_1 Reduce cardiac contractility 103598-03-4 ESMOLOL MECH_LEVEL_2 Beta antagonist 103598-03-4 ESMOLOL INDICATION Paroxysmal Supraventricular Tachycardia 103598-03-4 ESMOLOL MESH_LEVEL_2 Alcohols 103598-03-4 ESMOLOL PRODUCT_CLASS Cardiovasculars 103598-03-4 ESMOLOL THERAPEUTIC_CLASS Antihypertensive Agents 103598-03-4 ESMOLOL KNOWN_TOXICITY Cardiovascular Toxicity 103598-03-4 ESMOLOL ACTIVITY_CLASS Adrenergic antagonist 103598-03-4 ESMOLOL ADVERSE_EFFECT CVS_2_Sinus Bradycardia 103598-03-4 ESMOLOL ADVERSE_EFFECT NEU_2_Dizziness 103598-03-4 ESMOLOL MECHANISM Reduce muscle contractile force 103598-03-4 ESMOLOL TA_LEVEL_2 Hypertension 103598-03-4 ESMOLOL INDICATION Atrial Flutter 103598-03-4 ESMOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 103598-03-4 ESMOLOL TISSUE_TOXICITY Cardiac Arrest 103598-03-4 ESMOLOL ADVERSE_EFFECT CVS_1_Hypotension 29975-16-4 ESTAZOLAM INDICATION Insomnia 29975-16-4 ESTAZOLAM THERAPEUTIC_CLASS Sedatives/Hypnotics 29975-16-4 ESTAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 29975-16-4 ESTAZOLAM MODE_CLASS Channel enhancer /opener 29975-16-4 ESTAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 29975-16-4 ESTAZOLAM MECHANISM Modulate neural transmission 50-28-2 BETA-ESTRADIOL TISSUE_TOXICITY Thromboembolism 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT BIL_2_Gallbladder Disease 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT END_2_Glucose Intolerance 50-28-2 BETA-ESTRADIOL MODE_CLASS Endogenous Receptor /Channel Ligand 50-28-2 BETA-ESTRADIOL MECH_LEVEL_3 estrogen receptor 50-28-2 BETA-ESTRADIOL PRODUCT_CLASS Anti-cancers 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT GUS_2_Genital Moniliasis 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT GIS_1_Abdominal Pain 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT CVS_2_Hypertension 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT DNA_1_Carcinogenicity 50-28-2 BETA-ESTRADIOL TISSUE_TOXICITY Carcinogenicity 50-28-2 BETA-ESTRADIOL MECH_LEVEL_2 estrogen receptor agonist 50-28-2 BETA-ESTRADIOL THERAPEUTIC_CLASS Bone Mineral Homeostasis 50-28-2 BETA-ESTRADIOL ACTIVITY_CLASS Estrogen agonist 50-28-2 BETA-ESTRADIOL TA_LEVEL_3 SERM 50-28-2 BETA-ESTRADIOL INDICATION Prostatic Cancer / Carcinoma of the Prostate 50-28-2 BETA-ESTRADIOL INDICATION Menopausal Syndrome 50-28-2 BETA-ESTRADIOL KNOWN_TOXICITY Carcinogenicity 50-28-2 BETA-ESTRADIOL INDICATION Breast Cancer / Carcinoma of the Breast 50-28-2 BETA-ESTRADIOL TA_LEVEL_2 post-menapause 50-28-2 BETA-ESTRADIOL INDICATION Dysfunctional Uterine Bleeding (DUB) 50-28-2 BETA-ESTRADIOL INDICATION Prevention of Osteoporosis 50-28-2 BETA-ESTRADIOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 50-28-2 BETA-ESTRADIOL INDICATION Atrophic Vaginitis 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT ELT_2_Hypercalcemia 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT CVS_2_Thromboembolism 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT GUS_2_Genital Pruritis 50-28-2 BETA-ESTRADIOL MESH_LEVEL_2 Steroids 50-28-2 BETA-ESTRADIOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 50-28-2 BETA-ESTRADIOL MECHANISM Modulate gene transcription 50-28-2 BETA-ESTRADIOL INDICATION Ovarian Failure 50-28-2 BETA-ESTRADIOL INDICATION Hot Flashes 50-28-2 BETA-ESTRADIOL MECH_LEVEL_1 Hormone replacement 50-28-2 BETA-ESTRADIOL ZERO_CLASS N 50-28-2 BETA-ESTRADIOL MESH_LEVEL_1 Polycyclic Hydrocarbons 50-28-2 BETA-ESTRADIOL MESH_LEVEL_3 Estranes 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT NEU_1_Headache 50-28-2 BETA-ESTRADIOL KNOWN_TOXICITY Cardiovascular Toxicity 50-28-2 BETA-ESTRADIOL STRUCTURE_ACTIVITY Estrogen receptor agonist, steroidal 50-28-2 BETA-ESTRADIOL TISSUE_TOXICITY Hepatic Adenoma 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT MSK_1_Back Pain 50-28-2 BETA-ESTRADIOL ADVERSE_EFFECT DNA_2_Hepatic Adenoma 50-28-2 BETA-ESTRADIOL THERAPEUTIC_CLASS Gonadal Hormones 50-28-2 BETA-ESTRADIOL THERAPEUTIC_CLASS Antineoplastics 50-28-2 BETA-ESTRADIOL INDICATION Urethritis 50-28-2 BETA-ESTRADIOL INDICATION Hypogonadism 52205-73-9 ESTRAMUSTINE PHOSPHATE MODE_CLASS Receptor Agonist 52205-73-9 ESTRAMUSTINE PHOSPHATE MODE_CLASS Receptor Ligand Antagonist 52205-73-9 ESTRAMUSTINE PHOSPHATE MECHANISM Modulate gene transcription 52205-73-9 ESTRAMUSTINE PHOSPHATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 52205-73-9 ESTRAMUSTINE PHOSPHATE MECHANISM Inhibit mitosis 4891-15-0 ESTRAMUSTINE PHOSPHATE MODE_CLASS Receptor Agonist 4891-15-0 ESTRAMUSTINE PHOSPHATE MODE_CLASS Receptor Ligand Antagonist 4891-15-0 ESTRAMUSTINE PHOSPHATE MECHANISM Modulate gene transcription 4891-15-0 ESTRAMUSTINE PHOSPHATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 4891-15-0 ESTRAMUSTINE PHOSPHATE MECHANISM Inhibit mitosis 53-16-7 ESTRONE ADVERSE_EFFECT NEU_1_Headache 53-16-7 ESTRONE ADVERSE_EFFECT GIS_1_Abdominal Pain 53-16-7 ESTRONE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 53-16-7 ESTRONE INDICATION Kraurosis Vulvae 53-16-7 ESTRONE MODE_CLASS Endogenous Receptor /Channel Ligand 53-16-7 ESTRONE THERAPEUTIC_CLASS Gonadal Hormones 53-16-7 ESTRONE KNOWN_TOXICITY Carcinogenicity 53-16-7 ESTRONE ADVERSE_EFFECT CVS_2_Hypertension 53-16-7 ESTRONE ADVERSE_EFFECT BIL_2_Gallbladder Disease 53-16-7 ESTRONE ADVERSE_EFFECT MSK_1_Back Pain 53-16-7 ESTRONE TISSUE_TOXICITY Thromboembolism 53-16-7 ESTRONE ADVERSE_EFFECT END_2_Glucose Intolerance 53-16-7 ESTRONE INDICATION Atrophic Vaginitis 53-16-7 ESTRONE INDICATION Primary Ovarian Failure 53-16-7 ESTRONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 53-16-7 ESTRONE ADVERSE_EFFECT DNA_2_Hepatic Adenoma 53-16-7 ESTRONE ADVERSE_EFFECT DNA_1_Carcinogenicity 53-16-7 ESTRONE ADVERSE_EFFECT CVS_2_Thromboembolism 53-16-7 ESTRONE ADVERSE_EFFECT GUS_2_Genital Moniliasis 53-16-7 ESTRONE TISSUE_TOXICITY Hepatic Adenoma 53-16-7 ESTRONE INDICATION Menopausal Vasomotor Symptoms 53-16-7 ESTRONE INDICATION Female Castration 53-16-7 ESTRONE ADVERSE_EFFECT ELT_2_Hypercalcemia 53-16-7 ESTRONE ADVERSE_EFFECT GUS_2_Genital Pruritis 53-16-7 ESTRONE TISSUE_TOXICITY Carcinogenicity 53-16-7 ESTRONE STRUCTURE_ACTIVITY Estrogen receptor agonist, steroidal 53-16-7 ESTRONE MECHANISM Modulate gene transcription 53-16-7 ESTRONE INDICATION Female Hypogonadism 53-16-7 ESTRONE KNOWN_TOXICITY Cardiovascular Toxicity 481-97-0 ESTRONE 3-SULFATE THERAPEUTIC_CLASS Gonadal Hormones 481-97-0 ESTRONE 3-SULFATE MECHANISM Modulate gene transcription 481-97-0 ESTRONE 3-SULFATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 481-97-0 ESTRONE 3-SULFATE MODE_CLASS Endogenous Receptor /Channel Ligand 438-67-5 ESTRONE 3-SULFATE THERAPEUTIC_CLASS Gonadal Hormones 438-67-5 ESTRONE 3-SULFATE MODE_CLASS Endogenous Receptor /Channel Ligand 438-67-5 ESTRONE 3-SULFATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 438-67-5 ESTRONE 3-SULFATE MECHANISM Modulate gene transcription 74-55-5 ETHAMBUTOL INDICATION Nontuberculous Atypical Mycobacterial Diseases 74-55-5 ETHAMBUTOL ADVERSE_EFFECT NEU_3_Dizziness 74-55-5 ETHAMBUTOL ADVERSE_EFFECT MSK_3_Arthralgia 74-55-5 ETHAMBUTOL ADVERSE_EFFECT GIS_3_Abdominal Pain 74-55-5 ETHAMBUTOL MESH_LEVEL_3 Polyamines 74-55-5 ETHAMBUTOL TISSUE_TOXICITY Optic Neuritis 74-55-5 ETHAMBUTOL MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 74-55-5 ETHAMBUTOL ADVERSE_EFFECT PSY_3_Confusion 74-55-5 ETHAMBUTOL KNOWN_TOXICITY Nephrotoxicity 74-55-5 ETHAMBUTOL TA_LEVEL_1 Infectious Disease 74-55-5 ETHAMBUTOL MECH_LEVEL_3 Indolylacetylinositol arabinosyltransferase 74-55-5 ETHAMBUTOL THERAPEUTIC_CLASS Antibacterials, Systemic 74-55-5 ETHAMBUTOL TA_LEVEL_2 Anti-bacterial 74-55-5 ETHAMBUTOL ZERO_CLASS N 74-55-5 ETHAMBUTOL PRODUCT_CLASS Anti-infectives 74-55-5 ETHAMBUTOL ACTIVITY_CLASS Antibiotic 74-55-5 ETHAMBUTOL INDICATION Mycobacterium Avium Complex (MAC) Prophylaxis 74-55-5 ETHAMBUTOL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 74-55-5 ETHAMBUTOL TISSUE_TOXICITY Interstitial Nephritis 74-55-5 ETHAMBUTOL KNOWN_TOXICITY Neurotoxicity 74-55-5 ETHAMBUTOL MODE_CLASS Enzyme Inhibitor 74-55-5 ETHAMBUTOL ADVERSE_EFFECT NEU_3_Headache 74-55-5 ETHAMBUTOL TA_LEVEL_3 systemic infections 74-55-5 ETHAMBUTOL ADVERSE_EFFECT NEU_1_Optic Neuritis 74-55-5 ETHAMBUTOL ADVERSE_EFFECT KID_3_Azotemia 74-55-5 ETHAMBUTOL STRUCTURE_ACTIVITY Indolylacetylinositol arabinosyltransferase inhibitor 74-55-5 ETHAMBUTOL ADVERSE_EFFECT XXX_3_Fever 74-55-5 ETHAMBUTOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 74-55-5 ETHAMBUTOL ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 74-55-5 ETHAMBUTOL INDICATION Mycobacterium Tuberculosis Infections 74-55-5 ETHAMBUTOL ADVERSE_EFFECT BBM_3_Thrombocytopenia 74-55-5 ETHAMBUTOL ADVERSE_EFFECT XXX_3_Malaise 74-55-5 ETHAMBUTOL INDICATION Tuberculosis 74-55-5 ETHAMBUTOL MESH_LEVEL_2 Amines 74-55-5 ETHAMBUTOL MECH_LEVEL_1 Cell wall biosynthesis inhibitor 74-55-5 ETHAMBUTOL MESH_LEVEL_1 Organic Chemicals 74-55-5 ETHAMBUTOL ADVERSE_EFFECT KID_2_Hyperuricemia 74-55-5 ETHAMBUTOL ADVERSE_EFFECT KID_3_Proteinuria 74-55-5 ETHAMBUTOL ADVERSE_EFFECT KID_3_Interstitial Nephritis 74-55-5 ETHAMBUTOL MECH_LEVEL_2 Cell wall biosynthesis inhibitor 2272-11-9 MONOETHANOLAMINE OLEATE INDICATION Atherosclerosis 2272-11-9 MONOETHANOLAMINE OLEATE PRODUCT_CLASS Cardiovasculars 2272-11-9 MONOETHANOLAMINE OLEATE THERAPEUTIC_CLASS Hypolipidemic Agents 985-13-7 ETHAVERINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 985-13-7 ETHAVERINE ADVERSE_EFFECT NEU_2_Drowsiness 985-13-7 ETHAVERINE PRODUCT_CLASS Cardiovasculars 985-13-7 ETHAVERINE INDICATION Bladder Spasm 985-13-7 ETHAVERINE MECHANISM Prolong/enhance neural transmission 985-13-7 ETHAVERINE KNOWN_TOXICITY Cardiovascular Toxicity 985-13-7 ETHAVERINE TISSUE_TOXICITY Hypotension 985-13-7 ETHAVERINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker 985-13-7 ETHAVERINE ADVERSE_EFFECT NEU_1_Dizziness 985-13-7 ETHAVERINE ADVERSE_EFFECT CVS_1_Hypotension 985-13-7 ETHAVERINE ADVERSE_EFFECT SKN_1_Flushing 985-13-7 ETHAVERINE ADVERSE_EFFECT XXX_2_Malaise 985-13-7 ETHAVERINE ADVERSE_EFFECT LUN_3_Respiratory Depression 985-13-7 ETHAVERINE ADVERSE_EFFECT PSY_2_Anorexia 985-13-7 ETHAVERINE PRODUCT_CLASS Autonomic Nervous System (ANS) 985-13-7 ETHAVERINE MODE_CLASS Channel Blocker 985-13-7 ETHAVERINE TISSUE_TOXICITY Cardiac Arrhythmia 985-13-7 ETHAVERINE ADVERSE_EFFECT GIS_3_Abdominal Distress 985-13-7 ETHAVERINE ADVERSE_EFFECT XXX_2_Sweating 985-13-7 ETHAVERINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 985-13-7 ETHAVERINE MECHANISM Reduce muscle contractile force 985-13-7 ETHAVERINE INDICATION Peripheral Vascular Disease 985-13-7 ETHAVERINE MODE_CLASS Enzyme Inhibitor 985-13-7 ETHAVERINE THERAPEUTIC_CLASS Vasodilators 985-13-7 ETHAVERINE INDICATION Cerebrovascular Insufficiency 985-13-7 ETHAVERINE THERAPEUTIC_CLASS Antispasmodic Agents 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT GIS_2_Vomiting 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT END_1_Breast Tenderness 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT REP_2_Altered Libido 57-63-6 ETHINYLESTRADIOL INDICATION Female Hypogonadism 57-63-6 ETHINYLESTRADIOL INDICATION Breast Cancer / Carcinoma of the Breast 57-63-6 ETHINYLESTRADIOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 57-63-6 ETHINYLESTRADIOL MECH_LEVEL_2 estrogen receptor agonist 57-63-6 ETHINYLESTRADIOL TA_LEVEL_2 Part of birth control combination 57-63-6 ETHINYLESTRADIOL MESH_LEVEL_2 Steroids 57-63-6 ETHINYLESTRADIOL TA_LEVEL_3 SERM 57-63-6 ETHINYLESTRADIOL THERAPEUTIC_CLASS Gonadal Hormones 57-63-6 ETHINYLESTRADIOL STRUCTURE_ACTIVITY Estrogen receptor agonist, steroidal 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT GIS_1_Nausea 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT XXX_1_Decreased Appetite 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT XXX_1_Weight Gain 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT GIS_1_Abdominal Cramps 57-63-6 ETHINYLESTRADIOL MECH_LEVEL_3 estrogen receptor 57-63-6 ETHINYLESTRADIOL MECH_LEVEL_1 Hormone replacement 57-63-6 ETHINYLESTRADIOL INDICATION Menopausal Vasomotor Symptoms 57-63-6 ETHINYLESTRADIOL INDICATION Kraurosis Vulvae 57-63-6 ETHINYLESTRADIOL MODE_CLASS Receptor Agonist 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT GIS_2_Diarrhea 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT NEU_2_Dizziness 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT REP_3_Amenorrhea 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT NEU_2_Migraine 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT GUS_3_Vaginal Bleeding 57-63-6 ETHINYLESTRADIOL ZERO_CLASS N 57-63-6 ETHINYLESTRADIOL MECHANISM Modulate gene transcription 57-63-6 ETHINYLESTRADIOL MESH_LEVEL_3 Norsteroids 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT LIV_3_Hepatitis 57-63-6 ETHINYLESTRADIOL INDICATION Prostatic Cancer / Carcinoma of the Prostate 57-63-6 ETHINYLESTRADIOL INDICATION Atrophic Vaginitis 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT NEU_2_Headache 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT XXX_1_Peripheral Edema 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT CVS_3_Thromboembolism 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT XXX_1_Breast Enlargement 57-63-6 ETHINYLESTRADIOL INDICATION Turner's Syndrome / Gonadal Dysgenesis 57-63-6 ETHINYLESTRADIOL INDICATION Osteoporosis 57-63-6 ETHINYLESTRADIOL PRODUCT_CLASS Anti-cancers 57-63-6 ETHINYLESTRADIOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 57-63-6 ETHINYLESTRADIOL TISSUE_TOXICITY Thromboembolism 57-63-6 ETHINYLESTRADIOL KNOWN_TOXICITY Cardiovascular Toxicity 57-63-6 ETHINYLESTRADIOL ACTIVITY_CLASS Estrogen agonist 57-63-6 ETHINYLESTRADIOL MESH_LEVEL_1 Polycyclic Hydrocarbons 57-63-6 ETHINYLESTRADIOL ADVERSE_EFFECT GIS_1_Bloating 536-33-4 ETHIONAMIDE ADVERSE_EFFECT NEU_3_Peripheral Neuritis 536-33-4 ETHIONAMIDE ADVERSE_EFFECT XXX_2_Restlessness 536-33-4 ETHIONAMIDE ADVERSE_EFFECT SKN_3_Rash 536-33-4 ETHIONAMIDE ADVERSE_EFFECT END_3_Hypoglycemia 536-33-4 ETHIONAMIDE ADVERSE_EFFECT XXX_2_Salivation 536-33-4 ETHIONAMIDE STRUCTURE_ACTIVITY Mycolic acid biosynthesis inhibitor 536-33-4 ETHIONAMIDE THERAPEUTIC_CLASS Antibacterials, Systemic 536-33-4 ETHIONAMIDE ADVERSE_EFFECT LIV_1_Increased Liver Function Tests 536-33-4 ETHIONAMIDE ADVERSE_EFFECT XXX_2_Asthenia 536-33-4 ETHIONAMIDE ADVERSE_EFFECT NEU_3_Optic Neuritis 536-33-4 ETHIONAMIDE ADVERSE_EFFECT XXX_2_Weight Loss 536-33-4 ETHIONAMIDE ADVERSE_EFFECT NEU_2_Drowsiness 536-33-4 ETHIONAMIDE ADVERSE_EFFECT REP_3_Impotence 536-33-4 ETHIONAMIDE ADVERSE_EFFECT OCU_3_Blurred Vision 536-33-4 ETHIONAMIDE INDICATION Nontuberculous Atypical Mycobacterial Diseases 536-33-4 ETHIONAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 536-33-4 ETHIONAMIDE ADVERSE_EFFECT END_2_Difficulty in Diabetes Control 536-33-4 ETHIONAMIDE ADVERSE_EFFECT GIS_2_Gastritis 536-33-4 ETHIONAMIDE ADVERSE_EFFECT GIS_2_Stomatitis 536-33-4 ETHIONAMIDE ADVERSE_EFFECT PSY_3_Mental Depression 536-33-4 ETHIONAMIDE ADVERSE_EFFECT END_3_Gynecomastia 536-33-4 ETHIONAMIDE ADVERSE_EFFECT NEU_2_Headache 536-33-4 ETHIONAMIDE ADVERSE_EFFECT PSY_2_Anorexia 536-33-4 ETHIONAMIDE INDICATION Leprosy 536-33-4 ETHIONAMIDE INDICATION Tuberculosis 536-33-4 ETHIONAMIDE PRODUCT_CLASS Anti-infectives 536-33-4 ETHIONAMIDE ADVERSE_EFFECT BBM_3_Purpura 536-33-4 ETHIONAMIDE ADVERSE_EFFECT GIS_2_Metallic Taste 536-33-4 ETHIONAMIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 536-33-4 ETHIONAMIDE ADVERSE_EFFECT OCU_3_Diplopia 536-33-4 ETHIONAMIDE ADVERSE_EFFECT NEU_1_Dizziness 536-33-4 ETHIONAMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 536-33-4 ETHIONAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 536-33-4 ETHIONAMIDE ADVERSE_EFFECT END_3_Pellagra-Like Syndrome 536-33-4 ETHIONAMIDE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 536-33-4 ETHIONAMIDE ADVERSE_EFFECT END_2_Goiter 536-33-4 ETHIONAMIDE ADVERSE_EFFECT CVS_2_Postural Hypotension 77-67-8 ETHOSUXIMIDE MECH_LEVEL_1 Modulate neural transmission 77-67-8 ETHOSUXIMIDE TA_LEVEL_1 Central Nervous System (CNS) 77-67-8 ETHOSUXIMIDE MESH_LEVEL_1 Heterocyclic Compounds 77-67-8 ETHOSUXIMIDE INDICATION Absence (Petit Mal) Seizures 77-67-8 ETHOSUXIMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 77-67-8 ETHOSUXIMIDE MODE_CLASS Channel Blocker, selective 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT END_3_Hirsutism 77-67-8 ETHOSUXIMIDE MECH_LEVEL_2 Decrease neural membrane excitability 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 77-67-8 ETHOSUXIMIDE MESH_LEVEL_3 Pyrrolidines 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT PSY_2_Irritability 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Epigastric Pain 77-67-8 ETHOSUXIMIDE PRODUCT_CLASS Central Nervous System (CNS) 77-67-8 ETHOSUXIMIDE TA_LEVEL_3 Absence Seizures 77-67-8 ETHOSUXIMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT GIS_3_Gingival Hyperplasia 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT PSY_2_Euphoria 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT GIS_3_Swelling of Tongue 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Diarrhea 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT NEU_1_Headache 77-67-8 ETHOSUXIMIDE MECH_LEVEL_3 T-Type Ca++ channel CaV3.3 77-67-8 ETHOSUXIMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT NEU_3_Ataxia 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT PSY_3_Psychosis 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT SKN_2_Skin Rash 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT PSY_3_Depression 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 77-67-8 ETHOSUXIMIDE ACTIVITY_CLASS Na+ channel blocker 77-67-8 ETHOSUXIMIDE TA_LEVEL_2 CNS Depressant 77-67-8 ETHOSUXIMIDE MECHANISM Reduce muscle contractile force 77-67-8 ETHOSUXIMIDE ZERO_CLASS N 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT NEU_1_Drowsiness 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 77-67-8 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Leukopenia 39122-18-4 ETHOSUXIMIDE MECH_LEVEL_3 T-Type Ca++ channel CaV3.3 39122-18-4 ETHOSUXIMIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT NEU_3_Ataxia 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT PSY_3_Psychosis 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT SKN_2_Skin Rash 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT PSY_3_Depression 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 39122-18-4 ETHOSUXIMIDE ACTIVITY_CLASS Na+ channel blocker 39122-18-4 ETHOSUXIMIDE TA_LEVEL_2 CNS Depressant 39122-18-4 ETHOSUXIMIDE MECHANISM Reduce muscle contractile force 39122-18-4 ETHOSUXIMIDE ZERO_CLASS N 39122-18-4 ETHOSUXIMIDE PRODUCT_CLASS Central Nervous System (CNS) 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Leukopenia 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Diarrhea 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT NEU_1_Headache 39122-18-4 ETHOSUXIMIDE MECH_LEVEL_1 Modulate neural transmission 39122-18-4 ETHOSUXIMIDE TA_LEVEL_1 Central Nervous System (CNS) 39122-18-4 ETHOSUXIMIDE MESH_LEVEL_1 Heterocyclic Compounds 39122-18-4 ETHOSUXIMIDE INDICATION Absence (Petit Mal) Seizures 39122-18-4 ETHOSUXIMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 39122-18-4 ETHOSUXIMIDE MODE_CLASS Channel Blocker, selective 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT END_3_Hirsutism 39122-18-4 ETHOSUXIMIDE MECH_LEVEL_2 Decrease neural membrane excitability 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 39122-18-4 ETHOSUXIMIDE MESH_LEVEL_3 Pyrrolidines 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT PSY_2_Irritability 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Epigastric Pain 39122-18-4 ETHOSUXIMIDE TA_LEVEL_3 Absence Seizures 39122-18-4 ETHOSUXIMIDE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT GIS_3_Gingival Hyperplasia 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT PSY_2_Euphoria 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT GIS_3_Swelling of Tongue 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT NEU_1_Drowsiness 39122-18-4 ETHOSUXIMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 333-18-6 ETHYLENEDIAMINE THERAPEUTIC_CLASS Drug Delivery Systems 333-18-6 ETHYLENEDIAMINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 333-18-6 ETHYLENEDIAMINE ADVERSE_EFFECT IMU_3_Urticaria 333-18-6 ETHYLENEDIAMINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 120-47-8 ETHYLPARABEN THERAPEUTIC_CLASS Antiseptics / Disinfectants 120-47-8 ETHYLPARABEN PRODUCT_CLASS Anti-infectives 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT CVS_3_Thromboembolism 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT CVS_3_Cerebrovascular Accident 297-76-7 ETHYNODIOL DIACETATE MODE_CLASS Receptor Agonist 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT END_2_Decreases HDL 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT REP_1_Intermenstrual Bleeding 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT END_1_Breast Tenderness 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT CVS_3_Myocardial Infarction 297-76-7 ETHYNODIOL DIACETATE TISSUE_TOXICITY Myocardial Infarction 297-76-7 ETHYNODIOL DIACETATE TISSUE_TOXICITY Cerebrovascular Accident 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 297-76-7 ETHYNODIOL DIACETATE STRUCTURE_ACTIVITY Progesterone receptor agonist 297-76-7 ETHYNODIOL DIACETATE TISSUE_TOXICITY Thromboembolism 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT END_2_Glucose Intolerance 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT END_2_Hyperlipidemia 297-76-7 ETHYNODIOL DIACETATE KNOWN_TOXICITY Cardiovascular Toxicity 297-76-7 ETHYNODIOL DIACETATE THERAPEUTIC_CLASS Contraceptive Hormones 297-76-7 ETHYNODIOL DIACETATE MECHANISM Modulate gene transcription 297-76-7 ETHYNODIOL DIACETATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT END_2_Increases LDL 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT KID_2_Fluid Retention 297-76-7 ETHYNODIOL DIACETATE ADVERSE_EFFECT XXX_1_Weight Gain 297-76-7 ETHYNODIOL DIACETATE INDICATION Contraception 36637-18-0 ETIDOCAINE THERAPEUTIC_CLASS Local Anesthetics 36637-18-0 ETIDOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 36637-18-0 ETIDOCAINE PRODUCT_CLASS Central Nervous System (CNS) 36637-18-0 ETIDOCAINE MECHANISM Block neural transmission 36637-18-0 ETIDOCAINE MODE_CLASS Channel Blocker 2809-21-4 ETIDRONATE ADVERSE_EFFECT GIS_2_Esophagitis 2809-21-4 ETIDRONATE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 2809-21-4 ETIDRONATE ADVERSE_EFFECT NEU_1_Headache 2809-21-4 ETIDRONATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 2809-21-4 ETIDRONATE MESH_LEVEL_1 Organic Chemicals 2809-21-4 ETIDRONATE ADVERSE_EFFECT MSK_2_Arthropathy 2809-21-4 ETIDRONATE MESH_LEVEL_3 Diphosphonates 2809-21-4 ETIDRONATE TA_LEVEL_3 Bisphosphonate 2809-21-4 ETIDRONATE TA_LEVEL_2 Oesteoporosis 2809-21-4 ETIDRONATE INDICATION Paget's Disease of Bone / Osteitis Deformans 2809-21-4 ETIDRONATE MECH_LEVEL_2 Inhibit osteoclastic bone resorption via cholesterol biosynthesis pathway 2809-21-4 ETIDRONATE INDICATION Osteoporosis 2809-21-4 ETIDRONATE MESH_LEVEL_2 Organophosphorus Compounds 2809-21-4 ETIDRONATE KNOWN_TOXICITY Embryo/Fetal Toxicity 2809-21-4 ETIDRONATE ADVERSE_EFFECT GIS_1_Nausea 2809-21-4 ETIDRONATE ADVERSE_EFFECT PSY_3_Confusion 2809-21-4 ETIDRONATE ADVERSE_EFFECT BBM_3_Pancytopenia 2809-21-4 ETIDRONATE ADVERSE_EFFECT GIS_2_Exacerbation of Peptic Ulcer Disease 2809-21-4 ETIDRONATE ADVERSE_EFFECT NEU_3_Paresthesia 2809-21-4 ETIDRONATE ADVERSE_EFFECT END_3_Osteomalacia 2809-21-4 ETIDRONATE ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 2809-21-4 ETIDRONATE INDICATION Heterotopic Ossification 2809-21-4 ETIDRONATE MODE_CLASS Enzyme Inhibitor 2809-21-4 ETIDRONATE ZERO_CLASS N 2809-21-4 ETIDRONATE ADVERSE_EFFECT MSK_2_Increased Risk of Bone Fracture 2809-21-4 ETIDRONATE ADVERSE_EFFECT GIS_1_Diarrhea 2809-21-4 ETIDRONATE ADVERSE_EFFECT BBM_3_Agranulocytosis 2809-21-4 ETIDRONATE ADVERSE_EFFECT MSK_1_Bone Pain 2809-21-4 ETIDRONATE ADVERSE_EFFECT GIS_2_Gastritis 2809-21-4 ETIDRONATE ADVERSE_EFFECT END_2_Hyperphosphatemia 2809-21-4 ETIDRONATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 2809-21-4 ETIDRONATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 2809-21-4 ETIDRONATE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 2809-21-4 ETIDRONATE TISSUE_TOXICITY Teratogenicity 2809-21-4 ETIDRONATE ADVERSE_EFFECT NEU_3_Amnesia 2809-21-4 ETIDRONATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 2809-21-4 ETIDRONATE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 2809-21-4 ETIDRONATE INDICATION Hypercalcemia of Malignancy 2809-21-4 ETIDRONATE MECHANISM Inhibit bone re-absorption 2809-21-4 ETIDRONATE MECH_LEVEL_1 Inhibit bone re-absorption 2809-21-4 ETIDRONATE MECH_LEVEL_3 Farnesyl-diphosphate farnesyltransferase 2809-21-4 ETIDRONATE ADVERSE_EFFECT EMB_3_Teratogenicity 7414-83-7 ETIDRONATE INDICATION Paget's Disease of Bone / Osteitis Deformans 7414-83-7 ETIDRONATE TA_LEVEL_2 Oesteoporosis 7414-83-7 ETIDRONATE TA_LEVEL_3 Bisphosphonate 7414-83-7 ETIDRONATE MESH_LEVEL_3 Diphosphonates 7414-83-7 ETIDRONATE ADVERSE_EFFECT MSK_1_Bone Pain 7414-83-7 ETIDRONATE ZERO_CLASS N 7414-83-7 ETIDRONATE ADVERSE_EFFECT MSK_2_Increased Risk of Bone Fracture 7414-83-7 ETIDRONATE ADVERSE_EFFECT GIS_2_Esophagitis 7414-83-7 ETIDRONATE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 7414-83-7 ETIDRONATE ADVERSE_EFFECT NEU_1_Headache 7414-83-7 ETIDRONATE ADVERSE_EFFECT EMB_3_Teratogenicity 7414-83-7 ETIDRONATE KNOWN_TOXICITY Embryo/Fetal Toxicity 7414-83-7 ETIDRONATE TISSUE_TOXICITY Teratogenicity 7414-83-7 ETIDRONATE TA_LEVEL_1 Hormones, Endocrine and Metabolic 7414-83-7 ETIDRONATE PRODUCT_CLASS Hormones, Endocrine and Metabolic 7414-83-7 ETIDRONATE ADVERSE_EFFECT END_2_Hyperphosphatemia 7414-83-7 ETIDRONATE ADVERSE_EFFECT GIS_2_Gastritis 7414-83-7 ETIDRONATE ADVERSE_EFFECT BBM_3_Agranulocytosis 7414-83-7 ETIDRONATE ADVERSE_EFFECT GIS_1_Diarrhea 7414-83-7 ETIDRONATE THERAPEUTIC_CLASS Bone Mineral Homeostasis 7414-83-7 ETIDRONATE MODE_CLASS Enzyme Inhibitor 7414-83-7 ETIDRONATE INDICATION Heterotopic Ossification 7414-83-7 ETIDRONATE MESH_LEVEL_1 Organic Chemicals 7414-83-7 ETIDRONATE ADVERSE_EFFECT LUN_2_Exacerbation of Asthma 7414-83-7 ETIDRONATE ADVERSE_EFFECT END_3_Osteomalacia 7414-83-7 ETIDRONATE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 7414-83-7 ETIDRONATE ADVERSE_EFFECT NEU_3_Paresthesia 7414-83-7 ETIDRONATE ADVERSE_EFFECT NEU_3_Amnesia 7414-83-7 ETIDRONATE STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 7414-83-7 ETIDRONATE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 7414-83-7 ETIDRONATE INDICATION Hypercalcemia of Malignancy 7414-83-7 ETIDRONATE MECHANISM Inhibit bone re-absorption 7414-83-7 ETIDRONATE MECH_LEVEL_1 Inhibit bone re-absorption 7414-83-7 ETIDRONATE MECH_LEVEL_3 Farnesyl-diphosphate farnesyltransferase 7414-83-7 ETIDRONATE ADVERSE_EFFECT GIS_2_Exacerbation of Peptic Ulcer Disease 7414-83-7 ETIDRONATE ADVERSE_EFFECT MSK_2_Arthropathy 7414-83-7 ETIDRONATE ADVERSE_EFFECT BBM_3_Pancytopenia 7414-83-7 ETIDRONATE ADVERSE_EFFECT PSY_3_Confusion 7414-83-7 ETIDRONATE ADVERSE_EFFECT GIS_1_Nausea 7414-83-7 ETIDRONATE MESH_LEVEL_2 Organophosphorus Compounds 7414-83-7 ETIDRONATE INDICATION Osteoporosis 7414-83-7 ETIDRONATE MECH_LEVEL_2 Inhibit osteoclastic bone resorption via cholesterol biosynthesis pathway 41340-25-4 ETODOLAC INDICATION Pain 41340-25-4 ETODOLAC MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 41340-25-4 ETODOLAC MODE_CLASS Enzyme Inhibitor 41340-25-4 ETODOLAC ADVERSE_EFFECT LUN_3_Pulmonary Infiltrates 41340-25-4 ETODOLAC ADVERSE_EFFECT LIV_3_Hepatic Failure 41340-25-4 ETODOLAC ADVERSE_EFFECT SKN_1_Skin Rash 41340-25-4 ETODOLAC TISSUE_TOXICITY Hepatic Necrosis 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 41340-25-4 ETODOLAC ADVERSE_EFFECT BBM_3_Anemia 41340-25-4 ETODOLAC ACTIVITY_CLASS Anti-inflammatory 41340-25-4 ETODOLAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 41340-25-4 ETODOLAC ADVERSE_EFFECT KID_3_Renal Failure 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_3_Pancreatitis 41340-25-4 ETODOLAC ADVERSE_EFFECT CVS_2_Hypertension 41340-25-4 ETODOLAC MESH_LEVEL_3 Indoles 41340-25-4 ETODOLAC ADVERSE_EFFECT NEU_1_Dizziness 41340-25-4 ETODOLAC KNOWN_TOXICITY Nephrotoxicity 41340-25-4 ETODOLAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 41340-25-4 ETODOLAC INDICATION Musculoskeletal Pain 41340-25-4 ETODOLAC TISSUE_TOXICITY Hepatic Failure 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 41340-25-4 ETODOLAC ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 41340-25-4 ETODOLAC ADVERSE_EFFECT KID_3_Interstitial Nephritis 41340-25-4 ETODOLAC ADVERSE_EFFECT CVS_2_Vasculitis 41340-25-4 ETODOLAC KNOWN_TOXICITY Hepatotoxicity 41340-25-4 ETODOLAC INDICATION Osteoarthritis 41340-25-4 ETODOLAC PRODUCT_CLASS Anti-inflammatories 41340-25-4 ETODOLAC MECH_LEVEL_1 Immunomodulation 41340-25-4 ETODOLAC ZERO_CLASS N 41340-25-4 ETODOLAC ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 41340-25-4 ETODOLAC MESH_LEVEL_1 Heterocyclic Compounds 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_1_Diarrhea 41340-25-4 ETODOLAC MECHANISM Inhibit eicosanoid biosynthesis 41340-25-4 ETODOLAC TA_LEVEL_1 Anti-inflammatory 41340-25-4 ETODOLAC TA_LEVEL_2 NSAID 41340-25-4 ETODOLAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 41340-25-4 ETODOLAC INDICATION Rheumatoid Arthritis 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_2_Abdominal Pain 41340-25-4 ETODOLAC ADVERSE_EFFECT LIV_3_Hepatic Necrosis 41340-25-4 ETODOLAC ADVERSE_EFFECT PSY_3_Depression 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_2_Peptic Ulceration 41340-25-4 ETODOLAC ADVERSE_EFFECT GIS_3_Gastrointestinal Perforation 41340-25-4 ETODOLAC ADVERSE_EFFECT KID_1_Fluid Retention 41340-25-4 ETODOLAC ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 41340-25-4 ETODOLAC TISSUE_TOXICITY Renal Failure 41340-25-4 ETODOLAC STRUCTURE_ACTIVITY NSAID, COX-1/2, heterogenous 41340-25-4 ETODOLAC TA_LEVEL_3 NSAID 41340-25-4 ETODOLAC TISSUE_TOXICITY Interstitial Nephritis 41340-25-4 ETODOLAC TISSUE_TOXICITY Renal Papillary Necrosis 41340-25-4 ETODOLAC ADVERSE_EFFECT LUN_3_Bronchospasm 41340-25-4 ETODOLAC ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 41340-25-4 ETODOLAC ADVERSE_EFFECT IMU_3_Anaphylaxis 41340-25-4 ETODOLAC ADVERSE_EFFECT EMB_2_Premature Closure of Ductus Arteriosus 33125-97-2 ETOMIDATE MECHANISM Modulate neural transmission 33125-97-2 ETOMIDATE MODE_CLASS Channel Modulator 33125-97-2 ETOMIDATE MECHANISM Prolong/enhance neural transmission 33125-97-2 ETOMIDATE MODE_CLASS Channel Blocker 33125-97-2 ETOMIDATE MECHANISM Modulate channel gating 33125-97-2 ETOMIDATE MODE_CLASS Channel enhancer /opener 33125-97-2 ETOMIDATE MECHANISM Inhibit absorption of dietary carbohydrates 33125-97-2 ETOMIDATE MODE_CLASS Solute transporter inhibitor 54350-48-0 ETRETINATE MODE_CLASS Enzyme Inhibitor 54350-48-0 ETRETINATE THERAPEUTIC_CLASS Psoralens 54350-48-0 ETRETINATE PRODUCT_CLASS Dermatologicals 54350-48-0 ETRETINATE MECHANISM Enhance kinase mediated signal transduction 54350-48-0 ETRETINATE MECHANISM Inhibit precursor synthesis 54350-48-0 ETRETINATE INDICATION Psoriasis 54350-48-0 ETRETINATE MODE_CLASS Enzyme Activator 97-53-0 EUGENOL PRODUCT_CLASS Other Human Uses 97-53-0 EUGENOL MECHANISM Inhibit DNA synthesis, repair, and function 97-53-0 EUGENOL PRODUCT_CLASS Anti-infectives 97-53-0 EUGENOL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 97-53-0 EUGENOL ADVERSE_EFFECT IMU_3_Contact Dermatitis 97-53-0 EUGENOL THERAPEUTIC_CLASS Antiseptics / Disinfectants 97-53-0 EUGENOL INDICATION Dental Antisepsis 104227-87-4 FAMCICLOVIR MODE_CLASS Enzyme Inhibitor, selective 104227-87-4 FAMCICLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 104227-87-4 FAMCICLOVIR TA_LEVEL_2 Anti-viral 104227-87-4 FAMCICLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 104227-87-4 FAMCICLOVIR MECH_LEVEL_1 Anti-viral 104227-87-4 FAMCICLOVIR TA_LEVEL_1 Infectious Disease 104227-87-4 FAMCICLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 104227-87-4 FAMCICLOVIR ACTIVITY_CLASS Anti-viral 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT PSY_3_Hallucinations 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT BBM_2_Anemia 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT BBM_2_Neutropenia 104227-87-4 FAMCICLOVIR TA_LEVEL_3 viral replication inhibitor 104227-87-4 FAMCICLOVIR INDICATION Herpes Simplex Infection 104227-87-4 FAMCICLOVIR THERAPEUTIC_CLASS Antivirals 104227-87-4 FAMCICLOVIR MESH_LEVEL_3 Purines 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT BBM_2_Leukopenia 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT NEU_1_Headache 104227-87-4 FAMCICLOVIR MESH_LEVEL_1 Heterocyclic Compounds 104227-87-4 FAMCICLOVIR PRODUCT_CLASS Anti-infectives 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT DNA_2_Carcinogenicity 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT GIS_2_Nausea 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT SKN_2_Rash 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT PSY_3_Disorientation 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT REP_2_Testicular Toxicity 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT NEU_2_Migraine 104227-87-4 FAMCICLOVIR ZERO_CLASS N 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT REP_3_Dysmenorrhea 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT GIS_3_Abdominal Pain 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT IMU_3_Urticaria 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT NEU_1_Paresthesia 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT GIS_1_Vomiting 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT GIS_2_Diarrhea 104227-87-4 FAMCICLOVIR KNOWN_TOXICITY Carcinogenicity 104227-87-4 FAMCICLOVIR MECHANISM Inhibit viral DNA synthesis 104227-87-4 FAMCICLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 104227-87-4 FAMCICLOVIR INDICATION Herpes Zoster / Shingles 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT GIS_2_Flatulence 104227-87-4 FAMCICLOVIR TISSUE_TOXICITY Carcinogenicity 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT SKN_1_Pruritis 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT XXX_1_Fatigue 104227-87-4 FAMCICLOVIR ADVERSE_EFFECT PSY_3_Delirium 104227-87-4 FAMCICLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 76824-35-6 FAMOTIDINE TA_LEVEL_2 Duodenal ulcer treatment 76824-35-6 FAMOTIDINE MECH_LEVEL_3 histamine receptor H2 76824-35-6 FAMOTIDINE INDICATION Gastric Ulcer 76824-35-6 FAMOTIDINE TA_LEVEL_1 Gastrointestinal System 76824-35-6 FAMOTIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 76824-35-6 FAMOTIDINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 76824-35-6 FAMOTIDINE ADVERSE_EFFECT IMU_2_Anaphylaxis 76824-35-6 FAMOTIDINE ADVERSE_EFFECT IMU_2_Urticaria 76824-35-6 FAMOTIDINE STRUCTURE_ACTIVITY Histamine receptor (H2) antagonist 76824-35-6 FAMOTIDINE ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 76824-35-6 FAMOTIDINE INDICATION Multiple Endocrine Neoplasia (MEN) 76824-35-6 FAMOTIDINE INDICATION Duodenal Ulcer 76824-35-6 FAMOTIDINE ADVERSE_EFFECT GIS_1_Constipation 76824-35-6 FAMOTIDINE ADVERSE_EFFECT OTO_3_Tinnitus 76824-35-6 FAMOTIDINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 76824-35-6 FAMOTIDINE ADVERSE_EFFECT BBM_3_Leukopenia 76824-35-6 FAMOTIDINE ADVERSE_EFFECT BBM_3_Pancytopenia 76824-35-6 FAMOTIDINE ZERO_CLASS N 76824-35-6 FAMOTIDINE ACTIVITY_CLASS Histamine antagonist 76824-35-6 FAMOTIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 76824-35-6 FAMOTIDINE MECH_LEVEL_1 Ulcer healing 76824-35-6 FAMOTIDINE INDICATION Gastroesophageal Reflux Disease (GERD) 76824-35-6 FAMOTIDINE PRODUCT_CLASS Gastrointestinal System 76824-35-6 FAMOTIDINE MECH_LEVEL_2 Reduce stomach HCl secretion 76824-35-6 FAMOTIDINE ADVERSE_EFFECT XXX_2_Asthenia 76824-35-6 FAMOTIDINE ADVERSE_EFFECT XXX_2_Fever 76824-35-6 FAMOTIDINE ADVERSE_EFFECT NEU_1_Dizziness 76824-35-6 FAMOTIDINE ADVERSE_EFFECT IMU_2_Angioedema 76824-35-6 FAMOTIDINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 76824-35-6 FAMOTIDINE ADVERSE_EFFECT CVS_2_Palpitation 76824-35-6 FAMOTIDINE MESH_LEVEL_3 Thiazoles 76824-35-6 FAMOTIDINE MESH_LEVEL_1 Heterocyclic Compounds 76824-35-6 FAMOTIDINE TA_LEVEL_3 Gastric secretion inhibitors 76824-35-6 FAMOTIDINE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 76824-35-6 FAMOTIDINE THERAPEUTIC_CLASS Antiulcers 76824-35-6 FAMOTIDINE MECHANISM Reduce stomach HCl secretion 76824-35-6 FAMOTIDINE ADVERSE_EFFECT GIS_1_Diarrhea 76824-35-6 FAMOTIDINE ADVERSE_EFFECT NEU_1_Headache 76824-35-6 FAMOTIDINE ADVERSE_EFFECT BBM_3_Agranulocytosis 76824-35-6 FAMOTIDINE ADVERSE_EFFECT MSK_2_Arthralgia 76824-35-6 FAMOTIDINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 25451-15-4 FELBAMATE ADVERSE_EFFECT PSY_1_Anxiety 25451-15-4 FELBAMATE ADVERSE_EFFECT PSY_1_Anorexia 25451-15-4 FELBAMATE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 25451-15-4 FELBAMATE ADVERSE_EFFECT XXX_1_Rhinitis 25451-15-4 FELBAMATE PRODUCT_CLASS Central Nervous System (CNS) 25451-15-4 FELBAMATE INDICATION Epilepsy 25451-15-4 FELBAMATE ADVERSE_EFFECT LIV_3_Hepatic Failure 25451-15-4 FELBAMATE MECHANISM Reduce muscle contractile force 25451-15-4 FELBAMATE TISSUE_TOXICITY Hepatotoxicity 25451-15-4 FELBAMATE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, anticonvulsant 25451-15-4 FELBAMATE ADVERSE_EFFECT PSY_1_Insomnia 25451-15-4 FELBAMATE ADVERSE_EFFECT XXX_1_Fatigue 25451-15-4 FELBAMATE ADVERSE_EFFECT LIV_2_Hepatotoxicity 25451-15-4 FELBAMATE ADVERSE_EFFECT GIS_1_Constipation 25451-15-4 FELBAMATE ADVERSE_EFFECT NEU_1_Tremor 25451-15-4 FELBAMATE ADVERSE_EFFECT BBM_3_Agranulocytosis 25451-15-4 FELBAMATE ADVERSE_EFFECT SKN_2_Maculopapular Rash 25451-15-4 FELBAMATE ADVERSE_EFFECT BBM_3_Aplastic Anemia 25451-15-4 FELBAMATE ADVERSE_EFFECT GIS_1_Abdominal Pain 25451-15-4 FELBAMATE ADVERSE_EFFECT GIS_1_Dysgeusia 25451-15-4 FELBAMATE TISSUE_TOXICITY Hepatic Failure 25451-15-4 FELBAMATE KNOWN_TOXICITY Hepatotoxicity 25451-15-4 FELBAMATE ADVERSE_EFFECT BBM_3_Thrombocytopenia 25451-15-4 FELBAMATE ADVERSE_EFFECT NEU_1_Headache 25451-15-4 FELBAMATE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 25451-15-4 FELBAMATE ADVERSE_EFFECT BBM_3_Leukopenia 25451-15-4 FELBAMATE ADVERSE_EFFECT BBM_3_Pancytopenia 25451-15-4 FELBAMATE ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 25451-15-4 FELBAMATE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 25451-15-4 FELBAMATE ADVERSE_EFFECT NEU_1_Ataxia 25451-15-4 FELBAMATE ADVERSE_EFFECT XXX_1_Weight Loss 25451-15-4 FELBAMATE ADVERSE_EFFECT IMU_2_Photosensitivity 25451-15-4 FELBAMATE ADVERSE_EFFECT GIS_1_Dyspepsia 25451-15-4 FELBAMATE MODE_CLASS Channel Blocker, selective 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT REP_1_Decreased Libido 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_2_Ataxia 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_1_Drowsiness 438-41-5 CHLORDIAZEPOXIDE ACTIVITY_CLASS GABA agonist 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 438-41-5 CHLORDIAZEPOXIDE MECH_LEVEL_2 faciliates GABA binding 438-41-5 CHLORDIAZEPOXIDE THERAPEUTIC_CLASS Anxiolytics 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT CVS_2_Hypotension 438-41-5 CHLORDIAZEPOXIDE MODE_CLASS Channel Modulator 438-41-5 CHLORDIAZEPOXIDE MECHANISM Modulate neural transmission 438-41-5 CHLORDIAZEPOXIDE MESH_LEVEL_3 Benzazepines 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT XXX_1_Tolerance 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT EMB_3_Congenital Malformations 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT XXX_1_Withdrawal 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 438-41-5 CHLORDIAZEPOXIDE TA_LEVEL_1 Central Nervous System (CNS) 438-41-5 CHLORDIAZEPOXIDE STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 438-41-5 CHLORDIAZEPOXIDE TA_LEVEL_2 CNS Depressant 438-41-5 CHLORDIAZEPOXIDE PRODUCT_CLASS Central Nervous System (CNS) 438-41-5 CHLORDIAZEPOXIDE MECH_LEVEL_3 GABA-A receptor A 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT SKN_2_Skin Eruption 438-41-5 CHLORDIAZEPOXIDE INDICATION Anxiety Disorders 438-41-5 CHLORDIAZEPOXIDE MESH_LEVEL_1 Heterocyclic Compounds 438-41-5 CHLORDIAZEPOXIDE INDICATION Alcoholic Withdrawal 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT REP_1_Menstrual Irregularities 438-41-5 CHLORDIAZEPOXIDE MECH_LEVEL_1 Modulate neural transmission 438-41-5 CHLORDIAZEPOXIDE TA_LEVEL_3 Anxlytic 438-41-5 CHLORDIAZEPOXIDE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 438-41-5 CHLORDIAZEPOXIDE TISSUE_TOXICITY Hypotension 438-41-5 CHLORDIAZEPOXIDE KNOWN_TOXICITY Cardiovascular Toxicity 438-41-5 CHLORDIAZEPOXIDE ZERO_CLASS N 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT PSY_1_Dependence 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT PSY_2_Confusion 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT LIV_3_Jaundice 438-41-5 CHLORDIAZEPOXIDE ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 18472-51-0 CHLORHEXIDINE MECHANISM Destroy cell membrane / wall integrity 18472-51-0 CHLORHEXIDINE ADVERSE_EFFECT SKN_2_Skin Irritation 18472-51-0 CHLORHEXIDINE ADVERSE_EFFECT OTO_3_Hearing Loss 18472-51-0 CHLORHEXIDINE MODE_CLASS Distorts /blocks macromolecular scaffold function 18472-51-0 CHLORHEXIDINE ADVERSE_EFFECT IMU_2_Allergic Reactions 18472-51-0 CHLORHEXIDINE THERAPEUTIC_CLASS Antiseptics / Disinfectants 18472-51-0 CHLORHEXIDINE PRODUCT_CLASS Anti-infectives 18472-51-0 CHLORHEXIDINE THERAPEUTIC_CLASS Antibacterials, Topical 80-77-3 CHLORMEZANONE PRODUCT_CLASS Central Nervous System (CNS) 80-77-3 CHLORMEZANONE INDICATION Anxiety Disorders 80-77-3 CHLORMEZANONE ADVERSE_EFFECT SKN__Skin Toxicity 80-77-3 CHLORMEZANONE THERAPEUTIC_CLASS Anxiolytics 80-77-3 CHLORMEZANONE ADVERSE_EFFECT LIV__Jaundice 80-77-3 CHLORMEZANONE ADVERSE_EFFECT SKN__Stevens-Johnson Syndrome 57-15-8 CHLOROBUTANOL PRODUCT_CLASS Other Human Uses 133-16-4 CHLOROPROCAINE MODE_CLASS Channel Blocker 133-16-4 CHLOROPROCAINE PRODUCT_CLASS Central Nervous System (CNS) 133-16-4 CHLOROPROCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 133-16-4 CHLOROPROCAINE THERAPEUTIC_CLASS Local Anesthetics 133-16-4 CHLOROPROCAINE MECHANISM Block neural transmission 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT END_2_Hyperglycemia 58-94-6 CHLOROTHIAZIDE PRODUCT_CLASS Cardiovasculars 58-94-6 CHLOROTHIAZIDE MODE_CLASS Channel Blocker, selective 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_2_Constipation 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT IMU_3_Photosensitivity 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT END_3_Hypercholesteremia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT OCU_3_Xanthopsia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_2_Dyspepsia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT IMU_3_Hypersensitivity 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 58-94-6 CHLOROTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Pancreatitis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT EMB_3_Teratogenic Fetal Damage 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT ELT_3_Hyponatremia 58-94-6 CHLOROTHIAZIDE KNOWN_TOXICITY Nephrotoxicity 58-94-6 CHLOROTHIAZIDE INDICATION Nephrotic Syndrome 58-94-6 CHLOROTHIAZIDE INDICATION Hypercalciuria 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT ELT_2_Hypercalcemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT KID_3_Hyperuricemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT PSY_3_Anorexia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT _3_Transient vision loss 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT ELT_2_Hypochloremia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT KID_3_Interstitial Nephritis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT CVS_3_Thrombophlebitis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT KID_1_Polyuria 58-94-6 CHLOROTHIAZIDE INDICATION Edema 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_2_Diarrhea 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT LIV_3_Hepatitis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT NEU_2_Dizziness 58-94-6 CHLOROTHIAZIDE INDICATION Hypertension 58-94-6 CHLOROTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 58-94-6 CHLOROTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 58-94-6 CHLOROTHIAZIDE THERAPEUTIC_CLASS Diuretics 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT REP_3_Impotence 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT XXX_3_Hyperbilirubinemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT GIS_3_Sialadenitis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT ELT_3_Hypokalemic Metabolic Alkalosis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT CVS_1_Hypovolemia 58-94-6 CHLOROTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT ELT_2_Hypomagnesemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT ELT_1_Hypokalemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Hemolysis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT NEU_3_Syncope 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Pancytopenia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT END_3_Hypertriglyceridemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT SKN_3_Rash 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT BBM_3_Purpura 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT KID_3_Azotemia 58-94-6 CHLOROTHIAZIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 58-94-6 CHLOROTHIAZIDE TISSUE_TOXICITY Interstitial Nephritis 58-94-6 CHLOROTHIAZIDE INDICATION Heart Failure 569-57-3 CHLOROTRIANISENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 569-57-3 CHLOROTRIANISENE MODE_CLASS Receptor Partial Agonist 569-57-3 CHLOROTRIANISENE THERAPEUTIC_CLASS Gonadal Hormones 569-57-3 CHLOROTRIANISENE MECHANISM Modulate gene transcription 773-76-2 CHLOROXINE INDICATION Seborrhea 773-76-2 CHLOROXINE INDICATION Dandruff 773-76-2 CHLOROXINE PRODUCT_CLASS Dermatologicals 773-76-2 CHLOROXINE THERAPEUTIC_CLASS Antifungals, Topical 88-04-0 CHLOROXYLENOL INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 88-04-0 CHLOROXYLENOL MESH_LEVEL_2 Hydrocarbons 88-04-0 CHLOROXYLENOL INDICATION Skin Antisepsis 88-04-0 CHLOROXYLENOL THERAPEUTIC_CLASS Antiseptics / Disinfectants 88-04-0 CHLOROXYLENOL ACTIVITY_CLASS Unknown mechanism 88-04-0 CHLOROXYLENOL PRODUCT_CLASS Dermatologicals 88-04-0 CHLOROXYLENOL MESH_LEVEL_3 Hydrocarbons, Cyclic 88-04-0 CHLOROXYLENOL INDICATION Tinea Pedis / Athlete's Foot 88-04-0 CHLOROXYLENOL TA_LEVEL_3 Antiseptic, topical 88-04-0 CHLOROXYLENOL THERAPEUTIC_CLASS Antifungals, Topical 88-04-0 CHLOROXYLENOL ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 88-04-0 CHLOROXYLENOL ZERO_CLASS Y 88-04-0 CHLOROXYLENOL MECH_LEVEL_3 Unknown mechanism 88-04-0 CHLOROXYLENOL MECH_LEVEL_1 bacteriostatic 88-04-0 CHLOROXYLENOL TA_LEVEL_2 Antiseptics / Disinfectants 88-04-0 CHLOROXYLENOL STRUCTURE_ACTIVITY Unknown mechanism, antiseptic 88-04-0 CHLOROXYLENOL MECH_LEVEL_2 Unknown mechanism 88-04-0 CHLOROXYLENOL TA_LEVEL_1 Dermatology 88-04-0 CHLOROXYLENOL MESH_LEVEL_1 Organic Chemicals 132-22-9 CHLORPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT BBM_3_Aplastic Anemia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT NEU_3_Ataxia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT NEU_1_Dizziness 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypotension 132-22-9 CHLORPHENIRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 132-22-9 CHLORPHENIRAMINE INDICATION Motion Sickness 132-22-9 CHLORPHENIRAMINE INDICATION Urticaria / Hives 132-22-9 CHLORPHENIRAMINE INDICATION Allergic Conjunctivitis 132-22-9 CHLORPHENIRAMINE INDICATION Allergic Rhinitis 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Palpitation 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT XXX_3_Restlessness 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypertension 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT OCU_3_Blurred Vision 132-22-9 CHLORPHENIRAMINE TISSUE_TOXICITY Hypotension 132-22-9 CHLORPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 132-22-9 CHLORPHENIRAMINE INDICATION Dermatographism 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT GIS_3_Abdominal Pain 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_Psychosis 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Weakness 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT OCU_3_Mydriasis 132-22-9 CHLORPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 132-22-9 CHLORPHENIRAMINE INDICATION Nasal Congestion 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT XXX_2_Xerostomia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT NEU_3_Seizures 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT NEU_3_Headache 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_Insomnia 132-22-9 CHLORPHENIRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_CNS Stimulation 132-22-9 CHLORPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 132-22-9 CHLORPHENIRAMINE INDICATION Viral Rhinitis / Common Cold 132-22-9 CHLORPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 132-22-9 CHLORPHENIRAMINE INDICATION Anaphylaxis 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT PSY_3_Hallucinations 132-22-9 CHLORPHENIRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 132-22-9 CHLORPHENIRAMINE INDICATION Pruritus / Itching 50-53-3 CHLORPROMAZINE MECH_LEVEL_1 Modulate neural transmission 50-53-3 CHLORPROMAZINE TA_LEVEL_2 CNS Depressant 50-53-3 CHLORPROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 50-53-3 CHLORPROMAZINE MESH_LEVEL_1 Heterocyclic Compounds 50-53-3 CHLORPROMAZINE INDICATION Hiccups / Singultus 50-53-3 CHLORPROMAZINE MECHANISM Modulate G-protein coupled signal transduction 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Agranulocytosis 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Pancytopenia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT CVS_3_ECG Changes 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT CVS_3_Sudden Cardiac Death 50-53-3 CHLORPROMAZINE TA_LEVEL_3 Antipsychotics 50-53-3 CHLORPROMAZINE INDICATION Behavioral Problems in Children 50-53-3 CHLORPROMAZINE INDICATION Nausea / Vomiting 50-53-3 CHLORPROMAZINE INDICATION Mania 50-53-3 CHLORPROMAZINE TISSUE_TOXICITY Sudden Cardiac Death 50-53-3 CHLORPROMAZINE THERAPEUTIC_CLASS Antipsychotics 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT IMU_2_Eosinophilia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Aplastic Anemia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Thrombocytopenic Purpura 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Dizziness 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT SKN_3_Hyperpigmentation 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT NEU_3_Cerebral Edema 50-53-3 CHLORPROMAZINE KNOWN_TOXICITY Cardiovascular Toxicity 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT CVS_2_Tachycardia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT LIV_3_Jaundice 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT GIS_2_Constipation 50-53-3 CHLORPROMAZINE THERAPEUTIC_CLASS Antihistamines 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 50-53-3 CHLORPROMAZINE MODE_CLASS Receptor Ligand Antagonist 50-53-3 CHLORPROMAZINE INDICATION Psychotic Disorders / Psychosis 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT CVS_2_Postural Hypotension 50-53-3 CHLORPROMAZINE ACTIVITY_CLASS Dopamine antagonist 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Drowsiness 50-53-3 CHLORPROMAZINE ZERO_CLASS N 50-53-3 CHLORPROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 50-53-3 CHLORPROMAZINE MESH_LEVEL_3 Phenothiazines 50-53-3 CHLORPROMAZINE TA_LEVEL_1 Central Nervous System (CNS) 50-53-3 CHLORPROMAZINE INDICATION Restlessness and Apprehension Before Surgery 50-53-3 CHLORPROMAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 50-53-3 CHLORPROMAZINE MECH_LEVEL_3 dopamine receptor D2 50-53-3 CHLORPROMAZINE MECH_LEVEL_2 Dopamine antagonist 50-53-3 CHLORPROMAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 50-53-3 CHLORPROMAZINE MODE_CLASS Solute transporter inhibitor 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT GIS_2_Dry Mouth 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Leukopenia 50-53-3 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Dystonia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Pancytopenia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT CVS_3_ECG Changes 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT PSY_2_Neuroleptic Malignant Syndrome 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT GUS_2_Urinary Retention 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT CVS_3_Sudden Cardiac Death 69-09-0 CHLORPROMAZINE KNOWN_TOXICITY Cardiovascular Toxicity 69-09-0 CHLORPROMAZINE TA_LEVEL_3 Antipsychotics 69-09-0 CHLORPROMAZINE INDICATION Behavioral Problems in Children 69-09-0 CHLORPROMAZINE INDICATION Nausea / Vomiting 69-09-0 CHLORPROMAZINE THERAPEUTIC_CLASS Antipsychotics 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Aplastic Anemia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Thrombocytopenic Purpura 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Dizziness 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT PSY_2_Tardive Dyskinesia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT SKN_3_Hyperpigmentation 69-09-0 CHLORPROMAZINE ACTIVITY_CLASS Dopamine antagonist 69-09-0 CHLORPROMAZINE PRODUCT_CLASS Central Nervous System (CNS) 69-09-0 CHLORPROMAZINE MECH_LEVEL_1 Modulate neural transmission 69-09-0 CHLORPROMAZINE TA_LEVEL_2 CNS Depressant 69-09-0 CHLORPROMAZINE MECH_LEVEL_2 Dopamine antagonist 69-09-0 CHLORPROMAZINE INDICATION Psychotic Disorders / Psychosis 69-09-0 CHLORPROMAZINE MODE_CLASS Receptor Ligand Antagonist 69-09-0 CHLORPROMAZINE THERAPEUTIC_CLASS Antihistamines 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT GIS_2_Constipation 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT LIV_3_Jaundice 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT CVS_2_Tachycardia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Pseudo-Parkinsonism 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT NEU_3_Cerebral Edema 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Agranulocytosis 69-09-0 CHLORPROMAZINE STRUCTURE_ACTIVITY Dopamine receptor antagonist (D), phenothiazine 69-09-0 CHLORPROMAZINE MESH_LEVEL_1 Heterocyclic Compounds 69-09-0 CHLORPROMAZINE INDICATION Hiccups / Singultus 69-09-0 CHLORPROMAZINE MECHANISM Modulate G-protein coupled signal transduction 69-09-0 CHLORPROMAZINE INDICATION Mania 69-09-0 CHLORPROMAZINE TISSUE_TOXICITY Sudden Cardiac Death 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT IMU_2_Eosinophilia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT CVS_2_Postural Hypotension 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Dystonia 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT IMU_3_Contact Dermatitis 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT NEU_2_Drowsiness 69-09-0 CHLORPROMAZINE ZERO_CLASS N 69-09-0 CHLORPROMAZINE MESH_LEVEL_3 Phenothiazines 69-09-0 CHLORPROMAZINE TA_LEVEL_1 Central Nervous System (CNS) 69-09-0 CHLORPROMAZINE INDICATION Restlessness and Apprehension Before Surgery 69-09-0 CHLORPROMAZINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 69-09-0 CHLORPROMAZINE MECH_LEVEL_3 dopamine receptor D2 69-09-0 CHLORPROMAZINE MODE_CLASS Receptor Ligand Antagonist, Selective 69-09-0 CHLORPROMAZINE MODE_CLASS Solute transporter inhibitor 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT GIS_2_Dry Mouth 69-09-0 CHLORPROMAZINE ADVERSE_EFFECT BBM_2_Leukopenia 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT SKN_3_Porphyria Cutanea Tarda 94-20-2 CHLORPROPAMIDE ACTIVITY_CLASS Anti-diabetic 94-20-2 CHLORPROPAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 94-20-2 CHLORPROPAMIDE INDICATION Type II Diabetes Mellitus 94-20-2 CHLORPROPAMIDE TA_LEVEL_3 sulfonylurea 94-20-2 CHLORPROPAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT NEU_3_Paresthesia 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 94-20-2 CHLORPROPAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT LIV_3_Jaundice 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 94-20-2 CHLORPROPAMIDE MODE_CLASS Enzyme Inhibitor 94-20-2 CHLORPROPAMIDE MECH_LEVEL_2 stimulate insulin release 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT GIS_2_Constipation 94-20-2 CHLORPROPAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT GIS_2_Dyspepsia 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT LIV_3_Cholestasis 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 94-20-2 CHLORPROPAMIDE MODE_CLASS Channel Blocker, selective 94-20-2 CHLORPROPAMIDE MECH_LEVEL_3 ATP-sensitive K+ channel SUR1 94-20-2 CHLORPROPAMIDE TA_LEVEL_2 Diabetes 94-20-2 CHLORPROPAMIDE MESH_LEVEL_3 Sulfones 94-20-2 CHLORPROPAMIDE TA_LEVEL_1 Hormones, Endocrine and Metabolic 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT END_1_Hypoglycemia 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 94-20-2 CHLORPROPAMIDE ZERO_CLASS N 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT IMU_3_Photosensitivity 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 94-20-2 CHLORPROPAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 94-20-2 CHLORPROPAMIDE MESH_LEVEL_2 Sulfur Compounds 94-20-2 CHLORPROPAMIDE MESH_LEVEL_1 Organic Chemicals 94-20-2 CHLORPROPAMIDE MECH_LEVEL_1 Glycemia regulation 72-80-0 CHLORQUINALDOL THERAPEUTIC_CLASS Antibacterials, Topical 72-80-0 CHLORQUINALDOL PRODUCT_CLASS Anti-infectives 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 64-72-2 CHLORTETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 64-72-2 CHLORTETRACYCLINE TA_LEVEL_2 Antibacterials 64-72-2 CHLORTETRACYCLINE ZERO_CLASS N 64-72-2 CHLORTETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 64-72-2 CHLORTETRACYCLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 64-72-2 CHLORTETRACYCLINE TA_LEVEL_1 Infectious Disease 64-72-2 CHLORTETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 64-72-2 CHLORTETRACYCLINE INDICATION Bacterial Conjunctivitis 64-72-2 CHLORTETRACYCLINE INDICATION Respiratory Tract Infection 64-72-2 CHLORTETRACYCLINE THERAPEUTIC_CLASS Antibacterials, Topical 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT GIS_2_Vomiting 64-72-2 CHLORTETRACYCLINE TA_LEVEL_3 topical infections 64-72-2 CHLORTETRACYCLINE MECH_LEVEL_1 Anti-bacterial 64-72-2 CHLORTETRACYCLINE INDICATION Acne / Acne Vulgaris 64-72-2 CHLORTETRACYCLINE PRODUCT_CLASS Anti-infectives 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT GIS_1_Nausea 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT OCU_2_Ocular Irritation 64-72-2 CHLORTETRACYCLINE INDICATION Skin Infections 64-72-2 CHLORTETRACYCLINE INDICATION Gastrointestinal Infection 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT SKN_2_Skin Irritation 64-72-2 CHLORTETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 64-72-2 CHLORTETRACYCLINE THERAPEUTIC_CLASS Antibacterials, Systemic 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT IMU_3_Anaphylaxis 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT LIV_3_Jaundice 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT XXX_3_Xerostomia 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT GIS_3_Enterocolitis 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 64-72-2 CHLORTETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 64-72-2 CHLORTETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 64-72-2 CHLORTETRACYCLINE PRODUCT_CLASS Dermatologicals 64-72-2 CHLORTETRACYCLINE INDICATION Genitourinary Tract Infections 64-72-2 CHLORTETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 64-72-2 CHLORTETRACYCLINE INDICATION Chlamydia Trachomatis Infections 64-72-2 CHLORTETRACYCLINE MESH_LEVEL_3 Naphthalenes 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT OCU_3_Visual Disturbances 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT SKN_2_Skin Rash 64-72-2 CHLORTETRACYCLINE ADVERSE_EFFECT XXX_2_Staining of Developing Teeth 64-72-2 CHLORTETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 64-72-2 CHLORTETRACYCLINE INDICATION Bacterial Keratitis 57-62-5 CHLORTETRACYCLINE MECH_LEVEL_2 Inhibit ribosomal protein synthesis 57-62-5 CHLORTETRACYCLINE INDICATION Bacterial Conjunctivitis 57-62-5 CHLORTETRACYCLINE INDICATION Respiratory Tract Infection 57-62-5 CHLORTETRACYCLINE THERAPEUTIC_CLASS Antibacterials, Topical 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT GIS_2_Vomiting 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT SKN_2_Skin Irritation 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT OCU_2_Ocular Irritation 57-62-5 CHLORTETRACYCLINE TA_LEVEL_1 Infectious Disease 57-62-5 CHLORTETRACYCLINE TA_LEVEL_2 Antibacterials 57-62-5 CHLORTETRACYCLINE INDICATION Skin Infections 57-62-5 CHLORTETRACYCLINE INDICATION Gastrointestinal Infection 57-62-5 CHLORTETRACYCLINE MECH_LEVEL_1 Anti-bacterial 57-62-5 CHLORTETRACYCLINE INDICATION Acne / Acne Vulgaris 57-62-5 CHLORTETRACYCLINE PRODUCT_CLASS Anti-infectives 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT GIS_1_Nausea 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT BBM_3_Neutropenia 57-62-5 CHLORTETRACYCLINE MECH_LEVEL_3 30S Ribosomal Subunit 57-62-5 CHLORTETRACYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 57-62-5 CHLORTETRACYCLINE PRODUCT_CLASS Dermatologicals 57-62-5 CHLORTETRACYCLINE MECHANISM Inhibit ribosomal protein synthesis 57-62-5 CHLORTETRACYCLINE THERAPEUTIC_CLASS Antibacterials, Systemic 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT IMU_3_Anaphylaxis 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT LIV_3_Jaundice 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT XXX_3_Xerostomia 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT GIS_3_Enterocolitis 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT XXX_2_Enamel Hypoplasia 57-62-5 CHLORTETRACYCLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 57-62-5 CHLORTETRACYCLINE INDICATION Bacterial Keratitis 57-62-5 CHLORTETRACYCLINE INDICATION Genitourinary Tract Infections 57-62-5 CHLORTETRACYCLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 57-62-5 CHLORTETRACYCLINE INDICATION Chlamydia Trachomatis Infections 57-62-5 CHLORTETRACYCLINE MESH_LEVEL_3 Naphthalenes 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT OCU_3_Visual Disturbances 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT SKN_2_Skin Rash 57-62-5 CHLORTETRACYCLINE ADVERSE_EFFECT XXX_2_Staining of Developing Teeth 57-62-5 CHLORTETRACYCLINE ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 57-62-5 CHLORTETRACYCLINE ZERO_CLASS N 57-62-5 CHLORTETRACYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 57-62-5 CHLORTETRACYCLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 57-62-5 CHLORTETRACYCLINE TA_LEVEL_3 topical infections 77-36-1 CHLORTHALIDONE TISSUE_TOXICITY Cardiac Arrhythmia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT GIS_3_Pancreatitis 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT ELT_1_Hypokalemia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT BBM_3_Agranulocytosis 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT NEU_1_Dizziness 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT ELT_2_Hyponatremia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT BBM_3_Thrombocytopenia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT BBM_3_Aplastic Anemia 77-36-1 CHLORTHALIDONE INDICATION Congestive Heart Failure (CHF) 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT SKN_3_Skin Rash 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT KID_3_Azotemia 77-36-1 CHLORTHALIDONE MODE_CLASS Channel Blocker, selective 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 77-36-1 CHLORTHALIDONE INDICATION Edematous States 77-36-1 CHLORTHALIDONE THERAPEUTIC_CLASS Congestive Heart Failure 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT END_2_Hyperglycemia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT NEU_1_Headache 77-36-1 CHLORTHALIDONE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 77-36-1 CHLORTHALIDONE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 77-36-1 CHLORTHALIDONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT END_2_Hypercholesteremia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT BBM_3_Pancytopenia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT KID_1_Polyuria 77-36-1 CHLORTHALIDONE THERAPEUTIC_CLASS Diuretics 77-36-1 CHLORTHALIDONE KNOWN_TOXICITY Nephrotoxicity 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT END_2_Hypertriglyceridemia 77-36-1 CHLORTHALIDONE KNOWN_TOXICITY Cardiovascular Toxicity 77-36-1 CHLORTHALIDONE PRODUCT_CLASS Cardiovasculars 77-36-1 CHLORTHALIDONE INDICATION Hypertension 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT ELT_2_Hypochloremia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT PSN_3_Digitalis Poisoning 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT IMU_3_Polyarteritis Nodosa 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT BBM_3_Leukopenia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT END_2_Metabolic Alkalosis 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT ELT_2_Hypomagnesemia 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT REP_2_Impotence 77-36-1 CHLORTHALIDONE TISSUE_TOXICITY Interstitial Nephritis 77-36-1 CHLORTHALIDONE THERAPEUTIC_CLASS Antihypertensive Agents 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT END_2_Exacerbation of Gout 77-36-1 CHLORTHALIDONE ADVERSE_EFFECT KID_3_Interstitial Nephritis 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT NEU_2_Drowsiness 95-25-0 CHLORZOXAZONE TISSUE_TOXICITY Hepatic Necrosis 95-25-0 CHLORZOXAZONE INDICATION Skeletal Muscle Spasm 95-25-0 CHLORZOXAZONE MECH_LEVEL_3 Small conductance Ca++-activated K+ channel SKCa 95-25-0 CHLORZOXAZONE MESH_LEVEL_1 Heterocyclic Compounds 95-25-0 CHLORZOXAZONE ZERO_CLASS N 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT GUS_3_Discoloration of Urine 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 95-25-0 CHLORZOXAZONE STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) opener 95-25-0 CHLORZOXAZONE MECH_LEVEL_2 channel agonist 95-25-0 CHLORZOXAZONE TA_LEVEL_1 Central Nervous System (CNS) 95-25-0 CHLORZOXAZONE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 95-25-0 CHLORZOXAZONE INDICATION Musculoskeletal Pain 95-25-0 CHLORZOXAZONE TA_LEVEL_2 muscle relaxant 95-25-0 CHLORZOXAZONE KNOWN_TOXICITY Hepatotoxicity 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT NEU_2_Dizziness 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT IMU_3_Allergic Reactions 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 95-25-0 CHLORZOXAZONE MESH_LEVEL_3 Benzoxazoles 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT SKN_3_Skin Rash 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT LIV_3_Jaundice 95-25-0 CHLORZOXAZONE ADVERSE_EFFECT IMU_3_Anaphylaxis 95-25-0 CHLORZOXAZONE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 95-25-0 CHLORZOXAZONE PRODUCT_CLASS Central Nervous System (CNS) 95-25-0 CHLORZOXAZONE MECHANISM Modulate channel gating 95-25-0 CHLORZOXAZONE TA_LEVEL_3 Skeletal Muscle Relaxants 95-25-0 CHLORZOXAZONE MECH_LEVEL_1 Modulate channel gating 95-25-0 CHLORZOXAZONE ACTIVITY_CLASS K+ channel opener 95-25-0 CHLORZOXAZONE MODE_CLASS Channel enhancer /opener 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT NEU_3_Ataxia 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT GIS_3_Abdominal Cramps 67-97-0 CHOLECALCIFEROL MESH_LEVEL_2 Vitamins 67-97-0 CHOLECALCIFEROL MESH_LEVEL_3 Vitamin D 67-97-0 CHOLECALCIFEROL TA_LEVEL_3 Vitamin D 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT KID_3_Renal Stones 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT END_3_Ectopic Calcifications 67-97-0 CHOLECALCIFEROL MECH_LEVEL_2 Vitamin D 67-97-0 CHOLECALCIFEROL INDICATION Rickets 67-97-0 CHOLECALCIFEROL MECH_LEVEL_3 thyroid hormone receptor VDR 67-97-0 CHOLECALCIFEROL INDICATION Osteomalacia 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT ELT_3_Hypercalcemia 67-97-0 CHOLECALCIFEROL ACTIVITY_CLASS Vitamin D receptor agonist 67-97-0 CHOLECALCIFEROL ZERO_CLASS N 67-97-0 CHOLECALCIFEROL STRUCTURE_ACTIVITY Vitamin D receptor agonist 67-97-0 CHOLECALCIFEROL TA_LEVEL_2 Vitamine D precusors 67-97-0 CHOLECALCIFEROL INDICATION Hypocalcemia 67-97-0 CHOLECALCIFEROL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT XXX_3_Weakness 67-97-0 CHOLECALCIFEROL MECHANISM Modulate gene transcription 67-97-0 CHOLECALCIFEROL ADVERSE_EFFECT GIS_3_Pancreatitis 67-97-0 CHOLECALCIFEROL TA_LEVEL_1 Vitamins, Minerals and Nutrients 67-97-0 CHOLECALCIFEROL MODE_CLASS Receptor Agonist 67-97-0 CHOLECALCIFEROL MESH_LEVEL_1 Growth Substances, Pigments, and Vitamins 67-97-0 CHOLECALCIFEROL MECH_LEVEL_1 Vitamin D 67-97-0 CHOLECALCIFEROL PRODUCT_CLASS Vitamins, Minerals and Nutrients 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT PSY_2_Irritation 123-41-1 CHOLINE CHLORIDE TA_LEVEL_1 Vitamins, Minerals and Nutrients 123-41-1 CHOLINE CHLORIDE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 123-41-1 CHOLINE CHLORIDE MESH_LEVEL_1 Organic Chemicals 123-41-1 CHOLINE CHLORIDE MECH_LEVEL_3 Muscarinic acetylcholine receptor 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT XXX_1_Hyperthermia 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT END_3_Hyperglycemia 123-41-1 CHOLINE CHLORIDE ZERO_CLASS N 123-41-1 CHOLINE CHLORIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) agonist 123-41-1 CHOLINE CHLORIDE MODE_CLASS Receptor Agonist 123-41-1 CHOLINE CHLORIDE ACTIVITY_CLASS Muscarinic acetylcholine receptor agonist 123-41-1 CHOLINE CHLORIDE MECHANISM Prolong/enhance neural transmission 123-41-1 CHOLINE CHLORIDE MECH_LEVEL_1 Modulate neural transmission 123-41-1 CHOLINE CHLORIDE PRODUCT_CLASS Vitamins, Minerals and Nutrients 123-41-1 CHOLINE CHLORIDE MESH_LEVEL_2 Amines 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT GIS_1_Nausea 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT PSY_3_Depression 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT XXX_1_Sweating 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT END_3_Hypercholesteremia 123-41-1 CHOLINE CHLORIDE MODE_CLASS Channel Modulator 123-41-1 CHOLINE CHLORIDE MESH_LEVEL_3 Ammonium Compounds 123-41-1 CHOLINE CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 123-41-1 CHOLINE CHLORIDE ADVERSE_EFFECT XXX_1_Decreased Appetite 123-41-1 CHOLINE CHLORIDE MECH_LEVEL_2 Cholinergic receptor agonist 67-48-1 CHOLINE CHLORIDE MESH_LEVEL_1 Organic Chemicals 67-48-1 CHOLINE CHLORIDE MECH_LEVEL_3 Muscarinic acetylcholine receptor 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT XXX_1_Hyperthermia 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT END_3_Hyperglycemia 67-48-1 CHOLINE CHLORIDE ZERO_CLASS N 67-48-1 CHOLINE CHLORIDE MODE_CLASS Receptor Agonist 67-48-1 CHOLINE CHLORIDE ACTIVITY_CLASS Muscarinic acetylcholine receptor agonist 67-48-1 CHOLINE CHLORIDE MECHANISM Prolong/enhance neural transmission 67-48-1 CHOLINE CHLORIDE MECH_LEVEL_1 Modulate neural transmission 67-48-1 CHOLINE CHLORIDE PRODUCT_CLASS Vitamins, Minerals and Nutrients 67-48-1 CHOLINE CHLORIDE MESH_LEVEL_2 Amines 67-48-1 CHOLINE CHLORIDE MECH_LEVEL_2 Cholinergic receptor agonist 67-48-1 CHOLINE CHLORIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) agonist 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT GIS_1_Nausea 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT PSY_3_Depression 67-48-1 CHOLINE CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT XXX_1_Decreased Appetite 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT PSY_2_Irritation 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT XXX_1_Sweating 67-48-1 CHOLINE CHLORIDE ADVERSE_EFFECT END_3_Hypercholesteremia 67-48-1 CHOLINE CHLORIDE MODE_CLASS Channel Modulator 67-48-1 CHOLINE CHLORIDE MESH_LEVEL_3 Ammonium Compounds 67-48-1 CHOLINE CHLORIDE TA_LEVEL_1 Vitamins, Minerals and Nutrients 67-48-1 CHOLINE CHLORIDE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 2016-36-6 CHOLINE SALICYLATE INDICATION Acute Painful Shoulder 2016-36-6 CHOLINE SALICYLATE PRODUCT_CLASS Anti-inflammatories 2016-36-6 CHOLINE SALICYLATE INDICATION Osteoarthritis 2016-36-6 CHOLINE SALICYLATE INDICATION Rheumatoid Arthritis 2016-36-6 CHOLINE SALICYLATE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 2016-36-6 CHOLINE SALICYLATE MECHANISM Inhibit eicosanoid biosynthesis 2016-36-6 CHOLINE SALICYLATE MODE_CLASS Receptor Agonist 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT PSY_3_CNS Depression 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT GIS_3_Gastritis 10025-73-7 CHROMIUM(III) CHLORIDE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT END_3_Hypoglycemia 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT GIS_3_Gastric Ulceration 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT NEU_3_Seizures 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT NEU_3_Drowsiness 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT _3_Local Tissue Irritation 10025-73-7 CHROMIUM(III) CHLORIDE INDICATION Nutritional Supplement 10025-73-7 CHROMIUM(III) CHLORIDE PRODUCT_CLASS Vitamins, Minerals and Nutrients 10025-73-7 CHROMIUM(III) CHLORIDE ADVERSE_EFFECT CVS_3_Phlebitis 41621-49-2 CICLOPIROX INDICATION Tinea Pedis / Athlete's Foot 41621-49-2 CICLOPIROX ADVERSE_EFFECT SKN_2_Skin Rash 41621-49-2 CICLOPIROX INDICATION Tinea Versicolor / Pityriasis Versicolor 41621-49-2 CICLOPIROX INDICATION Seborrheic Dermatitis 41621-49-2 CICLOPIROX INDICATION Tinea Unguium / Onychomycosis 41621-49-2 CICLOPIROX ADVERSE_EFFECT SKN_2_Erythema 41621-49-2 CICLOPIROX INDICATION Cutaneous Candidiasis 41621-49-2 CICLOPIROX INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 41621-49-2 CICLOPIROX ADVERSE_EFFECT SKN_2_Pruritis 41621-49-2 CICLOPIROX ADVERSE_EFFECT SKN_2_Nail Discoloration 41621-49-2 CICLOPIROX INDICATION Tinea Cruris / Jock Itch 41621-49-2 CICLOPIROX PRODUCT_CLASS Dermatologicals 41621-49-2 CICLOPIROX ADVERSE_EFFECT IMU_3_Hypersensitivity 41621-49-2 CICLOPIROX ADVERSE_EFFECT SKN_2_Skin Irritation 41621-49-2 CICLOPIROX THERAPEUTIC_CLASS Antifungals, Topical 29342-05-0 CICLOPIROX INDICATION Tinea Corporis / Tinea Circinata / Body Ringworm 29342-05-0 CICLOPIROX ADVERSE_EFFECT SKN_2_Skin Irritation 29342-05-0 CICLOPIROX INDICATION Tinea Versicolor / Pityriasis Versicolor 29342-05-0 CICLOPIROX INDICATION Seborrheic Dermatitis 29342-05-0 CICLOPIROX INDICATION Tinea Unguium / Onychomycosis 29342-05-0 CICLOPIROX ADVERSE_EFFECT SKN_2_Erythema 29342-05-0 CICLOPIROX INDICATION Cutaneous Candidiasis 29342-05-0 CICLOPIROX ADVERSE_EFFECT SKN_2_Pruritis 29342-05-0 CICLOPIROX ADVERSE_EFFECT SKN_2_Nail Discoloration 29342-05-0 CICLOPIROX INDICATION Tinea Cruris / Jock Itch 29342-05-0 CICLOPIROX PRODUCT_CLASS Dermatologicals 29342-05-0 CICLOPIROX ADVERSE_EFFECT IMU_3_Hypersensitivity 29342-05-0 CICLOPIROX INDICATION Tinea Pedis / Athlete's Foot 29342-05-0 CICLOPIROX THERAPEUTIC_CLASS Antifungals, Topical 29342-05-0 CICLOPIROX ADVERSE_EFFECT SKN_2_Skin Rash 113852-37-2 CIDOFOVIR MECHANISM Inhibit viral DNA synthesis 113852-37-2 CIDOFOVIR INDICATION Cytomegalovirus (CMV) Retinitis 113852-37-2 CIDOFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 113852-37-2 CIDOFOVIR PRODUCT_CLASS Anti-infectives 113852-37-2 CIDOFOVIR MODE_CLASS Enzyme substrate mimic 120362-37-0 CIDOFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 120362-37-0 CIDOFOVIR MODE_CLASS Enzyme substrate mimic 120362-37-0 CIDOFOVIR MECHANISM Inhibit viral DNA synthesis 120362-37-0 CIDOFOVIR PRODUCT_CLASS Anti-infectives 120362-37-0 CIDOFOVIR INDICATION Cytomegalovirus (CMV) Retinitis 149394-66-1 CIDOFOVIR INDICATION Cytomegalovirus (CMV) Retinitis 149394-66-1 CIDOFOVIR THERAPEUTIC_CLASS Antivirals, Systemic 149394-66-1 CIDOFOVIR PRODUCT_CLASS Anti-infectives 149394-66-1 CIDOFOVIR MODE_CLASS Enzyme substrate mimic 149394-66-1 CIDOFOVIR MECHANISM Inhibit viral DNA synthesis 82009-34-5 CILASTATIN MODE_CLASS Enzyme Inhibitor 82009-34-5 CILASTATIN PRODUCT_CLASS Anti-infectives 54239-37-1 CIMATEROL PRODUCT_CLASS Autonomic Nervous System (ANS) 54239-37-1 CIMATEROL MECHANISM Modulate G-protein coupled signal transduction 54239-37-1 CIMATEROL THERAPEUTIC_CLASS Sympathomimetic Agents 51481-61-9 CIMETIDINE MECHANISM Reduce stomach HCl secretion 51481-61-9 CIMETIDINE ADVERSE_EFFECT PSY_2_Anxiety 51481-61-9 CIMETIDINE ACTIVITY_CLASS Histamine antagonist 51481-61-9 CIMETIDINE STRUCTURE_ACTIVITY Histamine receptor (H2) antagonist 51481-61-9 CIMETIDINE ADVERSE_EFFECT PSY_2_Mental Confusion 51481-61-9 CIMETIDINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 51481-61-9 CIMETIDINE ADVERSE_EFFECT IMU_3_Anaphylaxis 51481-61-9 CIMETIDINE ADVERSE_EFFECT REP_3_Impotence 51481-61-9 CIMETIDINE ADVERSE_EFFECT CVS_3_Bradycardia 51481-61-9 CIMETIDINE TISSUE_TOXICITY Carcinogenicity 51481-61-9 CIMETIDINE INDICATION Gastroesophageal Reflux Disease (GERD) 51481-61-9 CIMETIDINE MECH_LEVEL_2 Reduce stomach HCl secretion 51481-61-9 CIMETIDINE ADVERSE_EFFECT BBM_3_Pancytopenia 51481-61-9 CIMETIDINE ADVERSE_EFFECT PSY_2_Psychosis 51481-61-9 CIMETIDINE ADVERSE_EFFECT END_3_Gynecomastia 51481-61-9 CIMETIDINE ADVERSE_EFFECT NEU_1_Headache 51481-61-9 CIMETIDINE ADVERSE_EFFECT GIS_1_Diarrhea 51481-61-9 CIMETIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 51481-61-9 CIMETIDINE MESH_LEVEL_3 Imidazoles 51481-61-9 CIMETIDINE INDICATION Gastric Ulcer 51481-61-9 CIMETIDINE ZERO_CLASS N 51481-61-9 CIMETIDINE ADVERSE_EFFECT NEU_1_Somnolence 51481-61-9 CIMETIDINE ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 51481-61-9 CIMETIDINE ADVERSE_EFFECT PSY_2_Disorientation 51481-61-9 CIMETIDINE ADVERSE_EFFECT NEU_1_Dizziness 51481-61-9 CIMETIDINE ADVERSE_EFFECT PSY_2_Depression 51481-61-9 CIMETIDINE THERAPEUTIC_CLASS Antiulcers 51481-61-9 CIMETIDINE TA_LEVEL_3 Gastric secretion inhibitors 51481-61-9 CIMETIDINE PRODUCT_CLASS Gastrointestinal System 51481-61-9 CIMETIDINE INDICATION Zollinger-Ellison Syndrome / Gastrinoma 51481-61-9 CIMETIDINE MESH_LEVEL_1 Heterocyclic Compounds 51481-61-9 CIMETIDINE INDICATION Multiple Endocrine Neoplasia (MEN) 51481-61-9 CIMETIDINE TA_LEVEL_1 Gastrointestinal System 51481-61-9 CIMETIDINE MODE_CLASS Receptor Ligand Antagonist, Selective 51481-61-9 CIMETIDINE KNOWN_TOXICITY Carcinogenicity 51481-61-9 CIMETIDINE ADVERSE_EFFECT MSK_3_Myalgia 51481-61-9 CIMETIDINE ADVERSE_EFFECT PSY_2_Agitation 51481-61-9 CIMETIDINE ADVERSE_EFFECT SKN_3_Rash 51481-61-9 CIMETIDINE ADVERSE_EFFECT DNA_2_Carcinogenicity 51481-61-9 CIMETIDINE INDICATION Systemic Mastocytosis 51481-61-9 CIMETIDINE MECH_LEVEL_1 Ulcer healing 51481-61-9 CIMETIDINE MECH_LEVEL_3 histamine receptor H2 51481-61-9 CIMETIDINE INDICATION Duodenal Ulcer 51481-61-9 CIMETIDINE TA_LEVEL_2 Duodenal ulcer treatment 104-54-1 CINNAMYL ALCOHOL PRODUCT_CLASS Other Human Uses 28657-80-9 CINOXACIN ADVERSE_EFFECT SKN_3_Pruritis 28657-80-9 CINOXACIN MODE_CLASS Enzyme Inhibitor, selective 28657-80-9 CINOXACIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 28657-80-9 CINOXACIN ADVERSE_EFFECT NEU_2_Drowsiness 28657-80-9 CINOXACIN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 28657-80-9 CINOXACIN THERAPEUTIC_CLASS Antibacterials 28657-80-9 CINOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 28657-80-9 CINOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity 28657-80-9 CINOXACIN ADVERSE_EFFECT IMU_3_Urticaria 28657-80-9 CINOXACIN ADVERSE_EFFECT NEU_3_Headache 28657-80-9 CINOXACIN PRODUCT_CLASS Anti-infectives 28657-80-9 CINOXACIN INDICATION Urinary Tract Infection (UTI) 28657-80-9 CINOXACIN ADVERSE_EFFECT IMU_3_Eosinophilia 28657-80-9 CINOXACIN ADVERSE_EFFECT IMU_3_Angioedema 28657-80-9 CINOXACIN ADVERSE_EFFECT NEU_2_Dizziness 28657-80-9 CINOXACIN ADVERSE_EFFECT GIS_3_Abdominal Cramps 28657-80-9 CINOXACIN MECHANISM Inhibit bacterial DNA synthesis 28657-80-9 CINOXACIN ADVERSE_EFFECT SKN_3_Rash 28657-80-9 CINOXACIN ADVERSE_EFFECT GIS_3_Diarrhea 85721-33-1 CIPROFLOXACIN TISSUE_TOXICITY Renal Failure 85721-33-1 CIPROFLOXACIN INDICATION Chronic Bacterial Prostatitis 85721-33-1 CIPROFLOXACIN MESH_LEVEL_3 Quinolines 85721-33-1 CIPROFLOXACIN MECH_LEVEL_3 DNA gyrase 85721-33-1 CIPROFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 85721-33-1 CIPROFLOXACIN INDICATION Urinary Tract Infection (UTI) 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT SKN_1_Rash 85721-33-1 CIPROFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT GIS_2_Dysphagia 85721-33-1 CIPROFLOXACIN INDICATION Inhalational Anthrax 85721-33-1 CIPROFLOXACIN INDICATION Respiratory Tract Infection 85721-33-1 CIPROFLOXACIN PRODUCT_CLASS Anti-infectives 85721-33-1 CIPROFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 85721-33-1 CIPROFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 85721-33-1 CIPROFLOXACIN INDICATION Intra-Abdominal Infections 85721-33-1 CIPROFLOXACIN INDICATION Acute Sinusitis 85721-33-1 CIPROFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT IMU_2_Urticaria 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 85721-33-1 CIPROFLOXACIN INDICATION Skin and Skin Structure Infections 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 85721-33-1 CIPROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 85721-33-1 CIPROFLOXACIN TA_LEVEL_1 Infectious Disease 85721-33-1 CIPROFLOXACIN TA_LEVEL_2 Anti-bacterial 85721-33-1 CIPROFLOXACIN MECH_LEVEL_1 Anti-bacterial 85721-33-1 CIPROFLOXACIN INDICATION Enteric Fever / Typhoid Fever 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT KID_3_Renal Failure 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT CVS_2_Palpitation 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT PSY_2_Insomnia 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT NEU_1_Headache 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 85721-33-1 CIPROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT XXX_3_Epistaxis 85721-33-1 CIPROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 85721-33-1 CIPROFLOXACIN KNOWN_TOXICITY Nephrotoxicity 85721-33-1 CIPROFLOXACIN INDICATION Uncomplicated Cystitis 85721-33-1 CIPROFLOXACIN TA_LEVEL_3 quinolones 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 85721-33-1 CIPROFLOXACIN ZERO_CLASS N 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT IMU_2_Anaphylaxis 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Vomiting 85721-33-1 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 85721-33-1 CIPROFLOXACIN INDICATION Acute Infectious Diarrhea 85721-33-1 CIPROFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 85721-33-1 CIPROFLOXACIN INDICATION Bone and Joint Infection 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT SKN_1_Rash 93107-08-5 CIPROFLOXACIN THERAPEUTIC_CLASS Antibacterials, Systemic 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT GIS_2_Dysphagia 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Abdominal Pain 93107-08-5 CIPROFLOXACIN ZERO_CLASS N 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT IMU_2_Anaphylaxis 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Vomiting 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT NEU_1_Headache 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT PSY_2_Insomnia 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT KID_3_Renal Failure 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Diarrhea 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT CVS_2_Palpitation 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT GIS_3_Gastrointestinal Bleeding 93107-08-5 CIPROFLOXACIN STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Seizures 93107-08-5 CIPROFLOXACIN INDICATION Enteric Fever / Typhoid Fever 93107-08-5 CIPROFLOXACIN INDICATION Inhalational Anthrax 93107-08-5 CIPROFLOXACIN INDICATION Respiratory Tract Infection 93107-08-5 CIPROFLOXACIN INDICATION Bone and Joint Infection 93107-08-5 CIPROFLOXACIN INDICATION Acute, Uncomplicated Urethral and Cervical Gonorrhea 93107-08-5 CIPROFLOXACIN TA_LEVEL_3 quinolones 93107-08-5 CIPROFLOXACIN INDICATION Uncomplicated Cystitis 93107-08-5 CIPROFLOXACIN KNOWN_TOXICITY Nephrotoxicity 93107-08-5 CIPROFLOXACIN MESH_LEVEL_3 Quinolines 93107-08-5 CIPROFLOXACIN MECH_LEVEL_3 DNA gyrase 93107-08-5 CIPROFLOXACIN INDICATION Skin and Skin Structure Infections 93107-08-5 CIPROFLOXACIN MECH_LEVEL_2 Inhibit bacterial DNA synthesis 93107-08-5 CIPROFLOXACIN INDICATION Urinary Tract Infection (UTI) 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT IMU_3_Photosensitivity 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT GIS_1_Nausea 93107-08-5 CIPROFLOXACIN INDICATION Acute Infectious Diarrhea 93107-08-5 CIPROFLOXACIN PRODUCT_CLASS Anti-infectives 93107-08-5 CIPROFLOXACIN ACTIVITY_CLASS DNA gyrase inhibitor 93107-08-5 CIPROFLOXACIN MESH_LEVEL_1 Heterocyclic Compounds 93107-08-5 CIPROFLOXACIN INDICATION Intra-Abdominal Infections 93107-08-5 CIPROFLOXACIN INDICATION Acute Sinusitis 93107-08-5 CIPROFLOXACIN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT IMU_2_Urticaria 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Tremor 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT NEU_2_Dizziness 93107-08-5 CIPROFLOXACIN TA_LEVEL_1 Infectious Disease 93107-08-5 CIPROFLOXACIN TA_LEVEL_2 Anti-bacterial 93107-08-5 CIPROFLOXACIN MECH_LEVEL_1 Anti-bacterial 93107-08-5 CIPROFLOXACIN MODE_CLASS Enzyme Inhibitor, selective 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT XXX_3_Epistaxis 93107-08-5 CIPROFLOXACIN MECHANISM Inhibit bacterial DNA synthesis 93107-08-5 CIPROFLOXACIN ADVERSE_EFFECT SKN_2_Pruritis 93107-08-5 CIPROFLOXACIN TISSUE_TOXICITY Renal Failure 93107-08-5 CIPROFLOXACIN INDICATION Chronic Bacterial Prostatitis 59939-16-1 CIRAZOLINE THERAPEUTIC_CLASS Sympathomimetic Agents 59939-16-1 CIRAZOLINE PRODUCT_CLASS Autonomic Nervous System (ANS) 59939-16-1 CIRAZOLINE MECHANISM Modulate G-protein coupled signal transduction 81098-60-4 CISAPRIDE ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 81098-60-4 CISAPRIDE ADVERSE_EFFECT GIS_1_Diarrhea 81098-60-4 CISAPRIDE ADVERSE_EFFECT GUS_2_Urinary Tract Infection 81098-60-4 CISAPRIDE ADVERSE_EFFECT CVS_3_Chest Pain 81098-60-4 CISAPRIDE ADVERSE_EFFECT MSK_2_Myalgia 81098-60-4 CISAPRIDE ADVERSE_EFFECT SKN_3_Pruritis 81098-60-4 CISAPRIDE ADVERSE_EFFECT NEU_1_Headache 81098-60-4 CISAPRIDE TISSUE_TOXICITY Extrasystoles 81098-60-4 CISAPRIDE PRODUCT_CLASS Gastrointestinal System 81098-60-4 CISAPRIDE MESH_LEVEL_2 Amides 81098-60-4 CISAPRIDE MESH_LEVEL_3 Benzamides 81098-60-4 CISAPRIDE MESH_LEVEL_1 Organic Chemicals 81098-60-4 CISAPRIDE STRUCTURE_ACTIVITY 5HT4 agonist 81098-60-4 CISAPRIDE ADVERSE_EFFECT CVS_2_Hypertension 81098-60-4 CISAPRIDE ADVERSE_EFFECT XXX_2_Sinusitis 81098-60-4 CISAPRIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 81098-60-4 CISAPRIDE ZERO_CLASS N 81098-60-4 CISAPRIDE MECH_LEVEL_2 5HT antagonist 81098-60-4 CISAPRIDE MECH_LEVEL_3 5HT receptor 4 81098-60-4 CISAPRIDE TA_LEVEL_3 Antiemetic 81098-60-4 CISAPRIDE ADVERSE_EFFECT CVS_2_Extrasystoles 81098-60-4 CISAPRIDE MECHANISM Modulate neural transmission 81098-60-4 CISAPRIDE TISSUE_TOXICITY Cardiac Arrhythmia 81098-60-4 CISAPRIDE KNOWN_TOXICITY Cardiovascular Toxicity 81098-60-4 CISAPRIDE ADVERSE_EFFECT BBM_3_Pancytopenia 81098-60-4 CISAPRIDE ADVERSE_EFFECT BBM_3_Leukopenia 81098-60-4 CISAPRIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 81098-60-4 CISAPRIDE ADVERSE_EFFECT GUS_3_Urinary Frequency 81098-60-4 CISAPRIDE ADVERSE_EFFECT CVS_2_Tachycardia 81098-60-4 CISAPRIDE ADVERSE_EFFECT XXX_3_Dehydration 81098-60-4 CISAPRIDE ACTIVITY_CLASS Serotonin agonist 81098-60-4 CISAPRIDE ADVERSE_EFFECT SKN_3_Rash 81098-60-4 CISAPRIDE INDICATION Gastroesophageal Reflux Disease (GERD) 81098-60-4 CISAPRIDE MECH_LEVEL_1 Modulate neural transmission 81098-60-4 CISAPRIDE TA_LEVEL_2 CNS Depressant 81098-60-4 CISAPRIDE ADVERSE_EFFECT XXX_2_Fatigue 81098-60-4 CISAPRIDE ADVERSE_EFFECT PSY_2_Depression 81098-60-4 CISAPRIDE ADVERSE_EFFECT XXX_1_Rhinitis 81098-60-4 CISAPRIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 81098-60-4 CISAPRIDE ADVERSE_EFFECT MSK_3_Arthralgia 81098-60-4 CISAPRIDE ADVERSE_EFFECT NEU_2_Dizziness 81098-60-4 CISAPRIDE MODE_CLASS Receptor Agonist 81098-60-4 CISAPRIDE THERAPEUTIC_CLASS Prokinetic Agents 81098-60-4 CISAPRIDE TA_LEVEL_1 Central Nervous System (CNS) 15663-27-1 CISPLATIN ADVERSE_EFFECT KID_1_Nephrotoxicity 15663-27-1 CISPLATIN ADVERSE_EFFECT ELT_2_Disturbances in Electrolyte Balance 15663-27-1 CISPLATIN MODE_CLASS Distorts /blocks macromolecular scaffold function 15663-27-1 CISPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 15663-27-1 CISPLATIN INDICATION Testicular Cancer / Carcinoma of the Testis 15663-27-1 CISPLATIN ADVERSE_EFFECT BBM_2_Myelosuppression 15663-27-1 CISPLATIN ADVERSE_EFFECT NEU_2_Vertigo 15663-27-1 CISPLATIN ADVERSE_EFFECT IMU_3_Urticaria 15663-27-1 CISPLATIN ADVERSE_EFFECT NEU_3_Optic Neuritis 15663-27-1 CISPLATIN ADVERSE_EFFECT OTO_2_Ototoxicity 15663-27-1 CISPLATIN ADVERSE_EFFECT CVS_3_Hypotension 15663-27-1 CISPLATIN INDICATION Non-Small Cell Lung Carcinoma 15663-27-1 CISPLATIN INDICATION Head and Neck Cancer 15663-27-1 CISPLATIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 15663-27-1 CISPLATIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 15663-27-1 CISPLATIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 15663-27-1 CISPLATIN THERAPEUTIC_CLASS Antineoplastics 15663-27-1 CISPLATIN PRODUCT_CLASS Anti-cancers 15663-27-1 CISPLATIN MESH_LEVEL_3 Cisplatin 15663-27-1 CISPLATIN MESH_LEVEL_1 Inorganic Chemicals 15663-27-1 CISPLATIN MECH_LEVEL_3 DNA damage 15663-27-1 CISPLATIN INDICATION Neoplasm / Cancer / Tumor 15663-27-1 CISPLATIN TA_LEVEL_3 Solid Tumors 15663-27-1 CISPLATIN TA_LEVEL_1 Oncology 15663-27-1 CISPLATIN TISSUE_TOXICITY Hypotension 15663-27-1 CISPLATIN INDICATION Bladder Cancer / Carcinoma of the Bladder 15663-27-1 CISPLATIN ADVERSE_EFFECT GIS_2_Diarrhea 15663-27-1 CISPLATIN ADVERSE_EFFECT ELT_2_Hypokalemia 15663-27-1 CISPLATIN ADVERSE_EFFECT OTO_2_Tinnitus 15663-27-1 CISPLATIN ADVERSE_EFFECT BBM_2_Anemia 15663-27-1 CISPLATIN ADVERSE_EFFECT BBM_2_Leukopenia 15663-27-1 CISPLATIN ADVERSE_EFFECT OCU_3_Ocular Toxicity 15663-27-1 CISPLATIN MECHANISM Inhibit DNA synthesis, repair, and function 15663-27-1 CISPLATIN INDICATION Cervical Cancer / Carcinoma of the Cervix 15663-27-1 CISPLATIN INDICATION Esophageal Cancer / Carcinoma of the Esophagus 15663-27-1 CISPLATIN MESH_LEVEL_2 Platinum Compounds 15663-27-1 CISPLATIN TISSUE_TOXICITY Nephrotoxicity 15663-27-1 CISPLATIN ADVERSE_EFFECT GIS_1_Vomiting 15663-27-1 CISPLATIN ADVERSE_EFFECT ELT_2_Hypocalcemia 15663-27-1 CISPLATIN ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 15663-27-1 CISPLATIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 15663-27-1 CISPLATIN KNOWN_TOXICITY Cardiovascular Toxicity 15663-27-1 CISPLATIN KNOWN_TOXICITY Nephrotoxicity 15663-27-1 CISPLATIN ACTIVITY_CLASS DNA damager 15663-27-1 CISPLATIN TA_LEVEL_2 DNA damage 15663-27-1 CISPLATIN ZERO_CLASS N 15663-27-1 CISPLATIN INDICATION Ovarian Cancer / Carcinoma of the Ovary 15663-27-1 CISPLATIN ADVERSE_EFFECT GIS_1_Nausea 15663-27-1 CISPLATIN ADVERSE_EFFECT ELT_2_Hypomagnesemia 15663-27-1 CISPLATIN ADVERSE_EFFECT ELT_2_Hyponatremia 15663-27-1 CISPLATIN ADVERSE_EFFECT XXX_3_Facial Edema 77-92-9 CITRIC ACID TA_LEVEL_1 Electrolytic, Caloric and Water Balance 77-92-9 CITRIC ACID ADVERSE_EFFECT ELT_3_Hyperkalemia 77-92-9 CITRIC ACID THERAPEUTIC_CLASS Alkalinizing Agents 77-92-9 CITRIC ACID INDICATION Metabolic Acidosis 77-92-9 CITRIC ACID PRODUCT_CLASS Electrolytic, Caloric and Water Balance 77-92-9 CITRIC ACID STRUCTURE_ACTIVITY Unknown mechanism, acidifying agent 77-92-9 CITRIC ACID ADVERSE_EFFECT GIS_3_Diarrhea 77-92-9 CITRIC ACID MECH_LEVEL_1 blood ph modifier 77-92-9 CITRIC ACID TA_LEVEL_3 Alkalinizing Agents 77-92-9 CITRIC ACID ZERO_CLASS Y 77-92-9 CITRIC ACID MESH_LEVEL_3 Acids, Acyclic 77-92-9 CITRIC ACID ACTIVITY_CLASS Unknown mechanism 77-92-9 CITRIC ACID ADVERSE_EFFECT END_3_Metabolic Alkalosis 77-92-9 CITRIC ACID INDICATION Renal Tubular Acidosis 77-92-9 CITRIC ACID MECH_LEVEL_3 Unknown mechanism 77-92-9 CITRIC ACID MESH_LEVEL_2 Carboxylic Acids 77-92-9 CITRIC ACID MESH_LEVEL_1 Organic Chemicals 518-75-2 CITRININ ADVERSE_EFFECT DNA_3_Carcinogenicity 518-75-2 CITRININ ADVERSE_EFFECT _3_Intussusception 518-75-2 CITRININ ADVERSE_EFFECT KID_1_Proximal Tubular Damage 518-75-2 CITRININ ADVERSE_EFFECT KID_2_Polyuria 518-75-2 CITRININ ADVERSE_EFFECT PSY_1_Depression 518-75-2 CITRININ TISSUE_TOXICITY Hepatic Necrosis 518-75-2 CITRININ ADVERSE_EFFECT BBM_2_Bone Marrow Toxicity 518-75-2 CITRININ ADVERSE_EFFECT XXX_2_Dehydration 518-75-2 CITRININ ADVERSE_EFFECT LUN_2_Bronchoconstriction 518-75-2 CITRININ KNOWN_TOXICITY Hepatotoxicity 518-75-2 CITRININ STRUCTURE_ACTIVITY Toxicant 518-75-2 CITRININ ADVERSE_EFFECT PSY_1_Excitement 518-75-2 CITRININ ADVERSE_EFFECT LIV_1_Hepatic Necrosis 518-75-2 CITRININ MECHANISM Destroy cell membrane / wall integrity 518-75-2 CITRININ ADVERSE_EFFECT KID_2_Nephrotoxicity 518-75-2 CITRININ KNOWN_TOXICITY Nephrotoxicity 518-75-2 CITRININ ADVERSE_EFFECT XXX_1_Lacrimation 518-75-2 CITRININ ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 518-75-2 CITRININ ADVERSE_EFFECT KID_2_Proteinuria 518-75-2 CITRININ ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 518-75-2 CITRININ TISSUE_TOXICITY Carcinogenicity 518-75-2 CITRININ PRODUCT_CLASS Toxicants 518-75-2 CITRININ TISSUE_TOXICITY Nephrotoxicity 518-75-2 CITRININ ADVERSE_EFFECT GUS_1_Urination 518-75-2 CITRININ ADVERSE_EFFECT GIS_1_Emesis 518-75-2 CITRININ KNOWN_TOXICITY Carcinogenicity 106-22-9 CITRONELLOL PRODUCT_CLASS Botanicals 4291-63-8 CLADRIBINE MECHANISM Incorporate into DNA/RNA/Protein 4291-63-8 CLADRIBINE ADVERSE_EFFECT XXX_1_Fever 4291-63-8 CLADRIBINE ADVERSE_EFFECT LUN_2_Cough 4291-63-8 CLADRIBINE ADVERSE_EFFECT BBM_1_Anemia 4291-63-8 CLADRIBINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 4291-63-8 CLADRIBINE ADVERSE_EFFECT BBM_1_Neutropenia 4291-63-8 CLADRIBINE ADVERSE_EFFECT NEU_3_Neurotoxicity 4291-63-8 CLADRIBINE TISSUE_TOXICITY Myelosuppression 4291-63-8 CLADRIBINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 4291-63-8 CLADRIBINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, purine nucleoside 4291-63-8 CLADRIBINE PRODUCT_CLASS Anti-cancers 4291-63-8 CLADRIBINE ADVERSE_EFFECT GIS_2_Diarrhea 4291-63-8 CLADRIBINE ADVERSE_EFFECT XXX_1_Fatigue 4291-63-8 CLADRIBINE ADVERSE_EFFECT SKN_1_Rash 4291-63-8 CLADRIBINE ADVERSE_EFFECT LUN_3_Pulmonary Infiltrates 4291-63-8 CLADRIBINE ADVERSE_EFFECT BBM_1_Myelosuppression 4291-63-8 CLADRIBINE ADVERSE_EFFECT XXX_2_Malaise 4291-63-8 CLADRIBINE ADVERSE_EFFECT CVS_2_Tachycardia 4291-63-8 CLADRIBINE ADVERSE_EFFECT GIS_1_Nausea 4291-63-8 CLADRIBINE ADVERSE_EFFECT NEU_2_Dizziness 4291-63-8 CLADRIBINE ADVERSE_EFFECT XXX_1_Infection 4291-63-8 CLADRIBINE ADVERSE_EFFECT MSK_2_Myalgia 4291-63-8 CLADRIBINE ADVERSE_EFFECT XXX_2_Epistaxis 4291-63-8 CLADRIBINE MODE_CLASS Enzyme substrate mimic 4291-63-8 CLADRIBINE INDICATION Hairy Cell Leukemia 4291-63-8 CLADRIBINE THERAPEUTIC_CLASS Antineoplastics 4291-63-8 CLADRIBINE TISSUE_TOXICITY Neutropenia 4291-63-8 CLADRIBINE ADVERSE_EFFECT PSY_2_Insomnia 4291-63-8 CLADRIBINE ADVERSE_EFFECT NEU_1_Headache 4291-63-8 CLADRIBINE ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 4291-63-8 CLADRIBINE ADVERSE_EFFECT BBM_3_Pancytopenia 4291-63-8 CLADRIBINE TISSUE_TOXICITY Thrombocytopenia 4291-63-8 CLADRIBINE TISSUE_TOXICITY Anemia 4291-63-8 CLADRIBINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 81103-11-9 CLARITHROMYCIN INDICATION Tonsillitis 81103-11-9 CLARITHROMYCIN INDICATION Skin and Skin Structure Infections 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT NEU_1_Headache 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT OTO_2_Hearing Loss 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT XXX_3_Tooth Discoloration 81103-11-9 CLARITHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT GIS_1_Vomiting 81103-11-9 CLARITHROMYCIN MESH_LEVEL_3 Macrolides 81103-11-9 CLARITHROMYCIN INDICATION Pneumonia 81103-11-9 CLARITHROMYCIN INDICATION Pharyngitis 81103-11-9 CLARITHROMYCIN MECH_LEVEL_1 Anti-bacterial 81103-11-9 CLARITHROMYCIN MESH_LEVEL_2 Lactones 81103-11-9 CLARITHROMYCIN MESH_LEVEL_1 Organic Chemicals 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT BBM_2_Leukopenia 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 81103-11-9 CLARITHROMYCIN TA_LEVEL_2 Anti-bacterial 81103-11-9 CLARITHROMYCIN INDICATION Chronic Bronchitis 81103-11-9 CLARITHROMYCIN PRODUCT_CLASS Anti-infectives 81103-11-9 CLARITHROMYCIN TA_LEVEL_1 Infectious Disease 81103-11-9 CLARITHROMYCIN THERAPEUTIC_CLASS Antibacterials, Systemic 81103-11-9 CLARITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 81103-11-9 CLARITHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 81103-11-9 CLARITHROMYCIN ZERO_CLASS N 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT GIS_1_Nausea 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT IMU_3_Anaphylaxis 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT GIS_2_Stomatitis 81103-11-9 CLARITHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 81103-11-9 CLARITHROMYCIN INDICATION Acute Sinusitis 81103-11-9 CLARITHROMYCIN INDICATION Disseminated M. Avium Complex (MAC) Infection 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT PSY_2_Anorexia 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT NEU_2_Dizziness 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT IMU_2_Urticaria 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT BBM_2_Neutropenia 81103-11-9 CLARITHROMYCIN ADVERSE_EFFECT XXX_2_Oral Moniliasis 81103-11-9 CLARITHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 81103-11-9 CLARITHROMYCIN TA_LEVEL_3 Systemic infections 81103-11-9 CLARITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 58001-44-8 CLAVULANIC ACID MECHANISM Inhibit drug resistant enzyme/pump 58001-44-8 CLAVULANIC ACID THERAPEUTIC_CLASS Antibacterials 58001-44-8 CLAVULANIC ACID PRODUCT_CLASS Anti-infectives 58001-44-8 CLAVULANIC ACID MODE_CLASS Enzyme Inhibitor 14976-57-9 CLEMASTINE INDICATION Viral Rhinitis / Common Cold 14976-57-9 CLEMASTINE PRODUCT_CLASS Anti-inflammatories 14976-57-9 CLEMASTINE TISSUE_TOXICITY Hypotension 14976-57-9 CLEMASTINE ADVERSE_EFFECT GIS_2_Constipation 14976-57-9 CLEMASTINE ADVERSE_EFFECT CVS_3_Hypertension 14976-57-9 CLEMASTINE ADVERSE_EFFECT NEU_1_Dizziness 14976-57-9 CLEMASTINE ADVERSE_EFFECT CVS_1_Palpitation 14976-57-9 CLEMASTINE MESH_LEVEL_3 Pyrrolidines 14976-57-9 CLEMASTINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 14976-57-9 CLEMASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist, diphenylamine 14976-57-9 CLEMASTINE INDICATION Angioedema 14976-57-9 CLEMASTINE ADVERSE_EFFECT CVS_3_Hypotension 14976-57-9 CLEMASTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 14976-57-9 CLEMASTINE ADVERSE_EFFECT XXX_1_Restlessness 14976-57-9 CLEMASTINE MODE_CLASS Receptor Ligand Antagonist 14976-57-9 CLEMASTINE MECH_LEVEL_1 Immunomodulation 14976-57-9 CLEMASTINE MESH_LEVEL_1 Heterocyclic Compounds 14976-57-9 CLEMASTINE MECH_LEVEL_3 histamine receptor H1 14976-57-9 CLEMASTINE INDICATION Allergic Rhinitis 14976-57-9 CLEMASTINE INDICATION Urticaria / Hives 14976-57-9 CLEMASTINE THERAPEUTIC_CLASS Antihistamines 14976-57-9 CLEMASTINE ZERO_CLASS N 14976-57-9 CLEMASTINE ADVERSE_EFFECT PSY_1_CNS Depression 14976-57-9 CLEMASTINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 14976-57-9 CLEMASTINE ADVERSE_EFFECT NEU_2_Seizures 14976-57-9 CLEMASTINE ADVERSE_EFFECT XXX_2_Xerostomia 14976-57-9 CLEMASTINE ADVERSE_EFFECT GUS_2_Urinary Retention 14976-57-9 CLEMASTINE TA_LEVEL_1 Anti-inflammatory 14976-57-9 CLEMASTINE INDICATION Pruritus / Itching 14976-57-9 CLEMASTINE MECH_LEVEL_2 Anti-histamine 14976-57-9 CLEMASTINE TA_LEVEL_2 Anti-histamine 14976-57-9 CLEMASTINE MECHANISM Modulate G-protein coupled signal transduction 14976-57-9 CLEMASTINE KNOWN_TOXICITY Cardiovascular Toxicity 14976-57-9 CLEMASTINE ACTIVITY_CLASS Histamine antagonist 14976-57-9 CLEMASTINE ADVERSE_EFFECT OCU_2_Blurred Vision 14976-57-9 CLEMASTINE ADVERSE_EFFECT PSY_1_Insomnia 14976-57-9 CLEMASTINE ADVERSE_EFFECT NEU_1_Drowsiness 14976-57-9 CLEMASTINE ADVERSE_EFFECT GIS_2_Abdominal Pain 14976-57-9 CLEMASTINE ADVERSE_EFFECT GIS_3_Diarrhea 37148-27-9 CLENBUTEROL PRODUCT_CLASS Hormones, Endocrine and Metabolic 37148-27-9 CLENBUTEROL ADVERSE_EFFECT CVS_2_Palpitation 37148-27-9 CLENBUTEROL ADVERSE_EFFECT XXX_3_Thirst 37148-27-9 CLENBUTEROL ADVERSE_EFFECT MSK_2_Muscle Pain 37148-27-9 CLENBUTEROL ADVERSE_EFFECT XXX_3_Edema 37148-27-9 CLENBUTEROL MODE_CLASS Receptor Agonist, selective 37148-27-9 CLENBUTEROL ADVERSE_EFFECT NEU_1_Tremor 37148-27-9 CLENBUTEROL ADVERSE_EFFECT CVS_3_Hypertension 37148-27-9 CLENBUTEROL THERAPEUTIC_CLASS Sympathomimetic Agents 37148-27-9 CLENBUTEROL PRODUCT_CLASS Respiratory System 37148-27-9 CLENBUTEROL STRUCTURE_ACTIVITY Adrenoceptor-alpha2 agonist 37148-27-9 CLENBUTEROL ADVERSE_EFFECT CVS_3_Arrhythmia 37148-27-9 CLENBUTEROL ADVERSE_EFFECT GIS_3_Abdominal Pain 37148-27-9 CLENBUTEROL ADVERSE_EFFECT NEU_2_Headache 37148-27-9 CLENBUTEROL ADVERSE_EFFECT PSY_3_Anorexia 37148-27-9 CLENBUTEROL ADVERSE_EFFECT GIS_3_Diarrhea 37148-27-9 CLENBUTEROL PRODUCT_CLASS Autonomic Nervous System (ANS) 37148-27-9 CLENBUTEROL INDICATION Asthma 37148-27-9 CLENBUTEROL MECHANISM Reduce bronchoconstriction 37148-27-9 CLENBUTEROL INDICATION Stress Incontinence 37148-27-9 CLENBUTEROL TISSUE_TOXICITY Arrhythmia 37148-27-9 CLENBUTEROL ADVERSE_EFFECT GIS_3_Constipation 37148-27-9 CLENBUTEROL ADVERSE_EFFECT END_3_Hot Flashes 37148-27-9 CLENBUTEROL ADVERSE_EFFECT GIS_3_Heartburn 37148-27-9 CLENBUTEROL ADVERSE_EFFECT NEU_3_Dizziness 37148-27-9 CLENBUTEROL ADVERSE_EFFECT PSY_2_Insomnia 37148-27-9 CLENBUTEROL ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 37148-27-9 CLENBUTEROL ADVERSE_EFFECT SKN_2_Skin Rash 37148-27-9 CLENBUTEROL ADVERSE_EFFECT MSK_2_Spasm 37148-27-9 CLENBUTEROL THERAPEUTIC_CLASS Bronchodilators 37148-27-9 CLENBUTEROL KNOWN_TOXICITY Cardiovascular Toxicity 37148-27-9 CLENBUTEROL ADVERSE_EFFECT CVS_2_Tachycardia 37148-27-9 CLENBUTEROL ADVERSE_EFFECT PSY_2_Nervousness 37148-27-9 CLENBUTEROL ADVERSE_EFFECT GIS_2_Nausea 37148-27-9 CLENBUTEROL ADVERSE_EFFECT NEU_3_Sleepiness 3485-62-9 CLIDINIUM BROMIDE THERAPEUTIC_CLASS Antispasmodic Agents 3485-62-9 CLIDINIUM BROMIDE PRODUCT_CLASS Gastrointestinal System 3485-62-9 CLIDINIUM BROMIDE MECHANISM Modulate G-protein coupled signal transduction 3485-62-9 CLIDINIUM BROMIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 3485-62-9 CLIDINIUM BROMIDE THERAPEUTIC_CLASS Antiulcers 3485-62-9 CLIDINIUM BROMIDE MODE_CLASS Receptor Ligand Antagonist 18323-44-9 CLINDAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 18323-44-9 CLINDAMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 18323-44-9 CLINDAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, lincosamide 18323-44-9 CLINDAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 18323-44-9 CLINDAMYCIN INDICATION Bone and Joint Infection 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 18323-44-9 CLINDAMYCIN MESH_LEVEL_3 Glycosides 18323-44-9 CLINDAMYCIN PRODUCT_CLASS Anti-infectives 18323-44-9 CLINDAMYCIN MESH_LEVEL_2 Carbohydrates 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT KID_3_Proteinuria 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Esophagitis 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT KID_3_Azotemia 18323-44-9 CLINDAMYCIN TA_LEVEL_1 Infectious Disease 18323-44-9 CLINDAMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 18323-44-9 CLINDAMYCIN TA_LEVEL_2 Anti-bacterial 18323-44-9 CLINDAMYCIN INDICATION Bacteremia 18323-44-9 CLINDAMYCIN INDICATION Septicemia 18323-44-9 CLINDAMYCIN KNOWN_TOXICITY Gastrointestinal Toxicity 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 18323-44-9 CLINDAMYCIN INDICATION Skin and Skin Structure Infections 18323-44-9 CLINDAMYCIN TA_LEVEL_3 Systemic infections 18323-44-9 CLINDAMYCIN MECHANISM Inhibit ribosomal protein synthesis 18323-44-9 CLINDAMYCIN INDICATION Acne / Acne Vulgaris 18323-44-9 CLINDAMYCIN INDICATION Intra-Abdominal Infections 18323-44-9 CLINDAMYCIN TISSUE_TOXICITY Pseudomembranous Colitis 18323-44-9 CLINDAMYCIN THERAPEUTIC_CLASS Antibacterials 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Agranulocytosis 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Pruritis 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Urticaria 18323-44-9 CLINDAMYCIN MECH_LEVEL_1 Anti-bacterial 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT KID_3_Renal Dysfunction 18323-44-9 CLINDAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 18323-44-9 CLINDAMYCIN INDICATION Gynecologic Infections 18323-44-9 CLINDAMYCIN INDICATION Lower Respiratory Tract Infection 18323-44-9 CLINDAMYCIN ZERO_CLASS N 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Neutropenia 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 18323-44-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Pseudomembranous Colitis 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Neutropenia 17431-55-9 CLINDAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 17431-55-9 CLINDAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 17431-55-9 CLINDAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, lincosamide 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 17431-55-9 CLINDAMYCIN INDICATION Septicemia 17431-55-9 CLINDAMYCIN INDICATION Bacteremia 17431-55-9 CLINDAMYCIN TA_LEVEL_2 Anti-bacterial 17431-55-9 CLINDAMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 17431-55-9 CLINDAMYCIN TA_LEVEL_1 Infectious Disease 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT KID_3_Azotemia 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Esophagitis 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT KID_3_Renal Dysfunction 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Pseudomembranous Colitis 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Urticaria 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Pruritis 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Agranulocytosis 17431-55-9 CLINDAMYCIN THERAPEUTIC_CLASS Antibacterials 17431-55-9 CLINDAMYCIN TISSUE_TOXICITY Pseudomembranous Colitis 17431-55-9 CLINDAMYCIN INDICATION Intra-Abdominal Infections 17431-55-9 CLINDAMYCIN INDICATION Acne / Acne Vulgaris 17431-55-9 CLINDAMYCIN TA_LEVEL_3 Systemic infections 17431-55-9 CLINDAMYCIN MECH_LEVEL_1 Anti-bacterial 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 17431-55-9 CLINDAMYCIN MECHANISM Inhibit ribosomal protein synthesis 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 17431-55-9 CLINDAMYCIN KNOWN_TOXICITY Gastrointestinal Toxicity 17431-55-9 CLINDAMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 17431-55-9 CLINDAMYCIN INDICATION Gynecologic Infections 17431-55-9 CLINDAMYCIN INDICATION Lower Respiratory Tract Infection 17431-55-9 CLINDAMYCIN ZERO_CLASS N 17431-55-9 CLINDAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT KID_3_Proteinuria 17431-55-9 CLINDAMYCIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 17431-55-9 CLINDAMYCIN MESH_LEVEL_2 Carbohydrates 17431-55-9 CLINDAMYCIN PRODUCT_CLASS Anti-infectives 17431-55-9 CLINDAMYCIN MESH_LEVEL_3 Glycosides 17431-55-9 CLINDAMYCIN INDICATION Skin and Skin Structure Infections 17431-55-9 CLINDAMYCIN INDICATION Bone and Joint Infection 21462-39-5 CLINDAMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 21462-39-5 CLINDAMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 21462-39-5 CLINDAMYCIN TA_LEVEL_1 Infectious Disease 21462-39-5 CLINDAMYCIN KNOWN_TOXICITY Gastrointestinal Toxicity 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Esophagitis 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT KID_3_Proteinuria 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT SKN_2_Maculopapular Rash 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 21462-39-5 CLINDAMYCIN MESH_LEVEL_1 Carbohydrates and Hypoglycemic Agents 21462-39-5 CLINDAMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, lincosamide 21462-39-5 CLINDAMYCIN TA_LEVEL_3 Systemic infections 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT KID_3_Azotemia 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 21462-39-5 CLINDAMYCIN MECH_LEVEL_1 Anti-bacterial 21462-39-5 CLINDAMYCIN MECHANISM Inhibit ribosomal protein synthesis 21462-39-5 CLINDAMYCIN INDICATION Acne / Acne Vulgaris 21462-39-5 CLINDAMYCIN INDICATION Intra-Abdominal Infections 21462-39-5 CLINDAMYCIN TISSUE_TOXICITY Pseudomembranous Colitis 21462-39-5 CLINDAMYCIN THERAPEUTIC_CLASS Antibacterials 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Agranulocytosis 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Pruritis 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Urticaria 21462-39-5 CLINDAMYCIN MESH_LEVEL_2 Carbohydrates 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Pseudomembranous Colitis 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT KID_3_Renal Dysfunction 21462-39-5 CLINDAMYCIN INDICATION Septicemia 21462-39-5 CLINDAMYCIN PRODUCT_CLASS Anti-infectives 21462-39-5 CLINDAMYCIN MESH_LEVEL_3 Glycosides 21462-39-5 CLINDAMYCIN INDICATION Skin and Skin Structure Infections 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 21462-39-5 CLINDAMYCIN ZERO_CLASS N 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT IMU_2_Eosinophilia 21462-39-5 CLINDAMYCIN INDICATION Lower Respiratory Tract Infection 21462-39-5 CLINDAMYCIN INDICATION Gynecologic Infections 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 21462-39-5 CLINDAMYCIN INDICATION Bone and Joint Infection 21462-39-5 CLINDAMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 21462-39-5 CLINDAMYCIN TA_LEVEL_2 Anti-bacterial 21462-39-5 CLINDAMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 21462-39-5 CLINDAMYCIN INDICATION Bacteremia 21462-39-5 CLINDAMYCIN ADVERSE_EFFECT BBM_2_Neutropenia 145231-45-4 CLOBENPROPIT MODE_CLASS Receptor Ligand Antagonist 145231-45-4 CLOBENPROPIT MECHANISM Modulate G-protein coupled signal transduction 145231-45-4 CLOBENPROPIT PRODUCT_CLASS Biochemicals 25122-46-7 CLOBETASOL PROPIONATE PRODUCT_CLASS Dermatologicals 25122-46-7 CLOBETASOL PROPIONATE MODE_CLASS Receptor Agonist 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT XXX_3_Impaired Wound Healing 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT OCU_3_Papilledema 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_2_Skin Ulcer 25122-46-7 CLOBETASOL PROPIONATE INDICATION Seborrheic Dermatitis 25122-46-7 CLOBETASOL PROPIONATE INDICATION Dermatitis 25122-46-7 CLOBETASOL PROPIONATE INDICATION Lichen Planus 25122-46-7 CLOBETASOL PROPIONATE INDICATION Alopecia / Baldness / Hair Loss 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_1_Skin Irritation 25122-46-7 CLOBETASOL PROPIONATE MESH_LEVEL_3 Steroids, Fluorinated 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_2_Skin Atrophy 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT END_3_Hyperglycemia 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT IMU_2_Contact Dermatitis 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 25122-46-7 CLOBETASOL PROPIONATE MECHANISM Modulate gene transcription 25122-46-7 CLOBETASOL PROPIONATE MESH_LEVEL_1 Polycyclic Hydrocarbons 25122-46-7 CLOBETASOL PROPIONATE INDICATION Keloid Scarring 25122-46-7 CLOBETASOL PROPIONATE INDICATION Pruritus / Itching 25122-46-7 CLOBETASOL PROPIONATE INDICATION Allergic Contact Dermatitis 25122-46-7 CLOBETASOL PROPIONATE ZERO_CLASS N 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT XXX_2_Miliaria 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_2_Skin Hypopigmentation 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT XXX_3_Tolerance 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_2_Erythema 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT END_3_Adrenal Insufficiency 25122-46-7 CLOBETASOL PROPIONATE MESH_LEVEL_2 Steroids 25122-46-7 CLOBETASOL PROPIONATE INDICATION Psoriasis 25122-46-7 CLOBETASOL PROPIONATE INDICATION Urticaria / Hives 25122-46-7 CLOBETASOL PROPIONATE INDICATION Atopic Dermatitis / Eczema 25122-46-7 CLOBETASOL PROPIONATE TA_LEVEL_2 Steroid 25122-46-7 CLOBETASOL PROPIONATE MECH_LEVEL_3 Glucocorticoid receptor 25122-46-7 CLOBETASOL PROPIONATE TA_LEVEL_3 Topical steroid 25122-46-7 CLOBETASOL PROPIONATE TA_LEVEL_1 Anti-inflammatory 25122-46-7 CLOBETASOL PROPIONATE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 25122-46-7 CLOBETASOL PROPIONATE ACTIVITY_CLASS GR-MR agonist 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT END_3_Cushing's Syndrome 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT XXX_3_Infection 25122-46-7 CLOBETASOL PROPIONATE THERAPEUTIC_CLASS Corticosteroids, Topical 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT CVS_2_Telangiectasia 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT XXX_3_Withdrawal 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_2_Acneiform Rash 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT OCU_3_Cataracts 25122-46-7 CLOBETASOL PROPIONATE ADVERSE_EFFECT SKN_3_Hypertrichosis 25122-46-7 CLOBETASOL PROPIONATE INDICATION Exfoliative Dermatitis / Exfoliative Erythroderma 25122-46-7 CLOBETASOL PROPIONATE INDICATION Skin Diseases / Dermatoses 25122-46-7 CLOBETASOL PROPIONATE INDICATION Oral Lichen Planus 25122-46-7 CLOBETASOL PROPIONATE INDICATION Discoid Lupus Erythematosus / Chronic Cutaneous Lupus Erythematosus 25122-46-7 CLOBETASOL PROPIONATE MECH_LEVEL_2 Anti-inflammation and immunosuppression 25122-46-7 CLOBETASOL PROPIONATE MECH_LEVEL_1 Immunomodulation 34097-16-0 CLOCORTOLONE PIVALATE MECHANISM Modulate gene transcription 34097-16-0 CLOCORTOLONE PIVALATE MODE_CLASS Receptor Agonist 15690-55-8 CLOMIPHENE TISSUE_TOXICITY Endometrial Carcinoma 15690-55-8 CLOMIPHENE THERAPEUTIC_CLASS Gonadal Hormones 15690-55-8 CLOMIPHENE ADVERSE_EFFECT IMU_3_Hypersensitivity 15690-55-8 CLOMIPHENE ADVERSE_EFFECT DNA_3_Increased Incidence of Breast Carcinoma 15690-55-8 CLOMIPHENE ADVERSE_EFFECT CVS_3_Arrhythmia 15690-55-8 CLOMIPHENE ADVERSE_EFFECT REP_1_Ovarian Enlargement 15690-55-8 CLOMIPHENE TISSUE_TOXICITY Increased Incidence of Breast Carcinoma 15690-55-8 CLOMIPHENE ADVERSE_EFFECT PSY_3_Psychosis 15690-55-8 CLOMIPHENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 15690-55-8 CLOMIPHENE MESH_LEVEL_2 Hydrocarbons 15690-55-8 CLOMIPHENE TISSUE_TOXICITY Invasive Ovarian Tumor 15690-55-8 CLOMIPHENE TA_LEVEL_3 Fertility drug 15690-55-8 CLOMIPHENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 15690-55-8 CLOMIPHENE ADVERSE_EFFECT SKN_3_Hypertrichosis 15690-55-8 CLOMIPHENE ADVERSE_EFFECT OCU_3_Photophobia 15690-55-8 CLOMIPHENE ADVERSE_EFFECT REP_3_Ovarian Hyperstimulation Syndrome (OHSS) 15690-55-8 CLOMIPHENE TA_LEVEL_2 Ovulation inducer 15690-55-8 CLOMIPHENE MODE_CLASS Receptor Ligand Antagonist 15690-55-8 CLOMIPHENE ADVERSE_EFFECT DNA_3_Endometrial Carcinoma 15690-55-8 CLOMIPHENE ADVERSE_EFFECT CVS_3_Stroke 15690-55-8 CLOMIPHENE ADVERSE_EFFECT EMB_3_Congenital Malformations 15690-55-8 CLOMIPHENE ADVERSE_EFFECT LIV_3_Hepatitis 15690-55-8 CLOMIPHENE TISSUE_TOXICITY Hepatocellular Carcinoma 15690-55-8 CLOMIPHENE INDICATION Female Infertility 15690-55-8 CLOMIPHENE KNOWN_TOXICITY Carcinogenicity 15690-55-8 CLOMIPHENE MECH_LEVEL_1 initiate steroidogenesis and folliculogenesis 15690-55-8 CLOMIPHENE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 15690-55-8 CLOMIPHENE KNOWN_TOXICITY Cardiovascular Toxicity 15690-55-8 CLOMIPHENE ADVERSE_EFFECT END_2_Breast Discomfort 15690-55-8 CLOMIPHENE ADVERSE_EFFECT END_1_Hot Flashes 15690-55-8 CLOMIPHENE MECH_LEVEL_2 Estrogen receptor antagonist 15690-55-8 CLOMIPHENE ADVERSE_EFFECT DNA_3_Invasive Ovarian Tumor 15690-55-8 CLOMIPHENE MECH_LEVEL_3 estrogen receptor 15690-55-8 CLOMIPHENE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 15690-55-8 CLOMIPHENE ACTIVITY_CLASS Estrogen antagonist 15690-55-8 CLOMIPHENE MESH_LEVEL_3 Hydrocarbons, Cyclic 15690-55-8 CLOMIPHENE MESH_LEVEL_1 Organic Chemicals 15690-55-8 CLOMIPHENE TISSUE_TOXICITY Arrhythmia 15690-55-8 CLOMIPHENE ZERO_CLASS N 15690-55-8 CLOMIPHENE ADVERSE_EFFECT NEU_3_Seizures 15690-55-8 CLOMIPHENE ADVERSE_EFFECT OCU_2_Visual Impairment 15690-55-8 CLOMIPHENE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 15690-55-8 CLOMIPHENE ADVERSE_EFFECT GUS_2_Vaginal Spotting 15690-55-8 CLOMIPHENE ADVERSE_EFFECT GIS_1_Abdominal Distention 15690-55-8 CLOMIPHENE TA_LEVEL_1 Hormones, Endocrine and Metabolic 15690-55-8 CLOMIPHENE INDICATION Ovulation Dysfunction 15690-55-8 CLOMIPHENE MECHANISM Modulate gene transcription 15690-55-8 CLOMIPHENE TISSUE_TOXICITY Stroke 911-45-5 CLOMIPHENE ZERO_CLASS N 911-45-5 CLOMIPHENE ADVERSE_EFFECT SKN_3_Hypertrichosis 911-45-5 CLOMIPHENE ADVERSE_EFFECT OCU_3_Photophobia 911-45-5 CLOMIPHENE TA_LEVEL_2 Ovulation inducer 911-45-5 CLOMIPHENE STRUCTURE_ACTIVITY Estrogen receptor antagonist/agonist, tissue specific 911-45-5 CLOMIPHENE TA_LEVEL_3 Fertility drug 911-45-5 CLOMIPHENE MECH_LEVEL_2 Estrogen receptor antagonist 911-45-5 CLOMIPHENE PRODUCT_CLASS Hormones, Endocrine and Metabolic 911-45-5 CLOMIPHENE MESH_LEVEL_2 Hydrocarbons 911-45-5 CLOMIPHENE TISSUE_TOXICITY Invasive Ovarian Tumor 911-45-5 CLOMIPHENE TISSUE_TOXICITY Increased Incidence of Breast Carcinoma 911-45-5 CLOMIPHENE KNOWN_TOXICITY Cardiovascular Toxicity 911-45-5 CLOMIPHENE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 911-45-5 CLOMIPHENE INDICATION Female Infertility 911-45-5 CLOMIPHENE MECH_LEVEL_3 estrogen receptor 911-45-5 CLOMIPHENE ADVERSE_EFFECT EMB_3_Congenital Malformations 911-45-5 CLOMIPHENE ADVERSE_EFFECT DNA_3_Increased Incidence of Breast Carcinoma 911-45-5 CLOMIPHENE ADVERSE_EFFECT END_2_Breast Discomfort 911-45-5 CLOMIPHENE ADVERSE_EFFECT END_1_Hot Flashes 911-45-5 CLOMIPHENE ADVERSE_EFFECT DNA_3_Invasive Ovarian Tumor 911-45-5 CLOMIPHENE ADVERSE_EFFECT REP_1_Ovarian Enlargement 911-45-5 CLOMIPHENE MODE_CLASS Receptor Ligand Antagonist 911-45-5 CLOMIPHENE MECH_LEVEL_1 initiate steroidogenesis and folliculogenesis 911-45-5 CLOMIPHENE TISSUE_TOXICITY Hepatocellular Carcinoma 911-45-5 CLOMIPHENE KNOWN_TOXICITY Carcinogenicity 911-45-5 CLOMIPHENE ADVERSE_EFFECT LIV_3_Hepatitis 911-45-5 CLOMIPHENE ADVERSE_EFFECT CVS_3_Stroke 911-45-5 CLOMIPHENE ADVERSE_EFFECT DNA_3_Endometrial Carcinoma 911-45-5 CLOMIPHENE ADVERSE_EFFECT CVS_3_Arrhythmia 911-45-5 CLOMIPHENE ADVERSE_EFFECT REP_3_Ovarian Hyperstimulation Syndrome (OHSS) 911-45-5 CLOMIPHENE ACTIVITY_CLASS Estrogen antagonist 911-45-5 CLOMIPHENE MESH_LEVEL_3 Hydrocarbons, Cyclic 911-45-5 CLOMIPHENE MESH_LEVEL_1 Organic Chemicals 911-45-5 CLOMIPHENE TISSUE_TOXICITY Arrhythmia 911-45-5 CLOMIPHENE ADVERSE_EFFECT NEU_3_Seizures 911-45-5 CLOMIPHENE ADVERSE_EFFECT OCU_2_Visual Impairment 911-45-5 CLOMIPHENE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 911-45-5 CLOMIPHENE ADVERSE_EFFECT GUS_2_Vaginal Spotting 911-45-5 CLOMIPHENE ADVERSE_EFFECT GIS_1_Abdominal Distention 911-45-5 CLOMIPHENE TA_LEVEL_1 Hormones, Endocrine and Metabolic 911-45-5 CLOMIPHENE INDICATION Ovulation Dysfunction 911-45-5 CLOMIPHENE MECHANISM Modulate gene transcription 911-45-5 CLOMIPHENE TISSUE_TOXICITY Stroke 911-45-5 CLOMIPHENE TISSUE_TOXICITY Endometrial Carcinoma 911-45-5 CLOMIPHENE THERAPEUTIC_CLASS Gonadal Hormones 911-45-5 CLOMIPHENE ADVERSE_EFFECT IMU_3_Hypersensitivity 911-45-5 CLOMIPHENE ADVERSE_EFFECT PSY_3_Psychosis 911-45-5 CLOMIPHENE ADVERSE_EFFECT DNA_3_Hepatocellular Carcinoma 17321-77-6 CLOMIPRAMINE INDICATION Depression 17321-77-6 CLOMIPRAMINE MESH_LEVEL_1 Heterocyclic Compounds 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 17321-77-6 CLOMIPRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 17321-77-6 CLOMIPRAMINE THERAPEUTIC_CLASS Antidepressants 17321-77-6 CLOMIPRAMINE MODE_CLASS Solute transporter inhibitor 17321-77-6 CLOMIPRAMINE INDICATION Obsessive-Compulsive Disorder (OCD) 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT IMU_3_Eosinophilia 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT OCU_3_Glaucoma 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 17321-77-6 CLOMIPRAMINE TISSUE_TOXICITY Cardiac Failure 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 17321-77-6 CLOMIPRAMINE MESH_LEVEL_3 Dibenzazepines 17321-77-6 CLOMIPRAMINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT REP_3_Impotence 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT END_3_Gynecomastia 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 17321-77-6 CLOMIPRAMINE MECHANISM Prolong/enhance neural transmission 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Anemia 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Failure 17321-77-6 CLOMIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 17321-77-6 CLOMIPRAMINE TA_LEVEL_3 obsessive compulsive 17321-77-6 CLOMIPRAMINE ZERO_CLASS N 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT XXX_2_Breast Enlargement 17321-77-6 CLOMIPRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT END_2_Galactorrhea 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT BBM_3_Leukopenia 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 17321-77-6 CLOMIPRAMINE MECH_LEVEL_2 receptor ligand antagonist 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT LIV_3_Jaundice 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT NEU_3_Convulsions 17321-77-6 CLOMIPRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 17321-77-6 CLOMIPRAMINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 17321-77-6 CLOMIPRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 17321-77-6 CLOMIPRAMINE TA_LEVEL_1 Central Nervous System (CNS) 17321-77-6 CLOMIPRAMINE MECH_LEVEL_3 Dopamine (DA) Transporter DAT 17321-77-6 CLOMIPRAMINE TA_LEVEL_2 Anti-depressant 1622-61-3 CLONAZEPAM TA_LEVEL_1 Central Nervous System (CNS) 1622-61-3 CLONAZEPAM INDICATION Absence (Petit Mal) Seizures 1622-61-3 CLONAZEPAM INDICATION Panic Disorder 1622-61-3 CLONAZEPAM ADVERSE_EFFECT XXX_2_Salivation 1622-61-3 CLONAZEPAM ADVERSE_EFFECT SKN_2_Rash 1622-61-3 CLONAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 1622-61-3 CLONAZEPAM ADVERSE_EFFECT PSY_2_Confusion 1622-61-3 CLONAZEPAM ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 1622-61-3 CLONAZEPAM ADVERSE_EFFECT PSY_1_Behavioral Changes 1622-61-3 CLONAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_2_Impaired Motor Function 1622-61-3 CLONAZEPAM MODE_CLASS Channel enhancer /opener 1622-61-3 CLONAZEPAM MESH_LEVEL_3 Benzazepines 1622-61-3 CLONAZEPAM TA_LEVEL_2 CNS Depressant 1622-61-3 CLONAZEPAM ZERO_CLASS N 1622-61-3 CLONAZEPAM TA_LEVEL_3 Antiepileptics / Anticonvulsants 1622-61-3 CLONAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 1622-61-3 CLONAZEPAM MECH_LEVEL_2 faciliates GABA binding 1622-61-3 CLONAZEPAM MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 1622-61-3 CLONAZEPAM INDICATION Akinetic Seizures 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_2_Headache 1622-61-3 CLONAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_1_Ataxia 1622-61-3 CLONAZEPAM ADVERSE_EFFECT PSY_2_Irritability 1622-61-3 CLONAZEPAM ADVERSE_EFFECT CVS_2_Postural Hypotension 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_2_Impaired Mental Function 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 1622-61-3 CLONAZEPAM ACTIVITY_CLASS GABA agonist 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_2_Choreiform Movements 1622-61-3 CLONAZEPAM ADVERSE_EFFECT LIV_3_Hepatomegaly 1622-61-3 CLONAZEPAM ADVERSE_EFFECT GUS_3_Difficulty Urinating 1622-61-3 CLONAZEPAM ADVERSE_EFFECT OCU_3_Diplopia 1622-61-3 CLONAZEPAM ADVERSE_EFFECT XXX_1_Withdrawal 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 1622-61-3 CLONAZEPAM ADVERSE_EFFECT PSY_2_Depression 1622-61-3 CLONAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 1622-61-3 CLONAZEPAM TISSUE_TOXICITY Teratogenicity 1622-61-3 CLONAZEPAM THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 1622-61-3 CLONAZEPAM MECHANISM Modulate neural transmission 1622-61-3 CLONAZEPAM INDICATION Myoclonic Seizures 1622-61-3 CLONAZEPAM MESH_LEVEL_1 Heterocyclic Compounds 1622-61-3 CLONAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_2_Dysdiadochokinesis 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_1_Impaired Coordination 1622-61-3 CLONAZEPAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 1622-61-3 CLONAZEPAM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_2_Anterograde Amnesia 1622-61-3 CLONAZEPAM ADVERSE_EFFECT NEU_3_Coma 1622-61-3 CLONAZEPAM ADVERSE_EFFECT REP_3_Sexual Dysfunction 1622-61-3 CLONAZEPAM INDICATION Lennox-Gastaut Syndrome (Petit Mal Variant) 1622-61-3 CLONAZEPAM MECH_LEVEL_1 Modulate neural transmission 1622-61-3 CLONAZEPAM MECH_LEVEL_3 GABA-A receptor 1622-61-3 CLONAZEPAM THERAPEUTIC_CLASS Anxiolytics 1622-61-3 CLONAZEPAM ADVERSE_EFFECT LUN_3_Respiratory Depression 4205-91-8 CLONIDINE MECHANISM Modulate gene transcription 4205-91-8 CLONIDINE MESH_LEVEL_1 Heterocyclic Compounds 4205-91-8 CLONIDINE ZERO_CLASS N 4205-91-8 CLONIDINE MECH_LEVEL_3 adrenoceptor alpha2 4205-91-8 CLONIDINE MESH_LEVEL_3 Imidazoles 4205-91-8 CLONIDINE PRODUCT_CLASS Analgesics 4205-91-8 CLONIDINE TA_LEVEL_3 hypertension 4205-91-8 CLONIDINE INDICATION Pain 4205-91-8 CLONIDINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 4205-91-8 CLONIDINE STRUCTURE_ACTIVITY Adrenoceptor-alpha2 agonist, imidazoline receptor agonist 4205-91-8 CLONIDINE THERAPEUTIC_CLASS Antihypertensive Agents 4205-91-8 CLONIDINE KNOWN_TOXICITY Cardiovascular Toxicity 4205-91-8 CLONIDINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 4205-91-8 CLONIDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 4205-91-8 CLONIDINE ADVERSE_EFFECT NEU_1_Dizziness 4205-91-8 CLONIDINE ADVERSE_EFFECT XXX_1_Lethargy 4205-91-8 CLONIDINE ADVERSE_EFFECT SKN_2_Erythema 4205-91-8 CLONIDINE ADVERSE_EFFECT CVS_1_Palpitation 4205-91-8 CLONIDINE TA_LEVEL_1 Cardiovascular 4205-91-8 CLONIDINE MECH_LEVEL_2 alpha agonist 4205-91-8 CLONIDINE MECH_LEVEL_1 Vasorelaxation 4205-91-8 CLONIDINE ACTIVITY_CLASS Adrenergic agonist 4205-91-8 CLONIDINE INDICATION Hypertension 4205-91-8 CLONIDINE TISSUE_TOXICITY Hypotension 4205-91-8 CLONIDINE ADVERSE_EFFECT CVS_1_Hypotension 4205-91-8 CLONIDINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 4205-91-8 CLONIDINE ADVERSE_EFFECT NEU_2_Headache 4205-91-8 CLONIDINE ADVERSE_EFFECT PSY_1_Confusion 4205-91-8 CLONIDINE ADVERSE_EFFECT LUN_1_Dyspnea 4205-91-8 CLONIDINE ADVERSE_EFFECT GUS_2_Dysuria 4205-91-8 CLONIDINE ADVERSE_EFFECT XXX_1_Xerostomia 4205-91-8 CLONIDINE MECHANISM Reduce vasoconstriction 4205-91-8 CLONIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 4205-91-8 CLONIDINE PRODUCT_CLASS Cardiovasculars 4205-91-8 CLONIDINE MODE_CLASS Receptor Agonist 4205-91-8 CLONIDINE ADVERSE_EFFECT GIS_1_Constipation 4205-91-8 CLONIDINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 4205-91-8 CLONIDINE ADVERSE_EFFECT REP_2_Impotence 4205-91-8 CLONIDINE ADVERSE_EFFECT SKN_2_Pruritis 4205-91-8 CLONIDINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 4205-91-8 CLONIDINE ADVERSE_EFFECT XXX_1_Weight Gain 4205-91-8 CLONIDINE ADVERSE_EFFECT XXX_1_Asthenia 4205-91-8 CLONIDINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 4205-91-8 CLONIDINE TA_LEVEL_2 alpha agonist 4205-91-8 CLONIDINE ADVERSE_EFFECT GUS_2_Urinary Retention 4205-91-8 CLONIDINE ADVERSE_EFFECT PSY_1_Anxiety 4205-91-8 CLONIDINE ADVERSE_EFFECT XXX_2_Fatigue 4205-91-8 CLONIDINE ADVERSE_EFFECT NEU_1_Drowsiness 4205-91-8 CLONIDINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 4205-91-8 CLONIDINE ADVERSE_EFFECT REP_2_Decreased Libido 4205-91-8 CLONIDINE ADVERSE_EFFECT CVS_1_Chest Pain 4205-90-7 CLONIDINE ADVERSE_EFFECT CVS_1_Chest Pain 4205-90-7 CLONIDINE KNOWN_TOXICITY Cardiovascular Toxicity 4205-90-7 CLONIDINE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 4205-90-7 CLONIDINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 4205-90-7 CLONIDINE ADVERSE_EFFECT NEU_1_Dizziness 4205-90-7 CLONIDINE ADVERSE_EFFECT SKN_2_Erythema 4205-90-7 CLONIDINE ADVERSE_EFFECT CVS_1_Palpitation 4205-90-7 CLONIDINE MESH_LEVEL_1 Heterocyclic Compounds 4205-90-7 CLONIDINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 4205-90-7 CLONIDINE STRUCTURE_ACTIVITY Adrenoceptor-alpha2 agonist, imidazoline receptor agonist 4205-90-7 CLONIDINE MECH_LEVEL_3 adrenoceptor alpha2 4205-90-7 CLONIDINE MESH_LEVEL_3 Imidazoles 4205-90-7 CLONIDINE ADVERSE_EFFECT XXX_1_Lethargy 4205-90-7 CLONIDINE PRODUCT_CLASS Analgesics 4205-90-7 CLONIDINE TA_LEVEL_3 hypertension 4205-90-7 CLONIDINE INDICATION Pain 4205-90-7 CLONIDINE MODE_CLASS Receptor Agonist 4205-90-7 CLONIDINE ZERO_CLASS N 4205-90-7 CLONIDINE THERAPEUTIC_CLASS Antihypertensive Agents 4205-90-7 CLONIDINE TA_LEVEL_1 Cardiovascular 4205-90-7 CLONIDINE MECH_LEVEL_2 alpha agonist 4205-90-7 CLONIDINE MECH_LEVEL_1 Vasorelaxation 4205-90-7 CLONIDINE MECHANISM Modulate gene transcription 4205-90-7 CLONIDINE INDICATION Hypertension 4205-90-7 CLONIDINE TISSUE_TOXICITY Hypotension 4205-90-7 CLONIDINE ADVERSE_EFFECT CVS_1_Hypotension 4205-90-7 CLONIDINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 4205-90-7 CLONIDINE ADVERSE_EFFECT NEU_2_Headache 4205-90-7 CLONIDINE ADVERSE_EFFECT PSY_1_Confusion 4205-90-7 CLONIDINE ADVERSE_EFFECT LUN_1_Dyspnea 4205-90-7 CLONIDINE ADVERSE_EFFECT GUS_2_Dysuria 4205-90-7 CLONIDINE ADVERSE_EFFECT XXX_1_Xerostomia 4205-90-7 CLONIDINE MECHANISM Reduce vasoconstriction 4205-90-7 CLONIDINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 4205-90-7 CLONIDINE PRODUCT_CLASS Cardiovasculars 4205-90-7 CLONIDINE ADVERSE_EFFECT GIS_1_Constipation 4205-90-7 CLONIDINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 4205-90-7 CLONIDINE ADVERSE_EFFECT REP_2_Impotence 4205-90-7 CLONIDINE ADVERSE_EFFECT SKN_2_Pruritis 4205-90-7 CLONIDINE ADVERSE_EFFECT SKN_2_Hyperpigmentation 4205-90-7 CLONIDINE ADVERSE_EFFECT XXX_1_Weight Gain 4205-90-7 CLONIDINE ADVERSE_EFFECT XXX_1_Asthenia 4205-90-7 CLONIDINE ACTIVITY_CLASS Adrenergic agonist 4205-90-7 CLONIDINE TA_LEVEL_2 alpha agonist 4205-90-7 CLONIDINE THERAPEUTIC_CLASS Analgesics, Non-Opioid 4205-90-7 CLONIDINE ADVERSE_EFFECT GUS_2_Urinary Retention 4205-90-7 CLONIDINE ADVERSE_EFFECT PSY_1_Anxiety 4205-90-7 CLONIDINE ADVERSE_EFFECT XXX_2_Fatigue 4205-90-7 CLONIDINE ADVERSE_EFFECT NEU_1_Drowsiness 4205-90-7 CLONIDINE ADVERSE_EFFECT IMU_2_Contact Dermatitis 4205-90-7 CLONIDINE ADVERSE_EFFECT REP_2_Decreased Libido 57109-90-7 CLORAZEPATE DIPOTASSIUM MODE_CLASS Channel enhancer /opener 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT PSY_2_CNS Depression 57109-90-7 CLORAZEPATE DIPOTASSIUM INDICATION Anxiety Disorders 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT XXX_3_Xerostomia 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT OCU_2_Diplopia 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT NEU_1_Drowsiness 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT NEU_3_Tremor 57109-90-7 CLORAZEPATE DIPOTASSIUM THERAPEUTIC_CLASS Anxiolytics 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT PSY_2_Depression 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT NEU_3_Vertigo 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT PSY_2_Dependence 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT XXX_1_Fatigue 57109-90-7 CLORAZEPATE DIPOTASSIUM PRODUCT_CLASS Central Nervous System (CNS) 57109-90-7 CLORAZEPATE DIPOTASSIUM INDICATION Alcoholic Withdrawal 57109-90-7 CLORAZEPATE DIPOTASSIUM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT SKN_3_Skin Rash 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT XXX_2_Withdrawal 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT NEU_2_Headache 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT PSY_1_CNS Stimulation 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT NEU_3_Syncope 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT PSY_2_Confusion 57109-90-7 CLORAZEPATE DIPOTASSIUM ADVERSE_EFFECT NEU_1_Dizziness 57109-90-7 CLORAZEPATE DIPOTASSIUM THERAPEUTIC_CLASS Sedatives/Hypnotics 57109-90-7 CLORAZEPATE DIPOTASSIUM INDICATION Partial Seizures 57109-90-7 CLORAZEPATE DIPOTASSIUM MECHANISM Modulate neural transmission 61-72-3 CLOXACILLIN ADVERSE_EFFECT XXX_2_Glossitis 61-72-3 CLOXACILLIN ADVERSE_EFFECT LIV_3_Jaundice 61-72-3 CLOXACILLIN TISSUE_TOXICITY Interstitial Nephritis 61-72-3 CLOXACILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 61-72-3 CLOXACILLIN TA_LEVEL_2 Anti-bacterial 61-72-3 CLOXACILLIN MESH_LEVEL_3 Lactams 61-72-3 CLOXACILLIN INDICATION Osteomyelitis / Bone Infection 61-72-3 CLOXACILLIN ADVERSE_EFFECT SKN_3_Skin Rash 61-72-3 CLOXACILLIN PRODUCT_CLASS Anti-infectives 61-72-3 CLOXACILLIN KNOWN_TOXICITY Nephrotoxicity 61-72-3 CLOXACILLIN MESH_LEVEL_2 Amides 61-72-3 CLOXACILLIN TA_LEVEL_1 Infectious Disease 61-72-3 CLOXACILLIN INDICATION Cellulitis 61-72-3 CLOXACILLIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 61-72-3 CLOXACILLIN MODE_CLASS Enzyme Inhibitor 61-72-3 CLOXACILLIN ADVERSE_EFFECT NEU_3_Seizures 61-72-3 CLOXACILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 61-72-3 CLOXACILLIN INDICATION Upper Respiratory Tract Infection 61-72-3 CLOXACILLIN ADVERSE_EFFECT XXX_3_Superinfection 61-72-3 CLOXACILLIN ADVERSE_EFFECT PSY_1_Anorexia 61-72-3 CLOXACILLIN ADVERSE_EFFECT GIS_2_Gastritis 61-72-3 CLOXACILLIN ADVERSE_EFFECT GIS_2_Stomatitis 61-72-3 CLOXACILLIN INDICATION Diabetic Foot Ulcer 61-72-3 CLOXACILLIN MECH_LEVEL_1 Anti-bacterial 61-72-3 CLOXACILLIN MESH_LEVEL_1 Organic Chemicals 61-72-3 CLOXACILLIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 61-72-3 CLOXACILLIN ZERO_CLASS N 61-72-3 CLOXACILLIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 61-72-3 CLOXACILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 61-72-3 CLOXACILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 61-72-3 CLOXACILLIN ADVERSE_EFFECT GUS_2_Vaginitis 61-72-3 CLOXACILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 61-72-3 CLOXACILLIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function 61-72-3 CLOXACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 61-72-3 CLOXACILLIN TA_LEVEL_3 systemic infections 61-72-3 CLOXACILLIN INDICATION Lower Respiratory Tract Infection 61-72-3 CLOXACILLIN INDICATION Skin and Skin Structure Infections 61-72-3 CLOXACILLIN MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 61-72-3 CLOXACILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 61-72-3 CLOXACILLIN ADVERSE_EFFECT XXX_2_Drug Fever 61-72-3 CLOXACILLIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 5786-21-0 CLOZAPINE INDICATION Dementia 5786-21-0 CLOZAPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 5786-21-0 CLOZAPINE MECHANISM Prolong/enhance neural transmission 5786-21-0 CLOZAPINE TA_LEVEL_1 Central Nervous System (CNS) 5786-21-0 CLOZAPINE INDICATION Schizophrenia 5786-21-0 CLOZAPINE KNOWN_TOXICITY Cardiovascular Toxicity 5786-21-0 CLOZAPINE ADVERSE_EFFECT REP_3_Priapism 5786-21-0 CLOZAPINE ADVERSE_EFFECT GIS_2_Constipation 5786-21-0 CLOZAPINE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 5786-21-0 CLOZAPINE ADVERSE_EFFECT NEU_1_Dizziness 5786-21-0 CLOZAPINE ADVERSE_EFFECT NEU_3_Seizures 5786-21-0 CLOZAPINE ADVERSE_EFFECT PSY_1_Insomnia 5786-21-0 CLOZAPINE ADVERSE_EFFECT GIS_2_Heartburn 5786-21-0 CLOZAPINE TISSUE_TOXICITY Thromboembolism 5786-21-0 CLOZAPINE ADVERSE_EFFECT BBM_3_Reversible Agranulocytosis 5786-21-0 CLOZAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 5786-21-0 CLOZAPINE TA_LEVEL_2 Antipsychotics 5786-21-0 CLOZAPINE PRODUCT_CLASS Central Nervous System (CNS) 5786-21-0 CLOZAPINE MECH_LEVEL_1 signal transduction 5786-21-0 CLOZAPINE INDICATION Tremor 5786-21-0 CLOZAPINE THERAPEUTIC_CLASS Movement Disorders 5786-21-0 CLOZAPINE ADVERSE_EFFECT END_3_Hyperglycemia 5786-21-0 CLOZAPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 5786-21-0 CLOZAPINE ADVERSE_EFFECT GUS_2_Urinary Retention 5786-21-0 CLOZAPINE ADVERSE_EFFECT XXX_2_Xerostomia 5786-21-0 CLOZAPINE ADVERSE_EFFECT NEU_1_Vertigo 5786-21-0 CLOZAPINE ADVERSE_EFFECT NEU_1_Sedation 5786-21-0 CLOZAPINE ADVERSE_EFFECT PSY_1_Nightmares 5786-21-0 CLOZAPINE TISSUE_TOXICITY Hypersensitivity Myocarditis 5786-21-0 CLOZAPINE ZERO_CLASS N 5786-21-0 CLOZAPINE MODE_CLASS Receptor Ligand Antagonist 5786-21-0 CLOZAPINE ACTIVITY_CLASS Serotonin antagonist 5786-21-0 CLOZAPINE INDICATION Agitation 5786-21-0 CLOZAPINE MODE_CLASS Solute transporter inhibitor 5786-21-0 CLOZAPINE ADVERSE_EFFECT OCU_2_Blurred Vision 5786-21-0 CLOZAPINE ADVERSE_EFFECT CVS_3_Hypersensitivity Myocarditis 5786-21-0 CLOZAPINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 5786-21-0 CLOZAPINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 5786-21-0 CLOZAPINE ADVERSE_EFFECT PSY_1_Confusion 5786-21-0 CLOZAPINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 5786-21-0 CLOZAPINE MECHANISM Block neural transmission 5786-21-0 CLOZAPINE MECH_LEVEL_2 Modulate G-protein coupled signal transduction 5786-21-0 CLOZAPINE MECH_LEVEL_3 5-HT receptor, antagonist 5786-21-0 CLOZAPINE TA_LEVEL_3 Schizophrenia 5786-21-0 CLOZAPINE INDICATION Bipolar Disorders / Manic-Depression 5786-21-0 CLOZAPINE MECHANISM Modulate G-protein coupled signal transduction 5786-21-0 CLOZAPINE THERAPEUTIC_CLASS Antipsychotics 5786-21-0 CLOZAPINE TISSUE_TOXICITY Hypotension 5786-21-0 CLOZAPINE ADVERSE_EFFECT OCU_3_Acute Angle-Closure Glaucoma 5786-21-0 CLOZAPINE ADVERSE_EFFECT GIS_2_Sialorrhea 5786-21-0 CLOZAPINE ADVERSE_EFFECT CVS_3_Thromboembolism 5786-21-0 CLOZAPINE ADVERSE_EFFECT CVS_1_Hypotension 5786-21-0 CLOZAPINE ADVERSE_EFFECT NEU_1_Headache 5786-21-0 CLOZAPINE ADVERSE_EFFECT NEU_1_Drowsiness 5786-21-0 CLOZAPINE ADVERSE_EFFECT BBM_2_Leukopenia 5786-21-0 CLOZAPINE MESH_LEVEL_1 Heterocyclic Compounds 5786-21-0 CLOZAPINE MESH_LEVEL_3 Dibenzazepines 53-21-4 COCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 53-21-4 COCAINE TISSUE_TOXICITY Congestive Heart Failure 53-21-4 COCAINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 53-21-4 COCAINE ADVERSE_EFFECT _3_Cheyne-Stokes respiration 53-21-4 COCAINE ADVERSE_EFFECT LUN_2_Tachypnea 53-21-4 COCAINE ADVERSE_EFFECT XXX_3_Nasal Congestion 53-21-4 COCAINE TISSUE_TOXICITY Cardiac Arrest 53-21-4 COCAINE ADVERSE_EFFECT OCU_3_Mydriasis 53-21-4 COCAINE ADVERSE_EFFECT CVS_1_Vasoconstriction 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Seizures 53-21-4 COCAINE ADVERSE_EFFECT GIS_3_Small Bowel Mesenteric Ischemia 53-21-4 COCAINE ADVERSE_EFFECT XXX_3_Sinusitis 53-21-4 COCAINE ADVERSE_EFFECT OCU_3_Exophthalmos 53-21-4 COCAINE ADVERSE_EFFECT CVS_3_Circulatory Collapse 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 53-21-4 COCAINE ADVERSE_EFFECT XXX_1_Restlessness 53-21-4 COCAINE ADVERSE_EFFECT PSY_1_Anxiety 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Headache 53-21-4 COCAINE MODE_CLASS Solute transporter inhibitor 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Fecal Incontinence 53-21-4 COCAINE ADVERSE_EFFECT PSY_3_Psychosis 53-21-4 COCAINE ADVERSE_EFFECT EMB_3_Abortion 53-21-4 COCAINE ADVERSE_EFFECT XXX_3_Rhinitis 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Status Epilepticus 53-21-4 COCAINE ADVERSE_EFFECT LUN_3_Apnea 53-21-4 COCAINE ADVERSE_EFFECT LUN_3_Respiratory Depression 53-21-4 COCAINE ADVERSE_EFFECT PSY_2_Hallucinations 53-21-4 COCAINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 53-21-4 COCAINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 53-21-4 COCAINE ADVERSE_EFFECT CVS_3_Myocardial Ischemia 53-21-4 COCAINE ADVERSE_EFFECT XXX_3_Perforated Nasal Septum 53-21-4 COCAINE ADVERSE_EFFECT XXX_3_Diaphoresis 53-21-4 COCAINE ADVERSE_EFFECT GIS_2_Abdominal Pain 53-21-4 COCAINE ADVERSE_EFFECT MSK_3_Rhabdomyolysis 53-21-4 COCAINE ADVERSE_EFFECT PSY_1_Agitation 53-21-4 COCAINE ADVERSE_EFFECT NEU_1_Lightheadedness 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Hyperreflexia 53-21-4 COCAINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 53-21-4 COCAINE ADVERSE_EFFECT LUN_3_Pulmonary Edema 53-21-4 COCAINE ADVERSE_EFFECT CVS_2_Hypertension 53-21-4 COCAINE ADVERSE_EFFECT XXX_3_Hyperthermia 53-21-4 COCAINE TISSUE_TOXICITY Cardiovascular Collapse 53-21-4 COCAINE TISSUE_TOXICITY Myocardial Ischemia 53-21-4 COCAINE INDICATION Local Anesthesia 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Intracranial Bleeding 53-21-4 COCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 53-21-4 COCAINE ADVERSE_EFFECT PSY_2_Confusion 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Tics 53-21-4 COCAINE ADVERSE_EFFECT EMB_3_Fetal Toxicity 53-21-4 COCAINE ADVERSE_EFFECT PSY_2_Irritability 53-21-4 COCAINE ADVERSE_EFFECT PSY_3_Emotional Lability 53-21-4 COCAINE ADVERSE_EFFECT CVS_2_Premature Ventricular Contrations (PVCs) 53-21-4 COCAINE ADVERSE_EFFECT PSY_1_Excitement 53-21-4 COCAINE ADVERSE_EFFECT NEU_2_Dizziness 53-21-4 COCAINE ADVERSE_EFFECT NEU_3_Tremor 53-21-4 COCAINE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 53-21-4 COCAINE ADVERSE_EFFECT PSY_2_Delirium 53-21-4 COCAINE TISSUE_TOXICITY Cardiac Arrhythmia 53-21-4 COCAINE TISSUE_TOXICITY Circulatory Collapse 53-21-4 COCAINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 53-21-4 COCAINE THERAPEUTIC_CLASS Central Stimulants 53-21-4 COCAINE MECHANISM Prolong/enhance neural transmission 53-21-4 COCAINE THERAPEUTIC_CLASS Local Anesthetics 53-21-4 COCAINE ADVERSE_EFFECT _3_Preterm Labor 53-21-4 COCAINE PRODUCT_CLASS Central Nervous System (CNS) 53-21-4 COCAINE KNOWN_TOXICITY Cardiovascular Toxicity 53-21-4 COCAINE TISSUE_TOXICITY Myocardial Infarction 95522-45-5 COLESTILAN PRODUCT_CLASS Cardiovasculars 95522-45-5 COLESTILAN INDICATION Hypercholesterolemia 95522-45-5 COLESTILAN THERAPEUTIC_CLASS Hypolipidemic Agents 8068-28-8 COLISTIMETHATE PRODUCT_CLASS Anti-infectives 8068-28-8 COLISTIMETHATE THERAPEUTIC_CLASS Antibacterials, Systemic 21362-08-3 COLISTIMETHATE PRODUCT_CLASS Anti-infectives 21362-08-3 COLISTIMETHATE THERAPEUTIC_CLASS Antibacterials, Systemic 7722-44-3 COLISTIN ADVERSE_EFFECT NEU_2_Vertigo 7722-44-3 COLISTIN ADVERSE_EFFECT NEU_2_Slurred Speech 7722-44-3 COLISTIN ADVERSE_EFFECT KID_2_Azotemia 7722-44-3 COLISTIN ADVERSE_EFFECT LUN_2_Respiratory Arrest 7722-44-3 COLISTIN THERAPEUTIC_CLASS Antibacterials, Topical 7722-44-3 COLISTIN TA_LEVEL_3 topical infections 7722-44-3 COLISTIN MECH_LEVEL_1 antibacterial 7722-44-3 COLISTIN INDICATION Otitis Externa / External Otitis 7722-44-3 COLISTIN TA_LEVEL_1 Infectious Disease 7722-44-3 COLISTIN STRUCTURE_ACTIVITY Impairs cell membrane function 7722-44-3 COLISTIN ADVERSE_EFFECT KID_2_Decreased Urine Output 7722-44-3 COLISTIN ZERO_CLASS N 7722-44-3 COLISTIN MECHANISM Destroy cell membrane / wall integrity 7722-44-3 COLISTIN MESH_LEVEL_3 Peptides, Cyclic 7722-44-3 COLISTIN MECH_LEVEL_3 cell membrane 7722-44-3 COLISTIN MODE_CLASS Distorts /blocks macromolecular scaffold function 7722-44-3 COLISTIN ADVERSE_EFFECT IMU_2_Urticaria 7722-44-3 COLISTIN ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 7722-44-3 COLISTIN MESH_LEVEL_2 Peptides 7722-44-3 COLISTIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 7722-44-3 COLISTIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 7722-44-3 COLISTIN TA_LEVEL_2 Eye, Ear, Nose and Throat Preparations 7722-44-3 COLISTIN ADVERSE_EFFECT NEU_2_Paresthesia 7722-44-3 COLISTIN ADVERSE_EFFECT SKN_2_Pruritis 7722-44-3 COLISTIN ACTIVITY_CLASS Antibiotic 7722-44-3 COLISTIN MECH_LEVEL_2 Destroy cell membrane / wall integrity 1264-72-8 COLISTIN ADVERSE_EFFECT KID_2_Decreased Urine Output 1264-72-8 COLISTIN STRUCTURE_ACTIVITY Impairs cell membrane function 1264-72-8 COLISTIN TA_LEVEL_1 Infectious Disease 1264-72-8 COLISTIN MESH_LEVEL_2 Peptides 1264-72-8 COLISTIN INDICATION Otitis Externa / External Otitis 1264-72-8 COLISTIN MECH_LEVEL_1 antibacterial 1264-72-8 COLISTIN TA_LEVEL_3 topical infections 1264-72-8 COLISTIN THERAPEUTIC_CLASS Antibacterials, Topical 1264-72-8 COLISTIN ADVERSE_EFFECT KID_2_Azotemia 1264-72-8 COLISTIN TA_LEVEL_2 Eye, Ear, Nose and Throat Preparations 1264-72-8 COLISTIN ADVERSE_EFFECT LUN_2_Respiratory Arrest 1264-72-8 COLISTIN ADVERSE_EFFECT NEU_2_Paresthesia 1264-72-8 COLISTIN ADVERSE_EFFECT SKN_2_Pruritis 1264-72-8 COLISTIN ADVERSE_EFFECT NEU_2_Vertigo 1264-72-8 COLISTIN ACTIVITY_CLASS Antibiotic 1264-72-8 COLISTIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 1264-72-8 COLISTIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 1264-72-8 COLISTIN MECH_LEVEL_2 Destroy cell membrane / wall integrity 1264-72-8 COLISTIN ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 1264-72-8 COLISTIN ADVERSE_EFFECT IMU_2_Urticaria 1264-72-8 COLISTIN MODE_CLASS Distorts /blocks macromolecular scaffold function 1264-72-8 COLISTIN MECH_LEVEL_3 cell membrane 1264-72-8 COLISTIN MESH_LEVEL_3 Peptides, Cyclic 1264-72-8 COLISTIN MECHANISM Destroy cell membrane / wall integrity 1264-72-8 COLISTIN ZERO_CLASS N 1264-72-8 COLISTIN ADVERSE_EFFECT NEU_2_Slurred Speech 1404-31-5 COLISTIN MECHANISM Destroy cell membrane / wall integrity 1404-31-5 COLISTIN MESH_LEVEL_3 Peptides, Cyclic 1404-31-5 COLISTIN MECH_LEVEL_3 cell membrane 1404-31-5 COLISTIN MODE_CLASS Distorts /blocks macromolecular scaffold function 1404-31-5 COLISTIN ADVERSE_EFFECT IMU_2_Urticaria 1404-31-5 COLISTIN ADVERSE_EFFECT GIS_2_Gastrointestinal Upset 1404-31-5 COLISTIN MECH_LEVEL_2 Destroy cell membrane / wall integrity 1404-31-5 COLISTIN MESH_LEVEL_2 Peptides 1404-31-5 COLISTIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 1404-31-5 COLISTIN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 1404-31-5 COLISTIN ADVERSE_EFFECT NEU_2_Slurred Speech 1404-31-5 COLISTIN ADVERSE_EFFECT KID_2_Decreased Urine Output 1404-31-5 COLISTIN STRUCTURE_ACTIVITY Impairs cell membrane function 1404-31-5 COLISTIN TA_LEVEL_1 Infectious Disease 1404-31-5 COLISTIN ZERO_CLASS N 1404-31-5 COLISTIN INDICATION Otitis Externa / External Otitis 1404-31-5 COLISTIN MECH_LEVEL_1 antibacterial 1404-31-5 COLISTIN TA_LEVEL_3 topical infections 1404-31-5 COLISTIN THERAPEUTIC_CLASS Antibacterials, Topical 1404-31-5 COLISTIN ADVERSE_EFFECT LUN_2_Respiratory Arrest 1404-31-5 COLISTIN ADVERSE_EFFECT KID_2_Azotemia 1404-31-5 COLISTIN TA_LEVEL_2 Eye, Ear, Nose and Throat Preparations 1404-31-5 COLISTIN ADVERSE_EFFECT NEU_2_Paresthesia 1404-31-5 COLISTIN ADVERSE_EFFECT SKN_2_Pruritis 1404-31-5 COLISTIN ADVERSE_EFFECT NEU_2_Vertigo 1404-31-5 COLISTIN ACTIVITY_CLASS Antibiotic 9002-60-2 CORTICOTROPIN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 9002-60-2 CORTICOTROPIN MODE_CLASS Receptor Agonist 9002-60-2 CORTICOTROPIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 55127-96-3 CORTICOTROPIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 55127-96-3 CORTICOTROPIN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 55127-96-3 CORTICOTROPIN MODE_CLASS Receptor Agonist 53-06-5 CORTISONE TA_LEVEL_2 Steroid 53-06-5 CORTISONE INDICATION Inflammation 53-06-5 CORTISONE MECH_LEVEL_3 Glucocorticoid receptor 53-06-5 CORTISONE MECH_LEVEL_1 Immunomodulation 53-06-5 CORTISONE INDICATION Skin Diseases / Dermatoses 53-06-5 CORTISONE TA_LEVEL_3 Topical steroid 53-06-5 CORTISONE INDICATION Respiratory Diseases 53-06-5 CORTISONE INDICATION Endocrine Disorders 53-06-5 CORTISONE INDICATION Rheumatic Disorders 53-06-5 CORTISONE INDICATION Congenital Adrenal Hyperplasia 53-06-5 CORTISONE KNOWN_TOXICITY Cardiovascular Toxicity 53-06-5 CORTISONE ADVERSE_EFFECT IMU_2_Hypersensitivity 53-06-5 CORTISONE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 53-06-5 CORTISONE ADVERSE_EFFECT SKN_2_Skin Toxicity 53-06-5 CORTISONE ADVERSE_EFFECT XXX_2_Malaise 53-06-5 CORTISONE MODE_CLASS Endogenous Receptor /Channel Ligand 53-06-5 CORTISONE MESH_LEVEL_2 Steroids 53-06-5 CORTISONE TA_LEVEL_1 Anti-inflammatory 53-06-5 CORTISONE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 53-06-5 CORTISONE ADVERSE_EFFECT END_2_Endocrine System Toxicity 53-06-5 CORTISONE ADVERSE_EFFECT CVS_2_Cardiotoxicity 53-06-5 CORTISONE THERAPEUTIC_CLASS Corticosteroids 53-06-5 CORTISONE TISSUE_TOXICITY Cardiotoxicity 53-06-5 CORTISONE PRODUCT_CLASS Anti-inflammatories 53-06-5 CORTISONE INDICATION Chronic Adrenocortical Insufficiency / Addison's Disease 53-06-5 CORTISONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 53-06-5 CORTISONE MECH_LEVEL_2 Anti-inflammation and immunosuppression 53-06-5 CORTISONE MECHANISM Modulate gene transcription 53-06-5 CORTISONE INDICATION Collagen Diseases 53-06-5 CORTISONE INDICATION Gastrointestinal Diseases 53-06-5 CORTISONE TISSUE_TOXICITY Thromboembolism 53-06-5 CORTISONE ADVERSE_EFFECT GIS_2_Nausea 53-06-5 CORTISONE ADVERSE_EFFECT XXX_2_Weight Gain 53-06-5 CORTISONE ADVERSE_EFFECT NEU_2_Neurological Toxicity 53-06-5 CORTISONE ADVERSE_EFFECT END_2_Metabolic Disturbance 53-06-5 CORTISONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 53-06-5 CORTISONE MESH_LEVEL_3 Pregnanes 53-06-5 CORTISONE MESH_LEVEL_1 Polycyclic Hydrocarbons 53-06-5 CORTISONE ACTIVITY_CLASS GR-MR agonist 53-06-5 CORTISONE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 53-06-5 CORTISONE INDICATION Ophthalmic Diseases 53-06-5 CORTISONE INDICATION Hematologic Disorders 53-06-5 CORTISONE ADVERSE_EFFECT CVS_2_Thromboembolism 53-06-5 CORTISONE ADVERSE_EFFECT XXX_2_Increased Appetite 53-06-5 CORTISONE INDICATION Edematous States 53-06-5 CORTISONE INDICATION Neoplastic Diseases 53-06-5 CORTISONE INDICATION Allergic Diseases 53-06-5 CORTISONE ADVERSE_EFFECT OCU_2_Ocular Toxicity 157286-86-7 CP-154526 THERAPEUTIC_CLASS Antidepressants 157286-86-7 CP-154526 INDICATION Depression 157286-86-7 CP-154526 THERAPEUTIC_CLASS Sedatives/Hypnotics 157286-86-7 CP-154526 INDICATION Anxiety Disorders 157286-86-7 CP-154526 PRODUCT_CLASS Central Nervous System (CNS) 122-46-3 M-CRESYL ACETATE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 122-46-3 M-CRESYL ACETATE MECHANISM Inhibit DNA synthesis, repair, and function 150378-17-9 INDINAVIR TA_LEVEL_2 Anti-viral 150378-17-9 INDINAVIR ADVERSE_EFFECT XXX_1_Hyperbilirubinemia 150378-17-9 INDINAVIR ADVERSE_EFFECT XXX_3_Asthenia 150378-17-9 INDINAVIR ADVERSE_EFFECT GIS_2_Abdominal Pain 150378-17-9 INDINAVIR ADVERSE_EFFECT BBM_3_Anemia 150378-17-9 INDINAVIR ADVERSE_EFFECT LUN_2_Cough 150378-17-9 INDINAVIR ZERO_CLASS N 150378-17-9 INDINAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 150378-17-9 INDINAVIR MECH_LEVEL_3 HIV-1 retropepsin 150378-17-9 INDINAVIR PRODUCT_CLASS Anti-infectives 150378-17-9 INDINAVIR TA_LEVEL_3 viral replication inhibitor 150378-17-9 INDINAVIR MESH_LEVEL_1 Heterocyclic Compounds 150378-17-9 INDINAVIR MESH_LEVEL_3 Pyridines 150378-17-9 INDINAVIR MODE_CLASS Enzyme Inhibitor 150378-17-9 INDINAVIR ADVERSE_EFFECT KID_1_Nephrolithiasis 150378-17-9 INDINAVIR ADVERSE_EFFECT CVS_3_Angina Pectoris 150378-17-9 INDINAVIR ADVERSE_EFFECT GIS_3_Dyspepsia 150378-17-9 INDINAVIR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 150378-17-9 INDINAVIR ADVERSE_EFFECT NEU_3_Dizziness 150378-17-9 INDINAVIR ADVERSE_EFFECT GIS_1_Diarrhea 150378-17-9 INDINAVIR TISSUE_TOXICITY Angina Pectoris 150378-17-9 INDINAVIR THERAPEUTIC_CLASS Antivirals, Systemic 150378-17-9 INDINAVIR MECH_LEVEL_1 Anti-viral 150378-17-9 INDINAVIR MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 150378-17-9 INDINAVIR MECH_LEVEL_2 viral protease inhibition 150378-17-9 INDINAVIR ADVERSE_EFFECT XXX_3_Malaise 150378-17-9 INDINAVIR ADVERSE_EFFECT NEU_2_Somnolence 150378-17-9 INDINAVIR ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 150378-17-9 INDINAVIR ADVERSE_EFFECT XXX_1_Increased Appetite 150378-17-9 INDINAVIR ADVERSE_EFFECT XXX_2_Fever 150378-17-9 INDINAVIR MECHANISM Inhibit post transcriptional protein processing 150378-17-9 INDINAVIR ACTIVITY_CLASS Anti-viral 150378-17-9 INDINAVIR KNOWN_TOXICITY Cardiovascular Toxicity 150378-17-9 INDINAVIR ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 150378-17-9 INDINAVIR ADVERSE_EFFECT MSK_1_Back Pain 150378-17-9 INDINAVIR ADVERSE_EFFECT GUS_3_Dysuria 150378-17-9 INDINAVIR ADVERSE_EFFECT SKN_1_Pruritis 150378-17-9 INDINAVIR ADVERSE_EFFECT GIS_3_Vomiting 150378-17-9 INDINAVIR TA_LEVEL_1 Infectious Disease 150378-17-9 INDINAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 157810-81-6 INDINAVIR MECH_LEVEL_3 HIV-1 retropepsin 157810-81-6 INDINAVIR TA_LEVEL_2 Anti-viral 157810-81-6 INDINAVIR TA_LEVEL_1 Infectious Disease 157810-81-6 INDINAVIR ADVERSE_EFFECT GIS_3_Vomiting 157810-81-6 INDINAVIR ADVERSE_EFFECT SKN_1_Pruritis 157810-81-6 INDINAVIR ADVERSE_EFFECT GUS_3_Dysuria 157810-81-6 INDINAVIR ADVERSE_EFFECT MSK_1_Back Pain 157810-81-6 INDINAVIR ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 157810-81-6 INDINAVIR KNOWN_TOXICITY Cardiovascular Toxicity 157810-81-6 INDINAVIR ACTIVITY_CLASS Anti-viral 157810-81-6 INDINAVIR MECHANISM Inhibit post transcriptional protein processing 157810-81-6 INDINAVIR ADVERSE_EFFECT XXX_2_Fever 157810-81-6 INDINAVIR ADVERSE_EFFECT XXX_1_Increased Appetite 157810-81-6 INDINAVIR ADVERSE_EFFECT LIV_1_Increased Serum Transaminases 157810-81-6 INDINAVIR ADVERSE_EFFECT NEU_2_Somnolence 157810-81-6 INDINAVIR ADVERSE_EFFECT XXX_3_Malaise 157810-81-6 INDINAVIR MECH_LEVEL_2 viral protease inhibition 157810-81-6 INDINAVIR MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 157810-81-6 INDINAVIR MECH_LEVEL_1 Anti-viral 157810-81-6 INDINAVIR THERAPEUTIC_CLASS Antivirals, Systemic 157810-81-6 INDINAVIR TISSUE_TOXICITY Angina Pectoris 157810-81-6 INDINAVIR ADVERSE_EFFECT GIS_1_Diarrhea 157810-81-6 INDINAVIR ADVERSE_EFFECT NEU_3_Dizziness 157810-81-6 INDINAVIR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 157810-81-6 INDINAVIR ADVERSE_EFFECT GIS_3_Dyspepsia 157810-81-6 INDINAVIR ADVERSE_EFFECT CVS_3_Angina Pectoris 157810-81-6 INDINAVIR ADVERSE_EFFECT KID_1_Nephrolithiasis 157810-81-6 INDINAVIR MODE_CLASS Enzyme Inhibitor 157810-81-6 INDINAVIR MESH_LEVEL_3 Pyridines 157810-81-6 INDINAVIR MESH_LEVEL_1 Heterocyclic Compounds 157810-81-6 INDINAVIR PRODUCT_CLASS Anti-infectives 157810-81-6 INDINAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 157810-81-6 INDINAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 157810-81-6 INDINAVIR ZERO_CLASS N 157810-81-6 INDINAVIR ADVERSE_EFFECT LUN_2_Cough 157810-81-6 INDINAVIR ADVERSE_EFFECT BBM_3_Anemia 157810-81-6 INDINAVIR ADVERSE_EFFECT GIS_2_Abdominal Pain 157810-81-6 INDINAVIR ADVERSE_EFFECT XXX_3_Asthenia 157810-81-6 INDINAVIR ADVERSE_EFFECT XXX_1_Hyperbilirubinemia 157810-81-6 INDINAVIR TA_LEVEL_3 viral replication inhibitor 94535-50-9 LEVCROMAKALIM MECHANISM Reduce muscle contractile force 94535-50-9 LEVCROMAKALIM THERAPEUTIC_CLASS Parasympatholytic Agents 94535-50-9 LEVCROMAKALIM PRODUCT_CLASS Respiratory System 94535-50-9 LEVCROMAKALIM THERAPEUTIC_CLASS Vasodilators 94535-50-9 LEVCROMAKALIM PRODUCT_CLASS Cardiovasculars 94535-50-9 LEVCROMAKALIM THERAPEUTIC_CLASS Bronchodilators 94535-50-9 LEVCROMAKALIM PRODUCT_CLASS Autonomic Nervous System (ANS) 94535-50-9 LEVCROMAKALIM MODE_CLASS Channel enhancer /opener 94535-50-9 LEVCROMAKALIM THERAPEUTIC_CLASS Antihypertensive Agents 15826-37-6 CROMOLYN ADVERSE_EFFECT XXX_1_Sneezing 15826-37-6 CROMOLYN ADVERSE_EFFECT LUN_1_Cough 15826-37-6 CROMOLYN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 15826-37-6 CROMOLYN INDICATION Giant Papillary Conjunctivitis 15826-37-6 CROMOLYN INDICATION Prophylaxis of Asthma 15826-37-6 CROMOLYN MESH_LEVEL_1 Heterocyclic Compounds 15826-37-6 CROMOLYN STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 15826-37-6 CROMOLYN TA_LEVEL_1 Respiratory System 15826-37-6 CROMOLYN PRODUCT_CLASS Respiratory System 15826-37-6 CROMOLYN ADVERSE_EFFECT XXX_1_Throat Irritation 15826-37-6 CROMOLYN ADVERSE_EFFECT NEU_1_Headache 15826-37-6 CROMOLYN INDICATION Keratoconjunctivitis 15826-37-6 CROMOLYN INDICATION Food Allergy 15826-37-6 CROMOLYN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 15826-37-6 CROMOLYN ADVERSE_EFFECT XXX_1_Nasal Irritation 15826-37-6 CROMOLYN THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 15826-37-6 CROMOLYN ADVERSE_EFFECT GIS_1_Diarrhea 15826-37-6 CROMOLYN MECH_LEVEL_2 Unknown mechanism 15826-37-6 CROMOLYN MESH_LEVEL_3 Benzopyrans 15826-37-6 CROMOLYN ADVERSE_EFFECT LUN_1_Bronchospasm 15826-37-6 CROMOLYN ACTIVITY_CLASS Unknown mechanism 15826-37-6 CROMOLYN TA_LEVEL_2 Anti-allergic 15826-37-6 CROMOLYN INDICATION Ulcerative Colitis 15826-37-6 CROMOLYN PRODUCT_CLASS Gastrointestinal System 15826-37-6 CROMOLYN MECH_LEVEL_1 Immunomodulation 15826-37-6 CROMOLYN PRODUCT_CLASS Anti-inflammatories 15826-37-6 CROMOLYN TA_LEVEL_3 Rhinitis, Asthma 15826-37-6 CROMOLYN INDICATION Systemic Mastocytosis 15826-37-6 CROMOLYN MECH_LEVEL_3 Unknown mechanism 15826-37-6 CROMOLYN INDICATION Asthma 15826-37-6 CROMOLYN ADVERSE_EFFECT OCU_1_Ocular Irritation 15826-37-6 CROMOLYN INDICATION Vernal Keratoconjunctivitis 15826-37-6 CROMOLYN INDICATION Prophylaxis of Bronchospasm 15826-37-6 CROMOLYN INDICATION Allergic Rhinitis 15826-37-6 CROMOLYN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 15826-37-6 CROMOLYN ZERO_CLASS Y 15826-37-6 CROMOLYN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 16110-51-3 CROMOLYN ADVERSE_EFFECT NEU_1_Headache 16110-51-3 CROMOLYN INDICATION Allergic Rhinitis 16110-51-3 CROMOLYN INDICATION Prophylaxis of Bronchospasm 16110-51-3 CROMOLYN TA_LEVEL_3 Rhinitis, Asthma 16110-51-3 CROMOLYN PRODUCT_CLASS Anti-inflammatories 16110-51-3 CROMOLYN MECH_LEVEL_1 Immunomodulation 16110-51-3 CROMOLYN MESH_LEVEL_3 Benzopyrans 16110-51-3 CROMOLYN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 16110-51-3 CROMOLYN ADVERSE_EFFECT GIS_1_Diarrhea 16110-51-3 CROMOLYN ACTIVITY_CLASS Unknown mechanism 16110-51-3 CROMOLYN INDICATION Asthma 16110-51-3 CROMOLYN INDICATION Systemic Mastocytosis 16110-51-3 CROMOLYN INDICATION Vernal Keratoconjunctivitis 16110-51-3 CROMOLYN PRODUCT_CLASS Gastrointestinal System 16110-51-3 CROMOLYN INDICATION Ulcerative Colitis 16110-51-3 CROMOLYN TA_LEVEL_2 Anti-allergic 16110-51-3 CROMOLYN MECH_LEVEL_2 Unknown mechanism 16110-51-3 CROMOLYN THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 16110-51-3 CROMOLYN ADVERSE_EFFECT XXX_1_Nasal Irritation 16110-51-3 CROMOLYN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 16110-51-3 CROMOLYN ZERO_CLASS Y 16110-51-3 CROMOLYN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 16110-51-3 CROMOLYN MECH_LEVEL_3 Unknown mechanism 16110-51-3 CROMOLYN INDICATION Keratoconjunctivitis 16110-51-3 CROMOLYN INDICATION Food Allergy 16110-51-3 CROMOLYN ADVERSE_EFFECT OCU_1_Ocular Irritation 16110-51-3 CROMOLYN ADVERSE_EFFECT LUN_1_Bronchospasm 16110-51-3 CROMOLYN INDICATION Prophylaxis of Asthma 16110-51-3 CROMOLYN ADVERSE_EFFECT XXX_1_Sneezing 16110-51-3 CROMOLYN ADVERSE_EFFECT LUN_1_Cough 16110-51-3 CROMOLYN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 16110-51-3 CROMOLYN INDICATION Giant Papillary Conjunctivitis 16110-51-3 CROMOLYN MESH_LEVEL_1 Heterocyclic Compounds 16110-51-3 CROMOLYN STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 16110-51-3 CROMOLYN TA_LEVEL_1 Respiratory System 16110-51-3 CROMOLYN PRODUCT_CLASS Respiratory System 16110-51-3 CROMOLYN ADVERSE_EFFECT XXX_1_Throat Irritation 105878-73-7 CROMOLYN TA_LEVEL_1 Respiratory System 105878-73-7 CROMOLYN ADVERSE_EFFECT OCU_1_Ocular Irritation 105878-73-7 CROMOLYN MECH_LEVEL_3 Unknown mechanism 105878-73-7 CROMOLYN INDICATION Asthma 105878-73-7 CROMOLYN ADVERSE_EFFECT XXX_1_Sneezing 105878-73-7 CROMOLYN ADVERSE_EFFECT LUN_1_Cough 105878-73-7 CROMOLYN MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 105878-73-7 CROMOLYN INDICATION Giant Papillary Conjunctivitis 105878-73-7 CROMOLYN INDICATION Prophylaxis of Asthma 105878-73-7 CROMOLYN MESH_LEVEL_1 Heterocyclic Compounds 105878-73-7 CROMOLYN STRUCTURE_ACTIVITY Unknown mechanism, inhibit cytokine production 105878-73-7 CROMOLYN PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 105878-73-7 CROMOLYN PRODUCT_CLASS Respiratory System 105878-73-7 CROMOLYN ADVERSE_EFFECT XXX_1_Throat Irritation 105878-73-7 CROMOLYN ADVERSE_EFFECT NEU_1_Headache 105878-73-7 CROMOLYN INDICATION Keratoconjunctivitis 105878-73-7 CROMOLYN INDICATION Food Allergy 105878-73-7 CROMOLYN ADVERSE_EFFECT LUN_1_Bronchospasm 105878-73-7 CROMOLYN ADVERSE_EFFECT GIS_1_Diarrhea 105878-73-7 CROMOLYN ACTIVITY_CLASS Unknown mechanism 105878-73-7 CROMOLYN MECH_LEVEL_1 Immunomodulation 105878-73-7 CROMOLYN MESH_LEVEL_3 Benzopyrans 105878-73-7 CROMOLYN PRODUCT_CLASS Anti-inflammatories 105878-73-7 CROMOLYN INDICATION Vernal Keratoconjunctivitis 105878-73-7 CROMOLYN PRODUCT_CLASS Gastrointestinal System 105878-73-7 CROMOLYN INDICATION Ulcerative Colitis 105878-73-7 CROMOLYN TA_LEVEL_2 Anti-allergic 105878-73-7 CROMOLYN INDICATION Systemic Mastocytosis 105878-73-7 CROMOLYN MECH_LEVEL_2 Unknown mechanism 105878-73-7 CROMOLYN THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 105878-73-7 CROMOLYN ADVERSE_EFFECT XXX_1_Nasal Irritation 105878-73-7 CROMOLYN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 105878-73-7 CROMOLYN ZERO_CLASS Y 105878-73-7 CROMOLYN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 105878-73-7 CROMOLYN INDICATION Allergic Rhinitis 105878-73-7 CROMOLYN INDICATION Prophylaxis of Bronchospasm 105878-73-7 CROMOLYN TA_LEVEL_3 Rhinitis, Asthma 483-63-6 CROTAMITON ADVERSE_EFFECT SKN_3_Skin Irritation 483-63-6 CROTAMITON TA_LEVEL_3 Antipruritic Agents, Topical 483-63-6 CROTAMITON PRODUCT_CLASS Dermatologicals 483-63-6 CROTAMITON MESH_LEVEL_3 Aniline Compounds 483-63-6 CROTAMITON STRUCTURE_ACTIVITY Unknown mechanism, inflammation mediator/ blocker 483-63-6 CROTAMITON INDICATION Scabies 483-63-6 CROTAMITON MESH_LEVEL_1 Organic Chemicals 483-63-6 CROTAMITON TA_LEVEL_1 Dermatology 483-63-6 CROTAMITON MECH_LEVEL_1 Topical, antiparasitic, MOA unknown 483-63-6 CROTAMITON THERAPEUTIC_CLASS Antiparasitics 483-63-6 CROTAMITON INDICATION Pruritus / Itching 483-63-6 CROTAMITON MESH_LEVEL_2 Amines 483-63-6 CROTAMITON ADVERSE_EFFECT IMU_3_Allergic Reactions 483-63-6 CROTAMITON ZERO_CLASS Y 483-63-6 CROTAMITON THERAPEUTIC_CLASS Antipruritic Agents 483-63-6 CROTAMITON TA_LEVEL_2 anti-infective 483-63-6 CROTAMITON MECH_LEVEL_3 Unknown mechanism 483-63-6 CROTAMITON MECH_LEVEL_2 Unknown mechanism 483-63-6 CROTAMITON ACTIVITY_CLASS Unknown mechanism 1317-38-0 COPPER(II) OXIDE PRODUCT_CLASS Vitamins, Minerals and Nutrients 68-19-9 VITAMIN B12 MECHANISM Vitamin/ cofactor 456-59-7 CYCLANDELATE TISSUE_TOXICITY Hypotension 456-59-7 CYCLANDELATE TA_LEVEL_3 Vasodilators 456-59-7 CYCLANDELATE MECHANISM Block neural transmission 456-59-7 CYCLANDELATE INDICATION Intermittent Claudication 456-59-7 CYCLANDELATE MESH_LEVEL_3 Acids, Carbocyclic 456-59-7 CYCLANDELATE MODE_CLASS Enzyme Inhibitor 456-59-7 CYCLANDELATE ADVERSE_EFFECT CVS_3_Hypotension 456-59-7 CYCLANDELATE ADVERSE_EFFECT NEU_2_Paresthesia 456-59-7 CYCLANDELATE STRUCTURE_ACTIVITY Unknown mechanism 456-59-7 CYCLANDELATE THERAPEUTIC_CLASS Cerebral Vascular Disorders 456-59-7 CYCLANDELATE MESH_LEVEL_2 Carboxylic Acids 456-59-7 CYCLANDELATE INDICATION Arteriosclerosis Obliterans 456-59-7 CYCLANDELATE MODE_CLASS Channel Blocker, Non-selective 456-59-7 CYCLANDELATE MESH_LEVEL_1 Organic Chemicals 456-59-7 CYCLANDELATE ADVERSE_EFFECT GIS_2_Nausea 456-59-7 CYCLANDELATE ADVERSE_EFFECT GIS_2_Epigastric Pain 456-59-7 CYCLANDELATE ADVERSE_EFFECT SKN_2_Flushing 456-59-7 CYCLANDELATE PRODUCT_CLASS Cardiovasculars 456-59-7 CYCLANDELATE INDICATION Raynaud's Phenomenon 456-59-7 CYCLANDELATE MECHANISM Inhibit steroid biosynthesis/ metabolism 456-59-7 CYCLANDELATE ADVERSE_EFFECT CVS_2_Tachycardia 456-59-7 CYCLANDELATE ADVERSE_EFFECT GIS_2_Heartburn 456-59-7 CYCLANDELATE ADVERSE_EFFECT NEU_2_Headache 456-59-7 CYCLANDELATE INDICATION Cerebral Ischemia 456-59-7 CYCLANDELATE ACTIVITY_CLASS Unknown mechanism 456-59-7 CYCLANDELATE PRODUCT_CLASS Central Nervous System (CNS) 456-59-7 CYCLANDELATE TA_LEVEL_2 circulation 456-59-7 CYCLANDELATE MECH_LEVEL_2 calcium antagonist 456-59-7 CYCLANDELATE MECH_LEVEL_3 Unknown mechanism 456-59-7 CYCLANDELATE ADVERSE_EFFECT XXX_2_Sweating 456-59-7 CYCLANDELATE ADVERSE_EFFECT NEU_2_Dizziness 456-59-7 CYCLANDELATE ZERO_CLASS Y 456-59-7 CYCLANDELATE THERAPEUTIC_CLASS Vasodilators 456-59-7 CYCLANDELATE KNOWN_TOXICITY Cardiovascular Toxicity 456-59-7 CYCLANDELATE TA_LEVEL_1 Cardiovascular 6202-23-9 CYCLOBENZAPRINE INDICATION Skeletal Muscle Spasm 6202-23-9 CYCLOBENZAPRINE MODE_CLASS Receptor Ligand Antagonist 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_2_Asthenia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Palpitation 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT OCU_3_Diplopia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT OTO_3_Tinnitus 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Hypotension 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Constipation 6202-23-9 CYCLOBENZAPRINE PRODUCT_CLASS Central Nervous System (CNS) 6202-23-9 CYCLOBENZAPRINE INDICATION Fibromyalgia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Arrhythmia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Dyspepsia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT MSK_3_Muscle Twitching 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_3_Paresthesia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_2_Fatigue 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_2_Nervousness 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT OCU_2_Blurred Vision 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_3_Convulsions 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_3_Malaise 6202-23-9 CYCLOBENZAPRINE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 6202-23-9 CYCLOBENZAPRINE MECHANISM Modulate G-protein coupled signal transduction 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_3_Gastritis 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_3_Flatulence 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Disorientation 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_2_Headache 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Anxiety 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Depression 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_3_Diarrhea 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Disorientation 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_1_Xerostomia 6202-23-9 CYCLOBENZAPRINE TISSUE_TOXICITY Hypotension 6202-23-9 CYCLOBENZAPRINE KNOWN_TOXICITY Cardiovascular Toxicity 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_1_Drowsiness 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Excitement 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_3_Thirst 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_2_Confusion 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_1_Dizziness 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Hallucinations 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_3_Sweating 6202-23-9 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Dysgeusia 6202-23-9 CYCLOBENZAPRINE STRUCTURE_ACTIVITY 5HT2 antagonist 6202-23-9 CYCLOBENZAPRINE TISSUE_TOXICITY Arrhythmia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_1_Drowsiness 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Disorientation 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_3_Flatulence 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_3_Gastritis 303-53-7 CYCLOBENZAPRINE MECHANISM Modulate G-protein coupled signal transduction 303-53-7 CYCLOBENZAPRINE THERAPEUTIC_CLASS Skeletal Muscle Relaxants 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_3_Malaise 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_3_Convulsions 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT OCU_2_Blurred Vision 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_2_Nervousness 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_2_Fatigue 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_3_Paresthesia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_3_Sweating 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_1_Xerostomia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Dyspepsia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Hallucinations 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_1_Dizziness 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_2_Confusion 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_3_Thirst 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 303-53-7 CYCLOBENZAPRINE INDICATION Skeletal Muscle Spasm 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Hypotension 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Constipation 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Excitement 303-53-7 CYCLOBENZAPRINE PRODUCT_CLASS Central Nervous System (CNS) 303-53-7 CYCLOBENZAPRINE INDICATION Fibromyalgia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Arrhythmia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT NEU_2_Headache 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT MSK_3_Muscle Twitching 303-53-7 CYCLOBENZAPRINE MODE_CLASS Receptor Ligand Antagonist 303-53-7 CYCLOBENZAPRINE TISSUE_TOXICITY Arrhythmia 303-53-7 CYCLOBENZAPRINE STRUCTURE_ACTIVITY 5HT2 antagonist 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_2_Dysgeusia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT XXX_2_Asthenia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT CVS_3_Palpitation 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT OCU_3_Diplopia 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT OTO_3_Tinnitus 303-53-7 CYCLOBENZAPRINE KNOWN_TOXICITY Cardiovascular Toxicity 303-53-7 CYCLOBENZAPRINE TISSUE_TOXICITY Hypotension 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Disorientation 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT GIS_3_Diarrhea 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Depression 303-53-7 CYCLOBENZAPRINE ADVERSE_EFFECT PSY_3_Anxiety 5870-29-1 CYCLOPENTOLATE MODE_CLASS Receptor Ligand Antagonist 5870-29-1 CYCLOPENTOLATE MECHANISM Modulate G-protein coupled signal transduction 5870-29-1 CYCLOPENTOLATE PRODUCT_CLASS Other Human Uses 5870-29-1 CYCLOPENTOLATE INDICATION Induction of mydriasis for eye examinations 5870-29-1 CYCLOPENTOLATE INDICATION Induction of Cycloplegia for Eye Examinations 5870-29-1 CYCLOPENTOLATE THERAPEUTIC_CLASS Parasympatholytic Agents 2259-96-3 CYCLOTHIAZIDE PRODUCT_CLASS Cardiovasculars 2259-96-3 CYCLOTHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 2259-96-3 CYCLOTHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 2259-96-3 CYCLOTHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 2259-96-3 CYCLOTHIAZIDE MODE_CLASS Channel Blocker, selective 2259-96-3 CYCLOTHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 2259-96-3 CYCLOTHIAZIDE THERAPEUTIC_CLASS Diuretics 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT OCU_3_Eye Irritation 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT NEU_3_Paresthesia 52315-07-8 ALPHA-CYPERMETHRIN THERAPEUTIC_CLASS Insecticides / Pesticides 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT XXX_3_Throat Irritation 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT LUN_3_Airway Irritation 52315-07-8 ALPHA-CYPERMETHRIN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 52315-07-8 ALPHA-CYPERMETHRIN MODE_CLASS Channel Blocker 52315-07-8 ALPHA-CYPERMETHRIN MODE_CLASS Channel Modulator 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT IMU_3_Contact Dermatitis 52315-07-8 ALPHA-CYPERMETHRIN MECHANISM Modulate channel gating 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT LUN_3_Dyspnea 52315-07-8 ALPHA-CYPERMETHRIN ADVERSE_EFFECT SKN_3_Skin Irritation 52315-07-8 ALPHA-CYPERMETHRIN MECHANISM Prolong/enhance neural transmission 52315-07-8 ALPHA-CYPERMETHRIN PRODUCT_CLASS Toxicants 129-03-3 CYPROHEPTADINE PRODUCT_CLASS Anti-inflammatories 129-03-3 CYPROHEPTADINE TA_LEVEL_1 Anti-inflammatory 129-03-3 CYPROHEPTADINE TA_LEVEL_2 H1 antagonists 129-03-3 CYPROHEPTADINE INDICATION Allergic Rhinitis 129-03-3 CYPROHEPTADINE MECHANISM Modulate G-protein coupled signal transduction 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT OCU_2_Blurred Vision 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT PSY_2_Insomnia 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT NEU_2_Seizures 129-03-3 CYPROHEPTADINE ACTIVITY_CLASS Serotonin antagonist 129-03-3 CYPROHEPTADINE INDICATION Urticaria / Hives 129-03-3 CYPROHEPTADINE THERAPEUTIC_CLASS Antihistamines 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Abdominal Pain 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Hypotension 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT XXX_2_Restlessness 129-03-3 CYPROHEPTADINE TISSUE_TOXICITY Hypotension 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Constipation 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT NEU_1_Drowsiness 129-03-3 CYPROHEPTADINE INDICATION Allergic Conjunctivitis 129-03-3 CYPROHEPTADINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT XXX_2_Xerostomia 129-03-3 CYPROHEPTADINE MESH_LEVEL_3 Piperidines 129-03-3 CYPROHEPTADINE MECH_LEVEL_1 Immunomodulation 129-03-3 CYPROHEPTADINE MECH_LEVEL_2 5HT antagonist 129-03-3 CYPROHEPTADINE MESH_LEVEL_1 Heterocyclic Compounds 129-03-3 CYPROHEPTADINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 129-03-3 CYPROHEPTADINE STRUCTURE_ACTIVITY 5HT2/H1 antagonist, tricyclic 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT GUS_2_Urinary Retention 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Palpitation 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Diarrhea 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 129-03-3 CYPROHEPTADINE MECH_LEVEL_3 5HT receptor 2 129-03-3 CYPROHEPTADINE TA_LEVEL_3 Allergy medication 129-03-3 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 129-03-3 CYPROHEPTADINE KNOWN_TOXICITY Cardiovascular Toxicity 129-03-3 CYPROHEPTADINE ZERO_CLASS N 129-03-3 CYPROHEPTADINE INDICATION Cold Urticaria 969-33-5 CYPROHEPTADINE MECH_LEVEL_1 Immunomodulation 969-33-5 CYPROHEPTADINE MESH_LEVEL_1 Heterocyclic Compounds 969-33-5 CYPROHEPTADINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 969-33-5 CYPROHEPTADINE STRUCTURE_ACTIVITY 5HT2/H1 antagonist, tricyclic 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT GUS_2_Urinary Retention 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Palpitation 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Diarrhea 969-33-5 CYPROHEPTADINE INDICATION Cold Urticaria 969-33-5 CYPROHEPTADINE MECH_LEVEL_3 5HT receptor 2 969-33-5 CYPROHEPTADINE TA_LEVEL_3 Allergy medication 969-33-5 CYPROHEPTADINE ACTIVITY_CLASS Serotonin antagonist 969-33-5 CYPROHEPTADINE TISSUE_TOXICITY Hypotension 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT XXX_2_Xerostomia 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT XXX_2_Restlessness 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Hypotension 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Abdominal Pain 969-33-5 CYPROHEPTADINE THERAPEUTIC_CLASS Antihistamines 969-33-5 CYPROHEPTADINE INDICATION Urticaria / Hives 969-33-5 CYPROHEPTADINE MECH_LEVEL_2 5HT antagonist 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT NEU_2_Seizures 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT PSY_2_Insomnia 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT OCU_2_Blurred Vision 969-33-5 CYPROHEPTADINE MECHANISM Modulate G-protein coupled signal transduction 969-33-5 CYPROHEPTADINE INDICATION Allergic Rhinitis 969-33-5 CYPROHEPTADINE TA_LEVEL_2 H1 antagonists 969-33-5 CYPROHEPTADINE TA_LEVEL_1 Anti-inflammatory 969-33-5 CYPROHEPTADINE PRODUCT_CLASS Anti-inflammatories 969-33-5 CYPROHEPTADINE ZERO_CLASS N 969-33-5 CYPROHEPTADINE KNOWN_TOXICITY Cardiovascular Toxicity 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT CVS_2_Sinus Tachycardia 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT GIS_2_Constipation 969-33-5 CYPROHEPTADINE ADVERSE_EFFECT NEU_1_Drowsiness 969-33-5 CYPROHEPTADINE INDICATION Allergic Conjunctivitis 969-33-5 CYPROHEPTADINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 969-33-5 CYPROHEPTADINE MESH_LEVEL_3 Piperidines 60-23-1 CYSTEAMINE ADVERSE_EFFECT PSY_2_Depression 60-23-1 CYSTEAMINE MECHANISM Modulate amino acid metabolism 60-23-1 CYSTEAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 60-23-1 CYSTEAMINE ADVERSE_EFFECT IMU_2_Urticaria 60-23-1 CYSTEAMINE ADVERSE_EFFECT BBM_2_Anemia 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_2_Encephalopathy 60-23-1 CYSTEAMINE ADVERSE_EFFECT PSY_2_Hallucinations 60-23-1 CYSTEAMINE ADVERSE_EFFECT GIS_1_Diarrhea 60-23-1 CYSTEAMINE ADVERSE_EFFECT GIS_2_Dyspepsia 60-23-1 CYSTEAMINE ADVERSE_EFFECT PSY_2_Nightmares 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_1_Drowsiness 60-23-1 CYSTEAMINE ADVERSE_EFFECT XXX_2_Lethargy 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_2_Seizures 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_2_Headache 60-23-1 CYSTEAMINE ADVERSE_EFFECT CVS_2_Hypertension 60-23-1 CYSTEAMINE ADVERSE_EFFECT XXX_2_Fever 60-23-1 CYSTEAMINE ADVERSE_EFFECT GIS_1_Halitosis 60-23-1 CYSTEAMINE ADVERSE_EFFECT BBM_2_Leukopenia 60-23-1 CYSTEAMINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 60-23-1 CYSTEAMINE ADVERSE_EFFECT PSY_2_Confusion 60-23-1 CYSTEAMINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_2_Tremor 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_2_Ataxia 60-23-1 CYSTEAMINE ADVERSE_EFFECT OTO_2_Hearing Loss 60-23-1 CYSTEAMINE ADVERSE_EFFECT NEU_2_Dizziness 60-23-1 CYSTEAMINE ADVERSE_EFFECT PSY_1_Anorexia 60-23-1 CYSTEAMINE ADVERSE_EFFECT GIS_2_Constipation 60-23-1 CYSTEAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 60-23-1 CYSTEAMINE STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 60-23-1 CYSTEAMINE THERAPEUTIC_CLASS Amino acid metabolism Disorders 60-23-1 CYSTEAMINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 60-23-1 CYSTEAMINE INDICATION Nephropathic cystinosis 485-35-8 CYTISINE THERAPEUTIC_CLASS Drug Dependence Therapy 485-35-8 CYTISINE INDICATION Smoking Cessation 485-35-8 CYTISINE PRODUCT_CLASS Other Human Uses 485-35-8 CYTISINE MODE_CLASS Channel Modulator 485-35-8 CYTISINE MECHANISM Prolong/enhance neural transmission 22144-77-0 CYTOCHALASIN D STRUCTURE_ACTIVITY Actin filament inhibitor 138614-30-9 ICATIBANT STRUCTURE_ACTIVITY Bradykinin antagonist 138614-30-9 ICATIBANT INDICATION Hepato-renal Syndrome 138614-30-9 ICATIBANT MECHANISM Modulate G-protein coupled signal transduction 138614-30-9 ICATIBANT THERAPEUTIC_CLASS Immunomodulants 138614-30-9 ICATIBANT MODE_CLASS Receptor Ligand Antagonist 138614-30-9 ICATIBANT PRODUCT_CLASS Immune Response / Immunomodulators 138614-30-9 ICATIBANT INDICATION Late- stage Liver Cirrhosis 130308-48-4 ICATIBANT INDICATION Hepato-renal Syndrome 130308-48-4 ICATIBANT INDICATION Late- stage Liver Cirrhosis 130308-48-4 ICATIBANT MECHANISM Modulate G-protein coupled signal transduction 130308-48-4 ICATIBANT PRODUCT_CLASS Immune Response / Immunomodulators 130308-48-4 ICATIBANT STRUCTURE_ACTIVITY Bradykinin antagonist 130308-48-4 ICATIBANT MODE_CLASS Receptor Ligand Antagonist 130308-48-4 ICATIBANT THERAPEUTIC_CLASS Immunomodulants 148699-92-7 ICATIBANT MECHANISM Modulate G-protein coupled signal transduction 148699-92-7 ICATIBANT PRODUCT_CLASS Immune Response / Immunomodulators 148699-92-7 ICATIBANT THERAPEUTIC_CLASS Immunomodulants 148699-92-7 ICATIBANT INDICATION Hepato-renal Syndrome 148699-92-7 ICATIBANT STRUCTURE_ACTIVITY Bradykinin antagonist 148699-92-7 ICATIBANT INDICATION Late- stage Liver Cirrhosis 148699-92-7 ICATIBANT MODE_CLASS Receptor Ligand Antagonist 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_2_Vertigo 68-41-7 D-CYCLOSERINE MECHANISM Inhibit bacterial cell wall biosynthesis 68-41-7 D-CYCLOSERINE THERAPEUTIC_CLASS Antibacterials 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_1_Nervousness 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_1_Dizziness 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_1_Confusion 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_2_Memory Loss 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_3_Convulsions 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_1_Headache 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_3_Seizures 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_3_Psychosis 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_3_Aggression 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_1_Depression 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT XXX_2_Lethargy 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_1_Somnolence 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_1_Drowsiness 68-41-7 D-CYCLOSERINE INDICATION Urinary Tract Infection (UTI) 68-41-7 D-CYCLOSERINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 68-41-7 D-CYCLOSERINE PRODUCT_CLASS Anti-infectives 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_2_Dysarthria 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_1_Disorientation 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_2_Hyperreflexia 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT NEU_2_Tremor 68-41-7 D-CYCLOSERINE STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor 68-41-7 D-CYCLOSERINE INDICATION Extrapulmonary Tuberculosis 68-41-7 D-CYCLOSERINE INDICATION Tuberculosis 68-41-7 D-CYCLOSERINE ADVERSE_EFFECT PSY_1_Anxiety 4342-03-4 DACARBAZINE ADVERSE_EFFECT GIS_1_Vomiting 4342-03-4 DACARBAZINE ADVERSE_EFFECT IMU_3_Urticaria 4342-03-4 DACARBAZINE ADVERSE_EFFECT MSK_2_Myalgia 4342-03-4 DACARBAZINE ADVERSE_EFFECT BBM_1_Myelosuppression 4342-03-4 DACARBAZINE PRODUCT_CLASS Anti-cancers 4342-03-4 DACARBAZINE INDICATION Hodgkin's Disease 4342-03-4 DACARBAZINE TISSUE_TOXICITY Teratogenicity 4342-03-4 DACARBAZINE MECHANISM Inhibit DNA synthesis, repair, and function 4342-03-4 DACARBAZINE THERAPEUTIC_CLASS Antineoplastics 4342-03-4 DACARBAZINE TISSUE_TOXICITY Carcinogenicity 4342-03-4 DACARBAZINE STRUCTURE_ACTIVITY DNA-alkylator 4342-03-4 DACARBAZINE ADVERSE_EFFECT PSY_1_Anorexia 4342-03-4 DACARBAZINE ADVERSE_EFFECT XXX_2_Influenza-Like Syndrome 4342-03-4 DACARBAZINE ADVERSE_EFFECT BBM_1_Thrombocytopenia 4342-03-4 DACARBAZINE ADVERSE_EFFECT GIS_1_Nausea 4342-03-4 DACARBAZINE ADVERSE_EFFECT LIV_2_Hepatic Necrosis 4342-03-4 DACARBAZINE TISSUE_TOXICITY Hepatotoxicity 4342-03-4 DACARBAZINE TISSUE_TOXICITY Myelosuppression 4342-03-4 DACARBAZINE KNOWN_TOXICITY Embryo/Fetal Toxicity 4342-03-4 DACARBAZINE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 4342-03-4 DACARBAZINE ADVERSE_EFFECT BBM_1_Leukopenia 4342-03-4 DACARBAZINE ADVERSE_EFFECT LIV_2_Hepatotoxicity 4342-03-4 DACARBAZINE KNOWN_TOXICITY Hepatotoxicity 4342-03-4 DACARBAZINE KNOWN_TOXICITY Carcinogenicity 4342-03-4 DACARBAZINE TISSUE_TOXICITY Hepatic Necrosis 4342-03-4 DACARBAZINE ADVERSE_EFFECT DNA_2_Carcinogenicity 4342-03-4 DACARBAZINE ADVERSE_EFFECT IMU_2_Anaphylaxis 4342-03-4 DACARBAZINE ADVERSE_EFFECT SKN_3_Erythema 4342-03-4 DACARBAZINE ADVERSE_EFFECT IMU_3_Photosensitivity 4342-03-4 DACARBAZINE ADVERSE_EFFECT SKN_2_Flushing of the Skin 4342-03-4 DACARBAZINE MODE_CLASS Distorts /blocks macromolecular scaffold function 4342-03-4 DACARBAZINE KNOWN_TOXICITY Blood & Bone Marrow Toxicity 4342-03-4 DACARBAZINE INDICATION Malignant Melanoma 4342-03-4 DACARBAZINE TISSUE_TOXICITY Thrombocytopenia 4342-03-4 DACARBAZINE TISSUE_TOXICITY Leukopenia 4342-03-4 DACARBAZINE ADVERSE_EFFECT EMB_2_Teratogenicity 486-66-8 DAIDZEIN STRUCTURE_ACTIVITY Phytoestrogen 486-66-8 DAIDZEIN PRODUCT_CLASS Vitamins, Minerals and Nutrients 486-66-8 DAIDZEIN MODE_CLASS Receptor Agonist, selective 486-66-8 DAIDZEIN MECHANISM Modulate gene transcription 486-66-8 DAIDZEIN THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 78123-71-4 DAGO PRODUCT_CLASS Biochemicals 78123-71-4 DAGO MODE_CLASS Receptor Agonist, selective 78123-71-4 DAGO MECHANISM Modulate neural transmission 17230-88-5 DANAZOL ADVERSE_EFFECT OCU_3_Visual Disturbances 17230-88-5 DANAZOL ACTIVITY_CLASS Progesterone receptor antagonist 17230-88-5 DANAZOL KNOWN_TOXICITY Carcinogenicity 17230-88-5 DANAZOL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 17230-88-5 DANAZOL ADVERSE_EFFECT CVS_2_Thromboembolism 17230-88-5 DANAZOL ADVERSE_EFFECT GUS_2_Vaginal Dryness 17230-88-5 DANAZOL ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 17230-88-5 DANAZOL ADVERSE_EFFECT REP_1_Testicular Atrophy 17230-88-5 DANAZOL TISSUE_TOXICITY Thromboembolism 17230-88-5 DANAZOL ADVERSE_EFFECT LUN_1_Deepening of Voice 17230-88-5 DANAZOL MESH_LEVEL_1 Polycyclic Hydrocarbons 17230-88-5 DANAZOL MECH_LEVEL_2 anti-progestatgen 17230-88-5 DANAZOL MECH_LEVEL_3 Progesterone receptor 17230-88-5 DANAZOL ADVERSE_EFFECT SKN_1_Oily Skin 17230-88-5 DANAZOL ADVERSE_EFFECT LUN_1_Hoarseness of Voice 17230-88-5 DANAZOL ADVERSE_EFFECT SKN_2_Flushing 17230-88-5 DANAZOL ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 17230-88-5 DANAZOL ADVERSE_EFFECT NEU_3_Dizziness 17230-88-5 DANAZOL ADVERSE_EFFECT IMU_3_Photosensitivity 17230-88-5 DANAZOL STRUCTURE_ACTIVITY Progesterone receptor antagonist 17230-88-5 DANAZOL MESH_LEVEL_2 Steroids 17230-88-5 DANAZOL KNOWN_TOXICITY Reproductive System Toxicity 17230-88-5 DANAZOL ADVERSE_EFFECT XXX_1_Edema 17230-88-5 DANAZOL MESH_LEVEL_3 Pregnanes 17230-88-5 DANAZOL ADVERSE_EFFECT IMU_3_Urticaria 17230-88-5 DANAZOL ADVERSE_EFFECT DNA_2_Hepatic Adenoma 17230-88-5 DANAZOL TISSUE_TOXICITY Testicular Atrophy 17230-88-5 DANAZOL ADVERSE_EFFECT LIV_2_Hepatic Dysfunction 17230-88-5 DANAZOL ADVERSE_EFFECT GUS_2_Vaginitis 17230-88-5 DANAZOL ADVERSE_EFFECT END_1_Hirsutism 17230-88-5 DANAZOL ADVERSE_EFFECT XXX_1_Decreased Breast Size 17230-88-5 DANAZOL INDICATION Endometriosis 17230-88-5 DANAZOL ADVERSE_EFFECT SKN_3_Pruritis 17230-88-5 DANAZOL ADVERSE_EFFECT IMU_3_Allergic Reactions 17230-88-5 DANAZOL ADVERSE_EFFECT NEU_2_Benign Intracranial Hypertension 17230-88-5 DANAZOL ADVERSE_EFFECT GUS_2_Vaginal Itching 17230-88-5 DANAZOL ADVERSE_EFFECT XXX_1_Weight Gain 17230-88-5 DANAZOL ADVERSE_EFFECT SKN_1_Acne 17230-88-5 DANAZOL TISSUE_TOXICITY Hepatic Adenoma 17230-88-5 DANAZOL INDICATION Fibrocystic Breast Disease 17230-88-5 DANAZOL MODE_CLASS Receptor Ligand Antagonist 17230-88-5 DANAZOL MECH_LEVEL_1 Hormone modulation 17230-88-5 DANAZOL MECHANISM Modulate gene transcription 17230-88-5 DANAZOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 17230-88-5 DANAZOL TA_LEVEL_3 Progesterone receptor antagonists 17230-88-5 DANAZOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 17230-88-5 DANAZOL INDICATION Hereditary Angioedema 17230-88-5 DANAZOL ZERO_CLASS N 17230-88-5 DANAZOL KNOWN_TOXICITY Cardiovascular Toxicity 17230-88-5 DANAZOL THERAPEUTIC_CLASS Gonadal Hormones 7261-97-4 DANTROLENE INDICATION Spasticity 7261-97-4 DANTROLENE TISSUE_TOXICITY Liver Cirrhosis 7261-97-4 DANTROLENE THERAPEUTIC_CLASS Antispasmodic Agents 7261-97-4 DANTROLENE KNOWN_TOXICITY Neurotoxicity 7261-97-4 DANTROLENE ADVERSE_EFFECT CVS_1_Pericarditis 7261-97-4 DANTROLENE ADVERSE_EFFECT XXX_1_Lacrimation 7261-97-4 DANTROLENE ADVERSE_EFFECT XXX_2_Fatigue 7261-97-4 DANTROLENE ADVERSE_EFFECT LIV_2_Hepatic Dysfunction 7261-97-4 DANTROLENE ADVERSE_EFFECT LIV_2_Hepatic Failure 7261-97-4 DANTROLENE ADVERSE_EFFECT XXX_1_Malaise 7261-97-4 DANTROLENE ADVERSE_EFFECT LUN_1_Pleural Effusion 7261-97-4 DANTROLENE ADVERSE_EFFECT LIV_2_Jaundice 7261-97-4 DANTROLENE ADVERSE_EFFECT MSK_1_Muscle Weakness 7261-97-4 DANTROLENE ADVERSE_EFFECT LIV_2_Liver Cirrhosis 7261-97-4 DANTROLENE ADVERSE_EFFECT NEU_1_Dizziness 7261-97-4 DANTROLENE ADVERSE_EFFECT XXX_2_Fever 7261-97-4 DANTROLENE STRUCTURE_ACTIVITY Inhibits Ca++ release from intracellular stores 7261-97-4 DANTROLENE TISSUE_TOXICITY Hepatic Failure 7261-97-4 DANTROLENE ADVERSE_EFFECT GIS_2_Abdominal Pain 7261-97-4 DANTROLENE ADVERSE_EFFECT CVS_3_Phlebitis 7261-97-4 DANTROLENE ADVERSE_EFFECT LUN_3_Pulmonary Edema 7261-97-4 DANTROLENE ADVERSE_EFFECT XXX_2_Hyperbilirubinemia 7261-97-4 DANTROLENE TISSUE_TOXICITY Pericarditis 7261-97-4 DANTROLENE KNOWN_TOXICITY Hepatotoxicity 7261-97-4 DANTROLENE PRODUCT_CLASS Central Nervous System (CNS) 7261-97-4 DANTROLENE ADVERSE_EFFECT LIV_2_Hepatitis 7261-97-4 DANTROLENE ADVERSE_EFFECT NEU_1_Drowsiness 7261-97-4 DANTROLENE MECHANISM Block channel gating 7261-97-4 DANTROLENE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 7261-97-4 DANTROLENE ADVERSE_EFFECT NEU_1_Seizures 7261-97-4 DANTROLENE KNOWN_TOXICITY Cardiovascular Toxicity 7261-97-4 DANTROLENE ADVERSE_EFFECT IMU_3_Photosensitivity 7261-97-4 DANTROLENE ADVERSE_EFFECT NEU_1_Dysarthria 7261-97-4 DANTROLENE TISSUE_TOXICITY Seizures 7261-97-4 DANTROLENE MODE_CLASS Channel Blocker, selective 7261-97-4 DANTROLENE ADVERSE_EFFECT XXX_3_Injection Site Reaction 7261-97-4 DANTROLENE ADVERSE_EFFECT GIS_2_Diarrhea 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_1_Reddened Conjunctiva 72822-12-9 DAPIPRAZOLE PRODUCT_CLASS Other Human Uses 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_3_Blurred Vision 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_3_Eye Dryness 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Chemosis 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_1_Ptosis 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT DNA_2_Carcinogenicity 72822-12-9 DAPIPRAZOLE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist 72822-12-9 DAPIPRAZOLE KNOWN_TOXICITY Carcinogenicity 72822-12-9 DAPIPRAZOLE MECHANISM Reduce vasoconstriction 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_3_Tearing 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Punctate Keratitis 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT XXX_1_Burning Sensation 72822-12-9 DAPIPRAZOLE THERAPEUTIC_CLASS Sympatholytic Agents 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Corneal Edema 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Lid Erythema 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT NEU_2_Headache 72822-12-9 DAPIPRAZOLE TISSUE_TOXICITY Carcinogenicity 72822-12-9 DAPIPRAZOLE MODE_CLASS Receptor Ligand Antagonist, Selective 72822-12-9 DAPIPRAZOLE INDICATION Mydriasis Reversal 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Photophobia 72822-12-9 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Lid Edema 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_3_Blurred Vision 72822-13-0 DAPIPRAZOLE PRODUCT_CLASS Other Human Uses 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_1_Reddened Conjunctiva 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Lid Edema 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Photophobia 72822-13-0 DAPIPRAZOLE INDICATION Mydriasis Reversal 72822-13-0 DAPIPRAZOLE MODE_CLASS Receptor Ligand Antagonist, Selective 72822-13-0 DAPIPRAZOLE TISSUE_TOXICITY Carcinogenicity 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT NEU_2_Headache 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Lid Erythema 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Corneal Edema 72822-13-0 DAPIPRAZOLE THERAPEUTIC_CLASS Sympatholytic Agents 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_1_Ptosis 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT XXX_1_Burning Sensation 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Punctate Keratitis 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_3_Tearing 72822-13-0 DAPIPRAZOLE MECHANISM Reduce vasoconstriction 72822-13-0 DAPIPRAZOLE KNOWN_TOXICITY Carcinogenicity 72822-13-0 DAPIPRAZOLE STRUCTURE_ACTIVITY Adrenoceptor-alpha1 antagonist 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_2_Chemosis 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT OCU_3_Eye Dryness 72822-13-0 DAPIPRAZOLE ADVERSE_EFFECT DNA_2_Carcinogenicity 80-08-0 DAPSONE ADVERSE_EFFECT LIV__Jaundice 80-08-0 DAPSONE ADVERSE_EFFECT KID__Renal Papillary Necrosis 80-08-0 DAPSONE ADVERSE_EFFECT BBM__Methemoglobinemia 80-08-0 DAPSONE ADVERSE_EFFECT GIS__Nausea / Vomiting 80-08-0 DAPSONE PRODUCT_CLASS Immune Response / Immunomodulators 80-08-0 DAPSONE INDICATION Leprosy 80-08-0 DAPSONE THERAPEUTIC_CLASS Immunostimulants 80-08-0 DAPSONE ADVERSE_EFFECT BBM__Hemolysis 80-08-0 DAPSONE THERAPEUTIC_CLASS Antibacterials, Systemic 80-08-0 DAPSONE KNOWN_TOXICITY Nephrotoxicity 80-08-0 DAPSONE TISSUE_TOXICITY Nephrotic Syndrome 80-08-0 DAPSONE INDICATION Malaria Prophylaxis 80-08-0 DAPSONE INDICATION Malaria 80-08-0 DAPSONE ADVERSE_EFFECT _Erythema Nodosum 80-08-0 DAPSONE ADVERSE_EFFECT BBM__Pancytopenia 80-08-0 DAPSONE ADVERSE_EFFECT BBM__Aplastic Anemia 80-08-0 DAPSONE ADVERSE_EFFECT NEU__Peripheral Neuropathy 80-08-0 DAPSONE TISSUE_TOXICITY Renal Papillary Necrosis 80-08-0 DAPSONE THERAPEUTIC_CLASS Antiparasitics 80-08-0 DAPSONE PRODUCT_CLASS Anti-infectives 80-08-0 DAPSONE MECHANISM Inhibit precursor synthesis 80-08-0 DAPSONE INDICATION Mycobacterium Tuberculosis Infections 80-08-0 DAPSONE INDICATION Mycetoma / Maduromycosis / Actinomycetoma 80-08-0 DAPSONE INDICATION Idiopathic (Autoimmnune) Thrombocytopenic Purpura (ITP) 80-08-0 DAPSONE ADVERSE_EFFECT LIV__Hepatitis 80-08-0 DAPSONE ADVERSE_EFFECT LIV__Increased Liver Enzymes 80-08-0 DAPSONE ADVERSE_EFFECT SKN__Exfoliative Dermatitis 80-08-0 DAPSONE ADVERSE_EFFECT BBM__Agranulocytosis 80-08-0 DAPSONE ADVERSE_EFFECT KID__Nephrotic Syndrome 80-08-0 DAPSONE INDICATION Dermatitis Herpetiformis 80-08-0 DAPSONE INDICATION Pneumocystis Carinii Pneumonia (PCP) 80-08-0 DAPSONE THERAPEUTIC_CLASS Antivirals 80-08-0 DAPSONE ADVERSE_EFFECT SKN__Toxic Epidermal Necrolysis 80-08-0 DAPSONE ADVERSE_EFFECT IMU__Photosensitivity 80-08-0 DAPSONE ADVERSE_EFFECT GIS__Abdominal Pain 80-08-0 DAPSONE MODE_CLASS Enzyme Inhibitor 133099-04-4 DARIFENACIN MODE_CLASS Receptor Ligand Antagonist, Selective 133099-04-4 DARIFENACIN THERAPEUTIC_CLASS Parasympatholytic Agents 133099-04-4 DARIFENACIN MODE_CLASS Receptor Ligand Antagonist 133099-04-4 DARIFENACIN PRODUCT_CLASS Autonomic Nervous System (ANS) 133099-04-4 DARIFENACIN INDICATION Detrusor Instability 133099-04-4 DARIFENACIN MECHANISM Modulate G-protein coupled signal transduction 133099-07-7 DARIFENACIN INDICATION Detrusor Instability 133099-07-7 DARIFENACIN PRODUCT_CLASS Autonomic Nervous System (ANS) 133099-07-7 DARIFENACIN MODE_CLASS Receptor Ligand Antagonist 133099-07-7 DARIFENACIN THERAPEUTIC_CLASS Parasympatholytic Agents 133099-07-7 DARIFENACIN MECHANISM Modulate G-protein coupled signal transduction 133099-07-7 DARIFENACIN MODE_CLASS Receptor Ligand Antagonist, Selective 78218-09-4 DAZOXIBEN PRODUCT_CLASS Anti-inflammatories 78218-09-4 DAZOXIBEN MODE_CLASS Enzyme Inhibitor 78218-09-4 DAZOXIBEN STRUCTURE_ACTIVITY Antiinflammatory, thromboxane-A synthase inhibitor 78218-09-4 DAZOXIBEN MECHANISM Inhibit eicosanoid biosynthesis 78218-09-4 DAZOXIBEN THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 138-14-7 DEFEROXAMINE INDICATION Iron (Fe) Poisoning 138-14-7 DEFEROXAMINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 138-14-7 DEFEROXAMINE ADVERSE_EFFECT OTO_3_Hearing Loss 138-14-7 DEFEROXAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 138-14-7 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Pruritis 138-14-7 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Hypotension 138-14-7 DEFEROXAMINE STRUCTURE_ACTIVITY Iron chelator, HIF-1alpha stablizer 138-14-7 DEFEROXAMINE TISSUE_TOXICITY Shock 138-14-7 DEFEROXAMINE ADVERSE_EFFECT GIS_2_Diarrhea 138-14-7 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 138-14-7 DEFEROXAMINE ADVERSE_EFFECT IMU_3_Urticaria 138-14-7 DEFEROXAMINE ADVERSE_EFFECT BBM_3_Leukopenia 138-14-7 DEFEROXAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 138-14-7 DEFEROXAMINE TISSUE_TOXICITY Hypotension 138-14-7 DEFEROXAMINE KNOWN_TOXICITY Cardiovascular Toxicity 138-14-7 DEFEROXAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 138-14-7 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Rash 138-14-7 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Shock 138-14-7 DEFEROXAMINE ADVERSE_EFFECT IMU_2_Anaphylactic Shock 138-14-7 DEFEROXAMINE ADVERSE_EFFECT OCU_3_Impaired Night Vision 138-14-7 DEFEROXAMINE PRODUCT_CLASS Other Human Uses 138-14-7 DEFEROXAMINE MECHANISM chelate excess metal 138-14-7 DEFEROXAMINE ADVERSE_EFFECT XXX_3_Fever 138-14-7 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Flushing 138-14-7 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Erythema 138-14-7 DEFEROXAMINE ADVERSE_EFFECT OCU_2_Cataracts 138-14-7 DEFEROXAMINE ADVERSE_EFFECT MSK_3_Muscle Cramps 138-14-7 DEFEROXAMINE THERAPEUTIC_CLASS Chelating Agents / Heavy Metal Antagonists 70-51-9 DEFEROXAMINE ADVERSE_EFFECT IMU_3_Urticaria 70-51-9 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 70-51-9 DEFEROXAMINE ADVERSE_EFFECT GIS_2_Diarrhea 70-51-9 DEFEROXAMINE THERAPEUTIC_CLASS Chelating Agents / Heavy Metal Antagonists 70-51-9 DEFEROXAMINE ADVERSE_EFFECT MSK_3_Muscle Cramps 70-51-9 DEFEROXAMINE ADVERSE_EFFECT OCU_2_Cataracts 70-51-9 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Flushing 70-51-9 DEFEROXAMINE ADVERSE_EFFECT XXX_3_Fever 70-51-9 DEFEROXAMINE MECHANISM chelate excess metal 70-51-9 DEFEROXAMINE PRODUCT_CLASS Other Human Uses 70-51-9 DEFEROXAMINE ADVERSE_EFFECT OCU_3_Impaired Night Vision 70-51-9 DEFEROXAMINE ADVERSE_EFFECT IMU_2_Anaphylactic Shock 70-51-9 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Shock 70-51-9 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Rash 70-51-9 DEFEROXAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 70-51-9 DEFEROXAMINE KNOWN_TOXICITY Cardiovascular Toxicity 70-51-9 DEFEROXAMINE TISSUE_TOXICITY Hypotension 70-51-9 DEFEROXAMINE INDICATION Iron (Fe) Poisoning 70-51-9 DEFEROXAMINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 70-51-9 DEFEROXAMINE ADVERSE_EFFECT OTO_3_Hearing Loss 70-51-9 DEFEROXAMINE TISSUE_TOXICITY Shock 70-51-9 DEFEROXAMINE STRUCTURE_ACTIVITY Iron chelator, HIF-1alpha stablizer 70-51-9 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Hypotension 70-51-9 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Pruritis 70-51-9 DEFEROXAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 70-51-9 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Erythema 70-51-9 DEFEROXAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 70-51-9 DEFEROXAMINE ADVERSE_EFFECT BBM_3_Leukopenia 1950-39-6 DEFEROXAMINE KNOWN_TOXICITY Cardiovascular Toxicity 1950-39-6 DEFEROXAMINE TISSUE_TOXICITY Hypotension 1950-39-6 DEFEROXAMINE INDICATION Iron (Fe) Poisoning 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT XXX_2_Injection Site Reaction 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT OTO_3_Hearing Loss 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Pruritis 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Hypotension 1950-39-6 DEFEROXAMINE STRUCTURE_ACTIVITY Iron chelator, HIF-1alpha stablizer 1950-39-6 DEFEROXAMINE TISSUE_TOXICITY Shock 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Rash 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT MSK_3_Muscle Cramps 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT OCU_2_Cataracts 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Erythema 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT SKN_3_Flushing 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT OCU_3_Impaired Night Vision 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT GIS_2_Diarrhea 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT XXX_3_Fever 1950-39-6 DEFEROXAMINE MECHANISM chelate excess metal 1950-39-6 DEFEROXAMINE PRODUCT_CLASS Other Human Uses 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT IMU_2_Anaphylactic Shock 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Shock 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT BBM_3_Leukopenia 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT IMU_3_Urticaria 1950-39-6 DEFEROXAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 1950-39-6 DEFEROXAMINE THERAPEUTIC_CLASS Chelating Agents / Heavy Metal Antagonists 81-23-2 DEHYDROCHOLIC ACID PRODUCT_CLASS Gastrointestinal System 81-23-2 DEHYDROCHOLIC ACID THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 81-23-2 DEHYDROCHOLIC ACID INDICATION Constipation 81-23-2 DEHYDROCHOLIC ACID INDICATION Biliary Disease 81-23-2 DEHYDROCHOLIC ACID ADVERSE_EFFECT SKN_3_Dermatitis 81-23-2 DEHYDROCHOLIC ACID MECHANISM Mechanical 81-23-2 DEHYDROCHOLIC ACID THERAPEUTIC_CLASS Laxatives 81-23-2 DEHYDROCHOLIC ACID ADVERSE_EFFECT SKN_3_Pruritis 147221-93-0 DELAVIRDINE MODE_CLASS Enzyme Inhibitor 147221-93-0 DELAVIRDINE THERAPEUTIC_CLASS Antivirals, Systemic 147221-93-0 DELAVIRDINE PRODUCT_CLASS Anti-infectives 147221-93-0 DELAVIRDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 147221-93-0 DELAVIRDINE MECHANISM Inhibit viral DNA synthesis 148692-47-1 DELAVIRDINE MODE_CLASS Enzyme Inhibitor 148692-47-1 DELAVIRDINE THERAPEUTIC_CLASS Antivirals, Systemic 148692-47-1 DELAVIRDINE PRODUCT_CLASS Anti-infectives 148692-47-1 DELAVIRDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 148692-47-1 DELAVIRDINE MECHANISM Inhibit viral DNA synthesis 136817-59-9 DELAVIRDINE THERAPEUTIC_CLASS Antivirals, Systemic 136817-59-9 DELAVIRDINE PRODUCT_CLASS Anti-infectives 136817-59-9 DELAVIRDINE INDICATION Human Immunodeficiency Virus (HIV) Disease 136817-59-9 DELAVIRDINE MECHANISM Inhibit viral DNA synthesis 136817-59-9 DELAVIRDINE MODE_CLASS Enzyme Inhibitor 1972-08-3 DRONABINOL INDICATION Cachexia 1972-08-3 DRONABINOL MECHANISM Modulate G-protein coupled signal transduction 1972-08-3 DRONABINOL INDICATION Nausea / Vomiting 1972-08-3 DRONABINOL PRODUCT_CLASS Central Nervous System (CNS) 1972-08-3 DRONABINOL THERAPEUTIC_CLASS Appetite Stimulants 1972-08-3 DRONABINOL PRODUCT_CLASS Gastrointestinal System 1972-08-3 DRONABINOL MODE_CLASS Receptor Agonist 1972-08-3 DRONABINOL THERAPEUTIC_CLASS Antiemetics 56-94-0 DEMECARIUM BROMIDE MECHANISM Enhance cholinergic transmission 56-94-0 DEMECARIUM BROMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 56-94-0 DEMECARIUM BROMIDE INDICATION Glaucoma 56-94-0 DEMECARIUM BROMIDE MODE_CLASS Enzyme Inhibitor 56-94-0 DEMECARIUM BROMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 64-73-3 DEMECLOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 64-73-3 DEMECLOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 64-73-3 DEMECLOCYCLINE PRODUCT_CLASS Anti-infectives 64-73-3 DEMECLOCYCLINE THERAPEUTIC_CLASS Antibacterials, Systemic 64-73-3 DEMECLOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 127-33-3 DEMECLOCYCLINE THERAPEUTIC_CLASS Antibacterials, Systemic 127-33-3 DEMECLOCYCLINE STRUCTURE_ACTIVITY Bacterial ribosomal (30S) function inhibitor, tetracycline 127-33-3 DEMECLOCYCLINE MECHANISM Inhibit ribosomal protein synthesis 127-33-3 DEMECLOCYCLINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 127-33-3 DEMECLOCYCLINE PRODUCT_CLASS Anti-infectives 70161-09-0 DEMOCONAZOLE THERAPEUTIC_CLASS Antifungals 70161-09-0 DEMOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 70161-09-0 DEMOCONAZOLE PRODUCT_CLASS Anti-infectives 70161-09-0 DEMOCONAZOLE MODE_CLASS Enzyme Inhibitor 522-51-0 DEQUALINIUM CHLORIDE MECHANISM Inhibit kinase mediated signal transduction 522-51-0 DEQUALINIUM CHLORIDE MODE_CLASS Enzyme Inhibitor 522-51-0 DEQUALINIUM CHLORIDE INDICATION Gastrointestinal Infection 522-51-0 DEQUALINIUM CHLORIDE THERAPEUTIC_CLASS Antibacterials, Systemic 522-51-0 DEQUALINIUM CHLORIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 522-51-0 DEQUALINIUM CHLORIDE MODE_CLASS Channel Blocker, selective 522-51-0 DEQUALINIUM CHLORIDE INDICATION Fungal Infections 522-51-0 DEQUALINIUM CHLORIDE INDICATION Skin Infections 522-51-0 DEQUALINIUM CHLORIDE THERAPEUTIC_CLASS Antifungals, Systemic 522-51-0 DEQUALINIUM CHLORIDE STRUCTURE_ACTIVITY K+ Channel (Ca++ dependent) blocker 522-51-0 DEQUALINIUM CHLORIDE ADVERSE_EFFECT SKN_3_Skin Necrosis 522-51-0 DEQUALINIUM CHLORIDE PRODUCT_CLASS Anti-infectives 522-51-0 DEQUALINIUM CHLORIDE ADVERSE_EFFECT SKN_3_Skin Ulcer 522-51-0 DEQUALINIUM CHLORIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 522-51-0 DEQUALINIUM CHLORIDE MECHANISM Modulate channel gating 131-01-1 DESERPIDINE INDICATION Hypertension 131-01-1 DESERPIDINE MECHANISM Prolong/enhance neural transmission 131-01-1 DESERPIDINE MODE_CLASS Solute transporter inhibitor 131-01-1 DESERPIDINE PRODUCT_CLASS Cardiovasculars 131-01-1 DESERPIDINE THERAPEUTIC_CLASS Antihypertensive Agents 58-28-6 DESIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 58-28-6 DESIPRAMINE INDICATION Neuropathic Pain 58-28-6 DESIPRAMINE ADVERSE_EFFECT NEU_3_Convulsions 58-28-6 DESIPRAMINE INDICATION Depression 58-28-6 DESIPRAMINE ADVERSE_EFFECT OCU_3_Glaucoma 58-28-6 DESIPRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 58-28-6 DESIPRAMINE ADVERSE_EFFECT XXX_3_Withdrawal 58-28-6 DESIPRAMINE INDICATION Phobic Disorder 58-28-6 DESIPRAMINE INDICATION Bulimia Nervosa 58-28-6 DESIPRAMINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 58-28-6 DESIPRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 58-28-6 DESIPRAMINE ADVERSE_EFFECT REP_3_Impotence 58-28-6 DESIPRAMINE MODE_CLASS Solute transporter inhibitor 58-28-6 DESIPRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 58-28-6 DESIPRAMINE ADVERSE_EFFECT LIV_3_Jaundice 58-28-6 DESIPRAMINE TISSUE_TOXICITY Cardiac Failure 58-28-6 DESIPRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 58-28-6 DESIPRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 58-28-6 DESIPRAMINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 58-28-6 DESIPRAMINE INDICATION Postherpetic Neuralgia 58-28-6 DESIPRAMINE INDICATION Diabetic Neuropathy 58-28-6 DESIPRAMINE ADVERSE_EFFECT REP_3_Decreased Libido 58-28-6 DESIPRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 58-28-6 DESIPRAMINE ADVERSE_EFFECT IMU_3_Eosinophilia 58-28-6 DESIPRAMINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 58-28-6 DESIPRAMINE ADVERSE_EFFECT XXX_2_Breast Enlargement 58-28-6 DESIPRAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 58-28-6 DESIPRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 58-28-6 DESIPRAMINE THERAPEUTIC_CLASS Antidepressants 58-28-6 DESIPRAMINE INDICATION Panic Disorder 58-28-6 DESIPRAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 58-28-6 DESIPRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 58-28-6 DESIPRAMINE ADVERSE_EFFECT END_3_Gynecomastia 58-28-6 DESIPRAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 58-28-6 DESIPRAMINE MECHANISM Prolong/enhance neural transmission 58-28-6 DESIPRAMINE ADVERSE_EFFECT BBM_3_Anemia 58-28-6 DESIPRAMINE ADVERSE_EFFECT BBM_3_Leukopenia 58-28-6 DESIPRAMINE ADVERSE_EFFECT END_2_Galactorrhea 58-28-6 DESIPRAMINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 58-28-6 DESIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 58-28-6 DESIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Failure 58-28-6 DESIPRAMINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 58-28-6 DESIPRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-47-5 DESIPRAMINE INDICATION Diabetic Neuropathy 50-47-5 DESIPRAMINE INDICATION Postherpetic Neuralgia 50-47-5 DESIPRAMINE INDICATION Phobic Disorder 50-47-5 DESIPRAMINE INDICATION Bulimia Nervosa 50-47-5 DESIPRAMINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 50-47-5 DESIPRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 50-47-5 DESIPRAMINE ADVERSE_EFFECT REP_3_Impotence 50-47-5 DESIPRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 50-47-5 DESIPRAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 50-47-5 DESIPRAMINE THERAPEUTIC_CLASS Antidepressants 50-47-5 DESIPRAMINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 50-47-5 DESIPRAMINE ADVERSE_EFFECT LIV_3_Jaundice 50-47-5 DESIPRAMINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 50-47-5 DESIPRAMINE ADVERSE_EFFECT XXX_3_Withdrawal 50-47-5 DESIPRAMINE TISSUE_TOXICITY Cardiac Arrhythmia 50-47-5 DESIPRAMINE MECHANISM Prolong/enhance neural transmission 50-47-5 DESIPRAMINE ADVERSE_EFFECT NEU_3_Convulsions 50-47-5 DESIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 50-47-5 DESIPRAMINE ADVERSE_EFFECT END_3_Gynecomastia 50-47-5 DESIPRAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 50-47-5 DESIPRAMINE ADVERSE_EFFECT CVS_3_Cardiac Failure 50-47-5 DESIPRAMINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 50-47-5 DESIPRAMINE INDICATION Depression 50-47-5 DESIPRAMINE PRODUCT_CLASS Central Nervous System (CNS) 50-47-5 DESIPRAMINE INDICATION Neuropathic Pain 50-47-5 DESIPRAMINE TISSUE_TOXICITY Cardiac Failure 50-47-5 DESIPRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 50-47-5 DESIPRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 50-47-5 DESIPRAMINE ADVERSE_EFFECT REP_3_Decreased Libido 50-47-5 DESIPRAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 50-47-5 DESIPRAMINE ADVERSE_EFFECT IMU_3_Eosinophilia 50-47-5 DESIPRAMINE ADVERSE_EFFECT REP_2_Ejaculatory Disorder 50-47-5 DESIPRAMINE ADVERSE_EFFECT XXX_2_Breast Enlargement 50-47-5 DESIPRAMINE INDICATION Panic Disorder 50-47-5 DESIPRAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 50-47-5 DESIPRAMINE ADVERSE_EFFECT OCU_3_Glaucoma 50-47-5 DESIPRAMINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 50-47-5 DESIPRAMINE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-47-5 DESIPRAMINE ADVERSE_EFFECT BBM_3_Anemia 50-47-5 DESIPRAMINE ADVERSE_EFFECT BBM_3_Leukopenia 50-47-5 DESIPRAMINE ADVERSE_EFFECT END_2_Galactorrhea 50-47-5 DESIPRAMINE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 50-47-5 DESIPRAMINE MODE_CLASS Solute transporter inhibitor 62357-86-2 DESMOPRESSIN MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 62357-86-2 DESMOPRESSIN MODE_CLASS Receptor Agonist, selective 62357-86-2 DESMOPRESSIN PRODUCT_CLASS Hematologics 62357-86-2 DESMOPRESSIN INDICATION Nocturnal Enuresis 62357-86-2 DESMOPRESSIN INDICATION Hemophilia A / Factor VIII Deficiency 62357-86-2 DESMOPRESSIN THERAPEUTIC_CLASS Pituitary Hormones 62357-86-2 DESMOPRESSIN INDICATION Von Willebrand's Disease 62357-86-2 DESMOPRESSIN PRODUCT_CLASS Electrolytic, Caloric and Water Balance 62357-86-2 DESMOPRESSIN THERAPEUTIC_CLASS Hemostatic Agents 62357-86-2 DESMOPRESSIN INDICATION Central Diabetes Insipidus 62288-83-9 DESMOPRESSIN INDICATION Central Diabetes Insipidus 62288-83-9 DESMOPRESSIN MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 62288-83-9 DESMOPRESSIN MODE_CLASS Receptor Agonist, selective 62288-83-9 DESMOPRESSIN PRODUCT_CLASS Hematologics 62288-83-9 DESMOPRESSIN INDICATION Nocturnal Enuresis 62288-83-9 DESMOPRESSIN INDICATION Hemophilia A / Factor VIII Deficiency 62288-83-9 DESMOPRESSIN THERAPEUTIC_CLASS Pituitary Hormones 62288-83-9 DESMOPRESSIN INDICATION Von Willebrand's Disease 62288-83-9 DESMOPRESSIN THERAPEUTIC_CLASS Hemostatic Agents 62288-83-9 DESMOPRESSIN PRODUCT_CLASS Electrolytic, Caloric and Water Balance 16679-58-6 DESMOPRESSIN MODE_CLASS Receptor Agonist, selective 16679-58-6 DESMOPRESSIN PRODUCT_CLASS Hematologics 16679-58-6 DESMOPRESSIN INDICATION Nocturnal Enuresis 16679-58-6 DESMOPRESSIN INDICATION Hemophilia A / Factor VIII Deficiency 16679-58-6 DESMOPRESSIN THERAPEUTIC_CLASS Pituitary Hormones 16679-58-6 DESMOPRESSIN INDICATION Von Willebrand's Disease 16679-58-6 DESMOPRESSIN THERAPEUTIC_CLASS Hemostatic Agents 16679-58-6 DESMOPRESSIN PRODUCT_CLASS Electrolytic, Caloric and Water Balance 16679-58-6 DESMOPRESSIN INDICATION Central Diabetes Insipidus 16679-58-6 DESMOPRESSIN MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 54024-22-5 DESOGESTREL MECHANISM Modulate gene transcription 54024-22-5 DESOGESTREL PRODUCT_CLASS Hormones, Endocrine and Metabolic 54024-22-5 DESOGESTREL MODE_CLASS Receptor Agonist 54024-22-5 DESOGESTREL THERAPEUTIC_CLASS Contraceptive Hormones 638-94-8 DESONIDE MODE_CLASS Receptor Agonist 638-94-8 DESONIDE THERAPEUTIC_CLASS Corticosteroids, Topical 638-94-8 DESONIDE PRODUCT_CLASS Anti-inflammatories 638-94-8 DESONIDE MECHANISM Modulate gene transcription 382-67-2 DESOXIMETASONE INDICATION Rash 382-67-2 DESOXIMETASONE ADVERSE_EFFECT IMU_3_Contact Dermatitis 382-67-2 DESOXIMETASONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 382-67-2 DESOXIMETASONE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 382-67-2 DESOXIMETASONE ADVERSE_EFFECT END_3_Cushing's Syndrome 382-67-2 DESOXIMETASONE ADVERSE_EFFECT SKN_3_Acneiform Rash 382-67-2 DESOXIMETASONE ADVERSE_EFFECT XXX_3_Impaired Wound Healing 382-67-2 DESOXIMETASONE ADVERSE_EFFECT END_3_Hyperglycemia 382-67-2 DESOXIMETASONE ADVERSE_EFFECT XXX_2_Withdrawal 382-67-2 DESOXIMETASONE ADVERSE_EFFECT END_3_Adrenal Insufficiency 382-67-2 DESOXIMETASONE ADVERSE_EFFECT SKN_2_Skin Infection 382-67-2 DESOXIMETASONE ADVERSE_EFFECT END_3_Hypothalamic-Pituitary-Adrenal Suppression 382-67-2 DESOXIMETASONE PRODUCT_CLASS Dermatologicals 382-67-2 DESOXIMETASONE INDICATION Skin Diseases / Dermatoses 382-67-2 DESOXIMETASONE MECHANISM Modulate gene transcription 382-67-2 DESOXIMETASONE ADVERSE_EFFECT XXX_3_Tolerance 382-67-2 DESOXIMETASONE ADVERSE_EFFECT OCU_3_Cataracts 382-67-2 DESOXIMETASONE ADVERSE_EFFECT SKN_2_Skin Irritation 382-67-2 DESOXIMETASONE ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 382-67-2 DESOXIMETASONE INDICATION Allergic Contact Dermatitis 382-67-2 DESOXIMETASONE INDICATION Pruritus / Itching 382-67-2 DESOXIMETASONE INDICATION Dermatitis 382-67-2 DESOXIMETASONE THERAPEUTIC_CLASS Corticosteroids, Topical 382-67-2 DESOXIMETASONE ADVERSE_EFFECT SKN_2_Pruritis 382-67-2 DESOXIMETASONE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 382-67-2 DESOXIMETASONE ADVERSE_EFFECT SKN_3_Skin Atrophy 382-67-2 DESOXIMETASONE ADVERSE_EFFECT XXX_2_Xerosis 382-67-2 DESOXIMETASONE MODE_CLASS Receptor Agonist 103420-77-5 DEVAZEPIDE MECHANISM Reduce stomach HCl secretion 103420-77-5 DEVAZEPIDE THERAPEUTIC_CLASS Antineoplastics 103420-77-5 DEVAZEPIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 103420-77-5 DEVAZEPIDE MODE_CLASS Receptor Ligand Antagonist, Selective 103420-77-5 DEVAZEPIDE PRODUCT_CLASS Anti-cancers 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Seizures 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT REP_3_Impotence 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Insomnia 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypotension 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Constipation 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Vertigo 2391-03-9 DEXBROMPHENIRAMINE TISSUE_TOXICITY Hypotension 2391-03-9 DEXBROMPHENIRAMINE INDICATION Allergic Rhinitis 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT XXX_2_Lethargy 2391-03-9 DEXBROMPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT OCU_3_Diplopia 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Dizziness 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 2391-03-9 DEXBROMPHENIRAMINE INDICATION Nasal Congestion 2391-03-9 DEXBROMPHENIRAMINE INDICATION Viral Rhinitis / Common Cold 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Irritability 2391-03-9 DEXBROMPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Delirium 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_2_Anorexia 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 2391-03-9 DEXBROMPHENIRAMINE INDICATION Rhinorrhea 2391-03-9 DEXBROMPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 2391-03-9 DEXBROMPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 2391-03-9 DEXBROMPHENIRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Xerophthalmia 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypertension 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Diarrhea 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_2_Sedation 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Tremor 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Euphoria 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 2391-03-9 DEXBROMPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 2391-03-9 DEXBROMPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 132-21-8 DEXBROMPHENIRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 132-21-8 DEXBROMPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 132-21-8 DEXBROMPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 132-21-8 DEXBROMPHENIRAMINE INDICATION Rhinorrhea 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_2_Anorexia 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Delirium 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 132-21-8 DEXBROMPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Irritability 132-21-8 DEXBROMPHENIRAMINE INDICATION Viral Rhinitis / Common Cold 132-21-8 DEXBROMPHENIRAMINE INDICATION Nasal Congestion 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT XXX_2_Lethargy 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Seizures 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT REP_3_Impotence 132-21-8 DEXBROMPHENIRAMINE INDICATION Allergic Rhinitis 132-21-8 DEXBROMPHENIRAMINE TISSUE_TOXICITY Hypotension 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Vertigo 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Constipation 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypotension 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Insomnia 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 132-21-8 DEXBROMPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT OCU_3_Diplopia 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Dizziness 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypertension 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 132-21-8 DEXBROMPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Tremor 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT NEU_2_Sedation 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Diarrhea 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Euphoria 132-21-8 DEXBROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Xerophthalmia 3239-44-9 DEXFENFLURAMINE MESH_LEVEL_3 Ethylamines 3239-44-9 DEXFENFLURAMINE TISSUE_TOXICITY Cardiac Valvular Malfunction 3239-44-9 DEXFENFLURAMINE MODE_CLASS Solute transporter inhibitor 3239-44-9 DEXFENFLURAMINE MESH_LEVEL_2 Amines 3239-44-9 DEXFENFLURAMINE PRODUCT_CLASS Central Nervous System (CNS) 3239-44-9 DEXFENFLURAMINE INDICATION Obesity 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT GIS_1_Diarrhea 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT XXX_3_Asthenia 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT PSY_3_Insomnia 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT NEU_3_Dizziness 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT KID_3_Polyuria 3239-44-9 DEXFENFLURAMINE TA_LEVEL_1 Central Nervous System (CNS) 3239-44-9 DEXFENFLURAMINE TA_LEVEL_2 CNS Depressant 3239-44-9 DEXFENFLURAMINE MECH_LEVEL_1 Modulate neural transmission 3239-44-9 DEXFENFLURAMINE MECHANISM Modulate neural transmission 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT CVS_1_Hypotension 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT NEU_3_Headache 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT LUN_3_Pulmonary Hypertension 3239-44-9 DEXFENFLURAMINE TISSUE_TOXICITY Hypotension 3239-44-9 DEXFENFLURAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (SERT) inhibitor, heterogeneous structures 3239-44-9 DEXFENFLURAMINE MECHANISM Prolong/enhance neural transmission 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT PSY_3_Depression 3239-44-9 DEXFENFLURAMINE TA_LEVEL_3 Appetite suppressant 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT CVS_3_Cardiac Valvular Malfunction 3239-44-9 DEXFENFLURAMINE KNOWN_TOXICITY Cardiovascular Toxicity 3239-44-9 DEXFENFLURAMINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 3239-44-9 DEXFENFLURAMINE THERAPEUTIC_CLASS Anorexiants 3239-44-9 DEXFENFLURAMINE ZERO_CLASS N 3239-44-9 DEXFENFLURAMINE MODE_CLASS Receptor /Channel ligand mimic 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT PSY_3_Anxiety 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT GIS_1_Constipation 3239-44-9 DEXFENFLURAMINE MECH_LEVEL_2 5HT antagonist 3239-44-9 DEXFENFLURAMINE MECH_LEVEL_3 5HT receptor 2C 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT XXX_1_Xerostomia 3239-44-9 DEXFENFLURAMINE ADVERSE_EFFECT NEU_3_Drowsiness 3239-44-9 DEXFENFLURAMINE MESH_LEVEL_1 Organic Chemicals 81-13-0 DEXPANTHENOL MECHANISM Vitamin/ cofactor 81-13-0 DEXPANTHENOL INDICATION Paralytic Ileus 81-13-0 DEXPANTHENOL ADVERSE_EFFECT CVS_3_Hypotension 81-13-0 DEXPANTHENOL ADVERSE_EFFECT IMU_3_Urticaria 81-13-0 DEXPANTHENOL PRODUCT_CLASS Dermatologicals 81-13-0 DEXPANTHENOL INDICATION Dermatitis 81-13-0 DEXPANTHENOL TISSUE_TOXICITY Hypotension 81-13-0 DEXPANTHENOL ADVERSE_EFFECT GIS_3_Diarrhea 81-13-0 DEXPANTHENOL ADVERSE_EFFECT PSY_3_Agitation 81-13-0 DEXPANTHENOL STRUCTURE_ACTIVITY Vitamin/mineral, miscellaneous 81-13-0 DEXPANTHENOL INDICATION Pruritus / Itching 81-13-0 DEXPANTHENOL KNOWN_TOXICITY Cardiovascular Toxicity 81-13-0 DEXPANTHENOL ADVERSE_EFFECT SKN_3_Pruritis 81-13-0 DEXPANTHENOL ADVERSE_EFFECT GIS_3_Colic 81-13-0 DEXPANTHENOL PRODUCT_CLASS Gastrointestinal System 81-13-0 DEXPANTHENOL INDICATION Insect Bites or Stings 81-13-0 DEXPANTHENOL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 81-13-0 DEXPANTHENOL THERAPEUTIC_CLASS Prokinetic Agents 81-13-0 DEXPANTHENOL ADVERSE_EFFECT IMU_3_Allergic Reactions 81-13-0 DEXPANTHENOL ADVERSE_EFFECT IMU_3_Contact Dermatitis 81-13-0 DEXPANTHENOL INDICATION Gastroparesis 51-64-9 DEXTROAMPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 51-64-9 DEXTROAMPHETAMINE PRODUCT_CLASS Central Nervous System (CNS) 51-64-9 DEXTROAMPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 51-64-9 DEXTROAMPHETAMINE MECHANISM Prolong/enhance neural transmission 51-64-9 DEXTROAMPHETAMINE MODE_CLASS Receptor Partial Agonist 51-64-9 DEXTROAMPHETAMINE MECHANISM Block channel gating 51-64-9 DEXTROAMPHETAMINE INDICATION Narcolepsy 51-64-9 DEXTROAMPHETAMINE MODE_CLASS Enzyme substrate mimic 51-64-9 DEXTROAMPHETAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 51-64-9 DEXTROAMPHETAMINE THERAPEUTIC_CLASS Central Stimulants 51-64-9 DEXTROAMPHETAMINE MODE_CLASS Solute transporter inhibitor 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT CVS_3_Tachycardia 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Coma 125-71-3 DEXTROMETHORPHAN MODE_CLASS Receptor Agonist, selective 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Nystagmus 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Stupor 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Excitement 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Nervousness 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT SKN_3_Rash 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Drowsiness 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Confusion 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dystonia 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dysarthria 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Hallucinations 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Dizziness 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Ataxia 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Urticaria 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Toxic Psychosis 125-71-3 DEXTROMETHORPHAN STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 125-71-3 DEXTROMETHORPHAN INDICATION Cough / Tussis 125-71-3 DEXTROMETHORPHAN PRODUCT_CLASS Central Nervous System (CNS) 125-71-3 DEXTROMETHORPHAN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Seizures 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT LUN_3_Respiratory Depression 125-71-3 DEXTROMETHORPHAN MECHANISM Modulate neural transmission 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_2_Fatigue 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_3_Restlessness 125-71-3 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Irritability 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Urticaria 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Ataxia 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Dizziness 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Hallucinations 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dysarthria 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dystonia 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Confusion 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Drowsiness 510-53-2 DEXTROMETHORPHAN MODE_CLASS Receptor Agonist, selective 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Nystagmus 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Stupor 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Seizures 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Excitement 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Nervousness 510-53-2 DEXTROMETHORPHAN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Toxic Psychosis 510-53-2 DEXTROMETHORPHAN STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 510-53-2 DEXTROMETHORPHAN INDICATION Cough / Tussis 510-53-2 DEXTROMETHORPHAN PRODUCT_CLASS Central Nervous System (CNS) 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT SKN_3_Rash 510-53-2 DEXTROMETHORPHAN MECHANISM Modulate neural transmission 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT LUN_3_Respiratory Depression 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_2_Fatigue 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_3_Restlessness 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Irritability 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT CVS_3_Tachycardia 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 510-53-2 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Coma 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Nystagmus 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Stupor 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_3_Restlessness 125-69-9 DEXTROMETHORPHAN MECHANISM Modulate neural transmission 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Excitement 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Nervousness 125-69-9 DEXTROMETHORPHAN STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Ataxia 125-69-9 DEXTROMETHORPHAN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 125-69-9 DEXTROMETHORPHAN PRODUCT_CLASS Central Nervous System (CNS) 125-69-9 DEXTROMETHORPHAN INDICATION Cough / Tussis 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT LUN_3_Respiratory Depression 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Toxic Psychosis 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Urticaria 125-69-9 DEXTROMETHORPHAN MODE_CLASS Receptor Agonist, selective 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Dizziness 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Hallucinations 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dysarthria 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dystonia 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Confusion 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Drowsiness 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT SKN_3_Rash 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_2_Fatigue 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Seizures 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Irritability 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT CVS_3_Tachycardia 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 125-69-9 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Coma 18046-32-7 DEXTROMETHORPHAN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 18046-32-7 DEXTROMETHORPHAN PRODUCT_CLASS Central Nervous System (CNS) 18046-32-7 DEXTROMETHORPHAN STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Toxic Psychosis 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Urticaria 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Ataxia 18046-32-7 DEXTROMETHORPHAN MECHANISM Modulate neural transmission 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Seizures 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_3_Restlessness 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Irritability 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT CVS_3_Tachycardia 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Coma 18046-32-7 DEXTROMETHORPHAN MODE_CLASS Receptor Agonist, selective 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Nystagmus 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Stupor 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Excitement 18046-32-7 DEXTROMETHORPHAN INDICATION Cough / Tussis 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Nervousness 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT SKN_3_Rash 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Drowsiness 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Confusion 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT LUN_3_Respiratory Depression 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dystonia 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dysarthria 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Hallucinations 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Dizziness 18046-32-7 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_2_Fatigue 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Dizziness 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Hallucinations 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dysarthria 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Confusion 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_2_Drowsiness 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT SKN_3_Rash 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Nervousness 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Excitement 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Stupor 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Nystagmus 32062-10-5 DEXTROMETHORPHAN MODE_CLASS Receptor Agonist, selective 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Coma 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT GIS_3_Nausea / Vomiting 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT CVS_3_Tachycardia 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Irritability 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_3_Restlessness 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Seizures 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT XXX_2_Fatigue 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT LUN_3_Respiratory Depression 32062-10-5 DEXTROMETHORPHAN MECHANISM Modulate neural transmission 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Dystonia 32062-10-5 DEXTROMETHORPHAN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 32062-10-5 DEXTROMETHORPHAN PRODUCT_CLASS Central Nervous System (CNS) 32062-10-5 DEXTROMETHORPHAN INDICATION Cough / Tussis 32062-10-5 DEXTROMETHORPHAN STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT PSY_3_Toxic Psychosis 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT IMU_3_Urticaria 32062-10-5 DEXTROMETHORPHAN ADVERSE_EFFECT NEU_3_Ataxia 51-49-0 DEXTROTHYROXINE STRUCTURE_ACTIVITY T3 receptor agonist 51-49-0 DEXTROTHYROXINE INDICATION Hyperlipoproteinemia 51-49-0 DEXTROTHYROXINE INDICATION Hypercholesterolemia 51-49-0 DEXTROTHYROXINE THERAPEUTIC_CLASS Hypolipidemic Agents 51-49-0 DEXTROTHYROXINE MODE_CLASS Receptor Agonist 51-49-0 DEXTROTHYROXINE PRODUCT_CLASS Cardiovasculars 137-53-1 DEXTROTHYROXINE INDICATION Hypercholesterolemia 137-53-1 DEXTROTHYROXINE THERAPEUTIC_CLASS Hypolipidemic Agents 137-53-1 DEXTROTHYROXINE MODE_CLASS Receptor Agonist 137-53-1 DEXTROTHYROXINE PRODUCT_CLASS Cardiovasculars 137-53-1 DEXTROTHYROXINE STRUCTURE_ACTIVITY T3 receptor agonist 137-53-1 DEXTROTHYROXINE INDICATION Hyperlipoproteinemia 53648-55-8 DEZOCINE PRODUCT_CLASS Analgesics 53648-55-8 DEZOCINE MECHANISM Modulate neural transmission 53648-55-8 DEZOCINE THERAPEUTIC_CLASS Analgesics, Opioid 53648-55-8 DEZOCINE MODE_CLASS Receptor Partial Agonist 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_2_Confusion 439-14-5 DIAZEPAM ADVERSE_EFFECT LIV_3_Jaundice 439-14-5 DIAZEPAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 439-14-5 DIAZEPAM MESH_LEVEL_3 Benzazepines 439-14-5 DIAZEPAM TA_LEVEL_2 CNS Depressant 439-14-5 DIAZEPAM INDICATION Alcoholic Withdrawal 439-14-5 DIAZEPAM PRODUCT_CLASS Central Nervous System (CNS) 439-14-5 DIAZEPAM MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 439-14-5 DIAZEPAM TA_LEVEL_3 Benzodiazepine 439-14-5 DIAZEPAM INDICATION Skeletal Muscle Spasm 439-14-5 DIAZEPAM THERAPEUTIC_CLASS Skeletal Muscle Relaxants 439-14-5 DIAZEPAM ADVERSE_EFFECT NEU_1_Ataxia 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_3_Rage 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_3_CNS Excitation 439-14-5 DIAZEPAM MODE_CLASS Channel enhancer /opener 439-14-5 DIAZEPAM ADVERSE_EFFECT LUN_3_Respiratory Depression 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_3_Hallucinations 439-14-5 DIAZEPAM ADVERSE_EFFECT REP_2_Sexual Dysfunction 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_2_Physical Dependence 439-14-5 DIAZEPAM MECH_LEVEL_3 GABA-A receptor A 439-14-5 DIAZEPAM MECH_LEVEL_1 Modulate neural transmission 439-14-5 DIAZEPAM MECHANISM Modulate neural transmission 439-14-5 DIAZEPAM TISSUE_TOXICITY Hypotension 439-14-5 DIAZEPAM KNOWN_TOXICITY Cardiovascular Toxicity 439-14-5 DIAZEPAM ADVERSE_EFFECT EMB_3_Teratogenicity 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_2_Depression 439-14-5 DIAZEPAM ADVERSE_EFFECT XXX_1_Fatigue 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 439-14-5 DIAZEPAM ADVERSE_EFFECT NEU_2_Slurred Speech 439-14-5 DIAZEPAM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 439-14-5 DIAZEPAM ADVERSE_EFFECT SKN_2_Skin Rash 439-14-5 DIAZEPAM ACTIVITY_CLASS GABA agonist 439-14-5 DIAZEPAM TA_LEVEL_1 Central Nervous System (CNS) 439-14-5 DIAZEPAM THERAPEUTIC_CLASS Anxiolytics 439-14-5 DIAZEPAM THERAPEUTIC_CLASS Sedatives/Hypnotics 439-14-5 DIAZEPAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 439-14-5 DIAZEPAM ADVERSE_EFFECT XXX_2_Salivation 439-14-5 DIAZEPAM ADVERSE_EFFECT CVS_2_Hypotension 439-14-5 DIAZEPAM ADVERSE_EFFECT NEU_1_Drowsiness 439-14-5 DIAZEPAM ZERO_CLASS N 439-14-5 DIAZEPAM ADVERSE_EFFECT XXX_1_Withdrawal 439-14-5 DIAZEPAM MESH_LEVEL_1 Heterocyclic Compounds 439-14-5 DIAZEPAM INDICATION Anxiety Disorders 439-14-5 DIAZEPAM MECH_LEVEL_2 faciliates GABA binding 439-14-5 DIAZEPAM INDICATION Seizure Disorders 439-14-5 DIAZEPAM TISSUE_TOXICITY Teratogenicity 439-14-5 DIAZEPAM KNOWN_TOXICITY Embryo/Fetal Toxicity 439-14-5 DIAZEPAM THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 439-14-5 DIAZEPAM ADVERSE_EFFECT GUS_2_Urinary Retention 439-14-5 DIAZEPAM ADVERSE_EFFECT PSY_3_Insomnia 439-14-5 DIAZEPAM ADVERSE_EFFECT NEU_3_Coma 439-14-5 DIAZEPAM ADVERSE_EFFECT NEU_3_Spasticity 439-14-5 DIAZEPAM ADVERSE_EFFECT OCU_2_Diplopia 439-14-5 DIAZEPAM ADVERSE_EFFECT BBM_3_Neutropenia 364-98-7 DIAZOXIDE INDICATION Hypoglycemia 364-98-7 DIAZOXIDE INDICATION Insulinoma 364-98-7 DIAZOXIDE KNOWN_TOXICITY Cardiovascular Toxicity 364-98-7 DIAZOXIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR2 ) opener 364-98-7 DIAZOXIDE ADVERSE_EFFECT GIS_2_Diarrhea 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_1_Hypotension 364-98-7 DIAZOXIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 364-98-7 DIAZOXIDE ADVERSE_EFFECT SKN_2_Flushing 364-98-7 DIAZOXIDE ADVERSE_EFFECT SKN_3_Pruritis 364-98-7 DIAZOXIDE ADVERSE_EFFECT GIS_2_Loss of Sense of Taste 364-98-7 DIAZOXIDE TISSUE_TOXICITY Hypotension 364-98-7 DIAZOXIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_3_Myocardial Ischemia 364-98-7 DIAZOXIDE ADVERSE_EFFECT SKN_3_Hypertrichosis 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_2_Phlebitis 364-98-7 DIAZOXIDE MECHANISM Reduce muscle contractile force 364-98-7 DIAZOXIDE ADVERSE_EFFECT XXX_3_Fever 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 364-98-7 DIAZOXIDE ADVERSE_EFFECT NEU_1_Dizziness 364-98-7 DIAZOXIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 364-98-7 DIAZOXIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 364-98-7 DIAZOXIDE ADVERSE_EFFECT END_3_Ketoacidosis 364-98-7 DIAZOXIDE ADVERSE_EFFECT NEU_3_Cerebral Ischemia 364-98-7 DIAZOXIDE TISSUE_TOXICITY Congestive Heart Failure 364-98-7 DIAZOXIDE INDICATION Hypertension 364-98-7 DIAZOXIDE ADVERSE_EFFECT XXX_2_Sweating 364-98-7 DIAZOXIDE THERAPEUTIC_CLASS Antihypertensive Agents 364-98-7 DIAZOXIDE ADVERSE_EFFECT END_3_Hirsutism 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 364-98-7 DIAZOXIDE ADVERSE_EFFECT NEU_2_Headache 364-98-7 DIAZOXIDE ADVERSE_EFFECT XXX_2_Weight Gain 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_1_Palpitation 364-98-7 DIAZOXIDE ADVERSE_EFFECT SKN_2_Skin Rash 364-98-7 DIAZOXIDE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 364-98-7 DIAZOXIDE TISSUE_TOXICITY Myocardial Ischemia 364-98-7 DIAZOXIDE ADVERSE_EFFECT PSY_2_Anorexia 364-98-7 DIAZOXIDE ADVERSE_EFFECT END_1_Hyperglycemia 364-98-7 DIAZOXIDE MODE_CLASS Channel enhancer /opener 364-98-7 DIAZOXIDE PRODUCT_CLASS Cardiovasculars 364-98-7 DIAZOXIDE ADVERSE_EFFECT GIS_2_Constipation 364-98-7 DIAZOXIDE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 364-98-7 DIAZOXIDE ADVERSE_EFFECT XXX_2_Edema 364-98-7 DIAZOXIDE ADVERSE_EFFECT BBM_3_Leukopenia 364-98-7 DIAZOXIDE ADVERSE_EFFECT KID_2_Fluid Retention 85-79-0 DIBUCAINE INDICATION Hemorrhoids 85-79-0 DIBUCAINE PRODUCT_CLASS Dermatologicals 85-79-0 DIBUCAINE INDICATION Burns 85-79-0 DIBUCAINE ADVERSE_EFFECT XXX__Edema 85-79-0 DIBUCAINE THERAPEUTIC_CLASS Antipruritic Agents 85-79-0 DIBUCAINE ADVERSE_EFFECT IMU__Urticaria 85-79-0 DIBUCAINE ADVERSE_EFFECT IMU__Anaphylactoid Reactions 85-79-0 DIBUCAINE ADVERSE_EFFECT XXX__Stinging Sensation 85-79-0 DIBUCAINE INDICATION Allergic Contact Dermatitis 85-79-0 DIBUCAINE PRODUCT_CLASS Central Nervous System (CNS) 85-79-0 DIBUCAINE MECHANISM Block neural transmission 85-79-0 DIBUCAINE ADVERSE_EFFECT XXX__Burning Sensation 85-79-0 DIBUCAINE THERAPEUTIC_CLASS Local Anesthetics 85-79-0 DIBUCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 85-79-0 DIBUCAINE ADVERSE_EFFECT IMU__Contact Dermatitis 85-79-0 DIBUCAINE ADVERSE_EFFECT SKN__Skin Sloughing 85-79-0 DIBUCAINE INDICATION Local Anesthesia 85-79-0 DIBUCAINE MECHANISM Prolong/enhance neural transmission 85-79-0 DIBUCAINE MODE_CLASS Solute transporter inhibitor 85-79-0 DIBUCAINE MODE_CLASS Channel Blocker 79-43-6 DICHLOROACETIC ACID INDICATION Seborrheic Keratosis 79-43-6 DICHLOROACETIC ACID INDICATION Condylomata Acuminata 79-43-6 DICHLOROACETIC ACID INDICATION Warts 79-43-6 DICHLOROACETIC ACID PRODUCT_CLASS Anti-infectives 79-43-6 DICHLOROACETIC ACID INDICATION Epistaxis / Nose Bleed 79-43-6 DICHLOROACETIC ACID THERAPEUTIC_CLASS Antivirals, Topical 79-43-6 DICHLOROACETIC ACID INDICATION Verruca Vulgaris 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT XXX_3_Malaise 120-97-8 DICHLORPHENAMIDE INDICATION Glaucoma 120-97-8 DICHLORPHENAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT PSY_3_Anorexia 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT XXX_3_Weakness 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT ELT_2_Hyponatremia 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT GUS_3_Urinary Frequency 120-97-8 DICHLORPHENAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 120-97-8 DICHLORPHENAMIDE KNOWN_TOXICITY Nephrotoxicity 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT XXX_3_Fever 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT ELT_2_Hypokalemia 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT END_2_Metabolic Acidosis 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT XXX_1_Asthenia 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT NEU_3_Convulsions 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT XXX_1_Fatigue 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT SKN_3_Rash 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT XXX_3_Weight Loss 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT GIS_3_Melena 120-97-8 DICHLORPHENAMIDE MODE_CLASS Enzyme Inhibitor 120-97-8 DICHLORPHENAMIDE STRUCTURE_ACTIVITY Carbonic Anhydrase Inhibitor 120-97-8 DICHLORPHENAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 120-97-8 DICHLORPHENAMIDE TISSUE_TOXICITY Hematuria 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT SKN_3_Pruritis 120-97-8 DICHLORPHENAMIDE ADVERSE_EFFECT KID_3_Hematuria 15307-81-0 DICLOFENAC TISSUE_TOXICITY Congestive Heart Failure 15307-81-0 DICLOFENAC KNOWN_TOXICITY Cardiovascular Toxicity 15307-81-0 DICLOFENAC MESH_LEVEL_2 Carboxylic Acids 15307-81-0 DICLOFENAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 15307-81-0 DICLOFENAC INDICATION Dysmenorrhea 15307-81-0 DICLOFENAC INDICATION Musculoskeletal Pain 15307-81-0 DICLOFENAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 15307-81-0 DICLOFENAC TA_LEVEL_1 Anti-inflammatory 15307-81-0 DICLOFENAC ADVERSE_EFFECT KID_3_Acute Renal Failure 15307-81-0 DICLOFENAC ADVERSE_EFFECT BBM_3_Leukopenia 15307-81-0 DICLOFENAC ADVERSE_EFFECT SKN_2_Rash 15307-81-0 DICLOFENAC ADVERSE_EFFECT CVS_3_Congestive Heart Failure 15307-81-0 DICLOFENAC ADVERSE_EFFECT OTO_2_Tinnitus 15307-81-0 DICLOFENAC TA_LEVEL_3 NSAID 15307-81-0 DICLOFENAC INDICATION Ankylosing Spondylitis 15307-81-0 DICLOFENAC TISSUE_TOXICITY Nephrotic Syndrome 15307-81-0 DICLOFENAC MESH_LEVEL_1 Organic Chemicals 15307-81-0 DICLOFENAC PRODUCT_CLASS Anti-inflammatories 15307-81-0 DICLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 15307-81-0 DICLOFENAC ACTIVITY_CLASS Anti-inflammatory 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_1_Indigestion 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_1_Abdominal Pain 15307-81-0 DICLOFENAC ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 15307-81-0 DICLOFENAC ADVERSE_EFFECT IMU_3_Anaphylaxis 15307-81-0 DICLOFENAC TA_LEVEL_2 NSAID 15307-81-0 DICLOFENAC ADVERSE_EFFECT NEU_1_Headache 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_1_Diarrhea 15307-81-0 DICLOFENAC TISSUE_TOXICITY Acute Renal Failure 15307-81-0 DICLOFENAC MESH_LEVEL_3 Acids, Carbocyclic 15307-81-0 DICLOFENAC KNOWN_TOXICITY Nephrotoxicity 15307-81-0 DICLOFENAC MECH_LEVEL_1 Immunomodulation 15307-81-0 DICLOFENAC ADVERSE_EFFECT XXX_3_Malaise 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_2_Flatulence 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_2_Peptic Ulceration 15307-81-0 DICLOFENAC MODE_CLASS Enzyme Inhibitor 15307-81-0 DICLOFENAC ADVERSE_EFFECT SKN_2_Pruritis 15307-81-0 DICLOFENAC ADVERSE_EFFECT NEU_2_Dizziness 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_1_Constipation 15307-81-0 DICLOFENAC INDICATION Rheumatoid Arthritis 15307-81-0 DICLOFENAC STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 15307-81-0 DICLOFENAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 15307-81-0 DICLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 15307-81-0 DICLOFENAC ZERO_CLASS N 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_1_Nausea 15307-81-0 DICLOFENAC ADVERSE_EFFECT OCU_3_Diplopia 15307-81-0 DICLOFENAC ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 15307-81-0 DICLOFENAC ADVERSE_EFFECT KID_2_Fluid Retention 15307-81-0 DICLOFENAC ADVERSE_EFFECT GIS_2_Abdominal Distention 15307-81-0 DICLOFENAC INDICATION Osteoarthritis 15307-86-5 DICLOFENAC ADVERSE_EFFECT KID_3_Acute Renal Failure 15307-86-5 DICLOFENAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 15307-86-5 DICLOFENAC INDICATION Musculoskeletal Pain 15307-86-5 DICLOFENAC KNOWN_TOXICITY Nephrotoxicity 15307-86-5 DICLOFENAC ADVERSE_EFFECT BBM_3_Leukopenia 15307-86-5 DICLOFENAC INDICATION Dysmenorrhea 15307-86-5 DICLOFENAC TA_LEVEL_1 Anti-inflammatory 15307-86-5 DICLOFENAC KNOWN_TOXICITY Cardiovascular Toxicity 15307-86-5 DICLOFENAC INDICATION Osteoarthritis 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_2_Abdominal Distention 15307-86-5 DICLOFENAC ADVERSE_EFFECT KID_2_Fluid Retention 15307-86-5 DICLOFENAC ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 15307-86-5 DICLOFENAC ADVERSE_EFFECT OCU_3_Diplopia 15307-86-5 DICLOFENAC ADVERSE_EFFECT OTO_2_Tinnitus 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_1_Nausea 15307-86-5 DICLOFENAC ZERO_CLASS N 15307-86-5 DICLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 15307-86-5 DICLOFENAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 15307-86-5 DICLOFENAC MESH_LEVEL_2 Carboxylic Acids 15307-86-5 DICLOFENAC TA_LEVEL_2 NSAID 15307-86-5 DICLOFENAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 15307-86-5 DICLOFENAC TISSUE_TOXICITY Nephrotic Syndrome 15307-86-5 DICLOFENAC MODE_CLASS Enzyme Inhibitor 15307-86-5 DICLOFENAC STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 15307-86-5 DICLOFENAC INDICATION Rheumatoid Arthritis 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_1_Constipation 15307-86-5 DICLOFENAC ADVERSE_EFFECT NEU_2_Dizziness 15307-86-5 DICLOFENAC ADVERSE_EFFECT SKN_2_Pruritis 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_2_Peptic Ulceration 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_2_Flatulence 15307-86-5 DICLOFENAC ADVERSE_EFFECT XXX_3_Malaise 15307-86-5 DICLOFENAC MECH_LEVEL_1 Immunomodulation 15307-86-5 DICLOFENAC MESH_LEVEL_3 Acids, Carbocyclic 15307-86-5 DICLOFENAC TISSUE_TOXICITY Acute Renal Failure 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_1_Diarrhea 15307-86-5 DICLOFENAC ADVERSE_EFFECT NEU_1_Headache 15307-86-5 DICLOFENAC ADVERSE_EFFECT IMU_3_Anaphylaxis 15307-86-5 DICLOFENAC ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_1_Abdominal Pain 15307-86-5 DICLOFENAC ADVERSE_EFFECT GIS_1_Indigestion 15307-86-5 DICLOFENAC ACTIVITY_CLASS Anti-inflammatory 15307-86-5 DICLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 15307-86-5 DICLOFENAC PRODUCT_CLASS Anti-inflammatories 15307-86-5 DICLOFENAC MESH_LEVEL_1 Organic Chemicals 15307-86-5 DICLOFENAC INDICATION Ankylosing Spondylitis 15307-86-5 DICLOFENAC TA_LEVEL_3 NSAID 15307-86-5 DICLOFENAC TISSUE_TOXICITY Congestive Heart Failure 15307-86-5 DICLOFENAC ADVERSE_EFFECT CVS_3_Congestive Heart Failure 15307-86-5 DICLOFENAC ADVERSE_EFFECT SKN_2_Rash 15307-79-6 DICLOFENAC ADVERSE_EFFECT IMU_3_Anaphylaxis 15307-79-6 DICLOFENAC ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_1_Abdominal Pain 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_1_Indigestion 15307-79-6 DICLOFENAC ACTIVITY_CLASS Anti-inflammatory 15307-79-6 DICLOFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 15307-79-6 DICLOFENAC PRODUCT_CLASS Anti-inflammatories 15307-79-6 DICLOFENAC MESH_LEVEL_1 Organic Chemicals 15307-79-6 DICLOFENAC INDICATION Ankylosing Spondylitis 15307-79-6 DICLOFENAC TA_LEVEL_3 NSAID 15307-79-6 DICLOFENAC TISSUE_TOXICITY Congestive Heart Failure 15307-79-6 DICLOFENAC ADVERSE_EFFECT CVS_3_Congestive Heart Failure 15307-79-6 DICLOFENAC ADVERSE_EFFECT SKN_2_Rash 15307-79-6 DICLOFENAC ADVERSE_EFFECT BBM_3_Leukopenia 15307-79-6 DICLOFENAC ADVERSE_EFFECT KID_3_Acute Renal Failure 15307-79-6 DICLOFENAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 15307-79-6 DICLOFENAC INDICATION Musculoskeletal Pain 15307-79-6 DICLOFENAC KNOWN_TOXICITY Nephrotoxicity 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_2_Flatulence 15307-79-6 DICLOFENAC MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 15307-79-6 DICLOFENAC MECHANISM Inhibit eicosanoid biosynthesis 15307-79-6 DICLOFENAC ZERO_CLASS N 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_1_Nausea 15307-79-6 DICLOFENAC ADVERSE_EFFECT OTO_2_Tinnitus 15307-79-6 DICLOFENAC ADVERSE_EFFECT OCU_3_Diplopia 15307-79-6 DICLOFENAC ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 15307-79-6 DICLOFENAC ADVERSE_EFFECT KID_2_Fluid Retention 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_2_Abdominal Distention 15307-79-6 DICLOFENAC INDICATION Osteoarthritis 15307-79-6 DICLOFENAC KNOWN_TOXICITY Cardiovascular Toxicity 15307-79-6 DICLOFENAC TA_LEVEL_1 Anti-inflammatory 15307-79-6 DICLOFENAC MESH_LEVEL_2 Carboxylic Acids 15307-79-6 DICLOFENAC TA_LEVEL_2 NSAID 15307-79-6 DICLOFENAC MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 15307-79-6 DICLOFENAC INDICATION Dysmenorrhea 15307-79-6 DICLOFENAC TISSUE_TOXICITY Nephrotic Syndrome 15307-79-6 DICLOFENAC MODE_CLASS Enzyme Inhibitor 15307-79-6 DICLOFENAC STRUCTURE_ACTIVITY NSAID, COX-1/2, o-phenylamino-phenylacetic acid 15307-79-6 DICLOFENAC INDICATION Rheumatoid Arthritis 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_1_Constipation 15307-79-6 DICLOFENAC ADVERSE_EFFECT NEU_2_Dizziness 15307-79-6 DICLOFENAC ADVERSE_EFFECT SKN_2_Pruritis 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_2_Peptic Ulceration 15307-79-6 DICLOFENAC ADVERSE_EFFECT XXX_3_Malaise 15307-79-6 DICLOFENAC MECH_LEVEL_1 Immunomodulation 15307-79-6 DICLOFENAC MESH_LEVEL_3 Acids, Carbocyclic 15307-79-6 DICLOFENAC TISSUE_TOXICITY Acute Renal Failure 15307-79-6 DICLOFENAC ADVERSE_EFFECT GIS_1_Diarrhea 15307-79-6 DICLOFENAC ADVERSE_EFFECT NEU_1_Headache 3116-76-5 DICLOXACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 3116-76-5 DICLOXACILLIN MODE_CLASS Enzyme Inhibitor 3116-76-5 DICLOXACILLIN PRODUCT_CLASS Anti-infectives 3116-76-5 DICLOXACILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 13412-64-1 DICLOXACILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 13412-64-1 DICLOXACILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 13412-64-1 DICLOXACILLIN MODE_CLASS Enzyme Inhibitor 13412-64-1 DICLOXACILLIN PRODUCT_CLASS Anti-infectives 66-76-2 DICUMAROL TISSUE_TOXICITY Hemorrhage 66-76-2 DICUMAROL PRODUCT_CLASS Hematologics 66-76-2 DICUMAROL TA_LEVEL_3 anticoagulant 66-76-2 DICUMAROL MECH_LEVEL_1 Anti-clotting 66-76-2 DICUMAROL INDICATION Cerebrovascular Accident / Stroke 66-76-2 DICUMAROL INDICATION Thrombosis 66-76-2 DICUMAROL ADVERSE_EFFECT SKN_2_Dermatitis 66-76-2 DICUMAROL MODE_CLASS Enzyme Inhibitor 66-76-2 DICUMAROL ADVERSE_EFFECT LIV_3_Impaired Liver Function 66-76-2 DICUMAROL ADVERSE_EFFECT XXX_2_Edema 66-76-2 DICUMAROL ADVERSE_EFFECT EMB_1_Teratogenicity 66-76-2 DICUMAROL ADVERSE_EFFECT KID_3_Renal Dysfunction 66-76-2 DICUMAROL ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 66-76-2 DICUMAROL TISSUE_TOXICITY Teratogenicity 66-76-2 DICUMAROL MESH_LEVEL_1 Heterocyclic Compounds 66-76-2 DICUMAROL MESH_LEVEL_3 Benzopyrans 66-76-2 DICUMAROL INDICATION Myocardial Infarction 66-76-2 DICUMAROL TA_LEVEL_2 anticoagulant 66-76-2 DICUMAROL TA_LEVEL_1 Cardiovascular 66-76-2 DICUMAROL ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 66-76-2 DICUMAROL ADVERSE_EFFECT IMU_2_Allergic Reactions 66-76-2 DICUMAROL ADVERSE_EFFECT GIS_1_Diarrhea 66-76-2 DICUMAROL ZERO_CLASS N 66-76-2 DICUMAROL KNOWN_TOXICITY Embryo/Fetal Toxicity 66-76-2 DICUMAROL MECHANISM Inhibit platelet aggregation 66-76-2 DICUMAROL ADVERSE_EFFECT EMB_1_Abortion 66-76-2 DICUMAROL ADVERSE_EFFECT PSY_1_Anorexia 66-76-2 DICUMAROL ADVERSE_EFFECT END_3_Adrenal Insufficiency 66-76-2 DICUMAROL STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 66-76-2 DICUMAROL TISSUE_TOXICITY Abortion 66-76-2 DICUMAROL THERAPEUTIC_CLASS Anticoagulants 66-76-2 DICUMAROL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 66-76-2 DICUMAROL MECH_LEVEL_3 Vitamin-K-epoxide reductase 66-76-2 DICUMAROL ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 66-76-2 DICUMAROL INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 66-76-2 DICUMAROL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 66-76-2 DICUMAROL ADVERSE_EFFECT BBM_1_Hemorrhage 66-76-2 DICUMAROL ADVERSE_EFFECT BBM_3_Agranulocytosis 66-76-2 DICUMAROL ADVERSE_EFFECT OCU_1_Blurred Vision 66-76-2 DICUMAROL MECH_LEVEL_2 Inhibit platelet aggregation 77-19-0 DICYCLOMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 77-19-0 DICYCLOMINE ADVERSE_EFFECT OCU_1_Blurred Vision 77-19-0 DICYCLOMINE ZERO_CLASS N 77-19-0 DICYCLOMINE INDICATION Irritable Bowel Syndrome 77-19-0 DICYCLOMINE TA_LEVEL_3 urinary incontinence 77-19-0 DICYCLOMINE MECH_LEVEL_3 Muscarinic acetylcholine receptor M1 77-19-0 DICYCLOMINE ADVERSE_EFFECT XXX_3_Weakness 77-19-0 DICYCLOMINE ADVERSE_EFFECT NEU_2_Dizziness 77-19-0 DICYCLOMINE MESH_LEVEL_1 Organic Chemicals 77-19-0 DICYCLOMINE ADVERSE_EFFECT OCU_1_Cycloplegia 77-19-0 DICYCLOMINE ADVERSE_EFFECT SKN_1_Anhidrosis 77-19-0 DICYCLOMINE MODE_CLASS Receptor Ligand Antagonist, Selective 77-19-0 DICYCLOMINE MESH_LEVEL_3 Acids, Carbocyclic 77-19-0 DICYCLOMINE TA_LEVEL_2 Anti-spasmodics 77-19-0 DICYCLOMINE PRODUCT_CLASS Gastrointestinal System 77-19-0 DICYCLOMINE MECHANISM Modulate G-protein coupled signal transduction 77-19-0 DICYCLOMINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M1) antagonist 77-19-0 DICYCLOMINE MECH_LEVEL_2 Anti-muscarinic/Parasympatholytic 77-19-0 DICYCLOMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 77-19-0 DICYCLOMINE ADVERSE_EFFECT NEU_2_Headache 77-19-0 DICYCLOMINE ADVERSE_EFFECT GIS_2_Dysphagia 77-19-0 DICYCLOMINE ADVERSE_EFFECT GIS_2_Dysgeusia 77-19-0 DICYCLOMINE THERAPEUTIC_CLASS Antispasmodic Agents 77-19-0 DICYCLOMINE MESH_LEVEL_2 Carboxylic Acids 77-19-0 DICYCLOMINE TA_LEVEL_1 Gastrointestinal System 77-19-0 DICYCLOMINE ADVERSE_EFFECT GUS_1_Urinary Retention 77-19-0 DICYCLOMINE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 77-19-0 DICYCLOMINE ADVERSE_EFFECT OCU_1_Mydriasis 77-19-0 DICYCLOMINE ADVERSE_EFFECT REP_3_Impotence 77-19-0 DICYCLOMINE ADVERSE_EFFECT PSY_3_Insomnia 77-19-0 DICYCLOMINE ADVERSE_EFFECT OCU_1_Photophobia 77-19-0 DICYCLOMINE ADVERSE_EFFECT NEU_2_Drowsiness 77-19-0 DICYCLOMINE ADVERSE_EFFECT SKN_2_Flushing 77-19-0 DICYCLOMINE ADVERSE_EFFECT GIS_2_Constipation 77-19-0 DICYCLOMINE ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 77-19-0 DICYCLOMINE ADVERSE_EFFECT GIS_1_Dry Mouth 77-19-0 DICYCLOMINE MECH_LEVEL_1 Anti-muscarinic/Parasympatholytic 77-19-0 DICYCLOMINE ADVERSE_EFFECT IMU_3_Anaphylaxis 67-92-5 DICYCLOMINE ADVERSE_EFFECT NEU_2_Headache 67-92-5 DICYCLOMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 67-92-5 DICYCLOMINE ADVERSE_EFFECT OCU_1_Mydriasis 67-92-5 DICYCLOMINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M1) antagonist 67-92-5 DICYCLOMINE MECHANISM Modulate G-protein coupled signal transduction 67-92-5 DICYCLOMINE PRODUCT_CLASS Gastrointestinal System 67-92-5 DICYCLOMINE TA_LEVEL_2 Anti-spasmodics 67-92-5 DICYCLOMINE MESH_LEVEL_3 Acids, Carbocyclic 67-92-5 DICYCLOMINE MODE_CLASS Receptor Ligand Antagonist, Selective 67-92-5 DICYCLOMINE ADVERSE_EFFECT SKN_1_Anhidrosis 67-92-5 DICYCLOMINE ADVERSE_EFFECT OCU_1_Cycloplegia 67-92-5 DICYCLOMINE ADVERSE_EFFECT NEU_2_Dizziness 67-92-5 DICYCLOMINE ADVERSE_EFFECT XXX_3_Weakness 67-92-5 DICYCLOMINE ADVERSE_EFFECT GIS_1_Dry Mouth 67-92-5 DICYCLOMINE THERAPEUTIC_CLASS Antispasmodic Agents 67-92-5 DICYCLOMINE MESH_LEVEL_2 Carboxylic Acids 67-92-5 DICYCLOMINE TA_LEVEL_1 Gastrointestinal System 67-92-5 DICYCLOMINE ADVERSE_EFFECT GUS_1_Urinary Retention 67-92-5 DICYCLOMINE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 67-92-5 DICYCLOMINE ADVERSE_EFFECT IMU_3_Anaphylaxis 67-92-5 DICYCLOMINE ADVERSE_EFFECT REP_3_Impotence 67-92-5 DICYCLOMINE ADVERSE_EFFECT PSY_3_Insomnia 67-92-5 DICYCLOMINE ADVERSE_EFFECT GIS_2_Constipation 67-92-5 DICYCLOMINE ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 67-92-5 DICYCLOMINE MECH_LEVEL_1 Anti-muscarinic/Parasympatholytic 67-92-5 DICYCLOMINE MESH_LEVEL_1 Organic Chemicals 67-92-5 DICYCLOMINE MECH_LEVEL_2 Anti-muscarinic/Parasympatholytic 67-92-5 DICYCLOMINE ADVERSE_EFFECT NEU_2_Drowsiness 67-92-5 DICYCLOMINE ADVERSE_EFFECT SKN_2_Flushing 67-92-5 DICYCLOMINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 67-92-5 DICYCLOMINE ADVERSE_EFFECT OCU_1_Blurred Vision 67-92-5 DICYCLOMINE ZERO_CLASS N 67-92-5 DICYCLOMINE INDICATION Irritable Bowel Syndrome 67-92-5 DICYCLOMINE TA_LEVEL_3 urinary incontinence 67-92-5 DICYCLOMINE MECH_LEVEL_3 Muscarinic acetylcholine receptor M1 67-92-5 DICYCLOMINE ADVERSE_EFFECT OCU_1_Photophobia 67-92-5 DICYCLOMINE ADVERSE_EFFECT GIS_2_Dysgeusia 67-92-5 DICYCLOMINE ADVERSE_EFFECT GIS_2_Dysphagia 69655-05-6 DIDANOSINE ADVERSE_EFFECT LIV_2_Steatosis 69655-05-6 DIDANOSINE ADVERSE_EFFECT SKN_2_Rash 69655-05-6 DIDANOSINE ADVERSE_EFFECT BBM__Neutropenia 69655-05-6 DIDANOSINE ADVERSE_EFFECT MSK_2_Myalgia 69655-05-6 DIDANOSINE ADVERSE_EFFECT KID_2_Hyperuricemia 69655-05-6 DIDANOSINE ADVERSE_EFFECT XXX_2_Fever 69655-05-6 DIDANOSINE ADVERSE_EFFECT PSY_2_Depression 69655-05-6 DIDANOSINE ADVERSE_EFFECT XXX_2_Asthenia 69655-05-6 DIDANOSINE ADVERSE_EFFECT BBM_2_Anemia 69655-05-6 DIDANOSINE MODE_CLASS Enzyme substrate mimic 69655-05-6 DIDANOSINE INDICATION Hepatitis B 69655-05-6 DIDANOSINE STRUCTURE_ACTIVITY Viral RT inhibitor 69655-05-6 DIDANOSINE ADVERSE_EFFECT XXX_2_Xerostomia 69655-05-6 DIDANOSINE ADVERSE_EFFECT SKN_2_Pigmentary Disorders 69655-05-6 DIDANOSINE ADVERSE_EFFECT NEU_3_Optic Neuritis 69655-05-6 DIDANOSINE ADVERSE_EFFECT GIS_2_Pancreatitis 69655-05-6 DIDANOSINE ADVERSE_EFFECT END_2_Lactic Acidosis 69655-05-6 DIDANOSINE ADVERSE_EFFECT GIS_2_Flatulence 69655-05-6 DIDANOSINE ADVERSE_EFFECT GIS_2_Dyspepsia 69655-05-6 DIDANOSINE ADVERSE_EFFECT XXX_2_Chills 69655-05-6 DIDANOSINE ADVERSE_EFFECT PSY_2_Anorexia 69655-05-6 DIDANOSINE ADVERSE_EFFECT GIS_2_Abdominal Pain 69655-05-6 DIDANOSINE THERAPEUTIC_CLASS Antivirals, Systemic 69655-05-6 DIDANOSINE ADVERSE_EFFECT GIS_1_Diarrhea 69655-05-6 DIDANOSINE ADVERSE_EFFECT MSK_2_Rhabdomyolysis 69655-05-6 DIDANOSINE ADVERSE_EFFECT NEU_1_Peripheral Neuropathy 69655-05-6 DIDANOSINE ADVERSE_EFFECT MSK_2_Myopathy 69655-05-6 DIDANOSINE KNOWN_TOXICITY Hepatotoxicity 69655-05-6 DIDANOSINE ADVERSE_EFFECT BBM_2_Leukopenia 69655-05-6 DIDANOSINE ADVERSE_EFFECT NEU_2_Headache 69655-05-6 DIDANOSINE ADVERSE_EFFECT LUN_2_Dyspnea 69655-05-6 DIDANOSINE ADVERSE_EFFECT PSY_2_Confusion 69655-05-6 DIDANOSINE ADVERSE_EFFECT PSY_2_Anxiety 69655-05-6 DIDANOSINE PRODUCT_CLASS Anti-infectives 69655-05-6 DIDANOSINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 69655-05-6 DIDANOSINE MECHANISM Inhibit viral DNA synthesis 69655-05-6 DIDANOSINE ADVERSE_EFFECT SKN_2_Pruritis 69655-05-6 DIDANOSINE ADVERSE_EFFECT NEU_2_Seizures 69655-05-6 DIDANOSINE ACTIVITY_CLASS Anti-viral 69655-05-6 DIDANOSINE ADVERSE_EFFECT MSK_2_Arthralgia 69655-05-6 DIDANOSINE INDICATION Human Immunodeficiency Virus (HIV) Disease 69655-05-6 DIDANOSINE TISSUE_TOXICITY Hepatic Failure 69655-05-6 DIDANOSINE ADVERSE_EFFECT END_2_Lipodystrophy 69655-05-6 DIDANOSINE ADVERSE_EFFECT LIV_3_Hepatic Failure 69655-05-6 DIDANOSINE ADVERSE_EFFECT LIV_2_Hepatic Dysfunction 69655-05-6 DIDANOSINE ADVERSE_EFFECT END_2_Cushingoid Features 100-51-6 BENZYL ALCOHOL THERAPEUTIC_CLASS Analgesics, Topical 100-51-6 BENZYL ALCOHOL ADVERSE_EFFECT SKN_2_Pruritis 100-51-6 BENZYL ALCOHOL INDICATION Local Anesthesia 100-51-6 BENZYL ALCOHOL INDICATION Insect Bites or Stings 100-51-6 BENZYL ALCOHOL ADVERSE_EFFECT SKN_2_Dry Skin 100-51-6 BENZYL ALCOHOL PRODUCT_CLASS Dermatologicals 100-51-6 BENZYL ALCOHOL INDICATION Burn Wounds 100-51-6 BENZYL ALCOHOL ADVERSE_EFFECT SKN_2_Erythema 100-51-6 BENZYL ALCOHOL MECHANISM Block neural transmission 100-51-6 BENZYL ALCOHOL ADVERSE_EFFECT IMU_3_Contact Dermatitis 100-51-6 BENZYL ALCOHOL INDICATION Pruritus / Itching 100-51-6 BENZYL ALCOHOL INDICATION Allergic Contact Dermatitis 64706-54-3 BEPRIDIL MODE_CLASS Channel Blocker 64706-54-3 BEPRIDIL THERAPEUTIC_CLASS Antianginals 64706-54-3 BEPRIDIL INDICATION Angina Pectoris 64706-54-3 BEPRIDIL STRUCTURE_ACTIVITY Ca++ channel blocker 64706-54-3 BEPRIDIL MECHANISM Reduce muscle contractile force 64706-54-3 BEPRIDIL PRODUCT_CLASS Cardiovasculars 74764-40-2 BEPRIDIL MECHANISM Reduce muscle contractile force 74764-40-2 BEPRIDIL STRUCTURE_ACTIVITY Ca++ channel blocker 74764-40-2 BEPRIDIL INDICATION Angina Pectoris 74764-40-2 BEPRIDIL THERAPEUTIC_CLASS Antianginals 74764-40-2 BEPRIDIL PRODUCT_CLASS Cardiovasculars 74764-40-2 BEPRIDIL MODE_CLASS Channel Blocker 107-43-7 BETAINE ADVERSE_EFFECT GIS_1_Nausea 107-43-7 BETAINE MODE_CLASS Enzyme substrate mimic 107-43-7 BETAINE ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 107-43-7 BETAINE THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 107-43-7 BETAINE ADVERSE_EFFECT GIS_1_Diarrhea 107-43-7 BETAINE PRODUCT_CLASS Vitamins, Minerals and Nutrients 107-43-7 BETAINE INDICATION Homocystinuria 107-43-7 BETAINE MECHANISM Inhibit precursor synthesis 107-43-7 BETAINE ADVERSE_EFFECT IMU_3_Allergic Reactions 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT OCU_3_Blindness 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT END_2_Endocrine System Toxicity 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Allergic Diseases 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Gastrointestinal Diseases 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Respiratory Diseases 378-44-9 BETAMETHASONE PHOSPHATE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT ELT_2_Fluid and Electrolyte Disturbance 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Ophthalmic Diseases 378-44-9 BETAMETHASONE PHOSPHATE PRODUCT_CLASS Anti-inflammatories 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Collagen Diseases 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Rheumatic Disorders 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT END_2_Metabolic Disturbance 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT NEU_2_Neurological Toxicity 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 378-44-9 BETAMETHASONE PHOSPHATE THERAPEUTIC_CLASS Corticosteroids 378-44-9 BETAMETHASONE PHOSPHATE MECHANISM Modulate gene transcription 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Skin Diseases / Dermatoses 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Neoplastic Diseases 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Edematous States 378-44-9 BETAMETHASONE PHOSPHATE MODE_CLASS Receptor Agonist 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT MSK_2_Musculoskeletal System Toxicity 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT OCU_2_Ocular Toxicity 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT SKN_3_Hyperpigmentation 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Hematologic Disorders 378-44-9 BETAMETHASONE PHOSPHATE INDICATION Endocrine Disorders 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT SKN_3_Hypopigmentation 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT SKN_2_Skin Toxicity 378-44-9 BETAMETHASONE PHOSPHATE ADVERSE_EFFECT GIS_2_Gastrointestinal Toxicity 63659-18-7 BETAXOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 63659-18-7 BETAXOLOL THERAPEUTIC_CLASS Antihypertensive Agents 63659-18-7 BETAXOLOL INDICATION Glaucoma 63659-18-7 BETAXOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 63659-18-7 BETAXOLOL INDICATION Increased Intraocular Pressure 63659-18-7 BETAXOLOL MECHANISM Reduce muscle contractile force 63659-18-7 BETAXOLOL PRODUCT_CLASS Cardiovasculars 63659-18-7 BETAXOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 63659-18-7 BETAXOLOL INDICATION Hypertension 590-63-6 BETHANECHOL INDICATION Paralytic Ileus 590-63-6 BETHANECHOL TISSUE_TOXICITY Cardiac Arrest 590-63-6 BETHANECHOL INDICATION Urinary Retention 590-63-6 BETHANECHOL INDICATION Gastroparesis 590-63-6 BETHANECHOL ADVERSE_EFFECT GIS_1_Hypersalivation 590-63-6 BETHANECHOL ADVERSE_EFFECT LUN_2_Bronchospasm 590-63-6 BETHANECHOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 590-63-6 BETHANECHOL ADVERSE_EFFECT OCU_2_Blurred Vision 590-63-6 BETHANECHOL THERAPEUTIC_CLASS Prokinetic Agents 590-63-6 BETHANECHOL TISSUE_TOXICITY Hypotension 590-63-6 BETHANECHOL MECHANISM Enhance cholinergic transmission 590-63-6 BETHANECHOL PRODUCT_CLASS Gastrointestinal System 590-63-6 BETHANECHOL KNOWN_TOXICITY Cardiovascular Toxicity 590-63-6 BETHANECHOL ADVERSE_EFFECT GIS_2_Diarrhea 590-63-6 BETHANECHOL ADVERSE_EFFECT CVS_3_Hypotension 590-63-6 BETHANECHOL MODE_CLASS Receptor Agonist 590-63-6 BETHANECHOL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) agonist 590-63-6 BETHANECHOL ADVERSE_EFFECT GUS_1_Urinary Urgency 590-63-6 BETHANECHOL ADVERSE_EFFECT GIS_2_Abdominal Pain 590-63-6 BETHANECHOL ADVERSE_EFFECT SKN_1_Flushing 590-63-6 BETHANECHOL ADVERSE_EFFECT NEU_2_Headache 590-63-6 BETHANECHOL ADVERSE_EFFECT GIS_1_Flatulence 590-63-6 BETHANECHOL ADVERSE_EFFECT CVS_3_Cardiac Arrest 590-63-6 BETHANECHOL INDICATION Neurogenic Bladder 590-63-6 BETHANECHOL THERAPEUTIC_CLASS Parasympathomimetic Agents 590-63-6 BETHANECHOL ADVERSE_EFFECT OCU_1_Miosis 590-63-6 BETHANECHOL ADVERSE_EFFECT XXX_2_Hypothermia 590-63-6 BETHANECHOL ADVERSE_EFFECT XXX_2_Lacrimation 590-63-6 BETHANECHOL ADVERSE_EFFECT CVS_2_Sinus Tachycardia 590-63-6 BETHANECHOL ADVERSE_EFFECT XXX_2_Diaphoresis 590-63-6 BETHANECHOL PRODUCT_CLASS Autonomic Nervous System (ANS) 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_2_Infection 90357-06-5 (R)-BICALUTAMIDE TISSUE_TOXICITY Hematuria 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_3_Death 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT NEU_3_Headache 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT END_1_Hot Flashes 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT BBM_2_Anemia 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT GIS_1_Constipation 90357-06-5 (R)-BICALUTAMIDE STRUCTURE_ACTIVITY Androgen receptor antagonist 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT MSK_3_Myasthenia 90357-06-5 (R)-BICALUTAMIDE KNOWN_TOXICITY Nephrotoxicity 90357-06-5 (R)-BICALUTAMIDE TA_LEVEL_3 prostate cancer 90357-06-5 (R)-BICALUTAMIDE MESH_LEVEL_2 Amides 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_3_Flu-Like Syndrome 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT CVS_3_Chest Pain 90357-06-5 (R)-BICALUTAMIDE MECH_LEVEL_1 Hormone modulation 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT CVS_3_Angina Pectoris 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_3_Sepsis 90357-06-5 (R)-BICALUTAMIDE TISSUE_TOXICITY Death 90357-06-5 (R)-BICALUTAMIDE MODE_CLASS Receptor Ligand Antagonist, Selective 90357-06-5 (R)-BICALUTAMIDE ACTIVITY_CLASS Androgen antagonist 90357-06-5 (R)-BICALUTAMIDE MESH_LEVEL_1 Organic Chemicals 90357-06-5 (R)-BICALUTAMIDE PRODUCT_CLASS Anti-cancers 90357-06-5 (R)-BICALUTAMIDE KNOWN_TOXICITY Cardiovascular Toxicity 90357-06-5 (R)-BICALUTAMIDE MECH_LEVEL_2 Androgen receptor antagonist 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT GIS_2_Flatulence 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT END_1_Gynecomastia 90357-06-5 (R)-BICALUTAMIDE TA_LEVEL_2 Solid Tumors 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 90357-06-5 (R)-BICALUTAMIDE ZERO_CLASS N 90357-06-5 (R)-BICALUTAMIDE TISSUE_TOXICITY Hepatotoxicity 90357-06-5 (R)-BICALUTAMIDE MECH_LEVEL_3 androgen receptor 90357-06-5 (R)-BICALUTAMIDE TA_LEVEL_1 Oncology 90357-06-5 (R)-BICALUTAMIDE MECHANISM Modulate gene transcription 90357-06-5 (R)-BICALUTAMIDE MESH_LEVEL_3 Anilides 90357-06-5 (R)-BICALUTAMIDE KNOWN_TOXICITY Hepatotoxicity 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT END_3_Hyperglycemia 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_1_Pain 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT LUN_2_Dyspnea 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT END_1_Breast Tenderness 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT NEU_3_Neuropathy 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT MSK_1_Back Pain 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_3_Xerostomia 90357-06-5 (R)-BICALUTAMIDE TISSUE_TOXICITY Angina Pectoris 90357-06-5 (R)-BICALUTAMIDE TISSUE_TOXICITY Congestive Heart Failure 90357-06-5 (R)-BICALUTAMIDE INDICATION Prostatic Cancer / Carcinoma of the Prostate 90357-06-5 (R)-BICALUTAMIDE THERAPEUTIC_CLASS Gonadal Hormones 90357-06-5 (R)-BICALUTAMIDE KNOWN_TOXICITY Miscellaneous 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT XXX_1_Asthenia 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 90357-06-5 (R)-BICALUTAMIDE ADVERSE_EFFECT KID_2_Hematuria 485-49-4 (+)-BICUCULLINE PRODUCT_CLASS Biochemicals 485-49-4 (+)-BICUCULLINE MECHANISM Modulate neural transmission 485-49-4 (+)-BICUCULLINE MODE_CLASS Channel Modulator 58-85-5 BIOTIN MECHANISM Vitamin/ cofactor 514-65-8 BIPERIDEN MODE_CLASS Channel Blocker 514-65-8 BIPERIDEN MODE_CLASS Receptor Ligand Antagonist, Selective 514-65-8 BIPERIDEN THERAPEUTIC_CLASS Movement Disorders 514-65-8 BIPERIDEN INDICATION Parkinson's Disease 514-65-8 BIPERIDEN INDICATION Drug induced Extrapyramidal Symptoms 514-65-8 BIPERIDEN PRODUCT_CLASS Central Nervous System (CNS) 514-65-8 BIPERIDEN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker 514-65-8 BIPERIDEN MECHANISM Block neural transmission 514-65-8 BIPERIDEN MECHANISM Modulate G-protein coupled signal transduction 603-50-9 BISACODYL PRODUCT_CLASS Gastrointestinal System 603-50-9 BISACODYL MESH_LEVEL_2 Phenols 603-50-9 BISACODYL ADVERSE_EFFECT ELT_2_Hypokalemia 603-50-9 BISACODYL ADVERSE_EFFECT GIS_3_Proctitis 603-50-9 BISACODYL ZERO_CLASS Y 603-50-9 BISACODYL MESH_LEVEL_3 Cresols 603-50-9 BISACODYL ADVERSE_EFFECT PSY_2_Dependence 603-50-9 BISACODYL TA_LEVEL_1 Gastrointestinal System 603-50-9 BISACODYL INDICATION Constipation 603-50-9 BISACODYL ADVERSE_EFFECT GIS_1_Diarrhea 603-50-9 BISACODYL MECH_LEVEL_2 Stimulant laxative 603-50-9 BISACODYL STRUCTURE_ACTIVITY Unknown mechanism 603-50-9 BISACODYL ADVERSE_EFFECT GIS_1_Abdominal Cramps 603-50-9 BISACODYL ACTIVITY_CLASS Unknown mechanism 603-50-9 BISACODYL ADVERSE_EFFECT GIS_2_Constipation 603-50-9 BISACODYL ADVERSE_EFFECT ELT_1_Fluid and Electrolyte Loss 603-50-9 BISACODYL ADVERSE_EFFECT GIS_1_Abdominal Pain 603-50-9 BISACODYL THERAPEUTIC_CLASS Laxatives 603-50-9 BISACODYL INDICATION Bowel Preparation 603-50-9 BISACODYL MECH_LEVEL_1 Laxative 603-50-9 BISACODYL MECH_LEVEL_3 Unknown mechanism 603-50-9 BISACODYL MESH_LEVEL_1 Organic Chemicals 603-50-9 BISACODYL ADVERSE_EFFECT GIS_1_Gastrointestinal Irritation 603-50-9 BISACODYL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 603-50-9 BISACODYL TA_LEVEL_2 Laxatives 133052-90-1 BISINDOLYLMALEIMIDE I MODE_CLASS Enzyme Inhibitor, selective 133052-90-1 BISINDOLYLMALEIMIDE I THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 133052-90-1 BISINDOLYLMALEIMIDE I PRODUCT_CLASS Anti-inflammatories 133052-90-1 BISINDOLYLMALEIMIDE I MECHANISM Inhibit kinase mediated signal transduction 1304-85-4 BISMUTH SUBNITRATE ADVERSE_EFFECT NEU_3_Encephalopathy 1304-85-4 BISMUTH SUBNITRATE INDICATION Gastric Ulcer 1304-85-4 BISMUTH SUBNITRATE THERAPEUTIC_CLASS Antiulcers 1304-85-4 BISMUTH SUBNITRATE INDICATION Duodenal Ulcer 1304-85-4 BISMUTH SUBNITRATE PRODUCT_CLASS Gastrointestinal System 14882-18-9 BISMUTH SUBSALICYLATE INDICATION Systemic Lupus Erythromatosus (SLE) 14882-18-9 BISMUTH SUBSALICYLATE MODE_CLASS Enzyme Inhibitor 14882-18-9 BISMUTH SUBSALICYLATE MECHANISM Inhibit eicosanoid biosynthesis 14882-18-9 BISMUTH SUBSALICYLATE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 66722-44-9 BISOPROLOL MECHANISM Reduce muscle contractile force 66722-44-9 BISOPROLOL INDICATION Angina Pectoris 66722-44-9 BISOPROLOL THERAPEUTIC_CLASS Antihypertensive Agents 66722-44-9 BISOPROLOL INDICATION Hypertension 66722-44-9 BISOPROLOL MODE_CLASS Receptor Ligand Antagonist, Selective 66722-44-9 BISOPROLOL THERAPEUTIC_CLASS Antianginals 66722-44-9 BISOPROLOL PRODUCT_CLASS Cardiovasculars 85951-65-1 ETONITAZENE MODE_CLASS Receptor Agonist 85951-65-1 ETONITAZENE PRODUCT_CLASS Central Nervous System (CNS) 85951-65-1 ETONITAZENE PRODUCT_CLASS Biochemicals 85951-65-1 ETONITAZENE MECHANISM Modulate neural transmission 911-65-9 ETONITAZENE MODE_CLASS Receptor Agonist 911-65-9 ETONITAZENE MECHANISM Modulate neural transmission 911-65-9 ETONITAZENE PRODUCT_CLASS Central Nervous System (CNS) 911-65-9 ETONITAZENE PRODUCT_CLASS Biochemicals 30392-40-6 BITOLTEROL THERAPEUTIC_CLASS Bronchodilators 30392-40-6 BITOLTEROL MECHANISM Reduce bronchoconstriction 30392-40-6 BITOLTEROL INDICATION Asthma 30392-40-6 BITOLTEROL MODE_CLASS Receptor Agonist, selective 30392-40-6 BITOLTEROL INDICATION Prophylaxis of Bronchospasm 30392-40-6 BITOLTEROL INDICATION Bronchospasm 30392-40-6 BITOLTEROL PRODUCT_CLASS Respiratory System 153042-42-3 BMS-182874 PRODUCT_CLASS Cardiovasculars 153042-42-3 BMS-182874 INDICATION Hypertension 153042-42-3 BMS-182874 THERAPEUTIC_CLASS Antihypertensive Agents 10043-35-3 BORIC ACID THERAPEUTIC_CLASS Insecticides / Pesticides 10043-35-3 BORIC ACID TISSUE_TOXICITY Death 10043-35-3 BORIC ACID INDICATION Dry Skin 10043-35-3 BORIC ACID INDICATION Ocular Inflammation 10043-35-3 BORIC ACID ADVERSE_EFFECT XXX_3_Death 10043-35-3 BORIC ACID ADVERSE_EFFECT GIS_2_Vomiting 10043-35-3 BORIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 10043-35-3 BORIC ACID ADVERSE_EFFECT BBM_2_Disseminated Intravascular Coagulation (DIC) 10043-35-3 BORIC ACID ADVERSE_EFFECT GIS_2_Gastrointestinal Hemorrhage 10043-35-3 BORIC ACID ADVERSE_EFFECT CVS_3_Circulatory Collapse 10043-35-3 BORIC ACID TISSUE_TOXICITY Anuria 10043-35-3 BORIC ACID THERAPEUTIC_CLASS Antifungals, Topical 10043-35-3 BORIC ACID INDICATION Fungal Infections 10043-35-3 BORIC ACID INDICATION Skin Inflammation 10043-35-3 BORIC ACID PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 10043-35-3 BORIC ACID THERAPEUTIC_CLASS Antiseptics / Disinfectants 10043-35-3 BORIC ACID TISSUE_TOXICITY Renal Tubular Necrosis 10043-35-3 BORIC ACID INDICATION Skin Abrasions 10043-35-3 BORIC ACID PRODUCT_CLASS Other Human Uses 10043-35-3 BORIC ACID INDICATION Burns 10043-35-3 BORIC ACID ADVERSE_EFFECT PSN_2_Acute Poisoning 10043-35-3 BORIC ACID ADVERSE_EFFECT END_3_Metabolic Acidosis 10043-35-3 BORIC ACID ADVERSE_EFFECT GIS_2_Nausea 10043-35-3 BORIC ACID ADVERSE_EFFECT SKN_2_Skin Eruption 10043-35-3 BORIC ACID ADVERSE_EFFECT NEU_2_Seizures 10043-35-3 BORIC ACID ADVERSE_EFFECT LIV_2_Hepatomegaly 10043-35-3 BORIC ACID ADVERSE_EFFECT GIS_2_Epigastric Pain 10043-35-3 BORIC ACID INDICATION Insect Bites or Stings 10043-35-3 BORIC ACID ADVERSE_EFFECT XXX_2_Restlessness 10043-35-3 BORIC ACID THERAPEUTIC_CLASS Analgesics, Topical 10043-35-3 BORIC ACID ADVERSE_EFFECT KID_3_Oliguria 10043-35-3 BORIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 10043-35-3 BORIC ACID ADVERSE_EFFECT XXX_2_Weakness 10043-35-3 BORIC ACID ADVERSE_EFFECT PSY_2_CNS Depression 10043-35-3 BORIC ACID ADVERSE_EFFECT SKN_2_Exfoliation 10043-35-3 BORIC ACID ADVERSE_EFFECT KID_3_Anuria 10043-35-3 BORIC ACID ADVERSE_EFFECT LIV_2_Jaundice 10043-35-3 BORIC ACID ADVERSE_EFFECT CVS_3_Shock 10043-35-3 BORIC ACID TISSUE_TOXICITY Shock 10043-35-3 BORIC ACID PRODUCT_CLASS Dermatologicals 10043-35-3 BORIC ACID ADVERSE_EFFECT NEU_2_Headache 10043-35-3 BORIC ACID ADVERSE_EFFECT NEU_2_Tremor 10043-35-3 BORIC ACID ADVERSE_EFFECT KID_2_Renal Tubular Necrosis 10043-35-3 BORIC ACID ADVERSE_EFFECT LUN_3_Cyanosis 10043-35-3 BORIC ACID ADVERSE_EFFECT XXX_2_Lethargy 10043-35-3 BORIC ACID KNOWN_TOXICITY Nephrotoxicity 10043-35-3 BORIC ACID KNOWN_TOXICITY Miscellaneous 10043-35-3 BORIC ACID TISSUE_TOXICITY Circulatory Collapse 147536-97-8 BOSENTAN PRODUCT_CLASS Cardiovasculars 147536-97-8 BOSENTAN INDICATION Hypertension 147536-97-8 BOSENTAN PRODUCT_CLASS Anti-cancers 147536-97-8 BOSENTAN THERAPEUTIC_CLASS Antihypertensive Agents 147536-97-8 BOSENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 147536-97-8 BOSENTAN MODE_CLASS Receptor Ligand Antagonist, Non-selective 157212-55-0 BOSENTAN PRODUCT_CLASS Cardiovasculars 157212-55-0 BOSENTAN MODE_CLASS Receptor Ligand Antagonist, Non-selective 157212-55-0 BOSENTAN INDICATION Hypertension 157212-55-0 BOSENTAN THERAPEUTIC_CLASS Antihypertensive Agents 157212-55-0 BOSENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 157212-55-0 BOSENTAN PRODUCT_CLASS Anti-cancers 58-82-2 BRADYKININ INDICATION Hypertension 58-82-2 BRADYKININ THERAPEUTIC_CLASS Antihypertensive Agents 58-82-2 BRADYKININ PRODUCT_CLASS Cardiovasculars 61-75-6 BRETYLIUM TOSYLATE THERAPEUTIC_CLASS Antiarrhythmic Agents 61-75-6 BRETYLIUM TOSYLATE MODE_CLASS Solute transporter inhibitor 61-75-6 BRETYLIUM TOSYLATE STRUCTURE_ACTIVITY Cholinesterase (acetyl) inhibitor, heterogeneous 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT XXX_2_Hiccup 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_3_Ventricular Tachycardia 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT NEU_1_Headache 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_1_Orthostatic Hypotension 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT GIS_2_Diarrhea 61-75-6 BRETYLIUM TOSYLATE MECHANISM Enhance cholinergic transmission 61-75-6 BRETYLIUM TOSYLATE MECHANISM Prolong/enhance neural transmission 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT GIS_3_Parotitis 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT GIS_2_Abdominal Pain 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT NEU_1_Vertigo 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT NEU_1_Dizziness 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT XXX_3_Hyperthermia 61-75-6 BRETYLIUM TOSYLATE TISSUE_TOXICITY Ventricular Tachycardia 61-75-6 BRETYLIUM TOSYLATE PRODUCT_CLASS Cardiovasculars 61-75-6 BRETYLIUM TOSYLATE INDICATION Ventricular Tachycardia 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT NEU_1_Syncope 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_3_Ventricular Fibrillation 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_3_Angina 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_1_Hypotension 61-75-6 BRETYLIUM TOSYLATE TISSUE_TOXICITY Hypotension 61-75-6 BRETYLIUM TOSYLATE TISSUE_TOXICITY Ventricular Fibrillation 61-75-6 BRETYLIUM TOSYLATE KNOWN_TOXICITY Cardiovascular Toxicity 61-75-6 BRETYLIUM TOSYLATE MODE_CLASS Enzyme Inhibitor 61-75-6 BRETYLIUM TOSYLATE INDICATION Ventricular Fibrillation 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_3_Premature Ventricular Contrations (PVCs) 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT SKN_2_Rash 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 61-75-6 BRETYLIUM TOSYLATE ADVERSE_EFFECT CVS_3_Hypertension 61-75-6 BRETYLIUM TOSYLATE TISSUE_TOXICITY Angina 61-75-6 BRETYLIUM TOSYLATE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 98112-41-5 BREVETOXIN PBTX-1 PRODUCT_CLASS Toxicants 98112-41-5 BREVETOXIN PBTX-1 MECHANISM Block neural transmission 98112-41-5 BREVETOXIN PBTX-1 MODE_CLASS Channel Blocker 79580-28-2 BREVETOXIN PBTX-1 MODE_CLASS Channel Blocker 79580-28-2 BREVETOXIN PBTX-1 PRODUCT_CLASS Toxicants 79580-28-2 BREVETOXIN PBTX-1 MECHANISM Block neural transmission 633-03-4 BRILLIANT GREEN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_2_Photophobia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_2_Eyelid Erythema 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_3_Conjunctival Discharge 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_1_Foreign Body Sensation 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Pruritis 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Allergic Reactions 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_1_Xerostomia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_3_Taste Disturbances 59803-98-4 BRIMONIDINE ADVERSE_EFFECT NEU_1_Headache 59803-98-4 BRIMONIDINE ADVERSE_EFFECT CVS_3_Hypertension 59803-98-4 BRIMONIDINE TISSUE_TOXICITY Arrhythmia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_3_Ocular Pain 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_3_Nasal Dryness 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_3_Asthenia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT NEU_2_Dizziness 59803-98-4 BRIMONIDINE ADVERSE_EFFECT CVS_3_Palpitation 59803-98-4 BRIMONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 59803-98-4 BRIMONIDINE THERAPEUTIC_CLASS Antiglaucoma Agents 59803-98-4 BRIMONIDINE MODE_CLASS Receptor Agonist, selective 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_2_Tearing 59803-98-4 BRIMONIDINE MECHANISM Modulate G-protein coupled signal transduction 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Irritation 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_1_Burning Sensation 59803-98-4 BRIMONIDINE ADVERSE_EFFECT CVS_3_Arrhythmia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT NEU_1_Drowsiness 59803-98-4 BRIMONIDINE ADVERSE_EFFECT PSY_3_Anxiety 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_1_Blurred Vision 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_3_Conjunctival Hemorrhage 59803-98-4 BRIMONIDINE INDICATION Open-Angle Glaucoma 59803-98-4 BRIMONIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 59803-98-4 BRIMONIDINE INDICATION Ocular Hypertension 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_1_Conjunctival Hyperemia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT PSY_3_Insomnia 59803-98-4 BRIMONIDINE ADVERSE_EFFECT OCU_3_Blepharitis 59803-98-4 BRIMONIDINE ADVERSE_EFFECT PSY_3_Depression 59803-98-4 BRIMONIDINE ADVERSE_EFFECT XXX_1_Fatigue 59803-98-4 BRIMONIDINE ADVERSE_EFFECT NEU_3_Syncope 59803-98-4 BRIMONIDINE KNOWN_TOXICITY Cardiovascular Toxicity 59803-99-5 BRIMONIDINE INDICATION Ocular Hypertension 59803-99-5 BRIMONIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 59803-99-5 BRIMONIDINE INDICATION Open-Angle Glaucoma 59803-99-5 BRIMONIDINE KNOWN_TOXICITY Cardiovascular Toxicity 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_1_Blurred Vision 59803-99-5 BRIMONIDINE ADVERSE_EFFECT PSY_3_Anxiety 59803-99-5 BRIMONIDINE ADVERSE_EFFECT NEU_1_Drowsiness 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Irritation 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 59803-99-5 BRIMONIDINE MECHANISM Modulate G-protein coupled signal transduction 59803-99-5 BRIMONIDINE MODE_CLASS Receptor Agonist, selective 59803-99-5 BRIMONIDINE THERAPEUTIC_CLASS Antiglaucoma Agents 59803-99-5 BRIMONIDINE ADVERSE_EFFECT NEU_3_Syncope 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_2_Photophobia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_2_Eyelid Erythema 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_3_Conjunctival Discharge 59803-99-5 BRIMONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 59803-99-5 BRIMONIDINE ADVERSE_EFFECT PSY_3_Insomnia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT NEU_2_Dizziness 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_3_Asthenia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_1_Xerostomia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Allergic Reactions 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_3_Nasal Dryness 59803-99-5 BRIMONIDINE TISSUE_TOXICITY Arrhythmia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT CVS_3_Hypertension 59803-99-5 BRIMONIDINE ADVERSE_EFFECT NEU_1_Headache 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_3_Taste Disturbances 59803-99-5 BRIMONIDINE ADVERSE_EFFECT CVS_3_Arrhythmia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_2_Tearing 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_3_Conjunctival Hemorrhage 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_1_Conjunctival Hyperemia 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_3_Blepharitis 59803-99-5 BRIMONIDINE ADVERSE_EFFECT PSY_3_Depression 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_1_Fatigue 59803-99-5 BRIMONIDINE ADVERSE_EFFECT CVS_3_Palpitation 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_1_Foreign Body Sensation 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_3_Ocular Pain 59803-99-5 BRIMONIDINE ADVERSE_EFFECT XXX_1_Burning Sensation 59803-99-5 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Pruritis 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_3_Ocular Hemorrhage 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_2_Eyelid Erythema 79570-19-7 BRIMONIDINE ADVERSE_EFFECT CVS_3_Hypertension 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_3_Conjunctival Discharge 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_3_Nasal Dryness 79570-19-7 BRIMONIDINE INDICATION Ocular Hypertension 79570-19-7 BRIMONIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 79570-19-7 BRIMONIDINE INDICATION Open-Angle Glaucoma 79570-19-7 BRIMONIDINE KNOWN_TOXICITY Cardiovascular Toxicity 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_1_Blurred Vision 79570-19-7 BRIMONIDINE ADVERSE_EFFECT PSY_3_Anxiety 79570-19-7 BRIMONIDINE ADVERSE_EFFECT NEU_1_Drowsiness 79570-19-7 BRIMONIDINE ADVERSE_EFFECT CVS_3_Arrhythmia 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_1_Burning Sensation 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Pruritis 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Irritation 79570-19-7 BRIMONIDINE ADVERSE_EFFECT PSY_3_Depression 79570-19-7 BRIMONIDINE MECHANISM Modulate G-protein coupled signal transduction 79570-19-7 BRIMONIDINE MODE_CLASS Receptor Agonist, selective 79570-19-7 BRIMONIDINE THERAPEUTIC_CLASS Antiglaucoma Agents 79570-19-7 BRIMONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 79570-19-7 BRIMONIDINE ADVERSE_EFFECT PSY_3_Insomnia 79570-19-7 BRIMONIDINE ADVERSE_EFFECT NEU_2_Dizziness 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_3_Asthenia 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_1_Xerostomia 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_1_Ocular Allergic Reactions 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_3_Ocular Pain 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_1_Foreign Body Sensation 79570-19-7 BRIMONIDINE ADVERSE_EFFECT NEU_1_Headache 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_3_Taste Disturbances 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_1_Dryness of Mucus Membrane 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_2_Tearing 79570-19-7 BRIMONIDINE TISSUE_TOXICITY Arrhythmia 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_3_Conjunctival Hemorrhage 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_1_Conjunctival Hyperemia 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_3_Blepharitis 79570-19-7 BRIMONIDINE ADVERSE_EFFECT XXX_1_Fatigue 79570-19-7 BRIMONIDINE ADVERSE_EFFECT CVS_3_Palpitation 79570-19-7 BRIMONIDINE ADVERSE_EFFECT NEU_3_Syncope 79570-19-7 BRIMONIDINE ADVERSE_EFFECT OCU_2_Photophobia 138890-62-7 BRINZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 138890-62-7 BRINZOLAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 138890-62-7 BRINZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 138890-62-7 BRINZOLAMIDE INDICATION Glaucoma 138890-62-7 BRINZOLAMIDE MODE_CLASS Enzyme Inhibitor 91714-94-2 BROMFENAC ADVERSE_EFFECT KID_3_Hematuria 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_2_Eructation 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_2_Constipation 91714-94-2 BROMFENAC ACTIVITY_CLASS Anti-inflammatory 91714-94-2 BROMFENAC TISSUE_TOXICITY Nephrotoxicity 91714-94-2 BROMFENAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91714-94-2 BROMFENAC ADVERSE_EFFECT LIV_3_Hepatic Failure 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_2_Flatulence 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_2_Diarrhea 91714-94-2 BROMFENAC ZERO_CLASS N 91714-94-2 BROMFENAC KNOWN_TOXICITY Hepatotoxicity 91714-94-2 BROMFENAC TISSUE_TOXICITY Hematuria 91714-94-2 BROMFENAC TISSUE_TOXICITY Hepatotoxicity 91714-94-2 BROMFENAC INDICATION Pain 91714-94-2 BROMFENAC MODE_CLASS Enzyme Inhibitor 91714-94-2 BROMFENAC TISSUE_TOXICITY Renal Papillary Necrosis 91714-94-2 BROMFENAC INDICATION Dental Pain 91714-94-2 BROMFENAC INDICATION Pain 91714-94-2 BROMFENAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 91714-94-2 BROMFENAC ADVERSE_EFFECT LIV_3_Hepatotoxicity 91714-94-2 BROMFENAC ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 91714-94-2 BROMFENAC TISSUE_TOXICITY Interstitial Nephritis 91714-94-2 BROMFENAC ADVERSE_EFFECT NEU_2_Dizziness 91714-94-2 BROMFENAC TISSUE_TOXICITY Nephrotic Syndrome 91714-94-2 BROMFENAC INDICATION Dental Pain 91714-94-2 BROMFENAC INDICATION Ocular Inflammation 91714-94-2 BROMFENAC PRODUCT_CLASS Anti-inflammatories 91714-94-2 BROMFENAC INDICATION Moderate Pain 91714-94-2 BROMFENAC INDICATION Ocular Inflammation 91714-94-2 BROMFENAC KNOWN_TOXICITY Nephrotoxicity 91714-94-2 BROMFENAC ADVERSE_EFFECT KID_3_Nephrotoxicity 91714-94-2 BROMFENAC ADVERSE_EFFECT KID_3_Interstitial Nephritis 91714-94-2 BROMFENAC ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91714-94-2 BROMFENAC ADVERSE_EFFECT NEU_2_Headache 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_1_Dyspepsia 91714-94-2 BROMFENAC ADVERSE_EFFECT GIS_2_Abdominal Pain 91714-94-2 BROMFENAC TISSUE_TOXICITY Hepatic Failure 91714-94-2 BROMFENAC ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 91714-94-2 BROMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 91714-94-2 BROMFENAC TISSUE_TOXICITY Fulminant Hepatitis 91714-94-2 BROMFENAC MECHANISM Inhibit eicosanoid biosynthesis 91714-94-2 BROMFENAC INDICATION Moderate Pain 91714-94-2 BROMFENAC ADVERSE_EFFECT KID_3_Proteinuria 91714-94-2 BROMFENAC ADVERSE_EFFECT LIV_3_Jaundice 91714-93-1 BROMFENAC INDICATION Moderate Pain 91714-93-1 BROMFENAC ADVERSE_EFFECT KID_3_Proteinuria 91714-93-1 BROMFENAC ADVERSE_EFFECT LIV_3_Jaundice 91714-93-1 BROMFENAC ADVERSE_EFFECT KID_3_Hematuria 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_2_Eructation 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_2_Constipation 91714-93-1 BROMFENAC ACTIVITY_CLASS Anti-inflammatory 91714-93-1 BROMFENAC TISSUE_TOXICITY Nephrotoxicity 91714-93-1 BROMFENAC TISSUE_TOXICITY Interstitial Nephritis 91714-93-1 BROMFENAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_2_Nausea / Vomiting 91714-93-1 BROMFENAC ADVERSE_EFFECT LIV_3_Hepatic Failure 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_2_Flatulence 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_2_Diarrhea 91714-93-1 BROMFENAC ZERO_CLASS N 91714-93-1 BROMFENAC KNOWN_TOXICITY Hepatotoxicity 91714-93-1 BROMFENAC TISSUE_TOXICITY Hematuria 91714-93-1 BROMFENAC INDICATION Pain 91714-93-1 BROMFENAC INDICATION Dental Pain 91714-93-1 BROMFENAC TISSUE_TOXICITY Hepatic Failure 91714-93-1 BROMFENAC ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 91714-93-1 BROMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 91714-93-1 BROMFENAC TISSUE_TOXICITY Renal Papillary Necrosis 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_1_Dyspepsia 91714-93-1 BROMFENAC ADVERSE_EFFECT NEU_2_Headache 91714-93-1 BROMFENAC ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 91714-93-1 BROMFENAC ADVERSE_EFFECT KID_3_Interstitial Nephritis 91714-93-1 BROMFENAC ADVERSE_EFFECT KID_3_Nephrotoxicity 91714-93-1 BROMFENAC MECHANISM Inhibit eicosanoid biosynthesis 91714-93-1 BROMFENAC KNOWN_TOXICITY Nephrotoxicity 91714-93-1 BROMFENAC INDICATION Ocular Inflammation 91714-93-1 BROMFENAC INDICATION Ocular Inflammation 91714-93-1 BROMFENAC INDICATION Moderate Pain 91714-93-1 BROMFENAC PRODUCT_CLASS Anti-inflammatories 91714-93-1 BROMFENAC INDICATION Dental Pain 91714-93-1 BROMFENAC TISSUE_TOXICITY Nephrotic Syndrome 91714-93-1 BROMFENAC ADVERSE_EFFECT NEU_2_Dizziness 91714-93-1 BROMFENAC ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 91714-93-1 BROMFENAC ADVERSE_EFFECT LIV_3_Hepatotoxicity 91714-93-1 BROMFENAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 91714-93-1 BROMFENAC TISSUE_TOXICITY Fulminant Hepatitis 91714-93-1 BROMFENAC MODE_CLASS Enzyme Inhibitor 91714-93-1 BROMFENAC INDICATION Pain 91714-93-1 BROMFENAC TISSUE_TOXICITY Hepatotoxicity 91714-93-1 BROMFENAC ADVERSE_EFFECT GIS_2_Abdominal Pain 120638-55-3 BROMFENAC ADVERSE_EFFECT KID_3_Nephrotic Syndrome 120638-55-3 BROMFENAC INDICATION Dental Pain 120638-55-3 BROMFENAC INDICATION Pain 120638-55-3 BROMFENAC ADVERSE_EFFECT LIV_3_Hepatotoxicity 120638-55-3 BROMFENAC ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 120638-55-3 BROMFENAC ADVERSE_EFFECT NEU_2_Dizziness 120638-55-3 BROMFENAC TISSUE_TOXICITY Nephrotic Syndrome 120638-55-3 BROMFENAC INDICATION Dental Pain 120638-55-3 BROMFENAC INDICATION Ocular Inflammation 120638-55-3 BROMFENAC PRODUCT_CLASS Anti-inflammatories 120638-55-3 BROMFENAC INDICATION Moderate Pain 120638-55-3 BROMFENAC INDICATION Ocular Inflammation 120638-55-3 BROMFENAC KNOWN_TOXICITY Nephrotoxicity 120638-55-3 BROMFENAC ADVERSE_EFFECT KID_3_Nephrotoxicity 120638-55-3 BROMFENAC ADVERSE_EFFECT KID_3_Interstitial Nephritis 120638-55-3 BROMFENAC ADVERSE_EFFECT LIV_2_Increased Liver Enzymes 120638-55-3 BROMFENAC ADVERSE_EFFECT NEU_2_Headache 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_1_Dyspepsia 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_2_Abdominal Pain 120638-55-3 BROMFENAC TISSUE_TOXICITY Hepatic Failure 120638-55-3 BROMFENAC ADVERSE_EFFECT KID_3_Renal Papillary Necrosis 120638-55-3 BROMFENAC THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 120638-55-3 BROMFENAC TISSUE_TOXICITY Renal Papillary Necrosis 120638-55-3 BROMFENAC TISSUE_TOXICITY Fulminant Hepatitis 120638-55-3 BROMFENAC MECHANISM Inhibit eicosanoid biosynthesis 120638-55-3 BROMFENAC INDICATION Moderate Pain 120638-55-3 BROMFENAC ADVERSE_EFFECT KID_3_Proteinuria 120638-55-3 BROMFENAC ADVERSE_EFFECT LIV_3_Jaundice 120638-55-3 BROMFENAC ADVERSE_EFFECT KID_3_Hematuria 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_2_Eructation 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_2_Constipation 120638-55-3 BROMFENAC ACTIVITY_CLASS Anti-inflammatory 120638-55-3 BROMFENAC TISSUE_TOXICITY Nephrotoxicity 120638-55-3 BROMFENAC TISSUE_TOXICITY Interstitial Nephritis 120638-55-3 BROMFENAC STRUCTURE_ACTIVITY NSAID, COX-1, heterogeneous 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_2_Nausea / Vomiting 120638-55-3 BROMFENAC ADVERSE_EFFECT LIV_3_Hepatic Failure 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_2_Flatulence 120638-55-3 BROMFENAC ADVERSE_EFFECT GIS_2_Diarrhea 120638-55-3 BROMFENAC ZERO_CLASS N 120638-55-3 BROMFENAC KNOWN_TOXICITY Hepatotoxicity 120638-55-3 BROMFENAC TISSUE_TOXICITY Hematuria 120638-55-3 BROMFENAC TISSUE_TOXICITY Hepatotoxicity 120638-55-3 BROMFENAC INDICATION Pain 120638-55-3 BROMFENAC MODE_CLASS Enzyme Inhibitor 22260-51-1 BROMOCRIPTINE THERAPEUTIC_CLASS Movement Disorders 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT LUN_3_Thickening of Pleura 22260-51-1 BROMOCRIPTINE KNOWN_TOXICITY Cardiovascular Toxicity 22260-51-1 BROMOCRIPTINE THERAPEUTIC_CLASS Drug Dependence Therapy 22260-51-1 BROMOCRIPTINE TISSUE_TOXICITY Ventricular Tachycardia 22260-51-1 BROMOCRIPTINE TISSUE_TOXICITY Hypotension 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Hypotension 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_3_Shock 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Abdominal Pain 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_2_Retroperitoneal Fibroplasia 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT OCU_3_Ocular Irritation 22260-51-1 BROMOCRIPTINE MODE_CLASS Receptor Agonist 22260-51-1 BROMOCRIPTINE INDICATION Neuroleptic Malignant Syndrome (NMS) 22260-51-1 BROMOCRIPTINE PRODUCT_CLASS Other Human Uses 22260-51-1 BROMOCRIPTINE INDICATION Pituitary Adenoma 22260-51-1 BROMOCRIPTINE PRODUCT_CLASS Central Nervous System (CNS) 22260-51-1 BROMOCRIPTINE MECHANISM Block neural transmission 22260-51-1 BROMOCRIPTINE INDICATION Acromegaly 22260-51-1 BROMOCRIPTINE MECHANISM Prolong/enhance neural transmission 22260-51-1 BROMOCRIPTINE TISSUE_TOXICITY Shock 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT PSY_3_Hallucinations 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_3_Stroke 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT PSY_1_Anorexia 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 22260-51-1 BROMOCRIPTINE STRUCTURE_ACTIVITY Ergot alkaloid 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT LUN_2_Pulmonary Infiltrates 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Epigastric Pain 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_3_Metallic Taste 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT LUN_3_Pleural Effusion 22260-51-1 BROMOCRIPTINE INDICATION Cocaine Withdrawal 22260-51-1 BROMOCRIPTINE TISSUE_TOXICITY Myocardial Infarction 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Constipation 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT IMU_3_Urticaria 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_3_Peptic Ulceration 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT NEU_3_Syncope 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT XXX_3_Xerostomia 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT XXX_3_CSF Rhinorrhea 22260-51-1 BROMOCRIPTINE INDICATION Alcohol Dependency and Abuse / Alcoholism 22260-51-1 BROMOCRIPTINE INDICATION Parkinson's Disease 22260-51-1 BROMOCRIPTINE TISSUE_TOXICITY Stroke 22260-51-1 BROMOCRIPTINE THERAPEUTIC_CLASS Pituitary Hormones 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT NEU_3_Seizures 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT SKN_3_Rash 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Dyspepsia 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Indigestion 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT PSN_3_Ergotism 22260-51-1 BROMOCRIPTINE MODE_CLASS Receptor Partial Agonist 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Diarrhea 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Hypertension 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 22260-51-1 BROMOCRIPTINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 22260-51-1 BROMOCRIPTINE INDICATION Hyperprolactinemia 22260-51-1 BROMOCRIPTINE INDICATION Premenstrual Syndrome / Premenstrual Tension 22260-51-1 BROMOCRIPTINE INDICATION Infertility 22260-51-1 BROMOCRIPTINE ADVERSE_EFFECT PSY_2_Confusion 25614-03-3 BROMOCRIPTINE KNOWN_TOXICITY Cardiovascular Toxicity 25614-03-3 BROMOCRIPTINE THERAPEUTIC_CLASS Drug Dependence Therapy 25614-03-3 BROMOCRIPTINE TISSUE_TOXICITY Ventricular Tachycardia 25614-03-3 BROMOCRIPTINE TISSUE_TOXICITY Hypotension 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Hypotension 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_3_Shock 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Abdominal Pain 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_2_Retroperitoneal Fibroplasia 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT OCU_3_Ocular Irritation 25614-03-3 BROMOCRIPTINE MODE_CLASS Receptor Agonist 25614-03-3 BROMOCRIPTINE INDICATION Neuroleptic Malignant Syndrome (NMS) 25614-03-3 BROMOCRIPTINE PRODUCT_CLASS Other Human Uses 25614-03-3 BROMOCRIPTINE INDICATION Pituitary Adenoma 25614-03-3 BROMOCRIPTINE PRODUCT_CLASS Central Nervous System (CNS) 25614-03-3 BROMOCRIPTINE MECHANISM Block neural transmission 25614-03-3 BROMOCRIPTINE INDICATION Acromegaly 25614-03-3 BROMOCRIPTINE MECHANISM Prolong/enhance neural transmission 25614-03-3 BROMOCRIPTINE TISSUE_TOXICITY Shock 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT PSY_3_Hallucinations 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT PSY_1_Anorexia 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 25614-03-3 BROMOCRIPTINE STRUCTURE_ACTIVITY Ergot alkaloid 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT LUN_2_Pulmonary Infiltrates 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Epigastric Pain 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_3_Metallic Taste 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT LUN_3_Pleural Effusion 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT LUN_3_Thickening of Pleura 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 25614-03-3 BROMOCRIPTINE INDICATION Cocaine Withdrawal 25614-03-3 BROMOCRIPTINE TISSUE_TOXICITY Myocardial Infarction 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Constipation 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT SKN_3_Rash 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT PSY_2_Confusion 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT IMU_3_Urticaria 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_3_Peptic Ulceration 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT NEU_3_Syncope 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT XXX_3_Xerostomia 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT XXX_3_CSF Rhinorrhea 25614-03-3 BROMOCRIPTINE INDICATION Alcohol Dependency and Abuse / Alcoholism 25614-03-3 BROMOCRIPTINE INDICATION Parkinson's Disease 25614-03-3 BROMOCRIPTINE TISSUE_TOXICITY Stroke 25614-03-3 BROMOCRIPTINE THERAPEUTIC_CLASS Pituitary Hormones 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT NEU_3_Seizures 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_3_Stroke 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Dyspepsia 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Indigestion 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT PSN_3_Ergotism 25614-03-3 BROMOCRIPTINE MODE_CLASS Receptor Partial Agonist 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT GIS_1_Diarrhea 25614-03-3 BROMOCRIPTINE ADVERSE_EFFECT CVS_2_Hypertension 25614-03-3 BROMOCRIPTINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 25614-03-3 BROMOCRIPTINE INDICATION Hyperprolactinemia 25614-03-3 BROMOCRIPTINE INDICATION Premenstrual Syndrome / Premenstrual Tension 25614-03-3 BROMOCRIPTINE INDICATION Infertility 25614-03-3 BROMOCRIPTINE THERAPEUTIC_CLASS Movement Disorders 118-23-0 BROMODIPHENHYDRAMINE THERAPEUTIC_CLASS Antihistamines 118-23-0 BROMODIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 118-23-0 BROMODIPHENHYDRAMINE PRODUCT_CLASS Anti-inflammatories 118-23-0 BROMODIPHENHYDRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 118-23-0 BROMODIPHENHYDRAMINE MECHANISM Modulate G-protein coupled signal transduction 118-23-0 BROMODIPHENHYDRAMINE INDICATION Cough / Tussis 118-23-0 BROMODIPHENHYDRAMINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 118-23-0 BROMODIPHENHYDRAMINE PRODUCT_CLASS Respiratory System 118-23-0 BROMODIPHENHYDRAMINE INDICATION Nasal Congestion 1808-12-4 BROMODIPHENHYDRAMINE INDICATION Cough / Tussis 1808-12-4 BROMODIPHENHYDRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 1808-12-4 BROMODIPHENHYDRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 1808-12-4 BROMODIPHENHYDRAMINE INDICATION Nasal Congestion 1808-12-4 BROMODIPHENHYDRAMINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 1808-12-4 BROMODIPHENHYDRAMINE PRODUCT_CLASS Respiratory System 1808-12-4 BROMODIPHENHYDRAMINE MECHANISM Modulate G-protein coupled signal transduction 1808-12-4 BROMODIPHENHYDRAMINE THERAPEUTIC_CLASS Antihistamines 1808-12-4 BROMODIPHENHYDRAMINE PRODUCT_CLASS Anti-inflammatories 980-71-2 BROMPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Tremor 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_2_Sedation 980-71-2 BROMPHENIRAMINE INDICATION Rhinorrhea 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Diarrhea 980-71-2 BROMPHENIRAMINE INDICATION Angioedema 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT XXX_2_Lethargy 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Vertigo 980-71-2 BROMPHENIRAMINE INDICATION Allergic Conjunctivitis 980-71-2 BROMPHENIRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 980-71-2 BROMPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 980-71-2 BROMPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 980-71-2 BROMPHENIRAMINE INDICATION Urticaria / Hives 980-71-2 BROMPHENIRAMINE INDICATION Viral Rhinitis / Common Cold 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Delirium 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT PSY_2_Anorexia 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Irritability 980-71-2 BROMPHENIRAMINE INDICATION Dermatographism 980-71-2 BROMPHENIRAMINE INDICATION Pruritus / Itching 980-71-2 BROMPHENIRAMINE INDICATION Allergic Rhinitis 980-71-2 BROMPHENIRAMINE TISSUE_TOXICITY Hypotension 980-71-2 BROMPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT OCU_3_Diplopia 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Euphoria 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT REP_3_Impotence 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Insomnia 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Seizures 980-71-2 BROMPHENIRAMINE INDICATION Anaphylaxis 980-71-2 BROMPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 980-71-2 BROMPHENIRAMINE INDICATION Vasomotor Rhinitis 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypotension 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Constipation 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Dizziness 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Xerophthalmia 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 980-71-2 BROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypertension 86-22-6 BROMPHENIRAMINE INDICATION Vasomotor Rhinitis 86-22-6 BROMPHENIRAMINE INDICATION Anaphylaxis 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Seizures 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypertension 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Dizziness 86-22-6 BROMPHENIRAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 86-22-6 BROMPHENIRAMINE INDICATION Rhinorrhea 86-22-6 BROMPHENIRAMINE INDICATION Angioedema 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_1_Drowsiness 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT XXX_2_Lethargy 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Vertigo 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Constipation 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT CVS_3_Hypotension 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Insomnia 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT REP_3_Impotence 86-22-6 BROMPHENIRAMINE MODE_CLASS Receptor Ligand Antagonist, Selective 86-22-6 BROMPHENIRAMINE PRODUCT_CLASS Anti-inflammatories 86-22-6 BROMPHENIRAMINE INDICATION Urticaria / Hives 86-22-6 BROMPHENIRAMINE INDICATION Viral Rhinitis / Common Cold 86-22-6 BROMPHENIRAMINE INDICATION Allergic Conjunctivitis 86-22-6 BROMPHENIRAMINE KNOWN_TOXICITY Cardiovascular Toxicity 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Delirium 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT PSY_2_Anorexia 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT OTO_3_Tinnitus 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT BBM_3_Blood Dyscrasias 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Irritability 86-22-6 BROMPHENIRAMINE INDICATION Dermatographism 86-22-6 BROMPHENIRAMINE INDICATION Pruritus / Itching 86-22-6 BROMPHENIRAMINE INDICATION Allergic Rhinitis 86-22-6 BROMPHENIRAMINE TISSUE_TOXICITY Hypotension 86-22-6 BROMPHENIRAMINE THERAPEUTIC_CLASS Antihistamines 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT OCU_3_Diplopia 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT PSY_3_Euphoria 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT OCU_2_Xerophthalmia 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT GIS_3_Diarrhea 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_2_Sedation 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 86-22-6 BROMPHENIRAMINE ADVERSE_EFFECT NEU_3_Tremor 86-22-6 BROMPHENIRAMINE MECHANISM Modulate G-protein coupled signal transduction 51333-22-3 BUDESONIDE ADVERSE_EFFECT EMB_2_Embryotoxicity 51333-22-3 BUDESONIDE ADVERSE_EFFECT DNA_2_Carcinogenicity 51333-22-3 BUDESONIDE INDICATION Asthma 51333-22-3 BUDESONIDE ADVERSE_EFFECT LUN_1_Cough 51333-22-3 BUDESONIDE ADVERSE_EFFECT EMB_2_Teratogenicity 51333-22-3 BUDESONIDE ADVERSE_EFFECT CVS_3_Chest Pain 51333-22-3 BUDESONIDE ADVERSE_EFFECT SKN_3_Eczema 51333-22-3 BUDESONIDE ADVERSE_EFFECT OCU_3_Conjunctivitis 51333-22-3 BUDESONIDE ADVERSE_EFFECT XXX_3_Nasal Irritation 51333-22-3 BUDESONIDE ADVERSE_EFFECT SKN_2_Rash 51333-22-3 BUDESONIDE INDICATION Allergic Rhinitis 51333-22-3 BUDESONIDE KNOWN_TOXICITY Carcinogenicity 51333-22-3 BUDESONIDE TISSUE_TOXICITY Teratogenicity 51333-22-3 BUDESONIDE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 51333-22-3 BUDESONIDE ADVERSE_EFFECT XXX_3_Pharyngitis 51333-22-3 BUDESONIDE ADVERSE_EFFECT GUS_2_Genital Moniliasis 51333-22-3 BUDESONIDE INDICATION Rhinitis 51333-22-3 BUDESONIDE ADVERSE_EFFECT LUN_3_Bronchospasm 51333-22-3 BUDESONIDE ADVERSE_EFFECT GIS_3_Diarrhea 51333-22-3 BUDESONIDE MODE_CLASS Receptor Agonist 51333-22-3 BUDESONIDE THERAPEUTIC_CLASS Corticosteroids 51333-22-3 BUDESONIDE ADVERSE_EFFECT OTO_1_Otitis Media 51333-22-3 BUDESONIDE ADVERSE_EFFECT XXX_1_Rhinitis 51333-22-3 BUDESONIDE ADVERSE_EFFECT LUN_3_Dysphonia 51333-22-3 BUDESONIDE ADVERSE_EFFECT GIS_3_Abdominal Pain 51333-22-3 BUDESONIDE ADVERSE_EFFECT GIS_3_Vomiting 51333-22-3 BUDESONIDE MECHANISM Modulate gene transcription 51333-22-3 BUDESONIDE TISSUE_TOXICITY Carcinogenicity 51333-22-3 BUDESONIDE PRODUCT_CLASS Anti-inflammatories 51333-22-3 BUDESONIDE ADVERSE_EFFECT LUN_1_Respiratory Infection 51333-22-3 BUDESONIDE ADVERSE_EFFECT GIS_2_Gastroenteritis 51333-22-3 BUDESONIDE ADVERSE_EFFECT XXX_2_Epistaxis 51333-22-3 BUDESONIDE KNOWN_TOXICITY Embryo/Fetal Toxicity 57982-78-2 BUDIPINE MODE_CLASS Receptor Ligand Antagonist 57982-78-2 BUDIPINE MODE_CLASS Channel Blocker 57982-78-2 BUDIPINE INDICATION Parkinson's Disease 57982-78-2 BUDIPINE MECHANISM Modulate neural transmission 57982-78-2 BUDIPINE MECHANISM Block neural transmission 57982-78-2 BUDIPINE MODE_CLASS Enzyme Inhibitor 57982-78-2 BUDIPINE MODE_CLASS Solute transporter inhibitor 57982-78-2 BUDIPINE MECHANISM interferes with liver P450 enzyme funciton 57982-78-2 BUDIPINE MECHANISM Prolong/enhance neural transmission 28395-03-1 BUMETANIDE STRUCTURE_ACTIVITY Na+-K+-2Cl- cotransporter inhibitor, loop diuretic 28395-03-1 BUMETANIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 28395-03-1 BUMETANIDE INDICATION Edematous States 28395-03-1 BUMETANIDE THERAPEUTIC_CLASS Diuretics 28395-03-1 BUMETANIDE MODE_CLASS Channel Blocker, selective 28395-03-1 BUMETANIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Epidural Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Peripheral Nerve Block 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Spinal Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Retrobulbar Nerve Block 14252-80-3 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Angina 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Angina 14252-80-3 BUPIVACAINE HYDROCHLORIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT PSY_2_Anxiety 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Arrest 14252-80-3 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Cardiac Arrest 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Caudal Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Sympathetic Nerve Block 14252-80-3 BUPIVACAINE HYDROCHLORIDE MECHANISM Block neural transmission 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT EMB_2_Fetal Distress 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT PSY_3_CNS Toxicity 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_1_Headache 14252-80-3 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Atrioventricular Blockade 14252-80-3 BUPIVACAINE HYDROCHLORIDE MODE_CLASS Channel Blocker 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 14252-80-3 BUPIVACAINE HYDROCHLORIDE THERAPEUTIC_CLASS Local Anesthetics 14252-80-3 BUPIVACAINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Obstetric Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Infiltration Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Dental Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE INDICATION Local Anesthesia 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Cardiac Arrest 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_2_Tremor 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT SKN_2_Skin Rash 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Depression 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_1_Hypotension 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 14252-80-3 BUPIVACAINE HYDROCHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_3_Seizures 14252-80-3 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 14252-80-3 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Hypotension 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Angina 2180-92-9 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Angina 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Retrobulbar Nerve Block 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Spinal Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE MECHANISM Block neural transmission 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Caudal Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_3_Seizures 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 2180-92-9 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Hypotension 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Epidural Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Peripheral Nerve Block 2180-92-9 BUPIVACAINE HYDROCHLORIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT PSY_2_Anxiety 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Arrest 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 2180-92-9 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Cardiac Arrest 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Sympathetic Nerve Block 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT EMB_2_Fetal Distress 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_1_Hypotension 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT PSY_3_CNS Toxicity 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_1_Headache 2180-92-9 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Atrioventricular Blockade 2180-92-9 BUPIVACAINE HYDROCHLORIDE MODE_CLASS Channel Blocker 2180-92-9 BUPIVACAINE HYDROCHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 2180-92-9 BUPIVACAINE HYDROCHLORIDE THERAPEUTIC_CLASS Local Anesthetics 2180-92-9 BUPIVACAINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Obstetric Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Infiltration Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Dental Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE INDICATION Local Anesthesia 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_2_Tremor 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Depression 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT SKN_2_Skin Rash 2180-92-9 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Cardiac Arrest 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Local Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Dental Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Infiltration Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Obstetric Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE THERAPEUTIC_CLASS Local Anesthetics 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT PSY_2_Anxiety 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Arrest 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 18010-40-7 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Cardiac Arrest 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Caudal Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Sympathetic Nerve Block 18010-40-7 BUPIVACAINE HYDROCHLORIDE MECHANISM Block neural transmission 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_2_Sinus Bradycardia 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT EMB_2_Fetal Distress 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT PSY_3_CNS Toxicity 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_1_Headache 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Prolonged QT Interval 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 18010-40-7 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Atrioventricular Blockade 18010-40-7 BUPIVACAINE HYDROCHLORIDE PRODUCT_CLASS Central Nervous System (CNS) 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Epidural Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Hypotension 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT SKN_2_Skin Rash 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Spinal Anesthesia 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Retrobulbar Nerve Block 18010-40-7 BUPIVACAINE HYDROCHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 18010-40-7 BUPIVACAINE HYDROCHLORIDE TISSUE_TOXICITY Angina 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Angina 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Cardiac Arrest 18010-40-7 BUPIVACAINE HYDROCHLORIDE MODE_CLASS Channel Blocker 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_3_Prolonged PR Interval 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT LUN_3_Respiratory Depression 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_2_Tremor 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT CVS_1_Hypotension 18010-40-7 BUPIVACAINE HYDROCHLORIDE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, alpha-amino-acid arylamide 18010-40-7 BUPIVACAINE HYDROCHLORIDE INDICATION Peripheral Nerve Block 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 18010-40-7 BUPIVACAINE HYDROCHLORIDE ADVERSE_EFFECT NEU_3_Seizures 53152-21-9 BUPRENORPHINE MODE_CLASS Receptor Partial Agonist 53152-21-9 BUPRENORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 53152-21-9 BUPRENORPHINE INDICATION Moderate Pain 53152-21-9 BUPRENORPHINE MECHANISM Modulate neural transmission 53152-21-9 BUPRENORPHINE INDICATION Severe Pain 53152-21-9 BUPRENORPHINE STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 53152-21-9 BUPRENORPHINE PRODUCT_CLASS Analgesics 52485-79-7 BUPRENORPHINE INDICATION Moderate Pain 52485-79-7 BUPRENORPHINE MECHANISM Modulate neural transmission 52485-79-7 BUPRENORPHINE INDICATION Severe Pain 52485-79-7 BUPRENORPHINE STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 52485-79-7 BUPRENORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 52485-79-7 BUPRENORPHINE PRODUCT_CLASS Analgesics 52485-79-7 BUPRENORPHINE MODE_CLASS Receptor Partial Agonist 64425-21-4 BUPRENORPHINE STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 64425-21-4 BUPRENORPHINE PRODUCT_CLASS Analgesics 64425-21-4 BUPRENORPHINE THERAPEUTIC_CLASS Analgesics, Opioid 64425-21-4 BUPRENORPHINE INDICATION Moderate Pain 64425-21-4 BUPRENORPHINE MODE_CLASS Receptor Partial Agonist 64425-21-4 BUPRENORPHINE MECHANISM Modulate neural transmission 64425-21-4 BUPRENORPHINE INDICATION Severe Pain 31677-93-7 BUPROPION MECHANISM Modulate neural transmission 31677-93-7 BUPROPION INDICATION Diabetic Neuropathy 31677-93-7 BUPROPION MODE_CLASS Channel Blocker 31677-93-7 BUPROPION ZERO_CLASS N 31677-93-7 BUPROPION ADVERSE_EFFECT XXX_1_Sweating 31677-93-7 BUPROPION ADVERSE_EFFECT CVS_2_Hypertension 31677-93-7 BUPROPION ADVERSE_EFFECT CVS_2_Sinus Tachycardia 31677-93-7 BUPROPION ADVERSE_EFFECT NEU_1_Dizziness 31677-93-7 BUPROPION ADVERSE_EFFECT NEU_3_Seizures 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_1_Agitation 31677-93-7 BUPROPION ADVERSE_EFFECT SKN_3_Erythema Multiforme 31677-93-7 BUPROPION ADVERSE_EFFECT REP_2_Decreased Libido 31677-93-7 BUPROPION PRODUCT_CLASS Central Nervous System (CNS) 31677-93-7 BUPROPION KNOWN_TOXICITY Cardiovascular Toxicity 31677-93-7 BUPROPION INDICATION Depression 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_2_Hallucinations 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_1_Anxiety 31677-93-7 BUPROPION ADVERSE_EFFECT NEU_1_Headache 31677-93-7 BUPROPION ADVERSE_EFFECT SKN_2_Pruritis 31677-93-7 BUPROPION ADVERSE_EFFECT MSK_3_Muscle Weakness 31677-93-7 BUPROPION ADVERSE_EFFECT SKN_3_Maculopapular Rash 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_2_Psychosis 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_2_Paranoia 31677-93-7 BUPROPION ADVERSE_EFFECT BBM_2_Ecchymosis 31677-93-7 BUPROPION ADVERSE_EFFECT CVS_3_Arrhythmia 31677-93-7 BUPROPION STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT/NET) inhibitor, adrenoceptor-alpha antagonist 31677-93-7 BUPROPION ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 31677-93-7 BUPROPION ADVERSE_EFFECT GIS_3_Oral Ulceration 31677-93-7 BUPROPION INDICATION Nicotine Withdrawal 31677-93-7 BUPROPION TISSUE_TOXICITY Arrhythmia 31677-93-7 BUPROPION THERAPEUTIC_CLASS Antidepressants 31677-93-7 BUPROPION ADVERSE_EFFECT OCU_2_Blurred Vision 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_1_Insomnia 31677-93-7 BUPROPION ADVERSE_EFFECT GIS_2_Nausea / Vomiting 31677-93-7 BUPROPION ADVERSE_EFFECT IMU_3_Serum Sickness 31677-93-7 BUPROPION ADVERSE_EFFECT GIS_2_Flatulence 31677-93-7 BUPROPION ADVERSE_EFFECT REP_2_Menstrual Irregularities 31677-93-7 BUPROPION ADVERSE_EFFECT IMU_3_Anaphylaxis 31677-93-7 BUPROPION ADVERSE_EFFECT XXX_1_Restlessness 31677-93-7 BUPROPION ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 31677-93-7 BUPROPION ADVERSE_EFFECT LUN_3_Dyspnea 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_1_Irritability 31677-93-7 BUPROPION ADVERSE_EFFECT GIS_2_Dyspepsia 31677-93-7 BUPROPION ADVERSE_EFFECT XXX_2_Taste Disturbances 31677-93-7 BUPROPION ADVERSE_EFFECT XXX_3_Xerosis 31677-93-7 BUPROPION ADVERSE_EFFECT GIS_1_Constipation 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_3_Anorexia 31677-93-7 BUPROPION ADVERSE_EFFECT NEU_1_Tremor 31677-93-7 BUPROPION ADVERSE_EFFECT SKN_2_Rash 31677-93-7 BUPROPION ADVERSE_EFFECT PSY_2_Confusion 31677-93-7 BUPROPION ADVERSE_EFFECT IMU_3_Angioedema 31677-93-7 BUPROPION ADVERSE_EFFECT IMU_3_Urticaria 31677-93-7 BUPROPION ADVERSE_EFFECT XXX_1_Weight Loss 31677-93-7 BUPROPION ADVERSE_EFFECT CVS_2_Palpitation 31677-93-7 BUPROPION INDICATION Neuropathic Pain 31677-93-7 BUPROPION ADVERSE_EFFECT XXX_1_Xerostomia 31677-93-7 BUPROPION MODE_CLASS Solute transporter inhibitor 31677-93-7 BUPROPION MECHANISM Modulate G-protein coupled signal transduction 34911-55-2 BUPROPION STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT/NET) inhibitor, adrenoceptor-alpha antagonist 34911-55-2 BUPROPION ADVERSE_EFFECT CVS_3_Arrhythmia 34911-55-2 BUPROPION ADVERSE_EFFECT BBM_2_Ecchymosis 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_2_Paranoia 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_2_Psychosis 34911-55-2 BUPROPION ADVERSE_EFFECT MSK_3_Muscle Weakness 34911-55-2 BUPROPION ADVERSE_EFFECT SKN_2_Pruritis 34911-55-2 BUPROPION ADVERSE_EFFECT NEU_1_Headache 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_1_Anxiety 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_2_Hallucinations 34911-55-2 BUPROPION INDICATION Depression 34911-55-2 BUPROPION KNOWN_TOXICITY Cardiovascular Toxicity 34911-55-2 BUPROPION PRODUCT_CLASS Central Nervous System (CNS) 34911-55-2 BUPROPION INDICATION Neuropathic Pain 34911-55-2 BUPROPION MECHANISM Modulate neural transmission 34911-55-2 BUPROPION ADVERSE_EFFECT SKN_3_Maculopapular Rash 34911-55-2 BUPROPION ADVERSE_EFFECT IMU_3_Serum Sickness 34911-55-2 BUPROPION ADVERSE_EFFECT GIS_2_Flatulence 34911-55-2 BUPROPION ADVERSE_EFFECT REP_2_Menstrual Irregularities 34911-55-2 BUPROPION ADVERSE_EFFECT REP_2_Decreased Libido 34911-55-2 BUPROPION ADVERSE_EFFECT SKN_3_Erythema Multiforme 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_1_Agitation 34911-55-2 BUPROPION ADVERSE_EFFECT NEU_3_Seizures 34911-55-2 BUPROPION ADVERSE_EFFECT NEU_1_Dizziness 34911-55-2 BUPROPION ADVERSE_EFFECT CVS_2_Sinus Tachycardia 34911-55-2 BUPROPION ADVERSE_EFFECT CVS_2_Hypertension 34911-55-2 BUPROPION ADVERSE_EFFECT XXX_1_Sweating 34911-55-2 BUPROPION ZERO_CLASS N 34911-55-2 BUPROPION MODE_CLASS Channel Blocker 34911-55-2 BUPROPION INDICATION Diabetic Neuropathy 34911-55-2 BUPROPION MECHANISM Modulate G-protein coupled signal transduction 34911-55-2 BUPROPION MODE_CLASS Solute transporter inhibitor 34911-55-2 BUPROPION ADVERSE_EFFECT XXX_1_Xerostomia 34911-55-2 BUPROPION ADVERSE_EFFECT GIS_3_Oral Ulceration 34911-55-2 BUPROPION ADVERSE_EFFECT CVS_2_Palpitation 34911-55-2 BUPROPION ADVERSE_EFFECT XXX_1_Weight Loss 34911-55-2 BUPROPION ADVERSE_EFFECT IMU_3_Urticaria 34911-55-2 BUPROPION ADVERSE_EFFECT IMU_3_Angioedema 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_2_Confusion 34911-55-2 BUPROPION ADVERSE_EFFECT SKN_2_Rash 34911-55-2 BUPROPION ADVERSE_EFFECT NEU_1_Tremor 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_3_Anorexia 34911-55-2 BUPROPION ADVERSE_EFFECT GIS_1_Constipation 34911-55-2 BUPROPION ADVERSE_EFFECT XXX_3_Xerosis 34911-55-2 BUPROPION ADVERSE_EFFECT XXX_2_Taste Disturbances 34911-55-2 BUPROPION ADVERSE_EFFECT GIS_2_Dyspepsia 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_1_Irritability 34911-55-2 BUPROPION ADVERSE_EFFECT LUN_3_Dyspnea 34911-55-2 BUPROPION ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 34911-55-2 BUPROPION ADVERSE_EFFECT XXX_1_Restlessness 34911-55-2 BUPROPION ADVERSE_EFFECT IMU_3_Anaphylaxis 34911-55-2 BUPROPION ADVERSE_EFFECT GIS_2_Nausea / Vomiting 34911-55-2 BUPROPION ADVERSE_EFFECT PSY_1_Insomnia 34911-55-2 BUPROPION ADVERSE_EFFECT OCU_2_Blurred Vision 34911-55-2 BUPROPION THERAPEUTIC_CLASS Antidepressants 34911-55-2 BUPROPION TISSUE_TOXICITY Arrhythmia 34911-55-2 BUPROPION INDICATION Nicotine Withdrawal 34911-55-2 BUPROPION ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 55-98-1 BUSULFAN ADVERSE_EFFECT SKN_2_Hyperpigmentation 55-98-1 BUSULFAN MECH_LEVEL_3 DNA damage 55-98-1 BUSULFAN TA_LEVEL_3 Soft tumors 55-98-1 BUSULFAN PRODUCT_CLASS Anti-cancers 55-98-1 BUSULFAN ADVERSE_EFFECT LUN_3_Interstitial Pulmonary Fibrosis 55-98-1 BUSULFAN ADVERSE_EFFECT BBM_1_Thrombocytopenia 55-98-1 BUSULFAN TA_LEVEL_1 Oncology 55-98-1 BUSULFAN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 55-98-1 BUSULFAN ZERO_CLASS N 55-98-1 BUSULFAN STRUCTURE_ACTIVITY DNA-alkylator, methanesulfonate 55-98-1 BUSULFAN ADVERSE_EFFECT IMU_3_Myasthenia Gravis 55-98-1 BUSULFAN ADVERSE_EFFECT OCU_3_Cataracts 55-98-1 BUSULFAN ADVERSE_EFFECT GIS_2_Vomiting 55-98-1 BUSULFAN TISSUE_TOXICITY Leukopenia 55-98-1 BUSULFAN ADVERSE_EFFECT END_3_Gynecomastia 55-98-1 BUSULFAN ADVERSE_EFFECT PSY_2_Anorexia 55-98-1 BUSULFAN TISSUE_TOXICITY Endocardial Fibrosis 55-98-1 BUSULFAN MECHANISM Inhibit DNA synthesis, repair, and function 55-98-1 BUSULFAN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 55-98-1 BUSULFAN INDICATION Multiple Myeloma / Myelomatosis 55-98-1 BUSULFAN THERAPEUTIC_CLASS Antineoplastics 55-98-1 BUSULFAN INDICATION Chronic Myelogenous (Myeloid) Leukemia (CML) 55-98-1 BUSULFAN MODE_CLASS Distorts /blocks macromolecular scaffold function 55-98-1 BUSULFAN MESH_LEVEL_2 Alcohols 55-98-1 BUSULFAN ADVERSE_EFFECT SKN_3_Erythema Multiforme 55-98-1 BUSULFAN ADVERSE_EFFECT BBM_1_Myelosuppression 55-98-1 BUSULFAN TISSUE_TOXICITY Cardiac Tamponade 55-98-1 BUSULFAN TISSUE_TOXICITY Anemia 55-98-1 BUSULFAN ADVERSE_EFFECT BBM_1_Leukopenia 55-98-1 BUSULFAN ADVERSE_EFFECT IMU_3_Urticaria 55-98-1 BUSULFAN TISSUE_TOXICITY Myelosuppression 55-98-1 BUSULFAN ACTIVITY_CLASS DNA damager 55-98-1 BUSULFAN MESH_LEVEL_3 Glycols 55-98-1 BUSULFAN ADVERSE_EFFECT CVS_2_Cardiac Tamponade 55-98-1 BUSULFAN ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 55-98-1 BUSULFAN ADVERSE_EFFECT XXX_2_Weight Loss 55-98-1 BUSULFAN ADVERSE_EFFECT BBM_1_Anemia 55-98-1 BUSULFAN ADVERSE_EFFECT GIS_2_Nausea 55-98-1 BUSULFAN MESH_LEVEL_1 Organic Chemicals 55-98-1 BUSULFAN KNOWN_TOXICITY Cardiovascular Toxicity 55-98-1 BUSULFAN INDICATION Neoplasm / Cancer / Tumor 55-98-1 BUSULFAN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 55-98-1 BUSULFAN TISSUE_TOXICITY Thrombocytopenia 55-98-1 BUSULFAN TA_LEVEL_2 DNA damage 55-98-1 BUSULFAN ADVERSE_EFFECT XXX_2_Fatigue 55-98-1 BUSULFAN ADVERSE_EFFECT CVS_3_Endocardial Fibrosis 125-40-6 BUTABARBITAL PRODUCT_CLASS Central Nervous System (CNS) 125-40-6 BUTABARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 125-40-6 BUTABARBITAL MODE_CLASS Channel Modulator 125-40-6 BUTABARBITAL MECHANISM Modulate neural transmission 125-40-6 BUTABARBITAL INDICATION Insomnia 125-40-6 BUTABARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 77-26-9 BUTALBITAL INDICATION Tension Headache 77-26-9 BUTALBITAL ADVERSE_EFFECT IMU_3_Allergic Reactions 77-26-9 BUTALBITAL ADVERSE_EFFECT LUN_3_Respiratory Depression 77-26-9 BUTALBITAL MECHANISM Modulate neural transmission 77-26-9 BUTALBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 77-26-9 BUTALBITAL ADVERSE_EFFECT NEU_1_Dizziness 77-26-9 BUTALBITAL INDICATION Sedation 77-26-9 BUTALBITAL TISSUE_TOXICITY Hypotension 77-26-9 BUTALBITAL INDICATION Migraine Headache 77-26-9 BUTALBITAL ADVERSE_EFFECT PSY_3_Mental Confusion 77-26-9 BUTALBITAL ADVERSE_EFFECT PSY_3_CNS Depression 77-26-9 BUTALBITAL ADVERSE_EFFECT NEU_3_Paradoxical Reactions 77-26-9 BUTALBITAL ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 77-26-9 BUTALBITAL ADVERSE_EFFECT BBM_3_Agranulocytosis 77-26-9 BUTALBITAL INDICATION Pain 77-26-9 BUTALBITAL ADVERSE_EFFECT LUN_3_Bronchospasm 77-26-9 BUTALBITAL PRODUCT_CLASS Central Nervous System (CNS) 77-26-9 BUTALBITAL ADVERSE_EFFECT END_3_Osteopenia 77-26-9 BUTALBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 77-26-9 BUTALBITAL ADVERSE_EFFECT PSY_3_Dependence 77-26-9 BUTALBITAL ADVERSE_EFFECT NEU_1_Drowsiness 77-26-9 BUTALBITAL ADVERSE_EFFECT CVS_3_Hypotension 77-26-9 BUTALBITAL MODE_CLASS Channel Modulator 77-26-9 BUTALBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 77-26-9 BUTALBITAL ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 77-26-9 BUTALBITAL ADVERSE_EFFECT BBM_3_Thrombocytopenia 77-26-9 BUTALBITAL ADVERSE_EFFECT XXX_3_Withdrawal 77-26-9 BUTALBITAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 77-26-9 BUTALBITAL ADVERSE_EFFECT XXX_2_Tolerance 77-26-9 BUTALBITAL ADVERSE_EFFECT OCU_3_Miosis 77-26-9 BUTALBITAL KNOWN_TOXICITY Cardiovascular Toxicity 94-25-7 BUTAMBEN ADVERSE_EFFECT SKN_3_Skin Sloughing 94-25-7 BUTAMBEN ADVERSE_EFFECT IMU_3_Contact Dermatitis 94-25-7 BUTAMBEN MECHANISM Block neural transmission 94-25-7 BUTAMBEN ADVERSE_EFFECT NEU_3_Transverse Myelitis 94-25-7 BUTAMBEN ADVERSE_EFFECT XXX_3_Local Tissue Necrosis 94-25-7 BUTAMBEN THERAPEUTIC_CLASS Local Anesthetics 94-25-7 BUTAMBEN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 94-25-7 BUTAMBEN INDICATION Burns 94-25-7 BUTAMBEN MODE_CLASS Channel Blocker 94-25-7 BUTAMBEN INDICATION Local Anesthesia 94-25-7 BUTAMBEN ADVERSE_EFFECT IMU_3_Urticaria 94-25-7 BUTAMBEN ADVERSE_EFFECT SKN_3_Skin Irritation 94-25-7 BUTAMBEN INDICATION Allergic Contact Dermatitis 94-25-7 BUTAMBEN STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 94-25-7 BUTAMBEN PRODUCT_CLASS Dermatologicals 64872-76-0 BUTOCONAZOLE PRODUCT_CLASS Anti-infectives 64872-76-0 BUTOCONAZOLE MODE_CLASS Enzyme Inhibitor 64872-76-0 BUTOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 64872-76-0 BUTOCONAZOLE THERAPEUTIC_CLASS Antifungals 64872-77-1 BUTOCONAZOLE PRODUCT_CLASS Anti-infectives 64872-77-1 BUTOCONAZOLE MODE_CLASS Enzyme Inhibitor 64872-77-1 BUTOCONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 64872-77-1 BUTOCONAZOLE THERAPEUTIC_CLASS Antifungals 58786-99-5 BUTORPHANOL PRODUCT_CLASS Central Nervous System (CNS) 58786-99-5 BUTORPHANOL KNOWN_TOXICITY Cardiovascular Toxicity 58786-99-5 BUTORPHANOL MODE_CLASS Receptor Partial Agonist 58786-99-5 BUTORPHANOL ADVERSE_EFFECT GUS_2_Urinary Retention 58786-99-5 BUTORPHANOL ADVERSE_EFFECT CVS_3_Hypertension 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_2_Anxiety 58786-99-5 BUTORPHANOL ADVERSE_EFFECT NEU_2_Paresthesia 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_2_Physical Dependence 58786-99-5 BUTORPHANOL ADVERSE_EFFECT XXX_2_Asthenia 58786-99-5 BUTORPHANOL INDICATION Severe Pain 58786-99-5 BUTORPHANOL TISSUE_TOXICITY Hypotension 58786-99-5 BUTORPHANOL MODE_CLASS Receptor Agonist 58786-99-5 BUTORPHANOL ADVERSE_EFFECT LUN_3_Respiratory Depression 58786-99-5 BUTORPHANOL ADVERSE_EFFECT CVS_3_Hypotension 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_1_Insomnia 58786-99-5 BUTORPHANOL ADVERSE_EFFECT NEU_1_Dizziness 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_2_Euphoria 58786-99-5 BUTORPHANOL ADVERSE_EFFECT XXX_2_Diaphoresis 58786-99-5 BUTORPHANOL MECHANISM Modulate neural transmission 58786-99-5 BUTORPHANOL INDICATION Premedication in Anesthetia 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_1_CNS Depression 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_2_Anorexia 58786-99-5 BUTORPHANOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 58786-99-5 BUTORPHANOL ADVERSE_EFFECT SKN_3_Pruritis 58786-99-5 BUTORPHANOL ADVERSE_EFFECT PSY_2_Confusion 58786-99-5 BUTORPHANOL ADVERSE_EFFECT XXX_2_Nasal Congestion 58786-99-5 BUTORPHANOL INDICATION Induction / Maintenance of Anesthesia 58786-99-5 BUTORPHANOL THERAPEUTIC_CLASS General Anesthetics, Intravenous 58786-99-5 BUTORPHANOL MODE_CLASS Receptor Ligand Antagonist 58786-99-5 BUTORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 58786-99-5 BUTORPHANOL ADVERSE_EFFECT GIS_1_Constipation 58786-99-5 BUTORPHANOL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 58786-99-5 BUTORPHANOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 58786-99-5 BUTORPHANOL ADVERSE_EFFECT NEU_1_Drowsiness 58786-99-5 BUTORPHANOL ADVERSE_EFFECT XXX_2_Withdrawal 58786-99-5 BUTORPHANOL ADVERSE_EFFECT XXX_2_Xerostomia 58786-99-5 BUTORPHANOL STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 58786-99-5 BUTORPHANOL ADVERSE_EFFECT XXX_2_Tolerance 58786-99-5 BUTORPHANOL INDICATION Migraine Headache 58786-99-5 BUTORPHANOL PRODUCT_CLASS Analgesics 42408-82-2 BUTORPHANOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 42408-82-2 BUTORPHANOL ADVERSE_EFFECT NEU_1_Drowsiness 42408-82-2 BUTORPHANOL ADVERSE_EFFECT XXX_2_Withdrawal 42408-82-2 BUTORPHANOL ADVERSE_EFFECT XXX_2_Xerostomia 42408-82-2 BUTORPHANOL STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 42408-82-2 BUTORPHANOL KNOWN_TOXICITY Cardiovascular Toxicity 42408-82-2 BUTORPHANOL ADVERSE_EFFECT XXX_2_Nasal Congestion 42408-82-2 BUTORPHANOL INDICATION Induction / Maintenance of Anesthesia 42408-82-2 BUTORPHANOL THERAPEUTIC_CLASS General Anesthetics, Intravenous 42408-82-2 BUTORPHANOL MODE_CLASS Receptor Ligand Antagonist 42408-82-2 BUTORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 42408-82-2 BUTORPHANOL ADVERSE_EFFECT SKN_3_Pruritis 42408-82-2 BUTORPHANOL ADVERSE_EFFECT GIS_1_Constipation 42408-82-2 BUTORPHANOL INDICATION Migraine Headache 42408-82-2 BUTORPHANOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_2_Anorexia 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_1_CNS Depression 42408-82-2 BUTORPHANOL INDICATION Premedication in Anesthetia 42408-82-2 BUTORPHANOL MECHANISM Modulate neural transmission 42408-82-2 BUTORPHANOL ADVERSE_EFFECT XXX_2_Diaphoresis 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_2_Euphoria 42408-82-2 BUTORPHANOL ADVERSE_EFFECT XXX_2_Tolerance 42408-82-2 BUTORPHANOL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 42408-82-2 BUTORPHANOL ADVERSE_EFFECT NEU_1_Dizziness 42408-82-2 BUTORPHANOL ADVERSE_EFFECT CVS_3_Hypotension 42408-82-2 BUTORPHANOL ADVERSE_EFFECT LUN_3_Respiratory Depression 42408-82-2 BUTORPHANOL MODE_CLASS Receptor Agonist 42408-82-2 BUTORPHANOL INDICATION Severe Pain 42408-82-2 BUTORPHANOL ADVERSE_EFFECT XXX_2_Asthenia 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_2_Physical Dependence 42408-82-2 BUTORPHANOL ADVERSE_EFFECT NEU_2_Paresthesia 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_2_Anxiety 42408-82-2 BUTORPHANOL ADVERSE_EFFECT CVS_3_Hypertension 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_1_Insomnia 42408-82-2 BUTORPHANOL ADVERSE_EFFECT GUS_2_Urinary Retention 42408-82-2 BUTORPHANOL MODE_CLASS Receptor Partial Agonist 42408-82-2 BUTORPHANOL TISSUE_TOXICITY Hypotension 42408-82-2 BUTORPHANOL ADVERSE_EFFECT PSY_2_Confusion 42408-82-2 BUTORPHANOL PRODUCT_CLASS Analgesics 42408-82-2 BUTORPHANOL PRODUCT_CLASS Central Nervous System (CNS) 54965-23-0 BUTORPHANOL INDICATION Migraine Headache 54965-23-0 BUTORPHANOL PRODUCT_CLASS Analgesics 54965-23-0 BUTORPHANOL PRODUCT_CLASS Central Nervous System (CNS) 54965-23-0 BUTORPHANOL KNOWN_TOXICITY Cardiovascular Toxicity 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_2_Confusion 54965-23-0 BUTORPHANOL MODE_CLASS Receptor Partial Agonist 54965-23-0 BUTORPHANOL ADVERSE_EFFECT CVS_3_Hypertension 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_2_Anxiety 54965-23-0 BUTORPHANOL ADVERSE_EFFECT NEU_2_Paresthesia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_2_Physical Dependence 54965-23-0 BUTORPHANOL ADVERSE_EFFECT GUS_2_Urinary Retention 54965-23-0 BUTORPHANOL ADVERSE_EFFECT XXX_2_Withdrawal 54965-23-0 BUTORPHANOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 54965-23-0 BUTORPHANOL ADVERSE_EFFECT GIS_1_Constipation 54965-23-0 BUTORPHANOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 54965-23-0 BUTORPHANOL THERAPEUTIC_CLASS Analgesics, Opioid 54965-23-0 BUTORPHANOL MODE_CLASS Receptor Ligand Antagonist 54965-23-0 BUTORPHANOL ADVERSE_EFFECT NEU_1_Drowsiness 54965-23-0 BUTORPHANOL INDICATION Induction / Maintenance of Anesthesia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT XXX_2_Tolerance 54965-23-0 BUTORPHANOL ADVERSE_EFFECT XXX_2_Asthenia 54965-23-0 BUTORPHANOL MODE_CLASS Receptor Agonist 54965-23-0 BUTORPHANOL ADVERSE_EFFECT LUN_3_Respiratory Depression 54965-23-0 BUTORPHANOL ADVERSE_EFFECT CVS_3_Hypotension 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_1_Insomnia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT NEU_1_Dizziness 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_2_Euphoria 54965-23-0 BUTORPHANOL MECHANISM Modulate neural transmission 54965-23-0 BUTORPHANOL INDICATION Premedication in Anesthetia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT SKN_3_Pruritis 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_2_Anorexia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT PSY_1_CNS Depression 54965-23-0 BUTORPHANOL STRUCTURE_ACTIVITY Opioid receptor mixed agonist/antagonist 54965-23-0 BUTORPHANOL THERAPEUTIC_CLASS General Anesthetics, Intravenous 54965-23-0 BUTORPHANOL ADVERSE_EFFECT XXX_2_Xerostomia 54965-23-0 BUTORPHANOL ADVERSE_EFFECT XXX_2_Diaphoresis 54965-23-0 BUTORPHANOL INDICATION Severe Pain 54965-23-0 BUTORPHANOL TISSUE_TOXICITY Hypotension 54965-23-0 BUTORPHANOL ADVERSE_EFFECT XXX_2_Nasal Congestion 94-26-8 BUTYLPARABEN PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 75859-04-0 RIMCAZOLE PRODUCT_CLASS Central Nervous System (CNS) 75859-04-0 RIMCAZOLE THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 75859-04-0 RIMCAZOLE THERAPEUTIC_CLASS Antipsychotics 81409-90-7 CABERGOLINE MODE_CLASS Receptor Agonist 81409-90-7 CABERGOLINE THERAPEUTIC_CLASS Movement Disorders 81409-90-7 CABERGOLINE PRODUCT_CLASS Central Nervous System (CNS) 81409-90-7 CABERGOLINE STRUCTURE_ACTIVITY Ergot alkaloid 81409-90-7 CABERGOLINE PRODUCT_CLASS Hormones, Endocrine and Metabolic 81409-90-7 CABERGOLINE INDICATION Hyperprolactinemia 81409-90-7 CABERGOLINE INDICATION Parkinson's Disease 81409-90-7 CABERGOLINE MECHANISM Prolong/enhance neural transmission 81409-90-7 CABERGOLINE THERAPEUTIC_CLASS Pituitary Hormones 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 543-90-8 CADMIUM ACETATE KNOWN_TOXICITY Nephrotoxicity 543-90-8 CADMIUM ACETATE TISSUE_TOXICITY Hematuria 543-90-8 CADMIUM ACETATE TISSUE_TOXICITY Hepatotoxicity 543-90-8 CADMIUM ACETATE MECHANISM Reduce muscle contractile force 543-90-8 CADMIUM ACETATE MODE_CLASS Receptor /Channel ligand mimic 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Throat Irritation 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT CVS_1_Chest Pain 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Proteinuria 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Dyspnea 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 543-90-8 CADMIUM ACETATE TISSUE_TOXICITY Nephrotoxicity 543-90-8 CADMIUM ACETATE KNOWN_TOXICITY Carcinogenicity 543-90-8 CADMIUM ACETATE MECH_LEVEL_1 Toxicant 543-90-8 CADMIUM ACETATE MESH_LEVEL_2 Cadmium Compounds 543-90-8 CADMIUM ACETATE STRUCTURE_ACTIVITY Toxicant, heavy metal 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 543-90-8 CADMIUM ACETATE ZERO_CLASS N 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteoporosis 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Airway Irritation 543-90-8 CADMIUM ACETATE MECH_LEVEL_2 Interferes with Cell-Cell signaling 543-90-8 CADMIUM ACETATE PRODUCT_CLASS Toxicants 543-90-8 CADMIUM ACETATE MESH_LEVEL_1 Inorganic Chemicals 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteomalacia 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT OCU_1_Eye Irritation 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Nephrotoxicity 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT DNA_2_Carcinogenicity 543-90-8 CADMIUM ACETATE KNOWN_TOXICITY Hepatotoxicity 543-90-8 CADMIUM ACETATE TISSUE_TOXICITY Carcinogenicity 543-90-8 CADMIUM ACETATE TA_LEVEL_1 Toxicants 543-90-8 CADMIUM ACETATE TA_LEVEL_2 Toxicology Standard 543-90-8 CADMIUM ACETATE MECH_LEVEL_3 L-Type Ca++ channel 543-90-8 CADMIUM ACETATE TA_LEVEL_3 Cardiovascular toxicants 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT BBM_3_Anemia 543-90-8 CADMIUM ACETATE ACTIVITY_CLASS Toxicant 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Tooth Discoloration 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Nose Irritation 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Hematuria 543-90-8 CADMIUM ACETATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Nephrotoxicity 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT BBM_3_Anemia 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT DNA_2_Carcinogenicity 24558-49-4 CADMIUM ACETATE KNOWN_TOXICITY Hepatotoxicity 24558-49-4 CADMIUM ACETATE PRODUCT_CLASS Toxicants 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Airway Irritation 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteoporosis 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 24558-49-4 CADMIUM ACETATE ZERO_CLASS N 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 24558-49-4 CADMIUM ACETATE STRUCTURE_ACTIVITY Toxicant, heavy metal 24558-49-4 CADMIUM ACETATE MESH_LEVEL_2 Cadmium Compounds 24558-49-4 CADMIUM ACETATE MECH_LEVEL_1 Toxicant 24558-49-4 CADMIUM ACETATE KNOWN_TOXICITY Carcinogenicity 24558-49-4 CADMIUM ACETATE TISSUE_TOXICITY Nephrotoxicity 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Dyspnea 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Proteinuria 24558-49-4 CADMIUM ACETATE MECHANISM Reduce muscle contractile force 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT CVS_1_Chest Pain 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Throat Irritation 24558-49-4 CADMIUM ACETATE MODE_CLASS Receptor /Channel ligand mimic 24558-49-4 CADMIUM ACETATE TA_LEVEL_3 Cardiovascular toxicants 24558-49-4 CADMIUM ACETATE TISSUE_TOXICITY Hepatotoxicity 24558-49-4 CADMIUM ACETATE TISSUE_TOXICITY Hematuria 24558-49-4 CADMIUM ACETATE KNOWN_TOXICITY Nephrotoxicity 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Hematuria 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Nose Irritation 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Tooth Discoloration 24558-49-4 CADMIUM ACETATE ACTIVITY_CLASS Toxicant 24558-49-4 CADMIUM ACETATE TA_LEVEL_1 Toxicants 24558-49-4 CADMIUM ACETATE TA_LEVEL_2 Toxicology Standard 24558-49-4 CADMIUM ACETATE MECH_LEVEL_3 L-Type Ca++ channel 24558-49-4 CADMIUM ACETATE MESH_LEVEL_1 Inorganic Chemicals 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteomalacia 24558-49-4 CADMIUM ACETATE MECH_LEVEL_2 Interferes with Cell-Cell signaling 24558-49-4 CADMIUM ACETATE ADVERSE_EFFECT OCU_1_Eye Irritation 24558-49-4 CADMIUM ACETATE TISSUE_TOXICITY Carcinogenicity 29398-76-3 CADMIUM ACETATE TISSUE_TOXICITY Hepatotoxicity 29398-76-3 CADMIUM ACETATE TISSUE_TOXICITY Hematuria 29398-76-3 CADMIUM ACETATE KNOWN_TOXICITY Nephrotoxicity 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Hematuria 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Nose Irritation 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Tooth Discoloration 29398-76-3 CADMIUM ACETATE ACTIVITY_CLASS Toxicant 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteoporosis 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Airway Irritation 29398-76-3 CADMIUM ACETATE MECH_LEVEL_2 Interferes with Cell-Cell signaling 29398-76-3 CADMIUM ACETATE PRODUCT_CLASS Toxicants 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteomalacia 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT OCU_1_Eye Irritation 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Nephrotoxicity 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT BBM_3_Anemia 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT DNA_2_Carcinogenicity 29398-76-3 CADMIUM ACETATE KNOWN_TOXICITY Hepatotoxicity 29398-76-3 CADMIUM ACETATE TISSUE_TOXICITY Carcinogenicity 29398-76-3 CADMIUM ACETATE TA_LEVEL_1 Toxicants 29398-76-3 CADMIUM ACETATE TA_LEVEL_2 Toxicology Standard 29398-76-3 CADMIUM ACETATE MECH_LEVEL_3 L-Type Ca++ channel 29398-76-3 CADMIUM ACETATE MESH_LEVEL_1 Inorganic Chemicals 29398-76-3 CADMIUM ACETATE ZERO_CLASS N 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 29398-76-3 CADMIUM ACETATE STRUCTURE_ACTIVITY Toxicant, heavy metal 29398-76-3 CADMIUM ACETATE MESH_LEVEL_2 Cadmium Compounds 29398-76-3 CADMIUM ACETATE MECH_LEVEL_1 Toxicant 29398-76-3 CADMIUM ACETATE KNOWN_TOXICITY Carcinogenicity 29398-76-3 CADMIUM ACETATE TISSUE_TOXICITY Nephrotoxicity 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Dyspnea 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Proteinuria 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT CVS_1_Chest Pain 29398-76-3 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Throat Irritation 29398-76-3 CADMIUM ACETATE MODE_CLASS Receptor /Channel ligand mimic 29398-76-3 CADMIUM ACETATE TA_LEVEL_3 Cardiovascular toxicants 29398-76-3 CADMIUM ACETATE MECHANISM Reduce muscle contractile force 5743-04-4 CADMIUM ACETATE KNOWN_TOXICITY Hepatotoxicity 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteomalacia 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Hematuria 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT DNA_2_Carcinogenicity 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Dyspnea 5743-04-4 CADMIUM ACETATE MESH_LEVEL_2 Cadmium Compounds 5743-04-4 CADMIUM ACETATE MECH_LEVEL_2 Interferes with Cell-Cell signaling 5743-04-4 CADMIUM ACETATE PRODUCT_CLASS Toxicants 5743-04-4 CADMIUM ACETATE MESH_LEVEL_1 Inorganic Chemicals 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT BBM_3_Anemia 5743-04-4 CADMIUM ACETATE STRUCTURE_ACTIVITY Toxicant, heavy metal 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 5743-04-4 CADMIUM ACETATE ZERO_CLASS N 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT END_2_Osteoporosis 5743-04-4 CADMIUM ACETATE ACTIVITY_CLASS Toxicant 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_1_Airway Irritation 5743-04-4 CADMIUM ACETATE MECH_LEVEL_3 L-Type Ca++ channel 5743-04-4 CADMIUM ACETATE TA_LEVEL_2 Toxicology Standard 5743-04-4 CADMIUM ACETATE TA_LEVEL_1 Toxicants 5743-04-4 CADMIUM ACETATE TISSUE_TOXICITY Carcinogenicity 5743-04-4 CADMIUM ACETATE MECH_LEVEL_1 Toxicant 5743-04-4 CADMIUM ACETATE KNOWN_TOXICITY Carcinogenicity 5743-04-4 CADMIUM ACETATE TISSUE_TOXICITY Nephrotoxicity 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT KID_2_Proteinuria 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT CVS_1_Chest Pain 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Throat Irritation 5743-04-4 CADMIUM ACETATE MODE_CLASS Receptor /Channel ligand mimic 5743-04-4 CADMIUM ACETATE TA_LEVEL_3 Cardiovascular toxicants 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT KID_1_Nephrotoxicity 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT OCU_1_Eye Irritation 5743-04-4 CADMIUM ACETATE MECHANISM Reduce muscle contractile force 5743-04-4 CADMIUM ACETATE TISSUE_TOXICITY Hepatotoxicity 5743-04-4 CADMIUM ACETATE TISSUE_TOXICITY Hematuria 5743-04-4 CADMIUM ACETATE KNOWN_TOXICITY Nephrotoxicity 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT LUN_2_Pulmonary Edema 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT LIV_3_Hepatotoxicity 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_1_Nose Irritation 5743-04-4 CADMIUM ACETATE ADVERSE_EFFECT XXX_2_Tooth Discoloration 10108-64-2 CADMIUM CHLORIDE KNOWN_TOXICITY Respiratory Toxicity 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Fever 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Pulmonary Edema 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Throat Irritation 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Airway Irritation 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 10108-64-2 CADMIUM CHLORIDE TA_LEVEL_3 Kidney toxicants 10108-64-2 CADMIUM CHLORIDE MECHANISM Interferes with Cell-Cell signaling 10108-64-2 CADMIUM CHLORIDE KNOWN_TOXICITY Hepatotoxicity 10108-64-2 CADMIUM CHLORIDE TISSUE_TOXICITY Carcinogenicity 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT KID_2_Hematuria 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT CVS_2_Chest Pain 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Tooth Discoloration 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT OCU_1_Eye Irritation 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Dyspnea 10108-64-2 CADMIUM CHLORIDE ACTIVITY_CLASS Toxicant 10108-64-2 CADMIUM CHLORIDE TA_LEVEL_2 Toxicology Standard 10108-64-2 CADMIUM CHLORIDE MECH_LEVEL_3 L-Type Ca++ channel 10108-64-2 CADMIUM CHLORIDE TA_LEVEL_1 Toxicants 10108-64-2 CADMIUM CHLORIDE KNOWN_TOXICITY Nephrotoxicity 10108-64-2 CADMIUM CHLORIDE TISSUE_TOXICITY Pulmonary Edema 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Diarrhea 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteomalacia 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Nephrotoxicity 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT REP_1_Testicular Toxicity 10108-64-2 CADMIUM CHLORIDE MECHANISM Reduce muscle contractile force 10108-64-2 CADMIUM CHLORIDE MESH_LEVEL_2 Cadmium Compounds 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 10108-64-2 CADMIUM CHLORIDE MECH_LEVEL_1 Toxicant 10108-64-2 CADMIUM CHLORIDE MESH_LEVEL_1 Inorganic Chemicals 10108-64-2 CADMIUM CHLORIDE PRODUCT_CLASS Toxicants 10108-64-2 CADMIUM CHLORIDE MECH_LEVEL_2 Interferes with Cell-Cell signaling 10108-64-2 CADMIUM CHLORIDE MODE_CLASS Receptor /Channel ligand mimic 10108-64-2 CADMIUM CHLORIDE KNOWN_TOXICITY Carcinogenicity 10108-64-2 CADMIUM CHLORIDE TISSUE_TOXICITY Hepatotoxicity 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Vomiting 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteoporosis 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Nose Irritation 10108-64-2 CADMIUM CHLORIDE ADVERSE_EFFECT BBM_2_Anemia 10108-64-2 CADMIUM CHLORIDE ZERO_CLASS N 10108-64-2 CADMIUM CHLORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 10108-64-2 CADMIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 10108-64-2 CADMIUM CHLORIDE TISSUE_TOXICITY Nephrotoxicity 10108-64-2 CADMIUM CHLORIDE TISSUE_TOXICITY Hematuria 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Tooth Discoloration 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT OCU_1_Eye Irritation 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Dyspnea 7790-78-5 CADMIUM CHLORIDE ACTIVITY_CLASS Toxicant 7790-78-5 CADMIUM CHLORIDE TA_LEVEL_2 Toxicology Standard 7790-78-5 CADMIUM CHLORIDE MECH_LEVEL_3 L-Type Ca++ channel 7790-78-5 CADMIUM CHLORIDE TA_LEVEL_1 Toxicants 7790-78-5 CADMIUM CHLORIDE KNOWN_TOXICITY Nephrotoxicity 7790-78-5 CADMIUM CHLORIDE TISSUE_TOXICITY Pulmonary Edema 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Diarrhea 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT REP_1_Testicular Toxicity 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteomalacia 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT BBM_2_Anemia 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Nephrotoxicity 7790-78-5 CADMIUM CHLORIDE MESH_LEVEL_2 Cadmium Compounds 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Nose Irritation 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteoporosis 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Vomiting 7790-78-5 CADMIUM CHLORIDE TISSUE_TOXICITY Hepatotoxicity 7790-78-5 CADMIUM CHLORIDE KNOWN_TOXICITY Carcinogenicity 7790-78-5 CADMIUM CHLORIDE MODE_CLASS Receptor /Channel ligand mimic 7790-78-5 CADMIUM CHLORIDE MECH_LEVEL_2 Interferes with Cell-Cell signaling 7790-78-5 CADMIUM CHLORIDE PRODUCT_CLASS Toxicants 7790-78-5 CADMIUM CHLORIDE MESH_LEVEL_1 Inorganic Chemicals 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 7790-78-5 CADMIUM CHLORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 7790-78-5 CADMIUM CHLORIDE MECH_LEVEL_1 Toxicant 7790-78-5 CADMIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 7790-78-5 CADMIUM CHLORIDE ZERO_CLASS N 7790-78-5 CADMIUM CHLORIDE TISSUE_TOXICITY Nephrotoxicity 7790-78-5 CADMIUM CHLORIDE TISSUE_TOXICITY Hematuria 7790-78-5 CADMIUM CHLORIDE KNOWN_TOXICITY Respiratory Toxicity 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Fever 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Pulmonary Edema 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Throat Irritation 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Airway Irritation 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 7790-78-5 CADMIUM CHLORIDE TA_LEVEL_3 Kidney toxicants 7790-78-5 CADMIUM CHLORIDE MECHANISM Interferes with Cell-Cell signaling 7790-78-5 CADMIUM CHLORIDE KNOWN_TOXICITY Hepatotoxicity 7790-78-5 CADMIUM CHLORIDE TISSUE_TOXICITY Carcinogenicity 7790-78-5 CADMIUM CHLORIDE MECHANISM Reduce muscle contractile force 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT KID_2_Hematuria 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT CVS_2_Chest Pain 7790-78-5 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT KID_2_Hematuria 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT CVS_2_Chest Pain 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Tooth Discoloration 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT OCU_1_Eye Irritation 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Dyspnea 34330-64-8 CADMIUM CHLORIDE ACTIVITY_CLASS Toxicant 34330-64-8 CADMIUM CHLORIDE TA_LEVEL_2 Toxicology Standard 34330-64-8 CADMIUM CHLORIDE MECH_LEVEL_3 L-Type Ca++ channel 34330-64-8 CADMIUM CHLORIDE TA_LEVEL_1 Toxicants 34330-64-8 CADMIUM CHLORIDE KNOWN_TOXICITY Nephrotoxicity 34330-64-8 CADMIUM CHLORIDE TISSUE_TOXICITY Pulmonary Edema 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Diarrhea 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteomalacia 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Nephrotoxicity 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 34330-64-8 CADMIUM CHLORIDE MESH_LEVEL_1 Inorganic Chemicals 34330-64-8 CADMIUM CHLORIDE PRODUCT_CLASS Toxicants 34330-64-8 CADMIUM CHLORIDE MECH_LEVEL_2 Interferes with Cell-Cell signaling 34330-64-8 CADMIUM CHLORIDE MODE_CLASS Receptor /Channel ligand mimic 34330-64-8 CADMIUM CHLORIDE KNOWN_TOXICITY Carcinogenicity 34330-64-8 CADMIUM CHLORIDE TISSUE_TOXICITY Hepatotoxicity 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Vomiting 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteoporosis 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Nose Irritation 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT BBM_2_Anemia 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT REP_1_Testicular Toxicity 34330-64-8 CADMIUM CHLORIDE ZERO_CLASS N 34330-64-8 CADMIUM CHLORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 34330-64-8 CADMIUM CHLORIDE MESH_LEVEL_2 Cadmium Compounds 34330-64-8 CADMIUM CHLORIDE MECHANISM Reduce muscle contractile force 34330-64-8 CADMIUM CHLORIDE MECH_LEVEL_1 Toxicant 34330-64-8 CADMIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 34330-64-8 CADMIUM CHLORIDE TISSUE_TOXICITY Nephrotoxicity 34330-64-8 CADMIUM CHLORIDE TISSUE_TOXICITY Hematuria 34330-64-8 CADMIUM CHLORIDE KNOWN_TOXICITY Respiratory Toxicity 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Fever 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Pulmonary Edema 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Throat Irritation 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Airway Irritation 34330-64-8 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 34330-64-8 CADMIUM CHLORIDE TA_LEVEL_3 Kidney toxicants 34330-64-8 CADMIUM CHLORIDE MECHANISM Interferes with Cell-Cell signaling 34330-64-8 CADMIUM CHLORIDE KNOWN_TOXICITY Hepatotoxicity 34330-64-8 CADMIUM CHLORIDE TISSUE_TOXICITY Carcinogenicity 35658-65-2 CADMIUM CHLORIDE TA_LEVEL_3 Kidney toxicants 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Nose Irritation 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT BBM_2_Anemia 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT REP_1_Testicular Toxicity 35658-65-2 CADMIUM CHLORIDE ZERO_CLASS N 35658-65-2 CADMIUM CHLORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 35658-65-2 CADMIUM CHLORIDE MESH_LEVEL_2 Cadmium Compounds 35658-65-2 CADMIUM CHLORIDE MECHANISM Reduce muscle contractile force 35658-65-2 CADMIUM CHLORIDE MECH_LEVEL_1 Toxicant 35658-65-2 CADMIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 35658-65-2 CADMIUM CHLORIDE TISSUE_TOXICITY Nephrotoxicity 35658-65-2 CADMIUM CHLORIDE TISSUE_TOXICITY Hematuria 35658-65-2 CADMIUM CHLORIDE KNOWN_TOXICITY Respiratory Toxicity 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Fever 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Pulmonary Edema 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Throat Irritation 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Airway Irritation 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Nephrotoxicity 35658-65-2 CADMIUM CHLORIDE MECHANISM Interferes with Cell-Cell signaling 35658-65-2 CADMIUM CHLORIDE KNOWN_TOXICITY Hepatotoxicity 35658-65-2 CADMIUM CHLORIDE TISSUE_TOXICITY Carcinogenicity 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT CVS_2_Chest Pain 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT KID_2_Hematuria 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Diarrhea 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 35658-65-2 CADMIUM CHLORIDE TISSUE_TOXICITY Pulmonary Edema 35658-65-2 CADMIUM CHLORIDE KNOWN_TOXICITY Nephrotoxicity 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteomalacia 35658-65-2 CADMIUM CHLORIDE TA_LEVEL_1 Toxicants 35658-65-2 CADMIUM CHLORIDE MECH_LEVEL_3 L-Type Ca++ channel 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 35658-65-2 CADMIUM CHLORIDE TA_LEVEL_2 Toxicology Standard 35658-65-2 CADMIUM CHLORIDE ACTIVITY_CLASS Toxicant 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Dyspnea 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT OCU_1_Eye Irritation 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Tooth Discoloration 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteoporosis 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 35658-65-2 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Vomiting 35658-65-2 CADMIUM CHLORIDE TISSUE_TOXICITY Hepatotoxicity 35658-65-2 CADMIUM CHLORIDE KNOWN_TOXICITY Carcinogenicity 35658-65-2 CADMIUM CHLORIDE MODE_CLASS Receptor /Channel ligand mimic 35658-65-2 CADMIUM CHLORIDE MECH_LEVEL_2 Interferes with Cell-Cell signaling 35658-65-2 CADMIUM CHLORIDE PRODUCT_CLASS Toxicants 35658-65-2 CADMIUM CHLORIDE MESH_LEVEL_1 Inorganic Chemicals 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT OCU_1_Eye Irritation 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Nose Irritation 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT BBM_2_Anemia 72589-96-9 CADMIUM CHLORIDE ZERO_CLASS N 72589-96-9 CADMIUM CHLORIDE STRUCTURE_ACTIVITY Toxicant, heavy metal 72589-96-9 CADMIUM CHLORIDE MESH_LEVEL_2 Cadmium Compounds 72589-96-9 CADMIUM CHLORIDE MECHANISM Reduce muscle contractile force 72589-96-9 CADMIUM CHLORIDE MECH_LEVEL_1 Toxicant 72589-96-9 CADMIUM CHLORIDE MODE_CLASS Receptor Ligand Antagonist 72589-96-9 CADMIUM CHLORIDE TISSUE_TOXICITY Nephrotoxicity 72589-96-9 CADMIUM CHLORIDE TISSUE_TOXICITY Hematuria 72589-96-9 CADMIUM CHLORIDE KNOWN_TOXICITY Respiratory Toxicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Fever 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Pulmonary Edema 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Throat Irritation 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Airway Irritation 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Abnormal Kidney Function 72589-96-9 CADMIUM CHLORIDE TA_LEVEL_3 Kidney toxicants 72589-96-9 CADMIUM CHLORIDE MECHANISM Interferes with Cell-Cell signaling 72589-96-9 CADMIUM CHLORIDE KNOWN_TOXICITY Hepatotoxicity 72589-96-9 CADMIUM CHLORIDE TISSUE_TOXICITY Carcinogenicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT KID_2_Hematuria 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT CVS_2_Chest Pain 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Tooth Discoloration 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_2_Loss of Sense of Smell 72589-96-9 CADMIUM CHLORIDE ACTIVITY_CLASS Toxicant 72589-96-9 CADMIUM CHLORIDE TA_LEVEL_2 Toxicology Standard 72589-96-9 CADMIUM CHLORIDE MECH_LEVEL_3 L-Type Ca++ channel 72589-96-9 CADMIUM CHLORIDE TA_LEVEL_1 Toxicants 72589-96-9 CADMIUM CHLORIDE KNOWN_TOXICITY Nephrotoxicity 72589-96-9 CADMIUM CHLORIDE TISSUE_TOXICITY Pulmonary Edema 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT DNA_3_Carcinogenicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Diarrhea 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteomalacia 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT KID_1_Nephrotoxicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT XXX_1_Flu-Like Syndrome 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT REP_1_Testicular Toxicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT END_2_Osteoporosis 72589-96-9 CADMIUM CHLORIDE MESH_LEVEL_1 Inorganic Chemicals 72589-96-9 CADMIUM CHLORIDE PRODUCT_CLASS Toxicants 72589-96-9 CADMIUM CHLORIDE MECH_LEVEL_2 Interferes with Cell-Cell signaling 72589-96-9 CADMIUM CHLORIDE MODE_CLASS Receptor /Channel ligand mimic 72589-96-9 CADMIUM CHLORIDE KNOWN_TOXICITY Carcinogenicity 72589-96-9 CADMIUM CHLORIDE TISSUE_TOXICITY Hepatotoxicity 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT GIS_1_Vomiting 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 72589-96-9 CADMIUM CHLORIDE ADVERSE_EFFECT LUN_1_Dyspnea 58-08-2 CAFFEINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 58-08-2 CAFFEINE MECHANISM Reduce muscle contractile force 58-08-2 CAFFEINE INDICATION Fatigue 58-08-2 CAFFEINE TA_LEVEL_1 Central Nervous System (CNS) 58-08-2 CAFFEINE TISSUE_TOXICITY Cardiac Arrhythmia 58-08-2 CAFFEINE MODE_CLASS Enzyme Inhibitor 58-08-2 CAFFEINE ADVERSE_EFFECT NEU_3_Convulsions 58-08-2 CAFFEINE MECH_LEVEL_3 adenosine receptor A1 and A2, beta receptors, and PDE 58-08-2 CAFFEINE ADVERSE_EFFECT NEU_1_Tremor 58-08-2 CAFFEINE ADVERSE_EFFECT XXX_1_Restlessness 58-08-2 CAFFEINE MESH_LEVEL_2 Alkaloids 58-08-2 CAFFEINE INDICATION Drowsiness 58-08-2 CAFFEINE MECHANISM Reduce bronchoconstriction 58-08-2 CAFFEINE PRODUCT_CLASS Autonomic Nervous System (ANS) 58-08-2 CAFFEINE MECH_LEVEL_1 CNS stimulation 58-08-2 CAFFEINE ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 58-08-2 CAFFEINE ADVERSE_EFFECT PSY_1_Insomnia 58-08-2 CAFFEINE MODE_CLASS Receptor Ligand Antagonist 58-08-2 CAFFEINE ADVERSE_EFFECT CVS_1_Tachycardia 58-08-2 CAFFEINE ADVERSE_EFFECT GIS_2_Nausea 58-08-2 CAFFEINE ADVERSE_EFFECT PSY_1_Irritability 58-08-2 CAFFEINE MECHANISM Enhance kinase mediated signal transduction 58-08-2 CAFFEINE MECH_LEVEL_2 PDE inhibition 58-08-2 CAFFEINE TA_LEVEL_3 PDE inhibitors 58-08-2 CAFFEINE ADVERSE_EFFECT PSY_1_Nervousness 58-08-2 CAFFEINE STRUCTURE_ACTIVITY Adenosine receptor antagonist, xanthine 58-08-2 CAFFEINE KNOWN_TOXICITY Cardiovascular Toxicity 58-08-2 CAFFEINE ADVERSE_EFFECT GIS_2_Vomiting 58-08-2 CAFFEINE ADVERSE_EFFECT PSY_1_CNS Stimulation 58-08-2 CAFFEINE MODE_CLASS Receptor Agonist 58-08-2 CAFFEINE ZERO_CLASS N 58-08-2 CAFFEINE TA_LEVEL_2 CNS Stimulant 58-08-2 CAFFEINE ACTIVITY_CLASS Adenosine receptor antagonist, xanthine 58-08-2 CAFFEINE MESH_LEVEL_3 Xanthine Alkaloids 58-08-2 CAFFEINE THERAPEUTIC_CLASS Sympathomimetic Agents 58-08-2 CAFFEINE MESH_LEVEL_1 Heterocyclic Compounds 19356-17-3 CALCIFEDIOL THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 19356-17-3 CALCIFEDIOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT NEU_3_Paralytic Ileus 19356-17-3 CALCIFEDIOL MODE_CLASS Receptor Agonist 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT END_3_Hyperphosphatemia 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT KID_3_Renal Stones 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT PSY_3_Anorexia 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT ELT_3_Hypercalcemia 19356-17-3 CALCIFEDIOL INDICATION Hypophosphatemia 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT NEU_3_Somnolence 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 19356-17-3 CALCIFEDIOL TISSUE_TOXICITY Cardiac Arrhythmia 19356-17-3 CALCIFEDIOL KNOWN_TOXICITY Cardiovascular Toxicity 19356-17-3 CALCIFEDIOL INDICATION Vitamin D Deficiency 19356-17-3 CALCIFEDIOL INDICATION Hypocalcemia 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT XXX_3_Thirst 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 19356-17-3 CALCIFEDIOL INDICATION Rickets 19356-17-3 CALCIFEDIOL PRODUCT_CLASS Vitamins, Minerals and Nutrients 19356-17-3 CALCIFEDIOL MECHANISM Modulate gene transcription 19356-17-3 CALCIFEDIOL ADVERSE_EFFECT XXX_3_Weakness 19356-17-3 CALCIFEDIOL INDICATION Renal Osteodystrophy 112828-00-9 CALCIPOTRIENE MECHANISM Modulate gene transcription 112828-00-9 CALCIPOTRIENE STRUCTURE_ACTIVITY Vitamin D receptor agonist 112828-00-9 CALCIPOTRIENE MODE_CLASS Receptor Agonist 112828-00-9 CALCIPOTRIENE THERAPEUTIC_CLASS Psoralens 112828-00-9 CALCIPOTRIENE INDICATION Psoriasis 112828-00-9 CALCIPOTRIENE PRODUCT_CLASS Dermatologicals 112965-21-6 CALCIPOTRIENE INDICATION Psoriasis 112965-21-6 CALCIPOTRIENE PRODUCT_CLASS Dermatologicals 112965-21-6 CALCIPOTRIENE MECHANISM Modulate gene transcription 112965-21-6 CALCIPOTRIENE MODE_CLASS Receptor Agonist 112965-21-6 CALCIPOTRIENE THERAPEUTIC_CLASS Psoralens 112965-21-6 CALCIPOTRIENE STRUCTURE_ACTIVITY Vitamin D receptor agonist 47931-85-1 CALCITONIN, SALMON PRODUCT_CLASS Hormones, Endocrine and Metabolic 47931-85-1 CALCITONIN, SALMON INDICATION Hypercalcemia 47931-85-1 CALCITONIN, SALMON INDICATION Paget's Disease of Bone / Osteitis Deformans 47931-85-1 CALCITONIN, SALMON THERAPEUTIC_CLASS Bone Mineral Homeostasis 47931-85-1 CALCITONIN, SALMON INDICATION Osteoporosis 32222-06-3 CALCITRIOL MECHANISM Modulate gene transcription 32222-06-3 CALCITRIOL ADVERSE_EFFECT XXX_2_Injection Site Reaction 32222-06-3 CALCITRIOL ADVERSE_EFFECT SKN_3_Erythema Multiforme 32222-06-3 CALCITRIOL INDICATION Prevention of Osteoporosis 32222-06-3 CALCITRIOL INDICATION Hypocalcemia 32222-06-3 CALCITRIOL ADVERSE_EFFECT GIS_1_Metallic Taste 32222-06-3 CALCITRIOL ADVERSE_EFFECT ELT_1_Hypercalcemia 32222-06-3 CALCITRIOL INDICATION Renal Osteodystrophy 32222-06-3 CALCITRIOL STRUCTURE_ACTIVITY Vitamin D receptor agonist 32222-06-3 CALCITRIOL INDICATION Hypophosphatemia 32222-06-3 CALCITRIOL ADVERSE_EFFECT IMU_3_Urticaria 32222-06-3 CALCITRIOL ADVERSE_EFFECT END_1_Hyperphosphatemia 32222-06-3 CALCITRIOL MODE_CLASS Receptor Agonist 32222-06-3 CALCITRIOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 32222-06-3 CALCITRIOL INDICATION Secondary Hyperparathyroidism 32222-06-3 CALCITRIOL ADVERSE_EFFECT XXX_2_Weight Loss 32222-06-3 CALCITRIOL ADVERSE_EFFECT END_1_Hypervitaminosis 32222-06-3 CALCITRIOL ACTIVITY_CLASS Vitamin D receptor agonist 32222-06-3 CALCITRIOL THERAPEUTIC_CLASS Bone Mineral Homeostasis 32222-06-3 CALCITRIOL INDICATION Osteoporosis 94724-12-6 CALMIDAZOLIUM CHLORIDE MECHANISM Block neural transmission 94724-12-6 CALMIDAZOLIUM CHLORIDE MODE_CLASS Channel Blocker 464-48-2 L-CAMPHOR ADVERSE_EFFECT KID_2_Albuminuria 464-48-2 L-CAMPHOR PRODUCT_CLASS Analgesics 464-48-2 L-CAMPHOR ADVERSE_EFFECT XXX_1_Burning Sensation 464-48-2 L-CAMPHOR ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 464-48-2 L-CAMPHOR ADVERSE_EFFECT NEU_2_Coma 464-48-2 L-CAMPHOR ADVERSE_EFFECT PSY_2_Delirium 464-48-2 L-CAMPHOR KNOWN_TOXICITY Nephrotoxicity 464-48-2 L-CAMPHOR THERAPEUTIC_CLASS Analgesics, Topical 464-48-2 L-CAMPHOR TISSUE_TOXICITY Anuria 464-48-2 L-CAMPHOR INDICATION Cough / Tussis 464-48-2 L-CAMPHOR INDICATION Viral Rhinitis / Common Cold 464-48-2 L-CAMPHOR ADVERSE_EFFECT KID_2_Anuria 464-48-2 L-CAMPHOR ADVERSE_EFFECT NEU_1_Vertigo 464-48-2 L-CAMPHOR ADVERSE_EFFECT NEU_2_Seizures 464-48-2 L-CAMPHOR ADVERSE_EFFECT PSY_2_Hallucinations 464-48-2 L-CAMPHOR INDICATION Nasal Congestion 464-48-2 L-CAMPHOR THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 464-48-2 L-CAMPHOR INDICATION Pruritus / Itching 464-48-2 L-CAMPHOR ADVERSE_EFFECT GIS_1_Vomiting 464-48-2 L-CAMPHOR ADVERSE_EFFECT XXX_1_Restlessness 464-48-2 L-CAMPHOR ADVERSE_EFFECT OCU_1_Dilated Pupils 464-48-2 L-CAMPHOR ADVERSE_EFFECT NEU_3_Neuronal Necrosis 464-48-2 L-CAMPHOR PRODUCT_CLASS Respiratory System 464-48-2 L-CAMPHOR INDICATION Musculoskeletal Pain 464-48-2 L-CAMPHOR ADVERSE_EFFECT NEU_1_Tremor 464-48-2 L-CAMPHOR ADVERSE_EFFECT PSY_1_Confusion 464-48-2 L-CAMPHOR ADVERSE_EFFECT OCU_2_Amblyopia 464-48-2 L-CAMPHOR INDICATION Herpes Labialis / Cold or Fever Sore 76-22-2 L-CAMPHOR PRODUCT_CLASS Respiratory System 76-22-2 L-CAMPHOR INDICATION Musculoskeletal Pain 76-22-2 L-CAMPHOR ADVERSE_EFFECT NEU_1_Tremor 76-22-2 L-CAMPHOR ADVERSE_EFFECT PSY_1_Confusion 76-22-2 L-CAMPHOR ADVERSE_EFFECT OCU_2_Amblyopia 76-22-2 L-CAMPHOR ADVERSE_EFFECT KID_2_Albuminuria 76-22-2 L-CAMPHOR ADVERSE_EFFECT PSY_2_Hallucinations 76-22-2 L-CAMPHOR INDICATION Pruritus / Itching 76-22-2 L-CAMPHOR INDICATION Nasal Congestion 76-22-2 L-CAMPHOR ADVERSE_EFFECT NEU_2_Seizures 76-22-2 L-CAMPHOR ADVERSE_EFFECT NEU_1_Vertigo 76-22-2 L-CAMPHOR ADVERSE_EFFECT KID_2_Anuria 76-22-2 L-CAMPHOR INDICATION Herpes Labialis / Cold or Fever Sore 76-22-2 L-CAMPHOR INDICATION Cough / Tussis 76-22-2 L-CAMPHOR TISSUE_TOXICITY Anuria 76-22-2 L-CAMPHOR THERAPEUTIC_CLASS Analgesics, Topical 76-22-2 L-CAMPHOR KNOWN_TOXICITY Nephrotoxicity 76-22-2 L-CAMPHOR ADVERSE_EFFECT PSY_2_Delirium 76-22-2 L-CAMPHOR ADVERSE_EFFECT NEU_2_Coma 76-22-2 L-CAMPHOR ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 76-22-2 L-CAMPHOR ADVERSE_EFFECT XXX_1_Burning Sensation 76-22-2 L-CAMPHOR PRODUCT_CLASS Analgesics 76-22-2 L-CAMPHOR INDICATION Viral Rhinitis / Common Cold 76-22-2 L-CAMPHOR THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 76-22-2 L-CAMPHOR ADVERSE_EFFECT GIS_1_Vomiting 76-22-2 L-CAMPHOR ADVERSE_EFFECT XXX_1_Restlessness 76-22-2 L-CAMPHOR ADVERSE_EFFECT OCU_1_Dilated Pupils 76-22-2 L-CAMPHOR ADVERSE_EFFECT NEU_3_Neuronal Necrosis 595-31-3 L-CAMPHOR ADVERSE_EFFECT NEU_3_Neuronal Necrosis 595-31-3 L-CAMPHOR ADVERSE_EFFECT NEU_2_Seizures 595-31-3 L-CAMPHOR ADVERSE_EFFECT PSY_2_Hallucinations 595-31-3 L-CAMPHOR INDICATION Nasal Congestion 595-31-3 L-CAMPHOR INDICATION Pruritus / Itching 595-31-3 L-CAMPHOR ADVERSE_EFFECT PSY_1_Confusion 595-31-3 L-CAMPHOR ADVERSE_EFFECT PSY_2_Delirium 595-31-3 L-CAMPHOR ADVERSE_EFFECT NEU_2_Coma 595-31-3 L-CAMPHOR ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 595-31-3 L-CAMPHOR ADVERSE_EFFECT OCU_2_Amblyopia 595-31-3 L-CAMPHOR ADVERSE_EFFECT XXX_1_Burning Sensation 595-31-3 L-CAMPHOR PRODUCT_CLASS Analgesics 595-31-3 L-CAMPHOR INDICATION Musculoskeletal Pain 595-31-3 L-CAMPHOR ADVERSE_EFFECT NEU_1_Tremor 595-31-3 L-CAMPHOR ADVERSE_EFFECT KID_2_Albuminuria 595-31-3 L-CAMPHOR INDICATION Cough / Tussis 595-31-3 L-CAMPHOR THERAPEUTIC_CLASS Analgesics, Topical 595-31-3 L-CAMPHOR INDICATION Herpes Labialis / Cold or Fever Sore 595-31-3 L-CAMPHOR ADVERSE_EFFECT KID_2_Anuria 595-31-3 L-CAMPHOR ADVERSE_EFFECT NEU_1_Vertigo 595-31-3 L-CAMPHOR INDICATION Viral Rhinitis / Common Cold 595-31-3 L-CAMPHOR THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 595-31-3 L-CAMPHOR ADVERSE_EFFECT GIS_1_Vomiting 595-31-3 L-CAMPHOR TISSUE_TOXICITY Anuria 595-31-3 L-CAMPHOR ADVERSE_EFFECT XXX_1_Restlessness 595-31-3 L-CAMPHOR ADVERSE_EFFECT OCU_1_Dilated Pupils 595-31-3 L-CAMPHOR KNOWN_TOXICITY Nephrotoxicity 595-31-3 L-CAMPHOR PRODUCT_CLASS Respiratory System 464-49-3 D-CAMPHOR INDICATION Herpes Labialis / Cold or Fever Sore 464-49-3 D-CAMPHOR ADVERSE_EFFECT PSY_2_Delirium 464-49-3 D-CAMPHOR ADVERSE_EFFECT KID_2_Albuminuria 464-49-3 D-CAMPHOR ADVERSE_EFFECT OCU_2_Amblyopia 464-49-3 D-CAMPHOR ADVERSE_EFFECT PSY_1_Confusion 464-49-3 D-CAMPHOR ADVERSE_EFFECT NEU_1_Tremor 464-49-3 D-CAMPHOR INDICATION Cough / Tussis 464-49-3 D-CAMPHOR ADVERSE_EFFECT NEU_3_Neuronal Necrosis 464-49-3 D-CAMPHOR ADVERSE_EFFECT OCU_1_Dilated Pupils 464-49-3 D-CAMPHOR ADVERSE_EFFECT XXX_1_Restlessness 464-49-3 D-CAMPHOR ADVERSE_EFFECT GIS_1_Vomiting 464-49-3 D-CAMPHOR INDICATION Nasal Congestion 464-49-3 D-CAMPHOR INDICATION Pruritus / Itching 464-49-3 D-CAMPHOR ADVERSE_EFFECT XXX_1_Burning Sensation 464-49-3 D-CAMPHOR ADVERSE_EFFECT LIV_1_Increased Liver Enzymes 464-49-3 D-CAMPHOR ADVERSE_EFFECT NEU_2_Coma 464-49-3 D-CAMPHOR PRODUCT_CLASS Analgesics 464-49-3 D-CAMPHOR PRODUCT_CLASS Respiratory System 464-49-3 D-CAMPHOR INDICATION Musculoskeletal Pain 464-49-3 D-CAMPHOR ADVERSE_EFFECT KID_2_Anuria 464-49-3 D-CAMPHOR ADVERSE_EFFECT NEU_1_Vertigo 464-49-3 D-CAMPHOR ADVERSE_EFFECT NEU_2_Seizures 464-49-3 D-CAMPHOR ADVERSE_EFFECT PSY_2_Hallucinations 464-49-3 D-CAMPHOR TISSUE_TOXICITY Anuria 464-49-3 D-CAMPHOR KNOWN_TOXICITY Nephrotoxicity 464-49-3 D-CAMPHOR THERAPEUTIC_CLASS Analgesics, Topical 464-49-3 D-CAMPHOR THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 464-49-3 D-CAMPHOR INDICATION Viral Rhinitis / Common Cold 7689-03-4 CAMPTOTHECIN ZERO_CLASS N 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT GIS_2_Dysphagia 7689-03-4 CAMPTOTHECIN THERAPEUTIC_CLASS Antineoplastics 7689-03-4 CAMPTOTHECIN MESH_LEVEL_3 Camptothecin 7689-03-4 CAMPTOTHECIN INDICATION Neoplasm / Cancer / Tumor 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT SKN_2_Dry Skin 7689-03-4 CAMPTOTHECIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 7689-03-4 CAMPTOTHECIN MODE_CLASS Enzyme Inhibitor 7689-03-4 CAMPTOTHECIN MESH_LEVEL_1 Heterocyclic Compounds 7689-03-4 CAMPTOTHECIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 7689-03-4 CAMPTOTHECIN PRODUCT_CLASS Anti-cancers 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT SKN_2_Pruritis 7689-03-4 CAMPTOTHECIN TA_LEVEL_1 Oncology 7689-03-4 CAMPTOTHECIN TA_LEVEL_2 toposiomerase inhibitors 7689-03-4 CAMPTOTHECIN MESH_LEVEL_2 Alkaloids 7689-03-4 CAMPTOTHECIN MECH_LEVEL_3 DNA topoisomerase 7689-03-4 CAMPTOTHECIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT GUS_2_Cystitis 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT XXX_2_Mucositis 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT BBM_3_Leukopenia 7689-03-4 CAMPTOTHECIN TA_LEVEL_3 Solid and soft Tumors 7689-03-4 CAMPTOTHECIN MECHANISM Inhibit DNA synthesis, repair, and function 7689-03-4 CAMPTOTHECIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT GIS_1_Diarrhea 7689-03-4 CAMPTOTHECIN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 7689-03-4 CAMPTOTHECIN ADVERSE_EFFECT BBM_3_Hematotoxicity 19685-09-7 CAMPTOTHECIN THERAPEUTIC_CLASS Antineoplastics 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT GIS_2_Dysphagia 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT SKN_2_Pruritis 19685-09-7 CAMPTOTHECIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 19685-09-7 CAMPTOTHECIN MESH_LEVEL_1 Heterocyclic Compounds 19685-09-7 CAMPTOTHECIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 19685-09-7 CAMPTOTHECIN TA_LEVEL_1 Oncology 19685-09-7 CAMPTOTHECIN TA_LEVEL_2 toposiomerase inhibitors 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT SKN_2_Dry Skin 19685-09-7 CAMPTOTHECIN MESH_LEVEL_2 Alkaloids 19685-09-7 CAMPTOTHECIN MECH_LEVEL_3 DNA topoisomerase 19685-09-7 CAMPTOTHECIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT GUS_2_Cystitis 19685-09-7 CAMPTOTHECIN MODE_CLASS Enzyme Inhibitor 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 19685-09-7 CAMPTOTHECIN TA_LEVEL_3 Solid and soft Tumors 19685-09-7 CAMPTOTHECIN MECHANISM Inhibit DNA synthesis, repair, and function 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT BBM_3_Hematotoxicity 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT GIS_1_Diarrhea 19685-09-7 CAMPTOTHECIN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 19685-09-7 CAMPTOTHECIN INDICATION Neoplasm / Cancer / Tumor 19685-09-7 CAMPTOTHECIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 19685-09-7 CAMPTOTHECIN MESH_LEVEL_3 Camptothecin 19685-09-7 CAMPTOTHECIN ZERO_CLASS N 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT XXX_2_Mucositis 19685-09-7 CAMPTOTHECIN PRODUCT_CLASS Anti-cancers 19685-09-7 CAMPTOTHECIN ADVERSE_EFFECT BBM_3_Leukopenia 25387-67-1 CAMPTOTHECIN MODE_CLASS Enzyme Inhibitor 25387-67-1 CAMPTOTHECIN MESH_LEVEL_1 Heterocyclic Compounds 25387-67-1 CAMPTOTHECIN PRODUCT_CLASS Anti-cancers 25387-67-1 CAMPTOTHECIN THERAPEUTIC_CLASS Antineoplastics 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT GIS_2_Dysphagia 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT SKN_2_Pruritis 25387-67-1 CAMPTOTHECIN ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 25387-67-1 CAMPTOTHECIN ZERO_CLASS N 25387-67-1 CAMPTOTHECIN TA_LEVEL_1 Oncology 25387-67-1 CAMPTOTHECIN TA_LEVEL_2 toposiomerase inhibitors 25387-67-1 CAMPTOTHECIN MESH_LEVEL_2 Alkaloids 25387-67-1 CAMPTOTHECIN MECH_LEVEL_3 DNA topoisomerase 25387-67-1 CAMPTOTHECIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT GUS_2_Cystitis 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT XXX_2_Mucositis 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT BBM_3_Leukopenia 25387-67-1 CAMPTOTHECIN TA_LEVEL_3 Solid and soft Tumors 25387-67-1 CAMPTOTHECIN MECHANISM Inhibit DNA synthesis, repair, and function 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT BBM_3_Hematotoxicity 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT GIS_1_Diarrhea 25387-67-1 CAMPTOTHECIN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 25387-67-1 CAMPTOTHECIN MESH_LEVEL_3 Camptothecin 25387-67-1 CAMPTOTHECIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 25387-67-1 CAMPTOTHECIN INDICATION Neoplasm / Cancer / Tumor 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 25387-67-1 CAMPTOTHECIN ADVERSE_EFFECT SKN_2_Dry Skin 25387-67-1 CAMPTOTHECIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT BBM_3_Leukopenia 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT LUN_2_Cough 145040-37-5 CANDESARTAN CILEXETIL THERAPEUTIC_CLASS Antihypertensive Agents 145040-37-5 CANDESARTAN CILEXETIL KNOWN_TOXICITY Cardiovascular Toxicity 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT KID_3_Hyperuricemia 145040-37-5 CANDESARTAN CILEXETIL STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT NEU_2_Dizziness 145040-37-5 CANDESARTAN CILEXETIL MODE_CLASS Receptor Ligand Antagonist, Selective 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT EMB_3_Oligohydramnios 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT EMB_3_Fetal Renal Damage 145040-37-5 CANDESARTAN CILEXETIL MECHANISM Reduce vasoconstriction 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT BBM_3_Agranulocytosis 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT CVS_3_Hypotension 145040-37-5 CANDESARTAN CILEXETIL TISSUE_TOXICITY Hypotension 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT MSK_2_Back Pain 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT CVS_3_Tachycardia 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT NEU_2_Headache 145040-37-5 CANDESARTAN CILEXETIL INDICATION Hypertension 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 145040-37-5 CANDESARTAN CILEXETIL ADVERSE_EFFECT XXX_2_Peripheral Edema 145040-37-5 CANDESARTAN CILEXETIL PRODUCT_CLASS Cardiovasculars 56-25-7 CANTHARIDIN ADVERSE_EFFECT XXX_1_Burning Sensation 56-25-7 CANTHARIDIN INDICATION Warts 56-25-7 CANTHARIDIN PRODUCT_CLASS Dermatologicals 56-25-7 CANTHARIDIN ADVERSE_EFFECT XXX_1_Stinging Sensation 56-25-7 CANTHARIDIN THERAPEUTIC_CLASS Miscellaneous Dermatological Agents 56-25-7 CANTHARIDIN MECHANISM Modulate G-protein coupled signal transduction 56-25-7 CANTHARIDIN STRUCTURE_ACTIVITY Protein-serine/threonine phosphatase inhibitor 56-25-7 CANTHARIDIN MODE_CLASS Enzyme Inhibitor, selective 56-25-7 CANTHARIDIN ADVERSE_EFFECT SKN_1_Skin Irritation 56-25-7 CANTHARIDIN ADVERSE_EFFECT SKN_1_Erythema 56-25-7 CANTHARIDIN ADVERSE_EFFECT SKN_1_Blister Formation 104594-70-9 CAFFEIC ACID PHENETHYL ESTER PRODUCT_CLASS Biochemicals 104594-70-9 CAFFEIC ACID PHENETHYL ESTER MECHANISM Inhibit kinase mediated signal transduction 104594-70-9 CAFFEIC ACID PHENETHYL ESTER MODE_CLASS Enzyme Inhibitor 115610-29-2 CAFFEIC ACID PHENETHYL ESTER MECHANISM Inhibit kinase mediated signal transduction 115610-29-2 CAFFEIC ACID PHENETHYL ESTER PRODUCT_CLASS Biochemicals 115610-29-2 CAFFEIC ACID PHENETHYL ESTER MODE_CLASS Enzyme Inhibitor 132031-37-9 CAFFEIC ACID PHENETHYL ESTER PRODUCT_CLASS Biochemicals 132031-37-9 CAFFEIC ACID PHENETHYL ESTER MODE_CLASS Enzyme Inhibitor 132031-37-9 CAFFEIC ACID PHENETHYL ESTER MECHANISM Inhibit kinase mediated signal transduction 154361-50-9 CAPECITABINE INDICATION Breast Cancer / Carcinoma of the Breast 154361-50-9 CAPECITABINE MECHANISM Inhibit precursor synthesis 154361-50-9 CAPECITABINE STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 154361-50-9 CAPECITABINE MODE_CLASS Enzyme Inhibitor 11003-38-6 CAPREOMYCIN PRODUCT_CLASS Biochemicals 37280-35-6 CAPREOMYCIN PRODUCT_CLASS Biochemicals 404-86-4 CAPSAICIN PRODUCT_CLASS Analgesics 404-86-4 CAPSAICIN THERAPEUTIC_CLASS Analgesics, Topical 404-86-4 CAPSAICIN ADVERSE_EFFECT XXX_1_Stinging Sensation 404-86-4 CAPSAICIN ADVERSE_EFFECT XXX_1_Burning Sensation 404-86-4 CAPSAICIN ACTIVITY_CLASS Vanilloid receptor agonist 404-86-4 CAPSAICIN ADVERSE_EFFECT SKN_1_Skin Irritation 404-86-4 CAPSAICIN MESH_LEVEL_1 Organic Chemicals 404-86-4 CAPSAICIN INDICATION Neuropathic Pain 404-86-4 CAPSAICIN TA_LEVEL_2 Neuralgia 404-86-4 CAPSAICIN TA_LEVEL_1 Analgesics 404-86-4 CAPSAICIN ADVERSE_EFFECT LUN_1_Cough 404-86-4 CAPSAICIN INDICATION Diabetic Neuropathy 404-86-4 CAPSAICIN INDICATION Pain 404-86-4 CAPSAICIN ZERO_CLASS N 404-86-4 CAPSAICIN MECH_LEVEL_3 vanilloid receptor VR1 404-86-4 CAPSAICIN MECH_LEVEL_1 Modulate neural transmission 404-86-4 CAPSAICIN MECH_LEVEL_2 channel blocker 404-86-4 CAPSAICIN MESH_LEVEL_2 Carboxylic Acids 404-86-4 CAPSAICIN INDICATION Pruritus / Itching 404-86-4 CAPSAICIN INDICATION Arthralgia 404-86-4 CAPSAICIN MESH_LEVEL_3 Acids, Acyclic 404-86-4 CAPSAICIN INDICATION Osteoarthritis 404-86-4 CAPSAICIN INDICATION Rheumatoid Arthritis 404-86-4 CAPSAICIN TA_LEVEL_3 Analgesics, Topical 404-86-4 CAPSAICIN MECHANISM Modulate channel gating 404-86-4 CAPSAICIN STRUCTURE_ACTIVITY Vanilloid receptor agonist 404-86-4 CAPSAICIN MODE_CLASS Channel Modulator 404-86-4 CAPSAICIN INDICATION Postherpetic Neuralgia 138977-28-3 CAPSAZEPINE MODE_CLASS Receptor Ligand Antagonist 138977-28-3 CAPSAZEPINE MECHANISM Modulate channel gating 138977-28-3 CAPSAZEPINE PRODUCT_CLASS Biochemicals 77-22-5 CARAMIPHEN PRODUCT_CLASS Respiratory System 77-22-5 CARAMIPHEN MECHANISM Block channel gating 77-22-5 CARAMIPHEN MODE_CLASS Receptor Ligand Antagonist 77-22-5 CARAMIPHEN THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 77-22-5 CARAMIPHEN MECHANISM Block neural transmission 77-22-5 CARAMIPHEN INDICATION Cough / Tussis 77-22-5 CARAMIPHEN MODE_CLASS Channel Blocker 51-83-2 CARBACHOL PRODUCT_CLASS Other Human Uses 51-83-2 CARBACHOL TA_LEVEL_1 Ophthamology 51-83-2 CARBACHOL ADVERSE_EFFECT GUS_2_Frequent Urination 51-83-2 CARBACHOL MODE_CLASS Channel Modulator 51-83-2 CARBACHOL TA_LEVEL_3 anti-muscarinics 51-83-2 CARBACHOL MECH_LEVEL_3 Muscarinic acetylcholine receptor 51-83-2 CARBACHOL MECHANISM Prolong/enhance neural transmission 51-83-2 CARBACHOL ADVERSE_EFFECT XXX_1_Stinging Sensation 51-83-2 CARBACHOL KNOWN_TOXICITY Cardiovascular Toxicity 51-83-2 CARBACHOL ADVERSE_EFFECT XXX_2_Sweating 51-83-2 CARBACHOL ADVERSE_EFFECT LUN_2_Asthma 51-83-2 CARBACHOL ADVERSE_EFFECT OCU_2_Eye Irritation 51-83-2 CARBACHOL ADVERSE_EFFECT OCU_2_Ciliary Spasm 51-83-2 CARBACHOL ADVERSE_EFFECT NEU_2_Headache 51-83-2 CARBACHOL MECH_LEVEL_2 Cholinergic receptor agonist 51-83-2 CARBACHOL MODE_CLASS Receptor Agonist, Non-selective 51-83-2 CARBACHOL ZERO_CLASS N 51-83-2 CARBACHOL ADVERSE_EFFECT CVS_2_Hypotension 51-83-2 CARBACHOL TISSUE_TOXICITY Cardiac Arrhythmia 51-83-2 CARBACHOL TA_LEVEL_2 Antiglaucoma Agents 51-83-2 CARBACHOL MESH_LEVEL_3 Ammonium Compounds 51-83-2 CARBACHOL ACTIVITY_CLASS Muscarinic acetylcholine receptor agonist 51-83-2 CARBACHOL ADVERSE_EFFECT XXX_1_Burning Sensation 51-83-2 CARBACHOL ADVERSE_EFFECT OCU_2_Reddened Conjunctiva 51-83-2 CARBACHOL ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 51-83-2 CARBACHOL ADVERSE_EFFECT GIS_2_Diarrhea 51-83-2 CARBACHOL INDICATION Glaucoma 51-83-2 CARBACHOL ADVERSE_EFFECT NEU_2_Syncope 51-83-2 CARBACHOL ADVERSE_EFFECT GIS_2_Vomiting 51-83-2 CARBACHOL ADVERSE_EFFECT XXX_2_Salivation 51-83-2 CARBACHOL THERAPEUTIC_CLASS Antiglaucoma Agents 51-83-2 CARBACHOL MECHANISM Modulate G-protein coupled signal transduction 51-83-2 CARBACHOL MECH_LEVEL_1 Modulate neural transmission 51-83-2 CARBACHOL STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) agonist 51-83-2 CARBACHOL MESH_LEVEL_1 Organic Chemicals 51-83-2 CARBACHOL TISSUE_TOXICITY Hypotension 51-83-2 CARBACHOL MESH_LEVEL_2 Amines 124-43-6 CARBAMIDE PEROXIDE PRODUCT_CLASS Other Human Uses 124-43-6 CARBAMIDE PEROXIDE THERAPEUTIC_CLASS Dental Agents 124-43-6 CARBAMIDE PEROXIDE INDICATION Teeth Whitening 4697-36-3 CARBENICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 4697-36-3 CARBENICILLIN PRODUCT_CLASS Anti-infectives 4697-36-3 CARBENICILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 4697-36-3 CARBENICILLIN MODE_CLASS Enzyme Inhibitor 23142-01-0 CARBETAPENTANE MODE_CLASS Receptor Ligand Antagonist 23142-01-0 CARBETAPENTANE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 23142-01-0 CARBETAPENTANE PRODUCT_CLASS Respiratory System 23142-01-0 CARBETAPENTANE MODE_CLASS Receptor Agonist, selective 23142-01-0 CARBETAPENTANE STRUCTURE_ACTIVITY Sigma receptor modulator 23142-01-0 CARBETAPENTANE INDICATION Cough / Tussis 23142-01-0 CARBETAPENTANE MODE_CLASS Receptor Ligand Antagonist, Non-selective 23142-01-0 CARBETAPENTANE MECHANISM Modulate G-protein coupled signal transduction 23142-01-0 CARBETAPENTANE MECHANISM Modulate neural transmission 77-23-6 CARBETAPENTANE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 77-23-6 CARBETAPENTANE PRODUCT_CLASS Respiratory System 77-23-6 CARBETAPENTANE MODE_CLASS Receptor Agonist, selective 77-23-6 CARBETAPENTANE MODE_CLASS Receptor Ligand Antagonist 77-23-6 CARBETAPENTANE MECHANISM Modulate neural transmission 77-23-6 CARBETAPENTANE STRUCTURE_ACTIVITY Sigma receptor modulator 77-23-6 CARBETAPENTANE MODE_CLASS Receptor Ligand Antagonist, Non-selective 77-23-6 CARBETAPENTANE MECHANISM Modulate G-protein coupled signal transduction 77-23-6 CARBETAPENTANE INDICATION Cough / Tussis 5585-88-6 CARBETAPENTANE MODE_CLASS Receptor Agonist, selective 5585-88-6 CARBETAPENTANE MODE_CLASS Receptor Ligand Antagonist 5585-88-6 CARBETAPENTANE MECHANISM Modulate neural transmission 5585-88-6 CARBETAPENTANE MODE_CLASS Receptor Ligand Antagonist, Non-selective 5585-88-6 CARBETAPENTANE MECHANISM Modulate G-protein coupled signal transduction 5585-88-6 CARBETAPENTANE INDICATION Cough / Tussis 5585-88-6 CARBETAPENTANE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 5585-88-6 CARBETAPENTANE PRODUCT_CLASS Respiratory System 5585-88-6 CARBETAPENTANE STRUCTURE_ACTIVITY Sigma receptor modulator 38821-49-7 S(-)-CARBIDOPA MECHANISM Interferes with neural transmitter synthesis 38821-49-7 S(-)-CARBIDOPA ADVERSE_EFFECT NEU_3_Neurotoxicity 38821-49-7 S(-)-CARBIDOPA STRUCTURE_ACTIVITY Dopamine synthesis inhibitor, aromatic-L-amino-acid decarboxylase inhibitor 38821-49-7 S(-)-CARBIDOPA THERAPEUTIC_CLASS Movement Disorders 38821-49-7 S(-)-CARBIDOPA MESH_LEVEL_3 Catecholamines 38821-49-7 S(-)-CARBIDOPA TA_LEVEL_3 Parkinson's Disease 38821-49-7 S(-)-CARBIDOPA INDICATION Parkinsonism 38821-49-7 S(-)-CARBIDOPA MECH_LEVEL_3 Aromatic-L-amino-acid decarboxylase 38821-49-7 S(-)-CARBIDOPA PRODUCT_CLASS Central Nervous System (CNS) 38821-49-7 S(-)-CARBIDOPA TA_LEVEL_2 Dopamine modulators 38821-49-7 S(-)-CARBIDOPA TA_LEVEL_1 Central Nervous System (CNS) 38821-49-7 S(-)-CARBIDOPA MESH_LEVEL_2 Amines 38821-49-7 S(-)-CARBIDOPA INDICATION Parkinson's Disease 38821-49-7 S(-)-CARBIDOPA MECH_LEVEL_1 Modulate neural transmission 38821-49-7 S(-)-CARBIDOPA ADVERSE_EFFECT NEU_2_Dyskinesia 38821-49-7 S(-)-CARBIDOPA MECH_LEVEL_2 inhibit decarboxylation of levodopa to dopamine 38821-49-7 S(-)-CARBIDOPA ZERO_CLASS N 38821-49-7 S(-)-CARBIDOPA MODE_CLASS Enzyme Inhibitor 38821-49-7 S(-)-CARBIDOPA ACTIVITY_CLASS Dopamine antagonist 38821-49-7 S(-)-CARBIDOPA MESH_LEVEL_1 Organic Chemicals 28860-95-9 S(-)-CARBIDOPA MECH_LEVEL_2 inhibit decarboxylation of levodopa to dopamine 28860-95-9 S(-)-CARBIDOPA ADVERSE_EFFECT NEU_2_Dyskinesia 28860-95-9 S(-)-CARBIDOPA MESH_LEVEL_1 Organic Chemicals 28860-95-9 S(-)-CARBIDOPA MECH_LEVEL_1 Modulate neural transmission 28860-95-9 S(-)-CARBIDOPA INDICATION Parkinson's Disease 28860-95-9 S(-)-CARBIDOPA MESH_LEVEL_2 Amines 28860-95-9 S(-)-CARBIDOPA TA_LEVEL_1 Central Nervous System (CNS) 28860-95-9 S(-)-CARBIDOPA TA_LEVEL_2 Dopamine modulators 28860-95-9 S(-)-CARBIDOPA PRODUCT_CLASS Central Nervous System (CNS) 28860-95-9 S(-)-CARBIDOPA MECH_LEVEL_3 Aromatic-L-amino-acid decarboxylase 28860-95-9 S(-)-CARBIDOPA INDICATION Parkinsonism 28860-95-9 S(-)-CARBIDOPA MESH_LEVEL_3 Catecholamines 28860-95-9 S(-)-CARBIDOPA THERAPEUTIC_CLASS Movement Disorders 28860-95-9 S(-)-CARBIDOPA ACTIVITY_CLASS Dopamine antagonist 28860-95-9 S(-)-CARBIDOPA MODE_CLASS Enzyme Inhibitor 28860-95-9 S(-)-CARBIDOPA ZERO_CLASS N 28860-95-9 S(-)-CARBIDOPA MECHANISM Interferes with neural transmitter synthesis 28860-95-9 S(-)-CARBIDOPA ADVERSE_EFFECT NEU_3_Neurotoxicity 28860-95-9 S(-)-CARBIDOPA STRUCTURE_ACTIVITY Dopamine synthesis inhibitor, aromatic-L-amino-acid decarboxylase inhibitor 28860-95-9 S(-)-CARBIDOPA TA_LEVEL_3 Parkinson's Disease 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT PSY_2_Anorexia 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT NEU_3_Seizures 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT OCU_1_Eye Dryness 3505-38-2 CARBINOXAMINE INDICATION Rhinorrhea 3505-38-2 CARBINOXAMINE INDICATION Allergic Conjunctivitis 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT NEU_1_Drowsiness 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT PSY_3_Psychosis 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 3505-38-2 CARBINOXAMINE MODE_CLASS Receptor Ligand Antagonist 3505-38-2 CARBINOXAMINE INDICATION Allergic Rhinitis 3505-38-2 CARBINOXAMINE THERAPEUTIC_CLASS Antihistamines 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT CVS_3_Hypotension 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT XXX_2_Weakness 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT PSY_3_Confusion 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Dyspepsia 3505-38-2 CARBINOXAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 3505-38-2 CARBINOXAMINE MECHANISM Modulate G-protein coupled signal transduction 3505-38-2 CARBINOXAMINE PRODUCT_CLASS Anti-inflammatories 3505-38-2 CARBINOXAMINE INDICATION Pruritus / Itching 3505-38-2 CARBINOXAMINE KNOWN_TOXICITY Cardiovascular Toxicity 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT NEU_1_Sedation 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT NEU_3_Ataxia 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 3505-38-2 CARBINOXAMINE INDICATION Urticaria / Hives 3505-38-2 CARBINOXAMINE TISSUE_TOXICITY Hypotension 3505-38-2 CARBINOXAMINE ADVERSE_EFFECT PSY_1_CNS Depression 486-16-8 CARBINOXAMINE ADVERSE_EFFECT PSY_2_Anorexia 486-16-8 CARBINOXAMINE MECHANISM Modulate G-protein coupled signal transduction 486-16-8 CARBINOXAMINE PRODUCT_CLASS Anti-inflammatories 486-16-8 CARBINOXAMINE INDICATION Pruritus / Itching 486-16-8 CARBINOXAMINE KNOWN_TOXICITY Cardiovascular Toxicity 486-16-8 CARBINOXAMINE ADVERSE_EFFECT NEU_1_Sedation 486-16-8 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 486-16-8 CARBINOXAMINE ADVERSE_EFFECT NEU_3_Ataxia 486-16-8 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 486-16-8 CARBINOXAMINE INDICATION Allergic Rhinitis 486-16-8 CARBINOXAMINE MODE_CLASS Receptor Ligand Antagonist 486-16-8 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 486-16-8 CARBINOXAMINE ADVERSE_EFFECT PSY_3_Psychosis 486-16-8 CARBINOXAMINE ADVERSE_EFFECT NEU_1_Drowsiness 486-16-8 CARBINOXAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 486-16-8 CARBINOXAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 486-16-8 CARBINOXAMINE INDICATION Allergic Conjunctivitis 486-16-8 CARBINOXAMINE INDICATION Rhinorrhea 486-16-8 CARBINOXAMINE ADVERSE_EFFECT PSY_1_CNS Depression 486-16-8 CARBINOXAMINE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 486-16-8 CARBINOXAMINE THERAPEUTIC_CLASS Antihistamines 486-16-8 CARBINOXAMINE ADVERSE_EFFECT NEU_3_Seizures 486-16-8 CARBINOXAMINE ADVERSE_EFFECT IMU_3_Photosensitivity 486-16-8 CARBINOXAMINE ADVERSE_EFFECT OCU_1_Eye Dryness 486-16-8 CARBINOXAMINE TISSUE_TOXICITY Hypotension 486-16-8 CARBINOXAMINE ADVERSE_EFFECT GUS_3_Urinary Retention 486-16-8 CARBINOXAMINE INDICATION Urticaria / Hives 486-16-8 CARBINOXAMINE ADVERSE_EFFECT CVS_3_Hypotension 486-16-8 CARBINOXAMINE ADVERSE_EFFECT XXX_2_Weakness 486-16-8 CARBINOXAMINE ADVERSE_EFFECT PSY_3_Confusion 486-16-8 CARBINOXAMINE ADVERSE_EFFECT GIS_2_Dyspepsia 486-16-8 CARBINOXAMINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 555-60-2 CARBONYL CYANIDE 3-CHLOROPHENYLHYDRAZONE PRODUCT_CLASS Toxicants 555-60-2 CARBONYL CYANIDE 3-CHLOROPHENYLHYDRAZONE MECHANISM Inhibit mitochondrial function 555-60-2 CARBONYL CYANIDE 3-CHLOROPHENYLHYDRAZONE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 41575-94-4 CARBOPLATIN TISSUE_TOXICITY Hepatotoxicity 41575-94-4 CARBOPLATIN TISSUE_TOXICITY Neutropenia 41575-94-4 CARBOPLATIN ADVERSE_EFFECT OTO_2_Ototoxicity 41575-94-4 CARBOPLATIN ADVERSE_EFFECT XXX_1_Asthenia 41575-94-4 CARBOPLATIN ADVERSE_EFFECT KID_3_Reduced Creatine Clearance 41575-94-4 CARBOPLATIN ADVERSE_EFFECT BBM_1_Anemia 41575-94-4 CARBOPLATIN TA_LEVEL_3 Solid Tumors 41575-94-4 CARBOPLATIN ADVERSE_EFFECT BBM_1_Neutropenia 41575-94-4 CARBOPLATIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 41575-94-4 CARBOPLATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 41575-94-4 CARBOPLATIN ADVERSE_EFFECT BBM_1_Myelosuppression 41575-94-4 CARBOPLATIN ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 41575-94-4 CARBOPLATIN ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 41575-94-4 CARBOPLATIN TISSUE_TOXICITY Myelosuppression 41575-94-4 CARBOPLATIN ACTIVITY_CLASS DNA damager 41575-94-4 CARBOPLATIN MESH_LEVEL_3 Organoplatinum Compounds 41575-94-4 CARBOPLATIN MESH_LEVEL_1 Organic Chemicals 41575-94-4 CARBOPLATIN MECH_LEVEL_3 DNA damage 41575-94-4 CARBOPLATIN STRUCTURE_ACTIVITY DNA-alkylator, platin 41575-94-4 CARBOPLATIN TISSUE_TOXICITY Thrombocytopenia 41575-94-4 CARBOPLATIN TISSUE_TOXICITY Anemia 41575-94-4 CARBOPLATIN ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 41575-94-4 CARBOPLATIN ZERO_CLASS N 41575-94-4 CARBOPLATIN ADVERSE_EFFECT XXX_2_Mucositis 41575-94-4 CARBOPLATIN MECHANISM Inhibit DNA synthesis, repair, and function 41575-94-4 CARBOPLATIN INDICATION Ovarian Cancer / Carcinoma of the Ovary 41575-94-4 CARBOPLATIN PRODUCT_CLASS Anti-cancers 41575-94-4 CARBOPLATIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 41575-94-4 CARBOPLATIN TA_LEVEL_2 DNA damage 41575-94-4 CARBOPLATIN TISSUE_TOXICITY Leukopenia 41575-94-4 CARBOPLATIN ADVERSE_EFFECT BBM_3_Bleeding 41575-94-4 CARBOPLATIN ADVERSE_EFFECT BBM_1_Leukopenia 41575-94-4 CARBOPLATIN ADVERSE_EFFECT BBM_1_Thrombocytopenia 41575-94-4 CARBOPLATIN ADVERSE_EFFECT GIS_1_Vomiting 41575-94-4 CARBOPLATIN ADVERSE_EFFECT XXX_2_Infection 41575-94-4 CARBOPLATIN TA_LEVEL_1 Oncology 41575-94-4 CARBOPLATIN KNOWN_TOXICITY Blood & Bone Marrow Toxicity 41575-94-4 CARBOPLATIN THERAPEUTIC_CLASS Antineoplastics 41575-94-4 CARBOPLATIN MESH_LEVEL_2 Organometallic Compounds 41575-94-4 CARBOPLATIN ADVERSE_EFFECT XXX_2_Pain 41575-94-4 CARBOPLATIN KNOWN_TOXICITY Hepatotoxicity 41575-94-4 CARBOPLATIN INDICATION Neoplasm / Cancer / Tumor 41575-94-4 CARBOPLATIN MODE_CLASS Distorts /blocks macromolecular scaffold function 35700-23-3 CARBOPROST MECHANISM Modulate G-protein coupled signal transduction 35700-23-3 CARBOPROST MODE_CLASS Receptor Agonist 78-44-4 CARISOPRODOL ADVERSE_EFFECT OCU_3_Abnormal Vision 78-44-4 CARISOPRODOL PRODUCT_CLASS Central Nervous System (CNS) 78-44-4 CARISOPRODOL ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 78-44-4 CARISOPRODOL ADVERSE_EFFECT XXX_3_Weakness 78-44-4 CARISOPRODOL ADVERSE_EFFECT IMU_3_Allergic Reactions 78-44-4 CARISOPRODOL ADVERSE_EFFECT XXX_3_Lethargy 78-44-4 CARISOPRODOL ADVERSE_EFFECT PSY_3_Irritation 78-44-4 CARISOPRODOL MECHANISM Block neural transmission 78-44-4 CARISOPRODOL INDICATION Skeletal Muscle Spasm 78-44-4 CARISOPRODOL THERAPEUTIC_CLASS Skeletal Muscle Relaxants 78-44-4 CARISOPRODOL ADVERSE_EFFECT PSY_3_Depression 78-44-4 CARISOPRODOL ADVERSE_EFFECT GIS_3_Nausea / Vomiting 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_1_Dizziness 78-44-4 CARISOPRODOL ADVERSE_EFFECT PSY_3_Confusion 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_3_Vertigo 78-44-4 CARISOPRODOL ADVERSE_EFFECT XXX_3_Hiccup 78-44-4 CARISOPRODOL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 78-44-4 CARISOPRODOL MECHANISM Modulate neural transmission 78-44-4 CARISOPRODOL ADVERSE_EFFECT OCU_3_Mydriasis 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_3_Tremor 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_3_Headache 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_3_Ataxia 78-44-4 CARISOPRODOL ADVERSE_EFFECT PSY_3_Agitation 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_3_Syncope 78-44-4 CARISOPRODOL ADVERSE_EFFECT CVS_3_Tachycardia 78-44-4 CARISOPRODOL ADVERSE_EFFECT PSY_3_Insomnia 78-44-4 CARISOPRODOL ADVERSE_EFFECT SKN_3_Flushing 78-44-4 CARISOPRODOL ADVERSE_EFFECT NEU_1_Drowsiness 78-44-4 CARISOPRODOL ADVERSE_EFFECT PSY_3_Disorientation 78-44-4 CARISOPRODOL MODE_CLASS Channel Blocker 78-44-4 CARISOPRODOL MODE_CLASS Channel Modulator 154-93-8 CARMUSTINE PRODUCT_CLASS Anti-cancers 154-93-8 CARMUSTINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 154-93-8 CARMUSTINE ADVERSE_EFFECT XXX_1_Fever 154-93-8 CARMUSTINE ADVERSE_EFFECT SKN_2_Rash 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_3_Stupor 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_2_Cerebral Edema 154-93-8 CARMUSTINE MODE_CLASS Distorts /blocks macromolecular scaffold function 154-93-8 CARMUSTINE KNOWN_TOXICITY Cardiovascular Toxicity 154-93-8 CARMUSTINE MESH_LEVEL_3 Nitrosourea Compounds 154-93-8 CARMUSTINE MESH_LEVEL_1 Organic Chemicals 154-93-8 CARMUSTINE MECH_LEVEL_3 DNA damage 154-93-8 CARMUSTINE TA_LEVEL_3 Solid Tumors 154-93-8 CARMUSTINE INDICATION Glioblastoma Multiforme 154-93-8 CARMUSTINE TA_LEVEL_1 Oncology 154-93-8 CARMUSTINE THERAPEUTIC_CLASS Antineoplastics 154-93-8 CARMUSTINE ACTIVITY_CLASS DNA damager 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_2_Headache 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_3_Aphasia 154-93-8 CARMUSTINE ADVERSE_EFFECT GUS_2_Urinary Tract Infection 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_2_Meningitis 154-93-8 CARMUSTINE ZERO_CLASS N 154-93-8 CARMUSTINE STRUCTURE_ACTIVITY DNA damaging, free oxygen radical generator, nitrosourea 154-93-8 CARMUSTINE MESH_LEVEL_2 Nitroso Compounds 154-93-8 CARMUSTINE ADVERSE_EFFECT GIS_2_Vomiting 154-93-8 CARMUSTINE ADVERSE_EFFECT PSY_2_Confusion 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_2_Somnolence 154-93-8 CARMUSTINE ADVERSE_EFFECT CVS_3_Intracranial Hypertension 154-93-8 CARMUSTINE TA_LEVEL_2 DNA damage 154-93-8 CARMUSTINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 154-93-8 CARMUSTINE MECHANISM Inhibit DNA synthesis, repair, and function 154-93-8 CARMUSTINE ADVERSE_EFFECT GIS_2_Nausea 154-93-8 CARMUSTINE ADVERSE_EFFECT XXX_1_Pain 154-93-8 CARMUSTINE ADVERSE_EFFECT LUN_3_Pulmonary Embolism 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_3_Hemiplegia 154-93-8 CARMUSTINE TISSUE_TOXICITY Intracranial Hypertension 154-93-8 CARMUSTINE ADVERSE_EFFECT NEU_3_Convulsions 51781-06-7 CARTEOLOL THERAPEUTIC_CLASS Antihypertensive Agents 51781-06-7 CARTEOLOL INDICATION Open-Angle Glaucoma 51781-06-7 CARTEOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 51781-06-7 CARTEOLOL MECHANISM Reduce muscle contractile force 51781-06-7 CARTEOLOL INDICATION Increased Intraocular Pressure 51781-06-7 CARTEOLOL PRODUCT_CLASS Cardiovasculars 51781-06-7 CARTEOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 51781-06-7 CARTEOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 51781-06-7 CARTEOLOL MECHANISM Modulate G-protein coupled signal transduction 51781-06-7 CARTEOLOL INDICATION Hypertension 51781-21-6 CARTEOLOL MECHANISM Modulate G-protein coupled signal transduction 51781-21-6 CARTEOLOL INDICATION Increased Intraocular Pressure 51781-21-6 CARTEOLOL THERAPEUTIC_CLASS Antihypertensive Agents 51781-21-6 CARTEOLOL PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 51781-21-6 CARTEOLOL MECHANISM Reduce muscle contractile force 51781-21-6 CARTEOLOL INDICATION Hypertension 51781-21-6 CARTEOLOL PRODUCT_CLASS Cardiovasculars 51781-21-6 CARTEOLOL THERAPEUTIC_CLASS Antiglaucoma Agents 51781-21-6 CARTEOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 51781-21-6 CARTEOLOL INDICATION Open-Angle Glaucoma 72956-09-3 CARVEDILOL ADVERSE_EFFECT NEU_2_Syncope 72956-09-3 CARVEDILOL ADVERSE_EFFECT GUS_3_Discoloration of Urine 72956-09-3 CARVEDILOL ADVERSE_EFFECT BBM_3_Thrombocytopenia 72956-09-3 CARVEDILOL ADVERSE_EFFECT LUN_1_Bronchospasm 72956-09-3 CARVEDILOL ADVERSE_EFFECT XXX_1_Fatigue 72956-09-3 CARVEDILOL ADVERSE_EFFECT PSY_2_Insomnia 72956-09-3 CARVEDILOL THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 72956-09-3 CARVEDILOL INDICATION Cardiomyopathy 72956-09-3 CARVEDILOL MESH_LEVEL_1 Heterocyclic Compounds 72956-09-3 CARVEDILOL PRODUCT_CLASS Cardiovasculars 72956-09-3 CARVEDILOL TA_LEVEL_2 beta antagonists 72956-09-3 CARVEDILOL INDICATION Hypertension 72956-09-3 CARVEDILOL MODE_CLASS Channel Blocker 72956-09-3 CARVEDILOL ADVERSE_EFFECT MSK_2_Back Pain 72956-09-3 CARVEDILOL ADVERSE_EFFECT NEU_1_Vertigo 72956-09-3 CARVEDILOL ADVERSE_EFFECT SKN_1_Pruritis 72956-09-3 CARVEDILOL ADVERSE_EFFECT NEU_1_Headache 72956-09-3 CARVEDILOL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 72956-09-3 CARVEDILOL MECH_LEVEL_2 beta blocker 72956-09-3 CARVEDILOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 72956-09-3 CARVEDILOL ACTIVITY_CLASS Adrenergic antagonist 72956-09-3 CARVEDILOL ADVERSE_EFFECT XXX_3_Rhinitis 72956-09-3 CARVEDILOL ADVERSE_EFFECT LIV_3_Jaundice 72956-09-3 CARVEDILOL ADVERSE_EFFECT LUN_3_Dyspnea 72956-09-3 CARVEDILOL ADVERSE_EFFECT NEU_2_Dizziness 72956-09-3 CARVEDILOL ADVERSE_EFFECT END_3_Hypoglycemia 72956-09-3 CARVEDILOL ADVERSE_EFFECT GIS_2_Diarrhea 72956-09-3 CARVEDILOL THERAPEUTIC_CLASS Congestive Heart Failure 72956-09-3 CARVEDILOL MECHANISM Block neural transmission 72956-09-3 CARVEDILOL MECH_LEVEL_3 adrenoceptor beta 72956-09-3 CARVEDILOL ZERO_CLASS N 72956-09-3 CARVEDILOL ADVERSE_EFFECT XXX_3_Pharyngitis 72956-09-3 CARVEDILOL ADVERSE_EFFECT GIS_3_Abdominal Pain 72956-09-3 CARVEDILOL ADVERSE_EFFECT XXX_3_Peripheral Edema 72956-09-3 CARVEDILOL ADVERSE_EFFECT END_2_Hypertriglyceridemia 72956-09-3 CARVEDILOL ADVERSE_EFFECT END_3_Hyperglycemia 72956-09-3 CARVEDILOL ADVERSE_EFFECT PSY_3_Anorexia 72956-09-3 CARVEDILOL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 72956-09-3 CARVEDILOL THERAPEUTIC_CLASS Antihypertensive Agents 72956-09-3 CARVEDILOL INDICATION Acute Myocardial Infarction 72956-09-3 CARVEDILOL MECH_LEVEL_1 Modulate neural transmission 72956-09-3 CARVEDILOL MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 72956-09-3 CARVEDILOL MESH_LEVEL_3 Carbazoles 72956-09-3 CARVEDILOL MODE_CLASS Receptor Ligand Antagonist, Non-selective 72956-09-3 CARVEDILOL TA_LEVEL_1 Cardiovascular 72956-09-3 CARVEDILOL INDICATION Congestive Heart Failure (CHF) 72956-09-3 CARVEDILOL MECHANISM Reduce muscle contractile force 79831-76-8 CASTANOSPERMINE INDICATION Myocardial Ischemia 79831-76-8 CASTANOSPERMINE INDICATION Diabetes 35144-91-3 GASTRIN TETRAPEPTIDE MODE_CLASS Receptor Agonist 35144-91-3 GASTRIN TETRAPEPTIDE MECHANISM Modulate G-protein coupled signal transduction 1947-37-1 GASTRIN TETRAPEPTIDE MODE_CLASS Receptor Agonist 1947-37-1 GASTRIN TETRAPEPTIDE MECHANISM Modulate G-protein coupled signal transduction 53994-73-3 CEFACLOR PRODUCT_CLASS Anti-infectives 53994-73-3 CEFACLOR MECHANISM Inhibit bacterial cell wall biosynthesis 53994-73-3 CEFACLOR THERAPEUTIC_CLASS Antibacterials, Systemic 53994-73-3 CEFACLOR MODE_CLASS Enzyme Inhibitor 70356-03-5 CEFACLOR MODE_CLASS Enzyme Inhibitor 70356-03-5 CEFACLOR PRODUCT_CLASS Anti-infectives 70356-03-5 CEFACLOR MECHANISM Inhibit bacterial cell wall biosynthesis 70356-03-5 CEFACLOR THERAPEUTIC_CLASS Antibacterials, Systemic 50370-12-2 CEFADROXIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 50370-12-2 CEFADROXIL ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 50370-12-2 CEFADROXIL MODE_CLASS Enzyme Inhibitor 50370-12-2 CEFADROXIL INDICATION Pharyngitis 50370-12-2 CEFADROXIL THERAPEUTIC_CLASS Antibacterials, Systemic 50370-12-2 CEFADROXIL ADVERSE_EFFECT IMU_3_Hypersensitivity 50370-12-2 CEFADROXIL ADVERSE_EFFECT IMU_3_Urticaria 50370-12-2 CEFADROXIL KNOWN_TOXICITY Nephrotoxicity 50370-12-2 CEFADROXIL STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 50370-12-2 CEFADROXIL ADVERSE_EFFECT BBM_3_Leukopenia 50370-12-2 CEFADROXIL ADVERSE_EFFECT SKN_3_Maculopapular Rash 50370-12-2 CEFADROXIL ADVERSE_EFFECT XXX_3_Superinfection 50370-12-2 CEFADROXIL ADVERSE_EFFECT BBM_3_Neutropenia 50370-12-2 CEFADROXIL INDICATION Streptococcal Infections 50370-12-2 CEFADROXIL INDICATION Endocarditis Prophylaxis 50370-12-2 CEFADROXIL ADVERSE_EFFECT GIS_1_Diarrhea 50370-12-2 CEFADROXIL ADVERSE_EFFECT BBM_3_Anemia 50370-12-2 CEFADROXIL ADVERSE_EFFECT KID_3_Nephrotoxicity 50370-12-2 CEFADROXIL ADVERSE_EFFECT KID_3_Interstitial Nephritis 50370-12-2 CEFADROXIL INDICATION Tonsillitis 50370-12-2 CEFADROXIL TISSUE_TOXICITY Interstitial Nephritis 50370-12-2 CEFADROXIL ADVERSE_EFFECT NEU_3_Seizures 50370-12-2 CEFADROXIL INDICATION Urinary Tract Infection (UTI) 50370-12-2 CEFADROXIL PRODUCT_CLASS Anti-infectives 50370-12-2 CEFADROXIL INDICATION Skin and Skin Structure Infections 50370-12-2 CEFADROXIL INDICATION Impetigo 50370-12-2 CEFADROXIL MECHANISM Inhibit bacterial cell wall biosynthesis 50370-12-2 CEFADROXIL TISSUE_TOXICITY Nephrotoxicity 42540-40-9 CEFAMANDOLE MODE_CLASS Enzyme Inhibitor 42540-40-9 CEFAMANDOLE INDICATION Intraabdominal Infections 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT NEU_3_Seizures 42540-40-9 CEFAMANDOLE THERAPEUTIC_CLASS Antibacterials, Systemic 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT CVS_2_Phlebitis 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT XXX_2_Drug Fever 42540-40-9 CEFAMANDOLE STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 42540-40-9 CEFAMANDOLE INDICATION Skin and Skin Structure Infections 42540-40-9 CEFAMANDOLE INDICATION Bone and Joint Infection 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT IMU_2_Hypersensitivity 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT IMU_2_Urticaria 42540-40-9 CEFAMANDOLE INDICATION Urinary Tract Infection (UTI) 42540-40-9 CEFAMANDOLE INDICATION Septicemia 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 42540-40-9 CEFAMANDOLE PRODUCT_CLASS Anti-infectives 42540-40-9 CEFAMANDOLE INDICATION Surgical Prophylaxis 42540-40-9 CEFAMANDOLE INDICATION Bronchopulmonary Infection 42540-40-9 CEFAMANDOLE MECHANISM Inhibit bacterial cell wall biosynthesis 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT SKN_2_Maculopapular Rash 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT XXX_3_Superinfection 42540-40-9 CEFAMANDOLE ADVERSE_EFFECT XXX_2_Injection Site Reaction 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT XXX_2_Drug Fever 34444-01-4 CEFAMANDOLE STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 34444-01-4 CEFAMANDOLE INDICATION Skin and Skin Structure Infections 34444-01-4 CEFAMANDOLE INDICATION Bone and Joint Infection 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT IMU_2_Hypersensitivity 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 34444-01-4 CEFAMANDOLE INDICATION Surgical Prophylaxis 34444-01-4 CEFAMANDOLE INDICATION Bronchopulmonary Infection 34444-01-4 CEFAMANDOLE MECHANISM Inhibit bacterial cell wall biosynthesis 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT SKN_2_Maculopapular Rash 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT XXX_3_Superinfection 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT XXX_2_Injection Site Reaction 34444-01-4 CEFAMANDOLE MODE_CLASS Enzyme Inhibitor 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT IMU_2_Urticaria 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 34444-01-4 CEFAMANDOLE THERAPEUTIC_CLASS Antibacterials, Systemic 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT NEU_3_Seizures 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT CVS_2_Phlebitis 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 34444-01-4 CEFAMANDOLE INDICATION Septicemia 34444-01-4 CEFAMANDOLE INDICATION Urinary Tract Infection (UTI) 34444-01-4 CEFAMANDOLE INDICATION Intraabdominal Infections 34444-01-4 CEFAMANDOLE ADVERSE_EFFECT KID_2_Increased Blood Urea Nitrogen 34444-01-4 CEFAMANDOLE PRODUCT_CLASS Anti-infectives 25953-19-9 CEFAZOLIN PRODUCT_CLASS Anti-infectives 25953-19-9 CEFAZOLIN THERAPEUTIC_CLASS Antibacterials, Systemic 25953-19-9 CEFAZOLIN MODE_CLASS Enzyme Inhibitor 25953-19-9 CEFAZOLIN MECHANISM Inhibit bacterial cell wall biosynthesis 27164-46-1 CEFAZOLIN PRODUCT_CLASS Anti-infectives 27164-46-1 CEFAZOLIN THERAPEUTIC_CLASS Antibacterials, Systemic 27164-46-1 CEFAZOLIN MODE_CLASS Enzyme Inhibitor 27164-46-1 CEFAZOLIN MECHANISM Inhibit bacterial cell wall biosynthesis 135889-00-8 CEFCAPENE PRODUCT_CLASS Anti-infectives 135889-00-8 CEFCAPENE THERAPEUTIC_CLASS Antibacterials, Systemic 135889-00-8 CEFCAPENE MODE_CLASS Enzyme Inhibitor 135889-00-8 CEFCAPENE MECHANISM Inhibit bacterial cell wall biosynthesis 88040-23-7 CEFEPIME MECHANISM Inhibit bacterial cell wall biosynthesis 88040-23-7 CEFEPIME PRODUCT_CLASS Anti-infectives 88040-23-7 CEFEPIME THERAPEUTIC_CLASS Antibacterials, Systemic 88040-23-7 CEFEPIME MODE_CLASS Enzyme Inhibitor 143892-90-4 CEFEPIME MODE_CLASS Enzyme Inhibitor 143892-90-4 CEFEPIME THERAPEUTIC_CLASS Antibacterials, Systemic 143892-90-4 CEFEPIME PRODUCT_CLASS Anti-infectives 143892-90-4 CEFEPIME MECHANISM Inhibit bacterial cell wall biosynthesis 79350-37-1 CEFIXIME MECHANISM Inhibit bacterial cell wall biosynthesis 79350-37-1 CEFIXIME PRODUCT_CLASS Anti-infectives 79350-37-1 CEFIXIME THERAPEUTIC_CLASS Antibacterials, Systemic 79350-37-1 CEFIXIME MODE_CLASS Enzyme Inhibitor 56796-20-4 CEFMETAZOLE INDICATION Urinary Tract Infection (UTI) 56796-20-4 CEFMETAZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 56796-20-4 CEFMETAZOLE MODE_CLASS Enzyme Inhibitor 56796-20-4 CEFMETAZOLE INDICATION Surgical Prophylaxis 56796-20-4 CEFMETAZOLE INDICATION Intra-Abdominal Infections 56796-20-4 CEFMETAZOLE PRODUCT_CLASS Anti-infectives 56796-20-4 CEFMETAZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 56796-20-4 CEFMETAZOLE ADVERSE_EFFECT NEU_3_Seizures 56796-20-4 CEFMETAZOLE INDICATION Gonococcal Infections / Gonorrhea 56796-20-4 CEFMETAZOLE INDICATION Lower Respiratory Tract Infection 56796-20-4 CEFMETAZOLE THERAPEUTIC_CLASS Antibacterials, Systemic 56796-20-4 CEFMETAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56796-20-4 CEFMETAZOLE ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 56796-20-4 CEFMETAZOLE STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 56796-20-4 CEFMETAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 56796-20-4 CEFMETAZOLE INDICATION Skin and Skin Structure Infections 56796-20-4 CEFMETAZOLE ADVERSE_EFFECT XXX_3_Superinfection 56796-39-5 CEFMETAZOLE THERAPEUTIC_CLASS Antibacterials, Systemic 56796-39-5 CEFMETAZOLE INDICATION Urinary Tract Infection (UTI) 56796-39-5 CEFMETAZOLE ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 56796-39-5 CEFMETAZOLE MODE_CLASS Enzyme Inhibitor 56796-39-5 CEFMETAZOLE INDICATION Surgical Prophylaxis 56796-39-5 CEFMETAZOLE INDICATION Intra-Abdominal Infections 56796-39-5 CEFMETAZOLE PRODUCT_CLASS Anti-infectives 56796-39-5 CEFMETAZOLE MECHANISM Inhibit bacterial cell wall biosynthesis 56796-39-5 CEFMETAZOLE ADVERSE_EFFECT NEU_3_Seizures 56796-39-5 CEFMETAZOLE INDICATION Gonococcal Infections / Gonorrhea 56796-39-5 CEFMETAZOLE INDICATION Lower Respiratory Tract Infection 56796-39-5 CEFMETAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56796-39-5 CEFMETAZOLE ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 56796-39-5 CEFMETAZOLE STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 56796-39-5 CEFMETAZOLE INDICATION Skin and Skin Structure Infections 56796-39-5 CEFMETAZOLE ADVERSE_EFFECT GIS_1_Diarrhea 56796-39-5 CEFMETAZOLE ADVERSE_EFFECT XXX_3_Superinfection 61270-58-4 CEFONICID PRODUCT_CLASS Anti-infectives 61270-58-4 CEFONICID THERAPEUTIC_CLASS Antibacterials, Systemic 61270-58-4 CEFONICID MECHANISM Inhibit bacterial cell wall biosynthesis 61270-58-4 CEFONICID MODE_CLASS Enzyme Inhibitor 61270-78-8 CEFONICID PRODUCT_CLASS Anti-infectives 61270-78-8 CEFONICID THERAPEUTIC_CLASS Antibacterials, Systemic 61270-78-8 CEFONICID MECHANISM Inhibit bacterial cell wall biosynthesis 61270-78-8 CEFONICID MODE_CLASS Enzyme Inhibitor 62893-19-0 CEFOPERAZONE MECHANISM Inhibit bacterial cell wall biosynthesis 62893-19-0 CEFOPERAZONE THERAPEUTIC_CLASS Antibacterials, Systemic 62893-19-0 CEFOPERAZONE PRODUCT_CLASS Anti-infectives 62893-19-0 CEFOPERAZONE MODE_CLASS Enzyme Inhibitor 72448-63-6 CEFOPERAZONE THERAPEUTIC_CLASS Antibacterials, Systemic 72448-63-6 CEFOPERAZONE PRODUCT_CLASS Anti-infectives 72448-63-6 CEFOPERAZONE MODE_CLASS Enzyme Inhibitor 72448-63-6 CEFOPERAZONE MECHANISM Inhibit bacterial cell wall biosynthesis 62893-20-3 CEFOPERAZONE MECHANISM Inhibit bacterial cell wall biosynthesis 62893-20-3 CEFOPERAZONE THERAPEUTIC_CLASS Antibacterials, Systemic 62893-20-3 CEFOPERAZONE PRODUCT_CLASS Anti-infectives 62893-20-3 CEFOPERAZONE MODE_CLASS Enzyme Inhibitor 122841-10-5 CEFOSELIS MECHANISM Inhibit bacterial cell wall biosynthesis 122841-10-5 CEFOSELIS PRODUCT_CLASS Anti-infectives 122841-10-5 CEFOSELIS THERAPEUTIC_CLASS Antibacterials, Systemic 122841-10-5 CEFOSELIS MODE_CLASS Enzyme Inhibitor 63527-52-6 CEFOTAXIME MECHANISM Inhibit bacterial cell wall biosynthesis 63527-52-6 CEFOTAXIME INDICATION Sepsis 63527-52-6 CEFOTAXIME MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 63527-52-6 CEFOTAXIME STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 63527-52-6 CEFOTAXIME TA_LEVEL_3 systemic infections 63527-52-6 CEFOTAXIME ADVERSE_EFFECT KID_3_Interstitial Nephritis 63527-52-6 CEFOTAXIME KNOWN_TOXICITY Immune System Toxicity 63527-52-6 CEFOTAXIME INDICATION Meningitis 63527-52-6 CEFOTAXIME INDICATION Urinary Tract Infection (UTI) 63527-52-6 CEFOTAXIME ADVERSE_EFFECT IMU_1_Eosinophilia 63527-52-6 CEFOTAXIME ADVERSE_EFFECT IMU_1_Urticaria 63527-52-6 CEFOTAXIME ADVERSE_EFFECT NEU_3_Headache 63527-52-6 CEFOTAXIME ADVERSE_EFFECT GIS_2_Diarrhea 63527-52-6 CEFOTAXIME INDICATION Skin and Skin Structure Infections 63527-52-6 CEFOTAXIME INDICATION Pelvic Inflammatory Disease (PID) 63527-52-6 CEFOTAXIME TA_LEVEL_2 Anti-bacterial 63527-52-6 CEFOTAXIME MESH_LEVEL_3 Lactams 63527-52-6 CEFOTAXIME PRODUCT_CLASS Anti-infectives 63527-52-6 CEFOTAXIME INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 63527-52-6 CEFOTAXIME INDICATION Respiratory Tract Infection 63527-52-6 CEFOTAXIME KNOWN_TOXICITY Nephrotoxicity 63527-52-6 CEFOTAXIME MODE_CLASS Enzyme Inhibitor 63527-52-6 CEFOTAXIME THERAPEUTIC_CLASS Antibacterials 63527-52-6 CEFOTAXIME ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 63527-52-6 CEFOTAXIME ADVERSE_EFFECT SKN_1_Rash 63527-52-6 CEFOTAXIME ADVERSE_EFFECT CVS_3_Arrhythmia 63527-52-6 CEFOTAXIME MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 63527-52-6 CEFOTAXIME ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 63527-52-6 CEFOTAXIME MESH_LEVEL_1 Organic Chemicals 63527-52-6 CEFOTAXIME INDICATION Bone and Joint Infection 63527-52-6 CEFOTAXIME MECH_LEVEL_1 Anti-bacterial 63527-52-6 CEFOTAXIME INDICATION Bacteremia 63527-52-6 CEFOTAXIME INDICATION Ventriculitis 63527-52-6 CEFOTAXIME TISSUE_TOXICITY Arrhythmia 63527-52-6 CEFOTAXIME ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 63527-52-6 CEFOTAXIME TA_LEVEL_1 Infectious Disease 63527-52-6 CEFOTAXIME MESH_LEVEL_2 Amides 63527-52-6 CEFOTAXIME INDICATION Endometritis 63527-52-6 CEFOTAXIME ADVERSE_EFFECT SKN_1_Pruritis 63527-52-6 CEFOTAXIME INDICATION Peritonitis 63527-52-6 CEFOTAXIME ADVERSE_EFFECT BBM_3_Neutropenia 63527-52-6 CEFOTAXIME ADVERSE_EFFECT XXX_1_Fever 63527-52-6 CEFOTAXIME ADVERSE_EFFECT GIS_2_Colitis 63527-52-6 CEFOTAXIME INDICATION Gonoccocal Cervicitis 63527-52-6 CEFOTAXIME ADVERSE_EFFECT GIS_3_Vomiting 63527-52-6 CEFOTAXIME ADVERSE_EFFECT GUS_3_Vaginitis 63527-52-6 CEFOTAXIME TISSUE_TOXICITY Interstitial Nephritis 63527-52-6 CEFOTAXIME ADVERSE_EFFECT GIS_3_Nausea 63527-52-6 CEFOTAXIME ADVERSE_EFFECT IMU_1_Anaphylaxis 63527-52-6 CEFOTAXIME ZERO_CLASS N 63527-52-6 CEFOTAXIME INDICATION Pneumonia 63527-52-6 CEFOTAXIME TISSUE_TOXICITY Anaphylaxis 63527-52-6 CEFOTAXIME KNOWN_TOXICITY Cardiovascular Toxicity 64485-93-4 CEFOTAXIME THERAPEUTIC_CLASS Antibacterials 64485-93-4 CEFOTAXIME ADVERSE_EFFECT NEU_3_Headache 64485-93-4 CEFOTAXIME ADVERSE_EFFECT GIS_2_Diarrhea 64485-93-4 CEFOTAXIME INDICATION Pelvic Inflammatory Disease (PID) 64485-93-4 CEFOTAXIME TA_LEVEL_2 Anti-bacterial 64485-93-4 CEFOTAXIME INDICATION Gonoccocal Cervicitis 64485-93-4 CEFOTAXIME MESH_LEVEL_3 Lactams 64485-93-4 CEFOTAXIME PRODUCT_CLASS Anti-infectives 64485-93-4 CEFOTAXIME INDICATION Gonococcal Urethritis / Neisseria Gonorrhoeae Urethritis 64485-93-4 CEFOTAXIME INDICATION Respiratory Tract Infection 64485-93-4 CEFOTAXIME KNOWN_TOXICITY Nephrotoxicity 64485-93-4 CEFOTAXIME MODE_CLASS Enzyme Inhibitor 64485-93-4 CEFOTAXIME ADVERSE_EFFECT LIV_3_Increased Serum Transaminases 64485-93-4 CEFOTAXIME ADVERSE_EFFECT SKN_1_Rash 64485-93-4 CEFOTAXIME ADVERSE_EFFECT XXX_1_Fever 64485-93-4 CEFOTAXIME ADVERSE_EFFECT BBM_3_Neutropenia 64485-93-4 CEFOTAXIME INDICATION Peritonitis 64485-93-4 CEFOTAXIME INDICATION Skin and Skin Structure Infections 64485-93-4 CEFOTAXIME KNOWN_TOXICITY Cardiovascular Toxicity 64485-93-4 CEFOTAXIME INDICATION Pneumonia 64485-93-4 CEFOTAXIME ZERO_CLASS N 64485-93-4 CEFOTAXIME ADVERSE_EFFECT IMU_1_Anaphylaxis 64485-93-4 CEFOTAXIME ADVERSE_EFFECT GIS_3_Nausea 64485-93-4 CEFOTAXIME ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 64485-93-4 CEFOTAXIME TISSUE_TOXICITY Arrhythmia 64485-93-4 CEFOTAXIME TISSUE_TOXICITY Anaphylaxis 64485-93-4 CEFOTAXIME INDICATION Ventriculitis 64485-93-4 CEFOTAXIME INDICATION Bacteremia 64485-93-4 CEFOTAXIME MESH_LEVEL_1 Organic Chemicals 64485-93-4 CEFOTAXIME MECH_LEVEL_1 Anti-bacterial 64485-93-4 CEFOTAXIME INDICATION Bone and Joint Infection 64485-93-4 CEFOTAXIME ADVERSE_EFFECT GUS_3_Vaginitis 64485-93-4 CEFOTAXIME ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 64485-93-4 CEFOTAXIME MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 64485-93-4 CEFOTAXIME ADVERSE_EFFECT CVS_3_Arrhythmia 64485-93-4 CEFOTAXIME ADVERSE_EFFECT SKN_1_Pruritis 64485-93-4 CEFOTAXIME ADVERSE_EFFECT GIS_3_Vomiting 64485-93-4 CEFOTAXIME TISSUE_TOXICITY Interstitial Nephritis 64485-93-4 CEFOTAXIME MECHANISM Inhibit bacterial cell wall biosynthesis 64485-93-4 CEFOTAXIME INDICATION Sepsis 64485-93-4 CEFOTAXIME ADVERSE_EFFECT IMU_1_Eosinophilia 64485-93-4 CEFOTAXIME MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 64485-93-4 CEFOTAXIME STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 64485-93-4 CEFOTAXIME TA_LEVEL_3 systemic infections 64485-93-4 CEFOTAXIME ADVERSE_EFFECT KID_3_Interstitial Nephritis 64485-93-4 CEFOTAXIME KNOWN_TOXICITY Immune System Toxicity 64485-93-4 CEFOTAXIME INDICATION Meningitis 64485-93-4 CEFOTAXIME INDICATION Urinary Tract Infection (UTI) 64485-93-4 CEFOTAXIME ADVERSE_EFFECT GIS_2_Colitis 64485-93-4 CEFOTAXIME ADVERSE_EFFECT IMU_1_Urticaria 64485-93-4 CEFOTAXIME TA_LEVEL_1 Infectious Disease 64485-93-4 CEFOTAXIME MESH_LEVEL_2 Amides 64485-93-4 CEFOTAXIME INDICATION Endometritis 69712-56-7 CEFOTETAN PRODUCT_CLASS Anti-infectives 69712-56-7 CEFOTETAN MECHANISM Inhibit bacterial cell wall biosynthesis 69712-56-7 CEFOTETAN MODE_CLASS Enzyme Inhibitor 69712-56-7 CEFOTETAN THERAPEUTIC_CLASS Antibacterials, Systemic 35607-66-0 CEFOXITIN PRODUCT_CLASS Anti-infectives 35607-66-0 CEFOXITIN THERAPEUTIC_CLASS Antibacterials, Systemic 35607-66-0 CEFOXITIN MODE_CLASS Enzyme Inhibitor 35607-66-0 CEFOXITIN MECHANISM Inhibit bacterial cell wall biosynthesis 87239-81-4 CEFPODOXIME PROXETIL MODE_CLASS Enzyme Inhibitor 87239-81-4 CEFPODOXIME PROXETIL MECHANISM Inhibit bacterial cell wall biosynthesis 87239-81-4 CEFPODOXIME PROXETIL PRODUCT_CLASS Anti-infectives 87239-81-4 CEFPODOXIME PROXETIL THERAPEUTIC_CLASS Antibacterials, Systemic 62628-58-4 CEFPODOXIME PROXETIL MODE_CLASS Enzyme Inhibitor 62628-58-4 CEFPODOXIME PROXETIL MECHANISM Inhibit bacterial cell wall biosynthesis 62628-58-4 CEFPODOXIME PROXETIL PRODUCT_CLASS Anti-infectives 62628-58-4 CEFPODOXIME PROXETIL THERAPEUTIC_CLASS Antibacterials, Systemic 92665-29-7 CEFPROZIL PRODUCT_CLASS Anti-infectives 92665-29-7 CEFPROZIL MODE_CLASS Enzyme Inhibitor 92665-29-7 CEFPROZIL MECHANISM Inhibit bacterial cell wall biosynthesis 92665-29-7 CEFPROZIL THERAPEUTIC_CLASS Antibacterials, Systemic 121123-17-9 CEFPROZIL THERAPEUTIC_CLASS Antibacterials, Systemic 121123-17-9 CEFPROZIL MODE_CLASS Enzyme Inhibitor 121123-17-9 CEFPROZIL PRODUCT_CLASS Anti-infectives 121123-17-9 CEFPROZIL MECHANISM Inhibit bacterial cell wall biosynthesis 72558-82-8 CEFTAZIDIME THERAPEUTIC_CLASS Antibacterials, Systemic 72558-82-8 CEFTAZIDIME MECHANISM Inhibit bacterial cell wall biosynthesis 72558-82-8 CEFTAZIDIME PRODUCT_CLASS Anti-infectives 72558-82-8 CEFTAZIDIME MODE_CLASS Enzyme Inhibitor 97519-39-6 CEFTIBUTEN PRODUCT_CLASS Anti-infectives 97519-39-6 CEFTIBUTEN THERAPEUTIC_CLASS Antibacterials 97519-39-6 CEFTIBUTEN MODE_CLASS Enzyme Inhibitor 97519-39-6 CEFTIBUTEN MECHANISM Inhibit bacterial cell wall biosynthesis 97519-41-0 CEFTIBUTEN THERAPEUTIC_CLASS Antibacterials 97519-41-0 CEFTIBUTEN PRODUCT_CLASS Anti-infectives 97519-41-0 CEFTIBUTEN MODE_CLASS Enzyme Inhibitor 97519-41-0 CEFTIBUTEN MECHANISM Inhibit bacterial cell wall biosynthesis 97518-16-6 CEFTIBUTEN THERAPEUTIC_CLASS Antibacterials 97518-16-6 CEFTIBUTEN MECHANISM Inhibit bacterial cell wall biosynthesis 97518-16-6 CEFTIBUTEN MODE_CLASS Enzyme Inhibitor 97518-16-6 CEFTIBUTEN PRODUCT_CLASS Anti-infectives 68401-81-0 CEFTIZOXIME THERAPEUTIC_CLASS Antibacterials 68401-81-0 CEFTIZOXIME PRODUCT_CLASS Anti-infectives 68401-81-0 CEFTIZOXIME MECHANISM Inhibit bacterial cell wall biosynthesis 68401-81-0 CEFTIZOXIME MODE_CLASS Enzyme Inhibitor 74578-69-1 CEFTRIAXONE MECHANISM Inhibit bacterial cell wall biosynthesis 74578-69-1 CEFTRIAXONE PRODUCT_CLASS Anti-infectives 74578-69-1 CEFTRIAXONE THERAPEUTIC_CLASS Antibacterials 74578-69-1 CEFTRIAXONE MODE_CLASS Enzyme Inhibitor 73384-59-5 CEFTRIAXONE THERAPEUTIC_CLASS Antibacterials 73384-59-5 CEFTRIAXONE PRODUCT_CLASS Anti-infectives 73384-59-5 CEFTRIAXONE MODE_CLASS Enzyme Inhibitor 73384-59-5 CEFTRIAXONE MECHANISM Inhibit bacterial cell wall biosynthesis 55268-75-2 CEFUROXIME MODE_CLASS Enzyme Inhibitor 55268-75-2 CEFUROXIME THERAPEUTIC_CLASS Antibacterials, Systemic 55268-75-2 CEFUROXIME PRODUCT_CLASS Anti-infectives 55268-75-2 CEFUROXIME MECHANISM Inhibit bacterial cell wall biosynthesis 169590-42-5 CELECOXIB INDICATION Familial Adenomatous Polyposis 169590-42-5 CELECOXIB ADVERSE_EFFECT PSY_2_Insomnia 169590-42-5 CELECOXIB TA_LEVEL_3 COX2 inhbitor 169590-42-5 CELECOXIB ACTIVITY_CLASS Anti-inflammatory 169590-42-5 CELECOXIB ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 169590-42-5 CELECOXIB ADVERSE_EFFECT CVS_3_Palpitation 169590-42-5 CELECOXIB ADVERSE_EFFECT CVS_3_Myocardial Infarction 169590-42-5 CELECOXIB ADVERSE_EFFECT XXX_2_Rhinitis 169590-42-5 CELECOXIB ADVERSE_EFFECT XXX_2_Peripheral Edema 169590-42-5 CELECOXIB ADVERSE_EFFECT LUN_1_Upper Respiratory Tract Infection 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_1_Diarrhea 169590-42-5 CELECOXIB INDICATION Osteoarthritis 169590-42-5 CELECOXIB MECH_LEVEL_1 Immunomodulation 169590-42-5 CELECOXIB MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 2 169590-42-5 CELECOXIB MESH_LEVEL_3 Sulfonamides 169590-42-5 CELECOXIB STRUCTURE_ACTIVITY NSAID, COX-2/1, coxib like 169590-42-5 CELECOXIB ADVERSE_EFFECT LUN_3_Bronchospasm 169590-42-5 CELECOXIB ADVERSE_EFFECT CVS_3_Tachycardia 169590-42-5 CELECOXIB ADVERSE_EFFECT IMU_3_Allergic Reactions 169590-42-5 CELECOXIB ADVERSE_EFFECT SKN_2_Rash 169590-42-5 CELECOXIB ADVERSE_EFFECT NEU_2_Dizziness 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_2_Flatulence 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_1_Dyspepsia 169590-42-5 CELECOXIB ZERO_CLASS N 169590-42-5 CELECOXIB MODE_CLASS Enzyme Inhibitor 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_3_Gastroenteritis 169590-42-5 CELECOXIB TA_LEVEL_2 NSAID 169590-42-5 CELECOXIB TA_LEVEL_1 Anti-inflammatory 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 169590-42-5 CELECOXIB MECHANISM Inhibit eicosanoid biosynthesis 169590-42-5 CELECOXIB KNOWN_TOXICITY Cardiovascular Toxicity 169590-42-5 CELECOXIB ADVERSE_EFFECT NEU_1_Headache 169590-42-5 CELECOXIB ADVERSE_EFFECT BBM_3_Anemia 169590-42-5 CELECOXIB TISSUE_TOXICITY Angina Pectoris 169590-42-5 CELECOXIB INDICATION Rheumatoid Arthritis 169590-42-5 CELECOXIB PRODUCT_CLASS Anti-inflammatories 169590-42-5 CELECOXIB PRODUCT_CLASS Anti-cancers 169590-42-5 CELECOXIB MESH_LEVEL_2 Amides 169590-42-5 CELECOXIB MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 169590-42-5 CELECOXIB ADVERSE_EFFECT OCU_3_Blurred Vision 169590-42-5 CELECOXIB ADVERSE_EFFECT XXX_3_Infection 169590-42-5 CELECOXIB ADVERSE_EFFECT CVS_3_Angina Pectoris 169590-42-5 CELECOXIB ADVERSE_EFFECT XXX_2_Pharyngitis 169590-42-5 CELECOXIB ADVERSE_EFFECT MSK_2_Back Pain 169590-42-5 CELECOXIB ADVERSE_EFFECT XXX_1_Sinusitis 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_1_Abdominal Pain 169590-42-5 CELECOXIB THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 169590-42-5 CELECOXIB TISSUE_TOXICITY Myocardial Infarction 169590-42-5 CELECOXIB ADVERSE_EFFECT GIS_2_Nausea 169590-42-5 CELECOXIB MESH_LEVEL_1 Organic Chemicals 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GUS_3_Genital Pruritis 15686-71-2 CEPHALEXIN ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 15686-71-2 CEPHALEXIN ADVERSE_EFFECT IMU_2_Angioedema 15686-71-2 CEPHALEXIN ADVERSE_EFFECT NEU_3_Headache 15686-71-2 CEPHALEXIN TA_LEVEL_2 Anti-bacterial 15686-71-2 CEPHALEXIN MESH_LEVEL_3 Lactams 15686-71-2 CEPHALEXIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 15686-71-2 CEPHALEXIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 15686-71-2 CEPHALEXIN ADVERSE_EFFECT NEU_3_Dizziness 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_1_Diarrhea 15686-71-2 CEPHALEXIN KNOWN_TOXICITY Nephrotoxicity 15686-71-2 CEPHALEXIN INDICATION Otitis Media 15686-71-2 CEPHALEXIN TISSUE_TOXICITY Interstitial Nephritis 15686-71-2 CEPHALEXIN TA_LEVEL_1 Infectious Disease 15686-71-2 CEPHALEXIN MECHANISM Inhibit bacterial cell wall biosynthesis 15686-71-2 CEPHALEXIN MESH_LEVEL_2 Amides 15686-71-2 CEPHALEXIN INDICATION Skin and Skin Structure Infections 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GUS_3_Vaginal Discharge 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_2_Abdominal Pain 15686-71-2 CEPHALEXIN ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 15686-71-2 CEPHALEXIN ADVERSE_EFFECT SKN_2_Rash 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_3_Nausea 15686-71-2 CEPHALEXIN MESH_LEVEL_1 Organic Chemicals 15686-71-2 CEPHALEXIN MECH_LEVEL_1 Anti-bacterial 15686-71-2 CEPHALEXIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 15686-71-2 CEPHALEXIN INDICATION Osteomyelitis / Bone Infection 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GUS_3_Genital Moniliasis 15686-71-2 CEPHALEXIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 15686-71-2 CEPHALEXIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 15686-71-2 CEPHALEXIN INDICATION Genitourinary Tract Infections 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GUS_3_Vaginitis 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_2_Dyspepsia 15686-71-2 CEPHALEXIN ADVERSE_EFFECT IMU_2_Urticaria 15686-71-2 CEPHALEXIN ADVERSE_EFFECT LIV_3_Hepatitis 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_3_Vomiting 15686-71-2 CEPHALEXIN TA_LEVEL_3 systemic infections 15686-71-2 CEPHALEXIN MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 15686-71-2 CEPHALEXIN INDICATION Acute Prostatitis 15686-71-2 CEPHALEXIN INDICATION Respiratory Tract Infection 15686-71-2 CEPHALEXIN PRODUCT_CLASS Anti-infectives 15686-71-2 CEPHALEXIN ZERO_CLASS N 15686-71-2 CEPHALEXIN MODE_CLASS Enzyme Inhibitor 15686-71-2 CEPHALEXIN THERAPEUTIC_CLASS Antibacterials, Systemic 15686-71-2 CEPHALEXIN ADVERSE_EFFECT GIS_2_Gastritis 21593-23-7 CEPHAPIRIN MODE_CLASS Enzyme Inhibitor 21593-23-7 CEPHAPIRIN MECHANISM Inhibit bacterial cell wall biosynthesis 21593-23-7 CEPHAPIRIN THERAPEUTIC_CLASS Antibacterials, Systemic 21593-23-7 CEPHAPIRIN PRODUCT_CLASS Anti-infectives 38821-53-3 CEPHRADINE MODE_CLASS Enzyme Inhibitor 38821-53-3 CEPHRADINE PRODUCT_CLASS Anti-infectives 38821-53-3 CEPHRADINE THERAPEUTIC_CLASS Antibacterials, Systemic 38821-53-3 CEPHRADINE MECHANISM Inhibit bacterial cell wall biosynthesis 145599-86-6 CERIVASTATIN ADVERSE_EFFECT MSK_2_Myopathy 145599-86-6 CERIVASTATIN ADVERSE_EFFECT END_3_Gynecomastia 145599-86-6 CERIVASTATIN ADVERSE_EFFECT LIV_3_Fatty Liver 145599-86-6 CERIVASTATIN ADVERSE_EFFECT XXX_3_Death 145599-86-6 CERIVASTATIN ADVERSE_EFFECT OCU_3_Cataracts 145599-86-6 CERIVASTATIN ADVERSE_EFFECT IMU_3_Anaphylaxis 145599-86-6 CERIVASTATIN ADVERSE_EFFECT GIS_1_Abdominal Pain 145599-86-6 CERIVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 145599-86-6 CERIVASTATIN ADVERSE_EFFECT GIS_3_Pancreatitis 145599-86-6 CERIVASTATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 145599-86-6 CERIVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 145599-86-6 CERIVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 145599-86-6 CERIVASTATIN INDICATION Hypercholesterolemia 145599-86-6 CERIVASTATIN ADVERSE_EFFECT GIS_1_Flatulence 145599-86-6 CERIVASTATIN ADVERSE_EFFECT GIS_1_Diarrhea 145599-86-6 CERIVASTATIN ADVERSE_EFFECT CVS_2_Chest Pain 145599-86-6 CERIVASTATIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 145599-86-6 CERIVASTATIN PRODUCT_CLASS Cardiovasculars 145599-86-6 CERIVASTATIN MECHANISM Inhibit cholesterol biosynthesis 145599-86-6 CERIVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 145599-86-6 CERIVASTATIN ADVERSE_EFFECT MSK_2_Arthralgia 145599-86-6 CERIVASTATIN INDICATION Mixed Dyslipidemia 145599-86-6 CERIVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 145599-86-6 CERIVASTATIN MESH_LEVEL_3 Naphthalenes 145599-86-6 CERIVASTATIN MECH_LEVEL_3 HMG-CoA reductase 145599-86-6 CERIVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 145599-86-6 CERIVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 145599-86-6 CERIVASTATIN ADVERSE_EFFECT MSK_2_Rhabdomyolysis 145599-86-6 CERIVASTATIN INDICATION Hypercholesterolemia 145599-86-6 CERIVASTATIN TA_LEVEL_1 Cardiovascular 145599-86-6 CERIVASTATIN MODE_CLASS Enzyme Inhibitor 145599-86-6 CERIVASTATIN TISSUE_TOXICITY Death 145599-86-6 CERIVASTATIN KNOWN_TOXICITY Hepatotoxicity 145599-86-6 CERIVASTATIN ADVERSE_EFFECT IMU_2_Allergic Reactions 145599-86-6 CERIVASTATIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 145599-86-6 CERIVASTATIN ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 145599-86-6 CERIVASTATIN ADVERSE_EFFECT GIS_1_Dyspepsia 145599-86-6 CERIVASTATIN ZERO_CLASS N 145599-86-6 CERIVASTATIN ADVERSE_EFFECT MSK_2_Muscle Cramps 145599-86-6 CERIVASTATIN ADVERSE_EFFECT NEU_2_Paresthesia 145599-86-6 CERIVASTATIN KNOWN_TOXICITY Miscellaneous 145599-86-6 CERIVASTATIN ADVERSE_EFFECT XXX_1_Asthenia 145599-86-6 CERIVASTATIN ADVERSE_EFFECT REP_3_Erectile Dysfunction 145599-86-6 CERIVASTATIN TISSUE_TOXICITY Hepatotoxicity 145599-86-6 CERIVASTATIN INDICATION Mixed Dyslipidemia 145599-86-6 CERIVASTATIN MECH_LEVEL_1 Lipid lowering 145599-86-6 CERIVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 145599-86-6 CERIVASTATIN TA_LEVEL_2 Lipid lowering agent 145599-86-6 CERIVASTATIN ADVERSE_EFFECT MSK_1_Back Pain 143201-11-0 CERIVASTATIN ADVERSE_EFFECT XXX_3_Death 143201-11-0 CERIVASTATIN ADVERSE_EFFECT OCU_3_Cataracts 143201-11-0 CERIVASTATIN ADVERSE_EFFECT CVS_2_Chest Pain 143201-11-0 CERIVASTATIN ADVERSE_EFFECT GIS_1_Abdominal Pain 143201-11-0 CERIVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 143201-11-0 CERIVASTATIN MECH_LEVEL_1 Lipid lowering 143201-11-0 CERIVASTATIN ADVERSE_EFFECT GIS_3_Pancreatitis 143201-11-0 CERIVASTATIN ADVERSE_EFFECT LIV_3_Hepatotoxicity 143201-11-0 CERIVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 143201-11-0 CERIVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 143201-11-0 CERIVASTATIN INDICATION Hypercholesterolemia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT GIS_1_Flatulence 143201-11-0 CERIVASTATIN ADVERSE_EFFECT GIS_1_Diarrhea 143201-11-0 CERIVASTATIN ADVERSE_EFFECT MSK_2_Arthralgia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 143201-11-0 CERIVASTATIN PRODUCT_CLASS Cardiovasculars 143201-11-0 CERIVASTATIN MECHANISM Inhibit cholesterol biosynthesis 143201-11-0 CERIVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 143201-11-0 CERIVASTATIN ADVERSE_EFFECT NEU_2_Paresthesia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT MSK_2_Muscle Cramps 143201-11-0 CERIVASTATIN ZERO_CLASS N 143201-11-0 CERIVASTATIN ADVERSE_EFFECT GIS_1_Dyspepsia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT LIV_3_Chronic Active Hepatitis 143201-11-0 CERIVASTATIN ADVERSE_EFFECT XXX_1_Asthenia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT IMU_2_Allergic Reactions 143201-11-0 CERIVASTATIN ADVERSE_EFFECT IMU_3_Anaphylaxis 143201-11-0 CERIVASTATIN KNOWN_TOXICITY Hepatotoxicity 143201-11-0 CERIVASTATIN TISSUE_TOXICITY Death 143201-11-0 CERIVASTATIN MODE_CLASS Enzyme Inhibitor 143201-11-0 CERIVASTATIN TA_LEVEL_1 Cardiovascular 143201-11-0 CERIVASTATIN INDICATION Hypercholesterolemia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT MSK_2_Rhabdomyolysis 143201-11-0 CERIVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 143201-11-0 CERIVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 143201-11-0 CERIVASTATIN MECH_LEVEL_3 HMG-CoA reductase 143201-11-0 CERIVASTATIN TA_LEVEL_2 Lipid lowering agent 143201-11-0 CERIVASTATIN INDICATION Mixed Dyslipidemia 143201-11-0 CERIVASTATIN TISSUE_TOXICITY Hepatotoxicity 143201-11-0 CERIVASTATIN ADVERSE_EFFECT REP_3_Erectile Dysfunction 143201-11-0 CERIVASTATIN ADVERSE_EFFECT MSK_1_Back Pain 143201-11-0 CERIVASTATIN KNOWN_TOXICITY Miscellaneous 143201-11-0 CERIVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 143201-11-0 CERIVASTATIN INDICATION Mixed Dyslipidemia 143201-11-0 CERIVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 143201-11-0 CERIVASTATIN MESH_LEVEL_3 Naphthalenes 143201-11-0 CERIVASTATIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 143201-11-0 CERIVASTATIN ADVERSE_EFFECT MSK_2_Myopathy 143201-11-0 CERIVASTATIN ADVERSE_EFFECT END_3_Gynecomastia 143201-11-0 CERIVASTATIN ADVERSE_EFFECT LIV_3_Fatty Liver 120287-85-6 CETRORELIX MODE_CLASS Receptor Ligand Antagonist 130289-71-3 CETRORELIX MODE_CLASS Receptor Ligand Antagonist 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Throat Irritation 123-03-5 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_1 Heterocyclic Compounds 123-03-5 CETYLPYRIDINIUM BROMIDE PRODUCT_CLASS Anti-infectives 123-03-5 CETYLPYRIDINIUM BROMIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT IMU_1_Allergy 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT SKN_1_Skin Irritation 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT OCU_3_Corneal Ulceration 123-03-5 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_1 Anti-bacterial 123-03-5 CETYLPYRIDINIUM BROMIDE TA_LEVEL_3 Toxicology Standard 123-03-5 CETYLPYRIDINIUM BROMIDE TA_LEVEL_1 Biochemicals 123-03-5 CETYLPYRIDINIUM BROMIDE STRUCTURE_ACTIVITY Impairs cell membrane function 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT LUN_2_Respiratory Distress 123-03-5 CETYLPYRIDINIUM BROMIDE TA_LEVEL_2 Biochemicals 123-03-5 CETYLPYRIDINIUM BROMIDE MECHANISM Destroy cell membrane / wall integrity 123-03-5 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_3 Pyridines 123-03-5 CETYLPYRIDINIUM BROMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 123-03-5 CETYLPYRIDINIUM BROMIDE ZERO_CLASS N 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT OCU_1_Eye Irritation 123-03-5 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_3 cell membrane 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Nasal Irritation 123-03-5 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 123-03-5 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_2 Destroy cell membrane / wall integrity 123-03-5 CETYLPYRIDINIUM BROMIDE ACTIVITY_CLASS Antibiotic 123-03-5 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT LUN_2_Airway Irritation 140-72-7 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_3 Pyridines 140-72-7 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_3 cell membrane 140-72-7 CETYLPYRIDINIUM BROMIDE PRODUCT_CLASS Anti-infectives 140-72-7 CETYLPYRIDINIUM BROMIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Throat Irritation 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT LUN_2_Airway Irritation 140-72-7 CETYLPYRIDINIUM BROMIDE ACTIVITY_CLASS Antibiotic 140-72-7 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_2 Destroy cell membrane / wall integrity 140-72-7 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Nasal Irritation 140-72-7 CETYLPYRIDINIUM BROMIDE ZERO_CLASS N 140-72-7 CETYLPYRIDINIUM BROMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 140-72-7 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_1 Heterocyclic Compounds 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT OCU_1_Eye Irritation 140-72-7 CETYLPYRIDINIUM BROMIDE MECHANISM Destroy cell membrane / wall integrity 140-72-7 CETYLPYRIDINIUM BROMIDE TA_LEVEL_2 Biochemicals 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT LUN_2_Respiratory Distress 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 140-72-7 CETYLPYRIDINIUM BROMIDE STRUCTURE_ACTIVITY Impairs cell membrane function 140-72-7 CETYLPYRIDINIUM BROMIDE TA_LEVEL_1 Biochemicals 140-72-7 CETYLPYRIDINIUM BROMIDE TA_LEVEL_3 Toxicology Standard 140-72-7 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_1 Anti-bacterial 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT OCU_3_Corneal Ulceration 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT SKN_1_Skin Irritation 140-72-7 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT IMU_1_Allergy 6004-24-6 CETYLPYRIDINIUM BROMIDE TA_LEVEL_1 Biochemicals 6004-24-6 CETYLPYRIDINIUM BROMIDE TA_LEVEL_3 Toxicology Standard 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT LUN_2_Respiratory Distress 6004-24-6 CETYLPYRIDINIUM BROMIDE TA_LEVEL_2 Biochemicals 6004-24-6 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_2 Destroy cell membrane / wall integrity 6004-24-6 CETYLPYRIDINIUM BROMIDE MECHANISM Destroy cell membrane / wall integrity 6004-24-6 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_1 Heterocyclic Compounds 6004-24-6 CETYLPYRIDINIUM BROMIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 6004-24-6 CETYLPYRIDINIUM BROMIDE ZERO_CLASS N 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT OCU_1_Eye Irritation 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Nasal Irritation 6004-24-6 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 6004-24-6 CETYLPYRIDINIUM BROMIDE ACTIVITY_CLASS Antibiotic 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT LUN_2_Airway Irritation 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT XXX_2_Throat Irritation 6004-24-6 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_3 cell membrane 6004-24-6 CETYLPYRIDINIUM BROMIDE STRUCTURE_ACTIVITY Impairs cell membrane function 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT OCU_3_Corneal Ulceration 6004-24-6 CETYLPYRIDINIUM BROMIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT IMU_1_Allergy 6004-24-6 CETYLPYRIDINIUM BROMIDE ADVERSE_EFFECT SKN_1_Skin Irritation 6004-24-6 CETYLPYRIDINIUM BROMIDE PRODUCT_CLASS Anti-infectives 6004-24-6 CETYLPYRIDINIUM BROMIDE MECH_LEVEL_1 Anti-bacterial 6004-24-6 CETYLPYRIDINIUM BROMIDE MESH_LEVEL_3 Pyridines 124182-57-6 CGS-21680 PRODUCT_CLASS Cardiovasculars 124182-57-6 CGS-21680 THERAPEUTIC_CLASS Antihypertensive Agents 124182-57-6 CGS-21680 MECHANISM Modulate G-protein coupled signal transduction 147398-01-4 CGS-25019C MECHANISM Modulate gene transcription 147398-01-4 CGS-25019C PRODUCT_CLASS Anti-inflammatories 147398-01-4 CGS-25019C MODE_CLASS Receptor Ligand Antagonist, Selective 147398-01-4 CGS-25019C PRODUCT_CLASS Immune Response / Immunomodulators 147398-01-4 CGS-25019C THERAPEUTIC_CLASS Immunomodulants 147398-01-4 CGS-25019C INDICATION Rheumatoid Arthritis 146957-32-6 CGS-25019C THERAPEUTIC_CLASS Immunomodulants 146957-32-6 CGS-25019C PRODUCT_CLASS Immune Response / Immunomodulators 146957-32-6 CGS-25019C INDICATION Rheumatoid Arthritis 146957-32-6 CGS-25019C MODE_CLASS Receptor Ligand Antagonist, Selective 146957-32-6 CGS-25019C MECHANISM Modulate gene transcription 146957-32-6 CGS-25019C PRODUCT_CLASS Anti-inflammatories 147398-02-5 CGS-25019C MODE_CLASS Receptor Ligand Antagonist, Selective 147398-02-5 CGS-25019C MECHANISM Modulate gene transcription 147398-02-5 CGS-25019C PRODUCT_CLASS Immune Response / Immunomodulators 147398-02-5 CGS-25019C THERAPEUTIC_CLASS Immunomodulants 147398-02-5 CGS-25019C INDICATION Rheumatoid Arthritis 147398-02-5 CGS-25019C PRODUCT_CLASS Anti-inflammatories 146978-48-5 CGS-25019C MODE_CLASS Receptor Ligand Antagonist, Selective 146978-48-5 CGS-25019C PRODUCT_CLASS Anti-inflammatories 146978-48-5 CGS-25019C PRODUCT_CLASS Immune Response / Immunomodulators 146978-48-5 CGS-25019C THERAPEUTIC_CLASS Immunomodulants 146978-48-5 CGS-25019C INDICATION Rheumatoid Arthritis 146978-48-5 CGS-25019C MECHANISM Modulate gene transcription 302-17-0 CHLORAL HYDRATE THERAPEUTIC_CLASS Sedatives/Hypnotics 302-17-0 CHLORAL HYDRATE INDICATION Insomnia 302-17-0 CHLORAL HYDRATE THERAPEUTIC_CLASS Anxiolytics 302-17-0 CHLORAL HYDRATE INDICATION Anxiety 302-17-0 CHLORAL HYDRATE PRODUCT_CLASS Central Nervous System (CNS) 302-17-0 CHLORAL HYDRATE INDICATION Initiation / Maintenance of Sedation 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT LUN_3_Pulmonary Fibrosis 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT SKN_3_Skin Reactions 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT REP_2_Decreased Fertility 305-03-3 CHLORAMBUCIL TISSUE_TOXICITY Hepatotoxicity 305-03-3 CHLORAMBUCIL MESH_LEVEL_3 Hydrocarbons, Halogenated 305-03-3 CHLORAMBUCIL MESH_LEVEL_1 Organic Chemicals 305-03-3 CHLORAMBUCIL MECH_LEVEL_3 DNA damage 305-03-3 CHLORAMBUCIL TA_LEVEL_3 Soft tumors 305-03-3 CHLORAMBUCIL TA_LEVEL_1 Oncology 305-03-3 CHLORAMBUCIL TISSUE_TOXICITY Mutagenicity 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT LIV_3_Hepatotoxicity 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT GIS_2_Diarrhea 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT NEU_3_Ataxia 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT NEU_3_Tremor 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT EMB_2_Teratogenicity 305-03-3 CHLORAMBUCIL KNOWN_TOXICITY Embryo/Fetal Toxicity 305-03-3 CHLORAMBUCIL TISSUE_TOXICITY Bone Marrow Suppression 305-03-3 CHLORAMBUCIL MECHANISM Inhibit DNA synthesis, repair, and function 305-03-3 CHLORAMBUCIL MESH_LEVEL_2 Hydrocarbons 305-03-3 CHLORAMBUCIL INDICATION Giant Follicular Lymphoma 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT IMU_2_Urticaria 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT GUS_3_Cystitis 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT NEU_3_Myoclonus 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT DNA_2_Mutagenicity 305-03-3 CHLORAMBUCIL ACTIVITY_CLASS DNA damager 305-03-3 CHLORAMBUCIL KNOWN_TOXICITY Blood & Bone Marrow Toxicity 305-03-3 CHLORAMBUCIL TA_LEVEL_2 DNA damage 305-03-3 CHLORAMBUCIL KNOWN_TOXICITY Mutagenicity 305-03-3 CHLORAMBUCIL KNOWN_TOXICITY Carcinogenicity 305-03-3 CHLORAMBUCIL MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 305-03-3 CHLORAMBUCIL INDICATION Chronic Lymphocytic Leukemia (CLL) 305-03-3 CHLORAMBUCIL PRODUCT_CLASS Anti-cancers 305-03-3 CHLORAMBUCIL TISSUE_TOXICITY Carcinogenicity 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT GIS_2_Nausea 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT GIS_2_Vomiting 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT PSY_3_Confusion 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT PSY_3_Agitation 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT DNA_2_Carcinogenicity 305-03-3 CHLORAMBUCIL MODE_CLASS Distorts /blocks macromolecular scaffold function 305-03-3 CHLORAMBUCIL ZERO_CLASS N 305-03-3 CHLORAMBUCIL STRUCTURE_ACTIVITY DNA-alkylator, nitrogen mustard 305-03-3 CHLORAMBUCIL INDICATION Neoplasm / Cancer / Tumor 305-03-3 CHLORAMBUCIL INDICATION Lymphosarcoma 305-03-3 CHLORAMBUCIL MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 305-03-3 CHLORAMBUCIL INDICATION Hodgkin's Disease 305-03-3 CHLORAMBUCIL THERAPEUTIC_CLASS Antineoplastics 305-03-3 CHLORAMBUCIL TISSUE_TOXICITY Teratogenicity 305-03-3 CHLORAMBUCIL KNOWN_TOXICITY Hepatotoxicity 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT BBM_1_Bone Marrow Suppression 305-03-3 CHLORAMBUCIL ADVERSE_EFFECT IMU_2_Angioedema 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Bone Marrow Aplasia 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Thrombocytopenia 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Bone Marrow Hypoplasia 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT NEU_1_Headache 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT GIS_1_Diarrhea 56-75-7 CHLORAMPHENICOL INDICATION Rocky Mountain Spotted Fever 56-75-7 CHLORAMPHENICOL INDICATION Anthrax 56-75-7 CHLORAMPHENICOL MECH_LEVEL_3 50/60S Ribosomal Subunit 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Paroxymal Nocturnal Hematuria 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT GIS_2_Enterocolitis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT NEU_3_Optic Neuritis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Aplastic Anemia 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT IMU_3_Anaphylaxis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT PSY_2_Depression 56-75-7 CHLORAMPHENICOL MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 56-75-7 CHLORAMPHENICOL PRODUCT_CLASS Anti-infectives 56-75-7 CHLORAMPHENICOL INDICATION Rickettsial Diseases 56-75-7 CHLORAMPHENICOL INDICATION Inhalational Anthrax 56-75-7 CHLORAMPHENICOL INDICATION Psittacosis / Ornithosis 56-75-7 CHLORAMPHENICOL TA_LEVEL_3 Systemic infections 56-75-7 CHLORAMPHENICOL MECH_LEVEL_1 Anti-bacterial 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT KID_3_Interstitial Nephritis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT XXX_2_Gray Baby Syndrome 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Bone Marrow Depression 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Agranulocytosis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT PSY_3_Delirium 56-75-7 CHLORAMPHENICOL TISSUE_TOXICITY Interstitial Nephritis 56-75-7 CHLORAMPHENICOL KNOWN_TOXICITY Nephrotoxicity 56-75-7 CHLORAMPHENICOL THERAPEUTIC_CLASS Antibacterials, Systemic 56-75-7 CHLORAMPHENICOL INDICATION Brain Abscess 56-75-7 CHLORAMPHENICOL INDICATION Paratyphoid Fever 56-75-7 CHLORAMPHENICOL INDICATION Meningococcal Meningitis 56-75-7 CHLORAMPHENICOL MECHANISM Inhibit ribosomal protein synthesis 56-75-7 CHLORAMPHENICOL MECH_LEVEL_2 Inhibit ribosomal protein synthesis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT SKN_2_Skin Rash 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT XXX_2_Glossitis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT NEU_3_Peripheral Neuritis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT SKN_2_Pruritis 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 56-75-7 CHLORAMPHENICOL INDICATION Enteric Fever / Typhoid Fever 56-75-7 CHLORAMPHENICOL STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, amphenicol 56-75-7 CHLORAMPHENICOL MESH_LEVEL_2 Alcohols 56-75-7 CHLORAMPHENICOL INDICATION Pneumococcal Meningitis 56-75-7 CHLORAMPHENICOL TA_LEVEL_2 Anti-bacterial 56-75-7 CHLORAMPHENICOL INDICATION Haemophilus Influenzae Meningitis 56-75-7 CHLORAMPHENICOL MESH_LEVEL_3 Glycols 56-75-7 CHLORAMPHENICOL ZERO_CLASS N 56-75-7 CHLORAMPHENICOL ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 56-75-7 CHLORAMPHENICOL TA_LEVEL_1 Infectious Disease 56-75-7 CHLORAMPHENICOL MESH_LEVEL_1 Organic Chemicals 56-75-7 CHLORAMPHENICOL ADVERSE_EFFECT BBM_3_Irreversible Bone Marrow Depression 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT SKN_2_Skin Eruption 58-25-3 CHLORDIAZEPOXIDE INDICATION Anxiety Disorders 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT REP_1_Menstrual Irregularities 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT LIV_3_Hepatic Dysfunction 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT XXX_1_Tolerance 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT CVS_2_Hypotension 58-25-3 CHLORDIAZEPOXIDE MODE_CLASS Channel Modulator 58-25-3 CHLORDIAZEPOXIDE MECHANISM Modulate neural transmission 58-25-3 CHLORDIAZEPOXIDE INDICATION Alcoholic Withdrawal 58-25-3 CHLORDIAZEPOXIDE PRODUCT_CLASS Central Nervous System (CNS) 58-25-3 CHLORDIAZEPOXIDE MECH_LEVEL_1 Modulate neural transmission 58-25-3 CHLORDIAZEPOXIDE MECH_LEVEL_3 GABA-A receptor A 58-25-3 CHLORDIAZEPOXIDE MECH_LEVEL_2 faciliates GABA binding 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT PSY_2_Confusion 58-25-3 CHLORDIAZEPOXIDE THERAPEUTIC_CLASS Anxiolytics 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT PSY_1_Dependence 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 58-25-3 CHLORDIAZEPOXIDE ZERO_CLASS N 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT REP_1_Decreased Libido 58-25-3 CHLORDIAZEPOXIDE KNOWN_TOXICITY Cardiovascular Toxicity 58-25-3 CHLORDIAZEPOXIDE TISSUE_TOXICITY Hypotension 58-25-3 CHLORDIAZEPOXIDE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 58-25-3 CHLORDIAZEPOXIDE TA_LEVEL_3 Anxlytic 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT LIV_3_Jaundice 58-25-3 CHLORDIAZEPOXIDE TA_LEVEL_2 CNS Depressant 58-25-3 CHLORDIAZEPOXIDE MESH_LEVEL_3 Benzazepines 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT EMB_3_Congenital Malformations 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT XXX_1_Withdrawal 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 58-25-3 CHLORDIAZEPOXIDE TA_LEVEL_1 Central Nervous System (CNS) 58-25-3 CHLORDIAZEPOXIDE STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, long acting 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_3_Paradoxical Reactions 58-25-3 CHLORDIAZEPOXIDE ACTIVITY_CLASS GABA agonist 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_1_Drowsiness 58-25-3 CHLORDIAZEPOXIDE ADVERSE_EFFECT NEU_2_Ataxia 58-25-3 CHLORDIAZEPOXIDE MESH_LEVEL_1 Heterocyclic Compounds 136470-78-5 ABACAVIR PRODUCT_CLASS Anti-infectives 136470-78-5 ABACAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 136470-78-5 ABACAVIR MECHANISM Inhibit viral DNA synthesis 136470-78-5 ABACAVIR THERAPEUTIC_CLASS Antivirals, Systemic 136470-78-5 ABACAVIR MODE_CLASS Enzyme substrate mimic 188062-50-2 ABACAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 188062-50-2 ABACAVIR PRODUCT_CLASS Anti-infectives 188062-50-2 ABACAVIR MECHANISM Inhibit viral DNA synthesis 188062-50-2 ABACAVIR THERAPEUTIC_CLASS Antivirals, Systemic 188062-50-2 ABACAVIR MODE_CLASS Enzyme substrate mimic 168146-84-7 ABACAVIR PRODUCT_CLASS Anti-infectives 168146-84-7 ABACAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 168146-84-7 ABACAVIR MECHANISM Inhibit viral DNA synthesis 168146-84-7 ABACAVIR THERAPEUTIC_CLASS Antivirals, Systemic 168146-84-7 ABACAVIR MODE_CLASS Enzyme substrate mimic 136777-49-6 ABACAVIR MECHANISM Inhibit viral DNA synthesis 136777-49-6 ABACAVIR PRODUCT_CLASS Anti-infectives 136777-49-6 ABACAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 136777-49-6 ABACAVIR THERAPEUTIC_CLASS Antivirals, Systemic 136777-49-6 ABACAVIR MODE_CLASS Enzyme substrate mimic 136777-48-5 ABACAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 136777-48-5 ABACAVIR PRODUCT_CLASS Anti-infectives 136777-48-5 ABACAVIR THERAPEUTIC_CLASS Antivirals, Systemic 136777-48-5 ABACAVIR MODE_CLASS Enzyme substrate mimic 136777-48-5 ABACAVIR MECHANISM Inhibit viral DNA synthesis 147402-53-7 ABT-418 THERAPEUTIC_CLASS Anxiolytics 147402-53-7 ABT-418 PRODUCT_CLASS Central Nervous System (CNS) 147388-83-8 ABT-418 THERAPEUTIC_CLASS Anxiolytics 147388-83-8 ABT-418 PRODUCT_CLASS Central Nervous System (CNS) 147899-90-9 ABT-418 THERAPEUTIC_CLASS Anxiolytics 147899-90-9 ABT-418 PRODUCT_CLASS Central Nervous System (CNS) 147402-73-1 ABT-418 PRODUCT_CLASS Central Nervous System (CNS) 147402-73-1 ABT-418 THERAPEUTIC_CLASS Anxiolytics 56180-94-0 ACARBOSE INDICATION Type II Diabetes Mellitus 56180-94-0 ACARBOSE MESH_LEVEL_1 Carbohydrates and Hypoglycemics 56180-94-0 ACARBOSE MECH_LEVEL_2 Prevent carbohydrate absorbtion 56180-94-0 ACARBOSE MESH_LEVEL_3 Polysaccharides 56180-94-0 ACARBOSE ADVERSE_EFFECT GIS_1_Diarrhea 56180-94-0 ACARBOSE ADVERSE_EFFECT IMU_3_Hypersensitivity 56180-94-0 ACARBOSE TA_LEVEL_1 Hormones, Endocrine and Metabolic 56180-94-0 ACARBOSE MECHANISM Inhibit absorption of dietary carbohydrates 56180-94-0 ACARBOSE MECH_LEVEL_3 Maltose-6'-phosphate glucosidase inhibitor 56180-94-0 ACARBOSE TA_LEVEL_2 Energy metabolism 56180-94-0 ACARBOSE ZERO_CLASS N 56180-94-0 ACARBOSE ADVERSE_EFFECT GIS_1_Flatulence 56180-94-0 ACARBOSE ACTIVITY_CLASS Anti-diabetic 56180-94-0 ACARBOSE TA_LEVEL_3 Diabetes 56180-94-0 ACARBOSE PRODUCT_CLASS Hormones, Endocrine and Metabolic 56180-94-0 ACARBOSE MODE_CLASS Enzyme Inhibitor 56180-94-0 ACARBOSE MECH_LEVEL_1 Anti-absorbtion 56180-94-0 ACARBOSE ADVERSE_EFFECT LIV_3_Jaundice 56180-94-0 ACARBOSE ADVERSE_EFFECT GIS_1_Abdominal Pain 56180-94-0 ACARBOSE STRUCTURE_ACTIVITY Alpha-glucosidase inhibitor, antidiabetic 56180-94-0 ACARBOSE MESH_LEVEL_2 Carbohydrates 56180-94-0 ACARBOSE ADVERSE_EFFECT LIV_3_Increased Liver Enzymes 56180-94-0 ACARBOSE ADVERSE_EFFECT IMU_3_Eosinophilia 56180-94-0 ACARBOSE THERAPEUTIC_CLASS Antidiabetic Agents 56180-94-0 ACARBOSE ADVERSE_EFFECT SKN_3_Erythema Multiforme 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT CVS_2_Hypotension 34381-68-5 ACEBUTOLOL THERAPEUTIC_CLASS Antihypertensive Agents 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT PSY_2_Insomnia 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT LUN_3_Cough 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT SKN_2_Rash 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT MSK_2_Myalgia 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT IMU_3_Lupus Erythematosus Syndrome 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT LUN_3_Wheezing 34381-68-5 ACEBUTOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 34381-68-5 ACEBUTOLOL MECHANISM Reduce muscle contractile force 34381-68-5 ACEBUTOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT XXX_2_Edema 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT MSK_2_Arthralgia 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT CVS_2_Bradycardia 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT CVS_2_Chest Pain 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT XXX_3_Pharyngitis 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT PSY_2_Depression 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_3_Vomiting 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT NEU_1_Dizziness 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT LUN_1_Dyspnea 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_2_Constipation 34381-68-5 ACEBUTOLOL PRODUCT_CLASS Cardiovasculars 34381-68-5 ACEBUTOLOL INDICATION Hypertension 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_1_Diarrhea 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GUS_3_Dysuria 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT XXX_1_Fatigue 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_1_Nausea 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_2_Dyspepsia 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_3_Abdominal Pain 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT GIS_2_Flatulence 34381-68-5 ACEBUTOLOL TISSUE_TOXICITY Hypotension 34381-68-5 ACEBUTOLOL KNOWN_TOXICITY Cardiovascular Toxicity 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT SKN_2_Pruritis 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT MSK_3_Joint Pain 34381-68-5 ACEBUTOLOL INDICATION Ventricular Arrhythmias 34381-68-5 ACEBUTOLOL ADVERSE_EFFECT NEU_1_Headache 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT LUN_3_Wheezing 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT IMU_3_Lupus Erythematosus Syndrome 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT MSK_2_Myalgia 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT LUN_3_Cough 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT PSY_2_Insomnia 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_1_Diarrhea 37517-30-9 ACEBUTOLOL THERAPEUTIC_CLASS Antihypertensive Agents 37517-30-9 ACEBUTOLOL INDICATION Ventricular Arrhythmias 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT MSK_3_Joint Pain 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_2_Dyspepsia 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GUS_3_Dysuria 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT SKN_2_Pruritis 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT NEU_1_Headache 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_1_Nausea 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_2_Constipation 37517-30-9 ACEBUTOLOL PRODUCT_CLASS Cardiovasculars 37517-30-9 ACEBUTOLOL INDICATION Hypertension 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT SKN_2_Rash 37517-30-9 ACEBUTOLOL KNOWN_TOXICITY Cardiovascular Toxicity 37517-30-9 ACEBUTOLOL TISSUE_TOXICITY Hypotension 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_2_Flatulence 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_3_Abdominal Pain 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT LUN_1_Dyspnea 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT NEU_1_Dizziness 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT GIS_3_Vomiting 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT PSY_2_Depression 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT XXX_3_Pharyngitis 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT CVS_2_Chest Pain 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT MSK_2_Arthralgia 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT XXX_2_Edema 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT XXX_1_Fatigue 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT CVS_2_Hypotension 37517-30-9 ACEBUTOLOL ADVERSE_EFFECT CVS_2_Bradycardia 37517-30-9 ACEBUTOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 37517-30-9 ACEBUTOLOL MECHANISM Reduce muscle contractile force 37517-30-9 ACEBUTOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT ELT_2_Electrolyte Imbalance 59-66-5 ACETAZOLAMIDE TA_LEVEL_2 Hypertension 59-66-5 ACETAZOLAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 59-66-5 ACETAZOLAMIDE INDICATION Mountain Sickness / Altitude Sickness 59-66-5 ACETAZOLAMIDE TA_LEVEL_1 Cardiovascular 59-66-5 ACETAZOLAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 59-66-5 ACETAZOLAMIDE TA_LEVEL_3 Diuretic 59-66-5 ACETAZOLAMIDE MECH_LEVEL_1 Vasorelaxation 59-66-5 ACETAZOLAMIDE KNOWN_TOXICITY Nephrotoxicity 59-66-5 ACETAZOLAMIDE TISSUE_TOXICITY Hematuria 59-66-5 ACETAZOLAMIDE MECH_LEVEL_3 Carbonate anhydrase 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT END_2_Metabolic Acidosis 59-66-5 ACETAZOLAMIDE MESH_LEVEL_3 Thiazoles 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT OTO_1_Tinnitus 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT GIS_2_Melena 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT KID_1_Polyuria 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT KID_2_Hematuria 59-66-5 ACETAZOLAMIDE INDICATION Acute (Angle-Closure) Glaucoma 59-66-5 ACETAZOLAMIDE ACTIVITY_CLASS Diuretic 59-66-5 ACETAZOLAMIDE ZERO_CLASS N 59-66-5 ACETAZOLAMIDE KNOWN_TOXICITY Hepatotoxicity 59-66-5 ACETAZOLAMIDE TISSUE_TOXICITY Hepatic Necrosis 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT IMU_2_Photosensitivity 59-66-5 ACETAZOLAMIDE STRUCTURE_ACTIVITY Carbonic Anhydrase Inhibitor 59-66-5 ACETAZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 59-66-5 ACETAZOLAMIDE MODE_CLASS Enzyme Inhibitor 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT IMU_2_Urticaria 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT PSY_1_Confusion 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT NEU_1_Tingling 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 59-66-5 ACETAZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 59-66-5 ACETAZOLAMIDE THERAPEUTIC_CLASS Diuretics 59-66-5 ACETAZOLAMIDE MECH_LEVEL_2 Diuretic 59-66-5 ACETAZOLAMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 59-66-5 ACETAZOLAMIDE INDICATION Open-Angle Glaucoma 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 59-66-5 ACETAZOLAMIDE ADVERSE_EFFECT NEU_1_Paresthesia 59-66-5 ACETAZOLAMIDE MESH_LEVEL_1 Heterocyclic Compounds 1424-27-7 ACETAZOLAMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 1424-27-7 ACETAZOLAMIDE INDICATION Open-Angle Glaucoma 1424-27-7 ACETAZOLAMIDE MESH_LEVEL_1 Heterocyclic Compounds 1424-27-7 ACETAZOLAMIDE STRUCTURE_ACTIVITY Carbonic Anhydrase Inhibitor 1424-27-7 ACETAZOLAMIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 1424-27-7 ACETAZOLAMIDE MODE_CLASS Enzyme Inhibitor 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT NEU_1_Paresthesia 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT IMU_2_Urticaria 1424-27-7 ACETAZOLAMIDE INDICATION Mountain Sickness / Altitude Sickness 1424-27-7 ACETAZOLAMIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 1424-27-7 ACETAZOLAMIDE ACTIVITY_CLASS Diuretic 1424-27-7 ACETAZOLAMIDE TA_LEVEL_3 Diuretic 1424-27-7 ACETAZOLAMIDE MECH_LEVEL_1 Vasorelaxation 1424-27-7 ACETAZOLAMIDE KNOWN_TOXICITY Nephrotoxicity 1424-27-7 ACETAZOLAMIDE TISSUE_TOXICITY Hematuria 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT END_2_Metabolic Acidosis 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT OTO_1_Tinnitus 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT GIS_2_Melena 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT KID_1_Polyuria 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 1424-27-7 ACETAZOLAMIDE MESH_LEVEL_3 Thiazoles 1424-27-7 ACETAZOLAMIDE MECH_LEVEL_3 Carbonate anhydrase 1424-27-7 ACETAZOLAMIDE INDICATION Acute (Angle-Closure) Glaucoma 1424-27-7 ACETAZOLAMIDE ZERO_CLASS N 1424-27-7 ACETAZOLAMIDE KNOWN_TOXICITY Hepatotoxicity 1424-27-7 ACETAZOLAMIDE TISSUE_TOXICITY Hepatic Necrosis 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT PSY_1_Confusion 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT NEU_1_Tingling 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT IMU_2_Photosensitivity 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 1424-27-7 ACETAZOLAMIDE TA_LEVEL_2 Hypertension 1424-27-7 ACETAZOLAMIDE THERAPEUTIC_CLASS Antiglaucoma Agents 1424-27-7 ACETAZOLAMIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 1424-27-7 ACETAZOLAMIDE THERAPEUTIC_CLASS Diuretics 1424-27-7 ACETAZOLAMIDE MECH_LEVEL_2 Diuretic 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT NEU_1_Drowsiness 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT KID_2_Hematuria 1424-27-7 ACETAZOLAMIDE ADVERSE_EFFECT ELT_2_Electrolyte Imbalance 1424-27-7 ACETAZOLAMIDE TA_LEVEL_1 Cardiovascular 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT IMU_2_Photosensitivity Reaction 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 968-81-0 ACETOHEXAMIDE MECHANISM Trigger insulin release in pancreatic beta cells 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 968-81-0 ACETOHEXAMIDE PRODUCT_CLASS Hormones, Endocrine and Metabolic 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 968-81-0 ACETOHEXAMIDE THERAPEUTIC_CLASS Antidiabetic Agents 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT SKN_3_Porphyria Cutanea Tarda 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT END_3_Porphyria 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT BBM_3_Hemolytic Anemia 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT XXX_2_Secondary Failure 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT BBM_3_Leukopenia 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT NEU_2_Headache 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT GIS_2_Diarrhea 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT GIS_1_Dyspepsia 968-81-0 ACETOHEXAMIDE MODE_CLASS Channel Blocker, selective 968-81-0 ACETOHEXAMIDE STRUCTURE_ACTIVITY K+ Channel (KATP-SUR1) blocker, antidiabetic 968-81-0 ACETOHEXAMIDE INDICATION Type II Diabetes Mellitus 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT END_1_Hypoglycemia 968-81-0 ACETOHEXAMIDE ADVERSE_EFFECT BBM_3_Aplastic Anemia 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT XXX_1_Malaise 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT CVS_2_Phlebitis 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT NEU_1_Headache 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 546-88-3 ACETOHYDROXAMIC ACID INDICATION Urinary Tract Infection (UTI) 546-88-3 ACETOHYDROXAMIC ACID MODE_CLASS Enzyme Inhibitor 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT BBM_1_Reticulocytosis 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT SKN_1_Alopecia / Hair Loss 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT PSY_1_Mental Depression 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT PSY_1_Nervousness 546-88-3 ACETOHYDROXAMIC ACID THERAPEUTIC_CLASS Acidifying Agents 546-88-3 ACETOHYDROXAMIC ACID INDICATION Struvite Calculi / Struvite Stones 546-88-3 ACETOHYDROXAMIC ACID STRUCTURE_ACTIVITY Acidifying Agent 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT PSY_1_Mental Confusion 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT BBM_2_Bone Marrow Depression 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT PSY_1_Anorexia 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT CVS_2_Venous Thrombosis 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT CVS_3_Thromboembolism 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT BBM_2_Hemolytic Anemia 546-88-3 ACETOHYDROXAMIC ACID ADVERSE_EFFECT PSY_1_Anxiety 546-88-3 ACETOHYDROXAMIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 546-88-3 ACETOHYDROXAMIC ACID TISSUE_TOXICITY Thromboembolism 546-88-3 ACETOHYDROXAMIC ACID PRODUCT_CLASS Electrolytic, Caloric and Water Balance 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT OCU_2_Corneal Edema 60-31-1 ACETYLCHOLINE CHLORIDE TISSUE_TOXICITY Hypotension 60-31-1 ACETYLCHOLINE CHLORIDE INDICATION Induction of Miosis 60-31-1 ACETYLCHOLINE CHLORIDE MECHANISM Modulate channel gating 60-31-1 ACETYLCHOLINE CHLORIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 60-31-1 ACETYLCHOLINE CHLORIDE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) agonist 60-31-1 ACETYLCHOLINE CHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT XXX_3_Sweating 60-31-1 ACETYLCHOLINE CHLORIDE MODE_CLASS Endogenous Receptor /Channel Ligand 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT OCU_2_Corneal Clouding 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT CVS_3_Bradycardia 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT LUN_3_Dyspnea 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT SKN_3_Flushing 60-31-1 ACETYLCHOLINE CHLORIDE MECHANISM Modulate G-protein coupled signal transduction 60-31-1 ACETYLCHOLINE CHLORIDE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 60-31-1 ACETYLCHOLINE CHLORIDE ADVERSE_EFFECT CVS_3_Hypotension 616-91-1 ACETYLCYSTEINE THERAPEUTIC_CLASS Miscellaneous Gastrointestinal Agents 616-91-1 ACETYLCYSTEINE PRODUCT_CLASS Gastrointestinal System 616-91-1 ACETYLCYSTEINE THERAPEUTIC_CLASS Antidotes 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT SKN_2_Pruritis 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT GIS_1_Dyspepsia 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT SKN_2_Flushing 616-91-1 ACETYLCYSTEINE INDICATION Acetaminophen Overdose 616-91-1 ACETYLCYSTEINE PRODUCT_CLASS Other Human Uses 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT SKN_2_Maculopapular Rash 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT LUN_3_Hemoptysis 616-91-1 ACETYLCYSTEINE INDICATION Atelectasis 616-91-1 ACETYLCYSTEINE INDICATION Meconium Ileus 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT XXX_2_Rhinorrhea 616-91-1 ACETYLCYSTEINE INDICATION Amyloidosis 616-91-1 ACETYLCYSTEINE INDICATION Chronic Obstructive Pulmonary Disease (COPD) 616-91-1 ACETYLCYSTEINE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT XXX_2_Fever 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT LUN_2_Bronchospasm 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT GIS_3_Stomatitis 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT GIS_1_Dysgeusia 616-91-1 ACETYLCYSTEINE INDICATION Cystic Fibrosis (CF) 616-91-1 ACETYLCYSTEINE MECHANISM Reactive sulfhydryl 616-91-1 ACETYLCYSTEINE INDICATION Chronic Bronchitis 616-91-1 ACETYLCYSTEINE INDICATION Bronchospasm 616-91-1 ACETYLCYSTEINE PRODUCT_CLASS Respiratory System 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 616-91-1 ACETYLCYSTEINE ADVERSE_EFFECT NEU_2_Drowsiness 55079-83-9 ACITRETIN INDICATION Lichen Planus 55079-83-9 ACITRETIN PRODUCT_CLASS Dermatologicals 55079-83-9 ACITRETIN THERAPEUTIC_CLASS Psoralens 55079-83-9 ACITRETIN INDICATION Psoriasis 302-27-2 ACONITINE ADVERSE_EFFECT GIS_1_Diarrhea 302-27-2 ACONITINE ADVERSE_EFFECT CVS_1_Arrhythmia 302-27-2 ACONITINE KNOWN_TOXICITY Cardiovascular Toxicity 302-27-2 ACONITINE TISSUE_TOXICITY Fibrillation 302-27-2 ACONITINE MECHANISM Modulate channel gating 302-27-2 ACONITINE TA_LEVEL_3 Toxicant 302-27-2 ACONITINE TISSUE_TOXICITY Cardiac Arrest 302-27-2 ACONITINE MECH_LEVEL_2 Sodium channel agonist 302-27-2 ACONITINE TA_LEVEL_1 Toxicant 302-27-2 ACONITINE STRUCTURE_ACTIVITY Toxicant, voltage-gated Na+ channel opener 302-27-2 ACONITINE MODE_CLASS Channel enhancer /opener 302-27-2 ACONITINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 302-27-2 ACONITINE ADVERSE_EFFECT LUN_3_Pulmonary Edema 302-27-2 ACONITINE ADVERSE_EFFECT NEU_2_Neurotoxicity 302-27-2 ACONITINE TISSUE_TOXICITY Death 302-27-2 ACONITINE ADVERSE_EFFECT CVS_2_Ventricular Arrhythmia 302-27-2 ACONITINE KNOWN_TOXICITY Miscellaneous 302-27-2 ACONITINE MESH_LEVEL_1 Heterocyclic Compounds 302-27-2 ACONITINE TISSUE_TOXICITY Arrhythmia 302-27-2 ACONITINE ADVERSE_EFFECT CVS_2_Tachycardia 302-27-2 ACONITINE ADVERSE_EFFECT CVS_2_Extrasystoles 302-27-2 ACONITINE PRODUCT_CLASS Toxicants 302-27-2 ACONITINE MECH_LEVEL_1 Modulate channel gating 302-27-2 ACONITINE TISSUE_TOXICITY Extrasystoles 302-27-2 ACONITINE ADVERSE_EFFECT NEU_3_Cerebral Edema 302-27-2 ACONITINE MESH_LEVEL_2 Alkaloids 302-27-2 ACONITINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 302-27-2 ACONITINE ADVERSE_EFFECT XXX_3_Death 302-27-2 ACONITINE ZERO_CLASS N 302-27-2 ACONITINE ACTIVITY_CLASS Toxicant 302-27-2 ACONITINE TA_LEVEL_2 Toxicant 302-27-2 ACONITINE MESH_LEVEL_3 Aconite 302-27-2 ACONITINE MECH_LEVEL_3 Voltage-gated Na+ channel 302-27-2 ACONITINE ADVERSE_EFFECT CVS_2_Fibrillation 302-27-2 ACONITINE TISSUE_TOXICITY Ventricular Arrhythmia 8048-52-0 ACRIFLAVINE INDICATION Myocardial Ischemia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT MSK_2_Myalgia 50-76-0 DACTINOMYCIN THERAPEUTIC_CLASS Antineoplastics 50-76-0 DACTINOMYCIN INDICATION Testicular Cancer / Carcinoma of the Testis 50-76-0 DACTINOMYCIN TISSUE_TOXICITY Death 50-76-0 DACTINOMYCIN ADVERSE_EFFECT BBM_2_Thrombocytopenia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT BBM_2_Leukopenia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT GIS_2_Stomatitis 50-76-0 DACTINOMYCIN MECH_LEVEL_3 DNA damage 50-76-0 DACTINOMYCIN TA_LEVEL_3 Solid and soft Tumors 50-76-0 DACTINOMYCIN ADVERSE_EFFECT BBM_2_Agranulocytosis 50-76-0 DACTINOMYCIN MESH_LEVEL_1 Heterocyclic Compounds 50-76-0 DACTINOMYCIN MECHANISM Inhibit DNA synthesis, repair, and function 50-76-0 DACTINOMYCIN ADVERSE_EFFECT GIS_2_Dysphagia 50-76-0 DACTINOMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 50-76-0 DACTINOMYCIN MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 50-76-0 DACTINOMYCIN TA_LEVEL_1 Oncology 50-76-0 DACTINOMYCIN INDICATION Wilms' Tumor 50-76-0 DACTINOMYCIN INDICATION Gestational Trophoblastic Neoplasia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-76-0 DACTINOMYCIN ADVERSE_EFFECT ELT_2_Hypocalcemia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT XXX_2_Pharyngitis 50-76-0 DACTINOMYCIN ADVERSE_EFFECT GIS_2_Diarrhea 50-76-0 DACTINOMYCIN ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 50-76-0 DACTINOMYCIN ADVERSE_EFFECT XXX_3_Death 50-76-0 DACTINOMYCIN ACTIVITY_CLASS DNA damager 50-76-0 DACTINOMYCIN STRUCTURE_ACTIVITY DNA intercalator 50-76-0 DACTINOMYCIN INDICATION Ewing's Sarcoma 50-76-0 DACTINOMYCIN ADVERSE_EFFECT SKN_2_Acne 50-76-0 DACTINOMYCIN PRODUCT_CLASS Anti-cancers 50-76-0 DACTINOMYCIN MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 50-76-0 DACTINOMYCIN ADVERSE_EFFECT XXX_2_Malaise 50-76-0 DACTINOMYCIN ADVERSE_EFFECT END_2_Growth Inhibition 50-76-0 DACTINOMYCIN ADVERSE_EFFECT LUN_2_Pneumonia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT LIV_2_Hepatomegaly 50-76-0 DACTINOMYCIN ADVERSE_EFFECT BBM_2_Anemia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT BBM_2_Pancytopenia 50-76-0 DACTINOMYCIN MESH_LEVEL_3 Dactinomycin 50-76-0 DACTINOMYCIN ZERO_CLASS N 50-76-0 DACTINOMYCIN KNOWN_TOXICITY Miscellaneous 50-76-0 DACTINOMYCIN ADVERSE_EFFECT GIS_2_Abdominal Pain 50-76-0 DACTINOMYCIN ADVERSE_EFFECT PSY_2_Anorexia 50-76-0 DACTINOMYCIN ADVERSE_EFFECT XXX_2_Infection 50-76-0 DACTINOMYCIN ADVERSE_EFFECT XXX_2_Fatigue 50-76-0 DACTINOMYCIN INDICATION Neoplasm / Cancer / Tumor 50-76-0 DACTINOMYCIN MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 50-76-0 DACTINOMYCIN INDICATION Rhabdomyosarcoma 50-76-0 DACTINOMYCIN TA_LEVEL_2 DNA damage 59277-89-3 ACYCLOVIR TISSUE_TOXICITY Renal Failure 59277-89-3 ACYCLOVIR ADVERSE_EFFECT BBM_2_Anemia 59277-89-3 ACYCLOVIR ADVERSE_EFFECT GIS_1_Vomiting 59277-89-3 ACYCLOVIR ADVERSE_EFFECT GIS_1_Diarrhea 59277-89-3 ACYCLOVIR THERAPEUTIC_CLASS Antivirals, Systemic 59277-89-3 ACYCLOVIR INDICATION Herpes Zoster / Shingles 59277-89-3 ACYCLOVIR ADVERSE_EFFECT GIS_1_Nausea 59277-89-3 ACYCLOVIR ADVERSE_EFFECT GIS_2_Gastrointestinal Distress 59277-89-3 ACYCLOVIR ADVERSE_EFFECT XXX_2_Peripheral Edema 59277-89-3 ACYCLOVIR ADVERSE_EFFECT KID_2_Hematuria 59277-89-3 ACYCLOVIR MODE_CLASS Enzyme Inhibitor, selective 59277-89-3 ACYCLOVIR ACTIVITY_CLASS Anti-viral 59277-89-3 ACYCLOVIR KNOWN_TOXICITY Nephrotoxicity 59277-89-3 ACYCLOVIR ADVERSE_EFFECT IMU_2_Anaphylaxis 59277-89-3 ACYCLOVIR ADVERSE_EFFECT CVS_2_Hypotension 59277-89-3 ACYCLOVIR INDICATION Herpes Genitalis / Genital Herpes 59277-89-3 ACYCLOVIR MECH_LEVEL_2 Inhibit viral DNA synthesis 59277-89-3 ACYCLOVIR MECHANISM Inhibit viral DNA synthesis 59277-89-3 ACYCLOVIR MECH_LEVEL_3 DNA-directed DNA polymerase 59277-89-3 ACYCLOVIR MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 59277-89-3 ACYCLOVIR TA_LEVEL_2 Anti-viral 59277-89-3 ACYCLOVIR TA_LEVEL_1 Infectious Disease 59277-89-3 ACYCLOVIR MECH_LEVEL_1 Anti-viral 59277-89-3 ACYCLOVIR ADVERSE_EFFECT LIV_2_Increased Liver Function Tests 59277-89-3 ACYCLOVIR ADVERSE_EFFECT BBM_2_Leukopenia 59277-89-3 ACYCLOVIR ADVERSE_EFFECT PSY_2_Agitation 59277-89-3 ACYCLOVIR ADVERSE_EFFECT NEU_1_Headache 59277-89-3 ACYCLOVIR ADVERSE_EFFECT PSY_2_Delirium 59277-89-3 ACYCLOVIR PRODUCT_CLASS Anti-infectives 59277-89-3 ACYCLOVIR INDICATION Varicella / Chicken Pox 59277-89-3 ACYCLOVIR MESH_LEVEL_1 Heterocyclic Compounds 59277-89-3 ACYCLOVIR KNOWN_TOXICITY Cardiovascular Toxicity 59277-89-3 ACYCLOVIR TISSUE_TOXICITY Hypotension 59277-89-3 ACYCLOVIR ZERO_CLASS N 59277-89-3 ACYCLOVIR ADVERSE_EFFECT XXX_1_Malaise 59277-89-3 ACYCLOVIR MESH_LEVEL_3 Purines 59277-89-3 ACYCLOVIR ADVERSE_EFFECT IMU_2_Angioedema 59277-89-3 ACYCLOVIR ADVERSE_EFFECT MSK_2_Myalgia 59277-89-3 ACYCLOVIR STRUCTURE_ACTIVITY Viral DNA-polymerase inhibitor 59277-89-3 ACYCLOVIR THERAPEUTIC_CLASS Antivirals 59277-89-3 ACYCLOVIR TA_LEVEL_3 viral replication inhibitor 59277-89-3 ACYCLOVIR TISSUE_TOXICITY Hematuria 59277-89-3 ACYCLOVIR ADVERSE_EFFECT KID_2_Renal Failure 59277-89-3 ACYCLOVIR ADVERSE_EFFECT BBM_2_Thrombocytopenia 106685-40-9 ADAPALENE PRODUCT_CLASS Dermatologicals 106685-40-9 ADAPALENE STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 106685-40-9 ADAPALENE INDICATION Acne / Acne Vulgaris 106685-40-9 ADAPALENE MODE_CLASS Receptor Agonist, selective 106685-40-9 ADAPALENE THERAPEUTIC_CLASS Acne Preparations 106685-40-9 ADAPALENE MECHANISM Modulate gene transcription 58-61-7 ADENOSINE ADVERSE_EFFECT NEU_1_Headache 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_1_Sinus Bradycardia 58-61-7 ADENOSINE INDICATION Wolff-Parkinson-White (WPW) Syndrome 58-61-7 ADENOSINE ADVERSE_EFFECT NEU_1_Syncope 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_2_Ventricular Tachycardia 58-61-7 ADENOSINE ADVERSE_EFFECT NEU_1_Dizziness 58-61-7 ADENOSINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_1_Vasodilation 58-61-7 ADENOSINE TISSUE_TOXICITY Atrioventricular Blockade 58-61-7 ADENOSINE TISSUE_TOXICITY Premature Ventricular Contrations (PVCs) 58-61-7 ADENOSINE MECHANISM Modulate G-protein coupled signal transduction 58-61-7 ADENOSINE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 58-61-7 ADENOSINE PRODUCT_CLASS Cardiovasculars 58-61-7 ADENOSINE INDICATION Paroxysmal Supraventricular Tachycardia 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_1_Premature Atrial Contractions 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_3_Asystole 58-61-7 ADENOSINE MODE_CLASS Endogenous Receptor /Channel Ligand 58-61-7 ADENOSINE KNOWN_TOXICITY Cardiovascular Toxicity 58-61-7 ADENOSINE TISSUE_TOXICITY Myocardial Infarction 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_1_Sinus Tachycardia 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_1_Cardiac Arrhythmia 58-61-7 ADENOSINE STRUCTURE_ACTIVITY Adenosine receptor agonist, 58-61-7 ADENOSINE TISSUE_TOXICITY Cardiac Arrhythmia 58-61-7 ADENOSINE TISSUE_TOXICITY Hypotension 58-61-7 ADENOSINE TISSUE_TOXICITY Asystole 58-61-7 ADENOSINE TISSUE_TOXICITY Ventricular Tachycardia 58-61-7 ADENOSINE THERAPEUTIC_CLASS Antiarrhythmic Agents 58-61-7 ADENOSINE TISSUE_TOXICITY Ventricular Fibrillation 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 58-61-7 ADENOSINE TISSUE_TOXICITY Cardiac Arrest 58-61-7 ADENOSINE INDICATION Myocardial Perfusion Scintigraphy 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_2_Hypotension 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_3_Myocardial Infarction 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_2_Ventricular Fibrillation 58-61-7 ADENOSINE ADVERSE_EFFECT LUN_1_Bronchospasm 58-61-7 ADENOSINE ADVERSE_EFFECT CVS_1_Premature Ventricular Contrations (PVCs) 58-61-7 ADENOSINE ADVERSE_EFFECT LUN_2_Dyspnea 58-61-7 ADENOSINE ADVERSE_EFFECT NEU_1_Paresthesia 58-61-7 ADENOSINE ADVERSE_EFFECT SKN_1_Flushing 161814-49-9 AMPRENAVIR MESH_LEVEL_1 Organic Chemicals 161814-49-9 AMPRENAVIR MESH_LEVEL_3 Sulfonamides 161814-49-9 AMPRENAVIR ZERO_CLASS N 161814-49-9 AMPRENAVIR ADVERSE_EFFECT NEU_3_Paresthesia 161814-49-9 AMPRENAVIR ADVERSE_EFFECT GIS_1_Diarrhea 161814-49-9 AMPRENAVIR INDICATION Human Immunodeficiency Virus (HIV) Disease 161814-49-9 AMPRENAVIR MESH_LEVEL_2 Amides 161814-49-9 AMPRENAVIR MECHANISM Inhibit post transcriptional protein processing 161814-49-9 AMPRENAVIR MECH_LEVEL_2 viral protease inhibition 161814-49-9 AMPRENAVIR MECH_LEVEL_1 Anti-viral 161814-49-9 AMPRENAVIR MODE_CLASS Enzyme Inhibitor 161814-49-9 AMPRENAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 161814-49-9 AMPRENAVIR ADVERSE_EFFECT SKN_2_Pruritis 161814-49-9 AMPRENAVIR ADVERSE_EFFECT PSY_3_Depressed Mood 161814-49-9 AMPRENAVIR PRODUCT_CLASS Anti-infectives 161814-49-9 AMPRENAVIR ACTIVITY_CLASS Anti-viral 161814-49-9 AMPRENAVIR ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 161814-49-9 AMPRENAVIR ADVERSE_EFFECT GIS_1_Nausea 161814-49-9 AMPRENAVIR MECH_LEVEL_3 HIV-1 retropepsin 161814-49-9 AMPRENAVIR TA_LEVEL_2 Anti-viral 161814-49-9 AMPRENAVIR TA_LEVEL_1 Infectious Disease 161814-49-9 AMPRENAVIR ADVERSE_EFFECT GIS_1_Abdominal Pain 161814-49-9 AMPRENAVIR ADVERSE_EFFECT GIS_1_Vomiting 161814-49-9 AMPRENAVIR THERAPEUTIC_CLASS Antivirals, Systemic 161814-49-9 AMPRENAVIR TA_LEVEL_3 viral replication inhibitor 138112-76-2 AGOMELATINE PRODUCT_CLASS Central Nervous System (CNS) 138112-76-2 AGOMELATINE INDICATION Anxiety Disorders 138112-76-2 AGOMELATINE THERAPEUTIC_CLASS Sedatives/Hypnotics 138112-76-2 AGOMELATINE THERAPEUTIC_CLASS Antidepressants 138112-76-2 AGOMELATINE INDICATION Depression 4360-12-7 AJMALINE TISSUE_TOXICITY Cardiac Arrhythmia 4360-12-7 AJMALINE TISSUE_TOXICITY Hypotension 4360-12-7 AJMALINE INDICATION Ventricular Premature Beats (Ventricular Extrasystoles) 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 4360-12-7 AJMALINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 4360-12-7 AJMALINE MODE_CLASS Channel Blocker 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_2_Cardiac Insufficiency 4360-12-7 AJMALINE ADVERSE_EFFECT OCU_2_Diplopia 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_2_Ventricular Fibrillation 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_2_Tachycardia 4360-12-7 AJMALINE TISSUE_TOXICITY Cardiovascular Collapse 4360-12-7 AJMALINE ADVERSE_EFFECT NEU_3_Coma 4360-12-7 AJMALINE TISSUE_TOXICITY Anuria 4360-12-7 AJMALINE MECHANISM Block neural transmission 4360-12-7 AJMALINE KNOWN_TOXICITY Cardiovascular Toxicity 4360-12-7 AJMALINE TISSUE_TOXICITY Cardiac Insufficiency 4360-12-7 AJMALINE THERAPEUTIC_CLASS Antiarrhythmic Agents 4360-12-7 AJMALINE PRODUCT_CLASS Cardiovasculars 4360-12-7 AJMALINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 4360-12-7 AJMALINE ADVERSE_EFFECT LIV_3_Jaundice 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 4360-12-7 AJMALINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_2_Bradycardia 4360-12-7 AJMALINE TISSUE_TOXICITY Ventricular Fibrillation 4360-12-7 AJMALINE INDICATION Paroxysmal Supraventricular Tachycardia 4360-12-7 AJMALINE ADVERSE_EFFECT BBM_3_Agranulocytosis 4360-12-7 AJMALINE ADVERSE_EFFECT CVS_2_Hypotension 4360-12-7 AJMALINE KNOWN_TOXICITY Nephrotoxicity 4360-12-7 AJMALINE ADVERSE_EFFECT KID_3_Anuria 4410-48-4 AJMALINE ADVERSE_EFFECT NEU_3_Coma 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_2_Cardiac Arrhythmia 4410-48-4 AJMALINE TISSUE_TOXICITY Cardiac Insufficiency 4410-48-4 AJMALINE KNOWN_TOXICITY Cardiovascular Toxicity 4410-48-4 AJMALINE ADVERSE_EFFECT KID_3_Anuria 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 4410-48-4 AJMALINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_2_Bradycardia 4410-48-4 AJMALINE INDICATION Paroxysmal Supraventricular Tachycardia 4410-48-4 AJMALINE TISSUE_TOXICITY Ventricular Fibrillation 4410-48-4 AJMALINE MODE_CLASS Channel Blocker 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_2_Cardiac Insufficiency 4410-48-4 AJMALINE ADVERSE_EFFECT OCU_2_Diplopia 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_2_Ventricular Fibrillation 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_2_Tachycardia 4410-48-4 AJMALINE TISSUE_TOXICITY Cardiovascular Collapse 4410-48-4 AJMALINE TISSUE_TOXICITY Anuria 4410-48-4 AJMALINE THERAPEUTIC_CLASS Antiarrhythmic Agents 4410-48-4 AJMALINE PRODUCT_CLASS Cardiovasculars 4410-48-4 AJMALINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, lipophylic amine 4410-48-4 AJMALINE ADVERSE_EFFECT LIV_3_Jaundice 4410-48-4 AJMALINE ADVERSE_EFFECT BBM_3_Agranulocytosis 4410-48-4 AJMALINE ADVERSE_EFFECT CVS_2_Hypotension 4410-48-4 AJMALINE KNOWN_TOXICITY Nephrotoxicity 4410-48-4 AJMALINE TISSUE_TOXICITY Cardiac Arrhythmia 4410-48-4 AJMALINE TISSUE_TOXICITY Hypotension 4410-48-4 AJMALINE INDICATION Ventricular Premature Beats (Ventricular Extrasystoles) 4410-48-4 AJMALINE ADVERSE_EFFECT LIV_3_Acute Cholestatic Hepatitis 4410-48-4 AJMALINE MECHANISM Block neural transmission 60504-57-6 AKLAVINE THERAPEUTIC_CLASS Antineoplastics 60504-57-6 AKLAVINE PRODUCT_CLASS Anti-cancers 60504-57-6 AKLAVINE STRUCTURE_ACTIVITY DNA intercalator, anthracycline 11002-83-8 AKLAVINE PRODUCT_CLASS Anti-cancers 11002-83-8 AKLAVINE STRUCTURE_ACTIVITY DNA intercalator, anthracycline 11002-83-8 AKLAVINE THERAPEUTIC_CLASS Antineoplastics 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT NEU_2_Increased Intracranial Pressure 54965-21-8 ALBENDAZOLE THERAPEUTIC_CLASS Antiparasitics 54965-21-8 ALBENDAZOLE INDICATION Neurocysticercosis 54965-21-8 ALBENDAZOLE KNOWN_TOXICITY Nephrotoxicity 54965-21-8 ALBENDAZOLE MESH_LEVEL_3 Benzimidazoles 54965-21-8 ALBENDAZOLE PRODUCT_CLASS Anti-infectives 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT NEU_1_Vertigo 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT KID_3_Acute Renal Failure 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT NEU_1_Headache 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT BBM_3_Agranulocytosis 54965-21-8 ALBENDAZOLE ZERO_CLASS N 54965-21-8 ALBENDAZOLE TISSUE_TOXICITY Acute Renal Failure 54965-21-8 ALBENDAZOLE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 54965-21-8 ALBENDAZOLE MECHANISM Inhibit microtubule dependent glucose uptake 54965-21-8 ALBENDAZOLE MECH_LEVEL_3 Microtubule / tubulin 54965-21-8 ALBENDAZOLE MECH_LEVEL_1 anthelmintic 54965-21-8 ALBENDAZOLE TA_LEVEL_3 antiparasitic imidazoles 54965-21-8 ALBENDAZOLE MECH_LEVEL_2 Inhibit microtubule dependent glucose uptake 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT BBM_3_Leukopenia 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT BBM_3_Pancytopenia 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT SKN_3_Rash 54965-21-8 ALBENDAZOLE STRUCTURE_ACTIVITY Tubulin binder, benzimidazole 54965-21-8 ALBENDAZOLE MESH_LEVEL_1 Heterocyclic Compounds 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT BBM_3_Thrombocytopenia 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT SKN_2_Alopecia / Hair Loss 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT NEU_2_Meningeal Signs 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT XXX_2_Fever 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT IMU_3_Allergic Reactions 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT IMU_3_Urticaria 54965-21-8 ALBENDAZOLE MODE_CLASS Distorts /blocks macromolecular scaffold function 54965-21-8 ALBENDAZOLE TA_LEVEL_2 anthelmintic 54965-21-8 ALBENDAZOLE TA_LEVEL_1 Infectious Disease 54965-21-8 ALBENDAZOLE MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 54965-21-8 ALBENDAZOLE INDICATION Cystic Hydatid Disease / Unilocular Hydatid Disease 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT LIV_1_Abnormal Liver Function Tests 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 54965-21-8 ALBENDAZOLE ADVERSE_EFFECT NEU_1_Dizziness 148563-16-0 LEVALBUTEROL STRUCTURE_ACTIVITY Adrenoceptor agonist 148563-16-0 LEVALBUTEROL THERAPEUTIC_CLASS Bronchodilators 148563-16-0 LEVALBUTEROL MODE_CLASS Receptor Agonist, selective 148563-16-0 LEVALBUTEROL INDICATION Asthma 148563-16-0 LEVALBUTEROL INDICATION Prophylaxis of Bronchospasm 148563-16-0 LEVALBUTEROL INDICATION Bronchospasm 148563-16-0 LEVALBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 148563-16-0 LEVALBUTEROL PRODUCT_CLASS Respiratory System 148563-16-0 LEVALBUTEROL MECHANISM Reduce bronchoconstriction 50293-90-8 LEVALBUTEROL MODE_CLASS Receptor Agonist, selective 50293-90-8 LEVALBUTEROL INDICATION Asthma 50293-90-8 LEVALBUTEROL INDICATION Prophylaxis of Bronchospasm 50293-90-8 LEVALBUTEROL STRUCTURE_ACTIVITY Adrenoceptor agonist 50293-90-8 LEVALBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 50293-90-8 LEVALBUTEROL INDICATION Bronchospasm 50293-90-8 LEVALBUTEROL MECHANISM Reduce bronchoconstriction 50293-90-8 LEVALBUTEROL PRODUCT_CLASS Respiratory System 50293-90-8 LEVALBUTEROL THERAPEUTIC_CLASS Bronchodilators 35459-13-3 LEVALBUTEROL PRODUCT_CLASS Respiratory System 35459-13-3 LEVALBUTEROL MECHANISM Reduce bronchoconstriction 35459-13-3 LEVALBUTEROL THERAPEUTIC_CLASS Bronchodilators 35459-13-3 LEVALBUTEROL MODE_CLASS Receptor Agonist, selective 35459-13-3 LEVALBUTEROL INDICATION Asthma 35459-13-3 LEVALBUTEROL INDICATION Prophylaxis of Bronchospasm 35459-13-3 LEVALBUTEROL STRUCTURE_ACTIVITY Adrenoceptor agonist 35459-13-3 LEVALBUTEROL INDICATION Bronchospasm 35459-13-3 LEVALBUTEROL INDICATION Chronic Obstructive Pulmonary Disease (COPD) 66734-13-2 ALCLOMETASONE DIPROPIONATE MECHANISM Modulate gene transcription 66734-13-2 ALCLOMETASONE DIPROPIONATE MODE_CLASS Receptor Agonist 66734-13-2 ALCLOMETASONE DIPROPIONATE INDICATION Dermatitis 66734-13-2 ALCLOMETASONE DIPROPIONATE INDICATION Pruritus / Itching 66734-13-2 ALCLOMETASONE DIPROPIONATE INDICATION Skin Diseases / Dermatoses 66734-13-2 ALCLOMETASONE DIPROPIONATE THERAPEUTIC_CLASS Corticosteroids, Topical 66734-13-2 ALCLOMETASONE DIPROPIONATE PRODUCT_CLASS Dermatologicals 121268-17-5 ALENDRONIC ACID MECH_LEVEL_2 Inhibit osteoclastic bone resorption via cholesterol biosynthesis pathway 121268-17-5 ALENDRONIC ACID INDICATION Glucocorticoid-Induced Osteoporosis 121268-17-5 ALENDRONIC ACID KNOWN_TOXICITY Embryo/Fetal Toxicity 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT EMB_3_Teratogenicity 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Constipation 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Flatulence 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_3_Peptic Ulceration 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Nausea 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Gastritis 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 121268-17-5 ALENDRONIC ACID TA_LEVEL_1 Hormones, Endocrine and Metabolic 121268-17-5 ALENDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_3_Esophagitis 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT SKN_3_Skin Rash 121268-17-5 ALENDRONIC ACID MECHANISM Inhibit bone re-absorption 121268-17-5 ALENDRONIC ACID INDICATION Paget's Disease of Bone / Osteitis Deformans 121268-17-5 ALENDRONIC ACID MECH_LEVEL_3 Farnesyl-diphosphate farnesyltransferase 121268-17-5 ALENDRONIC ACID MECH_LEVEL_1 Increase bone mass 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT IMU_3_Angioedema 121268-17-5 ALENDRONIC ACID INDICATION Prevention of Osteoporosis 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Dyspepsia 121268-17-5 ALENDRONIC ACID TA_LEVEL_3 Bisphosphonate 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_3_Esophageal Ulceration 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT MSK_2_Musculoskeletal Pain 121268-17-5 ALENDRONIC ACID MESH_LEVEL_1 Organic Chemicals 121268-17-5 ALENDRONIC ACID TISSUE_TOXICITY Teratogenicity 121268-17-5 ALENDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT NEU_2_Headache 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Abdominal Pain 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Heartburn 121268-17-5 ALENDRONIC ACID ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 121268-17-5 ALENDRONIC ACID MODE_CLASS Enzyme Inhibitor 121268-17-5 ALENDRONIC ACID ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 121268-17-5 ALENDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 121268-17-5 ALENDRONIC ACID ZERO_CLASS N 121268-17-5 ALENDRONIC ACID MESH_LEVEL_3 Diphosphonates 121268-17-5 ALENDRONIC ACID MESH_LEVEL_2 Organophosphorus Compounds 121268-17-5 ALENDRONIC ACID TA_LEVEL_2 Oesteoporosis 121268-17-5 ALENDRONIC ACID INDICATION Osteoporosis 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Constipation 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT EMB_3_Teratogenicity 66376-36-1 ALENDRONIC ACID KNOWN_TOXICITY Embryo/Fetal Toxicity 66376-36-1 ALENDRONIC ACID INDICATION Glucocorticoid-Induced Osteoporosis 66376-36-1 ALENDRONIC ACID MECH_LEVEL_2 Inhibit osteoclastic bone resorption via cholesterol biosynthesis pathway 66376-36-1 ALENDRONIC ACID TA_LEVEL_3 Bisphosphonate 66376-36-1 ALENDRONIC ACID INDICATION Osteoporosis 66376-36-1 ALENDRONIC ACID MESH_LEVEL_2 Organophosphorus Compounds 66376-36-1 ALENDRONIC ACID MESH_LEVEL_3 Diphosphonates 66376-36-1 ALENDRONIC ACID ZERO_CLASS N 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Gastritis 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Flatulence 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_3_Peptic Ulceration 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Nausea 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 66376-36-1 ALENDRONIC ACID TA_LEVEL_1 Hormones, Endocrine and Metabolic 66376-36-1 ALENDRONIC ACID PRODUCT_CLASS Hormones, Endocrine and Metabolic 66376-36-1 ALENDRONIC ACID TA_LEVEL_2 Oesteoporosis 66376-36-1 ALENDRONIC ACID STRUCTURE_ACTIVITY Farnesyl-PP synthase inhibitor 66376-36-1 ALENDRONIC ACID ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 66376-36-1 ALENDRONIC ACID MODE_CLASS Enzyme Inhibitor 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Heartburn 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Abdominal Pain 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT NEU_2_Headache 66376-36-1 ALENDRONIC ACID THERAPEUTIC_CLASS Bone Mineral Homeostasis 66376-36-1 ALENDRONIC ACID TISSUE_TOXICITY Teratogenicity 66376-36-1 ALENDRONIC ACID INDICATION Prevention of Osteoporosis 66376-36-1 ALENDRONIC ACID MESH_LEVEL_1 Organic Chemicals 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT MSK_2_Musculoskeletal Pain 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_3_Esophageal Ulceration 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_2_Dyspepsia 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT IMU_3_Angioedema 66376-36-1 ALENDRONIC ACID MECH_LEVEL_1 Increase bone mass 66376-36-1 ALENDRONIC ACID MECH_LEVEL_3 Farnesyl-diphosphate farnesyltransferase 66376-36-1 ALENDRONIC ACID INDICATION Paget's Disease of Bone / Osteitis Deformans 66376-36-1 ALENDRONIC ACID MECHANISM Inhibit bone re-absorption 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT SKN_3_Skin Rash 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT GIS_3_Esophagitis 66376-36-1 ALENDRONIC ACID ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 1162-65-8 AFLATOXIN B1 MODE_CLASS Distorts /blocks macromolecular scaffold function 1162-65-8 AFLATOXIN B1 STRUCTURE_ACTIVITY Toxicant, DNA alkylator 1162-65-8 AFLATOXIN B1 KNOWN_TOXICITY Mutagenicity 1162-65-8 AFLATOXIN B1 TISSUE_TOXICITY Carcinogenicity 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT NEU_2_Convulsions 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT LIV_2_Fatty Liver 1162-65-8 AFLATOXIN B1 PRODUCT_CLASS Toxicants 1162-65-8 AFLATOXIN B1 KNOWN_TOXICITY Embryo/Fetal Toxicity 1162-65-8 AFLATOXIN B1 KNOWN_TOXICITY Miscellaneous 1162-65-8 AFLATOXIN B1 TISSUE_TOXICITY Genotoxicity 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT DNA_1_Carcinogenicity 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT XXX_3_Death 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT BBM_2_Anemia 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT IMU_3_Immunologic Toxicity 1162-65-8 AFLATOXIN B1 TISSUE_TOXICITY Death 1162-65-8 AFLATOXIN B1 KNOWN_TOXICITY Carcinogenicity 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT EMB_1_Teratogenicity 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT GIS_1_Nausea / Vomiting 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT NEU_2_Coma 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT LIV_2_Hepatic Damage 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT DNA_3_Genotoxicity 1162-65-8 AFLATOXIN B1 ACTIVITY_CLASS Toxicant, DNA damaging 1162-65-8 AFLATOXIN B1 ZERO_CLASS N 1162-65-8 AFLATOXIN B1 MECHANISM Inhibit DNA synthesis, repair, and function 1162-65-8 AFLATOXIN B1 TISSUE_TOXICITY Teratogenicity 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT LUN_2_Pulmonary Edema 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT XXX_3_Infection 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT NEU_2_Cerebral Edema 1162-65-8 AFLATOXIN B1 ADVERSE_EFFECT GIS_1_Abdominal Pain 11003-08-0 AFLATOXIN B1 KNOWN_TOXICITY Mutagenicity 11003-08-0 AFLATOXIN B1 TISSUE_TOXICITY Carcinogenicity 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT NEU_2_Convulsions 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT LIV_2_Fatty Liver 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT GIS_1_Abdominal Pain 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT NEU_2_Cerebral Edema 11003-08-0 AFLATOXIN B1 PRODUCT_CLASS Toxicants 11003-08-0 AFLATOXIN B1 KNOWN_TOXICITY Embryo/Fetal Toxicity 11003-08-0 AFLATOXIN B1 KNOWN_TOXICITY Miscellaneous 11003-08-0 AFLATOXIN B1 TISSUE_TOXICITY Genotoxicity 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT DNA_1_Carcinogenicity 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT XXX_3_Death 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT BBM_2_Anemia 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT IMU_3_Immunologic Toxicity 11003-08-0 AFLATOXIN B1 TISSUE_TOXICITY Death 11003-08-0 AFLATOXIN B1 KNOWN_TOXICITY Carcinogenicity 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT EMB_1_Teratogenicity 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT GIS_1_Nausea / Vomiting 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT NEU_2_Coma 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT LIV_2_Hepatic Damage 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT DNA_3_Genotoxicity 11003-08-0 AFLATOXIN B1 ACTIVITY_CLASS Toxicant, DNA damaging 11003-08-0 AFLATOXIN B1 ZERO_CLASS N 11003-08-0 AFLATOXIN B1 MECHANISM Inhibit DNA synthesis, repair, and function 11003-08-0 AFLATOXIN B1 TISSUE_TOXICITY Teratogenicity 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT LUN_2_Pulmonary Edema 11003-08-0 AFLATOXIN B1 ADVERSE_EFFECT XXX_3_Infection 11003-08-0 AFLATOXIN B1 MODE_CLASS Distorts /blocks macromolecular scaffold function 11003-08-0 AFLATOXIN B1 STRUCTURE_ACTIVITY Toxicant, DNA alkylator 71195-58-9 ALFENTANIL ADVERSE_EFFECT GIS_1_Constipation 71195-58-9 ALFENTANIL THERAPEUTIC_CLASS General Anesthetics, Intravenous 71195-58-9 ALFENTANIL TISSUE_TOXICITY Asystole 71195-58-9 ALFENTANIL ADVERSE_EFFECT CVS_2_Bradycardia 71195-58-9 ALFENTANIL ADVERSE_EFFECT OCU_3_Blurred Vision 71195-58-9 ALFENTANIL ADVERSE_EFFECT CVS_3_Hypertension 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_2_Dizziness 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_3_Seizures 71195-58-9 ALFENTANIL ADVERSE_EFFECT CVS_3_Asystole 71195-58-9 ALFENTANIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 71195-58-9 ALFENTANIL PRODUCT_CLASS Central Nervous System (CNS) 71195-58-9 ALFENTANIL INDICATION Initiation / Maintenance of Sedation 71195-58-9 ALFENTANIL ADVERSE_EFFECT CVS_2_Hypotension 71195-58-9 ALFENTANIL ADVERSE_EFFECT XXX_3_Tolerance 71195-58-9 ALFENTANIL ADVERSE_EFFECT CVS_1_Chest Wall Rigidity 71195-58-9 ALFENTANIL ADVERSE_EFFECT PSY_3_Euphoria 71195-58-9 ALFENTANIL ADVERSE_EFFECT XXX_3_Dysesthesia 71195-58-9 ALFENTANIL MODE_CLASS Receptor Agonist 71195-58-9 ALFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 71195-58-9 ALFENTANIL MECHANISM Modulate neural transmission 71195-58-9 ALFENTANIL INDICATION Severe Pain 71195-58-9 ALFENTANIL INDICATION Induction / Maintenance of Anesthesia 71195-58-9 ALFENTANIL KNOWN_TOXICITY Cardiovascular Toxicity 71195-58-9 ALFENTANIL ADVERSE_EFFECT GUS_3_Urinary Retention 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_1_Sedation 71195-58-9 ALFENTANIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 71195-58-9 ALFENTANIL ADVERSE_EFFECT SKN_2_Pruritis 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_2_Headache 71195-58-9 ALFENTANIL ADVERSE_EFFECT PSY_3_Confusion 71195-58-9 ALFENTANIL ADVERSE_EFFECT LUN_3_Apnea 71195-58-9 ALFENTANIL ADVERSE_EFFECT IMU_3_Urticaria 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_3_Involuntray Movements 71195-58-9 ALFENTANIL TISSUE_TOXICITY Hypotension 71195-58-9 ALFENTANIL ADVERSE_EFFECT LUN_3_Respiratory Depression 71195-58-9 ALFENTANIL ADVERSE_EFFECT PSY_3_CNS Depression 71195-58-9 ALFENTANIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 71195-58-9 ALFENTANIL ADVERSE_EFFECT NEU_1_Drowsiness 71195-58-9 ALFENTANIL ADVERSE_EFFECT LUN_3_Respiratory Arrest 71195-58-9 ALFENTANIL ADVERSE_EFFECT PSY_3_Agitation 69049-06-5 ALFENTANIL ADVERSE_EFFECT CVS_1_Chest Wall Rigidity 69049-06-5 ALFENTANIL ADVERSE_EFFECT XXX_3_Dysesthesia 69049-06-5 ALFENTANIL ADVERSE_EFFECT PSY_3_Euphoria 69049-06-5 ALFENTANIL ADVERSE_EFFECT XXX_3_Tolerance 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_2_Headache 69049-06-5 ALFENTANIL ADVERSE_EFFECT CVS_2_Hypotension 69049-06-5 ALFENTANIL ADVERSE_EFFECT GIS_1_Constipation 69049-06-5 ALFENTANIL INDICATION Initiation / Maintenance of Sedation 69049-06-5 ALFENTANIL PRODUCT_CLASS Central Nervous System (CNS) 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 69049-06-5 ALFENTANIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 69049-06-5 ALFENTANIL ADVERSE_EFFECT CVS_3_Asystole 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_3_Seizures 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_2_Dizziness 69049-06-5 ALFENTANIL ADVERSE_EFFECT CVS_3_Hypertension 69049-06-5 ALFENTANIL ADVERSE_EFFECT OCU_3_Blurred Vision 69049-06-5 ALFENTANIL ADVERSE_EFFECT CVS_2_Bradycardia 69049-06-5 ALFENTANIL TISSUE_TOXICITY Asystole 69049-06-5 ALFENTANIL THERAPEUTIC_CLASS General Anesthetics, Intravenous 69049-06-5 ALFENTANIL ADVERSE_EFFECT LUN_3_Apnea 69049-06-5 ALFENTANIL ADVERSE_EFFECT PSY_3_Agitation 69049-06-5 ALFENTANIL ADVERSE_EFFECT LUN_3_Respiratory Arrest 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_1_Drowsiness 69049-06-5 ALFENTANIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 69049-06-5 ALFENTANIL ADVERSE_EFFECT PSY_3_CNS Depression 69049-06-5 ALFENTANIL ADVERSE_EFFECT LUN_3_Respiratory Depression 69049-06-5 ALFENTANIL TISSUE_TOXICITY Hypotension 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_3_Involuntray Movements 69049-06-5 ALFENTANIL ADVERSE_EFFECT IMU_3_Urticaria 69049-06-5 ALFENTANIL ADVERSE_EFFECT PSY_3_Confusion 69049-06-5 ALFENTANIL ADVERSE_EFFECT SKN_2_Pruritis 69049-06-5 ALFENTANIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 69049-06-5 ALFENTANIL ADVERSE_EFFECT NEU_1_Sedation 69049-06-5 ALFENTANIL ADVERSE_EFFECT GUS_3_Urinary Retention 69049-06-5 ALFENTANIL KNOWN_TOXICITY Cardiovascular Toxicity 69049-06-5 ALFENTANIL INDICATION Induction / Maintenance of Anesthesia 69049-06-5 ALFENTANIL INDICATION Severe Pain 69049-06-5 ALFENTANIL MECHANISM Modulate neural transmission 69049-06-5 ALFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 69049-06-5 ALFENTANIL MODE_CLASS Receptor Agonist 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_2_Headache 70879-28-6 ALFENTANIL ADVERSE_EFFECT CVS_2_Bradycardia 70879-28-6 ALFENTANIL INDICATION Severe Pain 70879-28-6 ALFENTANIL TISSUE_TOXICITY Hypotension 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_3_Involuntray Movements 70879-28-6 ALFENTANIL ADVERSE_EFFECT IMU_3_Urticaria 70879-28-6 ALFENTANIL MODE_CLASS Receptor Agonist 70879-28-6 ALFENTANIL ADVERSE_EFFECT PSY_3_Confusion 70879-28-6 ALFENTANIL ADVERSE_EFFECT SKN_2_Pruritis 70879-28-6 ALFENTANIL ADVERSE_EFFECT GIS_1_Nausea / Vomiting 70879-28-6 ALFENTANIL MECHANISM Modulate neural transmission 70879-28-6 ALFENTANIL INDICATION Induction / Maintenance of Anesthesia 70879-28-6 ALFENTANIL STRUCTURE_ACTIVITY Opioid receptor (mu) agonist 70879-28-6 ALFENTANIL ADVERSE_EFFECT XXX_3_Dysesthesia 70879-28-6 ALFENTANIL ADVERSE_EFFECT LUN_3_Respiratory Depression 70879-28-6 ALFENTANIL ADVERSE_EFFECT LUN_3_Apnea 70879-28-6 ALFENTANIL ADVERSE_EFFECT PSY_3_Agitation 70879-28-6 ALFENTANIL ADVERSE_EFFECT LUN_3_Respiratory Arrest 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_1_Drowsiness 70879-28-6 ALFENTANIL ADVERSE_EFFECT PSY_3_Euphoria 70879-28-6 ALFENTANIL ADVERSE_EFFECT CVS_1_Chest Wall Rigidity 70879-28-6 ALFENTANIL ADVERSE_EFFECT XXX_3_Tolerance 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_1_Sedation 70879-28-6 ALFENTANIL ADVERSE_EFFECT CVS_2_Hypotension 70879-28-6 ALFENTANIL ADVERSE_EFFECT GIS_1_Constipation 70879-28-6 ALFENTANIL INDICATION Initiation / Maintenance of Sedation 70879-28-6 ALFENTANIL PRODUCT_CLASS Central Nervous System (CNS) 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_3_Opiate withdrawal symptoms 70879-28-6 ALFENTANIL ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 70879-28-6 ALFENTANIL ADVERSE_EFFECT CVS_3_Asystole 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_3_Seizures 70879-28-6 ALFENTANIL ADVERSE_EFFECT NEU_2_Dizziness 70879-28-6 ALFENTANIL ADVERSE_EFFECT CVS_3_Hypertension 70879-28-6 ALFENTANIL ADVERSE_EFFECT OCU_3_Blurred Vision 70879-28-6 ALFENTANIL ADVERSE_EFFECT CVS_3_Sinus Tachycardia 70879-28-6 ALFENTANIL TISSUE_TOXICITY Asystole 70879-28-6 ALFENTANIL THERAPEUTIC_CLASS General Anesthetics, Intravenous 70879-28-6 ALFENTANIL ADVERSE_EFFECT PSY_3_CNS Depression 70879-28-6 ALFENTANIL ADVERSE_EFFECT GUS_3_Urinary Retention 70879-28-6 ALFENTANIL KNOWN_TOXICITY Cardiovascular Toxicity 63824-12-4 ALICONAZOLE PRODUCT_CLASS Anti-infectives 63824-12-4 ALICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 63824-12-4 ALICONAZOLE THERAPEUTIC_CLASS Antifungals 63824-12-4 ALICONAZOLE MODE_CLASS Enzyme Inhibitor 315-30-0 ALLOPURINOL INDICATION Hyperuricemia 315-30-0 ALLOPURINOL MECH_LEVEL_1 Uric acid elimination 315-30-0 ALLOPURINOL ADVERSE_EFFECT IMU_3_Eosinophilia 315-30-0 ALLOPURINOL ADVERSE_EFFECT BBM_3_Leukopenia 315-30-0 ALLOPURINOL TA_LEVEL_3 Gout-Related Agents 315-30-0 ALLOPURINOL ADVERSE_EFFECT LIV_3_Hepatitis 315-30-0 ALLOPURINOL KNOWN_TOXICITY Nephrotoxicity 315-30-0 ALLOPURINOL INDICATION Gout 315-30-0 ALLOPURINOL STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, xanthine oxidase inhibitor 315-30-0 ALLOPURINOL ZERO_CLASS N 315-30-0 ALLOPURINOL ADVERSE_EFFECT GIS_2_Gastritis 315-30-0 ALLOPURINOL ADVERSE_EFFECT KID_3_Acute Renal Failure 315-30-0 ALLOPURINOL ADVERSE_EFFECT BBM_3_Aplastic Anemia 315-30-0 ALLOPURINOL ADVERSE_EFFECT IMU_3_Urticaria 315-30-0 ALLOPURINOL ADVERSE_EFFECT SKN_2_Stevens-Johnson Syndrome 315-30-0 ALLOPURINOL TA_LEVEL_1 Hormones, Endocrine and Metabolic 315-30-0 ALLOPURINOL MECH_LEVEL_2 Inhibit precursor synthesis 315-30-0 ALLOPURINOL MESH_LEVEL_1 Heterocyclic Compounds 315-30-0 ALLOPURINOL THERAPEUTIC_CLASS Gout-Related Agents 315-30-0 ALLOPURINOL TISSUE_TOXICITY Hepatic Necrosis 315-30-0 ALLOPURINOL ADVERSE_EFFECT BBM_3_Neutropenia 315-30-0 ALLOPURINOL KNOWN_TOXICITY Hepatotoxicity 315-30-0 ALLOPURINOL INDICATION Uric Acid Calculi / Uric Acid Stones 315-30-0 ALLOPURINOL ADVERSE_EFFECT GIS_2_Abdominal Pain 315-30-0 ALLOPURINOL ADVERSE_EFFECT SKN_1_Maculopapular Rash 315-30-0 ALLOPURINOL TA_LEVEL_2 Uric acid elimination 315-30-0 ALLOPURINOL ADVERSE_EFFECT BBM_3_Bone Marrow Depression 315-30-0 ALLOPURINOL ADVERSE_EFFECT SKN_2_Exfoliative Dermatitis 315-30-0 ALLOPURINOL ADVERSE_EFFECT SKN_2_Toxic Epidermal Necrolysis 315-30-0 ALLOPURINOL ADVERSE_EFFECT GIS_2_Diarrhea 315-30-0 ALLOPURINOL TISSUE_TOXICITY Acute Renal Failure 315-30-0 ALLOPURINOL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 315-30-0 ALLOPURINOL MECHANISM Inhibit precursor synthesis 315-30-0 ALLOPURINOL PRODUCT_CLASS Hormones, Endocrine and Metabolic 315-30-0 ALLOPURINOL MECH_LEVEL_3 Xanthine oxidase 315-30-0 ALLOPURINOL MESH_LEVEL_3 Purines 315-30-0 ALLOPURINOL MODE_CLASS Enzyme Inhibitor 315-30-0 ALLOPURINOL ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 315-30-0 ALLOPURINOL ADVERSE_EFFECT GIS_2_Dyspepsia 315-30-0 ALLOPURINOL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 315-30-0 ALLOPURINOL ADVERSE_EFFECT BBM_3_Leukocytosis 315-30-0 ALLOPURINOL ADVERSE_EFFECT IMU_1_Hypersensitivity Reactions 315-30-0 ALLOPURINOL ADVERSE_EFFECT XXX_3_Fever 304-52-9 ALPHA-METHYL-5-HYDROXYTRYPTAMINE MECHANISM Modulate neural transmission 304-52-9 ALPHA-METHYL-5-HYDROXYTRYPTAMINE PRODUCT_CLASS Biochemicals 304-52-9 ALPHA-METHYL-5-HYDROXYTRYPTAMINE MECHANISM Modulate G-protein coupled signal transduction 304-52-9 ALPHA-METHYL-5-HYDROXYTRYPTAMINE MODE_CLASS Receptor Agonist, Non-selective 28981-97-7 ALPRAZOLAM MECH_LEVEL_2 faciliates GABA binding 28981-97-7 ALPRAZOLAM TA_LEVEL_2 CNS Depressant 28981-97-7 ALPRAZOLAM TA_LEVEL_3 Anxiolytics 28981-97-7 ALPRAZOLAM MESH_LEVEL_3 Benzazepines 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Impaired Coordination 28981-97-7 ALPRAZOLAM STRUCTURE_ACTIVITY GABA-A agonist, benzodiazepin, medium acting 28981-97-7 ALPRAZOLAM ZERO_CLASS N 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Lightheadedness 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_2_Ataxia 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT PSY_2_Psychologic Dependence 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Headache 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT PSY_2_Insomnia 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT EMB_3_Teratogenicity 28981-97-7 ALPRAZOLAM KNOWN_TOXICITY Cardiovascular Toxicity 28981-97-7 ALPRAZOLAM TISSUE_TOXICITY Hypotension 28981-97-7 ALPRAZOLAM TA_LEVEL_1 Central Nervous System (CNS) 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT PSY_2_Confusion 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT PSY_2_Physical Dependence 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT SKN_2_Rash 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT GIS_1_Nausea / Vomiting 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT OCU_1_Blurred Vision 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Impaired Mental Function 28981-97-7 ALPRAZOLAM TISSUE_TOXICITY Teratogenicity 28981-97-7 ALPRAZOLAM KNOWN_TOXICITY Embryo/Fetal Toxicity 28981-97-7 ALPRAZOLAM PRODUCT_CLASS Central Nervous System (CNS) 28981-97-7 ALPRAZOLAM MESH_LEVEL_1 Heterocyclic Compounds 28981-97-7 ALPRAZOLAM ACTIVITY_CLASS GABA agonist 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT GUS_2_Difficulty Urinating 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT PSY_2_Irritability 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT OCU_2_Diplopia 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT XXX_1_Withdrawal 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Drowsiness 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT XXX_2_Weakness 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT PSY_2_Depression 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Impaired Motor Function 28981-97-7 ALPRAZOLAM INDICATION Anxiety Disorders 28981-97-7 ALPRAZOLAM MECH_LEVEL_1 Modulate neural transmission 28981-97-7 ALPRAZOLAM MECH_LEVEL_3 GABA-A receptor 28981-97-7 ALPRAZOLAM MECHANISM Modulate neural transmission 28981-97-7 ALPRAZOLAM MODE_CLASS Channel enhancer /opener 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_1_Anterograde Amnesia 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_3_Coma 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT REP_2_Sexual Dysfunction 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT CVS_2_Hypotension 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT GIS_2_Gastrointestinal Disturbances 28981-97-7 ALPRAZOLAM ADVERSE_EFFECT NEU_3_Paradoxical Reactions 28981-97-7 ALPRAZOLAM THERAPEUTIC_CLASS Anxiolytics 28981-97-7 ALPRAZOLAM MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 28981-97-7 ALPRAZOLAM INDICATION Panic Disorder 13655-52-2 ALPRENOLOL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 13655-52-2 ALPRENOLOL ADVERSE_EFFECT END_3_Hypoglycemia 13655-52-2 ALPRENOLOL ADVERSE_EFFECT PSY_3_Anorexia 13655-52-2 ALPRENOLOL ADVERSE_EFFECT CVS_1_Bradycardia 13655-52-2 ALPRENOLOL THERAPEUTIC_CLASS Antiarrhythmic Agents 13655-52-2 ALPRENOLOL TISSUE_TOXICITY Atrioventricular Blockade 13655-52-2 ALPRENOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta antagonist 13655-52-2 ALPRENOLOL INDICATION Cardiac Arrhythmias 13655-52-2 ALPRENOLOL ADVERSE_EFFECT CVS_2_Raynaud's Syndrome 13655-52-2 ALPRENOLOL ADVERSE_EFFECT GIS_3_Gastric Ulceration 13655-52-2 ALPRENOLOL ADVERSE_EFFECT SKN_3_Erythema 13655-52-2 ALPRENOLOL ADVERSE_EFFECT NEU_3_Paresthesia 13655-52-2 ALPRENOLOL ADVERSE_EFFECT GIS_3_Nausea 13655-52-2 ALPRENOLOL TISSUE_TOXICITY Cardiac Insufficiency 13655-52-2 ALPRENOLOL THERAPEUTIC_CLASS Antianginals 13655-52-2 ALPRENOLOL INDICATION Hypertension 13655-52-2 ALPRENOLOL TISSUE_TOXICITY Hypotension 13655-52-2 ALPRENOLOL KNOWN_TOXICITY Cardiovascular Toxicity 13655-52-2 ALPRENOLOL ADVERSE_EFFECT CVS_3_Hypotension 13655-52-2 ALPRENOLOL ADVERSE_EFFECT CVS_3_Atrioventricular Blockade 13655-52-2 ALPRENOLOL ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 13655-52-2 ALPRENOLOL THERAPEUTIC_CLASS Antihypertensive Agents 13655-52-2 ALPRENOLOL INDICATION Angina Pectoris 13655-52-2 ALPRENOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 13655-52-2 ALPRENOLOL ADVERSE_EFFECT END_3_Diabetes Mellitus 13655-52-2 ALPRENOLOL ADVERSE_EFFECT GIS_3_Epigastric Pain 13655-52-2 ALPRENOLOL ADVERSE_EFFECT IMU_2_Contact Dermatitis 13655-52-2 ALPRENOLOL ADVERSE_EFFECT PSY_3_Depression 13655-52-2 ALPRENOLOL ADVERSE_EFFECT CVS_3_Cardiac Insufficiency 13655-52-2 ALPRENOLOL ADVERSE_EFFECT XXX_3_Asthenia 13655-52-2 ALPRENOLOL MECHANISM Reduce muscle contractile force 13655-52-2 ALPRENOLOL PRODUCT_CLASS Cardiovasculars 13655-52-2 ALPRENOLOL INDICATION Myocardial Infarction Prophylaxis 13655-52-2 ALPRENOLOL TISSUE_TOXICITY Cardiovascular Collapse 13655-52-2 ALPRENOLOL ADVERSE_EFFECT PSY_3_Hallucinations 13655-52-2 ALPRENOLOL ADVERSE_EFFECT GIS_3_Vomiting 13655-52-2 ALPRENOLOL ADVERSE_EFFECT LUN_3_Bronchospasm 13655-52-2 ALPRENOLOL ADVERSE_EFFECT PSY_2_Nightmares 13655-52-2 ALPRENOLOL ADVERSE_EFFECT GIS_3_Esophageal Ulceration 13655-52-2 ALPRENOLOL ADVERSE_EFFECT GIS_3_Esophageal Stenosis 745-65-3 ALPROSTADIL MODE_CLASS Receptor Agonist 745-65-3 ALPROSTADIL MECHANISM Modulate G-protein coupled signal transduction 745-65-3 ALPROSTADIL INDICATION Ductus arteriosus maintenance 745-65-3 ALPROSTADIL PRODUCT_CLASS Cardiovasculars 745-65-3 ALPROSTADIL INDICATION Erectile Dysfunction 745-65-3 ALPROSTADIL PRODUCT_CLASS Other Human Uses 51411-04-2 ALRESTATIN INDICATION Diabetic Neuropathy 51411-04-2 ALRESTATIN MECHANISM Inhibit precursor synthesis 51411-04-2 ALRESTATIN THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 51411-04-2 ALRESTATIN MODE_CLASS Enzyme Inhibitor 51411-04-2 ALRESTATIN PRODUCT_CLASS Other Human Uses 645-05-6 ALTRETAMINE TA_LEVEL_2 DNA damage 645-05-6 ALTRETAMINE ADVERSE_EFFECT LIV_3_Hepatic Toxicity 645-05-6 ALTRETAMINE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 645-05-6 ALTRETAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 645-05-6 ALTRETAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 645-05-6 ALTRETAMINE ADVERSE_EFFECT XXX_3_Fatigue 645-05-6 ALTRETAMINE INDICATION Ovarian Cancer / Carcinoma of the Ovary 645-05-6 ALTRETAMINE PRODUCT_CLASS Anti-cancers 645-05-6 ALTRETAMINE STRUCTURE_ACTIVITY DNA-alkylator 645-05-6 ALTRETAMINE MECHANISM Inhibit DNA synthesis, repair, and function 645-05-6 ALTRETAMINE ACTIVITY_CLASS DNA damager 645-05-6 ALTRETAMINE TISSUE_TOXICITY Hepatic Toxicity 645-05-6 ALTRETAMINE ADVERSE_EFFECT SKN_3_Skin Rash 645-05-6 ALTRETAMINE ADVERSE_EFFECT NEU_2_Vertigo 645-05-6 ALTRETAMINE ADVERSE_EFFECT NEU_2_Ataxia 645-05-6 ALTRETAMINE ADVERSE_EFFECT SKN_3_Pruritis 645-05-6 ALTRETAMINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 645-05-6 ALTRETAMINE ADVERSE_EFFECT BBM_2_Myelosuppression 645-05-6 ALTRETAMINE MECH_LEVEL_3 DNA damage 645-05-6 ALTRETAMINE ADVERSE_EFFECT PSY_3_Anorexia 645-05-6 ALTRETAMINE MESH_LEVEL_1 Heterocyclic Compounds 645-05-6 ALTRETAMINE MESH_LEVEL_3 Triazines 645-05-6 ALTRETAMINE KNOWN_TOXICITY Hepatotoxicity 645-05-6 ALTRETAMINE THERAPEUTIC_CLASS Antineoplastics 645-05-6 ALTRETAMINE ADVERSE_EFFECT BBM_2_Leukopenia 645-05-6 ALTRETAMINE ADVERSE_EFFECT NEU_3_Seizures 645-05-6 ALTRETAMINE ADVERSE_EFFECT NEU_2_Dizziness 645-05-6 ALTRETAMINE TA_LEVEL_3 Solid Tumors 645-05-6 ALTRETAMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 645-05-6 ALTRETAMINE TA_LEVEL_1 Oncology 645-05-6 ALTRETAMINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 645-05-6 ALTRETAMINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 645-05-6 ALTRETAMINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 645-05-6 ALTRETAMINE ZERO_CLASS N 15468-34-5 ALTRETAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 15468-34-5 ALTRETAMINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 15468-34-5 ALTRETAMINE INDICATION Ovarian Cancer / Carcinoma of the Ovary 15468-34-5 ALTRETAMINE ADVERSE_EFFECT LIV_3_Hepatic Toxicity 15468-34-5 ALTRETAMINE TA_LEVEL_2 DNA damage 15468-34-5 ALTRETAMINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 15468-34-5 ALTRETAMINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 15468-34-5 ALTRETAMINE PRODUCT_CLASS Anti-cancers 15468-34-5 ALTRETAMINE THERAPEUTIC_CLASS Antineoplastics 15468-34-5 ALTRETAMINE ADVERSE_EFFECT PSY_3_Anorexia 15468-34-5 ALTRETAMINE ADVERSE_EFFECT SKN_3_Pruritis 15468-34-5 ALTRETAMINE STRUCTURE_ACTIVITY DNA-alkylator 15468-34-5 ALTRETAMINE ADVERSE_EFFECT NEU_2_Vertigo 15468-34-5 ALTRETAMINE ADVERSE_EFFECT SKN_3_Skin Rash 15468-34-5 ALTRETAMINE TISSUE_TOXICITY Hepatic Toxicity 15468-34-5 ALTRETAMINE ACTIVITY_CLASS DNA damager 15468-34-5 ALTRETAMINE TA_LEVEL_1 Oncology 15468-34-5 ALTRETAMINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 15468-34-5 ALTRETAMINE ADVERSE_EFFECT XXX_3_Fatigue 15468-34-5 ALTRETAMINE MECHANISM Inhibit DNA synthesis, repair, and function 15468-34-5 ALTRETAMINE MECH_LEVEL_2 Inhibit DNA synthesis, repair, and function 15468-34-5 ALTRETAMINE MESH_LEVEL_1 Heterocyclic Compounds 15468-34-5 ALTRETAMINE MESH_LEVEL_3 Triazines 15468-34-5 ALTRETAMINE ADVERSE_EFFECT NEU_2_Ataxia 15468-34-5 ALTRETAMINE KNOWN_TOXICITY Hepatotoxicity 15468-34-5 ALTRETAMINE ZERO_CLASS N 15468-34-5 ALTRETAMINE ADVERSE_EFFECT BBM_2_Myelosuppression 15468-34-5 ALTRETAMINE ADVERSE_EFFECT BBM_2_Leukopenia 15468-34-5 ALTRETAMINE ADVERSE_EFFECT NEU_3_Seizures 15468-34-5 ALTRETAMINE ADVERSE_EFFECT NEU_2_Dizziness 15468-34-5 ALTRETAMINE TA_LEVEL_3 Solid Tumors 15468-34-5 ALTRETAMINE MECH_LEVEL_3 DNA damage 15468-34-5 ALTRETAMINE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 15468-34-5 ALTRETAMINE ADVERSE_EFFECT NEU_2_Peripheral Neuropathy 8006-13-1 ALUMINUM ACETATE THERAPEUTIC_CLASS Antiarrhythmic Agents 8006-13-1 ALUMINUM ACETATE INDICATION Cardiac Arrhythmias 8006-13-1 ALUMINUM ACETATE PRODUCT_CLASS Cardiovasculars 139-12-8 ALUMINUM ACETATE PRODUCT_CLASS Cardiovasculars 139-12-8 ALUMINUM ACETATE THERAPEUTIC_CLASS Antiarrhythmic Agents 139-12-8 ALUMINUM ACETATE INDICATION Cardiac Arrhythmias 102121-60-8 AM 580 STRUCTURE_ACTIVITY Retinoic acid receptor (RAR) agonist 102121-60-8 AM 580 MODE_CLASS Receptor Agonist, selective 102121-60-8 AM 580 MECHANISM Modulate gene transcription 102121-60-8 AM 580 PRODUCT_CLASS Biochemicals 31377-23-8 AMANTADINE MECH_LEVEL_2 Block channel gating 31377-23-8 AMANTADINE TISSUE_TOXICITY Congestive Heart Failure 31377-23-8 AMANTADINE ADVERSE_EFFECT CVS_3_Hypertension 31377-23-8 AMANTADINE ADVERSE_EFFECT GUS_3_Urinary Retention 31377-23-8 AMANTADINE ADVERSE_EFFECT NEU_2_Somnolence 31377-23-8 AMANTADINE ADVERSE_EFFECT XXX_2_Peripheral Edema 31377-23-8 AMANTADINE ADVERSE_EFFECT NEU_2_Ataxia 31377-23-8 AMANTADINE ADVERSE_EFFECT GIS_1_Nausea 31377-23-8 AMANTADINE THERAPEUTIC_CLASS Antivirals 31377-23-8 AMANTADINE INDICATION Parkinsonism 31377-23-8 AMANTADINE TA_LEVEL_2 anti-viral 31377-23-8 AMANTADINE TA_LEVEL_1 Infectious Disease 31377-23-8 AMANTADINE THERAPEUTIC_CLASS Movement Disorders 31377-23-8 AMANTADINE PRODUCT_CLASS Central Nervous System (CNS) 31377-23-8 AMANTADINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 31377-23-8 AMANTADINE ADVERSE_EFFECT GIS_2_Constipation 31377-23-8 AMANTADINE ADVERSE_EFFECT SKN_3_Skin Rash 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_2_Irritability 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_2_Confusion 31377-23-8 AMANTADINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 31377-23-8 AMANTADINE MECH_LEVEL_1 Anti-viral 31377-23-8 AMANTADINE MECHANISM Block neural transmission 31377-23-8 AMANTADINE MESH_LEVEL_2 Hydrocarbons 31377-23-8 AMANTADINE ADVERSE_EFFECT NEU_1_Dizziness 31377-23-8 AMANTADINE ADVERSE_EFFECT LUN_3_Dyspnea 31377-23-8 AMANTADINE ADVERSE_EFFECT BBM_3_Leukopenia 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_2_Depression 31377-23-8 AMANTADINE ADVERSE_EFFECT GIS_2_Dry Mouth 31377-23-8 AMANTADINE MODE_CLASS Receptor Ligand Antagonist 31377-23-8 AMANTADINE ZERO_CLASS N 31377-23-8 AMANTADINE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 31377-23-8 AMANTADINE MESH_LEVEL_3 Hydrocarbons, Cyclic 31377-23-8 AMANTADINE INDICATION Influenza A Viral Infection 31377-23-8 AMANTADINE TA_LEVEL_3 Also used in Parkinson's 31377-23-8 AMANTADINE PRODUCT_CLASS Anti-infectives 31377-23-8 AMANTADINE MECH_LEVEL_3 Influenza A virus M2 protein 31377-23-8 AMANTADINE MESH_LEVEL_1 Organic Chemicals 31377-23-8 AMANTADINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 31377-23-8 AMANTADINE KNOWN_TOXICITY Cardiovascular Toxicity 31377-23-8 AMANTADINE MODE_CLASS Channel Blocker, selective 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_1_Insomnia 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_2_Hallucinations 31377-23-8 AMANTADINE ADVERSE_EFFECT BBM_3_Neutropenia 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_3_Psychosis 31377-23-8 AMANTADINE ADVERSE_EFFECT NEU_3_Slurred Speech 31377-23-8 AMANTADINE ADVERSE_EFFECT PSY_2_Anxiety 31377-23-8 AMANTADINE MECHANISM Block channel gating 768-94-5 AMANTADINE MESH_LEVEL_3 Hydrocarbons, Cyclic 768-94-5 AMANTADINE MESH_LEVEL_2 Hydrocarbons 768-94-5 AMANTADINE MECHANISM Block neural transmission 768-94-5 AMANTADINE MECH_LEVEL_1 Anti-viral 768-94-5 AMANTADINE MECH_LEVEL_2 Block channel gating 768-94-5 AMANTADINE MESH_LEVEL_1 Organic Chemicals 768-94-5 AMANTADINE TA_LEVEL_3 Also used in Parkinson's 768-94-5 AMANTADINE PRODUCT_CLASS Anti-infectives 768-94-5 AMANTADINE THERAPEUTIC_CLASS Movement Disorders 768-94-5 AMANTADINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_2_Confusion 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_2_Irritability 768-94-5 AMANTADINE ADVERSE_EFFECT SKN_3_Skin Rash 768-94-5 AMANTADINE ADVERSE_EFFECT GIS_2_Constipation 768-94-5 AMANTADINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 768-94-5 AMANTADINE PRODUCT_CLASS Central Nervous System (CNS) 768-94-5 AMANTADINE TA_LEVEL_1 Infectious Disease 768-94-5 AMANTADINE TA_LEVEL_2 anti-viral 768-94-5 AMANTADINE INDICATION Parkinsonism 768-94-5 AMANTADINE MECH_LEVEL_3 Influenza A virus M2 protein 768-94-5 AMANTADINE THERAPEUTIC_CLASS Antivirals 768-94-5 AMANTADINE MECHANISM Block channel gating 768-94-5 AMANTADINE TISSUE_TOXICITY Congestive Heart Failure 768-94-5 AMANTADINE ADVERSE_EFFECT CVS_3_Hypertension 768-94-5 AMANTADINE ADVERSE_EFFECT GUS_3_Urinary Retention 768-94-5 AMANTADINE ADVERSE_EFFECT NEU_2_Somnolence 768-94-5 AMANTADINE ADVERSE_EFFECT XXX_2_Peripheral Edema 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_2_Anxiety 768-94-5 AMANTADINE ADVERSE_EFFECT NEU_3_Slurred Speech 768-94-5 AMANTADINE ADVERSE_EFFECT NEU_2_Ataxia 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_3_Psychosis 768-94-5 AMANTADINE ADVERSE_EFFECT BBM_3_Neutropenia 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_2_Hallucinations 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_1_Insomnia 768-94-5 AMANTADINE MODE_CLASS Channel Blocker, selective 768-94-5 AMANTADINE KNOWN_TOXICITY Cardiovascular Toxicity 768-94-5 AMANTADINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 768-94-5 AMANTADINE INDICATION Influenza A Viral Infection 768-94-5 AMANTADINE ADVERSE_EFFECT GIS_1_Nausea 768-94-5 AMANTADINE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 768-94-5 AMANTADINE ZERO_CLASS N 768-94-5 AMANTADINE MODE_CLASS Receptor Ligand Antagonist 768-94-5 AMANTADINE ADVERSE_EFFECT GIS_2_Dry Mouth 768-94-5 AMANTADINE ADVERSE_EFFECT PSY_2_Depression 768-94-5 AMANTADINE ADVERSE_EFFECT BBM_3_Leukopenia 768-94-5 AMANTADINE ADVERSE_EFFECT LUN_3_Dyspnea 768-94-5 AMANTADINE ADVERSE_EFFECT NEU_1_Dizziness 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_2_Confusion 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_2_Irritability 665-66-7 AMANTADINE ADVERSE_EFFECT SKN_3_Skin Rash 665-66-7 AMANTADINE ADVERSE_EFFECT GIS_2_Constipation 665-66-7 AMANTADINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 665-66-7 AMANTADINE PRODUCT_CLASS Central Nervous System (CNS) 665-66-7 AMANTADINE TA_LEVEL_1 Infectious Disease 665-66-7 AMANTADINE TA_LEVEL_2 anti-viral 665-66-7 AMANTADINE MECH_LEVEL_3 Influenza A virus M2 protein 665-66-7 AMANTADINE THERAPEUTIC_CLASS Antivirals 665-66-7 AMANTADINE ADVERSE_EFFECT GIS_1_Nausea 665-66-7 AMANTADINE ADVERSE_EFFECT NEU_2_Ataxia 665-66-7 AMANTADINE ADVERSE_EFFECT XXX_2_Peripheral Edema 665-66-7 AMANTADINE ADVERSE_EFFECT NEU_2_Somnolence 665-66-7 AMANTADINE ADVERSE_EFFECT GUS_3_Urinary Retention 665-66-7 AMANTADINE ADVERSE_EFFECT CVS_3_Hypertension 665-66-7 AMANTADINE TISSUE_TOXICITY Congestive Heart Failure 665-66-7 AMANTADINE MECH_LEVEL_2 Block channel gating 665-66-7 AMANTADINE ADVERSE_EFFECT CVS_3_Congestive Heart Failure 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_2_Depression 665-66-7 AMANTADINE ADVERSE_EFFECT LUN_3_Dyspnea 665-66-7 AMANTADINE ADVERSE_EFFECT NEU_1_Dizziness 665-66-7 AMANTADINE MESH_LEVEL_2 Hydrocarbons 665-66-7 AMANTADINE MECHANISM Block neural transmission 665-66-7 AMANTADINE MECH_LEVEL_1 Anti-viral 665-66-7 AMANTADINE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 665-66-7 AMANTADINE INDICATION Parkinsonism 665-66-7 AMANTADINE MECHANISM Block channel gating 665-66-7 AMANTADINE THERAPEUTIC_CLASS Movement Disorders 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_2_Hallucinations 665-66-7 AMANTADINE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 665-66-7 AMANTADINE KNOWN_TOXICITY Cardiovascular Toxicity 665-66-7 AMANTADINE MODE_CLASS Channel Blocker, selective 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_1_Insomnia 665-66-7 AMANTADINE ADVERSE_EFFECT BBM_3_Neutropenia 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_3_Psychosis 665-66-7 AMANTADINE ADVERSE_EFFECT NEU_3_Slurred Speech 665-66-7 AMANTADINE ADVERSE_EFFECT PSY_2_Anxiety 665-66-7 AMANTADINE ADVERSE_EFFECT BBM_3_Leukopenia 665-66-7 AMANTADINE PRODUCT_CLASS Anti-infectives 665-66-7 AMANTADINE TA_LEVEL_3 Also used in Parkinson's 665-66-7 AMANTADINE MESH_LEVEL_1 Organic Chemicals 665-66-7 AMANTADINE INDICATION Influenza A Viral Infection 665-66-7 AMANTADINE MESH_LEVEL_3 Hydrocarbons, Cyclic 665-66-7 AMANTADINE ZERO_CLASS N 665-66-7 AMANTADINE MODE_CLASS Receptor Ligand Antagonist 665-66-7 AMANTADINE ADVERSE_EFFECT GIS_2_Dry Mouth 52022-31-8 AMBENONIUM CHLORIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 52022-31-8 AMBENONIUM CHLORIDE MODE_CLASS Enzyme Inhibitor 52022-31-8 AMBENONIUM CHLORIDE MECHANISM Enhance cholinergic transmission 52022-31-8 AMBENONIUM CHLORIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 52022-31-8 AMBENONIUM CHLORIDE INDICATION Myasthenia Gravis 115-79-7 AMBENONIUM CHLORIDE THERAPEUTIC_CLASS Parasympathomimetic Agents 115-79-7 AMBENONIUM CHLORIDE MODE_CLASS Enzyme Inhibitor 115-79-7 AMBENONIUM CHLORIDE PRODUCT_CLASS Autonomic Nervous System (ANS) 115-79-7 AMBENONIUM CHLORIDE MECHANISM Enhance cholinergic transmission 115-79-7 AMBENONIUM CHLORIDE INDICATION Myasthenia Gravis 51022-69-6 AMCINONIDE MODE_CLASS Receptor Agonist 51022-69-6 AMCINONIDE THERAPEUTIC_CLASS Corticosteroids, Topical 51022-69-6 AMCINONIDE MECHANISM Modulate gene transcription 51022-69-6 AMCINONIDE INDICATION Skin Diseases / Dermatoses 51022-69-6 AMCINONIDE PRODUCT_CLASS Dermatologicals 51022-69-6 AMCINONIDE INDICATION Dermatitis 20537-88-6 AMIFOSTINE PRODUCT_CLASS Other Human Uses 20537-88-6 AMIFOSTINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 20537-88-6 AMIFOSTINE ADVERSE_EFFECT EMB_2_Embryotoxicity 20537-88-6 AMIFOSTINE INDICATION Reduction of Renal Toxicity in Chemotherapy 20537-88-6 AMIFOSTINE ADVERSE_EFFECT CVS_1_Hypotension 20537-88-6 AMIFOSTINE ADVERSE_EFFECT SKN_3_Flushing 20537-88-6 AMIFOSTINE ADVERSE_EFFECT NEU_3_Dizziness 20537-88-6 AMIFOSTINE ADVERSE_EFFECT NEU_2_Loss of Consciousness 20537-88-6 AMIFOSTINE ADVERSE_EFFECT XXX_3_Chills 20537-88-6 AMIFOSTINE INDICATION Reduction of Xerostomia in Radiotherapy 20537-88-6 AMIFOSTINE KNOWN_TOXICITY Cardiovascular Toxicity 20537-88-6 AMIFOSTINE TISSUE_TOXICITY Hypotension 20537-88-6 AMIFOSTINE ADVERSE_EFFECT SKN_3_Skin Rash 20537-88-6 AMIFOSTINE MECHANISM Scavenges hydrogen peroxide and free radicals 20537-88-6 AMIFOSTINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 20537-88-6 AMIFOSTINE ADVERSE_EFFECT ELT_2_Hypocalcemia 20537-88-6 AMIFOSTINE THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 20537-88-6 AMIFOSTINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 20537-88-6 AMIFOSTINE ADVERSE_EFFECT IMU_3_Hypersensitivity 20537-88-6 AMIFOSTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 20537-88-6 AMIFOSTINE ADVERSE_EFFECT XXX_3_Fever 63717-27-1 AMIFOSTINE ADVERSE_EFFECT ELT_2_Hypocalcemia 63717-27-1 AMIFOSTINE THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 63717-27-1 AMIFOSTINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 63717-27-1 AMIFOSTINE ADVERSE_EFFECT IMU_3_Hypersensitivity 63717-27-1 AMIFOSTINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 63717-27-1 AMIFOSTINE ADVERSE_EFFECT XXX_3_Fever 63717-27-1 AMIFOSTINE INDICATION Reduction of Xerostomia in Radiotherapy 63717-27-1 AMIFOSTINE KNOWN_TOXICITY Cardiovascular Toxicity 63717-27-1 AMIFOSTINE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 63717-27-1 AMIFOSTINE ADVERSE_EFFECT SKN_3_Skin Rash 63717-27-1 AMIFOSTINE TISSUE_TOXICITY Hypotension 63717-27-1 AMIFOSTINE ADVERSE_EFFECT NEU_2_Loss of Consciousness 63717-27-1 AMIFOSTINE ADVERSE_EFFECT XXX_3_Chills 63717-27-1 AMIFOSTINE ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 63717-27-1 AMIFOSTINE INDICATION Reduction of Renal Toxicity in Chemotherapy 63717-27-1 AMIFOSTINE ADVERSE_EFFECT SKN_3_Flushing 63717-27-1 AMIFOSTINE ADVERSE_EFFECT CVS_1_Hypotension 63717-27-1 AMIFOSTINE MECHANISM Scavenges hydrogen peroxide and free radicals 63717-27-1 AMIFOSTINE ADVERSE_EFFECT EMB_2_Embryotoxicity 63717-27-1 AMIFOSTINE PRODUCT_CLASS Other Human Uses 63717-27-1 AMIFOSTINE ADVERSE_EFFECT NEU_3_Dizziness 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_3_Flatulence 2016-88-8 AMILORIDE ADVERSE_EFFECT MSK_3_Back Pain 2016-88-8 AMILORIDE MECH_LEVEL_2 Na channel antagonist 2016-88-8 AMILORIDE STRUCTURE_ACTIVITY Na+ channel (ENaC) inhibitor, distal tubule diuretic 2016-88-8 AMILORIDE THERAPEUTIC_CLASS Antihypertensive Agents 2016-88-8 AMILORIDE MECH_LEVEL_1 Diuretic 2016-88-8 AMILORIDE INDICATION Hypertension 2016-88-8 AMILORIDE TA_LEVEL_1 Cardiovascular 2016-88-8 AMILORIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 2016-88-8 AMILORIDE MECHANISM Block neural transmission 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_1_Diarrhea 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_1_Nausea 2016-88-8 AMILORIDE ADVERSE_EFFECT REP_2_Impotence 2016-88-8 AMILORIDE THERAPEUTIC_CLASS Congestive Heart Failure 2016-88-8 AMILORIDE ADVERSE_EFFECT END_3_Gynecomastia 2016-88-8 AMILORIDE ADVERSE_EFFECT GUS_3_Dysuria 2016-88-8 AMILORIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 2016-88-8 AMILORIDE ADVERSE_EFFECT MSK_3_Joint Pain 2016-88-8 AMILORIDE MODE_CLASS Enzyme Inhibitor 2016-88-8 AMILORIDE ZERO_CLASS N 2016-88-8 AMILORIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 2016-88-8 AMILORIDE ACTIVITY_CLASS Diuretic 2016-88-8 AMILORIDE MESH_LEVEL_3 Pyrazines 2016-88-8 AMILORIDE TA_LEVEL_2 Diuretic 2016-88-8 AMILORIDE PRODUCT_CLASS Cardiovasculars 2016-88-8 AMILORIDE ADVERSE_EFFECT PSY_1_Anorexia 2016-88-8 AMILORIDE ADVERSE_EFFECT XXX_2_Weakness 2016-88-8 AMILORIDE ADVERSE_EFFECT NEU_3_Paresthesia 2016-88-8 AMILORIDE ADVERSE_EFFECT NEU_3_Vertigo 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_3_Gastrointestinal Disturbances 2016-88-8 AMILORIDE ADVERSE_EFFECT CVS_3_Angina Pectoris 2016-88-8 AMILORIDE KNOWN_TOXICITY Cardiovascular Toxicity 2016-88-8 AMILORIDE TA_LEVEL_3 Potassium-sparing Diuretic 2016-88-8 AMILORIDE MESH_LEVEL_1 Heterocyclic Compounds 2016-88-8 AMILORIDE MECH_LEVEL_3 Na+ channel ENaC 2016-88-8 AMILORIDE INDICATION Congestive Heart Failure (CHF) 2016-88-8 AMILORIDE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 2016-88-8 AMILORIDE ADVERSE_EFFECT XXX_2_Fatigue 2016-88-8 AMILORIDE ADVERSE_EFFECT NEU_2_Dizziness 2016-88-8 AMILORIDE ADVERSE_EFFECT LUN_2_Dyspnea 2016-88-8 AMILORIDE TISSUE_TOXICITY Angina Pectoris 2016-88-8 AMILORIDE MODE_CLASS Channel Blocker 2016-88-8 AMILORIDE ADVERSE_EFFECT SKN_3_Skin Rash 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 2016-88-8 AMILORIDE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 2016-88-8 AMILORIDE ADVERSE_EFFECT NEU_1_Headache 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_1_Vomiting 2016-88-8 AMILORIDE ADVERSE_EFFECT GIS_2_Constipation 17440-83-4 AMILORIDE MECHANISM Block neural transmission 17440-83-4 AMILORIDE MESH_LEVEL_1 Heterocyclic Compounds 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_1_Vomiting 17440-83-4 AMILORIDE ADVERSE_EFFECT SKN_3_Skin Rash 17440-83-4 AMILORIDE MODE_CLASS Channel Blocker 17440-83-4 AMILORIDE TISSUE_TOXICITY Angina Pectoris 17440-83-4 AMILORIDE ADVERSE_EFFECT NEU_1_Headache 17440-83-4 AMILORIDE ADVERSE_EFFECT XXX_2_Weakness 17440-83-4 AMILORIDE ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 17440-83-4 AMILORIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 17440-83-4 AMILORIDE ADVERSE_EFFECT MSK_2_Muscle Cramps 17440-83-4 AMILORIDE TA_LEVEL_1 Cardiovascular 17440-83-4 AMILORIDE INDICATION Hypertension 17440-83-4 AMILORIDE THERAPEUTIC_CLASS Congestive Heart Failure 17440-83-4 AMILORIDE MECH_LEVEL_1 Diuretic 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_1_Diarrhea 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_1_Nausea 17440-83-4 AMILORIDE ADVERSE_EFFECT REP_2_Impotence 17440-83-4 AMILORIDE ADVERSE_EFFECT END_3_Gynecomastia 17440-83-4 AMILORIDE ADVERSE_EFFECT GUS_3_Dysuria 17440-83-4 AMILORIDE ADVERSE_EFFECT MSK_3_Joint Pain 17440-83-4 AMILORIDE MODE_CLASS Enzyme Inhibitor 17440-83-4 AMILORIDE ZERO_CLASS N 17440-83-4 AMILORIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 17440-83-4 AMILORIDE ACTIVITY_CLASS Diuretic 17440-83-4 AMILORIDE MESH_LEVEL_3 Pyrazines 17440-83-4 AMILORIDE TA_LEVEL_2 Diuretic 17440-83-4 AMILORIDE PRODUCT_CLASS Cardiovasculars 17440-83-4 AMILORIDE ADVERSE_EFFECT PSY_1_Anorexia 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_2_Abdominal Pain 17440-83-4 AMILORIDE ADVERSE_EFFECT NEU_3_Paresthesia 17440-83-4 AMILORIDE ADVERSE_EFFECT NEU_3_Vertigo 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_3_Gastrointestinal Disturbances 17440-83-4 AMILORIDE ADVERSE_EFFECT CVS_3_Angina Pectoris 17440-83-4 AMILORIDE KNOWN_TOXICITY Cardiovascular Toxicity 17440-83-4 AMILORIDE TA_LEVEL_3 Potassium-sparing Diuretic 17440-83-4 AMILORIDE MECH_LEVEL_3 Na+ channel ENaC 17440-83-4 AMILORIDE INDICATION Congestive Heart Failure (CHF) 17440-83-4 AMILORIDE ADVERSE_EFFECT CVS_3_Orthostatic Hypotension 17440-83-4 AMILORIDE ADVERSE_EFFECT XXX_2_Fatigue 17440-83-4 AMILORIDE ADVERSE_EFFECT NEU_2_Dizziness 17440-83-4 AMILORIDE ADVERSE_EFFECT LUN_2_Dyspnea 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_3_Flatulence 17440-83-4 AMILORIDE ADVERSE_EFFECT MSK_3_Back Pain 17440-83-4 AMILORIDE MECH_LEVEL_2 Na channel antagonist 17440-83-4 AMILORIDE STRUCTURE_ACTIVITY Na+ channel (ENaC) inhibitor, distal tubule diuretic 17440-83-4 AMILORIDE THERAPEUTIC_CLASS Antihypertensive Agents 17440-83-4 AMILORIDE ADVERSE_EFFECT GIS_2_Constipation 90-45-9 AMINACRINE MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 90-45-9 AMINACRINE THERAPEUTIC_CLASS Antibacterials, Topical 90-45-9 AMINACRINE STRUCTURE_ACTIVITY DNA intercalator 90-45-9 AMINACRINE MODE_CLASS Enzyme Inhibitor 90-45-9 AMINACRINE PRODUCT_CLASS Anti-infectives 90-45-9 AMINACRINE MECHANISM Inhibit DNA synthesis, repair, and function 90-45-9 AMINACRINE INDICATION Oral Ulcer 90-45-9 AMINACRINE INDICATION Oral Infections 3544-24-9 3-AMINOBENZAMIDE MECHANISM Inhibit DNA synthesis, repair, and function 3544-24-9 3-AMINOBENZAMIDE PRODUCT_CLASS Biochemicals 3544-24-9 3-AMINOBENZAMIDE MODE_CLASS Enzyme Inhibitor 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT SKN_3_Skin Rash 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT CVS_3_Thrombosis 60-32-2 AMINOCAPROIC ACID TISSUE_TOXICITY Stroke 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT PSY_3_Confusion 60-32-2 AMINOCAPROIC ACID MECH_LEVEL_3 plasmin 60-32-2 AMINOCAPROIC ACID INDICATION Hemorrhage / Bleeding 60-32-2 AMINOCAPROIC ACID MESH_LEVEL_2 Carboxylic Acids 60-32-2 AMINOCAPROIC ACID MESH_LEVEL_3 Acids, Acyclic 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT BBM_3_Agranulocytosis 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT GIS_2_Diarrhea 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT GIS_2_Abdominal Pain 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT BBM_3_Leukopenia 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT NEU_3_Increased Intracranial Pressure 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT NEU_2_Headache 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT PSY_3_Hallucinations 60-32-2 AMINOCAPROIC ACID TISSUE_TOXICITY Hypotension 60-32-2 AMINOCAPROIC ACID INDICATION Surgical Bleeding Prophylaxis 60-32-2 AMINOCAPROIC ACID TA_LEVEL_3 Hemostatic Agents 60-32-2 AMINOCAPROIC ACID ACTIVITY_CLASS Plasmin inhibitor 60-32-2 AMINOCAPROIC ACID ZERO_CLASS N 60-32-2 AMINOCAPROIC ACID MODE_CLASS Enzyme Inhibitor 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT CVS_3_Hypotension 60-32-2 AMINOCAPROIC ACID TISSUE_TOXICITY Thrombosis 60-32-2 AMINOCAPROIC ACID MESH_LEVEL_1 Organic Chemicals 60-32-2 AMINOCAPROIC ACID TA_LEVEL_1 Cardiovascular 60-32-2 AMINOCAPROIC ACID MECH_LEVEL_2 inhibits Plasminogen activation 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT KID_3_Acute Renal Failure 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT REP_2_Ejaculatory Disorder 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 60-32-2 AMINOCAPROIC ACID THERAPEUTIC_CLASS Hemostatic Agents 60-32-2 AMINOCAPROIC ACID TISSUE_TOXICITY Acute Renal Failure 60-32-2 AMINOCAPROIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 60-32-2 AMINOCAPROIC ACID STRUCTURE_ACTIVITY Plasmin inhibitor 60-32-2 AMINOCAPROIC ACID TA_LEVEL_2 antifibrolytic 60-32-2 AMINOCAPROIC ACID MECHANISM Stabilize blood clots 60-32-2 AMINOCAPROIC ACID TISSUE_TOXICITY Peripheral Ischemia 60-32-2 AMINOCAPROIC ACID MECH_LEVEL_1 Anti-clotting 60-32-2 AMINOCAPROIC ACID KNOWN_TOXICITY Nephrotoxicity 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT NEU_3_Seizures 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT CVS_3_Stroke 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT LUN_3_Pulmonary Embolism 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT BBM_3_Coagulopathy 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT NEU_2_Dizziness 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT CVS_3_Peripheral Ischemia 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT PSY_3_Delirium 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT CVS_3_Sinus Bradycardia 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT BBM_3_Thrombocytopenia 60-32-2 AMINOCAPROIC ACID PRODUCT_CLASS Hematologics 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT OCU_3_Visual Impairment 60-32-2 AMINOCAPROIC ACID ADVERSE_EFFECT MSK_3_Rhabdomyolysis 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_1_Drowsiness 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Adrenal Insufficiency 125-84-8 AMINOGLUTETHIMIDE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 125-84-8 AMINOGLUTETHIMIDE MESH_LEVEL_1 Heterocyclic Compounds 125-84-8 AMINOGLUTETHIMIDE MECH_LEVEL_1 Hormone modulation 125-84-8 AMINOGLUTETHIMIDE MESH_LEVEL_3 Piperidines 125-84-8 AMINOGLUTETHIMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 125-84-8 AMINOGLUTETHIMIDE INDICATION Metastatic Breast Cancer 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_3_Headache 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Hypothyroidism 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT XXX_1_Lethargy 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 125-84-8 AMINOGLUTETHIMIDE TISSUE_TOXICITY Hypotension 125-84-8 AMINOGLUTETHIMIDE KNOWN_TOXICITY Cardiovascular Toxicity 125-84-8 AMINOGLUTETHIMIDE TA_LEVEL_1 Oncology 125-84-8 AMINOGLUTETHIMIDE TA_LEVEL_2 Solid Tumors 125-84-8 AMINOGLUTETHIMIDE MECH_LEVEL_3 aromatase 125-84-8 AMINOGLUTETHIMIDE INDICATION Cushing's Syndrome / Hypercortisolism 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Hirsutism 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT LIV_3_Hepatitis 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Leukopenia 125-84-8 AMINOGLUTETHIMIDE ACTIVITY_CLASS Estrogen antagonist 125-84-8 AMINOGLUTETHIMIDE MODE_CLASS Enzyme Inhibitor, Non-selective 125-84-8 AMINOGLUTETHIMIDE TA_LEVEL_3 Aromatase 125-84-8 AMINOGLUTETHIMIDE INDICATION Adrenal Cancer / Carcinoma of the Adrenal Gland 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT GIS_2_Nausea 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT SKN_1_Rash 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_3_Ataxia 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 125-84-8 AMINOGLUTETHIMIDE ZERO_CLASS N 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT PSY_3_Depression 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT KID_3_Renal Dysfunction 125-84-8 AMINOGLUTETHIMIDE PRODUCT_CLASS Anti-cancers 125-84-8 AMINOGLUTETHIMIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 125-84-8 AMINOGLUTETHIMIDE INDICATION Prostatic Cancer / Carcinoma of the Prostate 125-84-8 AMINOGLUTETHIMIDE MECH_LEVEL_2 Inhibit estrogen biosynthesis 125-84-8 AMINOGLUTETHIMIDE THERAPEUTIC_CLASS Antineoplastics 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT CVS_3_Hypotension 125-84-8 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_2_Dizziness 23734-88-5 AMINOGLUTETHIMIDE MECH_LEVEL_2 Inhibit estrogen biosynthesis 23734-88-5 AMINOGLUTETHIMIDE INDICATION Prostatic Cancer / Carcinoma of the Prostate 23734-88-5 AMINOGLUTETHIMIDE MECHANISM Inhibit steroid biosynthesis/ metabolism 23734-88-5 AMINOGLUTETHIMIDE THERAPEUTIC_CLASS Antineoplastics 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT CVS_3_Hypotension 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_2_Dizziness 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_1_Drowsiness 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Adrenal Insufficiency 23734-88-5 AMINOGLUTETHIMIDE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 23734-88-5 AMINOGLUTETHIMIDE MESH_LEVEL_1 Heterocyclic Compounds 23734-88-5 AMINOGLUTETHIMIDE MECH_LEVEL_1 Hormone modulation 23734-88-5 AMINOGLUTETHIMIDE MESH_LEVEL_3 Piperidines 23734-88-5 AMINOGLUTETHIMIDE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 23734-88-5 AMINOGLUTETHIMIDE INDICATION Metastatic Breast Cancer 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT PSY_3_Depression 23734-88-5 AMINOGLUTETHIMIDE PRODUCT_CLASS Anti-cancers 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_3_Headache 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Hypothyroidism 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT XXX_1_Lethargy 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT LIV_3_Cholestatic Jaundice 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 23734-88-5 AMINOGLUTETHIMIDE TISSUE_TOXICITY Hypotension 23734-88-5 AMINOGLUTETHIMIDE KNOWN_TOXICITY Cardiovascular Toxicity 23734-88-5 AMINOGLUTETHIMIDE TA_LEVEL_1 Oncology 23734-88-5 AMINOGLUTETHIMIDE TA_LEVEL_2 Solid Tumors 23734-88-5 AMINOGLUTETHIMIDE MECH_LEVEL_3 aromatase 23734-88-5 AMINOGLUTETHIMIDE INDICATION Cushing's Syndrome / Hypercortisolism 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT END_3_Hirsutism 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT LIV_3_Hepatitis 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Leukopenia 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT KID_3_Renal Dysfunction 23734-88-5 AMINOGLUTETHIMIDE ACTIVITY_CLASS Estrogen antagonist 23734-88-5 AMINOGLUTETHIMIDE MODE_CLASS Enzyme Inhibitor, Non-selective 23734-88-5 AMINOGLUTETHIMIDE TA_LEVEL_3 Aromatase 23734-88-5 AMINOGLUTETHIMIDE INDICATION Adrenal Cancer / Carcinoma of the Adrenal Gland 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT SKN_1_Rash 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT NEU_3_Ataxia 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT BBM_3_Pancytopenia 23734-88-5 AMINOGLUTETHIMIDE ZERO_CLASS N 23734-88-5 AMINOGLUTETHIMIDE ADVERSE_EFFECT GIS_2_Nausea 54-62-6 AMINOPTERIN STRUCTURE_ACTIVITY Antifolate, dihydrofolate reductase inhibitor 54-62-6 AMINOPTERIN MECHANISM Inhibit precursor synthesis 54-62-6 AMINOPTERIN THERAPEUTIC_CLASS Antineoplastics 54-62-6 AMINOPTERIN MODE_CLASS Enzyme substrate mimic 54-62-6 AMINOPTERIN PRODUCT_CLASS Anti-cancers 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 65-49-6 AMINOSALICYLIC ACID MECH_LEVEL_2 Inhibit folic acid formation 65-49-6 AMINOSALICYLIC ACID MESH_LEVEL_3 Acids, Carbocyclic 65-49-6 AMINOSALICYLIC ACID STRUCTURE_ACTIVITY Mycobacterium folate synthesis inhibitor 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT BBM_2_Leukopenia 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT LIV_2_Hepatitis 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT END_2_Hypoglycemia 65-49-6 AMINOSALICYLIC ACID TISSUE_TOXICITY Pericarditis 65-49-6 AMINOSALICYLIC ACID MESH_LEVEL_2 Carboxylic Acids 65-49-6 AMINOSALICYLIC ACID TA_LEVEL_2 Anti-bacterial 65-49-6 AMINOSALICYLIC ACID MESH_LEVEL_1 Organic Chemicals 65-49-6 AMINOSALICYLIC ACID THERAPEUTIC_CLASS Antibacterials, Systemic 65-49-6 AMINOSALICYLIC ACID ACTIVITY_CLASS Anti-inflammatory 65-49-6 AMINOSALICYLIC ACID KNOWN_TOXICITY Cardiovascular Toxicity 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT END_2_Goiter 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT IMU_2_Hypersensitivity Reactions 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT BBM_2_Hemolytic Anemia 65-49-6 AMINOSALICYLIC ACID MECHANISM Inhibit precursor synthesis 65-49-6 AMINOSALICYLIC ACID MECH_LEVEL_1 Anti-bacterial 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 65-49-6 AMINOSALICYLIC ACID ZERO_CLASS N 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT XXX_1_Drug Fever 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT KID_2_Crystalluria 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT BBM_2_Agranulocytosis 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT GIS_1_Diarrhea 65-49-6 AMINOSALICYLIC ACID TA_LEVEL_1 Infectious Disease 65-49-6 AMINOSALICYLIC ACID MECH_LEVEL_3 Cyclooxgenase (?) 65-49-6 AMINOSALICYLIC ACID INDICATION Multi-drug Resistant Tuberculosis (MDR-TB) 65-49-6 AMINOSALICYLIC ACID TA_LEVEL_3 tuberculosis 65-49-6 AMINOSALICYLIC ACID PRODUCT_CLASS Anti-infectives 65-49-6 AMINOSALICYLIC ACID INDICATION Tuberculosis 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT CVS_3_Pericarditis 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT LIV_2_Jaundice 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT BBM_2_Thrombocytopenia 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT NEU_3_Encephalopathy 65-49-6 AMINOSALICYLIC ACID ADVERSE_EFFECT CVS_3_Vasculitis 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT XXX_2_Fatigue 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Vomiting 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT SKN_2_Pruritis 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GUS_1_Urinary Retention 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 50-48-6 AMITRIPTYLINE INDICATION Depressed Mood 50-48-6 AMITRIPTYLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 50-48-6 AMITRIPTYLINE MODE_CLASS Solute transporter inhibitor 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Agranulocytosis 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT END_3_Gynecomastia 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Stomatitis 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Heartburn 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT IMU_2_Urticaria 50-48-6 AMITRIPTYLINE TA_LEVEL_1 Central Nervous System (CNS) 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT CVS_1_Hypotension 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GIS_1_Dry Mouth 50-48-6 AMITRIPTYLINE MECH_LEVEL_1 Modulate neural transmission 50-48-6 AMITRIPTYLINE MECH_LEVEL_2 reuptake of Norepinephrine inhibition 50-48-6 AMITRIPTYLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Leukopenia 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT PSY_3_Disorientation 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT NEU_2_Dizziness 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT CVS_2_Tachycardia 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT CVS_1_Arrhythmia 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT OCU_1_Blurred Vision 50-48-6 AMITRIPTYLINE KNOWN_TOXICITY Cardiovascular Toxicity 50-48-6 AMITRIPTYLINE TA_LEVEL_3 Tricyclic antidepressant 50-48-6 AMITRIPTYLINE MECH_LEVEL_3 Norepinephrine Transporter NET 50-48-6 AMITRIPTYLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 50-48-6 AMITRIPTYLINE INDICATION Agitation 50-48-6 AMITRIPTYLINE MECHANISM Prolong/enhance neural transmission 50-48-6 AMITRIPTYLINE INDICATION Anxiety Disorders 50-48-6 AMITRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT PSY_3_Insomnia 50-48-6 AMITRIPTYLINE INDICATION Depression 50-48-6 AMITRIPTYLINE TISSUE_TOXICITY Hypotension 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT NEU_3_Ataxia 50-48-6 AMITRIPTYLINE THERAPEUTIC_CLASS Antidepressants 50-48-6 AMITRIPTYLINE ZERO_CLASS N 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GIS_1_Constipation 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT SKN_2_Rash 50-48-6 AMITRIPTYLINE THERAPEUTIC_CLASS Sedatives/Hypnotics 50-48-6 AMITRIPTYLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 50-48-6 AMITRIPTYLINE TISSUE_TOXICITY Arrhythmia 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 50-48-6 AMITRIPTYLINE MESH_LEVEL_3 Benzocycloheptenes 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Nausea 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT XXX_2_Weakness 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT PSY_3_Anxiety 50-48-6 AMITRIPTYLINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT CVS_1_Hypotension 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GIS_1_Dry Mouth 549-18-8 AMITRIPTYLINE MECH_LEVEL_1 Modulate neural transmission 549-18-8 AMITRIPTYLINE MECH_LEVEL_2 reuptake of Norepinephrine inhibition 549-18-8 AMITRIPTYLINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET/SERT) inhibitor, tricyclic 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Leukopenia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT PSY_3_Insomnia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT PSY_3_Disorientation 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT NEU_2_Dizziness 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT CVS_2_Tachycardia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT CVS_1_Arrhythmia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT OCU_1_Blurred Vision 549-18-8 AMITRIPTYLINE KNOWN_TOXICITY Cardiovascular Toxicity 549-18-8 AMITRIPTYLINE TA_LEVEL_3 Tricyclic antidepressant 549-18-8 AMITRIPTYLINE MECH_LEVEL_3 Norepinephrine Transporter NET 549-18-8 AMITRIPTYLINE MESH_LEVEL_1 Polycyclic Hydrocarbons 549-18-8 AMITRIPTYLINE INDICATION Agitation 549-18-8 AMITRIPTYLINE MECHANISM Prolong/enhance neural transmission 549-18-8 AMITRIPTYLINE INDICATION Anxiety Disorders 549-18-8 AMITRIPTYLINE PRODUCT_CLASS Central Nervous System (CNS) 549-18-8 AMITRIPTYLINE INDICATION Depression 549-18-8 AMITRIPTYLINE TISSUE_TOXICITY Hypotension 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT NEU_3_Ataxia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT PSY_3_Anxiety 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT XXX_2_Weakness 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT SKN_2_Rash 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GIS_1_Constipation 549-18-8 AMITRIPTYLINE ZERO_CLASS N 549-18-8 AMITRIPTYLINE THERAPEUTIC_CLASS Antidepressants 549-18-8 AMITRIPTYLINE THERAPEUTIC_CLASS Sedatives/Hypnotics 549-18-8 AMITRIPTYLINE TA_LEVEL_1 Central Nervous System (CNS) 549-18-8 AMITRIPTYLINE MESH_LEVEL_3 Benzocycloheptenes 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Nausea 549-18-8 AMITRIPTYLINE ACTIVITY_CLASS Monoamine re-uptake/oxidase inhibitor 549-18-8 AMITRIPTYLINE TISSUE_TOXICITY Arrhythmia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Bone Marrow Depression 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT XXX_2_Fatigue 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Vomiting 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT SKN_2_Pruritis 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GUS_1_Urinary Retention 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Thrombocytopenia 549-18-8 AMITRIPTYLINE INDICATION Depressed Mood 549-18-8 AMITRIPTYLINE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 549-18-8 AMITRIPTYLINE MODE_CLASS Solute transporter inhibitor 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT BBM_3_Agranulocytosis 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT END_3_Gynecomastia 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Stomatitis 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT GIS_2_Heartburn 549-18-8 AMITRIPTYLINE ADVERSE_EFFECT IMU_2_Urticaria 88150-42-9 AMLODIPINE TA_LEVEL_1 Cardiovascular 88150-42-9 AMLODIPINE MESH_LEVEL_3 Pyridines 88150-42-9 AMLODIPINE ACTIVITY_CLASS Ca++ channel (L-Type) blocker 88150-42-9 AMLODIPINE KNOWN_TOXICITY Cardiovascular Toxicity 88150-42-9 AMLODIPINE STRUCTURE_ACTIVITY Ca++ channel (L-Type) blocker, 1,4-DHP 88150-42-9 AMLODIPINE ADVERSE_EFFECT NEU_2_Somnolence 88150-42-9 AMLODIPINE ADVERSE_EFFECT IMU_3_Angioedema 88150-42-9 AMLODIPINE ADVERSE_EFFECT NEU_2_Dizziness 88150-42-9 AMLODIPINE ADVERSE_EFFECT XXX_2_Fatigue 88150-42-9 AMLODIPINE INDICATION Hypertension 88150-42-9 AMLODIPINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 88150-42-9 AMLODIPINE MECH_LEVEL_1 Anti-anginal 88150-42-9 AMLODIPINE THERAPEUTIC_CLASS Antihypertensive Agents 88150-42-9 AMLODIPINE ADVERSE_EFFECT CVS_3_Bradycardia 88150-42-9 AMLODIPINE MODE_CLASS Channel Blocker 88150-42-9 AMLODIPINE INDICATION Vasospastic Angina 88150-42-9 AMLODIPINE ADVERSE_EFFECT SKN_2_Flushing 88150-42-9 AMLODIPINE ADVERSE_EFFECT CVS_2_Palpitation 88150-42-9 AMLODIPINE TISSUE_TOXICITY Arrhythmia 88150-42-9 AMLODIPINE MESH_LEVEL_1 Heterocyclic Compounds 88150-42-9 AMLODIPINE MECH_LEVEL_2 Reduce muscle contractile force 88150-42-9 AMLODIPINE THERAPEUTIC_CLASS Antianginals 88150-42-9 AMLODIPINE ADVERSE_EFFECT REP_3_Sexual Dysfunction 88150-42-9 AMLODIPINE ADVERSE_EFFECT NEU_3_Paresthesia 88150-42-9 AMLODIPINE ADVERSE_EFFECT XXX_1_Edema 88150-42-9 AMLODIPINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 88150-42-9 AMLODIPINE ADVERSE_EFFECT CVS_3_Arrhythmia 88150-42-9 AMLODIPINE ZERO_CLASS N 88150-42-9 AMLODIPINE TA_LEVEL_3 Ca++ channel antagonists 88150-42-9 AMLODIPINE INDICATION Chronic Stable Angina 88150-42-9 AMLODIPINE ADVERSE_EFFECT GIS_2_Nausea 88150-42-9 AMLODIPINE ADVERSE_EFFECT NEU_1_Headache 88150-42-9 AMLODIPINE ADVERSE_EFFECT NEU_3_Peripheral Neuropathy 88150-42-9 AMLODIPINE ADVERSE_EFFECT GIS_2_Abdominal Pain 88150-42-9 AMLODIPINE TA_LEVEL_2 anti-angina 88150-42-9 AMLODIPINE PRODUCT_CLASS Cardiovasculars 88150-42-9 AMLODIPINE MECH_LEVEL_3 L-Type Ca++ channel 88150-42-9 AMLODIPINE MECHANISM Reduce muscle contractile force 57-43-2 AMOBARBITAL ADVERSE_EFFECT PSY_3_CNS Depression 57-43-2 AMOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 57-43-2 AMOBARBITAL ADVERSE_EFFECT NEU_1_Dizziness 57-43-2 AMOBARBITAL TISSUE_TOXICITY Hepatotoxicity 57-43-2 AMOBARBITAL MECHANISM Modulate neural transmission 57-43-2 AMOBARBITAL INDICATION Tonic-Clonic (Grand Mal) Seizures 57-43-2 AMOBARBITAL ADVERSE_EFFECT NEU_1_Impaired Motor Function 57-43-2 AMOBARBITAL ADVERSE_EFFECT BBM_3_Thrombocytopenia 57-43-2 AMOBARBITAL ADVERSE_EFFECT NEU_3_Nystagmus 57-43-2 AMOBARBITAL ADVERSE_EFFECT XXX_1_Withdrawal 57-43-2 AMOBARBITAL ADVERSE_EFFECT IMU_3_Allergic Reactions 57-43-2 AMOBARBITAL THERAPEUTIC_CLASS Anxiolytics 57-43-2 AMOBARBITAL INDICATION Induction / Maintenance of Anesthesia 57-43-2 AMOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 57-43-2 AMOBARBITAL KNOWN_TOXICITY Hepatotoxicity 57-43-2 AMOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 57-43-2 AMOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 57-43-2 AMOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 57-43-2 AMOBARBITAL ADVERSE_EFFECT SKN_2_Acneiform Rash 57-43-2 AMOBARBITAL ADVERSE_EFFECT NEU_2_Vertigo 57-43-2 AMOBARBITAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 57-43-2 AMOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 57-43-2 AMOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 57-43-2 AMOBARBITAL ADVERSE_EFFECT BBM_3_Agranulocytosis 57-43-2 AMOBARBITAL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 57-43-2 AMOBARBITAL INDICATION Anxiety 57-43-2 AMOBARBITAL ADVERSE_EFFECT PSY_2_Depression 57-43-2 AMOBARBITAL INDICATION Insomnia 57-43-2 AMOBARBITAL MODE_CLASS Channel Modulator 57-43-2 AMOBARBITAL ADVERSE_EFFECT END_3_Osteopenia 57-43-2 AMOBARBITAL ADVERSE_EFFECT IMU_3_Photosensitivity 57-43-2 AMOBARBITAL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 57-43-2 AMOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 57-43-2 AMOBARBITAL ADVERSE_EFFECT BBM_3_Blood Dyscrasias 57-43-2 AMOBARBITAL ADVERSE_EFFECT NEU_1_Drowsiness 57-43-2 AMOBARBITAL ADVERSE_EFFECT CVS_3_Hypotension 57-43-2 AMOBARBITAL ADVERSE_EFFECT LUN_3_Respiratory Depression 57-43-2 AMOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 57-43-2 AMOBARBITAL TISSUE_TOXICITY Hypotension 57-43-2 AMOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 57-43-2 AMOBARBITAL ADVERSE_EFFECT SKN_2_Skin Rash 57-43-2 AMOBARBITAL ADVERSE_EFFECT XXX_2_Lethargy 57-43-2 AMOBARBITAL ADVERSE_EFFECT PSY_2_Dependence 57-43-2 AMOBARBITAL ADVERSE_EFFECT PSY_2_Anxiety 64-43-7 AMOBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 64-43-7 AMOBARBITAL ADVERSE_EFFECT SKN_2_Acneiform Rash 64-43-7 AMOBARBITAL ADVERSE_EFFECT NEU_2_Vertigo 64-43-7 AMOBARBITAL ADVERSE_EFFECT LIV_3_Hepatotoxicity 64-43-7 AMOBARBITAL ADVERSE_EFFECT PSY_2_Confusion 64-43-7 AMOBARBITAL ADVERSE_EFFECT BBM_3_Agranulocytosis 64-43-7 AMOBARBITAL ADVERSE_EFFECT CVS_3_Sinus Bradycardia 64-43-7 AMOBARBITAL KNOWN_TOXICITY Cardiovascular Toxicity 64-43-7 AMOBARBITAL ADVERSE_EFFECT PSY_2_Depression 64-43-7 AMOBARBITAL INDICATION Insomnia 64-43-7 AMOBARBITAL MODE_CLASS Channel Modulator 64-43-7 AMOBARBITAL ADVERSE_EFFECT END_3_Osteopenia 64-43-7 AMOBARBITAL ADVERSE_EFFECT IMU_3_Photosensitivity 64-43-7 AMOBARBITAL ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 64-43-7 AMOBARBITAL ADVERSE_EFFECT PSY_2_Agitation 64-43-7 AMOBARBITAL ADVERSE_EFFECT PSY_3_CNS Depression 64-43-7 AMOBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 64-43-7 AMOBARBITAL INDICATION Induction / Maintenance of Anesthesia 64-43-7 AMOBARBITAL THERAPEUTIC_CLASS Anxiolytics 64-43-7 AMOBARBITAL KNOWN_TOXICITY Hepatotoxicity 64-43-7 AMOBARBITAL ADVERSE_EFFECT IMU_3_Allergic Reactions 64-43-7 AMOBARBITAL ADVERSE_EFFECT XXX_1_Withdrawal 64-43-7 AMOBARBITAL ADVERSE_EFFECT BBM_3_Thrombocytopenia 64-43-7 AMOBARBITAL ADVERSE_EFFECT NEU_1_Impaired Motor Function 64-43-7 AMOBARBITAL INDICATION Tonic-Clonic (Grand Mal) Seizures 64-43-7 AMOBARBITAL MECHANISM Modulate neural transmission 64-43-7 AMOBARBITAL TISSUE_TOXICITY Hepatotoxicity 64-43-7 AMOBARBITAL ADVERSE_EFFECT NEU_1_Dizziness 64-43-7 AMOBARBITAL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 64-43-7 AMOBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 64-43-7 AMOBARBITAL ADVERSE_EFFECT PSY_2_Anxiety 64-43-7 AMOBARBITAL ADVERSE_EFFECT PSY_2_Dependence 64-43-7 AMOBARBITAL ADVERSE_EFFECT XXX_2_Lethargy 64-43-7 AMOBARBITAL ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 64-43-7 AMOBARBITAL INDICATION Anxiety 64-43-7 AMOBARBITAL THERAPEUTIC_CLASS Antiepileptics / Anticonvulsants 64-43-7 AMOBARBITAL ADVERSE_EFFECT SKN_2_Skin Rash 64-43-7 AMOBARBITAL TISSUE_TOXICITY Hypotension 64-43-7 AMOBARBITAL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 64-43-7 AMOBARBITAL ADVERSE_EFFECT LUN_3_Respiratory Depression 64-43-7 AMOBARBITAL ADVERSE_EFFECT CVS_3_Hypotension 64-43-7 AMOBARBITAL ADVERSE_EFFECT NEU_1_Drowsiness 64-43-7 AMOBARBITAL ADVERSE_EFFECT BBM_3_Blood Dyscrasias 64-43-7 AMOBARBITAL ADVERSE_EFFECT NEU_3_Nystagmus 14028-44-5 AMOXAPINE ADVERSE_EFFECT CVS_3_Vasculitis 14028-44-5 AMOXAPINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 14028-44-5 AMOXAPINE ADVERSE_EFFECT NEU_2_Ataxia 14028-44-5 AMOXAPINE ADVERSE_EFFECT REP_2_Impotence 14028-44-5 AMOXAPINE ADVERSE_EFFECT PSY_2_Insomnia 14028-44-5 AMOXAPINE ADVERSE_EFFECT NEU_1_Sedation 14028-44-5 AMOXAPINE ADVERSE_EFFECT GUS_3_Urinary Retention 14028-44-5 AMOXAPINE INDICATION Major Depression / Major Depressive Disorder 14028-44-5 AMOXAPINE MECHANISM Prolong/enhance neural transmission 14028-44-5 AMOXAPINE MECH_LEVEL_1 Prolong/enhance neural transmission 14028-44-5 AMOXAPINE MECH_LEVEL_2 Channel blocker, non-selective 14028-44-5 AMOXAPINE ADVERSE_EFFECT END_2_Hyperprolactinemia 14028-44-5 AMOXAPINE ADVERSE_EFFECT IMU_3_Photosensitization 14028-44-5 AMOXAPINE ADVERSE_EFFECT END_2_Galactorrhea 14028-44-5 AMOXAPINE ADVERSE_EFFECT PSY_3_Neuroleptic Malignant Syndrome 14028-44-5 AMOXAPINE ADVERSE_EFFECT PSY_2_Confusion 14028-44-5 AMOXAPINE ADVERSE_EFFECT NEU_3_Paresthesia 14028-44-5 AMOXAPINE ADVERSE_EFFECT NEU_2_Tremor 14028-44-5 AMOXAPINE ADVERSE_EFFECT CVS_3_Hypertension 14028-44-5 AMOXAPINE ADVERSE_EFFECT OCU_1_Blurred Vision 14028-44-5 AMOXAPINE TA_LEVEL_2 Anti-depressant 14028-44-5 AMOXAPINE TA_LEVEL_1 Central Nervous System (CNS) 14028-44-5 AMOXAPINE ZERO_CLASS N 14028-44-5 AMOXAPINE MODE_CLASS Receptor Ligand Antagonist 14028-44-5 AMOXAPINE ADVERSE_EFFECT END_3_Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) 14028-44-5 AMOXAPINE ADVERSE_EFFECT BBM_3_Leukopenia 14028-44-5 AMOXAPINE ADVERSE_EFFECT XXX_2_Restlessness 14028-44-5 AMOXAPINE ADVERSE_EFFECT NEU_3_Seizures 14028-44-5 AMOXAPINE ADVERSE_EFFECT GIS_2_Nausea 14028-44-5 AMOXAPINE ADVERSE_EFFECT GIS_1_Dry Mouth 14028-44-5 AMOXAPINE ADVERSE_EFFECT OCU_3_Mydriasis 14028-44-5 AMOXAPINE ADVERSE_EFFECT CVS_3_Tachycardia 14028-44-5 AMOXAPINE KNOWN_TOXICITY Cardiovascular Toxicity 14028-44-5 AMOXAPINE MESH_LEVEL_2 Heterocyclic Compounds, 3-Ring 14028-44-5 AMOXAPINE MESH_LEVEL_3 Dibenzoxazepines 14028-44-5 AMOXAPINE ACTIVITY_CLASS Serotonin antagonist 14028-44-5 AMOXAPINE MODE_CLASS Solute transporter inhibitor 14028-44-5 AMOXAPINE ADVERSE_EFFECT CVS_2_Prolonged QT Interval 14028-44-5 AMOXAPINE ADVERSE_EFFECT GIS_3_Epigastric Pain 14028-44-5 AMOXAPINE ADVERSE_EFFECT NEU_3_Extrapyramidal Symptoms 14028-44-5 AMOXAPINE ADVERSE_EFFECT LIV_3_Abnormal Liver Function 14028-44-5 AMOXAPINE ADVERSE_EFFECT PSY_3_Tardive Dyskinesia 14028-44-5 AMOXAPINE ADVERSE_EFFECT LIV_3_Hepatitis 14028-44-5 AMOXAPINE ADVERSE_EFFECT BBM_3_Agranulocytosis 14028-44-5 AMOXAPINE ADVERSE_EFFECT PSY_2_Anxiety 14028-44-5 AMOXAPINE ADVERSE_EFFECT CVS_3_Hypotension 14028-44-5 AMOXAPINE ADVERSE_EFFECT GIS_1_Constipation 14028-44-5 AMOXAPINE TISSUE_TOXICITY Hypotension 14028-44-5 AMOXAPINE MECHANISM Block neural transmission 14028-44-5 AMOXAPINE TA_LEVEL_3 SERTs 14028-44-5 AMOXAPINE MECH_LEVEL_3 Norepinephrine Transporter NET 14028-44-5 AMOXAPINE THERAPEUTIC_CLASS Antidepressants 14028-44-5 AMOXAPINE MESH_LEVEL_1 Heterocyclic Compounds 14028-44-5 AMOXAPINE PRODUCT_CLASS Central Nervous System (CNS) 14028-44-5 AMOXAPINE STRUCTURE_ACTIVITY 5HT2/D4/D2 antagonist, tricyclic antipsychotic 26787-78-0 AMOXICILLIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 26787-78-0 AMOXICILLIN MODE_CLASS Enzyme Inhibitor 26787-78-0 AMOXICILLIN ZERO_CLASS N 26787-78-0 AMOXICILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT SKN_1_Skin Rash 26787-78-0 AMOXICILLIN ADVERSE_EFFECT LIV_3_Jaundice 26787-78-0 AMOXICILLIN ADVERSE_EFFECT BBM_3_Decreased Platelet Function 26787-78-0 AMOXICILLIN ADVERSE_EFFECT BBM_3_Thrombocytopenia 26787-78-0 AMOXICILLIN ADVERSE_EFFECT NEU_3_Seizures 26787-78-0 AMOXICILLIN ADVERSE_EFFECT BBM_3_Hemolytic Anemia 26787-78-0 AMOXICILLIN KNOWN_TOXICITY Nephrotoxicity 26787-78-0 AMOXICILLIN TISSUE_TOXICITY Interstitial Nephritis 26787-78-0 AMOXICILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 26787-78-0 AMOXICILLIN ADVERSE_EFFECT IMU_3_Anaphylactic Shock 26787-78-0 AMOXICILLIN ADVERSE_EFFECT IMU_1_Hypersensitivity Reactions 26787-78-0 AMOXICILLIN ADVERSE_EFFECT XXX_2_Candidiasis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 26787-78-0 AMOXICILLIN TISSUE_TOXICITY Nephrotic Syndrome 26787-78-0 AMOXICILLIN INDICATION Genitourinary Tract Infections 26787-78-0 AMOXICILLIN INDICATION Syphilis 26787-78-0 AMOXICILLIN INDICATION Lower Respiratory Tract Infection 26787-78-0 AMOXICILLIN INDICATION Urinary Tract Infection (UTI) 26787-78-0 AMOXICILLIN INDICATION Endocarditis Prophylaxis 26787-78-0 AMOXICILLIN PRODUCT_CLASS Anti-infectives 26787-78-0 AMOXICILLIN ADVERSE_EFFECT IMU_3_Serum Sickness 26787-78-0 AMOXICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT BBM_3_Neutropenia 26787-78-0 AMOXICILLIN ADVERSE_EFFECT PSY_1_Anorexia 26787-78-0 AMOXICILLIN ADVERSE_EFFECT GIS_1_Gastrointestinal Distress 26787-78-0 AMOXICILLIN ADVERSE_EFFECT CVS_3_Vasculitis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 26787-78-0 AMOXICILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT KID_3_Nephrotic Syndrome 26787-78-0 AMOXICILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 26787-78-0 AMOXICILLIN INDICATION Sinusitis 26787-78-0 AMOXICILLIN INDICATION Streptococcal Infections 26787-78-0 AMOXICILLIN INDICATION Upper Respiratory Tract Infection 26787-78-0 AMOXICILLIN ADVERSE_EFFECT GIS_1_Diarrhea 26787-78-0 AMOXICILLIN ADVERSE_EFFECT XXX_3_Superinfection 26787-78-0 AMOXICILLIN ADVERSE_EFFECT BBM_3_Leukopenia 26787-78-0 AMOXICILLIN ADVERSE_EFFECT LIV_3_Hepatitis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT BBM_3_Agranulocytosis 26787-78-0 AMOXICILLIN ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 26787-78-0 AMOXICILLIN INDICATION Skin and Skin Structure Infections 26787-78-0 AMOXICILLIN INDICATION Otitis Media 26787-78-0 AMOXICILLIN ADVERSE_EFFECT IMU_2_Anaphylactoid Reactions 26787-78-0 AMOXICILLIN ADVERSE_EFFECT GIS_2_Abdominal Pain 26787-78-0 AMOXICILLIN ADVERSE_EFFECT LIV_3_Cholestasis 61-19-8 AMP PRODUCT_CLASS Biochemicals 61-19-8 AMP MECHANISM Modulate G-protein coupled signal transduction 51-62-7 AMPHETAMINE ADVERSE_EFFECT XXX_1_Weight Loss 51-62-7 AMPHETAMINE ADVERSE_EFFECT NEU_3_Dyskinesia 51-62-7 AMPHETAMINE ADVERSE_EFFECT REP_3_Impotence 51-62-7 AMPHETAMINE ADVERSE_EFFECT PSY_2_Dysphoria 51-62-7 AMPHETAMINE ADVERSE_EFFECT PSY_1_Anorexia 51-62-7 AMPHETAMINE TISSUE_TOXICITY Cardiomyopathy 51-62-7 AMPHETAMINE MODE_CLASS Solute transporter inhibitor 51-62-7 AMPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 51-62-7 AMPHETAMINE ADVERSE_EFFECT PSY_2_Euphoria 51-62-7 AMPHETAMINE ADVERSE_EFFECT PSY_3_Psychosis 51-62-7 AMPHETAMINE ADVERSE_EFFECT NEU_1_Headache 51-62-7 AMPHETAMINE PRODUCT_CLASS Central Nervous System (CNS) 51-62-7 AMPHETAMINE INDICATION Narcolepsy 51-62-7 AMPHETAMINE INDICATION Attention Deficit Hyperactivity Disorder (ADHD) 51-62-7 AMPHETAMINE ADVERSE_EFFECT NEU_1_Dizziness 51-62-7 AMPHETAMINE ADVERSE_EFFECT PSY_1_Insomnia 51-62-7 AMPHETAMINE ADVERSE_EFFECT GIS_2_Constipation 51-62-7 AMPHETAMINE THERAPEUTIC_CLASS Anorexiants 51-62-7 AMPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 51-62-7 AMPHETAMINE INDICATION Obesity 51-62-7 AMPHETAMINE MODE_CLASS Enzyme substrate mimic 51-62-7 AMPHETAMINE MODE_CLASS Receptor Partial Agonist 51-62-7 AMPHETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 51-62-7 AMPHETAMINE ADVERSE_EFFECT XXX_1_Restlessness 51-62-7 AMPHETAMINE ADVERSE_EFFECT NEU_1_Tremor 51-62-7 AMPHETAMINE ADVERSE_EFFECT CVS_3_Hypertension 51-62-7 AMPHETAMINE ADVERSE_EFFECT CVS_2_Tachycardia 51-62-7 AMPHETAMINE MECHANISM Prolong/enhance neural transmission 51-62-7 AMPHETAMINE ADVERSE_EFFECT GIS_1_Diarrhea 51-62-7 AMPHETAMINE THERAPEUTIC_CLASS Central Stimulants 51-62-7 AMPHETAMINE ADVERSE_EFFECT NEU_3_CNS Overstimulation 51-62-7 AMPHETAMINE ADVERSE_EFFECT CVS_3_Cardiomyopathy 51-62-7 AMPHETAMINE ADVERSE_EFFECT GIS_1_Dry Mouth 69-53-4 AMPICILLIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 69-53-4 AMPICILLIN ADVERSE_EFFECT GIS_2_Enterocolitis 69-53-4 AMPICILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 69-53-4 AMPICILLIN INDICATION Pneumonia 69-53-4 AMPICILLIN ADVERSE_EFFECT LIV_2_Increased Serum Transaminases 69-53-4 AMPICILLIN TA_LEVEL_1 Infectious Disease 69-53-4 AMPICILLIN MESH_LEVEL_2 Amides 69-53-4 AMPICILLIN ADVERSE_EFFECT BBM_3_Agranulocytosis 69-53-4 AMPICILLIN INDICATION Meningitis 69-53-4 AMPICILLIN ADVERSE_EFFECT SKN_3_Exfoliative Dermatitis 69-53-4 AMPICILLIN ADVERSE_EFFECT GIS_2_Gastritis 69-53-4 AMPICILLIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 69-53-4 AMPICILLIN MESH_LEVEL_3 Lactams 69-53-4 AMPICILLIN ZERO_CLASS N 69-53-4 AMPICILLIN MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 69-53-4 AMPICILLIN TA_LEVEL_3 systemic infections 69-53-4 AMPICILLIN ADVERSE_EFFECT SKN_3_Erythema Multiforme 69-53-4 AMPICILLIN TA_LEVEL_2 Anti-bacterial 69-53-4 AMPICILLIN INDICATION Urinary Tract Infection (UTI) 69-53-4 AMPICILLIN PRODUCT_CLASS Anti-infectives 69-53-4 AMPICILLIN ADVERSE_EFFECT GIS_2_Stomatitis 69-53-4 AMPICILLIN MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 69-53-4 AMPICILLIN MESH_LEVEL_1 Organic Chemicals 69-53-4 AMPICILLIN MECH_LEVEL_1 Anti-bacterial 69-53-4 AMPICILLIN ADVERSE_EFFECT XXX_2_Candidiasis 69-53-4 AMPICILLIN INDICATION Enterococcal Endocarditis 69-53-4 AMPICILLIN ADVERSE_EFFECT GIS_1_Diarrhea 69-53-4 AMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 69-53-4 AMPICILLIN ADVERSE_EFFECT SKN_2_Erythema 69-53-4 AMPICILLIN ADVERSE_EFFECT CVS_2_Chest Pain 69-53-4 AMPICILLIN ADVERSE_EFFECT SKN_1_Rash 69-53-4 AMPICILLIN ADVERSE_EFFECT IMU_3_Urticaria 69-53-4 AMPICILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 69-53-4 AMPICILLIN INDICATION Gastrointestinal Infection 69-53-4 AMPICILLIN INDICATION Sepsis 69-53-4 AMPICILLIN MODE_CLASS Enzyme Inhibitor 69-53-4 AMPICILLIN INDICATION Soft Tissue Infections 60719-84-8 AMRINONE TISSUE_TOXICITY Hepatotoxicity 60719-84-8 AMRINONE KNOWN_TOXICITY Embryo/Fetal Toxicity 60719-84-8 AMRINONE INDICATION Congestive Heart Failure (CHF) 60719-84-8 AMRINONE ADVERSE_EFFECT CVS_2_Supraventricular Arrhythmia 60719-84-8 AMRINONE ADVERSE_EFFECT XXX_3_Fever 60719-84-8 AMRINONE ADVERSE_EFFECT GIS_3_Abdominal Pain 60719-84-8 AMRINONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 60719-84-8 AMRINONE KNOWN_TOXICITY Cardiovascular Toxicity 60719-84-8 AMRINONE TISSUE_TOXICITY Hypotension 60719-84-8 AMRINONE ADVERSE_EFFECT CVS_2_Hypotension 60719-84-8 AMRINONE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 60719-84-8 AMRINONE ADVERSE_EFFECT CVS_3_Chest Pain 60719-84-8 AMRINONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 60719-84-8 AMRINONE MODE_CLASS Enzyme Inhibitor 60719-84-8 AMRINONE STRUCTURE_ACTIVITY PDE3 inhibitor 60719-84-8 AMRINONE MECHANISM Enhance kinase mediated signal transduction 60719-84-8 AMRINONE TISSUE_TOXICITY Supraventricular Arrhythmia 60719-84-8 AMRINONE KNOWN_TOXICITY Hepatotoxicity 60719-84-8 AMRINONE ADVERSE_EFFECT BBM_2_Thrombocytopenia 60719-84-8 AMRINONE ADVERSE_EFFECT EMB_3_Teratogenicity 60719-84-8 AMRINONE PRODUCT_CLASS Cardiovasculars 60719-84-8 AMRINONE TISSUE_TOXICITY Ventricular Arrhythmia 60719-84-8 AMRINONE THERAPEUTIC_CLASS Congestive Heart Failure 60719-84-8 AMRINONE ADVERSE_EFFECT CVS_2_Ventricular Arrhythmia 60719-84-8 AMRINONE TISSUE_TOXICITY Teratogenicity 75898-90-7 AMRINONE ADVERSE_EFFECT BBM_2_Thrombocytopenia 75898-90-7 AMRINONE ADVERSE_EFFECT EMB_3_Teratogenicity 75898-90-7 AMRINONE PRODUCT_CLASS Cardiovasculars 75898-90-7 AMRINONE TISSUE_TOXICITY Ventricular Arrhythmia 75898-90-7 AMRINONE THERAPEUTIC_CLASS Congestive Heart Failure 75898-90-7 AMRINONE ADVERSE_EFFECT CVS_2_Ventricular Arrhythmia 75898-90-7 AMRINONE ADVERSE_EFFECT CVS_2_Supraventricular Arrhythmia 75898-90-7 AMRINONE INDICATION Congestive Heart Failure (CHF) 75898-90-7 AMRINONE KNOWN_TOXICITY Embryo/Fetal Toxicity 75898-90-7 AMRINONE TISSUE_TOXICITY Hepatotoxicity 75898-90-7 AMRINONE TISSUE_TOXICITY Teratogenicity 75898-90-7 AMRINONE MECHANISM Enhance kinase mediated signal transduction 75898-90-7 AMRINONE STRUCTURE_ACTIVITY PDE3 inhibitor 75898-90-7 AMRINONE MODE_CLASS Enzyme Inhibitor 75898-90-7 AMRINONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 75898-90-7 AMRINONE ADVERSE_EFFECT CVS_3_Chest Pain 75898-90-7 AMRINONE ADVERSE_EFFECT GIS_3_Nausea / Vomiting 75898-90-7 AMRINONE ADVERSE_EFFECT CVS_2_Hypotension 75898-90-7 AMRINONE TISSUE_TOXICITY Hypotension 75898-90-7 AMRINONE KNOWN_TOXICITY Cardiovascular Toxicity 75898-90-7 AMRINONE ADVERSE_EFFECT LIV_3_Hepatotoxicity 75898-90-7 AMRINONE ADVERSE_EFFECT GIS_3_Abdominal Pain 75898-90-7 AMRINONE ADVERSE_EFFECT XXX_3_Fever 75898-90-7 AMRINONE TISSUE_TOXICITY Supraventricular Arrhythmia 75898-90-7 AMRINONE KNOWN_TOXICITY Hepatotoxicity 110-46-3 AMYL NITRITE INDICATION Angina Pectoris 110-46-3 AMYL NITRITE INDICATION Cyanide (CN) Poisoning 110-46-3 AMYL NITRITE THERAPEUTIC_CLASS Antianginals 110-46-3 AMYL NITRITE PRODUCT_CLASS Other Human Uses 110-46-3 AMYL NITRITE THERAPEUTIC_CLASS Antidotes 110-46-3 AMYL NITRITE PRODUCT_CLASS Cardiovasculars 68475-42-3 ANAGRELIDE INDICATION Essential Thrombocytosis / Essential Thrombocythemia 68475-42-3 ANAGRELIDE MODE_CLASS Enzyme Inhibitor 68475-42-3 ANAGRELIDE MECHANISM Enhance kinase mediated signal transduction 68475-42-3 ANAGRELIDE PRODUCT_CLASS Hematologics 68475-42-3 ANAGRELIDE THERAPEUTIC_CLASS Antiplatelets 58579-51-4 ANAGRELIDE MECHANISM Enhance kinase mediated signal transduction 58579-51-4 ANAGRELIDE INDICATION Essential Thrombocytosis / Essential Thrombocythemia 58579-51-4 ANAGRELIDE PRODUCT_CLASS Hematologics 58579-51-4 ANAGRELIDE THERAPEUTIC_CLASS Antiplatelets 58579-51-4 ANAGRELIDE MODE_CLASS Enzyme Inhibitor 94421-68-8 ANANDAMIDE PRODUCT_CLASS Central Nervous System (CNS) 94421-68-8 ANANDAMIDE MODE_CLASS Receptor Agonist 94421-68-8 ANANDAMIDE MECHANISM Modulate G-protein coupled signal transduction 120511-73-1 ANASTROZOLE MESH_LEVEL_3 Azoles 120511-73-1 ANASTROZOLE INDICATION Breast Cancer / Carcinoma of the Breast 120511-73-1 ANASTROZOLE ACTIVITY_CLASS Estrogen antagonist 120511-73-1 ANASTROZOLE ADVERSE_EFFECT SKN_2_Rash 120511-73-1 ANASTROZOLE ADVERSE_EFFECT XXX_1_Peripheral Edema 120511-73-1 ANASTROZOLE ADVERSE_EFFECT CVS_1_Chest Pain 120511-73-1 ANASTROZOLE TA_LEVEL_3 Breast cancer 120511-73-1 ANASTROZOLE PRODUCT_CLASS Anti-cancers 120511-73-1 ANASTROZOLE TISSUE_TOXICITY Thromboembolism 120511-73-1 ANASTROZOLE KNOWN_TOXICITY Cardiovascular Toxicity 120511-73-1 ANASTROZOLE ADVERSE_EFFECT CVS_1_Vasodilation 120511-73-1 ANASTROZOLE ADVERSE_EFFECT BBM_2_Anemia 120511-73-1 ANASTROZOLE ADVERSE_EFFECT BBM_2_Leukopenia 120511-73-1 ANASTROZOLE MODE_CLASS Enzyme Inhibitor, selective 120511-73-1 ANASTROZOLE ADVERSE_EFFECT EMB_2_Fetal Toxicity 120511-73-1 ANASTROZOLE MECH_LEVEL_2 Inhibit estrogen biosynthesis 120511-73-1 ANASTROZOLE THERAPEUTIC_CLASS Antineoplastics 120511-73-1 ANASTROZOLE ADVERSE_EFFECT NEU_2_Paresthesia 120511-73-1 ANASTROZOLE ADVERSE_EFFECT MSK_1_Bone Pain 120511-73-1 ANASTROZOLE ADVERSE_EFFECT GIS_1_Abdominal Pain 120511-73-1 ANASTROZOLE ADVERSE_EFFECT XXX_1_Asthenia 120511-73-1 ANASTROZOLE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 120511-73-1 ANASTROZOLE MESH_LEVEL_1 Heterocyclic Compounds 120511-73-1 ANASTROZOLE MECH_LEVEL_1 Inhibit steroid biosynthesis 120511-73-1 ANASTROZOLE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 120511-73-1 ANASTROZOLE ADVERSE_EFFECT NEU_3_Somnolence 120511-73-1 ANASTROZOLE ADVERSE_EFFECT GUS_3_Vaginal Bleeding 120511-73-1 ANASTROZOLE TA_LEVEL_2 solid tumors 120511-73-1 ANASTROZOLE ZERO_CLASS N 120511-73-1 ANASTROZOLE MECH_LEVEL_3 aromatase 120511-73-1 ANASTROZOLE TA_LEVEL_1 Oncology 120511-73-1 ANASTROZOLE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 120511-73-1 ANASTROZOLE INDICATION Metastatic Breast Cancer 120511-73-1 ANASTROZOLE ADVERSE_EFFECT NEU_1_Headache 120511-73-1 ANASTROZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 120511-73-1 ANASTROZOLE ADVERSE_EFFECT CVS_2_Thromboembolism 120511-73-1 ANASTROZOLE ADVERSE_EFFECT GIS_1_Gastrointestinal Disturbances 120511-73-1 ANASTROZOLE ADVERSE_EFFECT GUS_2_Vaginal Dryness 120511-73-1 ANASTROZOLE MECHANISM Inhibit steroid biosynthesis/ metabolism 4474-91-3 ANGIOTENSIN II HUMAN ADVERSE_EFFECT CVS_1_Vasoconstriction 4474-91-3 ANGIOTENSIN II HUMAN ADVERSE_EFFECT CVS_1_Hypertension 4474-91-3 ANGIOTENSIN II HUMAN ADVERSE_EFFECT KID_2_Renal Insufficiency 4474-91-3 ANGIOTENSIN II HUMAN ADVERSE_EFFECT XXX_1_Weight Loss 4474-91-3 ANGIOTENSIN II HUMAN STRUCTURE_ACTIVITY Angiotensin receptor agonist 4474-91-3 ANGIOTENSIN II HUMAN ADVERSE_EFFECT KID_2_Kidney Damage 4474-91-3 ANGIOTENSIN II HUMAN ACTIVITY_CLASS Angiotensin receptor agonist 4474-91-3 ANGIOTENSIN II HUMAN ADVERSE_EFFECT LUN_2_Pulmonary Hypertension 4474-91-3 ANGIOTENSIN II HUMAN INDICATION Liver Metastases 4474-91-3 ANGIOTENSIN II HUMAN MECHANISM Increase vasoconstriction 4474-91-3 ANGIOTENSIN II HUMAN PRODUCT_CLASS Anti-cancers 4474-91-3 ANGIOTENSIN II HUMAN INDICATION Hypotension 4474-91-3 ANGIOTENSIN II HUMAN MODE_CLASS Receptor /Channel ligand mimic 4474-91-3 ANGIOTENSIN II HUMAN THERAPEUTIC_CLASS Antineoplastics 4474-91-3 ANGIOTENSIN II HUMAN THERAPEUTIC_CLASS Vasopressors 4474-91-3 ANGIOTENSIN II HUMAN PRODUCT_CLASS Cardiovasculars 117-37-3 ANISINDIONE TA_LEVEL_3 Wafarin like 117-37-3 ANISINDIONE ADVERSE_EFFECT IMU_3_Urticaria 117-37-3 ANISINDIONE ADVERSE_EFFECT BBM_2_Hemorrhage 117-37-3 ANISINDIONE STRUCTURE_ACTIVITY Vitamin-K-epoxide reductase inhibitor 117-37-3 ANISINDIONE MECH_LEVEL_2 Inhibit platelet aggregation 117-37-3 ANISINDIONE INDICATION Thrombosis Prophylaxis 117-37-3 ANISINDIONE THERAPEUTIC_CLASS Anticoagulants 117-37-3 ANISINDIONE ZERO_CLASS N 117-37-3 ANISINDIONE MODE_CLASS Enzyme Inhibitor 117-37-3 ANISINDIONE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 117-37-3 ANISINDIONE ADVERSE_EFFECT XXX_3_Pyrexia 117-37-3 ANISINDIONE TA_LEVEL_1 Hematologics 117-37-3 ANISINDIONE INDICATION Atrial Fibrillation 117-37-3 ANISINDIONE INDICATION Arterial Thromboembolism Prophylaxis 117-37-3 ANISINDIONE TA_LEVEL_2 Blood clotting 117-37-3 ANISINDIONE MESH_LEVEL_1 Polycyclic Hydrocarbons 117-37-3 ANISINDIONE MECHANISM Inhibit platelet aggregation 117-37-3 ANISINDIONE ACTIVITY_CLASS Vitamin-K-epoxide reductase inhibitor 117-37-3 ANISINDIONE ADVERSE_EFFECT GIS_2_Diarrhea 117-37-3 ANISINDIONE ADVERSE_EFFECT SKN_3_Dermatitis 117-37-3 ANISINDIONE MECH_LEVEL_3 Vitamin-K-epoxide reductase (warfarin-sensitive) 117-37-3 ANISINDIONE MESH_LEVEL_3 Indenes 117-37-3 ANISINDIONE MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 117-37-3 ANISINDIONE INDICATION Deep Vein Thrombosis 117-37-3 ANISINDIONE INDICATION Cerebral Thromboembolism 117-37-3 ANISINDIONE PRODUCT_CLASS Hematologics 117-37-3 ANISINDIONE ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 117-37-3 ANISINDIONE INDICATION Pulmonary Embolism / Pulmonary Thromboembolism 117-37-3 ANISINDIONE INDICATION Prevention of Hormone-Dependent Cancers 117-37-3 ANISINDIONE MECH_LEVEL_1 Anti-clotting 2508-72-7 ANTAZOLINE INDICATION Allergic Conjunctivitis 2508-72-7 ANTAZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 2508-72-7 ANTAZOLINE ADVERSE_EFFECT OCU_3_Eye Irritation 2508-72-7 ANTAZOLINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 2508-72-7 ANTAZOLINE MECHANISM Modulate G-protein coupled signal transduction 2508-72-7 ANTAZOLINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 2508-72-7 ANTAZOLINE THERAPEUTIC_CLASS Antihistamines 2508-72-7 ANTAZOLINE MODE_CLASS Receptor Ligand Antagonist 2508-72-7 ANTAZOLINE INDICATION Vernal Keratoconjunctivitis 91-75-8 ANTAZOLINE MODE_CLASS Receptor Ligand Antagonist 91-75-8 ANTAZOLINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 91-75-8 ANTAZOLINE INDICATION Vernal Keratoconjunctivitis 91-75-8 ANTAZOLINE ADVERSE_EFFECT OCU_3_Eye Irritation 91-75-8 ANTAZOLINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 91-75-8 ANTAZOLINE MECHANISM Modulate G-protein coupled signal transduction 91-75-8 ANTAZOLINE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 91-75-8 ANTAZOLINE THERAPEUTIC_CLASS Antihistamines 91-75-8 ANTAZOLINE INDICATION Allergic Conjunctivitis 1143-38-0 ANTHRALIN PRODUCT_CLASS Dermatologicals 1143-38-0 ANTHRALIN THERAPEUTIC_CLASS Psoralens 1143-38-0 ANTHRALIN MODE_CLASS Enzyme Inhibitor 1143-38-0 ANTHRALIN INDICATION Psoriasis 1143-38-0 ANTHRALIN MECHANISM Inhibit eicosanoid biosynthesis 1397-94-0 ANTIMYCIN A STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 1397-94-0 ANTIMYCIN A KNOWN_TOXICITY Respiratory Toxicity 1397-94-0 ANTIMYCIN A ADVERSE_EFFECT END_1_Metabolic Disturbance 1397-94-0 ANTIMYCIN A MECHANISM Inhibit mitochondrial function 1397-94-0 ANTIMYCIN A ACTIVITY_CLASS Mitochondrial toxicant 1397-94-0 ANTIMYCIN A ADVERSE_EFFECT KID_2_Proximal Tubular Damage 1397-94-0 ANTIMYCIN A ADVERSE_EFFECT LUN_2_Hypoxia 1397-94-0 ANTIMYCIN A TISSUE_TOXICITY Respiratory System Toxicity 1397-94-0 ANTIMYCIN A PRODUCT_CLASS Biochemicals 1397-94-0 ANTIMYCIN A ADVERSE_EFFECT REP_2_Changes in Reproductive Function 1397-94-0 ANTIMYCIN A ADVERSE_EFFECT LUN_2_Pulmonary Toxicity 1397-94-0 ANTIMYCIN A MODE_CLASS Distorts /blocks macromolecular scaffold function 1397-94-0 ANTIMYCIN A ADVERSE_EFFECT LUN_1_Respiratory System Toxicity 642-15-9 ANTIMYCIN A ADVERSE_EFFECT REP_2_Changes in Reproductive Function 642-15-9 ANTIMYCIN A PRODUCT_CLASS Biochemicals 642-15-9 ANTIMYCIN A TISSUE_TOXICITY Respiratory System Toxicity 642-15-9 ANTIMYCIN A ADVERSE_EFFECT LUN_2_Hypoxia 642-15-9 ANTIMYCIN A ADVERSE_EFFECT KID_2_Proximal Tubular Damage 642-15-9 ANTIMYCIN A ACTIVITY_CLASS Mitochondrial toxicant 642-15-9 ANTIMYCIN A MECHANISM Inhibit mitochondrial function 642-15-9 ANTIMYCIN A ADVERSE_EFFECT END_1_Metabolic Disturbance 642-15-9 ANTIMYCIN A KNOWN_TOXICITY Respiratory Toxicity 642-15-9 ANTIMYCIN A STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, inhibits electron transfer 642-15-9 ANTIMYCIN A ADVERSE_EFFECT LUN_1_Respiratory System Toxicity 642-15-9 ANTIMYCIN A MODE_CLASS Distorts /blocks macromolecular scaffold function 642-15-9 ANTIMYCIN A ADVERSE_EFFECT LUN_2_Pulmonary Toxicity 60-80-0 ANTIPYRINE ADVERSE_EFFECT GIS_1_Nausea 60-80-0 ANTIPYRINE ADVERSE_EFFECT BBM_2_Hemolytic Anemia 60-80-0 ANTIPYRINE ADVERSE_EFFECT OCU_2_Decreased Visual Acuity 60-80-0 ANTIPYRINE TA_LEVEL_3 Analgesics, Topical 60-80-0 ANTIPYRINE MECH_LEVEL_1 Immunomodulation 60-80-0 ANTIPYRINE INDICATION Otitis Media 60-80-0 ANTIPYRINE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 60-80-0 ANTIPYRINE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 60-80-0 ANTIPYRINE TA_LEVEL_2 NSAID 60-80-0 ANTIPYRINE INDICATION Otitis Externa / External Otitis 60-80-0 ANTIPYRINE TA_LEVEL_1 Anti-inflammatory 60-80-0 ANTIPYRINE ADVERSE_EFFECT NEU_1_Somnolence 60-80-0 ANTIPYRINE ADVERSE_EFFECT SKN_3_Erythema Multiforme 60-80-0 ANTIPYRINE MODE_CLASS Enzyme Inhibitor 60-80-0 ANTIPYRINE ACTIVITY_CLASS Anti-inflammatory 60-80-0 ANTIPYRINE MESH_LEVEL_2 Heterocyclic Compounds, 1-Ring 60-80-0 ANTIPYRINE MESH_LEVEL_3 Pyrazoles 60-80-0 ANTIPYRINE MESH_LEVEL_1 Heterocyclic Compounds 60-80-0 ANTIPYRINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 60-80-0 ANTIPYRINE ADVERSE_EFFECT IMU_1_Allergic Reactions 60-80-0 ANTIPYRINE ZERO_CLASS N 60-80-0 ANTIPYRINE ADVERSE_EFFECT BBM_3_Agranulocytosis 60-80-0 ANTIPYRINE MECHANISM Inhibit eicosanoid biosynthesis 60-80-0 ANTIPYRINE THERAPEUTIC_CLASS Analgesics, Topical 60-80-0 ANTIPYRINE ADVERSE_EFFECT IMU_2_Urticaria 60-80-0 ANTIPYRINE STRUCTURE_ACTIVITY NSAID, COX-3, antipyrine like 60-80-0 ANTIPYRINE ADVERSE_EFFECT NEU_2_Convulsions 60-80-0 ANTIPYRINE INDICATION Removal of Cerumen 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT CVS_2_Tachycardia 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 314-19-2 R(-)-APOMORPHINE INDICATION Parkinsonism 314-19-2 R(-)-APOMORPHINE THERAPEUTIC_CLASS Movement Disorders 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT NEU_2_Syncope 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT XXX_1_Sweating 314-19-2 R(-)-APOMORPHINE MECHANISM Prolong/enhance neural transmission 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT NEU_1_Drowsiness 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT XXX_1_Salivation 314-19-2 R(-)-APOMORPHINE INDICATION Erectile Dysfunction 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT GIS_1_Nausea 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT PSY_3_CNS Stimulation 314-19-2 R(-)-APOMORPHINE PRODUCT_CLASS Central Nervous System (CNS) 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT XXX_2_Weakness 314-19-2 R(-)-APOMORPHINE INDICATION Parkinson's Disease 314-19-2 R(-)-APOMORPHINE THERAPEUTIC_CLASS Vasodilators 314-19-2 R(-)-APOMORPHINE MODE_CLASS Receptor Agonist 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT GIS_2_Vomiting 314-19-2 R(-)-APOMORPHINE ADVERSE_EFFECT XXX_1_Diaphoresis 66711-21-5 APRACLONIDINE MECHANISM Modulate G-protein coupled signal transduction 66711-21-5 APRACLONIDINE INDICATION Glaucoma 66711-21-5 APRACLONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 66711-21-5 APRACLONIDINE THERAPEUTIC_CLASS Antiglaucoma Agents 66711-21-5 APRACLONIDINE MODE_CLASS Receptor Agonist 66711-21-5 APRACLONIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 73218-79-8 APRACLONIDINE MECHANISM Modulate G-protein coupled signal transduction 73218-79-8 APRACLONIDINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 73218-79-8 APRACLONIDINE THERAPEUTIC_CLASS Antiglaucoma Agents 73218-79-8 APRACLONIDINE MODE_CLASS Receptor Agonist 73218-79-8 APRACLONIDINE INDICATION Glaucoma 73218-79-8 APRACLONIDINE STRUCTURE_ACTIVITY Imidazoline receptor agonist 77-02-1 APROBARBITAL THERAPEUTIC_CLASS Anxiolytics 77-02-1 APROBARBITAL INDICATION Anxiety Disorders 77-02-1 APROBARBITAL PRODUCT_CLASS Central Nervous System (CNS) 77-02-1 APROBARBITAL THERAPEUTIC_CLASS Sedatives/Hypnotics 77-02-1 APROBARBITAL STRUCTURE_ACTIVITY GABA-A agonist, barbiturate 77-02-1 APROBARBITAL MODE_CLASS Channel Modulator 77-02-1 APROBARBITAL INDICATION Insomnia 77-02-1 APROBARBITAL MECHANISM Modulate neural transmission 69-74-9 CYTARABINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 69-74-9 CYTARABINE ADVERSE_EFFECT GIS_1_Vomiting 69-74-9 CYTARABINE MODE_CLASS Enzyme substrate mimic 69-74-9 CYTARABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 69-74-9 CYTARABINE MECHANISM Incorporate into DNA/RNA/Protein 69-74-9 CYTARABINE ZERO_CLASS N 69-74-9 CYTARABINE ADVERSE_EFFECT MSK_2_Back Pain 69-74-9 CYTARABINE ADVERSE_EFFECT XXX_2_Peripheral Edema 69-74-9 CYTARABINE ADVERSE_EFFECT NEU_1_Headache 69-74-9 CYTARABINE ADVERSE_EFFECT XXX_1_Fever 69-74-9 CYTARABINE INDICATION Lymphomatous Meningitis 69-74-9 CYTARABINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 69-74-9 CYTARABINE ADVERSE_EFFECT XXX_1_Asthenia 69-74-9 CYTARABINE MESH_LEVEL_2 Nucleosides 69-74-9 CYTARABINE TA_LEVEL_1 Oncology 69-74-9 CYTARABINE PRODUCT_CLASS Anti-cancers 69-74-9 CYTARABINE TA_LEVEL_2 DNA synthesis inhibitors 69-74-9 CYTARABINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 69-74-9 CYTARABINE MECH_LEVEL_3 DNA-directed DNA polymerase 69-74-9 CYTARABINE THERAPEUTIC_CLASS Antineoplastics 69-74-9 CYTARABINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 69-74-9 CYTARABINE ADVERSE_EFFECT PSY_2_Confusion 69-74-9 CYTARABINE ADVERSE_EFFECT GIS_2_Constipation 69-74-9 CYTARABINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 69-74-9 CYTARABINE MESH_LEVEL_3 Arabinonucleosides 69-74-9 CYTARABINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 69-74-9 CYTARABINE ADVERSE_EFFECT BBM_2_Neutropenia 69-74-9 CYTARABINE ADVERSE_EFFECT BBM_3_Anemia 69-74-9 CYTARABINE ADVERSE_EFFECT GIS_1_Nausea 69-74-9 CYTARABINE TA_LEVEL_3 Soft tumors 69-74-9 CYTARABINE ADVERSE_EFFECT NEU_2_Somnolence 147-94-4 CYTARABINE TA_LEVEL_3 Soft tumors 147-94-4 CYTARABINE MESH_LEVEL_2 Nucleosides 147-94-4 CYTARABINE TA_LEVEL_1 Oncology 147-94-4 CYTARABINE PRODUCT_CLASS Anti-cancers 147-94-4 CYTARABINE TA_LEVEL_2 DNA synthesis inhibitors 147-94-4 CYTARABINE ADVERSE_EFFECT XXX_1_Fever 147-94-4 CYTARABINE MECH_LEVEL_1 Inhibit DNA synthesis, repair, and function 147-94-4 CYTARABINE ADVERSE_EFFECT MSK_2_Back Pain 147-94-4 CYTARABINE ADVERSE_EFFECT XXX_2_Peripheral Edema 147-94-4 CYTARABINE ADVERSE_EFFECT NEU_1_Headache 147-94-4 CYTARABINE MECH_LEVEL_3 DNA-directed DNA polymerase 147-94-4 CYTARABINE INDICATION Lymphomatous Meningitis 147-94-4 CYTARABINE MESH_LEVEL_1 Nucleic Acids, Nucleotides, and Nucleosides 147-94-4 CYTARABINE ADVERSE_EFFECT XXX_1_Asthenia 147-94-4 CYTARABINE ADVERSE_EFFECT BBM_2_Thrombocytopenia 147-94-4 CYTARABINE ADVERSE_EFFECT PSY_2_Confusion 147-94-4 CYTARABINE ADVERSE_EFFECT GIS_2_Constipation 147-94-4 CYTARABINE MECH_LEVEL_2 Incorporate into DNA/RNA/Protein 147-94-4 CYTARABINE MESH_LEVEL_3 Arabinonucleosides 147-94-4 CYTARABINE ACTIVITY_CLASS Non-DNA reactive antiproliferative agent 147-94-4 CYTARABINE ADVERSE_EFFECT BBM_2_Neutropenia 147-94-4 CYTARABINE ADVERSE_EFFECT BBM_3_Anemia 147-94-4 CYTARABINE ADVERSE_EFFECT GIS_1_Nausea 147-94-4 CYTARABINE THERAPEUTIC_CLASS Antineoplastics 147-94-4 CYTARABINE ADVERSE_EFFECT NEU_2_Somnolence 147-94-4 CYTARABINE ADVERSE_EFFECT NEU_3_Urinary Incontinence 147-94-4 CYTARABINE ADVERSE_EFFECT GIS_1_Vomiting 147-94-4 CYTARABINE MODE_CLASS Enzyme substrate mimic 147-94-4 CYTARABINE STRUCTURE_ACTIVITY DNA-Polymerase Inhibitor, pyrimidine nucleoside 147-94-4 CYTARABINE MECHANISM Incorporate into DNA/RNA/Protein 147-94-4 CYTARABINE ZERO_CLASS N 36587-93-6 ARCAINE SULFATE MODE_CLASS Channel Blocker 36587-93-6 ARCAINE SULFATE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 36587-93-6 ARCAINE SULFATE MECHANISM Block neural transmission 36587-93-6 ARCAINE SULFATE PRODUCT_CLASS Biochemicals 14923-17-2 ARCAINE SULFATE PRODUCT_CLASS Biochemicals 14923-17-2 ARCAINE SULFATE MECHANISM Block neural transmission 14923-17-2 ARCAINE SULFATE MODE_CLASS Channel Blocker 14923-17-2 ARCAINE SULFATE STRUCTURE_ACTIVITY Glutamate receptor (NMDA) antagonist 499-04-7 ARECAIDINE BUT-2-YNYL ESTER PRODUCT_CLASS Biochemicals 147202-94-6 ARECAIDINE PROPARGYL ESTER PRODUCT_CLASS Biochemicals 84692-91-1 ARGLABIN PRODUCT_CLASS Anti-cancers 84692-91-1 ARGLABIN MODE_CLASS Enzyme Inhibitor 84692-91-1 ARGLABIN MECHANISM Induce Apoptosis 84692-91-1 ARGLABIN PRODUCT_CLASS Botanicals 50-81-7 ASCORBIC ACID ACTIVITY_CLASS H2O2 radical scavenger 50-81-7 ASCORBIC ACID ADVERSE_EFFECT KID_2_Hyperoxaluria 50-81-7 ASCORBIC ACID ADVERSE_EFFECT MSK_3_Back Pain 50-81-7 ASCORBIC ACID ADVERSE_EFFECT NEU_3_Headache 50-81-7 ASCORBIC ACID KNOWN_TOXICITY Nephrotoxicity 50-81-7 ASCORBIC ACID TISSUE_TOXICITY Renal Tubular Obstruction 50-81-7 ASCORBIC ACID MESH_LEVEL_2 Carboxylic Acids 50-81-7 ASCORBIC ACID INDICATION Nutritional Supplement 50-81-7 ASCORBIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 50-81-7 ASCORBIC ACID MECHANISM Vitamin/ cofactor 50-81-7 ASCORBIC ACID MESH_LEVEL_1 Organic Chemicals 50-81-7 ASCORBIC ACID TA_LEVEL_1 Vitamins, Minerals and Nutrients 50-81-7 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Sickle-cell Crisis 50-81-7 ASCORBIC ACID ADVERSE_EFFECT KID_3_Nephrolithiasis 50-81-7 ASCORBIC ACID ADVERSE_EFFECT NEU_3_Dizziness 50-81-7 ASCORBIC ACID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 50-81-7 ASCORBIC ACID STRUCTURE_ACTIVITY H2O2 radical scavenger 50-81-7 ASCORBIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 50-81-7 ASCORBIC ACID ZERO_CLASS N 50-81-7 ASCORBIC ACID ADVERSE_EFFECT XXX_2_Dental Caries 50-81-7 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Anemia 50-81-7 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Hemolytic Anemia 50-81-7 ASCORBIC ACID ADVERSE_EFFECT GIS_3_Diarrhea 50-81-7 ASCORBIC ACID INDICATION Scurvy 50-81-7 ASCORBIC ACID MECH_LEVEL_3 Unknown mechanism 50-81-7 ASCORBIC ACID ADVERSE_EFFECT KID_3_Renal Tubular Obstruction 50-81-7 ASCORBIC ACID TA_LEVEL_3 Anti-oxidant 50-81-7 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Hemolysis 50-81-7 ASCORBIC ACID INDICATION Methemoglobinemia 50-81-7 ASCORBIC ACID MECH_LEVEL_2 coenzyme 50-81-7 ASCORBIC ACID MESH_LEVEL_3 Acids, Acyclic 50-81-7 ASCORBIC ACID MECH_LEVEL_1 Vitamin C 50-81-7 ASCORBIC ACID ADVERSE_EFFECT SKN_3_Flushing 134-03-2 ASCORBIC ACID MESH_LEVEL_3 Acids, Acyclic 134-03-2 ASCORBIC ACID MECH_LEVEL_1 Vitamin C 134-03-2 ASCORBIC ACID TA_LEVEL_3 Anti-oxidant 134-03-2 ASCORBIC ACID INDICATION Methemoglobinemia 134-03-2 ASCORBIC ACID ADVERSE_EFFECT SKN_3_Flushing 134-03-2 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Hemolysis 134-03-2 ASCORBIC ACID MECH_LEVEL_2 coenzyme 134-03-2 ASCORBIC ACID MECH_LEVEL_3 Unknown mechanism 134-03-2 ASCORBIC ACID INDICATION Scurvy 134-03-2 ASCORBIC ACID ADVERSE_EFFECT GIS_3_Diarrhea 134-03-2 ASCORBIC ACID ACTIVITY_CLASS H2O2 radical scavenger 134-03-2 ASCORBIC ACID ADVERSE_EFFECT KID_2_Hyperoxaluria 134-03-2 ASCORBIC ACID ADVERSE_EFFECT MSK_3_Back Pain 134-03-2 ASCORBIC ACID ADVERSE_EFFECT NEU_3_Headache 134-03-2 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Hemolytic Anemia 134-03-2 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Anemia 134-03-2 ASCORBIC ACID KNOWN_TOXICITY Nephrotoxicity 134-03-2 ASCORBIC ACID TISSUE_TOXICITY Renal Tubular Obstruction 134-03-2 ASCORBIC ACID MESH_LEVEL_2 Carboxylic Acids 134-03-2 ASCORBIC ACID ADVERSE_EFFECT KID_3_Renal Tubular Obstruction 134-03-2 ASCORBIC ACID PRODUCT_CLASS Vitamins, Minerals and Nutrients 134-03-2 ASCORBIC ACID MECHANISM Vitamin/ cofactor 134-03-2 ASCORBIC ACID MESH_LEVEL_1 Organic Chemicals 134-03-2 ASCORBIC ACID TA_LEVEL_1 Vitamins, Minerals and Nutrients 134-03-2 ASCORBIC ACID ADVERSE_EFFECT BBM_3_Sickle-cell Crisis 134-03-2 ASCORBIC ACID ADVERSE_EFFECT KID_3_Nephrolithiasis 134-03-2 ASCORBIC ACID ADVERSE_EFFECT NEU_3_Dizziness 134-03-2 ASCORBIC ACID ADVERSE_EFFECT GIS_2_Nausea / Vomiting 134-03-2 ASCORBIC ACID STRUCTURE_ACTIVITY H2O2 radical scavenger 134-03-2 ASCORBIC ACID THERAPEUTIC_CLASS Vitamins / Minerals / Nutrients 134-03-2 ASCORBIC ACID ZERO_CLASS N 134-03-2 ASCORBIC ACID ADVERSE_EFFECT XXX_2_Dental Caries 134-03-2 ASCORBIC ACID INDICATION Nutritional Supplement 14216-34-3 ASPIRIN ADVERSE_EFFECT XXX_3_Dehydration 14216-34-3 ASPIRIN MODE_CLASS Enzyme Inhibitor 14216-34-3 ASPIRIN TISSUE_TOXICITY Gastrointestinal Toxicity 14216-34-3 ASPIRIN PRODUCT_CLASS Anti-inflammatories 14216-34-3 ASPIRIN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 14216-34-3 ASPIRIN TA_LEVEL_2 NSAID 14216-34-3 ASPIRIN MECHANISM Inhibit eicosanoid biosynthesis 14216-34-3 ASPIRIN TA_LEVEL_1 Anti-inflammatory 14216-34-3 ASPIRIN ADVERSE_EFFECT LUN_2_Respiratory Alkalosis 14216-34-3 ASPIRIN ADVERSE_EFFECT NEU_3_Coma 14216-34-3 ASPIRIN ACTIVITY_CLASS Anti-inflammatory 14216-34-3 ASPIRIN ZERO_CLASS N 14216-34-3 ASPIRIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 14216-34-3 ASPIRIN MESH_LEVEL_2 Carboxylic Acids 14216-34-3 ASPIRIN MESH_LEVEL_1 Organic Chemicals 14216-34-3 ASPIRIN INDICATION Pain 14216-34-3 ASPIRIN MESH_LEVEL_3 Acids, Carbocyclic 14216-34-3 ASPIRIN STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 14216-34-3 ASPIRIN MECHANISM Inhibit inflammatory response 14216-34-3 ASPIRIN ADVERSE_EFFECT NEU_2_Vertigo 14216-34-3 ASPIRIN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 14216-34-3 ASPIRIN TISSUE_TOXICITY Gastrointestinal Hemorrhage 14216-34-3 ASPIRIN MODE_CLASS Enzyme Inhibitor, selective 14216-34-3 ASPIRIN KNOWN_TOXICITY Gastrointestinal Toxicity 14216-34-3 ASPIRIN ADVERSE_EFFECT OTO_2_Tinnitus 14216-34-3 ASPIRIN ADVERSE_EFFECT XXX_3_Reye's Syndrome 14216-34-3 ASPIRIN ADVERSE_EFFECT END_3_Metabolic Acidosis 14216-34-3 ASPIRIN TA_LEVEL_3 NSAID 14216-34-3 ASPIRIN MECH_LEVEL_1 Immunomodulation 14216-34-3 ASPIRIN ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 14216-34-3 ASPIRIN ADVERSE_EFFECT GIS_1_Gastrointestinal Hemorrhage 14216-34-3 ASPIRIN ADVERSE_EFFECT LUN_2_Hyperventilation 50-78-2 ASPIRIN THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 50-78-2 ASPIRIN MESH_LEVEL_2 Carboxylic Acids 50-78-2 ASPIRIN MESH_LEVEL_1 Organic Chemicals 50-78-2 ASPIRIN INDICATION Pain 50-78-2 ASPIRIN MESH_LEVEL_3 Acids, Carbocyclic 50-78-2 ASPIRIN STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, salicylic acid 50-78-2 ASPIRIN MECHANISM Inhibit inflammatory response 50-78-2 ASPIRIN ADVERSE_EFFECT GIS_1_Gastrointestinal Hemorrhage 50-78-2 ASPIRIN ADVERSE_EFFECT LUN_2_Hyperventilation 50-78-2 ASPIRIN TISSUE_TOXICITY Gastrointestinal Hemorrhage 50-78-2 ASPIRIN MODE_CLASS Enzyme Inhibitor, selective 50-78-2 ASPIRIN ADVERSE_EFFECT LUN_2_Respiratory Alkalosis 50-78-2 ASPIRIN TA_LEVEL_1 Anti-inflammatory 50-78-2 ASPIRIN MECHANISM Inhibit eicosanoid biosynthesis 50-78-2 ASPIRIN TA_LEVEL_2 NSAID 50-78-2 ASPIRIN MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 50-78-2 ASPIRIN PRODUCT_CLASS Anti-inflammatories 50-78-2 ASPIRIN TISSUE_TOXICITY Gastrointestinal Toxicity 50-78-2 ASPIRIN MODE_CLASS Enzyme Inhibitor 50-78-2 ASPIRIN ADVERSE_EFFECT XXX_3_Dehydration 50-78-2 ASPIRIN ADVERSE_EFFECT XXX_3_Reye's Syndrome 50-78-2 ASPIRIN ADVERSE_EFFECT END_3_Metabolic Acidosis 50-78-2 ASPIRIN MECH_LEVEL_1 Immunomodulation 50-78-2 ASPIRIN ADVERSE_EFFECT GIS_1_Gastrointestinal Toxicity 50-78-2 ASPIRIN ADVERSE_EFFECT NEU_3_Coma 50-78-2 ASPIRIN ACTIVITY_CLASS Anti-inflammatory 50-78-2 ASPIRIN ZERO_CLASS N 50-78-2 ASPIRIN TA_LEVEL_3 NSAID 50-78-2 ASPIRIN MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 50-78-2 ASPIRIN KNOWN_TOXICITY Gastrointestinal Toxicity 50-78-2 ASPIRIN ADVERSE_EFFECT OTO_2_Tinnitus 50-78-2 ASPIRIN ADVERSE_EFFECT NEU_2_Vertigo 68844-77-9 ASTEMIZOLE INDICATION Asthma 68844-77-9 ASTEMIZOLE PRODUCT_CLASS Respiratory System 68844-77-9 ASTEMIZOLE MECHANISM Modulate G-protein coupled signal transduction 68844-77-9 ASTEMIZOLE THERAPEUTIC_CLASS Antihistamines 68844-77-9 ASTEMIZOLE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 68844-77-9 ASTEMIZOLE KNOWN_TOXICITY Cardiovascular Toxicity 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT CVS_3_Torsade de Pointes Arrhythmia 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT CVS_1_Cardiotoxicity 68844-77-9 ASTEMIZOLE INDICATION Allergic Contact Dermatitis 68844-77-9 ASTEMIZOLE INDICATION Allergic Conjunctivitis 68844-77-9 ASTEMIZOLE TISSUE_TOXICITY Cardiotoxicity 68844-77-9 ASTEMIZOLE THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 68844-77-9 ASTEMIZOLE TISSUE_TOXICITY Torsade de Pointes Arrhythmia 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT NEU_1_Headache 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 68844-77-9 ASTEMIZOLE PRODUCT_CLASS Anti-inflammatories 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT GIS_1_Dry Mouth 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT NEU_2_Drowsiness 68844-77-9 ASTEMIZOLE MODE_CLASS Receptor Ligand Antagonist, Selective 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT GIS_1_Nausea 68844-77-9 ASTEMIZOLE INDICATION Allergic Rhinitis 68844-77-9 ASTEMIZOLE ADVERSE_EFFECT XXX_2_Pain 29122-68-7 ATENOLOL TA_LEVEL_3 Beta blocker 29122-68-7 ATENOLOL MECH_LEVEL_2 Beta antagonist 29122-68-7 ATENOLOL ADVERSE_EFFECT GIS_2_Nausea 29122-68-7 ATENOLOL ADVERSE_EFFECT NEU_2_Lightheadedness 29122-68-7 ATENOLOL ADVERSE_EFFECT LUN_3_Pulmonary Embolism 29122-68-7 ATENOLOL MESH_LEVEL_2 Alcohols 29122-68-7 ATENOLOL INDICATION Acute Myocardial Infarction 29122-68-7 ATENOLOL THERAPEUTIC_CLASS Antianginals 29122-68-7 ATENOLOL MODE_CLASS Receptor Ligand Antagonist, Selective 29122-68-7 ATENOLOL ADVERSE_EFFECT GIS_2_Diarrhea 29122-68-7 ATENOLOL ADVERSE_EFFECT XXX_2_Lethargy 29122-68-7 ATENOLOL TA_LEVEL_2 Hypertension 29122-68-7 ATENOLOL THERAPEUTIC_CLASS Antihypertensive Agents 29122-68-7 ATENOLOL ADVERSE_EFFECT CVS_1_Bradycardia 29122-68-7 ATENOLOL ADVERSE_EFFECT XXX_2_Fatigue 29122-68-7 ATENOLOL ADVERSE_EFFECT NEU_1_Dizziness 29122-68-7 ATENOLOL MECHANISM Reduce muscle contractile force 29122-68-7 ATENOLOL MESH_LEVEL_1 Organic Chemicals 29122-68-7 ATENOLOL MECH_LEVEL_3 adrenoceptor beta1 29122-68-7 ATENOLOL TA_LEVEL_1 Cardiovascular 29122-68-7 ATENOLOL PRODUCT_CLASS Cardiovasculars 29122-68-7 ATENOLOL INDICATION Hypertension 29122-68-7 ATENOLOL MESH_LEVEL_3 Amino Alcohols 29122-68-7 ATENOLOL ZERO_CLASS N 29122-68-7 ATENOLOL STRUCTURE_ACTIVITY Adrenoceptor-beta1 antagonist, p-phenoxypropanoamine 29122-68-7 ATENOLOL ADVERSE_EFFECT NEU_2_Vertigo 29122-68-7 ATENOLOL ACTIVITY_CLASS Adrenergic antagonist 29122-68-7 ATENOLOL ADVERSE_EFFECT CVS_1_Postural Hypotension 29122-68-7 ATENOLOL MECH_LEVEL_1 Reduce cardiac contractility 29122-68-7 ATENOLOL INDICATION Angina Pectoris 134523-03-8 ATORVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 134523-03-8 ATORVASTATIN TISSUE_TOXICITY Carcinogenicity 134523-03-8 ATORVASTATIN MECHANISM Inhibit cholesterol biosynthesis 134523-03-8 ATORVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 134523-03-8 ATORVASTATIN INDICATION Familial Dysbetalipoproteinemia 134523-03-8 ATORVASTATIN ADVERSE_EFFECT IMU_2_Allergic Reactions 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 134523-03-8 ATORVASTATIN ADVERSE_EFFECT CVS_3_Chest Pain 134523-03-8 ATORVASTATIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 134523-03-8 ATORVASTATIN PRODUCT_CLASS Cardiovasculars 134523-03-8 ATORVASTATIN TA_LEVEL_1 Cardiovascular 134523-03-8 ATORVASTATIN INDICATION Familial Hypercholesterolemia 134523-03-8 ATORVASTATIN INDICATION Mixed Dyslipidemia 134523-03-8 ATORVASTATIN ADVERSE_EFFECT MSK_2_Back Pain 134523-03-8 ATORVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 134523-03-8 ATORVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Nausea 134523-03-8 ATORVASTATIN ZERO_CLASS N 134523-03-8 ATORVASTATIN KNOWN_TOXICITY Carcinogenicity 134523-03-8 ATORVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 134523-03-8 ATORVASTATIN MODE_CLASS Enzyme Inhibitor 134523-03-8 ATORVASTATIN MECH_LEVEL_3 HMG-CoA reductase 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Constipation 134523-03-8 ATORVASTATIN ADVERSE_EFFECT XXX_2_Pharyngitis 134523-03-8 ATORVASTATIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Dry Mouth 134523-03-8 ATORVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 134523-03-8 ATORVASTATIN TA_LEVEL_2 Lipid lowering agent 134523-03-8 ATORVASTATIN MECH_LEVEL_1 Lipid lowering 134523-03-8 ATORVASTATIN INDICATION Hypertriglyceridemia 134523-03-8 ATORVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 134523-03-8 ATORVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 134523-03-8 ATORVASTATIN ADVERSE_EFFECT XXX_2_Asthenia 134523-03-8 ATORVASTATIN ADVERSE_EFFECT XXX_2_Sinusitis 134523-03-8 ATORVASTATIN ADVERSE_EFFECT XXX_3_Fever 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Gastritis 134523-03-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 134523-03-8 ATORVASTATIN MESH_LEVEL_3 Naphthalenes 134523-03-8 ATORVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 110862-48-1 ATORVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 110862-48-1 ATORVASTATIN ADVERSE_EFFECT XXX_3_Fever 110862-48-1 ATORVASTATIN MECH_LEVEL_3 HMG-CoA reductase 110862-48-1 ATORVASTATIN TA_LEVEL_2 Lipid lowering agent 110862-48-1 ATORVASTATIN PRODUCT_CLASS Cardiovasculars 110862-48-1 ATORVASTATIN TA_LEVEL_1 Cardiovascular 110862-48-1 ATORVASTATIN INDICATION Familial Hypercholesterolemia 110862-48-1 ATORVASTATIN INDICATION Mixed Dyslipidemia 110862-48-1 ATORVASTATIN ADVERSE_EFFECT MSK_2_Back Pain 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 110862-48-1 ATORVASTATIN TISSUE_TOXICITY Carcinogenicity 110862-48-1 ATORVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_3_Nausea 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 110862-48-1 ATORVASTATIN ZERO_CLASS N 110862-48-1 ATORVASTATIN KNOWN_TOXICITY Carcinogenicity 110862-48-1 ATORVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_2_Constipation 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_3_Gastritis 110862-48-1 ATORVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 110862-48-1 ATORVASTATIN MESH_LEVEL_3 Naphthalenes 110862-48-1 ATORVASTATIN MECHANISM Inhibit cholesterol biosynthesis 110862-48-1 ATORVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 110862-48-1 ATORVASTATIN INDICATION Familial Dysbetalipoproteinemia 110862-48-1 ATORVASTATIN ADVERSE_EFFECT IMU_2_Allergic Reactions 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 110862-48-1 ATORVASTATIN ADVERSE_EFFECT CVS_3_Chest Pain 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 110862-48-1 ATORVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 110862-48-1 ATORVASTATIN MODE_CLASS Enzyme Inhibitor 110862-48-1 ATORVASTATIN ADVERSE_EFFECT XXX_2_Pharyngitis 110862-48-1 ATORVASTATIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 110862-48-1 ATORVASTATIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 110862-48-1 ATORVASTATIN ADVERSE_EFFECT GIS_3_Dry Mouth 110862-48-1 ATORVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 110862-48-1 ATORVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 110862-48-1 ATORVASTATIN MECH_LEVEL_1 Lipid lowering 110862-48-1 ATORVASTATIN INDICATION Hypertriglyceridemia 110862-48-1 ATORVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 110862-48-1 ATORVASTATIN ADVERSE_EFFECT XXX_2_Asthenia 110862-48-1 ATORVASTATIN ADVERSE_EFFECT XXX_2_Sinusitis 134523-00-5 ATORVASTATIN MODE_CLASS Enzyme Inhibitor 134523-00-5 ATORVASTATIN ADVERSE_EFFECT IMU_2_Allergic Reactions 134523-00-5 ATORVASTATIN INDICATION Familial Dysbetalipoproteinemia 134523-00-5 ATORVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 134523-00-5 ATORVASTATIN MECHANISM Inhibit cholesterol biosynthesis 134523-00-5 ATORVASTATIN TISSUE_TOXICITY Carcinogenicity 134523-00-5 ATORVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 134523-00-5 ATORVASTATIN MESH_LEVEL_3 Naphthalenes 134523-00-5 ATORVASTATIN MECH_LEVEL_3 HMG-CoA reductase 134523-00-5 ATORVASTATIN TA_LEVEL_2 Lipid lowering agent 134523-00-5 ATORVASTATIN PRODUCT_CLASS Cardiovasculars 134523-00-5 ATORVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 134523-00-5 ATORVASTATIN TA_LEVEL_1 Cardiovascular 134523-00-5 ATORVASTATIN INDICATION Familial Hypercholesterolemia 134523-00-5 ATORVASTATIN INDICATION Mixed Dyslipidemia 134523-00-5 ATORVASTATIN ADVERSE_EFFECT MSK_2_Back Pain 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 134523-00-5 ATORVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_3_Nausea 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 134523-00-5 ATORVASTATIN ZERO_CLASS N 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_3_Gastritis 134523-00-5 ATORVASTATIN ADVERSE_EFFECT XXX_3_Fever 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_2_Constipation 134523-00-5 ATORVASTATIN ADVERSE_EFFECT XXX_2_Pharyngitis 134523-00-5 ATORVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 134523-00-5 ATORVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 134523-00-5 ATORVASTATIN MECH_LEVEL_1 Lipid lowering 134523-00-5 ATORVASTATIN INDICATION Hypertriglyceridemia 134523-00-5 ATORVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 134523-00-5 ATORVASTATIN KNOWN_TOXICITY Carcinogenicity 134523-00-5 ATORVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 134523-00-5 ATORVASTATIN ADVERSE_EFFECT XXX_2_Asthenia 134523-00-5 ATORVASTATIN ADVERSE_EFFECT XXX_2_Sinusitis 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_3_Dry Mouth 134523-00-5 ATORVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 134523-00-5 ATORVASTATIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 134523-00-5 ATORVASTATIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 134523-00-5 ATORVASTATIN ADVERSE_EFFECT CVS_3_Chest Pain 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 134523-00-5 ATORVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 134523-05-8 ATORVASTATIN TA_LEVEL_2 Lipid lowering agent 134523-05-8 ATORVASTATIN TA_LEVEL_1 Cardiovascular 134523-05-8 ATORVASTATIN INDICATION Familial Hypercholesterolemia 134523-05-8 ATORVASTATIN INDICATION Mixed Dyslipidemia 134523-05-8 ATORVASTATIN ADVERSE_EFFECT MSK_2_Back Pain 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Diarrhea 134523-05-8 ATORVASTATIN ADVERSE_EFFECT MSK_2_Myalgia 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Nausea 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Rectal Hemorrhage 134523-05-8 ATORVASTATIN ZERO_CLASS N 134523-05-8 ATORVASTATIN ADVERSE_EFFECT LIV_3_Abnormal Liver Function Tests 134523-05-8 ATORVASTATIN ADVERSE_EFFECT CVS_3_Chest Pain 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Flatulence 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Dyspepsia 134523-05-8 ATORVASTATIN ADVERSE_EFFECT IMU_2_Allergic Reactions 134523-05-8 ATORVASTATIN INDICATION Familial Dysbetalipoproteinemia 134523-05-8 ATORVASTATIN TA_LEVEL_3 HMG-CoA reductase inhibitors 134523-05-8 ATORVASTATIN MECHANISM Inhibit cholesterol biosynthesis 134523-05-8 ATORVASTATIN TISSUE_TOXICITY Carcinogenicity 134523-05-8 ATORVASTATIN MESH_LEVEL_1 Polycyclic Hydrocarbons 134523-05-8 ATORVASTATIN MESH_LEVEL_3 Naphthalenes 134523-05-8 ATORVASTATIN STRUCTURE_ACTIVITY HMG-CoA reductase inhibitors 134523-05-8 ATORVASTATIN ACTIVITY_CLASS Cholesterol biosynthesis inhibitor 134523-05-8 ATORVASTATIN KNOWN_TOXICITY Carcinogenicity 134523-05-8 ATORVASTATIN MECH_LEVEL_2 Inhibit cholesterol biosynthesis 134523-05-8 ATORVASTATIN MODE_CLASS Enzyme Inhibitor 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Abdominal Pain 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_2_Constipation 134523-05-8 ATORVASTATIN ADVERSE_EFFECT XXX_2_Pharyngitis 134523-05-8 ATORVASTATIN ADVERSE_EFFECT IMU_3_Photosensitivity Reaction 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Dry Mouth 134523-05-8 ATORVASTATIN PRODUCT_CLASS Cardiovasculars 134523-05-8 ATORVASTATIN MESH_LEVEL_2 Polycyclic Hydrocarbons, Aromatic 134523-05-8 ATORVASTATIN MECH_LEVEL_1 Lipid lowering 134523-05-8 ATORVASTATIN INDICATION Hypertriglyceridemia 134523-05-8 ATORVASTATIN THERAPEUTIC_CLASS Hypolipidemic Agents 134523-05-8 ATORVASTATIN ADVERSE_EFFECT DNA_3_Carcinogenicity 134523-05-8 ATORVASTATIN ADVERSE_EFFECT XXX_2_Asthenia 134523-05-8 ATORVASTATIN ADVERSE_EFFECT XXX_2_Sinusitis 134523-05-8 ATORVASTATIN ADVERSE_EFFECT XXX_3_Fever 134523-05-8 ATORVASTATIN ADVERSE_EFFECT GIS_3_Gastritis 134523-05-8 ATORVASTATIN MECH_LEVEL_3 HMG-CoA reductase 95233-18-4 ATOVAQUONE INDICATION Pneumocystis Carinii Pneumonia (PCP) 95233-18-4 ATOVAQUONE PRODUCT_CLASS Anti-infectives 95233-18-4 ATOVAQUONE INDICATION Prevention of Pneumocystis Carinii Pneumonia 95233-18-4 ATOVAQUONE THERAPEUTIC_CLASS Antiparasitics 94015-53-9 ATOVAQUONE INDICATION Pneumocystis Carinii Pneumonia (PCP) 94015-53-9 ATOVAQUONE PRODUCT_CLASS Anti-infectives 94015-53-9 ATOVAQUONE INDICATION Prevention of Pneumocystis Carinii Pneumonia 94015-53-9 ATOVAQUONE THERAPEUTIC_CLASS Antiparasitics 17754-44-8 ATRACTYLOSIDE MECHANISM Inhibit mitochondrial function 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT LIV_1_Hepatic Necrosis 17754-44-8 ATRACTYLOSIDE STRUCTURE_ACTIVITY Toxicant, mitochondrial respiration inhibitor, uncouples Oxidative phosphorylation 17754-44-8 ATRACTYLOSIDE KNOWN_TOXICITY Nephrotoxicity 17754-44-8 ATRACTYLOSIDE KNOWN_TOXICITY Neurotoxicity 17754-44-8 ATRACTYLOSIDE TISSUE_TOXICITY Acute Renal Failure 17754-44-8 ATRACTYLOSIDE TISSUE_TOXICITY Renal Toxicity 17754-44-8 ATRACTYLOSIDE PRODUCT_CLASS Toxicants 17754-44-8 ATRACTYLOSIDE MODE_CLASS Solute transporter inhibitor 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT KID_2_Acute Tubular Necrosis 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT NEU_1_Convulsions 17754-44-8 ATRACTYLOSIDE TISSUE_TOXICITY Death 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT XXX_3_Death 17754-44-8 ATRACTYLOSIDE KNOWN_TOXICITY Miscellaneous 17754-44-8 ATRACTYLOSIDE TISSUE_TOXICITY Acute Tubular Necrosis 17754-44-8 ATRACTYLOSIDE TISSUE_TOXICITY Convulsions 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT KID_2_Acute Renal Failure 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT KID_1_Renal Toxicity 17754-44-8 ATRACTYLOSIDE KNOWN_TOXICITY Hepatotoxicity 17754-44-8 ATRACTYLOSIDE TISSUE_TOXICITY Hepatic Necrosis 17754-44-8 ATRACTYLOSIDE ADVERSE_EFFECT KID_1_Proximal Tubular Damage 64228-81-5 ATRACURIUM PRODUCT_CLASS Autonomic Nervous System (ANS) 64228-81-5 ATRACURIUM MODE_CLASS Channel Blocker 64228-81-5 ATRACURIUM MECHANISM Modulate neural transmission 64228-81-5 ATRACURIUM THERAPEUTIC_CLASS Skeletal Muscle Relaxants 64228-79-1 ATRACURIUM THERAPEUTIC_CLASS Skeletal Muscle Relaxants 64228-79-1 ATRACURIUM MODE_CLASS Channel Blocker 64228-79-1 ATRACURIUM PRODUCT_CLASS Autonomic Nervous System (ANS) 64228-79-1 ATRACURIUM MECHANISM Modulate neural transmission 89213-87-6 CARPERITIDE THERAPEUTIC_CLASS Miscellaneous Cardiac Agents 89213-87-6 CARPERITIDE PRODUCT_CLASS Cardiovasculars 89213-87-6 CARPERITIDE INDICATION Acute Heart Failure 51-55-8 ATROPINE MECH_LEVEL_3 Muscarinic acetylcholine receptor 51-55-8 ATROPINE ACTIVITY_CLASS Muscarinic acetylcholine receptor antagonist 51-55-8 ATROPINE ADVERSE_EFFECT SKN_2_Skin Rash 51-55-8 ATROPINE ADVERSE_EFFECT GIS_1_Dry Mouth 51-55-8 ATROPINE ADVERSE_EFFECT GIS_1_Constipation 51-55-8 ATROPINE STRUCTURE_ACTIVITY Muscarinic acetylcoline receptor (M) antagonist 51-55-8 ATROPINE PRODUCT_CLASS Respiratory System 51-55-8 ATROPINE PRODUCT_CLASS Autonomic Nervous System (ANS) 51-55-8 ATROPINE INDICATION Neurogenic Bladder 51-55-8 ATROPINE ADVERSE_EFFECT OCU_2_Increased Intraocular Pressure 51-55-8 ATROPINE ADVERSE_EFFECT NEU_2_Headache 51-55-8 ATROPINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 51-55-8 ATROPINE ADVERSE_EFFECT OCU_2_Blurred Vision 51-55-8 ATROPINE PRODUCT_CLASS Cardiovasculars 51-55-8 ATROPINE MESH_LEVEL_2 Alkaloids 51-55-8 ATROPINE INDICATION Inhibition of Salivation 51-55-8 ATROPINE INDICATION Renal Colic 51-55-8 ATROPINE TA_LEVEL_1 Respiratory System 51-55-8 ATROPINE INDICATION Bronchospasm 51-55-8 ATROPINE INDICATION Uveitis 51-55-8 ATROPINE MODE_CLASS Receptor Ligand Antagonist, Non-selective 51-55-8 ATROPINE ADVERSE_EFFECT IMU_3_Allergic Reactions 51-55-8 ATROPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 51-55-8 ATROPINE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 51-55-8 ATROPINE MECHANISM Modulate G-protein coupled signal transduction 51-55-8 ATROPINE TISSUE_TOXICITY Cardiac Arrhythmia 51-55-8 ATROPINE INDICATION Muscarine Toxicity 51-55-8 ATROPINE TA_LEVEL_2 anti-cholinergic 51-55-8 ATROPINE MESH_LEVEL_3 Tropanes 51-55-8 ATROPINE INDICATION Sinus Bradycardia 51-55-8 ATROPINE INDICATION Urinary Spasm 51-55-8 ATROPINE INDICATION Induction of mydriasis for eye examinations 51-55-8 ATROPINE ADVERSE_EFFECT XXX_1_Reduced Sweating 51-55-8 ATROPINE ADVERSE_EFFECT SKN_2_Flushing 51-55-8 ATROPINE THERAPEUTIC_CLASS Antidotes 51-55-8 ATROPINE KNOWN_TOXICITY Cardiovascular Toxicity 51-55-8 ATROPINE INDICATION Incontinence 51-55-8 ATROPINE INDICATION Induction of Cycloplegia for Eye Examinations 51-55-8 ATROPINE INDICATION Peptic Ulcer Disease (PUD) 51-55-8 ATROPINE MECH_LEVEL_1 Modulate neural transmission 51-55-8 ATROPINE INDICATION Biliary Colic 51-55-8 ATROPINE INDICATION Hypotonic Radiograph of Gastrointestinal Tract 51-55-8 ATROPINE MESH_LEVEL_1 Heterocyclic Compounds 51-55-8 ATROPINE MECHANISM Prolong/enhance neural transmission 51-55-8 ATROPINE MECH_LEVEL_2 Muscarinic receptor antagonist 51-55-8 ATROPINE ADVERSE_EFFECT NEU_2_Drowsiness 51-55-8 ATROPINE ADVERSE_EFFECT XXX_3_Weakness 51-55-8 ATROPINE ADVERSE_EFFECT GUS_2_Urinary Retention 51-55-8 ATROPINE ZERO_CLASS N 51-55-8 ATROPINE MODE_CLASS Solute transporter inhibitor 51-55-8 ATROPINE PRODUCT_CLASS Other Human Uses 51-55-8 ATROPINE THERAPEUTIC_CLASS Bronchodilators 51-55-8 ATROPINE THERAPEUTIC_CLASS Parasympatholytic Agents 51-55-8 ATROPINE INDICATION Symptomatic Sinus Bradycardia 51-55-8 ATROPINE INDICATION Cholinesterase Inhibitor Toxicity 51-55-8 ATROPINE TA_LEVEL_3 anti-muscarinic 51-55-8 ATROPINE INDICATION Organophosphate Poisoning 51-55-8 ATROPINE INDICATION Irritable Bowel Syndrome 12192-57-3 AUROTHIOGLUCOSE INDICATION Rheumatism 12192-57-3 AUROTHIOGLUCOSE THERAPEUTIC_CLASS Immunosuppressants 12192-57-3 AUROTHIOGLUCOSE PRODUCT_CLASS Immune Response / Immunomodulators 13539-59-8 APAZONE MODE_CLASS Enzyme Inhibitor 13539-59-8 APAZONE MECHANISM Inhibit eicosanoid biosynthesis 13539-59-8 APAZONE INDICATION Ankylosing Spondylitis 13539-59-8 APAZONE MECHANISM Inhibit precursor synthesis 13539-59-8 APAZONE THERAPEUTIC_CLASS Nonsteroidal Anti-Inflammatories (NSAIDs) 13539-59-8 APAZONE INDICATION Acute Gouty Arthritis 13539-59-8 APAZONE MECHANISM interferes with liver P450 enzyme funciton 13539-59-8 APAZONE PRODUCT_CLASS Anti-inflammatories 13539-59-8 APAZONE INDICATION Rheumatoid Arthritis 115-02-6 AZASERINE MECHANISM Inhibit DNA synthesis, repair, and function 115-02-6 AZASERINE THERAPEUTIC_CLASS Antineoplastics 115-02-6 AZASERINE ADVERSE_EFFECT DNA_1_Pancreatic Adenocarcinoma 115-02-6 AZASERINE MODE_CLASS Distorts /blocks macromolecular scaffold function 115-02-6 AZASERINE PRODUCT_CLASS Anti-cancers 115-02-6 AZASERINE KNOWN_TOXICITY Carcinogenicity 115-02-6 AZASERINE TISSUE_TOXICITY Pancreatic Adenocarcinoma 115-02-6 AZASERINE STRUCTURE_ACTIVITY DNA-alkylator 3964-81-6 AZATADINE PRODUCT_CLASS Anti-inflammatories 3964-81-6 AZATADINE INDICATION Pruritus / Itching 3964-81-6 AZATADINE INDICATION Nasal Congestion 3964-81-6 AZATADINE INDICATION Allergic Diseases 3964-81-6 AZATADINE INDICATION Allergic Rhinitis 3964-81-6 AZATADINE MECHANISM Modulate G-protein coupled signal transduction 3964-81-6 AZATADINE THERAPEUTIC_CLASS Antihistamines 3964-81-6 AZATADINE INDICATION Allergic Conjunctivitis 3964-81-6 AZATADINE MODE_CLASS Receptor Ligand Antagonist, Selective 123-99-9 AZELAIC ACID ADVERSE_EFFECT IMU_3_Contact Dermatitis 123-99-9 AZELAIC ACID INDICATION Melasma 123-99-9 AZELAIC ACID ADVERSE_EFFECT SKN_2_Skin Irritation 123-99-9 AZELAIC ACID THERAPEUTIC_CLASS Antineoplastics 123-99-9 AZELAIC ACID ADVERSE_EFFECT XXX_3_Infection 123-99-9 AZELAIC ACID ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 123-99-9 AZELAIC ACID PRODUCT_CLASS Anti-cancers 123-99-9 AZELAIC ACID INDICATION Lentigo Maligna 123-99-9 AZELAIC ACID ADVERSE_EFFECT SKN_2_Pruritis 123-99-9 AZELAIC ACID MODE_CLASS Enzyme Inhibitor 123-99-9 AZELAIC ACID INDICATION Acne / Acne Vulgaris 123-99-9 AZELAIC ACID ADVERSE_EFFECT SKN_3_Hypertrichosis 123-99-9 AZELAIC ACID ADVERSE_EFFECT IMU_3_Allergic Reactions 123-99-9 AZELAIC ACID ADVERSE_EFFECT SKN_2_Skin Rash 123-99-9 AZELAIC ACID INDICATION Malignant Melanoma 123-99-9 AZELAIC ACID ADVERSE_EFFECT SKN_2_Erythema 123-99-9 AZELAIC ACID PRODUCT_CLASS Dermatologicals 123-99-9 AZELAIC ACID THERAPEUTIC_CLASS Acne Preparations 123-99-9 AZELAIC ACID ADVERSE_EFFECT XXX_3_Xerosis 123-99-9 AZELAIC ACID INDICATION Propionibacterium Acnes 17265-13-3 AZELAIC ACID ADVERSE_EFFECT IMU_3_Contact Dermatitis 17265-13-3 AZELAIC ACID ADVERSE_EFFECT SKN_2_Skin Rash 17265-13-3 AZELAIC ACID ADVERSE_EFFECT SKN_2_Pruritis 17265-13-3 AZELAIC ACID INDICATION Propionibacterium Acnes 17265-13-3 AZELAIC ACID ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 17265-13-3 AZELAIC ACID ADVERSE_EFFECT XXX_3_Infection 17265-13-3 AZELAIC ACID ADVERSE_EFFECT IMU_3_Allergic Reactions 17265-13-3 AZELAIC ACID INDICATION Malignant Melanoma 17265-13-3 AZELAIC ACID PRODUCT_CLASS Dermatologicals 17265-13-3 AZELAIC ACID INDICATION Acne / Acne Vulgaris 17265-13-3 AZELAIC ACID MODE_CLASS Enzyme Inhibitor 17265-13-3 AZELAIC ACID ADVERSE_EFFECT XXX_3_Xerosis 17265-13-3 AZELAIC ACID ADVERSE_EFFECT SKN_3_Hypertrichosis 17265-13-3 AZELAIC ACID INDICATION Lentigo Maligna 17265-13-3 AZELAIC ACID PRODUCT_CLASS Anti-cancers 17265-13-3 AZELAIC ACID THERAPEUTIC_CLASS Acne Preparations 17265-13-3 AZELAIC ACID THERAPEUTIC_CLASS Antineoplastics 17265-13-3 AZELAIC ACID ADVERSE_EFFECT SKN_2_Erythema 17265-13-3 AZELAIC ACID ADVERSE_EFFECT SKN_2_Skin Irritation 17265-13-3 AZELAIC ACID INDICATION Melasma 14488-58-5 AZELAIC ACID INDICATION Malignant Melanoma 14488-58-5 AZELAIC ACID PRODUCT_CLASS Anti-cancers 14488-58-5 AZELAIC ACID INDICATION Melasma 14488-58-5 AZELAIC ACID ADVERSE_EFFECT SKN_2_Skin Irritation 14488-58-5 AZELAIC ACID THERAPEUTIC_CLASS Antineoplastics 14488-58-5 AZELAIC ACID INDICATION Acne / Acne Vulgaris 14488-58-5 AZELAIC ACID ADVERSE_EFFECT SKN_2_Erythema 14488-58-5 AZELAIC ACID THERAPEUTIC_CLASS Acne Preparations 14488-58-5 AZELAIC ACID ADVERSE_EFFECT IMU_3_Contact Dermatitis 14488-58-5 AZELAIC ACID ADVERSE_EFFECT SKN_2_Skin Rash 14488-58-5 AZELAIC ACID INDICATION Propionibacterium Acnes 14488-58-5 AZELAIC ACID ADVERSE_EFFECT SKN_3_Skin Hypopigmentation 14488-58-5 AZELAIC ACID ADVERSE_EFFECT XXX_3_Infection 14488-58-5 AZELAIC ACID ADVERSE_EFFECT IMU_3_Allergic Reactions 14488-58-5 AZELAIC ACID PRODUCT_CLASS Dermatologicals 14488-58-5 AZELAIC ACID MODE_CLASS Enzyme Inhibitor 14488-58-5 AZELAIC ACID ADVERSE_EFFECT XXX_3_Xerosis 14488-58-5 AZELAIC ACID ADVERSE_EFFECT SKN_3_Hypertrichosis 14488-58-5 AZELAIC ACID ADVERSE_EFFECT SKN_2_Pruritis 14488-58-5 AZELAIC ACID INDICATION Lentigo Maligna 37932-96-0 AZELASTINE INDICATION Ocular Pruritus 37932-96-0 AZELASTINE ADVERSE_EFFECT XXX_2_Pharyngitis 37932-96-0 AZELASTINE MECHANISM Modulate G-protein coupled signal transduction 37932-96-0 AZELASTINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 37932-96-0 AZELASTINE ADVERSE_EFFECT NEU_2_Drowsiness 37932-96-0 AZELASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 37932-96-0 AZELASTINE ADVERSE_EFFECT OCU_3_Blurred Vision 37932-96-0 AZELASTINE ADVERSE_EFFECT IMU_3_Allergic Reactions 37932-96-0 AZELASTINE ADVERSE_EFFECT XXX_1_Nasal Irritation 37932-96-0 AZELASTINE ADVERSE_EFFECT OCU_1_Ocular Irritation 37932-96-0 AZELASTINE INDICATION Allergic Rhinitis 37932-96-0 AZELASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 37932-96-0 AZELASTINE ADVERSE_EFFECT OCU_2_Eye Pain 37932-96-0 AZELASTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 37932-96-0 AZELASTINE ADVERSE_EFFECT XXX_2_Paroxysmal Sneezing 37932-96-0 AZELASTINE ADVERSE_EFFECT XXX_2_Xerostomia 37932-96-0 AZELASTINE ADVERSE_EFFECT LUN_3_Bronchospasm 37932-96-0 AZELASTINE INDICATION Vasomotor Rhinitis 37932-96-0 AZELASTINE ADVERSE_EFFECT NEU_2_Headache 37932-96-0 AZELASTINE INDICATION Allergic Conjunctivitis 37932-96-0 AZELASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 37932-96-0 AZELASTINE ADVERSE_EFFECT GIS_1_Bitter Taste 37932-96-0 AZELASTINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 37932-96-0 AZELASTINE ADVERSE_EFFECT XXX_2_Epistaxis 37932-96-0 AZELASTINE ADVERSE_EFFECT NEU_2_Dizziness 79307-93-0 AZELASTINE ADVERSE_EFFECT XXX_2_Epistaxis 79307-93-0 AZELASTINE ADVERSE_EFFECT NEU_2_Dizziness 79307-93-0 AZELASTINE INDICATION Allergic Rhinitis 79307-93-0 AZELASTINE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 79307-93-0 AZELASTINE MODE_CLASS Receptor Ligand Antagonist, Selective 79307-93-0 AZELASTINE ADVERSE_EFFECT OCU_1_Ocular Irritation 79307-93-0 AZELASTINE ADVERSE_EFFECT XXX_1_Nasal Irritation 79307-93-0 AZELASTINE ADVERSE_EFFECT IMU_3_Allergic Reactions 79307-93-0 AZELASTINE ADVERSE_EFFECT OCU_3_Blurred Vision 79307-93-0 AZELASTINE INDICATION Allergic Conjunctivitis 79307-93-0 AZELASTINE INDICATION Ocular Pruritus 79307-93-0 AZELASTINE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 79307-93-0 AZELASTINE INDICATION Vasomotor Rhinitis 79307-93-0 AZELASTINE ADVERSE_EFFECT OCU_2_Eye Pain 79307-93-0 AZELASTINE ADVERSE_EFFECT XXX_2_Pharyngitis 79307-93-0 AZELASTINE ADVERSE_EFFECT NEU_2_Drowsiness 79307-93-0 AZELASTINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 79307-93-0 AZELASTINE MECHANISM Modulate G-protein coupled signal transduction 79307-93-0 AZELASTINE ADVERSE_EFFECT XXX_2_Paroxysmal Sneezing 79307-93-0 AZELASTINE ADVERSE_EFFECT XXX_2_Xerostomia 79307-93-0 AZELASTINE ADVERSE_EFFECT LUN_3_Bronchospasm 79307-93-0 AZELASTINE ADVERSE_EFFECT NEU_2_Headache 79307-93-0 AZELASTINE STRUCTURE_ACTIVITY Histamine receptor (H1) antagonist 79307-93-0 AZELASTINE ADVERSE_EFFECT GIS_1_Bitter Taste 79307-93-0 AZELASTINE ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 83905-01-5 AZITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 83905-01-5 AZITHROMYCIN MESH_LEVEL_2 Lactones 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT XXX_2_Fatigue 83905-01-5 AZITHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Flatulence 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT CVS_2_Palpitation 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Dizziness 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 83905-01-5 AZITHROMYCIN TA_LEVEL_2 Anti-bacterial 83905-01-5 AZITHROMYCIN TA_LEVEL_3 Systemic infections 83905-01-5 AZITHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 83905-01-5 AZITHROMYCIN INDICATION Skin and Skin Structure Infections 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Somnolence 83905-01-5 AZITHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Vertigo 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Melena 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Dyspepsia 83905-01-5 AZITHROMYCIN MESH_LEVEL_1 Organic Chemicals 83905-01-5 AZITHROMYCIN INDICATION Community-Acquired Pneumonia 83905-01-5 AZITHROMYCIN INDICATION Tonsillitis 83905-01-5 AZITHROMYCIN MESH_LEVEL_3 Macrolides 83905-01-5 AZITHROMYCIN INDICATION Pharyngitis 83905-01-5 AZITHROMYCIN THERAPEUTIC_CLASS Antibacterials 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Nausea 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT SKN_2_Rash 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT KID_2_Nephritis 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 83905-01-5 AZITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 83905-01-5 AZITHROMYCIN ZERO_CLASS N 83905-01-5 AZITHROMYCIN MECH_LEVEL_1 Anti-bacterial 83905-01-5 AZITHROMYCIN PRODUCT_CLASS Anti-infectives 83905-01-5 AZITHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 83905-01-5 AZITHROMYCIN INDICATION Nongonoccocal Urethritis and Cervicitis 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT IMU_2_Photosensitivity 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT CVS_2_Chest Pain 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GUS_2_Genital Moniliasis 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Vomiting 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT IMU_2_Angioedema 83905-01-5 AZITHROMYCIN TA_LEVEL_1 Infectious Disease 83905-01-5 AZITHROMYCIN ADVERSE_EFFECT GUS_2_Vaginitis 90581-31-0 AZITHROMYCIN PRODUCT_CLASS Anti-infectives 90581-31-0 AZITHROMYCIN INDICATION Nongonoccocal Urethritis and Cervicitis 90581-31-0 AZITHROMYCIN MECH_LEVEL_2 Inhibit ribosomal protein synthesis 90581-31-0 AZITHROMYCIN TA_LEVEL_2 Anti-bacterial 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT SKN_2_Rash 90581-31-0 AZITHROMYCIN TA_LEVEL_3 Systemic infections 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Nausea 90581-31-0 AZITHROMYCIN THERAPEUTIC_CLASS Antibacterials 90581-31-0 AZITHROMYCIN MECHANISM Inhibit ribosomal protein synthesis 90581-31-0 AZITHROMYCIN MECH_LEVEL_1 Anti-bacterial 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GUS_2_Vaginitis 90581-31-0 AZITHROMYCIN MECH_LEVEL_3 50/60S Ribosomal Subunit 90581-31-0 AZITHROMYCIN INDICATION Skin and Skin Structure Infections 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Somnolence 90581-31-0 AZITHROMYCIN STRUCTURE_ACTIVITY Bacterial ribosomal (50S) function inhibitor, macrolide 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Vertigo 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Melena 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Dyspepsia 90581-31-0 AZITHROMYCIN MESH_LEVEL_1 Organic Chemicals 90581-31-0 AZITHROMYCIN INDICATION Pharyngitis 90581-31-0 AZITHROMYCIN INDICATION Community-Acquired Pneumonia 90581-31-0 AZITHROMYCIN INDICATION Tonsillitis 90581-31-0 AZITHROMYCIN MESH_LEVEL_3 Macrolides 90581-31-0 AZITHROMYCIN TA_LEVEL_1 Infectious Disease 90581-31-0 AZITHROMYCIN MESH_LEVEL_2 Lactones 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT CVS_2_Chest Pain 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GUS_2_Genital Moniliasis 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Vomiting 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT IMU_2_Angioedema 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT IMU_2_Photosensitivity 90581-31-0 AZITHROMYCIN ZERO_CLASS N 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT XXX_2_Fatigue 90581-31-0 AZITHROMYCIN ACTIVITY_CLASS Antibiotic, ribosomal inhibitor 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_2_Flatulence 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT CVS_2_Palpitation 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT LIV_2_Cholestatic Jaundice 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT NEU_2_Dizziness 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT KID_2_Nephritis 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Abdominal Pain 90581-31-0 AZITHROMYCIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 90581-31-0 AZITHROMYCIN ADVERSE_EFFECT GIS_1_Diarrhea 78110-38-0 AZTREONAM KNOWN_TOXICITY Cardiovascular Toxicity 78110-38-0 AZTREONAM INDICATION Intra-Abdominal Infections 78110-38-0 AZTREONAM INDICATION Urinary Tract Infection (UTI) 78110-38-0 AZTREONAM MECH_LEVEL_1 Anti-bacterial 78110-38-0 AZTREONAM MESH_LEVEL_1 Organic Chemicals 78110-38-0 AZTREONAM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 78110-38-0 AZTREONAM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 78110-38-0 AZTREONAM PRODUCT_CLASS Anti-infectives 78110-38-0 AZTREONAM TISSUE_TOXICITY Hypotension 78110-38-0 AZTREONAM ADVERSE_EFFECT PSY_3_Confusion 78110-38-0 AZTREONAM ADVERSE_EFFECT NEU_3_Paresthesia 78110-38-0 AZTREONAM ADVERSE_EFFECT BBM_3_Pancytopenia 78110-38-0 AZTREONAM ADVERSE_EFFECT IMU_3_Anaphylaxis 78110-38-0 AZTREONAM THERAPEUTIC_CLASS Antibacterials, Systemic 78110-38-0 AZTREONAM MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 78110-38-0 AZTREONAM INDICATION Pelvic Inflammatory Disease (PID) 78110-38-0 AZTREONAM TA_LEVEL_3 systemic infections 78110-38-0 AZTREONAM ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 78110-38-0 AZTREONAM ADVERSE_EFFECT CVS_3_Hypotension 78110-38-0 AZTREONAM ADVERSE_EFFECT LIV_3_Abnormal Liver Function 78110-38-0 AZTREONAM MODE_CLASS Enzyme Inhibitor 78110-38-0 AZTREONAM TISSUE_TOXICITY Bigeminy 78110-38-0 AZTREONAM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 78110-38-0 AZTREONAM ADVERSE_EFFECT SKN_2_Pruritis 78110-38-0 AZTREONAM INDICATION Lower Respiratory Tract Infection 78110-38-0 AZTREONAM TA_LEVEL_2 Anti-bacterial 78110-38-0 AZTREONAM MESH_LEVEL_3 Lactams 78110-38-0 AZTREONAM ADVERSE_EFFECT GIS_1_Abdominal Cramps 78110-38-0 AZTREONAM ADVERSE_EFFECT NEU_3_Seizures 78110-38-0 AZTREONAM ADVERSE_EFFECT GUS_2_Vaginal Candidiasis 78110-38-0 AZTREONAM ADVERSE_EFFECT SKN_2_Flushing 78110-38-0 AZTREONAM ZERO_CLASS N 78110-38-0 AZTREONAM MESH_LEVEL_2 Amides 78110-38-0 AZTREONAM INDICATION Septicemia 78110-38-0 AZTREONAM TA_LEVEL_1 Infectious Disease 78110-38-0 AZTREONAM MECHANISM Inhibit bacterial cell wall biosynthesis 78110-38-0 AZTREONAM ADVERSE_EFFECT LUN_2_Wheezing 78110-38-0 AZTREONAM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 78110-38-0 AZTREONAM ADVERSE_EFFECT CVS_1_Phlebitis 78110-38-0 AZTREONAM ADVERSE_EFFECT LIV_3_Hepatitis 78110-38-0 AZTREONAM INDICATION Skin and Skin Structure Infections 78110-38-0 AZTREONAM ADVERSE_EFFECT LIV_3_Jaundice 78110-38-0 AZTREONAM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 78110-38-0 AZTREONAM ADVERSE_EFFECT CVS_3_Bigeminy 78110-38-0 AZTREONAM ADVERSE_EFFECT XXX_2_Fever 80581-86-8 AZTREONAM ADVERSE_EFFECT GUS_2_Vaginal Candidiasis 80581-86-8 AZTREONAM ADVERSE_EFFECT SKN_2_Flushing 80581-86-8 AZTREONAM ZERO_CLASS N 80581-86-8 AZTREONAM MESH_LEVEL_2 Amides 80581-86-8 AZTREONAM THERAPEUTIC_CLASS Antibacterials, Systemic 80581-86-8 AZTREONAM INDICATION Skin and Skin Structure Infections 80581-86-8 AZTREONAM ADVERSE_EFFECT CVS_3_Hypotension 80581-86-8 AZTREONAM ADVERSE_EFFECT GIS_2_Pseudomembranous Colitis 80581-86-8 AZTREONAM ADVERSE_EFFECT LIV_3_Abnormal Liver Function 80581-86-8 AZTREONAM MESH_LEVEL_3 Lactams 80581-86-8 AZTREONAM ADVERSE_EFFECT GIS_1_Abdominal Cramps 80581-86-8 AZTREONAM ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 80581-86-8 AZTREONAM TISSUE_TOXICITY Hypotension 80581-86-8 AZTREONAM ADVERSE_EFFECT NEU_3_Seizures 80581-86-8 AZTREONAM TA_LEVEL_3 systemic infections 80581-86-8 AZTREONAM INDICATION Pelvic Inflammatory Disease (PID) 80581-86-8 AZTREONAM MECH_LEVEL_3 Muramoyltetrapeptide carboxypeptidase 80581-86-8 AZTREONAM ADVERSE_EFFECT XXX_2_Fever 80581-86-8 AZTREONAM ADVERSE_EFFECT IMU_3_Anaphylaxis 80581-86-8 AZTREONAM ADVERSE_EFFECT BBM_3_Pancytopenia 80581-86-8 AZTREONAM ADVERSE_EFFECT NEU_3_Paresthesia 80581-86-8 AZTREONAM ADVERSE_EFFECT PSY_3_Confusion 80581-86-8 AZTREONAM MECH_LEVEL_2 Inhibit bacterial cell wall biosynthesis 80581-86-8 AZTREONAM MESH_LEVEL_1 Organic Chemicals 80581-86-8 AZTREONAM MECH_LEVEL_1 Anti-bacterial 80581-86-8 AZTREONAM INDICATION Urinary Tract Infection (UTI) 80581-86-8 AZTREONAM INDICATION Intra-Abdominal Infections 80581-86-8 AZTREONAM MODE_CLASS Enzyme Inhibitor 80581-86-8 AZTREONAM KNOWN_TOXICITY Cardiovascular Toxicity 80581-86-8 AZTREONAM ADVERSE_EFFECT CVS_3_Bigeminy 80581-86-8 AZTREONAM STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 80581-86-8 AZTREONAM ADVERSE_EFFECT LIV_3_Jaundice 80581-86-8 AZTREONAM TA_LEVEL_1 Infectious Disease 80581-86-8 AZTREONAM MECHANISM Inhibit bacterial cell wall biosynthesis 80581-86-8 AZTREONAM PRODUCT_CLASS Anti-infectives 80581-86-8 AZTREONAM TISSUE_TOXICITY Bigeminy 80581-86-8 AZTREONAM ADVERSE_EFFECT SKN_3_Toxic Epidermal Necrolysis 80581-86-8 AZTREONAM ADVERSE_EFFECT SKN_2_Pruritis 80581-86-8 AZTREONAM INDICATION Lower Respiratory Tract Infection 80581-86-8 AZTREONAM ADVERSE_EFFECT LIV_3_Hepatitis 80581-86-8 AZTREONAM ADVERSE_EFFECT CVS_1_Phlebitis 80581-86-8 AZTREONAM ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 80581-86-8 AZTREONAM ADVERSE_EFFECT LUN_2_Wheezing 80581-86-8 AZTREONAM INDICATION Septicemia 80581-86-8 AZTREONAM TA_LEVEL_2 Anti-bacterial 36085-73-1 TALIPEXOLE MODE_CLASS Channel Modulator 36085-73-1 TALIPEXOLE MECHANISM Modulate G-protein coupled signal transduction 36085-73-1 TALIPEXOLE MECHANISM Modulate neural transmission 36085-73-1 TALIPEXOLE MODE_CLASS Receptor Agonist 36085-73-1 TALIPEXOLE MECHANISM Prolong/enhance neural transmission 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT XXX_2_Glossitis 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT XXX_3_Superinfection 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT SKN_3_Skin Rash 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT XXX_2_Drug Fever 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT PSY_1_Anorexia 37661-08-8 BACAMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 37661-08-8 BACAMPICILLIN INDICATION Sinusitis 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT GIS_2_Stomatitis 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 37661-08-8 BACAMPICILLIN TISSUE_TOXICITY Interstitial Nephritis 37661-08-8 BACAMPICILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 37661-08-8 BACAMPICILLIN INDICATION Lower Respiratory Tract Infection 37661-08-8 BACAMPICILLIN MODE_CLASS Enzyme Inhibitor 37661-08-8 BACAMPICILLIN INDICATION Skin and Skin Structure Infections 37661-08-8 BACAMPICILLIN INDICATION Gonococcal Infections / Gonorrhea 37661-08-8 BACAMPICILLIN KNOWN_TOXICITY Nephrotoxicity 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT GIS_2_Gastritis 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT GUS_2_Vaginitis 37661-08-8 BACAMPICILLIN INDICATION Urinary Tract Infection (UTI) 37661-08-8 BACAMPICILLIN INDICATION Bronchopulmonary Infection 37661-08-8 BACAMPICILLIN PRODUCT_CLASS Anti-infectives 37661-08-8 BACAMPICILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 37661-08-8 BACAMPICILLIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 50972-17-3 BACAMPICILLIN INDICATION Skin and Skin Structure Infections 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT KID_3_Interstitial Nephritis 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT GIS_2_Stomatitis 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT IMU_3_Anaphylaxis 50972-17-3 BACAMPICILLIN TISSUE_TOXICITY Interstitial Nephritis 50972-17-3 BACAMPICILLIN THERAPEUTIC_CLASS Antibacterials, Systemic 50972-17-3 BACAMPICILLIN INDICATION Lower Respiratory Tract Infection 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT XXX_2_Glossitis 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT GUS_2_Vaginitis 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 50972-17-3 BACAMPICILLIN INDICATION Gonococcal Infections / Gonorrhea 50972-17-3 BACAMPICILLIN MECHANISM Inhibit bacterial cell wall biosynthesis 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT PSY_1_Anorexia 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT XXX_2_Drug Fever 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT SKN_3_Skin Rash 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT XXX_3_Superinfection 50972-17-3 BACAMPICILLIN MODE_CLASS Enzyme Inhibitor 50972-17-3 BACAMPICILLIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor, PBP inhibitor 50972-17-3 BACAMPICILLIN PRODUCT_CLASS Anti-infectives 50972-17-3 BACAMPICILLIN INDICATION Bronchopulmonary Infection 50972-17-3 BACAMPICILLIN INDICATION Urinary Tract Infection (UTI) 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT GIS_1_Nausea / Vomiting 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT GIS_2_Gastritis 50972-17-3 BACAMPICILLIN ADVERSE_EFFECT GIS_3_Pseudomembranous Colitis 50972-17-3 BACAMPICILLIN KNOWN_TOXICITY Nephrotoxicity 50972-17-3 BACAMPICILLIN INDICATION Sinusitis 1405-87-4 BACITRACIN INDICATION Pseudomembranous Colitis 1405-87-4 BACITRACIN INDICATION Keratitis 1405-87-4 BACITRACIN ZERO_CLASS N 1405-87-4 BACITRACIN TA_LEVEL_2 Anti-bacterial 1405-87-4 BACITRACIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 1405-87-4 BACITRACIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 1405-87-4 BACITRACIN ADVERSE_EFFECT XXX_3_Chest Tightness 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_3_Azotemia 1405-87-4 BACITRACIN ADVERSE_EFFECT IMU_3_Eosinophilia 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_2_Hematuria 1405-87-4 BACITRACIN ADVERSE_EFFECT IMU_3_Urticaria 1405-87-4 BACITRACIN ADVERSE_EFFECT SKN_2_Rash 1405-87-4 BACITRACIN ADVERSE_EFFECT PSY_2_Anorexia 1405-87-4 BACITRACIN TISSUE_TOXICITY Oligemic Renal Failure 1405-87-4 BACITRACIN THERAPEUTIC_CLASS Antibacterials, Topical 1405-87-4 BACITRACIN INDICATION Bacterial Conjunctivitis 1405-87-4 BACITRACIN MECH_LEVEL_1 Cell wall biosynthesis inhibitor 1405-87-4 BACITRACIN MECHANISM Inhibit bacterial cell wall biosynthesis 1405-87-4 BACITRACIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor 1405-87-4 BACITRACIN TISSUE_TOXICITY Renal Tubular Necrosis 1405-87-4 BACITRACIN ADVERSE_EFFECT BBM_3_Hematological Reactions 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_2_Proteinuria 1405-87-4 BACITRACIN ADVERSE_EFFECT MSK_3_Myasthenia 1405-87-4 BACITRACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 1405-87-4 BACITRACIN ADVERSE_EFFECT GIS_2_Diarrhea 1405-87-4 BACITRACIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1405-87-4 BACITRACIN TA_LEVEL_1 Infectious Disease 1405-87-4 BACITRACIN PRODUCT_CLASS Anti-infectives 1405-87-4 BACITRACIN TA_LEVEL_3 anti-bacterial, topical 1405-87-4 BACITRACIN INDICATION Ophthalmic Infections 1405-87-4 BACITRACIN MECH_LEVEL_3 complexes with lipid 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_3_Oligemic Renal Failure 1405-87-4 BACITRACIN ADVERSE_EFFECT IMU_3_Swelling of Lips 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_3_Renal Failure 1405-87-4 BACITRACIN ADVERSE_EFFECT KID_2_Nephrotoxicity 1405-87-4 BACITRACIN ADVERSE_EFFECT SKN_3_Pruritis 1405-87-4 BACITRACIN ADVERSE_EFFECT XXX_3_Fever 1405-87-4 BACITRACIN TISSUE_TOXICITY Nephrotoxicity 1405-87-4 BACITRACIN TISSUE_TOXICITY Renal Failure 1405-87-4 BACITRACIN KNOWN_TOXICITY Nephrotoxicity 1405-87-4 BACITRACIN MESH_LEVEL_3 Peptides, Cyclic 1405-87-4 BACITRACIN INDICATION Blepharitis 1405-87-4 BACITRACIN INDICATION Pneumonia 1405-87-4 BACITRACIN MECH_LEVEL_2 Cell wall biosynthesis inhibitor 1405-87-4 BACITRACIN ADVERSE_EFFECT OCU_1_Blurred Vision 1405-87-4 BACITRACIN TISSUE_TOXICITY Hematuria 1405-87-4 BACITRACIN INDICATION Skin and Skin Structure Infections 1405-87-4 BACITRACIN MESH_LEVEL_2 Peptides 1405-87-4 BACITRACIN ADVERSE_EFFECT XXX_1_Injection Site Reaction 1405-87-4 BACITRACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 1405-87-4 BACITRACIN ADVERSE_EFFECT SKN_2_Anal Pruritis 1405-87-4 BACITRACIN ADVERSE_EFFECT XXX_3_Superinfection 1405-87-4 BACITRACIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 1405-87-4 BACITRACIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1403-00-5 BACITRACIN ADVERSE_EFFECT MSK_3_Myasthenia 1403-00-5 BACITRACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 1403-00-5 BACITRACIN ADVERSE_EFFECT XXX_1_Injection Site Reaction 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_3_Oligemic Renal Failure 1403-00-5 BACITRACIN ADVERSE_EFFECT IMU_3_Swelling of Lips 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_3_Renal Failure 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_2_Nephrotoxicity 1403-00-5 BACITRACIN ADVERSE_EFFECT SKN_3_Pruritis 1403-00-5 BACITRACIN ADVERSE_EFFECT XXX_3_Fever 1403-00-5 BACITRACIN TISSUE_TOXICITY Nephrotoxicity 1403-00-5 BACITRACIN TISSUE_TOXICITY Renal Failure 1403-00-5 BACITRACIN KNOWN_TOXICITY Nephrotoxicity 1403-00-5 BACITRACIN MESH_LEVEL_3 Peptides, Cyclic 1403-00-5 BACITRACIN INDICATION Blepharitis 1403-00-5 BACITRACIN INDICATION Pneumonia 1403-00-5 BACITRACIN MECH_LEVEL_2 Cell wall biosynthesis inhibitor 1403-00-5 BACITRACIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor 1403-00-5 BACITRACIN TISSUE_TOXICITY Renal Tubular Necrosis 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_2_Hematuria 1403-00-5 BACITRACIN ADVERSE_EFFECT BBM_3_Hematological Reactions 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_2_Proteinuria 1403-00-5 BACITRACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 1403-00-5 BACITRACIN ADVERSE_EFFECT GIS_2_Diarrhea 1403-00-5 BACITRACIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 1403-00-5 BACITRACIN TA_LEVEL_1 Infectious Disease 1403-00-5 BACITRACIN PRODUCT_CLASS Anti-infectives 1403-00-5 BACITRACIN TA_LEVEL_3 anti-bacterial, topical 1403-00-5 BACITRACIN INDICATION Ophthalmic Infections 1403-00-5 BACITRACIN MECH_LEVEL_3 complexes with lipid 1403-00-5 BACITRACIN MECHANISM Inhibit bacterial cell wall biosynthesis 1403-00-5 BACITRACIN MECH_LEVEL_1 Cell wall biosynthesis inhibitor 1403-00-5 BACITRACIN INDICATION Bacterial Conjunctivitis 1403-00-5 BACITRACIN THERAPEUTIC_CLASS Antibacterials, Topical 1403-00-5 BACITRACIN TISSUE_TOXICITY Oligemic Renal Failure 1403-00-5 BACITRACIN ADVERSE_EFFECT PSY_2_Anorexia 1403-00-5 BACITRACIN ADVERSE_EFFECT SKN_2_Rash 1403-00-5 BACITRACIN ADVERSE_EFFECT IMU_3_Urticaria 1403-00-5 BACITRACIN ADVERSE_EFFECT IMU_3_Eosinophilia 1403-00-5 BACITRACIN ADVERSE_EFFECT KID_3_Azotemia 1403-00-5 BACITRACIN ADVERSE_EFFECT XXX_3_Chest Tightness 1403-00-5 BACITRACIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 1403-00-5 BACITRACIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 1403-00-5 BACITRACIN TA_LEVEL_2 Anti-bacterial 1403-00-5 BACITRACIN ZERO_CLASS N 1403-00-5 BACITRACIN INDICATION Keratitis 1403-00-5 BACITRACIN INDICATION Pseudomembranous Colitis 1403-00-5 BACITRACIN MESH_LEVEL_2 Peptides 1403-00-5 BACITRACIN INDICATION Skin and Skin Structure Infections 1403-00-5 BACITRACIN TISSUE_TOXICITY Hematuria 1403-00-5 BACITRACIN ADVERSE_EFFECT OCU_1_Blurred Vision 1403-00-5 BACITRACIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 1403-00-5 BACITRACIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 1403-00-5 BACITRACIN ADVERSE_EFFECT XXX_3_Superinfection 1403-00-5 BACITRACIN ADVERSE_EFFECT SKN_2_Anal Pruritis 22601-59-8 BACITRACIN ZERO_CLASS N 22601-59-8 BACITRACIN TA_LEVEL_2 Anti-bacterial 22601-59-8 BACITRACIN MESH_LEVEL_1 Amino Acids, Peptides, and Proteins 22601-59-8 BACITRACIN ACTIVITY_CLASS Antibiotic, bacterial cell wall inhibitor 22601-59-8 BACITRACIN ADVERSE_EFFECT XXX_3_Chest Tightness 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_3_Azotemia 22601-59-8 BACITRACIN ADVERSE_EFFECT IMU_3_Eosinophilia 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_2_Hematuria 22601-59-8 BACITRACIN ADVERSE_EFFECT IMU_3_Urticaria 22601-59-8 BACITRACIN ADVERSE_EFFECT SKN_2_Rash 22601-59-8 BACITRACIN ADVERSE_EFFECT PSY_2_Anorexia 22601-59-8 BACITRACIN TISSUE_TOXICITY Oligemic Renal Failure 22601-59-8 BACITRACIN THERAPEUTIC_CLASS Antibacterials, Topical 22601-59-8 BACITRACIN INDICATION Bacterial Conjunctivitis 22601-59-8 BACITRACIN MECH_LEVEL_1 Cell wall biosynthesis inhibitor 22601-59-8 BACITRACIN MECHANISM Inhibit bacterial cell wall biosynthesis 22601-59-8 BACITRACIN STRUCTURE_ACTIVITY Bacterial Cell wall biosynthesis inhibitor 22601-59-8 BACITRACIN TISSUE_TOXICITY Renal Tubular Necrosis 22601-59-8 BACITRACIN ADVERSE_EFFECT BBM_3_Hematological Reactions 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_3_Renal Tubular Necrosis 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_2_Proteinuria 22601-59-8 BACITRACIN ADVERSE_EFFECT MSK_3_Myasthenia 22601-59-8 BACITRACIN ADVERSE_EFFECT IMU_3_Hypersensitivity 22601-59-8 BACITRACIN ADVERSE_EFFECT GIS_2_Diarrhea 22601-59-8 BACITRACIN MODE_CLASS Distorts /blocks macromolecular synthesis scaffold 22601-59-8 BACITRACIN TA_LEVEL_1 Infectious Disease 22601-59-8 BACITRACIN PRODUCT_CLASS Anti-infectives 22601-59-8 BACITRACIN TA_LEVEL_3 anti-bacterial, topical 22601-59-8 BACITRACIN INDICATION Ophthalmic Infections 22601-59-8 BACITRACIN MECH_LEVEL_3 complexes with lipid 22601-59-8 BACITRACIN MECH_LEVEL_2 Cell wall biosynthesis inhibitor 22601-59-8 BACITRACIN INDICATION Pneumonia 22601-59-8 BACITRACIN INDICATION Blepharitis 22601-59-8 BACITRACIN MESH_LEVEL_3 Peptides, Cyclic 22601-59-8 BACITRACIN KNOWN_TOXICITY Nephrotoxicity 22601-59-8 BACITRACIN TISSUE_TOXICITY Renal Failure 22601-59-8 BACITRACIN TISSUE_TOXICITY Nephrotoxicity 22601-59-8 BACITRACIN ADVERSE_EFFECT XXX_3_Fever 22601-59-8 BACITRACIN ADVERSE_EFFECT SKN_3_Pruritis 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_2_Nephrotoxicity 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_3_Renal Failure 22601-59-8 BACITRACIN ADVERSE_EFFECT IMU_3_Swelling of Lips 22601-59-8 BACITRACIN ADVERSE_EFFECT KID_3_Oligemic Renal Failure 22601-59-8 BACITRACIN ADVERSE_EFFECT XXX_1_Injection Site Reaction 22601-59-8 BACITRACIN ADVERSE_EFFECT IMU_3_Anaphylactoid Reactions 22601-59-8 BACITRACIN ADVERSE_EFFECT SKN_2_Anal Pruritis 22601-59-8 BACITRACIN ADVERSE_EFFECT XXX_3_Superinfection 22601-59-8 BACITRACIN ADVERSE_EFFECT LUN_3_Respiratory Paralysis 22601-59-8 BACITRACIN ADVERSE_EFFECT GIS_2_Nausea / Vomiting 22601-59-8 BACITRACIN ADVERSE_EFFECT OCU_1_Blurred Vision 22601-59-8 BACITRACIN TISSUE_TOXICITY Hematuria 22601-59-8 BACITRACIN INDICATION Skin and Skin Structure Infections 22601-59-8 BACITRACIN MESH_LEVEL_2 Peptides 22601-59-8 BACITRACIN INDICATION Pseudomembranous Colitis 22601-59-8 BACITRACIN INDICATION Keratitis 1134-47-0 BACLOFEN ADVERSE_EFFECT GIS_2_Nausea 1134-47-0 BACLOFEN ADVERSE_EFFECT OTO_3_Tinnitus 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_3_Slurred Speech 1134-47-0 BACLOFEN ADVERSE_EFFECT PSY_2_Mental Depression 1134-47-0 BACLOFEN ADVERSE_EFFECT XXX_3_Rigidity 1134-47-0 BACLOFEN ADVERSE_EFFECT GUS_3_Dysuria 1134-47-0 BACLOFEN TA_LEVEL_2 Muscle relaxant 1134-47-0 BACLOFEN MECH_LEVEL_3 GABA-B receptor 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_3_Tremor 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_2_Dizziness 1134-47-0 BACLOFEN ADVERSE_EFFECT MSK_2_Muscle Weakness 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_3_Paresthesia 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_2_Headache 1134-47-0 BACLOFEN ADVERSE_EFFECT PSY_3_Anxiety 1134-47-0 BACLOFEN MECH_LEVEL_2 GABA agonist 1134-47-0 BACLOFEN MESH_LEVEL_1 Organic Chemicals 1134-47-0 BACLOFEN ACTIVITY_CLASS GABA agonist 1134-47-0 BACLOFEN ADVERSE_EFFECT MSK_3_Muscle Pain 1134-47-0 BACLOFEN MECH_LEVEL_1 Modulate neural transmission 1134-47-0 BACLOFEN MESH_LEVEL_3 Acids, Acyclic 1134-47-0 BACLOFEN PRODUCT_CLASS Central Nervous System (CNS) 1134-47-0 BACLOFEN TA_LEVEL_1 Central Nervous System (CNS) 1134-47-0 BACLOFEN INDICATION Spasticity 1134-47-0 BACLOFEN THERAPEUTIC_CLASS Antispasmodic Agents 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_1_Drowsiness 1134-47-0 BACLOFEN ZERO_CLASS N 1134-47-0 BACLOFEN STRUCTURE_ACTIVITY GABA-B agonist 1134-47-0 BACLOFEN MODE_CLASS Receptor Agonist, selective 1134-47-0 BACLOFEN ADVERSE_EFFECT PSY_3_Hallucinations 1134-47-0 BACLOFEN ADVERSE_EFFECT XXX_2_Fatigue 1134-47-0 BACLOFEN ADVERSE_EFFECT IMU_3_Allergic Reactions 1134-47-0 BACLOFEN ADVERSE_EFFECT NEU_3_Ataxia 1134-47-0 BACLOFEN ADVERSE_EFFECT CVS_3_Chest Pain 1134-47-0 BACLOFEN MESH_LEVEL_2 Carboxylic Acids 1134-47-0 BACLOFEN MECHANISM Modulate neural transmission 1134-47-0 BACLOFEN TA_LEVEL_3 Antispasmodic Agents 1134-47-0 BACLOFEN ADVERSE_EFFECT OCU_3_Blurred Vision 150399-21-6 BALSALAZIDE MECHANISM Inhibit inflammatory response 150399-21-6 BALSALAZIDE THERAPEUTIC_CLASS Miscellaneous Anti-Inflammatory Agents 150399-21-6 BALSALAZIDE TISSUE_TOXICITY Interstitial Nephritis 150399-21-6 BALSALAZIDE ADVERSE_EFFECT CVS_2_Hypertension 150399-21-6 BALSALAZIDE ADVERSE_EFFECT KID_3_Interstitial Nephritis 150399-21-6 BALSALAZIDE TA_LEVEL_2 NSAID? 150399-21-6 BALSALAZIDE MECH_LEVEL_2 Inhibit eicosanoid biosynthesis 150399-21-6 BALSALAZIDE MECH_LEVEL_3 Prostaglandin-endoperoxide synthase 1 150399-21-6 BALSALAZIDE MECH_LEVEL_1 Immunomodulation 150399-21-6 BALSALAZIDE PRODUCT_CLASS Anti-inflammatories 150399-21-6 BALSALAZIDE ADVERSE_EFFECT LIV_3_Hepatotoxicity 150399-21-6 BALSALAZIDE ADVERSE_EFFECT BBM_3_Granulocytopenia 150399-21-6 BALSALAZIDE ADVERSE_EFFECT IMU_3_Eosinophilia 150399-21-6 BALSALAZIDE ADVERSE_EFFECT LUN_2_Respiratory Infection 150399-21-6 BALSALAZIDE MESH_LEVEL_3 Hydroxybenzoic Acids 150399-21-6 BALSALAZIDE MECHANISM Inhibit eicosanoid biosynthesis 150399-21-6 BALSALAZIDE TISSUE_TOXICITY Hepatotoxicity 150399-21-6 BALSALAZIDE KNOWN_TOXICITY Nephrotoxicity 150399-21-6 BALSALAZIDE INDICATION Ulcerative Colitis 150399-21-6 BALSALAZIDE ZERO_CLASS N 150399-21-6 BALSALAZIDE ACTIVITY_CLASS Anti-inflammatory 150399-21-6 BALSALAZIDE STRUCTURE_ACTIVITY Antiinflammatory, IkB kinase-beta (IKK-beta) inhibitor, aminosalicylic acid 150399-21-6 BALSALAZIDE MODE_CLASS Enzyme Inhibitor 150399-21-6 BALSALAZIDE ADVERSE_EFFECT GIS_1_Diarrhea 150399-21-6 BALSALAZIDE ADVERSE_EFFECT LUN_3_Bronchospasm 150399-21-6 BALSALAZIDE ADVERSE_EFFECT LIV_3_Hepatic Necrosis 150399-21-6 BALSALAZIDE ADVERSE_EFFECT GIS_1_Abdominal Pain 150399-21-6 BALSALAZIDE ADVERSE_EFFECT BBM_3_Bleeding Tendency 150399-21-6 BALSALAZIDE MESH_LEVEL_2 Phenols 150399-21-6 BALSALAZIDE TISSUE_TOXICITY Hepatic Failure 150399-21-6 BALSALAZIDE KNOWN_TOXICITY Hepatotoxicity 150399-21-6 BALSALAZIDE ADVERSE_EFFECT NEU_1_Headache 150399-21-6 BALSALAZIDE ADVERSE_EFFECT MSK_2_Arthralgia 150399-21-6 BALSALAZIDE ADVERSE_EFFECT GIS_3_Pancreatitis 150399-21-6 BALSALAZIDE ADVERSE_EFFECT BBM_3_Hemorrhage 150399-21-6 BALSALAZIDE TA_LEVEL_1 Anti-inflammatory 150399-21-6 BALSALAZIDE ADVERSE_EFFECT CVS_3_Deep Venous Thrombosis 150399-21-6 BALSALAZIDE MESH_LEVEL_1 Organic Chemicals 150399-21-6 BALSALAZIDE TISSUE_TOXICITY Hepatic Necrosis 150399-21-6 BALSALAZIDE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 150399-21-6 BALSALAZIDE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 150399-21-6 BALSALAZIDE ADVERSE_EFFECT LIV_3_Hepatic Failure 150399-21-6 BALSALAZIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 112893-26-2 BECLICONAZOLE THERAPEUTIC_CLASS Antifungals 112893-26-2 BECLICONAZOLE MECHANISM Inhibit fungal / microbial cell membrane biosynthesis 112893-26-2 BECLICONAZOLE MODE_CLASS Enzyme Inhibitor 112893-26-2 BECLICONAZOLE PRODUCT_CLASS Anti-infectives 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Pharyngitis 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Dysphonia 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT IMU_3_Angioedema 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT NEU_2_Headache 4419-39-0 BECLOMETHASONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 4419-39-0 BECLOMETHASONE INDICATION Prevention of Recurrence of Nasal Polyps 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT OCU_3_Glaucoma 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_3_Sinusitis 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_3_Epistaxis 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT IMU_3_Urticaria 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT SKN_3_Rash 4419-39-0 BECLOMETHASONE THERAPEUTIC_CLASS Corticosteroids 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Dryness of Mucus Membrane 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Nasal Irritation 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_3_Rhinorrhea 4419-39-0 BECLOMETHASONE MODE_CLASS Receptor Agonist 4419-39-0 BECLOMETHASONE MECHANISM Modulate gene transcription 4419-39-0 BECLOMETHASONE PRODUCT_CLASS Anti-inflammatories 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Bronchospasm 4419-39-0 BECLOMETHASONE INDICATION Rhinitis 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Sneezing 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Wheezing 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT OCU_3_Cataracts 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT NEU_2_Lightheadedness 4419-39-0 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Cough 4419-39-0 BECLOMETHASONE INDICATION Asthma 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Pharyngitis 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Dysphonia 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Wheezing 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT IMU_3_Angioedema 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT NEU_2_Headache 34135-07-4 BECLOMETHASONE STRUCTURE_ACTIVITY Glucocorticoid receptor agonist 34135-07-4 BECLOMETHASONE INDICATION Prevention of Recurrence of Nasal Polyps 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT OCU_3_Glaucoma 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_3_Sinusitis 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_3_Epistaxis 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT IMU_3_Urticaria 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT SKN_3_Rash 34135-07-4 BECLOMETHASONE THERAPEUTIC_CLASS Corticosteroids 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Sneezing 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Dryness of Mucus Membrane 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT OCU_3_Cataracts 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_2_Nasal Irritation 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT XXX_3_Rhinorrhea 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Bronchospasm 34135-07-4 BECLOMETHASONE MODE_CLASS Receptor Agonist 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT OCU_3_Increased Intraocular Pressure 34135-07-4 BECLOMETHASONE PRODUCT_CLASS Anti-inflammatories 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT NEU_2_Lightheadedness 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT LUN_3_Cough 34135-07-4 BECLOMETHASONE INDICATION Asthma 34135-07-4 BECLOMETHASONE INDICATION Rhinitis 34135-07-4 BECLOMETHASONE ADVERSE_EFFECT LUN_2_Upper Respiratory Tract Infection 34135-07-4 BECLOMETHASONE MECHANISM Modulate gene transcription 86541-75-5 BENAZEPRIL ADVERSE_EFFECT EMB_2_Teratogenicity 86541-75-5 BENAZEPRIL ADVERSE_EFFECT KID_3_Azotemia 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LIV_3_Cholestasis 86541-75-5 BENAZEPRIL ADVERSE_EFFECT BBM_2_Thrombocytopenia 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LIV_3_Hepatitis 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 86541-75-5 BENAZEPRIL TA_LEVEL_3 Diuretic 86541-75-5 BENAZEPRIL TA_LEVEL_1 Cardiovascular 86541-75-5 BENAZEPRIL THERAPEUTIC_CLASS Antihypertensive Agents 86541-75-5 BENAZEPRIL KNOWN_TOXICITY Hepatotoxicity 86541-75-5 BENAZEPRIL TISSUE_TOXICITY Hypotension 86541-75-5 BENAZEPRIL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 86541-75-5 BENAZEPRIL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 86541-75-5 BENAZEPRIL ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 86541-75-5 BENAZEPRIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 86541-75-5 BENAZEPRIL ADVERSE_EFFECT SKN_1_Flushing 86541-75-5 BENAZEPRIL TISSUE_TOXICITY Hepatic Necrosis 86541-75-5 BENAZEPRIL MESH_LEVEL_1 Heterocyclic Compounds 86541-75-5 BENAZEPRIL INDICATION Diabetic Nephropathy 86541-75-5 BENAZEPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 86541-75-5 BENAZEPRIL ADVERSE_EFFECT IMU_2_Angioedema 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 86541-75-5 BENAZEPRIL ADVERSE_EFFECT GIS_3_Pancreatitis 86541-75-5 BENAZEPRIL MODE_CLASS Enzyme Inhibitor 86541-75-5 BENAZEPRIL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 86541-75-5 BENAZEPRIL ADVERSE_EFFECT REP_3_Sexual Dysfunction 86541-75-5 BENAZEPRIL ACTIVITY_CLASS RAAS inhibitor 86541-75-5 BENAZEPRIL TISSUE_TOXICITY Teratogenicity 86541-75-5 BENAZEPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 86541-75-5 BENAZEPRIL MECH_LEVEL_2 ACE inhibitor 86541-75-5 BENAZEPRIL INDICATION Congestive Heart Failure (CHF) 86541-75-5 BENAZEPRIL INDICATION Hypertension 86541-75-5 BENAZEPRIL KNOWN_TOXICITY Cardiovascular Toxicity 86541-75-5 BENAZEPRIL TISSUE_TOXICITY Hepatic Failure 86541-75-5 BENAZEPRIL ADVERSE_EFFECT KID_3_Renal Insufficiency 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LIV_3_Hepatic Failure 86541-75-5 BENAZEPRIL ADVERSE_EFFECT CVS_1_Hypotension 86541-75-5 BENAZEPRIL ADVERSE_EFFECT BBM_3_Hemolytic Anemia 86541-75-5 BENAZEPRIL ADVERSE_EFFECT NEU_1_Headache 86541-75-5 BENAZEPRIL MESH_LEVEL_3 Benzazepines 86541-75-5 BENAZEPRIL PRODUCT_CLASS Cardiovasculars 86541-75-5 BENAZEPRIL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 86541-75-5 BENAZEPRIL THERAPEUTIC_CLASS Congestive Heart Failure 86541-75-5 BENAZEPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 86541-75-5 BENAZEPRIL ZERO_CLASS N 86541-75-5 BENAZEPRIL MECH_LEVEL_1 Vasorelaxation 86541-75-5 BENAZEPRIL MECHANISM Reduce vasoconstriction 86541-75-5 BENAZEPRIL ADVERSE_EFFECT LUN_1_Cough 86541-75-5 BENAZEPRIL ADVERSE_EFFECT ELT_2_Hyperkalemia 86541-75-5 BENAZEPRIL TA_LEVEL_2 Hypertension 86541-74-4 BENAZEPRIL ADVERSE_EFFECT BBM_3_Hemolytic Anemia 86541-74-4 BENAZEPRIL ADVERSE_EFFECT CVS_1_Hypotension 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LIV_3_Hepatic Failure 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LIV_3_Hepatic Necrosis 86541-74-4 BENAZEPRIL ADVERSE_EFFECT KID_3_Renal Insufficiency 86541-74-4 BENAZEPRIL TISSUE_TOXICITY Hepatic Failure 86541-74-4 BENAZEPRIL KNOWN_TOXICITY Cardiovascular Toxicity 86541-74-4 BENAZEPRIL ADVERSE_EFFECT REP_3_Sexual Dysfunction 86541-74-4 BENAZEPRIL INDICATION Congestive Heart Failure (CHF) 86541-74-4 BENAZEPRIL THERAPEUTIC_CLASS Antihypertensive Agents 86541-74-4 BENAZEPRIL MECH_LEVEL_1 Vasorelaxation 86541-74-4 BENAZEPRIL TA_LEVEL_2 Hypertension 86541-74-4 BENAZEPRIL MECH_LEVEL_2 ACE inhibitor 86541-74-4 BENAZEPRIL INDICATION Hypertension 86541-74-4 BENAZEPRIL TA_LEVEL_3 Diuretic 86541-74-4 BENAZEPRIL TISSUE_TOXICITY Teratogenicity 86541-74-4 BENAZEPRIL TA_LEVEL_1 Cardiovascular 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 86541-74-4 BENAZEPRIL ADVERSE_EFFECT IMU_2_Angioedema 86541-74-4 BENAZEPRIL MECH_LEVEL_3 Peptidyl-dipeptidase A 86541-74-4 BENAZEPRIL STRUCTURE_ACTIVITY Angiotensin converting enzyme (ACE) inhibitor 86541-74-4 BENAZEPRIL INDICATION Diabetic Nephropathy 86541-74-4 BENAZEPRIL MESH_LEVEL_1 Heterocyclic Compounds 86541-74-4 BENAZEPRIL ADVERSE_EFFECT SKN_1_Flushing 86541-74-4 BENAZEPRIL ADVERSE_EFFECT GIS_2_Nausea / Vomiting 86541-74-4 BENAZEPRIL ADVERSE_EFFECT IMU_3_Hypersensitivity Pneumonitis 86541-74-4 BENAZEPRIL ADVERSE_EFFECT SKN_3_Alopecia / Hair Loss 86541-74-4 BENAZEPRIL ADVERSE_EFFECT SKN_3_Stevens-Johnson Syndrome 86541-74-4 BENAZEPRIL TISSUE_TOXICITY Hypotension 86541-74-4 BENAZEPRIL MODE_CLASS Enzyme Inhibitor 86541-74-4 BENAZEPRIL ADVERSE_EFFECT GIS_3_Pancreatitis 86541-74-4 BENAZEPRIL ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LUN_1_Cough 86541-74-4 BENAZEPRIL ADVERSE_EFFECT ELT_2_Hyperkalemia 86541-74-4 BENAZEPRIL ADVERSE_EFFECT EMB_2_Teratogenicity 86541-74-4 BENAZEPRIL ADVERSE_EFFECT KID_3_Azotemia 86541-74-4 BENAZEPRIL ACTIVITY_CLASS RAAS inhibitor 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LIV_3_Cholestasis 86541-74-4 BENAZEPRIL ADVERSE_EFFECT BBM_2_Thrombocytopenia 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LIV_3_Hepatitis 86541-74-4 BENAZEPRIL ADVERSE_EFFECT LUN_3_Bronchospasm 86541-74-4 BENAZEPRIL TISSUE_TOXICITY Hepatic Necrosis 86541-74-4 BENAZEPRIL MECHANISM Reduce vasoconstriction 86541-74-4 BENAZEPRIL ZERO_CLASS N 86541-74-4 BENAZEPRIL KNOWN_TOXICITY Embryo/Fetal Toxicity 86541-74-4 BENAZEPRIL KNOWN_TOXICITY Hepatotoxicity 86541-74-4 BENAZEPRIL THERAPEUTIC_CLASS Congestive Heart Failure 86541-74-4 BENAZEPRIL MESH_LEVEL_2 Heterocyclic Compounds, 2-Ring 86541-74-4 BENAZEPRIL PRODUCT_CLASS Cardiovasculars 86541-74-4 BENAZEPRIL MESH_LEVEL_3 Benzazepines 86541-74-4 BENAZEPRIL ADVERSE_EFFECT NEU_1_Headache 73-48-3 BENDROFLUMETHIAZIDE TISSUE_TOXICITY Hypotension 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT END_2_Glucose Intolerance 73-48-3 BENDROFLUMETHIAZIDE MODE_CLASS Channel Blocker, selective 73-48-3 BENDROFLUMETHIAZIDE THERAPEUTIC_CLASS Antihypertensive Agents 73-48-3 BENDROFLUMETHIAZIDE PRODUCT_CLASS Electrolytic, Caloric and Water Balance 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT CVS_2_Orthostatic Hypotension 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT REP_2_Sexual Dysfunction 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT BBM_3_Agranulocytosis 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT IMU_3_Photosensitivity 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT BIL_3_Cholecystitis 73-48-3 BENDROFLUMETHIAZIDE STRUCTURE_ACTIVITY Na+-Cl- cotransporter (TSC) inhibitor, distal tubule diuretic 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT CVS_3_Hypotension 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT KID_2_Hyperuricemia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT IMU_3_Allergic Reactions 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT BBM_3_Thrombocytopenia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT LIV_2_Abnormal Liver Function 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT END_2_Exacerbation of Gout 73-48-3 BENDROFLUMETHIAZIDE INDICATION Hypertension 73-48-3 BENDROFLUMETHIAZIDE INDICATION Edematous States 73-48-3 BENDROFLUMETHIAZIDE THERAPEUTIC_CLASS Diuretics 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT END_2_Hyperlipidemia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypercalcemia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_1_Electrolyte Imbalance 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT GIS_3_Pancreatitis 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypochloremia 73-48-3 BENDROFLUMETHIAZIDE INDICATION Congestive Heart Failure (CHF) 73-48-3 BENDROFLUMETHIAZIDE THERAPEUTIC_CLASS Congestive Heart Failure 73-48-3 BENDROFLUMETHIAZIDE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 73-48-3 BENDROFLUMETHIAZIDE PRODUCT_CLASS Cardiovasculars 73-48-3 BENDROFLUMETHIAZIDE INDICATION Pulmonary Edema 73-48-3 BENDROFLUMETHIAZIDE KNOWN_TOXICITY Cardiovascular Toxicity 73-48-3 BENDROFLUMETHIAZIDE INDICATION Diabetes Insipidus 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_1_Hypokalemia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_2_Hypomagnesemia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT ELT_1_Hyponatremia 73-48-3 BENDROFLUMETHIAZIDE ADVERSE_EFFECT LIV_3_Jaundice 5987-82-6 BENOXINATE MECHANISM Block neural transmission 5987-82-6 BENOXINATE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 5987-82-6 BENOXINATE THERAPEUTIC_CLASS Local Anesthetics 5987-82-6 BENOXINATE ADVERSE_EFFECT OCU_3_Eye Irritation 5987-82-6 BENOXINATE PRODUCT_CLASS Eye, Ear, Nose and Throat Preparations 5987-82-6 BENOXINATE ADVERSE_EFFECT OCU_3_Iritis 5987-82-6 BENOXINATE ADVERSE_EFFECT OCU_3_Keratitis 5987-82-6 BENOXINATE ADVERSE_EFFECT OCU_3_Eye Pain 5987-82-6 BENOXINATE MODE_CLASS Channel Blocker 5987-82-6 BENOXINATE INDICATION Local Anesthesia 5987-82-6 BENOXINATE ADVERSE_EFFECT OCU_3_Corneal Clouding 5987-82-6 BENOXINATE ADVERSE_EFFECT IMU_3_Allergic Reactions 8001-54-5 BENZALKONIUM CHLORIDE ADVERSE_EFFECT IMU_3_Contact Dermatitis 8001-54-5 BENZALKONIUM CHLORIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 8001-54-5 BENZALKONIUM CHLORIDE PRODUCT_CLASS Dermatologicals 8001-54-5 BENZALKONIUM CHLORIDE PRODUCT_CLASS Other Human Uses 8001-54-5 BENZALKONIUM CHLORIDE INDICATION Skin Antisepsis 8001-54-5 BENZALKONIUM CHLORIDE INDICATION Spermicide 8001-54-5 BENZALKONIUM CHLORIDE PRODUCT_CLASS Anti-infectives 8001-54-5 BENZALKONIUM CHLORIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 8001-54-5 BENZALKONIUM CHLORIDE MECHANISM Destroy cell membrane / wall integrity 8001-54-5 BENZALKONIUM CHLORIDE THERAPEUTIC_CLASS Antibacterials, Topical 3562-84-3 BENZBROMARONE ADVERSE_EFFECT XXX_2_Edema 3562-84-3 BENZBROMARONE ADVERSE_EFFECT EMB_3_Teratogenicity 3562-84-3 BENZBROMARONE KNOWN_TOXICITY Carcinogenicity 3562-84-3 BENZBROMARONE TISSUE_TOXICITY Teratogenicity 3562-84-3 BENZBROMARONE THERAPEUTIC_CLASS Gout-Related Agents 3562-84-3 BENZBROMARONE PRODUCT_CLASS Hormones, Endocrine and Metabolic 3562-84-3 BENZBROMARONE INDICATION Hyperuricemia 3562-84-3 BENZBROMARONE ADVERSE_EFFECT LIV_3_Jaundice 3562-84-3 BENZBROMARONE TISSUE_TOXICITY Carcinogenicity 3562-84-3 BENZBROMARONE ADVERSE_EFFECT IMU_3_Urticaria 3562-84-3 BENZBROMARONE INDICATION Gout 3562-84-3 BENZBROMARONE MECHANISM Inhibit NaCl/ fluid reabsorption in kidney 3562-84-3 BENZBROMARONE ADVERSE_EFFECT GIS_1_Heartburn 3562-84-3 BENZBROMARONE ADVERSE_EFFECT GIS_1_Epigastric Pain 3562-84-3 BENZBROMARONE KNOWN_TOXICITY Embryo/Fetal Toxicity 3562-84-3 BENZBROMARONE ADVERSE_EFFECT LIV_3_Fulminant Hepatitis 3562-84-3 BENZBROMARONE STRUCTURE_ACTIVITY Organic anion transporter inhibitor 3562-84-3 BENZBROMARONE ADVERSE_EFFECT GIS_1_Nausea 3562-84-3 BENZBROMARONE ADVERSE_EFFECT LIV_2_Abnormal Liver Function Tests 3562-84-3 BENZBROMARONE ADVERSE_EFFECT SKN_3_Skin Rash 3562-84-3 BENZBROMARONE TISSUE_TOXICITY Fulminant Hepatitis 3562-84-3 BENZBROMARONE MODE_CLASS Solute transporter inhibitor 3562-84-3 BENZBROMARONE ADVERSE_EFFECT GIS_2_Diarrhea 3562-84-3 BENZBROMARONE ADVERSE_EFFECT DNA_3_Carcinogenicity 3562-84-3 BENZBROMARONE ADVERSE_EFFECT IMU_3_Hypersensitivity Reactions 3562-84-3 BENZBROMARONE KNOWN_TOXICITY Hepatotoxicity 121-54-0 BENZETHONIUM CHLORIDE ADVERSE_EFFECT CVS_3_Shock 121-54-0 BENZETHONIUM CHLORIDE STRUCTURE_ACTIVITY Nicotinic acetylcholine receptor antagonist 121-54-0 BENZETHONIUM CHLORIDE ZERO_CLASS N 121-54-0 BENZETHONIUM CHLORIDE THERAPEUTIC_CLASS Antiseptics / Disinfectants 121-54-0 BENZETHONIUM CHLORIDE TA_LEVEL_2 Antiseptics / Disinfectants 121-54-0 BENZETHONIUM CHLORIDE MECH_LEVEL_2 Block neural transmission 121-54-0 BENZETHONIUM CHLORIDE ADVERSE_EFFECT OCU_3_Eye Irritation 121-54-0 BENZETHONIUM CHLORIDE ADVERSE_EFFECT GIS_3_Vomiting 121-54-0 BENZETHONIUM CHLORIDE MECHANISM Block neural transmission 121-54-0 BENZETHONIUM CHLORIDE TA_LEVEL_1 Diagnostics and Pharmaceutical Aids 121-54-0 BENZETHONIUM CHLORIDE MESH_LEVEL_3 Ammonium Compounds 121-54-0 BENZETHONIUM CHLORIDE KNOWN_TOXICITY Cardiovascular Toxicity 121-54-0 BENZETHONIUM CHLORIDE MESH_LEVEL_1 Organic Chemicals 121-54-0 BENZETHONIUM CHLORIDE PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 121-54-0 BENZETHONIUM CHLORIDE ACTIVITY_CLASS Nicotinic acetylcoline receptor antagonist 121-54-0 BENZETHONIUM CHLORIDE MODE_CLASS Channel Blocker 121-54-0 BENZETHONIUM CHLORIDE MECH_LEVEL_3 Nicotinic acetylcholine receptor alpha-7 121-54-0 BENZETHONIUM CHLORIDE ADVERSE_EFFECT NEU_3_Coma 121-54-0 BENZETHONIUM CHLORIDE TISSUE_TOXICITY Death 121-54-0 BENZETHONIUM CHLORIDE TISSUE_TOXICITY Shock 121-54-0 BENZETHONIUM CHLORIDE MESH_LEVEL_2 Amines 121-54-0 BENZETHONIUM CHLORIDE MECH_LEVEL_1 Modulates channel gating 121-54-0 BENZETHONIUM CHLORIDE ADVERSE_EFFECT SKN_3_Skin Irritation 121-54-0 BENZETHONIUM CHLORIDE TA_LEVEL_3 Antiseptic, topical 121-54-0 BENZETHONIUM CHLORIDE ADVERSE_EFFECT XXX_3_Death 121-54-0 BENZETHONIUM CHLORIDE KNOWN_TOXICITY Miscellaneous 94-09-7 BENZOCAINE PRODUCT_CLASS Central Nervous System (CNS) 94-09-7 BENZOCAINE INDICATION Dental Anesthesia 94-09-7 BENZOCAINE INDICATION Local Anesthesia 94-09-7 BENZOCAINE MECH_LEVEL_2 Sodium channel antagonist 94-09-7 BENZOCAINE MECH_LEVEL_3 Voltage-gated Na+ channel 94-09-7 BENZOCAINE ADVERSE_EFFECT PSY_3_CNS Toxicity 94-09-7 BENZOCAINE ADVERSE_EFFECT IMU_2_Angioedema 94-09-7 BENZOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Collapse 94-09-7 BENZOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrest 94-09-7 BENZOCAINE ADVERSE_EFFECT NEU_3_Tremor 94-09-7 BENZOCAINE TISSUE_TOXICITY Cardiac Arrest 94-09-7 BENZOCAINE TA_LEVEL_2 Anesthesia 94-09-7 BENZOCAINE MESH_LEVEL_3 Acids, Carbocyclic 94-09-7 BENZOCAINE INDICATION Pain 94-09-7 BENZOCAINE ACTIVITY_CLASS Na+ channel blocker 94-09-7 BENZOCAINE ADVERSE_EFFECT CVS_3_Cardiovascular Toxicity 94-09-7 BENZOCAINE ADVERSE_EFFECT IMU_1_Urticaria 94-09-7 BENZOCAINE ADVERSE_EFFECT PSY_3_Confusion 94-09-7 BENZOCAINE ADVERSE_EFFECT SKN_1_Rash 94-09-7 BENZOCAINE ADVERSE_EFFECT BBM_3_Methemoglobinemia 94-09-7 BENZOCAINE ADVERSE_EFFECT CVS_3_Hypotension 94-09-7 BENZOCAINE TISSUE_TOXICITY Cardiac Arrhythmia 94-09-7 BENZOCAINE INDICATION Aphthous Ulcer (Canker Sore, Ulcerative Stomatitis) 94-09-7 BENZOCAINE INDICATION Burns 94-09-7 BENZOCAINE TA_LEVEL_1 Peripheral Nervous System (PNS) 94-09-7 BENZOCAINE INDICATION Hemorrhoids 94-09-7 BENZOCAINE MODE_CLASS Channel Blocker 94-09-7 BENZOCAINE ADVERSE_EFFECT IMU_1_Contact Dermatitis 94-09-7 BENZOCAINE ADVERSE_EFFECT PSY_3_Disorientation 94-09-7 BENZOCAINE ADVERSE_EFFECT XXX_1_Pain 94-09-7 BENZOCAINE ADVERSE_EFFECT NEU_3_Dizziness 94-09-7 BENZOCAINE ADVERSE_EFFECT CVS_3_Cardiac Arrhythmia 94-09-7 BENZOCAINE ZERO_CLASS N 94-09-7 BENZOCAINE KNOWN_TOXICITY Cardiovascular Toxicity 94-09-7 BENZOCAINE TISSUE_TOXICITY Cardiovascular Collapse 94-09-7 BENZOCAINE INDICATION Dental Pain 94-09-7 BENZOCAINE INDICATION Premature Ejaculation 94-09-7 BENZOCAINE MECHANISM Block neural transmission 94-09-7 BENZOCAINE MECH_LEVEL_1 Modulate neural transmission 94-09-7 BENZOCAINE MESH_LEVEL_1 Organic Chemicals 94-09-7 BENZOCAINE MESH_LEVEL_2 Carboxylic Acids 94-09-7 BENZOCAINE ADVERSE_EFFECT SKN_1_Erythema 94-09-7 BENZOCAINE ADVERSE_EFFECT XXX_3_Restlessness 94-09-7 BENZOCAINE ADVERSE_EFFECT SKN_1_Pruritis 94-09-7 BENZOCAINE ADVERSE_EFFECT XXX_1_Edema 94-09-7 BENZOCAINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 94-09-7 BENZOCAINE STRUCTURE_ACTIVITY Voltage gated Na+ channel blocker, p-aminobenzoate 94-09-7 BENZOCAINE THERAPEUTIC_CLASS Local Anesthetics 94-09-7 BENZOCAINE TISSUE_TOXICITY Hypotension 94-09-7 BENZOCAINE TISSUE_TOXICITY Cardiovascular Toxicity 65-85-0 BENZOIC ACID INDICATION Cystitis 65-85-0 BENZOIC ACID ADVERSE_EFFECT LUN_2_Airway Irritation 65-85-0 BENZOIC ACID TA_LEVEL_1 Infectious Disease 65-85-0 BENZOIC ACID MESH_LEVEL_3 Acids, Carbocyclic 65-85-0 BENZOIC ACID TA_LEVEL_2 Anti-bacterial/anti-fungal 65-85-0 BENZOIC ACID ADVERSE_EFFECT IMU_2_Allergic Reactions 65-85-0 BENZOIC ACID MESH_LEVEL_1 Organic Chemicals 65-85-0 BENZOIC ACID MESH_LEVEL_2 Carboxylic Acids 65-85-0 BENZOIC ACID INDICATION Urinary Tract Infection (UTI) 65-85-0 BENZOIC ACID ACTIVITY_CLASS Unknown mechanism 65-85-0 BENZOIC ACID THERAPEUTIC_CLASS Acidifying Agents 65-85-0 BENZOIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 65-85-0 BENZOIC ACID ADVERSE_EFFECT SKN_1_Skin Irritation 65-85-0 BENZOIC ACID ADVERSE_EFFECT XXX_1_Weight Loss 65-85-0 BENZOIC ACID ADVERSE_EFFECT XXX_1_Throat Irritation 65-85-0 BENZOIC ACID MECH_LEVEL_1 Preservative 65-85-0 BENZOIC ACID ADVERSE_EFFECT LUN_2_Interstitial Pulmonary Fibrosis 65-85-0 BENZOIC ACID ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 65-85-0 BENZOIC ACID ADVERSE_EFFECT XXX_1_Nasal Irritation 65-85-0 BENZOIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 65-85-0 BENZOIC ACID ADVERSE_EFFECT OCU_1_Eye Irritation 65-85-0 BENZOIC ACID ADVERSE_EFFECT IMU_3_Anaphylactic Shock 65-85-0 BENZOIC ACID STRUCTURE_ACTIVITY Unknown mechanism, acidifying agent 65-85-0 BENZOIC ACID PRODUCT_CLASS Electrolytic, Caloric and Water Balance 65-85-0 BENZOIC ACID MECH_LEVEL_2 Preservative 65-85-0 BENZOIC ACID ZERO_CLASS Y 532-32-1 BENZOIC ACID PRODUCT_CLASS Electrolytic, Caloric and Water Balance 532-32-1 BENZOIC ACID ADVERSE_EFFECT LUN_2_Interstitial Pulmonary Fibrosis 532-32-1 BENZOIC ACID ADVERSE_EFFECT XXX_1_Throat Irritation 532-32-1 BENZOIC ACID ADVERSE_EFFECT IMU_2_Allergic Reactions 532-32-1 BENZOIC ACID TA_LEVEL_2 Anti-bacterial/anti-fungal 532-32-1 BENZOIC ACID MESH_LEVEL_3 Acids, Carbocyclic 532-32-1 BENZOIC ACID TA_LEVEL_1 Infectious Disease 532-32-1 BENZOIC ACID ADVERSE_EFFECT LUN_2_Airway Irritation 532-32-1 BENZOIC ACID ADVERSE_EFFECT IMU_3_Anaphylactic Shock 532-32-1 BENZOIC ACID THERAPEUTIC_CLASS Acidifying Agents 532-32-1 BENZOIC ACID MECH_LEVEL_1 Preservative 532-32-1 BENZOIC ACID MESH_LEVEL_2 Carboxylic Acids 532-32-1 BENZOIC ACID INDICATION Urinary Tract Infection (UTI) 532-32-1 BENZOIC ACID STRUCTURE_ACTIVITY Unknown mechanism, acidifying agent 532-32-1 BENZOIC ACID ADVERSE_EFFECT OCU_1_Eye Irritation 532-32-1 BENZOIC ACID ADVERSE_EFFECT XXX_2_Irritation of Mucus Membrane 532-32-1 BENZOIC ACID ADVERSE_EFFECT XXX_1_Nasal Irritation 532-32-1 BENZOIC ACID ADVERSE_EFFECT GIS_1_Nausea / Vomiting 532-32-1 BENZOIC ACID ZERO_CLASS Y 532-32-1 BENZOIC ACID MECH_LEVEL_2 Preservative 532-32-1 BENZOIC ACID ADVERSE_EFFECT SKN_1_Skin Irritation 532-32-1 BENZOIC ACID ADVERSE_EFFECT XXX_1_Weight Loss 532-32-1 BENZOIC ACID MESH_LEVEL_1 Organic Chemicals 532-32-1 BENZOIC ACID ADVERSE_EFFECT GIS_1_Abdominal Pain 532-32-1 BENZOIC ACID ACTIVITY_CLASS Unknown mechanism 532-32-1 BENZOIC ACID INDICATION Cystitis 8050-35-9 BENZOIN INDICATION Croup / Acute Laryngotracheobronchitis 8050-35-9 BENZOIN THERAPEUTIC_CLASS Antibacterials, Topical 8050-35-9 BENZOIN PRODUCT_CLASS Anti-infectives 8050-35-9 BENZOIN PRODUCT_CLASS Respiratory System 8050-35-9 BENZOIN INDICATION Skin Antisepsis 119-53-9 BENZOIN INDICATION Skin Antisepsis 119-53-9 BENZOIN PRODUCT_CLASS Respiratory System 119-53-9 BENZOIN PRODUCT_CLASS Anti-infectives 119-53-9 BENZOIN THERAPEUTIC_CLASS Antibacterials, Topical 119-53-9 BENZOIN INDICATION Croup / Acute Laryngotracheobronchitis 104-31-4 BENZONATATE THERAPEUTIC_CLASS Local Anesthetics 104-31-4 BENZONATATE PRODUCT_CLASS Respiratory System 104-31-4 BENZONATATE MODE_CLASS Channel Blocker, selective 104-31-4 BENZONATATE MECHANISM Modulate channel gating 104-31-4 BENZONATATE THERAPEUTIC_CLASS Antitussives, Expectorants and Mucolytic Agents 104-31-4 BENZONATATE INDICATION Cough / Tussis 94-36-0 BENZOYL PEROXIDE INDICATION Acne / Acne Vulgaris 94-36-0 BENZOYL PEROXIDE ADVERSE_EFFECT SKN_1_Erythema 94-36-0 BENZOYL PEROXIDE MODE_CLASS Distorts /blocks macromolecular scaffold function 94-36-0 BENZOYL PEROXIDE ADVERSE_EFFECT SKN_1_Skin Irritation 94-36-0 BENZOYL PEROXIDE ADVERSE_EFFECT SKN_1_Pruritis 94-36-0 BENZOYL PEROXIDE THERAPEUTIC_CLASS Acne Preparations 94-36-0 BENZOYL PEROXIDE ADVERSE_EFFECT IMU_3_Contact Dermatitis 94-36-0 BENZOYL PEROXIDE ADVERSE_EFFECT XXX_1_Xerosis 94-36-0 BENZOYL PEROXIDE PRODUCT_CLASS Dermatologicals 94-36-0 BENZOYL PEROXIDE MECHANISM Inhibit DNA synthesis, repair, and function 94-36-0 BENZOYL PEROXIDE INDICATION Propionibacterium Acnes 94-36-0 BENZOYL PEROXIDE ADVERSE_EFFECT SKN_2_Skin Rash 5411-22-3 BENZPHETAMINE MECHANISM Modulate G-protein coupled signal transduction 5411-22-3 BENZPHETAMINE MODE_CLASS Enzyme substrate mimic 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT XXX_1_Withdrawal 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT NEU_1_Dizziness 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT NEU_2_Tremor 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_1_Insomnia 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_3_Delirium 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT XXX_3_Hyperthermia 5411-22-3 BENZPHETAMINE STRUCTURE_ACTIVITY Monoamine Re-uptake (NET) inhibitor 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT CVS_3_Cardiomyopathy 5411-22-3 BENZPHETAMINE MECHANISM Prolong/enhance neural transmission 5411-22-3 BENZPHETAMINE PRODUCT_CLASS Central Nervous System (CNS) 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT GIS_1_Dysgeusia 5411-22-3 BENZPHETAMINE MODE_CLASS Receptor Agonist 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT IMU_3_Allergic Reactions 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT GIS_1_Nausea / Vomiting 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_2_Anxiety 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_2_Hallucinations 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT GIS_1_Constipation 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_3_Serotonin Syndrome 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT NEU_3_Seizures 5411-22-3 BENZPHETAMINE MODE_CLASS Solute transporter inhibitor 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT XXX_2_Tolerance 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT XXX_1_Fatigue 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT CVS_3_Hypertension 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT OCU_2_Blurred Vision 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_1_Euphoria 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_2_Agitation 5411-22-3 BENZPHETAMINE INDICATION Obesity 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT GIS_2_Abdominal Pain 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_3_Psychosis 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_1_Physical Dependence 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT REP_3_Impotence 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT CVS_3_Sinus Bradycardia 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT PSY_1_Anorexia 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT OCU_2_Mydriasis 5411-22-3 BENZPHETAMINE ADVERSE_EFFECT GIS_1_Diarrhea 5411-22-3 BENZPHETAMINE TISSUE_TOXICITY Cardiomyopathy 5411-22-3 BENZPHETAMINE THERAPEUTIC_CLASS Anorexiants 5411-22-3 BENZPHETAMINE KNOWN_TOXICITY Cardiovascular Toxicity 132-17-2 BENZTROPINE ADVERSE_EFFECT CVS_3_Sinus Tachycardia 132-17-2 BENZTROPINE ADVERSE_EFFECT XXX_3_Hyperthermia 132-17-2 BENZTROPINE ADVERSE_EFFECT GIS_1_Constipation 132-17-2 BENZTROPINE ADVERSE_EFFECT NEU_2_Amnesia 132-17-2 BENZTROPINE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 132-17-2 BENZTROPINE ADVERSE_EFFECT GUS_3_Urinary Retention 132-17-2 BENZTROPINE STRUCTURE_ACTIVITY Monoamine Re-uptake (DAT) inhibitor 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_3_Psychosis 132-17-2 BENZTROPINE ADVERSE_EFFECT XXX_1_Restlessness 132-17-2 BENZTROPINE ADVERSE_EFFECT OCU_1_Cycloplegia 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_2_Delirium 132-17-2 BENZTROPINE ADVERSE_EFFECT OCU_1_Blurred Vision 132-17-2 BENZTROPINE ADVERSE_EFFECT XXX_3_Fever 132-17-2 BENZTROPINE INDICATION Tremor 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_1_Excitement 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_2_Paranoia 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_3_Delusions 132-17-2 BENZTROPINE ADVERSE_EFFECT NEU_2_Headache 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_1_Disorientation 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_3_Hallucinations 132-17-2 BENZTROPINE ADVERSE_EFFECT OCU_1_Mydriasis 132-17-2 BENZTROPINE ADVERSE_EFFECT OCU_2_Acute Angle-Closure Glaucoma 132-17-2 BENZTROPINE INDICATION Parkinson's Disease 132-17-2 BENZTROPINE MODE_CLASS Solute transporter inhibitor 132-17-2 BENZTROPINE INDICATION Extrapyramidal Disorders 132-17-2 BENZTROPINE INDICATION Parkinsonism 132-17-2 BENZTROPINE ADVERSE_EFFECT NEU_3_Paralytic Ileus 132-17-2 BENZTROPINE ADVERSE_EFFECT NEU_3_Paresthesia 132-17-2 BENZTROPINE ADVERSE_EFFECT IMU_3_Urticaria 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_1_Anxiety 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_2_Depression 132-17-2 BENZTROPINE ADVERSE_EFFECT PSY_3_Euphoria 132-17-2 BENZTROPINE ADVERSE_EFFECT XXX_1_Xerostomia 132-17-2 BENZTROPINE PRODUCT_CLASS Central Nervous System (CNS) 132-17-2 BENZTROPINE THERAPEUTIC_CLASS Movement Disorders 132-17-2 BENZTROPINE MECHANISM Prolong/enhance neural transmission 168560-79-0 AIDA PRODUCT_CLASS Biochemicals 168560-79-0 AIDA MECHANISM Modulate G-protein coupled signal transduction 168560-79-0 AIDA MODE_CLASS Receptor Ligand Antagonist 137548-41-5 3-(4-AMINOPHENYL)-3-CYCLOHEXYLPIPERIDINE-2,6-DIONE THERAPEUTIC_CLASS Antineoplastics 137548-41-5 3-(4-AMINOPHENYL)-3-CYCLOHEXYLPIPERIDINE-2,6-DIONE MODE_CLASS Enzyme Inhibitor 137548-41-5 3-(4-AMINOPHENYL)-3-CYCLOHEXYLPIPERIDINE-2,6-DIONE MECHANISM Inhibit steroid biosynthesis/ metabolism 137548-41-5 3-(4-AMINOPHENYL)-3-CYCLOHEXYLPIPERIDINE-2,6-DIONE STRUCTURE_ACTIVITY Estrogen antagonist, aromatase inhibitor 137548-41-5 3-(4-AMINOPHENYL)-3-CYCLOHEXYLPIPERIDINE-2,6-DIONE PRODUCT_CLASS Anti-cancers 173952-44-8 (+/-)-4-(4-AMINOPHENYL)-1,2-DIHYDRO-1-METHYL-2-PROPYLCARBAMOYL-6,7-METHYLENEDIOXYPHTHALAZINE PRODUCT_CLASS Biochemicals 71424-95-8 ACLATONIUM NAPADISILATE MECHANISM Modulate G-protein coupled signal transduction 71424-95-8 ACLATONIUM NAPADISILATE THERAPEUTIC_CLASS Prokinetic Agents 71424-95-8 ACLATONIUM NAPADISILATE MODE_CLASS Receptor Agonist 71424-95-8 ACLATONIUM NAPADISILATE PRODUCT_CLASS Gastrointestinal System 55077-30-0 ACLATONIUM NAPADISILATE MECHANISM Modulate G-protein coupled signal transduction 55077-30-0 ACLATONIUM NAPADISILATE THERAPEUTIC_CLASS Prokinetic Agents 55077-30-0 ACLATONIUM NAPADISILATE MODE_CLASS Receptor Agonist 55077-30-0 ACLATONIUM NAPADISILATE PRODUCT_CLASS Gastrointestinal System 81047-99-6 CGP 12177 MODE_CLASS Receptor Ligand Antagonist 81047-99-6 CGP 12177 MECHANISM Modulate G-protein coupled signal transduction 81047-99-6 CGP 12177 PRODUCT_CLASS Biochemicals 100828-16-8 (RS)-CPP MECHANISM Prolong/enhance neural transmission 100828-16-8 (RS)-CPP MODE_CLASS Channel Modulator 100828-16-8 (RS)-CPP PRODUCT_CLASS Biochemicals 83002-04-4 CP 55,940 MODE_CLASS Receptor Agonist 83002-04-4 CP 55,940 MECHANISM Modulate G-protein coupled signal transduction 83002-04-4 CP 55,940 PRODUCT_CLASS Biochemicals 169209-63-6 LY-314593 PRODUCT_CLASS Biochemicals 169209-63-6 LY-314593 MECHANISM Modulate G-protein coupled signal transduction 169209-63-6 LY-314593 MODE_CLASS Receptor Ligand Antagonist 117857-93-9 L-CCG-I MODE_CLASS Receptor Agonist 117857-93-9 L-CCG-I PRODUCT_CLASS Biochemicals 117857-93-9 L-CCG-I MECHANISM Modulate G-protein coupled signal transduction 27848-84-6 NICERGOLINE STRUCTURE_ACTIVITY Ergot alkaloid 27848-84-6 NICERGOLINE MODE_CLASS Receptor Ligand Antagonist 27848-84-6 NICERGOLINE MECHANISM Modulate G-protein coupled signal transduction 80300-09-0 (R)-(+)-8-HYDROXY-DPAT PRODUCT_CLASS Central Nervous System (CNS) 80300-09-0 (R)-(+)-8-HYDROXY-DPAT MECHANISM Modulate neural transmission 80300-09-0 (R)-(+)-8-HYDROXY-DPAT MODE_CLASS Receptor Agonist, selective 80300-09-0 (R)-(+)-8-HYDROXY-DPAT THERAPEUTIC_CLASS Sedatives/Hypnotics 127299-93-8 BRL-37344 MODE_CLASS Receptor Agonist, selective 127299-93-8 BRL-37344 PRODUCT_CLASS Autonomic Nervous System (ANS) 127299-93-8 BRL-37344 PRODUCT_CLASS Cardiovasculars 127299-93-8 BRL-37344 THERAPEUTIC_CLASS Hypolipidemic Agents 127299-93-8 BRL-37344 MECHANISM Modulate G-protein coupled signal transduction 127299-93-8 BRL-37344 THERAPEUTIC_CLASS Sympathomimetic Agents 127299-93-8 BRL-37344 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 145433-12-1 TRIFLUOROAMPA PRODUCT_CLASS Biochemicals 145433-12-1 TRIFLUOROAMPA MECHANISM Prolong/enhance neural transmission 145433-12-1 TRIFLUOROAMPA MODE_CLASS Channel Modulator 20698-16-2 (RS)-5-BROMOWILLARDIINE MODE_CLASS Channel Modulator 20698-16-2 (RS)-5-BROMOWILLARDIINE MECHANISM Prolong/enhance neural transmission 20698-16-2 (RS)-5-BROMOWILLARDIINE PRODUCT_CLASS Biochemicals 118896-96-1 (RS)-AMPA MODE_CLASS Channel Modulator 118896-96-1 (RS)-AMPA PRODUCT_CLASS Biochemicals 118896-96-1 (RS)-AMPA MECHANISM Prolong/enhance neural transmission 74341-63-2 (RS)-AMPA MECHANISM Prolong/enhance neural transmission 74341-63-2 (RS)-AMPA MODE_CLASS Channel Modulator 74341-63-2 (RS)-AMPA PRODUCT_CLASS Biochemicals 55136-48-6 (S)-3-CARBOXY-4-HYDROXYPHENYLGLYCINE MECHANISM Modulate G-protein coupled signal transduction 55136-48-6 (S)-3-CARBOXY-4-HYDROXYPHENYLGLYCINE MODE_CLASS Receptor Ligand Antagonist 55136-48-6 (S)-3-CARBOXY-4-HYDROXYPHENYLGLYCINE PRODUCT_CLASS Biochemicals 85148-82-9 (S)-4-CARBOXY-3-HYDROXYPHENYLGLYCINE PRODUCT_CLASS Biochemicals 85148-82-9 (S)-4-CARBOXY-3-HYDROXYPHENYLGLYCINE MECHANISM Modulate G-protein coupled signal transduction 85148-82-9 (S)-4-CARBOXY-3-HYDROXYPHENYLGLYCINE MODE_CLASS Receptor Ligand Antagonist 134052-73-6 (S)-4-CARBOXYPHENYLGLYCINE MODE_CLASS Receptor Ligand Antagonist 134052-73-6 (S)-4-CARBOXYPHENYLGLYCINE PRODUCT_CLASS Biochemicals 134052-73-6 (S)-4-CARBOXYPHENYLGLYCINE MECHANISM Modulate G-protein coupled signal transduction 129689-30-1 ZD-7114 STRUCTURE_ACTIVITY Adrenoceptor-beta3 agonist 129689-30-1 ZD-7114 MECHANISM Reduce muscle contractile force 129689-30-1 ZD-7114 MODE_CLASS Receptor Agonist, selective 129689-30-1 ZD-7114 PRODUCT_CLASS Biochemicals 19772-78-2 (S)-5-BROMOWILLARDIINE MODE_CLASS Channel Modulator 19772-78-2 (S)-5-BROMOWILLARDIINE PRODUCT_CLASS Biochemicals 19772-78-2 (S)-5-BROMOWILLARDIINE MECHANISM Prolong/enhance neural transmission 140187-23-1 (S)-5-FLUOROWILLARDIINE MECHANISM Prolong/enhance neural transmission 140187-23-1 (S)-5-FLUOROWILLARDIINE MODE_CLASS Channel Modulator 140187-23-1 (S)-5-FLUOROWILLARDIINE PRODUCT_CLASS Biochemicals 140187-25-3 (S)-5-IODOWILLARDIINE MODE_CLASS Channel Modulator 140187-25-3 (S)-5-IODOWILLARDIINE MECHANISM Prolong/enhance neural transmission 140187-25-3 (S)-5-IODOWILLARDIINE PRODUCT_CLASS Biochemicals 140385-36-0 (S)-5-NITROWILLARDINE MECHANISM Prolong/enhance neural transmission 140385-36-0 (S)-5-NITROWILLARDINE MODE_CLASS Channel Modulator 140385-36-0 (S)-5-NITROWILLARDINE PRODUCT_CLASS Biochemicals 97-39-2 1,3-DI-O-TOLYLGUANIDINE MODE_CLASS Receptor Agonist 97-39-2 1,3-DI-O-TOLYLGUANIDINE MECHANISM Modulate neural transmission 97-39-2 1,3-DI-O-TOLYLGUANIDINE PRODUCT_CLASS Biochemicals 2113-05-5 1-(3-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE PRODUCT_CLASS Biochemicals 2113-05-5 1-(3-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE MODE_CLASS Channel enhancer /opener 2113-05-5 1-(3-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE MECHANISM Prolong/enhance neural transmission 2113-05-5 1-(3-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE MECHANISM Inhibit absorption of dietary carbohydrates 2113-05-5 1-(3-CHLOROPHENYL)BIGUANIDE HYDROCHLORIDE MODE_CLASS Channel Blocker 6640-24-0 M-CPP PRODUCT_CLASS Central Nervous System (CNS) 6640-24-0 M-CPP THERAPEUTIC_CLASS Antidepressants 6640-24-0 M-CPP INDICATION Depression 135015-84-8 ICI-D8731 THERAPEUTIC_CLASS Antihypertensive Agents 135015-84-8 ICI-D8731 PRODUCT_CLASS Cardiovasculars 135015-84-8 ICI-D8731 INDICATION Hypertension 135015-84-8 ICI-D8731 MECHANISM Reduce vasoconstriction 135015-84-8 ICI-D8731 MODE_CLASS Receptor Ligand Antagonist, Selective 141646-08-4 SANFETRINEM CILEXITEL MODE_CLASS Enzyme Inhibitor 141646-08-4 SANFETRINEM CILEXITEL THERAPEUTIC_CLASS Antibacterials 141646-08-4 SANFETRINEM CILEXITEL MECHANISM Inhibit bacterial cell wall biosynthesis 141646-08-4 SANFETRINEM CILEXITEL PRODUCT_CLASS Anti-infectives 157182-23-5 METESIND MECHANISM Inhibit precursor synthesis 157182-23-5 METESIND STRUCTURE_ACTIVITY Inhibits pyrimidine /purine metabolism, thymidylate synthase inhibitor 157182-23-5 METESIND MODE_CLASS Enzyme Inhibitor 91421-43-1 9-AMINOCAMPTOTHECIN STRUCTURE_ACTIVITY DNA topoisomerase I inhibitor 131899-25-7 BRL-55834 MODE_CLASS Channel Modulator 131899-25-7 BRL-55834 MECHANISM Modulate channel gating 142494-87-9 E-1101 THERAPEUTIC_CLASS Antibacterials 142494-87-9 E-1101 MECHANISM Inhibit bacterial cell wall biosynthesis 142494-87-9 E-1101 MODE_CLASS Enzyme Inhibitor 142494-87-9 E-1101 PRODUCT_CLASS Anti-infectives 141450-48-8 E-7010 STRUCTURE_ACTIVITY Tubulin binder 141579-87-5 A-79175 MECHANISM Inhibit eicosanoid biosynthesis 141579-87-5 A-79175 MODE_CLASS Enzyme Inhibitor 141579-87-5 A-79175 PRODUCT_CLASS Anti-cancers 141579-87-5 A-79175 THERAPEUTIC_CLASS Antineoplastics 134564-82-2 BEFLOXATONE INDICATION Depression 134564-82-2 BEFLOXATONE PRODUCT_CLASS Central Nervous System (CNS) 134564-82-2 BEFLOXATONE THERAPEUTIC_CLASS Antidepressants 143538-48-1 BAY-X-7195 INDICATION Asthma 143538-48-1 BAY-X-7195 STRUCTURE_ACTIVITY Leukotriene receptor antagonist 143538-48-1 BAY-X-7195 MECHANISM Modulate G-protein coupled signal transduction 143538-48-1 BAY-X-7195 PRODUCT_CLASS Respiratory System 143538-48-1 BAY-X-7195 MODE_CLASS Receptor Ligand Antagonist 143538-48-1 BAY-X-7195 THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 147432-77-7 ONTAZOLAST INDICATION Asthma 147432-77-7 ONTAZOLAST PRODUCT_CLASS Respiratory System 147432-77-7 ONTAZOLAST THERAPEUTIC_CLASS Miscellaneous Anti-Asthmatic Agents 147254-64-6 AS-3201 PRODUCT_CLASS Other Human Uses 147254-64-6 AS-3201 INDICATION Diabetic Neuropathy 147254-64-6 AS-3201 THERAPEUTIC_CLASS Chemoprophylactics / Preventives / Protectives 147254-64-6 AS-3201 MODE_CLASS Enzyme Inhibitor 147254-64-6 AS-3201 MECHANISM Inhibit precursor synthesis 149193-59-9 XEMILOFIBAN MECHANISM Inhibit platelet aggregation 149193-59-9 XEMILOFIBAN MODE_CLASS Receptor Ligand Antagonist, Selective 151328-91-5 TO-195 INDICATION Nephritis 151328-91-5 TO-195 MODE_CLASS Enzyme Inhibitor 153250-07-8 HSR-609 INDICATION Viral Rhinitis / Common Cold 149950-60-7 MKC-442 THERAPEUTIC_CLASS Antivirals, Systemic 149950-60-7 MKC-442 INDICATION Human Immunodeficiency Virus (HIV) Disease 149950-60-7 MKC-442 MECHANISM Inhibit viral DNA synthesis 149950-60-7 MKC-442 PRODUCT_CLASS Anti-infectives 149950-60-7 MKC-442 MODE_CLASS Enzyme Inhibitor 161214-65-9 NC-1800 INDICATION Urinary Incontinence / Enuresis 153808-85-6 CS-940 THERAPEUTIC_CLASS Antibacterials 153808-85-6 CS-940 MECHANISM Inhibit bacterial DNA synthesis 153808-85-6 CS-940 MODE_CLASS Enzyme Inhibitor, selective 153808-85-6 CS-940 STRUCTURE_ACTIVITY Bacterial DNA gyrase inhibitor, fluoroquinolone 153808-85-6 CS-940 PRODUCT_CLASS Anti-infectives 148717-90-2 SQUALAMINE MODE_CLASS Enzyme Inhibitor 148717-90-2 SQUALAMINE MECHANISM Inhibit steroid biosynthesis/ metabolism 148717-90-2 SQUALAMINE STRUCTURE_ACTIVITY Angiogenesis inhibitor 173903-42-9 TRK-710 STRUCTURE_ACTIVITY DNA-alkylator, platin 937-13-3 OXONIC ACID MODE_CLASS Enzyme Inhibitor 135326-11-3 GADOXATE DISODIUM INDICATION Contrasting Agent 135326-11-3 GADOXATE DISODIUM PRODUCT_CLASS Diagnostics and Pharmaceutical Aids 144689-63-4 OLMESARTAN PRODUCT_CLASS Cardiovasculars 144689-63-4 OLMESARTAN STRUCTURE_ACTIVITY Angiotensin receptor AT1 antagonist 144689-63-4 OLMESARTAN MECHANISM Modulate G-protein coupled signal transduction 144689-63-4 OLMESARTAN THERAPEUTIC_CLASS Antihypertensive Agents 144689-63-4 OLMESARTAN INDICATION Hypertension 902-87-4 COCULINE INDICATION Arthritis 902-87-4 COCULINE PRODUCT_CLASS Cardiovasculars 902-87-4 COCULINE INDICATION Cardiac Arrhythmias 902-87-4 COCULINE INDICATION Rheumatism 902-87-4 COCULINE THERAPEUTIC_CLASS Antiarrhythmic Agents 902-87-4 COCULINE THERAPEUTIC_CLASS Immunosuppressants 902-87-4 COCULINE PRODUCT_CLASS Immune Response / Immunomodulators 902-87-4 COCULINE INDICATION Neuralgia 153182-59-3 XM-412 INDICATION Myocardial Ischemia 194093-42-0 MKC-733 MODE_CLASS Channel Blocker 194093-42-0 MKC-733 MECHANISM Block neural transmission 163009-72-1 FK-041 MECHANISM Inhibit bacterial cell wall biosynthesis 163009-72-1 FK-041 PRODUCT_CLASS Anti-infectives 163009-72-1 FK-041 MODE_CLASS Enzyme Inhibitor 163009-72-1 FK-041 THERAPEUTIC_CLASS Antibacterials 140703-51-1 EXAMORELIN STRUCTURE_ACTIVITY Gonadotropin-releasing hormone (GnRH) receptor agonist 140703-51-1 EXAMORELIN MODE_CLASS Receptor Agonist 140703-51-1 EXAMORELIN PRODUCT_CLASS Hormones, Endocrine and Metabolic 167354-41-8 ZOSUQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 167155-71-7 ZOSUQUIDAR STRUCTURE_ACTIVITY Multidrug resistant pump inhibitor 166336-55-6 U-103017 INDICATION Myocardial Ischemia 37025-55-1 CARBETOCIN MODE_CLASS Receptor Agonist 37025-55-1 CARBETOCIN MECHANISM Modulate G-protein coupled signal transduction 16208-51-8 DIMESNA INDICATION Urotoxicity 179634-04-9 RO-48-8684 INDICATION Anxiety Disorders 179634-04-9 RO-48-8684 THERAPEUTIC_CLASS Sedatives/Hypnotics 179634-04-9 RO-48-8684 PRODUCT_CLASS Central Nervous System (CNS) 180384-57-0 TEZOSENTAN PRODUCT_CLASS Cardiovasculars 180384-57-0 TEZOSENTAN MODE_CLASS Receptor Ligand Antagonist, Non-selective 180384-57-0 TEZOSENTAN STRUCTURE_ACTIVITY Endothelin receptor antagonist 180384-57-0 TEZOSENTAN THERAPEUTIC_CLASS Antihypertensive Agents 182367-47-1 GS-4071 PRODUCT_CLASS Anti-infectives 182367-47-1 GS-4071 MODE_CLASS Enzyme Inhibitor, selective 190841-79-3 SR-121787 MODE_CLASS Receptor Ligand Antagonist, Selective 190841-79-3 SR-121787 MECHANISM Inhibit platelet aggregation 183549-93-1 TAK-637 INDICATION Urinary Incontinence / Enuresis 217185-75-6 TAK-637 INDICATION Urinary Incontinence / Enuresis 192725-17-0 LOPINAVIR STRUCTURE_ACTIVITY Protease (HIV-1) inhibitor 192725-17-0 LOPINAVIR INDICATION Myocardial Ischemia 186033-14-7 NS-8 INDICATION Urinary Incontinence / Enuresis 186033-14-7 NS-8 MODE_CLASS Channel Modulator 186033-14-7 NS-8 MECHANISM Modulate channel gating 173997-06-3 NEPICASTAT HYDROCHLORIDE PRODUCT_CLASS Cardiovasculars 173997-06-3 NEPICASTAT HYDROCHLORIDE MECHANISM Interferes with neural transmitter synthesis 173997-06-3 NEPICASTAT HYDROCHLORIDE MODE_CLASS Enzyme Inhibitor 173997-06-3 NEPICASTAT HYDROCHLORIDE INDICATION Hypertension 173997-06-3 NEPICASTAT HYDROCHLORIDE THERAPEUTIC_CLASS Antihypertensive Agents 180272-15-5 YM-905 INDICATION Urinary Incontinence / Enuresis 180272-15-5 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 180272-15-5 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180468-38-6 YM-905 MECHANISM Modulate G-protein coupled signal transduction 180468-38-6 YM-905 MODE_CLASS Receptor Ligand Antagonist, Selective 180468-38-6 YM-905 INDICATION Urinary Incontinence / Enuresis 170902-81-5 APREPITANT THERAPEUTIC_CLASS Antidepressants 170902-81-5 APREPITANT THERAPEUTIC_CLASS Antiemetics 170902-81-5 APREPITANT MODE_CLASS Receptor Ligand Antagonist 170902-81-5 APREPITANT PRODUCT_CLASS Central Nervous System (CNS) 170902-81-5 APREPITANT STRUCTURE_ACTIVITY Anti-emetic, neurokinin-1 receptor antagonist 170902-81-5 APREPITANT PRODUCT_CLASS Gastrointestinal System 170902-81-5 APREPITANT MECHANISM Modulate G-protein coupled signal transduction 202409-33-4 ETORICOXIB MODE_CLASS Enzyme Inhibitor 225919-29-9 PDE4 INHIBITOR, CELLTECH/MERCK FROST MODE_CLASS Enzyme Inhibitor 225919-29-9 PDE4 INHIBITOR, CELLTECH/MERCK FROST STRUCTURE_ACTIVITY PDE4 inhibitor 17397-89-6 CERULENIN MODE_CLASS Enzyme Inhibitor 17397-89-6 CERULENIN STRUCTURE_ACTIVITY Fatty acid synthase inhibitor 55981-09-4 NITAZOXANIDE STRUCTURE_ACTIVITY Antibacterial, fungicidal, antiparasitic, MOA unknown 152802-07-8 BW-2164 MODE_CLASS Channel Modulator 152802-07-8 BW-2164 PRODUCT_CLASS Cardiovasculars 152802-07-8 BW-2164 STRUCTURE_ACTIVITY Bile acid transporter (ileal) inhibitor 152802-07-8 BW-2164 MECHANISM Decrease bile acid reabsorption 163133-43-5 NO-NAPROXEN MECHANISM Inhibit eicosanoid biosynthesis 163133-43-5 NO-NAPROXEN STRUCTURE_ACTIVITY NSAID, COX-1, 6-Methoxy-naphthalenyl-acetic acid 163133-43-5 NO-NAPROXEN MODE_CLASS Enzyme Inhibitor 214462-68-7 TRIDOLGOSIR STRUCTURE_ACTIVITY Mannosidase inhibitor 214462-68-7 TRIDOLGOSIR PRODUCT_CLASS Anti-cancers 214462-68-7 TRIDOLGOSIR MODE_CLASS Enzyme Inhibitor 318250-11-2 INS-37217 STRUCTURE_ACTIVITY P2Y receptor agonist 192185-72-1 TIPIFARNIB STRUCTURE_ACTIVITY Protein farnesyl transferase inhibitor 200631-89-6 EML-336 MODE_CLASS Receptor Agonist 200631-89-6 EML-336 MECHANISM Increase transcription of insulin responsive gene 200631-89-6 EML-336 THERAPEUTIC_CLASS Antidiabetic Agents 200631-89-6 EML-336 STRUCTURE_ACTIVITY PPAR gamma agonist, thiazolidinedione, antidiabetic 200631-89-6 EML-336 PRODUCT_CLASS Hormones, Endocrine and Metabolic 200631-89-6 EML-336 INDICATION Diabetes 159519-65-0 ENFUVIRTIDE STRUCTURE_ACTIVITY Viral (HIV) fusion inhibitor 109-52-4 VALERIC ACID ADVERSE_EFFECT NEU_1_Somnolence 109-52-4 VALERIC ACID ADVERSE_EFFECT SKN_1_Skin Erosion 109-52-4 VALERIC ACID ADVERSE_EFFECT GUS_1_Diuresis 109-52-4 VALERIC ACID STRUCTURE_ACTIVITY Toxicant 109-52-4 VALERIC ACID ADVERSE_EFFECT GIS_1_Nausea 109-52-4 VALERIC ACID ACTIVITY_CLASS Toxicant 109-52-4 VALERIC ACID TISSUE_TOXICITY Carcinoid Tumors 109-52-4 VALERIC ACID MODE_CLASS Enzyme Inhibitor 109-52-4 VALERIC ACID ADVERSE_EFFECT SKN_1_Skin Irritation 109-52-4 VALERIC ACID ADVERSE_EFFECT GIS_1_Vomiting 109-52-4 VALERIC ACID ADVERSE_EFFECT DNA_2_Carcinoid Tumors 109-52-4 VALERIC ACID PRODUCT_CLASS Toxicants 109-52-4 VALERIC ACID KNOWN_TOXICITY Carcinogenicity 95-94-3 1,2,4,5-TETRACHLOROBENZENE PRODUCT_CLASS Toxicants 95-94-3 1,2,4,5-TETRACHLOROBENZENE STRUCTURE_ACTIVITY Toxicant 106-87-6 4-VINYLCYCLOHEXENE DIOXIDE STRUCTURE_ACTIVITY Toxicant 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT LUN_2_Dyspnea 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT SKN_1_Skin Irritation 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT LUN_3_Pulmonary Hemorrhage 96-18-4 1,2,3-TRICHLOROPROPANE TISSUE_TOXICITY Liver Necrosis 96-18-4 1,2,3-TRICHLOROPROPANE KNOWN_TOXICITY Mutagenicity 96-18-4 1,2,3-TRICHLOROPROPANE ACTIVITY_CLASS Toxicant, DNA damaging 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT CVS_3_Cardiomyopathy 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT KID_2_Kidney Damage 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT GIS_1_Gastrointestinal Irritation 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT OCU_1_Eye Irritation 96-18-4 1,2,3-TRICHLOROPROPANE KNOWN_TOXICITY Hepatotoxicity 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT PSY_2_CNS Depression 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT LUN_1_Airway Irritation 96-18-4 1,2,3-TRICHLOROPROPANE STRUCTURE_ACTIVITY Toxicant, DNA alkylator 96-18-4 1,2,3-TRICHLOROPROPANE TISSUE_TOXICITY Carcinogenicity 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT XXX_2_Weight Loss 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT LIV_1_Hepatic Damage 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT LIV_2_Liver Necrosis 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT XXX_1_Throat Irritation 96-18-4 1,2,3-TRICHLOROPROPANE KNOWN_TOXICITY Carcinogenicity 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT NEU_3_Neurotoxicity 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT DNA_3_Carcinogenicity 96-18-4 1,2,3-TRICHLOROPROPANE TISSUE_TOXICITY Cardiomyopathy 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT XXX_2_Lethargy 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT DNA_3_Mutagenicity 96-18-4 1,2,3-TRICHLOROPROPANE TISSUE_TOXICITY Mutagenicity 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT PSY_2_CNS Dysfunction 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT LIV_1_Impaired Liver Function 96-18-4 1,2,3-TRICHLOROPROPANE ADVERSE_EFFECT NEU_3_Convulsions 96-18-4 1,2,3-TRICHLOROPROPANE KNOWN_TOXICITY Cardiovascular Toxicity 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_3_Amnesia 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_1_Sedation 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_2_Anesthesia 75-25-2 BROMOFORM ADVERSE_EFFECT PSY_2_CNS Depression 75-25-2 BROMOFORM KNOWN_TOXICITY Carcinogenicity 75-25-2 BROMOFORM TISSUE_TOXICITY Renal Toxicity 75-25-2 BROMOFORM TISSUE_TOXICITY Genotoxicity 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_1_Headache 75-25-2 BROMOFORM ADVERSE_EFFECT OCU_1_Eye Irritation 75-25-2 BROMOFORM ADVERSE_EFFECT MSK_1_Muscle Weakness 75-25-2 BROMOFORM ADVERSE_EFFECT XXX_3_Death 75-25-2 BROMOFORM KNOWN_TOXICITY Cardiovascular Toxicity 75-25-2 BROMOFORM ADVERSE_EFFECT LIV_2_Hepatotoxicity 75-25-2 BROMOFORM STRUCTURE_ACTIVITY Toxicant 75-25-2 BROMOFORM TISSUE_TOXICITY Carcinogenicity 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_3_Loss of Consciousness 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_1_Vertigo 75-25-2 BROMOFORM KNOWN_TOXICITY Mutagenicity 75-25-2 BROMOFORM TISSUE_TOXICITY Death 75-25-2 BROMOFORM TISSUE_TOXICITY Hepatotoxicity 75-25-2 BROMOFORM PRODUCT_CLASS Toxicants 75-25-2 BROMOFORM ADVERSE_EFFECT KID_2_Renal Toxicity 75-25-2 BROMOFORM ADVERSE_EFFECT CVS_3_Shock 75-25-2 BROMOFORM ADVERSE_EFFECT LUN_3_Respiratory Failure 75-25-2 BROMOFORM KNOWN_TOXICITY Miscellaneous 75-25-2 BROMOFORM ADVERSE_EFFECT LUN_1_Airway Irritation 75-25-2 BROMOFORM ADVERSE_EFFECT BBM_3_Hemorrhage 75-25-2 BROMOFORM ADVERSE_EFFECT DNA_3_Genotoxicity 75-25-2 BROMOFORM ADVERSE_EFFECT XXX_1_Lacrimation 75-25-2 BROMOFORM ADVERSE_EFFECT XXX_2_Prostration 75-25-2 BROMOFORM ADVERSE_EFFECT DNA_2_Carcinogenicity 75-25-2 BROMOFORM KNOWN_TOXICITY Hepatotoxicity 75-25-2 BROMOFORM ADVERSE_EFFECT SKN_2_Skin Irritation 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_3_Convulsions 75-25-2 BROMOFORM ADVERSE_EFFECT LIV_2_Abnormal Liver Function 75-25-2 BROMOFORM ADVERSE_EFFECT LUN_2_Pulmonary Edema 75-25-2 BROMOFORM TISSUE_TOXICITY Shock 75-25-2 BROMOFORM KNOWN_TOXICITY Nephrotoxicity 75-25-2 BROMOFORM ADVERSE_EFFECT NEU_2_Coma 102-54-5 FERROCENE ADVERSE_EFFECT DNA_3_Carcinogenicity 102-54-5 FERROCENE ADVERSE_EFFECT LUN_3_Pulmonary Impairment 102-54-5 FERROCENE ADVERSE_EFFECT BBM_2_Coagulopathy 102-54-5 FERROCENE ADVERSE_EFFECT XXX_1_Lethargy 102-54-5 FERROCENE KNOWN_TOXICITY Miscellaneous 102-54-5 FERROCENE TISSUE_TOXICITY Carcinogenicity 102-54-5 FERROCENE TISSUE_TOXICITY Shock 102-54-5 FERROCENE PRODUCT_CLASS Toxicants 102-54-5 FERROCENE ACTIVITY_CLASS Toxicant 102-54-5 FERROCENE TISSUE_TOXICITY Hepatotoxicity 102-54-5 FERROCENE KNOWN_TOXICITY Cardiovascular Toxicity 102-54-5 FERROCENE ADVERSE_EFFECT GIS_1_Nausea 102-54-5 FERROCENE STRUCTURE_ACTIVITY Toxicant, heavy metal 102-54-5 FERROCENE ADVERSE_EFFECT GIS_2_Hematemesis 102-54-5 FERROCENE ADVERSE_EFFECT XXX_3_Death 102-54-5 FERROCENE ADVERSE_EFFECT LIV_3_Hepatotoxicity 102-54-5 FERROCENE ADVERSE_EFFECT LUN_3_Cyanosis 102-54-5 FERROCENE ADVERSE_EFFECT GIS_1_Abdominal Pain 102-54-5 FERROCENE ADVERSE_EFFECT GIS_1_Diarrhea 102-54-5 FERROCENE ADVERSE_EFFECT NEU_2_Stupor 102-54-5 FERROCENE KNOWN_TOXICITY Hepatotoxicity 102-54-5 FERROCENE TISSUE_TOXICITY Death 102-54-5 FERROCENE ADVERSE_EFFECT GIS_1_Vomiting 102-54-5 FERROCENE ADVERSE_EFFECT CVS_2_Shock 102-54-5 FERROCENE ADVERSE_EFFECT LIV_3_Liver Cirrhosis 102-54-5 FERROCENE ADVERSE_EFFECT END_3_Hyperglycemia 102-54-5 FERROCENE ADVERSE_EFFECT CVS_2_Vasodilation 102-54-5 FERROCENE ADVERSE_EFFECT CVS_2_Hypotension 102-54-5 FERROCENE ADVERSE_EFFECT NEU_3_Coma 102-54-5 FERROCENE ADVERSE_EFFECT END_3_Diabetes Mellitus 102-54-5 FERROCENE TISSUE_TOXICITY Hypotension 102-54-5 FERROCENE TISSUE_TOXICITY Liver Cirrhosis 102-54-5 FERROCENE KNOWN_TOXICITY Carcinogenicity 102-54-5 FERROCENE ADVERSE_EFFECT GIS_2_Bloody Diarrhea 102-54-5 FERROCENE ADVERSE_EFFECT BBM_3_Leukocytosis 102-54-5 FERROCENE ADVERSE_EFFECT GIS_3_Gastrointestinal Necrosis 102-54-5 FERROCENE ADVERSE_EFFECT PSY_2_CNS Depression 102-54-5 FERROCENE ADVERSE_EFFECT GIS_3_Intestinal Necrosis 102-54-5 FERROCENE ADVERSE_EFFECT PSY_1_Irritability 102-54-5 FERROCENE ADVERSE_EFFECT XXX_2_Fever 99-08-1 3-NITROTOLUENE STRUCTURE_ACTIVITY Toxicant 67-64-1 ACETONE ADVERSE_EFFECT XXX_2_Inflammation 67-64-1 ACETONE ADVERSE_EFFECT XXX_3_Death 67-64-1 ACETONE KNOWN_TOXICITY Miscellaneous 67-64-1 ACETONE TISSUE_TOXICITY Cardiodepressant 67-64-1 ACETONE ADVERSE_EFFECT LUN_3_Respiratory Failure 67-64-1 ACETONE ADVERSE_EFFECT CVS_3_Shock 67-64-1 ACETONE ADVERSE_EFFECT NEU_3_Coma 67-64-1 ACETONE ADVERSE_EFFECT CVS_2_Tachycardia 67-64-1 ACETONE ADVERSE_EFFECT KID_2_Kidney Damage 67-64-1 ACETONE STRUCTURE_ACTIVITY Toxicant 67-64-1 ACETONE ACTIVITY_CLASS Toxicant 67-64-1 ACETONE TISSUE_TOXICITY Death 67-64-1 ACETONE ADVERSE_EFFECT OCU_1_Eye Irritation 67-64-1 ACETONE ADVERSE_EFFECT GIS_2_Nausea / Vomiting 67-64-1 ACETONE ADVERSE_EFFECT NEU_2_Dizziness 67-64-1 ACETONE ADVERSE_EFFECT NEU_2_Headache 67-64-1 ACETONE ADVERSE_EFFECT NEU_2_Vertigo 67-64-1 ACETONE KNOWN_TOXICITY Cardiovascular Toxicity 67-64-1 ACETONE ADVERSE_EFFECT CVS_3_Cardiodepressant 67-64-1 ACETONE ADVERSE_EFFECT NEU_2_Anesthesia 67-64-1 ACETONE ADVERSE_EFFECT SKN_3_Dermatitis 67-64-1 ACETONE ADVERSE_EFFECT OCU_2_Diplopia 67-64-1 ACETONE ADVERSE_EFFECT XXX_2_Hypothermia 67-64-1 ACETONE ADVERSE_EFFECT LIV_2_Hepatic Damage 67-64-1 ACETONE TISSUE_TOXICITY Shock 67-64-1 ACETONE ADVERSE_EFFECT EMB_3_Fetal Distress 67-64-1 ACETONE ADVERSE_EFFECT PSY_2_CNS Depression 67-64-1 ACETONE ADVERSE_EFFECT XXX_1_Restlessness 67-64-1 ACETONE ADVERSE_EFFECT XXX_2_Asthenia 67-64-1 ACETONE ADVERSE_EFFECT NEU_2_Drowsiness 67-64-1 ACETONE ADVERSE_EFFECT NEU_3_Stupor